cancer_type qtl_type tag_SNP LD SNP_id gene_id gene_symbol t-stat p-value FDR beta r Traits SNP_position Gene_position LUSC cis rs916888 0.773 rs199448 ENSG00000262539.1 RP11-259G18.3 31.25 8.15e-117 2.68e-109 1.15 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46259551~46260606:- LUSC cis rs1577917 0.655 rs1059307 ENSG00000203875.9 SNHG5 29.86 1.2e-110 1.97e-103 0.98 0.81 Response to antipsychotic treatment; chr6:85678170 chr6:85660950~85678736:- LUSC cis rs9326248 0.953 rs488962 ENSG00000254851.1 RP11-109L13.1 28.64 4e-105 4.38e-98 1.08 0.8 Blood protein levels; chr11:117201809 chr11:117135528~117138582:+ LUSC cis rs9326248 1 rs664922 ENSG00000254851.1 RP11-109L13.1 -28.47 2.42e-104 1.59e-97 -1.07 -0.8 Blood protein levels; chr11:117200179 chr11:117135528~117138582:+ LUSC cis rs9326248 1 rs664082 ENSG00000254851.1 RP11-109L13.1 -28.47 2.42e-104 1.59e-97 -1.07 -0.8 Blood protein levels; chr11:117200354 chr11:117135528~117138582:+ LUSC cis rs9326248 0.906 rs171052 ENSG00000254851.1 RP11-109L13.1 27.97 4.28e-102 8.28e-96 1.06 0.79 Blood protein levels; chr11:117211047 chr11:117135528~117138582:+ LUSC cis rs9326248 0.954 rs521171 ENSG00000254851.1 RP11-109L13.1 -27.96 4.99e-102 9.13e-96 -1.06 -0.79 Blood protein levels; chr11:117193977 chr11:117135528~117138582:+ LUSC cis rs9326248 0.953 rs634960 ENSG00000254851.1 RP11-109L13.1 27.95 5.63e-102 9.46e-96 1.06 0.79 Blood protein levels; chr11:117202247 chr11:117135528~117138582:+ LUSC cis rs1577917 0.561 rs3087978 ENSG00000203875.9 SNHG5 27.95 5.75e-102 9.46e-96 0.99 0.79 Response to antipsychotic treatment; chr6:85678505 chr6:85660950~85678736:- LUSC cis rs1577917 0.655 rs9450311 ENSG00000203875.9 SNHG5 27.84 1.74e-101 1.88e-95 0.98 0.79 Response to antipsychotic treatment; chr6:85666868 chr6:85660950~85678736:- LUSC cis rs1577917 0.655 rs2842605 ENSG00000203875.9 SNHG5 -27.84 1.74e-101 1.88e-95 -0.99 -0.79 Response to antipsychotic treatment; chr6:85625432 chr6:85660950~85678736:- LUSC cis rs1577917 0.655 rs2758848 ENSG00000203875.9 SNHG5 -27.84 1.74e-101 1.88e-95 -0.99 -0.79 Response to antipsychotic treatment; chr6:85637887 chr6:85660950~85678736:- LUSC cis rs1577917 0.727 rs9344539 ENSG00000203875.9 SNHG5 -27.84 1.77e-101 1.88e-95 -0.99 -0.79 Response to antipsychotic treatment; chr6:85643903 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs9362232 ENSG00000203875.9 SNHG5 -27.84 1.77e-101 1.88e-95 -0.99 -0.79 Response to antipsychotic treatment; chr6:85643904 chr6:85660950~85678736:- LUSC cis rs1577917 0.655 rs9444354 ENSG00000203875.9 SNHG5 27.7 7.5e-101 7.25e-95 0.98 0.79 Response to antipsychotic treatment; chr6:85582217 chr6:85660950~85678736:- LUSC cis rs9326248 0.954 rs4938349 ENSG00000254851.1 RP11-109L13.1 -27.61 1.97e-100 1.51e-94 -1.05 -0.79 Blood protein levels; chr11:117151207 chr11:117135528~117138582:+ LUSC cis rs9326248 0.954 rs8521 ENSG00000254851.1 RP11-109L13.1 -27.56 3.4e-100 2.43e-94 -1.05 -0.79 Blood protein levels; chr11:117196983 chr11:117135528~117138582:+ LUSC cis rs9326248 0.954 rs10790177 ENSG00000254851.1 RP11-109L13.1 -27.54 3.93e-100 2.75e-94 -1.04 -0.79 Blood protein levels; chr11:117177701 chr11:117135528~117138582:+ LUSC cis rs1577917 0.655 rs2758849 ENSG00000203875.9 SNHG5 -27.5 6.04e-100 3.9e-94 -0.99 -0.79 Response to antipsychotic treatment; chr6:85634578 chr6:85660950~85678736:- LUSC cis rs9326248 1 rs585849 ENSG00000254851.1 RP11-109L13.1 -27.43 1.25e-99 7.62e-94 -1.05 -0.78 Blood protein levels; chr11:117198345 chr11:117135528~117138582:+ LUSC cis rs1577917 0.559 rs1173418 ENSG00000203875.9 SNHG5 27.42 1.5e-99 8.82e-94 0.98 0.78 Response to antipsychotic treatment; chr6:85693198 chr6:85660950~85678736:- LUSC cis rs1577917 0.56 rs12193777 ENSG00000203875.9 SNHG5 27.32 4.01e-99 2.09e-93 0.97 0.78 Response to antipsychotic treatment; chr6:85536991 chr6:85660950~85678736:- LUSC cis rs1577917 0.655 rs9444351 ENSG00000203875.9 SNHG5 27.32 4.01e-99 2.09e-93 0.97 0.78 Response to antipsychotic treatment; chr6:85538081 chr6:85660950~85678736:- LUSC cis rs1577917 0.655 rs7766485 ENSG00000203875.9 SNHG5 27.32 4.01e-99 2.09e-93 0.97 0.78 Response to antipsychotic treatment; chr6:85553837 chr6:85660950~85678736:- LUSC cis rs9326248 1 rs7946257 ENSG00000254851.1 RP11-109L13.1 -27.25 8.65e-99 4.45e-93 -1.04 -0.78 Blood protein levels; chr11:117182449 chr11:117135528~117138582:+ LUSC cis rs9326248 1 rs3736120 ENSG00000254851.1 RP11-109L13.1 -27.14 2.74e-98 1.29e-92 -1.04 -0.78 Blood protein levels; chr11:117161409 chr11:117135528~117138582:+ LUSC cis rs9326248 0.817 rs1242127 ENSG00000254851.1 RP11-109L13.1 27.01 1.07e-97 4.71e-92 1.03 0.78 Blood protein levels; chr11:117205848 chr11:117135528~117138582:+ LUSC cis rs1577917 0.655 rs9444352 ENSG00000203875.9 SNHG5 27 1.27e-97 5.51e-92 0.97 0.78 Response to antipsychotic treatment; chr6:85547817 chr6:85660950~85678736:- LUSC cis rs1577917 0.681 rs4707211 ENSG00000203875.9 SNHG5 26.96 1.87e-97 7.87e-92 0.97 0.78 Response to antipsychotic treatment; chr6:85522992 chr6:85660950~85678736:- LUSC cis rs1577917 0.61 rs11752795 ENSG00000203875.9 SNHG5 26.91 3.19e-97 1.31e-91 0.97 0.78 Response to antipsychotic treatment; chr6:85577411 chr6:85660950~85678736:- LUSC cis rs1577917 0.566 rs2842611 ENSG00000203875.9 SNHG5 -26.91 3.19e-97 1.31e-91 -0.97 -0.78 Response to antipsychotic treatment; chr6:85592316 chr6:85660950~85678736:- LUSC cis rs1577917 0.655 rs6454472 ENSG00000203875.9 SNHG5 26.77 1.38e-96 5.47e-91 0.97 0.78 Response to antipsychotic treatment; chr6:85514335 chr6:85660950~85678736:- LUSC cis rs9326248 1 rs10790175 ENSG00000254851.1 RP11-109L13.1 -26.73 2.1e-96 8.13e-91 -1.01 -0.78 Blood protein levels; chr11:117164013 chr11:117135528~117138582:+ LUSC cis rs9326248 0.911 rs11216284 ENSG00000254851.1 RP11-109L13.1 -26.62 6.74e-96 2.46e-90 -1.05 -0.78 Blood protein levels; chr11:117132344 chr11:117135528~117138582:+ LUSC cis rs1577917 0.681 rs4348284 ENSG00000203875.9 SNHG5 -26.56 1.31e-95 4.62e-90 -0.98 -0.77 Response to antipsychotic treatment; chr6:85640676 chr6:85660950~85678736:- LUSC cis rs1577917 0.655 rs2842600 ENSG00000203875.9 SNHG5 -26.55 1.49e-95 5.22e-90 -0.97 -0.77 Response to antipsychotic treatment; chr6:85615914 chr6:85660950~85678736:- LUSC cis rs2739330 0.892 rs5751776 ENSG00000273295.1 AP000350.5 26.5 2.49e-95 8.53e-90 0.91 0.77 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23901432~23907068:- LUSC cis rs9326248 1 rs4938354 ENSG00000254851.1 RP11-109L13.1 -26.42 5.77e-95 1.94e-89 -1.03 -0.77 Blood protein levels; chr11:117180449 chr11:117135528~117138582:+ LUSC cis rs9326248 0.798 rs10892079 ENSG00000254851.1 RP11-109L13.1 -26.41 6.41e-95 2.13e-89 -1.04 -0.77 Blood protein levels; chr11:117146108 chr11:117135528~117138582:+ LUSC cis rs9326248 0.911 rs474339 ENSG00000254851.1 RP11-109L13.1 -26.32 1.63e-94 5.35e-89 -1.03 -0.77 Blood protein levels; chr11:117188836 chr11:117135528~117138582:+ LUSC cis rs1577917 0.655 rs12203963 ENSG00000203875.9 SNHG5 26.3 2.06e-94 6.71e-89 0.95 0.77 Response to antipsychotic treatment; chr6:85513598 chr6:85660950~85678736:- LUSC cis rs1577917 0.629 rs6927475 ENSG00000203875.9 SNHG5 26.28 2.75e-94 8.63e-89 0.96 0.77 Response to antipsychotic treatment; chr6:85497055 chr6:85660950~85678736:- LUSC cis rs1577917 0.629 rs9450285 ENSG00000203875.9 SNHG5 26.28 2.75e-94 8.63e-89 0.96 0.77 Response to antipsychotic treatment; chr6:85498378 chr6:85660950~85678736:- LUSC cis rs2739330 0.892 rs4822455 ENSG00000273295.1 AP000350.5 25.89 1.76e-92 5.35e-87 0.9 0.77 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23901432~23907068:- LUSC cis rs1577917 0.655 rs9342045 ENSG00000203875.9 SNHG5 25.81 4.14e-92 1.24e-86 0.97 0.77 Response to antipsychotic treatment; chr6:85715430 chr6:85660950~85678736:- LUSC cis rs9326248 1 rs4938344 ENSG00000254851.1 RP11-109L13.1 -25.66 1.87e-91 5.55e-86 -1.04 -0.76 Blood protein levels; chr11:117133033 chr11:117135528~117138582:+ LUSC cis rs9326248 1 rs664971 ENSG00000254851.1 RP11-109L13.1 25.28 1.09e-89 3.21e-84 1 0.76 Blood protein levels; chr11:117200141 chr11:117135528~117138582:+ LUSC cis rs9322193 0.962 rs2065664 ENSG00000231760.4 RP11-350J20.5 24.65 9.74e-87 2.15e-81 0.94 0.75 Lung cancer; chr6:149762485 chr6:149796151~149826294:- LUSC cis rs2739330 0.796 rs5760097 ENSG00000273295.1 AP000350.5 24.52 4e-86 7.31e-81 0.89 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23901432~23907068:- LUSC cis rs2739330 0.753 rs4822452 ENSG00000273295.1 AP000350.5 24.49 5.38e-86 9.67e-81 0.88 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23901432~23907068:- LUSC cis rs2739330 0.828 rs5760098 ENSG00000273295.1 AP000350.5 24.43 1.13e-85 2e-80 0.89 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23901432~23907068:- LUSC cis rs2739330 0.828 rs5760102 ENSG00000273295.1 AP000350.5 24.43 1.13e-85 2e-80 0.89 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23901432~23907068:- LUSC cis rs2739330 0.828 rs4822451 ENSG00000273295.1 AP000350.5 24.36 2.31e-85 4.04e-80 0.89 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23901432~23907068:- LUSC cis rs2739330 0.828 rs5760099 ENSG00000273295.1 AP000350.5 24.36 2.31e-85 4.04e-80 0.89 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23901432~23907068:- LUSC cis rs9326248 1 rs7107152 ENSG00000254851.1 RP11-109L13.1 24.31 4.13e-85 7.19e-80 0.99 0.75 Blood protein levels; chr11:117185364 chr11:117135528~117138582:+ LUSC cis rs2739330 0.828 rs5751770 ENSG00000273295.1 AP000350.5 24.26 6.46e-85 1.12e-79 0.87 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23901432~23907068:- LUSC cis rs2739330 0.796 rs5760106 ENSG00000273295.1 AP000350.5 -24.16 2e-84 3.43e-79 -0.87 -0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23901432~23907068:- LUSC cis rs1577917 0.56 rs9450288 ENSG00000203875.9 SNHG5 23.88 3.94e-83 6.18e-78 0.91 0.74 Response to antipsychotic treatment; chr6:85511868 chr6:85660950~85678736:- LUSC cis rs9322193 0.962 rs7818 ENSG00000231760.4 RP11-350J20.5 23.84 6.15e-83 9.6e-78 0.92 0.74 Lung cancer; chr6:149810956 chr6:149796151~149826294:- LUSC cis rs2739330 0.828 rs5760108 ENSG00000273295.1 AP000350.5 23.79 1.06e-82 1.65e-77 0.87 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23901432~23907068:- LUSC cis rs9326248 1 rs9326248 ENSG00000254851.1 RP11-109L13.1 -23.75 1.64e-82 2.53e-77 -0.99 -0.74 Blood protein levels; chr11:117128509 chr11:117135528~117138582:+ LUSC cis rs2739330 0.828 rs4820572 ENSG00000273295.1 AP000350.5 23.72 2.31e-82 3.53e-77 0.87 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23901432~23907068:- LUSC cis rs2739330 0.828 rs2154593 ENSG00000273295.1 AP000350.5 23.64 5.56e-82 8.39e-77 0.87 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23901432~23907068:- LUSC cis rs2739330 0.828 rs2877178 ENSG00000273295.1 AP000350.5 23.61 7.69e-82 1.14e-76 0.86 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23901432~23907068:- LUSC cis rs916888 0.773 rs199448 ENSG00000214401.4 KANSL1-AS1 23.58 1.04e-81 1.5e-76 1.11 0.74 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46193576~46196723:+ LUSC cis rs9322193 0.962 rs12175575 ENSG00000231760.4 RP11-350J20.5 23.46 4.03e-81 5.53e-76 0.93 0.73 Lung cancer; chr6:149763351 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs4869966 ENSG00000231760.4 RP11-350J20.5 23.46 4.03e-81 5.53e-76 0.93 0.73 Lung cancer; chr6:149763714 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs1112730 ENSG00000231760.4 RP11-350J20.5 23.46 4.03e-81 5.53e-76 0.93 0.73 Lung cancer; chr6:149766383 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs1112729 ENSG00000231760.4 RP11-350J20.5 23.46 4.03e-81 5.53e-76 0.93 0.73 Lung cancer; chr6:149766491 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs10452626 ENSG00000231760.4 RP11-350J20.5 23.46 4.03e-81 5.53e-76 0.93 0.73 Lung cancer; chr6:149767481 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs62441303 ENSG00000231760.4 RP11-350J20.5 23.46 4.03e-81 5.53e-76 0.93 0.73 Lung cancer; chr6:149767547 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs12211511 ENSG00000231760.4 RP11-350J20.5 23.4 7.11e-81 9.63e-76 0.94 0.73 Lung cancer; chr6:149745206 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9479810 ENSG00000231760.4 RP11-350J20.5 23.4 7.11e-81 9.63e-76 0.94 0.73 Lung cancer; chr6:149751359 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10872645 ENSG00000231760.4 RP11-350J20.5 23.4 7.35e-81 9.9e-76 0.94 0.73 Lung cancer; chr6:149742840 chr6:149796151~149826294:- LUSC cis rs2739330 0.828 rs2186366 ENSG00000273295.1 AP000350.5 -23.27 2.92e-80 3.87e-75 -0.86 -0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23901432~23907068:- LUSC cis rs2739330 0.796 rs2154594 ENSG00000273295.1 AP000350.5 -23.1 1.97e-79 2.53e-74 -0.85 -0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23901432~23907068:- LUSC cis rs9322193 0.962 rs10872653 ENSG00000231760.4 RP11-350J20.5 23.08 2.24e-79 2.83e-74 0.94 0.73 Lung cancer; chr6:149778907 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs3805748 ENSG00000231760.4 RP11-350J20.5 23.05 3.2e-79 3.78e-74 0.94 0.73 Lung cancer; chr6:149772542 chr6:149796151~149826294:- LUSC cis rs9322193 0.736 rs10457851 ENSG00000231760.4 RP11-350J20.5 23.05 3.2e-79 3.78e-74 0.94 0.73 Lung cancer; chr6:149775216 chr6:149796151~149826294:- LUSC cis rs9322193 0.886 rs10872652 ENSG00000231760.4 RP11-350J20.5 23.05 3.2e-79 3.78e-74 0.94 0.73 Lung cancer; chr6:149775303 chr6:149796151~149826294:- LUSC cis rs9322193 0.886 rs12525871 ENSG00000231760.4 RP11-350J20.5 23.05 3.2e-79 3.78e-74 0.94 0.73 Lung cancer; chr6:149775882 chr6:149796151~149826294:- LUSC cis rs9322193 0.886 rs17672976 ENSG00000231760.4 RP11-350J20.5 23.05 3.2e-79 3.78e-74 0.94 0.73 Lung cancer; chr6:149776207 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs2184369 ENSG00000231760.4 RP11-350J20.5 23.05 3.2e-79 3.78e-74 0.94 0.73 Lung cancer; chr6:149776681 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs2342861 ENSG00000231760.4 RP11-350J20.5 23.05 3.2e-79 3.78e-74 0.94 0.73 Lung cancer; chr6:149777561 chr6:149796151~149826294:- LUSC cis rs9322193 0.926 rs2342860 ENSG00000231760.4 RP11-350J20.5 23.05 3.2e-79 3.78e-74 0.94 0.73 Lung cancer; chr6:149777641 chr6:149796151~149826294:- LUSC cis rs2739330 0.828 rs5760107 ENSG00000273295.1 AP000350.5 23.05 3.39e-79 3.99e-74 0.86 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23901432~23907068:- LUSC cis rs9322193 0.923 rs7753812 ENSG00000231760.4 RP11-350J20.5 23.03 3.87e-79 4.5e-74 0.94 0.73 Lung cancer; chr6:149690150 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs12195866 ENSG00000231760.4 RP11-350J20.5 23.03 3.87e-79 4.5e-74 0.94 0.73 Lung cancer; chr6:149693334 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9285524 ENSG00000231760.4 RP11-350J20.5 23.03 3.87e-79 4.5e-74 0.94 0.73 Lung cancer; chr6:149694122 chr6:149796151~149826294:- LUSC cis rs2739330 0.789 rs5760109 ENSG00000273295.1 AP000350.5 23 5.38e-79 6.17e-74 0.86 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23901432~23907068:- LUSC cis rs9322193 0.923 rs12174035 ENSG00000231760.4 RP11-350J20.5 23 5.72e-79 6.53e-74 0.93 0.73 Lung cancer; chr6:149763311 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9505974 ENSG00000231760.4 RP11-350J20.5 22.98 6.72e-79 7.49e-74 0.93 0.73 Lung cancer; chr6:149779294 chr6:149796151~149826294:- LUSC cis rs9322193 0.926 rs9689036 ENSG00000231760.4 RP11-350J20.5 22.98 6.72e-79 7.49e-74 0.93 0.73 Lung cancer; chr6:149780563 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9322218 ENSG00000231760.4 RP11-350J20.5 22.98 6.72e-79 7.49e-74 0.93 0.73 Lung cancer; chr6:149782183 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9322219 ENSG00000231760.4 RP11-350J20.5 22.98 6.72e-79 7.49e-74 0.93 0.73 Lung cancer; chr6:149782263 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9322223 ENSG00000231760.4 RP11-350J20.5 22.98 6.72e-79 7.49e-74 0.93 0.73 Lung cancer; chr6:149801509 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs13215691 ENSG00000231760.4 RP11-350J20.5 22.98 7.1e-79 7.89e-74 0.93 0.73 Lung cancer; chr6:149792666 chr6:149796151~149826294:- LUSC cis rs2739330 0.828 rs2330635 ENSG00000273295.1 AP000350.5 22.97 7.39e-79 8.18e-74 0.86 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23901432~23907068:- LUSC cis rs9322193 0.962 rs9765929 ENSG00000231760.4 RP11-350J20.5 22.97 7.71e-79 8.42e-74 0.93 0.73 Lung cancer; chr6:149769680 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs3763163 ENSG00000231760.4 RP11-350J20.5 22.92 1.35e-78 1.46e-73 0.93 0.73 Lung cancer; chr6:149819770 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9478848 ENSG00000231760.4 RP11-350J20.5 22.91 1.55e-78 1.67e-73 0.94 0.73 Lung cancer; chr6:149825080 chr6:149796151~149826294:- LUSC cis rs2739330 0.828 rs4822454 ENSG00000273295.1 AP000350.5 22.89 1.93e-78 2.06e-73 0.86 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23901432~23907068:- LUSC cis rs9322193 0.962 rs9397022 ENSG00000231760.4 RP11-350J20.5 22.84 3.11e-78 3.27e-73 0.93 0.73 Lung cancer; chr6:149812052 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9397357 ENSG00000231760.4 RP11-350J20.5 22.84 3.11e-78 3.27e-73 0.93 0.73 Lung cancer; chr6:149812465 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs1889473 ENSG00000231760.4 RP11-350J20.5 22.81 4.5e-78 4.7e-73 0.94 0.72 Lung cancer; chr6:149825485 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs1984111 ENSG00000231760.4 RP11-350J20.5 22.81 4.5e-78 4.7e-73 0.94 0.72 Lung cancer; chr6:149831720 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs2342857 ENSG00000231760.4 RP11-350J20.5 22.77 6.66e-78 6.89e-73 0.93 0.72 Lung cancer; chr6:149809537 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs6899661 ENSG00000231760.4 RP11-350J20.5 22.77 6.85e-78 6.89e-73 0.93 0.72 Lung cancer; chr6:149818093 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9322220 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149782897 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs10214845 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149783124 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9767122 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149783553 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs1413654 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149783956 chr6:149796151~149826294:- LUSC cis rs9322193 0.683 rs113281309 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149787289 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9688809 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149787920 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9689242 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149787970 chr6:149796151~149826294:- LUSC cis rs9322193 1 rs9767077 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149788479 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9688938 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149788941 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9688940 ENSG00000231760.4 RP11-350J20.5 22.77 6.91e-78 6.89e-73 0.94 0.72 Lung cancer; chr6:149788977 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9688750 ENSG00000231760.4 RP11-350J20.5 22.75 8.03e-78 7.98e-73 0.93 0.72 Lung cancer; chr6:149657633 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9689447 ENSG00000231760.4 RP11-350J20.5 22.73 1.01e-77 1e-72 0.93 0.72 Lung cancer; chr6:149789350 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs17673294 ENSG00000231760.4 RP11-350J20.5 22.72 1.12e-77 1.1e-72 0.93 0.72 Lung cancer; chr6:149813857 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs6903998 ENSG00000231760.4 RP11-350J20.5 22.72 1.13e-77 1.11e-72 0.94 0.72 Lung cancer; chr6:149831357 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs3805753 ENSG00000231760.4 RP11-350J20.5 22.69 1.56e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149795662 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs11155683 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149779341 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9372044 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149780867 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs11155685 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149781649 chr6:149796151~149826294:- LUSC cis rs9322193 0.632 rs3828700 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149791033 chr6:149796151~149826294:- LUSC cis rs9322193 0.926 rs3805751 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149791193 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9689269 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149791861 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs62441335 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149792658 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs4816 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149793609 chr6:149796151~149826294:- LUSC cis rs9322193 0.926 rs952166 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149798774 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs952165 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149798900 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs10872656 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149799444 chr6:149796151~149826294:- LUSC cis rs9322193 0.926 rs9285525 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149801253 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs6914319 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149806304 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs2095375 ENSG00000231760.4 RP11-350J20.5 22.69 1.57e-77 1.46e-72 0.93 0.72 Lung cancer; chr6:149807037 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs4869730 ENSG00000231760.4 RP11-350J20.5 22.69 1.7e-77 1.56e-72 0.93 0.72 Lung cancer; chr6:149808187 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs11155689 ENSG00000231760.4 RP11-350J20.5 22.69 1.7e-77 1.56e-72 0.93 0.72 Lung cancer; chr6:149808470 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs2151913 ENSG00000231760.4 RP11-350J20.5 22.69 1.7e-77 1.56e-72 0.93 0.72 Lung cancer; chr6:149809506 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs933055 ENSG00000231760.4 RP11-350J20.5 22.69 1.7e-77 1.56e-72 0.93 0.72 Lung cancer; chr6:149809701 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs4869731 ENSG00000231760.4 RP11-350J20.5 22.69 1.7e-77 1.56e-72 0.93 0.72 Lung cancer; chr6:149810072 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9688412 ENSG00000231760.4 RP11-350J20.5 -22.68 1.77e-77 1.62e-72 -0.93 -0.72 Lung cancer; chr6:149803147 chr6:149796151~149826294:- LUSC cis rs3814244 0.528 rs12228471 ENSG00000255733.4 IFNG-AS1 22.67 1.93e-77 1.76e-72 0.66 0.72 Itch intensity from mosquito bite adjusted by bite size; chr12:68027842 chr12:67989445~68234686:+ LUSC cis rs9322193 0.884 rs2342858 ENSG00000231760.4 RP11-350J20.5 22.64 2.82e-77 2.54e-72 0.93 0.72 Lung cancer; chr6:149805967 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs1413655 ENSG00000231760.4 RP11-350J20.5 22.58 5.16e-77 4.59e-72 0.93 0.72 Lung cancer; chr6:149821815 chr6:149796151~149826294:- LUSC cis rs9322193 0.926 rs9383546 ENSG00000231760.4 RP11-350J20.5 22.58 5.16e-77 4.59e-72 0.93 0.72 Lung cancer; chr6:149822743 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs4552 ENSG00000231760.4 RP11-350J20.5 22.58 5.21e-77 4.62e-72 0.93 0.72 Lung cancer; chr6:149811183 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9322206 ENSG00000231760.4 RP11-350J20.5 22.58 5.35e-77 4.73e-72 0.92 0.72 Lung cancer; chr6:149641481 chr6:149796151~149826294:- LUSC cis rs9322193 0.736 rs3828701 ENSG00000231760.4 RP11-350J20.5 22.54 8.06e-77 6.98e-72 0.93 0.72 Lung cancer; chr6:149791063 chr6:149796151~149826294:- LUSC cis rs9322193 0.736 rs3805750 ENSG00000231760.4 RP11-350J20.5 22.54 8.06e-77 6.98e-72 0.93 0.72 Lung cancer; chr6:149791065 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs2151912 ENSG00000231760.4 RP11-350J20.5 22.46 1.89e-76 1.6e-71 0.94 0.72 Lung cancer; chr6:149831772 chr6:149796151~149826294:- LUSC cis rs62445005 1 rs62445005 ENSG00000211697.3 TRGV5 22.46 2.04e-76 1.72e-71 0.87 0.72 Shingles; chr7:38346957 chr7:38343894~38350022:- LUSC cis rs9322193 0.923 rs14314 ENSG00000231760.4 RP11-350J20.5 22.45 2.09e-76 1.76e-71 0.93 0.72 Lung cancer; chr6:149820395 chr6:149796151~149826294:- LUSC cis rs2882667 0.69 rs176382 ENSG00000253404.1 AC034243.1 22.45 2.24e-76 1.88e-71 0.91 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138891078 chr5:138744434~138753309:- LUSC cis rs3814244 0.528 rs2870960 ENSG00000255733.4 IFNG-AS1 22.43 2.6e-76 2.16e-71 0.66 0.72 Itch intensity from mosquito bite adjusted by bite size; chr12:68032848 chr12:67989445~68234686:+ LUSC cis rs9322193 0.923 rs12175504 ENSG00000231760.4 RP11-350J20.5 22.4 3.79e-76 3.09e-71 0.93 0.72 Lung cancer; chr6:149664079 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs62439843 ENSG00000231760.4 RP11-350J20.5 22.4 3.79e-76 3.09e-71 0.93 0.72 Lung cancer; chr6:149676521 chr6:149796151~149826294:- LUSC cis rs858239 0.6 rs7787110 ENSG00000230658.1 KLHL7-AS1 22.37 4.97e-76 4e-71 0.92 0.72 Cerebrospinal fluid biomarker levels; chr7:23098855 chr7:23101228~23105703:- LUSC cis rs3814244 0.528 rs56393928 ENSG00000255733.4 IFNG-AS1 22.35 6.15e-76 4.92e-71 0.66 0.72 Itch intensity from mosquito bite adjusted by bite size; chr12:68029927 chr12:67989445~68234686:+ LUSC cis rs9322193 0.962 rs7745915 ENSG00000231760.4 RP11-350J20.5 22.35 6.61e-76 5.27e-71 0.93 0.72 Lung cancer; chr6:149834111 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs3763162 ENSG00000231760.4 RP11-350J20.5 -22.32 9.27e-76 7.36e-71 -0.92 -0.72 Lung cancer; chr6:149819674 chr6:149796151~149826294:- LUSC cis rs9322193 0.926 rs9766562 ENSG00000231760.4 RP11-350J20.5 22.3 1.13e-75 8.95e-71 0.93 0.72 Lung cancer; chr6:149788709 chr6:149796151~149826294:- LUSC cis rs9326248 0.817 rs6589598 ENSG00000254851.1 RP11-109L13.1 -22.27 1.53e-75 1.21e-70 -1.05 -0.72 Blood protein levels; chr11:117131687 chr11:117135528~117138582:+ LUSC cis rs3814244 0.528 rs17104682 ENSG00000255733.4 IFNG-AS1 -22.26 1.68e-75 1.32e-70 -0.65 -0.72 Itch intensity from mosquito bite adjusted by bite size; chr12:68033256 chr12:67989445~68234686:+ LUSC cis rs858239 0.6 rs1115941 ENSG00000230658.1 KLHL7-AS1 22.23 2.45e-75 1.91e-70 0.92 0.72 Cerebrospinal fluid biomarker levels; chr7:23097569 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs2014768 ENSG00000230658.1 KLHL7-AS1 22.21 3.03e-75 2.35e-70 0.92 0.72 Cerebrospinal fluid biomarker levels; chr7:23082821 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs7790157 ENSG00000230658.1 KLHL7-AS1 22.21 3.03e-75 2.35e-70 0.92 0.72 Cerebrospinal fluid biomarker levels; chr7:23087379 chr7:23101228~23105703:- LUSC cis rs3814244 0.569 rs2051993 ENSG00000255733.4 IFNG-AS1 22.18 4.02e-75 3.11e-70 0.66 0.72 Itch intensity from mosquito bite adjusted by bite size; chr12:68019898 chr12:67989445~68234686:+ LUSC cis rs858239 0.6 rs6960001 ENSG00000230658.1 KLHL7-AS1 22.15 5.71e-75 4.35e-70 0.92 0.71 Cerebrospinal fluid biomarker levels; chr7:23091257 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs10237755 ENSG00000230658.1 KLHL7-AS1 22.15 5.71e-75 4.35e-70 0.92 0.71 Cerebrospinal fluid biomarker levels; chr7:23091945 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs6961131 ENSG00000230658.1 KLHL7-AS1 22.15 5.71e-75 4.35e-70 0.92 0.71 Cerebrospinal fluid biomarker levels; chr7:23095171 chr7:23101228~23105703:- LUSC cis rs9322193 0.962 rs35443312 ENSG00000231760.4 RP11-350J20.5 22.14 6.12e-75 4.65e-70 0.92 0.71 Lung cancer; chr6:149670625 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9322197 ENSG00000231760.4 RP11-350J20.5 22.12 7.97e-75 6.04e-70 0.91 0.71 Lung cancer; chr6:149622577 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs2275046 ENSG00000231760.4 RP11-350J20.5 22.11 8.6e-75 6.51e-70 0.93 0.71 Lung cancer; chr6:149835865 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs9688858 ENSG00000231760.4 RP11-350J20.5 22.11 9.09e-75 6.86e-70 0.91 0.71 Lung cancer; chr6:149637911 chr6:149796151~149826294:- LUSC cis rs858239 0.6 rs13438188 ENSG00000230658.1 KLHL7-AS1 -22.07 1.39e-74 1.04e-69 -0.89 -0.71 Cerebrospinal fluid biomarker levels; chr7:23104578 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs10256361 ENSG00000230658.1 KLHL7-AS1 22.06 1.58e-74 1.18e-69 0.92 0.71 Cerebrospinal fluid biomarker levels; chr7:23084266 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs6978827 ENSG00000230658.1 KLHL7-AS1 22.05 1.72e-74 1.28e-69 0.91 0.71 Cerebrospinal fluid biomarker levels; chr7:23085925 chr7:23101228~23105703:- LUSC cis rs9322193 0.962 rs35031906 ENSG00000231760.4 RP11-350J20.5 21.97 4.01e-74 2.97e-69 0.92 0.71 Lung cancer; chr6:149677438 chr6:149796151~149826294:- LUSC cis rs3814244 0.569 rs11177008 ENSG00000255733.4 IFNG-AS1 21.93 6.15e-74 4.53e-69 0.66 0.71 Itch intensity from mosquito bite adjusted by bite size; chr12:68021024 chr12:67989445~68234686:+ LUSC cis rs858239 0.6 rs2072368 ENSG00000230658.1 KLHL7-AS1 21.91 7.45e-74 5.44e-69 0.91 0.71 Cerebrospinal fluid biomarker levels; chr7:23106493 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs10256524 ENSG00000230658.1 KLHL7-AS1 21.84 1.61e-73 1.17e-68 0.91 0.71 Cerebrospinal fluid biomarker levels; chr7:23105328 chr7:23101228~23105703:- LUSC cis rs9322193 0.962 rs4870048 ENSG00000231760.4 RP11-350J20.5 21.8 2.43e-73 1.75e-68 0.91 0.71 Lung cancer; chr6:149834324 chr6:149796151~149826294:- LUSC cis rs858239 0.6 rs28646184 ENSG00000230658.1 KLHL7-AS1 21.67 1.08e-72 7.62e-68 0.92 0.71 Cerebrospinal fluid biomarker levels; chr7:23099976 chr7:23101228~23105703:- LUSC cis rs3814244 0.528 rs7306466 ENSG00000255733.4 IFNG-AS1 21.6 2.3e-72 1.62e-67 0.64 0.71 Itch intensity from mosquito bite adjusted by bite size; chr12:68014942 chr12:67989445~68234686:+ LUSC cis rs858239 0.601 rs6980224 ENSG00000230658.1 KLHL7-AS1 21.58 2.82e-72 1.98e-67 0.91 0.71 Cerebrospinal fluid biomarker levels; chr7:23109518 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs4321896 ENSG00000230658.1 KLHL7-AS1 21.47 9.25e-72 6.47e-67 0.91 0.7 Cerebrospinal fluid biomarker levels; chr7:23088437 chr7:23101228~23105703:- LUSC cis rs9322193 0.923 rs12660304 ENSG00000231760.4 RP11-350J20.5 21.47 9.34e-72 6.52e-67 0.9 0.7 Lung cancer; chr6:149739647 chr6:149796151~149826294:- LUSC cis rs858239 0.601 rs987257 ENSG00000230658.1 KLHL7-AS1 21.45 1.17e-71 8.09e-67 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23108221 chr7:23101228~23105703:- LUSC cis rs858239 0.57 rs10235467 ENSG00000230658.1 KLHL7-AS1 21.45 1.18e-71 8.18e-67 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23109189 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs61292332 ENSG00000230658.1 KLHL7-AS1 21.44 1.2e-71 8.25e-67 0.91 0.7 Cerebrospinal fluid biomarker levels; chr7:23092243 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs59073109 ENSG00000230658.1 KLHL7-AS1 21.44 1.2e-71 8.25e-67 0.91 0.7 Cerebrospinal fluid biomarker levels; chr7:23093607 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs7788821 ENSG00000230658.1 KLHL7-AS1 21.44 1.2e-71 8.25e-67 0.91 0.7 Cerebrospinal fluid biomarker levels; chr7:23094026 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs6956595 ENSG00000230658.1 KLHL7-AS1 21.44 1.2e-71 8.25e-67 0.91 0.7 Cerebrospinal fluid biomarker levels; chr7:23094637 chr7:23101228~23105703:- LUSC cis rs2739330 0.734 rs2000467 ENSG00000273295.1 AP000350.5 -21.41 1.81e-71 1.24e-66 -0.84 -0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23901432~23907068:- LUSC cis rs858239 0.6 rs13438179 ENSG00000230658.1 KLHL7-AS1 21.38 2.37e-71 1.62e-66 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23104232 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs1034963 ENSG00000230658.1 KLHL7-AS1 21.36 3.05e-71 2.08e-66 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23108854 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs10235786 ENSG00000230658.1 KLHL7-AS1 21.34 3.81e-71 2.59e-66 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23100321 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs7785842 ENSG00000230658.1 KLHL7-AS1 21.31 5.49e-71 3.7e-66 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23102087 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs7456915 ENSG00000230658.1 KLHL7-AS1 21.31 5.49e-71 3.7e-66 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23103430 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs10233039 ENSG00000230658.1 KLHL7-AS1 21.3 5.81e-71 3.91e-66 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23103494 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs10266123 ENSG00000230658.1 KLHL7-AS1 21.3 5.92e-71 3.98e-66 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23096868 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs7805206 ENSG00000230658.1 KLHL7-AS1 21.28 7.57e-71 5.07e-66 0.86 0.7 Cerebrospinal fluid biomarker levels; chr7:23120591 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs1468592 ENSG00000230658.1 KLHL7-AS1 -21.27 8.02e-71 5.36e-66 -0.9 -0.7 Cerebrospinal fluid biomarker levels; chr7:23101028 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs7341483 ENSG00000230658.1 KLHL7-AS1 -21.23 1.22e-70 8.12e-66 -0.89 -0.7 Cerebrospinal fluid biomarker levels; chr7:23088038 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs2072369 ENSG00000230658.1 KLHL7-AS1 21.18 2.07e-70 1.38e-65 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23106570 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs6461692 ENSG00000230658.1 KLHL7-AS1 21.16 2.65e-70 1.75e-65 0.91 0.7 Cerebrospinal fluid biomarker levels; chr7:23100076 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs1558313 ENSG00000230658.1 KLHL7-AS1 21.13 3.63e-70 2.39e-65 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23116460 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs6962526 ENSG00000230658.1 KLHL7-AS1 21.13 3.63e-70 2.39e-65 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23118614 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs6971673 ENSG00000230658.1 KLHL7-AS1 21.13 3.63e-70 2.39e-65 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23119904 chr7:23101228~23105703:- LUSC cis rs2882667 0.69 rs825669 ENSG00000253404.1 AC034243.1 -21.11 4.37e-70 2.87e-65 -0.89 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138731258 chr5:138744434~138753309:- LUSC cis rs858239 0.601 rs10278700 ENSG00000230658.1 KLHL7-AS1 21.11 4.57e-70 3e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23120910 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs10263110 ENSG00000230658.1 KLHL7-AS1 21.11 4.57e-70 3e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23120932 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs2003555 ENSG00000230658.1 KLHL7-AS1 21.09 5.57e-70 3.63e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23083296 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs7784929 ENSG00000230658.1 KLHL7-AS1 21.09 5.57e-70 3.63e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23084658 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs7799422 ENSG00000230658.1 KLHL7-AS1 21.07 7.17e-70 4.65e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23088794 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs11982002 ENSG00000230658.1 KLHL7-AS1 21.06 7.69e-70 4.98e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23123651 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs28483572 ENSG00000230658.1 KLHL7-AS1 21.04 9.41e-70 6.03e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23092166 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs6961406 ENSG00000230658.1 KLHL7-AS1 21.04 9.41e-70 6.03e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23095272 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs6461690 ENSG00000230658.1 KLHL7-AS1 21.04 9.41e-70 6.03e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23095915 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs6967419 ENSG00000230658.1 KLHL7-AS1 21.04 9.41e-70 6.03e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23096691 chr7:23101228~23105703:- LUSC cis rs2882667 0.69 rs9942422 ENSG00000253404.1 AC034243.1 21.04 1.03e-69 6.56e-65 0.93 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138936847 chr5:138744434~138753309:- LUSC cis rs858239 0.601 rs73272048 ENSG00000230658.1 KLHL7-AS1 21 1.47e-69 9.38e-65 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23113034 chr7:23101228~23105703:- LUSC cis rs2882667 0.69 rs160405 ENSG00000253404.1 AC034243.1 20.99 1.6e-69 1.01e-64 0.92 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138748387 chr5:138744434~138753309:- LUSC cis rs858239 0.601 rs10255228 ENSG00000230658.1 KLHL7-AS1 20.99 1.76e-69 1.11e-64 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23119244 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs6461691 ENSG00000230658.1 KLHL7-AS1 20.98 1.8e-69 1.14e-64 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23099726 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs10256359 ENSG00000230658.1 KLHL7-AS1 20.95 2.68e-69 1.69e-64 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23084258 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs10488077 ENSG00000230658.1 KLHL7-AS1 20.94 2.79e-69 1.76e-64 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23104563 chr7:23101228~23105703:- LUSC cis rs2739330 0.652 rs2000469 ENSG00000273295.1 AP000350.5 20.94 2.87e-69 1.8e-64 0.85 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23901432~23907068:- LUSC cis rs1577917 0.654 rs9450284 ENSG00000203875.9 SNHG5 20.93 3.39e-69 2.11e-64 0.87 0.69 Response to antipsychotic treatment; chr6:85489611 chr6:85660950~85678736:- LUSC cis rs858239 0.6 rs10241208 ENSG00000230658.1 KLHL7-AS1 20.92 3.43e-69 2.14e-64 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23105295 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs15775 ENSG00000230658.1 KLHL7-AS1 20.91 4.02e-69 2.5e-64 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23125082 chr7:23101228~23105703:- LUSC cis rs2882667 0.69 rs160401 ENSG00000253404.1 AC034243.1 -20.9 4.4e-69 2.72e-64 -0.91 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138725652 chr5:138744434~138753309:- LUSC cis rs9322193 1 rs9377229 ENSG00000231760.4 RP11-350J20.5 20.89 5.04e-69 3.12e-64 0.89 0.69 Lung cancer; chr6:149607655 chr6:149796151~149826294:- LUSC cis rs858239 0.57 rs10271613 ENSG00000230658.1 KLHL7-AS1 20.87 5.92e-69 3.65e-64 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23122967 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs7776649 ENSG00000230658.1 KLHL7-AS1 20.85 7.61e-69 4.67e-64 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23079698 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs4628176 ENSG00000230658.1 KLHL7-AS1 20.85 7.72e-69 4.73e-64 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23102947 chr7:23101228~23105703:- LUSC cis rs858239 0.57 rs10242166 ENSG00000230658.1 KLHL7-AS1 20.84 8.72e-69 5.32e-64 0.88 0.69 Cerebrospinal fluid biomarker levels; chr7:23123180 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs9691762 ENSG00000230658.1 KLHL7-AS1 20.83 9.08e-69 5.53e-64 0.88 0.69 Cerebrospinal fluid biomarker levels; chr7:23086303 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs6971002 ENSG00000230658.1 KLHL7-AS1 20.81 1.21e-68 7.34e-64 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23132685 chr7:23101228~23105703:- LUSC cis rs9322193 0.886 rs4039600 ENSG00000231760.4 RP11-350J20.5 20.75 2.39e-68 1.45e-63 0.89 0.69 Lung cancer; chr6:149576319 chr6:149796151~149826294:- LUSC cis rs9322193 1 rs9322193 ENSG00000231760.4 RP11-350J20.5 20.72 3.14e-68 1.9e-63 0.88 0.69 Lung cancer; chr6:149598007 chr6:149796151~149826294:- LUSC cis rs9322193 0.961 rs9027 ENSG00000231760.4 RP11-350J20.5 20.72 3.16e-68 1.9e-63 0.88 0.69 Lung cancer; chr6:149594921 chr6:149796151~149826294:- LUSC cis rs2739330 0.892 rs5751776 ENSG00000218537.1 MIF-AS1 20.7 3.81e-68 2.29e-63 0.92 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23894426~23898930:- LUSC cis rs3814244 0.528 rs61923060 ENSG00000255733.4 IFNG-AS1 20.67 5.28e-68 3.15e-63 0.62 0.69 Itch intensity from mosquito bite adjusted by bite size; chr12:67997341 chr12:67989445~68234686:+ LUSC cis rs858239 0.541 rs4624924 ENSG00000230658.1 KLHL7-AS1 20.67 5.54e-68 3.3e-63 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23129224 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs6948469 ENSG00000230658.1 KLHL7-AS1 20.63 8.08e-68 4.81e-63 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23135147 chr7:23101228~23105703:- LUSC cis rs4853012 0.838 rs2177707 ENSG00000217702.2 RP11-287D1.4 20.62 9.18e-68 5.4e-63 1.13 0.69 Gestational age at birth (maternal effect); chr2:74129723 chr2:74130583~74135395:+ LUSC cis rs858239 0.601 rs4140959 ENSG00000230658.1 KLHL7-AS1 20.6 1.13e-67 6.62e-63 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23131157 chr7:23101228~23105703:- LUSC cis rs2882667 0.69 rs9327829 ENSG00000253404.1 AC034243.1 -20.58 1.5e-67 8.73e-63 -0.89 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138925982 chr5:138744434~138753309:- LUSC cis rs4853012 0.838 rs72915068 ENSG00000217702.2 RP11-287D1.4 20.54 2.3e-67 1.33e-62 1.11 0.69 Gestational age at birth (maternal effect); chr2:74129058 chr2:74130583~74135395:+ LUSC cis rs858239 0.601 rs4599714 ENSG00000230658.1 KLHL7-AS1 20.53 2.6e-67 1.5e-62 0.88 0.69 Cerebrospinal fluid biomarker levels; chr7:23129182 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs10278776 ENSG00000230658.1 KLHL7-AS1 20.53 2.6e-67 1.5e-62 0.88 0.69 Cerebrospinal fluid biomarker levels; chr7:23130140 chr7:23101228~23105703:- LUSC cis rs3814244 0.528 rs12582272 ENSG00000255733.4 IFNG-AS1 20.5 3.39e-67 1.94e-62 0.62 0.69 Itch intensity from mosquito bite adjusted by bite size; chr12:68006298 chr12:67989445~68234686:+ LUSC cis rs858239 0.632 rs13438452 ENSG00000230658.1 KLHL7-AS1 20.5 3.59e-67 2.05e-62 0.88 0.69 Cerebrospinal fluid biomarker levels; chr7:23134563 chr7:23101228~23105703:- LUSC cis rs3814244 0.528 rs2906854 ENSG00000255733.4 IFNG-AS1 -20.46 5.53e-67 3.14e-62 -0.61 -0.69 Itch intensity from mosquito bite adjusted by bite size; chr12:67993566 chr12:67989445~68234686:+ LUSC cis rs3814244 0.528 rs1468487 ENSG00000255733.4 IFNG-AS1 -20.45 6.1e-67 3.45e-62 -0.61 -0.69 Itch intensity from mosquito bite adjusted by bite size; chr12:67996602 chr12:67989445~68234686:+ LUSC cis rs3814244 0.528 rs2860609 ENSG00000255733.4 IFNG-AS1 -20.45 6.1e-67 3.45e-62 -0.61 -0.69 Itch intensity from mosquito bite adjusted by bite size; chr12:67997215 chr12:67989445~68234686:+ LUSC cis rs858239 0.601 rs3735228 ENSG00000230658.1 KLHL7-AS1 20.44 6.61e-67 3.74e-62 0.88 0.69 Cerebrospinal fluid biomarker levels; chr7:23130808 chr7:23101228~23105703:- LUSC cis rs9322193 0.884 rs7450246 ENSG00000231760.4 RP11-350J20.5 20.42 8.02e-67 4.53e-62 0.89 0.69 Lung cancer; chr6:149702517 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs4354168 ENSG00000231760.4 RP11-350J20.5 20.41 9e-67 5.05e-62 0.89 0.69 Lung cancer; chr6:149696642 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs4455682 ENSG00000231760.4 RP11-350J20.5 20.41 9e-67 5.05e-62 0.89 0.69 Lung cancer; chr6:149700161 chr6:149796151~149826294:- LUSC cis rs3814244 0.528 rs11177002 ENSG00000255733.4 IFNG-AS1 20.4 1.03e-66 5.76e-62 0.61 0.69 Itch intensity from mosquito bite adjusted by bite size; chr12:68003377 chr12:67989445~68234686:+ LUSC cis rs3814244 0.528 rs10878723 ENSG00000255733.4 IFNG-AS1 20.4 1.03e-66 5.76e-62 0.61 0.69 Itch intensity from mosquito bite adjusted by bite size; chr12:68005493 chr12:67989445~68234686:+ LUSC cis rs9322193 0.923 rs2342765 ENSG00000231760.4 RP11-350J20.5 20.38 1.21e-66 6.75e-62 0.86 0.68 Lung cancer; chr6:149858873 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10782315 ENSG00000231760.4 RP11-350J20.5 20.38 1.24e-66 6.86e-62 0.89 0.68 Lung cancer; chr6:149743093 chr6:149796151~149826294:- LUSC cis rs858239 0.601 rs929507 ENSG00000230658.1 KLHL7-AS1 20.36 1.49e-66 8.21e-62 0.88 0.68 Cerebrospinal fluid biomarker levels; chr7:23127045 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs929508 ENSG00000230658.1 KLHL7-AS1 20.36 1.49e-66 8.21e-62 0.88 0.68 Cerebrospinal fluid biomarker levels; chr7:23127090 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs11984129 ENSG00000230658.1 KLHL7-AS1 20.35 1.77e-66 9.73e-62 0.88 0.68 Cerebrospinal fluid biomarker levels; chr7:23113058 chr7:23101228~23105703:- LUSC cis rs858239 0.57 rs6968242 ENSG00000230658.1 KLHL7-AS1 20.34 1.93e-66 1.06e-61 0.87 0.68 Cerebrospinal fluid biomarker levels; chr7:23127792 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs1981665 ENSG00000230658.1 KLHL7-AS1 20.34 1.93e-66 1.06e-61 0.87 0.68 Cerebrospinal fluid biomarker levels; chr7:23128350 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs764533 ENSG00000230658.1 KLHL7-AS1 20.34 1.99e-66 1.09e-61 0.88 0.68 Cerebrospinal fluid biomarker levels; chr7:23114256 chr7:23101228~23105703:- LUSC cis rs3814244 0.528 rs7952790 ENSG00000255733.4 IFNG-AS1 20.34 2e-66 1.09e-61 0.62 0.68 Itch intensity from mosquito bite adjusted by bite size; chr12:68012672 chr12:67989445~68234686:+ LUSC cis rs9322193 0.923 rs56397000 ENSG00000231760.4 RP11-350J20.5 20.33 2.07e-66 1.13e-61 0.89 0.68 Lung cancer; chr6:149739347 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs9689702 ENSG00000231760.4 RP11-350J20.5 20.33 2.07e-66 1.13e-61 0.89 0.68 Lung cancer; chr6:149740720 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10782316 ENSG00000231760.4 RP11-350J20.5 20.31 2.69e-66 1.45e-61 0.88 0.68 Lung cancer; chr6:149752755 chr6:149796151~149826294:- LUSC cis rs2739330 0.796 rs1006771 ENSG00000273295.1 AP000350.5 20.31 2.71e-66 1.46e-61 0.84 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23901432~23907068:- LUSC cis rs9322193 0.923 rs1934534 ENSG00000231760.4 RP11-350J20.5 20.3 3.02e-66 1.63e-61 0.88 0.68 Lung cancer; chr6:149711896 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs62441284 ENSG00000231760.4 RP11-350J20.5 20.29 3.2e-66 1.72e-61 0.88 0.68 Lung cancer; chr6:149751542 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9689599 ENSG00000231760.4 RP11-350J20.5 20.28 3.6e-66 1.93e-61 0.88 0.68 Lung cancer; chr6:149631973 chr6:149796151~149826294:- LUSC cis rs9322193 0.847 rs62439808 ENSG00000231760.4 RP11-350J20.5 20.28 3.66e-66 1.95e-61 0.88 0.68 Lung cancer; chr6:149629690 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9322200 ENSG00000231760.4 RP11-350J20.5 20.28 3.66e-66 1.95e-61 0.88 0.68 Lung cancer; chr6:149630078 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs4870529 ENSG00000231760.4 RP11-350J20.5 20.27 4.06e-66 2.16e-61 0.88 0.68 Lung cancer; chr6:149716436 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9767309 ENSG00000231760.4 RP11-350J20.5 20.27 4.06e-66 2.16e-61 0.88 0.68 Lung cancer; chr6:149716807 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10747276 ENSG00000231760.4 RP11-350J20.5 20.26 4.59e-66 2.44e-61 0.89 0.68 Lung cancer; chr6:149758739 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs4870267 ENSG00000231760.4 RP11-350J20.5 20.25 4.92e-66 2.61e-61 0.88 0.68 Lung cancer; chr6:149671572 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs1572229 ENSG00000231760.4 RP11-350J20.5 20.24 5.71e-66 3e-61 0.88 0.68 Lung cancer; chr6:149743841 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs10872646 ENSG00000231760.4 RP11-350J20.5 20.24 5.71e-66 3e-61 0.88 0.68 Lung cancer; chr6:149746539 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs12528279 ENSG00000231760.4 RP11-350J20.5 20.24 5.71e-66 3e-61 0.88 0.68 Lung cancer; chr6:149750892 chr6:149796151~149826294:- LUSC cis rs9322193 0.809 rs9479808 ENSG00000231760.4 RP11-350J20.5 20.24 5.71e-66 3e-61 0.88 0.68 Lung cancer; chr6:149751328 chr6:149796151~149826294:- LUSC cis rs1577917 0.629 rs7761762 ENSG00000203875.9 SNHG5 20.23 6.2e-66 3.26e-61 0.86 0.68 Response to antipsychotic treatment; chr6:85496250 chr6:85660950~85678736:- LUSC cis rs4853012 0.887 rs2280642 ENSG00000217702.2 RP11-287D1.4 20.23 6.37e-66 3.34e-61 1.13 0.68 Gestational age at birth (maternal effect); chr2:74131125 chr2:74130583~74135395:+ LUSC cis rs9322193 0.923 rs9800736 ENSG00000231760.4 RP11-350J20.5 20.23 6.44e-66 3.37e-61 0.89 0.68 Lung cancer; chr6:149661281 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9383812 ENSG00000231760.4 RP11-350J20.5 20.23 6.56e-66 3.43e-61 0.88 0.68 Lung cancer; chr6:149712355 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9767123 ENSG00000231760.4 RP11-350J20.5 20.21 7.58e-66 3.94e-61 0.89 0.68 Lung cancer; chr6:149660323 chr6:149796151~149826294:- LUSC cis rs858239 0.6 rs7776644 ENSG00000230658.1 KLHL7-AS1 20.21 7.87e-66 4.09e-61 0.88 0.68 Cerebrospinal fluid biomarker levels; chr7:23079688 chr7:23101228~23105703:- LUSC cis rs9322193 0.847 rs12234128 ENSG00000231760.4 RP11-350J20.5 20.2 8.61e-66 4.45e-61 0.87 0.68 Lung cancer; chr6:149627553 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs57012784 ENSG00000231760.4 RP11-350J20.5 20.2 8.61e-66 4.45e-61 0.87 0.68 Lung cancer; chr6:149627691 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10872649 ENSG00000231760.4 RP11-350J20.5 20.2 8.9e-66 4.58e-61 0.88 0.68 Lung cancer; chr6:149759454 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10872650 ENSG00000231760.4 RP11-350J20.5 20.2 8.9e-66 4.58e-61 0.88 0.68 Lung cancer; chr6:149760959 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9479494 ENSG00000231760.4 RP11-350J20.5 20.19 9.47e-66 4.85e-61 0.88 0.68 Lung cancer; chr6:149739108 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9800806 ENSG00000231760.4 RP11-350J20.5 20.19 9.47e-66 4.85e-61 0.88 0.68 Lung cancer; chr6:149740350 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9688517 ENSG00000231760.4 RP11-350J20.5 20.19 9.47e-66 4.85e-61 0.88 0.68 Lung cancer; chr6:149740655 chr6:149796151~149826294:- LUSC cis rs4853012 0.838 rs12619982 ENSG00000217702.2 RP11-287D1.4 20.19 1.03e-65 5.25e-61 1.13 0.68 Gestational age at birth (maternal effect); chr2:74128895 chr2:74130583~74135395:+ LUSC cis rs9322193 0.923 rs11155674 ENSG00000231760.4 RP11-350J20.5 20.18 1.06e-65 5.37e-61 0.88 0.68 Lung cancer; chr6:149711111 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs9322210 ENSG00000231760.4 RP11-350J20.5 20.17 1.17e-65 5.89e-61 0.88 0.68 Lung cancer; chr6:149695440 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs7767622 ENSG00000231760.4 RP11-350J20.5 20.17 1.19e-65 5.95e-61 0.88 0.68 Lung cancer; chr6:149681766 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs3798761 ENSG00000231760.4 RP11-350J20.5 20.17 1.19e-65 5.95e-61 0.88 0.68 Lung cancer; chr6:149683643 chr6:149796151~149826294:- LUSC cis rs9326248 0.813 rs588534 ENSG00000254851.1 RP11-109L13.1 -20.17 1.2e-65 6.03e-61 -0.99 -0.68 Blood protein levels; chr11:117197788 chr11:117135528~117138582:+ LUSC cis rs9326248 0.813 rs474488 ENSG00000254851.1 RP11-109L13.1 -20.17 1.29e-65 6.43e-61 -1 -0.68 Blood protein levels; chr11:117198261 chr11:117135528~117138582:+ LUSC cis rs9322193 0.923 rs4421206 ENSG00000231760.4 RP11-350J20.5 20.14 1.74e-65 8.66e-61 0.88 0.68 Lung cancer; chr6:149682891 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9478291 ENSG00000231760.4 RP11-350J20.5 20.13 1.91e-65 9.52e-61 0.88 0.68 Lung cancer; chr6:149729434 chr6:149796151~149826294:- LUSC cis rs2882667 0.69 rs288028 ENSG00000253404.1 AC034243.1 20.12 2.08e-65 1.03e-60 0.91 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138886300 chr5:138744434~138753309:- LUSC cis rs9322193 0.923 rs11155677 ENSG00000231760.4 RP11-350J20.5 20.12 2.13e-65 1.06e-60 0.88 0.68 Lung cancer; chr6:149756953 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs9480009 ENSG00000231760.4 RP11-350J20.5 20.12 2.13e-65 1.06e-60 0.88 0.68 Lung cancer; chr6:149758502 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9322214 ENSG00000231760.4 RP11-350J20.5 20.11 2.38e-65 1.17e-60 0.89 0.68 Lung cancer; chr6:149703986 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9480031 ENSG00000231760.4 RP11-350J20.5 20.1 2.7e-65 1.33e-60 0.88 0.68 Lung cancer; chr6:149758875 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs17745062 ENSG00000231760.4 RP11-350J20.5 20.09 2.79e-65 1.37e-60 0.88 0.68 Lung cancer; chr6:149721079 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs62441279 ENSG00000231760.4 RP11-350J20.5 20.09 2.79e-65 1.37e-60 0.88 0.68 Lung cancer; chr6:149721194 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs11155670 ENSG00000231760.4 RP11-350J20.5 20.09 2.87e-65 1.41e-60 0.88 0.68 Lung cancer; chr6:149644992 chr6:149796151~149826294:- LUSC cis rs3814244 0.528 rs7962511 ENSG00000255733.4 IFNG-AS1 20.09 2.87e-65 1.41e-60 0.6 0.68 Itch intensity from mosquito bite adjusted by bite size; chr12:68002854 chr12:67989445~68234686:+ LUSC cis rs9322193 0.923 rs4870509 ENSG00000231760.4 RP11-350J20.5 20.09 3.05e-65 1.49e-60 0.89 0.68 Lung cancer; chr6:149702212 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9322196 ENSG00000231760.4 RP11-350J20.5 20.08 3.16e-65 1.54e-60 0.87 0.68 Lung cancer; chr6:149619645 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9766037 ENSG00000231760.4 RP11-350J20.5 20.08 3.21e-65 1.56e-60 0.86 0.68 Lung cancer; chr6:149616921 chr6:149796151~149826294:- LUSC cis rs8013143 1 rs8013143 ENSG00000279656.1 RP11-298I3.6 -20.08 3.36e-65 1.63e-60 -0.89 -0.68 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23025068 chr14:23023083~23024217:- LUSC cis rs9322193 0.923 rs9505823 ENSG00000231760.4 RP11-350J20.5 20.08 3.38e-65 1.64e-60 0.87 0.68 Lung cancer; chr6:149628899 chr6:149796151~149826294:- LUSC cis rs858239 0.539 rs870476 ENSG00000230658.1 KLHL7-AS1 20.07 3.47e-65 1.68e-60 0.86 0.68 Cerebrospinal fluid biomarker levels; chr7:23153652 chr7:23101228~23105703:- LUSC cis rs9322193 0.923 rs10872651 ENSG00000231760.4 RP11-350J20.5 20.07 3.58e-65 1.73e-60 0.89 0.68 Lung cancer; chr6:149768273 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs2297930 ENSG00000231760.4 RP11-350J20.5 20.07 3.64e-65 1.76e-60 0.87 0.68 Lung cancer; chr6:149718360 chr6:149796151~149826294:- LUSC cis rs858239 0.6 rs4409314 ENSG00000230658.1 KLHL7-AS1 20.07 3.76e-65 1.81e-60 0.87 0.68 Cerebrospinal fluid biomarker levels; chr7:23088333 chr7:23101228~23105703:- LUSC cis rs9322193 0.923 rs9322209 ENSG00000231760.4 RP11-350J20.5 20.06 3.85e-65 1.85e-60 0.89 0.68 Lung cancer; chr6:149691226 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9689723 ENSG00000231760.4 RP11-350J20.5 20.06 4.13e-65 1.99e-60 0.88 0.68 Lung cancer; chr6:149655935 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs4380763 ENSG00000231760.4 RP11-350J20.5 20.04 4.83e-65 2.31e-60 0.89 0.68 Lung cancer; chr6:149678086 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs2185352 ENSG00000231760.4 RP11-350J20.5 20.03 5.33e-65 2.53e-60 0.87 0.68 Lung cancer; chr6:149714640 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs12174349 ENSG00000231760.4 RP11-350J20.5 20.03 5.33e-65 2.53e-60 0.87 0.68 Lung cancer; chr6:149718012 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs2297932 ENSG00000231760.4 RP11-350J20.5 20.03 5.33e-65 2.53e-60 0.87 0.68 Lung cancer; chr6:149718225 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs3924871 ENSG00000231760.4 RP11-350J20.5 20.03 5.61e-65 2.65e-60 0.88 0.68 Lung cancer; chr6:149662080 chr6:149796151~149826294:- LUSC cis rs9322193 0.887 rs9767113 ENSG00000231760.4 RP11-350J20.5 20.03 5.65e-65 2.67e-60 0.88 0.68 Lung cancer; chr6:149718157 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs12174716 ENSG00000231760.4 RP11-350J20.5 20.03 5.73e-65 2.7e-60 0.88 0.68 Lung cancer; chr6:149644487 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs3805749 ENSG00000231760.4 RP11-350J20.5 20 7.7e-65 3.61e-60 0.89 0.68 Lung cancer; chr6:149772546 chr6:149796151~149826294:- LUSC cis rs9322193 0.847 rs9505972 ENSG00000231760.4 RP11-350J20.5 20 7.7e-65 3.61e-60 0.89 0.68 Lung cancer; chr6:149775255 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs62439836 ENSG00000231760.4 RP11-350J20.5 19.99 8.95e-65 4.18e-60 0.88 0.68 Lung cancer; chr6:149669173 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs4869812 ENSG00000231760.4 RP11-350J20.5 19.99 8.95e-65 4.18e-60 0.88 0.68 Lung cancer; chr6:149669447 chr6:149796151~149826294:- LUSC cis rs9322193 0.886 rs2065663 ENSG00000231760.4 RP11-350J20.5 19.98 9.18e-65 4.28e-60 0.89 0.68 Lung cancer; chr6:149760331 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10872644 ENSG00000231760.4 RP11-350J20.5 19.98 9.26e-65 4.32e-60 0.88 0.68 Lung cancer; chr6:149741819 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs12529698 ENSG00000231760.4 RP11-350J20.5 19.98 9.29e-65 4.32e-60 0.88 0.68 Lung cancer; chr6:149650951 chr6:149796151~149826294:- LUSC cis rs858239 0.601 rs10239760 ENSG00000230658.1 KLHL7-AS1 19.98 9.7e-65 4.51e-60 0.87 0.68 Cerebrospinal fluid biomarker levels; chr7:23110331 chr7:23101228~23105703:- LUSC cis rs2882667 0.69 rs160404 ENSG00000253404.1 AC034243.1 19.98 1.01e-64 4.7e-60 0.86 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138748580 chr5:138744434~138753309:- LUSC cis rs3814244 0.528 rs2906859 ENSG00000255733.4 IFNG-AS1 19.97 1.04e-64 4.81e-60 0.6 0.68 Itch intensity from mosquito bite adjusted by bite size; chr12:68002355 chr12:67989445~68234686:+ LUSC cis rs858239 0.6 rs6967475 ENSG00000230658.1 KLHL7-AS1 19.97 1.04e-64 4.82e-60 0.9 0.68 Cerebrospinal fluid biomarker levels; chr7:23089363 chr7:23101228~23105703:- LUSC cis rs9322193 0.923 rs2297928 ENSG00000231760.4 RP11-350J20.5 19.97 1.05e-64 4.87e-60 0.88 0.68 Lung cancer; chr6:149718584 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs12205092 ENSG00000231760.4 RP11-350J20.5 19.97 1.09e-64 5.01e-60 0.89 0.68 Lung cancer; chr6:149761375 chr6:149796151~149826294:- LUSC cis rs858239 0.632 rs1985769 ENSG00000230658.1 KLHL7-AS1 19.97 1.11e-64 5.08e-60 0.86 0.68 Cerebrospinal fluid biomarker levels; chr7:23082887 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs28499396 ENSG00000230658.1 KLHL7-AS1 19.97 1.11e-64 5.08e-60 0.86 0.68 Cerebrospinal fluid biomarker levels; chr7:23084479 chr7:23101228~23105703:- LUSC cis rs858239 0.6 rs7789237 ENSG00000230658.1 KLHL7-AS1 19.97 1.11e-64 5.08e-60 0.86 0.68 Cerebrospinal fluid biomarker levels; chr7:23085094 chr7:23101228~23105703:- LUSC cis rs2882667 0.69 rs825672 ENSG00000253404.1 AC034243.1 -19.96 1.17e-64 5.39e-60 -0.9 -0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138759954 chr5:138744434~138753309:- LUSC cis rs9322193 0.923 rs10782317 ENSG00000231760.4 RP11-350J20.5 -19.96 1.2e-64 5.48e-60 -0.87 -0.68 Lung cancer; chr6:149753911 chr6:149796151~149826294:- LUSC cis rs9326248 0.652 rs7128382 ENSG00000254851.1 RP11-109L13.1 -19.95 1.29e-64 5.89e-60 -0.99 -0.68 Blood protein levels; chr11:117152771 chr11:117135528~117138582:+ LUSC cis rs9322193 0.923 rs9800871 ENSG00000231760.4 RP11-350J20.5 19.94 1.49e-64 6.78e-60 0.87 0.68 Lung cancer; chr6:149644540 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs11155671 ENSG00000231760.4 RP11-350J20.5 19.94 1.49e-64 6.78e-60 0.87 0.68 Lung cancer; chr6:149650996 chr6:149796151~149826294:- LUSC cis rs9322193 0.847 rs9383844 ENSG00000231760.4 RP11-350J20.5 19.94 1.49e-64 6.78e-60 0.87 0.68 Lung cancer; chr6:149716268 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs66516768 ENSG00000231760.4 RP11-350J20.5 19.94 1.52e-64 6.87e-60 0.88 0.68 Lung cancer; chr6:149671999 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs9688699 ENSG00000231760.4 RP11-350J20.5 19.92 1.94e-64 8.75e-60 0.88 0.68 Lung cancer; chr6:149733680 chr6:149796151~149826294:- LUSC cis rs2739330 0.892 rs4822455 ENSG00000218537.1 MIF-AS1 19.9 2.37e-64 1.07e-59 0.9 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23894426~23898930:- LUSC cis rs858239 0.601 rs6969733 ENSG00000230658.1 KLHL7-AS1 19.89 2.57e-64 1.16e-59 0.87 0.68 Cerebrospinal fluid biomarker levels; chr7:23128758 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs4440529 ENSG00000230658.1 KLHL7-AS1 19.89 2.57e-64 1.16e-59 0.87 0.68 Cerebrospinal fluid biomarker levels; chr7:23129132 chr7:23101228~23105703:- LUSC cis rs9322193 0.923 rs10782318 ENSG00000231760.4 RP11-350J20.5 19.89 2.59e-64 1.16e-59 0.88 0.68 Lung cancer; chr6:149754137 chr6:149796151~149826294:- LUSC cis rs9326248 0.861 rs4938353 ENSG00000254851.1 RP11-109L13.1 -19.87 3.18e-64 1.42e-59 -0.96 -0.68 Blood protein levels; chr11:117175481 chr11:117135528~117138582:+ LUSC cis rs9322193 0.923 rs9479094 ENSG00000231760.4 RP11-350J20.5 19.86 3.44e-64 1.53e-59 0.87 0.68 Lung cancer; chr6:149725083 chr6:149796151~149826294:- LUSC cis rs858239 0.571 rs6953020 ENSG00000230658.1 KLHL7-AS1 19.85 3.97e-64 1.77e-59 0.87 0.68 Cerebrospinal fluid biomarker levels; chr7:23132513 chr7:23101228~23105703:- LUSC cis rs4853012 0.838 rs6715351 ENSG00000217702.2 RP11-287D1.4 19.85 4.15e-64 1.84e-59 1.07 0.68 Gestational age at birth (maternal effect); chr2:74118992 chr2:74130583~74135395:+ LUSC cis rs4853012 0.838 rs61521879 ENSG00000217702.2 RP11-287D1.4 19.85 4.15e-64 1.84e-59 1.07 0.68 Gestational age at birth (maternal effect); chr2:74119081 chr2:74130583~74135395:+ LUSC cis rs4853012 0.838 rs60705299 ENSG00000217702.2 RP11-287D1.4 19.84 4.21e-64 1.86e-59 1.06 0.68 Gestational age at birth (maternal effect); chr2:74118243 chr2:74130583~74135395:+ LUSC cis rs9322193 0.923 rs9689716 ENSG00000231760.4 RP11-350J20.5 19.83 5.11e-64 2.25e-59 0.87 0.67 Lung cancer; chr6:149655662 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9322207 ENSG00000231760.4 RP11-350J20.5 19.83 5.11e-64 2.25e-59 0.87 0.67 Lung cancer; chr6:149657185 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9968911 ENSG00000231760.4 RP11-350J20.5 19.83 5.11e-64 2.25e-59 0.87 0.67 Lung cancer; chr6:149657419 chr6:149796151~149826294:- LUSC cis rs1577917 0.696 rs2842617 ENSG00000203875.9 SNHG5 -19.82 5.31e-64 2.33e-59 -0.85 -0.67 Response to antipsychotic treatment; chr6:85599980 chr6:85660950~85678736:- LUSC cis rs9322193 0.923 rs57938011 ENSG00000231760.4 RP11-350J20.5 19.82 5.37e-64 2.36e-59 0.88 0.67 Lung cancer; chr6:149642969 chr6:149796151~149826294:- LUSC cis rs9326248 0.768 rs4936366 ENSG00000254851.1 RP11-109L13.1 -19.82 5.61e-64 2.46e-59 -0.97 -0.67 Blood protein levels; chr11:117156169 chr11:117135528~117138582:+ LUSC cis rs9326248 0.813 rs4938350 ENSG00000254851.1 RP11-109L13.1 -19.81 5.84e-64 2.55e-59 -0.97 -0.67 Blood protein levels; chr11:117151560 chr11:117135528~117138582:+ LUSC cis rs9322193 1 rs58189451 ENSG00000231760.4 RP11-350J20.5 19.81 5.96e-64 2.6e-59 0.87 0.67 Lung cancer; chr6:149600252 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs35961297 ENSG00000231760.4 RP11-350J20.5 19.81 6.06e-64 2.63e-59 0.88 0.67 Lung cancer; chr6:149667929 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs35967444 ENSG00000231760.4 RP11-350J20.5 19.81 6.06e-64 2.63e-59 0.88 0.67 Lung cancer; chr6:149675588 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs62439842 ENSG00000231760.4 RP11-350J20.5 19.81 6.06e-64 2.63e-59 0.88 0.67 Lung cancer; chr6:149675847 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9322208 ENSG00000231760.4 RP11-350J20.5 19.8 6.85e-64 2.96e-59 0.87 0.67 Lung cancer; chr6:149658547 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs62439840 ENSG00000231760.4 RP11-350J20.5 19.78 8.29e-64 3.57e-59 0.89 0.67 Lung cancer; chr6:149674639 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs9393175 ENSG00000231760.4 RP11-350J20.5 19.78 8.29e-64 3.57e-59 0.89 0.67 Lung cancer; chr6:149677587 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs35830138 ENSG00000231760.4 RP11-350J20.5 19.76 1.1e-63 4.7e-59 0.88 0.67 Lung cancer; chr6:149668635 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs62439837 ENSG00000231760.4 RP11-350J20.5 19.75 1.2e-63 5.13e-59 0.89 0.67 Lung cancer; chr6:149670380 chr6:149796151~149826294:- LUSC cis rs4853012 0.838 rs4452177 ENSG00000217702.2 RP11-287D1.4 19.74 1.3e-63 5.55e-59 1.06 0.67 Gestational age at birth (maternal effect); chr2:74118079 chr2:74130583~74135395:+ LUSC cis rs9322193 0.884 rs10782312 ENSG00000231760.4 RP11-350J20.5 19.72 1.63e-63 6.87e-59 0.87 0.67 Lung cancer; chr6:149622669 chr6:149796151~149826294:- LUSC cis rs858239 0.601 rs12539331 ENSG00000230658.1 KLHL7-AS1 19.71 1.7e-63 7.13e-59 0.86 0.67 Cerebrospinal fluid biomarker levels; chr7:23111711 chr7:23101228~23105703:- LUSC cis rs9322193 0.923 rs9800614 ENSG00000231760.4 RP11-350J20.5 19.71 1.79e-63 7.48e-59 0.87 0.67 Lung cancer; chr6:149644604 chr6:149796151~149826294:- LUSC cis rs9322193 0.81 rs62439811 ENSG00000231760.4 RP11-350J20.5 19.7 1.97e-63 8.19e-59 0.88 0.67 Lung cancer; chr6:149640416 chr6:149796151~149826294:- LUSC cis rs858239 0.632 rs7811903 ENSG00000230658.1 KLHL7-AS1 19.7 2.01e-63 8.35e-59 0.87 0.67 Cerebrospinal fluid biomarker levels; chr7:23079437 chr7:23101228~23105703:- LUSC cis rs9322193 0.923 rs55849538 ENSG00000231760.4 RP11-350J20.5 19.7 2.03e-63 8.43e-59 0.87 0.67 Lung cancer; chr6:149635330 chr6:149796151~149826294:- LUSC cis rs4853012 0.838 rs59570457 ENSG00000217702.2 RP11-287D1.4 19.69 2.14e-63 8.88e-59 1.07 0.67 Gestational age at birth (maternal effect); chr2:74117155 chr2:74130583~74135395:+ LUSC cis rs4853012 0.752 rs13413795 ENSG00000217702.2 RP11-287D1.4 19.68 2.37e-63 9.8e-59 1.08 0.67 Gestational age at birth (maternal effect); chr2:74122712 chr2:74130583~74135395:+ LUSC cis rs9322193 0.923 rs12526675 ENSG00000231760.4 RP11-350J20.5 -19.68 2.37e-63 9.8e-59 -0.88 -0.67 Lung cancer; chr6:149729540 chr6:149796151~149826294:- LUSC cis rs2739330 0.892 rs5751776 ENSG00000225282.1 AP000350.6 19.66 3.07e-63 1.26e-58 0.81 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23926900~23929574:+ LUSC cis rs9322193 0.923 rs9767554 ENSG00000231760.4 RP11-350J20.5 19.66 3.23e-63 1.33e-58 0.86 0.67 Lung cancer; chr6:149616860 chr6:149796151~149826294:- LUSC cis rs9326248 0.861 rs4938352 ENSG00000254851.1 RP11-109L13.1 -19.65 3.55e-63 1.46e-58 -0.97 -0.67 Blood protein levels; chr11:117156765 chr11:117135528~117138582:+ LUSC cis rs9322193 0.923 rs9322204 ENSG00000231760.4 RP11-350J20.5 19.64 3.65e-63 1.49e-58 0.86 0.67 Lung cancer; chr6:149636047 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs3805752 ENSG00000231760.4 RP11-350J20.5 19.63 4.22e-63 1.72e-58 0.88 0.67 Lung cancer; chr6:149795490 chr6:149796151~149826294:- LUSC cis rs858239 0.601 rs764534 ENSG00000230658.1 KLHL7-AS1 19.62 4.57e-63 1.85e-58 0.85 0.67 Cerebrospinal fluid biomarker levels; chr7:23114316 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs2068459 ENSG00000230658.1 KLHL7-AS1 19.62 4.57e-63 1.85e-58 0.85 0.67 Cerebrospinal fluid biomarker levels; chr7:23114694 chr7:23101228~23105703:- LUSC cis rs858239 0.601 rs73272053 ENSG00000230658.1 KLHL7-AS1 19.62 4.57e-63 1.85e-58 0.85 0.67 Cerebrospinal fluid biomarker levels; chr7:23115906 chr7:23101228~23105703:- LUSC cis rs9326248 0.861 rs7120309 ENSG00000254851.1 RP11-109L13.1 -19.61 5.35e-63 2.16e-58 -0.96 -0.67 Blood protein levels; chr11:117172100 chr11:117135528~117138582:+ LUSC cis rs9326248 0.861 rs7120449 ENSG00000254851.1 RP11-109L13.1 -19.61 5.35e-63 2.16e-58 -0.96 -0.67 Blood protein levels; chr11:117172183 chr11:117135528~117138582:+ LUSC cis rs1577917 0.74 rs9353320 ENSG00000203875.9 SNHG5 19.6 5.65e-63 2.28e-58 0.84 0.67 Response to antipsychotic treatment; chr6:85535130 chr6:85660950~85678736:- LUSC cis rs1577917 0.74 rs9344533 ENSG00000203875.9 SNHG5 19.6 5.81e-63 2.34e-58 0.84 0.67 Response to antipsychotic treatment; chr6:85526470 chr6:85660950~85678736:- LUSC cis rs9326248 0.813 rs7115562 ENSG00000254851.1 RP11-109L13.1 -19.6 5.85e-63 2.35e-58 -0.98 -0.67 Blood protein levels; chr11:117149754 chr11:117135528~117138582:+ LUSC cis rs4853012 0.838 rs4429500 ENSG00000217702.2 RP11-287D1.4 19.6 5.85e-63 2.35e-58 1.05 0.67 Gestational age at birth (maternal effect); chr2:74118209 chr2:74130583~74135395:+ LUSC cis rs1577917 0.74 rs7775864 ENSG00000203875.9 SNHG5 19.6 5.87e-63 2.35e-58 0.84 0.67 Response to antipsychotic treatment; chr6:85538041 chr6:85660950~85678736:- LUSC cis rs1577917 0.74 rs7771612 ENSG00000203875.9 SNHG5 19.6 6.15e-63 2.46e-58 0.84 0.67 Response to antipsychotic treatment; chr6:85554656 chr6:85660950~85678736:- LUSC cis rs9322193 0.923 rs10782310 ENSG00000231760.4 RP11-350J20.5 19.59 6.21e-63 2.47e-58 0.86 0.67 Lung cancer; chr6:149622458 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10782311 ENSG00000231760.4 RP11-350J20.5 19.59 6.21e-63 2.47e-58 0.86 0.67 Lung cancer; chr6:149622592 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs55993747 ENSG00000231760.4 RP11-350J20.5 19.59 6.74e-63 2.67e-58 0.87 0.67 Lung cancer; chr6:149622016 chr6:149796151~149826294:- LUSC cis rs9322193 0.886 rs4870055 ENSG00000231760.4 RP11-350J20.5 19.59 6.89e-63 2.72e-58 0.86 0.67 Lung cancer; chr6:149848433 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9688861 ENSG00000231760.4 RP11-350J20.5 19.58 7.41e-63 2.92e-58 0.86 0.67 Lung cancer; chr6:149637924 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs7740278 ENSG00000231760.4 RP11-350J20.5 19.58 7.41e-63 2.92e-58 0.86 0.67 Lung cancer; chr6:149640116 chr6:149796151~149826294:- LUSC cis rs9326248 0.861 rs4938348 ENSG00000254851.1 RP11-109L13.1 -19.57 8.08e-63 3.17e-58 -0.97 -0.67 Blood protein levels; chr11:117151161 chr11:117135528~117138582:+ LUSC cis rs9322193 0.923 rs9800580 ENSG00000231760.4 RP11-350J20.5 19.56 8.6e-63 3.35e-58 0.86 0.67 Lung cancer; chr6:149632845 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs11155669 ENSG00000231760.4 RP11-350J20.5 19.56 8.6e-63 3.35e-58 0.86 0.67 Lung cancer; chr6:149633501 chr6:149796151~149826294:- LUSC cis rs9322193 0.887 rs9505824 ENSG00000231760.4 RP11-350J20.5 19.56 8.6e-63 3.35e-58 0.86 0.67 Lung cancer; chr6:149633663 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9505826 ENSG00000231760.4 RP11-350J20.5 19.56 8.6e-63 3.35e-58 0.86 0.67 Lung cancer; chr6:149633912 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9766886 ENSG00000231760.4 RP11-350J20.5 19.56 8.6e-63 3.35e-58 0.86 0.67 Lung cancer; chr6:149637048 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9766004 ENSG00000231760.4 RP11-350J20.5 19.56 9.27e-63 3.61e-58 0.87 0.67 Lung cancer; chr6:149754363 chr6:149796151~149826294:- LUSC cis rs9322193 0.962 rs7740784 ENSG00000231760.4 RP11-350J20.5 19.54 1.12e-62 4.34e-58 0.87 0.67 Lung cancer; chr6:149833364 chr6:149796151~149826294:- LUSC cis rs4853012 0.838 rs6707729 ENSG00000217702.2 RP11-287D1.4 19.54 1.14e-62 4.43e-58 1.06 0.67 Gestational age at birth (maternal effect); chr2:74117558 chr2:74130583~74135395:+ LUSC cis rs9322193 0.847 rs12210605 ENSG00000231760.4 RP11-350J20.5 19.53 1.26e-62 4.86e-58 0.88 0.67 Lung cancer; chr6:149817267 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9371199 ENSG00000231760.4 RP11-350J20.5 19.53 1.26e-62 4.86e-58 0.88 0.67 Lung cancer; chr6:149817526 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9688350 ENSG00000231760.4 RP11-350J20.5 19.53 1.29e-62 4.97e-58 0.87 0.67 Lung cancer; chr6:149730977 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9767652 ENSG00000231760.4 RP11-350J20.5 19.53 1.29e-62 4.97e-58 0.87 0.67 Lung cancer; chr6:149734502 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10782314 ENSG00000231760.4 RP11-350J20.5 19.53 1.29e-62 4.97e-58 0.87 0.67 Lung cancer; chr6:149735527 chr6:149796151~149826294:- LUSC cis rs9322193 0.847 rs12191643 ENSG00000231760.4 RP11-350J20.5 19.52 1.42e-62 5.45e-58 0.87 0.67 Lung cancer; chr6:149628912 chr6:149796151~149826294:- LUSC cis rs9322193 0.886 rs9485408 ENSG00000231760.4 RP11-350J20.5 19.52 1.46e-62 5.57e-58 0.86 0.67 Lung cancer; chr6:149618888 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs1080670 ENSG00000231760.4 RP11-350J20.5 19.52 1.46e-62 5.57e-58 0.86 0.67 Lung cancer; chr6:149620161 chr6:149796151~149826294:- LUSC cis rs9322193 0.886 rs9322198 ENSG00000231760.4 RP11-350J20.5 19.52 1.46e-62 5.57e-58 0.86 0.67 Lung cancer; chr6:149623772 chr6:149796151~149826294:- LUSC cis rs858239 0.601 rs6461693 ENSG00000230658.1 KLHL7-AS1 -19.51 1.54e-62 5.86e-58 -0.86 -0.67 Cerebrospinal fluid biomarker levels; chr7:23120514 chr7:23101228~23105703:- LUSC cis rs9322193 0.847 rs56103941 ENSG00000231760.4 RP11-350J20.5 19.5 1.75e-62 6.65e-58 0.88 0.67 Lung cancer; chr6:149816095 chr6:149796151~149826294:- LUSC cis rs4853012 0.838 rs72911122 ENSG00000217702.2 RP11-287D1.4 19.49 1.96e-62 7.44e-58 1.06 0.67 Gestational age at birth (maternal effect); chr2:74116992 chr2:74130583~74135395:+ LUSC cis rs9326248 0.861 rs7931335 ENSG00000254851.1 RP11-109L13.1 -19.49 2.03e-62 7.71e-58 -0.95 -0.67 Blood protein levels; chr11:117166089 chr11:117135528~117138582:+ LUSC cis rs2739330 0.892 rs4822455 ENSG00000225282.1 AP000350.6 19.48 2.16e-62 8.19e-58 0.81 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23926900~23929574:+ LUSC cis rs9326248 0.861 rs4938343 ENSG00000254851.1 RP11-109L13.1 -19.48 2.26e-62 8.52e-58 -0.99 -0.67 Blood protein levels; chr11:117132812 chr11:117135528~117138582:+ LUSC cis rs4853012 0.793 rs6707619 ENSG00000217702.2 RP11-287D1.4 19.47 2.4e-62 9.05e-58 1.06 0.67 Gestational age at birth (maternal effect); chr2:74117529 chr2:74130583~74135395:+ LUSC cis rs2739330 0.731 rs4822450 ENSG00000273295.1 AP000350.5 19.47 2.46e-62 9.25e-58 0.76 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23901432~23907068:- LUSC cis rs9326248 0.727 rs4938347 ENSG00000254851.1 RP11-109L13.1 -19.47 2.49e-62 9.36e-58 -0.97 -0.67 Blood protein levels; chr11:117151043 chr11:117135528~117138582:+ LUSC cis rs4853012 0.838 rs4563249 ENSG00000217702.2 RP11-287D1.4 19.47 2.52e-62 9.46e-58 1.06 0.67 Gestational age at birth (maternal effect); chr2:74126889 chr2:74130583~74135395:+ LUSC cis rs9322193 0.923 rs9800686 ENSG00000231760.4 RP11-350J20.5 19.45 3.01e-62 1.12e-57 0.87 0.67 Lung cancer; chr6:149634464 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9689084 ENSG00000231760.4 RP11-350J20.5 19.45 3.13e-62 1.16e-57 0.86 0.67 Lung cancer; chr6:149639648 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs9688794 ENSG00000231760.4 RP11-350J20.5 19.43 3.75e-62 1.37e-57 0.86 0.67 Lung cancer; chr6:149632121 chr6:149796151~149826294:- LUSC cis rs3814244 0.832 rs11177006 ENSG00000255733.4 IFNG-AS1 19.42 4.09e-62 1.5e-57 0.59 0.67 Itch intensity from mosquito bite adjusted by bite size; chr12:68019317 chr12:67989445~68234686:+ LUSC cis rs9322193 0.962 rs2342764 ENSG00000231760.4 RP11-350J20.5 19.41 4.58e-62 1.67e-57 0.87 0.67 Lung cancer; chr6:149835068 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9377230 ENSG00000231760.4 RP11-350J20.5 19.4 4.88e-62 1.78e-57 0.85 0.67 Lung cancer; chr6:149613607 chr6:149796151~149826294:- LUSC cis rs2739330 0.627 rs9608219 ENSG00000273295.1 AP000350.5 19.38 6.22e-62 2.26e-57 0.78 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23901432~23907068:- LUSC cis rs9322193 0.923 rs9505982 ENSG00000231760.4 RP11-350J20.5 19.38 6.38e-62 2.32e-57 0.86 0.67 Lung cancer; chr6:149618465 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs10747275 ENSG00000231760.4 RP11-350J20.5 19.38 6.38e-62 2.32e-57 0.86 0.67 Lung cancer; chr6:149622782 chr6:149796151~149826294:- LUSC cis rs4853012 1 rs2280643 ENSG00000217702.2 RP11-287D1.4 19.37 7.14e-62 2.58e-57 1.1 0.67 Gestational age at birth (maternal effect); chr2:74131159 chr2:74130583~74135395:+ LUSC cis rs4853012 0.887 rs2280644 ENSG00000217702.2 RP11-287D1.4 19.37 7.14e-62 2.58e-57 1.1 0.67 Gestational age at birth (maternal effect); chr2:74131284 chr2:74130583~74135395:+ LUSC cis rs1577917 0.655 rs7742691 ENSG00000203875.9 SNHG5 19.36 7.71e-62 2.79e-57 0.84 0.67 Response to antipsychotic treatment; chr6:85568973 chr6:85660950~85678736:- LUSC cis rs9322193 0.924 rs9498382 ENSG00000231760.4 RP11-350J20.5 19.35 8.54e-62 3.08e-57 0.86 0.67 Lung cancer; chr6:149610982 chr6:149796151~149826294:- LUSC cis rs2739330 0.828 rs5751770 ENSG00000225282.1 AP000350.6 19.32 1.18e-61 4.23e-57 0.8 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23926900~23929574:+ LUSC cis rs858239 0.539 rs7791200 ENSG00000230658.1 KLHL7-AS1 19.31 1.35e-61 4.83e-57 0.87 0.67 Cerebrospinal fluid biomarker levels; chr7:23142502 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs57864591 ENSG00000230658.1 KLHL7-AS1 19.31 1.35e-61 4.83e-57 0.87 0.67 Cerebrospinal fluid biomarker levels; chr7:23144805 chr7:23101228~23105703:- LUSC cis rs2906856 0.848 rs3015001 ENSG00000255733.4 IFNG-AS1 -19.3 1.54e-61 5.47e-57 -0.59 -0.66 Mosquito bite size; chr12:68003593 chr12:67989445~68234686:+ LUSC cis rs9326248 0.861 rs1871757 ENSG00000254851.1 RP11-109L13.1 -19.29 1.75e-61 6.21e-57 -0.95 -0.66 Blood protein levels; chr11:117159865 chr11:117135528~117138582:+ LUSC cis rs1577917 0.682 rs6909767 ENSG00000203875.9 SNHG5 19.28 1.81e-61 6.42e-57 0.85 0.66 Response to antipsychotic treatment; chr6:85518391 chr6:85660950~85678736:- LUSC cis rs858239 0.601 rs10224327 ENSG00000230658.1 KLHL7-AS1 19.27 2.13e-61 7.46e-57 0.85 0.66 Cerebrospinal fluid biomarker levels; chr7:23122201 chr7:23101228~23105703:- LUSC cis rs2739330 0.76 rs5760095 ENSG00000273295.1 AP000350.5 19.26 2.34e-61 8.18e-57 0.77 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23901432~23907068:- LUSC cis rs3814244 0.868 rs11177007 ENSG00000255733.4 IFNG-AS1 19.22 3.65e-61 1.26e-56 0.58 0.66 Itch intensity from mosquito bite adjusted by bite size; chr12:68020964 chr12:67989445~68234686:+ LUSC cis rs9322193 0.886 rs9718079 ENSG00000231760.4 RP11-350J20.5 19.21 4.02e-61 1.39e-56 0.87 0.66 Lung cancer; chr6:149645947 chr6:149796151~149826294:- LUSC cis rs1577917 0.74 rs7752502 ENSG00000203875.9 SNHG5 19.18 5.65e-61 1.92e-56 0.84 0.66 Response to antipsychotic treatment; chr6:85700933 chr6:85660950~85678736:- LUSC cis rs858239 0.539 rs6945510 ENSG00000230658.1 KLHL7-AS1 19.17 6.15e-61 2.09e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23152621 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs10279194 ENSG00000230658.1 KLHL7-AS1 19.16 6.51e-61 2.2e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23151464 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs3950345 ENSG00000230658.1 KLHL7-AS1 19.16 6.51e-61 2.2e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23151495 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs2178140 ENSG00000230658.1 KLHL7-AS1 19.16 6.51e-61 2.2e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23152006 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs2178139 ENSG00000230658.1 KLHL7-AS1 19.16 6.51e-61 2.2e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23152017 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs2141306 ENSG00000230658.1 KLHL7-AS1 19.16 6.51e-61 2.2e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23152045 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs2141305 ENSG00000230658.1 KLHL7-AS1 19.16 6.51e-61 2.2e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23152280 chr7:23101228~23105703:- LUSC cis rs1577917 0.74 rs2758845 ENSG00000203875.9 SNHG5 -19.16 6.79e-61 2.29e-56 -0.84 -0.66 Response to antipsychotic treatment; chr6:85625130 chr6:85660950~85678736:- LUSC cis rs858239 0.571 rs2390755 ENSG00000230658.1 KLHL7-AS1 19.15 7.33e-61 2.46e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23151097 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs4365988 ENSG00000230658.1 KLHL7-AS1 19.15 7.33e-61 2.46e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23151252 chr7:23101228~23105703:- LUSC cis rs1577917 0.839 rs6454492 ENSG00000203875.9 SNHG5 -19.13 9.66e-61 3.22e-56 -0.86 -0.66 Response to antipsychotic treatment; chr6:85773496 chr6:85660950~85678736:- LUSC cis rs2739330 0.753 rs4822452 ENSG00000225282.1 AP000350.6 19.12 1.02e-60 3.39e-56 0.79 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23926900~23929574:+ LUSC cis rs858239 0.539 rs4295546 ENSG00000230658.1 KLHL7-AS1 19.12 1.06e-60 3.51e-56 0.87 0.66 Cerebrospinal fluid biomarker levels; chr7:23151402 chr7:23101228~23105703:- LUSC cis rs1577917 0.74 rs9353327 ENSG00000203875.9 SNHG5 -19.11 1.23e-60 4.07e-56 -0.82 -0.66 Response to antipsychotic treatment; chr6:85684348 chr6:85660950~85678736:- LUSC cis rs4853012 0.941 rs60291089 ENSG00000217702.2 RP11-287D1.4 19.1 1.26e-60 4.16e-56 1.05 0.66 Gestational age at birth (maternal effect); chr2:74117763 chr2:74130583~74135395:+ LUSC cis rs4853012 0.838 rs58759652 ENSG00000217702.2 RP11-287D1.4 19.1 1.26e-60 4.16e-56 1.05 0.66 Gestational age at birth (maternal effect); chr2:74117775 chr2:74130583~74135395:+ LUSC cis rs9322193 0.886 rs9767555 ENSG00000231760.4 RP11-350J20.5 19.09 1.45e-60 4.78e-56 0.87 0.66 Lung cancer; chr6:149647022 chr6:149796151~149826294:- LUSC cis rs858239 0.539 rs4294098 ENSG00000230658.1 KLHL7-AS1 19.08 1.58e-60 5.18e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23146376 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs4504540 ENSG00000230658.1 KLHL7-AS1 19.08 1.58e-60 5.18e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23146579 chr7:23101228~23105703:- LUSC cis rs858239 0.509 rs6975524 ENSG00000230658.1 KLHL7-AS1 19.08 1.58e-60 5.18e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23146833 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs6955726 ENSG00000230658.1 KLHL7-AS1 19.08 1.58e-60 5.18e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23147072 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs6976957 ENSG00000230658.1 KLHL7-AS1 19.08 1.58e-60 5.18e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23147714 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs6956828 ENSG00000230658.1 KLHL7-AS1 19.08 1.58e-60 5.18e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23147728 chr7:23101228~23105703:- LUSC cis rs1577917 0.71 rs9342041 ENSG00000203875.9 SNHG5 19.08 1.6e-60 5.21e-56 0.83 0.66 Response to antipsychotic treatment; chr6:85571157 chr6:85660950~85678736:- LUSC cis rs858239 0.539 rs10280815 ENSG00000230658.1 KLHL7-AS1 19.07 1.84e-60 5.94e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23148751 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs10225608 ENSG00000230658.1 KLHL7-AS1 19.07 1.84e-60 5.94e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23149289 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs28624974 ENSG00000230658.1 KLHL7-AS1 19.07 1.84e-60 5.94e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23149317 chr7:23101228~23105703:- LUSC cis rs5850 0.557 rs10270788 ENSG00000230658.1 KLHL7-AS1 19.07 1.84e-60 5.94e-56 0.86 0.66 Blood protein levels; chr7:23149381 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs28716381 ENSG00000230658.1 KLHL7-AS1 19.07 1.84e-60 5.94e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23149396 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs1358442 ENSG00000230658.1 KLHL7-AS1 19.07 1.84e-60 5.94e-56 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23150120 chr7:23101228~23105703:- LUSC cis rs9322193 0.923 rs4869750 ENSG00000231760.4 RP11-350J20.5 19.06 2.06e-60 6.65e-56 0.85 0.66 Lung cancer; chr6:149855996 chr6:149796151~149826294:- LUSC cis rs1577917 0.682 rs6935918 ENSG00000203875.9 SNHG5 19.05 2.14e-60 6.9e-56 0.84 0.66 Response to antipsychotic treatment; chr6:85573857 chr6:85660950~85678736:- LUSC cis rs2739330 0.76 rs5751760 ENSG00000273295.1 AP000350.5 19.04 2.42e-60 7.8e-56 0.75 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23901432~23907068:- LUSC cis rs1577917 0.74 rs9344542 ENSG00000203875.9 SNHG5 19.04 2.5e-60 8.04e-56 0.83 0.66 Response to antipsychotic treatment; chr6:85684187 chr6:85660950~85678736:- LUSC cis rs858239 0.632 rs6952947 ENSG00000230658.1 KLHL7-AS1 -19.04 2.6e-60 8.35e-56 -0.85 -0.66 Cerebrospinal fluid biomarker levels; chr7:23081423 chr7:23101228~23105703:- LUSC cis rs2739330 0.791 rs9612520 ENSG00000273295.1 AP000350.5 19.04 2.61e-60 8.39e-56 0.77 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23901432~23907068:- LUSC cis rs858239 0.509 rs57611130 ENSG00000230658.1 KLHL7-AS1 19.03 2.88e-60 9.21e-56 0.87 0.66 Cerebrospinal fluid biomarker levels; chr7:23144933 chr7:23101228~23105703:- LUSC cis rs9322193 0.923 rs9404048 ENSG00000231760.4 RP11-350J20.5 19.02 2.92e-60 9.35e-56 0.84 0.66 Lung cancer; chr6:149616188 chr6:149796151~149826294:- LUSC cis rs2739330 0.703 rs5760112 ENSG00000273295.1 AP000350.5 19.01 3.48e-60 1.11e-55 0.77 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23901432~23907068:- LUSC cis rs2739330 0.828 rs2154593 ENSG00000225282.1 AP000350.6 18.97 5.52e-60 1.74e-55 0.79 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23926900~23929574:+ LUSC cis rs2739330 0.828 rs5760108 ENSG00000225282.1 AP000350.6 18.96 5.6e-60 1.77e-55 0.79 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23926900~23929574:+ LUSC cis rs2739330 0.828 rs2877178 ENSG00000225282.1 AP000350.6 18.91 1.05e-59 3.14e-55 0.79 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23926900~23929574:+ LUSC cis rs9322193 0.847 rs868375 ENSG00000231760.4 RP11-350J20.5 18.9 1.12e-59 3.36e-55 0.84 0.66 Lung cancer; chr6:149844905 chr6:149796151~149826294:- LUSC cis rs858239 0.511 rs10256996 ENSG00000230658.1 KLHL7-AS1 -18.9 1.15e-59 3.44e-55 -0.83 -0.66 Cerebrospinal fluid biomarker levels; chr7:23105676 chr7:23101228~23105703:- LUSC cis rs1577917 0.74 rs2758842 ENSG00000203875.9 SNHG5 -18.89 1.22e-59 3.64e-55 -0.83 -0.66 Response to antipsychotic treatment; chr6:85599013 chr6:85660950~85678736:- LUSC cis rs1577917 0.572 rs911927 ENSG00000203875.9 SNHG5 -18.89 1.22e-59 3.64e-55 -0.83 -0.66 Response to antipsychotic treatment; chr6:85618142 chr6:85660950~85678736:- LUSC cis rs916888 0.61 rs199442 ENSG00000262539.1 RP11-259G18.3 18.88 1.39e-59 4.12e-55 0.84 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46259551~46260606:- LUSC cis rs9322193 0.884 rs2064521 ENSG00000231760.4 RP11-350J20.5 -18.88 1.41e-59 4.2e-55 -0.84 -0.66 Lung cancer; chr6:149625336 chr6:149796151~149826294:- LUSC cis rs2739330 0.753 rs4822452 ENSG00000218537.1 MIF-AS1 18.86 1.69e-59 5.02e-55 0.87 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23894426~23898930:- LUSC cis rs9322193 0.886 rs4870049 ENSG00000231760.4 RP11-350J20.5 18.85 1.84e-59 5.43e-55 0.87 0.66 Lung cancer; chr6:149837058 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs4870052 ENSG00000231760.4 RP11-350J20.5 18.85 1.84e-59 5.44e-55 0.87 0.66 Lung cancer; chr6:149839978 chr6:149796151~149826294:- LUSC cis rs2739330 0.76 rs1007888 ENSG00000273295.1 AP000350.5 18.81 2.95e-59 8.68e-55 0.74 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23901432~23907068:- LUSC cis rs2739330 0.796 rs5760097 ENSG00000218537.1 MIF-AS1 18.78 4.06e-59 1.19e-54 0.88 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23894426~23898930:- LUSC cis rs916888 0.61 rs142167 ENSG00000262539.1 RP11-259G18.3 -18.77 4.36e-59 1.28e-54 -0.83 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46259551~46260606:- LUSC cis rs2739330 0.828 rs5760098 ENSG00000218537.1 MIF-AS1 18.77 4.56e-59 1.33e-54 0.88 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23894426~23898930:- LUSC cis rs2739330 0.828 rs5760102 ENSG00000218537.1 MIF-AS1 18.77 4.56e-59 1.33e-54 0.88 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23894426~23898930:- LUSC cis rs1577917 0.696 rs2842603 ENSG00000203875.9 SNHG5 -18.77 4.8e-59 1.4e-54 -0.83 -0.65 Response to antipsychotic treatment; chr6:85626619 chr6:85660950~85678736:- LUSC cis rs1577917 0.74 rs9450302 ENSG00000203875.9 SNHG5 18.76 5.05e-59 1.47e-54 0.84 0.65 Response to antipsychotic treatment; chr6:85579955 chr6:85660950~85678736:- LUSC cis rs1577917 0.74 rs2842614 ENSG00000203875.9 SNHG5 -18.76 5.31e-59 1.54e-54 -0.83 -0.65 Response to antipsychotic treatment; chr6:85596351 chr6:85660950~85678736:- LUSC cis rs1577917 0.74 rs12212560 ENSG00000203875.9 SNHG5 -18.76 5.32e-59 1.55e-54 -0.83 -0.65 Response to antipsychotic treatment; chr6:85632961 chr6:85660950~85678736:- LUSC cis rs2739330 0.828 rs5751770 ENSG00000218537.1 MIF-AS1 18.73 6.65e-59 1.93e-54 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23894426~23898930:- LUSC cis rs3814244 0.868 rs10878726 ENSG00000255733.4 IFNG-AS1 18.73 6.76e-59 1.96e-54 0.57 0.65 Itch intensity from mosquito bite adjusted by bite size; chr12:68022865 chr12:67989445~68234686:+ LUSC cis rs1577917 0.74 rs2758843 ENSG00000203875.9 SNHG5 -18.71 8.38e-59 2.42e-54 -0.83 -0.65 Response to antipsychotic treatment; chr6:85618713 chr6:85660950~85678736:- LUSC cis rs858239 0.539 rs6955969 ENSG00000230658.1 KLHL7-AS1 18.71 8.47e-59 2.44e-54 0.86 0.65 Cerebrospinal fluid biomarker levels; chr7:23147080 chr7:23101228~23105703:- LUSC cis rs2658782 1 rs2019814 ENSG00000279684.1 RP11-755E23.2 -18.7 9.61e-59 2.76e-54 -0.98 -0.65 Pulmonary function decline; chr11:93435719 chr11:93286629~93288903:- LUSC cis rs858239 0.539 rs6965833 ENSG00000230658.1 KLHL7-AS1 18.7 9.84e-59 2.82e-54 0.86 0.65 Cerebrospinal fluid biomarker levels; chr7:23152747 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs6949363 ENSG00000230658.1 KLHL7-AS1 18.7 9.84e-59 2.82e-54 0.86 0.65 Cerebrospinal fluid biomarker levels; chr7:23152775 chr7:23101228~23105703:- LUSC cis rs2739330 0.828 rs4822451 ENSG00000218537.1 MIF-AS1 18.66 1.5e-58 4.26e-54 0.88 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23894426~23898930:- LUSC cis rs2739330 0.828 rs5760099 ENSG00000218537.1 MIF-AS1 18.66 1.5e-58 4.26e-54 0.88 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23894426~23898930:- LUSC cis rs2739330 0.76 rs1002286 ENSG00000273295.1 AP000350.5 -18.61 2.41e-58 6.83e-54 -0.75 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23901432~23907068:- LUSC cis rs916888 0.61 rs199444 ENSG00000262539.1 RP11-259G18.3 18.61 2.59e-58 7.33e-54 0.84 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46259551~46260606:- LUSC cis rs9322193 0.923 rs9767105 ENSG00000231760.4 RP11-350J20.5 18.6 2.8e-58 7.89e-54 0.84 0.65 Lung cancer; chr6:149659591 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9688452 ENSG00000231760.4 RP11-350J20.5 18.6 2.91e-58 8.2e-54 0.86 0.65 Lung cancer; chr6:149658764 chr6:149796151~149826294:- LUSC cis rs1577917 0.682 rs1173419 ENSG00000203875.9 SNHG5 -18.57 3.76e-58 1.05e-53 -0.83 -0.65 Response to antipsychotic treatment; chr6:85692445 chr6:85660950~85678736:- LUSC cis rs9322193 1 rs9377228 ENSG00000231760.4 RP11-350J20.5 18.57 3.78e-58 1.06e-53 0.84 0.65 Lung cancer; chr6:149600862 chr6:149796151~149826294:- LUSC cis rs2739330 0.828 rs5760108 ENSG00000218537.1 MIF-AS1 18.56 4.22e-58 1.18e-53 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23894426~23898930:- LUSC cis rs9322193 1 rs9399693 ENSG00000231760.4 RP11-350J20.5 18.56 4.43e-58 1.23e-53 0.84 0.65 Lung cancer; chr6:149612718 chr6:149796151~149826294:- LUSC cis rs916888 0.647 rs199449 ENSG00000262539.1 RP11-259G18.3 18.55 4.98e-58 1.38e-53 0.83 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46259551~46260606:- LUSC cis rs2882667 0.69 rs825747 ENSG00000253404.1 AC034243.1 -18.54 5.21e-58 1.45e-53 -0.89 -0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138800896 chr5:138744434~138753309:- LUSC cis rs2739330 0.796 rs5760097 ENSG00000225282.1 AP000350.6 18.53 5.94e-58 1.65e-53 0.79 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23926900~23929574:+ LUSC cis rs916888 0.61 rs199452 ENSG00000262539.1 RP11-259G18.3 18.53 6.13e-58 1.7e-53 0.83 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46259551~46260606:- LUSC cis rs1577917 0.793 rs9362245 ENSG00000203875.9 SNHG5 -18.52 6.37e-58 1.77e-53 -0.84 -0.65 Response to antipsychotic treatment; chr6:85786602 chr6:85660950~85678736:- LUSC cis rs9322193 0.923 rs6913486 ENSG00000231760.4 RP11-350J20.5 -18.52 6.46e-58 1.79e-53 -0.88 -0.65 Lung cancer; chr6:149705060 chr6:149796151~149826294:- LUSC cis rs916888 0.531 rs183211 ENSG00000262539.1 RP11-259G18.3 18.51 7.81e-58 2.16e-53 0.83 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46259551~46260606:- LUSC cis rs2739330 0.685 rs4822453 ENSG00000273295.1 AP000350.5 18.48 1.03e-57 2.83e-53 0.75 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23901432~23907068:- LUSC cis rs2739330 0.828 rs4820572 ENSG00000218537.1 MIF-AS1 18.46 1.34e-57 3.68e-53 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23894426~23898930:- LUSC cis rs916888 0.61 rs199536 ENSG00000262539.1 RP11-259G18.3 -18.45 1.37e-57 3.76e-53 -0.83 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46259551~46260606:- LUSC cis rs916888 0.61 rs199453 ENSG00000262539.1 RP11-259G18.3 18.43 1.79e-57 4.86e-53 0.83 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46259551~46260606:- LUSC cis rs2658782 1 rs2658782 ENSG00000279684.1 RP11-755E23.2 -18.43 1.83e-57 4.98e-53 -0.96 -0.65 Pulmonary function decline; chr11:93433565 chr11:93286629~93288903:- LUSC cis rs2739330 0.828 rs5760098 ENSG00000225282.1 AP000350.6 18.42 1.87e-57 5.08e-53 0.79 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23926900~23929574:+ LUSC cis rs2739330 0.828 rs5760102 ENSG00000225282.1 AP000350.6 18.42 1.87e-57 5.08e-53 0.79 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23926900~23929574:+ LUSC cis rs2739330 0.828 rs4820572 ENSG00000225282.1 AP000350.6 18.4 2.36e-57 6.39e-53 0.78 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23926900~23929574:+ LUSC cis rs2739330 0.828 rs2154593 ENSG00000218537.1 MIF-AS1 18.39 2.69e-57 7.26e-53 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23894426~23898930:- LUSC cis rs2739330 0.796 rs2154594 ENSG00000218537.1 MIF-AS1 -18.37 3.46e-57 9.33e-53 -0.85 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23894426~23898930:- LUSC cis rs1577917 0.771 rs7762321 ENSG00000203875.9 SNHG5 18.36 3.74e-57 1.01e-52 0.82 0.65 Response to antipsychotic treatment; chr6:85702428 chr6:85660950~85678736:- LUSC cis rs9326248 0.773 rs1060211 ENSG00000254851.1 RP11-109L13.1 -18.36 3.88e-57 1.04e-52 -0.95 -0.65 Blood protein levels; chr11:117169081 chr11:117135528~117138582:+ LUSC cis rs858239 0.509 rs6962213 ENSG00000230658.1 KLHL7-AS1 18.35 4.16e-57 1.12e-52 0.85 0.65 Cerebrospinal fluid biomarker levels; chr7:23148490 chr7:23101228~23105703:- LUSC cis rs2739330 0.828 rs4822451 ENSG00000225282.1 AP000350.6 18.35 4.18e-57 1.12e-52 0.79 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23926900~23929574:+ LUSC cis rs2739330 0.828 rs5760099 ENSG00000225282.1 AP000350.6 18.35 4.18e-57 1.12e-52 0.79 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23926900~23929574:+ LUSC cis rs9322193 0.924 rs9322189 ENSG00000231760.4 RP11-350J20.5 18.34 4.52e-57 1.21e-52 0.84 0.65 Lung cancer; chr6:149588797 chr6:149796151~149826294:- LUSC cis rs916888 0.61 rs199436 ENSG00000262539.1 RP11-259G18.3 -18.34 4.69e-57 1.25e-52 -0.82 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46259551~46260606:- LUSC cis rs1577917 0.682 rs1173417 ENSG00000203875.9 SNHG5 18.33 4.87e-57 1.3e-52 0.82 0.65 Response to antipsychotic treatment; chr6:85694223 chr6:85660950~85678736:- LUSC cis rs2739330 0.828 rs2877178 ENSG00000218537.1 MIF-AS1 18.33 5.1e-57 1.36e-52 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23894426~23898930:- LUSC cis rs2739330 0.731 rs2000468 ENSG00000273295.1 AP000350.5 18.33 5.14e-57 1.37e-52 0.72 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23901432~23907068:- LUSC cis rs916888 0.61 rs199438 ENSG00000262539.1 RP11-259G18.3 18.33 5.29e-57 1.4e-52 0.83 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46259551~46260606:- LUSC cis rs1577917 0.655 rs9359658 ENSG00000203875.9 SNHG5 18.32 5.91e-57 1.56e-52 0.81 0.65 Response to antipsychotic treatment; chr6:85596051 chr6:85660950~85678736:- LUSC cis rs2739330 0.796 rs5760106 ENSG00000218537.1 MIF-AS1 -18.31 6.37e-57 1.69e-52 -0.85 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23894426~23898930:- LUSC cis rs9322193 0.961 rs2064520 ENSG00000231760.4 RP11-350J20.5 18.3 6.83e-57 1.8e-52 0.84 0.65 Lung cancer; chr6:149603650 chr6:149796151~149826294:- LUSC cis rs2739330 0.828 rs2330635 ENSG00000225282.1 AP000350.6 18.3 6.97e-57 1.84e-52 0.78 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23926900~23929574:+ LUSC cis rs1577917 0.74 rs2475792 ENSG00000203875.9 SNHG5 18.3 7.14e-57 1.88e-52 0.8 0.65 Response to antipsychotic treatment; chr6:85682384 chr6:85660950~85678736:- LUSC cis rs2658782 1 rs2658779 ENSG00000279684.1 RP11-755E23.2 18.28 8.83e-57 2.32e-52 0.93 0.64 Pulmonary function decline; chr11:93429971 chr11:93286629~93288903:- LUSC cis rs9322193 0.923 rs7769101 ENSG00000231760.4 RP11-350J20.5 18.28 8.96e-57 2.36e-52 0.84 0.64 Lung cancer; chr6:149848768 chr6:149796151~149826294:- LUSC cis rs2739330 0.828 rs5760107 ENSG00000225282.1 AP000350.6 18.27 1e-56 2.63e-52 0.78 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23926900~23929574:+ LUSC cis rs2658782 1 rs2608216 ENSG00000279684.1 RP11-755E23.2 -18.26 1.1e-56 2.87e-52 -0.95 -0.64 Pulmonary function decline; chr11:93416006 chr11:93286629~93288903:- LUSC cis rs2658782 0.95 rs2446061 ENSG00000279684.1 RP11-755E23.2 -18.26 1.1e-56 2.87e-52 -0.95 -0.64 Pulmonary function decline; chr11:93416111 chr11:93286629~93288903:- LUSC cis rs2739330 0.828 rs2186366 ENSG00000225282.1 AP000350.6 -18.25 1.24e-56 3.22e-52 -0.77 -0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23926900~23929574:+ LUSC cis rs858239 0.601 rs2141307 ENSG00000230658.1 KLHL7-AS1 18.25 1.26e-56 3.26e-52 0.82 0.64 Cerebrospinal fluid biomarker levels; chr7:23151805 chr7:23101228~23105703:- LUSC cis rs2739330 0.789 rs5760109 ENSG00000225282.1 AP000350.6 18.24 1.32e-56 3.42e-52 0.78 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23926900~23929574:+ LUSC cis rs2658782 1 rs2658778 ENSG00000279684.1 RP11-755E23.2 -18.23 1.52e-56 3.94e-52 -0.96 -0.64 Pulmonary function decline; chr11:93415782 chr11:93286629~93288903:- LUSC cis rs858239 0.665 rs6964665 ENSG00000230658.1 KLHL7-AS1 18.22 1.71e-56 4.42e-52 0.82 0.64 Cerebrospinal fluid biomarker levels; chr7:23171733 chr7:23101228~23105703:- LUSC cis rs858239 0.699 rs858260 ENSG00000230658.1 KLHL7-AS1 18.18 2.43e-56 6.19e-52 0.82 0.64 Cerebrospinal fluid biomarker levels; chr7:23173315 chr7:23101228~23105703:- LUSC cis rs4853012 0.838 rs60964317 ENSG00000217702.2 RP11-287D1.4 18.18 2.5e-56 6.37e-52 1.02 0.64 Gestational age at birth (maternal effect); chr2:74116296 chr2:74130583~74135395:+ LUSC cis rs2658782 1 rs2605583 ENSG00000279684.1 RP11-755E23.2 -18.16 3.22e-56 8.1e-52 -0.95 -0.64 Pulmonary function decline; chr11:93431791 chr11:93286629~93288903:- LUSC cis rs2739330 0.828 rs4822454 ENSG00000225282.1 AP000350.6 18.14 3.76e-56 9.42e-52 0.78 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23926900~23929574:+ LUSC cis rs858239 0.602 rs6953996 ENSG00000230658.1 KLHL7-AS1 18.11 5.19e-56 1.29e-51 0.82 0.64 Cerebrospinal fluid biomarker levels; chr7:23136327 chr7:23101228~23105703:- LUSC cis rs916888 0.647 rs199523 ENSG00000262539.1 RP11-259G18.3 -18.11 5.39e-56 1.34e-51 -0.82 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46259551~46260606:- LUSC cis rs2739330 0.828 rs5760107 ENSG00000218537.1 MIF-AS1 18.1 6.09e-56 1.51e-51 0.85 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23894426~23898930:- LUSC cis rs916888 0.61 rs199446 ENSG00000262539.1 RP11-259G18.3 -18.08 7.11e-56 1.76e-51 -0.82 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46259551~46260606:- LUSC cis rs2739330 0.828 rs2186366 ENSG00000218537.1 MIF-AS1 -18.08 7.55e-56 1.86e-51 -0.85 -0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23894426~23898930:- LUSC cis rs2739330 0.796 rs5760106 ENSG00000225282.1 AP000350.6 -18.07 8.54e-56 2.11e-51 -0.77 -0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23926900~23929574:+ LUSC cis rs2739330 0.789 rs5760109 ENSG00000218537.1 MIF-AS1 18.06 8.8e-56 2.17e-51 0.85 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23894426~23898930:- LUSC cis rs916888 0.61 rs199454 ENSG00000262539.1 RP11-259G18.3 -18.05 1.04e-55 2.57e-51 -0.82 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46259551~46260606:- LUSC cis rs916888 0.647 rs199524 ENSG00000262539.1 RP11-259G18.3 -18.05 1.07e-55 2.63e-51 -0.82 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46259551~46260606:- LUSC cis rs858239 0.539 rs2103281 ENSG00000230658.1 KLHL7-AS1 18.02 1.35e-55 3.3e-51 0.8 0.64 Cerebrospinal fluid biomarker levels; chr7:23154612 chr7:23101228~23105703:- LUSC cis rs916888 0.61 rs199530 ENSG00000262539.1 RP11-259G18.3 -18.02 1.39e-55 3.4e-51 -0.81 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46259551~46260606:- LUSC cis rs1577917 0.796 rs12661231 ENSG00000203875.9 SNHG5 -18.02 1.45e-55 3.55e-51 -0.83 -0.64 Response to antipsychotic treatment; chr6:85834753 chr6:85660950~85678736:- LUSC cis rs9322193 0.961 rs9767713 ENSG00000231760.4 RP11-350J20.5 18.02 1.46e-55 3.57e-51 0.84 0.64 Lung cancer; chr6:149588241 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs12176034 ENSG00000231760.4 RP11-350J20.5 17.99 1.89e-55 4.6e-51 0.85 0.64 Lung cancer; chr6:149800557 chr6:149796151~149826294:- LUSC cis rs1577917 0.839 rs1596990 ENSG00000203875.9 SNHG5 -17.99 2.04e-55 4.95e-51 -0.83 -0.64 Response to antipsychotic treatment; chr6:85840974 chr6:85660950~85678736:- LUSC cis rs1577917 0.637 rs1838957 ENSG00000203875.9 SNHG5 -17.99 2.04e-55 4.95e-51 -0.83 -0.64 Response to antipsychotic treatment; chr6:85855338 chr6:85660950~85678736:- LUSC cis rs1577917 0.839 rs1838956 ENSG00000203875.9 SNHG5 -17.99 2.04e-55 4.95e-51 -0.83 -0.64 Response to antipsychotic treatment; chr6:85855545 chr6:85660950~85678736:- LUSC cis rs1577917 0.839 rs12216103 ENSG00000203875.9 SNHG5 -17.99 2.04e-55 4.95e-51 -0.83 -0.64 Response to antipsychotic treatment; chr6:85861410 chr6:85660950~85678736:- LUSC cis rs1577917 0.839 rs6929514 ENSG00000203875.9 SNHG5 -17.98 2.14e-55 5.18e-51 -0.82 -0.64 Response to antipsychotic treatment; chr6:85816050 chr6:85660950~85678736:- LUSC cis rs2739330 0.828 rs2330635 ENSG00000218537.1 MIF-AS1 17.96 2.81e-55 6.8e-51 0.85 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23894426~23898930:- LUSC cis rs1577917 0.839 rs12055653 ENSG00000203875.9 SNHG5 -17.95 3.13e-55 7.55e-51 -0.83 -0.64 Response to antipsychotic treatment; chr6:85836945 chr6:85660950~85678736:- LUSC cis rs1577917 0.916 rs12661611 ENSG00000203875.9 SNHG5 -17.94 3.21e-55 7.74e-51 -0.82 -0.64 Response to antipsychotic treatment; chr6:85844117 chr6:85660950~85678736:- LUSC cis rs2739330 0.828 rs4822454 ENSG00000218537.1 MIF-AS1 17.94 3.49e-55 8.38e-51 0.85 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23894426~23898930:- LUSC cis rs2658782 0.951 rs2608215 ENSG00000279684.1 RP11-755E23.2 -17.9 5.08e-55 1.22e-50 -0.93 -0.64 Pulmonary function decline; chr11:93415651 chr11:93286629~93288903:- LUSC cis rs1577917 0.839 rs12664634 ENSG00000203875.9 SNHG5 -17.88 6.55e-55 1.57e-50 -0.83 -0.64 Response to antipsychotic treatment; chr6:85869696 chr6:85660950~85678736:- LUSC cis rs1577917 0.839 rs6454504 ENSG00000203875.9 SNHG5 -17.88 6.55e-55 1.57e-50 -0.83 -0.64 Response to antipsychotic treatment; chr6:85870612 chr6:85660950~85678736:- LUSC cis rs9322193 0.961 rs4870144 ENSG00000231760.4 RP11-350J20.5 17.81 1.27e-54 3.01e-50 0.83 0.63 Lung cancer; chr6:149575540 chr6:149796151~149826294:- LUSC cis rs1577917 0.839 rs9450333 ENSG00000203875.9 SNHG5 -17.78 1.9e-54 4.5e-50 -0.81 -0.63 Response to antipsychotic treatment; chr6:85810037 chr6:85660950~85678736:- LUSC cis rs2739330 0.796 rs2154594 ENSG00000225282.1 AP000350.6 -17.77 2.07e-54 4.9e-50 -0.76 -0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23926900~23929574:+ LUSC cis rs9322193 0.923 rs2880436 ENSG00000231760.4 RP11-350J20.5 17.74 2.72e-54 6.42e-50 0.81 0.63 Lung cancer; chr6:149859123 chr6:149796151~149826294:- LUSC cis rs9322193 0.847 rs880246 ENSG00000231760.4 RP11-350J20.5 17.74 2.83e-54 6.67e-50 0.82 0.63 Lung cancer; chr6:149845972 chr6:149796151~149826294:- LUSC cis rs9322193 0.887 rs3777949 ENSG00000231760.4 RP11-350J20.5 17.68 5.47e-54 1.28e-49 0.83 0.63 Lung cancer; chr6:149596021 chr6:149796151~149826294:- LUSC cis rs2658782 0.951 rs117384439 ENSG00000279684.1 RP11-755E23.2 17.65 7.12e-54 1.66e-49 0.96 0.63 Pulmonary function decline; chr11:93378312 chr11:93286629~93288903:- LUSC cis rs1577917 0.883 rs1337854 ENSG00000203875.9 SNHG5 17.65 7.67e-54 1.78e-49 0.82 0.63 Response to antipsychotic treatment; chr6:86014297 chr6:85660950~85678736:- LUSC cis rs4853012 0.941 rs4852329 ENSG00000217702.2 RP11-287D1.4 17.63 9.27e-54 2.15e-49 1.1 0.63 Gestational age at birth (maternal effect); chr2:74127417 chr2:74130583~74135395:+ LUSC cis rs9322193 0.887 rs11155662 ENSG00000231760.4 RP11-350J20.5 17.63 9.35e-54 2.17e-49 0.85 0.63 Lung cancer; chr6:149592731 chr6:149796151~149826294:- LUSC cis rs2658782 0.756 rs3019205 ENSG00000279684.1 RP11-755E23.2 -17.62 1.05e-53 2.43e-49 -0.93 -0.63 Pulmonary function decline; chr11:93376387 chr11:93286629~93288903:- LUSC cis rs858239 0.539 rs6461695 ENSG00000230658.1 KLHL7-AS1 17.61 1.07e-53 2.48e-49 0.8 0.63 Cerebrospinal fluid biomarker levels; chr7:23158165 chr7:23101228~23105703:- LUSC cis rs1577917 0.883 rs1415749 ENSG00000203875.9 SNHG5 17.6 1.21e-53 2.78e-49 0.82 0.63 Response to antipsychotic treatment; chr6:86069366 chr6:85660950~85678736:- LUSC cis rs2658782 0.951 rs2608214 ENSG00000279684.1 RP11-755E23.2 -17.58 1.55e-53 3.55e-49 -0.9 -0.63 Pulmonary function decline; chr11:93415499 chr11:93286629~93288903:- LUSC cis rs9322193 0.961 rs9285521 ENSG00000231760.4 RP11-350J20.5 17.56 1.93e-53 4.41e-49 0.82 0.63 Lung cancer; chr6:149585576 chr6:149796151~149826294:- LUSC cis rs2658782 1 rs2658781 ENSG00000279684.1 RP11-755E23.2 17.56 1.93e-53 4.41e-49 0.9 0.63 Pulmonary function decline; chr11:93433202 chr11:93286629~93288903:- LUSC cis rs1577917 0.883 rs9450375 ENSG00000203875.9 SNHG5 17.56 2.02e-53 4.59e-49 0.82 0.63 Response to antipsychotic treatment; chr6:86046911 chr6:85660950~85678736:- LUSC cis rs2658782 1 rs2605582 ENSG00000279684.1 RP11-755E23.2 -17.55 2.05e-53 4.68e-49 -0.92 -0.63 Pulmonary function decline; chr11:93430633 chr11:93286629~93288903:- LUSC cis rs1577917 0.816 rs1838952 ENSG00000203875.9 SNHG5 -17.52 2.86e-53 6.48e-49 -0.82 -0.63 Response to antipsychotic treatment; chr6:85891426 chr6:85660950~85678736:- LUSC cis rs1577917 0.883 rs2660575 ENSG00000203875.9 SNHG5 -17.5 3.5e-53 7.86e-49 -0.82 -0.63 Response to antipsychotic treatment; chr6:85975277 chr6:85660950~85678736:- LUSC cis rs9322193 0.884 rs1108889 ENSG00000231760.4 RP11-350J20.5 17.49 3.84e-53 8.63e-49 0.82 0.63 Lung cancer; chr6:149845433 chr6:149796151~149826294:- LUSC cis rs2739330 0.734 rs2000467 ENSG00000225282.1 AP000350.6 -17.48 4.51e-53 1.01e-48 -0.77 -0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23926900~23929574:+ LUSC cis rs858239 0.539 rs10254544 ENSG00000230658.1 KLHL7-AS1 17.48 4.7e-53 1.05e-48 0.8 0.63 Cerebrospinal fluid biomarker levels; chr7:23180616 chr7:23101228~23105703:- LUSC cis rs2658782 0.789 rs3020073 ENSG00000279684.1 RP11-755E23.2 -17.46 5.3e-53 1.19e-48 -0.93 -0.63 Pulmonary function decline; chr11:93370664 chr11:93286629~93288903:- LUSC cis rs858239 0.539 rs2390757 ENSG00000230658.1 KLHL7-AS1 17.42 8.13e-53 1.81e-48 0.81 0.63 Cerebrospinal fluid biomarker levels; chr7:23151873 chr7:23101228~23105703:- LUSC cis rs858239 0.508 rs10242104 ENSG00000230658.1 KLHL7-AS1 17.4 1.07e-52 2.38e-48 0.8 0.63 Cerebrospinal fluid biomarker levels; chr7:23180831 chr7:23101228~23105703:- LUSC cis rs2739330 0.761 rs5760176 ENSG00000250470.1 AP000351.3 -17.39 1.19e-52 2.64e-48 -0.83 -0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23976904~23977585:- LUSC cis rs2658782 0.951 rs72972357 ENSG00000279684.1 RP11-755E23.2 17.39 1.2e-52 2.65e-48 0.94 0.63 Pulmonary function decline; chr11:93385674 chr11:93286629~93288903:- LUSC cis rs2658782 0.789 rs2658775 ENSG00000279684.1 RP11-755E23.2 -17.37 1.45e-52 3.2e-48 -0.92 -0.63 Pulmonary function decline; chr11:93393633 chr11:93286629~93288903:- LUSC cis rs2658782 0.789 rs2658773 ENSG00000279684.1 RP11-755E23.2 -17.37 1.45e-52 3.2e-48 -0.92 -0.63 Pulmonary function decline; chr11:93393748 chr11:93286629~93288903:- LUSC cis rs4853012 0.941 rs7571083 ENSG00000217702.2 RP11-287D1.4 17.36 1.54e-52 3.39e-48 1.05 0.63 Gestational age at birth (maternal effect); chr2:74115133 chr2:74130583~74135395:+ LUSC cis rs9326248 0.689 rs4516002 ENSG00000254851.1 RP11-109L13.1 -17.35 1.76e-52 3.86e-48 -1.02 -0.62 Blood protein levels; chr11:117128343 chr11:117135528~117138582:+ LUSC cis rs858239 0.508 rs2390754 ENSG00000230658.1 KLHL7-AS1 17.35 1.77e-52 3.89e-48 0.81 0.62 Cerebrospinal fluid biomarker levels; chr7:23150875 chr7:23101228~23105703:- LUSC cis rs4853012 0.941 rs2421752 ENSG00000217702.2 RP11-287D1.4 17.34 1.92e-52 4.22e-48 1.06 0.62 Gestational age at birth (maternal effect); chr2:74114488 chr2:74130583~74135395:+ LUSC cis rs1577917 0.959 rs2816822 ENSG00000203875.9 SNHG5 -17.33 2.27e-52 4.95e-48 -0.82 -0.62 Response to antipsychotic treatment; chr6:85948574 chr6:85660950~85678736:- LUSC cis rs2739330 0.732 rs5760175 ENSG00000250470.1 AP000351.3 17.33 2.3e-52 5.01e-48 0.83 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23976904~23977585:- LUSC cis rs858239 0.508 rs7805085 ENSG00000230658.1 KLHL7-AS1 17.33 2.3e-52 5.02e-48 0.8 0.62 Cerebrospinal fluid biomarker levels; chr7:23150624 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs4559148 ENSG00000230658.1 KLHL7-AS1 17.32 2.49e-52 5.42e-48 0.8 0.62 Cerebrospinal fluid biomarker levels; chr7:23146348 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs4377861 ENSG00000230658.1 KLHL7-AS1 17.32 2.49e-52 5.42e-48 0.8 0.62 Cerebrospinal fluid biomarker levels; chr7:23146350 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs6975852 ENSG00000230658.1 KLHL7-AS1 17.32 2.49e-52 5.42e-48 0.8 0.62 Cerebrospinal fluid biomarker levels; chr7:23147035 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs10247268 ENSG00000230658.1 KLHL7-AS1 17.32 2.49e-52 5.42e-48 0.8 0.62 Cerebrospinal fluid biomarker levels; chr7:23147560 chr7:23101228~23105703:- LUSC cis rs858239 0.539 rs6461694 ENSG00000230658.1 KLHL7-AS1 17.32 2.49e-52 5.42e-48 0.8 0.62 Cerebrospinal fluid biomarker levels; chr7:23148160 chr7:23101228~23105703:- LUSC cis rs858239 0.508 rs7805071 ENSG00000230658.1 KLHL7-AS1 17.32 2.49e-52 5.42e-48 0.8 0.62 Cerebrospinal fluid biomarker levels; chr7:23150593 chr7:23101228~23105703:- LUSC cis rs9322193 0.887 rs3734295 ENSG00000231760.4 RP11-350J20.5 17.32 2.58e-52 5.59e-48 0.83 0.62 Lung cancer; chr6:149593917 chr6:149796151~149826294:- LUSC cis rs1577917 0.92 rs1337842 ENSG00000203875.9 SNHG5 -17.31 2.85e-52 6.16e-48 -0.81 -0.62 Response to antipsychotic treatment; chr6:85965379 chr6:85660950~85678736:- LUSC cis rs2658782 0.756 rs2658777 ENSG00000279684.1 RP11-755E23.2 -17.3 2.96e-52 6.39e-48 -0.91 -0.62 Pulmonary function decline; chr11:93415257 chr11:93286629~93288903:- LUSC cis rs1577917 0.883 rs12214536 ENSG00000203875.9 SNHG5 -17.3 2.99e-52 6.46e-48 -0.82 -0.62 Response to antipsychotic treatment; chr6:86080592 chr6:85660950~85678736:- LUSC cis rs2658782 0.826 rs2925355 ENSG00000279684.1 RP11-755E23.2 -17.3 3.07e-52 6.62e-48 -0.94 -0.62 Pulmonary function decline; chr11:93357721 chr11:93286629~93288903:- LUSC cis rs1577917 0.883 rs9450348 ENSG00000203875.9 SNHG5 -17.29 3.35e-52 7.19e-48 -0.81 -0.62 Response to antipsychotic treatment; chr6:85888318 chr6:85660950~85678736:- LUSC cis rs4853012 0.941 rs78128123 ENSG00000217702.2 RP11-287D1.4 17.29 3.54e-52 7.6e-48 1.1 0.62 Gestational age at birth (maternal effect); chr2:74120398 chr2:74130583~74135395:+ LUSC cis rs2739330 0.731 rs5751792 ENSG00000250470.1 AP000351.3 17.27 4.35e-52 9.28e-48 0.82 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23976904~23977585:- LUSC cis rs1577917 0.883 rs13212415 ENSG00000203875.9 SNHG5 -17.26 4.44e-52 9.46e-48 -0.81 -0.62 Response to antipsychotic treatment; chr6:85898365 chr6:85660950~85678736:- LUSC cis rs1577917 0.839 rs1447159 ENSG00000203875.9 SNHG5 -17.26 4.44e-52 9.46e-48 -0.81 -0.62 Response to antipsychotic treatment; chr6:85899531 chr6:85660950~85678736:- LUSC cis rs9322193 0.887 rs4870139 ENSG00000231760.4 RP11-350J20.5 17.25 4.99e-52 1.06e-47 0.83 0.62 Lung cancer; chr6:149575182 chr6:149796151~149826294:- LUSC cis rs2658782 0.789 rs2658776 ENSG00000279684.1 RP11-755E23.2 -17.25 5.28e-52 1.12e-47 -0.91 -0.62 Pulmonary function decline; chr11:93414761 chr11:93286629~93288903:- LUSC cis rs1577917 0.804 rs2786854 ENSG00000203875.9 SNHG5 -17.25 5.29e-52 1.12e-47 -0.81 -0.62 Response to antipsychotic treatment; chr6:85959022 chr6:85660950~85678736:- LUSC cis rs9322193 0.884 rs11155679 ENSG00000231760.4 RP11-350J20.5 17.25 5.33e-52 1.13e-47 0.85 0.62 Lung cancer; chr6:149758881 chr6:149796151~149826294:- LUSC cis rs2739330 0.76 rs5751760 ENSG00000225282.1 AP000350.6 17.24 5.8e-52 1.23e-47 0.72 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23926900~23929574:+ LUSC cis rs9322193 0.851 rs9322194 ENSG00000231760.4 RP11-350J20.5 17.23 6.08e-52 1.28e-47 0.83 0.62 Lung cancer; chr6:149599113 chr6:149796151~149826294:- LUSC cis rs1577917 0.696 rs10806334 ENSG00000203875.9 SNHG5 -17.23 6.12e-52 1.29e-47 -0.8 -0.62 Response to antipsychotic treatment; chr6:85729611 chr6:85660950~85678736:- LUSC cis rs2658782 0.756 rs3019223 ENSG00000279684.1 RP11-755E23.2 -17.23 6.54e-52 1.37e-47 -0.92 -0.62 Pulmonary function decline; chr11:93351016 chr11:93286629~93288903:- LUSC cis rs2486288 0.656 rs6493144 ENSG00000259520.4 CTD-2651B20.3 -17.22 6.77e-52 1.42e-47 -0.77 -0.62 Glomerular filtration rate; chr15:45281291 chr15:45251580~45279251:- LUSC cis rs9322193 0.884 rs880245 ENSG00000231760.4 RP11-350J20.5 -17.22 6.9e-52 1.44e-47 -0.8 -0.62 Lung cancer; chr6:149846262 chr6:149796151~149826294:- LUSC cis rs2486288 0.656 rs11631021 ENSG00000259520.4 CTD-2651B20.3 17.21 7.75e-52 1.62e-47 0.77 0.62 Glomerular filtration rate; chr15:45264631 chr15:45251580~45279251:- LUSC cis rs2658782 0.666 rs2925361 ENSG00000279684.1 RP11-755E23.2 -17.18 1.06e-51 2.2e-47 -0.92 -0.62 Pulmonary function decline; chr11:93365657 chr11:93286629~93288903:- LUSC cis rs9322193 0.884 rs9397036 ENSG00000231760.4 RP11-350J20.5 17.18 1.13e-51 2.34e-47 0.8 0.62 Lung cancer; chr6:149851787 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs9383864 ENSG00000231760.4 RP11-350J20.5 17.18 1.13e-51 2.34e-47 0.8 0.62 Lung cancer; chr6:149851969 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs9383865 ENSG00000231760.4 RP11-350J20.5 17.18 1.13e-51 2.34e-47 0.8 0.62 Lung cancer; chr6:149852043 chr6:149796151~149826294:- LUSC cis rs2739330 0.627 rs9608219 ENSG00000225282.1 AP000350.6 17.16 1.29e-51 2.66e-47 0.74 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23926900~23929574:+ LUSC cis rs858239 0.539 rs10270695 ENSG00000230658.1 KLHL7-AS1 -17.15 1.49e-51 3.08e-47 -0.82 -0.62 Cerebrospinal fluid biomarker levels; chr7:23149369 chr7:23101228~23105703:- LUSC cis rs7301826 0.651 rs7132657 ENSG00000256250.1 RP11-989F5.1 -17.15 1.55e-51 3.19e-47 -0.73 -0.62 Plasma plasminogen activator levels; chr12:130800642 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs7971046 ENSG00000256250.1 RP11-989F5.1 -17.15 1.55e-51 3.19e-47 -0.73 -0.62 Plasma plasminogen activator levels; chr12:130802262 chr12:130810606~130812438:+ LUSC cis rs9322193 0.884 rs1125 ENSG00000231760.4 RP11-350J20.5 17.14 1.61e-51 3.3e-47 0.84 0.62 Lung cancer; chr6:149658280 chr6:149796151~149826294:- LUSC cis rs7301826 0.651 rs4759517 ENSG00000256250.1 RP11-989F5.1 -17.14 1.64e-51 3.35e-47 -0.73 -0.62 Plasma plasminogen activator levels; chr12:130799153 chr12:130810606~130812438:+ LUSC cis rs2658782 0.789 rs3019206 ENSG00000279684.1 RP11-755E23.2 -17.13 1.77e-51 3.62e-47 -0.91 -0.62 Pulmonary function decline; chr11:93377907 chr11:93286629~93288903:- LUSC cis rs9322193 0.772 rs7738696 ENSG00000231760.4 RP11-350J20.5 17.13 1.8e-51 3.68e-47 0.8 0.62 Lung cancer; chr6:149848985 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs11155675 ENSG00000231760.4 RP11-350J20.5 17.13 1.83e-51 3.75e-47 0.84 0.62 Lung cancer; chr6:149742883 chr6:149796151~149826294:- LUSC cis rs2658782 0.789 rs3020076 ENSG00000279684.1 RP11-755E23.2 -17.13 1.87e-51 3.82e-47 -0.9 -0.62 Pulmonary function decline; chr11:93407892 chr11:93286629~93288903:- LUSC cis rs9322193 0.884 rs7743823 ENSG00000231760.4 RP11-350J20.5 17.13 1.89e-51 3.85e-47 0.8 0.62 Lung cancer; chr6:149849744 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs10872647 ENSG00000231760.4 RP11-350J20.5 17.12 2e-51 4.09e-47 0.84 0.62 Lung cancer; chr6:149758687 chr6:149796151~149826294:- LUSC cis rs2739330 0.76 rs1002286 ENSG00000225282.1 AP000350.6 -17.11 2.25e-51 4.59e-47 -0.74 -0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23926900~23929574:+ LUSC cis rs9326248 0.861 rs11216172 ENSG00000254851.1 RP11-109L13.1 -17.11 2.27e-51 4.63e-47 -0.86 -0.62 Blood protein levels; chr11:116879162 chr11:117135528~117138582:+ LUSC cis rs2658782 0.951 rs72972364 ENSG00000279684.1 RP11-755E23.2 17.1 2.43e-51 4.94e-47 0.94 0.62 Pulmonary function decline; chr11:93388962 chr11:93286629~93288903:- LUSC cis rs9322193 0.651 rs9322188 ENSG00000231760.4 RP11-350J20.5 -17.1 2.46e-51 4.99e-47 -0.8 -0.62 Lung cancer; chr6:149588355 chr6:149796151~149826294:- LUSC cis rs2658782 0.789 rs3020057 ENSG00000279684.1 RP11-755E23.2 -17.1 2.57e-51 5.21e-47 -0.89 -0.62 Pulmonary function decline; chr11:93385349 chr11:93286629~93288903:- LUSC cis rs858239 0.537 rs2286272 ENSG00000230658.1 KLHL7-AS1 17.07 3.31e-51 6.69e-47 0.78 0.62 Cerebrospinal fluid biomarker levels; chr7:23184748 chr7:23101228~23105703:- LUSC cis rs2658782 0.789 rs2259633 ENSG00000279684.1 RP11-755E23.2 -17.07 3.38e-51 6.82e-47 -0.9 -0.62 Pulmonary function decline; chr11:93408414 chr11:93286629~93288903:- LUSC cis rs7301826 0.627 rs1077317 ENSG00000256250.1 RP11-989F5.1 -17.07 3.46e-51 6.97e-47 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130830432 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs4759525 ENSG00000256250.1 RP11-989F5.1 -17.07 3.46e-51 6.97e-47 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130831736 chr12:130810606~130812438:+ LUSC cis rs2739330 0.703 rs5760112 ENSG00000225282.1 AP000350.6 17.06 3.77e-51 7.58e-47 0.74 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23926900~23929574:+ LUSC cis rs2739330 0.732 rs5760175 ENSG00000273295.1 AP000350.5 17.06 3.94e-51 7.91e-47 0.7 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23901432~23907068:- LUSC cis rs7301826 0.651 rs10848206 ENSG00000256250.1 RP11-989F5.1 -17.05 4.07e-51 8.15e-47 -0.73 -0.62 Plasma plasminogen activator levels; chr12:130796926 chr12:130810606~130812438:+ LUSC cis rs2486288 0.656 rs8039352 ENSG00000259520.4 CTD-2651B20.3 17.05 4.14e-51 8.27e-47 0.77 0.62 Glomerular filtration rate; chr15:45259592 chr15:45251580~45279251:- LUSC cis rs858239 0.537 rs6942981 ENSG00000230658.1 KLHL7-AS1 17.05 4.19e-51 8.37e-47 0.79 0.62 Cerebrospinal fluid biomarker levels; chr7:23191929 chr7:23101228~23105703:- LUSC cis rs916888 0.779 rs199498 ENSG00000262539.1 RP11-259G18.3 17.05 4.41e-51 8.79e-47 0.79 0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:46259551~46260606:- LUSC cis rs9322193 0.884 rs10872648 ENSG00000231760.4 RP11-350J20.5 17.05 4.49e-51 8.97e-47 0.84 0.62 Lung cancer; chr6:149758699 chr6:149796151~149826294:- LUSC cis rs9322193 0.923 rs9371486 ENSG00000231760.4 RP11-350J20.5 17.04 4.88e-51 9.72e-47 0.83 0.62 Lung cancer; chr6:149832090 chr6:149796151~149826294:- LUSC cis rs7301826 0.61 rs9668291 ENSG00000256250.1 RP11-989F5.1 -17.01 6.18e-51 1.22e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130812363 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs4759794 ENSG00000256250.1 RP11-989F5.1 -17.01 6.18e-51 1.22e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130812803 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs10744485 ENSG00000256250.1 RP11-989F5.1 -17.01 6.18e-51 1.22e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130814005 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs10773824 ENSG00000256250.1 RP11-989F5.1 -17.01 6.18e-51 1.22e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130814306 chr12:130810606~130812438:+ LUSC cis rs2739330 0.76 rs5760095 ENSG00000225282.1 AP000350.6 17.01 6.28e-51 1.24e-46 0.73 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23926900~23929574:+ LUSC cis rs858239 0.537 rs6955115 ENSG00000230658.1 KLHL7-AS1 17 7e-51 1.38e-46 0.78 0.62 Cerebrospinal fluid biomarker levels; chr7:23187525 chr7:23101228~23105703:- LUSC cis rs858239 0.537 rs10279691 ENSG00000230658.1 KLHL7-AS1 17 7e-51 1.38e-46 0.78 0.62 Cerebrospinal fluid biomarker levels; chr7:23188768 chr7:23101228~23105703:- LUSC cis rs1577917 0.883 rs6454505 ENSG00000203875.9 SNHG5 -16.98 8.52e-51 1.66e-46 -0.81 -0.62 Response to antipsychotic treatment; chr6:85882644 chr6:85660950~85678736:- LUSC cis rs7301826 0.651 rs1554807 ENSG00000256250.1 RP11-989F5.1 16.97 9.94e-51 1.94e-46 0.73 0.62 Plasma plasminogen activator levels; chr12:130795872 chr12:130810606~130812438:+ LUSC cis rs858239 0.536 rs6956974 ENSG00000230658.1 KLHL7-AS1 -16.96 1.1e-50 2.13e-46 -0.76 -0.62 Cerebrospinal fluid biomarker levels; chr7:23212699 chr7:23101228~23105703:- LUSC cis rs2658782 0.724 rs1869914 ENSG00000279684.1 RP11-755E23.2 -16.96 1.12e-50 2.18e-46 -0.91 -0.62 Pulmonary function decline; chr11:93379326 chr11:93286629~93288903:- LUSC cis rs1577917 0.883 rs2166664 ENSG00000203875.9 SNHG5 -16.96 1.13e-50 2.2e-46 -0.8 -0.62 Response to antipsychotic treatment; chr6:85886904 chr6:85660950~85678736:- LUSC cis rs2739330 0.652 rs2000469 ENSG00000225282.1 AP000350.6 16.95 1.19e-50 2.29e-46 0.77 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23926900~23929574:+ LUSC cis rs4853012 0.887 rs77148265 ENSG00000217702.2 RP11-287D1.4 16.94 1.31e-50 2.51e-46 1.04 0.62 Gestational age at birth (maternal effect); chr2:74112392 chr2:74130583~74135395:+ LUSC cis rs9322193 0.884 rs7769115 ENSG00000231760.4 RP11-350J20.5 16.94 1.37e-50 2.63e-46 0.8 0.62 Lung cancer; chr6:149848796 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs9371201 ENSG00000231760.4 RP11-350J20.5 16.93 1.5e-50 2.87e-46 0.84 0.62 Lung cancer; chr6:149823865 chr6:149796151~149826294:- LUSC cis rs7301826 0.651 rs10734979 ENSG00000256250.1 RP11-989F5.1 -16.91 1.78e-50 3.37e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130804409 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs4759519 ENSG00000256250.1 RP11-989F5.1 -16.91 1.78e-50 3.37e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130804963 chr12:130810606~130812438:+ LUSC cis rs7301826 0.627 rs10773823 ENSG00000256250.1 RP11-989F5.1 -16.91 1.78e-50 3.37e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130809956 chr12:130810606~130812438:+ LUSC cis rs7301826 0.61 rs4759791 ENSG00000256250.1 RP11-989F5.1 -16.91 1.78e-50 3.37e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130811950 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs4759521 ENSG00000256250.1 RP11-989F5.1 -16.91 1.78e-50 3.37e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130812768 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs10734981 ENSG00000256250.1 RP11-989F5.1 -16.91 1.78e-50 3.37e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130813350 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs10744483 ENSG00000256250.1 RP11-989F5.1 -16.91 1.78e-50 3.37e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130813661 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs10744484 ENSG00000256250.1 RP11-989F5.1 -16.91 1.78e-50 3.37e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130813961 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs10773825 ENSG00000256250.1 RP11-989F5.1 -16.91 1.78e-50 3.37e-46 -0.72 -0.62 Plasma plasminogen activator levels; chr12:130814368 chr12:130810606~130812438:+ LUSC cis rs2486288 0.656 rs2413771 ENSG00000259520.4 CTD-2651B20.3 16.91 1.85e-50 3.5e-46 0.75 0.62 Glomerular filtration rate; chr15:45260942 chr15:45251580~45279251:- LUSC cis rs2739330 0.796 rs1006771 ENSG00000225282.1 AP000350.6 16.9 1.99e-50 3.74e-46 0.77 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23926900~23929574:+ LUSC cis rs2739330 0.731 rs5751792 ENSG00000273295.1 AP000350.5 16.9 2.07e-50 3.9e-46 0.69 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23901432~23907068:- LUSC cis rs2658782 0.789 rs1456238 ENSG00000279684.1 RP11-755E23.2 -16.9 2.14e-50 4.02e-46 -0.9 -0.61 Pulmonary function decline; chr11:93384204 chr11:93286629~93288903:- LUSC cis rs7301826 0.651 rs4514465 ENSG00000256250.1 RP11-989F5.1 -16.89 2.3e-50 4.32e-46 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130829124 chr12:130810606~130812438:+ LUSC cis rs7301826 0.627 rs73162873 ENSG00000256250.1 RP11-989F5.1 -16.89 2.36e-50 4.42e-46 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130811468 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs12228957 ENSG00000256250.1 RP11-989F5.1 -16.89 2.36e-50 4.42e-46 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130811521 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs12228959 ENSG00000256250.1 RP11-989F5.1 -16.89 2.36e-50 4.42e-46 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130811523 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs2037789 ENSG00000256250.1 RP11-989F5.1 16.88 2.64e-50 4.9e-46 0.72 0.61 Plasma plasminogen activator levels; chr12:130803747 chr12:130810606~130812438:+ LUSC cis rs7301826 0.627 rs4325342 ENSG00000256250.1 RP11-989F5.1 -16.87 2.72e-50 5.04e-46 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130827937 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs7295705 ENSG00000256250.1 RP11-989F5.1 -16.87 2.84e-50 5.23e-46 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130817340 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs10848210 ENSG00000256250.1 RP11-989F5.1 -16.84 4e-50 7.31e-46 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130827475 chr12:130810606~130812438:+ LUSC cis rs3814244 0.515 rs2906856 ENSG00000255733.4 IFNG-AS1 -16.82 4.62e-50 8.35e-46 -0.54 -0.61 Itch intensity from mosquito bite adjusted by bite size; chr12:67996421 chr12:67989445~68234686:+ LUSC cis rs3814244 1 rs3814244 ENSG00000255733.4 IFNG-AS1 -16.81 5.11e-50 9.17e-46 -0.52 -0.61 Itch intensity from mosquito bite adjusted by bite size; chr12:68019691 chr12:67989445~68234686:+ LUSC cis rs1577917 0.633 rs7770835 ENSG00000203875.9 SNHG5 -16.81 5.13e-50 9.2e-46 -0.8 -0.61 Response to antipsychotic treatment; chr6:85899189 chr6:85660950~85678736:- LUSC cis rs9322193 0.923 rs9371207 ENSG00000231760.4 RP11-350J20.5 16.81 5.13e-50 9.2e-46 0.79 0.61 Lung cancer; chr6:149858087 chr6:149796151~149826294:- LUSC cis rs7301826 0.651 rs10848209 ENSG00000256250.1 RP11-989F5.1 -16.8 5.79e-50 1.03e-45 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130826727 chr12:130810606~130812438:+ LUSC cis rs2739330 0.734 rs2000467 ENSG00000218537.1 MIF-AS1 -16.8 6.12e-50 1.09e-45 -0.83 -0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23894426~23898930:- LUSC cis rs7301826 0.651 rs7968675 ENSG00000256250.1 RP11-989F5.1 -16.77 7.79e-50 1.37e-45 -0.71 -0.61 Plasma plasminogen activator levels; chr12:130818832 chr12:130810606~130812438:+ LUSC cis rs2739330 0.76 rs5751761 ENSG00000273295.1 AP000350.5 -16.77 7.83e-50 1.37e-45 -0.67 -0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23901432~23907068:- LUSC cis rs1577917 0.771 rs4441928 ENSG00000203875.9 SNHG5 16.77 8.58e-50 1.5e-45 0.8 0.61 Response to antipsychotic treatment; chr6:85532176 chr6:85660950~85678736:- LUSC cis rs2739330 0.685 rs4822453 ENSG00000225282.1 AP000350.6 16.77 8.59e-50 1.5e-45 0.72 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23926900~23929574:+ LUSC cis rs2486288 0.656 rs12440356 ENSG00000259520.4 CTD-2651B20.3 -16.76 9.19e-50 1.6e-45 -0.76 -0.61 Glomerular filtration rate; chr15:45275331 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11639349 ENSG00000259520.4 CTD-2651B20.3 16.76 9.19e-50 1.6e-45 0.76 0.61 Glomerular filtration rate; chr15:45276062 chr15:45251580~45279251:- LUSC cis rs7301826 0.61 rs7957899 ENSG00000256250.1 RP11-989F5.1 -16.76 9.3e-50 1.61e-45 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130794531 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs1973834 ENSG00000256250.1 RP11-989F5.1 -16.76 9.3e-50 1.61e-45 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130795612 chr12:130810606~130812438:+ LUSC cis rs2739330 0.731 rs4822450 ENSG00000225282.1 AP000350.6 16.75 9.69e-50 1.68e-45 0.71 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23926900~23929574:+ LUSC cis rs2739330 0.761 rs5760176 ENSG00000273295.1 AP000350.5 -16.75 1.02e-49 1.77e-45 -0.69 -0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23901432~23907068:- LUSC cis rs4853012 0.887 rs6737314 ENSG00000217702.2 RP11-287D1.4 16.75 1.04e-49 1.81e-45 1.03 0.61 Gestational age at birth (maternal effect); chr2:74112459 chr2:74130583~74135395:+ LUSC cis rs2739330 0.791 rs9612520 ENSG00000250470.1 AP000351.3 16.73 1.2e-49 2.05e-45 0.84 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23976904~23977585:- LUSC cis rs2739330 0.627 rs9608219 ENSG00000250470.1 AP000351.3 16.73 1.27e-49 2.16e-45 0.83 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23976904~23977585:- LUSC cis rs1577917 0.816 rs12664099 ENSG00000203875.9 SNHG5 -16.73 1.27e-49 2.17e-45 -0.79 -0.61 Response to antipsychotic treatment; chr6:85938854 chr6:85660950~85678736:- LUSC cis rs2739330 0.703 rs5760112 ENSG00000250470.1 AP000351.3 16.71 1.6e-49 2.71e-45 0.83 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23976904~23977585:- LUSC cis rs3814244 0.515 rs3015002 ENSG00000255733.4 IFNG-AS1 -16.69 1.92e-49 3.23e-45 -0.53 -0.61 Itch intensity from mosquito bite adjusted by bite size; chr12:68010853 chr12:67989445~68234686:+ LUSC cis rs9326248 0.689 rs236916 ENSG00000254851.1 RP11-109L13.1 16.67 2.32e-49 3.89e-45 1 0.61 Blood protein levels; chr11:117218912 chr11:117135528~117138582:+ LUSC cis rs2658782 0.826 rs1975820 ENSG00000279684.1 RP11-755E23.2 -16.67 2.36e-49 3.96e-45 -0.9 -0.61 Pulmonary function decline; chr11:93348649 chr11:93286629~93288903:- LUSC cis rs7301826 0.571 rs4759788 ENSG00000256250.1 RP11-989F5.1 -16.65 2.81e-49 4.7e-45 -0.72 -0.61 Plasma plasminogen activator levels; chr12:130811769 chr12:130810606~130812438:+ LUSC cis rs2486288 0.656 rs8039153 ENSG00000259520.4 CTD-2651B20.3 16.62 3.84e-49 6.35e-45 0.76 0.61 Glomerular filtration rate; chr15:45287615 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs2461705 ENSG00000259520.4 CTD-2651B20.3 16.6 4.76e-49 7.82e-45 0.76 0.61 Glomerular filtration rate; chr15:45278043 chr15:45251580~45279251:- LUSC cis rs9326248 0.581 rs10892076 ENSG00000254851.1 RP11-109L13.1 -16.6 4.78e-49 7.85e-45 -0.76 -0.61 Blood protein levels; chr11:117118220 chr11:117135528~117138582:+ LUSC cis rs2739330 0.731 rs2000468 ENSG00000225282.1 AP000350.6 16.6 5.04e-49 8.27e-45 0.7 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23926900~23929574:+ LUSC cis rs2739330 0.652 rs2000469 ENSG00000218537.1 MIF-AS1 16.58 5.8e-49 9.48e-45 0.84 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23894426~23898930:- LUSC cis rs9326248 0.581 rs7106437 ENSG00000254851.1 RP11-109L13.1 -16.58 6.14e-49 1e-44 -0.75 -0.61 Blood protein levels; chr11:117121360 chr11:117135528~117138582:+ LUSC cis rs858239 0.601 rs28673077 ENSG00000230658.1 KLHL7-AS1 16.57 6.54e-49 1.07e-44 0.79 0.61 Cerebrospinal fluid biomarker levels; chr7:23211235 chr7:23101228~23105703:- LUSC cis rs2486288 0.656 rs1706768 ENSG00000259520.4 CTD-2651B20.3 16.57 6.9e-49 1.12e-44 0.76 0.61 Glomerular filtration rate; chr15:45277245 chr15:45251580~45279251:- LUSC cis rs2739330 0.791 rs9612520 ENSG00000225282.1 AP000350.6 16.56 7.5e-49 1.22e-44 0.73 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23926900~23929574:+ LUSC cis rs7301826 0.61 rs4759789 ENSG00000256250.1 RP11-989F5.1 -16.56 7.82e-49 1.27e-44 -0.71 -0.61 Plasma plasminogen activator levels; chr12:130811835 chr12:130810606~130812438:+ LUSC cis rs2486288 0.656 rs1719232 ENSG00000259520.4 CTD-2651B20.3 16.54 9.46e-49 1.53e-44 0.76 0.61 Glomerular filtration rate; chr15:45279874 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs12911861 ENSG00000259520.4 CTD-2651B20.3 16.54 9.5e-49 1.53e-44 0.75 0.61 Glomerular filtration rate; chr15:45274520 chr15:45251580~45279251:- LUSC cis rs2739330 0.76 rs5760095 ENSG00000250470.1 AP000351.3 16.52 1.15e-48 1.84e-44 0.82 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23976904~23977585:- LUSC cis rs858239 0.601 rs6461702 ENSG00000230658.1 KLHL7-AS1 16.52 1.17e-48 1.87e-44 0.78 0.61 Cerebrospinal fluid biomarker levels; chr7:23209654 chr7:23101228~23105703:- LUSC cis rs9326248 0.581 rs7120515 ENSG00000254851.1 RP11-109L13.1 -16.5 1.35e-48 2.14e-44 -0.74 -0.61 Blood protein levels; chr11:117121210 chr11:117135528~117138582:+ LUSC cis rs2739330 0.76 rs1007888 ENSG00000225282.1 AP000350.6 16.49 1.55e-48 2.45e-44 0.7 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23926900~23929574:+ LUSC cis rs2486288 0.656 rs1706770 ENSG00000259520.4 CTD-2651B20.3 16.47 1.91e-48 3e-44 0.76 0.6 Glomerular filtration rate; chr15:45282864 chr15:45251580~45279251:- LUSC cis rs858239 0.568 rs6970694 ENSG00000230658.1 KLHL7-AS1 16.47 2.02e-48 3.17e-44 0.78 0.6 Cerebrospinal fluid biomarker levels; chr7:23211209 chr7:23101228~23105703:- LUSC cis rs916888 0.779 rs199498 ENSG00000214401.4 KANSL1-AS1 16.46 2.12e-48 3.33e-44 0.84 0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:46193576~46196723:+ LUSC cis rs2739330 0.76 rs1002286 ENSG00000250470.1 AP000351.3 -16.45 2.28e-48 3.57e-44 -0.82 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23976904~23977585:- LUSC cis rs1153858 0.621 rs12913645 ENSG00000259520.4 CTD-2651B20.3 16.45 2.47e-48 3.87e-44 0.8 0.6 Homoarginine levels; chr15:45262868 chr15:45251580~45279251:- LUSC cis rs1153858 0.621 rs2413769 ENSG00000259520.4 CTD-2651B20.3 -16.44 2.53e-48 3.96e-44 -0.81 -0.6 Homoarginine levels; chr15:45269670 chr15:45251580~45279251:- LUSC cis rs2906856 0.921 rs1019076 ENSG00000255733.4 IFNG-AS1 -16.42 3.13e-48 4.84e-44 -0.53 -0.6 Mosquito bite size; chr12:68004338 chr12:67989445~68234686:+ LUSC cis rs3814244 0.515 rs2906862 ENSG00000255733.4 IFNG-AS1 -16.41 3.51e-48 5.42e-44 -0.53 -0.6 Itch intensity from mosquito bite adjusted by bite size; chr12:68005371 chr12:67989445~68234686:+ LUSC cis rs7301826 0.557 rs7953184 ENSG00000256250.1 RP11-989F5.1 16.41 3.6e-48 5.55e-44 0.71 0.6 Plasma plasminogen activator levels; chr12:130800307 chr12:130810606~130812438:+ LUSC cis rs997154 0.579 rs12889177 ENSG00000279656.1 RP11-298I3.6 -16.4 3.81e-48 5.86e-44 -0.81 -0.6 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:23022120 chr14:23023083~23024217:- LUSC cis rs858239 0.536 rs6961109 ENSG00000230658.1 KLHL7-AS1 16.39 4.31e-48 6.61e-44 0.75 0.6 Cerebrospinal fluid biomarker levels; chr7:23212794 chr7:23101228~23105703:- LUSC cis rs7301826 0.651 rs7956851 ENSG00000256250.1 RP11-989F5.1 -16.36 6.19e-48 9.44e-44 -0.71 -0.6 Plasma plasminogen activator levels; chr12:130834554 chr12:130810606~130812438:+ LUSC cis rs2658782 0.906 rs2658791 ENSG00000279684.1 RP11-755E23.2 -16.36 6.22e-48 9.48e-44 -0.92 -0.6 Pulmonary function decline; chr11:93465817 chr11:93286629~93288903:- LUSC cis rs2486288 0.656 rs6493145 ENSG00000259520.4 CTD-2651B20.3 16.36 6.27e-48 9.54e-44 0.75 0.6 Glomerular filtration rate; chr15:45281664 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs8024620 ENSG00000259520.4 CTD-2651B20.3 16.36 6.27e-48 9.54e-44 0.75 0.6 Glomerular filtration rate; chr15:45282131 chr15:45251580~45279251:- LUSC cis rs2658782 0.756 rs3019222 ENSG00000279684.1 RP11-755E23.2 -16.36 6.34e-48 9.65e-44 -0.89 -0.6 Pulmonary function decline; chr11:93346552 chr11:93286629~93288903:- LUSC cis rs2486288 0.656 rs62026703 ENSG00000259520.4 CTD-2651B20.3 16.34 7.21e-48 1.09e-43 0.75 0.6 Glomerular filtration rate; chr15:45277731 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs7171312 ENSG00000259520.4 CTD-2651B20.3 16.34 7.21e-48 1.09e-43 0.75 0.6 Glomerular filtration rate; chr15:45278027 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs7165039 ENSG00000259520.4 CTD-2651B20.3 16.34 7.21e-48 1.09e-43 0.75 0.6 Glomerular filtration rate; chr15:45278215 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs6493143 ENSG00000259520.4 CTD-2651B20.3 16.34 7.21e-48 1.09e-43 0.75 0.6 Glomerular filtration rate; chr15:45278583 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs7166580 ENSG00000259520.4 CTD-2651B20.3 16.34 7.21e-48 1.09e-43 0.75 0.6 Glomerular filtration rate; chr15:45279011 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11632920 ENSG00000259520.4 CTD-2651B20.3 16.34 7.34e-48 1.11e-43 0.73 0.6 Glomerular filtration rate; chr15:45259066 chr15:45251580~45279251:- LUSC cis rs1153858 0.621 rs1706824 ENSG00000259520.4 CTD-2651B20.3 -16.34 7.84e-48 1.18e-43 -0.79 -0.6 Homoarginine levels; chr15:45287750 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11632419 ENSG00000259520.4 CTD-2651B20.3 16.33 8.17e-48 1.23e-43 0.74 0.6 Glomerular filtration rate; chr15:45265258 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs2271438 ENSG00000259520.4 CTD-2651B20.3 16.33 8.17e-48 1.23e-43 0.74 0.6 Glomerular filtration rate; chr15:45265270 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11854365 ENSG00000259520.4 CTD-2651B20.3 16.33 8.17e-48 1.23e-43 0.74 0.6 Glomerular filtration rate; chr15:45265885 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs12908818 ENSG00000259520.4 CTD-2651B20.3 16.31 1.01e-47 1.52e-43 0.75 0.6 Glomerular filtration rate; chr15:45279470 chr15:45251580~45279251:- LUSC cis rs2486288 0.586 rs12909625 ENSG00000259520.4 CTD-2651B20.3 16.31 1.01e-47 1.52e-43 0.75 0.6 Glomerular filtration rate; chr15:45279855 chr15:45251580~45279251:- LUSC cis rs2486288 0.586 rs12909883 ENSG00000259520.4 CTD-2651B20.3 16.31 1.01e-47 1.52e-43 0.75 0.6 Glomerular filtration rate; chr15:45279856 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs12910009 ENSG00000259520.4 CTD-2651B20.3 16.31 1.01e-47 1.52e-43 0.75 0.6 Glomerular filtration rate; chr15:45280210 chr15:45251580~45279251:- LUSC cis rs2486288 0.554 rs1719235 ENSG00000259520.4 CTD-2651B20.3 16.29 1.23e-47 1.83e-43 0.76 0.6 Glomerular filtration rate; chr15:45283910 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs2413768 ENSG00000259520.4 CTD-2651B20.3 16.29 1.25e-47 1.86e-43 0.74 0.6 Glomerular filtration rate; chr15:45269786 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11637364 ENSG00000259520.4 CTD-2651B20.3 16.26 1.7e-47 2.52e-43 0.75 0.6 Glomerular filtration rate; chr15:45287040 chr15:45251580~45279251:- LUSC cis rs858239 0.669 rs10950940 ENSG00000230658.1 KLHL7-AS1 -16.23 2.4e-47 3.54e-43 -0.75 -0.6 Cerebrospinal fluid biomarker levels; chr7:23157197 chr7:23101228~23105703:- LUSC cis rs1577917 0.771 rs9450319 ENSG00000203875.9 SNHG5 16.22 2.55e-47 3.76e-43 0.77 0.6 Response to antipsychotic treatment; chr6:85717607 chr6:85660950~85678736:- LUSC cis rs1153858 0.621 rs1719237 ENSG00000259520.4 CTD-2651B20.3 -16.22 2.69e-47 3.96e-43 -0.8 -0.6 Homoarginine levels; chr15:45287624 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs7167146 ENSG00000259520.4 CTD-2651B20.3 -16.22 2.75e-47 4.04e-43 -0.74 -0.6 Glomerular filtration rate; chr15:45279188 chr15:45251580~45279251:- LUSC cis rs4853012 0.887 rs7570950 ENSG00000217702.2 RP11-287D1.4 16.18 3.96e-47 5.79e-43 1 0.6 Gestational age at birth (maternal effect); chr2:74111815 chr2:74130583~74135395:+ LUSC cis rs858239 0.699 rs955187 ENSG00000230658.1 KLHL7-AS1 -16.16 4.9e-47 7.12e-43 -0.75 -0.6 Cerebrospinal fluid biomarker levels; chr7:23154986 chr7:23101228~23105703:- LUSC cis rs2486288 0.656 rs11637838 ENSG00000259520.4 CTD-2651B20.3 16.15 5.71e-47 8.29e-43 0.74 0.6 Glomerular filtration rate; chr15:45258459 chr15:45251580~45279251:- LUSC cis rs1577917 0.883 rs2782263 ENSG00000203875.9 SNHG5 -16.13 6.98e-47 1.01e-42 -0.74 -0.6 Response to antipsychotic treatment; chr6:86081589 chr6:85660950~85678736:- LUSC cis rs2739330 0.791 rs4822458 ENSG00000273295.1 AP000350.5 16.09 1.01e-46 1.46e-42 0.67 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23901432~23907068:- LUSC cis rs2658782 0.789 rs2605574 ENSG00000279684.1 RP11-755E23.2 -16.08 1.13e-46 1.62e-42 -0.86 -0.6 Pulmonary function decline; chr11:93403278 chr11:93286629~93288903:- LUSC cis rs2486288 0.656 rs9921035 ENSG00000259520.4 CTD-2651B20.3 16.07 1.22e-46 1.75e-42 0.73 0.6 Glomerular filtration rate; chr15:45254462 chr15:45251580~45279251:- LUSC cis rs1577917 0.771 rs2842608 ENSG00000203875.9 SNHG5 -16.07 1.26e-46 1.81e-42 -0.78 -0.6 Response to antipsychotic treatment; chr6:85586140 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs9294337 ENSG00000203875.9 SNHG5 16.05 1.53e-46 2.2e-42 0.79 0.6 Response to antipsychotic treatment; chr6:85538742 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs4383777 ENSG00000203875.9 SNHG5 16.05 1.54e-46 2.2e-42 0.77 0.6 Response to antipsychotic treatment; chr6:85726242 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs7452605 ENSG00000203875.9 SNHG5 16.05 1.59e-46 2.28e-42 0.79 0.59 Response to antipsychotic treatment; chr6:85531233 chr6:85660950~85678736:- LUSC cis rs2486288 0.656 rs12911186 ENSG00000259520.4 CTD-2651B20.3 16.04 1.71e-46 2.43e-42 0.74 0.59 Glomerular filtration rate; chr15:45259225 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs12915314 ENSG00000259520.4 CTD-2651B20.3 16.04 1.71e-46 2.43e-42 0.74 0.59 Glomerular filtration rate; chr15:45259293 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs8039138 ENSG00000259520.4 CTD-2651B20.3 16.04 1.71e-46 2.43e-42 0.74 0.59 Glomerular filtration rate; chr15:45259394 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs8039540 ENSG00000259520.4 CTD-2651B20.3 16.04 1.71e-46 2.43e-42 0.74 0.59 Glomerular filtration rate; chr15:45259644 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs8040185 ENSG00000259520.4 CTD-2651B20.3 16.04 1.71e-46 2.43e-42 0.74 0.59 Glomerular filtration rate; chr15:45259883 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs1060896 ENSG00000259520.4 CTD-2651B20.3 16.04 1.71e-46 2.43e-42 0.74 0.59 Glomerular filtration rate; chr15:45262069 chr15:45251580~45279251:- LUSC cis rs9322193 0.884 rs7744105 ENSG00000231760.4 RP11-350J20.5 16.03 1.91e-46 2.71e-42 0.77 0.59 Lung cancer; chr6:149849308 chr6:149796151~149826294:- LUSC cis rs2739330 0.796 rs1006771 ENSG00000218537.1 MIF-AS1 16 2.5e-46 3.52e-42 0.82 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23894426~23898930:- LUSC cis rs7301826 0.627 rs4334059 ENSG00000256250.1 RP11-989F5.1 -15.99 2.81e-46 3.97e-42 -0.7 -0.59 Plasma plasminogen activator levels; chr12:130829669 chr12:130810606~130812438:+ LUSC cis rs2486288 0.656 rs9921025 ENSG00000259520.4 CTD-2651B20.3 15.99 2.94e-46 4.14e-42 0.73 0.59 Glomerular filtration rate; chr15:45254404 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs2413774 ENSG00000259520.4 CTD-2651B20.3 15.99 2.95e-46 4.15e-42 0.74 0.59 Glomerular filtration rate; chr15:45257225 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs8041702 ENSG00000259520.4 CTD-2651B20.3 15.97 3.36e-46 4.73e-42 0.74 0.59 Glomerular filtration rate; chr15:45254895 chr15:45251580~45279251:- LUSC cis rs1153858 0.621 rs2687512 ENSG00000259520.4 CTD-2651B20.3 15.97 3.52e-46 4.93e-42 0.8 0.59 Homoarginine levels; chr15:45289297 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs10519018 ENSG00000259520.4 CTD-2651B20.3 15.96 4.08e-46 5.69e-42 0.73 0.59 Glomerular filtration rate; chr15:45257067 chr15:45251580~45279251:- LUSC cis rs2658782 0.789 rs2605580 ENSG00000279684.1 RP11-755E23.2 -15.95 4.15e-46 5.78e-42 -0.86 -0.59 Pulmonary function decline; chr11:93413888 chr11:93286629~93288903:- LUSC cis rs2486288 0.656 rs11854325 ENSG00000259520.4 CTD-2651B20.3 15.95 4.28e-46 5.96e-42 0.73 0.59 Glomerular filtration rate; chr15:45256761 chr15:45251580~45279251:- LUSC cis rs1933112 1 rs1040509 ENSG00000227777.1 RP4-738P11.3 -15.95 4.43e-46 6.15e-42 -0.68 -0.59 Blood protein levels; chr1:168531746 chr1:168542737~168543354:+ LUSC cis rs1577917 0.739 rs9450318 ENSG00000203875.9 SNHG5 15.94 4.6e-46 6.39e-42 0.77 0.59 Response to antipsychotic treatment; chr6:85717459 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs9450290 ENSG00000203875.9 SNHG5 15.94 4.79e-46 6.64e-42 0.79 0.59 Response to antipsychotic treatment; chr6:85523679 chr6:85660950~85678736:- LUSC cis rs2486288 0.656 rs11629807 ENSG00000259520.4 CTD-2651B20.3 15.93 5.14e-46 7.1e-42 0.73 0.59 Glomerular filtration rate; chr15:45254839 chr15:45251580~45279251:- LUSC cis rs2486288 0.587 rs12899942 ENSG00000259520.4 CTD-2651B20.3 15.93 5.14e-46 7.1e-42 0.73 0.59 Glomerular filtration rate; chr15:45255082 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs12899058 ENSG00000259520.4 CTD-2651B20.3 15.93 5.14e-46 7.1e-42 0.73 0.59 Glomerular filtration rate; chr15:45255126 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs12904150 ENSG00000259520.4 CTD-2651B20.3 15.93 5.14e-46 7.1e-42 0.73 0.59 Glomerular filtration rate; chr15:45255407 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs9920290 ENSG00000259520.4 CTD-2651B20.3 15.93 5.14e-46 7.1e-42 0.73 0.59 Glomerular filtration rate; chr15:45255837 chr15:45251580~45279251:- LUSC cis rs7301826 0.585 rs6486600 ENSG00000256250.1 RP11-989F5.1 -15.93 5.19e-46 7.16e-42 -0.69 -0.59 Plasma plasminogen activator levels; chr12:130808432 chr12:130810606~130812438:+ LUSC cis rs2486288 0.656 rs8039354 ENSG00000259520.4 CTD-2651B20.3 -15.93 5.23e-46 7.22e-42 -0.72 -0.59 Glomerular filtration rate; chr15:45259558 chr15:45251580~45279251:- LUSC cis rs7301826 0.651 rs7299281 ENSG00000256250.1 RP11-989F5.1 15.93 5.44e-46 7.5e-42 0.7 0.59 Plasma plasminogen activator levels; chr12:130818587 chr12:130810606~130812438:+ LUSC cis rs7301826 0.58 rs61938969 ENSG00000256250.1 RP11-989F5.1 15.93 5.58e-46 7.69e-42 0.7 0.59 Plasma plasminogen activator levels; chr12:130831525 chr12:130810606~130812438:+ LUSC cis rs1577917 0.771 rs4419647 ENSG00000203875.9 SNHG5 15.91 6.27e-46 8.64e-42 0.79 0.59 Response to antipsychotic treatment; chr6:85516021 chr6:85660950~85678736:- LUSC cis rs9326248 0.52 rs74830 ENSG00000254851.1 RP11-109L13.1 15.91 6.6e-46 9.07e-42 0.73 0.59 Blood protein levels; chr11:117219842 chr11:117135528~117138582:+ LUSC cis rs2739330 0.587 rs4820571 ENSG00000273295.1 AP000350.5 15.91 6.86e-46 9.43e-42 0.68 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23901432~23907068:- LUSC cis rs1577917 0.74 rs6926049 ENSG00000203875.9 SNHG5 15.9 7.21e-46 9.9e-42 0.78 0.59 Response to antipsychotic treatment; chr6:85556415 chr6:85660950~85678736:- LUSC cis rs950027 0.549 rs1719250 ENSG00000259520.4 CTD-2651B20.3 -15.9 7.22e-46 9.91e-42 -0.72 -0.59 Response to fenofibrate (adiponectin levels); chr15:45317575 chr15:45251580~45279251:- LUSC cis rs1577917 0.771 rs9353318 ENSG00000203875.9 SNHG5 15.9 7.28e-46 9.96e-42 0.79 0.59 Response to antipsychotic treatment; chr6:85522003 chr6:85660950~85678736:- LUSC cis rs2486288 0.656 rs11632724 ENSG00000259520.4 CTD-2651B20.3 15.89 7.93e-46 1.08e-41 0.73 0.59 Glomerular filtration rate; chr15:45258593 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11632651 ENSG00000259520.4 CTD-2651B20.3 15.89 7.93e-46 1.08e-41 0.73 0.59 Glomerular filtration rate; chr15:45258640 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11637920 ENSG00000259520.4 CTD-2651B20.3 15.89 7.93e-46 1.08e-41 0.73 0.59 Glomerular filtration rate; chr15:45258707 chr15:45251580~45279251:- LUSC cis rs1577917 0.771 rs4351223 ENSG00000203875.9 SNHG5 15.89 8.1e-46 1.11e-41 0.78 0.59 Response to antipsychotic treatment; chr6:85528079 chr6:85660950~85678736:- LUSC cis rs2486288 0.656 rs11632777 ENSG00000259520.4 CTD-2651B20.3 15.88 9.23e-46 1.25e-41 0.73 0.59 Glomerular filtration rate; chr15:45258847 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11632778 ENSG00000259520.4 CTD-2651B20.3 15.88 9.23e-46 1.25e-41 0.73 0.59 Glomerular filtration rate; chr15:45258858 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11632752 ENSG00000259520.4 CTD-2651B20.3 15.88 9.23e-46 1.25e-41 0.73 0.59 Glomerular filtration rate; chr15:45258942 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs2413772 ENSG00000259520.4 CTD-2651B20.3 15.87 9.57e-46 1.3e-41 0.73 0.59 Glomerular filtration rate; chr15:45257664 chr15:45251580~45279251:- LUSC cis rs858239 0.899 rs28635122 ENSG00000230658.1 KLHL7-AS1 15.86 1.09e-45 1.47e-41 0.75 0.59 Cerebrospinal fluid biomarker levels; chr7:23270562 chr7:23101228~23105703:- LUSC cis rs1577917 0.771 rs9362239 ENSG00000203875.9 SNHG5 15.85 1.18e-45 1.6e-41 0.77 0.59 Response to antipsychotic treatment; chr6:85719545 chr6:85660950~85678736:- LUSC cis rs858239 0.867 rs10250602 ENSG00000230658.1 KLHL7-AS1 15.85 1.26e-45 1.7e-41 0.74 0.59 Cerebrospinal fluid biomarker levels; chr7:23264082 chr7:23101228~23105703:- LUSC cis rs2486288 0.656 rs11639420 ENSG00000259520.4 CTD-2651B20.3 15.85 1.28e-45 1.73e-41 0.74 0.59 Glomerular filtration rate; chr15:45267070 chr15:45251580~45279251:- LUSC cis rs1577917 0.771 rs12199873 ENSG00000203875.9 SNHG5 -15.84 1.38e-45 1.85e-41 -0.78 -0.59 Response to antipsychotic treatment; chr6:85585229 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs2842609 ENSG00000203875.9 SNHG5 -15.84 1.38e-45 1.85e-41 -0.78 -0.59 Response to antipsychotic treatment; chr6:85587070 chr6:85660950~85678736:- LUSC cis rs2739330 0.731 rs4822450 ENSG00000218537.1 MIF-AS1 15.84 1.43e-45 1.92e-41 0.76 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23894426~23898930:- LUSC cis rs1577917 0.666 rs6454471 ENSG00000203875.9 SNHG5 15.83 1.47e-45 1.97e-41 0.79 0.59 Response to antipsychotic treatment; chr6:85504738 chr6:85660950~85678736:- LUSC cis rs1577917 0.665 rs4304137 ENSG00000203875.9 SNHG5 15.83 1.47e-45 1.97e-41 0.79 0.59 Response to antipsychotic treatment; chr6:85507730 chr6:85660950~85678736:- LUSC cis rs7301826 0.651 rs2277336 ENSG00000256250.1 RP11-989F5.1 15.83 1.48e-45 1.99e-41 0.7 0.59 Plasma plasminogen activator levels; chr12:130801574 chr12:130810606~130812438:+ LUSC cis rs2486288 0.656 rs2413773 ENSG00000259520.4 CTD-2651B20.3 15.82 1.61e-45 2.16e-41 0.73 0.59 Glomerular filtration rate; chr15:45257244 chr15:45251580~45279251:- LUSC cis rs858239 0.899 rs7794684 ENSG00000230658.1 KLHL7-AS1 15.82 1.7e-45 2.27e-41 0.75 0.59 Cerebrospinal fluid biomarker levels; chr7:23271186 chr7:23101228~23105703:- LUSC cis rs7301826 0.627 rs7978987 ENSG00000256250.1 RP11-989F5.1 15.81 1.83e-45 2.46e-41 0.7 0.59 Plasma plasminogen activator levels; chr12:130796949 chr12:130810606~130812438:+ LUSC cis rs7301826 0.61 rs7961690 ENSG00000256250.1 RP11-989F5.1 15.81 1.85e-45 2.48e-41 0.69 0.59 Plasma plasminogen activator levels; chr12:130812335 chr12:130810606~130812438:+ LUSC cis rs7301826 0.58 rs12821464 ENSG00000256250.1 RP11-989F5.1 15.81 1.93e-45 2.58e-41 0.7 0.59 Plasma plasminogen activator levels; chr12:130838174 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs34749116 ENSG00000256250.1 RP11-989F5.1 15.78 2.48e-45 3.28e-41 0.7 0.59 Plasma plasminogen activator levels; chr12:130796207 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs6486601 ENSG00000256250.1 RP11-989F5.1 15.77 2.76e-45 3.65e-41 0.69 0.59 Plasma plasminogen activator levels; chr12:130816692 chr12:130810606~130812438:+ LUSC cis rs7301826 0.627 rs61937256 ENSG00000256250.1 RP11-989F5.1 15.77 2.76e-45 3.65e-41 0.69 0.59 Plasma plasminogen activator levels; chr12:130818100 chr12:130810606~130812438:+ LUSC cis rs4853012 0.775 rs12465641 ENSG00000217702.2 RP11-287D1.4 -15.77 2.84e-45 3.76e-41 -0.94 -0.59 Gestational age at birth (maternal effect); chr2:74110588 chr2:74130583~74135395:+ LUSC cis rs2658782 0.694 rs3019221 ENSG00000279684.1 RP11-755E23.2 -15.76 3.23e-45 4.26e-41 -0.87 -0.59 Pulmonary function decline; chr11:93346534 chr11:93286629~93288903:- LUSC cis rs7301826 0.56 rs12829294 ENSG00000256250.1 RP11-989F5.1 15.74 3.7e-45 4.87e-41 0.69 0.59 Plasma plasminogen activator levels; chr12:130825427 chr12:130810606~130812438:+ LUSC cis rs2739330 0.731 rs4822450 ENSG00000250470.1 AP000351.3 15.74 3.8e-45 4.99e-41 0.78 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23976904~23977585:- LUSC cis rs2739330 0.627 rs9608219 ENSG00000218537.1 MIF-AS1 15.71 5.39e-45 7.05e-41 0.77 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23894426~23898930:- LUSC cis rs1577917 0.771 rs2842612 ENSG00000203875.9 SNHG5 -15.7 5.65e-45 7.38e-41 -0.77 -0.59 Response to antipsychotic treatment; chr6:85593373 chr6:85660950~85678736:- LUSC cis rs1577917 0.727 rs2758840 ENSG00000203875.9 SNHG5 -15.7 5.65e-45 7.38e-41 -0.77 -0.59 Response to antipsychotic treatment; chr6:85594907 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs9362230 ENSG00000203875.9 SNHG5 -15.7 5.65e-45 7.38e-41 -0.77 -0.59 Response to antipsychotic treatment; chr6:85595295 chr6:85660950~85678736:- LUSC cis rs2486288 0.656 rs7162022 ENSG00000259520.4 CTD-2651B20.3 15.7 5.79e-45 7.56e-41 0.74 0.59 Glomerular filtration rate; chr15:45273055 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs8037583 ENSG00000259520.4 CTD-2651B20.3 15.67 7.74e-45 1.01e-40 0.72 0.59 Glomerular filtration rate; chr15:45254180 chr15:45251580~45279251:- LUSC cis rs2739330 0.76 rs1007888 ENSG00000250470.1 AP000351.3 15.67 8.32e-45 1.08e-40 0.77 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23976904~23977585:- LUSC cis rs7301826 0.627 rs34103763 ENSG00000256250.1 RP11-989F5.1 15.66 8.49e-45 1.1e-40 0.69 0.59 Plasma plasminogen activator levels; chr12:130805604 chr12:130810606~130812438:+ LUSC cis rs858239 0.669 rs1006709 ENSG00000230658.1 KLHL7-AS1 15.65 9.35e-45 1.21e-40 0.74 0.59 Cerebrospinal fluid biomarker levels; chr7:23100480 chr7:23101228~23105703:- LUSC cis rs1577917 0.771 rs2842602 ENSG00000203875.9 SNHG5 -15.62 1.29e-44 1.65e-40 -0.78 -0.58 Response to antipsychotic treatment; chr6:85622169 chr6:85660950~85678736:- LUSC cis rs7301826 0.61 rs36051740 ENSG00000256250.1 RP11-989F5.1 15.62 1.35e-44 1.73e-40 0.68 0.58 Plasma plasminogen activator levels; chr12:130808177 chr12:130810606~130812438:+ LUSC cis rs1577917 0.785 rs1885607 ENSG00000203875.9 SNHG5 15.61 1.52e-44 1.95e-40 0.76 0.58 Response to antipsychotic treatment; chr6:85685187 chr6:85660950~85678736:- LUSC cis rs2739330 0.791 rs9612520 ENSG00000218537.1 MIF-AS1 15.59 1.73e-44 2.21e-40 0.77 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23894426~23898930:- LUSC cis rs2658782 0.901 rs11604909 ENSG00000279684.1 RP11-755E23.2 -15.59 1.89e-44 2.4e-40 -0.87 -0.58 Pulmonary function decline; chr11:93485189 chr11:93286629~93288903:- LUSC cis rs858239 0.899 rs2268747 ENSG00000230658.1 KLHL7-AS1 15.56 2.49e-44 3.15e-40 0.74 0.58 Cerebrospinal fluid biomarker levels; chr7:23273843 chr7:23101228~23105703:- LUSC cis rs1577917 0.771 rs12205013 ENSG00000203875.9 SNHG5 -15.55 2.76e-44 3.49e-40 -0.78 -0.58 Response to antipsychotic treatment; chr6:85623311 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs9362233 ENSG00000203875.9 SNHG5 -15.55 2.82e-44 3.56e-40 -0.77 -0.58 Response to antipsychotic treatment; chr6:85648529 chr6:85660950~85678736:- LUSC cis rs1577917 0.727 rs9351065 ENSG00000203875.9 SNHG5 -15.55 2.82e-44 3.56e-40 -0.77 -0.58 Response to antipsychotic treatment; chr6:85650710 chr6:85660950~85678736:- LUSC cis rs1577917 0.739 rs2758846 ENSG00000203875.9 SNHG5 -15.55 2.83e-44 3.58e-40 -0.78 -0.58 Response to antipsychotic treatment; chr6:85639852 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs2842601 ENSG00000203875.9 SNHG5 -15.53 3.33e-44 4.18e-40 -0.77 -0.58 Response to antipsychotic treatment; chr6:85620415 chr6:85660950~85678736:- LUSC cis rs858239 0.899 rs28458177 ENSG00000230658.1 KLHL7-AS1 15.53 3.36e-44 4.21e-40 0.72 0.58 Cerebrospinal fluid biomarker levels; chr7:23255253 chr7:23101228~23105703:- LUSC cis rs1577917 0.74 rs2842604 ENSG00000203875.9 SNHG5 -15.51 3.99e-44 4.99e-40 -0.78 -0.58 Response to antipsychotic treatment; chr6:85626582 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs2842607 ENSG00000203875.9 SNHG5 -15.51 3.99e-44 4.99e-40 -0.78 -0.58 Response to antipsychotic treatment; chr6:85635321 chr6:85660950~85678736:- LUSC cis rs2739330 0.703 rs5760112 ENSG00000218537.1 MIF-AS1 15.5 4.8e-44 5.98e-40 0.77 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23894426~23898930:- LUSC cis rs1577917 0.771 rs2475791 ENSG00000203875.9 SNHG5 -15.49 4.84e-44 6.03e-40 -0.77 -0.58 Response to antipsychotic treatment; chr6:85658446 chr6:85660950~85678736:- LUSC cis rs7301826 0.651 rs12820597 ENSG00000256250.1 RP11-989F5.1 15.48 5.43e-44 6.76e-40 0.69 0.58 Plasma plasminogen activator levels; chr12:130795640 chr12:130810606~130812438:+ LUSC cis rs1577917 0.739 rs6922 ENSG00000203875.9 SNHG5 15.48 5.63e-44 7e-40 0.78 0.58 Response to antipsychotic treatment; chr6:85495605 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs4145082 ENSG00000203875.9 SNHG5 -15.47 6.06e-44 7.53e-40 -0.77 -0.58 Response to antipsychotic treatment; chr6:85642298 chr6:85660950~85678736:- LUSC cis rs1577917 0.739 rs9344532 ENSG00000203875.9 SNHG5 15.47 6.45e-44 8e-40 0.78 0.58 Response to antipsychotic treatment; chr6:85524352 chr6:85660950~85678736:- LUSC cis rs1933112 1 rs2223582 ENSG00000227777.1 RP4-738P11.3 -15.46 6.95e-44 8.6e-40 -0.68 -0.58 Blood protein levels; chr1:168537297 chr1:168542737~168543354:+ LUSC cis rs1577917 0.771 rs2758847 ENSG00000203875.9 SNHG5 -15.44 8.37e-44 1.03e-39 -0.77 -0.58 Response to antipsychotic treatment; chr6:85639385 chr6:85660950~85678736:- LUSC cis rs1577917 0.71 rs1059306 ENSG00000203875.9 SNHG5 15.43 9.19e-44 1.13e-39 0.77 0.58 Response to antipsychotic treatment; chr6:85678391 chr6:85660950~85678736:- LUSC cis rs9326248 0.559 rs12808524 ENSG00000254851.1 RP11-109L13.1 -15.43 9.29e-44 1.14e-39 -0.72 -0.58 Blood protein levels; chr11:117020277 chr11:117135528~117138582:+ LUSC cis rs1153858 0.723 rs1719238 ENSG00000259520.4 CTD-2651B20.3 15.43 9.54e-44 1.17e-39 0.79 0.58 Homoarginine levels; chr15:45302568 chr15:45251580~45279251:- LUSC cis rs1153858 0.723 rs4580098 ENSG00000259520.4 CTD-2651B20.3 -15.41 1.14e-43 1.4e-39 -0.78 -0.58 Homoarginine levels; chr15:45304711 chr15:45251580~45279251:- LUSC cis rs1933112 0.808 rs55863344 ENSG00000227777.1 RP4-738P11.3 -15.4 1.24e-43 1.51e-39 -0.68 -0.58 Blood protein levels; chr1:168542884 chr1:168542737~168543354:+ LUSC cis rs1577917 0.771 rs10944133 ENSG00000203875.9 SNHG5 -15.4 1.29e-43 1.57e-39 -0.77 -0.58 Response to antipsychotic treatment; chr6:85649266 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs2783171 ENSG00000203875.9 SNHG5 15.39 1.36e-43 1.65e-39 0.77 0.58 Response to antipsychotic treatment; chr6:85673047 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs2758844 ENSG00000203875.9 SNHG5 -15.39 1.48e-43 1.8e-39 -0.77 -0.58 Response to antipsychotic treatment; chr6:85620397 chr6:85660950~85678736:- LUSC cis rs1577917 0.771 rs2484355 ENSG00000203875.9 SNHG5 -15.38 1.53e-43 1.86e-39 -0.75 -0.58 Response to antipsychotic treatment; chr6:85684685 chr6:85660950~85678736:- LUSC cis rs9326248 0.52 rs6589602 ENSG00000254851.1 RP11-109L13.1 -15.37 1.78e-43 2.14e-39 -0.71 -0.58 Blood protein levels; chr11:117166349 chr11:117135528~117138582:+ LUSC cis rs1577917 0.771 rs2842613 ENSG00000203875.9 SNHG5 15.36 1.92e-43 2.31e-39 0.76 0.58 Response to antipsychotic treatment; chr6:85595984 chr6:85660950~85678736:- LUSC cis rs9326248 0.539 rs7120565 ENSG00000254851.1 RP11-109L13.1 -15.36 1.93e-43 2.32e-39 -0.71 -0.58 Blood protein levels; chr11:117172233 chr11:117135528~117138582:+ LUSC cis rs1933112 1 rs7529824 ENSG00000227777.1 RP4-738P11.3 -15.35 2.15e-43 2.59e-39 -0.67 -0.58 Blood protein levels; chr1:168531220 chr1:168542737~168543354:+ LUSC cis rs2739330 0.76 rs5760095 ENSG00000218537.1 MIF-AS1 15.34 2.37e-43 2.84e-39 0.76 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23894426~23898930:- LUSC cis rs858239 0.899 rs5850 ENSG00000230658.1 KLHL7-AS1 15.33 2.55e-43 3.06e-39 0.73 0.58 Cerebrospinal fluid biomarker levels; chr7:23274928 chr7:23101228~23105703:- LUSC cis rs1577917 0.538 rs6454483 ENSG00000203875.9 SNHG5 15.33 2.67e-43 3.2e-39 0.74 0.58 Response to antipsychotic treatment; chr6:85708565 chr6:85660950~85678736:- LUSC cis rs858239 0.738 rs13225593 ENSG00000230658.1 KLHL7-AS1 15.32 2.93e-43 3.51e-39 0.73 0.58 Cerebrospinal fluid biomarker levels; chr7:23220688 chr7:23101228~23105703:- LUSC cis rs2739330 0.731 rs2000468 ENSG00000218537.1 MIF-AS1 15.31 3.14e-43 3.76e-39 0.73 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23894426~23898930:- LUSC cis rs858239 0.738 rs7807879 ENSG00000230658.1 KLHL7-AS1 15.3 3.5e-43 4.18e-39 0.73 0.58 Cerebrospinal fluid biomarker levels; chr7:23220969 chr7:23101228~23105703:- LUSC cis rs1153858 0.668 rs63603561 ENSG00000259520.4 CTD-2651B20.3 15.29 3.94e-43 4.68e-39 0.79 0.58 Homoarginine levels; chr15:45301125 chr15:45251580~45279251:- LUSC cis rs2739330 0.76 rs5751760 ENSG00000218537.1 MIF-AS1 15.28 4.38e-43 5.2e-39 0.74 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23894426~23898930:- LUSC cis rs9326248 0.52 rs2735183 ENSG00000254851.1 RP11-109L13.1 -15.28 4.6e-43 5.46e-39 -0.71 -0.58 Blood protein levels; chr11:117144479 chr11:117135528~117138582:+ LUSC cis rs2739330 0.76 rs1002286 ENSG00000218537.1 MIF-AS1 -15.27 4.87e-43 5.77e-39 -0.75 -0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23894426~23898930:- LUSC cis rs2739330 0.76 rs1007888 ENSG00000218537.1 MIF-AS1 15.27 5.09e-43 6.04e-39 0.73 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23894426~23898930:- LUSC cis rs2739330 0.791 rs4822458 ENSG00000250470.1 AP000351.3 15.25 6.17e-43 7.31e-39 0.76 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23976904~23977585:- LUSC cis rs9326248 0.501 rs4938351 ENSG00000254851.1 RP11-109L13.1 -15.25 6.18e-43 7.32e-39 -0.71 -0.58 Blood protein levels; chr11:117151636 chr11:117135528~117138582:+ LUSC cis rs858239 0.699 rs1881201 ENSG00000230658.1 KLHL7-AS1 -15.19 1.05e-42 1.24e-38 -0.7 -0.57 Cerebrospinal fluid biomarker levels; chr7:23154394 chr7:23101228~23105703:- LUSC cis rs1933112 0.9 rs7519937 ENSG00000227777.1 RP4-738P11.3 -15.19 1.11e-42 1.31e-38 -0.68 -0.57 Blood protein levels; chr1:168535403 chr1:168542737~168543354:+ LUSC cis rs1577917 0.771 rs9362237 ENSG00000203875.9 SNHG5 15.19 1.15e-42 1.35e-38 0.77 0.57 Response to antipsychotic treatment; chr6:85699346 chr6:85660950~85678736:- LUSC cis rs858239 0.899 rs2268745 ENSG00000230658.1 KLHL7-AS1 15.18 1.28e-42 1.51e-38 0.74 0.57 Cerebrospinal fluid biomarker levels; chr7:23277981 chr7:23101228~23105703:- LUSC cis rs2658782 0.789 rs56091149 ENSG00000279684.1 RP11-755E23.2 15.17 1.39e-42 1.63e-38 0.88 0.57 Pulmonary function decline; chr11:93340474 chr11:93286629~93288903:- LUSC cis rs858239 0.699 rs1881200 ENSG00000230658.1 KLHL7-AS1 -15.17 1.41e-42 1.66e-38 -0.71 -0.57 Cerebrospinal fluid biomarker levels; chr7:23162018 chr7:23101228~23105703:- LUSC cis rs858239 0.899 rs1881203 ENSG00000230658.1 KLHL7-AS1 15.16 1.57e-42 1.84e-38 0.71 0.57 Cerebrospinal fluid biomarker levels; chr7:23253189 chr7:23101228~23105703:- LUSC cis rs1933112 1 rs1323534 ENSG00000227777.1 RP4-738P11.3 -15.15 1.62e-42 1.89e-38 -0.68 -0.57 Blood protein levels; chr1:168534039 chr1:168542737~168543354:+ LUSC cis rs2739330 0.731 rs2000468 ENSG00000250470.1 AP000351.3 15.14 1.85e-42 2.16e-38 0.75 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23976904~23977585:- LUSC cis rs858239 0.899 rs10262243 ENSG00000230658.1 KLHL7-AS1 15.14 1.87e-42 2.18e-38 0.71 0.57 Cerebrospinal fluid biomarker levels; chr7:23251368 chr7:23101228~23105703:- LUSC cis rs1933112 0.9 rs1040508 ENSG00000227777.1 RP4-738P11.3 -15.13 2.11e-42 2.46e-38 -0.66 -0.57 Blood protein levels; chr1:168531512 chr1:168542737~168543354:+ LUSC cis rs1577917 0.771 rs2475790 ENSG00000203875.9 SNHG5 -15.12 2.17e-42 2.52e-38 -0.76 -0.57 Response to antipsychotic treatment; chr6:85658350 chr6:85660950~85678736:- LUSC cis rs9326248 0.769 rs499910 ENSG00000254851.1 RP11-109L13.1 -15.12 2.28e-42 2.65e-38 -0.79 -0.57 Blood protein levels; chr11:116892318 chr11:117135528~117138582:+ LUSC cis rs2739330 0.76 rs5751761 ENSG00000225282.1 AP000350.6 -15.12 2.35e-42 2.73e-38 -0.65 -0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23926900~23929574:+ LUSC cis rs9326248 0.581 rs10892053 ENSG00000254851.1 RP11-109L13.1 -15.11 2.44e-42 2.84e-38 -0.7 -0.57 Blood protein levels; chr11:116986287 chr11:117135528~117138582:+ LUSC cis rs1577917 0.727 rs9444361 ENSG00000203875.9 SNHG5 15.1 2.77e-42 3.21e-38 0.76 0.57 Response to antipsychotic treatment; chr6:85691182 chr6:85660950~85678736:- LUSC cis rs9326248 0.648 rs11216257 ENSG00000254851.1 RP11-109L13.1 -15.1 2.85e-42 3.31e-38 -0.85 -0.57 Blood protein levels; chr11:117061845 chr11:117135528~117138582:+ LUSC cis rs2739330 0.685 rs4822453 ENSG00000218537.1 MIF-AS1 15.08 3.26e-42 3.78e-38 0.74 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23894426~23898930:- LUSC cis rs858239 0.636 rs7808488 ENSG00000230658.1 KLHL7-AS1 15.08 3.55e-42 4.1e-38 0.71 0.57 Cerebrospinal fluid biomarker levels; chr7:23182251 chr7:23101228~23105703:- LUSC cis rs2486288 0.656 rs11629858 ENSG00000259520.4 CTD-2651B20.3 15.07 3.81e-42 4.4e-38 0.72 0.57 Glomerular filtration rate; chr15:45254916 chr15:45251580~45279251:- LUSC cis rs2486288 0.656 rs11629859 ENSG00000259520.4 CTD-2651B20.3 15.07 3.81e-42 4.4e-38 0.72 0.57 Glomerular filtration rate; chr15:45254923 chr15:45251580~45279251:- LUSC cis rs1577917 0.771 rs6454486 ENSG00000203875.9 SNHG5 15.06 4.28e-42 4.93e-38 0.74 0.57 Response to antipsychotic treatment; chr6:85723869 chr6:85660950~85678736:- LUSC cis rs9326248 0.581 rs10892061 ENSG00000254851.1 RP11-109L13.1 -15.03 5.42e-42 6.21e-38 -0.7 -0.57 Blood protein levels; chr11:117015398 chr11:117135528~117138582:+ LUSC cis rs2739330 0.76 rs5751760 ENSG00000250470.1 AP000351.3 15.01 6.84e-42 7.82e-38 0.75 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23976904~23977585:- LUSC cis rs3814244 0.54 rs2159064 ENSG00000255733.4 IFNG-AS1 -15.01 7.04e-42 8.04e-38 -0.49 -0.57 Itch intensity from mosquito bite adjusted by bite size; chr12:68017126 chr12:67989445~68234686:+ LUSC cis rs858239 0.899 rs10085838 ENSG00000230658.1 KLHL7-AS1 15.01 7.11e-42 8.11e-38 0.72 0.57 Cerebrospinal fluid biomarker levels; chr7:23258796 chr7:23101228~23105703:- LUSC cis rs2739330 0.76 rs5751761 ENSG00000250470.1 AP000351.3 -15 7.49e-42 8.54e-38 -0.73 -0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23976904~23977585:- LUSC cis rs9326248 0.52 rs236919 ENSG00000254851.1 RP11-109L13.1 -14.99 8.75e-42 9.96e-38 -0.69 -0.57 Blood protein levels; chr11:117224645 chr11:117135528~117138582:+ LUSC cis rs9326248 0.581 rs11216242 ENSG00000254851.1 RP11-109L13.1 -14.98 9.6e-42 1.09e-37 -0.7 -0.57 Blood protein levels; chr11:117030833 chr11:117135528~117138582:+ LUSC cis rs9326248 0.581 rs12804122 ENSG00000254851.1 RP11-109L13.1 -14.98 9.6e-42 1.09e-37 -0.7 -0.57 Blood protein levels; chr11:117031900 chr11:117135528~117138582:+ LUSC cis rs1577917 0.771 rs7742201 ENSG00000203875.9 SNHG5 -14.97 1.02e-41 1.16e-37 -0.76 -0.57 Response to antipsychotic treatment; chr6:85723212 chr6:85660950~85678736:- LUSC cis rs9326248 0.581 rs10892063 ENSG00000254851.1 RP11-109L13.1 -14.96 1.11e-41 1.25e-37 -0.69 -0.57 Blood protein levels; chr11:117025439 chr11:117135528~117138582:+ LUSC cis rs9326248 0.559 rs10892064 ENSG00000254851.1 RP11-109L13.1 -14.96 1.11e-41 1.25e-37 -0.69 -0.57 Blood protein levels; chr11:117025837 chr11:117135528~117138582:+ LUSC cis rs9326248 0.539 rs10892065 ENSG00000254851.1 RP11-109L13.1 -14.96 1.11e-41 1.25e-37 -0.69 -0.57 Blood protein levels; chr11:117026308 chr11:117135528~117138582:+ LUSC cis rs2739330 0.587 rs4820571 ENSG00000225282.1 AP000350.6 14.94 1.42e-41 1.61e-37 0.66 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23926900~23929574:+ LUSC cis rs950027 0.572 rs12910764 ENSG00000259520.4 CTD-2651B20.3 14.93 1.57e-41 1.77e-37 0.7 0.57 Response to fenofibrate (adiponectin levels); chr15:45317162 chr15:45251580~45279251:- LUSC cis rs1577917 0.518 rs2475787 ENSG00000203875.9 SNHG5 14.9 2.1e-41 2.37e-37 0.72 0.57 Response to antipsychotic treatment; chr6:85705518 chr6:85660950~85678736:- LUSC cis rs9326248 0.53 rs11216171 ENSG00000254851.1 RP11-109L13.1 -14.89 2.27e-41 2.56e-37 -0.78 -0.57 Blood protein levels; chr11:116878397 chr11:117135528~117138582:+ LUSC cis rs2739330 0.685 rs4822453 ENSG00000250470.1 AP000351.3 14.86 3.07e-41 3.45e-37 0.76 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23976904~23977585:- LUSC cis rs3814244 0.966 rs10784666 ENSG00000255733.4 IFNG-AS1 -14.85 3.62e-41 4.06e-37 -0.48 -0.57 Itch intensity from mosquito bite adjusted by bite size; chr12:68021923 chr12:67989445~68234686:+ LUSC cis rs3814244 0.966 rs10784667 ENSG00000255733.4 IFNG-AS1 -14.85 3.62e-41 4.06e-37 -0.48 -0.57 Itch intensity from mosquito bite adjusted by bite size; chr12:68021996 chr12:67989445~68234686:+ LUSC cis rs7301826 0.603 rs7975825 ENSG00000256250.1 RP11-989F5.1 -14.83 4.15e-41 4.64e-37 -0.66 -0.56 Plasma plasminogen activator levels; chr12:130803899 chr12:130810606~130812438:+ LUSC cis rs858239 0.67 rs3807452 ENSG00000230658.1 KLHL7-AS1 -14.83 4.2e-41 4.69e-37 -0.71 -0.56 Cerebrospinal fluid biomarker levels; chr7:23122462 chr7:23101228~23105703:- LUSC cis rs950027 0.549 rs9920634 ENSG00000259520.4 CTD-2651B20.3 14.83 4.28e-41 4.78e-37 0.71 0.56 Response to fenofibrate (adiponectin levels); chr15:45304348 chr15:45251580~45279251:- LUSC cis rs950027 0.549 rs11070452 ENSG00000259520.4 CTD-2651B20.3 14.83 4.31e-41 4.81e-37 0.71 0.56 Response to fenofibrate (adiponectin levels); chr15:45302638 chr15:45251580~45279251:- LUSC cis rs1933112 1 rs2179500 ENSG00000227777.1 RP4-738P11.3 -14.83 4.37e-41 4.87e-37 -0.67 -0.56 Blood protein levels; chr1:168546589 chr1:168542737~168543354:+ LUSC cis rs1933112 1 rs1024176 ENSG00000227777.1 RP4-738P11.3 -14.81 5.42e-41 6.04e-37 -0.67 -0.56 Blood protein levels; chr1:168556865 chr1:168542737~168543354:+ LUSC cis rs507080 0.922 rs525485 ENSG00000255239.1 AP002954.6 14.8 5.93e-41 6.6e-37 0.65 0.56 Serum metabolite levels; chr11:118685045 chr11:118688039~118690600:- LUSC cis rs3814244 0.933 rs10878725 ENSG00000255733.4 IFNG-AS1 -14.76 8.5e-41 9.39e-37 -0.47 -0.56 Itch intensity from mosquito bite adjusted by bite size; chr12:68020930 chr12:67989445~68234686:+ LUSC cis rs2739330 0.732 rs5760175 ENSG00000225282.1 AP000350.6 14.76 8.59e-41 9.48e-37 0.66 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23926900~23929574:+ LUSC cis rs1933112 1 rs1933112 ENSG00000227777.1 RP4-738P11.3 -14.76 9.22e-41 1.02e-36 -0.66 -0.56 Blood protein levels; chr1:168552179 chr1:168542737~168543354:+ LUSC cis rs916888 0.647 rs199523 ENSG00000214401.4 KANSL1-AS1 -14.73 1.23e-40 1.35e-36 -0.78 -0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46193576~46196723:+ LUSC cis rs2658782 0.901 rs7116173 ENSG00000279684.1 RP11-755E23.2 14.73 1.24e-40 1.36e-36 0.84 0.56 Pulmonary function decline; chr11:93489145 chr11:93286629~93288903:- LUSC cis rs916888 0.61 rs142167 ENSG00000214401.4 KANSL1-AS1 -14.72 1.32e-40 1.44e-36 -0.77 -0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46193576~46196723:+ LUSC cis rs2739330 0.761 rs5760176 ENSG00000225282.1 AP000350.6 -14.69 1.78e-40 1.95e-36 -0.65 -0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23926900~23929574:+ LUSC cis rs2739330 0.731 rs5751792 ENSG00000225282.1 AP000350.6 14.69 1.79e-40 1.96e-36 0.65 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23926900~23929574:+ LUSC cis rs858239 0.806 rs10268610 ENSG00000230658.1 KLHL7-AS1 14.68 2.07e-40 2.26e-36 0.7 0.56 Cerebrospinal fluid biomarker levels; chr7:23235145 chr7:23101228~23105703:- LUSC cis rs916888 0.647 rs199524 ENSG00000214401.4 KANSL1-AS1 -14.66 2.5e-40 2.73e-36 -0.77 -0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46193576~46196723:+ LUSC cis rs2658782 0.654 rs2605617 ENSG00000279684.1 RP11-755E23.2 -14.66 2.53e-40 2.75e-36 -0.8 -0.56 Pulmonary function decline; chr11:93510167 chr11:93286629~93288903:- LUSC cis rs1933112 1 rs2223583 ENSG00000227777.1 RP4-738P11.3 -14.65 2.56e-40 2.79e-36 -0.67 -0.56 Blood protein levels; chr1:168556178 chr1:168542737~168543354:+ LUSC cis rs1933112 0.966 rs4656605 ENSG00000227777.1 RP4-738P11.3 -14.65 2.56e-40 2.79e-36 -0.67 -0.56 Blood protein levels; chr1:168556659 chr1:168542737~168543354:+ LUSC cis rs1577917 0.518 rs6454482 ENSG00000203875.9 SNHG5 14.63 3.19e-40 3.46e-36 0.72 0.56 Response to antipsychotic treatment; chr6:85708470 chr6:85660950~85678736:- LUSC cis rs916888 0.531 rs183211 ENSG00000214401.4 KANSL1-AS1 14.62 3.73e-40 4.05e-36 0.77 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46193576~46196723:+ LUSC cis rs916888 0.61 rs199452 ENSG00000214401.4 KANSL1-AS1 14.61 3.88e-40 4.2e-36 0.77 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46193576~46196723:+ LUSC cis rs950027 0.549 rs2899375 ENSG00000259520.4 CTD-2651B20.3 14.61 4.19e-40 4.53e-36 0.7 0.56 Response to fenofibrate (adiponectin levels); chr15:45306137 chr15:45251580~45279251:- LUSC cis rs916888 0.61 rs199453 ENSG00000214401.4 KANSL1-AS1 14.6 4.31e-40 4.65e-36 0.77 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46193576~46196723:+ LUSC cis rs858239 0.67 rs6967526 ENSG00000230658.1 KLHL7-AS1 14.6 4.4e-40 4.75e-36 0.7 0.56 Cerebrospinal fluid biomarker levels; chr7:23119622 chr7:23101228~23105703:- LUSC cis rs1153858 1 rs11858495 ENSG00000259520.4 CTD-2651B20.3 14.58 5.3e-40 5.7e-36 0.72 0.56 Homoarginine levels; chr15:45345464 chr15:45251580~45279251:- LUSC cis rs916888 0.61 rs199442 ENSG00000214401.4 KANSL1-AS1 14.58 5.51e-40 5.9e-36 0.77 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46193576~46196723:+ LUSC cis rs858239 0.72 rs10227559 ENSG00000230658.1 KLHL7-AS1 14.57 6.02e-40 6.43e-36 0.71 0.56 Cerebrospinal fluid biomarker levels; chr7:23232525 chr7:23101228~23105703:- LUSC cis rs9326248 0.603 rs7396061 ENSG00000254851.1 RP11-109L13.1 -14.57 6.31e-40 6.73e-36 -0.67 -0.56 Blood protein levels; chr11:116880158 chr11:117135528~117138582:+ LUSC cis rs2658782 0.724 rs1563445 ENSG00000279684.1 RP11-755E23.2 -14.56 6.45e-40 6.87e-36 -0.81 -0.56 Pulmonary function decline; chr11:93512876 chr11:93286629~93288903:- LUSC cis rs916888 0.61 rs199438 ENSG00000214401.4 KANSL1-AS1 14.56 6.55e-40 6.98e-36 0.77 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46193576~46196723:+ LUSC cis rs9399135 0.967 rs7750300 ENSG00000232876.1 CTA-212D2.2 -14.56 6.91e-40 7.35e-36 -0.64 -0.56 Red blood cell count; chr6:135029812 chr6:135055033~135060550:+ LUSC cis rs858239 0.698 rs858295 ENSG00000230658.1 KLHL7-AS1 14.55 7.4e-40 7.85e-36 0.7 0.56 Cerebrospinal fluid biomarker levels; chr7:23205950 chr7:23101228~23105703:- LUSC cis rs2658782 0.704 rs2605614 ENSG00000279684.1 RP11-755E23.2 -14.55 7.44e-40 7.89e-36 -0.79 -0.56 Pulmonary function decline; chr11:93499579 chr11:93286629~93288903:- LUSC cis rs2658782 0.615 rs2605615 ENSG00000279684.1 RP11-755E23.2 -14.55 7.44e-40 7.89e-36 -0.79 -0.56 Pulmonary function decline; chr11:93499902 chr11:93286629~93288903:- LUSC cis rs916888 0.61 rs199436 ENSG00000214401.4 KANSL1-AS1 -14.53 8.57e-40 9.04e-36 -0.76 -0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46193576~46196723:+ LUSC cis rs2658782 0.547 rs4344448 ENSG00000279684.1 RP11-755E23.2 -14.51 1.1e-39 1.15e-35 -0.76 -0.56 Pulmonary function decline; chr11:93313881 chr11:93286629~93288903:- LUSC cis rs1933112 1 rs1024177 ENSG00000227777.1 RP4-738P11.3 -14.5 1.21e-39 1.27e-35 -0.66 -0.56 Blood protein levels; chr1:168557477 chr1:168542737~168543354:+ LUSC cis rs9326248 0.581 rs4938331 ENSG00000254851.1 RP11-109L13.1 -14.5 1.23e-39 1.29e-35 -0.68 -0.56 Blood protein levels; chr11:117059966 chr11:117135528~117138582:+ LUSC cis rs9326248 0.51 rs4938332 ENSG00000254851.1 RP11-109L13.1 -14.5 1.23e-39 1.29e-35 -0.68 -0.56 Blood protein levels; chr11:117060082 chr11:117135528~117138582:+ LUSC cis rs9326248 0.559 rs4938334 ENSG00000254851.1 RP11-109L13.1 -14.5 1.23e-39 1.29e-35 -0.68 -0.56 Blood protein levels; chr11:117060326 chr11:117135528~117138582:+ LUSC cis rs9326248 0.581 rs6589590 ENSG00000254851.1 RP11-109L13.1 -14.5 1.23e-39 1.29e-35 -0.68 -0.56 Blood protein levels; chr11:117065365 chr11:117135528~117138582:+ LUSC cis rs858239 0.665 rs858306 ENSG00000230658.1 KLHL7-AS1 14.5 1.26e-39 1.32e-35 0.69 0.56 Cerebrospinal fluid biomarker levels; chr7:23203135 chr7:23101228~23105703:- LUSC cis rs5850 0.602 rs1005786 ENSG00000230658.1 KLHL7-AS1 14.49 1.36e-39 1.43e-35 0.71 0.56 Blood protein levels; chr7:23106218 chr7:23101228~23105703:- LUSC cis rs9326248 0.581 rs10502222 ENSG00000254851.1 RP11-109L13.1 -14.49 1.39e-39 1.45e-35 -0.68 -0.56 Blood protein levels; chr11:116963014 chr11:117135528~117138582:+ LUSC cis rs9326248 0.559 rs10892052 ENSG00000254851.1 RP11-109L13.1 -14.49 1.39e-39 1.45e-35 -0.68 -0.56 Blood protein levels; chr11:116963597 chr11:117135528~117138582:+ LUSC cis rs1933112 1 rs1933109 ENSG00000227777.1 RP4-738P11.3 -14.47 1.68e-39 1.74e-35 -0.66 -0.56 Blood protein levels; chr1:168554386 chr1:168542737~168543354:+ LUSC cis rs507080 0.922 rs546890 ENSG00000255239.1 AP002954.6 14.46 1.79e-39 1.84e-35 0.64 0.55 Serum metabolite levels; chr11:118686489 chr11:118688039~118690600:- LUSC cis rs507080 0.883 rs693306 ENSG00000255239.1 AP002954.6 14.46 1.79e-39 1.84e-35 0.64 0.55 Serum metabolite levels; chr11:118687624 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs561845 ENSG00000255239.1 AP002954.6 14.46 1.79e-39 1.84e-35 0.64 0.55 Serum metabolite levels; chr11:118688118 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs638805 ENSG00000255239.1 AP002954.6 14.46 1.79e-39 1.84e-35 0.64 0.55 Serum metabolite levels; chr11:118688180 chr11:118688039~118690600:- LUSC cis rs507080 0.845 rs510408 ENSG00000255239.1 AP002954.6 14.46 1.79e-39 1.84e-35 0.64 0.55 Serum metabolite levels; chr11:118688192 chr11:118688039~118690600:- LUSC cis rs507080 0.845 rs509641 ENSG00000255239.1 AP002954.6 14.46 1.79e-39 1.84e-35 0.64 0.55 Serum metabolite levels; chr11:118688243 chr11:118688039~118690600:- LUSC cis rs507080 0.883 rs563549 ENSG00000255239.1 AP002954.6 14.46 1.79e-39 1.84e-35 0.64 0.55 Serum metabolite levels; chr11:118688244 chr11:118688039~118690600:- LUSC cis rs507080 0.885 rs533144 ENSG00000255239.1 AP002954.6 14.46 1.79e-39 1.84e-35 0.64 0.55 Serum metabolite levels; chr11:118688538 chr11:118688039~118690600:- LUSC cis rs858239 0.633 rs858300 ENSG00000230658.1 KLHL7-AS1 14.46 1.8e-39 1.85e-35 0.7 0.55 Cerebrospinal fluid biomarker levels; chr7:23205012 chr7:23101228~23105703:- LUSC cis rs507080 0.922 rs555356 ENSG00000255239.1 AP002954.6 14.46 1.85e-39 1.9e-35 0.64 0.55 Serum metabolite levels; chr11:118687369 chr11:118688039~118690600:- LUSC cis rs950027 0.549 rs12909409 ENSG00000259520.4 CTD-2651B20.3 14.46 1.85e-39 1.9e-35 0.69 0.55 Response to fenofibrate (adiponectin levels); chr15:45316384 chr15:45251580~45279251:- LUSC cis rs858239 0.73 rs858290 ENSG00000230658.1 KLHL7-AS1 14.45 1.99e-39 2.05e-35 0.7 0.55 Cerebrospinal fluid biomarker levels; chr7:23208417 chr7:23101228~23105703:- LUSC cis rs858239 0.73 rs858289 ENSG00000230658.1 KLHL7-AS1 14.45 1.99e-39 2.05e-35 0.7 0.55 Cerebrospinal fluid biomarker levels; chr7:23208539 chr7:23101228~23105703:- LUSC cis rs9399135 0.967 rs2183709 ENSG00000232876.1 CTA-212D2.2 -14.44 2.22e-39 2.27e-35 -0.65 -0.55 Red blood cell count; chr6:135055953 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs4142299 ENSG00000232876.1 CTA-212D2.2 -14.44 2.22e-39 2.27e-35 -0.65 -0.55 Red blood cell count; chr6:135056048 chr6:135055033~135060550:+ LUSC cis rs507080 0.845 rs613377 ENSG00000255239.1 AP002954.6 14.44 2.23e-39 2.29e-35 0.64 0.55 Serum metabolite levels; chr11:118685375 chr11:118688039~118690600:- LUSC cis rs2658782 0.547 rs10765602 ENSG00000279684.1 RP11-755E23.2 -14.44 2.24e-39 2.3e-35 -0.75 -0.55 Pulmonary function decline; chr11:93314999 chr11:93286629~93288903:- LUSC cis rs1933112 1 rs1933110 ENSG00000227777.1 RP4-738P11.3 -14.43 2.45e-39 2.49e-35 -0.66 -0.55 Blood protein levels; chr1:168554217 chr1:168542737~168543354:+ LUSC cis rs916888 0.61 rs199530 ENSG00000214401.4 KANSL1-AS1 -14.43 2.46e-39 2.5e-35 -0.76 -0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46193576~46196723:+ LUSC cis rs2486288 0.656 rs1719236 ENSG00000259520.4 CTD-2651B20.3 14.43 2.5e-39 2.55e-35 0.71 0.55 Glomerular filtration rate; chr15:45285585 chr15:45251580~45279251:- LUSC cis rs916888 0.61 rs199444 ENSG00000214401.4 KANSL1-AS1 14.42 2.6e-39 2.65e-35 0.77 0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46193576~46196723:+ LUSC cis rs9399135 0.967 rs10872427 ENSG00000232876.1 CTA-212D2.2 -14.42 2.61e-39 2.65e-35 -0.64 -0.55 Red blood cell count; chr6:135032314 chr6:135055033~135060550:+ LUSC cis rs1153858 1 rs4775895 ENSG00000259520.4 CTD-2651B20.3 -14.42 2.64e-39 2.68e-35 -0.74 -0.55 Homoarginine levels; chr15:45325759 chr15:45251580~45279251:- LUSC cis rs3814244 0.933 rs12423194 ENSG00000255733.4 IFNG-AS1 14.42 2.7e-39 2.74e-35 0.46 0.55 Itch intensity from mosquito bite adjusted by bite size; chr12:68020387 chr12:67989445~68234686:+ LUSC cis rs9399135 0.967 rs7766189 ENSG00000232876.1 CTA-212D2.2 -14.4 3.3e-39 3.34e-35 -0.64 -0.55 Red blood cell count; chr6:135032713 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9402676 ENSG00000232876.1 CTA-212D2.2 -14.4 3.3e-39 3.34e-35 -0.64 -0.55 Red blood cell count; chr6:135034369 chr6:135055033~135060550:+ LUSC cis rs507080 0.922 rs625513 ENSG00000255239.1 AP002954.6 14.4 3.46e-39 3.5e-35 0.64 0.55 Serum metabolite levels; chr11:118685010 chr11:118688039~118690600:- LUSC cis rs1933112 1 rs10753777 ENSG00000227777.1 RP4-738P11.3 -14.39 3.52e-39 3.55e-35 -0.66 -0.55 Blood protein levels; chr1:168558549 chr1:168542737~168543354:+ LUSC cis rs507080 0.885 rs693037 ENSG00000255239.1 AP002954.6 14.39 3.59e-39 3.62e-35 0.64 0.55 Serum metabolite levels; chr11:118682617 chr11:118688039~118690600:- LUSC cis rs9399135 0.967 rs2150681 ENSG00000232876.1 CTA-212D2.2 14.39 3.61e-39 3.64e-35 0.64 0.55 Red blood cell count; chr6:135054094 chr6:135055033~135060550:+ LUSC cis rs507080 0.922 rs558907 ENSG00000255239.1 AP002954.6 14.39 3.73e-39 3.76e-35 0.64 0.55 Serum metabolite levels; chr11:118687746 chr11:118688039~118690600:- LUSC cis rs507080 0.663 rs7926970 ENSG00000255239.1 AP002954.6 14.39 3.73e-39 3.76e-35 0.64 0.55 Serum metabolite levels; chr11:118689172 chr11:118688039~118690600:- LUSC cis rs507080 0.885 rs4938530 ENSG00000255239.1 AP002954.6 14.39 3.73e-39 3.76e-35 0.64 0.55 Serum metabolite levels; chr11:118689861 chr11:118688039~118690600:- LUSC cis rs916888 0.647 rs199449 ENSG00000214401.4 KANSL1-AS1 14.39 3.77e-39 3.8e-35 0.76 0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46193576~46196723:+ LUSC cis rs507080 0.922 rs514143 ENSG00000255239.1 AP002954.6 14.38 3.93e-39 3.95e-35 0.64 0.55 Serum metabolite levels; chr11:118687740 chr11:118688039~118690600:- LUSC cis rs1153858 1 rs28679834 ENSG00000259520.4 CTD-2651B20.3 -14.38 4.15e-39 4.18e-35 -0.74 -0.55 Homoarginine levels; chr15:45324008 chr15:45251580~45279251:- LUSC cis rs9326248 0.53 rs11216316 ENSG00000254851.1 RP11-109L13.1 14.38 4.19e-39 4.21e-35 1.04 0.55 Blood protein levels; chr11:117210784 chr11:117135528~117138582:+ LUSC cis rs3814244 0.933 rs11610126 ENSG00000255733.4 IFNG-AS1 -14.37 4.46e-39 4.48e-35 -0.46 -0.55 Itch intensity from mosquito bite adjusted by bite size; chr12:68026493 chr12:67989445~68234686:+ LUSC cis rs1577917 0.538 rs7755996 ENSG00000203875.9 SNHG5 14.37 4.56e-39 4.58e-35 0.71 0.55 Response to antipsychotic treatment; chr6:85714002 chr6:85660950~85678736:- LUSC cis rs2658782 0.547 rs4753453 ENSG00000279684.1 RP11-755E23.2 -14.37 4.6e-39 4.61e-35 -0.75 -0.55 Pulmonary function decline; chr11:93308008 chr11:93286629~93288903:- LUSC cis rs9399135 0.967 rs2297338 ENSG00000232876.1 CTA-212D2.2 -14.36 4.93e-39 4.93e-35 -0.64 -0.55 Red blood cell count; chr6:135054624 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs2297340 ENSG00000232876.1 CTA-212D2.2 -14.36 4.93e-39 4.93e-35 -0.64 -0.55 Red blood cell count; chr6:135054920 chr6:135055033~135060550:+ LUSC cis rs507080 0.885 rs7926959 ENSG00000255239.1 AP002954.6 14.35 5.22e-39 5.22e-35 0.64 0.55 Serum metabolite levels; chr11:118689157 chr11:118688039~118690600:- LUSC cis rs9326248 0.731 rs90192 ENSG00000254851.1 RP11-109L13.1 -14.35 5.48e-39 5.47e-35 -0.85 -0.55 Blood protein levels; chr11:117188631 chr11:117135528~117138582:+ LUSC cis rs9326248 0.53 rs236918 ENSG00000254851.1 RP11-109L13.1 14.34 6e-39 5.97e-35 1.04 0.55 Blood protein levels; chr11:117220893 chr11:117135528~117138582:+ LUSC cis rs916888 0.61 rs199454 ENSG00000214401.4 KANSL1-AS1 -14.33 6.4e-39 6.36e-35 -0.76 -0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46193576~46196723:+ LUSC cis rs9399135 0.967 rs1590975 ENSG00000232876.1 CTA-212D2.2 -14.33 6.66e-39 6.62e-35 -0.63 -0.55 Red blood cell count; chr6:135030950 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs6919862 ENSG00000232876.1 CTA-212D2.2 -14.32 7.23e-39 7.17e-35 -0.63 -0.55 Red blood cell count; chr6:135031305 chr6:135055033~135060550:+ LUSC cis rs1153858 1 rs9783731 ENSG00000259520.4 CTD-2651B20.3 14.32 7.49e-39 7.42e-35 0.71 0.55 Homoarginine levels; chr15:45350686 chr15:45251580~45279251:- LUSC cis rs9399135 0.933 rs41294852 ENSG00000232876.1 CTA-212D2.2 -14.32 7.57e-39 7.5e-35 -0.64 -0.55 Red blood cell count; chr6:135055241 chr6:135055033~135060550:+ LUSC cis rs11155671 0.53 rs9371215 ENSG00000231760.4 RP11-350J20.5 14.32 7.74e-39 7.66e-35 0.69 0.55 Testicular germ cell tumor; chr6:149873162 chr6:149796151~149826294:- LUSC cis rs2658782 0.507 rs4457713 ENSG00000279684.1 RP11-755E23.2 -14.31 8.09e-39 8e-35 -0.75 -0.55 Pulmonary function decline; chr11:93304264 chr11:93286629~93288903:- LUSC cis rs9322193 0.543 rs9371533 ENSG00000231760.4 RP11-350J20.5 14.31 8.44e-39 8.34e-35 0.7 0.55 Lung cancer; chr6:149889545 chr6:149796151~149826294:- LUSC cis rs9399135 0.967 rs2327580 ENSG00000232876.1 CTA-212D2.2 -14.3 9.29e-39 9.17e-35 -0.63 -0.55 Red blood cell count; chr6:135043279 chr6:135055033~135060550:+ LUSC cis rs9399135 0.844 rs13209789 ENSG00000232876.1 CTA-212D2.2 -14.3 9.33e-39 9.19e-35 -0.63 -0.55 Red blood cell count; chr6:135046778 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs6915770 ENSG00000232876.1 CTA-212D2.2 -14.3 9.33e-39 9.19e-35 -0.63 -0.55 Red blood cell count; chr6:135048076 chr6:135055033~135060550:+ LUSC cis rs9399135 0.935 rs11759999 ENSG00000232876.1 CTA-212D2.2 -14.3 9.33e-39 9.19e-35 -0.63 -0.55 Red blood cell count; chr6:135049357 chr6:135055033~135060550:+ LUSC cis rs9399135 0.935 rs11760000 ENSG00000232876.1 CTA-212D2.2 -14.3 9.33e-39 9.19e-35 -0.63 -0.55 Red blood cell count; chr6:135049358 chr6:135055033~135060550:+ LUSC cis rs9399135 0.935 rs9376086 ENSG00000232876.1 CTA-212D2.2 -14.3 9.33e-39 9.19e-35 -0.63 -0.55 Red blood cell count; chr6:135050191 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs1041480 ENSG00000232876.1 CTA-212D2.2 -14.3 9.33e-39 9.19e-35 -0.63 -0.55 Red blood cell count; chr6:135051938 chr6:135055033~135060550:+ LUSC cis rs1153858 1 rs1554521 ENSG00000259520.4 CTD-2651B20.3 14.29 9.98e-39 9.81e-35 0.71 0.55 Homoarginine levels; chr15:45371991 chr15:45251580~45279251:- LUSC cis rs6700559 1 rs4311922 ENSG00000260088.1 RP11-92G12.3 -14.29 1.01e-38 9.9e-35 -0.69 -0.55 Coronary artery disease; chr1:200674257 chr1:200669507~200694250:+ LUSC cis rs6700559 0.967 rs4447009 ENSG00000260088.1 RP11-92G12.3 -14.29 1.01e-38 9.9e-35 -0.69 -0.55 Coronary artery disease; chr1:200674278 chr1:200669507~200694250:+ LUSC cis rs6700559 1 rs4265457 ENSG00000260088.1 RP11-92G12.3 -14.29 1.01e-38 9.9e-35 -0.69 -0.55 Coronary artery disease; chr1:200674326 chr1:200669507~200694250:+ LUSC cis rs507080 0.807 rs7926944 ENSG00000255239.1 AP002954.6 14.28 1.09e-38 1.07e-34 0.64 0.55 Serum metabolite levels; chr11:118689119 chr11:118688039~118690600:- LUSC cis rs1577917 0.958 rs6454487 ENSG00000203875.9 SNHG5 14.28 1.1e-38 1.08e-34 0.73 0.55 Response to antipsychotic treatment; chr6:85737150 chr6:85660950~85678736:- LUSC cis rs9399135 0.967 rs12527683 ENSG00000232876.1 CTA-212D2.2 -14.27 1.19e-38 1.16e-34 -0.64 -0.55 Red blood cell count; chr6:135003396 chr6:135055033~135060550:+ LUSC cis rs858239 0.636 rs28706766 ENSG00000230658.1 KLHL7-AS1 14.27 1.22e-38 1.19e-34 0.69 0.55 Cerebrospinal fluid biomarker levels; chr7:23130215 chr7:23101228~23105703:- LUSC cis rs9326248 0.574 rs1263173 ENSG00000254851.1 RP11-109L13.1 -14.26 1.29e-38 1.26e-34 -0.7 -0.55 Blood protein levels; chr11:116810292 chr11:117135528~117138582:+ LUSC cis rs1153858 1 rs59889118 ENSG00000259520.4 CTD-2651B20.3 -14.26 1.3e-38 1.27e-34 -0.73 -0.55 Homoarginine levels; chr15:45326532 chr15:45251580~45279251:- LUSC cis rs6700559 1 rs12061346 ENSG00000260088.1 RP11-92G12.3 -14.26 1.31e-38 1.28e-34 -0.68 -0.55 Coronary artery disease; chr1:200677648 chr1:200669507~200694250:+ LUSC cis rs6700559 1 rs7533971 ENSG00000260088.1 RP11-92G12.3 -14.26 1.31e-38 1.28e-34 -0.68 -0.55 Coronary artery disease; chr1:200678243 chr1:200669507~200694250:+ LUSC cis rs6700559 1 rs10919998 ENSG00000260088.1 RP11-92G12.3 -14.26 1.31e-38 1.28e-34 -0.68 -0.55 Coronary artery disease; chr1:200679182 chr1:200669507~200694250:+ LUSC cis rs6700559 0.967 rs4072552 ENSG00000260088.1 RP11-92G12.3 -14.26 1.31e-38 1.28e-34 -0.68 -0.55 Coronary artery disease; chr1:200680003 chr1:200669507~200694250:+ LUSC cis rs9326248 0.581 rs10892072 ENSG00000254851.1 RP11-109L13.1 -14.26 1.4e-38 1.37e-34 -0.67 -0.55 Blood protein levels; chr11:117089597 chr11:117135528~117138582:+ LUSC cis rs9399135 0.967 rs34546690 ENSG00000232876.1 CTA-212D2.2 -14.25 1.45e-38 1.41e-34 -0.63 -0.55 Red blood cell count; chr6:135048571 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9373122 ENSG00000232876.1 CTA-212D2.2 -14.25 1.45e-38 1.41e-34 -0.63 -0.55 Red blood cell count; chr6:135052396 chr6:135055033~135060550:+ LUSC cis rs6700559 1 rs6667172 ENSG00000260088.1 RP11-92G12.3 -14.25 1.46e-38 1.42e-34 -0.68 -0.55 Coronary artery disease; chr1:200674710 chr1:200669507~200694250:+ LUSC cis rs6700559 1 rs7527499 ENSG00000260088.1 RP11-92G12.3 -14.25 1.46e-38 1.42e-34 -0.68 -0.55 Coronary artery disease; chr1:200676217 chr1:200669507~200694250:+ LUSC cis rs6700559 1 rs6427838 ENSG00000260088.1 RP11-92G12.3 -14.25 1.46e-38 1.42e-34 -0.68 -0.55 Coronary artery disease; chr1:200676519 chr1:200669507~200694250:+ LUSC cis rs7188445 0.556 rs7194711 ENSG00000261390.4 RP11-345M22.2 -14.25 1.46e-38 1.42e-34 -0.68 -0.55 Urate levels; chr16:79715134 chr16:79715232~79770563:- LUSC cis rs9399135 0.967 rs12661423 ENSG00000232876.1 CTA-212D2.2 -14.25 1.47e-38 1.43e-34 -0.63 -0.55 Red blood cell count; chr6:135028432 chr6:135055033~135060550:+ LUSC cis rs3814244 0.897 rs4141135 ENSG00000255733.4 IFNG-AS1 14.25 1.49e-38 1.44e-34 0.46 0.55 Itch intensity from mosquito bite adjusted by bite size; chr12:68025050 chr12:67989445~68234686:+ LUSC cis rs6700559 1 rs10494821 ENSG00000260088.1 RP11-92G12.3 -14.25 1.51e-38 1.47e-34 -0.68 -0.55 Coronary artery disease; chr1:200673357 chr1:200669507~200694250:+ LUSC cis rs950027 0.62 rs872192 ENSG00000259520.4 CTD-2651B20.3 -14.24 1.67e-38 1.61e-34 -0.67 -0.55 Response to fenofibrate (adiponectin levels); chr15:45322304 chr15:45251580~45279251:- LUSC cis rs950027 0.62 rs1617634 ENSG00000259520.4 CTD-2651B20.3 -14.24 1.67e-38 1.61e-34 -0.67 -0.55 Response to fenofibrate (adiponectin levels); chr15:45323380 chr15:45251580~45279251:- LUSC cis rs507080 0.883 rs12798453 ENSG00000255239.1 AP002954.6 14.22 1.92e-38 1.84e-34 0.63 0.55 Serum metabolite levels; chr11:118690701 chr11:118688039~118690600:- LUSC cis rs916888 0.61 rs199536 ENSG00000214401.4 KANSL1-AS1 -14.22 1.95e-38 1.87e-34 -0.75 -0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46193576~46196723:+ LUSC cis rs1577917 0.958 rs12190603 ENSG00000203875.9 SNHG5 -14.22 1.97e-38 1.89e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85766000 chr6:85660950~85678736:- LUSC cis rs2658782 0.654 rs2605622 ENSG00000279684.1 RP11-755E23.2 -14.22 2e-38 1.91e-34 -0.79 -0.55 Pulmonary function decline; chr11:93515076 chr11:93286629~93288903:- LUSC cis rs3814244 0.933 rs10748093 ENSG00000255733.4 IFNG-AS1 -14.22 2.02e-38 1.94e-34 -0.46 -0.55 Itch intensity from mosquito bite adjusted by bite size; chr12:68024469 chr12:67989445~68234686:+ LUSC cis rs3814244 0.902 rs2870961 ENSG00000255733.4 IFNG-AS1 -14.22 2.06e-38 1.98e-34 -0.46 -0.55 Itch intensity from mosquito bite adjusted by bite size; chr12:68024262 chr12:67989445~68234686:+ LUSC cis rs9399135 0.816 rs4134030 ENSG00000232876.1 CTA-212D2.2 -14.22 2.07e-38 1.99e-34 -0.63 -0.55 Red blood cell count; chr6:135032956 chr6:135055033~135060550:+ LUSC cis rs9322193 0.847 rs4870054 ENSG00000231760.4 RP11-350J20.5 14.21 2.19e-38 2.1e-34 0.73 0.55 Lung cancer; chr6:149848402 chr6:149796151~149826294:- LUSC cis rs1153858 1 rs12593370 ENSG00000259520.4 CTD-2651B20.3 -14.21 2.22e-38 2.12e-34 -0.73 -0.55 Homoarginine levels; chr15:45325219 chr15:45251580~45279251:- LUSC cis rs1153858 0.895 rs12593402 ENSG00000259520.4 CTD-2651B20.3 -14.21 2.28e-38 2.18e-34 -0.73 -0.55 Homoarginine levels; chr15:45325194 chr15:45251580~45279251:- LUSC cis rs9326248 0.581 rs11216267 ENSG00000254851.1 RP11-109L13.1 -14.2 2.37e-38 2.27e-34 -0.67 -0.55 Blood protein levels; chr11:117081676 chr11:117135528~117138582:+ LUSC cis rs9326248 0.581 rs7120706 ENSG00000254851.1 RP11-109L13.1 14.2 2.47e-38 2.36e-34 0.66 0.55 Blood protein levels; chr11:116959371 chr11:117135528~117138582:+ LUSC cis rs9326248 0.581 rs6589582 ENSG00000254851.1 RP11-109L13.1 -14.19 2.62e-38 2.5e-34 -0.67 -0.55 Blood protein levels; chr11:116958484 chr11:117135528~117138582:+ LUSC cis rs1577917 0.958 rs12192033 ENSG00000203875.9 SNHG5 -14.19 2.67e-38 2.55e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85762841 chr6:85660950~85678736:- LUSC cis rs9399135 0.967 rs9389258 ENSG00000232876.1 CTA-212D2.2 -14.19 2.69e-38 2.56e-34 -0.63 -0.55 Red blood cell count; chr6:135040002 chr6:135055033~135060550:+ LUSC cis rs1577917 0.958 rs2324817 ENSG00000203875.9 SNHG5 -14.19 2.78e-38 2.64e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85752936 chr6:85660950~85678736:- LUSC cis rs1577917 0.837 rs806529 ENSG00000203875.9 SNHG5 -14.19 2.78e-38 2.64e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85757403 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs6921315 ENSG00000203875.9 SNHG5 -14.19 2.78e-38 2.64e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85761950 chr6:85660950~85678736:- LUSC cis rs9399135 0.967 rs4896125 ENSG00000232876.1 CTA-212D2.2 -14.19 2.86e-38 2.7e-34 -0.63 -0.55 Red blood cell count; chr6:135021431 chr6:135055033~135060550:+ LUSC cis rs9399135 0.935 rs949547 ENSG00000232876.1 CTA-212D2.2 -14.19 2.86e-38 2.7e-34 -0.63 -0.55 Red blood cell count; chr6:135022361 chr6:135055033~135060550:+ LUSC cis rs9399135 0.935 rs2150680 ENSG00000232876.1 CTA-212D2.2 -14.19 2.86e-38 2.7e-34 -0.63 -0.55 Red blood cell count; chr6:135025993 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs11756988 ENSG00000232876.1 CTA-212D2.2 -14.19 2.86e-38 2.7e-34 -0.63 -0.55 Red blood cell count; chr6:135026457 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs11754783 ENSG00000232876.1 CTA-212D2.2 -14.19 2.86e-38 2.7e-34 -0.63 -0.55 Red blood cell count; chr6:135026523 chr6:135055033~135060550:+ LUSC cis rs9399135 0.935 rs987690 ENSG00000232876.1 CTA-212D2.2 -14.18 2.88e-38 2.73e-34 -0.63 -0.55 Red blood cell count; chr6:135029241 chr6:135055033~135060550:+ LUSC cis rs9399135 0.838 rs4896126 ENSG00000232876.1 CTA-212D2.2 -14.18 2.93e-38 2.76e-34 -0.63 -0.55 Red blood cell count; chr6:135021648 chr6:135055033~135060550:+ LUSC cis rs9402673 0.517 rs978036 ENSG00000232876.1 CTA-212D2.2 -14.18 2.93e-38 2.76e-34 -0.63 -0.55 High light scatter reticulocyte count;Reticulocyte count; chr6:135021765 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs1023179 ENSG00000232876.1 CTA-212D2.2 -14.18 2.93e-38 2.76e-34 -0.63 -0.55 Red blood cell count; chr6:135022691 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs952674 ENSG00000232876.1 CTA-212D2.2 -14.18 2.93e-38 2.76e-34 -0.63 -0.55 Red blood cell count; chr6:135028019 chr6:135055033~135060550:+ LUSC cis rs9399135 0.933 rs9389262 ENSG00000232876.1 CTA-212D2.2 -14.18 2.93e-38 2.76e-34 -0.63 -0.55 Red blood cell count; chr6:135055271 chr6:135055033~135060550:+ LUSC cis rs6700559 1 rs6700559 ENSG00000260088.1 RP11-92G12.3 14.18 2.94e-38 2.77e-34 0.68 0.55 Coronary artery disease; chr1:200676945 chr1:200669507~200694250:+ LUSC cis rs1933112 1 rs10918925 ENSG00000227777.1 RP4-738P11.3 14.17 3.19e-38 3.01e-34 0.63 0.55 Blood protein levels; chr1:168556009 chr1:168542737~168543354:+ LUSC cis rs1153858 1 rs1980288 ENSG00000259520.4 CTD-2651B20.3 -14.17 3.35e-38 3.15e-34 -0.72 -0.55 Homoarginine levels; chr15:45328414 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs12909158 ENSG00000259520.4 CTD-2651B20.3 -14.17 3.35e-38 3.15e-34 -0.72 -0.55 Homoarginine levels; chr15:45328976 chr15:45251580~45279251:- LUSC cis rs1577917 0.958 rs6454488 ENSG00000203875.9 SNHG5 -14.17 3.35e-38 3.15e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85741124 chr6:85660950~85678736:- LUSC cis rs9399135 1 rs1014021 ENSG00000232876.1 CTA-212D2.2 14.17 3.37e-38 3.17e-34 0.63 0.55 Red blood cell count; chr6:135013462 chr6:135055033~135060550:+ LUSC cis rs1577917 0.958 rs11752180 ENSG00000203875.9 SNHG5 -14.17 3.4e-38 3.19e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85863447 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12195776 ENSG00000203875.9 SNHG5 -14.17 3.42e-38 3.21e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85778881 chr6:85660950~85678736:- LUSC cis rs507080 0.922 rs4589335 ENSG00000255239.1 AP002954.6 14.16 3.57e-38 3.35e-34 0.63 0.55 Serum metabolite levels; chr11:118668431 chr11:118688039~118690600:- LUSC cis rs9326248 0.52 rs10892060 ENSG00000254851.1 RP11-109L13.1 -14.16 3.82e-38 3.57e-34 -0.66 -0.55 Blood protein levels; chr11:117010946 chr11:117135528~117138582:+ LUSC cis rs9399135 0.967 rs6925424 ENSG00000232876.1 CTA-212D2.2 -14.16 3.82e-38 3.57e-34 -0.63 -0.55 Red blood cell count; chr6:134992810 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs17638970 ENSG00000232876.1 CTA-212D2.2 -14.16 3.82e-38 3.57e-34 -0.63 -0.55 Red blood cell count; chr6:134998925 chr6:135055033~135060550:+ LUSC cis rs9402673 0.558 rs9688342 ENSG00000232876.1 CTA-212D2.2 -14.16 3.82e-38 3.57e-34 -0.63 -0.55 High light scatter reticulocyte count;Reticulocyte count; chr6:135001888 chr6:135055033~135060550:+ LUSC cis rs9399135 0.933 rs4559100 ENSG00000232876.1 CTA-212D2.2 -14.16 3.82e-38 3.57e-34 -0.63 -0.55 Red blood cell count; chr6:135002947 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs12527707 ENSG00000232876.1 CTA-212D2.2 -14.16 3.82e-38 3.57e-34 -0.63 -0.55 Red blood cell count; chr6:135003373 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9389251 ENSG00000232876.1 CTA-212D2.2 -14.16 3.82e-38 3.57e-34 -0.63 -0.55 Red blood cell count; chr6:135004579 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs6929661 ENSG00000232876.1 CTA-212D2.2 -14.16 3.82e-38 3.57e-34 -0.63 -0.55 Red blood cell count; chr6:135007654 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs2327578 ENSG00000232876.1 CTA-212D2.2 -14.16 3.82e-38 3.57e-34 -0.63 -0.55 Red blood cell count; chr6:135008831 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs7741626 ENSG00000232876.1 CTA-212D2.2 -14.15 3.96e-38 3.69e-34 -0.63 -0.55 Red blood cell count; chr6:134993044 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs4895439 ENSG00000232876.1 CTA-212D2.2 -14.15 3.96e-38 3.69e-34 -0.63 -0.55 Red blood cell count; chr6:134997716 chr6:135055033~135060550:+ LUSC cis rs9399135 0.935 rs11754504 ENSG00000232876.1 CTA-212D2.2 -14.15 3.96e-38 3.69e-34 -0.63 -0.55 Red blood cell count; chr6:135000371 chr6:135055033~135060550:+ LUSC cis rs9399135 0.869 rs9402675 ENSG00000232876.1 CTA-212D2.2 -14.15 3.96e-38 3.69e-34 -0.63 -0.55 Red blood cell count; chr6:135004656 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9389253 ENSG00000232876.1 CTA-212D2.2 -14.15 3.96e-38 3.69e-34 -0.63 -0.55 Red blood cell count; chr6:135008617 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9389254 ENSG00000232876.1 CTA-212D2.2 -14.15 3.96e-38 3.69e-34 -0.63 -0.55 Red blood cell count; chr6:135009571 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs1014020 ENSG00000232876.1 CTA-212D2.2 -14.15 3.96e-38 3.69e-34 -0.63 -0.55 Red blood cell count; chr6:135013288 chr6:135055033~135060550:+ LUSC cis rs9326248 0.581 rs10892048 ENSG00000254851.1 RP11-109L13.1 -14.15 4.04e-38 3.76e-34 -0.67 -0.55 Blood protein levels; chr11:116943880 chr11:117135528~117138582:+ LUSC cis rs7188445 0.592 rs17767281 ENSG00000261390.4 RP11-345M22.2 -14.15 4.1e-38 3.81e-34 -0.68 -0.55 Urate levels; chr16:79708544 chr16:79715232~79770563:- LUSC cis rs9326248 0.52 rs1446105 ENSG00000254851.1 RP11-109L13.1 -14.15 4.14e-38 3.85e-34 -0.67 -0.55 Blood protein levels; chr11:116927828 chr11:117135528~117138582:+ LUSC cis rs9399135 0.933 rs28384512 ENSG00000232876.1 CTA-212D2.2 -14.14 4.31e-38 4e-34 -0.63 -0.55 Red blood cell count; chr6:135055094 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs4896119 ENSG00000232876.1 CTA-212D2.2 -14.14 4.33e-38 4.02e-34 -0.63 -0.55 Red blood cell count; chr6:134972253 chr6:135055033~135060550:+ LUSC cis rs9326248 0.539 rs10892058 ENSG00000254851.1 RP11-109L13.1 -14.14 4.59e-38 4.26e-34 -0.66 -0.55 Blood protein levels; chr11:117005905 chr11:117135528~117138582:+ LUSC cis rs9326248 0.52 rs7127881 ENSG00000254851.1 RP11-109L13.1 -14.14 4.59e-38 4.26e-34 -0.66 -0.55 Blood protein levels; chr11:117010082 chr11:117135528~117138582:+ LUSC cis rs1577917 0.958 rs66807489 ENSG00000203875.9 SNHG5 -14.14 4.66e-38 4.32e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85730984 chr6:85660950~85678736:- LUSC cis rs9399135 0.967 rs7763836 ENSG00000232876.1 CTA-212D2.2 -14.13 4.8e-38 4.45e-34 -0.63 -0.55 Red blood cell count; chr6:135041240 chr6:135055033~135060550:+ LUSC cis rs2658782 0.654 rs2605623 ENSG00000279684.1 RP11-755E23.2 -14.13 5.11e-38 4.73e-34 -0.79 -0.55 Pulmonary function decline; chr11:93516193 chr11:93286629~93288903:- LUSC cis rs9399135 0.967 rs6902438 ENSG00000232876.1 CTA-212D2.2 -14.12 5.31e-38 4.9e-34 -0.63 -0.55 Red blood cell count; chr6:135015449 chr6:135055033~135060550:+ LUSC cis rs9399135 0.935 rs6908681 ENSG00000232876.1 CTA-212D2.2 -14.12 5.31e-38 4.9e-34 -0.63 -0.55 Red blood cell count; chr6:135016595 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs1041481 ENSG00000232876.1 CTA-212D2.2 -14.12 5.36e-38 4.95e-34 -0.63 -0.55 Red blood cell count; chr6:135013925 chr6:135055033~135060550:+ LUSC cis rs507080 0.883 rs527475 ENSG00000255239.1 AP002954.6 14.12 5.63e-38 5.18e-34 0.63 0.55 Serum metabolite levels; chr11:118692530 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs585039 ENSG00000255239.1 AP002954.6 14.12 5.63e-38 5.18e-34 0.63 0.55 Serum metabolite levels; chr11:118692672 chr11:118688039~118690600:- LUSC cis rs1577917 0.916 rs12206726 ENSG00000203875.9 SNHG5 -14.11 5.74e-38 5.28e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85789998 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs7453105 ENSG00000203875.9 SNHG5 -14.11 5.74e-38 5.28e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85791043 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12209259 ENSG00000203875.9 SNHG5 -14.11 5.74e-38 5.28e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85792630 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs34795473 ENSG00000203875.9 SNHG5 -14.11 5.91e-38 5.43e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85752081 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs1414201 ENSG00000203875.9 SNHG5 -14.1 6.38e-38 5.84e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85790598 chr6:85660950~85678736:- LUSC cis rs9399135 0.967 rs1854865 ENSG00000232876.1 CTA-212D2.2 -14.1 6.66e-38 6.09e-34 -0.63 -0.55 Red blood cell count; chr6:135039162 chr6:135055033~135060550:+ LUSC cis rs1577917 0.958 rs9647601 ENSG00000203875.9 SNHG5 -14.1 6.69e-38 6.12e-34 -0.74 -0.55 Response to antipsychotic treatment; chr6:85740109 chr6:85660950~85678736:- LUSC cis rs10256972 0.577 rs6962809 ENSG00000229043.2 AC091729.9 -14.1 6.71e-38 6.13e-34 -0.65 -0.55 Endometriosis;Longevity; chr7:1169253 chr7:1160374~1165267:+ LUSC cis rs7188445 0.592 rs7196490 ENSG00000261390.4 RP11-345M22.2 -14.09 7.03e-38 6.42e-34 -0.68 -0.55 Urate levels; chr16:79718572 chr16:79715232~79770563:- LUSC cis rs2658782 0.688 rs2658768 ENSG00000279684.1 RP11-755E23.2 -14.09 7.12e-38 6.5e-34 -0.8 -0.55 Pulmonary function decline; chr11:93517661 chr11:93286629~93288903:- LUSC cis rs6700559 1 rs6656619 ENSG00000260088.1 RP11-92G12.3 14.09 7.74e-38 7.05e-34 0.68 0.54 Coronary artery disease; chr1:200671664 chr1:200669507~200694250:+ LUSC cis rs9389248 0.5 rs116273677 ENSG00000232876.1 CTA-212D2.2 -14.08 7.77e-38 7.08e-34 -0.63 -0.54 High light scatter reticulocyte percentage of red cells; chr6:135017997 chr6:135055033~135060550:+ LUSC cis rs507080 0.961 rs34413584 ENSG00000255239.1 AP002954.6 14.08 7.79e-38 7.09e-34 0.63 0.54 Serum metabolite levels; chr11:118675072 chr11:118688039~118690600:- LUSC cis rs9399135 0.967 rs6569990 ENSG00000232876.1 CTA-212D2.2 -14.08 7.88e-38 7.17e-34 -0.63 -0.54 Red blood cell count; chr6:135044680 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs13191501 ENSG00000232876.1 CTA-212D2.2 -14.08 7.88e-38 7.17e-34 -0.63 -0.54 Red blood cell count; chr6:135045742 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs6908512 ENSG00000232876.1 CTA-212D2.2 -14.08 7.88e-38 7.17e-34 -0.63 -0.54 Red blood cell count; chr6:135046619 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs11755229 ENSG00000232876.1 CTA-212D2.2 -14.08 7.88e-38 7.17e-34 -0.63 -0.54 Red blood cell count; chr6:135048775 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9389261 ENSG00000232876.1 CTA-212D2.2 -14.08 7.88e-38 7.17e-34 -0.63 -0.54 Red blood cell count; chr6:135050010 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9376085 ENSG00000232876.1 CTA-212D2.2 -14.08 7.88e-38 7.17e-34 -0.63 -0.54 Red blood cell count; chr6:135050086 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs45544135 ENSG00000232876.1 CTA-212D2.2 -14.08 8.36e-38 7.59e-34 -0.63 -0.54 Red blood cell count; chr6:135002913 chr6:135055033~135060550:+ LUSC cis rs2658782 0.526 rs7131487 ENSG00000279684.1 RP11-755E23.2 -14.08 8.43e-38 7.66e-34 -0.72 -0.54 Pulmonary function decline; chr11:93452786 chr11:93286629~93288903:- LUSC cis rs9399135 0.967 rs7741515 ENSG00000232876.1 CTA-212D2.2 14.07 8.84e-38 8.02e-34 0.62 0.54 Red blood cell count; chr6:135053230 chr6:135055033~135060550:+ LUSC cis rs10256972 0.552 rs2960831 ENSG00000229043.2 AC091729.9 -14.07 8.85e-38 8.03e-34 -0.65 -0.54 Endometriosis;Longevity; chr7:1161556 chr7:1160374~1165267:+ LUSC cis rs507080 0.922 rs582630 ENSG00000255239.1 AP002954.6 14.07 9.2e-38 8.34e-34 0.63 0.54 Serum metabolite levels; chr11:118692090 chr11:118688039~118690600:- LUSC cis rs507080 0.961 rs520543 ENSG00000255239.1 AP002954.6 14.07 9.24e-38 8.38e-34 0.62 0.54 Serum metabolite levels; chr11:118667448 chr11:118688039~118690600:- LUSC cis rs6700559 0.804 rs11588318 ENSG00000260088.1 RP11-92G12.3 -14.06 9.66e-38 8.74e-34 -0.68 -0.54 Coronary artery disease; chr1:200669534 chr1:200669507~200694250:+ LUSC cis rs6700559 0.903 rs6661240 ENSG00000260088.1 RP11-92G12.3 -14.06 9.66e-38 8.74e-34 -0.68 -0.54 Coronary artery disease; chr1:200669719 chr1:200669507~200694250:+ LUSC cis rs6700559 0.967 rs6688581 ENSG00000260088.1 RP11-92G12.3 -14.06 9.66e-38 8.74e-34 -0.68 -0.54 Coronary artery disease; chr1:200670028 chr1:200669507~200694250:+ LUSC cis rs6700559 1 rs3806358 ENSG00000260088.1 RP11-92G12.3 -14.06 9.66e-38 8.74e-34 -0.68 -0.54 Coronary artery disease; chr1:200670555 chr1:200669507~200694250:+ LUSC cis rs507080 0.961 rs4457789 ENSG00000255239.1 AP002954.6 14.06 1.01e-37 9.14e-34 0.62 0.54 Serum metabolite levels; chr11:118668461 chr11:118688039~118690600:- LUSC cis rs7188445 0.556 rs7203910 ENSG00000261390.4 RP11-345M22.2 -14.05 1.07e-37 9.69e-34 -0.68 -0.54 Urate levels; chr16:79711722 chr16:79715232~79770563:- LUSC cis rs2658782 0.547 rs3020064 ENSG00000279684.1 RP11-755E23.2 -14.05 1.07e-37 9.7e-34 -0.74 -0.54 Pulmonary function decline; chr11:93327685 chr11:93286629~93288903:- LUSC cis rs7188445 0.592 rs4404082 ENSG00000261390.4 RP11-345M22.2 14.05 1.08e-37 9.78e-34 0.67 0.54 Urate levels; chr16:79716615 chr16:79715232~79770563:- LUSC cis rs1891275 0.513 rs1539041 ENSG00000228701.1 TNKS2-AS1 -14.05 1.15e-37 1.03e-33 -0.7 -0.54 Intelligence (multi-trait analysis); chr10:91817384 chr10:91782839~91798291:- LUSC cis rs9399135 0.933 rs7755680 ENSG00000232876.1 CTA-212D2.2 -14.04 1.19e-37 1.07e-33 -0.63 -0.54 Red blood cell count; chr6:134973121 chr6:135055033~135060550:+ LUSC cis rs12439619 0.846 rs62012059 ENSG00000278603.1 RP13-608F4.5 14.04 1.24e-37 1.12e-33 0.77 0.54 Intelligence (multi-trait analysis); chr15:82251669 chr15:82472203~82472426:+ LUSC cis rs1577917 0.57 rs114854865 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85844518 chr6:85660950~85678736:- LUSC cis rs1577917 0.916 rs4706252 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85845462 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs1838959 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85847086 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs1579886 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85847473 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs1816937 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85847533 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs2324840 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85847902 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs7382798 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85850116 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12202188 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85852982 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs36035797 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85853162 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs1838958 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85854250 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs2084293 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85856284 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12209668 ENSG00000203875.9 SNHG5 -14.04 1.25e-37 1.12e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85856799 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs11852800 ENSG00000259520.4 CTD-2651B20.3 14.03 1.28e-37 1.15e-33 0.7 0.54 Homoarginine levels; chr15:45346933 chr15:45251580~45279251:- LUSC cis rs1577917 0.958 rs12213343 ENSG00000203875.9 SNHG5 -14.03 1.29e-37 1.15e-33 -0.73 -0.54 Response to antipsychotic treatment; chr6:85733301 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12215265 ENSG00000203875.9 SNHG5 -14.03 1.29e-37 1.15e-33 -0.73 -0.54 Response to antipsychotic treatment; chr6:85734251 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12197463 ENSG00000203875.9 SNHG5 -14.03 1.29e-37 1.15e-33 -0.73 -0.54 Response to antipsychotic treatment; chr6:85735524 chr6:85660950~85678736:- LUSC cis rs916888 0.61 rs199446 ENSG00000214401.4 KANSL1-AS1 -14.03 1.3e-37 1.16e-33 -0.75 -0.54 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46193576~46196723:+ LUSC cis rs950027 0.62 rs1145093 ENSG00000259520.4 CTD-2651B20.3 -14.03 1.31e-37 1.17e-33 -0.66 -0.54 Response to fenofibrate (adiponectin levels); chr15:45357615 chr15:45251580~45279251:- LUSC cis rs1577917 0.958 rs13207173 ENSG00000203875.9 SNHG5 -14.03 1.32e-37 1.18e-33 -0.73 -0.54 Response to antipsychotic treatment; chr6:85747804 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs4098044 ENSG00000203875.9 SNHG5 -14.03 1.32e-37 1.18e-33 -0.73 -0.54 Response to antipsychotic treatment; chr6:85752348 chr6:85660950~85678736:- LUSC cis rs9399135 0.967 rs9321481 ENSG00000232876.1 CTA-212D2.2 14.02 1.53e-37 1.35e-33 0.62 0.54 Red blood cell count; chr6:135031510 chr6:135055033~135060550:+ LUSC cis rs507080 0.883 rs692750 ENSG00000255239.1 AP002954.6 14.02 1.54e-37 1.36e-33 0.63 0.54 Serum metabolite levels; chr11:118667599 chr11:118688039~118690600:- LUSC cis rs1577917 0.917 rs12665464 ENSG00000203875.9 SNHG5 -14.01 1.56e-37 1.38e-33 -0.74 -0.54 Response to antipsychotic treatment; chr6:85864415 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs4775909 ENSG00000259520.4 CTD-2651B20.3 -14.01 1.57e-37 1.39e-33 -0.7 -0.54 Homoarginine levels; chr15:45350844 chr15:45251580~45279251:- LUSC cis rs9326248 0.581 rs7121898 ENSG00000254851.1 RP11-109L13.1 -14.01 1.58e-37 1.4e-33 -0.67 -0.54 Blood protein levels; chr11:116926130 chr11:117135528~117138582:+ LUSC cis rs10256972 0.552 rs2960830 ENSG00000229043.2 AC091729.9 -14.01 1.61e-37 1.42e-33 -0.65 -0.54 Endometriosis;Longevity; chr7:1161005 chr7:1160374~1165267:+ LUSC cis rs507080 0.733 rs517445 ENSG00000255422.1 AP002954.4 -14.01 1.64e-37 1.44e-33 -0.6 -0.54 Serum metabolite levels; chr11:118702826 chr11:118704607~118750263:+ LUSC cis rs9399135 0.967 rs6909975 ENSG00000232876.1 CTA-212D2.2 -14.01 1.65e-37 1.45e-33 -0.64 -0.54 Red blood cell count; chr6:134994432 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs7773126 ENSG00000232876.1 CTA-212D2.2 -14.01 1.65e-37 1.45e-33 -0.64 -0.54 Red blood cell count; chr6:134997252 chr6:135055033~135060550:+ LUSC cis rs9326248 0.53 rs7940310 ENSG00000254851.1 RP11-109L13.1 -14.01 1.71e-37 1.51e-33 -0.99 -0.54 Blood protein levels; chr11:117153765 chr11:117135528~117138582:+ LUSC cis rs507080 0.771 rs687664 ENSG00000255422.1 AP002954.4 -14 1.72e-37 1.51e-33 -0.6 -0.54 Serum metabolite levels; chr11:118703476 chr11:118704607~118750263:+ LUSC cis rs507080 0.771 rs523715 ENSG00000255422.1 AP002954.4 -14 1.72e-37 1.51e-33 -0.6 -0.54 Serum metabolite levels; chr11:118703479 chr11:118704607~118750263:+ LUSC cis rs9399135 0.967 rs9376082 ENSG00000232876.1 CTA-212D2.2 -14 1.87e-37 1.63e-33 -0.62 -0.54 Red blood cell count; chr6:135025251 chr6:135055033~135060550:+ LUSC cis rs1577917 0.958 rs10944136 ENSG00000203875.9 SNHG5 -13.99 1.92e-37 1.68e-33 -0.73 -0.54 Response to antipsychotic treatment; chr6:85738781 chr6:85660950~85678736:- LUSC cis rs12439619 0.846 rs62012056 ENSG00000278603.1 RP13-608F4.5 13.99 2.02e-37 1.76e-33 0.77 0.54 Intelligence (multi-trait analysis); chr15:82247278 chr15:82472203~82472426:+ LUSC cis rs507080 0.733 rs4486664 ENSG00000255422.1 AP002954.4 -13.98 2.11e-37 1.84e-33 -0.61 -0.54 Serum metabolite levels; chr11:118698358 chr11:118704607~118750263:+ LUSC cis rs1153858 1 rs72623915 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.23e-37 1.93e-33 -0.7 -0.54 Homoarginine levels; chr15:45355235 chr15:45251580~45279251:- LUSC cis rs1153858 0.725 rs74572151 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.23e-37 1.93e-33 -0.7 -0.54 Homoarginine levels; chr15:45355328 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs66714503 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.23e-37 1.93e-33 -0.7 -0.54 Homoarginine levels; chr15:45355840 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs2066090 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.23e-37 1.93e-33 -0.7 -0.54 Homoarginine levels; chr15:45357820 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs61365925 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.23e-37 1.93e-33 -0.7 -0.54 Homoarginine levels; chr15:45358113 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs16952714 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.23e-37 1.93e-33 -0.7 -0.54 Homoarginine levels; chr15:45358160 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs12101539 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.23e-37 1.93e-33 -0.7 -0.54 Homoarginine levels; chr15:45358468 chr15:45251580~45279251:- LUSC cis rs950027 0.62 rs2467862 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.28e-37 1.98e-33 -0.66 -0.54 Response to fenofibrate (adiponectin levels); chr15:45351645 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs4774577 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.29e-37 1.98e-33 -0.71 -0.54 Homoarginine levels; chr15:45352487 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs11070453 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.29e-37 1.98e-33 -0.71 -0.54 Homoarginine levels; chr15:45352956 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs4774578 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.29e-37 1.98e-33 -0.71 -0.54 Homoarginine levels; chr15:45353853 chr15:45251580~45279251:- LUSC cis rs61524473 1 rs61524473 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.29e-37 1.98e-33 -0.71 -0.54 Metabolite levels (small molecules and protein measures); chr15:45354085 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs10444821 ENSG00000259520.4 CTD-2651B20.3 -13.98 2.29e-37 1.98e-33 -0.71 -0.54 Homoarginine levels; chr15:45355038 chr15:45251580~45279251:- LUSC cis rs858239 0.896 rs1637193 ENSG00000230658.1 KLHL7-AS1 13.97 2.34e-37 2.02e-33 0.67 0.54 Cerebrospinal fluid biomarker levels; chr7:23220632 chr7:23101228~23105703:- LUSC cis rs2658782 0.724 rs2658769 ENSG00000279684.1 RP11-755E23.2 -13.97 2.44e-37 2.1e-33 -0.8 -0.54 Pulmonary function decline; chr11:93518864 chr11:93286629~93288903:- LUSC cis rs9399135 0.904 rs4895438 ENSG00000232876.1 CTA-212D2.2 -13.96 2.56e-37 2.2e-33 -0.63 -0.54 Red blood cell count; chr6:134996527 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9389256 ENSG00000232876.1 CTA-212D2.2 -13.96 2.56e-37 2.2e-33 -0.63 -0.54 Red blood cell count; chr6:135010116 chr6:135055033~135060550:+ LUSC cis rs1153858 1 rs12593230 ENSG00000259520.4 CTD-2651B20.3 -13.96 2.57e-37 2.21e-33 -0.71 -0.54 Homoarginine levels; chr15:45354770 chr15:45251580~45279251:- LUSC cis rs2739330 0.76 rs5751761 ENSG00000218537.1 MIF-AS1 -13.96 2.61e-37 2.24e-33 -0.68 -0.54 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23894426~23898930:- LUSC cis rs1153858 1 rs7171577 ENSG00000259520.4 CTD-2651B20.3 -13.96 2.67e-37 2.29e-33 -0.71 -0.54 Homoarginine levels; chr15:45335781 chr15:45251580~45279251:- LUSC cis rs9399135 0.967 rs4896120 ENSG00000232876.1 CTA-212D2.2 -13.96 2.77e-37 2.35e-33 -0.64 -0.54 Red blood cell count; chr6:134972374 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs6910530 ENSG00000232876.1 CTA-212D2.2 -13.96 2.8e-37 2.37e-33 -0.63 -0.54 Red blood cell count; chr6:135011632 chr6:135055033~135060550:+ LUSC cis rs7188445 0.615 rs4340340 ENSG00000261390.4 RP11-345M22.2 -13.95 2.95e-37 2.5e-33 -0.67 -0.54 Urate levels; chr16:79716720 chr16:79715232~79770563:- LUSC cis rs9326248 0.581 rs10790167 ENSG00000254851.1 RP11-109L13.1 -13.95 2.97e-37 2.52e-33 -0.67 -0.54 Blood protein levels; chr11:116930227 chr11:117135528~117138582:+ LUSC cis rs2739330 0.791 rs4822458 ENSG00000225282.1 AP000350.6 13.95 2.99e-37 2.53e-33 0.62 0.54 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23926900~23929574:+ LUSC cis rs6700559 0.683 rs4915450 ENSG00000260088.1 RP11-92G12.3 -13.95 3.1e-37 2.61e-33 -0.67 -0.54 Coronary artery disease; chr1:200672461 chr1:200669507~200694250:+ LUSC cis rs2658782 0.654 rs2605620 ENSG00000279684.1 RP11-755E23.2 -13.94 3.17e-37 2.67e-33 -0.77 -0.54 Pulmonary function decline; chr11:93514480 chr11:93286629~93288903:- LUSC cis rs507080 0.733 rs7108144 ENSG00000255422.1 AP002954.4 -13.94 3.19e-37 2.68e-33 -0.61 -0.54 Serum metabolite levels; chr11:118698985 chr11:118704607~118750263:+ LUSC cis rs507080 0.663 rs523793 ENSG00000255422.1 AP002954.4 -13.94 3.19e-37 2.68e-33 -0.61 -0.54 Serum metabolite levels; chr11:118699988 chr11:118704607~118750263:+ LUSC cis rs507080 0.736 rs659564 ENSG00000255422.1 AP002954.4 -13.94 3.19e-37 2.68e-33 -0.61 -0.54 Serum metabolite levels; chr11:118700205 chr11:118704607~118750263:+ LUSC cis rs507080 0.736 rs642224 ENSG00000255422.1 AP002954.4 -13.94 3.19e-37 2.68e-33 -0.61 -0.54 Serum metabolite levels; chr11:118700210 chr11:118704607~118750263:+ LUSC cis rs507080 0.733 rs541631 ENSG00000255422.1 AP002954.4 -13.94 3.19e-37 2.68e-33 -0.61 -0.54 Serum metabolite levels; chr11:118700314 chr11:118704607~118750263:+ LUSC cis rs507080 0.736 rs658676 ENSG00000255422.1 AP002954.4 -13.94 3.19e-37 2.68e-33 -0.61 -0.54 Serum metabolite levels; chr11:118700414 chr11:118704607~118750263:+ LUSC cis rs507080 0.733 rs488141 ENSG00000255422.1 AP002954.4 -13.94 3.19e-37 2.68e-33 -0.61 -0.54 Serum metabolite levels; chr11:118700459 chr11:118704607~118750263:+ LUSC cis rs507080 0.733 rs657769 ENSG00000255422.1 AP002954.4 -13.94 3.19e-37 2.68e-33 -0.61 -0.54 Serum metabolite levels; chr11:118700607 chr11:118704607~118750263:+ LUSC cis rs507080 0.733 rs544452 ENSG00000255422.1 AP002954.4 -13.94 3.19e-37 2.68e-33 -0.61 -0.54 Serum metabolite levels; chr11:118700648 chr11:118704607~118750263:+ LUSC cis rs1153858 1 rs2056493 ENSG00000259520.4 CTD-2651B20.3 -13.94 3.32e-37 2.78e-33 -0.7 -0.54 Homoarginine levels; chr15:45356074 chr15:45251580~45279251:- LUSC cis rs507080 0.733 rs552079 ENSG00000255422.1 AP002954.4 -13.93 3.49e-37 2.92e-33 -0.61 -0.54 Serum metabolite levels; chr11:118702313 chr11:118704607~118750263:+ LUSC cis rs950027 0.549 rs11636114 ENSG00000259520.4 CTD-2651B20.3 -13.93 3.53e-37 2.95e-33 -0.68 -0.54 Response to fenofibrate (adiponectin levels); chr15:45309214 chr15:45251580~45279251:- LUSC cis rs950027 0.62 rs1153857 ENSG00000259520.4 CTD-2651B20.3 -13.93 3.55e-37 2.96e-33 -0.66 -0.54 Response to fenofibrate (adiponectin levels); chr15:45366897 chr15:45251580~45279251:- LUSC cis rs950027 0.62 rs1153855 ENSG00000259520.4 CTD-2651B20.3 -13.93 3.55e-37 2.96e-33 -0.65 -0.54 Response to fenofibrate (adiponectin levels); chr15:45368560 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs8032904 ENSG00000259520.4 CTD-2651B20.3 -13.93 3.65e-37 3.04e-33 -0.71 -0.54 Homoarginine levels; chr15:45359111 chr15:45251580~45279251:- LUSC cis rs1153858 0.943 rs8038342 ENSG00000259520.4 CTD-2651B20.3 -13.93 3.65e-37 3.04e-33 -0.71 -0.54 Homoarginine levels; chr15:45359339 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs4774579 ENSG00000259520.4 CTD-2651B20.3 -13.93 3.65e-37 3.04e-33 -0.71 -0.54 Homoarginine levels; chr15:45359605 chr15:45251580~45279251:- LUSC cis rs1577917 0.874 rs1838954 ENSG00000203875.9 SNHG5 -13.92 3.83e-37 3.19e-33 -0.73 -0.54 Response to antipsychotic treatment; chr6:85855760 chr6:85660950~85678736:- LUSC cis rs9399135 1 rs35123050 ENSG00000232876.1 CTA-212D2.2 -13.92 3.91e-37 3.25e-33 -0.64 -0.54 Red blood cell count; chr6:134981602 chr6:135055033~135060550:+ LUSC cis rs12439619 0.774 rs2867649 ENSG00000278603.1 RP13-608F4.5 13.92 3.98e-37 3.3e-33 0.76 0.54 Intelligence (multi-trait analysis); chr15:82262331 chr15:82472203~82472426:+ LUSC cis rs12439619 0.846 rs28697264 ENSG00000278603.1 RP13-608F4.5 13.92 3.98e-37 3.3e-33 0.76 0.54 Intelligence (multi-trait analysis); chr15:82265559 chr15:82472203~82472426:+ LUSC cis rs950027 0.62 rs1049518 ENSG00000259520.4 CTD-2651B20.3 -13.92 4.04e-37 3.35e-33 -0.65 -0.54 Response to fenofibrate (adiponectin levels); chr15:45361169 chr15:45251580~45279251:- LUSC cis rs950027 0.584 rs1145086 ENSG00000259520.4 CTD-2651B20.3 -13.92 4.04e-37 3.35e-33 -0.65 -0.54 Response to fenofibrate (adiponectin levels); chr15:45362129 chr15:45251580~45279251:- LUSC cis rs9399135 0.967 rs4896121 ENSG00000232876.1 CTA-212D2.2 -13.92 4.18e-37 3.46e-33 -0.62 -0.54 Red blood cell count; chr6:134972507 chr6:135055033~135060550:+ LUSC cis rs507080 0.697 rs656287 ENSG00000255422.1 AP002954.4 -13.91 4.29e-37 3.55e-33 -0.61 -0.54 Serum metabolite levels; chr11:118701081 chr11:118704607~118750263:+ LUSC cis rs507080 0.733 rs570949 ENSG00000255422.1 AP002954.4 -13.91 4.29e-37 3.55e-33 -0.61 -0.54 Serum metabolite levels; chr11:118701202 chr11:118704607~118750263:+ LUSC cis rs950027 0.62 rs1145089 ENSG00000259520.4 CTD-2651B20.3 -13.91 4.48e-37 3.7e-33 -0.65 -0.54 Response to fenofibrate (adiponectin levels); chr15:45359856 chr15:45251580~45279251:- LUSC cis rs9399135 0.967 rs12526055 ENSG00000232876.1 CTA-212D2.2 -13.91 4.58e-37 3.78e-33 -0.62 -0.54 Red blood cell count; chr6:135004780 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs59329760 ENSG00000232876.1 CTA-212D2.2 -13.9 4.73e-37 3.91e-33 -0.62 -0.54 Red blood cell count; chr6:135021299 chr6:135055033~135060550:+ LUSC cis rs950027 0.62 rs1153860 ENSG00000259520.4 CTD-2651B20.3 13.9 4.76e-37 3.93e-33 0.64 0.54 Response to fenofibrate (adiponectin levels); chr15:45344386 chr15:45251580~45279251:- LUSC cis rs1933112 1 rs1933104 ENSG00000227777.1 RP4-738P11.3 -13.9 4.77e-37 3.93e-33 -0.64 -0.54 Blood protein levels; chr1:168559648 chr1:168542737~168543354:+ LUSC cis rs507080 0.733 rs673547 ENSG00000255422.1 AP002954.4 -13.9 4.86e-37 4.01e-33 -0.6 -0.54 Serum metabolite levels; chr11:118702630 chr11:118704607~118750263:+ LUSC cis rs2658782 0.526 rs7127240 ENSG00000279684.1 RP11-755E23.2 -13.9 4.97e-37 4.1e-33 -0.71 -0.54 Pulmonary function decline; chr11:93451726 chr11:93286629~93288903:- LUSC cis rs9399135 1 rs11754265 ENSG00000232876.1 CTA-212D2.2 -13.9 5e-37 4.12e-33 -0.64 -0.54 Red blood cell count; chr6:135035078 chr6:135055033~135060550:+ LUSC cis rs950027 0.62 rs1145077 ENSG00000259520.4 CTD-2651B20.3 13.9 5.04e-37 4.15e-33 0.65 0.54 Response to fenofibrate (adiponectin levels); chr15:45391597 chr15:45251580~45279251:- LUSC cis rs507080 0.883 rs558593 ENSG00000255239.1 AP002954.6 13.89 5.11e-37 4.21e-33 0.63 0.54 Serum metabolite levels; chr11:118691811 chr11:118688039~118690600:- LUSC cis rs858239 0.698 rs4265084 ENSG00000230658.1 KLHL7-AS1 13.89 5.46e-37 4.49e-33 0.68 0.54 Cerebrospinal fluid biomarker levels; chr7:23367621 chr7:23101228~23105703:- LUSC cis rs9399135 1 rs4475342 ENSG00000232876.1 CTA-212D2.2 -13.89 5.51e-37 4.53e-33 -0.64 -0.54 Red blood cell count; chr6:134962210 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9399129 ENSG00000232876.1 CTA-212D2.2 -13.88 5.71e-37 4.69e-33 -0.63 -0.54 Red blood cell count; chr6:134964010 chr6:135055033~135060550:+ LUSC cis rs1153858 1 rs67831559 ENSG00000259520.4 CTD-2651B20.3 -13.88 5.74e-37 4.72e-33 -0.7 -0.54 Homoarginine levels; chr15:45357109 chr15:45251580~45279251:- LUSC cis rs9399135 0.967 rs6902954 ENSG00000232876.1 CTA-212D2.2 -13.87 6.3e-37 5.17e-33 -0.62 -0.54 Red blood cell count; chr6:134992856 chr6:135055033~135060550:+ LUSC cis rs507080 0.922 rs4938524 ENSG00000255239.1 AP002954.6 13.87 6.31e-37 5.18e-33 0.61 0.54 Serum metabolite levels; chr11:118681365 chr11:118688039~118690600:- LUSC cis rs2882667 0.964 rs11958050 ENSG00000253404.1 AC034243.1 13.87 6.43e-37 5.26e-33 0.66 0.54 Age-related hearing impairment (SNP x SNP interaction); chr5:138966139 chr5:138744434~138753309:- LUSC cis rs9399135 0.967 rs4451151 ENSG00000232876.1 CTA-212D2.2 -13.87 6.51e-37 5.32e-33 -0.62 -0.54 Red blood cell count; chr6:134989408 chr6:135055033~135060550:+ LUSC cis rs2739330 0.791 rs4822458 ENSG00000218537.1 MIF-AS1 13.87 6.67e-37 5.44e-33 0.69 0.54 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23894426~23898930:- LUSC cis rs9399135 0.967 rs3756799 ENSG00000232876.1 CTA-212D2.2 -13.87 6.77e-37 5.52e-33 -0.63 -0.54 Red blood cell count; chr6:135019873 chr6:135055033~135060550:+ LUSC cis rs2882667 0.898 rs4380651 ENSG00000253404.1 AC034243.1 13.86 7.05e-37 5.73e-33 0.66 0.54 Age-related hearing impairment (SNP x SNP interaction); chr5:139055383 chr5:138744434~138753309:- LUSC cis rs9326248 0.515 rs2727793 ENSG00000254851.1 RP11-109L13.1 -13.86 7.09e-37 5.77e-33 -0.71 -0.54 Blood protein levels; chr11:116812658 chr11:117135528~117138582:+ LUSC cis rs1153858 1 rs10519021 ENSG00000259520.4 CTD-2651B20.3 -13.86 7.12e-37 5.79e-33 -0.71 -0.54 Homoarginine levels; chr15:45339597 chr15:45251580~45279251:- LUSC cis rs507080 0.733 rs611733 ENSG00000255422.1 AP002954.4 -13.86 7.16e-37 5.82e-33 -0.6 -0.54 Serum metabolite levels; chr11:118702051 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs12788848 ENSG00000255239.1 AP002954.6 13.86 7.57e-37 6.14e-33 0.62 0.54 Serum metabolite levels; chr11:118683079 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs4474473 ENSG00000255239.1 AP002954.6 13.86 7.57e-37 6.14e-33 0.62 0.54 Serum metabolite levels; chr11:118683180 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs12796373 ENSG00000255239.1 AP002954.6 13.86 7.57e-37 6.14e-33 0.62 0.54 Serum metabolite levels; chr11:118684230 chr11:118688039~118690600:- LUSC cis rs9399135 1 rs4896130 ENSG00000232876.1 CTA-212D2.2 -13.85 7.64e-37 6.2e-33 -0.63 -0.54 Red blood cell count; chr6:135033980 chr6:135055033~135060550:+ LUSC cis rs858239 0.965 rs156429 ENSG00000230658.1 KLHL7-AS1 13.85 7.98e-37 6.46e-33 0.66 0.54 Cerebrospinal fluid biomarker levels; chr7:23266401 chr7:23101228~23105703:- LUSC cis rs1153858 0.723 rs11855527 ENSG00000259520.4 CTD-2651B20.3 13.85 8.05e-37 6.52e-33 0.74 0.54 Homoarginine levels; chr15:45314487 chr15:45251580~45279251:- LUSC cis rs9399135 0.935 rs4445070 ENSG00000232876.1 CTA-212D2.2 -13.84 8.81e-37 7.11e-33 -0.62 -0.54 Red blood cell count; chr6:134988074 chr6:135055033~135060550:+ LUSC cis rs2658782 0.724 rs2605629 ENSG00000279684.1 RP11-755E23.2 13.84 8.89e-37 7.18e-33 0.77 0.54 Pulmonary function decline; chr11:93530871 chr11:93286629~93288903:- LUSC cis rs9399135 0.967 rs9376077 ENSG00000232876.1 CTA-212D2.2 -13.83 9.54e-37 7.69e-33 -0.62 -0.54 Red blood cell count; chr6:134978575 chr6:135055033~135060550:+ LUSC cis rs9326248 0.53 rs7112513 ENSG00000254851.1 RP11-109L13.1 -13.83 9.65e-37 7.78e-33 -0.96 -0.54 Blood protein levels; chr11:117166645 chr11:117135528~117138582:+ LUSC cis rs2658782 0.593 rs2243410 ENSG00000279684.1 RP11-755E23.2 -13.83 9.67e-37 7.79e-33 -0.77 -0.54 Pulmonary function decline; chr11:93522353 chr11:93286629~93288903:- LUSC cis rs9399135 0.967 rs13199205 ENSG00000232876.1 CTA-212D2.2 -13.83 9.81e-37 7.9e-33 -0.63 -0.54 Red blood cell count; chr6:134965367 chr6:135055033~135060550:+ LUSC cis rs1577917 0.958 rs72907388 ENSG00000203875.9 SNHG5 -13.82 1.04e-36 8.38e-33 -0.76 -0.54 Response to antipsychotic treatment; chr6:85730489 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs4775911 ENSG00000259520.4 CTD-2651B20.3 13.82 1.05e-36 8.43e-33 0.69 0.54 Homoarginine levels; chr15:45357589 chr15:45251580~45279251:- LUSC cis rs507080 0.733 rs489126 ENSG00000255422.1 AP002954.4 -13.82 1.05e-36 8.46e-33 -0.6 -0.54 Serum metabolite levels; chr11:118702038 chr11:118704607~118750263:+ LUSC cis rs12439619 0.846 rs62013464 ENSG00000278603.1 RP13-608F4.5 13.82 1.05e-36 8.46e-33 0.76 0.54 Intelligence (multi-trait analysis); chr15:82288250 chr15:82472203~82472426:+ LUSC cis rs858239 1 rs858239 ENSG00000230658.1 KLHL7-AS1 13.82 1.09e-36 8.72e-33 0.66 0.54 Cerebrospinal fluid biomarker levels; chr7:23246696 chr7:23101228~23105703:- LUSC cis rs1577917 0.958 rs4707236 ENSG00000203875.9 SNHG5 -13.81 1.18e-36 9.46e-33 -0.72 -0.54 Response to antipsychotic treatment; chr6:85874249 chr6:85660950~85678736:- LUSC cis rs9326248 0.581 rs7120963 ENSG00000254851.1 RP11-109L13.1 13.8 1.25e-36 9.99e-33 0.66 0.54 Blood protein levels; chr11:116959545 chr11:117135528~117138582:+ LUSC cis rs507080 0.961 rs642497 ENSG00000255239.1 AP002954.6 13.8 1.36e-36 1.09e-32 0.61 0.54 Serum metabolite levels; chr11:118680075 chr11:118688039~118690600:- LUSC cis rs1153858 1 rs1890565 ENSG00000259520.4 CTD-2651B20.3 -13.8 1.37e-36 1.09e-32 -0.7 -0.54 Homoarginine levels; chr15:45371101 chr15:45251580~45279251:- LUSC cis rs9326248 0.53 rs1242229 ENSG00000254851.1 RP11-109L13.1 -13.79 1.44e-36 1.15e-32 -0.97 -0.54 Blood protein levels; chr11:117191654 chr11:117135528~117138582:+ LUSC cis rs9326248 0.59 rs2542063 ENSG00000254851.1 RP11-109L13.1 -13.79 1.48e-36 1.18e-32 -0.69 -0.54 Blood protein levels; chr11:116814051 chr11:117135528~117138582:+ LUSC cis rs9660180 0.62 rs3817856 ENSG00000268575.1 RP1-283E3.8 13.79 1.48e-36 1.18e-32 0.49 0.54 Body mass index; chr1:1732392 chr1:1702736~1737688:- LUSC cis rs950027 0.62 rs1346267 ENSG00000259520.4 CTD-2651B20.3 -13.78 1.52e-36 1.21e-32 -0.66 -0.54 Response to fenofibrate (adiponectin levels); chr15:45398791 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs2467863 ENSG00000259520.4 CTD-2651B20.3 -13.78 1.57e-36 1.25e-32 -0.71 -0.54 Homoarginine levels; chr15:45349682 chr15:45251580~45279251:- LUSC cis rs9399135 0.967 rs13218642 ENSG00000232876.1 CTA-212D2.2 -13.78 1.58e-36 1.26e-32 -0.62 -0.54 Red blood cell count; chr6:134988802 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs4388304 ENSG00000232876.1 CTA-212D2.2 -13.78 1.6e-36 1.27e-32 -0.62 -0.54 Red blood cell count; chr6:134988459 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs4376365 ENSG00000232876.1 CTA-212D2.2 -13.77 1.79e-36 1.42e-32 -0.62 -0.54 Red blood cell count; chr6:134986602 chr6:135055033~135060550:+ LUSC cis rs1153858 1 rs4271549 ENSG00000259520.4 CTD-2651B20.3 -13.77 1.8e-36 1.43e-32 -0.7 -0.54 Homoarginine levels; chr15:45360532 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs4627277 ENSG00000259520.4 CTD-2651B20.3 -13.77 1.8e-36 1.43e-32 -0.7 -0.54 Homoarginine levels; chr15:45360570 chr15:45251580~45279251:- LUSC cis rs2658782 0.654 rs2248524 ENSG00000279684.1 RP11-755E23.2 -13.77 1.84e-36 1.46e-32 -0.75 -0.54 Pulmonary function decline; chr11:93522549 chr11:93286629~93288903:- LUSC cis rs9399135 0.967 rs4637662 ENSG00000232876.1 CTA-212D2.2 -13.76 1.95e-36 1.55e-32 -0.62 -0.54 Red blood cell count; chr6:134977020 chr6:135055033~135060550:+ LUSC cis rs2658782 0.547 rs3020052 ENSG00000279684.1 RP11-755E23.2 -13.76 2.02e-36 1.6e-32 -0.72 -0.54 Pulmonary function decline; chr11:93322018 chr11:93286629~93288903:- LUSC cis rs1577917 0.958 rs1545376 ENSG00000203875.9 SNHG5 13.75 2.06e-36 1.63e-32 0.74 0.54 Response to antipsychotic treatment; chr6:85794864 chr6:85660950~85678736:- LUSC cis rs9399135 1 rs6569988 ENSG00000232876.1 CTA-212D2.2 -13.75 2.11e-36 1.67e-32 -0.63 -0.54 Red blood cell count; chr6:135031165 chr6:135055033~135060550:+ LUSC cis rs1153858 0.943 rs28605551 ENSG00000259520.4 CTD-2651B20.3 -13.75 2.11e-36 1.67e-32 -0.7 -0.54 Homoarginine levels; chr15:45349522 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs12595087 ENSG00000259520.4 CTD-2651B20.3 -13.75 2.12e-36 1.67e-32 -0.69 -0.54 Homoarginine levels; chr15:45363034 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs3759899 ENSG00000259520.4 CTD-2651B20.3 -13.75 2.12e-36 1.67e-32 -0.69 -0.54 Homoarginine levels; chr15:45363705 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs4625670 ENSG00000259520.4 CTD-2651B20.3 -13.75 2.15e-36 1.7e-32 -0.7 -0.54 Homoarginine levels; chr15:45360728 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs4534782 ENSG00000259520.4 CTD-2651B20.3 -13.75 2.15e-36 1.7e-32 -0.7 -0.54 Homoarginine levels; chr15:45360735 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs1049503 ENSG00000259520.4 CTD-2651B20.3 -13.75 2.15e-36 1.7e-32 -0.7 -0.54 Homoarginine levels; chr15:45361509 chr15:45251580~45279251:- LUSC cis rs9399135 0.967 rs4895436 ENSG00000232876.1 CTA-212D2.2 -13.75 2.18e-36 1.72e-32 -0.62 -0.54 Red blood cell count; chr6:134973863 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs4896122 ENSG00000232876.1 CTA-212D2.2 -13.75 2.18e-36 1.72e-32 -0.62 -0.54 Red blood cell count; chr6:134973943 chr6:135055033~135060550:+ LUSC cis rs9399135 0.967 rs9376075 ENSG00000232876.1 CTA-212D2.2 -13.75 2.18e-36 1.72e-32 -0.62 -0.54 Red blood cell count; chr6:134975825 chr6:135055033~135060550:+ LUSC cis rs9399135 0.935 rs4273704 ENSG00000232876.1 CTA-212D2.2 -13.75 2.18e-36 1.72e-32 -0.62 -0.54 Red blood cell count; chr6:134976382 chr6:135055033~135060550:+ LUSC cis rs2283792 0.633 rs240068 ENSG00000228050.1 TOP3BP1 13.75 2.22e-36 1.75e-32 0.64 0.54 Multiple sclerosis; chr22:21936031 chr22:22223187~22224566:- LUSC cis rs1153858 0.887 rs7171163 ENSG00000259520.4 CTD-2651B20.3 -13.74 2.37e-36 1.86e-32 -0.69 -0.54 Homoarginine levels; chr15:45344197 chr15:45251580~45279251:- LUSC cis rs11155671 0.53 rs9397398 ENSG00000231760.4 RP11-350J20.5 13.74 2.39e-36 1.88e-32 0.67 0.54 Testicular germ cell tumor; chr6:149872467 chr6:149796151~149826294:- LUSC cis rs1577917 0.916 rs7759727 ENSG00000203875.9 SNHG5 -13.74 2.43e-36 1.91e-32 -0.72 -0.54 Response to antipsychotic treatment; chr6:85809160 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12196230 ENSG00000203875.9 SNHG5 -13.74 2.43e-36 1.91e-32 -0.72 -0.54 Response to antipsychotic treatment; chr6:85810242 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs34994386 ENSG00000203875.9 SNHG5 -13.74 2.43e-36 1.91e-32 -0.72 -0.54 Response to antipsychotic treatment; chr6:85814417 chr6:85660950~85678736:- LUSC cis rs507080 0.922 rs519848 ENSG00000255239.1 AP002954.6 13.73 2.53e-36 1.99e-32 0.61 0.54 Serum metabolite levels; chr11:118682006 chr11:118688039~118690600:- LUSC cis rs1577917 0.958 rs12213431 ENSG00000203875.9 SNHG5 -13.73 2.53e-36 1.99e-32 -0.72 -0.54 Response to antipsychotic treatment; chr6:85791238 chr6:85660950~85678736:- LUSC cis rs12439619 0.846 rs7496227 ENSG00000278603.1 RP13-608F4.5 13.73 2.6e-36 2.04e-32 0.77 0.54 Intelligence (multi-trait analysis); chr15:82275241 chr15:82472203~82472426:+ LUSC cis rs1153858 0.943 rs4774580 ENSG00000259520.4 CTD-2651B20.3 -13.73 2.62e-36 2.05e-32 -0.7 -0.54 Homoarginine levels; chr15:45359888 chr15:45251580~45279251:- LUSC cis rs1577917 0.958 rs7739241 ENSG00000203875.9 SNHG5 -13.72 2.81e-36 2.2e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85866078 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12202712 ENSG00000203875.9 SNHG5 -13.72 2.81e-36 2.2e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85868823 chr6:85660950~85678736:- LUSC cis rs507080 0.733 rs4393358 ENSG00000255422.1 AP002954.4 -13.72 2.81e-36 2.21e-32 -0.59 -0.53 Serum metabolite levels; chr11:118698388 chr11:118704607~118750263:+ LUSC cis rs1153858 1 rs16942000 ENSG00000259520.4 CTD-2651B20.3 -13.72 2.94e-36 2.3e-32 -0.69 -0.53 Homoarginine levels; chr15:45340805 chr15:45251580~45279251:- LUSC cis rs1153858 0.945 rs7182300 ENSG00000259520.4 CTD-2651B20.3 -13.72 2.94e-36 2.3e-32 -0.69 -0.53 Homoarginine levels; chr15:45342730 chr15:45251580~45279251:- LUSC cis rs9326248 0.53 rs2127905 ENSG00000254851.1 RP11-109L13.1 -13.72 2.96e-36 2.32e-32 -1 -0.53 Blood protein levels; chr11:117155658 chr11:117135528~117138582:+ LUSC cis rs2658782 0.724 rs2248655 ENSG00000279684.1 RP11-755E23.2 -13.72 2.97e-36 2.33e-32 -0.78 -0.53 Pulmonary function decline; chr11:93521446 chr11:93286629~93288903:- LUSC cis rs507080 0.961 rs642530 ENSG00000255239.1 AP002954.6 13.71 3.27e-36 2.56e-32 0.6 0.53 Serum metabolite levels; chr11:118680047 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs508640 ENSG00000255239.1 AP002954.6 13.71 3.29e-36 2.57e-32 0.62 0.53 Serum metabolite levels; chr11:118693704 chr11:118688039~118690600:- LUSC cis rs1153858 1 rs56850226 ENSG00000259520.4 CTD-2651B20.3 -13.71 3.3e-36 2.58e-32 -0.7 -0.53 Homoarginine levels; chr15:45340920 chr15:45251580~45279251:- LUSC cis rs507080 0.922 rs558781 ENSG00000255239.1 AP002954.6 13.7 3.44e-36 2.68e-32 0.62 0.53 Serum metabolite levels; chr11:118693688 chr11:118688039~118690600:- LUSC cis rs9326248 0.53 rs7123517 ENSG00000254851.1 RP11-109L13.1 -13.7 3.54e-36 2.76e-32 -1 -0.53 Blood protein levels; chr11:117157039 chr11:117135528~117138582:+ LUSC cis rs2283792 0.812 rs240064 ENSG00000228050.1 TOP3BP1 -13.7 3.62e-36 2.82e-32 -0.62 -0.53 Multiple sclerosis; chr22:21927265 chr22:22223187~22224566:- LUSC cis rs2006771 0.81 rs2006648 ENSG00000236132.1 CTA-440B3.1 13.69 3.87e-36 3.01e-32 0.65 0.53 Nonsyndromic cleft lip with cleft palate; chr22:31685943 chr22:31816379~31817491:- LUSC cis rs950027 0.62 rs1145076 ENSG00000259520.4 CTD-2651B20.3 -13.68 4.12e-36 3.2e-32 -0.65 -0.53 Response to fenofibrate (adiponectin levels); chr15:45392310 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs56669689 ENSG00000259520.4 CTD-2651B20.3 -13.68 4.2e-36 3.26e-32 -0.69 -0.53 Homoarginine levels; chr15:45345531 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs56806728 ENSG00000259520.4 CTD-2651B20.3 -13.68 4.2e-36 3.26e-32 -0.69 -0.53 Homoarginine levels; chr15:45345616 chr15:45251580~45279251:- LUSC cis rs12439619 0.846 rs62011975 ENSG00000278603.1 RP13-608F4.5 13.68 4.2e-36 3.26e-32 0.76 0.53 Intelligence (multi-trait analysis); chr15:82159213 chr15:82472203~82472426:+ LUSC cis rs1577917 0.876 rs4618490 ENSG00000203875.9 SNHG5 -13.68 4.27e-36 3.31e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85808685 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12191340 ENSG00000203875.9 SNHG5 -13.68 4.27e-36 3.31e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85811682 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs1414199 ENSG00000203875.9 SNHG5 -13.68 4.27e-36 3.31e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85812652 chr6:85660950~85678736:- LUSC cis rs2658782 0.526 rs3020062 ENSG00000279684.1 RP11-755E23.2 -13.67 4.82e-36 3.73e-32 -0.72 -0.53 Pulmonary function decline; chr11:93327993 chr11:93286629~93288903:- LUSC cis rs507080 0.922 rs592280 ENSG00000255239.1 AP002954.6 13.66 5.01e-36 3.87e-32 0.61 0.53 Serum metabolite levels; chr11:118682509 chr11:118688039~118690600:- LUSC cis rs950027 0.62 rs1145080 ENSG00000259520.4 CTD-2651B20.3 -13.66 5.09e-36 3.94e-32 -0.65 -0.53 Response to fenofibrate (adiponectin levels); chr15:45389140 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs4775906 ENSG00000259520.4 CTD-2651B20.3 -13.66 5.22e-36 4.03e-32 -0.69 -0.53 Homoarginine levels; chr15:45346096 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs7179743 ENSG00000259520.4 CTD-2651B20.3 -13.66 5.22e-36 4.03e-32 -0.69 -0.53 Homoarginine levels; chr15:45346133 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs7163720 ENSG00000259520.4 CTD-2651B20.3 -13.66 5.25e-36 4.05e-32 -0.69 -0.53 Homoarginine levels; chr15:45347176 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs7167900 ENSG00000259520.4 CTD-2651B20.3 -13.66 5.25e-36 4.05e-32 -0.69 -0.53 Homoarginine levels; chr15:45347273 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs12591058 ENSG00000259520.4 CTD-2651B20.3 -13.66 5.25e-36 4.05e-32 -0.69 -0.53 Homoarginine levels; chr15:45347974 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs7169587 ENSG00000259520.4 CTD-2651B20.3 -13.66 5.25e-36 4.05e-32 -0.69 -0.53 Homoarginine levels; chr15:45348181 chr15:45251580~45279251:- LUSC cis rs950027 0.62 rs2486274 ENSG00000259520.4 CTD-2651B20.3 -13.66 5.36e-36 4.13e-32 -0.65 -0.53 Response to fenofibrate (adiponectin levels); chr15:45374030 chr15:45251580~45279251:- LUSC cis rs9326248 0.53 rs7122944 ENSG00000254851.1 RP11-109L13.1 -13.66 5.37e-36 4.14e-32 -0.99 -0.53 Blood protein levels; chr11:117163903 chr11:117135528~117138582:+ LUSC cis rs507080 0.961 rs673770 ENSG00000255239.1 AP002954.6 13.66 5.41e-36 4.17e-32 0.61 0.53 Serum metabolite levels; chr11:118679892 chr11:118688039~118690600:- LUSC cis rs1933112 1 rs7514168 ENSG00000227777.1 RP4-738P11.3 -13.65 5.52e-36 4.25e-32 -0.65 -0.53 Blood protein levels; chr1:168561499 chr1:168542737~168543354:+ LUSC cis rs10256972 0.552 rs7805591 ENSG00000229043.2 AC091729.9 -13.65 5.55e-36 4.27e-32 -0.64 -0.53 Endometriosis;Longevity; chr7:1171109 chr7:1160374~1165267:+ LUSC cis rs2658782 0.654 rs2248531 ENSG00000279684.1 RP11-755E23.2 -13.65 5.56e-36 4.28e-32 -0.75 -0.53 Pulmonary function decline; chr11:93522197 chr11:93286629~93288903:- LUSC cis rs1577917 0.837 rs10944157 ENSG00000203875.9 SNHG5 -13.65 5.57e-36 4.28e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85867481 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs7181167 ENSG00000259520.4 CTD-2651B20.3 -13.65 5.58e-36 4.29e-32 -0.7 -0.53 Homoarginine levels; chr15:45394038 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs11070457 ENSG00000259520.4 CTD-2651B20.3 -13.65 5.58e-36 4.29e-32 -0.7 -0.53 Homoarginine levels; chr15:45394745 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs3809472 ENSG00000259520.4 CTD-2651B20.3 -13.65 5.58e-36 4.29e-32 -0.7 -0.53 Homoarginine levels; chr15:45402120 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs1820518 ENSG00000259520.4 CTD-2651B20.3 -13.65 5.58e-36 4.29e-32 -0.7 -0.53 Homoarginine levels; chr15:45402381 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs1365610 ENSG00000259520.4 CTD-2651B20.3 -13.65 5.58e-36 4.29e-32 -0.7 -0.53 Homoarginine levels; chr15:45402412 chr15:45251580~45279251:- LUSC cis rs507080 0.922 rs471227 ENSG00000255239.1 AP002954.6 13.65 5.68e-36 4.36e-32 0.62 0.53 Serum metabolite levels; chr11:118693892 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs516153 ENSG00000255239.1 AP002954.6 13.65 5.68e-36 4.36e-32 0.62 0.53 Serum metabolite levels; chr11:118694053 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs518028 ENSG00000255239.1 AP002954.6 13.65 5.68e-36 4.36e-32 0.62 0.53 Serum metabolite levels; chr11:118694273 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs519982 ENSG00000255239.1 AP002954.6 13.65 5.68e-36 4.36e-32 0.62 0.53 Serum metabolite levels; chr11:118694522 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs478371 ENSG00000255239.1 AP002954.6 13.65 5.68e-36 4.36e-32 0.62 0.53 Serum metabolite levels; chr11:118694627 chr11:118688039~118690600:- LUSC cis rs507080 0.961 rs1784298 ENSG00000255239.1 AP002954.6 13.65 5.83e-36 4.47e-32 0.6 0.53 Serum metabolite levels; chr11:118677956 chr11:118688039~118690600:- LUSC cis rs507080 0.961 rs4938522 ENSG00000255239.1 AP002954.6 13.65 5.83e-36 4.47e-32 0.6 0.53 Serum metabolite levels; chr11:118677962 chr11:118688039~118690600:- LUSC cis rs507080 1 rs659969 ENSG00000255239.1 AP002954.6 13.65 5.83e-36 4.47e-32 0.6 0.53 Serum metabolite levels; chr11:118679094 chr11:118688039~118690600:- LUSC cis rs507080 0.961 rs600969 ENSG00000255239.1 AP002954.6 13.64 6.06e-36 4.63e-32 0.61 0.53 Serum metabolite levels; chr11:118675087 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs12577485 ENSG00000255239.1 AP002954.6 13.64 6.06e-36 4.63e-32 0.61 0.53 Serum metabolite levels; chr11:118676793 chr11:118688039~118690600:- LUSC cis rs1577917 0.958 rs1447160 ENSG00000203875.9 SNHG5 -13.64 6.09e-36 4.64e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85836405 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs4707229 ENSG00000203875.9 SNHG5 -13.64 6.09e-36 4.64e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85836519 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12198061 ENSG00000203875.9 SNHG5 -13.64 6.09e-36 4.64e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85841267 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs1838955 ENSG00000203875.9 SNHG5 -13.64 6.09e-36 4.64e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85855731 chr6:85660950~85678736:- LUSC cis rs950027 0.62 rs1617984 ENSG00000259520.4 CTD-2651B20.3 -13.64 6.14e-36 4.69e-32 -0.65 -0.53 Response to fenofibrate (adiponectin levels); chr15:45330464 chr15:45251580~45279251:- LUSC cis rs1577917 0.958 rs1335442 ENSG00000203875.9 SNHG5 -13.64 6.17e-36 4.71e-32 -0.74 -0.53 Response to antipsychotic treatment; chr6:85756974 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs13213899 ENSG00000203875.9 SNHG5 -13.64 6.2e-36 4.73e-32 -0.74 -0.53 Response to antipsychotic treatment; chr6:85763422 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs10806337 ENSG00000203875.9 SNHG5 -13.64 6.2e-36 4.73e-32 -0.74 -0.53 Response to antipsychotic treatment; chr6:85764531 chr6:85660950~85678736:- LUSC cis rs12439619 0.846 rs62010071 ENSG00000278603.1 RP13-608F4.5 13.64 6.21e-36 4.73e-32 0.76 0.53 Intelligence (multi-trait analysis); chr15:82289442 chr15:82472203~82472426:+ LUSC cis rs950027 0.62 rs1145084 ENSG00000259520.4 CTD-2651B20.3 -13.64 6.27e-36 4.77e-32 -0.65 -0.53 Response to fenofibrate (adiponectin levels); chr15:45383242 chr15:45251580~45279251:- LUSC cis rs1577917 0.958 rs2225754 ENSG00000203875.9 SNHG5 -13.64 6.5e-36 4.95e-32 -0.74 -0.53 Response to antipsychotic treatment; chr6:85739980 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs12440038 ENSG00000259520.4 CTD-2651B20.3 -13.63 6.73e-36 5.12e-32 -0.7 -0.53 Homoarginine levels; chr15:45414541 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs60476496 ENSG00000259520.4 CTD-2651B20.3 -13.63 6.73e-36 5.12e-32 -0.7 -0.53 Homoarginine levels; chr15:45421603 chr15:45251580~45279251:- LUSC cis rs2006771 0.846 rs6518754 ENSG00000236132.1 CTA-440B3.1 -13.63 6.84e-36 5.2e-32 -0.65 -0.53 Nonsyndromic cleft lip with cleft palate; chr22:31701789 chr22:31816379~31817491:- LUSC cis rs1153858 1 rs4775907 ENSG00000259520.4 CTD-2651B20.3 -13.63 6.91e-36 5.25e-32 -0.69 -0.53 Homoarginine levels; chr15:45346449 chr15:45251580~45279251:- LUSC cis rs2882667 0.858 rs11959851 ENSG00000253404.1 AC034243.1 13.62 7.56e-36 5.74e-32 0.68 0.53 Age-related hearing impairment (SNP x SNP interaction); chr5:139085716 chr5:138744434~138753309:- LUSC cis rs1153858 1 rs9788780 ENSG00000259520.4 CTD-2651B20.3 -13.62 7.8e-36 5.91e-32 -0.7 -0.53 Homoarginine levels; chr15:45393289 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs11070456 ENSG00000259520.4 CTD-2651B20.3 -13.62 7.8e-36 5.91e-32 -0.7 -0.53 Homoarginine levels; chr15:45394637 chr15:45251580~45279251:- LUSC cis rs1577917 0.876 rs11752223 ENSG00000203875.9 SNHG5 -13.62 7.92e-36 6e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85863676 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12660846 ENSG00000203875.9 SNHG5 -13.61 8.33e-36 6.31e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85864091 chr6:85660950~85678736:- LUSC cis rs507080 0.845 rs667982 ENSG00000255239.1 AP002954.6 13.6 9e-36 6.81e-32 0.61 0.53 Serum metabolite levels; chr11:118692058 chr11:118688039~118690600:- LUSC cis rs1577917 0.958 rs12205492 ENSG00000203875.9 SNHG5 -13.6 9.26e-36 7e-32 -0.74 -0.53 Response to antipsychotic treatment; chr6:85766258 chr6:85660950~85678736:- LUSC cis rs2486288 0.539 rs2433601 ENSG00000259520.4 CTD-2651B20.3 -13.6 9.52e-36 7.19e-32 -0.65 -0.53 Glomerular filtration rate; chr15:45424227 chr15:45251580~45279251:- LUSC cis rs1577917 0.958 rs2084294 ENSG00000203875.9 SNHG5 -13.59 1.01e-35 7.62e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85856225 chr6:85660950~85678736:- LUSC cis rs9399135 0.967 rs6923765 ENSG00000232876.1 CTA-212D2.2 13.59 1.06e-35 7.99e-32 0.62 0.53 Red blood cell count; chr6:135014038 chr6:135055033~135060550:+ LUSC cis rs1577917 0.958 rs2100109 ENSG00000203875.9 SNHG5 -13.59 1.08e-35 8.11e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85835208 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs2218594 ENSG00000203875.9 SNHG5 -13.58 1.13e-35 8.5e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85834048 chr6:85660950~85678736:- LUSC cis rs1577917 0.916 rs4142546 ENSG00000203875.9 SNHG5 -13.58 1.18e-35 8.85e-32 -0.72 -0.53 Response to antipsychotic treatment; chr6:85795593 chr6:85660950~85678736:- LUSC cis rs507080 1 rs507080 ENSG00000255239.1 AP002954.6 13.58 1.19e-35 8.94e-32 0.6 0.53 Serum metabolite levels; chr11:118678873 chr11:118688039~118690600:- LUSC cis rs950027 0.62 rs1426932 ENSG00000259520.4 CTD-2651B20.3 -13.57 1.21e-35 9.05e-32 -0.65 -0.53 Response to fenofibrate (adiponectin levels); chr15:45395058 chr15:45251580~45279251:- LUSC cis rs3814244 0.751 rs12832728 ENSG00000255733.4 IFNG-AS1 -13.57 1.24e-35 9.28e-32 -0.45 -0.53 Itch intensity from mosquito bite adjusted by bite size; chr12:68026623 chr12:67989445~68234686:+ LUSC cis rs2739330 0.587 rs4820571 ENSG00000250470.1 AP000351.3 13.57 1.28e-35 9.62e-32 0.71 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23976904~23977585:- LUSC cis rs507080 0.883 rs656575 ENSG00000255239.1 AP002954.6 13.57 1.3e-35 9.75e-32 0.6 0.53 Serum metabolite levels; chr11:118679199 chr11:118688039~118690600:- LUSC cis rs9399135 0.967 rs6923827 ENSG00000232876.1 CTA-212D2.2 -13.56 1.4e-35 1.05e-31 -0.63 -0.53 Red blood cell count; chr6:135014244 chr6:135055033~135060550:+ LUSC cis rs1153858 0.943 rs12439575 ENSG00000259520.4 CTD-2651B20.3 -13.56 1.42e-35 1.06e-31 -0.7 -0.53 Homoarginine levels; chr15:45392618 chr15:45251580~45279251:- LUSC cis rs2658782 0.738 rs2605628 ENSG00000279684.1 RP11-755E23.2 -13.56 1.42e-35 1.06e-31 -0.77 -0.53 Pulmonary function decline; chr11:93528394 chr11:93286629~93288903:- LUSC cis rs1153858 1 rs12594857 ENSG00000259520.4 CTD-2651B20.3 -13.56 1.43e-35 1.06e-31 -0.69 -0.53 Homoarginine levels; chr15:45374980 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs7402650 ENSG00000259520.4 CTD-2651B20.3 -13.56 1.44e-35 1.07e-31 -0.7 -0.53 Homoarginine levels; chr15:45409697 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs8042786 ENSG00000259520.4 CTD-2651B20.3 -13.56 1.44e-35 1.07e-31 -0.7 -0.53 Homoarginine levels; chr15:45411341 chr15:45251580~45279251:- LUSC cis rs1577917 1 rs16876529 ENSG00000203875.9 SNHG5 -13.56 1.44e-35 1.07e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85881484 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs7164602 ENSG00000259520.4 CTD-2651B20.3 -13.55 1.52e-35 1.13e-31 -0.7 -0.53 Homoarginine levels; chr15:45379127 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs12441971 ENSG00000259520.4 CTD-2651B20.3 -13.55 1.52e-35 1.13e-31 -0.7 -0.53 Homoarginine levels; chr15:45379759 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs1346268 ENSG00000259520.4 CTD-2651B20.3 -13.55 1.52e-35 1.13e-31 -0.7 -0.53 Homoarginine levels; chr15:45380831 chr15:45251580~45279251:- LUSC cis rs1153858 0.943 rs67045941 ENSG00000259520.4 CTD-2651B20.3 -13.55 1.52e-35 1.13e-31 -0.7 -0.53 Homoarginine levels; chr15:45384813 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs67744121 ENSG00000259520.4 CTD-2651B20.3 -13.55 1.52e-35 1.13e-31 -0.7 -0.53 Homoarginine levels; chr15:45385039 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs16942568 ENSG00000259520.4 CTD-2651B20.3 -13.55 1.52e-35 1.13e-31 -0.7 -0.53 Homoarginine levels; chr15:45385192 chr15:45251580~45279251:- LUSC cis rs1153858 0.943 rs11070454 ENSG00000259520.4 CTD-2651B20.3 -13.55 1.52e-35 1.13e-31 -0.7 -0.53 Homoarginine levels; chr15:45388054 chr15:45251580~45279251:- LUSC cis rs2739330 0.587 rs4820571 ENSG00000218537.1 MIF-AS1 13.55 1.56e-35 1.16e-31 0.68 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23894426~23898930:- LUSC cis rs4423214 1 rs4944959 ENSG00000254682.1 RP11-660L16.2 -13.55 1.58e-35 1.17e-31 -0.69 -0.53 Vitamin D levels; chr11:71457188 chr11:71448674~71452157:+ LUSC cis rs950027 0.62 rs1153862 ENSG00000259520.4 CTD-2651B20.3 -13.54 1.62e-35 1.2e-31 -0.64 -0.53 Response to fenofibrate (adiponectin levels); chr15:45339670 chr15:45251580~45279251:- LUSC cis rs10256972 0.567 rs2949185 ENSG00000229043.2 AC091729.9 -13.54 1.74e-35 1.29e-31 -0.63 -0.53 Endometriosis;Longevity; chr7:1169377 chr7:1160374~1165267:+ LUSC cis rs1577917 0.958 rs6900436 ENSG00000203875.9 SNHG5 -13.53 1.79e-35 1.32e-31 -0.72 -0.53 Response to antipsychotic treatment; chr6:85796570 chr6:85660950~85678736:- LUSC cis rs10256972 0.552 rs2949195 ENSG00000229043.2 AC091729.9 -13.53 1.86e-35 1.38e-31 -0.63 -0.53 Endometriosis;Longevity; chr7:1163069 chr7:1160374~1165267:+ LUSC cis rs1153858 1 rs66528868 ENSG00000259520.4 CTD-2651B20.3 -13.53 1.94e-35 1.43e-31 -0.7 -0.53 Homoarginine levels; chr15:45376349 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs7494956 ENSG00000259520.4 CTD-2651B20.3 -13.53 1.94e-35 1.43e-31 -0.7 -0.53 Homoarginine levels; chr15:45376367 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs12437840 ENSG00000259520.4 CTD-2651B20.3 -13.53 1.94e-35 1.43e-31 -0.7 -0.53 Homoarginine levels; chr15:45376857 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs12437887 ENSG00000259520.4 CTD-2651B20.3 -13.53 1.94e-35 1.43e-31 -0.7 -0.53 Homoarginine levels; chr15:45376896 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs2114501 ENSG00000259520.4 CTD-2651B20.3 -13.53 1.94e-35 1.43e-31 -0.7 -0.53 Homoarginine levels; chr15:45378118 chr15:45251580~45279251:- LUSC cis rs1153858 0.887 rs7164139 ENSG00000259520.4 CTD-2651B20.3 -13.53 1.94e-35 1.43e-31 -0.7 -0.53 Homoarginine levels; chr15:45378653 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs67461176 ENSG00000259520.4 CTD-2651B20.3 -13.53 1.94e-35 1.43e-31 -0.7 -0.53 Homoarginine levels; chr15:45384621 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs66939267 ENSG00000259520.4 CTD-2651B20.3 -13.53 1.94e-35 1.43e-31 -0.7 -0.53 Homoarginine levels; chr15:45384704 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs4775937 ENSG00000259520.4 CTD-2651B20.3 -13.53 1.94e-35 1.43e-31 -0.7 -0.53 Homoarginine levels; chr15:45386416 chr15:45251580~45279251:- LUSC cis rs1577917 0.917 rs2197651 ENSG00000203875.9 SNHG5 -13.53 1.94e-35 1.43e-31 -0.74 -0.53 Response to antipsychotic treatment; chr6:85785724 chr6:85660950~85678736:- LUSC cis rs2658782 0.724 rs2248020 ENSG00000279684.1 RP11-755E23.2 -13.53 1.95e-35 1.44e-31 -0.73 -0.53 Pulmonary function decline; chr11:93526799 chr11:93286629~93288903:- LUSC cis rs4423214 1 rs2002063 ENSG00000254682.1 RP11-660L16.2 13.52 1.95e-35 1.44e-31 0.69 0.53 Vitamin D levels; chr11:71452430 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs11600860 ENSG00000254682.1 RP11-660L16.2 13.52 1.95e-35 1.44e-31 0.69 0.53 Vitamin D levels; chr11:71452973 chr11:71448674~71452157:+ LUSC cis rs4423214 0.959 rs11606611 ENSG00000254682.1 RP11-660L16.2 13.52 1.95e-35 1.44e-31 0.69 0.53 Vitamin D levels; chr11:71453000 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs11606612 ENSG00000254682.1 RP11-660L16.2 13.52 1.95e-35 1.44e-31 0.69 0.53 Vitamin D levels; chr11:71453001 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs11606631 ENSG00000254682.1 RP11-660L16.2 13.52 1.95e-35 1.44e-31 0.69 0.53 Vitamin D levels; chr11:71453075 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs12789751 ENSG00000254682.1 RP11-660L16.2 13.52 1.95e-35 1.44e-31 0.69 0.53 Vitamin D levels; chr11:71453425 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs12791871 ENSG00000254682.1 RP11-660L16.2 13.52 1.95e-35 1.44e-31 0.69 0.53 Vitamin D levels; chr11:71453498 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs7944926 ENSG00000254682.1 RP11-660L16.2 13.52 1.95e-35 1.44e-31 0.69 0.53 Vitamin D levels; chr11:71454579 chr11:71448674~71452157:+ LUSC cis rs2283792 0.622 rs5756323 ENSG00000228050.1 TOP3BP1 -13.52 1.98e-35 1.46e-31 -0.64 -0.53 Multiple sclerosis; chr22:21980398 chr22:22223187~22224566:- LUSC cis rs10256972 0.552 rs2960837 ENSG00000229043.2 AC091729.9 -13.52 2.03e-35 1.5e-31 -0.63 -0.53 Endometriosis;Longevity; chr7:1164321 chr7:1160374~1165267:+ LUSC cis rs858239 1 rs858240 ENSG00000230658.1 KLHL7-AS1 13.52 2.07e-35 1.52e-31 0.65 0.53 Cerebrospinal fluid biomarker levels; chr7:23244618 chr7:23101228~23105703:- LUSC cis rs507080 0.922 rs502601 ENSG00000255239.1 AP002954.6 13.52 2.08e-35 1.53e-31 0.62 0.53 Serum metabolite levels; chr11:118694970 chr11:118688039~118690600:- LUSC cis rs9399135 1 rs9399135 ENSG00000232876.1 CTA-212D2.2 -13.52 2.1e-35 1.55e-31 -0.62 -0.53 Red blood cell count; chr6:135047176 chr6:135055033~135060550:+ LUSC cis rs73086581 0.787 rs67633417 ENSG00000229539.1 RP11-119B16.2 13.52 2.12e-35 1.56e-31 0.74 0.53 Response to antidepressants in depression; chr20:3887610 chr20:3888239~3888868:- LUSC cis rs73086581 0.787 rs68127408 ENSG00000229539.1 RP11-119B16.2 13.52 2.12e-35 1.56e-31 0.74 0.53 Response to antidepressants in depression; chr20:3887800 chr20:3888239~3888868:- LUSC cis rs1153858 0.943 rs7402632 ENSG00000259520.4 CTD-2651B20.3 -13.52 2.13e-35 1.57e-31 -0.7 -0.53 Homoarginine levels; chr15:45409715 chr15:45251580~45279251:- LUSC cis rs1577917 1 rs12204015 ENSG00000203875.9 SNHG5 -13.51 2.17e-35 1.59e-31 -0.72 -0.53 Response to antipsychotic treatment; chr6:85888616 chr6:85660950~85678736:- LUSC cis rs7115242 0.514 rs4936367 ENSG00000254851.1 RP11-109L13.1 -13.51 2.17e-35 1.6e-31 -0.97 -0.53 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117171661 chr11:117135528~117138582:+ LUSC cis rs9326248 0.53 rs4604928 ENSG00000254851.1 RP11-109L13.1 -13.51 2.17e-35 1.6e-31 -0.97 -0.53 Blood protein levels; chr11:117173487 chr11:117135528~117138582:+ LUSC cis rs2658782 0.724 rs2605627 ENSG00000279684.1 RP11-755E23.2 -13.51 2.18e-35 1.6e-31 -0.77 -0.53 Pulmonary function decline; chr11:93526349 chr11:93286629~93288903:- LUSC cis rs1577917 0.958 rs12193904 ENSG00000203875.9 SNHG5 -13.51 2.2e-35 1.61e-31 -0.73 -0.53 Response to antipsychotic treatment; chr6:85742985 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs11754330 ENSG00000203875.9 SNHG5 -13.51 2.2e-35 1.61e-31 -0.73 -0.53 Response to antipsychotic treatment; chr6:85745352 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs34622605 ENSG00000203875.9 SNHG5 -13.51 2.2e-35 1.61e-31 -0.73 -0.53 Response to antipsychotic treatment; chr6:85746801 chr6:85660950~85678736:- LUSC cis rs2658782 0.547 rs3020065 ENSG00000279684.1 RP11-755E23.2 -13.51 2.29e-35 1.68e-31 -0.71 -0.53 Pulmonary function decline; chr11:93326733 chr11:93286629~93288903:- LUSC cis rs950027 0.62 rs35861938 ENSG00000259520.4 CTD-2651B20.3 -13.5 2.46e-35 1.8e-31 -0.63 -0.53 Response to fenofibrate (adiponectin levels); chr15:45345145 chr15:45251580~45279251:- LUSC cis rs950027 0.596 rs2467865 ENSG00000259520.4 CTD-2651B20.3 -13.5 2.46e-35 1.8e-31 -0.63 -0.53 Response to fenofibrate (adiponectin levels); chr15:45346109 chr15:45251580~45279251:- LUSC cis rs1577917 1 rs6923148 ENSG00000203875.9 SNHG5 13.5 2.53e-35 1.85e-31 0.72 0.53 Response to antipsychotic treatment; chr6:86058068 chr6:85660950~85678736:- LUSC cis rs2283792 0.622 rs2266979 ENSG00000228050.1 TOP3BP1 13.5 2.54e-35 1.85e-31 0.63 0.53 Multiple sclerosis; chr22:21977447 chr22:22223187~22224566:- LUSC cis rs950027 0.62 rs2461700 ENSG00000259520.4 CTD-2651B20.3 -13.5 2.54e-35 1.86e-31 -0.63 -0.53 Response to fenofibrate (adiponectin levels); chr15:45348429 chr15:45251580~45279251:- LUSC cis rs507080 0.961 rs656505 ENSG00000255239.1 AP002954.6 13.5 2.58e-35 1.89e-31 0.6 0.53 Serum metabolite levels; chr11:118679245 chr11:118688039~118690600:- LUSC cis rs507080 0.961 rs660489 ENSG00000255239.1 AP002954.6 13.5 2.58e-35 1.89e-31 0.6 0.53 Serum metabolite levels; chr11:118679255 chr11:118688039~118690600:- LUSC cis rs1153858 1 rs10519022 ENSG00000259520.4 CTD-2651B20.3 13.49 2.65e-35 1.94e-31 0.7 0.53 Homoarginine levels; chr15:45371486 chr15:45251580~45279251:- LUSC cis rs1577917 0.687 rs1470531 ENSG00000203875.9 SNHG5 -13.49 2.69e-35 1.96e-31 -0.72 -0.53 Response to antipsychotic treatment; chr6:85797651 chr6:85660950~85678736:- LUSC cis rs950027 0.62 rs2453533 ENSG00000259520.4 CTD-2651B20.3 -13.49 2.75e-35 2e-31 -0.63 -0.53 Response to fenofibrate (adiponectin levels); chr15:45349027 chr15:45251580~45279251:- LUSC cis rs7188445 0.614 rs62043313 ENSG00000261390.4 RP11-345M22.2 -13.47 3.23e-35 2.35e-31 -0.66 -0.53 Urate levels; chr16:79710237 chr16:79715232~79770563:- LUSC cis rs2658782 0.547 rs3020054 ENSG00000279684.1 RP11-755E23.2 -13.46 3.52e-35 2.55e-31 -0.7 -0.53 Pulmonary function decline; chr11:93322390 chr11:93286629~93288903:- LUSC cis rs73086581 0.787 rs73084505 ENSG00000229539.1 RP11-119B16.2 13.46 3.65e-35 2.65e-31 0.73 0.53 Response to antidepressants in depression; chr20:3876227 chr20:3888239~3888868:- LUSC cis rs1577917 0.958 rs2197648 ENSG00000203875.9 SNHG5 -13.46 3.78e-35 2.75e-31 -0.72 -0.53 Response to antipsychotic treatment; chr6:85834169 chr6:85660950~85678736:- LUSC cis rs1577917 0.816 rs9353349 ENSG00000203875.9 SNHG5 13.45 3.87e-35 2.81e-31 0.71 0.53 Response to antipsychotic treatment; chr6:85998007 chr6:85660950~85678736:- LUSC cis rs2658782 0.547 rs3133454 ENSG00000279684.1 RP11-755E23.2 -13.45 3.92e-35 2.84e-31 -0.72 -0.53 Pulmonary function decline; chr11:93325853 chr11:93286629~93288903:- LUSC cis rs858239 1 rs199347 ENSG00000230658.1 KLHL7-AS1 13.45 3.93e-35 2.85e-31 0.64 0.53 Cerebrospinal fluid biomarker levels; chr7:23254127 chr7:23101228~23105703:- LUSC cis rs950027 0.62 rs1719245 ENSG00000259520.4 CTD-2651B20.3 -13.45 3.94e-35 2.85e-31 -0.64 -0.53 Response to fenofibrate (adiponectin levels); chr15:45331584 chr15:45251580~45279251:- LUSC cis rs2739330 0.732 rs5760175 ENSG00000218537.1 MIF-AS1 13.45 4.06e-35 2.94e-31 0.68 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23894426~23898930:- LUSC cis rs858239 0.899 rs858271 ENSG00000230658.1 KLHL7-AS1 13.45 4.12e-35 2.99e-31 0.65 0.53 Cerebrospinal fluid biomarker levels; chr7:23238664 chr7:23101228~23105703:- LUSC cis rs73086581 0.741 rs17212649 ENSG00000229539.1 RP11-119B16.2 13.44 4.39e-35 3.18e-31 0.74 0.53 Response to antidepressants in depression; chr20:3872446 chr20:3888239~3888868:- LUSC cis rs7115242 0.8 rs7131536 ENSG00000254851.1 RP11-109L13.1 -13.44 4.43e-35 3.21e-31 -0.96 -0.53 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117128730 chr11:117135528~117138582:+ LUSC cis rs507080 0.961 rs543327 ENSG00000255239.1 AP002954.6 13.43 4.76e-35 3.44e-31 0.6 0.53 Serum metabolite levels; chr11:118679276 chr11:118688039~118690600:- LUSC cis rs950027 0.596 rs2467853 ENSG00000259520.4 CTD-2651B20.3 -13.43 4.85e-35 3.5e-31 -0.65 -0.53 Response to fenofibrate (adiponectin levels); chr15:45406595 chr15:45251580~45279251:- LUSC cis rs507080 0.961 rs607527 ENSG00000255239.1 AP002954.6 -13.43 5.09e-35 3.67e-31 -0.59 -0.53 Serum metabolite levels; chr11:118667478 chr11:118688039~118690600:- LUSC cis rs507080 0.961 rs4938523 ENSG00000255239.1 AP002954.6 13.42 5.64e-35 4.05e-31 0.6 0.53 Serum metabolite levels; chr11:118678129 chr11:118688039~118690600:- LUSC cis rs507080 0.961 rs543413 ENSG00000255239.1 AP002954.6 13.41 5.81e-35 4.18e-31 0.6 0.53 Serum metabolite levels; chr11:118679308 chr11:118688039~118690600:- LUSC cis rs858239 1 rs199351 ENSG00000230658.1 KLHL7-AS1 13.41 5.89e-35 4.24e-31 0.65 0.53 Cerebrospinal fluid biomarker levels; chr7:23260430 chr7:23101228~23105703:- LUSC cis rs950027 0.595 rs2486288 ENSG00000259520.4 CTD-2651B20.3 -13.41 6.1e-35 4.38e-31 -0.64 -0.53 Response to fenofibrate (adiponectin levels); chr15:45420141 chr15:45251580~45279251:- LUSC cis rs9326248 0.53 rs2471884 ENSG00000254851.1 RP11-109L13.1 -13.41 6.17e-35 4.44e-31 -0.98 -0.53 Blood protein levels; chr11:117139604 chr11:117135528~117138582:+ LUSC cis rs7617773 0.694 rs13099560 ENSG00000229759.1 MRPS18AP1 -13.4 6.89e-35 4.94e-31 -0.52 -0.53 Coronary artery disease; chr3:48163278 chr3:48256350~48256938:- LUSC cis rs1153858 1 rs2453541 ENSG00000259520.4 CTD-2651B20.3 -13.39 7.59e-35 5.42e-31 -0.69 -0.53 Homoarginine levels; chr15:45353180 chr15:45251580~45279251:- LUSC cis rs858239 0.932 rs1637190 ENSG00000230658.1 KLHL7-AS1 13.38 7.74e-35 5.53e-31 0.64 0.53 Cerebrospinal fluid biomarker levels; chr7:23229446 chr7:23101228~23105703:- LUSC cis rs858239 0.896 rs1637192 ENSG00000230658.1 KLHL7-AS1 13.38 7.91e-35 5.65e-31 0.65 0.53 Cerebrospinal fluid biomarker levels; chr7:23220895 chr7:23101228~23105703:- LUSC cis rs950027 0.62 rs1719246 ENSG00000259520.4 CTD-2651B20.3 -13.38 7.94e-35 5.66e-31 -0.63 -0.53 Response to fenofibrate (adiponectin levels); chr15:45333281 chr15:45251580~45279251:- LUSC cis rs1577917 0.958 rs12192546 ENSG00000203875.9 SNHG5 13.38 7.95e-35 5.67e-31 0.73 0.53 Response to antipsychotic treatment; chr6:85766766 chr6:85660950~85678736:- LUSC cis rs7195287 0.826 rs9925824 ENSG00000276791.1 CTD-2270P14.5 -13.38 8.16e-35 5.82e-31 -0.53 -0.53 Eosinophil counts; chr16:2777972 chr16:2777319~2780568:+ LUSC cis rs858239 1 rs199357 ENSG00000230658.1 KLHL7-AS1 -13.38 8.21e-35 5.85e-31 -0.63 -0.53 Cerebrospinal fluid biomarker levels; chr7:23248690 chr7:23101228~23105703:- LUSC cis rs2487048 0.725 rs2246293 ENSG00000226334.1 RP11-217B7.2 13.38 8.28e-35 5.89e-31 0.62 0.53 Intraocular pressure; chr9:104928557 chr9:104927553~104928892:+ LUSC cis rs1577917 0.958 rs36042496 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85814496 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs1584273 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85814859 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12198971 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85815727 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs34230196 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85816304 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs4707226 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85818110 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs10455448 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85823893 chr6:85660950~85678736:- LUSC cis rs1577917 0.876 rs12212808 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85824254 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs13196576 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85824348 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs13213603 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85825040 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs3857480 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85825431 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs2324839 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85827224 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs3900313 ENSG00000203875.9 SNHG5 -13.38 8.3e-35 5.89e-31 -0.71 -0.53 Response to antipsychotic treatment; chr6:85827436 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs34765423 ENSG00000203875.9 SNHG5 -13.37 8.64e-35 6.13e-31 -0.73 -0.52 Response to antipsychotic treatment; chr6:85774730 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs4707223 ENSG00000203875.9 SNHG5 -13.37 8.69e-35 6.16e-31 -0.72 -0.52 Response to antipsychotic treatment; chr6:85800084 chr6:85660950~85678736:- LUSC cis rs858239 1 rs156407 ENSG00000230658.1 KLHL7-AS1 13.35 1.03e-34 7.29e-31 0.66 0.52 Cerebrospinal fluid biomarker levels; chr7:23276020 chr7:23101228~23105703:- LUSC cis rs10256972 0.577 rs4999286 ENSG00000229043.2 AC091729.9 -13.35 1.08e-34 7.59e-31 -0.63 -0.52 Endometriosis;Longevity; chr7:1159870 chr7:1160374~1165267:+ LUSC cis rs11155671 0.53 rs4458704 ENSG00000231760.4 RP11-350J20.5 13.35 1.08e-34 7.6e-31 0.66 0.52 Testicular germ cell tumor; chr6:149911743 chr6:149796151~149826294:- LUSC cis rs1153858 1 rs1153858 ENSG00000259520.4 CTD-2651B20.3 13.35 1.09e-34 7.69e-31 0.68 0.52 Homoarginine levels; chr15:45360505 chr15:45251580~45279251:- LUSC cis rs9326248 0.581 rs12225187 ENSG00000254851.1 RP11-109L13.1 -13.35 1.13e-34 7.91e-31 -0.64 -0.52 Blood protein levels; chr11:116922515 chr11:117135528~117138582:+ LUSC cis rs858239 0.932 rs858272 ENSG00000230658.1 KLHL7-AS1 13.34 1.24e-34 8.68e-31 0.65 0.52 Cerebrospinal fluid biomarker levels; chr7:23237166 chr7:23101228~23105703:- LUSC cis rs1153858 1 rs2461702 ENSG00000259520.4 CTD-2651B20.3 -13.33 1.3e-34 9.13e-31 -0.68 -0.52 Homoarginine levels; chr15:45355229 chr15:45251580~45279251:- LUSC cis rs10256972 0.552 rs2949192 ENSG00000229043.2 AC091729.9 -13.33 1.33e-34 9.28e-31 -0.63 -0.52 Endometriosis;Longevity; chr7:1164205 chr7:1160374~1165267:+ LUSC cis rs12439619 0.846 rs62012003 ENSG00000278603.1 RP13-608F4.5 13.33 1.33e-34 9.31e-31 0.73 0.52 Intelligence (multi-trait analysis); chr15:82183236 chr15:82472203~82472426:+ LUSC cis rs12439619 0.846 rs28470877 ENSG00000278603.1 RP13-608F4.5 13.33 1.35e-34 9.41e-31 0.75 0.52 Intelligence (multi-trait analysis); chr15:82245797 chr15:82472203~82472426:+ LUSC cis rs6538678 0.824 rs1436120 ENSG00000258343.1 RP11-536G4.2 13.32 1.45e-34 1.01e-30 0.78 0.52 Lupus nephritis in systemic lupus erythematosus; chr12:95826872 chr12:95795345~95858839:- LUSC cis rs1577917 1 rs4706254 ENSG00000203875.9 SNHG5 -13.31 1.55e-34 1.08e-30 -0.71 -0.52 Response to antipsychotic treatment; chr6:85893095 chr6:85660950~85678736:- LUSC cis rs10256972 0.577 rs2949179 ENSG00000229043.2 AC091729.9 -13.31 1.59e-34 1.11e-30 -0.61 -0.52 Endometriosis;Longevity; chr7:1170249 chr7:1160374~1165267:+ LUSC cis rs10256972 0.504 rs2949178 ENSG00000229043.2 AC091729.9 -13.31 1.59e-34 1.11e-30 -0.61 -0.52 Endometriosis;Longevity; chr7:1170289 chr7:1160374~1165267:+ LUSC cis rs11155671 0.53 rs9383940 ENSG00000231760.4 RP11-350J20.5 13.31 1.61e-34 1.12e-30 0.66 0.52 Testicular germ cell tumor; chr6:149904923 chr6:149796151~149826294:- LUSC cis rs1577917 0.958 rs12216074 ENSG00000203875.9 SNHG5 -13.31 1.62e-34 1.13e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85810284 chr6:85660950~85678736:- LUSC cis rs11155671 0.53 rs1334510 ENSG00000231760.4 RP11-350J20.5 13.3 1.73e-34 1.2e-30 0.65 0.52 Testicular germ cell tumor; chr6:149880043 chr6:149796151~149826294:- LUSC cis rs1577917 1 rs6454513 ENSG00000203875.9 SNHG5 13.3 1.8e-34 1.25e-30 0.7 0.52 Response to antipsychotic treatment; chr6:86010331 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs12439274 ENSG00000259520.4 CTD-2651B20.3 -13.29 1.86e-34 1.29e-30 -0.67 -0.52 Homoarginine levels; chr15:45344469 chr15:45251580~45279251:- LUSC cis rs9326248 0.539 rs660443 ENSG00000254851.1 RP11-109L13.1 -13.29 1.89e-34 1.31e-30 -0.64 -0.52 Blood protein levels; chr11:116889977 chr11:117135528~117138582:+ LUSC cis rs12439619 0.768 rs28694364 ENSG00000278603.1 RP13-608F4.5 13.28 2.06e-34 1.42e-30 0.73 0.52 Intelligence (multi-trait analysis); chr15:82208119 chr15:82472203~82472426:+ LUSC cis rs1577917 0.917 rs35038582 ENSG00000203875.9 SNHG5 -13.28 2.09e-34 1.44e-30 -0.71 -0.52 Response to antipsychotic treatment; chr6:86011587 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs7760207 ENSG00000203875.9 SNHG5 -13.28 2.09e-34 1.44e-30 -0.71 -0.52 Response to antipsychotic treatment; chr6:86011982 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12207305 ENSG00000203875.9 SNHG5 -13.28 2.09e-34 1.44e-30 -0.71 -0.52 Response to antipsychotic treatment; chr6:86013784 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12199784 ENSG00000203875.9 SNHG5 -13.28 2.09e-34 1.44e-30 -0.71 -0.52 Response to antipsychotic treatment; chr6:86017090 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs791856 ENSG00000203875.9 SNHG5 13.28 2.19e-34 1.51e-30 0.71 0.52 Response to antipsychotic treatment; chr6:85972123 chr6:85660950~85678736:- LUSC cis rs858239 0.932 rs1728320 ENSG00000230658.1 KLHL7-AS1 13.27 2.26e-34 1.55e-30 0.66 0.52 Cerebrospinal fluid biomarker levels; chr7:23280170 chr7:23101228~23105703:- LUSC cis rs1577917 1 rs2816815 ENSG00000203875.9 SNHG5 -13.27 2.28e-34 1.56e-30 -0.71 -0.52 Response to antipsychotic treatment; chr6:85981938 chr6:85660950~85678736:- LUSC cis rs9399135 0.967 rs4895434 ENSG00000232876.1 CTA-212D2.2 -13.27 2.4e-34 1.64e-30 -0.62 -0.52 Red blood cell count; chr6:134972227 chr6:135055033~135060550:+ LUSC cis rs9399135 1 rs4895435 ENSG00000232876.1 CTA-212D2.2 -13.27 2.4e-34 1.64e-30 -0.62 -0.52 Red blood cell count; chr6:134972325 chr6:135055033~135060550:+ LUSC cis rs9326248 0.559 rs609177 ENSG00000254851.1 RP11-109L13.1 -13.27 2.44e-34 1.67e-30 -0.64 -0.52 Blood protein levels; chr11:116899801 chr11:117135528~117138582:+ LUSC cis rs73086581 0.787 rs67724338 ENSG00000229539.1 RP11-119B16.2 13.25 2.79e-34 1.9e-30 0.73 0.52 Response to antidepressants in depression; chr20:3888410 chr20:3888239~3888868:- LUSC cis rs73086581 0.787 rs67202952 ENSG00000229539.1 RP11-119B16.2 13.25 2.79e-34 1.9e-30 0.73 0.52 Response to antidepressants in depression; chr20:3888452 chr20:3888239~3888868:- LUSC cis rs9326248 0.509 rs533556 ENSG00000254851.1 RP11-109L13.1 -13.25 2.8e-34 1.91e-30 -0.63 -0.52 Blood protein levels; chr11:116870856 chr11:117135528~117138582:+ LUSC cis rs10129255 0.53 rs11624912 ENSG00000223648.3 IGHV3-64 13.25 2.88e-34 1.96e-30 0.42 0.52 Kawasaki disease; chr14:106673891 chr14:106643132~106658258:- LUSC cis rs2739330 0.731 rs5751792 ENSG00000218537.1 MIF-AS1 13.24 3.03e-34 2.06e-30 0.66 0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23894426~23898930:- LUSC cis rs9399135 0.967 rs4896123 ENSG00000232876.1 CTA-212D2.2 -13.24 3.05e-34 2.07e-30 -0.61 -0.52 Red blood cell count; chr6:134974272 chr6:135055033~135060550:+ LUSC cis rs10129255 0.518 rs7143784 ENSG00000223648.3 IGHV3-64 13.24 3.09e-34 2.09e-30 0.42 0.52 Kawasaki disease; chr14:106687277 chr14:106643132~106658258:- LUSC cis rs1577917 1 rs12199516 ENSG00000203875.9 SNHG5 -13.24 3.15e-34 2.13e-30 -0.71 -0.52 Response to antipsychotic treatment; chr6:86016503 chr6:85660950~85678736:- LUSC cis rs10129255 0.5 rs10143242 ENSG00000223648.3 IGHV3-64 13.24 3.16e-34 2.14e-30 0.42 0.52 Kawasaki disease; chr14:106681814 chr14:106643132~106658258:- LUSC cis rs1577917 0.958 rs10944137 ENSG00000203875.9 SNHG5 -13.24 3.27e-34 2.21e-30 -0.73 -0.52 Response to antipsychotic treatment; chr6:85744596 chr6:85660950~85678736:- LUSC cis rs9326248 0.559 rs1269329 ENSG00000254851.1 RP11-109L13.1 -13.23 3.36e-34 2.27e-30 -0.64 -0.52 Blood protein levels; chr11:116884325 chr11:117135528~117138582:+ LUSC cis rs9326248 0.559 rs482371 ENSG00000254851.1 RP11-109L13.1 -13.23 3.36e-34 2.27e-30 -0.64 -0.52 Blood protein levels; chr11:116881447 chr11:117135528~117138582:+ LUSC cis rs2739330 0.761 rs5760176 ENSG00000218537.1 MIF-AS1 -13.23 3.48e-34 2.35e-30 -0.66 -0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23894426~23898930:- LUSC cis rs10256972 0.514 rs2140578 ENSG00000229043.2 AC091729.9 -13.22 3.7e-34 2.49e-30 -0.64 -0.52 Endometriosis;Longevity; chr7:1174367 chr7:1160374~1165267:+ LUSC cis rs1577917 1 rs2166663 ENSG00000203875.9 SNHG5 -13.22 3.76e-34 2.53e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85884178 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs1145074 ENSG00000259520.4 CTD-2651B20.3 -13.22 3.8e-34 2.56e-30 -0.69 -0.52 Homoarginine levels; chr15:45411626 chr15:45251580~45279251:- LUSC cis rs2658782 0.724 rs2658770 ENSG00000279684.1 RP11-755E23.2 -13.22 3.96e-34 2.66e-30 -0.76 -0.52 Pulmonary function decline; chr11:93528720 chr11:93286629~93288903:- LUSC cis rs1577917 0.958 rs16876530 ENSG00000203875.9 SNHG5 -13.21 4.2e-34 2.82e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85885923 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs1145085 ENSG00000259520.4 CTD-2651B20.3 -13.21 4.25e-34 2.85e-30 -0.68 -0.52 Homoarginine levels; chr15:45365606 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs1288775 ENSG00000259520.4 CTD-2651B20.3 -13.21 4.25e-34 2.85e-30 -0.68 -0.52 Homoarginine levels; chr15:45369480 chr15:45251580~45279251:- LUSC cis rs507080 0.922 rs7114458 ENSG00000255239.1 AP002954.6 13.19 4.87e-34 3.26e-30 0.61 0.52 Serum metabolite levels; chr11:118695466 chr11:118688039~118690600:- LUSC cis rs12439619 0.693 rs4778989 ENSG00000278603.1 RP13-608F4.5 13.19 5.23e-34 3.5e-30 0.73 0.52 Intelligence (multi-trait analysis); chr15:82276963 chr15:82472203~82472426:+ LUSC cis rs10129255 0.5 rs1974468 ENSG00000223648.3 IGHV3-64 13.18 5.82e-34 3.89e-30 0.42 0.52 Kawasaki disease; chr14:106686149 chr14:106643132~106658258:- LUSC cis rs1153858 1 rs2668747 ENSG00000259520.4 CTD-2651B20.3 -13.18 5.85e-34 3.91e-30 -0.69 -0.52 Homoarginine levels; chr15:45325018 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs1049508 ENSG00000259520.4 CTD-2651B20.3 -13.17 6.14e-34 4.11e-30 -0.68 -0.52 Homoarginine levels; chr15:45361394 chr15:45251580~45279251:- LUSC cis rs10129255 0.5 rs2105991 ENSG00000223648.3 IGHV3-64 13.17 6.24e-34 4.17e-30 0.42 0.52 Kawasaki disease; chr14:106682022 chr14:106643132~106658258:- LUSC cis rs12439619 0.693 rs7165536 ENSG00000278603.1 RP13-608F4.5 13.16 6.61e-34 4.41e-30 0.73 0.52 Intelligence (multi-trait analysis); chr15:82273743 chr15:82472203~82472426:+ LUSC cis rs1577917 1 rs12215037 ENSG00000203875.9 SNHG5 -13.15 7.32e-34 4.88e-30 -0.72 -0.52 Response to antipsychotic treatment; chr6:86017913 chr6:85660950~85678736:- LUSC cis rs4423214 1 rs4944958 ENSG00000254682.1 RP11-660L16.2 13.15 7.39e-34 4.92e-30 0.68 0.52 Vitamin D levels; chr11:71457027 chr11:71448674~71452157:+ LUSC cis rs858239 1 rs166663 ENSG00000230658.1 KLHL7-AS1 13.14 7.93e-34 5.28e-30 0.65 0.52 Cerebrospinal fluid biomarker levels; chr7:23277123 chr7:23101228~23105703:- LUSC cis rs10129255 0.5 rs1024350 ENSG00000223648.3 IGHV3-64 13.14 8e-34 5.32e-30 0.41 0.52 Kawasaki disease; chr14:106685105 chr14:106643132~106658258:- LUSC cis rs1577917 1 rs955196 ENSG00000203875.9 SNHG5 13.14 8.15e-34 5.42e-30 0.71 0.52 Response to antipsychotic treatment; chr6:86020233 chr6:85660950~85678736:- LUSC cis rs507080 0.922 rs533646 ENSG00000255239.1 AP002954.6 13.14 8.51e-34 5.66e-30 0.61 0.52 Serum metabolite levels; chr11:118696037 chr11:118688039~118690600:- LUSC cis rs507080 0.922 rs7114216 ENSG00000255239.1 AP002954.6 13.13 8.99e-34 5.97e-30 0.61 0.52 Serum metabolite levels; chr11:118695525 chr11:118688039~118690600:- LUSC cis rs858239 0.932 rs1624451 ENSG00000230658.1 KLHL7-AS1 -13.13 9.19e-34 6.1e-30 -0.64 -0.52 Cerebrospinal fluid biomarker levels; chr7:23222816 chr7:23101228~23105703:- LUSC cis rs10256972 0.539 rs2949174 ENSG00000229043.2 AC091729.9 -13.13 9.41e-34 6.24e-30 -0.63 -0.52 Endometriosis;Longevity; chr7:1174287 chr7:1160374~1165267:+ LUSC cis rs1577917 0.958 rs11758508 ENSG00000203875.9 SNHG5 13.12 1e-33 6.63e-30 0.73 0.52 Response to antipsychotic treatment; chr6:85797160 chr6:85660950~85678736:- LUSC cis rs12439619 0.81 rs28876157 ENSG00000278603.1 RP13-608F4.5 13.12 1.01e-33 6.7e-30 0.72 0.52 Intelligence (multi-trait analysis); chr15:82216708 chr15:82472203~82472426:+ LUSC cis rs1153858 1 rs1719247 ENSG00000259520.4 CTD-2651B20.3 -13.12 1.03e-33 6.81e-30 -0.68 -0.52 Homoarginine levels; chr15:45328787 chr15:45251580~45279251:- LUSC cis rs507080 0.769 rs570836 ENSG00000255239.1 AP002954.6 13.12 1.03e-33 6.83e-30 0.6 0.52 Serum metabolite levels; chr11:118641444 chr11:118688039~118690600:- LUSC cis rs1577917 0.958 rs2660576 ENSG00000203875.9 SNHG5 -13.12 1.04e-33 6.85e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85941885 chr6:85660950~85678736:- LUSC cis rs9326248 0.559 rs476399 ENSG00000254851.1 RP11-109L13.1 -13.12 1.04e-33 6.87e-30 -0.63 -0.52 Blood protein levels; chr11:116863012 chr11:117135528~117138582:+ LUSC cis rs10129255 0.5 rs9324092 ENSG00000223648.3 IGHV3-64 -13.11 1.05e-33 6.95e-30 -0.42 -0.52 Kawasaki disease; chr14:106683806 chr14:106643132~106658258:- LUSC cis rs1577917 1 rs2812972 ENSG00000203875.9 SNHG5 -13.11 1.12e-33 7.37e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85960162 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs1337843 ENSG00000203875.9 SNHG5 -13.11 1.14e-33 7.49e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85965827 chr6:85660950~85678736:- LUSC cis rs4423214 1 rs12790010 ENSG00000254682.1 RP11-660L16.2 13.1 1.17e-33 7.67e-30 0.68 0.52 Vitamin D levels; chr11:71459607 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs12806844 ENSG00000254682.1 RP11-660L16.2 13.1 1.17e-33 7.67e-30 0.68 0.52 Vitamin D levels; chr11:71459724 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs12790558 ENSG00000254682.1 RP11-660L16.2 13.1 1.17e-33 7.67e-30 0.68 0.52 Vitamin D levels; chr11:71459859 chr11:71448674~71452157:+ LUSC cis rs4423214 0.959 rs11233747 ENSG00000254682.1 RP11-660L16.2 13.1 1.17e-33 7.67e-30 0.68 0.52 Vitamin D levels; chr11:71460596 chr11:71448674~71452157:+ LUSC cis rs1153858 1 rs1613559 ENSG00000259520.4 CTD-2651B20.3 -13.1 1.17e-33 7.7e-30 -0.68 -0.52 Homoarginine levels; chr15:45329918 chr15:45251580~45279251:- LUSC cis rs1577917 1 rs13199006 ENSG00000203875.9 SNHG5 -13.1 1.17e-33 7.7e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85898990 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs4707239 ENSG00000203875.9 SNHG5 -13.1 1.17e-33 7.7e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85900999 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs7766645 ENSG00000203875.9 SNHG5 -13.1 1.17e-33 7.7e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85912520 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1911552 ENSG00000203875.9 SNHG5 -13.1 1.17e-33 7.7e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85928306 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs9647603 ENSG00000203875.9 SNHG5 -13.1 1.17e-33 7.7e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85929623 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs7747824 ENSG00000203875.9 SNHG5 -13.1 1.17e-33 7.7e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85937388 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs35385043 ENSG00000203875.9 SNHG5 -13.1 1.17e-33 7.7e-30 -0.7 -0.52 Response to antipsychotic treatment; chr6:85938828 chr6:85660950~85678736:- LUSC cis rs10129255 0.5 rs4774008 ENSG00000223648.3 IGHV3-64 13.1 1.21e-33 7.93e-30 0.42 0.52 Kawasaki disease; chr14:106681273 chr14:106643132~106658258:- LUSC cis rs1153858 1 rs2467864 ENSG00000259520.4 CTD-2651B20.3 13.09 1.28e-33 8.36e-30 0.67 0.52 Homoarginine levels; chr15:45348900 chr15:45251580~45279251:- LUSC cis rs73086581 1 rs73084575 ENSG00000229539.1 RP11-119B16.2 13.08 1.42e-33 9.27e-30 0.7 0.52 Response to antidepressants in depression; chr20:3926121 chr20:3888239~3888868:- LUSC cis rs3931020 0.53 rs6668736 ENSG00000272864.1 RP11-17E13.2 -13.08 1.46e-33 9.5e-30 -0.58 -0.52 Resistin levels; chr1:74768866 chr1:74698769~74699333:- LUSC cis rs2739330 0.892 rs4822455 ENSG00000250470.1 AP000351.3 13.07 1.55e-33 1.01e-29 0.71 0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23976904~23977585:- LUSC cis rs2739330 0.892 rs5751776 ENSG00000250470.1 AP000351.3 13.07 1.63e-33 1.06e-29 0.71 0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23976904~23977585:- LUSC cis rs858239 0.831 rs7796541 ENSG00000230658.1 KLHL7-AS1 13.07 1.65e-33 1.07e-29 0.66 0.52 Cerebrospinal fluid biomarker levels; chr7:23349454 chr7:23101228~23105703:- LUSC cis rs1577917 1 rs12212733 ENSG00000203875.9 SNHG5 -13.07 1.66e-33 1.08e-29 -0.71 -0.52 Response to antipsychotic treatment; chr6:86016295 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs11755864 ENSG00000203875.9 SNHG5 -13.07 1.69e-33 1.09e-29 -0.71 -0.52 Response to antipsychotic treatment; chr6:85982073 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1999852 ENSG00000203875.9 SNHG5 -13.06 1.71e-33 1.11e-29 -0.7 -0.52 Response to antipsychotic treatment; chr6:85996020 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs35797755 ENSG00000203875.9 SNHG5 -13.06 1.71e-33 1.11e-29 -0.7 -0.52 Response to antipsychotic treatment; chr6:85996836 chr6:85660950~85678736:- LUSC cis rs858239 0.932 rs1728313 ENSG00000230658.1 KLHL7-AS1 13.06 1.73e-33 1.12e-29 0.63 0.52 Cerebrospinal fluid biomarker levels; chr7:23231412 chr7:23101228~23105703:- LUSC cis rs10129255 0.536 rs17113249 ENSG00000223648.3 IGHV3-64 13.06 1.77e-33 1.15e-29 0.41 0.52 Kawasaki disease; chr14:106678273 chr14:106643132~106658258:- LUSC cis rs1577917 0.958 rs12212480 ENSG00000203875.9 SNHG5 -13.06 1.83e-33 1.18e-29 -0.72 -0.52 Response to antipsychotic treatment; chr6:85749059 chr6:85660950~85678736:- LUSC cis rs10256972 0.567 rs2960835 ENSG00000229043.2 AC091729.9 -13.06 1.86e-33 1.21e-29 -0.62 -0.52 Endometriosis;Longevity; chr7:1163327 chr7:1160374~1165267:+ LUSC cis rs4423214 0.959 rs12793224 ENSG00000254682.1 RP11-660L16.2 13.05 1.91e-33 1.24e-29 0.68 0.52 Vitamin D levels; chr11:71457664 chr11:71448674~71452157:+ LUSC cis rs4423214 0.959 rs12794668 ENSG00000254682.1 RP11-660L16.2 13.05 1.91e-33 1.24e-29 0.68 0.52 Vitamin D levels; chr11:71457669 chr11:71448674~71452157:+ LUSC cis rs1577917 1 rs35760725 ENSG00000203875.9 SNHG5 -13.05 1.97e-33 1.27e-29 -0.7 -0.52 Response to antipsychotic treatment; chr6:85939267 chr6:85660950~85678736:- LUSC cis rs10129255 0.518 rs10150460 ENSG00000223648.3 IGHV3-64 -13.05 2e-33 1.29e-29 -0.41 -0.52 Kawasaki disease; chr14:106677179 chr14:106643132~106658258:- LUSC cis rs977987 0.735 rs11149831 ENSG00000261783.1 RP11-252K23.2 -13.04 2.07e-33 1.34e-29 -0.73 -0.52 Dupuytren's disease; chr16:75417563 chr16:75379818~75381260:- LUSC cis rs4423214 1 rs12785878 ENSG00000254682.1 RP11-660L16.2 13.04 2.26e-33 1.45e-29 0.67 0.52 Vitamin D levels; chr11:71456403 chr11:71448674~71452157:+ LUSC cis rs1577917 0.958 rs11755642 ENSG00000203875.9 SNHG5 -13.03 2.28e-33 1.47e-29 -0.7 -0.52 Response to antipsychotic treatment; chr6:85740348 chr6:85660950~85678736:- LUSC cis rs9326248 0.559 rs484646 ENSG00000254851.1 RP11-109L13.1 -13.03 2.3e-33 1.48e-29 -0.63 -0.52 Blood protein levels; chr11:116862140 chr11:117135528~117138582:+ LUSC cis rs507080 0.769 rs483283 ENSG00000255239.1 AP002954.6 13.03 2.33e-33 1.49e-29 0.6 0.52 Serum metabolite levels; chr11:118635684 chr11:118688039~118690600:- LUSC cis rs10129255 0.518 rs12590732 ENSG00000223648.3 IGHV3-64 -13.03 2.35e-33 1.51e-29 -0.41 -0.52 Kawasaki disease; chr14:106779612 chr14:106643132~106658258:- LUSC cis rs35955747 0.539 rs738685 ENSG00000236132.1 CTA-440B3.1 13.03 2.38e-33 1.53e-29 0.64 0.52 Neutrophil count;Sum basophil neutrophil counts; chr22:31636292 chr22:31816379~31817491:- LUSC cis rs858239 0.614 rs10229956 ENSG00000230658.1 KLHL7-AS1 -13.03 2.48e-33 1.59e-29 -0.63 -0.52 Cerebrospinal fluid biomarker levels; chr7:23363317 chr7:23101228~23105703:- LUSC cis rs507080 0.769 rs645637 ENSG00000255239.1 AP002954.6 13.02 2.59e-33 1.66e-29 0.6 0.51 Serum metabolite levels; chr11:118634373 chr11:118688039~118690600:- LUSC cis rs858239 1 rs156421 ENSG00000230658.1 KLHL7-AS1 13.02 2.61e-33 1.67e-29 0.64 0.51 Cerebrospinal fluid biomarker levels; chr7:23272868 chr7:23101228~23105703:- LUSC cis rs2283792 0.622 rs239917 ENSG00000228050.1 TOP3BP1 13.01 2.76e-33 1.76e-29 0.61 0.51 Multiple sclerosis; chr22:21960091 chr22:22223187~22224566:- LUSC cis rs9399135 0.636 rs4646871 ENSG00000232876.1 CTA-212D2.2 13.01 2.84e-33 1.81e-29 0.6 0.51 Red blood cell count; chr6:134944479 chr6:135055033~135060550:+ LUSC cis rs1577917 1 rs12205336 ENSG00000203875.9 SNHG5 -13.01 2.86e-33 1.83e-29 -0.71 -0.51 Response to antipsychotic treatment; chr6:86012649 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12209127 ENSG00000203875.9 SNHG5 -13.01 2.86e-33 1.83e-29 -0.71 -0.51 Response to antipsychotic treatment; chr6:86014709 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1337850 ENSG00000203875.9 SNHG5 -13.01 2.86e-33 1.83e-29 -0.71 -0.51 Response to antipsychotic treatment; chr6:86019385 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs1346266 ENSG00000259520.4 CTD-2651B20.3 -13.01 2.88e-33 1.84e-29 -0.68 -0.51 Homoarginine levels; chr15:45402318 chr15:45251580~45279251:- LUSC cis rs2487048 0.725 rs2422493 ENSG00000226334.1 RP11-217B7.2 -13.01 2.96e-33 1.89e-29 -0.61 -0.51 Intraocular pressure; chr9:104928714 chr9:104927553~104928892:+ LUSC cis rs4423214 1 rs4944957 ENSG00000254682.1 RP11-660L16.2 -13 3.3e-33 2.1e-29 -0.67 -0.51 Vitamin D levels; chr11:71456989 chr11:71448674~71452157:+ LUSC cis rs10256972 0.567 rs2960850 ENSG00000229043.2 AC091729.9 -12.99 3.45e-33 2.19e-29 -0.64 -0.51 Endometriosis;Longevity; chr7:1172013 chr7:1160374~1165267:+ LUSC cis rs1577917 1 rs12203493 ENSG00000203875.9 SNHG5 -12.99 3.57e-33 2.26e-29 -0.73 -0.51 Response to antipsychotic treatment; chr6:86048924 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12205548 ENSG00000203875.9 SNHG5 -12.99 3.57e-33 2.26e-29 -0.73 -0.51 Response to antipsychotic treatment; chr6:86050052 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12665321 ENSG00000203875.9 SNHG5 -12.99 3.57e-33 2.26e-29 -0.73 -0.51 Response to antipsychotic treatment; chr6:86059571 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12196175 ENSG00000203875.9 SNHG5 -12.99 3.57e-33 2.26e-29 -0.73 -0.51 Response to antipsychotic treatment; chr6:86069652 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs4395020 ENSG00000259520.4 CTD-2651B20.3 -12.99 3.57e-33 2.26e-29 -0.67 -0.51 Homoarginine levels; chr15:45360691 chr15:45251580~45279251:- LUSC cis rs1153858 0.832 rs1145078 ENSG00000259520.4 CTD-2651B20.3 -12.98 3.7e-33 2.34e-29 -0.68 -0.51 Homoarginine levels; chr15:45390079 chr15:45251580~45279251:- LUSC cis rs1577917 1 rs955197 ENSG00000203875.9 SNHG5 -12.98 4.03e-33 2.54e-29 -0.71 -0.51 Response to antipsychotic treatment; chr6:86019957 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1018184 ENSG00000203875.9 SNHG5 12.97 4.05e-33 2.56e-29 0.7 0.51 Response to antipsychotic treatment; chr6:85938757 chr6:85660950~85678736:- LUSC cis rs1153858 1 rs1618874 ENSG00000259520.4 CTD-2651B20.3 -12.97 4.17e-33 2.63e-29 -0.68 -0.51 Homoarginine levels; chr15:45330588 chr15:45251580~45279251:- LUSC cis rs1577917 1 rs6914463 ENSG00000203875.9 SNHG5 -12.97 4.2e-33 2.65e-29 -0.7 -0.51 Response to antipsychotic treatment; chr6:85943697 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs2816821 ENSG00000203875.9 SNHG5 -12.97 4.2e-33 2.65e-29 -0.7 -0.51 Response to antipsychotic treatment; chr6:85947366 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs13217384 ENSG00000203875.9 SNHG5 -12.97 4.29e-33 2.71e-29 -0.69 -0.51 Response to antipsychotic treatment; chr6:86010282 chr6:85660950~85678736:- LUSC cis rs2283792 0.566 rs1005579 ENSG00000228050.1 TOP3BP1 12.97 4.32e-33 2.72e-29 0.6 0.51 Multiple sclerosis; chr22:21946569 chr22:22223187~22224566:- LUSC cis rs858239 0.863 rs466225 ENSG00000230658.1 KLHL7-AS1 12.96 4.58e-33 2.88e-29 0.66 0.51 Cerebrospinal fluid biomarker levels; chr7:23292784 chr7:23101228~23105703:- LUSC cis rs1577917 0.958 rs12215232 ENSG00000203875.9 SNHG5 -12.96 4.85e-33 3.05e-29 -0.73 -0.51 Response to antipsychotic treatment; chr6:86075712 chr6:85660950~85678736:- LUSC cis rs10256972 0.552 rs6978842 ENSG00000229043.2 AC091729.9 -12.95 5.3e-33 3.32e-29 -0.59 -0.51 Endometriosis;Longevity; chr7:1164963 chr7:1160374~1165267:+ LUSC cis rs9326248 0.539 rs518181 ENSG00000254851.1 RP11-109L13.1 -12.94 5.41e-33 3.38e-29 -0.63 -0.51 Blood protein levels; chr11:116902071 chr11:117135528~117138582:+ LUSC cis rs1577917 0.958 rs2121594 ENSG00000203875.9 SNHG5 -12.94 5.52e-33 3.45e-29 -0.71 -0.51 Response to antipsychotic treatment; chr6:85867136 chr6:85660950~85678736:- LUSC cis rs3931020 0.53 rs12125889 ENSG00000272864.1 RP11-17E13.2 -12.94 5.84e-33 3.64e-29 -0.58 -0.51 Resistin levels; chr1:74776287 chr1:74698769~74699333:- LUSC cis rs11155671 0.53 rs7742993 ENSG00000231760.4 RP11-350J20.5 12.93 5.97e-33 3.72e-29 0.64 0.51 Testicular germ cell tumor; chr6:149883959 chr6:149796151~149826294:- LUSC cis rs10129255 0.5 rs988132 ENSG00000223648.3 IGHV3-64 12.93 6.48e-33 4.03e-29 0.42 0.51 Kawasaki disease; chr14:106776758 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs8021941 ENSG00000223648.3 IGHV3-64 12.92 6.55e-33 4.07e-29 0.41 0.51 Kawasaki disease; chr14:106781490 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs10142931 ENSG00000223648.3 IGHV3-64 12.92 6.55e-33 4.07e-29 0.41 0.51 Kawasaki disease; chr14:106782288 chr14:106643132~106658258:- LUSC cis rs1577917 1 rs1577919 ENSG00000203875.9 SNHG5 -12.92 6.56e-33 4.07e-29 -0.72 -0.51 Response to antipsychotic treatment; chr6:86047578 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12190604 ENSG00000203875.9 SNHG5 -12.92 6.73e-33 4.18e-29 -0.7 -0.51 Response to antipsychotic treatment; chr6:86006497 chr6:85660950~85678736:- LUSC cis rs4423214 1 rs4944946 ENSG00000254682.1 RP11-660L16.2 12.92 6.8e-33 4.22e-29 0.67 0.51 Vitamin D levels; chr11:71448383 chr11:71448674~71452157:+ LUSC cis rs1577917 1 rs10498958 ENSG00000203875.9 SNHG5 12.92 7.03e-33 4.36e-29 0.71 0.51 Response to antipsychotic treatment; chr6:85939987 chr6:85660950~85678736:- LUSC cis rs6597981 0.675 rs4963120 ENSG00000279672.1 CMB9-55F22.1 -12.91 7.68e-33 4.75e-29 -0.51 -0.51 Breast cancer; chr11:825777 chr11:779617~780755:+ LUSC cis rs1153858 1 rs7169818 ENSG00000259520.4 CTD-2651B20.3 -12.91 7.73e-33 4.79e-29 -0.66 -0.51 Homoarginine levels; chr15:45347993 chr15:45251580~45279251:- LUSC cis rs1577917 1 rs34581302 ENSG00000203875.9 SNHG5 -12.9 8.28e-33 5.12e-29 -0.7 -0.51 Response to antipsychotic treatment; chr6:85996230 chr6:85660950~85678736:- LUSC cis rs507080 0.769 rs2077173 ENSG00000255239.1 AP002954.6 12.9 8.3e-33 5.13e-29 0.59 0.51 Serum metabolite levels; chr11:118621876 chr11:118688039~118690600:- LUSC cis rs1153858 0.943 rs1145079 ENSG00000259520.4 CTD-2651B20.3 -12.89 8.84e-33 5.46e-29 -0.67 -0.51 Homoarginine levels; chr15:45389563 chr15:45251580~45279251:- LUSC cis rs858239 0.73 rs10255155 ENSG00000230658.1 KLHL7-AS1 -12.89 9.05e-33 5.58e-29 -0.65 -0.51 Cerebrospinal fluid biomarker levels; chr7:23362528 chr7:23101228~23105703:- LUSC cis rs1153858 1 rs1153849 ENSG00000259520.4 CTD-2651B20.3 -12.89 9.33e-33 5.75e-29 -0.67 -0.51 Homoarginine levels; chr15:45403497 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs1145081 ENSG00000259520.4 CTD-2651B20.3 -12.89 9.4e-33 5.79e-29 -0.67 -0.51 Homoarginine levels; chr15:45387469 chr15:45251580~45279251:- LUSC cis rs1577917 0.652 rs75593931 ENSG00000203875.9 SNHG5 -12.89 9.45e-33 5.82e-29 -0.7 -0.51 Response to antipsychotic treatment; chr6:86009821 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1415753 ENSG00000203875.9 SNHG5 -12.88 9.88e-33 6.08e-29 -0.72 -0.51 Response to antipsychotic treatment; chr6:86043356 chr6:85660950~85678736:- LUSC cis rs6700559 1 rs10800720 ENSG00000260088.1 RP11-92G12.3 -12.88 1.04e-32 6.38e-29 -0.63 -0.51 Coronary artery disease; chr1:200679441 chr1:200669507~200694250:+ LUSC cis rs6700559 0.935 rs4072553 ENSG00000260088.1 RP11-92G12.3 -12.88 1.04e-32 6.38e-29 -0.63 -0.51 Coronary artery disease; chr1:200680036 chr1:200669507~200694250:+ LUSC cis rs1577917 0.959 rs12201739 ENSG00000203875.9 SNHG5 -12.88 1.05e-32 6.46e-29 -0.7 -0.51 Response to antipsychotic treatment; chr6:86011021 chr6:85660950~85678736:- LUSC cis rs4423214 1 rs28364617 ENSG00000254682.1 RP11-660L16.2 12.87 1.06e-32 6.48e-29 0.66 0.51 Vitamin D levels; chr11:71448718 chr11:71448674~71452157:+ LUSC cis rs1577917 1 rs12664335 ENSG00000203875.9 SNHG5 12.87 1.06e-32 6.52e-29 0.71 0.51 Response to antipsychotic treatment; chr6:85888056 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs35283633 ENSG00000203875.9 SNHG5 -12.87 1.08e-32 6.65e-29 -0.71 -0.51 Response to antipsychotic treatment; chr6:85981069 chr6:85660950~85678736:- LUSC cis rs2283792 0.622 rs381523 ENSG00000228050.1 TOP3BP1 12.87 1.12e-32 6.84e-29 0.6 0.51 Multiple sclerosis; chr22:21951257 chr22:22223187~22224566:- LUSC cis rs11155671 0.53 rs7758033 ENSG00000231760.4 RP11-350J20.5 12.87 1.12e-32 6.87e-29 0.64 0.51 Testicular germ cell tumor; chr6:149886999 chr6:149796151~149826294:- LUSC cis rs507080 0.769 rs11603616 ENSG00000255239.1 AP002954.6 12.87 1.13e-32 6.95e-29 0.59 0.51 Serum metabolite levels; chr11:118625350 chr11:118688039~118690600:- LUSC cis rs1577917 0.916 rs12198730 ENSG00000203875.9 SNHG5 -12.86 1.17e-32 7.14e-29 -0.72 -0.51 Response to antipsychotic treatment; chr6:85845420 chr6:85660950~85678736:- LUSC cis rs1153858 0.945 rs2467854 ENSG00000259520.4 CTD-2651B20.3 -12.86 1.22e-32 7.44e-29 -0.67 -0.51 Homoarginine levels; chr15:45409399 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs2461701 ENSG00000259520.4 CTD-2651B20.3 -12.86 1.22e-32 7.44e-29 -0.67 -0.51 Homoarginine levels; chr15:45411193 chr15:45251580~45279251:- LUSC cis rs1153858 1 rs2467858 ENSG00000259520.4 CTD-2651B20.3 -12.86 1.22e-32 7.44e-29 -0.67 -0.51 Homoarginine levels; chr15:45419294 chr15:45251580~45279251:- LUSC cis rs3096299 0.509 rs4785691 ENSG00000274627.1 RP11-104N10.2 12.86 1.26e-32 7.72e-29 0.44 0.51 Multiple myeloma (IgH translocation); chr16:89530813 chr16:89516797~89522217:+ LUSC cis rs507080 0.769 rs570952 ENSG00000255239.1 AP002954.6 12.85 1.37e-32 8.34e-29 0.59 0.51 Serum metabolite levels; chr11:118629477 chr11:118688039~118690600:- LUSC cis rs3814244 0.788 rs3741649 ENSG00000255733.4 IFNG-AS1 -12.85 1.4e-32 8.5e-29 -0.43 -0.51 Itch intensity from mosquito bite adjusted by bite size; chr12:68028351 chr12:67989445~68234686:+ LUSC cis rs3814244 0.788 rs11177014 ENSG00000255733.4 IFNG-AS1 -12.85 1.4e-32 8.51e-29 -0.43 -0.51 Itch intensity from mosquito bite adjusted by bite size; chr12:68031871 chr12:67989445~68234686:+ LUSC cis rs1577917 1 rs68171315 ENSG00000203875.9 SNHG5 -12.84 1.43e-32 8.7e-29 -0.71 -0.51 Response to antipsychotic treatment; chr6:85997682 chr6:85660950~85678736:- LUSC cis rs7188445 0.787 rs7189954 ENSG00000261390.4 RP11-345M22.2 12.84 1.46e-32 8.84e-29 0.65 0.51 Urate levels; chr16:79701150 chr16:79715232~79770563:- LUSC cis rs1577917 1 rs12203924 ENSG00000203875.9 SNHG5 -12.84 1.46e-32 8.88e-29 -0.72 -0.51 Response to antipsychotic treatment; chr6:86066694 chr6:85660950~85678736:- LUSC cis rs7617773 0.817 rs6796490 ENSG00000229759.1 MRPS18AP1 12.83 1.57e-32 9.51e-29 0.5 0.51 Coronary artery disease; chr3:48195614 chr3:48256350~48256938:- LUSC cis rs10129255 0.5 rs988134 ENSG00000223648.3 IGHV3-64 12.83 1.65e-32 1e-28 0.41 0.51 Kawasaki disease; chr14:106776698 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs988133 ENSG00000223648.3 IGHV3-64 12.83 1.65e-32 1e-28 0.41 0.51 Kawasaki disease; chr14:106776724 chr14:106643132~106658258:- LUSC cis rs9322193 0.504 rs7771014 ENSG00000231760.4 RP11-350J20.5 12.82 1.8e-32 1.09e-28 0.64 0.51 Lung cancer; chr6:149884310 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs9397420 ENSG00000231760.4 RP11-350J20.5 -12.82 1.87e-32 1.13e-28 -0.64 -0.51 Testicular germ cell tumor; chr6:149885645 chr6:149796151~149826294:- LUSC cis rs1577917 0.958 rs10944147 ENSG00000203875.9 SNHG5 -12.81 1.94e-32 1.17e-28 -0.72 -0.51 Response to antipsychotic treatment; chr6:85841068 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs13201730 ENSG00000203875.9 SNHG5 -12.81 1.94e-32 1.17e-28 -0.72 -0.51 Response to antipsychotic treatment; chr6:85846929 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12196377 ENSG00000203875.9 SNHG5 -12.81 1.94e-32 1.17e-28 -0.72 -0.51 Response to antipsychotic treatment; chr6:85857057 chr6:85660950~85678736:- LUSC cis rs10129255 0.5 rs12101190 ENSG00000223648.3 IGHV3-64 12.81 1.96e-32 1.18e-28 0.42 0.51 Kawasaki disease; chr14:106784149 chr14:106643132~106658258:- LUSC cis rs10129255 0.518 rs8004895 ENSG00000223648.3 IGHV3-64 12.81 1.96e-32 1.18e-28 0.42 0.51 Kawasaki disease; chr14:106785139 chr14:106643132~106658258:- LUSC cis rs2739330 0.828 rs4820572 ENSG00000250470.1 AP000351.3 12.81 1.99e-32 1.2e-28 0.7 0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23976904~23977585:- LUSC cis rs507080 0.769 rs527290 ENSG00000255239.1 AP002954.6 12.81 2e-32 1.2e-28 0.6 0.51 Serum metabolite levels; chr11:118644898 chr11:118688039~118690600:- LUSC cis rs11155671 0.53 rs9383912 ENSG00000231760.4 RP11-350J20.5 12.81 2.02e-32 1.21e-28 0.64 0.51 Testicular germ cell tumor; chr6:149885479 chr6:149796151~149826294:- LUSC cis rs10129255 0.5 rs8014529 ENSG00000223648.3 IGHV3-64 12.8 2.13e-32 1.28e-28 0.42 0.51 Kawasaki disease; chr14:106784065 chr14:106643132~106658258:- LUSC cis rs4423214 1 rs11600569 ENSG00000254682.1 RP11-660L16.2 12.8 2.16e-32 1.3e-28 0.66 0.51 Vitamin D levels; chr11:71462701 chr11:71448674~71452157:+ LUSC cis rs11155671 0.53 rs7756850 ENSG00000231760.4 RP11-350J20.5 12.79 2.35e-32 1.41e-28 0.64 0.51 Testicular germ cell tumor; chr6:149891460 chr6:149796151~149826294:- LUSC cis rs507080 0.769 rs571001 ENSG00000255239.1 AP002954.6 12.79 2.48e-32 1.49e-28 0.59 0.51 Serum metabolite levels; chr11:118629457 chr11:118688039~118690600:- LUSC cis rs507080 0.883 rs656575 ENSG00000255422.1 AP002954.4 -12.78 2.5e-32 1.5e-28 -0.56 -0.51 Serum metabolite levels; chr11:118679199 chr11:118704607~118750263:+ LUSC cis rs3931020 0.548 rs17618340 ENSG00000272864.1 RP11-17E13.2 -12.78 2.55e-32 1.53e-28 -0.57 -0.51 Resistin levels; chr1:74781933 chr1:74698769~74699333:- LUSC cis rs10129255 0.5 rs2105989 ENSG00000223648.3 IGHV3-64 12.78 2.63e-32 1.57e-28 0.4 0.51 Kawasaki disease; chr14:106682199 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs8022547 ENSG00000223648.3 IGHV3-64 12.78 2.68e-32 1.6e-28 0.41 0.51 Kawasaki disease; chr14:106781985 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs8006888 ENSG00000223648.3 IGHV3-64 12.78 2.68e-32 1.6e-28 0.41 0.51 Kawasaki disease; chr14:106782219 chr14:106643132~106658258:- LUSC cis rs10129255 0.536 rs10142951 ENSG00000223648.3 IGHV3-64 12.77 2.77e-32 1.65e-28 0.41 0.51 Kawasaki disease; chr14:106782337 chr14:106643132~106658258:- LUSC cis rs507080 0.961 rs600969 ENSG00000255422.1 AP002954.4 -12.77 2.78e-32 1.66e-28 -0.56 -0.51 Serum metabolite levels; chr11:118675087 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs12577485 ENSG00000255422.1 AP002954.4 -12.77 2.78e-32 1.66e-28 -0.56 -0.51 Serum metabolite levels; chr11:118676793 chr11:118704607~118750263:+ LUSC cis rs2739330 0.828 rs2186366 ENSG00000250470.1 AP000351.3 -12.77 2.8e-32 1.67e-28 -0.69 -0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23976904~23977585:- LUSC cis rs4423214 1 rs7928249 ENSG00000254682.1 RP11-660L16.2 12.77 2.91e-32 1.73e-28 0.67 0.51 Vitamin D levels; chr11:71450017 chr11:71448674~71452157:+ LUSC cis rs10129255 0.518 rs8009594 ENSG00000223648.3 IGHV3-64 12.77 2.92e-32 1.74e-28 0.41 0.51 Kawasaki disease; chr14:106777494 chr14:106643132~106658258:- LUSC cis rs10129255 0.518 rs8009612 ENSG00000223648.3 IGHV3-64 12.77 2.92e-32 1.74e-28 0.41 0.51 Kawasaki disease; chr14:106777510 chr14:106643132~106658258:- LUSC cis rs507080 0.961 rs673770 ENSG00000255422.1 AP002954.4 -12.77 2.95e-32 1.76e-28 -0.56 -0.51 Serum metabolite levels; chr11:118679892 chr11:118704607~118750263:+ LUSC cis rs10129255 0.5 rs10131875 ENSG00000223648.3 IGHV3-64 12.77 3e-32 1.78e-28 0.41 0.51 Kawasaki disease; chr14:106792798 chr14:106643132~106658258:- LUSC cis rs6700559 1 rs12076877 ENSG00000260088.1 RP11-92G12.3 -12.76 3.03e-32 1.81e-28 -0.63 -0.51 Coronary artery disease; chr1:200674277 chr1:200669507~200694250:+ LUSC cis rs12439619 0.693 rs9944185 ENSG00000278603.1 RP13-608F4.5 12.76 3.15e-32 1.88e-28 0.67 0.51 Intelligence (multi-trait analysis); chr15:82157927 chr15:82472203~82472426:+ LUSC cis rs1577917 1 rs10944169 ENSG00000203875.9 SNHG5 -12.76 3.19e-32 1.9e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85973318 chr6:85660950~85678736:- LUSC cis rs10129255 0.518 rs2006284 ENSG00000223648.3 IGHV3-64 12.76 3.22e-32 1.91e-28 0.41 0.51 Kawasaki disease; chr14:106676185 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs59939897 ENSG00000223648.3 IGHV3-64 12.76 3.24e-32 1.92e-28 0.41 0.51 Kawasaki disease; chr14:106783414 chr14:106643132~106658258:- LUSC cis rs3931020 0.548 rs969435 ENSG00000272864.1 RP11-17E13.2 12.75 3.35e-32 1.99e-28 0.61 0.51 Resistin levels; chr1:74808182 chr1:74698769~74699333:- LUSC cis rs10129255 0.518 rs11847766 ENSG00000223648.3 IGHV3-64 12.75 3.42e-32 2.03e-28 0.41 0.51 Kawasaki disease; chr14:106779186 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs6576230 ENSG00000223648.3 IGHV3-64 12.75 3.48e-32 2.06e-28 0.41 0.51 Kawasaki disease; chr14:106778539 chr14:106643132~106658258:- LUSC cis rs1577917 0.958 rs2875456 ENSG00000203875.9 SNHG5 -12.74 3.66e-32 2.17e-28 -0.71 -0.51 Response to antipsychotic treatment; chr6:85892566 chr6:85660950~85678736:- LUSC cis rs11155671 0.53 rs9383577 ENSG00000231760.4 RP11-350J20.5 12.74 3.69e-32 2.18e-28 0.63 0.51 Testicular germ cell tumor; chr6:149886059 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs9383914 ENSG00000231760.4 RP11-350J20.5 12.74 3.69e-32 2.18e-28 0.63 0.51 Testicular germ cell tumor; chr6:149886098 chr6:149796151~149826294:- LUSC cis rs11155671 0.517 rs9397058 ENSG00000231760.4 RP11-350J20.5 12.74 3.69e-32 2.18e-28 0.63 0.51 Testicular germ cell tumor; chr6:149886113 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs7768626 ENSG00000231760.4 RP11-350J20.5 12.74 3.69e-32 2.18e-28 0.63 0.51 Testicular germ cell tumor; chr6:149886826 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs7768665 ENSG00000231760.4 RP11-350J20.5 12.74 3.69e-32 2.18e-28 0.63 0.51 Testicular germ cell tumor; chr6:149886888 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs7758020 ENSG00000231760.4 RP11-350J20.5 12.74 3.69e-32 2.18e-28 0.63 0.51 Testicular germ cell tumor; chr6:149886975 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs4870080 ENSG00000231760.4 RP11-350J20.5 12.74 3.92e-32 2.31e-28 0.63 0.51 Testicular germ cell tumor; chr6:149881508 chr6:149796151~149826294:- LUSC cis rs507080 0.961 rs1784298 ENSG00000255422.1 AP002954.4 -12.74 3.96e-32 2.34e-28 -0.55 -0.51 Serum metabolite levels; chr11:118677956 chr11:118704607~118750263:+ LUSC cis rs507080 0.961 rs4938522 ENSG00000255422.1 AP002954.4 -12.74 3.96e-32 2.34e-28 -0.55 -0.51 Serum metabolite levels; chr11:118677962 chr11:118704607~118750263:+ LUSC cis rs507080 1 rs659969 ENSG00000255422.1 AP002954.4 -12.74 3.96e-32 2.34e-28 -0.55 -0.51 Serum metabolite levels; chr11:118679094 chr11:118704607~118750263:+ LUSC cis rs9601248 0.529 rs2783125 ENSG00000227676.3 LINC01068 12.73 4.19e-32 2.46e-28 0.63 0.51 Major depressive disorder; chr13:79583755 chr13:79566727~79571436:+ LUSC cis rs11155671 0.53 rs4869763 ENSG00000231760.4 RP11-350J20.5 12.73 4.2e-32 2.47e-28 0.64 0.51 Testicular germ cell tumor; chr6:149890548 chr6:149796151~149826294:- LUSC cis rs9326248 0.53 rs10750101 ENSG00000254851.1 RP11-109L13.1 -12.73 4.28e-32 2.52e-28 -0.94 -0.51 Blood protein levels; chr11:117108973 chr11:117135528~117138582:+ LUSC cis rs1577917 0.958 rs12665542 ENSG00000203875.9 SNHG5 -12.73 4.36e-32 2.56e-28 -0.72 -0.51 Response to antipsychotic treatment; chr6:85834725 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs34281561 ENSG00000203875.9 SNHG5 -12.73 4.39e-32 2.58e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85992154 chr6:85660950~85678736:- LUSC cis rs858239 0.665 rs858305 ENSG00000230658.1 KLHL7-AS1 -12.72 4.58e-32 2.69e-28 -0.63 -0.51 Cerebrospinal fluid biomarker levels; chr7:23203211 chr7:23101228~23105703:- LUSC cis rs507080 0.961 rs4938523 ENSG00000255422.1 AP002954.4 -12.72 4.62e-32 2.71e-28 -0.55 -0.51 Serum metabolite levels; chr11:118678129 chr11:118704607~118750263:+ LUSC cis rs858239 0.799 rs10279941 ENSG00000230658.1 KLHL7-AS1 12.71 4.93e-32 2.89e-28 0.65 0.51 Cerebrospinal fluid biomarker levels; chr7:23330889 chr7:23101228~23105703:- LUSC cis rs6782228 0.675 rs6806687 ENSG00000242551.2 POU5F1P6 12.71 4.95e-32 2.9e-28 0.56 0.51 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128672946 chr3:128674735~128677005:- LUSC cis rs4423214 1 rs12808368 ENSG00000254682.1 RP11-660L16.2 12.71 5.07e-32 2.96e-28 0.66 0.51 Vitamin D levels; chr11:71459771 chr11:71448674~71452157:+ LUSC cis rs9545047 0.901 rs1212082 ENSG00000227676.3 LINC01068 12.71 5.13e-32 3e-28 0.61 0.51 Schizophrenia; chr13:79552633 chr13:79566727~79571436:+ LUSC cis rs10129255 0.518 rs10136903 ENSG00000223648.3 IGHV3-64 12.71 5.24e-32 3.06e-28 0.41 0.51 Kawasaki disease; chr14:106778866 chr14:106643132~106658258:- LUSC cis rs1577917 0.876 rs1582126 ENSG00000203875.9 SNHG5 -12.71 5.25e-32 3.07e-28 -0.71 -0.51 Response to antipsychotic treatment; chr6:85987487 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs1591438 ENSG00000203875.9 SNHG5 -12.7 5.42e-32 3.16e-28 -0.71 -0.51 Response to antipsychotic treatment; chr6:85815496 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs1591437 ENSG00000203875.9 SNHG5 -12.7 5.42e-32 3.16e-28 -0.71 -0.51 Response to antipsychotic treatment; chr6:85815587 chr6:85660950~85678736:- LUSC cis rs10129255 0.5 rs6576225 ENSG00000223648.3 IGHV3-64 12.7 5.44e-32 3.17e-28 0.41 0.51 Kawasaki disease; chr14:106778120 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs6576226 ENSG00000223648.3 IGHV3-64 12.7 5.44e-32 3.17e-28 0.41 0.51 Kawasaki disease; chr14:106778135 chr14:106643132~106658258:- LUSC cis rs2906856 0.524 rs56236103 ENSG00000255733.4 IFNG-AS1 12.7 5.47e-32 3.19e-28 0.51 0.51 Mosquito bite size; chr12:67937437 chr12:67989445~68234686:+ LUSC cis rs10129255 0.556 rs8010005 ENSG00000223648.3 IGHV3-64 12.7 5.49e-32 3.2e-28 0.41 0.51 Kawasaki disease; chr14:106777987 chr14:106643132~106658258:- LUSC cis rs10129255 0.556 rs6576224 ENSG00000223648.3 IGHV3-64 12.7 5.49e-32 3.2e-28 0.41 0.51 Kawasaki disease; chr14:106777997 chr14:106643132~106658258:- LUSC cis rs10129255 0.518 rs8010020 ENSG00000223648.3 IGHV3-64 12.7 5.49e-32 3.2e-28 0.41 0.51 Kawasaki disease; chr14:106778016 chr14:106643132~106658258:- LUSC cis rs1577917 1 rs12207610 ENSG00000203875.9 SNHG5 -12.7 5.52e-32 3.22e-28 -0.69 -0.51 Response to antipsychotic treatment; chr6:85978298 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12203457 ENSG00000203875.9 SNHG5 -12.7 5.52e-32 3.22e-28 -0.69 -0.51 Response to antipsychotic treatment; chr6:85979559 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12201571 ENSG00000203875.9 SNHG5 -12.7 5.65e-32 3.29e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85900032 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs11759855 ENSG00000203875.9 SNHG5 -12.7 5.65e-32 3.29e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85901123 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1857964 ENSG00000203875.9 SNHG5 -12.7 5.65e-32 3.29e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85926276 chr6:85660950~85678736:- LUSC cis rs1577917 0.798 rs7772384 ENSG00000203875.9 SNHG5 -12.7 5.65e-32 3.29e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85929962 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs13194429 ENSG00000203875.9 SNHG5 -12.7 5.65e-32 3.29e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85936987 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12216203 ENSG00000203875.9 SNHG5 -12.69 5.9e-32 3.42e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85965583 chr6:85660950~85678736:- LUSC cis rs10129255 0.5 rs11628999 ENSG00000223648.3 IGHV3-64 12.69 5.91e-32 3.43e-28 0.41 0.51 Kawasaki disease; chr14:106800208 chr14:106643132~106658258:- LUSC cis rs2882667 0.898 rs6863347 ENSG00000253404.1 AC034243.1 12.69 5.97e-32 3.46e-28 0.63 0.51 Age-related hearing impairment (SNP x SNP interaction); chr5:139025446 chr5:138744434~138753309:- LUSC cis rs858239 0.932 rs858275 ENSG00000230658.1 KLHL7-AS1 12.69 6.09e-32 3.53e-28 0.61 0.51 Cerebrospinal fluid biomarker levels; chr7:23254525 chr7:23101228~23105703:- LUSC cis rs6538678 0.857 rs4762626 ENSG00000258343.1 RP11-536G4.2 -12.69 6.34e-32 3.67e-28 -0.78 -0.51 Lupus nephritis in systemic lupus erythematosus; chr12:95811383 chr12:95795345~95858839:- LUSC cis rs1577917 1 rs35419329 ENSG00000203875.9 SNHG5 -12.69 6.44e-32 3.72e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85992573 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12216328 ENSG00000203875.9 SNHG5 -12.69 6.44e-32 3.72e-28 -0.7 -0.51 Response to antipsychotic treatment; chr6:85993700 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs10944168 ENSG00000203875.9 SNHG5 -12.68 6.61e-32 3.82e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:85970438 chr6:85660950~85678736:- LUSC cis rs10129255 0.5 rs8004923 ENSG00000223648.3 IGHV3-64 12.68 6.67e-32 3.85e-28 0.41 0.5 Kawasaki disease; chr14:106785926 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs6576232 ENSG00000223648.3 IGHV3-64 12.68 6.67e-32 3.85e-28 0.41 0.5 Kawasaki disease; chr14:106787090 chr14:106643132~106658258:- LUSC cis rs507080 0.961 rs543327 ENSG00000255422.1 AP002954.4 -12.68 6.81e-32 3.92e-28 -0.56 -0.5 Serum metabolite levels; chr11:118679276 chr11:118704607~118750263:+ LUSC cis rs1577917 1 rs13196930 ENSG00000203875.9 SNHG5 -12.68 6.92e-32 3.98e-28 -0.7 -0.5 Response to antipsychotic treatment; chr6:85942527 chr6:85660950~85678736:- LUSC cis rs507080 1 rs507080 ENSG00000255422.1 AP002954.4 -12.68 7.05e-32 4.05e-28 -0.55 -0.5 Serum metabolite levels; chr11:118678873 chr11:118704607~118750263:+ LUSC cis rs7188445 0.592 rs7199794 ENSG00000261390.4 RP11-345M22.2 12.67 7.3e-32 4.19e-28 0.62 0.5 Urate levels; chr16:79708296 chr16:79715232~79770563:- LUSC cis rs1577917 0.958 rs11756510 ENSG00000203875.9 SNHG5 -12.67 7.45e-32 4.28e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:85990076 chr6:85660950~85678736:- LUSC cis rs73086581 0.687 rs16989002 ENSG00000229539.1 RP11-119B16.2 12.67 7.55e-32 4.33e-28 0.7 0.5 Response to antidepressants in depression; chr20:3870056 chr20:3888239~3888868:- LUSC cis rs6452524 0.618 rs2306336 ENSG00000249664.1 CTD-2227C6.2 12.67 7.73e-32 4.42e-28 0.51 0.5 Hypertension (SNP x SNP interaction); chr5:83064964 chr5:83012285~83013109:- LUSC cis rs6452524 0.589 rs6882386 ENSG00000249664.1 CTD-2227C6.2 12.67 7.73e-32 4.42e-28 0.51 0.5 Hypertension (SNP x SNP interaction); chr5:83065555 chr5:83012285~83013109:- LUSC cis rs6452524 0.618 rs6860752 ENSG00000249664.1 CTD-2227C6.2 12.67 7.73e-32 4.42e-28 0.51 0.5 Hypertension (SNP x SNP interaction); chr5:83065587 chr5:83012285~83013109:- LUSC cis rs11155671 0.53 rs9968871 ENSG00000231760.4 RP11-350J20.5 12.67 7.79e-32 4.46e-28 0.64 0.5 Testicular germ cell tumor; chr6:149888060 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs9969044 ENSG00000231760.4 RP11-350J20.5 12.67 7.79e-32 4.46e-28 0.64 0.5 Testicular germ cell tumor; chr6:149888068 chr6:149796151~149826294:- LUSC cis rs6452524 0.618 rs10051445 ENSG00000249664.1 CTD-2227C6.2 12.66 7.86e-32 4.5e-28 0.51 0.5 Hypertension (SNP x SNP interaction); chr5:83060280 chr5:83012285~83013109:- LUSC cis rs6452524 0.618 rs6867727 ENSG00000249664.1 CTD-2227C6.2 12.66 7.86e-32 4.5e-28 0.51 0.5 Hypertension (SNP x SNP interaction); chr5:83061333 chr5:83012285~83013109:- LUSC cis rs6452524 0.618 rs7723639 ENSG00000249664.1 CTD-2227C6.2 12.66 7.86e-32 4.5e-28 0.51 0.5 Hypertension (SNP x SNP interaction); chr5:83062610 chr5:83012285~83013109:- LUSC cis rs1577917 0.958 rs13219504 ENSG00000203875.9 SNHG5 -12.66 7.94e-32 4.54e-28 -0.72 -0.5 Response to antipsychotic treatment; chr6:85847199 chr6:85660950~85678736:- LUSC cis rs6452524 0.618 rs1871203 ENSG00000249664.1 CTD-2227C6.2 12.66 8.08e-32 4.61e-28 0.51 0.5 Hypertension (SNP x SNP interaction); chr5:83059567 chr5:83012285~83013109:- LUSC cis rs507080 0.769 rs745663 ENSG00000255239.1 AP002954.6 12.66 8.41e-32 4.8e-28 0.58 0.5 Serum metabolite levels; chr11:118658886 chr11:118688039~118690600:- LUSC cis rs1577917 1 rs12208493 ENSG00000203875.9 SNHG5 -12.66 8.56e-32 4.86e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:85952549 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12213149 ENSG00000203875.9 SNHG5 -12.66 8.56e-32 4.86e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:85958926 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs10455455 ENSG00000203875.9 SNHG5 -12.66 8.56e-32 4.86e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:85960496 chr6:85660950~85678736:- LUSC cis rs1153858 0.887 rs28569043 ENSG00000259520.4 CTD-2651B20.3 -12.65 8.73e-32 4.96e-28 -0.67 -0.5 Homoarginine levels; chr15:45438728 chr15:45251580~45279251:- LUSC cis rs6452524 0.618 rs3899556 ENSG00000249664.1 CTD-2227C6.2 12.65 9.06e-32 5.14e-28 0.5 0.5 Hypertension (SNP x SNP interaction); chr5:83067862 chr5:83012285~83013109:- LUSC cis rs858239 1 rs156425 ENSG00000230658.1 KLHL7-AS1 -12.65 9.2e-32 5.21e-28 -0.62 -0.5 Cerebrospinal fluid biomarker levels; chr7:23269500 chr7:23101228~23105703:- LUSC cis rs7188445 0.736 rs11642757 ENSG00000261390.4 RP11-345M22.2 -12.65 9.4e-32 5.32e-28 -0.65 -0.5 Urate levels; chr16:79719570 chr16:79715232~79770563:- LUSC cis rs1799949 1 rs8070085 ENSG00000198496.9 NBR2 12.64 9.56e-32 5.41e-28 0.55 0.5 Menopause (age at onset); chr17:43189967 chr17:43125610~43153671:+ LUSC cis rs1577917 0.958 rs12213331 ENSG00000203875.9 SNHG5 -12.64 9.59e-32 5.42e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:85795079 chr6:85660950~85678736:- LUSC cis rs2658782 0.724 rs2605626 ENSG00000279684.1 RP11-755E23.2 -12.64 9.69e-32 5.47e-28 -0.74 -0.5 Pulmonary function decline; chr11:93520737 chr11:93286629~93288903:- LUSC cis rs1577917 1 rs12192992 ENSG00000203875.9 SNHG5 -12.64 9.71e-32 5.48e-28 -0.7 -0.5 Response to antipsychotic treatment; chr6:85900197 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs2324843 ENSG00000203875.9 SNHG5 -12.64 9.71e-32 5.48e-28 -0.7 -0.5 Response to antipsychotic treatment; chr6:85907783 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs35738006 ENSG00000203875.9 SNHG5 -12.64 9.71e-32 5.48e-28 -0.7 -0.5 Response to antipsychotic treatment; chr6:85936591 chr6:85660950~85678736:- LUSC cis rs11155671 0.53 rs9371542 ENSG00000231760.4 RP11-350J20.5 12.64 9.81e-32 5.53e-28 0.63 0.5 Testicular germ cell tumor; chr6:149891949 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs9371223 ENSG00000231760.4 RP11-350J20.5 12.64 9.81e-32 5.53e-28 0.63 0.5 Testicular germ cell tumor; chr6:149893670 chr6:149796151~149826294:- LUSC cis rs9399135 0.684 rs1135205 ENSG00000232876.1 CTA-212D2.2 -12.64 9.92e-32 5.58e-28 -0.6 -0.5 Red blood cell count; chr6:134960657 chr6:135055033~135060550:+ LUSC cis rs1577917 0.958 rs11756615 ENSG00000203875.9 SNHG5 -12.64 1e-31 5.65e-28 -0.7 -0.5 Response to antipsychotic treatment; chr6:85970117 chr6:85660950~85678736:- LUSC cis rs12439619 0.693 rs17269819 ENSG00000278603.1 RP13-608F4.5 12.64 1.03e-31 5.79e-28 0.68 0.5 Intelligence (multi-trait analysis); chr15:82174660 chr15:82472203~82472426:+ LUSC cis rs10129255 0.5 rs34326748 ENSG00000223648.3 IGHV3-64 12.64 1.04e-31 5.83e-28 0.41 0.5 Kawasaki disease; chr14:106782523 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs10143385 ENSG00000223648.3 IGHV3-64 12.64 1.04e-31 5.83e-28 0.41 0.5 Kawasaki disease; chr14:106782559 chr14:106643132~106658258:- LUSC cis rs507080 0.961 rs642530 ENSG00000255422.1 AP002954.4 -12.63 1.06e-31 5.96e-28 -0.55 -0.5 Serum metabolite levels; chr11:118680047 chr11:118704607~118750263:+ LUSC cis rs10129255 0.518 rs28378320 ENSG00000223648.3 IGHV3-64 12.63 1.07e-31 6e-28 0.41 0.5 Kawasaki disease; chr14:106808609 chr14:106643132~106658258:- LUSC cis rs507080 0.883 rs558593 ENSG00000255422.1 AP002954.4 -12.63 1.07e-31 6e-28 -0.56 -0.5 Serum metabolite levels; chr11:118691811 chr11:118704607~118750263:+ LUSC cis rs1577917 1 rs12663690 ENSG00000203875.9 SNHG5 12.63 1.09e-31 6.14e-28 0.69 0.5 Response to antipsychotic treatment; chr6:85930444 chr6:85660950~85678736:- LUSC cis rs11155671 0.53 rs2342769 ENSG00000231760.4 RP11-350J20.5 12.63 1.09e-31 6.14e-28 0.63 0.5 Testicular germ cell tumor; chr6:149895371 chr6:149796151~149826294:- LUSC cis rs977987 0.735 rs166013 ENSG00000261783.1 RP11-252K23.2 12.63 1.11e-31 6.2e-28 0.71 0.5 Dupuytren's disease; chr16:75400248 chr16:75379818~75381260:- LUSC cis rs73086581 0.687 rs73082600 ENSG00000229539.1 RP11-119B16.2 12.63 1.12e-31 6.28e-28 0.68 0.5 Response to antidepressants in depression; chr20:3863718 chr20:3888239~3888868:- LUSC cis rs1577917 1 rs12201741 ENSG00000203875.9 SNHG5 -12.63 1.13e-31 6.32e-28 -0.69 -0.5 Response to antipsychotic treatment; chr6:85892901 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12196411 ENSG00000203875.9 SNHG5 -12.62 1.15e-31 6.4e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:86070044 chr6:85660950~85678736:- LUSC cis rs507080 0.961 rs543413 ENSG00000255422.1 AP002954.4 -12.62 1.15e-31 6.42e-28 -0.55 -0.5 Serum metabolite levels; chr11:118679308 chr11:118704607~118750263:+ LUSC cis rs1577917 0.874 rs11756621 ENSG00000203875.9 SNHG5 -12.62 1.16e-31 6.49e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:86030345 chr6:85660950~85678736:- LUSC cis rs1577917 0.876 rs1582127 ENSG00000203875.9 SNHG5 -12.62 1.17e-31 6.53e-28 -0.69 -0.5 Response to antipsychotic treatment; chr6:85987486 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs36053156 ENSG00000203875.9 SNHG5 -12.62 1.19e-31 6.62e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:85865791 chr6:85660950~85678736:- LUSC cis rs4423214 1 rs12797951 ENSG00000254682.1 RP11-660L16.2 -12.62 1.19e-31 6.62e-28 -0.64 -0.5 Vitamin D levels; chr11:71432220 chr11:71448674~71452157:+ LUSC cis rs7535099 0.909 rs3790432 ENSG00000224570.1 RP11-430H12.2 -12.62 1.21e-31 6.75e-28 -0.7 -0.5 Blood protein levels; chr1:65570056 chr1:65576129~65578380:- LUSC cis rs10129255 0.5 rs6576231 ENSG00000223648.3 IGHV3-64 12.62 1.23e-31 6.84e-28 0.41 0.5 Kawasaki disease; chr14:106783693 chr14:106643132~106658258:- LUSC cis rs9322193 0.567 rs7742692 ENSG00000231760.4 RP11-350J20.5 12.62 1.23e-31 6.85e-28 0.63 0.5 Lung cancer; chr6:149892363 chr6:149796151~149826294:- LUSC cis rs10129255 0.5 rs7161740 ENSG00000223648.3 IGHV3-64 12.62 1.23e-31 6.86e-28 0.41 0.5 Kawasaki disease; chr14:106776119 chr14:106643132~106658258:- LUSC cis rs10129255 0.556 rs6576222 ENSG00000223648.3 IGHV3-64 12.62 1.23e-31 6.86e-28 0.41 0.5 Kawasaki disease; chr14:106776442 chr14:106643132~106658258:- LUSC cis rs10129255 0.536 rs6576223 ENSG00000223648.3 IGHV3-64 12.62 1.23e-31 6.86e-28 0.41 0.5 Kawasaki disease; chr14:106776448 chr14:106643132~106658258:- LUSC cis rs1577917 1 rs36096931 ENSG00000203875.9 SNHG5 -12.62 1.23e-31 6.87e-28 -0.69 -0.5 Response to antipsychotic treatment; chr6:85983416 chr6:85660950~85678736:- LUSC cis rs10129255 0.5 rs2027903 ENSG00000223648.3 IGHV3-64 12.62 1.24e-31 6.9e-28 0.41 0.5 Kawasaki disease; chr14:106807047 chr14:106643132~106658258:- LUSC cis rs1153858 0.945 rs16943246 ENSG00000259520.4 CTD-2651B20.3 -12.62 1.24e-31 6.91e-28 -0.68 -0.5 Homoarginine levels; chr15:45428399 chr15:45251580~45279251:- LUSC cis rs9322193 0.567 rs7747457 ENSG00000231760.4 RP11-350J20.5 12.61 1.28e-31 7.1e-28 0.63 0.5 Lung cancer; chr6:149892366 chr6:149796151~149826294:- LUSC cis rs507080 0.961 rs656505 ENSG00000255422.1 AP002954.4 -12.61 1.29e-31 7.16e-28 -0.55 -0.5 Serum metabolite levels; chr11:118679245 chr11:118704607~118750263:+ LUSC cis rs507080 0.961 rs660489 ENSG00000255422.1 AP002954.4 -12.61 1.29e-31 7.16e-28 -0.55 -0.5 Serum metabolite levels; chr11:118679255 chr11:118704607~118750263:+ LUSC cis rs9326248 0.569 rs10892082 ENSG00000254851.1 RP11-109L13.1 -12.61 1.33e-31 7.37e-28 -0.87 -0.5 Blood protein levels; chr11:117168609 chr11:117135528~117138582:+ LUSC cis rs7301826 1 rs4759523 ENSG00000256250.1 RP11-989F5.1 -12.61 1.36e-31 7.57e-28 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130830867 chr12:130810606~130812438:+ LUSC cis rs11155671 0.53 rs9322228 ENSG00000231760.4 RP11-350J20.5 12.6 1.41e-31 7.82e-28 0.63 0.5 Testicular germ cell tumor; chr6:149888173 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs2342767 ENSG00000231760.4 RP11-350J20.5 12.6 1.41e-31 7.82e-28 0.63 0.5 Testicular germ cell tumor; chr6:149888581 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs7764376 ENSG00000231760.4 RP11-350J20.5 12.6 1.41e-31 7.82e-28 0.63 0.5 Testicular germ cell tumor; chr6:149889208 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs6933882 ENSG00000231760.4 RP11-350J20.5 12.6 1.41e-31 7.82e-28 0.63 0.5 Testicular germ cell tumor; chr6:149889666 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs6939761 ENSG00000231760.4 RP11-350J20.5 12.6 1.41e-31 7.82e-28 0.63 0.5 Testicular germ cell tumor; chr6:149889858 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs3823021 ENSG00000231760.4 RP11-350J20.5 12.6 1.41e-31 7.82e-28 0.63 0.5 Testicular germ cell tumor; chr6:149889863 chr6:149796151~149826294:- LUSC cis rs11155671 0.53 rs4869764 ENSG00000231760.4 RP11-350J20.5 12.6 1.41e-31 7.82e-28 0.63 0.5 Testicular germ cell tumor; chr6:149890692 chr6:149796151~149826294:- LUSC cis rs1577917 0.876 rs66986937 ENSG00000203875.9 SNHG5 -12.6 1.42e-31 7.84e-28 -0.71 -0.5 Response to antipsychotic treatment; chr6:85822473 chr6:85660950~85678736:- LUSC cis rs7301826 1 rs4759524 ENSG00000256250.1 RP11-989F5.1 -12.6 1.43e-31 7.92e-28 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130831065 chr12:130810606~130812438:+ LUSC cis rs6597981 0.592 rs10902218 ENSG00000279672.1 CMB9-55F22.1 -12.6 1.45e-31 7.99e-28 -0.49 -0.5 Breast cancer; chr11:743813 chr11:779617~780755:+ LUSC cis rs7617773 0.746 rs11713476 ENSG00000229759.1 MRPS18AP1 12.6 1.47e-31 8.1e-28 0.52 0.5 Coronary artery disease; chr3:48333944 chr3:48256350~48256938:- LUSC cis rs9545047 0.837 rs9601242 ENSG00000227676.3 LINC01068 12.6 1.5e-31 8.28e-28 0.61 0.5 Schizophrenia; chr13:79561543 chr13:79566727~79571436:+ LUSC cis rs9326248 0.559 rs573549 ENSG00000254851.1 RP11-109L13.1 -12.59 1.52e-31 8.38e-28 -0.61 -0.5 Blood protein levels; chr11:116865963 chr11:117135528~117138582:+ LUSC cis rs507080 0.845 rs667982 ENSG00000255422.1 AP002954.4 -12.59 1.54e-31 8.45e-28 -0.56 -0.5 Serum metabolite levels; chr11:118692058 chr11:118704607~118750263:+ LUSC cis rs1577917 1 rs12200330 ENSG00000203875.9 SNHG5 -12.58 1.68e-31 9.21e-28 -0.7 -0.5 Response to antipsychotic treatment; chr6:85946935 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs884842 ENSG00000203875.9 SNHG5 -12.58 1.74e-31 9.54e-28 -0.69 -0.5 Response to antipsychotic treatment; chr6:85970679 chr6:85660950~85678736:- LUSC cis rs507080 0.922 rs592280 ENSG00000255422.1 AP002954.4 -12.58 1.76e-31 9.65e-28 -0.55 -0.5 Serum metabolite levels; chr11:118682509 chr11:118704607~118750263:+ LUSC cis rs858239 1 rs199348 ENSG00000230658.1 KLHL7-AS1 12.57 1.85e-31 1.01e-27 0.61 0.5 Cerebrospinal fluid biomarker levels; chr7:23253479 chr7:23101228~23105703:- LUSC cis rs2739330 0.828 rs4822454 ENSG00000250470.1 AP000351.3 12.57 1.86e-31 1.02e-27 0.69 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23976904~23977585:- LUSC cis rs7617773 0.746 rs4130995 ENSG00000229759.1 MRPS18AP1 12.57 1.86e-31 1.02e-27 0.51 0.5 Coronary artery disease; chr3:48316765 chr3:48256350~48256938:- LUSC cis rs1577917 1 rs10944170 ENSG00000203875.9 SNHG5 -12.57 1.97e-31 1.08e-27 -0.69 -0.5 Response to antipsychotic treatment; chr6:85975751 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12208227 ENSG00000203875.9 SNHG5 -12.56 2.17e-31 1.18e-27 -0.69 -0.5 Response to antipsychotic treatment; chr6:85961226 chr6:85660950~85678736:- LUSC cis rs2739330 0.828 rs5760107 ENSG00000250470.1 AP000351.3 12.56 2.19e-31 1.19e-27 0.69 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23976904~23977585:- LUSC cis rs7301826 0.651 rs7132657 ENSG00000256299.1 RP11-989F5.3 -12.55 2.24e-31 1.22e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130800642 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs7971046 ENSG00000256299.1 RP11-989F5.3 -12.55 2.24e-31 1.22e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130802262 chr12:130810821~130812622:- LUSC cis rs507080 0.922 rs7114458 ENSG00000255422.1 AP002954.4 -12.55 2.24e-31 1.22e-27 -0.57 -0.5 Serum metabolite levels; chr11:118695466 chr11:118704607~118750263:+ LUSC cis rs2283792 0.745 rs5756306 ENSG00000228050.1 TOP3BP1 -12.55 2.32e-31 1.26e-27 -0.58 -0.5 Multiple sclerosis; chr22:21978846 chr22:22223187~22224566:- LUSC cis rs2739330 0.789 rs5760109 ENSG00000250470.1 AP000351.3 12.55 2.34e-31 1.27e-27 0.69 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23976904~23977585:- LUSC cis rs1577917 1 rs11758849 ENSG00000203875.9 SNHG5 -12.55 2.38e-31 1.29e-27 -0.67 -0.5 Response to antipsychotic treatment; chr6:85998544 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs13213551 ENSG00000203875.9 SNHG5 -12.54 2.49e-31 1.35e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85898983 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs34622557 ENSG00000203875.9 SNHG5 -12.54 2.49e-31 1.35e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85921134 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1911553 ENSG00000203875.9 SNHG5 -12.54 2.49e-31 1.35e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85921174 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1995688 ENSG00000203875.9 SNHG5 -12.54 2.49e-31 1.35e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85922601 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs6940458 ENSG00000203875.9 SNHG5 -12.54 2.49e-31 1.35e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85935274 chr6:85660950~85678736:- LUSC cis rs7104764 0.957 rs519592 ENSG00000277290.1 RP11-326C3.16 -12.54 2.5e-31 1.35e-27 -0.46 -0.5 Menarche (age at onset); chr11:236811 chr11:243099~243483:- LUSC cis rs1930961 0.85 rs5996945 ENSG00000272977.1 CTA-390C10.10 12.54 2.51e-31 1.36e-27 0.88 0.5 Bipolar disorder with mood-incongruent psychosis; chr22:25479606 chr22:25476218~25479971:+ LUSC cis rs9399135 0.66 rs4646868 ENSG00000232876.1 CTA-212D2.2 -12.54 2.52e-31 1.36e-27 -0.59 -0.5 Red blood cell count; chr6:134950808 chr6:135055033~135060550:+ LUSC cis rs507080 0.922 rs7114216 ENSG00000255422.1 AP002954.4 -12.54 2.53e-31 1.37e-27 -0.57 -0.5 Serum metabolite levels; chr11:118695525 chr11:118704607~118750263:+ LUSC cis rs7115242 0.8 rs6589597 ENSG00000254851.1 RP11-109L13.1 12.54 2.54e-31 1.37e-27 0.89 0.5 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117127082 chr11:117135528~117138582:+ LUSC cis rs1577917 1 rs34106666 ENSG00000203875.9 SNHG5 -12.54 2.56e-31 1.38e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85966540 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1337844 ENSG00000203875.9 SNHG5 -12.54 2.56e-31 1.38e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85967555 chr6:85660950~85678736:- LUSC cis rs7301826 0.651 rs4759517 ENSG00000256299.1 RP11-989F5.3 -12.54 2.67e-31 1.43e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130799153 chr12:130810821~130812622:- LUSC cis rs2882667 0.858 rs10900856 ENSG00000253404.1 AC034243.1 -12.53 2.68e-31 1.44e-27 -0.66 -0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139082057 chr5:138744434~138753309:- LUSC cis rs11155671 0.53 rs6935829 ENSG00000231760.4 RP11-350J20.5 12.53 2.73e-31 1.46e-27 0.62 0.5 Testicular germ cell tumor; chr6:149896675 chr6:149796151~149826294:- LUSC cis rs858239 0.932 rs199355 ENSG00000230658.1 KLHL7-AS1 12.53 2.73e-31 1.47e-27 0.6 0.5 Cerebrospinal fluid biomarker levels; chr7:23256914 chr7:23101228~23105703:- LUSC cis rs2283792 0.792 rs151680 ENSG00000228050.1 TOP3BP1 12.53 2.75e-31 1.48e-27 0.59 0.5 Multiple sclerosis; chr22:21918869 chr22:22223187~22224566:- LUSC cis rs1577917 1 rs884841 ENSG00000203875.9 SNHG5 -12.53 2.8e-31 1.5e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85970582 chr6:85660950~85678736:- LUSC cis rs1153858 0.945 rs1974981 ENSG00000259520.4 CTD-2651B20.3 12.53 2.84e-31 1.52e-27 0.67 0.5 Homoarginine levels; chr15:45436925 chr15:45251580~45279251:- LUSC cis rs1577917 1 rs34852683 ENSG00000203875.9 SNHG5 -12.53 2.88e-31 1.54e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85992612 chr6:85660950~85678736:- LUSC cis rs2739330 0.796 rs2154594 ENSG00000250470.1 AP000351.3 -12.52 3.04e-31 1.63e-27 -0.68 -0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23976904~23977585:- LUSC cis rs7301826 0.967 rs4759792 ENSG00000256250.1 RP11-989F5.1 -12.52 3.09e-31 1.65e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130812086 chr12:130810606~130812438:+ LUSC cis rs7301826 1 rs2001483 ENSG00000256250.1 RP11-989F5.1 -12.52 3.15e-31 1.68e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130834100 chr12:130810606~130812438:+ LUSC cis rs7301826 0.61 rs7957899 ENSG00000256299.1 RP11-989F5.3 -12.52 3.18e-31 1.7e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130794531 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs1973834 ENSG00000256299.1 RP11-989F5.3 -12.52 3.18e-31 1.7e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130795612 chr12:130810821~130812622:- LUSC cis rs507080 0.922 rs533646 ENSG00000255422.1 AP002954.4 -12.51 3.24e-31 1.73e-27 -0.57 -0.5 Serum metabolite levels; chr11:118696037 chr11:118704607~118750263:+ LUSC cis rs2739330 0.828 rs2330635 ENSG00000250470.1 AP000351.3 12.51 3.52e-31 1.88e-27 0.69 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23976904~23977585:- LUSC cis rs7301826 1 rs7301826 ENSG00000256250.1 RP11-989F5.1 -12.51 3.55e-31 1.89e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130806556 chr12:130810606~130812438:+ LUSC cis rs2739330 0.828 rs5760098 ENSG00000250470.1 AP000351.3 12.5 3.64e-31 1.93e-27 0.69 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23976904~23977585:- LUSC cis rs2739330 0.828 rs5760102 ENSG00000250470.1 AP000351.3 12.5 3.64e-31 1.93e-27 0.69 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23976904~23977585:- LUSC cis rs1577917 0.958 rs13207354 ENSG00000203875.9 SNHG5 -12.5 3.7e-31 1.96e-27 -0.69 -0.5 Response to antipsychotic treatment; chr6:85990545 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12204365 ENSG00000203875.9 SNHG5 -12.5 3.7e-31 1.96e-27 -0.69 -0.5 Response to antipsychotic treatment; chr6:85990814 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12663651 ENSG00000203875.9 SNHG5 -12.5 3.7e-31 1.96e-27 -0.69 -0.5 Response to antipsychotic treatment; chr6:85991937 chr6:85660950~85678736:- LUSC cis rs507080 0.769 rs7389 ENSG00000255239.1 AP002954.6 -12.5 3.7e-31 1.96e-27 -0.58 -0.5 Serum metabolite levels; chr11:118657756 chr11:118688039~118690600:- LUSC cis rs9545047 0.935 rs2760102 ENSG00000227676.3 LINC01068 12.5 3.71e-31 1.96e-27 0.61 0.5 Schizophrenia; chr13:79555193 chr13:79566727~79571436:+ LUSC cis rs9545047 0.901 rs73235963 ENSG00000227676.3 LINC01068 12.5 3.74e-31 1.98e-27 0.61 0.5 Schizophrenia; chr13:79562805 chr13:79566727~79571436:+ LUSC cis rs9545047 0.935 rs2484343 ENSG00000227676.3 LINC01068 12.5 3.74e-31 1.98e-27 0.61 0.5 Schizophrenia; chr13:79563587 chr13:79566727~79571436:+ LUSC cis rs9545047 0.868 rs2476173 ENSG00000227676.3 LINC01068 12.5 3.74e-31 1.98e-27 0.61 0.5 Schizophrenia; chr13:79565740 chr13:79566727~79571436:+ LUSC cis rs9545047 0.868 rs1208049 ENSG00000227676.3 LINC01068 12.5 3.74e-31 1.98e-27 0.61 0.5 Schizophrenia; chr13:79570220 chr13:79566727~79571436:+ LUSC cis rs7104764 1 rs6598060 ENSG00000277290.1 RP11-326C3.16 -12.49 3.93e-31 2.08e-27 -0.46 -0.5 Menarche (age at onset); chr11:243987 chr11:243099~243483:- LUSC cis rs507080 0.961 rs642497 ENSG00000255422.1 AP002954.4 -12.49 4.01e-31 2.12e-27 -0.54 -0.5 Serum metabolite levels; chr11:118680075 chr11:118704607~118750263:+ LUSC cis rs6452524 0.618 rs4266384 ENSG00000249664.1 CTD-2227C6.2 12.49 4.1e-31 2.17e-27 0.51 0.5 Hypertension (SNP x SNP interaction); chr5:83080872 chr5:83012285~83013109:- LUSC cis rs7104764 0.879 rs6598070 ENSG00000277290.1 RP11-326C3.16 -12.49 4.15e-31 2.2e-27 -0.46 -0.5 Menarche (age at onset); chr11:225466 chr11:243099~243483:- LUSC cis rs11155671 0.53 rs7757984 ENSG00000231760.4 RP11-350J20.5 12.49 4.18e-31 2.21e-27 0.63 0.5 Testicular germ cell tumor; chr6:149887515 chr6:149796151~149826294:- LUSC cis rs1577917 0.958 rs10944144 ENSG00000203875.9 SNHG5 -12.49 4.25e-31 2.25e-27 -0.71 -0.5 Response to antipsychotic treatment; chr6:85828037 chr6:85660950~85678736:- LUSC cis rs2739330 0.828 rs4822451 ENSG00000250470.1 AP000351.3 12.48 4.35e-31 2.3e-27 0.69 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23976904~23977585:- LUSC cis rs2739330 0.828 rs5760099 ENSG00000250470.1 AP000351.3 12.48 4.35e-31 2.3e-27 0.69 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23976904~23977585:- LUSC cis rs1577917 1 rs10455456 ENSG00000203875.9 SNHG5 -12.48 4.36e-31 2.3e-27 -0.69 -0.5 Response to antipsychotic treatment; chr6:85960604 chr6:85660950~85678736:- LUSC cis rs11155671 0.53 rs7774787 ENSG00000231760.4 RP11-350J20.5 12.48 4.38e-31 2.31e-27 0.63 0.5 Testicular germ cell tumor; chr6:149888296 chr6:149796151~149826294:- LUSC cis rs1577917 0.876 rs12201992 ENSG00000203875.9 SNHG5 -12.48 4.46e-31 2.34e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85908501 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12201880 ENSG00000203875.9 SNHG5 -12.48 4.46e-31 2.34e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85917289 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs7756203 ENSG00000203875.9 SNHG5 -12.48 4.46e-31 2.34e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85917989 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs10944161 ENSG00000203875.9 SNHG5 -12.48 4.46e-31 2.34e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85920658 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs1857965 ENSG00000203875.9 SNHG5 -12.48 4.46e-31 2.34e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85921058 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs7771342 ENSG00000203875.9 SNHG5 -12.48 4.46e-31 2.34e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85922218 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12154056 ENSG00000203875.9 SNHG5 -12.48 4.46e-31 2.34e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85924376 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs7747897 ENSG00000203875.9 SNHG5 -12.48 4.46e-31 2.34e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85937631 chr6:85660950~85678736:- LUSC cis rs9326248 0.53 rs2000616 ENSG00000254851.1 RP11-109L13.1 -12.48 4.56e-31 2.39e-27 -0.9 -0.5 Blood protein levels; chr11:117045813 chr11:117135528~117138582:+ LUSC cis rs9326248 0.53 rs10750100 ENSG00000254851.1 RP11-109L13.1 -12.48 4.56e-31 2.39e-27 -0.9 -0.5 Blood protein levels; chr11:117046528 chr11:117135528~117138582:+ LUSC cis rs507080 0.922 rs12788848 ENSG00000255422.1 AP002954.4 -12.48 4.67e-31 2.45e-27 -0.55 -0.5 Serum metabolite levels; chr11:118683079 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs4474473 ENSG00000255422.1 AP002954.4 -12.48 4.67e-31 2.45e-27 -0.55 -0.5 Serum metabolite levels; chr11:118683180 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs12796373 ENSG00000255422.1 AP002954.4 -12.48 4.67e-31 2.45e-27 -0.55 -0.5 Serum metabolite levels; chr11:118684230 chr11:118704607~118750263:+ LUSC cis rs7301826 0.932 rs1007246 ENSG00000256250.1 RP11-989F5.1 -12.47 5.02e-31 2.63e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130795585 chr12:130810606~130812438:+ LUSC cis rs7301826 0.651 rs10848206 ENSG00000256299.1 RP11-989F5.3 -12.47 5.02e-31 2.63e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130796926 chr12:130810821~130812622:- LUSC cis rs10129255 0.5 rs7157975 ENSG00000223648.3 IGHV3-64 12.47 5.04e-31 2.64e-27 0.41 0.5 Kawasaki disease; chr14:106804049 chr14:106643132~106658258:- LUSC cis rs9399135 0.66 rs9376072 ENSG00000232876.1 CTA-212D2.2 -12.46 5.35e-31 2.8e-27 -0.58 -0.5 Red blood cell count; chr6:134959381 chr6:135055033~135060550:+ LUSC cis rs858239 0.796 rs433395 ENSG00000230658.1 KLHL7-AS1 12.46 5.36e-31 2.8e-27 0.62 0.5 Cerebrospinal fluid biomarker levels; chr7:23362336 chr7:23101228~23105703:- LUSC cis rs73086581 0.947 rs11906612 ENSG00000229539.1 RP11-119B16.2 12.46 5.58e-31 2.91e-27 0.69 0.5 Response to antidepressants in depression; chr20:3922987 chr20:3888239~3888868:- LUSC cis rs7847628 0.587 rs4837796 ENSG00000226752.6 PSMD5-AS1 12.46 5.61e-31 2.93e-27 0.55 0.5 Birth weight; chr9:120848010 chr9:120824828~120854385:+ LUSC cis rs6452524 0.618 rs255561 ENSG00000249664.1 CTD-2227C6.2 12.45 5.8e-31 3.02e-27 0.5 0.5 Hypertension (SNP x SNP interaction); chr5:83054991 chr5:83012285~83013109:- LUSC cis rs6782228 0.675 rs9813845 ENSG00000242551.2 POU5F1P6 -12.45 6.03e-31 3.15e-27 -0.57 -0.5 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128680780 chr3:128674735~128677005:- LUSC cis rs2006771 0.81 rs4820988 ENSG00000236132.1 CTA-440B3.1 12.44 6.33e-31 3.3e-27 0.62 0.5 Nonsyndromic cleft lip with cleft palate; chr22:31669821 chr22:31816379~31817491:- LUSC cis rs7301826 1 rs1609985 ENSG00000256250.1 RP11-989F5.1 -12.44 6.57e-31 3.42e-27 -0.56 -0.5 Plasma plasminogen activator levels; chr12:130835625 chr12:130810606~130812438:+ LUSC cis rs6538678 0.824 rs4762633 ENSG00000258343.1 RP11-536G4.2 -12.43 7.21e-31 3.75e-27 -0.73 -0.5 Lupus nephritis in systemic lupus erythematosus; chr12:95860295 chr12:95795345~95858839:- LUSC cis rs7301826 1 rs10773822 ENSG00000256250.1 RP11-989F5.1 -12.43 7.25e-31 3.77e-27 -0.55 -0.5 Plasma plasminogen activator levels; chr12:130804562 chr12:130810606~130812438:+ LUSC cis rs7301826 0.966 rs10734980 ENSG00000256250.1 RP11-989F5.1 -12.43 7.25e-31 3.77e-27 -0.55 -0.5 Plasma plasminogen activator levels; chr12:130810081 chr12:130810606~130812438:+ LUSC cis rs7301826 1 rs4759793 ENSG00000256250.1 RP11-989F5.1 -12.43 7.26e-31 3.77e-27 -0.55 -0.5 Plasma plasminogen activator levels; chr12:130812693 chr12:130810606~130812438:+ LUSC cis rs7617773 0.817 rs11130163 ENSG00000229759.1 MRPS18AP1 12.43 7.47e-31 3.88e-27 0.5 0.5 Coronary artery disease; chr3:48271168 chr3:48256350~48256938:- LUSC cis rs9399135 0.66 rs4267967 ENSG00000232876.1 CTA-212D2.2 -12.43 7.52e-31 3.9e-27 -0.59 -0.5 Red blood cell count; chr6:134951339 chr6:135055033~135060550:+ LUSC cis rs3091242 0.9 rs669063 ENSG00000261349.1 RP3-465N24.5 -12.43 7.54e-31 3.91e-27 -0.61 -0.5 Erythrocyte sedimentation rate; chr1:25394663 chr1:25266102~25267136:- LUSC cis rs1815787 1 rs1815787 ENSG00000254851.1 RP11-109L13.1 -12.42 7.64e-31 3.96e-27 -0.9 -0.5 Subjective well-being; chr11:117050681 chr11:117135528~117138582:+ LUSC cis rs10129255 0.536 rs10139058 ENSG00000223648.3 IGHV3-64 12.42 7.91e-31 4.1e-27 0.4 0.5 Kawasaki disease; chr14:106685899 chr14:106643132~106658258:- LUSC cis rs6452524 0.618 rs1478487 ENSG00000249664.1 CTD-2227C6.2 12.42 8e-31 4.14e-27 0.5 0.5 Hypertension (SNP x SNP interaction); chr5:83080900 chr5:83012285~83013109:- LUSC cis rs6700559 0.81 rs10919990 ENSG00000260088.1 RP11-92G12.3 -12.42 8.22e-31 4.25e-27 -0.61 -0.5 Coronary artery disease; chr1:200627076 chr1:200669507~200694250:+ LUSC cis rs11155671 0.53 rs9371544 ENSG00000231760.4 RP11-350J20.5 12.42 8.24e-31 4.26e-27 0.61 0.5 Testicular germ cell tumor; chr6:149896224 chr6:149796151~149826294:- LUSC cis rs2739330 0.796 rs5760106 ENSG00000250470.1 AP000351.3 -12.41 8.33e-31 4.31e-27 -0.68 -0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23976904~23977585:- LUSC cis rs4423214 1 rs12792306 ENSG00000254682.1 RP11-660L16.2 12.41 8.48e-31 4.38e-27 0.65 0.5 Vitamin D levels; chr11:71455946 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs4944955 ENSG00000254682.1 RP11-660L16.2 12.41 8.48e-31 4.38e-27 0.65 0.5 Vitamin D levels; chr11:71456631 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs4944956 ENSG00000254682.1 RP11-660L16.2 12.41 8.48e-31 4.38e-27 0.65 0.5 Vitamin D levels; chr11:71456719 chr11:71448674~71452157:+ LUSC cis rs7396835 0.5 rs5092 ENSG00000254851.1 RP11-109L13.1 -12.41 8.55e-31 4.41e-27 -0.79 -0.5 Quantitative traits; chr11:116822748 chr11:117135528~117138582:+ LUSC cis rs4423214 1 rs7935125 ENSG00000254682.1 RP11-660L16.2 12.41 8.84e-31 4.56e-27 0.65 0.5 Vitamin D levels; chr11:71473144 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs3794060 ENSG00000254682.1 RP11-660L16.2 12.41 8.84e-31 4.56e-27 0.65 0.5 Vitamin D levels; chr11:71476633 chr11:71448674~71452157:+ LUSC cis rs801193 1 rs2055682 ENSG00000226824.5 RP4-756H11.3 -12.41 8.97e-31 4.63e-27 -0.59 -0.5 Aortic root size; chr7:66795302 chr7:66654538~66669855:+ LUSC cis rs1933112 0.527 rs12090218 ENSG00000227777.1 RP4-738P11.3 -12.41 9.1e-31 4.69e-27 -0.56 -0.5 Blood protein levels; chr1:168529966 chr1:168542737~168543354:+ LUSC cis rs7115242 0.8 rs7931770 ENSG00000254851.1 RP11-109L13.1 -12.4 9.28e-31 4.78e-27 -0.88 -0.5 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116995574 chr11:117135528~117138582:+ LUSC cis rs1577917 1 rs10455158 ENSG00000203875.9 SNHG5 -12.4 9.37e-31 4.83e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85963107 chr6:85660950~85678736:- LUSC cis rs1577917 0.959 rs34258068 ENSG00000203875.9 SNHG5 -12.4 9.37e-31 4.83e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85969731 chr6:85660950~85678736:- LUSC cis rs9326248 0.53 rs2000614 ENSG00000254851.1 RP11-109L13.1 -12.4 9.42e-31 4.85e-27 -0.91 -0.5 Blood protein levels; chr11:117045026 chr11:117135528~117138582:+ LUSC cis rs7115242 0.8 rs519794 ENSG00000254851.1 RP11-109L13.1 -12.4 9.45e-31 4.86e-27 -0.87 -0.5 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116988737 chr11:117135528~117138582:+ LUSC cis rs3096299 0.685 rs4785676 ENSG00000274627.1 RP11-104N10.2 12.4 9.66e-31 4.97e-27 0.44 0.5 Multiple myeloma (IgH translocation); chr16:89487216 chr16:89516797~89522217:+ LUSC cis rs1577917 1 rs12213740 ENSG00000203875.9 SNHG5 -12.4 9.71e-31 5e-27 -0.68 -0.5 Response to antipsychotic treatment; chr6:85947015 chr6:85660950~85678736:- LUSC cis rs2283792 0.812 rs94194 ENSG00000228050.1 TOP3BP1 12.4 9.72e-31 5e-27 0.58 0.5 Multiple sclerosis; chr22:21933937 chr22:22223187~22224566:- LUSC cis rs2283792 0.812 rs5995269 ENSG00000228050.1 TOP3BP1 12.4 9.72e-31 5e-27 0.58 0.5 Multiple sclerosis; chr22:21935025 chr22:22223187~22224566:- LUSC cis rs507080 0.961 rs34413584 ENSG00000255422.1 AP002954.4 -12.39 1.02e-30 5.25e-27 -0.55 -0.5 Serum metabolite levels; chr11:118675072 chr11:118704607~118750263:+ LUSC cis rs10129255 0.536 rs8004835 ENSG00000223648.3 IGHV3-64 12.39 1.08e-30 5.54e-27 0.4 0.5 Kawasaki disease; chr14:106686361 chr14:106643132~106658258:- LUSC cis rs2739330 0.753 rs4822452 ENSG00000250470.1 AP000351.3 12.39 1.09e-30 5.57e-27 0.68 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23976904~23977585:- LUSC cis rs1577917 1 rs12196037 ENSG00000203875.9 SNHG5 -12.38 1.14e-30 5.82e-27 -0.69 -0.5 Response to antipsychotic treatment; chr6:85984913 chr6:85660950~85678736:- LUSC cis rs9545047 0.935 rs7988601 ENSG00000227676.3 LINC01068 -12.38 1.18e-30 6.03e-27 -0.6 -0.5 Schizophrenia; chr13:79475648 chr13:79566727~79571436:+ LUSC cis rs9545047 0.935 rs6563110 ENSG00000227676.3 LINC01068 -12.38 1.18e-30 6.03e-27 -0.6 -0.5 Schizophrenia; chr13:79477137 chr13:79566727~79571436:+ LUSC cis rs9601248 0.529 rs2783126 ENSG00000227676.3 LINC01068 12.38 1.18e-30 6.05e-27 0.61 0.5 Major depressive disorder; chr13:79584566 chr13:79566727~79571436:+ LUSC cis rs1577917 0.958 rs11755048 ENSG00000203875.9 SNHG5 -12.37 1.22e-30 6.25e-27 -0.71 -0.5 Response to antipsychotic treatment; chr6:85804616 chr6:85660950~85678736:- LUSC cis rs7301826 1 rs4759787 ENSG00000256250.1 RP11-989F5.1 -12.37 1.23e-30 6.31e-27 -0.55 -0.5 Plasma plasminogen activator levels; chr12:130805635 chr12:130810606~130812438:+ LUSC cis rs1577917 1 rs1962716 ENSG00000203875.9 SNHG5 -12.37 1.26e-30 6.42e-27 -0.69 -0.5 Response to antipsychotic treatment; chr6:85938718 chr6:85660950~85678736:- LUSC cis rs73086581 1 rs3746666 ENSG00000229539.1 RP11-119B16.2 12.36 1.34e-30 6.84e-27 0.65 0.5 Response to antidepressants in depression; chr20:3930214 chr20:3888239~3888868:- LUSC cis rs7301826 0.934 rs10773826 ENSG00000256250.1 RP11-989F5.1 -12.36 1.39e-30 7.09e-27 -0.55 -0.5 Plasma plasminogen activator levels; chr12:130836629 chr12:130810606~130812438:+ LUSC cis rs10129255 0.576 rs2157616 ENSG00000223648.3 IGHV3-64 12.36 1.45e-30 7.4e-27 0.4 0.5 Kawasaki disease; chr14:106767802 chr14:106643132~106658258:- LUSC cis rs2739330 0.796 rs5760097 ENSG00000250470.1 AP000351.3 12.35 1.47e-30 7.47e-27 0.69 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23976904~23977585:- LUSC cis rs7115242 0.8 rs4245168 ENSG00000254851.1 RP11-109L13.1 -12.35 1.48e-30 7.54e-27 -0.88 -0.5 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117011922 chr11:117135528~117138582:+ LUSC cis rs9326248 0.53 rs10790172 ENSG00000254851.1 RP11-109L13.1 -12.35 1.51e-30 7.7e-27 -0.91 -0.5 Blood protein levels; chr11:117057024 chr11:117135528~117138582:+ LUSC cis rs10129255 0.556 rs9324093 ENSG00000223648.3 IGHV3-64 12.35 1.57e-30 7.96e-27 0.4 0.49 Kawasaki disease; chr14:106683893 chr14:106643132~106658258:- LUSC cis rs10129255 0.5 rs8011115 ENSG00000223648.3 IGHV3-64 12.34 1.61e-30 8.19e-27 0.4 0.49 Kawasaki disease; chr14:106786292 chr14:106643132~106658258:- LUSC cis rs6700559 0.81 rs2809344 ENSG00000260088.1 RP11-92G12.3 12.34 1.73e-30 8.77e-27 0.6 0.49 Coronary artery disease; chr1:200627478 chr1:200669507~200694250:+ LUSC cis rs1577917 0.958 rs12199832 ENSG00000203875.9 SNHG5 -12.34 1.73e-30 8.79e-27 -0.68 -0.49 Response to antipsychotic treatment; chr6:85943030 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs12207374 ENSG00000203875.9 SNHG5 -12.34 1.73e-30 8.79e-27 -0.68 -0.49 Response to antipsychotic treatment; chr6:85946927 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs12201735 ENSG00000203875.9 SNHG5 -12.34 1.73e-30 8.79e-27 -0.68 -0.49 Response to antipsychotic treatment; chr6:85947221 chr6:85660950~85678736:- LUSC cis rs9326248 0.53 rs900012 ENSG00000254851.1 RP11-109L13.1 -12.34 1.74e-30 8.83e-27 -0.89 -0.49 Blood protein levels; chr11:117095719 chr11:117135528~117138582:+ LUSC cis rs507080 0.922 rs519848 ENSG00000255422.1 AP002954.4 -12.33 1.82e-30 9.22e-27 -0.54 -0.49 Serum metabolite levels; chr11:118682006 chr11:118704607~118750263:+ LUSC cis rs4423214 0.819 rs7938885 ENSG00000254682.1 RP11-660L16.2 12.33 1.9e-30 9.62e-27 0.64 0.49 Vitamin D levels; chr11:71458997 chr11:71448674~71452157:+ LUSC cis rs4423214 0.959 rs12800438 ENSG00000254682.1 RP11-660L16.2 12.33 1.9e-30 9.62e-27 0.64 0.49 Vitamin D levels; chr11:71459957 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs12807718 ENSG00000254682.1 RP11-660L16.2 12.33 1.9e-30 9.62e-27 0.64 0.49 Vitamin D levels; chr11:71460124 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs4423214 ENSG00000254682.1 RP11-660L16.2 12.33 1.9e-30 9.62e-27 0.64 0.49 Vitamin D levels; chr11:71462208 chr11:71448674~71452157:+ LUSC cis rs12594515 0.967 rs11854477 ENSG00000273972.1 CTD-2306A12.1 -12.32 2.07e-30 1.05e-26 -0.58 -0.49 Weight;Waist circumference; chr15:45706147 chr15:45702640~45703183:+ LUSC cis rs12594515 0.967 rs11857628 ENSG00000273972.1 CTD-2306A12.1 -12.32 2.07e-30 1.05e-26 -0.58 -0.49 Weight;Waist circumference; chr15:45706008 chr15:45702640~45703183:+ LUSC cis rs801193 1 rs2659909 ENSG00000226824.5 RP4-756H11.3 -12.31 2.14e-30 1.08e-26 -0.58 -0.49 Aortic root size; chr7:66695292 chr7:66654538~66669855:+ LUSC cis rs977987 0.705 rs4888377 ENSG00000261783.1 RP11-252K23.2 -12.31 2.14e-30 1.08e-26 -0.68 -0.49 Dupuytren's disease; chr16:75291788 chr16:75379818~75381260:- LUSC cis rs1577917 1 rs1577917 ENSG00000203875.9 SNHG5 -12.31 2.21e-30 1.12e-26 -0.69 -0.49 Response to antipsychotic treatment; chr6:85982222 chr6:85660950~85678736:- LUSC cis rs1577917 0.917 rs12202170 ENSG00000203875.9 SNHG5 -12.31 2.26e-30 1.14e-26 -0.69 -0.49 Response to antipsychotic treatment; chr6:85880668 chr6:85660950~85678736:- LUSC cis rs1577917 1 rs10455449 ENSG00000203875.9 SNHG5 -12.31 2.26e-30 1.14e-26 -0.69 -0.49 Response to antipsychotic treatment; chr6:85882508 chr6:85660950~85678736:- LUSC cis rs6700559 0.81 rs10399615 ENSG00000260088.1 RP11-92G12.3 12.31 2.26e-30 1.14e-26 0.61 0.49 Coronary artery disease; chr1:200626145 chr1:200669507~200694250:+ LUSC cis rs7104764 1 rs7104764 ENSG00000277290.1 RP11-326C3.16 -12.31 2.33e-30 1.17e-26 -0.45 -0.49 Menarche (age at onset); chr11:229977 chr11:243099~243483:- LUSC cis rs7301826 0.651 rs2037789 ENSG00000256299.1 RP11-989F5.3 12.3 2.34e-30 1.18e-26 0.55 0.49 Plasma plasminogen activator levels; chr12:130803747 chr12:130810821~130812622:- LUSC cis rs1577917 0.916 rs12203358 ENSG00000203875.9 SNHG5 -12.3 2.45e-30 1.23e-26 -0.68 -0.49 Response to antipsychotic treatment; chr6:85893506 chr6:85660950~85678736:- LUSC cis rs507080 0.697 rs653008 ENSG00000255239.1 AP002954.6 12.3 2.47e-30 1.24e-26 0.58 0.49 Serum metabolite levels; chr11:118649775 chr11:118688039~118690600:- LUSC cis rs1577917 1 rs10944163 ENSG00000203875.9 SNHG5 -12.29 2.68e-30 1.35e-26 -0.69 -0.49 Response to antipsychotic treatment; chr6:85948975 chr6:85660950~85678736:- LUSC cis rs6782228 0.628 rs7641584 ENSG00000242551.2 POU5F1P6 -12.29 2.69e-30 1.35e-26 -0.56 -0.49 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128673787 chr3:128674735~128677005:- LUSC cis rs801193 1 rs2707856 ENSG00000226824.5 RP4-756H11.3 -12.29 2.7e-30 1.36e-26 -0.57 -0.49 Aortic root size; chr7:66746023 chr7:66654538~66669855:+ LUSC cis rs9326248 0.53 rs6589589 ENSG00000254851.1 RP11-109L13.1 -12.29 2.73e-30 1.37e-26 -0.9 -0.49 Blood protein levels; chr11:117061712 chr11:117135528~117138582:+ LUSC cis rs801193 0.967 rs2420827 ENSG00000226824.5 RP4-756H11.3 12.29 2.73e-30 1.37e-26 0.59 0.49 Aortic root size; chr7:66682114 chr7:66654538~66669855:+ LUSC cis rs3814244 0.788 rs3741647 ENSG00000255733.4 IFNG-AS1 -12.28 2.87e-30 1.44e-26 -0.41 -0.49 Itch intensity from mosquito bite adjusted by bite size; chr12:68028249 chr12:67989445~68234686:+ LUSC cis rs801193 1 rs2659912 ENSG00000226824.5 RP4-756H11.3 -12.28 2.9e-30 1.45e-26 -0.57 -0.49 Aortic root size; chr7:66693012 chr7:66654538~66669855:+ LUSC cis rs801193 0.935 rs3800820 ENSG00000226824.5 RP4-756H11.3 12.28 2.96e-30 1.48e-26 0.57 0.49 Aortic root size; chr7:66682191 chr7:66654538~66669855:+ LUSC cis rs9601248 0.529 rs9545142 ENSG00000227676.3 LINC01068 12.28 2.96e-30 1.48e-26 0.61 0.49 Major depressive disorder; chr13:79588420 chr13:79566727~79571436:+ LUSC cis rs7104764 1 rs2272563 ENSG00000277290.1 RP11-326C3.16 -12.28 2.99e-30 1.5e-26 -0.45 -0.49 Menarche (age at onset); chr11:236871 chr11:243099~243483:- LUSC cis rs7104764 0.917 rs1045288 ENSG00000277290.1 RP11-326C3.16 -12.28 2.99e-30 1.5e-26 -0.45 -0.49 Menarche (age at onset); chr11:237087 chr11:243099~243483:- LUSC cis rs4423214 1 rs2852853 ENSG00000254682.1 RP11-660L16.2 12.28 3.02e-30 1.51e-26 0.63 0.49 Vitamin D levels; chr11:71439171 chr11:71448674~71452157:+ LUSC cis rs9326248 0.53 rs2000615 ENSG00000254851.1 RP11-109L13.1 -12.28 3.02e-30 1.51e-26 -0.91 -0.49 Blood protein levels; chr11:117045103 chr11:117135528~117138582:+ LUSC cis rs801193 0.967 rs3800823 ENSG00000226824.5 RP4-756H11.3 12.27 3.12e-30 1.56e-26 0.59 0.49 Aortic root size; chr7:66682123 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs7785213 ENSG00000226824.5 RP4-756H11.3 12.27 3.17e-30 1.58e-26 0.57 0.49 Aortic root size; chr7:66673991 chr7:66654538~66669855:+ LUSC cis rs1577917 1 rs955227 ENSG00000203875.9 SNHG5 -12.27 3.21e-30 1.6e-26 -0.69 -0.49 Response to antipsychotic treatment; chr6:85941314 chr6:85660950~85678736:- LUSC cis rs1577917 0.958 rs67024565 ENSG00000203875.9 SNHG5 -12.27 3.24e-30 1.62e-26 -0.7 -0.49 Response to antipsychotic treatment; chr6:85844279 chr6:85660950~85678736:- LUSC cis rs7535099 1 rs3790426 ENSG00000224570.1 RP11-430H12.2 -12.26 3.49e-30 1.74e-26 -0.7 -0.49 Blood protein levels; chr1:65577336 chr1:65576129~65578380:- LUSC cis rs9399135 0.66 rs9389248 ENSG00000232876.1 CTA-212D2.2 -12.26 3.49e-30 1.74e-26 -0.58 -0.49 Red blood cell count; chr6:134961518 chr6:135055033~135060550:+ LUSC cis rs12439619 0.693 rs8034801 ENSG00000278603.1 RP13-608F4.5 12.26 3.52e-30 1.75e-26 0.67 0.49 Intelligence (multi-trait analysis); chr15:82183996 chr15:82472203~82472426:+ LUSC cis rs4853012 0.539 rs9789534 ENSG00000217702.2 RP11-287D1.4 12.26 3.55e-30 1.77e-26 0.84 0.49 Gestational age at birth (maternal effect); chr2:74135863 chr2:74130583~74135395:+ LUSC cis rs9399135 0.66 rs4440481 ENSG00000232876.1 CTA-212D2.2 -12.26 3.57e-30 1.77e-26 -0.57 -0.49 Red blood cell count; chr6:134955558 chr6:135055033~135060550:+ LUSC cis rs1577917 1 rs35761942 ENSG00000203875.9 SNHG5 -12.26 3.59e-30 1.78e-26 -0.68 -0.49 Response to antipsychotic treatment; chr6:85919786 chr6:85660950~85678736:- LUSC cis rs7535099 0.954 rs3790431 ENSG00000224570.1 RP11-430H12.2 -12.26 3.61e-30 1.79e-26 -0.69 -0.49 Blood protein levels; chr1:65570345 chr1:65576129~65578380:- LUSC cis rs801193 1 rs11773829 ENSG00000226824.5 RP4-756H11.3 12.26 3.61e-30 1.79e-26 0.57 0.49 Aortic root size; chr7:66676087 chr7:66654538~66669855:+ LUSC cis rs12594515 1 rs8032835 ENSG00000273972.1 CTD-2306A12.1 -12.26 3.67e-30 1.82e-26 -0.58 -0.49 Weight;Waist circumference; chr15:45705699 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs8033148 ENSG00000273972.1 CTD-2306A12.1 -12.26 3.67e-30 1.82e-26 -0.58 -0.49 Weight;Waist circumference; chr15:45705731 chr15:45702640~45703183:+ LUSC cis rs12594515 0.904 rs8032875 ENSG00000273972.1 CTD-2306A12.1 -12.26 3.67e-30 1.82e-26 -0.58 -0.49 Weight;Waist circumference; chr15:45705812 chr15:45702640~45703183:+ LUSC cis rs12594515 0.874 rs8032878 ENSG00000273972.1 CTD-2306A12.1 -12.26 3.67e-30 1.82e-26 -0.58 -0.49 Weight;Waist circumference; chr15:45705817 chr15:45702640~45703183:+ LUSC cis rs11155671 0.53 rs2342770 ENSG00000231760.4 RP11-350J20.5 12.26 3.68e-30 1.83e-26 0.61 0.49 Testicular germ cell tumor; chr6:149895549 chr6:149796151~149826294:- LUSC cis rs507080 0.922 rs4936433 ENSG00000255422.1 AP002954.4 12.26 3.71e-30 1.84e-26 0.56 0.49 Serum metabolite levels; chr11:118681711 chr11:118704607~118750263:+ LUSC cis rs7104764 1 rs9795476 ENSG00000277290.1 RP11-326C3.16 -12.25 3.77e-30 1.87e-26 -0.45 -0.49 Menarche (age at onset); chr11:235894 chr11:243099~243483:- LUSC cis rs3096299 0.685 rs4785571 ENSG00000274627.1 RP11-104N10.2 12.25 4.01e-30 1.99e-26 0.42 0.49 Multiple myeloma (IgH translocation); chr16:89498761 chr16:89516797~89522217:+ LUSC cis rs12439619 0.693 rs28689861 ENSG00000278603.1 RP13-608F4.5 12.25 4.02e-30 1.99e-26 0.67 0.49 Intelligence (multi-trait analysis); chr15:82206369 chr15:82472203~82472426:+ LUSC cis rs3096299 0.685 rs8050512 ENSG00000274627.1 RP11-104N10.2 12.25 4.02e-30 1.99e-26 0.43 0.49 Multiple myeloma (IgH translocation); chr16:89485912 chr16:89516797~89522217:+ LUSC cis rs6538678 0.824 rs2367583 ENSG00000258343.1 RP11-536G4.2 -12.24 4.12e-30 2.04e-26 -0.78 -0.49 Lupus nephritis in systemic lupus erythematosus; chr12:95856582 chr12:95795345~95858839:- LUSC cis rs73086581 0.947 rs67356712 ENSG00000229539.1 RP11-119B16.2 12.24 4.28e-30 2.12e-26 0.66 0.49 Response to antidepressants in depression; chr20:3912239 chr20:3888239~3888868:- LUSC cis rs1577917 1 rs12215903 ENSG00000203875.9 SNHG5 -12.24 4.3e-30 2.13e-26 -0.67 -0.49 Response to antipsychotic treatment; chr6:85965310 chr6:85660950~85678736:- LUSC cis rs6700559 0.81 rs10919991 ENSG00000260088.1 RP11-92G12.3 -12.24 4.41e-30 2.17e-26 -0.61 -0.49 Coronary artery disease; chr1:200627217 chr1:200669507~200694250:+ LUSC cis rs10129255 0.509 rs756583 ENSG00000223648.3 IGHV3-64 12.24 4.45e-30 2.2e-26 0.4 0.49 Kawasaki disease; chr14:106680002 chr14:106643132~106658258:- LUSC cis rs7115242 0.8 rs1320668 ENSG00000254851.1 RP11-109L13.1 -12.24 4.45e-30 2.2e-26 -0.9 -0.49 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117096950 chr11:117135528~117138582:+ LUSC cis rs3096299 0.685 rs4785568 ENSG00000274627.1 RP11-104N10.2 12.23 4.51e-30 2.22e-26 0.43 0.49 Multiple myeloma (IgH translocation); chr16:89487299 chr16:89516797~89522217:+ LUSC cis rs7301826 1 rs10848205 ENSG00000256250.1 RP11-989F5.1 -12.23 4.54e-30 2.24e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130796169 chr12:130810606~130812438:+ LUSC cis rs6700559 0.967 rs12041320 ENSG00000260088.1 RP11-92G12.3 -12.23 4.55e-30 2.24e-26 -0.61 -0.49 Coronary artery disease; chr1:200652107 chr1:200669507~200694250:+ LUSC cis rs7104764 1 rs10794302 ENSG00000277290.1 RP11-326C3.16 -12.23 4.56e-30 2.25e-26 -0.45 -0.49 Menarche (age at onset); chr11:234102 chr11:243099~243483:- LUSC cis rs507080 0.922 rs4589335 ENSG00000255422.1 AP002954.4 -12.23 4.75e-30 2.34e-26 -0.54 -0.49 Serum metabolite levels; chr11:118668431 chr11:118704607~118750263:+ LUSC cis rs7104764 0.957 rs3829998 ENSG00000277290.1 RP11-326C3.16 -12.23 4.77e-30 2.35e-26 -0.45 -0.49 Menarche (age at onset); chr11:230751 chr11:243099~243483:- LUSC cis rs7104764 1 rs7483951 ENSG00000277290.1 RP11-326C3.16 -12.23 4.77e-30 2.35e-26 -0.45 -0.49 Menarche (age at onset); chr11:231758 chr11:243099~243483:- LUSC cis rs2739330 0.828 rs5751770 ENSG00000250470.1 AP000351.3 12.23 4.78e-30 2.35e-26 0.67 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23976904~23977585:- LUSC cis rs9326248 0.53 rs7950364 ENSG00000254851.1 RP11-109L13.1 -12.23 4.89e-30 2.4e-26 -0.91 -0.49 Blood protein levels; chr11:117028170 chr11:117135528~117138582:+ LUSC cis rs1577917 1 rs12190598 ENSG00000203875.9 SNHG5 -12.23 4.9e-30 2.41e-26 -0.67 -0.49 Response to antipsychotic treatment; chr6:85976356 chr6:85660950~85678736:- LUSC cis rs6700559 0.742 rs10399790 ENSG00000260088.1 RP11-92G12.3 -12.23 4.93e-30 2.42e-26 -0.6 -0.49 Coronary artery disease; chr1:200626241 chr1:200669507~200694250:+ LUSC cis rs11155671 0.53 rs9397420 ENSG00000216906.2 RP11-350J20.9 -12.22 5.01e-30 2.46e-26 -0.57 -0.49 Testicular germ cell tumor; chr6:149885645 chr6:149904243~149906418:+ LUSC cis rs73086581 0.947 rs73084523 ENSG00000229539.1 RP11-119B16.2 12.22 5.03e-30 2.47e-26 0.66 0.49 Response to antidepressants in depression; chr20:3894979 chr20:3888239~3888868:- LUSC cis rs4423214 1 rs11233746 ENSG00000254682.1 RP11-660L16.2 12.22 5.1e-30 2.5e-26 0.64 0.49 Vitamin D levels; chr11:71460394 chr11:71448674~71452157:+ LUSC cis rs7301826 1 rs4619189 ENSG00000256250.1 RP11-989F5.1 -12.22 5.29e-30 2.59e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130829252 chr12:130810606~130812438:+ LUSC cis rs7301826 1 rs1106369 ENSG00000256250.1 RP11-989F5.1 -12.22 5.39e-30 2.64e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130815550 chr12:130810606~130812438:+ LUSC cis rs7104764 1 rs6598066 ENSG00000277290.1 RP11-326C3.16 -12.21 5.42e-30 2.65e-26 -0.45 -0.49 Menarche (age at onset); chr11:243185 chr11:243099~243483:- LUSC cis rs73086581 1 rs6052220 ENSG00000229539.1 RP11-119B16.2 12.21 5.48e-30 2.68e-26 0.63 0.49 Response to antidepressants in depression; chr20:3989947 chr20:3888239~3888868:- LUSC cis rs507080 0.733 rs601318 ENSG00000255239.1 AP002954.6 12.21 5.54e-30 2.71e-26 0.58 0.49 Serum metabolite levels; chr11:118648845 chr11:118688039~118690600:- LUSC cis rs7301826 0.651 rs1554807 ENSG00000256299.1 RP11-989F5.3 12.21 5.59e-30 2.73e-26 0.55 0.49 Plasma plasminogen activator levels; chr12:130795872 chr12:130810821~130812622:- LUSC cis rs1577917 0.958 rs12198876 ENSG00000203875.9 SNHG5 -12.21 5.59e-30 2.74e-26 -0.7 -0.49 Response to antipsychotic treatment; chr6:85815758 chr6:85660950~85678736:- LUSC cis rs10129255 0.536 rs3944157 ENSG00000223648.3 IGHV3-64 12.21 5.78e-30 2.82e-26 0.39 0.49 Kawasaki disease; chr14:106682286 chr14:106643132~106658258:- LUSC cis rs3096299 0.685 rs12935112 ENSG00000274627.1 RP11-104N10.2 -12.2 6.01e-30 2.93e-26 -0.42 -0.49 Multiple myeloma (IgH translocation); chr16:89476450 chr16:89516797~89522217:+ LUSC cis rs801193 1 rs2420824 ENSG00000226824.5 RP4-756H11.3 12.2 6.05e-30 2.95e-26 0.57 0.49 Aortic root size; chr7:66666129 chr7:66654538~66669855:+ LUSC cis rs507080 0.922 rs4938524 ENSG00000255422.1 AP002954.4 -12.2 6.05e-30 2.95e-26 -0.53 -0.49 Serum metabolite levels; chr11:118681365 chr11:118704607~118750263:+ LUSC cis rs2283792 0.812 rs240066 ENSG00000228050.1 TOP3BP1 -12.2 6.13e-30 2.99e-26 -0.58 -0.49 Multiple sclerosis; chr22:21938623 chr22:22223187~22224566:- LUSC cis rs7301826 0.61 rs9668291 ENSG00000256299.1 RP11-989F5.3 -12.2 6.25e-30 3.04e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130812363 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs4759794 ENSG00000256299.1 RP11-989F5.3 -12.2 6.25e-30 3.04e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130812803 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs10744485 ENSG00000256299.1 RP11-989F5.3 -12.2 6.25e-30 3.04e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130814005 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs10773824 ENSG00000256299.1 RP11-989F5.3 -12.2 6.25e-30 3.04e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130814306 chr12:130810821~130812622:- LUSC cis rs9322193 0.516 rs1999632 ENSG00000231760.4 RP11-350J20.5 12.2 6.38e-30 3.1e-26 0.72 0.49 Lung cancer; chr6:149866737 chr6:149796151~149826294:- LUSC cis rs858239 0.863 rs274058 ENSG00000230658.1 KLHL7-AS1 12.2 6.42e-30 3.12e-26 0.62 0.49 Cerebrospinal fluid biomarker levels; chr7:23351890 chr7:23101228~23105703:- LUSC cis rs507080 0.883 rs527475 ENSG00000255422.1 AP002954.4 -12.2 6.45e-30 3.13e-26 -0.55 -0.49 Serum metabolite levels; chr11:118692530 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs585039 ENSG00000255422.1 AP002954.4 -12.2 6.45e-30 3.13e-26 -0.55 -0.49 Serum metabolite levels; chr11:118692672 chr11:118704607~118750263:+ LUSC cis rs7301826 0.967 rs4759790 ENSG00000256250.1 RP11-989F5.1 -12.19 6.67e-30 3.24e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130811845 chr12:130810606~130812438:+ LUSC cis rs1577917 1 rs6936048 ENSG00000203875.9 SNHG5 -12.19 6.75e-30 3.27e-26 -0.68 -0.49 Response to antipsychotic treatment; chr6:85992890 chr6:85660950~85678736:- LUSC cis rs200367988 1 rs200367988 ENSG00000271670.1 RP11-95I16.4 -12.19 6.87e-30 3.33e-26 -0.52 -0.49 Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels; chr10:120915337 chr10:120879256~120880667:- LUSC cis rs5760092 0.755 rs4585126 ENSG00000273295.1 AP000350.5 -12.19 6.9e-30 3.35e-26 -0.65 -0.49 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23901432~23907068:- LUSC cis rs7617773 0.817 rs936427 ENSG00000229759.1 MRPS18AP1 -12.19 6.93e-30 3.36e-26 -0.5 -0.49 Coronary artery disease; chr3:48259584 chr3:48256350~48256938:- LUSC cis rs7301826 0.627 rs73162873 ENSG00000256299.1 RP11-989F5.3 -12.19 6.96e-30 3.37e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130811468 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs12228957 ENSG00000256299.1 RP11-989F5.3 -12.19 6.96e-30 3.37e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130811521 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs12228959 ENSG00000256299.1 RP11-989F5.3 -12.19 6.96e-30 3.37e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130811523 chr12:130810821~130812622:- LUSC cis rs1577917 0.958 rs28442244 ENSG00000203875.9 SNHG5 12.18 7.31e-30 3.54e-26 0.68 0.49 Response to antipsychotic treatment; chr6:85991518 chr6:85660950~85678736:- LUSC cis rs801193 0.904 rs4718405 ENSG00000226824.5 RP4-756H11.3 -12.18 7.33e-30 3.54e-26 -0.58 -0.49 Aortic root size; chr7:66789659 chr7:66654538~66669855:+ LUSC cis rs1577917 1 rs12661204 ENSG00000203875.9 SNHG5 -12.18 7.33e-30 3.54e-26 -0.69 -0.49 Response to antipsychotic treatment; chr6:85968868 chr6:85660950~85678736:- LUSC cis rs12594515 1 rs12594515 ENSG00000273972.1 CTD-2306A12.1 12.18 7.35e-30 3.55e-26 0.57 0.49 Weight;Waist circumference; chr15:45692873 chr15:45702640~45703183:+ LUSC cis rs7301826 1 rs10773819 ENSG00000256250.1 RP11-989F5.1 -12.18 7.49e-30 3.62e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130794477 chr12:130810606~130812438:+ LUSC cis rs73086581 0.947 rs73084531 ENSG00000229539.1 RP11-119B16.2 12.17 7.88e-30 3.8e-26 0.67 0.49 Response to antidepressants in depression; chr20:3897782 chr20:3888239~3888868:- LUSC cis rs10129255 0.5 rs11627315 ENSG00000223648.3 IGHV3-64 12.17 8.29e-30 3.99e-26 0.4 0.49 Kawasaki disease; chr14:106802182 chr14:106643132~106658258:- LUSC cis rs7301826 0.627 rs1077317 ENSG00000256299.1 RP11-989F5.3 -12.16 9.14e-30 4.39e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130830432 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs4759525 ENSG00000256299.1 RP11-989F5.3 -12.16 9.14e-30 4.39e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130831736 chr12:130810821~130812622:- LUSC cis rs9326248 0.53 rs2155583 ENSG00000254851.1 RP11-109L13.1 -12.16 9.14e-30 4.39e-26 -0.9 -0.49 Blood protein levels; chr11:117044501 chr11:117135528~117138582:+ LUSC cis rs7115242 0.8 rs10736487 ENSG00000254851.1 RP11-109L13.1 -12.16 9.19e-30 4.41e-26 -0.89 -0.49 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117079516 chr11:117135528~117138582:+ LUSC cis rs7104764 1 rs10902113 ENSG00000277290.1 RP11-326C3.16 -12.16 9.19e-30 4.41e-26 -0.45 -0.49 Menarche (age at onset); chr11:245523 chr11:243099~243483:- LUSC cis rs7104764 1 rs7482591 ENSG00000277290.1 RP11-326C3.16 -12.16 9.19e-30 4.41e-26 -0.45 -0.49 Menarche (age at onset); chr11:245861 chr11:243099~243483:- LUSC cis rs7104764 1 rs10902114 ENSG00000277290.1 RP11-326C3.16 -12.16 9.19e-30 4.41e-26 -0.45 -0.49 Menarche (age at onset); chr11:246234 chr11:243099~243483:- LUSC cis rs7301826 0.651 rs10734979 ENSG00000256299.1 RP11-989F5.3 -12.16 9.32e-30 4.47e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130804409 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs4759519 ENSG00000256299.1 RP11-989F5.3 -12.16 9.32e-30 4.47e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130804963 chr12:130810821~130812622:- LUSC cis rs7301826 0.627 rs10773823 ENSG00000256299.1 RP11-989F5.3 -12.16 9.32e-30 4.47e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130809956 chr12:130810821~130812622:- LUSC cis rs7301826 0.61 rs4759791 ENSG00000256299.1 RP11-989F5.3 -12.16 9.32e-30 4.47e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130811950 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs4759521 ENSG00000256299.1 RP11-989F5.3 -12.16 9.32e-30 4.47e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130812768 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs10734981 ENSG00000256299.1 RP11-989F5.3 -12.16 9.32e-30 4.47e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130813350 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs10744483 ENSG00000256299.1 RP11-989F5.3 -12.16 9.32e-30 4.47e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130813661 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs10744484 ENSG00000256299.1 RP11-989F5.3 -12.16 9.32e-30 4.47e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130813961 chr12:130810821~130812622:- LUSC cis rs7301826 0.651 rs10773825 ENSG00000256299.1 RP11-989F5.3 -12.16 9.32e-30 4.47e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130814368 chr12:130810821~130812622:- LUSC cis rs507080 0.922 rs502601 ENSG00000255422.1 AP002954.4 -12.16 9.33e-30 4.47e-26 -0.55 -0.49 Serum metabolite levels; chr11:118694970 chr11:118704607~118750263:+ LUSC cis rs507080 0.883 rs12798453 ENSG00000255422.1 AP002954.4 -12.15 9.79e-30 4.67e-26 -0.54 -0.49 Serum metabolite levels; chr11:118690701 chr11:118704607~118750263:+ LUSC cis rs7104764 1 rs10902110 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:237648 chr11:243099~243483:- LUSC cis rs7104764 1 rs7481993 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:237875 chr11:243099~243483:- LUSC cis rs7104764 1 rs6598069 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:240664 chr11:243099~243483:- LUSC cis rs7104764 1 rs7395328 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:242624 chr11:243099~243483:- LUSC cis rs7104764 0.917 rs6598068 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:243092 chr11:243099~243483:- LUSC cis rs7104764 0.917 rs6598067 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:243093 chr11:243099~243483:- LUSC cis rs7104764 1 rs6598065 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:243211 chr11:243099~243483:- LUSC cis rs7104764 0.957 rs6598064 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:243557 chr11:243099~243483:- LUSC cis rs7104764 1 rs6598063 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:243672 chr11:243099~243483:- LUSC cis rs7104764 1 rs6598062 ENSG00000277290.1 RP11-326C3.16 -12.15 9.79e-30 4.67e-26 -0.45 -0.49 Menarche (age at onset); chr11:243712 chr11:243099~243483:- LUSC cis rs9326248 0.53 rs7114963 ENSG00000254851.1 RP11-109L13.1 -12.15 9.89e-30 4.72e-26 -0.89 -0.49 Blood protein levels; chr11:117005267 chr11:117135528~117138582:+ LUSC cis rs7115242 0.72 rs10790169 ENSG00000254851.1 RP11-109L13.1 -12.15 9.89e-30 4.72e-26 -0.89 -0.49 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117006443 chr11:117135528~117138582:+ LUSC cis rs1577917 0.959 rs16876540 ENSG00000203875.9 SNHG5 -12.15 9.95e-30 4.75e-26 -0.68 -0.49 Response to antipsychotic treatment; chr6:85902801 chr6:85660950~85678736:- LUSC cis rs73086581 0.947 rs56123574 ENSG00000229539.1 RP11-119B16.2 12.15 9.98e-30 4.76e-26 0.66 0.49 Response to antidepressants in depression; chr20:3897434 chr20:3888239~3888868:- LUSC cis rs801193 0.935 rs2659916 ENSG00000226824.5 RP4-756H11.3 -12.15 1e-29 4.77e-26 -0.57 -0.49 Aortic root size; chr7:66686365 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs6958520 ENSG00000226824.5 RP4-756H11.3 -12.15 1e-29 4.77e-26 -0.57 -0.49 Aortic root size; chr7:66686466 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs7788576 ENSG00000226824.5 RP4-756H11.3 12.15 1e-29 4.77e-26 0.57 0.49 Aortic root size; chr7:66683315 chr7:66654538~66669855:+ LUSC cis rs6782228 0.675 rs4443194 ENSG00000242551.2 POU5F1P6 -12.15 1.03e-29 4.89e-26 -0.55 -0.49 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128664603 chr3:128674735~128677005:- LUSC cis rs6782228 0.675 rs9841987 ENSG00000242551.2 POU5F1P6 -12.15 1.03e-29 4.89e-26 -0.55 -0.49 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128666299 chr3:128674735~128677005:- LUSC cis rs6782228 0.675 rs56141228 ENSG00000242551.2 POU5F1P6 -12.15 1.03e-29 4.89e-26 -0.55 -0.49 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128667199 chr3:128674735~128677005:- LUSC cis rs507080 0.922 rs582630 ENSG00000255422.1 AP002954.4 -12.15 1.04e-29 4.93e-26 -0.55 -0.49 Serum metabolite levels; chr11:118692090 chr11:118704607~118750263:+ LUSC cis rs7301826 0.651 rs7295705 ENSG00000256299.1 RP11-989F5.3 -12.14 1.05e-29 5.01e-26 -0.54 -0.49 Plasma plasminogen activator levels; chr12:130817340 chr12:130810821~130812622:- LUSC cis rs4423214 1 rs2040323 ENSG00000254682.1 RP11-660L16.2 12.14 1.06e-29 5.04e-26 0.64 0.49 Vitamin D levels; chr11:71461737 chr11:71448674~71452157:+ LUSC cis rs507080 0.922 rs4936433 ENSG00000255239.1 AP002954.6 -12.14 1.07e-29 5.08e-26 -0.58 -0.49 Serum metabolite levels; chr11:118681711 chr11:118688039~118690600:- LUSC cis rs7301826 1 rs10744482 ENSG00000256250.1 RP11-989F5.1 -12.14 1.08e-29 5.13e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130813650 chr12:130810606~130812438:+ LUSC cis rs7301826 0.966 rs4759795 ENSG00000256250.1 RP11-989F5.1 -12.14 1.08e-29 5.13e-26 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130816355 chr12:130810606~130812438:+ LUSC cis rs507080 0.961 rs607527 ENSG00000255422.1 AP002954.4 12.13 1.17e-29 5.55e-26 0.53 0.49 Serum metabolite levels; chr11:118667478 chr11:118704607~118750263:+ LUSC cis rs10129255 0.5 rs4774189 ENSG00000223648.3 IGHV3-64 12.13 1.18e-29 5.56e-26 0.4 0.49 Kawasaki disease; chr14:106768275 chr14:106643132~106658258:- LUSC cis rs801193 0.967 rs2707849 ENSG00000226824.5 RP4-756H11.3 -12.13 1.18e-29 5.59e-26 -0.57 -0.49 Aortic root size; chr7:66687725 chr7:66654538~66669855:+ LUSC cis rs801193 0.967 rs2707841 ENSG00000226824.5 RP4-756H11.3 -12.13 1.18e-29 5.59e-26 -0.57 -0.49 Aortic root size; chr7:66692033 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs4717310 ENSG00000226824.5 RP4-756H11.3 -12.13 1.18e-29 5.59e-26 -0.57 -0.49 Aortic root size; chr7:66696020 chr7:66654538~66669855:+ LUSC cis rs801193 0.844 rs7779971 ENSG00000226824.5 RP4-756H11.3 -12.13 1.18e-29 5.59e-26 -0.57 -0.49 Aortic root size; chr7:66696803 chr7:66654538~66669855:+ LUSC cis rs7301826 0.557 rs7953184 ENSG00000256299.1 RP11-989F5.3 12.13 1.25e-29 5.89e-26 0.55 0.49 Plasma plasminogen activator levels; chr12:130800307 chr12:130810821~130812622:- LUSC cis rs6782228 0.675 rs4857918 ENSG00000242551.2 POU5F1P6 -12.12 1.34e-29 6.3e-26 -0.55 -0.49 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128665117 chr3:128674735~128677005:- LUSC cis rs507080 0.885 rs7926959 ENSG00000255422.1 AP002954.4 -12.12 1.36e-29 6.39e-26 -0.54 -0.49 Serum metabolite levels; chr11:118689157 chr11:118704607~118750263:+ LUSC cis rs801193 1 rs4717319 ENSG00000226824.5 RP4-756H11.3 -12.12 1.37e-29 6.47e-26 -0.57 -0.49 Aortic root size; chr7:66777606 chr7:66654538~66669855:+ LUSC cis rs801193 0.904 rs4718403 ENSG00000226824.5 RP4-756H11.3 -12.12 1.37e-29 6.47e-26 -0.57 -0.49 Aortic root size; chr7:66777742 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs3778909 ENSG00000226824.5 RP4-756H11.3 -12.12 1.37e-29 6.47e-26 -0.57 -0.49 Aortic root size; chr7:66790659 chr7:66654538~66669855:+ LUSC cis rs507080 0.885 rs693037 ENSG00000255422.1 AP002954.4 -12.11 1.44e-29 6.78e-26 -0.54 -0.49 Serum metabolite levels; chr11:118682617 chr11:118704607~118750263:+ LUSC cis rs6782228 0.651 rs9852825 ENSG00000242551.2 POU5F1P6 -12.11 1.44e-29 6.78e-26 -0.55 -0.49 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128668514 chr3:128674735~128677005:- LUSC cis rs6782228 0.651 rs9289332 ENSG00000242551.2 POU5F1P6 -12.11 1.44e-29 6.78e-26 -0.55 -0.49 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128669041 chr3:128674735~128677005:- LUSC cis rs6782228 0.606 rs7613073 ENSG00000242551.2 POU5F1P6 -12.11 1.44e-29 6.78e-26 -0.55 -0.49 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128669660 chr3:128674735~128677005:- LUSC cis rs507080 0.922 rs508640 ENSG00000255422.1 AP002954.4 -12.11 1.45e-29 6.8e-26 -0.55 -0.49 Serum metabolite levels; chr11:118693704 chr11:118704607~118750263:+ LUSC cis rs4423214 1 rs12419334 ENSG00000254682.1 RP11-660L16.2 12.11 1.45e-29 6.8e-26 0.63 0.49 Vitamin D levels; chr11:71428426 chr11:71448674~71452157:+ LUSC cis rs9326248 0.53 rs7121347 ENSG00000254851.1 RP11-109L13.1 -12.11 1.46e-29 6.84e-26 -0.89 -0.49 Blood protein levels; chr11:116996493 chr11:117135528~117138582:+ LUSC cis rs507080 0.807 rs7926944 ENSG00000255422.1 AP002954.4 -12.1 1.53e-29 7.17e-26 -0.54 -0.49 Serum metabolite levels; chr11:118689119 chr11:118704607~118750263:+ LUSC cis rs3096299 0.658 rs3934737 ENSG00000274627.1 RP11-104N10.2 12.1 1.55e-29 7.27e-26 0.43 0.49 Multiple myeloma (IgH translocation); chr16:89493801 chr16:89516797~89522217:+ LUSC cis rs507080 0.845 rs613377 ENSG00000255422.1 AP002954.4 -12.09 1.67e-29 7.81e-26 -0.54 -0.49 Serum metabolite levels; chr11:118685375 chr11:118704607~118750263:+ LUSC cis rs73086581 1 rs14047 ENSG00000229539.1 RP11-119B16.2 12.09 1.67e-29 7.84e-26 0.64 0.49 Response to antidepressants in depression; chr20:3933568 chr20:3888239~3888868:- LUSC cis rs7104764 1 rs1128320 ENSG00000277290.1 RP11-326C3.16 -12.09 1.69e-29 7.92e-26 -0.45 -0.49 Menarche (age at onset); chr11:244167 chr11:243099~243483:- LUSC cis rs7104764 0.957 rs1128321 ENSG00000277290.1 RP11-326C3.16 -12.09 1.69e-29 7.92e-26 -0.45 -0.49 Menarche (age at onset); chr11:244171 chr11:243099~243483:- LUSC cis rs7104764 1 rs2272565 ENSG00000277290.1 RP11-326C3.16 -12.09 1.69e-29 7.92e-26 -0.45 -0.49 Menarche (age at onset); chr11:244414 chr11:243099~243483:- LUSC cis rs6700559 0.81 rs2808250 ENSG00000260088.1 RP11-92G12.3 -12.09 1.75e-29 8.18e-26 -0.58 -0.49 Coronary artery disease; chr1:200623419 chr1:200669507~200694250:+ LUSC cis rs6538678 0.746 rs4762630 ENSG00000258343.1 RP11-536G4.2 -12.09 1.75e-29 8.18e-26 -0.78 -0.49 Lupus nephritis in systemic lupus erythematosus; chr12:95850631 chr12:95795345~95858839:- LUSC cis rs507080 0.922 rs471227 ENSG00000255422.1 AP002954.4 -12.09 1.76e-29 8.19e-26 -0.55 -0.49 Serum metabolite levels; chr11:118693892 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs516153 ENSG00000255422.1 AP002954.4 -12.09 1.76e-29 8.19e-26 -0.55 -0.49 Serum metabolite levels; chr11:118694053 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs518028 ENSG00000255422.1 AP002954.4 -12.09 1.76e-29 8.19e-26 -0.55 -0.49 Serum metabolite levels; chr11:118694273 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs519982 ENSG00000255422.1 AP002954.4 -12.09 1.76e-29 8.19e-26 -0.55 -0.49 Serum metabolite levels; chr11:118694522 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs478371 ENSG00000255422.1 AP002954.4 -12.09 1.76e-29 8.19e-26 -0.55 -0.49 Serum metabolite levels; chr11:118694627 chr11:118704607~118750263:+ LUSC cis rs801193 0.761 rs2659888 ENSG00000226824.5 RP4-756H11.3 -12.09 1.78e-29 8.29e-26 -0.57 -0.49 Aortic root size; chr7:66765184 chr7:66654538~66669855:+ LUSC cis rs1799949 0.93 rs35292991 ENSG00000198496.9 NBR2 -12.09 1.79e-29 8.36e-26 -0.54 -0.49 Menopause (age at onset); chr17:43181999 chr17:43125610~43153671:+ LUSC cis rs2906856 0.526 rs2906852 ENSG00000255733.4 IFNG-AS1 12.08 1.96e-29 9.11e-26 0.47 0.49 Mosquito bite size; chr12:67985701 chr12:67989445~68234686:+ LUSC cis rs7104764 0.957 rs3817629 ENSG00000277290.1 RP11-326C3.16 -12.08 1.99e-29 9.25e-26 -0.45 -0.49 Menarche (age at onset); chr11:237312 chr11:243099~243483:- LUSC cis rs507080 0.922 rs546890 ENSG00000255422.1 AP002954.4 -12.07 2e-29 9.28e-26 -0.54 -0.49 Serum metabolite levels; chr11:118686489 chr11:118704607~118750263:+ LUSC cis rs507080 0.883 rs693306 ENSG00000255422.1 AP002954.4 -12.07 2e-29 9.28e-26 -0.54 -0.49 Serum metabolite levels; chr11:118687624 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs561845 ENSG00000255422.1 AP002954.4 -12.07 2e-29 9.28e-26 -0.54 -0.49 Serum metabolite levels; chr11:118688118 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs638805 ENSG00000255422.1 AP002954.4 -12.07 2e-29 9.28e-26 -0.54 -0.49 Serum metabolite levels; chr11:118688180 chr11:118704607~118750263:+ LUSC cis rs507080 0.845 rs510408 ENSG00000255422.1 AP002954.4 -12.07 2e-29 9.28e-26 -0.54 -0.49 Serum metabolite levels; chr11:118688192 chr11:118704607~118750263:+ LUSC cis rs507080 0.845 rs509641 ENSG00000255422.1 AP002954.4 -12.07 2e-29 9.28e-26 -0.54 -0.49 Serum metabolite levels; chr11:118688243 chr11:118704607~118750263:+ LUSC cis rs507080 0.883 rs563549 ENSG00000255422.1 AP002954.4 -12.07 2e-29 9.28e-26 -0.54 -0.49 Serum metabolite levels; chr11:118688244 chr11:118704607~118750263:+ LUSC cis rs507080 0.885 rs533144 ENSG00000255422.1 AP002954.4 -12.07 2e-29 9.28e-26 -0.54 -0.49 Serum metabolite levels; chr11:118688538 chr11:118704607~118750263:+ LUSC cis rs801193 1 rs2707836 ENSG00000226824.5 RP4-756H11.3 -12.07 2.05e-29 9.53e-26 -0.57 -0.49 Aortic root size; chr7:66695448 chr7:66654538~66669855:+ LUSC cis rs11155671 0.53 rs9383912 ENSG00000216906.2 RP11-350J20.9 12.07 2.1e-29 9.75e-26 0.56 0.49 Testicular germ cell tumor; chr6:149885479 chr6:149904243~149906418:+ LUSC cis rs3091242 1 rs3091242 ENSG00000261349.1 RP3-465N24.5 -12.07 2.12e-29 9.83e-26 -0.6 -0.49 Erythrocyte sedimentation rate; chr1:25348294 chr1:25266102~25267136:- LUSC cis rs1799949 1 rs8176126 ENSG00000198496.9 NBR2 12.06 2.23e-29 1.03e-25 0.55 0.49 Menopause (age at onset); chr17:43107032 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs11650132 ENSG00000198496.9 NBR2 -12.06 2.26e-29 1.04e-25 -0.54 -0.49 Menopause (age at onset); chr17:43174070 chr17:43125610~43153671:+ LUSC cis rs507080 0.922 rs558907 ENSG00000255422.1 AP002954.4 -12.06 2.29e-29 1.06e-25 -0.54 -0.49 Serum metabolite levels; chr11:118687746 chr11:118704607~118750263:+ LUSC cis rs507080 0.663 rs7926970 ENSG00000255422.1 AP002954.4 -12.06 2.29e-29 1.06e-25 -0.54 -0.49 Serum metabolite levels; chr11:118689172 chr11:118704607~118750263:+ LUSC cis rs507080 0.885 rs4938530 ENSG00000255422.1 AP002954.4 -12.06 2.29e-29 1.06e-25 -0.54 -0.49 Serum metabolite levels; chr11:118689861 chr11:118704607~118750263:+ LUSC cis rs12594515 1 rs8027000 ENSG00000273972.1 CTD-2306A12.1 -12.06 2.32e-29 1.07e-25 -0.56 -0.49 Weight;Waist circumference; chr15:45695597 chr15:45702640~45703183:+ LUSC cis rs3096299 0.685 rs4329923 ENSG00000274627.1 RP11-104N10.2 12.06 2.38e-29 1.1e-25 0.44 0.49 Multiple myeloma (IgH translocation); chr16:89493770 chr16:89516797~89522217:+ LUSC cis rs7301826 0.571 rs4759788 ENSG00000256299.1 RP11-989F5.3 -12.05 2.4e-29 1.11e-25 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130811769 chr12:130810821~130812622:- LUSC cis rs801193 1 rs2003301 ENSG00000226824.5 RP4-756H11.3 12.05 2.55e-29 1.17e-25 0.57 0.49 Aortic root size; chr7:66682669 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs2027902 ENSG00000223648.3 IGHV3-64 12.04 2.64e-29 1.22e-25 0.4 0.49 Kawasaki disease; chr14:106807157 chr14:106643132~106658258:- LUSC cis rs1185460 0.967 rs1784460 ENSG00000271751.1 RP11-110I1.14 12.04 2.65e-29 1.22e-25 0.6 0.49 Coronary artery disease; chr11:119067660 chr11:119065263~119065677:- LUSC cis rs3096299 0.685 rs3803682 ENSG00000274627.1 RP11-104N10.2 12.04 2.73e-29 1.26e-25 0.43 0.49 Multiple myeloma (IgH translocation); chr16:89478228 chr16:89516797~89522217:+ LUSC cis rs3096299 0.685 rs3803681 ENSG00000274627.1 RP11-104N10.2 12.04 2.73e-29 1.26e-25 0.43 0.49 Multiple myeloma (IgH translocation); chr16:89478348 chr16:89516797~89522217:+ LUSC cis rs4423214 1 rs2276362 ENSG00000254682.1 RP11-660L16.2 12.04 2.73e-29 1.26e-25 0.63 0.49 Vitamin D levels; chr11:71463406 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs2276361 ENSG00000254682.1 RP11-660L16.2 12.04 2.8e-29 1.29e-25 0.63 0.49 Vitamin D levels; chr11:71458602 chr11:71448674~71452157:+ LUSC cis rs2283792 0.718 rs239918 ENSG00000228050.1 TOP3BP1 12.04 2.87e-29 1.32e-25 0.56 0.49 Multiple sclerosis; chr22:21959457 chr22:22223187~22224566:- LUSC cis rs12594515 1 rs8025258 ENSG00000273972.1 CTD-2306A12.1 -12.03 2.91e-29 1.34e-25 -0.57 -0.49 Weight;Waist circumference; chr15:45695356 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs57299255 ENSG00000273972.1 CTD-2306A12.1 -12.03 3.13e-29 1.44e-25 -0.57 -0.49 Weight;Waist circumference; chr15:45704334 chr15:45702640~45703183:+ LUSC cis rs507080 0.922 rs555356 ENSG00000255422.1 AP002954.4 -12.02 3.2e-29 1.47e-25 -0.54 -0.49 Serum metabolite levels; chr11:118687369 chr11:118704607~118750263:+ LUSC cis rs6538678 0.824 rs2887026 ENSG00000258343.1 RP11-536G4.2 -12.02 3.2e-29 1.47e-25 -0.77 -0.49 Lupus nephritis in systemic lupus erythematosus; chr12:95854713 chr12:95795345~95858839:- LUSC cis rs6538678 0.824 rs4762631 ENSG00000258343.1 RP11-536G4.2 -12.02 3.2e-29 1.47e-25 -0.77 -0.49 Lupus nephritis in systemic lupus erythematosus; chr12:95855698 chr12:95795345~95858839:- LUSC cis rs12594515 1 rs8026221 ENSG00000273972.1 CTD-2306A12.1 -12.02 3.26e-29 1.49e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45695712 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs8031128 ENSG00000273972.1 CTD-2306A12.1 -12.02 3.26e-29 1.49e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45696330 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs8032361 ENSG00000273972.1 CTD-2306A12.1 -12.02 3.26e-29 1.49e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45696355 chr15:45702640~45703183:+ LUSC cis rs12594515 0.967 rs71405295 ENSG00000273972.1 CTD-2306A12.1 -12.02 3.26e-29 1.49e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45696723 chr15:45702640~45703183:+ LUSC cis rs73086581 0.891 rs11907503 ENSG00000229539.1 RP11-119B16.2 12.02 3.27e-29 1.5e-25 0.64 0.48 Response to antidepressants in depression; chr20:3906943 chr20:3888239~3888868:- LUSC cis rs4423214 1 rs909217 ENSG00000254682.1 RP11-660L16.2 12.02 3.28e-29 1.5e-25 0.63 0.48 Vitamin D levels; chr11:71435531 chr11:71448674~71452157:+ LUSC cis rs6538678 0.746 rs1865736 ENSG00000258343.1 RP11-536G4.2 -12.02 3.31e-29 1.51e-25 -0.78 -0.48 Lupus nephritis in systemic lupus erythematosus; chr12:95854051 chr12:95795345~95858839:- LUSC cis rs801193 0.967 rs34356500 ENSG00000226824.5 RP4-756H11.3 -12.02 3.31e-29 1.52e-25 -0.58 -0.48 Aortic root size; chr7:66771620 chr7:66654538~66669855:+ LUSC cis rs12594515 0.506 rs74199860 ENSG00000273972.1 CTD-2306A12.1 -12.02 3.31e-29 1.52e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45696992 chr15:45702640~45703183:+ LUSC cis rs1799949 1 rs8176120 ENSG00000198496.9 NBR2 -12.02 3.36e-29 1.54e-25 -0.54 -0.48 Menopause (age at onset); chr17:43109216 chr17:43125610~43153671:+ LUSC cis rs801193 1 rs13239306 ENSG00000226824.5 RP4-756H11.3 12.02 3.37e-29 1.54e-25 0.57 0.48 Aortic root size; chr7:66671030 chr7:66654538~66669855:+ LUSC cis rs7104764 1 rs6598061 ENSG00000277290.1 RP11-326C3.16 -12.02 3.4e-29 1.56e-25 -0.44 -0.48 Menarche (age at onset); chr11:243853 chr11:243099~243483:- LUSC cis rs3091242 0.967 rs3091240 ENSG00000261349.1 RP3-465N24.5 -12.01 3.5e-29 1.6e-25 -0.6 -0.48 Erythrocyte sedimentation rate; chr1:25350444 chr1:25266102~25267136:- LUSC cis rs7301826 0.61 rs4759789 ENSG00000256299.1 RP11-989F5.3 -12.01 3.55e-29 1.62e-25 -0.54 -0.48 Plasma plasminogen activator levels; chr12:130811835 chr12:130810821~130812622:- LUSC cis rs507080 0.922 rs625513 ENSG00000255422.1 AP002954.4 -12.01 3.58e-29 1.63e-25 -0.54 -0.48 Serum metabolite levels; chr11:118685010 chr11:118704607~118750263:+ LUSC cis rs875971 0.638 rs7793569 ENSG00000226824.5 RP4-756H11.3 12.01 3.59e-29 1.64e-25 0.56 0.48 Aortic root size; chr7:66651646 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs6975195 ENSG00000226824.5 RP4-756H11.3 12.01 3.59e-29 1.64e-25 0.56 0.48 Aortic root size; chr7:66659787 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs3857688 ENSG00000226824.5 RP4-756H11.3 12.01 3.59e-29 1.64e-25 0.56 0.48 Aortic root size; chr7:66662819 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs2286684 ENSG00000226824.5 RP4-756H11.3 12.01 3.59e-29 1.64e-25 0.56 0.48 Aortic root size; chr7:66664843 chr7:66654538~66669855:+ LUSC cis rs801193 0.935 rs2286683 ENSG00000226824.5 RP4-756H11.3 12.01 3.59e-29 1.64e-25 0.56 0.48 Aortic root size; chr7:66664856 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs10274773 ENSG00000226824.5 RP4-756H11.3 12.01 3.59e-29 1.64e-25 0.56 0.48 Aortic root size; chr7:66668591 chr7:66654538~66669855:+ LUSC cis rs7301826 0.627 rs4325342 ENSG00000256299.1 RP11-989F5.3 -12.01 3.63e-29 1.65e-25 -0.54 -0.48 Plasma plasminogen activator levels; chr12:130827937 chr12:130810821~130812622:- LUSC cis rs507080 0.883 rs692750 ENSG00000255422.1 AP002954.4 -12.01 3.65e-29 1.66e-25 -0.54 -0.48 Serum metabolite levels; chr11:118667599 chr11:118704607~118750263:+ LUSC cis rs1799949 1 rs11653231 ENSG00000198496.9 NBR2 -12.01 3.67e-29 1.67e-25 -0.53 -0.48 Menopause (age at onset); chr17:43179443 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs1399323 ENSG00000198496.9 NBR2 -12.01 3.67e-29 1.67e-25 -0.53 -0.48 Menopause (age at onset); chr17:43180313 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs35954893 ENSG00000198496.9 NBR2 -12.01 3.67e-29 1.67e-25 -0.53 -0.48 Menopause (age at onset); chr17:43181769 chr17:43125610~43153671:+ LUSC cis rs1799949 0.896 rs35908185 ENSG00000198496.9 NBR2 -12.01 3.8e-29 1.73e-25 -0.54 -0.48 Menopause (age at onset); chr17:43103094 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs8176130 ENSG00000198496.9 NBR2 -12.01 3.8e-29 1.73e-25 -0.54 -0.48 Menopause (age at onset); chr17:43106026 chr17:43125610~43153671:+ LUSC cis rs507080 0.922 rs558781 ENSG00000255422.1 AP002954.4 -12 3.82e-29 1.74e-25 -0.55 -0.48 Serum metabolite levels; chr11:118693688 chr11:118704607~118750263:+ LUSC cis rs7104764 1 rs6598074 ENSG00000277290.1 RP11-326C3.16 -12 3.83e-29 1.74e-25 -0.45 -0.48 Menarche (age at onset); chr11:219398 chr11:243099~243483:- LUSC cis rs1799949 1 rs12936831 ENSG00000198496.9 NBR2 -12 3.94e-29 1.79e-25 -0.53 -0.48 Menopause (age at onset); chr17:43179799 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs11658499 ENSG00000198496.9 NBR2 -12 3.94e-29 1.79e-25 -0.53 -0.48 Menopause (age at onset); chr17:43182732 chr17:43125610~43153671:+ LUSC cis rs9322193 0.504 rs7771014 ENSG00000216906.2 RP11-350J20.9 12 4.01e-29 1.82e-25 0.56 0.48 Lung cancer; chr6:149884310 chr6:149904243~149906418:+ LUSC cis rs1799949 1 rs67060599 ENSG00000198496.9 NBR2 -12 4.04e-29 1.83e-25 -0.54 -0.48 Menopause (age at onset); chr17:43103085 chr17:43125610~43153671:+ LUSC cis rs12594515 1 rs56220882 ENSG00000273972.1 CTD-2306A12.1 -11.99 4.2e-29 1.91e-25 -0.57 -0.48 Weight;Waist circumference; chr15:45704877 chr15:45702640~45703183:+ LUSC cis rs3096299 0.658 rs12443705 ENSG00000274627.1 RP11-104N10.2 11.99 4.22e-29 1.91e-25 0.43 0.48 Multiple myeloma (IgH translocation); chr16:89480646 chr16:89516797~89522217:+ LUSC cis rs55726902 0.506 rs1006476 ENSG00000276691.1 RP5-1057I20.5 11.99 4.23e-29 1.92e-25 0.64 0.48 Allergic disease (asthma, hay fever or eczema); chr12:47785564 chr12:47788426~47788971:+ LUSC cis rs1799949 0.93 rs4445938 ENSG00000198496.9 NBR2 -11.99 4.26e-29 1.93e-25 -0.53 -0.48 Menopause (age at onset); chr17:43185883 chr17:43125610~43153671:+ LUSC cis rs7301826 0.651 rs4514465 ENSG00000256299.1 RP11-989F5.3 -11.99 4.32e-29 1.95e-25 -0.54 -0.48 Plasma plasminogen activator levels; chr12:130829124 chr12:130810821~130812622:- LUSC cis rs1799949 0.896 rs8176098 ENSG00000198496.9 NBR2 -11.99 4.34e-29 1.97e-25 -0.54 -0.48 Menopause (age at onset); chr17:43116189 chr17:43125610~43153671:+ LUSC cis rs7301826 0.651 rs7968675 ENSG00000256299.1 RP11-989F5.3 -11.99 4.35e-29 1.97e-25 -0.54 -0.48 Plasma plasminogen activator levels; chr12:130818832 chr12:130810821~130812622:- LUSC cis rs7104764 1 rs10902112 ENSG00000277290.1 RP11-326C3.16 -11.99 4.43e-29 2e-25 -0.44 -0.48 Menarche (age at onset); chr11:244106 chr11:243099~243483:- LUSC cis rs7104764 0.917 rs7107362 ENSG00000277290.1 RP11-326C3.16 -11.99 4.43e-29 2e-25 -0.44 -0.48 Menarche (age at onset); chr11:244108 chr11:243099~243483:- LUSC cis rs7104764 1 rs7128044 ENSG00000277290.1 RP11-326C3.16 -11.99 4.43e-29 2e-25 -0.44 -0.48 Menarche (age at onset); chr11:244115 chr11:243099~243483:- LUSC cis rs7104764 0.957 rs7116130 ENSG00000277290.1 RP11-326C3.16 -11.99 4.43e-29 2e-25 -0.44 -0.48 Menarche (age at onset); chr11:244129 chr11:243099~243483:- LUSC cis rs7104764 1 rs7128029 ENSG00000277290.1 RP11-326C3.16 -11.99 4.43e-29 2e-25 -0.44 -0.48 Menarche (age at onset); chr11:244141 chr11:243099~243483:- LUSC cis rs2739330 0.828 rs5760108 ENSG00000250470.1 AP000351.3 11.99 4.48e-29 2.02e-25 0.66 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23976904~23977585:- LUSC cis rs7535099 1 rs7524458 ENSG00000224570.1 RP11-430H12.2 -11.98 4.6e-29 2.08e-25 -0.69 -0.48 Blood protein levels; chr1:65585217 chr1:65576129~65578380:- LUSC cis rs7535099 1 rs7535099 ENSG00000224570.1 RP11-430H12.2 -11.98 4.6e-29 2.08e-25 -0.69 -0.48 Blood protein levels; chr1:65585314 chr1:65576129~65578380:- LUSC cis rs1799949 0.965 rs11656945 ENSG00000198496.9 NBR2 -11.98 4.77e-29 2.15e-25 -0.53 -0.48 Menopause (age at onset); chr17:43178248 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs8176133 ENSG00000198496.9 NBR2 -11.98 4.77e-29 2.15e-25 -0.54 -0.48 Menopause (age at onset); chr17:43105441 chr17:43125610~43153671:+ LUSC cis rs12594515 1 rs7162201 ENSG00000273972.1 CTD-2306A12.1 -11.98 4.85e-29 2.18e-25 -0.57 -0.48 Weight;Waist circumference; chr15:45700460 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs6493172 ENSG00000273972.1 CTD-2306A12.1 -11.98 4.88e-29 2.2e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45695015 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs6493167 ENSG00000273972.1 CTD-2306A12.1 -11.98 4.93e-29 2.22e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45694611 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs6493170 ENSG00000273972.1 CTD-2306A12.1 -11.98 4.93e-29 2.22e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45694821 chr15:45702640~45703183:+ LUSC cis rs801193 1 rs2659889 ENSG00000226824.5 RP4-756H11.3 -11.98 4.96e-29 2.23e-25 -0.56 -0.48 Aortic root size; chr7:66752125 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs3800812 ENSG00000226824.5 RP4-756H11.3 -11.98 4.96e-29 2.23e-25 -0.56 -0.48 Aortic root size; chr7:66758474 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs4279493 ENSG00000226824.5 RP4-756H11.3 -11.98 4.96e-29 2.23e-25 -0.56 -0.48 Aortic root size; chr7:66761633 chr7:66654538~66669855:+ LUSC cis rs1799949 1 rs8176109 ENSG00000198496.9 NBR2 -11.97 5.28e-29 2.37e-25 -0.54 -0.48 Menopause (age at onset); chr17:43113759 chr17:43125610~43153671:+ LUSC cis rs11155671 0.53 rs4870080 ENSG00000216906.2 RP11-350J20.9 11.97 5.34e-29 2.4e-25 0.56 0.48 Testicular germ cell tumor; chr6:149881508 chr6:149904243~149906418:+ LUSC cis rs6700559 0.81 rs2808248 ENSG00000260088.1 RP11-92G12.3 11.96 5.53e-29 2.48e-25 0.58 0.48 Coronary artery disease; chr1:200623147 chr1:200669507~200694250:+ LUSC cis rs6538678 0.824 rs7299632 ENSG00000258343.1 RP11-536G4.2 -11.96 5.57e-29 2.5e-25 -0.77 -0.48 Lupus nephritis in systemic lupus erythematosus; chr12:95838376 chr12:95795345~95858839:- LUSC cis rs1799949 1 rs8074136 ENSG00000198496.9 NBR2 -11.96 5.66e-29 2.54e-25 -0.53 -0.48 Menopause (age at onset); chr17:43190296 chr17:43125610~43153671:+ LUSC cis rs7617773 0.78 rs35411187 ENSG00000229759.1 MRPS18AP1 11.96 5.73e-29 2.57e-25 0.5 0.48 Coronary artery disease; chr3:48318527 chr3:48256350~48256938:- LUSC cis rs7617773 0.78 rs11714176 ENSG00000229759.1 MRPS18AP1 11.96 5.73e-29 2.57e-25 0.5 0.48 Coronary artery disease; chr3:48319372 chr3:48256350~48256938:- LUSC cis rs1799949 1 rs2271574 ENSG00000198496.9 NBR2 -11.96 5.74e-29 2.57e-25 -0.53 -0.48 Menopause (age at onset); chr17:43175631 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs33994002 ENSG00000198496.9 NBR2 -11.96 5.74e-29 2.57e-25 -0.53 -0.48 Menopause (age at onset); chr17:43176801 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs33920795 ENSG00000198496.9 NBR2 -11.96 5.74e-29 2.57e-25 -0.53 -0.48 Menopause (age at onset); chr17:43176993 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs33918839 ENSG00000198496.9 NBR2 -11.96 5.74e-29 2.57e-25 -0.53 -0.48 Menopause (age at onset); chr17:43177155 chr17:43125610~43153671:+ LUSC cis rs7301826 0.651 rs10848210 ENSG00000256299.1 RP11-989F5.3 -11.96 5.79e-29 2.59e-25 -0.54 -0.48 Plasma plasminogen activator levels; chr12:130827475 chr12:130810821~130812622:- LUSC cis rs55794721 0.543 rs1293260 ENSG00000261349.1 RP3-465N24.5 -11.96 5.83e-29 2.61e-25 -0.59 -0.48 Mean corpuscular volume;Plateletcrit; chr1:25382613 chr1:25266102~25267136:- LUSC cis rs9326248 0.53 rs6589576 ENSG00000254851.1 RP11-109L13.1 11.96 5.93e-29 2.65e-25 0.84 0.48 Blood protein levels; chr11:116865072 chr11:117135528~117138582:+ LUSC cis rs3096299 0.658 rs4291902 ENSG00000274627.1 RP11-104N10.2 11.96 5.99e-29 2.68e-25 0.42 0.48 Multiple myeloma (IgH translocation); chr16:89493907 chr16:89516797~89522217:+ LUSC cis rs507080 0.922 rs514143 ENSG00000255422.1 AP002954.4 -11.95 6.07e-29 2.71e-25 -0.54 -0.48 Serum metabolite levels; chr11:118687740 chr11:118704607~118750263:+ LUSC cis rs1799949 1 rs2037075 ENSG00000198496.9 NBR2 -11.95 6.12e-29 2.73e-25 -0.53 -0.48 Menopause (age at onset); chr17:43153809 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11654731 ENSG00000198496.9 NBR2 -11.95 6.22e-29 2.78e-25 -0.53 -0.48 Menopause (age at onset); chr17:43174923 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs11651623 ENSG00000198496.9 NBR2 -11.95 6.22e-29 2.78e-25 -0.53 -0.48 Menopause (age at onset); chr17:43177830 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs11657883 ENSG00000198496.9 NBR2 -11.95 6.22e-29 2.78e-25 -0.53 -0.48 Menopause (age at onset); chr17:43178007 chr17:43125610~43153671:+ LUSC cis rs11155671 0.53 rs4869763 ENSG00000216906.2 RP11-350J20.9 11.95 6.25e-29 2.79e-25 0.56 0.48 Testicular germ cell tumor; chr6:149890548 chr6:149904243~149906418:+ LUSC cis rs3091242 0.935 rs3093632 ENSG00000261349.1 RP3-465N24.5 -11.95 6.26e-29 2.79e-25 -0.59 -0.48 Erythrocyte sedimentation rate; chr1:25357521 chr1:25266102~25267136:- LUSC cis rs4423214 1 rs1981412 ENSG00000254682.1 RP11-660L16.2 11.95 6.31e-29 2.81e-25 0.62 0.48 Vitamin D levels; chr11:71427664 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs12419279 ENSG00000254682.1 RP11-660L16.2 11.95 6.31e-29 2.81e-25 0.62 0.48 Vitamin D levels; chr11:71428015 chr11:71448674~71452157:+ LUSC cis rs2739330 0.828 rs2154593 ENSG00000250470.1 AP000351.3 11.95 6.35e-29 2.83e-25 0.66 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23976904~23977585:- LUSC cis rs2739330 0.791 rs4822458 ENSG00000231271.1 AP000350.8 11.95 6.45e-29 2.88e-25 0.6 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23949918~23954042:+ LUSC cis rs1799949 0.965 rs35521261 ENSG00000198496.9 NBR2 -11.95 6.49e-29 2.89e-25 -0.53 -0.48 Menopause (age at onset); chr17:43161595 chr17:43125610~43153671:+ LUSC cis rs11155671 0.53 rs9322228 ENSG00000216906.2 RP11-350J20.9 11.94 6.99e-29 3.11e-25 0.56 0.48 Testicular germ cell tumor; chr6:149888173 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs2342767 ENSG00000216906.2 RP11-350J20.9 11.94 6.99e-29 3.11e-25 0.56 0.48 Testicular germ cell tumor; chr6:149888581 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs7764376 ENSG00000216906.2 RP11-350J20.9 11.94 6.99e-29 3.11e-25 0.56 0.48 Testicular germ cell tumor; chr6:149889208 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs6933882 ENSG00000216906.2 RP11-350J20.9 11.94 6.99e-29 3.11e-25 0.56 0.48 Testicular germ cell tumor; chr6:149889666 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs6939761 ENSG00000216906.2 RP11-350J20.9 11.94 6.99e-29 3.11e-25 0.56 0.48 Testicular germ cell tumor; chr6:149889858 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs3823021 ENSG00000216906.2 RP11-350J20.9 11.94 6.99e-29 3.11e-25 0.56 0.48 Testicular germ cell tumor; chr6:149889863 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs4869764 ENSG00000216906.2 RP11-350J20.9 11.94 6.99e-29 3.11e-25 0.56 0.48 Testicular germ cell tumor; chr6:149890692 chr6:149904243~149906418:+ LUSC cis rs12594515 1 rs6493175 ENSG00000273972.1 CTD-2306A12.1 -11.94 7.01e-29 3.11e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45697700 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs6493176 ENSG00000273972.1 CTD-2306A12.1 -11.94 7.01e-29 3.11e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45697828 chr15:45702640~45703183:+ LUSC cis rs12594515 0.967 rs8039088 ENSG00000273972.1 CTD-2306A12.1 -11.94 7.01e-29 3.11e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45697980 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs8038320 ENSG00000273972.1 CTD-2306A12.1 -11.94 7.01e-29 3.11e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45698069 chr15:45702640~45703183:+ LUSC cis rs12594515 0.967 rs67854274 ENSG00000273972.1 CTD-2306A12.1 -11.94 7.01e-29 3.11e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45698320 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs58368732 ENSG00000273972.1 CTD-2306A12.1 -11.94 7.01e-29 3.11e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45698333 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs7172161 ENSG00000273972.1 CTD-2306A12.1 -11.94 7.01e-29 3.11e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45698582 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs7173144 ENSG00000273972.1 CTD-2306A12.1 -11.94 7.01e-29 3.11e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45698998 chr15:45702640~45703183:+ LUSC cis rs2739330 0.828 rs2877178 ENSG00000250470.1 AP000351.3 11.93 7.35e-29 3.26e-25 0.66 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23976904~23977585:- LUSC cis rs11155671 0.53 rs9383577 ENSG00000216906.2 RP11-350J20.9 11.93 7.91e-29 3.5e-25 0.56 0.48 Testicular germ cell tumor; chr6:149886059 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs9383914 ENSG00000216906.2 RP11-350J20.9 11.93 7.91e-29 3.5e-25 0.56 0.48 Testicular germ cell tumor; chr6:149886098 chr6:149904243~149906418:+ LUSC cis rs11155671 0.517 rs9397058 ENSG00000216906.2 RP11-350J20.9 11.93 7.91e-29 3.5e-25 0.56 0.48 Testicular germ cell tumor; chr6:149886113 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs7768626 ENSG00000216906.2 RP11-350J20.9 11.93 7.91e-29 3.5e-25 0.56 0.48 Testicular germ cell tumor; chr6:149886826 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs7768665 ENSG00000216906.2 RP11-350J20.9 11.93 7.91e-29 3.5e-25 0.56 0.48 Testicular germ cell tumor; chr6:149886888 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs7758020 ENSG00000216906.2 RP11-350J20.9 11.93 7.91e-29 3.5e-25 0.56 0.48 Testicular germ cell tumor; chr6:149886975 chr6:149904243~149906418:+ LUSC cis rs801193 0.967 rs2707853 ENSG00000226824.5 RP4-756H11.3 -11.93 7.95e-29 3.52e-25 -0.56 -0.48 Aortic root size; chr7:66749023 chr7:66654538~66669855:+ LUSC cis rs875971 0.706 rs1643374 ENSG00000226824.5 RP4-756H11.3 -11.92 7.99e-29 3.53e-25 -0.57 -0.48 Aortic root size; chr7:66407695 chr7:66654538~66669855:+ LUSC cis rs7104764 1 rs1128322 ENSG00000277290.1 RP11-326C3.16 11.92 8.66e-29 3.82e-25 0.44 0.48 Menarche (age at onset); chr11:244197 chr11:243099~243483:- LUSC cis rs507080 0.733 rs673547 ENSG00000255239.1 AP002954.6 11.91 8.86e-29 3.91e-25 0.56 0.48 Serum metabolite levels; chr11:118702630 chr11:118688039~118690600:- LUSC cis rs801193 1 rs2659906 ENSG00000226824.5 RP4-756H11.3 -11.91 8.87e-29 3.91e-25 -0.56 -0.48 Aortic root size; chr7:66700323 chr7:66654538~66669855:+ LUSC cis rs875971 0.628 rs6974355 ENSG00000226824.5 RP4-756H11.3 -11.91 8.87e-29 3.91e-25 -0.57 -0.48 Aortic root size; chr7:66376994 chr7:66654538~66669855:+ LUSC cis rs7535099 0.954 rs6588152 ENSG00000224570.1 RP11-430H12.2 -11.91 8.92e-29 3.93e-25 -0.69 -0.48 Blood protein levels; chr1:65573315 chr1:65576129~65578380:- LUSC cis rs1799949 1 rs16941 ENSG00000198496.9 NBR2 -11.91 8.97e-29 3.95e-25 -0.53 -0.48 Menopause (age at onset); chr17:43092418 chr17:43125610~43153671:+ LUSC cis rs801193 0.935 rs2659899 ENSG00000226824.5 RP4-756H11.3 -11.91 9.09e-29 4e-25 -0.56 -0.48 Aortic root size; chr7:66721734 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs1553609 ENSG00000226824.5 RP4-756H11.3 -11.91 9.09e-29 4e-25 -0.56 -0.48 Aortic root size; chr7:66732152 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs1553610 ENSG00000226824.5 RP4-756H11.3 -11.91 9.09e-29 4e-25 -0.56 -0.48 Aortic root size; chr7:66732246 chr7:66654538~66669855:+ LUSC cis rs12594515 1 rs8029209 ENSG00000273972.1 CTD-2306A12.1 -11.91 9.14e-29 4.02e-25 -0.57 -0.48 Weight;Waist circumference; chr15:45701291 chr15:45702640~45703183:+ LUSC cis rs7535099 0.954 rs6678948 ENSG00000224570.1 RP11-430H12.2 -11.91 9.25e-29 4.06e-25 -0.69 -0.48 Blood protein levels; chr1:65571906 chr1:65576129~65578380:- LUSC cis rs11155671 0.53 rs7774787 ENSG00000216906.2 RP11-350J20.9 11.91 9.32e-29 4.09e-25 0.56 0.48 Testicular germ cell tumor; chr6:149888296 chr6:149904243~149906418:+ LUSC cis rs801193 1 rs2707845 ENSG00000226824.5 RP4-756H11.3 -11.91 9.37e-29 4.11e-25 -0.56 -0.48 Aortic root size; chr7:66733811 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs2707850 ENSG00000226824.5 RP4-756H11.3 -11.91 9.37e-29 4.11e-25 -0.56 -0.48 Aortic root size; chr7:66738883 chr7:66654538~66669855:+ LUSC cis rs801193 0.967 rs1110414 ENSG00000226824.5 RP4-756H11.3 -11.91 9.37e-29 4.11e-25 -0.56 -0.48 Aortic root size; chr7:66740595 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs7783924 ENSG00000226824.5 RP4-756H11.3 -11.91 9.37e-29 4.11e-25 -0.56 -0.48 Aortic root size; chr7:66744070 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs7789184 ENSG00000226824.5 RP4-756H11.3 -11.91 9.37e-29 4.11e-25 -0.56 -0.48 Aortic root size; chr7:66745208 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs2707854 ENSG00000226824.5 RP4-756H11.3 -11.91 9.37e-29 4.11e-25 -0.56 -0.48 Aortic root size; chr7:66747610 chr7:66654538~66669855:+ LUSC cis rs1799949 1 rs33946455 ENSG00000198496.9 NBR2 -11.91 9.38e-29 4.11e-25 -0.53 -0.48 Menopause (age at onset); chr17:43169829 chr17:43125610~43153671:+ LUSC cis rs1150668 0.835 rs1233696 ENSG00000216901.1 AL022393.7 11.91 9.5e-29 4.16e-25 0.53 0.48 Pubertal anthropometrics; chr6:28175232 chr6:28176188~28176674:+ LUSC cis rs801193 1 rs2659915 ENSG00000226824.5 RP4-756H11.3 -11.91 9.58e-29 4.2e-25 -0.56 -0.48 Aortic root size; chr7:66688114 chr7:66654538~66669855:+ LUSC cis rs12594515 1 rs6493168 ENSG00000273972.1 CTD-2306A12.1 -11.9 9.67e-29 4.23e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45694613 chr15:45702640~45703183:+ LUSC cis rs7535099 0.954 rs10889562 ENSG00000224570.1 RP11-430H12.2 -11.9 9.71e-29 4.25e-25 -0.67 -0.48 Blood protein levels; chr1:65564762 chr1:65576129~65578380:- LUSC cis rs4423214 0.921 rs11603330 ENSG00000254682.1 RP11-660L16.2 11.9 1.01e-28 4.42e-25 0.61 0.48 Vitamin D levels; chr11:71442413 chr11:71448674~71452157:+ LUSC cis rs17507216 0.958 rs72751643 ENSG00000278603.1 RP13-608F4.5 11.9 1.02e-28 4.48e-25 0.68 0.48 Excessive daytime sleepiness; chr15:82559444 chr15:82472203~82472426:+ LUSC cis rs507080 0.733 rs552079 ENSG00000255239.1 AP002954.6 11.9 1.04e-28 4.53e-25 0.56 0.48 Serum metabolite levels; chr11:118702313 chr11:118688039~118690600:- LUSC cis rs6700559 0.967 rs10919992 ENSG00000260088.1 RP11-92G12.3 -11.9 1.05e-28 4.57e-25 -0.61 -0.48 Coronary artery disease; chr1:200638338 chr1:200669507~200694250:+ LUSC cis rs7301826 0.934 rs10848212 ENSG00000256250.1 RP11-989F5.1 11.9 1.05e-28 4.58e-25 0.53 0.48 Plasma plasminogen activator levels; chr12:130837455 chr12:130810606~130812438:+ LUSC cis rs9322193 0.607 rs9322229 ENSG00000231760.4 RP11-350J20.5 11.89 1.06e-28 4.61e-25 0.68 0.48 Lung cancer; chr6:149908949 chr6:149796151~149826294:- LUSC cis rs1799949 1 rs12944430 ENSG00000198496.9 NBR2 -11.89 1.06e-28 4.64e-25 -0.53 -0.48 Menopause (age at onset); chr17:43178803 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11653460 ENSG00000198496.9 NBR2 -11.89 1.06e-28 4.64e-25 -0.53 -0.48 Menopause (age at onset); chr17:43179289 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs11650913 ENSG00000198496.9 NBR2 -11.89 1.06e-28 4.64e-25 -0.53 -0.48 Menopause (age at onset); chr17:43179580 chr17:43125610~43153671:+ LUSC cis rs3096299 0.658 rs4785679 ENSG00000274627.1 RP11-104N10.2 11.89 1.11e-28 4.85e-25 0.42 0.48 Multiple myeloma (IgH translocation); chr16:89499705 chr16:89516797~89522217:+ LUSC cis rs875971 0.666 rs13242072 ENSG00000226824.5 RP4-756H11.3 11.89 1.12e-28 4.87e-25 0.56 0.48 Aortic root size; chr7:66301001 chr7:66654538~66669855:+ LUSC cis rs1799949 1 rs1060915 ENSG00000198496.9 NBR2 -11.89 1.12e-28 4.87e-25 -0.53 -0.48 Menopause (age at onset); chr17:43082453 chr17:43125610~43153671:+ LUSC cis rs1799949 0.896 rs33933393 ENSG00000198496.9 NBR2 -11.88 1.21e-28 5.23e-25 -0.53 -0.48 Menopause (age at onset); chr17:43165415 chr17:43125610~43153671:+ LUSC cis rs977987 0.654 rs8054194 ENSG00000261783.1 RP11-252K23.2 -11.87 1.29e-28 5.57e-25 -0.66 -0.48 Dupuytren's disease; chr16:75463262 chr16:75379818~75381260:- LUSC cis rs977987 0.581 rs8056141 ENSG00000261783.1 RP11-252K23.2 -11.87 1.29e-28 5.57e-25 -0.66 -0.48 Dupuytren's disease; chr16:75463264 chr16:75379818~75381260:- LUSC cis rs1799949 1 rs4793215 ENSG00000198496.9 NBR2 -11.87 1.29e-28 5.57e-25 -0.53 -0.48 Menopause (age at onset); chr17:43166915 chr17:43125610~43153671:+ LUSC cis rs3096299 0.632 rs8051537 ENSG00000274627.1 RP11-104N10.2 11.87 1.3e-28 5.6e-25 0.43 0.48 Multiple myeloma (IgH translocation); chr16:89477976 chr16:89516797~89522217:+ LUSC cis rs11155671 0.53 rs1334510 ENSG00000216906.2 RP11-350J20.9 11.87 1.3e-28 5.61e-25 0.55 0.48 Testicular germ cell tumor; chr6:149880043 chr6:149904243~149906418:+ LUSC cis rs10129255 0.536 rs6576201 ENSG00000223648.3 IGHV3-64 -11.87 1.3e-28 5.62e-25 -0.38 -0.48 Kawasaki disease; chr14:106683696 chr14:106643132~106658258:- LUSC cis rs12594515 1 rs11070467 ENSG00000273972.1 CTD-2306A12.1 11.87 1.3e-28 5.63e-25 0.56 0.48 Weight;Waist circumference; chr15:45692803 chr15:45702640~45703183:+ LUSC cis rs858239 0.863 rs274054 ENSG00000230658.1 KLHL7-AS1 11.87 1.3e-28 5.63e-25 0.61 0.48 Cerebrospinal fluid biomarker levels; chr7:23350848 chr7:23101228~23105703:- LUSC cis rs507080 0.961 rs520543 ENSG00000255422.1 AP002954.4 -11.87 1.31e-28 5.67e-25 -0.52 -0.48 Serum metabolite levels; chr11:118667448 chr11:118704607~118750263:+ LUSC cis rs12594515 0.967 rs11856523 ENSG00000273972.1 CTD-2306A12.1 -11.87 1.32e-28 5.68e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45697297 chr15:45702640~45703183:+ LUSC cis rs1799949 1 rs2271573 ENSG00000198496.9 NBR2 -11.87 1.32e-28 5.69e-25 -0.53 -0.48 Menopause (age at onset); chr17:43175604 chr17:43125610~43153671:+ LUSC cis rs12594515 1 rs35182335 ENSG00000273972.1 CTD-2306A12.1 -11.87 1.33e-28 5.72e-25 -0.57 -0.48 Weight;Waist circumference; chr15:45702986 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs11855509 ENSG00000273972.1 CTD-2306A12.1 -11.87 1.33e-28 5.72e-25 -0.57 -0.48 Weight;Waist circumference; chr15:45703276 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs11855562 ENSG00000273972.1 CTD-2306A12.1 -11.87 1.33e-28 5.72e-25 -0.57 -0.48 Weight;Waist circumference; chr15:45703461 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs8043291 ENSG00000273972.1 CTD-2306A12.1 -11.87 1.33e-28 5.72e-25 -0.57 -0.48 Weight;Waist circumference; chr15:45704049 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs56412446 ENSG00000273972.1 CTD-2306A12.1 -11.87 1.33e-28 5.72e-25 -0.57 -0.48 Weight;Waist circumference; chr15:45704226 chr15:45702640~45703183:+ LUSC cis rs1799949 0.929 rs12937015 ENSG00000198496.9 NBR2 -11.87 1.33e-28 5.75e-25 -0.52 -0.48 Menopause (age at onset); chr17:43155456 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs4340367 ENSG00000198496.9 NBR2 -11.87 1.33e-28 5.75e-25 -0.52 -0.48 Menopause (age at onset); chr17:43155755 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs4792981 ENSG00000198496.9 NBR2 -11.87 1.33e-28 5.75e-25 -0.52 -0.48 Menopause (age at onset); chr17:43156257 chr17:43125610~43153671:+ LUSC cis rs12594515 1 rs11854554 ENSG00000273972.1 CTD-2306A12.1 -11.87 1.34e-28 5.76e-25 -0.57 -0.48 Weight;Waist circumference; chr15:45702348 chr15:45702640~45703183:+ LUSC cis rs7174755 0.923 rs11634149 ENSG00000260657.2 RP11-315D16.4 11.87 1.36e-28 5.88e-25 0.59 0.48 Major depressive disorder; chr15:68306072 chr15:68267792~68277994:- LUSC cis rs12594515 1 rs8038058 ENSG00000273972.1 CTD-2306A12.1 -11.87 1.37e-28 5.89e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45698074 chr15:45702640~45703183:+ LUSC cis rs9481169 0.85 rs13210247 ENSG00000255389.1 C6orf3 -11.86 1.4e-28 6.02e-25 -0.79 -0.48 Inflammatory skin disease; chr6:111601517 chr6:111599875~111602295:+ LUSC cis rs801193 1 rs10234018 ENSG00000226824.5 RP4-756H11.3 11.86 1.41e-28 6.05e-25 0.56 0.48 Aortic root size; chr7:66681297 chr7:66654538~66669855:+ LUSC cis rs6782228 0.606 rs6775270 ENSG00000242551.2 POU5F1P6 -11.86 1.42e-28 6.1e-25 -0.55 -0.48 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128684655 chr3:128674735~128677005:- LUSC cis rs12594515 1 rs12592190 ENSG00000273972.1 CTD-2306A12.1 -11.86 1.42e-28 6.1e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45701830 chr15:45702640~45703183:+ LUSC cis rs6700559 0.81 rs7521550 ENSG00000260088.1 RP11-92G12.3 -11.86 1.42e-28 6.11e-25 -0.58 -0.48 Coronary artery disease; chr1:200623235 chr1:200669507~200694250:+ LUSC cis rs1799949 1 rs1973646 ENSG00000198496.9 NBR2 -11.86 1.43e-28 6.14e-25 -0.52 -0.48 Menopause (age at onset); chr17:43158478 chr17:43125610~43153671:+ LUSC cis rs12594515 0.967 rs11070465 ENSG00000273972.1 CTD-2306A12.1 -11.86 1.45e-28 6.22e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45692701 chr15:45702640~45703183:+ LUSC cis rs12594515 0.967 rs11070466 ENSG00000273972.1 CTD-2306A12.1 -11.86 1.45e-28 6.22e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45692757 chr15:45702640~45703183:+ LUSC cis rs3096299 0.719 rs2965945 ENSG00000274627.1 RP11-104N10.2 11.86 1.47e-28 6.29e-25 0.42 0.48 Multiple myeloma (IgH translocation); chr16:89447609 chr16:89516797~89522217:+ LUSC cis rs507080 0.733 rs4393358 ENSG00000255239.1 AP002954.6 11.86 1.47e-28 6.29e-25 0.55 0.48 Serum metabolite levels; chr11:118698388 chr11:118688039~118690600:- LUSC cis rs9322193 0.566 rs5024811 ENSG00000231760.4 RP11-350J20.5 -11.86 1.48e-28 6.34e-25 -0.69 -0.48 Lung cancer; chr6:149924898 chr6:149796151~149826294:- LUSC cis rs12594515 1 rs12185095 ENSG00000273972.1 CTD-2306A12.1 -11.86 1.5e-28 6.41e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45702437 chr15:45702640~45703183:+ LUSC cis rs875971 0.577 rs35072105 ENSG00000226824.5 RP4-756H11.3 11.86 1.51e-28 6.45e-25 0.57 0.48 Aortic root size; chr7:66144830 chr7:66654538~66669855:+ LUSC cis rs4423214 1 rs2276360 ENSG00000254682.1 RP11-660L16.2 11.85 1.53e-28 6.55e-25 0.62 0.48 Vitamin D levels; chr11:71458501 chr11:71448674~71452157:+ LUSC cis rs11155671 0.53 rs9371215 ENSG00000216906.2 RP11-350J20.9 11.85 1.54e-28 6.59e-25 0.56 0.48 Testicular germ cell tumor; chr6:149873162 chr6:149904243~149906418:+ LUSC cis rs55794721 0.509 rs6699113 ENSG00000261349.1 RP3-465N24.5 -11.85 1.57e-28 6.69e-25 -0.59 -0.48 Mean corpuscular volume;Plateletcrit; chr1:25451252 chr1:25266102~25267136:- LUSC cis rs9399135 0.66 rs4472368 ENSG00000232876.1 CTA-212D2.2 -11.85 1.57e-28 6.69e-25 -0.56 -0.48 Red blood cell count; chr6:134953094 chr6:135055033~135060550:+ LUSC cis rs1150688 1 rs1150688 ENSG00000216901.1 AL022393.7 11.85 1.57e-28 6.69e-25 0.53 0.48 Autism spectrum disorder or schizophrenia; chr6:28195002 chr6:28176188~28176674:+ LUSC cis rs73086581 1 rs73086512 ENSG00000229539.1 RP11-119B16.2 11.85 1.59e-28 6.78e-25 0.64 0.48 Response to antidepressants in depression; chr20:3942125 chr20:3888239~3888868:- LUSC cis rs7535099 1 rs1938489 ENSG00000224570.1 RP11-430H12.2 -11.85 1.6e-28 6.83e-25 -0.68 -0.48 Blood protein levels; chr1:65582939 chr1:65576129~65578380:- LUSC cis rs7535099 0.954 rs12067730 ENSG00000224570.1 RP11-430H12.2 -11.85 1.61e-28 6.85e-25 -0.68 -0.48 Blood protein levels; chr1:65583339 chr1:65576129~65578380:- LUSC cis rs1799949 0.965 rs12950779 ENSG00000198496.9 NBR2 -11.85 1.61e-28 6.86e-25 -0.52 -0.48 Menopause (age at onset); chr17:43154506 chr17:43125610~43153671:+ LUSC cis rs172166 0.538 rs1150686 ENSG00000216901.1 AL022393.7 11.85 1.65e-28 7.05e-25 0.53 0.48 Cardiac Troponin-T levels; chr6:28193493 chr6:28176188~28176674:+ LUSC cis rs3096299 0.754 rs2965816 ENSG00000274627.1 RP11-104N10.2 -11.84 1.67e-28 7.13e-25 -0.42 -0.48 Multiple myeloma (IgH translocation); chr16:89447775 chr16:89516797~89522217:+ LUSC cis rs73086581 1 rs73086588 ENSG00000229539.1 RP11-119B16.2 11.84 1.69e-28 7.22e-25 0.65 0.48 Response to antidepressants in depression; chr20:4001577 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs73086595 ENSG00000229539.1 RP11-119B16.2 11.84 1.69e-28 7.22e-25 0.65 0.48 Response to antidepressants in depression; chr20:4002801 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs73086597 ENSG00000229539.1 RP11-119B16.2 11.84 1.69e-28 7.22e-25 0.65 0.48 Response to antidepressants in depression; chr20:4002924 chr20:3888239~3888868:- LUSC cis rs977987 0.671 rs9922008 ENSG00000261783.1 RP11-252K23.2 -11.84 1.7e-28 7.24e-25 -0.66 -0.48 Dupuytren's disease; chr16:75301508 chr16:75379818~75381260:- LUSC cis rs801193 1 rs62466793 ENSG00000226824.5 RP4-756H11.3 -11.84 1.71e-28 7.3e-25 -0.56 -0.48 Aortic root size; chr7:66726530 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs62466794 ENSG00000226824.5 RP4-756H11.3 -11.84 1.71e-28 7.3e-25 -0.56 -0.48 Aortic root size; chr7:66726592 chr7:66654538~66669855:+ LUSC cis rs4423214 1 rs12422045 ENSG00000254682.1 RP11-660L16.2 11.84 1.76e-28 7.5e-25 0.6 0.48 Vitamin D levels; chr11:71443774 chr11:71448674~71452157:+ LUSC cis rs507080 0.733 rs611733 ENSG00000255239.1 AP002954.6 11.84 1.76e-28 7.5e-25 0.56 0.48 Serum metabolite levels; chr11:118702051 chr11:118688039~118690600:- LUSC cis rs7617773 0.78 rs13067450 ENSG00000229759.1 MRPS18AP1 11.84 1.77e-28 7.52e-25 0.49 0.48 Coronary artery disease; chr3:48295716 chr3:48256350~48256938:- LUSC cis rs7617773 0.78 rs4479622 ENSG00000229759.1 MRPS18AP1 11.84 1.77e-28 7.52e-25 0.49 0.48 Coronary artery disease; chr3:48296683 chr3:48256350~48256938:- LUSC cis rs7617773 0.78 rs34946886 ENSG00000229759.1 MRPS18AP1 11.84 1.77e-28 7.52e-25 0.49 0.48 Coronary artery disease; chr3:48296997 chr3:48256350~48256938:- LUSC cis rs7617773 0.78 rs34589064 ENSG00000229759.1 MRPS18AP1 11.84 1.77e-28 7.52e-25 0.49 0.48 Coronary artery disease; chr3:48298059 chr3:48256350~48256938:- LUSC cis rs7617773 0.78 rs2541 ENSG00000229759.1 MRPS18AP1 11.84 1.77e-28 7.52e-25 0.49 0.48 Coronary artery disease; chr3:48298128 chr3:48256350~48256938:- LUSC cis rs7617773 0.78 rs13085251 ENSG00000229759.1 MRPS18AP1 11.84 1.77e-28 7.52e-25 0.49 0.48 Coronary artery disease; chr3:48298555 chr3:48256350~48256938:- LUSC cis rs1799949 1 rs33926631 ENSG00000198496.9 NBR2 -11.84 1.77e-28 7.53e-25 -0.52 -0.48 Menopause (age at onset); chr17:43152446 chr17:43125610~43153671:+ LUSC cis rs7535099 0.909 rs72681384 ENSG00000224570.1 RP11-430H12.2 -11.84 1.8e-28 7.64e-25 -0.67 -0.48 Blood protein levels; chr1:65566256 chr1:65576129~65578380:- LUSC cis rs7617773 0.78 rs11718350 ENSG00000229759.1 MRPS18AP1 11.84 1.81e-28 7.7e-25 0.5 0.48 Coronary artery disease; chr3:48319502 chr3:48256350~48256938:- LUSC cis rs507080 0.697 rs656287 ENSG00000255239.1 AP002954.6 11.83 1.84e-28 7.79e-25 0.56 0.48 Serum metabolite levels; chr11:118701081 chr11:118688039~118690600:- LUSC cis rs507080 0.733 rs570949 ENSG00000255239.1 AP002954.6 11.83 1.84e-28 7.79e-25 0.56 0.48 Serum metabolite levels; chr11:118701202 chr11:118688039~118690600:- LUSC cis rs5760092 0.755 rs915589 ENSG00000273295.1 AP000350.5 -11.83 1.85e-28 7.85e-25 -0.66 -0.48 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23901432~23907068:- LUSC cis rs1799949 0.894 rs8176160 ENSG00000198496.9 NBR2 -11.83 1.86e-28 7.88e-25 -0.53 -0.48 Menopause (age at onset); chr17:43089486 chr17:43125610~43153671:+ LUSC cis rs7104764 1 rs10400248 ENSG00000277290.1 RP11-326C3.16 -11.83 1.94e-28 8.21e-25 -0.44 -0.48 Menarche (age at onset); chr11:247029 chr11:243099~243483:- LUSC cis rs875971 0.66 rs10272357 ENSG00000226824.5 RP4-756H11.3 11.83 1.95e-28 8.25e-25 0.55 0.48 Aortic root size; chr7:66598087 chr7:66654538~66669855:+ LUSC cis rs1799949 1 rs1960605 ENSG00000198496.9 NBR2 -11.83 2e-28 8.45e-25 -0.52 -0.48 Menopause (age at onset); chr17:43153380 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs2037076 ENSG00000198496.9 NBR2 -11.83 2e-28 8.45e-25 -0.52 -0.48 Menopause (age at onset); chr17:43153866 chr17:43125610~43153671:+ LUSC cis rs1799949 0.896 rs8176086 ENSG00000198496.9 NBR2 -11.82 2.01e-28 8.48e-25 -0.53 -0.48 Menopause (age at onset); chr17:43122761 chr17:43125610~43153671:+ LUSC cis rs7535099 1 rs12059300 ENSG00000224570.1 RP11-430H12.2 -11.82 2.03e-28 8.57e-25 -0.68 -0.48 Blood protein levels; chr1:65581389 chr1:65576129~65578380:- LUSC cis rs73086581 1 rs73084594 ENSG00000229539.1 RP11-119B16.2 11.82 2.03e-28 8.58e-25 0.63 0.48 Response to antidepressants in depression; chr20:3935733 chr20:3888239~3888868:- LUSC cis rs3096299 0.685 rs12446145 ENSG00000274627.1 RP11-104N10.2 11.82 2.04e-28 8.62e-25 0.42 0.48 Multiple myeloma (IgH translocation); chr16:89476287 chr16:89516797~89522217:+ LUSC cis rs2882667 0.627 rs1549203 ENSG00000253404.1 AC034243.1 -11.82 2.05e-28 8.67e-25 -0.58 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139132655 chr5:138744434~138753309:- LUSC cis rs7174755 1 rs7174755 ENSG00000260657.2 RP11-315D16.4 -11.82 2.08e-28 8.79e-25 -0.57 -0.48 Major depressive disorder; chr15:68304789 chr15:68267792~68277994:- LUSC cis rs12594515 1 rs11070464 ENSG00000273972.1 CTD-2306A12.1 -11.82 2.17e-28 9.14e-25 -0.56 -0.48 Weight;Waist circumference; chr15:45692578 chr15:45702640~45703183:+ LUSC cis rs1799949 0.794 rs116409325 ENSG00000198496.9 NBR2 -11.82 2.19e-28 9.22e-25 -0.52 -0.48 Menopause (age at onset); chr17:43368092 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11658754 ENSG00000198496.9 NBR2 -11.81 2.21e-28 9.32e-25 -0.53 -0.48 Menopause (age at onset); chr17:43140722 chr17:43125610~43153671:+ LUSC cis rs1799949 0.93 rs33968979 ENSG00000198496.9 NBR2 -11.81 2.21e-28 9.32e-25 -0.53 -0.48 Menopause (age at onset); chr17:43145975 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs12952790 ENSG00000198496.9 NBR2 -11.81 2.21e-28 9.32e-25 -0.53 -0.48 Menopause (age at onset); chr17:43147590 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs12950607 ENSG00000198496.9 NBR2 -11.81 2.21e-28 9.32e-25 -0.53 -0.48 Menopause (age at onset); chr17:43147911 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11079056 ENSG00000198496.9 NBR2 -11.81 2.21e-28 9.32e-25 -0.53 -0.48 Menopause (age at onset); chr17:43148782 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs12936816 ENSG00000198496.9 NBR2 -11.81 2.21e-28 9.32e-25 -0.53 -0.48 Menopause (age at onset); chr17:43149692 chr17:43125610~43153671:+ LUSC cis rs2455601 0.638 rs2568092 ENSG00000254860.4 TMEM9B-AS1 -11.81 2.23e-28 9.39e-25 -0.59 -0.48 Schizophrenia; chr11:8965891 chr11:8964675~8977527:+ LUSC cis rs875971 0.66 rs2013222 ENSG00000226824.5 RP4-756H11.3 11.81 2.25e-28 9.47e-25 0.56 0.48 Aortic root size; chr7:66570949 chr7:66654538~66669855:+ LUSC cis rs9545047 0.935 rs9530922 ENSG00000227676.3 LINC01068 -11.81 2.27e-28 9.56e-25 -0.59 -0.48 Schizophrenia; chr13:79469002 chr13:79566727~79571436:+ LUSC cis rs7104764 0.879 rs6598072 ENSG00000277290.1 RP11-326C3.16 -11.81 2.28e-28 9.57e-25 -0.44 -0.48 Menarche (age at onset); chr11:219793 chr11:243099~243483:- LUSC cis rs7104764 0.957 rs6598071 ENSG00000277290.1 RP11-326C3.16 -11.81 2.28e-28 9.57e-25 -0.44 -0.48 Menarche (age at onset); chr11:219800 chr11:243099~243483:- LUSC cis rs7104764 0.957 rs10794301 ENSG00000277290.1 RP11-326C3.16 -11.81 2.28e-28 9.57e-25 -0.44 -0.48 Menarche (age at onset); chr11:220401 chr11:243099~243483:- LUSC cis rs1501911 0.509 rs330422 ENSG00000248489.1 CTD-2007H13.3 11.81 2.33e-28 9.77e-25 0.56 0.48 Lung function (FEV1/FVC); chr5:98859184 chr5:98929171~98995013:+ LUSC cis rs172166 0.516 rs1225618 ENSG00000216901.1 AL022393.7 11.81 2.36e-28 9.89e-25 0.53 0.48 Cardiac Troponin-T levels; chr6:28161935 chr6:28176188~28176674:+ LUSC cis rs1799949 1 rs8176083 ENSG00000198496.9 NBR2 -11.81 2.37e-28 9.94e-25 -0.53 -0.48 Menopause (age at onset); chr17:43123134 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11657835 ENSG00000198496.9 NBR2 -11.81 2.37e-28 9.94e-25 -0.53 -0.48 Menopause (age at onset); chr17:43139936 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs1135214 ENSG00000198496.9 NBR2 -11.81 2.37e-28 9.94e-25 -0.53 -0.48 Menopause (age at onset); chr17:43140306 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11652332 ENSG00000198496.9 NBR2 -11.81 2.37e-28 9.94e-25 -0.53 -0.48 Menopause (age at onset); chr17:43143472 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs4793212 ENSG00000198496.9 NBR2 -11.81 2.37e-28 9.94e-25 -0.53 -0.48 Menopause (age at onset); chr17:43150733 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs34534709 ENSG00000198496.9 NBR2 -11.81 2.37e-28 9.94e-25 -0.53 -0.48 Menopause (age at onset); chr17:43150923 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs34059614 ENSG00000198496.9 NBR2 -11.81 2.37e-28 9.94e-25 -0.53 -0.48 Menopause (age at onset); chr17:43151054 chr17:43125610~43153671:+ LUSC cis rs875971 0.66 rs12698534 ENSG00000226824.5 RP4-756H11.3 -11.81 2.38e-28 9.98e-25 -0.56 -0.48 Aortic root size; chr7:66521858 chr7:66654538~66669855:+ LUSC cis rs7104764 1 rs1533825 ENSG00000277290.1 RP11-326C3.16 11.81 2.39e-28 1e-24 0.45 0.48 Menarche (age at onset); chr11:214163 chr11:243099~243483:- LUSC cis rs11155671 0.53 rs7742993 ENSG00000216906.2 RP11-350J20.9 11.81 2.39e-28 1e-24 0.56 0.48 Testicular germ cell tumor; chr6:149883959 chr6:149904243~149906418:+ LUSC cis rs73086581 1 rs73086581 ENSG00000229539.1 RP11-119B16.2 11.8 2.48e-28 1.04e-24 0.64 0.48 Response to antidepressants in depression; chr20:3996678 chr20:3888239~3888868:- LUSC cis rs1799949 1 rs4793197 ENSG00000198496.9 NBR2 -11.8 2.52e-28 1.05e-24 -0.53 -0.48 Menopause (age at onset); chr17:43079885 chr17:43125610~43153671:+ LUSC cis rs7104764 0.957 rs56357554 ENSG00000277290.1 RP11-326C3.16 11.8 2.57e-28 1.07e-24 0.45 0.48 Menarche (age at onset); chr11:204715 chr11:243099~243483:- LUSC cis rs7535099 0.954 rs11208680 ENSG00000224570.1 RP11-430H12.2 -11.79 2.7e-28 1.13e-24 -0.68 -0.48 Blood protein levels; chr1:65587380 chr1:65576129~65578380:- LUSC cis rs1799949 1 rs34942571 ENSG00000198496.9 NBR2 -11.79 2.76e-28 1.15e-24 -0.53 -0.48 Menopause (age at onset); chr17:43121362 chr17:43125610~43153671:+ LUSC cis rs73086581 1 rs34640283 ENSG00000229539.1 RP11-119B16.2 11.79 2.77e-28 1.15e-24 0.64 0.48 Response to antidepressants in depression; chr20:4008929 chr20:3888239~3888868:- LUSC cis rs1799949 1 rs35668327 ENSG00000198496.9 NBR2 -11.79 2.78e-28 1.16e-24 -0.53 -0.48 Menopause (age at onset); chr17:43121078 chr17:43125610~43153671:+ LUSC cis rs3091242 0.904 rs6661533 ENSG00000261349.1 RP3-465N24.5 -11.79 2.78e-28 1.16e-24 -0.58 -0.48 Erythrocyte sedimentation rate; chr1:25445224 chr1:25266102~25267136:- LUSC cis rs11155671 0.53 rs7756850 ENSG00000216906.2 RP11-350J20.9 11.79 2.84e-28 1.18e-24 0.56 0.48 Testicular germ cell tumor; chr6:149891460 chr6:149904243~149906418:+ LUSC cis rs1799949 0.965 rs8176161 ENSG00000198496.9 NBR2 -11.79 2.86e-28 1.19e-24 -0.53 -0.48 Menopause (age at onset); chr17:43089373 chr17:43125610~43153671:+ LUSC cis rs55794721 0.509 rs7554255 ENSG00000261349.1 RP3-465N24.5 -11.78 2.89e-28 1.2e-24 -0.58 -0.48 Mean corpuscular volume;Plateletcrit; chr1:25451615 chr1:25266102~25267136:- LUSC cis rs55794721 0.509 rs4649085 ENSG00000261349.1 RP3-465N24.5 -11.78 2.89e-28 1.2e-24 -0.58 -0.48 Mean corpuscular volume;Plateletcrit; chr1:25452341 chr1:25266102~25267136:- LUSC cis rs11155671 0.53 rs9397398 ENSG00000216906.2 RP11-350J20.9 11.78 2.97e-28 1.24e-24 0.55 0.48 Testicular germ cell tumor; chr6:149872467 chr6:149904243~149906418:+ LUSC cis rs2283792 0.687 rs381849 ENSG00000228050.1 TOP3BP1 11.78 3e-28 1.25e-24 0.56 0.48 Multiple sclerosis; chr22:21951341 chr22:22223187~22224566:- LUSC cis rs12594515 0.935 rs8042519 ENSG00000273972.1 CTD-2306A12.1 -11.78 3.06e-28 1.27e-24 -0.56 -0.48 Weight;Waist circumference; chr15:45704143 chr15:45702640~45703183:+ LUSC cis rs9326248 0.53 rs588918 ENSG00000254851.1 RP11-109L13.1 -11.78 3.07e-28 1.27e-24 -0.84 -0.48 Blood protein levels; chr11:116985926 chr11:117135528~117138582:+ LUSC cis rs1799949 0.965 rs8176087 ENSG00000198496.9 NBR2 -11.78 3.11e-28 1.29e-24 -0.53 -0.48 Menopause (age at onset); chr17:43118649 chr17:43125610~43153671:+ LUSC cis rs9545047 0.935 rs4885633 ENSG00000227676.3 LINC01068 -11.78 3.13e-28 1.3e-24 -0.59 -0.48 Schizophrenia; chr13:79469720 chr13:79566727~79571436:+ LUSC cis rs9326248 0.53 rs473188 ENSG00000254851.1 RP11-109L13.1 -11.77 3.22e-28 1.33e-24 -0.85 -0.48 Blood protein levels; chr11:116941313 chr11:117135528~117138582:+ LUSC cis rs11155671 0.53 rs9371544 ENSG00000216906.2 RP11-350J20.9 11.77 3.24e-28 1.34e-24 0.55 0.48 Testicular germ cell tumor; chr6:149896224 chr6:149904243~149906418:+ LUSC cis rs507080 0.733 rs517445 ENSG00000255239.1 AP002954.6 11.77 3.31e-28 1.37e-24 0.55 0.48 Serum metabolite levels; chr11:118702826 chr11:118688039~118690600:- LUSC cis rs17507216 1 rs17507216 ENSG00000278603.1 RP13-608F4.5 -11.77 3.32e-28 1.37e-24 -0.67 -0.48 Excessive daytime sleepiness; chr15:82558175 chr15:82472203~82472426:+ LUSC cis rs801193 1 rs10252765 ENSG00000226824.5 RP4-756H11.3 -11.77 3.32e-28 1.37e-24 -0.56 -0.48 Aortic root size; chr7:66763745 chr7:66654538~66669855:+ LUSC cis rs12594515 1 rs8039622 ENSG00000273972.1 CTD-2306A12.1 -11.77 3.35e-28 1.38e-24 -0.56 -0.48 Weight;Waist circumference; chr15:45694233 chr15:45702640~45703183:+ LUSC cis rs12594515 1 rs8039974 ENSG00000273972.1 CTD-2306A12.1 -11.77 3.35e-28 1.38e-24 -0.56 -0.48 Weight;Waist circumference; chr15:45694467 chr15:45702640~45703183:+ LUSC cis rs507080 0.961 rs4457789 ENSG00000255422.1 AP002954.4 -11.77 3.44e-28 1.42e-24 -0.52 -0.48 Serum metabolite levels; chr11:118668461 chr11:118704607~118750263:+ LUSC cis rs1799949 1 rs11656097 ENSG00000198496.9 NBR2 -11.76 3.51e-28 1.45e-24 -0.53 -0.48 Menopause (age at onset); chr17:43138596 chr17:43125610~43153671:+ LUSC cis rs977987 0.832 rs37597 ENSG00000261783.1 RP11-252K23.2 11.76 3.59e-28 1.48e-24 0.65 0.48 Dupuytren's disease; chr16:75466377 chr16:75379818~75381260:- LUSC cis rs9322193 0.567 rs7742692 ENSG00000216906.2 RP11-350J20.9 11.76 3.59e-28 1.48e-24 0.55 0.48 Lung cancer; chr6:149892363 chr6:149904243~149906418:+ LUSC cis rs7617773 0.817 rs13094727 ENSG00000229759.1 MRPS18AP1 11.76 3.64e-28 1.5e-24 0.5 0.48 Coronary artery disease; chr3:48281999 chr3:48256350~48256938:- LUSC cis rs3091242 0.934 rs666686 ENSG00000261349.1 RP3-465N24.5 -11.76 3.7e-28 1.52e-24 -0.58 -0.48 Erythrocyte sedimentation rate; chr1:25393020 chr1:25266102~25267136:- LUSC cis rs11155671 0.53 rs9371542 ENSG00000216906.2 RP11-350J20.9 11.76 3.72e-28 1.53e-24 0.56 0.48 Testicular germ cell tumor; chr6:149891949 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs9371223 ENSG00000216906.2 RP11-350J20.9 11.76 3.72e-28 1.53e-24 0.56 0.48 Testicular germ cell tumor; chr6:149893670 chr6:149904243~149906418:+ LUSC cis rs3096299 0.658 rs34590044 ENSG00000274627.1 RP11-104N10.2 11.76 3.76e-28 1.54e-24 0.42 0.48 Multiple myeloma (IgH translocation); chr16:89476749 chr16:89516797~89522217:+ LUSC cis rs9481169 0.85 rs60962769 ENSG00000255389.1 C6orf3 -11.76 3.8e-28 1.56e-24 -0.82 -0.48 Inflammatory skin disease; chr6:111598221 chr6:111599875~111602295:+ LUSC cis rs1799949 0.55 rs2343818 ENSG00000198496.9 NBR2 -11.75 3.99e-28 1.64e-24 -0.52 -0.48 Menopause (age at onset); chr17:43332406 chr17:43125610~43153671:+ LUSC cis rs1799949 0.526 rs4352088 ENSG00000198496.9 NBR2 -11.75 3.99e-28 1.64e-24 -0.52 -0.48 Menopause (age at onset); chr17:43337311 chr17:43125610~43153671:+ LUSC cis rs7174755 0.924 rs8035431 ENSG00000260657.2 RP11-315D16.4 11.75 4.09e-28 1.67e-24 0.57 0.48 Major depressive disorder; chr15:68305012 chr15:68267792~68277994:- LUSC cis rs1799949 0.93 rs3765640 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43124230 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs8176077 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43124331 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11655505 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43126360 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs4793204 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43127281 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs12947782 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43127865 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs33945274 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43128056 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs33925201 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43128665 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11653069 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43131360 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs2175957 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43134805 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs33988650 ENSG00000198496.9 NBR2 -11.74 4.18e-28 1.71e-24 -0.53 -0.48 Menopause (age at onset); chr17:43135863 chr17:43125610~43153671:+ LUSC cis rs875971 0.619 rs12533585 ENSG00000226824.5 RP4-756H11.3 -11.74 4.28e-28 1.75e-24 -0.55 -0.48 Aortic root size; chr7:66519618 chr7:66654538~66669855:+ LUSC cis rs9322193 0.607 rs12210822 ENSG00000231760.4 RP11-350J20.5 11.74 4.44e-28 1.81e-24 0.69 0.48 Lung cancer; chr6:149905356 chr6:149796151~149826294:- LUSC cis rs7104764 0.879 rs6421986 ENSG00000277290.1 RP11-326C3.16 -11.74 4.46e-28 1.82e-24 -0.44 -0.48 Menarche (age at onset); chr11:221659 chr11:243099~243483:- LUSC cis rs1799949 0.965 rs33961729 ENSG00000198496.9 NBR2 -11.74 4.49e-28 1.83e-24 -0.53 -0.48 Menopause (age at onset); chr17:43135907 chr17:43125610~43153671:+ LUSC cis rs875971 0.66 rs13224319 ENSG00000226824.5 RP4-756H11.3 -11.74 4.49e-28 1.83e-24 -0.55 -0.48 Aortic root size; chr7:66542376 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs801217 ENSG00000226824.5 RP4-756H11.3 11.74 4.49e-28 1.83e-24 0.55 0.48 Aortic root size; chr7:66545590 chr7:66654538~66669855:+ LUSC cis rs875971 0.638 rs801216 ENSG00000226824.5 RP4-756H11.3 11.74 4.49e-28 1.83e-24 0.55 0.48 Aortic root size; chr7:66546680 chr7:66654538~66669855:+ LUSC cis rs1799949 1 rs2292595 ENSG00000198496.9 NBR2 -11.73 4.74e-28 1.93e-24 -0.52 -0.48 Menopause (age at onset); chr17:43138657 chr17:43125610~43153671:+ LUSC cis rs1799949 0.501 rs2343819 ENSG00000198496.9 NBR2 -11.73 4.83e-28 1.96e-24 -0.52 -0.48 Menopause (age at onset); chr17:43332285 chr17:43125610~43153671:+ LUSC cis rs1799949 0.501 rs35399157 ENSG00000198496.9 NBR2 -11.73 4.83e-28 1.96e-24 -0.52 -0.48 Menopause (age at onset); chr17:43334234 chr17:43125610~43153671:+ LUSC cis rs1799949 0.602 rs4600503 ENSG00000198496.9 NBR2 -11.73 4.83e-28 1.96e-24 -0.52 -0.48 Menopause (age at onset); chr17:43336956 chr17:43125610~43153671:+ LUSC cis rs1799949 0.501 rs9675035 ENSG00000198496.9 NBR2 -11.73 4.83e-28 1.96e-24 -0.52 -0.48 Menopause (age at onset); chr17:43337648 chr17:43125610~43153671:+ LUSC cis rs12594515 1 rs12906442 ENSG00000273972.1 CTD-2306A12.1 -11.73 4.95e-28 2.01e-24 -0.56 -0.48 Weight;Waist circumference; chr15:45693056 chr15:45702640~45703183:+ LUSC cis rs73086581 1 rs17286349 ENSG00000229539.1 RP11-119B16.2 11.73 4.98e-28 2.02e-24 0.64 0.48 Response to antidepressants in depression; chr20:3933655 chr20:3888239~3888868:- LUSC cis rs3096299 0.719 rs2911265 ENSG00000274627.1 RP11-104N10.2 11.72 5.09e-28 2.06e-24 0.42 0.48 Multiple myeloma (IgH translocation); chr16:89444920 chr16:89516797~89522217:+ LUSC cis rs9322193 0.566 rs3922947 ENSG00000231760.4 RP11-350J20.5 -11.72 5.2e-28 2.1e-24 -0.69 -0.48 Lung cancer; chr6:149924856 chr6:149796151~149826294:- LUSC cis rs172166 0.516 rs2791333 ENSG00000216901.1 AL022393.7 11.72 5.23e-28 2.12e-24 0.53 0.48 Cardiac Troponin-T levels; chr6:28143336 chr6:28176188~28176674:+ LUSC cis rs7301826 0.58 rs12821464 ENSG00000256299.1 RP11-989F5.3 11.72 5.34e-28 2.16e-24 0.54 0.48 Plasma plasminogen activator levels; chr12:130838174 chr12:130810821~130812622:- LUSC cis rs9322193 0.607 rs9383941 ENSG00000231760.4 RP11-350J20.5 -11.71 5.55e-28 2.24e-24 -0.69 -0.48 Lung cancer; chr6:149912100 chr6:149796151~149826294:- LUSC cis rs6952407 1 rs6952407 ENSG00000226824.5 RP4-756H11.3 11.71 5.84e-28 2.36e-24 0.54 0.48 Cotinine glucuronidation; chr7:66580525 chr7:66654538~66669855:+ LUSC cis rs9322193 0.566 rs6912330 ENSG00000231760.4 RP11-350J20.5 -11.71 5.9e-28 2.38e-24 -0.68 -0.48 Lung cancer; chr6:149908811 chr6:149796151~149826294:- LUSC cis rs875971 0.558 rs4433015 ENSG00000226824.5 RP4-756H11.3 11.71 5.98e-28 2.41e-24 0.57 0.48 Aortic root size; chr7:66174736 chr7:66654538~66669855:+ LUSC cis rs3091242 0.866 rs11249249 ENSG00000261349.1 RP3-465N24.5 -11.7 6.05e-28 2.44e-24 -0.58 -0.48 Erythrocyte sedimentation rate; chr1:25431643 chr1:25266102~25267136:- LUSC cis rs801193 1 rs17566701 ENSG00000226824.5 RP4-756H11.3 -11.7 6.1e-28 2.46e-24 -0.57 -0.48 Aortic root size; chr7:66728196 chr7:66654538~66669855:+ LUSC cis rs73086581 1 rs73088416 ENSG00000229539.1 RP11-119B16.2 11.7 6.12e-28 2.46e-24 0.64 0.48 Response to antidepressants in depression; chr20:4014629 chr20:3888239~3888868:- LUSC cis rs3096299 0.563 rs4600467 ENSG00000274627.1 RP11-104N10.2 11.7 6.13e-28 2.47e-24 0.42 0.48 Multiple myeloma (IgH translocation); chr16:89496108 chr16:89516797~89522217:+ LUSC cis rs9322193 0.607 rs9371228 ENSG00000231760.4 RP11-350J20.5 -11.7 6.16e-28 2.48e-24 -0.69 -0.47 Lung cancer; chr6:149921977 chr6:149796151~149826294:- LUSC cis rs73086581 1 rs56324992 ENSG00000229539.1 RP11-119B16.2 11.7 6.19e-28 2.49e-24 0.63 0.47 Response to antidepressants in depression; chr20:3997506 chr20:3888239~3888868:- LUSC cis rs875971 0.66 rs79009421 ENSG00000226824.5 RP4-756H11.3 11.7 6.2e-28 2.49e-24 0.55 0.47 Aortic root size; chr7:66603522 chr7:66654538~66669855:+ LUSC cis rs875971 0.619 rs2302918 ENSG00000226824.5 RP4-756H11.3 -11.7 6.27e-28 2.52e-24 -0.56 -0.47 Aortic root size; chr7:66535945 chr7:66654538~66669855:+ LUSC cis rs1185460 0.967 rs1784461 ENSG00000271751.1 RP11-110I1.14 -11.7 6.28e-28 2.52e-24 -0.59 -0.47 Coronary artery disease; chr11:119067274 chr11:119065263~119065677:- LUSC cis rs1799949 0.93 rs8176194 ENSG00000198496.9 NBR2 -11.7 6.32e-28 2.54e-24 -0.53 -0.47 Menopause (age at onset); chr17:43079204 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs8176193 ENSG00000198496.9 NBR2 -11.7 6.32e-28 2.54e-24 -0.53 -0.47 Menopause (age at onset); chr17:43079499 chr17:43125610~43153671:+ LUSC cis rs7301826 0.651 rs10848209 ENSG00000256299.1 RP11-989F5.3 -11.7 6.34e-28 2.55e-24 -0.53 -0.47 Plasma plasminogen activator levels; chr12:130826727 chr12:130810821~130812622:- LUSC cis rs11155671 0.53 rs7757984 ENSG00000216906.2 RP11-350J20.9 11.7 6.42e-28 2.58e-24 0.56 0.47 Testicular germ cell tumor; chr6:149887515 chr6:149904243~149906418:+ LUSC cis rs1799949 1 rs4793229 ENSG00000198496.9 NBR2 11.7 6.42e-28 2.58e-24 0.53 0.47 Menopause (age at onset); chr17:43340966 chr17:43125610~43153671:+ LUSC cis rs507080 0.771 rs687664 ENSG00000255239.1 AP002954.6 11.7 6.49e-28 2.6e-24 0.55 0.47 Serum metabolite levels; chr11:118703476 chr11:118688039~118690600:- LUSC cis rs507080 0.771 rs523715 ENSG00000255239.1 AP002954.6 11.7 6.49e-28 2.6e-24 0.55 0.47 Serum metabolite levels; chr11:118703479 chr11:118688039~118690600:- LUSC cis rs875971 0.66 rs28698552 ENSG00000226824.5 RP4-756H11.3 -11.69 6.58e-28 2.64e-24 -0.55 -0.47 Aortic root size; chr7:66540031 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs62465434 ENSG00000226824.5 RP4-756H11.3 -11.69 6.58e-28 2.64e-24 -0.55 -0.47 Aortic root size; chr7:66540165 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs801211 ENSG00000226824.5 RP4-756H11.3 11.69 6.58e-28 2.64e-24 0.55 0.47 Aortic root size; chr7:66550702 chr7:66654538~66669855:+ LUSC cis rs875971 0.638 rs801205 ENSG00000226824.5 RP4-756H11.3 11.69 6.58e-28 2.64e-24 0.55 0.47 Aortic root size; chr7:66557157 chr7:66654538~66669855:+ LUSC cis rs875971 0.617 rs810400 ENSG00000226824.5 RP4-756H11.3 11.69 6.58e-28 2.64e-24 0.55 0.47 Aortic root size; chr7:66557902 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs7807930 ENSG00000226824.5 RP4-756H11.3 11.69 6.65e-28 2.66e-24 0.55 0.47 Aortic root size; chr7:66622178 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs801192 ENSG00000226824.5 RP4-756H11.3 11.69 6.7e-28 2.68e-24 0.55 0.47 Aortic root size; chr7:66566965 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs801190 ENSG00000226824.5 RP4-756H11.3 11.69 6.7e-28 2.68e-24 0.55 0.47 Aortic root size; chr7:66568046 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs3857686 ENSG00000226824.5 RP4-756H11.3 11.69 6.7e-28 2.68e-24 0.55 0.47 Aortic root size; chr7:66571204 chr7:66654538~66669855:+ LUSC cis rs875971 0.638 rs3898855 ENSG00000226824.5 RP4-756H11.3 11.69 6.7e-28 2.68e-24 0.55 0.47 Aortic root size; chr7:66571411 chr7:66654538~66669855:+ LUSC cis rs875971 0.638 rs10278816 ENSG00000226824.5 RP4-756H11.3 11.69 6.7e-28 2.68e-24 0.55 0.47 Aortic root size; chr7:66572000 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs6460308 ENSG00000226824.5 RP4-756H11.3 11.69 6.7e-28 2.68e-24 0.55 0.47 Aortic root size; chr7:66619753 chr7:66654538~66669855:+ LUSC cis rs73086581 1 rs17214949 ENSG00000229539.1 RP11-119B16.2 11.69 6.74e-28 2.69e-24 0.64 0.47 Response to antidepressants in depression; chr20:3960305 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs17215054 ENSG00000229539.1 RP11-119B16.2 11.69 6.74e-28 2.69e-24 0.64 0.47 Response to antidepressants in depression; chr20:3964132 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs17287486 ENSG00000229539.1 RP11-119B16.2 11.69 6.74e-28 2.69e-24 0.64 0.47 Response to antidepressants in depression; chr20:3965620 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs73086540 ENSG00000229539.1 RP11-119B16.2 11.69 6.74e-28 2.69e-24 0.64 0.47 Response to antidepressants in depression; chr20:3970203 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs73086544 ENSG00000229539.1 RP11-119B16.2 11.69 6.74e-28 2.69e-24 0.64 0.47 Response to antidepressants in depression; chr20:3970281 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs2326289 ENSG00000229539.1 RP11-119B16.2 11.69 6.74e-28 2.69e-24 0.64 0.47 Response to antidepressants in depression; chr20:3971653 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs73086549 ENSG00000229539.1 RP11-119B16.2 11.69 6.74e-28 2.69e-24 0.64 0.47 Response to antidepressants in depression; chr20:3974015 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs113812453 ENSG00000229539.1 RP11-119B16.2 11.69 6.74e-28 2.69e-24 0.64 0.47 Response to antidepressants in depression; chr20:3982546 chr20:3888239~3888868:- LUSC cis rs73086581 0.947 rs17287577 ENSG00000229539.1 RP11-119B16.2 11.69 6.74e-28 2.69e-24 0.64 0.47 Response to antidepressants in depression; chr20:3985607 chr20:3888239~3888868:- LUSC cis rs507080 0.733 rs7108144 ENSG00000255239.1 AP002954.6 11.69 6.82e-28 2.72e-24 0.55 0.47 Serum metabolite levels; chr11:118698985 chr11:118688039~118690600:- LUSC cis rs507080 0.663 rs523793 ENSG00000255239.1 AP002954.6 11.69 6.82e-28 2.72e-24 0.55 0.47 Serum metabolite levels; chr11:118699988 chr11:118688039~118690600:- LUSC cis rs507080 0.736 rs659564 ENSG00000255239.1 AP002954.6 11.69 6.82e-28 2.72e-24 0.55 0.47 Serum metabolite levels; chr11:118700205 chr11:118688039~118690600:- LUSC cis rs507080 0.736 rs642224 ENSG00000255239.1 AP002954.6 11.69 6.82e-28 2.72e-24 0.55 0.47 Serum metabolite levels; chr11:118700210 chr11:118688039~118690600:- LUSC cis rs507080 0.733 rs541631 ENSG00000255239.1 AP002954.6 11.69 6.82e-28 2.72e-24 0.55 0.47 Serum metabolite levels; chr11:118700314 chr11:118688039~118690600:- LUSC cis rs507080 0.736 rs658676 ENSG00000255239.1 AP002954.6 11.69 6.82e-28 2.72e-24 0.55 0.47 Serum metabolite levels; chr11:118700414 chr11:118688039~118690600:- LUSC cis rs507080 0.733 rs488141 ENSG00000255239.1 AP002954.6 11.69 6.82e-28 2.72e-24 0.55 0.47 Serum metabolite levels; chr11:118700459 chr11:118688039~118690600:- LUSC cis rs507080 0.733 rs657769 ENSG00000255239.1 AP002954.6 11.69 6.82e-28 2.72e-24 0.55 0.47 Serum metabolite levels; chr11:118700607 chr11:118688039~118690600:- LUSC cis rs507080 0.733 rs544452 ENSG00000255239.1 AP002954.6 11.69 6.82e-28 2.72e-24 0.55 0.47 Serum metabolite levels; chr11:118700648 chr11:118688039~118690600:- LUSC cis rs875971 0.66 rs7807944 ENSG00000226824.5 RP4-756H11.3 11.69 6.85e-28 2.73e-24 0.55 0.47 Aortic root size; chr7:66622208 chr7:66654538~66669855:+ LUSC cis rs7104764 1 rs76552490 ENSG00000277290.1 RP11-326C3.16 11.69 6.91e-28 2.75e-24 0.45 0.47 Menarche (age at onset); chr11:212015 chr11:243099~243483:- LUSC cis rs73086581 1 rs3746665 ENSG00000229539.1 RP11-119B16.2 -11.69 6.92e-28 2.75e-24 -0.61 -0.47 Response to antidepressants in depression; chr20:3929759 chr20:3888239~3888868:- LUSC cis rs1185460 0.967 rs4454730 ENSG00000271751.1 RP11-110I1.14 -11.69 6.94e-28 2.76e-24 -0.59 -0.47 Coronary artery disease; chr11:119066733 chr11:119065263~119065677:- LUSC cis rs1185460 0.967 rs4545564 ENSG00000271751.1 RP11-110I1.14 -11.69 6.94e-28 2.76e-24 -0.59 -0.47 Coronary artery disease; chr11:119066807 chr11:119065263~119065677:- LUSC cis rs9322193 0.607 rs12209310 ENSG00000231760.4 RP11-350J20.5 11.69 6.94e-28 2.76e-24 0.69 0.47 Lung cancer; chr6:149904882 chr6:149796151~149826294:- LUSC cis rs9322193 0.566 rs4870118 ENSG00000231760.4 RP11-350J20.5 -11.69 6.98e-28 2.77e-24 -0.7 -0.47 Lung cancer; chr6:149923877 chr6:149796151~149826294:- LUSC cis rs9322193 0.566 rs4869767 ENSG00000231760.4 RP11-350J20.5 -11.69 6.98e-28 2.77e-24 -0.7 -0.47 Lung cancer; chr6:149923974 chr6:149796151~149826294:- LUSC cis rs9322193 0.566 rs4869768 ENSG00000231760.4 RP11-350J20.5 -11.69 6.98e-28 2.77e-24 -0.7 -0.47 Lung cancer; chr6:149924067 chr6:149796151~149826294:- LUSC cis rs1185460 0.967 rs1784459 ENSG00000271751.1 RP11-110I1.14 -11.69 7e-28 2.78e-24 -0.59 -0.47 Coronary artery disease; chr11:119067677 chr11:119065263~119065677:- LUSC cis rs1185460 0.967 rs1786684 ENSG00000271751.1 RP11-110I1.14 -11.69 7e-28 2.78e-24 -0.59 -0.47 Coronary artery disease; chr11:119067724 chr11:119065263~119065677:- LUSC cis rs12439619 0.705 rs17354185 ENSG00000278603.1 RP13-608F4.5 -11.69 7.14e-28 2.84e-24 -0.7 -0.47 Intelligence (multi-trait analysis); chr15:82133829 chr15:82472203~82472426:+ LUSC cis rs7174755 1 rs68069953 ENSG00000260657.2 RP11-315D16.4 11.68 7.27e-28 2.89e-24 0.57 0.47 Major depressive disorder; chr15:68304235 chr15:68267792~68277994:- LUSC cis rs73086581 1 rs73086505 ENSG00000229539.1 RP11-119B16.2 11.68 7.48e-28 2.97e-24 0.63 0.47 Response to antidepressants in depression; chr20:3940924 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs73086508 ENSG00000229539.1 RP11-119B16.2 11.68 7.48e-28 2.97e-24 0.63 0.47 Response to antidepressants in depression; chr20:3941068 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs73086510 ENSG00000229539.1 RP11-119B16.2 11.68 7.48e-28 2.97e-24 0.63 0.47 Response to antidepressants in depression; chr20:3941484 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs17286768 ENSG00000229539.1 RP11-119B16.2 11.68 7.48e-28 2.97e-24 0.63 0.47 Response to antidepressants in depression; chr20:3943922 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs17214621 ENSG00000229539.1 RP11-119B16.2 11.68 7.48e-28 2.97e-24 0.63 0.47 Response to antidepressants in depression; chr20:3945277 chr20:3888239~3888868:- LUSC cis rs1185460 0.967 rs1786685 ENSG00000271751.1 RP11-110I1.14 -11.68 7.49e-28 2.97e-24 -0.59 -0.47 Coronary artery disease; chr11:119068246 chr11:119065263~119065677:- LUSC cis rs1185460 0.967 rs1784302 ENSG00000271751.1 RP11-110I1.14 -11.68 7.49e-28 2.97e-24 -0.59 -0.47 Coronary artery disease; chr11:119070247 chr11:119065263~119065677:- LUSC cis rs73086581 1 rs73086535 ENSG00000229539.1 RP11-119B16.2 11.68 7.83e-28 3.1e-24 0.64 0.47 Response to antidepressants in depression; chr20:3963503 chr20:3888239~3888868:- LUSC cis rs73086581 0.947 rs55794220 ENSG00000229539.1 RP11-119B16.2 11.68 7.83e-28 3.1e-24 0.64 0.47 Response to antidepressants in depression; chr20:3975755 chr20:3888239~3888868:- LUSC cis rs73086581 0.891 rs55871214 ENSG00000229539.1 RP11-119B16.2 11.68 7.83e-28 3.1e-24 0.64 0.47 Response to antidepressants in depression; chr20:3985059 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs56069856 ENSG00000229539.1 RP11-119B16.2 11.68 7.83e-28 3.1e-24 0.64 0.47 Response to antidepressants in depression; chr20:3985062 chr20:3888239~3888868:- LUSC cis rs1799949 1 rs8176202 ENSG00000198496.9 NBR2 -11.68 7.87e-28 3.11e-24 -0.52 -0.47 Menopause (age at onset); chr17:43078211 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs16942 ENSG00000198496.9 NBR2 -11.67 8.03e-28 3.17e-24 -0.53 -0.47 Menopause (age at onset); chr17:43091983 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs8176145 ENSG00000198496.9 NBR2 -11.67 8.03e-28 3.17e-24 -0.53 -0.47 Menopause (age at onset); chr17:43097077 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs8176140 ENSG00000198496.9 NBR2 -11.67 8.03e-28 3.17e-24 -0.53 -0.47 Menopause (age at onset); chr17:43099629 chr17:43125610~43153671:+ LUSC cis rs1150668 0.796 rs2531832 ENSG00000216901.1 AL022393.7 11.67 8.11e-28 3.2e-24 0.53 0.47 Pubertal anthropometrics; chr6:28421445 chr6:28176188~28176674:+ LUSC cis rs7104764 0.957 rs1045454 ENSG00000277290.1 RP11-326C3.16 11.67 8.22e-28 3.25e-24 0.45 0.47 Menarche (age at onset); chr11:204228 chr11:243099~243483:- LUSC cis rs1799949 1 rs8176103 ENSG00000198496.9 NBR2 -11.67 8.33e-28 3.28e-24 -0.53 -0.47 Menopause (age at onset); chr17:43115033 chr17:43125610~43153671:+ LUSC cis rs73086581 1 rs73088421 ENSG00000229539.1 RP11-119B16.2 11.67 8.44e-28 3.33e-24 0.67 0.47 Response to antidepressants in depression; chr20:4017224 chr20:3888239~3888868:- LUSC cis rs1799949 0.93 rs66499067 ENSG00000198496.9 NBR2 -11.67 8.5e-28 3.35e-24 -0.53 -0.47 Menopause (age at onset); chr17:43096467 chr17:43125610~43153671:+ LUSC cis rs7301826 0.651 rs7956851 ENSG00000256299.1 RP11-989F5.3 -11.67 8.53e-28 3.36e-24 -0.53 -0.47 Plasma plasminogen activator levels; chr12:130834554 chr12:130810821~130812622:- LUSC cis rs875971 0.522 rs1968127 ENSG00000226824.5 RP4-756H11.3 11.67 8.54e-28 3.36e-24 0.55 0.47 Aortic root size; chr7:66591816 chr7:66654538~66669855:+ LUSC cis rs507080 0.733 rs4486664 ENSG00000255239.1 AP002954.6 11.66 8.68e-28 3.42e-24 0.55 0.47 Serum metabolite levels; chr11:118698358 chr11:118688039~118690600:- LUSC cis rs1799949 0.965 rs4793233 ENSG00000198496.9 NBR2 -11.66 8.74e-28 3.44e-24 -0.53 -0.47 Menopause (age at onset); chr17:43358069 chr17:43125610~43153671:+ LUSC cis rs875971 0.638 rs35986979 ENSG00000226824.5 RP4-756H11.3 11.66 8.78e-28 3.45e-24 0.55 0.47 Aortic root size; chr7:66624003 chr7:66654538~66669855:+ LUSC cis rs875971 0.638 rs6460305 ENSG00000226824.5 RP4-756H11.3 11.66 8.87e-28 3.49e-24 0.55 0.47 Aortic root size; chr7:66595421 chr7:66654538~66669855:+ LUSC cis rs2455601 0.638 rs2742484 ENSG00000254860.4 TMEM9B-AS1 11.66 8.89e-28 3.5e-24 0.63 0.47 Schizophrenia; chr11:8966536 chr11:8964675~8977527:+ LUSC cis rs2455601 0.638 rs2248245 ENSG00000254860.4 TMEM9B-AS1 11.66 8.89e-28 3.5e-24 0.63 0.47 Schizophrenia; chr11:8966803 chr11:8964675~8977527:+ LUSC cis rs1799949 1 rs35956818 ENSG00000198496.9 NBR2 -11.66 8.96e-28 3.52e-24 -0.53 -0.47 Menopause (age at onset); chr17:43345617 chr17:43125610~43153671:+ LUSC cis rs875971 0.642 rs35526611 ENSG00000226824.5 RP4-756H11.3 11.66 9.1e-28 3.57e-24 0.55 0.47 Aortic root size; chr7:66629021 chr7:66654538~66669855:+ LUSC cis rs12594515 1 rs6493169 ENSG00000273972.1 CTD-2306A12.1 11.66 9.13e-28 3.59e-24 0.55 0.47 Weight;Waist circumference; chr15:45694796 chr15:45702640~45703183:+ LUSC cis rs3096299 0.685 rs4238830 ENSG00000274627.1 RP11-104N10.2 11.66 9.21e-28 3.62e-24 0.42 0.47 Multiple myeloma (IgH translocation); chr16:89473833 chr16:89516797~89522217:+ LUSC cis rs875971 0.619 rs10278371 ENSG00000226824.5 RP4-756H11.3 11.66 9.25e-28 3.63e-24 0.55 0.47 Aortic root size; chr7:66586553 chr7:66654538~66669855:+ LUSC cis rs11155671 0.53 rs9968871 ENSG00000216906.2 RP11-350J20.9 11.66 9.26e-28 3.63e-24 0.56 0.47 Testicular germ cell tumor; chr6:149888060 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs9969044 ENSG00000216906.2 RP11-350J20.9 11.66 9.26e-28 3.63e-24 0.56 0.47 Testicular germ cell tumor; chr6:149888068 chr6:149904243~149906418:+ LUSC cis rs875971 0.66 rs10281080 ENSG00000226824.5 RP4-756H11.3 11.66 9.29e-28 3.65e-24 0.55 0.47 Aortic root size; chr7:66577454 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs10950044 ENSG00000226824.5 RP4-756H11.3 11.66 9.29e-28 3.65e-24 0.55 0.47 Aortic root size; chr7:66577989 chr7:66654538~66669855:+ LUSC cis rs11155671 0.546 rs1999633 ENSG00000231760.4 RP11-350J20.5 11.66 9.37e-28 3.67e-24 0.67 0.47 Testicular germ cell tumor; chr6:149866576 chr6:149796151~149826294:- LUSC cis rs1185460 0.967 rs1786141 ENSG00000271751.1 RP11-110I1.14 -11.66 9.42e-28 3.69e-24 -0.6 -0.47 Coronary artery disease; chr11:119067604 chr11:119065263~119065677:- LUSC cis rs875971 0.66 rs10215132 ENSG00000226824.5 RP4-756H11.3 11.65 9.74e-28 3.81e-24 0.55 0.47 Aortic root size; chr7:66589419 chr7:66654538~66669855:+ LUSC cis rs11155671 0.53 rs2342770 ENSG00000216906.2 RP11-350J20.9 11.65 1e-27 3.92e-24 0.55 0.47 Testicular germ cell tumor; chr6:149895549 chr6:149904243~149906418:+ LUSC cis rs9326248 0.53 rs1351452 ENSG00000254851.1 RP11-109L13.1 11.65 1.01e-27 3.96e-24 0.86 0.47 Blood protein levels; chr11:117072638 chr11:117135528~117138582:+ LUSC cis rs7104764 1 rs2293167 ENSG00000277290.1 RP11-326C3.16 11.65 1.03e-27 4.04e-24 0.44 0.47 Menarche (age at onset); chr11:211644 chr11:243099~243483:- LUSC cis rs1799949 0.965 rs4793234 ENSG00000198496.9 NBR2 -11.63 1.16e-27 4.51e-24 -0.53 -0.47 Menopause (age at onset); chr17:43358815 chr17:43125610~43153671:+ LUSC cis rs3096299 0.728 rs1011749 ENSG00000274627.1 RP11-104N10.2 11.63 1.18e-27 4.6e-24 0.42 0.47 Multiple myeloma (IgH translocation); chr16:89444461 chr16:89516797~89522217:+ LUSC cis rs9322193 0.566 rs12528243 ENSG00000231760.4 RP11-350J20.5 11.63 1.18e-27 4.61e-24 0.68 0.47 Lung cancer; chr6:149898491 chr6:149796151~149826294:- LUSC cis rs9322193 0.607 rs915140 ENSG00000231760.4 RP11-350J20.5 11.63 1.18e-27 4.61e-24 0.68 0.47 Lung cancer; chr6:149899674 chr6:149796151~149826294:- LUSC cis rs1799949 1 rs1824889 ENSG00000198496.9 NBR2 -11.63 1.2e-27 4.67e-24 -0.52 -0.47 Menopause (age at onset); chr17:43344508 chr17:43125610~43153671:+ LUSC cis rs2739330 0.761 rs5760176 ENSG00000231271.1 AP000350.8 -11.63 1.2e-27 4.68e-24 -0.59 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23949918~23954042:+ LUSC cis rs7115242 0.8 rs493134 ENSG00000254851.1 RP11-109L13.1 -11.63 1.21e-27 4.71e-24 -0.85 -0.47 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116962963 chr11:117135528~117138582:+ LUSC cis rs2739330 0.732 rs5760175 ENSG00000231271.1 AP000350.8 11.63 1.23e-27 4.78e-24 0.6 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23949918~23954042:+ LUSC cis rs3096299 0.685 rs4785675 ENSG00000274627.1 RP11-104N10.2 11.63 1.23e-27 4.79e-24 0.42 0.47 Multiple myeloma (IgH translocation); chr16:89473566 chr16:89516797~89522217:+ LUSC cis rs1799949 1 rs2070834 ENSG00000198496.9 NBR2 -11.63 1.24e-27 4.83e-24 -0.53 -0.47 Menopause (age at onset); chr17:43090268 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs2298862 ENSG00000198496.9 NBR2 -11.62 1.25e-27 4.85e-24 -0.54 -0.47 Menopause (age at onset); chr17:43024671 chr17:43125610~43153671:+ LUSC cis rs1799949 0.93 rs2298861 ENSG00000198496.9 NBR2 -11.62 1.25e-27 4.85e-24 -0.54 -0.47 Menopause (age at onset); chr17:43024814 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs915945 ENSG00000198496.9 NBR2 -11.62 1.25e-27 4.85e-24 -0.54 -0.47 Menopause (age at onset); chr17:43027847 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs36036395 ENSG00000198496.9 NBR2 -11.62 1.25e-27 4.85e-24 -0.54 -0.47 Menopause (age at onset); chr17:43029280 chr17:43125610~43153671:+ LUSC cis rs875971 0.638 rs10249404 ENSG00000226824.5 RP4-756H11.3 11.62 1.25e-27 4.85e-24 0.55 0.47 Aortic root size; chr7:66581737 chr7:66654538~66669855:+ LUSC cis rs2455601 0.638 rs2742485 ENSG00000254860.4 TMEM9B-AS1 11.62 1.25e-27 4.88e-24 0.63 0.47 Schizophrenia; chr11:8965240 chr11:8964675~8977527:+ LUSC cis rs1799949 0.965 rs34633610 ENSG00000198496.9 NBR2 -11.62 1.28e-27 4.97e-24 -0.52 -0.47 Menopause (age at onset); chr17:43342017 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs11654051 ENSG00000198496.9 NBR2 -11.62 1.28e-27 4.97e-24 -0.52 -0.47 Menopause (age at onset); chr17:43342288 chr17:43125610~43153671:+ LUSC cis rs1799949 0.93 rs56729776 ENSG00000198496.9 NBR2 -11.62 1.28e-27 4.97e-24 -0.52 -0.47 Menopause (age at onset); chr17:43344763 chr17:43125610~43153671:+ LUSC cis rs9322193 0.566 rs9397070 ENSG00000231760.4 RP11-350J20.5 -11.62 1.29e-27 5.01e-24 -0.69 -0.47 Lung cancer; chr6:149922073 chr6:149796151~149826294:- LUSC cis rs55794721 0.509 rs6699896 ENSG00000261349.1 RP3-465N24.5 -11.62 1.3e-27 5.04e-24 -0.58 -0.47 Mean corpuscular volume;Plateletcrit; chr1:25436411 chr1:25266102~25267136:- LUSC cis rs801193 0.901 rs4273746 ENSG00000226824.5 RP4-756H11.3 11.62 1.31e-27 5.07e-24 0.56 0.47 Aortic root size; chr7:66836124 chr7:66654538~66669855:+ LUSC cis rs9481169 0.85 rs35815577 ENSG00000255389.1 C6orf3 -11.62 1.36e-27 5.28e-24 -0.86 -0.47 Inflammatory skin disease; chr6:111603527 chr6:111599875~111602295:+ LUSC cis rs7617773 0.78 rs13084616 ENSG00000229759.1 MRPS18AP1 -11.61 1.37e-27 5.3e-24 -0.47 -0.47 Coronary artery disease; chr3:48298209 chr3:48256350~48256938:- LUSC cis rs3931020 0.772 rs1475396 ENSG00000272864.1 RP11-17E13.2 -11.61 1.37e-27 5.31e-24 -0.55 -0.47 Resistin levels; chr1:74776712 chr1:74698769~74699333:- LUSC cis rs1799949 0.93 rs4584865 ENSG00000198496.9 NBR2 -11.61 1.37e-27 5.32e-24 -0.53 -0.47 Menopause (age at onset); chr17:43347551 chr17:43125610~43153671:+ LUSC cis rs2739330 0.731 rs5751792 ENSG00000231271.1 AP000350.8 11.61 1.4e-27 5.4e-24 0.59 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23949918~23954042:+ LUSC cis rs875971 0.638 rs6960778 ENSG00000226824.5 RP4-756H11.3 11.61 1.45e-27 5.63e-24 0.55 0.47 Aortic root size; chr7:66606610 chr7:66654538~66669855:+ LUSC cis rs9545047 1 rs56911077 ENSG00000227676.3 LINC01068 11.61 1.46e-27 5.64e-24 0.57 0.47 Schizophrenia; chr13:79354126 chr13:79566727~79571436:+ LUSC cis rs1799949 1 rs1545764 ENSG00000198496.9 NBR2 -11.61 1.46e-27 5.65e-24 -0.53 -0.47 Menopause (age at onset); chr17:43347197 chr17:43125610~43153671:+ LUSC cis rs9545047 0.901 rs314688 ENSG00000227676.3 LINC01068 11.61 1.47e-27 5.68e-24 0.56 0.47 Schizophrenia; chr13:79449171 chr13:79566727~79571436:+ LUSC cis rs4423214 1 rs4944062 ENSG00000254682.1 RP11-660L16.2 11.61 1.48e-27 5.73e-24 0.61 0.47 Vitamin D levels; chr11:71476248 chr11:71448674~71452157:+ LUSC cis rs7617773 0.744 rs2125482 ENSG00000229759.1 MRPS18AP1 11.6 1.49e-27 5.77e-24 0.48 0.47 Coronary artery disease; chr3:48281643 chr3:48256350~48256938:- LUSC cis rs3096299 0.719 rs2965817 ENSG00000274627.1 RP11-104N10.2 11.6 1.5e-27 5.8e-24 0.41 0.47 Multiple myeloma (IgH translocation); chr16:89446826 chr16:89516797~89522217:+ LUSC cis rs9545047 0.869 rs3742119 ENSG00000227676.3 LINC01068 11.6 1.51e-27 5.84e-24 0.57 0.47 Schizophrenia; chr13:79342859 chr13:79566727~79571436:+ LUSC cis rs9545047 1 rs9318626 ENSG00000227676.3 LINC01068 11.6 1.51e-27 5.84e-24 0.57 0.47 Schizophrenia; chr13:79351820 chr13:79566727~79571436:+ LUSC cis rs4423214 0.879 rs12803256 ENSG00000254682.1 RP11-660L16.2 11.6 1.53e-27 5.9e-24 0.62 0.47 Vitamin D levels; chr11:71421822 chr11:71448674~71452157:+ LUSC cis rs9322193 0.607 rs10457852 ENSG00000231760.4 RP11-350J20.5 11.6 1.54e-27 5.93e-24 0.67 0.47 Lung cancer; chr6:149880584 chr6:149796151~149826294:- LUSC cis rs1799949 1 rs11649954 ENSG00000198496.9 NBR2 -11.6 1.55e-27 5.99e-24 -0.52 -0.47 Menopause (age at onset); chr17:43342667 chr17:43125610~43153671:+ LUSC cis rs10256972 0.567 rs7782651 ENSG00000229043.2 AC091729.9 -11.6 1.56e-27 6e-24 -0.57 -0.47 Endometriosis;Longevity; chr7:1120259 chr7:1160374~1165267:+ LUSC cis rs1799949 0.965 rs1842147 ENSG00000198496.9 NBR2 -11.6 1.58e-27 6.11e-24 -0.53 -0.47 Menopause (age at onset); chr17:43357824 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs4793190 ENSG00000198496.9 NBR2 -11.6 1.59e-27 6.14e-24 -0.53 -0.47 Menopause (age at onset); chr17:43048092 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs3092988 ENSG00000198496.9 NBR2 -11.6 1.59e-27 6.14e-24 -0.53 -0.47 Menopause (age at onset); chr17:43049685 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs8176297 ENSG00000198496.9 NBR2 -11.6 1.59e-27 6.14e-24 -0.53 -0.47 Menopause (age at onset); chr17:43051308 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs8176296 ENSG00000198496.9 NBR2 -11.6 1.59e-27 6.14e-24 -0.53 -0.47 Menopause (age at onset); chr17:43051574 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs4793191 ENSG00000198496.9 NBR2 -11.6 1.59e-27 6.14e-24 -0.53 -0.47 Menopause (age at onset); chr17:43052360 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs4793192 ENSG00000198496.9 NBR2 -11.6 1.59e-27 6.14e-24 -0.53 -0.47 Menopause (age at onset); chr17:43052373 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs8176289 ENSG00000198496.9 NBR2 -11.6 1.59e-27 6.14e-24 -0.53 -0.47 Menopause (age at onset); chr17:43054039 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs16940 ENSG00000198496.9 NBR2 -11.6 1.6e-27 6.15e-24 -0.52 -0.47 Menopause (age at onset); chr17:43093220 chr17:43125610~43153671:+ LUSC cis rs9322193 0.567 rs7747457 ENSG00000216906.2 RP11-350J20.9 11.6 1.62e-27 6.22e-24 0.55 0.47 Lung cancer; chr6:149892366 chr6:149904243~149906418:+ LUSC cis rs150992 0.673 rs161953 ENSG00000248489.1 CTD-2007H13.3 11.59 1.64e-27 6.31e-24 0.55 0.47 Body mass index; chr5:98921201 chr5:98929171~98995013:+ LUSC cis rs150992 0.673 rs161952 ENSG00000248489.1 CTD-2007H13.3 11.59 1.64e-27 6.31e-24 0.55 0.47 Body mass index; chr5:98921665 chr5:98929171~98995013:+ LUSC cis rs1799949 1 rs9646417 ENSG00000198496.9 NBR2 -11.59 1.64e-27 6.33e-24 -0.53 -0.47 Menopause (age at onset); chr17:43346885 chr17:43125610~43153671:+ LUSC cis rs73086581 0.786 rs6037705 ENSG00000229539.1 RP11-119B16.2 11.59 1.65e-27 6.33e-24 0.63 0.47 Response to antidepressants in depression; chr20:3972183 chr20:3888239~3888868:- LUSC cis rs11155671 0.53 rs7758033 ENSG00000216906.2 RP11-350J20.9 11.59 1.72e-27 6.59e-24 0.55 0.47 Testicular germ cell tumor; chr6:149886999 chr6:149904243~149906418:+ LUSC cis rs172166 0.516 rs1150670 ENSG00000216901.1 AL022393.7 11.59 1.72e-27 6.6e-24 0.52 0.47 Cardiac Troponin-T levels; chr6:28162781 chr6:28176188~28176674:+ LUSC cis rs172166 0.516 rs2021826 ENSG00000216901.1 AL022393.7 11.59 1.72e-27 6.6e-24 0.52 0.47 Cardiac Troponin-T levels; chr6:28164978 chr6:28176188~28176674:+ LUSC cis rs73086581 1 rs6037708 ENSG00000229539.1 RP11-119B16.2 11.59 1.74e-27 6.67e-24 0.63 0.47 Response to antidepressants in depression; chr20:3980606 chr20:3888239~3888868:- LUSC cis rs11155671 0.53 rs2342769 ENSG00000216906.2 RP11-350J20.9 11.59 1.75e-27 6.71e-24 0.55 0.47 Testicular germ cell tumor; chr6:149895371 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs6935829 ENSG00000216906.2 RP11-350J20.9 11.59 1.77e-27 6.78e-24 0.54 0.47 Testicular germ cell tumor; chr6:149896675 chr6:149904243~149906418:+ LUSC cis rs4423214 0.918 rs11233789 ENSG00000254682.1 RP11-660L16.2 11.58 1.9e-27 7.29e-24 0.62 0.47 Vitamin D levels; chr11:71470039 chr11:71448674~71452157:+ LUSC cis rs801193 0.935 rs11772264 ENSG00000226824.5 RP4-756H11.3 -11.57 1.98e-27 7.59e-24 -0.55 -0.47 Aortic root size; chr7:66711400 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs7782320 ENSG00000226824.5 RP4-756H11.3 -11.57 1.98e-27 7.59e-24 -0.55 -0.47 Aortic root size; chr7:66712111 chr7:66654538~66669855:+ LUSC cis rs2455601 0.671 rs2568091 ENSG00000254860.4 TMEM9B-AS1 11.57 2.04e-27 7.81e-24 0.63 0.47 Schizophrenia; chr11:8964501 chr11:8964675~8977527:+ LUSC cis rs6782228 0.606 rs6807019 ENSG00000242551.2 POU5F1P6 -11.57 2.04e-27 7.81e-24 -0.54 -0.47 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128687091 chr3:128674735~128677005:- LUSC cis rs7617773 0.817 rs6800492 ENSG00000229759.1 MRPS18AP1 11.57 2.12e-27 8.11e-24 0.48 0.47 Coronary artery disease; chr3:48282400 chr3:48256350~48256938:- LUSC cis rs10256972 0.591 rs10229680 ENSG00000229043.2 AC091729.9 -11.56 2.17e-27 8.27e-24 -0.57 -0.47 Endometriosis;Longevity; chr7:1118929 chr7:1160374~1165267:+ LUSC cis rs12594515 1 rs12911309 ENSG00000273972.1 CTD-2306A12.1 -11.56 2.18e-27 8.3e-24 -0.55 -0.47 Weight;Waist circumference; chr15:45693521 chr15:45702640~45703183:+ LUSC cis rs6921919 0.638 rs1416920 ENSG00000216901.1 AL022393.7 11.56 2.2e-27 8.4e-24 0.58 0.47 Autism spectrum disorder or schizophrenia; chr6:28335007 chr6:28176188~28176674:+ LUSC cis rs1799949 0.931 rs34410138 ENSG00000198496.9 NBR2 -11.56 2.24e-27 8.54e-24 -0.52 -0.47 Menopause (age at onset); chr17:43127753 chr17:43125610~43153671:+ LUSC cis rs12439619 0.921 rs4778672 ENSG00000278603.1 RP13-608F4.5 -11.55 2.47e-27 9.41e-24 -0.62 -0.47 Intelligence (multi-trait analysis); chr15:82245013 chr15:82472203~82472426:+ LUSC cis rs7617773 0.817 rs9818937 ENSG00000229759.1 MRPS18AP1 11.55 2.55e-27 9.71e-24 0.48 0.47 Coronary artery disease; chr3:48283791 chr3:48256350~48256938:- LUSC cis rs3096299 0.632 rs4399533 ENSG00000274627.1 RP11-104N10.2 11.54 2.57e-27 9.78e-24 0.41 0.47 Multiple myeloma (IgH translocation); chr16:89472974 chr16:89516797~89522217:+ LUSC cis rs2739330 0.791 rs9612520 ENSG00000231271.1 AP000350.8 11.54 2.62e-27 9.93e-24 0.61 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23949918~23954042:+ LUSC cis rs7115242 0.669 rs1241658 ENSG00000254851.1 RP11-109L13.1 -11.54 2.68e-27 1.02e-23 -0.86 -0.47 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116948901 chr11:117135528~117138582:+ LUSC cis rs9326248 0.53 rs511676 ENSG00000254851.1 RP11-109L13.1 -11.54 2.68e-27 1.02e-23 -0.86 -0.47 Blood protein levels; chr11:116954168 chr11:117135528~117138582:+ LUSC cis rs12594515 1 rs12595137 ENSG00000273972.1 CTD-2306A12.1 -11.54 2.69e-27 1.02e-23 -0.55 -0.47 Weight;Waist circumference; chr15:45693907 chr15:45702640~45703183:+ LUSC cis rs12594515 0.967 rs12595138 ENSG00000273972.1 CTD-2306A12.1 -11.54 2.69e-27 1.02e-23 -0.55 -0.47 Weight;Waist circumference; chr15:45693910 chr15:45702640~45703183:+ LUSC cis rs73086581 1 rs17215529 ENSG00000229539.1 RP11-119B16.2 11.54 2.71e-27 1.03e-23 0.63 0.47 Response to antidepressants in depression; chr20:3994755 chr20:3888239~3888868:- LUSC cis rs150992 0.512 rs161954 ENSG00000248489.1 CTD-2007H13.3 11.54 2.71e-27 1.03e-23 0.54 0.47 Body mass index; chr5:98920833 chr5:98929171~98995013:+ LUSC cis rs1799949 1 rs3950989 ENSG00000198496.9 NBR2 -11.54 2.71e-27 1.03e-23 -0.53 -0.47 Menopause (age at onset); chr17:43085936 chr17:43125610~43153671:+ LUSC cis rs507080 0.733 rs489126 ENSG00000255239.1 AP002954.6 11.54 2.74e-27 1.04e-23 0.55 0.47 Serum metabolite levels; chr11:118702038 chr11:118688039~118690600:- LUSC cis rs6538678 0.784 rs7297403 ENSG00000258343.1 RP11-536G4.2 -11.54 2.79e-27 1.06e-23 -0.77 -0.47 Lupus nephritis in systemic lupus erythematosus; chr12:95846683 chr12:95795345~95858839:- LUSC cis rs7617773 0.817 rs13072018 ENSG00000229759.1 MRPS18AP1 11.53 2.83e-27 1.07e-23 0.49 0.47 Coronary artery disease; chr3:48278842 chr3:48256350~48256938:- LUSC cis rs1930961 1 rs6004669 ENSG00000272977.1 CTA-390C10.10 -11.53 2.85e-27 1.08e-23 -0.83 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25476218~25479971:+ LUSC cis rs73086581 0.945 rs6037715 ENSG00000229539.1 RP11-119B16.2 11.53 2.88e-27 1.09e-23 0.63 0.47 Response to antidepressants in depression; chr20:3991519 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs6107391 ENSG00000229539.1 RP11-119B16.2 11.53 3.02e-27 1.14e-23 0.62 0.47 Response to antidepressants in depression; chr20:4002436 chr20:3888239~3888868:- LUSC cis rs1150668 0.796 rs1124132 ENSG00000216901.1 AL022393.7 11.53 3.07e-27 1.16e-23 0.52 0.47 Pubertal anthropometrics; chr6:28412544 chr6:28176188~28176674:+ LUSC cis rs2739330 0.627 rs9608219 ENSG00000231271.1 AP000350.8 11.52 3.09e-27 1.16e-23 0.61 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23949918~23954042:+ LUSC cis rs7104764 0.957 rs3782120 ENSG00000277290.1 RP11-326C3.16 11.52 3.09e-27 1.17e-23 0.44 0.47 Menarche (age at onset); chr11:206089 chr11:243099~243483:- LUSC cis rs1799949 1 rs12944458 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43028755 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs72829113 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43029818 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11653253 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43030645 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs12951869 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43035550 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs12944597 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43035667 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs12942277 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43035957 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs34616041 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43036769 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11654452 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43037366 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs4793189 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43038698 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs11657053 ENSG00000198496.9 NBR2 -11.52 3.14e-27 1.18e-23 -0.53 -0.47 Menopause (age at onset); chr17:43039112 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs8176323 ENSG00000198496.9 NBR2 -11.52 3.15e-27 1.19e-23 -0.53 -0.47 Menopause (age at onset); chr17:43043694 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs8176322 ENSG00000198496.9 NBR2 -11.52 3.15e-27 1.19e-23 -0.53 -0.47 Menopause (age at onset); chr17:43043756 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs12516 ENSG00000198496.9 NBR2 -11.52 3.15e-27 1.19e-23 -0.53 -0.47 Menopause (age at onset); chr17:43044391 chr17:43125610~43153671:+ LUSC cis rs507080 0.922 rs525485 ENSG00000255422.1 AP002954.4 -11.52 3.22e-27 1.21e-23 -0.52 -0.47 Serum metabolite levels; chr11:118685045 chr11:118704607~118750263:+ LUSC cis rs9399135 0.636 rs7749106 ENSG00000232876.1 CTA-212D2.2 -11.52 3.29e-27 1.24e-23 -0.57 -0.47 Red blood cell count; chr6:134947004 chr6:135055033~135060550:+ LUSC cis rs977987 0.902 rs34539062 ENSG00000261783.1 RP11-252K23.2 -11.52 3.33e-27 1.25e-23 -0.64 -0.47 Dupuytren's disease; chr16:75459381 chr16:75379818~75381260:- LUSC cis rs977987 0.898 rs12918797 ENSG00000261783.1 RP11-252K23.2 -11.52 3.33e-27 1.25e-23 -0.64 -0.47 Dupuytren's disease; chr16:75459912 chr16:75379818~75381260:- LUSC cis rs6782228 0.606 rs10048945 ENSG00000242551.2 POU5F1P6 -11.52 3.35e-27 1.26e-23 -0.54 -0.47 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128690837 chr3:128674735~128677005:- LUSC cis rs7617773 0.817 rs936426 ENSG00000229759.1 MRPS18AP1 11.51 3.56e-27 1.33e-23 0.47 0.47 Coronary artery disease; chr3:48173763 chr3:48256350~48256938:- LUSC cis rs875971 1 rs9986696 ENSG00000226824.5 RP4-756H11.3 11.5 3.71e-27 1.39e-23 0.56 0.47 Aortic root size; chr7:66239589 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs4774189 ENSG00000280411.1 IGHV1-69-2 -11.5 3.76e-27 1.4e-23 -0.29 -0.47 Kawasaki disease; chr14:106768275 chr14:106762092~106762588:- LUSC cis rs875971 0.66 rs801193 ENSG00000226824.5 RP4-756H11.3 11.5 4.03e-27 1.5e-23 0.53 0.47 Aortic root size; chr7:66565625 chr7:66654538~66669855:+ LUSC cis rs3931020 0.745 rs10874274 ENSG00000272864.1 RP11-17E13.2 -11.49 4.13e-27 1.54e-23 -0.55 -0.47 Resistin levels; chr1:74786450 chr1:74698769~74699333:- LUSC cis rs7617773 0.817 rs9819094 ENSG00000229759.1 MRPS18AP1 11.49 4.14e-27 1.54e-23 0.46 0.47 Coronary artery disease; chr3:48278068 chr3:48256350~48256938:- LUSC cis rs977987 0.742 rs34624768 ENSG00000261783.1 RP11-252K23.2 -11.49 4.38e-27 1.63e-23 -0.64 -0.47 Dupuytren's disease; chr16:75297674 chr16:75379818~75381260:- LUSC cis rs977987 0.8 rs4888378 ENSG00000261783.1 RP11-252K23.2 -11.49 4.38e-27 1.63e-23 -0.64 -0.47 Dupuytren's disease; chr16:75298143 chr16:75379818~75381260:- LUSC cis rs977987 0.8 rs12935787 ENSG00000261783.1 RP11-252K23.2 -11.49 4.38e-27 1.63e-23 -0.64 -0.47 Dupuytren's disease; chr16:75298437 chr16:75379818~75381260:- LUSC cis rs2455601 0.638 rs3815991 ENSG00000254860.4 TMEM9B-AS1 -11.49 4.38e-27 1.63e-23 -0.64 -0.47 Schizophrenia; chr11:8986122 chr11:8964675~8977527:+ LUSC cis rs1799949 1 rs4793231 ENSG00000198496.9 NBR2 -11.48 4.58e-27 1.7e-23 -0.52 -0.47 Menopause (age at onset); chr17:43350101 chr17:43125610~43153671:+ LUSC cis rs977987 0.898 rs12918974 ENSG00000261783.1 RP11-252K23.2 -11.48 4.62e-27 1.71e-23 -0.64 -0.47 Dupuytren's disease; chr16:75460045 chr16:75379818~75381260:- LUSC cis rs977987 0.866 rs12932606 ENSG00000261783.1 RP11-252K23.2 -11.48 4.62e-27 1.71e-23 -0.64 -0.47 Dupuytren's disease; chr16:75460046 chr16:75379818~75381260:- LUSC cis rs7617773 0.779 rs9833309 ENSG00000229759.1 MRPS18AP1 11.48 4.63e-27 1.72e-23 0.48 0.47 Coronary artery disease; chr3:48285960 chr3:48256350~48256938:- LUSC cis rs7617773 0.817 rs9853804 ENSG00000229759.1 MRPS18AP1 11.48 4.63e-27 1.72e-23 0.48 0.47 Coronary artery disease; chr3:48286239 chr3:48256350~48256938:- LUSC cis rs7617773 0.817 rs9834095 ENSG00000229759.1 MRPS18AP1 11.48 4.63e-27 1.72e-23 0.48 0.47 Coronary artery disease; chr3:48286261 chr3:48256350~48256938:- LUSC cis rs7617773 0.817 rs4131361 ENSG00000229759.1 MRPS18AP1 11.48 4.63e-27 1.72e-23 0.48 0.47 Coronary artery disease; chr3:48287322 chr3:48256350~48256938:- LUSC cis rs7617773 0.817 rs4131362 ENSG00000229759.1 MRPS18AP1 11.48 4.63e-27 1.72e-23 0.48 0.47 Coronary artery disease; chr3:48287546 chr3:48256350~48256938:- LUSC cis rs172166 0.516 rs2622322 ENSG00000216901.1 AL022393.7 11.48 4.7e-27 1.74e-23 0.52 0.47 Cardiac Troponin-T levels; chr6:28149665 chr6:28176188~28176674:+ LUSC cis rs73086581 1 rs6107393 ENSG00000229539.1 RP11-119B16.2 11.48 4.84e-27 1.8e-23 0.62 0.47 Response to antidepressants in depression; chr20:4007091 chr20:3888239~3888868:- LUSC cis rs2729354 0.909 rs2729374 ENSG00000265566.2 RN7SL605P -11.47 4.85e-27 1.8e-23 -0.65 -0.47 Blood protein levels; chr11:57559454 chr11:57528085~57528365:- LUSC cis rs2739330 0.76 rs5760095 ENSG00000231271.1 AP000350.8 11.47 5.02e-27 1.86e-23 0.6 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23949918~23954042:+ LUSC cis rs1799949 1 rs11659028 ENSG00000198496.9 NBR2 -11.47 5.03e-27 1.86e-23 -0.53 -0.47 Menopause (age at onset); chr17:43043008 chr17:43125610~43153671:+ LUSC cis rs6782228 0.565 rs12695509 ENSG00000242551.2 POU5F1P6 -11.47 5.13e-27 1.9e-23 -0.54 -0.47 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128698201 chr3:128674735~128677005:- LUSC cis rs1799949 0.965 rs4239149 ENSG00000198496.9 NBR2 11.47 5.2e-27 1.92e-23 0.5 0.47 Menopause (age at onset); chr17:43176078 chr17:43125610~43153671:+ LUSC cis rs3931020 0.772 rs1409785 ENSG00000272864.1 RP11-17E13.2 -11.47 5.29e-27 1.95e-23 -0.55 -0.47 Resistin levels; chr1:74782438 chr1:74698769~74699333:- LUSC cis rs507080 0.501 rs626645 ENSG00000255422.1 AP002954.4 -11.46 5.46e-27 2.01e-23 -0.49 -0.47 Serum metabolite levels; chr11:118704471 chr11:118704607~118750263:+ LUSC cis rs73086581 1 rs11906274 ENSG00000229539.1 RP11-119B16.2 11.46 5.77e-27 2.12e-23 0.63 0.47 Response to antidepressants in depression; chr20:3964889 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs6052196 ENSG00000229539.1 RP11-119B16.2 11.46 5.77e-27 2.12e-23 0.63 0.47 Response to antidepressants in depression; chr20:3965177 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs6116130 ENSG00000229539.1 RP11-119B16.2 11.46 5.77e-27 2.12e-23 0.63 0.47 Response to antidepressants in depression; chr20:3966379 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs6052217 ENSG00000229539.1 RP11-119B16.2 11.46 5.77e-27 2.12e-23 0.63 0.47 Response to antidepressants in depression; chr20:3989564 chr20:3888239~3888868:- LUSC cis rs73086581 1 rs6052218 ENSG00000229539.1 RP11-119B16.2 11.46 5.77e-27 2.12e-23 0.63 0.47 Response to antidepressants in depression; chr20:3989565 chr20:3888239~3888868:- LUSC cis rs73086581 0.945 rs6052219 ENSG00000229539.1 RP11-119B16.2 11.46 5.77e-27 2.12e-23 0.63 0.47 Response to antidepressants in depression; chr20:3989660 chr20:3888239~3888868:- LUSC cis rs1799949 1 rs11651341 ENSG00000198496.9 NBR2 -11.45 5.88e-27 2.15e-23 -0.52 -0.47 Menopause (age at onset); chr17:43350693 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs34572725 ENSG00000198496.9 NBR2 -11.45 5.88e-27 2.15e-23 -0.52 -0.47 Menopause (age at onset); chr17:43351298 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs4534897 ENSG00000198496.9 NBR2 -11.45 5.88e-27 2.15e-23 -0.52 -0.47 Menopause (age at onset); chr17:43354440 chr17:43125610~43153671:+ LUSC cis rs7208859 0.673 rs9911989 ENSG00000263531.1 RP13-753N3.1 -11.45 5.98e-27 2.19e-23 -0.84 -0.47 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910684 chr17:30863921~30864940:- LUSC cis rs977987 0.866 rs17696831 ENSG00000261783.1 RP11-252K23.2 -11.45 6.08e-27 2.23e-23 -0.64 -0.47 Dupuytren's disease; chr16:75459400 chr16:75379818~75381260:- LUSC cis rs4423214 1 rs12278461 ENSG00000254682.1 RP11-660L16.2 11.45 6.1e-27 2.23e-23 0.62 0.47 Vitamin D levels; chr11:71471139 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs2282621 ENSG00000254682.1 RP11-660L16.2 11.45 6.1e-27 2.23e-23 0.62 0.47 Vitamin D levels; chr11:71472428 chr11:71448674~71452157:+ LUSC cis rs4423214 1 rs2282620 ENSG00000254682.1 RP11-660L16.2 11.45 6.1e-27 2.23e-23 0.62 0.47 Vitamin D levels; chr11:71472431 chr11:71448674~71452157:+ LUSC cis rs1150668 0.83 rs2023493 ENSG00000216901.1 AL022393.7 11.45 6.13e-27 2.25e-23 0.52 0.47 Pubertal anthropometrics; chr6:28432385 chr6:28176188~28176674:+ LUSC cis rs9326248 0.53 rs10732856 ENSG00000254851.1 RP11-109L13.1 -11.45 6.27e-27 2.29e-23 -0.83 -0.47 Blood protein levels; chr11:117036397 chr11:117135528~117138582:+ LUSC cis rs9322193 0.607 rs12527391 ENSG00000231760.4 RP11-350J20.5 11.44 6.44e-27 2.35e-23 0.69 0.47 Lung cancer; chr6:149882156 chr6:149796151~149826294:- LUSC cis rs55794721 0.509 rs873308 ENSG00000261349.1 RP3-465N24.5 11.44 6.46e-27 2.36e-23 0.57 0.47 Mean corpuscular volume;Plateletcrit; chr1:25432164 chr1:25266102~25267136:- LUSC cis rs6782228 0.606 rs6787559 ENSG00000242551.2 POU5F1P6 -11.44 6.71e-27 2.45e-23 -0.53 -0.47 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128662243 chr3:128674735~128677005:- LUSC cis rs6782228 0.606 rs2001703 ENSG00000242551.2 POU5F1P6 -11.44 6.71e-27 2.45e-23 -0.53 -0.47 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128664254 chr3:128674735~128677005:- LUSC cis rs875971 0.577 rs34888281 ENSG00000226824.5 RP4-756H11.3 11.44 6.79e-27 2.48e-23 0.56 0.47 Aortic root size; chr7:66120784 chr7:66654538~66669855:+ LUSC cis rs73086581 1 rs6052209 ENSG00000229539.1 RP11-119B16.2 11.44 6.82e-27 2.49e-23 0.63 0.47 Response to antidepressants in depression; chr20:3981100 chr20:3888239~3888868:- LUSC cis rs6964833 1 rs6964833 ENSG00000123965.13 PMS2P5 11.43 7.13e-27 2.6e-23 0.75 0.47 Menarche (age at onset); chr7:74687575 chr7:74894116~74897835:+ LUSC cis rs6964833 1 rs13227433 ENSG00000123965.13 PMS2P5 11.43 7.18e-27 2.62e-23 0.75 0.47 Menarche (age at onset); chr7:74680386 chr7:74894116~74897835:+ LUSC cis rs1185460 0.967 rs1177563 ENSG00000271751.1 RP11-110I1.14 -11.43 7.35e-27 2.67e-23 -0.59 -0.47 Coronary artery disease; chr11:119078373 chr11:119065263~119065677:- LUSC cis rs1799949 0.864 rs60309406 ENSG00000198496.9 NBR2 -11.43 7.5e-27 2.73e-23 -0.52 -0.47 Menopause (age at onset); chr17:43358297 chr17:43125610~43153671:+ LUSC cis rs9322193 0.607 rs7764677 ENSG00000231760.4 RP11-350J20.5 11.43 7.6e-27 2.76e-23 0.67 0.47 Lung cancer; chr6:149906197 chr6:149796151~149826294:- LUSC cis rs507080 0.697 rs653008 ENSG00000255422.1 AP002954.4 -11.42 7.64e-27 2.77e-23 -0.53 -0.47 Serum metabolite levels; chr11:118649775 chr11:118704607~118750263:+ LUSC cis rs977987 0.931 rs11641430 ENSG00000261783.1 RP11-252K23.2 -11.42 7.79e-27 2.83e-23 -0.64 -0.47 Dupuytren's disease; chr16:75461378 chr16:75379818~75381260:- LUSC cis rs977987 0.931 rs7195161 ENSG00000261783.1 RP11-252K23.2 -11.42 7.79e-27 2.83e-23 -0.64 -0.47 Dupuytren's disease; chr16:75461674 chr16:75379818~75381260:- LUSC cis rs977987 0.931 rs1424013 ENSG00000261783.1 RP11-252K23.2 -11.42 7.79e-27 2.83e-23 -0.64 -0.47 Dupuytren's disease; chr16:75462088 chr16:75379818~75381260:- LUSC cis rs17507216 1 rs17356118 ENSG00000278603.1 RP13-608F4.5 11.42 7.92e-27 2.87e-23 0.65 0.47 Excessive daytime sleepiness; chr15:82569149 chr15:82472203~82472426:+ LUSC cis rs1799949 1 rs9646412 ENSG00000198496.9 NBR2 -11.41 8.43e-27 3.06e-23 -0.51 -0.47 Menopause (age at onset); chr17:43348525 chr17:43125610~43153671:+ LUSC cis rs2739330 0.796 rs1006771 ENSG00000099984.9 GSTT2 -11.41 8.51e-27 3.08e-23 -0.59 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23980123~23983911:+ LUSC cis rs73086581 1 rs6107386 ENSG00000229539.1 RP11-119B16.2 11.41 8.82e-27 3.19e-23 0.62 0.47 Response to antidepressants in depression; chr20:3992109 chr20:3888239~3888868:- LUSC cis rs875971 0.965 rs28682868 ENSG00000226824.5 RP4-756H11.3 11.41 8.92e-27 3.23e-23 0.55 0.47 Aortic root size; chr7:66224822 chr7:66654538~66669855:+ LUSC cis rs9322193 0.607 rs4869755 ENSG00000231760.4 RP11-350J20.5 11.4 9.12e-27 3.3e-23 0.68 0.47 Lung cancer; chr6:149886347 chr6:149796151~149826294:- LUSC cis rs9322193 0.639 rs4869756 ENSG00000231760.4 RP11-350J20.5 11.4 9.12e-27 3.3e-23 0.68 0.47 Lung cancer; chr6:149886360 chr6:149796151~149826294:- LUSC cis rs6782228 0.606 rs6439135 ENSG00000242551.2 POU5F1P6 -11.4 9.22e-27 3.33e-23 -0.53 -0.47 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128639790 chr3:128674735~128677005:- LUSC cis rs9326248 0.53 rs510988 ENSG00000254851.1 RP11-109L13.1 -11.4 9.28e-27 3.35e-23 -0.85 -0.47 Blood protein levels; chr11:116943088 chr11:117135528~117138582:+ LUSC cis rs1799949 1 rs3092994 ENSG00000198496.9 NBR2 -11.4 9.59e-27 3.46e-23 -0.52 -0.47 Menopause (age at onset); chr17:43063808 chr17:43125610~43153671:+ LUSC cis rs6782228 0.606 rs7650156 ENSG00000242551.2 POU5F1P6 -11.4 9.62e-27 3.47e-23 -0.53 -0.47 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128642712 chr3:128674735~128677005:- LUSC cis rs1799949 0.965 rs8067269 ENSG00000198496.9 NBR2 -11.4 9.92e-27 3.57e-23 -0.5 -0.47 Menopause (age at onset); chr17:43083782 chr17:43125610~43153671:+ LUSC cis rs73086581 0.945 rs6052222 ENSG00000229539.1 RP11-119B16.2 11.4 9.96e-27 3.59e-23 0.62 0.47 Response to antidepressants in depression; chr20:3992146 chr20:3888239~3888868:- LUSC cis rs875971 1 rs55962648 ENSG00000226824.5 RP4-756H11.3 11.39 1.01e-26 3.64e-23 0.56 0.47 Aortic root size; chr7:66160764 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs2420168 ENSG00000226824.5 RP4-756H11.3 11.39 1.01e-26 3.64e-23 0.56 0.47 Aortic root size; chr7:66165644 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6963646 ENSG00000226824.5 RP4-756H11.3 11.39 1.02e-26 3.67e-23 0.55 0.47 Aortic root size; chr7:66220780 chr7:66654538~66669855:+ LUSC cis rs2712381 0.797 rs62270806 ENSG00000242551.2 POU5F1P6 -11.39 1.06e-26 3.8e-23 -0.53 -0.47 Monocyte count; chr3:128657426 chr3:128674735~128677005:- LUSC cis rs1150668 0.835 rs203869 ENSG00000216901.1 AL022393.7 11.39 1.06e-26 3.82e-23 0.51 0.47 Pubertal anthropometrics; chr6:28073041 chr6:28176188~28176674:+ LUSC cis rs3091242 0.9 rs1811832 ENSG00000261349.1 RP3-465N24.5 -11.38 1.11e-26 3.97e-23 -0.57 -0.46 Erythrocyte sedimentation rate; chr1:25427074 chr1:25266102~25267136:- LUSC cis rs929843 1 rs929843 ENSG00000226232.7 RP11-419C5.2 -11.38 1.12e-26 4.01e-23 -0.52 -0.46 Menarche (age at onset); chr16:70011845 chr16:69976388~69996188:- LUSC cis rs1799949 1 rs8176242 ENSG00000198496.9 NBR2 -11.38 1.12e-26 4.03e-23 -0.52 -0.46 Menopause (age at onset); chr17:43065857 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs4793194 ENSG00000198496.9 NBR2 -11.38 1.12e-26 4.03e-23 -0.52 -0.46 Menopause (age at onset); chr17:43066316 chr17:43125610~43153671:+ LUSC cis rs7208859 0.614 rs73265646 ENSG00000263531.1 RP13-753N3.1 11.38 1.14e-26 4.07e-23 0.85 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917005 chr17:30863921~30864940:- LUSC cis rs6782228 0.509 rs2811495 ENSG00000242551.2 POU5F1P6 -11.38 1.19e-26 4.25e-23 -0.53 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128641114 chr3:128674735~128677005:- LUSC cis rs6782228 0.565 rs2811496 ENSG00000242551.2 POU5F1P6 -11.38 1.19e-26 4.25e-23 -0.53 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128641115 chr3:128674735~128677005:- LUSC cis rs875971 1 rs4718307 ENSG00000226824.5 RP4-756H11.3 11.37 1.2e-26 4.29e-23 0.55 0.46 Aortic root size; chr7:66146001 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs7801282 ENSG00000226824.5 RP4-756H11.3 11.37 1.2e-26 4.29e-23 0.55 0.46 Aortic root size; chr7:66148700 chr7:66654538~66669855:+ LUSC cis rs2739330 0.703 rs5760112 ENSG00000231271.1 AP000350.8 11.37 1.23e-26 4.4e-23 0.6 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23949918~23954042:+ LUSC cis rs9481169 1 rs9481169 ENSG00000255389.1 C6orf3 -11.37 1.25e-26 4.46e-23 -0.74 -0.46 Inflammatory skin disease; chr6:111608659 chr6:111599875~111602295:+ LUSC cis rs6700559 0.81 rs7529962 ENSG00000260088.1 RP11-92G12.3 -11.37 1.25e-26 4.46e-23 -0.55 -0.46 Coronary artery disease; chr1:200627849 chr1:200669507~200694250:+ LUSC cis rs9322193 0.607 rs3798763 ENSG00000231760.4 RP11-350J20.5 11.37 1.28e-26 4.58e-23 0.68 0.46 Lung cancer; chr6:149889964 chr6:149796151~149826294:- LUSC cis rs9322193 0.607 rs12204653 ENSG00000231760.4 RP11-350J20.5 11.37 1.28e-26 4.58e-23 0.68 0.46 Lung cancer; chr6:149891885 chr6:149796151~149826294:- LUSC cis rs7617773 0.78 rs13090538 ENSG00000229759.1 MRPS18AP1 11.36 1.31e-26 4.69e-23 0.47 0.46 Coronary artery disease; chr3:48329279 chr3:48256350~48256938:- LUSC cis rs6782228 0.527 rs6767383 ENSG00000242551.2 POU5F1P6 -11.36 1.32e-26 4.72e-23 -0.54 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694744 chr3:128674735~128677005:- LUSC cis rs6538678 0.895 rs7137751 ENSG00000258343.1 RP11-536G4.2 -11.36 1.33e-26 4.73e-23 -0.65 -0.46 Lupus nephritis in systemic lupus erythematosus; chr12:95861806 chr12:95795345~95858839:- LUSC cis rs1799949 1 rs8176273 ENSG00000198496.9 NBR2 -11.36 1.33e-26 4.75e-23 -0.52 -0.46 Menopause (age at onset); chr17:43059636 chr17:43125610~43153671:+ LUSC cis rs7617773 0.817 rs6801801 ENSG00000229759.1 MRPS18AP1 11.36 1.38e-26 4.9e-23 0.47 0.46 Coronary artery disease; chr3:48284943 chr3:48256350~48256938:- LUSC cis rs875971 1 rs11974219 ENSG00000226824.5 RP4-756H11.3 11.36 1.38e-26 4.92e-23 0.55 0.46 Aortic root size; chr7:66182423 chr7:66654538~66669855:+ LUSC cis rs16828019 0.852 rs12742379 ENSG00000235358.1 RP11-399E6.1 11.36 1.39e-26 4.95e-23 0.85 0.46 Intelligence (multi-trait analysis); chr1:41060709 chr1:41242373~41284861:+ LUSC cis rs73086581 1 rs56141565 ENSG00000229539.1 RP11-119B16.2 11.35 1.44e-26 5.12e-23 0.66 0.46 Response to antidepressants in depression; chr20:4017956 chr20:3888239~3888868:- LUSC cis rs9322193 0.543 rs9371533 ENSG00000216906.2 RP11-350J20.9 11.35 1.44e-26 5.13e-23 0.55 0.46 Lung cancer; chr6:149889545 chr6:149904243~149906418:+ LUSC cis rs10256972 0.591 rs6968988 ENSG00000229043.2 AC091729.9 -11.35 1.45e-26 5.14e-23 -0.56 -0.46 Endometriosis;Longevity; chr7:1129983 chr7:1160374~1165267:+ LUSC cis rs12439619 0.883 rs62012045 ENSG00000278603.1 RP13-608F4.5 11.35 1.45e-26 5.15e-23 0.61 0.46 Intelligence (multi-trait analysis); chr15:82229366 chr15:82472203~82472426:+ LUSC cis rs1799949 1 rs8176265 ENSG00000198496.9 NBR2 -11.35 1.46e-26 5.2e-23 -0.52 -0.46 Menopause (age at onset); chr17:43061979 chr17:43125610~43153671:+ LUSC cis rs875971 0.54 rs35510581 ENSG00000226824.5 RP4-756H11.3 11.35 1.47e-26 5.21e-23 0.55 0.46 Aortic root size; chr7:66113790 chr7:66654538~66669855:+ LUSC cis rs6782228 0.527 rs7426806 ENSG00000242551.2 POU5F1P6 -11.35 1.48e-26 5.26e-23 -0.54 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694087 chr3:128674735~128677005:- LUSC cis rs16828019 0.852 rs12729586 ENSG00000235358.1 RP11-399E6.1 11.35 1.49e-26 5.27e-23 0.85 0.46 Intelligence (multi-trait analysis); chr1:41056705 chr1:41242373~41284861:+ LUSC cis rs16828019 0.704 rs34486565 ENSG00000235358.1 RP11-399E6.1 11.35 1.49e-26 5.27e-23 0.85 0.46 Intelligence (multi-trait analysis); chr1:41056838 chr1:41242373~41284861:+ LUSC cis rs6782228 0.606 rs2811489 ENSG00000242551.2 POU5F1P6 11.35 1.5e-26 5.33e-23 0.53 0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128618528 chr3:128674735~128677005:- LUSC cis rs6964833 1 rs4717906 ENSG00000123965.13 PMS2P5 11.35 1.51e-26 5.35e-23 0.73 0.46 Menarche (age at onset); chr7:74671923 chr7:74894116~74897835:+ LUSC cis rs7617773 0.78 rs6442111 ENSG00000229759.1 MRPS18AP1 11.35 1.52e-26 5.37e-23 0.48 0.46 Coronary artery disease; chr3:48270570 chr3:48256350~48256938:- LUSC cis rs7617773 0.851 rs6775179 ENSG00000229759.1 MRPS18AP1 11.35 1.52e-26 5.37e-23 0.48 0.46 Coronary artery disease; chr3:48271928 chr3:48256350~48256938:- LUSC cis rs7301826 0.58 rs61938969 ENSG00000256299.1 RP11-989F5.3 11.35 1.54e-26 5.45e-23 0.52 0.46 Plasma plasminogen activator levels; chr12:130831525 chr12:130810821~130812622:- LUSC cis rs7535099 0.954 rs2376016 ENSG00000224570.1 RP11-430H12.2 11.34 1.62e-26 5.72e-23 0.65 0.46 Blood protein levels; chr1:65568313 chr1:65576129~65578380:- LUSC cis rs10256972 0.553 rs4236381 ENSG00000229043.2 AC091729.9 -11.34 1.64e-26 5.81e-23 -0.55 -0.46 Endometriosis;Longevity; chr7:1126087 chr7:1160374~1165267:+ LUSC cis rs172166 0.516 rs1225710 ENSG00000216901.1 AL022393.7 -11.34 1.66e-26 5.85e-23 -0.52 -0.46 Cardiac Troponin-T levels; chr6:28132862 chr6:28176188~28176674:+ LUSC cis rs7301826 0.627 rs4334059 ENSG00000256299.1 RP11-989F5.3 -11.33 1.75e-26 6.17e-23 -0.52 -0.46 Plasma plasminogen activator levels; chr12:130829669 chr12:130810821~130812622:- LUSC cis rs12439619 0.921 rs56042848 ENSG00000278603.1 RP13-608F4.5 11.33 1.78e-26 6.28e-23 0.61 0.46 Intelligence (multi-trait analysis); chr15:82235244 chr15:82472203~82472426:+ LUSC cis rs3096299 0.667 rs2965947 ENSG00000274627.1 RP11-104N10.2 11.33 1.78e-26 6.29e-23 0.41 0.46 Multiple myeloma (IgH translocation); chr16:89452262 chr16:89516797~89522217:+ LUSC cis rs6782228 0.509 rs6780447 ENSG00000242551.2 POU5F1P6 -11.33 1.79e-26 6.3e-23 -0.54 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694965 chr3:128674735~128677005:- LUSC cis rs3096299 0.692 rs4785565 ENSG00000274627.1 RP11-104N10.2 11.33 1.82e-26 6.42e-23 0.41 0.46 Multiple myeloma (IgH translocation); chr16:89449351 chr16:89516797~89522217:+ LUSC cis rs11155671 0.53 rs9383940 ENSG00000216906.2 RP11-350J20.9 11.33 1.83e-26 6.44e-23 0.54 0.46 Testicular germ cell tumor; chr6:149904923 chr6:149904243~149906418:+ LUSC cis rs9326248 0.53 rs2513095 ENSG00000254851.1 RP11-109L13.1 -11.33 1.83e-26 6.46e-23 -0.85 -0.46 Blood protein levels; chr11:116935553 chr11:117135528~117138582:+ LUSC cis rs8062405 1 rs8061590 ENSG00000259982.1 CDC37P1 11.32 1.88e-26 6.61e-23 0.58 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28883809 chr16:28700294~28701540:- LUSC cis rs2729354 1 rs2848630 ENSG00000265566.2 RN7SL605P -11.32 1.88e-26 6.62e-23 -0.65 -0.46 Blood protein levels; chr11:57589434 chr11:57528085~57528365:- LUSC cis rs6782228 0.606 rs4857919 ENSG00000242551.2 POU5F1P6 -11.32 1.93e-26 6.8e-23 -0.53 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128688652 chr3:128674735~128677005:- LUSC cis rs10256972 0.591 rs11766651 ENSG00000229043.2 AC091729.9 -11.32 1.99e-26 7e-23 -0.55 -0.46 Endometriosis;Longevity; chr7:1122010 chr7:1160374~1165267:+ LUSC cis rs528808 1 rs528808 ENSG00000219755.1 RP1-199J3.5 11.32 2.04e-26 7.15e-23 0.65 0.46 Age-related hearing impairment; chr6:99656413 chr6:99575712~99576456:+ LUSC cis rs1799949 1 rs8176318 ENSG00000198496.9 NBR2 -11.31 2.04e-26 7.18e-23 -0.51 -0.46 Menopause (age at onset); chr17:43045257 chr17:43125610~43153671:+ LUSC cis rs7617773 0.779 rs11718329 ENSG00000229759.1 MRPS18AP1 11.31 2.09e-26 7.35e-23 0.48 0.46 Coronary artery disease; chr3:48268338 chr3:48256350~48256938:- LUSC cis rs7174755 0.923 rs9672310 ENSG00000260657.2 RP11-315D16.4 11.31 2.16e-26 7.58e-23 0.57 0.46 Major depressive disorder; chr15:68306578 chr15:68267792~68277994:- LUSC cis rs7301826 0.651 rs2277336 ENSG00000256299.1 RP11-989F5.3 11.31 2.22e-26 7.8e-23 0.52 0.46 Plasma plasminogen activator levels; chr12:130801574 chr12:130810821~130812622:- LUSC cis rs172166 0.56 rs203878 ENSG00000216901.1 AL022393.7 11.31 2.23e-26 7.8e-23 0.51 0.46 Cardiac Troponin-T levels; chr6:28081218 chr6:28176188~28176674:+ LUSC cis rs875971 1 rs709597 ENSG00000226824.5 RP4-756H11.3 11.31 2.23e-26 7.8e-23 0.55 0.46 Aortic root size; chr7:66360996 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs875971 ENSG00000226824.5 RP4-756H11.3 11.3 2.28e-26 8e-23 0.55 0.46 Aortic root size; chr7:66152608 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs1860468 ENSG00000226824.5 RP4-756H11.3 11.3 2.31e-26 8.08e-23 0.54 0.46 Aortic root size; chr7:66642265 chr7:66654538~66669855:+ LUSC cis rs9326248 0.53 rs579890 ENSG00000254851.1 RP11-109L13.1 -11.3 2.31e-26 8.1e-23 -0.86 -0.46 Blood protein levels; chr11:116928247 chr11:117135528~117138582:+ LUSC cis rs9545047 1 rs2484345 ENSG00000227676.3 LINC01068 -11.29 2.5e-26 8.75e-23 -0.57 -0.46 Schizophrenia; chr13:79427913 chr13:79566727~79571436:+ LUSC cis rs6782228 0.585 rs6774515 ENSG00000242551.2 POU5F1P6 -11.29 2.51e-26 8.78e-23 -0.53 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128697035 chr3:128674735~128677005:- LUSC cis rs6700559 0.873 rs6427840 ENSG00000260088.1 RP11-92G12.3 -11.29 2.61e-26 9.12e-23 -0.59 -0.46 Coronary artery disease; chr1:200685659 chr1:200669507~200694250:+ LUSC cis rs977987 0.8 rs3784935 ENSG00000261783.1 RP11-252K23.2 -11.29 2.64e-26 9.21e-23 -0.64 -0.46 Dupuytren's disease; chr16:75302532 chr16:75379818~75381260:- LUSC cis rs977987 0.8 rs11645329 ENSG00000261783.1 RP11-252K23.2 -11.29 2.64e-26 9.21e-23 -0.64 -0.46 Dupuytren's disease; chr16:75302781 chr16:75379818~75381260:- LUSC cis rs2729354 0.953 rs2649650 ENSG00000265566.2 RN7SL605P -11.28 2.78e-26 9.7e-23 -0.65 -0.46 Blood protein levels; chr11:57560094 chr11:57528085~57528365:- LUSC cis rs3096299 0.642 rs12934829 ENSG00000274627.1 RP11-104N10.2 11.28 2.81e-26 9.78e-23 0.41 0.46 Multiple myeloma (IgH translocation); chr16:89456941 chr16:89516797~89522217:+ LUSC cis rs875971 0.66 rs3764903 ENSG00000226824.5 RP4-756H11.3 11.28 2.85e-26 9.9e-23 0.54 0.46 Aortic root size; chr7:66633495 chr7:66654538~66669855:+ LUSC cis rs875971 0.66 rs1860470 ENSG00000226824.5 RP4-756H11.3 11.28 2.85e-26 9.9e-23 0.54 0.46 Aortic root size; chr7:66638707 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1565531 ENSG00000226824.5 RP4-756H11.3 11.28 2.86e-26 9.94e-23 0.55 0.46 Aortic root size; chr7:66198126 chr7:66654538~66669855:+ LUSC cis rs8062405 0.679 rs72793818 ENSG00000259982.1 CDC37P1 11.28 2.87e-26 1e-22 0.58 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28881816 chr16:28700294~28701540:- LUSC cis rs1799949 0.965 rs9646418 ENSG00000198496.9 NBR2 -11.27 2.95e-26 1.02e-22 -0.5 -0.46 Menopause (age at onset); chr17:43348533 chr17:43125610~43153671:+ LUSC cis rs16828019 0.852 rs12406620 ENSG00000235358.1 RP11-399E6.1 11.27 2.96e-26 1.03e-22 0.86 0.46 Intelligence (multi-trait analysis); chr1:41046992 chr1:41242373~41284861:+ LUSC cis rs1799949 1 rs35070007 ENSG00000198496.9 NBR2 11.27 2.97e-26 1.03e-22 0.49 0.46 Menopause (age at onset); chr17:43164730 chr17:43125610~43153671:+ LUSC cis rs172166 0.516 rs1225715 ENSG00000216901.1 AL022393.7 -11.27 2.98e-26 1.04e-22 -0.51 -0.46 Cardiac Troponin-T levels; chr6:28145595 chr6:28176188~28176674:+ LUSC cis rs507080 0.769 rs7389 ENSG00000255422.1 AP002954.4 11.27 3e-26 1.04e-22 0.52 0.46 Serum metabolite levels; chr11:118657756 chr11:118704607~118750263:+ LUSC cis rs507080 0.922 rs654792 ENSG00000255239.1 AP002954.6 -11.27 3.08e-26 1.07e-22 -0.56 -0.46 Serum metabolite levels; chr11:118682287 chr11:118688039~118690600:- LUSC cis rs875971 1 rs778726 ENSG00000226824.5 RP4-756H11.3 -11.27 3.16e-26 1.09e-22 -0.55 -0.46 Aortic root size; chr7:66363744 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs778723 ENSG00000226824.5 RP4-756H11.3 -11.27 3.16e-26 1.09e-22 -0.55 -0.46 Aortic root size; chr7:66364510 chr7:66654538~66669855:+ LUSC cis rs875971 0.767 rs1695815 ENSG00000226824.5 RP4-756H11.3 -11.27 3.16e-26 1.09e-22 -0.55 -0.46 Aortic root size; chr7:66366357 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs778685 ENSG00000226824.5 RP4-756H11.3 -11.27 3.16e-26 1.09e-22 -0.55 -0.46 Aortic root size; chr7:66371189 chr7:66654538~66669855:+ LUSC cis rs875971 0.929 rs778682 ENSG00000226824.5 RP4-756H11.3 -11.27 3.16e-26 1.09e-22 -0.55 -0.46 Aortic root size; chr7:66372947 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs11765965 ENSG00000226824.5 RP4-756H11.3 -11.27 3.16e-26 1.09e-22 -0.55 -0.46 Aortic root size; chr7:66377234 chr7:66654538~66669855:+ LUSC cis rs6782228 0.585 rs2811492 ENSG00000242551.2 POU5F1P6 -11.27 3.18e-26 1.1e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128637436 chr3:128674735~128677005:- LUSC cis rs6782228 0.606 rs1697 ENSG00000242551.2 POU5F1P6 -11.27 3.18e-26 1.1e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128638009 chr3:128674735~128677005:- LUSC cis rs1799949 1 rs35330014 ENSG00000198496.9 NBR2 -11.26 3.21e-26 1.11e-22 -0.52 -0.46 Menopause (age at onset); chr17:43060530 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs8176269 ENSG00000198496.9 NBR2 -11.26 3.21e-26 1.11e-22 -0.52 -0.46 Menopause (age at onset); chr17:43061609 chr17:43125610~43153671:+ LUSC cis rs2729354 1 rs2729355 ENSG00000265566.2 RN7SL605P -11.26 3.24e-26 1.12e-22 -0.65 -0.46 Blood protein levels; chr11:57586510 chr11:57528085~57528365:- LUSC cis rs6782228 0.585 rs3122175 ENSG00000242551.2 POU5F1P6 -11.26 3.28e-26 1.14e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128642433 chr3:128674735~128677005:- LUSC cis rs6782228 0.606 rs2811497 ENSG00000242551.2 POU5F1P6 -11.26 3.28e-26 1.14e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128644489 chr3:128674735~128677005:- LUSC cis rs7104764 0.957 rs58692051 ENSG00000277290.1 RP11-326C3.16 11.26 3.29e-26 1.14e-22 0.43 0.46 Menarche (age at onset); chr11:207410 chr11:243099~243483:- LUSC cis rs875971 0.964 rs778721 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66380410 chr7:66654538~66669855:+ LUSC cis rs875971 0.929 rs778712 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66384991 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs778710 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66389847 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs778708 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66391332 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs778706 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66395437 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs778700 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66401463 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs778699 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66403303 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs778696 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66405826 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs778694 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66406571 chr7:66654538~66669855:+ LUSC cis rs875971 0.929 rs778692 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66407462 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs4718343 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66409301 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs4718344 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66409394 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1968225 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66409786 chr7:66654538~66669855:+ LUSC cis rs875971 0.737 rs7803424 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66415618 chr7:66654538~66669855:+ LUSC cis rs875971 0.83 rs7799834 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66415707 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6460295 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66417741 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs6978721 ENSG00000226824.5 RP4-756H11.3 -11.26 3.31e-26 1.14e-22 -0.55 -0.46 Aortic root size; chr7:66418217 chr7:66654538~66669855:+ LUSC cis rs7617773 0.817 rs9837228 ENSG00000229759.1 MRPS18AP1 -11.26 3.4e-26 1.17e-22 -0.47 -0.46 Coronary artery disease; chr3:48282976 chr3:48256350~48256938:- LUSC cis rs875971 0.964 rs1643388 ENSG00000226824.5 RP4-756H11.3 -11.26 3.43e-26 1.18e-22 -0.55 -0.46 Aortic root size; chr7:66379575 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs778722 ENSG00000226824.5 RP4-756H11.3 -11.26 3.43e-26 1.18e-22 -0.55 -0.46 Aortic root size; chr7:66379841 chr7:66654538~66669855:+ LUSC cis rs6782228 0.606 rs2811500 ENSG00000242551.2 POU5F1P6 -11.25 3.52e-26 1.21e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128647413 chr3:128674735~128677005:- LUSC cis rs1150668 0.796 rs1005125 ENSG00000216901.1 AL022393.7 11.25 3.54e-26 1.22e-22 0.51 0.46 Pubertal anthropometrics; chr6:28399578 chr6:28176188~28176674:+ LUSC cis rs6782228 0.606 rs2811490 ENSG00000242551.2 POU5F1P6 -11.25 3.55e-26 1.22e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128632912 chr3:128674735~128677005:- LUSC cis rs8062405 1 rs3888190 ENSG00000259982.1 CDC37P1 11.25 3.56e-26 1.23e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878165 chr16:28700294~28701540:- LUSC cis rs1930961 1 rs5996946 ENSG00000272977.1 CTA-390C10.10 -11.25 3.58e-26 1.23e-22 -0.81 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25476218~25479971:+ LUSC cis rs6921919 0.525 rs1361386 ENSG00000216901.1 AL022393.7 11.25 3.67e-26 1.26e-22 0.56 0.46 Autism spectrum disorder or schizophrenia; chr6:28337827 chr6:28176188~28176674:+ LUSC cis rs6921919 0.638 rs6456815 ENSG00000216901.1 AL022393.7 11.25 3.67e-26 1.26e-22 0.56 0.46 Autism spectrum disorder or schizophrenia; chr6:28338360 chr6:28176188~28176674:+ LUSC cis rs6921919 0.638 rs2108926 ENSG00000216901.1 AL022393.7 11.25 3.67e-26 1.26e-22 0.56 0.46 Autism spectrum disorder or schizophrenia; chr6:28340970 chr6:28176188~28176674:+ LUSC cis rs16828019 0.777 rs16911 ENSG00000235358.1 RP11-399E6.1 11.25 3.76e-26 1.29e-22 0.85 0.46 Intelligence (multi-trait analysis); chr1:41032349 chr1:41242373~41284861:+ LUSC cis rs16828019 0.777 rs2300658 ENSG00000235358.1 RP11-399E6.1 11.25 3.76e-26 1.29e-22 0.85 0.46 Intelligence (multi-trait analysis); chr1:41039350 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs12729448 ENSG00000235358.1 RP11-399E6.1 11.25 3.76e-26 1.29e-22 0.85 0.46 Intelligence (multi-trait analysis); chr1:41044162 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs2268678 ENSG00000235358.1 RP11-399E6.1 11.25 3.76e-26 1.29e-22 0.85 0.46 Intelligence (multi-trait analysis); chr1:41045381 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs10489520 ENSG00000235358.1 RP11-399E6.1 11.25 3.76e-26 1.29e-22 0.85 0.46 Intelligence (multi-trait analysis); chr1:41046083 chr1:41242373~41284861:+ LUSC cis rs875971 0.965 rs10267430 ENSG00000226824.5 RP4-756H11.3 11.25 3.77e-26 1.29e-22 0.55 0.46 Aortic root size; chr7:66278036 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs10257427 ENSG00000226824.5 RP4-756H11.3 11.25 3.77e-26 1.29e-22 0.55 0.46 Aortic root size; chr7:66278221 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs10215948 ENSG00000226824.5 RP4-756H11.3 11.25 3.77e-26 1.29e-22 0.55 0.46 Aortic root size; chr7:66282799 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs55748098 ENSG00000226824.5 RP4-756H11.3 11.25 3.77e-26 1.29e-22 0.55 0.46 Aortic root size; chr7:66298631 chr7:66654538~66669855:+ LUSC cis rs2739330 0.76 rs1002286 ENSG00000231271.1 AP000350.8 -11.25 3.77e-26 1.29e-22 -0.59 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23949918~23954042:+ LUSC cis rs9326248 0.53 rs562179 ENSG00000254851.1 RP11-109L13.1 -11.24 3.84e-26 1.32e-22 -0.82 -0.46 Blood protein levels; chr11:116934488 chr11:117135528~117138582:+ LUSC cis rs875971 1 rs6961717 ENSG00000226824.5 RP4-756H11.3 11.24 3.84e-26 1.32e-22 0.55 0.46 Aortic root size; chr7:66122550 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs2027902 ENSG00000280411.1 IGHV1-69-2 -11.24 3.96e-26 1.36e-22 -0.29 -0.46 Kawasaki disease; chr14:106807157 chr14:106762092~106762588:- LUSC cis rs6782228 0.606 rs7627549 ENSG00000242551.2 POU5F1P6 -11.24 4.05e-26 1.38e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128634236 chr3:128674735~128677005:- LUSC cis rs6964833 1 rs36044436 ENSG00000123965.13 PMS2P5 11.24 4.14e-26 1.42e-22 0.75 0.46 Menarche (age at onset); chr7:74675495 chr7:74894116~74897835:+ LUSC cis rs977987 0.736 rs11865296 ENSG00000261783.1 RP11-252K23.2 -11.23 4.21e-26 1.44e-22 -0.62 -0.46 Dupuytren's disease; chr16:75439795 chr16:75379818~75381260:- LUSC cis rs875971 1 rs6945843 ENSG00000226824.5 RP4-756H11.3 11.23 4.29e-26 1.46e-22 0.55 0.46 Aortic root size; chr7:66269796 chr7:66654538~66669855:+ LUSC cis rs10129255 0.556 rs8010005 ENSG00000280411.1 IGHV1-69-2 -11.23 4.3e-26 1.47e-22 -0.29 -0.46 Kawasaki disease; chr14:106777987 chr14:106762092~106762588:- LUSC cis rs10129255 0.556 rs6576224 ENSG00000280411.1 IGHV1-69-2 -11.23 4.3e-26 1.47e-22 -0.29 -0.46 Kawasaki disease; chr14:106777997 chr14:106762092~106762588:- LUSC cis rs10129255 0.518 rs8010020 ENSG00000280411.1 IGHV1-69-2 -11.23 4.3e-26 1.47e-22 -0.29 -0.46 Kawasaki disease; chr14:106778016 chr14:106762092~106762588:- LUSC cis rs507080 0.733 rs601318 ENSG00000255422.1 AP002954.4 -11.23 4.32e-26 1.47e-22 -0.52 -0.46 Serum metabolite levels; chr11:118648845 chr11:118704607~118750263:+ LUSC cis rs801193 0.844 rs2244022 ENSG00000226824.5 RP4-756H11.3 -11.23 4.46e-26 1.52e-22 -0.53 -0.46 Aortic root size; chr7:66737443 chr7:66654538~66669855:+ LUSC cis rs1799949 0.773 rs2137990 ENSG00000198496.9 NBR2 11.23 4.5e-26 1.53e-22 0.49 0.46 Menopause (age at onset); chr17:43165879 chr17:43125610~43153671:+ LUSC cis rs3096299 0.719 rs2353581 ENSG00000274627.1 RP11-104N10.2 11.23 4.55e-26 1.55e-22 0.41 0.46 Multiple myeloma (IgH translocation); chr16:89452500 chr16:89516797~89522217:+ LUSC cis rs1150668 0.796 rs2247002 ENSG00000216901.1 AL022393.7 11.22 4.66e-26 1.59e-22 0.51 0.46 Pubertal anthropometrics; chr6:28430174 chr6:28176188~28176674:+ LUSC cis rs875971 1 rs2087647 ENSG00000226824.5 RP4-756H11.3 11.22 4.66e-26 1.59e-22 0.55 0.46 Aortic root size; chr7:66128201 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6956179 ENSG00000226824.5 RP4-756H11.3 11.22 4.67e-26 1.59e-22 0.55 0.46 Aortic root size; chr7:66341672 chr7:66654538~66669855:+ LUSC cis rs7208859 0.673 rs12103759 ENSG00000263531.1 RP13-753N3.1 11.22 4.69e-26 1.6e-22 0.83 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908669 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs59029591 ENSG00000263531.1 RP13-753N3.1 11.22 4.69e-26 1.6e-22 0.83 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908728 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs73265633 ENSG00000263531.1 RP13-753N3.1 11.22 4.69e-26 1.6e-22 0.83 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30909288 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs9913782 ENSG00000263531.1 RP13-753N3.1 11.22 4.69e-26 1.6e-22 0.83 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910366 chr17:30863921~30864940:- LUSC cis rs7104764 0.957 rs6598075 ENSG00000277290.1 RP11-326C3.16 11.22 4.7e-26 1.6e-22 0.43 0.46 Menarche (age at onset); chr11:207275 chr11:243099~243483:- LUSC cis rs7301826 0.585 rs6486600 ENSG00000256299.1 RP11-989F5.3 -11.22 4.77e-26 1.62e-22 -0.51 -0.46 Plasma plasminogen activator levels; chr12:130808432 chr12:130810821~130812622:- LUSC cis rs2455601 0.744 rs2163626 ENSG00000254860.4 TMEM9B-AS1 11.22 4.87e-26 1.65e-22 0.61 0.46 Schizophrenia; chr11:8962000 chr11:8964675~8977527:+ LUSC cis rs6782228 0.606 rs4857861 ENSG00000242551.2 POU5F1P6 -11.22 4.94e-26 1.68e-22 -0.53 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128687924 chr3:128674735~128677005:- LUSC cis rs6782228 0.509 rs4481172 ENSG00000242551.2 POU5F1P6 -11.21 5.01e-26 1.7e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128653814 chr3:128674735~128677005:- LUSC cis rs10129255 0.5 rs2027903 ENSG00000280411.1 IGHV1-69-2 -11.21 5.09e-26 1.73e-22 -0.29 -0.46 Kawasaki disease; chr14:106807047 chr14:106762092~106762588:- LUSC cis rs1150668 0.83 rs2859365 ENSG00000216901.1 AL022393.7 -11.21 5.09e-26 1.73e-22 -0.52 -0.46 Pubertal anthropometrics; chr6:28423688 chr6:28176188~28176674:+ LUSC cis rs875971 1 rs11971949 ENSG00000226824.5 RP4-756H11.3 11.21 5.29e-26 1.79e-22 0.55 0.46 Aortic root size; chr7:66161027 chr7:66654538~66669855:+ LUSC cis rs9326248 0.53 rs2513093 ENSG00000254851.1 RP11-109L13.1 -11.21 5.3e-26 1.79e-22 -0.84 -0.46 Blood protein levels; chr11:116935971 chr11:117135528~117138582:+ LUSC cis rs875971 0.965 rs9969301 ENSG00000226824.5 RP4-756H11.3 11.21 5.31e-26 1.8e-22 0.55 0.46 Aortic root size; chr7:66316668 chr7:66654538~66669855:+ LUSC cis rs17507216 0.958 rs28648832 ENSG00000278603.1 RP13-608F4.5 11.21 5.35e-26 1.81e-22 0.65 0.46 Excessive daytime sleepiness; chr15:82567642 chr15:82472203~82472426:+ LUSC cis rs8062405 1 rs62037364 ENSG00000259982.1 CDC37P1 11.21 5.36e-26 1.81e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857374 chr16:28700294~28701540:- LUSC cis rs977987 0.966 rs6564261 ENSG00000261783.1 RP11-252K23.2 -11.21 5.36e-26 1.81e-22 -0.62 -0.46 Dupuytren's disease; chr16:75458344 chr16:75379818~75381260:- LUSC cis rs1799949 0.894 rs36062488 ENSG00000198496.9 NBR2 11.21 5.44e-26 1.84e-22 0.49 0.46 Menopause (age at onset); chr17:43185455 chr17:43125610~43153671:+ LUSC cis rs8062405 0.964 rs78613234 ENSG00000259982.1 CDC37P1 11.21 5.45e-26 1.84e-22 0.56 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828104 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs62036624 ENSG00000259982.1 CDC37P1 11.21 5.45e-26 1.84e-22 0.56 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828609 chr16:28700294~28701540:- LUSC cis rs10129255 0.576 rs2157616 ENSG00000280411.1 IGHV1-69-2 -11.21 5.45e-26 1.84e-22 -0.28 -0.46 Kawasaki disease; chr14:106767802 chr14:106762092~106762588:- LUSC cis rs7301826 0.56 rs12829294 ENSG00000256299.1 RP11-989F5.3 11.2 5.52e-26 1.86e-22 0.52 0.46 Plasma plasminogen activator levels; chr12:130825427 chr12:130810821~130812622:- LUSC cis rs7617773 0.78 rs11706277 ENSG00000229759.1 MRPS18AP1 11.2 5.54e-26 1.87e-22 0.51 0.46 Coronary artery disease; chr3:48318943 chr3:48256350~48256938:- LUSC cis rs1799949 1 rs8176234 ENSG00000198496.9 NBR2 -11.2 5.54e-26 1.87e-22 -0.51 -0.46 Menopause (age at onset); chr17:43067763 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs8176233 ENSG00000198496.9 NBR2 -11.2 5.54e-26 1.87e-22 -0.51 -0.46 Menopause (age at onset); chr17:43067787 chr17:43125610~43153671:+ LUSC cis rs9481169 0.85 rs4947128 ENSG00000255389.1 C6orf3 -11.2 5.55e-26 1.87e-22 -0.79 -0.46 Inflammatory skin disease; chr6:111597665 chr6:111599875~111602295:+ LUSC cis rs10129255 0.5 rs11627315 ENSG00000280411.1 IGHV1-69-2 -11.2 5.58e-26 1.88e-22 -0.29 -0.46 Kawasaki disease; chr14:106802182 chr14:106762092~106762588:- LUSC cis rs16828019 0.852 rs71648534 ENSG00000235358.1 RP11-399E6.1 11.2 5.74e-26 1.93e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41148075 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs71648535 ENSG00000235358.1 RP11-399E6.1 11.2 5.74e-26 1.93e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41148078 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs12048187 ENSG00000235358.1 RP11-399E6.1 11.2 5.74e-26 1.93e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41150511 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs71648536 ENSG00000235358.1 RP11-399E6.1 11.2 5.74e-26 1.93e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41166336 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs12742803 ENSG00000235358.1 RP11-399E6.1 11.2 5.74e-26 1.93e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41182459 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs12408956 ENSG00000235358.1 RP11-399E6.1 11.2 5.74e-26 1.93e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41186280 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs35992757 ENSG00000235358.1 RP11-399E6.1 11.2 5.74e-26 1.93e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41187190 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs12044539 ENSG00000235358.1 RP11-399E6.1 11.2 5.74e-26 1.93e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41196060 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs12759050 ENSG00000235358.1 RP11-399E6.1 11.2 5.74e-26 1.93e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41198532 chr1:41242373~41284861:+ LUSC cis rs7301826 0.627 rs7978987 ENSG00000256299.1 RP11-989F5.3 11.2 5.81e-26 1.95e-22 0.52 0.46 Plasma plasminogen activator levels; chr12:130796949 chr12:130810821~130812622:- LUSC cis rs1930961 1 rs6004673 ENSG00000272977.1 CTA-390C10.10 -11.2 5.82e-26 1.96e-22 -0.78 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25476218~25479971:+ LUSC cis rs875971 0.964 rs6978429 ENSG00000226824.5 RP4-756H11.3 -11.2 5.82e-26 1.96e-22 -0.55 -0.46 Aortic root size; chr7:66494889 chr7:66654538~66669855:+ LUSC cis rs875971 0.929 rs12535036 ENSG00000226824.5 RP4-756H11.3 -11.2 5.82e-26 1.96e-22 -0.55 -0.46 Aortic root size; chr7:66499076 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs12533997 ENSG00000226824.5 RP4-756H11.3 -11.2 5.82e-26 1.96e-22 -0.55 -0.46 Aortic root size; chr7:66500390 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs12532998 ENSG00000226824.5 RP4-756H11.3 -11.2 5.82e-26 1.96e-22 -0.55 -0.46 Aortic root size; chr7:66502472 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6970030 ENSG00000226824.5 RP4-756H11.3 -11.2 5.82e-26 1.96e-22 -0.55 -0.46 Aortic root size; chr7:66503692 chr7:66654538~66669855:+ LUSC cis rs875971 0.928 rs6970357 ENSG00000226824.5 RP4-756H11.3 -11.2 5.82e-26 1.96e-22 -0.55 -0.46 Aortic root size; chr7:66503891 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs3735148 ENSG00000226824.5 RP4-756H11.3 -11.2 5.82e-26 1.96e-22 -0.55 -0.46 Aortic root size; chr7:66506022 chr7:66654538~66669855:+ LUSC cis rs2019137 0.539 rs6755040 ENSG00000189223.12 PAX8-AS1 -11.2 5.83e-26 1.96e-22 -0.62 -0.46 Lymphocyte counts; chr2:113223560 chr2:113211522~113276581:+ LUSC cis rs8062405 1 rs3088215 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28842675 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs28403629 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28843448 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs61737565 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844201 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs4788099 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844406 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs9972693 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28848481 chr16:28700294~28701540:- LUSC cis rs8062405 0.964 rs9972768 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850413 chr16:28700294~28701540:- LUSC cis rs8062405 0.965 rs62037363 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28853721 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs7205323 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854571 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs4788101 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28856483 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs62037365 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857641 chr16:28700294~28701540:- LUSC cis rs8062405 0.929 rs11150609 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859275 chr16:28700294~28701540:- LUSC cis rs8062405 0.737 rs11861132 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860539 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs11861174 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860668 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs4788102 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28862077 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs62037367 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863226 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs7198606 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863801 chr16:28700294~28701540:- LUSC cis rs8062405 0.929 rs11864750 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863883 chr16:28700294~28701540:- LUSC cis rs8062405 0.964 rs7193733 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28864161 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs8055982 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28869881 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs7498665 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28871920 chr16:28700294~28701540:- LUSC cis rs8062405 0.964 rs11864107 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874610 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs62037371 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878810 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs8055138 ENSG00000259982.1 CDC37P1 11.19 6.08e-26 2.03e-22 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28880144 chr16:28700294~28701540:- LUSC cis rs875971 1 rs6958484 ENSG00000226824.5 RP4-756H11.3 11.19 6.08e-26 2.03e-22 0.55 0.46 Aortic root size; chr7:66134459 chr7:66654538~66669855:+ LUSC cis rs10129255 0.518 rs28378320 ENSG00000280411.1 IGHV1-69-2 -11.19 6.17e-26 2.06e-22 -0.29 -0.46 Kawasaki disease; chr14:106808609 chr14:106762092~106762588:- LUSC cis rs507080 0.501 rs637563 ENSG00000255422.1 AP002954.4 -11.18 6.54e-26 2.18e-22 -0.47 -0.46 Serum metabolite levels; chr11:118704770 chr11:118704607~118750263:+ LUSC cis rs7301826 0.651 rs7299281 ENSG00000256299.1 RP11-989F5.3 11.18 6.54e-26 2.18e-22 0.52 0.46 Plasma plasminogen activator levels; chr12:130818587 chr12:130810821~130812622:- LUSC cis rs2729354 1 rs2729354 ENSG00000265566.2 RN7SL605P -11.18 6.55e-26 2.18e-22 -0.64 -0.46 Blood protein levels; chr11:57588497 chr11:57528085~57528365:- LUSC cis rs875971 0.898 rs6977501 ENSG00000226824.5 RP4-756H11.3 11.18 6.61e-26 2.21e-22 0.54 0.46 Aortic root size; chr7:66228355 chr7:66654538~66669855:+ LUSC cis rs7301826 0.651 rs34749116 ENSG00000256299.1 RP11-989F5.3 11.18 6.66e-26 2.22e-22 0.52 0.46 Plasma plasminogen activator levels; chr12:130796207 chr12:130810821~130812622:- LUSC cis rs977987 0.836 rs34673655 ENSG00000261783.1 RP11-252K23.2 -11.18 6.75e-26 2.25e-22 -0.63 -0.46 Dupuytren's disease; chr16:75289661 chr16:75379818~75381260:- LUSC cis rs875971 1 rs3981131 ENSG00000226824.5 RP4-756H11.3 -11.18 6.85e-26 2.28e-22 -0.55 -0.46 Aortic root size; chr7:66486690 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs34326748 ENSG00000280411.1 IGHV1-69-2 -11.18 6.86e-26 2.29e-22 -0.28 -0.46 Kawasaki disease; chr14:106782523 chr14:106762092~106762588:- LUSC cis rs10129255 0.5 rs10143385 ENSG00000280411.1 IGHV1-69-2 -11.18 6.86e-26 2.29e-22 -0.28 -0.46 Kawasaki disease; chr14:106782559 chr14:106762092~106762588:- LUSC cis rs7208859 0.673 rs75142521 ENSG00000263531.1 RP13-753N3.1 11.18 6.99e-26 2.33e-22 0.82 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913519 chr17:30863921~30864940:- LUSC cis rs16828019 0.852 rs12759023 ENSG00000235358.1 RP11-399E6.1 11.17 7.23e-26 2.41e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41138306 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs34286980 ENSG00000235358.1 RP11-399E6.1 11.17 7.23e-26 2.41e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41142717 chr1:41242373~41284861:+ LUSC cis rs875971 0.929 rs34406470 ENSG00000226824.5 RP4-756H11.3 -11.17 7.34e-26 2.44e-22 -0.55 -0.46 Aortic root size; chr7:66464969 chr7:66654538~66669855:+ LUSC cis rs977987 0.836 rs17685540 ENSG00000261783.1 RP11-252K23.2 -11.17 7.48e-26 2.49e-22 -0.62 -0.46 Dupuytren's disease; chr16:75289942 chr16:75379818~75381260:- LUSC cis rs875971 1 rs709595 ENSG00000226824.5 RP4-756H11.3 -11.17 7.48e-26 2.49e-22 -0.55 -0.46 Aortic root size; chr7:66352346 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs811880 ENSG00000226824.5 RP4-756H11.3 -11.17 7.48e-26 2.49e-22 -0.55 -0.46 Aortic root size; chr7:66353659 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs3857684 ENSG00000226824.5 RP4-756H11.3 -11.17 7.72e-26 2.57e-22 -0.55 -0.46 Aortic root size; chr7:66473171 chr7:66654538~66669855:+ LUSC cis rs5760092 0.627 rs6519489 ENSG00000273295.1 AP000350.5 -11.16 7.81e-26 2.6e-22 -0.65 -0.46 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23901432~23907068:- LUSC cis rs507080 0.769 rs745663 ENSG00000255422.1 AP002954.4 -11.16 7.92e-26 2.63e-22 -0.51 -0.46 Serum metabolite levels; chr11:118658886 chr11:118704607~118750263:+ LUSC cis rs3096299 0.719 rs12934708 ENSG00000274627.1 RP11-104N10.2 11.16 8.01e-26 2.66e-22 0.41 0.46 Multiple myeloma (IgH translocation); chr16:89457382 chr16:89516797~89522217:+ LUSC cis rs1930961 1 rs997873 ENSG00000272977.1 CTA-390C10.10 -11.16 8.13e-26 2.7e-22 -0.8 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25482315 chr22:25476218~25479971:+ LUSC cis rs1930961 1 rs997872 ENSG00000272977.1 CTA-390C10.10 -11.16 8.13e-26 2.7e-22 -0.8 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25476218~25479971:+ LUSC cis rs1930961 1 rs6004671 ENSG00000272977.1 CTA-390C10.10 -11.16 8.13e-26 2.7e-22 -0.8 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25483507 chr22:25476218~25479971:+ LUSC cis rs2019137 0.56 rs7578633 ENSG00000189223.12 PAX8-AS1 -11.16 8.18e-26 2.71e-22 -0.62 -0.46 Lymphocyte counts; chr2:113221073 chr2:113211522~113276581:+ LUSC cis rs2019137 0.539 rs11123170 ENSG00000189223.12 PAX8-AS1 -11.16 8.18e-26 2.71e-22 -0.62 -0.46 Lymphocyte counts; chr2:113221363 chr2:113211522~113276581:+ LUSC cis rs2729354 0.953 rs1846567 ENSG00000265566.2 RN7SL605P -11.15 8.56e-26 2.83e-22 -0.65 -0.46 Blood protein levels; chr11:57590120 chr11:57528085~57528365:- LUSC cis rs7301826 0.61 rs7961690 ENSG00000256299.1 RP11-989F5.3 11.15 8.65e-26 2.86e-22 0.51 0.46 Plasma plasminogen activator levels; chr12:130812335 chr12:130810821~130812622:- LUSC cis rs875971 1 rs6979382 ENSG00000226824.5 RP4-756H11.3 -11.15 8.68e-26 2.87e-22 -0.54 -0.46 Aortic root size; chr7:66421388 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6961990 ENSG00000226824.5 RP4-756H11.3 -11.15 8.68e-26 2.87e-22 -0.54 -0.46 Aortic root size; chr7:66423583 chr7:66654538~66669855:+ LUSC cis rs4423214 0.959 rs11606033 ENSG00000254682.1 RP11-660L16.2 11.15 8.7e-26 2.88e-22 0.57 0.46 Vitamin D levels; chr11:71443158 chr11:71448674~71452157:+ LUSC cis rs150992 0.638 rs466340 ENSG00000248489.1 CTD-2007H13.3 11.15 8.77e-26 2.9e-22 0.54 0.46 Body mass index; chr5:98904318 chr5:98929171~98995013:+ LUSC cis rs150992 0.673 rs326463 ENSG00000248489.1 CTD-2007H13.3 11.15 8.77e-26 2.9e-22 0.54 0.46 Body mass index; chr5:98905785 chr5:98929171~98995013:+ LUSC cis rs150992 0.673 rs327792 ENSG00000248489.1 CTD-2007H13.3 11.15 8.77e-26 2.9e-22 0.54 0.46 Body mass index; chr5:98909802 chr5:98929171~98995013:+ LUSC cis rs2739330 0.732 rs5760175 ENSG00000235689.1 AP000351.13 11.15 8.86e-26 2.93e-22 0.47 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:24006305~24008258:- LUSC cis rs2019137 0.56 rs4849179 ENSG00000189223.12 PAX8-AS1 -11.15 8.89e-26 2.94e-22 -0.61 -0.46 Lymphocyte counts; chr2:113227593 chr2:113211522~113276581:+ LUSC cis rs950027 0.787 rs2433616 ENSG00000259520.4 CTD-2651B20.3 -11.15 8.98e-26 2.96e-22 -0.56 -0.46 Response to fenofibrate (adiponectin levels); chr15:45436401 chr15:45251580~45279251:- LUSC cis rs8062405 1 rs55991577 ENSG00000259982.1 CDC37P1 11.15 9.03e-26 2.98e-22 0.56 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831704 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs56358680 ENSG00000259982.1 CDC37P1 11.15 9.03e-26 2.98e-22 0.56 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831797 chr16:28700294~28701540:- LUSC cis rs150992 0.678 rs327793 ENSG00000248489.1 CTD-2007H13.3 11.15 9.19e-26 3.03e-22 0.54 0.46 Body mass index; chr5:98913717 chr5:98929171~98995013:+ LUSC cis rs16828019 0.929 rs111309254 ENSG00000235358.1 RP11-399E6.1 11.15 9.3e-26 3.06e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41270328 chr1:41242373~41284861:+ LUSC cis rs16828019 0.929 rs4131949 ENSG00000235358.1 RP11-399E6.1 11.15 9.3e-26 3.06e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41272965 chr1:41242373~41284861:+ LUSC cis rs16828019 0.929 rs35813191 ENSG00000235358.1 RP11-399E6.1 11.15 9.3e-26 3.06e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41277128 chr1:41242373~41284861:+ LUSC cis rs6700559 0.683 rs7526136 ENSG00000260088.1 RP11-92G12.3 -11.14 9.35e-26 3.08e-22 -0.58 -0.46 Coronary artery disease; chr1:200687911 chr1:200669507~200694250:+ LUSC cis rs6700559 0.733 rs7526265 ENSG00000260088.1 RP11-92G12.3 -11.14 9.35e-26 3.08e-22 -0.58 -0.46 Coronary artery disease; chr1:200687916 chr1:200669507~200694250:+ LUSC cis rs801193 0.66 rs1962050 ENSG00000226824.5 RP4-756H11.3 11.14 9.46e-26 3.11e-22 0.54 0.46 Aortic root size; chr7:66775021 chr7:66654538~66669855:+ LUSC cis rs7174755 0.961 rs11631030 ENSG00000260657.2 RP11-315D16.4 11.14 9.48e-26 3.12e-22 0.56 0.46 Major depressive disorder; chr15:68303463 chr15:68267792~68277994:- LUSC cis rs7301826 0.651 rs6486601 ENSG00000256299.1 RP11-989F5.3 11.14 9.64e-26 3.16e-22 0.51 0.46 Plasma plasminogen activator levels; chr12:130816692 chr12:130810821~130812622:- LUSC cis rs7301826 0.627 rs61937256 ENSG00000256299.1 RP11-989F5.3 11.14 9.64e-26 3.16e-22 0.51 0.46 Plasma plasminogen activator levels; chr12:130818100 chr12:130810821~130812622:- LUSC cis rs16828019 0.852 rs12045171 ENSG00000235358.1 RP11-399E6.1 11.14 9.65e-26 3.16e-22 0.81 0.46 Intelligence (multi-trait analysis); chr1:41063133 chr1:41242373~41284861:+ LUSC cis rs4423214 1 rs1044482 ENSG00000254682.1 RP11-660L16.2 11.14 9.83e-26 3.21e-22 0.57 0.46 Vitamin D levels; chr11:71444125 chr11:71448674~71452157:+ LUSC cis rs3091242 0.804 rs631133 ENSG00000261349.1 RP3-465N24.5 -11.14 9.86e-26 3.22e-22 -0.56 -0.46 Erythrocyte sedimentation rate; chr1:25397655 chr1:25266102~25267136:- LUSC cis rs7301826 0.651 rs12820597 ENSG00000256299.1 RP11-989F5.3 11.14 9.9e-26 3.23e-22 0.52 0.46 Plasma plasminogen activator levels; chr12:130795640 chr12:130810821~130812622:- LUSC cis rs16828019 0.929 rs12029321 ENSG00000235358.1 RP11-399E6.1 11.14 1.01e-25 3.3e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41216858 chr1:41242373~41284861:+ LUSC cis rs16828019 0.929 rs11209734 ENSG00000235358.1 RP11-399E6.1 11.14 1.01e-25 3.3e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41232402 chr1:41242373~41284861:+ LUSC cis rs16828019 0.929 rs12037037 ENSG00000235358.1 RP11-399E6.1 11.14 1.01e-25 3.3e-22 0.84 0.46 Intelligence (multi-trait analysis); chr1:41232584 chr1:41242373~41284861:+ LUSC cis rs875971 1 rs12698523 ENSG00000226824.5 RP4-756H11.3 -11.14 1.01e-25 3.31e-22 -0.55 -0.46 Aortic root size; chr7:66503126 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs12698520 ENSG00000226824.5 RP4-756H11.3 -11.13 1.03e-25 3.34e-22 -0.54 -0.46 Aortic root size; chr7:66453720 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs2077593 ENSG00000226824.5 RP4-756H11.3 -11.13 1.03e-25 3.36e-22 -0.54 -0.46 Aortic root size; chr7:66427543 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6460296 ENSG00000226824.5 RP4-756H11.3 -11.13 1.04e-25 3.36e-22 -0.54 -0.46 Aortic root size; chr7:66430152 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs4717292 ENSG00000226824.5 RP4-756H11.3 -11.13 1.04e-25 3.36e-22 -0.54 -0.46 Aortic root size; chr7:66430611 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs7788984 ENSG00000226824.5 RP4-756H11.3 -11.13 1.04e-25 3.38e-22 -0.54 -0.46 Aortic root size; chr7:66450629 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1981798 ENSG00000226824.5 RP4-756H11.3 -11.13 1.04e-25 3.38e-22 -0.54 -0.46 Aortic root size; chr7:66489916 chr7:66654538~66669855:+ LUSC cis rs875971 0.508 rs10258739 ENSG00000226824.5 RP4-756H11.3 11.13 1.07e-25 3.46e-22 0.52 0.46 Aortic root size; chr7:66597948 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs4718349 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66444024 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs2420591 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66447394 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs10755833 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66448930 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs12668936 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66449417 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs1833495 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66456608 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs6945032 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66457499 chr7:66654538~66669855:+ LUSC cis rs875971 0.929 rs12673810 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66458866 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs35149210 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66464938 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs2042133 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66466935 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs2161065 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66467918 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6961155 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66468308 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs7789768 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66473993 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs12698521 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66474502 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1363055 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66478288 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs9691480 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66479319 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs7789554 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66481051 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs4717300 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66482393 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs1974769 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66485627 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs6460300 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66487937 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs7803416 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66489212 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs1981799 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66490572 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs2277911 ENSG00000226824.5 RP4-756H11.3 -11.13 1.07e-25 3.46e-22 -0.54 -0.46 Aortic root size; chr7:66493638 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs7161740 ENSG00000280411.1 IGHV1-69-2 -11.13 1.07e-25 3.46e-22 -0.28 -0.46 Kawasaki disease; chr14:106776119 chr14:106762092~106762588:- LUSC cis rs10129255 0.556 rs6576222 ENSG00000280411.1 IGHV1-69-2 -11.13 1.07e-25 3.46e-22 -0.28 -0.46 Kawasaki disease; chr14:106776442 chr14:106762092~106762588:- LUSC cis rs10129255 0.536 rs6576223 ENSG00000280411.1 IGHV1-69-2 -11.13 1.07e-25 3.46e-22 -0.28 -0.46 Kawasaki disease; chr14:106776448 chr14:106762092~106762588:- LUSC cis rs7208859 0.673 rs2269915 ENSG00000263531.1 RP13-753N3.1 11.13 1.09e-25 3.52e-22 0.81 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906326 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs2269916 ENSG00000263531.1 RP13-753N3.1 11.13 1.09e-25 3.52e-22 0.81 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906745 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs11649765 ENSG00000263531.1 RP13-753N3.1 11.13 1.09e-25 3.52e-22 0.81 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906870 chr17:30863921~30864940:- LUSC cis rs875971 0.867 rs1002053 ENSG00000226824.5 RP4-756H11.3 11.13 1.09e-25 3.52e-22 0.55 0.46 Aortic root size; chr7:66333558 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6460292 ENSG00000226824.5 RP4-756H11.3 11.13 1.09e-25 3.52e-22 0.55 0.46 Aortic root size; chr7:66345088 chr7:66654538~66669855:+ LUSC cis rs1799949 0.894 rs71367985 ENSG00000198496.9 NBR2 -11.13 1.09e-25 3.53e-22 -0.49 -0.46 Menopause (age at onset); chr17:43222443 chr17:43125610~43153671:+ LUSC cis rs6782228 0.606 rs1127030 ENSG00000242551.2 POU5F1P6 -11.13 1.1e-25 3.54e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128620110 chr3:128674735~128677005:- LUSC cis rs6782228 0.606 rs2712419 ENSG00000242551.2 POU5F1P6 -11.13 1.1e-25 3.54e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128622053 chr3:128674735~128677005:- LUSC cis rs6782228 0.606 rs2712417 ENSG00000242551.2 POU5F1P6 -11.13 1.1e-25 3.54e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128626336 chr3:128674735~128677005:- LUSC cis rs6782228 0.527 rs2712371 ENSG00000242551.2 POU5F1P6 -11.13 1.1e-25 3.54e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128627371 chr3:128674735~128677005:- LUSC cis rs875971 1 rs11974264 ENSG00000226824.5 RP4-756H11.3 11.13 1.1e-25 3.55e-22 0.54 0.46 Aortic root size; chr7:66182595 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1540651 ENSG00000226824.5 RP4-756H11.3 11.13 1.1e-25 3.55e-22 0.54 0.46 Aortic root size; chr7:66185134 chr7:66654538~66669855:+ LUSC cis rs6782228 0.606 rs58977394 ENSG00000242551.2 POU5F1P6 -11.12 1.13e-25 3.64e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619074 chr3:128674735~128677005:- LUSC cis rs6782228 0.606 rs2712381 ENSG00000242551.2 POU5F1P6 -11.12 1.13e-25 3.64e-22 -0.52 -0.46 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619757 chr3:128674735~128677005:- LUSC cis rs6964833 1 rs34324835 ENSG00000123965.13 PMS2P5 11.12 1.13e-25 3.65e-22 0.74 0.46 Menarche (age at onset); chr7:74717986 chr7:74894116~74897835:+ LUSC cis rs73086581 0.838 rs73088424 ENSG00000229539.1 RP11-119B16.2 11.12 1.15e-25 3.7e-22 0.63 0.46 Response to antidepressants in depression; chr20:4020359 chr20:3888239~3888868:- LUSC cis rs1185460 0.967 rs1184902 ENSG00000271751.1 RP11-110I1.14 -11.12 1.15e-25 3.72e-22 -0.57 -0.46 Coronary artery disease; chr11:119074627 chr11:119065263~119065677:- LUSC cis rs1799949 0.93 rs34210004 ENSG00000198496.9 NBR2 -11.12 1.19e-25 3.84e-22 -0.49 -0.46 Menopause (age at onset); chr17:43218318 chr17:43125610~43153671:+ LUSC cis rs6964833 1 rs35203738 ENSG00000123965.13 PMS2P5 11.12 1.2e-25 3.86e-22 0.74 0.46 Menarche (age at onset); chr7:74690864 chr7:74894116~74897835:+ LUSC cis rs9322193 0.607 rs6925151 ENSG00000231760.4 RP11-350J20.5 11.11 1.23e-25 3.96e-22 0.66 0.46 Lung cancer; chr6:149889587 chr6:149796151~149826294:- LUSC cis rs1799949 1 rs8176220 ENSG00000198496.9 NBR2 -11.11 1.24e-25 3.97e-22 -0.51 -0.46 Menopause (age at onset); chr17:43070445 chr17:43125610~43153671:+ LUSC cis rs1799949 0.93 rs3092987 ENSG00000198496.9 NBR2 -11.11 1.24e-25 3.97e-22 -0.51 -0.46 Menopause (age at onset); chr17:43070706 chr17:43125610~43153671:+ LUSC cis rs1799949 1 rs1799966 ENSG00000198496.9 NBR2 -11.11 1.24e-25 3.97e-22 -0.51 -0.46 Menopause (age at onset); chr17:43071077 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs799910 ENSG00000198496.9 NBR2 -11.11 1.26e-25 4.04e-22 -0.5 -0.46 Menopause (age at onset); chr17:43127544 chr17:43125610~43153671:+ LUSC cis rs875971 1 rs10244498 ENSG00000226824.5 RP4-756H11.3 -11.11 1.27e-25 4.08e-22 -0.54 -0.46 Aortic root size; chr7:66651069 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs6945019 ENSG00000226824.5 RP4-756H11.3 -11.11 1.29e-25 4.13e-22 -0.54 -0.46 Aortic root size; chr7:66457471 chr7:66654538~66669855:+ LUSC cis rs7188445 0.932 rs17767491 ENSG00000261390.4 RP11-345M22.2 -11.11 1.29e-25 4.15e-22 -0.61 -0.46 Urate levels; chr16:79711590 chr16:79715232~79770563:- LUSC cis rs8062405 1 rs62036626 ENSG00000259982.1 CDC37P1 11.11 1.3e-25 4.17e-22 0.56 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28832963 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs62036657 ENSG00000259982.1 CDC37P1 11.11 1.3e-25 4.17e-22 0.56 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833044 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs12444171 ENSG00000259982.1 CDC37P1 11.11 1.3e-25 4.17e-22 0.56 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833930 chr16:28700294~28701540:- LUSC cis rs977987 0.645 rs10871311 ENSG00000261783.1 RP11-252K23.2 -11.11 1.3e-25 4.18e-22 -0.63 -0.46 Dupuytren's disease; chr16:75417014 chr16:75379818~75381260:- LUSC cis rs507080 0.769 rs570836 ENSG00000255422.1 AP002954.4 -11.11 1.31e-25 4.19e-22 -0.51 -0.46 Serum metabolite levels; chr11:118641444 chr11:118704607~118750263:+ LUSC cis rs507080 0.769 rs527290 ENSG00000255422.1 AP002954.4 -11.11 1.32e-25 4.24e-22 -0.51 -0.46 Serum metabolite levels; chr11:118644898 chr11:118704607~118750263:+ LUSC cis rs977987 0.806 rs11862684 ENSG00000261783.1 RP11-252K23.2 -11.11 1.32e-25 4.25e-22 -0.62 -0.46 Dupuytren's disease; chr16:75427848 chr16:75379818~75381260:- LUSC cis rs2739330 0.731 rs4822450 ENSG00000231271.1 AP000350.8 11.11 1.33e-25 4.25e-22 0.58 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23949918~23954042:+ LUSC cis rs2019137 0.56 rs6707386 ENSG00000189223.12 PAX8-AS1 -11.1 1.35e-25 4.32e-22 -0.61 -0.46 Lymphocyte counts; chr2:113223445 chr2:113211522~113276581:+ LUSC cis rs997154 0.655 rs7147394 ENSG00000279656.1 RP11-298I3.6 11.1 1.37e-25 4.39e-22 0.61 0.46 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22941845 chr14:23023083~23024217:- LUSC cis rs2729354 0.953 rs2848625 ENSG00000265566.2 RN7SL605P -11.1 1.37e-25 4.4e-22 -0.65 -0.46 Blood protein levels; chr11:57563177 chr11:57528085~57528365:- LUSC cis rs1799949 0.965 rs11080034 ENSG00000198496.9 NBR2 -11.1 1.38e-25 4.41e-22 -0.49 -0.46 Menopause (age at onset); chr17:43365646 chr17:43125610~43153671:+ LUSC cis rs977987 0.815 rs11861810 ENSG00000261783.1 RP11-252K23.2 -11.1 1.38e-25 4.41e-22 -0.62 -0.46 Dupuytren's disease; chr16:75427931 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs12930452 ENSG00000261783.1 RP11-252K23.2 -11.1 1.38e-25 4.41e-22 -0.62 -0.46 Dupuytren's disease; chr16:75428157 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs12929908 ENSG00000261783.1 RP11-252K23.2 -11.1 1.38e-25 4.41e-22 -0.62 -0.46 Dupuytren's disease; chr16:75428173 chr16:75379818~75381260:- LUSC cis rs977987 0.742 rs12928898 ENSG00000261783.1 RP11-252K23.2 -11.1 1.38e-25 4.41e-22 -0.62 -0.46 Dupuytren's disease; chr16:75428183 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs11149832 ENSG00000261783.1 RP11-252K23.2 -11.1 1.38e-25 4.41e-22 -0.62 -0.46 Dupuytren's disease; chr16:75428815 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs12448947 ENSG00000261783.1 RP11-252K23.2 -11.1 1.38e-25 4.41e-22 -0.62 -0.46 Dupuytren's disease; chr16:75429056 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs4888420 ENSG00000261783.1 RP11-252K23.2 -11.1 1.38e-25 4.41e-22 -0.62 -0.46 Dupuytren's disease; chr16:75429100 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs12449170 ENSG00000261783.1 RP11-252K23.2 -11.1 1.38e-25 4.41e-22 -0.62 -0.46 Dupuytren's disease; chr16:75429114 chr16:75379818~75381260:- LUSC cis rs801193 0.66 rs2659914 ENSG00000226824.5 RP4-756H11.3 -11.1 1.39e-25 4.46e-22 -0.54 -0.46 Aortic root size; chr7:66691927 chr7:66654538~66669855:+ LUSC cis rs977987 0.778 rs12445726 ENSG00000261783.1 RP11-252K23.2 -11.1 1.41e-25 4.52e-22 -0.62 -0.46 Dupuytren's disease; chr16:75431677 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs11644741 ENSG00000261783.1 RP11-252K23.2 -11.1 1.41e-25 4.52e-22 -0.62 -0.46 Dupuytren's disease; chr16:75432535 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs12917651 ENSG00000261783.1 RP11-252K23.2 -11.1 1.41e-25 4.52e-22 -0.62 -0.46 Dupuytren's disease; chr16:75432798 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs35787595 ENSG00000261783.1 RP11-252K23.2 -11.1 1.41e-25 4.52e-22 -0.62 -0.46 Dupuytren's disease; chr16:75432949 chr16:75379818~75381260:- LUSC cis rs10129255 0.5 rs6576225 ENSG00000280411.1 IGHV1-69-2 -11.1 1.43e-25 4.55e-22 -0.28 -0.46 Kawasaki disease; chr14:106778120 chr14:106762092~106762588:- LUSC cis rs10129255 0.5 rs6576226 ENSG00000280411.1 IGHV1-69-2 -11.1 1.43e-25 4.55e-22 -0.28 -0.46 Kawasaki disease; chr14:106778135 chr14:106762092~106762588:- LUSC cis rs5760092 0.755 rs4585126 ENSG00000250470.1 AP000351.3 -11.1 1.43e-25 4.57e-22 -0.71 -0.46 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23976904~23977585:- LUSC cis rs6700559 0.683 rs7548530 ENSG00000260088.1 RP11-92G12.3 -11.1 1.44e-25 4.6e-22 -0.58 -0.46 Coronary artery disease; chr1:200687904 chr1:200669507~200694250:+ LUSC cis rs977987 0.8 rs1011121 ENSG00000261783.1 RP11-252K23.2 -11.1 1.45e-25 4.61e-22 -0.62 -0.46 Dupuytren's disease; chr16:75292035 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs11149833 ENSG00000261783.1 RP11-252K23.2 -11.09 1.48e-25 4.71e-22 -0.62 -0.46 Dupuytren's disease; chr16:75430104 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs11641587 ENSG00000261783.1 RP11-252K23.2 -11.09 1.48e-25 4.71e-22 -0.62 -0.46 Dupuytren's disease; chr16:75430521 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs12930768 ENSG00000261783.1 RP11-252K23.2 -11.09 1.48e-25 4.71e-22 -0.62 -0.46 Dupuytren's disease; chr16:75430602 chr16:75379818~75381260:- LUSC cis rs6964833 1 rs4717907 ENSG00000123965.13 PMS2P5 11.09 1.52e-25 4.86e-22 0.71 0.46 Menarche (age at onset); chr7:74672169 chr7:74894116~74897835:+ LUSC cis rs10129255 0.5 rs7157975 ENSG00000280411.1 IGHV1-69-2 -11.09 1.55e-25 4.93e-22 -0.29 -0.46 Kawasaki disease; chr14:106804049 chr14:106762092~106762588:- LUSC cis rs977987 0.806 rs4888418 ENSG00000261783.1 RP11-252K23.2 -11.09 1.56e-25 4.96e-22 -0.62 -0.46 Dupuytren's disease; chr16:75426408 chr16:75379818~75381260:- LUSC cis rs10129255 0.5 rs8011115 ENSG00000280411.1 IGHV1-69-2 -11.08 1.59e-25 5.07e-22 -0.28 -0.46 Kawasaki disease; chr14:106786292 chr14:106762092~106762588:- LUSC cis rs875971 1 rs6957199 ENSG00000226824.5 RP4-756H11.3 -11.08 1.62e-25 5.16e-22 -0.54 -0.46 Aortic root size; chr7:66513532 chr7:66654538~66669855:+ LUSC cis rs1577917 0.876 rs12190735 ENSG00000203875.9 SNHG5 -11.08 1.66e-25 5.28e-22 -0.61 -0.46 Response to antipsychotic treatment; chr6:85976749 chr6:85660950~85678736:- LUSC cis rs977987 0.778 rs2113232 ENSG00000261783.1 RP11-252K23.2 -11.08 1.67e-25 5.32e-22 -0.62 -0.46 Dupuytren's disease; chr16:75357287 chr16:75379818~75381260:- LUSC cis rs875971 0.964 rs60193905 ENSG00000226824.5 RP4-756H11.3 -11.08 1.68e-25 5.33e-22 -0.54 -0.46 Aortic root size; chr7:66506273 chr7:66654538~66669855:+ LUSC cis rs875971 0.929 rs10950041 ENSG00000226824.5 RP4-756H11.3 -11.08 1.68e-25 5.33e-22 -0.54 -0.46 Aortic root size; chr7:66508888 chr7:66654538~66669855:+ LUSC cis rs875971 0.929 rs6970860 ENSG00000226824.5 RP4-756H11.3 -11.08 1.68e-25 5.33e-22 -0.54 -0.46 Aortic root size; chr7:66511647 chr7:66654538~66669855:+ LUSC cis rs9545047 1 rs9545047 ENSG00000227676.3 LINC01068 11.08 1.69e-25 5.35e-22 0.56 0.46 Schizophrenia; chr13:79285321 chr13:79566727~79571436:+ LUSC cis rs977987 0.836 rs8055974 ENSG00000261783.1 RP11-252K23.2 -11.08 1.71e-25 5.42e-22 -0.61 -0.45 Dupuytren's disease; chr16:75437088 chr16:75379818~75381260:- LUSC cis rs8062405 0.965 rs56040780 ENSG00000259982.1 CDC37P1 11.08 1.71e-25 5.44e-22 0.57 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850560 chr16:28700294~28701540:- LUSC cis rs9322193 0.607 rs4870078 ENSG00000231760.4 RP11-350J20.5 -11.08 1.73e-25 5.47e-22 -0.67 -0.45 Lung cancer; chr6:149880676 chr6:149796151~149826294:- LUSC cis rs977987 0.806 rs2865531 ENSG00000261783.1 RP11-252K23.2 -11.08 1.73e-25 5.49e-22 -0.62 -0.45 Dupuytren's disease; chr16:75356418 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs11641801 ENSG00000261783.1 RP11-252K23.2 -11.07 1.75e-25 5.55e-22 -0.62 -0.45 Dupuytren's disease; chr16:75421550 chr16:75379818~75381260:- LUSC cis rs507080 0.769 rs483283 ENSG00000255422.1 AP002954.4 -11.07 1.78e-25 5.64e-22 -0.51 -0.45 Serum metabolite levels; chr11:118635684 chr11:118704607~118750263:+ LUSC cis rs10129255 0.518 rs8009594 ENSG00000280411.1 IGHV1-69-2 -11.07 1.79e-25 5.67e-22 -0.28 -0.45 Kawasaki disease; chr14:106777494 chr14:106762092~106762588:- LUSC cis rs10129255 0.518 rs8009612 ENSG00000280411.1 IGHV1-69-2 -11.07 1.79e-25 5.67e-22 -0.28 -0.45 Kawasaki disease; chr14:106777510 chr14:106762092~106762588:- LUSC cis rs875971 1 rs937495 ENSG00000226824.5 RP4-756H11.3 11.07 1.8e-25 5.69e-22 0.54 0.45 Aortic root size; chr7:66314811 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs2036264 ENSG00000226824.5 RP4-756H11.3 11.07 1.8e-25 5.69e-22 0.54 0.45 Aortic root size; chr7:66334917 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs7783613 ENSG00000226824.5 RP4-756H11.3 11.07 1.8e-25 5.69e-22 0.54 0.45 Aortic root size; chr7:66340274 chr7:66654538~66669855:+ LUSC cis rs6964833 0.786 rs35633336 ENSG00000123965.13 PMS2P5 11.07 1.81e-25 5.74e-22 0.72 0.45 Menarche (age at onset); chr7:74643961 chr7:74894116~74897835:+ LUSC cis rs6964833 0.935 rs35735900 ENSG00000123965.13 PMS2P5 11.07 1.81e-25 5.74e-22 0.72 0.45 Menarche (age at onset); chr7:74651887 chr7:74894116~74897835:+ LUSC cis rs6964833 0.872 rs4717903 ENSG00000123965.13 PMS2P5 11.07 1.81e-25 5.74e-22 0.72 0.45 Menarche (age at onset); chr7:74653827 chr7:74894116~74897835:+ LUSC cis rs1799949 0.929 rs799905 ENSG00000198496.9 NBR2 -11.07 1.81e-25 5.74e-22 -0.5 -0.45 Menopause (age at onset); chr17:43125170 chr17:43125610~43153671:+ LUSC cis rs1501911 0.53 rs161933 ENSG00000248489.1 CTD-2007H13.3 11.07 1.82e-25 5.75e-22 0.53 0.45 Lung function (FEV1/FVC); chr5:98874643 chr5:98929171~98995013:+ LUSC cis rs1501911 0.53 rs161938 ENSG00000248489.1 CTD-2007H13.3 11.07 1.82e-25 5.75e-22 0.53 0.45 Lung function (FEV1/FVC); chr5:98875501 chr5:98929171~98995013:+ LUSC cis rs1799949 0.859 rs11657004 ENSG00000198496.9 NBR2 -11.07 1.82e-25 5.76e-22 -0.49 -0.45 Menopause (age at onset); chr17:43365383 chr17:43125610~43153671:+ LUSC cis rs875971 1 rs4718357 ENSG00000226824.5 RP4-756H11.3 -11.07 1.83e-25 5.79e-22 -0.54 -0.45 Aortic root size; chr7:66495891 chr7:66654538~66669855:+ LUSC cis rs3096299 0.503 rs9925045 ENSG00000274627.1 RP11-104N10.2 11.07 1.85e-25 5.84e-22 0.4 0.45 Multiple myeloma (IgH translocation); chr16:89490068 chr16:89516797~89522217:+ LUSC cis rs2739330 0.731 rs5751792 ENSG00000235689.1 AP000351.13 11.07 1.85e-25 5.85e-22 0.46 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:24006305~24008258:- LUSC cis rs10129255 0.5 rs4774008 ENSG00000280411.1 IGHV1-69-2 -11.07 1.85e-25 5.85e-22 -0.28 -0.45 Kawasaki disease; chr14:106681273 chr14:106762092~106762588:- LUSC cis rs977987 0.806 rs7188604 ENSG00000261783.1 RP11-252K23.2 -11.07 1.87e-25 5.9e-22 -0.62 -0.45 Dupuytren's disease; chr16:75417272 chr16:75379818~75381260:- LUSC cis rs1930961 1 rs7285549 ENSG00000272977.1 CTA-390C10.10 -11.07 1.88e-25 5.94e-22 -0.82 -0.45 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25476218~25479971:+ LUSC cis rs875971 0.66 rs10229345 ENSG00000226824.5 RP4-756H11.3 -11.07 1.89e-25 5.97e-22 -0.54 -0.45 Aortic root size; chr7:66517181 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs12101190 ENSG00000280411.1 IGHV1-69-2 -11.06 1.9e-25 5.99e-22 -0.28 -0.45 Kawasaki disease; chr14:106784149 chr14:106762092~106762588:- LUSC cis rs10129255 0.518 rs8004895 ENSG00000280411.1 IGHV1-69-2 -11.06 1.9e-25 5.99e-22 -0.28 -0.45 Kawasaki disease; chr14:106785139 chr14:106762092~106762588:- LUSC cis rs10129255 0.5 rs988134 ENSG00000280411.1 IGHV1-69-2 -11.06 1.91e-25 6.03e-22 -0.28 -0.45 Kawasaki disease; chr14:106776698 chr14:106762092~106762588:- LUSC cis rs10129255 0.5 rs988133 ENSG00000280411.1 IGHV1-69-2 -11.06 1.91e-25 6.03e-22 -0.28 -0.45 Kawasaki disease; chr14:106776724 chr14:106762092~106762588:- LUSC cis rs875971 0.965 rs6971509 ENSG00000226824.5 RP4-756H11.3 11.06 1.94e-25 6.11e-22 0.54 0.45 Aortic root size; chr7:66249983 chr7:66654538~66669855:+ LUSC cis rs7301826 0.627 rs34103763 ENSG00000256299.1 RP11-989F5.3 11.06 1.99e-25 6.27e-22 0.51 0.45 Plasma plasminogen activator levels; chr12:130805604 chr12:130810821~130812622:- LUSC cis rs7208859 0.673 rs73263776 ENSG00000263531.1 RP13-753N3.1 11.06 1.99e-25 6.28e-22 0.8 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30884313 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11650271 ENSG00000263531.1 RP13-753N3.1 11.06 1.99e-25 6.28e-22 0.8 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30886925 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs73263785 ENSG00000263531.1 RP13-753N3.1 11.06 1.99e-25 6.28e-22 0.8 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887790 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs78799101 ENSG00000263531.1 RP13-753N3.1 11.06 1.99e-25 6.28e-22 0.8 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888142 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs55904046 ENSG00000263531.1 RP13-753N3.1 11.06 1.99e-25 6.28e-22 0.8 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888373 chr17:30863921~30864940:- LUSC cis rs9399135 0.622 rs3817776 ENSG00000232876.1 CTA-212D2.2 11.06 2e-25 6.29e-22 0.55 0.45 Red blood cell count; chr6:134935618 chr6:135055033~135060550:+ LUSC cis rs875971 0.83 rs4718358 ENSG00000226824.5 RP4-756H11.3 -11.06 2.01e-25 6.33e-22 -0.54 -0.45 Aortic root size; chr7:66508681 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs6576230 ENSG00000280411.1 IGHV1-69-2 -11.06 2.03e-25 6.4e-22 -0.28 -0.45 Kawasaki disease; chr14:106778539 chr14:106762092~106762588:- LUSC cis rs150992 0.673 rs692832 ENSG00000248489.1 CTD-2007H13.3 11.05 2.09e-25 6.58e-22 0.56 0.45 Body mass index; chr5:98856761 chr5:98929171~98995013:+ LUSC cis rs977987 0.843 rs12149063 ENSG00000261783.1 RP11-252K23.2 -11.05 2.12e-25 6.67e-22 -0.62 -0.45 Dupuytren's disease; chr16:75417860 chr16:75379818~75381260:- LUSC cis rs1799949 0.683 rs55737636 ENSG00000198496.9 NBR2 -11.05 2.15e-25 6.75e-22 -0.49 -0.45 Menopause (age at onset); chr17:43112722 chr17:43125610~43153671:+ LUSC cis rs1799949 0.931 rs34474989 ENSG00000198496.9 NBR2 -11.05 2.17e-25 6.81e-22 -0.48 -0.45 Menopause (age at onset); chr17:43368042 chr17:43125610~43153671:+ LUSC cis rs8062405 1 rs8062405 ENSG00000259982.1 CDC37P1 -11.05 2.18e-25 6.83e-22 -0.56 -0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826585 chr16:28700294~28701540:- LUSC cis rs507080 0.501 rs625735 ENSG00000255422.1 AP002954.4 -11.05 2.2e-25 6.89e-22 -0.47 -0.45 Serum metabolite levels; chr11:118704710 chr11:118704607~118750263:+ LUSC cis rs2739330 0.76 rs1007888 ENSG00000231271.1 AP000350.8 11.05 2.2e-25 6.91e-22 0.57 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23949918~23954042:+ LUSC cis rs150992 0.673 rs330419 ENSG00000248489.1 CTD-2007H13.3 -11.05 2.22e-25 6.95e-22 -0.56 -0.45 Body mass index; chr5:98857460 chr5:98929171~98995013:+ LUSC cis rs2929278 0.561 rs3099045 ENSG00000249839.1 AC011330.5 -11.05 2.24e-25 7.04e-22 -0.59 -0.45 Schizophrenia; chr15:43631757 chr15:43663654~43684339:- LUSC cis rs10129255 0.536 rs10142951 ENSG00000280411.1 IGHV1-69-2 -11.04 2.28e-25 7.14e-22 -0.28 -0.45 Kawasaki disease; chr14:106782337 chr14:106762092~106762588:- LUSC cis rs977987 0.806 rs4888416 ENSG00000261783.1 RP11-252K23.2 -11.04 2.28e-25 7.14e-22 -0.62 -0.45 Dupuytren's disease; chr16:75415278 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs7199132 ENSG00000261783.1 RP11-252K23.2 -11.04 2.28e-25 7.14e-22 -0.62 -0.45 Dupuytren's disease; chr16:75416141 chr16:75379818~75381260:- LUSC cis rs6991838 0.557 rs7012578 ENSG00000272010.1 CTD-3025N20.3 -11.04 2.29e-25 7.18e-22 -0.52 -0.45 Intelligence (multi-trait analysis); chr8:65592592 chr8:65591850~65592472:- LUSC cis rs7301826 0.603 rs7975825 ENSG00000256299.1 RP11-989F5.3 -11.04 2.29e-25 7.19e-22 -0.5 -0.45 Plasma plasminogen activator levels; chr12:130803899 chr12:130810821~130812622:- LUSC cis rs7626444 0.647 rs844546 ENSG00000272359.1 U4 -11.04 2.31e-25 7.25e-22 -0.48 -0.45 Monocyte count; chr3:196748403 chr3:196747192~196747324:- LUSC cis rs7626444 0.625 rs843540 ENSG00000272359.1 U4 -11.04 2.31e-25 7.25e-22 -0.48 -0.45 Monocyte count; chr3:196748442 chr3:196747192~196747324:- LUSC cis rs875971 0.964 rs778735 ENSG00000226824.5 RP4-756H11.3 -11.04 2.34e-25 7.33e-22 -0.54 -0.45 Aortic root size; chr7:66349822 chr7:66654538~66669855:+ LUSC cis rs3091242 0.967 rs665372 ENSG00000261349.1 RP3-465N24.5 -11.04 2.36e-25 7.38e-22 -0.55 -0.45 Erythrocyte sedimentation rate; chr1:25392744 chr1:25266102~25267136:- LUSC cis rs3091242 1 rs9689 ENSG00000261349.1 RP3-465N24.5 -11.04 2.38e-25 7.46e-22 -0.54 -0.45 Erythrocyte sedimentation rate; chr1:25361785 chr1:25266102~25267136:- LUSC cis rs977987 0.806 rs11642572 ENSG00000261783.1 RP11-252K23.2 -11.04 2.41e-25 7.54e-22 -0.62 -0.45 Dupuytren's disease; chr16:75418884 chr16:75379818~75381260:- LUSC cis rs3931020 0.745 rs1969111 ENSG00000272864.1 RP11-17E13.2 11.04 2.46e-25 7.68e-22 0.54 0.45 Resistin levels; chr1:74797801 chr1:74698769~74699333:- LUSC cis rs10129255 0.5 rs8022547 ENSG00000280411.1 IGHV1-69-2 -11.04 2.46e-25 7.68e-22 -0.28 -0.45 Kawasaki disease; chr14:106781985 chr14:106762092~106762588:- LUSC cis rs10129255 0.5 rs8006888 ENSG00000280411.1 IGHV1-69-2 -11.04 2.46e-25 7.68e-22 -0.28 -0.45 Kawasaki disease; chr14:106782219 chr14:106762092~106762588:- LUSC cis rs977987 0.806 rs11648176 ENSG00000261783.1 RP11-252K23.2 -11.03 2.49e-25 7.77e-22 -0.62 -0.45 Dupuytren's disease; chr16:75422525 chr16:75379818~75381260:- LUSC cis rs1799949 0.965 rs6503726 ENSG00000198496.9 NBR2 -11.03 2.5e-25 7.81e-22 -0.5 -0.45 Menopause (age at onset); chr17:43132725 chr17:43125610~43153671:+ LUSC cis rs977987 0.931 rs8057084 ENSG00000261783.1 RP11-252K23.2 11.03 2.51e-25 7.83e-22 0.62 0.45 Dupuytren's disease; chr16:75458808 chr16:75379818~75381260:- LUSC cis rs8062405 1 rs56404918 ENSG00000259982.1 CDC37P1 11.03 2.55e-25 7.95e-22 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835519 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs55719896 ENSG00000259982.1 CDC37P1 11.03 2.55e-25 7.95e-22 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835545 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs55830740 ENSG00000259982.1 CDC37P1 11.03 2.55e-25 7.95e-22 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835828 chr16:28700294~28701540:- LUSC cis rs1185460 0.967 rs1168568 ENSG00000271751.1 RP11-110I1.14 -11.03 2.56e-25 7.98e-22 -0.58 -0.45 Coronary artery disease; chr11:119079089 chr11:119065263~119065677:- LUSC cis rs875971 0.838 rs2173570 ENSG00000226824.5 RP4-756H11.3 11.03 2.57e-25 8.01e-22 0.54 0.45 Aortic root size; chr7:66297976 chr7:66654538~66669855:+ LUSC cis rs1930961 1 rs6004672 ENSG00000272977.1 CTA-390C10.10 -11.03 2.59e-25 8.08e-22 -0.8 -0.45 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25476218~25479971:+ LUSC cis rs10129255 0.5 rs8014529 ENSG00000280411.1 IGHV1-69-2 -11.03 2.6e-25 8.09e-22 -0.28 -0.45 Kawasaki disease; chr14:106784065 chr14:106762092~106762588:- LUSC cis rs10129255 0.5 rs8004923 ENSG00000280411.1 IGHV1-69-2 -11.03 2.6e-25 8.1e-22 -0.28 -0.45 Kawasaki disease; chr14:106785926 chr14:106762092~106762588:- LUSC cis rs10129255 0.5 rs6576232 ENSG00000280411.1 IGHV1-69-2 -11.03 2.6e-25 8.1e-22 -0.28 -0.45 Kawasaki disease; chr14:106787090 chr14:106762092~106762588:- LUSC cis rs5760092 0.755 rs915589 ENSG00000250470.1 AP000351.3 -11.03 2.62e-25 8.17e-22 -0.73 -0.45 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23976904~23977585:- LUSC cis rs10129255 0.518 rs11847766 ENSG00000280411.1 IGHV1-69-2 -11.03 2.63e-25 8.19e-22 -0.28 -0.45 Kawasaki disease; chr14:106779186 chr14:106762092~106762588:- LUSC cis rs1185460 0.967 rs1307145 ENSG00000271751.1 RP11-110I1.14 -11.03 2.69e-25 8.36e-22 -0.58 -0.45 Coronary artery disease; chr11:119079507 chr11:119065263~119065677:- LUSC cis rs2739330 0.761 rs5760176 ENSG00000235689.1 AP000351.13 -11.02 2.73e-25 8.48e-22 -0.46 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:24006305~24008258:- LUSC cis rs3096299 0.503 rs4785677 ENSG00000274627.1 RP11-104N10.2 11.02 2.83e-25 8.8e-22 0.4 0.45 Multiple myeloma (IgH translocation); chr16:89488693 chr16:89516797~89522217:+ LUSC cis rs977987 0.806 rs8050059 ENSG00000261783.1 RP11-252K23.2 -11.02 2.87e-25 8.91e-22 -0.62 -0.45 Dupuytren's disease; chr16:75354833 chr16:75379818~75381260:- LUSC cis rs3091242 0.867 rs602052 ENSG00000261349.1 RP3-465N24.5 -11.02 2.89e-25 8.98e-22 -0.55 -0.45 Erythrocyte sedimentation rate; chr1:25395715 chr1:25266102~25267136:- LUSC cis rs10129255 0.518 rs7143784 ENSG00000280411.1 IGHV1-69-2 -11.02 2.9e-25 9.01e-22 -0.28 -0.45 Kawasaki disease; chr14:106687277 chr14:106762092~106762588:- LUSC cis rs7208859 0.673 rs11657270 ENSG00000263531.1 RP13-753N3.1 11.02 2.92e-25 9.05e-22 0.8 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887369 chr17:30863921~30864940:- LUSC cis rs977987 0.836 rs4888376 ENSG00000261783.1 RP11-252K23.2 -11.02 2.92e-25 9.06e-22 -0.62 -0.45 Dupuytren's disease; chr16:75288675 chr16:75379818~75381260:- LUSC cis rs16828019 0.929 rs2363805 ENSG00000235358.1 RP11-399E6.1 11.02 2.94e-25 9.13e-22 0.85 0.45 Intelligence (multi-trait analysis); chr1:41253762 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs71648540 ENSG00000235358.1 RP11-399E6.1 11.02 2.94e-25 9.13e-22 0.85 0.45 Intelligence (multi-trait analysis); chr1:41256623 chr1:41242373~41284861:+ LUSC cis rs977987 0.806 rs12051136 ENSG00000261783.1 RP11-252K23.2 -11.01 2.99e-25 9.27e-22 -0.62 -0.45 Dupuytren's disease; chr16:75401833 chr16:75379818~75381260:- LUSC cis rs16828019 0.852 rs11209531 ENSG00000235358.1 RP11-399E6.1 11.01 2.99e-25 9.29e-22 0.82 0.45 Intelligence (multi-trait analysis); chr1:41105349 chr1:41242373~41284861:+ LUSC cis rs10129255 0.5 rs11628999 ENSG00000280411.1 IGHV1-69-2 -11.01 3.01e-25 9.33e-22 -0.28 -0.45 Kawasaki disease; chr14:106800208 chr14:106762092~106762588:- LUSC cis rs507080 0.769 rs645637 ENSG00000255422.1 AP002954.4 -11.01 3.04e-25 9.44e-22 -0.51 -0.45 Serum metabolite levels; chr11:118634373 chr11:118704607~118750263:+ LUSC cis rs2739330 0.731 rs2000468 ENSG00000231271.1 AP000350.8 11.01 3.04e-25 9.44e-22 0.56 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23949918~23954042:+ LUSC cis rs10129255 0.5 rs10131875 ENSG00000280411.1 IGHV1-69-2 -11.01 3.07e-25 9.52e-22 -0.28 -0.45 Kawasaki disease; chr14:106792798 chr14:106762092~106762588:- LUSC cis rs977987 0.585 rs62059845 ENSG00000261783.1 RP11-252K23.2 -11.01 3.08e-25 9.53e-22 -0.62 -0.45 Dupuytren's disease; chr16:75396815 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs62059846 ENSG00000261783.1 RP11-252K23.2 -11.01 3.08e-25 9.53e-22 -0.62 -0.45 Dupuytren's disease; chr16:75396911 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs11862719 ENSG00000261783.1 RP11-252K23.2 -11.01 3.08e-25 9.53e-22 -0.62 -0.45 Dupuytren's disease; chr16:75397810 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs11149824 ENSG00000261783.1 RP11-252K23.2 -11.01 3.08e-25 9.53e-22 -0.62 -0.45 Dupuytren's disease; chr16:75397932 chr16:75379818~75381260:- LUSC cis rs1799949 0.929 rs799906 ENSG00000198496.9 NBR2 -11.01 3.08e-25 9.55e-22 -0.49 -0.45 Menopause (age at onset); chr17:43126099 chr17:43125610~43153671:+ LUSC cis rs1799949 0.965 rs799908 ENSG00000198496.9 NBR2 -11.01 3.08e-25 9.55e-22 -0.49 -0.45 Menopause (age at onset); chr17:43126899 chr17:43125610~43153671:+ LUSC cis rs1799949 0.93 rs1554063 ENSG00000198496.9 NBR2 -11.01 3.08e-25 9.55e-22 -0.49 -0.45 Menopause (age at onset); chr17:43135128 chr17:43125610~43153671:+ LUSC cis rs977987 0.778 rs4888409 ENSG00000261783.1 RP11-252K23.2 -11 3.22e-25 9.96e-22 -0.62 -0.45 Dupuytren's disease; chr16:75402333 chr16:75379818~75381260:- LUSC cis rs6964833 0.935 rs34630792 ENSG00000123965.13 PMS2P5 11 3.22e-25 9.96e-22 0.72 0.45 Menarche (age at onset); chr7:74646869 chr7:74894116~74897835:+ LUSC cis rs1799949 0.965 rs799917 ENSG00000198496.9 NBR2 -11 3.23e-25 9.99e-22 -0.49 -0.45 Menopause (age at onset); chr17:43092919 chr17:43125610~43153671:+ LUSC cis rs977987 0.75 rs4888414 ENSG00000261783.1 RP11-252K23.2 -11 3.29e-25 1.02e-21 -0.62 -0.45 Dupuytren's disease; chr16:75413335 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs6564258 ENSG00000261783.1 RP11-252K23.2 -11 3.29e-25 1.02e-21 -0.62 -0.45 Dupuytren's disease; chr16:75413465 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs6564259 ENSG00000261783.1 RP11-252K23.2 -11 3.29e-25 1.02e-21 -0.62 -0.45 Dupuytren's disease; chr16:75413495 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs6564260 ENSG00000261783.1 RP11-252K23.2 -11 3.29e-25 1.02e-21 -0.62 -0.45 Dupuytren's disease; chr16:75413528 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs8056236 ENSG00000261783.1 RP11-252K23.2 -11 3.29e-25 1.02e-21 -0.62 -0.45 Dupuytren's disease; chr16:75414375 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs8051407 ENSG00000261783.1 RP11-252K23.2 -11 3.29e-25 1.02e-21 -0.62 -0.45 Dupuytren's disease; chr16:75414761 chr16:75379818~75381260:- LUSC cis rs10256972 0.616 rs4585652 ENSG00000229043.2 AC091729.9 -11 3.3e-25 1.02e-21 -0.54 -0.45 Endometriosis;Longevity; chr7:1105760 chr7:1160374~1165267:+ LUSC cis rs977987 0.806 rs12051326 ENSG00000261783.1 RP11-252K23.2 -11 3.32e-25 1.02e-21 -0.62 -0.45 Dupuytren's disease; chr16:75403989 chr16:75379818~75381260:- LUSC cis rs9322193 0.607 rs6557165 ENSG00000231760.4 RP11-350J20.5 -11 3.33e-25 1.03e-21 -0.64 -0.45 Lung cancer; chr6:149906883 chr6:149796151~149826294:- LUSC cis rs1799949 0.965 rs799912 ENSG00000198496.9 NBR2 -11 3.37e-25 1.04e-21 -0.49 -0.45 Menopause (age at onset); chr17:43105117 chr17:43125610~43153671:+ LUSC cis rs2455601 0.638 rs11042148 ENSG00000254860.4 TMEM9B-AS1 11 3.38e-25 1.04e-21 0.61 0.45 Schizophrenia; chr11:8987127 chr11:8964675~8977527:+ LUSC cis rs977987 0.872 rs4887825 ENSG00000261783.1 RP11-252K23.2 -11 3.39e-25 1.05e-21 -0.61 -0.45 Dupuytren's disease; chr16:75438524 chr16:75379818~75381260:- LUSC cis rs7186831 1 rs7186831 ENSG00000261783.1 RP11-252K23.2 -11 3.39e-25 1.05e-21 -0.61 -0.45 Chronic obstructive pulmonary disease; chr16:75439257 chr16:75379818~75381260:- LUSC cis rs875971 1 rs6958271 ENSG00000226824.5 RP4-756H11.3 -11 3.42e-25 1.05e-21 -0.54 -0.45 Aortic root size; chr7:66514344 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6958277 ENSG00000226824.5 RP4-756H11.3 -11 3.42e-25 1.05e-21 -0.54 -0.45 Aortic root size; chr7:66514362 chr7:66654538~66669855:+ LUSC cis rs977987 0.771 rs12929673 ENSG00000261783.1 RP11-252K23.2 -11 3.44e-25 1.06e-21 -0.61 -0.45 Dupuytren's disease; chr16:75436397 chr16:75379818~75381260:- LUSC cis rs977987 0.836 rs35209155 ENSG00000261783.1 RP11-252K23.2 -11 3.44e-25 1.06e-21 -0.61 -0.45 Dupuytren's disease; chr16:75436598 chr16:75379818~75381260:- LUSC cis rs1799949 0.965 rs6503727 ENSG00000198496.9 NBR2 -11 3.48e-25 1.07e-21 -0.49 -0.45 Menopause (age at onset); chr17:43160842 chr17:43125610~43153671:+ LUSC cis rs977987 0.806 rs4887823 ENSG00000261783.1 RP11-252K23.2 -11 3.49e-25 1.07e-21 -0.61 -0.45 Dupuytren's disease; chr16:75399176 chr16:75379818~75381260:- LUSC cis rs10129255 0.5 rs8021941 ENSG00000280411.1 IGHV1-69-2 -10.99 3.57e-25 1.1e-21 -0.28 -0.45 Kawasaki disease; chr14:106781490 chr14:106762092~106762588:- LUSC cis rs10129255 0.5 rs10142931 ENSG00000280411.1 IGHV1-69-2 -10.99 3.57e-25 1.1e-21 -0.28 -0.45 Kawasaki disease; chr14:106782288 chr14:106762092~106762588:- LUSC cis rs977987 0.806 rs34021527 ENSG00000261783.1 RP11-252K23.2 -10.99 3.57e-25 1.1e-21 -0.61 -0.45 Dupuytren's disease; chr16:75440192 chr16:75379818~75381260:- LUSC cis rs977987 0.751 rs56004344 ENSG00000261783.1 RP11-252K23.2 -10.99 3.57e-25 1.1e-21 -0.61 -0.45 Dupuytren's disease; chr16:75440291 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs72787160 ENSG00000261783.1 RP11-252K23.2 -10.99 3.58e-25 1.1e-21 -0.62 -0.45 Dupuytren's disease; chr16:75411264 chr16:75379818~75381260:- LUSC cis rs6700559 0.873 rs7524025 ENSG00000260088.1 RP11-92G12.3 -10.99 3.61e-25 1.11e-21 -0.57 -0.45 Coronary artery disease; chr1:200687859 chr1:200669507~200694250:+ LUSC cis rs977987 0.778 rs8057849 ENSG00000261783.1 RP11-252K23.2 -10.99 3.64e-25 1.12e-21 -0.62 -0.45 Dupuytren's disease; chr16:75409918 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs7206541 ENSG00000261783.1 RP11-252K23.2 -10.98 3.86e-25 1.19e-21 -0.62 -0.45 Dupuytren's disease; chr16:75402815 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs12443834 ENSG00000261783.1 RP11-252K23.2 -10.98 3.86e-25 1.19e-21 -0.62 -0.45 Dupuytren's disease; chr16:75404571 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs12924920 ENSG00000261783.1 RP11-252K23.2 -10.98 3.86e-25 1.19e-21 -0.62 -0.45 Dupuytren's disease; chr16:75406235 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs4887824 ENSG00000261783.1 RP11-252K23.2 -10.98 3.86e-25 1.19e-21 -0.62 -0.45 Dupuytren's disease; chr16:75407715 chr16:75379818~75381260:- LUSC cis rs9545047 0.967 rs9318627 ENSG00000227676.3 LINC01068 10.98 3.9e-25 1.2e-21 0.57 0.45 Schizophrenia; chr13:79355944 chr13:79566727~79571436:+ LUSC cis rs6700559 0.873 rs7542840 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200686558 chr1:200669507~200694250:+ LUSC cis rs6700559 0.815 rs7526365 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200688020 chr1:200669507~200694250:+ LUSC cis rs6700559 0.873 rs7526482 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200688310 chr1:200669507~200694250:+ LUSC cis rs6700559 0.873 rs7526853 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200688529 chr1:200669507~200694250:+ LUSC cis rs6700559 0.844 rs61825137 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200689267 chr1:200669507~200694250:+ LUSC cis rs6700559 0.873 rs7545177 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200690727 chr1:200669507~200694250:+ LUSC cis rs6700559 0.873 rs7539646 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200692534 chr1:200669507~200694250:+ LUSC cis rs6700559 0.873 rs7519383 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200692968 chr1:200669507~200694250:+ LUSC cis rs6700559 0.815 rs12141497 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200693389 chr1:200669507~200694250:+ LUSC cis rs6700559 0.873 rs12126708 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200693397 chr1:200669507~200694250:+ LUSC cis rs6700559 0.873 rs10920008 ENSG00000260088.1 RP11-92G12.3 -10.98 3.96e-25 1.21e-21 -0.57 -0.45 Coronary artery disease; chr1:200694546 chr1:200669507~200694250:+ LUSC cis rs977987 0.806 rs4888411 ENSG00000261783.1 RP11-252K23.2 -10.98 3.99e-25 1.22e-21 -0.62 -0.45 Dupuytren's disease; chr16:75409285 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs4888412 ENSG00000261783.1 RP11-252K23.2 -10.98 3.99e-25 1.22e-21 -0.62 -0.45 Dupuytren's disease; chr16:75409298 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs4888413 ENSG00000261783.1 RP11-252K23.2 -10.98 3.99e-25 1.22e-21 -0.62 -0.45 Dupuytren's disease; chr16:75409325 chr16:75379818~75381260:- LUSC cis rs2019137 0.539 rs4849177 ENSG00000189223.12 PAX8-AS1 -10.98 4.05e-25 1.24e-21 -0.61 -0.45 Lymphocyte counts; chr2:113225007 chr2:113211522~113276581:+ LUSC cis rs2455601 0.638 rs2742478 ENSG00000254860.4 TMEM9B-AS1 10.98 4.1e-25 1.26e-21 0.61 0.45 Schizophrenia; chr11:8974552 chr11:8964675~8977527:+ LUSC cis rs8062405 1 rs62036617 ENSG00000259982.1 CDC37P1 10.98 4.17e-25 1.27e-21 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28816177 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs4788095 ENSG00000259982.1 CDC37P1 10.98 4.17e-25 1.27e-21 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28820038 chr16:28700294~28701540:- LUSC cis rs8062405 0.964 rs72793809 ENSG00000259982.1 CDC37P1 10.98 4.17e-25 1.27e-21 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821061 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs62036620 ENSG00000259982.1 CDC37P1 10.98 4.17e-25 1.27e-21 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821776 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs62036621 ENSG00000259982.1 CDC37P1 10.98 4.17e-25 1.27e-21 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821978 chr16:28700294~28701540:- LUSC cis rs801193 0.66 rs10950049 ENSG00000226824.5 RP4-756H11.3 -10.97 4.2e-25 1.28e-21 -0.54 -0.45 Aortic root size; chr7:66765873 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs6576231 ENSG00000280411.1 IGHV1-69-2 -10.97 4.2e-25 1.28e-21 -0.28 -0.45 Kawasaki disease; chr14:106783693 chr14:106762092~106762588:- LUSC cis rs10129255 0.518 rs10136903 ENSG00000280411.1 IGHV1-69-2 -10.97 4.23e-25 1.29e-21 -0.28 -0.45 Kawasaki disease; chr14:106778866 chr14:106762092~106762588:- LUSC cis rs1799949 0.965 rs7212284 ENSG00000198496.9 NBR2 -10.97 4.25e-25 1.3e-21 -0.49 -0.45 Menopause (age at onset); chr17:43053924 chr17:43125610~43153671:+ LUSC cis rs16828019 0.789 rs34216154 ENSG00000235358.1 RP11-399E6.1 10.97 4.25e-25 1.3e-21 0.83 0.45 Intelligence (multi-trait analysis); chr1:41205235 chr1:41242373~41284861:+ LUSC cis rs11155671 0.53 rs6557133 ENSG00000231760.4 RP11-350J20.5 10.97 4.33e-25 1.32e-21 0.58 0.45 Testicular germ cell tumor; chr6:149874248 chr6:149796151~149826294:- LUSC cis rs7174755 0.961 rs12148843 ENSG00000260657.2 RP11-315D16.4 10.97 4.36e-25 1.33e-21 0.56 0.45 Major depressive disorder; chr15:68302184 chr15:68267792~68277994:- LUSC cis rs7174755 0.961 rs1122247 ENSG00000260657.2 RP11-315D16.4 10.97 4.36e-25 1.33e-21 0.56 0.45 Major depressive disorder; chr15:68302523 chr15:68267792~68277994:- LUSC cis rs2729354 0.953 rs2649663 ENSG00000265566.2 RN7SL605P -10.97 4.37e-25 1.33e-21 -0.63 -0.45 Blood protein levels; chr11:57589832 chr11:57528085~57528365:- LUSC cis rs977987 0.843 rs10431974 ENSG00000261783.1 RP11-252K23.2 -10.97 4.42e-25 1.35e-21 -0.62 -0.45 Dupuytren's disease; chr16:75401563 chr16:75379818~75381260:- LUSC cis rs10256972 0.591 rs6950319 ENSG00000229043.2 AC091729.9 -10.97 4.48e-25 1.37e-21 -0.54 -0.45 Endometriosis;Longevity; chr7:1121688 chr7:1160374~1165267:+ LUSC cis rs977987 0.872 rs4887816 ENSG00000261783.1 RP11-252K23.2 -10.97 4.56e-25 1.39e-21 -0.61 -0.45 Dupuytren's disease; chr16:75285818 chr16:75379818~75381260:- LUSC cis rs3931020 0.508 rs4145871 ENSG00000272864.1 RP11-17E13.2 -10.96 4.58e-25 1.4e-21 -0.56 -0.45 Resistin levels; chr1:74753020 chr1:74698769~74699333:- LUSC cis rs977987 0.778 rs4243112 ENSG00000261783.1 RP11-252K23.2 -10.96 4.62e-25 1.41e-21 -0.61 -0.45 Dupuytren's disease; chr16:75287133 chr16:75379818~75381260:- LUSC cis rs507080 0.769 rs11603616 ENSG00000255422.1 AP002954.4 -10.96 4.64e-25 1.41e-21 -0.51 -0.45 Serum metabolite levels; chr11:118625350 chr11:118704607~118750263:+ LUSC cis rs6782228 0.565 rs11719239 ENSG00000242551.2 POU5F1P6 -10.96 4.66e-25 1.42e-21 -0.53 -0.45 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128700211 chr3:128674735~128677005:- LUSC cis rs6782228 0.606 rs2001950 ENSG00000242551.2 POU5F1P6 -10.96 4.66e-25 1.42e-21 -0.53 -0.45 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128700913 chr3:128674735~128677005:- LUSC cis rs1799949 0.965 rs8176310 ENSG00000198496.9 NBR2 -10.96 4.75e-25 1.45e-21 -0.49 -0.45 Menopause (age at onset); chr17:43047896 chr17:43125610~43153671:+ LUSC cis rs150992 0.632 rs34489 ENSG00000248489.1 CTD-2007H13.3 -10.96 4.76e-25 1.45e-21 -0.52 -0.45 Body mass index; chr5:98977180 chr5:98929171~98995013:+ LUSC cis rs977987 0.806 rs17696696 ENSG00000261783.1 RP11-252K23.2 10.96 4.81e-25 1.46e-21 0.6 0.45 Dupuytren's disease; chr16:75359454 chr16:75379818~75381260:- LUSC cis rs1263173 0.696 rs1263172 ENSG00000254851.1 RP11-109L13.1 -10.96 4.82e-25 1.47e-21 -0.59 -0.45 HDL cholesterol; chr11:116810202 chr11:117135528~117138582:+ LUSC cis rs7188445 1 rs7190187 ENSG00000261390.4 RP11-345M22.2 -10.96 4.91e-25 1.49e-21 -0.62 -0.45 Urate levels; chr16:79701281 chr16:79715232~79770563:- LUSC cis rs507080 0.524 rs524409 ENSG00000255422.1 AP002954.4 -10.96 4.92e-25 1.49e-21 -0.46 -0.45 Serum metabolite levels; chr11:118703602 chr11:118704607~118750263:+ LUSC cis rs16828019 0.929 rs1032728 ENSG00000235358.1 RP11-399E6.1 10.96 4.93e-25 1.5e-21 0.83 0.45 Intelligence (multi-trait analysis); chr1:41213894 chr1:41242373~41284861:+ LUSC cis rs16828019 0.929 rs35286837 ENSG00000235358.1 RP11-399E6.1 10.96 4.93e-25 1.5e-21 0.83 0.45 Intelligence (multi-trait analysis); chr1:41217326 chr1:41242373~41284861:+ LUSC cis rs2455601 0.574 rs2568094 ENSG00000254860.4 TMEM9B-AS1 10.95 5.17e-25 1.57e-21 0.6 0.45 Schizophrenia; chr11:8970671 chr11:8964675~8977527:+ LUSC cis rs977987 0.806 rs4888390 ENSG00000261783.1 RP11-252K23.2 -10.95 5.21e-25 1.58e-21 -0.61 -0.45 Dupuytren's disease; chr16:75366422 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs4888391 ENSG00000261783.1 RP11-252K23.2 -10.95 5.21e-25 1.58e-21 -0.61 -0.45 Dupuytren's disease; chr16:75366848 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs8054769 ENSG00000261783.1 RP11-252K23.2 -10.95 5.21e-25 1.58e-21 -0.61 -0.45 Dupuytren's disease; chr16:75367215 chr16:75379818~75381260:- LUSC cis rs9545047 0.613 rs79774056 ENSG00000227676.3 LINC01068 10.95 5.29e-25 1.61e-21 0.56 0.45 Schizophrenia; chr13:79421486 chr13:79566727~79571436:+ LUSC cis rs7301826 0.61 rs36051740 ENSG00000256299.1 RP11-989F5.3 10.95 5.31e-25 1.61e-21 0.5 0.45 Plasma plasminogen activator levels; chr12:130808177 chr12:130810821~130812622:- LUSC cis rs977987 0.806 rs1364077 ENSG00000261783.1 RP11-252K23.2 -10.95 5.31e-25 1.61e-21 -0.61 -0.45 Dupuytren's disease; chr16:75363093 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs4887820 ENSG00000261783.1 RP11-252K23.2 -10.95 5.31e-25 1.61e-21 -0.61 -0.45 Dupuytren's disease; chr16:75363389 chr16:75379818~75381260:- LUSC cis rs950027 0.787 rs1547487 ENSG00000259520.4 CTD-2651B20.3 -10.95 5.4e-25 1.64e-21 -0.55 -0.45 Response to fenofibrate (adiponectin levels); chr15:45431785 chr15:45251580~45279251:- LUSC cis rs977987 0.806 rs4888383 ENSG00000261783.1 RP11-252K23.2 -10.95 5.45e-25 1.65e-21 -0.62 -0.45 Dupuytren's disease; chr16:75352451 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs8050769 ENSG00000261783.1 RP11-252K23.2 -10.95 5.45e-25 1.65e-21 -0.62 -0.45 Dupuytren's disease; chr16:75354536 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs4888388 ENSG00000261783.1 RP11-252K23.2 -10.94 5.46e-25 1.65e-21 -0.61 -0.45 Dupuytren's disease; chr16:75360250 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs4888389 ENSG00000261783.1 RP11-252K23.2 -10.94 5.46e-25 1.65e-21 -0.61 -0.45 Dupuytren's disease; chr16:75361330 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs11865004 ENSG00000261783.1 RP11-252K23.2 -10.94 5.46e-25 1.65e-21 -0.61 -0.45 Dupuytren's disease; chr16:75361879 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs6564252 ENSG00000261783.1 RP11-252K23.2 -10.94 5.64e-25 1.71e-21 -0.62 -0.45 Dupuytren's disease; chr16:75355042 chr16:75379818~75381260:- LUSC cis rs7174755 0.961 rs58175526 ENSG00000260657.2 RP11-315D16.4 10.94 5.65e-25 1.71e-21 0.56 0.45 Major depressive disorder; chr15:68300789 chr15:68267792~68277994:- LUSC cis rs10129255 0.5 rs2105991 ENSG00000280411.1 IGHV1-69-2 -10.94 5.69e-25 1.72e-21 -0.28 -0.45 Kawasaki disease; chr14:106682022 chr14:106762092~106762588:- LUSC cis rs2019137 0.56 rs10175462 ENSG00000189223.12 PAX8-AS1 -10.94 5.7e-25 1.72e-21 -0.6 -0.45 Lymphocyte counts; chr2:113230915 chr2:113211522~113276581:+ LUSC cis rs977987 0.806 rs2285225 ENSG00000261783.1 RP11-252K23.2 -10.94 5.71e-25 1.73e-21 -0.61 -0.45 Dupuytren's disease; chr16:75395354 chr16:75379818~75381260:- LUSC cis rs977987 0.527 rs62059844 ENSG00000261783.1 RP11-252K23.2 -10.94 5.71e-25 1.73e-21 -0.61 -0.45 Dupuytren's disease; chr16:75395839 chr16:75379818~75381260:- LUSC cis rs507080 0.769 rs2077173 ENSG00000255422.1 AP002954.4 -10.94 5.72e-25 1.73e-21 -0.5 -0.45 Serum metabolite levels; chr11:118621876 chr11:118704607~118750263:+ LUSC cis rs977987 0.771 rs4888387 ENSG00000261783.1 RP11-252K23.2 -10.94 5.82e-25 1.76e-21 -0.62 -0.45 Dupuytren's disease; chr16:75355857 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs1109341 ENSG00000261783.1 RP11-252K23.2 -10.94 5.88e-25 1.77e-21 -0.62 -0.45 Dupuytren's disease; chr16:75411707 chr16:75379818~75381260:- LUSC cis rs3091242 0.933 rs12402120 ENSG00000261349.1 RP3-465N24.5 -10.94 5.92e-25 1.79e-21 -0.56 -0.45 Erythrocyte sedimentation rate; chr1:25425141 chr1:25266102~25267136:- LUSC cis rs801193 0.636 rs10233806 ENSG00000226824.5 RP4-756H11.3 10.93 5.99e-25 1.81e-21 0.54 0.45 Aortic root size; chr7:66653261 chr7:66654538~66669855:+ LUSC cis rs1799949 0.965 rs4793230 ENSG00000198496.9 NBR2 -10.93 6.26e-25 1.89e-21 -0.49 -0.45 Menopause (age at onset); chr17:43350035 chr17:43125610~43153671:+ LUSC cis rs1501911 0.53 rs326468 ENSG00000248489.1 CTD-2007H13.3 10.93 6.26e-25 1.89e-21 0.53 0.45 Lung function (FEV1/FVC); chr5:98897105 chr5:98929171~98995013:+ LUSC cis rs977987 0.788 rs7184525 ENSG00000261783.1 RP11-252K23.2 -10.93 6.27e-25 1.89e-21 -0.62 -0.45 Dupuytren's disease; chr16:75403288 chr16:75379818~75381260:- LUSC cis rs494459 0.964 rs576283 ENSG00000255422.1 AP002954.4 -10.93 6.37e-25 1.92e-21 -0.46 -0.45 Height; chr11:118703185 chr11:118704607~118750263:+ LUSC cis rs494459 0.929 rs627391 ENSG00000255422.1 AP002954.4 -10.93 6.37e-25 1.92e-21 -0.46 -0.45 Height; chr11:118703207 chr11:118704607~118750263:+ LUSC cis rs977987 0.806 rs7185640 ENSG00000261783.1 RP11-252K23.2 -10.93 6.43e-25 1.94e-21 -0.61 -0.45 Dupuytren's disease; chr16:75360501 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs11640674 ENSG00000261783.1 RP11-252K23.2 -10.93 6.43e-25 1.94e-21 -0.61 -0.45 Dupuytren's disease; chr16:75361046 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs1895490 ENSG00000261783.1 RP11-252K23.2 -10.93 6.43e-25 1.94e-21 -0.61 -0.45 Dupuytren's disease; chr16:75358908 chr16:75379818~75381260:- LUSC cis rs73086581 1 rs17287822 ENSG00000229539.1 RP11-119B16.2 10.93 6.48e-25 1.95e-21 0.57 0.45 Response to antidepressants in depression; chr20:3997889 chr20:3888239~3888868:- LUSC cis rs150992 0.517 rs326464 ENSG00000248489.1 CTD-2007H13.3 10.93 6.49e-25 1.95e-21 0.53 0.45 Body mass index; chr5:98906499 chr5:98929171~98995013:+ LUSC cis rs16828019 0.789 rs36084778 ENSG00000235358.1 RP11-399E6.1 10.93 6.5e-25 1.96e-21 0.84 0.45 Intelligence (multi-trait analysis); chr1:41013866 chr1:41242373~41284861:+ LUSC cis rs16828019 0.777 rs11209363 ENSG00000235358.1 RP11-399E6.1 10.93 6.5e-25 1.96e-21 0.84 0.45 Intelligence (multi-trait analysis); chr1:41019405 chr1:41242373~41284861:+ LUSC cis rs1799949 0.536 rs4793227 ENSG00000198496.9 NBR2 -10.92 6.53e-25 1.96e-21 -0.49 -0.45 Menopause (age at onset); chr17:43334882 chr17:43125610~43153671:+ LUSC cis rs977987 0.806 rs2903033 ENSG00000261783.1 RP11-252K23.2 -10.92 6.82e-25 2.05e-21 -0.62 -0.45 Dupuytren's disease; chr16:75355708 chr16:75379818~75381260:- LUSC cis rs997154 0.655 rs4981454 ENSG00000279656.1 RP11-298I3.6 10.92 6.98e-25 2.1e-21 0.61 0.45 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22952977 chr14:23023083~23024217:- LUSC cis rs67383717 0.689 rs1836404 ENSG00000175611.10 LINC00476 -10.92 7e-25 2.1e-21 -0.49 -0.45 Parkinson's disease (pesticide exposure interaction); chr9:95787982 chr9:95759231~95875977:- LUSC cis rs507080 0.769 rs570952 ENSG00000255422.1 AP002954.4 -10.92 7.01e-25 2.1e-21 -0.5 -0.45 Serum metabolite levels; chr11:118629477 chr11:118704607~118750263:+ LUSC cis rs2729354 0.903 rs2729371 ENSG00000265566.2 RN7SL605P -10.92 7.02e-25 2.11e-21 -0.63 -0.45 Blood protein levels; chr11:57553849 chr11:57528085~57528365:- LUSC cis rs1501911 0.53 rs162150 ENSG00000248489.1 CTD-2007H13.3 10.92 7.05e-25 2.12e-21 0.53 0.45 Lung function (FEV1/FVC); chr5:98913909 chr5:98929171~98995013:+ LUSC cis rs8062405 1 rs4451951 ENSG00000259982.1 CDC37P1 10.91 7.27e-25 2.18e-21 0.55 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28824884 chr16:28700294~28701540:- LUSC cis rs10129255 0.5 rs59939897 ENSG00000280411.1 IGHV1-69-2 -10.91 7.3e-25 2.19e-21 -0.28 -0.45 Kawasaki disease; chr14:106783414 chr14:106762092~106762588:- LUSC cis rs10129255 0.518 rs12590732 ENSG00000280411.1 IGHV1-69-2 10.91 7.31e-25 2.19e-21 0.28 0.45 Kawasaki disease; chr14:106779612 chr14:106762092~106762588:- LUSC cis rs2729354 1 rs2511983 ENSG00000265566.2 RN7SL605P -10.91 7.32e-25 2.19e-21 -0.63 -0.45 Blood protein levels; chr11:57579401 chr11:57528085~57528365:- LUSC cis rs977987 0.843 rs59155720 ENSG00000261783.1 RP11-252K23.2 -10.91 7.44e-25 2.23e-21 -0.61 -0.45 Dupuytren's disease; chr16:75449908 chr16:75379818~75381260:- LUSC cis rs7626444 0.584 rs7633044 ENSG00000272359.1 U4 -10.91 7.5e-25 2.25e-21 -0.48 -0.45 Monocyte count; chr3:196763772 chr3:196747192~196747324:- LUSC cis rs8062405 0.964 rs11860513 ENSG00000259982.1 CDC37P1 10.91 7.65e-25 2.29e-21 0.55 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814099 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs1987472 ENSG00000259982.1 CDC37P1 10.91 7.65e-25 2.29e-21 0.55 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814456 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs80275162 ENSG00000259982.1 CDC37P1 10.91 7.67e-25 2.29e-21 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28852196 chr16:28700294~28701540:- LUSC cis rs977987 0.806 rs11864102 ENSG00000261783.1 RP11-252K23.2 -10.9 7.77e-25 2.32e-21 -0.61 -0.45 Dupuytren's disease; chr16:75408462 chr16:75379818~75381260:- LUSC cis rs7626444 0.625 rs2931210 ENSG00000272359.1 U4 -10.9 7.79e-25 2.33e-21 -0.47 -0.45 Monocyte count; chr3:196749805 chr3:196747192~196747324:- LUSC cis rs55794721 0.509 rs12027135 ENSG00000261349.1 RP3-465N24.5 -10.9 7.89e-25 2.36e-21 -0.54 -0.45 Mean corpuscular volume;Plateletcrit; chr1:25449242 chr1:25266102~25267136:- LUSC cis rs977987 0.778 rs11149825 ENSG00000261783.1 RP11-252K23.2 -10.9 7.92e-25 2.37e-21 -0.61 -0.45 Dupuytren's disease; chr16:75400980 chr16:75379818~75381260:- LUSC cis rs507080 0.769 rs571001 ENSG00000255422.1 AP002954.4 -10.9 8.09e-25 2.42e-21 -0.5 -0.45 Serum metabolite levels; chr11:118629457 chr11:118704607~118750263:+ LUSC cis rs801193 0.591 rs2707839 ENSG00000226824.5 RP4-756H11.3 -10.9 8.12e-25 2.42e-21 -0.54 -0.45 Aortic root size; chr7:66728097 chr7:66654538~66669855:+ LUSC cis rs2019137 0.56 rs11123172 ENSG00000189223.12 PAX8-AS1 10.9 8.22e-25 2.45e-21 0.6 0.45 Lymphocyte counts; chr2:113226726 chr2:113211522~113276581:+ LUSC cis rs7626444 0.625 rs1357287 ENSG00000272359.1 U4 -10.9 8.36e-25 2.49e-21 -0.47 -0.45 Monocyte count; chr3:196758096 chr3:196747192~196747324:- LUSC cis rs977987 0.778 rs35415181 ENSG00000261783.1 RP11-252K23.2 -10.9 8.45e-25 2.52e-21 -0.61 -0.45 Dupuytren's disease; chr16:75369226 chr16:75379818~75381260:- LUSC cis rs10256972 0.568 rs1133043 ENSG00000229043.2 AC091729.9 -10.89 8.5e-25 2.53e-21 -0.55 -0.45 Endometriosis;Longevity; chr7:1093669 chr7:1160374~1165267:+ LUSC cis rs1799949 0.965 rs9897425 ENSG00000198496.9 NBR2 -10.89 8.66e-25 2.58e-21 -0.49 -0.45 Menopause (age at onset); chr17:43352811 chr17:43125610~43153671:+ LUSC cis rs7188445 0.899 rs7195321 ENSG00000261390.4 RP11-345M22.2 -10.89 8.68e-25 2.58e-21 -0.61 -0.45 Urate levels; chr16:79701065 chr16:79715232~79770563:- LUSC cis rs2412819 0.599 rs2470120 ENSG00000249839.1 AC011330.5 -10.89 8.72e-25 2.6e-21 -0.59 -0.45 Lung cancer; chr15:43636872 chr15:43663654~43684339:- LUSC cis rs977987 0.806 rs11862582 ENSG00000261783.1 RP11-252K23.2 -10.89 8.76e-25 2.61e-21 -0.61 -0.45 Dupuytren's disease; chr16:75397397 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs4146809 ENSG00000261783.1 RP11-252K23.2 10.89 8.77e-25 2.61e-21 0.61 0.45 Dupuytren's disease; chr16:75381877 chr16:75379818~75381260:- LUSC cis rs8062405 0.895 rs56186137 ENSG00000259982.1 CDC37P1 10.89 8.9e-25 2.65e-21 0.55 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814632 chr16:28700294~28701540:- LUSC cis rs7626444 0.625 rs1798636 ENSG00000272359.1 U4 -10.89 8.9e-25 2.65e-21 -0.47 -0.45 Monocyte count; chr3:196749733 chr3:196747192~196747324:- LUSC cis rs8062405 0.691 rs11646653 ENSG00000259982.1 CDC37P1 -10.89 9.01e-25 2.68e-21 -0.56 -0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910828 chr16:28700294~28701540:- LUSC cis rs35955747 0.633 rs7287937 ENSG00000236132.1 CTA-440B3.1 10.89 9.02e-25 2.68e-21 0.54 0.45 Neutrophil count;Sum basophil neutrophil counts; chr22:31624759 chr22:31816379~31817491:- LUSC cis rs875971 1 rs2220626 ENSG00000226824.5 RP4-756H11.3 10.89 9.06e-25 2.7e-21 0.54 0.45 Aortic root size; chr7:66081075 chr7:66654538~66669855:+ LUSC cis rs6782228 0.527 rs2811491 ENSG00000242551.2 POU5F1P6 -10.88 9.31e-25 2.77e-21 -0.51 -0.45 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128635107 chr3:128674735~128677005:- LUSC cis rs150992 0.587 rs4703052 ENSG00000248489.1 CTD-2007H13.3 -10.88 9.44e-25 2.81e-21 -0.51 -0.45 Body mass index; chr5:99008818 chr5:98929171~98995013:+ LUSC cis rs8062405 1 rs2008514 ENSG00000259982.1 CDC37P1 -10.88 9.5e-25 2.82e-21 -0.55 -0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814284 chr16:28700294~28701540:- LUSC cis rs977987 0.778 rs7203157 ENSG00000261783.1 RP11-252K23.2 -10.88 9.6e-25 2.85e-21 -0.6 -0.45 Dupuytren's disease; chr16:75384022 chr16:75379818~75381260:- LUSC cis rs977987 0.815 rs11149821 ENSG00000261783.1 RP11-252K23.2 -10.88 9.6e-25 2.85e-21 -0.6 -0.45 Dupuytren's disease; chr16:75388919 chr16:75379818~75381260:- LUSC cis rs875971 0.508 rs10950045 ENSG00000226824.5 RP4-756H11.3 10.88 9.71e-25 2.88e-21 0.52 0.45 Aortic root size; chr7:66601386 chr7:66654538~66669855:+ LUSC cis rs801193 0.839 rs6968619 ENSG00000226824.5 RP4-756H11.3 10.88 9.71e-25 2.88e-21 0.52 0.45 Aortic root size; chr7:66603880 chr7:66654538~66669855:+ LUSC cis rs801193 0.839 rs12534943 ENSG00000226824.5 RP4-756H11.3 10.88 9.71e-25 2.88e-21 0.52 0.45 Aortic root size; chr7:66605533 chr7:66654538~66669855:+ LUSC cis rs801193 0.805 rs12532355 ENSG00000226824.5 RP4-756H11.3 10.88 9.71e-25 2.88e-21 0.52 0.45 Aortic root size; chr7:66605597 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs10143242 ENSG00000280411.1 IGHV1-69-2 -10.88 9.81e-25 2.91e-21 -0.28 -0.45 Kawasaki disease; chr14:106681814 chr14:106762092~106762588:- LUSC cis rs150992 0.609 rs366000 ENSG00000248489.1 CTD-2007H13.3 -10.88 9.87e-25 2.93e-21 -0.52 -0.45 Body mass index; chr5:98991705 chr5:98929171~98995013:+ LUSC cis rs875971 1 rs7781698 ENSG00000226824.5 RP4-756H11.3 -10.88 9.93e-25 2.95e-21 -0.54 -0.45 Aortic root size; chr7:66431325 chr7:66654538~66669855:+ LUSC cis rs977987 0.586 rs12920883 ENSG00000261783.1 RP11-252K23.2 -10.87 1.01e-24 3e-21 -0.61 -0.45 Dupuytren's disease; chr16:75398783 chr16:75379818~75381260:- LUSC cis rs977987 0.624 rs59867374 ENSG00000261783.1 RP11-252K23.2 -10.87 1.01e-24 3e-21 -0.61 -0.45 Dupuytren's disease; chr16:75398784 chr16:75379818~75381260:- LUSC cis rs7208859 0.573 rs11656121 ENSG00000263531.1 RP13-753N3.1 10.87 1.03e-24 3.05e-21 0.78 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887025 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11650973 ENSG00000263531.1 RP13-753N3.1 10.87 1.03e-24 3.05e-21 0.78 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887027 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs56085216 ENSG00000263531.1 RP13-753N3.1 10.87 1.03e-24 3.05e-21 0.78 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30890216 chr17:30863921~30864940:- LUSC cis rs1799949 0.931 rs9912203 ENSG00000198496.9 NBR2 10.87 1.03e-24 3.06e-21 0.48 0.45 Menopause (age at onset); chr17:43367777 chr17:43125610~43153671:+ LUSC cis rs801193 0.66 rs4610622 ENSG00000226824.5 RP4-756H11.3 -10.87 1.04e-24 3.07e-21 -0.54 -0.45 Aortic root size; chr7:66759510 chr7:66654538~66669855:+ LUSC cis rs9545047 1 rs9574422 ENSG00000227676.3 LINC01068 10.87 1.05e-24 3.1e-21 0.55 0.45 Schizophrenia; chr13:79415246 chr13:79566727~79571436:+ LUSC cis rs1185460 0.967 rs2509121 ENSG00000271751.1 RP11-110I1.14 -10.87 1.07e-24 3.15e-21 -0.57 -0.45 Coronary artery disease; chr11:119057542 chr11:119065263~119065677:- LUSC cis rs10256972 0.641 rs12702017 ENSG00000229043.2 AC091729.9 -10.87 1.08e-24 3.18e-21 -0.54 -0.45 Endometriosis;Longevity; chr7:1089777 chr7:1160374~1165267:+ LUSC cis rs875971 0.929 rs4122249 ENSG00000226824.5 RP4-756H11.3 -10.87 1.09e-24 3.21e-21 -0.53 -0.45 Aortic root size; chr7:66455949 chr7:66654538~66669855:+ LUSC cis rs7208859 0.623 rs9900144 ENSG00000263531.1 RP13-753N3.1 10.87 1.1e-24 3.25e-21 0.78 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881371 chr17:30863921~30864940:- LUSC cis rs875971 0.522 rs781144 ENSG00000226824.5 RP4-756H11.3 -10.86 1.14e-24 3.38e-21 -0.53 -0.45 Aortic root size; chr7:65975357 chr7:66654538~66669855:+ LUSC cis rs16828019 0.852 rs34979067 ENSG00000235358.1 RP11-399E6.1 10.86 1.15e-24 3.38e-21 0.83 0.45 Intelligence (multi-trait analysis); chr1:41077412 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs35190461 ENSG00000235358.1 RP11-399E6.1 10.86 1.15e-24 3.38e-21 0.83 0.45 Intelligence (multi-trait analysis); chr1:41077463 chr1:41242373~41284861:+ LUSC cis rs150992 0.609 rs78721487 ENSG00000248489.1 CTD-2007H13.3 10.86 1.16e-24 3.43e-21 0.52 0.45 Body mass index; chr5:98992926 chr5:98929171~98995013:+ LUSC cis rs10129255 0.536 rs17113249 ENSG00000280411.1 IGHV1-69-2 -10.86 1.19e-24 3.51e-21 -0.27 -0.45 Kawasaki disease; chr14:106678273 chr14:106762092~106762588:- LUSC cis rs1150668 0.796 rs728122 ENSG00000216901.1 AL022393.7 10.86 1.2e-24 3.54e-21 0.5 0.45 Pubertal anthropometrics; chr6:28431347 chr6:28176188~28176674:+ LUSC cis rs10256972 0.681 rs12702016 ENSG00000229043.2 AC091729.9 -10.85 1.21e-24 3.56e-21 -0.54 -0.45 Endometriosis;Longevity; chr7:1089756 chr7:1160374~1165267:+ LUSC cis rs6991838 0.584 rs34494846 ENSG00000272010.1 CTD-3025N20.3 -10.85 1.22e-24 3.58e-21 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65602397 chr8:65591850~65592472:- LUSC cis rs9399137 0.507 rs11154791 ENSG00000232876.1 CTA-212D2.2 -10.85 1.23e-24 3.62e-21 -0.54 -0.45 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135058010 chr6:135055033~135060550:+ LUSC cis rs9326248 0.569 rs4938315 ENSG00000254851.1 RP11-109L13.1 -10.85 1.24e-24 3.64e-21 -0.78 -0.45 Blood protein levels; chr11:116860489 chr11:117135528~117138582:+ LUSC cis rs3931020 0.508 rs2345436 ENSG00000272864.1 RP11-17E13.2 -10.85 1.24e-24 3.66e-21 -0.56 -0.45 Resistin levels; chr1:74733056 chr1:74698769~74699333:- LUSC cis rs7626444 0.625 rs1798637 ENSG00000272359.1 U4 -10.85 1.25e-24 3.67e-21 -0.47 -0.45 Monocyte count; chr3:196749768 chr3:196747192~196747324:- LUSC cis rs853679 0.527 rs853683 ENSG00000216901.1 AL022393.7 10.85 1.26e-24 3.69e-21 0.51 0.45 Depression; chr6:28327262 chr6:28176188~28176674:+ LUSC cis rs977987 0.836 rs7200053 ENSG00000261783.1 RP11-252K23.2 -10.85 1.26e-24 3.71e-21 -0.6 -0.45 Dupuytren's disease; chr16:75440720 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs7204984 ENSG00000261783.1 RP11-252K23.2 -10.85 1.26e-24 3.71e-21 -0.6 -0.45 Dupuytren's disease; chr16:75441622 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs35214308 ENSG00000261783.1 RP11-252K23.2 -10.85 1.26e-24 3.71e-21 -0.6 -0.45 Dupuytren's disease; chr16:75442190 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs4888425 ENSG00000261783.1 RP11-252K23.2 -10.85 1.26e-24 3.71e-21 -0.6 -0.45 Dupuytren's disease; chr16:75442465 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs4888426 ENSG00000261783.1 RP11-252K23.2 -10.85 1.26e-24 3.71e-21 -0.6 -0.45 Dupuytren's disease; chr16:75442553 chr16:75379818~75381260:- LUSC cis rs10129255 0.5 rs9324092 ENSG00000280411.1 IGHV1-69-2 10.85 1.26e-24 3.71e-21 0.28 0.45 Kawasaki disease; chr14:106683806 chr14:106762092~106762588:- LUSC cis rs7626444 0.625 rs7638090 ENSG00000272359.1 U4 -10.85 1.26e-24 3.71e-21 -0.47 -0.45 Monocyte count; chr3:196749965 chr3:196747192~196747324:- LUSC cis rs977987 0.806 rs4888404 ENSG00000261783.1 RP11-252K23.2 -10.85 1.27e-24 3.73e-21 -0.6 -0.45 Dupuytren's disease; chr16:75394199 chr16:75379818~75381260:- LUSC cis rs16828019 0.852 rs2300649 ENSG00000235358.1 RP11-399E6.1 10.85 1.27e-24 3.74e-21 0.81 0.45 Intelligence (multi-trait analysis); chr1:41103531 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs3904243 ENSG00000235358.1 RP11-399E6.1 10.85 1.27e-24 3.74e-21 0.81 0.45 Intelligence (multi-trait analysis); chr1:41109180 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs11209545 ENSG00000235358.1 RP11-399E6.1 10.85 1.27e-24 3.74e-21 0.81 0.45 Intelligence (multi-trait analysis); chr1:41110685 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs11209576 ENSG00000235358.1 RP11-399E6.1 10.85 1.27e-24 3.74e-21 0.81 0.45 Intelligence (multi-trait analysis); chr1:41120357 chr1:41242373~41284861:+ LUSC cis rs16828019 0.852 rs3766324 ENSG00000235358.1 RP11-399E6.1 10.85 1.27e-24 3.74e-21 0.81 0.45 Intelligence (multi-trait analysis); chr1:41122981 chr1:41242373~41284861:+ LUSC cis rs977987 0.806 rs1544810 ENSG00000261783.1 RP11-252K23.2 -10.85 1.27e-24 3.74e-21 -0.61 -0.45 Dupuytren's disease; chr16:75377265 chr16:75379818~75381260:- LUSC cis rs9399137 0.507 rs4896118 ENSG00000232876.1 CTA-212D2.2 10.85 1.27e-24 3.74e-21 0.53 0.45 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954927 chr6:135055033~135060550:+ LUSC cis rs16828019 0.929 rs8179465 ENSG00000235358.1 RP11-399E6.1 10.85 1.28e-24 3.76e-21 0.83 0.45 Intelligence (multi-trait analysis); chr1:41236075 chr1:41242373~41284861:+ LUSC cis rs7188445 0.899 rs17689024 ENSG00000261390.4 RP11-345M22.2 -10.85 1.28e-24 3.76e-21 -0.62 -0.45 Urate levels; chr16:79706081 chr16:79715232~79770563:- LUSC cis rs3931020 0.508 rs28568334 ENSG00000272864.1 RP11-17E13.2 -10.85 1.3e-24 3.81e-21 -0.56 -0.45 Resistin levels; chr1:74733615 chr1:74698769~74699333:- LUSC cis rs801193 0.636 rs2659895 ENSG00000226824.5 RP4-756H11.3 -10.85 1.31e-24 3.84e-21 -0.54 -0.45 Aortic root size; chr7:66731484 chr7:66654538~66669855:+ LUSC cis rs10256972 0.706 rs12701969 ENSG00000229043.2 AC091729.9 -10.84 1.34e-24 3.93e-21 -0.55 -0.45 Endometriosis;Longevity; chr7:1082213 chr7:1160374~1165267:+ LUSC cis rs6991838 0.584 rs35790435 ENSG00000272010.1 CTD-3025N20.3 -10.84 1.34e-24 3.94e-21 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65590288 chr8:65591850~65592472:- LUSC cis rs875971 0.508 rs10242423 ENSG00000226824.5 RP4-756H11.3 10.84 1.35e-24 3.96e-21 0.51 0.45 Aortic root size; chr7:66594188 chr7:66654538~66669855:+ LUSC cis rs875971 0.508 rs10253883 ENSG00000226824.5 RP4-756H11.3 10.84 1.35e-24 3.96e-21 0.51 0.45 Aortic root size; chr7:66596151 chr7:66654538~66669855:+ LUSC cis rs977987 0.806 rs11643410 ENSG00000261783.1 RP11-252K23.2 -10.84 1.36e-24 3.97e-21 -0.61 -0.45 Dupuytren's disease; chr16:75394408 chr16:75379818~75381260:- LUSC cis rs875971 1 rs1167612 ENSG00000226824.5 RP4-756H11.3 10.84 1.37e-24 4e-21 0.54 0.45 Aortic root size; chr7:66102989 chr7:66654538~66669855:+ LUSC cis rs977987 0.835 rs1010630 ENSG00000261783.1 RP11-252K23.2 -10.84 1.37e-24 4e-21 -0.61 -0.45 Dupuytren's disease; chr16:75294693 chr16:75379818~75381260:- LUSC cis rs858239 0.676 rs3807459 ENSG00000230658.1 KLHL7-AS1 10.84 1.4e-24 4.11e-21 0.56 0.45 Cerebrospinal fluid biomarker levels; chr7:23350132 chr7:23101228~23105703:- LUSC cis rs2739330 0.828 rs4822454 ENSG00000099984.9 GSTT2 -10.84 1.43e-24 4.18e-21 -0.55 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23980123~23983911:+ LUSC cis rs875971 0.522 rs6960048 ENSG00000226824.5 RP4-756H11.3 -10.83 1.44e-24 4.21e-21 -0.53 -0.45 Aortic root size; chr7:65943052 chr7:66654538~66669855:+ LUSC cis rs2739330 0.652 rs2000469 ENSG00000250470.1 AP000351.3 10.83 1.44e-24 4.21e-21 0.64 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23976904~23977585:- LUSC cis rs11155671 0.53 rs7763849 ENSG00000231760.4 RP11-350J20.5 10.83 1.45e-24 4.24e-21 0.6 0.45 Testicular germ cell tumor; chr6:149885244 chr6:149796151~149826294:- LUSC cis rs1799949 0.965 rs8070179 ENSG00000198496.9 NBR2 -10.83 1.46e-24 4.26e-21 -0.49 -0.45 Menopause (age at onset); chr17:43050671 chr17:43125610~43153671:+ LUSC cis rs3096299 0.719 rs2911262 ENSG00000274627.1 RP11-104N10.2 10.83 1.46e-24 4.26e-21 0.39 0.45 Multiple myeloma (IgH translocation); chr16:89448633 chr16:89516797~89522217:+ LUSC cis rs977987 0.778 rs4888400 ENSG00000261783.1 RP11-252K23.2 -10.83 1.47e-24 4.29e-21 -0.6 -0.45 Dupuytren's disease; chr16:75391698 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs12927562 ENSG00000261783.1 RP11-252K23.2 -10.83 1.53e-24 4.47e-21 -0.61 -0.45 Dupuytren's disease; chr16:75448962 chr16:75379818~75381260:- LUSC cis rs801193 0.66 rs974239 ENSG00000226824.5 RP4-756H11.3 -10.83 1.54e-24 4.5e-21 -0.54 -0.45 Aortic root size; chr7:66748504 chr7:66654538~66669855:+ LUSC cis rs801193 0.66 rs1016265 ENSG00000226824.5 RP4-756H11.3 -10.83 1.54e-24 4.5e-21 -0.54 -0.45 Aortic root size; chr7:66749580 chr7:66654538~66669855:+ LUSC cis rs977987 0.806 rs2161684 ENSG00000261783.1 RP11-252K23.2 -10.82 1.57e-24 4.57e-21 -0.6 -0.45 Dupuytren's disease; chr16:75445255 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs34996006 ENSG00000261783.1 RP11-252K23.2 -10.82 1.57e-24 4.57e-21 -0.6 -0.45 Dupuytren's disease; chr16:75445536 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs35937717 ENSG00000261783.1 RP11-252K23.2 -10.82 1.57e-24 4.58e-21 -0.61 -0.45 Dupuytren's disease; chr16:75297669 chr16:75379818~75381260:- LUSC cis rs3091242 0.967 rs3093614 ENSG00000261349.1 RP3-465N24.5 10.82 1.57e-24 4.58e-21 0.55 0.45 Erythrocyte sedimentation rate; chr1:25351353 chr1:25266102~25267136:- LUSC cis rs7626444 0.625 rs7648479 ENSG00000272359.1 U4 -10.82 1.59e-24 4.63e-21 -0.47 -0.45 Monocyte count; chr3:196750342 chr3:196747192~196747324:- LUSC cis rs977987 0.806 rs12933281 ENSG00000261783.1 RP11-252K23.2 -10.82 1.6e-24 4.65e-21 -0.6 -0.45 Dupuytren's disease; chr16:75449166 chr16:75379818~75381260:- LUSC cis rs5760092 0.627 rs6519489 ENSG00000250470.1 AP000351.3 -10.82 1.61e-24 4.69e-21 -0.74 -0.45 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23976904~23977585:- LUSC cis rs1501911 0.53 rs161941 ENSG00000248489.1 CTD-2007H13.3 -10.82 1.69e-24 4.92e-21 -0.51 -0.45 Lung function (FEV1/FVC); chr5:98863500 chr5:98929171~98995013:+ LUSC cis rs875971 0.522 rs9530 ENSG00000226824.5 RP4-756H11.3 -10.82 1.7e-24 4.93e-21 -0.53 -0.45 Aortic root size; chr7:65960907 chr7:66654538~66669855:+ LUSC cis rs9660180 0.846 rs10907195 ENSG00000268575.1 RP1-283E3.8 10.82 1.7e-24 4.93e-21 0.41 0.45 Body mass index; chr1:1781909 chr1:1702736~1737688:- LUSC cis rs875971 0.862 rs11773628 ENSG00000226824.5 RP4-756H11.3 10.81 1.71e-24 4.97e-21 0.53 0.45 Aortic root size; chr7:66517644 chr7:66654538~66669855:+ LUSC cis rs2929278 0.561 rs2927071 ENSG00000249839.1 AC011330.5 -10.81 1.73e-24 5.02e-21 -0.59 -0.45 Schizophrenia; chr15:43626883 chr15:43663654~43684339:- LUSC cis rs1501911 0.53 rs162149 ENSG00000248489.1 CTD-2007H13.3 10.81 1.73e-24 5.03e-21 0.52 0.45 Lung function (FEV1/FVC); chr5:98913851 chr5:98929171~98995013:+ LUSC cis rs3096299 0.503 rs9940093 ENSG00000274627.1 RP11-104N10.2 10.81 1.74e-24 5.04e-21 0.39 0.45 Multiple myeloma (IgH translocation); chr16:89492297 chr16:89516797~89522217:+ LUSC cis rs5760092 0.572 rs738806 ENSG00000273295.1 AP000350.5 10.8 1.86e-24 5.38e-21 0.58 0.45 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23901432~23907068:- LUSC cis rs9660180 0.875 rs4648727 ENSG00000268575.1 RP1-283E3.8 10.8 1.91e-24 5.51e-21 0.41 0.45 Body mass index; chr1:1844830 chr1:1702736~1737688:- LUSC cis rs16828019 0.64 rs1140227 ENSG00000235358.1 RP11-399E6.1 10.8 1.92e-24 5.54e-21 0.85 0.45 Intelligence (multi-trait analysis); chr1:41028139 chr1:41242373~41284861:+ LUSC cis rs977987 0.843 rs11860231 ENSG00000261783.1 RP11-252K23.2 -10.8 1.93e-24 5.55e-21 -0.62 -0.45 Dupuytren's disease; chr16:75351261 chr16:75379818~75381260:- LUSC cis rs3096299 0.559 rs9931073 ENSG00000274627.1 RP11-104N10.2 10.8 1.94e-24 5.6e-21 0.39 0.45 Multiple myeloma (IgH translocation); chr16:89502105 chr16:89516797~89522217:+ LUSC cis rs3096299 0.504 rs4785574 ENSG00000274627.1 RP11-104N10.2 10.8 1.96e-24 5.65e-21 0.39 0.45 Multiple myeloma (IgH translocation); chr16:89502467 chr16:89516797~89522217:+ LUSC cis rs7188445 1 rs11150190 ENSG00000261390.4 RP11-345M22.2 -10.8 1.99e-24 5.73e-21 -0.6 -0.45 Urate levels; chr16:79700352 chr16:79715232~79770563:- LUSC cis rs150992 0.632 rs1472622 ENSG00000248489.1 CTD-2007H13.3 -10.8 1.99e-24 5.74e-21 -0.51 -0.45 Body mass index; chr5:99000749 chr5:98929171~98995013:+ LUSC cis rs6782228 0.675 rs2253151 ENSG00000242551.2 POU5F1P6 -10.8 2.01e-24 5.8e-21 -0.51 -0.45 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611294 chr3:128674735~128677005:- LUSC cis rs801193 0.613 rs2659900 ENSG00000226824.5 RP4-756H11.3 -10.8 2.03e-24 5.84e-21 -0.53 -0.45 Aortic root size; chr7:66719456 chr7:66654538~66669855:+ LUSC cis rs8062405 0.698 rs7188071 ENSG00000259982.1 CDC37P1 -10.79 2.04e-24 5.87e-21 -0.57 -0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28906323 chr16:28700294~28701540:- LUSC cis rs977987 0.835 rs3851733 ENSG00000261783.1 RP11-252K23.2 -10.79 2.08e-24 5.99e-21 -0.61 -0.45 Dupuytren's disease; chr16:75336365 chr16:75379818~75381260:- LUSC cis rs1799949 0.86 rs8176279 ENSG00000198496.9 NBR2 -10.79 2.09e-24 6e-21 -0.49 -0.45 Menopause (age at onset); chr17:43058379 chr17:43125610~43153671:+ LUSC cis rs2019137 0.539 rs4849181 ENSG00000189223.12 PAX8-AS1 -10.79 2.11e-24 6.07e-21 -0.6 -0.45 Lymphocyte counts; chr2:113234393 chr2:113211522~113276581:+ LUSC cis rs73086581 1 rs17215340 ENSG00000229539.1 RP11-119B16.2 -10.79 2.16e-24 6.2e-21 -0.6 -0.45 Response to antidepressants in depression; chr20:3989526 chr20:3888239~3888868:- LUSC cis rs875971 1 rs1167411 ENSG00000226824.5 RP4-756H11.3 10.79 2.18e-24 6.26e-21 0.54 0.45 Aortic root size; chr7:66074277 chr7:66654538~66669855:+ LUSC cis rs9399137 0.507 rs12663810 ENSG00000232876.1 CTA-212D2.2 -10.79 2.2e-24 6.33e-21 -0.54 -0.45 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134968644 chr6:135055033~135060550:+ LUSC cis rs977987 0.778 rs34222958 ENSG00000261783.1 RP11-252K23.2 -10.78 2.23e-24 6.4e-21 -0.6 -0.45 Dupuytren's disease; chr16:75364354 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs4887821 ENSG00000261783.1 RP11-252K23.2 -10.78 2.23e-24 6.4e-21 -0.6 -0.45 Dupuytren's disease; chr16:75364676 chr16:75379818~75381260:- LUSC cis rs17711722 0.565 rs4717276 ENSG00000164669.11 INTS4P1 -10.78 2.25e-24 6.44e-21 -0.49 -0.45 Calcium levels; chr7:65829754 chr7:65141225~65234216:+ LUSC cis rs6700559 0.873 rs7526367 ENSG00000260088.1 RP11-92G12.3 -10.78 2.26e-24 6.49e-21 -0.57 -0.45 Coronary artery disease; chr1:200688025 chr1:200669507~200694250:+ LUSC cis rs62229266 0.682 rs11700546 ENSG00000231106.2 LINC01436 10.78 2.28e-24 6.54e-21 0.6 0.45 Mitral valve prolapse; chr21:35998841 chr21:36005338~36007838:+ LUSC cis rs6991838 0.584 rs1053087 ENSG00000272010.1 CTD-3025N20.3 -10.78 2.28e-24 6.54e-21 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65603630 chr8:65591850~65592472:- LUSC cis rs9399137 0.507 rs6569986 ENSG00000232876.1 CTA-212D2.2 -10.78 2.28e-24 6.54e-21 -0.54 -0.45 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134990503 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs13197750 ENSG00000232876.1 CTA-212D2.2 -10.78 2.28e-24 6.54e-21 -0.54 -0.45 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134991242 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs7761964 ENSG00000232876.1 CTA-212D2.2 -10.78 2.28e-24 6.54e-21 -0.54 -0.45 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134993127 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs11753673 ENSG00000232876.1 CTA-212D2.2 -10.78 2.28e-24 6.54e-21 -0.54 -0.45 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134995338 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs12663447 ENSG00000232876.1 CTA-212D2.2 -10.78 2.28e-24 6.54e-21 -0.54 -0.45 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134995888 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs4895437 ENSG00000232876.1 CTA-212D2.2 -10.78 2.28e-24 6.54e-21 -0.54 -0.45 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134996216 chr6:135055033~135060550:+ LUSC cis rs875971 0.522 rs7784623 ENSG00000226824.5 RP4-756H11.3 -10.78 2.32e-24 6.63e-21 -0.53 -0.45 Aortic root size; chr7:65930047 chr7:66654538~66669855:+ LUSC cis rs1501911 0.53 rs161942 ENSG00000248489.1 CTD-2007H13.3 10.78 2.32e-24 6.65e-21 0.53 0.45 Lung function (FEV1/FVC); chr5:98868016 chr5:98929171~98995013:+ LUSC cis rs17711722 0.701 rs55773927 ENSG00000226824.5 RP4-756H11.3 -10.77 2.45e-24 7.01e-21 -0.52 -0.45 Calcium levels; chr7:65872915 chr7:66654538~66669855:+ LUSC cis rs17711722 0.727 rs35850374 ENSG00000226824.5 RP4-756H11.3 -10.77 2.45e-24 7.01e-21 -0.52 -0.45 Calcium levels; chr7:65892789 chr7:66654538~66669855:+ LUSC cis rs977987 0.843 rs10871312 ENSG00000261783.1 RP11-252K23.2 -10.77 2.51e-24 7.16e-21 -0.6 -0.44 Dupuytren's disease; chr16:75452304 chr16:75379818~75381260:- LUSC cis rs2006771 0.618 rs470072 ENSG00000236132.1 CTA-440B3.1 -10.77 2.52e-24 7.19e-21 -0.53 -0.44 Nonsyndromic cleft lip with cleft palate; chr22:31867145 chr22:31816379~31817491:- LUSC cis rs801193 0.844 rs732465 ENSG00000226824.5 RP4-756H11.3 -10.77 2.53e-24 7.21e-21 -0.51 -0.44 Aortic root size; chr7:66533463 chr7:66654538~66669855:+ LUSC cis rs801193 0.773 rs801207 ENSG00000226824.5 RP4-756H11.3 10.77 2.53e-24 7.21e-21 0.51 0.44 Aortic root size; chr7:66555603 chr7:66654538~66669855:+ LUSC cis rs875971 0.543 rs801191 ENSG00000226824.5 RP4-756H11.3 10.77 2.53e-24 7.21e-21 0.51 0.44 Aortic root size; chr7:66567968 chr7:66654538~66669855:+ LUSC cis rs4423214 1 rs3750997 ENSG00000254682.1 RP11-660L16.2 10.77 2.54e-24 7.25e-21 0.58 0.44 Vitamin D levels; chr11:71447795 chr11:71448674~71452157:+ LUSC cis rs507080 0.501 rs516503 ENSG00000255422.1 AP002954.4 -10.77 2.55e-24 7.28e-21 -0.47 -0.44 Serum metabolite levels; chr11:118709639 chr11:118704607~118750263:+ LUSC cis rs853679 0.527 rs707907 ENSG00000216901.1 AL022393.7 10.77 2.59e-24 7.39e-21 0.51 0.44 Depression; chr6:28323463 chr6:28176188~28176674:+ LUSC cis rs16828019 0.852 rs12022978 ENSG00000235358.1 RP11-399E6.1 10.76 2.68e-24 7.64e-21 0.81 0.44 Intelligence (multi-trait analysis); chr1:41088416 chr1:41242373~41284861:+ LUSC cis rs6991838 0.584 rs7812446 ENSG00000272010.1 CTD-3025N20.3 -10.76 2.69e-24 7.65e-21 -0.51 -0.44 Intelligence (multi-trait analysis); chr8:65593753 chr8:65591850~65592472:- LUSC cis rs6991838 0.557 rs7812390 ENSG00000272010.1 CTD-3025N20.3 -10.76 2.69e-24 7.65e-21 -0.51 -0.44 Intelligence (multi-trait analysis); chr8:65593982 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs16932245 ENSG00000272010.1 CTD-3025N20.3 -10.76 2.69e-24 7.65e-21 -0.51 -0.44 Intelligence (multi-trait analysis); chr8:65597810 chr8:65591850~65592472:- LUSC cis rs6991838 0.557 rs57419568 ENSG00000272010.1 CTD-3025N20.3 -10.76 2.69e-24 7.65e-21 -0.51 -0.44 Intelligence (multi-trait analysis); chr8:65598633 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs16932250 ENSG00000272010.1 CTD-3025N20.3 -10.76 2.69e-24 7.65e-21 -0.51 -0.44 Intelligence (multi-trait analysis); chr8:65598779 chr8:65591850~65592472:- LUSC cis rs9399137 0.507 rs13196486 ENSG00000232876.1 CTA-212D2.2 -10.76 2.7e-24 7.67e-21 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134962736 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs6918512 ENSG00000232876.1 CTA-212D2.2 -10.76 2.7e-24 7.67e-21 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134963701 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs13064 ENSG00000232876.1 CTA-212D2.2 -10.76 2.7e-24 7.67e-21 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134966395 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs12664898 ENSG00000232876.1 CTA-212D2.2 -10.76 2.7e-24 7.67e-21 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134967525 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs35571217 ENSG00000232876.1 CTA-212D2.2 -10.76 2.7e-24 7.67e-21 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134969217 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs11757723 ENSG00000232876.1 CTA-212D2.2 -10.76 2.7e-24 7.67e-21 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134970155 chr6:135055033~135060550:+ LUSC cis rs2729354 0.903 rs1846568 ENSG00000265566.2 RN7SL605P -10.76 2.74e-24 7.78e-21 -0.62 -0.44 Blood protein levels; chr11:57590241 chr11:57528085~57528365:- LUSC cis rs2019137 0.56 rs10206269 ENSG00000189223.12 PAX8-AS1 -10.76 2.74e-24 7.79e-21 -0.59 -0.44 Lymphocyte counts; chr2:113232816 chr2:113211522~113276581:+ LUSC cis rs3091242 0.934 rs686631 ENSG00000261349.1 RP3-465N24.5 -10.76 2.77e-24 7.88e-21 -0.53 -0.44 Erythrocyte sedimentation rate; chr1:25393108 chr1:25266102~25267136:- LUSC cis rs10129255 0.53 rs11624912 ENSG00000280411.1 IGHV1-69-2 -10.76 2.77e-24 7.88e-21 -0.28 -0.44 Kawasaki disease; chr14:106673891 chr14:106762092~106762588:- LUSC cis rs6452524 0.711 rs1478486 ENSG00000249664.1 CTD-2227C6.2 10.76 2.8e-24 7.94e-21 0.45 0.44 Hypertension (SNP x SNP interaction); chr5:83081185 chr5:83012285~83013109:- LUSC cis rs2019137 0.56 rs7421852 ENSG00000189223.12 PAX8-AS1 -10.76 2.85e-24 8.07e-21 -0.59 -0.44 Lymphocyte counts; chr2:113232684 chr2:113211522~113276581:+ LUSC cis rs9399137 0.507 rs4580893 ENSG00000232876.1 CTA-212D2.2 -10.76 2.86e-24 8.11e-21 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134976524 chr6:135055033~135060550:+ LUSC cis rs9389248 0.737 rs56358308 ENSG00000232876.1 CTA-212D2.2 -10.76 2.87e-24 8.15e-21 -0.54 -0.44 High light scatter reticulocyte percentage of red cells; chr6:134985842 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs11754021 ENSG00000232876.1 CTA-212D2.2 -10.76 2.87e-24 8.15e-21 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134987237 chr6:135055033~135060550:+ LUSC cis rs1501911 0.509 rs330421 ENSG00000248489.1 CTD-2007H13.3 10.75 2.89e-24 8.2e-21 0.53 0.44 Lung function (FEV1/FVC); chr5:98859077 chr5:98929171~98995013:+ LUSC cis rs10129255 0.5 rs1974468 ENSG00000280411.1 IGHV1-69-2 -10.75 2.96e-24 8.37e-21 -0.27 -0.44 Kawasaki disease; chr14:106686149 chr14:106762092~106762588:- LUSC cis rs5760092 0.755 rs4585126 ENSG00000225282.1 AP000350.6 -10.75 3.04e-24 8.59e-21 -0.61 -0.44 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23926900~23929574:+ LUSC cis rs507080 0.501 rs494459 ENSG00000255422.1 AP002954.4 10.75 3.08e-24 8.71e-21 0.45 0.44 Serum metabolite levels; chr11:118703966 chr11:118704607~118750263:+ LUSC cis rs2739330 0.734 rs2000467 ENSG00000250470.1 AP000351.3 -10.74 3.14e-24 8.86e-21 -0.62 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23976904~23977585:- LUSC cis rs16828019 0.929 rs10524 ENSG00000235358.1 RP11-399E6.1 10.74 3.15e-24 8.89e-21 0.81 0.44 Intelligence (multi-trait analysis); chr1:41260801 chr1:41242373~41284861:+ LUSC cis rs1799949 0.965 rs8071278 ENSG00000198496.9 NBR2 -10.74 3.21e-24 9.05e-21 -0.49 -0.44 Menopause (age at onset); chr17:43041893 chr17:43125610~43153671:+ LUSC cis rs17270561 0.525 rs10484432 ENSG00000272462.2 U91328.19 -10.74 3.23e-24 9.1e-21 -0.64 -0.44 Iron status biomarkers; chr6:26008648 chr6:25992662~26001775:+ LUSC cis rs8062405 0.656 rs7189927 ENSG00000259982.1 CDC37P1 -10.74 3.23e-24 9.11e-21 -0.57 -0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28902466 chr16:28700294~28701540:- LUSC cis rs6538678 0.818 rs7976294 ENSG00000258343.1 RP11-536G4.2 -10.74 3.24e-24 9.13e-21 -0.62 -0.44 Lupus nephritis in systemic lupus erythematosus; chr12:95876868 chr12:95795345~95858839:- LUSC cis rs801193 0.66 rs2659897 ENSG00000226824.5 RP4-756H11.3 10.74 3.26e-24 9.18e-21 0.53 0.44 Aortic root size; chr7:66722728 chr7:66654538~66669855:+ LUSC cis rs10129255 0.5 rs1024350 ENSG00000280411.1 IGHV1-69-2 -10.74 3.28e-24 9.23e-21 -0.27 -0.44 Kawasaki disease; chr14:106685105 chr14:106762092~106762588:- LUSC cis rs6991838 0.584 rs1053085 ENSG00000272010.1 CTD-3025N20.3 -10.74 3.33e-24 9.38e-21 -0.51 -0.44 Intelligence (multi-trait analysis); chr8:65603753 chr8:65591850~65592472:- LUSC cis rs875971 0.508 rs6947808 ENSG00000226824.5 RP4-756H11.3 10.73 3.42e-24 9.63e-21 0.51 0.44 Aortic root size; chr7:66580095 chr7:66654538~66669855:+ LUSC cis rs875971 0.965 rs697968 ENSG00000226824.5 RP4-756H11.3 10.73 3.43e-24 9.65e-21 0.54 0.44 Aortic root size; chr7:66070046 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1183245 ENSG00000226824.5 RP4-756H11.3 10.73 3.43e-24 9.65e-21 0.54 0.44 Aortic root size; chr7:66076198 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1144895 ENSG00000226824.5 RP4-756H11.3 10.73 3.43e-24 9.65e-21 0.54 0.44 Aortic root size; chr7:66076320 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1144894 ENSG00000226824.5 RP4-756H11.3 10.73 3.43e-24 9.65e-21 0.54 0.44 Aortic root size; chr7:66077907 chr7:66654538~66669855:+ LUSC cis rs7208859 0.623 rs9914242 ENSG00000263531.1 RP13-753N3.1 10.73 3.44e-24 9.65e-21 0.74 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889227 chr17:30863921~30864940:- LUSC cis rs7626444 0.625 rs2669638 ENSG00000272359.1 U4 -10.73 3.44e-24 9.66e-21 -0.47 -0.44 Monocyte count; chr3:196750527 chr3:196747192~196747324:- LUSC cis rs7626444 0.625 rs2686593 ENSG00000272359.1 U4 -10.73 3.44e-24 9.66e-21 -0.47 -0.44 Monocyte count; chr3:196750530 chr3:196747192~196747324:- LUSC cis rs17711722 0.701 rs781145 ENSG00000226824.5 RP4-756H11.3 -10.73 3.44e-24 9.68e-21 -0.52 -0.44 Calcium levels; chr7:65975383 chr7:66654538~66669855:+ LUSC cis rs150992 0.673 rs161747 ENSG00000248489.1 CTD-2007H13.3 -10.73 3.46e-24 9.73e-21 -0.52 -0.44 Body mass index; chr5:98920433 chr5:98929171~98995013:+ LUSC cis rs172166 0.561 rs149976 ENSG00000216901.1 AL022393.7 -10.73 3.48e-24 9.77e-21 -0.48 -0.44 Cardiac Troponin-T levels; chr6:28019998 chr6:28176188~28176674:+ LUSC cis rs977987 0.836 rs7198873 ENSG00000261783.1 RP11-252K23.2 -10.73 3.53e-24 9.91e-21 -0.6 -0.44 Dupuytren's disease; chr16:75440856 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs11640473 ENSG00000261783.1 RP11-252K23.2 -10.73 3.54e-24 9.93e-21 -0.6 -0.44 Dupuytren's disease; chr16:75369391 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs8057203 ENSG00000261783.1 RP11-252K23.2 -10.73 3.54e-24 9.93e-21 -0.6 -0.44 Dupuytren's disease; chr16:75371076 chr16:75379818~75381260:- LUSC cis rs875971 0.862 rs908915 ENSG00000226824.5 RP4-756H11.3 10.73 3.58e-24 1e-20 0.54 0.44 Aortic root size; chr7:66149664 chr7:66654538~66669855:+ LUSC cis rs6538678 0.818 rs1036429 ENSG00000258343.1 RP11-536G4.2 -10.73 3.63e-24 1.02e-20 -0.62 -0.44 Lupus nephritis in systemic lupus erythematosus; chr12:95877650 chr12:95795345~95858839:- LUSC cis rs801193 0.548 rs2659904 ENSG00000226824.5 RP4-756H11.3 -10.73 3.7e-24 1.04e-20 -0.54 -0.44 Aortic root size; chr7:66713615 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1544549 ENSG00000226824.5 RP4-756H11.3 10.72 3.82e-24 1.07e-20 0.53 0.44 Aortic root size; chr7:66625676 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs2420820 ENSG00000226824.5 RP4-756H11.3 10.72 3.82e-24 1.07e-20 0.53 0.44 Aortic root size; chr7:66626920 chr7:66654538~66669855:+ LUSC cis rs977987 0.806 rs35552529 ENSG00000261783.1 RP11-252K23.2 -10.72 3.82e-24 1.07e-20 -0.6 -0.44 Dupuytren's disease; chr16:75371981 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs56343285 ENSG00000261783.1 RP11-252K23.2 -10.72 3.82e-24 1.07e-20 -0.6 -0.44 Dupuytren's disease; chr16:75375899 chr16:75379818~75381260:- LUSC cis rs7188445 0.932 rs17689159 ENSG00000261390.4 RP11-345M22.2 -10.72 3.91e-24 1.09e-20 -0.6 -0.44 Urate levels; chr16:79708493 chr16:79715232~79770563:- LUSC cis rs7626444 0.625 rs843531 ENSG00000272359.1 U4 -10.72 3.98e-24 1.11e-20 -0.47 -0.44 Monocyte count; chr3:196754900 chr3:196747192~196747324:- LUSC cis rs7626444 0.625 rs9877495 ENSG00000272359.1 U4 -10.72 3.98e-24 1.11e-20 -0.47 -0.44 Monocyte count; chr3:196756409 chr3:196747192~196747324:- LUSC cis rs7626444 0.625 rs2686599 ENSG00000272359.1 U4 -10.72 3.98e-24 1.11e-20 -0.47 -0.44 Monocyte count; chr3:196756923 chr3:196747192~196747324:- LUSC cis rs7626444 0.625 rs1403101 ENSG00000272359.1 U4 -10.72 3.98e-24 1.11e-20 -0.47 -0.44 Monocyte count; chr3:196758203 chr3:196747192~196747324:- LUSC cis rs7626444 0.628 rs1684464 ENSG00000272359.1 U4 -10.72 3.98e-24 1.11e-20 -0.47 -0.44 Monocyte count; chr3:196758643 chr3:196747192~196747324:- LUSC cis rs7626444 0.625 rs1486358 ENSG00000272359.1 U4 -10.72 3.98e-24 1.11e-20 -0.47 -0.44 Monocyte count; chr3:196758719 chr3:196747192~196747324:- LUSC cis rs1799949 0.965 rs7223952 ENSG00000198496.9 NBR2 -10.72 4.06e-24 1.13e-20 -0.49 -0.44 Menopause (age at onset); chr17:43042868 chr17:43125610~43153671:+ LUSC cis rs11098499 0.954 rs13145352 ENSG00000245958.5 RP11-33B1.1 10.72 4.07e-24 1.13e-20 0.45 0.44 Corneal astigmatism; chr4:119488808 chr4:119454791~119552025:+ LUSC cis rs875971 0.66 rs10263935 ENSG00000226824.5 RP4-756H11.3 -10.71 4.08e-24 1.14e-20 -0.52 -0.44 Aortic root size; chr7:66631041 chr7:66654538~66669855:+ LUSC cis rs8062405 0.728 rs9931989 ENSG00000259982.1 CDC37P1 -10.71 4.1e-24 1.14e-20 -0.57 -0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28894763 chr16:28700294~28701540:- LUSC cis rs7626444 0.625 rs1104375 ENSG00000272359.1 U4 -10.71 4.13e-24 1.15e-20 -0.47 -0.44 Monocyte count; chr3:196749172 chr3:196747192~196747324:- LUSC cis rs6991838 0.584 rs73236948 ENSG00000272010.1 CTD-3025N20.3 -10.71 4.19e-24 1.17e-20 -0.51 -0.44 Intelligence (multi-trait analysis); chr8:65609176 chr8:65591850~65592472:- LUSC cis rs7626444 0.625 rs2669637 ENSG00000272359.1 U4 -10.71 4.21e-24 1.17e-20 -0.46 -0.44 Monocyte count; chr3:196750498 chr3:196747192~196747324:- LUSC cis rs7626444 0.625 rs1718410 ENSG00000272359.1 U4 -10.71 4.21e-24 1.17e-20 -0.46 -0.44 Monocyte count; chr3:196750789 chr3:196747192~196747324:- LUSC cis rs9399137 0.507 rs10484496 ENSG00000232876.1 CTA-212D2.2 -10.71 4.22e-24 1.17e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134978544 chr6:135055033~135060550:+ LUSC cis rs7208859 0.623 rs73263788 ENSG00000263531.1 RP13-753N3.1 10.71 4.24e-24 1.18e-20 0.77 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889472 chr17:30863921~30864940:- LUSC cis rs7188445 0.932 rs56738967 ENSG00000261390.4 RP11-345M22.2 -10.71 4.28e-24 1.19e-20 -0.62 -0.44 Urate levels; chr16:79706644 chr16:79715232~79770563:- LUSC cis rs7188445 0.932 rs11150191 ENSG00000261390.4 RP11-345M22.2 -10.71 4.44e-24 1.23e-20 -0.6 -0.44 Urate levels; chr16:79700390 chr16:79715232~79770563:- LUSC cis rs6921919 0.697 rs12180820 ENSG00000216901.1 AL022393.7 -10.7 4.45e-24 1.24e-20 -0.52 -0.44 Autism spectrum disorder or schizophrenia; chr6:28348701 chr6:28176188~28176674:+ LUSC cis rs977987 0.902 rs4888430 ENSG00000261783.1 RP11-252K23.2 -10.7 4.48e-24 1.25e-20 -0.61 -0.44 Dupuytren's disease; chr16:75460526 chr16:75379818~75381260:- LUSC cis rs55794721 0.509 rs909834 ENSG00000261349.1 RP3-465N24.5 -10.7 4.52e-24 1.26e-20 -0.54 -0.44 Mean corpuscular volume;Plateletcrit; chr1:25431505 chr1:25266102~25267136:- LUSC cis rs977987 0.806 rs1549306 ENSG00000261783.1 RP11-252K23.2 -10.7 4.56e-24 1.26e-20 -0.59 -0.44 Dupuytren's disease; chr16:75381443 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs35263058 ENSG00000261783.1 RP11-252K23.2 -10.7 4.6e-24 1.28e-20 -0.61 -0.44 Dupuytren's disease; chr16:75358039 chr16:75379818~75381260:- LUSC cis rs17711722 0.565 rs4275112 ENSG00000164669.11 INTS4P1 10.7 4.64e-24 1.29e-20 0.49 0.44 Calcium levels; chr7:65733651 chr7:65141225~65234216:+ LUSC cis rs7188445 1 rs7188445 ENSG00000261390.4 RP11-345M22.2 -10.7 4.72e-24 1.31e-20 -0.59 -0.44 Urate levels; chr16:79701090 chr16:79715232~79770563:- LUSC cis rs875971 1 rs6946143 ENSG00000226824.5 RP4-756H11.3 -10.7 4.73e-24 1.31e-20 -0.52 -0.44 Aortic root size; chr7:66114735 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs1983372 ENSG00000226824.5 RP4-756H11.3 10.7 4.74e-24 1.31e-20 0.53 0.44 Aortic root size; chr7:66146364 chr7:66654538~66669855:+ LUSC cis rs73086581 0.838 rs73088426 ENSG00000229539.1 RP11-119B16.2 10.69 4.94e-24 1.37e-20 0.62 0.44 Response to antidepressants in depression; chr20:4022636 chr20:3888239~3888868:- LUSC cis rs17711722 0.522 rs6957759 ENSG00000164669.11 INTS4P1 -10.69 4.98e-24 1.38e-20 -0.48 -0.44 Calcium levels; chr7:65806798 chr7:65141225~65234216:+ LUSC cis rs150992 0.609 rs447044 ENSG00000248489.1 CTD-2007H13.3 10.69 4.99e-24 1.38e-20 0.5 0.44 Body mass index; chr5:98995572 chr5:98929171~98995013:+ LUSC cis rs6991838 0.584 rs1053088 ENSG00000272010.1 CTD-3025N20.3 10.69 5.02e-24 1.39e-20 0.51 0.44 Intelligence (multi-trait analysis); chr8:65603548 chr8:65591850~65592472:- LUSC cis rs10256972 0.63 rs13235747 ENSG00000229043.2 AC091729.9 -10.69 5.04e-24 1.39e-20 -0.54 -0.44 Endometriosis;Longevity; chr7:1089487 chr7:1160374~1165267:+ LUSC cis rs73086581 0.838 rs11907416 ENSG00000229539.1 RP11-119B16.2 10.69 5.15e-24 1.42e-20 0.62 0.44 Response to antidepressants in depression; chr20:4024972 chr20:3888239~3888868:- LUSC cis rs1150668 0.699 rs2394049 ENSG00000216901.1 AL022393.7 10.69 5.19e-24 1.43e-20 0.48 0.44 Pubertal anthropometrics; chr6:28271903 chr6:28176188~28176674:+ LUSC cis rs16828019 0.852 rs16827876 ENSG00000235358.1 RP11-399E6.1 10.69 5.25e-24 1.45e-20 0.82 0.44 Intelligence (multi-trait analysis); chr1:41073864 chr1:41242373~41284861:+ LUSC cis rs16828019 0.929 rs35883594 ENSG00000235358.1 RP11-399E6.1 10.68 5.31e-24 1.46e-20 0.84 0.44 Intelligence (multi-trait analysis); chr1:41278421 chr1:41242373~41284861:+ LUSC cis rs1150668 0.796 rs213236 ENSG00000216901.1 AL022393.7 10.68 5.34e-24 1.47e-20 0.49 0.44 Pubertal anthropometrics; chr6:28356620 chr6:28176188~28176674:+ LUSC cis rs150992 0.609 rs4703049 ENSG00000248489.1 CTD-2007H13.3 10.68 5.35e-24 1.47e-20 0.5 0.44 Body mass index; chr5:99004679 chr5:98929171~98995013:+ LUSC cis rs10256972 0.706 rs12701970 ENSG00000229043.2 AC091729.9 -10.68 5.5e-24 1.51e-20 -0.53 -0.44 Endometriosis;Longevity; chr7:1082322 chr7:1160374~1165267:+ LUSC cis rs9399137 0.507 rs4289677 ENSG00000232876.1 CTA-212D2.2 -10.68 5.52e-24 1.52e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954347 chr6:135055033~135060550:+ LUSC cis rs1150668 0.83 rs2531831 ENSG00000216901.1 AL022393.7 10.68 5.56e-24 1.53e-20 0.49 0.44 Pubertal anthropometrics; chr6:28420988 chr6:28176188~28176674:+ LUSC cis rs7208859 0.623 rs56325146 ENSG00000263531.1 RP13-753N3.1 10.68 5.56e-24 1.53e-20 0.77 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824006 chr17:30863921~30864940:- LUSC cis rs6991838 0.584 rs4275254 ENSG00000272010.1 CTD-3025N20.3 -10.68 5.59e-24 1.54e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65589129 chr8:65591850~65592472:- LUSC cis rs150992 0.72 rs469018 ENSG00000248489.1 CTD-2007H13.3 10.68 5.65e-24 1.55e-20 0.51 0.44 Body mass index; chr5:98953530 chr5:98929171~98995013:+ LUSC cis rs977987 0.931 rs1834013 ENSG00000261783.1 RP11-252K23.2 -10.68 5.7e-24 1.56e-20 -0.61 -0.44 Dupuytren's disease; chr16:75462265 chr16:75379818~75381260:- LUSC cis rs977987 0.835 rs11641532 ENSG00000261783.1 RP11-252K23.2 -10.67 5.91e-24 1.62e-20 -0.6 -0.44 Dupuytren's disease; chr16:75295582 chr16:75379818~75381260:- LUSC cis rs6964833 1 rs17515241 ENSG00000123965.13 PMS2P5 -10.67 5.92e-24 1.63e-20 -0.71 -0.44 Menarche (age at onset); chr7:74717695 chr7:74894116~74897835:+ LUSC cis rs8046696 1 rs8046696 ENSG00000261783.1 RP11-252K23.2 -10.67 5.94e-24 1.63e-20 -0.61 -0.44 Coronary artery disease; chr16:75408245 chr16:75379818~75381260:- LUSC cis rs977987 0.737 rs8046697 ENSG00000261783.1 RP11-252K23.2 -10.67 5.94e-24 1.63e-20 -0.61 -0.44 Dupuytren's disease; chr16:75408246 chr16:75379818~75381260:- LUSC cis rs6964833 0.935 rs13238996 ENSG00000123965.13 PMS2P5 10.67 5.96e-24 1.64e-20 0.72 0.44 Menarche (age at onset); chr7:74655318 chr7:74894116~74897835:+ LUSC cis rs73086581 0.838 rs11906481 ENSG00000229539.1 RP11-119B16.2 10.67 5.96e-24 1.64e-20 0.59 0.44 Response to antidepressants in depression; chr20:4048059 chr20:3888239~3888868:- LUSC cis rs1799949 1 rs8077486 ENSG00000198496.9 NBR2 -10.67 6.04e-24 1.66e-20 -0.48 -0.44 Menopause (age at onset); chr17:43060788 chr17:43125610~43153671:+ LUSC cis rs977987 0.806 rs1109342 ENSG00000261783.1 RP11-252K23.2 10.66 6.35e-24 1.74e-20 0.61 0.44 Dupuytren's disease; chr16:75411777 chr16:75379818~75381260:- LUSC cis rs875971 1 rs7792762 ENSG00000226824.5 RP4-756H11.3 -10.66 6.36e-24 1.74e-20 -0.52 -0.44 Aortic root size; chr7:66539151 chr7:66654538~66669855:+ LUSC cis rs6991838 0.556 rs7846527 ENSG00000272010.1 CTD-3025N20.3 -10.66 6.47e-24 1.77e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65586522 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs4320587 ENSG00000272010.1 CTD-3025N20.3 -10.66 6.47e-24 1.77e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65586991 chr8:65591850~65592472:- LUSC cis rs950027 1 rs950027 ENSG00000259520.4 CTD-2651B20.3 10.66 6.47e-24 1.77e-20 0.51 0.44 Response to fenofibrate (adiponectin levels); chr15:45508837 chr15:45251580~45279251:- LUSC cis rs992157 1 rs6736362 ENSG00000261338.2 RP11-378A13.1 10.66 6.53e-24 1.79e-20 0.45 0.44 Colorectal cancer; chr2:218250385 chr2:218255319~218257366:+ LUSC cis rs1150668 0.796 rs213237 ENSG00000216901.1 AL022393.7 10.66 6.53e-24 1.79e-20 0.49 0.44 Pubertal anthropometrics; chr6:28356161 chr6:28176188~28176674:+ LUSC cis rs801193 0.591 rs4506088 ENSG00000226824.5 RP4-756H11.3 10.66 6.77e-24 1.85e-20 0.53 0.44 Aortic root size; chr7:66670470 chr7:66654538~66669855:+ LUSC cis rs2739330 0.791 rs9612520 ENSG00000235689.1 AP000351.13 10.66 6.81e-24 1.86e-20 0.47 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:24006305~24008258:- LUSC cis rs7626444 0.563 rs2686598 ENSG00000272359.1 U4 -10.66 6.83e-24 1.87e-20 -0.46 -0.44 Monocyte count; chr3:196760848 chr3:196747192~196747324:- LUSC cis rs62229266 0.682 rs2835224 ENSG00000231106.2 LINC01436 10.65 6.86e-24 1.87e-20 0.59 0.44 Mitral valve prolapse; chr21:35997732 chr21:36005338~36007838:+ LUSC cis rs150992 0.593 rs34496 ENSG00000248489.1 CTD-2007H13.3 10.65 6.87e-24 1.88e-20 0.51 0.44 Body mass index; chr5:98963812 chr5:98929171~98995013:+ LUSC cis rs17270561 0.562 rs74293932 ENSG00000272462.2 U91328.19 -10.65 6.91e-24 1.89e-20 -0.64 -0.44 Iron status biomarkers; chr6:26014583 chr6:25992662~26001775:+ LUSC cis rs150992 0.609 rs161935 ENSG00000248489.1 CTD-2007H13.3 10.65 6.93e-24 1.89e-20 0.51 0.44 Body mass index; chr5:98982733 chr5:98929171~98995013:+ LUSC cis rs150992 0.632 rs161936 ENSG00000248489.1 CTD-2007H13.3 10.65 6.93e-24 1.89e-20 0.51 0.44 Body mass index; chr5:98982953 chr5:98929171~98995013:+ LUSC cis rs6991838 0.55 rs4737750 ENSG00000272010.1 CTD-3025N20.3 10.65 7.06e-24 1.93e-20 0.5 0.44 Intelligence (multi-trait analysis); chr8:65638724 chr8:65591850~65592472:- LUSC cis rs10129255 0.556 rs9324093 ENSG00000211972.2 IGHV3-66 10.65 7.44e-24 2.03e-20 0.29 0.44 Kawasaki disease; chr14:106683893 chr14:106675017~106675544:- LUSC cis rs1799949 0.965 rs799916 ENSG00000198496.9 NBR2 10.64 7.5e-24 2.04e-20 0.46 0.44 Menopause (age at onset); chr17:43091173 chr17:43125610~43153671:+ LUSC cis rs9399137 0.507 rs13209780 ENSG00000232876.1 CTA-212D2.2 -10.64 7.73e-24 2.1e-20 -0.53 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135023657 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs4896129 ENSG00000232876.1 CTA-212D2.2 -10.64 7.73e-24 2.1e-20 -0.53 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135028707 chr6:135055033~135060550:+ LUSC cis rs2739330 0.627 rs9608219 ENSG00000235689.1 AP000351.13 10.64 7.75e-24 2.11e-20 0.46 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:24006305~24008258:- LUSC cis rs997154 0.655 rs2008345 ENSG00000279656.1 RP11-298I3.6 10.64 7.75e-24 2.11e-20 0.6 0.44 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22932233 chr14:23023083~23024217:- LUSC cis rs7188445 1 rs11150189 ENSG00000261390.4 RP11-345M22.2 -10.64 7.79e-24 2.12e-20 -0.6 -0.44 Urate levels; chr16:79700330 chr16:79715232~79770563:- LUSC cis rs3091242 0.933 rs1534954 ENSG00000261349.1 RP3-465N24.5 -10.64 7.83e-24 2.13e-20 -0.54 -0.44 Erythrocyte sedimentation rate; chr1:25435433 chr1:25266102~25267136:- LUSC cis rs6991838 0.584 rs4737747 ENSG00000272010.1 CTD-3025N20.3 -10.64 7.85e-24 2.14e-20 -0.5 -0.44 Intelligence (multi-trait analysis); chr8:65607024 chr8:65591850~65592472:- LUSC cis rs6921919 0.789 rs6456814 ENSG00000216901.1 AL022393.7 10.64 8.07e-24 2.19e-20 0.58 0.44 Autism spectrum disorder or schizophrenia; chr6:28338035 chr6:28176188~28176674:+ LUSC cis rs6921919 0.789 rs13210258 ENSG00000216901.1 AL022393.7 10.64 8.07e-24 2.19e-20 0.58 0.44 Autism spectrum disorder or schizophrenia; chr6:28340894 chr6:28176188~28176674:+ LUSC cis rs9399137 0.507 rs7745289 ENSG00000232876.1 CTA-212D2.2 -10.63 8.15e-24 2.21e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135059189 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs11759062 ENSG00000232876.1 CTA-212D2.2 -10.63 8.15e-24 2.21e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135060110 chr6:135055033~135060550:+ LUSC cis rs9399137 0.507 rs11759077 ENSG00000232876.1 CTA-212D2.2 -10.63 8.15e-24 2.21e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135060213 chr6:135055033~135060550:+ LUSC cis rs10129255 0.518 rs10150460 ENSG00000280411.1 IGHV1-69-2 10.63 8.2e-24 2.23e-20 0.27 0.44 Kawasaki disease; chr14:106677179 chr14:106762092~106762588:- LUSC cis rs9399137 0.507 rs28384513 ENSG00000232876.1 CTA-212D2.2 -10.63 8.23e-24 2.23e-20 -0.53 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135055071 chr6:135055033~135060550:+ LUSC cis rs6991838 0.584 rs6993876 ENSG00000272010.1 CTD-3025N20.3 10.63 8.38e-24 2.27e-20 0.5 0.44 Intelligence (multi-trait analysis); chr8:65601240 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs35941313 ENSG00000272010.1 CTD-3025N20.3 -10.63 8.41e-24 2.28e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65587498 chr8:65591850~65592472:- LUSC cis rs977987 0.835 rs7200616 ENSG00000261783.1 RP11-252K23.2 -10.63 8.47e-24 2.29e-20 -0.6 -0.44 Dupuytren's disease; chr16:75332191 chr16:75379818~75381260:- LUSC cis rs875971 0.862 rs10256544 ENSG00000226824.5 RP4-756H11.3 -10.63 8.56e-24 2.32e-20 -0.54 -0.44 Aortic root size; chr7:66210141 chr7:66654538~66669855:+ LUSC cis rs9399137 0.507 rs13214669 ENSG00000232876.1 CTA-212D2.2 -10.63 8.56e-24 2.32e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134978821 chr6:135055033~135060550:+ LUSC cis rs150992 0.609 rs1093794 ENSG00000248489.1 CTD-2007H13.3 -10.63 8.66e-24 2.34e-20 -0.51 -0.44 Body mass index; chr5:98993334 chr5:98929171~98995013:+ LUSC cis rs977987 0.806 rs2865530 ENSG00000261783.1 RP11-252K23.2 -10.63 8.79e-24 2.38e-20 -0.59 -0.44 Dupuytren's disease; chr16:75380478 chr16:75379818~75381260:- LUSC cis rs1930961 1 rs6004667 ENSG00000272977.1 CTA-390C10.10 10.62 9.11e-24 2.46e-20 0.77 0.44 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25476218~25479971:+ LUSC cis rs7617773 0.817 rs9830016 ENSG00000229759.1 MRPS18AP1 10.62 9.12e-24 2.46e-20 0.42 0.44 Coronary artery disease; chr3:48241004 chr3:48256350~48256938:- LUSC cis rs875971 0.516 rs6945322 ENSG00000226824.5 RP4-756H11.3 -10.62 9.19e-24 2.48e-20 -0.52 -0.44 Aortic root size; chr7:65871069 chr7:66654538~66669855:+ LUSC cis rs7188445 0.932 rs17767383 ENSG00000261390.4 RP11-345M22.2 -10.62 9.26e-24 2.5e-20 -0.59 -0.44 Urate levels; chr16:79710504 chr16:79715232~79770563:- LUSC cis rs2739330 0.76 rs5751761 ENSG00000231271.1 AP000350.8 -10.62 9.27e-24 2.5e-20 -0.54 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23949918~23954042:+ LUSC cis rs9545047 0.967 rs9545097 ENSG00000227676.3 LINC01068 10.62 9.35e-24 2.52e-20 0.55 0.44 Schizophrenia; chr13:79387352 chr13:79566727~79571436:+ LUSC cis rs9545047 0.967 rs9593396 ENSG00000227676.3 LINC01068 10.62 9.35e-24 2.52e-20 0.55 0.44 Schizophrenia; chr13:79396164 chr13:79566727~79571436:+ LUSC cis rs9545047 1 rs9545101 ENSG00000227676.3 LINC01068 10.62 9.35e-24 2.52e-20 0.55 0.44 Schizophrenia; chr13:79399806 chr13:79566727~79571436:+ LUSC cis rs10129255 0.536 rs6576201 ENSG00000211972.2 IGHV3-66 -10.62 9.43e-24 2.54e-20 -0.29 -0.44 Kawasaki disease; chr14:106683696 chr14:106675017~106675544:- LUSC cis rs6964833 1 rs34324835 ENSG00000277053.3 GTF2IP1 -10.62 9.51e-24 2.56e-20 -0.66 -0.44 Menarche (age at onset); chr7:74717986 chr7:75185385~75237696:- LUSC cis rs977987 0.806 rs766521 ENSG00000261783.1 RP11-252K23.2 10.62 9.65e-24 2.6e-20 0.59 0.44 Dupuytren's disease; chr16:75390256 chr16:75379818~75381260:- LUSC cis rs7188445 0.932 rs17767419 ENSG00000261390.4 RP11-345M22.2 -10.62 9.67e-24 2.6e-20 -0.59 -0.44 Urate levels; chr16:79710651 chr16:79715232~79770563:- LUSC cis rs10129255 0.5 rs988132 ENSG00000280411.1 IGHV1-69-2 -10.61 9.71e-24 2.61e-20 -0.28 -0.44 Kawasaki disease; chr14:106776758 chr14:106762092~106762588:- LUSC cis rs6991838 0.584 rs4388482 ENSG00000272010.1 CTD-3025N20.3 -10.61 9.91e-24 2.67e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65583968 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs4637885 ENSG00000272010.1 CTD-3025N20.3 -10.61 9.91e-24 2.67e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65584849 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs34226237 ENSG00000272010.1 CTD-3025N20.3 -10.61 9.94e-24 2.67e-20 -0.5 -0.44 Intelligence (multi-trait analysis); chr8:65600930 chr8:65591850~65592472:- LUSC cis rs977987 0.778 rs11858992 ENSG00000261783.1 RP11-252K23.2 -10.61 9.98e-24 2.68e-20 -0.59 -0.44 Dupuytren's disease; chr16:75377547 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs4993970 ENSG00000261783.1 RP11-252K23.2 -10.61 9.98e-24 2.68e-20 -0.59 -0.44 Dupuytren's disease; chr16:75377721 chr16:75379818~75381260:- LUSC cis rs977987 0.736 rs4888392 ENSG00000261783.1 RP11-252K23.2 -10.61 9.98e-24 2.68e-20 -0.59 -0.44 Dupuytren's disease; chr16:75378364 chr16:75379818~75381260:- LUSC cis rs875971 0.964 rs697969 ENSG00000226824.5 RP4-756H11.3 10.61 1e-23 2.69e-20 0.53 0.44 Aortic root size; chr7:66093491 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs1182882 ENSG00000226824.5 RP4-756H11.3 10.61 1e-23 2.69e-20 0.53 0.44 Aortic root size; chr7:66097076 chr7:66654538~66669855:+ LUSC cis rs977987 0.806 rs7202596 ENSG00000261783.1 RP11-252K23.2 -10.61 1.01e-23 2.71e-20 -0.6 -0.44 Dupuytren's disease; chr16:75457174 chr16:75379818~75381260:- LUSC cis rs6991838 0.557 rs67685675 ENSG00000272010.1 CTD-3025N20.3 -10.61 1.01e-23 2.72e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65574371 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs66486920 ENSG00000272010.1 CTD-3025N20.3 -10.61 1.01e-23 2.72e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65574458 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs60023200 ENSG00000272010.1 CTD-3025N20.3 -10.61 1.01e-23 2.72e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65574547 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs61083799 ENSG00000272010.1 CTD-3025N20.3 -10.61 1.01e-23 2.72e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65574868 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs4449837 ENSG00000272010.1 CTD-3025N20.3 -10.61 1.01e-23 2.72e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65575917 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs57042777 ENSG00000272010.1 CTD-3025N20.3 -10.61 1.01e-23 2.72e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65576855 chr8:65591850~65592472:- LUSC cis rs6991838 0.557 rs67046768 ENSG00000272010.1 CTD-3025N20.3 -10.61 1.01e-23 2.72e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65577486 chr8:65591850~65592472:- LUSC cis rs2739330 0.828 rs5760098 ENSG00000099984.9 GSTT2 -10.61 1.01e-23 2.72e-20 -0.54 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23980123~23983911:+ LUSC cis rs2739330 0.828 rs5760102 ENSG00000099984.9 GSTT2 -10.61 1.01e-23 2.72e-20 -0.54 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23980123~23983911:+ LUSC cis rs17270561 0.525 rs12201678 ENSG00000272462.2 U91328.19 -10.61 1.02e-23 2.73e-20 -0.64 -0.44 Iron status biomarkers; chr6:25978765 chr6:25992662~26001775:+ LUSC cis rs6991838 0.584 rs6994213 ENSG00000272010.1 CTD-3025N20.3 -10.61 1.02e-23 2.73e-20 -0.5 -0.44 Intelligence (multi-trait analysis); chr8:65601497 chr8:65591850~65592472:- LUSC cis rs2739330 0.828 rs4822451 ENSG00000099984.9 GSTT2 -10.61 1.04e-23 2.79e-20 -0.54 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23980123~23983911:+ LUSC cis rs2739330 0.828 rs5760099 ENSG00000099984.9 GSTT2 -10.61 1.04e-23 2.79e-20 -0.54 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23980123~23983911:+ LUSC cis rs150992 0.57 rs10050423 ENSG00000248489.1 CTD-2007H13.3 -10.61 1.05e-23 2.8e-20 -0.51 -0.44 Body mass index; chr5:99006312 chr5:98929171~98995013:+ LUSC cis rs2739330 0.796 rs2154594 ENSG00000099984.9 GSTT2 10.61 1.05e-23 2.81e-20 0.53 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23980123~23983911:+ LUSC cis rs1799949 0.965 rs2236762 ENSG00000198496.9 NBR2 -10.61 1.05e-23 2.82e-20 -0.48 -0.44 Menopause (age at onset); chr17:43074658 chr17:43125610~43153671:+ LUSC cis rs17711722 0.585 rs6942660 ENSG00000226824.5 RP4-756H11.3 -10.61 1.05e-23 2.82e-20 -0.52 -0.44 Calcium levels; chr7:65837419 chr7:66654538~66669855:+ LUSC cis rs977987 0.806 rs12444589 ENSG00000261783.1 RP11-252K23.2 10.61 1.05e-23 2.82e-20 0.6 0.44 Dupuytren's disease; chr16:75420506 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs1030262 ENSG00000261783.1 RP11-252K23.2 -10.6 1.07e-23 2.86e-20 -0.6 -0.44 Dupuytren's disease; chr16:75457429 chr16:75379818~75381260:- LUSC cis rs9481169 0.557 rs13190932 ENSG00000255389.1 C6orf3 -10.6 1.07e-23 2.87e-20 -0.82 -0.44 Inflammatory skin disease; chr6:111591867 chr6:111599875~111602295:+ LUSC cis rs11317778 1 rs11317778 ENSG00000248489.1 CTD-2007H13.3 10.6 1.08e-23 2.89e-20 0.53 0.44 Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr5:98905525 chr5:98929171~98995013:+ LUSC cis rs16828019 0.777 rs12023079 ENSG00000235358.1 RP11-399E6.1 10.6 1.08e-23 2.89e-20 0.83 0.44 Intelligence (multi-trait analysis); chr1:41004439 chr1:41242373~41284861:+ LUSC cis rs875971 0.756 rs4718328 ENSG00000226824.5 RP4-756H11.3 10.6 1.09e-23 2.92e-20 0.53 0.44 Aortic root size; chr7:66228350 chr7:66654538~66669855:+ LUSC cis rs9399135 0.527 rs61738492 ENSG00000232876.1 CTA-212D2.2 -10.6 1.09e-23 2.93e-20 -0.54 -0.44 Red blood cell count; chr6:134961633 chr6:135055033~135060550:+ LUSC cis rs2929278 0.617 rs4617832 ENSG00000249839.1 AC011330.5 10.6 1.1e-23 2.94e-20 0.57 0.44 Schizophrenia; chr15:43738381 chr15:43663654~43684339:- LUSC cis rs6991838 0.584 rs4737221 ENSG00000272010.1 CTD-3025N20.3 -10.6 1.1e-23 2.94e-20 -0.5 -0.44 Intelligence (multi-trait analysis); chr8:65569075 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs7459944 ENSG00000272010.1 CTD-3025N20.3 -10.6 1.1e-23 2.95e-20 -0.5 -0.44 Intelligence (multi-trait analysis); chr8:65566040 chr8:65591850~65592472:- LUSC cis rs1799949 0.965 rs9911630 ENSG00000198496.9 NBR2 -10.6 1.1e-23 2.96e-20 -0.48 -0.44 Menopause (age at onset); chr17:43036325 chr17:43125610~43153671:+ LUSC cis rs875971 0.522 rs4718286 ENSG00000226824.5 RP4-756H11.3 -10.6 1.12e-23 2.99e-20 -0.52 -0.44 Aortic root size; chr7:65827777 chr7:66654538~66669855:+ LUSC cis rs9399137 0.507 rs7768278 ENSG00000232876.1 CTA-212D2.2 -10.6 1.13e-23 3.02e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134953819 chr6:135055033~135060550:+ LUSC cis rs2739330 0.828 rs2186366 ENSG00000099984.9 GSTT2 10.6 1.13e-23 3.03e-20 0.53 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23980123~23983911:+ LUSC cis rs9399137 0.507 rs6940258 ENSG00000232876.1 CTA-212D2.2 -10.6 1.14e-23 3.06e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135044994 chr6:135055033~135060550:+ LUSC cis rs1930961 1 rs6004668 ENSG00000272977.1 CTA-390C10.10 10.59 1.17e-23 3.13e-20 0.78 0.44 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25476218~25479971:+ LUSC cis rs6991838 0.584 rs7463649 ENSG00000272010.1 CTD-3025N20.3 -10.59 1.17e-23 3.14e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65573760 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs66467166 ENSG00000272010.1 CTD-3025N20.3 -10.59 1.17e-23 3.14e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65574165 chr8:65591850~65592472:- LUSC cis rs875971 0.825 rs1129531 ENSG00000226824.5 RP4-756H11.3 10.59 1.19e-23 3.17e-20 0.53 0.44 Aortic root size; chr7:66154117 chr7:66654538~66669855:+ LUSC cis rs62229266 0.654 rs62230787 ENSG00000231106.2 LINC01436 10.59 1.19e-23 3.17e-20 0.59 0.44 Mitral valve prolapse; chr21:36004182 chr21:36005338~36007838:+ LUSC cis rs6782228 0.606 rs2712404 ENSG00000242551.2 POU5F1P6 10.59 1.19e-23 3.18e-20 0.5 0.44 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613836 chr3:128674735~128677005:- LUSC cis rs3091242 0.967 rs1053438 ENSG00000261349.1 RP3-465N24.5 10.59 1.19e-23 3.19e-20 0.53 0.44 Erythrocyte sedimentation rate; chr1:25361410 chr1:25266102~25267136:- LUSC cis rs16828019 0.777 rs67460888 ENSG00000235358.1 RP11-399E6.1 10.59 1.2e-23 3.19e-20 0.83 0.44 Intelligence (multi-trait analysis); chr1:41003665 chr1:41242373~41284861:+ LUSC cis rs10875746 0.903 rs58952582 ENSG00000240399.1 RP1-228P16.1 -10.59 1.2e-23 3.2e-20 -0.5 -0.44 Longevity (90 years and older); chr12:48064665 chr12:48054813~48055591:- LUSC cis rs875971 0.522 rs1880556 ENSG00000226824.5 RP4-756H11.3 -10.59 1.21e-23 3.22e-20 -0.52 -0.44 Aortic root size; chr7:65967557 chr7:66654538~66669855:+ LUSC cis rs6964833 1 rs17515241 ENSG00000277053.3 GTF2IP1 10.59 1.22e-23 3.25e-20 0.65 0.44 Menarche (age at onset); chr7:74717695 chr7:75185385~75237696:- LUSC cis rs875971 0.505 rs1723275 ENSG00000226824.5 RP4-756H11.3 10.59 1.22e-23 3.26e-20 0.52 0.44 Aortic root size; chr7:66039646 chr7:66654538~66669855:+ LUSC cis rs7626444 0.543 rs843528 ENSG00000272359.1 U4 -10.58 1.26e-23 3.35e-20 -0.46 -0.44 Monocyte count; chr3:196753464 chr3:196747192~196747324:- LUSC cis rs10256972 0.706 rs4285396 ENSG00000229043.2 AC091729.9 -10.58 1.26e-23 3.37e-20 -0.53 -0.44 Endometriosis;Longevity; chr7:1084102 chr7:1160374~1165267:+ LUSC cis rs875971 0.862 rs7786892 ENSG00000226824.5 RP4-756H11.3 10.58 1.27e-23 3.38e-20 0.53 0.44 Aortic root size; chr7:66163889 chr7:66654538~66669855:+ LUSC cis rs73086581 0.735 rs6037730 ENSG00000229539.1 RP11-119B16.2 10.58 1.28e-23 3.4e-20 0.59 0.44 Response to antidepressants in depression; chr20:4046171 chr20:3888239~3888868:- LUSC cis rs73086581 0.838 rs6052265 ENSG00000229539.1 RP11-119B16.2 10.58 1.28e-23 3.4e-20 0.59 0.44 Response to antidepressants in depression; chr20:4046188 chr20:3888239~3888868:- LUSC cis rs6782228 0.606 rs2811488 ENSG00000242551.2 POU5F1P6 -10.58 1.28e-23 3.41e-20 -0.5 -0.44 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128617674 chr3:128674735~128677005:- LUSC cis rs11763147 1 rs11763147 ENSG00000226824.5 RP4-756H11.3 10.58 1.29e-23 3.43e-20 0.51 0.44 Corneal structure; chr7:65861834 chr7:66654538~66669855:+ LUSC cis rs9389248 0.708 rs7750574 ENSG00000232876.1 CTA-212D2.2 -10.58 1.29e-23 3.43e-20 -0.53 -0.44 High light scatter reticulocyte percentage of red cells; chr6:135029794 chr6:135055033~135060550:+ LUSC cis rs875971 0.965 rs7794930 ENSG00000226824.5 RP4-756H11.3 10.58 1.29e-23 3.44e-20 0.53 0.44 Aortic root size; chr7:66313559 chr7:66654538~66669855:+ LUSC cis rs7626444 0.584 rs844542 ENSG00000272359.1 U4 -10.58 1.3e-23 3.45e-20 -0.46 -0.44 Monocyte count; chr3:196752432 chr3:196747192~196747324:- LUSC cis rs977987 0.806 rs11860284 ENSG00000261783.1 RP11-252K23.2 -10.58 1.34e-23 3.55e-20 -0.59 -0.44 Dupuytren's disease; chr16:75379009 chr16:75379818~75381260:- LUSC cis rs6991838 0.584 rs7463740 ENSG00000272010.1 CTD-3025N20.3 -10.58 1.34e-23 3.55e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65573950 chr8:65591850~65592472:- LUSC cis rs875971 0.862 rs12537823 ENSG00000226824.5 RP4-756H11.3 -10.58 1.34e-23 3.57e-20 -0.53 -0.44 Aortic root size; chr7:66255897 chr7:66654538~66669855:+ LUSC cis rs150992 0.609 rs7711061 ENSG00000248489.1 CTD-2007H13.3 -10.58 1.35e-23 3.58e-20 -0.51 -0.44 Body mass index; chr5:99003535 chr5:98929171~98995013:+ LUSC cis rs10129255 0.536 rs3944157 ENSG00000211972.2 IGHV3-66 10.58 1.36e-23 3.62e-20 0.29 0.44 Kawasaki disease; chr14:106682286 chr14:106675017~106675544:- LUSC cis rs150992 0.632 rs34491 ENSG00000248489.1 CTD-2007H13.3 10.57 1.38e-23 3.65e-20 0.5 0.44 Body mass index; chr5:98974118 chr5:98929171~98995013:+ LUSC cis rs875971 0.862 rs7809814 ENSG00000226824.5 RP4-756H11.3 10.57 1.39e-23 3.67e-20 0.53 0.44 Aortic root size; chr7:66150410 chr7:66654538~66669855:+ LUSC cis rs10256972 0.516 rs12702081 ENSG00000229043.2 AC091729.9 -10.57 1.39e-23 3.68e-20 -0.52 -0.44 Endometriosis;Longevity; chr7:1101892 chr7:1160374~1165267:+ LUSC cis rs992157 1 rs4791 ENSG00000261338.2 RP11-378A13.1 10.57 1.42e-23 3.75e-20 0.45 0.44 Colorectal cancer; chr2:218274217 chr2:218255319~218257366:+ LUSC cis rs6991838 0.584 rs7836349 ENSG00000272010.1 CTD-3025N20.3 -10.57 1.43e-23 3.8e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65591328 chr8:65591850~65592472:- LUSC cis rs977987 0.806 rs4888386 ENSG00000261783.1 RP11-252K23.2 -10.56 1.49e-23 3.95e-20 -0.6 -0.44 Dupuytren's disease; chr16:75355842 chr16:75379818~75381260:- LUSC cis rs150992 0.593 rs34497 ENSG00000248489.1 CTD-2007H13.3 10.56 1.5e-23 3.97e-20 0.51 0.44 Body mass index; chr5:98962885 chr5:98929171~98995013:+ LUSC cis rs150992 0.632 rs326493 ENSG00000248489.1 CTD-2007H13.3 10.56 1.5e-23 3.97e-20 0.51 0.44 Body mass index; chr5:98966251 chr5:98929171~98995013:+ LUSC cis rs2739330 0.734 rs2000467 ENSG00000099984.9 GSTT2 10.56 1.51e-23 4e-20 0.55 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23980123~23983911:+ LUSC cis rs9399137 0.507 rs7748708 ENSG00000232876.1 CTA-212D2.2 -10.56 1.53e-23 4.04e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954004 chr6:135055033~135060550:+ LUSC cis rs2487048 0.773 rs2472493 ENSG00000226334.1 RP11-217B7.2 -10.56 1.54e-23 4.07e-20 -0.53 -0.44 Intraocular pressure; chr9:104933567 chr9:104927553~104928892:+ LUSC cis rs17711722 0.74 rs7809991 ENSG00000226824.5 RP4-756H11.3 -10.56 1.54e-23 4.08e-20 -0.52 -0.44 Calcium levels; chr7:65941231 chr7:66654538~66669855:+ LUSC cis rs6921919 0.638 rs7772827 ENSG00000216901.1 AL022393.7 10.56 1.55e-23 4.09e-20 0.55 0.44 Autism spectrum disorder or schizophrenia; chr6:28333366 chr6:28176188~28176674:+ LUSC cis rs977987 0.872 rs10781976 ENSG00000261783.1 RP11-252K23.2 -10.56 1.57e-23 4.15e-20 -0.58 -0.44 Dupuytren's disease; chr16:75280940 chr16:75379818~75381260:- LUSC cis rs17711722 0.522 rs62469933 ENSG00000164669.11 INTS4P1 -10.56 1.58e-23 4.16e-20 -0.48 -0.44 Calcium levels; chr7:65800652 chr7:65141225~65234216:+ LUSC cis rs2729354 1 rs2649662 ENSG00000265566.2 RN7SL605P 10.56 1.58e-23 4.17e-20 0.6 0.44 Blood protein levels; chr11:57585089 chr11:57528085~57528365:- LUSC cis rs875971 0.505 rs1167386 ENSG00000226824.5 RP4-756H11.3 10.56 1.59e-23 4.18e-20 0.52 0.44 Aortic root size; chr7:66048109 chr7:66654538~66669855:+ LUSC cis rs16828019 0.777 rs35044078 ENSG00000235358.1 RP11-399E6.1 10.56 1.6e-23 4.22e-20 0.83 0.44 Intelligence (multi-trait analysis); chr1:41008728 chr1:41242373~41284861:+ LUSC cis rs3091242 0.933 rs932372 ENSG00000261349.1 RP3-465N24.5 -10.56 1.62e-23 4.26e-20 -0.54 -0.44 Erythrocyte sedimentation rate; chr1:25428523 chr1:25266102~25267136:- LUSC cis rs875971 0.862 rs6460290 ENSG00000226824.5 RP4-756H11.3 10.55 1.65e-23 4.34e-20 0.53 0.44 Aortic root size; chr7:66344119 chr7:66654538~66669855:+ LUSC cis rs875971 0.505 rs2462573 ENSG00000226824.5 RP4-756H11.3 10.55 1.65e-23 4.35e-20 0.51 0.44 Aortic root size; chr7:66042405 chr7:66654538~66669855:+ LUSC cis rs10875746 0.807 rs12297004 ENSG00000240399.1 RP1-228P16.1 -10.55 1.66e-23 4.37e-20 -0.5 -0.44 Longevity (90 years and older); chr12:48060037 chr12:48054813~48055591:- LUSC cis rs875971 0.522 rs709604 ENSG00000226824.5 RP4-756H11.3 10.55 1.69e-23 4.45e-20 0.51 0.44 Aortic root size; chr7:66032447 chr7:66654538~66669855:+ LUSC cis rs977987 0.806 rs11862095 ENSG00000261783.1 RP11-252K23.2 -10.55 1.7e-23 4.47e-20 -0.6 -0.44 Dupuytren's disease; chr16:75351520 chr16:75379818~75381260:- LUSC cis rs2739330 0.796 rs5760097 ENSG00000099984.9 GSTT2 -10.55 1.7e-23 4.48e-20 -0.54 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23980123~23983911:+ LUSC cis rs17270561 0.579 rs10456326 ENSG00000272462.2 U91328.19 -10.55 1.74e-23 4.56e-20 -0.61 -0.44 Iron status biomarkers; chr6:25919434 chr6:25992662~26001775:+ LUSC cis rs12216125 0.537 rs12207059 ENSG00000272462.2 U91328.19 -10.55 1.74e-23 4.56e-20 -0.61 -0.44 Iron status biomarkers; chr6:25922157 chr6:25992662~26001775:+ LUSC cis rs9399137 0.507 rs4594969 ENSG00000232876.1 CTA-212D2.2 -10.55 1.75e-23 4.59e-20 -0.53 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134964448 chr6:135055033~135060550:+ LUSC cis rs977987 0.645 rs34904236 ENSG00000261783.1 RP11-252K23.2 -10.55 1.75e-23 4.59e-20 -0.61 -0.44 Dupuytren's disease; chr16:75464355 chr16:75379818~75381260:- LUSC cis rs73086581 0.838 rs56401022 ENSG00000229539.1 RP11-119B16.2 10.54 1.78e-23 4.66e-20 0.58 0.44 Response to antidepressants in depression; chr20:4043634 chr20:3888239~3888868:- LUSC cis rs875971 0.862 rs709596 ENSG00000226824.5 RP4-756H11.3 -10.54 1.81e-23 4.75e-20 -0.53 -0.44 Aortic root size; chr7:66360926 chr7:66654538~66669855:+ LUSC cis rs2739330 0.828 rs2330635 ENSG00000099984.9 GSTT2 -10.54 1.82e-23 4.78e-20 -0.54 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23980123~23983911:+ LUSC cis rs875971 0.862 rs2420174 ENSG00000226824.5 RP4-756H11.3 10.54 1.89e-23 4.94e-20 0.53 0.44 Aortic root size; chr7:66180374 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs2420173 ENSG00000226824.5 RP4-756H11.3 10.54 1.89e-23 4.94e-20 0.53 0.44 Aortic root size; chr7:66180412 chr7:66654538~66669855:+ LUSC cis rs1185460 0.967 rs11217137 ENSG00000271751.1 RP11-110I1.14 -10.54 1.91e-23 5.01e-20 -0.57 -0.44 Coronary artery disease; chr11:119060319 chr11:119065263~119065677:- LUSC cis rs35955747 0.601 rs5749302 ENSG00000236132.1 CTA-440B3.1 -10.53 1.95e-23 5.11e-20 -0.53 -0.44 Neutrophil count;Sum basophil neutrophil counts; chr22:31554632 chr22:31816379~31817491:- LUSC cis rs17507216 1 rs17158413 ENSG00000278603.1 RP13-608F4.5 10.53 1.96e-23 5.12e-20 0.61 0.44 Excessive daytime sleepiness; chr15:82566658 chr15:82472203~82472426:+ LUSC cis rs875971 0.522 rs34973832 ENSG00000226824.5 RP4-756H11.3 -10.53 1.97e-23 5.16e-20 -0.52 -0.44 Aortic root size; chr7:65931217 chr7:66654538~66669855:+ LUSC cis rs17711722 0.701 rs4467826 ENSG00000226824.5 RP4-756H11.3 -10.53 1.99e-23 5.2e-20 -0.51 -0.44 Calcium levels; chr7:65903721 chr7:66654538~66669855:+ LUSC cis rs875971 0.522 rs10807697 ENSG00000226824.5 RP4-756H11.3 -10.53 2.06e-23 5.38e-20 -0.51 -0.44 Aortic root size; chr7:65951183 chr7:66654538~66669855:+ LUSC cis rs875971 0.522 rs2949690 ENSG00000226824.5 RP4-756H11.3 10.53 2.06e-23 5.39e-20 0.51 0.44 Aortic root size; chr7:66018255 chr7:66654538~66669855:+ LUSC cis rs875971 0.522 rs2008188 ENSG00000226824.5 RP4-756H11.3 -10.53 2.08e-23 5.43e-20 -0.51 -0.44 Aortic root size; chr7:65964026 chr7:66654538~66669855:+ LUSC cis rs977987 0.843 rs4888415 ENSG00000261783.1 RP11-252K23.2 -10.52 2.1e-23 5.49e-20 -0.6 -0.44 Dupuytren's disease; chr16:75415023 chr16:75379818~75381260:- LUSC cis rs9399137 0.507 rs4896128 ENSG00000232876.1 CTA-212D2.2 10.52 2.12e-23 5.54e-20 0.52 0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135028618 chr6:135055033~135060550:+ LUSC cis rs875971 1 rs697970 ENSG00000226824.5 RP4-756H11.3 10.52 2.13e-23 5.55e-20 0.52 0.44 Aortic root size; chr7:66095065 chr7:66654538~66669855:+ LUSC cis rs11155671 0.53 rs4458704 ENSG00000216906.2 RP11-350J20.9 10.52 2.16e-23 5.64e-20 0.51 0.44 Testicular germ cell tumor; chr6:149911743 chr6:149904243~149906418:+ LUSC cis rs801193 0.569 rs10950050 ENSG00000226824.5 RP4-756H11.3 -10.52 2.21e-23 5.76e-20 -0.52 -0.44 Aortic root size; chr7:66774601 chr7:66654538~66669855:+ LUSC cis rs16828019 0.777 rs34502739 ENSG00000235358.1 RP11-399E6.1 10.52 2.24e-23 5.83e-20 0.82 0.44 Intelligence (multi-trait analysis); chr1:40993474 chr1:41242373~41284861:+ LUSC cis rs16828019 0.777 rs67450703 ENSG00000235358.1 RP11-399E6.1 10.52 2.24e-23 5.83e-20 0.82 0.44 Intelligence (multi-trait analysis); chr1:40994457 chr1:41242373~41284861:+ LUSC cis rs9399137 0.507 rs56164974 ENSG00000232876.1 CTA-212D2.2 -10.51 2.29e-23 5.97e-20 -0.53 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134967578 chr6:135055033~135060550:+ LUSC cis rs875971 0.54 rs781152 ENSG00000226824.5 RP4-756H11.3 -10.51 2.3e-23 5.99e-20 -0.53 -0.44 Aortic root size; chr7:66014585 chr7:66654538~66669855:+ LUSC cis rs17711722 0.727 rs781151 ENSG00000226824.5 RP4-756H11.3 -10.51 2.3e-23 5.99e-20 -0.53 -0.44 Calcium levels; chr7:66014891 chr7:66654538~66669855:+ LUSC cis rs6921919 0.638 rs9468344 ENSG00000216901.1 AL022393.7 10.51 2.31e-23 6.01e-20 0.53 0.44 Autism spectrum disorder or schizophrenia; chr6:28341792 chr6:28176188~28176674:+ LUSC cis rs875971 0.862 rs778724 ENSG00000226824.5 RP4-756H11.3 -10.51 2.34e-23 6.09e-20 -0.52 -0.44 Aortic root size; chr7:66364304 chr7:66654538~66669855:+ LUSC cis rs11155671 0.53 rs7763849 ENSG00000216906.2 RP11-350J20.9 10.51 2.36e-23 6.13e-20 0.54 0.44 Testicular germ cell tumor; chr6:149885244 chr6:149904243~149906418:+ LUSC cis rs6782228 0.675 rs9813845 ENSG00000277250.1 Metazoa_SRP -10.51 2.38e-23 6.17e-20 -0.49 -0.44 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128680780 chr3:128673681~128674021:- LUSC cis rs16828019 0.852 rs34386859 ENSG00000235358.1 RP11-399E6.1 10.51 2.4e-23 6.24e-20 0.79 0.44 Intelligence (multi-trait analysis); chr1:41098352 chr1:41242373~41284861:+ LUSC cis rs6991838 0.557 rs4737222 ENSG00000272010.1 CTD-3025N20.3 -10.51 2.41e-23 6.26e-20 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65587878 chr8:65591850~65592472:- LUSC cis rs16828019 0.704 rs4996176 ENSG00000235358.1 RP11-399E6.1 10.51 2.43e-23 6.3e-20 0.83 0.44 Intelligence (multi-trait analysis); chr1:41022496 chr1:41242373~41284861:+ LUSC cis rs16828019 0.777 rs35496942 ENSG00000235358.1 RP11-399E6.1 10.51 2.43e-23 6.3e-20 0.83 0.44 Intelligence (multi-trait analysis); chr1:41023232 chr1:41242373~41284861:+ LUSC cis rs875971 0.862 rs4718319 ENSG00000226824.5 RP4-756H11.3 10.51 2.46e-23 6.38e-20 0.53 0.44 Aortic root size; chr7:66187797 chr7:66654538~66669855:+ LUSC cis rs875971 0.723 rs28391294 ENSG00000226824.5 RP4-756H11.3 10.51 2.46e-23 6.38e-20 0.53 0.44 Aortic root size; chr7:66189328 chr7:66654538~66669855:+ LUSC cis rs875971 0.83 rs6967708 ENSG00000226824.5 RP4-756H11.3 10.51 2.46e-23 6.38e-20 0.53 0.44 Aortic root size; chr7:66192326 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs7782806 ENSG00000226824.5 RP4-756H11.3 10.51 2.46e-23 6.38e-20 0.53 0.44 Aortic root size; chr7:66192910 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs880166 ENSG00000226824.5 RP4-756H11.3 10.51 2.46e-23 6.38e-20 0.53 0.44 Aortic root size; chr7:66205775 chr7:66654538~66669855:+ LUSC cis rs977987 0.815 rs1364078 ENSG00000261783.1 RP11-252K23.2 -10.51 2.47e-23 6.41e-20 -0.59 -0.44 Dupuytren's disease; chr16:75362983 chr16:75379818~75381260:- LUSC cis rs977987 0.75 rs4888407 ENSG00000261783.1 RP11-252K23.2 -10.51 2.47e-23 6.41e-20 -0.6 -0.44 Dupuytren's disease; chr16:75398492 chr16:75379818~75381260:- LUSC cis rs992157 1 rs736730 ENSG00000261338.2 RP11-378A13.1 10.51 2.48e-23 6.43e-20 0.45 0.44 Colorectal cancer; chr2:218255532 chr2:218255319~218257366:+ LUSC cis rs992157 1 rs736731 ENSG00000261338.2 RP11-378A13.1 10.51 2.48e-23 6.43e-20 0.45 0.44 Colorectal cancer; chr2:218255865 chr2:218255319~218257366:+ LUSC cis rs7188445 0.932 rs73575085 ENSG00000261390.4 RP11-345M22.2 -10.51 2.49e-23 6.44e-20 -0.6 -0.44 Urate levels; chr16:79714179 chr16:79715232~79770563:- LUSC cis rs7188445 0.932 rs73575086 ENSG00000261390.4 RP11-345M22.2 -10.51 2.49e-23 6.44e-20 -0.6 -0.44 Urate levels; chr16:79714588 chr16:79715232~79770563:- LUSC cis rs35955747 0.633 rs1916 ENSG00000236132.1 CTA-440B3.1 -10.5 2.51e-23 6.5e-20 -0.52 -0.44 Neutrophil count;Sum basophil neutrophil counts; chr22:31496135 chr22:31816379~31817491:- LUSC cis rs977987 0.843 rs2059256 ENSG00000261783.1 RP11-252K23.2 -10.5 2.53e-23 6.55e-20 -0.59 -0.44 Dupuytren's disease; chr16:75361937 chr16:75379818~75381260:- LUSC cis rs150992 0.587 rs10040066 ENSG00000248489.1 CTD-2007H13.3 -10.5 2.53e-23 6.56e-20 -0.51 -0.44 Body mass index; chr5:99001333 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs4565239 ENSG00000248489.1 CTD-2007H13.3 -10.5 2.53e-23 6.56e-20 -0.51 -0.44 Body mass index; chr5:99002144 chr5:98929171~98995013:+ LUSC cis rs2487048 0.773 rs2472494 ENSG00000226334.1 RP11-217B7.2 -10.5 2.54e-23 6.58e-20 -0.53 -0.44 Intraocular pressure; chr9:104933258 chr9:104927553~104928892:+ LUSC cis rs2739330 0.76 rs5751760 ENSG00000231271.1 AP000350.8 10.5 2.56e-23 6.62e-20 0.55 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23949918~23954042:+ LUSC cis rs2929278 0.617 rs11070410 ENSG00000249839.1 AC011330.5 10.5 2.58e-23 6.66e-20 0.57 0.44 Schizophrenia; chr15:43764847 chr15:43663654~43684339:- LUSC cis rs7208859 0.673 rs9889968 ENSG00000263531.1 RP13-753N3.1 10.5 2.59e-23 6.69e-20 0.78 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30893110 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs61348930 ENSG00000263531.1 RP13-753N3.1 10.5 2.59e-23 6.69e-20 0.78 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30894745 chr17:30863921~30864940:- LUSC cis rs7208859 0.614 rs28758251 ENSG00000263531.1 RP13-753N3.1 10.5 2.59e-23 6.69e-20 0.78 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896294 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs9899943 ENSG00000263531.1 RP13-753N3.1 10.5 2.59e-23 6.69e-20 0.78 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896907 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs11080138 ENSG00000263531.1 RP13-753N3.1 10.5 2.59e-23 6.69e-20 0.78 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30897524 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs2433 ENSG00000263531.1 RP13-753N3.1 10.5 2.59e-23 6.69e-20 0.78 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30899210 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs11658435 ENSG00000263531.1 RP13-753N3.1 10.5 2.59e-23 6.69e-20 0.78 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30901543 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs73265624 ENSG00000263531.1 RP13-753N3.1 10.5 2.59e-23 6.69e-20 0.78 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905048 chr17:30863921~30864940:- LUSC cis rs150992 0.609 rs709390 ENSG00000248489.1 CTD-2007H13.3 10.5 2.6e-23 6.71e-20 0.51 0.44 Body mass index; chr5:98993771 chr5:98929171~98995013:+ LUSC cis rs9545047 1 rs9574418 ENSG00000227676.3 LINC01068 10.49 2.78e-23 7.16e-20 0.54 0.44 Schizophrenia; chr13:79393874 chr13:79566727~79571436:+ LUSC cis rs2929278 0.561 rs62018952 ENSG00000249839.1 AC011330.5 10.49 2.79e-23 7.19e-20 0.58 0.44 Schizophrenia; chr15:43788539 chr15:43663654~43684339:- LUSC cis rs875971 0.862 rs4718330 ENSG00000226824.5 RP4-756H11.3 10.49 2.8e-23 7.23e-20 0.52 0.44 Aortic root size; chr7:66250256 chr7:66654538~66669855:+ LUSC cis rs6991838 0.584 rs3812412 ENSG00000272010.1 CTD-3025N20.3 10.49 2.82e-23 7.27e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65634857 chr8:65591850~65592472:- LUSC cis rs875971 0.893 rs62465470 ENSG00000226824.5 RP4-756H11.3 10.49 2.84e-23 7.32e-20 0.53 0.44 Aortic root size; chr7:66136231 chr7:66654538~66669855:+ LUSC cis rs6991838 0.612 rs7832407 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65621071 chr8:65591850~65592472:- LUSC cis rs6991838 0.551 rs7007505 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65621719 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs7012856 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65622740 chr8:65591850~65592472:- LUSC cis rs6991838 0.55 rs7817112 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65624885 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs2048650 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65625664 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs4737749 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65627672 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs10092109 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65627683 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs6997959 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65628247 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs7814841 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65629328 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs11985628 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65630504 chr8:65591850~65592472:- LUSC cis rs6991838 0.557 rs13266834 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65631303 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs13268343 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65631742 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs7835313 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65633891 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs1533285 ENSG00000272010.1 CTD-3025N20.3 10.49 2.87e-23 7.36e-20 0.49 0.44 Intelligence (multi-trait analysis); chr8:65637129 chr8:65591850~65592472:- LUSC cis rs7188445 0.932 rs73575076 ENSG00000261390.4 RP11-345M22.2 -10.49 2.87e-23 7.38e-20 -0.59 -0.44 Urate levels; chr16:79710251 chr16:79715232~79770563:- LUSC cis rs875971 0.862 rs4368860 ENSG00000226824.5 RP4-756H11.3 10.49 2.88e-23 7.39e-20 0.52 0.44 Aortic root size; chr7:66143495 chr7:66654538~66669855:+ LUSC cis rs150992 0.609 rs449204 ENSG00000248489.1 CTD-2007H13.3 10.49 2.93e-23 7.52e-20 0.5 0.44 Body mass index; chr5:98991775 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs378089 ENSG00000248489.1 CTD-2007H13.3 10.49 2.93e-23 7.52e-20 0.5 0.44 Body mass index; chr5:98991818 chr5:98929171~98995013:+ LUSC cis rs150992 0.587 rs422127 ENSG00000248489.1 CTD-2007H13.3 10.49 2.93e-23 7.52e-20 0.5 0.44 Body mass index; chr5:98991984 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs113423144 ENSG00000248489.1 CTD-2007H13.3 10.49 2.93e-23 7.52e-20 0.5 0.44 Body mass index; chr5:98992055 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs380156 ENSG00000248489.1 CTD-2007H13.3 10.49 2.93e-23 7.52e-20 0.5 0.44 Body mass index; chr5:98992386 chr5:98929171~98995013:+ LUSC cis rs9399137 0.507 rs6923512 ENSG00000232876.1 CTA-212D2.2 10.49 2.94e-23 7.53e-20 0.53 0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135014130 chr6:135055033~135060550:+ LUSC cis rs2006771 0.836 rs7285777 ENSG00000236132.1 CTA-440B3.1 10.48 2.98e-23 7.63e-20 0.53 0.44 Nonsyndromic cleft lip with cleft palate; chr22:31586255 chr22:31816379~31817491:- LUSC cis rs801193 0.569 rs881285 ENSG00000226824.5 RP4-756H11.3 10.48 2.98e-23 7.64e-20 0.53 0.44 Aortic root size; chr7:66654433 chr7:66654538~66669855:+ LUSC cis rs150992 0.711 rs2617507 ENSG00000248489.1 CTD-2007H13.3 10.48 2.99e-23 7.66e-20 0.53 0.44 Body mass index; chr5:98912548 chr5:98929171~98995013:+ LUSC cis rs17270561 0.578 rs76182885 ENSG00000272462.2 U91328.19 -10.48 3.03e-23 7.77e-20 -0.61 -0.44 Iron status biomarkers; chr6:25903857 chr6:25992662~26001775:+ LUSC cis rs10875746 0.855 rs2269936 ENSG00000240399.1 RP1-228P16.1 -10.48 3.06e-23 7.8e-20 -0.5 -0.44 Longevity (90 years and older); chr12:48031452 chr12:48054813~48055591:- LUSC cis rs2739330 0.789 rs5760109 ENSG00000099984.9 GSTT2 -10.48 3.06e-23 7.82e-20 -0.53 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23980123~23983911:+ LUSC cis rs7188445 0.932 rs73575079 ENSG00000261390.4 RP11-345M22.2 -10.48 3.07e-23 7.83e-20 -0.59 -0.44 Urate levels; chr16:79711344 chr16:79715232~79770563:- LUSC cis rs977987 0.843 rs10459859 ENSG00000261783.1 RP11-252K23.2 -10.48 3.08e-23 7.86e-20 -0.6 -0.44 Dupuytren's disease; chr16:75348052 chr16:75379818~75381260:- LUSC cis rs17711722 0.701 rs781143 ENSG00000226824.5 RP4-756H11.3 -10.48 3.08e-23 7.87e-20 -0.51 -0.44 Calcium levels; chr7:65974892 chr7:66654538~66669855:+ LUSC cis rs10129255 0.509 rs756583 ENSG00000211972.2 IGHV3-66 10.48 3.11e-23 7.95e-20 0.29 0.44 Kawasaki disease; chr14:106680002 chr14:106675017~106675544:- LUSC cis rs10129255 0.879 rs7160512 ENSG00000223648.3 IGHV3-64 10.48 3.13e-23 7.98e-20 0.39 0.44 Kawasaki disease; chr14:106694574 chr14:106643132~106658258:- LUSC cis rs10129255 0.879 rs7159157 ENSG00000223648.3 IGHV3-64 10.48 3.13e-23 7.98e-20 0.39 0.44 Kawasaki disease; chr14:106694578 chr14:106643132~106658258:- LUSC cis rs875971 0.862 rs10274883 ENSG00000226824.5 RP4-756H11.3 10.48 3.14e-23 8.01e-20 0.53 0.44 Aortic root size; chr7:66651104 chr7:66654538~66669855:+ LUSC cis rs9399137 0.507 rs4451150 ENSG00000232876.1 CTA-212D2.2 -10.48 3.16e-23 8.06e-20 -0.54 -0.44 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134957925 chr6:135055033~135060550:+ LUSC cis rs2929278 0.589 rs2411284 ENSG00000249839.1 AC011330.5 10.47 3.23e-23 8.23e-20 0.57 0.44 Schizophrenia; chr15:43746701 chr15:43663654~43684339:- LUSC cis rs150992 0.532 rs416750 ENSG00000248489.1 CTD-2007H13.3 10.47 3.27e-23 8.32e-20 0.5 0.44 Body mass index; chr5:98999046 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs819232 ENSG00000248489.1 CTD-2007H13.3 10.47 3.27e-23 8.32e-20 0.5 0.44 Body mass index; chr5:98999416 chr5:98929171~98995013:+ LUSC cis rs1185460 0.967 rs1177562 ENSG00000271751.1 RP11-110I1.14 -10.47 3.29e-23 8.38e-20 -0.55 -0.43 Coronary artery disease; chr11:119078621 chr11:119065263~119065677:- LUSC cis rs7188445 0.932 rs73575083 ENSG00000261390.4 RP11-345M22.2 -10.47 3.31e-23 8.44e-20 -0.6 -0.43 Urate levels; chr16:79713958 chr16:79715232~79770563:- LUSC cis rs6991838 0.584 rs4737748 ENSG00000272010.1 CTD-3025N20.3 10.47 3.34e-23 8.49e-20 0.49 0.43 Intelligence (multi-trait analysis); chr8:65613630 chr8:65591850~65592472:- LUSC cis rs6991838 0.55 rs12335006 ENSG00000272010.1 CTD-3025N20.3 10.47 3.34e-23 8.49e-20 0.49 0.43 Intelligence (multi-trait analysis); chr8:65619394 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs10957361 ENSG00000272010.1 CTD-3025N20.3 10.47 3.34e-23 8.49e-20 0.49 0.43 Intelligence (multi-trait analysis); chr8:65619626 chr8:65591850~65592472:- LUSC cis rs6991838 0.612 rs12335276 ENSG00000272010.1 CTD-3025N20.3 10.47 3.34e-23 8.49e-20 0.49 0.43 Intelligence (multi-trait analysis); chr8:65619668 chr8:65591850~65592472:- LUSC cis rs6991838 0.53 rs35038843 ENSG00000272010.1 CTD-3025N20.3 -10.47 3.34e-23 8.49e-20 -0.49 -0.43 Intelligence (multi-trait analysis); chr8:65610263 chr8:65591850~65592472:- LUSC cis rs17270561 0.541 rs12192932 ENSG00000272462.2 U91328.19 -10.47 3.36e-23 8.54e-20 -0.61 -0.43 Iron status biomarkers; chr6:25911274 chr6:25992662~26001775:+ LUSC cis rs6700559 0.873 rs7542210 ENSG00000260088.1 RP11-92G12.3 -10.47 3.39e-23 8.61e-20 -0.55 -0.43 Coronary artery disease; chr1:200693087 chr1:200669507~200694250:+ LUSC cis rs73086581 0.838 rs41398349 ENSG00000229539.1 RP11-119B16.2 -10.47 3.46e-23 8.8e-20 -0.57 -0.43 Response to antidepressants in depression; chr20:4043792 chr20:3888239~3888868:- LUSC cis rs7115242 1 rs7115242 ENSG00000254851.1 RP11-109L13.1 10.47 3.48e-23 8.84e-20 0.93 0.43 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117037567 chr11:117135528~117138582:+ LUSC cis rs17711722 0.727 rs1880555 ENSG00000226824.5 RP4-756H11.3 -10.47 3.48e-23 8.84e-20 -0.51 -0.43 Calcium levels; chr7:65967580 chr7:66654538~66669855:+ LUSC cis rs2739330 0.828 rs5760107 ENSG00000099984.9 GSTT2 -10.46 3.55e-23 9.01e-20 -0.53 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23980123~23983911:+ LUSC cis rs801193 0.569 rs3846973 ENSG00000226824.5 RP4-756H11.3 10.46 3.58e-23 9.08e-20 0.53 0.43 Aortic root size; chr7:66655048 chr7:66654538~66669855:+ LUSC cis rs801193 0.569 rs2013908 ENSG00000226824.5 RP4-756H11.3 10.46 3.58e-23 9.08e-20 0.53 0.43 Aortic root size; chr7:66656082 chr7:66654538~66669855:+ LUSC cis rs801193 0.569 rs6951302 ENSG00000226824.5 RP4-756H11.3 10.46 3.58e-23 9.08e-20 0.53 0.43 Aortic root size; chr7:66667525 chr7:66654538~66669855:+ LUSC cis rs10875746 0.81 rs10875732 ENSG00000240399.1 RP1-228P16.1 -10.46 3.59e-23 9.1e-20 -0.5 -0.43 Longevity (90 years and older); chr12:48048322 chr12:48054813~48055591:- LUSC cis rs5760092 0.755 rs4585126 ENSG00000218537.1 MIF-AS1 -10.46 3.59e-23 9.11e-20 -0.66 -0.43 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23894426~23898930:- LUSC cis rs10129255 0.701 rs2005643 ENSG00000223648.3 IGHV3-64 10.46 3.61e-23 9.15e-20 0.38 0.43 Kawasaki disease; chr14:106676288 chr14:106643132~106658258:- LUSC cis rs7188445 0.932 rs17689455 ENSG00000261390.4 RP11-345M22.2 -10.46 3.63e-23 9.2e-20 -0.6 -0.43 Urate levels; chr16:79712438 chr16:79715232~79770563:- LUSC cis rs9399137 0.507 rs6940878 ENSG00000232876.1 CTA-212D2.2 -10.46 3.64e-23 9.22e-20 -0.53 -0.43 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135045171 chr6:135055033~135060550:+ LUSC cis rs977987 0.806 rs12599361 ENSG00000261783.1 RP11-252K23.2 -10.46 3.64e-23 9.23e-20 -0.6 -0.43 Dupuytren's disease; chr16:75401075 chr16:75379818~75381260:- LUSC cis rs35955747 0.633 rs4541328 ENSG00000236132.1 CTA-440B3.1 10.46 3.76e-23 9.53e-20 0.52 0.43 Neutrophil count;Sum basophil neutrophil counts; chr22:31500186 chr22:31816379~31817491:- LUSC cis rs992157 0.965 rs13419763 ENSG00000261338.2 RP11-378A13.1 10.46 3.78e-23 9.56e-20 0.45 0.43 Colorectal cancer; chr2:218270227 chr2:218255319~218257366:+ LUSC cis rs801193 0.548 rs2109297 ENSG00000226824.5 RP4-756H11.3 10.46 3.78e-23 9.57e-20 0.53 0.43 Aortic root size; chr7:66657397 chr7:66654538~66669855:+ LUSC cis rs801193 0.591 rs721717 ENSG00000226824.5 RP4-756H11.3 10.46 3.78e-23 9.57e-20 0.53 0.43 Aortic root size; chr7:66665305 chr7:66654538~66669855:+ LUSC cis rs150992 0.587 rs4703340 ENSG00000248489.1 CTD-2007H13.3 -10.45 3.84e-23 9.73e-20 -0.49 -0.43 Body mass index; chr5:99009083 chr5:98929171~98995013:+ LUSC cis rs17711722 0.64 rs13237956 ENSG00000226824.5 RP4-756H11.3 -10.45 3.86e-23 9.77e-20 -0.51 -0.43 Calcium levels; chr7:65853042 chr7:66654538~66669855:+ LUSC cis rs150992 0.57 rs7710032 ENSG00000248489.1 CTD-2007H13.3 -10.45 3.88e-23 9.82e-20 -0.51 -0.43 Body mass index; chr5:99007501 chr5:98929171~98995013:+ LUSC cis rs875971 0.862 rs778702 ENSG00000226824.5 RP4-756H11.3 -10.45 3.93e-23 9.94e-20 -0.52 -0.43 Aortic root size; chr7:66399848 chr7:66654538~66669855:+ LUSC cis rs2739330 0.753 rs4822452 ENSG00000099984.9 GSTT2 -10.45 3.98e-23 1.01e-19 -0.53 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23980123~23983911:+ LUSC cis rs6991838 0.584 rs7823840 ENSG00000272010.1 CTD-3025N20.3 -10.45 4.03e-23 1.02e-19 -0.49 -0.43 Intelligence (multi-trait analysis); chr8:65606766 chr8:65591850~65592472:- LUSC cis rs875971 0.928 rs2036263 ENSG00000226824.5 RP4-756H11.3 10.45 4.04e-23 1.02e-19 0.52 0.43 Aortic root size; chr7:66335210 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs10240949 ENSG00000226824.5 RP4-756H11.3 10.45 4.04e-23 1.02e-19 0.52 0.43 Aortic root size; chr7:66339430 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs7782704 ENSG00000226824.5 RP4-756H11.3 10.45 4.04e-23 1.02e-19 0.52 0.43 Aortic root size; chr7:66340379 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6959268 ENSG00000226824.5 RP4-756H11.3 10.45 4.04e-23 1.02e-19 0.52 0.43 Aortic root size; chr7:66347979 chr7:66654538~66669855:+ LUSC cis rs10716631 1 rs10716631 ENSG00000261338.2 RP11-378A13.1 10.45 4.06e-23 1.03e-19 0.45 0.43 Plateletcrit;High light scatter reticulocyte percentage of red cells; chr2:218273447 chr2:218255319~218257366:+ LUSC cis rs875971 0.522 rs4718285 ENSG00000226824.5 RP4-756H11.3 -10.45 4.09e-23 1.03e-19 -0.51 -0.43 Aortic root size; chr7:65827018 chr7:66654538~66669855:+ LUSC cis rs4774565 0.762 rs11634585 ENSG00000244879.4 GABPB1-AS1 10.45 4.11e-23 1.04e-19 0.39 0.43 Breast cancer; chr15:50364252 chr15:50354959~50372202:+ LUSC cis rs977987 0.806 rs4888405 ENSG00000261783.1 RP11-252K23.2 -10.44 4.18e-23 1.05e-19 -0.59 -0.43 Dupuytren's disease; chr16:75394298 chr16:75379818~75381260:- LUSC cis rs2739330 0.828 rs2154593 ENSG00000099984.9 GSTT2 -10.44 4.18e-23 1.05e-19 -0.53 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23980123~23983911:+ LUSC cis rs875971 0.862 rs10276077 ENSG00000226824.5 RP4-756H11.3 10.44 4.23e-23 1.07e-19 0.52 0.43 Aortic root size; chr7:66263424 chr7:66654538~66669855:+ LUSC cis rs16828019 0.704 rs12031277 ENSG00000235358.1 RP11-399E6.1 10.44 4.27e-23 1.08e-19 0.83 0.43 Intelligence (multi-trait analysis); chr1:41026129 chr1:41242373~41284861:+ LUSC cis rs10875746 0.951 rs11168433 ENSG00000240399.1 RP1-228P16.1 -10.44 4.28e-23 1.08e-19 -0.5 -0.43 Longevity (90 years and older); chr12:48164281 chr12:48054813~48055591:- LUSC cis rs875971 0.825 rs1000464 ENSG00000226824.5 RP4-756H11.3 10.44 4.28e-23 1.08e-19 0.52 0.43 Aortic root size; chr7:66312922 chr7:66654538~66669855:+ LUSC cis rs875971 0.505 rs6955582 ENSG00000226824.5 RP4-756H11.3 -10.44 4.3e-23 1.08e-19 -0.51 -0.43 Aortic root size; chr7:65966699 chr7:66654538~66669855:+ LUSC cis rs2739330 0.828 rs4820572 ENSG00000099984.9 GSTT2 -10.44 4.3e-23 1.08e-19 -0.53 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23980123~23983911:+ LUSC cis rs875971 0.862 rs6945775 ENSG00000226824.5 RP4-756H11.3 -10.44 4.31e-23 1.09e-19 -0.52 -0.43 Aortic root size; chr7:66503987 chr7:66654538~66669855:+ LUSC cis rs150992 0.632 rs162341 ENSG00000248489.1 CTD-2007H13.3 10.44 4.47e-23 1.13e-19 0.5 0.43 Body mass index; chr5:98967230 chr5:98929171~98995013:+ LUSC cis rs6782228 0.675 rs6806687 ENSG00000277250.1 Metazoa_SRP 10.44 4.48e-23 1.13e-19 0.47 0.43 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128672946 chr3:128673681~128674021:- LUSC cis rs2455601 0.786 rs56680262 ENSG00000254860.4 TMEM9B-AS1 10.44 4.49e-23 1.13e-19 0.61 0.43 Schizophrenia; chr11:8950008 chr11:8964675~8977527:+ LUSC cis rs875971 0.798 rs6460304 ENSG00000226824.5 RP4-756H11.3 -10.43 4.55e-23 1.14e-19 -0.52 -0.43 Aortic root size; chr7:66499741 chr7:66654538~66669855:+ LUSC cis rs875971 0.792 rs6971752 ENSG00000226824.5 RP4-756H11.3 10.43 4.57e-23 1.15e-19 0.52 0.43 Aortic root size; chr7:66272999 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs10950033 ENSG00000226824.5 RP4-756H11.3 10.43 4.57e-23 1.15e-19 0.52 0.43 Aortic root size; chr7:66274686 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs11760844 ENSG00000226824.5 RP4-756H11.3 10.43 4.57e-23 1.15e-19 0.52 0.43 Aortic root size; chr7:66274896 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs4149461 ENSG00000226824.5 RP4-756H11.3 10.43 4.57e-23 1.15e-19 0.52 0.43 Aortic root size; chr7:66279745 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs4236208 ENSG00000226824.5 RP4-756H11.3 10.43 4.57e-23 1.15e-19 0.52 0.43 Aortic root size; chr7:66284091 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs10261398 ENSG00000226824.5 RP4-756H11.3 10.43 4.57e-23 1.15e-19 0.52 0.43 Aortic root size; chr7:66285177 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs10224872 ENSG00000226824.5 RP4-756H11.3 10.43 4.57e-23 1.15e-19 0.52 0.43 Aortic root size; chr7:66294786 chr7:66654538~66669855:+ LUSC cis rs992157 1 rs2292553 ENSG00000261338.2 RP11-378A13.1 10.43 4.6e-23 1.16e-19 0.44 0.43 Colorectal cancer; chr2:218282080 chr2:218255319~218257366:+ LUSC cis rs801193 0.569 rs13226966 ENSG00000226824.5 RP4-756H11.3 -10.43 4.67e-23 1.17e-19 -0.53 -0.43 Aortic root size; chr7:66768636 chr7:66654538~66669855:+ LUSC cis rs7188445 0.836 rs3813580 ENSG00000261390.4 RP11-345M22.2 -10.43 4.67e-23 1.17e-19 -0.59 -0.43 Urate levels; chr16:79715383 chr16:79715232~79770563:- LUSC cis rs875971 0.522 rs4502988 ENSG00000226824.5 RP4-756H11.3 -10.43 4.71e-23 1.18e-19 -0.51 -0.43 Aortic root size; chr7:65832759 chr7:66654538~66669855:+ LUSC cis rs4423214 0.84 rs1792315 ENSG00000254682.1 RP11-660L16.2 -10.43 4.75e-23 1.19e-19 -0.61 -0.43 Vitamin D levels; chr11:71454501 chr11:71448674~71452157:+ LUSC cis rs9399137 0.507 rs61738647 ENSG00000232876.1 CTA-212D2.2 -10.43 4.78e-23 1.2e-19 -0.53 -0.43 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134961597 chr6:135055033~135060550:+ LUSC cis rs875971 0.505 rs1167385 ENSG00000226824.5 RP4-756H11.3 10.43 4.81e-23 1.21e-19 0.51 0.43 Aortic root size; chr7:66048321 chr7:66654538~66669855:+ LUSC cis rs150992 0.609 rs78254063 ENSG00000248489.1 CTD-2007H13.3 10.43 4.81e-23 1.21e-19 0.5 0.43 Body mass index; chr5:98990803 chr5:98929171~98995013:+ LUSC cis rs10129255 0.536 rs8004835 ENSG00000211972.2 IGHV3-66 10.43 4.93e-23 1.24e-19 0.29 0.43 Kawasaki disease; chr14:106686361 chr14:106675017~106675544:- LUSC cis rs977987 0.806 rs4993969 ENSG00000261783.1 RP11-252K23.2 -10.42 4.96e-23 1.24e-19 -0.57 -0.43 Dupuytren's disease; chr16:75377623 chr16:75379818~75381260:- LUSC cis rs7208859 0.623 rs7220999 ENSG00000263531.1 RP13-753N3.1 10.42 5.02e-23 1.26e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822280 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs55638872 ENSG00000263531.1 RP13-753N3.1 10.42 5.02e-23 1.26e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822534 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9899268 ENSG00000263531.1 RP13-753N3.1 10.42 5.02e-23 1.26e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30823237 chr17:30863921~30864940:- LUSC cis rs6991838 0.584 rs3765205 ENSG00000272010.1 CTD-3025N20.3 -10.42 5.07e-23 1.27e-19 -0.49 -0.43 Intelligence (multi-trait analysis); chr8:65605251 chr8:65591850~65592472:- LUSC cis rs10129255 0.5 rs2105989 ENSG00000280411.1 IGHV1-69-2 -10.42 5.09e-23 1.28e-19 -0.26 -0.43 Kawasaki disease; chr14:106682199 chr14:106762092~106762588:- LUSC cis rs6700559 0.873 rs7526031 ENSG00000260088.1 RP11-92G12.3 -10.42 5.11e-23 1.28e-19 -0.55 -0.43 Coronary artery disease; chr1:200695174 chr1:200669507~200694250:+ LUSC cis rs4423214 0.765 rs2002064 ENSG00000254682.1 RP11-660L16.2 -10.42 5.11e-23 1.28e-19 -0.61 -0.43 Vitamin D levels; chr11:71452374 chr11:71448674~71452157:+ LUSC cis rs35955747 0.633 rs2006771 ENSG00000236132.1 CTA-440B3.1 10.42 5.16e-23 1.29e-19 0.51 0.43 Neutrophil count;Sum basophil neutrophil counts; chr22:31602626 chr22:31816379~31817491:- LUSC cis rs977987 0.933 rs1834014 ENSG00000261783.1 RP11-252K23.2 -10.42 5.19e-23 1.3e-19 -0.6 -0.43 Dupuytren's disease; chr16:75467376 chr16:75379818~75381260:- LUSC cis rs977987 0.872 rs3743609 ENSG00000261783.1 RP11-252K23.2 -10.42 5.27e-23 1.32e-19 -0.6 -0.43 Dupuytren's disease; chr16:75433123 chr16:75379818~75381260:- LUSC cis rs10875746 0.855 rs10875730 ENSG00000240399.1 RP1-228P16.1 -10.42 5.33e-23 1.33e-19 -0.5 -0.43 Longevity (90 years and older); chr12:48034092 chr12:48054813~48055591:- LUSC cis rs8062405 1 rs7187776 ENSG00000259982.1 CDC37P1 10.42 5.38e-23 1.35e-19 0.54 0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28846324 chr16:28700294~28701540:- LUSC cis rs1185460 0.967 rs11217133 ENSG00000271751.1 RP11-110I1.14 -10.41 5.45e-23 1.36e-19 -0.57 -0.43 Coronary artery disease; chr11:119057538 chr11:119065263~119065677:- LUSC cis rs7188445 0.932 rs17689625 ENSG00000261390.4 RP11-345M22.2 -10.41 5.53e-23 1.38e-19 -0.59 -0.43 Urate levels; chr16:79715065 chr16:79715232~79770563:- LUSC cis rs875971 0.825 rs4587224 ENSG00000226824.5 RP4-756H11.3 10.41 5.59e-23 1.4e-19 0.52 0.43 Aortic root size; chr7:66271195 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs778734 ENSG00000226824.5 RP4-756H11.3 -10.41 5.63e-23 1.41e-19 -0.52 -0.43 Aortic root size; chr7:66349862 chr7:66654538~66669855:+ LUSC cis rs1150668 0.699 rs1531681 ENSG00000216901.1 AL022393.7 10.41 5.73e-23 1.43e-19 0.47 0.43 Pubertal anthropometrics; chr6:28259100 chr6:28176188~28176674:+ LUSC cis rs875971 0.83 rs778715 ENSG00000226824.5 RP4-756H11.3 -10.41 5.79e-23 1.44e-19 -0.52 -0.43 Aortic root size; chr7:66384222 chr7:66654538~66669855:+ LUSC cis rs875971 0.83 rs809025 ENSG00000226824.5 RP4-756H11.3 -10.41 5.79e-23 1.44e-19 -0.52 -0.43 Aortic root size; chr7:66384832 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs1643375 ENSG00000226824.5 RP4-756H11.3 -10.41 5.79e-23 1.44e-19 -0.52 -0.43 Aortic root size; chr7:66407690 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6962717 ENSG00000226824.5 RP4-756H11.3 -10.41 5.79e-23 1.44e-19 -0.52 -0.43 Aortic root size; chr7:66418748 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs778686 ENSG00000226824.5 RP4-756H11.3 -10.41 5.82e-23 1.45e-19 -0.52 -0.43 Aortic root size; chr7:66370923 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs778684 ENSG00000226824.5 RP4-756H11.3 -10.41 5.82e-23 1.45e-19 -0.52 -0.43 Aortic root size; chr7:66371416 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs778680 ENSG00000226824.5 RP4-756H11.3 -10.41 5.82e-23 1.45e-19 -0.52 -0.43 Aortic root size; chr7:66375427 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs11769079 ENSG00000226824.5 RP4-756H11.3 -10.41 5.82e-23 1.45e-19 -0.52 -0.43 Aortic root size; chr7:66377141 chr7:66654538~66669855:+ LUSC cis rs2929278 0.589 rs7174732 ENSG00000249839.1 AC011330.5 10.41 5.82e-23 1.45e-19 0.57 0.43 Schizophrenia; chr15:43746265 chr15:43663654~43684339:- LUSC cis rs16828019 0.704 rs12743340 ENSG00000235358.1 RP11-399E6.1 10.41 5.84e-23 1.46e-19 0.81 0.43 Intelligence (multi-trait analysis); chr1:40990360 chr1:41242373~41284861:+ LUSC cis rs977987 0.771 rs8048527 ENSG00000261783.1 RP11-252K23.2 -10.41 5.84e-23 1.46e-19 -0.58 -0.43 Dupuytren's disease; chr16:75388156 chr16:75379818~75381260:- LUSC cis rs7188445 0.932 rs3813582 ENSG00000261390.4 RP11-345M22.2 -10.4 5.91e-23 1.47e-19 -0.57 -0.43 Urate levels; chr16:79715456 chr16:79715232~79770563:- LUSC cis rs977987 0.843 rs60730309 ENSG00000261783.1 RP11-252K23.2 -10.4 5.93e-23 1.48e-19 -0.59 -0.43 Dupuytren's disease; chr16:75397871 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs67409275 ENSG00000261783.1 RP11-252K23.2 -10.4 5.99e-23 1.49e-19 -0.59 -0.43 Dupuytren's disease; chr16:75423314 chr16:75379818~75381260:- LUSC cis rs9399137 0.507 rs6904897 ENSG00000232876.1 CTA-212D2.2 -10.4 6.06e-23 1.51e-19 -0.53 -0.43 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135061842 chr6:135055033~135060550:+ LUSC cis rs875971 0.862 rs1695820 ENSG00000226824.5 RP4-756H11.3 -10.4 6.07e-23 1.51e-19 -0.52 -0.43 Aortic root size; chr7:66379576 chr7:66654538~66669855:+ LUSC cis rs6991838 0.584 rs7841652 ENSG00000272010.1 CTD-3025N20.3 -10.4 6.08e-23 1.51e-19 -0.49 -0.43 Intelligence (multi-trait analysis); chr8:65606392 chr8:65591850~65592472:- LUSC cis rs150992 0.673 rs331549 ENSG00000248489.1 CTD-2007H13.3 -10.4 6.08e-23 1.51e-19 -0.54 -0.43 Body mass index; chr5:98805731 chr5:98929171~98995013:+ LUSC cis rs150992 0.673 rs992775 ENSG00000248489.1 CTD-2007H13.3 -10.4 6.08e-23 1.51e-19 -0.54 -0.43 Body mass index; chr5:98807754 chr5:98929171~98995013:+ LUSC cis rs150992 0.673 rs331545 ENSG00000248489.1 CTD-2007H13.3 -10.4 6.08e-23 1.51e-19 -0.54 -0.43 Body mass index; chr5:98810402 chr5:98929171~98995013:+ LUSC cis rs2929278 0.617 rs693919 ENSG00000249839.1 AC011330.5 10.4 6.19e-23 1.54e-19 0.56 0.43 Schizophrenia; chr15:43810130 chr15:43663654~43684339:- LUSC cis rs801193 0.569 rs6978178 ENSG00000226824.5 RP4-756H11.3 10.4 6.25e-23 1.55e-19 0.53 0.43 Aortic root size; chr7:66658097 chr7:66654538~66669855:+ LUSC cis rs150992 0.673 rs331934 ENSG00000248489.1 CTD-2007H13.3 -10.4 6.28e-23 1.56e-19 -0.54 -0.43 Body mass index; chr5:98804016 chr5:98929171~98995013:+ LUSC cis rs150992 0.57 rs398436 ENSG00000248489.1 CTD-2007H13.3 10.4 6.38e-23 1.58e-19 0.5 0.43 Body mass index; chr5:98991352 chr5:98929171~98995013:+ LUSC cis rs977987 0.75 rs4888406 ENSG00000261783.1 RP11-252K23.2 -10.39 6.48e-23 1.61e-19 -0.59 -0.43 Dupuytren's disease; chr16:75398436 chr16:75379818~75381260:- LUSC cis rs977987 0.778 rs2865528 ENSG00000261783.1 RP11-252K23.2 -10.39 6.49e-23 1.61e-19 -0.59 -0.43 Dupuytren's disease; chr16:75422044 chr16:75379818~75381260:- LUSC cis rs9322193 0.923 rs9371207 ENSG00000216906.2 RP11-350J20.9 10.39 6.52e-23 1.62e-19 0.52 0.43 Lung cancer; chr6:149858087 chr6:149904243~149906418:+ LUSC cis rs10129255 0.872 rs10133674 ENSG00000223648.3 IGHV3-64 10.39 6.53e-23 1.62e-19 0.39 0.43 Kawasaki disease; chr14:106692788 chr14:106643132~106658258:- LUSC cis rs3091242 0.9 rs4649086 ENSG00000261349.1 RP3-465N24.5 -10.39 6.65e-23 1.65e-19 -0.52 -0.43 Erythrocyte sedimentation rate; chr1:25452476 chr1:25266102~25267136:- LUSC cis rs10875746 0.859 rs11168371 ENSG00000240399.1 RP1-228P16.1 -10.39 6.82e-23 1.69e-19 -0.48 -0.43 Longevity (90 years and older); chr12:48043903 chr12:48054813~48055591:- LUSC cis rs875971 0.83 rs6976714 ENSG00000226824.5 RP4-756H11.3 -10.39 6.92e-23 1.71e-19 -0.52 -0.43 Aortic root size; chr7:66426474 chr7:66654538~66669855:+ LUSC cis rs10129255 0.536 rs10139058 ENSG00000211972.2 IGHV3-66 10.39 6.94e-23 1.72e-19 0.29 0.43 Kawasaki disease; chr14:106685899 chr14:106675017~106675544:- LUSC cis rs2739330 0.796 rs5760106 ENSG00000099984.9 GSTT2 10.39 6.96e-23 1.72e-19 0.52 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23980123~23983911:+ LUSC cis rs875971 0.862 rs949930 ENSG00000226824.5 RP4-756H11.3 10.38 7.05e-23 1.74e-19 0.52 0.43 Aortic root size; chr7:66301835 chr7:66654538~66669855:+ LUSC cis rs1150668 0.796 rs9468372 ENSG00000216901.1 AL022393.7 10.38 7.1e-23 1.75e-19 0.48 0.43 Pubertal anthropometrics; chr6:28411584 chr6:28176188~28176674:+ LUSC cis rs11155671 0.53 rs9371215 ENSG00000223701.3 RAET1E-AS1 10.38 7.21e-23 1.78e-19 0.48 0.43 Testicular germ cell tumor; chr6:149873162 chr6:149884431~149919508:+ LUSC cis rs10129255 0.719 rs7156660 ENSG00000223648.3 IGHV3-64 10.38 7.22e-23 1.78e-19 0.39 0.43 Kawasaki disease; chr14:106673171 chr14:106643132~106658258:- LUSC cis rs875971 0.651 rs2420596 ENSG00000226824.5 RP4-756H11.3 -10.38 7.3e-23 1.8e-19 -0.52 -0.43 Aortic root size; chr7:66450996 chr7:66654538~66669855:+ LUSC cis rs875971 0.52 rs2420597 ENSG00000226824.5 RP4-756H11.3 -10.38 7.3e-23 1.8e-19 -0.52 -0.43 Aortic root size; chr7:66450999 chr7:66654538~66669855:+ LUSC cis rs7208859 0.673 rs9915139 ENSG00000263531.1 RP13-753N3.1 10.38 7.38e-23 1.82e-19 0.73 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831497 chr17:30863921~30864940:- LUSC cis rs6782228 0.606 rs9828893 ENSG00000242551.2 POU5F1P6 -10.38 7.39e-23 1.82e-19 -0.49 -0.43 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128614082 chr3:128674735~128677005:- LUSC cis rs7208859 0.623 rs11657662 ENSG00000263531.1 RP13-753N3.1 -10.38 7.39e-23 1.82e-19 -0.76 -0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749329 chr17:30863921~30864940:- LUSC cis rs2929278 0.562 rs8033846 ENSG00000249839.1 AC011330.5 10.38 7.47e-23 1.84e-19 0.57 0.43 Schizophrenia; chr15:43743165 chr15:43663654~43684339:- LUSC cis rs17711722 1 rs17711722 ENSG00000226824.5 RP4-756H11.3 10.37 7.6e-23 1.87e-19 0.51 0.43 Calcium levels; chr7:65806210 chr7:66654538~66669855:+ LUSC cis rs977987 0.835 rs4888380 ENSG00000261783.1 RP11-252K23.2 -10.37 7.61e-23 1.87e-19 -0.59 -0.43 Dupuytren's disease; chr16:75313792 chr16:75379818~75381260:- LUSC cis rs977987 0.835 rs8057535 ENSG00000261783.1 RP11-252K23.2 -10.37 7.61e-23 1.87e-19 -0.59 -0.43 Dupuytren's disease; chr16:75314043 chr16:75379818~75381260:- LUSC cis rs977987 0.8 rs12922951 ENSG00000261783.1 RP11-252K23.2 -10.37 7.61e-23 1.87e-19 -0.59 -0.43 Dupuytren's disease; chr16:75321198 chr16:75379818~75381260:- LUSC cis rs17711722 0.675 rs6947132 ENSG00000226824.5 RP4-756H11.3 10.37 7.66e-23 1.89e-19 0.51 0.43 Calcium levels; chr7:65808508 chr7:66654538~66669855:+ LUSC cis rs17270561 0.514 rs10946805 ENSG00000272462.2 U91328.19 -10.37 7.73e-23 1.9e-19 -0.61 -0.43 Iron status biomarkers; chr6:26077663 chr6:25992662~26001775:+ LUSC cis rs875971 0.862 rs10282433 ENSG00000226824.5 RP4-756H11.3 10.37 7.76e-23 1.91e-19 0.52 0.43 Aortic root size; chr7:66256452 chr7:66654538~66669855:+ LUSC cis rs997154 0.608 rs8007089 ENSG00000279656.1 RP11-298I3.6 10.37 7.98e-23 1.96e-19 0.59 0.43 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22922704 chr14:23023083~23024217:- LUSC cis rs1150668 0.699 rs1736895 ENSG00000216901.1 AL022393.7 10.37 8.03e-23 1.98e-19 0.47 0.43 Pubertal anthropometrics; chr6:28252048 chr6:28176188~28176674:+ LUSC cis rs3091242 1 rs646867 ENSG00000261349.1 RP3-465N24.5 -10.37 8.06e-23 1.98e-19 -0.52 -0.43 Erythrocyte sedimentation rate; chr1:25382767 chr1:25266102~25267136:- LUSC cis rs11098499 0.954 rs12510138 ENSG00000245958.5 RP11-33B1.1 -10.37 8.12e-23 2e-19 -0.44 -0.43 Corneal astigmatism; chr4:119502780 chr4:119454791~119552025:+ LUSC cis rs16828019 0.777 rs3738369 ENSG00000235358.1 RP11-399E6.1 10.36 8.29e-23 2.04e-19 0.82 0.43 Intelligence (multi-trait analysis); chr1:41020736 chr1:41242373~41284861:+ LUSC cis rs977987 0.843 rs62062568 ENSG00000261783.1 RP11-252K23.2 -10.36 8.44e-23 2.07e-19 -0.59 -0.43 Dupuytren's disease; chr16:75411426 chr16:75379818~75381260:- LUSC cis rs10875746 0.951 rs2286021 ENSG00000240399.1 RP1-228P16.1 -10.36 8.49e-23 2.09e-19 -0.5 -0.43 Longevity (90 years and older); chr12:48134437 chr12:48054813~48055591:- LUSC cis rs2929278 0.617 rs12908467 ENSG00000249839.1 AC011330.5 10.36 8.62e-23 2.12e-19 0.57 0.43 Schizophrenia; chr15:43755232 chr15:43663654~43684339:- LUSC cis rs4423214 0.84 rs1629220 ENSG00000254682.1 RP11-660L16.2 -10.36 8.64e-23 2.12e-19 -0.6 -0.43 Vitamin D levels; chr11:71463507 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1792224 ENSG00000254682.1 RP11-660L16.2 -10.36 8.64e-23 2.12e-19 -0.6 -0.43 Vitamin D levels; chr11:71465095 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1792226 ENSG00000254682.1 RP11-660L16.2 -10.36 8.64e-23 2.12e-19 -0.6 -0.43 Vitamin D levels; chr11:71465528 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1790344 ENSG00000254682.1 RP11-660L16.2 -10.36 8.64e-23 2.12e-19 -0.6 -0.43 Vitamin D levels; chr11:71465851 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1790343 ENSG00000254682.1 RP11-660L16.2 -10.36 8.64e-23 2.12e-19 -0.6 -0.43 Vitamin D levels; chr11:71466161 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1792227 ENSG00000254682.1 RP11-660L16.2 -10.36 8.64e-23 2.12e-19 -0.6 -0.43 Vitamin D levels; chr11:71466366 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1790341 ENSG00000254682.1 RP11-660L16.2 -10.36 8.64e-23 2.12e-19 -0.6 -0.43 Vitamin D levels; chr11:71466532 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1540127 ENSG00000254682.1 RP11-660L16.2 -10.36 8.64e-23 2.12e-19 -0.6 -0.43 Vitamin D levels; chr11:71467992 chr11:71448674~71452157:+ LUSC cis rs977987 0.806 rs4638613 ENSG00000261783.1 RP11-252K23.2 -10.36 8.77e-23 2.15e-19 -0.58 -0.43 Dupuytren's disease; chr16:75391655 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs7188231 ENSG00000261783.1 RP11-252K23.2 -10.36 8.79e-23 2.15e-19 -0.59 -0.43 Dupuytren's disease; chr16:75402663 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs12443904 ENSG00000261783.1 RP11-252K23.2 -10.36 8.79e-23 2.15e-19 -0.59 -0.43 Dupuytren's disease; chr16:75404872 chr16:75379818~75381260:- LUSC cis rs2455601 0.786 rs3751064 ENSG00000254860.4 TMEM9B-AS1 10.36 8.82e-23 2.16e-19 0.61 0.43 Schizophrenia; chr11:8937356 chr11:8964675~8977527:+ LUSC cis rs150992 0.609 rs363929 ENSG00000248489.1 CTD-2007H13.3 10.36 8.83e-23 2.16e-19 0.51 0.43 Body mass index; chr5:98985933 chr5:98929171~98995013:+ LUSC cis rs2739330 0.703 rs5760112 ENSG00000235689.1 AP000351.13 10.36 8.85e-23 2.17e-19 0.45 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:24006305~24008258:- LUSC cis rs10129255 0.828 rs10140989 ENSG00000223648.3 IGHV3-64 10.36 8.89e-23 2.18e-19 0.4 0.43 Kawasaki disease; chr14:106668657 chr14:106643132~106658258:- LUSC cis rs73086581 0.617 rs2300213 ENSG00000229539.1 RP11-119B16.2 -10.36 8.92e-23 2.18e-19 -0.48 -0.43 Response to antidepressants in depression; chr20:4006076 chr20:3888239~3888868:- LUSC cis rs17711722 0.522 rs4642526 ENSG00000164669.11 INTS4P1 -10.36 8.95e-23 2.19e-19 -0.48 -0.43 Calcium levels; chr7:65751755 chr7:65141225~65234216:+ LUSC cis rs977987 0.843 rs62062564 ENSG00000261783.1 RP11-252K23.2 -10.35 9.1e-23 2.22e-19 -0.59 -0.43 Dupuytren's disease; chr16:75408724 chr16:75379818~75381260:- LUSC cis rs16828019 0.704 rs12024115 ENSG00000235358.1 RP11-399E6.1 10.35 9.13e-23 2.23e-19 0.76 0.43 Intelligence (multi-trait analysis); chr1:41068685 chr1:41242373~41284861:+ LUSC cis rs10875746 0.951 rs2228500 ENSG00000240399.1 RP1-228P16.1 10.35 9.21e-23 2.25e-19 0.49 0.43 Longevity (90 years and older); chr12:48132929 chr12:48054813~48055591:- LUSC cis rs2739330 0.828 rs5760108 ENSG00000099984.9 GSTT2 -10.35 9.22e-23 2.25e-19 -0.52 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23980123~23983911:+ LUSC cis rs2739330 0.76 rs5760095 ENSG00000235689.1 AP000351.13 10.35 9.24e-23 2.26e-19 0.45 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:24006305~24008258:- LUSC cis rs2739330 0.828 rs2877178 ENSG00000099984.9 GSTT2 -10.35 9.43e-23 2.3e-19 -0.53 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23980123~23983911:+ LUSC cis rs6782228 0.585 rs9841161 ENSG00000242551.2 POU5F1P6 -10.35 9.62e-23 2.34e-19 -0.49 -0.43 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613027 chr3:128674735~128677005:- LUSC cis rs6782228 0.606 rs2712405 ENSG00000242551.2 POU5F1P6 -10.35 9.62e-23 2.34e-19 -0.49 -0.43 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613239 chr3:128674735~128677005:- LUSC cis rs150992 0.609 rs393697 ENSG00000248489.1 CTD-2007H13.3 10.34 9.86e-23 2.4e-19 0.5 0.43 Body mass index; chr5:98991357 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs539024 ENSG00000248489.1 CTD-2007H13.3 10.34 9.97e-23 2.43e-19 0.5 0.43 Body mass index; chr5:98997103 chr5:98929171~98995013:+ LUSC cis rs9326248 1 rs664971 ENSG00000280143.1 AP000892.6 -10.34 1e-22 2.44e-19 -0.48 -0.43 Blood protein levels; chr11:117200141 chr11:117204967~117210292:+ LUSC cis rs992157 1 rs13429408 ENSG00000261338.2 RP11-378A13.1 10.34 1.01e-22 2.45e-19 0.44 0.43 Colorectal cancer; chr2:218278137 chr2:218255319~218257366:+ LUSC cis rs150992 0.609 rs2927648 ENSG00000248489.1 CTD-2007H13.3 10.34 1.01e-22 2.45e-19 0.5 0.43 Body mass index; chr5:98990273 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs116183885 ENSG00000248489.1 CTD-2007H13.3 10.34 1.01e-22 2.45e-19 0.5 0.43 Body mass index; chr5:98990735 chr5:98929171~98995013:+ LUSC cis rs150992 0.534 rs115121903 ENSG00000248489.1 CTD-2007H13.3 10.34 1.01e-22 2.45e-19 0.5 0.43 Body mass index; chr5:98990736 chr5:98929171~98995013:+ LUSC cis rs150992 0.592 rs2455423 ENSG00000248489.1 CTD-2007H13.3 10.34 1.01e-22 2.45e-19 0.5 0.43 Body mass index; chr5:98990844 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs559574 ENSG00000248489.1 CTD-2007H13.3 10.34 1.01e-22 2.45e-19 0.5 0.43 Body mass index; chr5:98991122 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs443726 ENSG00000248489.1 CTD-2007H13.3 10.34 1.01e-22 2.45e-19 0.5 0.43 Body mass index; chr5:98991163 chr5:98929171~98995013:+ LUSC cis rs150992 0.592 rs407562 ENSG00000248489.1 CTD-2007H13.3 10.34 1.01e-22 2.45e-19 0.5 0.43 Body mass index; chr5:98991512 chr5:98929171~98995013:+ LUSC cis rs150992 0.632 rs395668 ENSG00000248489.1 CTD-2007H13.3 10.34 1.01e-22 2.45e-19 0.5 0.43 Body mass index; chr5:98991611 chr5:98929171~98995013:+ LUSC cis rs801193 0.569 rs7800620 ENSG00000226824.5 RP4-756H11.3 -10.34 1.01e-22 2.45e-19 -0.53 -0.43 Aortic root size; chr7:66758701 chr7:66654538~66669855:+ LUSC cis rs977987 0.835 rs3863445 ENSG00000261783.1 RP11-252K23.2 -10.34 1.01e-22 2.46e-19 -0.6 -0.43 Dupuytren's disease; chr16:75337846 chr16:75379818~75381260:- LUSC cis rs9399137 0.507 rs11758774 ENSG00000232876.1 CTA-212D2.2 -10.34 1.02e-22 2.48e-19 -0.53 -0.43 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135062651 chr6:135055033~135060550:+ LUSC cis rs7188445 0.932 rs17767904 ENSG00000261390.4 RP11-345M22.2 -10.34 1.03e-22 2.49e-19 -0.59 -0.43 Urate levels; chr16:79716078 chr16:79715232~79770563:- LUSC cis rs2455601 0.786 rs2568068 ENSG00000254860.4 TMEM9B-AS1 10.34 1.03e-22 2.5e-19 0.55 0.43 Schizophrenia; chr11:8956283 chr11:8964675~8977527:+ LUSC cis rs2455601 0.766 rs1109304 ENSG00000254860.4 TMEM9B-AS1 10.34 1.04e-22 2.52e-19 0.61 0.43 Schizophrenia; chr11:8933908 chr11:8964675~8977527:+ LUSC cis rs977987 0.835 rs4888379 ENSG00000261783.1 RP11-252K23.2 -10.33 1.08e-22 2.63e-19 -0.59 -0.43 Dupuytren's disease; chr16:75306333 chr16:75379818~75381260:- LUSC cis rs7188445 0.932 rs17767742 ENSG00000261390.4 RP11-345M22.2 -10.33 1.09e-22 2.64e-19 -0.59 -0.43 Urate levels; chr16:79715108 chr16:79715232~79770563:- LUSC cis rs17711722 0.523 rs365896 ENSG00000164669.11 INTS4P1 10.33 1.1e-22 2.66e-19 0.47 0.43 Calcium levels; chr7:66045710 chr7:65141225~65234216:+ LUSC cis rs10129255 0.518 rs2006284 ENSG00000280411.1 IGHV1-69-2 -10.33 1.13e-22 2.73e-19 -0.27 -0.43 Kawasaki disease; chr14:106676185 chr14:106762092~106762588:- LUSC cis rs10875746 0.855 rs11168369 ENSG00000240399.1 RP1-228P16.1 -10.33 1.14e-22 2.76e-19 -0.5 -0.43 Longevity (90 years and older); chr12:48037385 chr12:48054813~48055591:- LUSC cis rs875971 0.522 rs1917563 ENSG00000226824.5 RP4-756H11.3 10.33 1.14e-22 2.77e-19 0.5 0.43 Aortic root size; chr7:65950660 chr7:66654538~66669855:+ LUSC cis rs2108622 0.727 rs7251296 ENSG00000267453.5 AC004791.2 -10.32 1.16e-22 2.82e-19 -0.55 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872926 chr19:15851993~15864904:- LUSC cis rs150992 0.587 rs10076291 ENSG00000248489.1 CTD-2007H13.3 -10.32 1.18e-22 2.85e-19 -0.51 -0.43 Body mass index; chr5:99012954 chr5:98929171~98995013:+ LUSC cis rs7188445 0.932 rs4575545 ENSG00000261390.4 RP11-345M22.2 -10.32 1.2e-22 2.91e-19 -0.59 -0.43 Urate levels; chr16:79721549 chr16:79715232~79770563:- LUSC cis rs992157 1 rs2168704 ENSG00000261338.2 RP11-378A13.1 10.32 1.2e-22 2.91e-19 0.43 0.43 Colorectal cancer; chr2:218277769 chr2:218255319~218257366:+ LUSC cis rs16828019 0.852 rs3820090 ENSG00000235358.1 RP11-399E6.1 10.32 1.2e-22 2.91e-19 0.79 0.43 Intelligence (multi-trait analysis); chr1:41107980 chr1:41242373~41284861:+ LUSC cis rs7208859 0.673 rs11650305 ENSG00000263531.1 RP13-753N3.1 10.32 1.22e-22 2.94e-19 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902343 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs11654914 ENSG00000263531.1 RP13-753N3.1 10.32 1.22e-22 2.94e-19 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902406 chr17:30863921~30864940:- LUSC cis rs7188445 0.871 rs8047723 ENSG00000261390.4 RP11-345M22.2 10.32 1.23e-22 2.98e-19 0.56 0.43 Urate levels; chr16:79671018 chr16:79715232~79770563:- LUSC cis rs992157 1 rs992157 ENSG00000261338.2 RP11-378A13.1 -10.32 1.24e-22 2.99e-19 -0.42 -0.43 Colorectal cancer; chr2:218290058 chr2:218255319~218257366:+ LUSC cis rs6700559 0.654 rs2809345 ENSG00000260088.1 RP11-92G12.3 10.32 1.25e-22 3.02e-19 0.51 0.43 Coronary artery disease; chr1:200627135 chr1:200669507~200694250:+ LUSC cis rs801193 0.569 rs2707824 ENSG00000226824.5 RP4-756H11.3 -10.32 1.25e-22 3.02e-19 -0.52 -0.43 Aortic root size; chr7:66724256 chr7:66654538~66669855:+ LUSC cis rs801193 0.569 rs2659893 ENSG00000226824.5 RP4-756H11.3 -10.32 1.25e-22 3.02e-19 -0.52 -0.43 Aortic root size; chr7:66735006 chr7:66654538~66669855:+ LUSC cis rs801193 0.569 rs2659892 ENSG00000226824.5 RP4-756H11.3 -10.32 1.25e-22 3.02e-19 -0.52 -0.43 Aortic root size; chr7:66735318 chr7:66654538~66669855:+ LUSC cis rs801193 0.569 rs2707847 ENSG00000226824.5 RP4-756H11.3 -10.32 1.25e-22 3.02e-19 -0.52 -0.43 Aortic root size; chr7:66737884 chr7:66654538~66669855:+ LUSC cis rs7188445 0.899 rs58722186 ENSG00000261390.4 RP11-345M22.2 -10.32 1.26e-22 3.04e-19 -0.59 -0.43 Urate levels; chr16:79717694 chr16:79715232~79770563:- LUSC cis rs9399137 0.507 rs7771310 ENSG00000232876.1 CTA-212D2.2 -10.31 1.29e-22 3.11e-19 -0.53 -0.43 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134951397 chr6:135055033~135060550:+ LUSC cis rs875971 0.862 rs6460302 ENSG00000226824.5 RP4-756H11.3 -10.31 1.29e-22 3.11e-19 -0.52 -0.43 Aortic root size; chr7:66495270 chr7:66654538~66669855:+ LUSC cis rs977987 0.933 rs4888431 ENSG00000261783.1 RP11-252K23.2 -10.31 1.31e-22 3.14e-19 -0.59 -0.43 Dupuytren's disease; chr16:75466801 chr16:75379818~75381260:- LUSC cis rs977987 1 rs62060550 ENSG00000261783.1 RP11-252K23.2 -10.31 1.31e-22 3.14e-19 -0.59 -0.43 Dupuytren's disease; chr16:75468354 chr16:75379818~75381260:- LUSC cis rs977987 0.966 rs62060551 ENSG00000261783.1 RP11-252K23.2 -10.31 1.31e-22 3.14e-19 -0.59 -0.43 Dupuytren's disease; chr16:75468414 chr16:75379818~75381260:- LUSC cis rs801193 0.548 rs2659891 ENSG00000226824.5 RP4-756H11.3 -10.31 1.32e-22 3.19e-19 -0.52 -0.43 Aortic root size; chr7:66736127 chr7:66654538~66669855:+ LUSC cis rs801193 0.548 rs7805152 ENSG00000226824.5 RP4-756H11.3 -10.31 1.32e-22 3.19e-19 -0.52 -0.43 Aortic root size; chr7:66744266 chr7:66654538~66669855:+ LUSC cis rs6538678 1 rs6538678 ENSG00000258343.1 RP11-536G4.2 -10.31 1.32e-22 3.19e-19 -0.59 -0.43 Lupus nephritis in systemic lupus erythematosus; chr12:95867790 chr12:95795345~95858839:- LUSC cis rs7208859 0.573 rs55661352 ENSG00000263531.1 RP13-753N3.1 10.31 1.33e-22 3.2e-19 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30718610 chr17:30863921~30864940:- LUSC cis rs7188445 0.932 rs7203756 ENSG00000261390.4 RP11-345M22.2 10.31 1.33e-22 3.21e-19 0.58 0.43 Urate levels; chr16:79711709 chr16:79715232~79770563:- LUSC cis rs150992 0.64 rs326485 ENSG00000248489.1 CTD-2007H13.3 10.31 1.35e-22 3.25e-19 0.52 0.43 Body mass index; chr5:98845717 chr5:98929171~98995013:+ LUSC cis rs801193 0.569 rs2659908 ENSG00000226824.5 RP4-756H11.3 -10.31 1.35e-22 3.25e-19 -0.52 -0.43 Aortic root size; chr7:66695835 chr7:66654538~66669855:+ LUSC cis rs801193 0.569 rs7782587 ENSG00000226824.5 RP4-756H11.3 -10.31 1.35e-22 3.25e-19 -0.52 -0.43 Aortic root size; chr7:66701485 chr7:66654538~66669855:+ LUSC cis rs801193 0.527 rs2707837 ENSG00000226824.5 RP4-756H11.3 -10.31 1.35e-22 3.25e-19 -0.52 -0.43 Aortic root size; chr7:66716086 chr7:66654538~66669855:+ LUSC cis rs10875746 0.855 rs12296244 ENSG00000240399.1 RP1-228P16.1 -10.31 1.37e-22 3.3e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48047696 chr12:48054813~48055591:- LUSC cis rs1501911 0.713 rs10479344 ENSG00000248489.1 CTD-2007H13.3 -10.31 1.37e-22 3.31e-19 -0.5 -0.43 Lung function (FEV1/FVC); chr5:99012676 chr5:98929171~98995013:+ LUSC cis rs10875746 0.903 rs11168414 ENSG00000240399.1 RP1-228P16.1 -10.3 1.39e-22 3.34e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48118548 chr12:48054813~48055591:- LUSC cis rs977987 0.843 rs8056080 ENSG00000261783.1 RP11-252K23.2 -10.3 1.41e-22 3.39e-19 -0.59 -0.43 Dupuytren's disease; chr16:75376900 chr16:75379818~75381260:- LUSC cis rs801193 0.569 rs4717315 ENSG00000226824.5 RP4-756H11.3 -10.3 1.43e-22 3.43e-19 -0.52 -0.43 Aortic root size; chr7:66713338 chr7:66654538~66669855:+ LUSC cis rs3091242 0.933 rs10903130 ENSG00000261349.1 RP3-465N24.5 -10.3 1.43e-22 3.45e-19 -0.51 -0.43 Erythrocyte sedimentation rate; chr1:25442730 chr1:25266102~25267136:- LUSC cis rs3091242 0.933 rs11249251 ENSG00000261349.1 RP3-465N24.5 -10.3 1.43e-22 3.45e-19 -0.51 -0.43 Erythrocyte sedimentation rate; chr1:25443697 chr1:25266102~25267136:- LUSC cis rs7104764 0.917 rs3825075 ENSG00000277290.1 RP11-326C3.16 10.3 1.44e-22 3.45e-19 0.37 0.43 Menarche (age at onset); chr11:217140 chr11:243099~243483:- LUSC cis rs801193 0.548 rs6975044 ENSG00000226824.5 RP4-756H11.3 -10.3 1.45e-22 3.48e-19 -0.53 -0.43 Aortic root size; chr7:66762495 chr7:66654538~66669855:+ LUSC cis rs16828019 0.777 rs12739052 ENSG00000235358.1 RP11-399E6.1 10.29 1.5e-22 3.6e-19 0.82 0.43 Intelligence (multi-trait analysis); chr1:40998783 chr1:41242373~41284861:+ LUSC cis rs16828019 0.777 rs12748235 ENSG00000235358.1 RP11-399E6.1 10.29 1.5e-22 3.6e-19 0.82 0.43 Intelligence (multi-trait analysis); chr1:41000549 chr1:41242373~41284861:+ LUSC cis rs2929278 0.617 rs694461 ENSG00000249839.1 AC011330.5 10.29 1.5e-22 3.6e-19 0.56 0.43 Schizophrenia; chr15:43803865 chr15:43663654~43684339:- LUSC cis rs150992 0.714 rs76798907 ENSG00000248489.1 CTD-2007H13.3 10.29 1.51e-22 3.61e-19 0.5 0.43 Body mass index; chr5:98990780 chr5:98929171~98995013:+ LUSC cis rs10875746 0.903 rs11168427 ENSG00000240399.1 RP1-228P16.1 -10.29 1.54e-22 3.7e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48145196 chr12:48054813~48055591:- LUSC cis rs10875746 0.951 rs61918826 ENSG00000240399.1 RP1-228P16.1 -10.29 1.54e-22 3.7e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48150195 chr12:48054813~48055591:- LUSC cis rs10875746 0.904 rs10875750 ENSG00000240399.1 RP1-228P16.1 -10.29 1.54e-22 3.7e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48151847 chr12:48054813~48055591:- LUSC cis rs875971 0.798 rs57739047 ENSG00000226824.5 RP4-756H11.3 -10.29 1.59e-22 3.81e-19 -0.52 -0.43 Aortic root size; chr7:66507579 chr7:66654538~66669855:+ LUSC cis rs150992 0.609 rs113868271 ENSG00000248489.1 CTD-2007H13.3 10.29 1.59e-22 3.81e-19 0.5 0.43 Body mass index; chr5:98992741 chr5:98929171~98995013:+ LUSC cis rs150992 0.631 rs112393710 ENSG00000248489.1 CTD-2007H13.3 10.29 1.59e-22 3.81e-19 0.5 0.43 Body mass index; chr5:98992761 chr5:98929171~98995013:+ LUSC cis rs150992 0.631 rs111871078 ENSG00000248489.1 CTD-2007H13.3 10.29 1.59e-22 3.81e-19 0.5 0.43 Body mass index; chr5:98992766 chr5:98929171~98995013:+ LUSC cis rs801193 0.569 rs11761542 ENSG00000226824.5 RP4-756H11.3 -10.29 1.6e-22 3.82e-19 -0.52 -0.43 Aortic root size; chr7:66753209 chr7:66654538~66669855:+ LUSC cis rs1150668 0.764 rs9368565 ENSG00000216901.1 AL022393.7 -10.29 1.6e-22 3.83e-19 -0.48 -0.43 Pubertal anthropometrics; chr6:28377433 chr6:28176188~28176674:+ LUSC cis rs1150668 0.796 rs1052215 ENSG00000216901.1 AL022393.7 -10.29 1.6e-22 3.83e-19 -0.48 -0.43 Pubertal anthropometrics; chr6:28380381 chr6:28176188~28176674:+ LUSC cis rs875971 0.755 rs76288834 ENSG00000226824.5 RP4-756H11.3 10.29 1.6e-22 3.83e-19 0.52 0.43 Aortic root size; chr7:66604815 chr7:66654538~66669855:+ LUSC cis rs150992 0.678 rs161950 ENSG00000248489.1 CTD-2007H13.3 -10.29 1.63e-22 3.89e-19 -0.5 -0.43 Body mass index; chr5:98924533 chr5:98929171~98995013:+ LUSC cis rs4774565 0.762 rs34565064 ENSG00000244879.4 GABPB1-AS1 -10.29 1.63e-22 3.89e-19 -0.39 -0.43 Breast cancer; chr15:50371706 chr15:50354959~50372202:+ LUSC cis rs3091242 0.933 rs35497030 ENSG00000261349.1 RP3-465N24.5 10.28 1.64e-22 3.93e-19 0.52 0.43 Erythrocyte sedimentation rate; chr1:25456575 chr1:25266102~25267136:- LUSC cis rs875971 0.83 rs6950137 ENSG00000226824.5 RP4-756H11.3 -10.28 1.65e-22 3.95e-19 -0.52 -0.43 Aortic root size; chr7:66511623 chr7:66654538~66669855:+ LUSC cis rs6991838 0.584 rs14213 ENSG00000272010.1 CTD-3025N20.3 10.28 1.65e-22 3.95e-19 0.49 0.43 Intelligence (multi-trait analysis); chr8:65602719 chr8:65591850~65592472:- LUSC cis rs150992 0.609 rs2937709 ENSG00000248489.1 CTD-2007H13.3 10.28 1.66e-22 3.95e-19 0.5 0.43 Body mass index; chr5:98993120 chr5:98929171~98995013:+ LUSC cis rs150992 0.632 rs1104262 ENSG00000248489.1 CTD-2007H13.3 10.28 1.66e-22 3.95e-19 0.5 0.43 Body mass index; chr5:98993145 chr5:98929171~98995013:+ LUSC cis rs3091242 0.933 rs34006994 ENSG00000261349.1 RP3-465N24.5 10.28 1.66e-22 3.97e-19 0.52 0.43 Erythrocyte sedimentation rate; chr1:25454177 chr1:25266102~25267136:- LUSC cis rs3091242 0.933 rs61775167 ENSG00000261349.1 RP3-465N24.5 10.28 1.66e-22 3.97e-19 0.52 0.43 Erythrocyte sedimentation rate; chr1:25454402 chr1:25266102~25267136:- LUSC cis rs2929278 0.589 rs11638972 ENSG00000249839.1 AC011330.5 10.28 1.69e-22 4.02e-19 0.56 0.43 Schizophrenia; chr15:43782493 chr15:43663654~43684339:- LUSC cis rs801193 0.569 rs11772819 ENSG00000226824.5 RP4-756H11.3 -10.28 1.69e-22 4.03e-19 -0.52 -0.43 Aortic root size; chr7:66752983 chr7:66654538~66669855:+ LUSC cis rs977987 0.843 rs11149820 ENSG00000261783.1 RP11-252K23.2 -10.28 1.7e-22 4.05e-19 -0.58 -0.43 Dupuytren's disease; chr16:75388862 chr16:75379818~75381260:- LUSC cis rs977987 0.843 rs10514396 ENSG00000261783.1 RP11-252K23.2 -10.28 1.7e-22 4.05e-19 -0.58 -0.43 Dupuytren's disease; chr16:75389005 chr16:75379818~75381260:- LUSC cis rs150992 0.609 rs77892628 ENSG00000248489.1 CTD-2007H13.3 10.28 1.7e-22 4.06e-19 0.5 0.43 Body mass index; chr5:98990624 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs77231989 ENSG00000248489.1 CTD-2007H13.3 10.28 1.7e-22 4.06e-19 0.5 0.43 Body mass index; chr5:98990650 chr5:98929171~98995013:+ LUSC cis rs150992 0.631 rs79191251 ENSG00000248489.1 CTD-2007H13.3 10.28 1.7e-22 4.06e-19 0.5 0.43 Body mass index; chr5:98990680 chr5:98929171~98995013:+ LUSC cis rs977987 0.741 rs10514393 ENSG00000261783.1 RP11-252K23.2 -10.28 1.73e-22 4.11e-19 -0.59 -0.43 Dupuytren's disease; chr16:75310578 chr16:75379818~75381260:- LUSC cis rs9399137 0.507 rs4520025 ENSG00000232876.1 CTA-212D2.2 -10.28 1.74e-22 4.14e-19 -0.52 -0.43 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134957481 chr6:135055033~135060550:+ LUSC cis rs977987 0.815 rs11646677 ENSG00000261783.1 RP11-252K23.2 -10.28 1.75e-22 4.17e-19 -0.58 -0.43 Dupuytren's disease; chr16:75375083 chr16:75379818~75381260:- LUSC cis rs801193 0.569 rs35070132 ENSG00000226824.5 RP4-756H11.3 -10.28 1.76e-22 4.2e-19 -0.53 -0.43 Aortic root size; chr7:66773096 chr7:66654538~66669855:+ LUSC cis rs875971 0.767 rs1643394 ENSG00000226824.5 RP4-756H11.3 -10.28 1.77e-22 4.21e-19 -0.52 -0.43 Aortic root size; chr7:66371107 chr7:66654538~66669855:+ LUSC cis rs7188445 0.932 rs73575095 ENSG00000261390.4 RP11-345M22.2 -10.27 1.78e-22 4.25e-19 -0.58 -0.43 Urate levels; chr16:79716435 chr16:79715232~79770563:- LUSC cis rs992157 0.965 rs62182826 ENSG00000261338.2 RP11-378A13.1 10.27 1.81e-22 4.31e-19 0.43 0.43 Colorectal cancer; chr2:218284000 chr2:218255319~218257366:+ LUSC cis rs16828019 0.777 rs12047078 ENSG00000235358.1 RP11-399E6.1 10.27 1.82e-22 4.33e-19 0.82 0.43 Intelligence (multi-trait analysis); chr1:40997314 chr1:41242373~41284861:+ LUSC cis rs875971 0.862 rs28470208 ENSG00000226824.5 RP4-756H11.3 10.27 1.86e-22 4.42e-19 0.51 0.43 Aortic root size; chr7:66119713 chr7:66654538~66669855:+ LUSC cis rs10875746 0.951 rs10875747 ENSG00000240399.1 RP1-228P16.1 -10.27 1.86e-22 4.43e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48132078 chr12:48054813~48055591:- LUSC cis rs17711722 0.523 rs313812 ENSG00000164669.11 INTS4P1 10.27 1.88e-22 4.48e-19 0.47 0.43 Calcium levels; chr7:66040056 chr7:65141225~65234216:+ LUSC cis rs7115242 0.858 rs6589592 ENSG00000254851.1 RP11-109L13.1 -10.27 1.9e-22 4.52e-19 -0.96 -0.43 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117087191 chr11:117135528~117138582:+ LUSC cis rs6782228 0.565 rs67445542 ENSG00000242551.2 POU5F1P6 -10.27 1.92e-22 4.56e-19 -0.48 -0.43 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611683 chr3:128674735~128677005:- LUSC cis rs11155671 0.53 rs4870080 ENSG00000223701.3 RAET1E-AS1 10.26 2e-22 4.74e-19 0.48 0.43 Testicular germ cell tumor; chr6:149881508 chr6:149884431~149919508:+ LUSC cis rs17826219 0.706 rs8075357 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Body mass index; chr17:30730179 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs59447372 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30730567 chr17:30863921~30864940:- LUSC cis rs17826219 0.706 rs61643715 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Body mass index; chr17:30730744 chr17:30863921~30864940:- LUSC cis rs17826219 0.636 rs8080829 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Body mass index; chr17:30731712 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs8079891 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30731845 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs73267858 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732719 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs56018041 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732967 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs56095789 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733152 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11656844 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733579 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11652533 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733583 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11652631 ENSG00000263531.1 RP13-753N3.1 10.26 2.01e-22 4.76e-19 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733748 chr17:30863921~30864940:- LUSC cis rs9326248 1 rs3736120 ENSG00000280143.1 AP000892.6 10.26 2.05e-22 4.86e-19 0.48 0.43 Blood protein levels; chr11:117161409 chr11:117204967~117210292:+ LUSC cis rs2739330 0.796 rs1006771 ENSG00000250470.1 AP000351.3 10.26 2.05e-22 4.86e-19 0.61 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23976904~23977585:- LUSC cis rs1150668 0.699 rs12214383 ENSG00000216901.1 AL022393.7 -10.26 2.09e-22 4.95e-19 -0.46 -0.43 Pubertal anthropometrics; chr6:28255953 chr6:28176188~28176674:+ LUSC cis rs977987 0.872 rs1559339 ENSG00000261783.1 RP11-252K23.2 -10.25 2.13e-22 5.04e-19 -0.57 -0.43 Dupuytren's disease; chr16:75284748 chr16:75379818~75381260:- LUSC cis rs150992 0.609 rs2927654 ENSG00000248489.1 CTD-2007H13.3 10.25 2.18e-22 5.15e-19 0.5 0.43 Body mass index; chr5:98993195 chr5:98929171~98995013:+ LUSC cis rs2455601 0.744 rs11042133 ENSG00000254860.4 TMEM9B-AS1 10.25 2.2e-22 5.21e-19 0.6 0.43 Schizophrenia; chr11:8944964 chr11:8964675~8977527:+ LUSC cis rs977987 0.872 rs4243111 ENSG00000261783.1 RP11-252K23.2 -10.25 2.21e-22 5.22e-19 -0.58 -0.43 Dupuytren's disease; chr16:75286929 chr16:75379818~75381260:- LUSC cis rs1185460 0.967 rs3825061 ENSG00000271751.1 RP11-110I1.14 -10.25 2.22e-22 5.25e-19 -0.56 -0.43 Coronary artery disease; chr11:119073965 chr11:119065263~119065677:- LUSC cis rs35955747 0.659 rs11704494 ENSG00000236132.1 CTA-440B3.1 10.25 2.23e-22 5.26e-19 0.52 0.43 Neutrophil count;Sum basophil neutrophil counts; chr22:31517285 chr22:31816379~31817491:- LUSC cis rs10875746 0.951 rs10875748 ENSG00000240399.1 RP1-228P16.1 -10.25 2.26e-22 5.35e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48132577 chr12:48054813~48055591:- LUSC cis rs9399135 0.773 rs949895 ENSG00000232876.1 CTA-212D2.2 -10.24 2.29e-22 5.4e-19 -0.51 -0.43 Red blood cell count; chr6:135084221 chr6:135055033~135060550:+ LUSC cis rs875971 0.862 rs6944374 ENSG00000226824.5 RP4-756H11.3 10.24 2.32e-22 5.47e-19 0.51 0.43 Aortic root size; chr7:66221942 chr7:66654538~66669855:+ LUSC cis rs992157 0.965 rs13427681 ENSG00000261338.2 RP11-378A13.1 10.24 2.33e-22 5.49e-19 0.44 0.43 Colorectal cancer; chr2:218302840 chr2:218255319~218257366:+ LUSC cis rs977987 0.843 rs35737321 ENSG00000261783.1 RP11-252K23.2 -10.24 2.38e-22 5.61e-19 -0.59 -0.43 Dupuytren's disease; chr16:75405287 chr16:75379818~75381260:- LUSC cis rs150992 0.79 rs325220 ENSG00000248489.1 CTD-2007H13.3 10.24 2.39e-22 5.63e-19 0.51 0.43 Body mass index; chr5:98968860 chr5:98929171~98995013:+ LUSC cis rs10875746 0.951 rs7485355 ENSG00000240399.1 RP1-228P16.1 -10.24 2.41e-22 5.68e-19 -0.5 -0.43 Longevity (90 years and older); chr12:48154559 chr12:48054813~48055591:- LUSC cis rs875971 0.522 rs1617484 ENSG00000226824.5 RP4-756H11.3 -10.24 2.42e-22 5.69e-19 -0.51 -0.43 Aortic root size; chr7:65998108 chr7:66654538~66669855:+ LUSC cis rs7188445 0.899 rs57652769 ENSG00000261390.4 RP11-345M22.2 -10.24 2.42e-22 5.69e-19 -0.58 -0.43 Urate levels; chr16:79720079 chr16:79715232~79770563:- LUSC cis rs950027 0.967 rs2643718 ENSG00000259520.4 CTD-2651B20.3 -10.24 2.43e-22 5.72e-19 -0.51 -0.43 Response to fenofibrate (adiponectin levels); chr15:45502464 chr15:45251580~45279251:- LUSC cis rs977987 0.762 rs1364079 ENSG00000261783.1 RP11-252K23.2 -10.23 2.49e-22 5.85e-19 -0.58 -0.43 Dupuytren's disease; chr16:75359233 chr16:75379818~75381260:- LUSC cis rs875971 0.862 rs6964437 ENSG00000226824.5 RP4-756H11.3 10.23 2.52e-22 5.92e-19 0.51 0.43 Aortic root size; chr7:66221457 chr7:66654538~66669855:+ LUSC cis rs875971 0.755 rs10228885 ENSG00000226824.5 RP4-756H11.3 10.23 2.52e-22 5.92e-19 0.52 0.43 Aortic root size; chr7:66315542 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs3893216 ENSG00000226824.5 RP4-756H11.3 10.23 2.52e-22 5.92e-19 0.52 0.43 Aortic root size; chr7:66325720 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6958294 ENSG00000226824.5 RP4-756H11.3 10.23 2.52e-22 5.92e-19 0.52 0.43 Aortic root size; chr7:66329809 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs2088655 ENSG00000226824.5 RP4-756H11.3 10.23 2.52e-22 5.92e-19 0.52 0.43 Aortic root size; chr7:66330724 chr7:66654538~66669855:+ LUSC cis rs875971 0.895 rs10447522 ENSG00000226824.5 RP4-756H11.3 10.23 2.52e-22 5.92e-19 0.52 0.43 Aortic root size; chr7:66331087 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs2088653 ENSG00000226824.5 RP4-756H11.3 10.23 2.52e-22 5.92e-19 0.52 0.43 Aortic root size; chr7:66343621 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6460293 ENSG00000226824.5 RP4-756H11.3 10.23 2.52e-22 5.92e-19 0.52 0.43 Aortic root size; chr7:66345205 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs778736 ENSG00000226824.5 RP4-756H11.3 -10.23 2.52e-22 5.92e-19 -0.52 -0.43 Aortic root size; chr7:66348861 chr7:66654538~66669855:+ LUSC cis rs977987 0.843 rs7499872 ENSG00000261783.1 RP11-252K23.2 -10.23 2.55e-22 5.98e-19 -0.58 -0.43 Dupuytren's disease; chr16:75392631 chr16:75379818~75381260:- LUSC cis rs977987 0.806 rs4887818 ENSG00000261783.1 RP11-252K23.2 -10.23 2.57e-22 6.04e-19 -0.58 -0.43 Dupuytren's disease; chr16:75328097 chr16:75379818~75381260:- LUSC cis rs10129255 0.833 rs61997797 ENSG00000223648.3 IGHV3-64 10.23 2.6e-22 6.1e-19 0.39 0.43 Kawasaki disease; chr14:106815190 chr14:106643132~106658258:- LUSC cis rs977987 0.843 rs4146810 ENSG00000261783.1 RP11-252K23.2 -10.23 2.6e-22 6.11e-19 -0.58 -0.43 Dupuytren's disease; chr16:75381933 chr16:75379818~75381260:- LUSC cis rs1501911 0.53 rs331926 ENSG00000248489.1 CTD-2007H13.3 10.23 2.61e-22 6.11e-19 0.52 0.43 Lung function (FEV1/FVC); chr5:98828697 chr5:98929171~98995013:+ LUSC cis rs2929278 0.617 rs3087657 ENSG00000249839.1 AC011330.5 -10.23 2.61e-22 6.11e-19 -0.55 -0.43 Schizophrenia; chr15:43771661 chr15:43663654~43684339:- LUSC cis rs9326248 0.954 rs4938349 ENSG00000280143.1 AP000892.6 10.23 2.63e-22 6.15e-19 0.48 0.43 Blood protein levels; chr11:117151207 chr11:117204967~117210292:+ LUSC cis rs10129255 0.833 rs7156689 ENSG00000223648.3 IGHV3-64 10.22 2.77e-22 6.48e-19 0.39 0.43 Kawasaki disease; chr14:106816039 chr14:106643132~106658258:- LUSC cis rs6991838 0.53 rs6472217 ENSG00000272010.1 CTD-3025N20.3 10.22 2.79e-22 6.52e-19 0.48 0.43 Intelligence (multi-trait analysis); chr8:65635496 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs6472218 ENSG00000272010.1 CTD-3025N20.3 10.22 2.79e-22 6.52e-19 0.48 0.43 Intelligence (multi-trait analysis); chr8:65635502 chr8:65591850~65592472:- LUSC cis rs3091242 0.933 rs10903129 ENSG00000261349.1 RP3-465N24.5 -10.22 2.83e-22 6.62e-19 -0.51 -0.43 Erythrocyte sedimentation rate; chr1:25442446 chr1:25266102~25267136:- LUSC cis rs16828019 0.777 rs13376450 ENSG00000235358.1 RP11-399E6.1 10.22 2.86e-22 6.68e-19 0.79 0.43 Intelligence (multi-trait analysis); chr1:41003371 chr1:41242373~41284861:+ LUSC cis rs9322193 0.923 rs12660304 ENSG00000216906.2 RP11-350J20.9 10.22 2.88e-22 6.73e-19 0.51 0.43 Lung cancer; chr6:149739647 chr6:149904243~149906418:+ LUSC cis rs992157 1 rs4674280 ENSG00000261338.2 RP11-378A13.1 -10.22 2.92e-22 6.83e-19 -0.44 -0.43 Colorectal cancer; chr2:218276735 chr2:218255319~218257366:+ LUSC cis rs875971 0.54 rs1723268 ENSG00000226824.5 RP4-756H11.3 -10.22 2.92e-22 6.83e-19 -0.5 -0.43 Aortic root size; chr7:66008093 chr7:66654538~66669855:+ LUSC cis rs7617773 0.925 rs6442105 ENSG00000229759.1 MRPS18AP1 -10.21 2.96e-22 6.91e-19 -0.43 -0.43 Coronary artery disease; chr3:48140836 chr3:48256350~48256938:- LUSC cis rs9322193 0.923 rs9766037 ENSG00000216906.2 RP11-350J20.9 10.21 2.96e-22 6.92e-19 0.5 0.43 Lung cancer; chr6:149616921 chr6:149904243~149906418:+ LUSC cis rs17711722 0.727 rs2658585 ENSG00000226824.5 RP4-756H11.3 -10.21 2.98e-22 6.95e-19 -0.5 -0.43 Calcium levels; chr7:65996954 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs11763189 ENSG00000226824.5 RP4-756H11.3 -10.21 3e-22 7.01e-19 -0.51 -0.43 Aortic root size; chr7:66518542 chr7:66654538~66669855:+ LUSC cis rs992157 0.932 rs56109829 ENSG00000261338.2 RP11-378A13.1 10.21 3.06e-22 7.13e-19 0.43 0.43 Colorectal cancer; chr2:218285017 chr2:218255319~218257366:+ LUSC cis rs12439619 1 rs12439619 ENSG00000255769.6 GOLGA2P10 -10.21 3.1e-22 7.21e-19 -0.53 -0.43 Intelligence (multi-trait analysis); chr15:82254605 chr15:82472993~82513950:- LUSC cis rs875971 0.862 rs3926380 ENSG00000226824.5 RP4-756H11.3 10.21 3.12e-22 7.27e-19 0.51 0.43 Aortic root size; chr7:66615658 chr7:66654538~66669855:+ LUSC cis rs875971 0.825 rs1860472 ENSG00000226824.5 RP4-756H11.3 10.21 3.12e-22 7.27e-19 0.51 0.43 Aortic root size; chr7:66617736 chr7:66654538~66669855:+ LUSC cis rs16828019 0.632 rs12749196 ENSG00000235358.1 RP11-399E6.1 10.21 3.14e-22 7.3e-19 0.82 0.43 Intelligence (multi-trait analysis); chr1:40995111 chr1:41242373~41284861:+ LUSC cis rs16828019 0.777 rs12047657 ENSG00000235358.1 RP11-399E6.1 10.21 3.14e-22 7.3e-19 0.82 0.43 Intelligence (multi-trait analysis); chr1:40995841 chr1:41242373~41284861:+ LUSC cis rs16828019 0.85 rs12027691 ENSG00000235358.1 RP11-399E6.1 10.21 3.14e-22 7.3e-19 0.82 0.43 Intelligence (multi-trait analysis); chr1:40996360 chr1:41242373~41284861:+ LUSC cis rs875971 0.862 rs1167390 ENSG00000226824.5 RP4-756H11.3 10.21 3.14e-22 7.31e-19 0.51 0.43 Aortic root size; chr7:66110906 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs35034167 ENSG00000226824.5 RP4-756H11.3 10.21 3.14e-22 7.31e-19 0.51 0.43 Aortic root size; chr7:66115179 chr7:66654538~66669855:+ LUSC cis rs2455601 0.786 rs11042127 ENSG00000254860.4 TMEM9B-AS1 10.21 3.16e-22 7.35e-19 0.61 0.43 Schizophrenia; chr11:8926039 chr11:8964675~8977527:+ LUSC cis rs172166 0.561 rs149976 ENSG00000204709.4 LINC01556 -10.21 3.17e-22 7.37e-19 -0.5 -0.43 Cardiac Troponin-T levels; chr6:28019998 chr6:28943877~28944537:+ LUSC cis rs3931020 1 rs10874122 ENSG00000272864.1 RP11-17E13.2 -10.21 3.18e-22 7.4e-19 -0.53 -0.43 Resistin levels; chr1:74770182 chr1:74698769~74699333:- LUSC cis rs1799949 0.965 rs8176198 ENSG00000198496.9 NBR2 -10.2 3.21e-22 7.46e-19 -0.44 -0.43 Menopause (age at onset); chr17:43078520 chr17:43125610~43153671:+ LUSC cis rs7208859 0.573 rs56031503 ENSG00000263531.1 RP13-753N3.1 10.2 3.22e-22 7.49e-19 0.75 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30863921~30864940:- LUSC cis rs6782228 0.585 rs2712392 ENSG00000242551.2 POU5F1P6 -10.2 3.22e-22 7.5e-19 -0.5 -0.43 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128705414 chr3:128674735~128677005:- LUSC cis rs11155671 0.53 rs9397398 ENSG00000223701.3 RAET1E-AS1 10.2 3.29e-22 7.64e-19 0.47 0.43 Testicular germ cell tumor; chr6:149872467 chr6:149884431~149919508:+ LUSC cis rs3091242 0.933 rs61775174 ENSG00000261349.1 RP3-465N24.5 10.2 3.29e-22 7.65e-19 0.52 0.43 Erythrocyte sedimentation rate; chr1:25460822 chr1:25266102~25267136:- LUSC cis rs875971 0.862 rs1612452 ENSG00000226824.5 RP4-756H11.3 10.19 3.51e-22 8.14e-19 0.51 0.43 Aortic root size; chr7:66108909 chr7:66654538~66669855:+ LUSC cis rs10875746 0.951 rs4760689 ENSG00000240399.1 RP1-228P16.1 -10.19 3.51e-22 8.15e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48169861 chr12:48054813~48055591:- LUSC cis rs10875746 0.951 rs58865997 ENSG00000240399.1 RP1-228P16.1 -10.19 3.51e-22 8.15e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48173090 chr12:48054813~48055591:- LUSC cis rs875971 0.789 rs7808013 ENSG00000226824.5 RP4-756H11.3 10.19 3.53e-22 8.18e-19 0.51 0.43 Aortic root size; chr7:66606209 chr7:66654538~66669855:+ LUSC cis rs2487048 0.804 rs2472496 ENSG00000226334.1 RP11-217B7.2 -10.19 3.61e-22 8.37e-19 -0.51 -0.43 Intraocular pressure; chr9:104933072 chr9:104927553~104928892:+ LUSC cis rs9399135 0.773 rs1331308 ENSG00000232876.1 CTA-212D2.2 10.19 3.62e-22 8.39e-19 0.5 0.43 Red blood cell count; chr6:135083984 chr6:135055033~135060550:+ LUSC cis rs977987 0.843 rs17696749 ENSG00000261783.1 RP11-252K23.2 -10.19 3.67e-22 8.5e-19 -0.58 -0.43 Dupuytren's disease; chr16:75369164 chr16:75379818~75381260:- LUSC cis rs977987 0.966 rs8055490 ENSG00000261783.1 RP11-252K23.2 -10.19 3.7e-22 8.56e-19 -0.59 -0.43 Dupuytren's disease; chr16:75463237 chr16:75379818~75381260:- LUSC cis rs67383717 0.672 rs589458 ENSG00000175611.10 LINC00476 10.19 3.74e-22 8.65e-19 0.46 0.43 Parkinson's disease (pesticide exposure interaction); chr9:95878389 chr9:95759231~95875977:- LUSC cis rs6782228 0.606 rs4634140 ENSG00000242551.2 POU5F1P6 10.19 3.79e-22 8.77e-19 0.5 0.43 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128705613 chr3:128674735~128677005:- LUSC cis rs9322193 0.504 rs7771014 ENSG00000223701.3 RAET1E-AS1 10.18 3.8e-22 8.79e-19 0.48 0.43 Lung cancer; chr6:149884310 chr6:149884431~149919508:+ LUSC cis rs875971 0.862 rs6460282 ENSG00000226824.5 RP4-756H11.3 10.18 3.81e-22 8.81e-19 0.51 0.43 Aortic root size; chr7:66226259 chr7:66654538~66669855:+ LUSC cis rs7104764 0.833 rs12574034 ENSG00000277290.1 RP11-326C3.16 10.18 3.89e-22 8.99e-19 0.38 0.43 Menarche (age at onset); chr11:212262 chr11:243099~243483:- LUSC cis rs10875746 0.903 rs3782911 ENSG00000240399.1 RP1-228P16.1 -10.18 3.9e-22 9.01e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48089709 chr12:48054813~48055591:- LUSC cis rs10875746 0.859 rs3782910 ENSG00000240399.1 RP1-228P16.1 -10.18 3.9e-22 9.01e-19 -0.49 -0.43 Longevity (90 years and older); chr12:48089724 chr12:48054813~48055591:- LUSC cis rs875971 0.862 rs10250544 ENSG00000226824.5 RP4-756H11.3 10.18 3.92e-22 9.04e-19 0.51 0.43 Aortic root size; chr7:66301574 chr7:66654538~66669855:+ LUSC cis rs977987 0.835 rs8046109 ENSG00000261783.1 RP11-252K23.2 -10.18 3.92e-22 9.05e-19 -0.57 -0.43 Dupuytren's disease; chr16:75326198 chr16:75379818~75381260:- LUSC cis rs2929278 0.617 rs663214 ENSG00000249839.1 AC011330.5 10.18 3.93e-22 9.08e-19 0.57 0.43 Schizophrenia; chr15:43821584 chr15:43663654~43684339:- LUSC cis rs875971 0.79 rs10257911 ENSG00000226824.5 RP4-756H11.3 10.18 3.99e-22 9.19e-19 0.51 0.43 Aortic root size; chr7:66278783 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6971059 ENSG00000226824.5 RP4-756H11.3 10.18 4.06e-22 9.36e-19 0.51 0.42 Aortic root size; chr7:66602045 chr7:66654538~66669855:+ LUSC cis rs875971 0.825 rs66981195 ENSG00000226824.5 RP4-756H11.3 10.18 4.06e-22 9.36e-19 0.51 0.42 Aortic root size; chr7:66614048 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs1875057 ENSG00000226824.5 RP4-756H11.3 10.18 4.07e-22 9.36e-19 0.51 0.42 Aortic root size; chr7:66266868 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6960446 ENSG00000226824.5 RP4-756H11.3 10.18 4.07e-22 9.36e-19 0.51 0.42 Aortic root size; chr7:66268272 chr7:66654538~66669855:+ LUSC cis rs875971 0.789 rs10260426 ENSG00000226824.5 RP4-756H11.3 10.18 4.07e-22 9.36e-19 0.51 0.42 Aortic root size; chr7:66271055 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs10263690 ENSG00000226824.5 RP4-756H11.3 10.18 4.07e-22 9.36e-19 0.51 0.42 Aortic root size; chr7:66301466 chr7:66654538~66669855:+ LUSC cis rs17507216 1 rs3850610 ENSG00000278603.1 RP13-608F4.5 -10.17 4.13e-22 9.5e-19 -0.57 -0.42 Excessive daytime sleepiness; chr15:82552642 chr15:82472203~82472426:+ LUSC cis rs150992 0.593 rs326491 ENSG00000248489.1 CTD-2007H13.3 10.17 4.14e-22 9.52e-19 0.49 0.42 Body mass index; chr5:98972225 chr5:98929171~98995013:+ LUSC cis rs150992 0.711 rs161735 ENSG00000248489.1 CTD-2007H13.3 10.17 4.24e-22 9.74e-19 0.54 0.42 Body mass index; chr5:98862026 chr5:98929171~98995013:+ LUSC cis rs9399137 0.561 rs11753985 ENSG00000232876.1 CTA-212D2.2 -10.17 4.26e-22 9.78e-19 -0.53 -0.42 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134959300 chr6:135055033~135060550:+ LUSC cis rs150992 0.721 rs2937706 ENSG00000248489.1 CTD-2007H13.3 10.17 4.27e-22 9.82e-19 0.5 0.42 Body mass index; chr5:98990434 chr5:98929171~98995013:+ LUSC cis rs10256972 0.681 rs6979076 ENSG00000229043.2 AC091729.9 10.17 4.28e-22 9.83e-19 0.5 0.42 Endometriosis;Longevity; chr7:1076611 chr7:1160374~1165267:+ LUSC cis rs875971 0.895 rs12531677 ENSG00000226824.5 RP4-756H11.3 10.17 4.29e-22 9.86e-19 0.51 0.42 Aortic root size; chr7:66304099 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs7798630 ENSG00000226824.5 RP4-756H11.3 10.17 4.29e-22 9.86e-19 0.51 0.42 Aortic root size; chr7:66306492 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs11984115 ENSG00000226824.5 RP4-756H11.3 10.17 4.29e-22 9.86e-19 0.51 0.42 Aortic root size; chr7:66308872 chr7:66654538~66669855:+ LUSC cis rs875971 0.825 rs7384021 ENSG00000226824.5 RP4-756H11.3 10.17 4.3e-22 9.88e-19 0.51 0.42 Aortic root size; chr7:66612917 chr7:66654538~66669855:+ LUSC cis rs2929278 0.617 rs575082 ENSG00000249839.1 AC011330.5 10.17 4.42e-22 1.01e-18 0.57 0.42 Schizophrenia; chr15:43817944 chr15:43663654~43684339:- LUSC cis rs875971 0.862 rs6952182 ENSG00000226824.5 RP4-756H11.3 10.17 4.43e-22 1.02e-18 0.51 0.42 Aortic root size; chr7:66218330 chr7:66654538~66669855:+ LUSC cis rs73086581 0.592 rs2300217 ENSG00000229539.1 RP11-119B16.2 10.17 4.45e-22 1.02e-18 0.46 0.42 Response to antidepressants in depression; chr20:3957928 chr20:3888239~3888868:- LUSC cis rs7208859 0.673 rs12949860 ENSG00000263531.1 RP13-753N3.1 10.17 4.47e-22 1.02e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896014 chr17:30863921~30864940:- LUSC cis rs35955747 0.714 rs5997989 ENSG00000236132.1 CTA-440B3.1 10.16 4.58e-22 1.05e-18 0.52 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31443964 chr22:31816379~31817491:- LUSC cis rs9487094 0.689 rs9480949 ENSG00000260273.1 RP11-425D10.10 10.16 4.62e-22 1.06e-18 0.5 0.42 Height; chr6:109407238 chr6:109382795~109383666:+ LUSC cis rs748404 0.588 rs2255410 ENSG00000249839.1 AC011330.5 -10.16 4.64e-22 1.06e-18 -0.57 -0.42 Lung cancer; chr15:43538899 chr15:43663654~43684339:- LUSC cis rs10875746 0.951 rs8804 ENSG00000240399.1 RP1-228P16.1 -10.16 4.71e-22 1.08e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48147974 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs11168401 ENSG00000240399.1 RP1-228P16.1 -10.16 4.71e-22 1.08e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48087736 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs12304476 ENSG00000240399.1 RP1-228P16.1 -10.16 4.71e-22 1.08e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48088370 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs12306451 ENSG00000240399.1 RP1-228P16.1 -10.16 4.71e-22 1.08e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48089458 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs989144 ENSG00000240399.1 RP1-228P16.1 -10.16 4.71e-22 1.08e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48090190 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs61918806 ENSG00000240399.1 RP1-228P16.1 -10.16 4.71e-22 1.08e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48090650 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs11168403 ENSG00000240399.1 RP1-228P16.1 -10.16 4.71e-22 1.08e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48091175 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs10875740 ENSG00000240399.1 RP1-228P16.1 -10.16 4.71e-22 1.08e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48095334 chr12:48054813~48055591:- LUSC cis rs17270561 0.562 rs12199626 ENSG00000272462.2 U91328.19 -10.16 4.78e-22 1.09e-18 -0.62 -0.42 Iron status biomarkers; chr6:26013376 chr6:25992662~26001775:+ LUSC cis rs2455601 0.786 rs3763914 ENSG00000254860.4 TMEM9B-AS1 10.16 4.81e-22 1.1e-18 0.59 0.42 Schizophrenia; chr11:8919156 chr11:8964675~8977527:+ LUSC cis rs875971 0.895 rs6460278 ENSG00000226824.5 RP4-756H11.3 10.16 4.83e-22 1.11e-18 0.51 0.42 Aortic root size; chr7:66197749 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6460279 ENSG00000226824.5 RP4-756H11.3 10.16 4.83e-22 1.11e-18 0.51 0.42 Aortic root size; chr7:66197774 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs28491091 ENSG00000226824.5 RP4-756H11.3 10.16 4.83e-22 1.11e-18 0.51 0.42 Aortic root size; chr7:66204077 chr7:66654538~66669855:+ LUSC cis rs11155671 0.53 rs1334510 ENSG00000223701.3 RAET1E-AS1 10.15 4.91e-22 1.12e-18 0.47 0.42 Testicular germ cell tumor; chr6:149880043 chr6:149884431~149919508:+ LUSC cis rs150992 0.587 rs12189335 ENSG00000248489.1 CTD-2007H13.3 -10.15 4.93e-22 1.13e-18 -0.49 -0.42 Body mass index; chr5:99009311 chr5:98929171~98995013:+ LUSC cis rs9326248 0.911 rs474339 ENSG00000280143.1 AP000892.6 10.15 4.94e-22 1.13e-18 0.48 0.42 Blood protein levels; chr11:117188836 chr11:117204967~117210292:+ LUSC cis rs875971 0.862 rs7796162 ENSG00000226824.5 RP4-756H11.3 10.15 4.95e-22 1.13e-18 0.51 0.42 Aortic root size; chr7:66280771 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs2901152 ENSG00000226824.5 RP4-756H11.3 10.15 4.95e-22 1.13e-18 0.51 0.42 Aortic root size; chr7:66300017 chr7:66654538~66669855:+ LUSC cis rs150992 0.547 rs325217 ENSG00000248489.1 CTD-2007H13.3 10.15 4.97e-22 1.14e-18 0.54 0.42 Body mass index; chr5:98844109 chr5:98929171~98995013:+ LUSC cis rs977987 0.872 rs7206665 ENSG00000261783.1 RP11-252K23.2 -10.15 5.01e-22 1.14e-18 -0.58 -0.42 Dupuytren's disease; chr16:75441389 chr16:75379818~75381260:- LUSC cis rs801193 0.569 rs13242290 ENSG00000226824.5 RP4-756H11.3 10.15 5.08e-22 1.16e-18 0.52 0.42 Aortic root size; chr7:66656898 chr7:66654538~66669855:+ LUSC cis rs858239 0.712 rs200717 ENSG00000230658.1 KLHL7-AS1 10.15 5.08e-22 1.16e-18 0.52 0.42 Cerebrospinal fluid biomarker levels; chr7:23352652 chr7:23101228~23105703:- LUSC cis rs7188445 1 rs61221126 ENSG00000261390.4 RP11-345M22.2 -10.15 5.1e-22 1.16e-18 -0.59 -0.42 Urate levels; chr16:79699377 chr16:79715232~79770563:- LUSC cis rs150992 0.632 rs34490 ENSG00000248489.1 CTD-2007H13.3 10.15 5.27e-22 1.2e-18 0.49 0.42 Body mass index; chr5:98974967 chr5:98929171~98995013:+ LUSC cis rs4423214 0.84 rs1123007 ENSG00000254682.1 RP11-660L16.2 -10.15 5.28e-22 1.2e-18 -0.6 -0.42 Vitamin D levels; chr11:71474311 chr11:71448674~71452157:+ LUSC cis rs10129255 0.872 rs8015406 ENSG00000223648.3 IGHV3-64 10.14 5.33e-22 1.22e-18 0.39 0.42 Kawasaki disease; chr14:106670611 chr14:106643132~106658258:- LUSC cis rs9326248 0.911 rs11216284 ENSG00000280143.1 AP000892.6 10.14 5.37e-22 1.22e-18 0.49 0.42 Blood protein levels; chr11:117132344 chr11:117204967~117210292:+ LUSC cis rs6991838 0.584 rs10089708 ENSG00000272010.1 CTD-3025N20.3 10.14 5.37e-22 1.22e-18 0.48 0.42 Intelligence (multi-trait analysis); chr8:65642927 chr8:65591850~65592472:- LUSC cis rs6991838 0.584 rs6991731 ENSG00000272010.1 CTD-3025N20.3 10.14 5.37e-22 1.22e-18 0.48 0.42 Intelligence (multi-trait analysis); chr8:65643232 chr8:65591850~65592472:- LUSC cis rs11155671 0.53 rs9968871 ENSG00000223701.3 RAET1E-AS1 10.14 5.41e-22 1.23e-18 0.48 0.42 Testicular germ cell tumor; chr6:149888060 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs9969044 ENSG00000223701.3 RAET1E-AS1 10.14 5.41e-22 1.23e-18 0.48 0.42 Testicular germ cell tumor; chr6:149888068 chr6:149884431~149919508:+ LUSC cis rs9326248 0.954 rs521171 ENSG00000280143.1 AP000892.6 10.14 5.43e-22 1.24e-18 0.48 0.42 Blood protein levels; chr11:117193977 chr11:117204967~117210292:+ LUSC cis rs11155671 0.53 rs7756850 ENSG00000223701.3 RAET1E-AS1 10.14 5.43e-22 1.24e-18 0.48 0.42 Testicular germ cell tumor; chr6:149891460 chr6:149884431~149919508:+ LUSC cis rs977987 0.872 rs1542864 ENSG00000261783.1 RP11-252K23.2 -10.14 5.44e-22 1.24e-18 -0.58 -0.42 Dupuytren's disease; chr16:75437480 chr16:75379818~75381260:- LUSC cis rs6538678 0.824 rs7307510 ENSG00000258343.1 RP11-536G4.2 -10.14 5.46e-22 1.24e-18 -0.66 -0.42 Lupus nephritis in systemic lupus erythematosus; chr12:95843792 chr12:95795345~95858839:- LUSC cis rs875971 0.862 rs17747530 ENSG00000226824.5 RP4-756H11.3 -10.14 5.47e-22 1.25e-18 -0.51 -0.42 Aortic root size; chr7:66529742 chr7:66654538~66669855:+ LUSC cis rs2929278 0.617 rs2955969 ENSG00000249839.1 AC011330.5 10.14 5.48e-22 1.25e-18 0.56 0.42 Schizophrenia; chr15:43822329 chr15:43663654~43684339:- LUSC cis rs875971 0.825 rs6951503 ENSG00000226824.5 RP4-756H11.3 10.14 5.49e-22 1.25e-18 0.51 0.42 Aortic root size; chr7:66253949 chr7:66654538~66669855:+ LUSC cis rs977987 0.806 rs35683383 ENSG00000261783.1 RP11-252K23.2 -10.14 5.5e-22 1.25e-18 -0.58 -0.42 Dupuytren's disease; chr16:75445379 chr16:75379818~75381260:- LUSC cis rs2929278 0.588 rs688009 ENSG00000249839.1 AC011330.5 -10.14 5.52e-22 1.26e-18 -0.56 -0.42 Schizophrenia; chr15:43864104 chr15:43663654~43684339:- LUSC cis rs1799949 0.965 rs9646413 ENSG00000198496.9 NBR2 -10.14 5.56e-22 1.26e-18 -0.46 -0.42 Menopause (age at onset); chr17:43348789 chr17:43125610~43153671:+ LUSC cis rs35955747 0.714 rs4820048 ENSG00000236132.1 CTA-440B3.1 10.14 5.61e-22 1.28e-18 0.52 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31458384 chr22:31816379~31817491:- LUSC cis rs2455601 0.786 rs3763913 ENSG00000254860.4 TMEM9B-AS1 10.14 5.63e-22 1.28e-18 0.61 0.42 Schizophrenia; chr11:8929683 chr11:8964675~8977527:+ LUSC cis rs875971 0.798 rs12698522 ENSG00000226824.5 RP4-756H11.3 -10.14 5.69e-22 1.29e-18 -0.51 -0.42 Aortic root size; chr7:66502354 chr7:66654538~66669855:+ LUSC cis rs875971 0.83 rs28714531 ENSG00000226824.5 RP4-756H11.3 -10.14 5.69e-22 1.29e-18 -0.51 -0.42 Aortic root size; chr7:66503250 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs12698526 ENSG00000226824.5 RP4-756H11.3 -10.14 5.69e-22 1.29e-18 -0.51 -0.42 Aortic root size; chr7:66504118 chr7:66654538~66669855:+ LUSC cis rs3096299 0.781 rs2965819 ENSG00000274627.1 RP11-104N10.2 -10.14 5.71e-22 1.3e-18 -0.37 -0.42 Multiple myeloma (IgH translocation); chr16:89434622 chr16:89516797~89522217:+ LUSC cis rs9481169 0.85 rs4947129 ENSG00000255389.1 C6orf3 -10.14 5.76e-22 1.31e-18 -0.75 -0.42 Inflammatory skin disease; chr6:111609703 chr6:111599875~111602295:+ LUSC cis rs150992 0.673 rs331929 ENSG00000248489.1 CTD-2007H13.3 10.14 5.76e-22 1.31e-18 0.54 0.42 Body mass index; chr5:98830528 chr5:98929171~98995013:+ LUSC cis rs150992 0.585 rs331931 ENSG00000248489.1 CTD-2007H13.3 10.14 5.76e-22 1.31e-18 0.54 0.42 Body mass index; chr5:98834012 chr5:98929171~98995013:+ LUSC cis rs3091242 0.933 rs4649084 ENSG00000261349.1 RP3-465N24.5 -10.13 5.92e-22 1.34e-18 -0.52 -0.42 Erythrocyte sedimentation rate; chr1:25426126 chr1:25266102~25267136:- LUSC cis rs9326248 0.954 rs8521 ENSG00000280143.1 AP000892.6 10.13 5.95e-22 1.35e-18 0.48 0.42 Blood protein levels; chr11:117196983 chr11:117204967~117210292:+ LUSC cis rs7208859 0.524 rs11653098 ENSG00000263531.1 RP13-753N3.1 10.13 6.06e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30863921~30864940:- LUSC cis rs7208859 0.524 rs77498725 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30863921~30864940:- LUSC cis rs7208859 0.573 rs73267865 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737186 chr17:30863921~30864940:- LUSC cis rs7208859 0.524 rs59923796 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30863921~30864940:- LUSC cis rs17826219 0.5 rs57005940 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Body mass index; chr17:30739311 chr17:30863921~30864940:- LUSC cis rs7208859 0.573 rs73267872 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30863921~30864940:- LUSC cis rs17826219 0.706 rs9893922 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Body mass index; chr17:30741407 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs56812022 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30863921~30864940:- LUSC cis rs7208859 0.524 rs57670615 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30863921~30864940:- LUSC cis rs17826219 0.5 rs2874724 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Body mass index; chr17:30745415 chr17:30863921~30864940:- LUSC cis rs17826219 0.568 rs9898097 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Body mass index; chr17:30745654 chr17:30863921~30864940:- LUSC cis rs17826219 0.5 rs9891256 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Body mass index; chr17:30745674 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9911490 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs7503542 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs7503335 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30863921~30864940:- LUSC cis rs7208859 0.573 rs11656278 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs6505207 ENSG00000263531.1 RP13-753N3.1 10.13 6.1e-22 1.37e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30863921~30864940:- LUSC cis rs9326248 1 rs7107152 ENSG00000280143.1 AP000892.6 -10.13 6.11e-22 1.38e-18 -0.48 -0.42 Blood protein levels; chr11:117185364 chr11:117204967~117210292:+ LUSC cis rs3091242 0.935 rs4233043 ENSG00000261349.1 RP3-465N24.5 -10.13 6.13e-22 1.38e-18 -0.52 -0.42 Erythrocyte sedimentation rate; chr1:25438992 chr1:25266102~25267136:- LUSC cis rs3091242 0.933 rs11249250 ENSG00000261349.1 RP3-465N24.5 -10.13 6.13e-22 1.38e-18 -0.52 -0.42 Erythrocyte sedimentation rate; chr1:25441118 chr1:25266102~25267136:- LUSC cis rs172166 0.516 rs1225715 ENSG00000204709.4 LINC01556 -10.13 6.23e-22 1.4e-18 -0.51 -0.42 Cardiac Troponin-T levels; chr6:28145595 chr6:28943877~28944537:+ LUSC cis rs7188445 0.871 rs7202770 ENSG00000261390.4 RP11-345M22.2 -10.13 6.28e-22 1.41e-18 -0.56 -0.42 Urate levels; chr16:79672643 chr16:79715232~79770563:- LUSC cis rs7188445 0.835 rs1424231 ENSG00000261390.4 RP11-345M22.2 -10.13 6.28e-22 1.41e-18 -0.56 -0.42 Urate levels; chr16:79672854 chr16:79715232~79770563:- LUSC cis rs7188445 0.871 rs16950997 ENSG00000261390.4 RP11-345M22.2 -10.13 6.28e-22 1.41e-18 -0.56 -0.42 Urate levels; chr16:79673733 chr16:79715232~79770563:- LUSC cis rs2929278 0.546 rs686666 ENSG00000249839.1 AC011330.5 -10.12 6.38e-22 1.43e-18 -0.56 -0.42 Schizophrenia; chr15:43869352 chr15:43663654~43684339:- LUSC cis rs3931020 1 rs12410060 ENSG00000272864.1 RP11-17E13.2 -10.12 6.39e-22 1.44e-18 -0.53 -0.42 Resistin levels; chr1:74780164 chr1:74698769~74699333:- LUSC cis rs977987 0.872 rs4888422 ENSG00000261783.1 RP11-252K23.2 -10.12 6.44e-22 1.45e-18 -0.57 -0.42 Dupuytren's disease; chr16:75436678 chr16:75379818~75381260:- LUSC cis rs7104764 0.507 rs7121085 ENSG00000277290.1 RP11-326C3.16 -10.12 6.46e-22 1.45e-18 -0.44 -0.42 Menarche (age at onset); chr11:258523 chr11:243099~243483:- LUSC cis rs875971 0.862 rs1968126 ENSG00000226824.5 RP4-756H11.3 10.12 6.51e-22 1.46e-18 0.51 0.42 Aortic root size; chr7:66592017 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6460306 ENSG00000226824.5 RP4-756H11.3 10.12 6.51e-22 1.46e-18 0.51 0.42 Aortic root size; chr7:66595806 chr7:66654538~66669855:+ LUSC cis rs1707322 0.721 rs11211181 ENSG00000280836.1 AL355480.1 -10.12 6.64e-22 1.49e-18 -0.48 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45771128 chr1:45581219~45581321:- LUSC cis rs7208859 0.573 rs7223803 ENSG00000263531.1 RP13-753N3.1 10.12 6.65e-22 1.49e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750175 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs55814012 ENSG00000263531.1 RP13-753N3.1 10.12 6.65e-22 1.49e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750679 chr17:30863921~30864940:- LUSC cis rs17826219 0.5 rs2449749 ENSG00000263531.1 RP13-753N3.1 10.12 6.65e-22 1.49e-18 0.75 0.42 Body mass index; chr17:30751280 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9894709 ENSG00000263531.1 RP13-753N3.1 10.12 6.65e-22 1.49e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751436 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9896603 ENSG00000263531.1 RP13-753N3.1 10.12 6.65e-22 1.49e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751494 chr17:30863921~30864940:- LUSC cis rs7208859 0.573 rs8078656 ENSG00000263531.1 RP13-753N3.1 10.12 6.65e-22 1.49e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753953 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs8080882 ENSG00000263531.1 RP13-753N3.1 10.12 6.65e-22 1.49e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30754128 chr17:30863921~30864940:- LUSC cis rs1972460 0.506 rs62012050 ENSG00000255769.6 GOLGA2P10 -10.12 6.7e-22 1.5e-18 -0.54 -0.42 Intelligence (multi-trait analysis); chr15:82239933 chr15:82472993~82513950:- LUSC cis rs9389248 0.737 rs12664956 ENSG00000232876.1 CTA-212D2.2 -10.12 6.72e-22 1.51e-18 -0.52 -0.42 High light scatter reticulocyte percentage of red cells; chr6:135063050 chr6:135055033~135060550:+ LUSC cis rs150992 0.861 rs467728 ENSG00000248489.1 CTD-2007H13.3 10.12 6.77e-22 1.52e-18 0.49 0.42 Body mass index; chr5:98953863 chr5:98929171~98995013:+ LUSC cis rs875971 0.54 rs736270 ENSG00000226824.5 RP4-756H11.3 -10.11 6.86e-22 1.53e-18 -0.51 -0.42 Aortic root size; chr7:65963835 chr7:66654538~66669855:+ LUSC cis rs2739330 0.685 rs4822453 ENSG00000231271.1 AP000350.8 10.11 6.86e-22 1.54e-18 0.54 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23949918~23954042:+ LUSC cis rs4423214 0.84 rs1792233 ENSG00000254682.1 RP11-660L16.2 -10.11 6.93e-22 1.55e-18 -0.6 -0.42 Vitamin D levels; chr11:71471133 chr11:71448674~71452157:+ LUSC cis rs7188445 0.871 rs8048928 ENSG00000261390.4 RP11-345M22.2 -10.11 7.02e-22 1.57e-18 -0.56 -0.42 Urate levels; chr16:79671039 chr16:79715232~79770563:- LUSC cis rs6921919 0.789 rs1119211 ENSG00000216901.1 AL022393.7 -10.11 7.07e-22 1.58e-18 -0.55 -0.42 Autism spectrum disorder or schizophrenia; chr6:28341359 chr6:28176188~28176674:+ LUSC cis rs150992 0.609 rs2927647 ENSG00000248489.1 CTD-2007H13.3 10.11 7.09e-22 1.59e-18 0.49 0.42 Body mass index; chr5:98990161 chr5:98929171~98995013:+ LUSC cis rs7188445 1 rs16950982 ENSG00000261390.4 RP11-345M22.2 -10.11 7.12e-22 1.59e-18 -0.58 -0.42 Urate levels; chr16:79668474 chr16:79715232~79770563:- LUSC cis rs977987 0.835 rs3851734 ENSG00000261783.1 RP11-252K23.2 -10.11 7.4e-22 1.65e-18 -0.58 -0.42 Dupuytren's disease; chr16:75338022 chr16:75379818~75381260:- LUSC cis rs9322193 0.923 rs2880436 ENSG00000216906.2 RP11-350J20.9 10.1 7.5e-22 1.67e-18 0.5 0.42 Lung cancer; chr6:149859123 chr6:149904243~149906418:+ LUSC cis rs875971 0.83 rs778711 ENSG00000226824.5 RP4-756H11.3 -10.1 7.54e-22 1.68e-18 -0.51 -0.42 Aortic root size; chr7:66386670 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs1083554 ENSG00000226824.5 RP4-756H11.3 -10.1 7.54e-22 1.68e-18 -0.51 -0.42 Aortic root size; chr7:66387354 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs778707 ENSG00000226824.5 RP4-756H11.3 -10.1 7.54e-22 1.68e-18 -0.51 -0.42 Aortic root size; chr7:66392040 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs778705 ENSG00000226824.5 RP4-756H11.3 -10.1 7.54e-22 1.68e-18 -0.51 -0.42 Aortic root size; chr7:66396128 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs778697 ENSG00000226824.5 RP4-756H11.3 -10.1 7.54e-22 1.68e-18 -0.51 -0.42 Aortic root size; chr7:66405439 chr7:66654538~66669855:+ LUSC cis rs875971 0.798 rs7789615 ENSG00000226824.5 RP4-756H11.3 -10.1 7.54e-22 1.68e-18 -0.51 -0.42 Aortic root size; chr7:66413674 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6978028 ENSG00000226824.5 RP4-756H11.3 -10.1 7.54e-22 1.68e-18 -0.51 -0.42 Aortic root size; chr7:66421313 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6947339 ENSG00000226824.5 RP4-756H11.3 -10.1 7.54e-22 1.68e-18 -0.51 -0.42 Aortic root size; chr7:66423483 chr7:66654538~66669855:+ LUSC cis rs858239 0.712 rs199650 ENSG00000230658.1 KLHL7-AS1 -10.1 7.59e-22 1.69e-18 -0.52 -0.42 Cerebrospinal fluid biomarker levels; chr7:23327570 chr7:23101228~23105703:- LUSC cis rs73086581 0.898 rs11906452 ENSG00000229539.1 RP11-119B16.2 10.1 7.61e-22 1.7e-18 0.56 0.42 Response to antidepressants in depression; chr20:4000912 chr20:3888239~3888868:- LUSC cis rs7208859 0.623 rs7208441 ENSG00000263531.1 RP13-753N3.1 10.1 7.68e-22 1.71e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30863921~30864940:- LUSC cis rs4423214 0.879 rs10898144 ENSG00000254682.1 RP11-660L16.2 -10.1 7.74e-22 1.73e-18 -0.55 -0.42 Vitamin D levels; chr11:71440494 chr11:71448674~71452157:+ LUSC cis rs6964833 1 rs36044436 ENSG00000277053.3 GTF2IP1 -10.1 7.76e-22 1.73e-18 -0.64 -0.42 Menarche (age at onset); chr7:74675495 chr7:75185385~75237696:- LUSC cis rs9322193 0.886 rs4870049 ENSG00000216906.2 RP11-350J20.9 10.1 7.83e-22 1.74e-18 0.52 0.42 Lung cancer; chr6:149837058 chr6:149904243~149906418:+ LUSC cis rs9341808 0.529 rs4706840 ENSG00000272129.1 RP11-250B2.6 10.1 7.87e-22 1.76e-18 0.51 0.42 Sitting height ratio; chr6:80348052 chr6:80355424~80356859:+ LUSC cis rs6782228 0.628 rs7641584 ENSG00000277250.1 Metazoa_SRP -10.1 7.99e-22 1.78e-18 -0.47 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128673787 chr3:128673681~128674021:- LUSC cis rs7208859 0.623 rs7219712 ENSG00000263531.1 RP13-753N3.1 10.1 8.05e-22 1.79e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753552 chr17:30863921~30864940:- LUSC cis rs2739330 0.652 rs2000469 ENSG00000099984.9 GSTT2 -10.1 8.06e-22 1.8e-18 -0.53 -0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23980123~23983911:+ LUSC cis rs4423214 0.84 rs1792234 ENSG00000254682.1 RP11-660L16.2 -10.09 8.16e-22 1.82e-18 -0.59 -0.42 Vitamin D levels; chr11:71470972 chr11:71448674~71452157:+ LUSC cis rs17826219 0.706 rs57698184 ENSG00000263531.1 RP13-753N3.1 10.09 8.19e-22 1.82e-18 0.75 0.42 Body mass index; chr17:30737900 chr17:30863921~30864940:- LUSC cis rs875971 0.895 rs4145009 ENSG00000226824.5 RP4-756H11.3 10.09 8.21e-22 1.83e-18 0.52 0.42 Aortic root size; chr7:66261628 chr7:66654538~66669855:+ LUSC cis rs7208859 0.524 rs60114476 ENSG00000263531.1 RP13-753N3.1 10.09 8.24e-22 1.83e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30863921~30864940:- LUSC cis rs7208859 0.524 rs8065744 ENSG00000263531.1 RP13-753N3.1 10.09 8.24e-22 1.83e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30863921~30864940:- LUSC cis rs17826219 0.706 rs8071236 ENSG00000263531.1 RP13-753N3.1 10.09 8.24e-22 1.83e-18 0.75 0.42 Body mass index; chr17:30772984 chr17:30863921~30864940:- LUSC cis rs17826219 0.636 rs2449770 ENSG00000263531.1 RP13-753N3.1 10.09 8.24e-22 1.83e-18 0.75 0.42 Body mass index; chr17:30774046 chr17:30863921~30864940:- LUSC cis rs7208859 0.524 rs59913838 ENSG00000263531.1 RP13-753N3.1 10.09 8.24e-22 1.83e-18 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30863921~30864940:- LUSC cis rs17826219 0.636 rs12946563 ENSG00000263531.1 RP13-753N3.1 10.09 8.3e-22 1.84e-18 0.74 0.42 Body mass index; chr17:30776148 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs8068645 ENSG00000263531.1 RP13-753N3.1 10.09 8.3e-22 1.84e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777324 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs55811708 ENSG00000263531.1 RP13-753N3.1 10.09 8.3e-22 1.84e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777713 chr17:30863921~30864940:- LUSC cis rs2739330 0.76 rs1002286 ENSG00000235689.1 AP000351.13 -10.09 8.37e-22 1.86e-18 -0.44 -0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:24006305~24008258:- LUSC cis rs11098499 1 rs1011054 ENSG00000245958.5 RP11-33B1.1 10.09 8.41e-22 1.87e-18 0.44 0.42 Corneal astigmatism; chr4:119281232 chr4:119454791~119552025:+ LUSC cis rs6782228 0.606 rs2253144 ENSG00000242551.2 POU5F1P6 10.09 8.43e-22 1.87e-18 0.47 0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611077 chr3:128674735~128677005:- LUSC cis rs17826219 0.568 rs2626985 ENSG00000263531.1 RP13-753N3.1 10.09 8.49e-22 1.89e-18 0.75 0.42 Body mass index; chr17:30750419 chr17:30863921~30864940:- LUSC cis rs17711722 0.565 rs73372653 ENSG00000164669.11 INTS4P1 -10.09 8.6e-22 1.91e-18 -0.47 -0.42 Calcium levels; chr7:65977808 chr7:65141225~65234216:+ LUSC cis rs2739330 0.828 rs5751770 ENSG00000099984.9 GSTT2 -10.09 8.63e-22 1.92e-18 -0.51 -0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23980123~23983911:+ LUSC cis rs7188445 0.966 rs11150188 ENSG00000261390.4 RP11-345M22.2 -10.09 8.64e-22 1.92e-18 -0.57 -0.42 Urate levels; chr16:79673401 chr16:79715232~79770563:- LUSC cis rs8062405 0.965 rs8049439 ENSG00000259982.1 CDC37P1 10.08 8.83e-22 1.96e-18 0.52 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826194 chr16:28700294~28701540:- LUSC cis rs11155671 0.53 rs7742993 ENSG00000223701.3 RAET1E-AS1 10.08 8.93e-22 1.98e-18 0.47 0.42 Testicular germ cell tumor; chr6:149883959 chr6:149884431~149919508:+ LUSC cis rs4423214 0.84 rs1792235 ENSG00000254682.1 RP11-660L16.2 -10.08 9.06e-22 2.01e-18 -0.59 -0.42 Vitamin D levels; chr11:71470427 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1619577 ENSG00000254682.1 RP11-660L16.2 -10.08 9.06e-22 2.01e-18 -0.59 -0.42 Vitamin D levels; chr11:71470439 chr11:71448674~71452157:+ LUSC cis rs11155671 0.53 rs9383912 ENSG00000223701.3 RAET1E-AS1 10.08 9.07e-22 2.01e-18 0.47 0.42 Testicular germ cell tumor; chr6:149885479 chr6:149884431~149919508:+ LUSC cis rs10875746 0.855 rs12310999 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48053875 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs61918774 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48054351 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs10875735 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48070023 chr12:48054813~48055591:- LUSC cis rs10875746 0.855 rs17122620 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48070692 chr12:48054813~48055591:- LUSC cis rs10875746 0.859 rs4760680 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48072914 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs11168386 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48074194 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs12315625 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48078670 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs10875738 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48079956 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs12301339 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48081450 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs886588 ENSG00000240399.1 RP1-228P16.1 -10.08 9.15e-22 2.02e-18 -0.49 -0.42 Longevity (90 years and older); chr12:48083639 chr12:48054813~48055591:- LUSC cis rs875971 0.767 rs12668005 ENSG00000226824.5 RP4-756H11.3 -10.08 9.46e-22 2.09e-18 -0.51 -0.42 Aortic root size; chr7:66444034 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs11765791 ENSG00000226824.5 RP4-756H11.3 -10.08 9.46e-22 2.09e-18 -0.51 -0.42 Aortic root size; chr7:66471587 chr7:66654538~66669855:+ LUSC cis rs9326248 0.906 rs171052 ENSG00000280143.1 AP000892.6 -10.08 9.46e-22 2.09e-18 -0.48 -0.42 Blood protein levels; chr11:117211047 chr11:117204967~117210292:+ LUSC cis rs11098499 0.954 rs12502423 ENSG00000245958.5 RP11-33B1.1 -10.08 9.49e-22 2.1e-18 -0.43 -0.42 Corneal astigmatism; chr4:119503017 chr4:119454791~119552025:+ LUSC cis rs2929278 0.588 rs1975364 ENSG00000249839.1 AC011330.5 -10.07 9.56e-22 2.11e-18 -0.56 -0.42 Schizophrenia; chr15:43857991 chr15:43663654~43684339:- LUSC cis rs3096299 0.746 rs9931120 ENSG00000274627.1 RP11-104N10.2 10.07 9.57e-22 2.11e-18 0.37 0.42 Multiple myeloma (IgH translocation); chr16:89434949 chr16:89516797~89522217:+ LUSC cis rs11098499 0.954 rs1480931 ENSG00000245958.5 RP11-33B1.1 -10.07 9.86e-22 2.17e-18 -0.43 -0.42 Corneal astigmatism; chr4:119474654 chr4:119454791~119552025:+ LUSC cis rs875971 0.862 rs778720 ENSG00000226824.5 RP4-756H11.3 10.07 9.96e-22 2.2e-18 0.51 0.42 Aortic root size; chr7:66381288 chr7:66654538~66669855:+ LUSC cis rs9399137 0.529 rs7739722 ENSG00000232876.1 CTA-212D2.2 -10.07 1.01e-21 2.22e-18 -0.52 -0.42 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134961087 chr6:135055033~135060550:+ LUSC cis rs55794721 0.509 rs11249248 ENSG00000261349.1 RP3-465N24.5 -10.06 1.05e-21 2.31e-18 -0.51 -0.42 Mean corpuscular volume;Plateletcrit; chr1:25426560 chr1:25266102~25267136:- LUSC cis rs3091242 0.933 rs909833 ENSG00000261349.1 RP3-465N24.5 -10.06 1.05e-21 2.31e-18 -0.51 -0.42 Erythrocyte sedimentation rate; chr1:25427649 chr1:25266102~25267136:- LUSC cis rs7626444 0.625 rs843529 ENSG00000272359.1 U4 10.06 1.05e-21 2.32e-18 0.46 0.42 Monocyte count; chr3:196753724 chr3:196747192~196747324:- LUSC cis rs977987 0.815 rs11149818 ENSG00000261783.1 RP11-252K23.2 -10.06 1.06e-21 2.33e-18 -0.57 -0.42 Dupuytren's disease; chr16:75385475 chr16:75379818~75381260:- LUSC cis rs875971 0.862 rs801195 ENSG00000226824.5 RP4-756H11.3 10.06 1.07e-21 2.36e-18 0.51 0.42 Aortic root size; chr7:66561128 chr7:66654538~66669855:+ LUSC cis rs4423214 0.84 rs1792231 ENSG00000254682.1 RP11-660L16.2 -10.06 1.08e-21 2.38e-18 -0.59 -0.42 Vitamin D levels; chr11:71471635 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1790339 ENSG00000254682.1 RP11-660L16.2 -10.06 1.08e-21 2.38e-18 -0.59 -0.42 Vitamin D levels; chr11:71471715 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs4435028 ENSG00000254682.1 RP11-660L16.2 -10.06 1.08e-21 2.38e-18 -0.59 -0.42 Vitamin D levels; chr11:71472644 chr11:71448674~71452157:+ LUSC cis rs4423214 0.802 rs4616066 ENSG00000254682.1 RP11-660L16.2 -10.06 1.08e-21 2.38e-18 -0.59 -0.42 Vitamin D levels; chr11:71472800 chr11:71448674~71452157:+ LUSC cis rs4423214 0.802 rs4402322 ENSG00000254682.1 RP11-660L16.2 -10.06 1.08e-21 2.38e-18 -0.59 -0.42 Vitamin D levels; chr11:71472969 chr11:71448674~71452157:+ LUSC cis rs4423214 0.802 rs2276358 ENSG00000254682.1 RP11-660L16.2 -10.06 1.08e-21 2.38e-18 -0.59 -0.42 Vitamin D levels; chr11:71473452 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs3794057 ENSG00000254682.1 RP11-660L16.2 -10.06 1.08e-21 2.38e-18 -0.59 -0.42 Vitamin D levels; chr11:71475698 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs2017686 ENSG00000254682.1 RP11-660L16.2 -10.06 1.08e-21 2.38e-18 -0.59 -0.42 Vitamin D levels; chr11:71476015 chr11:71448674~71452157:+ LUSC cis rs3091242 0.933 rs35530120 ENSG00000261349.1 RP3-465N24.5 10.06 1.09e-21 2.39e-18 0.51 0.42 Erythrocyte sedimentation rate; chr1:25458960 chr1:25266102~25267136:- LUSC cis rs1185460 0.934 rs10892328 ENSG00000271751.1 RP11-110I1.14 -10.06 1.1e-21 2.41e-18 -0.55 -0.42 Coronary artery disease; chr11:119071944 chr11:119065263~119065677:- LUSC cis rs3931020 1 rs3931020 ENSG00000272864.1 RP11-17E13.2 -10.06 1.12e-21 2.45e-18 -0.53 -0.42 Resistin levels; chr1:74769633 chr1:74698769~74699333:- LUSC cis rs7208859 0.623 rs56163556 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs8067338 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30863921~30864940:- LUSC cis rs7208859 0.573 rs4055105 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs73269923 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775553 chr17:30863921~30864940:- LUSC cis rs7208859 0.562 rs8078897 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs8075163 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30863921~30864940:- LUSC cis rs17826219 0.706 rs8075107 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Body mass index; chr17:30779631 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs7223209 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs7223404 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9916725 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9916727 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9914499 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs73269945 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9897728 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs1054400 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs1054397 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9890558 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9912283 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783355 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs12006 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs3752021 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs3752020 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9890855 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9893422 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9891166 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs73269974 ENSG00000263531.1 RP13-753N3.1 10.06 1.12e-21 2.45e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30863921~30864940:- LUSC cis rs6700559 0.654 rs2809346 ENSG00000260088.1 RP11-92G12.3 10.06 1.12e-21 2.45e-18 0.51 0.42 Coronary artery disease; chr1:200627089 chr1:200669507~200694250:+ LUSC cis rs733592 1 rs1859440 ENSG00000240399.1 RP1-228P16.1 -10.06 1.12e-21 2.45e-18 -0.39 -0.42 Plateletcrit; chr12:48033546 chr12:48054813~48055591:- LUSC cis rs748404 0.518 rs480108 ENSG00000249839.1 AC011330.5 -10.05 1.13e-21 2.47e-18 -0.56 -0.42 Lung cancer; chr15:43525208 chr15:43663654~43684339:- LUSC cis rs3091242 0.933 rs9438905 ENSG00000261349.1 RP3-465N24.5 -10.05 1.14e-21 2.49e-18 -0.51 -0.42 Erythrocyte sedimentation rate; chr1:25437686 chr1:25266102~25267136:- LUSC cis rs35955747 0.633 rs5998012 ENSG00000236132.1 CTA-440B3.1 10.05 1.14e-21 2.49e-18 0.51 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31493858 chr22:31816379~31817491:- LUSC cis rs9326248 1 rs10790175 ENSG00000280143.1 AP000892.6 10.05 1.14e-21 2.49e-18 0.47 0.42 Blood protein levels; chr11:117164013 chr11:117204967~117210292:+ LUSC cis rs10129255 1 rs8010605 ENSG00000223648.3 IGHV3-64 10.05 1.15e-21 2.53e-18 0.38 0.42 Kawasaki disease; chr14:106678742 chr14:106643132~106658258:- LUSC cis rs4423214 0.84 rs1792229 ENSG00000254682.1 RP11-660L16.2 -10.05 1.16e-21 2.55e-18 -0.6 -0.42 Vitamin D levels; chr11:71468349 chr11:71448674~71452157:+ LUSC cis rs7208859 0.623 rs34756112 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30863921~30864940:- LUSC cis rs7208859 0.573 rs60724269 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs76633166 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs1061346 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs1061343 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs1061342 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs55938328 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs73269988 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs55961983 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs9899525 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30863921~30864940:- LUSC cis rs17826219 0.568 rs7213925 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Body mass index; chr17:30794616 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11658945 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11657990 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9911784 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9911997 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9890862 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs78071511 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11650982 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs2035494 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs3794796 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs9915546 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30863921~30864940:- LUSC cis rs7208859 0.573 rs8064686 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30863921~30864940:- LUSC cis rs7208859 0.573 rs11654035 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809408 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11657369 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs8075341 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs73271842 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs9895815 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs8077116 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30863921~30864940:- LUSC cis rs7208859 0.524 rs28760584 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30863921~30864940:- LUSC cis rs17826219 0.706 rs73271850 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Body mass index; chr17:30815122 chr17:30863921~30864940:- LUSC cis rs17826219 0.636 rs79565452 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Body mass index; chr17:30815823 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs7208088 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs7212991 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs28627615 ENSG00000263531.1 RP13-753N3.1 10.05 1.17e-21 2.55e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30863921~30864940:- LUSC cis rs73086581 0.592 rs6037702 ENSG00000229539.1 RP11-119B16.2 -10.05 1.18e-21 2.56e-18 -0.46 -0.42 Response to antidepressants in depression; chr20:3955745 chr20:3888239~3888868:- LUSC cis rs10875746 0.903 rs11168420 ENSG00000240399.1 RP1-228P16.1 -10.05 1.18e-21 2.58e-18 -0.48 -0.42 Longevity (90 years and older); chr12:48122113 chr12:48054813~48055591:- LUSC cis rs11098499 0.908 rs1002152 ENSG00000245958.5 RP11-33B1.1 -10.05 1.19e-21 2.59e-18 -0.43 -0.42 Corneal astigmatism; chr4:119352232 chr4:119454791~119552025:+ LUSC cis rs7104764 0.507 rs7111364 ENSG00000277290.1 RP11-326C3.16 -10.05 1.21e-21 2.62e-18 -0.44 -0.42 Menarche (age at onset); chr11:258542 chr11:243099~243483:- LUSC cis rs7396835 0.866 rs6589571 ENSG00000254851.1 RP11-109L13.1 -10.05 1.23e-21 2.67e-18 -0.77 -0.42 Quantitative traits; chr11:116809702 chr11:117135528~117138582:+ LUSC cis rs7188445 0.966 rs79193369 ENSG00000261390.4 RP11-345M22.2 -10.04 1.24e-21 2.71e-18 -0.59 -0.42 Urate levels; chr16:79691119 chr16:79715232~79770563:- LUSC cis rs748404 0.56 rs689797 ENSG00000249839.1 AC011330.5 -10.04 1.25e-21 2.71e-18 -0.57 -0.42 Lung cancer; chr15:43534359 chr15:43663654~43684339:- LUSC cis rs11155671 0.53 rs4869763 ENSG00000223701.3 RAET1E-AS1 10.04 1.3e-21 2.83e-18 0.47 0.42 Testicular germ cell tumor; chr6:149890548 chr6:149884431~149919508:+ LUSC cis rs10129255 0.536 rs8004835 ENSG00000280411.1 IGHV1-69-2 -10.04 1.31e-21 2.85e-18 -0.26 -0.42 Kawasaki disease; chr14:106686361 chr14:106762092~106762588:- LUSC cis rs748404 0.56 rs570933 ENSG00000249839.1 AC011330.5 -10.04 1.33e-21 2.88e-18 -0.57 -0.42 Lung cancer; chr15:43531832 chr15:43663654~43684339:- LUSC cis rs10875746 0.951 rs10875756 ENSG00000240399.1 RP1-228P16.1 -10.03 1.33e-21 2.89e-18 -0.48 -0.42 Longevity (90 years and older); chr12:48168521 chr12:48054813~48055591:- LUSC cis rs6782228 0.675 rs4443194 ENSG00000277250.1 Metazoa_SRP -10.03 1.34e-21 2.91e-18 -0.47 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128664603 chr3:128673681~128674021:- LUSC cis rs9326248 1 rs585849 ENSG00000280143.1 AP000892.6 10.03 1.38e-21 2.98e-18 0.48 0.42 Blood protein levels; chr11:117198345 chr11:117204967~117210292:+ LUSC cis rs875971 0.862 rs13536 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66554203 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs801209 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66554403 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs801206 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66556979 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs801204 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66557934 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs801203 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66558025 chr7:66654538~66669855:+ LUSC cis rs875971 0.825 rs801202 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66558942 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs801194 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66563508 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs2024192 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66576460 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6955837 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66578155 chr7:66654538~66669855:+ LUSC cis rs875971 0.825 rs10281499 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66583979 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs4718377 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66584691 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs10278014 ENSG00000226824.5 RP4-756H11.3 10.03 1.38e-21 2.99e-18 0.51 0.42 Aortic root size; chr7:66586277 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs13232191 ENSG00000226824.5 RP4-756H11.3 -10.03 1.38e-21 2.99e-18 -0.51 -0.42 Aortic root size; chr7:66521661 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs35378740 ENSG00000226824.5 RP4-756H11.3 -10.03 1.38e-21 2.99e-18 -0.51 -0.42 Aortic root size; chr7:66522725 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs10950043 ENSG00000226824.5 RP4-756H11.3 -10.03 1.38e-21 2.99e-18 -0.51 -0.42 Aortic root size; chr7:66523623 chr7:66654538~66669855:+ LUSC cis rs875971 0.767 rs61348003 ENSG00000226824.5 RP4-756H11.3 -10.03 1.38e-21 2.99e-18 -0.51 -0.42 Aortic root size; chr7:66540947 chr7:66654538~66669855:+ LUSC cis rs9341808 0.529 rs9350851 ENSG00000272129.1 RP11-250B2.6 10.03 1.4e-21 3.02e-18 0.51 0.42 Sitting height ratio; chr6:80349471 chr6:80355424~80356859:+ LUSC cis rs9341808 0.529 rs9352826 ENSG00000272129.1 RP11-250B2.6 10.03 1.4e-21 3.02e-18 0.51 0.42 Sitting height ratio; chr6:80349654 chr6:80355424~80356859:+ LUSC cis rs35955747 0.677 rs4820974 ENSG00000236132.1 CTA-440B3.1 10.03 1.42e-21 3.07e-18 0.51 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31473481 chr22:31816379~31817491:- LUSC cis rs875971 0.862 rs7783779 ENSG00000226824.5 RP4-756H11.3 10.03 1.45e-21 3.13e-18 0.51 0.42 Aortic root size; chr7:66331639 chr7:66654538~66669855:+ LUSC cis rs150992 0.655 rs327807 ENSG00000248489.1 CTD-2007H13.3 -10.02 1.47e-21 3.17e-18 -0.5 -0.42 Body mass index; chr5:98942448 chr5:98929171~98995013:+ LUSC cis rs7301826 0.932 rs1007246 ENSG00000256299.1 RP11-989F5.3 -10.02 1.47e-21 3.18e-18 -0.45 -0.42 Plasma plasminogen activator levels; chr12:130795585 chr12:130810821~130812622:- LUSC cis rs7104764 0.507 rs6598054 ENSG00000277290.1 RP11-326C3.16 10.02 1.49e-21 3.2e-18 0.43 0.42 Menarche (age at onset); chr11:254010 chr11:243099~243483:- LUSC cis rs10129255 0.957 rs10138532 ENSG00000223648.3 IGHV3-64 10.02 1.49e-21 3.22e-18 0.4 0.42 Kawasaki disease; chr14:106803901 chr14:106643132~106658258:- LUSC cis rs1707322 0.717 rs1547925 ENSG00000280836.1 AL355480.1 10.02 1.5e-21 3.23e-18 0.49 0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619684 chr1:45581219~45581321:- LUSC cis rs11155671 0.53 rs9371542 ENSG00000223701.3 RAET1E-AS1 10.02 1.53e-21 3.29e-18 0.47 0.42 Testicular germ cell tumor; chr6:149891949 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs9371223 ENSG00000223701.3 RAET1E-AS1 10.02 1.53e-21 3.29e-18 0.47 0.42 Testicular germ cell tumor; chr6:149893670 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs10872649 ENSG00000216906.2 RP11-350J20.9 10.02 1.53e-21 3.3e-18 0.5 0.42 Lung cancer; chr6:149759454 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs10872650 ENSG00000216906.2 RP11-350J20.9 10.02 1.53e-21 3.3e-18 0.5 0.42 Lung cancer; chr6:149760959 chr6:149904243~149906418:+ LUSC cis rs3091242 0.902 rs36003018 ENSG00000261349.1 RP3-465N24.5 10.02 1.56e-21 3.36e-18 0.51 0.42 Erythrocyte sedimentation rate; chr1:25457827 chr1:25266102~25267136:- LUSC cis rs172166 0.516 rs1150670 ENSG00000204709.4 LINC01556 10.01 1.59e-21 3.41e-18 0.5 0.42 Cardiac Troponin-T levels; chr6:28162781 chr6:28943877~28944537:+ LUSC cis rs172166 0.516 rs2021826 ENSG00000204709.4 LINC01556 10.01 1.59e-21 3.41e-18 0.5 0.42 Cardiac Troponin-T levels; chr6:28164978 chr6:28943877~28944537:+ LUSC cis rs875971 0.83 rs587360 ENSG00000226824.5 RP4-756H11.3 -10.01 1.59e-21 3.42e-18 -0.51 -0.42 Aortic root size; chr7:66057711 chr7:66654538~66669855:+ LUSC cis rs9326248 0.798 rs10892079 ENSG00000280143.1 AP000892.6 10.01 1.59e-21 3.42e-18 0.48 0.42 Blood protein levels; chr11:117146108 chr11:117204967~117210292:+ LUSC cis rs9322193 0.923 rs9766004 ENSG00000216906.2 RP11-350J20.9 10.01 1.6e-21 3.44e-18 0.5 0.42 Lung cancer; chr6:149754363 chr6:149904243~149906418:+ LUSC cis rs875971 0.862 rs13226170 ENSG00000226824.5 RP4-756H11.3 -10.01 1.61e-21 3.46e-18 -0.51 -0.42 Aortic root size; chr7:66534311 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs2420611 ENSG00000226824.5 RP4-756H11.3 -10.01 1.61e-21 3.46e-18 -0.51 -0.42 Aortic root size; chr7:66534333 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs6460307 ENSG00000226824.5 RP4-756H11.3 -10.01 1.62e-21 3.47e-18 -0.5 -0.42 Aortic root size; chr7:66595884 chr7:66654538~66669855:+ LUSC cis rs10875746 0.807 rs12313300 ENSG00000240399.1 RP1-228P16.1 -10.01 1.63e-21 3.5e-18 -0.48 -0.42 Longevity (90 years and older); chr12:48076934 chr12:48054813~48055591:- LUSC cis rs7104764 0.673 rs3782118 ENSG00000277290.1 RP11-326C3.16 -10.01 1.64e-21 3.52e-18 -0.36 -0.42 Menarche (age at onset); chr11:222620 chr11:243099~243483:- LUSC cis rs6700559 0.654 rs66717951 ENSG00000260088.1 RP11-92G12.3 10.01 1.65e-21 3.53e-18 0.51 0.42 Coronary artery disease; chr1:200626437 chr1:200669507~200694250:+ LUSC cis rs3091242 0.933 rs35403885 ENSG00000261349.1 RP3-465N24.5 10.01 1.66e-21 3.56e-18 0.51 0.42 Erythrocyte sedimentation rate; chr1:25458060 chr1:25266102~25267136:- LUSC cis rs7535099 0.563 rs12069188 ENSG00000224570.1 RP11-430H12.2 -10.01 1.67e-21 3.57e-18 -0.63 -0.42 Blood protein levels; chr1:65593340 chr1:65576129~65578380:- LUSC cis rs2455601 0.529 rs2653569 ENSG00000254860.4 TMEM9B-AS1 10.01 1.67e-21 3.58e-18 0.53 0.42 Schizophrenia; chr11:8965431 chr11:8964675~8977527:+ LUSC cis rs7208859 0.623 rs9915566 ENSG00000263531.1 RP13-753N3.1 10.01 1.68e-21 3.59e-18 0.73 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30863921~30864940:- LUSC cis rs172166 0.516 rs2622322 ENSG00000204709.4 LINC01556 10.01 1.69e-21 3.61e-18 0.5 0.42 Cardiac Troponin-T levels; chr6:28149665 chr6:28943877~28944537:+ LUSC cis rs11155671 0.53 rs9397420 ENSG00000223701.3 RAET1E-AS1 -10 1.74e-21 3.71e-18 -0.47 -0.42 Testicular germ cell tumor; chr6:149885645 chr6:149884431~149919508:+ LUSC cis rs3091242 0.933 rs9438904 ENSG00000261349.1 RP3-465N24.5 -10 1.74e-21 3.72e-18 -0.51 -0.42 Erythrocyte sedimentation rate; chr1:25430369 chr1:25266102~25267136:- LUSC cis rs875971 0.8 rs427557 ENSG00000226824.5 RP4-756H11.3 -10 1.75e-21 3.74e-18 -0.5 -0.42 Aortic root size; chr7:66054263 chr7:66654538~66669855:+ LUSC cis rs10875746 0.903 rs17122666 ENSG00000240399.1 RP1-228P16.1 -10 1.76e-21 3.75e-18 -0.48 -0.42 Longevity (90 years and older); chr12:48108791 chr12:48054813~48055591:- LUSC cis rs10875746 0.951 rs4760690 ENSG00000240399.1 RP1-228P16.1 -10 1.77e-21 3.78e-18 -0.48 -0.42 Longevity (90 years and older); chr12:48169870 chr12:48054813~48055591:- LUSC cis rs9326248 1 rs7946257 ENSG00000280143.1 AP000892.6 10 1.79e-21 3.83e-18 0.47 0.42 Blood protein levels; chr11:117182449 chr11:117204967~117210292:+ LUSC cis rs7208859 0.623 rs28556733 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30863921~30864940:- LUSC cis rs17826219 0.5 rs28452421 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Body mass index; chr17:30756962 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs28433704 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30863921~30864940:- LUSC cis rs7208859 0.573 rs28779471 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11658022 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758341 chr17:30863921~30864940:- LUSC cis rs17826219 0.5 rs61685770 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Body mass index; chr17:30758695 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs57486336 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30863921~30864940:- LUSC cis rs17826219 0.706 rs55764512 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Body mass index; chr17:30758740 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs12103440 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs12103508 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30863921~30864940:- LUSC cis rs7208859 0.524 rs11653605 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs11657777 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs73269913 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs7217984 ENSG00000263531.1 RP13-753N3.1 10 1.82e-21 3.87e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30863921~30864940:- LUSC cis rs9322193 0.923 rs9478291 ENSG00000216906.2 RP11-350J20.9 10 1.82e-21 3.88e-18 0.5 0.42 Lung cancer; chr6:149729434 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9688350 ENSG00000216906.2 RP11-350J20.9 10 1.82e-21 3.88e-18 0.51 0.42 Lung cancer; chr6:149730977 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9767652 ENSG00000216906.2 RP11-350J20.9 10 1.82e-21 3.88e-18 0.51 0.42 Lung cancer; chr6:149734502 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs10782314 ENSG00000216906.2 RP11-350J20.9 10 1.82e-21 3.88e-18 0.51 0.42 Lung cancer; chr6:149735527 chr6:149904243~149906418:+ LUSC cis rs875971 0.54 rs4717275 ENSG00000226824.5 RP4-756H11.3 10 1.83e-21 3.89e-18 0.5 0.42 Aortic root size; chr7:65800193 chr7:66654538~66669855:+ LUSC cis rs977987 0.836 rs7199062 ENSG00000261783.1 RP11-252K23.2 -10 1.86e-21 3.96e-18 -0.57 -0.42 Dupuytren's disease; chr16:75440929 chr16:75379818~75381260:- LUSC cis rs858239 0.676 rs274032 ENSG00000230658.1 KLHL7-AS1 9.99 1.87e-21 3.98e-18 0.52 0.42 Cerebrospinal fluid biomarker levels; chr7:23334940 chr7:23101228~23105703:- LUSC cis rs6538678 0.746 rs12820313 ENSG00000258343.1 RP11-536G4.2 -9.99 1.9e-21 4.05e-18 -0.56 -0.42 Lupus nephritis in systemic lupus erythematosus; chr12:95861926 chr12:95795345~95858839:- LUSC cis rs7396835 0.866 rs7927820 ENSG00000254851.1 RP11-109L13.1 -9.99 1.9e-21 4.05e-18 -0.76 -0.42 Quantitative traits; chr11:116811440 chr11:117135528~117138582:+ LUSC cis rs801193 0.569 rs2659907 ENSG00000226824.5 RP4-756H11.3 -9.99 1.92e-21 4.09e-18 -0.51 -0.42 Aortic root size; chr7:66699045 chr7:66654538~66669855:+ LUSC cis rs9322193 0.923 rs62441284 ENSG00000216906.2 RP11-350J20.9 9.99 1.94e-21 4.12e-18 0.5 0.42 Lung cancer; chr6:149751542 chr6:149904243~149906418:+ LUSC cis rs875971 0.83 rs427575 ENSG00000226824.5 RP4-756H11.3 -9.99 1.95e-21 4.14e-18 -0.5 -0.42 Aortic root size; chr7:66054232 chr7:66654538~66669855:+ LUSC cis rs7208859 0.623 rs9898084 ENSG00000263531.1 RP13-753N3.1 9.99 1.99e-21 4.22e-18 0.73 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30863921~30864940:- LUSC cis rs172166 0.516 rs2791333 ENSG00000204709.4 LINC01556 9.99 2e-21 4.24e-18 0.5 0.42 Cardiac Troponin-T levels; chr6:28143336 chr6:28943877~28944537:+ LUSC cis rs11098499 0.865 rs11722183 ENSG00000245958.5 RP11-33B1.1 -9.99 2e-21 4.25e-18 -0.42 -0.42 Corneal astigmatism; chr4:119359442 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs1572229 ENSG00000216906.2 RP11-350J20.9 9.99 2e-21 4.25e-18 0.5 0.42 Lung cancer; chr6:149743841 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs10872646 ENSG00000216906.2 RP11-350J20.9 9.99 2e-21 4.25e-18 0.5 0.42 Lung cancer; chr6:149746539 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs12528279 ENSG00000216906.2 RP11-350J20.9 9.99 2e-21 4.25e-18 0.5 0.42 Lung cancer; chr6:149750892 chr6:149904243~149906418:+ LUSC cis rs9322193 0.809 rs9479808 ENSG00000216906.2 RP11-350J20.9 9.99 2e-21 4.25e-18 0.5 0.42 Lung cancer; chr6:149751328 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9479494 ENSG00000216906.2 RP11-350J20.9 9.99 2.01e-21 4.25e-18 0.5 0.42 Lung cancer; chr6:149739108 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9800806 ENSG00000216906.2 RP11-350J20.9 9.99 2.01e-21 4.25e-18 0.5 0.42 Lung cancer; chr6:149740350 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9688517 ENSG00000216906.2 RP11-350J20.9 9.99 2.01e-21 4.25e-18 0.5 0.42 Lung cancer; chr6:149740655 chr6:149904243~149906418:+ LUSC cis rs1501911 0.53 rs162473 ENSG00000248489.1 CTD-2007H13.3 -9.98 2.03e-21 4.3e-18 -0.51 -0.42 Lung function (FEV1/FVC); chr5:98805276 chr5:98929171~98995013:+ LUSC cis rs1501911 0.53 rs162611 ENSG00000248489.1 CTD-2007H13.3 -9.98 2.03e-21 4.3e-18 -0.51 -0.42 Lung function (FEV1/FVC); chr5:98809801 chr5:98929171~98995013:+ LUSC cis rs9322193 0.923 rs10782317 ENSG00000216906.2 RP11-350J20.9 -9.98 2.03e-21 4.31e-18 -0.5 -0.42 Lung cancer; chr6:149753911 chr6:149904243~149906418:+ LUSC cis rs4774565 0.762 rs8041193 ENSG00000244879.4 GABPB1-AS1 -9.98 2.07e-21 4.39e-18 -0.37 -0.42 Breast cancer; chr15:50369960 chr15:50354959~50372202:+ LUSC cis rs6538678 0.746 rs703693 ENSG00000258343.1 RP11-536G4.2 -9.98 2.08e-21 4.41e-18 -0.58 -0.42 Lupus nephritis in systemic lupus erythematosus; chr12:95866214 chr12:95795345~95858839:- LUSC cis rs9326248 1 rs9326248 ENSG00000280143.1 AP000892.6 9.98 2.15e-21 4.55e-18 0.48 0.42 Blood protein levels; chr11:117128509 chr11:117204967~117210292:+ LUSC cis rs150992 0.79 rs161731 ENSG00000248489.1 CTD-2007H13.3 9.98 2.17e-21 4.59e-18 0.5 0.42 Body mass index; chr5:98984339 chr5:98929171~98995013:+ LUSC cis rs7208859 0.623 rs73269916 ENSG00000263531.1 RP13-753N3.1 9.98 2.17e-21 4.59e-18 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30863921~30864940:- LUSC cis rs9322193 0.923 rs4870052 ENSG00000216906.2 RP11-350J20.9 9.97 2.2e-21 4.66e-18 0.51 0.42 Lung cancer; chr6:149839978 chr6:149904243~149906418:+ LUSC cis rs3931020 0.671 rs1327088 ENSG00000272864.1 RP11-17E13.2 -9.97 2.2e-21 4.66e-18 -0.47 -0.42 Resistin levels; chr1:74789807 chr1:74698769~74699333:- LUSC cis rs9322193 0.567 rs7747457 ENSG00000223701.3 RAET1E-AS1 9.97 2.21e-21 4.67e-18 0.47 0.42 Lung cancer; chr6:149892366 chr6:149884431~149919508:+ LUSC cis rs10129255 0.789 rs61997796 ENSG00000223648.3 IGHV3-64 9.97 2.26e-21 4.77e-18 0.39 0.42 Kawasaki disease; chr14:106813798 chr14:106643132~106658258:- LUSC cis rs10875746 0.903 rs2158516 ENSG00000240399.1 RP1-228P16.1 -9.97 2.27e-21 4.79e-18 -0.48 -0.42 Longevity (90 years and older); chr12:48097051 chr12:48054813~48055591:- LUSC cis rs3931020 0.962 rs2185695 ENSG00000272864.1 RP11-17E13.2 -9.97 2.28e-21 4.81e-18 -0.53 -0.42 Resistin levels; chr1:74792197 chr1:74698769~74699333:- LUSC cis rs6921919 0.848 rs9468350 ENSG00000216901.1 AL022393.7 9.97 2.3e-21 4.85e-18 0.55 0.42 Autism spectrum disorder or schizophrenia; chr6:28351330 chr6:28176188~28176674:+ LUSC cis rs1150668 0.835 rs1233696 ENSG00000204709.4 LINC01556 9.97 2.3e-21 4.85e-18 0.5 0.42 Pubertal anthropometrics; chr6:28175232 chr6:28943877~28944537:+ LUSC cis rs733592 0.56 rs2158515 ENSG00000240399.1 RP1-228P16.1 -9.97 2.32e-21 4.9e-18 -0.4 -0.42 Plateletcrit; chr12:48113885 chr12:48054813~48055591:- LUSC cis rs9322193 0.923 rs10782316 ENSG00000216906.2 RP11-350J20.9 9.97 2.32e-21 4.9e-18 0.5 0.42 Lung cancer; chr6:149752755 chr6:149904243~149906418:+ LUSC cis rs1707322 0.721 rs4559551 ENSG00000280836.1 AL355480.1 -9.97 2.35e-21 4.95e-18 -0.49 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701861 chr1:45581219~45581321:- LUSC cis rs7617773 0.963 rs9822496 ENSG00000229759.1 MRPS18AP1 9.96 2.41e-21 5.07e-18 0.41 0.42 Coronary artery disease; chr3:48139843 chr3:48256350~48256938:- LUSC cis rs6782228 0.675 rs4857918 ENSG00000277250.1 Metazoa_SRP -9.96 2.42e-21 5.08e-18 -0.46 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128665117 chr3:128673681~128674021:- LUSC cis rs9326248 0.954 rs10790177 ENSG00000280143.1 AP000892.6 9.96 2.42e-21 5.1e-18 0.47 0.42 Blood protein levels; chr11:117177701 chr11:117204967~117210292:+ LUSC cis rs6452524 0.935 rs1017794 ENSG00000249664.1 CTD-2227C6.2 9.96 2.44e-21 5.14e-18 0.43 0.42 Hypertension (SNP x SNP interaction); chr5:83086236 chr5:83012285~83013109:- LUSC cis rs875971 0.825 rs59466412 ENSG00000226824.5 RP4-756H11.3 9.96 2.49e-21 5.23e-18 0.51 0.42 Aortic root size; chr7:66100371 chr7:66654538~66669855:+ LUSC cis rs9322193 0.923 rs9480031 ENSG00000216906.2 RP11-350J20.9 9.96 2.49e-21 5.25e-18 0.5 0.42 Lung cancer; chr6:149758875 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs7774787 ENSG00000223701.3 RAET1E-AS1 9.96 2.5e-21 5.25e-18 0.47 0.42 Testicular germ cell tumor; chr6:149888296 chr6:149884431~149919508:+ LUSC cis rs748404 0.56 rs572837 ENSG00000249839.1 AC011330.5 -9.96 2.53e-21 5.31e-18 -0.57 -0.42 Lung cancer; chr15:43531615 chr15:43663654~43684339:- LUSC cis rs6782228 0.876 rs34198449 ENSG00000242551.2 POU5F1P6 9.96 2.53e-21 5.32e-18 0.52 0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128662427 chr3:128674735~128677005:- LUSC cis rs1185460 1 rs1784305 ENSG00000271751.1 RP11-110I1.14 -9.96 2.56e-21 5.37e-18 -0.53 -0.42 Coronary artery disease; chr11:119071338 chr11:119065263~119065677:- LUSC cis rs172166 0.516 rs1225710 ENSG00000204709.4 LINC01556 -9.96 2.58e-21 5.41e-18 -0.51 -0.42 Cardiac Troponin-T levels; chr6:28132862 chr6:28943877~28944537:+ LUSC cis rs9322193 0.884 rs9688699 ENSG00000216906.2 RP11-350J20.9 9.96 2.58e-21 5.42e-18 0.51 0.42 Lung cancer; chr6:149733680 chr6:149904243~149906418:+ LUSC cis rs9660180 0.783 rs1107910 ENSG00000268575.1 RP1-283E3.8 -9.95 2.65e-21 5.56e-18 -0.38 -0.42 Body mass index; chr1:1760882 chr1:1702736~1737688:- LUSC cis rs10129255 0.957 rs8009948 ENSG00000223648.3 IGHV3-64 9.95 2.66e-21 5.59e-18 0.39 0.42 Kawasaki disease; chr14:106805607 chr14:106643132~106658258:- LUSC cis rs8062405 0.824 rs28698667 ENSG00000259982.1 CDC37P1 9.95 2.69e-21 5.63e-18 0.52 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28521750 chr16:28700294~28701540:- LUSC cis rs875971 0.862 rs709609 ENSG00000226824.5 RP4-756H11.3 9.95 2.73e-21 5.72e-18 0.5 0.42 Aortic root size; chr7:66095574 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs1167399 ENSG00000226824.5 RP4-756H11.3 9.95 2.73e-21 5.72e-18 0.5 0.42 Aortic root size; chr7:66096890 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs57866200 ENSG00000226824.5 RP4-756H11.3 9.95 2.73e-21 5.72e-18 0.5 0.42 Aortic root size; chr7:66100405 chr7:66654538~66669855:+ LUSC cis rs10875746 0.855 rs10875731 ENSG00000240399.1 RP1-228P16.1 -9.95 2.79e-21 5.84e-18 -0.48 -0.42 Longevity (90 years and older); chr12:48038960 chr12:48054813~48055591:- LUSC cis rs11155671 0.53 rs9383577 ENSG00000223701.3 RAET1E-AS1 9.95 2.81e-21 5.88e-18 0.47 0.42 Testicular germ cell tumor; chr6:149886059 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs9383914 ENSG00000223701.3 RAET1E-AS1 9.95 2.81e-21 5.88e-18 0.47 0.42 Testicular germ cell tumor; chr6:149886098 chr6:149884431~149919508:+ LUSC cis rs11155671 0.517 rs9397058 ENSG00000223701.3 RAET1E-AS1 9.95 2.81e-21 5.88e-18 0.47 0.42 Testicular germ cell tumor; chr6:149886113 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs7768626 ENSG00000223701.3 RAET1E-AS1 9.95 2.81e-21 5.88e-18 0.47 0.42 Testicular germ cell tumor; chr6:149886826 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs7768665 ENSG00000223701.3 RAET1E-AS1 9.95 2.81e-21 5.88e-18 0.47 0.42 Testicular germ cell tumor; chr6:149886888 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs7758020 ENSG00000223701.3 RAET1E-AS1 9.95 2.81e-21 5.88e-18 0.47 0.42 Testicular germ cell tumor; chr6:149886975 chr6:149884431~149919508:+ LUSC cis rs977987 0.843 rs4888427 ENSG00000261783.1 RP11-252K23.2 -9.94 2.83e-21 5.92e-18 -0.57 -0.42 Dupuytren's disease; chr16:75444549 chr16:75379818~75381260:- LUSC cis rs875971 0.862 rs1167408 ENSG00000226824.5 RP4-756H11.3 9.94 2.85e-21 5.95e-18 0.5 0.42 Aortic root size; chr7:66091121 chr7:66654538~66669855:+ LUSC cis rs875971 0.83 rs1167406 ENSG00000226824.5 RP4-756H11.3 9.94 2.85e-21 5.95e-18 0.5 0.42 Aortic root size; chr7:66091949 chr7:66654538~66669855:+ LUSC cis rs1707322 0.686 rs1250 ENSG00000280836.1 AL355480.1 -9.94 2.89e-21 6.03e-18 -0.51 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628355 chr1:45581219~45581321:- LUSC cis rs4423214 0.798 rs12224205 ENSG00000254682.1 RP11-660L16.2 -9.94 2.91e-21 6.07e-18 -0.58 -0.42 Vitamin D levels; chr11:71469946 chr11:71448674~71452157:+ LUSC cis rs2108622 0.727 rs9305069 ENSG00000267453.5 AC004791.2 -9.94 2.91e-21 6.07e-18 -0.55 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872576 chr19:15851993~15864904:- LUSC cis rs3091242 0.933 rs7541095 ENSG00000261349.1 RP3-465N24.5 -9.94 2.93e-21 6.12e-18 -0.5 -0.42 Erythrocyte sedimentation rate; chr1:25434800 chr1:25266102~25267136:- LUSC cis rs7396835 0.8 rs6589572 ENSG00000254851.1 RP11-109L13.1 -9.94 2.95e-21 6.17e-18 -0.76 -0.42 Quantitative traits; chr11:116810847 chr11:117135528~117138582:+ LUSC cis rs7208859 0.623 rs9895785 ENSG00000263531.1 RP13-753N3.1 -9.94 2.97e-21 6.2e-18 -0.75 -0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780690 chr17:30863921~30864940:- LUSC cis rs875971 0.756 rs2901210 ENSG00000226824.5 RP4-756H11.3 9.94 2.99e-21 6.23e-18 0.5 0.42 Aortic root size; chr7:66552518 chr7:66654538~66669855:+ LUSC cis rs11168351 0.517 rs10875754 ENSG00000240399.1 RP1-228P16.1 9.94 3e-21 6.26e-18 0.39 0.42 Bipolar disorder and schizophrenia; chr12:48164139 chr12:48054813~48055591:- LUSC cis rs150992 0.751 rs172874 ENSG00000248489.1 CTD-2007H13.3 9.94 3.01e-21 6.29e-18 0.49 0.42 Body mass index; chr5:98969402 chr5:98929171~98995013:+ LUSC cis rs10129255 0.912 rs67410411 ENSG00000223648.3 IGHV3-64 9.94 3.02e-21 6.29e-18 0.39 0.42 Kawasaki disease; chr14:106680324 chr14:106643132~106658258:- LUSC cis rs10129255 1 rs11621409 ENSG00000223648.3 IGHV3-64 9.94 3.03e-21 6.32e-18 0.39 0.42 Kawasaki disease; chr14:106695603 chr14:106643132~106658258:- LUSC cis rs7208859 0.623 rs7214570 ENSG00000263531.1 RP13-753N3.1 9.93 3.15e-21 6.56e-18 0.73 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30820146 chr17:30863921~30864940:- LUSC cis rs11155671 0.53 rs9322228 ENSG00000223701.3 RAET1E-AS1 9.93 3.17e-21 6.6e-18 0.47 0.42 Testicular germ cell tumor; chr6:149888173 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs2342767 ENSG00000223701.3 RAET1E-AS1 9.93 3.17e-21 6.6e-18 0.47 0.42 Testicular germ cell tumor; chr6:149888581 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs7764376 ENSG00000223701.3 RAET1E-AS1 9.93 3.17e-21 6.6e-18 0.47 0.42 Testicular germ cell tumor; chr6:149889208 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs6933882 ENSG00000223701.3 RAET1E-AS1 9.93 3.17e-21 6.6e-18 0.47 0.42 Testicular germ cell tumor; chr6:149889666 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs6939761 ENSG00000223701.3 RAET1E-AS1 9.93 3.17e-21 6.6e-18 0.47 0.42 Testicular germ cell tumor; chr6:149889858 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs3823021 ENSG00000223701.3 RAET1E-AS1 9.93 3.17e-21 6.6e-18 0.47 0.42 Testicular germ cell tumor; chr6:149889863 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs4869764 ENSG00000223701.3 RAET1E-AS1 9.93 3.17e-21 6.6e-18 0.47 0.42 Testicular germ cell tumor; chr6:149890692 chr6:149884431~149919508:+ LUSC cis rs10129255 1 rs8012033 ENSG00000223648.3 IGHV3-64 9.93 3.19e-21 6.64e-18 0.38 0.42 Kawasaki disease; chr14:106678854 chr14:106643132~106658258:- LUSC cis rs10129255 0.912 rs8011090 ENSG00000223648.3 IGHV3-64 9.93 3.19e-21 6.64e-18 0.38 0.42 Kawasaki disease; chr14:106678896 chr14:106643132~106658258:- LUSC cis rs9322193 0.923 rs11155677 ENSG00000216906.2 RP11-350J20.9 9.93 3.21e-21 6.67e-18 0.5 0.42 Lung cancer; chr6:149756953 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs9480009 ENSG00000216906.2 RP11-350J20.9 9.93 3.21e-21 6.67e-18 0.5 0.42 Lung cancer; chr6:149758502 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs7769101 ENSG00000216906.2 RP11-350J20.9 9.93 3.22e-21 6.68e-18 0.5 0.42 Lung cancer; chr6:149848768 chr6:149904243~149906418:+ LUSC cis rs875971 0.861 rs801215 ENSG00000226824.5 RP4-756H11.3 9.93 3.23e-21 6.71e-18 0.5 0.42 Aortic root size; chr7:66546951 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs1860469 ENSG00000226824.5 RP4-756H11.3 9.93 3.27e-21 6.8e-18 0.51 0.42 Aortic root size; chr7:66641888 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs4718383 ENSG00000226824.5 RP4-756H11.3 9.93 3.27e-21 6.8e-18 0.51 0.42 Aortic root size; chr7:66643422 chr7:66654538~66669855:+ LUSC cis rs150992 0.711 rs331918 ENSG00000248489.1 CTD-2007H13.3 9.93 3.31e-21 6.86e-18 0.53 0.42 Body mass index; chr5:98823040 chr5:98929171~98995013:+ LUSC cis rs8062405 1 rs12443881 ENSG00000259982.1 CDC37P1 9.92 3.37e-21 6.99e-18 0.52 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28830456 chr16:28700294~28701540:- LUSC cis rs10129255 0.957 rs17113284 ENSG00000223648.3 IGHV3-64 -9.92 3.38e-21 7.01e-18 -0.37 -0.42 Kawasaki disease; chr14:106684476 chr14:106643132~106658258:- LUSC cis rs150992 0.821 rs326480 ENSG00000248489.1 CTD-2007H13.3 9.92 3.39e-21 7.02e-18 0.48 0.42 Body mass index; chr5:98949263 chr5:98929171~98995013:+ LUSC cis rs6452524 0.901 rs1600362 ENSG00000249664.1 CTD-2227C6.2 9.92 3.4e-21 7.04e-18 0.43 0.42 Hypertension (SNP x SNP interaction); chr5:83091354 chr5:83012285~83013109:- LUSC cis rs6782228 0.651 rs9852825 ENSG00000277250.1 Metazoa_SRP -9.92 3.52e-21 7.29e-18 -0.46 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128668514 chr3:128673681~128674021:- LUSC cis rs6782228 0.651 rs9289332 ENSG00000277250.1 Metazoa_SRP -9.92 3.52e-21 7.29e-18 -0.46 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128669041 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs7613073 ENSG00000277250.1 Metazoa_SRP -9.92 3.52e-21 7.29e-18 -0.46 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128669660 chr3:128673681~128674021:- LUSC cis rs7301826 1 rs1106369 ENSG00000256299.1 RP11-989F5.3 -9.92 3.56e-21 7.37e-18 -0.44 -0.42 Plasma plasminogen activator levels; chr12:130815550 chr12:130810821~130812622:- LUSC cis rs2455601 0.507 rs2568044 ENSG00000254860.4 TMEM9B-AS1 -9.92 3.6e-21 7.44e-18 -0.53 -0.42 Schizophrenia; chr11:8980930 chr11:8964675~8977527:+ LUSC cis rs35955747 0.533 rs5998004 ENSG00000236132.1 CTA-440B3.1 9.92 3.6e-21 7.45e-18 0.5 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31485843 chr22:31816379~31817491:- LUSC cis rs10129255 0.53 rs11624912 ENSG00000211972.2 IGHV3-66 9.91 3.62e-21 7.49e-18 0.28 0.42 Kawasaki disease; chr14:106673891 chr14:106675017~106675544:- LUSC cis rs6782228 0.675 rs9841987 ENSG00000277250.1 Metazoa_SRP -9.91 3.63e-21 7.5e-18 -0.46 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128666299 chr3:128673681~128674021:- LUSC cis rs6782228 0.675 rs56141228 ENSG00000277250.1 Metazoa_SRP -9.91 3.63e-21 7.5e-18 -0.46 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128667199 chr3:128673681~128674021:- LUSC cis rs10875746 0.951 rs2269935 ENSG00000240399.1 RP1-228P16.1 -9.91 3.65e-21 7.54e-18 -0.5 -0.42 Longevity (90 years and older); chr12:48122681 chr12:48054813~48055591:- LUSC cis rs7301826 1 rs1609985 ENSG00000256299.1 RP11-989F5.3 -9.91 3.66e-21 7.56e-18 -0.45 -0.42 Plasma plasminogen activator levels; chr12:130835625 chr12:130810821~130812622:- LUSC cis rs9326248 1 rs664922 ENSG00000280143.1 AP000892.6 9.91 3.66e-21 7.56e-18 0.47 0.42 Blood protein levels; chr11:117200179 chr11:117204967~117210292:+ LUSC cis rs9326248 1 rs664082 ENSG00000280143.1 AP000892.6 9.91 3.66e-21 7.56e-18 0.47 0.42 Blood protein levels; chr11:117200354 chr11:117204967~117210292:+ LUSC cis rs17826219 0.561 rs11655876 ENSG00000263531.1 RP13-753N3.1 9.91 3.7e-21 7.64e-18 0.7 0.42 Body mass index; chr17:30690132 chr17:30863921~30864940:- LUSC cis rs9322193 0.923 rs10872644 ENSG00000216906.2 RP11-350J20.9 9.91 3.71e-21 7.67e-18 0.5 0.42 Lung cancer; chr6:149741819 chr6:149904243~149906418:+ LUSC cis rs733592 0.524 rs10875726 ENSG00000240399.1 RP1-228P16.1 -9.91 3.72e-21 7.67e-18 -0.4 -0.42 Plateletcrit; chr12:48032209 chr12:48054813~48055591:- LUSC cis rs733592 0.524 rs10875727 ENSG00000240399.1 RP1-228P16.1 -9.91 3.72e-21 7.67e-18 -0.4 -0.42 Plateletcrit; chr12:48032360 chr12:48054813~48055591:- LUSC cis rs2019137 0.56 rs7578633 ENSG00000274877.1 RP11-65I12.1 -9.91 3.72e-21 7.68e-18 -0.52 -0.42 Lymphocyte counts; chr2:113221073 chr2:113237595~113240825:+ LUSC cis rs2019137 0.539 rs11123170 ENSG00000274877.1 RP11-65I12.1 -9.91 3.72e-21 7.68e-18 -0.52 -0.42 Lymphocyte counts; chr2:113221363 chr2:113237595~113240825:+ LUSC cis rs6452524 0.868 rs10071617 ENSG00000249664.1 CTD-2227C6.2 9.91 3.74e-21 7.72e-18 0.42 0.42 Hypertension (SNP x SNP interaction); chr5:83103207 chr5:83012285~83013109:- LUSC cis rs150992 0.861 rs428836 ENSG00000248489.1 CTD-2007H13.3 9.91 3.75e-21 7.73e-18 0.49 0.42 Body mass index; chr5:98951673 chr5:98929171~98995013:+ LUSC cis rs2455601 0.882 rs11042106 ENSG00000254860.4 TMEM9B-AS1 -9.91 3.82e-21 7.88e-18 -0.57 -0.42 Schizophrenia; chr11:8874536 chr11:8964675~8977527:+ LUSC cis rs7208859 0.673 rs9907197 ENSG00000263531.1 RP13-753N3.1 9.91 3.85e-21 7.93e-18 0.7 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30691245 chr17:30863921~30864940:- LUSC cis rs7208859 0.673 rs9915963 ENSG00000263531.1 RP13-753N3.1 9.91 3.85e-21 7.93e-18 0.7 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30692625 chr17:30863921~30864940:- LUSC cis rs35955747 0.633 rs5998002 ENSG00000236132.1 CTA-440B3.1 9.91 3.86e-21 7.96e-18 0.5 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31485183 chr22:31816379~31817491:- LUSC cis rs7208859 0.725 rs9891656 ENSG00000263531.1 RP13-753N3.1 9.91 3.87e-21 7.96e-18 0.67 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916337 chr17:30863921~30864940:- LUSC cis rs9322193 0.962 rs2342764 ENSG00000216906.2 RP11-350J20.9 9.91 3.88e-21 7.98e-18 0.51 0.42 Lung cancer; chr6:149835068 chr6:149904243~149906418:+ LUSC cis rs2108622 0.727 rs55954696 ENSG00000267453.5 AC004791.2 -9.91 3.9e-21 8.03e-18 -0.54 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870995 chr19:15851993~15864904:- LUSC cis rs2108622 0.683 rs56228205 ENSG00000267453.5 AC004791.2 -9.91 3.9e-21 8.03e-18 -0.54 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871163 chr19:15851993~15864904:- LUSC cis rs62229266 0.773 rs878606 ENSG00000231106.2 LINC01436 9.91 3.91e-21 8.05e-18 0.55 0.42 Mitral valve prolapse; chr21:36034394 chr21:36005338~36007838:+ LUSC cis rs2108622 0.727 rs62106155 ENSG00000267453.5 AC004791.2 -9.91 3.92e-21 8.06e-18 -0.54 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869550 chr19:15851993~15864904:- LUSC cis rs35955747 0.738 rs2012451 ENSG00000236132.1 CTA-440B3.1 9.9 4.12e-21 8.47e-18 0.51 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31448387 chr22:31816379~31817491:- LUSC cis rs7188445 0.871 rs11150187 ENSG00000261390.4 RP11-345M22.2 9.9 4.15e-21 8.53e-18 0.55 0.42 Urate levels; chr16:79670515 chr16:79715232~79770563:- LUSC cis rs10129255 1 rs61997605 ENSG00000223648.3 IGHV3-64 9.9 4.19e-21 8.6e-18 0.38 0.42 Kawasaki disease; chr14:106678368 chr14:106643132~106658258:- LUSC cis rs10875746 0.855 rs73102067 ENSG00000240399.1 RP1-228P16.1 -9.9 4.23e-21 8.68e-18 -0.48 -0.42 Longevity (90 years and older); chr12:48100643 chr12:48054813~48055591:- LUSC cis rs6921919 0.515 rs1339898 ENSG00000216901.1 AL022393.7 9.9 4.23e-21 8.69e-18 0.47 0.42 Autism spectrum disorder or schizophrenia; chr6:28427729 chr6:28176188~28176674:+ LUSC cis rs1891275 0.551 rs7900863 ENSG00000228701.1 TNKS2-AS1 -9.89 4.32e-21 8.85e-18 -0.51 -0.42 Intelligence (multi-trait analysis); chr10:91665737 chr10:91782839~91798291:- LUSC cis rs1891275 0.588 rs6583782 ENSG00000228701.1 TNKS2-AS1 -9.89 4.32e-21 8.85e-18 -0.51 -0.42 Intelligence (multi-trait analysis); chr10:91666022 chr10:91782839~91798291:- LUSC cis rs1891275 0.576 rs1891272 ENSG00000228701.1 TNKS2-AS1 -9.89 4.32e-21 8.85e-18 -0.51 -0.42 Intelligence (multi-trait analysis); chr10:91666306 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs1891271 ENSG00000228701.1 TNKS2-AS1 -9.89 4.32e-21 8.85e-18 -0.51 -0.42 Intelligence (multi-trait analysis); chr10:91666566 chr10:91782839~91798291:- LUSC cis rs8062405 1 rs12446589 ENSG00000259982.1 CDC37P1 9.89 4.4e-21 9.02e-18 0.52 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859641 chr16:28700294~28701540:- LUSC cis rs2019137 0.539 rs6755040 ENSG00000274877.1 RP11-65I12.1 -9.89 4.45e-21 9.11e-18 -0.52 -0.42 Lymphocyte counts; chr2:113223560 chr2:113237595~113240825:+ LUSC cis rs11098499 0.954 rs17005535 ENSG00000245958.5 RP11-33B1.1 -9.89 4.49e-21 9.21e-18 -0.42 -0.41 Corneal astigmatism; chr4:119490407 chr4:119454791~119552025:+ LUSC cis rs10875746 0.903 rs11168418 ENSG00000240399.1 RP1-228P16.1 -9.89 4.52e-21 9.25e-18 -0.47 -0.41 Longevity (90 years and older); chr12:48121971 chr12:48054813~48055591:- LUSC cis rs7104764 0.778 rs7930823 ENSG00000277290.1 RP11-326C3.16 9.89 4.52e-21 9.26e-18 0.35 0.41 Menarche (age at onset); chr11:206767 chr11:243099~243483:- LUSC cis rs8062405 1 rs72793812 ENSG00000259982.1 CDC37P1 9.89 4.53e-21 9.27e-18 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28829060 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs7498555 ENSG00000259982.1 CDC37P1 9.89 4.55e-21 9.31e-18 0.53 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28882250 chr16:28700294~28701540:- LUSC cis rs765787 0.53 rs4774542 ENSG00000259520.4 CTD-2651B20.3 -9.89 4.59e-21 9.39e-18 -0.52 -0.41 Uric acid levels; chr15:45233828 chr15:45251580~45279251:- LUSC cis rs10129255 0.509 rs756583 ENSG00000280411.1 IGHV1-69-2 -9.89 4.6e-21 9.41e-18 -0.26 -0.41 Kawasaki disease; chr14:106680002 chr14:106762092~106762588:- LUSC cis rs10875746 0.903 rs725454 ENSG00000240399.1 RP1-228P16.1 -9.89 4.61e-21 9.43e-18 -0.48 -0.41 Longevity (90 years and older); chr12:48108317 chr12:48054813~48055591:- LUSC cis rs875971 0.964 rs160635 ENSG00000226824.5 RP4-756H11.3 -9.88 4.66e-21 9.54e-18 -0.5 -0.41 Aortic root size; chr7:66063931 chr7:66654538~66669855:+ LUSC cis rs7188445 1 rs11646791 ENSG00000261390.4 RP11-345M22.2 -9.88 4.7e-21 9.61e-18 -0.57 -0.41 Urate levels; chr16:79667641 chr16:79715232~79770563:- LUSC cis rs11089937 0.963 rs5757078 ENSG00000211639.2 IGLV4-60 9.88 4.74e-21 9.68e-18 0.42 0.41 Periodontitis (PAL4Q3); chr22:22145526 chr22:22162199~22162681:+ LUSC cis rs6452524 0.836 rs1478484 ENSG00000249664.1 CTD-2227C6.2 9.88 4.74e-21 9.69e-18 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83085055 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs7714710 ENSG00000249664.1 CTD-2227C6.2 9.88 4.74e-21 9.69e-18 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83085750 chr5:83012285~83013109:- LUSC cis rs12439619 1 rs35152457 ENSG00000255769.6 GOLGA2P10 -9.88 4.77e-21 9.75e-18 -0.53 -0.41 Intelligence (multi-trait analysis); chr15:82254207 chr15:82472993~82513950:- LUSC cis rs10129255 0.956 rs10137268 ENSG00000223648.3 IGHV3-64 9.88 4.78e-21 9.77e-18 0.39 0.41 Kawasaki disease; chr14:106697402 chr14:106643132~106658258:- LUSC cis rs10875746 0.903 rs12313404 ENSG00000240399.1 RP1-228P16.1 -9.88 4.79e-21 9.78e-18 -0.48 -0.41 Longevity (90 years and older); chr12:48098265 chr12:48054813~48055591:- LUSC cis rs6921919 0.515 rs1558205 ENSG00000216901.1 AL022393.7 -9.88 4.8e-21 9.81e-18 -0.47 -0.41 Autism spectrum disorder or schizophrenia; chr6:28414485 chr6:28176188~28176674:+ LUSC cis rs8062405 0.824 rs62034319 ENSG00000259982.1 CDC37P1 9.88 4.81e-21 9.83e-18 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28520867 chr16:28700294~28701540:- LUSC cis rs11098499 0.954 rs12508504 ENSG00000245958.5 RP11-33B1.1 -9.88 4.84e-21 9.88e-18 -0.42 -0.41 Corneal astigmatism; chr4:119489452 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs10006525 ENSG00000245958.5 RP11-33B1.1 -9.88 4.95e-21 1.01e-17 -0.43 -0.41 Corneal astigmatism; chr4:119487776 chr4:119454791~119552025:+ LUSC cis rs10875746 0.903 rs4760681 ENSG00000240399.1 RP1-228P16.1 -9.88 4.99e-21 1.02e-17 -0.47 -0.41 Longevity (90 years and older); chr12:48111447 chr12:48054813~48055591:- LUSC cis rs10875746 0.904 rs11168422 ENSG00000240399.1 RP1-228P16.1 -9.88 5.02e-21 1.02e-17 -0.47 -0.41 Longevity (90 years and older); chr12:48125722 chr12:48054813~48055591:- LUSC cis rs17826219 0.568 rs11658027 ENSG00000263531.1 RP13-753N3.1 -9.87 5.05e-21 1.03e-17 -0.72 -0.41 Body mass index; chr17:30767864 chr17:30863921~30864940:- LUSC cis rs507080 0.922 rs654792 ENSG00000255422.1 AP002954.4 9.87 5.17e-21 1.05e-17 0.48 0.41 Serum metabolite levels; chr11:118682287 chr11:118704607~118750263:+ LUSC cis rs7208859 0.573 rs8070182 ENSG00000263531.1 RP13-753N3.1 9.87 5.21e-21 1.06e-17 0.71 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30863921~30864940:- LUSC cis rs507080 0.501 rs494459 ENSG00000255239.1 AP002954.6 -9.87 5.22e-21 1.06e-17 -0.44 -0.41 Serum metabolite levels; chr11:118703966 chr11:118688039~118690600:- LUSC cis rs1891275 0.527 rs35812291 ENSG00000228701.1 TNKS2-AS1 -9.87 5.25e-21 1.07e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91642584 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs4933681 ENSG00000228701.1 TNKS2-AS1 -9.87 5.25e-21 1.07e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91643365 chr10:91782839~91798291:- LUSC cis rs6452524 0.935 rs6868416 ENSG00000249664.1 CTD-2227C6.2 9.87 5.26e-21 1.07e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83084320 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs1478485 ENSG00000249664.1 CTD-2227C6.2 9.87 5.26e-21 1.07e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83084708 chr5:83012285~83013109:- LUSC cis rs8062405 0.824 rs4788083 ENSG00000259982.1 CDC37P1 9.87 5.26e-21 1.07e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534128 chr16:28700294~28701540:- LUSC cis rs748404 0.56 rs1869258 ENSG00000249839.1 AC011330.5 -9.87 5.28e-21 1.07e-17 -0.56 -0.41 Lung cancer; chr15:43511423 chr15:43663654~43684339:- LUSC cis rs733592 1 rs733592 ENSG00000240399.1 RP1-228P16.1 -9.87 5.36e-21 1.09e-17 -0.38 -0.41 Plateletcrit; chr12:48035993 chr12:48054813~48055591:- LUSC cis rs733592 0.931 rs765260 ENSG00000240399.1 RP1-228P16.1 -9.87 5.36e-21 1.09e-17 -0.38 -0.41 Plateletcrit; chr12:48038153 chr12:48054813~48055591:- LUSC cis rs9322193 0.884 rs9397036 ENSG00000216906.2 RP11-350J20.9 9.87 5.44e-21 1.11e-17 0.5 0.41 Lung cancer; chr6:149851787 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs9383864 ENSG00000216906.2 RP11-350J20.9 9.87 5.44e-21 1.11e-17 0.5 0.41 Lung cancer; chr6:149851969 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs9383865 ENSG00000216906.2 RP11-350J20.9 9.87 5.44e-21 1.11e-17 0.5 0.41 Lung cancer; chr6:149852043 chr6:149904243~149906418:+ LUSC cis rs2019137 0.56 rs6707386 ENSG00000274877.1 RP11-65I12.1 -9.86 5.54e-21 1.13e-17 -0.52 -0.41 Lymphocyte counts; chr2:113223445 chr2:113237595~113240825:+ LUSC cis rs1891275 0.551 rs7071844 ENSG00000228701.1 TNKS2-AS1 -9.86 5.55e-21 1.13e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91644092 chr10:91782839~91798291:- LUSC cis rs977987 0.843 rs11649638 ENSG00000261783.1 RP11-252K23.2 -9.86 5.6e-21 1.14e-17 -0.57 -0.41 Dupuytren's disease; chr16:75454387 chr16:75379818~75381260:- LUSC cis rs7301826 0.934 rs10773826 ENSG00000256299.1 RP11-989F5.3 -9.86 5.64e-21 1.15e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130836629 chr12:130810821~130812622:- LUSC cis rs9322193 0.884 rs880245 ENSG00000216906.2 RP11-350J20.9 -9.86 5.68e-21 1.15e-17 -0.5 -0.41 Lung cancer; chr6:149846262 chr6:149904243~149906418:+ LUSC cis rs11155671 0.53 rs2342769 ENSG00000223701.3 RAET1E-AS1 9.86 5.68e-21 1.15e-17 0.46 0.41 Testicular germ cell tumor; chr6:149895371 chr6:149884431~149919508:+ LUSC cis rs10875746 0.859 rs4760695 ENSG00000240399.1 RP1-228P16.1 -9.86 5.79e-21 1.17e-17 -0.46 -0.41 Longevity (90 years and older); chr12:48198065 chr12:48054813~48055591:- LUSC cis rs2108622 0.727 rs62106156 ENSG00000267453.5 AC004791.2 -9.86 5.81e-21 1.18e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869614 chr19:15851993~15864904:- LUSC cis rs150992 0.631 rs112047336 ENSG00000248489.1 CTD-2007H13.3 9.86 5.85e-21 1.19e-17 0.48 0.41 Body mass index; chr5:98990041 chr5:98929171~98995013:+ LUSC cis rs150992 0.609 rs112042355 ENSG00000248489.1 CTD-2007H13.3 9.86 5.85e-21 1.19e-17 0.48 0.41 Body mass index; chr5:98990046 chr5:98929171~98995013:+ LUSC cis rs150992 0.587 rs75001231 ENSG00000248489.1 CTD-2007H13.3 9.86 5.85e-21 1.19e-17 0.48 0.41 Body mass index; chr5:98990085 chr5:98929171~98995013:+ LUSC cis rs2455601 0.882 rs11042105 ENSG00000254860.4 TMEM9B-AS1 9.86 5.88e-21 1.19e-17 0.57 0.41 Schizophrenia; chr11:8872963 chr11:8964675~8977527:+ LUSC cis rs875971 0.862 rs2460432 ENSG00000226824.5 RP4-756H11.3 9.86 5.88e-21 1.19e-17 0.5 0.41 Aortic root size; chr7:66089398 chr7:66654538~66669855:+ LUSC cis rs8062405 1 rs12325113 ENSG00000259982.1 CDC37P1 9.86 5.9e-21 1.2e-17 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28837347 chr16:28700294~28701540:- LUSC cis rs56163509 1 rs56163509 ENSG00000259982.1 CDC37P1 9.86 5.9e-21 1.2e-17 0.52 0.41 Tonsillectomy;Mean corpuscular volume; chr16:28853150 chr16:28700294~28701540:- LUSC cis rs8062405 0.964 rs7187333 ENSG00000259982.1 CDC37P1 9.86 5.9e-21 1.2e-17 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854595 chr16:28700294~28701540:- LUSC cis rs8062405 1 rs62037369 ENSG00000259982.1 CDC37P1 9.86 5.9e-21 1.2e-17 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28872520 chr16:28700294~28701540:- LUSC cis rs8062405 0.965 rs7359397 ENSG00000259982.1 CDC37P1 9.86 5.9e-21 1.2e-17 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874338 chr16:28700294~28701540:- LUSC cis rs9322193 0.923 rs12526675 ENSG00000216906.2 RP11-350J20.9 -9.86 5.92e-21 1.2e-17 -0.5 -0.41 Lung cancer; chr6:149729540 chr6:149904243~149906418:+ LUSC cis rs2108622 0.727 rs12609900 ENSG00000267453.5 AC004791.2 -9.85 5.97e-21 1.21e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871604 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs62107763 ENSG00000267453.5 AC004791.2 -9.85 5.97e-21 1.21e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871788 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs62107764 ENSG00000267453.5 AC004791.2 -9.85 5.97e-21 1.21e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871848 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs76984410 ENSG00000267453.5 AC004791.2 -9.85 5.97e-21 1.21e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871890 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs77780918 ENSG00000267453.5 AC004791.2 -9.85 5.97e-21 1.21e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871897 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs8104311 ENSG00000267453.5 AC004791.2 -9.85 5.97e-21 1.21e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871950 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs8101038 ENSG00000267453.5 AC004791.2 -9.85 5.97e-21 1.21e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872054 chr19:15851993~15864904:- LUSC cis rs9322193 0.923 rs9383812 ENSG00000216906.2 RP11-350J20.9 9.85 5.98e-21 1.21e-17 0.5 0.41 Lung cancer; chr6:149712355 chr6:149904243~149906418:+ LUSC cis rs1891275 0.551 rs7088831 ENSG00000228701.1 TNKS2-AS1 -9.85 5.99e-21 1.21e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91652695 chr10:91782839~91798291:- LUSC cis rs1891275 0.576 rs2000178 ENSG00000228701.1 TNKS2-AS1 -9.85 5.99e-21 1.21e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91653287 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs2027486 ENSG00000228701.1 TNKS2-AS1 -9.85 5.99e-21 1.21e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91654229 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs2421623 ENSG00000228701.1 TNKS2-AS1 -9.85 5.99e-21 1.21e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91654700 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs10881941 ENSG00000228701.1 TNKS2-AS1 -9.85 5.99e-21 1.21e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91655154 chr10:91782839~91798291:- LUSC cis rs1891275 0.516 rs10881943 ENSG00000228701.1 TNKS2-AS1 -9.85 5.99e-21 1.21e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91655373 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs7087959 ENSG00000228701.1 TNKS2-AS1 -9.85 5.99e-21 1.21e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91656160 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs4933692 ENSG00000228701.1 TNKS2-AS1 -9.85 6.1e-21 1.23e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91664876 chr10:91782839~91798291:- LUSC cis rs7301826 1 rs2001483 ENSG00000256299.1 RP11-989F5.3 -9.85 6.12e-21 1.24e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130834100 chr12:130810821~130812622:- LUSC cis rs2108622 0.727 rs62107770 ENSG00000267453.5 AC004791.2 -9.85 6.15e-21 1.24e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15874615 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs2158511 ENSG00000267453.5 AC004791.2 -9.85 6.15e-21 1.24e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15875837 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs3093207 ENSG00000267453.5 AC004791.2 -9.85 6.15e-21 1.24e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15877848 chr19:15851993~15864904:- LUSC cis rs507080 0.501 rs516503 ENSG00000255239.1 AP002954.6 9.85 6.2e-21 1.25e-17 0.45 0.41 Serum metabolite levels; chr11:118709639 chr11:118688039~118690600:- LUSC cis rs1891275 0.551 rs4933213 ENSG00000228701.1 TNKS2-AS1 -9.85 6.31e-21 1.27e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91657947 chr10:91782839~91798291:- LUSC cis rs6921919 0.789 rs11970439 ENSG00000216901.1 AL022393.7 9.85 6.33e-21 1.28e-17 0.56 0.41 Autism spectrum disorder or schizophrenia; chr6:28335687 chr6:28176188~28176674:+ LUSC cis rs875971 0.862 rs2909688 ENSG00000226824.5 RP4-756H11.3 -9.85 6.37e-21 1.28e-17 -0.5 -0.41 Aortic root size; chr7:66376625 chr7:66654538~66669855:+ LUSC cis rs1891275 0.54 rs10732773 ENSG00000228701.1 TNKS2-AS1 -9.85 6.43e-21 1.3e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91656468 chr10:91782839~91798291:- LUSC cis rs2108622 0.727 rs8102532 ENSG00000267453.5 AC004791.2 -9.85 6.43e-21 1.3e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869250 chr19:15851993~15864904:- LUSC cis rs875971 0.522 rs1701760 ENSG00000226824.5 RP4-756H11.3 -9.85 6.45e-21 1.3e-17 -0.49 -0.41 Aortic root size; chr7:66008701 chr7:66654538~66669855:+ LUSC cis rs150992 0.711 rs326489 ENSG00000248489.1 CTD-2007H13.3 9.84 6.47e-21 1.3e-17 0.53 0.41 Body mass index; chr5:98841105 chr5:98929171~98995013:+ LUSC cis rs875971 0.793 rs460678 ENSG00000226824.5 RP4-756H11.3 -9.84 6.56e-21 1.32e-17 -0.5 -0.41 Aortic root size; chr7:66062213 chr7:66654538~66669855:+ LUSC cis rs1707322 0.721 rs11211157 ENSG00000280836.1 AL355480.1 -9.84 6.65e-21 1.34e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667172 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs11211158 ENSG00000280836.1 AL355480.1 -9.84 6.65e-21 1.34e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667178 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs6429575 ENSG00000280836.1 AL355480.1 -9.84 6.65e-21 1.34e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668544 chr1:45581219~45581321:- LUSC cis rs1707322 0.685 rs6690926 ENSG00000280836.1 AL355480.1 -9.84 6.65e-21 1.34e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669306 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs8179402 ENSG00000280836.1 AL355480.1 -9.84 6.65e-21 1.34e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45676794 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs8179296 ENSG00000280836.1 AL355480.1 -9.84 6.65e-21 1.34e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45678119 chr1:45581219~45581321:- LUSC cis rs7301826 1 rs10773819 ENSG00000256299.1 RP11-989F5.3 -9.84 6.73e-21 1.36e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130794477 chr12:130810821~130812622:- LUSC cis rs7396835 0.866 rs6589570 ENSG00000254851.1 RP11-109L13.1 -9.84 6.77e-21 1.36e-17 -0.77 -0.41 Quantitative traits; chr11:116804578 chr11:117135528~117138582:+ LUSC cis rs977987 0.843 rs4888372 ENSG00000261783.1 RP11-252K23.2 -9.84 6.78e-21 1.37e-17 -0.56 -0.41 Dupuytren's disease; chr16:75279587 chr16:75379818~75381260:- LUSC cis rs6452524 0.967 rs10065973 ENSG00000249664.1 CTD-2227C6.2 9.84 6.82e-21 1.37e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83123181 chr5:83012285~83013109:- LUSC cis rs9322193 0.884 rs1108889 ENSG00000216906.2 RP11-350J20.9 9.84 6.91e-21 1.39e-17 0.5 0.41 Lung cancer; chr6:149845433 chr6:149904243~149906418:+ LUSC cis rs1891275 0.551 rs7908547 ENSG00000228701.1 TNKS2-AS1 -9.83 7.01e-21 1.41e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91659230 chr10:91782839~91798291:- LUSC cis rs5760092 0.755 rs915589 ENSG00000225282.1 AP000350.6 -9.83 7.04e-21 1.41e-17 -0.59 -0.41 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23926900~23929574:+ LUSC cis rs9322193 0.847 rs9383844 ENSG00000216906.2 RP11-350J20.9 9.83 7.05e-21 1.42e-17 0.49 0.41 Lung cancer; chr6:149716268 chr6:149904243~149906418:+ LUSC cis rs875971 0.83 rs427973 ENSG00000226824.5 RP4-756H11.3 -9.83 7.28e-21 1.46e-17 -0.5 -0.41 Aortic root size; chr7:66061661 chr7:66654538~66669855:+ LUSC cis rs6452524 0.967 rs6897075 ENSG00000249664.1 CTD-2227C6.2 9.83 7.29e-21 1.46e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83122959 chr5:83012285~83013109:- LUSC cis rs9322193 0.567 rs7742692 ENSG00000223701.3 RAET1E-AS1 9.83 7.32e-21 1.47e-17 0.46 0.41 Lung cancer; chr6:149892363 chr6:149884431~149919508:+ LUSC cis rs8091660 0.929 rs3744827 ENSG00000278983.1 RP11-426J5.3 -9.83 7.35e-21 1.47e-17 -0.54 -0.41 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48569572 chr18:48564795~48568342:+ LUSC cis rs977987 0.843 rs59465235 ENSG00000261783.1 RP11-252K23.2 -9.83 7.44e-21 1.49e-17 -0.57 -0.41 Dupuytren's disease; chr16:75449912 chr16:75379818~75381260:- LUSC cis rs2019137 0.56 rs4849179 ENSG00000274877.1 RP11-65I12.1 -9.83 7.46e-21 1.5e-17 -0.51 -0.41 Lymphocyte counts; chr2:113227593 chr2:113237595~113240825:+ LUSC cis rs2337406 0.789 rs60000589 ENSG00000274576.2 IGHV2-70 -9.83 7.47e-21 1.5e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106782459 chr14:106770577~106771020:- LUSC cis rs1891275 0.506 rs4933214 ENSG00000228701.1 TNKS2-AS1 -9.83 7.54e-21 1.51e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91658004 chr10:91782839~91798291:- LUSC cis rs977987 0.815 rs4887829 ENSG00000261783.1 RP11-252K23.2 -9.83 7.55e-21 1.51e-17 -0.57 -0.41 Dupuytren's disease; chr16:75455037 chr16:75379818~75381260:- LUSC cis rs1891275 0.551 rs2421624 ENSG00000228701.1 TNKS2-AS1 -9.83 7.58e-21 1.52e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91656659 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs2421625 ENSG00000228701.1 TNKS2-AS1 -9.83 7.58e-21 1.52e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91656744 chr10:91782839~91798291:- LUSC cis rs1891275 0.576 rs7900117 ENSG00000228701.1 TNKS2-AS1 -9.83 7.58e-21 1.52e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91657530 chr10:91782839~91798291:- LUSC cis rs7301826 1 rs4759524 ENSG00000256299.1 RP11-989F5.3 -9.82 7.65e-21 1.53e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130831065 chr12:130810821~130812622:- LUSC cis rs977987 0.843 rs12928036 ENSG00000261783.1 RP11-252K23.2 -9.82 7.65e-21 1.53e-17 -0.57 -0.41 Dupuytren's disease; chr16:75449234 chr16:75379818~75381260:- LUSC cis rs11155671 0.53 rs7757984 ENSG00000223701.3 RAET1E-AS1 9.82 7.69e-21 1.54e-17 0.46 0.41 Testicular germ cell tumor; chr6:149887515 chr6:149884431~149919508:+ LUSC cis rs11089937 0.926 rs5750601 ENSG00000211639.2 IGLV4-60 9.82 7.76e-21 1.55e-17 0.42 0.41 Periodontitis (PAL4Q3); chr22:22144396 chr22:22162199~22162681:+ LUSC cis rs1707322 0.721 rs10430124 ENSG00000280836.1 AL355480.1 -9.82 7.82e-21 1.57e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755945 chr1:45581219~45581321:- LUSC cis rs2108622 0.727 rs62106157 ENSG00000267453.5 AC004791.2 -9.82 7.84e-21 1.57e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869638 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs62106158 ENSG00000267453.5 AC004791.2 -9.82 7.84e-21 1.57e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869682 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs7256877 ENSG00000267453.5 AC004791.2 -9.82 7.84e-21 1.57e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869873 chr19:15851993~15864904:- LUSC cis rs2108622 0.559 rs7252638 ENSG00000267453.5 AC004791.2 -9.82 7.84e-21 1.57e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870215 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs7253684 ENSG00000267453.5 AC004791.2 -9.82 7.84e-21 1.57e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870316 chr19:15851993~15864904:- LUSC cis rs1891275 0.551 rs4933684 ENSG00000228701.1 TNKS2-AS1 -9.82 7.85e-21 1.57e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91647805 chr10:91782839~91798291:- LUSC cis rs10875746 0.855 rs73102065 ENSG00000240399.1 RP1-228P16.1 -9.82 7.92e-21 1.58e-17 -0.48 -0.41 Longevity (90 years and older); chr12:48098824 chr12:48054813~48055591:- LUSC cis rs7301826 1 rs4759523 ENSG00000256299.1 RP11-989F5.3 -9.82 7.92e-21 1.58e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130830867 chr12:130810821~130812622:- LUSC cis rs17826219 0.706 rs2322197 ENSG00000263531.1 RP13-753N3.1 9.82 8.02e-21 1.6e-17 0.72 0.41 Body mass index; chr17:30778787 chr17:30863921~30864940:- LUSC cis rs1891275 0.515 rs7358148 ENSG00000228701.1 TNKS2-AS1 -9.82 8.05e-21 1.61e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91658775 chr10:91782839~91798291:- LUSC cis rs1891275 0.601 rs7358034 ENSG00000228701.1 TNKS2-AS1 -9.82 8.05e-21 1.61e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91659007 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs2421626 ENSG00000228701.1 TNKS2-AS1 -9.82 8.05e-21 1.61e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91661177 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs2421627 ENSG00000228701.1 TNKS2-AS1 -9.82 8.05e-21 1.61e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91662226 chr10:91782839~91798291:- LUSC cis rs1891275 0.515 rs10881945 ENSG00000228701.1 TNKS2-AS1 -9.82 8.05e-21 1.61e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91663826 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs2421629 ENSG00000228701.1 TNKS2-AS1 -9.82 8.05e-21 1.61e-17 -0.51 -0.41 Intelligence (multi-trait analysis); chr10:91664018 chr10:91782839~91798291:- LUSC cis rs1707322 0.721 rs11211178 ENSG00000280836.1 AL355480.1 -9.82 8.11e-21 1.62e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45761894 chr1:45581219~45581321:- LUSC cis rs11098499 0.954 rs17006190 ENSG00000245958.5 RP11-33B1.1 -9.82 8.14e-21 1.63e-17 -0.42 -0.41 Corneal astigmatism; chr4:119497683 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs3733519 ENSG00000245958.5 RP11-33B1.1 -9.82 8.14e-21 1.63e-17 -0.42 -0.41 Corneal astigmatism; chr4:119502293 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs56397000 ENSG00000216906.2 RP11-350J20.9 9.82 8.22e-21 1.64e-17 0.49 0.41 Lung cancer; chr6:149739347 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs9689702 ENSG00000216906.2 RP11-350J20.9 9.82 8.22e-21 1.64e-17 0.49 0.41 Lung cancer; chr6:149740720 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs10782315 ENSG00000216906.2 RP11-350J20.9 9.82 8.24e-21 1.64e-17 0.49 0.41 Lung cancer; chr6:149743093 chr6:149904243~149906418:+ LUSC cis rs733592 0.507 rs7299704 ENSG00000240399.1 RP1-228P16.1 9.81 8.3e-21 1.66e-17 0.4 0.41 Plateletcrit; chr12:48050705 chr12:48054813~48055591:- LUSC cis rs1707322 0.721 rs10890337 ENSG00000280836.1 AL355480.1 -9.81 8.31e-21 1.66e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658855 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs3811435 ENSG00000280836.1 AL355480.1 -9.81 8.31e-21 1.66e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660118 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs9793568 ENSG00000280836.1 AL355480.1 -9.81 8.31e-21 1.66e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664701 chr1:45581219~45581321:- LUSC cis rs875971 0.862 rs9791713 ENSG00000226824.5 RP4-756H11.3 9.81 8.52e-21 1.7e-17 0.5 0.41 Aortic root size; chr7:66640211 chr7:66654538~66669855:+ LUSC cis rs875971 0.825 rs28480509 ENSG00000226824.5 RP4-756H11.3 9.81 8.54e-21 1.7e-17 0.5 0.41 Aortic root size; chr7:66634237 chr7:66654538~66669855:+ LUSC cis rs8062405 1 rs72793811 ENSG00000259982.1 CDC37P1 9.81 8.58e-21 1.71e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828071 chr16:28700294~28701540:- LUSC cis rs9481169 0.557 rs13194006 ENSG00000255389.1 C6orf3 -9.81 8.63e-21 1.72e-17 -0.74 -0.41 Inflammatory skin disease; chr6:111575051 chr6:111599875~111602295:+ LUSC cis rs1933112 0.5 rs10918926 ENSG00000227777.1 RP4-738P11.3 -9.81 8.69e-21 1.73e-17 -0.58 -0.41 Blood protein levels; chr1:168560474 chr1:168542737~168543354:+ LUSC cis rs8091660 0.929 rs11082685 ENSG00000278983.1 RP11-426J5.3 9.81 8.71e-21 1.73e-17 0.54 0.41 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48566806 chr18:48564795~48568342:+ LUSC cis rs9326248 1 rs4938354 ENSG00000280143.1 AP000892.6 9.81 8.72e-21 1.73e-17 0.47 0.41 Blood protein levels; chr11:117180449 chr11:117204967~117210292:+ LUSC cis rs9545047 0.735 rs314690 ENSG00000227676.3 LINC01068 9.81 8.74e-21 1.74e-17 0.51 0.41 Schizophrenia; chr13:79434822 chr13:79566727~79571436:+ LUSC cis rs6452524 0.935 rs1011979 ENSG00000249664.1 CTD-2227C6.2 9.81 8.8e-21 1.75e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83097431 chr5:83012285~83013109:- LUSC cis rs875971 0.862 rs9791712 ENSG00000226824.5 RP4-756H11.3 9.81 8.9e-21 1.77e-17 0.5 0.41 Aortic root size; chr7:66640176 chr7:66654538~66669855:+ LUSC cis rs2108622 0.727 rs7253873 ENSG00000267453.5 AC004791.2 -9.8 9e-21 1.79e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870090 chr19:15851993~15864904:- LUSC cis rs1933112 0.5 rs12049040 ENSG00000227777.1 RP4-738P11.3 9.8 9.01e-21 1.79e-17 0.55 0.41 Blood protein levels; chr1:168552377 chr1:168542737~168543354:+ LUSC cis rs10129255 0.872 rs1858683 ENSG00000223648.3 IGHV3-64 9.8 9.01e-21 1.79e-17 0.39 0.41 Kawasaki disease; chr14:106670217 chr14:106643132~106658258:- LUSC cis rs12429206 0.512 rs9535530 ENSG00000233672.5 RNASEH2B-AS1 -9.8 9.02e-21 1.79e-17 -0.46 -0.41 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50925136 chr13:50862172~50910764:- LUSC cis rs6452524 0.905 rs7736289 ENSG00000249664.1 CTD-2227C6.2 9.8 9.08e-21 1.8e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83082401 chr5:83012285~83013109:- LUSC cis rs10740039 0.583 rs2170005 ENSG00000254271.1 RP11-131N11.4 9.8 9.12e-21 1.81e-17 0.57 0.41 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740842 chr10:60734342~60741828:+ LUSC cis rs8062405 0.824 rs153106 ENSG00000259982.1 CDC37P1 9.8 9.16e-21 1.82e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28515576 chr16:28700294~28701540:- LUSC cis rs6452524 0.967 rs11741420 ENSG00000249664.1 CTD-2227C6.2 9.8 9.17e-21 1.82e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83174913 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs4401555 ENSG00000249664.1 CTD-2227C6.2 9.8 9.17e-21 1.82e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83175267 chr5:83012285~83013109:- LUSC cis rs11155671 0.53 rs2342770 ENSG00000223701.3 RAET1E-AS1 9.8 9.19e-21 1.82e-17 0.46 0.41 Testicular germ cell tumor; chr6:149895549 chr6:149884431~149919508:+ LUSC cis rs10129255 0.912 rs61997792 ENSG00000223648.3 IGHV3-64 9.8 9.25e-21 1.83e-17 0.39 0.41 Kawasaki disease; chr14:106799304 chr14:106643132~106658258:- LUSC cis rs765787 0.53 rs2554454 ENSG00000259520.4 CTD-2651B20.3 9.8 9.34e-21 1.85e-17 0.5 0.41 Uric acid levels; chr15:45229338 chr15:45251580~45279251:- LUSC cis rs10129255 0.5 rs4774189 ENSG00000211972.2 IGHV3-66 9.8 9.35e-21 1.85e-17 0.28 0.41 Kawasaki disease; chr14:106768275 chr14:106675017~106675544:- LUSC cis rs765787 0.53 rs2433228 ENSG00000259520.4 CTD-2651B20.3 9.8 9.62e-21 1.9e-17 0.51 0.41 Uric acid levels; chr15:45223173 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11854690 ENSG00000259520.4 CTD-2651B20.3 9.8 9.62e-21 1.9e-17 0.51 0.41 Uric acid levels; chr15:45223818 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs28733848 ENSG00000259520.4 CTD-2651B20.3 9.8 9.62e-21 1.9e-17 0.51 0.41 Uric acid levels; chr15:45223849 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11854689 ENSG00000259520.4 CTD-2651B20.3 9.8 9.62e-21 1.9e-17 0.51 0.41 Uric acid levels; chr15:45223854 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs1706830 ENSG00000259520.4 CTD-2651B20.3 9.8 9.62e-21 1.9e-17 0.51 0.41 Uric acid levels; chr15:45224031 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs1706831 ENSG00000259520.4 CTD-2651B20.3 9.8 9.62e-21 1.9e-17 0.51 0.41 Uric acid levels; chr15:45224032 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs2433227 ENSG00000259520.4 CTD-2651B20.3 9.8 9.62e-21 1.9e-17 0.51 0.41 Uric acid levels; chr15:45224921 chr15:45251580~45279251:- LUSC cis rs10129255 0.5 rs4774008 ENSG00000211972.2 IGHV3-66 9.79 9.74e-21 1.93e-17 0.27 0.41 Kawasaki disease; chr14:106681273 chr14:106675017~106675544:- LUSC cis rs2739330 0.892 rs5751776 ENSG00000099984.9 GSTT2 -9.79 9.87e-21 1.95e-17 -0.51 -0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23980123~23983911:+ LUSC cis rs6452524 0.901 rs10079680 ENSG00000249664.1 CTD-2227C6.2 9.79 9.91e-21 1.96e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83082746 chr5:83012285~83013109:- LUSC cis rs2442825 0.693 rs2596916 ENSG00000206573.7 THUMPD3-AS1 9.79 1e-20 1.98e-17 0.34 0.41 Cerebrospinal fluid clusterin levels; chr3:9380526 chr3:9349689~9398579:- LUSC cis rs2729354 0.817 rs2649667 ENSG00000265566.2 RN7SL605P -9.79 1e-20 1.98e-17 -0.56 -0.41 Blood protein levels; chr11:57503036 chr11:57528085~57528365:- LUSC cis rs11089937 0.929 rs5750624 ENSG00000211639.2 IGLV4-60 9.79 1e-20 1.98e-17 0.41 0.41 Periodontitis (PAL4Q3); chr22:22165354 chr22:22162199~22162681:+ LUSC cis rs6452524 0.934 rs12153179 ENSG00000249664.1 CTD-2227C6.2 9.79 1.02e-20 2.01e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83125109 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs12153441 ENSG00000249664.1 CTD-2227C6.2 9.79 1.02e-20 2.01e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83125181 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs12152891 ENSG00000249664.1 CTD-2227C6.2 9.79 1.02e-20 2.01e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83125217 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs6452507 ENSG00000249664.1 CTD-2227C6.2 9.79 1.02e-20 2.01e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83125537 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs6452508 ENSG00000249664.1 CTD-2227C6.2 9.79 1.02e-20 2.01e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83125546 chr5:83012285~83013109:- LUSC cis rs748404 0.56 rs529611 ENSG00000249839.1 AC011330.5 -9.79 1.03e-20 2.03e-17 -0.55 -0.41 Lung cancer; chr15:43513790 chr15:43663654~43684339:- LUSC cis rs73086581 0.68 rs11908158 ENSG00000229539.1 RP11-119B16.2 9.79 1.04e-20 2.04e-17 0.54 0.41 Response to antidepressants in depression; chr20:3956025 chr20:3888239~3888868:- LUSC cis rs150992 0.79 rs45931 ENSG00000248489.1 CTD-2007H13.3 9.79 1.04e-20 2.04e-17 0.49 0.41 Body mass index; chr5:98978344 chr5:98929171~98995013:+ LUSC cis rs7208859 0.562 rs11650923 ENSG00000263531.1 RP13-753N3.1 9.79 1.04e-20 2.06e-17 0.74 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30681149 chr17:30863921~30864940:- LUSC cis rs7396835 1 rs7396835 ENSG00000254851.1 RP11-109L13.1 -9.79 1.04e-20 2.06e-17 -0.73 -0.41 Quantitative traits; chr11:116813312 chr11:117135528~117138582:+ LUSC cis rs11098499 0.954 rs3733520 ENSG00000245958.5 RP11-33B1.1 -9.79 1.05e-20 2.08e-17 -0.42 -0.41 Corneal astigmatism; chr4:119502325 chr4:119454791~119552025:+ LUSC cis rs172166 0.516 rs1225618 ENSG00000204709.4 LINC01556 9.78 1.07e-20 2.12e-17 0.49 0.41 Cardiac Troponin-T levels; chr6:28161935 chr6:28943877~28944537:+ LUSC cis rs765787 0.53 rs1706832 ENSG00000259520.4 CTD-2651B20.3 9.78 1.08e-20 2.12e-17 0.51 0.41 Uric acid levels; chr15:45224975 chr15:45251580~45279251:- LUSC cis rs10875746 0.859 rs12305511 ENSG00000240399.1 RP1-228P16.1 9.78 1.08e-20 2.12e-17 0.45 0.41 Longevity (90 years and older); chr12:48188933 chr12:48054813~48055591:- LUSC cis rs6452524 0.934 rs1120477 ENSG00000249664.1 CTD-2227C6.2 9.78 1.08e-20 2.13e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83127062 chr5:83012285~83013109:- LUSC cis rs6452524 0.934 rs1120478 ENSG00000249664.1 CTD-2227C6.2 9.78 1.08e-20 2.13e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83127072 chr5:83012285~83013109:- LUSC cis rs6452524 0.934 rs6452512 ENSG00000249664.1 CTD-2227C6.2 9.78 1.08e-20 2.13e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83127523 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs6452514 ENSG00000249664.1 CTD-2227C6.2 9.78 1.08e-20 2.13e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83127627 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs6884543 ENSG00000249664.1 CTD-2227C6.2 9.78 1.08e-20 2.13e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83127939 chr5:83012285~83013109:- LUSC cis rs7208859 0.623 rs8067035 ENSG00000263531.1 RP13-753N3.1 9.78 1.08e-20 2.13e-17 0.72 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30863921~30864940:- LUSC cis rs1707322 0.691 rs61784803 ENSG00000280836.1 AL355480.1 9.78 1.1e-20 2.16e-17 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45713599 chr1:45581219~45581321:- LUSC cis rs1707322 0.663 rs3935296 ENSG00000280836.1 AL355480.1 9.78 1.1e-20 2.16e-17 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45714798 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs11211163 ENSG00000280836.1 AL355480.1 -9.78 1.1e-20 2.16e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45687876 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs12037803 ENSG00000280836.1 AL355480.1 -9.78 1.1e-20 2.16e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690820 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs10789470 ENSG00000280836.1 AL355480.1 -9.78 1.1e-20 2.16e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692659 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs61784796 ENSG00000280836.1 AL355480.1 -9.78 1.1e-20 2.16e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697584 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs10749856 ENSG00000280836.1 AL355480.1 -9.78 1.1e-20 2.16e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45699174 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs10890344 ENSG00000280836.1 AL355480.1 -9.78 1.1e-20 2.16e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45700418 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs4564187 ENSG00000280836.1 AL355480.1 -9.78 1.1e-20 2.16e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701189 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs28438704 ENSG00000280836.1 AL355480.1 -9.78 1.1e-20 2.16e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45704872 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs28442079 ENSG00000280836.1 AL355480.1 -9.78 1.1e-20 2.16e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706329 chr1:45581219~45581321:- LUSC cis rs11098499 0.954 rs7681544 ENSG00000245958.5 RP11-33B1.1 -9.78 1.11e-20 2.18e-17 -0.42 -0.41 Corneal astigmatism; chr4:119490100 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs11940028 ENSG00000245958.5 RP11-33B1.1 -9.78 1.11e-20 2.18e-17 -0.42 -0.41 Corneal astigmatism; chr4:119490752 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs11935596 ENSG00000245958.5 RP11-33B1.1 -9.78 1.11e-20 2.18e-17 -0.42 -0.41 Corneal astigmatism; chr4:119491302 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs12507964 ENSG00000245958.5 RP11-33B1.1 -9.78 1.11e-20 2.18e-17 -0.42 -0.41 Corneal astigmatism; chr4:119491906 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs11098530 ENSG00000245958.5 RP11-33B1.1 -9.78 1.11e-20 2.18e-17 -0.42 -0.41 Corneal astigmatism; chr4:119491999 chr4:119454791~119552025:+ LUSC cis rs494459 0.838 rs567680 ENSG00000255422.1 AP002954.4 -9.78 1.12e-20 2.2e-17 -0.43 -0.41 Height; chr11:118737823 chr11:118704607~118750263:+ LUSC cis rs6452524 0.935 rs1580310 ENSG00000249664.1 CTD-2227C6.2 9.78 1.12e-20 2.2e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83091792 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs10942321 ENSG00000249664.1 CTD-2227C6.2 9.78 1.12e-20 2.21e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83083200 chr5:83012285~83013109:- LUSC cis rs494459 0.838 rs555639 ENSG00000255422.1 AP002954.4 9.78 1.13e-20 2.21e-17 0.42 0.41 Height; chr11:118758322 chr11:118704607~118750263:+ LUSC cis rs6921919 0.789 rs17301128 ENSG00000216901.1 AL022393.7 9.78 1.13e-20 2.21e-17 0.55 0.41 Autism spectrum disorder or schizophrenia; chr6:28340257 chr6:28176188~28176674:+ LUSC cis rs2729354 0.768 rs2729384 ENSG00000265566.2 RN7SL605P -9.78 1.13e-20 2.22e-17 -0.57 -0.41 Blood protein levels; chr11:57491144 chr11:57528085~57528365:- LUSC cis rs7208859 0.573 rs7214313 ENSG00000263531.1 RP13-753N3.1 9.78 1.13e-20 2.23e-17 0.72 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30863921~30864940:- LUSC cis rs10129255 0.5 rs2105991 ENSG00000211972.2 IGHV3-66 9.78 1.14e-20 2.23e-17 0.27 0.41 Kawasaki disease; chr14:106682022 chr14:106675017~106675544:- LUSC cis rs2455601 0.882 rs10840139 ENSG00000254860.4 TMEM9B-AS1 9.78 1.14e-20 2.23e-17 0.57 0.41 Schizophrenia; chr11:8873291 chr11:8964675~8977527:+ LUSC cis rs7301826 1 rs7301826 ENSG00000256299.1 RP11-989F5.3 -9.78 1.15e-20 2.25e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130806556 chr12:130810821~130812622:- LUSC cis rs6452524 1 rs7710900 ENSG00000249664.1 CTD-2227C6.2 9.77 1.15e-20 2.25e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83137201 chr5:83012285~83013109:- LUSC cis rs7301826 1 rs4759787 ENSG00000256299.1 RP11-989F5.3 -9.77 1.15e-20 2.26e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130805635 chr12:130810821~130812622:- LUSC cis rs35955747 0.633 rs5998021 ENSG00000236132.1 CTA-440B3.1 9.77 1.17e-20 2.29e-17 0.5 0.41 Neutrophil count;Sum basophil neutrophil counts; chr22:31511441 chr22:31816379~31817491:- LUSC cis rs10129255 0.536 rs17113249 ENSG00000211972.2 IGHV3-66 9.77 1.17e-20 2.29e-17 0.27 0.41 Kawasaki disease; chr14:106678273 chr14:106675017~106675544:- LUSC cis rs6452524 0.935 rs11750799 ENSG00000249664.1 CTD-2227C6.2 9.77 1.17e-20 2.29e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83082983 chr5:83012285~83013109:- LUSC cis rs11098499 0.954 rs6822679 ENSG00000245958.5 RP11-33B1.1 -9.77 1.17e-20 2.3e-17 -0.42 -0.41 Corneal astigmatism; chr4:119481547 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs4577559 ENSG00000245958.5 RP11-33B1.1 -9.77 1.17e-20 2.3e-17 -0.42 -0.41 Corneal astigmatism; chr4:119482888 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs7656252 ENSG00000245958.5 RP11-33B1.1 -9.77 1.17e-20 2.3e-17 -0.42 -0.41 Corneal astigmatism; chr4:119483113 chr4:119454791~119552025:+ LUSC cis rs11098499 0.865 rs28845498 ENSG00000245958.5 RP11-33B1.1 -9.77 1.17e-20 2.3e-17 -0.42 -0.41 Corneal astigmatism; chr4:119484031 chr4:119454791~119552025:+ LUSC cis rs11098499 0.865 rs28753180 ENSG00000245958.5 RP11-33B1.1 -9.77 1.17e-20 2.3e-17 -0.42 -0.41 Corneal astigmatism; chr4:119484212 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs56270433 ENSG00000245958.5 RP11-33B1.1 -9.77 1.17e-20 2.3e-17 -0.42 -0.41 Corneal astigmatism; chr4:119484875 chr4:119454791~119552025:+ LUSC cis rs6452524 0.905 rs6896548 ENSG00000249664.1 CTD-2227C6.2 9.77 1.18e-20 2.31e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83089247 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs1580311 ENSG00000249664.1 CTD-2227C6.2 9.77 1.18e-20 2.31e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83091667 chr5:83012285~83013109:- LUSC cis rs10875746 0.859 rs12305647 ENSG00000240399.1 RP1-228P16.1 -9.77 1.18e-20 2.32e-17 -0.46 -0.41 Longevity (90 years and older); chr12:48189178 chr12:48054813~48055591:- LUSC cis rs1933112 0.5 rs1123864 ENSG00000227777.1 RP4-738P11.3 -9.77 1.2e-20 2.36e-17 -0.57 -0.41 Blood protein levels; chr1:168559223 chr1:168542737~168543354:+ LUSC cis rs35955747 0.689 rs5997988 ENSG00000236132.1 CTA-440B3.1 9.77 1.2e-20 2.36e-17 0.5 0.41 Neutrophil count;Sum basophil neutrophil counts; chr22:31442099 chr22:31816379~31817491:- LUSC cis rs3091242 0.933 rs926438 ENSG00000261349.1 RP3-465N24.5 -9.77 1.21e-20 2.37e-17 -0.5 -0.41 Erythrocyte sedimentation rate; chr1:25427147 chr1:25266102~25267136:- LUSC cis rs10129255 1 rs9324091 ENSG00000223648.3 IGHV3-64 9.77 1.23e-20 2.4e-17 0.38 0.41 Kawasaki disease; chr14:106676625 chr14:106643132~106658258:- LUSC cis rs733592 0.524 rs10875744 ENSG00000240399.1 RP1-228P16.1 9.77 1.24e-20 2.43e-17 0.39 0.41 Plateletcrit; chr12:48104657 chr12:48054813~48055591:- LUSC cis rs6452524 0.935 rs6880566 ENSG00000249664.1 CTD-2227C6.2 9.76 1.25e-20 2.45e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83086909 chr5:83012285~83013109:- LUSC cis rs6452524 0.905 rs6884981 ENSG00000249664.1 CTD-2227C6.2 9.76 1.25e-20 2.45e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83087339 chr5:83012285~83013109:- LUSC cis rs733592 0.524 rs10875741 ENSG00000240399.1 RP1-228P16.1 -9.76 1.26e-20 2.45e-17 -0.39 -0.41 Plateletcrit; chr12:48099139 chr12:48054813~48055591:- LUSC cis rs3091242 0.933 rs11802413 ENSG00000261349.1 RP3-465N24.5 9.76 1.26e-20 2.46e-17 0.5 0.41 Erythrocyte sedimentation rate; chr1:25434429 chr1:25266102~25267136:- LUSC cis rs733592 0.507 rs56129148 ENSG00000240399.1 RP1-228P16.1 -9.76 1.27e-20 2.48e-17 -0.39 -0.41 Plateletcrit; chr12:48091747 chr12:48054813~48055591:- LUSC cis rs11168351 0.591 rs4258439 ENSG00000240399.1 RP1-228P16.1 -9.76 1.27e-20 2.48e-17 -0.39 -0.41 Bipolar disorder and schizophrenia; chr12:48074869 chr12:48054813~48055591:- LUSC cis rs733592 0.507 rs10747529 ENSG00000240399.1 RP1-228P16.1 -9.76 1.27e-20 2.48e-17 -0.39 -0.41 Plateletcrit; chr12:48079586 chr12:48054813~48055591:- LUSC cis rs17711722 0.653 rs2460421 ENSG00000226824.5 RP4-756H11.3 9.76 1.28e-20 2.49e-17 0.48 0.41 Calcium levels; chr7:66026136 chr7:66654538~66669855:+ LUSC cis rs8062405 1 rs62036622 ENSG00000259982.1 CDC37P1 9.76 1.28e-20 2.5e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28825882 chr16:28700294~28701540:- LUSC cis rs733592 0.507 rs3825403 ENSG00000240399.1 RP1-228P16.1 -9.76 1.28e-20 2.5e-17 -0.39 -0.41 Plateletcrit; chr12:48063376 chr12:48054813~48055591:- LUSC cis rs10129255 1 rs11627342 ENSG00000223648.3 IGHV3-64 9.76 1.29e-20 2.51e-17 0.38 0.41 Kawasaki disease; chr14:106675823 chr14:106643132~106658258:- LUSC cis rs11155671 0.53 rs7758033 ENSG00000223701.3 RAET1E-AS1 9.76 1.29e-20 2.52e-17 0.46 0.41 Testicular germ cell tumor; chr6:149886999 chr6:149884431~149919508:+ LUSC cis rs1707322 0.685 rs28617418 ENSG00000280836.1 AL355480.1 -9.76 1.29e-20 2.52e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723854 chr1:45581219~45581321:- LUSC cis rs1707322 0.682 rs28490344 ENSG00000280836.1 AL355480.1 -9.76 1.29e-20 2.52e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45732276 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs28501477 ENSG00000280836.1 AL355480.1 -9.76 1.29e-20 2.52e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45733412 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs28641748 ENSG00000280836.1 AL355480.1 -9.76 1.29e-20 2.52e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747164 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs6697821 ENSG00000280836.1 AL355480.1 -9.76 1.29e-20 2.52e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751050 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs4330955 ENSG00000280836.1 AL355480.1 -9.76 1.29e-20 2.52e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751813 chr1:45581219~45581321:- LUSC cis rs1707322 0.691 rs12031182 ENSG00000280836.1 AL355480.1 -9.76 1.29e-20 2.52e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755327 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs10430123 ENSG00000280836.1 AL355480.1 -9.76 1.29e-20 2.52e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755768 chr1:45581219~45581321:- LUSC cis rs6452524 0.508 rs256795 ENSG00000249664.1 CTD-2227C6.2 -9.76 1.3e-20 2.53e-17 -0.41 -0.41 Hypertension (SNP x SNP interaction); chr5:83001543 chr5:83012285~83013109:- LUSC cis rs10129255 0.518 rs7143784 ENSG00000211972.2 IGHV3-66 9.76 1.3e-20 2.53e-17 0.27 0.41 Kawasaki disease; chr14:106687277 chr14:106675017~106675544:- LUSC cis rs1707322 0.721 rs11211165 ENSG00000280836.1 AL355480.1 -9.76 1.3e-20 2.54e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692234 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs11211166 ENSG00000280836.1 AL355480.1 -9.76 1.3e-20 2.54e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692270 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs6429574 ENSG00000280836.1 AL355480.1 -9.76 1.3e-20 2.54e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668382 chr1:45581219~45581321:- LUSC cis rs9322193 0.923 rs10747276 ENSG00000216906.2 RP11-350J20.9 9.76 1.31e-20 2.55e-17 0.49 0.41 Lung cancer; chr6:149758739 chr6:149904243~149906418:+ LUSC cis rs1891275 0.551 rs4933687 ENSG00000228701.1 TNKS2-AS1 -9.76 1.31e-20 2.56e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91650642 chr10:91782839~91798291:- LUSC cis rs2337406 0.714 rs117798641 ENSG00000274576.2 IGHV2-70 -9.76 1.31e-20 2.56e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106777984 chr14:106770577~106771020:- LUSC cis rs150992 0.79 rs40075 ENSG00000248489.1 CTD-2007H13.3 9.76 1.33e-20 2.58e-17 0.49 0.41 Body mass index; chr5:98976743 chr5:98929171~98995013:+ LUSC cis rs2108622 0.727 rs3093216 ENSG00000267453.5 AC004791.2 -9.76 1.33e-20 2.58e-17 -0.53 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15876927 chr19:15851993~15864904:- LUSC cis rs2108622 0.701 rs3093209 ENSG00000267453.5 AC004791.2 -9.76 1.33e-20 2.58e-17 -0.53 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15877610 chr19:15851993~15864904:- LUSC cis rs6452524 0.967 rs62374400 ENSG00000249664.1 CTD-2227C6.2 9.76 1.34e-20 2.6e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83177053 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs10040363 ENSG00000249664.1 CTD-2227C6.2 9.76 1.34e-20 2.6e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83177826 chr5:83012285~83013109:- LUSC cis rs11089937 0.963 rs2226943 ENSG00000211639.2 IGLV4-60 9.76 1.34e-20 2.61e-17 0.42 0.41 Periodontitis (PAL4Q3); chr22:22143100 chr22:22162199~22162681:+ LUSC cis rs10129255 0.5 rs1024350 ENSG00000211972.2 IGHV3-66 9.76 1.35e-20 2.63e-17 0.27 0.41 Kawasaki disease; chr14:106685105 chr14:106675017~106675544:- LUSC cis rs1707322 0.686 rs2991986 ENSG00000280836.1 AL355480.1 9.75 1.35e-20 2.64e-17 0.5 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615610 chr1:45581219~45581321:- LUSC cis rs1707322 0.686 rs2275085 ENSG00000280836.1 AL355480.1 9.75 1.36e-20 2.64e-17 0.5 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620180 chr1:45581219~45581321:- LUSC cis rs8062405 0.789 rs2106480 ENSG00000259982.1 CDC37P1 9.75 1.36e-20 2.65e-17 0.5 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28526650 chr16:28700294~28701540:- LUSC cis rs2739330 0.731 rs4822450 ENSG00000235689.1 AP000351.13 9.75 1.37e-20 2.67e-17 0.42 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:24006305~24008258:- LUSC cis rs17826219 0.706 rs28469200 ENSG00000263531.1 RP13-753N3.1 9.75 1.38e-20 2.68e-17 0.72 0.41 Body mass index; chr17:30806554 chr17:30863921~30864940:- LUSC cis rs7301826 1 rs4759793 ENSG00000256299.1 RP11-989F5.3 -9.75 1.38e-20 2.68e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130812693 chr12:130810821~130812622:- LUSC cis rs1707322 0.721 rs28817701 ENSG00000280836.1 AL355480.1 -9.75 1.38e-20 2.68e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720378 chr1:45581219~45581321:- LUSC cis rs1707322 0.691 rs28495425 ENSG00000280836.1 AL355480.1 -9.75 1.38e-20 2.68e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45721648 chr1:45581219~45581321:- LUSC cis rs6452524 0.935 rs7718472 ENSG00000249664.1 CTD-2227C6.2 9.75 1.39e-20 2.7e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83082603 chr5:83012285~83013109:- LUSC cis rs9487094 0.666 rs13219952 ENSG00000260273.1 RP11-425D10.10 9.75 1.39e-20 2.71e-17 0.48 0.41 Height; chr6:109391084 chr6:109382795~109383666:+ LUSC cis rs11155671 0.53 rs6935829 ENSG00000223701.3 RAET1E-AS1 9.75 1.43e-20 2.78e-17 0.46 0.41 Testicular germ cell tumor; chr6:149896675 chr6:149884431~149919508:+ LUSC cis rs7301826 1 rs10773822 ENSG00000256299.1 RP11-989F5.3 -9.75 1.44e-20 2.79e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130804562 chr12:130810821~130812622:- LUSC cis rs7301826 0.966 rs10734980 ENSG00000256299.1 RP11-989F5.3 -9.75 1.44e-20 2.79e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130810081 chr12:130810821~130812622:- LUSC cis rs7208859 0.623 rs56378576 ENSG00000263531.1 RP13-753N3.1 9.75 1.45e-20 2.82e-17 0.74 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30683102 chr17:30863921~30864940:- LUSC cis rs7208859 0.623 rs35916850 ENSG00000263531.1 RP13-753N3.1 9.75 1.45e-20 2.82e-17 0.74 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30684155 chr17:30863921~30864940:- LUSC cis rs1891275 0.576 rs10881942 ENSG00000228701.1 TNKS2-AS1 -9.75 1.46e-20 2.83e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91655263 chr10:91782839~91798291:- LUSC cis rs1707322 0.721 rs10890343 ENSG00000280836.1 AL355480.1 -9.74 1.48e-20 2.87e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692250 chr1:45581219~45581321:- LUSC cis rs2108622 0.727 rs12609468 ENSG00000267453.5 AC004791.2 -9.74 1.49e-20 2.88e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867004 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs12610967 ENSG00000267453.5 AC004791.2 -9.74 1.49e-20 2.88e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867119 chr19:15851993~15864904:- LUSC cis rs2108622 0.711 rs12609820 ENSG00000267453.5 AC004791.2 -9.74 1.49e-20 2.88e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867247 chr19:15851993~15864904:- LUSC cis rs2108622 0.668 rs62106153 ENSG00000267453.5 AC004791.2 -9.74 1.49e-20 2.88e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867697 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs12611242 ENSG00000267453.5 AC004791.2 -9.74 1.49e-20 2.88e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867754 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs12611308 ENSG00000267453.5 AC004791.2 -9.74 1.49e-20 2.88e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867776 chr19:15851993~15864904:- LUSC cis rs2108622 0.727 rs12610189 ENSG00000267453.5 AC004791.2 -9.74 1.49e-20 2.88e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867831 chr19:15851993~15864904:- LUSC cis rs2108622 0.711 rs113343664 ENSG00000267453.5 AC004791.2 -9.74 1.49e-20 2.88e-17 -0.54 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15868183 chr19:15851993~15864904:- LUSC cis rs10129255 0.701 rs2005643 ENSG00000211970.3 IGHV4-61 -9.74 1.49e-20 2.89e-17 -0.28 -0.41 Kawasaki disease; chr14:106676288 chr14:106639119~106639657:- LUSC cis rs62229266 0.804 rs62230821 ENSG00000231106.2 LINC01436 9.74 1.5e-20 2.91e-17 0.53 0.41 Mitral valve prolapse; chr21:36052818 chr21:36005338~36007838:+ LUSC cis rs150992 0.861 rs151102 ENSG00000248489.1 CTD-2007H13.3 -9.74 1.5e-20 2.91e-17 -0.47 -0.41 Body mass index; chr5:98947626 chr5:98929171~98995013:+ LUSC cis rs10129255 0.5 rs10143242 ENSG00000211972.2 IGHV3-66 9.74 1.51e-20 2.92e-17 0.27 0.41 Kawasaki disease; chr14:106681814 chr14:106675017~106675544:- LUSC cis rs12429206 0.547 rs75419800 ENSG00000233672.5 RNASEH2B-AS1 -9.74 1.52e-20 2.95e-17 -0.5 -0.41 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50898897 chr13:50862172~50910764:- LUSC cis rs62229266 0.804 rs2835259 ENSG00000231106.2 LINC01436 9.74 1.52e-20 2.95e-17 0.53 0.41 Mitral valve prolapse; chr21:36053004 chr21:36005338~36007838:+ LUSC cis rs1891275 0.551 rs2421621 ENSG00000228701.1 TNKS2-AS1 -9.74 1.54e-20 2.98e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91640344 chr10:91782839~91798291:- LUSC cis rs1891275 0.515 rs7092745 ENSG00000228701.1 TNKS2-AS1 -9.74 1.58e-20 3.05e-17 -0.47 -0.41 Intelligence (multi-trait analysis); chr10:91724063 chr10:91782839~91798291:- LUSC cis rs10129255 0.957 rs2013423 ENSG00000223648.3 IGHV3-64 9.74 1.58e-20 3.06e-17 0.38 0.41 Kawasaki disease; chr14:106690675 chr14:106643132~106658258:- LUSC cis rs11155671 0.53 rs9371544 ENSG00000223701.3 RAET1E-AS1 9.74 1.58e-20 3.07e-17 0.45 0.41 Testicular germ cell tumor; chr6:149896224 chr6:149884431~149919508:+ LUSC cis rs494459 0.838 rs566733 ENSG00000255422.1 AP002954.4 -9.74 1.59e-20 3.07e-17 -0.42 -0.41 Height; chr11:118737916 chr11:118704607~118750263:+ LUSC cis rs150992 0.587 rs11949103 ENSG00000248489.1 CTD-2007H13.3 -9.73 1.61e-20 3.11e-17 -0.47 -0.41 Body mass index; chr5:99011939 chr5:98929171~98995013:+ LUSC cis rs10129255 0.957 rs10132367 ENSG00000223648.3 IGHV3-64 9.73 1.61e-20 3.12e-17 0.38 0.41 Kawasaki disease; chr14:106690981 chr14:106643132~106658258:- LUSC cis rs8062405 0.792 rs12446550 ENSG00000259982.1 CDC37P1 9.73 1.62e-20 3.12e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28532060 chr16:28700294~28701540:- LUSC cis rs1707322 0.721 rs10789468 ENSG00000280836.1 AL355480.1 -9.73 1.62e-20 3.13e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658886 chr1:45581219~45581321:- LUSC cis rs1891275 0.551 rs2000177 ENSG00000228701.1 TNKS2-AS1 -9.73 1.62e-20 3.14e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91653237 chr10:91782839~91798291:- LUSC cis rs2455601 0.744 rs7938995 ENSG00000254860.4 TMEM9B-AS1 9.73 1.64e-20 3.17e-17 0.53 0.41 Schizophrenia; chr11:8954128 chr11:8964675~8977527:+ LUSC cis rs2455601 0.786 rs2568070 ENSG00000254860.4 TMEM9B-AS1 9.73 1.64e-20 3.17e-17 0.53 0.41 Schizophrenia; chr11:8955346 chr11:8964675~8977527:+ LUSC cis rs733592 0.507 rs7304428 ENSG00000240399.1 RP1-228P16.1 -9.73 1.64e-20 3.17e-17 -0.39 -0.41 Plateletcrit; chr12:48100492 chr12:48054813~48055591:- LUSC cis rs10129255 0.83 rs61997609 ENSG00000223648.3 IGHV3-64 9.73 1.67e-20 3.22e-17 0.38 0.41 Kawasaki disease; chr14:106692376 chr14:106643132~106658258:- LUSC cis rs2455601 0.573 rs2653573 ENSG00000254860.4 TMEM9B-AS1 9.73 1.67e-20 3.22e-17 0.53 0.41 Schizophrenia; chr11:8968327 chr11:8964675~8977527:+ LUSC cis rs62229266 0.771 rs7280136 ENSG00000231106.2 LINC01436 -9.73 1.68e-20 3.24e-17 -0.52 -0.41 Mitral valve prolapse; chr21:36060612 chr21:36005338~36007838:+ LUSC cis rs1707322 0.721 rs56255771 ENSG00000280836.1 AL355480.1 -9.73 1.69e-20 3.26e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45758647 chr1:45581219~45581321:- LUSC cis rs62229266 0.804 rs56279140 ENSG00000231106.2 LINC01436 9.73 1.69e-20 3.26e-17 0.53 0.41 Mitral valve prolapse; chr21:36052063 chr21:36005338~36007838:+ LUSC cis rs9322193 0.923 rs4870529 ENSG00000216906.2 RP11-350J20.9 9.73 1.69e-20 3.26e-17 0.49 0.41 Lung cancer; chr6:149716436 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9767309 ENSG00000216906.2 RP11-350J20.9 9.73 1.69e-20 3.26e-17 0.49 0.41 Lung cancer; chr6:149716807 chr6:149904243~149906418:+ LUSC cis rs172166 0.538 rs1150686 ENSG00000204709.4 LINC01556 9.73 1.7e-20 3.28e-17 0.5 0.41 Cardiac Troponin-T levels; chr6:28193493 chr6:28943877~28944537:+ LUSC cis rs10129255 0.957 rs1024349 ENSG00000223648.3 IGHV3-64 9.73 1.73e-20 3.33e-17 0.37 0.41 Kawasaki disease; chr14:106689997 chr14:106643132~106658258:- LUSC cis rs765787 0.53 rs4774550 ENSG00000259520.4 CTD-2651B20.3 9.72 1.73e-20 3.33e-17 0.51 0.41 Uric acid levels; chr15:45250114 chr15:45251580~45279251:- LUSC cis rs8062405 0.789 rs240704 ENSG00000259982.1 CDC37P1 9.72 1.73e-20 3.33e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28518628 chr16:28700294~28701540:- LUSC cis rs9322193 0.923 rs9800736 ENSG00000216906.2 RP11-350J20.9 9.72 1.74e-20 3.34e-17 0.49 0.41 Lung cancer; chr6:149661281 chr6:149904243~149906418:+ LUSC cis rs11098499 0.954 rs11729521 ENSG00000245958.5 RP11-33B1.1 -9.72 1.75e-20 3.37e-17 -0.42 -0.41 Corneal astigmatism; chr4:119495633 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs11734241 ENSG00000245958.5 RP11-33B1.1 -9.72 1.75e-20 3.37e-17 -0.42 -0.41 Corneal astigmatism; chr4:119495717 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs28685688 ENSG00000245958.5 RP11-33B1.1 -9.72 1.75e-20 3.37e-17 -0.42 -0.41 Corneal astigmatism; chr4:119499179 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs7687843 ENSG00000245958.5 RP11-33B1.1 -9.72 1.75e-20 3.37e-17 -0.42 -0.41 Corneal astigmatism; chr4:119500056 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs2306455 ENSG00000245958.5 RP11-33B1.1 -9.72 1.75e-20 3.37e-17 -0.42 -0.41 Corneal astigmatism; chr4:119500814 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs10031483 ENSG00000245958.5 RP11-33B1.1 -9.72 1.75e-20 3.37e-17 -0.42 -0.41 Corneal astigmatism; chr4:119501481 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs10031665 ENSG00000245958.5 RP11-33B1.1 -9.72 1.75e-20 3.37e-17 -0.42 -0.41 Corneal astigmatism; chr4:119501697 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs3733523 ENSG00000245958.5 RP11-33B1.1 -9.72 1.75e-20 3.37e-17 -0.42 -0.41 Corneal astigmatism; chr4:119502564 chr4:119454791~119552025:+ LUSC cis rs8062405 0.824 rs240702 ENSG00000259982.1 CDC37P1 9.72 1.75e-20 3.37e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28520032 chr16:28700294~28701540:- LUSC cis rs2337406 0.866 rs7152038 ENSG00000274576.2 IGHV2-70 -9.72 1.77e-20 3.4e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106778230 chr14:106770577~106771020:- LUSC cis rs2108622 0.785 rs3093199 ENSG00000267453.5 AC004791.2 -9.72 1.77e-20 3.41e-17 -0.53 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15879061 chr19:15851993~15864904:- LUSC cis rs7208859 0.524 rs73988172 ENSG00000263531.1 RP13-753N3.1 9.72 1.78e-20 3.43e-17 0.72 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30863921~30864940:- LUSC cis rs1150688 1 rs1150688 ENSG00000204709.4 LINC01556 9.72 1.79e-20 3.44e-17 0.5 0.41 Autism spectrum disorder or schizophrenia; chr6:28195002 chr6:28943877~28944537:+ LUSC cis rs2729354 0.817 rs2250673 ENSG00000265566.2 RN7SL605P -9.72 1.79e-20 3.44e-17 -0.56 -0.41 Blood protein levels; chr11:57500697 chr11:57528085~57528365:- LUSC cis rs1150668 0.796 rs2531825 ENSG00000216901.1 AL022393.7 9.72 1.83e-20 3.51e-17 0.46 0.41 Pubertal anthropometrics; chr6:28381487 chr6:28176188~28176674:+ LUSC cis rs1707322 0.656 rs3014210 ENSG00000280836.1 AL355480.1 9.72 1.84e-20 3.53e-17 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45600936 chr1:45581219~45581321:- LUSC cis rs748404 0.66 rs2444251 ENSG00000249839.1 AC011330.5 -9.72 1.85e-20 3.55e-17 -0.54 -0.41 Lung cancer; chr15:43496397 chr15:43663654~43684339:- LUSC cis rs733592 0.894 rs886589 ENSG00000240399.1 RP1-228P16.1 -9.72 1.85e-20 3.56e-17 -0.38 -0.41 Plateletcrit; chr12:48083414 chr12:48054813~48055591:- LUSC cis rs875971 0.83 rs12673450 ENSG00000226824.5 RP4-756H11.3 -9.72 1.86e-20 3.57e-17 -0.51 -0.41 Aortic root size; chr7:66544233 chr7:66654538~66669855:+ LUSC cis rs11098499 0.954 rs6834796 ENSG00000245958.5 RP11-33B1.1 -9.72 1.87e-20 3.59e-17 -0.42 -0.41 Corneal astigmatism; chr4:119493538 chr4:119454791~119552025:+ LUSC cis rs748404 0.66 rs548704 ENSG00000249839.1 AC011330.5 -9.71 1.88e-20 3.6e-17 -0.54 -0.41 Lung cancer; chr15:43499508 chr15:43663654~43684339:- LUSC cis rs1707322 0.721 rs10890336 ENSG00000280836.1 AL355480.1 -9.71 1.89e-20 3.62e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645384 chr1:45581219~45581321:- LUSC cis rs4774565 0.724 rs606118 ENSG00000244879.4 GABPB1-AS1 -9.71 1.9e-20 3.65e-17 -0.37 -0.41 Breast cancer; chr15:50362974 chr15:50354959~50372202:+ LUSC cis rs10129255 0.556 rs9324093 ENSG00000280411.1 IGHV1-69-2 -9.71 1.91e-20 3.67e-17 -0.25 -0.41 Kawasaki disease; chr14:106683893 chr14:106762092~106762588:- LUSC cis rs10129255 0.536 rs10139058 ENSG00000280411.1 IGHV1-69-2 -9.71 1.91e-20 3.67e-17 -0.25 -0.41 Kawasaki disease; chr14:106685899 chr14:106762092~106762588:- LUSC cis rs2729354 0.768 rs2848640 ENSG00000265566.2 RN7SL605P -9.71 1.92e-20 3.69e-17 -0.57 -0.41 Blood protein levels; chr11:57495207 chr11:57528085~57528365:- LUSC cis rs1707322 0.721 rs61784800 ENSG00000280836.1 AL355480.1 9.71 1.94e-20 3.71e-17 0.48 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45712440 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs6665808 ENSG00000280836.1 AL355480.1 -9.71 1.94e-20 3.71e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45696611 chr1:45581219~45581321:- LUSC cis rs1891275 0.551 rs4933691 ENSG00000228701.1 TNKS2-AS1 -9.71 1.94e-20 3.72e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91660200 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs2421628 ENSG00000228701.1 TNKS2-AS1 -9.71 1.94e-20 3.72e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91662412 chr10:91782839~91798291:- LUSC cis rs6782228 0.606 rs6775270 ENSG00000277250.1 Metazoa_SRP -9.71 1.96e-20 3.76e-17 -0.46 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128684655 chr3:128673681~128674021:- LUSC cis rs6921919 0.789 rs6912584 ENSG00000216901.1 AL022393.7 9.71 1.97e-20 3.77e-17 0.55 0.41 Autism spectrum disorder or schizophrenia; chr6:28341813 chr6:28176188~28176674:+ LUSC cis rs9322193 0.923 rs12529698 ENSG00000216906.2 RP11-350J20.9 9.71 1.97e-20 3.78e-17 0.49 0.41 Lung cancer; chr6:149650951 chr6:149904243~149906418:+ LUSC cis rs10129255 1 rs10141557 ENSG00000223648.3 IGHV3-64 9.71 1.98e-20 3.79e-17 0.38 0.41 Kawasaki disease; chr14:106767990 chr14:106643132~106658258:- LUSC cis rs10129255 0.744 rs28517388 ENSG00000223648.3 IGHV3-64 9.71 1.99e-20 3.81e-17 0.39 0.41 Kawasaki disease; chr14:106704323 chr14:106643132~106658258:- LUSC cis rs9322193 0.923 rs17745062 ENSG00000216906.2 RP11-350J20.9 9.71 1.99e-20 3.81e-17 0.49 0.41 Lung cancer; chr6:149721079 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs62441279 ENSG00000216906.2 RP11-350J20.9 9.71 1.99e-20 3.81e-17 0.49 0.41 Lung cancer; chr6:149721194 chr6:149904243~149906418:+ LUSC cis rs8062405 0.754 rs62034323 ENSG00000259982.1 CDC37P1 9.7 2.07e-20 3.96e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525152 chr16:28700294~28701540:- LUSC cis rs8062405 0.824 rs62034324 ENSG00000259982.1 CDC37P1 9.7 2.07e-20 3.96e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525441 chr16:28700294~28701540:- LUSC cis rs8062405 0.824 rs62034326 ENSG00000259982.1 CDC37P1 9.7 2.07e-20 3.96e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28527972 chr16:28700294~28701540:- LUSC cis rs8062405 0.824 rs4788084 ENSG00000259982.1 CDC37P1 9.7 2.07e-20 3.96e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28528527 chr16:28700294~28701540:- LUSC cis rs2337406 0.866 rs988130 ENSG00000274576.2 IGHV2-70 -9.7 2.07e-20 3.97e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106777154 chr14:106770577~106771020:- LUSC cis rs5760092 0.572 rs738806 ENSG00000218537.1 MIF-AS1 9.7 2.07e-20 3.97e-17 0.6 0.41 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23894426~23898930:- LUSC cis rs1891275 0.551 rs7908678 ENSG00000228701.1 TNKS2-AS1 9.7 2.08e-20 3.98e-17 0.5 0.41 Intelligence (multi-trait analysis); chr10:91659253 chr10:91782839~91798291:- LUSC cis rs1707322 0.685 rs56177313 ENSG00000280836.1 AL355480.1 -9.7 2.09e-20 3.99e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760134 chr1:45581219~45581321:- LUSC cis rs10129255 1 rs10129407 ENSG00000223648.3 IGHV3-64 9.7 2.14e-20 4.09e-17 0.38 0.41 Kawasaki disease; chr14:106767956 chr14:106643132~106658258:- LUSC cis rs1891275 0.515 rs1418161 ENSG00000228701.1 TNKS2-AS1 -9.7 2.15e-20 4.11e-17 -0.47 -0.41 Intelligence (multi-trait analysis); chr10:91724898 chr10:91782839~91798291:- LUSC cis rs8062405 0.824 rs4788085 ENSG00000259982.1 CDC37P1 9.7 2.17e-20 4.15e-17 0.5 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523682 chr16:28700294~28701540:- LUSC cis rs8062405 0.824 rs28772958 ENSG00000259982.1 CDC37P1 9.7 2.17e-20 4.15e-17 0.5 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523984 chr16:28700294~28701540:- LUSC cis rs733592 0.929 rs4760678 ENSG00000240399.1 RP1-228P16.1 -9.7 2.18e-20 4.17e-17 -0.38 -0.41 Plateletcrit; chr12:48067798 chr12:48054813~48055591:- LUSC cis rs733592 0.965 rs1978161 ENSG00000240399.1 RP1-228P16.1 -9.7 2.18e-20 4.17e-17 -0.38 -0.41 Plateletcrit; chr12:48073938 chr12:48054813~48055591:- LUSC cis rs853679 0.517 rs6932109 ENSG00000219392.1 RP1-265C24.5 9.7 2.18e-20 4.17e-17 0.57 0.41 Depression; chr6:28110525 chr6:28115628~28116551:+ LUSC cis rs2929278 0.617 rs524908 ENSG00000249839.1 AC011330.5 9.7 2.2e-20 4.19e-17 0.54 0.41 Schizophrenia; chr15:43895793 chr15:43663654~43684339:- LUSC cis rs6452524 1 rs10067439 ENSG00000249664.1 CTD-2227C6.2 9.69 2.21e-20 4.23e-17 0.43 0.41 Hypertension (SNP x SNP interaction); chr5:83136274 chr5:83012285~83013109:- LUSC cis rs9326248 0.953 rs634960 ENSG00000280143.1 AP000892.6 -9.69 2.22e-20 4.24e-17 -0.47 -0.41 Blood protein levels; chr11:117202247 chr11:117204967~117210292:+ LUSC cis rs7115242 0.92 rs6589574 ENSG00000254851.1 RP11-109L13.1 -9.69 2.23e-20 4.25e-17 -0.88 -0.41 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116859922 chr11:117135528~117138582:+ LUSC cis rs1707322 0.682 rs28508523 ENSG00000280836.1 AL355480.1 -9.69 2.24e-20 4.28e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723953 chr1:45581219~45581321:- LUSC cis rs1707322 0.691 rs11211175 ENSG00000280836.1 AL355480.1 -9.69 2.24e-20 4.28e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755212 chr1:45581219~45581321:- LUSC cis rs2019137 0.56 rs11123172 ENSG00000274877.1 RP11-65I12.1 9.69 2.24e-20 4.28e-17 0.51 0.41 Lymphocyte counts; chr2:113226726 chr2:113237595~113240825:+ LUSC cis rs1707322 0.691 rs11211174 ENSG00000280836.1 AL355480.1 -9.69 2.25e-20 4.3e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755144 chr1:45581219~45581321:- LUSC cis rs733592 0.507 rs10875739 ENSG00000240399.1 RP1-228P16.1 9.69 2.25e-20 4.3e-17 0.39 0.41 Plateletcrit; chr12:48087136 chr12:48054813~48055591:- LUSC cis rs150992 0.711 rs1069182 ENSG00000248489.1 CTD-2007H13.3 -9.69 2.25e-20 4.3e-17 -0.51 -0.41 Body mass index; chr5:98806512 chr5:98929171~98995013:+ LUSC cis rs150992 0.673 rs992773 ENSG00000248489.1 CTD-2007H13.3 -9.69 2.25e-20 4.3e-17 -0.51 -0.41 Body mass index; chr5:98808169 chr5:98929171~98995013:+ LUSC cis rs9326248 0.953 rs488962 ENSG00000280143.1 AP000892.6 -9.69 2.26e-20 4.3e-17 -0.47 -0.41 Blood protein levels; chr11:117201809 chr11:117204967~117210292:+ LUSC cis rs801193 0.613 rs2016325 ENSG00000226824.5 RP4-756H11.3 9.69 2.26e-20 4.31e-17 0.48 0.41 Aortic root size; chr7:66858513 chr7:66654538~66669855:+ LUSC cis rs2524005 1 rs2524005 ENSG00000228078.1 HLA-U -9.69 2.27e-20 4.34e-17 -0.62 -0.41 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29934101~29934286:+ LUSC cis rs2108622 0.527 rs67617968 ENSG00000267453.5 AC004791.2 -9.69 2.3e-20 4.39e-17 -0.52 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866755 chr19:15851993~15864904:- LUSC cis rs62229266 0.771 rs11701590 ENSG00000231106.2 LINC01436 9.69 2.31e-20 4.41e-17 0.53 0.41 Mitral valve prolapse; chr21:36012432 chr21:36005338~36007838:+ LUSC cis rs6452524 1 rs9986131 ENSG00000249664.1 CTD-2227C6.2 9.69 2.33e-20 4.44e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83149037 chr5:83012285~83013109:- LUSC cis rs1707322 0.65 rs4553239 ENSG00000280836.1 AL355480.1 -9.69 2.34e-20 4.45e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684814 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs11211145 ENSG00000280836.1 AL355480.1 -9.69 2.34e-20 4.46e-17 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642819 chr1:45581219~45581321:- LUSC cis rs2019137 0.56 rs10175462 ENSG00000274877.1 RP11-65I12.1 -9.68 2.43e-20 4.62e-17 -0.5 -0.41 Lymphocyte counts; chr2:113230915 chr2:113237595~113240825:+ LUSC cis rs9322193 0.884 rs7743823 ENSG00000216906.2 RP11-350J20.9 9.68 2.45e-20 4.66e-17 0.49 0.41 Lung cancer; chr6:149849744 chr6:149904243~149906418:+ LUSC cis rs748404 0.56 rs2255663 ENSG00000249839.1 AC011330.5 9.68 2.48e-20 4.71e-17 0.55 0.41 Lung cancer; chr15:43536810 chr15:43663654~43684339:- LUSC cis rs1891275 0.515 rs1080496 ENSG00000228701.1 TNKS2-AS1 9.68 2.48e-20 4.72e-17 0.47 0.41 Intelligence (multi-trait analysis); chr10:91684505 chr10:91782839~91798291:- LUSC cis rs7617773 0.963 rs6766754 ENSG00000229759.1 MRPS18AP1 -9.68 2.5e-20 4.76e-17 -0.4 -0.41 Coronary artery disease; chr3:48141099 chr3:48256350~48256938:- LUSC cis rs7617773 0.832 rs6775114 ENSG00000229759.1 MRPS18AP1 -9.68 2.5e-20 4.76e-17 -0.4 -0.41 Coronary artery disease; chr3:48141130 chr3:48256350~48256938:- LUSC cis rs2337406 0.866 rs988131 ENSG00000274576.2 IGHV2-70 -9.68 2.5e-20 4.76e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106776833 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs8005518 ENSG00000274576.2 IGHV2-70 -9.68 2.5e-20 4.76e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106777009 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs57684263 ENSG00000274576.2 IGHV2-70 -9.68 2.5e-20 4.76e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106777263 chr14:106770577~106771020:- LUSC cis rs10129255 0.957 rs56134540 ENSG00000223648.3 IGHV3-64 9.68 2.54e-20 4.82e-17 0.38 0.41 Kawasaki disease; chr14:106691290 chr14:106643132~106658258:- LUSC cis rs1707322 0.686 rs2050376 ENSG00000280836.1 AL355480.1 -9.68 2.55e-20 4.83e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45612958 chr1:45581219~45581321:- LUSC cis rs6452524 1 rs62374374 ENSG00000249664.1 CTD-2227C6.2 9.68 2.58e-20 4.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83144838 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs1382372 ENSG00000249664.1 CTD-2227C6.2 9.68 2.58e-20 4.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83145237 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs1382371 ENSG00000249664.1 CTD-2227C6.2 9.68 2.58e-20 4.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83145300 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs1382369 ENSG00000249664.1 CTD-2227C6.2 9.68 2.58e-20 4.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83145610 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs2386240 ENSG00000249664.1 CTD-2227C6.2 9.68 2.58e-20 4.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83147192 chr5:83012285~83013109:- LUSC cis rs5760092 0.755 rs915589 ENSG00000218537.1 MIF-AS1 -9.68 2.58e-20 4.9e-17 -0.64 -0.41 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23894426~23898930:- LUSC cis rs6452524 1 rs62374373 ENSG00000249664.1 CTD-2227C6.2 9.68 2.6e-20 4.93e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83137389 chr5:83012285~83013109:- LUSC cis rs2019137 0.539 rs4849181 ENSG00000274877.1 RP11-65I12.1 -9.67 2.61e-20 4.95e-17 -0.51 -0.41 Lymphocyte counts; chr2:113234393 chr2:113237595~113240825:+ LUSC cis rs10256972 0.732 rs1574108 ENSG00000229043.2 AC091729.9 -9.67 2.61e-20 4.95e-17 -0.48 -0.41 Endometriosis;Longevity; chr7:1066169 chr7:1160374~1165267:+ LUSC cis rs2019137 0.539 rs4849177 ENSG00000274877.1 RP11-65I12.1 -9.67 2.62e-20 4.96e-17 -0.5 -0.41 Lymphocyte counts; chr2:113225007 chr2:113237595~113240825:+ LUSC cis rs7301826 0.967 rs4759792 ENSG00000256299.1 RP11-989F5.3 -9.67 2.64e-20 5e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130812086 chr12:130810821~130812622:- LUSC cis rs1707322 0.647 rs6686944 ENSG00000280836.1 AL355480.1 -9.67 2.66e-20 5.04e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690636 chr1:45581219~45581321:- LUSC cis rs8062405 1 rs62036616 ENSG00000259982.1 CDC37P1 9.67 2.67e-20 5.06e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814986 chr16:28700294~28701540:- LUSC cis rs150992 0.609 rs366353 ENSG00000248489.1 CTD-2007H13.3 -9.67 2.69e-20 5.1e-17 -0.46 -0.41 Body mass index; chr5:98995663 chr5:98929171~98995013:+ LUSC cis rs9322193 0.923 rs2342765 ENSG00000216906.2 RP11-350J20.9 9.67 2.7e-20 5.12e-17 0.47 0.41 Lung cancer; chr6:149858873 chr6:149904243~149906418:+ LUSC cis rs10129255 0.719 rs7156660 ENSG00000211970.3 IGHV4-61 -9.67 2.71e-20 5.14e-17 -0.28 -0.41 Kawasaki disease; chr14:106673171 chr14:106639119~106639657:- LUSC cis rs6452524 0.967 rs10051542 ENSG00000249664.1 CTD-2227C6.2 9.67 2.73e-20 5.17e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83178268 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs10051557 ENSG00000249664.1 CTD-2227C6.2 9.67 2.73e-20 5.17e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83178307 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs9293334 ENSG00000249664.1 CTD-2227C6.2 9.67 2.75e-20 5.21e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83156984 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs10037872 ENSG00000249664.1 CTD-2227C6.2 9.67 2.77e-20 5.23e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83144101 chr5:83012285~83013109:- LUSC cis rs2337406 0.789 rs12050392 ENSG00000274576.2 IGHV2-70 -9.67 2.79e-20 5.27e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106779073 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs74092505 ENSG00000274576.2 IGHV2-70 -9.67 2.79e-20 5.27e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106779163 chr14:106770577~106771020:- LUSC cis rs2337406 0.789 rs74092507 ENSG00000274576.2 IGHV2-70 -9.67 2.79e-20 5.27e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106779174 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs74092511 ENSG00000274576.2 IGHV2-70 -9.67 2.79e-20 5.27e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106779234 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs74092512 ENSG00000274576.2 IGHV2-70 -9.67 2.79e-20 5.27e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106779306 chr14:106770577~106771020:- LUSC cis rs2337406 0.789 rs74092514 ENSG00000274576.2 IGHV2-70 -9.67 2.79e-20 5.27e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106779385 chr14:106770577~106771020:- LUSC cis rs9322193 0.884 rs7769115 ENSG00000216906.2 RP11-350J20.9 9.67 2.8e-20 5.28e-17 0.49 0.41 Lung cancer; chr6:149848796 chr6:149904243~149906418:+ LUSC cis rs7301826 1 rs4619189 ENSG00000256299.1 RP11-989F5.3 -9.67 2.8e-20 5.29e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130829252 chr12:130810821~130812622:- LUSC cis rs2337406 0.866 rs79901786 ENSG00000274576.2 IGHV2-70 -9.67 2.8e-20 5.29e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106777623 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs7152809 ENSG00000274576.2 IGHV2-70 -9.67 2.8e-20 5.29e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106778385 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs7152832 ENSG00000274576.2 IGHV2-70 -9.67 2.8e-20 5.29e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106778427 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs8003852 ENSG00000274576.2 IGHV2-70 -9.66 2.83e-20 5.34e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106776648 chr14:106770577~106771020:- LUSC cis rs6452524 1 rs6882220 ENSG00000249664.1 CTD-2227C6.2 9.66 2.83e-20 5.34e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83139715 chr5:83012285~83013109:- LUSC cis rs9322193 0.886 rs2065663 ENSG00000216906.2 RP11-350J20.9 9.66 2.83e-20 5.35e-17 0.49 0.41 Lung cancer; chr6:149760331 chr6:149904243~149906418:+ LUSC cis rs2337406 0.866 rs74092520 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106779632 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs4583128 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106780669 chr14:106770577~106771020:- LUSC cis rs2337406 0.929 rs12050200 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106780983 chr14:106770577~106771020:- LUSC cis rs2337406 0.852 rs12050239 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781132 chr14:106770577~106771020:- LUSC cis rs2337406 0.929 rs59263250 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781183 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs58083017 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781256 chr14:106770577~106771020:- LUSC cis rs2337406 0.789 rs60390024 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781327 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs74092532 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781363 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs74092534 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781364 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs74092535 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781722 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs74092537 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781883 chr14:106770577~106771020:- LUSC cis rs2337406 0.81 rs74092538 ENSG00000274576.2 IGHV2-70 -9.66 2.85e-20 5.37e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781942 chr14:106770577~106771020:- LUSC cis rs2337406 0.5 rs7152934 ENSG00000274576.2 IGHV2-70 -9.66 2.91e-20 5.49e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106778702 chr14:106770577~106771020:- LUSC cis rs1729407 0.647 rs2727791 ENSG00000254851.1 RP11-109L13.1 -9.66 2.93e-20 5.52e-17 -0.52 -0.41 Apolipoprotein A-IV levels; chr11:116813846 chr11:117135528~117138582:+ LUSC cis rs6452524 0.935 rs1382376 ENSG00000249664.1 CTD-2227C6.2 9.66 2.99e-20 5.63e-17 0.41 0.41 Hypertension (SNP x SNP interaction); chr5:83095418 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs12109517 ENSG00000249664.1 CTD-2227C6.2 9.66 2.99e-20 5.63e-17 0.41 0.41 Hypertension (SNP x SNP interaction); chr5:83095947 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs12109514 ENSG00000249664.1 CTD-2227C6.2 9.66 2.99e-20 5.63e-17 0.41 0.41 Hypertension (SNP x SNP interaction); chr5:83095965 chr5:83012285~83013109:- LUSC cis rs1707322 0.721 rs11211151 ENSG00000280836.1 AL355480.1 -9.66 2.99e-20 5.64e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45647080 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs12045096 ENSG00000280836.1 AL355480.1 -9.66 2.99e-20 5.64e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648756 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs4609469 ENSG00000280836.1 AL355480.1 -9.66 2.99e-20 5.64e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651513 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs12049027 ENSG00000280836.1 AL355480.1 -9.66 2.99e-20 5.64e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45652512 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs10789467 ENSG00000280836.1 AL355480.1 -9.66 2.99e-20 5.64e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45653073 chr1:45581219~45581321:- LUSC cis rs6452524 0.901 rs17284211 ENSG00000249664.1 CTD-2227C6.2 9.66 3e-20 5.65e-17 0.41 0.41 Hypertension (SNP x SNP interaction); chr5:83098706 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs1382374 ENSG00000249664.1 CTD-2227C6.2 9.66 3e-20 5.65e-17 0.41 0.41 Hypertension (SNP x SNP interaction); chr5:83101010 chr5:83012285~83013109:- LUSC cis rs10129255 0.957 rs10136817 ENSG00000223648.3 IGHV3-64 9.66 3.02e-20 5.68e-17 0.38 0.41 Kawasaki disease; chr14:106787730 chr14:106643132~106658258:- LUSC cis rs748404 0.66 rs2467742 ENSG00000249839.1 AC011330.5 -9.66 3.03e-20 5.7e-17 -0.53 -0.41 Lung cancer; chr15:43458039 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs694725 ENSG00000249839.1 AC011330.5 -9.66 3.03e-20 5.7e-17 -0.53 -0.41 Lung cancer; chr15:43464012 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs518288 ENSG00000249839.1 AC011330.5 -9.66 3.03e-20 5.7e-17 -0.53 -0.41 Lung cancer; chr15:43471801 chr15:43663654~43684339:- LUSC cis rs4774565 0.762 rs720599 ENSG00000244879.4 GABPB1-AS1 -9.66 3.03e-20 5.7e-17 -0.38 -0.41 Breast cancer; chr15:50372318 chr15:50354959~50372202:+ LUSC cis rs1707322 0.752 rs11211168 ENSG00000280836.1 AL355480.1 -9.65 3.06e-20 5.76e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697975 chr1:45581219~45581321:- LUSC cis rs8062405 0.964 rs62036614 ENSG00000259982.1 CDC37P1 9.65 3.08e-20 5.8e-17 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28813364 chr16:28700294~28701540:- LUSC cis rs748404 0.69 rs2244981 ENSG00000249839.1 AC011330.5 -9.65 3.09e-20 5.81e-17 -0.53 -0.41 Lung cancer; chr15:43460553 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs690446 ENSG00000249839.1 AC011330.5 -9.65 3.09e-20 5.81e-17 -0.53 -0.41 Lung cancer; chr15:43469066 chr15:43663654~43684339:- LUSC cis rs748404 0.631 rs560191 ENSG00000249839.1 AC011330.5 -9.65 3.09e-20 5.81e-17 -0.53 -0.41 Lung cancer; chr15:43475576 chr15:43663654~43684339:- LUSC cis rs6782228 0.606 rs6787559 ENSG00000277250.1 Metazoa_SRP -9.65 3.12e-20 5.86e-17 -0.45 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128662243 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs2001703 ENSG00000277250.1 Metazoa_SRP -9.65 3.12e-20 5.86e-17 -0.45 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128664254 chr3:128673681~128674021:- LUSC cis rs11098499 0.954 rs3733524 ENSG00000245958.5 RP11-33B1.1 -9.65 3.13e-20 5.89e-17 -0.42 -0.41 Corneal astigmatism; chr4:119502574 chr4:119454791~119552025:+ LUSC cis rs6964833 1 rs35203738 ENSG00000277053.3 GTF2IP1 -9.65 3.14e-20 5.91e-17 -0.61 -0.41 Menarche (age at onset); chr7:74690864 chr7:75185385~75237696:- LUSC cis rs9322193 0.923 rs1934534 ENSG00000216906.2 RP11-350J20.9 9.65 3.15e-20 5.92e-17 0.49 0.41 Lung cancer; chr6:149711896 chr6:149904243~149906418:+ LUSC cis rs10875746 0.855 rs10875728 ENSG00000240399.1 RP1-228P16.1 -9.65 3.16e-20 5.95e-17 -0.45 -0.41 Longevity (90 years and older); chr12:48032609 chr12:48054813~48055591:- LUSC cis rs9322193 0.923 rs2297930 ENSG00000216906.2 RP11-350J20.9 9.65 3.16e-20 5.95e-17 0.49 0.41 Lung cancer; chr6:149718360 chr6:149904243~149906418:+ LUSC cis rs11098499 0.954 rs10518328 ENSG00000245958.5 RP11-33B1.1 -9.65 3.17e-20 5.95e-17 -0.41 -0.41 Corneal astigmatism; chr4:119480624 chr4:119454791~119552025:+ LUSC cis rs7301826 1 rs10848205 ENSG00000256299.1 RP11-989F5.3 -9.65 3.17e-20 5.96e-17 -0.44 -0.41 Plasma plasminogen activator levels; chr12:130796169 chr12:130810821~130812622:- LUSC cis rs6452524 1 rs7733151 ENSG00000249664.1 CTD-2227C6.2 9.65 3.24e-20 6.08e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83134655 chr5:83012285~83013109:- LUSC cis rs10129255 0.957 rs8014696 ENSG00000223648.3 IGHV3-64 -9.65 3.25e-20 6.1e-17 -0.37 -0.41 Kawasaki disease; chr14:106769752 chr14:106643132~106658258:- LUSC cis rs9322193 0.962 rs3805749 ENSG00000216906.2 RP11-350J20.9 9.65 3.3e-20 6.19e-17 0.5 0.41 Lung cancer; chr6:149772546 chr6:149904243~149906418:+ LUSC cis rs9322193 0.847 rs9505972 ENSG00000216906.2 RP11-350J20.9 9.65 3.3e-20 6.19e-17 0.5 0.41 Lung cancer; chr6:149775255 chr6:149904243~149906418:+ LUSC cis rs2337406 0.929 rs12050233 ENSG00000274576.2 IGHV2-70 -9.65 3.31e-20 6.22e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781123 chr14:106770577~106771020:- LUSC cis rs2337406 0.852 rs12050466 ENSG00000274576.2 IGHV2-70 -9.65 3.31e-20 6.22e-17 -0.4 -0.41 Alzheimer's disease (late onset); chr14:106781131 chr14:106770577~106771020:- LUSC cis rs1707322 0.686 rs3014251 ENSG00000280836.1 AL355480.1 9.64 3.32e-20 6.24e-17 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45611756 chr1:45581219~45581321:- LUSC cis rs7301826 0.967 rs4759790 ENSG00000256299.1 RP11-989F5.3 -9.64 3.34e-20 6.27e-17 -0.43 -0.41 Plasma plasminogen activator levels; chr12:130811845 chr12:130810821~130812622:- LUSC cis rs11098499 0.863 rs12508173 ENSG00000245958.5 RP11-33B1.1 -9.64 3.35e-20 6.28e-17 -0.42 -0.41 Corneal astigmatism; chr4:119397371 chr4:119454791~119552025:+ LUSC cis rs11098499 0.908 rs12504149 ENSG00000245958.5 RP11-33B1.1 -9.64 3.35e-20 6.28e-17 -0.42 -0.41 Corneal astigmatism; chr4:119397422 chr4:119454791~119552025:+ LUSC cis rs6452524 1 rs6452519 ENSG00000249664.1 CTD-2227C6.2 9.64 3.36e-20 6.3e-17 0.41 0.41 Hypertension (SNP x SNP interaction); chr5:83133429 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs10474094 ENSG00000249664.1 CTD-2227C6.2 9.64 3.38e-20 6.34e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83154678 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs7733330 ENSG00000249664.1 CTD-2227C6.2 9.64 3.4e-20 6.37e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83134774 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs7733354 ENSG00000249664.1 CTD-2227C6.2 9.64 3.4e-20 6.37e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83134859 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs4634330 ENSG00000249664.1 CTD-2227C6.2 9.64 3.4e-20 6.37e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83134963 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs2386238 ENSG00000249664.1 CTD-2227C6.2 9.64 3.4e-20 6.37e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83135266 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs2386239 ENSG00000249664.1 CTD-2227C6.2 9.64 3.4e-20 6.37e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83135339 chr5:83012285~83013109:- LUSC cis rs1707322 0.686 rs3014239 ENSG00000280836.1 AL355480.1 9.64 3.4e-20 6.37e-17 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624129 chr1:45581219~45581321:- LUSC cis rs1707322 0.686 rs3014236 ENSG00000280836.1 AL355480.1 9.64 3.4e-20 6.37e-17 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625633 chr1:45581219~45581321:- LUSC cis rs11155671 0.53 rs9383940 ENSG00000223701.3 RAET1E-AS1 9.64 3.41e-20 6.4e-17 0.46 0.41 Testicular germ cell tumor; chr6:149904923 chr6:149884431~149919508:+ LUSC cis rs4774565 0.724 rs2555486 ENSG00000244879.4 GABPB1-AS1 9.64 3.42e-20 6.42e-17 0.37 0.41 Breast cancer; chr15:50363924 chr15:50354959~50372202:+ LUSC cis rs4774565 0.762 rs7182201 ENSG00000244879.4 GABPB1-AS1 -9.64 3.42e-20 6.42e-17 -0.37 -0.41 Breast cancer; chr15:50364377 chr15:50354959~50372202:+ LUSC cis rs1707322 0.752 rs12062535 ENSG00000280836.1 AL355480.1 -9.64 3.43e-20 6.43e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45757208 chr1:45581219~45581321:- LUSC cis rs9322193 0.847 rs880246 ENSG00000216906.2 RP11-350J20.9 9.64 3.44e-20 6.44e-17 0.48 0.41 Lung cancer; chr6:149845972 chr6:149904243~149906418:+ LUSC cis rs6452524 0.934 rs7700253 ENSG00000249664.1 CTD-2227C6.2 9.64 3.44e-20 6.44e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83135510 chr5:83012285~83013109:- LUSC cis rs4774565 0.762 rs1056682 ENSG00000244879.4 GABPB1-AS1 -9.64 3.46e-20 6.48e-17 -0.37 -0.41 Breast cancer; chr15:50368004 chr15:50354959~50372202:+ LUSC cis rs992157 0.798 rs4996257 ENSG00000261338.2 RP11-378A13.1 9.64 3.47e-20 6.49e-17 0.42 0.41 Colorectal cancer; chr2:218298113 chr2:218255319~218257366:+ LUSC cis rs11155671 0.53 rs6557133 ENSG00000216906.2 RP11-350J20.9 9.64 3.48e-20 6.52e-17 0.48 0.41 Testicular germ cell tumor; chr6:149874248 chr6:149904243~149906418:+ LUSC cis rs1891275 0.515 rs7908980 ENSG00000228701.1 TNKS2-AS1 -9.64 3.52e-20 6.59e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91659545 chr10:91782839~91798291:- LUSC cis rs1891275 0.551 rs4933690 ENSG00000228701.1 TNKS2-AS1 -9.64 3.52e-20 6.59e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91659810 chr10:91782839~91798291:- LUSC cis rs1891275 0.576 rs4933216 ENSG00000228701.1 TNKS2-AS1 -9.64 3.52e-20 6.59e-17 -0.5 -0.41 Intelligence (multi-trait analysis); chr10:91659825 chr10:91782839~91798291:- LUSC cis rs1707322 0.721 rs12043945 ENSG00000280836.1 AL355480.1 -9.64 3.53e-20 6.6e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45641250 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs12091503 ENSG00000280836.1 AL355480.1 -9.64 3.53e-20 6.6e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642196 chr1:45581219~45581321:- LUSC cis rs1707322 0.686 rs2230659 ENSG00000280836.1 AL355480.1 9.64 3.55e-20 6.65e-17 0.5 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613212 chr1:45581219~45581321:- LUSC cis rs62229266 0.804 rs62230822 ENSG00000231106.2 LINC01436 9.64 3.56e-20 6.66e-17 0.52 0.41 Mitral valve prolapse; chr21:36057647 chr21:36005338~36007838:+ LUSC cis rs1167827 1 rs1167827 ENSG00000127957.15 PMS2P3 -9.64 3.57e-20 6.68e-17 -0.37 -0.41 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75533848 chr7:75502930~75528148:- LUSC cis rs7208859 0.623 rs8082537 ENSG00000263531.1 RP13-753N3.1 9.64 3.59e-20 6.71e-17 0.7 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30688914 chr17:30863921~30864940:- LUSC cis rs1707322 0.721 rs4660883 ENSG00000280836.1 AL355480.1 -9.64 3.59e-20 6.71e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45770426 chr1:45581219~45581321:- LUSC cis rs7301826 0.934 rs10848212 ENSG00000256299.1 RP11-989F5.3 9.63 3.67e-20 6.86e-17 0.43 0.41 Plasma plasminogen activator levels; chr12:130837455 chr12:130810821~130812622:- LUSC cis rs1707322 0.686 rs2991987 ENSG00000280836.1 AL355480.1 9.63 3.67e-20 6.86e-17 0.5 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615750 chr1:45581219~45581321:- LUSC cis rs6452524 1 rs2126990 ENSG00000249664.1 CTD-2227C6.2 9.63 3.68e-20 6.87e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83161351 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs10043018 ENSG00000249664.1 CTD-2227C6.2 9.63 3.69e-20 6.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83138498 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs10037501 ENSG00000249664.1 CTD-2227C6.2 9.63 3.69e-20 6.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83138722 chr5:83012285~83013109:- LUSC cis rs6452524 0.904 rs6452525 ENSG00000249664.1 CTD-2227C6.2 9.63 3.69e-20 6.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83138752 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs7716931 ENSG00000249664.1 CTD-2227C6.2 9.63 3.69e-20 6.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83138856 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs7721416 ENSG00000249664.1 CTD-2227C6.2 9.63 3.69e-20 6.89e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83139174 chr5:83012285~83013109:- LUSC cis rs9322193 0.923 rs4869750 ENSG00000216906.2 RP11-350J20.9 9.63 3.69e-20 6.89e-17 0.48 0.41 Lung cancer; chr6:149855996 chr6:149904243~149906418:+ LUSC cis rs150992 0.574 rs2927655 ENSG00000248489.1 CTD-2007H13.3 9.63 3.75e-20 7.01e-17 0.5 0.41 Body mass index; chr5:98839049 chr5:98929171~98995013:+ LUSC cis rs6452524 0.935 rs1542539 ENSG00000249664.1 CTD-2227C6.2 9.63 3.79e-20 7.08e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83116033 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs6452524 ENSG00000249664.1 CTD-2227C6.2 -9.63 3.79e-20 7.08e-17 -0.41 -0.41 Hypertension (SNP x SNP interaction); chr5:83137962 chr5:83012285~83013109:- LUSC cis rs1933112 0.5 rs12021763 ENSG00000227777.1 RP4-738P11.3 -9.63 3.8e-20 7.09e-17 -0.55 -0.41 Blood protein levels; chr1:168558845 chr1:168542737~168543354:+ LUSC cis rs1891275 0.515 rs7911755 ENSG00000228701.1 TNKS2-AS1 -9.63 3.84e-20 7.17e-17 -0.47 -0.41 Intelligence (multi-trait analysis); chr10:91730060 chr10:91782839~91798291:- LUSC cis rs867371 0.502 rs8025964 ENSG00000255769.6 GOLGA2P10 -9.63 3.85e-20 7.18e-17 -0.48 -0.41 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82229429 chr15:82472993~82513950:- LUSC cis rs10129255 0.536 rs3944157 ENSG00000280411.1 IGHV1-69-2 -9.63 3.86e-20 7.2e-17 -0.25 -0.41 Kawasaki disease; chr14:106682286 chr14:106762092~106762588:- LUSC cis rs6452524 0.935 rs1543847 ENSG00000249664.1 CTD-2227C6.2 9.63 3.86e-20 7.2e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83116044 chr5:83012285~83013109:- LUSC cis rs494459 0.838 rs2510897 ENSG00000255422.1 AP002954.4 -9.63 3.88e-20 7.23e-17 -0.42 -0.41 Height; chr11:118773873 chr11:118704607~118750263:+ LUSC cis rs765787 0.53 rs1706837 ENSG00000259520.4 CTD-2651B20.3 9.63 3.88e-20 7.24e-17 0.5 0.41 Uric acid levels; chr15:45226838 chr15:45251580~45279251:- LUSC cis rs6782228 0.675 rs2253151 ENSG00000277250.1 Metazoa_SRP -9.63 3.89e-20 7.24e-17 -0.45 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611294 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs6807019 ENSG00000277250.1 Metazoa_SRP -9.63 3.89e-20 7.25e-17 -0.46 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128687091 chr3:128673681~128674021:- LUSC cis rs10256972 0.758 rs2280724 ENSG00000229043.2 AC091729.9 -9.62 3.93e-20 7.33e-17 -0.47 -0.41 Endometriosis;Longevity; chr7:1025084 chr7:1160374~1165267:+ LUSC cis rs1167827 0.805 rs809439 ENSG00000127957.15 PMS2P3 9.62 3.97e-20 7.39e-17 0.39 0.41 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75531992 chr7:75502930~75528148:- LUSC cis rs6452524 1 rs1382364 ENSG00000249664.1 CTD-2227C6.2 9.62 4.01e-20 7.46e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83156677 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs1382363 ENSG00000249664.1 CTD-2227C6.2 9.62 4.01e-20 7.46e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83156753 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs11741897 ENSG00000249664.1 CTD-2227C6.2 9.62 4.01e-20 7.46e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83157246 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs10076000 ENSG00000249664.1 CTD-2227C6.2 9.62 4.01e-20 7.46e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83161629 chr5:83012285~83013109:- LUSC cis rs10129255 0.646 rs55995061 ENSG00000223648.3 IGHV3-64 9.62 4.03e-20 7.5e-17 0.36 0.41 Kawasaki disease; chr14:106799309 chr14:106643132~106658258:- LUSC cis rs6452524 0.935 rs10076059 ENSG00000249664.1 CTD-2227C6.2 9.62 4.03e-20 7.51e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83105698 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs7736783 ENSG00000249664.1 CTD-2227C6.2 9.62 4.03e-20 7.51e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83107050 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs11951257 ENSG00000249664.1 CTD-2227C6.2 9.62 4.03e-20 7.51e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83107492 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs767771 ENSG00000249664.1 CTD-2227C6.2 9.62 4.03e-20 7.51e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83108117 chr5:83012285~83013109:- LUSC cis rs10256972 0.684 rs4724039 ENSG00000229043.2 AC091729.9 -9.62 4.04e-20 7.51e-17 -0.47 -0.41 Endometriosis;Longevity; chr7:1071997 chr7:1160374~1165267:+ LUSC cis rs2019137 0.56 rs10206269 ENSG00000274877.1 RP11-65I12.1 -9.62 4.12e-20 7.66e-17 -0.5 -0.41 Lymphocyte counts; chr2:113232816 chr2:113237595~113240825:+ LUSC cis rs6452524 1 rs9293332 ENSG00000249664.1 CTD-2227C6.2 9.62 4.17e-20 7.76e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83141546 chr5:83012285~83013109:- LUSC cis rs8062405 0.655 rs7184597 ENSG00000259982.1 CDC37P1 -9.62 4.18e-20 7.76e-17 -0.52 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910488 chr16:28700294~28701540:- LUSC cis rs10256972 0.732 rs12701856 ENSG00000229043.2 AC091729.9 -9.61 4.24e-20 7.88e-17 -0.48 -0.41 Endometriosis;Longevity; chr7:1068071 chr7:1160374~1165267:+ LUSC cis rs62229266 0.804 rs12483151 ENSG00000231106.2 LINC01436 9.61 4.25e-20 7.9e-17 0.52 0.41 Mitral valve prolapse; chr21:36047280 chr21:36005338~36007838:+ LUSC cis rs9322193 0.923 rs9377230 ENSG00000216906.2 RP11-350J20.9 9.61 4.25e-20 7.9e-17 0.48 0.41 Lung cancer; chr6:149613607 chr6:149904243~149906418:+ LUSC cis rs6452524 0.967 rs1564211 ENSG00000249664.1 CTD-2227C6.2 9.61 4.32e-20 8.02e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83117014 chr5:83012285~83013109:- LUSC cis rs7174755 0.772 rs8025474 ENSG00000260657.2 RP11-315D16.4 9.61 4.35e-20 8.08e-17 0.53 0.41 Major depressive disorder; chr15:68094185 chr15:68267792~68277994:- LUSC cis rs6452524 1 rs6864479 ENSG00000249664.1 CTD-2227C6.2 9.61 4.41e-20 8.18e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83166421 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs13436667 ENSG00000249664.1 CTD-2227C6.2 9.61 4.41e-20 8.18e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83168948 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs7726564 ENSG00000249664.1 CTD-2227C6.2 9.61 4.41e-20 8.18e-17 0.42 0.41 Hypertension (SNP x SNP interaction); chr5:83170274 chr5:83012285~83013109:- LUSC cis rs748404 0.66 rs2467741 ENSG00000249839.1 AC011330.5 -9.61 4.41e-20 8.18e-17 -0.53 -0.41 Lung cancer; chr15:43450428 chr15:43663654~43684339:- LUSC cis rs9322193 0.923 rs2185352 ENSG00000216906.2 RP11-350J20.9 9.61 4.43e-20 8.22e-17 0.48 0.41 Lung cancer; chr6:149714640 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs12174349 ENSG00000216906.2 RP11-350J20.9 9.61 4.43e-20 8.22e-17 0.48 0.41 Lung cancer; chr6:149718012 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs2297932 ENSG00000216906.2 RP11-350J20.9 9.61 4.43e-20 8.22e-17 0.48 0.41 Lung cancer; chr6:149718225 chr6:149904243~149906418:+ LUSC cis rs992157 0.731 rs1399132 ENSG00000261338.2 RP11-378A13.1 9.61 4.43e-20 8.22e-17 0.41 0.41 Colorectal cancer; chr2:218295047 chr2:218255319~218257366:+ LUSC cis rs992157 0.796 rs55680399 ENSG00000261338.2 RP11-378A13.1 9.61 4.43e-20 8.22e-17 0.41 0.41 Colorectal cancer; chr2:218295898 chr2:218255319~218257366:+ LUSC cis rs11089937 0.963 rs5757098 ENSG00000211639.2 IGLV4-60 -9.61 4.44e-20 8.23e-17 -0.41 -0.41 Periodontitis (PAL4Q3); chr22:22154322 chr22:22162199~22162681:+ LUSC cis rs2337406 0.866 rs61419485 ENSG00000274576.2 IGHV2-70 -9.61 4.45e-20 8.25e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106783374 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs8015361 ENSG00000274576.2 IGHV2-70 -9.61 4.45e-20 8.25e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106783991 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs74090151 ENSG00000274576.2 IGHV2-70 -9.61 4.45e-20 8.25e-17 -0.41 -0.41 Alzheimer's disease (late onset); chr14:106785377 chr14:106770577~106771020:- LUSC cis rs2019137 0.56 rs7421852 ENSG00000274877.1 RP11-65I12.1 -9.61 4.53e-20 8.4e-17 -0.5 -0.41 Lymphocyte counts; chr2:113232684 chr2:113237595~113240825:+ LUSC cis rs2739330 0.76 rs1007888 ENSG00000235689.1 AP000351.13 9.61 4.54e-20 8.42e-17 0.41 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:24006305~24008258:- LUSC cis rs1707322 0.717 rs11211161 ENSG00000280836.1 AL355480.1 -9.6 4.6e-20 8.53e-17 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45682466 chr1:45581219~45581321:- LUSC cis rs6782228 0.565 rs12695509 ENSG00000277250.1 Metazoa_SRP -9.6 4.63e-20 8.57e-17 -0.46 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128698201 chr3:128673681~128674021:- LUSC cis rs1707322 0.686 rs2230658 ENSG00000280836.1 AL355480.1 9.6 4.63e-20 8.57e-17 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613182 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs10890333 ENSG00000280836.1 AL355480.1 -9.6 4.68e-20 8.66e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634650 chr1:45581219~45581321:- LUSC cis rs6452524 0.935 rs7703318 ENSG00000249664.1 CTD-2227C6.2 9.6 4.7e-20 8.69e-17 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83118234 chr5:83012285~83013109:- LUSC cis rs9322193 0.884 rs7450246 ENSG00000216906.2 RP11-350J20.9 9.6 4.7e-20 8.69e-17 0.49 0.4 Lung cancer; chr6:149702517 chr6:149904243~149906418:+ LUSC cis rs2108622 0.545 rs59140933 ENSG00000267453.5 AC004791.2 -9.6 4.7e-20 8.7e-17 -0.51 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15864498 chr19:15851993~15864904:- LUSC cis rs6452524 0.935 rs10045744 ENSG00000249664.1 CTD-2227C6.2 9.6 4.71e-20 8.72e-17 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83113688 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs2974443 ENSG00000249664.1 CTD-2227C6.2 9.6 4.72e-20 8.74e-17 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83184595 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs2974441 ENSG00000249664.1 CTD-2227C6.2 9.6 4.72e-20 8.74e-17 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83193330 chr5:83012285~83013109:- LUSC cis rs9322193 0.923 rs57938011 ENSG00000216906.2 RP11-350J20.9 9.6 4.73e-20 8.75e-17 0.49 0.4 Lung cancer; chr6:149642969 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs10872651 ENSG00000216906.2 RP11-350J20.9 9.6 4.73e-20 8.75e-17 0.49 0.4 Lung cancer; chr6:149768273 chr6:149904243~149906418:+ LUSC cis rs748404 0.56 rs1060939 ENSG00000249839.1 AC011330.5 -9.6 4.77e-20 8.82e-17 -0.54 -0.4 Lung cancer; chr15:43524719 chr15:43663654~43684339:- LUSC cis rs2108622 0.683 rs111388185 ENSG00000267453.5 AC004791.2 -9.6 4.78e-20 8.84e-17 -0.53 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866604 chr19:15851993~15864904:- LUSC cis rs2108622 0.683 rs112571591 ENSG00000267453.5 AC004791.2 -9.6 4.78e-20 8.84e-17 -0.53 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866635 chr19:15851993~15864904:- LUSC cis rs2108622 0.647 rs111427692 ENSG00000267453.5 AC004791.2 -9.6 4.78e-20 8.84e-17 -0.53 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866669 chr19:15851993~15864904:- LUSC cis rs6452524 1 rs10076271 ENSG00000249664.1 CTD-2227C6.2 9.6 4.78e-20 8.84e-17 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83133875 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs10076274 ENSG00000249664.1 CTD-2227C6.2 9.6 4.78e-20 8.84e-17 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83133908 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs10061521 ENSG00000249664.1 CTD-2227C6.2 9.6 4.78e-20 8.84e-17 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83133936 chr5:83012285~83013109:- LUSC cis rs494459 0.838 rs555649 ENSG00000255422.1 AP002954.4 -9.6 4.79e-20 8.86e-17 -0.42 -0.4 Height; chr11:118781100 chr11:118704607~118750263:+ LUSC cis rs765787 0.53 rs16941017 ENSG00000259520.4 CTD-2651B20.3 9.6 4.83e-20 8.93e-17 0.5 0.4 Uric acid levels; chr15:45251083 chr15:45251580~45279251:- LUSC cis rs992157 0.798 rs1017698 ENSG00000261338.2 RP11-378A13.1 -9.6 4.9e-20 9.06e-17 -0.42 -0.4 Colorectal cancer; chr2:218305802 chr2:218255319~218257366:+ LUSC cis rs1185460 1 rs1614264 ENSG00000271751.1 RP11-110I1.14 -9.6 4.93e-20 9.11e-17 -0.52 -0.4 Coronary artery disease; chr11:119071928 chr11:119065263~119065677:- LUSC cis rs10129255 0.957 rs28887506 ENSG00000223648.3 IGHV3-64 9.6 4.94e-20 9.12e-17 0.37 0.4 Kawasaki disease; chr14:106785589 chr14:106643132~106658258:- LUSC cis rs1707322 0.752 rs11488313 ENSG00000280836.1 AL355480.1 -9.6 4.95e-20 9.13e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45759108 chr1:45581219~45581321:- LUSC cis rs11098499 0.955 rs35434465 ENSG00000245958.5 RP11-33B1.1 -9.6 4.96e-20 9.15e-17 -0.41 -0.4 Corneal astigmatism; chr4:119248223 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs11155670 ENSG00000216906.2 RP11-350J20.9 9.6 4.96e-20 9.16e-17 0.49 0.4 Lung cancer; chr6:149644992 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9322209 ENSG00000216906.2 RP11-350J20.9 9.59 5.04e-20 9.29e-17 0.49 0.4 Lung cancer; chr6:149691226 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs3805752 ENSG00000216906.2 RP11-350J20.9 9.59 5.07e-20 9.35e-17 0.49 0.4 Lung cancer; chr6:149795490 chr6:149904243~149906418:+ LUSC cis rs10875746 0.855 rs10875729 ENSG00000240399.1 RP1-228P16.1 -9.59 5.1e-20 9.41e-17 -0.46 -0.4 Longevity (90 years and older); chr12:48032943 chr12:48054813~48055591:- LUSC cis rs6452524 1 rs17284288 ENSG00000249664.1 CTD-2227C6.2 9.59 5.1e-20 9.41e-17 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83148997 chr5:83012285~83013109:- LUSC cis rs1707322 0.752 rs11211173 ENSG00000280836.1 AL355480.1 -9.59 5.12e-20 9.44e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45753704 chr1:45581219~45581321:- LUSC cis rs10129255 0.576 rs2157616 ENSG00000211972.2 IGHV3-66 9.59 5.14e-20 9.47e-17 0.27 0.4 Kawasaki disease; chr14:106767802 chr14:106675017~106675544:- LUSC cis rs9322193 0.923 rs9479094 ENSG00000216906.2 RP11-350J20.9 9.59 5.16e-20 9.52e-17 0.48 0.4 Lung cancer; chr6:149725083 chr6:149904243~149906418:+ LUSC cis rs507080 0.524 rs524409 ENSG00000255239.1 AP002954.6 9.59 5.19e-20 9.56e-17 0.43 0.4 Serum metabolite levels; chr11:118703602 chr11:118688039~118690600:- LUSC cis rs17711722 0.51 rs11767457 ENSG00000164669.11 INTS4P1 -9.59 5.22e-20 9.62e-17 -0.45 -0.4 Calcium levels; chr7:65825628 chr7:65141225~65234216:+ LUSC cis rs8062405 0.895 rs62036658 ENSG00000259982.1 CDC37P1 9.59 5.24e-20 9.66e-17 0.51 0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28839050 chr16:28700294~28701540:- LUSC cis rs2455601 0.882 rs11042115 ENSG00000254860.4 TMEM9B-AS1 9.59 5.25e-20 9.67e-17 0.58 0.4 Schizophrenia; chr11:8905132 chr11:8964675~8977527:+ LUSC cis rs6452524 1 rs2126988 ENSG00000249664.1 CTD-2227C6.2 9.59 5.3e-20 9.77e-17 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83146496 chr5:83012285~83013109:- LUSC cis rs494459 0.964 rs576283 ENSG00000255239.1 AP002954.6 9.59 5.31e-20 9.77e-17 0.43 0.4 Height; chr11:118703185 chr11:118688039~118690600:- LUSC cis rs494459 0.929 rs627391 ENSG00000255239.1 AP002954.6 9.59 5.31e-20 9.77e-17 0.43 0.4 Height; chr11:118703207 chr11:118688039~118690600:- LUSC cis rs9322193 0.887 rs9767113 ENSG00000216906.2 RP11-350J20.9 9.59 5.31e-20 9.77e-17 0.49 0.4 Lung cancer; chr6:149718157 chr6:149904243~149906418:+ LUSC cis rs9322193 0.886 rs4870055 ENSG00000216906.2 RP11-350J20.9 9.59 5.32e-20 9.79e-17 0.48 0.4 Lung cancer; chr6:149848433 chr6:149904243~149906418:+ LUSC cis rs1707322 0.752 rs4660313 ENSG00000280836.1 AL355480.1 9.59 5.32e-20 9.8e-17 0.47 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645169 chr1:45581219~45581321:- LUSC cis rs11098499 0.954 rs9998585 ENSG00000245958.5 RP11-33B1.1 -9.59 5.33e-20 9.8e-17 -0.42 -0.4 Corneal astigmatism; chr4:119475647 chr4:119454791~119552025:+ LUSC cis rs6921919 0.583 rs6907950 ENSG00000216901.1 AL022393.7 9.59 5.35e-20 9.84e-17 0.47 0.4 Autism spectrum disorder or schizophrenia; chr6:28402469 chr6:28176188~28176674:+ LUSC cis rs2337406 0.866 rs111881598 ENSG00000274576.2 IGHV2-70 -9.59 5.36e-20 9.87e-17 -0.41 -0.4 Alzheimer's disease (late onset); chr14:106783113 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs61164979 ENSG00000274576.2 IGHV2-70 -9.59 5.36e-20 9.87e-17 -0.41 -0.4 Alzheimer's disease (late onset); chr14:106783133 chr14:106770577~106771020:- LUSC cis rs765787 0.53 rs28756676 ENSG00000259520.4 CTD-2651B20.3 9.59 5.37e-20 9.88e-17 0.5 0.4 Uric acid levels; chr15:45248162 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs55771002 ENSG00000259520.4 CTD-2651B20.3 9.59 5.37e-20 9.88e-17 0.5 0.4 Uric acid levels; chr15:45249368 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs55920042 ENSG00000259520.4 CTD-2651B20.3 9.59 5.37e-20 9.88e-17 0.5 0.4 Uric acid levels; chr15:45249379 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4238376 ENSG00000259520.4 CTD-2651B20.3 9.59 5.37e-20 9.88e-17 0.5 0.4 Uric acid levels; chr15:45249689 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4238377 ENSG00000259520.4 CTD-2651B20.3 9.59 5.37e-20 9.88e-17 0.5 0.4 Uric acid levels; chr15:45249783 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4775844 ENSG00000259520.4 CTD-2651B20.3 9.59 5.37e-20 9.88e-17 0.5 0.4 Uric acid levels; chr15:45249850 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs3759893 ENSG00000259520.4 CTD-2651B20.3 9.59 5.37e-20 9.88e-17 0.5 0.4 Uric acid levels; chr15:45250752 chr15:45251580~45279251:- LUSC cis rs10129255 0.912 rs6576227 ENSG00000223648.3 IGHV3-64 9.59 5.39e-20 9.91e-17 0.36 0.4 Kawasaki disease; chr14:106778202 chr14:106643132~106658258:- LUSC cis rs10129255 0.957 rs6576228 ENSG00000223648.3 IGHV3-64 9.59 5.39e-20 9.91e-17 0.36 0.4 Kawasaki disease; chr14:106778401 chr14:106643132~106658258:- LUSC cis rs9322193 0.576 rs7452592 ENSG00000231760.4 RP11-350J20.5 9.59 5.4e-20 9.93e-17 0.61 0.4 Lung cancer; chr6:149875445 chr6:149796151~149826294:- LUSC cis rs2455601 0.935 rs12049908 ENSG00000254860.4 TMEM9B-AS1 9.58 5.43e-20 9.97e-17 0.58 0.4 Schizophrenia; chr11:8897762 chr11:8964675~8977527:+ LUSC cis rs1891275 0.516 rs10881935 ENSG00000228701.1 TNKS2-AS1 -9.58 5.43e-20 9.97e-17 -0.5 -0.4 Intelligence (multi-trait analysis); chr10:91637944 chr10:91782839~91798291:- LUSC cis rs6452524 1 rs1031902 ENSG00000249664.1 CTD-2227C6.2 9.58 5.44e-20 9.98e-17 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83152308 chr5:83012285~83013109:- LUSC cis rs1707322 0.716 rs10890342 ENSG00000280836.1 AL355480.1 -9.58 5.44e-20 9.98e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45691415 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs6658700 ENSG00000280836.1 AL355480.1 -9.58 5.44e-20 9.98e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45694588 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs12047629 ENSG00000280836.1 AL355480.1 -9.58 5.44e-20 9.98e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697130 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs11211169 ENSG00000280836.1 AL355480.1 -9.58 5.44e-20 9.98e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701037 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs11211171 ENSG00000280836.1 AL355480.1 -9.58 5.44e-20 9.98e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45702970 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs28623463 ENSG00000280836.1 AL355480.1 -9.58 5.44e-20 9.98e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45705086 chr1:45581219~45581321:- LUSC cis rs1707322 0.716 rs28370457 ENSG00000280836.1 AL355480.1 -9.58 5.44e-20 9.98e-17 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706390 chr1:45581219~45581321:- LUSC cis rs6452524 1 rs6452526 ENSG00000249664.1 CTD-2227C6.2 9.58 5.56e-20 1.02e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83140992 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs6452527 ENSG00000249664.1 CTD-2227C6.2 9.58 5.56e-20 1.02e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83141021 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs10055844 ENSG00000249664.1 CTD-2227C6.2 9.58 5.56e-20 1.02e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83141276 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs10077862 ENSG00000249664.1 CTD-2227C6.2 9.58 5.56e-20 1.02e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83141322 chr5:83012285~83013109:- LUSC cis rs9322193 0.923 rs12205092 ENSG00000216906.2 RP11-350J20.9 9.58 5.59e-20 1.03e-16 0.49 0.4 Lung cancer; chr6:149761375 chr6:149904243~149906418:+ LUSC cis rs765787 0.53 rs2668751 ENSG00000259520.4 CTD-2651B20.3 9.58 5.62e-20 1.03e-16 0.5 0.4 Uric acid levels; chr15:45225095 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs1648286 ENSG00000259520.4 CTD-2651B20.3 9.58 5.62e-20 1.03e-16 0.5 0.4 Uric acid levels; chr15:45225188 chr15:45251580~45279251:- LUSC cis rs6782228 0.606 rs2811500 ENSG00000277250.1 Metazoa_SRP -9.58 5.62e-20 1.03e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128647413 chr3:128673681~128674021:- LUSC cis rs10875746 0.859 rs4760622 ENSG00000240399.1 RP1-228P16.1 -9.58 5.64e-20 1.03e-16 -0.44 -0.4 Longevity (90 years and older); chr12:48198177 chr12:48054813~48055591:- LUSC cis rs1707322 0.721 rs4415615 ENSG00000280836.1 AL355480.1 -9.58 5.65e-20 1.03e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45666437 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs7529699 ENSG00000280836.1 AL355480.1 -9.58 5.65e-20 1.03e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668962 chr1:45581219~45581321:- LUSC cis rs1707322 0.716 rs6699444 ENSG00000280836.1 AL355480.1 -9.58 5.65e-20 1.03e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669448 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs10430105 ENSG00000280836.1 AL355480.1 -9.58 5.65e-20 1.03e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45673204 chr1:45581219~45581321:- LUSC cis rs11098499 0.954 rs6849171 ENSG00000245958.5 RP11-33B1.1 -9.58 5.77e-20 1.06e-16 -0.41 -0.4 Corneal astigmatism; chr4:119488394 chr4:119454791~119552025:+ LUSC cis rs9322193 0.847 rs56103941 ENSG00000216906.2 RP11-350J20.9 9.58 5.83e-20 1.07e-16 0.49 0.4 Lung cancer; chr6:149816095 chr6:149904243~149906418:+ LUSC cis rs150992 0.587 rs1393210 ENSG00000248489.1 CTD-2007H13.3 -9.58 5.84e-20 1.07e-16 -0.48 -0.4 Body mass index; chr5:99025892 chr5:98929171~98995013:+ LUSC cis rs150992 0.587 rs11242567 ENSG00000248489.1 CTD-2007H13.3 -9.58 5.84e-20 1.07e-16 -0.48 -0.4 Body mass index; chr5:99028686 chr5:98929171~98995013:+ LUSC cis rs4774565 0.762 rs7164848 ENSG00000244879.4 GABPB1-AS1 9.57 5.91e-20 1.08e-16 0.37 0.4 Breast cancer; chr15:50370833 chr15:50354959~50372202:+ LUSC cis rs7301826 1 rs10744482 ENSG00000256299.1 RP11-989F5.3 -9.57 6.05e-20 1.11e-16 -0.43 -0.4 Plasma plasminogen activator levels; chr12:130813650 chr12:130810821~130812622:- LUSC cis rs7301826 0.966 rs4759795 ENSG00000256299.1 RP11-989F5.3 -9.57 6.05e-20 1.11e-16 -0.43 -0.4 Plasma plasminogen activator levels; chr12:130816355 chr12:130810821~130812622:- LUSC cis rs1933112 0.5 rs1998510 ENSG00000227777.1 RP4-738P11.3 -9.57 6.08e-20 1.11e-16 -0.56 -0.4 Blood protein levels; chr1:168533924 chr1:168542737~168543354:+ LUSC cis rs1933112 0.5 rs4656599 ENSG00000227777.1 RP4-738P11.3 -9.57 6.08e-20 1.11e-16 -0.56 -0.4 Blood protein levels; chr1:168534148 chr1:168542737~168543354:+ LUSC cis rs8062405 0.688 rs3924376 ENSG00000259982.1 CDC37P1 -9.57 6.09e-20 1.11e-16 -0.52 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28914657 chr16:28700294~28701540:- LUSC cis rs1707322 0.686 rs11211179 ENSG00000280836.1 AL355480.1 -9.57 6.11e-20 1.12e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45762410 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs10157795 ENSG00000280836.1 AL355480.1 -9.57 6.11e-20 1.12e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45762520 chr1:45581219~45581321:- LUSC cis rs765787 0.53 rs2413776 ENSG00000259520.4 CTD-2651B20.3 9.57 6.13e-20 1.12e-16 0.5 0.4 Uric acid levels; chr15:45251972 chr15:45251580~45279251:- LUSC cis rs494459 0.726 rs1784300 ENSG00000255422.1 AP002954.4 -9.57 6.2e-20 1.13e-16 -0.42 -0.4 Height; chr11:118808920 chr11:118704607~118750263:+ LUSC cis rs6782228 0.606 rs7650156 ENSG00000277250.1 Metazoa_SRP -9.57 6.25e-20 1.14e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128642712 chr3:128673681~128674021:- LUSC cis rs62229266 0.804 rs2835241 ENSG00000231106.2 LINC01436 -9.57 6.26e-20 1.14e-16 -0.53 -0.4 Mitral valve prolapse; chr21:36039082 chr21:36005338~36007838:+ LUSC cis rs1707322 0.752 rs28550303 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723242 chr1:45581219~45581321:- LUSC cis rs1707322 0.716 rs28375469 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45729703 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs28545085 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736278 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs28719889 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736611 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs28812624 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45738064 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs28507722 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45740868 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs28568986 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45742071 chr1:45581219~45581321:- LUSC cis rs1707322 0.717 rs28396194 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747555 chr1:45581219~45581321:- LUSC cis rs1707322 0.717 rs28752166 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747637 chr1:45581219~45581321:- LUSC cis rs1707322 0.717 rs10890345 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45748255 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs10789471 ENSG00000280836.1 AL355480.1 -9.56 6.41e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45749947 chr1:45581219~45581321:- LUSC cis rs6452524 0.935 rs7718284 ENSG00000249664.1 CTD-2227C6.2 -9.56 6.44e-20 1.17e-16 -0.42 -0.4 Hypertension (SNP x SNP interaction); chr5:83082488 chr5:83012285~83013109:- LUSC cis rs8091660 0.929 rs4939780 ENSG00000278983.1 RP11-426J5.3 9.56 6.45e-20 1.17e-16 0.53 0.4 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48568873 chr18:48564795~48568342:+ LUSC cis rs1707322 0.752 rs61784793 ENSG00000280836.1 AL355480.1 -9.56 6.45e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45683613 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs4586014 ENSG00000280836.1 AL355480.1 -9.56 6.45e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684771 chr1:45581219~45581321:- LUSC cis rs1707322 0.648 rs4439382 ENSG00000280836.1 AL355480.1 -9.56 6.45e-20 1.17e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45685133 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs6699418 ENSG00000280836.1 AL355480.1 -9.56 6.46e-20 1.18e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634509 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs4431884 ENSG00000280836.1 AL355480.1 -9.56 6.46e-20 1.18e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45635651 chr1:45581219~45581321:- LUSC cis rs1707322 0.65 rs4660879 ENSG00000280836.1 AL355480.1 -9.56 6.46e-20 1.18e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45639729 chr1:45581219~45581321:- LUSC cis rs1707322 0.686 rs1547924 ENSG00000280836.1 AL355480.1 -9.56 6.48e-20 1.18e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619440 chr1:45581219~45581321:- LUSC cis rs992157 0.732 rs10932771 ENSG00000261338.2 RP11-378A13.1 9.56 6.55e-20 1.19e-16 0.41 0.4 Colorectal cancer; chr2:218305513 chr2:218255319~218257366:+ LUSC cis rs6782228 0.565 rs11719239 ENSG00000277250.1 Metazoa_SRP -9.56 6.63e-20 1.21e-16 -0.46 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128700211 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs2001950 ENSG00000277250.1 Metazoa_SRP -9.56 6.63e-20 1.21e-16 -0.46 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128700913 chr3:128673681~128674021:- LUSC cis rs150992 0.711 rs170734 ENSG00000248489.1 CTD-2007H13.3 9.56 6.67e-20 1.21e-16 0.48 0.4 Body mass index; chr5:98811337 chr5:98929171~98995013:+ LUSC cis rs10875746 0.859 rs11558768 ENSG00000240399.1 RP1-228P16.1 -9.56 6.69e-20 1.22e-16 -0.45 -0.4 Longevity (90 years and older); chr12:48184006 chr12:48054813~48055591:- LUSC cis rs10129255 0.957 rs10150241 ENSG00000223648.3 IGHV3-64 -9.56 6.7e-20 1.22e-16 -0.37 -0.4 Kawasaki disease; chr14:106775945 chr14:106643132~106658258:- LUSC cis rs733592 0.723 rs10875766 ENSG00000240399.1 RP1-228P16.1 9.56 6.71e-20 1.22e-16 0.38 0.4 Plateletcrit; chr12:48199797 chr12:48054813~48055591:- LUSC cis rs5760092 0.627 rs6519489 ENSG00000218537.1 MIF-AS1 -9.56 6.72e-20 1.22e-16 -0.64 -0.4 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23894426~23898930:- LUSC cis rs9322193 0.847 rs12210605 ENSG00000216906.2 RP11-350J20.9 9.56 6.83e-20 1.24e-16 0.49 0.4 Lung cancer; chr6:149817267 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9371199 ENSG00000216906.2 RP11-350J20.9 9.56 6.83e-20 1.24e-16 0.49 0.4 Lung cancer; chr6:149817526 chr6:149904243~149906418:+ LUSC cis rs1707322 0.752 rs28890893 ENSG00000280836.1 AL355480.1 -9.56 6.84e-20 1.24e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720904 chr1:45581219~45581321:- LUSC cis rs494459 0.838 rs632124 ENSG00000255422.1 AP002954.4 -9.55 6.95e-20 1.26e-16 -0.41 -0.4 Height; chr11:118742526 chr11:118704607~118750263:+ LUSC cis rs2108622 0.701 rs118144071 ENSG00000267453.5 AC004791.2 -9.55 6.98e-20 1.26e-16 -0.53 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15868384 chr19:15851993~15864904:- LUSC cis rs9322193 0.923 rs9767123 ENSG00000216906.2 RP11-350J20.9 9.55 7.01e-20 1.27e-16 0.49 0.4 Lung cancer; chr6:149660323 chr6:149904243~149906418:+ LUSC cis rs1707322 0.752 rs3811436 ENSG00000280836.1 AL355480.1 -9.55 7.06e-20 1.28e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660208 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs12024590 ENSG00000280836.1 AL355480.1 -9.55 7.06e-20 1.28e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45661824 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs12027622 ENSG00000280836.1 AL355480.1 -9.55 7.06e-20 1.28e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664580 chr1:45581219~45581321:- LUSC cis rs1707322 0.686 rs3014242 ENSG00000280836.1 AL355480.1 9.55 7.07e-20 1.28e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621905 chr1:45581219~45581321:- LUSC cis rs6452524 0.934 rs12153440 ENSG00000249664.1 CTD-2227C6.2 9.55 7.1e-20 1.28e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83125097 chr5:83012285~83013109:- LUSC cis rs12429206 0.52 rs75594262 ENSG00000233672.5 RNASEH2B-AS1 -9.55 7.1e-20 1.29e-16 -0.5 -0.4 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50900249 chr13:50862172~50910764:- LUSC cis rs4423214 0.84 rs1790340 ENSG00000254682.1 RP11-660L16.2 -9.55 7.14e-20 1.29e-16 -0.58 -0.4 Vitamin D levels; chr11:71471543 chr11:71448674~71452157:+ LUSC cis rs6538678 0.895 rs1436124 ENSG00000258343.1 RP11-536G4.2 -9.55 7.18e-20 1.3e-16 -0.57 -0.4 Lupus nephritis in systemic lupus erythematosus; chr12:95889654 chr12:95795345~95858839:- LUSC cis rs1707322 0.686 rs1084086 ENSG00000280836.1 AL355480.1 9.55 7.21e-20 1.3e-16 0.47 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45575428 chr1:45581219~45581321:- LUSC cis rs1891275 0.515 rs1361552 ENSG00000228701.1 TNKS2-AS1 -9.55 7.23e-20 1.31e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91774867 chr10:91782839~91798291:- LUSC cis rs6452524 1 rs10474093 ENSG00000249664.1 CTD-2227C6.2 9.55 7.25e-20 1.31e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83141612 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs10473868 ENSG00000249664.1 CTD-2227C6.2 9.55 7.25e-20 1.31e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83141628 chr5:83012285~83013109:- LUSC cis rs7396835 0.741 rs7396851 ENSG00000254851.1 RP11-109L13.1 9.55 7.27e-20 1.31e-16 0.7 0.4 Quantitative traits; chr11:116813448 chr11:117135528~117138582:+ LUSC cis rs1707322 0.721 rs10890346 ENSG00000280836.1 AL355480.1 9.55 7.3e-20 1.32e-16 0.48 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45758220 chr1:45581219~45581321:- LUSC cis rs10129255 1 rs10129319 ENSG00000223648.3 IGHV3-64 9.55 7.31e-20 1.32e-16 0.37 0.4 Kawasaki disease; chr14:106767996 chr14:106643132~106658258:- LUSC cis rs10129255 0.957 rs4387509 ENSG00000223648.3 IGHV3-64 9.55 7.35e-20 1.33e-16 0.38 0.4 Kawasaki disease; chr14:106704386 chr14:106643132~106658258:- LUSC cis rs1707322 0.721 rs10890341 ENSG00000280836.1 AL355480.1 -9.55 7.43e-20 1.34e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45681568 chr1:45581219~45581321:- LUSC cis rs950027 0.787 rs1153845 ENSG00000259520.4 CTD-2651B20.3 9.55 7.45e-20 1.35e-16 0.48 0.4 Response to fenofibrate (adiponectin levels); chr15:45432531 chr15:45251580~45279251:- LUSC cis rs9322193 0.923 rs9767554 ENSG00000216906.2 RP11-350J20.9 9.55 7.46e-20 1.35e-16 0.48 0.4 Lung cancer; chr6:149616860 chr6:149904243~149906418:+ LUSC cis rs765787 0.53 rs11636367 ENSG00000259520.4 CTD-2651B20.3 9.55 7.46e-20 1.35e-16 0.5 0.4 Uric acid levels; chr15:45243664 chr15:45251580~45279251:- LUSC cis rs2712381 0.797 rs62270806 ENSG00000277250.1 Metazoa_SRP -9.54 7.49e-20 1.35e-16 -0.45 -0.4 Monocyte count; chr3:128657426 chr3:128673681~128674021:- LUSC cis rs10129255 0.5 rs9324092 ENSG00000211972.2 IGHV3-66 -9.54 7.51e-20 1.36e-16 -0.27 -0.4 Kawasaki disease; chr14:106683806 chr14:106675017~106675544:- LUSC cis rs6782228 0.606 rs58977394 ENSG00000277250.1 Metazoa_SRP -9.54 7.53e-20 1.36e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619074 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs2712381 ENSG00000277250.1 Metazoa_SRP -9.54 7.53e-20 1.36e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619757 chr3:128673681~128674021:- LUSC cis rs853679 0.527 rs853693 ENSG00000216901.1 AL022393.7 9.54 7.69e-20 1.39e-16 0.47 0.4 Depression; chr6:28314871 chr6:28176188~28176674:+ LUSC cis rs1707322 0.686 rs1541131 ENSG00000280836.1 AL355480.1 9.54 7.76e-20 1.4e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619262 chr1:45581219~45581321:- LUSC cis rs6782228 1 rs6775011 ENSG00000242551.2 POU5F1P6 9.54 7.82e-20 1.41e-16 0.5 0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128677640 chr3:128674735~128677005:- LUSC cis rs2108622 0.727 rs7254940 ENSG00000267453.5 AC004791.2 -9.54 7.82e-20 1.41e-16 -0.52 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15873698 chr19:15851993~15864904:- LUSC cis rs765787 0.53 rs2433229 ENSG00000259520.4 CTD-2651B20.3 9.54 7.87e-20 1.42e-16 0.5 0.4 Uric acid levels; chr15:45223037 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4331289 ENSG00000259520.4 CTD-2651B20.3 9.54 7.87e-20 1.42e-16 0.5 0.4 Uric acid levels; chr15:45223140 chr15:45251580~45279251:- LUSC cis rs10129255 0.912 rs8009135 ENSG00000223648.3 IGHV3-64 9.54 7.87e-20 1.42e-16 0.37 0.4 Kawasaki disease; chr14:106777528 chr14:106643132~106658258:- LUSC cis rs6782228 0.509 rs4481172 ENSG00000277250.1 Metazoa_SRP -9.54 7.88e-20 1.42e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128653814 chr3:128673681~128674021:- LUSC cis rs1707322 0.717 rs3014246 ENSG00000280836.1 AL355480.1 9.54 7.9e-20 1.42e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620405 chr1:45581219~45581321:- LUSC cis rs748404 0.646 rs2253268 ENSG00000249839.1 AC011330.5 -9.54 8.06e-20 1.45e-16 -0.54 -0.4 Lung cancer; chr15:43508770 chr15:43663654~43684339:- LUSC cis rs6782228 0.606 rs1127030 ENSG00000277250.1 Metazoa_SRP -9.54 8.06e-20 1.45e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128620110 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs2712419 ENSG00000277250.1 Metazoa_SRP -9.54 8.06e-20 1.45e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128622053 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs2712417 ENSG00000277250.1 Metazoa_SRP -9.54 8.06e-20 1.45e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128626336 chr3:128673681~128674021:- LUSC cis rs6782228 0.527 rs2712371 ENSG00000277250.1 Metazoa_SRP -9.54 8.06e-20 1.45e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128627371 chr3:128673681~128674021:- LUSC cis rs11098499 0.908 rs11098527 ENSG00000245958.5 RP11-33B1.1 -9.54 8.09e-20 1.46e-16 -0.42 -0.4 Corneal astigmatism; chr4:119478751 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs4354168 ENSG00000216906.2 RP11-350J20.9 9.53 8.13e-20 1.46e-16 0.48 0.4 Lung cancer; chr6:149696642 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs4455682 ENSG00000216906.2 RP11-350J20.9 9.53 8.13e-20 1.46e-16 0.48 0.4 Lung cancer; chr6:149700161 chr6:149904243~149906418:+ LUSC cis rs9399137 0.507 rs7754722 ENSG00000232876.1 CTA-212D2.2 9.53 8.18e-20 1.47e-16 0.51 0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134939165 chr6:135055033~135060550:+ LUSC cis rs6782228 0.606 rs4857919 ENSG00000277250.1 Metazoa_SRP -9.53 8.19e-20 1.47e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128688652 chr3:128673681~128674021:- LUSC cis rs11098499 0.954 rs10008392 ENSG00000245958.5 RP11-33B1.1 -9.53 8.23e-20 1.48e-16 -0.42 -0.4 Corneal astigmatism; chr4:119397684 chr4:119454791~119552025:+ LUSC cis rs1707322 0.686 rs2991977 ENSG00000280836.1 AL355480.1 9.53 8.27e-20 1.49e-16 0.48 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45588011 chr1:45581219~45581321:- LUSC cis rs1707322 0.656 rs2991981 ENSG00000280836.1 AL355480.1 9.53 8.27e-20 1.49e-16 0.48 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45591472 chr1:45581219~45581321:- LUSC cis rs11098499 0.909 rs6842762 ENSG00000245958.5 RP11-33B1.1 -9.53 8.29e-20 1.49e-16 -0.41 -0.4 Corneal astigmatism; chr4:119477081 chr4:119454791~119552025:+ LUSC cis rs6452524 1 rs1382368 ENSG00000249664.1 CTD-2227C6.2 9.53 8.3e-20 1.49e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83155256 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs1382366 ENSG00000249664.1 CTD-2227C6.2 9.53 8.3e-20 1.49e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83156352 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs13358361 ENSG00000249664.1 CTD-2227C6.2 9.53 8.3e-20 1.49e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83160237 chr5:83012285~83013109:- LUSC cis rs62229266 0.804 rs880221 ENSG00000231106.2 LINC01436 9.53 8.36e-20 1.5e-16 0.52 0.4 Mitral valve prolapse; chr21:36048487 chr21:36005338~36007838:+ LUSC cis rs62229266 0.804 rs11088331 ENSG00000231106.2 LINC01436 9.53 8.36e-20 1.5e-16 0.52 0.4 Mitral valve prolapse; chr21:36049574 chr21:36005338~36007838:+ LUSC cis rs748404 0.69 rs2924369 ENSG00000249839.1 AC011330.5 9.53 8.4e-20 1.51e-16 0.53 0.4 Lung cancer; chr15:43485787 chr15:43663654~43684339:- LUSC cis rs6782228 0.585 rs3122175 ENSG00000277250.1 Metazoa_SRP -9.53 8.46e-20 1.52e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128642433 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs2811497 ENSG00000277250.1 Metazoa_SRP -9.53 8.46e-20 1.52e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128644489 chr3:128673681~128674021:- LUSC cis rs10129255 0.518 rs2006284 ENSG00000211972.2 IGHV3-66 9.53 8.5e-20 1.53e-16 0.27 0.4 Kawasaki disease; chr14:106676185 chr14:106675017~106675544:- LUSC cis rs1933112 0.5 rs34328291 ENSG00000227777.1 RP4-738P11.3 -9.53 8.56e-20 1.54e-16 -0.56 -0.4 Blood protein levels; chr1:168545108 chr1:168542737~168543354:+ LUSC cis rs9487094 0.517 rs3778474 ENSG00000260273.1 RP11-425D10.10 9.53 8.61e-20 1.54e-16 0.48 0.4 Height; chr6:109374782 chr6:109382795~109383666:+ LUSC cis rs9322193 0.923 rs11155674 ENSG00000216906.2 RP11-350J20.9 9.53 8.62e-20 1.54e-16 0.48 0.4 Lung cancer; chr6:149711111 chr6:149904243~149906418:+ LUSC cis rs6782228 0.606 rs4857861 ENSG00000277250.1 Metazoa_SRP -9.53 8.72e-20 1.56e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128687924 chr3:128673681~128674021:- LUSC cis rs6782228 0.585 rs2811492 ENSG00000277250.1 Metazoa_SRP -9.52 8.82e-20 1.58e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128637436 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs1697 ENSG00000277250.1 Metazoa_SRP -9.52 8.82e-20 1.58e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128638009 chr3:128673681~128674021:- LUSC cis rs1972460 0.506 rs62012050 ENSG00000278603.1 RP13-608F4.5 9.52 8.86e-20 1.59e-16 0.52 0.4 Intelligence (multi-trait analysis); chr15:82239933 chr15:82472203~82472426:+ LUSC cis rs765787 0.53 rs1648285 ENSG00000259520.4 CTD-2651B20.3 9.52 8.88e-20 1.59e-16 0.5 0.4 Uric acid levels; chr15:45225307 chr15:45251580~45279251:- LUSC cis rs8081395 0.801 rs2777895 ENSG00000266992.1 DHX40P1 -9.52 9.07e-20 1.62e-16 -0.46 -0.4 White blood cell count; chr17:59802249 chr17:59976009~60002384:- LUSC cis rs8081395 0.769 rs12449331 ENSG00000266992.1 DHX40P1 -9.52 9.07e-20 1.62e-16 -0.46 -0.4 White blood cell count; chr17:59806285 chr17:59976009~60002384:- LUSC cis rs8081395 0.801 rs2665404 ENSG00000266992.1 DHX40P1 9.52 9.07e-20 1.62e-16 0.46 0.4 White blood cell count; chr17:59798035 chr17:59976009~60002384:- LUSC cis rs7174755 0.772 rs80187654 ENSG00000260657.2 RP11-315D16.4 9.52 9.1e-20 1.63e-16 0.53 0.4 Major depressive disorder; chr15:68082833 chr15:68267792~68277994:- LUSC cis rs9326248 1 rs4938344 ENSG00000280143.1 AP000892.6 9.52 9.25e-20 1.65e-16 0.47 0.4 Blood protein levels; chr11:117133033 chr11:117204967~117210292:+ LUSC cis rs1707322 0.717 rs2275086 ENSG00000280836.1 AL355480.1 9.52 9.26e-20 1.66e-16 0.47 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620207 chr1:45581219~45581321:- LUSC cis rs1891275 0.601 rs1970506 ENSG00000228701.1 TNKS2-AS1 -9.52 9.28e-20 1.66e-16 -0.5 -0.4 Intelligence (multi-trait analysis); chr10:91668529 chr10:91782839~91798291:- LUSC cis rs11098499 0.865 rs11098513 ENSG00000245958.5 RP11-33B1.1 -9.52 9.3e-20 1.66e-16 -0.42 -0.4 Corneal astigmatism; chr4:119394920 chr4:119454791~119552025:+ LUSC cis rs494459 0.838 rs488219 ENSG00000255422.1 AP002954.4 -9.51 9.52e-20 1.7e-16 -0.41 -0.4 Height; chr11:118749988 chr11:118704607~118750263:+ LUSC cis rs6452524 1 rs6452528 ENSG00000249664.1 CTD-2227C6.2 9.51 9.6e-20 1.71e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83162560 chr5:83012285~83013109:- LUSC cis rs9326248 0.817 rs1242127 ENSG00000280143.1 AP000892.6 -9.51 9.86e-20 1.76e-16 -0.45 -0.4 Blood protein levels; chr11:117205848 chr11:117204967~117210292:+ LUSC cis rs2337406 0.866 rs112089985 ENSG00000274576.2 IGHV2-70 -9.51 1e-19 1.78e-16 -0.4 -0.4 Alzheimer's disease (late onset); chr14:106780074 chr14:106770577~106771020:- LUSC cis rs2739330 0.587 rs4820571 ENSG00000231271.1 AP000350.8 9.51 1e-19 1.79e-16 0.51 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23949918~23954042:+ LUSC cis rs10129255 0.957 rs10136560 ENSG00000223648.3 IGHV3-64 9.51 1e-19 1.79e-16 0.37 0.4 Kawasaki disease; chr14:106787630 chr14:106643132~106658258:- LUSC cis rs1933112 0.5 rs7543171 ENSG00000227777.1 RP4-738P11.3 -9.51 1.01e-19 1.79e-16 -0.56 -0.4 Blood protein levels; chr1:168535895 chr1:168542737~168543354:+ LUSC cis rs9322193 0.847 rs12191643 ENSG00000216906.2 RP11-350J20.9 9.51 1.01e-19 1.8e-16 0.48 0.4 Lung cancer; chr6:149628912 chr6:149904243~149906418:+ LUSC cis rs35160687 0.862 rs13023154 ENSG00000273080.1 RP11-301O19.1 -9.51 1.02e-19 1.81e-16 -0.38 -0.4 Night sleep phenotypes; chr2:86289861 chr2:86195590~86196049:+ LUSC cis rs9322193 0.923 rs2297928 ENSG00000216906.2 RP11-350J20.9 9.51 1.02e-19 1.81e-16 0.48 0.4 Lung cancer; chr6:149718584 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs7740784 ENSG00000216906.2 RP11-350J20.9 9.51 1.02e-19 1.81e-16 0.49 0.4 Lung cancer; chr6:149833364 chr6:149904243~149906418:+ LUSC cis rs2739330 0.731 rs2000468 ENSG00000235689.1 AP000351.13 9.5 1.05e-19 1.87e-16 0.41 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:24006305~24008258:- LUSC cis rs2739330 0.685 rs4822453 ENSG00000235689.1 AP000351.13 9.5 1.06e-19 1.88e-16 0.42 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:24006305~24008258:- LUSC cis rs9487094 0.689 rs699700 ENSG00000260273.1 RP11-425D10.10 9.5 1.09e-19 1.94e-16 0.47 0.4 Height; chr6:109367528 chr6:109382795~109383666:+ LUSC cis rs9487094 0.689 rs11251 ENSG00000260273.1 RP11-425D10.10 9.5 1.09e-19 1.94e-16 0.47 0.4 Height; chr6:109368704 chr6:109382795~109383666:+ LUSC cis rs6964833 1 rs6964833 ENSG00000277053.3 GTF2IP1 -9.5 1.1e-19 1.94e-16 -0.59 -0.4 Menarche (age at onset); chr7:74687575 chr7:75185385~75237696:- LUSC cis rs1707322 0.717 rs2253862 ENSG00000280836.1 AL355480.1 9.5 1.1e-19 1.95e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616288 chr1:45581219~45581321:- LUSC cis rs1707322 0.717 rs2991988 ENSG00000280836.1 AL355480.1 9.5 1.1e-19 1.95e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616759 chr1:45581219~45581321:- LUSC cis rs1707322 0.717 rs2991989 ENSG00000280836.1 AL355480.1 9.5 1.1e-19 1.95e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45617293 chr1:45581219~45581321:- LUSC cis rs1707322 0.656 rs9429172 ENSG00000280836.1 AL355480.1 9.5 1.11e-19 1.96e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45626804 chr1:45581219~45581321:- LUSC cis rs4888378 0.535 rs9319483 ENSG00000261783.1 RP11-252K23.2 9.5 1.11e-19 1.96e-16 0.6 0.4 Coronary artery disease; chr16:75311893 chr16:75379818~75381260:- LUSC cis rs12439619 1 rs35152457 ENSG00000278603.1 RP13-608F4.5 9.5 1.11e-19 1.97e-16 0.52 0.4 Intelligence (multi-trait analysis); chr15:82254207 chr15:82472203~82472426:+ LUSC cis rs6782228 0.606 rs7627549 ENSG00000277250.1 Metazoa_SRP -9.5 1.11e-19 1.97e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128634236 chr3:128673681~128674021:- LUSC cis rs1976403 0.659 rs10799700 ENSG00000227001.3 NBPF2P 9.5 1.11e-19 1.98e-16 0.48 0.4 Liver enzyme levels (alkaline phosphatase); chr1:21494475 chr1:21424625~21427967:- LUSC cis rs8091660 0.929 rs12456253 ENSG00000278983.1 RP11-426J5.3 -9.5 1.12e-19 1.98e-16 -0.53 -0.4 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48550603 chr18:48564795~48568342:+ LUSC cis rs11098499 0.662 rs13108589 ENSG00000245958.5 RP11-33B1.1 -9.49 1.12e-19 1.99e-16 -0.4 -0.4 Corneal astigmatism; chr4:119346947 chr4:119454791~119552025:+ LUSC cis rs2108622 0.711 rs113059233 ENSG00000267453.5 AC004791.2 -9.49 1.12e-19 1.99e-16 -0.52 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866558 chr19:15851993~15864904:- LUSC cis rs6782228 0.606 rs2811490 ENSG00000277250.1 Metazoa_SRP -9.49 1.14e-19 2.01e-16 -0.44 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128632912 chr3:128673681~128674021:- LUSC cis rs17711722 0.528 rs73138179 ENSG00000164669.11 INTS4P1 -9.49 1.14e-19 2.03e-16 -0.45 -0.4 Calcium levels; chr7:65829495 chr7:65141225~65234216:+ LUSC cis rs494459 0.657 rs614554 ENSG00000255422.1 AP002954.4 -9.49 1.15e-19 2.03e-16 -0.41 -0.4 Height; chr11:118764443 chr11:118704607~118750263:+ LUSC cis rs6782228 0.509 rs2811495 ENSG00000277250.1 Metazoa_SRP -9.49 1.15e-19 2.03e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128641114 chr3:128673681~128674021:- LUSC cis rs6782228 0.565 rs2811496 ENSG00000277250.1 Metazoa_SRP -9.49 1.15e-19 2.03e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128641115 chr3:128673681~128674021:- LUSC cis rs11098499 0.954 rs10006706 ENSG00000245958.5 RP11-33B1.1 -9.49 1.15e-19 2.03e-16 -0.42 -0.4 Corneal astigmatism; chr4:119487997 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs55993747 ENSG00000216906.2 RP11-350J20.9 9.49 1.15e-19 2.04e-16 0.48 0.4 Lung cancer; chr6:149622016 chr6:149904243~149906418:+ LUSC cis rs10129255 0.912 rs730099 ENSG00000223648.3 IGHV3-64 9.49 1.15e-19 2.04e-16 0.37 0.4 Kawasaki disease; chr14:106711838 chr14:106643132~106658258:- LUSC cis rs748404 0.66 rs2439846 ENSG00000249839.1 AC011330.5 -9.49 1.17e-19 2.06e-16 -0.52 -0.4 Lung cancer; chr15:43448772 chr15:43663654~43684339:- LUSC cis rs6452524 0.935 rs9293330 ENSG00000249664.1 CTD-2227C6.2 9.49 1.17e-19 2.06e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83102299 chr5:83012285~83013109:- LUSC cis rs11098499 0.954 rs11098524 ENSG00000245958.5 RP11-33B1.1 -9.49 1.17e-19 2.07e-16 -0.41 -0.4 Corneal astigmatism; chr4:119468877 chr4:119454791~119552025:+ LUSC cis rs2117029 0.521 rs11168910 ENSG00000258017.1 RP11-386G11.10 -9.49 1.17e-19 2.07e-16 -0.52 -0.4 Intelligence (multi-trait analysis); chr12:49192707 chr12:49127782~49147869:+ LUSC cis rs1707322 0.721 rs12069121 ENSG00000280836.1 AL355480.1 -9.49 1.18e-19 2.08e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45766312 chr1:45581219~45581321:- LUSC cis rs9322193 0.923 rs55849538 ENSG00000216906.2 RP11-350J20.9 9.49 1.19e-19 2.09e-16 0.48 0.4 Lung cancer; chr6:149635330 chr6:149904243~149906418:+ LUSC cis rs10129255 0.957 rs7493713 ENSG00000223648.3 IGHV3-64 9.49 1.19e-19 2.1e-16 0.36 0.4 Kawasaki disease; chr14:106783685 chr14:106643132~106658258:- LUSC cis rs10129255 0.912 rs35468694 ENSG00000223648.3 IGHV3-64 9.49 1.19e-19 2.1e-16 0.36 0.4 Kawasaki disease; chr14:106784199 chr14:106643132~106658258:- LUSC cis rs10129255 0.957 rs8019272 ENSG00000223648.3 IGHV3-64 9.49 1.19e-19 2.1e-16 0.36 0.4 Kawasaki disease; chr14:106784709 chr14:106643132~106658258:- LUSC cis rs9322193 0.81 rs62439811 ENSG00000216906.2 RP11-350J20.9 9.49 1.19e-19 2.1e-16 0.49 0.4 Lung cancer; chr6:149640416 chr6:149904243~149906418:+ LUSC cis rs867371 0.519 rs1566560 ENSG00000255769.6 GOLGA2P10 -9.49 1.2e-19 2.12e-16 -0.47 -0.4 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82232116 chr15:82472993~82513950:- LUSC cis rs867371 0.519 rs1566559 ENSG00000255769.6 GOLGA2P10 -9.49 1.2e-19 2.12e-16 -0.47 -0.4 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82232120 chr15:82472993~82513950:- LUSC cis rs16863064 0.66 rs1007308 ENSG00000279891.1 FLJ42393 -9.49 1.2e-19 2.12e-16 -0.57 -0.4 Schizophrenia; chr3:188171935 chr3:188178543~188180812:+ LUSC cis rs11089937 0.929 rs2236727 ENSG00000211639.2 IGLV4-60 9.48 1.21e-19 2.14e-16 0.41 0.4 Periodontitis (PAL4Q3); chr22:22156654 chr22:22162199~22162681:+ LUSC cis rs748404 0.587 rs690276 ENSG00000249839.1 AC011330.5 -9.48 1.22e-19 2.15e-16 -0.53 -0.4 Lung cancer; chr15:43412360 chr15:43663654~43684339:- LUSC cis rs9322193 0.923 rs9800686 ENSG00000216906.2 RP11-350J20.9 9.48 1.23e-19 2.17e-16 0.48 0.4 Lung cancer; chr6:149634464 chr6:149904243~149906418:+ LUSC cis rs6452524 1 rs11740478 ENSG00000249664.1 CTD-2227C6.2 9.48 1.24e-19 2.19e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83150567 chr5:83012285~83013109:- LUSC cis rs4774565 0.762 rs17431150 ENSG00000244879.4 GABPB1-AS1 -9.48 1.25e-19 2.2e-16 -0.37 -0.4 Breast cancer; chr15:50371385 chr15:50354959~50372202:+ LUSC cis rs4774565 0.762 rs17431171 ENSG00000244879.4 GABPB1-AS1 -9.48 1.25e-19 2.2e-16 -0.37 -0.4 Breast cancer; chr15:50371424 chr15:50354959~50372202:+ LUSC cis rs10129255 0.518 rs10150460 ENSG00000211972.2 IGHV3-66 -9.48 1.25e-19 2.2e-16 -0.26 -0.4 Kawasaki disease; chr14:106677179 chr14:106675017~106675544:- LUSC cis rs10129255 0.518 rs12590732 ENSG00000211972.2 IGHV3-66 -9.48 1.25e-19 2.21e-16 -0.26 -0.4 Kawasaki disease; chr14:106779612 chr14:106675017~106675544:- LUSC cis rs11155671 0.53 rs4458704 ENSG00000223701.3 RAET1E-AS1 9.48 1.26e-19 2.22e-16 0.45 0.4 Testicular germ cell tumor; chr6:149911743 chr6:149884431~149919508:+ LUSC cis rs12439619 0.739 rs4778988 ENSG00000255769.6 GOLGA2P10 -9.48 1.27e-19 2.23e-16 -0.51 -0.4 Intelligence (multi-trait analysis); chr15:82247996 chr15:82472993~82513950:- LUSC cis rs11098499 0.909 rs11723839 ENSG00000245958.5 RP11-33B1.1 -9.48 1.27e-19 2.24e-16 -0.41 -0.4 Corneal astigmatism; chr4:119378518 chr4:119454791~119552025:+ LUSC cis rs9487094 0.666 rs4946967 ENSG00000260273.1 RP11-425D10.10 9.48 1.27e-19 2.24e-16 0.47 0.4 Height; chr6:109357369 chr6:109382795~109383666:+ LUSC cis rs11098499 0.954 rs12506546 ENSG00000245958.5 RP11-33B1.1 -9.48 1.28e-19 2.25e-16 -0.41 -0.4 Corneal astigmatism; chr4:119380463 chr4:119454791~119552025:+ LUSC cis rs9322193 0.607 rs6925151 ENSG00000216906.2 RP11-350J20.9 9.48 1.28e-19 2.26e-16 0.53 0.4 Lung cancer; chr6:149889587 chr6:149904243~149906418:+ LUSC cis rs765787 0.53 rs3759895 ENSG00000259520.4 CTD-2651B20.3 9.48 1.29e-19 2.27e-16 0.5 0.4 Uric acid levels; chr15:45251672 chr15:45251580~45279251:- LUSC cis rs10129255 0.957 rs10142918 ENSG00000223648.3 IGHV3-64 9.48 1.31e-19 2.3e-16 0.36 0.4 Kawasaki disease; chr14:106782206 chr14:106643132~106658258:- LUSC cis rs10129255 0.957 rs10142859 ENSG00000223648.3 IGHV3-64 9.48 1.31e-19 2.3e-16 0.36 0.4 Kawasaki disease; chr14:106782238 chr14:106643132~106658258:- LUSC cis rs6452524 0.967 rs7718278 ENSG00000249664.1 CTD-2227C6.2 9.48 1.31e-19 2.31e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83126600 chr5:83012285~83013109:- LUSC cis rs1891275 0.515 rs6583784 ENSG00000228701.1 TNKS2-AS1 9.48 1.31e-19 2.31e-16 0.46 0.4 Intelligence (multi-trait analysis); chr10:91731819 chr10:91782839~91798291:- LUSC cis rs2739330 0.892 rs4822455 ENSG00000099984.9 GSTT2 -9.48 1.31e-19 2.31e-16 -0.49 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23980123~23983911:+ LUSC cis rs1891275 0.515 rs2153653 ENSG00000228701.1 TNKS2-AS1 -9.47 1.31e-19 2.31e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91736169 chr10:91782839~91798291:- LUSC cis rs6991838 0.584 rs1053088 ENSG00000200714.1 Y_RNA 9.47 1.32e-19 2.32e-16 0.5 0.4 Intelligence (multi-trait analysis); chr8:65603548 chr8:65592731~65592820:+ LUSC cis rs62229266 0.771 rs62230790 ENSG00000231106.2 LINC01436 9.47 1.32e-19 2.33e-16 0.52 0.4 Mitral valve prolapse; chr21:36016613 chr21:36005338~36007838:+ LUSC cis rs10129255 0.957 rs8022165 ENSG00000223648.3 IGHV3-64 9.47 1.33e-19 2.33e-16 0.36 0.4 Kawasaki disease; chr14:106781682 chr14:106643132~106658258:- LUSC cis rs494459 0.838 rs12796102 ENSG00000255422.1 AP002954.4 -9.47 1.33e-19 2.34e-16 -0.42 -0.4 Height; chr11:118791319 chr11:118704607~118750263:+ LUSC cis rs6452524 0.935 rs7736296 ENSG00000249664.1 CTD-2227C6.2 -9.47 1.33e-19 2.34e-16 -0.4 -0.4 Hypertension (SNP x SNP interaction); chr5:83082421 chr5:83012285~83013109:- LUSC cis rs11098499 0.58 rs12509234 ENSG00000245958.5 RP11-33B1.1 -9.47 1.33e-19 2.35e-16 -0.42 -0.4 Corneal astigmatism; chr4:119398279 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs10014719 ENSG00000245958.5 RP11-33B1.1 -9.47 1.33e-19 2.35e-16 -0.42 -0.4 Corneal astigmatism; chr4:119399560 chr4:119454791~119552025:+ LUSC cis rs2729354 0.768 rs2584856 ENSG00000265566.2 RN7SL605P -9.47 1.34e-19 2.35e-16 -0.54 -0.4 Blood protein levels; chr11:57499839 chr11:57528085~57528365:- LUSC cis rs10129255 0.957 rs12590799 ENSG00000223648.3 IGHV3-64 9.47 1.35e-19 2.37e-16 0.36 0.4 Kawasaki disease; chr14:106779713 chr14:106643132~106658258:- LUSC cis rs10129255 0.957 rs10136781 ENSG00000223648.3 IGHV3-64 9.47 1.35e-19 2.37e-16 0.36 0.4 Kawasaki disease; chr14:106780451 chr14:106643132~106658258:- LUSC cis rs2455601 1 rs72632952 ENSG00000254860.4 TMEM9B-AS1 9.47 1.35e-19 2.37e-16 0.58 0.4 Schizophrenia; chr11:8896429 chr11:8964675~8977527:+ LUSC cis rs2455601 1 rs11042114 ENSG00000254860.4 TMEM9B-AS1 9.47 1.35e-19 2.37e-16 0.58 0.4 Schizophrenia; chr11:8898342 chr11:8964675~8977527:+ LUSC cis rs8062405 0.698 rs8046545 ENSG00000259982.1 CDC37P1 -9.47 1.36e-19 2.39e-16 -0.52 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28903896 chr16:28700294~28701540:- LUSC cis rs8062405 0.698 rs10499 ENSG00000259982.1 CDC37P1 -9.47 1.36e-19 2.39e-16 -0.52 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28904206 chr16:28700294~28701540:- LUSC cis rs9399137 0.507 rs7772031 ENSG00000232876.1 CTA-212D2.2 9.47 1.37e-19 2.4e-16 0.51 0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134938596 chr6:135055033~135060550:+ LUSC cis rs9322193 0.923 rs4421206 ENSG00000216906.2 RP11-350J20.9 9.47 1.37e-19 2.41e-16 0.48 0.4 Lung cancer; chr6:149682891 chr6:149904243~149906418:+ LUSC cis rs1976403 0.659 rs10799699 ENSG00000227001.3 NBPF2P 9.47 1.38e-19 2.42e-16 0.48 0.4 Liver enzyme levels (alkaline phosphatase); chr1:21494468 chr1:21424625~21427967:- LUSC cis rs10129255 0.917 rs8022493 ENSG00000223648.3 IGHV3-64 9.47 1.39e-19 2.43e-16 0.36 0.4 Kawasaki disease; chr14:106781820 chr14:106643132~106658258:- LUSC cis rs10129255 0.957 rs2007467 ENSG00000211970.3 IGHV4-61 9.47 1.4e-19 2.45e-16 0.29 0.4 Kawasaki disease; chr14:106771605 chr14:106639119~106639657:- LUSC cis rs9341808 0.556 rs10455370 ENSG00000272129.1 RP11-250B2.6 -9.47 1.4e-19 2.46e-16 -0.48 -0.4 Sitting height ratio; chr6:80331150 chr6:80355424~80356859:+ LUSC cis rs1707322 0.721 rs11211149 ENSG00000280836.1 AL355480.1 -9.47 1.41e-19 2.46e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45646546 chr1:45581219~45581321:- LUSC cis rs2729354 0.768 rs1001956 ENSG00000265566.2 RN7SL605P -9.47 1.41e-19 2.47e-16 -0.55 -0.4 Blood protein levels; chr11:57499476 chr11:57528085~57528365:- LUSC cis rs10129255 0.957 rs12590735 ENSG00000223648.3 IGHV3-64 9.47 1.42e-19 2.48e-16 0.36 0.4 Kawasaki disease; chr14:106779660 chr14:106643132~106658258:- LUSC cis rs765787 0.53 rs4775834 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45245313 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4775835 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45245355 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4775836 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45245466 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4775837 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45245486 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs12917187 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45246099 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11639403 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45246152 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs2413782 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45246292 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs2413780 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45246668 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11636018 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45246939 chr15:45251580~45279251:- LUSC cis rs765787 0.556 rs2413778 ENSG00000259520.4 CTD-2651B20.3 9.46 1.43e-19 2.5e-16 0.5 0.4 Uric acid levels; chr15:45247199 chr15:45251580~45279251:- LUSC cis rs11089937 0.929 rs5757155 ENSG00000211639.2 IGLV4-60 9.46 1.44e-19 2.51e-16 0.4 0.4 Periodontitis (PAL4Q3); chr22:22165378 chr22:22162199~22162681:+ LUSC cis rs6782228 0.585 rs6774515 ENSG00000277250.1 Metazoa_SRP -9.46 1.45e-19 2.53e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128697035 chr3:128673681~128674021:- LUSC cis rs10875746 0.669 rs10875792 ENSG00000240399.1 RP1-228P16.1 -9.46 1.45e-19 2.54e-16 -0.46 -0.4 Longevity (90 years and older); chr12:48303640 chr12:48054813~48055591:- LUSC cis rs10875746 0.623 rs10875793 ENSG00000240399.1 RP1-228P16.1 -9.46 1.45e-19 2.54e-16 -0.46 -0.4 Longevity (90 years and older); chr12:48303647 chr12:48054813~48055591:- LUSC cis rs1707322 0.752 rs11211146 ENSG00000280836.1 AL355480.1 -9.46 1.46e-19 2.55e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644122 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs11211147 ENSG00000280836.1 AL355480.1 -9.46 1.46e-19 2.55e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644422 chr1:45581219~45581321:- LUSC cis rs765787 0.53 rs7165889 ENSG00000259520.4 CTD-2651B20.3 9.46 1.46e-19 2.56e-16 0.49 0.4 Uric acid levels; chr15:45239442 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11070451 ENSG00000259520.4 CTD-2651B20.3 9.46 1.46e-19 2.56e-16 0.49 0.4 Uric acid levels; chr15:45241343 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs28897155 ENSG00000259520.4 CTD-2651B20.3 9.46 1.46e-19 2.56e-16 0.49 0.4 Uric acid levels; chr15:45241776 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4775831 ENSG00000259520.4 CTD-2651B20.3 9.46 1.46e-19 2.56e-16 0.49 0.4 Uric acid levels; chr15:45242524 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4775832 ENSG00000259520.4 CTD-2651B20.3 9.46 1.46e-19 2.56e-16 0.49 0.4 Uric acid levels; chr15:45242630 chr15:45251580~45279251:- LUSC cis rs2455601 0.786 rs10279 ENSG00000254860.4 TMEM9B-AS1 9.46 1.47e-19 2.56e-16 0.53 0.4 Schizophrenia; chr11:8947762 chr11:8964675~8977527:+ LUSC cis rs1891275 0.508 rs2096079 ENSG00000228701.1 TNKS2-AS1 -9.46 1.47e-19 2.57e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91736910 chr10:91782839~91798291:- LUSC cis rs2929278 0.617 rs533143 ENSG00000249839.1 AC011330.5 -9.46 1.48e-19 2.58e-16 -0.51 -0.4 Schizophrenia; chr15:43896656 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs493377 ENSG00000249839.1 AC011330.5 -9.46 1.48e-19 2.58e-16 -0.53 -0.4 Lung cancer; chr15:43481269 chr15:43663654~43684339:- LUSC cis rs2455601 0.882 rs11042116 ENSG00000254860.4 TMEM9B-AS1 9.46 1.48e-19 2.59e-16 0.58 0.4 Schizophrenia; chr11:8906925 chr11:8964675~8977527:+ LUSC cis rs10129255 0.957 rs8009464 ENSG00000223648.3 IGHV3-64 9.46 1.49e-19 2.59e-16 0.37 0.4 Kawasaki disease; chr14:106777611 chr14:106643132~106658258:- LUSC cis rs9322193 0.923 rs9800871 ENSG00000216906.2 RP11-350J20.9 9.46 1.49e-19 2.6e-16 0.48 0.4 Lung cancer; chr6:149644540 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs11155671 ENSG00000216906.2 RP11-350J20.9 9.46 1.49e-19 2.6e-16 0.48 0.4 Lung cancer; chr6:149650996 chr6:149904243~149906418:+ LUSC cis rs8062405 0.625 rs8060365 ENSG00000259982.1 CDC37P1 -9.46 1.49e-19 2.6e-16 -0.52 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28899988 chr16:28700294~28701540:- LUSC cis rs2117029 0.521 rs1039225 ENSG00000258017.1 RP11-386G11.10 -9.46 1.49e-19 2.61e-16 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49188909 chr12:49127782~49147869:+ LUSC cis rs765787 0.53 rs11636440 ENSG00000259520.4 CTD-2651B20.3 9.46 1.49e-19 2.61e-16 0.5 0.4 Uric acid levels; chr15:45243784 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs28396110 ENSG00000259520.4 CTD-2651B20.3 9.46 1.49e-19 2.61e-16 0.5 0.4 Uric acid levels; chr15:45244711 chr15:45251580~45279251:- LUSC cis rs1891275 0.508 rs7099557 ENSG00000228701.1 TNKS2-AS1 -9.46 1.49e-19 2.61e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91685607 chr10:91782839~91798291:- LUSC cis rs6452524 1 rs10069402 ENSG00000249664.1 CTD-2227C6.2 9.46 1.52e-19 2.66e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83133776 chr5:83012285~83013109:- LUSC cis rs765787 0.53 rs28414644 ENSG00000259520.4 CTD-2651B20.3 9.46 1.53e-19 2.66e-16 0.5 0.4 Uric acid levels; chr15:45244523 chr15:45251580~45279251:- LUSC cis rs6782228 0.527 rs7426806 ENSG00000277250.1 Metazoa_SRP -9.45 1.55e-19 2.7e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694087 chr3:128673681~128674021:- LUSC cis rs62229266 0.804 rs2835263 ENSG00000231106.2 LINC01436 -9.45 1.56e-19 2.72e-16 -0.5 -0.4 Mitral valve prolapse; chr21:36057947 chr21:36005338~36007838:+ LUSC cis rs11098499 0.954 rs6848389 ENSG00000245958.5 RP11-33B1.1 -9.45 1.57e-19 2.73e-16 -0.4 -0.4 Corneal astigmatism; chr4:119481467 chr4:119454791~119552025:+ LUSC cis rs6921919 0.583 rs7759191 ENSG00000216901.1 AL022393.7 9.45 1.58e-19 2.75e-16 0.47 0.4 Autism spectrum disorder or schizophrenia; chr6:28385657 chr6:28176188~28176674:+ LUSC cis rs9322193 0.772 rs7738696 ENSG00000216906.2 RP11-350J20.9 9.45 1.58e-19 2.76e-16 0.48 0.4 Lung cancer; chr6:149848985 chr6:149904243~149906418:+ LUSC cis rs6964833 1 rs13227433 ENSG00000277053.3 GTF2IP1 -9.45 1.59e-19 2.77e-16 -0.59 -0.4 Menarche (age at onset); chr7:74680386 chr7:75185385~75237696:- LUSC cis rs765787 0.53 rs28815867 ENSG00000259520.4 CTD-2651B20.3 9.45 1.6e-19 2.78e-16 0.49 0.4 Uric acid levels; chr15:45234607 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4775822 ENSG00000259520.4 CTD-2651B20.3 9.45 1.6e-19 2.78e-16 0.49 0.4 Uric acid levels; chr15:45234929 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11854294 ENSG00000259520.4 CTD-2651B20.3 9.45 1.6e-19 2.78e-16 0.49 0.4 Uric acid levels; chr15:45235798 chr15:45251580~45279251:- LUSC cis rs6452524 0.967 rs4616871 ENSG00000249664.1 CTD-2227C6.2 9.45 1.61e-19 2.79e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83175271 chr5:83012285~83013109:- LUSC cis rs9322193 0.923 rs4870267 ENSG00000216906.2 RP11-350J20.9 9.45 1.61e-19 2.81e-16 0.48 0.4 Lung cancer; chr6:149671572 chr6:149904243~149906418:+ LUSC cis rs494459 0.688 rs1048040 ENSG00000255422.1 AP002954.4 -9.45 1.63e-19 2.83e-16 -0.41 -0.4 Height; chr11:118747911 chr11:118704607~118750263:+ LUSC cis rs6452524 0.686 rs6452518 ENSG00000249664.1 CTD-2227C6.2 9.45 1.64e-19 2.86e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83133043 chr5:83012285~83013109:- LUSC cis rs10129255 0.5 rs1974468 ENSG00000211972.2 IGHV3-66 9.45 1.65e-19 2.86e-16 0.26 0.4 Kawasaki disease; chr14:106686149 chr14:106675017~106675544:- LUSC cis rs4141404 0.582 rs5753630 ENSG00000236132.1 CTA-440B3.1 -9.45 1.65e-19 2.87e-16 -0.49 -0.4 Paclitaxel-induced neuropathy; chr22:31465964 chr22:31816379~31817491:- LUSC cis rs6452524 1 rs10055948 ENSG00000249664.1 CTD-2227C6.2 9.45 1.65e-19 2.87e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83143437 chr5:83012285~83013109:- LUSC cis rs9322193 0.607 rs12527391 ENSG00000216906.2 RP11-350J20.9 9.45 1.66e-19 2.88e-16 0.55 0.4 Lung cancer; chr6:149882156 chr6:149904243~149906418:+ LUSC cis rs6452524 1 rs11958314 ENSG00000249664.1 CTD-2227C6.2 9.45 1.66e-19 2.88e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83132929 chr5:83012285~83013109:- LUSC cis rs6452524 0.686 rs6452517 ENSG00000249664.1 CTD-2227C6.2 9.45 1.66e-19 2.88e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83133041 chr5:83012285~83013109:- LUSC cis rs1707322 0.627 rs3014213 ENSG00000280836.1 AL355480.1 9.45 1.66e-19 2.89e-16 0.48 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45579850 chr1:45581219~45581321:- LUSC cis rs1707322 0.686 rs2152078 ENSG00000280836.1 AL355480.1 9.45 1.66e-19 2.89e-16 0.48 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45589928 chr1:45581219~45581321:- LUSC cis rs1707322 0.686 rs2991979 ENSG00000280836.1 AL355480.1 9.45 1.66e-19 2.89e-16 0.48 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45590186 chr1:45581219~45581321:- LUSC cis rs9322193 0.851 rs9322194 ENSG00000216906.2 RP11-350J20.9 9.45 1.67e-19 2.89e-16 0.49 0.4 Lung cancer; chr6:149599113 chr6:149904243~149906418:+ LUSC cis rs6452524 1 rs6868817 ENSG00000249664.1 CTD-2227C6.2 9.44 1.68e-19 2.92e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83142287 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs10042018 ENSG00000249664.1 CTD-2227C6.2 9.44 1.68e-19 2.92e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83142490 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs10036418 ENSG00000249664.1 CTD-2227C6.2 9.44 1.68e-19 2.92e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83142493 chr5:83012285~83013109:- LUSC cis rs6782228 0.527 rs2811491 ENSG00000277250.1 Metazoa_SRP -9.44 1.69e-19 2.93e-16 -0.45 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128635107 chr3:128673681~128674021:- LUSC cis rs9322193 0.923 rs9322214 ENSG00000216906.2 RP11-350J20.9 9.44 1.7e-19 2.95e-16 0.48 0.4 Lung cancer; chr6:149703986 chr6:149904243~149906418:+ LUSC cis rs765787 0.53 rs2899381 ENSG00000259520.4 CTD-2651B20.3 9.44 1.72e-19 2.98e-16 0.49 0.4 Uric acid levels; chr15:45237432 chr15:45251580~45279251:- LUSC cis rs6782228 1 rs11711038 ENSG00000242551.2 POU5F1P6 9.44 1.73e-19 2.99e-16 0.5 0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128675467 chr3:128674735~128677005:- LUSC cis rs9322193 0.923 rs4870509 ENSG00000216906.2 RP11-350J20.9 9.44 1.73e-19 3e-16 0.48 0.4 Lung cancer; chr6:149702212 chr6:149904243~149906418:+ LUSC cis rs1707322 0.682 rs10890334 ENSG00000280836.1 AL355480.1 -9.44 1.76e-19 3.04e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634706 chr1:45581219~45581321:- LUSC cis rs1707322 0.682 rs10890335 ENSG00000280836.1 AL355480.1 -9.44 1.76e-19 3.04e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634722 chr1:45581219~45581321:- LUSC cis rs10256972 0.758 rs4723649 ENSG00000229043.2 AC091729.9 -9.44 1.76e-19 3.05e-16 -0.47 -0.4 Endometriosis;Longevity; chr7:1032269 chr7:1160374~1165267:+ LUSC cis rs494459 0.838 rs607125 ENSG00000255422.1 AP002954.4 -9.44 1.76e-19 3.05e-16 -0.41 -0.4 Height; chr11:118746590 chr11:118704607~118750263:+ LUSC cis rs10129255 0.913 rs10140943 ENSG00000223648.3 IGHV3-64 9.44 1.79e-19 3.09e-16 0.37 0.4 Kawasaki disease; chr14:106767441 chr14:106643132~106658258:- LUSC cis rs11098499 0.908 rs71614449 ENSG00000245958.5 RP11-33B1.1 -9.44 1.79e-19 3.1e-16 -0.41 -0.4 Corneal astigmatism; chr4:119465900 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs35063680 ENSG00000245958.5 RP11-33B1.1 -9.44 1.79e-19 3.1e-16 -0.41 -0.4 Corneal astigmatism; chr4:119465947 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs34858317 ENSG00000245958.5 RP11-33B1.1 -9.44 1.79e-19 3.1e-16 -0.41 -0.4 Corneal astigmatism; chr4:119465955 chr4:119454791~119552025:+ LUSC cis rs1707322 0.506 rs2991983 ENSG00000280836.1 AL355480.1 9.44 1.8e-19 3.11e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613719 chr1:45581219~45581321:- LUSC cis rs11098499 0.908 rs28559989 ENSG00000245958.5 RP11-33B1.1 -9.44 1.8e-19 3.12e-16 -0.41 -0.4 Corneal astigmatism; chr4:119465472 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs28632018 ENSG00000245958.5 RP11-33B1.1 -9.44 1.8e-19 3.12e-16 -0.41 -0.4 Corneal astigmatism; chr4:119465575 chr4:119454791~119552025:+ LUSC cis rs765787 0.53 rs4442750 ENSG00000259520.4 CTD-2651B20.3 9.44 1.81e-19 3.12e-16 0.49 0.4 Uric acid levels; chr15:45243130 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4444275 ENSG00000259520.4 CTD-2651B20.3 9.44 1.81e-19 3.12e-16 0.49 0.4 Uric acid levels; chr15:45243149 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4270107 ENSG00000259520.4 CTD-2651B20.3 9.44 1.81e-19 3.12e-16 0.49 0.4 Uric acid levels; chr15:45243152 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs4544188 ENSG00000259520.4 CTD-2651B20.3 9.44 1.81e-19 3.12e-16 0.49 0.4 Uric acid levels; chr15:45243195 chr15:45251580~45279251:- LUSC cis rs8091660 0.929 rs2175564 ENSG00000278983.1 RP11-426J5.3 9.43 1.82e-19 3.14e-16 0.52 0.4 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48570838 chr18:48564795~48568342:+ LUSC cis rs507080 0.501 rs626645 ENSG00000255239.1 AP002954.6 9.43 1.82e-19 3.14e-16 0.43 0.4 Serum metabolite levels; chr11:118704471 chr11:118688039~118690600:- LUSC cis rs1891275 0.515 rs7475294 ENSG00000228701.1 TNKS2-AS1 -9.43 1.85e-19 3.19e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91748442 chr10:91782839~91798291:- LUSC cis rs494459 0.756 rs570806 ENSG00000255422.1 AP002954.4 -9.43 1.85e-19 3.19e-16 -0.42 -0.4 Height; chr11:118786602 chr11:118704607~118750263:+ LUSC cis rs6452524 1 rs4591730 ENSG00000249664.1 CTD-2227C6.2 9.43 1.85e-19 3.2e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83151983 chr5:83012285~83013109:- LUSC cis rs62229266 0.804 rs2255858 ENSG00000231106.2 LINC01436 9.43 1.86e-19 3.21e-16 0.52 0.4 Mitral valve prolapse; chr21:36040454 chr21:36005338~36007838:+ LUSC cis rs7174755 0.772 rs75395345 ENSG00000260657.2 RP11-315D16.4 9.43 1.87e-19 3.22e-16 0.51 0.4 Major depressive disorder; chr15:68081380 chr15:68267792~68277994:- LUSC cis rs1891275 0.515 rs2421694 ENSG00000228701.1 TNKS2-AS1 -9.43 1.87e-19 3.23e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91756347 chr10:91782839~91798291:- LUSC cis rs494459 0.838 rs581045 ENSG00000255422.1 AP002954.4 -9.43 1.88e-19 3.25e-16 -0.41 -0.4 Height; chr11:118761813 chr11:118704607~118750263:+ LUSC cis rs9487094 0.67 rs6911700 ENSG00000260273.1 RP11-425D10.10 9.43 1.9e-19 3.28e-16 0.47 0.4 Height; chr6:109676091 chr6:109382795~109383666:+ LUSC cis rs1707322 0.655 rs3014240 ENSG00000280836.1 AL355480.1 9.43 1.92e-19 3.31e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45623553 chr1:45581219~45581321:- LUSC cis rs10256972 0.524 rs6945202 ENSG00000229043.2 AC091729.9 -9.42 1.96e-19 3.38e-16 -0.46 -0.4 Endometriosis;Longevity; chr7:1076922 chr7:1160374~1165267:+ LUSC cis rs1933112 0.5 rs12409982 ENSG00000227777.1 RP4-738P11.3 -9.42 1.97e-19 3.4e-16 -0.55 -0.4 Blood protein levels; chr1:168553146 chr1:168542737~168543354:+ LUSC cis rs1933112 0.5 rs12568619 ENSG00000227777.1 RP4-738P11.3 -9.42 1.97e-19 3.4e-16 -0.55 -0.4 Blood protein levels; chr1:168553496 chr1:168542737~168543354:+ LUSC cis rs11098499 0.954 rs10017543 ENSG00000245958.5 RP11-33B1.1 -9.42 1.98e-19 3.41e-16 -0.41 -0.4 Corneal astigmatism; chr4:119400265 chr4:119454791~119552025:+ LUSC cis rs1707322 0.717 rs1135850 ENSG00000280836.1 AL355480.1 -9.42 1.99e-19 3.42e-16 -0.49 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628020 chr1:45581219~45581321:- LUSC cis rs1707322 0.686 rs3014235 ENSG00000280836.1 AL355480.1 9.42 1.99e-19 3.42e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625840 chr1:45581219~45581321:- LUSC cis rs992157 0.835 rs7559416 ENSG00000261338.2 RP11-378A13.1 -9.42 2e-19 3.45e-16 -0.41 -0.4 Colorectal cancer; chr2:218285488 chr2:218255319~218257366:+ LUSC cis rs10129255 0.957 rs11846893 ENSG00000223648.3 IGHV3-64 9.42 2.03e-19 3.49e-16 0.35 0.4 Kawasaki disease; chr14:106779068 chr14:106643132~106658258:- LUSC cis rs5760092 0.627 rs6519489 ENSG00000225282.1 AP000350.6 -9.42 2.04e-19 3.51e-16 -0.58 -0.4 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23926900~23929574:+ LUSC cis rs6452524 0.901 rs1842020 ENSG00000249664.1 CTD-2227C6.2 9.42 2.05e-19 3.53e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83125814 chr5:83012285~83013109:- LUSC cis rs9322193 0.884 rs9322210 ENSG00000216906.2 RP11-350J20.9 9.42 2.06e-19 3.54e-16 0.48 0.4 Lung cancer; chr6:149695440 chr6:149904243~149906418:+ LUSC cis rs10129255 0.957 rs12589190 ENSG00000223648.3 IGHV3-64 9.42 2.06e-19 3.54e-16 0.36 0.4 Kawasaki disease; chr14:106783079 chr14:106643132~106658258:- LUSC cis rs6782228 0.606 rs6439135 ENSG00000277250.1 Metazoa_SRP -9.42 2.07e-19 3.57e-16 -0.44 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128639790 chr3:128673681~128674021:- LUSC cis rs11098499 0.779 rs80242894 ENSG00000245958.5 RP11-33B1.1 -9.42 2.09e-19 3.6e-16 -0.41 -0.4 Corneal astigmatism; chr4:119454597 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs9689599 ENSG00000216906.2 RP11-350J20.9 9.42 2.09e-19 3.6e-16 0.47 0.4 Lung cancer; chr6:149631973 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs2064521 ENSG00000216906.2 RP11-350J20.9 -9.42 2.1e-19 3.61e-16 -0.47 -0.4 Lung cancer; chr6:149625336 chr6:149904243~149906418:+ LUSC cis rs507080 0.501 rs637563 ENSG00000255239.1 AP002954.6 9.42 2.1e-19 3.61e-16 0.43 0.4 Serum metabolite levels; chr11:118704770 chr11:118688039~118690600:- LUSC cis rs2337406 0.866 rs8012619 ENSG00000274576.2 IGHV2-70 -9.42 2.1e-19 3.62e-16 -0.41 -0.4 Alzheimer's disease (late onset); chr14:106793907 chr14:106770577~106771020:- LUSC cis rs4728142 0.604 rs6467222 ENSG00000275106.1 RP11-309L24.10 -9.42 2.11e-19 3.62e-16 -0.52 -0.4 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129034365 chr7:128952527~128953316:- LUSC cis rs765787 0.53 rs2554457 ENSG00000259520.4 CTD-2651B20.3 9.42 2.11e-19 3.62e-16 0.49 0.4 Uric acid levels; chr15:45228728 chr15:45251580~45279251:- LUSC cis rs11098499 0.909 rs10017335 ENSG00000245958.5 RP11-33B1.1 9.42 2.11e-19 3.63e-16 0.41 0.4 Corneal astigmatism; chr4:119460368 chr4:119454791~119552025:+ LUSC cis rs11098499 0.908 rs7695996 ENSG00000245958.5 RP11-33B1.1 -9.41 2.13e-19 3.66e-16 -0.41 -0.4 Corneal astigmatism; chr4:119400878 chr4:119454791~119552025:+ LUSC cis rs11098499 0.908 rs7696649 ENSG00000245958.5 RP11-33B1.1 -9.41 2.13e-19 3.66e-16 -0.41 -0.4 Corneal astigmatism; chr4:119401022 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs7767622 ENSG00000216906.2 RP11-350J20.9 9.41 2.14e-19 3.68e-16 0.48 0.4 Lung cancer; chr6:149681766 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs3798761 ENSG00000216906.2 RP11-350J20.9 9.41 2.14e-19 3.68e-16 0.48 0.4 Lung cancer; chr6:149683643 chr6:149904243~149906418:+ LUSC cis rs11098499 0.779 rs28495013 ENSG00000245958.5 RP11-33B1.1 -9.41 2.14e-19 3.68e-16 -0.41 -0.4 Corneal astigmatism; chr4:119454676 chr4:119454791~119552025:+ LUSC cis rs6782228 0.606 rs4634140 ENSG00000277250.1 Metazoa_SRP 9.41 2.18e-19 3.73e-16 0.46 0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128705613 chr3:128673681~128674021:- LUSC cis rs10129255 0.957 rs11847726 ENSG00000223648.3 IGHV3-64 9.41 2.19e-19 3.76e-16 0.36 0.4 Kawasaki disease; chr14:106779116 chr14:106643132~106658258:- LUSC cis rs6452524 0.934 rs1120476 ENSG00000249664.1 CTD-2227C6.2 9.41 2.2e-19 3.78e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83126824 chr5:83012285~83013109:- LUSC cis rs765787 0.53 rs2554456 ENSG00000259520.4 CTD-2651B20.3 9.41 2.21e-19 3.79e-16 0.49 0.4 Uric acid levels; chr15:45228940 chr15:45251580~45279251:- LUSC cis rs867371 0.502 rs28610286 ENSG00000255769.6 GOLGA2P10 -9.41 2.22e-19 3.81e-16 -0.47 -0.4 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82233314 chr15:82472993~82513950:- LUSC cis rs11098499 0.738 rs72918577 ENSG00000245958.5 RP11-33B1.1 -9.41 2.22e-19 3.82e-16 -0.41 -0.4 Corneal astigmatism; chr4:119405546 chr4:119454791~119552025:+ LUSC cis rs9487094 0.67 rs13220915 ENSG00000260273.1 RP11-425D10.10 9.41 2.24e-19 3.85e-16 0.46 0.4 Height; chr6:109503623 chr6:109382795~109383666:+ LUSC cis rs1707322 0.717 rs12023439 ENSG00000280836.1 AL355480.1 -9.41 2.25e-19 3.86e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638964 chr1:45581219~45581321:- LUSC cis rs867371 0.502 rs1846908 ENSG00000255769.6 GOLGA2P10 -9.41 2.28e-19 3.9e-16 -0.47 -0.4 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82230185 chr15:82472993~82513950:- LUSC cis rs2665103 0.655 rs1501367 ENSG00000255769.6 GOLGA2P10 -9.41 2.28e-19 3.9e-16 -0.47 -0.4 Intelligence (multi-trait analysis); chr15:82230475 chr15:82472993~82513950:- LUSC cis rs12134133 1 rs1782468 ENSG00000274245.1 RP11-357P18.2 9.41 2.28e-19 3.91e-16 0.51 0.4 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207297070 chr1:207372559~207373252:+ LUSC cis rs11098499 0.909 rs9759478 ENSG00000245958.5 RP11-33B1.1 -9.41 2.29e-19 3.92e-16 -0.41 -0.4 Corneal astigmatism; chr4:119446843 chr4:119454791~119552025:+ LUSC cis rs9322193 0.884 rs62439837 ENSG00000216906.2 RP11-350J20.9 9.41 2.29e-19 3.92e-16 0.49 0.4 Lung cancer; chr6:149670380 chr6:149904243~149906418:+ LUSC cis rs9487094 0.626 rs12192776 ENSG00000260273.1 RP11-425D10.10 9.41 2.3e-19 3.94e-16 0.47 0.4 Height; chr6:109634150 chr6:109382795~109383666:+ LUSC cis rs6782228 0.606 rs2811488 ENSG00000277250.1 Metazoa_SRP -9.41 2.3e-19 3.94e-16 -0.44 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128617674 chr3:128673681~128674021:- LUSC cis rs1891275 0.515 rs7093728 ENSG00000228701.1 TNKS2-AS1 -9.4 2.31e-19 3.95e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91683860 chr10:91782839~91798291:- LUSC cis rs1891275 0.515 rs10786010 ENSG00000228701.1 TNKS2-AS1 -9.4 2.31e-19 3.95e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91684016 chr10:91782839~91798291:- LUSC cis rs1891275 0.515 rs1986941 ENSG00000228701.1 TNKS2-AS1 -9.4 2.31e-19 3.95e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91684586 chr10:91782839~91798291:- LUSC cis rs1891275 0.515 rs7098763 ENSG00000228701.1 TNKS2-AS1 -9.4 2.31e-19 3.95e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91685070 chr10:91782839~91798291:- LUSC cis rs1707322 0.691 rs61784799 ENSG00000280836.1 AL355480.1 9.4 2.31e-19 3.95e-16 0.48 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45712076 chr1:45581219~45581321:- LUSC cis rs9487094 0.626 rs1980591 ENSG00000260273.1 RP11-425D10.10 9.4 2.31e-19 3.96e-16 0.47 0.4 Height; chr6:109618620 chr6:109382795~109383666:+ LUSC cis rs9487094 0.696 rs12191353 ENSG00000260273.1 RP11-425D10.10 9.4 2.31e-19 3.96e-16 0.47 0.4 Height; chr6:109620772 chr6:109382795~109383666:+ LUSC cis rs10875746 0.669 rs11168487 ENSG00000240399.1 RP1-228P16.1 -9.4 2.32e-19 3.98e-16 -0.47 -0.4 Longevity (90 years and older); chr12:48246926 chr12:48054813~48055591:- LUSC cis rs10875746 0.624 rs11168498 ENSG00000240399.1 RP1-228P16.1 -9.4 2.32e-19 3.98e-16 -0.47 -0.4 Longevity (90 years and older); chr12:48261305 chr12:48054813~48055591:- LUSC cis rs1707322 0.682 rs12037459 ENSG00000280836.1 AL355480.1 -9.4 2.33e-19 3.99e-16 -0.49 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629287 chr1:45581219~45581321:- LUSC cis rs9322193 0.847 rs12234128 ENSG00000216906.2 RP11-350J20.9 9.4 2.36e-19 4.04e-16 0.47 0.4 Lung cancer; chr6:149627553 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs57012784 ENSG00000216906.2 RP11-350J20.9 9.4 2.36e-19 4.04e-16 0.47 0.4 Lung cancer; chr6:149627691 chr6:149904243~149906418:+ LUSC cis rs7104764 0.507 rs6598056 ENSG00000277290.1 RP11-326C3.16 9.4 2.37e-19 4.05e-16 0.38 0.4 Menarche (age at onset); chr11:252283 chr11:243099~243483:- LUSC cis rs11098499 0.754 rs9991959 ENSG00000245958.5 RP11-33B1.1 9.4 2.37e-19 4.06e-16 0.38 0.4 Corneal astigmatism; chr4:119332618 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs13133522 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119403269 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs35091806 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119404374 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs35165976 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119404475 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs3890049 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119405128 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs6846442 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119405168 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs71614438 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119450097 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs66506550 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119450290 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs7659501 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119450397 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs71629403 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119451412 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs28571712 ENSG00000245958.5 RP11-33B1.1 -9.4 2.41e-19 4.11e-16 -0.41 -0.4 Corneal astigmatism; chr4:119454825 chr4:119454791~119552025:+ LUSC cis rs1707322 0.686 rs61784833 ENSG00000280836.1 AL355480.1 -9.4 2.42e-19 4.13e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45768100 chr1:45581219~45581321:- LUSC cis rs1707322 0.721 rs7519900 ENSG00000280836.1 AL355480.1 -9.4 2.42e-19 4.13e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769275 chr1:45581219~45581321:- LUSC cis rs11098499 0.913 rs11098496 ENSG00000245958.5 RP11-33B1.1 -9.4 2.44e-19 4.15e-16 -0.4 -0.4 Corneal astigmatism; chr4:119246311 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs35197422 ENSG00000245958.5 RP11-33B1.1 -9.4 2.44e-19 4.15e-16 -0.4 -0.4 Corneal astigmatism; chr4:119248159 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs1511015 ENSG00000245958.5 RP11-33B1.1 -9.4 2.44e-19 4.15e-16 -0.4 -0.4 Corneal astigmatism; chr4:119249318 chr4:119454791~119552025:+ LUSC cis rs1891275 0.515 rs11186666 ENSG00000228701.1 TNKS2-AS1 -9.4 2.45e-19 4.17e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91718162 chr10:91782839~91798291:- LUSC cis rs11098499 0.738 rs34965784 ENSG00000245958.5 RP11-33B1.1 -9.4 2.47e-19 4.2e-16 -0.41 -0.4 Corneal astigmatism; chr4:119440431 chr4:119454791~119552025:+ LUSC cis rs1707322 0.752 rs11211152 ENSG00000280836.1 AL355480.1 -9.4 2.47e-19 4.21e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648485 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs4607935 ENSG00000280836.1 AL355480.1 -9.4 2.47e-19 4.21e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651489 chr1:45581219~45581321:- LUSC cis rs1707322 0.681 rs12048866 ENSG00000280836.1 AL355480.1 -9.4 2.47e-19 4.21e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651820 chr1:45581219~45581321:- LUSC cis rs9322193 0.924 rs9322189 ENSG00000216906.2 RP11-350J20.9 9.39 2.51e-19 4.27e-16 0.48 0.4 Lung cancer; chr6:149588797 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs62439840 ENSG00000216906.2 RP11-350J20.9 9.39 2.52e-19 4.29e-16 0.49 0.4 Lung cancer; chr6:149674639 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9393175 ENSG00000216906.2 RP11-350J20.9 9.39 2.52e-19 4.29e-16 0.49 0.4 Lung cancer; chr6:149677587 chr6:149904243~149906418:+ LUSC cis rs10129255 0.913 rs28861466 ENSG00000223648.3 IGHV3-64 9.39 2.53e-19 4.3e-16 0.37 0.4 Kawasaki disease; chr14:106718572 chr14:106643132~106658258:- LUSC cis rs6452524 0.967 rs4290995 ENSG00000249664.1 CTD-2227C6.2 9.39 2.58e-19 4.38e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83182177 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs965674 ENSG00000249664.1 CTD-2227C6.2 9.39 2.58e-19 4.38e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83186765 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs2662242 ENSG00000249664.1 CTD-2227C6.2 9.39 2.58e-19 4.38e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83189066 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs2731844 ENSG00000249664.1 CTD-2227C6.2 9.39 2.58e-19 4.38e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83192627 chr5:83012285~83013109:- LUSC cis rs6452524 0.901 rs2940540 ENSG00000249664.1 CTD-2227C6.2 9.39 2.58e-19 4.38e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83193004 chr5:83012285~83013109:- LUSC cis rs9322193 0.884 rs62439836 ENSG00000216906.2 RP11-350J20.9 9.39 2.59e-19 4.4e-16 0.48 0.4 Lung cancer; chr6:149669173 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs4869812 ENSG00000216906.2 RP11-350J20.9 9.39 2.59e-19 4.4e-16 0.48 0.4 Lung cancer; chr6:149669447 chr6:149904243~149906418:+ LUSC cis rs11098499 0.697 rs28655325 ENSG00000245958.5 RP11-33B1.1 -9.39 2.61e-19 4.43e-16 -0.41 -0.4 Corneal astigmatism; chr4:119451844 chr4:119454791~119552025:+ LUSC cis rs9487094 0.67 rs12528781 ENSG00000260273.1 RP11-425D10.10 9.39 2.63e-19 4.46e-16 0.47 0.4 Height; chr6:109608105 chr6:109382795~109383666:+ LUSC cis rs2108622 0.727 rs3093193 ENSG00000267453.5 AC004791.2 -9.39 2.63e-19 4.47e-16 -0.52 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15881104 chr19:15851993~15864904:- LUSC cis rs1707322 0.752 rs4660880 ENSG00000280836.1 AL355480.1 -9.39 2.63e-19 4.47e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645368 chr1:45581219~45581321:- LUSC cis rs9322193 0.923 rs66516768 ENSG00000216906.2 RP11-350J20.9 9.39 2.63e-19 4.47e-16 0.48 0.4 Lung cancer; chr6:149671999 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs4380763 ENSG00000216906.2 RP11-350J20.9 9.39 2.64e-19 4.48e-16 0.48 0.4 Lung cancer; chr6:149678086 chr6:149904243~149906418:+ LUSC cis rs9322193 1 rs9377228 ENSG00000216906.2 RP11-350J20.9 9.39 2.64e-19 4.48e-16 0.48 0.4 Lung cancer; chr6:149600862 chr6:149904243~149906418:+ LUSC cis rs35160687 0.829 rs13017143 ENSG00000273080.1 RP11-301O19.1 -9.39 2.64e-19 4.49e-16 -0.38 -0.4 Night sleep phenotypes; chr2:86239426 chr2:86195590~86196049:+ LUSC cis rs507080 0.501 rs625735 ENSG00000255239.1 AP002954.6 9.39 2.65e-19 4.49e-16 0.42 0.4 Serum metabolite levels; chr11:118704710 chr11:118688039~118690600:- LUSC cis rs733592 0.507 rs7138917 ENSG00000240399.1 RP1-228P16.1 -9.39 2.66e-19 4.52e-16 -0.38 -0.4 Plateletcrit; chr12:48061472 chr12:48054813~48055591:- LUSC cis rs9322193 0.923 rs3924871 ENSG00000216906.2 RP11-350J20.9 9.39 2.68e-19 4.55e-16 0.48 0.4 Lung cancer; chr6:149662080 chr6:149904243~149906418:+ LUSC cis rs1707322 0.717 rs1135812 ENSG00000280836.1 AL355480.1 -9.38 2.72e-19 4.62e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629600 chr1:45581219~45581321:- LUSC cis rs1707322 0.752 rs6703748 ENSG00000280836.1 AL355480.1 -9.38 2.72e-19 4.62e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45630304 chr1:45581219~45581321:- LUSC cis rs11098499 0.954 rs4309825 ENSG00000245958.5 RP11-33B1.1 9.38 2.73e-19 4.63e-16 0.38 0.4 Corneal astigmatism; chr4:119393726 chr4:119454791~119552025:+ LUSC cis rs9487094 0.67 rs12212476 ENSG00000260273.1 RP11-425D10.10 9.38 2.73e-19 4.63e-16 0.46 0.4 Height; chr6:109501402 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs12198938 ENSG00000260273.1 RP11-425D10.10 9.38 2.73e-19 4.63e-16 0.46 0.4 Height; chr6:109501429 chr6:109382795~109383666:+ LUSC cis rs765787 0.53 rs1706835 ENSG00000259520.4 CTD-2651B20.3 9.38 2.76e-19 4.68e-16 0.49 0.4 Uric acid levels; chr15:45225686 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs1631533 ENSG00000259520.4 CTD-2651B20.3 9.38 2.76e-19 4.68e-16 0.49 0.4 Uric acid levels; chr15:45226430 chr15:45251580~45279251:- LUSC cis rs494459 0.691 rs607472 ENSG00000255422.1 AP002954.4 -9.38 2.78e-19 4.7e-16 -0.41 -0.4 Height; chr11:118809363 chr11:118704607~118750263:+ LUSC cis rs8040855 0.644 rs4635318 ENSG00000259295.5 CSPG4P12 -9.38 2.79e-19 4.73e-16 -0.47 -0.4 Bulimia nervosa; chr15:85183506 chr15:85191438~85213905:+ LUSC cis rs1707322 0.717 rs3014245 ENSG00000280836.1 AL355480.1 9.38 2.82e-19 4.77e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621241 chr1:45581219~45581321:- LUSC cis rs11098499 0.505 rs75122014 ENSG00000245958.5 RP11-33B1.1 -9.38 2.82e-19 4.78e-16 -0.41 -0.4 Corneal astigmatism; chr4:119441271 chr4:119454791~119552025:+ LUSC cis rs748404 0.516 rs523156 ENSG00000249839.1 AC011330.5 9.38 2.82e-19 4.78e-16 0.53 0.4 Lung cancer; chr15:43519645 chr15:43663654~43684339:- LUSC cis rs172166 0.56 rs203878 ENSG00000204709.4 LINC01556 9.38 2.89e-19 4.9e-16 0.48 0.4 Cardiac Troponin-T levels; chr6:28081218 chr6:28943877~28944537:+ LUSC cis rs10129255 1 rs61997605 ENSG00000211970.3 IGHV4-61 -9.38 2.91e-19 4.93e-16 -0.28 -0.4 Kawasaki disease; chr14:106678368 chr14:106639119~106639657:- LUSC cis rs1707322 0.682 rs3014241 ENSG00000280836.1 AL355480.1 9.38 2.91e-19 4.93e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45622207 chr1:45581219~45581321:- LUSC cis rs11098499 0.954 rs10518331 ENSG00000245958.5 RP11-33B1.1 -9.37 2.96e-19 5e-16 -0.41 -0.4 Corneal astigmatism; chr4:119402440 chr4:119454791~119552025:+ LUSC cis rs1707322 0.716 rs6694889 ENSG00000280836.1 AL355480.1 -9.37 2.96e-19 5e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45636134 chr1:45581219~45581321:- LUSC cis rs1707322 0.682 rs12041197 ENSG00000280836.1 AL355480.1 -9.37 2.96e-19 5e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638792 chr1:45581219~45581321:- LUSC cis rs765787 0.53 rs10467979 ENSG00000259520.4 CTD-2651B20.3 9.37 2.97e-19 5.03e-16 0.49 0.4 Uric acid levels; chr15:45229072 chr15:45251580~45279251:- LUSC cis rs10129255 1 rs8010605 ENSG00000211970.3 IGHV4-61 -9.37 2.98e-19 5.03e-16 -0.28 -0.4 Kawasaki disease; chr14:106678742 chr14:106639119~106639657:- LUSC cis rs6452524 0.967 rs1031901 ENSG00000249664.1 CTD-2227C6.2 9.37 3.01e-19 5.1e-16 0.42 0.4 Hypertension (SNP x SNP interaction); chr5:83147904 chr5:83012285~83013109:- LUSC cis rs1707322 0.721 rs4660314 ENSG00000280836.1 AL355480.1 -9.37 3.02e-19 5.1e-16 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764213 chr1:45581219~45581321:- LUSC cis rs9487094 0.644 rs1960325 ENSG00000260273.1 RP11-425D10.10 9.37 3.02e-19 5.11e-16 0.47 0.4 Height; chr6:109592105 chr6:109382795~109383666:+ LUSC cis rs494459 0.838 rs1784543 ENSG00000255422.1 AP002954.4 -9.37 3.03e-19 5.12e-16 -0.41 -0.4 Height; chr11:118760944 chr11:118704607~118750263:+ LUSC cis rs11098499 0.779 rs7699346 ENSG00000245958.5 RP11-33B1.1 -9.37 3.05e-19 5.15e-16 -0.41 -0.4 Corneal astigmatism; chr4:119389387 chr4:119454791~119552025:+ LUSC cis rs748404 0.66 rs690472 ENSG00000249839.1 AC011330.5 -9.37 3.06e-19 5.16e-16 -0.52 -0.4 Lung cancer; chr15:43472170 chr15:43663654~43684339:- LUSC cis rs765787 0.53 rs7167389 ENSG00000259520.4 CTD-2651B20.3 9.37 3.06e-19 5.17e-16 0.5 0.4 Uric acid levels; chr15:45243485 chr15:45251580~45279251:- LUSC cis rs11098499 0.955 rs1511019 ENSG00000245958.5 RP11-33B1.1 -9.37 3.11e-19 5.25e-16 -0.41 -0.4 Corneal astigmatism; chr4:119244852 chr4:119454791~119552025:+ LUSC cis rs6538678 0.833 rs10859966 ENSG00000258343.1 RP11-536G4.2 9.37 3.13e-19 5.28e-16 0.52 0.4 Lupus nephritis in systemic lupus erythematosus; chr12:95859597 chr12:95795345~95858839:- LUSC cis rs9487094 0.696 rs11153188 ENSG00000260273.1 RP11-425D10.10 9.37 3.14e-19 5.31e-16 0.47 0.4 Height; chr6:109558247 chr6:109382795~109383666:+ LUSC cis rs6991838 0.557 rs7012578 ENSG00000200714.1 Y_RNA -9.36 3.17e-19 5.35e-16 -0.49 -0.4 Intelligence (multi-trait analysis); chr8:65592592 chr8:65592731~65592820:+ LUSC cis rs62229266 0.804 rs2835231 ENSG00000231106.2 LINC01436 9.36 3.18e-19 5.36e-16 0.51 0.4 Mitral valve prolapse; chr21:36018300 chr21:36005338~36007838:+ LUSC cis rs1891275 0.55 rs4933694 ENSG00000228701.1 TNKS2-AS1 -9.36 3.18e-19 5.37e-16 -0.46 -0.4 Intelligence (multi-trait analysis); chr10:91739456 chr10:91782839~91798291:- LUSC cis rs10129255 1 rs4612959 ENSG00000223648.3 IGHV3-64 9.36 3.23e-19 5.45e-16 0.37 0.4 Kawasaki disease; chr14:106767055 chr14:106643132~106658258:- LUSC cis rs6921919 0.848 rs56131013 ENSG00000216901.1 AL022393.7 9.36 3.23e-19 5.45e-16 0.52 0.4 Autism spectrum disorder or schizophrenia; chr6:28352900 chr6:28176188~28176674:+ LUSC cis rs11098499 0.779 rs10011097 ENSG00000245958.5 RP11-33B1.1 -9.36 3.27e-19 5.51e-16 -0.4 -0.4 Corneal astigmatism; chr4:119389204 chr4:119454791~119552025:+ LUSC cis rs1707322 0.717 rs3014249 ENSG00000280836.1 AL355480.1 9.36 3.27e-19 5.51e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613821 chr1:45581219~45581321:- LUSC cis rs9322193 0.923 rs12174716 ENSG00000216906.2 RP11-350J20.9 9.36 3.3e-19 5.56e-16 0.47 0.4 Lung cancer; chr6:149644487 chr6:149904243~149906418:+ LUSC cis rs11098499 0.954 rs17009122 ENSG00000245958.5 RP11-33B1.1 -9.36 3.31e-19 5.58e-16 -0.41 -0.4 Corneal astigmatism; chr4:119441248 chr4:119454791~119552025:+ LUSC cis rs9322193 0.887 rs3734295 ENSG00000216906.2 RP11-350J20.9 9.36 3.34e-19 5.63e-16 0.49 0.4 Lung cancer; chr6:149593917 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9505823 ENSG00000216906.2 RP11-350J20.9 9.36 3.35e-19 5.64e-16 0.47 0.4 Lung cancer; chr6:149628899 chr6:149904243~149906418:+ LUSC cis rs748404 0.66 rs693510 ENSG00000249839.1 AC011330.5 -9.36 3.41e-19 5.73e-16 -0.52 -0.4 Lung cancer; chr15:43422427 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs509306 ENSG00000249839.1 AC011330.5 -9.36 3.41e-19 5.73e-16 -0.52 -0.4 Lung cancer; chr15:43422973 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs690512 ENSG00000249839.1 AC011330.5 -9.36 3.41e-19 5.73e-16 -0.52 -0.4 Lung cancer; chr15:43425480 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs2249952 ENSG00000249839.1 AC011330.5 -9.36 3.41e-19 5.73e-16 -0.52 -0.4 Lung cancer; chr15:43428335 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs2439845 ENSG00000249839.1 AC011330.5 -9.36 3.41e-19 5.73e-16 -0.52 -0.4 Lung cancer; chr15:43430412 chr15:43663654~43684339:- LUSC cis rs748404 0.631 rs2467745 ENSG00000249839.1 AC011330.5 -9.36 3.41e-19 5.73e-16 -0.52 -0.4 Lung cancer; chr15:43430544 chr15:43663654~43684339:- LUSC cis rs9322193 0.886 rs9767555 ENSG00000216906.2 RP11-350J20.9 9.36 3.41e-19 5.74e-16 0.48 0.4 Lung cancer; chr6:149647022 chr6:149904243~149906418:+ LUSC cis rs6452524 0.71 rs7708124 ENSG00000249664.1 CTD-2227C6.2 9.35 3.43e-19 5.77e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83132035 chr5:83012285~83013109:- LUSC cis rs694739 0.796 rs479777 ENSG00000236935.1 AP003774.1 9.35 3.46e-19 5.82e-16 0.39 0.4 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64340005 chr11:64325050~64329504:- LUSC cis rs1707322 0.717 rs3014237 ENSG00000280836.1 AL355480.1 9.35 3.47e-19 5.83e-16 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624580 chr1:45581219~45581321:- LUSC cis rs9322193 0.543 rs9371533 ENSG00000223701.3 RAET1E-AS1 9.35 3.48e-19 5.85e-16 0.45 0.4 Lung cancer; chr6:149889545 chr6:149884431~149919508:+ LUSC cis rs748404 0.66 rs542898 ENSG00000249839.1 AC011330.5 -9.35 3.49e-19 5.86e-16 -0.52 -0.4 Lung cancer; chr15:43427194 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs689767 ENSG00000249839.1 AC011330.5 -9.35 3.49e-19 5.86e-16 -0.52 -0.4 Lung cancer; chr15:43429879 chr15:43663654~43684339:- LUSC cis rs6782228 0.585 rs2712392 ENSG00000277250.1 Metazoa_SRP -9.35 3.52e-19 5.91e-16 -0.46 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128705414 chr3:128673681~128674021:- LUSC cis rs1707322 0.717 rs1972410 ENSG00000280836.1 AL355480.1 -9.35 3.56e-19 5.99e-16 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615275 chr1:45581219~45581321:- LUSC cis rs9322193 0.887 rs11155662 ENSG00000216906.2 RP11-350J20.9 9.35 3.58e-19 6.01e-16 0.49 0.4 Lung cancer; chr6:149592731 chr6:149904243~149906418:+ LUSC cis rs6452524 1 rs6452531 ENSG00000249664.1 CTD-2227C6.2 9.35 3.6e-19 6.05e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83170355 chr5:83012285~83013109:- LUSC cis rs12439619 0.739 rs4778988 ENSG00000278603.1 RP13-608F4.5 9.35 3.64e-19 6.11e-16 0.51 0.4 Intelligence (multi-trait analysis); chr15:82247996 chr15:82472203~82472426:+ LUSC cis rs9487094 0.67 rs7767525 ENSG00000260273.1 RP11-425D10.10 9.35 3.64e-19 6.11e-16 0.47 0.4 Height; chr6:109646187 chr6:109382795~109383666:+ LUSC cis rs9487094 0.504 rs71541003 ENSG00000260273.1 RP11-425D10.10 9.35 3.64e-19 6.11e-16 0.47 0.4 Height; chr6:109652694 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs3899233 ENSG00000260273.1 RP11-425D10.10 9.35 3.64e-19 6.11e-16 0.47 0.4 Height; chr6:109655791 chr6:109382795~109383666:+ LUSC cis rs2455601 0.882 rs11042118 ENSG00000254860.4 TMEM9B-AS1 9.35 3.65e-19 6.13e-16 0.57 0.4 Schizophrenia; chr11:8907244 chr11:8964675~8977527:+ LUSC cis rs2882667 0.638 rs2351905 ENSG00000253404.1 AC034243.1 9.35 3.66e-19 6.13e-16 0.5 0.4 Age-related hearing impairment (SNP x SNP interaction); chr5:139135641 chr5:138744434~138753309:- LUSC cis rs9322193 0.923 rs9800580 ENSG00000216906.2 RP11-350J20.9 9.35 3.67e-19 6.16e-16 0.47 0.4 Lung cancer; chr6:149632845 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs11155669 ENSG00000216906.2 RP11-350J20.9 9.35 3.67e-19 6.16e-16 0.47 0.4 Lung cancer; chr6:149633501 chr6:149904243~149906418:+ LUSC cis rs9322193 0.887 rs9505824 ENSG00000216906.2 RP11-350J20.9 9.35 3.67e-19 6.16e-16 0.47 0.4 Lung cancer; chr6:149633663 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9505826 ENSG00000216906.2 RP11-350J20.9 9.35 3.67e-19 6.16e-16 0.47 0.4 Lung cancer; chr6:149633912 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9766886 ENSG00000216906.2 RP11-350J20.9 9.35 3.67e-19 6.16e-16 0.47 0.4 Lung cancer; chr6:149637048 chr6:149904243~149906418:+ LUSC cis rs11098499 0.865 rs1112817 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119376645 chr4:119454791~119552025:+ LUSC cis rs11098499 0.779 rs10016060 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119377257 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs10005644 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119377322 chr4:119454791~119552025:+ LUSC cis rs11098499 0.697 rs10016448 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119377690 chr4:119454791~119552025:+ LUSC cis rs11098499 0.657 rs9996569 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119377849 chr4:119454791~119552025:+ LUSC cis rs11098499 0.908 rs11729050 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119378911 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs28429722 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119378938 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs10014845 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119379922 chr4:119454791~119552025:+ LUSC cis rs11098499 0.779 rs7674500 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119382438 chr4:119454791~119552025:+ LUSC cis rs11098499 0.697 rs4373140 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119386543 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs13113483 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119387884 chr4:119454791~119552025:+ LUSC cis rs11098499 0.542 rs10440343 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119388632 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs28668716 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119388720 chr4:119454791~119552025:+ LUSC cis rs11098499 0.542 rs7677836 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119389483 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs10002083 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119389997 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs10024844 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119390373 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs4345162 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119391804 chr4:119454791~119552025:+ LUSC cis rs11098499 0.657 rs4463052 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119392103 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs13151285 ENSG00000245958.5 RP11-33B1.1 -9.34 3.73e-19 6.23e-16 -0.4 -0.4 Corneal astigmatism; chr4:119393586 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs9800614 ENSG00000216906.2 RP11-350J20.9 9.34 3.73e-19 6.25e-16 0.47 0.4 Lung cancer; chr6:149644604 chr6:149904243~149906418:+ LUSC cis rs11098499 0.909 rs11723757 ENSG00000245958.5 RP11-33B1.1 -9.34 3.74e-19 6.25e-16 -0.41 -0.4 Corneal astigmatism; chr4:119378514 chr4:119454791~119552025:+ LUSC cis rs9341808 0.559 rs7762895 ENSG00000272129.1 RP11-250B2.6 9.34 3.75e-19 6.27e-16 0.48 0.4 Sitting height ratio; chr6:80351714 chr6:80355424~80356859:+ LUSC cis rs9487094 0.67 rs12194157 ENSG00000260273.1 RP11-425D10.10 9.34 3.8e-19 6.35e-16 0.47 0.4 Height; chr6:109640141 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs12197950 ENSG00000260273.1 RP11-425D10.10 9.34 3.8e-19 6.35e-16 0.47 0.4 Height; chr6:109642186 chr6:109382795~109383666:+ LUSC cis rs10129255 0.957 rs10140904 ENSG00000223648.3 IGHV3-64 9.34 3.8e-19 6.36e-16 0.36 0.4 Kawasaki disease; chr14:106776558 chr14:106643132~106658258:- LUSC cis rs2108622 0.649 rs113055956 ENSG00000267453.5 AC004791.2 -9.34 3.82e-19 6.38e-16 -0.52 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866502 chr19:15851993~15864904:- LUSC cis rs10875746 0.669 rs11168499 ENSG00000240399.1 RP1-228P16.1 -9.34 3.82e-19 6.38e-16 -0.45 -0.4 Longevity (90 years and older); chr12:48268887 chr12:48054813~48055591:- LUSC cis rs10129255 0.957 rs10141052 ENSG00000223648.3 IGHV3-64 9.34 3.83e-19 6.4e-16 0.36 0.4 Kawasaki disease; chr14:106776528 chr14:106643132~106658258:- LUSC cis rs10129255 0.957 rs10141009 ENSG00000223648.3 IGHV3-64 9.34 3.83e-19 6.4e-16 0.36 0.4 Kawasaki disease; chr14:106776695 chr14:106643132~106658258:- LUSC cis rs12429206 0.52 rs1870839 ENSG00000233672.5 RNASEH2B-AS1 -9.34 3.93e-19 6.57e-16 -0.47 -0.4 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50899732 chr13:50862172~50910764:- LUSC cis rs9322193 0.607 rs3798763 ENSG00000216906.2 RP11-350J20.9 9.34 3.98e-19 6.63e-16 0.54 0.4 Lung cancer; chr6:149889964 chr6:149904243~149906418:+ LUSC cis rs9322193 0.607 rs12204653 ENSG00000216906.2 RP11-350J20.9 9.34 3.98e-19 6.63e-16 0.54 0.4 Lung cancer; chr6:149891885 chr6:149904243~149906418:+ LUSC cis rs2739330 0.76 rs5751760 ENSG00000235689.1 AP000351.13 9.34 4e-19 6.68e-16 0.41 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:24006305~24008258:- LUSC cis rs6452524 0.901 rs1580309 ENSG00000249664.1 CTD-2227C6.2 9.33 4.03e-19 6.72e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83091948 chr5:83012285~83013109:- LUSC cis rs9487094 0.67 rs12197838 ENSG00000260273.1 RP11-425D10.10 9.33 4.03e-19 6.73e-16 0.47 0.4 Height; chr6:109672088 chr6:109382795~109383666:+ LUSC cis rs12134133 1 rs28371614 ENSG00000274245.1 RP11-357P18.2 9.33 4.06e-19 6.77e-16 0.51 0.4 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207331929 chr1:207372559~207373252:+ LUSC cis rs9322193 0.887 rs3777949 ENSG00000216906.2 RP11-350J20.9 9.33 4.08e-19 6.79e-16 0.48 0.4 Lung cancer; chr6:149596021 chr6:149904243~149906418:+ LUSC cis rs10129255 1 rs8012033 ENSG00000211970.3 IGHV4-61 -9.33 4.09e-19 6.82e-16 -0.28 -0.4 Kawasaki disease; chr14:106678854 chr14:106639119~106639657:- LUSC cis rs10129255 0.912 rs8011090 ENSG00000211970.3 IGHV4-61 -9.33 4.09e-19 6.82e-16 -0.28 -0.4 Kawasaki disease; chr14:106678896 chr14:106639119~106639657:- LUSC cis rs9487094 0.689 rs7754650 ENSG00000260273.1 RP11-425D10.10 9.33 4.1e-19 6.83e-16 0.46 0.4 Height; chr6:109405536 chr6:109382795~109383666:+ LUSC cis rs6452524 1 rs4590162 ENSG00000249664.1 CTD-2227C6.2 9.33 4.11e-19 6.85e-16 0.41 0.4 Hypertension (SNP x SNP interaction); chr5:83145621 chr5:83012285~83013109:- LUSC cis rs11098499 1 rs7659194 ENSG00000245958.5 RP11-33B1.1 -9.33 4.22e-19 7.02e-16 -0.4 -0.4 Corneal astigmatism; chr4:119285992 chr4:119454791~119552025:+ LUSC cis rs4423214 0.879 rs1792283 ENSG00000254682.1 RP11-660L16.2 -9.33 4.24e-19 7.05e-16 -0.55 -0.4 Vitamin D levels; chr11:71424090 chr11:71448674~71452157:+ LUSC cis rs4423214 0.879 rs1792282 ENSG00000254682.1 RP11-660L16.2 -9.33 4.24e-19 7.05e-16 -0.55 -0.4 Vitamin D levels; chr11:71424120 chr11:71448674~71452157:+ LUSC cis rs9322193 0.884 rs7744105 ENSG00000216906.2 RP11-350J20.9 9.33 4.25e-19 7.07e-16 0.48 0.4 Lung cancer; chr6:149849308 chr6:149904243~149906418:+ LUSC cis rs694739 0.734 rs663743 ENSG00000236935.1 AP003774.1 9.33 4.3e-19 7.15e-16 0.39 0.4 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64340263 chr11:64325050~64329504:- LUSC cis rs7208859 0.623 rs426434 ENSG00000263531.1 RP13-753N3.1 9.33 4.3e-19 7.15e-16 0.7 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30598335 chr17:30863921~30864940:- LUSC cis rs11098499 0.954 rs7654587 ENSG00000245958.5 RP11-33B1.1 -9.33 4.31e-19 7.17e-16 -0.41 -0.4 Corneal astigmatism; chr4:119467251 chr4:119454791~119552025:+ LUSC cis rs10129255 0.957 rs8009073 ENSG00000223648.3 IGHV3-64 9.33 4.31e-19 7.17e-16 0.36 0.4 Kawasaki disease; chr14:106777278 chr14:106643132~106658258:- LUSC cis rs765787 0.53 rs2413785 ENSG00000259520.4 CTD-2651B20.3 9.32 4.41e-19 7.33e-16 0.49 0.4 Uric acid levels; chr15:45238183 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11636410 ENSG00000259520.4 CTD-2651B20.3 -9.32 4.43e-19 7.37e-16 -0.5 -0.4 Uric acid levels; chr15:45243715 chr15:45251580~45279251:- LUSC cis rs6921919 0.848 rs6903823 ENSG00000216901.1 AL022393.7 9.32 4.49e-19 7.47e-16 0.53 0.39 Autism spectrum disorder or schizophrenia; chr6:28354519 chr6:28176188~28176674:+ LUSC cis rs9487094 0.67 rs749517 ENSG00000260273.1 RP11-425D10.10 -9.32 4.5e-19 7.48e-16 -0.46 -0.39 Height; chr6:109531713 chr6:109382795~109383666:+ LUSC cis rs6782228 0.527 rs6767383 ENSG00000277250.1 Metazoa_SRP -9.32 4.5e-19 7.48e-16 -0.45 -0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694744 chr3:128673681~128674021:- LUSC cis rs11098499 0.954 rs11098525 ENSG00000245958.5 RP11-33B1.1 -9.32 4.54e-19 7.55e-16 -0.41 -0.39 Corneal astigmatism; chr4:119468997 chr4:119454791~119552025:+ LUSC cis rs17507216 0.718 rs4779033 ENSG00000278603.1 RP13-608F4.5 -9.32 4.55e-19 7.55e-16 -0.6 -0.39 Excessive daytime sleepiness; chr15:82576634 chr15:82472203~82472426:+ LUSC cis rs62229266 0.74 rs4817759 ENSG00000231106.2 LINC01436 9.32 4.57e-19 7.58e-16 0.51 0.39 Mitral valve prolapse; chr21:36017261 chr21:36005338~36007838:+ LUSC cis rs9322193 0.886 rs9485408 ENSG00000216906.2 RP11-350J20.9 9.32 4.57e-19 7.58e-16 0.47 0.39 Lung cancer; chr6:149618888 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs1080670 ENSG00000216906.2 RP11-350J20.9 9.32 4.57e-19 7.58e-16 0.47 0.39 Lung cancer; chr6:149620161 chr6:149904243~149906418:+ LUSC cis rs9322193 0.886 rs9322198 ENSG00000216906.2 RP11-350J20.9 9.32 4.57e-19 7.58e-16 0.47 0.39 Lung cancer; chr6:149623772 chr6:149904243~149906418:+ LUSC cis rs11098499 0.954 rs10017371 ENSG00000245958.5 RP11-33B1.1 -9.32 4.58e-19 7.61e-16 -0.41 -0.39 Corneal astigmatism; chr4:119372621 chr4:119454791~119552025:+ LUSC cis rs1729407 0.933 rs1729405 ENSG00000254851.1 RP11-109L13.1 -9.32 4.61e-19 7.65e-16 -0.49 -0.39 Apolipoprotein A-IV levels; chr11:116808044 chr11:117135528~117138582:+ LUSC cis rs2739330 0.892 rs5751776 ENSG00000231271.1 AP000350.8 9.32 4.62e-19 7.66e-16 0.52 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23949918~23954042:+ LUSC cis rs6452524 1 rs7716962 ENSG00000249664.1 CTD-2227C6.2 9.32 4.64e-19 7.69e-16 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83138913 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs6882179 ENSG00000249664.1 CTD-2227C6.2 9.32 4.64e-19 7.69e-16 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83139582 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs6863300 ENSG00000249664.1 CTD-2227C6.2 9.32 4.64e-19 7.69e-16 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83139629 chr5:83012285~83013109:- LUSC cis rs11098499 0.909 rs10026736 ENSG00000245958.5 RP11-33B1.1 -9.32 4.65e-19 7.71e-16 -0.42 -0.39 Corneal astigmatism; chr4:119463167 chr4:119454791~119552025:+ LUSC cis rs765787 0.53 rs2554455 ENSG00000259520.4 CTD-2651B20.3 9.32 4.66e-19 7.74e-16 0.49 0.39 Uric acid levels; chr15:45229106 chr15:45251580~45279251:- LUSC cis rs853679 0.527 rs213228 ENSG00000216901.1 AL022393.7 9.32 4.67e-19 7.75e-16 0.47 0.39 Depression; chr6:28363475 chr6:28176188~28176674:+ LUSC cis rs6782228 0.606 rs10048945 ENSG00000277250.1 Metazoa_SRP -9.32 4.68e-19 7.76e-16 -0.45 -0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128690837 chr3:128673681~128674021:- LUSC cis rs11098499 0.909 rs7681214 ENSG00000245958.5 RP11-33B1.1 -9.32 4.69e-19 7.77e-16 -0.41 -0.39 Corneal astigmatism; chr4:119464165 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs17046116 ENSG00000245958.5 RP11-33B1.1 -9.32 4.69e-19 7.77e-16 -0.41 -0.39 Corneal astigmatism; chr4:119466104 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs17046118 ENSG00000245958.5 RP11-33B1.1 -9.32 4.69e-19 7.77e-16 -0.41 -0.39 Corneal astigmatism; chr4:119466341 chr4:119454791~119552025:+ LUSC cis rs1707322 0.721 rs7520123 ENSG00000280836.1 AL355480.1 -9.32 4.71e-19 7.81e-16 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769547 chr1:45581219~45581321:- LUSC cis rs11098499 0.865 rs4507344 ENSG00000245958.5 RP11-33B1.1 -9.31 4.75e-19 7.87e-16 -0.4 -0.39 Corneal astigmatism; chr4:119386330 chr4:119454791~119552025:+ LUSC cis rs765787 0.53 rs2413784 ENSG00000259520.4 CTD-2651B20.3 9.31 4.75e-19 7.87e-16 0.49 0.39 Uric acid levels; chr15:45238318 chr15:45251580~45279251:- LUSC cis rs9322193 0.924 rs9498382 ENSG00000216906.2 RP11-350J20.9 9.31 4.75e-19 7.87e-16 0.47 0.39 Lung cancer; chr6:149610982 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9404048 ENSG00000216906.2 RP11-350J20.9 9.31 4.76e-19 7.88e-16 0.47 0.39 Lung cancer; chr6:149616188 chr6:149904243~149906418:+ LUSC cis rs11098499 0.722 rs1814814 ENSG00000245958.5 RP11-33B1.1 -9.31 4.77e-19 7.91e-16 -0.38 -0.39 Corneal astigmatism; chr4:119336969 chr4:119454791~119552025:+ LUSC cis rs6452524 0.967 rs11949474 ENSG00000249664.1 CTD-2227C6.2 9.31 4.77e-19 7.91e-16 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83179759 chr5:83012285~83013109:- LUSC cis rs1933112 0.5 rs1933100 ENSG00000227777.1 RP4-738P11.3 -9.31 4.79e-19 7.93e-16 -0.55 -0.39 Blood protein levels; chr1:168562714 chr1:168542737~168543354:+ LUSC cis rs11098499 0.954 rs7437420 ENSG00000245958.5 RP11-33B1.1 -9.31 4.86e-19 8.05e-16 -0.4 -0.39 Corneal astigmatism; chr4:119391748 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs59866101 ENSG00000245958.5 RP11-33B1.1 -9.31 4.89e-19 8.1e-16 -0.4 -0.39 Corneal astigmatism; chr4:119375436 chr4:119454791~119552025:+ LUSC cis rs11098499 0.618 rs6858383 ENSG00000245958.5 RP11-33B1.1 -9.31 4.89e-19 8.1e-16 -0.4 -0.39 Corneal astigmatism; chr4:119375617 chr4:119454791~119552025:+ LUSC cis rs11098499 0.697 rs6832410 ENSG00000245958.5 RP11-33B1.1 -9.31 4.89e-19 8.1e-16 -0.4 -0.39 Corneal astigmatism; chr4:119375645 chr4:119454791~119552025:+ LUSC cis rs6782228 1 rs7429360 ENSG00000242551.2 POU5F1P6 9.31 4.92e-19 8.14e-16 0.49 0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128645954 chr3:128674735~128677005:- LUSC cis rs6452524 0.935 rs6896953 ENSG00000249664.1 CTD-2227C6.2 -9.31 4.93e-19 8.16e-16 -0.41 -0.39 Hypertension (SNP x SNP interaction); chr5:83089284 chr5:83012285~83013109:- LUSC cis rs9487094 0.67 rs11752791 ENSG00000260273.1 RP11-425D10.10 9.31 4.94e-19 8.18e-16 0.46 0.39 Height; chr6:109564443 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs4490694 ENSG00000260273.1 RP11-425D10.10 9.31 4.94e-19 8.18e-16 0.46 0.39 Height; chr6:109571489 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs12214639 ENSG00000260273.1 RP11-425D10.10 9.31 4.94e-19 8.18e-16 0.46 0.39 Height; chr6:109576414 chr6:109382795~109383666:+ LUSC cis rs1976403 0.633 rs1697422 ENSG00000227001.3 NBPF2P 9.31 4.96e-19 8.2e-16 0.48 0.39 Liver enzyme levels (alkaline phosphatase); chr1:21495404 chr1:21424625~21427967:- LUSC cis rs9322193 0.923 rs9689723 ENSG00000216906.2 RP11-350J20.9 9.31 4.96e-19 8.21e-16 0.47 0.39 Lung cancer; chr6:149655935 chr6:149904243~149906418:+ LUSC cis rs1707322 0.662 rs11211160 ENSG00000280836.1 AL355480.1 -9.31 5.02e-19 8.3e-16 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680557 chr1:45581219~45581321:- LUSC cis rs765787 0.53 rs2413786 ENSG00000259520.4 CTD-2651B20.3 9.31 5.04e-19 8.33e-16 0.48 0.39 Uric acid levels; chr15:45233196 chr15:45251580~45279251:- LUSC cis rs748404 0.631 rs7163288 ENSG00000249839.1 AC011330.5 -9.31 5.06e-19 8.36e-16 -0.52 -0.39 Lung cancer; chr15:43379157 chr15:43663654~43684339:- LUSC cis rs10129255 0.912 rs67410411 ENSG00000211970.3 IGHV4-61 -9.31 5.06e-19 8.37e-16 -0.28 -0.39 Kawasaki disease; chr14:106680324 chr14:106639119~106639657:- LUSC cis rs12594515 0.6 rs12903858 ENSG00000273972.1 CTD-2306A12.1 -9.31 5.06e-19 8.37e-16 -0.46 -0.39 Weight;Waist circumference; chr15:45679968 chr15:45702640~45703183:+ LUSC cis rs11098499 0.657 rs71614442 ENSG00000245958.5 RP11-33B1.1 -9.31 5.07e-19 8.38e-16 -0.41 -0.39 Corneal astigmatism; chr4:119458191 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs2892848 ENSG00000245958.5 RP11-33B1.1 -9.31 5.07e-19 8.38e-16 -0.41 -0.39 Corneal astigmatism; chr4:119460186 chr4:119454791~119552025:+ LUSC cis rs11098499 0.865 rs9994730 ENSG00000245958.5 RP11-33B1.1 -9.31 5.07e-19 8.38e-16 -0.41 -0.39 Corneal astigmatism; chr4:119460409 chr4:119454791~119552025:+ LUSC cis rs55879323 1 rs55879323 ENSG00000237975.5 FLG-AS1 -9.3 5.12e-19 8.46e-16 -0.4 -0.39 Inflammatory skin disease; chr1:152196264 chr1:152168125~152445456:+ LUSC cis rs1891275 0.515 rs1592051 ENSG00000228701.1 TNKS2-AS1 9.3 5.13e-19 8.48e-16 0.45 0.39 Intelligence (multi-trait analysis); chr10:91782429 chr10:91782839~91798291:- LUSC cis rs10875746 0.669 rs2279464 ENSG00000240399.1 RP1-228P16.1 -9.3 5.17e-19 8.53e-16 -0.47 -0.39 Longevity (90 years and older); chr12:48296626 chr12:48054813~48055591:- LUSC cis rs12130219 0.5 rs1552991 ENSG00000237975.5 FLG-AS1 -9.3 5.17e-19 8.54e-16 -0.4 -0.39 Inflammatory skin disease; chr1:152193402 chr1:152168125~152445456:+ LUSC cis rs11098499 0.69 rs34818745 ENSG00000245958.5 RP11-33B1.1 -9.3 5.17e-19 8.54e-16 -0.4 -0.39 Corneal astigmatism; chr4:119335900 chr4:119454791~119552025:+ LUSC cis rs9487094 0.644 rs13201430 ENSG00000260273.1 RP11-425D10.10 9.3 5.18e-19 8.55e-16 0.46 0.39 Height; chr6:109634847 chr6:109382795~109383666:+ LUSC cis rs4984778 0.75 rs7198064 ENSG00000260182.1 RP11-616M22.5 9.3 5.25e-19 8.66e-16 0.5 0.39 Blood protein levels; chr16:1222472 chr16:1257339~1258074:+ LUSC cis rs6991838 0.584 rs4737747 ENSG00000200714.1 Y_RNA -9.3 5.26e-19 8.68e-16 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65607024 chr8:65592731~65592820:+ LUSC cis rs9487094 0.689 rs9487069 ENSG00000260273.1 RP11-425D10.10 9.3 5.26e-19 8.69e-16 0.46 0.39 Height; chr6:109358652 chr6:109382795~109383666:+ LUSC cis rs17711722 0.503 rs453835 ENSG00000164669.11 INTS4P1 9.3 5.27e-19 8.7e-16 0.44 0.39 Calcium levels; chr7:66046172 chr7:65141225~65234216:+ LUSC cis rs9322193 0.847 rs62439808 ENSG00000216906.2 RP11-350J20.9 9.3 5.29e-19 8.72e-16 0.47 0.39 Lung cancer; chr6:149629690 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9322200 ENSG00000216906.2 RP11-350J20.9 9.3 5.29e-19 8.72e-16 0.47 0.39 Lung cancer; chr6:149630078 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9688412 ENSG00000216906.2 RP11-350J20.9 -9.3 5.32e-19 8.78e-16 -0.47 -0.39 Lung cancer; chr6:149803147 chr6:149904243~149906418:+ LUSC cis rs11168854 0.62 rs11168888 ENSG00000258017.1 RP11-386G11.10 -9.3 5.35e-19 8.83e-16 -0.51 -0.39 Body mass index; chr12:49149614 chr12:49127782~49147869:+ LUSC cis rs6991838 0.584 rs73236948 ENSG00000200714.1 Y_RNA -9.3 5.41e-19 8.93e-16 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65609176 chr8:65592731~65592820:+ LUSC cis rs11098499 1 rs10029750 ENSG00000245958.5 RP11-33B1.1 -9.3 5.42e-19 8.94e-16 -0.4 -0.39 Corneal astigmatism; chr4:119251388 chr4:119454791~119552025:+ LUSC cis rs2006771 0.818 rs8142376 ENSG00000236132.1 CTA-440B3.1 9.3 5.5e-19 9.06e-16 0.47 0.39 Nonsyndromic cleft lip with cleft palate; chr22:31605051 chr22:31816379~31817491:- LUSC cis rs9487094 0.67 rs12199154 ENSG00000260273.1 RP11-425D10.10 -9.3 5.52e-19 9.1e-16 -0.45 -0.39 Height; chr6:109501793 chr6:109382795~109383666:+ LUSC cis rs10875746 0.669 rs61941006 ENSG00000240399.1 RP1-228P16.1 -9.3 5.52e-19 9.1e-16 -0.46 -0.39 Longevity (90 years and older); chr12:48237350 chr12:48054813~48055591:- LUSC cis rs4728142 0.604 rs4731541 ENSG00000275106.1 RP11-309L24.10 -9.29 5.59e-19 9.21e-16 -0.51 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129038182 chr7:128952527~128953316:- LUSC cis rs6921919 0.583 rs9468367 ENSG00000216901.1 AL022393.7 9.29 5.59e-19 9.21e-16 0.46 0.39 Autism spectrum disorder or schizophrenia; chr6:28392469 chr6:28176188~28176674:+ LUSC cis rs6991838 0.584 rs1053085 ENSG00000200714.1 Y_RNA -9.29 5.62e-19 9.26e-16 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65603753 chr8:65592731~65592820:+ LUSC cis rs10129255 1 rs10129255 ENSG00000223648.3 IGHV3-64 -9.29 5.64e-19 9.29e-16 -0.36 -0.39 Kawasaki disease; chr14:106767970 chr14:106643132~106658258:- LUSC cis rs11098499 0.687 rs71610270 ENSG00000245958.5 RP11-33B1.1 -9.29 5.66e-19 9.33e-16 -0.39 -0.39 Corneal astigmatism; chr4:119366281 chr4:119454791~119552025:+ LUSC cis rs9341808 0.5 rs2223873 ENSG00000272129.1 RP11-250B2.6 9.29 5.67e-19 9.33e-16 0.48 0.39 Sitting height ratio; chr6:80338571 chr6:80355424~80356859:+ LUSC cis rs11098499 0.738 rs34566984 ENSG00000245958.5 RP11-33B1.1 -9.29 5.67e-19 9.34e-16 -0.41 -0.39 Corneal astigmatism; chr4:119440115 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs9685777 ENSG00000245958.5 RP11-33B1.1 -9.29 5.67e-19 9.34e-16 -0.41 -0.39 Corneal astigmatism; chr4:119444810 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs9688861 ENSG00000216906.2 RP11-350J20.9 9.29 5.68e-19 9.34e-16 0.47 0.39 Lung cancer; chr6:149637924 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs7740278 ENSG00000216906.2 RP11-350J20.9 9.29 5.68e-19 9.34e-16 0.47 0.39 Lung cancer; chr6:149640116 chr6:149904243~149906418:+ LUSC cis rs748404 0.69 rs2467737 ENSG00000249839.1 AC011330.5 -9.29 5.69e-19 9.37e-16 -0.52 -0.39 Lung cancer; chr15:43444990 chr15:43663654~43684339:- LUSC cis rs2117029 0.554 rs35884657 ENSG00000258017.1 RP11-386G11.10 -9.29 5.7e-19 9.38e-16 -0.51 -0.39 Intelligence (multi-trait analysis); chr12:49137317 chr12:49127782~49147869:+ LUSC cis rs6782228 0.509 rs6780447 ENSG00000277250.1 Metazoa_SRP -9.29 5.71e-19 9.39e-16 -0.45 -0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694965 chr3:128673681~128674021:- LUSC cis rs9322193 0.886 rs9718079 ENSG00000216906.2 RP11-350J20.9 9.29 5.73e-19 9.42e-16 0.48 0.39 Lung cancer; chr6:149645947 chr6:149904243~149906418:+ LUSC cis rs10875746 1 rs10875746 ENSG00000240399.1 RP1-228P16.1 -9.29 5.74e-19 9.44e-16 -0.43 -0.39 Longevity (90 years and older); chr12:48124481 chr12:48054813~48055591:- LUSC cis rs11098499 0.954 rs67265404 ENSG00000245958.5 RP11-33B1.1 -9.29 5.75e-19 9.46e-16 -0.41 -0.39 Corneal astigmatism; chr4:119438115 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs71614422 ENSG00000245958.5 RP11-33B1.1 -9.29 5.75e-19 9.46e-16 -0.41 -0.39 Corneal astigmatism; chr4:119438185 chr4:119454791~119552025:+ LUSC cis rs9322193 0.884 rs10782312 ENSG00000216906.2 RP11-350J20.9 9.29 5.8e-19 9.54e-16 0.47 0.39 Lung cancer; chr6:149622669 chr6:149904243~149906418:+ LUSC cis rs1891275 0.509 rs34190234 ENSG00000228701.1 TNKS2-AS1 -9.29 5.85e-19 9.62e-16 -0.46 -0.39 Intelligence (multi-trait analysis); chr10:91683317 chr10:91782839~91798291:- LUSC cis rs1891275 0.509 rs76313529 ENSG00000228701.1 TNKS2-AS1 -9.29 5.85e-19 9.62e-16 -0.46 -0.39 Intelligence (multi-trait analysis); chr10:91683319 chr10:91782839~91798291:- LUSC cis rs9481169 0.717 rs13191781 ENSG00000255389.1 C6orf3 -9.29 5.89e-19 9.69e-16 -0.74 -0.39 Inflammatory skin disease; chr6:111620083 chr6:111599875~111602295:+ LUSC cis rs8040855 0.559 rs6496801 ENSG00000259295.5 CSPG4P12 -9.29 5.93e-19 9.75e-16 -0.47 -0.39 Bulimia nervosa; chr15:85185168 chr15:85191438~85213905:+ LUSC cis rs77505915 0.512 rs12921808 ENSG00000261783.1 RP11-252K23.2 9.29 5.94e-19 9.75e-16 0.59 0.39 Migraine; chr16:75350086 chr16:75379818~75381260:- LUSC cis rs6921919 0.583 rs7764737 ENSG00000216901.1 AL022393.7 9.29 5.95e-19 9.77e-16 0.46 0.39 Autism spectrum disorder or schizophrenia; chr6:28386838 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs9461458 ENSG00000216901.1 AL022393.7 9.29 5.95e-19 9.77e-16 0.46 0.39 Autism spectrum disorder or schizophrenia; chr6:28388098 chr6:28176188~28176674:+ LUSC cis rs6921919 0.609 rs9468365 ENSG00000216901.1 AL022393.7 9.29 5.95e-19 9.77e-16 0.46 0.39 Autism spectrum disorder or schizophrenia; chr6:28390189 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs1361385 ENSG00000216901.1 AL022393.7 9.29 5.95e-19 9.77e-16 0.46 0.39 Autism spectrum disorder or schizophrenia; chr6:28390543 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs1416918 ENSG00000216901.1 AL022393.7 9.29 5.95e-19 9.77e-16 0.46 0.39 Autism spectrum disorder or schizophrenia; chr6:28390558 chr6:28176188~28176674:+ LUSC cis rs6921919 1 rs6922111 ENSG00000216901.1 AL022393.7 9.29 5.95e-19 9.78e-16 0.52 0.39 Autism spectrum disorder or schizophrenia; chr6:28357531 chr6:28176188~28176674:+ LUSC cis rs2739330 0.791 rs4822458 ENSG00000235689.1 AP000351.13 9.29 5.96e-19 9.79e-16 0.4 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:24006305~24008258:- LUSC cis rs10129255 1 rs10134517 ENSG00000223648.3 IGHV3-64 9.28 5.99e-19 9.83e-16 0.36 0.39 Kawasaki disease; chr14:106718498 chr14:106643132~106658258:- LUSC cis rs6991838 0.584 rs1053087 ENSG00000200714.1 Y_RNA -9.28 6.09e-19 1e-15 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65603630 chr8:65592731~65592820:+ LUSC cis rs4423214 0.879 rs1790324 ENSG00000254682.1 RP11-660L16.2 -9.28 6.21e-19 1.02e-15 -0.53 -0.39 Vitamin D levels; chr11:71439474 chr11:71448674~71452157:+ LUSC cis rs9322193 0.961 rs2064520 ENSG00000216906.2 RP11-350J20.9 9.28 6.24e-19 1.02e-15 0.47 0.39 Lung cancer; chr6:149603650 chr6:149904243~149906418:+ LUSC cis rs6991838 0.584 rs34494846 ENSG00000200714.1 Y_RNA -9.28 6.31e-19 1.03e-15 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65602397 chr8:65592731~65592820:+ LUSC cis rs6452524 0.934 rs6452510 ENSG00000249664.1 CTD-2227C6.2 9.28 6.36e-19 1.04e-15 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83127401 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs62372752 ENSG00000249664.1 CTD-2227C6.2 9.28 6.42e-19 1.05e-15 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83134239 chr5:83012285~83013109:- LUSC cis rs9322193 0.923 rs35830138 ENSG00000216906.2 RP11-350J20.9 9.28 6.48e-19 1.06e-15 0.47 0.39 Lung cancer; chr6:149668635 chr6:149904243~149906418:+ LUSC cis rs6452524 1 rs10042854 ENSG00000249664.1 CTD-2227C6.2 -9.27 6.51e-19 1.07e-15 -0.4 -0.39 Hypertension (SNP x SNP interaction); chr5:83143876 chr5:83012285~83013109:- LUSC cis rs11098499 1 rs58601355 ENSG00000245958.5 RP11-33B1.1 -9.27 6.56e-19 1.07e-15 -0.41 -0.39 Corneal astigmatism; chr4:119265212 chr4:119454791~119552025:+ LUSC cis rs9322193 0.847 rs868375 ENSG00000216906.2 RP11-350J20.9 9.27 6.57e-19 1.08e-15 0.47 0.39 Lung cancer; chr6:149844905 chr6:149904243~149906418:+ LUSC cis rs6538678 0.929 rs10777744 ENSG00000258343.1 RP11-536G4.2 -9.27 6.57e-19 1.08e-15 -0.52 -0.39 Lupus nephritis in systemic lupus erythematosus; chr12:95864561 chr12:95795345~95858839:- LUSC cis rs9322193 0.923 rs35961297 ENSG00000216906.2 RP11-350J20.9 9.27 6.62e-19 1.08e-15 0.47 0.39 Lung cancer; chr6:149667929 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs35967444 ENSG00000216906.2 RP11-350J20.9 9.27 6.62e-19 1.08e-15 0.47 0.39 Lung cancer; chr6:149675588 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs62439842 ENSG00000216906.2 RP11-350J20.9 9.27 6.62e-19 1.08e-15 0.47 0.39 Lung cancer; chr6:149675847 chr6:149904243~149906418:+ LUSC cis rs853679 0.517 rs9393887 ENSG00000219392.1 RP1-265C24.5 -9.27 6.68e-19 1.09e-15 -0.55 -0.39 Depression; chr6:28091242 chr6:28115628~28116551:+ LUSC cis rs11098499 0.955 rs1511018 ENSG00000245958.5 RP11-33B1.1 -9.27 6.69e-19 1.09e-15 -0.4 -0.39 Corneal astigmatism; chr4:119240425 chr4:119454791~119552025:+ LUSC cis rs748404 0.66 rs690012 ENSG00000249839.1 AC011330.5 -9.27 6.69e-19 1.09e-15 -0.52 -0.39 Lung cancer; chr15:43427557 chr15:43663654~43684339:- LUSC cis rs6452524 1 rs7732092 ENSG00000249664.1 CTD-2227C6.2 9.27 6.73e-19 1.1e-15 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83141110 chr5:83012285~83013109:- LUSC cis rs9341808 0.528 rs2322753 ENSG00000272129.1 RP11-250B2.6 9.27 6.74e-19 1.1e-15 0.47 0.39 Sitting height ratio; chr6:80333148 chr6:80355424~80356859:+ LUSC cis rs9341808 0.556 rs2223875 ENSG00000272129.1 RP11-250B2.6 9.27 6.74e-19 1.1e-15 0.47 0.39 Sitting height ratio; chr6:80335735 chr6:80355424~80356859:+ LUSC cis rs9322193 0.923 rs10782318 ENSG00000216906.2 RP11-350J20.9 9.27 6.75e-19 1.1e-15 0.47 0.39 Lung cancer; chr6:149754137 chr6:149904243~149906418:+ LUSC cis rs10875746 0.537 rs4760625 ENSG00000240399.1 RP1-228P16.1 -9.27 6.78e-19 1.11e-15 -0.46 -0.39 Longevity (90 years and older); chr12:48279960 chr12:48054813~48055591:- LUSC cis rs10875746 0.669 rs11168510 ENSG00000240399.1 RP1-228P16.1 -9.27 6.78e-19 1.11e-15 -0.46 -0.39 Longevity (90 years and older); chr12:48291772 chr12:48054813~48055591:- LUSC cis rs8062405 0.754 rs3859172 ENSG00000259982.1 CDC37P1 9.27 6.88e-19 1.12e-15 0.48 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554837 chr16:28700294~28701540:- LUSC cis rs11098499 0.909 rs28884220 ENSG00000245958.5 RP11-33B1.1 -9.27 6.89e-19 1.12e-15 -0.4 -0.39 Corneal astigmatism; chr4:119386056 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs28793658 ENSG00000245958.5 RP11-33B1.1 -9.27 6.89e-19 1.12e-15 -0.4 -0.39 Corneal astigmatism; chr4:119386059 chr4:119454791~119552025:+ LUSC cis rs6991838 0.584 rs7812446 ENSG00000200714.1 Y_RNA -9.27 6.9e-19 1.13e-15 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65593753 chr8:65592731~65592820:+ LUSC cis rs6991838 0.557 rs7812390 ENSG00000200714.1 Y_RNA -9.27 6.9e-19 1.13e-15 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65593982 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs16932245 ENSG00000200714.1 Y_RNA -9.27 6.9e-19 1.13e-15 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65597810 chr8:65592731~65592820:+ LUSC cis rs6991838 0.557 rs57419568 ENSG00000200714.1 Y_RNA -9.27 6.9e-19 1.13e-15 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65598633 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs16932250 ENSG00000200714.1 Y_RNA -9.27 6.9e-19 1.13e-15 -0.49 -0.39 Intelligence (multi-trait analysis); chr8:65598779 chr8:65592731~65592820:+ LUSC cis rs11098499 0.564 rs11098507 ENSG00000245958.5 RP11-33B1.1 -9.27 6.96e-19 1.14e-15 -0.39 -0.39 Corneal astigmatism; chr4:119367131 chr4:119454791~119552025:+ LUSC cis rs1707322 0.685 rs11211177 ENSG00000280836.1 AL355480.1 -9.26 7.04e-19 1.15e-15 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760677 chr1:45581219~45581321:- LUSC cis rs4728142 0.604 rs2272347 ENSG00000275106.1 RP11-309L24.10 9.26 7.07e-19 1.15e-15 0.5 0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128979361 chr7:128952527~128953316:- LUSC cis rs11098499 0.954 rs7436506 ENSG00000245958.5 RP11-33B1.1 -9.26 7.09e-19 1.16e-15 -0.41 -0.39 Corneal astigmatism; chr4:119472614 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs12499324 ENSG00000245958.5 RP11-33B1.1 -9.26 7.09e-19 1.16e-15 -0.41 -0.39 Corneal astigmatism; chr4:119472631 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs10008459 ENSG00000245958.5 RP11-33B1.1 -9.26 7.09e-19 1.16e-15 -0.41 -0.39 Corneal astigmatism; chr4:119473076 chr4:119454791~119552025:+ LUSC cis rs10129255 0.536 rs6576201 ENSG00000280411.1 IGHV1-69-2 9.26 7.1e-19 1.16e-15 0.24 0.39 Kawasaki disease; chr14:106683696 chr14:106762092~106762588:- LUSC cis rs11098499 0.909 rs2127821 ENSG00000245958.5 RP11-33B1.1 -9.26 7.14e-19 1.16e-15 -0.41 -0.39 Corneal astigmatism; chr4:119473380 chr4:119454791~119552025:+ LUSC cis rs9487094 0.67 rs10782163 ENSG00000260273.1 RP11-425D10.10 9.26 7.15e-19 1.17e-15 0.46 0.39 Height; chr6:109533040 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs10457195 ENSG00000260273.1 RP11-425D10.10 9.26 7.15e-19 1.17e-15 0.46 0.39 Height; chr6:109534269 chr6:109382795~109383666:+ LUSC cis rs62229266 0.771 rs2835232 ENSG00000231106.2 LINC01436 9.26 7.16e-19 1.17e-15 0.5 0.39 Mitral valve prolapse; chr21:36021129 chr21:36005338~36007838:+ LUSC cis rs62229266 0.74 rs2835233 ENSG00000231106.2 LINC01436 9.26 7.16e-19 1.17e-15 0.5 0.39 Mitral valve prolapse; chr21:36021284 chr21:36005338~36007838:+ LUSC cis rs8062405 0.823 rs7202948 ENSG00000259982.1 CDC37P1 9.26 7.27e-19 1.19e-15 0.48 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546968 chr16:28700294~28701540:- LUSC cis rs10129255 0.957 rs10137980 ENSG00000223648.3 IGHV3-64 9.26 7.28e-19 1.19e-15 0.36 0.39 Kawasaki disease; chr14:106775735 chr14:106643132~106658258:- LUSC cis rs10875746 0.669 rs61941003 ENSG00000240399.1 RP1-228P16.1 -9.26 7.34e-19 1.2e-15 -0.46 -0.39 Longevity (90 years and older); chr12:48225842 chr12:48054813~48055591:- LUSC cis rs10875746 0.579 rs10875778 ENSG00000240399.1 RP1-228P16.1 -9.26 7.34e-19 1.2e-15 -0.46 -0.39 Longevity (90 years and older); chr12:48230872 chr12:48054813~48055591:- LUSC cis rs10875746 0.669 rs10875779 ENSG00000240399.1 RP1-228P16.1 -9.26 7.34e-19 1.2e-15 -0.46 -0.39 Longevity (90 years and older); chr12:48236086 chr12:48054813~48055591:- LUSC cis rs9487094 0.67 rs11754340 ENSG00000260273.1 RP11-425D10.10 9.26 7.37e-19 1.2e-15 0.46 0.39 Height; chr6:109584789 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs13199135 ENSG00000260273.1 RP11-425D10.10 9.26 7.37e-19 1.2e-15 0.46 0.39 Height; chr6:109588639 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs12193719 ENSG00000260273.1 RP11-425D10.10 9.26 7.37e-19 1.2e-15 0.46 0.39 Height; chr6:109589051 chr6:109382795~109383666:+ LUSC cis rs11098499 0.697 rs11941899 ENSG00000245958.5 RP11-33B1.1 -9.26 7.39e-19 1.2e-15 -0.41 -0.39 Corneal astigmatism; chr4:119461603 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs7681978 ENSG00000245958.5 RP11-33B1.1 -9.26 7.39e-19 1.2e-15 -0.41 -0.39 Corneal astigmatism; chr4:119462620 chr4:119454791~119552025:+ LUSC cis rs11098499 0.821 rs28665282 ENSG00000245958.5 RP11-33B1.1 -9.26 7.39e-19 1.2e-15 -0.41 -0.39 Corneal astigmatism; chr4:119463031 chr4:119454791~119552025:+ LUSC cis rs11098499 0.738 rs10026493 ENSG00000245958.5 RP11-33B1.1 -9.26 7.39e-19 1.2e-15 -0.41 -0.39 Corneal astigmatism; chr4:119463039 chr4:119454791~119552025:+ LUSC cis rs6964833 1 rs4717906 ENSG00000277053.3 GTF2IP1 -9.26 7.43e-19 1.21e-15 -0.57 -0.39 Menarche (age at onset); chr7:74671923 chr7:75185385~75237696:- LUSC cis rs9487094 0.67 rs2024850 ENSG00000260273.1 RP11-425D10.10 -9.26 7.48e-19 1.22e-15 -0.46 -0.39 Height; chr6:109497253 chr6:109382795~109383666:+ LUSC cis rs9322193 0.962 rs7818 ENSG00000216906.2 RP11-350J20.9 9.26 7.53e-19 1.23e-15 0.45 0.39 Lung cancer; chr6:149810956 chr6:149904243~149906418:+ LUSC cis rs2337406 0.866 rs4280141 ENSG00000274576.2 IGHV2-70 9.26 7.54e-19 1.23e-15 0.38 0.39 Alzheimer's disease (late onset); chr14:106780476 chr14:106770577~106771020:- LUSC cis rs6991838 0.584 rs6993876 ENSG00000200714.1 Y_RNA 9.25 7.66e-19 1.25e-15 0.48 0.39 Intelligence (multi-trait analysis); chr8:65601240 chr8:65592731~65592820:+ LUSC cis rs1707322 0.752 rs7541962 ENSG00000280836.1 AL355480.1 -9.25 7.73e-19 1.26e-15 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769445 chr1:45581219~45581321:- LUSC cis rs6452524 1 rs6887846 ENSG00000249664.1 CTD-2227C6.2 -9.25 7.75e-19 1.26e-15 -0.4 -0.39 Hypertension (SNP x SNP interaction); chr5:83140542 chr5:83012285~83013109:- LUSC cis rs1729407 1 rs1729407 ENSG00000254851.1 RP11-109L13.1 -9.25 7.86e-19 1.28e-15 -0.49 -0.39 Apolipoprotein A-IV levels; chr11:116806654 chr11:117135528~117138582:+ LUSC cis rs765787 0.53 rs2668737 ENSG00000259520.4 CTD-2651B20.3 9.25 7.87e-19 1.28e-15 0.48 0.39 Uric acid levels; chr15:45230601 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs1706764 ENSG00000259520.4 CTD-2651B20.3 9.25 7.87e-19 1.28e-15 0.48 0.39 Uric acid levels; chr15:45232058 chr15:45251580~45279251:- LUSC cis rs748404 0.631 rs2412781 ENSG00000249839.1 AC011330.5 9.25 7.93e-19 1.29e-15 0.52 0.39 Lung cancer; chr15:43375702 chr15:43663654~43684339:- LUSC cis rs748404 0.66 rs2602141 ENSG00000249839.1 AC011330.5 -9.25 7.94e-19 1.29e-15 -0.51 -0.39 Lung cancer; chr15:43432448 chr15:43663654~43684339:- LUSC cis rs4423214 0.879 rs1792264 ENSG00000254682.1 RP11-660L16.2 -9.25 8.01e-19 1.3e-15 -0.54 -0.39 Vitamin D levels; chr11:71439201 chr11:71448674~71452157:+ LUSC cis rs748404 0.69 rs1079309 ENSG00000249839.1 AC011330.5 -9.25 8.14e-19 1.32e-15 -0.52 -0.39 Lung cancer; chr15:43490966 chr15:43663654~43684339:- LUSC cis rs9322193 0.923 rs9322204 ENSG00000216906.2 RP11-350J20.9 9.25 8.15e-19 1.32e-15 0.47 0.39 Lung cancer; chr6:149636047 chr6:149904243~149906418:+ LUSC cis rs5760092 0.627 rs6519489 ENSG00000231271.1 AP000350.8 -9.25 8.21e-19 1.33e-15 -0.62 -0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23949918~23954042:+ LUSC cis rs11098499 0.866 rs12501602 ENSG00000245958.5 RP11-33B1.1 -9.24 8.24e-19 1.34e-15 -0.39 -0.39 Corneal astigmatism; chr4:119366780 chr4:119454791~119552025:+ LUSC cis rs1113500 0.836 rs1122158 ENSG00000226822.1 RP11-356N1.2 9.24 8.27e-19 1.34e-15 0.41 0.39 Growth-regulated protein alpha levels; chr1:108046046 chr1:108071482~108074519:+ LUSC cis rs9322193 0.923 rs9322208 ENSG00000216906.2 RP11-350J20.9 9.24 8.29e-19 1.34e-15 0.47 0.39 Lung cancer; chr6:149658547 chr6:149904243~149906418:+ LUSC cis rs9487094 0.67 rs1476388 ENSG00000260273.1 RP11-425D10.10 9.24 8.33e-19 1.35e-15 0.46 0.39 Height; chr6:109518783 chr6:109382795~109383666:+ LUSC cis rs8062405 0.72 rs9926245 ENSG00000259982.1 CDC37P1 9.24 8.38e-19 1.36e-15 0.48 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544385 chr16:28700294~28701540:- LUSC cis rs10129255 0.917 rs7142373 ENSG00000223648.3 IGHV3-64 9.24 8.41e-19 1.36e-15 0.37 0.39 Kawasaki disease; chr14:106708947 chr14:106643132~106658258:- LUSC cis rs11098499 0.697 rs4560394 ENSG00000245958.5 RP11-33B1.1 -9.24 8.46e-19 1.37e-15 -0.4 -0.39 Corneal astigmatism; chr4:119392280 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs9767105 ENSG00000216906.2 RP11-350J20.9 9.24 8.55e-19 1.38e-15 0.47 0.39 Lung cancer; chr6:149659591 chr6:149904243~149906418:+ LUSC cis rs9487094 0.67 rs12194061 ENSG00000260273.1 RP11-425D10.10 9.24 8.57e-19 1.39e-15 0.46 0.39 Height; chr6:109546439 chr6:109382795~109383666:+ LUSC cis rs6920372 0.731 rs2357124 ENSG00000260273.1 RP11-425D10.10 9.24 8.57e-19 1.39e-15 0.46 0.39 Height; chr6:109551060 chr6:109382795~109383666:+ LUSC cis rs10129255 0.784 rs7147210 ENSG00000223648.3 IGHV3-64 9.24 8.58e-19 1.39e-15 0.37 0.39 Kawasaki disease; chr14:106705271 chr14:106643132~106658258:- LUSC cis rs10129255 0.826 rs7150693 ENSG00000223648.3 IGHV3-64 9.24 8.58e-19 1.39e-15 0.37 0.39 Kawasaki disease; chr14:106705382 chr14:106643132~106658258:- LUSC cis rs10129255 0.869 rs7150549 ENSG00000223648.3 IGHV3-64 9.24 8.58e-19 1.39e-15 0.37 0.39 Kawasaki disease; chr14:106705441 chr14:106643132~106658258:- LUSC cis rs9322193 0.847 rs4870054 ENSG00000216906.2 RP11-350J20.9 9.24 8.66e-19 1.4e-15 0.48 0.39 Lung cancer; chr6:149848402 chr6:149904243~149906418:+ LUSC cis rs10875746 0.669 rs10875772 ENSG00000240399.1 RP1-228P16.1 -9.24 8.67e-19 1.4e-15 -0.47 -0.39 Longevity (90 years and older); chr12:48215770 chr12:48054813~48055591:- LUSC cis rs6903823 0.508 rs1778484 ENSG00000216901.1 AL022393.7 9.24 8.71e-19 1.41e-15 0.44 0.39 Pulmonary function; chr6:28273021 chr6:28176188~28176674:+ LUSC cis rs6921919 0.789 rs6912584 ENSG00000204709.4 LINC01556 9.24 8.73e-19 1.41e-15 0.58 0.39 Autism spectrum disorder or schizophrenia; chr6:28341813 chr6:28943877~28944537:+ LUSC cis rs1891275 0.515 rs4244930 ENSG00000228701.1 TNKS2-AS1 -9.24 8.74e-19 1.41e-15 -0.45 -0.39 Intelligence (multi-trait analysis); chr10:91707092 chr10:91782839~91798291:- LUSC cis rs9322193 0.607 rs4869755 ENSG00000216906.2 RP11-350J20.9 9.24 8.76e-19 1.42e-15 0.53 0.39 Lung cancer; chr6:149886347 chr6:149904243~149906418:+ LUSC cis rs9322193 0.639 rs4869756 ENSG00000216906.2 RP11-350J20.9 9.24 8.76e-19 1.42e-15 0.53 0.39 Lung cancer; chr6:149886360 chr6:149904243~149906418:+ LUSC cis rs9341808 0.587 rs3805859 ENSG00000272129.1 RP11-250B2.6 9.24 8.76e-19 1.42e-15 0.47 0.39 Sitting height ratio; chr6:80339229 chr6:80355424~80356859:+ LUSC cis rs11098499 0.954 rs2389802 ENSG00000245958.5 RP11-33B1.1 -9.23 8.94e-19 1.45e-15 -0.41 -0.39 Corneal astigmatism; chr4:119404577 chr4:119454791~119552025:+ LUSC cis rs6964833 0.935 rs13238996 ENSG00000277053.3 GTF2IP1 -9.23 9.21e-19 1.49e-15 -0.59 -0.39 Menarche (age at onset); chr7:74655318 chr7:75185385~75237696:- LUSC cis rs10875746 0.624 rs10875777 ENSG00000240399.1 RP1-228P16.1 -9.23 9.27e-19 1.5e-15 -0.45 -0.39 Longevity (90 years and older); chr12:48228288 chr12:48054813~48055591:- LUSC cis rs10875746 0.551 rs2054904 ENSG00000240399.1 RP1-228P16.1 -9.23 9.35e-19 1.51e-15 -0.46 -0.39 Longevity (90 years and older); chr12:48330571 chr12:48054813~48055591:- LUSC cis rs4889009 0.533 rs12596569 ENSG00000261390.4 RP11-345M22.2 9.23 9.46e-19 1.53e-15 0.47 0.39 Thyroid peroxidase antibody positivity; chr16:79701354 chr16:79715232~79770563:- LUSC cis rs1185460 0.967 rs1786690 ENSG00000271751.1 RP11-110I1.14 -9.22 9.65e-19 1.56e-15 -0.52 -0.39 Coronary artery disease; chr11:119071357 chr11:119065263~119065677:- LUSC cis rs9487094 0.67 rs34928881 ENSG00000260273.1 RP11-425D10.10 9.22 9.66e-19 1.56e-15 0.46 0.39 Height; chr6:109526846 chr6:109382795~109383666:+ LUSC cis rs1707322 0.752 rs6678444 ENSG00000280836.1 AL355480.1 -9.22 9.66e-19 1.56e-15 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764175 chr1:45581219~45581321:- LUSC cis rs6782228 1 rs12495411 ENSG00000242551.2 POU5F1P6 9.22 9.74e-19 1.57e-15 0.49 0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128676852 chr3:128674735~128677005:- LUSC cis rs10129255 0.834 rs10139893 ENSG00000223648.3 IGHV3-64 9.22 9.83e-19 1.58e-15 0.37 0.39 Kawasaki disease; chr14:106711377 chr14:106643132~106658258:- LUSC cis rs10740039 0.549 rs9414741 ENSG00000254271.1 RP11-131N11.4 -9.22 9.94e-19 1.6e-15 -0.54 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60738510 chr10:60734342~60741828:+ LUSC cis rs7397814 0.558 rs4764447 ENSG00000278635.1 CTD-2318O12.1 9.22 9.99e-19 1.61e-15 0.33 0.39 IgG glycosylation; chr12:9426513 chr12:9415641~9416718:+ LUSC cis rs10129255 0.957 rs6576233 ENSG00000223648.3 IGHV3-64 9.22 1e-18 1.62e-15 0.35 0.39 Kawasaki disease; chr14:106787239 chr14:106643132~106658258:- LUSC cis rs9322193 0.923 rs10782310 ENSG00000216906.2 RP11-350J20.9 9.22 1.01e-18 1.63e-15 0.47 0.39 Lung cancer; chr6:149622458 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs10782311 ENSG00000216906.2 RP11-350J20.9 9.22 1.01e-18 1.63e-15 0.47 0.39 Lung cancer; chr6:149622592 chr6:149904243~149906418:+ LUSC cis rs6538678 0.929 rs10745733 ENSG00000258343.1 RP11-536G4.2 -9.22 1.02e-18 1.64e-15 -0.52 -0.39 Lupus nephritis in systemic lupus erythematosus; chr12:95868728 chr12:95795345~95858839:- LUSC cis rs6782228 0.606 rs2811489 ENSG00000277250.1 Metazoa_SRP 9.22 1.02e-18 1.64e-15 0.44 0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128618528 chr3:128673681~128674021:- LUSC cis rs9487094 0.67 rs13203587 ENSG00000260273.1 RP11-425D10.10 9.22 1.03e-18 1.66e-15 0.46 0.39 Height; chr6:109499759 chr6:109382795~109383666:+ LUSC cis rs9487094 0.626 rs7773950 ENSG00000260273.1 RP11-425D10.10 9.22 1.03e-18 1.66e-15 0.46 0.39 Height; chr6:109494237 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs11153183 ENSG00000260273.1 RP11-425D10.10 9.22 1.03e-18 1.66e-15 0.46 0.39 Height; chr6:109496073 chr6:109382795~109383666:+ LUSC cis rs11098499 0.954 rs28572238 ENSG00000245958.5 RP11-33B1.1 -9.22 1.03e-18 1.66e-15 -0.4 -0.39 Corneal astigmatism; chr4:119395531 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs28714195 ENSG00000245958.5 RP11-33B1.1 -9.22 1.03e-18 1.66e-15 -0.4 -0.39 Corneal astigmatism; chr4:119395795 chr4:119454791~119552025:+ LUSC cis rs748404 0.631 rs7167882 ENSG00000249839.1 AC011330.5 -9.22 1.04e-18 1.66e-15 -0.52 -0.39 Lung cancer; chr15:43386465 chr15:43663654~43684339:- LUSC cis rs6538678 0.895 rs4762637 ENSG00000258343.1 RP11-536G4.2 -9.22 1.04e-18 1.67e-15 -0.55 -0.39 Lupus nephritis in systemic lupus erythematosus; chr12:95888877 chr12:95795345~95858839:- LUSC cis rs10129255 0.536 rs10142951 ENSG00000211972.2 IGHV3-66 9.22 1.04e-18 1.68e-15 0.26 0.39 Kawasaki disease; chr14:106782337 chr14:106675017~106675544:- LUSC cis rs11098499 0.738 rs28687057 ENSG00000245958.5 RP11-33B1.1 -9.21 1.05e-18 1.68e-15 -0.39 -0.39 Corneal astigmatism; chr4:119359657 chr4:119454791~119552025:+ LUSC cis rs11098499 0.774 rs73842616 ENSG00000245958.5 RP11-33B1.1 -9.21 1.05e-18 1.68e-15 -0.39 -0.39 Corneal astigmatism; chr4:119369528 chr4:119454791~119552025:+ LUSC cis rs11098499 0.645 rs72676059 ENSG00000245958.5 RP11-33B1.1 -9.21 1.05e-18 1.68e-15 -0.39 -0.39 Corneal astigmatism; chr4:119369673 chr4:119454791~119552025:+ LUSC cis rs11098499 0.569 rs55845118 ENSG00000245958.5 RP11-33B1.1 -9.21 1.05e-18 1.68e-15 -0.39 -0.39 Corneal astigmatism; chr4:119369758 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs7677068 ENSG00000245958.5 RP11-33B1.1 -9.21 1.05e-18 1.68e-15 -0.39 -0.39 Corneal astigmatism; chr4:119370549 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs9991221 ENSG00000245958.5 RP11-33B1.1 -9.21 1.05e-18 1.68e-15 -0.39 -0.39 Corneal astigmatism; chr4:119370952 chr4:119454791~119552025:+ LUSC cis rs11098499 1 rs6837898 ENSG00000245958.5 RP11-33B1.1 -9.21 1.06e-18 1.7e-15 -0.4 -0.39 Corneal astigmatism; chr4:119257999 chr4:119454791~119552025:+ LUSC cis rs6921919 0.789 rs11970439 ENSG00000204709.4 LINC01556 9.21 1.06e-18 1.71e-15 0.57 0.39 Autism spectrum disorder or schizophrenia; chr6:28335687 chr6:28943877~28944537:+ LUSC cis rs12439619 1 rs12439619 ENSG00000278603.1 RP13-608F4.5 9.21 1.07e-18 1.71e-15 0.49 0.39 Intelligence (multi-trait analysis); chr15:82254605 chr15:82472203~82472426:+ LUSC cis rs1976403 0.659 rs10799701 ENSG00000227001.3 NBPF2P 9.21 1.08e-18 1.73e-15 0.46 0.39 Liver enzyme levels (alkaline phosphatase); chr1:21494497 chr1:21424625~21427967:- LUSC cis rs8091660 0.893 rs1567656 ENSG00000278983.1 RP11-426J5.3 -9.21 1.09e-18 1.75e-15 -0.51 -0.39 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48568420 chr18:48564795~48568342:+ LUSC cis rs4423214 0.879 rs1792281 ENSG00000254682.1 RP11-660L16.2 -9.21 1.1e-18 1.76e-15 -0.54 -0.39 Vitamin D levels; chr11:71424450 chr11:71448674~71452157:+ LUSC cis rs748404 0.66 rs2467738 ENSG00000249839.1 AC011330.5 -9.21 1.1e-18 1.77e-15 -0.51 -0.39 Lung cancer; chr15:43447738 chr15:43663654~43684339:- LUSC cis rs6991838 0.584 rs7836349 ENSG00000200714.1 Y_RNA -9.21 1.1e-18 1.77e-15 -0.48 -0.39 Intelligence (multi-trait analysis); chr8:65591328 chr8:65592731~65592820:+ LUSC cis rs9487094 0.626 rs10457192 ENSG00000260273.1 RP11-425D10.10 9.21 1.1e-18 1.77e-15 0.45 0.39 Height; chr6:109507271 chr6:109382795~109383666:+ LUSC cis rs10256972 0.721 rs4720249 ENSG00000229043.2 AC091729.9 -9.21 1.11e-18 1.78e-15 -0.46 -0.39 Endometriosis;Longevity; chr7:1032927 chr7:1160374~1165267:+ LUSC cis rs8072100 0.84 rs4968319 ENSG00000228782.6 CTD-2026D20.3 9.21 1.11e-18 1.78e-15 0.36 0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47387601 chr17:47450568~47492492:- LUSC cis rs4728142 0.604 rs10239340 ENSG00000275106.1 RP11-309L24.10 -9.21 1.12e-18 1.8e-15 -0.5 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129028456 chr7:128952527~128953316:- LUSC cis rs9487094 0.666 rs7748669 ENSG00000260273.1 RP11-425D10.10 9.21 1.12e-18 1.8e-15 0.46 0.39 Height; chr6:109424139 chr6:109382795~109383666:+ LUSC cis rs10129255 0.785 rs10150044 ENSG00000223648.3 IGHV3-64 9.21 1.12e-18 1.8e-15 0.36 0.39 Kawasaki disease; chr14:106775695 chr14:106643132~106658258:- LUSC cis rs11098499 0.954 rs10034623 ENSG00000245958.5 RP11-33B1.1 -9.21 1.12e-18 1.8e-15 -0.4 -0.39 Corneal astigmatism; chr4:119476674 chr4:119454791~119552025:+ LUSC cis rs4423214 0.879 rs1630498 ENSG00000254682.1 RP11-660L16.2 -9.2 1.13e-18 1.81e-15 -0.53 -0.39 Vitamin D levels; chr11:71439739 chr11:71448674~71452157:+ LUSC cis rs11098499 0.865 rs28634456 ENSG00000245958.5 RP11-33B1.1 -9.2 1.13e-18 1.81e-15 -0.41 -0.39 Corneal astigmatism; chr4:119454623 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs78332141 ENSG00000245958.5 RP11-33B1.1 -9.2 1.13e-18 1.81e-15 -0.41 -0.39 Corneal astigmatism; chr4:119454627 chr4:119454791~119552025:+ LUSC cis rs10129255 0.5 rs6576225 ENSG00000211972.2 IGHV3-66 9.2 1.13e-18 1.82e-15 0.26 0.39 Kawasaki disease; chr14:106778120 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs6576226 ENSG00000211972.2 IGHV3-66 9.2 1.13e-18 1.82e-15 0.26 0.39 Kawasaki disease; chr14:106778135 chr14:106675017~106675544:- LUSC cis rs11098499 0.954 rs11098526 ENSG00000245958.5 RP11-33B1.1 -9.2 1.14e-18 1.82e-15 -0.41 -0.39 Corneal astigmatism; chr4:119469204 chr4:119454791~119552025:+ LUSC cis rs62388641 0.802 rs13202504 ENSG00000272279.1 RP11-157J24.2 9.2 1.15e-18 1.84e-15 0.71 0.39 Daytime sleep phenotypes; chr6:1537640 chr6:1528364~1528911:- LUSC cis rs1707322 0.964 rs7512395 ENSG00000280836.1 AL355480.1 -9.2 1.16e-18 1.85e-15 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45895505 chr1:45581219~45581321:- LUSC cis rs11098499 1 rs11098499 ENSG00000245958.5 RP11-33B1.1 -9.2 1.17e-18 1.87e-15 -0.4 -0.39 Corneal astigmatism; chr4:119266456 chr4:119454791~119552025:+ LUSC cis rs3931020 0.657 rs7522428 ENSG00000272864.1 RP11-17E13.2 -9.2 1.17e-18 1.88e-15 -0.53 -0.39 Resistin levels; chr1:74712676 chr1:74698769~74699333:- LUSC cis rs11098499 0.908 rs2017057 ENSG00000245958.5 RP11-33B1.1 -9.2 1.17e-18 1.88e-15 -0.4 -0.39 Corneal astigmatism; chr4:119336556 chr4:119454791~119552025:+ LUSC cis rs4423214 0.625 rs78685409 ENSG00000254682.1 RP11-660L16.2 -9.2 1.18e-18 1.88e-15 -0.54 -0.39 Vitamin D levels; chr11:71426337 chr11:71448674~71452157:+ LUSC cis rs7189233 0.531 rs9929873 ENSG00000279344.1 RP11-44F14.7 9.2 1.2e-18 1.92e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53456764 chr16:53478957~53481550:- LUSC cis rs11098499 0.697 rs35280960 ENSG00000245958.5 RP11-33B1.1 -9.2 1.21e-18 1.94e-15 -0.39 -0.39 Corneal astigmatism; chr4:119335904 chr4:119454791~119552025:+ LUSC cis rs10875746 0.587 rs9788082 ENSG00000240399.1 RP1-228P16.1 -9.19 1.22e-18 1.96e-15 -0.46 -0.39 Longevity (90 years and older); chr12:48358273 chr12:48054813~48055591:- LUSC cis rs11098499 0.754 rs10213554 ENSG00000245958.5 RP11-33B1.1 9.19 1.22e-18 1.96e-15 0.39 0.39 Corneal astigmatism; chr4:119339630 chr4:119454791~119552025:+ LUSC cis rs6921919 0.525 rs16894095 ENSG00000216901.1 AL022393.7 9.19 1.23e-18 1.96e-15 0.44 0.39 Autism spectrum disorder or schizophrenia; chr6:28422453 chr6:28176188~28176674:+ LUSC cis rs9322193 0.923 rs9689716 ENSG00000216906.2 RP11-350J20.9 9.19 1.23e-18 1.96e-15 0.47 0.39 Lung cancer; chr6:149655662 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9322207 ENSG00000216906.2 RP11-350J20.9 9.19 1.23e-18 1.96e-15 0.47 0.39 Lung cancer; chr6:149657185 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9968911 ENSG00000216906.2 RP11-350J20.9 9.19 1.23e-18 1.96e-15 0.47 0.39 Lung cancer; chr6:149657419 chr6:149904243~149906418:+ LUSC cis rs6452524 1 rs6452520 ENSG00000249664.1 CTD-2227C6.2 9.19 1.23e-18 1.97e-15 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83133452 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs6452521 ENSG00000249664.1 CTD-2227C6.2 9.19 1.23e-18 1.97e-15 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83133453 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs6452522 ENSG00000249664.1 CTD-2227C6.2 9.19 1.23e-18 1.97e-15 0.41 0.39 Hypertension (SNP x SNP interaction); chr5:83133471 chr5:83012285~83013109:- LUSC cis rs10129255 0.957 rs61997760 ENSG00000223648.3 IGHV3-64 9.19 1.24e-18 1.98e-15 0.37 0.39 Kawasaki disease; chr14:106716993 chr14:106643132~106658258:- LUSC cis rs1707322 0.896 rs809774 ENSG00000280836.1 AL355480.1 9.19 1.24e-18 1.98e-15 0.46 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46094572 chr1:45581219~45581321:- LUSC cis rs6903823 0.508 rs1150726 ENSG00000216901.1 AL022393.7 9.19 1.26e-18 2.01e-15 0.43 0.39 Pulmonary function; chr6:28275265 chr6:28176188~28176674:+ LUSC cis rs9322193 0.962 rs3763162 ENSG00000216906.2 RP11-350J20.9 -9.19 1.26e-18 2.01e-15 -0.47 -0.39 Lung cancer; chr6:149819674 chr6:149904243~149906418:+ LUSC cis rs748404 0.66 rs690367 ENSG00000249839.1 AC011330.5 9.19 1.26e-18 2.01e-15 0.52 0.39 Lung cancer; chr15:43456106 chr15:43663654~43684339:- LUSC cis rs6538678 0.926 rs10745734 ENSG00000258343.1 RP11-536G4.2 -9.19 1.27e-18 2.03e-15 -0.52 -0.39 Lupus nephritis in systemic lupus erythematosus; chr12:95868936 chr12:95795345~95858839:- LUSC cis rs11098499 0.775 rs67281037 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119360002 chr4:119454791~119552025:+ LUSC cis rs10028773 0.506 rs12374346 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Educational attainment; chr4:119360550 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs12374244 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119360817 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs12374352 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119360822 chr4:119454791~119552025:+ LUSC cis rs11098499 0.775 rs10021601 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119361408 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs6857892 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119361541 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs28581362 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119362393 chr4:119454791~119552025:+ LUSC cis rs11098499 0.82 rs12503082 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119363162 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs12499602 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119363232 chr4:119454791~119552025:+ LUSC cis rs11098499 0.774 rs11098505 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119363472 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs13105020 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119364533 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs6824111 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119364813 chr4:119454791~119552025:+ LUSC cis rs11098499 0.779 rs10857066 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119365441 chr4:119454791~119552025:+ LUSC cis rs11098499 0.775 rs10029303 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119365600 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs9995136 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119365690 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs13125526 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119366864 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs12513310 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119366884 chr4:119454791~119552025:+ LUSC cis rs11098499 0.866 rs12510451 ENSG00000245958.5 RP11-33B1.1 -9.19 1.28e-18 2.04e-15 -0.39 -0.39 Corneal astigmatism; chr4:119367988 chr4:119454791~119552025:+ LUSC cis rs6991838 0.798 rs6994889 ENSG00000272010.1 CTD-3025N20.3 9.19 1.28e-18 2.04e-15 0.43 0.39 Intelligence (multi-trait analysis); chr8:65562547 chr8:65591850~65592472:- LUSC cis rs2337406 0.866 rs78462736 ENSG00000274576.2 IGHV2-70 -9.19 1.29e-18 2.05e-15 -0.4 -0.39 Alzheimer's disease (late onset); chr14:106779942 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs8016203 ENSG00000274576.2 IGHV2-70 -9.19 1.29e-18 2.05e-15 -0.4 -0.39 Alzheimer's disease (late onset); chr14:106780575 chr14:106770577~106771020:- LUSC cis rs1707322 0.827 rs10890347 ENSG00000280836.1 AL355480.1 9.19 1.29e-18 2.05e-15 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45776660 chr1:45581219~45581321:- LUSC cis rs12439619 0.53 rs7162177 ENSG00000255769.6 GOLGA2P10 -9.19 1.3e-18 2.07e-15 -0.47 -0.39 Intelligence (multi-trait analysis); chr15:82181728 chr15:82472993~82513950:- LUSC cis rs1113500 0.966 rs11185249 ENSG00000226822.1 RP11-356N1.2 9.19 1.31e-18 2.08e-15 0.4 0.39 Growth-regulated protein alpha levels; chr1:108069024 chr1:108071482~108074519:+ LUSC cis rs3931020 0.688 rs455032 ENSG00000272864.1 RP11-17E13.2 9.19 1.31e-18 2.09e-15 0.52 0.39 Resistin levels; chr1:74730804 chr1:74698769~74699333:- LUSC cis rs10129255 0.5 rs59939897 ENSG00000211972.2 IGHV3-66 9.18 1.32e-18 2.1e-15 0.26 0.39 Kawasaki disease; chr14:106783414 chr14:106675017~106675544:- LUSC cis rs9487094 0.67 rs2024852 ENSG00000260273.1 RP11-425D10.10 9.18 1.32e-18 2.11e-15 0.46 0.39 Height; chr6:109498586 chr6:109382795~109383666:+ LUSC cis rs2337406 0.81 rs7161739 ENSG00000274576.2 IGHV2-70 -9.18 1.33e-18 2.12e-15 -0.4 -0.39 Alzheimer's disease (late onset); chr14:106776118 chr14:106770577~106771020:- LUSC cis rs10875746 0.669 rs10467101 ENSG00000240399.1 RP1-228P16.1 -9.18 1.33e-18 2.12e-15 -0.46 -0.39 Longevity (90 years and older); chr12:48213954 chr12:48054813~48055591:- LUSC cis rs6991838 0.8 rs28547533 ENSG00000272010.1 CTD-3025N20.3 9.18 1.34e-18 2.13e-15 0.43 0.39 Intelligence (multi-trait analysis); chr8:65559318 chr8:65591850~65592472:- LUSC cis rs6991838 0.8 rs28626262 ENSG00000272010.1 CTD-3025N20.3 9.18 1.34e-18 2.13e-15 0.43 0.39 Intelligence (multi-trait analysis); chr8:65559335 chr8:65591850~65592472:- LUSC cis rs6991838 0.8 rs28709439 ENSG00000272010.1 CTD-3025N20.3 9.18 1.34e-18 2.13e-15 0.43 0.39 Intelligence (multi-trait analysis); chr8:65559337 chr8:65591850~65592472:- LUSC cis rs2337406 0.866 rs2301536 ENSG00000274576.2 IGHV2-70 -9.18 1.36e-18 2.15e-15 -0.41 -0.39 Alzheimer's disease (late onset); chr14:106790636 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs7144369 ENSG00000274576.2 IGHV2-70 -9.18 1.36e-18 2.15e-15 -0.41 -0.39 Alzheimer's disease (late onset); chr14:106793065 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs78525520 ENSG00000274576.2 IGHV2-70 -9.18 1.36e-18 2.15e-15 -0.41 -0.39 Alzheimer's disease (late onset); chr14:106795643 chr14:106770577~106771020:- LUSC cis rs10129255 0.5 rs7161740 ENSG00000211972.2 IGHV3-66 9.18 1.36e-18 2.17e-15 0.26 0.39 Kawasaki disease; chr14:106776119 chr14:106675017~106675544:- LUSC cis rs10129255 0.556 rs6576222 ENSG00000211972.2 IGHV3-66 9.18 1.36e-18 2.17e-15 0.26 0.39 Kawasaki disease; chr14:106776442 chr14:106675017~106675544:- LUSC cis rs10129255 0.536 rs6576223 ENSG00000211972.2 IGHV3-66 9.18 1.36e-18 2.17e-15 0.26 0.39 Kawasaki disease; chr14:106776448 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs34326748 ENSG00000211972.2 IGHV3-66 9.18 1.38e-18 2.19e-15 0.26 0.39 Kawasaki disease; chr14:106782523 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs10143385 ENSG00000211972.2 IGHV3-66 9.18 1.38e-18 2.19e-15 0.26 0.39 Kawasaki disease; chr14:106782559 chr14:106675017~106675544:- LUSC cis rs1185460 0.934 rs1006195 ENSG00000271751.1 RP11-110I1.14 9.18 1.39e-18 2.2e-15 0.5 0.39 Coronary artery disease; chr11:119088159 chr11:119065263~119065677:- LUSC cis rs10129255 0.912 rs61996059 ENSG00000223648.3 IGHV3-64 9.18 1.4e-18 2.22e-15 0.37 0.39 Kawasaki disease; chr14:106716897 chr14:106643132~106658258:- LUSC cis rs9322193 0.923 rs9322196 ENSG00000216906.2 RP11-350J20.9 9.18 1.41e-18 2.24e-15 0.46 0.39 Lung cancer; chr6:149619645 chr6:149904243~149906418:+ LUSC cis rs10129255 0.518 rs8009594 ENSG00000211972.2 IGHV3-66 9.17 1.44e-18 2.28e-15 0.26 0.39 Kawasaki disease; chr14:106777494 chr14:106675017~106675544:- LUSC cis rs10129255 0.518 rs8009612 ENSG00000211972.2 IGHV3-66 9.17 1.44e-18 2.28e-15 0.26 0.39 Kawasaki disease; chr14:106777510 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs6576230 ENSG00000211972.2 IGHV3-66 9.17 1.45e-18 2.3e-15 0.26 0.39 Kawasaki disease; chr14:106778539 chr14:106675017~106675544:- LUSC cis rs3931020 0.688 rs968358 ENSG00000272864.1 RP11-17E13.2 -9.17 1.45e-18 2.3e-15 -0.53 -0.39 Resistin levels; chr1:74728305 chr1:74698769~74699333:- LUSC cis rs6964833 1 rs4717907 ENSG00000277053.3 GTF2IP1 -9.17 1.46e-18 2.31e-15 -0.56 -0.39 Menarche (age at onset); chr7:74672169 chr7:75185385~75237696:- LUSC cis rs1707322 1 rs785480 ENSG00000280836.1 AL355480.1 -9.17 1.48e-18 2.34e-15 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46026492 chr1:45581219~45581321:- LUSC cis rs3931020 0.688 rs277374 ENSG00000272864.1 RP11-17E13.2 9.17 1.48e-18 2.34e-15 0.53 0.39 Resistin levels; chr1:74734802 chr1:74698769~74699333:- LUSC cis rs2117029 0.553 rs11168903 ENSG00000258017.1 RP11-386G11.10 -9.17 1.48e-18 2.35e-15 -0.5 -0.39 Intelligence (multi-trait analysis); chr12:49174883 chr12:49127782~49147869:+ LUSC cis rs11098499 0.863 rs6534139 ENSG00000245958.5 RP11-33B1.1 9.17 1.49e-18 2.36e-15 0.41 0.39 Corneal astigmatism; chr4:119528301 chr4:119454791~119552025:+ LUSC cis rs1150668 0.699 rs2394049 ENSG00000204709.4 LINC01556 9.17 1.5e-18 2.37e-15 0.46 0.39 Pubertal anthropometrics; chr6:28271903 chr6:28943877~28944537:+ LUSC cis rs10875746 0.625 rs2898065 ENSG00000240399.1 RP1-228P16.1 -9.17 1.5e-18 2.37e-15 -0.45 -0.39 Longevity (90 years and older); chr12:48250836 chr12:48054813~48055591:- LUSC cis rs10875746 0.669 rs11168496 ENSG00000240399.1 RP1-228P16.1 -9.17 1.5e-18 2.37e-15 -0.45 -0.39 Longevity (90 years and older); chr12:48257072 chr12:48054813~48055591:- LUSC cis rs526231 0.511 rs158402 ENSG00000175749.11 EIF3KP1 9.17 1.5e-18 2.38e-15 0.48 0.39 Primary biliary cholangitis; chr5:103079821 chr5:103032376~103033031:+ LUSC cis rs8062405 0.824 rs7191618 ENSG00000259982.1 CDC37P1 9.17 1.5e-18 2.38e-15 0.48 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554346 chr16:28700294~28701540:- LUSC cis rs10740039 0.583 rs1904399 ENSG00000254271.1 RP11-131N11.4 -9.17 1.51e-18 2.39e-15 -0.53 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739240 chr10:60734342~60741828:+ LUSC cis rs10740039 0.583 rs1904400 ENSG00000254271.1 RP11-131N11.4 -9.17 1.51e-18 2.39e-15 -0.53 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739361 chr10:60734342~60741828:+ LUSC cis rs10740039 0.515 rs9414742 ENSG00000254271.1 RP11-131N11.4 -9.17 1.51e-18 2.39e-15 -0.53 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739769 chr10:60734342~60741828:+ LUSC cis rs10740039 0.583 rs9415609 ENSG00000254271.1 RP11-131N11.4 -9.17 1.51e-18 2.39e-15 -0.53 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739832 chr10:60734342~60741828:+ LUSC cis rs10740039 0.583 rs4948263 ENSG00000254271.1 RP11-131N11.4 -9.17 1.51e-18 2.39e-15 -0.53 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740132 chr10:60734342~60741828:+ LUSC cis rs10740039 0.583 rs4948264 ENSG00000254271.1 RP11-131N11.4 -9.17 1.51e-18 2.39e-15 -0.53 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740484 chr10:60734342~60741828:+ LUSC cis rs10740039 0.583 rs4948265 ENSG00000254271.1 RP11-131N11.4 -9.17 1.51e-18 2.39e-15 -0.53 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740495 chr10:60734342~60741828:+ LUSC cis rs10740039 0.583 rs7917700 ENSG00000254271.1 RP11-131N11.4 -9.17 1.51e-18 2.39e-15 -0.53 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740596 chr10:60734342~60741828:+ LUSC cis rs11098499 0.821 rs10032151 ENSG00000245958.5 RP11-33B1.1 -9.17 1.51e-18 2.39e-15 -0.4 -0.39 Corneal astigmatism; chr4:119470473 chr4:119454791~119552025:+ LUSC cis rs11098499 0.865 rs10032158 ENSG00000245958.5 RP11-33B1.1 -9.17 1.51e-18 2.39e-15 -0.4 -0.39 Corneal astigmatism; chr4:119470477 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs6838814 ENSG00000245958.5 RP11-33B1.1 -9.17 1.51e-18 2.39e-15 -0.4 -0.39 Corneal astigmatism; chr4:119471288 chr4:119454791~119552025:+ LUSC cis rs12130219 0.5 rs4845737 ENSG00000237975.5 FLG-AS1 -9.17 1.52e-18 2.4e-15 -0.39 -0.39 Inflammatory skin disease; chr1:152205063 chr1:152168125~152445456:+ LUSC cis rs3096299 0.967 rs2965935 ENSG00000274627.1 RP11-104N10.2 -9.17 1.53e-18 2.42e-15 -0.34 -0.39 Multiple myeloma (IgH translocation); chr16:89414866 chr16:89516797~89522217:+ LUSC cis rs11098499 0.863 rs1010740 ENSG00000245958.5 RP11-33B1.1 9.16 1.56e-18 2.47e-15 0.39 0.39 Corneal astigmatism; chr4:119542254 chr4:119454791~119552025:+ LUSC cis rs10129255 0.957 rs8005468 ENSG00000223648.3 IGHV3-64 9.16 1.57e-18 2.49e-15 0.35 0.39 Kawasaki disease; chr14:106686431 chr14:106643132~106658258:- LUSC cis rs1150668 0.699 rs1531681 ENSG00000204709.4 LINC01556 9.16 1.57e-18 2.49e-15 0.46 0.39 Pubertal anthropometrics; chr6:28259100 chr6:28943877~28944537:+ LUSC cis rs2337406 0.866 rs7140974 ENSG00000274576.2 IGHV2-70 -9.16 1.58e-18 2.49e-15 -0.41 -0.39 Alzheimer's disease (late onset); chr14:106795976 chr14:106770577~106771020:- LUSC cis rs1707322 0.964 rs785516 ENSG00000280836.1 AL355480.1 9.16 1.58e-18 2.5e-15 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46099086 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs785517 ENSG00000280836.1 AL355480.1 9.16 1.58e-18 2.5e-15 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46101863 chr1:45581219~45581321:- LUSC cis rs4728142 0.604 rs7783384 ENSG00000275106.1 RP11-309L24.10 -9.16 1.61e-18 2.53e-15 -0.51 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129041243 chr7:128952527~128953316:- LUSC cis rs3931020 0.688 rs1051122 ENSG00000272864.1 RP11-17E13.2 -9.16 1.62e-18 2.56e-15 -0.53 -0.39 Resistin levels; chr1:74724768 chr1:74698769~74699333:- LUSC cis rs4728142 0.584 rs6965542 ENSG00000275106.1 RP11-309L24.10 -9.16 1.63e-18 2.57e-15 -0.5 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129015864 chr7:128952527~128953316:- LUSC cis rs1150668 0.835 rs203869 ENSG00000204709.4 LINC01556 9.16 1.63e-18 2.57e-15 0.47 0.39 Pubertal anthropometrics; chr6:28073041 chr6:28943877~28944537:+ LUSC cis rs10129255 0.646 rs55995061 ENSG00000274576.2 IGHV2-70 -9.16 1.64e-18 2.58e-15 -0.41 -0.39 Kawasaki disease; chr14:106799309 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs76871148 ENSG00000274576.2 IGHV2-70 -9.16 1.64e-18 2.58e-15 -0.41 -0.39 Alzheimer's disease (late onset); chr14:106799722 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs61521632 ENSG00000274576.2 IGHV2-70 -9.16 1.64e-18 2.58e-15 -0.41 -0.39 Alzheimer's disease (late onset); chr14:106801091 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs7153964 ENSG00000274576.2 IGHV2-70 -9.16 1.64e-18 2.58e-15 -0.41 -0.39 Alzheimer's disease (late onset); chr14:106790480 chr14:106770577~106771020:- LUSC cis rs4706831 0.663 rs1984242 ENSG00000272129.1 RP11-250B2.6 9.16 1.64e-18 2.59e-15 0.47 0.39 Joint mobility (Beighton score); chr6:80341528 chr6:80355424~80356859:+ LUSC cis rs6991838 0.584 rs7823840 ENSG00000200714.1 Y_RNA -9.16 1.64e-18 2.59e-15 -0.48 -0.39 Intelligence (multi-trait analysis); chr8:65606766 chr8:65592731~65592820:+ LUSC cis rs11098499 0.909 rs73842633 ENSG00000245958.5 RP11-33B1.1 -9.16 1.64e-18 2.59e-15 -0.41 -0.39 Corneal astigmatism; chr4:119454309 chr4:119454791~119552025:+ LUSC cis rs1185460 1 rs7127212 ENSG00000271751.1 RP11-110I1.14 9.16 1.65e-18 2.6e-15 0.5 0.39 Coronary artery disease; chr11:119082492 chr11:119065263~119065677:- LUSC cis rs6920372 0.748 rs12190372 ENSG00000260273.1 RP11-425D10.10 9.16 1.65e-18 2.61e-15 0.46 0.39 Height; chr6:109763331 chr6:109382795~109383666:+ LUSC cis rs9341808 0.586 rs3805869 ENSG00000272129.1 RP11-250B2.6 9.16 1.66e-18 2.61e-15 0.47 0.39 Sitting height ratio; chr6:80336200 chr6:80355424~80356859:+ LUSC cis rs6921919 0.848 rs6903652 ENSG00000216901.1 AL022393.7 9.16 1.66e-18 2.62e-15 0.52 0.39 Autism spectrum disorder or schizophrenia; chr6:28354343 chr6:28176188~28176674:+ LUSC cis rs992157 0.798 rs7557709 ENSG00000261338.2 RP11-378A13.1 9.16 1.66e-18 2.62e-15 0.4 0.39 Colorectal cancer; chr2:218302806 chr2:218255319~218257366:+ LUSC cis rs1707322 1 rs785484 ENSG00000280836.1 AL355480.1 9.15 1.67e-18 2.64e-15 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46108343 chr1:45581219~45581321:- LUSC cis rs10129255 0.957 rs2007467 ENSG00000223648.3 IGHV3-64 -9.15 1.68e-18 2.65e-15 -0.36 -0.39 Kawasaki disease; chr14:106771605 chr14:106643132~106658258:- LUSC cis rs992157 0.835 rs6707559 ENSG00000261338.2 RP11-378A13.1 9.15 1.68e-18 2.65e-15 0.4 0.39 Colorectal cancer; chr2:218278050 chr2:218255319~218257366:+ LUSC cis rs9487094 0.67 rs12192268 ENSG00000260273.1 RP11-425D10.10 9.15 1.7e-18 2.68e-15 0.47 0.39 Height; chr6:109690255 chr6:109382795~109383666:+ LUSC cis rs748404 0.586 rs2584700 ENSG00000249839.1 AC011330.5 -9.15 1.72e-18 2.7e-15 -0.52 -0.39 Lung cancer; chr15:43393134 chr15:43663654~43684339:- LUSC cis rs10129255 0.5 rs2105989 ENSG00000211972.2 IGHV3-66 9.15 1.72e-18 2.71e-15 0.25 0.39 Kawasaki disease; chr14:106682199 chr14:106675017~106675544:- LUSC cis rs10129255 0.957 rs8009638 ENSG00000223648.3 IGHV3-64 9.15 1.72e-18 2.71e-15 0.36 0.39 Kawasaki disease; chr14:106777570 chr14:106643132~106658258:- LUSC cis rs11098499 0.908 rs9995234 ENSG00000245958.5 RP11-33B1.1 -9.15 1.73e-18 2.73e-15 -0.42 -0.39 Corneal astigmatism; chr4:119400672 chr4:119454791~119552025:+ LUSC cis rs10129255 0.556 rs8010005 ENSG00000211972.2 IGHV3-66 9.15 1.75e-18 2.76e-15 0.26 0.39 Kawasaki disease; chr14:106777987 chr14:106675017~106675544:- LUSC cis rs10129255 0.556 rs6576224 ENSG00000211972.2 IGHV3-66 9.15 1.75e-18 2.76e-15 0.26 0.39 Kawasaki disease; chr14:106777997 chr14:106675017~106675544:- LUSC cis rs10129255 0.518 rs8010020 ENSG00000211972.2 IGHV3-66 9.15 1.75e-18 2.76e-15 0.26 0.39 Kawasaki disease; chr14:106778016 chr14:106675017~106675544:- LUSC cis rs9322193 0.961 rs9767713 ENSG00000216906.2 RP11-350J20.9 9.15 1.76e-18 2.76e-15 0.47 0.39 Lung cancer; chr6:149588241 chr6:149904243~149906418:+ LUSC cis rs4728142 0.564 rs11767711 ENSG00000275106.1 RP11-309L24.10 -9.15 1.77e-18 2.78e-15 -0.5 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129011778 chr7:128952527~128953316:- LUSC cis rs7189233 0.531 rs8062535 ENSG00000279344.1 RP11-44F14.7 9.15 1.77e-18 2.78e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53478576 chr16:53478957~53481550:- LUSC cis rs992157 0.798 rs2382817 ENSG00000261338.2 RP11-378A13.1 9.15 1.78e-18 2.8e-15 0.39 0.39 Colorectal cancer; chr2:218286495 chr2:218255319~218257366:+ LUSC cis rs4423214 0.879 rs1790353 ENSG00000254682.1 RP11-660L16.2 -9.15 1.79e-18 2.82e-15 -0.54 -0.39 Vitamin D levels; chr11:71425684 chr11:71448674~71452157:+ LUSC cis rs4423214 0.879 rs1792277 ENSG00000254682.1 RP11-660L16.2 -9.15 1.79e-18 2.82e-15 -0.54 -0.39 Vitamin D levels; chr11:71427872 chr11:71448674~71452157:+ LUSC cis rs10740039 0.548 rs9415607 ENSG00000254271.1 RP11-131N11.4 -9.14 1.82e-18 2.86e-15 -0.54 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60737616 chr10:60734342~60741828:+ LUSC cis rs853679 0.517 rs9393884 ENSG00000219392.1 RP1-265C24.5 -9.14 1.82e-18 2.87e-15 -0.54 -0.39 Depression; chr6:28079011 chr6:28115628~28116551:+ LUSC cis rs10129255 0.957 rs8009073 ENSG00000211970.3 IGHV4-61 -9.14 1.84e-18 2.89e-15 -0.28 -0.39 Kawasaki disease; chr14:106777278 chr14:106639119~106639657:- LUSC cis rs3931020 0.657 rs10890142 ENSG00000272864.1 RP11-17E13.2 -9.14 1.85e-18 2.9e-15 -0.53 -0.39 Resistin levels; chr1:74713445 chr1:74698769~74699333:- LUSC cis rs3931020 0.688 rs525487 ENSG00000272864.1 RP11-17E13.2 9.14 1.88e-18 2.94e-15 0.53 0.39 Resistin levels; chr1:74751736 chr1:74698769~74699333:- LUSC cis rs748404 0.631 rs1133395 ENSG00000249839.1 AC011330.5 -9.14 1.88e-18 2.94e-15 -0.53 -0.39 Lung cancer; chr15:43358186 chr15:43663654~43684339:- LUSC cis rs4774565 0.762 rs17431095 ENSG00000244879.4 GABPB1-AS1 -9.14 1.88e-18 2.95e-15 -0.35 -0.39 Breast cancer; chr15:50369252 chr15:50354959~50372202:+ LUSC cis rs10256972 0.758 rs11979275 ENSG00000229043.2 AC091729.9 -9.14 1.88e-18 2.96e-15 -0.45 -0.39 Endometriosis;Longevity; chr7:1029699 chr7:1160374~1165267:+ LUSC cis rs10256972 0.758 rs11980081 ENSG00000229043.2 AC091729.9 -9.14 1.88e-18 2.96e-15 -0.45 -0.39 Endometriosis;Longevity; chr7:1029736 chr7:1160374~1165267:+ LUSC cis rs2929278 0.736 rs2412823 ENSG00000249839.1 AC011330.5 9.14 1.94e-18 3.04e-15 0.5 0.39 Schizophrenia; chr15:43935072 chr15:43663654~43684339:- LUSC cis rs1823913 1 rs13019004 ENSG00000227542.1 AC092614.2 9.14 1.94e-18 3.04e-15 0.52 0.39 Obesity-related traits; chr2:191245493 chr2:191229165~191246172:- LUSC cis rs6452524 0.967 rs4541638 ENSG00000249664.1 CTD-2227C6.2 9.14 1.95e-18 3.06e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83181325 chr5:83012285~83013109:- LUSC cis rs9322193 0.884 rs9688794 ENSG00000216906.2 RP11-350J20.9 9.14 1.95e-18 3.06e-15 0.46 0.39 Lung cancer; chr6:149632121 chr6:149904243~149906418:+ LUSC cis rs748404 0.631 rs7166812 ENSG00000249839.1 AC011330.5 -9.13 1.96e-18 3.07e-15 -0.53 -0.39 Lung cancer; chr15:43352562 chr15:43663654~43684339:- LUSC cis rs9487094 0.67 rs11755641 ENSG00000260273.1 RP11-425D10.10 9.13 1.97e-18 3.08e-15 0.45 0.39 Height; chr6:109586733 chr6:109382795~109383666:+ LUSC cis rs6452524 0.967 rs2974445 ENSG00000249664.1 CTD-2227C6.2 -9.13 1.97e-18 3.09e-15 -0.39 -0.39 Hypertension (SNP x SNP interaction); chr5:83185561 chr5:83012285~83013109:- LUSC cis rs2283792 0.935 rs5750113 ENSG00000228050.1 TOP3BP1 9.13 1.99e-18 3.12e-15 0.46 0.39 Multiple sclerosis; chr22:21865784 chr22:22223187~22224566:- LUSC cis rs73086581 0.645 rs2103659 ENSG00000229539.1 RP11-119B16.2 -9.13 2e-18 3.13e-15 -0.42 -0.39 Response to antidepressants in depression; chr20:4001925 chr20:3888239~3888868:- LUSC cis rs10129255 0.5 rs8014529 ENSG00000211972.2 IGHV3-66 9.13 2.03e-18 3.18e-15 0.26 0.39 Kawasaki disease; chr14:106784065 chr14:106675017~106675544:- LUSC cis rs526231 0.543 rs158244 ENSG00000175749.11 EIF3KP1 9.13 2.03e-18 3.18e-15 0.48 0.39 Primary biliary cholangitis; chr5:103075062 chr5:103032376~103033031:+ LUSC cis rs748404 0.587 rs9920879 ENSG00000249839.1 AC011330.5 -9.13 2.04e-18 3.19e-15 -0.53 -0.39 Lung cancer; chr15:43347572 chr15:43663654~43684339:- LUSC cis rs6920372 0.748 rs12528392 ENSG00000260273.1 RP11-425D10.10 9.13 2.04e-18 3.19e-15 0.46 0.39 Height; chr6:109747411 chr6:109382795~109383666:+ LUSC cis rs6920372 0.692 rs11153216 ENSG00000260273.1 RP11-425D10.10 9.13 2.04e-18 3.19e-15 0.46 0.39 Height; chr6:109748819 chr6:109382795~109383666:+ LUSC cis rs6920372 0.748 rs2025147 ENSG00000260273.1 RP11-425D10.10 9.13 2.04e-18 3.19e-15 0.46 0.39 Height; chr6:109749564 chr6:109382795~109383666:+ LUSC cis rs10875746 0.551 rs1471998 ENSG00000240399.1 RP1-228P16.1 -9.13 2.07e-18 3.24e-15 -0.45 -0.39 Longevity (90 years and older); chr12:48318219 chr12:48054813~48055591:- LUSC cis rs10740039 0.583 rs9415608 ENSG00000254271.1 RP11-131N11.4 -9.13 2.1e-18 3.28e-15 -0.54 -0.39 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60737680 chr10:60734342~60741828:+ LUSC cis rs6991838 0.798 rs62507575 ENSG00000272010.1 CTD-3025N20.3 9.13 2.11e-18 3.3e-15 0.42 0.39 Intelligence (multi-trait analysis); chr8:65566486 chr8:65591850~65592472:- LUSC cis rs7189233 0.531 rs8055279 ENSG00000279344.1 RP11-44F14.7 9.13 2.11e-18 3.31e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53488837 chr16:53478957~53481550:- LUSC cis rs2739330 0.76 rs5751761 ENSG00000235689.1 AP000351.13 -9.12 2.12e-18 3.32e-15 -0.39 -0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:24006305~24008258:- LUSC cis rs1891275 0.515 rs7092884 ENSG00000228701.1 TNKS2-AS1 9.12 2.13e-18 3.33e-15 0.44 0.39 Intelligence (multi-trait analysis); chr10:91724115 chr10:91782839~91798291:- LUSC cis rs10129255 0.5 rs8022547 ENSG00000211972.2 IGHV3-66 9.12 2.14e-18 3.34e-15 0.26 0.39 Kawasaki disease; chr14:106781985 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs8006888 ENSG00000211972.2 IGHV3-66 9.12 2.14e-18 3.34e-15 0.26 0.39 Kawasaki disease; chr14:106782219 chr14:106675017~106675544:- LUSC cis rs853679 0.517 rs2273564 ENSG00000219392.1 RP1-265C24.5 -9.12 2.14e-18 3.34e-15 -0.54 -0.39 Depression; chr6:28089816 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs1853097 ENSG00000219392.1 RP1-265C24.5 -9.12 2.14e-18 3.34e-15 -0.54 -0.39 Depression; chr6:28090857 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9393888 ENSG00000219392.1 RP1-265C24.5 -9.12 2.14e-18 3.34e-15 -0.54 -0.39 Depression; chr6:28091439 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs3734573 ENSG00000219392.1 RP1-265C24.5 -9.12 2.14e-18 3.34e-15 -0.54 -0.39 Depression; chr6:28091659 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9357063 ENSG00000219392.1 RP1-265C24.5 -9.12 2.14e-18 3.34e-15 -0.54 -0.39 Depression; chr6:28092227 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs3823180 ENSG00000219392.1 RP1-265C24.5 -9.12 2.14e-18 3.34e-15 -0.54 -0.39 Depression; chr6:28093966 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9368551 ENSG00000219392.1 RP1-265C24.5 -9.12 2.14e-18 3.34e-15 -0.54 -0.39 Depression; chr6:28094014 chr6:28115628~28116551:+ LUSC cis rs7397814 0.558 rs4764447 ENSG00000256673.1 RP11-599J14.2 9.12 2.14e-18 3.34e-15 0.4 0.39 IgG glycosylation; chr12:9426513 chr12:9398355~9414851:- LUSC cis rs992157 0.798 rs10193383 ENSG00000261338.2 RP11-378A13.1 9.12 2.15e-18 3.35e-15 0.4 0.39 Colorectal cancer; chr2:218292969 chr2:218255319~218257366:+ LUSC cis rs992157 0.798 rs10206064 ENSG00000261338.2 RP11-378A13.1 9.12 2.15e-18 3.35e-15 0.4 0.39 Colorectal cancer; chr2:218293236 chr2:218255319~218257366:+ LUSC cis rs62388641 0.547 rs2745610 ENSG00000272279.1 RP11-157J24.2 -9.12 2.16e-18 3.37e-15 -0.54 -0.39 Daytime sleep phenotypes; chr6:1553741 chr6:1528364~1528911:- LUSC cis rs6782228 1 rs6801509 ENSG00000242551.2 POU5F1P6 9.12 2.2e-18 3.44e-15 0.49 0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128645426 chr3:128674735~128677005:- LUSC cis rs12439619 0.508 rs8042665 ENSG00000255769.6 GOLGA2P10 -9.12 2.23e-18 3.47e-15 -0.47 -0.39 Intelligence (multi-trait analysis); chr15:82189008 chr15:82472993~82513950:- LUSC cis rs10256972 0.616 rs6463001 ENSG00000229043.2 AC091729.9 -9.12 2.23e-18 3.48e-15 -0.45 -0.39 Endometriosis;Longevity; chr7:1068636 chr7:1160374~1165267:+ LUSC cis rs853679 0.517 rs17711344 ENSG00000219392.1 RP1-265C24.5 9.12 2.24e-18 3.49e-15 0.53 0.39 Depression; chr6:28109824 chr6:28115628~28116551:+ LUSC cis rs10875746 0.669 rs1021313 ENSG00000240399.1 RP1-228P16.1 -9.12 2.28e-18 3.55e-15 -0.45 -0.39 Longevity (90 years and older); chr12:48244258 chr12:48054813~48055591:- LUSC cis rs11098499 0.78 rs10013652 ENSG00000245958.5 RP11-33B1.1 -9.11 2.29e-18 3.58e-15 -0.38 -0.39 Corneal astigmatism; chr4:119371101 chr4:119454791~119552025:+ LUSC cis rs6452524 0.934 rs2940543 ENSG00000249664.1 CTD-2227C6.2 9.11 2.3e-18 3.58e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83187297 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs2974450 ENSG00000249664.1 CTD-2227C6.2 9.11 2.3e-18 3.58e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83187323 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs2974449 ENSG00000249664.1 CTD-2227C6.2 9.11 2.3e-18 3.58e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83187465 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs2662241 ENSG00000249664.1 CTD-2227C6.2 9.11 2.3e-18 3.58e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83188774 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs2940544 ENSG00000249664.1 CTD-2227C6.2 9.11 2.3e-18 3.58e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83189785 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs2731865 ENSG00000249664.1 CTD-2227C6.2 9.11 2.3e-18 3.58e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83190570 chr5:83012285~83013109:- LUSC cis rs8091660 0.929 rs12606093 ENSG00000278983.1 RP11-426J5.3 9.11 2.3e-18 3.59e-15 0.52 0.39 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48550924 chr18:48564795~48568342:+ LUSC cis rs853679 0.517 rs9393891 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Depression; chr6:28111382 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9468286 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Depression; chr6:28111650 chr6:28115628~28116551:+ LUSC cis rs4713118 0.516 rs7739216 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Parkinson's disease; chr6:28112168 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs35512245 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Depression; chr6:28112175 chr6:28115628~28116551:+ LUSC cis rs853679 0.542 rs9393892 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Depression; chr6:28113616 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9380055 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Depression; chr6:28113851 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9368553 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Depression; chr6:28114487 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9368554 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Depression; chr6:28114933 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs4713137 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Depression; chr6:28115743 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9348793 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Depression; chr6:28116411 chr6:28115628~28116551:+ LUSC cis rs4713118 0.586 rs6905516 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Parkinson's disease; chr6:28118700 chr6:28115628~28116551:+ LUSC cis rs4713118 0.586 rs6905522 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Parkinson's disease; chr6:28118701 chr6:28115628~28116551:+ LUSC cis rs4713118 0.586 rs9468290 ENSG00000219392.1 RP1-265C24.5 -9.11 2.3e-18 3.59e-15 -0.54 -0.39 Parkinson's disease; chr6:28119896 chr6:28115628~28116551:+ LUSC cis rs6452524 0.967 rs2974444 ENSG00000249664.1 CTD-2227C6.2 9.11 2.31e-18 3.6e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83185174 chr5:83012285~83013109:- LUSC cis rs6452524 0.967 rs2940542 ENSG00000249664.1 CTD-2227C6.2 9.11 2.31e-18 3.6e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83185734 chr5:83012285~83013109:- LUSC cis rs6782228 1 rs6782407 ENSG00000242551.2 POU5F1P6 9.11 2.32e-18 3.62e-15 0.49 0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619905 chr3:128674735~128677005:- LUSC cis rs11098499 0.954 rs9993199 ENSG00000245958.5 RP11-33B1.1 9.11 2.33e-18 3.63e-15 0.4 0.39 Corneal astigmatism; chr4:119471718 chr4:119454791~119552025:+ LUSC cis rs3931020 0.688 rs277396 ENSG00000272864.1 RP11-17E13.2 9.11 2.34e-18 3.63e-15 0.52 0.39 Resistin levels; chr1:74747964 chr1:74698769~74699333:- LUSC cis rs11098499 0.908 rs28499576 ENSG00000245958.5 RP11-33B1.1 -9.11 2.34e-18 3.65e-15 -0.4 -0.39 Corneal astigmatism; chr4:119465522 chr4:119454791~119552025:+ LUSC cis rs11168854 0.719 rs11168902 ENSG00000258017.1 RP11-386G11.10 -9.11 2.36e-18 3.67e-15 -0.5 -0.39 Body mass index; chr12:49174483 chr12:49127782~49147869:+ LUSC cis rs765787 0.53 rs2554453 ENSG00000259520.4 CTD-2651B20.3 9.11 2.4e-18 3.73e-15 0.48 0.39 Uric acid levels; chr15:45229909 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11858988 ENSG00000259520.4 CTD-2651B20.3 9.11 2.4e-18 3.73e-15 0.48 0.39 Uric acid levels; chr15:45229916 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11855435 ENSG00000259520.4 CTD-2651B20.3 9.11 2.4e-18 3.73e-15 0.48 0.39 Uric acid levels; chr15:45229919 chr15:45251580~45279251:- LUSC cis rs992157 0.7 rs10165153 ENSG00000261338.2 RP11-378A13.1 9.11 2.41e-18 3.75e-15 0.4 0.39 Colorectal cancer; chr2:218294906 chr2:218255319~218257366:+ LUSC cis rs7189233 0.55 rs3803657 ENSG00000279344.1 RP11-44F14.7 9.11 2.42e-18 3.77e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53482047 chr16:53478957~53481550:- LUSC cis rs150992 0.592 rs10038192 ENSG00000248489.1 CTD-2007H13.3 9.11 2.43e-18 3.77e-15 0.45 0.39 Body mass index; chr5:98989755 chr5:98929171~98995013:+ LUSC cis rs150992 0.571 rs10045959 ENSG00000248489.1 CTD-2007H13.3 9.11 2.43e-18 3.77e-15 0.45 0.39 Body mass index; chr5:98989767 chr5:98929171~98995013:+ LUSC cis rs150992 0.571 rs10037147 ENSG00000248489.1 CTD-2007H13.3 9.11 2.43e-18 3.77e-15 0.45 0.39 Body mass index; chr5:98989768 chr5:98929171~98995013:+ LUSC cis rs9322193 0.923 rs9505982 ENSG00000216906.2 RP11-350J20.9 9.11 2.43e-18 3.78e-15 0.46 0.39 Lung cancer; chr6:149618465 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs10747275 ENSG00000216906.2 RP11-350J20.9 9.11 2.43e-18 3.78e-15 0.46 0.39 Lung cancer; chr6:149622782 chr6:149904243~149906418:+ LUSC cis rs11098499 0.865 rs4001305 ENSG00000245958.5 RP11-33B1.1 -9.11 2.45e-18 3.81e-15 -0.4 -0.39 Corneal astigmatism; chr4:119438081 chr4:119454791~119552025:+ LUSC cis rs853679 0.517 rs36078605 ENSG00000219392.1 RP1-265C24.5 -9.11 2.46e-18 3.81e-15 -0.54 -0.39 Depression; chr6:28110254 chr6:28115628~28116551:+ LUSC cis rs3931020 0.626 rs277402 ENSG00000272864.1 RP11-17E13.2 9.1 2.48e-18 3.86e-15 0.54 0.39 Resistin levels; chr1:74722637 chr1:74698769~74699333:- LUSC cis rs9341808 0.529 rs2322765 ENSG00000272129.1 RP11-250B2.6 9.1 2.5e-18 3.88e-15 0.47 0.39 Sitting height ratio; chr6:80354879 chr6:80355424~80356859:+ LUSC cis rs526231 0.543 rs158395 ENSG00000175749.11 EIF3KP1 9.1 2.5e-18 3.88e-15 0.48 0.39 Primary biliary cholangitis; chr5:103075685 chr5:103032376~103033031:+ LUSC cis rs526231 0.543 rs158400 ENSG00000175749.11 EIF3KP1 9.1 2.5e-18 3.88e-15 0.48 0.39 Primary biliary cholangitis; chr5:103077628 chr5:103032376~103033031:+ LUSC cis rs526231 0.543 rs257302 ENSG00000175749.11 EIF3KP1 9.1 2.5e-18 3.88e-15 0.48 0.39 Primary biliary cholangitis; chr5:103080426 chr5:103032376~103033031:+ LUSC cis rs526231 0.543 rs257303 ENSG00000175749.11 EIF3KP1 9.1 2.5e-18 3.88e-15 0.48 0.39 Primary biliary cholangitis; chr5:103081023 chr5:103032376~103033031:+ LUSC cis rs6452524 0.836 rs10041617 ENSG00000249664.1 CTD-2227C6.2 9.1 2.52e-18 3.91e-15 0.39 0.39 Hypertension (SNP x SNP interaction); chr5:83096535 chr5:83012285~83013109:- LUSC cis rs1707322 1 rs1612419 ENSG00000280836.1 AL355480.1 9.1 2.54e-18 3.94e-15 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46081273 chr1:45581219~45581321:- LUSC cis rs2665103 0.589 rs3858953 ENSG00000255769.6 GOLGA2P10 -9.1 2.54e-18 3.94e-15 -0.46 -0.39 Intelligence (multi-trait analysis); chr15:82238049 chr15:82472993~82513950:- LUSC cis rs765787 0.53 rs2458224 ENSG00000259520.4 CTD-2651B20.3 9.1 2.55e-18 3.96e-15 0.48 0.39 Uric acid levels; chr15:45229932 chr15:45251580~45279251:- LUSC cis rs2729354 0.729 rs2581923 ENSG00000265566.2 RN7SL605P -9.1 2.56e-18 3.97e-15 -0.52 -0.39 Blood protein levels; chr11:57482518 chr11:57528085~57528365:- LUSC cis rs7189233 0.531 rs4783813 ENSG00000279344.1 RP11-44F14.7 9.1 2.58e-18 4e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53484458 chr16:53478957~53481550:- LUSC cis rs10256972 0.721 rs2030959 ENSG00000229043.2 AC091729.9 -9.1 2.61e-18 4.04e-15 -0.45 -0.39 Endometriosis;Longevity; chr7:1036270 chr7:1160374~1165267:+ LUSC cis rs73086581 0.524 rs2253977 ENSG00000229539.1 RP11-119B16.2 -9.1 2.61e-18 4.05e-15 -0.42 -0.39 Response to antidepressants in depression; chr20:3958493 chr20:3888239~3888868:- LUSC cis rs7189233 0.531 rs13337544 ENSG00000279344.1 RP11-44F14.7 9.1 2.62e-18 4.06e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53485123 chr16:53478957~53481550:- LUSC cis rs2337406 0.866 rs11488879 ENSG00000274576.2 IGHV2-70 -9.1 2.63e-18 4.08e-15 -0.4 -0.39 Alzheimer's disease (late onset); chr14:106786097 chr14:106770577~106771020:- LUSC cis rs7189233 0.531 rs8046307 ENSG00000279344.1 RP11-44F14.7 9.1 2.65e-18 4.11e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53484774 chr16:53478957~53481550:- LUSC cis rs11098499 0.954 rs12505469 ENSG00000245958.5 RP11-33B1.1 -9.09 2.72e-18 4.21e-15 -0.4 -0.39 Corneal astigmatism; chr4:119328430 chr4:119454791~119552025:+ LUSC cis rs10129255 0.518 rs11847766 ENSG00000211972.2 IGHV3-66 9.09 2.73e-18 4.23e-15 0.26 0.39 Kawasaki disease; chr14:106779186 chr14:106675017~106675544:- LUSC cis rs4423214 0.879 rs1790345 ENSG00000254682.1 RP11-660L16.2 -9.09 2.75e-18 4.25e-15 -0.53 -0.39 Vitamin D levels; chr11:71434895 chr11:71448674~71452157:+ LUSC cis rs4728142 0.604 rs10954215 ENSG00000275106.1 RP11-309L24.10 -9.09 2.78e-18 4.3e-15 -0.49 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129005459 chr7:128952527~128953316:- LUSC cis rs62229266 0.659 rs2835258 ENSG00000231106.2 LINC01436 9.09 2.79e-18 4.32e-15 0.49 0.39 Mitral valve prolapse; chr21:36052067 chr21:36005338~36007838:+ LUSC cis rs10129255 0.5 rs988134 ENSG00000211972.2 IGHV3-66 9.09 2.8e-18 4.33e-15 0.26 0.39 Kawasaki disease; chr14:106776698 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs988133 ENSG00000211972.2 IGHV3-66 9.09 2.8e-18 4.33e-15 0.26 0.39 Kawasaki disease; chr14:106776724 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs12101190 ENSG00000211972.2 IGHV3-66 9.09 2.81e-18 4.35e-15 0.26 0.39 Kawasaki disease; chr14:106784149 chr14:106675017~106675544:- LUSC cis rs10129255 0.518 rs8004895 ENSG00000211972.2 IGHV3-66 9.09 2.81e-18 4.35e-15 0.26 0.39 Kawasaki disease; chr14:106785139 chr14:106675017~106675544:- LUSC cis rs2665103 0.61 rs56398167 ENSG00000255769.6 GOLGA2P10 -9.09 2.82e-18 4.36e-15 -0.46 -0.39 Intelligence (multi-trait analysis); chr15:82237482 chr15:82472993~82513950:- LUSC cis rs5760092 0.755 rs4585126 ENSG00000231271.1 AP000350.8 -9.09 2.87e-18 4.44e-15 -0.57 -0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23949918~23954042:+ LUSC cis rs1823913 0.892 rs35596292 ENSG00000227542.1 AC092614.2 9.09 2.89e-18 4.47e-15 0.52 0.39 Obesity-related traits; chr2:191246890 chr2:191229165~191246172:- LUSC cis rs1823913 0.927 rs35530564 ENSG00000227542.1 AC092614.2 9.09 2.89e-18 4.47e-15 0.52 0.39 Obesity-related traits; chr2:191247324 chr2:191229165~191246172:- LUSC cis rs6991838 0.55 rs4737750 ENSG00000200714.1 Y_RNA 9.08 2.9e-18 4.49e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65638724 chr8:65592731~65592820:+ LUSC cis rs7684253 0.565 rs7680140 ENSG00000269949.1 RP11-738E22.3 -9.08 2.91e-18 4.49e-15 -0.46 -0.39 Migraine; chr4:56957291 chr4:56960927~56961373:- LUSC cis rs1150668 0.699 rs12214383 ENSG00000204709.4 LINC01556 -9.08 2.93e-18 4.53e-15 -0.46 -0.39 Pubertal anthropometrics; chr6:28255953 chr6:28943877~28944537:+ LUSC cis rs2882667 0.522 rs7731574 ENSG00000253404.1 AC034243.1 -9.08 2.97e-18 4.58e-15 -0.46 -0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139118503 chr5:138744434~138753309:- LUSC cis rs7189233 0.531 rs9941254 ENSG00000279344.1 RP11-44F14.7 9.08 2.98e-18 4.61e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53453306 chr16:53478957~53481550:- LUSC cis rs7189233 0.531 rs7194730 ENSG00000279344.1 RP11-44F14.7 9.08 2.98e-18 4.61e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53455278 chr16:53478957~53481550:- LUSC cis rs7189233 0.531 rs13332406 ENSG00000279344.1 RP11-44F14.7 9.08 2.98e-18 4.61e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53455793 chr16:53478957~53481550:- LUSC cis rs9322193 0.923 rs9689084 ENSG00000216906.2 RP11-350J20.9 9.08 2.99e-18 4.61e-15 0.46 0.39 Lung cancer; chr6:149639648 chr6:149904243~149906418:+ LUSC cis rs6921919 1 rs6921919 ENSG00000216901.1 AL022393.7 9.08 3.01e-18 4.65e-15 0.52 0.39 Autism spectrum disorder or schizophrenia; chr6:28357424 chr6:28176188~28176674:+ LUSC cis rs201673768 1 rs201673768 ENSG00000240399.1 RP1-228P16.1 9.08 3.02e-18 4.66e-15 0.36 0.39 Platelet count; chr12:48305834 chr12:48054813~48055591:- LUSC cis rs11098499 0.738 rs28408407 ENSG00000245958.5 RP11-33B1.1 -9.08 3.02e-18 4.67e-15 -0.39 -0.39 Corneal astigmatism; chr4:119454875 chr4:119454791~119552025:+ LUSC cis rs1707322 0.789 rs10789473 ENSG00000280836.1 AL355480.1 -9.08 3.03e-18 4.68e-15 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45782459 chr1:45581219~45581321:- LUSC cis rs1707322 0.826 rs10890349 ENSG00000280836.1 AL355480.1 -9.08 3.03e-18 4.68e-15 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45784283 chr1:45581219~45581321:- LUSC cis rs1707322 0.758 rs10789474 ENSG00000280836.1 AL355480.1 -9.08 3.03e-18 4.68e-15 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45784368 chr1:45581219~45581321:- LUSC cis rs9322193 0.923 rs9688452 ENSG00000216906.2 RP11-350J20.9 9.08 3.04e-18 4.69e-15 0.47 0.39 Lung cancer; chr6:149658764 chr6:149904243~149906418:+ LUSC cis rs4423214 0.879 rs1790330 ENSG00000254682.1 RP11-660L16.2 -9.08 3.06e-18 4.72e-15 -0.53 -0.39 Vitamin D levels; chr11:71436779 chr11:71448674~71452157:+ LUSC cis rs4423214 0.84 rs1790328 ENSG00000254682.1 RP11-660L16.2 -9.08 3.06e-18 4.72e-15 -0.53 -0.39 Vitamin D levels; chr11:71436992 chr11:71448674~71452157:+ LUSC cis rs3931020 0.657 rs277368 ENSG00000272864.1 RP11-17E13.2 9.08 3.11e-18 4.8e-15 0.53 0.39 Resistin levels; chr1:74764922 chr1:74698769~74699333:- LUSC cis rs992157 0.698 rs6746089 ENSG00000261338.2 RP11-378A13.1 9.08 3.12e-18 4.81e-15 0.39 0.39 Colorectal cancer; chr2:218305654 chr2:218255319~218257366:+ LUSC cis rs11098499 0.754 rs4107728 ENSG00000245958.5 RP11-33B1.1 -9.07 3.14e-18 4.83e-15 -0.38 -0.39 Corneal astigmatism; chr4:119332755 chr4:119454791~119552025:+ LUSC cis rs9341808 0.754 rs3805907 ENSG00000272129.1 RP11-250B2.6 -9.07 3.15e-18 4.86e-15 -0.46 -0.39 Sitting height ratio; chr6:80263948 chr6:80355424~80356859:+ LUSC cis rs11098499 0.954 rs59394118 ENSG00000245958.5 RP11-33B1.1 -9.07 3.16e-18 4.86e-15 -0.4 -0.39 Corneal astigmatism; chr4:119374396 chr4:119454791~119552025:+ LUSC cis rs11098499 0.865 rs9996417 ENSG00000245958.5 RP11-33B1.1 -9.07 3.16e-18 4.86e-15 -0.4 -0.39 Corneal astigmatism; chr4:119374707 chr4:119454791~119552025:+ LUSC cis rs5760092 0.755 rs915589 ENSG00000231271.1 AP000350.8 -9.07 3.18e-18 4.9e-15 -0.6 -0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23949918~23954042:+ LUSC cis rs12439619 0.508 rs11856561 ENSG00000255769.6 GOLGA2P10 -9.07 3.21e-18 4.94e-15 -0.47 -0.39 Intelligence (multi-trait analysis); chr15:82161415 chr15:82472993~82513950:- LUSC cis rs11098499 0.618 rs28491261 ENSG00000245958.5 RP11-33B1.1 -9.07 3.21e-18 4.95e-15 -0.4 -0.39 Corneal astigmatism; chr4:119373745 chr4:119454791~119552025:+ LUSC cis rs1707322 1 rs4539075 ENSG00000280836.1 AL355480.1 -9.07 3.22e-18 4.96e-15 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45892338 chr1:45581219~45581321:- LUSC cis rs9322193 0.923 rs14314 ENSG00000216906.2 RP11-350J20.9 9.07 3.29e-18 5.07e-15 0.46 0.39 Lung cancer; chr6:149820395 chr6:149904243~149906418:+ LUSC cis rs6921919 0.789 rs17301128 ENSG00000204709.4 LINC01556 9.07 3.31e-18 5.09e-15 0.56 0.39 Autism spectrum disorder or schizophrenia; chr6:28340257 chr6:28943877~28944537:+ LUSC cis rs11089937 1 rs6001121 ENSG00000211639.2 IGLV4-60 9.07 3.33e-18 5.12e-15 0.39 0.39 Periodontitis (PAL4Q3); chr22:22149505 chr22:22162199~22162681:+ LUSC cis rs2729354 0.729 rs2848634 ENSG00000265566.2 RN7SL605P -9.07 3.34e-18 5.14e-15 -0.52 -0.39 Blood protein levels; chr11:57484855 chr11:57528085~57528365:- LUSC cis rs2665103 0.632 rs3902959 ENSG00000255769.6 GOLGA2P10 -9.07 3.37e-18 5.18e-15 -0.46 -0.39 Intelligence (multi-trait analysis); chr15:82252586 chr15:82472993~82513950:- LUSC cis rs11098499 0.954 rs10006877 ENSG00000245958.5 RP11-33B1.1 -9.07 3.38e-18 5.2e-15 -0.4 -0.39 Corneal astigmatism; chr4:119321638 chr4:119454791~119552025:+ LUSC cis rs2108622 0.683 rs6512067 ENSG00000267453.5 AC004791.2 -9.06 3.39e-18 5.22e-15 -0.5 -0.39 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872141 chr19:15851993~15864904:- LUSC cis rs748404 0.631 rs6493084 ENSG00000249839.1 AC011330.5 -9.06 3.42e-18 5.26e-15 -0.52 -0.39 Lung cancer; chr15:43355429 chr15:43663654~43684339:- LUSC cis rs748404 0.631 rs12905772 ENSG00000249839.1 AC011330.5 -9.06 3.42e-18 5.26e-15 -0.52 -0.39 Lung cancer; chr15:43356246 chr15:43663654~43684339:- LUSC cis rs6991838 0.584 rs3765205 ENSG00000200714.1 Y_RNA -9.06 3.47e-18 5.33e-15 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65605251 chr8:65592731~65592820:+ LUSC cis rs10256972 0.713 rs10435026 ENSG00000229043.2 AC091729.9 -9.06 3.48e-18 5.34e-15 -0.45 -0.39 Endometriosis;Longevity; chr7:1026312 chr7:1160374~1165267:+ LUSC cis rs8040855 0.621 rs6496796 ENSG00000259295.5 CSPG4P12 -9.06 3.51e-18 5.39e-15 -0.45 -0.39 Bulimia nervosa; chr15:85183617 chr15:85191438~85213905:+ LUSC cis rs6991838 0.584 rs7841652 ENSG00000200714.1 Y_RNA -9.06 3.52e-18 5.4e-15 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65606392 chr8:65592731~65592820:+ LUSC cis rs748404 0.631 rs4296223 ENSG00000249839.1 AC011330.5 -9.06 3.56e-18 5.47e-15 -0.52 -0.39 Lung cancer; chr15:43353048 chr15:43663654~43684339:- LUSC cis rs9322193 0.887 rs4870139 ENSG00000216906.2 RP11-350J20.9 9.06 3.58e-18 5.5e-15 0.48 0.39 Lung cancer; chr6:149575182 chr6:149904243~149906418:+ LUSC cis rs6921919 0.583 rs7764722 ENSG00000216901.1 AL022393.7 9.06 3.62e-18 5.55e-15 0.45 0.39 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28176188~28176674:+ LUSC cis rs748404 0.676 rs4401024 ENSG00000249839.1 AC011330.5 -9.06 3.63e-18 5.56e-15 -0.52 -0.39 Lung cancer; chr15:43358137 chr15:43663654~43684339:- LUSC cis rs9322193 0.962 rs17673294 ENSG00000216906.2 RP11-350J20.9 9.06 3.64e-18 5.58e-15 0.46 0.39 Lung cancer; chr6:149813857 chr6:149904243~149906418:+ LUSC cis rs7189233 0.531 rs1072910 ENSG00000279344.1 RP11-44F14.7 9.05 3.66e-18 5.6e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53465687 chr16:53478957~53481550:- LUSC cis rs6991838 0.584 rs4737748 ENSG00000200714.1 Y_RNA 9.05 3.66e-18 5.6e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65613630 chr8:65592731~65592820:+ LUSC cis rs6991838 0.55 rs12335006 ENSG00000200714.1 Y_RNA 9.05 3.66e-18 5.6e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65619394 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs10957361 ENSG00000200714.1 Y_RNA 9.05 3.66e-18 5.6e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65619626 chr8:65592731~65592820:+ LUSC cis rs6991838 0.612 rs12335276 ENSG00000200714.1 Y_RNA 9.05 3.66e-18 5.6e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65619668 chr8:65592731~65592820:+ LUSC cis rs6991838 0.53 rs35038843 ENSG00000200714.1 Y_RNA -9.05 3.66e-18 5.6e-15 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65610263 chr8:65592731~65592820:+ LUSC cis rs765787 0.53 rs10851423 ENSG00000259520.4 CTD-2651B20.3 -9.05 3.67e-18 5.62e-15 -0.49 -0.39 Uric acid levels; chr15:45223752 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs12913123 ENSG00000259520.4 CTD-2651B20.3 -9.05 3.67e-18 5.62e-15 -0.49 -0.39 Uric acid levels; chr15:45224227 chr15:45251580~45279251:- LUSC cis rs10129255 1 rs9324091 ENSG00000211970.3 IGHV4-61 -9.05 3.68e-18 5.64e-15 -0.27 -0.39 Kawasaki disease; chr14:106676625 chr14:106639119~106639657:- LUSC cis rs992157 0.798 rs10932772 ENSG00000261338.2 RP11-378A13.1 9.05 3.68e-18 5.64e-15 0.4 0.39 Colorectal cancer; chr2:218312425 chr2:218255319~218257366:+ LUSC cis rs7189233 0.531 rs56126229 ENSG00000279344.1 RP11-44F14.7 9.05 3.68e-18 5.64e-15 0.33 0.39 Intelligence (multi-trait analysis); chr16:53476775 chr16:53478957~53481550:- LUSC cis rs853679 0.517 rs9393890 ENSG00000219392.1 RP1-265C24.5 -9.05 3.72e-18 5.68e-15 -0.54 -0.39 Depression; chr6:28096077 chr6:28115628~28116551:+ LUSC cis rs6452524 0.967 rs28360104 ENSG00000249664.1 CTD-2227C6.2 9.05 3.73e-18 5.71e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83181525 chr5:83012285~83013109:- LUSC cis rs6452524 1 rs7349753 ENSG00000249664.1 CTD-2227C6.2 9.05 3.75e-18 5.73e-15 0.4 0.39 Hypertension (SNP x SNP interaction); chr5:83165632 chr5:83012285~83013109:- LUSC cis rs6921919 0.583 rs6908137 ENSG00000216901.1 AL022393.7 9.05 3.76e-18 5.75e-15 0.44 0.39 Autism spectrum disorder or schizophrenia; chr6:28402616 chr6:28176188~28176674:+ LUSC cis rs11098499 1 rs6849889 ENSG00000245958.5 RP11-33B1.1 -9.05 3.8e-18 5.81e-15 -0.4 -0.39 Corneal astigmatism; chr4:119265193 chr4:119454791~119552025:+ LUSC cis rs10129255 0.872 rs10133674 ENSG00000211970.3 IGHV4-61 -9.05 3.8e-18 5.81e-15 -0.27 -0.39 Kawasaki disease; chr14:106692788 chr14:106639119~106639657:- LUSC cis rs765787 0.53 rs1648289 ENSG00000259520.4 CTD-2651B20.3 9.05 3.8e-18 5.81e-15 0.48 0.39 Uric acid levels; chr15:45224296 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs1648287 ENSG00000259520.4 CTD-2651B20.3 9.05 3.8e-18 5.81e-15 0.48 0.39 Uric acid levels; chr15:45224758 chr15:45251580~45279251:- LUSC cis rs10129255 0.879 rs7160512 ENSG00000211970.3 IGHV4-61 -9.05 3.83e-18 5.85e-15 -0.27 -0.39 Kawasaki disease; chr14:106694574 chr14:106639119~106639657:- LUSC cis rs10129255 0.879 rs7159157 ENSG00000211970.3 IGHV4-61 -9.05 3.83e-18 5.85e-15 -0.27 -0.39 Kawasaki disease; chr14:106694578 chr14:106639119~106639657:- LUSC cis rs6991838 0.584 rs3812412 ENSG00000200714.1 Y_RNA 9.05 3.85e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65634857 chr8:65592731~65592820:+ LUSC cis rs6991838 0.612 rs7832407 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65621071 chr8:65592731~65592820:+ LUSC cis rs6991838 0.551 rs7007505 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65621719 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs7012856 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65622740 chr8:65592731~65592820:+ LUSC cis rs6991838 0.55 rs7817112 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65624885 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs2048650 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65625664 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs4737749 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65627672 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs10092109 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65627683 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs6997959 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65628247 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs7814841 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65629328 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs11985628 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65630504 chr8:65592731~65592820:+ LUSC cis rs6991838 0.557 rs13266834 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65631303 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs13268343 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65631742 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs7835313 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65633891 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs1533285 ENSG00000200714.1 Y_RNA 9.05 3.86e-18 5.89e-15 0.47 0.39 Intelligence (multi-trait analysis); chr8:65637129 chr8:65592731~65592820:+ LUSC cis rs6452524 1 rs67683443 ENSG00000249664.1 CTD-2227C6.2 9.05 3.88e-18 5.92e-15 0.39 0.39 Hypertension (SNP x SNP interaction); chr5:83167884 chr5:83012285~83013109:- LUSC cis rs12134133 1 rs2802235 ENSG00000274245.1 RP11-357P18.2 9.05 3.92e-18 5.99e-15 0.5 0.39 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207298454 chr1:207372559~207373252:+ LUSC cis rs992157 0.798 rs7587220 ENSG00000261338.2 RP11-378A13.1 -9.05 3.93e-18 5.99e-15 -0.39 -0.39 Colorectal cancer; chr2:218296141 chr2:218255319~218257366:+ LUSC cis rs992157 0.798 rs4674284 ENSG00000261338.2 RP11-378A13.1 -9.05 3.93e-18 5.99e-15 -0.39 -0.39 Colorectal cancer; chr2:218296518 chr2:218255319~218257366:+ LUSC cis rs992157 0.798 rs12053514 ENSG00000261338.2 RP11-378A13.1 -9.05 3.93e-18 5.99e-15 -0.39 -0.39 Colorectal cancer; chr2:218303242 chr2:218255319~218257366:+ LUSC cis rs11098499 0.954 rs878373 ENSG00000245958.5 RP11-33B1.1 -9.05 3.94e-18 6e-15 -0.4 -0.39 Corneal astigmatism; chr4:119316329 chr4:119454791~119552025:+ LUSC cis rs9487094 0.626 rs11153213 ENSG00000260273.1 RP11-425D10.10 9.05 3.94e-18 6.01e-15 0.46 0.39 Height; chr6:109693890 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs12201356 ENSG00000260273.1 RP11-425D10.10 9.05 3.94e-18 6.01e-15 0.46 0.39 Height; chr6:109694672 chr6:109382795~109383666:+ LUSC cis rs12134133 1 rs2490261 ENSG00000274245.1 RP11-357P18.2 9.04 3.97e-18 6.05e-15 0.5 0.39 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207304124 chr1:207372559~207373252:+ LUSC cis rs11098499 0.866 rs72676074 ENSG00000245958.5 RP11-33B1.1 -9.04 3.97e-18 6.05e-15 -0.4 -0.39 Corneal astigmatism; chr4:119438686 chr4:119454791~119552025:+ LUSC cis rs12134133 1 rs4844590 ENSG00000274245.1 RP11-357P18.2 9.04 3.97e-18 6.05e-15 0.51 0.39 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207322784 chr1:207372559~207373252:+ LUSC cis rs733592 0.504 rs2261608 ENSG00000240399.1 RP1-228P16.1 9.04 4e-18 6.09e-15 0.36 0.38 Plateletcrit; chr12:48327851 chr12:48054813~48055591:- LUSC cis rs10875746 0.669 rs9634261 ENSG00000240399.1 RP1-228P16.1 -9.04 4.02e-18 6.12e-15 -0.44 -0.38 Longevity (90 years and older); chr12:48293088 chr12:48054813~48055591:- LUSC cis rs11098499 1 rs28374891 ENSG00000245958.5 RP11-33B1.1 -9.04 4.02e-18 6.12e-15 -0.39 -0.38 Corneal astigmatism; chr4:119262395 chr4:119454791~119552025:+ LUSC cis rs35955747 0.601 rs7289941 ENSG00000236132.1 CTA-440B3.1 -9.04 4.08e-18 6.22e-15 -0.48 -0.38 Neutrophil count;Sum basophil neutrophil counts; chr22:31488419 chr22:31816379~31817491:- LUSC cis rs992157 0.835 rs11677953 ENSG00000261338.2 RP11-378A13.1 -9.04 4.08e-18 6.22e-15 -0.4 -0.38 Colorectal cancer; chr2:218256940 chr2:218255319~218257366:+ LUSC cis rs7189233 0.531 rs8043918 ENSG00000279344.1 RP11-44F14.7 9.04 4.13e-18 6.29e-15 0.33 0.38 Intelligence (multi-trait analysis); chr16:53479121 chr16:53478957~53481550:- LUSC cis rs6452524 0.967 rs2662243 ENSG00000249664.1 CTD-2227C6.2 9.04 4.15e-18 6.32e-15 0.4 0.38 Hypertension (SNP x SNP interaction); chr5:83192630 chr5:83012285~83013109:- LUSC cis rs748404 0.631 rs8042688 ENSG00000249839.1 AC011330.5 -9.04 4.18e-18 6.36e-15 -0.52 -0.38 Lung cancer; chr15:43346327 chr15:43663654~43684339:- LUSC cis rs2739330 0.892 rs4822455 ENSG00000231271.1 AP000350.8 9.04 4.18e-18 6.36e-15 0.5 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23949918~23954042:+ LUSC cis rs2117029 0.521 rs12229524 ENSG00000258017.1 RP11-386G11.10 -9.04 4.18e-18 6.37e-15 -0.49 -0.38 Intelligence (multi-trait analysis); chr12:49191570 chr12:49127782~49147869:+ LUSC cis rs1707322 1 rs4524994 ENSG00000280836.1 AL355480.1 -9.04 4.19e-18 6.37e-15 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45904591 chr1:45581219~45581321:- LUSC cis rs10875746 0.551 rs1471997 ENSG00000240399.1 RP1-228P16.1 -9.04 4.19e-18 6.38e-15 -0.45 -0.38 Longevity (90 years and older); chr12:48329812 chr12:48054813~48055591:- LUSC cis rs6991838 0.771 rs13282323 ENSG00000272010.1 CTD-3025N20.3 9.04 4.21e-18 6.41e-15 0.42 0.38 Intelligence (multi-trait analysis); chr8:65560557 chr8:65591850~65592472:- LUSC cis rs10129255 0.5 rs6576231 ENSG00000211972.2 IGHV3-66 9.04 4.21e-18 6.41e-15 0.26 0.38 Kawasaki disease; chr14:106783693 chr14:106675017~106675544:- LUSC cis rs6991838 0.584 rs6994213 ENSG00000200714.1 Y_RNA -9.04 4.22e-18 6.42e-15 -0.47 -0.38 Intelligence (multi-trait analysis); chr8:65601497 chr8:65592731~65592820:+ LUSC cis rs7396835 0.551 rs10750098 ENSG00000254851.1 RP11-109L13.1 -9.04 4.23e-18 6.43e-15 -0.78 -0.38 Quantitative traits; chr11:116834852 chr11:117135528~117138582:+ LUSC cis rs1707322 0.827 rs12125508 ENSG00000280836.1 AL355480.1 -9.04 4.23e-18 6.44e-15 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45780338 chr1:45581219~45581321:- LUSC cis rs9322193 1 rs9399693 ENSG00000216906.2 RP11-350J20.9 9.04 4.26e-18 6.47e-15 0.46 0.38 Lung cancer; chr6:149612718 chr6:149904243~149906418:+ LUSC cis rs5760092 0.572 rs738806 ENSG00000250470.1 AP000351.3 9.03 4.3e-18 6.54e-15 0.59 0.38 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23976904~23977585:- LUSC cis rs1707322 1 rs11211232 ENSG00000280836.1 AL355480.1 -9.03 4.32e-18 6.56e-15 -0.47 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45945474 chr1:45581219~45581321:- LUSC cis rs10129255 0.957 rs8009948 ENSG00000211970.3 IGHV4-61 -9.03 4.33e-18 6.58e-15 -0.28 -0.38 Kawasaki disease; chr14:106805607 chr14:106639119~106639657:- LUSC cis rs9341808 0.727 rs4706834 ENSG00000272129.1 RP11-250B2.6 9.03 4.35e-18 6.6e-15 0.46 0.38 Sitting height ratio; chr6:80302888 chr6:80355424~80356859:+ LUSC cis rs6991838 0.584 rs34226237 ENSG00000200714.1 Y_RNA -9.03 4.37e-18 6.63e-15 -0.47 -0.38 Intelligence (multi-trait analysis); chr8:65600930 chr8:65592731~65592820:+ LUSC cis rs11098499 0.865 rs2389809 ENSG00000245958.5 RP11-33B1.1 -9.03 4.38e-18 6.65e-15 -0.39 -0.38 Corneal astigmatism; chr4:119456244 chr4:119454791~119552025:+ LUSC cis rs6452524 0.967 rs2731861 ENSG00000249664.1 CTD-2227C6.2 9.03 4.39e-18 6.67e-15 0.39 0.38 Hypertension (SNP x SNP interaction); chr5:83189445 chr5:83012285~83013109:- LUSC cis rs4728142 0.604 rs6969930 ENSG00000275106.1 RP11-309L24.10 -9.03 4.43e-18 6.72e-15 -0.49 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128990259 chr7:128952527~128953316:- LUSC cis rs4728142 0.604 rs4731536 ENSG00000275106.1 RP11-309L24.10 -9.03 4.43e-18 6.72e-15 -0.49 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129000239 chr7:128952527~128953316:- LUSC cis rs11098499 0.754 rs7689729 ENSG00000245958.5 RP11-33B1.1 -9.03 4.44e-18 6.73e-15 -0.38 -0.38 Corneal astigmatism; chr4:119335037 chr4:119454791~119552025:+ LUSC cis rs10028773 0.7 rs7690338 ENSG00000245958.5 RP11-33B1.1 -9.03 4.44e-18 6.73e-15 -0.38 -0.38 Educational attainment; chr4:119335313 chr4:119454791~119552025:+ LUSC cis rs11098499 0.865 rs3956464 ENSG00000245958.5 RP11-33B1.1 -9.03 4.44e-18 6.73e-15 -0.38 -0.38 Corneal astigmatism; chr4:119335609 chr4:119454791~119552025:+ LUSC cis rs11098499 0.619 rs28502463 ENSG00000245958.5 RP11-33B1.1 -9.03 4.44e-18 6.73e-15 -0.38 -0.38 Corneal astigmatism; chr4:119335868 chr4:119454791~119552025:+ LUSC cis rs11098499 0.648 rs2002047 ENSG00000245958.5 RP11-33B1.1 -9.03 4.44e-18 6.73e-15 -0.38 -0.38 Corneal astigmatism; chr4:119336073 chr4:119454791~119552025:+ LUSC cis rs11098499 0.775 rs2002049 ENSG00000245958.5 RP11-33B1.1 -9.03 4.44e-18 6.73e-15 -0.38 -0.38 Corneal astigmatism; chr4:119336262 chr4:119454791~119552025:+ LUSC cis rs2337406 0.866 rs4774019 ENSG00000274576.2 IGHV2-70 -9.03 4.44e-18 6.75e-15 -0.4 -0.38 Alzheimer's disease (late onset); chr14:106805386 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs58850145 ENSG00000274576.2 IGHV2-70 -9.03 4.44e-18 6.75e-15 -0.4 -0.38 Alzheimer's disease (late onset); chr14:106806185 chr14:106770577~106771020:- LUSC cis rs6991838 0.584 rs7459944 ENSG00000200714.1 Y_RNA -9.03 4.46e-18 6.76e-15 -0.47 -0.38 Intelligence (multi-trait analysis); chr8:65566040 chr8:65592731~65592820:+ LUSC cis rs10129255 0.957 rs10138532 ENSG00000211970.3 IGHV4-61 -9.03 4.48e-18 6.8e-15 -0.28 -0.38 Kawasaki disease; chr14:106803901 chr14:106639119~106639657:- LUSC cis rs6452524 1 rs6860239 ENSG00000249664.1 CTD-2227C6.2 9.03 4.48e-18 6.8e-15 0.4 0.38 Hypertension (SNP x SNP interaction); chr5:83136022 chr5:83012285~83013109:- LUSC cis rs6452524 0.935 rs2731846 ENSG00000249664.1 CTD-2227C6.2 9.03 4.56e-18 6.92e-15 0.4 0.38 Hypertension (SNP x SNP interaction); chr5:83193781 chr5:83012285~83013109:- LUSC cis rs11098499 0.955 rs13113112 ENSG00000245958.5 RP11-33B1.1 -9.03 4.56e-18 6.92e-15 -0.39 -0.38 Corneal astigmatism; chr4:119234885 chr4:119454791~119552025:+ LUSC cis rs9322193 0.962 rs9322220 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149782897 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs10214845 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149783124 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9767122 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149783553 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs1413654 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149783956 chr6:149904243~149906418:+ LUSC cis rs9322193 0.683 rs113281309 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149787289 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9688809 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149787920 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9689242 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149787970 chr6:149904243~149906418:+ LUSC cis rs9322193 1 rs9767077 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149788479 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9688938 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149788941 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9688940 ENSG00000216906.2 RP11-350J20.9 9.03 4.57e-18 6.92e-15 0.46 0.38 Lung cancer; chr6:149788977 chr6:149904243~149906418:+ LUSC cis rs10875746 0.551 rs11168536 ENSG00000240399.1 RP1-228P16.1 -9.03 4.6e-18 6.97e-15 -0.46 -0.38 Longevity (90 years and older); chr12:48351268 chr12:48054813~48055591:- LUSC cis rs6921919 0.848 rs56131013 ENSG00000204709.4 LINC01556 9.02 4.63e-18 7.01e-15 0.55 0.38 Autism spectrum disorder or schizophrenia; chr6:28352900 chr6:28943877~28944537:+ LUSC cis rs10129255 0.5 rs8011115 ENSG00000211972.2 IGHV3-66 9.02 4.66e-18 7.05e-15 0.26 0.38 Kawasaki disease; chr14:106786292 chr14:106675017~106675544:- LUSC cis rs9341808 0.739 rs4706831 ENSG00000272129.1 RP11-250B2.6 9.02 4.68e-18 7.09e-15 0.46 0.38 Sitting height ratio; chr6:80297982 chr6:80355424~80356859:+ LUSC cis rs10740039 0.583 rs2127348 ENSG00000254271.1 RP11-131N11.4 -9.02 4.69e-18 7.09e-15 -0.53 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740945 chr10:60734342~60741828:+ LUSC cis rs10740039 0.583 rs2127349 ENSG00000254271.1 RP11-131N11.4 -9.02 4.69e-18 7.09e-15 -0.53 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740947 chr10:60734342~60741828:+ LUSC cis rs2337406 0.866 rs2301535 ENSG00000274576.2 IGHV2-70 -9.02 4.71e-18 7.13e-15 -0.41 -0.38 Alzheimer's disease (late onset); chr14:106790663 chr14:106770577~106771020:- LUSC cis rs11098499 0.789 rs10212719 ENSG00000245958.5 RP11-33B1.1 -9.02 4.71e-18 7.13e-15 -0.38 -0.38 Corneal astigmatism; chr4:119333282 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs17049949 ENSG00000245958.5 RP11-33B1.1 -9.02 4.71e-18 7.13e-15 -0.38 -0.38 Corneal astigmatism; chr4:119334135 chr4:119454791~119552025:+ LUSC cis rs2729354 0.729 rs2729353 ENSG00000265566.2 RN7SL605P -9.02 4.72e-18 7.14e-15 -0.54 -0.38 Blood protein levels; chr11:57480530 chr11:57528085~57528365:- LUSC cis rs6538678 0.929 rs7962359 ENSG00000258343.1 RP11-536G4.2 -9.02 4.72e-18 7.14e-15 -0.51 -0.38 Lupus nephritis in systemic lupus erythematosus; chr12:95862566 chr12:95795345~95858839:- LUSC cis rs6822297 0.522 rs7700108 ENSG00000240005.4 RP11-293A21.1 9.02 4.76e-18 7.2e-15 0.5 0.38 Obesity-related traits; chr4:26967785 chr4:26859806~26860599:- LUSC cis rs992157 0.835 rs12987219 ENSG00000261338.2 RP11-378A13.1 -9.02 4.76e-18 7.21e-15 -0.39 -0.38 Colorectal cancer; chr2:218279426 chr2:218255319~218257366:+ LUSC cis rs10875746 0.669 rs11168508 ENSG00000240399.1 RP1-228P16.1 -9.02 4.76e-18 7.21e-15 -0.44 -0.38 Longevity (90 years and older); chr12:48289728 chr12:48054813~48055591:- LUSC cis rs9487094 0.6 rs1885690 ENSG00000260273.1 RP11-425D10.10 9.02 4.77e-18 7.22e-15 0.45 0.38 Height; chr6:109351795 chr6:109382795~109383666:+ LUSC cis rs11098499 0.866 rs11098506 ENSG00000245958.5 RP11-33B1.1 -9.02 4.83e-18 7.3e-15 -0.38 -0.38 Corneal astigmatism; chr4:119363816 chr4:119454791~119552025:+ LUSC cis rs1707322 1 rs12097761 ENSG00000280836.1 AL355480.1 -9.02 4.83e-18 7.3e-15 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45825490 chr1:45581219~45581321:- LUSC cis rs6452524 1 rs10068099 ENSG00000249664.1 CTD-2227C6.2 9.02 4.83e-18 7.31e-15 0.39 0.38 Hypertension (SNP x SNP interaction); chr5:83161373 chr5:83012285~83013109:- LUSC cis rs1707322 1 rs12124847 ENSG00000280836.1 AL355480.1 -9.02 4.84e-18 7.31e-15 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45915178 chr1:45581219~45581321:- LUSC cis rs1799949 0.587 rs1824890 ENSG00000198496.9 NBR2 -9.02 4.85e-18 7.34e-15 -0.49 -0.38 Menopause (age at onset); chr17:43344536 chr17:43125610~43153671:+ LUSC cis rs9487094 0.626 rs3799845 ENSG00000260273.1 RP11-425D10.10 9.02 4.88e-18 7.38e-15 0.45 0.38 Height; chr6:109706514 chr6:109382795~109383666:+ LUSC cis rs9341808 0.556 rs1535075 ENSG00000272129.1 RP11-250B2.6 9.02 4.9e-18 7.41e-15 0.47 0.38 Sitting height ratio; chr6:80325089 chr6:80355424~80356859:+ LUSC cis rs494459 0.838 rs1784543 ENSG00000255239.1 AP002954.6 9.02 4.9e-18 7.41e-15 0.41 0.38 Height; chr11:118760944 chr11:118688039~118690600:- LUSC cis rs1707322 1 rs10890370 ENSG00000280836.1 AL355480.1 -9.02 4.9e-18 7.41e-15 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45923545 chr1:45581219~45581321:- LUSC cis rs12134133 1 rs2661357 ENSG00000274245.1 RP11-357P18.2 9.02 4.91e-18 7.42e-15 0.5 0.38 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310593 chr1:207372559~207373252:+ LUSC cis rs8040855 0.542 rs2342122 ENSG00000259295.5 CSPG4P12 -9.02 4.92e-18 7.44e-15 -0.45 -0.38 Bulimia nervosa; chr15:85185304 chr15:85191438~85213905:+ LUSC cis rs8040855 0.644 rs2342120 ENSG00000259295.5 CSPG4P12 -9.02 4.92e-18 7.44e-15 -0.45 -0.38 Bulimia nervosa; chr15:85185589 chr15:85191438~85213905:+ LUSC cis rs765787 0.53 rs12440238 ENSG00000259520.4 CTD-2651B20.3 -9.02 4.95e-18 7.47e-15 -0.49 -0.38 Uric acid levels; chr15:45220707 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11070444 ENSG00000259520.4 CTD-2651B20.3 -9.02 4.95e-18 7.47e-15 -0.49 -0.38 Uric acid levels; chr15:45220923 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11070445 ENSG00000259520.4 CTD-2651B20.3 -9.02 4.95e-18 7.47e-15 -0.49 -0.38 Uric acid levels; chr15:45220965 chr15:45251580~45279251:- LUSC cis rs765787 0.556 rs10851422 ENSG00000259520.4 CTD-2651B20.3 -9.02 4.95e-18 7.47e-15 -0.49 -0.38 Uric acid levels; chr15:45221540 chr15:45251580~45279251:- LUSC cis rs10875746 0.551 rs12322347 ENSG00000240399.1 RP1-228P16.1 -9.02 4.96e-18 7.49e-15 -0.45 -0.38 Longevity (90 years and older); chr12:48313915 chr12:48054813~48055591:- LUSC cis rs10875746 0.551 rs12322348 ENSG00000240399.1 RP1-228P16.1 -9.02 4.96e-18 7.49e-15 -0.45 -0.38 Longevity (90 years and older); chr12:48313916 chr12:48054813~48055591:- LUSC cis rs11098499 0.913 rs10010696 ENSG00000245958.5 RP11-33B1.1 -9.02 4.97e-18 7.51e-15 -0.39 -0.38 Corneal astigmatism; chr4:119243148 chr4:119454791~119552025:+ LUSC cis rs10875746 0.669 rs10431526 ENSG00000240399.1 RP1-228P16.1 -9.01 5.01e-18 7.56e-15 -0.45 -0.38 Longevity (90 years and older); chr12:48296360 chr12:48054813~48055591:- LUSC cis rs9487094 0.626 rs12204548 ENSG00000260273.1 RP11-425D10.10 9.01 5.03e-18 7.6e-15 0.46 0.38 Height; chr6:109715504 chr6:109382795~109383666:+ LUSC cis rs9487094 0.626 rs3799849 ENSG00000260273.1 RP11-425D10.10 9.01 5.03e-18 7.6e-15 0.46 0.38 Height; chr6:109715560 chr6:109382795~109383666:+ LUSC cis rs12134133 1 rs2782840 ENSG00000274245.1 RP11-357P18.2 9.01 5.08e-18 7.67e-15 0.5 0.38 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310838 chr1:207372559~207373252:+ LUSC cis rs992157 0.835 rs2045434 ENSG00000261338.2 RP11-378A13.1 -9.01 5.08e-18 7.67e-15 -0.39 -0.38 Colorectal cancer; chr2:218279775 chr2:218255319~218257366:+ LUSC cis rs867371 0.502 rs2047679 ENSG00000255769.6 GOLGA2P10 -9.01 5.15e-18 7.77e-15 -0.45 -0.38 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82239540 chr15:82472993~82513950:- LUSC cis rs35955747 0.669 rs878718 ENSG00000236132.1 CTA-440B3.1 -9.01 5.17e-18 7.8e-15 -0.47 -0.38 Neutrophil count;Sum basophil neutrophil counts; chr22:31156716 chr22:31816379~31817491:- LUSC cis rs10875746 0.669 rs11168459 ENSG00000240399.1 RP1-228P16.1 -9.01 5.17e-18 7.8e-15 -0.45 -0.38 Longevity (90 years and older); chr12:48202458 chr12:48054813~48055591:- LUSC cis rs526231 0.511 rs10434793 ENSG00000175749.11 EIF3KP1 9.01 5.18e-18 7.81e-15 0.47 0.38 Primary biliary cholangitis; chr5:103054111 chr5:103032376~103033031:+ LUSC cis rs992157 0.866 rs2292554 ENSG00000261338.2 RP11-378A13.1 -9.01 5.26e-18 7.93e-15 -0.39 -0.38 Colorectal cancer; chr2:218282145 chr2:218255319~218257366:+ LUSC cis rs1113500 0.933 rs11185250 ENSG00000226822.1 RP11-356N1.2 9.01 5.28e-18 7.95e-15 0.4 0.38 Growth-regulated protein alpha levels; chr1:108073795 chr1:108071482~108074519:+ LUSC cis rs1113500 0.933 rs1419003 ENSG00000226822.1 RP11-356N1.2 9.01 5.28e-18 7.95e-15 0.4 0.38 Growth-regulated protein alpha levels; chr1:108074333 chr1:108071482~108074519:+ LUSC cis rs1113500 0.933 rs11185259 ENSG00000226822.1 RP11-356N1.2 -9.01 5.29e-18 7.97e-15 -0.41 -0.38 Growth-regulated protein alpha levels; chr1:108092440 chr1:108071482~108074519:+ LUSC cis rs867371 0.502 rs7176926 ENSG00000255769.6 GOLGA2P10 -9.01 5.34e-18 8.05e-15 -0.45 -0.38 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82245753 chr15:82472993~82513950:- LUSC cis rs1707322 0.928 rs7527244 ENSG00000280836.1 AL355480.1 -9.01 5.35e-18 8.06e-15 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45903100 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs785498 ENSG00000280836.1 AL355480.1 9.01 5.36e-18 8.07e-15 0.46 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126742 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211200 ENSG00000280836.1 AL355480.1 -9.01 5.37e-18 8.1e-15 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45822680 chr1:45581219~45581321:- LUSC cis rs6597981 0.604 rs7945912 ENSG00000279672.1 CMB9-55F22.1 9.01 5.38e-18 8.11e-15 0.38 0.38 Breast cancer; chr11:750849 chr11:779617~780755:+ LUSC cis rs2729354 0.768 rs2581922 ENSG00000265566.2 RN7SL605P -9 5.42e-18 8.17e-15 -0.51 -0.38 Blood protein levels; chr11:57497927 chr11:57528085~57528365:- LUSC cis rs2739330 0.587 rs4820571 ENSG00000235689.1 AP000351.13 9 5.47e-18 8.24e-15 0.4 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:24006305~24008258:- LUSC cis rs9487094 0.67 rs11754455 ENSG00000260273.1 RP11-425D10.10 9 5.47e-18 8.24e-15 0.45 0.38 Height; chr6:109496680 chr6:109382795~109383666:+ LUSC cis rs494459 0.838 rs2510897 ENSG00000255239.1 AP002954.6 9 5.48e-18 8.25e-15 0.41 0.38 Height; chr11:118773873 chr11:118688039~118690600:- LUSC cis rs1707322 1 rs785490 ENSG00000280836.1 AL355480.1 9 5.53e-18 8.32e-15 0.47 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46111452 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs785493 ENSG00000280836.1 AL355480.1 9 5.53e-18 8.32e-15 0.47 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46119187 chr1:45581219~45581321:- LUSC cis rs1707322 0.964 rs785496 ENSG00000280836.1 AL355480.1 9 5.53e-18 8.32e-15 0.47 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46122334 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs785497 ENSG00000280836.1 AL355480.1 9 5.53e-18 8.32e-15 0.47 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126231 chr1:45581219~45581321:- LUSC cis rs12134133 1 rs28371583 ENSG00000274245.1 RP11-357P18.2 9 5.54e-18 8.34e-15 0.5 0.38 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207321334 chr1:207372559~207373252:+ LUSC cis rs17507216 0.718 rs72751675 ENSG00000278603.1 RP13-608F4.5 9 5.55e-18 8.35e-15 0.6 0.38 Excessive daytime sleepiness; chr15:82630452 chr15:82472203~82472426:+ LUSC cis rs7397814 0.558 rs4764447 ENSG00000256975.1 RP11-525E9.1 -9 5.55e-18 8.36e-15 -0.48 -0.38 IgG glycosylation; chr12:9426513 chr12:9506347~9508440:- LUSC cis rs11098499 0.955 rs11944880 ENSG00000245958.5 RP11-33B1.1 9 5.56e-18 8.37e-15 0.39 0.38 Corneal astigmatism; chr4:119238179 chr4:119454791~119552025:+ LUSC cis rs748404 0.631 rs3809482 ENSG00000249839.1 AC011330.5 -9 5.59e-18 8.42e-15 -0.52 -0.38 Lung cancer; chr15:43369604 chr15:43663654~43684339:- LUSC cis rs9341808 0.718 rs9359408 ENSG00000272129.1 RP11-250B2.6 9 5.64e-18 8.49e-15 0.46 0.38 Sitting height ratio; chr6:80110415 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs9443734 ENSG00000272129.1 RP11-250B2.6 9 5.64e-18 8.49e-15 0.46 0.38 Sitting height ratio; chr6:80110576 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs9443735 ENSG00000272129.1 RP11-250B2.6 9 5.64e-18 8.49e-15 0.46 0.38 Sitting height ratio; chr6:80110757 chr6:80355424~80356859:+ LUSC cis rs6921919 0.609 rs1005127 ENSG00000216901.1 AL022393.7 9 5.65e-18 8.49e-15 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28399881 chr6:28176188~28176674:+ LUSC cis rs853679 0.515 rs4580862 ENSG00000216901.1 AL022393.7 9 5.65e-18 8.49e-15 0.44 0.38 Depression; chr6:28399886 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs4357130 ENSG00000216901.1 AL022393.7 9 5.65e-18 8.49e-15 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28399906 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs9461459 ENSG00000216901.1 AL022393.7 9 5.66e-18 8.51e-15 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28394139 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs28360638 ENSG00000216901.1 AL022393.7 9 5.66e-18 8.51e-15 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28394552 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs9468368 ENSG00000216901.1 AL022393.7 9 5.66e-18 8.51e-15 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28397172 chr6:28176188~28176674:+ LUSC cis rs9487094 0.67 rs12197180 ENSG00000260273.1 RP11-425D10.10 9 5.71e-18 8.58e-15 0.45 0.38 Height; chr6:109500687 chr6:109382795~109383666:+ LUSC cis rs7189233 0.531 rs8049033 ENSG00000279344.1 RP11-44F14.7 9 5.73e-18 8.61e-15 0.33 0.38 Intelligence (multi-trait analysis); chr16:53479143 chr16:53478957~53481550:- LUSC cis rs9487094 0.67 rs7755941 ENSG00000260273.1 RP11-425D10.10 9 5.74e-18 8.63e-15 0.45 0.38 Height; chr6:109494148 chr6:109382795~109383666:+ LUSC cis rs9487094 0.626 rs12195904 ENSG00000260273.1 RP11-425D10.10 9 5.74e-18 8.63e-15 0.45 0.38 Height; chr6:109494760 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs1406899 ENSG00000260273.1 RP11-425D10.10 9 5.74e-18 8.63e-15 0.45 0.38 Height; chr6:109495102 chr6:109382795~109383666:+ LUSC cis rs9487094 0.67 rs2024849 ENSG00000260273.1 RP11-425D10.10 9 5.74e-18 8.63e-15 0.45 0.38 Height; chr6:109497088 chr6:109382795~109383666:+ LUSC cis rs1075265 0.584 rs1862122 ENSG00000233266.1 HMGB1P31 -9 5.76e-18 8.65e-15 -0.48 -0.38 Chronotype;Morning vs. evening chronotype; chr2:54052992 chr2:54051334~54051760:+ LUSC cis rs9341808 0.718 rs35447745 ENSG00000272129.1 RP11-250B2.6 9 5.78e-18 8.69e-15 0.46 0.38 Sitting height ratio; chr6:80107031 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs9352801 ENSG00000272129.1 RP11-250B2.6 9 5.78e-18 8.69e-15 0.46 0.38 Sitting height ratio; chr6:80107751 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs9361584 ENSG00000272129.1 RP11-250B2.6 9 5.78e-18 8.69e-15 0.46 0.38 Sitting height ratio; chr6:80110229 chr6:80355424~80356859:+ LUSC cis rs9487094 0.689 rs9487064 ENSG00000260273.1 RP11-425D10.10 9 5.79e-18 8.69e-15 0.45 0.38 Height; chr6:109346560 chr6:109382795~109383666:+ LUSC cis rs9487094 0.689 rs9487066 ENSG00000260273.1 RP11-425D10.10 9 5.79e-18 8.69e-15 0.45 0.38 Height; chr6:109347707 chr6:109382795~109383666:+ LUSC cis rs853679 0.517 rs9380047 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28070115 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs7755442 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28071237 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs55747925 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28076559 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs34716816 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28078391 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9380049 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28080757 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9380050 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28080760 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9393885 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28082231 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9393886 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28082261 chr6:28115628~28116551:+ LUSC cis rs4713118 0.515 rs9368549 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Parkinson's disease; chr6:28082269 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs56364346 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28082984 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9357061 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28083994 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9368550 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28084025 chr6:28115628~28116551:+ LUSC cis rs853679 0.542 rs2295594 ENSG00000219392.1 RP1-265C24.5 -9 5.79e-18 8.69e-15 -0.53 -0.38 Depression; chr6:28085319 chr6:28115628~28116551:+ LUSC cis rs6920372 0.708 rs13198852 ENSG00000260273.1 RP11-425D10.10 8.99 5.85e-18 8.77e-15 0.46 0.38 Height; chr6:109747119 chr6:109382795~109383666:+ LUSC cis rs9341808 0.754 rs9341811 ENSG00000272129.1 RP11-250B2.6 8.99 5.86e-18 8.79e-15 0.46 0.38 Sitting height ratio; chr6:80272984 chr6:80355424~80356859:+ LUSC cis rs1799949 0.628 rs4474733 ENSG00000198496.9 NBR2 -8.99 5.87e-18 8.81e-15 -0.47 -0.38 Menopause (age at onset); chr17:43356292 chr17:43125610~43153671:+ LUSC cis rs526231 0.511 rs62362558 ENSG00000175749.11 EIF3KP1 8.99 5.89e-18 8.83e-15 0.47 0.38 Primary biliary cholangitis; chr5:103032789 chr5:103032376~103033031:+ LUSC cis rs526231 0.511 rs4421079 ENSG00000175749.11 EIF3KP1 8.99 5.89e-18 8.83e-15 0.47 0.38 Primary biliary cholangitis; chr5:103033372 chr5:103032376~103033031:+ LUSC cis rs6991838 0.8 rs11786598 ENSG00000272010.1 CTD-3025N20.3 -8.99 5.9e-18 8.84e-15 -0.42 -0.38 Intelligence (multi-trait analysis); chr8:65559944 chr8:65591850~65592472:- LUSC cis rs9322193 0.923 rs12176034 ENSG00000216906.2 RP11-350J20.9 8.99 5.95e-18 8.92e-15 0.47 0.38 Lung cancer; chr6:149800557 chr6:149904243~149906418:+ LUSC cis rs9487094 0.67 rs2024853 ENSG00000260273.1 RP11-425D10.10 8.99 5.96e-18 8.93e-15 0.45 0.38 Height; chr6:109498751 chr6:109382795~109383666:+ LUSC cis rs494459 0.756 rs570806 ENSG00000255239.1 AP002954.6 8.99 5.96e-18 8.93e-15 0.41 0.38 Height; chr11:118786602 chr11:118688039~118690600:- LUSC cis rs10875746 0.669 rs4760701 ENSG00000240399.1 RP1-228P16.1 -8.99 6.02e-18 9.03e-15 -0.43 -0.38 Longevity (90 years and older); chr12:48304735 chr12:48054813~48055591:- LUSC cis rs6991838 0.584 rs35790435 ENSG00000200714.1 Y_RNA -8.99 6.04e-18 9.05e-15 -0.47 -0.38 Intelligence (multi-trait analysis); chr8:65590288 chr8:65592731~65592820:+ LUSC cis rs9322193 0.962 rs9322206 ENSG00000216906.2 RP11-350J20.9 8.99 6.06e-18 9.07e-15 0.45 0.38 Lung cancer; chr6:149641481 chr6:149904243~149906418:+ LUSC cis rs10754283 0.756 rs17441836 ENSG00000231613.1 RP5-943J3.1 8.99 6.06e-18 9.08e-15 0.44 0.38 Amyotrophic lateral sclerosis (sporadic); chr1:89669874 chr1:89788914~89790492:+ LUSC cis rs73086581 0.568 rs6084541 ENSG00000229539.1 RP11-119B16.2 -8.99 6.07e-18 9.09e-15 -0.42 -0.38 Response to antidepressants in depression; chr20:3982084 chr20:3888239~3888868:- LUSC cis rs2729354 0.768 rs2848635 ENSG00000265566.2 RN7SL605P -8.99 6.1e-18 9.13e-15 -0.55 -0.38 Blood protein levels; chr11:57486458 chr11:57528085~57528365:- LUSC cis rs2337406 0.789 rs9324095 ENSG00000274576.2 IGHV2-70 -8.99 6.1e-18 9.14e-15 -0.39 -0.38 Alzheimer's disease (late onset); chr14:106795885 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs58154560 ENSG00000274576.2 IGHV2-70 -8.99 6.1e-18 9.14e-15 -0.39 -0.38 Alzheimer's disease (late onset); chr14:106799601 chr14:106770577~106771020:- LUSC cis rs10256972 0.758 rs7799391 ENSG00000229043.2 AC091729.9 -8.99 6.11e-18 9.15e-15 -0.45 -0.38 Endometriosis;Longevity; chr7:1042930 chr7:1160374~1165267:+ LUSC cis rs7684253 0.565 rs7697176 ENSG00000269949.1 RP11-738E22.3 -8.99 6.13e-18 9.18e-15 -0.46 -0.38 Migraine; chr4:56956882 chr4:56960927~56961373:- LUSC cis rs2882667 0.537 rs7704790 ENSG00000253404.1 AC034243.1 8.99 6.13e-18 9.18e-15 0.46 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139074407 chr5:138744434~138753309:- LUSC cis rs11098499 0.909 rs1809406 ENSG00000245958.5 RP11-33B1.1 -8.99 6.14e-18 9.19e-15 -0.39 -0.38 Corneal astigmatism; chr4:119455967 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs9994810 ENSG00000245958.5 RP11-33B1.1 -8.99 6.14e-18 9.19e-15 -0.39 -0.38 Corneal astigmatism; chr4:119460435 chr4:119454791~119552025:+ LUSC cis rs11098499 0.697 rs10020027 ENSG00000245958.5 RP11-33B1.1 -8.99 6.14e-18 9.19e-15 -0.39 -0.38 Corneal astigmatism; chr4:119460724 chr4:119454791~119552025:+ LUSC cis rs11098499 0.779 rs7356491 ENSG00000245958.5 RP11-33B1.1 -8.99 6.14e-18 9.19e-15 -0.39 -0.38 Corneal astigmatism; chr4:119460819 chr4:119454791~119552025:+ LUSC cis rs6538678 0.929 rs10735336 ENSG00000258343.1 RP11-536G4.2 -8.99 6.14e-18 9.19e-15 -0.51 -0.38 Lupus nephritis in systemic lupus erythematosus; chr12:95869661 chr12:95795345~95858839:- LUSC cis rs1707322 1 rs10890382 ENSG00000280836.1 AL355480.1 -8.99 6.2e-18 9.28e-15 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46004002 chr1:45581219~45581321:- LUSC cis rs9487094 0.6 rs10457193 ENSG00000260273.1 RP11-425D10.10 8.99 6.23e-18 9.32e-15 0.44 0.38 Height; chr6:109507364 chr6:109382795~109383666:+ LUSC cis rs9487094 0.558 rs10457194 ENSG00000260273.1 RP11-425D10.10 8.99 6.23e-18 9.32e-15 0.44 0.38 Height; chr6:109507366 chr6:109382795~109383666:+ LUSC cis rs9601248 0.874 rs2093621 ENSG00000227676.3 LINC01068 8.98 6.33e-18 9.47e-15 0.47 0.38 Major depressive disorder; chr13:79613953 chr13:79566727~79571436:+ LUSC cis rs9601248 0.874 rs2093620 ENSG00000227676.3 LINC01068 8.98 6.33e-18 9.47e-15 0.47 0.38 Major depressive disorder; chr13:79613954 chr13:79566727~79571436:+ LUSC cis rs9322193 0.923 rs7753812 ENSG00000216906.2 RP11-350J20.9 8.98 6.34e-18 9.47e-15 0.46 0.38 Lung cancer; chr6:149690150 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs12195866 ENSG00000216906.2 RP11-350J20.9 8.98 6.34e-18 9.47e-15 0.46 0.38 Lung cancer; chr6:149693334 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9285524 ENSG00000216906.2 RP11-350J20.9 8.98 6.34e-18 9.47e-15 0.46 0.38 Lung cancer; chr6:149694122 chr6:149904243~149906418:+ LUSC cis rs6921919 0.848 rs6903652 ENSG00000204709.4 LINC01556 8.98 6.34e-18 9.48e-15 0.56 0.38 Autism spectrum disorder or schizophrenia; chr6:28354343 chr6:28943877~28944537:+ LUSC cis rs26232 0.583 rs26434 ENSG00000175749.11 EIF3KP1 -8.98 6.37e-18 9.53e-15 -0.47 -0.38 Rheumatoid arthritis; chr5:103027698 chr5:103032376~103033031:+ LUSC cis rs1823913 0.927 rs13025919 ENSG00000227542.1 AC092614.2 8.98 6.38e-18 9.54e-15 0.52 0.38 Obesity-related traits; chr2:191260175 chr2:191229165~191246172:- LUSC cis rs7189233 0.531 rs62048526 ENSG00000279344.1 RP11-44F14.7 8.98 6.41e-18 9.59e-15 0.33 0.38 Intelligence (multi-trait analysis); chr16:53478014 chr16:53478957~53481550:- LUSC cis rs992157 0.717 rs3817266 ENSG00000261338.2 RP11-378A13.1 -8.98 6.42e-18 9.59e-15 -0.39 -0.38 Colorectal cancer; chr2:218277871 chr2:218255319~218257366:+ LUSC cis rs992157 0.835 rs2292551 ENSG00000261338.2 RP11-378A13.1 -8.98 6.42e-18 9.59e-15 -0.39 -0.38 Colorectal cancer; chr2:218278506 chr2:218255319~218257366:+ LUSC cis rs992157 0.835 rs12987180 ENSG00000261338.2 RP11-378A13.1 -8.98 6.42e-18 9.59e-15 -0.39 -0.38 Colorectal cancer; chr2:218279366 chr2:218255319~218257366:+ LUSC cis rs992157 0.835 rs4674283 ENSG00000261338.2 RP11-378A13.1 -8.98 6.42e-18 9.59e-15 -0.39 -0.38 Colorectal cancer; chr2:218279531 chr2:218255319~218257366:+ LUSC cis rs62229266 0.609 rs12482541 ENSG00000231106.2 LINC01436 8.98 6.43e-18 9.61e-15 0.49 0.38 Mitral valve prolapse; chr21:36047445 chr21:36005338~36007838:+ LUSC cis rs62229266 0.609 rs2835253 ENSG00000231106.2 LINC01436 8.98 6.43e-18 9.61e-15 0.49 0.38 Mitral valve prolapse; chr21:36047447 chr21:36005338~36007838:+ LUSC cis rs6782228 1 rs35604103 ENSG00000242551.2 POU5F1P6 8.98 6.44e-18 9.63e-15 0.48 0.38 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128616009 chr3:128674735~128677005:- LUSC cis rs765787 0.53 rs4775819 ENSG00000259520.4 CTD-2651B20.3 8.98 6.46e-18 9.65e-15 0.47 0.38 Uric acid levels; chr15:45233768 chr15:45251580~45279251:- LUSC cis rs11098499 0.865 rs10213221 ENSG00000245958.5 RP11-33B1.1 -8.98 6.49e-18 9.7e-15 -0.38 -0.38 Corneal astigmatism; chr4:119334771 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs1397608 ENSG00000245958.5 RP11-33B1.1 -8.98 6.53e-18 9.75e-15 -0.39 -0.38 Corneal astigmatism; chr4:119240589 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs7685268 ENSG00000245958.5 RP11-33B1.1 -8.98 6.53e-18 9.75e-15 -0.39 -0.38 Corneal astigmatism; chr4:119241033 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs7684942 ENSG00000245958.5 RP11-33B1.1 -8.98 6.53e-18 9.75e-15 -0.39 -0.38 Corneal astigmatism; chr4:119241046 chr4:119454791~119552025:+ LUSC cis rs9341808 0.754 rs6907729 ENSG00000272129.1 RP11-250B2.6 -8.98 6.54e-18 9.77e-15 -0.46 -0.38 Sitting height ratio; chr6:80295205 chr6:80355424~80356859:+ LUSC cis rs12022452 0.506 rs11208363 ENSG00000238287.1 RP11-656D10.3 -8.98 6.6e-18 9.84e-15 -0.55 -0.38 Age-related hearing impairment (SNP x SNP interaction); chr1:40544782 chr1:40493157~40508661:- LUSC cis rs1707322 0.789 rs7540578 ENSG00000280836.1 AL355480.1 -8.98 6.64e-18 9.91e-15 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45786472 chr1:45581219~45581321:- LUSC cis rs11098499 0.954 rs13107475 ENSG00000245958.5 RP11-33B1.1 -8.98 6.65e-18 9.93e-15 -0.39 -0.38 Corneal astigmatism; chr4:119471856 chr4:119454791~119552025:+ LUSC cis rs867371 0.502 rs3759800 ENSG00000255769.6 GOLGA2P10 8.98 6.68e-18 9.96e-15 0.44 0.38 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82240622 chr15:82472993~82513950:- LUSC cis rs6991838 0.53 rs6472217 ENSG00000200714.1 Y_RNA 8.98 6.68e-18 9.97e-15 0.47 0.38 Intelligence (multi-trait analysis); chr8:65635496 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs6472218 ENSG00000200714.1 Y_RNA 8.98 6.68e-18 9.97e-15 0.47 0.38 Intelligence (multi-trait analysis); chr8:65635502 chr8:65592731~65592820:+ LUSC cis rs9322193 0.923 rs2342857 ENSG00000216906.2 RP11-350J20.9 8.98 6.68e-18 9.97e-15 0.46 0.38 Lung cancer; chr6:149809537 chr6:149904243~149906418:+ LUSC cis rs1707322 0.963 rs10890373 ENSG00000280836.1 AL355480.1 -8.98 6.69e-18 9.97e-15 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45928083 chr1:45581219~45581321:- LUSC cis rs11098499 0.82 rs2389885 ENSG00000249244.1 RP11-548H18.2 8.98 6.7e-18 9.99e-15 0.5 0.38 Corneal astigmatism; chr4:119612776 chr4:119391831~119395335:- LUSC cis rs1707322 1 rs11211222 ENSG00000280836.1 AL355480.1 -8.98 6.7e-18 9.99e-15 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45902085 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs9787412 ENSG00000280836.1 AL355480.1 -8.98 6.7e-18 9.99e-15 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45905924 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4660896 ENSG00000280836.1 AL355480.1 -8.98 6.7e-18 9.99e-15 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45906744 chr1:45581219~45581321:- LUSC cis rs1707322 0.928 rs10732844 ENSG00000280836.1 AL355480.1 -8.98 6.7e-18 9.99e-15 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45907016 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs12133129 ENSG00000280836.1 AL355480.1 -8.98 6.7e-18 9.99e-15 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45907676 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs4553121 ENSG00000280836.1 AL355480.1 -8.98 6.7e-18 9.99e-15 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45909581 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs6690652 ENSG00000280836.1 AL355480.1 -8.98 6.7e-18 9.99e-15 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45911020 chr1:45581219~45581321:- LUSC cis rs8040855 0.644 rs7495437 ENSG00000259295.5 CSPG4P12 -8.98 6.73e-18 1e-14 -0.44 -0.38 Bulimia nervosa; chr15:85183059 chr15:85191438~85213905:+ LUSC cis rs12439619 0.508 rs8023960 ENSG00000255769.6 GOLGA2P10 -8.98 6.74e-18 1e-14 -0.47 -0.38 Intelligence (multi-trait analysis); chr15:82206704 chr15:82472993~82513950:- LUSC cis rs7208859 0.673 rs2470251 ENSG00000263531.1 RP13-753N3.1 8.98 6.74e-18 1e-14 0.61 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30768043 chr17:30863921~30864940:- LUSC cis rs9341808 0.556 rs1474791 ENSG00000272129.1 RP11-250B2.6 8.98 6.74e-18 1e-14 0.47 0.38 Sitting height ratio; chr6:80323380 chr6:80355424~80356859:+ LUSC cis rs853679 0.517 rs9366715 ENSG00000219392.1 RP1-265C24.5 -8.98 6.74e-18 1e-14 -0.53 -0.38 Depression; chr6:28096855 chr6:28115628~28116551:+ LUSC cis rs11098499 0.754 rs1980027 ENSG00000245958.5 RP11-33B1.1 -8.98 6.76e-18 1.01e-14 -0.38 -0.38 Corneal astigmatism; chr4:119330422 chr4:119454791~119552025:+ LUSC cis rs9341808 0.53 rs3805877 ENSG00000272129.1 RP11-250B2.6 8.97 6.83e-18 1.02e-14 0.46 0.38 Sitting height ratio; chr6:80321812 chr6:80355424~80356859:+ LUSC cis rs9341808 0.53 rs3805876 ENSG00000272129.1 RP11-250B2.6 8.97 6.83e-18 1.02e-14 0.46 0.38 Sitting height ratio; chr6:80321822 chr6:80355424~80356859:+ LUSC cis rs1113500 0.965 rs10881495 ENSG00000226822.1 RP11-356N1.2 8.97 6.84e-18 1.02e-14 0.4 0.38 Growth-regulated protein alpha levels; chr1:108068364 chr1:108071482~108074519:+ LUSC cis rs2283792 0.776 rs9610458 ENSG00000228050.1 TOP3BP1 8.97 6.88e-18 1.02e-14 0.45 0.38 Multiple sclerosis; chr22:21851064 chr22:22223187~22224566:- LUSC cis rs2337406 0.866 rs2027901 ENSG00000274576.2 IGHV2-70 -8.97 6.89e-18 1.03e-14 -0.4 -0.38 Alzheimer's disease (late onset); chr14:106807164 chr14:106770577~106771020:- LUSC cis rs6538678 0.963 rs11108310 ENSG00000258343.1 RP11-536G4.2 -8.97 6.91e-18 1.03e-14 -0.51 -0.38 Lupus nephritis in systemic lupus erythematosus; chr12:95864164 chr12:95795345~95858839:- LUSC cis rs1150668 0.796 rs213236 ENSG00000204709.4 LINC01556 8.97 6.94e-18 1.03e-14 0.46 0.38 Pubertal anthropometrics; chr6:28356620 chr6:28943877~28944537:+ LUSC cis rs10256972 0.721 rs6975972 ENSG00000229043.2 AC091729.9 -8.97 6.97e-18 1.04e-14 -0.45 -0.38 Endometriosis;Longevity; chr7:1030832 chr7:1160374~1165267:+ LUSC cis rs1150668 0.796 rs213237 ENSG00000204709.4 LINC01556 8.97 7.01e-18 1.04e-14 0.46 0.38 Pubertal anthropometrics; chr6:28356161 chr6:28943877~28944537:+ LUSC cis rs10740039 0.583 rs2127350 ENSG00000254271.1 RP11-131N11.4 -8.97 7.03e-18 1.05e-14 -0.53 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60741079 chr10:60734342~60741828:+ LUSC cis rs992157 0.835 rs7585702 ENSG00000261338.2 RP11-378A13.1 -8.97 7.08e-18 1.05e-14 -0.39 -0.38 Colorectal cancer; chr2:218281884 chr2:218255319~218257366:+ LUSC cis rs992157 0.835 rs10932769 ENSG00000261338.2 RP11-378A13.1 -8.97 7.08e-18 1.05e-14 -0.39 -0.38 Colorectal cancer; chr2:218282522 chr2:218255319~218257366:+ LUSC cis rs992157 0.835 rs6729058 ENSG00000261338.2 RP11-378A13.1 -8.97 7.08e-18 1.05e-14 -0.39 -0.38 Colorectal cancer; chr2:218283646 chr2:218255319~218257366:+ LUSC cis rs1577917 1 rs6933377 ENSG00000203875.9 SNHG5 8.97 7.11e-18 1.06e-14 0.48 0.38 Response to antipsychotic treatment; chr6:85995537 chr6:85660950~85678736:- LUSC cis rs494459 0.657 rs614554 ENSG00000255239.1 AP002954.6 8.97 7.13e-18 1.06e-14 0.41 0.38 Height; chr11:118764443 chr11:118688039~118690600:- LUSC cis rs9322193 0.923 rs6913486 ENSG00000216906.2 RP11-350J20.9 -8.97 7.17e-18 1.07e-14 -0.48 -0.38 Lung cancer; chr6:149705060 chr6:149904243~149906418:+ LUSC cis rs9341808 0.727 rs1324120 ENSG00000272129.1 RP11-250B2.6 8.97 7.19e-18 1.07e-14 0.46 0.38 Sitting height ratio; chr6:80266408 chr6:80355424~80356859:+ LUSC cis rs6921919 0.583 rs4642462 ENSG00000216901.1 AL022393.7 8.97 7.22e-18 1.07e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28421474 chr6:28176188~28176674:+ LUSC cis rs17507216 0.718 rs72751657 ENSG00000278603.1 RP13-608F4.5 8.97 7.23e-18 1.07e-14 0.6 0.38 Excessive daytime sleepiness; chr15:82581259 chr15:82472203~82472426:+ LUSC cis rs748404 0.631 rs6493086 ENSG00000249839.1 AC011330.5 -8.97 7.27e-18 1.08e-14 -0.52 -0.38 Lung cancer; chr15:43363196 chr15:43663654~43684339:- LUSC cis rs6921919 0.583 rs2027361 ENSG00000216901.1 AL022393.7 8.96 7.39e-18 1.1e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28420531 chr6:28176188~28176674:+ LUSC cis rs10875746 0.551 rs2054903 ENSG00000240399.1 RP1-228P16.1 -8.96 7.42e-18 1.1e-14 -0.44 -0.38 Longevity (90 years and older); chr12:48330710 chr12:48054813~48055591:- LUSC cis rs4728142 0.604 rs7807018 ENSG00000275106.1 RP11-309L24.10 -8.96 7.43e-18 1.1e-14 -0.49 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129000134 chr7:128952527~128953316:- LUSC cis rs853679 0.517 rs9283884 ENSG00000219392.1 RP1-265C24.5 8.96 7.44e-18 1.1e-14 0.54 0.38 Depression; chr6:28167882 chr6:28115628~28116551:+ LUSC cis rs6921919 0.559 rs13210866 ENSG00000216901.1 AL022393.7 8.96 7.49e-18 1.11e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28416065 chr6:28176188~28176674:+ LUSC cis rs6921919 0.609 rs36018474 ENSG00000216901.1 AL022393.7 8.96 7.49e-18 1.11e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28417752 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs13201726 ENSG00000216901.1 AL022393.7 8.96 7.49e-18 1.11e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28417774 chr6:28176188~28176674:+ LUSC cis rs11098499 0.82 rs11737395 ENSG00000249244.1 RP11-548H18.2 8.96 7.5e-18 1.11e-14 0.49 0.38 Corneal astigmatism; chr4:119599549 chr4:119391831~119395335:- LUSC cis rs992157 0.775 rs7559428 ENSG00000261338.2 RP11-378A13.1 -8.96 7.51e-18 1.11e-14 -0.39 -0.38 Colorectal cancer; chr2:218285515 chr2:218255319~218257366:+ LUSC cis rs992157 0.804 rs7559525 ENSG00000261338.2 RP11-378A13.1 -8.96 7.51e-18 1.11e-14 -0.39 -0.38 Colorectal cancer; chr2:218285584 chr2:218255319~218257366:+ LUSC cis rs992157 0.835 rs13005100 ENSG00000261338.2 RP11-378A13.1 -8.96 7.51e-18 1.11e-14 -0.39 -0.38 Colorectal cancer; chr2:218287044 chr2:218255319~218257366:+ LUSC cis rs992157 0.835 rs13031757 ENSG00000261338.2 RP11-378A13.1 -8.96 7.51e-18 1.11e-14 -0.39 -0.38 Colorectal cancer; chr2:218287203 chr2:218255319~218257366:+ LUSC cis rs9322193 0.607 rs12210822 ENSG00000216906.2 RP11-350J20.9 8.96 7.65e-18 1.14e-14 0.51 0.38 Lung cancer; chr6:149905356 chr6:149904243~149906418:+ LUSC cis rs11098499 0.754 rs66900435 ENSG00000245958.5 RP11-33B1.1 -8.96 7.68e-18 1.14e-14 -0.38 -0.38 Corneal astigmatism; chr4:119328270 chr4:119454791~119552025:+ LUSC cis rs62229266 0.659 rs62230814 ENSG00000231106.2 LINC01436 8.96 7.69e-18 1.14e-14 0.49 0.38 Mitral valve prolapse; chr21:36031248 chr21:36005338~36007838:+ LUSC cis rs992157 0.835 rs10932768 ENSG00000261338.2 RP11-378A13.1 -8.96 7.71e-18 1.14e-14 -0.39 -0.38 Colorectal cancer; chr2:218281476 chr2:218255319~218257366:+ LUSC cis rs1707322 1 rs11211223 ENSG00000280836.1 AL355480.1 -8.96 7.75e-18 1.15e-14 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45914933 chr1:45581219~45581321:- LUSC cis rs12134133 1 rs6660557 ENSG00000274245.1 RP11-357P18.2 8.96 7.75e-18 1.15e-14 0.48 0.38 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207281251 chr1:207372559~207373252:+ LUSC cis rs9487094 0.666 rs9480956 ENSG00000260273.1 RP11-425D10.10 8.96 7.83e-18 1.16e-14 0.45 0.38 Height; chr6:109424305 chr6:109382795~109383666:+ LUSC cis rs9487094 0.689 rs12214147 ENSG00000260273.1 RP11-425D10.10 8.96 7.83e-18 1.16e-14 0.45 0.38 Height; chr6:109425054 chr6:109382795~109383666:+ LUSC cis rs9487094 0.689 rs17070591 ENSG00000260273.1 RP11-425D10.10 8.96 7.83e-18 1.16e-14 0.45 0.38 Height; chr6:109426518 chr6:109382795~109383666:+ LUSC cis rs9487094 0.666 rs7751582 ENSG00000260273.1 RP11-425D10.10 8.96 7.83e-18 1.16e-14 0.45 0.38 Height; chr6:109427644 chr6:109382795~109383666:+ LUSC cis rs9487094 0.689 rs9487103 ENSG00000260273.1 RP11-425D10.10 8.96 7.83e-18 1.16e-14 0.45 0.38 Height; chr6:109430292 chr6:109382795~109383666:+ LUSC cis rs853679 0.55 rs1233707 ENSG00000219392.1 RP1-265C24.5 -8.96 7.84e-18 1.16e-14 -0.52 -0.38 Depression; chr6:28205175 chr6:28115628~28116551:+ LUSC cis rs9341808 0.718 rs4437429 ENSG00000272129.1 RP11-250B2.6 8.96 7.85e-18 1.16e-14 0.46 0.38 Sitting height ratio; chr6:80118875 chr6:80355424~80356859:+ LUSC cis rs1707322 1 rs10789479 ENSG00000280836.1 AL355480.1 -8.96 7.88e-18 1.17e-14 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45886828 chr1:45581219~45581321:- LUSC cis rs7189233 0.531 rs7199401 ENSG00000279344.1 RP11-44F14.7 8.96 7.9e-18 1.17e-14 0.33 0.38 Intelligence (multi-trait analysis); chr16:53483038 chr16:53478957~53481550:- LUSC cis rs11098499 0.954 rs2389803 ENSG00000245958.5 RP11-33B1.1 8.96 7.9e-18 1.17e-14 0.39 0.38 Corneal astigmatism; chr4:119472356 chr4:119454791~119552025:+ LUSC cis rs10875746 0.551 rs3751273 ENSG00000240399.1 RP1-228P16.1 -8.96 7.91e-18 1.17e-14 -0.45 -0.38 Longevity (90 years and older); chr12:48345655 chr12:48054813~48055591:- LUSC cis rs10875746 0.551 rs10875799 ENSG00000240399.1 RP1-228P16.1 -8.96 7.91e-18 1.17e-14 -0.45 -0.38 Longevity (90 years and older); chr12:48347096 chr12:48054813~48055591:- LUSC cis rs11098499 0.82 rs13122709 ENSG00000249244.1 RP11-548H18.2 8.96 7.95e-18 1.18e-14 0.49 0.38 Corneal astigmatism; chr4:119634201 chr4:119391831~119395335:- LUSC cis rs6782228 0.585 rs9841161 ENSG00000277250.1 Metazoa_SRP -8.95 8e-18 1.18e-14 -0.42 -0.38 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613027 chr3:128673681~128674021:- LUSC cis rs6782228 0.606 rs2712405 ENSG00000277250.1 Metazoa_SRP -8.95 8e-18 1.18e-14 -0.42 -0.38 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613239 chr3:128673681~128674021:- LUSC cis rs9322193 0.926 rs9766562 ENSG00000216906.2 RP11-350J20.9 8.95 8.09e-18 1.2e-14 0.46 0.38 Lung cancer; chr6:149788709 chr6:149904243~149906418:+ LUSC cis rs6991838 0.831 rs4394432 ENSG00000272010.1 CTD-3025N20.3 8.95 8.09e-18 1.2e-14 0.42 0.38 Intelligence (multi-trait analysis); chr8:65560939 chr8:65591850~65592472:- LUSC cis rs1150668 0.796 rs1124132 ENSG00000204709.4 LINC01556 8.95 8.1e-18 1.2e-14 0.46 0.38 Pubertal anthropometrics; chr6:28412544 chr6:28943877~28944537:+ LUSC cis rs1150668 0.699 rs1736895 ENSG00000204709.4 LINC01556 8.95 8.12e-18 1.2e-14 0.45 0.38 Pubertal anthropometrics; chr6:28252048 chr6:28943877~28944537:+ LUSC cis rs9341808 0.754 rs9341810 ENSG00000272129.1 RP11-250B2.6 8.95 8.12e-18 1.2e-14 0.46 0.38 Sitting height ratio; chr6:80265121 chr6:80355424~80356859:+ LUSC cis rs9341808 0.7 rs12215236 ENSG00000272129.1 RP11-250B2.6 8.95 8.12e-18 1.2e-14 0.46 0.38 Sitting height ratio; chr6:80265341 chr6:80355424~80356859:+ LUSC cis rs4728142 0.584 rs7796963 ENSG00000275106.1 RP11-309L24.10 -8.95 8.17e-18 1.21e-14 -0.49 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128988947 chr7:128952527~128953316:- LUSC cis rs9487094 0.689 rs4636056 ENSG00000260273.1 RP11-425D10.10 8.95 8.18e-18 1.21e-14 0.45 0.38 Height; chr6:109409679 chr6:109382795~109383666:+ LUSC cis rs6822297 0.504 rs9291487 ENSG00000240005.4 RP11-293A21.1 8.95 8.27e-18 1.22e-14 0.49 0.38 Obesity-related traits; chr4:26965862 chr4:26859806~26860599:- LUSC cis rs853679 0.517 rs56310871 ENSG00000219392.1 RP1-265C24.5 -8.95 8.27e-18 1.22e-14 -0.53 -0.38 Depression; chr6:28076704 chr6:28115628~28116551:+ LUSC cis rs6991838 0.584 rs2175810 ENSG00000272010.1 CTD-3025N20.3 -8.95 8.29e-18 1.23e-14 -0.43 -0.38 Intelligence (multi-trait analysis); chr8:65643583 chr8:65591850~65592472:- LUSC cis rs6921919 0.806 rs213230 ENSG00000216901.1 AL022393.7 8.95 8.33e-18 1.23e-14 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28362487 chr6:28176188~28176674:+ LUSC cis rs1150668 0.796 rs1005125 ENSG00000204709.4 LINC01556 8.95 8.34e-18 1.23e-14 0.46 0.38 Pubertal anthropometrics; chr6:28399578 chr6:28943877~28944537:+ LUSC cis rs10875746 0.669 rs10875767 ENSG00000240399.1 RP1-228P16.1 -8.95 8.41e-18 1.24e-14 -0.45 -0.38 Longevity (90 years and older); chr12:48205474 chr12:48054813~48055591:- LUSC cis rs10875746 0.903 rs11168370 ENSG00000240399.1 RP1-228P16.1 -8.95 8.47e-18 1.25e-14 -0.44 -0.38 Longevity (90 years and older); chr12:48041497 chr12:48054813~48055591:- LUSC cis rs9322193 0.962 rs3805753 ENSG00000216906.2 RP11-350J20.9 8.95 8.52e-18 1.26e-14 0.46 0.38 Lung cancer; chr6:149795662 chr6:149904243~149906418:+ LUSC cis rs11098499 0.863 rs10019674 ENSG00000249244.1 RP11-548H18.2 -8.95 8.53e-18 1.26e-14 -0.5 -0.38 Corneal astigmatism; chr4:119522334 chr4:119391831~119395335:- LUSC cis rs9601248 0.845 rs1932197 ENSG00000227676.3 LINC01068 8.95 8.58e-18 1.27e-14 0.47 0.38 Major depressive disorder; chr13:79609218 chr13:79566727~79571436:+ LUSC cis rs11098499 0.863 rs13136462 ENSG00000249244.1 RP11-548H18.2 8.94 8.64e-18 1.28e-14 0.49 0.38 Corneal astigmatism; chr4:119622018 chr4:119391831~119395335:- LUSC cis rs1707322 0.827 rs6683274 ENSG00000280836.1 AL355480.1 -8.94 8.68e-18 1.28e-14 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45775966 chr1:45581219~45581321:- LUSC cis rs8062405 0.721 rs151181 ENSG00000259982.1 CDC37P1 8.94 8.69e-18 1.28e-14 0.47 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28479196 chr16:28700294~28701540:- LUSC cis rs11118620 0.535 rs1389750 ENSG00000272823.1 RP11-295M18.6 8.94 8.72e-18 1.29e-14 0.43 0.38 Heart failure; chr1:220866829 chr1:220828676~220829211:- LUSC cis rs3931020 0.657 rs277369 ENSG00000272864.1 RP11-17E13.2 8.94 8.78e-18 1.29e-14 0.52 0.38 Resistin levels; chr1:74768977 chr1:74698769~74699333:- LUSC cis rs6538678 0.777 rs10745736 ENSG00000258343.1 RP11-536G4.2 -8.94 8.78e-18 1.29e-14 -0.53 -0.38 Lupus nephritis in systemic lupus erythematosus; chr12:95889308 chr12:95795345~95858839:- LUSC cis rs10875746 0.669 rs10783244 ENSG00000240399.1 RP1-228P16.1 -8.94 8.78e-18 1.29e-14 -0.44 -0.38 Longevity (90 years and older); chr12:48271206 chr12:48054813~48055591:- LUSC cis rs1707322 1 rs785507 ENSG00000280836.1 AL355480.1 8.94 8.83e-18 1.3e-14 0.47 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46075886 chr1:45581219~45581321:- LUSC cis rs1707322 0.785 rs10890348 ENSG00000280836.1 AL355480.1 -8.94 8.84e-18 1.3e-14 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45776751 chr1:45581219~45581321:- LUSC cis rs9322193 0.961 rs4870144 ENSG00000216906.2 RP11-350J20.9 8.94 8.84e-18 1.3e-14 0.46 0.38 Lung cancer; chr6:149575540 chr6:149904243~149906418:+ LUSC cis rs17507216 0.718 rs7161977 ENSG00000278603.1 RP13-608F4.5 8.94 8.89e-18 1.31e-14 0.59 0.38 Excessive daytime sleepiness; chr15:82646782 chr15:82472203~82472426:+ LUSC cis rs6782228 0.606 rs9828893 ENSG00000277250.1 Metazoa_SRP -8.94 8.98e-18 1.32e-14 -0.42 -0.38 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128614082 chr3:128673681~128674021:- LUSC cis rs11098499 0.754 rs1980025 ENSG00000245958.5 RP11-33B1.1 8.94 8.99e-18 1.32e-14 0.37 0.38 Corneal astigmatism; chr4:119331651 chr4:119454791~119552025:+ LUSC cis rs6921919 0.525 rs11760133 ENSG00000216901.1 AL022393.7 8.94 9.01e-18 1.33e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28418962 chr6:28176188~28176674:+ LUSC cis rs10740039 0.583 rs1904401 ENSG00000254271.1 RP11-131N11.4 -8.94 9.05e-18 1.33e-14 -0.53 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60741809 chr10:60734342~60741828:+ LUSC cis rs992157 0.835 rs34353396 ENSG00000261338.2 RP11-378A13.1 -8.94 9.07e-18 1.34e-14 -0.39 -0.38 Colorectal cancer; chr2:218289259 chr2:218255319~218257366:+ LUSC cis rs12439619 0.53 rs28883606 ENSG00000255769.6 GOLGA2P10 -8.94 9.08e-18 1.34e-14 -0.45 -0.38 Intelligence (multi-trait analysis); chr15:82216713 chr15:82472993~82513950:- LUSC cis rs12439619 0.693 rs28665836 ENSG00000255769.6 GOLGA2P10 -8.94 9.08e-18 1.34e-14 -0.45 -0.38 Intelligence (multi-trait analysis); chr15:82218955 chr15:82472993~82513950:- LUSC cis rs62229266 0.625 rs62230813 ENSG00000231106.2 LINC01436 8.94 9.08e-18 1.34e-14 0.49 0.38 Mitral valve prolapse; chr21:36031134 chr21:36005338~36007838:+ LUSC cis rs62229266 0.659 rs2835245 ENSG00000231106.2 LINC01436 8.94 9.1e-18 1.34e-14 0.48 0.38 Mitral valve prolapse; chr21:36044410 chr21:36005338~36007838:+ LUSC cis rs1113500 0.933 rs61797345 ENSG00000226822.1 RP11-356N1.2 8.94 9.13e-18 1.34e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108081106 chr1:108071482~108074519:+ LUSC cis rs4927850 1 rs7614767 ENSG00000231464.1 AC024937.4 8.94 9.14e-18 1.35e-14 0.4 0.38 Pancreatic cancer; chr3:196026580 chr3:195996738~195998233:+ LUSC cis rs9322193 0.962 rs9689447 ENSG00000216906.2 RP11-350J20.9 8.94 9.15e-18 1.35e-14 0.46 0.38 Lung cancer; chr6:149789350 chr6:149904243~149906418:+ LUSC cis rs992157 0.835 rs2271543 ENSG00000261338.2 RP11-378A13.1 -8.94 9.19e-18 1.35e-14 -0.39 -0.38 Colorectal cancer; chr2:218277768 chr2:218255319~218257366:+ LUSC cis rs11098499 0.618 rs35265692 ENSG00000245958.5 RP11-33B1.1 -8.94 9.19e-18 1.35e-14 -0.39 -0.38 Corneal astigmatism; chr4:119403980 chr4:119454791~119552025:+ LUSC cis rs9322193 0.962 rs4869730 ENSG00000216906.2 RP11-350J20.9 8.94 9.22e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149808187 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs11155689 ENSG00000216906.2 RP11-350J20.9 8.94 9.22e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149808470 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs2151913 ENSG00000216906.2 RP11-350J20.9 8.94 9.22e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149809506 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs933055 ENSG00000216906.2 RP11-350J20.9 8.94 9.22e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149809701 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs4869731 ENSG00000216906.2 RP11-350J20.9 8.94 9.22e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149810072 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs11155683 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149779341 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9372044 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149780867 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs11155685 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149781649 chr6:149904243~149906418:+ LUSC cis rs9322193 0.632 rs3828700 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149791033 chr6:149904243~149906418:+ LUSC cis rs9322193 0.926 rs3805751 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149791193 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9689269 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149791861 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs62441335 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149792658 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs4816 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149793609 chr6:149904243~149906418:+ LUSC cis rs9322193 0.926 rs952166 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149798774 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs952165 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149798900 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs10872656 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149799444 chr6:149904243~149906418:+ LUSC cis rs9322193 0.926 rs9285525 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149801253 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs6914319 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149806304 chr6:149904243~149906418:+ LUSC cis rs9322193 0.884 rs2095375 ENSG00000216906.2 RP11-350J20.9 8.94 9.24e-18 1.36e-14 0.45 0.38 Lung cancer; chr6:149807037 chr6:149904243~149906418:+ LUSC cis rs494459 0.838 rs581045 ENSG00000255239.1 AP002954.6 8.94 9.24e-18 1.36e-14 0.41 0.38 Height; chr11:118761813 chr11:118688039~118690600:- LUSC cis rs7189233 0.531 rs7202621 ENSG00000279344.1 RP11-44F14.7 8.93 9.3e-18 1.37e-14 0.33 0.38 Intelligence (multi-trait analysis); chr16:53452125 chr16:53478957~53481550:- LUSC cis rs62388641 0.813 rs62390562 ENSG00000272279.1 RP11-157J24.2 8.93 9.3e-18 1.37e-14 0.63 0.38 Daytime sleep phenotypes; chr6:1551467 chr6:1528364~1528911:- LUSC cis rs62229266 0.659 rs2835243 ENSG00000231106.2 LINC01436 8.93 9.31e-18 1.37e-14 0.48 0.38 Mitral valve prolapse; chr21:36041648 chr21:36005338~36007838:+ LUSC cis rs11098499 0.754 rs17595608 ENSG00000245958.5 RP11-33B1.1 -8.93 9.38e-18 1.38e-14 -0.38 -0.38 Corneal astigmatism; chr4:119329351 chr4:119454791~119552025:+ LUSC cis rs6921919 0.583 rs7740351 ENSG00000216901.1 AL022393.7 8.93 9.4e-18 1.38e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28431635 chr6:28176188~28176674:+ LUSC cis rs10129255 0.5 rs988132 ENSG00000211972.2 IGHV3-66 8.93 9.41e-18 1.38e-14 0.26 0.38 Kawasaki disease; chr14:106776758 chr14:106675017~106675544:- LUSC cis rs1707322 1 rs4298677 ENSG00000280836.1 AL355480.1 -8.93 9.41e-18 1.38e-14 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45840947 chr1:45581219~45581321:- LUSC cis rs9322193 0.962 rs3805748 ENSG00000216906.2 RP11-350J20.9 8.93 9.44e-18 1.39e-14 0.45 0.38 Lung cancer; chr6:149772542 chr6:149904243~149906418:+ LUSC cis rs9322193 0.736 rs10457851 ENSG00000216906.2 RP11-350J20.9 8.93 9.44e-18 1.39e-14 0.45 0.38 Lung cancer; chr6:149775216 chr6:149904243~149906418:+ LUSC cis rs9322193 0.886 rs10872652 ENSG00000216906.2 RP11-350J20.9 8.93 9.44e-18 1.39e-14 0.45 0.38 Lung cancer; chr6:149775303 chr6:149904243~149906418:+ LUSC cis rs9322193 0.886 rs12525871 ENSG00000216906.2 RP11-350J20.9 8.93 9.44e-18 1.39e-14 0.45 0.38 Lung cancer; chr6:149775882 chr6:149904243~149906418:+ LUSC cis rs9322193 0.886 rs17672976 ENSG00000216906.2 RP11-350J20.9 8.93 9.44e-18 1.39e-14 0.45 0.38 Lung cancer; chr6:149776207 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs2184369 ENSG00000216906.2 RP11-350J20.9 8.93 9.44e-18 1.39e-14 0.45 0.38 Lung cancer; chr6:149776681 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs2342861 ENSG00000216906.2 RP11-350J20.9 8.93 9.44e-18 1.39e-14 0.45 0.38 Lung cancer; chr6:149777561 chr6:149904243~149906418:+ LUSC cis rs9322193 0.926 rs2342860 ENSG00000216906.2 RP11-350J20.9 8.93 9.44e-18 1.39e-14 0.45 0.38 Lung cancer; chr6:149777641 chr6:149904243~149906418:+ LUSC cis rs12134133 1 rs2782842 ENSG00000274245.1 RP11-357P18.2 8.93 9.45e-18 1.39e-14 0.51 0.38 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310231 chr1:207372559~207373252:+ LUSC cis rs6921919 0.583 rs6922169 ENSG00000216901.1 AL022393.7 8.93 9.45e-18 1.39e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28415155 chr6:28176188~28176674:+ LUSC cis rs6991838 0.765 rs10957358 ENSG00000272010.1 CTD-3025N20.3 8.93 9.65e-18 1.41e-14 0.41 0.38 Intelligence (multi-trait analysis); chr8:65590067 chr8:65591850~65592472:- LUSC cis rs9487094 0.689 rs1074766 ENSG00000260273.1 RP11-425D10.10 8.93 9.65e-18 1.41e-14 0.45 0.38 Height; chr6:109360263 chr6:109382795~109383666:+ LUSC cis rs526231 0.511 rs10434792 ENSG00000175749.11 EIF3KP1 8.93 9.68e-18 1.42e-14 0.46 0.38 Primary biliary cholangitis; chr5:103053898 chr5:103032376~103033031:+ LUSC cis rs526231 0.511 rs12109860 ENSG00000175749.11 EIF3KP1 8.93 9.68e-18 1.42e-14 0.46 0.38 Primary biliary cholangitis; chr5:103057408 chr5:103032376~103033031:+ LUSC cis rs1707322 1 rs6695421 ENSG00000280836.1 AL355480.1 -8.93 9.69e-18 1.42e-14 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45914535 chr1:45581219~45581321:- LUSC cis rs2739330 0.828 rs4820572 ENSG00000231271.1 AP000350.8 8.93 9.72e-18 1.42e-14 0.5 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23949918~23954042:+ LUSC cis rs526231 0.543 rs4386712 ENSG00000175749.11 EIF3KP1 8.93 9.76e-18 1.43e-14 0.47 0.38 Primary biliary cholangitis; chr5:103033530 chr5:103032376~103033031:+ LUSC cis rs526231 0.511 rs56235607 ENSG00000175749.11 EIF3KP1 8.93 9.76e-18 1.43e-14 0.47 0.38 Primary biliary cholangitis; chr5:103036902 chr5:103032376~103033031:+ LUSC cis rs526231 0.511 rs55741939 ENSG00000175749.11 EIF3KP1 8.93 9.76e-18 1.43e-14 0.47 0.38 Primary biliary cholangitis; chr5:103036984 chr5:103032376~103033031:+ LUSC cis rs526231 0.511 rs17155009 ENSG00000175749.11 EIF3KP1 8.93 9.76e-18 1.43e-14 0.47 0.38 Primary biliary cholangitis; chr5:103038440 chr5:103032376~103033031:+ LUSC cis rs26232 0.521 rs67019105 ENSG00000175749.11 EIF3KP1 8.93 9.76e-18 1.43e-14 0.47 0.38 Rheumatoid arthritis; chr5:103038459 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs72785733 ENSG00000175749.11 EIF3KP1 8.93 9.76e-18 1.43e-14 0.47 0.38 Parkinson's disease; chr5:103038488 chr5:103032376~103033031:+ LUSC cis rs1823913 0.927 rs35339956 ENSG00000227542.1 AC092614.2 8.93 9.86e-18 1.44e-14 0.53 0.38 Obesity-related traits; chr2:191261668 chr2:191229165~191246172:- LUSC cis rs1823913 0.963 rs4146105 ENSG00000227542.1 AC092614.2 8.93 9.91e-18 1.45e-14 0.52 0.38 Obesity-related traits; chr2:191245240 chr2:191229165~191246172:- LUSC cis rs1707322 0.827 rs6694302 ENSG00000280836.1 AL355480.1 -8.93 9.93e-18 1.45e-14 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45779973 chr1:45581219~45581321:- LUSC cis rs1823913 0.927 rs1454761 ENSG00000227542.1 AC092614.2 8.93 9.98e-18 1.46e-14 0.52 0.38 Obesity-related traits; chr2:191237092 chr2:191229165~191246172:- LUSC cis rs7189233 0.513 rs2908797 ENSG00000279344.1 RP11-44F14.7 8.93 9.99e-18 1.46e-14 0.33 0.38 Intelligence (multi-trait analysis); chr16:53395261 chr16:53478957~53481550:- LUSC cis rs10129255 0.5 rs8021941 ENSG00000211972.2 IGHV3-66 8.93 1e-17 1.47e-14 0.25 0.38 Kawasaki disease; chr14:106781490 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs10142931 ENSG00000211972.2 IGHV3-66 8.93 1e-17 1.47e-14 0.25 0.38 Kawasaki disease; chr14:106782288 chr14:106675017~106675544:- LUSC cis rs7189233 0.592 rs2024449 ENSG00000279344.1 RP11-44F14.7 8.93 1e-17 1.47e-14 0.33 0.38 Intelligence (multi-trait analysis); chr16:53460705 chr16:53478957~53481550:- LUSC cis rs9341808 0.727 rs9352809 ENSG00000272129.1 RP11-250B2.6 8.92 1e-17 1.47e-14 0.46 0.38 Sitting height ratio; chr6:80289599 chr6:80355424~80356859:+ LUSC cis rs9322193 0.962 rs10872653 ENSG00000216906.2 RP11-350J20.9 8.92 1e-17 1.47e-14 0.45 0.38 Lung cancer; chr6:149778907 chr6:149904243~149906418:+ LUSC cis rs67383717 0.527 rs10760718 ENSG00000175611.10 LINC00476 8.92 1.01e-17 1.47e-14 0.4 0.38 Parkinson's disease (pesticide exposure interaction); chr9:96032397 chr9:95759231~95875977:- LUSC cis rs12134133 1 rs28371597 ENSG00000274245.1 RP11-357P18.2 8.92 1.01e-17 1.48e-14 0.5 0.38 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207323551 chr1:207372559~207373252:+ LUSC cis rs494459 0.838 rs607125 ENSG00000255239.1 AP002954.6 8.92 1.01e-17 1.48e-14 0.41 0.38 Height; chr11:118746590 chr11:118688039~118690600:- LUSC cis rs765787 0.53 rs3759892 ENSG00000259520.4 CTD-2651B20.3 -8.92 1.01e-17 1.48e-14 -0.49 -0.38 Uric acid levels; chr15:45250511 chr15:45251580~45279251:- LUSC cis rs526231 0.543 rs257310 ENSG00000175749.11 EIF3KP1 8.92 1.02e-17 1.49e-14 0.47 0.38 Primary biliary cholangitis; chr5:103083149 chr5:103032376~103033031:+ LUSC cis rs9322193 0.736 rs3828701 ENSG00000216906.2 RP11-350J20.9 8.92 1.03e-17 1.5e-14 0.45 0.38 Lung cancer; chr6:149791063 chr6:149904243~149906418:+ LUSC cis rs9322193 0.736 rs3805750 ENSG00000216906.2 RP11-350J20.9 8.92 1.03e-17 1.5e-14 0.45 0.38 Lung cancer; chr6:149791065 chr6:149904243~149906418:+ LUSC cis rs62388641 0.813 rs55821127 ENSG00000272279.1 RP11-157J24.2 8.92 1.04e-17 1.51e-14 0.63 0.38 Daytime sleep phenotypes; chr6:1550635 chr6:1528364~1528911:- LUSC cis rs9322193 0.962 rs4552 ENSG00000216906.2 RP11-350J20.9 8.92 1.04e-17 1.52e-14 0.45 0.38 Lung cancer; chr6:149811183 chr6:149904243~149906418:+ LUSC cis rs9341808 0.683 rs9359409 ENSG00000272129.1 RP11-250B2.6 8.92 1.04e-17 1.52e-14 0.46 0.38 Sitting height ratio; chr6:80117180 chr6:80355424~80356859:+ LUSC cis rs11098499 0.82 rs13128602 ENSG00000245958.5 RP11-33B1.1 8.92 1.04e-17 1.52e-14 0.39 0.38 Corneal astigmatism; chr4:119538211 chr4:119454791~119552025:+ LUSC cis rs62229266 0.659 rs2835242 ENSG00000231106.2 LINC01436 8.92 1.05e-17 1.54e-14 0.48 0.38 Mitral valve prolapse; chr21:36041234 chr21:36005338~36007838:+ LUSC cis rs6538678 0.712 rs10777748 ENSG00000258343.1 RP11-536G4.2 -8.92 1.06e-17 1.54e-14 -0.51 -0.38 Lupus nephritis in systemic lupus erythematosus; chr12:95880227 chr12:95795345~95858839:- LUSC cis rs1707322 0.821 rs10749857 ENSG00000280836.1 AL355480.1 -8.92 1.07e-17 1.56e-14 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45782471 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211219 ENSG00000280836.1 AL355480.1 -8.92 1.07e-17 1.57e-14 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893806 chr1:45581219~45581321:- LUSC cis rs11089937 1 rs11089937 ENSG00000211639.2 IGLV4-60 8.92 1.08e-17 1.57e-14 0.39 0.38 Periodontitis (PAL4Q3); chr22:22152176 chr22:22162199~22162681:+ LUSC cis rs4728142 0.604 rs12155080 ENSG00000275106.1 RP11-309L24.10 -8.92 1.08e-17 1.57e-14 -0.49 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129018685 chr7:128952527~128953316:- LUSC cis rs6991838 0.765 rs4424306 ENSG00000272010.1 CTD-3025N20.3 8.92 1.08e-17 1.58e-14 0.41 0.38 Intelligence (multi-trait analysis); chr8:65618674 chr8:65591850~65592472:- LUSC cis rs62229266 0.659 rs7275820 ENSG00000231106.2 LINC01436 8.91 1.09e-17 1.58e-14 0.48 0.38 Mitral valve prolapse; chr21:36037116 chr21:36005338~36007838:+ LUSC cis rs494459 0.688 rs1048040 ENSG00000255239.1 AP002954.6 8.91 1.09e-17 1.59e-14 0.41 0.38 Height; chr11:118747911 chr11:118688039~118690600:- LUSC cis rs2455601 1 rs56336128 ENSG00000254860.4 TMEM9B-AS1 8.91 1.09e-17 1.59e-14 0.57 0.38 Schizophrenia; chr11:8886752 chr11:8964675~8977527:+ LUSC cis rs2337406 0.636 rs74090069 ENSG00000274576.2 IGHV2-70 -8.91 1.1e-17 1.6e-14 -0.39 -0.38 Alzheimer's disease (late onset); chr14:106777532 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs74090071 ENSG00000274576.2 IGHV2-70 -8.91 1.1e-17 1.6e-14 -0.39 -0.38 Alzheimer's disease (late onset); chr14:106777533 chr14:106770577~106771020:- LUSC cis rs9322193 0.923 rs12660304 ENSG00000223701.3 RAET1E-AS1 8.91 1.1e-17 1.6e-14 0.44 0.38 Lung cancer; chr6:149739647 chr6:149884431~149919508:+ LUSC cis rs62229266 0.652 rs7280551 ENSG00000231106.2 LINC01436 8.91 1.1e-17 1.61e-14 0.48 0.38 Mitral valve prolapse; chr21:36037311 chr21:36005338~36007838:+ LUSC cis rs9341808 0.727 rs9361599 ENSG00000272129.1 RP11-250B2.6 8.91 1.1e-17 1.61e-14 0.45 0.38 Sitting height ratio; chr6:80315525 chr6:80355424~80356859:+ LUSC cis rs9341808 0.754 rs9352817 ENSG00000272129.1 RP11-250B2.6 8.91 1.1e-17 1.61e-14 0.45 0.38 Sitting height ratio; chr6:80316162 chr6:80355424~80356859:+ LUSC cis rs9487094 0.961 rs9487100 ENSG00000260273.1 RP11-425D10.10 8.91 1.1e-17 1.61e-14 0.47 0.38 Height; chr6:109429207 chr6:109382795~109383666:+ LUSC cis rs2665103 0.61 rs1972460 ENSG00000255769.6 GOLGA2P10 -8.91 1.11e-17 1.61e-14 -0.44 -0.38 Intelligence (multi-trait analysis); chr15:82238289 chr15:82472993~82513950:- LUSC cis rs9487094 0.643 rs730089 ENSG00000260273.1 RP11-425D10.10 8.91 1.12e-17 1.63e-14 0.45 0.38 Height; chr6:109393881 chr6:109382795~109383666:+ LUSC cis rs6921919 0.583 rs2071965 ENSG00000216901.1 AL022393.7 8.91 1.12e-17 1.63e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28435448 chr6:28176188~28176674:+ LUSC cis rs9322193 0.607 rs12209310 ENSG00000216906.2 RP11-350J20.9 8.91 1.12e-17 1.64e-14 0.51 0.38 Lung cancer; chr6:149904882 chr6:149904243~149906418:+ LUSC cis rs9322193 0.961 rs9285521 ENSG00000216906.2 RP11-350J20.9 8.91 1.14e-17 1.66e-14 0.46 0.38 Lung cancer; chr6:149585576 chr6:149904243~149906418:+ LUSC cis rs9487094 0.62 rs7768973 ENSG00000260273.1 RP11-425D10.10 8.91 1.14e-17 1.66e-14 0.45 0.38 Height; chr6:109424122 chr6:109382795~109383666:+ LUSC cis rs6920372 0.799 rs9480947 ENSG00000260273.1 RP11-425D10.10 8.91 1.14e-17 1.66e-14 0.45 0.38 Height; chr6:109397362 chr6:109382795~109383666:+ LUSC cis rs6782228 0.565 rs67445542 ENSG00000277250.1 Metazoa_SRP -8.91 1.14e-17 1.66e-14 -0.42 -0.38 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611683 chr3:128673681~128674021:- LUSC cis rs11098499 0.863 rs1552095 ENSG00000249244.1 RP11-548H18.2 8.91 1.14e-17 1.67e-14 0.51 0.38 Corneal astigmatism; chr4:119539151 chr4:119391831~119395335:- LUSC cis rs9322193 0.923 rs2880436 ENSG00000223701.3 RAET1E-AS1 8.91 1.15e-17 1.67e-14 0.44 0.38 Lung cancer; chr6:149859123 chr6:149884431~149919508:+ LUSC cis rs11098499 0.863 rs3736115 ENSG00000245958.5 RP11-33B1.1 8.91 1.16e-17 1.68e-14 0.38 0.38 Corneal astigmatism; chr4:119567548 chr4:119454791~119552025:+ LUSC cis rs6452524 0.967 rs2974448 ENSG00000249664.1 CTD-2227C6.2 8.91 1.16e-17 1.69e-14 0.39 0.38 Hypertension (SNP x SNP interaction); chr5:83190937 chr5:83012285~83013109:- LUSC cis rs10875746 0.669 rs17122812 ENSG00000240399.1 RP1-228P16.1 -8.91 1.16e-17 1.69e-14 -0.46 -0.38 Longevity (90 years and older); chr12:48203270 chr12:48054813~48055591:- LUSC cis rs1707322 0.964 rs796773 ENSG00000280836.1 AL355480.1 8.91 1.16e-17 1.69e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46098803 chr1:45581219~45581321:- LUSC cis rs1707322 0.896 rs785518 ENSG00000280836.1 AL355480.1 8.91 1.16e-17 1.69e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46102750 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs785519 ENSG00000280836.1 AL355480.1 8.91 1.16e-17 1.69e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46102890 chr1:45581219~45581321:- LUSC cis rs494459 0.838 rs488219 ENSG00000255239.1 AP002954.6 8.91 1.16e-17 1.69e-14 0.41 0.38 Height; chr11:118749988 chr11:118688039~118690600:- LUSC cis rs765787 0.53 rs12915804 ENSG00000259520.4 CTD-2651B20.3 -8.91 1.17e-17 1.7e-14 -0.48 -0.38 Uric acid levels; chr15:45220364 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs12915027 ENSG00000259520.4 CTD-2651B20.3 -8.91 1.17e-17 1.7e-14 -0.48 -0.38 Uric acid levels; chr15:45220428 chr15:45251580~45279251:- LUSC cis rs765787 0.556 rs12915965 ENSG00000259520.4 CTD-2651B20.3 -8.91 1.17e-17 1.7e-14 -0.48 -0.38 Uric acid levels; chr15:45220449 chr15:45251580~45279251:- LUSC cis rs9341808 0.718 rs9448893 ENSG00000272129.1 RP11-250B2.6 8.9 1.18e-17 1.71e-14 0.46 0.38 Sitting height ratio; chr6:80127522 chr6:80355424~80356859:+ LUSC cis rs1707322 1 rs6672115 ENSG00000280836.1 AL355480.1 -8.9 1.18e-17 1.71e-14 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45807207 chr1:45581219~45581321:- LUSC cis rs11098499 1 rs11726229 ENSG00000245958.5 RP11-33B1.1 -8.9 1.19e-17 1.73e-14 -0.39 -0.38 Corneal astigmatism; chr4:119290425 chr4:119454791~119552025:+ LUSC cis rs17507216 0.718 rs72751662 ENSG00000278603.1 RP13-608F4.5 8.9 1.2e-17 1.74e-14 0.59 0.38 Excessive daytime sleepiness; chr15:82594705 chr15:82472203~82472426:+ LUSC cis rs10740039 0.583 rs2127351 ENSG00000254271.1 RP11-131N11.4 -8.9 1.2e-17 1.74e-14 -0.52 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60741425 chr10:60734342~60741828:+ LUSC cis rs150992 0.688 rs161947 ENSG00000248489.1 CTD-2007H13.3 8.9 1.21e-17 1.76e-14 0.48 0.38 Body mass index; chr5:98932868 chr5:98929171~98995013:+ LUSC cis rs11098499 0.863 rs17050695 ENSG00000245958.5 RP11-33B1.1 -8.9 1.21e-17 1.76e-14 -0.36 -0.38 Corneal astigmatism; chr4:119568372 chr4:119454791~119552025:+ LUSC cis rs765787 0.53 rs12904331 ENSG00000259520.4 CTD-2651B20.3 -8.9 1.23e-17 1.78e-14 -0.48 -0.38 Uric acid levels; chr15:45226095 chr15:45251580~45279251:- LUSC cis rs9322193 0.962 rs6899661 ENSG00000216906.2 RP11-350J20.9 8.9 1.23e-17 1.79e-14 0.45 0.38 Lung cancer; chr6:149818093 chr6:149904243~149906418:+ LUSC cis rs10129255 0.912 rs61997792 ENSG00000211970.3 IGHV4-61 -8.9 1.24e-17 1.8e-14 -0.28 -0.38 Kawasaki disease; chr14:106799304 chr14:106639119~106639657:- LUSC cis rs4927850 1 rs4927850 ENSG00000231464.1 AC024937.4 -8.9 1.24e-17 1.8e-14 -0.41 -0.38 Pancreatic cancer; chr3:196024759 chr3:195996738~195998233:+ LUSC cis rs9322193 1 rs58189451 ENSG00000216906.2 RP11-350J20.9 8.9 1.26e-17 1.82e-14 0.45 0.38 Lung cancer; chr6:149600252 chr6:149904243~149906418:+ LUSC cis rs10129255 0.5 rs8004923 ENSG00000211972.2 IGHV3-66 8.9 1.26e-17 1.82e-14 0.25 0.38 Kawasaki disease; chr14:106785926 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs6576232 ENSG00000211972.2 IGHV3-66 8.9 1.26e-17 1.82e-14 0.25 0.38 Kawasaki disease; chr14:106787090 chr14:106675017~106675544:- LUSC cis rs1976403 0.633 rs1780324 ENSG00000227001.3 NBPF2P 8.9 1.26e-17 1.83e-14 0.45 0.38 Liver enzyme levels (alkaline phosphatase); chr1:21495264 chr1:21424625~21427967:- LUSC cis rs62229266 0.633 rs34259635 ENSG00000231106.2 LINC01436 8.89 1.27e-17 1.83e-14 0.48 0.38 Mitral valve prolapse; chr21:36031272 chr21:36005338~36007838:+ LUSC cis rs1113500 0.933 rs10785834 ENSG00000226822.1 RP11-356N1.2 8.89 1.27e-17 1.84e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108096479 chr1:108071482~108074519:+ LUSC cis rs853679 0.517 rs4713135 ENSG00000219392.1 RP1-265C24.5 -8.89 1.27e-17 1.84e-14 -0.53 -0.38 Depression; chr6:28071808 chr6:28115628~28116551:+ LUSC cis rs1707322 0.964 rs785499 ENSG00000280836.1 AL355480.1 8.89 1.29e-17 1.87e-14 0.47 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126748 chr1:45581219~45581321:- LUSC cis rs7189233 0.55 rs4784312 ENSG00000279344.1 RP11-44F14.7 8.89 1.29e-17 1.87e-14 0.33 0.38 Intelligence (multi-trait analysis); chr16:53464490 chr16:53478957~53481550:- LUSC cis rs1113500 0.933 rs11185255 ENSG00000226822.1 RP11-356N1.2 8.89 1.31e-17 1.89e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108090569 chr1:108071482~108074519:+ LUSC cis rs1113500 0.933 rs11185256 ENSG00000226822.1 RP11-356N1.2 8.89 1.31e-17 1.89e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108091335 chr1:108071482~108074519:+ LUSC cis rs1113500 0.933 rs10881498 ENSG00000226822.1 RP11-356N1.2 8.89 1.31e-17 1.89e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108092362 chr1:108071482~108074519:+ LUSC cis rs6921919 0.583 rs16894060 ENSG00000216901.1 AL022393.7 8.89 1.31e-17 1.89e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28394694 chr6:28176188~28176674:+ LUSC cis rs1707322 1 rs4134387 ENSG00000280836.1 AL355480.1 -8.89 1.31e-17 1.9e-14 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45929486 chr1:45581219~45581321:- LUSC cis rs9322193 0.566 rs12528243 ENSG00000216906.2 RP11-350J20.9 8.89 1.32e-17 1.92e-14 0.51 0.38 Lung cancer; chr6:149898491 chr6:149904243~149906418:+ LUSC cis rs9322193 0.607 rs915140 ENSG00000216906.2 RP11-350J20.9 8.89 1.32e-17 1.92e-14 0.51 0.38 Lung cancer; chr6:149899674 chr6:149904243~149906418:+ LUSC cis rs526231 0.543 rs34767 ENSG00000175749.11 EIF3KP1 8.89 1.34e-17 1.94e-14 0.46 0.38 Primary biliary cholangitis; chr5:103153807 chr5:103032376~103033031:+ LUSC cis rs6991838 0.584 rs7463740 ENSG00000200714.1 Y_RNA -8.89 1.34e-17 1.94e-14 -0.46 -0.38 Intelligence (multi-trait analysis); chr8:65573950 chr8:65592731~65592820:+ LUSC cis rs12439619 0.846 rs62013464 ENSG00000255769.6 GOLGA2P10 -8.89 1.35e-17 1.95e-14 -0.53 -0.38 Intelligence (multi-trait analysis); chr15:82288250 chr15:82472993~82513950:- LUSC cis rs12594515 0.694 rs2068295 ENSG00000273972.1 CTD-2306A12.1 -8.89 1.36e-17 1.96e-14 -0.43 -0.38 Weight;Waist circumference; chr15:45693348 chr15:45702640~45703183:+ LUSC cis rs12594515 0.694 rs2068294 ENSG00000273972.1 CTD-2306A12.1 -8.89 1.36e-17 1.96e-14 -0.43 -0.38 Weight;Waist circumference; chr15:45693350 chr15:45702640~45703183:+ LUSC cis rs10129255 0.518 rs10136903 ENSG00000211972.2 IGHV3-66 8.88 1.37e-17 1.98e-14 0.25 0.38 Kawasaki disease; chr14:106778866 chr14:106675017~106675544:- LUSC cis rs3931020 0.688 rs452242 ENSG00000272864.1 RP11-17E13.2 8.88 1.37e-17 1.99e-14 0.52 0.38 Resistin levels; chr1:74759941 chr1:74698769~74699333:- LUSC cis rs11098499 0.955 rs6815725 ENSG00000245958.5 RP11-33B1.1 -8.88 1.38e-17 2e-14 -0.38 -0.38 Corneal astigmatism; chr4:119237255 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs1551 ENSG00000245958.5 RP11-33B1.1 -8.88 1.38e-17 2e-14 -0.38 -0.38 Corneal astigmatism; chr4:119237345 chr4:119454791~119552025:+ LUSC cis rs494459 0.838 rs555649 ENSG00000255239.1 AP002954.6 8.88 1.39e-17 2.01e-14 0.41 0.38 Height; chr11:118781100 chr11:118688039~118690600:- LUSC cis rs17507216 0.671 rs4779035 ENSG00000278603.1 RP13-608F4.5 8.88 1.39e-17 2.01e-14 0.59 0.38 Excessive daytime sleepiness; chr15:82591686 chr15:82472203~82472426:+ LUSC cis rs7044106 0.791 rs10760116 ENSG00000226752.6 PSMD5-AS1 -8.88 1.41e-17 2.03e-14 -0.45 -0.38 Hip circumference adjusted for BMI; chr9:120732403 chr9:120824828~120854385:+ LUSC cis rs748404 0.631 rs11070399 ENSG00000249839.1 AC011330.5 -8.88 1.41e-17 2.04e-14 -0.51 -0.38 Lung cancer; chr15:43354149 chr15:43663654~43684339:- LUSC cis rs9322193 0.962 rs1413655 ENSG00000216906.2 RP11-350J20.9 8.88 1.41e-17 2.04e-14 0.45 0.38 Lung cancer; chr6:149821815 chr6:149904243~149906418:+ LUSC cis rs9322193 0.926 rs9383546 ENSG00000216906.2 RP11-350J20.9 8.88 1.41e-17 2.04e-14 0.45 0.38 Lung cancer; chr6:149822743 chr6:149904243~149906418:+ LUSC cis rs1707322 1 rs34444543 ENSG00000280836.1 AL355480.1 -8.88 1.42e-17 2.05e-14 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893190 chr1:45581219~45581321:- LUSC cis rs1799949 0.602 rs8176257 ENSG00000198496.9 NBR2 -8.88 1.42e-17 2.05e-14 -0.47 -0.38 Menopause (age at onset); chr17:43064188 chr17:43125610~43153671:+ LUSC cis rs9322193 0.962 rs2275046 ENSG00000216906.2 RP11-350J20.9 8.88 1.42e-17 2.05e-14 0.46 0.38 Lung cancer; chr6:149835865 chr6:149904243~149906418:+ LUSC cis rs853679 0.55 rs1225599 ENSG00000219392.1 RP1-265C24.5 -8.88 1.42e-17 2.05e-14 -0.52 -0.38 Depression; chr6:28197412 chr6:28115628~28116551:+ LUSC cis rs853679 0.574 rs1233705 ENSG00000219392.1 RP1-265C24.5 -8.88 1.42e-17 2.05e-14 -0.52 -0.38 Depression; chr6:28198669 chr6:28115628~28116551:+ LUSC cis rs494459 0.838 rs632124 ENSG00000255239.1 AP002954.6 8.88 1.43e-17 2.06e-14 0.4 0.38 Height; chr11:118742526 chr11:118688039~118690600:- LUSC cis rs9341808 0.754 rs3793000 ENSG00000272129.1 RP11-250B2.6 8.88 1.43e-17 2.06e-14 0.46 0.38 Sitting height ratio; chr6:80285420 chr6:80355424~80356859:+ LUSC cis rs853679 0.517 rs12174753 ENSG00000219392.1 RP1-265C24.5 -8.88 1.44e-17 2.08e-14 -0.53 -0.38 Depression; chr6:28074687 chr6:28115628~28116551:+ LUSC cis rs7684253 0.565 rs6830774 ENSG00000269949.1 RP11-738E22.3 -8.88 1.44e-17 2.08e-14 -0.45 -0.38 Migraine; chr4:56950140 chr4:56960927~56961373:- LUSC cis rs9322193 0.923 rs9322197 ENSG00000216906.2 RP11-350J20.9 8.88 1.45e-17 2.09e-14 0.45 0.38 Lung cancer; chr6:149622577 chr6:149904243~149906418:+ LUSC cis rs1075265 0.584 rs1559037 ENSG00000233266.1 HMGB1P31 8.88 1.45e-17 2.09e-14 0.48 0.38 Chronotype;Morning vs. evening chronotype; chr2:54051448 chr2:54051334~54051760:+ LUSC cis rs1075265 0.584 rs7590846 ENSG00000233266.1 HMGB1P31 8.88 1.45e-17 2.09e-14 0.48 0.38 Chronotype;Morning vs. evening chronotype; chr2:54051530 chr2:54051334~54051760:+ LUSC cis rs6921919 0.583 rs3800328 ENSG00000216901.1 AL022393.7 8.88 1.45e-17 2.1e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28423066 chr6:28176188~28176674:+ LUSC cis rs6921919 0.609 rs67211468 ENSG00000216901.1 AL022393.7 8.88 1.45e-17 2.1e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28424210 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs35560946 ENSG00000216901.1 AL022393.7 8.88 1.45e-17 2.1e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28427660 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs740622 ENSG00000216901.1 AL022393.7 8.88 1.45e-17 2.1e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28430514 chr6:28176188~28176674:+ LUSC cis rs7684253 0.565 rs12641030 ENSG00000269949.1 RP11-738E22.3 -8.88 1.46e-17 2.1e-14 -0.45 -0.38 Migraine; chr4:56937339 chr4:56960927~56961373:- LUSC cis rs992157 0.835 rs2292555 ENSG00000261338.2 RP11-378A13.1 -8.88 1.47e-17 2.12e-14 -0.39 -0.38 Colorectal cancer; chr2:218282159 chr2:218255319~218257366:+ LUSC cis rs10129255 1 rs11627342 ENSG00000211970.3 IGHV4-61 -8.88 1.47e-17 2.12e-14 -0.27 -0.38 Kawasaki disease; chr14:106675823 chr14:106639119~106639657:- LUSC cis rs494459 0.838 rs555639 ENSG00000255239.1 AP002954.6 -8.88 1.47e-17 2.13e-14 -0.4 -0.38 Height; chr11:118758322 chr11:118688039~118690600:- LUSC cis rs10875746 0.729 rs11168355 ENSG00000240399.1 RP1-228P16.1 8.87 1.49e-17 2.15e-14 0.42 0.38 Longevity (90 years and older); chr12:48017195 chr12:48054813~48055591:- LUSC cis rs10256972 0.616 rs7806746 ENSG00000229043.2 AC091729.9 -8.87 1.5e-17 2.15e-14 -0.43 -0.38 Endometriosis;Longevity; chr7:1035937 chr7:1160374~1165267:+ LUSC cis rs7684253 0.565 rs13108570 ENSG00000269949.1 RP11-738E22.3 -8.87 1.5e-17 2.16e-14 -0.45 -0.38 Migraine; chr4:56940917 chr4:56960927~56961373:- LUSC cis rs1707322 1 rs785467 ENSG00000280836.1 AL355480.1 8.87 1.51e-17 2.18e-14 0.46 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055887 chr1:45581219~45581321:- LUSC cis rs9322193 0.962 rs7745915 ENSG00000216906.2 RP11-350J20.9 8.87 1.52e-17 2.19e-14 0.46 0.38 Lung cancer; chr6:149834111 chr6:149904243~149906418:+ LUSC cis rs67383717 0.527 rs12004422 ENSG00000175611.10 LINC00476 8.87 1.52e-17 2.2e-14 0.4 0.38 Parkinson's disease (pesticide exposure interaction); chr9:95873393 chr9:95759231~95875977:- LUSC cis rs9341808 0.754 rs9294173 ENSG00000272129.1 RP11-250B2.6 8.87 1.53e-17 2.2e-14 0.46 0.38 Sitting height ratio; chr6:80281913 chr6:80355424~80356859:+ LUSC cis rs875971 1 rs6946143 ENSG00000222364.1 RNU6-96P -8.87 1.53e-17 2.21e-14 -0.44 -0.38 Aortic root size; chr7:66114735 chr7:66395191~66395286:+ LUSC cis rs11098499 0.754 rs12711071 ENSG00000245958.5 RP11-33B1.1 -8.87 1.54e-17 2.22e-14 -0.37 -0.38 Corneal astigmatism; chr4:119319779 chr4:119454791~119552025:+ LUSC cis rs1707322 0.963 rs6429581 ENSG00000280836.1 AL355480.1 -8.87 1.55e-17 2.23e-14 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853424 chr1:45581219~45581321:- LUSC cis rs526231 0.543 rs34377 ENSG00000175749.11 EIF3KP1 8.87 1.55e-17 2.24e-14 0.46 0.38 Primary biliary cholangitis; chr5:103064852 chr5:103032376~103033031:+ LUSC cis rs9487094 0.666 rs746794 ENSG00000260273.1 RP11-425D10.10 8.87 1.57e-17 2.25e-14 0.44 0.38 Height; chr6:109391534 chr6:109382795~109383666:+ LUSC cis rs9487094 0.666 rs736830 ENSG00000260273.1 RP11-425D10.10 8.87 1.57e-17 2.26e-14 0.44 0.38 Height; chr6:109392096 chr6:109382795~109383666:+ LUSC cis rs12134133 1 rs2802237 ENSG00000274245.1 RP11-357P18.2 8.87 1.57e-17 2.26e-14 0.49 0.38 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207300825 chr1:207372559~207373252:+ LUSC cis rs4713118 0.587 rs61471148 ENSG00000219392.1 RP1-265C24.5 -8.87 1.58e-17 2.27e-14 -0.53 -0.38 Parkinson's disease; chr6:28069254 chr6:28115628~28116551:+ LUSC cis rs11098499 0.754 rs9999724 ENSG00000245958.5 RP11-33B1.1 -8.87 1.58e-17 2.27e-14 -0.38 -0.38 Corneal astigmatism; chr4:119318789 chr4:119454791~119552025:+ LUSC cis rs12134133 1 rs2782846 ENSG00000274245.1 RP11-357P18.2 8.87 1.58e-17 2.27e-14 0.49 0.38 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207300495 chr1:207372559~207373252:+ LUSC cis rs11098499 0.863 rs2127823 ENSG00000249244.1 RP11-548H18.2 8.87 1.58e-17 2.28e-14 0.49 0.38 Corneal astigmatism; chr4:119564515 chr4:119391831~119395335:- LUSC cis rs1823913 1 rs68014803 ENSG00000227542.1 AC092614.2 8.87 1.59e-17 2.28e-14 0.51 0.38 Obesity-related traits; chr2:191241877 chr2:191229165~191246172:- LUSC cis rs1501911 0.611 rs1875529 ENSG00000248489.1 CTD-2007H13.3 -8.86 1.61e-17 2.31e-14 -0.48 -0.38 Lung function (FEV1/FVC); chr5:99033350 chr5:98929171~98995013:+ LUSC cis rs35160687 0.862 rs17737955 ENSG00000273080.1 RP11-301O19.1 8.86 1.61e-17 2.31e-14 0.38 0.38 Night sleep phenotypes; chr2:86280891 chr2:86195590~86196049:+ LUSC cis rs11098499 0.955 rs11931312 ENSG00000245958.5 RP11-33B1.1 -8.86 1.61e-17 2.31e-14 -0.38 -0.38 Corneal astigmatism; chr4:119237868 chr4:119454791~119552025:+ LUSC cis rs35160687 0.862 rs13024964 ENSG00000273080.1 RP11-301O19.1 8.86 1.62e-17 2.33e-14 0.37 0.38 Night sleep phenotypes; chr2:86284745 chr2:86195590~86196049:+ LUSC cis rs853679 0.55 rs1233704 ENSG00000219392.1 RP1-265C24.5 8.86 1.66e-17 2.38e-14 0.5 0.38 Depression; chr6:28199145 chr6:28115628~28116551:+ LUSC cis rs6921919 0.583 rs9468370 ENSG00000216901.1 AL022393.7 8.86 1.66e-17 2.38e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28401163 chr6:28176188~28176674:+ LUSC cis rs62229266 0.659 rs2255734 ENSG00000231106.2 LINC01436 8.86 1.66e-17 2.39e-14 0.48 0.38 Mitral valve prolapse; chr21:36039611 chr21:36005338~36007838:+ LUSC cis rs765787 0.53 rs2899379 ENSG00000259520.4 CTD-2651B20.3 -8.86 1.66e-17 2.39e-14 -0.48 -0.38 Uric acid levels; chr15:45242601 chr15:45251580~45279251:- LUSC cis rs9341808 0.791 rs1324122 ENSG00000272129.1 RP11-250B2.6 8.86 1.68e-17 2.4e-14 0.46 0.38 Sitting height ratio; chr6:80236344 chr6:80355424~80356859:+ LUSC cis rs1113500 0.933 rs61797344 ENSG00000226822.1 RP11-356N1.2 8.86 1.68e-17 2.41e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108079958 chr1:108071482~108074519:+ LUSC cis rs9487094 0.689 rs9480936 ENSG00000260273.1 RP11-425D10.10 8.86 1.68e-17 2.41e-14 0.45 0.38 Height; chr6:109358227 chr6:109382795~109383666:+ LUSC cis rs992157 0.804 rs6758540 ENSG00000261338.2 RP11-378A13.1 -8.86 1.7e-17 2.44e-14 -0.39 -0.38 Colorectal cancer; chr2:218273902 chr2:218255319~218257366:+ LUSC cis rs992157 0.835 rs2292550 ENSG00000261338.2 RP11-378A13.1 -8.86 1.7e-17 2.44e-14 -0.39 -0.38 Colorectal cancer; chr2:218275565 chr2:218255319~218257366:+ LUSC cis rs765787 0.53 rs12903149 ENSG00000259520.4 CTD-2651B20.3 -8.86 1.71e-17 2.45e-14 -0.48 -0.38 Uric acid levels; chr15:45246878 chr15:45251580~45279251:- LUSC cis rs11098499 1 rs13435802 ENSG00000245958.5 RP11-33B1.1 8.86 1.71e-17 2.45e-14 0.38 0.38 Corneal astigmatism; chr4:119256805 chr4:119454791~119552025:+ LUSC cis rs1707322 0.963 rs10789478 ENSG00000280836.1 AL355480.1 -8.86 1.72e-17 2.46e-14 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45884834 chr1:45581219~45581321:- LUSC cis rs765787 0.53 rs12904265 ENSG00000259520.4 CTD-2651B20.3 -8.86 1.72e-17 2.46e-14 -0.48 -0.38 Uric acid levels; chr15:45234515 chr15:45251580~45279251:- LUSC cis rs11098499 0.909 rs1546502 ENSG00000245958.5 RP11-33B1.1 -8.85 1.72e-17 2.47e-14 -0.39 -0.38 Corneal astigmatism; chr4:119314743 chr4:119454791~119552025:+ LUSC cis rs62388641 1 rs62388641 ENSG00000272279.1 RP11-157J24.2 8.85 1.73e-17 2.48e-14 0.69 0.38 Daytime sleep phenotypes; chr6:1539849 chr6:1528364~1528911:- LUSC cis rs11098499 0.535 rs7671759 ENSG00000245958.5 RP11-33B1.1 -8.85 1.74e-17 2.49e-14 -0.38 -0.38 Corneal astigmatism; chr4:119326939 chr4:119454791~119552025:+ LUSC cis rs9487094 0.696 rs1853330 ENSG00000260273.1 RP11-425D10.10 8.85 1.76e-17 2.51e-14 0.45 0.38 Height; chr6:109375548 chr6:109382795~109383666:+ LUSC cis rs1707322 0.964 rs1768802 ENSG00000280836.1 AL355480.1 8.85 1.77e-17 2.53e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46082196 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs1588663 ENSG00000280836.1 AL355480.1 8.85 1.77e-17 2.53e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46083153 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs1768801 ENSG00000280836.1 AL355480.1 8.85 1.77e-17 2.53e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46083465 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs1768800 ENSG00000280836.1 AL355480.1 8.85 1.77e-17 2.53e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46083516 chr1:45581219~45581321:- LUSC cis rs1707322 0.964 rs785483 ENSG00000280836.1 AL355480.1 8.85 1.77e-17 2.53e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46093499 chr1:45581219~45581321:- LUSC cis rs9341808 0.718 rs2322631 ENSG00000272129.1 RP11-250B2.6 8.85 1.78e-17 2.54e-14 0.46 0.38 Sitting height ratio; chr6:80134239 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs9448898 ENSG00000272129.1 RP11-250B2.6 8.85 1.78e-17 2.54e-14 0.46 0.38 Sitting height ratio; chr6:80135624 chr6:80355424~80356859:+ LUSC cis rs526231 0.543 rs152134 ENSG00000175749.11 EIF3KP1 8.85 1.78e-17 2.55e-14 0.45 0.38 Primary biliary cholangitis; chr5:103176745 chr5:103032376~103033031:+ LUSC cis rs9487094 0.601 rs4945831 ENSG00000260273.1 RP11-425D10.10 8.85 1.78e-17 2.55e-14 0.45 0.38 Height; chr6:109440234 chr6:109382795~109383666:+ LUSC cis rs11098499 0.754 rs714899 ENSG00000245958.5 RP11-33B1.1 -8.85 1.79e-17 2.56e-14 -0.38 -0.38 Corneal astigmatism; chr4:119321880 chr4:119454791~119552025:+ LUSC cis rs9487094 0.666 rs6920372 ENSG00000260273.1 RP11-425D10.10 8.85 1.8e-17 2.57e-14 0.44 0.38 Height; chr6:109402736 chr6:109382795~109383666:+ LUSC cis rs9487094 0.644 rs9320286 ENSG00000260273.1 RP11-425D10.10 8.85 1.8e-17 2.57e-14 0.44 0.38 Height; chr6:109403734 chr6:109382795~109383666:+ LUSC cis rs11098499 0.863 rs1383532 ENSG00000249244.1 RP11-548H18.2 -8.85 1.81e-17 2.59e-14 -0.48 -0.38 Corneal astigmatism; chr4:119513249 chr4:119391831~119395335:- LUSC cis rs7189233 0.571 rs4146344 ENSG00000279344.1 RP11-44F14.7 8.85 1.82e-17 2.6e-14 0.33 0.38 Intelligence (multi-trait analysis); chr16:53435050 chr16:53478957~53481550:- LUSC cis rs1113500 0.836 rs1618973 ENSG00000226822.1 RP11-356N1.2 -8.85 1.82e-17 2.6e-14 -0.39 -0.38 Growth-regulated protein alpha levels; chr1:108044145 chr1:108071482~108074519:+ LUSC cis rs2283792 0.935 rs2283794 ENSG00000228050.1 TOP3BP1 8.85 1.82e-17 2.6e-14 0.45 0.38 Multiple sclerosis; chr22:21858180 chr22:22223187~22224566:- LUSC cis rs4423214 0.57 rs7118246 ENSG00000254682.1 RP11-660L16.2 8.85 1.83e-17 2.61e-14 0.54 0.38 Vitamin D levels; chr11:71520078 chr11:71448674~71452157:+ LUSC cis rs9322193 0.962 rs9688750 ENSG00000216906.2 RP11-350J20.9 8.85 1.83e-17 2.62e-14 0.45 0.38 Lung cancer; chr6:149657633 chr6:149904243~149906418:+ LUSC cis rs9341808 0.718 rs12203867 ENSG00000272129.1 RP11-250B2.6 8.85 1.84e-17 2.63e-14 0.46 0.38 Sitting height ratio; chr6:80111116 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs11962614 ENSG00000272129.1 RP11-250B2.6 8.85 1.84e-17 2.63e-14 0.46 0.38 Sitting height ratio; chr6:80113589 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs12208016 ENSG00000272129.1 RP11-250B2.6 8.85 1.84e-17 2.63e-14 0.46 0.38 Sitting height ratio; chr6:80113846 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs9448886 ENSG00000272129.1 RP11-250B2.6 8.85 1.84e-17 2.63e-14 0.46 0.38 Sitting height ratio; chr6:80116184 chr6:80355424~80356859:+ LUSC cis rs9341808 0.754 rs1015158 ENSG00000272129.1 RP11-250B2.6 8.85 1.84e-17 2.63e-14 0.46 0.38 Sitting height ratio; chr6:80236028 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs7740627 ENSG00000272129.1 RP11-250B2.6 8.85 1.85e-17 2.64e-14 0.46 0.38 Sitting height ratio; chr6:80206630 chr6:80355424~80356859:+ LUSC cis rs1707322 0.963 rs12145287 ENSG00000280836.1 AL355480.1 -8.85 1.85e-17 2.64e-14 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45859330 chr1:45581219~45581321:- LUSC cis rs853679 0.517 rs9380056 ENSG00000219392.1 RP1-265C24.5 -8.85 1.85e-17 2.65e-14 -0.53 -0.38 Depression; chr6:28136698 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9380057 ENSG00000219392.1 RP1-265C24.5 -8.85 1.85e-17 2.65e-14 -0.53 -0.38 Depression; chr6:28136856 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs6941992 ENSG00000219392.1 RP1-265C24.5 -8.85 1.85e-17 2.65e-14 -0.53 -0.38 Depression; chr6:28138363 chr6:28115628~28116551:+ LUSC cis rs4713118 0.516 rs4713142 ENSG00000219392.1 RP1-265C24.5 -8.85 1.85e-17 2.65e-14 -0.53 -0.38 Parkinson's disease; chr6:28138569 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs4713143 ENSG00000219392.1 RP1-265C24.5 -8.85 1.85e-17 2.65e-14 -0.53 -0.38 Depression; chr6:28138981 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs4713144 ENSG00000219392.1 RP1-265C24.5 -8.85 1.85e-17 2.65e-14 -0.53 -0.38 Depression; chr6:28139012 chr6:28115628~28116551:+ LUSC cis rs7189233 0.531 rs9932007 ENSG00000279344.1 RP11-44F14.7 8.84 1.86e-17 2.65e-14 0.33 0.38 Intelligence (multi-trait analysis); chr16:53422749 chr16:53478957~53481550:- LUSC cis rs9918079 0.506 rs10214 ENSG00000273133.1 RP11-799M12.2 8.84 1.89e-17 2.69e-14 0.5 0.38 Obesity-related traits; chr4:15604808 chr4:15563698~15564253:- LUSC cis rs9341808 0.718 rs2143887 ENSG00000272129.1 RP11-250B2.6 8.84 1.89e-17 2.7e-14 0.46 0.38 Sitting height ratio; chr6:80207570 chr6:80355424~80356859:+ LUSC cis rs9341808 0.683 rs7771449 ENSG00000272129.1 RP11-250B2.6 8.84 1.89e-17 2.7e-14 0.46 0.38 Sitting height ratio; chr6:80210260 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs910266 ENSG00000272129.1 RP11-250B2.6 8.84 1.89e-17 2.7e-14 0.46 0.38 Sitting height ratio; chr6:80211453 chr6:80355424~80356859:+ LUSC cis rs10129255 0.5 rs2027902 ENSG00000211972.2 IGHV3-66 8.84 1.9e-17 2.71e-14 0.25 0.38 Kawasaki disease; chr14:106807157 chr14:106675017~106675544:- LUSC cis rs526231 0.511 rs1011453 ENSG00000175749.11 EIF3KP1 8.84 1.9e-17 2.71e-14 0.47 0.38 Primary biliary cholangitis; chr5:103032323 chr5:103032376~103033031:+ LUSC cis rs62229266 0.633 rs743420 ENSG00000231106.2 LINC01436 8.84 1.91e-17 2.72e-14 0.48 0.38 Mitral valve prolapse; chr21:36015104 chr21:36005338~36007838:+ LUSC cis rs9660180 0.967 rs9660106 ENSG00000268575.1 RP1-283E3.8 -8.84 1.91e-17 2.72e-14 -0.34 -0.38 Body mass index; chr1:1866508 chr1:1702736~1737688:- LUSC cis rs8072100 0.875 rs4794047 ENSG00000228782.6 CTD-2026D20.3 -8.84 1.91e-17 2.73e-14 -0.36 -0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47685639 chr17:47450568~47492492:- LUSC cis rs9322193 0.923 rs10872645 ENSG00000216906.2 RP11-350J20.9 8.84 1.92e-17 2.73e-14 0.45 0.38 Lung cancer; chr6:149742840 chr6:149904243~149906418:+ LUSC cis rs1075265 0.584 rs1833497 ENSG00000233266.1 HMGB1P31 8.84 1.92e-17 2.73e-14 0.47 0.38 Chronotype;Morning vs. evening chronotype; chr2:54052186 chr2:54051334~54051760:+ LUSC cis rs9322193 0.962 rs2151912 ENSG00000216906.2 RP11-350J20.9 8.84 1.92e-17 2.74e-14 0.46 0.38 Lung cancer; chr6:149831772 chr6:149904243~149906418:+ LUSC cis rs7044106 0.791 rs12554440 ENSG00000226752.6 PSMD5-AS1 -8.84 1.93e-17 2.75e-14 -0.44 -0.38 Hip circumference adjusted for BMI; chr9:120723055 chr9:120824828~120854385:+ LUSC cis rs9660180 0.967 rs2272908 ENSG00000268575.1 RP1-283E3.8 8.84 1.93e-17 2.75e-14 0.34 0.38 Body mass index; chr1:1790040 chr1:1702736~1737688:- LUSC cis rs4927850 0.918 rs4361313 ENSG00000231464.1 AC024937.4 8.84 1.93e-17 2.75e-14 0.41 0.38 Pancreatic cancer; chr3:196025389 chr3:195996738~195998233:+ LUSC cis rs12134133 1 rs2564973 ENSG00000274245.1 RP11-357P18.2 8.84 1.95e-17 2.77e-14 0.49 0.38 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207306759 chr1:207372559~207373252:+ LUSC cis rs10129255 0.957 rs10140904 ENSG00000211970.3 IGHV4-61 -8.84 1.96e-17 2.8e-14 -0.27 -0.38 Kawasaki disease; chr14:106776558 chr14:106639119~106639657:- LUSC cis rs6782228 0.606 rs2712404 ENSG00000277250.1 Metazoa_SRP 8.84 1.97e-17 2.8e-14 0.42 0.38 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613836 chr3:128673681~128674021:- LUSC cis rs9487094 0.626 rs2025148 ENSG00000260273.1 RP11-425D10.10 8.84 1.97e-17 2.81e-14 0.44 0.38 Height; chr6:109706740 chr6:109382795~109383666:+ LUSC cis rs12439619 0.846 rs62010071 ENSG00000255769.6 GOLGA2P10 -8.84 1.97e-17 2.81e-14 -0.53 -0.38 Intelligence (multi-trait analysis); chr15:82289442 chr15:82472993~82513950:- LUSC cis rs9341808 0.69 rs3805926 ENSG00000272129.1 RP11-250B2.6 8.84 1.98e-17 2.82e-14 0.46 0.38 Sitting height ratio; chr6:80169563 chr6:80355424~80356859:+ LUSC cis rs1075265 0.584 rs1862121 ENSG00000233266.1 HMGB1P31 8.84 1.99e-17 2.83e-14 0.47 0.38 Chronotype;Morning vs. evening chronotype; chr2:54058102 chr2:54051334~54051760:+ LUSC cis rs1113500 0.933 rs12132785 ENSG00000226822.1 RP11-356N1.2 8.84 1.99e-17 2.83e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108090461 chr1:108071482~108074519:+ LUSC cis rs992157 0.767 rs2014615 ENSG00000261338.2 RP11-378A13.1 8.84 2e-17 2.85e-14 0.38 0.38 Colorectal cancer; chr2:218306468 chr2:218255319~218257366:+ LUSC cis rs853679 0.55 rs1150689 ENSG00000219392.1 RP1-265C24.5 -8.83 2.01e-17 2.86e-14 -0.52 -0.38 Depression; chr6:28197321 chr6:28115628~28116551:+ LUSC cis rs9341808 0.718 rs9343978 ENSG00000272129.1 RP11-250B2.6 8.83 2.01e-17 2.86e-14 0.46 0.38 Sitting height ratio; chr6:80262261 chr6:80355424~80356859:+ LUSC cis rs9322193 0.884 rs9688858 ENSG00000216906.2 RP11-350J20.9 8.83 2.02e-17 2.88e-14 0.45 0.38 Lung cancer; chr6:149637911 chr6:149904243~149906418:+ LUSC cis rs6964833 0.786 rs35633336 ENSG00000277053.3 GTF2IP1 -8.83 2.03e-17 2.89e-14 -0.55 -0.38 Menarche (age at onset); chr7:74643961 chr7:75185385~75237696:- LUSC cis rs6964833 0.935 rs35735900 ENSG00000277053.3 GTF2IP1 -8.83 2.03e-17 2.89e-14 -0.55 -0.38 Menarche (age at onset); chr7:74651887 chr7:75185385~75237696:- LUSC cis rs6964833 0.872 rs4717903 ENSG00000277053.3 GTF2IP1 -8.83 2.03e-17 2.89e-14 -0.55 -0.38 Menarche (age at onset); chr7:74653827 chr7:75185385~75237696:- LUSC cis rs3096299 0.9 rs3114867 ENSG00000274627.1 RP11-104N10.2 8.83 2.04e-17 2.9e-14 0.33 0.38 Multiple myeloma (IgH translocation); chr16:89362559 chr16:89516797~89522217:+ LUSC cis rs6991838 0.584 rs7463649 ENSG00000200714.1 Y_RNA -8.83 2.05e-17 2.92e-14 -0.46 -0.38 Intelligence (multi-trait analysis); chr8:65573760 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs66467166 ENSG00000200714.1 Y_RNA -8.83 2.05e-17 2.92e-14 -0.46 -0.38 Intelligence (multi-trait analysis); chr8:65574165 chr8:65592731~65592820:+ LUSC cis rs11098499 0.73 rs78971550 ENSG00000245958.5 RP11-33B1.1 -8.83 2.05e-17 2.92e-14 -0.38 -0.38 Corneal astigmatism; chr4:119359886 chr4:119454791~119552025:+ LUSC cis rs11098499 0.645 rs78422072 ENSG00000245958.5 RP11-33B1.1 -8.83 2.05e-17 2.92e-14 -0.38 -0.38 Corneal astigmatism; chr4:119359887 chr4:119454791~119552025:+ LUSC cis rs853679 0.55 rs1225598 ENSG00000219392.1 RP1-265C24.5 -8.83 2.05e-17 2.92e-14 -0.52 -0.38 Depression; chr6:28193021 chr6:28115628~28116551:+ LUSC cis rs6921919 0.583 rs16894108 ENSG00000216901.1 AL022393.7 8.83 2.06e-17 2.92e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28434013 chr6:28176188~28176674:+ LUSC cis rs9322193 0.923 rs9688350 ENSG00000223701.3 RAET1E-AS1 8.83 2.06e-17 2.93e-14 0.44 0.38 Lung cancer; chr6:149730977 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9767652 ENSG00000223701.3 RAET1E-AS1 8.83 2.06e-17 2.93e-14 0.44 0.38 Lung cancer; chr6:149734502 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs10782314 ENSG00000223701.3 RAET1E-AS1 8.83 2.06e-17 2.93e-14 0.44 0.38 Lung cancer; chr6:149735527 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs12211511 ENSG00000216906.2 RP11-350J20.9 8.83 2.07e-17 2.94e-14 0.45 0.38 Lung cancer; chr6:149745206 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9479810 ENSG00000216906.2 RP11-350J20.9 8.83 2.07e-17 2.94e-14 0.45 0.38 Lung cancer; chr6:149751359 chr6:149904243~149906418:+ LUSC cis rs2729354 0.52 rs2729377 ENSG00000265566.2 RN7SL605P -8.83 2.08e-17 2.96e-14 -0.53 -0.38 Blood protein levels; chr11:57482611 chr11:57528085~57528365:- LUSC cis rs7174755 0.558 rs11071975 ENSG00000260657.2 RP11-315D16.4 -8.83 2.08e-17 2.96e-14 -0.5 -0.38 Major depressive disorder; chr15:68037106 chr15:68267792~68277994:- LUSC cis rs6991838 0.584 rs4737221 ENSG00000200714.1 Y_RNA -8.83 2.08e-17 2.96e-14 -0.46 -0.38 Intelligence (multi-trait analysis); chr8:65569075 chr8:65592731~65592820:+ LUSC cis rs10129255 0.5 rs10131875 ENSG00000211972.2 IGHV3-66 8.83 2.09e-17 2.97e-14 0.25 0.38 Kawasaki disease; chr14:106792798 chr14:106675017~106675544:- LUSC cis rs9322193 0.884 rs9688699 ENSG00000223701.3 RAET1E-AS1 8.83 2.09e-17 2.97e-14 0.44 0.38 Lung cancer; chr6:149733680 chr6:149884431~149919508:+ LUSC cis rs9341808 0.718 rs9448899 ENSG00000272129.1 RP11-250B2.6 8.83 2.1e-17 2.98e-14 0.46 0.38 Sitting height ratio; chr6:80136147 chr6:80355424~80356859:+ LUSC cis rs853679 0.542 rs6934769 ENSG00000219392.1 RP1-265C24.5 -8.83 2.12e-17 3.01e-14 -0.52 -0.38 Depression; chr6:28123153 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs17711801 ENSG00000219392.1 RP1-265C24.5 -8.83 2.12e-17 3.01e-14 -0.52 -0.38 Depression; chr6:28124529 chr6:28115628~28116551:+ LUSC cis rs4713118 0.527 rs9461433 ENSG00000219392.1 RP1-265C24.5 -8.83 2.12e-17 3.01e-14 -0.52 -0.38 Parkinson's disease; chr6:28127394 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9468292 ENSG00000219392.1 RP1-265C24.5 -8.83 2.12e-17 3.01e-14 -0.52 -0.38 Depression; chr6:28127577 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs1947863 ENSG00000219392.1 RP1-265C24.5 -8.83 2.12e-17 3.01e-14 -0.52 -0.38 Depression; chr6:28131566 chr6:28115628~28116551:+ LUSC cis rs1823913 1 rs12623832 ENSG00000227542.1 AC092614.2 -8.83 2.13e-17 3.02e-14 -0.5 -0.38 Obesity-related traits; chr2:191260918 chr2:191229165~191246172:- LUSC cis rs1823913 0.927 rs56209234 ENSG00000227542.1 AC092614.2 8.83 2.14e-17 3.03e-14 0.52 0.38 Obesity-related traits; chr2:191261748 chr2:191229165~191246172:- LUSC cis rs9389248 0.69 rs728030 ENSG00000232876.1 CTA-212D2.2 8.83 2.14e-17 3.03e-14 0.47 0.38 High light scatter reticulocyte percentage of red cells; chr6:134925156 chr6:135055033~135060550:+ LUSC cis rs4927850 0.958 rs1975582 ENSG00000231464.1 AC024937.4 8.83 2.15e-17 3.05e-14 0.41 0.38 Pancreatic cancer; chr3:196024568 chr3:195996738~195998233:+ LUSC cis rs1707322 1 rs785486 ENSG00000280836.1 AL355480.1 8.83 2.15e-17 3.05e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46109476 chr1:45581219~45581321:- LUSC cis rs1707322 0.865 rs785501 ENSG00000280836.1 AL355480.1 8.83 2.15e-17 3.05e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46113939 chr1:45581219~45581321:- LUSC cis rs1707322 0.929 rs785500 ENSG00000280836.1 AL355480.1 8.83 2.15e-17 3.05e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46127372 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs785504 ENSG00000280836.1 AL355480.1 8.83 2.15e-17 3.05e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46130024 chr1:45581219~45581321:- LUSC cis rs2283792 0.967 rs5999823 ENSG00000228050.1 TOP3BP1 8.83 2.16e-17 3.07e-14 0.44 0.38 Multiple sclerosis; chr22:21856587 chr22:22223187~22224566:- LUSC cis rs11098499 0.954 rs6849561 ENSG00000245958.5 RP11-33B1.1 8.82 2.17e-17 3.08e-14 0.4 0.38 Corneal astigmatism; chr4:119488539 chr4:119454791~119552025:+ LUSC cis rs853679 0.517 rs9380052 ENSG00000219392.1 RP1-265C24.5 -8.82 2.18e-17 3.09e-14 -0.53 -0.38 Depression; chr6:28096845 chr6:28115628~28116551:+ LUSC cis rs11155671 0.53 rs7763849 ENSG00000223701.3 RAET1E-AS1 8.82 2.19e-17 3.1e-14 0.45 0.38 Testicular germ cell tumor; chr6:149885244 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9765929 ENSG00000216906.2 RP11-350J20.9 8.82 2.19e-17 3.1e-14 0.45 0.38 Lung cancer; chr6:149769680 chr6:149904243~149906418:+ LUSC cis rs1113500 0.933 rs12035689 ENSG00000226822.1 RP11-356N1.2 8.82 2.2e-17 3.12e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108094134 chr1:108071482~108074519:+ LUSC cis rs1113500 0.862 rs3853494 ENSG00000226822.1 RP11-356N1.2 8.82 2.2e-17 3.12e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108094712 chr1:108071482~108074519:+ LUSC cis rs1113500 0.933 rs745795 ENSG00000226822.1 RP11-356N1.2 8.82 2.2e-17 3.12e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108086723 chr1:108071482~108074519:+ LUSC cis rs1113500 0.933 rs2077259 ENSG00000226822.1 RP11-356N1.2 8.82 2.2e-17 3.12e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108086929 chr1:108071482~108074519:+ LUSC cis rs1113500 0.933 rs3909076 ENSG00000226822.1 RP11-356N1.2 8.82 2.2e-17 3.12e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108089138 chr1:108071482~108074519:+ LUSC cis rs1113500 0.933 rs3893034 ENSG00000226822.1 RP11-356N1.2 8.82 2.2e-17 3.12e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108089556 chr1:108071482~108074519:+ LUSC cis rs1707322 1 rs4606257 ENSG00000280836.1 AL355480.1 -8.82 2.22e-17 3.14e-14 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45841596 chr1:45581219~45581321:- LUSC cis rs765787 0.53 rs11636404 ENSG00000259520.4 CTD-2651B20.3 8.82 2.22e-17 3.15e-14 0.47 0.38 Uric acid levels; chr15:45243663 chr15:45251580~45279251:- LUSC cis rs7208859 0.623 rs122898 ENSG00000263531.1 RP13-753N3.1 -8.82 2.24e-17 3.18e-14 -0.65 -0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30578236 chr17:30863921~30864940:- LUSC cis rs9341808 0.754 rs9343973 ENSG00000272129.1 RP11-250B2.6 8.82 2.25e-17 3.19e-14 0.46 0.38 Sitting height ratio; chr6:80203499 chr6:80355424~80356859:+ LUSC cis rs853679 0.517 rs9357065 ENSG00000219392.1 RP1-265C24.5 -8.82 2.25e-17 3.19e-14 -0.53 -0.38 Depression; chr6:28161802 chr6:28115628~28116551:+ LUSC cis rs765787 0.53 rs2899378 ENSG00000259520.4 CTD-2651B20.3 -8.82 2.26e-17 3.2e-14 -0.48 -0.38 Uric acid levels; chr15:45245386 chr15:45251580~45279251:- LUSC cis rs6991838 0.584 rs14213 ENSG00000200714.1 Y_RNA 8.82 2.27e-17 3.21e-14 0.47 0.38 Intelligence (multi-trait analysis); chr8:65602719 chr8:65592731~65592820:+ LUSC cis rs765787 0.53 rs7167731 ENSG00000259520.4 CTD-2651B20.3 -8.82 2.28e-17 3.22e-14 -0.48 -0.38 Uric acid levels; chr15:45218702 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs12910270 ENSG00000259520.4 CTD-2651B20.3 -8.82 2.28e-17 3.22e-14 -0.48 -0.38 Uric acid levels; chr15:45219888 chr15:45251580~45279251:- LUSC cis rs6921919 0.583 rs4254981 ENSG00000216901.1 AL022393.7 8.82 2.29e-17 3.23e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28403625 chr6:28176188~28176674:+ LUSC cis rs6921919 0.525 rs6929825 ENSG00000216901.1 AL022393.7 8.82 2.29e-17 3.23e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28411182 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs35599905 ENSG00000216901.1 AL022393.7 8.82 2.29e-17 3.23e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28411886 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs1124131 ENSG00000216901.1 AL022393.7 8.82 2.29e-17 3.23e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28412471 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs6899389 ENSG00000216901.1 AL022393.7 8.82 2.29e-17 3.23e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28413363 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs6922374 ENSG00000216901.1 AL022393.7 8.82 2.29e-17 3.23e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28413495 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs6899603 ENSG00000216901.1 AL022393.7 8.82 2.29e-17 3.23e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28413528 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs6922429 ENSG00000216901.1 AL022393.7 8.82 2.29e-17 3.23e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28413568 chr6:28176188~28176674:+ LUSC cis rs62229266 0.659 rs2026259 ENSG00000231106.2 LINC01436 8.82 2.3e-17 3.25e-14 0.48 0.38 Mitral valve prolapse; chr21:36058329 chr21:36005338~36007838:+ LUSC cis rs765787 0.53 rs12440321 ENSG00000259520.4 CTD-2651B20.3 -8.82 2.31e-17 3.26e-14 -0.48 -0.38 Uric acid levels; chr15:45237187 chr15:45251580~45279251:- LUSC cis rs11098499 0.863 rs7669520 ENSG00000249244.1 RP11-548H18.2 8.82 2.31e-17 3.26e-14 0.48 0.38 Corneal astigmatism; chr4:119594123 chr4:119391831~119395335:- LUSC cis rs5769707 0.632 rs135872 ENSG00000235111.1 RP1-29C18.8 -8.82 2.31e-17 3.27e-14 -0.47 -0.38 Monocyte percentage of white cells;Monocyte count; chr22:49615652 chr22:49612657~49615716:- LUSC cis rs1707322 0.964 rs6697830 ENSG00000280836.1 AL355480.1 -8.82 2.31e-17 3.27e-14 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45824805 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs12060274 ENSG00000280836.1 AL355480.1 -8.82 2.31e-17 3.27e-14 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45825390 chr1:45581219~45581321:- LUSC cis rs11098499 0.863 rs10018280 ENSG00000249244.1 RP11-548H18.2 8.82 2.32e-17 3.27e-14 0.48 0.38 Corneal astigmatism; chr4:119556984 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs6534141 ENSG00000249244.1 RP11-548H18.2 8.82 2.32e-17 3.27e-14 0.48 0.38 Corneal astigmatism; chr4:119564068 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3775858 ENSG00000249244.1 RP11-548H18.2 8.82 2.32e-17 3.27e-14 0.48 0.38 Corneal astigmatism; chr4:119564873 chr4:119391831~119395335:- LUSC cis rs2283792 1 rs3788332 ENSG00000228050.1 TOP3BP1 8.82 2.34e-17 3.3e-14 0.44 0.38 Multiple sclerosis; chr22:21817278 chr22:22223187~22224566:- LUSC cis rs11098499 0.82 rs28535956 ENSG00000249244.1 RP11-548H18.2 -8.81 2.34e-17 3.3e-14 -0.49 -0.38 Corneal astigmatism; chr4:119615703 chr4:119391831~119395335:- LUSC cis rs9322193 0.962 rs12175575 ENSG00000216906.2 RP11-350J20.9 8.81 2.36e-17 3.33e-14 0.44 0.38 Lung cancer; chr6:149763351 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs4869966 ENSG00000216906.2 RP11-350J20.9 8.81 2.36e-17 3.33e-14 0.44 0.38 Lung cancer; chr6:149763714 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs1112730 ENSG00000216906.2 RP11-350J20.9 8.81 2.36e-17 3.33e-14 0.44 0.38 Lung cancer; chr6:149766383 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs1112729 ENSG00000216906.2 RP11-350J20.9 8.81 2.36e-17 3.33e-14 0.44 0.38 Lung cancer; chr6:149766491 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs10452626 ENSG00000216906.2 RP11-350J20.9 8.81 2.36e-17 3.33e-14 0.44 0.38 Lung cancer; chr6:149767481 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs62441303 ENSG00000216906.2 RP11-350J20.9 8.81 2.36e-17 3.33e-14 0.44 0.38 Lung cancer; chr6:149767547 chr6:149904243~149906418:+ LUSC cis rs1075265 0.584 rs7558126 ENSG00000233266.1 HMGB1P31 8.81 2.37e-17 3.34e-14 0.47 0.38 Chronotype;Morning vs. evening chronotype; chr2:54053847 chr2:54051334~54051760:+ LUSC cis rs526231 0.512 rs34797 ENSG00000175749.11 EIF3KP1 8.81 2.37e-17 3.34e-14 0.46 0.38 Primary biliary cholangitis; chr5:103090023 chr5:103032376~103033031:+ LUSC cis rs526231 0.543 rs34801 ENSG00000175749.11 EIF3KP1 8.81 2.37e-17 3.34e-14 0.46 0.38 Primary biliary cholangitis; chr5:103090809 chr5:103032376~103033031:+ LUSC cis rs9918079 0.56 rs10008975 ENSG00000273133.1 RP11-799M12.2 -8.81 2.37e-17 3.34e-14 -0.5 -0.38 Obesity-related traits; chr4:15622948 chr4:15563698~15564253:- LUSC cis rs1113500 0.933 rs4590700 ENSG00000226822.1 RP11-356N1.2 8.81 2.38e-17 3.35e-14 0.39 0.38 Growth-regulated protein alpha levels; chr1:108095722 chr1:108071482~108074519:+ LUSC cis rs1707322 1 rs785510 ENSG00000280836.1 AL355480.1 8.81 2.41e-17 3.4e-14 0.46 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46062946 chr1:45581219~45581321:- LUSC cis rs10463554 0.927 rs158250 ENSG00000175749.11 EIF3KP1 8.81 2.43e-17 3.42e-14 0.45 0.38 Parkinson's disease; chr5:103071075 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs464702 ENSG00000175749.11 EIF3KP1 8.81 2.43e-17 3.42e-14 0.45 0.38 Parkinson's disease; chr5:103071180 chr5:103032376~103033031:+ LUSC cis rs7945705 0.747 rs1980429 ENSG00000254860.4 TMEM9B-AS1 8.81 2.46e-17 3.45e-14 0.41 0.38 Hemoglobin concentration; chr11:8988927 chr11:8964675~8977527:+ LUSC cis rs526231 0.543 rs34808 ENSG00000175749.11 EIF3KP1 8.81 2.46e-17 3.46e-14 0.47 0.38 Primary biliary cholangitis; chr5:103093484 chr5:103032376~103033031:+ LUSC cis rs526231 0.543 rs34809 ENSG00000175749.11 EIF3KP1 8.81 2.46e-17 3.46e-14 0.47 0.38 Primary biliary cholangitis; chr5:103094413 chr5:103032376~103033031:+ LUSC cis rs12439619 0.768 rs28694364 ENSG00000255769.6 GOLGA2P10 -8.81 2.46e-17 3.46e-14 -0.52 -0.38 Intelligence (multi-trait analysis); chr15:82208119 chr15:82472993~82513950:- LUSC cis rs1861353 0.863 rs16952252 ENSG00000279344.1 RP11-44F14.7 8.81 2.47e-17 3.48e-14 0.32 0.38 Intelligence (multi-trait analysis); chr16:53450068 chr16:53478957~53481550:- LUSC cis rs2739330 0.828 rs4822454 ENSG00000231271.1 AP000350.8 8.81 2.48e-17 3.48e-14 0.49 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23949918~23954042:+ LUSC cis rs11098499 1 rs11098500 ENSG00000245958.5 RP11-33B1.1 -8.81 2.48e-17 3.49e-14 -0.39 -0.38 Corneal astigmatism; chr4:119298084 chr4:119454791~119552025:+ LUSC cis rs12439619 0.81 rs28876157 ENSG00000255769.6 GOLGA2P10 -8.81 2.49e-17 3.49e-14 -0.52 -0.38 Intelligence (multi-trait analysis); chr15:82216708 chr15:82472993~82513950:- LUSC cis rs853679 0.55 rs1237875 ENSG00000219392.1 RP1-265C24.5 8.81 2.49e-17 3.49e-14 0.52 0.38 Depression; chr6:28205232 chr6:28115628~28116551:+ LUSC cis rs11098499 1 rs13116504 ENSG00000245958.5 RP11-33B1.1 -8.81 2.49e-17 3.49e-14 -0.38 -0.38 Corneal astigmatism; chr4:119288257 chr4:119454791~119552025:+ LUSC cis rs9487094 0.689 rs2884037 ENSG00000260273.1 RP11-425D10.10 8.81 2.49e-17 3.49e-14 0.44 0.38 Height; chr6:109354092 chr6:109382795~109383666:+ LUSC cis rs1707322 0.821 rs11211182 ENSG00000280836.1 AL355480.1 -8.81 2.49e-17 3.5e-14 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45774498 chr1:45581219~45581321:- LUSC cis rs6921919 0.583 rs11755942 ENSG00000216901.1 AL022393.7 8.81 2.49e-17 3.5e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28401760 chr6:28176188~28176674:+ LUSC cis rs765787 0.53 rs12442533 ENSG00000259520.4 CTD-2651B20.3 -8.81 2.5e-17 3.5e-14 -0.48 -0.38 Uric acid levels; chr15:45237433 chr15:45251580~45279251:- LUSC cis rs9487094 0.666 rs1074765 ENSG00000260273.1 RP11-425D10.10 -8.81 2.51e-17 3.53e-14 -0.44 -0.38 Height; chr6:109360458 chr6:109382795~109383666:+ LUSC cis rs6452524 0.935 rs1478480 ENSG00000249664.1 CTD-2227C6.2 8.81 2.52e-17 3.54e-14 0.39 0.38 Hypertension (SNP x SNP interaction); chr5:83112117 chr5:83012285~83013109:- LUSC cis rs853679 0.517 rs4713141 ENSG00000219392.1 RP1-265C24.5 -8.81 2.52e-17 3.54e-14 -0.53 -0.38 Depression; chr6:28133900 chr6:28115628~28116551:+ LUSC cis rs1729407 0.774 rs2849167 ENSG00000254851.1 RP11-109L13.1 8.8 2.53e-17 3.55e-14 0.47 0.38 Apolipoprotein A-IV levels; chr11:116814028 chr11:117135528~117138582:+ LUSC cis rs11168854 0.656 rs7969963 ENSG00000258017.1 RP11-386G11.10 -8.8 2.55e-17 3.57e-14 -0.48 -0.38 Body mass index; chr12:49118222 chr12:49127782~49147869:+ LUSC cis rs8062405 0.755 rs62034325 ENSG00000259982.1 CDC37P1 8.8 2.55e-17 3.58e-14 0.47 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28527319 chr16:28700294~28701540:- LUSC cis rs9660180 0.967 rs11260623 ENSG00000268575.1 RP1-283E3.8 -8.8 2.59e-17 3.63e-14 -0.34 -0.38 Body mass index; chr1:1850017 chr1:1702736~1737688:- LUSC cis rs7189233 0.531 rs7204758 ENSG00000279344.1 RP11-44F14.7 8.8 2.59e-17 3.63e-14 0.32 0.38 Intelligence (multi-trait analysis); chr16:53448453 chr16:53478957~53481550:- LUSC cis rs7189233 0.531 rs9921627 ENSG00000279344.1 RP11-44F14.7 8.8 2.59e-17 3.63e-14 0.32 0.38 Intelligence (multi-trait analysis); chr16:53448780 chr16:53478957~53481550:- LUSC cis rs6991838 0.584 rs4275254 ENSG00000200714.1 Y_RNA -8.8 2.6e-17 3.64e-14 -0.45 -0.38 Intelligence (multi-trait analysis); chr8:65589129 chr8:65592731~65592820:+ LUSC cis rs11098499 0.863 rs3822192 ENSG00000249244.1 RP11-548H18.2 8.8 2.6e-17 3.65e-14 0.49 0.38 Corneal astigmatism; chr4:119524565 chr4:119391831~119395335:- LUSC cis rs12439619 0.846 rs62012003 ENSG00000255769.6 GOLGA2P10 -8.8 2.61e-17 3.66e-14 -0.52 -0.38 Intelligence (multi-trait analysis); chr15:82183236 chr15:82472993~82513950:- LUSC cis rs9487094 0.689 rs1476387 ENSG00000260273.1 RP11-425D10.10 8.8 2.63e-17 3.68e-14 0.44 0.38 Height; chr6:109443332 chr6:109382795~109383666:+ LUSC cis rs7811142 0.83 rs6955367 ENSG00000242294.5 STAG3L5P 8.8 2.63e-17 3.69e-14 0.29 0.38 Platelet count; chr7:100363571 chr7:100336079~100351900:+ LUSC cis rs8062405 0.754 rs151179 ENSG00000259982.1 CDC37P1 8.8 2.63e-17 3.69e-14 0.47 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28475735 chr16:28700294~28701540:- LUSC cis rs9341808 0.727 rs10943697 ENSG00000272129.1 RP11-250B2.6 8.8 2.64e-17 3.7e-14 0.46 0.38 Sitting height ratio; chr6:80221789 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs1324123 ENSG00000272129.1 RP11-250B2.6 8.8 2.64e-17 3.7e-14 0.46 0.38 Sitting height ratio; chr6:80223177 chr6:80355424~80356859:+ LUSC cis rs9322193 0.607 rs4870078 ENSG00000216906.2 RP11-350J20.9 -8.8 2.65e-17 3.71e-14 -0.51 -0.38 Lung cancer; chr6:149880676 chr6:149904243~149906418:+ LUSC cis rs9341808 0.754 rs6916405 ENSG00000272129.1 RP11-250B2.6 8.8 2.65e-17 3.71e-14 0.45 0.38 Sitting height ratio; chr6:80314471 chr6:80355424~80356859:+ LUSC cis rs4713118 0.621 rs9295756 ENSG00000219392.1 RP1-265C24.5 -8.8 2.66e-17 3.72e-14 -0.52 -0.38 Parkinson's disease; chr6:28065618 chr6:28115628~28116551:+ LUSC cis rs1061377 1 rs7685468 ENSG00000249207.1 RP11-360F5.1 -8.8 2.66e-17 3.72e-14 -0.4 -0.38 Uric acid levels; chr4:39116649 chr4:39112677~39126818:- LUSC cis rs526231 0.543 rs34807 ENSG00000175749.11 EIF3KP1 8.8 2.67e-17 3.73e-14 0.47 0.38 Primary biliary cholangitis; chr5:103092818 chr5:103032376~103033031:+ LUSC cis rs11098499 1 rs3749591 ENSG00000245958.5 RP11-33B1.1 -8.8 2.67e-17 3.74e-14 -0.39 -0.38 Corneal astigmatism; chr4:119292875 chr4:119454791~119552025:+ LUSC cis rs9487094 0.62 rs6939953 ENSG00000260273.1 RP11-425D10.10 8.8 2.68e-17 3.75e-14 0.44 0.38 Height; chr6:109390116 chr6:109382795~109383666:+ LUSC cis rs9487094 0.666 rs3757235 ENSG00000260273.1 RP11-425D10.10 8.8 2.68e-17 3.75e-14 0.44 0.38 Height; chr6:109390638 chr6:109382795~109383666:+ LUSC cis rs10129255 0.5 rs7157975 ENSG00000211972.2 IGHV3-66 8.8 2.69e-17 3.76e-14 0.25 0.38 Kawasaki disease; chr14:106804049 chr14:106675017~106675544:- LUSC cis rs4927850 0.957 rs4927851 ENSG00000231464.1 AC024937.4 8.8 2.7e-17 3.78e-14 0.4 0.38 Pancreatic cancer; chr3:196024982 chr3:195996738~195998233:+ LUSC cis rs7189233 0.55 rs9938788 ENSG00000279344.1 RP11-44F14.7 8.8 2.71e-17 3.79e-14 0.33 0.38 Intelligence (multi-trait analysis); chr16:53447510 chr16:53478957~53481550:- LUSC cis rs9322193 0.962 rs1889473 ENSG00000216906.2 RP11-350J20.9 8.8 2.72e-17 3.8e-14 0.45 0.38 Lung cancer; chr6:149825485 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs1984111 ENSG00000216906.2 RP11-350J20.9 8.8 2.72e-17 3.8e-14 0.45 0.38 Lung cancer; chr6:149831720 chr6:149904243~149906418:+ LUSC cis rs853679 0.517 rs12332979 ENSG00000219392.1 RP1-265C24.5 -8.79 2.73e-17 3.82e-14 -0.53 -0.38 Depression; chr6:28173770 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs67878650 ENSG00000219392.1 RP1-265C24.5 -8.79 2.73e-17 3.82e-14 -0.53 -0.38 Depression; chr6:28174809 chr6:28115628~28116551:+ LUSC cis rs853679 0.569 rs9348798 ENSG00000219392.1 RP1-265C24.5 -8.79 2.73e-17 3.82e-14 -0.53 -0.38 Depression; chr6:28175233 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9380065 ENSG00000219392.1 RP1-265C24.5 -8.79 2.73e-17 3.82e-14 -0.53 -0.38 Depression; chr6:28176973 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9295761 ENSG00000219392.1 RP1-265C24.5 -8.79 2.73e-17 3.82e-14 -0.53 -0.38 Depression; chr6:28180209 chr6:28115628~28116551:+ LUSC cis rs6964833 0.935 rs34630792 ENSG00000277053.3 GTF2IP1 -8.79 2.74e-17 3.83e-14 -0.55 -0.38 Menarche (age at onset); chr7:74646869 chr7:75185385~75237696:- LUSC cis rs2455601 1 rs12223690 ENSG00000254860.4 TMEM9B-AS1 8.79 2.74e-17 3.83e-14 0.56 0.38 Schizophrenia; chr11:8880277 chr11:8964675~8977527:+ LUSC cis rs2455601 1 rs7104661 ENSG00000254860.4 TMEM9B-AS1 8.79 2.74e-17 3.83e-14 0.56 0.38 Schizophrenia; chr11:8880954 chr11:8964675~8977527:+ LUSC cis rs2455601 1 rs11042108 ENSG00000254860.4 TMEM9B-AS1 8.79 2.74e-17 3.83e-14 0.56 0.38 Schizophrenia; chr11:8884474 chr11:8964675~8977527:+ LUSC cis rs526231 0.578 rs34794 ENSG00000175749.11 EIF3KP1 8.79 2.75e-17 3.84e-14 0.46 0.38 Primary biliary cholangitis; chr5:103087664 chr5:103032376~103033031:+ LUSC cis rs765787 0.53 rs1706834 ENSG00000259520.4 CTD-2651B20.3 8.79 2.75e-17 3.84e-14 0.47 0.38 Uric acid levels; chr15:45225656 chr15:45251580~45279251:- LUSC cis rs1501911 0.588 rs709389 ENSG00000248489.1 CTD-2007H13.3 8.79 2.75e-17 3.85e-14 0.44 0.38 Lung function (FEV1/FVC); chr5:98994011 chr5:98929171~98995013:+ LUSC cis rs11098499 0.82 rs6829903 ENSG00000249244.1 RP11-548H18.2 8.79 2.76e-17 3.85e-14 0.48 0.38 Corneal astigmatism; chr4:119585729 chr4:119391831~119395335:- LUSC cis rs35160687 0.64 rs13015186 ENSG00000273080.1 RP11-301O19.1 8.79 2.77e-17 3.86e-14 0.37 0.38 Night sleep phenotypes; chr2:86258455 chr2:86195590~86196049:+ LUSC cis rs10463554 0.927 rs158396 ENSG00000175749.11 EIF3KP1 8.79 2.78e-17 3.89e-14 0.46 0.38 Parkinson's disease; chr5:103076015 chr5:103032376~103033031:+ LUSC cis rs11098499 0.789 rs1980024 ENSG00000245958.5 RP11-33B1.1 -8.79 2.79e-17 3.89e-14 -0.37 -0.38 Corneal astigmatism; chr4:119331892 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs34425882 ENSG00000245958.5 RP11-33B1.1 -8.79 2.79e-17 3.89e-14 -0.37 -0.38 Corneal astigmatism; chr4:119332022 chr4:119454791~119552025:+ LUSC cis rs5769707 0.632 rs135871 ENSG00000235111.1 RP1-29C18.8 -8.79 2.82e-17 3.93e-14 -0.47 -0.38 Monocyte percentage of white cells;Monocyte count; chr22:49615321 chr22:49612657~49615716:- LUSC cis rs9341808 0.754 rs6918172 ENSG00000272129.1 RP11-250B2.6 8.79 2.83e-17 3.95e-14 0.45 0.38 Sitting height ratio; chr6:80309525 chr6:80355424~80356859:+ LUSC cis rs11098499 0.863 rs7664986 ENSG00000245958.5 RP11-33B1.1 -8.79 2.85e-17 3.97e-14 -0.38 -0.38 Corneal astigmatism; chr4:119508797 chr4:119454791~119552025:+ LUSC cis rs11098499 0.818 rs10008791 ENSG00000245958.5 RP11-33B1.1 -8.79 2.85e-17 3.97e-14 -0.38 -0.38 Corneal astigmatism; chr4:119510314 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs11736416 ENSG00000245958.5 RP11-33B1.1 -8.79 2.85e-17 3.97e-14 -0.38 -0.38 Corneal astigmatism; chr4:119510506 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs3775845 ENSG00000245958.5 RP11-33B1.1 -8.79 2.85e-17 3.97e-14 -0.38 -0.38 Corneal astigmatism; chr4:119511292 chr4:119454791~119552025:+ LUSC cis rs853679 0.517 rs9468298 ENSG00000219392.1 RP1-265C24.5 -8.79 2.85e-17 3.97e-14 -0.53 -0.38 Depression; chr6:28154567 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9295759 ENSG00000219392.1 RP1-265C24.5 -8.79 2.85e-17 3.97e-14 -0.53 -0.38 Depression; chr6:28156691 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9348796 ENSG00000219392.1 RP1-265C24.5 -8.79 2.85e-17 3.97e-14 -0.53 -0.38 Depression; chr6:28158424 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs11552219 ENSG00000219392.1 RP1-265C24.5 -8.79 2.85e-17 3.97e-14 -0.53 -0.38 Depression; chr6:28159056 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9393895 ENSG00000219392.1 RP1-265C24.5 -8.79 2.85e-17 3.97e-14 -0.53 -0.38 Depression; chr6:28159843 chr6:28115628~28116551:+ LUSC cis rs10875746 0.768 rs4760676 ENSG00000240399.1 RP1-228P16.1 -8.79 2.85e-17 3.98e-14 -0.42 -0.38 Longevity (90 years and older); chr12:48027880 chr12:48054813~48055591:- LUSC cis rs1707322 1 rs1707317 ENSG00000280836.1 AL355480.1 8.79 2.86e-17 3.99e-14 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46044970 chr1:45581219~45581321:- LUSC cis rs2179367 1 rs2179367 ENSG00000231760.4 RP11-350J20.5 8.79 2.87e-17 4e-14 0.48 0.38 Dupuytren's disease; chr6:149441401 chr6:149796151~149826294:- LUSC cis rs526231 0.543 rs40092 ENSG00000175749.11 EIF3KP1 8.79 2.87e-17 4e-14 0.47 0.38 Primary biliary cholangitis; chr5:103088509 chr5:103032376~103033031:+ LUSC cis rs10129255 0.957 rs10141052 ENSG00000211970.3 IGHV4-61 -8.79 2.9e-17 4.03e-14 -0.26 -0.38 Kawasaki disease; chr14:106776528 chr14:106639119~106639657:- LUSC cis rs10129255 0.957 rs10141009 ENSG00000211970.3 IGHV4-61 -8.79 2.9e-17 4.03e-14 -0.26 -0.38 Kawasaki disease; chr14:106776695 chr14:106639119~106639657:- LUSC cis rs9487094 0.689 rs9487076 ENSG00000260273.1 RP11-425D10.10 8.79 2.93e-17 4.08e-14 0.44 0.38 Height; chr6:109371524 chr6:109382795~109383666:+ LUSC cis rs10875746 0.768 rs12305182 ENSG00000240399.1 RP1-228P16.1 -8.79 2.94e-17 4.1e-14 -0.41 -0.38 Longevity (90 years and older); chr12:48027624 chr12:48054813~48055591:- LUSC cis rs1707322 0.964 rs7546237 ENSG00000280836.1 AL355480.1 -8.78 2.94e-17 4.1e-14 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45819938 chr1:45581219~45581321:- LUSC cis rs6921919 0.583 rs2041230 ENSG00000216901.1 AL022393.7 8.78 2.96e-17 4.11e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28397738 chr6:28176188~28176674:+ LUSC cis rs765787 0.53 rs12906537 ENSG00000259520.4 CTD-2651B20.3 -8.78 2.96e-17 4.11e-14 -0.48 -0.38 Uric acid levels; chr15:45227863 chr15:45251580~45279251:- LUSC cis rs494459 0.838 rs566733 ENSG00000255239.1 AP002954.6 8.78 2.96e-17 4.12e-14 0.4 0.38 Height; chr11:118737916 chr11:118688039~118690600:- LUSC cis rs11098499 0.909 rs28555550 ENSG00000245958.5 RP11-33B1.1 -8.78 2.97e-17 4.13e-14 -0.39 -0.38 Corneal astigmatism; chr4:119289885 chr4:119454791~119552025:+ LUSC cis rs11098499 1 rs28419773 ENSG00000245958.5 RP11-33B1.1 -8.78 2.97e-17 4.13e-14 -0.39 -0.38 Corneal astigmatism; chr4:119289906 chr4:119454791~119552025:+ LUSC cis rs6782228 1 rs35871360 ENSG00000242551.2 POU5F1P6 8.78 2.97e-17 4.13e-14 0.47 0.38 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128617286 chr3:128674735~128677005:- LUSC cis rs11098499 0.863 rs3822195 ENSG00000249244.1 RP11-548H18.2 8.78 2.98e-17 4.15e-14 0.48 0.38 Corneal astigmatism; chr4:119550505 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3775854 ENSG00000249244.1 RP11-548H18.2 8.78 2.98e-17 4.15e-14 0.48 0.38 Corneal astigmatism; chr4:119550816 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs2306457 ENSG00000249244.1 RP11-548H18.2 8.78 2.98e-17 4.15e-14 0.48 0.38 Corneal astigmatism; chr4:119551684 chr4:119391831~119395335:- LUSC cis rs9322193 0.607 rs7764677 ENSG00000216906.2 RP11-350J20.9 8.78 3.01e-17 4.18e-14 0.5 0.38 Lung cancer; chr6:149906197 chr6:149904243~149906418:+ LUSC cis rs2283792 0.967 rs5749998 ENSG00000228050.1 TOP3BP1 8.78 3.02e-17 4.19e-14 0.44 0.38 Multiple sclerosis; chr22:21808085 chr22:22223187~22224566:- LUSC cis rs7189233 0.55 rs13330182 ENSG00000279344.1 RP11-44F14.7 8.78 3.06e-17 4.25e-14 0.32 0.38 Intelligence (multi-trait analysis); chr16:53438473 chr16:53478957~53481550:- LUSC cis rs1707322 0.963 rs11211202 ENSG00000280836.1 AL355480.1 -8.78 3.08e-17 4.28e-14 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45826710 chr1:45581219~45581321:- LUSC cis rs6921919 0.609 rs9461455 ENSG00000216901.1 AL022393.7 8.78 3.08e-17 4.28e-14 0.44 0.38 Autism spectrum disorder or schizophrenia; chr6:28361954 chr6:28176188~28176674:+ LUSC cis rs1185460 1 rs1799993 ENSG00000271751.1 RP11-110I1.14 8.78 3.09e-17 4.29e-14 0.48 0.38 Coronary artery disease; chr11:119087417 chr11:119065263~119065677:- LUSC cis rs1113500 1 rs1777483 ENSG00000226822.1 RP11-356N1.2 -8.78 3.09e-17 4.3e-14 -0.39 -0.38 Growth-regulated protein alpha levels; chr1:108066786 chr1:108071482~108074519:+ LUSC cis rs11098499 0.863 rs6853998 ENSG00000249244.1 RP11-548H18.2 8.78 3.1e-17 4.3e-14 0.48 0.38 Corneal astigmatism; chr4:119554705 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs6858777 ENSG00000249244.1 RP11-548H18.2 8.78 3.1e-17 4.3e-14 0.48 0.38 Corneal astigmatism; chr4:119554811 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs11731756 ENSG00000249244.1 RP11-548H18.2 8.78 3.1e-17 4.3e-14 0.48 0.38 Corneal astigmatism; chr4:119557541 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs34308924 ENSG00000249244.1 RP11-548H18.2 8.78 3.1e-17 4.3e-14 0.48 0.38 Corneal astigmatism; chr4:119560276 chr4:119391831~119395335:- LUSC cis rs6921919 0.583 rs6928771 ENSG00000216901.1 AL022393.7 8.78 3.11e-17 4.32e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28407432 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs6928773 ENSG00000216901.1 AL022393.7 8.78 3.11e-17 4.32e-14 0.43 0.38 Autism spectrum disorder or schizophrenia; chr6:28407433 chr6:28176188~28176674:+ LUSC cis rs1185460 1 rs1185460 ENSG00000271751.1 RP11-110I1.14 8.78 3.11e-17 4.32e-14 0.48 0.38 Coronary artery disease; chr11:119072723 chr11:119065263~119065677:- LUSC cis rs992157 0.717 rs11692780 ENSG00000261338.2 RP11-378A13.1 -8.78 3.13e-17 4.34e-14 -0.38 -0.38 Colorectal cancer; chr2:218284440 chr2:218255319~218257366:+ LUSC cis rs6921919 0.848 rs6903823 ENSG00000204709.4 LINC01556 8.78 3.13e-17 4.34e-14 0.55 0.38 Autism spectrum disorder or schizophrenia; chr6:28354519 chr6:28943877~28944537:+ LUSC cis rs9487094 0.689 rs8465 ENSG00000260273.1 RP11-425D10.10 8.78 3.13e-17 4.34e-14 0.44 0.38 Height; chr6:109367335 chr6:109382795~109383666:+ LUSC cis rs9487094 0.666 rs974034 ENSG00000260273.1 RP11-425D10.10 8.78 3.13e-17 4.34e-14 0.44 0.38 Height; chr6:109368228 chr6:109382795~109383666:+ LUSC cis rs9487094 0.689 rs3818933 ENSG00000260273.1 RP11-425D10.10 8.78 3.13e-17 4.34e-14 0.44 0.38 Height; chr6:109370741 chr6:109382795~109383666:+ LUSC cis rs7189233 0.531 rs16952246 ENSG00000279344.1 RP11-44F14.7 8.78 3.15e-17 4.36e-14 0.32 0.38 Intelligence (multi-trait analysis); chr16:53446797 chr16:53478957~53481550:- LUSC cis rs11098499 0.863 rs1383532 ENSG00000245958.5 RP11-33B1.1 8.78 3.16e-17 4.38e-14 0.38 0.38 Corneal astigmatism; chr4:119513249 chr4:119454791~119552025:+ LUSC cis rs9918079 0.56 rs7685083 ENSG00000273133.1 RP11-799M12.2 8.77 3.19e-17 4.42e-14 0.5 0.38 Obesity-related traits; chr4:15609148 chr4:15563698~15564253:- LUSC cis rs9341808 0.754 rs1324121 ENSG00000272129.1 RP11-250B2.6 8.77 3.2e-17 4.43e-14 0.46 0.38 Sitting height ratio; chr6:80236360 chr6:80355424~80356859:+ LUSC cis rs12439619 0.774 rs2867649 ENSG00000255769.6 GOLGA2P10 -8.77 3.21e-17 4.45e-14 -0.52 -0.38 Intelligence (multi-trait analysis); chr15:82262331 chr15:82472993~82513950:- LUSC cis rs12439619 0.846 rs28697264 ENSG00000255769.6 GOLGA2P10 -8.77 3.21e-17 4.45e-14 -0.52 -0.38 Intelligence (multi-trait analysis); chr15:82265559 chr15:82472993~82513950:- LUSC cis rs9322193 0.884 rs2342858 ENSG00000216906.2 RP11-350J20.9 8.77 3.22e-17 4.46e-14 0.45 0.38 Lung cancer; chr6:149805967 chr6:149904243~149906418:+ LUSC cis rs6051080 1 rs6051080 ENSG00000274973.1 RP13-401N8.7 -8.77 3.25e-17 4.5e-14 -0.39 -0.38 Colorectal or endometrial cancer; chr20:25995038 chr20:25845497~25845862:+ LUSC cis rs6991838 0.556 rs7846527 ENSG00000200714.1 Y_RNA -8.77 3.26e-17 4.52e-14 -0.45 -0.38 Intelligence (multi-trait analysis); chr8:65586522 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs4320587 ENSG00000200714.1 Y_RNA -8.77 3.26e-17 4.52e-14 -0.45 -0.38 Intelligence (multi-trait analysis); chr8:65586991 chr8:65592731~65592820:+ LUSC cis rs11098499 0.863 rs9884402 ENSG00000249244.1 RP11-548H18.2 8.77 3.28e-17 4.54e-14 0.48 0.38 Corneal astigmatism; chr4:119568827 chr4:119391831~119395335:- LUSC cis rs11098499 0.731 rs9995026 ENSG00000249244.1 RP11-548H18.2 8.77 3.28e-17 4.54e-14 0.48 0.38 Corneal astigmatism; chr4:119569344 chr4:119391831~119395335:- LUSC cis rs10129255 0.518 rs28378320 ENSG00000211972.2 IGHV3-66 8.77 3.28e-17 4.54e-14 0.25 0.38 Kawasaki disease; chr14:106808609 chr14:106675017~106675544:- LUSC cis rs11098499 0.863 rs9997631 ENSG00000249244.1 RP11-548H18.2 8.77 3.3e-17 4.56e-14 0.48 0.38 Corneal astigmatism; chr4:119548840 chr4:119391831~119395335:- LUSC cis rs765787 0.53 rs12592055 ENSG00000259520.4 CTD-2651B20.3 -8.77 3.3e-17 4.57e-14 -0.47 -0.38 Uric acid levels; chr15:45222279 chr15:45251580~45279251:- LUSC cis rs2455601 0.744 rs2568085 ENSG00000254860.4 TMEM9B-AS1 -8.77 3.31e-17 4.58e-14 -0.45 -0.37 Schizophrenia; chr11:8954201 chr11:8964675~8977527:+ LUSC cis rs11098499 0.754 rs10212714 ENSG00000245958.5 RP11-33B1.1 -8.77 3.31e-17 4.59e-14 -0.37 -0.37 Corneal astigmatism; chr4:119333147 chr4:119454791~119552025:+ LUSC cis rs4713118 0.621 rs10484403 ENSG00000219392.1 RP1-265C24.5 -8.77 3.31e-17 4.59e-14 -0.53 -0.37 Parkinson's disease; chr6:28065745 chr6:28115628~28116551:+ LUSC cis rs17507216 0.681 rs28877110 ENSG00000278603.1 RP13-608F4.5 8.77 3.31e-17 4.59e-14 0.58 0.37 Excessive daytime sleepiness; chr15:82672111 chr15:82472203~82472426:+ LUSC cis rs9487094 0.666 rs2277113 ENSG00000260273.1 RP11-425D10.10 8.77 3.32e-17 4.59e-14 0.44 0.37 Height; chr6:109454233 chr6:109382795~109383666:+ LUSC cis rs9322193 0.962 rs9505974 ENSG00000216906.2 RP11-350J20.9 8.77 3.32e-17 4.59e-14 0.45 0.37 Lung cancer; chr6:149779294 chr6:149904243~149906418:+ LUSC cis rs9322193 0.926 rs9689036 ENSG00000216906.2 RP11-350J20.9 8.77 3.32e-17 4.59e-14 0.45 0.37 Lung cancer; chr6:149780563 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9322218 ENSG00000216906.2 RP11-350J20.9 8.77 3.32e-17 4.59e-14 0.45 0.37 Lung cancer; chr6:149782183 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9322219 ENSG00000216906.2 RP11-350J20.9 8.77 3.32e-17 4.59e-14 0.45 0.37 Lung cancer; chr6:149782263 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9322223 ENSG00000216906.2 RP11-350J20.9 8.77 3.32e-17 4.59e-14 0.45 0.37 Lung cancer; chr6:149801509 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs13215691 ENSG00000216906.2 RP11-350J20.9 8.77 3.34e-17 4.62e-14 0.45 0.37 Lung cancer; chr6:149792666 chr6:149904243~149906418:+ LUSC cis rs10256972 0.521 rs871019 ENSG00000229043.2 AC091729.9 -8.77 3.35e-17 4.64e-14 -0.42 -0.37 Endometriosis;Longevity; chr7:1065594 chr7:1160374~1165267:+ LUSC cis rs9322193 0.607 rs10457852 ENSG00000216906.2 RP11-350J20.9 8.77 3.36e-17 4.65e-14 0.49 0.37 Lung cancer; chr6:149880584 chr6:149904243~149906418:+ LUSC cis rs4927850 1 rs7627706 ENSG00000231464.1 AC024937.4 8.77 3.37e-17 4.66e-14 0.4 0.37 Pancreatic cancer; chr3:196026482 chr3:195996738~195998233:+ LUSC cis rs1113500 0.933 rs10494089 ENSG00000226822.1 RP11-356N1.2 8.77 3.37e-17 4.66e-14 0.39 0.37 Growth-regulated protein alpha levels; chr1:108084073 chr1:108071482~108074519:+ LUSC cis rs9322193 0.962 rs3763163 ENSG00000216906.2 RP11-350J20.9 8.77 3.37e-17 4.66e-14 0.45 0.37 Lung cancer; chr6:149819770 chr6:149904243~149906418:+ LUSC cis rs26232 0.521 rs11958562 ENSG00000175749.11 EIF3KP1 8.77 3.4e-17 4.7e-14 0.46 0.37 Rheumatoid arthritis; chr5:103027357 chr5:103032376~103033031:+ LUSC cis rs10875746 0.669 rs11168516 ENSG00000240399.1 RP1-228P16.1 -8.77 3.41e-17 4.71e-14 -0.43 -0.37 Longevity (90 years and older); chr12:48308282 chr12:48054813~48055591:- LUSC cis rs10875746 0.669 rs61940962 ENSG00000240399.1 RP1-228P16.1 -8.77 3.42e-17 4.72e-14 -0.44 -0.37 Longevity (90 years and older); chr12:48201694 chr12:48054813~48055591:- LUSC cis rs11098499 0.82 rs28578366 ENSG00000249244.1 RP11-548H18.2 -8.76 3.44e-17 4.75e-14 -0.47 -0.37 Corneal astigmatism; chr4:119615750 chr4:119391831~119395335:- LUSC cis rs9389248 0.69 rs2064101 ENSG00000232876.1 CTA-212D2.2 8.76 3.46e-17 4.78e-14 0.48 0.37 High light scatter reticulocyte percentage of red cells; chr6:134929392 chr6:135055033~135060550:+ LUSC cis rs1799949 0.602 rs8176235 ENSG00000198496.9 NBR2 -8.76 3.46e-17 4.78e-14 -0.46 -0.37 Menopause (age at onset); chr17:43067543 chr17:43125610~43153671:+ LUSC cis rs1113500 0.933 rs11185260 ENSG00000226822.1 RP11-356N1.2 -8.76 3.48e-17 4.8e-14 -0.39 -0.37 Growth-regulated protein alpha levels; chr1:108092457 chr1:108071482~108074519:+ LUSC cis rs9322193 0.962 rs9397022 ENSG00000216906.2 RP11-350J20.9 8.76 3.49e-17 4.81e-14 0.45 0.37 Lung cancer; chr6:149812052 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs9397357 ENSG00000216906.2 RP11-350J20.9 8.76 3.49e-17 4.81e-14 0.45 0.37 Lung cancer; chr6:149812465 chr6:149904243~149906418:+ LUSC cis rs1707322 1 rs4660335 ENSG00000280836.1 AL355480.1 -8.76 3.51e-17 4.85e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46009046 chr1:45581219~45581321:- LUSC cis rs1150668 0.796 rs2247002 ENSG00000204709.4 LINC01556 8.76 3.52e-17 4.86e-14 0.45 0.37 Pubertal anthropometrics; chr6:28430174 chr6:28943877~28944537:+ LUSC cis rs1113500 1 rs1113500 ENSG00000226822.1 RP11-356N1.2 -8.76 3.53e-17 4.87e-14 -0.39 -0.37 Growth-regulated protein alpha levels; chr1:108052820 chr1:108071482~108074519:+ LUSC cis rs11098499 0.863 rs3775843 ENSG00000245958.5 RP11-33B1.1 -8.76 3.54e-17 4.88e-14 -0.38 -0.37 Corneal astigmatism; chr4:119506689 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs3775844 ENSG00000245958.5 RP11-33B1.1 -8.76 3.54e-17 4.88e-14 -0.38 -0.37 Corneal astigmatism; chr4:119506878 chr4:119454791~119552025:+ LUSC cis rs9341808 0.754 rs10806185 ENSG00000272129.1 RP11-250B2.6 8.76 3.54e-17 4.88e-14 0.46 0.37 Sitting height ratio; chr6:80244794 chr6:80355424~80356859:+ LUSC cis rs9918079 0.542 rs12499412 ENSG00000273133.1 RP11-799M12.2 8.76 3.54e-17 4.89e-14 0.49 0.37 Obesity-related traits; chr4:15600629 chr4:15563698~15564253:- LUSC cis rs7044106 0.791 rs4617229 ENSG00000226752.6 PSMD5-AS1 -8.76 3.56e-17 4.9e-14 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120718418 chr9:120824828~120854385:+ LUSC cis rs10875746 0.551 rs3185921 ENSG00000240399.1 RP1-228P16.1 -8.76 3.56e-17 4.91e-14 -0.45 -0.37 Longevity (90 years and older); chr12:48340948 chr12:48054813~48055591:- LUSC cis rs12134133 1 rs61822669 ENSG00000274245.1 RP11-357P18.2 8.76 3.56e-17 4.91e-14 0.49 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207247869 chr1:207372559~207373252:+ LUSC cis rs2739330 0.828 rs2186366 ENSG00000231271.1 AP000350.8 -8.76 3.56e-17 4.91e-14 -0.49 -0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23949918~23954042:+ LUSC cis rs853679 0.517 rs9380058 ENSG00000219392.1 RP1-265C24.5 -8.76 3.57e-17 4.93e-14 -0.53 -0.37 Depression; chr6:28159666 chr6:28115628~28116551:+ LUSC cis rs1707322 1 rs10890353 ENSG00000280836.1 AL355480.1 -8.76 3.58e-17 4.94e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45832711 chr1:45581219~45581321:- LUSC cis rs11098499 0.863 rs59732491 ENSG00000245958.5 RP11-33B1.1 -8.76 3.59e-17 4.94e-14 -0.38 -0.37 Corneal astigmatism; chr4:119568433 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs11723090 ENSG00000245958.5 RP11-33B1.1 -8.76 3.59e-17 4.94e-14 -0.38 -0.37 Corneal astigmatism; chr4:119569437 chr4:119454791~119552025:+ LUSC cis rs2283792 1 rs9607287 ENSG00000228050.1 TOP3BP1 8.76 3.6e-17 4.96e-14 0.44 0.37 Multiple sclerosis; chr22:21809136 chr22:22223187~22224566:- LUSC cis rs4713118 0.621 rs9368548 ENSG00000219392.1 RP1-265C24.5 -8.76 3.6e-17 4.96e-14 -0.53 -0.37 Parkinson's disease; chr6:28066959 chr6:28115628~28116551:+ LUSC cis rs1075265 0.584 rs4671178 ENSG00000233266.1 HMGB1P31 -8.76 3.61e-17 4.97e-14 -0.47 -0.37 Chronotype;Morning vs. evening chronotype; chr2:54056356 chr2:54051334~54051760:+ LUSC cis rs6921919 0.583 rs740621 ENSG00000216901.1 AL022393.7 8.76 3.64e-17 5.01e-14 0.43 0.37 Autism spectrum disorder or schizophrenia; chr6:28430010 chr6:28176188~28176674:+ LUSC cis rs9322193 0.962 rs6903998 ENSG00000216906.2 RP11-350J20.9 8.76 3.64e-17 5.01e-14 0.45 0.37 Lung cancer; chr6:149831357 chr6:149904243~149906418:+ LUSC cis rs10129255 0.957 rs8014696 ENSG00000211970.3 IGHV4-61 8.76 3.64e-17 5.02e-14 0.27 0.37 Kawasaki disease; chr14:106769752 chr14:106639119~106639657:- LUSC cis rs9341808 0.69 rs6930534 ENSG00000272129.1 RP11-250B2.6 8.76 3.66e-17 5.04e-14 0.46 0.37 Sitting height ratio; chr6:80186333 chr6:80355424~80356859:+ LUSC cis rs1150668 0.796 rs2531832 ENSG00000204709.4 LINC01556 8.75 3.7e-17 5.09e-14 0.45 0.37 Pubertal anthropometrics; chr6:28421445 chr6:28943877~28944537:+ LUSC cis rs2283792 0.905 rs5755694 ENSG00000228050.1 TOP3BP1 8.75 3.7e-17 5.1e-14 0.42 0.37 Multiple sclerosis; chr22:21846241 chr22:22223187~22224566:- LUSC cis rs12130219 0.5 rs4845743 ENSG00000237975.5 FLG-AS1 -8.75 3.72e-17 5.11e-14 -0.38 -0.37 Inflammatory skin disease; chr1:152211673 chr1:152168125~152445456:+ LUSC cis rs853679 0.55 rs1233699 ENSG00000219392.1 RP1-265C24.5 -8.75 3.72e-17 5.12e-14 -0.5 -0.37 Depression; chr6:28201380 chr6:28115628~28116551:+ LUSC cis rs9341808 0.754 rs10733162 ENSG00000272129.1 RP11-250B2.6 8.75 3.73e-17 5.12e-14 0.45 0.37 Sitting height ratio; chr6:80313672 chr6:80355424~80356859:+ LUSC cis rs7684253 0.565 rs13130605 ENSG00000269949.1 RP11-738E22.3 -8.75 3.73e-17 5.13e-14 -0.45 -0.37 Migraine; chr4:56943905 chr4:56960927~56961373:- LUSC cis rs9487094 0.626 rs4141930 ENSG00000260273.1 RP11-425D10.10 8.75 3.75e-17 5.16e-14 0.44 0.37 Height; chr6:109739615 chr6:109382795~109383666:+ LUSC cis rs9918079 0.506 rs7696127 ENSG00000273133.1 RP11-799M12.2 -8.75 3.76e-17 5.17e-14 -0.5 -0.37 Obesity-related traits; chr4:15641330 chr4:15563698~15564253:- LUSC cis rs7189233 0.55 rs17193176 ENSG00000279344.1 RP11-44F14.7 8.75 3.79e-17 5.2e-14 0.32 0.37 Intelligence (multi-trait analysis); chr16:53484316 chr16:53478957~53481550:- LUSC cis rs2739330 0.685 rs4822453 ENSG00000099984.9 GSTT2 -8.75 3.8e-17 5.21e-14 -0.45 -0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23980123~23983911:+ LUSC cis rs853679 0.517 rs9357066 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28162053 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9368556 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28163375 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9368557 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28163759 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9380059 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28164580 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9380060 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28164825 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs35227624 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28164948 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9380061 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28165025 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9368558 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28165528 chr6:28115628~28116551:+ LUSC cis rs4713118 0.587 rs9393899 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Parkinson's disease; chr6:28165750 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs4713150 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28168434 chr6:28115628~28116551:+ LUSC cis rs4713118 0.527 rs4713151 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Parkinson's disease; chr6:28168578 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9393901 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28169019 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs3173443 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28169249 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs4713152 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28169676 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9348797 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28169755 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9380062 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28169791 chr6:28115628~28116551:+ LUSC cis rs853679 0.542 rs9380063 ENSG00000219392.1 RP1-265C24.5 -8.75 3.8e-17 5.21e-14 -0.52 -0.37 Depression; chr6:28170075 chr6:28115628~28116551:+ LUSC cis rs9487094 0.666 rs9480958 ENSG00000260273.1 RP11-425D10.10 -8.75 3.82e-17 5.24e-14 -0.44 -0.37 Height; chr6:109432968 chr6:109382795~109383666:+ LUSC cis rs7044106 0.791 rs10818473 ENSG00000226752.6 PSMD5-AS1 -8.75 3.82e-17 5.24e-14 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120721877 chr9:120824828~120854385:+ LUSC cis rs4728142 0.525 rs4731534 ENSG00000275106.1 RP11-309L24.10 -8.75 3.85e-17 5.28e-14 -0.48 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128965540 chr7:128952527~128953316:- LUSC cis rs11098499 0.863 rs6835635 ENSG00000245958.5 RP11-33B1.1 -8.75 3.87e-17 5.3e-14 -0.37 -0.37 Corneal astigmatism; chr4:119537712 chr4:119454791~119552025:+ LUSC cis rs35160687 0.862 rs12476706 ENSG00000273080.1 RP11-301O19.1 8.75 3.87e-17 5.31e-14 0.37 0.37 Night sleep phenotypes; chr2:86301247 chr2:86195590~86196049:+ LUSC cis rs6991838 0.584 rs10089708 ENSG00000200714.1 Y_RNA 8.75 3.88e-17 5.32e-14 0.46 0.37 Intelligence (multi-trait analysis); chr8:65642927 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs6991731 ENSG00000200714.1 Y_RNA 8.75 3.88e-17 5.32e-14 0.46 0.37 Intelligence (multi-trait analysis); chr8:65643232 chr8:65592731~65592820:+ LUSC cis rs7189233 0.531 rs7204496 ENSG00000279344.1 RP11-44F14.7 -8.75 3.89e-17 5.33e-14 -0.32 -0.37 Intelligence (multi-trait analysis); chr16:53462686 chr16:53478957~53481550:- LUSC cis rs11098499 0.73 rs12505735 ENSG00000249244.1 RP11-548H18.2 8.75 3.9e-17 5.34e-14 0.47 0.37 Corneal astigmatism; chr4:119611801 chr4:119391831~119395335:- LUSC cis rs1707322 0.964 rs785508 ENSG00000280836.1 AL355480.1 8.75 3.93e-17 5.37e-14 0.45 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46061487 chr1:45581219~45581321:- LUSC cis rs1707322 0.964 rs785509 ENSG00000280836.1 AL355480.1 8.75 3.93e-17 5.37e-14 0.45 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46061628 chr1:45581219~45581321:- LUSC cis rs9322193 0.962 rs2065664 ENSG00000216906.2 RP11-350J20.9 8.75 3.93e-17 5.37e-14 0.43 0.37 Lung cancer; chr6:149762485 chr6:149904243~149906418:+ LUSC cis rs4927850 1 rs10881564 ENSG00000231464.1 AC024937.4 8.75 3.93e-17 5.38e-14 0.4 0.37 Pancreatic cancer; chr3:196023455 chr3:195996738~195998233:+ LUSC cis rs10463554 0.927 rs464720 ENSG00000175749.11 EIF3KP1 8.75 3.94e-17 5.39e-14 0.45 0.37 Parkinson's disease; chr5:103071183 chr5:103032376~103033031:+ LUSC cis rs853679 0.517 rs6922063 ENSG00000219392.1 RP1-265C24.5 -8.75 3.96e-17 5.42e-14 -0.52 -0.37 Depression; chr6:28126588 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs2275508 ENSG00000219392.1 RP1-265C24.5 -8.75 3.96e-17 5.42e-14 -0.52 -0.37 Depression; chr6:28126953 chr6:28115628~28116551:+ LUSC cis rs6991838 0.733 rs13281981 ENSG00000272010.1 CTD-3025N20.3 8.75 3.98e-17 5.44e-14 0.41 0.37 Intelligence (multi-trait analysis); chr8:65611649 chr8:65591850~65592472:- LUSC cis rs7188445 0.736 rs7500666 ENSG00000261390.4 RP11-345M22.2 8.74 4e-17 5.47e-14 0.48 0.37 Urate levels; chr16:79672509 chr16:79715232~79770563:- LUSC cis rs1113500 0.862 rs11185264 ENSG00000226822.1 RP11-356N1.2 8.74 4.01e-17 5.48e-14 0.39 0.37 Growth-regulated protein alpha levels; chr1:108097884 chr1:108071482~108074519:+ LUSC cis rs7044106 0.791 rs10984998 ENSG00000226752.6 PSMD5-AS1 -8.74 4.02e-17 5.49e-14 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120719238 chr9:120824828~120854385:+ LUSC cis rs11098499 0.863 rs2170276 ENSG00000249244.1 RP11-548H18.2 8.74 4.02e-17 5.49e-14 0.48 0.37 Corneal astigmatism; chr4:119564669 chr4:119391831~119395335:- LUSC cis rs9341808 0.718 rs9352803 ENSG00000272129.1 RP11-250B2.6 8.74 4.04e-17 5.51e-14 0.46 0.37 Sitting height ratio; chr6:80154950 chr6:80355424~80356859:+ LUSC cis rs9341808 0.655 rs9350846 ENSG00000272129.1 RP11-250B2.6 8.74 4.04e-17 5.51e-14 0.46 0.37 Sitting height ratio; chr6:80155764 chr6:80355424~80356859:+ LUSC cis rs12439619 0.846 rs7496227 ENSG00000255769.6 GOLGA2P10 -8.74 4.05e-17 5.54e-14 -0.53 -0.37 Intelligence (multi-trait analysis); chr15:82275241 chr15:82472993~82513950:- LUSC cis rs1707322 1 rs6687301 ENSG00000280836.1 AL355480.1 -8.74 4.07e-17 5.56e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45917180 chr1:45581219~45581321:- LUSC cis rs765787 0.53 rs28526629 ENSG00000259520.4 CTD-2651B20.3 8.74 4.08e-17 5.57e-14 0.47 0.37 Uric acid levels; chr15:45248264 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs28524974 ENSG00000259520.4 CTD-2651B20.3 8.74 4.08e-17 5.57e-14 0.47 0.37 Uric acid levels; chr15:45251330 chr15:45251580~45279251:- LUSC cis rs11098499 0.955 rs56386062 ENSG00000245958.5 RP11-33B1.1 -8.74 4.11e-17 5.6e-14 -0.38 -0.37 Corneal astigmatism; chr4:119233980 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs4145951 ENSG00000245958.5 RP11-33B1.1 -8.74 4.11e-17 5.6e-14 -0.38 -0.37 Corneal astigmatism; chr4:119234662 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs35916640 ENSG00000245958.5 RP11-33B1.1 -8.74 4.11e-17 5.6e-14 -0.38 -0.37 Corneal astigmatism; chr4:119234697 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs13114751 ENSG00000245958.5 RP11-33B1.1 -8.74 4.11e-17 5.6e-14 -0.38 -0.37 Corneal astigmatism; chr4:119235462 chr4:119454791~119552025:+ LUSC cis rs11098499 0.913 rs35271032 ENSG00000245958.5 RP11-33B1.1 -8.74 4.11e-17 5.6e-14 -0.38 -0.37 Corneal astigmatism; chr4:119235504 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs7672372 ENSG00000245958.5 RP11-33B1.1 -8.74 4.11e-17 5.6e-14 -0.37 -0.37 Corneal astigmatism; chr4:119327251 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs1010740 ENSG00000249244.1 RP11-548H18.2 -8.74 4.14e-17 5.65e-14 -0.47 -0.37 Corneal astigmatism; chr4:119542254 chr4:119391831~119395335:- LUSC cis rs765787 0.505 rs11630884 ENSG00000259520.4 CTD-2651B20.3 8.74 4.17e-17 5.68e-14 0.47 0.37 Uric acid levels; chr15:45240048 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs13329228 ENSG00000259520.4 CTD-2651B20.3 8.74 4.17e-17 5.68e-14 0.47 0.37 Uric acid levels; chr15:45240819 chr15:45251580~45279251:- LUSC cis rs765787 0.53 rs11634794 ENSG00000259520.4 CTD-2651B20.3 8.74 4.17e-17 5.68e-14 0.47 0.37 Uric acid levels; chr15:45242294 chr15:45251580~45279251:- LUSC cis rs9487094 0.626 rs2273752 ENSG00000260273.1 RP11-425D10.10 8.74 4.18e-17 5.7e-14 0.44 0.37 Height; chr6:109738307 chr6:109382795~109383666:+ LUSC cis rs9487094 0.626 rs12201444 ENSG00000260273.1 RP11-425D10.10 8.74 4.18e-17 5.7e-14 0.44 0.37 Height; chr6:109738751 chr6:109382795~109383666:+ LUSC cis rs2739330 0.796 rs5760106 ENSG00000231271.1 AP000350.8 -8.74 4.2e-17 5.72e-14 -0.49 -0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23949918~23954042:+ LUSC cis rs1707322 1 rs11211217 ENSG00000280836.1 AL355480.1 -8.74 4.22e-17 5.76e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45882557 chr1:45581219~45581321:- LUSC cis rs12134133 1 rs1583090 ENSG00000274245.1 RP11-357P18.2 8.74 4.23e-17 5.76e-14 0.49 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207262438 chr1:207372559~207373252:+ LUSC cis rs10463554 0.963 rs61418746 ENSG00000175749.11 EIF3KP1 8.74 4.24e-17 5.77e-14 0.45 0.37 Parkinson's disease; chr5:103043914 chr5:103032376~103033031:+ LUSC cis rs6991838 0.557 rs67685675 ENSG00000200714.1 Y_RNA -8.74 4.25e-17 5.78e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65574371 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs66486920 ENSG00000200714.1 Y_RNA -8.74 4.25e-17 5.78e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65574458 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs60023200 ENSG00000200714.1 Y_RNA -8.74 4.25e-17 5.78e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65574547 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs61083799 ENSG00000200714.1 Y_RNA -8.74 4.25e-17 5.78e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65574868 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs4449837 ENSG00000200714.1 Y_RNA -8.74 4.25e-17 5.78e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65575917 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs57042777 ENSG00000200714.1 Y_RNA -8.74 4.25e-17 5.78e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65576855 chr8:65592731~65592820:+ LUSC cis rs6991838 0.557 rs67046768 ENSG00000200714.1 Y_RNA -8.74 4.25e-17 5.78e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65577486 chr8:65592731~65592820:+ LUSC cis rs1707322 1 rs4074225 ENSG00000280836.1 AL355480.1 -8.74 4.28e-17 5.82e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45926692 chr1:45581219~45581321:- LUSC cis rs2739330 0.828 rs5760107 ENSG00000231271.1 AP000350.8 8.74 4.29e-17 5.83e-14 0.49 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23949918~23954042:+ LUSC cis rs1113500 0.933 rs4517375 ENSG00000226822.1 RP11-356N1.2 -8.73 4.32e-17 5.87e-14 -0.38 -0.37 Growth-regulated protein alpha levels; chr1:108095708 chr1:108071482~108074519:+ LUSC cis rs10875746 0.624 rs7297298 ENSG00000240399.1 RP1-228P16.1 -8.73 4.33e-17 5.89e-14 -0.44 -0.37 Longevity (90 years and older); chr12:48278523 chr12:48054813~48055591:- LUSC cis rs7044106 0.791 rs2416799 ENSG00000226752.6 PSMD5-AS1 -8.73 4.34e-17 5.9e-14 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120718588 chr9:120824828~120854385:+ LUSC cis rs2665103 0.589 rs2134046 ENSG00000255769.6 GOLGA2P10 -8.73 4.36e-17 5.93e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr15:82232203 chr15:82472993~82513950:- LUSC cis rs526231 0.511 rs6881612 ENSG00000175749.11 EIF3KP1 8.73 4.39e-17 5.97e-14 0.46 0.37 Primary biliary cholangitis; chr5:103041309 chr5:103032376~103033031:+ LUSC cis rs11098499 0.863 rs12498539 ENSG00000249244.1 RP11-548H18.2 8.73 4.4e-17 5.99e-14 0.48 0.37 Corneal astigmatism; chr4:119547215 chr4:119391831~119395335:- LUSC cis rs853679 0.55 rs6901017 ENSG00000219392.1 RP1-265C24.5 -8.73 4.44e-17 6.03e-14 -0.51 -0.37 Depression; chr6:28184805 chr6:28115628~28116551:+ LUSC cis rs12439619 0.693 rs8034801 ENSG00000255769.6 GOLGA2P10 -8.73 4.44e-17 6.04e-14 -0.5 -0.37 Intelligence (multi-trait analysis); chr15:82183996 chr15:82472993~82513950:- LUSC cis rs11098499 0.909 rs10020034 ENSG00000245958.5 RP11-33B1.1 -8.73 4.45e-17 6.04e-14 -0.38 -0.37 Corneal astigmatism; chr4:119373176 chr4:119454791~119552025:+ LUSC cis rs992157 0.767 rs2382822 ENSG00000261338.2 RP11-378A13.1 -8.73 4.47e-17 6.08e-14 -0.38 -0.37 Colorectal cancer; chr2:218308604 chr2:218255319~218257366:+ LUSC cis rs11098499 0.691 rs12510133 ENSG00000245958.5 RP11-33B1.1 -8.73 4.49e-17 6.1e-14 -0.36 -0.37 Corneal astigmatism; chr4:119350189 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs12506487 ENSG00000245958.5 RP11-33B1.1 -8.73 4.49e-17 6.1e-14 -0.36 -0.37 Corneal astigmatism; chr4:119350206 chr4:119454791~119552025:+ LUSC cis rs11098499 0.691 rs12502524 ENSG00000245958.5 RP11-33B1.1 -8.73 4.49e-17 6.1e-14 -0.36 -0.37 Corneal astigmatism; chr4:119350259 chr4:119454791~119552025:+ LUSC cis rs10463554 0.892 rs158401 ENSG00000175749.11 EIF3KP1 8.73 4.5e-17 6.12e-14 0.45 0.37 Parkinson's disease; chr5:103079764 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs257304 ENSG00000175749.11 EIF3KP1 8.73 4.5e-17 6.12e-14 0.45 0.37 Parkinson's disease; chr5:103081114 chr5:103032376~103033031:+ LUSC cis rs6991838 0.584 rs35941313 ENSG00000200714.1 Y_RNA -8.73 4.53e-17 6.15e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65587498 chr8:65592731~65592820:+ LUSC cis rs1707322 1 rs4660889 ENSG00000280836.1 AL355480.1 -8.73 4.55e-17 6.18e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45831659 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs10890355 ENSG00000280836.1 AL355480.1 -8.73 4.55e-17 6.18e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45851676 chr1:45581219~45581321:- LUSC cis rs10028773 0.7 rs7671797 ENSG00000245958.5 RP11-33B1.1 -8.73 4.56e-17 6.2e-14 -0.37 -0.37 Educational attainment; chr4:119327002 chr4:119454791~119552025:+ LUSC cis rs9918079 0.542 rs6414765 ENSG00000273133.1 RP11-799M12.2 -8.73 4.57e-17 6.2e-14 -0.49 -0.37 Obesity-related traits; chr4:15624870 chr4:15563698~15564253:- LUSC cis rs7201929 1 rs7499878 ENSG00000259982.1 CDC37P1 -8.73 4.59e-17 6.23e-14 -0.5 -0.37 QT interval; chr16:28857143 chr16:28700294~28701540:- LUSC cis rs10740039 0.583 rs2127352 ENSG00000254271.1 RP11-131N11.4 -8.73 4.6e-17 6.25e-14 -0.52 -0.37 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60742129 chr10:60734342~60741828:+ LUSC cis rs5769707 0.554 rs10854876 ENSG00000235111.1 RP1-29C18.8 -8.73 4.62e-17 6.27e-14 -0.47 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49616922 chr22:49612657~49615716:- LUSC cis rs9487094 0.67 rs1885691 ENSG00000260273.1 RP11-425D10.10 8.73 4.64e-17 6.29e-14 0.44 0.37 Height; chr6:109382188 chr6:109382795~109383666:+ LUSC cis rs9487094 0.644 rs3757230 ENSG00000260273.1 RP11-425D10.10 8.73 4.64e-17 6.29e-14 0.44 0.37 Height; chr6:109383239 chr6:109382795~109383666:+ LUSC cis rs9487094 0.644 rs3757231 ENSG00000260273.1 RP11-425D10.10 8.73 4.64e-17 6.29e-14 0.44 0.37 Height; chr6:109383248 chr6:109382795~109383666:+ LUSC cis rs9487094 0.666 rs4946970 ENSG00000260273.1 RP11-425D10.10 8.73 4.64e-17 6.29e-14 0.44 0.37 Height; chr6:109384807 chr6:109382795~109383666:+ LUSC cis rs6991838 0.584 rs4388482 ENSG00000200714.1 Y_RNA -8.73 4.65e-17 6.3e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65583968 chr8:65592731~65592820:+ LUSC cis rs6991838 0.584 rs4637885 ENSG00000200714.1 Y_RNA -8.73 4.65e-17 6.3e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65584849 chr8:65592731~65592820:+ LUSC cis rs1113500 0.932 rs1343205 ENSG00000226822.1 RP11-356N1.2 8.72 4.67e-17 6.33e-14 0.38 0.37 Growth-regulated protein alpha levels; chr1:108055251 chr1:108071482~108074519:+ LUSC cis rs1185460 0.904 rs1003081 ENSG00000271751.1 RP11-110I1.14 8.72 4.67e-17 6.33e-14 0.48 0.37 Coronary artery disease; chr11:119043282 chr11:119065263~119065677:- LUSC cis rs1113500 0.933 rs10785833 ENSG00000226822.1 RP11-356N1.2 8.72 4.67e-17 6.34e-14 0.39 0.37 Growth-regulated protein alpha levels; chr1:108096460 chr1:108071482~108074519:+ LUSC cis rs1113500 0.897 rs55980437 ENSG00000226822.1 RP11-356N1.2 8.72 4.67e-17 6.34e-14 0.39 0.37 Growth-regulated protein alpha levels; chr1:108096876 chr1:108071482~108074519:+ LUSC cis rs10740039 0.583 rs9415612 ENSG00000254271.1 RP11-131N11.4 -8.72 4.71e-17 6.38e-14 -0.52 -0.37 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60746638 chr10:60734342~60741828:+ LUSC cis rs6991838 0.673 rs7462352 ENSG00000272010.1 CTD-3025N20.3 8.72 4.71e-17 6.39e-14 0.4 0.37 Intelligence (multi-trait analysis); chr8:65584378 chr8:65591850~65592472:- LUSC cis rs7044106 0.791 rs7043969 ENSG00000226752.6 PSMD5-AS1 -8.72 4.71e-17 6.39e-14 -0.44 -0.37 Hip circumference adjusted for BMI; chr9:120731711 chr9:120824828~120854385:+ LUSC cis rs9918079 0.56 rs4698402 ENSG00000273133.1 RP11-799M12.2 -8.72 4.72e-17 6.4e-14 -0.49 -0.37 Obesity-related traits; chr4:15628180 chr4:15563698~15564253:- LUSC cis rs10875746 0.768 rs10875724 ENSG00000240399.1 RP1-228P16.1 -8.72 4.73e-17 6.41e-14 -0.42 -0.37 Longevity (90 years and older); chr12:48026470 chr12:48054813~48055591:- LUSC cis rs9322193 0.962 rs9478848 ENSG00000216906.2 RP11-350J20.9 8.72 4.73e-17 6.42e-14 0.45 0.37 Lung cancer; chr6:149825080 chr6:149904243~149906418:+ LUSC cis rs3823536 0.583 rs921403 ENSG00000275106.1 RP11-309L24.10 -8.72 4.75e-17 6.43e-14 -0.51 -0.37 Sjögren's syndrome; chr7:129036670 chr7:128952527~128953316:- LUSC cis rs853679 0.517 rs9393898 ENSG00000219392.1 RP1-265C24.5 -8.72 4.77e-17 6.46e-14 -0.52 -0.37 Depression; chr6:28162598 chr6:28115628~28116551:+ LUSC cis rs7189233 0.531 rs7203132 ENSG00000279344.1 RP11-44F14.7 -8.72 4.77e-17 6.47e-14 -0.32 -0.37 Intelligence (multi-trait analysis); chr16:53395863 chr16:53478957~53481550:- LUSC cis rs9487094 0.689 rs9487070 ENSG00000260273.1 RP11-425D10.10 8.72 4.77e-17 6.47e-14 0.44 0.37 Height; chr6:109361200 chr6:109382795~109383666:+ LUSC cis rs9918079 0.56 rs7662032 ENSG00000273133.1 RP11-799M12.2 -8.72 4.78e-17 6.47e-14 -0.49 -0.37 Obesity-related traits; chr4:15633791 chr4:15563698~15564253:- LUSC cis rs9918079 0.56 rs12651550 ENSG00000273133.1 RP11-799M12.2 -8.72 4.78e-17 6.47e-14 -0.49 -0.37 Obesity-related traits; chr4:15639395 chr4:15563698~15564253:- LUSC cis rs1789 0.839 rs9997068 ENSG00000273133.1 RP11-799M12.2 -8.72 4.78e-17 6.47e-14 -0.49 -0.37 Blood protein levels; chr4:15649367 chr4:15563698~15564253:- LUSC cis rs4423214 0.879 rs1792284 ENSG00000254682.1 RP11-660L16.2 8.72 4.79e-17 6.49e-14 0.52 0.37 Vitamin D levels; chr11:71423920 chr11:71448674~71452157:+ LUSC cis rs1185460 1 rs7938944 ENSG00000271751.1 RP11-110I1.14 -8.72 4.85e-17 6.56e-14 -0.48 -0.37 Coronary artery disease; chr11:119083356 chr11:119065263~119065677:- LUSC cis rs17507216 0.609 rs1431716 ENSG00000278603.1 RP13-608F4.5 8.72 4.86e-17 6.57e-14 0.57 0.37 Excessive daytime sleepiness; chr15:82676180 chr15:82472203~82472426:+ LUSC cis rs11098499 0.754 rs1511017 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119329650 chr4:119454791~119552025:+ LUSC cis rs11098499 0.789 rs12498994 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119329663 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs12507565 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119329966 chr4:119454791~119552025:+ LUSC cis rs11098499 0.826 rs12511640 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119330093 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs1980026 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119330488 chr4:119454791~119552025:+ LUSC cis rs11098499 0.722 rs28713555 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119330840 chr4:119454791~119552025:+ LUSC cis rs11098499 0.743 rs11098501 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119330862 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs11098502 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119330908 chr4:119454791~119552025:+ LUSC cis rs11098499 0.708 rs11732686 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119331175 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs11724409 ENSG00000245958.5 RP11-33B1.1 -8.72 4.86e-17 6.57e-14 -0.37 -0.37 Corneal astigmatism; chr4:119331206 chr4:119454791~119552025:+ LUSC cis rs10875746 0.669 rs10875770 ENSG00000240399.1 RP1-228P16.1 -8.72 4.89e-17 6.61e-14 -0.43 -0.37 Longevity (90 years and older); chr12:48206737 chr12:48054813~48055591:- LUSC cis rs4927850 0.881 rs7630489 ENSG00000231464.1 AC024937.4 8.72 4.9e-17 6.62e-14 0.4 0.37 Pancreatic cancer; chr3:196026530 chr3:195996738~195998233:+ LUSC cis rs4927850 1 rs7627868 ENSG00000231464.1 AC024937.4 8.72 4.9e-17 6.62e-14 0.4 0.37 Pancreatic cancer; chr3:196026602 chr3:195996738~195998233:+ LUSC cis rs1707322 1 rs11211190 ENSG00000280836.1 AL355480.1 -8.72 4.9e-17 6.63e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45800583 chr1:45581219~45581321:- LUSC cis rs9487094 0.626 rs4947016 ENSG00000260273.1 RP11-425D10.10 8.72 4.95e-17 6.68e-14 0.44 0.37 Height; chr6:109740895 chr6:109382795~109383666:+ LUSC cis rs9487094 0.666 rs2211288 ENSG00000260273.1 RP11-425D10.10 8.72 4.96e-17 6.7e-14 0.44 0.37 Height; chr6:109383848 chr6:109382795~109383666:+ LUSC cis rs853679 0.598 rs9380054 ENSG00000219392.1 RP1-265C24.5 -8.72 4.97e-17 6.71e-14 -0.52 -0.37 Depression; chr6:28099759 chr6:28115628~28116551:+ LUSC cis rs7174755 0.743 rs4777035 ENSG00000260657.2 RP11-315D16.4 -8.72 4.99e-17 6.74e-14 -0.43 -0.37 Major depressive disorder; chr15:68312831 chr15:68267792~68277994:- LUSC cis rs10129255 0.957 rs12590667 ENSG00000223648.3 IGHV3-64 -8.72 5e-17 6.75e-14 -0.33 -0.37 Kawasaki disease; chr14:106779223 chr14:106643132~106658258:- LUSC cis rs2283792 1 rs2283792 ENSG00000228050.1 TOP3BP1 8.72 5e-17 6.75e-14 0.43 0.37 Multiple sclerosis; chr22:21776836 chr22:22223187~22224566:- LUSC cis rs2283792 0.967 rs3810609 ENSG00000228050.1 TOP3BP1 8.72 5.01e-17 6.77e-14 0.43 0.37 Multiple sclerosis; chr22:21758513 chr22:22223187~22224566:- LUSC cis rs10463554 0.892 rs158408 ENSG00000175749.11 EIF3KP1 8.71 5.02e-17 6.77e-14 0.44 0.37 Parkinson's disease; chr5:103071670 chr5:103032376~103033031:+ LUSC cis rs10129255 0.5 rs11628999 ENSG00000211972.2 IGHV3-66 8.71 5.07e-17 6.84e-14 0.25 0.37 Kawasaki disease; chr14:106800208 chr14:106675017~106675544:- LUSC cis rs11098499 0.866 rs3756156 ENSG00000249244.1 RP11-548H18.2 8.71 5.08e-17 6.85e-14 0.47 0.37 Corneal astigmatism; chr4:119603686 chr4:119391831~119395335:- LUSC cis rs3091242 0.934 rs666686 ENSG00000224183.1 SDHDP6 -8.71 5.09e-17 6.87e-14 -0.45 -0.37 Erythrocyte sedimentation rate; chr1:25393020 chr1:25294164~25294643:- LUSC cis rs9918079 0.56 rs6414767 ENSG00000273133.1 RP11-799M12.2 -8.71 5.11e-17 6.89e-14 -0.49 -0.37 Obesity-related traits; chr4:15654098 chr4:15563698~15564253:- LUSC cis rs526231 0.511 rs58344084 ENSG00000175749.11 EIF3KP1 8.71 5.12e-17 6.91e-14 0.46 0.37 Primary biliary cholangitis; chr5:103042508 chr5:103032376~103033031:+ LUSC cis rs12439619 0.846 rs62012056 ENSG00000255769.6 GOLGA2P10 -8.71 5.12e-17 6.91e-14 -0.52 -0.37 Intelligence (multi-trait analysis); chr15:82247278 chr15:82472993~82513950:- LUSC cis rs2283792 0.567 rs2027789 ENSG00000228050.1 TOP3BP1 8.71 5.13e-17 6.92e-14 0.46 0.37 Multiple sclerosis; chr22:21933490 chr22:22223187~22224566:- LUSC cis rs694739 1 rs499425 ENSG00000236935.1 AP003774.1 -8.71 5.13e-17 6.92e-14 -0.36 -0.37 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338457 chr11:64325050~64329504:- LUSC cis rs1150668 0.83 rs2023493 ENSG00000204709.4 LINC01556 8.71 5.16e-17 6.96e-14 0.46 0.37 Pubertal anthropometrics; chr6:28432385 chr6:28943877~28944537:+ LUSC cis rs9487094 0.922 rs2275650 ENSG00000260273.1 RP11-425D10.10 8.71 5.17e-17 6.97e-14 0.46 0.37 Height; chr6:109347085 chr6:109382795~109383666:+ LUSC cis rs9487094 0.885 rs3818934 ENSG00000260273.1 RP11-425D10.10 8.71 5.17e-17 6.97e-14 0.46 0.37 Height; chr6:109347277 chr6:109382795~109383666:+ LUSC cis rs9341808 0.69 rs9343970 ENSG00000272129.1 RP11-250B2.6 8.71 5.2e-17 7.01e-14 0.46 0.37 Sitting height ratio; chr6:80171572 chr6:80355424~80356859:+ LUSC cis rs17837474 0.656 rs17273 ENSG00000276597.1 TRBV11-3 8.71 5.2e-17 7.01e-14 0.5 0.37 Cancer; chr7:142407435 chr7:142554836~142555318:+ LUSC cis rs7739264 0.563 rs9465516 ENSG00000237404.1 RP3-471C18.2 -8.71 5.21e-17 7.02e-14 -0.42 -0.37 Endometriosis; chr6:19771767 chr6:19689825~19753113:- LUSC cis rs2739330 0.789 rs5760109 ENSG00000231271.1 AP000350.8 8.71 5.23e-17 7.04e-14 0.49 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23949918~23954042:+ LUSC cis rs10129255 1 rs10141557 ENSG00000211970.3 IGHV4-61 -8.71 5.23e-17 7.05e-14 -0.27 -0.37 Kawasaki disease; chr14:106767990 chr14:106639119~106639657:- LUSC cis rs6921919 0.789 rs1119211 ENSG00000204709.4 LINC01556 -8.71 5.26e-17 7.08e-14 -0.53 -0.37 Autism spectrum disorder or schizophrenia; chr6:28341359 chr6:28943877~28944537:+ LUSC cis rs11098499 0.691 rs28396837 ENSG00000245958.5 RP11-33B1.1 -8.71 5.26e-17 7.09e-14 -0.36 -0.37 Corneal astigmatism; chr4:119350386 chr4:119454791~119552025:+ LUSC cis rs11098499 0.629 rs28369518 ENSG00000245958.5 RP11-33B1.1 -8.71 5.26e-17 7.09e-14 -0.36 -0.37 Corneal astigmatism; chr4:119350475 chr4:119454791~119552025:+ LUSC cis rs2283792 1 rs1892846 ENSG00000228050.1 TOP3BP1 8.71 5.27e-17 7.1e-14 0.43 0.37 Multiple sclerosis; chr22:21832190 chr22:22223187~22224566:- LUSC cis rs2283792 1 rs1892848 ENSG00000228050.1 TOP3BP1 8.71 5.27e-17 7.1e-14 0.43 0.37 Multiple sclerosis; chr22:21832273 chr22:22223187~22224566:- LUSC cis rs2283792 1 rs5999750 ENSG00000228050.1 TOP3BP1 8.71 5.27e-17 7.1e-14 0.43 0.37 Multiple sclerosis; chr22:21833720 chr22:22223187~22224566:- LUSC cis rs11098499 0.863 rs13134665 ENSG00000245958.5 RP11-33B1.1 -8.71 5.28e-17 7.11e-14 -0.38 -0.37 Corneal astigmatism; chr4:119505275 chr4:119454791~119552025:+ LUSC cis rs11098499 0.691 rs17009144 ENSG00000245958.5 RP11-33B1.1 8.71 5.29e-17 7.12e-14 0.36 0.37 Corneal astigmatism; chr4:119349640 chr4:119454791~119552025:+ LUSC cis rs7189233 0.531 rs4281707 ENSG00000279344.1 RP11-44F14.7 8.71 5.3e-17 7.13e-14 0.32 0.37 Intelligence (multi-trait analysis); chr16:53468034 chr16:53478957~53481550:- LUSC cis rs1707322 1 rs11211204 ENSG00000280836.1 AL355480.1 -8.71 5.31e-17 7.14e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45852192 chr1:45581219~45581321:- LUSC cis rs7044106 0.791 rs7036196 ENSG00000226752.6 PSMD5-AS1 -8.71 5.31e-17 7.15e-14 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120717179 chr9:120824828~120854385:+ LUSC cis rs9918079 0.56 rs4557256 ENSG00000273133.1 RP11-799M12.2 -8.71 5.36e-17 7.21e-14 -0.49 -0.37 Obesity-related traits; chr4:15625024 chr4:15563698~15564253:- LUSC cis rs1891275 0.515 rs10881957 ENSG00000228701.1 TNKS2-AS1 -8.71 5.36e-17 7.21e-14 -0.43 -0.37 Intelligence (multi-trait analysis); chr10:91742119 chr10:91782839~91798291:- LUSC cis rs6991838 0.806 rs11781358 ENSG00000272010.1 CTD-3025N20.3 8.71 5.36e-17 7.21e-14 0.42 0.37 Intelligence (multi-trait analysis); chr8:65557691 chr8:65591850~65592472:- LUSC cis rs17507216 0.718 rs7165690 ENSG00000278603.1 RP13-608F4.5 8.71 5.38e-17 7.24e-14 0.57 0.37 Excessive daytime sleepiness; chr15:82654804 chr15:82472203~82472426:+ LUSC cis rs9807989 0.507 rs6734762 ENSG00000234389.1 AC007278.3 8.71 5.38e-17 7.24e-14 0.36 0.37 Asthma; chr2:102446466 chr2:102438713~102440475:+ LUSC cis rs1113500 0.933 rs10881500 ENSG00000226822.1 RP11-356N1.2 8.71 5.38e-17 7.24e-14 0.38 0.37 Growth-regulated protein alpha levels; chr1:108096273 chr1:108071482~108074519:+ LUSC cis rs1113500 0.897 rs10785832 ENSG00000226822.1 RP11-356N1.2 8.71 5.38e-17 7.24e-14 0.38 0.37 Growth-regulated protein alpha levels; chr1:108096277 chr1:108071482~108074519:+ LUSC cis rs5769707 0.616 rs135869 ENSG00000235111.1 RP1-29C18.8 -8.71 5.41e-17 7.28e-14 -0.47 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49614718 chr22:49612657~49615716:- LUSC cis rs1707322 1 rs6429580 ENSG00000280836.1 AL355480.1 -8.7 5.41e-17 7.28e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45809976 chr1:45581219~45581321:- LUSC cis rs11098499 0.754 rs12513083 ENSG00000245958.5 RP11-33B1.1 -8.7 5.44e-17 7.31e-14 -0.37 -0.37 Corneal astigmatism; chr4:119328457 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs12509621 ENSG00000245958.5 RP11-33B1.1 -8.7 5.44e-17 7.31e-14 -0.37 -0.37 Corneal astigmatism; chr4:119328505 chr4:119454791~119552025:+ LUSC cis rs9807989 0.507 rs13021177 ENSG00000234389.1 AC007278.3 8.7 5.47e-17 7.35e-14 0.35 0.37 Asthma; chr2:102440033 chr2:102438713~102440475:+ LUSC cis rs10463554 0.963 rs1595553 ENSG00000175749.11 EIF3KP1 8.7 5.48e-17 7.36e-14 0.45 0.37 Parkinson's disease; chr5:103043164 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs12655592 ENSG00000175749.11 EIF3KP1 8.7 5.48e-17 7.36e-14 0.45 0.37 Parkinson's disease; chr5:103043715 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs12054848 ENSG00000175749.11 EIF3KP1 8.7 5.48e-17 7.36e-14 0.45 0.37 Parkinson's disease; chr5:103044736 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs11242484 ENSG00000175749.11 EIF3KP1 8.7 5.48e-17 7.36e-14 0.45 0.37 Parkinson's disease; chr5:103046172 chr5:103032376~103033031:+ LUSC cis rs526231 0.543 rs42431 ENSG00000175749.11 EIF3KP1 -8.7 5.51e-17 7.41e-14 -0.46 -0.37 Primary biliary cholangitis; chr5:103064359 chr5:103032376~103033031:+ LUSC cis rs11098499 0.954 rs1022145 ENSG00000245958.5 RP11-33B1.1 -8.7 5.55e-17 7.46e-14 -0.39 -0.37 Corneal astigmatism; chr4:119309824 chr4:119454791~119552025:+ LUSC cis rs17507216 0.718 rs17158403 ENSG00000278603.1 RP13-608F4.5 8.7 5.57e-17 7.48e-14 0.56 0.37 Excessive daytime sleepiness; chr15:82572478 chr15:82472203~82472426:+ LUSC cis rs11098499 0.863 rs2306456 ENSG00000249244.1 RP11-548H18.2 8.7 5.57e-17 7.48e-14 0.48 0.37 Corneal astigmatism; chr4:119551267 chr4:119391831~119395335:- LUSC cis rs7189233 0.55 rs9927982 ENSG00000279344.1 RP11-44F14.7 8.7 5.57e-17 7.49e-14 0.32 0.37 Intelligence (multi-trait analysis); chr16:53440196 chr16:53478957~53481550:- LUSC cis rs1707322 1 rs7531911 ENSG00000280836.1 AL355480.1 -8.7 5.6e-17 7.51e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45864751 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs34694458 ENSG00000280836.1 AL355480.1 -8.7 5.6e-17 7.51e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45867024 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs10890359 ENSG00000280836.1 AL355480.1 -8.7 5.6e-17 7.51e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45870963 chr1:45581219~45581321:- LUSC cis rs7189233 0.531 rs17800577 ENSG00000279344.1 RP11-44F14.7 8.7 5.63e-17 7.55e-14 0.32 0.37 Intelligence (multi-trait analysis); chr16:53442892 chr16:53478957~53481550:- LUSC cis rs9341808 0.718 rs9343971 ENSG00000272129.1 RP11-250B2.6 8.7 5.63e-17 7.55e-14 0.46 0.37 Sitting height ratio; chr6:80172339 chr6:80355424~80356859:+ LUSC cis rs1707322 0.963 rs4630155 ENSG00000280836.1 AL355480.1 -8.7 5.63e-17 7.56e-14 -0.46 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45791438 chr1:45581219~45581321:- LUSC cis rs11098499 0.754 rs7672778 ENSG00000245958.5 RP11-33B1.1 -8.7 5.66e-17 7.59e-14 -0.37 -0.37 Corneal astigmatism; chr4:119327430 chr4:119454791~119552025:+ LUSC cis rs62229266 0.625 rs2051395 ENSG00000231106.2 LINC01436 -8.7 5.7e-17 7.65e-14 -0.47 -0.37 Mitral valve prolapse; chr21:36058967 chr21:36005338~36007838:+ LUSC cis rs9322193 0.567 rs7747457 ENSG00000268592.3 RAET1E-AS1 8.7 5.72e-17 7.67e-14 0.46 0.37 Lung cancer; chr6:149892366 chr6:149863494~149919507:+ LUSC cis rs10463554 0.963 rs11242485 ENSG00000175749.11 EIF3KP1 8.7 5.74e-17 7.7e-14 0.45 0.37 Parkinson's disease; chr5:103046330 chr5:103032376~103033031:+ LUSC cis rs4927850 0.881 rs7624638 ENSG00000231464.1 AC024937.4 8.7 5.74e-17 7.71e-14 0.4 0.37 Pancreatic cancer; chr3:196021858 chr3:195996738~195998233:+ LUSC cis rs1707322 1 rs10890378 ENSG00000280836.1 AL355480.1 8.7 5.76e-17 7.72e-14 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45944985 chr1:45581219~45581321:- LUSC cis rs9341808 0.754 rs3805925 ENSG00000272129.1 RP11-250B2.6 8.7 5.76e-17 7.72e-14 0.46 0.37 Sitting height ratio; chr6:80174116 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs3805922 ENSG00000272129.1 RP11-250B2.6 8.7 5.76e-17 7.72e-14 0.46 0.37 Sitting height ratio; chr6:80182272 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs3805920 ENSG00000272129.1 RP11-250B2.6 8.7 5.76e-17 7.72e-14 0.46 0.37 Sitting height ratio; chr6:80183028 chr6:80355424~80356859:+ LUSC cis rs4713118 0.621 rs4713132 ENSG00000219392.1 RP1-265C24.5 -8.7 5.76e-17 7.72e-14 -0.53 -0.37 Parkinson's disease; chr6:28066257 chr6:28115628~28116551:+ LUSC cis rs4713118 0.621 rs4713133 ENSG00000219392.1 RP1-265C24.5 -8.7 5.76e-17 7.72e-14 -0.53 -0.37 Parkinson's disease; chr6:28066263 chr6:28115628~28116551:+ LUSC cis rs4713118 0.621 rs4713134 ENSG00000219392.1 RP1-265C24.5 -8.7 5.76e-17 7.72e-14 -0.53 -0.37 Parkinson's disease; chr6:28066343 chr6:28115628~28116551:+ LUSC cis rs7044106 0.791 rs4837793 ENSG00000226752.6 PSMD5-AS1 -8.7 5.76e-17 7.72e-14 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120721343 chr9:120824828~120854385:+ LUSC cis rs9341808 0.718 rs3812121 ENSG00000272129.1 RP11-250B2.6 8.7 5.77e-17 7.73e-14 0.45 0.37 Sitting height ratio; chr6:80259010 chr6:80355424~80356859:+ LUSC cis rs11098499 0.863 rs11947234 ENSG00000249244.1 RP11-548H18.2 8.7 5.8e-17 7.76e-14 0.48 0.37 Corneal astigmatism; chr4:119553704 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs11933966 ENSG00000249244.1 RP11-548H18.2 8.7 5.8e-17 7.76e-14 0.48 0.37 Corneal astigmatism; chr4:119555560 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs36040693 ENSG00000249244.1 RP11-548H18.2 8.7 5.8e-17 7.76e-14 0.48 0.37 Corneal astigmatism; chr4:119556461 chr4:119391831~119395335:- LUSC cis rs1707322 1 rs1622208 ENSG00000280836.1 AL355480.1 8.7 5.81e-17 7.78e-14 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46032703 chr1:45581219~45581321:- LUSC cis rs11098499 1 rs35643470 ENSG00000245958.5 RP11-33B1.1 -8.7 5.81e-17 7.79e-14 -0.38 -0.37 Corneal astigmatism; chr4:119263793 chr4:119454791~119552025:+ LUSC cis rs6921919 1 rs6922111 ENSG00000204709.4 LINC01556 8.7 5.81e-17 7.79e-14 0.54 0.37 Autism spectrum disorder or schizophrenia; chr6:28357531 chr6:28943877~28944537:+ LUSC cis rs494459 0.838 rs12796102 ENSG00000255239.1 AP002954.6 8.7 5.81e-17 7.79e-14 0.4 0.37 Height; chr11:118791319 chr11:118688039~118690600:- LUSC cis rs7044106 0.791 rs3904196 ENSG00000226752.6 PSMD5-AS1 -8.7 5.83e-17 7.81e-14 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120718091 chr9:120824828~120854385:+ LUSC cis rs10129255 0.957 rs10150241 ENSG00000211970.3 IGHV4-61 8.69 5.95e-17 7.96e-14 0.26 0.37 Kawasaki disease; chr14:106775945 chr14:106639119~106639657:- LUSC cis rs5769707 0.732 rs135865 ENSG00000235111.1 RP1-29C18.8 -8.69 5.99e-17 8.02e-14 -0.46 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49611181 chr22:49612657~49615716:- LUSC cis rs9487094 0.961 rs1040284 ENSG00000260273.1 RP11-425D10.10 8.69 6.01e-17 8.04e-14 0.45 0.37 Height; chr6:109352730 chr6:109382795~109383666:+ LUSC cis rs9487094 0.961 rs11153174 ENSG00000260273.1 RP11-425D10.10 8.69 6.01e-17 8.04e-14 0.45 0.37 Height; chr6:109352852 chr6:109382795~109383666:+ LUSC cis rs9487094 0.961 rs34202013 ENSG00000260273.1 RP11-425D10.10 8.69 6.01e-17 8.04e-14 0.45 0.37 Height; chr6:109353355 chr6:109382795~109383666:+ LUSC cis rs11155671 0.53 rs7756850 ENSG00000268592.3 RAET1E-AS1 8.69 6.02e-17 8.05e-14 0.46 0.37 Testicular germ cell tumor; chr6:149891460 chr6:149863494~149919507:+ LUSC cis rs9487094 0.922 rs11153181 ENSG00000260273.1 RP11-425D10.10 8.69 6.05e-17 8.09e-14 0.46 0.37 Height; chr6:109428824 chr6:109382795~109383666:+ LUSC cis rs2236295 0.814 rs1848797 ENSG00000238280.1 RP11-436D10.3 -8.69 6.09e-17 8.15e-14 -0.46 -0.37 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks); chr10:62793174 chr10:62793562~62805887:- LUSC cis rs9341808 0.754 rs9361591 ENSG00000272129.1 RP11-250B2.6 8.69 6.1e-17 8.15e-14 0.45 0.37 Sitting height ratio; chr6:80243538 chr6:80355424~80356859:+ LUSC cis rs1707322 1 rs10890365 ENSG00000280836.1 AL355480.1 -8.69 6.11e-17 8.17e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893676 chr1:45581219~45581321:- LUSC cis rs11098499 0.863 rs11098532 ENSG00000249244.1 RP11-548H18.2 8.69 6.11e-17 8.17e-14 0.47 0.37 Corneal astigmatism; chr4:119569571 chr4:119391831~119395335:- LUSC cis rs11098499 0.82 rs28394116 ENSG00000249244.1 RP11-548H18.2 8.69 6.13e-17 8.19e-14 0.47 0.37 Corneal astigmatism; chr4:119603128 chr4:119391831~119395335:- LUSC cis rs4423214 0.798 rs1894100 ENSG00000254682.1 RP11-660L16.2 -8.69 6.14e-17 8.21e-14 -0.53 -0.37 Vitamin D levels; chr11:71419297 chr11:71448674~71452157:+ LUSC cis rs11098499 0.874 rs13139045 ENSG00000245958.5 RP11-33B1.1 -8.69 6.17e-17 8.24e-14 -0.37 -0.37 Corneal astigmatism; chr4:119247433 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs3822194 ENSG00000249244.1 RP11-548H18.2 8.69 6.17e-17 8.24e-14 0.48 0.37 Corneal astigmatism; chr4:119550493 chr4:119391831~119395335:- LUSC cis rs10129255 0.957 rs17113284 ENSG00000211970.3 IGHV4-61 8.69 6.18e-17 8.25e-14 0.26 0.37 Kawasaki disease; chr14:106684476 chr14:106639119~106639657:- LUSC cis rs9487094 0.961 rs11153180 ENSG00000260273.1 RP11-425D10.10 8.69 6.22e-17 8.31e-14 0.46 0.37 Height; chr6:109423238 chr6:109382795~109383666:+ LUSC cis rs853679 0.517 rs4713145 ENSG00000219392.1 RP1-265C24.5 -8.69 6.22e-17 8.31e-14 -0.52 -0.37 Depression; chr6:28139049 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9393896 ENSG00000219392.1 RP1-265C24.5 -8.69 6.25e-17 8.35e-14 -0.52 -0.37 Depression; chr6:28159925 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9393897 ENSG00000219392.1 RP1-265C24.5 -8.69 6.25e-17 8.35e-14 -0.52 -0.37 Depression; chr6:28159932 chr6:28115628~28116551:+ LUSC cis rs9341808 0.754 rs9352808 ENSG00000272129.1 RP11-250B2.6 8.69 6.26e-17 8.36e-14 0.45 0.37 Sitting height ratio; chr6:80287625 chr6:80355424~80356859:+ LUSC cis rs1707322 1 rs4390216 ENSG00000280836.1 AL355480.1 -8.68 6.34e-17 8.46e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45800784 chr1:45581219~45581321:- LUSC cis rs3931020 0.688 rs277375 ENSG00000272864.1 RP11-17E13.2 -8.68 6.34e-17 8.46e-14 -0.49 -0.37 Resistin levels; chr1:74738459 chr1:74698769~74699333:- LUSC cis rs10129255 0.5 rs2027903 ENSG00000211972.2 IGHV3-66 8.68 6.35e-17 8.47e-14 0.25 0.37 Kawasaki disease; chr14:106807047 chr14:106675017~106675544:- LUSC cis rs10463554 0.927 rs12055075 ENSG00000175749.11 EIF3KP1 8.68 6.38e-17 8.5e-14 0.45 0.37 Parkinson's disease; chr5:103044553 chr5:103032376~103033031:+ LUSC cis rs2283792 1 rs6928 ENSG00000228050.1 TOP3BP1 8.68 6.38e-17 8.5e-14 0.43 0.37 Multiple sclerosis; chr22:21760715 chr22:22223187~22224566:- LUSC cis rs11098499 0.754 rs2036860 ENSG00000245958.5 RP11-33B1.1 -8.68 6.39e-17 8.52e-14 -0.37 -0.37 Corneal astigmatism; chr4:119327779 chr4:119454791~119552025:+ LUSC cis rs6921919 1 rs6921919 ENSG00000204709.4 LINC01556 8.68 6.41e-17 8.54e-14 0.54 0.37 Autism spectrum disorder or schizophrenia; chr6:28357424 chr6:28943877~28944537:+ LUSC cis rs11098499 0.863 rs6835635 ENSG00000249244.1 RP11-548H18.2 8.68 6.44e-17 8.59e-14 0.47 0.37 Corneal astigmatism; chr4:119537712 chr4:119391831~119395335:- LUSC cis rs11098499 0.818 rs55825515 ENSG00000245958.5 RP11-33B1.1 -8.68 6.44e-17 8.59e-14 -0.38 -0.37 Corneal astigmatism; chr4:119565247 chr4:119454791~119552025:+ LUSC cis rs10129255 0.5 rs10143242 ENSG00000211970.3 IGHV4-61 -8.68 6.46e-17 8.6e-14 -0.23 -0.37 Kawasaki disease; chr14:106681814 chr14:106639119~106639657:- LUSC cis rs853679 0.517 rs35193936 ENSG00000219392.1 RP1-265C24.5 -8.68 6.48e-17 8.63e-14 -0.53 -0.37 Depression; chr6:28108492 chr6:28115628~28116551:+ LUSC cis rs10129255 0.872 rs1858683 ENSG00000211970.3 IGHV4-61 -8.68 6.48e-17 8.63e-14 -0.27 -0.37 Kawasaki disease; chr14:106670217 chr14:106639119~106639657:- LUSC cis rs10262624 0.528 rs722294 ENSG00000234286.1 AC006026.13 8.68 6.49e-17 8.64e-14 0.45 0.37 Schizophrenia; chr7:23706966 chr7:23680195~23680786:- LUSC cis rs4423214 0.879 rs736894 ENSG00000254682.1 RP11-660L16.2 8.68 6.53e-17 8.69e-14 0.5 0.37 Vitamin D levels; chr11:71441212 chr11:71448674~71452157:+ LUSC cis rs11098499 0.909 rs1546504 ENSG00000245958.5 RP11-33B1.1 -8.68 6.57e-17 8.75e-14 -0.39 -0.37 Corneal astigmatism; chr4:119320024 chr4:119454791~119552025:+ LUSC cis rs12022452 0.591 rs12042242 ENSG00000238287.1 RP11-656D10.3 8.68 6.6e-17 8.79e-14 0.54 0.37 Age-related hearing impairment (SNP x SNP interaction); chr1:40528201 chr1:40493157~40508661:- LUSC cis rs1155848 0.892 rs9574424 ENSG00000227354.5 RBM26-AS1 -8.68 6.65e-17 8.86e-14 -0.72 -0.37 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79448541 chr13:79406309~79424328:+ LUSC cis rs9487094 0.961 rs9480948 ENSG00000260273.1 RP11-425D10.10 8.68 6.69e-17 8.89e-14 0.46 0.37 Height; chr6:109407148 chr6:109382795~109383666:+ LUSC cis rs9322193 0.886 rs4870049 ENSG00000223701.3 RAET1E-AS1 8.68 6.69e-17 8.91e-14 0.44 0.37 Lung cancer; chr6:149837058 chr6:149884431~149919508:+ LUSC cis rs11098499 0.863 rs11098531 ENSG00000245958.5 RP11-33B1.1 -8.68 6.71e-17 8.93e-14 -0.38 -0.37 Corneal astigmatism; chr4:119543846 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs28718422 ENSG00000245958.5 RP11-33B1.1 -8.68 6.71e-17 8.93e-14 -0.38 -0.37 Corneal astigmatism; chr4:119545149 chr4:119454791~119552025:+ LUSC cis rs11098499 0.818 rs12498599 ENSG00000245958.5 RP11-33B1.1 -8.68 6.71e-17 8.93e-14 -0.38 -0.37 Corneal astigmatism; chr4:119547348 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs10009626 ENSG00000245958.5 RP11-33B1.1 -8.68 6.71e-17 8.93e-14 -0.38 -0.37 Corneal astigmatism; chr4:119548850 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs28643450 ENSG00000245958.5 RP11-33B1.1 -8.68 6.72e-17 8.94e-14 -0.37 -0.37 Corneal astigmatism; chr4:119324087 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs7672594 ENSG00000245958.5 RP11-33B1.1 -8.68 6.72e-17 8.94e-14 -0.37 -0.37 Corneal astigmatism; chr4:119327388 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs6857105 ENSG00000245958.5 RP11-33B1.1 -8.68 6.75e-17 8.98e-14 -0.39 -0.37 Corneal astigmatism; chr4:119301143 chr4:119454791~119552025:+ LUSC cis rs1707322 1 rs785478 ENSG00000280836.1 AL355480.1 8.68 6.75e-17 8.98e-14 0.43 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46025963 chr1:45581219~45581321:- LUSC cis rs9322193 0.566 rs6912330 ENSG00000216906.2 RP11-350J20.9 -8.68 6.76e-17 8.99e-14 -0.5 -0.37 Lung cancer; chr6:149908811 chr6:149904243~149906418:+ LUSC cis rs1707322 1 rs7553924 ENSG00000280836.1 AL355480.1 -8.68 6.77e-17 9e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45886952 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4641257 ENSG00000280836.1 AL355480.1 -8.68 6.77e-17 9e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45887917 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs6693336 ENSG00000280836.1 AL355480.1 -8.68 6.77e-17 9e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45888923 chr1:45581219~45581321:- LUSC cis rs7945705 0.747 rs10840158 ENSG00000254860.4 TMEM9B-AS1 8.68 6.77e-17 9e-14 0.4 0.37 Hemoglobin concentration; chr11:8999350 chr11:8964675~8977527:+ LUSC cis rs8072100 0.84 rs9912311 ENSG00000228782.6 CTD-2026D20.3 8.67 6.82e-17 9.06e-14 0.35 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469766 chr17:47450568~47492492:- LUSC cis rs11118620 0.535 rs1389750 ENSG00000238078.1 LINC01352 8.67 6.85e-17 9.1e-14 0.39 0.37 Heart failure; chr1:220866829 chr1:220829255~220832429:+ LUSC cis rs1799949 0.602 rs8176199 ENSG00000198496.9 NBR2 -8.67 6.88e-17 9.13e-14 -0.48 -0.37 Menopause (age at onset); chr17:43078507 chr17:43125610~43153671:+ LUSC cis rs11098499 0.863 rs3822190 ENSG00000245958.5 RP11-33B1.1 -8.67 6.91e-17 9.17e-14 -0.38 -0.37 Corneal astigmatism; chr4:119506943 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs3822191 ENSG00000245958.5 RP11-33B1.1 -8.67 6.91e-17 9.17e-14 -0.38 -0.37 Corneal astigmatism; chr4:119506946 chr4:119454791~119552025:+ LUSC cis rs26232 0.583 rs154258 ENSG00000175749.11 EIF3KP1 -8.67 6.92e-17 9.18e-14 -0.45 -0.37 Rheumatoid arthritis; chr5:103027919 chr5:103032376~103033031:+ LUSC cis rs1113500 0.702 rs11185262 ENSG00000226822.1 RP11-356N1.2 8.67 6.93e-17 9.2e-14 0.38 0.37 Growth-regulated protein alpha levels; chr1:108097120 chr1:108071482~108074519:+ LUSC cis rs853679 0.517 rs9295758 ENSG00000219392.1 RP1-265C24.5 -8.67 6.95e-17 9.22e-14 -0.52 -0.37 Depression; chr6:28152885 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs17774663 ENSG00000219392.1 RP1-265C24.5 -8.67 6.95e-17 9.22e-14 -0.52 -0.37 Depression; chr6:28153120 chr6:28115628~28116551:+ LUSC cis rs1707322 1 rs7547189 ENSG00000280836.1 AL355480.1 -8.67 6.96e-17 9.23e-14 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853842 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs7547284 ENSG00000280836.1 AL355480.1 -8.67 6.96e-17 9.23e-14 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853893 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211205 ENSG00000280836.1 AL355480.1 -8.67 6.96e-17 9.23e-14 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45856202 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs6675222 ENSG00000280836.1 AL355480.1 -8.67 6.96e-17 9.23e-14 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45860904 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4660895 ENSG00000280836.1 AL355480.1 -8.67 6.96e-17 9.23e-14 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45864067 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs10158032 ENSG00000280836.1 AL355480.1 -8.67 6.96e-17 9.23e-14 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45867029 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4660318 ENSG00000280836.1 AL355480.1 -8.67 6.96e-17 9.23e-14 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45869204 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs10890360 ENSG00000280836.1 AL355480.1 -8.67 6.96e-17 9.23e-14 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45872772 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs6682683 ENSG00000280836.1 AL355480.1 -8.67 6.96e-17 9.23e-14 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45876665 chr1:45581219~45581321:- LUSC cis rs11098499 0.754 rs1849457 ENSG00000245958.5 RP11-33B1.1 -8.67 6.96e-17 9.24e-14 -0.37 -0.37 Corneal astigmatism; chr4:119333200 chr4:119454791~119552025:+ LUSC cis rs1707322 1 rs10890381 ENSG00000280836.1 AL355480.1 -8.67 6.97e-17 9.24e-14 -0.45 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45986099 chr1:45581219~45581321:- LUSC cis rs526231 0.511 rs17154965 ENSG00000175749.11 EIF3KP1 8.67 6.97e-17 9.25e-14 0.46 0.37 Primary biliary cholangitis; chr5:103023862 chr5:103032376~103033031:+ LUSC cis rs1707322 0.964 rs10437063 ENSG00000280836.1 AL355480.1 -8.67 6.99e-17 9.27e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45807994 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs6676982 ENSG00000280836.1 AL355480.1 -8.67 6.99e-17 9.27e-14 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45809729 chr1:45581219~45581321:- LUSC cis rs9322193 1 rs9377229 ENSG00000216906.2 RP11-350J20.9 8.67 6.99e-17 9.27e-14 0.44 0.37 Lung cancer; chr6:149607655 chr6:149904243~149906418:+ LUSC cis rs494459 0.838 rs567680 ENSG00000255239.1 AP002954.6 8.67 7e-17 9.27e-14 0.4 0.37 Height; chr11:118737823 chr11:118688039~118690600:- LUSC cis rs853679 0.517 rs4713148 ENSG00000219392.1 RP1-265C24.5 -8.67 7.02e-17 9.31e-14 -0.53 -0.37 Depression; chr6:28148143 chr6:28115628~28116551:+ LUSC cis rs10463554 0.927 rs158403 ENSG00000175749.11 EIF3KP1 8.67 7.02e-17 9.31e-14 0.45 0.37 Parkinson's disease; chr5:103080064 chr5:103032376~103033031:+ LUSC cis rs853679 0.55 rs9295762 ENSG00000219392.1 RP1-265C24.5 8.67 7.09e-17 9.39e-14 0.5 0.37 Depression; chr6:28187640 chr6:28115628~28116551:+ LUSC cis rs1113500 0.862 rs2336128 ENSG00000226822.1 RP11-356N1.2 8.67 7.15e-17 9.47e-14 0.39 0.37 Growth-regulated protein alpha levels; chr1:108098117 chr1:108071482~108074519:+ LUSC cis rs11155671 0.546 rs1999633 ENSG00000216906.2 RP11-350J20.9 8.67 7.16e-17 9.48e-14 0.48 0.37 Testicular germ cell tumor; chr6:149866576 chr6:149904243~149906418:+ LUSC cis rs7189233 0.531 rs1131220 ENSG00000279344.1 RP11-44F14.7 8.67 7.23e-17 9.57e-14 0.32 0.37 Intelligence (multi-trait analysis); chr16:53470022 chr16:53478957~53481550:- LUSC cis rs992157 0.798 rs2382818 ENSG00000261338.2 RP11-378A13.1 -8.67 7.24e-17 9.58e-14 -0.38 -0.37 Colorectal cancer; chr2:218291184 chr2:218255319~218257366:+ LUSC cis rs992157 0.798 rs2382819 ENSG00000261338.2 RP11-378A13.1 -8.67 7.24e-17 9.58e-14 -0.38 -0.37 Colorectal cancer; chr2:218291186 chr2:218255319~218257366:+ LUSC cis rs2117029 0.556 rs1057725 ENSG00000258017.1 RP11-386G11.10 -8.67 7.28e-17 9.63e-14 -0.46 -0.37 Intelligence (multi-trait analysis); chr12:49128795 chr12:49127782~49147869:+ LUSC cis rs5769707 0.592 rs6009783 ENSG00000235111.1 RP1-29C18.8 -8.66 7.34e-17 9.71e-14 -0.46 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49617353 chr22:49612657~49615716:- LUSC cis rs7189233 0.513 rs10748 ENSG00000279344.1 RP11-44F14.7 8.66 7.36e-17 9.74e-14 0.32 0.37 Intelligence (multi-trait analysis); chr16:53470809 chr16:53478957~53481550:- LUSC cis rs7044106 0.791 rs7036766 ENSG00000226752.6 PSMD5-AS1 -8.66 7.37e-17 9.75e-14 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120717343 chr9:120824828~120854385:+ LUSC cis rs853679 0.517 rs3757187 ENSG00000219392.1 RP1-265C24.5 -8.66 7.43e-17 9.82e-14 -0.52 -0.37 Depression; chr6:28139876 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs3757185 ENSG00000219392.1 RP1-265C24.5 -8.66 7.43e-17 9.82e-14 -0.52 -0.37 Depression; chr6:28139998 chr6:28115628~28116551:+ LUSC cis rs9341808 0.718 rs9448908 ENSG00000272129.1 RP11-250B2.6 8.66 7.47e-17 9.87e-14 0.46 0.37 Sitting height ratio; chr6:80188352 chr6:80355424~80356859:+ LUSC cis rs5769707 0.632 rs6009782 ENSG00000235111.1 RP1-29C18.8 -8.66 7.5e-17 9.91e-14 -0.46 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49617164 chr22:49612657~49615716:- LUSC cis rs6991838 0.557 rs4737222 ENSG00000200714.1 Y_RNA -8.66 7.5e-17 9.92e-14 -0.45 -0.37 Intelligence (multi-trait analysis); chr8:65587878 chr8:65592731~65592820:+ LUSC cis rs7189233 0.531 rs8045674 ENSG00000279344.1 RP11-44F14.7 8.66 7.53e-17 9.95e-14 0.32 0.37 Intelligence (multi-trait analysis); chr16:53476024 chr16:53478957~53481550:- LUSC cis rs11098499 0.863 rs10004484 ENSG00000249244.1 RP11-548H18.2 8.66 7.55e-17 9.97e-14 0.48 0.37 Corneal astigmatism; chr4:119521273 chr4:119391831~119395335:- LUSC cis rs4728142 0.604 rs10229001 ENSG00000275106.1 RP11-309L24.10 -8.66 7.55e-17 9.97e-14 -0.48 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128959343 chr7:128952527~128953316:- LUSC cis rs8062405 0.723 rs113208333 ENSG00000259982.1 CDC37P1 8.66 7.58e-17 1e-13 0.46 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28594839 chr16:28700294~28701540:- LUSC cis rs853679 0.517 rs9348794 ENSG00000219392.1 RP1-265C24.5 -8.66 7.58e-17 1e-13 -0.52 -0.37 Depression; chr6:28149979 chr6:28115628~28116551:+ LUSC cis rs9918079 0.58 rs13120905 ENSG00000273133.1 RP11-799M12.2 8.66 7.65e-17 1.01e-13 0.49 0.37 Obesity-related traits; chr4:15610665 chr4:15563698~15564253:- LUSC cis rs11098499 0.691 rs9996644 ENSG00000245958.5 RP11-33B1.1 -8.66 7.65e-17 1.01e-13 -0.37 -0.37 Corneal astigmatism; chr4:119317722 chr4:119454791~119552025:+ LUSC cis rs11098499 0.691 rs9996494 ENSG00000245958.5 RP11-33B1.1 -8.66 7.65e-17 1.01e-13 -0.37 -0.37 Corneal astigmatism; chr4:119317725 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs3775841 ENSG00000245958.5 RP11-33B1.1 -8.66 7.75e-17 1.02e-13 -0.38 -0.37 Corneal astigmatism; chr4:119504622 chr4:119454791~119552025:+ LUSC cis rs1113500 0.836 rs2801220 ENSG00000226822.1 RP11-356N1.2 -8.66 7.83e-17 1.03e-13 -0.38 -0.37 Growth-regulated protein alpha levels; chr1:108042027 chr1:108071482~108074519:+ LUSC cis rs11098499 0.863 rs10019674 ENSG00000245958.5 RP11-33B1.1 8.66 7.85e-17 1.04e-13 0.38 0.37 Corneal astigmatism; chr4:119522334 chr4:119454791~119552025:+ LUSC cis rs10463554 0.963 rs62364875 ENSG00000175749.11 EIF3KP1 8.65 7.91e-17 1.04e-13 0.44 0.37 Parkinson's disease; chr5:103056486 chr5:103032376~103033031:+ LUSC cis rs62388641 0.813 rs34114087 ENSG00000272279.1 RP11-157J24.2 8.65 7.92e-17 1.04e-13 0.61 0.37 Daytime sleep phenotypes; chr6:1553203 chr6:1528364~1528911:- LUSC cis rs9487094 0.626 rs11153215 ENSG00000260273.1 RP11-425D10.10 8.65 7.93e-17 1.05e-13 0.44 0.37 Height; chr6:109732518 chr6:109382795~109383666:+ LUSC cis rs10256972 0.616 rs6957733 ENSG00000229043.2 AC091729.9 -8.65 7.96e-17 1.05e-13 -0.42 -0.37 Endometriosis;Longevity; chr7:1066691 chr7:1160374~1165267:+ LUSC cis rs9322193 0.607 rs9383941 ENSG00000216906.2 RP11-350J20.9 -8.65 8.02e-17 1.06e-13 -0.5 -0.37 Lung cancer; chr6:149912100 chr6:149904243~149906418:+ LUSC cis rs2739330 0.828 rs2330635 ENSG00000231271.1 AP000350.8 8.65 8.06e-17 1.06e-13 0.49 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23949918~23954042:+ LUSC cis rs9807989 0.507 rs11465721 ENSG00000234389.1 AC007278.3 8.65 8.06e-17 1.06e-13 0.35 0.37 Asthma; chr2:102446780 chr2:102438713~102440475:+ LUSC cis rs10740039 0.583 rs1904404 ENSG00000254271.1 RP11-131N11.4 -8.65 8.16e-17 1.08e-13 -0.5 -0.37 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60742428 chr10:60734342~60741828:+ LUSC cis rs10129255 0.834 rs10139893 ENSG00000211970.3 IGHV4-61 -8.65 8.18e-17 1.08e-13 -0.27 -0.37 Kawasaki disease; chr14:106711377 chr14:106639119~106639657:- LUSC cis rs143626010 1 rs143626010 ENSG00000259982.1 CDC37P1 8.65 8.18e-17 1.08e-13 0.46 0.37 Mosquito bite size; chr16:28528081 chr16:28700294~28701540:- LUSC cis rs11098499 0.863 rs11098531 ENSG00000249244.1 RP11-548H18.2 8.65 8.19e-17 1.08e-13 0.47 0.37 Corneal astigmatism; chr4:119543846 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs28718422 ENSG00000249244.1 RP11-548H18.2 8.65 8.19e-17 1.08e-13 0.47 0.37 Corneal astigmatism; chr4:119545149 chr4:119391831~119395335:- LUSC cis rs11098499 0.818 rs12498599 ENSG00000249244.1 RP11-548H18.2 8.65 8.19e-17 1.08e-13 0.47 0.37 Corneal astigmatism; chr4:119547348 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs10009626 ENSG00000249244.1 RP11-548H18.2 8.65 8.19e-17 1.08e-13 0.47 0.37 Corneal astigmatism; chr4:119548850 chr4:119391831~119395335:- LUSC cis rs9918079 0.542 rs1789 ENSG00000273133.1 RP11-799M12.2 -8.65 8.21e-17 1.08e-13 -0.49 -0.37 Obesity-related traits; chr4:15662912 chr4:15563698~15564253:- LUSC cis rs1113500 0.933 rs11185261 ENSG00000226822.1 RP11-356N1.2 8.65 8.27e-17 1.09e-13 0.38 0.37 Growth-regulated protein alpha levels; chr1:108096081 chr1:108071482~108074519:+ LUSC cis rs1113500 0.897 rs4628530 ENSG00000226822.1 RP11-356N1.2 8.65 8.27e-17 1.09e-13 0.38 0.37 Growth-regulated protein alpha levels; chr1:108096086 chr1:108071482~108074519:+ LUSC cis rs11098499 0.863 rs7699064 ENSG00000249244.1 RP11-548H18.2 -8.65 8.27e-17 1.09e-13 -0.48 -0.37 Corneal astigmatism; chr4:119507154 chr4:119391831~119395335:- LUSC cis rs9322193 0.923 rs10782317 ENSG00000223701.3 RAET1E-AS1 -8.65 8.27e-17 1.09e-13 -0.43 -0.37 Lung cancer; chr6:149753911 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs12175504 ENSG00000216906.2 RP11-350J20.9 8.65 8.29e-17 1.09e-13 0.44 0.37 Lung cancer; chr6:149664079 chr6:149904243~149906418:+ LUSC cis rs9322193 0.962 rs62439843 ENSG00000216906.2 RP11-350J20.9 8.65 8.29e-17 1.09e-13 0.44 0.37 Lung cancer; chr6:149676521 chr6:149904243~149906418:+ LUSC cis rs10256972 0.685 rs10263665 ENSG00000229043.2 AC091729.9 -8.65 8.4e-17 1.11e-13 -0.43 -0.37 Endometriosis;Longevity; chr7:1070992 chr7:1160374~1165267:+ LUSC cis rs2549794 0.537 rs34755 ENSG00000248734.2 CTD-2260A17.1 -8.65 8.43e-17 1.11e-13 -0.34 -0.37 Crohn's disease; chr5:96816057 chr5:96784777~96785999:+ LUSC cis rs12439619 0.693 rs28689861 ENSG00000255769.6 GOLGA2P10 -8.65 8.43e-17 1.11e-13 -0.5 -0.37 Intelligence (multi-trait analysis); chr15:82206369 chr15:82472993~82513950:- LUSC cis rs8062405 0.691 rs743590 ENSG00000259982.1 CDC37P1 8.65 8.45e-17 1.11e-13 0.46 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28596909 chr16:28700294~28701540:- LUSC cis rs11098499 0.575 rs907204 ENSG00000245958.5 RP11-33B1.1 -8.65 8.47e-17 1.11e-13 -0.37 -0.37 Corneal astigmatism; chr4:119317499 chr4:119454791~119552025:+ LUSC cis rs11098499 0.575 rs907205 ENSG00000245958.5 RP11-33B1.1 -8.65 8.47e-17 1.11e-13 -0.37 -0.37 Corneal astigmatism; chr4:119317509 chr4:119454791~119552025:+ LUSC cis rs4141404 0.604 rs2103853 ENSG00000236132.1 CTA-440B3.1 -8.65 8.48e-17 1.11e-13 -0.45 -0.37 Paclitaxel-induced neuropathy; chr22:31459489 chr22:31816379~31817491:- LUSC cis rs1707322 0.927 rs11211194 ENSG00000280836.1 AL355480.1 -8.65 8.49e-17 1.12e-13 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45816412 chr1:45581219~45581321:- LUSC cis rs6921919 0.638 rs7772827 ENSG00000204709.4 LINC01556 8.65 8.51e-17 1.12e-13 0.51 0.37 Autism spectrum disorder or schizophrenia; chr6:28333366 chr6:28943877~28944537:+ LUSC cis rs11098499 0.863 rs1552092 ENSG00000249244.1 RP11-548H18.2 8.65 8.52e-17 1.12e-13 0.48 0.37 Corneal astigmatism; chr4:119567341 chr4:119391831~119395335:- LUSC cis rs10875746 0.68 rs4760610 ENSG00000240399.1 RP1-228P16.1 -8.65 8.52e-17 1.12e-13 -0.41 -0.37 Longevity (90 years and older); chr12:48024442 chr12:48054813~48055591:- LUSC cis rs10129255 0.957 rs8005468 ENSG00000211970.3 IGHV4-61 -8.64 8.55e-17 1.12e-13 -0.26 -0.37 Kawasaki disease; chr14:106686431 chr14:106639119~106639657:- LUSC cis rs4927850 1 rs7625570 ENSG00000231464.1 AC024937.4 8.64 8.56e-17 1.12e-13 0.4 0.37 Pancreatic cancer; chr3:196020527 chr3:195996738~195998233:+ LUSC cis rs9389248 0.69 rs6939543 ENSG00000232876.1 CTA-212D2.2 8.64 8.66e-17 1.14e-13 0.47 0.37 High light scatter reticulocyte percentage of red cells; chr6:134934005 chr6:135055033~135060550:+ LUSC cis rs10463554 0.927 rs40061 ENSG00000175749.11 EIF3KP1 8.64 8.78e-17 1.15e-13 0.45 0.37 Parkinson's disease; chr5:103067412 chr5:103032376~103033031:+ LUSC cis rs9487094 0.67 rs1998811 ENSG00000260273.1 RP11-425D10.10 8.64 8.86e-17 1.16e-13 0.43 0.37 Height; chr6:109490935 chr6:109382795~109383666:+ LUSC cis rs9341808 0.718 rs10943699 ENSG00000272129.1 RP11-250B2.6 8.64 8.86e-17 1.16e-13 0.45 0.37 Sitting height ratio; chr6:80230824 chr6:80355424~80356859:+ LUSC cis rs9918079 0.56 rs7438356 ENSG00000273133.1 RP11-799M12.2 -8.64 8.87e-17 1.16e-13 -0.49 -0.37 Obesity-related traits; chr4:15623147 chr4:15563698~15564253:- LUSC cis rs9389248 0.69 rs1028314 ENSG00000232876.1 CTA-212D2.2 8.64 8.9e-17 1.17e-13 0.47 0.37 High light scatter reticulocyte percentage of red cells; chr6:134934572 chr6:135055033~135060550:+ LUSC cis rs526231 0.511 rs28062 ENSG00000175749.11 EIF3KP1 8.64 8.92e-17 1.17e-13 0.45 0.37 Primary biliary cholangitis; chr5:103204500 chr5:103032376~103033031:+ LUSC cis rs5769707 0.616 rs6009786 ENSG00000235111.1 RP1-29C18.8 -8.64 8.96e-17 1.17e-13 -0.46 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49621497 chr22:49612657~49615716:- LUSC cis rs765787 0.53 rs11636395 ENSG00000259520.4 CTD-2651B20.3 8.64 8.96e-17 1.18e-13 0.47 0.37 Uric acid levels; chr15:45243486 chr15:45251580~45279251:- LUSC cis rs10463554 0.927 rs34373 ENSG00000175749.11 EIF3KP1 8.64 8.97e-17 1.18e-13 0.45 0.37 Parkinson's disease; chr5:103068590 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs158253 ENSG00000175749.11 EIF3KP1 8.64 8.97e-17 1.18e-13 0.45 0.37 Parkinson's disease; chr5:103069502 chr5:103032376~103033031:+ LUSC cis rs10463554 0.892 rs158252 ENSG00000175749.11 EIF3KP1 8.64 8.97e-17 1.18e-13 0.45 0.37 Parkinson's disease; chr5:103070546 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs154369 ENSG00000175749.11 EIF3KP1 8.64 8.97e-17 1.18e-13 0.45 0.37 Parkinson's disease; chr5:103071140 chr5:103032376~103033031:+ LUSC cis rs10463554 0.892 rs158246 ENSG00000175749.11 EIF3KP1 8.64 8.97e-17 1.18e-13 0.45 0.37 Parkinson's disease; chr5:103073145 chr5:103032376~103033031:+ LUSC cis rs3823536 0.583 rs6973975 ENSG00000275106.1 RP11-309L24.10 -8.64 9.04e-17 1.18e-13 -0.51 -0.37 Sjögren's syndrome; chr7:129035495 chr7:128952527~128953316:- LUSC cis rs7044106 0.791 rs10985000 ENSG00000226752.6 PSMD5-AS1 -8.64 9.1e-17 1.19e-13 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120721837 chr9:120824828~120854385:+ LUSC cis rs7044106 0.791 rs10985001 ENSG00000226752.6 PSMD5-AS1 -8.64 9.1e-17 1.19e-13 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120721954 chr9:120824828~120854385:+ LUSC cis rs11155671 0.53 rs9968871 ENSG00000268592.3 RAET1E-AS1 8.64 9.13e-17 1.2e-13 0.46 0.37 Testicular germ cell tumor; chr6:149888060 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs9969044 ENSG00000268592.3 RAET1E-AS1 8.64 9.13e-17 1.2e-13 0.46 0.37 Testicular germ cell tumor; chr6:149888068 chr6:149863494~149919507:+ LUSC cis rs9341808 0.618 rs6916507 ENSG00000272129.1 RP11-250B2.6 8.64 9.13e-17 1.2e-13 0.45 0.37 Sitting height ratio; chr6:80152548 chr6:80355424~80356859:+ LUSC cis rs9341808 0.65 rs6909546 ENSG00000272129.1 RP11-250B2.6 8.64 9.13e-17 1.2e-13 0.45 0.37 Sitting height ratio; chr6:80160206 chr6:80355424~80356859:+ LUSC cis rs7044106 0.791 rs4836829 ENSG00000226752.6 PSMD5-AS1 -8.63 9.2e-17 1.2e-13 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120720469 chr9:120824828~120854385:+ LUSC cis rs10463554 0.963 rs6596530 ENSG00000175749.11 EIF3KP1 8.63 9.24e-17 1.21e-13 0.45 0.37 Parkinson's disease; chr5:103035736 chr5:103032376~103033031:+ LUSC cis rs1707322 1 rs7532204 ENSG00000280836.1 AL355480.1 8.63 9.27e-17 1.21e-13 0.43 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46019403 chr1:45581219~45581321:- LUSC cis rs1707322 0.835 rs946525 ENSG00000280836.1 AL355480.1 8.63 9.27e-17 1.21e-13 0.43 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46021605 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs946524 ENSG00000280836.1 AL355480.1 8.63 9.27e-17 1.21e-13 0.43 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46021888 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4660336 ENSG00000280836.1 AL355480.1 8.63 9.27e-17 1.21e-13 0.43 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46022304 chr1:45581219~45581321:- LUSC cis rs9322193 0.962 rs35031906 ENSG00000216906.2 RP11-350J20.9 8.63 9.28e-17 1.21e-13 0.44 0.37 Lung cancer; chr6:149677438 chr6:149904243~149906418:+ LUSC cis rs17507216 0.718 rs28587782 ENSG00000278603.1 RP13-608F4.5 8.63 9.31e-17 1.22e-13 0.56 0.37 Excessive daytime sleepiness; chr15:82576881 chr15:82472203~82472426:+ LUSC cis rs9341808 0.718 rs10080237 ENSG00000272129.1 RP11-250B2.6 8.63 9.33e-17 1.22e-13 0.45 0.37 Sitting height ratio; chr6:80144753 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs2874829 ENSG00000272129.1 RP11-250B2.6 8.63 9.33e-17 1.22e-13 0.45 0.37 Sitting height ratio; chr6:80146380 chr6:80355424~80356859:+ LUSC cis rs9341808 0.69 rs2322634 ENSG00000272129.1 RP11-250B2.6 8.63 9.33e-17 1.22e-13 0.45 0.37 Sitting height ratio; chr6:80164297 chr6:80355424~80356859:+ LUSC cis rs7849270 1 rs10819471 ENSG00000268707.1 RP11-247A12.7 -8.63 9.34e-17 1.22e-13 -0.43 -0.37 Blood metabolite ratios; chr9:129134046 chr9:129170434~129170940:+ LUSC cis rs1707322 1 rs1707322 ENSG00000280836.1 AL355480.1 -8.63 9.35e-17 1.22e-13 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46039475 chr1:45581219~45581321:- LUSC cis rs7208859 0.673 rs423151 ENSG00000263531.1 RP13-753N3.1 8.63 9.35e-17 1.22e-13 0.59 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30625268 chr17:30863921~30864940:- LUSC cis rs9322193 0.923 rs9766004 ENSG00000223701.3 RAET1E-AS1 8.63 9.38e-17 1.23e-13 0.43 0.37 Lung cancer; chr6:149754363 chr6:149884431~149919508:+ LUSC cis rs7189233 0.531 rs8061398 ENSG00000279344.1 RP11-44F14.7 8.63 9.38e-17 1.23e-13 0.33 0.37 Intelligence (multi-trait analysis); chr16:53420239 chr16:53478957~53481550:- LUSC cis rs11098499 0.754 rs2036857 ENSG00000245958.5 RP11-33B1.1 -8.63 9.43e-17 1.23e-13 -0.37 -0.37 Corneal astigmatism; chr4:119328085 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs2036856 ENSG00000245958.5 RP11-33B1.1 -8.63 9.43e-17 1.23e-13 -0.37 -0.37 Corneal astigmatism; chr4:119328133 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs4443261 ENSG00000245958.5 RP11-33B1.1 -8.63 9.43e-17 1.23e-13 -0.37 -0.37 Corneal astigmatism; chr4:119328146 chr4:119454791~119552025:+ LUSC cis rs694739 1 rs11231757 ENSG00000236935.1 AP003774.1 8.63 9.44e-17 1.23e-13 0.36 0.37 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338845 chr11:64325050~64329504:- LUSC cis rs12134133 0.962 rs17258843 ENSG00000274245.1 RP11-357P18.2 8.63 9.46e-17 1.24e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207241387 chr1:207372559~207373252:+ LUSC cis rs11089937 0.963 rs2073454 ENSG00000211639.2 IGLV4-60 8.63 9.47e-17 1.24e-13 0.37 0.37 Periodontitis (PAL4Q3); chr22:22163086 chr22:22162199~22162681:+ LUSC cis rs1707322 0.964 rs10890358 ENSG00000280836.1 AL355480.1 -8.63 9.48e-17 1.24e-13 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853353 chr1:45581219~45581321:- LUSC cis rs6921919 0.848 rs9468350 ENSG00000204709.4 LINC01556 8.63 9.48e-17 1.24e-13 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28351330 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs1947862 ENSG00000219392.1 RP1-265C24.5 -8.63 9.53e-17 1.25e-13 -0.52 -0.37 Depression; chr6:28137418 chr6:28115628~28116551:+ LUSC cis rs9341808 0.754 rs3805885 ENSG00000272129.1 RP11-250B2.6 -8.63 9.55e-17 1.25e-13 -0.45 -0.37 Sitting height ratio; chr6:80287034 chr6:80355424~80356859:+ LUSC cis rs10463554 0.927 rs185387 ENSG00000175749.11 EIF3KP1 8.63 9.56e-17 1.25e-13 0.44 0.37 Parkinson's disease; chr5:103084315 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs257315 ENSG00000175749.11 EIF3KP1 8.63 9.56e-17 1.25e-13 0.44 0.37 Parkinson's disease; chr5:103085725 chr5:103032376~103033031:+ LUSC cis rs9389248 0.69 rs2294321 ENSG00000232876.1 CTA-212D2.2 8.63 9.61e-17 1.26e-13 0.47 0.37 High light scatter reticulocyte percentage of red cells; chr6:134931910 chr6:135055033~135060550:+ LUSC cis rs9399135 0.507 rs2072825 ENSG00000232876.1 CTA-212D2.2 8.63 9.61e-17 1.26e-13 0.47 0.37 Red blood cell count; chr6:134932313 chr6:135055033~135060550:+ LUSC cis rs9389248 0.69 rs2072826 ENSG00000232876.1 CTA-212D2.2 8.63 9.61e-17 1.26e-13 0.47 0.37 High light scatter reticulocyte percentage of red cells; chr6:134932420 chr6:135055033~135060550:+ LUSC cis rs9918079 0.56 rs13147590 ENSG00000273133.1 RP11-799M12.2 8.63 9.62e-17 1.26e-13 0.49 0.37 Obesity-related traits; chr4:15619565 chr4:15563698~15564253:- LUSC cis rs9487094 0.67 rs729888 ENSG00000260273.1 RP11-425D10.10 -8.63 9.73e-17 1.27e-13 -0.44 -0.37 Height; chr6:109636120 chr6:109382795~109383666:+ LUSC cis rs2455601 1 rs12418190 ENSG00000254860.4 TMEM9B-AS1 8.63 9.75e-17 1.27e-13 0.55 0.37 Schizophrenia; chr11:8878271 chr11:8964675~8977527:+ LUSC cis rs4728142 0.625 rs4731533 ENSG00000275106.1 RP11-309L24.10 -8.63 9.75e-17 1.27e-13 -0.47 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128962088 chr7:128952527~128953316:- LUSC cis rs1707322 0.963 rs4508055 ENSG00000280836.1 AL355480.1 -8.63 9.77e-17 1.28e-13 -0.46 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45792059 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs12076580 ENSG00000280836.1 AL355480.1 -8.63 9.77e-17 1.28e-13 -0.46 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45792487 chr1:45581219~45581321:- LUSC cis rs11155671 0.53 rs9371542 ENSG00000268592.3 RAET1E-AS1 8.63 9.78e-17 1.28e-13 0.46 0.37 Testicular germ cell tumor; chr6:149891949 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs9371223 ENSG00000268592.3 RAET1E-AS1 8.63 9.78e-17 1.28e-13 0.46 0.37 Testicular germ cell tumor; chr6:149893670 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs35443312 ENSG00000216906.2 RP11-350J20.9 8.63 9.8e-17 1.28e-13 0.44 0.37 Lung cancer; chr6:149670625 chr6:149904243~149906418:+ LUSC cis rs9341808 0.718 rs2322636 ENSG00000272129.1 RP11-250B2.6 8.63 9.84e-17 1.28e-13 0.46 0.37 Sitting height ratio; chr6:80187719 chr6:80355424~80356859:+ LUSC cis rs7174755 0.923 rs4777036 ENSG00000260657.2 RP11-315D16.4 -8.63 9.85e-17 1.28e-13 -0.44 -0.37 Major depressive disorder; chr15:68313230 chr15:68267792~68277994:- LUSC cis rs11098499 0.863 rs11098532 ENSG00000245958.5 RP11-33B1.1 -8.63 9.89e-17 1.29e-13 -0.37 -0.37 Corneal astigmatism; chr4:119569571 chr4:119454791~119552025:+ LUSC cis rs12439619 0.693 rs17269819 ENSG00000255769.6 GOLGA2P10 -8.62 9.91e-17 1.29e-13 -0.5 -0.37 Intelligence (multi-trait analysis); chr15:82174660 chr15:82472993~82513950:- LUSC cis rs12439619 0.846 rs62012059 ENSG00000255769.6 GOLGA2P10 -8.62 9.95e-17 1.3e-13 -0.52 -0.37 Intelligence (multi-trait analysis); chr15:82251669 chr15:82472993~82513950:- LUSC cis rs11098499 0.863 rs6833334 ENSG00000249244.1 RP11-548H18.2 8.62 1e-16 1.31e-13 0.47 0.37 Corneal astigmatism; chr4:119583072 chr4:119391831~119395335:- LUSC cis rs12134133 1 rs11584921 ENSG00000274245.1 RP11-357P18.2 8.62 1e-16 1.31e-13 0.49 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207268630 chr1:207372559~207373252:+ LUSC cis rs10256972 0.786 rs3735686 ENSG00000229043.2 AC091729.9 -8.62 1.01e-16 1.31e-13 -0.43 -0.37 Endometriosis;Longevity; chr7:1022891 chr7:1160374~1165267:+ LUSC cis rs6991838 0.831 rs11992528 ENSG00000272010.1 CTD-3025N20.3 8.62 1.01e-16 1.32e-13 0.4 0.37 Intelligence (multi-trait analysis); chr8:65561644 chr8:65591850~65592472:- LUSC cis rs7617773 0.78 rs13067450 ENSG00000228638.1 FCF1P2 -8.62 1.01e-16 1.32e-13 -0.43 -0.37 Coronary artery disease; chr3:48295716 chr3:48290793~48291375:- LUSC cis rs7617773 0.78 rs4479622 ENSG00000228638.1 FCF1P2 -8.62 1.01e-16 1.32e-13 -0.43 -0.37 Coronary artery disease; chr3:48296683 chr3:48290793~48291375:- LUSC cis rs7617773 0.78 rs34946886 ENSG00000228638.1 FCF1P2 -8.62 1.01e-16 1.32e-13 -0.43 -0.37 Coronary artery disease; chr3:48296997 chr3:48290793~48291375:- LUSC cis rs7617773 0.78 rs34589064 ENSG00000228638.1 FCF1P2 -8.62 1.01e-16 1.32e-13 -0.43 -0.37 Coronary artery disease; chr3:48298059 chr3:48290793~48291375:- LUSC cis rs7617773 0.78 rs2541 ENSG00000228638.1 FCF1P2 -8.62 1.01e-16 1.32e-13 -0.43 -0.37 Coronary artery disease; chr3:48298128 chr3:48290793~48291375:- LUSC cis rs7617773 0.78 rs13085251 ENSG00000228638.1 FCF1P2 -8.62 1.01e-16 1.32e-13 -0.43 -0.37 Coronary artery disease; chr3:48298555 chr3:48290793~48291375:- LUSC cis rs7044106 0.791 rs10984994 ENSG00000226752.6 PSMD5-AS1 8.62 1.01e-16 1.32e-13 0.43 0.37 Hip circumference adjusted for BMI; chr9:120716491 chr9:120824828~120854385:+ LUSC cis rs7189233 0.531 rs1072911 ENSG00000279344.1 RP11-44F14.7 8.62 1.01e-16 1.32e-13 0.32 0.37 Intelligence (multi-trait analysis); chr16:53465813 chr16:53478957~53481550:- LUSC cis rs10129255 0.784 rs7147210 ENSG00000211970.3 IGHV4-61 -8.62 1.03e-16 1.34e-13 -0.27 -0.37 Kawasaki disease; chr14:106705271 chr14:106639119~106639657:- LUSC cis rs10129255 0.826 rs7150693 ENSG00000211970.3 IGHV4-61 -8.62 1.03e-16 1.34e-13 -0.27 -0.37 Kawasaki disease; chr14:106705382 chr14:106639119~106639657:- LUSC cis rs10129255 0.869 rs7150549 ENSG00000211970.3 IGHV4-61 -8.62 1.03e-16 1.34e-13 -0.27 -0.37 Kawasaki disease; chr14:106705441 chr14:106639119~106639657:- LUSC cis rs9322193 0.543 rs9371533 ENSG00000268592.3 RAET1E-AS1 8.62 1.03e-16 1.34e-13 0.46 0.37 Lung cancer; chr6:149889545 chr6:149863494~149919507:+ LUSC cis rs10463554 0.892 rs10434791 ENSG00000175749.11 EIF3KP1 8.62 1.03e-16 1.34e-13 0.44 0.37 Parkinson's disease; chr5:103053768 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs34382 ENSG00000175749.11 EIF3KP1 8.62 1.03e-16 1.34e-13 0.44 0.37 Parkinson's disease; chr5:103060521 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs34380 ENSG00000175749.11 EIF3KP1 8.62 1.03e-16 1.34e-13 0.44 0.37 Parkinson's disease; chr5:103061245 chr5:103032376~103033031:+ LUSC cis rs5769707 0.656 rs135878 ENSG00000235111.1 RP1-29C18.8 -8.62 1.03e-16 1.34e-13 -0.47 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49620721 chr22:49612657~49615716:- LUSC cis rs10129255 0.957 rs17113284 ENSG00000211972.2 IGHV3-66 -8.62 1.03e-16 1.34e-13 -0.27 -0.37 Kawasaki disease; chr14:106684476 chr14:106675017~106675544:- LUSC cis rs12134133 0.962 rs11120512 ENSG00000274245.1 RP11-357P18.2 -8.62 1.03e-16 1.35e-13 -0.48 -0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207240370 chr1:207372559~207373252:+ LUSC cis rs7189233 0.531 rs17801498 ENSG00000279344.1 RP11-44F14.7 8.62 1.04e-16 1.35e-13 0.31 0.37 Intelligence (multi-trait analysis); chr16:53479540 chr16:53478957~53481550:- LUSC cis rs4713118 0.547 rs2116981 ENSG00000219392.1 RP1-265C24.5 -8.62 1.04e-16 1.35e-13 -0.52 -0.37 Parkinson's disease; chr6:28100173 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9368552 ENSG00000219392.1 RP1-265C24.5 -8.62 1.04e-16 1.35e-13 -0.52 -0.37 Depression; chr6:28100648 chr6:28115628~28116551:+ LUSC cis rs853679 0.542 rs34131763 ENSG00000219392.1 RP1-265C24.5 -8.62 1.04e-16 1.35e-13 -0.52 -0.37 Depression; chr6:28107222 chr6:28115628~28116551:+ LUSC cis rs10463554 0.927 rs158245 ENSG00000175749.11 EIF3KP1 8.62 1.04e-16 1.35e-13 0.45 0.37 Parkinson's disease; chr5:103073801 chr5:103032376~103033031:+ LUSC cis rs1185460 0.565 rs584115 ENSG00000271751.1 RP11-110I1.14 8.62 1.04e-16 1.35e-13 0.48 0.37 Coronary artery disease; chr11:119068169 chr11:119065263~119065677:- LUSC cis rs1113500 0.933 rs10881497 ENSG00000226822.1 RP11-356N1.2 -8.62 1.04e-16 1.35e-13 -0.38 -0.37 Growth-regulated protein alpha levels; chr1:108091893 chr1:108071482~108074519:+ LUSC cis rs11098499 0.863 rs3775847 ENSG00000249244.1 RP11-548H18.2 8.62 1.04e-16 1.35e-13 0.48 0.37 Corneal astigmatism; chr4:119526487 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3775848 ENSG00000249244.1 RP11-548H18.2 8.62 1.04e-16 1.35e-13 0.48 0.37 Corneal astigmatism; chr4:119526569 chr4:119391831~119395335:- LUSC cis rs8072100 0.744 rs34537623 ENSG00000228782.6 CTD-2026D20.3 8.62 1.04e-16 1.36e-13 0.35 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47452837 chr17:47450568~47492492:- LUSC cis rs1707322 1 rs785469 ENSG00000280836.1 AL355480.1 8.62 1.04e-16 1.36e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055419 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs785468 ENSG00000280836.1 AL355480.1 8.62 1.04e-16 1.36e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055845 chr1:45581219~45581321:- LUSC cis rs7044106 0.791 rs10984995 ENSG00000226752.6 PSMD5-AS1 -8.62 1.05e-16 1.36e-13 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120716932 chr9:120824828~120854385:+ LUSC cis rs10129255 0.957 rs8009464 ENSG00000211970.3 IGHV4-61 -8.62 1.05e-16 1.36e-13 -0.26 -0.37 Kawasaki disease; chr14:106777611 chr14:106639119~106639657:- LUSC cis rs17608059 0.518 rs4792436 ENSG00000141028.6 CDRT15P1 8.62 1.06e-16 1.37e-13 0.41 0.37 Temperament; chr17:14068990 chr17:14024514~14025488:+ LUSC cis rs2283792 0.871 rs8136867 ENSG00000228050.1 TOP3BP1 8.62 1.06e-16 1.37e-13 0.43 0.37 Multiple sclerosis; chr22:21850504 chr22:22223187~22224566:- LUSC cis rs9918079 0.56 rs10008376 ENSG00000273133.1 RP11-799M12.2 8.62 1.06e-16 1.38e-13 0.48 0.37 Obesity-related traits; chr4:15622332 chr4:15563698~15564253:- LUSC cis rs8062405 0.721 rs151303 ENSG00000259982.1 CDC37P1 8.62 1.06e-16 1.38e-13 0.46 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28481189 chr16:28700294~28701540:- LUSC cis rs11098499 0.954 rs9998585 ENSG00000249244.1 RP11-548H18.2 8.61 1.07e-16 1.39e-13 0.48 0.37 Corneal astigmatism; chr4:119475647 chr4:119391831~119395335:- LUSC cis rs9341808 0.718 rs2322630 ENSG00000272129.1 RP11-250B2.6 8.61 1.08e-16 1.4e-13 0.45 0.37 Sitting height ratio; chr6:80131316 chr6:80355424~80356859:+ LUSC cis rs62388641 0.813 rs34779492 ENSG00000272279.1 RP11-157J24.2 8.61 1.08e-16 1.4e-13 0.61 0.37 Daytime sleep phenotypes; chr6:1547737 chr6:1528364~1528911:- LUSC cis rs11098499 0.863 rs1155576 ENSG00000249244.1 RP11-548H18.2 8.61 1.08e-16 1.4e-13 0.48 0.37 Corneal astigmatism; chr4:119529004 chr4:119391831~119395335:- LUSC cis rs7617773 0.779 rs9833309 ENSG00000228638.1 FCF1P2 -8.61 1.08e-16 1.4e-13 -0.43 -0.37 Coronary artery disease; chr3:48285960 chr3:48290793~48291375:- LUSC cis rs7617773 0.817 rs9853804 ENSG00000228638.1 FCF1P2 -8.61 1.08e-16 1.4e-13 -0.43 -0.37 Coronary artery disease; chr3:48286239 chr3:48290793~48291375:- LUSC cis rs7617773 0.817 rs9834095 ENSG00000228638.1 FCF1P2 -8.61 1.08e-16 1.4e-13 -0.43 -0.37 Coronary artery disease; chr3:48286261 chr3:48290793~48291375:- LUSC cis rs7617773 0.817 rs4131361 ENSG00000228638.1 FCF1P2 -8.61 1.08e-16 1.4e-13 -0.43 -0.37 Coronary artery disease; chr3:48287322 chr3:48290793~48291375:- LUSC cis rs7617773 0.817 rs4131362 ENSG00000228638.1 FCF1P2 -8.61 1.08e-16 1.4e-13 -0.43 -0.37 Coronary artery disease; chr3:48287546 chr3:48290793~48291375:- LUSC cis rs11098499 0.863 rs3733525 ENSG00000249244.1 RP11-548H18.2 8.61 1.08e-16 1.41e-13 0.48 0.37 Corneal astigmatism; chr4:119525893 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs938056 ENSG00000245958.5 RP11-33B1.1 -8.61 1.09e-16 1.42e-13 -0.37 -0.37 Corneal astigmatism; chr4:119316298 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs59732491 ENSG00000249244.1 RP11-548H18.2 8.61 1.09e-16 1.42e-13 0.47 0.37 Corneal astigmatism; chr4:119568433 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs11723090 ENSG00000249244.1 RP11-548H18.2 8.61 1.09e-16 1.42e-13 0.47 0.37 Corneal astigmatism; chr4:119569437 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs1383533 ENSG00000245958.5 RP11-33B1.1 -8.61 1.09e-16 1.42e-13 -0.37 -0.37 Corneal astigmatism; chr4:119513421 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs2291185 ENSG00000245958.5 RP11-33B1.1 -8.61 1.09e-16 1.42e-13 -0.37 -0.37 Corneal astigmatism; chr4:119513678 chr4:119454791~119552025:+ LUSC cis rs1707322 1 rs1707337 ENSG00000280836.1 AL355480.1 8.61 1.1e-16 1.43e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46043097 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs1768807 ENSG00000280836.1 AL355480.1 8.61 1.1e-16 1.43e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46044898 chr1:45581219~45581321:- LUSC cis rs694739 1 rs1783521 ENSG00000236935.1 AP003774.1 8.61 1.11e-16 1.43e-13 0.35 0.37 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338819 chr11:64325050~64329504:- LUSC cis rs26232 0.526 rs61654927 ENSG00000175749.11 EIF3KP1 8.61 1.12e-16 1.46e-13 0.45 0.37 Rheumatoid arthritis; chr5:103047021 chr5:103032376~103033031:+ LUSC cis rs10463554 0.892 rs59292735 ENSG00000175749.11 EIF3KP1 8.61 1.12e-16 1.46e-13 0.45 0.37 Parkinson's disease; chr5:103047047 chr5:103032376~103033031:+ LUSC cis rs4927850 1 rs10881563 ENSG00000231464.1 AC024937.4 8.61 1.13e-16 1.46e-13 0.4 0.37 Pancreatic cancer; chr3:196023354 chr3:195996738~195998233:+ LUSC cis rs1707322 1 rs4660334 ENSG00000280836.1 AL355480.1 -8.61 1.13e-16 1.46e-13 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45996454 chr1:45581219~45581321:- LUSC cis rs8062405 0.756 rs151182 ENSG00000259982.1 CDC37P1 8.61 1.13e-16 1.47e-13 0.46 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28484431 chr16:28700294~28701540:- LUSC cis rs8072100 0.84 rs12452796 ENSG00000228782.6 CTD-2026D20.3 -8.61 1.13e-16 1.47e-13 -0.35 -0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402367 chr17:47450568~47492492:- LUSC cis rs10463554 0.857 rs158397 ENSG00000175749.11 EIF3KP1 8.61 1.14e-16 1.47e-13 0.45 0.37 Parkinson's disease; chr5:103076497 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs158399 ENSG00000175749.11 EIF3KP1 8.61 1.14e-16 1.47e-13 0.45 0.37 Parkinson's disease; chr5:103077564 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs158404 ENSG00000175749.11 EIF3KP1 8.61 1.14e-16 1.47e-13 0.45 0.37 Parkinson's disease; chr5:103080206 chr5:103032376~103033031:+ LUSC cis rs10463554 0.892 rs257305 ENSG00000175749.11 EIF3KP1 8.61 1.14e-16 1.47e-13 0.45 0.37 Parkinson's disease; chr5:103081533 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs257306 ENSG00000175749.11 EIF3KP1 8.61 1.14e-16 1.47e-13 0.45 0.37 Parkinson's disease; chr5:103081770 chr5:103032376~103033031:+ LUSC cis rs10463554 0.892 rs257307 ENSG00000175749.11 EIF3KP1 8.61 1.14e-16 1.47e-13 0.45 0.37 Parkinson's disease; chr5:103081805 chr5:103032376~103033031:+ LUSC cis rs7044106 0.791 rs735110 ENSG00000226752.6 PSMD5-AS1 -8.61 1.15e-16 1.48e-13 -0.42 -0.37 Hip circumference adjusted for BMI; chr9:120726662 chr9:120824828~120854385:+ LUSC cis rs11098499 0.754 rs878376 ENSG00000245958.5 RP11-33B1.1 -8.61 1.15e-16 1.48e-13 -0.37 -0.37 Corneal astigmatism; chr4:119316547 chr4:119454791~119552025:+ LUSC cis rs11098499 0.789 rs9991166 ENSG00000245958.5 RP11-33B1.1 -8.61 1.15e-16 1.48e-13 -0.37 -0.37 Corneal astigmatism; chr4:119316696 chr4:119454791~119552025:+ LUSC cis rs11098499 0.708 rs10005237 ENSG00000245958.5 RP11-33B1.1 -8.61 1.15e-16 1.48e-13 -0.37 -0.37 Corneal astigmatism; chr4:119316742 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs10213267 ENSG00000245958.5 RP11-33B1.1 -8.61 1.15e-16 1.48e-13 -0.37 -0.37 Corneal astigmatism; chr4:119317919 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs10212775 ENSG00000245958.5 RP11-33B1.1 -8.61 1.15e-16 1.48e-13 -0.37 -0.37 Corneal astigmatism; chr4:119318089 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs11732087 ENSG00000245958.5 RP11-33B1.1 -8.61 1.15e-16 1.48e-13 -0.37 -0.37 Corneal astigmatism; chr4:119318676 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs2964 ENSG00000245958.5 RP11-33B1.1 -8.61 1.15e-16 1.48e-13 -0.37 -0.37 Corneal astigmatism; chr4:119318976 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs1511025 ENSG00000245958.5 RP11-33B1.1 -8.61 1.15e-16 1.48e-13 -0.37 -0.37 Corneal astigmatism; chr4:119319083 chr4:119454791~119552025:+ LUSC cis rs765787 0.505 rs4439707 ENSG00000259520.4 CTD-2651B20.3 -8.61 1.15e-16 1.49e-13 -0.47 -0.37 Uric acid levels; chr15:45232018 chr15:45251580~45279251:- LUSC cis rs1707322 0.964 rs6675259 ENSG00000280836.1 AL355480.1 8.61 1.15e-16 1.49e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46036623 chr1:45581219~45581321:- LUSC cis rs10463554 0.856 rs26427 ENSG00000175749.11 EIF3KP1 -8.6 1.16e-16 1.5e-13 -0.43 -0.37 Parkinson's disease; chr5:103031079 chr5:103032376~103033031:+ LUSC cis rs2739330 0.828 rs5760098 ENSG00000231271.1 AP000350.8 8.6 1.16e-16 1.5e-13 0.49 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23949918~23954042:+ LUSC cis rs2739330 0.828 rs5760102 ENSG00000231271.1 AP000350.8 8.6 1.16e-16 1.5e-13 0.49 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23949918~23954042:+ LUSC cis rs10129255 0.912 rs61996059 ENSG00000211970.3 IGHV4-61 -8.6 1.17e-16 1.51e-13 -0.27 -0.37 Kawasaki disease; chr14:106716897 chr14:106639119~106639657:- LUSC cis rs11098499 0.909 rs79026312 ENSG00000249244.1 RP11-548H18.2 8.6 1.17e-16 1.51e-13 0.48 0.37 Corneal astigmatism; chr4:119519522 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs35111518 ENSG00000249244.1 RP11-548H18.2 8.6 1.17e-16 1.51e-13 0.48 0.37 Corneal astigmatism; chr4:119519527 chr4:119391831~119395335:- LUSC cis rs9487094 0.961 rs3778475 ENSG00000260273.1 RP11-425D10.10 8.6 1.19e-16 1.53e-13 0.45 0.37 Height; chr6:109375003 chr6:109382795~109383666:+ LUSC cis rs1707322 0.929 rs785513 ENSG00000280836.1 AL355480.1 8.6 1.19e-16 1.53e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46072648 chr1:45581219~45581321:- LUSC cis rs9660180 0.934 rs12729990 ENSG00000268575.1 RP1-283E3.8 -8.6 1.2e-16 1.54e-13 -0.33 -0.37 Body mass index; chr1:1880596 chr1:1702736~1737688:- LUSC cis rs11098499 0.863 rs13140391 ENSG00000249244.1 RP11-548H18.2 8.6 1.2e-16 1.54e-13 0.47 0.37 Corneal astigmatism; chr4:119582282 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs13140409 ENSG00000249244.1 RP11-548H18.2 8.6 1.2e-16 1.54e-13 0.47 0.37 Corneal astigmatism; chr4:119582305 chr4:119391831~119395335:- LUSC cis rs11098499 0.722 rs7673476 ENSG00000245958.5 RP11-33B1.1 -8.6 1.21e-16 1.55e-13 -0.36 -0.37 Corneal astigmatism; chr4:119327528 chr4:119454791~119552025:+ LUSC cis rs8072100 0.84 rs2136751 ENSG00000228782.6 CTD-2026D20.3 8.6 1.21e-16 1.56e-13 0.35 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47378727 chr17:47450568~47492492:- LUSC cis rs9918079 0.56 rs4698409 ENSG00000273133.1 RP11-799M12.2 -8.6 1.21e-16 1.56e-13 -0.49 -0.37 Obesity-related traits; chr4:15658143 chr4:15563698~15564253:- LUSC cis rs35955747 0.869 rs131213 ENSG00000236132.1 CTA-440B3.1 -8.6 1.21e-16 1.56e-13 -0.43 -0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31357863 chr22:31816379~31817491:- LUSC cis rs62229266 0.557 rs4817761 ENSG00000231106.2 LINC01436 8.6 1.22e-16 1.57e-13 0.5 0.37 Mitral valve prolapse; chr21:36023258 chr21:36005338~36007838:+ LUSC cis rs11155671 0.53 rs2342770 ENSG00000268592.3 RAET1E-AS1 8.6 1.22e-16 1.58e-13 0.45 0.37 Testicular germ cell tumor; chr6:149895549 chr6:149863494~149919507:+ LUSC cis rs2739330 0.796 rs2154594 ENSG00000231271.1 AP000350.8 -8.6 1.23e-16 1.58e-13 -0.48 -0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23949918~23954042:+ LUSC cis rs12134133 1 rs7522618 ENSG00000274245.1 RP11-357P18.2 8.6 1.23e-16 1.59e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207244081 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs11580382 ENSG00000274245.1 RP11-357P18.2 8.6 1.23e-16 1.59e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207245047 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs11580387 ENSG00000274245.1 RP11-357P18.2 8.6 1.23e-16 1.59e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207245063 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs7518565 ENSG00000274245.1 RP11-357P18.2 8.6 1.23e-16 1.59e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207246998 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs7532664 ENSG00000274245.1 RP11-357P18.2 8.6 1.23e-16 1.59e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207253598 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs55638602 ENSG00000274245.1 RP11-357P18.2 8.6 1.23e-16 1.59e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207255597 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs4844588 ENSG00000274245.1 RP11-357P18.2 8.6 1.23e-16 1.59e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207256323 chr1:207372559~207373252:+ LUSC cis rs1707322 1 rs4660906 ENSG00000280836.1 AL355480.1 -8.6 1.23e-16 1.59e-13 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46005188 chr1:45581219~45581321:- LUSC cis rs6471393 0.964 rs16916186 ENSG00000253848.1 RP11-10N23.5 8.6 1.24e-16 1.6e-13 0.46 0.37 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93733158 chr8:93741193~93744534:+ LUSC cis rs9341808 0.754 rs978814 ENSG00000272129.1 RP11-250B2.6 8.59 1.25e-16 1.6e-13 0.45 0.37 Sitting height ratio; chr6:80250195 chr6:80355424~80356859:+ LUSC cis rs11098499 0.863 rs34868248 ENSG00000249244.1 RP11-548H18.2 8.59 1.26e-16 1.62e-13 0.48 0.37 Corneal astigmatism; chr4:119521275 chr4:119391831~119395335:- LUSC cis rs12439619 0.846 rs62011975 ENSG00000255769.6 GOLGA2P10 -8.59 1.27e-16 1.63e-13 -0.52 -0.37 Intelligence (multi-trait analysis); chr15:82159213 chr15:82472993~82513950:- LUSC cis rs10129255 0.5 rs11627315 ENSG00000211972.2 IGHV3-66 8.59 1.28e-16 1.65e-13 0.25 0.37 Kawasaki disease; chr14:106802182 chr14:106675017~106675544:- LUSC cis rs7189233 0.531 rs13332071 ENSG00000279344.1 RP11-44F14.7 8.59 1.28e-16 1.65e-13 0.32 0.37 Intelligence (multi-trait analysis); chr16:53409724 chr16:53478957~53481550:- LUSC cis rs11098499 0.863 rs12498539 ENSG00000245958.5 RP11-33B1.1 -8.59 1.29e-16 1.65e-13 -0.37 -0.37 Corneal astigmatism; chr4:119547215 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs1010739 ENSG00000245958.5 RP11-33B1.1 -8.59 1.29e-16 1.66e-13 -0.37 -0.37 Corneal astigmatism; chr4:119542316 chr4:119454791~119552025:+ LUSC cis rs7189233 0.513 rs8044091 ENSG00000279344.1 RP11-44F14.7 8.59 1.3e-16 1.67e-13 0.32 0.37 Intelligence (multi-trait analysis); chr16:53487086 chr16:53478957~53481550:- LUSC cis rs11098499 0.754 rs12506610 ENSG00000245958.5 RP11-33B1.1 -8.59 1.3e-16 1.67e-13 -0.37 -0.37 Corneal astigmatism; chr4:119320504 chr4:119454791~119552025:+ LUSC cis rs11098499 0.743 rs10003567 ENSG00000245958.5 RP11-33B1.1 -8.59 1.3e-16 1.67e-13 -0.37 -0.37 Corneal astigmatism; chr4:119320519 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs10006259 ENSG00000245958.5 RP11-33B1.1 -8.59 1.3e-16 1.67e-13 -0.37 -0.37 Corneal astigmatism; chr4:119320990 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs28652763 ENSG00000245958.5 RP11-33B1.1 -8.59 1.3e-16 1.67e-13 -0.37 -0.37 Corneal astigmatism; chr4:119321157 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs56397000 ENSG00000223701.3 RAET1E-AS1 8.59 1.3e-16 1.67e-13 0.43 0.37 Lung cancer; chr6:149739347 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs9689702 ENSG00000223701.3 RAET1E-AS1 8.59 1.3e-16 1.67e-13 0.43 0.37 Lung cancer; chr6:149740720 chr6:149884431~149919508:+ LUSC cis rs9341808 0.718 rs2179842 ENSG00000272129.1 RP11-250B2.6 8.59 1.3e-16 1.67e-13 0.44 0.37 Sitting height ratio; chr6:80269336 chr6:80355424~80356859:+ LUSC cis rs9322193 0.923 rs4870052 ENSG00000223701.3 RAET1E-AS1 8.59 1.31e-16 1.68e-13 0.44 0.37 Lung cancer; chr6:149839978 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs2342764 ENSG00000223701.3 RAET1E-AS1 8.59 1.31e-16 1.68e-13 0.43 0.37 Lung cancer; chr6:149835068 chr6:149884431~149919508:+ LUSC cis rs10463554 0.667 rs57714862 ENSG00000175749.11 EIF3KP1 8.59 1.31e-16 1.68e-13 0.44 0.37 Parkinson's disease; chr5:103047025 chr5:103032376~103033031:+ LUSC cis rs9487094 0.885 rs12524273 ENSG00000260273.1 RP11-425D10.10 8.59 1.33e-16 1.71e-13 0.45 0.37 Height; chr6:109395761 chr6:109382795~109383666:+ LUSC cis rs2283792 1 rs5749806 ENSG00000228050.1 TOP3BP1 8.59 1.33e-16 1.71e-13 0.43 0.37 Multiple sclerosis; chr22:21752329 chr22:22223187~22224566:- LUSC cis rs9322193 0.566 rs9397070 ENSG00000216906.2 RP11-350J20.9 -8.59 1.34e-16 1.72e-13 -0.5 -0.37 Lung cancer; chr6:149922073 chr6:149904243~149906418:+ LUSC cis rs9487094 0.961 rs12193493 ENSG00000260273.1 RP11-425D10.10 8.58 1.34e-16 1.72e-13 0.45 0.37 Height; chr6:109371573 chr6:109382795~109383666:+ LUSC cis rs11098499 0.863 rs3822194 ENSG00000245958.5 RP11-33B1.1 -8.58 1.35e-16 1.73e-13 -0.37 -0.37 Corneal astigmatism; chr4:119550493 chr4:119454791~119552025:+ LUSC cis rs9322193 1 rs9322193 ENSG00000216906.2 RP11-350J20.9 8.58 1.35e-16 1.73e-13 0.44 0.37 Lung cancer; chr6:149598007 chr6:149904243~149906418:+ LUSC cis rs17507216 0.588 rs28864981 ENSG00000278603.1 RP13-608F4.5 8.58 1.37e-16 1.75e-13 0.56 0.37 Excessive daytime sleepiness; chr15:82695420 chr15:82472203~82472426:+ LUSC cis rs853679 0.517 rs9468297 ENSG00000219392.1 RP1-265C24.5 -8.58 1.37e-16 1.76e-13 -0.52 -0.37 Depression; chr6:28151096 chr6:28115628~28116551:+ LUSC cis rs7044106 0.762 rs3904197 ENSG00000226752.6 PSMD5-AS1 -8.58 1.37e-16 1.76e-13 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120718100 chr9:120824828~120854385:+ LUSC cis rs2739330 0.828 rs4822451 ENSG00000231271.1 AP000350.8 8.58 1.37e-16 1.76e-13 0.49 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23949918~23954042:+ LUSC cis rs2739330 0.828 rs5760099 ENSG00000231271.1 AP000350.8 8.58 1.37e-16 1.76e-13 0.49 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23949918~23954042:+ LUSC cis rs7044106 0.791 rs4837792 ENSG00000226752.6 PSMD5-AS1 -8.58 1.37e-16 1.76e-13 -0.42 -0.37 Hip circumference adjusted for BMI; chr9:120721281 chr9:120824828~120854385:+ LUSC cis rs6921919 0.789 rs6456814 ENSG00000204709.4 LINC01556 8.58 1.38e-16 1.77e-13 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28338035 chr6:28943877~28944537:+ LUSC cis rs6921919 0.789 rs13210258 ENSG00000204709.4 LINC01556 8.58 1.38e-16 1.77e-13 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28340894 chr6:28943877~28944537:+ LUSC cis rs9341808 0.718 rs3828754 ENSG00000272129.1 RP11-250B2.6 8.58 1.39e-16 1.78e-13 0.45 0.37 Sitting height ratio; chr6:80190923 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs10943696 ENSG00000272129.1 RP11-250B2.6 8.58 1.39e-16 1.78e-13 0.45 0.37 Sitting height ratio; chr6:80191555 chr6:80355424~80356859:+ LUSC cis rs9341808 0.718 rs6910201 ENSG00000272129.1 RP11-250B2.6 8.58 1.39e-16 1.78e-13 0.45 0.37 Sitting height ratio; chr6:80195221 chr6:80355424~80356859:+ LUSC cis rs9341808 0.69 rs9448909 ENSG00000272129.1 RP11-250B2.6 8.58 1.39e-16 1.78e-13 0.45 0.37 Sitting height ratio; chr6:80199314 chr6:80355424~80356859:+ LUSC cis rs17023223 0.537 rs12097967 ENSG00000231365.4 RP11-418J17.1 -8.58 1.4e-16 1.79e-13 -0.45 -0.37 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119160290 chr1:119140396~119275973:+ LUSC cis rs9322193 0.923 rs10782315 ENSG00000223701.3 RAET1E-AS1 8.58 1.41e-16 1.81e-13 0.42 0.37 Lung cancer; chr6:149743093 chr6:149884431~149919508:+ LUSC cis rs10463554 0.927 rs56361326 ENSG00000175749.11 EIF3KP1 8.58 1.41e-16 1.81e-13 0.44 0.37 Parkinson's disease; chr5:103054184 chr5:103032376~103033031:+ LUSC cis rs8072100 0.84 rs12453233 ENSG00000228782.6 CTD-2026D20.3 8.58 1.42e-16 1.82e-13 0.35 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47377204 chr17:47450568~47492492:- LUSC cis rs8072100 0.84 rs1912482 ENSG00000228782.6 CTD-2026D20.3 8.58 1.42e-16 1.82e-13 0.35 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47377517 chr17:47450568~47492492:- LUSC cis rs9322193 0.516 rs1999632 ENSG00000216906.2 RP11-350J20.9 8.58 1.43e-16 1.83e-13 0.5 0.37 Lung cancer; chr6:149866737 chr6:149904243~149906418:+ LUSC cis rs5769707 0.632 rs135877 ENSG00000235111.1 RP1-29C18.8 -8.58 1.44e-16 1.84e-13 -0.46 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49620354 chr22:49612657~49615716:- LUSC cis rs11098499 0.954 rs1546505 ENSG00000245958.5 RP11-33B1.1 -8.57 1.45e-16 1.85e-13 -0.39 -0.37 Corneal astigmatism; chr4:119320069 chr4:119454791~119552025:+ LUSC cis rs10129255 0.912 rs6576227 ENSG00000211970.3 IGHV4-61 -8.57 1.45e-16 1.86e-13 -0.26 -0.37 Kawasaki disease; chr14:106778202 chr14:106639119~106639657:- LUSC cis rs10129255 0.957 rs6576228 ENSG00000211970.3 IGHV4-61 -8.57 1.45e-16 1.86e-13 -0.26 -0.37 Kawasaki disease; chr14:106778401 chr14:106639119~106639657:- LUSC cis rs11098499 0.754 rs878372 ENSG00000245958.5 RP11-33B1.1 -8.57 1.45e-16 1.86e-13 -0.37 -0.37 Corneal astigmatism; chr4:119317625 chr4:119454791~119552025:+ LUSC cis rs12134133 0.927 rs4844589 ENSG00000274245.1 RP11-357P18.2 8.57 1.46e-16 1.86e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207259285 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs6540893 ENSG00000274245.1 RP11-357P18.2 8.57 1.46e-16 1.86e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207262382 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs61822674 ENSG00000274245.1 RP11-357P18.2 8.57 1.46e-16 1.86e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207263378 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs10442696 ENSG00000274245.1 RP11-357P18.2 8.57 1.46e-16 1.86e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207264783 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs7535532 ENSG00000274245.1 RP11-357P18.2 8.57 1.46e-16 1.86e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207264991 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs7543117 ENSG00000274245.1 RP11-357P18.2 8.57 1.46e-16 1.86e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207265351 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs6684804 ENSG00000274245.1 RP11-357P18.2 8.57 1.46e-16 1.86e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207265670 chr1:207372559~207373252:+ LUSC cis rs12134133 1 rs11582249 ENSG00000274245.1 RP11-357P18.2 8.57 1.46e-16 1.86e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207268263 chr1:207372559~207373252:+ LUSC cis rs7044106 0.791 rs10985008 ENSG00000226752.6 PSMD5-AS1 -8.57 1.46e-16 1.86e-13 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120730682 chr9:120824828~120854385:+ LUSC cis rs1707322 1 rs11211248 ENSG00000280836.1 AL355480.1 -8.57 1.47e-16 1.88e-13 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46011172 chr1:45581219~45581321:- LUSC cis rs9487094 0.626 rs12215077 ENSG00000260273.1 RP11-425D10.10 -8.57 1.47e-16 1.88e-13 -0.43 -0.37 Height; chr6:109731677 chr6:109382795~109383666:+ LUSC cis rs11098499 0.826 rs4472123 ENSG00000245958.5 RP11-33B1.1 -8.57 1.48e-16 1.89e-13 -0.37 -0.37 Corneal astigmatism; chr4:119315475 chr4:119454791~119552025:+ LUSC cis rs7174755 0.608 rs62004789 ENSG00000260657.2 RP11-315D16.4 8.57 1.49e-16 1.9e-13 0.45 0.37 Major depressive disorder; chr15:68148268 chr15:68267792~68277994:- LUSC cis rs6921919 0.945 rs7765989 ENSG00000216901.1 AL022393.7 8.57 1.5e-16 1.92e-13 0.5 0.37 Autism spectrum disorder or schizophrenia; chr6:28432518 chr6:28176188~28176674:+ LUSC cis rs9322193 0.923 rs9766037 ENSG00000223701.3 RAET1E-AS1 8.57 1.51e-16 1.92e-13 0.42 0.37 Lung cancer; chr6:149616921 chr6:149884431~149919508:+ LUSC cis rs3096299 0.967 rs2911255 ENSG00000274627.1 RP11-104N10.2 8.57 1.51e-16 1.93e-13 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89420729 chr16:89516797~89522217:+ LUSC cis rs9487094 0.885 rs1358997 ENSG00000260273.1 RP11-425D10.10 8.57 1.51e-16 1.93e-13 0.45 0.37 Height; chr6:109380457 chr6:109382795~109383666:+ LUSC cis rs9487094 0.885 rs3799839 ENSG00000260273.1 RP11-425D10.10 8.57 1.51e-16 1.93e-13 0.45 0.37 Height; chr6:109380990 chr6:109382795~109383666:+ LUSC cis rs1113500 0.799 rs1777459 ENSG00000226822.1 RP11-356N1.2 -8.57 1.51e-16 1.93e-13 -0.38 -0.37 Growth-regulated protein alpha levels; chr1:108042377 chr1:108071482~108074519:+ LUSC cis rs10463554 0.927 rs257312 ENSG00000175749.11 EIF3KP1 8.57 1.52e-16 1.93e-13 0.44 0.37 Parkinson's disease; chr5:103083923 chr5:103032376~103033031:+ LUSC cis rs10463554 0.892 rs257313 ENSG00000175749.11 EIF3KP1 8.57 1.52e-16 1.93e-13 0.44 0.37 Parkinson's disease; chr5:103084943 chr5:103032376~103033031:+ LUSC cis rs6471393 0.964 rs11549490 ENSG00000253848.1 RP11-10N23.5 -8.57 1.53e-16 1.95e-13 -0.46 -0.37 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93732822 chr8:93741193~93744534:+ LUSC cis rs62388641 0.774 rs13212794 ENSG00000272279.1 RP11-157J24.2 8.57 1.54e-16 1.96e-13 0.61 0.37 Daytime sleep phenotypes; chr6:1548349 chr6:1528364~1528911:- LUSC cis rs8062405 0.755 rs7193402 ENSG00000259982.1 CDC37P1 8.57 1.54e-16 1.97e-13 0.46 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574806 chr16:28700294~28701540:- LUSC cis rs11098499 0.663 rs9996501 ENSG00000245958.5 RP11-33B1.1 -8.56 1.56e-16 1.99e-13 -0.37 -0.37 Corneal astigmatism; chr4:119317763 chr4:119454791~119552025:+ LUSC cis rs11098499 0.697 rs28458294 ENSG00000245958.5 RP11-33B1.1 -8.56 1.56e-16 1.99e-13 -0.37 -0.37 Corneal astigmatism; chr4:119317769 chr4:119454791~119552025:+ LUSC cis rs11098499 0.663 rs28369503 ENSG00000245958.5 RP11-33B1.1 -8.56 1.56e-16 1.99e-13 -0.37 -0.37 Corneal astigmatism; chr4:119317770 chr4:119454791~119552025:+ LUSC cis rs1823913 1 rs1823913 ENSG00000227542.1 AC092614.2 8.56 1.57e-16 1.99e-13 0.49 0.37 Obesity-related traits; chr2:191253321 chr2:191229165~191246172:- LUSC cis rs26232 0.551 rs26431 ENSG00000175749.11 EIF3KP1 -8.56 1.57e-16 2e-13 -0.45 -0.37 Rheumatoid arthritis; chr5:103030090 chr5:103032376~103033031:+ LUSC cis rs9322193 0.884 rs1125 ENSG00000216906.2 RP11-350J20.9 8.56 1.57e-16 2e-13 0.46 0.37 Lung cancer; chr6:149658280 chr6:149904243~149906418:+ LUSC cis rs11098499 1 rs12506395 ENSG00000245958.5 RP11-33B1.1 -8.56 1.58e-16 2.01e-13 -0.38 -0.37 Corneal astigmatism; chr4:119263939 chr4:119454791~119552025:+ LUSC cis rs9487094 0.961 rs7773095 ENSG00000260273.1 RP11-425D10.10 -8.56 1.59e-16 2.02e-13 -0.45 -0.37 Height; chr6:109405874 chr6:109382795~109383666:+ LUSC cis rs9322193 0.923 rs9479494 ENSG00000223701.3 RAET1E-AS1 8.56 1.6e-16 2.04e-13 0.42 0.37 Lung cancer; chr6:149739108 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9800806 ENSG00000223701.3 RAET1E-AS1 8.56 1.6e-16 2.04e-13 0.42 0.37 Lung cancer; chr6:149740350 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9688517 ENSG00000223701.3 RAET1E-AS1 8.56 1.6e-16 2.04e-13 0.42 0.37 Lung cancer; chr6:149740655 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs12529698 ENSG00000223701.3 RAET1E-AS1 8.56 1.62e-16 2.06e-13 0.42 0.37 Lung cancer; chr6:149650951 chr6:149884431~149919508:+ LUSC cis rs1707322 1 rs6657720 ENSG00000280836.1 AL355480.1 -8.56 1.62e-16 2.06e-13 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45920597 chr1:45581219~45581321:- LUSC cis rs12134133 0.888 rs11580394 ENSG00000274245.1 RP11-357P18.2 8.56 1.65e-16 2.1e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207238567 chr1:207372559~207373252:+ LUSC cis rs12134133 0.962 rs7526658 ENSG00000274245.1 RP11-357P18.2 8.56 1.65e-16 2.1e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207240098 chr1:207372559~207373252:+ LUSC cis rs12134133 0.962 rs7516416 ENSG00000274245.1 RP11-357P18.2 8.56 1.65e-16 2.1e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207241050 chr1:207372559~207373252:+ LUSC cis rs12134133 0.962 rs6673890 ENSG00000274245.1 RP11-357P18.2 8.56 1.65e-16 2.1e-13 0.48 0.37 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207241788 chr1:207372559~207373252:+ LUSC cis rs7189233 0.531 rs11859538 ENSG00000279344.1 RP11-44F14.7 8.56 1.65e-16 2.1e-13 0.32 0.37 Intelligence (multi-trait analysis); chr16:53463133 chr16:53478957~53481550:- LUSC cis rs6471393 0.964 rs16916191 ENSG00000253848.1 RP11-10N23.5 8.56 1.65e-16 2.1e-13 0.45 0.37 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93737337 chr8:93741193~93744534:+ LUSC cis rs2283792 1 rs2006893 ENSG00000228050.1 TOP3BP1 8.56 1.66e-16 2.11e-13 0.43 0.37 Multiple sclerosis; chr22:21774389 chr22:22223187~22224566:- LUSC cis rs10129255 0.917 rs7142373 ENSG00000211970.3 IGHV4-61 -8.56 1.68e-16 2.13e-13 -0.27 -0.37 Kawasaki disease; chr14:106708947 chr14:106639119~106639657:- LUSC cis rs9322193 0.923 rs62441284 ENSG00000223701.3 RAET1E-AS1 8.56 1.68e-16 2.13e-13 0.42 0.37 Lung cancer; chr6:149751542 chr6:149884431~149919508:+ LUSC cis rs11098499 0.505 rs75122014 ENSG00000249244.1 RP11-548H18.2 8.55 1.68e-16 2.13e-13 0.48 0.37 Corneal astigmatism; chr4:119441271 chr4:119391831~119395335:- LUSC cis rs1707322 0.964 rs12067716 ENSG00000280836.1 AL355480.1 -8.55 1.68e-16 2.14e-13 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45968756 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4660332 ENSG00000280836.1 AL355480.1 -8.55 1.68e-16 2.14e-13 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45995746 chr1:45581219~45581321:- LUSC cis rs17507216 0.628 rs8032321 ENSG00000278603.1 RP13-608F4.5 8.55 1.71e-16 2.17e-13 0.56 0.37 Excessive daytime sleepiness; chr15:82698956 chr15:82472203~82472426:+ LUSC cis rs17507216 0.628 rs8040488 ENSG00000278603.1 RP13-608F4.5 8.55 1.71e-16 2.17e-13 0.56 0.37 Excessive daytime sleepiness; chr15:82699081 chr15:82472203~82472426:+ LUSC cis rs2283792 1 rs3810610 ENSG00000228050.1 TOP3BP1 8.55 1.71e-16 2.17e-13 0.42 0.37 Multiple sclerosis; chr22:21761209 chr22:22223187~22224566:- LUSC cis rs9487094 0.961 rs1923725 ENSG00000260273.1 RP11-425D10.10 8.55 1.72e-16 2.19e-13 0.45 0.37 Height; chr6:109387685 chr6:109382795~109383666:+ LUSC cis rs9487094 0.961 rs12524639 ENSG00000260273.1 RP11-425D10.10 8.55 1.72e-16 2.19e-13 0.45 0.37 Height; chr6:109388256 chr6:109382795~109383666:+ LUSC cis rs11098499 0.955 rs13129661 ENSG00000245958.5 RP11-33B1.1 -8.55 1.73e-16 2.19e-13 -0.37 -0.37 Corneal astigmatism; chr4:119231754 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs1572229 ENSG00000223701.3 RAET1E-AS1 8.55 1.73e-16 2.19e-13 0.42 0.37 Lung cancer; chr6:149743841 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs10872646 ENSG00000223701.3 RAET1E-AS1 8.55 1.73e-16 2.19e-13 0.42 0.37 Lung cancer; chr6:149746539 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs12528279 ENSG00000223701.3 RAET1E-AS1 8.55 1.73e-16 2.19e-13 0.42 0.37 Lung cancer; chr6:149750892 chr6:149884431~149919508:+ LUSC cis rs9322193 0.809 rs9479808 ENSG00000223701.3 RAET1E-AS1 8.55 1.73e-16 2.19e-13 0.42 0.37 Lung cancer; chr6:149751328 chr6:149884431~149919508:+ LUSC cis rs7617773 0.817 rs6801801 ENSG00000228638.1 FCF1P2 -8.55 1.73e-16 2.2e-13 -0.43 -0.37 Coronary artery disease; chr3:48284943 chr3:48290793~48291375:- LUSC cis rs5769707 0.632 rs135876 ENSG00000235111.1 RP1-29C18.8 -8.55 1.73e-16 2.2e-13 -0.46 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49619925 chr22:49612657~49615716:- LUSC cis rs1707322 1 rs10789485 ENSG00000280836.1 AL355480.1 -8.55 1.76e-16 2.23e-13 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45941636 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs6677777 ENSG00000280836.1 AL355480.1 -8.55 1.77e-16 2.25e-13 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46010164 chr1:45581219~45581321:- LUSC cis rs62229266 0.557 rs4817760 ENSG00000231106.2 LINC01436 8.55 1.78e-16 2.25e-13 0.5 0.37 Mitral valve prolapse; chr21:36023003 chr21:36005338~36007838:+ LUSC cis rs11098499 0.863 rs12502389 ENSG00000249244.1 RP11-548H18.2 8.55 1.78e-16 2.26e-13 0.48 0.37 Corneal astigmatism; chr4:119533036 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs10013305 ENSG00000249244.1 RP11-548H18.2 8.55 1.79e-16 2.27e-13 0.48 0.37 Corneal astigmatism; chr4:119529269 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3775849 ENSG00000249244.1 RP11-548H18.2 8.55 1.79e-16 2.27e-13 0.48 0.37 Corneal astigmatism; chr4:119529753 chr4:119391831~119395335:- LUSC cis rs11098499 0.818 rs7688802 ENSG00000249244.1 RP11-548H18.2 8.55 1.79e-16 2.27e-13 0.48 0.37 Corneal astigmatism; chr4:119530513 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs7695620 ENSG00000249244.1 RP11-548H18.2 8.55 1.79e-16 2.27e-13 0.48 0.37 Corneal astigmatism; chr4:119531621 chr4:119391831~119395335:- LUSC cis rs11098499 0.821 rs3775852 ENSG00000249244.1 RP11-548H18.2 8.55 1.79e-16 2.27e-13 0.48 0.37 Corneal astigmatism; chr4:119533401 chr4:119391831~119395335:- LUSC cis rs11098499 0.82 rs6534140 ENSG00000249244.1 RP11-548H18.2 8.55 1.79e-16 2.27e-13 0.48 0.37 Corneal astigmatism; chr4:119534156 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs7657849 ENSG00000249244.1 RP11-548H18.2 8.55 1.79e-16 2.27e-13 0.48 0.37 Corneal astigmatism; chr4:119534339 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs10034450 ENSG00000249244.1 RP11-548H18.2 8.55 1.79e-16 2.27e-13 0.48 0.37 Corneal astigmatism; chr4:119534494 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs1480939 ENSG00000249244.1 RP11-548H18.2 8.55 1.79e-16 2.27e-13 0.48 0.37 Corneal astigmatism; chr4:119535772 chr4:119391831~119395335:- LUSC cis rs3931020 0.688 rs405445 ENSG00000272864.1 RP11-17E13.2 8.55 1.79e-16 2.27e-13 0.49 0.37 Resistin levels; chr1:74755466 chr1:74698769~74699333:- LUSC cis rs875971 1 rs12698523 ENSG00000222364.1 RNU6-96P -8.54 1.81e-16 2.29e-13 -0.43 -0.37 Aortic root size; chr7:66503126 chr7:66395191~66395286:+ LUSC cis rs1707322 1 rs3922887 ENSG00000280836.1 AL355480.1 -8.54 1.83e-16 2.31e-13 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46008130 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs3922886 ENSG00000280836.1 AL355480.1 -8.54 1.83e-16 2.31e-13 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46008230 chr1:45581219~45581321:- LUSC cis rs5769707 0.681 rs9616329 ENSG00000235111.1 RP1-29C18.8 -8.54 1.83e-16 2.31e-13 -0.44 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49632666 chr22:49612657~49615716:- LUSC cis rs9487094 0.922 rs10872034 ENSG00000260273.1 RP11-425D10.10 8.54 1.83e-16 2.31e-13 0.45 0.37 Height; chr6:109486036 chr6:109382795~109383666:+ LUSC cis rs11098499 0.909 rs6842762 ENSG00000249244.1 RP11-548H18.2 8.54 1.83e-16 2.32e-13 0.48 0.37 Corneal astigmatism; chr4:119477081 chr4:119391831~119395335:- LUSC cis rs9487094 0.848 rs1322816 ENSG00000260273.1 RP11-425D10.10 8.54 1.83e-16 2.32e-13 0.45 0.37 Height; chr6:109382524 chr6:109382795~109383666:+ LUSC cis rs9487094 0.885 rs13212766 ENSG00000260273.1 RP11-425D10.10 8.54 1.83e-16 2.32e-13 0.45 0.37 Height; chr6:109384228 chr6:109382795~109383666:+ LUSC cis rs9487094 0.961 rs3757234 ENSG00000260273.1 RP11-425D10.10 8.54 1.83e-16 2.32e-13 0.45 0.37 Height; chr6:109385087 chr6:109382795~109383666:+ LUSC cis rs10463554 0.927 rs257317 ENSG00000175749.11 EIF3KP1 8.54 1.84e-16 2.33e-13 0.43 0.37 Parkinson's disease; chr5:103086881 chr5:103032376~103033031:+ LUSC cis rs1707322 0.89 rs2297883 ENSG00000280836.1 AL355480.1 8.54 1.88e-16 2.37e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46045815 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs1707338 ENSG00000280836.1 AL355480.1 8.54 1.88e-16 2.37e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46046309 chr1:45581219~45581321:- LUSC cis rs1707322 0.964 rs1707339 ENSG00000280836.1 AL355480.1 8.54 1.88e-16 2.37e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46047507 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs1768818 ENSG00000280836.1 AL355480.1 8.54 1.88e-16 2.37e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46048614 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs1768817 ENSG00000280836.1 AL355480.1 8.54 1.88e-16 2.37e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46048862 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs785470 ENSG00000280836.1 AL355480.1 8.54 1.88e-16 2.37e-13 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46053950 chr1:45581219~45581321:- LUSC cis rs11098499 0.863 rs9884402 ENSG00000245958.5 RP11-33B1.1 -8.54 1.88e-16 2.37e-13 -0.37 -0.37 Corneal astigmatism; chr4:119568827 chr4:119454791~119552025:+ LUSC cis rs11098499 0.731 rs9995026 ENSG00000245958.5 RP11-33B1.1 -8.54 1.88e-16 2.37e-13 -0.37 -0.37 Corneal astigmatism; chr4:119569344 chr4:119454791~119552025:+ LUSC cis rs11098499 0.722 rs10025925 ENSG00000245958.5 RP11-33B1.1 -8.54 1.89e-16 2.38e-13 -0.36 -0.37 Corneal astigmatism; chr4:119350589 chr4:119454791~119552025:+ LUSC cis rs11098499 0.731 rs10015579 ENSG00000245958.5 RP11-33B1.1 -8.54 1.89e-16 2.38e-13 -0.36 -0.37 Corneal astigmatism; chr4:119350647 chr4:119454791~119552025:+ LUSC cis rs11098499 0.82 rs13128602 ENSG00000249244.1 RP11-548H18.2 -8.54 1.89e-16 2.39e-13 -0.47 -0.37 Corneal astigmatism; chr4:119538211 chr4:119391831~119395335:- LUSC cis rs35955747 0.869 rs131219 ENSG00000236132.1 CTA-440B3.1 -8.54 1.9e-16 2.4e-13 -0.43 -0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31364264 chr22:31816379~31817491:- LUSC cis rs6921919 0.945 rs16901847 ENSG00000216901.1 AL022393.7 8.54 1.91e-16 2.41e-13 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28408074 chr6:28176188~28176674:+ LUSC cis rs875971 0.964 rs778735 ENSG00000222364.1 RNU6-96P -8.54 1.91e-16 2.41e-13 -0.43 -0.37 Aortic root size; chr7:66349822 chr7:66395191~66395286:+ LUSC cis rs35955747 0.869 rs5753576 ENSG00000236132.1 CTA-440B3.1 -8.54 1.91e-16 2.42e-13 -0.43 -0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31361749 chr22:31816379~31817491:- LUSC cis rs9322193 0.923 rs57938011 ENSG00000223701.3 RAET1E-AS1 8.54 1.92e-16 2.42e-13 0.43 0.37 Lung cancer; chr6:149642969 chr6:149884431~149919508:+ LUSC cis rs694739 0.857 rs574835 ENSG00000236935.1 AP003774.1 8.54 1.94e-16 2.45e-13 0.36 0.37 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64343196 chr11:64325050~64329504:- LUSC cis rs10793273 1 rs10793273 ENSG00000246174.6 KCTD21-AS1 -8.54 1.95e-16 2.45e-13 -0.39 -0.37 Pelvic organ prolapse; chr11:78031549 chr11:78139771~78175323:+ LUSC cis rs7811142 1 rs7783550 ENSG00000242294.5 STAG3L5P -8.54 1.95e-16 2.46e-13 -0.28 -0.37 Platelet count; chr7:100390182 chr7:100336079~100351900:+ LUSC cis rs11098499 0.863 rs7699064 ENSG00000245958.5 RP11-33B1.1 8.54 1.95e-16 2.46e-13 0.38 0.37 Corneal astigmatism; chr4:119507154 chr4:119454791~119552025:+ LUSC cis rs7739264 0.602 rs6925511 ENSG00000237404.1 RP3-471C18.2 8.53 1.95e-16 2.46e-13 0.41 0.37 Endometriosis; chr6:19773322 chr6:19689825~19753113:- LUSC cis rs10463554 0.963 rs62364874 ENSG00000175749.11 EIF3KP1 8.53 1.95e-16 2.46e-13 0.44 0.37 Parkinson's disease; chr5:103056475 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs62364876 ENSG00000175749.11 EIF3KP1 8.53 1.95e-16 2.46e-13 0.44 0.37 Parkinson's disease; chr5:103058454 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs158254 ENSG00000175749.11 EIF3KP1 8.53 1.95e-16 2.46e-13 0.44 0.37 Parkinson's disease; chr5:103059179 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs34381 ENSG00000175749.11 EIF3KP1 8.53 1.95e-16 2.46e-13 0.44 0.37 Parkinson's disease; chr5:103060852 chr5:103032376~103033031:+ LUSC cis rs2283792 1 rs6518986 ENSG00000228050.1 TOP3BP1 8.53 1.96e-16 2.47e-13 0.42 0.37 Multiple sclerosis; chr22:21831058 chr22:22223187~22224566:- LUSC cis rs526231 0.511 rs55810112 ENSG00000175749.11 EIF3KP1 8.53 1.96e-16 2.47e-13 0.45 0.37 Primary biliary cholangitis; chr5:103026645 chr5:103032376~103033031:+ LUSC cis rs6471393 0.929 rs56108220 ENSG00000253848.1 RP11-10N23.5 8.53 1.98e-16 2.49e-13 0.46 0.37 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93736965 chr8:93741193~93744534:+ LUSC cis rs10875746 0.729 rs1990028 ENSG00000240399.1 RP1-228P16.1 -8.53 1.98e-16 2.49e-13 -0.41 -0.37 Longevity (90 years and older); chr12:48014230 chr12:48054813~48055591:- LUSC cis rs10129255 0.912 rs8009135 ENSG00000211970.3 IGHV4-61 -8.53 1.98e-16 2.5e-13 -0.26 -0.37 Kawasaki disease; chr14:106777528 chr14:106639119~106639657:- LUSC cis rs35955747 0.902 rs140074 ENSG00000236132.1 CTA-440B3.1 -8.53 1.99e-16 2.5e-13 -0.43 -0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31329648 chr22:31816379~31817491:- LUSC cis rs1707322 1 rs785465 ENSG00000280836.1 AL355480.1 -8.53 2e-16 2.52e-13 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46056905 chr1:45581219~45581321:- LUSC cis rs12439619 0.508 rs8032033 ENSG00000255769.6 GOLGA2P10 -8.53 2.01e-16 2.53e-13 -0.44 -0.37 Intelligence (multi-trait analysis); chr15:82165555 chr15:82472993~82513950:- LUSC cis rs1185460 0.547 rs34150933 ENSG00000271751.1 RP11-110I1.14 8.53 2.02e-16 2.54e-13 0.46 0.37 Coronary artery disease; chr11:119040329 chr11:119065263~119065677:- LUSC cis rs9322193 0.886 rs4039600 ENSG00000216906.2 RP11-350J20.9 8.53 2.04e-16 2.57e-13 0.44 0.37 Lung cancer; chr6:149576319 chr6:149904243~149906418:+ LUSC cis rs9322193 0.961 rs9027 ENSG00000216906.2 RP11-350J20.9 8.53 2.05e-16 2.58e-13 0.43 0.37 Lung cancer; chr6:149594921 chr6:149904243~149906418:+ LUSC cis rs8062405 0.573 rs6565300 ENSG00000259982.1 CDC37P1 8.53 2.06e-16 2.59e-13 0.49 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28981728 chr16:28700294~28701540:- LUSC cis rs10129255 0.957 rs10136817 ENSG00000211970.3 IGHV4-61 -8.53 2.07e-16 2.61e-13 -0.26 -0.37 Kawasaki disease; chr14:106787730 chr14:106639119~106639657:- LUSC cis rs7044106 0.5 rs56725168 ENSG00000226752.6 PSMD5-AS1 -8.53 2.08e-16 2.62e-13 -0.43 -0.37 Hip circumference adjusted for BMI; chr9:120730298 chr9:120824828~120854385:+ LUSC cis rs11098499 0.657 rs71614442 ENSG00000249244.1 RP11-548H18.2 8.53 2.09e-16 2.62e-13 0.47 0.37 Corneal astigmatism; chr4:119458191 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs2892848 ENSG00000249244.1 RP11-548H18.2 8.53 2.09e-16 2.62e-13 0.47 0.37 Corneal astigmatism; chr4:119460186 chr4:119391831~119395335:- LUSC cis rs11098499 0.865 rs9994730 ENSG00000249244.1 RP11-548H18.2 8.53 2.09e-16 2.62e-13 0.47 0.37 Corneal astigmatism; chr4:119460409 chr4:119391831~119395335:- LUSC cis rs526231 0.578 rs42860 ENSG00000175749.11 EIF3KP1 8.53 2.09e-16 2.63e-13 0.44 0.37 Primary biliary cholangitis; chr5:103092414 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs34806 ENSG00000175749.11 EIF3KP1 8.53 2.09e-16 2.63e-13 0.44 0.37 Parkinson's disease; chr5:103092733 chr5:103032376~103033031:+ LUSC cis rs1150668 0.796 rs728122 ENSG00000204709.4 LINC01556 8.53 2.1e-16 2.64e-13 0.45 0.37 Pubertal anthropometrics; chr6:28431347 chr6:28943877~28944537:+ LUSC cis rs9487094 0.644 rs910730 ENSG00000260273.1 RP11-425D10.10 8.53 2.1e-16 2.64e-13 0.43 0.37 Height; chr6:109447092 chr6:109382795~109383666:+ LUSC cis rs150992 0.536 rs10479348 ENSG00000248489.1 CTD-2007H13.3 -8.52 2.1e-16 2.65e-13 -0.49 -0.37 Body mass index; chr5:99013022 chr5:98929171~98995013:+ LUSC cis rs4988958 0.565 rs3755265 ENSG00000234389.1 AC007278.3 8.52 2.13e-16 2.68e-13 0.35 0.37 Asthma (childhood onset); chr2:102436356 chr2:102438713~102440475:+ LUSC cis rs875971 1 rs937495 ENSG00000222364.1 RNU6-96P 8.52 2.13e-16 2.68e-13 0.43 0.37 Aortic root size; chr7:66314811 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs2036264 ENSG00000222364.1 RNU6-96P 8.52 2.13e-16 2.68e-13 0.43 0.37 Aortic root size; chr7:66334917 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs7783613 ENSG00000222364.1 RNU6-96P 8.52 2.13e-16 2.68e-13 0.43 0.37 Aortic root size; chr7:66340274 chr7:66395191~66395286:+ LUSC cis rs7174755 0.637 rs113002386 ENSG00000260657.2 RP11-315D16.4 8.52 2.14e-16 2.68e-13 0.45 0.37 Major depressive disorder; chr15:68172375 chr15:68267792~68277994:- LUSC cis rs9807989 0.507 rs6755905 ENSG00000234389.1 AC007278.3 8.52 2.14e-16 2.69e-13 0.35 0.37 Asthma; chr2:102431747 chr2:102438713~102440475:+ LUSC cis rs4988958 0.527 rs6756161 ENSG00000234389.1 AC007278.3 8.52 2.14e-16 2.69e-13 0.35 0.37 Asthma (childhood onset); chr2:102431957 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs3755266 ENSG00000234389.1 AC007278.3 8.52 2.14e-16 2.69e-13 0.35 0.37 Asthma; chr2:102426252 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs2110659 ENSG00000234389.1 AC007278.3 8.52 2.14e-16 2.69e-13 0.35 0.37 Asthma; chr2:102427407 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs7605284 ENSG00000234389.1 AC007278.3 8.52 2.14e-16 2.69e-13 0.35 0.37 Asthma; chr2:102427715 chr2:102438713~102440475:+ LUSC cis rs4988958 0.584 rs12712149 ENSG00000234389.1 AC007278.3 8.52 2.14e-16 2.69e-13 0.35 0.37 Asthma (childhood onset); chr2:102428733 chr2:102438713~102440475:+ LUSC cis rs4988958 0.584 rs7559845 ENSG00000234389.1 AC007278.3 8.52 2.14e-16 2.69e-13 0.35 0.37 Asthma (childhood onset); chr2:102429754 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs6726985 ENSG00000234389.1 AC007278.3 8.52 2.16e-16 2.71e-13 0.35 0.37 Asthma; chr2:102432120 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs2310300 ENSG00000234389.1 AC007278.3 8.52 2.16e-16 2.71e-13 0.35 0.37 Asthma; chr2:102432614 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs7581119 ENSG00000234389.1 AC007278.3 8.52 2.16e-16 2.71e-13 0.35 0.37 Asthma; chr2:102433405 chr2:102438713~102440475:+ LUSC cis rs11098499 0.954 rs11722872 ENSG00000245958.5 RP11-33B1.1 -8.52 2.17e-16 2.72e-13 -0.38 -0.37 Corneal astigmatism; chr4:119311875 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs1809406 ENSG00000249244.1 RP11-548H18.2 8.52 2.19e-16 2.74e-13 0.47 0.37 Corneal astigmatism; chr4:119455967 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs9994810 ENSG00000249244.1 RP11-548H18.2 8.52 2.19e-16 2.74e-13 0.47 0.37 Corneal astigmatism; chr4:119460435 chr4:119391831~119395335:- LUSC cis rs11098499 0.697 rs10020027 ENSG00000249244.1 RP11-548H18.2 8.52 2.19e-16 2.74e-13 0.47 0.37 Corneal astigmatism; chr4:119460724 chr4:119391831~119395335:- LUSC cis rs11098499 0.779 rs7356491 ENSG00000249244.1 RP11-548H18.2 8.52 2.19e-16 2.74e-13 0.47 0.37 Corneal astigmatism; chr4:119460819 chr4:119391831~119395335:- LUSC cis rs10740039 0.583 rs9415611 ENSG00000254271.1 RP11-131N11.4 -8.52 2.22e-16 2.78e-13 -0.51 -0.37 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60743440 chr10:60734342~60741828:+ LUSC cis rs9341808 0.754 rs3812126 ENSG00000272129.1 RP11-250B2.6 -8.52 2.23e-16 2.79e-13 -0.44 -0.37 Sitting height ratio; chr6:80242984 chr6:80355424~80356859:+ LUSC cis rs11098499 0.661 rs10015965 ENSG00000245958.5 RP11-33B1.1 -8.52 2.24e-16 2.8e-13 -0.36 -0.37 Corneal astigmatism; chr4:119347082 chr4:119454791~119552025:+ LUSC cis rs11098499 0.535 rs10005542 ENSG00000245958.5 RP11-33B1.1 -8.52 2.24e-16 2.8e-13 -0.36 -0.37 Corneal astigmatism; chr4:119347147 chr4:119454791~119552025:+ LUSC cis rs853679 0.517 rs16893666 ENSG00000219392.1 RP1-265C24.5 8.52 2.26e-16 2.83e-13 0.5 0.37 Depression; chr6:28086929 chr6:28115628~28116551:+ LUSC cis rs11155671 0.53 rs6935829 ENSG00000268592.3 RAET1E-AS1 8.52 2.26e-16 2.84e-13 0.45 0.37 Testicular germ cell tumor; chr6:149896675 chr6:149863494~149919507:+ LUSC cis rs17023223 0.537 rs61806983 ENSG00000231365.4 RP11-418J17.1 -8.51 2.27e-16 2.85e-13 -0.45 -0.37 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119188901 chr1:119140396~119275973:+ LUSC cis rs9660180 0.967 rs6603802 ENSG00000268575.1 RP1-283E3.8 -8.51 2.29e-16 2.87e-13 -0.33 -0.37 Body mass index; chr1:1881082 chr1:1702736~1737688:- LUSC cis rs2019137 0.868 rs6755639 ENSG00000189223.12 PAX8-AS1 -8.51 2.3e-16 2.88e-13 -0.48 -0.37 Lymphocyte counts; chr2:113224233 chr2:113211522~113276581:+ LUSC cis rs9322193 0.923 rs10872649 ENSG00000223701.3 RAET1E-AS1 8.51 2.33e-16 2.92e-13 0.42 0.37 Lung cancer; chr6:149759454 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs10872650 ENSG00000223701.3 RAET1E-AS1 8.51 2.33e-16 2.92e-13 0.42 0.37 Lung cancer; chr6:149760959 chr6:149884431~149919508:+ LUSC cis rs2117029 0.521 rs11168885 ENSG00000258017.1 RP11-386G11.10 -8.51 2.34e-16 2.93e-13 -0.47 -0.37 Intelligence (multi-trait analysis); chr12:49146204 chr12:49127782~49147869:+ LUSC cis rs8072100 0.84 rs11079774 ENSG00000228782.6 CTD-2026D20.3 8.51 2.34e-16 2.93e-13 0.35 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402340 chr17:47450568~47492492:- LUSC cis rs9322193 0.504 rs7771014 ENSG00000268592.3 RAET1E-AS1 8.51 2.36e-16 2.95e-13 0.45 0.37 Lung cancer; chr6:149884310 chr6:149863494~149919507:+ LUSC cis rs6538678 0.864 rs10777749 ENSG00000258343.1 RP11-536G4.2 -8.51 2.36e-16 2.95e-13 -0.47 -0.37 Lupus nephritis in systemic lupus erythematosus; chr12:95883182 chr12:95795345~95858839:- LUSC cis rs9322193 0.923 rs10782316 ENSG00000223701.3 RAET1E-AS1 8.51 2.36e-16 2.96e-13 0.42 0.37 Lung cancer; chr6:149752755 chr6:149884431~149919508:+ LUSC cis rs8062405 0.573 rs7140 ENSG00000259982.1 CDC37P1 -8.51 2.37e-16 2.96e-13 -0.49 -0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28984436 chr16:28700294~28701540:- LUSC cis rs4988958 0.565 rs885088 ENSG00000234389.1 AC007278.3 8.51 2.39e-16 2.98e-13 0.35 0.37 Asthma (childhood onset); chr2:102422584 chr2:102438713~102440475:+ LUSC cis rs12439619 0.693 rs4778989 ENSG00000255769.6 GOLGA2P10 -8.51 2.4e-16 3e-13 -0.51 -0.37 Intelligence (multi-trait analysis); chr15:82276963 chr15:82472993~82513950:- LUSC cis rs5769707 0.632 rs5770601 ENSG00000235111.1 RP1-29C18.8 -8.51 2.41e-16 3e-13 -0.46 -0.37 Monocyte percentage of white cells;Monocyte count; chr22:49628255 chr22:49612657~49615716:- LUSC cis rs1150668 0.83 rs2531831 ENSG00000204709.4 LINC01556 8.51 2.41e-16 3.01e-13 0.44 0.37 Pubertal anthropometrics; chr6:28420988 chr6:28943877~28944537:+ LUSC cis rs875971 0.895 rs3857684 ENSG00000222364.1 RNU6-96P -8.51 2.42e-16 3.02e-13 -0.43 -0.37 Aortic root size; chr7:66473171 chr7:66395191~66395286:+ LUSC cis rs2117029 0.586 rs11168874 ENSG00000258017.1 RP11-386G11.10 -8.51 2.42e-16 3.02e-13 -0.47 -0.37 Intelligence (multi-trait analysis); chr12:49133753 chr12:49127782~49147869:+ LUSC cis rs11098499 0.866 rs6847778 ENSG00000245958.5 RP11-33B1.1 -8.51 2.42e-16 3.02e-13 -0.37 -0.37 Corneal astigmatism; chr4:119372427 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs10030660 ENSG00000249244.1 RP11-548H18.2 8.51 2.43e-16 3.04e-13 0.48 0.37 Corneal astigmatism; chr4:119515549 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs13149407 ENSG00000249244.1 RP11-548H18.2 8.51 2.43e-16 3.04e-13 0.48 0.37 Corneal astigmatism; chr4:119516670 chr4:119391831~119395335:- LUSC cis rs7189233 0.55 rs4783811 ENSG00000279344.1 RP11-44F14.7 8.5 2.44e-16 3.04e-13 0.32 0.37 Intelligence (multi-trait analysis); chr16:53449464 chr16:53478957~53481550:- LUSC cis rs7044106 0.791 rs747819 ENSG00000226752.6 PSMD5-AS1 -8.5 2.44e-16 3.05e-13 -0.42 -0.37 Hip circumference adjusted for BMI; chr9:120726163 chr9:120824828~120854385:+ LUSC cis rs11155671 0.53 rs2342769 ENSG00000268592.3 RAET1E-AS1 8.5 2.46e-16 3.06e-13 0.45 0.37 Testicular germ cell tumor; chr6:149895371 chr6:149863494~149919507:+ LUSC cis rs6471393 0.929 rs4464937 ENSG00000253848.1 RP11-10N23.5 8.5 2.46e-16 3.07e-13 0.46 0.37 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93744689 chr8:93741193~93744534:+ LUSC cis rs2283792 0.967 rs5999550 ENSG00000228050.1 TOP3BP1 8.5 2.48e-16 3.09e-13 0.42 0.37 Multiple sclerosis; chr22:21796997 chr22:22223187~22224566:- LUSC cis rs6471393 0.929 rs7016930 ENSG00000253848.1 RP11-10N23.5 8.5 2.48e-16 3.1e-13 0.46 0.37 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93743185 chr8:93741193~93744534:+ LUSC cis rs6471393 0.929 rs7017036 ENSG00000253848.1 RP11-10N23.5 8.5 2.48e-16 3.1e-13 0.46 0.37 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93743216 chr8:93741193~93744534:+ LUSC cis rs10463554 0.963 rs34829 ENSG00000175749.11 EIF3KP1 8.5 2.49e-16 3.1e-13 0.42 0.37 Parkinson's disease; chr5:103108260 chr5:103032376~103033031:+ LUSC cis rs8072100 0.84 rs9895746 ENSG00000228782.6 CTD-2026D20.3 8.5 2.49e-16 3.1e-13 0.34 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47401733 chr17:47450568~47492492:- LUSC cis rs853679 0.55 rs1233701 ENSG00000219392.1 RP1-265C24.5 8.5 2.49e-16 3.1e-13 0.49 0.37 Depression; chr6:28200948 chr6:28115628~28116551:+ LUSC cis rs11098499 0.698 rs4422403 ENSG00000245958.5 RP11-33B1.1 -8.5 2.49e-16 3.11e-13 -0.35 -0.37 Corneal astigmatism; chr4:119337039 chr4:119454791~119552025:+ LUSC cis rs2283792 1 rs13943 ENSG00000228050.1 TOP3BP1 8.5 2.51e-16 3.12e-13 0.42 0.37 Multiple sclerosis; chr22:21761913 chr22:22223187~22224566:- LUSC cis rs9487094 0.689 rs1046943 ENSG00000260273.1 RP11-425D10.10 8.5 2.52e-16 3.13e-13 0.43 0.37 Height; chr6:109462738 chr6:109382795~109383666:+ LUSC cis rs2117029 0.555 rs9788140 ENSG00000258017.1 RP11-386G11.10 -8.5 2.52e-16 3.13e-13 -0.46 -0.37 Intelligence (multi-trait analysis); chr12:49126738 chr12:49127782~49147869:+ LUSC cis rs10875746 0.729 rs11168357 ENSG00000240399.1 RP1-228P16.1 -8.5 2.53e-16 3.14e-13 -0.41 -0.37 Longevity (90 years and older); chr12:48018355 chr12:48054813~48055591:- LUSC cis rs8072100 0.777 rs9914653 ENSG00000228782.6 CTD-2026D20.3 8.5 2.53e-16 3.14e-13 0.34 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47460029 chr17:47450568~47492492:- LUSC cis rs765787 0.505 rs1648302 ENSG00000259520.4 CTD-2651B20.3 8.5 2.55e-16 3.17e-13 0.46 0.36 Uric acid levels; chr15:45202040 chr15:45251580~45279251:- LUSC cis rs7044106 0.791 rs10985009 ENSG00000226752.6 PSMD5-AS1 8.5 2.57e-16 3.19e-13 0.43 0.36 Hip circumference adjusted for BMI; chr9:120730761 chr9:120824828~120854385:+ LUSC cis rs11098499 0.954 rs17009122 ENSG00000249244.1 RP11-548H18.2 8.5 2.57e-16 3.19e-13 0.47 0.36 Corneal astigmatism; chr4:119441248 chr4:119391831~119395335:- LUSC cis rs9322193 0.923 rs10747276 ENSG00000223701.3 RAET1E-AS1 8.5 2.6e-16 3.22e-13 0.42 0.36 Lung cancer; chr6:149758739 chr6:149884431~149919508:+ LUSC cis rs694739 0.894 rs11601860 ENSG00000236935.1 AP003774.1 8.5 2.62e-16 3.25e-13 0.36 0.36 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64342950 chr11:64325050~64329504:- LUSC cis rs10129255 0.957 rs28887506 ENSG00000211970.3 IGHV4-61 -8.5 2.62e-16 3.25e-13 -0.26 -0.36 Kawasaki disease; chr14:106785589 chr14:106639119~106639657:- LUSC cis rs1707322 1 rs4660331 ENSG00000280836.1 AL355480.1 -8.49 2.63e-16 3.27e-13 -0.44 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45993111 chr1:45581219~45581321:- LUSC cis rs6471393 0.929 rs4734251 ENSG00000253848.1 RP11-10N23.5 8.49 2.63e-16 3.27e-13 0.46 0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93744195 chr8:93741193~93744534:+ LUSC cis rs6471393 0.929 rs4734252 ENSG00000253848.1 RP11-10N23.5 8.49 2.63e-16 3.27e-13 0.46 0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93744286 chr8:93741193~93744534:+ LUSC cis rs11098499 0.863 rs11947234 ENSG00000245958.5 RP11-33B1.1 -8.49 2.63e-16 3.27e-13 -0.37 -0.36 Corneal astigmatism; chr4:119553704 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs11933966 ENSG00000245958.5 RP11-33B1.1 -8.49 2.63e-16 3.27e-13 -0.37 -0.36 Corneal astigmatism; chr4:119555560 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs36040693 ENSG00000245958.5 RP11-33B1.1 -8.49 2.63e-16 3.27e-13 -0.37 -0.36 Corneal astigmatism; chr4:119556461 chr4:119454791~119552025:+ LUSC cis rs10129255 0.913 rs10140943 ENSG00000211970.3 IGHV4-61 -8.49 2.64e-16 3.27e-13 -0.27 -0.36 Kawasaki disease; chr14:106767441 chr14:106639119~106639657:- LUSC cis rs35955747 0.934 rs5994397 ENSG00000236132.1 CTA-440B3.1 8.49 2.64e-16 3.28e-13 0.44 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31430164 chr22:31816379~31817491:- LUSC cis rs7189233 0.531 rs1074182 ENSG00000279344.1 RP11-44F14.7 8.49 2.65e-16 3.29e-13 0.32 0.36 Intelligence (multi-trait analysis); chr16:53437445 chr16:53478957~53481550:- LUSC cis rs150992 0.609 rs451141 ENSG00000248489.1 CTD-2007H13.3 -8.49 2.65e-16 3.29e-13 -0.43 -0.36 Body mass index; chr5:98991691 chr5:98929171~98995013:+ LUSC cis rs7849270 1 rs6478867 ENSG00000268707.1 RP11-247A12.7 8.49 2.66e-16 3.3e-13 0.43 0.36 Blood metabolite ratios; chr9:129141644 chr9:129170434~129170940:+ LUSC cis rs875971 1 rs6945843 ENSG00000222364.1 RNU6-96P 8.49 2.67e-16 3.31e-13 0.43 0.36 Aortic root size; chr7:66269796 chr7:66395191~66395286:+ LUSC cis rs11098499 0.731 rs6846966 ENSG00000245958.5 RP11-33B1.1 -8.49 2.67e-16 3.31e-13 -0.37 -0.36 Corneal astigmatism; chr4:119372053 chr4:119454791~119552025:+ LUSC cis rs875971 0.965 rs10267430 ENSG00000222364.1 RNU6-96P 8.49 2.68e-16 3.32e-13 0.43 0.36 Aortic root size; chr7:66278036 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs10257427 ENSG00000222364.1 RNU6-96P 8.49 2.68e-16 3.32e-13 0.43 0.36 Aortic root size; chr7:66278221 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs10215948 ENSG00000222364.1 RNU6-96P 8.49 2.68e-16 3.32e-13 0.43 0.36 Aortic root size; chr7:66282799 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs55748098 ENSG00000222364.1 RNU6-96P 8.49 2.68e-16 3.32e-13 0.43 0.36 Aortic root size; chr7:66298631 chr7:66395191~66395286:+ LUSC cis rs7617773 0.817 rs9818937 ENSG00000228638.1 FCF1P2 -8.49 2.69e-16 3.33e-13 -0.43 -0.36 Coronary artery disease; chr3:48283791 chr3:48290793~48291375:- LUSC cis rs7189233 0.531 rs1362429 ENSG00000279344.1 RP11-44F14.7 8.49 2.69e-16 3.34e-13 0.32 0.36 Intelligence (multi-trait analysis); chr16:53445172 chr16:53478957~53481550:- LUSC cis rs526231 0.543 rs34379 ENSG00000175749.11 EIF3KP1 -8.49 2.73e-16 3.38e-13 -0.45 -0.36 Primary biliary cholangitis; chr5:103062994 chr5:103032376~103033031:+ LUSC cis rs5769707 0.706 rs2071903 ENSG00000235111.1 RP1-29C18.8 -8.49 2.74e-16 3.39e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49640869 chr22:49612657~49615716:- LUSC cis rs1113500 0.897 rs11185263 ENSG00000226822.1 RP11-356N1.2 8.49 2.76e-16 3.42e-13 0.38 0.36 Growth-regulated protein alpha levels; chr1:108097182 chr1:108071482~108074519:+ LUSC cis rs11098499 0.908 rs28559989 ENSG00000249244.1 RP11-548H18.2 8.49 2.76e-16 3.42e-13 0.48 0.36 Corneal astigmatism; chr4:119465472 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs28632018 ENSG00000249244.1 RP11-548H18.2 8.49 2.76e-16 3.42e-13 0.48 0.36 Corneal astigmatism; chr4:119465575 chr4:119391831~119395335:- LUSC cis rs875971 0.965 rs9969301 ENSG00000222364.1 RNU6-96P 8.49 2.76e-16 3.42e-13 0.43 0.36 Aortic root size; chr7:66316668 chr7:66395191~66395286:+ LUSC cis rs150992 0.569 rs326482 ENSG00000248489.1 CTD-2007H13.3 8.49 2.78e-16 3.44e-13 0.44 0.36 Body mass index; chr5:98951115 chr5:98929171~98995013:+ LUSC cis rs11098499 0.908 rs71614449 ENSG00000249244.1 RP11-548H18.2 8.49 2.79e-16 3.46e-13 0.48 0.36 Corneal astigmatism; chr4:119465900 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs35063680 ENSG00000249244.1 RP11-548H18.2 8.49 2.79e-16 3.46e-13 0.48 0.36 Corneal astigmatism; chr4:119465947 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs34858317 ENSG00000249244.1 RP11-548H18.2 8.49 2.79e-16 3.46e-13 0.48 0.36 Corneal astigmatism; chr4:119465955 chr4:119391831~119395335:- LUSC cis rs5769707 0.667 rs4824069 ENSG00000235111.1 RP1-29C18.8 -8.49 2.8e-16 3.46e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49636677 chr22:49612657~49615716:- LUSC cis rs11098499 0.863 rs3775843 ENSG00000249244.1 RP11-548H18.2 8.49 2.8e-16 3.46e-13 0.47 0.36 Corneal astigmatism; chr4:119506689 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3775844 ENSG00000249244.1 RP11-548H18.2 8.49 2.8e-16 3.46e-13 0.47 0.36 Corneal astigmatism; chr4:119506878 chr4:119391831~119395335:- LUSC cis rs1150668 0.796 rs9468372 ENSG00000204709.4 LINC01556 8.49 2.8e-16 3.47e-13 0.44 0.36 Pubertal anthropometrics; chr6:28411584 chr6:28943877~28944537:+ LUSC cis rs150992 0.568 rs34498 ENSG00000248489.1 CTD-2007H13.3 8.49 2.81e-16 3.48e-13 0.43 0.36 Body mass index; chr5:98960690 chr5:98929171~98995013:+ LUSC cis rs12134133 0.962 rs6682586 ENSG00000274245.1 RP11-357P18.2 8.49 2.81e-16 3.48e-13 0.48 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207243122 chr1:207372559~207373252:+ LUSC cis rs12134133 0.962 rs6668560 ENSG00000274245.1 RP11-357P18.2 8.49 2.81e-16 3.48e-13 0.48 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207243462 chr1:207372559~207373252:+ LUSC cis rs6471393 0.964 rs12056877 ENSG00000253848.1 RP11-10N23.5 -8.49 2.83e-16 3.49e-13 -0.46 -0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93710234 chr8:93741193~93744534:+ LUSC cis rs1150668 0.764 rs9368565 ENSG00000204709.4 LINC01556 -8.49 2.83e-16 3.49e-13 -0.45 -0.36 Pubertal anthropometrics; chr6:28377433 chr6:28943877~28944537:+ LUSC cis rs1150668 0.796 rs1052215 ENSG00000204709.4 LINC01556 -8.49 2.83e-16 3.49e-13 -0.45 -0.36 Pubertal anthropometrics; chr6:28380381 chr6:28943877~28944537:+ LUSC cis rs10129255 0.912 rs730099 ENSG00000211970.3 IGHV4-61 -8.49 2.83e-16 3.5e-13 -0.26 -0.36 Kawasaki disease; chr14:106711838 chr14:106639119~106639657:- LUSC cis rs10129255 0.701 rs2005643 ENSG00000224373.3 IGHV4-59 8.48 2.84e-16 3.5e-13 0.2 0.36 Kawasaki disease; chr14:106676288 chr14:106627249~106627825:- LUSC cis rs4423214 0.65 rs2186777 ENSG00000254682.1 RP11-660L16.2 8.48 2.85e-16 3.51e-13 0.51 0.36 Vitamin D levels; chr11:71508757 chr11:71448674~71452157:+ LUSC cis rs1707322 0.963 rs4459051 ENSG00000280836.1 AL355480.1 -8.48 2.86e-16 3.54e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45985531 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211239 ENSG00000280836.1 AL355480.1 -8.48 2.86e-16 3.54e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45986275 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211243 ENSG00000280836.1 AL355480.1 -8.48 2.86e-16 3.54e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45989761 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211244 ENSG00000280836.1 AL355480.1 -8.48 2.86e-16 3.54e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45991001 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4660903 ENSG00000280836.1 AL355480.1 -8.48 2.86e-16 3.54e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45991929 chr1:45581219~45581321:- LUSC cis rs9322193 0.567 rs7742692 ENSG00000268592.3 RAET1E-AS1 8.48 2.87e-16 3.55e-13 0.45 0.36 Lung cancer; chr6:149892363 chr6:149863494~149919507:+ LUSC cis rs62229266 1 rs62229266 ENSG00000231106.2 LINC01436 8.48 2.88e-16 3.56e-13 0.48 0.36 Mitral valve prolapse; chr21:36087973 chr21:36005338~36007838:+ LUSC cis rs1707322 1 rs7519181 ENSG00000280836.1 AL355480.1 -8.48 2.89e-16 3.57e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45922157 chr1:45581219~45581321:- LUSC cis rs9487094 0.666 rs2236084 ENSG00000260273.1 RP11-425D10.10 8.48 2.89e-16 3.57e-13 0.43 0.36 Height; chr6:109476101 chr6:109382795~109383666:+ LUSC cis rs9487094 0.643 rs35146243 ENSG00000260273.1 RP11-425D10.10 8.48 2.9e-16 3.58e-13 0.43 0.36 Height; chr6:109477209 chr6:109382795~109383666:+ LUSC cis rs11098499 0.908 rs28499576 ENSG00000249244.1 RP11-548H18.2 8.48 2.9e-16 3.58e-13 0.47 0.36 Corneal astigmatism; chr4:119465522 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs67265404 ENSG00000249244.1 RP11-548H18.2 8.48 2.92e-16 3.6e-13 0.47 0.36 Corneal astigmatism; chr4:119438115 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs71614422 ENSG00000249244.1 RP11-548H18.2 8.48 2.92e-16 3.6e-13 0.47 0.36 Corneal astigmatism; chr4:119438185 chr4:119391831~119395335:- LUSC cis rs1707322 1 rs10890376 ENSG00000280836.1 AL355480.1 -8.48 2.93e-16 3.61e-13 -0.44 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940910 chr1:45581219~45581321:- LUSC cis rs9807989 0.507 rs6706002 ENSG00000234389.1 AC007278.3 8.48 2.93e-16 3.61e-13 0.35 0.36 Asthma; chr2:102389644 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs6749014 ENSG00000234389.1 AC007278.3 8.48 2.93e-16 3.61e-13 0.35 0.36 Asthma; chr2:102389988 chr2:102438713~102440475:+ LUSC cis rs11098499 0.739 rs10031033 ENSG00000245958.5 RP11-33B1.1 -8.48 2.94e-16 3.62e-13 -0.34 -0.36 Corneal astigmatism; chr4:119230297 chr4:119454791~119552025:+ LUSC cis rs6471393 0.964 rs2914944 ENSG00000253848.1 RP11-10N23.5 -8.48 2.94e-16 3.63e-13 -0.45 -0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93711815 chr8:93741193~93744534:+ LUSC cis rs6471393 0.964 rs2914942 ENSG00000253848.1 RP11-10N23.5 -8.48 2.94e-16 3.63e-13 -0.45 -0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93714189 chr8:93741193~93744534:+ LUSC cis rs17023223 0.537 rs12083510 ENSG00000231365.4 RP11-418J17.1 -8.48 2.94e-16 3.63e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119203997 chr1:119140396~119275973:+ LUSC cis rs9322193 0.923 rs12526675 ENSG00000223701.3 RAET1E-AS1 -8.48 2.95e-16 3.63e-13 -0.42 -0.36 Lung cancer; chr6:149729540 chr6:149884431~149919508:+ LUSC cis rs1707322 0.963 rs34907901 ENSG00000280836.1 AL355480.1 -8.48 2.96e-16 3.65e-13 -0.44 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45939542 chr1:45581219~45581321:- LUSC cis rs2117029 0.521 rs1056875 ENSG00000258017.1 RP11-386G11.10 -8.48 2.97e-16 3.66e-13 -0.46 -0.36 Intelligence (multi-trait analysis); chr12:49186397 chr12:49127782~49147869:+ LUSC cis rs11098499 0.954 rs10034623 ENSG00000249244.1 RP11-548H18.2 8.48 2.98e-16 3.67e-13 0.47 0.36 Corneal astigmatism; chr4:119476674 chr4:119391831~119395335:- LUSC cis rs1075232 0.826 rs16956738 ENSG00000215302.7 CTD-3092A11.1 8.48 2.99e-16 3.69e-13 0.79 0.36 Survival in colorectal cancer (non-distant metastatic); chr15:31444028 chr15:30470779~30507623:+ LUSC cis rs6471393 0.929 rs62525163 ENSG00000253848.1 RP11-10N23.5 8.48 2.99e-16 3.69e-13 0.46 0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93749824 chr8:93741193~93744534:+ LUSC cis rs2283792 0.935 rs8141851 ENSG00000228050.1 TOP3BP1 8.48 3e-16 3.69e-13 0.42 0.36 Multiple sclerosis; chr22:21812161 chr22:22223187~22224566:- LUSC cis rs526231 0.511 rs55896090 ENSG00000175749.11 EIF3KP1 8.48 3.02e-16 3.72e-13 0.45 0.36 Primary biliary cholangitis; chr5:103026300 chr5:103032376~103033031:+ LUSC cis rs10129255 0.833 rs7156689 ENSG00000211972.2 IGHV3-66 8.48 3.04e-16 3.74e-13 0.28 0.36 Kawasaki disease; chr14:106816039 chr14:106675017~106675544:- LUSC cis rs12439619 0.693 rs9944185 ENSG00000255769.6 GOLGA2P10 -8.48 3.05e-16 3.75e-13 -0.48 -0.36 Intelligence (multi-trait analysis); chr15:82157927 chr15:82472993~82513950:- LUSC cis rs6931421 0.8 rs12662365 ENSG00000272129.1 RP11-250B2.6 8.47 3.06e-16 3.76e-13 0.48 0.36 Sitting height ratio; chr6:80195672 chr6:80355424~80356859:+ LUSC cis rs1707322 1 rs7539800 ENSG00000280836.1 AL355480.1 8.47 3.06e-16 3.77e-13 0.44 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45796457 chr1:45581219~45581321:- LUSC cis rs9487094 0.922 rs59056467 ENSG00000260273.1 RP11-425D10.10 8.47 3.14e-16 3.86e-13 0.45 0.36 Height; chr6:109446728 chr6:109382795~109383666:+ LUSC cis rs1707322 1 rs12097799 ENSG00000280836.1 AL355480.1 -8.47 3.16e-16 3.88e-13 -0.44 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45994214 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs946527 ENSG00000280836.1 AL355480.1 -8.47 3.16e-16 3.88e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46020298 chr1:45581219~45581321:- LUSC cis rs2117029 0.586 rs1874908 ENSG00000258017.1 RP11-386G11.10 -8.47 3.17e-16 3.89e-13 -0.46 -0.36 Intelligence (multi-trait analysis); chr12:49190247 chr12:49127782~49147869:+ LUSC cis rs9322193 0.923 rs11155677 ENSG00000223701.3 RAET1E-AS1 8.47 3.17e-16 3.9e-13 0.42 0.36 Lung cancer; chr6:149756953 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs9480009 ENSG00000223701.3 RAET1E-AS1 8.47 3.17e-16 3.9e-13 0.42 0.36 Lung cancer; chr6:149758502 chr6:149884431~149919508:+ LUSC cis rs875971 1 rs709595 ENSG00000222364.1 RNU6-96P -8.47 3.18e-16 3.91e-13 -0.43 -0.36 Aortic root size; chr7:66352346 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs811880 ENSG00000222364.1 RNU6-96P -8.47 3.18e-16 3.91e-13 -0.43 -0.36 Aortic root size; chr7:66353659 chr7:66395191~66395286:+ LUSC cis rs6452524 0.935 rs72767160 ENSG00000249664.1 CTD-2227C6.2 8.47 3.19e-16 3.91e-13 0.38 0.36 Hypertension (SNP x SNP interaction); chr5:83161102 chr5:83012285~83013109:- LUSC cis rs10129255 0.957 rs1024349 ENSG00000211970.3 IGHV4-61 -8.47 3.2e-16 3.93e-13 -0.26 -0.36 Kawasaki disease; chr14:106689997 chr14:106639119~106639657:- LUSC cis rs9487094 0.961 rs12528822 ENSG00000260273.1 RP11-425D10.10 8.47 3.2e-16 3.93e-13 0.44 0.36 Height; chr6:109340338 chr6:109382795~109383666:+ LUSC cis rs11098499 0.78 rs7680914 ENSG00000249244.1 RP11-548H18.2 8.47 3.21e-16 3.94e-13 0.48 0.36 Corneal astigmatism; chr4:119641898 chr4:119391831~119395335:- LUSC cis rs1707322 1 rs4660905 ENSG00000280836.1 AL355480.1 8.47 3.22e-16 3.95e-13 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45995915 chr1:45581219~45581321:- LUSC cis rs11098499 0.865 rs2389809 ENSG00000249244.1 RP11-548H18.2 8.47 3.22e-16 3.96e-13 0.47 0.36 Corneal astigmatism; chr4:119456244 chr4:119391831~119395335:- LUSC cis rs7189233 0.531 rs8056349 ENSG00000279344.1 RP11-44F14.7 8.47 3.23e-16 3.96e-13 0.32 0.36 Intelligence (multi-trait analysis); chr16:53434114 chr16:53478957~53481550:- LUSC cis rs17023223 0.537 rs12087987 ENSG00000231365.4 RP11-418J17.1 -8.47 3.23e-16 3.97e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119192198 chr1:119140396~119275973:+ LUSC cis rs6991838 0.584 rs7842085 ENSG00000200714.1 Y_RNA 8.47 3.26e-16 4e-13 0.47 0.36 Intelligence (multi-trait analysis); chr8:65636787 chr8:65592731~65592820:+ LUSC cis rs6471393 0.929 rs62525164 ENSG00000253848.1 RP11-10N23.5 8.47 3.26e-16 4e-13 0.46 0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93750084 chr8:93741193~93744534:+ LUSC cis rs11155671 0.53 rs7774787 ENSG00000268592.3 RAET1E-AS1 8.47 3.27e-16 4.01e-13 0.45 0.36 Testicular germ cell tumor; chr6:149888296 chr6:149863494~149919507:+ LUSC cis rs875971 1 rs709597 ENSG00000222364.1 RNU6-96P 8.47 3.27e-16 4.02e-13 0.43 0.36 Aortic root size; chr7:66360996 chr7:66395191~66395286:+ LUSC cis rs4141404 0.604 rs5753625 ENSG00000236132.1 CTA-440B3.1 8.47 3.28e-16 4.02e-13 0.44 0.36 Paclitaxel-induced neuropathy; chr22:31458860 chr22:31816379~31817491:- LUSC cis rs853679 0.628 rs9368560 ENSG00000219392.1 RP1-265C24.5 -8.47 3.29e-16 4.03e-13 -0.51 -0.36 Depression; chr6:28192182 chr6:28115628~28116551:+ LUSC cis rs11098499 0.863 rs1383533 ENSG00000249244.1 RP11-548H18.2 8.46 3.29e-16 4.03e-13 0.46 0.36 Corneal astigmatism; chr4:119513421 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs2291185 ENSG00000249244.1 RP11-548H18.2 8.46 3.29e-16 4.03e-13 0.46 0.36 Corneal astigmatism; chr4:119513678 chr4:119391831~119395335:- LUSC cis rs1707322 1 rs7526369 ENSG00000280836.1 AL355480.1 -8.46 3.29e-16 4.04e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45924888 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs10890371 ENSG00000280836.1 AL355480.1 -8.46 3.29e-16 4.04e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45925225 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs10890372 ENSG00000280836.1 AL355480.1 -8.46 3.29e-16 4.04e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45925348 chr1:45581219~45581321:- LUSC cis rs9322193 0.923 rs9480031 ENSG00000223701.3 RAET1E-AS1 8.46 3.3e-16 4.05e-13 0.42 0.36 Lung cancer; chr6:149758875 chr6:149884431~149919508:+ LUSC cis rs9487094 0.626 rs1322124 ENSG00000260273.1 RP11-425D10.10 8.46 3.3e-16 4.05e-13 0.43 0.36 Height; chr6:109741670 chr6:109382795~109383666:+ LUSC cis rs2117029 0.587 rs57853986 ENSG00000258017.1 RP11-386G11.10 -8.46 3.3e-16 4.05e-13 -0.46 -0.36 Intelligence (multi-trait analysis); chr12:49124612 chr12:49127782~49147869:+ LUSC cis rs9918079 0.524 rs4235379 ENSG00000273133.1 RP11-799M12.2 -8.46 3.31e-16 4.05e-13 -0.5 -0.36 Obesity-related traits; chr4:15657655 chr4:15563698~15564253:- LUSC cis rs17507216 0.628 rs4627310 ENSG00000278603.1 RP13-608F4.5 8.46 3.33e-16 4.08e-13 0.56 0.36 Excessive daytime sleepiness; chr15:82708330 chr15:82472203~82472426:+ LUSC cis rs875971 1 rs11971949 ENSG00000222364.1 RNU6-96P 8.46 3.33e-16 4.08e-13 0.43 0.36 Aortic root size; chr7:66161027 chr7:66395191~66395286:+ LUSC cis rs6452524 0.935 rs5000997 ENSG00000249664.1 CTD-2227C6.2 8.46 3.35e-16 4.1e-13 0.38 0.36 Hypertension (SNP x SNP interaction); chr5:83164248 chr5:83012285~83013109:- LUSC cis rs11098499 0.863 rs2306456 ENSG00000245958.5 RP11-33B1.1 -8.46 3.35e-16 4.11e-13 -0.37 -0.36 Corneal astigmatism; chr4:119551267 chr4:119454791~119552025:+ LUSC cis rs526231 0.543 rs246900 ENSG00000175749.11 EIF3KP1 8.46 3.35e-16 4.11e-13 0.45 0.36 Primary biliary cholangitis; chr5:103198928 chr5:103032376~103033031:+ LUSC cis rs875971 0.964 rs6978429 ENSG00000222364.1 RNU6-96P -8.46 3.36e-16 4.11e-13 -0.43 -0.36 Aortic root size; chr7:66494889 chr7:66395191~66395286:+ LUSC cis rs875971 0.929 rs12535036 ENSG00000222364.1 RNU6-96P -8.46 3.36e-16 4.11e-13 -0.43 -0.36 Aortic root size; chr7:66499076 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs12533997 ENSG00000222364.1 RNU6-96P -8.46 3.36e-16 4.11e-13 -0.43 -0.36 Aortic root size; chr7:66500390 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs12532998 ENSG00000222364.1 RNU6-96P -8.46 3.36e-16 4.11e-13 -0.43 -0.36 Aortic root size; chr7:66502472 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs6970030 ENSG00000222364.1 RNU6-96P -8.46 3.36e-16 4.11e-13 -0.43 -0.36 Aortic root size; chr7:66503692 chr7:66395191~66395286:+ LUSC cis rs875971 0.928 rs6970357 ENSG00000222364.1 RNU6-96P -8.46 3.36e-16 4.11e-13 -0.43 -0.36 Aortic root size; chr7:66503891 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs3735148 ENSG00000222364.1 RNU6-96P -8.46 3.36e-16 4.11e-13 -0.43 -0.36 Aortic root size; chr7:66506022 chr7:66395191~66395286:+ LUSC cis rs8062405 0.756 rs151301 ENSG00000259982.1 CDC37P1 8.46 3.37e-16 4.12e-13 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28485738 chr16:28700294~28701540:- LUSC cis rs5769707 0.605 rs6009791 ENSG00000235111.1 RP1-29C18.8 -8.46 3.37e-16 4.13e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49631617 chr22:49612657~49615716:- LUSC cis rs77204473 0.655 rs11216183 ENSG00000254851.1 RP11-109L13.1 8.46 3.39e-16 4.14e-13 0.72 0.36 Sum eosinophil basophil counts;Eosinophil counts; chr11:116910829 chr11:117135528~117138582:+ LUSC cis rs10129255 1 rs10129407 ENSG00000211970.3 IGHV4-61 -8.46 3.41e-16 4.17e-13 -0.26 -0.36 Kawasaki disease; chr14:106767956 chr14:106639119~106639657:- LUSC cis rs2117029 0.587 rs1865157 ENSG00000258017.1 RP11-386G11.10 -8.46 3.41e-16 4.17e-13 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49129003 chr12:49127782~49147869:+ LUSC cis rs9487094 0.848 rs7372 ENSG00000260273.1 RP11-425D10.10 8.46 3.41e-16 4.17e-13 0.45 0.36 Height; chr6:109366911 chr6:109382795~109383666:+ LUSC cis rs9487094 0.961 rs11967108 ENSG00000260273.1 RP11-425D10.10 8.46 3.43e-16 4.2e-13 0.44 0.36 Height; chr6:109354040 chr6:109382795~109383666:+ LUSC cis rs17023223 0.537 rs12065809 ENSG00000231365.4 RP11-418J17.1 -8.46 3.44e-16 4.21e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119181912 chr1:119140396~119275973:+ LUSC cis rs17023223 0.553 rs11484962 ENSG00000231365.4 RP11-418J17.1 -8.46 3.44e-16 4.21e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119182563 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs55836852 ENSG00000231365.4 RP11-418J17.1 -8.46 3.44e-16 4.21e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119182778 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs66715579 ENSG00000231365.4 RP11-418J17.1 -8.46 3.44e-16 4.21e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119182809 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs11487668 ENSG00000231365.4 RP11-418J17.1 -8.46 3.44e-16 4.21e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119184173 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs10923766 ENSG00000231365.4 RP11-418J17.1 -8.46 3.44e-16 4.21e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119184309 chr1:119140396~119275973:+ LUSC cis rs9807989 0.507 rs2058659 ENSG00000234389.1 AC007278.3 -8.46 3.45e-16 4.22e-13 -0.34 -0.36 Asthma; chr2:102438096 chr2:102438713~102440475:+ LUSC cis rs2739330 0.796 rs5760097 ENSG00000231271.1 AP000350.8 8.46 3.49e-16 4.27e-13 0.48 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23949918~23954042:+ LUSC cis rs1707322 0.963 rs1768815 ENSG00000280836.1 AL355480.1 8.46 3.5e-16 4.28e-13 0.44 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46062931 chr1:45581219~45581321:- LUSC cis rs1707322 0.927 rs6690386 ENSG00000280836.1 AL355480.1 -8.46 3.5e-16 4.28e-13 -0.44 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45787339 chr1:45581219~45581321:- LUSC cis rs9487094 0.885 rs59906308 ENSG00000260273.1 RP11-425D10.10 8.46 3.51e-16 4.29e-13 0.45 0.36 Height; chr6:109438349 chr6:109382795~109383666:+ LUSC cis rs9487094 0.922 rs1048203 ENSG00000260273.1 RP11-425D10.10 8.46 3.51e-16 4.29e-13 0.45 0.36 Height; chr6:109441033 chr6:109382795~109383666:+ LUSC cis rs6471393 0.964 rs3813853 ENSG00000253848.1 RP11-10N23.5 8.46 3.52e-16 4.29e-13 0.46 0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93740526 chr8:93741193~93744534:+ LUSC cis rs11098499 0.863 rs7664986 ENSG00000249244.1 RP11-548H18.2 8.46 3.52e-16 4.3e-13 0.47 0.36 Corneal astigmatism; chr4:119508797 chr4:119391831~119395335:- LUSC cis rs11098499 0.818 rs10008791 ENSG00000249244.1 RP11-548H18.2 8.46 3.52e-16 4.3e-13 0.47 0.36 Corneal astigmatism; chr4:119510314 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs11736416 ENSG00000249244.1 RP11-548H18.2 8.46 3.52e-16 4.3e-13 0.47 0.36 Corneal astigmatism; chr4:119510506 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3775845 ENSG00000249244.1 RP11-548H18.2 8.46 3.52e-16 4.3e-13 0.47 0.36 Corneal astigmatism; chr4:119511292 chr4:119391831~119395335:- LUSC cis rs8062405 0.723 rs35175818 ENSG00000259982.1 CDC37P1 8.45 3.54e-16 4.33e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597425 chr16:28700294~28701540:- LUSC cis rs1501911 0.566 rs709387 ENSG00000248489.1 CTD-2007H13.3 8.45 3.56e-16 4.34e-13 0.45 0.36 Lung function (FEV1/FVC); chr5:98994337 chr5:98929171~98995013:+ LUSC cis rs1501911 0.588 rs709386 ENSG00000248489.1 CTD-2007H13.3 8.45 3.56e-16 4.34e-13 0.45 0.36 Lung function (FEV1/FVC); chr5:98994346 chr5:98929171~98995013:+ LUSC cis rs8062405 0.723 rs4788079 ENSG00000259982.1 CDC37P1 8.45 3.57e-16 4.36e-13 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548042 chr16:28700294~28701540:- LUSC cis rs1891275 0.551 rs11186640 ENSG00000228701.1 TNKS2-AS1 -8.45 3.58e-16 4.37e-13 -0.45 -0.36 Intelligence (multi-trait analysis); chr10:91640674 chr10:91782839~91798291:- LUSC cis rs3096299 0.967 rs2911256 ENSG00000274627.1 RP11-104N10.2 8.45 3.59e-16 4.38e-13 0.33 0.36 Multiple myeloma (IgH translocation); chr16:89418688 chr16:89516797~89522217:+ LUSC cis rs9487094 0.689 rs6939548 ENSG00000260273.1 RP11-425D10.10 8.45 3.6e-16 4.4e-13 0.43 0.36 Height; chr6:109464011 chr6:109382795~109383666:+ LUSC cis rs9487094 0.666 rs3734652 ENSG00000260273.1 RP11-425D10.10 8.45 3.6e-16 4.4e-13 0.43 0.36 Height; chr6:109465777 chr6:109382795~109383666:+ LUSC cis rs9487094 1 rs12197114 ENSG00000260273.1 RP11-425D10.10 8.45 3.61e-16 4.41e-13 0.45 0.36 Height; chr6:109414295 chr6:109382795~109383666:+ LUSC cis rs8072100 0.807 rs2175290 ENSG00000228782.6 CTD-2026D20.3 8.45 3.62e-16 4.42e-13 0.34 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402551 chr17:47450568~47492492:- LUSC cis rs11155671 0.53 rs4869763 ENSG00000268592.3 RAET1E-AS1 8.45 3.65e-16 4.45e-13 0.45 0.36 Testicular germ cell tumor; chr6:149890548 chr6:149863494~149919507:+ LUSC cis rs875971 1 rs55962648 ENSG00000222364.1 RNU6-96P 8.45 3.65e-16 4.45e-13 0.43 0.36 Aortic root size; chr7:66160764 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs2420168 ENSG00000222364.1 RNU6-96P 8.45 3.65e-16 4.45e-13 0.43 0.36 Aortic root size; chr7:66165644 chr7:66395191~66395286:+ LUSC cis rs875971 0.838 rs2173570 ENSG00000222364.1 RNU6-96P 8.45 3.65e-16 4.45e-13 0.43 0.36 Aortic root size; chr7:66297976 chr7:66395191~66395286:+ LUSC cis rs8062405 0.723 rs62031562 ENSG00000259982.1 CDC37P1 8.45 3.66e-16 4.46e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28598008 chr16:28700294~28701540:- LUSC cis rs10875746 0.768 rs4760609 ENSG00000240399.1 RP1-228P16.1 8.45 3.67e-16 4.47e-13 0.39 0.36 Longevity (90 years and older); chr12:48021974 chr12:48054813~48055591:- LUSC cis rs10463554 0.927 rs257308 ENSG00000175749.11 EIF3KP1 8.45 3.69e-16 4.5e-13 0.44 0.36 Parkinson's disease; chr5:103082557 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs257311 ENSG00000175749.11 EIF3KP1 8.45 3.69e-16 4.5e-13 0.44 0.36 Parkinson's disease; chr5:103083394 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs257314 ENSG00000175749.11 EIF3KP1 8.45 3.69e-16 4.5e-13 0.44 0.36 Parkinson's disease; chr5:103085391 chr5:103032376~103033031:+ LUSC cis rs2283792 1 rs5999515 ENSG00000228050.1 TOP3BP1 -8.45 3.69e-16 4.5e-13 -0.42 -0.36 Multiple sclerosis; chr22:21790812 chr22:22223187~22224566:- LUSC cis rs8062405 0.755 rs7186573 ENSG00000259982.1 CDC37P1 8.45 3.69e-16 4.5e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576068 chr16:28700294~28701540:- LUSC cis rs8072100 0.745 rs7214410 ENSG00000228782.6 CTD-2026D20.3 8.45 3.69e-16 4.5e-13 0.35 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47345262 chr17:47450568~47492492:- LUSC cis rs526231 0.543 rs34766 ENSG00000175749.11 EIF3KP1 8.45 3.7e-16 4.5e-13 0.44 0.36 Primary biliary cholangitis; chr5:103175219 chr5:103032376~103033031:+ LUSC cis rs11098499 0.863 rs9997631 ENSG00000245958.5 RP11-33B1.1 -8.45 3.71e-16 4.51e-13 -0.37 -0.36 Corneal astigmatism; chr4:119548840 chr4:119454791~119552025:+ LUSC cis rs875971 0.895 rs7788984 ENSG00000222364.1 RNU6-96P -8.45 3.71e-16 4.52e-13 -0.43 -0.36 Aortic root size; chr7:66450629 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs1981798 ENSG00000222364.1 RNU6-96P -8.45 3.71e-16 4.52e-13 -0.43 -0.36 Aortic root size; chr7:66489916 chr7:66395191~66395286:+ LUSC cis rs1707322 1 rs2458400 ENSG00000280836.1 AL355480.1 8.45 3.74e-16 4.55e-13 0.44 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46065126 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs9429186 ENSG00000280836.1 AL355480.1 8.45 3.74e-16 4.55e-13 0.44 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46074015 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs785506 ENSG00000280836.1 AL355480.1 8.45 3.74e-16 4.55e-13 0.44 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46074980 chr1:45581219~45581321:- LUSC cis rs9660180 0.967 rs6687065 ENSG00000268575.1 RP1-283E3.8 -8.45 3.75e-16 4.56e-13 -0.33 -0.36 Body mass index; chr1:1847030 chr1:1702736~1737688:- LUSC cis rs9322193 0.923 rs10872651 ENSG00000223701.3 RAET1E-AS1 8.45 3.75e-16 4.56e-13 0.43 0.36 Lung cancer; chr6:149768273 chr6:149884431~149919508:+ LUSC cis rs4728142 0.564 rs10954213 ENSG00000275106.1 RP11-309L24.10 -8.45 3.75e-16 4.57e-13 -0.47 -0.36 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128949373 chr7:128952527~128953316:- LUSC cis rs4728142 0.604 rs13242262 ENSG00000275106.1 RP11-309L24.10 -8.45 3.75e-16 4.57e-13 -0.47 -0.36 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128951310 chr7:128952527~128953316:- LUSC cis rs9807989 0.507 rs4479442 ENSG00000234389.1 AC007278.3 8.45 3.76e-16 4.57e-13 0.35 0.36 Asthma; chr2:102437614 chr2:102438713~102440475:+ LUSC cis rs8062405 0.723 rs762633 ENSG00000259982.1 CDC37P1 8.45 3.8e-16 4.63e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597020 chr16:28700294~28701540:- LUSC cis rs9322193 0.962 rs3805749 ENSG00000223701.3 RAET1E-AS1 8.44 3.84e-16 4.67e-13 0.43 0.36 Lung cancer; chr6:149772546 chr6:149884431~149919508:+ LUSC cis rs9322193 0.847 rs9505972 ENSG00000223701.3 RAET1E-AS1 8.44 3.84e-16 4.67e-13 0.43 0.36 Lung cancer; chr6:149775255 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9371207 ENSG00000223701.3 RAET1E-AS1 8.44 3.84e-16 4.67e-13 0.42 0.36 Lung cancer; chr6:149858087 chr6:149884431~149919508:+ LUSC cis rs9322193 0.566 rs5024811 ENSG00000216906.2 RP11-350J20.9 -8.44 3.87e-16 4.71e-13 -0.48 -0.36 Lung cancer; chr6:149924898 chr6:149904243~149906418:+ LUSC cis rs10463554 0.963 rs67068617 ENSG00000175749.11 EIF3KP1 8.44 3.88e-16 4.71e-13 0.44 0.36 Parkinson's disease; chr5:103039977 chr5:103032376~103033031:+ LUSC cis rs11098499 0.863 rs13140391 ENSG00000245958.5 RP11-33B1.1 -8.44 3.88e-16 4.71e-13 -0.37 -0.36 Corneal astigmatism; chr4:119582282 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs13140409 ENSG00000245958.5 RP11-33B1.1 -8.44 3.88e-16 4.71e-13 -0.37 -0.36 Corneal astigmatism; chr4:119582305 chr4:119454791~119552025:+ LUSC cis rs3823536 0.604 rs13221560 ENSG00000275106.1 RP11-309L24.10 -8.44 3.89e-16 4.72e-13 -0.48 -0.36 Sjögren's syndrome; chr7:129023121 chr7:128952527~128953316:- LUSC cis rs6471393 0.929 rs62525162 ENSG00000253848.1 RP11-10N23.5 8.44 3.89e-16 4.72e-13 0.46 0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93749654 chr8:93741193~93744534:+ LUSC cis rs1155848 0.892 rs1023293 ENSG00000227354.5 RBM26-AS1 8.44 3.91e-16 4.74e-13 0.72 0.36 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79480285 chr13:79406309~79424328:+ LUSC cis rs11098499 0.863 rs6833334 ENSG00000245958.5 RP11-33B1.1 -8.44 3.91e-16 4.75e-13 -0.37 -0.36 Corneal astigmatism; chr4:119583072 chr4:119454791~119552025:+ LUSC cis rs11098499 0.78 rs12504773 ENSG00000249244.1 RP11-548H18.2 8.44 3.94e-16 4.78e-13 0.47 0.36 Corneal astigmatism; chr4:119640994 chr4:119391831~119395335:- LUSC cis rs11098499 0.738 rs34566984 ENSG00000249244.1 RP11-548H18.2 8.44 3.95e-16 4.79e-13 0.47 0.36 Corneal astigmatism; chr4:119440115 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs9685777 ENSG00000249244.1 RP11-548H18.2 8.44 3.95e-16 4.79e-13 0.47 0.36 Corneal astigmatism; chr4:119444810 chr4:119391831~119395335:- LUSC cis rs35955747 0.934 rs5997966 ENSG00000236132.1 CTA-440B3.1 8.44 3.95e-16 4.79e-13 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31380260 chr22:31816379~31817491:- LUSC cis rs26232 0.521 rs3776855 ENSG00000175749.11 EIF3KP1 8.44 3.96e-16 4.81e-13 0.45 0.36 Rheumatoid arthritis; chr5:103023111 chr5:103032376~103033031:+ LUSC cis rs11098499 0.697 rs11941899 ENSG00000249244.1 RP11-548H18.2 8.44 3.98e-16 4.83e-13 0.48 0.36 Corneal astigmatism; chr4:119461603 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs7681978 ENSG00000249244.1 RP11-548H18.2 8.44 3.98e-16 4.83e-13 0.48 0.36 Corneal astigmatism; chr4:119462620 chr4:119391831~119395335:- LUSC cis rs11098499 0.821 rs28665282 ENSG00000249244.1 RP11-548H18.2 8.44 3.98e-16 4.83e-13 0.48 0.36 Corneal astigmatism; chr4:119463031 chr4:119391831~119395335:- LUSC cis rs11098499 0.738 rs10026493 ENSG00000249244.1 RP11-548H18.2 8.44 3.98e-16 4.83e-13 0.48 0.36 Corneal astigmatism; chr4:119463039 chr4:119391831~119395335:- LUSC cis rs9487094 0.961 rs752262 ENSG00000260273.1 RP11-425D10.10 8.44 3.98e-16 4.83e-13 0.45 0.36 Height; chr6:109449796 chr6:109382795~109383666:+ LUSC cis rs9487094 0.961 rs12206928 ENSG00000260273.1 RP11-425D10.10 8.44 3.98e-16 4.83e-13 0.45 0.36 Height; chr6:109357908 chr6:109382795~109383666:+ LUSC cis rs7189233 0.531 rs9921587 ENSG00000279344.1 RP11-44F14.7 8.44 3.99e-16 4.83e-13 0.32 0.36 Intelligence (multi-trait analysis); chr16:53441738 chr16:53478957~53481550:- LUSC cis rs8062405 0.755 rs55792032 ENSG00000259982.1 CDC37P1 8.44 3.99e-16 4.84e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28588090 chr16:28700294~28701540:- LUSC cis rs3823536 0.583 rs1072767 ENSG00000275106.1 RP11-309L24.10 -8.44 4.02e-16 4.87e-13 -0.5 -0.36 Sjögren's syndrome; chr7:129033151 chr7:128952527~128953316:- LUSC cis rs875971 1 rs6961717 ENSG00000222364.1 RNU6-96P 8.44 4.04e-16 4.9e-13 0.43 0.36 Aortic root size; chr7:66122550 chr7:66395191~66395286:+ LUSC cis rs875971 0.867 rs1002053 ENSG00000222364.1 RNU6-96P 8.44 4.05e-16 4.91e-13 0.43 0.36 Aortic root size; chr7:66333558 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs6460292 ENSG00000222364.1 RNU6-96P 8.44 4.05e-16 4.91e-13 0.43 0.36 Aortic root size; chr7:66345088 chr7:66395191~66395286:+ LUSC cis rs1113500 0.933 rs1414674 ENSG00000226822.1 RP11-356N1.2 8.44 4.06e-16 4.92e-13 0.38 0.36 Growth-regulated protein alpha levels; chr1:108083325 chr1:108071482~108074519:+ LUSC cis rs7044106 0.791 rs4836830 ENSG00000226752.6 PSMD5-AS1 -8.44 4.08e-16 4.94e-13 -0.42 -0.36 Hip circumference adjusted for BMI; chr9:120721390 chr9:120824828~120854385:+ LUSC cis rs10129255 0.957 rs12590735 ENSG00000211970.3 IGHV4-61 -8.44 4.08e-16 4.94e-13 -0.25 -0.36 Kawasaki disease; chr14:106779660 chr14:106639119~106639657:- LUSC cis rs875971 1 rs4718357 ENSG00000222364.1 RNU6-96P -8.44 4.09e-16 4.95e-13 -0.43 -0.36 Aortic root size; chr7:66495891 chr7:66395191~66395286:+ LUSC cis rs11098499 0.691 rs10010355 ENSG00000245958.5 RP11-33B1.1 -8.44 4.09e-16 4.95e-13 -0.36 -0.36 Corneal astigmatism; chr4:119339888 chr4:119454791~119552025:+ LUSC cis rs11098499 0.691 rs9307471 ENSG00000245958.5 RP11-33B1.1 -8.44 4.09e-16 4.95e-13 -0.36 -0.36 Corneal astigmatism; chr4:119340107 chr4:119454791~119552025:+ LUSC cis rs875971 0.964 rs1643388 ENSG00000222364.1 RNU6-96P -8.44 4.1e-16 4.96e-13 -0.43 -0.36 Aortic root size; chr7:66379575 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs778722 ENSG00000222364.1 RNU6-96P -8.44 4.1e-16 4.96e-13 -0.43 -0.36 Aortic root size; chr7:66379841 chr7:66395191~66395286:+ LUSC cis rs7617773 0.817 rs6800492 ENSG00000228638.1 FCF1P2 -8.44 4.11e-16 4.97e-13 -0.42 -0.36 Coronary artery disease; chr3:48282400 chr3:48290793~48291375:- LUSC cis rs8062405 0.755 rs4788073 ENSG00000259982.1 CDC37P1 8.43 4.13e-16 5e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28583228 chr16:28700294~28701540:- LUSC cis rs10256972 0.521 rs7811577 ENSG00000229043.2 AC091729.9 -8.43 4.13e-16 5e-13 -0.41 -0.36 Endometriosis;Longevity; chr7:1063193 chr7:1160374~1165267:+ LUSC cis rs11098499 0.863 rs1552092 ENSG00000245958.5 RP11-33B1.1 -8.43 4.14e-16 5.01e-13 -0.37 -0.36 Corneal astigmatism; chr4:119567341 chr4:119454791~119552025:+ LUSC cis rs150992 0.603 rs326481 ENSG00000248489.1 CTD-2007H13.3 8.43 4.14e-16 5.01e-13 0.43 0.36 Body mass index; chr5:98949581 chr5:98929171~98995013:+ LUSC cis rs1707322 1 rs7527079 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45947778 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs34446427 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45951983 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs4660900 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45953933 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4454479 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45957883 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs12077546 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45966134 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs12124291 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45966460 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs6671754 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45968318 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs6666763 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45970779 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4489497 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45973026 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211235 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45974703 chr1:45581219~45581321:- LUSC cis rs1707322 0.893 rs9919275 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45975688 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211236 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45978095 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4660328 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45979159 chr1:45581219~45581321:- LUSC cis rs1707322 0.928 rs61785614 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45980375 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs9793167 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45981128 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211237 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45981657 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs11211238 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45983743 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs4460583 ENSG00000280836.1 AL355480.1 -8.43 4.14e-16 5.01e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45984246 chr1:45581219~45581321:- LUSC cis rs875971 0.83 rs4718358 ENSG00000222364.1 RNU6-96P -8.43 4.15e-16 5.01e-13 -0.43 -0.36 Aortic root size; chr7:66508681 chr7:66395191~66395286:+ LUSC cis rs5769707 0.681 rs4824068 ENSG00000235111.1 RP1-29C18.8 -8.43 4.15e-16 5.02e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49631153 chr22:49612657~49615716:- LUSC cis rs11098499 0.954 rs1480931 ENSG00000249244.1 RP11-548H18.2 8.43 4.17e-16 5.04e-13 0.46 0.36 Corneal astigmatism; chr4:119474654 chr4:119391831~119395335:- LUSC cis rs2337406 0.866 rs4773949 ENSG00000274576.2 IGHV2-70 8.43 4.2e-16 5.07e-13 0.36 0.36 Alzheimer's disease (late onset); chr14:106808070 chr14:106770577~106771020:- LUSC cis rs2337406 0.789 rs112027230 ENSG00000274576.2 IGHV2-70 -8.43 4.2e-16 5.07e-13 -0.39 -0.36 Alzheimer's disease (late onset); chr14:106810329 chr14:106770577~106771020:- LUSC cis rs5769707 0.681 rs6009803 ENSG00000235111.1 RP1-29C18.8 -8.43 4.2e-16 5.08e-13 -0.46 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49657359 chr22:49612657~49615716:- LUSC cis rs17507216 0.628 rs28737193 ENSG00000278603.1 RP13-608F4.5 8.43 4.21e-16 5.08e-13 0.54 0.36 Excessive daytime sleepiness; chr15:82701318 chr15:82472203~82472426:+ LUSC cis rs992157 0.835 rs4674282 ENSG00000261338.2 RP11-378A13.1 -8.43 4.22e-16 5.09e-13 -0.37 -0.36 Colorectal cancer; chr2:218279507 chr2:218255319~218257366:+ LUSC cis rs4927850 1 rs7630875 ENSG00000231464.1 AC024937.4 8.43 4.22e-16 5.1e-13 0.39 0.36 Pancreatic cancer; chr3:196026895 chr3:195996738~195998233:+ LUSC cis rs7201929 1 rs7201929 ENSG00000259982.1 CDC37P1 8.43 4.22e-16 5.1e-13 0.48 0.36 QT interval; chr16:28860645 chr16:28700294~28701540:- LUSC cis rs6471393 0.929 rs58575315 ENSG00000253848.1 RP11-10N23.5 8.43 4.23e-16 5.1e-13 0.46 0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93749495 chr8:93741193~93744534:+ LUSC cis rs2283792 0.967 rs11704205 ENSG00000228050.1 TOP3BP1 8.43 4.23e-16 5.11e-13 0.42 0.36 Multiple sclerosis; chr22:21790964 chr22:22223187~22224566:- LUSC cis rs9322193 0.923 rs11155670 ENSG00000223701.3 RAET1E-AS1 8.43 4.23e-16 5.11e-13 0.42 0.36 Lung cancer; chr6:149644992 chr6:149884431~149919508:+ LUSC cis rs1707322 1 rs12403666 ENSG00000280836.1 AL355480.1 -8.43 4.24e-16 5.11e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45965949 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs6429588 ENSG00000280836.1 AL355480.1 -8.43 4.24e-16 5.11e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45988386 chr1:45581219~45581321:- LUSC cis rs11155671 0.53 rs6557133 ENSG00000223701.3 RAET1E-AS1 8.43 4.24e-16 5.12e-13 0.41 0.36 Testicular germ cell tumor; chr6:149874248 chr6:149884431~149919508:+ LUSC cis rs7617773 0.817 rs9837228 ENSG00000228638.1 FCF1P2 8.43 4.27e-16 5.15e-13 0.42 0.36 Coronary artery disease; chr3:48282976 chr3:48290793~48291375:- LUSC cis rs2882667 0.537 rs7701338 ENSG00000253404.1 AC034243.1 8.43 4.28e-16 5.16e-13 0.43 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139070305 chr5:138744434~138753309:- LUSC cis rs9487094 0.961 rs1546980 ENSG00000260273.1 RP11-425D10.10 8.43 4.29e-16 5.17e-13 0.45 0.36 Height; chr6:109452743 chr6:109382795~109383666:+ LUSC cis rs9487094 0.885 rs1590306 ENSG00000260273.1 RP11-425D10.10 8.43 4.32e-16 5.2e-13 0.45 0.36 Height; chr6:109359747 chr6:109382795~109383666:+ LUSC cis rs1707322 1 rs10890380 ENSG00000280836.1 AL355480.1 -8.43 4.35e-16 5.24e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45983797 chr1:45581219~45581321:- LUSC cis rs10129255 0.957 rs10137980 ENSG00000211970.3 IGHV4-61 -8.43 4.35e-16 5.24e-13 -0.26 -0.36 Kawasaki disease; chr14:106775735 chr14:106639119~106639657:- LUSC cis rs8062405 0.755 rs4787457 ENSG00000259982.1 CDC37P1 8.43 4.35e-16 5.24e-13 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544079 chr16:28700294~28701540:- LUSC cis rs8062405 0.755 rs4788080 ENSG00000259982.1 CDC37P1 8.43 4.35e-16 5.24e-13 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546760 chr16:28700294~28701540:- LUSC cis rs8062405 0.755 rs4787456 ENSG00000259982.1 CDC37P1 8.43 4.35e-16 5.24e-13 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548252 chr16:28700294~28701540:- LUSC cis rs7849270 1 rs713219 ENSG00000268707.1 RP11-247A12.7 -8.43 4.4e-16 5.3e-13 -0.41 -0.36 Blood metabolite ratios; chr9:129138641 chr9:129170434~129170940:+ LUSC cis rs8062405 0.755 rs4149398 ENSG00000259982.1 CDC37P1 8.43 4.41e-16 5.31e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597617 chr16:28700294~28701540:- LUSC cis rs9322193 0.923 rs9478291 ENSG00000223701.3 RAET1E-AS1 8.43 4.41e-16 5.31e-13 0.42 0.36 Lung cancer; chr6:149729434 chr6:149884431~149919508:+ LUSC cis rs1707322 1 rs7517560 ENSG00000280836.1 AL355480.1 -8.43 4.42e-16 5.32e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45960271 chr1:45581219~45581321:- LUSC cis rs5769707 0.568 rs2011097 ENSG00000235111.1 RP1-29C18.8 -8.43 4.43e-16 5.32e-13 -0.44 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49624421 chr22:49612657~49615716:- LUSC cis rs875971 0.964 rs778721 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66380410 chr7:66395191~66395286:+ LUSC cis rs875971 0.929 rs778712 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66384991 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs778710 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66389847 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs778708 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66391332 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs778706 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66395437 chr7:66395191~66395286:+ LUSC cis rs875971 0.895 rs778700 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66401463 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs778699 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66403303 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs778696 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66405826 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs778694 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66406571 chr7:66395191~66395286:+ LUSC cis rs875971 0.929 rs778692 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66407462 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs4718343 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66409301 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs4718344 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66409394 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs1968225 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66409786 chr7:66395191~66395286:+ LUSC cis rs875971 0.737 rs7803424 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66415618 chr7:66395191~66395286:+ LUSC cis rs875971 0.83 rs7799834 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66415707 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs6460295 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66417741 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs6978721 ENSG00000222364.1 RNU6-96P -8.43 4.43e-16 5.32e-13 -0.43 -0.36 Aortic root size; chr7:66418217 chr7:66395191~66395286:+ LUSC cis rs5769707 0.749 rs8137251 ENSG00000235111.1 RP1-29C18.8 -8.42 4.48e-16 5.38e-13 -0.44 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49643021 chr22:49612657~49615716:- LUSC cis rs11098499 0.863 rs1480940 ENSG00000249244.1 RP11-548H18.2 8.42 4.54e-16 5.45e-13 0.47 0.36 Corneal astigmatism; chr4:119536527 chr4:119391831~119395335:- LUSC cis rs1501911 0.566 rs709388 ENSG00000248489.1 CTD-2007H13.3 8.42 4.54e-16 5.46e-13 0.44 0.36 Lung function (FEV1/FVC); chr5:98994037 chr5:98929171~98995013:+ LUSC cis rs11098499 0.863 rs7678400 ENSG00000245958.5 RP11-33B1.1 -8.42 4.54e-16 5.46e-13 -0.37 -0.36 Corneal astigmatism; chr4:119540802 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs1480936 ENSG00000245958.5 RP11-33B1.1 -8.42 4.54e-16 5.46e-13 -0.37 -0.36 Corneal astigmatism; chr4:119541706 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs9800736 ENSG00000223701.3 RAET1E-AS1 8.42 4.57e-16 5.49e-13 0.42 0.36 Lung cancer; chr6:149661281 chr6:149884431~149919508:+ LUSC cis rs875971 0.895 rs12698520 ENSG00000222364.1 RNU6-96P -8.42 4.58e-16 5.5e-13 -0.43 -0.36 Aortic root size; chr7:66453720 chr7:66395191~66395286:+ LUSC cis rs2412819 0.571 rs8030536 ENSG00000249839.1 AC011330.5 -8.42 4.58e-16 5.5e-13 -0.61 -0.36 Lung cancer; chr15:43627365 chr15:43663654~43684339:- LUSC cis rs875971 1 rs2087647 ENSG00000222364.1 RNU6-96P 8.42 4.59e-16 5.51e-13 0.42 0.36 Aortic root size; chr7:66128201 chr7:66395191~66395286:+ LUSC cis rs1707322 1 rs12077974 ENSG00000280836.1 AL355480.1 -8.42 4.61e-16 5.54e-13 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45918469 chr1:45581219~45581321:- LUSC cis rs748404 0.578 rs2278856 ENSG00000249839.1 AC011330.5 -8.42 4.62e-16 5.55e-13 -0.49 -0.36 Lung cancer; chr15:43339158 chr15:43663654~43684339:- LUSC cis rs9322193 0.886 rs2065663 ENSG00000223701.3 RAET1E-AS1 8.42 4.64e-16 5.57e-13 0.42 0.36 Lung cancer; chr6:149760331 chr6:149884431~149919508:+ LUSC cis rs1155848 0.892 rs9565508 ENSG00000227354.5 RBM26-AS1 8.42 4.66e-16 5.59e-13 0.71 0.36 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79482451 chr13:79406309~79424328:+ LUSC cis rs733592 0.56 rs61918773 ENSG00000240399.1 RP1-228P16.1 -8.42 4.68e-16 5.62e-13 -0.35 -0.36 Plateletcrit; chr12:48027991 chr12:48054813~48055591:- LUSC cis rs6452524 0.935 rs6887915 ENSG00000249664.1 CTD-2227C6.2 8.42 4.69e-16 5.63e-13 0.38 0.36 Hypertension (SNP x SNP interaction); chr5:83170837 chr5:83012285~83013109:- LUSC cis rs875971 0.895 rs4718349 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66444024 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs2420591 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66447394 chr7:66395191~66395286:+ LUSC cis rs875971 0.895 rs10755833 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66448930 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs12668936 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66449417 chr7:66395191~66395286:+ LUSC cis rs875971 0.895 rs1833495 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66456608 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs6945032 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66457499 chr7:66395191~66395286:+ LUSC cis rs875971 0.929 rs12673810 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66458866 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs35149210 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66464938 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs2042133 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66466935 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs2161065 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66467918 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs6961155 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66468308 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs7789768 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66473993 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs12698521 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66474502 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs1363055 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66478288 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs9691480 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66479319 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs7789554 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66481051 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs4717300 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66482393 chr7:66395191~66395286:+ LUSC cis rs875971 0.895 rs1974769 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66485627 chr7:66395191~66395286:+ LUSC cis rs875971 0.895 rs6460300 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66487937 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs7803416 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66489212 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs1981799 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66490572 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs2277911 ENSG00000222364.1 RNU6-96P -8.42 4.73e-16 5.66e-13 -0.43 -0.36 Aortic root size; chr7:66493638 chr7:66395191~66395286:+ LUSC cis rs9322193 0.81 rs62439811 ENSG00000223701.3 RAET1E-AS1 8.42 4.73e-16 5.67e-13 0.42 0.36 Lung cancer; chr6:149640416 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9383812 ENSG00000223701.3 RAET1E-AS1 8.42 4.74e-16 5.68e-13 0.42 0.36 Lung cancer; chr6:149712355 chr6:149884431~149919508:+ LUSC cis rs9487094 0.961 rs11153177 ENSG00000260273.1 RP11-425D10.10 8.42 4.74e-16 5.68e-13 0.45 0.36 Height; chr6:109416225 chr6:109382795~109383666:+ LUSC cis rs10028773 0.6 rs4001390 ENSG00000245958.5 RP11-33B1.1 -8.42 4.74e-16 5.68e-13 -0.36 -0.36 Educational attainment; chr4:119344628 chr4:119454791~119552025:+ LUSC cis rs11098499 0.691 rs2136911 ENSG00000245958.5 RP11-33B1.1 -8.42 4.74e-16 5.68e-13 -0.36 -0.36 Corneal astigmatism; chr4:119344704 chr4:119454791~119552025:+ LUSC cis rs11098499 0.779 rs6815934 ENSG00000245958.5 RP11-33B1.1 -8.42 4.74e-16 5.68e-13 -0.36 -0.36 Corneal astigmatism; chr4:119346155 chr4:119454791~119552025:+ LUSC cis rs10028773 0.568 rs6838457 ENSG00000245958.5 RP11-33B1.1 -8.42 4.74e-16 5.68e-13 -0.36 -0.36 Educational attainment; chr4:119346212 chr4:119454791~119552025:+ LUSC cis rs6921919 0.887 rs16894116 ENSG00000216901.1 AL022393.7 8.42 4.75e-16 5.69e-13 0.49 0.36 Autism spectrum disorder or schizophrenia; chr6:28447190 chr6:28176188~28176674:+ LUSC cis rs5769707 0.605 rs2071900 ENSG00000235111.1 RP1-29C18.8 -8.42 4.75e-16 5.69e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49658527 chr22:49612657~49615716:- LUSC cis rs2283792 1 rs2266967 ENSG00000228050.1 TOP3BP1 8.42 4.77e-16 5.71e-13 0.42 0.36 Multiple sclerosis; chr22:21802500 chr22:22223187~22224566:- LUSC cis rs35955747 0.934 rs926928 ENSG00000236132.1 CTA-440B3.1 8.42 4.77e-16 5.71e-13 0.44 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31425733 chr22:31816379~31817491:- LUSC cis rs7044106 0.762 rs3903886 ENSG00000226752.6 PSMD5-AS1 8.41 4.79e-16 5.74e-13 0.41 0.36 Hip circumference adjusted for BMI; chr9:120621368 chr9:120824828~120854385:+ LUSC cis rs17023223 0.537 rs10923767 ENSG00000231365.4 RP11-418J17.1 -8.41 4.8e-16 5.75e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119189724 chr1:119140396~119275973:+ LUSC cis rs11098499 0.863 rs2170276 ENSG00000245958.5 RP11-33B1.1 -8.41 4.82e-16 5.77e-13 -0.37 -0.36 Corneal astigmatism; chr4:119564669 chr4:119454791~119552025:+ LUSC cis rs7189233 0.531 rs6499617 ENSG00000279344.1 RP11-44F14.7 8.41 4.83e-16 5.78e-13 0.32 0.36 Intelligence (multi-trait analysis); chr16:53433810 chr16:53478957~53481550:- LUSC cis rs526231 0.543 rs26819 ENSG00000175749.11 EIF3KP1 8.41 4.83e-16 5.78e-13 0.44 0.36 Primary biliary cholangitis; chr5:103193700 chr5:103032376~103033031:+ LUSC cis rs526231 0.615 rs26818 ENSG00000175749.11 EIF3KP1 8.41 4.83e-16 5.78e-13 0.44 0.36 Primary biliary cholangitis; chr5:103194018 chr5:103032376~103033031:+ LUSC cis rs875971 1 rs2077593 ENSG00000222364.1 RNU6-96P -8.41 4.85e-16 5.8e-13 -0.43 -0.36 Aortic root size; chr7:66427543 chr7:66395191~66395286:+ LUSC cis rs10463554 0.963 rs6883113 ENSG00000175749.11 EIF3KP1 8.41 4.86e-16 5.82e-13 0.44 0.36 Parkinson's disease; chr5:103042185 chr5:103032376~103033031:+ LUSC cis rs11155671 0.53 rs9383912 ENSG00000268592.3 RAET1E-AS1 8.41 4.87e-16 5.83e-13 0.44 0.36 Testicular germ cell tumor; chr6:149885479 chr6:149863494~149919507:+ LUSC cis rs11098499 0.554 rs2175381 ENSG00000245958.5 RP11-33B1.1 -8.41 4.88e-16 5.84e-13 -0.36 -0.36 Corneal astigmatism; chr4:119344812 chr4:119454791~119552025:+ LUSC cis rs11098499 0.599 rs3864142 ENSG00000245958.5 RP11-33B1.1 -8.41 4.88e-16 5.84e-13 -0.36 -0.36 Corneal astigmatism; chr4:119345036 chr4:119454791~119552025:+ LUSC cis rs11098499 0.605 rs6833140 ENSG00000245958.5 RP11-33B1.1 -8.41 4.88e-16 5.84e-13 -0.36 -0.36 Corneal astigmatism; chr4:119345667 chr4:119454791~119552025:+ LUSC cis rs875971 0.929 rs34406470 ENSG00000222364.1 RNU6-96P -8.41 4.88e-16 5.84e-13 -0.43 -0.36 Aortic root size; chr7:66464969 chr7:66395191~66395286:+ LUSC cis rs7189233 0.531 rs9931702 ENSG00000279344.1 RP11-44F14.7 8.41 4.89e-16 5.85e-13 0.31 0.36 Intelligence (multi-trait analysis); chr16:53492639 chr16:53478957~53481550:- LUSC cis rs11168854 0.656 rs7969967 ENSG00000258017.1 RP11-386G11.10 8.41 4.91e-16 5.87e-13 0.47 0.36 Body mass index; chr12:49118234 chr12:49127782~49147869:+ LUSC cis rs10129255 0.785 rs10150044 ENSG00000211970.3 IGHV4-61 -8.41 4.93e-16 5.89e-13 -0.26 -0.36 Kawasaki disease; chr14:106775695 chr14:106639119~106639657:- LUSC cis rs875971 1 rs6460296 ENSG00000222364.1 RNU6-96P -8.41 4.93e-16 5.9e-13 -0.43 -0.36 Aortic root size; chr7:66430152 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs4717292 ENSG00000222364.1 RNU6-96P -8.41 4.93e-16 5.9e-13 -0.43 -0.36 Aortic root size; chr7:66430611 chr7:66395191~66395286:+ LUSC cis rs12439619 0.693 rs7165536 ENSG00000255769.6 GOLGA2P10 -8.41 4.95e-16 5.92e-13 -0.5 -0.36 Intelligence (multi-trait analysis); chr15:82273743 chr15:82472993~82513950:- LUSC cis rs10463554 0.857 rs34376 ENSG00000175749.11 EIF3KP1 8.41 4.99e-16 5.96e-13 0.44 0.36 Parkinson's disease; chr5:103065409 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs34375 ENSG00000175749.11 EIF3KP1 8.41 4.99e-16 5.96e-13 0.44 0.36 Parkinson's disease; chr5:103065419 chr5:103032376~103033031:+ LUSC cis rs11098499 0.863 rs6853998 ENSG00000245958.5 RP11-33B1.1 -8.41 5e-16 5.97e-13 -0.37 -0.36 Corneal astigmatism; chr4:119554705 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs6858777 ENSG00000245958.5 RP11-33B1.1 -8.41 5e-16 5.97e-13 -0.37 -0.36 Corneal astigmatism; chr4:119554811 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs11731756 ENSG00000245958.5 RP11-33B1.1 -8.41 5e-16 5.97e-13 -0.37 -0.36 Corneal astigmatism; chr4:119557541 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs34308924 ENSG00000245958.5 RP11-33B1.1 -8.41 5e-16 5.97e-13 -0.37 -0.36 Corneal astigmatism; chr4:119560276 chr4:119454791~119552025:+ LUSC cis rs7617773 0.78 rs13084616 ENSG00000228638.1 FCF1P2 8.41 5e-16 5.97e-13 0.41 0.36 Coronary artery disease; chr3:48298209 chr3:48290793~48291375:- LUSC cis rs1150668 0.83 rs2859365 ENSG00000204709.4 LINC01556 -8.41 5.05e-16 6.03e-13 -0.44 -0.36 Pubertal anthropometrics; chr6:28423688 chr6:28943877~28944537:+ LUSC cis rs765787 0.53 rs12905246 ENSG00000259520.4 CTD-2651B20.3 -8.41 5.07e-16 6.06e-13 -0.46 -0.36 Uric acid levels; chr15:45208643 chr15:45251580~45279251:- LUSC cis rs875971 1 rs6979382 ENSG00000222364.1 RNU6-96P -8.41 5.08e-16 6.06e-13 -0.42 -0.36 Aortic root size; chr7:66421388 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs6961990 ENSG00000222364.1 RNU6-96P -8.41 5.08e-16 6.06e-13 -0.42 -0.36 Aortic root size; chr7:66423583 chr7:66395191~66395286:+ LUSC cis rs11098499 0.908 rs7695996 ENSG00000249244.1 RP11-548H18.2 8.4 5.16e-16 6.15e-13 0.47 0.36 Corneal astigmatism; chr4:119400878 chr4:119391831~119395335:- LUSC cis rs11098499 0.908 rs7696649 ENSG00000249244.1 RP11-548H18.2 8.4 5.16e-16 6.15e-13 0.47 0.36 Corneal astigmatism; chr4:119401022 chr4:119391831~119395335:- LUSC cis rs8062405 0.754 rs149299 ENSG00000259982.1 CDC37P1 8.4 5.16e-16 6.16e-13 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28473820 chr16:28700294~28701540:- LUSC cis rs7189233 0.531 rs9302648 ENSG00000279344.1 RP11-44F14.7 8.4 5.17e-16 6.17e-13 0.31 0.36 Intelligence (multi-trait analysis); chr16:53493869 chr16:53478957~53481550:- LUSC cis rs6782228 1 rs6782228 ENSG00000242551.2 POU5F1P6 8.4 5.18e-16 6.18e-13 0.45 0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128604581 chr3:128674735~128677005:- LUSC cis rs11098499 0.569 rs10023641 ENSG00000245958.5 RP11-33B1.1 -8.4 5.19e-16 6.2e-13 -0.35 -0.36 Corneal astigmatism; chr4:119337255 chr4:119454791~119552025:+ LUSC cis rs875971 1 rs11974219 ENSG00000222364.1 RNU6-96P 8.4 5.2e-16 6.2e-13 0.43 0.36 Aortic root size; chr7:66182423 chr7:66395191~66395286:+ LUSC cis rs11155671 0.53 rs9397420 ENSG00000268592.3 RAET1E-AS1 -8.4 5.2e-16 6.2e-13 -0.44 -0.36 Testicular germ cell tumor; chr6:149885645 chr6:149863494~149919507:+ LUSC cis rs1150668 0.796 rs2531825 ENSG00000204709.4 LINC01556 8.4 5.21e-16 6.21e-13 0.44 0.36 Pubertal anthropometrics; chr6:28381487 chr6:28943877~28944537:+ LUSC cis rs9487094 0.666 rs12529733 ENSG00000260273.1 RP11-425D10.10 8.4 5.22e-16 6.23e-13 0.43 0.36 Height; chr6:109332929 chr6:109382795~109383666:+ LUSC cis rs5769707 0.706 rs763128 ENSG00000235111.1 RP1-29C18.8 -8.4 5.23e-16 6.24e-13 -0.44 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49624397 chr22:49612657~49615716:- LUSC cis rs5769707 0.605 rs9616702 ENSG00000235111.1 RP1-29C18.8 -8.4 5.24e-16 6.25e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49632290 chr22:49612657~49615716:- LUSC cis rs9322193 0.923 rs12205092 ENSG00000223701.3 RAET1E-AS1 8.4 5.24e-16 6.25e-13 0.42 0.36 Lung cancer; chr6:149761375 chr6:149884431~149919508:+ LUSC cis rs10740039 0.583 rs2127353 ENSG00000254271.1 RP11-131N11.4 -8.4 5.24e-16 6.25e-13 -0.52 -0.36 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60750206 chr10:60734342~60741828:+ LUSC cis rs9322193 0.886 rs9767555 ENSG00000223701.3 RAET1E-AS1 8.4 5.25e-16 6.26e-13 0.42 0.36 Lung cancer; chr6:149647022 chr6:149884431~149919508:+ LUSC cis rs11098499 0.954 rs11098525 ENSG00000249244.1 RP11-548H18.2 8.4 5.28e-16 6.3e-13 0.47 0.36 Corneal astigmatism; chr4:119468997 chr4:119391831~119395335:- LUSC cis rs7201929 0.801 rs9933198 ENSG00000259982.1 CDC37P1 -8.4 5.29e-16 6.3e-13 -0.49 -0.36 QT interval; chr16:28877088 chr16:28700294~28701540:- LUSC cis rs494459 0.726 rs1784300 ENSG00000255239.1 AP002954.6 8.4 5.29e-16 6.31e-13 0.39 0.36 Height; chr11:118808920 chr11:118688039~118690600:- LUSC cis rs11155671 0.53 rs9322228 ENSG00000268592.3 RAET1E-AS1 8.4 5.3e-16 6.31e-13 0.44 0.36 Testicular germ cell tumor; chr6:149888173 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs2342767 ENSG00000268592.3 RAET1E-AS1 8.4 5.3e-16 6.31e-13 0.44 0.36 Testicular germ cell tumor; chr6:149888581 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs7764376 ENSG00000268592.3 RAET1E-AS1 8.4 5.3e-16 6.31e-13 0.44 0.36 Testicular germ cell tumor; chr6:149889208 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs6933882 ENSG00000268592.3 RAET1E-AS1 8.4 5.3e-16 6.31e-13 0.44 0.36 Testicular germ cell tumor; chr6:149889666 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs6939761 ENSG00000268592.3 RAET1E-AS1 8.4 5.3e-16 6.31e-13 0.44 0.36 Testicular germ cell tumor; chr6:149889858 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs3823021 ENSG00000268592.3 RAET1E-AS1 8.4 5.3e-16 6.31e-13 0.44 0.36 Testicular germ cell tumor; chr6:149889863 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs4869764 ENSG00000268592.3 RAET1E-AS1 8.4 5.3e-16 6.31e-13 0.44 0.36 Testicular germ cell tumor; chr6:149890692 chr6:149863494~149919507:+ LUSC cis rs875971 0.964 rs6945019 ENSG00000222364.1 RNU6-96P -8.4 5.31e-16 6.33e-13 -0.43 -0.36 Aortic root size; chr7:66457471 chr7:66395191~66395286:+ LUSC cis rs1185460 0.565 rs538478 ENSG00000271751.1 RP11-110I1.14 8.4 5.32e-16 6.34e-13 0.46 0.36 Coronary artery disease; chr11:119054629 chr11:119065263~119065677:- LUSC cis rs150992 0.536 rs161730 ENSG00000248489.1 CTD-2007H13.3 8.4 5.33e-16 6.34e-13 0.45 0.36 Body mass index; chr5:98982631 chr5:98929171~98995013:+ LUSC cis rs17507216 0.628 rs4513065 ENSG00000278603.1 RP13-608F4.5 8.4 5.36e-16 6.38e-13 0.55 0.36 Excessive daytime sleepiness; chr15:82712096 chr15:82472203~82472426:+ LUSC cis rs5769707 0.681 rs135879 ENSG00000235111.1 RP1-29C18.8 -8.4 5.38e-16 6.4e-13 -0.44 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49625003 chr22:49612657~49615716:- LUSC cis rs5769707 0.642 rs135880 ENSG00000235111.1 RP1-29C18.8 -8.4 5.38e-16 6.4e-13 -0.44 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49625006 chr22:49612657~49615716:- LUSC cis rs7617773 0.744 rs2125482 ENSG00000228638.1 FCF1P2 -8.4 5.41e-16 6.44e-13 -0.42 -0.36 Coronary artery disease; chr3:48281643 chr3:48290793~48291375:- LUSC cis rs11098499 0.863 rs6858592 ENSG00000249244.1 RP11-548H18.2 8.4 5.42e-16 6.45e-13 0.47 0.36 Corneal astigmatism; chr4:119537537 chr4:119391831~119395335:- LUSC cis rs853679 0.517 rs2281588 ENSG00000219392.1 RP1-265C24.5 -8.4 5.42e-16 6.45e-13 -0.51 -0.36 Depression; chr6:28104824 chr6:28115628~28116551:+ LUSC cis rs10129255 0.957 rs11847726 ENSG00000211970.3 IGHV4-61 -8.4 5.44e-16 6.47e-13 -0.25 -0.36 Kawasaki disease; chr14:106779116 chr14:106639119~106639657:- LUSC cis rs150992 0.536 rs179053 ENSG00000248489.1 CTD-2007H13.3 8.4 5.45e-16 6.48e-13 0.45 0.36 Body mass index; chr5:98979890 chr5:98929171~98995013:+ LUSC cis rs748404 0.631 rs28702649 ENSG00000249839.1 AC011330.5 -8.4 5.45e-16 6.49e-13 -0.5 -0.36 Lung cancer; chr15:43356431 chr15:43663654~43684339:- LUSC cis rs9807989 0.507 rs4851004 ENSG00000234389.1 AC007278.3 -8.4 5.46e-16 6.5e-13 -0.34 -0.36 Asthma; chr2:102393077 chr2:102438713~102440475:+ LUSC cis rs7849270 1 rs932835 ENSG00000268707.1 RP11-247A12.7 -8.4 5.49e-16 6.53e-13 -0.41 -0.36 Blood metabolite ratios; chr9:129124792 chr9:129170434~129170940:+ LUSC cis rs1707322 1 rs4073847 ENSG00000280836.1 AL355480.1 8.4 5.5e-16 6.54e-13 0.41 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45997340 chr1:45581219~45581321:- LUSC cis rs11098499 0.909 rs9759478 ENSG00000249244.1 RP11-548H18.2 8.4 5.5e-16 6.54e-13 0.47 0.36 Corneal astigmatism; chr4:119446843 chr4:119391831~119395335:- LUSC cis rs10129255 0.957 rs10132367 ENSG00000211970.3 IGHV4-61 -8.4 5.51e-16 6.55e-13 -0.26 -0.36 Kawasaki disease; chr14:106690981 chr14:106639119~106639657:- LUSC cis rs6782228 0.883 rs11712115 ENSG00000242551.2 POU5F1P6 8.4 5.52e-16 6.56e-13 0.45 0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128685426 chr3:128674735~128677005:- LUSC cis rs4713118 0.621 rs9295755 ENSG00000219392.1 RP1-265C24.5 8.4 5.53e-16 6.57e-13 0.51 0.36 Parkinson's disease; chr6:28065396 chr6:28115628~28116551:+ LUSC cis rs7849270 1 rs2541161 ENSG00000268707.1 RP11-247A12.7 8.39 5.54e-16 6.58e-13 0.41 0.36 Blood metabolite ratios; chr9:129122523 chr9:129170434~129170940:+ LUSC cis rs5769707 0.681 rs2071902 ENSG00000235111.1 RP1-29C18.8 -8.39 5.57e-16 6.62e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49640890 chr22:49612657~49615716:- LUSC cis rs8062405 0.755 rs2077031 ENSG00000259982.1 CDC37P1 8.39 5.61e-16 6.67e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28591847 chr16:28700294~28701540:- LUSC cis rs9322193 0.884 rs7744105 ENSG00000223701.3 RAET1E-AS1 8.39 5.62e-16 6.67e-13 0.42 0.36 Lung cancer; chr6:149849308 chr6:149884431~149919508:+ LUSC cis rs10129255 0.913 rs28861466 ENSG00000211970.3 IGHV4-61 -8.39 5.63e-16 6.69e-13 -0.26 -0.36 Kawasaki disease; chr14:106718572 chr14:106639119~106639657:- LUSC cis rs67180937 0.961 rs2133189 ENSG00000272750.1 RP11-378J18.8 -8.39 5.71e-16 6.78e-13 -0.39 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222641100 chr1:222658867~222661512:- LUSC cis rs9918079 0.56 rs4698406 ENSG00000273133.1 RP11-799M12.2 -8.39 5.72e-16 6.79e-13 -0.5 -0.36 Obesity-related traits; chr4:15638994 chr4:15563698~15564253:- LUSC cis rs26232 0.521 rs3776856 ENSG00000175749.11 EIF3KP1 8.39 5.75e-16 6.82e-13 0.44 0.36 Rheumatoid arthritis; chr5:103023102 chr5:103032376~103033031:+ LUSC cis rs10129255 0.957 rs2013423 ENSG00000211970.3 IGHV4-61 -8.39 5.75e-16 6.82e-13 -0.26 -0.36 Kawasaki disease; chr14:106690675 chr14:106639119~106639657:- LUSC cis rs35955747 0.934 rs13053245 ENSG00000236132.1 CTA-440B3.1 8.39 5.75e-16 6.83e-13 0.44 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31420756 chr22:31816379~31817491:- LUSC cis rs526231 0.511 rs7731395 ENSG00000175749.11 EIF3KP1 8.39 5.8e-16 6.88e-13 0.44 0.36 Primary biliary cholangitis; chr5:103026057 chr5:103032376~103033031:+ LUSC cis rs2283792 1 rs5749986 ENSG00000228050.1 TOP3BP1 -8.39 5.81e-16 6.89e-13 -0.42 -0.36 Multiple sclerosis; chr22:21803372 chr22:22223187~22224566:- LUSC cis rs11098499 0.863 rs58452170 ENSG00000245958.5 RP11-33B1.1 -8.39 5.82e-16 6.91e-13 -0.37 -0.36 Corneal astigmatism; chr4:119538519 chr4:119454791~119552025:+ LUSC cis rs2412819 0.545 rs17795279 ENSG00000249839.1 AC011330.5 8.39 5.84e-16 6.93e-13 0.58 0.36 Lung cancer; chr15:43637180 chr15:43663654~43684339:- LUSC cis rs2739330 0.753 rs4822452 ENSG00000231271.1 AP000350.8 8.39 5.88e-16 6.98e-13 0.47 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23949918~23954042:+ LUSC cis rs17507216 0.628 rs28371837 ENSG00000278603.1 RP13-608F4.5 8.39 5.89e-16 6.98e-13 0.55 0.36 Excessive daytime sleepiness; chr15:82714435 chr15:82472203~82472426:+ LUSC cis rs11155671 0.53 rs4870080 ENSG00000268592.3 RAET1E-AS1 8.39 5.9e-16 7e-13 0.44 0.36 Testicular germ cell tumor; chr6:149881508 chr6:149863494~149919507:+ LUSC cis rs11098499 0.865 rs4001305 ENSG00000249244.1 RP11-548H18.2 8.39 5.91e-16 7e-13 0.46 0.36 Corneal astigmatism; chr4:119438081 chr4:119391831~119395335:- LUSC cis rs1823913 1 rs11691372 ENSG00000227542.1 AC092614.2 -8.39 5.95e-16 7.05e-13 -0.48 -0.36 Obesity-related traits; chr2:191249952 chr2:191229165~191246172:- LUSC cis rs11098499 0.954 rs6847248 ENSG00000245958.5 RP11-33B1.1 -8.38 5.96e-16 7.06e-13 -0.38 -0.36 Corneal astigmatism; chr4:119304800 chr4:119454791~119552025:+ LUSC cis rs5769707 0.681 rs739240 ENSG00000235111.1 RP1-29C18.8 -8.38 5.96e-16 7.06e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49658959 chr22:49612657~49615716:- LUSC cis rs6782228 0.848 rs3935016 ENSG00000242551.2 POU5F1P6 8.38 5.99e-16 7.1e-13 0.45 0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128701591 chr3:128674735~128677005:- LUSC cis rs6782228 0.848 rs6439141 ENSG00000242551.2 POU5F1P6 8.38 5.99e-16 7.1e-13 0.45 0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128701691 chr3:128674735~128677005:- LUSC cis rs1823913 1 rs6749232 ENSG00000227542.1 AC092614.2 -8.38 5.99e-16 7.1e-13 -0.47 -0.36 Obesity-related traits; chr2:191250326 chr2:191229165~191246172:- LUSC cis rs875971 0.964 rs60193905 ENSG00000222364.1 RNU6-96P -8.38 6.03e-16 7.14e-13 -0.43 -0.36 Aortic root size; chr7:66506273 chr7:66395191~66395286:+ LUSC cis rs875971 0.929 rs10950041 ENSG00000222364.1 RNU6-96P -8.38 6.03e-16 7.14e-13 -0.43 -0.36 Aortic root size; chr7:66508888 chr7:66395191~66395286:+ LUSC cis rs875971 0.929 rs6970860 ENSG00000222364.1 RNU6-96P -8.38 6.03e-16 7.14e-13 -0.43 -0.36 Aortic root size; chr7:66511647 chr7:66395191~66395286:+ LUSC cis rs9322193 0.923 rs10872644 ENSG00000223701.3 RAET1E-AS1 8.38 6.03e-16 7.14e-13 0.42 0.36 Lung cancer; chr6:149741819 chr6:149884431~149919508:+ LUSC cis rs6921919 0.551 rs13201753 ENSG00000216901.1 AL022393.7 8.38 6.04e-16 7.15e-13 0.43 0.36 Autism spectrum disorder or schizophrenia; chr6:28363351 chr6:28176188~28176674:+ LUSC cis rs150992 0.505 rs167798 ENSG00000248489.1 CTD-2007H13.3 8.38 6.11e-16 7.24e-13 0.44 0.36 Body mass index; chr5:98972150 chr5:98929171~98995013:+ LUSC cis rs10129255 0.646 rs55995061 ENSG00000211970.3 IGHV4-61 -8.38 6.11e-16 7.24e-13 -0.25 -0.36 Kawasaki disease; chr14:106799309 chr14:106639119~106639657:- LUSC cis rs11098499 0.913 rs13126596 ENSG00000245958.5 RP11-33B1.1 -8.38 6.17e-16 7.3e-13 -0.37 -0.36 Corneal astigmatism; chr4:119219574 chr4:119454791~119552025:+ LUSC cis rs1155848 0.892 rs953005 ENSG00000227354.5 RBM26-AS1 8.38 6.18e-16 7.31e-13 0.71 0.36 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79480544 chr13:79406309~79424328:+ LUSC cis rs11098499 0.954 rs13133522 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119403269 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs35091806 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119404374 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs35165976 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119404475 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs3890049 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119405128 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs6846442 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119405168 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs71614438 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119450097 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs66506550 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119450290 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs7659501 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119450397 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs71629403 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119451412 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs28571712 ENSG00000249244.1 RP11-548H18.2 8.38 6.21e-16 7.34e-13 0.47 0.36 Corneal astigmatism; chr4:119454825 chr4:119391831~119395335:- LUSC cis rs17023223 0.537 rs61319010 ENSG00000231365.4 RP11-418J17.1 -8.38 6.26e-16 7.39e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119200388 chr1:119140396~119275973:+ LUSC cis rs7174755 0.608 rs10162905 ENSG00000260657.2 RP11-315D16.4 8.38 6.28e-16 7.42e-13 0.45 0.36 Major depressive disorder; chr15:68103709 chr15:68267792~68277994:- LUSC cis rs1113500 0.58 rs1781058 ENSG00000226822.1 RP11-356N1.2 8.38 6.29e-16 7.43e-13 0.37 0.36 Growth-regulated protein alpha levels; chr1:108021437 chr1:108071482~108074519:+ LUSC cis rs875971 1 rs6958484 ENSG00000222364.1 RNU6-96P 8.38 6.29e-16 7.43e-13 0.42 0.36 Aortic root size; chr7:66134459 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs6957199 ENSG00000222364.1 RNU6-96P -8.38 6.3e-16 7.43e-13 -0.43 -0.36 Aortic root size; chr7:66513532 chr7:66395191~66395286:+ LUSC cis rs875971 0.965 rs28682868 ENSG00000222364.1 RNU6-96P 8.38 6.32e-16 7.46e-13 0.42 0.36 Aortic root size; chr7:66224822 chr7:66395191~66395286:+ LUSC cis rs5769707 0.681 rs2319346 ENSG00000235111.1 RP1-29C18.8 -8.38 6.32e-16 7.46e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49635992 chr22:49612657~49615716:- LUSC cis rs11098499 0.909 rs2127821 ENSG00000249244.1 RP11-548H18.2 8.38 6.34e-16 7.49e-13 0.47 0.36 Corneal astigmatism; chr4:119473380 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3822195 ENSG00000245958.5 RP11-33B1.1 -8.38 6.35e-16 7.5e-13 -0.37 -0.36 Corneal astigmatism; chr4:119550505 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs3775854 ENSG00000245958.5 RP11-33B1.1 -8.38 6.35e-16 7.5e-13 -0.37 -0.36 Corneal astigmatism; chr4:119550816 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs2306457 ENSG00000245958.5 RP11-33B1.1 -8.38 6.35e-16 7.5e-13 -0.37 -0.36 Corneal astigmatism; chr4:119551684 chr4:119454791~119552025:+ LUSC cis rs9322193 0.607 rs9371228 ENSG00000216906.2 RP11-350J20.9 -8.38 6.35e-16 7.5e-13 -0.49 -0.36 Lung cancer; chr6:149921977 chr6:149904243~149906418:+ LUSC cis rs2283792 1 rs5999521 ENSG00000228050.1 TOP3BP1 8.38 6.37e-16 7.52e-13 0.42 0.36 Multiple sclerosis; chr22:21792110 chr22:22223187~22224566:- LUSC cis rs9807989 0.524 rs4851576 ENSG00000234389.1 AC007278.3 8.38 6.4e-16 7.55e-13 0.34 0.36 Asthma; chr2:102412435 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs4851577 ENSG00000234389.1 AC007278.3 8.38 6.4e-16 7.55e-13 0.34 0.36 Asthma; chr2:102412461 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs4851579 ENSG00000234389.1 AC007278.3 8.38 6.4e-16 7.55e-13 0.34 0.36 Asthma; chr2:102412524 chr2:102438713~102440475:+ LUSC cis rs11098499 0.738 rs28408407 ENSG00000249244.1 RP11-548H18.2 8.37 6.44e-16 7.6e-13 0.46 0.36 Corneal astigmatism; chr4:119454875 chr4:119391831~119395335:- LUSC cis rs9487094 0.961 rs11153175 ENSG00000260273.1 RP11-425D10.10 8.37 6.44e-16 7.6e-13 0.45 0.36 Height; chr6:109361318 chr6:109382795~109383666:+ LUSC cis rs10129255 0.719 rs7156660 ENSG00000224373.3 IGHV4-59 8.37 6.45e-16 7.61e-13 0.2 0.36 Kawasaki disease; chr14:106673171 chr14:106627249~106627825:- LUSC cis rs875971 1 rs778726 ENSG00000222364.1 RNU6-96P -8.37 6.47e-16 7.63e-13 -0.42 -0.36 Aortic root size; chr7:66363744 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs778723 ENSG00000222364.1 RNU6-96P -8.37 6.47e-16 7.63e-13 -0.42 -0.36 Aortic root size; chr7:66364510 chr7:66395191~66395286:+ LUSC cis rs875971 0.767 rs1695815 ENSG00000222364.1 RNU6-96P -8.37 6.47e-16 7.63e-13 -0.42 -0.36 Aortic root size; chr7:66366357 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs778685 ENSG00000222364.1 RNU6-96P -8.37 6.47e-16 7.63e-13 -0.42 -0.36 Aortic root size; chr7:66371189 chr7:66395191~66395286:+ LUSC cis rs875971 0.929 rs778682 ENSG00000222364.1 RNU6-96P -8.37 6.47e-16 7.63e-13 -0.42 -0.36 Aortic root size; chr7:66372947 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs11765965 ENSG00000222364.1 RNU6-96P -8.37 6.47e-16 7.63e-13 -0.42 -0.36 Aortic root size; chr7:66377234 chr7:66395191~66395286:+ LUSC cis rs10129255 0.872 rs8015406 ENSG00000211970.3 IGHV4-61 -8.37 6.53e-16 7.69e-13 -0.26 -0.36 Kawasaki disease; chr14:106670611 chr14:106639119~106639657:- LUSC cis rs11098499 0.954 rs10518331 ENSG00000249244.1 RP11-548H18.2 8.37 6.56e-16 7.73e-13 0.47 0.36 Corneal astigmatism; chr4:119402440 chr4:119391831~119395335:- LUSC cis rs17023223 0.537 rs4590715 ENSG00000231365.4 RP11-418J17.1 -8.37 6.56e-16 7.73e-13 -0.44 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119207578 chr1:119140396~119275973:+ LUSC cis rs8081395 0.737 rs4968401 ENSG00000266992.1 DHX40P1 -8.37 6.56e-16 7.73e-13 -0.42 -0.36 White blood cell count; chr17:59963369 chr17:59976009~60002384:- LUSC cis rs9807989 0.507 rs6543133 ENSG00000234389.1 AC007278.3 8.37 6.57e-16 7.74e-13 0.34 0.36 Asthma; chr2:102423717 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs6743516 ENSG00000234389.1 AC007278.3 8.37 6.58e-16 7.75e-13 0.34 0.36 Asthma; chr2:102419875 chr2:102438713~102440475:+ LUSC cis rs4988958 0.565 rs1420100 ENSG00000234389.1 AC007278.3 8.37 6.58e-16 7.75e-13 0.34 0.36 Asthma (childhood onset); chr2:102420542 chr2:102438713~102440475:+ LUSC cis rs7945705 0.712 rs61876274 ENSG00000254860.4 TMEM9B-AS1 -8.37 6.59e-16 7.76e-13 -0.39 -0.36 Hemoglobin concentration; chr11:8997643 chr11:8964675~8977527:+ LUSC cis rs2412819 0.571 rs56226333 ENSG00000249839.1 AC011330.5 -8.37 6.6e-16 7.78e-13 -0.6 -0.36 Lung cancer; chr15:43632410 chr15:43663654~43684339:- LUSC cis rs9807989 0.507 rs2293224 ENSG00000234389.1 AC007278.3 8.37 6.62e-16 7.79e-13 0.34 0.36 Asthma; chr2:102419319 chr2:102438713~102440475:+ LUSC cis rs11098499 0.738 rs34965784 ENSG00000249244.1 RP11-548H18.2 8.37 6.62e-16 7.8e-13 0.47 0.36 Corneal astigmatism; chr4:119440431 chr4:119391831~119395335:- LUSC cis rs8072100 0.84 rs9893901 ENSG00000228782.6 CTD-2026D20.3 8.37 6.64e-16 7.82e-13 0.34 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47429316 chr17:47450568~47492492:- LUSC cis rs9322193 0.884 rs11155675 ENSG00000216906.2 RP11-350J20.9 8.37 6.65e-16 7.82e-13 0.45 0.36 Lung cancer; chr6:149742883 chr6:149904243~149906418:+ LUSC cis rs9322193 0.923 rs9371486 ENSG00000216906.2 RP11-350J20.9 8.37 6.66e-16 7.84e-13 0.45 0.36 Lung cancer; chr6:149832090 chr6:149904243~149906418:+ LUSC cis rs4988958 0.565 rs6732138 ENSG00000234389.1 AC007278.3 8.37 6.69e-16 7.88e-13 0.34 0.36 Asthma (childhood onset); chr2:102393202 chr2:102438713~102440475:+ LUSC cis rs17507216 0.628 rs28607761 ENSG00000278603.1 RP13-608F4.5 8.37 6.7e-16 7.88e-13 0.55 0.36 Excessive daytime sleepiness; chr15:82715317 chr15:82472203~82472426:+ LUSC cis rs10463554 0.927 rs34799 ENSG00000175749.11 EIF3KP1 8.37 6.71e-16 7.89e-13 0.44 0.36 Parkinson's disease; chr5:103090498 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs34800 ENSG00000175749.11 EIF3KP1 8.37 6.71e-16 7.89e-13 0.44 0.36 Parkinson's disease; chr5:103090799 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs34802 ENSG00000175749.11 EIF3KP1 8.37 6.71e-16 7.89e-13 0.44 0.36 Parkinson's disease; chr5:103091301 chr5:103032376~103033031:+ LUSC cis rs526231 0.508 rs34805 ENSG00000175749.11 EIF3KP1 8.37 6.71e-16 7.89e-13 0.44 0.36 Primary biliary cholangitis; chr5:103092608 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs34810 ENSG00000175749.11 EIF3KP1 8.37 6.71e-16 7.89e-13 0.44 0.36 Parkinson's disease; chr5:103095045 chr5:103032376~103033031:+ LUSC cis rs8072100 0.84 rs56952963 ENSG00000228782.6 CTD-2026D20.3 8.37 6.71e-16 7.89e-13 0.34 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47416460 chr17:47450568~47492492:- LUSC cis rs11098499 0.779 rs28495013 ENSG00000249244.1 RP11-548H18.2 8.37 6.71e-16 7.89e-13 0.47 0.36 Corneal astigmatism; chr4:119454676 chr4:119391831~119395335:- LUSC cis rs8081395 0.741 rs180519 ENSG00000266992.1 DHX40P1 8.37 6.72e-16 7.9e-13 0.42 0.36 White blood cell count; chr17:59938910 chr17:59976009~60002384:- LUSC cis rs4988958 0.565 rs12712146 ENSG00000234389.1 AC007278.3 8.37 6.72e-16 7.9e-13 0.34 0.36 Asthma (childhood onset); chr2:102392254 chr2:102438713~102440475:+ LUSC cis rs1823913 1 rs1454749 ENSG00000227542.1 AC092614.2 8.37 6.74e-16 7.92e-13 0.48 0.36 Obesity-related traits; chr2:191240909 chr2:191229165~191246172:- LUSC cis rs11098499 0.909 rs7681214 ENSG00000249244.1 RP11-548H18.2 8.37 6.76e-16 7.95e-13 0.47 0.36 Corneal astigmatism; chr4:119464165 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs17046116 ENSG00000249244.1 RP11-548H18.2 8.37 6.76e-16 7.95e-13 0.47 0.36 Corneal astigmatism; chr4:119466104 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs17046118 ENSG00000249244.1 RP11-548H18.2 8.37 6.76e-16 7.95e-13 0.47 0.36 Corneal astigmatism; chr4:119466341 chr4:119391831~119395335:- LUSC cis rs9322193 0.923 rs9800686 ENSG00000223701.3 RAET1E-AS1 8.37 6.79e-16 7.97e-13 0.42 0.36 Lung cancer; chr6:149634464 chr6:149884431~149919508:+ LUSC cis rs11155671 0.53 rs9383577 ENSG00000268592.3 RAET1E-AS1 8.37 6.85e-16 8.04e-13 0.44 0.36 Testicular germ cell tumor; chr6:149886059 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs9383914 ENSG00000268592.3 RAET1E-AS1 8.37 6.85e-16 8.04e-13 0.44 0.36 Testicular germ cell tumor; chr6:149886098 chr6:149863494~149919507:+ LUSC cis rs11155671 0.517 rs9397058 ENSG00000268592.3 RAET1E-AS1 8.37 6.85e-16 8.04e-13 0.44 0.36 Testicular germ cell tumor; chr6:149886113 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs7768626 ENSG00000268592.3 RAET1E-AS1 8.37 6.85e-16 8.04e-13 0.44 0.36 Testicular germ cell tumor; chr6:149886826 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs7768665 ENSG00000268592.3 RAET1E-AS1 8.37 6.85e-16 8.04e-13 0.44 0.36 Testicular germ cell tumor; chr6:149886888 chr6:149863494~149919507:+ LUSC cis rs11155671 0.53 rs7758020 ENSG00000268592.3 RAET1E-AS1 8.37 6.85e-16 8.04e-13 0.44 0.36 Testicular germ cell tumor; chr6:149886975 chr6:149863494~149919507:+ LUSC cis rs5769707 0.604 rs1018814 ENSG00000235111.1 RP1-29C18.8 -8.37 6.86e-16 8.06e-13 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49643252 chr22:49612657~49615716:- LUSC cis rs9487094 0.961 rs3778477 ENSG00000260273.1 RP11-425D10.10 8.37 6.87e-16 8.06e-13 0.45 0.36 Height; chr6:109454855 chr6:109382795~109383666:+ LUSC cis rs1075265 0.584 rs2357954 ENSG00000233266.1 HMGB1P31 8.37 6.89e-16 8.09e-13 0.45 0.36 Chronotype;Morning vs. evening chronotype; chr2:54135300 chr2:54051334~54051760:+ LUSC cis rs8062405 0.722 rs3785354 ENSG00000259982.1 CDC37P1 8.36 6.92e-16 8.12e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28539346 chr16:28700294~28701540:- LUSC cis rs6991838 1 rs6991838 ENSG00000272010.1 CTD-3025N20.3 -8.36 6.93e-16 8.13e-13 -0.39 -0.36 Intelligence (multi-trait analysis); chr8:65558727 chr8:65591850~65592472:- LUSC cis rs853679 0.517 rs4711164 ENSG00000219392.1 RP1-265C24.5 -8.36 6.96e-16 8.16e-13 -0.51 -0.36 Depression; chr6:28147378 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs4711165 ENSG00000219392.1 RP1-265C24.5 -8.36 6.96e-16 8.16e-13 -0.51 -0.36 Depression; chr6:28147406 chr6:28115628~28116551:+ LUSC cis rs9807989 0.507 rs1420094 ENSG00000234389.1 AC007278.3 8.36 6.97e-16 8.18e-13 0.34 0.36 Asthma; chr2:102399227 chr2:102438713~102440475:+ LUSC cis rs2117029 0.586 rs10875928 ENSG00000258017.1 RP11-386G11.10 -8.36 6.97e-16 8.18e-13 -0.44 -0.36 Intelligence (multi-trait analysis); chr12:49162520 chr12:49127782~49147869:+ LUSC cis rs9807989 0.507 rs6745614 ENSG00000234389.1 AC007278.3 8.36 6.99e-16 8.2e-13 0.34 0.36 Asthma; chr2:102374753 chr2:102438713~102440475:+ LUSC cis rs11098499 0.863 rs10013305 ENSG00000245958.5 RP11-33B1.1 -8.36 6.99e-16 8.2e-13 -0.37 -0.36 Corneal astigmatism; chr4:119529269 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs3775849 ENSG00000245958.5 RP11-33B1.1 -8.36 6.99e-16 8.2e-13 -0.37 -0.36 Corneal astigmatism; chr4:119529753 chr4:119454791~119552025:+ LUSC cis rs11098499 0.818 rs7688802 ENSG00000245958.5 RP11-33B1.1 -8.36 6.99e-16 8.2e-13 -0.37 -0.36 Corneal astigmatism; chr4:119530513 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs7695620 ENSG00000245958.5 RP11-33B1.1 -8.36 6.99e-16 8.2e-13 -0.37 -0.36 Corneal astigmatism; chr4:119531621 chr4:119454791~119552025:+ LUSC cis rs11098499 0.821 rs3775852 ENSG00000245958.5 RP11-33B1.1 -8.36 6.99e-16 8.2e-13 -0.37 -0.36 Corneal astigmatism; chr4:119533401 chr4:119454791~119552025:+ LUSC cis rs11098499 0.82 rs6534140 ENSG00000245958.5 RP11-33B1.1 -8.36 6.99e-16 8.2e-13 -0.37 -0.36 Corneal astigmatism; chr4:119534156 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs7657849 ENSG00000245958.5 RP11-33B1.1 -8.36 6.99e-16 8.2e-13 -0.37 -0.36 Corneal astigmatism; chr4:119534339 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs10034450 ENSG00000245958.5 RP11-33B1.1 -8.36 6.99e-16 8.2e-13 -0.37 -0.36 Corneal astigmatism; chr4:119534494 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs1480939 ENSG00000245958.5 RP11-33B1.1 -8.36 6.99e-16 8.2e-13 -0.37 -0.36 Corneal astigmatism; chr4:119535772 chr4:119454791~119552025:+ LUSC cis rs17023223 0.537 rs3934789 ENSG00000231365.4 RP11-418J17.1 -8.36 6.99e-16 8.2e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119140440 chr1:119140396~119275973:+ LUSC cis rs9807989 0.507 rs10208196 ENSG00000234389.1 AC007278.3 8.36 7e-16 8.2e-13 0.34 0.36 Asthma; chr2:102379885 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs3213732 ENSG00000234389.1 AC007278.3 8.36 7e-16 8.2e-13 0.34 0.36 Asthma; chr2:102381819 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs10204757 ENSG00000234389.1 AC007278.3 8.36 7e-16 8.2e-13 0.34 0.36 Asthma; chr2:102382514 chr2:102438713~102440475:+ LUSC cis rs9807989 0.524 rs7591246 ENSG00000234389.1 AC007278.3 8.36 7e-16 8.2e-13 0.34 0.36 Asthma; chr2:102382943 chr2:102438713~102440475:+ LUSC cis rs4988958 0.565 rs6760621 ENSG00000234389.1 AC007278.3 8.36 7e-16 8.2e-13 0.34 0.36 Asthma (childhood onset); chr2:102383492 chr2:102438713~102440475:+ LUSC cis rs4988958 0.527 rs11465641 ENSG00000234389.1 AC007278.3 8.36 7e-16 8.2e-13 0.34 0.36 Asthma (childhood onset); chr2:102384408 chr2:102438713~102440475:+ LUSC cis rs11098499 0.818 rs55825515 ENSG00000249244.1 RP11-548H18.2 8.36 7e-16 8.21e-13 0.47 0.36 Corneal astigmatism; chr4:119565247 chr4:119391831~119395335:- LUSC cis rs3823536 0.583 rs11760442 ENSG00000275106.1 RP11-309L24.10 -8.36 7.03e-16 8.24e-13 -0.48 -0.36 Sjögren's syndrome; chr7:129016066 chr7:128952527~128953316:- LUSC cis rs3823536 0.583 rs3847099 ENSG00000275106.1 RP11-309L24.10 -8.36 7.03e-16 8.24e-13 -0.48 -0.36 Sjögren's syndrome; chr7:129016777 chr7:128952527~128953316:- LUSC cis rs11098499 0.738 rs72918577 ENSG00000249244.1 RP11-548H18.2 8.36 7.04e-16 8.26e-13 0.46 0.36 Corneal astigmatism; chr4:119405546 chr4:119391831~119395335:- LUSC cis rs4988958 0.525 rs3771159 ENSG00000234389.1 AC007278.3 8.36 7.07e-16 8.28e-13 0.34 0.36 Asthma (childhood onset); chr2:102388498 chr2:102438713~102440475:+ LUSC cis rs9807989 0.501 rs11903946 ENSG00000234389.1 AC007278.3 8.36 7.07e-16 8.28e-13 0.34 0.36 Asthma; chr2:102388870 chr2:102438713~102440475:+ LUSC cis rs8059260 0.604 rs78753859 ENSG00000274038.1 RP11-66H6.4 -8.36 7.07e-16 8.28e-13 -0.62 -0.36 Alcohol consumption over the past year; chr16:11052774 chr16:11056556~11057034:+ LUSC cis rs11098499 0.913 rs56122576 ENSG00000245958.5 RP11-33B1.1 -8.36 7.07e-16 8.28e-13 -0.37 -0.36 Corneal astigmatism; chr4:119208181 chr4:119454791~119552025:+ LUSC cis rs10256972 0.758 rs9801444 ENSG00000229043.2 AC091729.9 8.36 7.07e-16 8.29e-13 0.42 0.36 Endometriosis;Longevity; chr7:1040808 chr7:1160374~1165267:+ LUSC cis rs17023223 0.537 rs10923759 ENSG00000231365.4 RP11-418J17.1 8.36 7.13e-16 8.35e-13 0.44 0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119149571 chr1:119140396~119275973:+ LUSC cis rs8062405 0.755 rs56209193 ENSG00000259982.1 CDC37P1 8.36 7.15e-16 8.37e-13 0.44 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574315 chr16:28700294~28701540:- LUSC cis rs7739264 0.602 rs9350179 ENSG00000237404.1 RP3-471C18.2 -8.36 7.15e-16 8.37e-13 -0.41 -0.36 Endometriosis; chr6:19763864 chr6:19689825~19753113:- LUSC cis rs17023223 0.553 rs56234947 ENSG00000231365.4 RP11-418J17.1 -8.36 7.15e-16 8.38e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119165121 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs6677107 ENSG00000231365.4 RP11-418J17.1 -8.36 7.15e-16 8.38e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119166142 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs12064033 ENSG00000231365.4 RP11-418J17.1 -8.36 7.15e-16 8.38e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119166935 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs12064137 ENSG00000231365.4 RP11-418J17.1 -8.36 7.15e-16 8.38e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119167126 chr1:119140396~119275973:+ LUSC cis rs17023223 0.509 rs61806978 ENSG00000231365.4 RP11-418J17.1 -8.36 7.15e-16 8.38e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119170592 chr1:119140396~119275973:+ LUSC cis rs17023223 0.509 rs56195272 ENSG00000231365.4 RP11-418J17.1 -8.36 7.15e-16 8.38e-13 -0.45 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119171374 chr1:119140396~119275973:+ LUSC cis rs10463554 0.927 rs257316 ENSG00000175749.11 EIF3KP1 -8.36 7.22e-16 8.45e-13 -0.43 -0.36 Parkinson's disease; chr5:103086739 chr5:103032376~103033031:+ LUSC cis rs760794 0.533 rs2206034 ENSG00000237404.1 RP3-471C18.2 -8.36 7.23e-16 8.46e-13 -0.41 -0.36 Endometriosis; chr6:19796632 chr6:19689825~19753113:- LUSC cis rs1113500 0.862 rs2336129 ENSG00000226822.1 RP11-356N1.2 -8.36 7.28e-16 8.51e-13 -0.37 -0.36 Growth-regulated protein alpha levels; chr1:108098047 chr1:108071482~108074519:+ LUSC cis rs9322193 0.847 rs12191643 ENSG00000223701.3 RAET1E-AS1 8.36 7.3e-16 8.54e-13 0.42 0.36 Lung cancer; chr6:149628912 chr6:149884431~149919508:+ LUSC cis rs17608059 0.504 rs11656981 ENSG00000141028.6 CDRT15P1 -8.36 7.3e-16 8.54e-13 -0.4 -0.36 Temperament; chr17:14075460 chr17:14024514~14025488:+ LUSC cis rs11098499 0.863 rs1552095 ENSG00000245958.5 RP11-33B1.1 -8.36 7.31e-16 8.55e-13 -0.38 -0.36 Corneal astigmatism; chr4:119539151 chr4:119454791~119552025:+ LUSC cis rs10129255 0.744 rs28517388 ENSG00000211970.3 IGHV4-61 -8.36 7.33e-16 8.57e-13 -0.27 -0.36 Kawasaki disease; chr14:106704323 chr14:106639119~106639657:- LUSC cis rs3096299 0.9 rs4785663 ENSG00000274627.1 RP11-104N10.2 8.36 7.35e-16 8.6e-13 0.32 0.36 Multiple myeloma (IgH translocation); chr16:89368480 chr16:89516797~89522217:+ LUSC cis rs7044106 0.762 rs10760110 ENSG00000226752.6 PSMD5-AS1 8.36 7.36e-16 8.6e-13 0.4 0.36 Hip circumference adjusted for BMI; chr9:120650285 chr9:120824828~120854385:+ LUSC cis rs9322193 0.847 rs56103941 ENSG00000223701.3 RAET1E-AS1 8.36 7.39e-16 8.64e-13 0.42 0.36 Lung cancer; chr6:149816095 chr6:149884431~149919508:+ LUSC cis rs150992 0.571 rs34488 ENSG00000248489.1 CTD-2007H13.3 8.36 7.4e-16 8.65e-13 0.45 0.36 Body mass index; chr5:98977773 chr5:98929171~98995013:+ LUSC cis rs11098499 0.754 rs12510269 ENSG00000245958.5 RP11-33B1.1 -8.36 7.41e-16 8.66e-13 -0.36 -0.36 Corneal astigmatism; chr4:119320491 chr4:119454791~119552025:+ LUSC cis rs3823536 0.604 rs3857852 ENSG00000275106.1 RP11-309L24.10 -8.36 7.42e-16 8.67e-13 -0.48 -0.36 Sjögren's syndrome; chr7:129017223 chr7:128952527~128953316:- LUSC cis rs11098499 0.691 rs10028773 ENSG00000245958.5 RP11-33B1.1 8.35 7.5e-16 8.76e-13 0.36 0.36 Corneal astigmatism; chr4:119344104 chr4:119454791~119552025:+ LUSC cis rs2117029 0.619 rs2753 ENSG00000258017.1 RP11-386G11.10 -8.35 7.5e-16 8.76e-13 -0.44 -0.36 Intelligence (multi-trait analysis); chr12:49127889 chr12:49127782~49147869:+ LUSC cis rs11089937 0.626 rs5757013 ENSG00000211639.2 IGLV4-60 8.35 7.51e-16 8.77e-13 0.41 0.36 Periodontitis (PAL4Q3); chr22:22135544 chr22:22162199~22162681:+ LUSC cis rs2117029 0.554 rs12306494 ENSG00000258017.1 RP11-386G11.10 -8.35 7.58e-16 8.85e-13 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49136998 chr12:49127782~49147869:+ LUSC cis rs2117029 0.586 rs11168884 ENSG00000258017.1 RP11-386G11.10 -8.35 7.58e-16 8.85e-13 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49146109 chr12:49127782~49147869:+ LUSC cis rs11168854 0.719 rs11168890 ENSG00000258017.1 RP11-386G11.10 -8.35 7.58e-16 8.85e-13 -0.45 -0.36 Body mass index; chr12:49150130 chr12:49127782~49147869:+ LUSC cis rs2117029 0.586 rs7954521 ENSG00000258017.1 RP11-386G11.10 -8.35 7.58e-16 8.85e-13 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49151857 chr12:49127782~49147869:+ LUSC cis rs875971 1 rs6963646 ENSG00000222364.1 RNU6-96P 8.35 7.59e-16 8.86e-13 0.42 0.36 Aortic root size; chr7:66220780 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs11974264 ENSG00000222364.1 RNU6-96P 8.35 7.61e-16 8.88e-13 0.42 0.36 Aortic root size; chr7:66182595 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs1540651 ENSG00000222364.1 RNU6-96P 8.35 7.61e-16 8.88e-13 0.42 0.36 Aortic root size; chr7:66185134 chr7:66395191~66395286:+ LUSC cis rs6471393 0.964 rs2976366 ENSG00000253848.1 RP11-10N23.5 -8.35 7.64e-16 8.91e-13 -0.46 -0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93708829 chr8:93741193~93744534:+ LUSC cis rs11098499 0.604 rs2389886 ENSG00000249244.1 RP11-548H18.2 8.35 7.64e-16 8.91e-13 0.46 0.36 Corneal astigmatism; chr4:119649267 chr4:119391831~119395335:- LUSC cis rs10129255 0.83 rs61997609 ENSG00000211970.3 IGHV4-61 -8.35 7.69e-16 8.97e-13 -0.26 -0.36 Kawasaki disease; chr14:106692376 chr14:106639119~106639657:- LUSC cis rs6782228 0.883 rs6439142 ENSG00000242551.2 POU5F1P6 8.35 7.73e-16 9.01e-13 0.45 0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128701714 chr3:128674735~128677005:- LUSC cis rs4988958 0.565 rs3771154 ENSG00000234389.1 AC007278.3 8.35 7.73e-16 9.01e-13 0.34 0.36 Asthma (childhood onset); chr2:102422900 chr2:102438713~102440475:+ LUSC cis rs9807989 0.524 rs6759479 ENSG00000234389.1 AC007278.3 8.35 7.73e-16 9.01e-13 0.34 0.36 Asthma; chr2:102423587 chr2:102438713~102440475:+ LUSC cis rs11098499 0.863 rs3822190 ENSG00000249244.1 RP11-548H18.2 8.35 7.75e-16 9.03e-13 0.47 0.36 Corneal astigmatism; chr4:119506943 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3822191 ENSG00000249244.1 RP11-548H18.2 8.35 7.75e-16 9.03e-13 0.47 0.36 Corneal astigmatism; chr4:119506946 chr4:119391831~119395335:- LUSC cis rs4988958 0.527 rs3771155 ENSG00000234389.1 AC007278.3 8.35 7.78e-16 9.06e-13 0.34 0.36 Asthma (childhood onset); chr2:102421366 chr2:102438713~102440475:+ LUSC cis rs4988958 0.565 rs10206291 ENSG00000234389.1 AC007278.3 8.35 7.78e-16 9.06e-13 0.34 0.36 Asthma (childhood onset); chr2:102422403 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs7584093 ENSG00000234389.1 AC007278.3 8.35 7.78e-16 9.07e-13 0.34 0.36 Asthma; chr2:102381261 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs4851571 ENSG00000234389.1 AC007278.3 8.35 7.79e-16 9.08e-13 0.34 0.36 Asthma; chr2:102402540 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs4851572 ENSG00000234389.1 AC007278.3 8.35 7.79e-16 9.08e-13 0.34 0.36 Asthma; chr2:102402571 chr2:102438713~102440475:+ LUSC cis rs7044106 0.791 rs2416797 ENSG00000226752.6 PSMD5-AS1 -8.35 7.82e-16 9.11e-13 -0.42 -0.36 Hip circumference adjusted for BMI; chr9:120718322 chr9:120824828~120854385:+ LUSC cis rs7044106 0.791 rs2416798 ENSG00000226752.6 PSMD5-AS1 -8.35 7.82e-16 9.11e-13 -0.42 -0.36 Hip circumference adjusted for BMI; chr9:120718325 chr9:120824828~120854385:+ LUSC cis rs11089937 0.626 rs5757014 ENSG00000211639.2 IGLV4-60 8.35 7.91e-16 9.21e-13 0.4 0.36 Periodontitis (PAL4Q3); chr22:22135612 chr22:22162199~22162681:+ LUSC cis rs10262624 0.504 rs4722255 ENSG00000234286.1 AC006026.13 -8.35 7.96e-16 9.27e-13 -0.43 -0.36 Schizophrenia; chr7:23706453 chr7:23680195~23680786:- LUSC cis rs526231 0.543 rs26820 ENSG00000175749.11 EIF3KP1 8.35 7.99e-16 9.3e-13 0.44 0.36 Primary biliary cholangitis; chr5:103192391 chr5:103032376~103033031:+ LUSC cis rs1012068 0.686 rs5753818 ENSG00000236132.1 CTA-440B3.1 8.35 8e-16 9.31e-13 0.47 0.36 Chronic hepatitis C infection; chr22:31917947 chr22:31816379~31817491:- LUSC cis rs1075265 0.584 rs11896781 ENSG00000233266.1 HMGB1P31 8.34 8.02e-16 9.33e-13 0.45 0.36 Chronotype;Morning vs. evening chronotype; chr2:54096987 chr2:54051334~54051760:+ LUSC cis rs62229266 0.804 rs998383 ENSG00000231106.2 LINC01436 8.34 8.04e-16 9.36e-13 0.47 0.36 Mitral valve prolapse; chr21:36073441 chr21:36005338~36007838:+ LUSC cis rs11098499 0.644 rs17517414 ENSG00000245958.5 RP11-33B1.1 -8.34 8.1e-16 9.43e-13 -0.35 -0.36 Corneal astigmatism; chr4:119340946 chr4:119454791~119552025:+ LUSC cis rs748404 0.604 rs2278857 ENSG00000249839.1 AC011330.5 -8.34 8.15e-16 9.49e-13 -0.48 -0.36 Lung cancer; chr15:43340351 chr15:43663654~43684339:- LUSC cis rs9322193 0.923 rs55849538 ENSG00000223701.3 RAET1E-AS1 8.34 8.17e-16 9.5e-13 0.42 0.36 Lung cancer; chr6:149635330 chr6:149884431~149919508:+ LUSC cis rs2117029 0.619 rs9325145 ENSG00000258017.1 RP11-386G11.10 -8.34 8.21e-16 9.55e-13 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49132101 chr12:49127782~49147869:+ LUSC cis rs17270561 0.779 rs12209218 ENSG00000272462.2 U91328.19 -8.34 8.22e-16 9.56e-13 -0.47 -0.36 Iron status biomarkers; chr6:25887548 chr6:25992662~26001775:+ LUSC cis rs9487094 0.813 rs12528712 ENSG00000260273.1 RP11-425D10.10 8.34 8.22e-16 9.56e-13 0.45 0.36 Height; chr6:109339681 chr6:109382795~109383666:+ LUSC cis rs1823913 1 rs10445782 ENSG00000227542.1 AC092614.2 -8.34 8.26e-16 9.6e-13 -0.48 -0.36 Obesity-related traits; chr2:191236639 chr2:191229165~191246172:- LUSC cis rs11098499 0.697 rs28655325 ENSG00000249244.1 RP11-548H18.2 8.34 8.26e-16 9.6e-13 0.47 0.36 Corneal astigmatism; chr4:119451844 chr4:119391831~119395335:- LUSC cis rs8062405 0.755 rs4788074 ENSG00000259982.1 CDC37P1 -8.34 8.27e-16 9.61e-13 -0.45 -0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582276 chr16:28700294~28701540:- LUSC cis rs10129255 0.5 rs2105991 ENSG00000211970.3 IGHV4-61 -8.34 8.28e-16 9.62e-13 -0.22 -0.36 Kawasaki disease; chr14:106682022 chr14:106639119~106639657:- LUSC cis rs11098499 0.644 rs3986377 ENSG00000245958.5 RP11-33B1.1 -8.34 8.3e-16 9.65e-13 -0.35 -0.36 Corneal astigmatism; chr4:119339115 chr4:119454791~119552025:+ LUSC cis rs10028773 0.556 rs4473640 ENSG00000245958.5 RP11-33B1.1 -8.34 8.3e-16 9.65e-13 -0.35 -0.36 Educational attainment; chr4:119339282 chr4:119454791~119552025:+ LUSC cis rs10463554 0.963 rs1011454 ENSG00000175749.11 EIF3KP1 8.34 8.32e-16 9.67e-13 0.43 0.36 Parkinson's disease; chr5:103032551 chr5:103032376~103033031:+ LUSC cis rs11155671 0.53 rs9371544 ENSG00000268592.3 RAET1E-AS1 8.34 8.37e-16 9.72e-13 0.43 0.36 Testicular germ cell tumor; chr6:149896224 chr6:149863494~149919507:+ LUSC cis rs8062405 0.755 rs17640009 ENSG00000259982.1 CDC37P1 8.34 8.37e-16 9.73e-13 0.44 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28584379 chr16:28700294~28701540:- LUSC cis rs9918079 0.542 rs7688984 ENSG00000273133.1 RP11-799M12.2 -8.34 8.42e-16 9.78e-13 -0.5 -0.36 Obesity-related traits; chr4:15655630 chr4:15563698~15564253:- LUSC cis rs10129255 0.828 rs10140989 ENSG00000211970.3 IGHV4-61 -8.34 8.44e-16 9.81e-13 -0.26 -0.36 Kawasaki disease; chr14:106668657 chr14:106639119~106639657:- LUSC cis rs9322193 0.847 rs12210605 ENSG00000223701.3 RAET1E-AS1 8.34 8.47e-16 9.83e-13 0.42 0.36 Lung cancer; chr6:149817267 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9371199 ENSG00000223701.3 RAET1E-AS1 8.34 8.47e-16 9.83e-13 0.42 0.36 Lung cancer; chr6:149817526 chr6:149884431~149919508:+ LUSC cis rs1061377 1 rs56119980 ENSG00000249207.1 RP11-360F5.1 -8.34 8.52e-16 9.9e-13 -0.39 -0.36 Uric acid levels; chr4:39139390 chr4:39112677~39126818:- LUSC cis rs8062405 0.723 rs12445744 ENSG00000259982.1 CDC37P1 8.34 8.53e-16 9.9e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28577074 chr16:28700294~28701540:- LUSC cis rs8062405 0.755 rs4787455 ENSG00000259982.1 CDC37P1 8.34 8.53e-16 9.9e-13 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28578134 chr16:28700294~28701540:- LUSC cis rs11098499 0.863 rs17050695 ENSG00000249244.1 RP11-548H18.2 8.34 8.54e-16 9.91e-13 0.43 0.36 Corneal astigmatism; chr4:119568372 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs7436506 ENSG00000249244.1 RP11-548H18.2 8.34 8.58e-16 9.96e-13 0.47 0.36 Corneal astigmatism; chr4:119472614 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs12499324 ENSG00000249244.1 RP11-548H18.2 8.34 8.58e-16 9.96e-13 0.47 0.36 Corneal astigmatism; chr4:119472631 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs10008459 ENSG00000249244.1 RP11-548H18.2 8.34 8.58e-16 9.96e-13 0.47 0.36 Corneal astigmatism; chr4:119473076 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs7654587 ENSG00000249244.1 RP11-548H18.2 8.34 8.59e-16 9.96e-13 0.47 0.36 Corneal astigmatism; chr4:119467251 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs10518300 ENSG00000245958.5 RP11-33B1.1 8.33 8.69e-16 1.01e-12 0.36 0.36 Corneal astigmatism; chr4:119328344 chr4:119454791~119552025:+ LUSC cis rs875971 0.898 rs6977501 ENSG00000222364.1 RNU6-96P 8.33 8.69e-16 1.01e-12 0.42 0.36 Aortic root size; chr7:66228355 chr7:66395191~66395286:+ LUSC cis rs2412819 0.571 rs8038068 ENSG00000249839.1 AC011330.5 -8.33 8.71e-16 1.01e-12 -0.6 -0.36 Lung cancer; chr15:43622175 chr15:43663654~43684339:- LUSC cis rs2412819 0.571 rs56246169 ENSG00000249839.1 AC011330.5 -8.33 8.71e-16 1.01e-12 -0.6 -0.36 Lung cancer; chr15:43628358 chr15:43663654~43684339:- LUSC cis rs7849270 1 rs10819469 ENSG00000268707.1 RP11-247A12.7 -8.33 8.72e-16 1.01e-12 -0.41 -0.36 Blood metabolite ratios; chr9:129119788 chr9:129170434~129170940:+ LUSC cis rs10463554 0.927 rs468844 ENSG00000175749.11 EIF3KP1 8.33 8.79e-16 1.02e-12 0.44 0.36 Parkinson's disease; chr5:103087872 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs469094 ENSG00000175749.11 EIF3KP1 8.33 8.79e-16 1.02e-12 0.44 0.36 Parkinson's disease; chr5:103087875 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs34795 ENSG00000175749.11 EIF3KP1 8.33 8.79e-16 1.02e-12 0.44 0.36 Parkinson's disease; chr5:103088716 chr5:103032376~103033031:+ LUSC cis rs10463554 0.927 rs34796 ENSG00000175749.11 EIF3KP1 8.33 8.79e-16 1.02e-12 0.44 0.36 Parkinson's disease; chr5:103088725 chr5:103032376~103033031:+ LUSC cis rs2739330 0.828 rs5751770 ENSG00000231271.1 AP000350.8 8.33 8.82e-16 1.02e-12 0.47 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23949918~23954042:+ LUSC cis rs7208859 0.673 rs9889755 ENSG00000263531.1 RP13-753N3.1 -8.33 8.84e-16 1.02e-12 -0.58 -0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30907487 chr17:30863921~30864940:- LUSC cis rs1789 0.903 rs4470622 ENSG00000273133.1 RP11-799M12.2 -8.33 8.85e-16 1.03e-12 -0.48 -0.36 Blood protein levels; chr4:15672552 chr4:15563698~15564253:- LUSC cis rs875971 1 rs1565531 ENSG00000222364.1 RNU6-96P 8.33 8.88e-16 1.03e-12 0.42 0.36 Aortic root size; chr7:66198126 chr7:66395191~66395286:+ LUSC cis rs11098499 0.863 rs1480940 ENSG00000245958.5 RP11-33B1.1 -8.33 8.91e-16 1.03e-12 -0.37 -0.36 Corneal astigmatism; chr4:119536527 chr4:119454791~119552025:+ LUSC cis rs10463554 0.89 rs26428 ENSG00000175749.11 EIF3KP1 -8.33 8.92e-16 1.03e-12 -0.43 -0.36 Parkinson's disease; chr5:103030780 chr5:103032376~103033031:+ LUSC cis rs694739 0.93 rs574087 ENSG00000236935.1 AP003774.1 8.33 8.93e-16 1.03e-12 0.35 0.36 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64335476 chr11:64325050~64329504:- LUSC cis rs6471393 0.964 rs10504930 ENSG00000253848.1 RP11-10N23.5 -8.33 8.93e-16 1.03e-12 -0.46 -0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93732585 chr8:93741193~93744534:+ LUSC cis rs1930961 1 rs6004667 ENSG00000100058.11 CRYBB2P1 -8.33 8.93e-16 1.03e-12 -0.66 -0.36 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25448105~25520854:+ LUSC cis rs2117029 0.586 rs10783307 ENSG00000258017.1 RP11-386G11.10 -8.33 8.94e-16 1.03e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49135822 chr12:49127782~49147869:+ LUSC cis rs2117029 0.586 rs10783308 ENSG00000258017.1 RP11-386G11.10 -8.33 8.94e-16 1.03e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49137675 chr12:49127782~49147869:+ LUSC cis rs2117029 0.586 rs2114846 ENSG00000258017.1 RP11-386G11.10 -8.33 8.94e-16 1.03e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49154493 chr12:49127782~49147869:+ LUSC cis rs8062405 0.755 rs62034358 ENSG00000259982.1 CDC37P1 8.33 8.94e-16 1.04e-12 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576276 chr16:28700294~28701540:- LUSC cis rs8062405 0.755 rs12445823 ENSG00000259982.1 CDC37P1 8.33 8.94e-16 1.04e-12 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576728 chr16:28700294~28701540:- LUSC cis rs9322193 0.962 rs4870048 ENSG00000216906.2 RP11-350J20.9 8.33 9.06e-16 1.05e-12 0.43 0.36 Lung cancer; chr6:149834324 chr6:149904243~149906418:+ LUSC cis rs3096299 0.933 rs889576 ENSG00000274627.1 RP11-104N10.2 -8.33 9.08e-16 1.05e-12 -0.32 -0.36 Multiple myeloma (IgH translocation); chr16:89363245 chr16:89516797~89522217:+ LUSC cis rs875971 1 rs9986696 ENSG00000222364.1 RNU6-96P 8.33 9.09e-16 1.05e-12 0.42 0.36 Aortic root size; chr7:66239589 chr7:66395191~66395286:+ LUSC cis rs35955747 0.811 rs9606835 ENSG00000236132.1 CTA-440B3.1 -8.33 9.14e-16 1.06e-12 -0.43 -0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31370974 chr22:31816379~31817491:- LUSC cis rs10129255 0.833 rs61997797 ENSG00000211972.2 IGHV3-66 8.33 9.15e-16 1.06e-12 0.27 0.36 Kawasaki disease; chr14:106815190 chr14:106675017~106675544:- LUSC cis rs2412819 0.571 rs66903736 ENSG00000249839.1 AC011330.5 -8.33 9.25e-16 1.07e-12 -0.61 -0.36 Lung cancer; chr15:43619435 chr15:43663654~43684339:- LUSC cis rs2412819 0.571 rs66749753 ENSG00000249839.1 AC011330.5 -8.33 9.25e-16 1.07e-12 -0.61 -0.36 Lung cancer; chr15:43619601 chr15:43663654~43684339:- LUSC cis rs526231 0.543 rs34765 ENSG00000175749.11 EIF3KP1 8.32 9.35e-16 1.08e-12 0.44 0.36 Primary biliary cholangitis; chr5:103171160 chr5:103032376~103033031:+ LUSC cis rs4988958 0.548 rs6543127 ENSG00000234389.1 AC007278.3 8.32 9.37e-16 1.08e-12 0.34 0.36 Asthma (childhood onset); chr2:102411841 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs1592459 ENSG00000234389.1 AC007278.3 8.32 9.37e-16 1.08e-12 0.34 0.36 Asthma; chr2:102415109 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs1592458 ENSG00000234389.1 AC007278.3 8.32 9.37e-16 1.08e-12 0.34 0.36 Asthma; chr2:102415289 chr2:102438713~102440475:+ LUSC cis rs4988958 0.565 rs1035125 ENSG00000234389.1 AC007278.3 8.32 9.37e-16 1.08e-12 0.34 0.36 Asthma (childhood onset); chr2:102417379 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs2160201 ENSG00000234389.1 AC007278.3 8.32 9.37e-16 1.08e-12 0.34 0.36 Asthma; chr2:102417501 chr2:102438713~102440475:+ LUSC cis rs9322193 0.962 rs3805752 ENSG00000223701.3 RAET1E-AS1 8.32 9.44e-16 1.09e-12 0.42 0.36 Lung cancer; chr6:149795490 chr6:149884431~149919508:+ LUSC cis rs7208859 0.573 rs216443 ENSG00000263531.1 RP13-753N3.1 8.32 9.46e-16 1.09e-12 0.62 0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604853 chr17:30863921~30864940:- LUSC cis rs150992 0.536 rs161729 ENSG00000248489.1 CTD-2007H13.3 8.32 9.48e-16 1.09e-12 0.44 0.36 Body mass index; chr5:98982477 chr5:98929171~98995013:+ LUSC cis rs3823536 0.544 rs12532542 ENSG00000275106.1 RP11-309L24.10 -8.32 9.51e-16 1.1e-12 -0.48 -0.36 Sjögren's syndrome; chr7:129027358 chr7:128952527~128953316:- LUSC cis rs9660180 0.967 rs6603803 ENSG00000268575.1 RP1-283E3.8 -8.32 9.54e-16 1.1e-12 -0.32 -0.36 Body mass index; chr1:1881249 chr1:1702736~1737688:- LUSC cis rs35955747 0.87 rs4820969 ENSG00000236132.1 CTA-440B3.1 8.32 9.57e-16 1.1e-12 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31377587 chr22:31816379~31817491:- LUSC cis rs9308062 1 rs9308062 ENSG00000273449.1 RP11-218F10.3 -8.32 9.57e-16 1.1e-12 -0.26 -0.36 Small cell lung carcinoma; chr4:163517048 chr4:163529771~163530697:+ LUSC cis rs1707322 0.896 rs785512 ENSG00000280836.1 AL355480.1 8.32 9.58e-16 1.11e-12 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46068871 chr1:45581219~45581321:- LUSC cis rs11098499 0.863 rs7678400 ENSG00000249244.1 RP11-548H18.2 8.32 9.61e-16 1.11e-12 0.46 0.36 Corneal astigmatism; chr4:119540802 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs1480936 ENSG00000249244.1 RP11-548H18.2 8.32 9.61e-16 1.11e-12 0.46 0.36 Corneal astigmatism; chr4:119541706 chr4:119391831~119395335:- LUSC cis rs1113500 0.933 rs4593854 ENSG00000226822.1 RP11-356N1.2 8.32 9.62e-16 1.11e-12 0.37 0.36 Growth-regulated protein alpha levels; chr1:108095897 chr1:108071482~108074519:+ LUSC cis rs10129255 0.957 rs56134540 ENSG00000211970.3 IGHV4-61 -8.32 9.66e-16 1.12e-12 -0.26 -0.36 Kawasaki disease; chr14:106691290 chr14:106639119~106639657:- LUSC cis rs9322193 0.887 rs9767113 ENSG00000223701.3 RAET1E-AS1 8.32 9.74e-16 1.12e-12 0.42 0.36 Lung cancer; chr6:149718157 chr6:149884431~149919508:+ LUSC cis rs1823913 1 rs4853561 ENSG00000227542.1 AC092614.2 -8.32 9.75e-16 1.12e-12 -0.48 -0.36 Obesity-related traits; chr2:191242980 chr2:191229165~191246172:- LUSC cis rs1823913 1 rs6704784 ENSG00000227542.1 AC092614.2 -8.32 9.75e-16 1.12e-12 -0.48 -0.36 Obesity-related traits; chr2:191244832 chr2:191229165~191246172:- LUSC cis rs35955747 0.871 rs2013254 ENSG00000236132.1 CTA-440B3.1 8.32 9.76e-16 1.13e-12 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31294817 chr22:31816379~31817491:- LUSC cis rs2412819 0.571 rs62018900 ENSG00000249839.1 AC011330.5 -8.32 9.8e-16 1.13e-12 -0.59 -0.36 Lung cancer; chr15:43633252 chr15:43663654~43684339:- LUSC cis rs2412819 0.545 rs35333173 ENSG00000249839.1 AC011330.5 -8.32 9.8e-16 1.13e-12 -0.59 -0.36 Lung cancer; chr15:43640818 chr15:43663654~43684339:- LUSC cis rs2412819 0.571 rs112667279 ENSG00000249839.1 AC011330.5 -8.32 9.8e-16 1.13e-12 -0.59 -0.36 Lung cancer; chr15:43649258 chr15:43663654~43684339:- LUSC cis rs9487094 0.922 rs10782162 ENSG00000260273.1 RP11-425D10.10 -8.32 9.83e-16 1.13e-12 -0.44 -0.36 Height; chr6:109485060 chr6:109382795~109383666:+ LUSC cis rs9807989 0.524 rs6543126 ENSG00000234389.1 AC007278.3 8.32 9.83e-16 1.13e-12 0.34 0.36 Asthma; chr2:102410644 chr2:102438713~102440475:+ LUSC cis rs6921919 0.945 rs16901847 ENSG00000204709.4 LINC01556 8.32 9.85e-16 1.14e-12 0.53 0.36 Autism spectrum disorder or schizophrenia; chr6:28408074 chr6:28943877~28944537:+ LUSC cis rs7739264 0.564 rs2223361 ENSG00000237404.1 RP3-471C18.2 -8.32 9.97e-16 1.15e-12 -0.4 -0.36 Endometriosis; chr6:19790578 chr6:19689825~19753113:- LUSC cis rs9322193 0.651 rs9322188 ENSG00000216906.2 RP11-350J20.9 -8.32 9.97e-16 1.15e-12 -0.43 -0.36 Lung cancer; chr6:149588355 chr6:149904243~149906418:+ LUSC cis rs12439619 0.846 rs28470877 ENSG00000255769.6 GOLGA2P10 -8.31 9.99e-16 1.15e-12 -0.51 -0.36 Intelligence (multi-trait analysis); chr15:82245797 chr15:82472993~82513950:- LUSC cis rs11098499 0.863 rs6534139 ENSG00000249244.1 RP11-548H18.2 -8.31 1e-15 1.16e-12 -0.48 -0.36 Corneal astigmatism; chr4:119528301 chr4:119391831~119395335:- LUSC cis rs9322193 0.566 rs4870118 ENSG00000216906.2 RP11-350J20.9 -8.31 1.01e-15 1.17e-12 -0.49 -0.36 Lung cancer; chr6:149923877 chr6:149904243~149906418:+ LUSC cis rs9322193 0.566 rs4869767 ENSG00000216906.2 RP11-350J20.9 -8.31 1.01e-15 1.17e-12 -0.49 -0.36 Lung cancer; chr6:149923974 chr6:149904243~149906418:+ LUSC cis rs9322193 0.566 rs4869768 ENSG00000216906.2 RP11-350J20.9 -8.31 1.01e-15 1.17e-12 -0.49 -0.36 Lung cancer; chr6:149924067 chr6:149904243~149906418:+ LUSC cis rs1707322 0.896 rs946528 ENSG00000280836.1 AL355480.1 8.31 1.01e-15 1.17e-12 0.42 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46019890 chr1:45581219~45581321:- LUSC cis rs5769707 0.609 rs135861 ENSG00000235111.1 RP1-29C18.8 -8.31 1.01e-15 1.17e-12 -0.44 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49604470 chr22:49612657~49615716:- LUSC cis rs853679 0.517 rs868987 ENSG00000219392.1 RP1-265C24.5 8.31 1.01e-15 1.17e-12 0.5 0.36 Depression; chr6:28142370 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs4713146 ENSG00000219392.1 RP1-265C24.5 -8.31 1.02e-15 1.17e-12 -0.51 -0.36 Depression; chr6:28143758 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9393894 ENSG00000219392.1 RP1-265C24.5 -8.31 1.02e-15 1.17e-12 -0.51 -0.36 Depression; chr6:28144784 chr6:28115628~28116551:+ LUSC cis rs10129255 0.957 rs61997760 ENSG00000211970.3 IGHV4-61 -8.31 1.02e-15 1.17e-12 -0.26 -0.36 Kawasaki disease; chr14:106716993 chr14:106639119~106639657:- LUSC cis rs11098499 0.954 rs13107475 ENSG00000249244.1 RP11-548H18.2 8.31 1.02e-15 1.17e-12 0.46 0.36 Corneal astigmatism; chr4:119471856 chr4:119391831~119395335:- LUSC cis rs5769707 0.609 rs2071890 ENSG00000235111.1 RP1-29C18.8 -8.31 1.03e-15 1.19e-12 -0.44 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49607643 chr22:49612657~49615716:- LUSC cis rs17270561 0.779 rs17271767 ENSG00000272462.2 U91328.19 -8.31 1.03e-15 1.19e-12 -0.47 -0.36 Iron status biomarkers; chr6:25886693 chr6:25992662~26001775:+ LUSC cis rs1707322 1 rs10890350 ENSG00000280836.1 AL355480.1 -8.31 1.03e-15 1.19e-12 -0.42 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45796706 chr1:45581219~45581321:- LUSC cis rs875971 0.965 rs6971509 ENSG00000222364.1 RNU6-96P 8.31 1.03e-15 1.19e-12 0.42 0.36 Aortic root size; chr7:66249983 chr7:66395191~66395286:+ LUSC cis rs11098499 0.604 rs2389887 ENSG00000249244.1 RP11-548H18.2 8.31 1.04e-15 1.19e-12 0.46 0.36 Corneal astigmatism; chr4:119649489 chr4:119391831~119395335:- LUSC cis rs694739 0.894 rs887314 ENSG00000236935.1 AP003774.1 8.31 1.05e-15 1.21e-12 0.35 0.36 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64285685 chr11:64325050~64329504:- LUSC cis rs11098499 0.954 rs11098526 ENSG00000249244.1 RP11-548H18.2 8.31 1.06e-15 1.22e-12 0.47 0.36 Corneal astigmatism; chr4:119469204 chr4:119391831~119395335:- LUSC cis rs2283792 0.967 rs5755099 ENSG00000228050.1 TOP3BP1 8.31 1.07e-15 1.23e-12 0.42 0.36 Multiple sclerosis; chr22:21770751 chr22:22223187~22224566:- LUSC cis rs10463554 0.926 rs26429 ENSG00000175749.11 EIF3KP1 -8.3 1.07e-15 1.23e-12 -0.42 -0.36 Parkinson's disease; chr5:103030349 chr5:103032376~103033031:+ LUSC cis rs2739330 0.828 rs4820572 ENSG00000235689.1 AP000351.13 8.3 1.08e-15 1.24e-12 0.38 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:24006305~24008258:- LUSC cis rs17270561 0.723 rs12213243 ENSG00000272462.2 U91328.19 -8.3 1.08e-15 1.24e-12 -0.47 -0.36 Iron status biomarkers; chr6:25889880 chr6:25992662~26001775:+ LUSC cis rs26232 0.583 rs26430 ENSG00000175749.11 EIF3KP1 -8.3 1.08e-15 1.24e-12 -0.43 -0.36 Rheumatoid arthritis; chr5:103030228 chr5:103032376~103033031:+ LUSC cis rs8072100 0.84 rs9900360 ENSG00000228782.6 CTD-2026D20.3 8.3 1.08e-15 1.25e-12 0.34 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47414613 chr17:47450568~47492492:- LUSC cis rs2712431 0.554 rs2010054 ENSG00000242551.2 POU5F1P6 -8.3 1.09e-15 1.25e-12 -0.42 -0.36 Monocyte chemoattractant protein-1 levels; chr3:128586459 chr3:128674735~128677005:- LUSC cis rs11098499 0.604 rs10022185 ENSG00000249244.1 RP11-548H18.2 8.3 1.1e-15 1.26e-12 0.46 0.36 Corneal astigmatism; chr4:119650610 chr4:119391831~119395335:- LUSC cis rs11089937 0.626 rs5757011 ENSG00000211639.2 IGLV4-60 8.3 1.1e-15 1.26e-12 0.4 0.36 Periodontitis (PAL4Q3); chr22:22135336 chr22:22162199~22162681:+ LUSC cis rs9807989 0.507 rs10203558 ENSG00000234389.1 AC007278.3 8.3 1.1e-15 1.27e-12 0.34 0.36 Asthma; chr2:102411180 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs10200952 ENSG00000234389.1 AC007278.3 8.3 1.1e-15 1.27e-12 0.34 0.36 Asthma; chr2:102411191 chr2:102438713~102440475:+ LUSC cis rs6452524 0.904 rs10474095 ENSG00000249664.1 CTD-2227C6.2 8.3 1.11e-15 1.27e-12 0.38 0.36 Hypertension (SNP x SNP interaction); chr5:83154887 chr5:83012285~83013109:- LUSC cis rs1061377 1 rs12499266 ENSG00000249207.1 RP11-360F5.1 8.3 1.12e-15 1.28e-12 0.38 0.36 Uric acid levels; chr4:39118133 chr4:39112677~39126818:- LUSC cis rs11098499 0.913 rs68128210 ENSG00000245958.5 RP11-33B1.1 -8.3 1.12e-15 1.28e-12 -0.36 -0.36 Corneal astigmatism; chr4:119216664 chr4:119454791~119552025:+ LUSC cis rs2117029 0.521 rs6580702 ENSG00000258017.1 RP11-386G11.10 -8.3 1.12e-15 1.29e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49169483 chr12:49127782~49147869:+ LUSC cis rs1823913 0.927 rs35092718 ENSG00000227542.1 AC092614.2 8.3 1.13e-15 1.29e-12 0.47 0.36 Obesity-related traits; chr2:191243882 chr2:191229165~191246172:- LUSC cis rs10129255 1 rs11621409 ENSG00000211970.3 IGHV4-61 -8.3 1.13e-15 1.3e-12 -0.26 -0.36 Kawasaki disease; chr14:106695603 chr14:106639119~106639657:- LUSC cis rs10129255 0.957 rs6576233 ENSG00000211970.3 IGHV4-61 -8.3 1.13e-15 1.3e-12 -0.25 -0.36 Kawasaki disease; chr14:106787239 chr14:106639119~106639657:- LUSC cis rs1185460 0.565 rs1182922 ENSG00000271751.1 RP11-110I1.14 8.3 1.14e-15 1.3e-12 0.46 0.36 Coronary artery disease; chr11:119062148 chr11:119065263~119065677:- LUSC cis rs9322193 0.847 rs9383844 ENSG00000223701.3 RAET1E-AS1 8.3 1.14e-15 1.3e-12 0.41 0.36 Lung cancer; chr6:149716268 chr6:149884431~149919508:+ LUSC cis rs11098499 0.863 rs12502389 ENSG00000245958.5 RP11-33B1.1 -8.3 1.14e-15 1.31e-12 -0.37 -0.36 Corneal astigmatism; chr4:119533036 chr4:119454791~119552025:+ LUSC cis rs10129255 1 rs10129255 ENSG00000211970.3 IGHV4-61 8.3 1.14e-15 1.31e-12 0.26 0.36 Kawasaki disease; chr14:106767970 chr14:106639119~106639657:- LUSC cis rs11089937 0.825 rs5757012 ENSG00000211639.2 IGLV4-60 8.3 1.15e-15 1.32e-12 0.35 0.36 Periodontitis (PAL4Q3); chr22:22135515 chr22:22162199~22162681:+ LUSC cis rs11098499 0.863 rs13134665 ENSG00000249244.1 RP11-548H18.2 8.29 1.16e-15 1.32e-12 0.46 0.36 Corneal astigmatism; chr4:119505275 chr4:119391831~119395335:- LUSC cis rs9807989 0.507 rs1833174 ENSG00000234389.1 AC007278.3 8.29 1.16e-15 1.33e-12 0.34 0.36 Asthma; chr2:102418383 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs10439410 ENSG00000234389.1 AC007278.3 -8.29 1.16e-15 1.33e-12 -0.34 -0.36 Asthma; chr2:102374328 chr2:102438713~102440475:+ LUSC cis rs7739264 0.602 rs1121384 ENSG00000237404.1 RP3-471C18.2 -8.29 1.17e-15 1.33e-12 -0.41 -0.36 Endometriosis; chr6:19771276 chr6:19689825~19753113:- LUSC cis rs9322193 0.923 rs55993747 ENSG00000223701.3 RAET1E-AS1 8.29 1.17e-15 1.33e-12 0.41 0.36 Lung cancer; chr6:149622016 chr6:149884431~149919508:+ LUSC cis rs5769707 0.967 rs5770585 ENSG00000235111.1 RP1-29C18.8 -8.29 1.17e-15 1.34e-12 -0.41 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49614226 chr22:49612657~49615716:- LUSC cis rs9322193 0.566 rs3922947 ENSG00000216906.2 RP11-350J20.9 -8.29 1.17e-15 1.34e-12 -0.48 -0.36 Lung cancer; chr6:149924856 chr6:149904243~149906418:+ LUSC cis rs62229266 0.835 rs998384 ENSG00000231106.2 LINC01436 8.29 1.17e-15 1.34e-12 0.46 0.36 Mitral valve prolapse; chr21:36073228 chr21:36005338~36007838:+ LUSC cis rs11098499 0.863 rs58452170 ENSG00000249244.1 RP11-548H18.2 8.29 1.17e-15 1.34e-12 0.47 0.36 Corneal astigmatism; chr4:119538519 chr4:119391831~119395335:- LUSC cis rs748404 0.578 rs507178 ENSG00000249839.1 AC011330.5 -8.29 1.18e-15 1.34e-12 -0.47 -0.36 Lung cancer; chr15:43317937 chr15:43663654~43684339:- LUSC cis rs748404 0.578 rs478028 ENSG00000249839.1 AC011330.5 -8.29 1.18e-15 1.34e-12 -0.47 -0.36 Lung cancer; chr15:43318574 chr15:43663654~43684339:- LUSC cis rs35955747 0.934 rs5997981 ENSG00000236132.1 CTA-440B3.1 8.29 1.18e-15 1.35e-12 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31412841 chr22:31816379~31817491:- LUSC cis rs875971 1 rs6956179 ENSG00000222364.1 RNU6-96P 8.29 1.18e-15 1.35e-12 0.43 0.36 Aortic root size; chr7:66341672 chr7:66395191~66395286:+ LUSC cis rs3823536 0.583 rs4731540 ENSG00000275106.1 RP11-309L24.10 -8.29 1.2e-15 1.37e-12 -0.48 -0.36 Sjögren's syndrome; chr7:129028196 chr7:128952527~128953316:- LUSC cis rs11098499 0.909 rs79026312 ENSG00000245958.5 RP11-33B1.1 -8.29 1.2e-15 1.37e-12 -0.37 -0.36 Corneal astigmatism; chr4:119519522 chr4:119454791~119552025:+ LUSC cis rs11098499 0.909 rs35111518 ENSG00000245958.5 RP11-33B1.1 -8.29 1.2e-15 1.37e-12 -0.37 -0.36 Corneal astigmatism; chr4:119519527 chr4:119454791~119552025:+ LUSC cis rs11089937 0.626 rs5757017 ENSG00000211639.2 IGLV4-60 8.29 1.2e-15 1.37e-12 0.4 0.36 Periodontitis (PAL4Q3); chr22:22135947 chr22:22162199~22162681:+ LUSC cis rs1823913 1 rs11681777 ENSG00000227542.1 AC092614.2 -8.29 1.2e-15 1.37e-12 -0.47 -0.36 Obesity-related traits; chr2:191256741 chr2:191229165~191246172:- LUSC cis rs1823913 1 rs4853564 ENSG00000227542.1 AC092614.2 -8.29 1.2e-15 1.37e-12 -0.47 -0.36 Obesity-related traits; chr2:191258939 chr2:191229165~191246172:- LUSC cis rs1823913 1 rs4853565 ENSG00000227542.1 AC092614.2 -8.29 1.2e-15 1.37e-12 -0.47 -0.36 Obesity-related traits; chr2:191259020 chr2:191229165~191246172:- LUSC cis rs1823913 1 rs4853462 ENSG00000227542.1 AC092614.2 -8.29 1.2e-15 1.37e-12 -0.47 -0.36 Obesity-related traits; chr2:191259078 chr2:191229165~191246172:- LUSC cis rs526231 0.511 rs11951374 ENSG00000175749.11 EIF3KP1 8.29 1.22e-15 1.39e-12 0.43 0.36 Primary biliary cholangitis; chr5:103020094 chr5:103032376~103033031:+ LUSC cis rs7945705 0.747 rs1980428 ENSG00000254860.4 TMEM9B-AS1 -8.29 1.22e-15 1.39e-12 -0.39 -0.36 Hemoglobin concentration; chr11:8988950 chr11:8964675~8977527:+ LUSC cis rs8062405 0.755 rs12447461 ENSG00000259982.1 CDC37P1 8.29 1.23e-15 1.4e-12 0.44 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28571620 chr16:28700294~28701540:- LUSC cis rs8062405 0.755 rs111693583 ENSG00000259982.1 CDC37P1 8.29 1.23e-15 1.4e-12 0.44 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28572289 chr16:28700294~28701540:- LUSC cis rs17023223 0.537 rs12081198 ENSG00000231365.4 RP11-418J17.1 -8.29 1.23e-15 1.41e-12 -0.44 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119143481 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs12081327 ENSG00000231365.4 RP11-418J17.1 -8.29 1.23e-15 1.41e-12 -0.44 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119143735 chr1:119140396~119275973:+ LUSC cis rs9322193 0.923 rs9322214 ENSG00000223701.3 RAET1E-AS1 8.29 1.24e-15 1.41e-12 0.42 0.36 Lung cancer; chr6:149703986 chr6:149884431~149919508:+ LUSC cis rs6452524 0.869 rs10051155 ENSG00000249664.1 CTD-2227C6.2 8.28 1.25e-15 1.42e-12 0.38 0.36 Hypertension (SNP x SNP interaction); chr5:83160851 chr5:83012285~83013109:- LUSC cis rs11098499 0.566 rs7664440 ENSG00000249244.1 RP11-548H18.2 8.28 1.25e-15 1.43e-12 0.46 0.36 Corneal astigmatism; chr4:119657385 chr4:119391831~119395335:- LUSC cis rs5769707 0.681 rs8140095 ENSG00000235111.1 RP1-29C18.8 -8.28 1.25e-15 1.43e-12 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49650147 chr22:49612657~49615716:- LUSC cis rs1707322 0.963 rs10789484 ENSG00000280836.1 AL355480.1 -8.28 1.25e-15 1.43e-12 -0.42 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45941306 chr1:45581219~45581321:- LUSC cis rs3096299 0.967 rs11648663 ENSG00000274627.1 RP11-104N10.2 8.28 1.26e-15 1.43e-12 0.32 0.36 Multiple myeloma (IgH translocation); chr16:89399899 chr16:89516797~89522217:+ LUSC cis rs150992 0.603 rs246251 ENSG00000248489.1 CTD-2007H13.3 8.28 1.26e-15 1.43e-12 0.43 0.36 Body mass index; chr5:98942362 chr5:98929171~98995013:+ LUSC cis rs9487094 0.744 rs13192476 ENSG00000260273.1 RP11-425D10.10 8.28 1.26e-15 1.44e-12 0.46 0.36 Height; chr6:109403951 chr6:109382795~109383666:+ LUSC cis rs9322193 0.924 rs9498382 ENSG00000223701.3 RAET1E-AS1 8.28 1.27e-15 1.45e-12 0.41 0.36 Lung cancer; chr6:149610982 chr6:149884431~149919508:+ LUSC cis rs26232 0.52 rs26432 ENSG00000175749.11 EIF3KP1 -8.28 1.27e-15 1.45e-12 -0.43 -0.36 Rheumatoid arthritis; chr5:103030006 chr5:103032376~103033031:+ LUSC cis rs8062405 0.755 rs4788078 ENSG00000259982.1 CDC37P1 8.28 1.28e-15 1.46e-12 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548660 chr16:28700294~28701540:- LUSC cis rs3931020 0.657 rs277376 ENSG00000272864.1 RP11-17E13.2 8.28 1.28e-15 1.46e-12 0.48 0.36 Resistin levels; chr1:74776562 chr1:74698769~74699333:- LUSC cis rs10129255 0.536 rs17113249 ENSG00000211970.3 IGHV4-61 -8.28 1.29e-15 1.46e-12 -0.22 -0.36 Kawasaki disease; chr14:106678273 chr14:106639119~106639657:- LUSC cis rs11098499 0.863 rs3775841 ENSG00000249244.1 RP11-548H18.2 8.28 1.29e-15 1.46e-12 0.46 0.36 Corneal astigmatism; chr4:119504622 chr4:119391831~119395335:- LUSC cis rs875971 1 rs6958271 ENSG00000222364.1 RNU6-96P -8.28 1.29e-15 1.47e-12 -0.42 -0.36 Aortic root size; chr7:66514344 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs6958277 ENSG00000222364.1 RNU6-96P -8.28 1.29e-15 1.47e-12 -0.42 -0.36 Aortic root size; chr7:66514362 chr7:66395191~66395286:+ LUSC cis rs4266144 1 rs4266144 ENSG00000244515.1 KRT18P34 -8.28 1.29e-15 1.47e-12 -0.44 -0.36 Coronary artery disease; chr3:157134803 chr3:157162663~157163932:- LUSC cis rs11155671 0.53 rs7757984 ENSG00000268592.3 RAET1E-AS1 8.28 1.29e-15 1.47e-12 0.44 0.36 Testicular germ cell tumor; chr6:149887515 chr6:149863494~149919507:+ LUSC cis rs2117029 0.554 rs2334931 ENSG00000258017.1 RP11-386G11.10 -8.28 1.29e-15 1.47e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49174130 chr12:49127782~49147869:+ LUSC cis rs11098499 0.955 rs13113112 ENSG00000249244.1 RP11-548H18.2 8.28 1.29e-15 1.47e-12 0.46 0.36 Corneal astigmatism; chr4:119234885 chr4:119391831~119395335:- LUSC cis rs9487094 0.922 rs2236582 ENSG00000260273.1 RP11-425D10.10 -8.28 1.3e-15 1.47e-12 -0.43 -0.36 Height; chr6:109444615 chr6:109382795~109383666:+ LUSC cis rs1075265 0.584 rs34769118 ENSG00000233266.1 HMGB1P31 8.28 1.3e-15 1.48e-12 0.45 0.36 Chronotype;Morning vs. evening chronotype; chr2:54102173 chr2:54051334~54051760:+ LUSC cis rs10129255 0.957 rs4387509 ENSG00000211970.3 IGHV4-61 -8.28 1.3e-15 1.48e-12 -0.26 -0.36 Kawasaki disease; chr14:106704386 chr14:106639119~106639657:- LUSC cis rs10463554 0.963 rs257115 ENSG00000175749.11 EIF3KP1 8.28 1.31e-15 1.49e-12 0.42 0.36 Parkinson's disease; chr5:103196107 chr5:103032376~103033031:+ LUSC cis rs2117029 0.586 rs10875929 ENSG00000258017.1 RP11-386G11.10 -8.28 1.31e-15 1.49e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49174605 chr12:49127782~49147869:+ LUSC cis rs2117029 0.554 rs2334930 ENSG00000258017.1 RP11-386G11.10 -8.28 1.31e-15 1.49e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49175528 chr12:49127782~49147869:+ LUSC cis rs2117029 0.586 rs11168904 ENSG00000258017.1 RP11-386G11.10 -8.28 1.31e-15 1.49e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49177234 chr12:49127782~49147869:+ LUSC cis rs2117029 0.586 rs10875931 ENSG00000258017.1 RP11-386G11.10 -8.28 1.31e-15 1.49e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49179513 chr12:49127782~49147869:+ LUSC cis rs2117029 0.554 rs7954530 ENSG00000258017.1 RP11-386G11.10 -8.28 1.31e-15 1.49e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49179742 chr12:49127782~49147869:+ LUSC cis rs2117029 0.586 rs7957998 ENSG00000258017.1 RP11-386G11.10 -8.28 1.31e-15 1.49e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49180240 chr12:49127782~49147869:+ LUSC cis rs2117029 0.553 rs11168909 ENSG00000258017.1 RP11-386G11.10 -8.28 1.31e-15 1.49e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49183092 chr12:49127782~49147869:+ LUSC cis rs853679 0.55 rs1150692 ENSG00000219392.1 RP1-265C24.5 -8.28 1.32e-15 1.5e-12 -0.49 -0.36 Depression; chr6:28206179 chr6:28115628~28116551:+ LUSC cis rs6452524 0.935 rs10043698 ENSG00000249664.1 CTD-2227C6.2 8.28 1.33e-15 1.51e-12 0.38 0.36 Hypertension (SNP x SNP interaction); chr5:83169100 chr5:83012285~83013109:- LUSC cis rs5769707 0.681 rs4622843 ENSG00000235111.1 RP1-29C18.8 -8.28 1.33e-15 1.51e-12 -0.43 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49643268 chr22:49612657~49615716:- LUSC cis rs783540 0.5 rs783541 ENSG00000276710.3 CSPG4P8 8.27 1.35e-15 1.53e-12 0.42 0.36 Schizophrenia; chr15:82586310 chr15:82459472~82477258:+ LUSC cis rs748404 0.578 rs510108 ENSG00000249839.1 AC011330.5 -8.27 1.35e-15 1.53e-12 -0.48 -0.36 Lung cancer; chr15:43313241 chr15:43663654~43684339:- LUSC cis rs11098499 1 rs13435802 ENSG00000249244.1 RP11-548H18.2 -8.27 1.35e-15 1.53e-12 -0.45 -0.36 Corneal astigmatism; chr4:119256805 chr4:119391831~119395335:- LUSC cis rs9487094 0.961 rs9487068 ENSG00000260273.1 RP11-425D10.10 8.27 1.35e-15 1.53e-12 0.43 0.36 Height; chr6:109350642 chr6:109382795~109383666:+ LUSC cis rs9807989 0.507 rs1035129 ENSG00000234389.1 AC007278.3 8.27 1.35e-15 1.54e-12 0.34 0.36 Asthma; chr2:102403325 chr2:102438713~102440475:+ LUSC cis rs9807989 0.524 rs2110662 ENSG00000234389.1 AC007278.3 8.27 1.35e-15 1.54e-12 0.34 0.36 Asthma; chr2:102403679 chr2:102438713~102440475:+ LUSC cis rs9807989 0.524 rs7594402 ENSG00000234389.1 AC007278.3 8.27 1.35e-15 1.54e-12 0.34 0.36 Asthma; chr2:102404807 chr2:102438713~102440475:+ LUSC cis rs9807989 0.507 rs6710034 ENSG00000234389.1 AC007278.3 8.27 1.35e-15 1.54e-12 0.34 0.36 Asthma; chr2:102407218 chr2:102438713~102440475:+ LUSC cis rs4988958 0.584 rs7589142 ENSG00000234389.1 AC007278.3 8.27 1.35e-15 1.54e-12 0.34 0.36 Asthma (childhood onset); chr2:102408200 chr2:102438713~102440475:+ LUSC cis rs1061377 1 rs35116118 ENSG00000249207.1 RP11-360F5.1 -8.27 1.35e-15 1.54e-12 -0.38 -0.36 Uric acid levels; chr4:39127293 chr4:39112677~39126818:- LUSC cis rs11098499 0.863 rs7669520 ENSG00000245958.5 RP11-33B1.1 -8.27 1.36e-15 1.54e-12 -0.36 -0.36 Corneal astigmatism; chr4:119594123 chr4:119454791~119552025:+ LUSC cis rs35955747 0.869 rs5997971 ENSG00000236132.1 CTA-440B3.1 8.27 1.36e-15 1.54e-12 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31396306 chr22:31816379~31817491:- LUSC cis rs9322193 0.962 rs7740784 ENSG00000223701.3 RAET1E-AS1 8.27 1.36e-15 1.54e-12 0.42 0.36 Lung cancer; chr6:149833364 chr6:149884431~149919508:+ LUSC cis rs7617773 0.746 rs4130995 ENSG00000228638.1 FCF1P2 -8.27 1.36e-15 1.55e-12 -0.41 -0.36 Coronary artery disease; chr3:48316765 chr3:48290793~48291375:- LUSC cis rs760794 0.765 rs7759616 ENSG00000237404.1 RP3-471C18.2 -8.27 1.37e-15 1.55e-12 -0.39 -0.36 Endometriosis; chr6:19794354 chr6:19689825~19753113:- LUSC cis rs11098499 0.863 rs3822192 ENSG00000245958.5 RP11-33B1.1 -8.27 1.37e-15 1.56e-12 -0.37 -0.36 Corneal astigmatism; chr4:119524565 chr4:119454791~119552025:+ LUSC cis rs9322193 0.851 rs9322194 ENSG00000223701.3 RAET1E-AS1 8.27 1.37e-15 1.56e-12 0.42 0.36 Lung cancer; chr6:149599113 chr6:149884431~149919508:+ LUSC cis rs9487094 0.922 rs13204102 ENSG00000260273.1 RP11-425D10.10 8.27 1.37e-15 1.56e-12 0.44 0.36 Height; chr6:109617741 chr6:109382795~109383666:+ LUSC cis rs9487094 0.922 rs10499053 ENSG00000260273.1 RP11-425D10.10 8.27 1.37e-15 1.56e-12 0.44 0.36 Height; chr6:109619295 chr6:109382795~109383666:+ LUSC cis rs11098499 0.954 rs10017543 ENSG00000249244.1 RP11-548H18.2 8.27 1.38e-15 1.57e-12 0.47 0.36 Corneal astigmatism; chr4:119400265 chr4:119391831~119395335:- LUSC cis rs9322193 0.923 rs4870509 ENSG00000223701.3 RAET1E-AS1 8.27 1.38e-15 1.57e-12 0.42 0.36 Lung cancer; chr6:149702212 chr6:149884431~149919508:+ LUSC cis rs10129255 1 rs10129319 ENSG00000211970.3 IGHV4-61 -8.27 1.38e-15 1.57e-12 -0.26 -0.36 Kawasaki disease; chr14:106767996 chr14:106639119~106639657:- LUSC cis rs11098499 0.863 rs10018280 ENSG00000245958.5 RP11-33B1.1 -8.27 1.4e-15 1.59e-12 -0.36 -0.36 Corneal astigmatism; chr4:119556984 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs6534141 ENSG00000245958.5 RP11-33B1.1 -8.27 1.4e-15 1.59e-12 -0.36 -0.36 Corneal astigmatism; chr4:119564068 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs3775858 ENSG00000245958.5 RP11-33B1.1 -8.27 1.4e-15 1.59e-12 -0.36 -0.36 Corneal astigmatism; chr4:119564873 chr4:119454791~119552025:+ LUSC cis rs765787 0.53 rs12439643 ENSG00000259520.4 CTD-2651B20.3 -8.27 1.41e-15 1.6e-12 -0.45 -0.36 Uric acid levels; chr15:45237569 chr15:45251580~45279251:- LUSC cis rs3096299 0.967 rs28644774 ENSG00000274627.1 RP11-104N10.2 8.27 1.41e-15 1.6e-12 0.31 0.36 Multiple myeloma (IgH translocation); chr16:89405773 chr16:89516797~89522217:+ LUSC cis rs11098499 0.604 rs34278750 ENSG00000249244.1 RP11-548H18.2 8.27 1.42e-15 1.61e-12 0.46 0.36 Corneal astigmatism; chr4:119649981 chr4:119391831~119395335:- LUSC cis rs11089937 0.568 rs59356111 ENSG00000211639.2 IGLV4-60 8.27 1.42e-15 1.61e-12 0.4 0.36 Periodontitis (PAL4Q3); chr22:22136175 chr22:22162199~22162681:+ LUSC cis rs9322193 0.884 rs9371201 ENSG00000216906.2 RP11-350J20.9 8.27 1.42e-15 1.61e-12 0.45 0.36 Lung cancer; chr6:149823865 chr6:149904243~149906418:+ LUSC cis rs11098499 0.779 rs80242894 ENSG00000249244.1 RP11-548H18.2 8.27 1.42e-15 1.61e-12 0.46 0.36 Corneal astigmatism; chr4:119454597 chr4:119391831~119395335:- LUSC cis rs11089937 0.597 rs5750579 ENSG00000211639.2 IGLV4-60 8.27 1.43e-15 1.61e-12 0.4 0.36 Periodontitis (PAL4Q3); chr22:22136581 chr22:22162199~22162681:+ LUSC cis rs9322193 0.884 rs9397036 ENSG00000223701.3 RAET1E-AS1 8.27 1.43e-15 1.62e-12 0.41 0.36 Lung cancer; chr6:149851787 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs9383864 ENSG00000223701.3 RAET1E-AS1 8.27 1.43e-15 1.62e-12 0.41 0.36 Lung cancer; chr6:149851969 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs9383865 ENSG00000223701.3 RAET1E-AS1 8.27 1.43e-15 1.62e-12 0.41 0.36 Lung cancer; chr6:149852043 chr6:149884431~149919508:+ LUSC cis rs7044106 0.791 rs10984997 ENSG00000226752.6 PSMD5-AS1 -8.26 1.44e-15 1.63e-12 -0.42 -0.36 Hip circumference adjusted for BMI; chr9:120718928 chr9:120824828~120854385:+ LUSC cis rs6921919 0.638 rs1416920 ENSG00000204709.4 LINC01556 8.26 1.44e-15 1.63e-12 0.48 0.36 Autism spectrum disorder or schizophrenia; chr6:28335007 chr6:28943877~28944537:+ LUSC cis rs875971 1 rs3981131 ENSG00000222364.1 RNU6-96P -8.26 1.44e-15 1.63e-12 -0.42 -0.36 Aortic root size; chr7:66486690 chr7:66395191~66395286:+ LUSC cis rs367615 0.552 rs7720036 ENSG00000249476.1 CTD-2587M2.1 -8.26 1.44e-15 1.63e-12 -0.41 -0.36 Colorectal cancer (SNP x SNP interaction); chr5:109374998 chr5:109237120~109326369:- LUSC cis rs2117029 0.653 rs1476137 ENSG00000258017.1 RP11-386G11.10 -8.26 1.45e-15 1.64e-12 -0.44 -0.36 Intelligence (multi-trait analysis); chr12:49129930 chr12:49127782~49147869:+ LUSC cis rs2117029 0.553 rs731350 ENSG00000258017.1 RP11-386G11.10 -8.26 1.45e-15 1.64e-12 -0.44 -0.36 Intelligence (multi-trait analysis); chr12:49130804 chr12:49127782~49147869:+ LUSC cis rs11098499 0.909 rs10026736 ENSG00000249244.1 RP11-548H18.2 8.26 1.45e-15 1.64e-12 0.47 0.36 Corneal astigmatism; chr4:119463167 chr4:119391831~119395335:- LUSC cis rs9487094 1 rs36035949 ENSG00000260273.1 RP11-425D10.10 8.26 1.46e-15 1.64e-12 0.44 0.36 Height; chr6:109415411 chr6:109382795~109383666:+ LUSC cis rs9322193 0.607 rs9322229 ENSG00000216906.2 RP11-350J20.9 8.26 1.46e-15 1.65e-12 0.46 0.36 Lung cancer; chr6:149908949 chr6:149904243~149906418:+ LUSC cis rs3823536 0.583 rs10279821 ENSG00000275106.1 RP11-309L24.10 -8.26 1.47e-15 1.66e-12 -0.49 -0.36 Sjögren's syndrome; chr7:129043493 chr7:128952527~128953316:- LUSC cis rs11089937 0.626 rs5757019 ENSG00000211639.2 IGLV4-60 8.26 1.48e-15 1.67e-12 0.4 0.36 Periodontitis (PAL4Q3); chr22:22136286 chr22:22162199~22162681:+ LUSC cis rs35955747 0.902 rs12167361 ENSG00000236132.1 CTA-440B3.1 8.26 1.48e-15 1.67e-12 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31300292 chr22:31816379~31817491:- LUSC cis rs11098499 0.913 rs10006304 ENSG00000245958.5 RP11-33B1.1 -8.26 1.48e-15 1.68e-12 -0.37 -0.36 Corneal astigmatism; chr4:119203150 chr4:119454791~119552025:+ LUSC cis rs1707322 0.928 rs6681068 ENSG00000280836.1 AL355480.1 -8.26 1.49e-15 1.68e-12 -0.42 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45932710 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs11211228 ENSG00000280836.1 AL355480.1 -8.26 1.49e-15 1.68e-12 -0.42 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45934168 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs11211229 ENSG00000280836.1 AL355480.1 -8.26 1.49e-15 1.68e-12 -0.42 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45934845 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs9803784 ENSG00000280836.1 AL355480.1 -8.26 1.49e-15 1.68e-12 -0.42 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45936235 chr1:45581219~45581321:- LUSC cis rs1707322 0.963 rs12022335 ENSG00000280836.1 AL355480.1 -8.26 1.49e-15 1.68e-12 -0.42 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45937060 chr1:45581219~45581321:- LUSC cis rs9322193 0.884 rs7450246 ENSG00000223701.3 RAET1E-AS1 8.26 1.49e-15 1.68e-12 0.41 0.36 Lung cancer; chr6:149702517 chr6:149884431~149919508:+ LUSC cis rs11098499 0.955 rs13129661 ENSG00000249244.1 RP11-548H18.2 8.26 1.49e-15 1.68e-12 0.46 0.36 Corneal astigmatism; chr4:119231754 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs2389803 ENSG00000249244.1 RP11-548H18.2 -8.26 1.49e-15 1.68e-12 -0.46 -0.36 Corneal astigmatism; chr4:119472356 chr4:119391831~119395335:- LUSC cis rs853679 0.517 rs1340004 ENSG00000219392.1 RP1-265C24.5 -8.26 1.5e-15 1.69e-12 -0.51 -0.36 Depression; chr6:28135913 chr6:28115628~28116551:+ LUSC cis rs10262624 0.528 rs5029444 ENSG00000234286.1 AC006026.13 8.26 1.51e-15 1.7e-12 0.43 0.36 Schizophrenia; chr7:23698176 chr7:23680195~23680786:- LUSC cis rs11098499 0.908 rs11098527 ENSG00000249244.1 RP11-548H18.2 8.26 1.51e-15 1.71e-12 0.47 0.36 Corneal astigmatism; chr4:119478751 chr4:119391831~119395335:- LUSC cis rs10463554 0.926 rs5855 ENSG00000175749.11 EIF3KP1 -8.26 1.52e-15 1.71e-12 -0.43 -0.36 Parkinson's disease; chr5:103029482 chr5:103032376~103033031:+ LUSC cis rs5769707 0.967 rs9616327 ENSG00000235111.1 RP1-29C18.8 -8.26 1.53e-15 1.72e-12 -0.41 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49617243 chr22:49612657~49615716:- LUSC cis rs9322193 0.884 rs11155679 ENSG00000216906.2 RP11-350J20.9 8.26 1.53e-15 1.73e-12 0.45 0.36 Lung cancer; chr6:149758881 chr6:149904243~149906418:+ LUSC cis rs35955747 0.902 rs12166373 ENSG00000236132.1 CTA-440B3.1 8.26 1.53e-15 1.73e-12 0.42 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31304522 chr22:31816379~31817491:- LUSC cis rs5769707 0.681 rs8137111 ENSG00000235111.1 RP1-29C18.8 -8.26 1.54e-15 1.74e-12 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49650102 chr22:49612657~49615716:- LUSC cis rs11155671 0.53 rs1334510 ENSG00000268592.3 RAET1E-AS1 8.26 1.54e-15 1.74e-12 0.43 0.36 Testicular germ cell tumor; chr6:149880043 chr6:149863494~149919507:+ LUSC cis rs11098499 0.821 rs10032151 ENSG00000249244.1 RP11-548H18.2 8.26 1.55e-15 1.74e-12 0.47 0.36 Corneal astigmatism; chr4:119470473 chr4:119391831~119395335:- LUSC cis rs11098499 0.865 rs10032158 ENSG00000249244.1 RP11-548H18.2 8.26 1.55e-15 1.74e-12 0.47 0.36 Corneal astigmatism; chr4:119470477 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs6838814 ENSG00000249244.1 RP11-548H18.2 8.26 1.55e-15 1.74e-12 0.47 0.36 Corneal astigmatism; chr4:119471288 chr4:119391831~119395335:- LUSC cis rs7811142 1 rs1000215 ENSG00000242294.5 STAG3L5P 8.25 1.55e-15 1.75e-12 0.28 0.36 Platelet count; chr7:100406920 chr7:100336079~100351900:+ LUSC cis rs17023223 0.537 rs12086686 ENSG00000231365.4 RP11-418J17.1 -8.25 1.55e-15 1.75e-12 -0.44 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119146461 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs12085616 ENSG00000231365.4 RP11-418J17.1 -8.25 1.55e-15 1.75e-12 -0.44 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119146525 chr1:119140396~119275973:+ LUSC cis rs11098499 0.955 rs56386062 ENSG00000249244.1 RP11-548H18.2 8.25 1.56e-15 1.76e-12 0.45 0.36 Corneal astigmatism; chr4:119233980 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs4145951 ENSG00000249244.1 RP11-548H18.2 8.25 1.56e-15 1.76e-12 0.45 0.36 Corneal astigmatism; chr4:119234662 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs35916640 ENSG00000249244.1 RP11-548H18.2 8.25 1.56e-15 1.76e-12 0.45 0.36 Corneal astigmatism; chr4:119234697 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs13114751 ENSG00000249244.1 RP11-548H18.2 8.25 1.56e-15 1.76e-12 0.45 0.36 Corneal astigmatism; chr4:119235462 chr4:119391831~119395335:- LUSC cis rs11098499 0.913 rs35271032 ENSG00000249244.1 RP11-548H18.2 8.25 1.56e-15 1.76e-12 0.45 0.36 Corneal astigmatism; chr4:119235504 chr4:119391831~119395335:- LUSC cis rs10129255 0.912 rs67410411 ENSG00000211972.2 IGHV3-66 8.25 1.56e-15 1.76e-12 0.27 0.36 Kawasaki disease; chr14:106680324 chr14:106675017~106675544:- LUSC cis rs9322193 0.923 rs9767554 ENSG00000223701.3 RAET1E-AS1 8.25 1.56e-15 1.76e-12 0.4 0.36 Lung cancer; chr6:149616860 chr6:149884431~149919508:+ LUSC cis rs1061377 1 rs1897136 ENSG00000249207.1 RP11-360F5.1 -8.25 1.56e-15 1.76e-12 -0.37 -0.36 Uric acid levels; chr4:39131242 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs1897137 ENSG00000249207.1 RP11-360F5.1 -8.25 1.56e-15 1.76e-12 -0.37 -0.36 Uric acid levels; chr4:39131387 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs35437629 ENSG00000249207.1 RP11-360F5.1 -8.25 1.56e-15 1.76e-12 -0.37 -0.36 Uric acid levels; chr4:39131712 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs7657926 ENSG00000249207.1 RP11-360F5.1 -8.25 1.56e-15 1.76e-12 -0.37 -0.36 Uric acid levels; chr4:39132443 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs7681116 ENSG00000249207.1 RP11-360F5.1 -8.25 1.56e-15 1.76e-12 -0.37 -0.36 Uric acid levels; chr4:39133015 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs11096982 ENSG00000249207.1 RP11-360F5.1 -8.25 1.56e-15 1.76e-12 -0.37 -0.36 Uric acid levels; chr4:39133247 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs11727875 ENSG00000249207.1 RP11-360F5.1 -8.25 1.56e-15 1.76e-12 -0.37 -0.36 Uric acid levels; chr4:39133699 chr4:39112677~39126818:- LUSC cis rs1061377 0.965 rs10018622 ENSG00000249207.1 RP11-360F5.1 -8.25 1.56e-15 1.76e-12 -0.37 -0.36 Uric acid levels; chr4:39133944 chr4:39112677~39126818:- LUSC cis rs694739 0.628 rs538147 ENSG00000236935.1 AP003774.1 8.25 1.56e-15 1.76e-12 0.35 0.36 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64362250 chr11:64325050~64329504:- LUSC cis rs9487094 0.67 rs2277114 ENSG00000260273.1 RP11-425D10.10 8.25 1.57e-15 1.77e-12 0.42 0.36 Height; chr6:109506513 chr6:109382795~109383666:+ LUSC cis rs5769707 0.656 rs135875 ENSG00000235111.1 RP1-29C18.8 -8.25 1.57e-15 1.77e-12 -0.45 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49618771 chr22:49612657~49615716:- LUSC cis rs11098499 0.618 rs35265692 ENSG00000249244.1 RP11-548H18.2 8.25 1.58e-15 1.77e-12 0.46 0.36 Corneal astigmatism; chr4:119403980 chr4:119391831~119395335:- LUSC cis rs1061377 1 rs9999327 ENSG00000249207.1 RP11-360F5.1 -8.25 1.59e-15 1.78e-12 -0.38 -0.36 Uric acid levels; chr4:39110111 chr4:39112677~39126818:- LUSC cis rs9807989 0.507 rs1420096 ENSG00000234389.1 AC007278.3 8.25 1.59e-15 1.78e-12 0.34 0.36 Asthma; chr2:102394452 chr2:102438713~102440475:+ LUSC cis rs5769707 0.609 rs739247 ENSG00000235111.1 RP1-29C18.8 -8.25 1.59e-15 1.79e-12 -0.44 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49603009 chr22:49612657~49615716:- LUSC cis rs11098499 0.954 rs2389802 ENSG00000249244.1 RP11-548H18.2 8.25 1.59e-15 1.79e-12 0.47 0.36 Corneal astigmatism; chr4:119404577 chr4:119391831~119395335:- LUSC cis rs9322193 0.923 rs1934534 ENSG00000223701.3 RAET1E-AS1 8.25 1.59e-15 1.79e-12 0.41 0.36 Lung cancer; chr6:149711896 chr6:149884431~149919508:+ LUSC cis rs10256972 0.521 rs10280960 ENSG00000229043.2 AC091729.9 -8.25 1.61e-15 1.81e-12 -0.4 -0.36 Endometriosis;Longevity; chr7:1064061 chr7:1160374~1165267:+ LUSC cis rs9341808 0.718 rs9352806 ENSG00000272129.1 RP11-250B2.6 8.25 1.62e-15 1.81e-12 0.42 0.36 Sitting height ratio; chr6:80270340 chr6:80355424~80356859:+ LUSC cis rs1075265 0.633 rs7591431 ENSG00000233266.1 HMGB1P31 8.25 1.62e-15 1.82e-12 0.47 0.36 Chronotype;Morning vs. evening chronotype; chr2:53995028 chr2:54051334~54051760:+ LUSC cis rs1501911 0.588 rs819227 ENSG00000248489.1 CTD-2007H13.3 -8.25 1.62e-15 1.82e-12 -0.45 -0.36 Lung function (FEV1/FVC); chr5:98994161 chr5:98929171~98995013:+ LUSC cis rs7739264 0.564 rs760796 ENSG00000237404.1 RP3-471C18.2 -8.25 1.63e-15 1.83e-12 -0.4 -0.36 Endometriosis; chr6:19790156 chr6:19689825~19753113:- LUSC cis rs1075265 0.568 rs10865278 ENSG00000233266.1 HMGB1P31 8.25 1.63e-15 1.83e-12 0.44 0.36 Chronotype;Morning vs. evening chronotype; chr2:54074902 chr2:54051334~54051760:+ LUSC cis rs3091242 0.9 rs669063 ENSG00000224183.1 SDHDP6 -8.25 1.63e-15 1.83e-12 -0.44 -0.36 Erythrocyte sedimentation rate; chr1:25394663 chr1:25294164~25294643:- LUSC cis rs1707322 1 rs6661500 ENSG00000280836.1 AL355480.1 -8.25 1.63e-15 1.83e-12 -0.42 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45999990 chr1:45581219~45581321:- LUSC cis rs9487094 0.778 rs6914498 ENSG00000260273.1 RP11-425D10.10 8.25 1.63e-15 1.83e-12 0.44 0.36 Height; chr6:109613205 chr6:109382795~109383666:+ LUSC cis rs10129255 0.956 rs10137268 ENSG00000211970.3 IGHV4-61 -8.25 1.64e-15 1.84e-12 -0.26 -0.36 Kawasaki disease; chr14:106697402 chr14:106639119~106639657:- LUSC cis rs6538678 0.864 rs4762249 ENSG00000258343.1 RP11-536G4.2 8.25 1.64e-15 1.84e-12 0.46 0.36 Lupus nephritis in systemic lupus erythematosus; chr12:95884183 chr12:95795345~95858839:- LUSC cis rs494459 0.691 rs607472 ENSG00000255239.1 AP002954.6 8.25 1.64e-15 1.84e-12 0.38 0.36 Height; chr11:118809363 chr11:118688039~118690600:- LUSC cis rs11089937 0.597 rs11089925 ENSG00000211639.2 IGLV4-60 8.25 1.64e-15 1.85e-12 0.4 0.36 Periodontitis (PAL4Q3); chr22:22137267 chr22:22162199~22162681:+ LUSC cis rs694739 0.726 rs516124 ENSG00000236935.1 AP003774.1 8.25 1.65e-15 1.85e-12 0.34 0.36 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64360951 chr11:64325050~64329504:- LUSC cis rs9322193 0.847 rs12234128 ENSG00000223701.3 RAET1E-AS1 8.25 1.65e-15 1.85e-12 0.41 0.36 Lung cancer; chr6:149627553 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs57012784 ENSG00000223701.3 RAET1E-AS1 8.25 1.65e-15 1.85e-12 0.41 0.36 Lung cancer; chr6:149627691 chr6:149884431~149919508:+ LUSC cis rs875971 1 rs4718307 ENSG00000222364.1 RNU6-96P 8.25 1.66e-15 1.86e-12 0.42 0.36 Aortic root size; chr7:66146001 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs7801282 ENSG00000222364.1 RNU6-96P 8.25 1.66e-15 1.86e-12 0.42 0.36 Aortic root size; chr7:66148700 chr7:66395191~66395286:+ LUSC cis rs875971 0.929 rs4122249 ENSG00000222364.1 RNU6-96P -8.25 1.67e-15 1.87e-12 -0.42 -0.36 Aortic root size; chr7:66455949 chr7:66395191~66395286:+ LUSC cis rs11098499 0.863 rs6858592 ENSG00000245958.5 RP11-33B1.1 -8.24 1.67e-15 1.87e-12 -0.37 -0.36 Corneal astigmatism; chr4:119537537 chr4:119454791~119552025:+ LUSC cis rs367615 0.537 rs17161729 ENSG00000249476.1 CTD-2587M2.1 -8.24 1.67e-15 1.87e-12 -0.41 -0.36 Colorectal cancer (SNP x SNP interaction); chr5:109324827 chr5:109237120~109326369:- LUSC cis rs10463554 0.824 rs427430 ENSG00000175749.11 EIF3KP1 8.24 1.67e-15 1.87e-12 0.43 0.36 Parkinson's disease; chr5:103096320 chr5:103032376~103033031:+ LUSC cis rs11098499 0.754 rs1814813 ENSG00000245958.5 RP11-33B1.1 8.24 1.67e-15 1.88e-12 0.35 0.36 Corneal astigmatism; chr4:119337052 chr4:119454791~119552025:+ LUSC cis rs7500321 1 rs7500321 ENSG00000259982.1 CDC37P1 -8.24 1.68e-15 1.88e-12 -0.47 -0.36 Intelligence (multi-trait analysis); chr16:28965699 chr16:28700294~28701540:- LUSC cis rs1061377 1 rs2381284 ENSG00000249207.1 RP11-360F5.1 -8.24 1.68e-15 1.88e-12 -0.38 -0.36 Uric acid levels; chr4:39117976 chr4:39112677~39126818:- LUSC cis rs35955747 0.902 rs2413048 ENSG00000236132.1 CTA-440B3.1 8.24 1.7e-15 1.9e-12 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31290116 chr22:31816379~31817491:- LUSC cis rs9322193 0.923 rs9689599 ENSG00000223701.3 RAET1E-AS1 8.24 1.7e-15 1.9e-12 0.41 0.36 Lung cancer; chr6:149631973 chr6:149884431~149919508:+ LUSC cis rs2117029 0.586 rs6580701 ENSG00000258017.1 RP11-386G11.10 -8.24 1.7e-15 1.91e-12 -0.44 -0.36 Intelligence (multi-trait analysis); chr12:49163482 chr12:49127782~49147869:+ LUSC cis rs10129255 0.957 rs12589190 ENSG00000211970.3 IGHV4-61 -8.24 1.71e-15 1.92e-12 -0.25 -0.36 Kawasaki disease; chr14:106783079 chr14:106639119~106639657:- LUSC cis rs748404 0.578 rs4547312 ENSG00000249839.1 AC011330.5 -8.24 1.72e-15 1.92e-12 -0.47 -0.36 Lung cancer; chr15:43339940 chr15:43663654~43684339:- LUSC cis rs2283792 0.73 rs2329884 ENSG00000228050.1 TOP3BP1 8.24 1.72e-15 1.93e-12 0.42 0.36 Multiple sclerosis; chr22:21927890 chr22:22223187~22224566:- LUSC cis rs9487094 0.778 rs61318425 ENSG00000260273.1 RP11-425D10.10 8.24 1.72e-15 1.93e-12 0.47 0.36 Height; chr6:109427303 chr6:109382795~109383666:+ LUSC cis rs1061377 0.965 rs7669376 ENSG00000249207.1 RP11-360F5.1 -8.24 1.73e-15 1.93e-12 -0.38 -0.36 Uric acid levels; chr4:39116717 chr4:39112677~39126818:- LUSC cis rs1155848 0.892 rs9565509 ENSG00000227354.5 RBM26-AS1 8.24 1.74e-15 1.94e-12 0.73 0.36 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79483696 chr13:79406309~79424328:+ LUSC cis rs35955747 0.87 rs5997986 ENSG00000236132.1 CTA-440B3.1 8.24 1.74e-15 1.95e-12 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31438953 chr22:31816379~31817491:- LUSC cis rs2117029 0.521 rs58336603 ENSG00000258017.1 RP11-386G11.10 -8.24 1.74e-15 1.95e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49163105 chr12:49127782~49147869:+ LUSC cis rs2117029 0.553 rs1991427 ENSG00000258017.1 RP11-386G11.10 -8.24 1.74e-15 1.95e-12 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49164175 chr12:49127782~49147869:+ LUSC cis rs9487094 0.922 rs68042406 ENSG00000260273.1 RP11-425D10.10 8.24 1.76e-15 1.96e-12 0.44 0.36 Height; chr6:109482392 chr6:109382795~109383666:+ LUSC cis rs10463554 0.963 rs26817 ENSG00000175749.11 EIF3KP1 -8.24 1.76e-15 1.97e-12 -0.42 -0.36 Parkinson's disease; chr5:103204665 chr5:103032376~103033031:+ LUSC cis rs9322193 1 rs58189451 ENSG00000223701.3 RAET1E-AS1 8.24 1.76e-15 1.97e-12 0.41 0.36 Lung cancer; chr6:149600252 chr6:149884431~149919508:+ LUSC cis rs6471393 0.964 rs2914940 ENSG00000253848.1 RP11-10N23.5 8.24 1.77e-15 1.97e-12 0.44 0.36 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93719598 chr8:93741193~93744534:+ LUSC cis rs9322193 0.923 rs2297930 ENSG00000223701.3 RAET1E-AS1 8.24 1.77e-15 1.97e-12 0.41 0.36 Lung cancer; chr6:149718360 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9479094 ENSG00000223701.3 RAET1E-AS1 8.24 1.77e-15 1.98e-12 0.41 0.36 Lung cancer; chr6:149725083 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs11155674 ENSG00000223701.3 RAET1E-AS1 8.23 1.79e-15 2e-12 0.41 0.36 Lung cancer; chr6:149711111 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs10872647 ENSG00000216906.2 RP11-350J20.9 8.23 1.8e-15 2.01e-12 0.45 0.36 Lung cancer; chr6:149758687 chr6:149904243~149906418:+ LUSC cis rs11089937 0.864 rs5757041 ENSG00000211639.2 IGLV4-60 8.23 1.8e-15 2.01e-12 0.34 0.36 Periodontitis (PAL4Q3); chr22:22140538 chr22:22162199~22162681:+ LUSC cis rs9807989 0.507 rs3732124 ENSG00000234389.1 AC007278.3 -8.23 1.8e-15 2.01e-12 -0.34 -0.36 Asthma; chr2:102401592 chr2:102438713~102440475:+ LUSC cis rs760794 0.729 rs2206033 ENSG00000237404.1 RP3-471C18.2 -8.23 1.82e-15 2.03e-12 -0.39 -0.36 Endometriosis; chr6:19796647 chr6:19689825~19753113:- LUSC cis rs11098499 0.82 rs11737395 ENSG00000245958.5 RP11-33B1.1 -8.23 1.82e-15 2.03e-12 -0.36 -0.36 Corneal astigmatism; chr4:119599549 chr4:119454791~119552025:+ LUSC cis rs11155671 0.53 rs7742993 ENSG00000268592.3 RAET1E-AS1 8.23 1.82e-15 2.03e-12 0.44 0.36 Testicular germ cell tumor; chr6:149883959 chr6:149863494~149919507:+ LUSC cis rs10129255 0.53 rs11624912 ENSG00000211970.3 IGHV4-61 -8.23 1.83e-15 2.04e-12 -0.22 -0.35 Kawasaki disease; chr14:106673891 chr14:106639119~106639657:- LUSC cis rs10262624 0.504 rs59865844 ENSG00000234286.1 AC006026.13 8.23 1.83e-15 2.04e-12 0.43 0.35 Schizophrenia; chr7:23693421 chr7:23680195~23680786:- LUSC cis rs7811142 1 rs7783159 ENSG00000242294.5 STAG3L5P 8.23 1.86e-15 2.07e-12 0.29 0.35 Platelet count; chr7:100419831 chr7:100336079~100351900:+ LUSC cis rs4660456 0.826 rs3767952 ENSG00000237899.1 RP4-739H11.3 -8.23 1.86e-15 2.07e-12 -0.5 -0.35 Platelet count; chr1:40765360 chr1:40669089~40687588:- LUSC cis rs17023223 0.537 rs4508058 ENSG00000231365.4 RP11-418J17.1 -8.23 1.87e-15 2.08e-12 -0.44 -0.35 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119141627 chr1:119140396~119275973:+ LUSC cis rs875971 1 rs875971 ENSG00000222364.1 RNU6-96P 8.23 1.87e-15 2.08e-12 0.42 0.35 Aortic root size; chr7:66152608 chr7:66395191~66395286:+ LUSC cis rs2712381 0.517 rs62273237 ENSG00000242551.2 POU5F1P6 -8.23 1.9e-15 2.12e-12 -0.42 -0.35 Monocyte count; chr3:128591264 chr3:128674735~128677005:- LUSC cis rs80285556 1 rs111902838 ENSG00000161643.11 SIGLEC16 8.23 1.92e-15 2.14e-12 0.81 0.35 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49993357 chr19:49969673~49975814:+ LUSC cis rs853679 0.657 rs1778483 ENSG00000216901.1 AL022393.7 8.23 1.93e-15 2.14e-12 0.42 0.35 Depression; chr6:28273214 chr6:28176188~28176674:+ LUSC cis rs853679 0.657 rs1778482 ENSG00000216901.1 AL022393.7 8.23 1.93e-15 2.14e-12 0.42 0.35 Depression; chr6:28273215 chr6:28176188~28176674:+ LUSC cis rs5769707 0.967 rs1018812 ENSG00000235111.1 RP1-29C18.8 -8.22 1.93e-15 2.14e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49616425 chr22:49612657~49615716:- LUSC cis rs1707322 1 rs10890375 ENSG00000280836.1 AL355480.1 -8.22 1.94e-15 2.16e-12 -0.42 -0.35 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940909 chr1:45581219~45581321:- LUSC cis rs1707322 1 rs10890377 ENSG00000280836.1 AL355480.1 -8.22 1.94e-15 2.16e-12 -0.42 -0.35 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940922 chr1:45581219~45581321:- LUSC cis rs526231 0.511 rs3776861 ENSG00000175749.11 EIF3KP1 8.22 1.95e-15 2.17e-12 0.43 0.35 Primary biliary cholangitis; chr5:103013958 chr5:103032376~103033031:+ LUSC cis rs2739330 0.828 rs2186366 ENSG00000235689.1 AP000351.13 -8.22 1.96e-15 2.18e-12 -0.38 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:24006305~24008258:- LUSC cis rs5769707 1 rs5769707 ENSG00000235111.1 RP1-29C18.8 -8.22 1.96e-15 2.18e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49619754 chr22:49612657~49615716:- LUSC cis rs1061377 0.965 rs6833654 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39110701 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs1036037 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39111272 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs1036038 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39111383 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs1560396 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39112092 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs2381285 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39112775 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs2163272 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39112790 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs2163273 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39112835 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs62310332 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39112939 chr4:39112677~39126818:- LUSC cis rs1061377 0.965 rs3796510 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39113309 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs10030904 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39113603 chr4:39112677~39126818:- LUSC cis rs1061377 0.932 rs6855118 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39114322 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs6829234 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39114586 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs6812540 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39114803 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs10026775 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39115155 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs3733276 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39115291 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs3733277 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39115483 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs3733278 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39115615 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs3733279 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39115625 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs10018049 ENSG00000249207.1 RP11-360F5.1 -8.22 1.97e-15 2.19e-12 -0.38 -0.35 Uric acid levels; chr4:39115781 chr4:39112677~39126818:- LUSC cis rs853679 0.513 rs9468296 ENSG00000219392.1 RP1-265C24.5 -8.22 1.98e-15 2.2e-12 -0.51 -0.35 Depression; chr6:28145952 chr6:28115628~28116551:+ LUSC cis rs11098499 0.82 rs28578366 ENSG00000245958.5 RP11-33B1.1 8.22 1.98e-15 2.2e-12 0.35 0.35 Corneal astigmatism; chr4:119615750 chr4:119454791~119552025:+ LUSC cis rs10129255 0.833 rs61997797 ENSG00000211970.3 IGHV4-61 -8.22 1.99e-15 2.21e-12 -0.25 -0.35 Kawasaki disease; chr14:106815190 chr14:106639119~106639657:- LUSC cis rs5769707 0.967 rs2051626 ENSG00000235111.1 RP1-29C18.8 -8.22 1.99e-15 2.21e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49615325 chr22:49612657~49615716:- LUSC cis rs11098499 0.863 rs2127823 ENSG00000245958.5 RP11-33B1.1 -8.22 1.99e-15 2.21e-12 -0.36 -0.35 Corneal astigmatism; chr4:119564515 chr4:119454791~119552025:+ LUSC cis rs9487094 0.922 rs13204500 ENSG00000260273.1 RP11-425D10.10 8.22 1.99e-15 2.21e-12 0.44 0.35 Height; chr6:109640682 chr6:109382795~109383666:+ LUSC cis rs9487094 0.922 rs1321328 ENSG00000260273.1 RP11-425D10.10 8.22 1.99e-15 2.21e-12 0.44 0.35 Height; chr6:109655182 chr6:109382795~109383666:+ LUSC cis rs9487094 0.922 rs971434 ENSG00000260273.1 RP11-425D10.10 8.22 1.99e-15 2.21e-12 0.44 0.35 Height; chr6:109656105 chr6:109382795~109383666:+ LUSC cis rs2117029 0.555 rs9788139 ENSG00000258017.1 RP11-386G11.10 -8.22 2e-15 2.22e-12 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49126886 chr12:49127782~49147869:+ LUSC cis rs2739330 0.828 rs5760107 ENSG00000235689.1 AP000351.13 8.22 2e-15 2.22e-12 0.38 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:24006305~24008258:- LUSC cis rs9322193 0.923 rs2185352 ENSG00000223701.3 RAET1E-AS1 8.22 2.01e-15 2.23e-12 0.41 0.35 Lung cancer; chr6:149714640 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs12174349 ENSG00000223701.3 RAET1E-AS1 8.22 2.01e-15 2.23e-12 0.41 0.35 Lung cancer; chr6:149718012 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs2297932 ENSG00000223701.3 RAET1E-AS1 8.22 2.01e-15 2.23e-12 0.41 0.35 Lung cancer; chr6:149718225 chr6:149884431~149919508:+ LUSC cis rs7945705 0.692 rs2742470 ENSG00000254860.4 TMEM9B-AS1 8.22 2.01e-15 2.23e-12 0.39 0.35 Hemoglobin concentration; chr11:8982455 chr11:8964675~8977527:+ LUSC cis rs11089937 0.895 rs5756985 ENSG00000211639.2 IGLV4-60 8.22 2.01e-15 2.23e-12 0.35 0.35 Periodontitis (PAL4Q3); chr22:22131847 chr22:22162199~22162681:+ LUSC cis rs11098499 0.954 rs6848389 ENSG00000249244.1 RP11-548H18.2 8.22 2.02e-15 2.24e-12 0.45 0.35 Corneal astigmatism; chr4:119481467 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs3756156 ENSG00000245958.5 RP11-33B1.1 -8.22 2.02e-15 2.24e-12 -0.35 -0.35 Corneal astigmatism; chr4:119603686 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs9767105 ENSG00000223701.3 RAET1E-AS1 8.22 2.03e-15 2.25e-12 0.41 0.35 Lung cancer; chr6:149659591 chr6:149884431~149919508:+ LUSC cis rs2455601 1 rs2455601 ENSG00000254860.4 TMEM9B-AS1 8.22 2.03e-15 2.25e-12 0.49 0.35 Schizophrenia; chr11:8877853 chr11:8964675~8977527:+ LUSC cis rs11098499 0.82 rs28394116 ENSG00000245958.5 RP11-33B1.1 -8.22 2.04e-15 2.26e-12 -0.35 -0.35 Corneal astigmatism; chr4:119603128 chr4:119454791~119552025:+ LUSC cis rs6920372 0.731 rs9386799 ENSG00000260273.1 RP11-425D10.10 8.22 2.04e-15 2.26e-12 0.41 0.35 Height; chr6:109333398 chr6:109382795~109383666:+ LUSC cis rs2019137 1 rs2019137 ENSG00000189223.12 PAX8-AS1 8.22 2.05e-15 2.27e-12 0.46 0.35 Lymphocyte counts; chr2:113216055 chr2:113211522~113276581:+ LUSC cis rs2019137 0.967 rs895412 ENSG00000189223.12 PAX8-AS1 8.22 2.05e-15 2.27e-12 0.46 0.35 Lymphocyte counts; chr2:113216387 chr2:113211522~113276581:+ LUSC cis rs2739330 0.828 rs4822454 ENSG00000235689.1 AP000351.13 8.22 2.06e-15 2.29e-12 0.38 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:24006305~24008258:- LUSC cis rs4423214 0.515 rs4944042 ENSG00000254682.1 RP11-660L16.2 8.21 2.08e-15 2.31e-12 0.43 0.35 Vitamin D levels; chr11:71407742 chr11:71448674~71452157:+ LUSC cis rs7044106 0.664 rs7861679 ENSG00000226752.6 PSMD5-AS1 8.21 2.09e-15 2.32e-12 0.4 0.35 Hip circumference adjusted for BMI; chr9:120613311 chr9:120824828~120854385:+ LUSC cis rs10129255 1 rs9324091 ENSG00000211972.2 IGHV3-66 8.21 2.1e-15 2.33e-12 0.27 0.35 Kawasaki disease; chr14:106676625 chr14:106675017~106675544:- LUSC cis rs7044106 0.762 rs7044226 ENSG00000226752.6 PSMD5-AS1 -8.21 2.11e-15 2.33e-12 -0.41 -0.35 Hip circumference adjusted for BMI; chr9:120704050 chr9:120824828~120854385:+ LUSC cis rs10129255 0.872 rs1858683 ENSG00000211972.2 IGHV3-66 8.21 2.12e-15 2.34e-12 0.27 0.35 Kawasaki disease; chr14:106670217 chr14:106675017~106675544:- LUSC cis rs7945705 0.747 rs2742480 ENSG00000254860.4 TMEM9B-AS1 8.21 2.12e-15 2.35e-12 0.39 0.35 Hemoglobin concentration; chr11:8971583 chr11:8964675~8977527:+ LUSC cis rs11098499 0.754 rs1546503 ENSG00000245958.5 RP11-33B1.1 -8.21 2.13e-15 2.35e-12 -0.36 -0.35 Corneal astigmatism; chr4:119320012 chr4:119454791~119552025:+ LUSC cis rs11098499 0.708 rs1546506 ENSG00000245958.5 RP11-33B1.1 -8.21 2.13e-15 2.35e-12 -0.36 -0.35 Corneal astigmatism; chr4:119320085 chr4:119454791~119552025:+ LUSC cis rs2117029 0.521 rs7953169 ENSG00000258017.1 RP11-386G11.10 -8.21 2.13e-15 2.36e-12 -0.45 -0.35 Intelligence (multi-trait analysis); chr12:49184389 chr12:49127782~49147869:+ LUSC cis rs13403656 1 rs13403656 ENSG00000240350.2 AC017002.1 8.21 2.14e-15 2.36e-12 0.48 0.35 Allergic disease (asthma, hay fever or eczema); chr2:111511550 chr2:111491273~111570974:+ LUSC cis rs17507216 0.718 rs4779034 ENSG00000278603.1 RP13-608F4.5 8.21 2.15e-15 2.37e-12 0.54 0.35 Excessive daytime sleepiness; chr15:82576799 chr15:82472203~82472426:+ LUSC cis rs9322193 0.923 rs6913486 ENSG00000223701.3 RAET1E-AS1 -8.21 2.15e-15 2.38e-12 -0.43 -0.35 Lung cancer; chr6:149705060 chr6:149884431~149919508:+ LUSC cis rs4660456 0.711 rs12409109 ENSG00000237899.1 RP4-739H11.3 -8.21 2.15e-15 2.38e-12 -0.49 -0.35 Platelet count; chr1:40727216 chr1:40669089~40687588:- LUSC cis rs12439619 0.921 rs56042848 ENSG00000255769.6 GOLGA2P10 -8.21 2.15e-15 2.38e-12 -0.46 -0.35 Intelligence (multi-trait analysis); chr15:82235244 chr15:82472993~82513950:- LUSC cis rs8062405 0.755 rs4788076 ENSG00000259982.1 CDC37P1 8.21 2.16e-15 2.38e-12 0.44 0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558684 chr16:28700294~28701540:- LUSC cis rs11098499 0.866 rs10518329 ENSG00000245958.5 RP11-33B1.1 -8.21 2.17e-15 2.39e-12 -0.34 -0.35 Corneal astigmatism; chr4:119480680 chr4:119454791~119552025:+ LUSC cis rs9322193 0.924 rs9322189 ENSG00000223701.3 RAET1E-AS1 8.21 2.17e-15 2.4e-12 0.41 0.35 Lung cancer; chr6:149588797 chr6:149884431~149919508:+ LUSC cis rs6782228 1 rs34890930 ENSG00000242551.2 POU5F1P6 8.21 2.2e-15 2.42e-12 0.44 0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128610380 chr3:128674735~128677005:- LUSC cis rs8072100 0.817 rs6505049 ENSG00000228782.6 CTD-2026D20.3 -8.21 2.2e-15 2.43e-12 -0.34 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47598415 chr17:47450568~47492492:- LUSC cis rs11098499 0.863 rs34868248 ENSG00000245958.5 RP11-33B1.1 -8.21 2.21e-15 2.44e-12 -0.37 -0.35 Corneal astigmatism; chr4:119521275 chr4:119454791~119552025:+ LUSC cis rs35955747 0.934 rs131200 ENSG00000236132.1 CTA-440B3.1 -8.21 2.22e-15 2.44e-12 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31307286 chr22:31816379~31817491:- LUSC cis rs1061377 1 rs28607301 ENSG00000249207.1 RP11-360F5.1 -8.21 2.22e-15 2.45e-12 -0.37 -0.35 Uric acid levels; chr4:39136460 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs36090629 ENSG00000249207.1 RP11-360F5.1 -8.21 2.22e-15 2.45e-12 -0.37 -0.35 Uric acid levels; chr4:39137195 chr4:39112677~39126818:- LUSC cis rs1061377 0.87 rs73238544 ENSG00000249207.1 RP11-360F5.1 -8.21 2.22e-15 2.45e-12 -0.37 -0.35 Uric acid levels; chr4:39137343 chr4:39112677~39126818:- LUSC cis rs7945705 0.692 rs11042149 ENSG00000254860.4 TMEM9B-AS1 8.2 2.23e-15 2.46e-12 0.38 0.35 Hemoglobin concentration; chr11:8989190 chr11:8964675~8977527:+ LUSC cis rs7945705 0.747 rs11042150 ENSG00000254860.4 TMEM9B-AS1 8.2 2.23e-15 2.46e-12 0.38 0.35 Hemoglobin concentration; chr11:8989272 chr11:8964675~8977527:+ LUSC cis rs10740039 0.729 rs6479728 ENSG00000254271.1 RP11-131N11.4 -8.2 2.23e-15 2.46e-12 -0.47 -0.35 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60731043 chr10:60734342~60741828:+ LUSC cis rs67180937 0.922 rs1133220 ENSG00000272750.1 RP11-378J18.8 -8.2 2.24e-15 2.47e-12 -0.39 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222661461 chr1:222658867~222661512:- LUSC cis rs10129255 1 rs8010605 ENSG00000211972.2 IGHV3-66 8.2 2.25e-15 2.47e-12 0.27 0.35 Kawasaki disease; chr14:106678742 chr14:106675017~106675544:- LUSC cis rs875971 0.965 rs7794930 ENSG00000222364.1 RNU6-96P 8.2 2.26e-15 2.49e-12 0.42 0.35 Aortic root size; chr7:66313559 chr7:66395191~66395286:+ LUSC cis rs8062405 0.755 rs17707300 ENSG00000259982.1 CDC37P1 8.2 2.26e-15 2.49e-12 0.44 0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582026 chr16:28700294~28701540:- LUSC cis rs9918079 0.56 rs4270584 ENSG00000273133.1 RP11-799M12.2 8.2 2.26e-15 2.49e-12 0.47 0.35 Obesity-related traits; chr4:15599176 chr4:15563698~15564253:- LUSC cis rs2739330 0.789 rs5760109 ENSG00000235689.1 AP000351.13 8.2 2.27e-15 2.5e-12 0.38 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:24006305~24008258:- LUSC cis rs9487094 0.961 rs12209691 ENSG00000260273.1 RP11-425D10.10 8.2 2.27e-15 2.5e-12 0.44 0.35 Height; chr6:109465229 chr6:109382795~109383666:+ LUSC cis rs7811142 0.83 rs10085549 ENSG00000242294.5 STAG3L5P 8.2 2.27e-15 2.5e-12 0.28 0.35 Platelet count; chr7:100385512 chr7:100336079~100351900:+ LUSC cis rs1167827 0.68 rs1167800 ENSG00000127957.15 PMS2P3 -8.2 2.29e-15 2.52e-12 -0.33 -0.35 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75546898 chr7:75502930~75528148:- LUSC cis rs1075265 0.547 rs6741891 ENSG00000233266.1 HMGB1P31 8.2 2.29e-15 2.52e-12 0.44 0.35 Chronotype;Morning vs. evening chronotype; chr2:54088529 chr2:54051334~54051760:+ LUSC cis rs1061377 1 rs1560397 ENSG00000249207.1 RP11-360F5.1 -8.2 2.3e-15 2.53e-12 -0.38 -0.35 Uric acid levels; chr4:39112265 chr4:39112677~39126818:- LUSC cis rs11098499 0.954 rs12505469 ENSG00000249244.1 RP11-548H18.2 8.2 2.3e-15 2.53e-12 0.46 0.35 Corneal astigmatism; chr4:119328430 chr4:119391831~119395335:- LUSC cis rs7849270 1 rs2541164 ENSG00000268707.1 RP11-247A12.7 -8.2 2.3e-15 2.53e-12 -0.4 -0.35 Blood metabolite ratios; chr9:129114629 chr9:129170434~129170940:+ LUSC cis rs17023223 0.581 rs11811859 ENSG00000231365.4 RP11-418J17.1 -8.2 2.32e-15 2.56e-12 -0.44 -0.35 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119165057 chr1:119140396~119275973:+ LUSC cis rs17507216 0.671 rs28582623 ENSG00000278603.1 RP13-608F4.5 8.2 2.35e-15 2.58e-12 0.54 0.35 Excessive daytime sleepiness; chr15:82577381 chr15:82472203~82472426:+ LUSC cis rs8081395 0.741 rs1292056 ENSG00000266992.1 DHX40P1 8.2 2.35e-15 2.58e-12 0.4 0.35 White blood cell count; chr17:59881686 chr17:59976009~60002384:- LUSC cis rs11098499 0.82 rs6829903 ENSG00000245958.5 RP11-33B1.1 -8.2 2.36e-15 2.59e-12 -0.36 -0.35 Corneal astigmatism; chr4:119585729 chr4:119454791~119552025:+ LUSC cis rs2745572 0.557 rs2745569 ENSG00000272279.1 RP11-157J24.2 -8.2 2.36e-15 2.59e-12 -0.45 -0.35 Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure); chr6:1547396 chr6:1528364~1528911:- LUSC cis rs77204473 0.549 rs12280210 ENSG00000254851.1 RP11-109L13.1 8.2 2.36e-15 2.6e-12 0.66 0.35 Sum eosinophil basophil counts;Eosinophil counts; chr11:117069733 chr11:117135528~117138582:+ LUSC cis rs9322193 0.887 rs11155662 ENSG00000223701.3 RAET1E-AS1 8.2 2.37e-15 2.6e-12 0.42 0.35 Lung cancer; chr6:149592731 chr6:149884431~149919508:+ LUSC cis rs694739 0.628 rs508168 ENSG00000236935.1 AP003774.1 8.2 2.37e-15 2.6e-12 0.35 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64367963 chr11:64325050~64329504:- LUSC cis rs694739 0.595 rs11606015 ENSG00000236935.1 AP003774.1 8.2 2.37e-15 2.6e-12 0.35 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64369405 chr11:64325050~64329504:- LUSC cis rs7945705 0.747 rs2568020 ENSG00000254860.4 TMEM9B-AS1 8.2 2.37e-15 2.6e-12 0.38 0.35 Hemoglobin concentration; chr11:8973168 chr11:8964675~8977527:+ LUSC cis rs8062405 0.755 rs62034350 ENSG00000259982.1 CDC37P1 8.2 2.38e-15 2.62e-12 0.44 0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28550935 chr16:28700294~28701540:- LUSC cis rs765787 0.53 rs4514617 ENSG00000259520.4 CTD-2651B20.3 8.2 2.39e-15 2.62e-12 0.44 0.35 Uric acid levels; chr15:45243241 chr15:45251580~45279251:- LUSC cis rs10129255 0.957 rs10136560 ENSG00000211970.3 IGHV4-61 -8.2 2.39e-15 2.63e-12 -0.25 -0.35 Kawasaki disease; chr14:106787630 chr14:106639119~106639657:- LUSC cis rs9322193 0.887 rs4870139 ENSG00000223701.3 RAET1E-AS1 8.19 2.4e-15 2.63e-12 0.42 0.35 Lung cancer; chr6:149575182 chr6:149884431~149919508:+ LUSC cis rs760794 0.764 rs7764632 ENSG00000237404.1 RP3-471C18.2 -8.19 2.41e-15 2.64e-12 -0.42 -0.35 Endometriosis; chr6:19795354 chr6:19689825~19753113:- LUSC cis rs9322193 0.923 rs17745062 ENSG00000223701.3 RAET1E-AS1 8.19 2.41e-15 2.64e-12 0.41 0.35 Lung cancer; chr6:149721079 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs62441279 ENSG00000223701.3 RAET1E-AS1 8.19 2.41e-15 2.64e-12 0.41 0.35 Lung cancer; chr6:149721194 chr6:149884431~149919508:+ LUSC cis rs6700559 0.647 rs11801159 ENSG00000260088.1 RP11-92G12.3 8.19 2.42e-15 2.66e-12 0.44 0.35 Coronary artery disease; chr1:200623974 chr1:200669507~200694250:+ LUSC cis rs6700559 0.692 rs12744809 ENSG00000260088.1 RP11-92G12.3 8.19 2.43e-15 2.66e-12 0.44 0.35 Coronary artery disease; chr1:200624197 chr1:200669507~200694250:+ LUSC cis rs10129255 0.957 rs7493713 ENSG00000211970.3 IGHV4-61 -8.19 2.43e-15 2.67e-12 -0.25 -0.35 Kawasaki disease; chr14:106783685 chr14:106639119~106639657:- LUSC cis rs10129255 0.912 rs35468694 ENSG00000211970.3 IGHV4-61 -8.19 2.43e-15 2.67e-12 -0.25 -0.35 Kawasaki disease; chr14:106784199 chr14:106639119~106639657:- LUSC cis rs10129255 0.957 rs8019272 ENSG00000211970.3 IGHV4-61 -8.19 2.43e-15 2.67e-12 -0.25 -0.35 Kawasaki disease; chr14:106784709 chr14:106639119~106639657:- LUSC cis rs35955747 0.87 rs7289189 ENSG00000236132.1 CTA-440B3.1 8.19 2.44e-15 2.67e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31261196 chr22:31816379~31817491:- LUSC cis rs11098499 0.58 rs12509234 ENSG00000249244.1 RP11-548H18.2 8.19 2.46e-15 2.69e-12 0.46 0.35 Corneal astigmatism; chr4:119398279 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs10014719 ENSG00000249244.1 RP11-548H18.2 8.19 2.46e-15 2.69e-12 0.46 0.35 Corneal astigmatism; chr4:119399560 chr4:119391831~119395335:- LUSC cis rs6471393 0.964 rs2914953 ENSG00000253848.1 RP11-10N23.5 8.19 2.46e-15 2.69e-12 0.44 0.35 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93730122 chr8:93741193~93744534:+ LUSC cis rs9322193 0.923 rs9800614 ENSG00000223701.3 RAET1E-AS1 8.19 2.46e-15 2.7e-12 0.41 0.35 Lung cancer; chr6:149644604 chr6:149884431~149919508:+ LUSC cis rs2117029 0.523 rs12227296 ENSG00000258017.1 RP11-386G11.10 -8.19 2.47e-15 2.71e-12 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49136712 chr12:49127782~49147869:+ LUSC cis rs2117029 0.521 rs10875925 ENSG00000258017.1 RP11-386G11.10 -8.19 2.47e-15 2.71e-12 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49142575 chr12:49127782~49147869:+ LUSC cis rs2117029 0.586 rs11168882 ENSG00000258017.1 RP11-386G11.10 -8.19 2.47e-15 2.71e-12 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49143560 chr12:49127782~49147869:+ LUSC cis rs2117029 0.521 rs12227610 ENSG00000258017.1 RP11-386G11.10 -8.19 2.47e-15 2.71e-12 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49146153 chr12:49127782~49147869:+ LUSC cis rs11098499 0.954 rs10008392 ENSG00000249244.1 RP11-548H18.2 8.19 2.47e-15 2.71e-12 0.46 0.35 Corneal astigmatism; chr4:119397684 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs11931312 ENSG00000249244.1 RP11-548H18.2 8.19 2.47e-15 2.71e-12 0.45 0.35 Corneal astigmatism; chr4:119237868 chr4:119391831~119395335:- LUSC cis rs80285556 0.51 rs75463146 ENSG00000161643.11 SIGLEC16 8.19 2.49e-15 2.73e-12 0.81 0.35 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49989087 chr19:49969673~49975814:+ LUSC cis rs80285556 1 rs80202648 ENSG00000161643.11 SIGLEC16 8.19 2.49e-15 2.73e-12 0.81 0.35 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49991129 chr19:49969673~49975814:+ LUSC cis rs35955747 0.902 rs713947 ENSG00000236132.1 CTA-440B3.1 8.19 2.5e-15 2.73e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31243523 chr22:31816379~31817491:- LUSC cis rs35955747 0.902 rs11703927 ENSG00000236132.1 CTA-440B3.1 8.19 2.5e-15 2.73e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31248978 chr22:31816379~31817491:- LUSC cis rs748404 0.578 rs512628 ENSG00000249839.1 AC011330.5 -8.19 2.51e-15 2.74e-12 -0.48 -0.35 Lung cancer; chr15:43326536 chr15:43663654~43684339:- LUSC cis rs526231 0.511 rs45518833 ENSG00000175749.11 EIF3KP1 8.19 2.51e-15 2.74e-12 0.43 0.35 Primary biliary cholangitis; chr5:103007286 chr5:103032376~103033031:+ LUSC cis rs6700559 0.605 rs11802836 ENSG00000260088.1 RP11-92G12.3 8.19 2.53e-15 2.76e-12 0.44 0.35 Coronary artery disease; chr1:200624027 chr1:200669507~200694250:+ LUSC cis rs2739330 0.828 rs5760108 ENSG00000231271.1 AP000350.8 8.19 2.53e-15 2.77e-12 0.46 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23949918~23954042:+ LUSC cis rs748404 0.578 rs576557 ENSG00000249839.1 AC011330.5 -8.19 2.54e-15 2.78e-12 -0.47 -0.35 Lung cancer; chr15:43305539 chr15:43663654~43684339:- LUSC cis rs12439619 0.508 rs8032033 ENSG00000278603.1 RP13-608F4.5 8.19 2.55e-15 2.79e-12 0.42 0.35 Intelligence (multi-trait analysis); chr15:82165555 chr15:82472203~82472426:+ LUSC cis rs9322193 0.923 rs2297928 ENSG00000223701.3 RAET1E-AS1 8.19 2.55e-15 2.79e-12 0.41 0.35 Lung cancer; chr6:149718584 chr6:149884431~149919508:+ LUSC cis rs9487094 0.885 rs2208209 ENSG00000260273.1 RP11-425D10.10 8.19 2.56e-15 2.8e-12 0.44 0.35 Height; chr6:109581800 chr6:109382795~109383666:+ LUSC cis rs9322193 0.884 rs10872648 ENSG00000216906.2 RP11-350J20.9 8.19 2.57e-15 2.81e-12 0.44 0.35 Lung cancer; chr6:149758699 chr6:149904243~149906418:+ LUSC cis rs8072100 1 rs7210738 ENSG00000228782.6 CTD-2026D20.3 -8.19 2.57e-15 2.81e-12 -0.33 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47680232 chr17:47450568~47492492:- LUSC cis rs6921919 0.525 rs1361386 ENSG00000204709.4 LINC01556 8.19 2.58e-15 2.82e-12 0.47 0.35 Autism spectrum disorder or schizophrenia; chr6:28337827 chr6:28943877~28944537:+ LUSC cis rs6921919 0.638 rs6456815 ENSG00000204709.4 LINC01556 8.19 2.58e-15 2.82e-12 0.47 0.35 Autism spectrum disorder or schizophrenia; chr6:28338360 chr6:28943877~28944537:+ LUSC cis rs6921919 0.638 rs2108926 ENSG00000204709.4 LINC01556 8.19 2.58e-15 2.82e-12 0.47 0.35 Autism spectrum disorder or schizophrenia; chr6:28340970 chr6:28943877~28944537:+ LUSC cis rs6538678 0.864 rs7308921 ENSG00000258343.1 RP11-536G4.2 8.18 2.6e-15 2.83e-12 0.45 0.35 Lupus nephritis in systemic lupus erythematosus; chr12:95870757 chr12:95795345~95858839:- LUSC cis rs6538678 0.864 rs10777747 ENSG00000258343.1 RP11-536G4.2 -8.18 2.6e-15 2.83e-12 -0.45 -0.35 Lupus nephritis in systemic lupus erythematosus; chr12:95870192 chr12:95795345~95858839:- LUSC cis rs67180937 0.961 rs17465637 ENSG00000272750.1 RP11-378J18.8 8.18 2.6e-15 2.84e-12 0.38 0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222650187 chr1:222658867~222661512:- LUSC cis rs11098499 0.955 rs1511018 ENSG00000249244.1 RP11-548H18.2 8.18 2.6e-15 2.84e-12 0.45 0.35 Corneal astigmatism; chr4:119240425 chr4:119391831~119395335:- LUSC cis rs526231 0.511 rs1826673 ENSG00000175749.11 EIF3KP1 8.18 2.6e-15 2.84e-12 0.43 0.35 Primary biliary cholangitis; chr5:103010212 chr5:103032376~103033031:+ LUSC cis rs12439619 0.883 rs62012045 ENSG00000255769.6 GOLGA2P10 -8.18 2.61e-15 2.85e-12 -0.46 -0.35 Intelligence (multi-trait analysis); chr15:82229366 chr15:82472993~82513950:- LUSC cis rs5769707 0.935 rs5770594 ENSG00000235111.1 RP1-29C18.8 -8.18 2.62e-15 2.86e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49624849 chr22:49612657~49615716:- LUSC cis rs5769707 0.967 rs739248 ENSG00000235111.1 RP1-29C18.8 -8.18 2.62e-15 2.86e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49631557 chr22:49612657~49615716:- LUSC cis rs875971 1 rs7792762 ENSG00000222364.1 RNU6-96P -8.18 2.63e-15 2.87e-12 -0.41 -0.35 Aortic root size; chr7:66539151 chr7:66395191~66395286:+ LUSC cis rs367615 0.537 rs431669 ENSG00000249476.1 CTD-2587M2.1 8.18 2.63e-15 2.87e-12 0.42 0.35 Colorectal cancer (SNP x SNP interaction); chr5:109327414 chr5:109237120~109326369:- LUSC cis rs367615 0.537 rs10463600 ENSG00000249476.1 CTD-2587M2.1 8.18 2.63e-15 2.87e-12 0.42 0.35 Colorectal cancer (SNP x SNP interaction); chr5:109327935 chr5:109237120~109326369:- LUSC cis rs10129255 0.5 rs4774008 ENSG00000211970.3 IGHV4-61 -8.18 2.63e-15 2.87e-12 -0.22 -0.35 Kawasaki disease; chr14:106681273 chr14:106639119~106639657:- LUSC cis rs465969 0.744 rs79052344 ENSG00000255389.1 C6orf3 -8.18 2.65e-15 2.89e-12 -0.61 -0.35 Psoriasis; chr6:111550755 chr6:111599875~111602295:+ LUSC cis rs8072100 0.934 rs9905583 ENSG00000228782.6 CTD-2026D20.3 8.18 2.65e-15 2.89e-12 0.33 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47663650 chr17:47450568~47492492:- LUSC cis rs7811142 0.83 rs11768967 ENSG00000242294.5 STAG3L5P 8.18 2.65e-15 2.89e-12 0.28 0.35 Platelet count; chr7:100370021 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs7792959 ENSG00000242294.5 STAG3L5P 8.18 2.65e-15 2.89e-12 0.28 0.35 Platelet count; chr7:100374780 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs6975660 ENSG00000242294.5 STAG3L5P 8.18 2.65e-15 2.89e-12 0.28 0.35 Platelet count; chr7:100377643 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs73401443 ENSG00000242294.5 STAG3L5P 8.18 2.65e-15 2.89e-12 0.28 0.35 Platelet count; chr7:100379959 chr7:100336079~100351900:+ LUSC cis rs7617773 0.817 rs13094727 ENSG00000228638.1 FCF1P2 -8.18 2.66e-15 2.9e-12 -0.42 -0.35 Coronary artery disease; chr3:48281999 chr3:48290793~48291375:- LUSC cis rs62388641 0.539 rs56304710 ENSG00000272279.1 RP11-157J24.2 8.18 2.67e-15 2.91e-12 0.49 0.35 Daytime sleep phenotypes; chr6:1542341 chr6:1528364~1528911:- LUSC cis rs9807989 0.507 rs6758936 ENSG00000234389.1 AC007278.3 -8.18 2.68e-15 2.92e-12 -0.34 -0.35 Asthma; chr2:102374909 chr2:102438713~102440475:+ LUSC cis rs9322193 0.961 rs9767713 ENSG00000223701.3 RAET1E-AS1 8.18 2.68e-15 2.92e-12 0.41 0.35 Lung cancer; chr6:149588241 chr6:149884431~149919508:+ LUSC cis rs1075265 0.588 rs1477258 ENSG00000233266.1 HMGB1P31 8.18 2.71e-15 2.95e-12 0.45 0.35 Chronotype;Morning vs. evening chronotype; chr2:54000031 chr2:54051334~54051760:+ LUSC cis rs1823913 1 rs4853562 ENSG00000227542.1 AC092614.2 -8.18 2.71e-15 2.95e-12 -0.47 -0.35 Obesity-related traits; chr2:191253696 chr2:191229165~191246172:- LUSC cis rs9807989 0.507 rs1420105 ENSG00000234389.1 AC007278.3 8.18 2.71e-15 2.95e-12 0.33 0.35 Asthma; chr2:102418659 chr2:102438713~102440475:+ LUSC cis rs67180937 0.961 rs17465940 ENSG00000272750.1 RP11-378J18.8 -8.18 2.71e-15 2.95e-12 -0.39 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222663654 chr1:222658867~222661512:- LUSC cis rs67180937 0.922 rs17465982 ENSG00000272750.1 RP11-378J18.8 -8.18 2.71e-15 2.95e-12 -0.39 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222664597 chr1:222658867~222661512:- LUSC cis rs67180937 0.849 rs4575092 ENSG00000272750.1 RP11-378J18.8 -8.18 2.71e-15 2.96e-12 -0.39 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222661161 chr1:222658867~222661512:- LUSC cis rs9322193 0.923 rs4870529 ENSG00000223701.3 RAET1E-AS1 8.18 2.72e-15 2.96e-12 0.41 0.35 Lung cancer; chr6:149716436 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9767309 ENSG00000223701.3 RAET1E-AS1 8.18 2.72e-15 2.96e-12 0.41 0.35 Lung cancer; chr6:149716807 chr6:149884431~149919508:+ LUSC cis rs11089937 0.597 rs5757024 ENSG00000211639.2 IGLV4-60 8.18 2.72e-15 2.96e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22137415 chr22:22162199~22162681:+ LUSC cis rs1075265 0.568 rs7604357 ENSG00000233266.1 HMGB1P31 8.18 2.72e-15 2.96e-12 0.44 0.35 Chronotype;Morning vs. evening chronotype; chr2:54074026 chr2:54051334~54051760:+ LUSC cis rs1823913 1 rs4853461 ENSG00000227542.1 AC092614.2 -8.18 2.72e-15 2.96e-12 -0.47 -0.35 Obesity-related traits; chr2:191254572 chr2:191229165~191246172:- LUSC cis rs1823913 1 rs4853563 ENSG00000227542.1 AC092614.2 -8.18 2.72e-15 2.96e-12 -0.47 -0.35 Obesity-related traits; chr2:191254808 chr2:191229165~191246172:- LUSC cis rs1823913 1 rs1840377 ENSG00000227542.1 AC092614.2 -8.18 2.72e-15 2.96e-12 -0.47 -0.35 Obesity-related traits; chr2:191257992 chr2:191229165~191246172:- LUSC cis rs694739 0.964 rs2510066 ENSG00000236935.1 AP003774.1 8.18 2.74e-15 2.98e-12 0.35 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64284975 chr11:64325050~64329504:- LUSC cis rs1061377 1 rs9998481 ENSG00000249207.1 RP11-360F5.1 -8.18 2.75e-15 3e-12 -0.38 -0.35 Uric acid levels; chr4:39117215 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs9998867 ENSG00000249207.1 RP11-360F5.1 -8.18 2.75e-15 3e-12 -0.38 -0.35 Uric acid levels; chr4:39117542 chr4:39112677~39126818:- LUSC cis rs7811142 0.943 rs10241492 ENSG00000242294.5 STAG3L5P 8.18 2.76e-15 3e-12 0.28 0.35 Platelet count; chr7:100397190 chr7:100336079~100351900:+ LUSC cis rs1061377 1 rs1036036 ENSG00000249207.1 RP11-360F5.1 -8.18 2.76e-15 3.01e-12 -0.38 -0.35 Uric acid levels; chr4:39111104 chr4:39112677~39126818:- LUSC cis rs6538678 0.833 rs1898178 ENSG00000258343.1 RP11-536G4.2 -8.17 2.77e-15 3.02e-12 -0.47 -0.35 Lupus nephritis in systemic lupus erythematosus; chr12:95887554 chr12:95795345~95858839:- LUSC cis rs6538678 0.833 rs1898177 ENSG00000258343.1 RP11-536G4.2 -8.17 2.77e-15 3.02e-12 -0.47 -0.35 Lupus nephritis in systemic lupus erythematosus; chr12:95887568 chr12:95795345~95858839:- LUSC cis rs9322193 0.923 rs9505823 ENSG00000223701.3 RAET1E-AS1 8.17 2.78e-15 3.02e-12 0.4 0.35 Lung cancer; chr6:149628899 chr6:149884431~149919508:+ LUSC cis rs10463554 0.963 rs7721530 ENSG00000175749.11 EIF3KP1 8.17 2.78e-15 3.03e-12 0.43 0.35 Parkinson's disease; chr5:103026488 chr5:103032376~103033031:+ LUSC cis rs1061377 1 rs7685082 ENSG00000249207.1 RP11-360F5.1 -8.17 2.78e-15 3.03e-12 -0.38 -0.35 Uric acid levels; chr4:39116472 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs7664078 ENSG00000249207.1 RP11-360F5.1 -8.17 2.78e-15 3.03e-12 -0.38 -0.35 Uric acid levels; chr4:39116583 chr4:39112677~39126818:- LUSC cis rs11098499 0.863 rs1155576 ENSG00000245958.5 RP11-33B1.1 -8.17 2.8e-15 3.04e-12 -0.36 -0.35 Corneal astigmatism; chr4:119529004 chr4:119454791~119552025:+ LUSC cis rs367615 0.512 rs414724 ENSG00000249476.1 CTD-2587M2.1 8.17 2.8e-15 3.04e-12 0.41 0.35 Colorectal cancer (SNP x SNP interaction); chr5:109334720 chr5:109237120~109326369:- LUSC cis rs7617773 0.78 rs35411187 ENSG00000228638.1 FCF1P2 -8.17 2.8e-15 3.05e-12 -0.42 -0.35 Coronary artery disease; chr3:48318527 chr3:48290793~48291375:- LUSC cis rs7617773 0.78 rs11714176 ENSG00000228638.1 FCF1P2 -8.17 2.8e-15 3.05e-12 -0.42 -0.35 Coronary artery disease; chr3:48319372 chr3:48290793~48291375:- LUSC cis rs7945705 0.719 rs2012680 ENSG00000254860.4 TMEM9B-AS1 8.17 2.81e-15 3.05e-12 0.38 0.35 Hemoglobin concentration; chr11:8974512 chr11:8964675~8977527:+ LUSC cis rs5769707 0.967 rs4524218 ENSG00000235111.1 RP1-29C18.8 -8.17 2.81e-15 3.05e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49624991 chr22:49612657~49615716:- LUSC cis rs150992 0.603 rs161732 ENSG00000248489.1 CTD-2007H13.3 -8.17 2.81e-15 3.05e-12 -0.41 -0.35 Body mass index; chr5:98941418 chr5:98929171~98995013:+ LUSC cis rs7945705 0.747 rs1123936 ENSG00000254860.4 TMEM9B-AS1 8.17 2.81e-15 3.06e-12 0.38 0.35 Hemoglobin concentration; chr11:8981759 chr11:8964675~8977527:+ LUSC cis rs67180937 0.921 rs17163360 ENSG00000272750.1 RP11-378J18.8 -8.17 2.82e-15 3.06e-12 -0.38 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222647448 chr1:222658867~222661512:- LUSC cis rs8059260 0.604 rs16957984 ENSG00000274038.1 RP11-66H6.4 -8.17 2.83e-15 3.07e-12 -0.59 -0.35 Alcohol consumption over the past year; chr16:11051105 chr16:11056556~11057034:+ LUSC cis rs7617773 0.817 rs6796490 ENSG00000228638.1 FCF1P2 -8.17 2.84e-15 3.08e-12 -0.4 -0.35 Coronary artery disease; chr3:48195614 chr3:48290793~48291375:- LUSC cis rs11098499 0.722 rs10006192 ENSG00000245958.5 RP11-33B1.1 -8.17 2.87e-15 3.11e-12 -0.35 -0.35 Corneal astigmatism; chr4:119341867 chr4:119454791~119552025:+ LUSC cis rs11098499 0.615 rs28551750 ENSG00000245958.5 RP11-33B1.1 -8.17 2.87e-15 3.11e-12 -0.35 -0.35 Corneal astigmatism; chr4:119343746 chr4:119454791~119552025:+ LUSC cis rs10129255 1 rs11627342 ENSG00000211972.2 IGHV3-66 8.17 2.88e-15 3.12e-12 0.27 0.35 Kawasaki disease; chr14:106675823 chr14:106675017~106675544:- LUSC cis rs35955747 0.902 rs131209 ENSG00000236132.1 CTA-440B3.1 -8.17 2.88e-15 3.13e-12 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31336475 chr22:31816379~31817491:- LUSC cis rs9322193 0.923 rs10782318 ENSG00000223701.3 RAET1E-AS1 8.17 2.9e-15 3.15e-12 0.41 0.35 Lung cancer; chr6:149754137 chr6:149884431~149919508:+ LUSC cis rs35955747 0.838 rs28716 ENSG00000236132.1 CTA-440B3.1 -8.17 2.92e-15 3.16e-12 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31334203 chr22:31816379~31817491:- LUSC cis rs367615 0.512 rs814153 ENSG00000249476.1 CTD-2587M2.1 8.17 2.92e-15 3.17e-12 0.41 0.35 Colorectal cancer (SNP x SNP interaction); chr5:109332128 chr5:109237120~109326369:- LUSC cis rs6471393 0.895 rs4255106 ENSG00000253848.1 RP11-10N23.5 8.17 2.94e-15 3.18e-12 0.44 0.35 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93766367 chr8:93741193~93744534:+ LUSC cis rs6921919 1 rs35875412 ENSG00000204709.4 LINC01556 8.17 2.94e-15 3.18e-12 0.54 0.35 Autism spectrum disorder or schizophrenia; chr6:28364041 chr6:28943877~28944537:+ LUSC cis rs10129255 0.957 rs10142918 ENSG00000211970.3 IGHV4-61 -8.17 2.95e-15 3.19e-12 -0.25 -0.35 Kawasaki disease; chr14:106782206 chr14:106639119~106639657:- LUSC cis rs10129255 0.957 rs10142859 ENSG00000211970.3 IGHV4-61 -8.17 2.95e-15 3.19e-12 -0.25 -0.35 Kawasaki disease; chr14:106782238 chr14:106639119~106639657:- LUSC cis rs9322193 0.923 rs4421206 ENSG00000223701.3 RAET1E-AS1 8.17 2.95e-15 3.2e-12 0.41 0.35 Lung cancer; chr6:149682891 chr6:149884431~149919508:+ LUSC cis rs17270561 0.779 rs12210620 ENSG00000272462.2 U91328.19 -8.17 2.95e-15 3.2e-12 -0.46 -0.35 Iron status biomarkers; chr6:25884557 chr6:25992662~26001775:+ LUSC cis rs1823913 0.895 rs10931491 ENSG00000227542.1 AC092614.2 -8.17 2.96e-15 3.21e-12 -0.47 -0.35 Obesity-related traits; chr2:191256087 chr2:191229165~191246172:- LUSC cis rs9487094 0.922 rs12208933 ENSG00000260273.1 RP11-425D10.10 8.17 2.98e-15 3.22e-12 0.44 0.35 Height; chr6:109582583 chr6:109382795~109383666:+ LUSC cis rs10129255 0.83 rs61997609 ENSG00000211972.2 IGHV3-66 8.16 2.98e-15 3.23e-12 0.27 0.35 Kawasaki disease; chr14:106692376 chr14:106675017~106675544:- LUSC cis rs1075265 0.633 rs10183655 ENSG00000233266.1 HMGB1P31 8.16 2.99e-15 3.24e-12 0.44 0.35 Chronotype;Morning vs. evening chronotype; chr2:53983644 chr2:54051334~54051760:+ LUSC cis rs11098499 0.604 rs12642411 ENSG00000249244.1 RP11-548H18.2 8.16 2.99e-15 3.24e-12 0.46 0.35 Corneal astigmatism; chr4:119659370 chr4:119391831~119395335:- LUSC cis rs3823536 0.583 rs3778750 ENSG00000275106.1 RP11-309L24.10 -8.16 3e-15 3.25e-12 -0.47 -0.35 Sjögren's syndrome; chr7:128977035 chr7:128952527~128953316:- LUSC cis rs4266144 1 rs4561781 ENSG00000244515.1 KRT18P34 8.16 3.01e-15 3.26e-12 0.42 0.35 Coronary artery disease; chr3:157135154 chr3:157162663~157163932:- LUSC cis rs6471393 0.964 rs7001808 ENSG00000253848.1 RP11-10N23.5 8.16 3.05e-15 3.3e-12 0.44 0.35 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93725043 chr8:93741193~93744534:+ LUSC cis rs2739330 0.828 rs2330635 ENSG00000235689.1 AP000351.13 8.16 3.06e-15 3.31e-12 0.38 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:24006305~24008258:- LUSC cis rs7945705 0.714 rs2653570 ENSG00000254860.4 TMEM9B-AS1 8.16 3.07e-15 3.32e-12 0.38 0.35 Hemoglobin concentration; chr11:8966276 chr11:8964675~8977527:+ LUSC cis rs9918079 0.56 rs6449153 ENSG00000273133.1 RP11-799M12.2 -8.16 3.08e-15 3.33e-12 -0.49 -0.35 Obesity-related traits; chr4:15629593 chr4:15563698~15564253:- LUSC cis rs8081395 0.707 rs1024637 ENSG00000266992.1 DHX40P1 -8.16 3.1e-15 3.35e-12 -0.41 -0.35 White blood cell count; chr17:59961532 chr17:59976009~60002384:- LUSC cis rs9326248 0.817 rs6589598 ENSG00000280143.1 AP000892.6 8.16 3.1e-15 3.36e-12 0.44 0.35 Blood protein levels; chr11:117131687 chr11:117204967~117210292:+ LUSC cis rs9322193 0.923 rs12174035 ENSG00000216906.2 RP11-350J20.9 8.16 3.11e-15 3.36e-12 0.42 0.35 Lung cancer; chr6:149763311 chr6:149904243~149906418:+ LUSC cis rs67180937 0.922 rs10495198 ENSG00000272750.1 RP11-378J18.8 -8.16 3.11e-15 3.36e-12 -0.38 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222652375 chr1:222658867~222661512:- LUSC cis rs748404 0.578 rs552701 ENSG00000249839.1 AC011330.5 -8.16 3.11e-15 3.36e-12 -0.47 -0.35 Lung cancer; chr15:43321612 chr15:43663654~43684339:- LUSC cis rs11098499 0.955 rs1397608 ENSG00000249244.1 RP11-548H18.2 8.16 3.12e-15 3.37e-12 0.45 0.35 Corneal astigmatism; chr4:119240589 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs7685268 ENSG00000249244.1 RP11-548H18.2 8.16 3.12e-15 3.37e-12 0.45 0.35 Corneal astigmatism; chr4:119241033 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs7684942 ENSG00000249244.1 RP11-548H18.2 8.16 3.12e-15 3.37e-12 0.45 0.35 Corneal astigmatism; chr4:119241046 chr4:119391831~119395335:- LUSC cis rs10463554 0.927 rs7717343 ENSG00000175749.11 EIF3KP1 8.16 3.12e-15 3.38e-12 0.42 0.35 Parkinson's disease; chr5:103026279 chr5:103032376~103033031:+ LUSC cis rs55665837 1 rs7121171 ENSG00000251991.1 RNU7-49P 8.16 3.14e-15 3.4e-12 0.39 0.35 Vitamin D levels; chr11:14424874 chr11:14478892~14478953:+ LUSC cis rs2117029 0.555 rs7978448 ENSG00000258017.1 RP11-386G11.10 -8.16 3.15e-15 3.4e-12 -0.46 -0.35 Intelligence (multi-trait analysis); chr12:49113157 chr12:49127782~49147869:+ LUSC cis rs67180937 0.921 rs2291834 ENSG00000272750.1 RP11-378J18.8 -8.16 3.2e-15 3.45e-12 -0.38 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222658953 chr1:222658867~222661512:- LUSC cis rs4713118 0.662 rs9357060 ENSG00000219392.1 RP1-265C24.5 -8.16 3.2e-15 3.45e-12 -0.48 -0.35 Parkinson's disease; chr6:28056708 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs9468271 ENSG00000219392.1 RP1-265C24.5 -8.16 3.2e-15 3.45e-12 -0.48 -0.35 Parkinson's disease; chr6:28056792 chr6:28115628~28116551:+ LUSC cis rs7044106 0.762 rs1324473 ENSG00000226752.6 PSMD5-AS1 8.16 3.21e-15 3.46e-12 0.4 0.35 Hip circumference adjusted for BMI; chr9:120642332 chr9:120824828~120854385:+ LUSC cis rs5769707 0.967 rs763127 ENSG00000235111.1 RP1-29C18.8 -8.15 3.21e-15 3.46e-12 -0.4 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49612430 chr22:49612657~49615716:- LUSC cis rs1061377 1 rs1982009 ENSG00000249207.1 RP11-360F5.1 -8.15 3.22e-15 3.47e-12 -0.37 -0.35 Uric acid levels; chr4:39123253 chr4:39112677~39126818:- LUSC cis rs1061377 0.965 rs1138494 ENSG00000249207.1 RP11-360F5.1 -8.15 3.22e-15 3.47e-12 -0.37 -0.35 Uric acid levels; chr4:39123315 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs2890659 ENSG00000249207.1 RP11-360F5.1 -8.15 3.22e-15 3.47e-12 -0.37 -0.35 Uric acid levels; chr4:39125401 chr4:39112677~39126818:- LUSC cis rs1061377 0.965 rs1046655 ENSG00000249207.1 RP11-360F5.1 -8.15 3.22e-15 3.47e-12 -0.37 -0.35 Uric acid levels; chr4:39126127 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs7694760 ENSG00000249207.1 RP11-360F5.1 -8.15 3.22e-15 3.47e-12 -0.37 -0.35 Uric acid levels; chr4:39126481 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs34771104 ENSG00000249207.1 RP11-360F5.1 -8.15 3.22e-15 3.47e-12 -0.37 -0.35 Uric acid levels; chr4:39127432 chr4:39112677~39126818:- LUSC cis rs1061377 0.932 rs35464499 ENSG00000249207.1 RP11-360F5.1 -8.15 3.22e-15 3.47e-12 -0.37 -0.35 Uric acid levels; chr4:39127670 chr4:39112677~39126818:- LUSC cis rs1061377 0.965 rs11728058 ENSG00000249207.1 RP11-360F5.1 -8.15 3.22e-15 3.47e-12 -0.37 -0.35 Uric acid levels; chr4:39128224 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs17508864 ENSG00000249207.1 RP11-360F5.1 -8.15 3.22e-15 3.47e-12 -0.37 -0.35 Uric acid levels; chr4:39129025 chr4:39112677~39126818:- LUSC cis rs9487094 0.961 rs1358998 ENSG00000260273.1 RP11-425D10.10 -8.15 3.24e-15 3.49e-12 -0.42 -0.35 Height; chr6:109380015 chr6:109382795~109383666:+ LUSC cis rs10129255 0.957 rs56134540 ENSG00000211972.2 IGHV3-66 8.15 3.25e-15 3.51e-12 0.27 0.35 Kawasaki disease; chr14:106691290 chr14:106675017~106675544:- LUSC cis rs2412819 0.571 rs17727853 ENSG00000249839.1 AC011330.5 -8.15 3.25e-15 3.51e-12 -0.58 -0.35 Lung cancer; chr15:43630299 chr15:43663654~43684339:- LUSC cis rs9389248 0.69 rs6569982 ENSG00000232876.1 CTA-212D2.2 -8.15 3.28e-15 3.54e-12 -0.44 -0.35 High light scatter reticulocyte percentage of red cells; chr6:134935357 chr6:135055033~135060550:+ LUSC cis rs17023223 0.508 rs12096448 ENSG00000231365.4 RP11-418J17.1 -8.15 3.29e-15 3.55e-12 -0.44 -0.35 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119140767 chr1:119140396~119275973:+ LUSC cis rs9322193 0.884 rs7743823 ENSG00000223701.3 RAET1E-AS1 8.15 3.3e-15 3.56e-12 0.41 0.35 Lung cancer; chr6:149849744 chr6:149884431~149919508:+ LUSC cis rs9322193 0.847 rs62439808 ENSG00000223701.3 RAET1E-AS1 8.15 3.3e-15 3.56e-12 0.4 0.35 Lung cancer; chr6:149629690 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9322200 ENSG00000223701.3 RAET1E-AS1 8.15 3.3e-15 3.56e-12 0.4 0.35 Lung cancer; chr6:149630078 chr6:149884431~149919508:+ LUSC cis rs4660456 0.913 rs16827569 ENSG00000237899.1 RP4-739H11.3 -8.15 3.32e-15 3.57e-12 -0.49 -0.35 Platelet count; chr1:40761655 chr1:40669089~40687588:- LUSC cis rs1061377 0.803 rs6857761 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39118353 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs9997089 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39119263 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs28465556 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39119569 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs10027813 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39119818 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs9990755 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39119819 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs7676008 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39120154 chr4:39112677~39126818:- LUSC cis rs1061377 0.965 rs7677729 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39120370 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs7655122 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39120396 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs3796511 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39120586 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs3733274 ENSG00000249207.1 RP11-360F5.1 -8.15 3.33e-15 3.59e-12 -0.37 -0.35 Uric acid levels; chr4:39120957 chr4:39112677~39126818:- LUSC cis rs9322193 0.923 rs9800871 ENSG00000223701.3 RAET1E-AS1 8.15 3.34e-15 3.6e-12 0.41 0.35 Lung cancer; chr6:149644540 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs11155671 ENSG00000223701.3 RAET1E-AS1 8.15 3.34e-15 3.6e-12 0.41 0.35 Lung cancer; chr6:149650996 chr6:149884431~149919508:+ LUSC cis rs801193 0.66 rs10950049 ENSG00000222364.1 RNU6-96P -8.15 3.34e-15 3.6e-12 -0.42 -0.35 Aortic root size; chr7:66765873 chr7:66395191~66395286:+ LUSC cis rs35955747 0.871 rs5994392 ENSG00000236132.1 CTA-440B3.1 8.15 3.34e-15 3.6e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31387920 chr22:31816379~31817491:- LUSC cis rs9322193 0.923 rs7767622 ENSG00000223701.3 RAET1E-AS1 8.15 3.36e-15 3.61e-12 0.4 0.35 Lung cancer; chr6:149681766 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs3798761 ENSG00000223701.3 RAET1E-AS1 8.15 3.36e-15 3.61e-12 0.4 0.35 Lung cancer; chr6:149683643 chr6:149884431~149919508:+ LUSC cis rs10028773 0.666 rs12498657 ENSG00000245958.5 RP11-33B1.1 -8.15 3.36e-15 3.61e-12 -0.35 -0.35 Educational attainment; chr4:119341711 chr4:119454791~119552025:+ LUSC cis rs1075265 0.633 rs28653587 ENSG00000233266.1 HMGB1P31 8.15 3.36e-15 3.61e-12 0.45 0.35 Chronotype;Morning vs. evening chronotype; chr2:53992435 chr2:54051334~54051760:+ LUSC cis rs1061377 0.965 rs3733275 ENSG00000249207.1 RP11-360F5.1 -8.15 3.36e-15 3.61e-12 -0.37 -0.35 Uric acid levels; chr4:39121077 chr4:39112677~39126818:- LUSC cis rs3823536 0.583 rs3807302 ENSG00000275106.1 RP11-309L24.10 -8.15 3.36e-15 3.61e-12 -0.47 -0.35 Sjögren's syndrome; chr7:129004803 chr7:128952527~128953316:- LUSC cis rs11089937 0.597 rs5757026 ENSG00000211639.2 IGLV4-60 8.15 3.37e-15 3.63e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22137556 chr22:22162199~22162681:+ LUSC cis rs11089937 0.597 rs5750582 ENSG00000211639.2 IGLV4-60 8.15 3.37e-15 3.63e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22137690 chr22:22162199~22162681:+ LUSC cis rs2117029 0.619 rs2241727 ENSG00000258017.1 RP11-386G11.10 -8.15 3.42e-15 3.67e-12 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49131225 chr12:49127782~49147869:+ LUSC cis rs10129255 1 rs4612959 ENSG00000211970.3 IGHV4-61 -8.15 3.43e-15 3.69e-12 -0.25 -0.35 Kawasaki disease; chr14:106767055 chr14:106639119~106639657:- LUSC cis rs3096299 0.967 rs2965830 ENSG00000274627.1 RP11-104N10.2 8.15 3.44e-15 3.7e-12 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89393882 chr16:89516797~89522217:+ LUSC cis rs11098499 0.863 rs12508173 ENSG00000249244.1 RP11-548H18.2 8.15 3.45e-15 3.7e-12 0.46 0.35 Corneal astigmatism; chr4:119397371 chr4:119391831~119395335:- LUSC cis rs11098499 0.908 rs12504149 ENSG00000249244.1 RP11-548H18.2 8.15 3.45e-15 3.7e-12 0.46 0.35 Corneal astigmatism; chr4:119397422 chr4:119391831~119395335:- LUSC cis rs2739330 0.796 rs5760106 ENSG00000235689.1 AP000351.13 -8.14 3.45e-15 3.71e-12 -0.37 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:24006305~24008258:- LUSC cis rs9487094 0.922 rs6916579 ENSG00000260273.1 RP11-425D10.10 8.14 3.46e-15 3.72e-12 0.43 0.35 Height; chr6:109530435 chr6:109382795~109383666:+ LUSC cis rs150992 0.504 rs11745405 ENSG00000248489.1 CTD-2007H13.3 -8.14 3.47e-15 3.73e-12 -0.43 -0.35 Body mass index; chr5:99047700 chr5:98929171~98995013:+ LUSC cis rs11098499 0.955 rs6815725 ENSG00000249244.1 RP11-548H18.2 8.14 3.5e-15 3.76e-12 0.45 0.35 Corneal astigmatism; chr4:119237255 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs1551 ENSG00000249244.1 RP11-548H18.2 8.14 3.5e-15 3.76e-12 0.45 0.35 Corneal astigmatism; chr4:119237345 chr4:119391831~119395335:- LUSC cis rs9487094 0.961 rs12190920 ENSG00000260273.1 RP11-425D10.10 8.14 3.5e-15 3.76e-12 0.44 0.35 Height; chr6:109479396 chr6:109382795~109383666:+ LUSC cis rs9341808 0.718 rs9294171 ENSG00000272129.1 RP11-250B2.6 8.14 3.51e-15 3.77e-12 0.43 0.35 Sitting height ratio; chr6:80130098 chr6:80355424~80356859:+ LUSC cis rs7188445 0.736 rs4243177 ENSG00000261390.4 RP11-345M22.2 8.14 3.53e-15 3.79e-12 0.45 0.35 Urate levels; chr16:79669932 chr16:79715232~79770563:- LUSC cis rs10129255 1 rs8012033 ENSG00000211972.2 IGHV3-66 8.14 3.53e-15 3.79e-12 0.27 0.35 Kawasaki disease; chr14:106678854 chr14:106675017~106675544:- LUSC cis rs10129255 0.912 rs8011090 ENSG00000211972.2 IGHV3-66 8.14 3.53e-15 3.79e-12 0.27 0.35 Kawasaki disease; chr14:106678896 chr14:106675017~106675544:- LUSC cis rs2117029 0.553 rs2162644 ENSG00000258017.1 RP11-386G11.10 -8.14 3.54e-15 3.8e-12 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49154407 chr12:49127782~49147869:+ LUSC cis rs3096299 0.933 rs2965824 ENSG00000274627.1 RP11-104N10.2 8.14 3.54e-15 3.8e-12 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89388898 chr16:89516797~89522217:+ LUSC cis rs6782228 0.848 rs6439140 ENSG00000242551.2 POU5F1P6 8.14 3.54e-15 3.81e-12 0.44 0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128699917 chr3:128674735~128677005:- LUSC cis rs67180937 0.884 rs2291832 ENSG00000272750.1 RP11-378J18.8 -8.14 3.55e-15 3.81e-12 -0.38 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222653139 chr1:222658867~222661512:- LUSC cis rs35158675 1 rs35158675 ENSG00000272750.1 RP11-378J18.8 -8.14 3.55e-15 3.81e-12 -0.38 -0.35 Coronary artery disease; chr1:222656208 chr1:222658867~222661512:- LUSC cis rs9322193 0.923 rs9767123 ENSG00000223701.3 RAET1E-AS1 8.14 3.6e-15 3.86e-12 0.41 0.35 Lung cancer; chr6:149660323 chr6:149884431~149919508:+ LUSC cis rs4660456 0.827 rs10736404 ENSG00000237899.1 RP4-739H11.3 8.14 3.62e-15 3.89e-12 0.49 0.35 Platelet count; chr1:40710331 chr1:40669089~40687588:- LUSC cis rs10129255 0.957 rs8022165 ENSG00000211970.3 IGHV4-61 -8.14 3.63e-15 3.89e-12 -0.24 -0.35 Kawasaki disease; chr14:106781682 chr14:106639119~106639657:- LUSC cis rs10129255 0.913 rs10140943 ENSG00000211972.2 IGHV3-66 8.14 3.64e-15 3.9e-12 0.27 0.35 Kawasaki disease; chr14:106767441 chr14:106675017~106675544:- LUSC cis rs9487094 0.666 rs3778478 ENSG00000260273.1 RP11-425D10.10 8.14 3.64e-15 3.91e-12 0.41 0.35 Height; chr6:109470427 chr6:109382795~109383666:+ LUSC cis rs9487094 0.644 rs9791241 ENSG00000260273.1 RP11-425D10.10 8.14 3.64e-15 3.91e-12 0.41 0.35 Height; chr6:109470900 chr6:109382795~109383666:+ LUSC cis rs11098499 0.691 rs9995716 ENSG00000245958.5 RP11-33B1.1 -8.14 3.65e-15 3.92e-12 -0.35 -0.35 Corneal astigmatism; chr4:119343841 chr4:119454791~119552025:+ LUSC cis rs9322193 0.887 rs3734295 ENSG00000223701.3 RAET1E-AS1 8.14 3.67e-15 3.93e-12 0.42 0.35 Lung cancer; chr6:149593917 chr6:149884431~149919508:+ LUSC cis rs10256972 0.621 rs2280725 ENSG00000229043.2 AC091729.9 -8.14 3.67e-15 3.94e-12 -0.4 -0.35 Endometriosis;Longevity; chr7:1047790 chr7:1160374~1165267:+ LUSC cis rs35955747 0.902 rs5997929 ENSG00000236132.1 CTA-440B3.1 8.14 3.68e-15 3.94e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31268046 chr22:31816379~31817491:- LUSC cis rs1789 0.903 rs4453929 ENSG00000273133.1 RP11-799M12.2 -8.14 3.69e-15 3.96e-12 -0.47 -0.35 Blood protein levels; chr4:15670550 chr4:15563698~15564253:- LUSC cis rs1789 0.903 rs4616746 ENSG00000273133.1 RP11-799M12.2 -8.14 3.69e-15 3.96e-12 -0.47 -0.35 Blood protein levels; chr4:15671475 chr4:15563698~15564253:- LUSC cis rs1789 0.868 rs4631041 ENSG00000273133.1 RP11-799M12.2 -8.14 3.69e-15 3.96e-12 -0.47 -0.35 Blood protein levels; chr4:15671772 chr4:15563698~15564253:- LUSC cis rs760794 0.729 rs6921786 ENSG00000237404.1 RP3-471C18.2 8.14 3.7e-15 3.96e-12 0.39 0.35 Endometriosis; chr6:19793785 chr6:19689825~19753113:- LUSC cis rs1075265 0.547 rs10865279 ENSG00000233266.1 HMGB1P31 8.14 3.7e-15 3.97e-12 0.44 0.35 Chronotype;Morning vs. evening chronotype; chr2:54097564 chr2:54051334~54051760:+ LUSC cis rs5760092 0.572 rs738806 ENSG00000225282.1 AP000350.6 8.14 3.7e-15 3.97e-12 0.47 0.35 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23926900~23929574:+ LUSC cis rs11098499 0.913 rs13126596 ENSG00000249244.1 RP11-548H18.2 8.13 3.71e-15 3.98e-12 0.45 0.35 Corneal astigmatism; chr4:119219574 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3733525 ENSG00000245958.5 RP11-33B1.1 -8.13 3.74e-15 4.01e-12 -0.36 -0.35 Corneal astigmatism; chr4:119525893 chr4:119454791~119552025:+ LUSC cis rs1075265 0.568 rs10865277 ENSG00000233266.1 HMGB1P31 8.13 3.76e-15 4.02e-12 0.43 0.35 Chronotype;Morning vs. evening chronotype; chr2:54074865 chr2:54051334~54051760:+ LUSC cis rs11089937 0.597 rs5757027 ENSG00000211639.2 IGLV4-60 8.13 3.77e-15 4.04e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22137683 chr22:22162199~22162681:+ LUSC cis rs11089937 0.626 rs5757028 ENSG00000211639.2 IGLV4-60 8.13 3.77e-15 4.04e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22137699 chr22:22162199~22162681:+ LUSC cis rs11089937 0.597 rs2213156 ENSG00000211639.2 IGLV4-60 8.13 3.77e-15 4.04e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22137852 chr22:22162199~22162681:+ LUSC cis rs11089937 0.626 rs2213157 ENSG00000211639.2 IGLV4-60 8.13 3.77e-15 4.04e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22137997 chr22:22162199~22162681:+ LUSC cis rs11089937 0.626 rs9622955 ENSG00000211639.2 IGLV4-60 8.13 3.77e-15 4.04e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22138343 chr22:22162199~22162681:+ LUSC cis rs11089937 0.626 rs4821781 ENSG00000211639.2 IGLV4-60 8.13 3.77e-15 4.04e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22138845 chr22:22162199~22162681:+ LUSC cis rs11089937 0.626 rs5750589 ENSG00000211639.2 IGLV4-60 8.13 3.77e-15 4.04e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22139655 chr22:22162199~22162681:+ LUSC cis rs11089937 0.626 rs5757038 ENSG00000211639.2 IGLV4-60 8.13 3.77e-15 4.04e-12 0.39 0.35 Periodontitis (PAL4Q3); chr22:22140149 chr22:22162199~22162681:+ LUSC cis rs1061377 1 rs12646251 ENSG00000249207.1 RP11-360F5.1 -8.13 3.79e-15 4.06e-12 -0.37 -0.35 Uric acid levels; chr4:39132751 chr4:39112677~39126818:- LUSC cis rs10256972 0.621 rs10951594 ENSG00000229043.2 AC091729.9 -8.13 3.8e-15 4.06e-12 -0.4 -0.35 Endometriosis;Longevity; chr7:1048971 chr7:1160374~1165267:+ LUSC cis rs3096299 0.933 rs2965934 ENSG00000274627.1 RP11-104N10.2 8.13 3.8e-15 4.06e-12 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89414821 chr16:89516797~89522217:+ LUSC cis rs80285556 1 rs77187281 ENSG00000161643.11 SIGLEC16 8.13 3.81e-15 4.08e-12 0.82 0.35 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50004410 chr19:49969673~49975814:+ LUSC cis rs12439619 0.53 rs7162177 ENSG00000278603.1 RP13-608F4.5 8.13 3.82e-15 4.09e-12 0.43 0.35 Intelligence (multi-trait analysis); chr15:82181728 chr15:82472203~82472426:+ LUSC cis rs875971 1 rs1544549 ENSG00000222364.1 RNU6-96P 8.13 3.83e-15 4.1e-12 0.41 0.35 Aortic root size; chr7:66625676 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs2420820 ENSG00000222364.1 RNU6-96P 8.13 3.83e-15 4.1e-12 0.41 0.35 Aortic root size; chr7:66626920 chr7:66395191~66395286:+ LUSC cis rs55665837 1 rs4412729 ENSG00000251991.1 RNU7-49P 8.13 3.83e-15 4.1e-12 0.41 0.35 Vitamin D levels; chr11:14417454 chr11:14478892~14478953:+ LUSC cis rs2739330 0.828 rs2154593 ENSG00000231271.1 AP000350.8 8.13 3.84e-15 4.11e-12 0.46 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23949918~23954042:+ LUSC cis rs5769707 0.967 rs2071904 ENSG00000235111.1 RP1-29C18.8 -8.13 3.86e-15 4.12e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49640829 chr22:49612657~49615716:- LUSC cis rs5769707 0.846 rs5770610 ENSG00000235111.1 RP1-29C18.8 -8.13 3.86e-15 4.12e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49643249 chr22:49612657~49615716:- LUSC cis rs6921919 0.583 rs3734563 ENSG00000216901.1 AL022393.7 8.13 3.86e-15 4.13e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28381948 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs1591913 ENSG00000216901.1 AL022393.7 8.13 3.86e-15 4.13e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28383951 chr6:28176188~28176674:+ LUSC cis rs6921919 0.945 rs7765989 ENSG00000204709.4 LINC01556 8.13 3.87e-15 4.14e-12 0.52 0.35 Autism spectrum disorder or schizophrenia; chr6:28432518 chr6:28943877~28944537:+ LUSC cis rs8081395 0.741 rs180532 ENSG00000266992.1 DHX40P1 8.13 3.88e-15 4.15e-12 0.41 0.35 White blood cell count; chr17:59925936 chr17:59976009~60002384:- LUSC cis rs8081395 0.741 rs180530 ENSG00000266992.1 DHX40P1 8.13 3.88e-15 4.15e-12 0.41 0.35 White blood cell count; chr17:59926233 chr17:59976009~60002384:- LUSC cis rs6782228 0.606 rs2253144 ENSG00000277250.1 Metazoa_SRP 8.13 3.9e-15 4.16e-12 0.38 0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611077 chr3:128673681~128674021:- LUSC cis rs9487094 0.961 rs12192847 ENSG00000260273.1 RP11-425D10.10 8.13 3.9e-15 4.17e-12 0.44 0.35 Height; chr6:109480428 chr6:109382795~109383666:+ LUSC cis rs6991838 0.806 rs11777025 ENSG00000272010.1 CTD-3025N20.3 -8.13 3.9e-15 4.17e-12 -0.39 -0.35 Intelligence (multi-trait analysis); chr8:65551438 chr8:65591850~65592472:- LUSC cis rs4660456 0.913 rs12727412 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40723243 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs4660448 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40724682 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs7532802 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40725528 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs2361648 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40726825 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs6675886 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40727955 chr1:40669089~40687588:- LUSC cis rs4660456 0.83 rs12742219 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40728665 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs6668453 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40733299 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs35881320 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40733893 chr1:40669089~40687588:- LUSC cis rs4660456 0.871 rs34512220 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40733912 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs6664044 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40735089 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs6702983 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40735585 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs12566733 ENSG00000237899.1 RP4-739H11.3 -8.13 3.95e-15 4.21e-12 -0.49 -0.35 Platelet count; chr1:40736067 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs2744799 ENSG00000237899.1 RP4-739H11.3 8.13 3.95e-15 4.21e-12 0.49 0.35 Platelet count; chr1:40719862 chr1:40669089~40687588:- LUSC cis rs9322193 0.886 rs9718079 ENSG00000223701.3 RAET1E-AS1 8.13 3.95e-15 4.22e-12 0.41 0.35 Lung cancer; chr6:149645947 chr6:149884431~149919508:+ LUSC cis rs4713118 0.629 rs149899 ENSG00000219392.1 RP1-265C24.5 -8.13 3.96e-15 4.22e-12 -0.49 -0.35 Parkinson's disease; chr6:28052201 chr6:28115628~28116551:+ LUSC cis rs4713118 0.629 rs172165 ENSG00000219392.1 RP1-265C24.5 -8.13 3.96e-15 4.22e-12 -0.49 -0.35 Parkinson's disease; chr6:28053036 chr6:28115628~28116551:+ LUSC cis rs4713118 0.597 rs172166 ENSG00000219392.1 RP1-265C24.5 -8.13 3.96e-15 4.22e-12 -0.49 -0.35 Parkinson's disease; chr6:28053042 chr6:28115628~28116551:+ LUSC cis rs11098499 1 rs6837898 ENSG00000249244.1 RP11-548H18.2 8.13 3.97e-15 4.24e-12 0.45 0.35 Corneal astigmatism; chr4:119257999 chr4:119391831~119395335:- LUSC cis rs11089937 0.857 rs5750580 ENSG00000211639.2 IGLV4-60 8.13 3.98e-15 4.24e-12 0.34 0.35 Periodontitis (PAL4Q3); chr22:22137471 chr22:22162199~22162681:+ LUSC cis rs10129255 0.917 rs8022493 ENSG00000211970.3 IGHV4-61 -8.12 4.01e-15 4.27e-12 -0.24 -0.35 Kawasaki disease; chr14:106781820 chr14:106639119~106639657:- LUSC cis rs853679 0.567 rs2232427 ENSG00000216901.1 AL022393.7 8.12 4.02e-15 4.28e-12 0.44 0.35 Depression; chr6:28391932 chr6:28176188~28176674:+ LUSC cis rs526231 0.511 rs73179850 ENSG00000175749.11 EIF3KP1 8.12 4.05e-15 4.32e-12 0.43 0.35 Primary biliary cholangitis; chr5:103012873 chr5:103032376~103033031:+ LUSC cis rs67180937 1 rs67180937 ENSG00000272750.1 RP11-378J18.8 -8.12 4.05e-15 4.32e-12 -0.38 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222650401 chr1:222658867~222661512:- LUSC cis rs67180937 0.961 rs17011681 ENSG00000272750.1 RP11-378J18.8 -8.12 4.05e-15 4.32e-12 -0.38 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222651746 chr1:222658867~222661512:- LUSC cis rs67180937 0.961 rs17163363 ENSG00000272750.1 RP11-378J18.8 -8.12 4.05e-15 4.32e-12 -0.38 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222655362 chr1:222658867~222661512:- LUSC cis rs1930961 1 rs6004668 ENSG00000100058.11 CRYBB2P1 -8.12 4.06e-15 4.33e-12 -0.65 -0.35 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25448105~25520854:+ LUSC cis rs4660456 0.913 rs2361650 ENSG00000237899.1 RP4-739H11.3 -8.12 4.1e-15 4.36e-12 -0.49 -0.35 Platelet count; chr1:40764678 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs954654 ENSG00000237899.1 RP4-739H11.3 -8.12 4.1e-15 4.36e-12 -0.49 -0.35 Platelet count; chr1:40764979 chr1:40669089~40687588:- LUSC cis rs10829156 0.625 rs10828906 ENSG00000240291.1 RP11-499P20.2 8.12 4.1e-15 4.37e-12 0.37 0.35 Sudden cardiac arrest; chr10:18552866 chr10:18513115~18545651:- LUSC cis rs7811142 1 rs68116612 ENSG00000242294.5 STAG3L5P 8.12 4.11e-15 4.38e-12 0.28 0.35 Platelet count; chr7:100408870 chr7:100336079~100351900:+ LUSC cis rs10129255 1 rs61997605 ENSG00000211972.2 IGHV3-66 8.12 4.11e-15 4.38e-12 0.27 0.35 Kawasaki disease; chr14:106678368 chr14:106675017~106675544:- LUSC cis rs5769707 0.609 rs2007024 ENSG00000235111.1 RP1-29C18.8 -8.12 4.15e-15 4.42e-12 -0.43 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49595167 chr22:49612657~49615716:- LUSC cis rs783540 0.656 rs783538 ENSG00000276710.3 CSPG4P8 8.12 4.18e-15 4.45e-12 0.39 0.35 Schizophrenia; chr15:82584394 chr15:82459472~82477258:+ LUSC cis rs9322193 0.923 rs9322196 ENSG00000223701.3 RAET1E-AS1 8.12 4.18e-15 4.45e-12 0.4 0.35 Lung cancer; chr6:149619645 chr6:149884431~149919508:+ LUSC cis rs2739330 0.828 rs2877178 ENSG00000231271.1 AP000350.8 8.12 4.22e-15 4.49e-12 0.46 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23949918~23954042:+ LUSC cis rs10129255 0.957 rs12590799 ENSG00000211970.3 IGHV4-61 -8.12 4.23e-15 4.49e-12 -0.24 -0.35 Kawasaki disease; chr14:106779713 chr14:106639119~106639657:- LUSC cis rs10129255 0.957 rs10136781 ENSG00000211970.3 IGHV4-61 -8.12 4.23e-15 4.49e-12 -0.24 -0.35 Kawasaki disease; chr14:106780451 chr14:106639119~106639657:- LUSC cis rs8081395 0.741 rs180520 ENSG00000266992.1 DHX40P1 8.12 4.24e-15 4.51e-12 0.41 0.35 White blood cell count; chr17:59937788 chr17:59976009~60002384:- LUSC cis rs1113500 0.897 rs2336127 ENSG00000226822.1 RP11-356N1.2 8.12 4.26e-15 4.53e-12 0.37 0.35 Growth-regulated protein alpha levels; chr1:108098248 chr1:108071482~108074519:+ LUSC cis rs9322193 0.923 rs2342765 ENSG00000223701.3 RAET1E-AS1 8.12 4.28e-15 4.54e-12 0.39 0.35 Lung cancer; chr6:149858873 chr6:149884431~149919508:+ LUSC cis rs7811142 1 rs11771419 ENSG00000242294.5 STAG3L5P 8.11 4.29e-15 4.56e-12 0.28 0.35 Platelet count; chr7:100390780 chr7:100336079~100351900:+ LUSC cis rs526231 0.511 rs62362545 ENSG00000175749.11 EIF3KP1 8.11 4.36e-15 4.63e-12 0.43 0.35 Primary biliary cholangitis; chr5:103011748 chr5:103032376~103033031:+ LUSC cis rs526231 0.511 rs3910557 ENSG00000175749.11 EIF3KP1 8.11 4.36e-15 4.63e-12 0.43 0.35 Primary biliary cholangitis; chr5:103014767 chr5:103032376~103033031:+ LUSC cis rs526231 0.511 rs2288389 ENSG00000175749.11 EIF3KP1 8.11 4.36e-15 4.63e-12 0.43 0.35 Primary biliary cholangitis; chr5:103018104 chr5:103032376~103033031:+ LUSC cis rs11098499 0.866 rs72676074 ENSG00000249244.1 RP11-548H18.2 8.11 4.36e-15 4.63e-12 0.45 0.35 Corneal astigmatism; chr4:119438686 chr4:119391831~119395335:- LUSC cis rs9807989 0.507 rs6710528 ENSG00000234389.1 AC007278.3 -8.11 4.37e-15 4.64e-12 -0.33 -0.35 Asthma; chr2:102399682 chr2:102438713~102440475:+ LUSC cis rs11098499 0.954 rs6847248 ENSG00000249244.1 RP11-548H18.2 8.11 4.38e-15 4.65e-12 0.47 0.35 Corneal astigmatism; chr4:119304800 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs3736115 ENSG00000249244.1 RP11-548H18.2 -8.11 4.39e-15 4.66e-12 -0.45 -0.35 Corneal astigmatism; chr4:119567548 chr4:119391831~119395335:- LUSC cis rs8072100 0.811 rs1912483 ENSG00000228782.6 CTD-2026D20.3 8.11 4.42e-15 4.69e-12 0.34 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47366128 chr17:47450568~47492492:- LUSC cis rs8072100 0.811 rs9889709 ENSG00000228782.6 CTD-2026D20.3 8.11 4.42e-15 4.69e-12 0.34 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47367863 chr17:47450568~47492492:- LUSC cis rs8062405 0.573 rs7187575 ENSG00000259982.1 CDC37P1 -8.11 4.43e-15 4.7e-12 -0.47 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28978780 chr16:28700294~28701540:- LUSC cis rs10129255 0.5 rs9324092 ENSG00000211970.3 IGHV4-61 8.11 4.44e-15 4.71e-12 0.22 0.35 Kawasaki disease; chr14:106683806 chr14:106639119~106639657:- LUSC cis rs2019137 0.868 rs3748916 ENSG00000189223.12 PAX8-AS1 8.11 4.44e-15 4.71e-12 0.46 0.35 Lymphocyte counts; chr2:113226456 chr2:113211522~113276581:+ LUSC cis rs1075265 0.568 rs959286 ENSG00000233266.1 HMGB1P31 8.11 4.45e-15 4.72e-12 0.43 0.35 Chronotype;Morning vs. evening chronotype; chr2:54078941 chr2:54051334~54051760:+ LUSC cis rs1075265 0.527 rs959285 ENSG00000233266.1 HMGB1P31 8.11 4.45e-15 4.72e-12 0.43 0.35 Chronotype;Morning vs. evening chronotype; chr2:54078964 chr2:54051334~54051760:+ LUSC cis rs2019137 0.901 rs4849176 ENSG00000189223.12 PAX8-AS1 8.11 4.45e-15 4.72e-12 0.46 0.35 Lymphocyte counts; chr2:113220359 chr2:113211522~113276581:+ LUSC cis rs6471393 0.964 rs2914941 ENSG00000253848.1 RP11-10N23.5 8.11 4.5e-15 4.77e-12 0.44 0.35 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93716983 chr8:93741193~93744534:+ LUSC cis rs6931421 1 rs6931421 ENSG00000272129.1 RP11-250B2.6 8.11 4.5e-15 4.77e-12 0.46 0.35 Sitting height ratio; chr6:80170421 chr6:80355424~80356859:+ LUSC cis rs7044106 0.762 rs966396 ENSG00000226752.6 PSMD5-AS1 -8.11 4.52e-15 4.79e-12 -0.4 -0.35 Hip circumference adjusted for BMI; chr9:120691003 chr9:120824828~120854385:+ LUSC cis rs17270561 0.779 rs78589800 ENSG00000272462.2 U91328.19 -8.11 4.52e-15 4.79e-12 -0.46 -0.35 Iron status biomarkers; chr6:25883272 chr6:25992662~26001775:+ LUSC cis rs3091242 0.867 rs602052 ENSG00000224183.1 SDHDP6 -8.11 4.53e-15 4.81e-12 -0.43 -0.35 Erythrocyte sedimentation rate; chr1:25395715 chr1:25294164~25294643:- LUSC cis rs748404 0.578 rs573615 ENSG00000249839.1 AC011330.5 -8.11 4.55e-15 4.82e-12 -0.47 -0.35 Lung cancer; chr15:43322083 chr15:43663654~43684339:- LUSC cis rs1061377 1 rs1061377 ENSG00000249207.1 RP11-360F5.1 -8.11 4.55e-15 4.82e-12 -0.37 -0.35 Uric acid levels; chr4:39123130 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs13109200 ENSG00000249207.1 RP11-360F5.1 -8.11 4.55e-15 4.82e-12 -0.37 -0.35 Uric acid levels; chr4:39124396 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs13144374 ENSG00000249207.1 RP11-360F5.1 -8.11 4.55e-15 4.82e-12 -0.37 -0.35 Uric acid levels; chr4:39128859 chr4:39112677~39126818:- LUSC cis rs3091242 1 rs9689 ENSG00000224183.1 SDHDP6 -8.11 4.56e-15 4.83e-12 -0.42 -0.35 Erythrocyte sedimentation rate; chr1:25361785 chr1:25294164~25294643:- LUSC cis rs694739 0.628 rs645078 ENSG00000236935.1 AP003774.1 8.11 4.58e-15 4.85e-12 0.34 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64367826 chr11:64325050~64329504:- LUSC cis rs1061377 1 rs7675782 ENSG00000249207.1 RP11-360F5.1 -8.11 4.58e-15 4.85e-12 -0.37 -0.35 Uric acid levels; chr4:39120048 chr4:39112677~39126818:- LUSC cis rs9487094 0.813 rs13203252 ENSG00000260273.1 RP11-425D10.10 8.11 4.59e-15 4.86e-12 0.45 0.35 Height; chr6:109351533 chr6:109382795~109383666:+ LUSC cis rs526231 0.511 rs34823 ENSG00000175749.11 EIF3KP1 -8.1 4.62e-15 4.89e-12 -0.42 -0.35 Primary biliary cholangitis; chr5:103102587 chr5:103032376~103033031:+ LUSC cis rs4423214 0.569 rs4944044 ENSG00000254682.1 RP11-660L16.2 8.1 4.63e-15 4.9e-12 0.42 0.35 Vitamin D levels; chr11:71409167 chr11:71448674~71452157:+ LUSC cis rs9487094 0.621 rs9398202 ENSG00000260273.1 RP11-425D10.10 8.1 4.63e-15 4.9e-12 0.41 0.35 Height; chr6:109458989 chr6:109382795~109383666:+ LUSC cis rs875971 0.862 rs11773628 ENSG00000222364.1 RNU6-96P 8.1 4.67e-15 4.95e-12 0.41 0.35 Aortic root size; chr7:66517644 chr7:66395191~66395286:+ LUSC cis rs1061377 1 rs13182 ENSG00000249207.1 RP11-360F5.1 -8.1 4.68e-15 4.95e-12 -0.37 -0.35 Uric acid levels; chr4:39121293 chr4:39112677~39126818:- LUSC cis rs694739 0.541 rs61886926 ENSG00000236935.1 AP003774.1 8.1 4.71e-15 4.98e-12 0.34 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64366080 chr11:64325050~64329504:- LUSC cis rs694739 0.628 rs617051 ENSG00000236935.1 AP003774.1 8.1 4.71e-15 4.98e-12 0.34 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64366166 chr11:64325050~64329504:- LUSC cis rs853679 0.567 rs3799499 ENSG00000216901.1 AL022393.7 8.1 4.74e-15 5.01e-12 0.44 0.35 Depression; chr6:28386473 chr6:28176188~28176674:+ LUSC cis rs11098499 0.863 rs3775847 ENSG00000245958.5 RP11-33B1.1 -8.1 4.77e-15 5.04e-12 -0.36 -0.35 Corneal astigmatism; chr4:119526487 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs3775848 ENSG00000245958.5 RP11-33B1.1 -8.1 4.77e-15 5.04e-12 -0.36 -0.35 Corneal astigmatism; chr4:119526569 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs10030660 ENSG00000245958.5 RP11-33B1.1 -8.1 4.82e-15 5.1e-12 -0.36 -0.35 Corneal astigmatism; chr4:119515549 chr4:119454791~119552025:+ LUSC cis rs11098499 0.863 rs13149407 ENSG00000245958.5 RP11-33B1.1 -8.1 4.82e-15 5.1e-12 -0.36 -0.35 Corneal astigmatism; chr4:119516670 chr4:119454791~119552025:+ LUSC cis rs11098499 0.955 rs1511019 ENSG00000249244.1 RP11-548H18.2 8.1 4.85e-15 5.13e-12 0.45 0.35 Corneal astigmatism; chr4:119244852 chr4:119391831~119395335:- LUSC cis rs1075265 0.547 rs11125520 ENSG00000233266.1 HMGB1P31 8.1 4.86e-15 5.13e-12 0.43 0.35 Chronotype;Morning vs. evening chronotype; chr2:54076696 chr2:54051334~54051760:+ LUSC cis rs11098499 0.909 rs11723757 ENSG00000249244.1 RP11-548H18.2 8.1 4.86e-15 5.14e-12 0.45 0.35 Corneal astigmatism; chr4:119378514 chr4:119391831~119395335:- LUSC cis rs875971 0.862 rs28470208 ENSG00000222364.1 RNU6-96P 8.1 4.87e-15 5.14e-12 0.41 0.35 Aortic root size; chr7:66119713 chr7:66395191~66395286:+ LUSC cis rs34779708 0.966 rs1478463 ENSG00000230534.5 RP11-297A16.2 8.1 4.87e-15 5.14e-12 0.39 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35184107 chr10:35098006~35127020:- LUSC cis rs4713118 0.662 rs9380045 ENSG00000219392.1 RP1-265C24.5 -8.1 4.87e-15 5.14e-12 -0.48 -0.35 Parkinson's disease; chr6:28057501 chr6:28115628~28116551:+ LUSC cis rs4713118 0.616 rs9348789 ENSG00000219392.1 RP1-265C24.5 -8.1 4.87e-15 5.14e-12 -0.48 -0.35 Parkinson's disease; chr6:28057708 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs9468274 ENSG00000219392.1 RP1-265C24.5 -8.1 4.87e-15 5.14e-12 -0.48 -0.35 Parkinson's disease; chr6:28058299 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs9468275 ENSG00000219392.1 RP1-265C24.5 -8.1 4.87e-15 5.14e-12 -0.48 -0.35 Parkinson's disease; chr6:28058358 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs9468276 ENSG00000219392.1 RP1-265C24.5 -8.1 4.87e-15 5.14e-12 -0.48 -0.35 Parkinson's disease; chr6:28059910 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs9468277 ENSG00000219392.1 RP1-265C24.5 -8.1 4.87e-15 5.14e-12 -0.48 -0.35 Parkinson's disease; chr6:28060612 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs9468278 ENSG00000219392.1 RP1-265C24.5 -8.1 4.87e-15 5.14e-12 -0.48 -0.35 Parkinson's disease; chr6:28060704 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs13218430 ENSG00000219392.1 RP1-265C24.5 -8.1 4.87e-15 5.14e-12 -0.48 -0.35 Parkinson's disease; chr6:28062059 chr6:28115628~28116551:+ LUSC cis rs10129255 0.5 rs7161740 ENSG00000211970.3 IGHV4-61 -8.1 4.87e-15 5.14e-12 -0.22 -0.35 Kawasaki disease; chr14:106776119 chr14:106639119~106639657:- LUSC cis rs10129255 0.556 rs6576222 ENSG00000211970.3 IGHV4-61 -8.1 4.87e-15 5.14e-12 -0.22 -0.35 Kawasaki disease; chr14:106776442 chr14:106639119~106639657:- LUSC cis rs10129255 0.536 rs6576223 ENSG00000211970.3 IGHV4-61 -8.1 4.87e-15 5.14e-12 -0.22 -0.35 Kawasaki disease; chr14:106776448 chr14:106639119~106639657:- LUSC cis rs11098499 0.954 rs10006877 ENSG00000249244.1 RP11-548H18.2 8.1 4.87e-15 5.14e-12 0.45 0.35 Corneal astigmatism; chr4:119321638 chr4:119391831~119395335:- LUSC cis rs8062405 0.69 rs7187604 ENSG00000259982.1 CDC37P1 8.1 4.88e-15 5.15e-12 0.44 0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554632 chr16:28700294~28701540:- LUSC cis rs1061377 0.76 rs7678457 ENSG00000249207.1 RP11-360F5.1 -8.1 4.89e-15 5.16e-12 -0.37 -0.35 Uric acid levels; chr4:39136041 chr4:39112677~39126818:- LUSC cis rs875971 1 rs1167612 ENSG00000222364.1 RNU6-96P 8.1 4.9e-15 5.17e-12 0.42 0.35 Aortic root size; chr7:66102989 chr7:66395191~66395286:+ LUSC cis rs10129255 1 rs11621409 ENSG00000211972.2 IGHV3-66 8.1 4.91e-15 5.18e-12 0.27 0.35 Kawasaki disease; chr14:106695603 chr14:106675017~106675544:- LUSC cis rs8062405 0.573 rs8045689 ENSG00000259982.1 CDC37P1 -8.1 4.93e-15 5.2e-12 -0.48 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28976948 chr16:28700294~28701540:- LUSC cis rs9487094 0.813 rs34320275 ENSG00000260273.1 RP11-425D10.10 8.1 4.94e-15 5.21e-12 0.46 0.35 Height; chr6:109436760 chr6:109382795~109383666:+ LUSC cis rs526231 0.575 rs55652053 ENSG00000175749.11 EIF3KP1 8.09 4.96e-15 5.23e-12 0.42 0.35 Primary biliary cholangitis; chr5:103001466 chr5:103032376~103033031:+ LUSC cis rs5769707 0.967 rs8141807 ENSG00000235111.1 RP1-29C18.8 -8.09 4.97e-15 5.24e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49650090 chr22:49612657~49615716:- LUSC cis rs783540 0.592 rs2567632 ENSG00000276710.3 CSPG4P8 8.09 5e-15 5.27e-12 0.4 0.35 Schizophrenia; chr15:82616053 chr15:82459472~82477258:+ LUSC cis rs853679 0.517 rs1904840 ENSG00000219392.1 RP1-265C24.5 -8.09 5e-15 5.27e-12 -0.5 -0.35 Depression; chr6:28140454 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9368555 ENSG00000219392.1 RP1-265C24.5 -8.09 5e-15 5.27e-12 -0.5 -0.35 Depression; chr6:28141189 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9393893 ENSG00000219392.1 RP1-265C24.5 -8.09 5e-15 5.27e-12 -0.5 -0.35 Depression; chr6:28141484 chr6:28115628~28116551:+ LUSC cis rs7811142 0.83 rs6979910 ENSG00000242294.5 STAG3L5P 8.09 5e-15 5.28e-12 0.28 0.35 Platelet count; chr7:100343007 chr7:100336079~100351900:+ LUSC cis rs992157 0.687 rs35271699 ENSG00000261338.2 RP11-378A13.1 8.09 5.01e-15 5.28e-12 0.36 0.35 Colorectal cancer; chr2:218252759 chr2:218255319~218257366:+ LUSC cis rs9322193 0.884 rs880245 ENSG00000223701.3 RAET1E-AS1 -8.09 5.01e-15 5.29e-12 -0.4 -0.35 Lung cancer; chr6:149846262 chr6:149884431~149919508:+ LUSC cis rs10129255 0.5 rs2027903 ENSG00000211970.3 IGHV4-61 -8.09 5.03e-15 5.3e-12 -0.22 -0.35 Kawasaki disease; chr14:106807047 chr14:106639119~106639657:- LUSC cis rs1061377 0.722 rs34803689 ENSG00000249207.1 RP11-360F5.1 -8.09 5.04e-15 5.31e-12 -0.37 -0.35 Uric acid levels; chr4:39116665 chr4:39112677~39126818:- LUSC cis rs11098499 0.908 rs9995234 ENSG00000249244.1 RP11-548H18.2 8.09 5.05e-15 5.32e-12 0.47 0.35 Corneal astigmatism; chr4:119400672 chr4:119391831~119395335:- LUSC cis rs904251 0.523 rs10947675 ENSG00000204110.6 RP1-153P14.8 -8.09 5.06e-15 5.33e-12 -0.34 -0.35 Cognitive performance; chr6:37512196 chr6:37507348~37535616:+ LUSC cis rs3096299 0.967 rs16965692 ENSG00000274627.1 RP11-104N10.2 8.09 5.06e-15 5.33e-12 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89405074 chr16:89516797~89522217:+ LUSC cis rs2337406 0.714 rs2337463 ENSG00000274576.2 IGHV2-70 -8.09 5.13e-15 5.4e-12 -0.37 -0.35 Alzheimer's disease (late onset); chr14:106816066 chr14:106770577~106771020:- LUSC cis rs10129255 0.833 rs7156689 ENSG00000211970.3 IGHV4-61 -8.09 5.13e-15 5.4e-12 -0.25 -0.35 Kawasaki disease; chr14:106816039 chr14:106639119~106639657:- LUSC cis rs1075265 0.633 rs7564912 ENSG00000233266.1 HMGB1P31 8.09 5.14e-15 5.41e-12 0.44 0.35 Chronotype;Morning vs. evening chronotype; chr2:53995048 chr2:54051334~54051760:+ LUSC cis rs9322193 0.884 rs9322210 ENSG00000223701.3 RAET1E-AS1 8.09 5.14e-15 5.42e-12 0.4 0.35 Lung cancer; chr6:149695440 chr6:149884431~149919508:+ LUSC cis rs2739330 0.761 rs5760176 ENSG00000099984.9 GSTT2 8.09 5.16e-15 5.43e-12 0.41 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23980123~23983911:+ LUSC cis rs8072100 1 rs11870935 ENSG00000228782.6 CTD-2026D20.3 -8.09 5.17e-15 5.44e-12 -0.33 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47655239 chr17:47450568~47492492:- LUSC cis rs3931020 0.72 rs927904 ENSG00000272864.1 RP11-17E13.2 -8.09 5.21e-15 5.48e-12 -0.46 -0.35 Resistin levels; chr1:74794644 chr1:74698769~74699333:- LUSC cis rs2117029 0.554 rs12579015 ENSG00000258017.1 RP11-386G11.10 -8.09 5.23e-15 5.5e-12 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49162648 chr12:49127782~49147869:+ LUSC cis rs2117029 0.521 rs2114845 ENSG00000258017.1 RP11-386G11.10 -8.09 5.23e-15 5.5e-12 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49164750 chr12:49127782~49147869:+ LUSC cis rs3096299 0.933 rs2965823 ENSG00000274627.1 RP11-104N10.2 8.09 5.26e-15 5.53e-12 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89388516 chr16:89516797~89522217:+ LUSC cis rs5769707 0.935 rs739239 ENSG00000235111.1 RP1-29C18.8 -8.09 5.27e-15 5.53e-12 -0.41 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49656820 chr22:49612657~49615716:- LUSC cis rs2117029 0.555 rs3741621 ENSG00000258017.1 RP11-386G11.10 -8.09 5.3e-15 5.57e-12 -0.45 -0.35 Intelligence (multi-trait analysis); chr12:49100242 chr12:49127782~49147869:+ LUSC cis rs853679 0.506 rs1150693 ENSG00000219392.1 RP1-265C24.5 -8.09 5.31e-15 5.58e-12 -0.48 -0.35 Depression; chr6:28206812 chr6:28115628~28116551:+ LUSC cis rs8072100 0.967 rs4580230 ENSG00000228782.6 CTD-2026D20.3 8.08 5.34e-15 5.61e-12 0.33 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47661495 chr17:47450568~47492492:- LUSC cis rs11098499 0.954 rs878373 ENSG00000249244.1 RP11-548H18.2 8.08 5.37e-15 5.64e-12 0.45 0.35 Corneal astigmatism; chr4:119316329 chr4:119391831~119395335:- LUSC cis rs8062405 0.573 rs11645306 ENSG00000259982.1 CDC37P1 -8.08 5.38e-15 5.65e-12 -0.47 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28972615 chr16:28700294~28701540:- LUSC cis rs2739330 0.731 rs5751792 ENSG00000099984.9 GSTT2 -8.08 5.41e-15 5.68e-12 -0.41 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23980123~23983911:+ LUSC cis rs875971 0.964 rs697969 ENSG00000222364.1 RNU6-96P 8.08 5.46e-15 5.72e-12 0.41 0.35 Aortic root size; chr7:66093491 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs1182882 ENSG00000222364.1 RNU6-96P 8.08 5.46e-15 5.72e-12 0.41 0.35 Aortic root size; chr7:66097076 chr7:66395191~66395286:+ LUSC cis rs9322193 0.923 rs62439840 ENSG00000223701.3 RAET1E-AS1 8.08 5.46e-15 5.73e-12 0.41 0.35 Lung cancer; chr6:149674639 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9393175 ENSG00000223701.3 RAET1E-AS1 8.08 5.46e-15 5.73e-12 0.41 0.35 Lung cancer; chr6:149677587 chr6:149884431~149919508:+ LUSC cis rs10129255 0.957 rs11846893 ENSG00000211970.3 IGHV4-61 -8.08 5.47e-15 5.74e-12 -0.24 -0.35 Kawasaki disease; chr14:106779068 chr14:106639119~106639657:- LUSC cis rs55794721 0.543 rs1293260 ENSG00000224183.1 SDHDP6 -8.08 5.49e-15 5.75e-12 -0.43 -0.35 Mean corpuscular volume;Plateletcrit; chr1:25382613 chr1:25294164~25294643:- LUSC cis rs783540 0.656 rs783524 ENSG00000276710.3 CSPG4P8 8.08 5.51e-15 5.77e-12 0.4 0.35 Schizophrenia; chr15:82615393 chr15:82459472~82477258:+ LUSC cis rs10129255 0.834 rs10139893 ENSG00000211972.2 IGHV3-66 8.08 5.51e-15 5.77e-12 0.27 0.35 Kawasaki disease; chr14:106711377 chr14:106675017~106675544:- LUSC cis rs11098499 0.954 rs9993199 ENSG00000249244.1 RP11-548H18.2 -8.08 5.52e-15 5.79e-12 -0.45 -0.35 Corneal astigmatism; chr4:119471718 chr4:119391831~119395335:- LUSC cis rs4713118 0.662 rs156744 ENSG00000219392.1 RP1-265C24.5 -8.08 5.55e-15 5.81e-12 -0.48 -0.35 Parkinson's disease; chr6:27999496 chr6:28115628~28116551:+ LUSC cis rs9322193 0.923 rs3924871 ENSG00000223701.3 RAET1E-AS1 8.08 5.56e-15 5.83e-12 0.4 0.35 Lung cancer; chr6:149662080 chr6:149884431~149919508:+ LUSC cis rs10463554 0.963 rs3776857 ENSG00000175749.11 EIF3KP1 8.08 5.63e-15 5.89e-12 0.42 0.35 Parkinson's disease; chr5:103022456 chr5:103032376~103033031:+ LUSC cis rs9807989 0.507 rs2041739 ENSG00000234389.1 AC007278.3 -8.08 5.68e-15 5.95e-12 -0.33 -0.35 Asthma; chr2:102377873 chr2:102438713~102440475:+ LUSC cis rs7188445 0.736 rs4888043 ENSG00000261390.4 RP11-345M22.2 8.08 5.69e-15 5.95e-12 0.44 0.35 Urate levels; chr16:79668744 chr16:79715232~79770563:- LUSC cis rs7044106 0.762 rs7849566 ENSG00000226752.6 PSMD5-AS1 -8.08 5.69e-15 5.95e-12 -0.4 -0.35 Hip circumference adjusted for BMI; chr9:120698491 chr9:120824828~120854385:+ LUSC cis rs3096299 0.967 rs2965827 ENSG00000274627.1 RP11-104N10.2 -8.08 5.7e-15 5.96e-12 -0.31 -0.35 Multiple myeloma (IgH translocation); chr16:89390942 chr16:89516797~89522217:+ LUSC cis rs34779708 0.966 rs12260130 ENSG00000230534.5 RP11-297A16.2 8.07 5.74e-15 6e-12 0.38 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35178743 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs4934539 ENSG00000230534.5 RP11-297A16.2 8.07 5.74e-15 6e-12 0.39 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35183271 chr10:35098006~35127020:- LUSC cis rs3091242 0.967 rs3093614 ENSG00000224183.1 SDHDP6 8.07 5.74e-15 6e-12 0.43 0.35 Erythrocyte sedimentation rate; chr1:25351353 chr1:25294164~25294643:- LUSC cis rs1577917 0.545 rs9294338 ENSG00000203875.9 SNHG5 8.07 5.74e-15 6e-12 0.45 0.35 Response to antipsychotic treatment; chr6:85764650 chr6:85660950~85678736:- LUSC cis rs367615 0.552 rs2963010 ENSG00000249476.1 CTD-2587M2.1 -8.07 5.75e-15 6.01e-12 -0.41 -0.35 Colorectal cancer (SNP x SNP interaction); chr5:109401342 chr5:109237120~109326369:- LUSC cis rs34779708 0.966 rs4934538 ENSG00000230534.5 RP11-297A16.2 8.07 5.75e-15 6.01e-12 0.39 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35183222 chr10:35098006~35127020:- LUSC cis rs11118620 0.853 rs12037861 ENSG00000272823.1 RP11-295M18.6 8.07 5.75e-15 6.01e-12 0.43 0.35 Heart failure; chr1:220864835 chr1:220828676~220829211:- LUSC cis rs34779708 0.833 rs12777517 ENSG00000230534.5 RP11-297A16.2 8.07 5.76e-15 6.02e-12 0.39 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35184999 chr10:35098006~35127020:- LUSC cis rs12439619 0.508 rs17354842 ENSG00000278603.1 RP13-608F4.5 -8.07 5.83e-15 6.1e-12 -0.43 -0.35 Intelligence (multi-trait analysis); chr15:82177259 chr15:82472203~82472426:+ LUSC cis rs35955747 0.934 rs4820045 ENSG00000236132.1 CTA-440B3.1 8.07 5.85e-15 6.11e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31389983 chr22:31816379~31817491:- LUSC cis rs7811142 0.667 rs3873746 ENSG00000242294.5 STAG3L5P 8.07 5.86e-15 6.12e-12 0.28 0.35 Platelet count; chr7:100337474 chr7:100336079~100351900:+ LUSC cis rs11098499 0.954 rs6857105 ENSG00000249244.1 RP11-548H18.2 8.07 5.88e-15 6.14e-12 0.46 0.35 Corneal astigmatism; chr4:119301143 chr4:119391831~119395335:- LUSC cis rs9487094 0.813 rs35969918 ENSG00000260273.1 RP11-425D10.10 8.07 5.93e-15 6.19e-12 0.45 0.35 Height; chr6:109441837 chr6:109382795~109383666:+ LUSC cis rs526231 0.543 rs62362544 ENSG00000175749.11 EIF3KP1 8.07 5.93e-15 6.19e-12 0.42 0.35 Primary biliary cholangitis; chr5:102998543 chr5:103032376~103033031:+ LUSC cis rs9487094 0.813 rs13195517 ENSG00000260273.1 RP11-425D10.10 8.07 5.94e-15 6.21e-12 0.45 0.35 Height; chr6:109415050 chr6:109382795~109383666:+ LUSC cis rs10463554 0.963 rs26261 ENSG00000175749.11 EIF3KP1 8.07 5.95e-15 6.21e-12 0.42 0.35 Parkinson's disease; chr5:103209992 chr5:103032376~103033031:+ LUSC cis rs5769707 0.967 rs9616701 ENSG00000235111.1 RP1-29C18.8 -8.07 5.95e-15 6.21e-12 -0.4 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49631898 chr22:49612657~49615716:- LUSC cis rs4713118 0.662 rs9393881 ENSG00000219392.1 RP1-265C24.5 -8.07 6e-15 6.26e-12 -0.47 -0.35 Parkinson's disease; chr6:28055973 chr6:28115628~28116551:+ LUSC cis rs80285556 1 rs17605685 ENSG00000161643.11 SIGLEC16 8.07 6.01e-15 6.28e-12 0.81 0.35 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49983484 chr19:49969673~49975814:+ LUSC cis rs11098499 0.954 rs28572238 ENSG00000249244.1 RP11-548H18.2 8.07 6.03e-15 6.29e-12 0.45 0.35 Corneal astigmatism; chr4:119395531 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs28714195 ENSG00000249244.1 RP11-548H18.2 8.07 6.03e-15 6.29e-12 0.45 0.35 Corneal astigmatism; chr4:119395795 chr4:119391831~119395335:- LUSC cis rs10463554 0.963 rs26816 ENSG00000175749.11 EIF3KP1 8.07 6.06e-15 6.32e-12 0.41 0.35 Parkinson's disease; chr5:103204821 chr5:103032376~103033031:+ LUSC cis rs67180937 0.844 rs35626308 ENSG00000272750.1 RP11-378J18.8 -8.07 6.1e-15 6.36e-12 -0.38 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222643014 chr1:222658867~222661512:- LUSC cis rs853679 0.517 rs1904841 ENSG00000219392.1 RP1-265C24.5 -8.07 6.12e-15 6.38e-12 -0.5 -0.35 Depression; chr6:28140307 chr6:28115628~28116551:+ LUSC cis rs11098499 0.69 rs34818745 ENSG00000249244.1 RP11-548H18.2 8.07 6.12e-15 6.39e-12 0.45 0.35 Corneal astigmatism; chr4:119335900 chr4:119391831~119395335:- LUSC cis rs12439619 0.508 rs17354842 ENSG00000255769.6 GOLGA2P10 8.07 6.13e-15 6.39e-12 0.43 0.35 Intelligence (multi-trait analysis); chr15:82177259 chr15:82472993~82513950:- LUSC cis rs11098499 1 rs28374891 ENSG00000249244.1 RP11-548H18.2 8.06 6.14e-15 6.4e-12 0.45 0.35 Corneal astigmatism; chr4:119262395 chr4:119391831~119395335:- LUSC cis rs10129255 0.556 rs8010005 ENSG00000211970.3 IGHV4-61 -8.06 6.15e-15 6.41e-12 -0.22 -0.35 Kawasaki disease; chr14:106777987 chr14:106639119~106639657:- LUSC cis rs10129255 0.556 rs6576224 ENSG00000211970.3 IGHV4-61 -8.06 6.15e-15 6.41e-12 -0.22 -0.35 Kawasaki disease; chr14:106777997 chr14:106639119~106639657:- LUSC cis rs10129255 0.518 rs8010020 ENSG00000211970.3 IGHV4-61 -8.06 6.15e-15 6.41e-12 -0.22 -0.35 Kawasaki disease; chr14:106778016 chr14:106639119~106639657:- LUSC cis rs10829156 0.699 rs4747353 ENSG00000240291.1 RP11-499P20.2 8.06 6.16e-15 6.42e-12 0.36 0.35 Sudden cardiac arrest; chr10:18548028 chr10:18513115~18545651:- LUSC cis rs7044106 0.762 rs1867254 ENSG00000226752.6 PSMD5-AS1 -8.06 6.24e-15 6.5e-12 -0.4 -0.35 Hip circumference adjusted for BMI; chr9:120666800 chr9:120824828~120854385:+ LUSC cis rs7044106 0.708 rs991121 ENSG00000226752.6 PSMD5-AS1 -8.06 6.29e-15 6.55e-12 -0.39 -0.35 Hip circumference adjusted for BMI; chr9:120608067 chr9:120824828~120854385:+ LUSC cis rs1823913 1 rs4853568 ENSG00000227542.1 AC092614.2 -8.06 6.31e-15 6.56e-12 -0.47 -0.35 Obesity-related traits; chr2:191261464 chr2:191229165~191246172:- LUSC cis rs10129255 1 rs10134517 ENSG00000211970.3 IGHV4-61 -8.06 6.32e-15 6.58e-12 -0.25 -0.35 Kawasaki disease; chr14:106718498 chr14:106639119~106639657:- LUSC cis rs9322193 0.886 rs4870055 ENSG00000223701.3 RAET1E-AS1 8.06 6.35e-15 6.61e-12 0.4 0.35 Lung cancer; chr6:149848433 chr6:149884431~149919508:+ LUSC cis rs35955747 0.902 rs7287402 ENSG00000236132.1 CTA-440B3.1 -8.06 6.38e-15 6.64e-12 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31258837 chr22:31816379~31817491:- LUSC cis rs10129255 0.957 rs2013423 ENSG00000211972.2 IGHV3-66 8.06 6.39e-15 6.65e-12 0.26 0.35 Kawasaki disease; chr14:106690675 chr14:106675017~106675544:- LUSC cis rs10129255 0.912 rs61996059 ENSG00000211972.2 IGHV3-66 8.06 6.4e-15 6.66e-12 0.27 0.35 Kawasaki disease; chr14:106716897 chr14:106675017~106675544:- LUSC cis rs4910157 1 rs4910157 ENSG00000254860.4 TMEM9B-AS1 -8.06 6.42e-15 6.67e-12 -0.37 -0.35 Tonsillectomy; chr11:8919668 chr11:8964675~8977527:+ LUSC cis rs9322193 0.923 rs7769101 ENSG00000223701.3 RAET1E-AS1 8.06 6.43e-15 6.69e-12 0.4 0.35 Lung cancer; chr6:149848768 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs12174716 ENSG00000223701.3 RAET1E-AS1 8.06 6.56e-15 6.81e-12 0.4 0.35 Lung cancer; chr6:149644487 chr6:149884431~149919508:+ LUSC cis rs875971 1 rs697970 ENSG00000222364.1 RNU6-96P 8.06 6.58e-15 6.84e-12 0.41 0.35 Aortic root size; chr7:66095065 chr7:66395191~66395286:+ LUSC cis rs7811142 0.562 rs7786844 ENSG00000242294.5 STAG3L5P 8.06 6.59e-15 6.85e-12 0.28 0.35 Platelet count; chr7:100336385 chr7:100336079~100351900:+ LUSC cis rs783540 0.681 rs1259178 ENSG00000276710.3 CSPG4P8 8.05 6.66e-15 6.92e-12 0.39 0.35 Schizophrenia; chr15:82603127 chr15:82459472~82477258:+ LUSC cis rs3096299 0.967 rs3102341 ENSG00000274627.1 RP11-104N10.2 8.05 6.68e-15 6.94e-12 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89384336 chr16:89516797~89522217:+ LUSC cis rs1012068 0.686 rs5994451 ENSG00000236132.1 CTA-440B3.1 -8.05 6.71e-15 6.96e-12 -0.45 -0.35 Chronic hepatitis C infection; chr22:31927525 chr22:31816379~31817491:- LUSC cis rs1012068 0.686 rs4820996 ENSG00000236132.1 CTA-440B3.1 -8.05 6.73e-15 6.99e-12 -0.45 -0.35 Chronic hepatitis C infection; chr22:31928044 chr22:31816379~31817491:- LUSC cis rs1823913 0.927 rs13013390 ENSG00000227542.1 AC092614.2 8.05 6.74e-15 6.99e-12 0.46 0.35 Obesity-related traits; chr2:191262001 chr2:191229165~191246172:- LUSC cis rs9322193 0.884 rs62439837 ENSG00000223701.3 RAET1E-AS1 8.05 6.79e-15 7.04e-12 0.41 0.35 Lung cancer; chr6:149670380 chr6:149884431~149919508:+ LUSC cis rs11098499 0.913 rs56122576 ENSG00000249244.1 RP11-548H18.2 8.05 6.79e-15 7.04e-12 0.45 0.35 Corneal astigmatism; chr4:119208181 chr4:119391831~119395335:- LUSC cis rs5769707 0.904 rs7288869 ENSG00000235111.1 RP1-29C18.8 -8.05 6.8e-15 7.05e-12 -0.4 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49621679 chr22:49612657~49615716:- LUSC cis rs3930017 1 rs7783809 ENSG00000242435.1 UPK3BP1 8.05 6.82e-15 7.07e-12 0.37 0.35 Body mass index; chr7:77090234 chr7:77004662~77005774:+ LUSC cis rs8072100 1 rs3809868 ENSG00000228782.6 CTD-2026D20.3 -8.05 6.84e-15 7.09e-12 -0.33 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47673230 chr17:47450568~47492492:- LUSC cis rs10800713 0.954 rs4623737 ENSG00000260088.1 RP11-92G12.3 -8.05 6.94e-15 7.19e-12 -0.42 -0.35 Tandem gait; chr1:200594578 chr1:200669507~200694250:+ LUSC cis rs6921919 1 rs35875412 ENSG00000216901.1 AL022393.7 8.05 6.97e-15 7.22e-12 0.49 0.35 Autism spectrum disorder or schizophrenia; chr6:28364041 chr6:28176188~28176674:+ LUSC cis rs875971 1 rs7781698 ENSG00000222364.1 RNU6-96P -8.05 6.98e-15 7.23e-12 -0.41 -0.35 Aortic root size; chr7:66431325 chr7:66395191~66395286:+ LUSC cis rs9322193 0.923 rs4354168 ENSG00000223701.3 RAET1E-AS1 8.05 7e-15 7.25e-12 0.4 0.35 Lung cancer; chr6:149696642 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs4455682 ENSG00000223701.3 RAET1E-AS1 8.05 7e-15 7.25e-12 0.4 0.35 Lung cancer; chr6:149700161 chr6:149884431~149919508:+ LUSC cis rs9326248 0.813 rs7115562 ENSG00000280143.1 AP000892.6 8.05 7.04e-15 7.29e-12 0.43 0.35 Blood protein levels; chr11:117149754 chr11:117204967~117210292:+ LUSC cis rs3823536 0.583 rs7789423 ENSG00000275106.1 RP11-309L24.10 -8.04 7.14e-15 7.39e-12 -0.46 -0.35 Sjögren's syndrome; chr7:128981150 chr7:128952527~128953316:- LUSC cis rs3096299 0.933 rs3114848 ENSG00000274627.1 RP11-104N10.2 8.04 7.18e-15 7.42e-12 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89386363 chr16:89516797~89522217:+ LUSC cis rs1061377 1 rs9996285 ENSG00000249207.1 RP11-360F5.1 -8.04 7.18e-15 7.42e-12 -0.36 -0.35 Uric acid levels; chr4:39130556 chr4:39112677~39126818:- LUSC cis rs2283792 0.73 rs738858 ENSG00000228050.1 TOP3BP1 8.04 7.22e-15 7.47e-12 0.41 0.35 Multiple sclerosis; chr22:21926544 chr22:22223187~22224566:- LUSC cis rs1061377 1 rs9990742 ENSG00000249207.1 RP11-360F5.1 -8.04 7.25e-15 7.49e-12 -0.37 -0.35 Uric acid levels; chr4:39119794 chr4:39112677~39126818:- LUSC cis rs11098499 0.913 rs68128210 ENSG00000249244.1 RP11-548H18.2 8.04 7.27e-15 7.51e-12 0.45 0.35 Corneal astigmatism; chr4:119216664 chr4:119391831~119395335:- LUSC cis rs35955747 0.902 rs5997932 ENSG00000236132.1 CTA-440B3.1 8.04 7.29e-15 7.53e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31272168 chr22:31816379~31817491:- LUSC cis rs7811142 1 rs11771241 ENSG00000242294.5 STAG3L5P 8.04 7.32e-15 7.56e-12 0.28 0.35 Platelet count; chr7:100397162 chr7:100336079~100351900:+ LUSC cis rs7617773 0.817 rs13072018 ENSG00000228638.1 FCF1P2 -8.04 7.33e-15 7.57e-12 -0.42 -0.35 Coronary artery disease; chr3:48278842 chr3:48290793~48291375:- LUSC cis rs35955747 0.902 rs7288643 ENSG00000236132.1 CTA-440B3.1 8.04 7.37e-15 7.61e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31283683 chr22:31816379~31817491:- LUSC cis rs6921919 0.583 rs1054372 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28368965 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs9468354 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28370024 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs7773051 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28372539 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs12697938 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28373322 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs13437294 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28373758 chr6:28176188~28176674:+ LUSC cis rs6921919 0.609 rs9468357 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28374276 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs34513104 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28375566 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs9461456 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28376039 chr6:28176188~28176674:+ LUSC cis rs6921919 0.525 rs9468360 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28376661 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs16894021 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28377249 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs11751693 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28377306 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs7749736 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28378254 chr6:28176188~28176674:+ LUSC cis rs6921919 0.525 rs9468361 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28378541 chr6:28176188~28176674:+ LUSC cis rs6921919 0.583 rs7775132 ENSG00000216901.1 AL022393.7 8.04 7.41e-15 7.65e-12 0.41 0.35 Autism spectrum disorder or schizophrenia; chr6:28379236 chr6:28176188~28176674:+ LUSC cis rs4660456 0.913 rs3754179 ENSG00000237899.1 RP4-739H11.3 -8.04 7.41e-15 7.65e-12 -0.49 -0.35 Platelet count; chr1:40768464 chr1:40669089~40687588:- LUSC cis rs12134133 0.688 rs6540875 ENSG00000274245.1 RP11-357P18.2 8.04 7.43e-15 7.67e-12 0.48 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207221686 chr1:207372559~207373252:+ LUSC cis rs11098499 0.908 rs2017057 ENSG00000249244.1 RP11-548H18.2 8.04 7.43e-15 7.67e-12 0.45 0.35 Corneal astigmatism; chr4:119336556 chr4:119391831~119395335:- LUSC cis rs875971 0.862 rs1167390 ENSG00000222364.1 RNU6-96P 8.04 7.52e-15 7.76e-12 0.41 0.35 Aortic root size; chr7:66110906 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs35034167 ENSG00000222364.1 RNU6-96P 8.04 7.52e-15 7.76e-12 0.41 0.35 Aortic root size; chr7:66115179 chr7:66395191~66395286:+ LUSC cis rs2108622 0.958 rs56340170 ENSG00000267453.5 AC004791.2 -8.04 7.53e-15 7.77e-12 -0.49 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871067 chr19:15851993~15864904:- LUSC cis rs6452524 0.935 rs2386241 ENSG00000249664.1 CTD-2227C6.2 -8.04 7.61e-15 7.85e-12 -0.37 -0.35 Hypertension (SNP x SNP interaction); chr5:83149872 chr5:83012285~83013109:- LUSC cis rs9487094 0.961 rs9480957 ENSG00000260273.1 RP11-425D10.10 8.03 7.63e-15 7.87e-12 0.42 0.35 Height; chr6:109430398 chr6:109382795~109383666:+ LUSC cis rs11098499 0.866 rs7665125 ENSG00000245958.5 RP11-33B1.1 -8.03 7.65e-15 7.88e-12 -0.34 -0.35 Corneal astigmatism; chr4:119480924 chr4:119454791~119552025:+ LUSC cis rs35955747 0.902 rs7288735 ENSG00000236132.1 CTA-440B3.1 8.03 7.69e-15 7.92e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31283560 chr22:31816379~31817491:- LUSC cis rs10129255 0.789 rs61997796 ENSG00000211970.3 IGHV4-61 -8.03 7.7e-15 7.94e-12 -0.25 -0.35 Kawasaki disease; chr14:106813798 chr14:106639119~106639657:- LUSC cis rs875971 1 rs2220626 ENSG00000222364.1 RNU6-96P 8.03 7.71e-15 7.95e-12 0.41 0.35 Aortic root size; chr7:66081075 chr7:66395191~66395286:+ LUSC cis rs7617773 0.817 rs11130163 ENSG00000228638.1 FCF1P2 -8.03 7.72e-15 7.96e-12 -0.4 -0.35 Coronary artery disease; chr3:48271168 chr3:48290793~48291375:- LUSC cis rs3096299 0.967 rs28575874 ENSG00000274627.1 RP11-104N10.2 8.03 7.76e-15 8e-12 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89403482 chr16:89516797~89522217:+ LUSC cis rs4713118 0.662 rs9380046 ENSG00000219392.1 RP1-265C24.5 -8.03 7.77e-15 8e-12 -0.48 -0.35 Parkinson's disease; chr6:28062721 chr6:28115628~28116551:+ LUSC cis rs1012068 0.624 rs4820997 ENSG00000236132.1 CTA-440B3.1 -8.03 7.8e-15 8.03e-12 -0.47 -0.35 Chronic hepatitis C infection; chr22:31928154 chr22:31816379~31817491:- LUSC cis rs3091242 1 rs646867 ENSG00000224183.1 SDHDP6 -8.03 7.82e-15 8.05e-12 -0.42 -0.35 Erythrocyte sedimentation rate; chr1:25382767 chr1:25294164~25294643:- LUSC cis rs1577917 0.545 rs9450325 ENSG00000203875.9 SNHG5 8.03 7.82e-15 8.06e-12 0.46 0.35 Response to antipsychotic treatment; chr6:85766096 chr6:85660950~85678736:- LUSC cis rs8072100 0.935 rs12150231 ENSG00000228782.6 CTD-2026D20.3 -8.03 7.86e-15 8.09e-12 -0.33 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47639725 chr17:47450568~47492492:- LUSC cis rs8072100 1 rs8065437 ENSG00000228782.6 CTD-2026D20.3 8.03 7.86e-15 8.09e-12 0.33 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47644287 chr17:47450568~47492492:- LUSC cis rs9487094 0.6 rs9372213 ENSG00000260273.1 RP11-425D10.10 8.03 7.91e-15 8.14e-12 0.4 0.35 Height; chr6:109370985 chr6:109382795~109383666:+ LUSC cis rs9322193 0.887 rs3777949 ENSG00000223701.3 RAET1E-AS1 8.03 7.92e-15 8.15e-12 0.41 0.35 Lung cancer; chr6:149596021 chr6:149884431~149919508:+ LUSC cis rs4713118 0.662 rs149900 ENSG00000219392.1 RP1-265C24.5 -8.03 7.97e-15 8.2e-12 -0.48 -0.35 Parkinson's disease; chr6:28046819 chr6:28115628~28116551:+ LUSC cis rs9322193 0.923 rs4870267 ENSG00000223701.3 RAET1E-AS1 8.03 7.98e-15 8.21e-12 0.4 0.35 Lung cancer; chr6:149671572 chr6:149884431~149919508:+ LUSC cis rs6991838 0.725 rs6995134 ENSG00000272010.1 CTD-3025N20.3 8.03 7.98e-15 8.21e-12 0.39 0.35 Intelligence (multi-trait analysis); chr8:65555472 chr8:65591850~65592472:- LUSC cis rs9487094 0.744 rs13199519 ENSG00000260273.1 RP11-425D10.10 8.03 7.99e-15 8.22e-12 0.45 0.35 Height; chr6:109387972 chr6:109382795~109383666:+ LUSC cis rs6142102 0.602 rs2268086 ENSG00000276073.1 RP5-1125A11.7 8.03 8e-15 8.23e-12 0.34 0.35 Skin pigmentation; chr20:34060932 chr20:33985617~33988989:- LUSC cis rs12439619 0.508 rs8042665 ENSG00000278603.1 RP13-608F4.5 8.03 8e-15 8.23e-12 0.43 0.35 Intelligence (multi-trait analysis); chr15:82189008 chr15:82472203~82472426:+ LUSC cis rs10129255 0.518 rs10136903 ENSG00000211970.3 IGHV4-61 -8.03 8.02e-15 8.25e-12 -0.22 -0.35 Kawasaki disease; chr14:106778866 chr14:106639119~106639657:- LUSC cis rs8072100 1 rs4375701 ENSG00000228782.6 CTD-2026D20.3 8.03 8.06e-15 8.29e-12 0.33 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47634852 chr17:47450568~47492492:- LUSC cis rs3096299 0.933 rs747485 ENSG00000274627.1 RP11-104N10.2 8.03 8.12e-15 8.35e-12 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89407686 chr16:89516797~89522217:+ LUSC cis rs3091242 0.804 rs631133 ENSG00000224183.1 SDHDP6 -8.03 8.14e-15 8.37e-12 -0.43 -0.35 Erythrocyte sedimentation rate; chr1:25397655 chr1:25294164~25294643:- LUSC cis rs6921919 0.887 rs16894116 ENSG00000204709.4 LINC01556 8.03 8.15e-15 8.38e-12 0.51 0.35 Autism spectrum disorder or schizophrenia; chr6:28447190 chr6:28943877~28944537:+ LUSC cis rs765787 0.505 rs12593605 ENSG00000259520.4 CTD-2651B20.3 -8.03 8.16e-15 8.39e-12 -0.45 -0.35 Uric acid levels; chr15:45205250 chr15:45251580~45279251:- LUSC cis rs11118620 0.81 rs1603047 ENSG00000272823.1 RP11-295M18.6 8.03 8.18e-15 8.41e-12 0.43 0.35 Heart failure; chr1:220849953 chr1:220828676~220829211:- LUSC cis rs5769707 0.967 rs9616713 ENSG00000235111.1 RP1-29C18.8 -8.03 8.18e-15 8.41e-12 -0.4 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49655461 chr22:49612657~49615716:- LUSC cis rs801193 0.66 rs2659914 ENSG00000222364.1 RNU6-96P -8.02 8.2e-15 8.42e-12 -0.41 -0.35 Aortic root size; chr7:66691927 chr7:66395191~66395286:+ LUSC cis rs8059260 0.604 rs11863415 ENSG00000274038.1 RP11-66H6.4 -8.02 8.22e-15 8.45e-12 -0.56 -0.35 Alcohol consumption over the past year; chr16:11053237 chr16:11056556~11057034:+ LUSC cis rs35955747 0.869 rs8143002 ENSG00000236132.1 CTA-440B3.1 8.02 8.23e-15 8.45e-12 0.42 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31191205 chr22:31816379~31817491:- LUSC cis rs7945705 0.782 rs2742545 ENSG00000254860.4 TMEM9B-AS1 8.02 8.31e-15 8.53e-12 0.38 0.35 Hemoglobin concentration; chr11:8862761 chr11:8964675~8977527:+ LUSC cis rs7945705 0.84 rs10840136 ENSG00000254860.4 TMEM9B-AS1 8.02 8.31e-15 8.53e-12 0.38 0.35 Hemoglobin concentration; chr11:8863477 chr11:8964675~8977527:+ LUSC cis rs7811142 1 rs4472444 ENSG00000242294.5 STAG3L5P 8.02 8.32e-15 8.54e-12 0.27 0.35 Platelet count; chr7:100473135 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs7809801 ENSG00000242294.5 STAG3L5P 8.02 8.32e-15 8.54e-12 0.27 0.35 Platelet count; chr7:100474408 chr7:100336079~100351900:+ LUSC cis rs9322193 0.607 rs12527391 ENSG00000223701.3 RAET1E-AS1 8.02 8.36e-15 8.58e-12 0.46 0.35 Lung cancer; chr6:149882156 chr6:149884431~149919508:+ LUSC cis rs10129255 0.917 rs7142373 ENSG00000211972.2 IGHV3-66 8.02 8.41e-15 8.63e-12 0.27 0.35 Kawasaki disease; chr14:106708947 chr14:106675017~106675544:- LUSC cis rs10129255 0.957 rs8009638 ENSG00000211970.3 IGHV4-61 -8.02 8.45e-15 8.66e-12 -0.25 -0.35 Kawasaki disease; chr14:106777570 chr14:106639119~106639657:- LUSC cis rs9487094 0.813 rs3799840 ENSG00000260273.1 RP11-425D10.10 8.02 8.49e-15 8.7e-12 0.45 0.35 Height; chr6:109381443 chr6:109382795~109383666:+ LUSC cis rs9487094 0.744 rs2275652 ENSG00000260273.1 RP11-425D10.10 8.02 8.49e-15 8.7e-12 0.45 0.35 Height; chr6:109382480 chr6:109382795~109383666:+ LUSC cis rs2280018 0.526 rs1510148 ENSG00000260735.1 RP11-72I8.1 -8.02 8.5e-15 8.71e-12 -0.43 -0.35 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15073522 chr16:15094411~15109197:+ LUSC cis rs17023223 0.537 rs12092807 ENSG00000231365.4 RP11-418J17.1 8.02 8.51e-15 8.72e-12 0.44 0.35 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119208021 chr1:119140396~119275973:+ LUSC cis rs3091242 1 rs3091242 ENSG00000224183.1 SDHDP6 -8.02 8.52e-15 8.73e-12 -0.43 -0.35 Erythrocyte sedimentation rate; chr1:25348294 chr1:25294164~25294643:- LUSC cis rs4927850 0.666 rs4927853 ENSG00000231464.1 AC024937.4 8.02 8.52e-15 8.73e-12 0.38 0.35 Pancreatic cancer; chr3:196025182 chr3:195996738~195998233:+ LUSC cis rs7811142 1 rs7803454 ENSG00000242294.5 STAG3L5P 8.02 8.54e-15 8.75e-12 0.29 0.35 Platelet count; chr7:100393925 chr7:100336079~100351900:+ LUSC cis rs7811142 0.943 rs11769886 ENSG00000242294.5 STAG3L5P 8.02 8.54e-15 8.75e-12 0.29 0.35 Platelet count; chr7:100400984 chr7:100336079~100351900:+ LUSC cis rs80285556 1 rs79602855 ENSG00000161643.11 SIGLEC16 8.02 8.57e-15 8.78e-12 0.79 0.35 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50022468 chr19:49969673~49975814:+ LUSC cis rs11098499 0.863 rs10004484 ENSG00000245958.5 RP11-33B1.1 -8.02 8.65e-15 8.85e-12 -0.36 -0.35 Corneal astigmatism; chr4:119521273 chr4:119454791~119552025:+ LUSC cis rs801193 0.66 rs1962050 ENSG00000222364.1 RNU6-96P 8.02 8.65e-15 8.86e-12 0.4 0.35 Aortic root size; chr7:66775021 chr7:66395191~66395286:+ LUSC cis rs4660456 0.913 rs6661855 ENSG00000237899.1 RP4-739H11.3 8.02 8.72e-15 8.93e-12 0.49 0.35 Platelet count; chr1:40703245 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs7542019 ENSG00000237899.1 RP4-739H11.3 8.02 8.72e-15 8.93e-12 0.49 0.35 Platelet count; chr1:40704039 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs1494 ENSG00000237899.1 RP4-739H11.3 8.02 8.72e-15 8.93e-12 0.49 0.35 Platelet count; chr1:40706176 chr1:40669089~40687588:- LUSC cis rs4660456 0.83 rs12566786 ENSG00000237899.1 RP4-739H11.3 -8.02 8.74e-15 8.95e-12 -0.48 -0.35 Platelet count; chr1:40742709 chr1:40669089~40687588:- LUSC cis rs4660456 0.871 rs2274957 ENSG00000237899.1 RP4-739H11.3 -8.02 8.74e-15 8.95e-12 -0.48 -0.35 Platelet count; chr1:40747290 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs4660173 ENSG00000237899.1 RP4-739H11.3 -8.02 8.74e-15 8.95e-12 -0.48 -0.35 Platelet count; chr1:40747876 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs4660452 ENSG00000237899.1 RP4-739H11.3 -8.02 8.74e-15 8.95e-12 -0.48 -0.35 Platelet count; chr1:40748519 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs12567925 ENSG00000237899.1 RP4-739H11.3 -8.02 8.74e-15 8.95e-12 -0.48 -0.35 Platelet count; chr1:40751428 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs12728776 ENSG00000237899.1 RP4-739H11.3 -8.02 8.74e-15 8.95e-12 -0.48 -0.35 Platelet count; chr1:40751718 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs12567755 ENSG00000237899.1 RP4-739H11.3 -8.02 8.74e-15 8.95e-12 -0.48 -0.35 Platelet count; chr1:40751813 chr1:40669089~40687588:- LUSC cis rs17608059 1 rs17608059 ENSG00000141028.6 CDRT15P1 -8.02 8.74e-15 8.95e-12 -0.37 -0.35 Temperament; chr17:14007232 chr17:14024514~14025488:+ LUSC cis rs11098499 0.954 rs12508504 ENSG00000249244.1 RP11-548H18.2 8.02 8.77e-15 8.98e-12 0.44 0.35 Corneal astigmatism; chr4:119489452 chr4:119391831~119395335:- LUSC cis rs11118620 1 rs11118620 ENSG00000272823.1 RP11-295M18.6 8.02 8.78e-15 8.98e-12 0.43 0.35 Heart failure; chr1:220855166 chr1:220828676~220829211:- LUSC cis rs10129255 0.957 rs10132367 ENSG00000211972.2 IGHV3-66 8.01 8.83e-15 9.04e-12 0.26 0.35 Kawasaki disease; chr14:106690981 chr14:106675017~106675544:- LUSC cis rs10129255 0.536 rs10142951 ENSG00000211970.3 IGHV4-61 -8.01 8.85e-15 9.06e-12 -0.22 -0.35 Kawasaki disease; chr14:106782337 chr14:106639119~106639657:- LUSC cis rs7945705 0.869 rs7925728 ENSG00000254860.4 TMEM9B-AS1 8.01 8.86e-15 9.07e-12 0.38 0.35 Hemoglobin concentration; chr11:8991455 chr11:8964675~8977527:+ LUSC cis rs1075265 0.528 rs2018747 ENSG00000233266.1 HMGB1P31 8.01 8.86e-15 9.07e-12 0.43 0.35 Chronotype;Morning vs. evening chronotype; chr2:54082487 chr2:54051334~54051760:+ LUSC cis rs7811142 0.775 rs1059129 ENSG00000242294.5 STAG3L5P 8.01 8.87e-15 9.07e-12 0.28 0.35 Platelet count; chr7:100328899 chr7:100336079~100351900:+ LUSC cis rs875971 0.862 rs1612452 ENSG00000222364.1 RNU6-96P 8.01 8.89e-15 9.09e-12 0.41 0.35 Aortic root size; chr7:66108909 chr7:66395191~66395286:+ LUSC cis rs10129255 0.5 rs8021941 ENSG00000211970.3 IGHV4-61 -8.01 8.9e-15 9.1e-12 -0.22 -0.35 Kawasaki disease; chr14:106781490 chr14:106639119~106639657:- LUSC cis rs10129255 0.5 rs10142931 ENSG00000211970.3 IGHV4-61 -8.01 8.9e-15 9.1e-12 -0.22 -0.35 Kawasaki disease; chr14:106782288 chr14:106639119~106639657:- LUSC cis rs4713118 0.662 rs149961 ENSG00000219392.1 RP1-265C24.5 -8.01 8.9e-15 9.1e-12 -0.48 -0.35 Parkinson's disease; chr6:28047791 chr6:28115628~28116551:+ LUSC cis rs1061377 1 rs3796509 ENSG00000249207.1 RP11-360F5.1 -8.01 8.91e-15 9.11e-12 -0.37 -0.35 Uric acid levels; chr4:39108566 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs4974998 ENSG00000249207.1 RP11-360F5.1 -8.01 8.91e-15 9.11e-12 -0.37 -0.35 Uric acid levels; chr4:39109129 chr4:39112677~39126818:- LUSC cis rs1061377 1 rs7673299 ENSG00000249207.1 RP11-360F5.1 -8.01 8.91e-15 9.11e-12 -0.37 -0.35 Uric acid levels; chr4:39109138 chr4:39112677~39126818:- LUSC cis rs7684253 0.587 rs2002154 ENSG00000269949.1 RP11-738E22.3 -8.01 8.96e-15 9.16e-12 -0.42 -0.35 Migraine; chr4:56879851 chr4:56960927~56961373:- LUSC cis rs9601248 0.838 rs6563121 ENSG00000227676.3 LINC01068 -8.01 8.97e-15 9.17e-12 -0.42 -0.35 Major depressive disorder; chr13:79600865 chr13:79566727~79571436:+ LUSC cis rs11098499 0.913 rs10010696 ENSG00000249244.1 RP11-548H18.2 8.01 9.01e-15 9.21e-12 0.45 0.35 Corneal astigmatism; chr4:119243148 chr4:119391831~119395335:- LUSC cis rs5769707 0.935 rs9616332 ENSG00000235111.1 RP1-29C18.8 -8.01 9.02e-15 9.21e-12 -0.4 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49654030 chr22:49612657~49615716:- LUSC cis rs8040855 0.86 rs6496775 ENSG00000259295.5 CSPG4P12 -8.01 9.03e-15 9.23e-12 -0.44 -0.35 Bulimia nervosa; chr15:85164910 chr15:85191438~85213905:+ LUSC cis rs765787 0.53 rs12909987 ENSG00000259520.4 CTD-2651B20.3 8.01 9.07e-15 9.26e-12 0.43 0.35 Uric acid levels; chr15:45220009 chr15:45251580~45279251:- LUSC cis rs12280210 0.557 rs7112937 ENSG00000254851.1 RP11-109L13.1 8.01 9.08e-15 9.27e-12 0.64 0.35 Lobe attachment (rater-scored or self-reported); chr11:117009740 chr11:117135528~117138582:+ LUSC cis rs7811142 0.943 rs28660238 ENSG00000242294.5 STAG3L5P 8.01 9.09e-15 9.28e-12 0.27 0.35 Platelet count; chr7:100425685 chr7:100336079~100351900:+ LUSC cis rs9322193 0.923 rs9322208 ENSG00000223701.3 RAET1E-AS1 8.01 9.13e-15 9.32e-12 0.4 0.35 Lung cancer; chr6:149658547 chr6:149884431~149919508:+ LUSC cis rs11098499 0.954 rs4309825 ENSG00000249244.1 RP11-548H18.2 -8.01 9.13e-15 9.32e-12 -0.42 -0.35 Corneal astigmatism; chr4:119393726 chr4:119391831~119395335:- LUSC cis rs2108622 1 rs55744319 ENSG00000267453.5 AC004791.2 -8.01 9.14e-15 9.33e-12 -0.49 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871011 chr19:15851993~15864904:- LUSC cis rs9487094 0.813 rs3799835 ENSG00000260273.1 RP11-425D10.10 8.01 9.14e-15 9.33e-12 0.44 0.35 Height; chr6:109372084 chr6:109382795~109383666:+ LUSC cis rs9487094 0.813 rs11753645 ENSG00000260273.1 RP11-425D10.10 8.01 9.14e-15 9.33e-12 0.44 0.35 Height; chr6:109373851 chr6:109382795~109383666:+ LUSC cis rs9487094 0.813 rs34131679 ENSG00000260273.1 RP11-425D10.10 8.01 9.14e-15 9.33e-12 0.44 0.35 Height; chr6:109375848 chr6:109382795~109383666:+ LUSC cis rs3091242 0.967 rs1053438 ENSG00000224183.1 SDHDP6 8.01 9.16e-15 9.35e-12 0.42 0.35 Erythrocyte sedimentation rate; chr1:25361410 chr1:25294164~25294643:- LUSC cis rs2739330 0.796 rs2154594 ENSG00000235689.1 AP000351.13 -8.01 9.19e-15 9.38e-12 -0.36 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:24006305~24008258:- LUSC cis rs9322193 1 rs9377228 ENSG00000223701.3 RAET1E-AS1 8.01 9.23e-15 9.42e-12 0.4 0.35 Lung cancer; chr6:149600862 chr6:149884431~149919508:+ LUSC cis rs2283792 0.967 rs743409 ENSG00000228050.1 TOP3BP1 8.01 9.24e-15 9.43e-12 0.4 0.35 Multiple sclerosis; chr22:21774926 chr22:22223187~22224566:- LUSC cis rs3091242 0.967 rs665372 ENSG00000224183.1 SDHDP6 -8.01 9.24e-15 9.43e-12 -0.42 -0.35 Erythrocyte sedimentation rate; chr1:25392744 chr1:25294164~25294643:- LUSC cis rs992157 0.71 rs13026485 ENSG00000261338.2 RP11-378A13.1 -8.01 9.28e-15 9.47e-12 -0.34 -0.35 Colorectal cancer; chr2:218193261 chr2:218255319~218257366:+ LUSC cis rs9322193 0.884 rs1108889 ENSG00000223701.3 RAET1E-AS1 8.01 9.3e-15 9.49e-12 0.4 0.35 Lung cancer; chr6:149845433 chr6:149884431~149919508:+ LUSC cis rs694739 0.628 rs11606081 ENSG00000236935.1 AP003774.1 8.01 9.31e-15 9.5e-12 0.34 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64370403 chr11:64325050~64329504:- LUSC cis rs1012068 0.662 rs5753816 ENSG00000236132.1 CTA-440B3.1 -8.01 9.4e-15 9.59e-12 -0.45 -0.35 Chronic hepatitis C infection; chr22:31916856 chr22:31816379~31817491:- LUSC cis rs5769707 0.681 rs739236 ENSG00000235111.1 RP1-29C18.8 -8 9.5e-15 9.68e-12 -0.44 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49647954 chr22:49612657~49615716:- LUSC cis rs5769707 0.681 rs1107514 ENSG00000235111.1 RP1-29C18.8 -8 9.5e-15 9.68e-12 -0.44 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49648735 chr22:49612657~49615716:- LUSC cis rs5769707 0.632 rs1476037 ENSG00000235111.1 RP1-29C18.8 -8 9.54e-15 9.72e-12 -0.42 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49597729 chr22:49612657~49615716:- LUSC cis rs5769707 0.837 rs5769709 ENSG00000235111.1 RP1-29C18.8 -8 9.55e-15 9.73e-12 -0.39 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49628109 chr22:49612657~49615716:- LUSC cis rs10129255 0.833 rs7156689 ENSG00000224373.3 IGHV4-59 8 9.56e-15 9.74e-12 0.2 0.35 Kawasaki disease; chr14:106816039 chr14:106627249~106627825:- LUSC cis rs4660456 0.869 rs7518344 ENSG00000237899.1 RP4-739H11.3 8 9.57e-15 9.75e-12 0.49 0.35 Platelet count; chr1:40708327 chr1:40669089~40687588:- LUSC cis rs11155671 0.53 rs7758033 ENSG00000268592.3 RAET1E-AS1 8 9.66e-15 9.84e-12 0.42 0.35 Testicular germ cell tumor; chr6:149886999 chr6:149863494~149919507:+ LUSC cis rs9487094 0.614 rs11968978 ENSG00000260273.1 RP11-425D10.10 8 9.68e-15 9.86e-12 0.46 0.35 Height; chr6:109775693 chr6:109382795~109383666:+ LUSC cis rs11098499 0.955 rs35434465 ENSG00000249244.1 RP11-548H18.2 8 9.69e-15 9.87e-12 0.45 0.35 Corneal astigmatism; chr4:119248223 chr4:119391831~119395335:- LUSC cis rs748404 0.631 rs6493083 ENSG00000249839.1 AC011330.5 -8 9.69e-15 9.87e-12 -0.47 -0.35 Lung cancer; chr15:43345787 chr15:43663654~43684339:- LUSC cis rs11098499 1 rs10029750 ENSG00000249244.1 RP11-548H18.2 8 9.7e-15 9.87e-12 0.44 0.35 Corneal astigmatism; chr4:119251388 chr4:119391831~119395335:- LUSC cis rs7617773 0.78 rs11718350 ENSG00000228638.1 FCF1P2 -8 9.83e-15 1e-11 -0.41 -0.35 Coronary artery disease; chr3:48319502 chr3:48290793~48291375:- LUSC cis rs1075265 0.633 rs3731967 ENSG00000233266.1 HMGB1P31 -8 9.89e-15 1.01e-11 -0.44 -0.35 Chronotype;Morning vs. evening chronotype; chr2:53975311 chr2:54051334~54051760:+ LUSC cis rs10129255 0.957 rs8014696 ENSG00000211972.2 IGHV3-66 -8 9.95e-15 1.01e-11 -0.26 -0.35 Kawasaki disease; chr14:106769752 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs6576225 ENSG00000211970.3 IGHV4-61 -8 9.98e-15 1.02e-11 -0.22 -0.35 Kawasaki disease; chr14:106778120 chr14:106639119~106639657:- LUSC cis rs10129255 0.5 rs6576226 ENSG00000211970.3 IGHV4-61 -8 9.98e-15 1.02e-11 -0.22 -0.35 Kawasaki disease; chr14:106778135 chr14:106639119~106639657:- LUSC cis rs10129255 0.5 rs8022547 ENSG00000211970.3 IGHV4-61 -8 1e-14 1.02e-11 -0.22 -0.35 Kawasaki disease; chr14:106781985 chr14:106639119~106639657:- LUSC cis rs10129255 0.5 rs8006888 ENSG00000211970.3 IGHV4-61 -8 1e-14 1.02e-11 -0.22 -0.35 Kawasaki disease; chr14:106782219 chr14:106639119~106639657:- LUSC cis rs7811142 0.83 rs6948685 ENSG00000242294.5 STAG3L5P 8 1e-14 1.02e-11 0.28 0.35 Platelet count; chr7:100372565 chr7:100336079~100351900:+ LUSC cis rs9322193 0.923 rs9689716 ENSG00000223701.3 RAET1E-AS1 8 1.01e-14 1.02e-11 0.4 0.35 Lung cancer; chr6:149655662 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9322207 ENSG00000223701.3 RAET1E-AS1 8 1.01e-14 1.02e-11 0.4 0.35 Lung cancer; chr6:149657185 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9968911 ENSG00000223701.3 RAET1E-AS1 8 1.01e-14 1.02e-11 0.4 0.35 Lung cancer; chr6:149657419 chr6:149884431~149919508:+ LUSC cis rs17711722 0.523 rs365896 ENSG00000224316.1 RP11-479O9.2 -8 1.01e-14 1.03e-11 -0.33 -0.35 Calcium levels; chr7:66045710 chr7:65773620~65802067:+ LUSC cis rs8072100 0.905 rs8077106 ENSG00000228782.6 CTD-2026D20.3 -8 1.01e-14 1.03e-11 -0.33 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47575925 chr17:47450568~47492492:- LUSC cis rs8072100 0.754 rs8081717 ENSG00000228782.6 CTD-2026D20.3 -8 1.01e-14 1.03e-11 -0.33 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47576555 chr17:47450568~47492492:- LUSC cis rs4713118 0.662 rs149947 ENSG00000219392.1 RP1-265C24.5 -7.99 1.02e-14 1.03e-11 -0.47 -0.35 Parkinson's disease; chr6:28004655 chr6:28115628~28116551:+ LUSC cis rs4713118 0.629 rs203890 ENSG00000219392.1 RP1-265C24.5 -7.99 1.02e-14 1.03e-11 -0.48 -0.35 Parkinson's disease; chr6:28054470 chr6:28115628~28116551:+ LUSC cis rs526231 0.511 rs3756582 ENSG00000175749.11 EIF3KP1 7.99 1.02e-14 1.03e-11 0.42 0.35 Primary biliary cholangitis; chr5:103003848 chr5:103032376~103033031:+ LUSC cis rs4713118 0.629 rs203889 ENSG00000219392.1 RP1-265C24.5 -7.99 1.02e-14 1.03e-11 -0.47 -0.35 Parkinson's disease; chr6:28053997 chr6:28115628~28116551:+ LUSC cis rs11098499 0.913 rs11098496 ENSG00000249244.1 RP11-548H18.2 7.99 1.02e-14 1.04e-11 0.44 0.35 Corneal astigmatism; chr4:119246311 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs35197422 ENSG00000249244.1 RP11-548H18.2 7.99 1.02e-14 1.04e-11 0.44 0.35 Corneal astigmatism; chr4:119248159 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs1511015 ENSG00000249244.1 RP11-548H18.2 7.99 1.02e-14 1.04e-11 0.44 0.35 Corneal astigmatism; chr4:119249318 chr4:119391831~119395335:- LUSC cis rs11089937 0.857 rs5750578 ENSG00000211639.2 IGLV4-60 7.99 1.02e-14 1.04e-11 0.33 0.35 Periodontitis (PAL4Q3); chr22:22136444 chr22:22162199~22162681:+ LUSC cis rs2739330 0.732 rs5760175 ENSG00000099984.9 GSTT2 -7.99 1.03e-14 1.04e-11 -0.41 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23980123~23983911:+ LUSC cis rs7811142 0.943 rs67196635 ENSG00000242294.5 STAG3L5P 7.99 1.03e-14 1.05e-11 0.27 0.35 Platelet count; chr7:100427941 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs6962151 ENSG00000242294.5 STAG3L5P 7.99 1.03e-14 1.05e-11 0.27 0.35 Platelet count; chr7:100430861 chr7:100336079~100351900:+ LUSC cis rs7811142 0.943 rs67483801 ENSG00000242294.5 STAG3L5P 7.99 1.03e-14 1.05e-11 0.27 0.35 Platelet count; chr7:100434135 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs11761784 ENSG00000242294.5 STAG3L5P 7.99 1.03e-14 1.05e-11 0.27 0.35 Platelet count; chr7:100442347 chr7:100336079~100351900:+ LUSC cis rs10463554 0.963 rs26262 ENSG00000175749.11 EIF3KP1 7.99 1.04e-14 1.05e-11 0.41 0.35 Parkinson's disease; chr5:103209462 chr5:103032376~103033031:+ LUSC cis rs10129255 0.5 rs6576230 ENSG00000211970.3 IGHV4-61 -7.99 1.04e-14 1.05e-11 -0.22 -0.35 Kawasaki disease; chr14:106778539 chr14:106639119~106639657:- LUSC cis rs8059260 0.604 rs76969865 ENSG00000274038.1 RP11-66H6.4 -7.99 1.05e-14 1.06e-11 -0.58 -0.35 Alcohol consumption over the past year; chr16:11050092 chr16:11056556~11057034:+ LUSC cis rs11098499 0.754 rs1814813 ENSG00000249244.1 RP11-548H18.2 -7.99 1.05e-14 1.07e-11 -0.42 -0.35 Corneal astigmatism; chr4:119337052 chr4:119391831~119395335:- LUSC cis rs9322193 0.607 rs3798763 ENSG00000223701.3 RAET1E-AS1 7.99 1.05e-14 1.07e-11 0.45 0.35 Lung cancer; chr6:149889964 chr6:149884431~149919508:+ LUSC cis rs9322193 0.607 rs12204653 ENSG00000223701.3 RAET1E-AS1 7.99 1.05e-14 1.07e-11 0.45 0.35 Lung cancer; chr6:149891885 chr6:149884431~149919508:+ LUSC cis rs11098499 0.82 rs13122709 ENSG00000245958.5 RP11-33B1.1 -7.99 1.06e-14 1.07e-11 -0.35 -0.35 Corneal astigmatism; chr4:119634201 chr4:119454791~119552025:+ LUSC cis rs12439619 0.508 rs8023960 ENSG00000278603.1 RP13-608F4.5 7.99 1.06e-14 1.07e-11 0.43 0.35 Intelligence (multi-trait analysis); chr15:82206704 chr15:82472203~82472426:+ LUSC cis rs11098499 0.954 rs6834796 ENSG00000249244.1 RP11-548H18.2 7.99 1.06e-14 1.07e-11 0.44 0.35 Corneal astigmatism; chr4:119493538 chr4:119391831~119395335:- LUSC cis rs9322193 0.923 rs9800580 ENSG00000223701.3 RAET1E-AS1 7.99 1.06e-14 1.08e-11 0.4 0.35 Lung cancer; chr6:149632845 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs11155669 ENSG00000223701.3 RAET1E-AS1 7.99 1.06e-14 1.08e-11 0.4 0.35 Lung cancer; chr6:149633501 chr6:149884431~149919508:+ LUSC cis rs9322193 0.887 rs9505824 ENSG00000223701.3 RAET1E-AS1 7.99 1.06e-14 1.08e-11 0.4 0.35 Lung cancer; chr6:149633663 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9505826 ENSG00000223701.3 RAET1E-AS1 7.99 1.06e-14 1.08e-11 0.4 0.35 Lung cancer; chr6:149633912 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9766886 ENSG00000223701.3 RAET1E-AS1 7.99 1.06e-14 1.08e-11 0.4 0.35 Lung cancer; chr6:149637048 chr6:149884431~149919508:+ LUSC cis rs7739264 0.544 rs6456266 ENSG00000237404.1 RP3-471C18.2 -7.99 1.07e-14 1.08e-11 -0.39 -0.35 Endometriosis; chr6:19791053 chr6:19689825~19753113:- LUSC cis rs35955747 0.838 rs5997900 ENSG00000236132.1 CTA-440B3.1 7.99 1.07e-14 1.09e-11 0.41 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31184360 chr22:31816379~31817491:- LUSC cis rs148406912 1 rs148406912 ENSG00000254851.1 RP11-109L13.1 7.99 1.07e-14 1.09e-11 0.68 0.35 Lobe attachment (rater-scored or self-reported); chr11:116967001 chr11:117135528~117138582:+ LUSC cis rs904251 0.504 rs12202664 ENSG00000204110.6 RP1-153P14.8 -7.99 1.07e-14 1.09e-11 -0.33 -0.35 Cognitive performance; chr6:37513422 chr6:37507348~37535616:+ LUSC cis rs11098499 0.954 rs7681544 ENSG00000249244.1 RP11-548H18.2 7.99 1.07e-14 1.09e-11 0.44 0.35 Corneal astigmatism; chr4:119490100 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs11940028 ENSG00000249244.1 RP11-548H18.2 7.99 1.07e-14 1.09e-11 0.44 0.35 Corneal astigmatism; chr4:119490752 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs11935596 ENSG00000249244.1 RP11-548H18.2 7.99 1.07e-14 1.09e-11 0.44 0.35 Corneal astigmatism; chr4:119491302 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs12507964 ENSG00000249244.1 RP11-548H18.2 7.99 1.07e-14 1.09e-11 0.44 0.35 Corneal astigmatism; chr4:119491906 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs11098530 ENSG00000249244.1 RP11-548H18.2 7.99 1.07e-14 1.09e-11 0.44 0.35 Corneal astigmatism; chr4:119491999 chr4:119391831~119395335:- LUSC cis rs10129255 0.518 rs8009594 ENSG00000211970.3 IGHV4-61 -7.99 1.08e-14 1.09e-11 -0.22 -0.35 Kawasaki disease; chr14:106777494 chr14:106639119~106639657:- LUSC cis rs10129255 0.518 rs8009612 ENSG00000211970.3 IGHV4-61 -7.99 1.08e-14 1.09e-11 -0.22 -0.35 Kawasaki disease; chr14:106777510 chr14:106639119~106639657:- LUSC cis rs10129255 0.784 rs7147210 ENSG00000211972.2 IGHV3-66 7.99 1.08e-14 1.09e-11 0.27 0.35 Kawasaki disease; chr14:106705271 chr14:106675017~106675544:- LUSC cis rs10129255 0.826 rs7150693 ENSG00000211972.2 IGHV3-66 7.99 1.08e-14 1.09e-11 0.27 0.35 Kawasaki disease; chr14:106705382 chr14:106675017~106675544:- LUSC cis rs10129255 0.869 rs7150549 ENSG00000211972.2 IGHV3-66 7.99 1.08e-14 1.09e-11 0.27 0.35 Kawasaki disease; chr14:106705441 chr14:106675017~106675544:- LUSC cis rs2117029 0.555 rs10783304 ENSG00000258017.1 RP11-386G11.10 -7.99 1.08e-14 1.1e-11 -0.45 -0.35 Intelligence (multi-trait analysis); chr12:49106615 chr12:49127782~49147869:+ LUSC cis rs7811142 1 rs28490152 ENSG00000242294.5 STAG3L5P 7.98 1.09e-14 1.1e-11 0.27 0.35 Platelet count; chr7:100423359 chr7:100336079~100351900:+ LUSC cis rs7617773 0.694 rs13099560 ENSG00000228638.1 FCF1P2 7.98 1.09e-14 1.11e-11 0.39 0.35 Coronary artery disease; chr3:48163278 chr3:48290793~48291375:- LUSC cis rs2108622 1 rs62107762 ENSG00000267453.5 AC004791.2 -7.98 1.09e-14 1.11e-11 -0.48 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871728 chr19:15851993~15864904:- LUSC cis rs9322193 0.607 rs6557165 ENSG00000216906.2 RP11-350J20.9 -7.98 1.1e-14 1.11e-11 -0.45 -0.35 Lung cancer; chr6:149906883 chr6:149904243~149906418:+ LUSC cis rs9322193 0.961 rs9285521 ENSG00000223701.3 RAET1E-AS1 7.98 1.1e-14 1.11e-11 0.4 0.35 Lung cancer; chr6:149585576 chr6:149884431~149919508:+ LUSC cis rs17711722 0.565 rs73372653 ENSG00000224316.1 RP11-479O9.2 7.98 1.1e-14 1.11e-11 0.34 0.35 Calcium levels; chr7:65977808 chr7:65773620~65802067:+ LUSC cis rs12134133 0.719 rs6696142 ENSG00000274245.1 RP11-357P18.2 7.98 1.1e-14 1.12e-11 0.48 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207228898 chr1:207372559~207373252:+ LUSC cis rs12134133 0.752 rs57003024 ENSG00000274245.1 RP11-357P18.2 7.98 1.1e-14 1.12e-11 0.48 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207230999 chr1:207372559~207373252:+ LUSC cis rs10829156 0.699 rs6482516 ENSG00000240291.1 RP11-499P20.2 7.98 1.1e-14 1.12e-11 0.36 0.35 Sudden cardiac arrest; chr10:18550421 chr10:18513115~18545651:- LUSC cis rs10829156 0.66 rs11014830 ENSG00000240291.1 RP11-499P20.2 7.98 1.1e-14 1.12e-11 0.36 0.35 Sudden cardiac arrest; chr10:18551504 chr10:18513115~18545651:- LUSC cis rs10129255 0.957 rs10138532 ENSG00000224373.3 IGHV4-59 7.98 1.11e-14 1.12e-11 0.2 0.35 Kawasaki disease; chr14:106803901 chr14:106627249~106627825:- LUSC cis rs35955747 0.869 rs34873968 ENSG00000236132.1 CTA-440B3.1 7.98 1.12e-14 1.13e-11 0.41 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31185787 chr22:31816379~31817491:- LUSC cis rs3823536 0.583 rs6948928 ENSG00000275106.1 RP11-309L24.10 -7.98 1.12e-14 1.13e-11 -0.46 -0.35 Sjögren's syndrome; chr7:128983043 chr7:128952527~128953316:- LUSC cis rs8072100 0.967 rs2317826 ENSG00000228782.6 CTD-2026D20.3 7.98 1.12e-14 1.13e-11 0.33 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47653533 chr17:47450568~47492492:- LUSC cis rs67180937 0.885 rs2133187 ENSG00000272750.1 RP11-378J18.8 -7.98 1.12e-14 1.13e-11 -0.37 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222640383 chr1:222658867~222661512:- LUSC cis rs10129255 0.518 rs28378320 ENSG00000211970.3 IGHV4-61 -7.98 1.12e-14 1.13e-11 -0.22 -0.35 Kawasaki disease; chr14:106808609 chr14:106639119~106639657:- LUSC cis rs2117029 0.555 rs2047101 ENSG00000258017.1 RP11-386G11.10 -7.98 1.13e-14 1.14e-11 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49103860 chr12:49127782~49147869:+ LUSC cis rs9322193 1 rs9399693 ENSG00000223701.3 RAET1E-AS1 7.98 1.13e-14 1.14e-11 0.4 0.35 Lung cancer; chr6:149612718 chr6:149884431~149919508:+ LUSC cis rs7044106 0.762 rs4142158 ENSG00000226752.6 PSMD5-AS1 -7.98 1.13e-14 1.14e-11 -0.39 -0.35 Hip circumference adjusted for BMI; chr9:120648541 chr9:120824828~120854385:+ LUSC cis rs526231 0.543 rs27698 ENSG00000175749.11 EIF3KP1 -7.98 1.14e-14 1.15e-11 -0.42 -0.35 Primary biliary cholangitis; chr5:103190474 chr5:103032376~103033031:+ LUSC cis rs1075265 0.633 rs4671190 ENSG00000233266.1 HMGB1P31 7.98 1.14e-14 1.15e-11 0.43 0.35 Chronotype;Morning vs. evening chronotype; chr2:54085604 chr2:54051334~54051760:+ LUSC cis rs34779708 0.966 rs4934540 ENSG00000230534.5 RP11-297A16.2 7.98 1.15e-14 1.16e-11 0.38 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35185771 chr10:35098006~35127020:- LUSC cis rs11098499 0.913 rs10006304 ENSG00000249244.1 RP11-548H18.2 7.98 1.15e-14 1.16e-11 0.45 0.35 Corneal astigmatism; chr4:119203150 chr4:119391831~119395335:- LUSC cis rs4423214 0.65 rs7940244 ENSG00000254682.1 RP11-660L16.2 -7.98 1.15e-14 1.16e-11 -0.5 -0.35 Vitamin D levels; chr11:71510528 chr11:71448674~71452157:+ LUSC cis rs3930017 1 rs3930016 ENSG00000242435.1 UPK3BP1 7.98 1.15e-14 1.16e-11 0.37 0.35 Body mass index; chr7:77091132 chr7:77004662~77005774:+ LUSC cis rs80285556 1 rs17311679 ENSG00000161643.11 SIGLEC16 -7.98 1.15e-14 1.16e-11 -0.76 -0.35 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50018074 chr19:49969673~49975814:+ LUSC cis rs3091242 0.967 rs3091240 ENSG00000224183.1 SDHDP6 -7.98 1.16e-14 1.17e-11 -0.43 -0.35 Erythrocyte sedimentation rate; chr1:25350444 chr1:25294164~25294643:- LUSC cis rs9487094 0.813 rs12528566 ENSG00000260273.1 RP11-425D10.10 7.98 1.17e-14 1.18e-11 0.45 0.35 Height; chr6:109416945 chr6:109382795~109383666:+ LUSC cis rs1061377 0.71 rs12503506 ENSG00000249207.1 RP11-360F5.1 -7.97 1.17e-14 1.18e-11 -0.38 -0.35 Uric acid levels; chr4:39082553 chr4:39112677~39126818:- LUSC cis rs11098499 0.954 rs17005535 ENSG00000249244.1 RP11-548H18.2 7.97 1.18e-14 1.19e-11 0.44 0.35 Corneal astigmatism; chr4:119490407 chr4:119391831~119395335:- LUSC cis rs10129255 0.701 rs2005643 ENSG00000280411.1 IGHV1-69-2 -7.97 1.18e-14 1.19e-11 -0.23 -0.35 Kawasaki disease; chr14:106676288 chr14:106762092~106762588:- LUSC cis rs7201929 1 rs11644151 ENSG00000259982.1 CDC37P1 -7.97 1.18e-14 1.19e-11 -0.48 -0.35 QT interval; chr16:28884339 chr16:28700294~28701540:- LUSC cis rs10129255 1 rs10141557 ENSG00000211972.2 IGHV3-66 7.97 1.19e-14 1.2e-11 0.27 0.35 Kawasaki disease; chr14:106767990 chr14:106675017~106675544:- LUSC cis rs12134133 0.752 rs61821050 ENSG00000274245.1 RP11-357P18.2 7.97 1.19e-14 1.2e-11 0.48 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207235253 chr1:207372559~207373252:+ LUSC cis rs12134133 0.752 rs61821051 ENSG00000274245.1 RP11-357P18.2 7.97 1.19e-14 1.2e-11 0.48 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207235624 chr1:207372559~207373252:+ LUSC cis rs10129255 0.518 rs10150460 ENSG00000211970.3 IGHV4-61 7.97 1.19e-14 1.2e-11 0.21 0.35 Kawasaki disease; chr14:106677179 chr14:106639119~106639657:- LUSC cis rs10129255 0.957 rs1024349 ENSG00000211972.2 IGHV3-66 7.97 1.21e-14 1.21e-11 0.26 0.35 Kawasaki disease; chr14:106689997 chr14:106675017~106675544:- LUSC cis rs80285556 1 rs79633979 ENSG00000161643.11 SIGLEC16 7.97 1.21e-14 1.22e-11 0.81 0.35 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49985355 chr19:49969673~49975814:+ LUSC cis rs1012068 0.686 rs5998176 ENSG00000236132.1 CTA-440B3.1 -7.97 1.21e-14 1.22e-11 -0.45 -0.35 Chronic hepatitis C infection; chr22:31922107 chr22:31816379~31817491:- LUSC cis rs7811142 0.943 rs111757992 ENSG00000242294.5 STAG3L5P 7.97 1.22e-14 1.22e-11 0.27 0.35 Platelet count; chr7:100418731 chr7:100336079~100351900:+ LUSC cis rs7811142 0.943 rs3900792 ENSG00000242294.5 STAG3L5P 7.97 1.22e-14 1.23e-11 0.28 0.35 Platelet count; chr7:100406954 chr7:100336079~100351900:+ LUSC cis rs10129255 0.518 rs11847766 ENSG00000211970.3 IGHV4-61 -7.97 1.23e-14 1.23e-11 -0.22 -0.34 Kawasaki disease; chr14:106779186 chr14:106639119~106639657:- LUSC cis rs11089937 0.609 rs2213158 ENSG00000211639.2 IGLV4-60 7.97 1.23e-14 1.23e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22138099 chr22:22162199~22162681:+ LUSC cis rs11089937 0.637 rs2213159 ENSG00000211639.2 IGLV4-60 7.97 1.23e-14 1.23e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22138100 chr22:22162199~22162681:+ LUSC cis rs7044106 0.762 rs10760107 ENSG00000226752.6 PSMD5-AS1 -7.97 1.23e-14 1.24e-11 -0.39 -0.34 Hip circumference adjusted for BMI; chr9:120621352 chr9:120824828~120854385:+ LUSC cis rs55665837 1 rs12283797 ENSG00000251991.1 RNU7-49P 7.97 1.23e-14 1.24e-11 0.38 0.34 Vitamin D levels; chr11:14420716 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs10832256 ENSG00000251991.1 RNU7-49P 7.97 1.23e-14 1.24e-11 0.38 0.34 Vitamin D levels; chr11:14421329 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs10832257 ENSG00000251991.1 RNU7-49P 7.97 1.23e-14 1.24e-11 0.38 0.34 Vitamin D levels; chr11:14421770 chr11:14478892~14478953:+ LUSC cis rs55665837 0.961 rs12795972 ENSG00000251991.1 RNU7-49P 7.97 1.23e-14 1.24e-11 0.38 0.34 Vitamin D levels; chr11:14422229 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs12287715 ENSG00000251991.1 RNU7-49P 7.97 1.23e-14 1.24e-11 0.38 0.34 Vitamin D levels; chr11:14423029 chr11:14478892~14478953:+ LUSC cis rs4660456 0.913 rs7551747 ENSG00000237899.1 RP4-739H11.3 7.97 1.23e-14 1.24e-11 0.51 0.34 Platelet count; chr1:40699407 chr1:40669089~40687588:- LUSC cis rs9322193 0.884 rs7769115 ENSG00000223701.3 RAET1E-AS1 7.97 1.24e-14 1.24e-11 0.4 0.34 Lung cancer; chr6:149848796 chr6:149884431~149919508:+ LUSC cis rs7188445 0.736 rs4889012 ENSG00000261390.4 RP11-345M22.2 7.97 1.24e-14 1.25e-11 0.45 0.34 Urate levels; chr16:79667485 chr16:79715232~79770563:- LUSC cis rs853679 0.567 rs6905380 ENSG00000204709.4 LINC01556 7.97 1.24e-14 1.25e-11 0.46 0.34 Depression; chr6:28407125 chr6:28943877~28944537:+ LUSC cis rs1075265 0.61 rs6746965 ENSG00000233266.1 HMGB1P31 7.97 1.25e-14 1.26e-11 0.44 0.34 Chronotype;Morning vs. evening chronotype; chr2:53996388 chr2:54051334~54051760:+ LUSC cis rs55665837 1 rs10047429 ENSG00000251991.1 RNU7-49P 7.97 1.25e-14 1.26e-11 0.38 0.34 Vitamin D levels; chr11:14417486 chr11:14478892~14478953:+ LUSC cis rs875971 0.862 rs10282433 ENSG00000222364.1 RNU6-96P 7.97 1.25e-14 1.26e-11 0.41 0.34 Aortic root size; chr7:66256452 chr7:66395191~66395286:+ LUSC cis rs7044106 0.762 rs4837789 ENSG00000226752.6 PSMD5-AS1 -7.97 1.26e-14 1.26e-11 -0.39 -0.34 Hip circumference adjusted for BMI; chr9:120663978 chr9:120824828~120854385:+ LUSC cis rs8072100 1 rs4794016 ENSG00000228782.6 CTD-2026D20.3 -7.96 1.26e-14 1.26e-11 -0.33 -0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47648565 chr17:47450568~47492492:- LUSC cis rs8059260 0.542 rs6498148 ENSG00000274038.1 RP11-66H6.4 -7.96 1.26e-14 1.27e-11 -0.59 -0.34 Alcohol consumption over the past year; chr16:11018374 chr16:11056556~11057034:+ LUSC cis rs9322193 0.923 rs66516768 ENSG00000223701.3 RAET1E-AS1 7.96 1.26e-14 1.27e-11 0.4 0.34 Lung cancer; chr6:149671999 chr6:149884431~149919508:+ LUSC cis rs12134133 0.752 rs4844579 ENSG00000274245.1 RP11-357P18.2 7.96 1.26e-14 1.27e-11 0.48 0.34 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207204546 chr1:207372559~207373252:+ LUSC cis rs11098499 1 rs3749591 ENSG00000249244.1 RP11-548H18.2 7.96 1.26e-14 1.27e-11 0.45 0.34 Corneal astigmatism; chr4:119292875 chr4:119391831~119395335:- LUSC cis rs6991838 0.8 rs28547533 ENSG00000200714.1 Y_RNA 7.96 1.27e-14 1.27e-11 0.41 0.34 Intelligence (multi-trait analysis); chr8:65559318 chr8:65592731~65592820:+ LUSC cis rs6991838 0.8 rs28626262 ENSG00000200714.1 Y_RNA 7.96 1.27e-14 1.27e-11 0.41 0.34 Intelligence (multi-trait analysis); chr8:65559335 chr8:65592731~65592820:+ LUSC cis rs6991838 0.8 rs28709439 ENSG00000200714.1 Y_RNA 7.96 1.27e-14 1.27e-11 0.41 0.34 Intelligence (multi-trait analysis); chr8:65559337 chr8:65592731~65592820:+ LUSC cis rs10129255 0.5 rs988134 ENSG00000211970.3 IGHV4-61 -7.96 1.27e-14 1.27e-11 -0.22 -0.34 Kawasaki disease; chr14:106776698 chr14:106639119~106639657:- LUSC cis rs10129255 0.5 rs988133 ENSG00000211970.3 IGHV4-61 -7.96 1.27e-14 1.27e-11 -0.22 -0.34 Kawasaki disease; chr14:106776724 chr14:106639119~106639657:- LUSC cis rs875971 0.862 rs12537823 ENSG00000222364.1 RNU6-96P -7.96 1.27e-14 1.27e-11 -0.41 -0.34 Aortic root size; chr7:66255897 chr7:66395191~66395286:+ LUSC cis rs34779708 0.966 rs4934536 ENSG00000230534.5 RP11-297A16.2 7.96 1.27e-14 1.27e-11 0.39 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35152241 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs4934537 ENSG00000230534.5 RP11-297A16.2 7.96 1.27e-14 1.27e-11 0.39 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35152584 chr10:35098006~35127020:- LUSC cis rs35955747 0.902 rs5997938 ENSG00000236132.1 CTA-440B3.1 7.96 1.27e-14 1.28e-11 0.41 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31281006 chr22:31816379~31817491:- LUSC cis rs3091242 0.935 rs3093632 ENSG00000224183.1 SDHDP6 -7.96 1.28e-14 1.28e-11 -0.42 -0.34 Erythrocyte sedimentation rate; chr1:25357521 chr1:25294164~25294643:- LUSC cis rs11168854 0.651 rs12227770 ENSG00000258017.1 RP11-386G11.10 -7.96 1.28e-14 1.28e-11 -0.44 -0.34 Body mass index; chr12:49183065 chr12:49127782~49147869:+ LUSC cis rs7945705 0.87 rs1109305 ENSG00000254860.4 TMEM9B-AS1 -7.96 1.28e-14 1.29e-11 -0.38 -0.34 Hemoglobin concentration; chr11:8933725 chr11:8964675~8977527:+ LUSC cis rs5769707 0.967 rs763126 ENSG00000235111.1 RP1-29C18.8 7.96 1.29e-14 1.29e-11 0.39 0.34 Monocyte percentage of white cells;Monocyte count; chr22:49594926 chr22:49612657~49615716:- LUSC cis rs12439619 0.705 rs17354185 ENSG00000255769.6 GOLGA2P10 7.96 1.29e-14 1.29e-11 0.5 0.34 Intelligence (multi-trait analysis); chr15:82133829 chr15:82472993~82513950:- LUSC cis rs9322193 0.923 rs9688452 ENSG00000223701.3 RAET1E-AS1 7.96 1.29e-14 1.3e-11 0.4 0.34 Lung cancer; chr6:149658764 chr6:149884431~149919508:+ LUSC cis rs12280210 0.557 rs11216225 ENSG00000254851.1 RP11-109L13.1 7.96 1.31e-14 1.31e-11 0.64 0.34 Lobe attachment (rater-scored or self-reported); chr11:117007298 chr11:117135528~117138582:+ LUSC cis rs1075265 0.527 rs10167891 ENSG00000233266.1 HMGB1P31 7.96 1.31e-14 1.31e-11 0.44 0.34 Chronotype;Morning vs. evening chronotype; chr2:54003658 chr2:54051334~54051760:+ LUSC cis rs34779708 0.966 rs12769484 ENSG00000230534.5 RP11-297A16.2 7.96 1.32e-14 1.32e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35176818 chr10:35098006~35127020:- LUSC cis rs10463554 0.963 rs17154959 ENSG00000175749.11 EIF3KP1 7.96 1.32e-14 1.32e-11 0.41 0.34 Parkinson's disease; chr5:103020587 chr5:103032376~103033031:+ LUSC cis rs4660456 0.913 rs16827552 ENSG00000237899.1 RP4-739H11.3 -7.96 1.33e-14 1.33e-11 -0.48 -0.34 Platelet count; chr1:40758336 chr1:40669089~40687588:- LUSC cis rs11098499 0.954 rs11729521 ENSG00000249244.1 RP11-548H18.2 7.96 1.33e-14 1.34e-11 0.44 0.34 Corneal astigmatism; chr4:119495633 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs11734241 ENSG00000249244.1 RP11-548H18.2 7.96 1.33e-14 1.34e-11 0.44 0.34 Corneal astigmatism; chr4:119495717 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs28685688 ENSG00000249244.1 RP11-548H18.2 7.96 1.33e-14 1.34e-11 0.44 0.34 Corneal astigmatism; chr4:119499179 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs7687843 ENSG00000249244.1 RP11-548H18.2 7.96 1.33e-14 1.34e-11 0.44 0.34 Corneal astigmatism; chr4:119500056 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs2306455 ENSG00000249244.1 RP11-548H18.2 7.96 1.33e-14 1.34e-11 0.44 0.34 Corneal astigmatism; chr4:119500814 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs10031483 ENSG00000249244.1 RP11-548H18.2 7.96 1.33e-14 1.34e-11 0.44 0.34 Corneal astigmatism; chr4:119501481 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs10031665 ENSG00000249244.1 RP11-548H18.2 7.96 1.33e-14 1.34e-11 0.44 0.34 Corneal astigmatism; chr4:119501697 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs3733523 ENSG00000249244.1 RP11-548H18.2 7.96 1.33e-14 1.34e-11 0.44 0.34 Corneal astigmatism; chr4:119502564 chr4:119391831~119395335:- LUSC cis rs7739264 0.564 rs760794 ENSG00000237404.1 RP3-471C18.2 -7.96 1.34e-14 1.34e-11 -0.39 -0.34 Endometriosis; chr6:19790329 chr6:19689825~19753113:- LUSC cis rs875971 0.862 rs778734 ENSG00000222364.1 RNU6-96P -7.96 1.34e-14 1.35e-11 -0.41 -0.34 Aortic root size; chr7:66349862 chr7:66395191~66395286:+ LUSC cis rs4660456 0.913 rs34212676 ENSG00000237899.1 RP4-739H11.3 -7.96 1.35e-14 1.35e-11 -0.49 -0.34 Platelet count; chr1:40766522 chr1:40669089~40687588:- LUSC cis rs9326248 0.652 rs7128382 ENSG00000280143.1 AP000892.6 7.96 1.35e-14 1.35e-11 0.43 0.34 Blood protein levels; chr11:117152771 chr11:117204967~117210292:+ LUSC cis rs875971 0.862 rs6944374 ENSG00000237310.1 GS1-124K5.4 -7.95 1.35e-14 1.35e-11 -0.36 -0.34 Aortic root size; chr7:66221942 chr7:66493706~66495474:+ LUSC cis rs67180937 0.961 rs17163358 ENSG00000272750.1 RP11-378J18.8 -7.95 1.36e-14 1.36e-11 -0.37 -0.34 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222647297 chr1:222658867~222661512:- LUSC cis rs9322193 0.923 rs9689723 ENSG00000223701.3 RAET1E-AS1 7.95 1.36e-14 1.36e-11 0.4 0.34 Lung cancer; chr6:149655935 chr6:149884431~149919508:+ LUSC cis rs3096299 0.935 rs3102387 ENSG00000274627.1 RP11-104N10.2 7.95 1.37e-14 1.37e-11 0.31 0.34 Multiple myeloma (IgH translocation); chr16:89365868 chr16:89516797~89522217:+ LUSC cis rs35955747 1 rs35955747 ENSG00000236132.1 CTA-440B3.1 7.95 1.37e-14 1.37e-11 0.42 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31417072 chr22:31816379~31817491:- LUSC cis rs8059260 0.668 rs79389789 ENSG00000274038.1 RP11-66H6.4 -7.95 1.37e-14 1.37e-11 -0.58 -0.34 Alcohol consumption over the past year; chr16:11015168 chr16:11056556~11057034:+ LUSC cis rs11098499 0.604 rs17051352 ENSG00000249244.1 RP11-548H18.2 7.95 1.38e-14 1.37e-11 0.45 0.34 Corneal astigmatism; chr4:119660272 chr4:119391831~119395335:- LUSC cis rs4660456 0.913 rs3767950 ENSG00000237899.1 RP4-739H11.3 -7.95 1.38e-14 1.38e-11 -0.49 -0.34 Platelet count; chr1:40767541 chr1:40669089~40687588:- LUSC cis rs11118620 0.81 rs4587570 ENSG00000272823.1 RP11-295M18.6 7.95 1.38e-14 1.38e-11 0.43 0.34 Heart failure; chr1:220860693 chr1:220828676~220829211:- LUSC cis rs2280018 0.526 rs2966128 ENSG00000260735.1 RP11-72I8.1 -7.95 1.38e-14 1.38e-11 -0.43 -0.34 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059532 chr16:15094411~15109197:+ LUSC cis rs9322193 0.847 rs880246 ENSG00000223701.3 RAET1E-AS1 7.95 1.39e-14 1.39e-11 0.4 0.34 Lung cancer; chr6:149845972 chr6:149884431~149919508:+ LUSC cis rs11098499 0.909 rs10020034 ENSG00000249244.1 RP11-548H18.2 7.95 1.39e-14 1.39e-11 0.45 0.34 Corneal astigmatism; chr4:119373176 chr4:119391831~119395335:- LUSC cis rs34779708 0.931 rs55724039 ENSG00000230534.5 RP11-297A16.2 7.95 1.39e-14 1.39e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35176469 chr10:35098006~35127020:- LUSC cis rs10129255 0.5 rs8014529 ENSG00000211970.3 IGHV4-61 -7.95 1.39e-14 1.39e-11 -0.22 -0.34 Kawasaki disease; chr14:106784065 chr14:106639119~106639657:- LUSC cis rs10829156 0.66 rs10828901 ENSG00000240291.1 RP11-499P20.2 7.95 1.4e-14 1.39e-11 0.36 0.34 Sudden cardiac arrest; chr10:18552161 chr10:18513115~18545651:- LUSC cis rs11098499 0.954 rs3733520 ENSG00000249244.1 RP11-548H18.2 7.95 1.4e-14 1.4e-11 0.44 0.34 Corneal astigmatism; chr4:119502325 chr4:119391831~119395335:- LUSC cis rs1075265 0.567 rs66773232 ENSG00000233266.1 HMGB1P31 7.95 1.4e-14 1.4e-11 0.43 0.34 Chronotype;Morning vs. evening chronotype; chr2:53973970 chr2:54051334~54051760:+ LUSC cis rs35955747 0.902 rs739427 ENSG00000236132.1 CTA-440B3.1 -7.95 1.4e-14 1.4e-11 -0.42 -0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31263115 chr22:31816379~31817491:- LUSC cis rs10129255 0.5 rs34326748 ENSG00000211970.3 IGHV4-61 -7.95 1.41e-14 1.41e-11 -0.22 -0.34 Kawasaki disease; chr14:106782523 chr14:106639119~106639657:- LUSC cis rs10129255 0.5 rs10143385 ENSG00000211970.3 IGHV4-61 -7.95 1.41e-14 1.41e-11 -0.22 -0.34 Kawasaki disease; chr14:106782559 chr14:106639119~106639657:- LUSC cis rs55665837 1 rs10047457 ENSG00000251991.1 RNU7-49P 7.95 1.41e-14 1.41e-11 0.38 0.34 Vitamin D levels; chr11:14417913 chr11:14478892~14478953:+ LUSC cis rs10129255 0.5 rs59939897 ENSG00000211970.3 IGHV4-61 -7.95 1.42e-14 1.42e-11 -0.22 -0.34 Kawasaki disease; chr14:106783414 chr14:106639119~106639657:- LUSC cis rs9322193 0.884 rs10782312 ENSG00000223701.3 RAET1E-AS1 7.95 1.42e-14 1.42e-11 0.4 0.34 Lung cancer; chr6:149622669 chr6:149884431~149919508:+ LUSC cis rs11098499 0.644 rs10050092 ENSG00000245958.5 RP11-33B1.1 -7.95 1.42e-14 1.42e-11 -0.34 -0.34 Corneal astigmatism; chr4:119610930 chr4:119454791~119552025:+ LUSC cis rs10129255 0.5 rs12101190 ENSG00000211970.3 IGHV4-61 -7.95 1.43e-14 1.43e-11 -0.22 -0.34 Kawasaki disease; chr14:106784149 chr14:106639119~106639657:- LUSC cis rs10129255 0.518 rs8004895 ENSG00000211970.3 IGHV4-61 -7.95 1.43e-14 1.43e-11 -0.22 -0.34 Kawasaki disease; chr14:106785139 chr14:106639119~106639657:- LUSC cis rs11098499 0.954 rs1022145 ENSG00000249244.1 RP11-548H18.2 7.95 1.44e-14 1.44e-11 0.45 0.34 Corneal astigmatism; chr4:119309824 chr4:119391831~119395335:- LUSC cis rs11089937 0.626 rs5757056 ENSG00000211639.2 IGLV4-60 7.95 1.45e-14 1.44e-11 0.38 0.34 Periodontitis (PAL4Q3); chr22:22142491 chr22:22162199~22162681:+ LUSC cis rs4423214 0.61 rs12789253 ENSG00000254682.1 RP11-660L16.2 7.95 1.45e-14 1.44e-11 0.42 0.34 Vitamin D levels; chr11:71414719 chr11:71448674~71452157:+ LUSC cis rs2739330 0.828 rs5760098 ENSG00000235689.1 AP000351.13 7.94 1.45e-14 1.45e-11 0.37 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:24006305~24008258:- LUSC cis rs2739330 0.828 rs5760102 ENSG00000235689.1 AP000351.13 7.94 1.45e-14 1.45e-11 0.37 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:24006305~24008258:- LUSC cis rs694739 0.657 rs11231770 ENSG00000236935.1 AP003774.1 7.94 1.45e-14 1.45e-11 0.34 0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373153 chr11:64325050~64329504:- LUSC cis rs694739 0.687 rs11231771 ENSG00000236935.1 AP003774.1 7.94 1.45e-14 1.45e-11 0.34 0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373170 chr11:64325050~64329504:- LUSC cis rs2412819 0.571 rs12900924 ENSG00000249839.1 AC011330.5 -7.94 1.46e-14 1.45e-11 -0.58 -0.34 Lung cancer; chr15:43737329 chr15:43663654~43684339:- LUSC cis rs6921919 0.638 rs9468344 ENSG00000204709.4 LINC01556 7.94 1.46e-14 1.45e-11 0.46 0.34 Autism spectrum disorder or schizophrenia; chr6:28341792 chr6:28943877~28944537:+ LUSC cis rs875971 0.862 rs6460302 ENSG00000222364.1 RNU6-96P -7.94 1.47e-14 1.46e-11 -0.41 -0.34 Aortic root size; chr7:66495270 chr7:66395191~66395286:+ LUSC cis rs1061377 1 rs4974997 ENSG00000249207.1 RP11-360F5.1 -7.94 1.47e-14 1.47e-11 -0.37 -0.34 Uric acid levels; chr4:39109151 chr4:39112677~39126818:- LUSC cis rs9322193 0.772 rs7738696 ENSG00000223701.3 RAET1E-AS1 7.94 1.48e-14 1.47e-11 0.4 0.34 Lung cancer; chr6:149848985 chr6:149884431~149919508:+ LUSC cis rs3096299 0.933 rs28608022 ENSG00000274627.1 RP11-104N10.2 7.94 1.49e-14 1.48e-11 0.31 0.34 Multiple myeloma (IgH translocation); chr16:89387884 chr16:89516797~89522217:+ LUSC cis rs9322193 0.607 rs4869755 ENSG00000223701.3 RAET1E-AS1 7.94 1.49e-14 1.48e-11 0.45 0.34 Lung cancer; chr6:149886347 chr6:149884431~149919508:+ LUSC cis rs9322193 0.639 rs4869756 ENSG00000223701.3 RAET1E-AS1 7.94 1.49e-14 1.48e-11 0.45 0.34 Lung cancer; chr6:149886360 chr6:149884431~149919508:+ LUSC cis rs1976403 0.51 rs1697421 ENSG00000227001.3 NBPF2P 7.94 1.49e-14 1.49e-11 0.42 0.34 Liver enzyme levels (alkaline phosphatase); chr1:21496799 chr1:21424625~21427967:- LUSC cis rs9487094 0.778 rs13214717 ENSG00000260273.1 RP11-425D10.10 7.94 1.5e-14 1.49e-11 0.45 0.34 Height; chr6:109573151 chr6:109382795~109383666:+ LUSC cis rs1185460 1 rs15818 ENSG00000271751.1 RP11-110I1.14 -7.94 1.5e-14 1.49e-11 -0.44 -0.34 Coronary artery disease; chr11:119081463 chr11:119065263~119065677:- LUSC cis rs10129255 0.518 rs12590732 ENSG00000211970.3 IGHV4-61 7.94 1.5e-14 1.49e-11 0.21 0.34 Kawasaki disease; chr14:106779612 chr14:106639119~106639657:- LUSC cis rs55665837 0.922 rs12287212 ENSG00000251991.1 RNU7-49P 7.94 1.5e-14 1.49e-11 0.38 0.34 Vitamin D levels; chr11:14428315 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs10832268 ENSG00000251991.1 RNU7-49P 7.94 1.5e-14 1.49e-11 0.38 0.34 Vitamin D levels; chr11:14443522 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs10832269 ENSG00000251991.1 RNU7-49P 7.94 1.5e-14 1.49e-11 0.38 0.34 Vitamin D levels; chr11:14443523 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs10832271 ENSG00000251991.1 RNU7-49P 7.94 1.5e-14 1.49e-11 0.38 0.34 Vitamin D levels; chr11:14445373 chr11:14478892~14478953:+ LUSC cis rs1292048 1 rs1292048 ENSG00000266992.1 DHX40P1 7.94 1.51e-14 1.5e-11 0.39 0.34 Red cell distribution width; chr17:59877710 chr17:59976009~60002384:- LUSC cis rs8072100 0.817 rs9912101 ENSG00000228782.6 CTD-2026D20.3 7.94 1.52e-14 1.51e-11 0.33 0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469712 chr17:47450568~47492492:- LUSC cis rs9322193 0.884 rs9688794 ENSG00000223701.3 RAET1E-AS1 7.94 1.52e-14 1.51e-11 0.39 0.34 Lung cancer; chr6:149632121 chr6:149884431~149919508:+ LUSC cis rs10129255 0.956 rs10137268 ENSG00000211972.2 IGHV3-66 7.94 1.53e-14 1.52e-11 0.26 0.34 Kawasaki disease; chr14:106697402 chr14:106675017~106675544:- LUSC cis rs11098499 0.722 rs17595727 ENSG00000245958.5 RP11-33B1.1 7.94 1.53e-14 1.52e-11 0.34 0.34 Corneal astigmatism; chr4:119340919 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs9688861 ENSG00000223701.3 RAET1E-AS1 7.94 1.53e-14 1.52e-11 0.4 0.34 Lung cancer; chr6:149637924 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs7740278 ENSG00000223701.3 RAET1E-AS1 7.94 1.53e-14 1.52e-11 0.4 0.34 Lung cancer; chr6:149640116 chr6:149884431~149919508:+ LUSC cis rs875971 1 rs10244498 ENSG00000222364.1 RNU6-96P -7.94 1.54e-14 1.53e-11 -0.41 -0.34 Aortic root size; chr7:66651069 chr7:66395191~66395286:+ LUSC cis rs875971 0.825 rs1000464 ENSG00000222364.1 RNU6-96P 7.94 1.54e-14 1.53e-11 0.41 0.34 Aortic root size; chr7:66312922 chr7:66395191~66395286:+ LUSC cis rs1577917 0.545 rs1832070 ENSG00000203875.9 SNHG5 7.94 1.54e-14 1.53e-11 0.45 0.34 Response to antipsychotic treatment; chr6:85773454 chr6:85660950~85678736:- LUSC cis rs765787 0.53 rs12323957 ENSG00000259520.4 CTD-2651B20.3 -7.94 1.54e-14 1.53e-11 -0.44 -0.34 Uric acid levels; chr15:45198575 chr15:45251580~45279251:- LUSC cis rs11098499 0.865 rs11098513 ENSG00000249244.1 RP11-548H18.2 7.94 1.54e-14 1.53e-11 0.45 0.34 Corneal astigmatism; chr4:119394920 chr4:119391831~119395335:- LUSC cis rs34779708 0.966 rs17591163 ENSG00000230534.5 RP11-297A16.2 7.94 1.54e-14 1.53e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35176351 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs2126984 ENSG00000230534.5 RP11-297A16.2 7.94 1.54e-14 1.53e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35121363 chr10:35098006~35127020:- LUSC cis rs7429990 0.965 rs1550914 ENSG00000229759.1 MRPS18AP1 7.94 1.54e-14 1.53e-11 0.35 0.34 Educational attainment (years of education); chr3:47953678 chr3:48256350~48256938:- LUSC cis rs11098499 0.71 rs4145952 ENSG00000245958.5 RP11-33B1.1 -7.94 1.55e-14 1.54e-11 -0.33 -0.34 Corneal astigmatism; chr4:119234651 chr4:119454791~119552025:+ LUSC cis rs2980439 0.846 rs2980437 ENSG00000253893.2 FAM85B 7.94 1.55e-14 1.54e-11 0.41 0.34 Neuroticism; chr8:8237241 chr8:8167819~8226614:- LUSC cis rs17507216 1 rs17507216 ENSG00000255769.6 GOLGA2P10 7.94 1.55e-14 1.54e-11 0.48 0.34 Excessive daytime sleepiness; chr15:82558175 chr15:82472993~82513950:- LUSC cis rs875971 0.928 rs2036263 ENSG00000222364.1 RNU6-96P 7.94 1.55e-14 1.54e-11 0.41 0.34 Aortic root size; chr7:66335210 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs10240949 ENSG00000222364.1 RNU6-96P 7.94 1.55e-14 1.54e-11 0.41 0.34 Aortic root size; chr7:66339430 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs7782704 ENSG00000222364.1 RNU6-96P 7.94 1.55e-14 1.54e-11 0.41 0.34 Aortic root size; chr7:66340379 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6959268 ENSG00000222364.1 RNU6-96P 7.94 1.55e-14 1.54e-11 0.41 0.34 Aortic root size; chr7:66347979 chr7:66395191~66395286:+ LUSC cis rs17711722 0.523 rs313812 ENSG00000224316.1 RP11-479O9.2 -7.93 1.56e-14 1.55e-11 -0.33 -0.34 Calcium levels; chr7:66040056 chr7:65773620~65802067:+ LUSC cis rs9322193 0.923 rs9404048 ENSG00000223701.3 RAET1E-AS1 7.93 1.56e-14 1.55e-11 0.39 0.34 Lung cancer; chr6:149616188 chr6:149884431~149919508:+ LUSC cis rs2282300 0.739 rs1222210 ENSG00000254532.1 RP11-624D11.2 -7.93 1.57e-14 1.55e-11 -0.46 -0.34 Morning vs. evening chronotype; chr11:30340578 chr11:30044058~30084343:- LUSC cis rs34779708 0.966 rs12782948 ENSG00000230534.5 RP11-297A16.2 7.93 1.57e-14 1.56e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35161679 chr10:35098006~35127020:- LUSC cis rs17507216 1 rs17356118 ENSG00000255769.6 GOLGA2P10 -7.93 1.57e-14 1.56e-11 -0.47 -0.34 Excessive daytime sleepiness; chr15:82569149 chr15:82472993~82513950:- LUSC cis rs17711722 0.522 rs62469933 ENSG00000224316.1 RP11-479O9.2 7.93 1.57e-14 1.56e-11 0.33 0.34 Calcium levels; chr7:65800652 chr7:65773620~65802067:+ LUSC cis rs9322193 0.923 rs9377230 ENSG00000223701.3 RAET1E-AS1 7.93 1.57e-14 1.56e-11 0.39 0.34 Lung cancer; chr6:149613607 chr6:149884431~149919508:+ LUSC cis rs55665837 1 rs12276938 ENSG00000251991.1 RNU7-49P 7.93 1.58e-14 1.57e-11 0.38 0.34 Vitamin D levels; chr11:14441942 chr11:14478892~14478953:+ LUSC cis rs9487094 0.813 rs67857472 ENSG00000260273.1 RP11-425D10.10 7.93 1.58e-14 1.57e-11 0.44 0.34 Height; chr6:109359125 chr6:109382795~109383666:+ LUSC cis rs9807989 0.507 rs2287033 ENSG00000234389.1 AC007278.3 -7.93 1.59e-14 1.57e-11 -0.33 -0.34 Asthma; chr2:102394777 chr2:102438713~102440475:+ LUSC cis rs17711722 0.565 rs4275112 ENSG00000224316.1 RP11-479O9.2 -7.93 1.59e-14 1.58e-11 -0.33 -0.34 Calcium levels; chr7:65733651 chr7:65773620~65802067:+ LUSC cis rs80285556 1 rs10500303 ENSG00000161643.11 SIGLEC16 7.93 1.6e-14 1.59e-11 0.81 0.34 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50008776 chr19:49969673~49975814:+ LUSC cis rs17507216 1 rs3850610 ENSG00000255769.6 GOLGA2P10 7.93 1.61e-14 1.6e-11 0.46 0.34 Excessive daytime sleepiness; chr15:82552642 chr15:82472993~82513950:- LUSC cis rs9322193 0.607 rs9383941 ENSG00000223701.3 RAET1E-AS1 -7.93 1.62e-14 1.6e-11 -0.44 -0.34 Lung cancer; chr6:149912100 chr6:149884431~149919508:+ LUSC cis rs11098499 0.954 rs3733524 ENSG00000249244.1 RP11-548H18.2 7.93 1.63e-14 1.61e-11 0.45 0.34 Corneal astigmatism; chr4:119502574 chr4:119391831~119395335:- LUSC cis rs9487094 0.885 rs11153214 ENSG00000260273.1 RP11-425D10.10 7.93 1.63e-14 1.62e-11 0.43 0.34 Height; chr6:109694120 chr6:109382795~109383666:+ LUSC cis rs1113500 0.748 rs1781048 ENSG00000226822.1 RP11-356N1.2 7.93 1.63e-14 1.62e-11 0.35 0.34 Growth-regulated protein alpha levels; chr1:108012428 chr1:108071482~108074519:+ LUSC cis rs11098499 0.909 rs1546504 ENSG00000249244.1 RP11-548H18.2 7.93 1.64e-14 1.62e-11 0.45 0.34 Corneal astigmatism; chr4:119320024 chr4:119391831~119395335:- LUSC cis rs11098499 0.779 rs10011097 ENSG00000249244.1 RP11-548H18.2 7.93 1.64e-14 1.63e-11 0.44 0.34 Corneal astigmatism; chr4:119389204 chr4:119391831~119395335:- LUSC cis rs55665837 1 rs12792120 ENSG00000251991.1 RNU7-49P 7.93 1.65e-14 1.63e-11 0.38 0.34 Vitamin D levels; chr11:14447897 chr11:14478892~14478953:+ LUSC cis rs34779708 0.966 rs10827493 ENSG00000230534.5 RP11-297A16.2 7.93 1.65e-14 1.63e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35166048 chr10:35098006~35127020:- LUSC cis rs8081395 0.775 rs2526355 ENSG00000266992.1 DHX40P1 7.93 1.66e-14 1.64e-11 0.39 0.34 White blood cell count; chr17:59875872 chr17:59976009~60002384:- LUSC cis rs5769707 0.933 rs2157444 ENSG00000235111.1 RP1-29C18.8 -7.93 1.66e-14 1.64e-11 -0.39 -0.34 Monocyte percentage of white cells;Monocyte count; chr22:49600644 chr22:49612657~49615716:- LUSC cis rs4660456 0.913 rs12743517 ENSG00000237899.1 RP4-739H11.3 7.93 1.67e-14 1.65e-11 0.46 0.34 Platelet count; chr1:40759682 chr1:40669089~40687588:- LUSC cis rs783540 0.542 rs62009945 ENSG00000276710.3 CSPG4P8 7.92 1.67e-14 1.65e-11 0.4 0.34 Schizophrenia; chr15:82631205 chr15:82459472~82477258:+ LUSC cis rs34779708 0.966 rs34630580 ENSG00000230534.5 RP11-297A16.2 7.92 1.67e-14 1.65e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35160300 chr10:35098006~35127020:- LUSC cis rs10463554 0.926 rs3776858 ENSG00000175749.11 EIF3KP1 7.92 1.67e-14 1.65e-11 0.41 0.34 Parkinson's disease; chr5:103021790 chr5:103032376~103033031:+ LUSC cis rs62229266 0.618 rs11088334 ENSG00000231106.2 LINC01436 7.92 1.68e-14 1.66e-11 0.45 0.34 Mitral valve prolapse; chr21:36094531 chr21:36005338~36007838:+ LUSC cis rs7684253 0.587 rs7670313 ENSG00000269949.1 RP11-738E22.3 -7.92 1.68e-14 1.66e-11 -0.42 -0.34 Migraine; chr4:56880007 chr4:56960927~56961373:- LUSC cis rs7684253 0.587 rs2170074 ENSG00000269949.1 RP11-738E22.3 -7.92 1.68e-14 1.66e-11 -0.42 -0.34 Migraine; chr4:56880190 chr4:56960927~56961373:- LUSC cis rs7684253 0.587 rs2170073 ENSG00000269949.1 RP11-738E22.3 -7.92 1.68e-14 1.66e-11 -0.42 -0.34 Migraine; chr4:56880659 chr4:56960927~56961373:- LUSC cis rs11098499 0.954 rs10518328 ENSG00000249244.1 RP11-548H18.2 7.92 1.7e-14 1.68e-11 0.44 0.34 Corneal astigmatism; chr4:119480624 chr4:119391831~119395335:- LUSC cis rs694739 0.628 rs10897487 ENSG00000236935.1 AP003774.1 7.92 1.71e-14 1.68e-11 0.34 0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373232 chr11:64325050~64329504:- LUSC cis rs694739 0.654 rs10897488 ENSG00000236935.1 AP003774.1 7.92 1.71e-14 1.68e-11 0.34 0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373334 chr11:64325050~64329504:- LUSC cis rs2282300 0.739 rs1631451 ENSG00000254532.1 RP11-624D11.2 7.92 1.71e-14 1.69e-11 0.47 0.34 Morning vs. evening chronotype; chr11:30327586 chr11:30044058~30084343:- LUSC cis rs17711722 0.503 rs453835 ENSG00000224316.1 RP11-479O9.2 -7.92 1.72e-14 1.69e-11 -0.33 -0.34 Calcium levels; chr7:66046172 chr7:65773620~65802067:+ LUSC cis rs10129255 0.5 rs11627315 ENSG00000211970.3 IGHV4-61 -7.92 1.72e-14 1.7e-11 -0.22 -0.34 Kawasaki disease; chr14:106802182 chr14:106639119~106639657:- LUSC cis rs8081395 0.741 rs1292053 ENSG00000266992.1 DHX40P1 -7.92 1.72e-14 1.7e-11 -0.39 -0.34 White blood cell count; chr17:59886176 chr17:59976009~60002384:- LUSC cis rs34779708 0.931 rs35126129 ENSG00000230534.5 RP11-297A16.2 7.92 1.72e-14 1.7e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35163213 chr10:35098006~35127020:- LUSC cis rs9326248 0.813 rs588534 ENSG00000280143.1 AP000892.6 7.92 1.73e-14 1.7e-11 0.43 0.34 Blood protein levels; chr11:117197788 chr11:117204967~117210292:+ LUSC cis rs9322193 0.923 rs9322209 ENSG00000223701.3 RAET1E-AS1 7.92 1.73e-14 1.71e-11 0.4 0.34 Lung cancer; chr6:149691226 chr6:149884431~149919508:+ LUSC cis rs1012068 0.541 rs11703587 ENSG00000236132.1 CTA-440B3.1 -7.92 1.73e-14 1.71e-11 -0.47 -0.34 Chronic hepatitis C infection; chr22:31926428 chr22:31816379~31817491:- LUSC cis rs9322193 0.923 rs35961297 ENSG00000223701.3 RAET1E-AS1 7.92 1.73e-14 1.71e-11 0.4 0.34 Lung cancer; chr6:149667929 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs35967444 ENSG00000223701.3 RAET1E-AS1 7.92 1.73e-14 1.71e-11 0.4 0.34 Lung cancer; chr6:149675588 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs62439842 ENSG00000223701.3 RAET1E-AS1 7.92 1.73e-14 1.71e-11 0.4 0.34 Lung cancer; chr6:149675847 chr6:149884431~149919508:+ LUSC cis rs9322193 0.847 rs4870054 ENSG00000223701.3 RAET1E-AS1 7.92 1.74e-14 1.71e-11 0.41 0.34 Lung cancer; chr6:149848402 chr6:149884431~149919508:+ LUSC cis rs5753618 0.539 rs5753596 ENSG00000236132.1 CTA-440B3.1 7.92 1.74e-14 1.71e-11 0.43 0.34 Colorectal cancer; chr22:31391486 chr22:31816379~31817491:- LUSC cis rs34779708 0.966 rs35079558 ENSG00000230534.5 RP11-297A16.2 7.92 1.75e-14 1.72e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35190958 chr10:35098006~35127020:- LUSC cis rs10129255 0.5 rs988132 ENSG00000211970.3 IGHV4-61 -7.92 1.75e-14 1.73e-11 -0.22 -0.34 Kawasaki disease; chr14:106776758 chr14:106639119~106639657:- LUSC cis rs35955747 0.777 rs5997895 ENSG00000236132.1 CTA-440B3.1 7.92 1.76e-14 1.73e-11 0.4 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31170187 chr22:31816379~31817491:- LUSC cis rs9322193 0.886 rs9485408 ENSG00000223701.3 RAET1E-AS1 7.92 1.76e-14 1.73e-11 0.39 0.34 Lung cancer; chr6:149618888 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs1080670 ENSG00000223701.3 RAET1E-AS1 7.92 1.76e-14 1.73e-11 0.39 0.34 Lung cancer; chr6:149620161 chr6:149884431~149919508:+ LUSC cis rs9322193 0.886 rs9322198 ENSG00000223701.3 RAET1E-AS1 7.92 1.76e-14 1.73e-11 0.39 0.34 Lung cancer; chr6:149623772 chr6:149884431~149919508:+ LUSC cis rs34779708 0.931 rs4934535 ENSG00000230534.5 RP11-297A16.2 7.92 1.76e-14 1.74e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35143793 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs4934734 ENSG00000230534.5 RP11-297A16.2 7.92 1.76e-14 1.74e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35145445 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs12769575 ENSG00000230534.5 RP11-297A16.2 7.92 1.76e-14 1.74e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35146999 chr10:35098006~35127020:- LUSC cis rs4660456 0.913 rs16827532 ENSG00000237899.1 RP4-739H11.3 -7.92 1.77e-14 1.74e-11 -0.48 -0.34 Platelet count; chr1:40755064 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs12729696 ENSG00000237899.1 RP4-739H11.3 -7.92 1.77e-14 1.74e-11 -0.48 -0.34 Platelet count; chr1:40755099 chr1:40669089~40687588:- LUSC cis rs588177 1 rs588177 ENSG00000236935.1 AP003774.1 7.92 1.77e-14 1.74e-11 0.32 0.34 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells; chr11:64256584 chr11:64325050~64329504:- LUSC cis rs588177 0.919 rs2244625 ENSG00000236935.1 AP003774.1 7.92 1.77e-14 1.74e-11 0.32 0.34 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells; chr11:64258672 chr11:64325050~64329504:- LUSC cis rs8040855 0.794 rs4843024 ENSG00000259295.5 CSPG4P12 -7.92 1.77e-14 1.74e-11 -0.43 -0.34 Bulimia nervosa; chr15:85162669 chr15:85191438~85213905:+ LUSC cis rs34779708 1 rs34779708 ENSG00000230534.5 RP11-297A16.2 7.92 1.77e-14 1.74e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35177257 chr10:35098006~35127020:- LUSC cis rs2739330 0.828 rs4822451 ENSG00000235689.1 AP000351.13 7.92 1.77e-14 1.75e-11 0.37 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:24006305~24008258:- LUSC cis rs2739330 0.828 rs5760099 ENSG00000235689.1 AP000351.13 7.92 1.77e-14 1.75e-11 0.37 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:24006305~24008258:- LUSC cis rs11098499 0.954 rs6849171 ENSG00000249244.1 RP11-548H18.2 7.92 1.78e-14 1.76e-11 0.44 0.34 Corneal astigmatism; chr4:119488394 chr4:119391831~119395335:- LUSC cis rs3096299 1 rs3096299 ENSG00000274627.1 RP11-104N10.2 7.92 1.79e-14 1.76e-11 0.31 0.34 Multiple myeloma (IgH translocation); chr16:89382255 chr16:89516797~89522217:+ LUSC cis rs10129255 0.872 rs8015406 ENSG00000211972.2 IGHV3-66 7.92 1.79e-14 1.76e-11 0.26 0.34 Kawasaki disease; chr14:106670611 chr14:106675017~106675544:- LUSC cis rs6991838 0.806 rs17302392 ENSG00000272010.1 CTD-3025N20.3 7.92 1.79e-14 1.76e-11 0.38 0.34 Intelligence (multi-trait analysis); chr8:65551073 chr8:65591850~65592472:- LUSC cis rs801193 0.66 rs4610622 ENSG00000222364.1 RNU6-96P -7.91 1.8e-14 1.77e-11 -0.41 -0.34 Aortic root size; chr7:66759510 chr7:66395191~66395286:+ LUSC cis rs3096299 0.967 rs7205785 ENSG00000274627.1 RP11-104N10.2 7.91 1.8e-14 1.77e-11 0.3 0.34 Multiple myeloma (IgH translocation); chr16:89392576 chr16:89516797~89522217:+ LUSC cis rs367615 0.512 rs246105 ENSG00000249476.1 CTD-2587M2.1 7.91 1.8e-14 1.77e-11 0.4 0.34 Colorectal cancer (SNP x SNP interaction); chr5:109337245 chr5:109237120~109326369:- LUSC cis rs9322193 0.961 rs2064520 ENSG00000223701.3 RAET1E-AS1 7.91 1.81e-14 1.78e-11 0.4 0.34 Lung cancer; chr6:149603650 chr6:149884431~149919508:+ LUSC cis rs1075232 0.826 rs16956738 ENSG00000270055.1 CTD-3092A11.2 7.91 1.82e-14 1.79e-11 0.66 0.34 Survival in colorectal cancer (non-distant metastatic); chr15:31444028 chr15:30487963~30490313:+ LUSC cis rs11098499 0.954 rs6822679 ENSG00000249244.1 RP11-548H18.2 7.91 1.83e-14 1.8e-11 0.44 0.34 Corneal astigmatism; chr4:119481547 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs4577559 ENSG00000249244.1 RP11-548H18.2 7.91 1.83e-14 1.8e-11 0.44 0.34 Corneal astigmatism; chr4:119482888 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs7656252 ENSG00000249244.1 RP11-548H18.2 7.91 1.83e-14 1.8e-11 0.44 0.34 Corneal astigmatism; chr4:119483113 chr4:119391831~119395335:- LUSC cis rs11098499 0.865 rs28845498 ENSG00000249244.1 RP11-548H18.2 7.91 1.83e-14 1.8e-11 0.44 0.34 Corneal astigmatism; chr4:119484031 chr4:119391831~119395335:- LUSC cis rs11098499 0.865 rs28753180 ENSG00000249244.1 RP11-548H18.2 7.91 1.83e-14 1.8e-11 0.44 0.34 Corneal astigmatism; chr4:119484212 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs56270433 ENSG00000249244.1 RP11-548H18.2 7.91 1.83e-14 1.8e-11 0.44 0.34 Corneal astigmatism; chr4:119484875 chr4:119391831~119395335:- LUSC cis rs4706831 0.647 rs9350847 ENSG00000272129.1 RP11-250B2.6 7.91 1.86e-14 1.82e-11 0.42 0.34 Joint mobility (Beighton score); chr6:80179300 chr6:80355424~80356859:+ LUSC cis rs17711722 0.51 rs11767457 ENSG00000224316.1 RP11-479O9.2 7.91 1.86e-14 1.82e-11 0.33 0.34 Calcium levels; chr7:65825628 chr7:65773620~65802067:+ LUSC cis rs2179367 0.959 rs4897125 ENSG00000231760.4 RP11-350J20.5 7.91 1.86e-14 1.83e-11 0.44 0.34 Dupuytren's disease; chr6:149445072 chr6:149796151~149826294:- LUSC cis rs11089937 0.559 rs2330014 ENSG00000211639.2 IGLV4-60 7.91 1.86e-14 1.83e-11 0.37 0.34 Periodontitis (PAL4Q3); chr22:22166155 chr22:22162199~22162681:+ LUSC cis rs2248020 0.501 rs2263368 ENSG00000279684.1 RP11-755E23.2 -7.91 1.87e-14 1.83e-11 -0.43 -0.34 Insulin levels in response to oral glucose tolerance test (30 minutes); chr11:93531514 chr11:93286629~93288903:- LUSC cis rs10829156 0.699 rs10764584 ENSG00000240291.1 RP11-499P20.2 -7.91 1.88e-14 1.84e-11 -0.36 -0.34 Sudden cardiac arrest; chr10:18546396 chr10:18513115~18545651:- LUSC cis rs8059260 0.736 rs80207136 ENSG00000274038.1 RP11-66H6.4 -7.91 1.9e-14 1.86e-11 -0.59 -0.34 Alcohol consumption over the past year; chr16:11015480 chr16:11056556~11057034:+ LUSC cis rs8059260 0.668 rs78573173 ENSG00000274038.1 RP11-66H6.4 -7.91 1.9e-14 1.86e-11 -0.59 -0.34 Alcohol consumption over the past year; chr16:11017642 chr16:11056556~11057034:+ LUSC cis rs11155671 0.53 rs9397398 ENSG00000268592.3 RAET1E-AS1 7.91 1.9e-14 1.86e-11 0.42 0.34 Testicular germ cell tumor; chr6:149872467 chr6:149863494~149919507:+ LUSC cis rs35160687 0.798 rs6547674 ENSG00000273080.1 RP11-301O19.1 -7.91 1.9e-14 1.86e-11 -0.33 -0.34 Night sleep phenotypes; chr2:86325796 chr2:86195590~86196049:+ LUSC cis rs35160687 0.798 rs11127029 ENSG00000273080.1 RP11-301O19.1 -7.91 1.9e-14 1.86e-11 -0.33 -0.34 Night sleep phenotypes; chr2:86327502 chr2:86195590~86196049:+ LUSC cis rs17711722 0.522 rs4642526 ENSG00000224316.1 RP11-479O9.2 7.91 1.92e-14 1.88e-11 0.33 0.34 Calcium levels; chr7:65751755 chr7:65773620~65802067:+ LUSC cis rs34779708 0.966 rs1545757 ENSG00000230534.5 RP11-297A16.2 7.91 1.92e-14 1.88e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35156660 chr10:35098006~35127020:- LUSC cis rs2019137 0.936 rs3811059 ENSG00000189223.12 PAX8-AS1 7.91 1.92e-14 1.88e-11 0.45 0.34 Lymphocyte counts; chr2:113204494 chr2:113211522~113276581:+ LUSC cis rs2019137 0.936 rs12620738 ENSG00000189223.12 PAX8-AS1 7.91 1.92e-14 1.88e-11 0.45 0.34 Lymphocyte counts; chr2:113206162 chr2:113211522~113276581:+ LUSC cis rs2179367 0.959 rs4895789 ENSG00000231760.4 RP11-350J20.5 7.9 1.93e-14 1.89e-11 0.44 0.34 Dupuytren's disease; chr6:149443518 chr6:149796151~149826294:- LUSC cis rs7811142 0.943 rs111493473 ENSG00000242294.5 STAG3L5P 7.9 1.93e-14 1.89e-11 0.27 0.34 Platelet count; chr7:100452119 chr7:100336079~100351900:+ LUSC cis rs17023223 0.537 rs12085308 ENSG00000231365.4 RP11-418J17.1 -7.9 1.93e-14 1.89e-11 -0.43 -0.34 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119134930 chr1:119140396~119275973:+ LUSC cis rs11098499 0.954 rs7437420 ENSG00000249244.1 RP11-548H18.2 7.9 1.94e-14 1.9e-11 0.44 0.34 Corneal astigmatism; chr4:119391748 chr4:119391831~119395335:- LUSC cis rs9322193 0.884 rs11155675 ENSG00000223701.3 RAET1E-AS1 7.9 1.94e-14 1.9e-11 0.41 0.34 Lung cancer; chr6:149742883 chr6:149884431~149919508:+ LUSC cis rs1577917 0.545 rs1335443 ENSG00000203875.9 SNHG5 -7.9 1.96e-14 1.92e-11 -0.45 -0.34 Response to antipsychotic treatment; chr6:85769019 chr6:85660950~85678736:- LUSC cis rs11098499 0.909 rs28884220 ENSG00000249244.1 RP11-548H18.2 7.9 1.98e-14 1.93e-11 0.44 0.34 Corneal astigmatism; chr4:119386056 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs28793658 ENSG00000249244.1 RP11-548H18.2 7.9 1.98e-14 1.93e-11 0.44 0.34 Corneal astigmatism; chr4:119386059 chr4:119391831~119395335:- LUSC cis rs7772486 0.558 rs7753273 ENSG00000235652.6 RP11-545I5.3 -7.9 2e-14 1.95e-11 -0.36 -0.34 Lobe attachment (rater-scored or self-reported); chr6:145744903 chr6:145799409~145886585:+ LUSC cis rs7772486 0.59 rs1890170 ENSG00000235652.6 RP11-545I5.3 -7.9 2e-14 1.95e-11 -0.36 -0.34 Lobe attachment (rater-scored or self-reported); chr6:145750703 chr6:145799409~145886585:+ LUSC cis rs853679 0.567 rs13209596 ENSG00000216901.1 AL022393.7 7.9 2e-14 1.95e-11 0.42 0.34 Depression; chr6:28428413 chr6:28176188~28176674:+ LUSC cis rs7772486 0.597 rs1970306 ENSG00000235652.6 RP11-545I5.3 7.9 2.01e-14 1.96e-11 0.36 0.34 Lobe attachment (rater-scored or self-reported); chr6:145833407 chr6:145799409~145886585:+ LUSC cis rs7772486 0.597 rs9386136 ENSG00000235652.6 RP11-545I5.3 7.9 2.01e-14 1.96e-11 0.36 0.34 Lobe attachment (rater-scored or self-reported); chr6:145837164 chr6:145799409~145886585:+ LUSC cis rs9487094 0.813 rs61233650 ENSG00000260273.1 RP11-425D10.10 7.9 2.01e-14 1.96e-11 0.44 0.34 Height; chr6:109365409 chr6:109382795~109383666:+ LUSC cis rs2980439 0.818 rs2945249 ENSG00000253893.2 FAM85B -7.9 2.01e-14 1.97e-11 -0.42 -0.34 Neuroticism; chr8:8237204 chr8:8167819~8226614:- LUSC cis rs748404 0.723 rs11853991 ENSG00000249839.1 AC011330.5 -7.9 2.02e-14 1.97e-11 -0.46 -0.34 Lung cancer; chr15:43265351 chr15:43663654~43684339:- LUSC cis rs3096299 0.967 rs28689480 ENSG00000274627.1 RP11-104N10.2 7.9 2.02e-14 1.97e-11 0.31 0.34 Multiple myeloma (IgH translocation); chr16:89393685 chr16:89516797~89522217:+ LUSC cis rs1113500 0.565 rs1781071 ENSG00000226822.1 RP11-356N1.2 7.9 2.03e-14 1.98e-11 0.38 0.34 Growth-regulated protein alpha levels; chr1:108028412 chr1:108071482~108074519:+ LUSC cis rs5769707 0.837 rs1573726 ENSG00000235111.1 RP1-29C18.8 -7.9 2.03e-14 1.98e-11 -0.39 -0.34 Monocyte percentage of white cells;Monocyte count; chr22:49639224 chr22:49612657~49615716:- LUSC cis rs10129255 0.518 rs7143784 ENSG00000211970.3 IGHV4-61 -7.9 2.04e-14 1.99e-11 -0.21 -0.34 Kawasaki disease; chr14:106687277 chr14:106639119~106639657:- LUSC cis rs9322193 0.566 rs9397070 ENSG00000223701.3 RAET1E-AS1 -7.9 2.04e-14 1.99e-11 -0.45 -0.34 Lung cancer; chr6:149922073 chr6:149884431~149919508:+ LUSC cis rs2282300 0.739 rs1717775 ENSG00000254532.1 RP11-624D11.2 7.9 2.04e-14 1.99e-11 0.47 0.34 Morning vs. evening chronotype; chr11:30328707 chr11:30044058~30084343:- LUSC cis rs34779708 0.966 rs12784482 ENSG00000230534.5 RP11-297A16.2 7.89 2.07e-14 2.02e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35157937 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs17499811 ENSG00000230534.5 RP11-297A16.2 7.89 2.07e-14 2.02e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35167287 chr10:35098006~35127020:- LUSC cis rs9322193 0.923 rs9322204 ENSG00000223701.3 RAET1E-AS1 7.89 2.07e-14 2.02e-11 0.39 0.34 Lung cancer; chr6:149636047 chr6:149884431~149919508:+ LUSC cis rs17711722 0.522 rs6957759 ENSG00000224316.1 RP11-479O9.2 7.89 2.09e-14 2.03e-11 0.33 0.34 Calcium levels; chr7:65806798 chr7:65773620~65802067:+ LUSC cis rs2006771 0.765 rs6518752 ENSG00000236132.1 CTA-440B3.1 -7.89 2.09e-14 2.03e-11 -0.41 -0.34 Nonsyndromic cleft lip with cleft palate; chr22:31603141 chr22:31816379~31817491:- LUSC cis rs7044106 0.708 rs959558 ENSG00000226752.6 PSMD5-AS1 -7.89 2.12e-14 2.06e-11 -0.38 -0.34 Hip circumference adjusted for BMI; chr9:120606633 chr9:120824828~120854385:+ LUSC cis rs3096299 0.967 rs2911257 ENSG00000274627.1 RP11-104N10.2 7.89 2.13e-14 2.07e-11 0.3 0.34 Multiple myeloma (IgH translocation); chr16:89417726 chr16:89516797~89522217:+ LUSC cis rs11098499 0.909 rs10017335 ENSG00000249244.1 RP11-548H18.2 -7.89 2.13e-14 2.08e-11 -0.44 -0.34 Corneal astigmatism; chr4:119460368 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs59866101 ENSG00000249244.1 RP11-548H18.2 7.89 2.14e-14 2.08e-11 0.44 0.34 Corneal astigmatism; chr4:119375436 chr4:119391831~119395335:- LUSC cis rs11098499 0.618 rs6858383 ENSG00000249244.1 RP11-548H18.2 7.89 2.14e-14 2.08e-11 0.44 0.34 Corneal astigmatism; chr4:119375617 chr4:119391831~119395335:- LUSC cis rs11098499 0.697 rs6832410 ENSG00000249244.1 RP11-548H18.2 7.89 2.14e-14 2.08e-11 0.44 0.34 Corneal astigmatism; chr4:119375645 chr4:119391831~119395335:- LUSC cis rs34779708 0.966 rs113170867 ENSG00000230534.5 RP11-297A16.2 7.89 2.14e-14 2.08e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35161219 chr10:35098006~35127020:- LUSC cis rs801193 0.66 rs974239 ENSG00000222364.1 RNU6-96P -7.89 2.14e-14 2.08e-11 -0.4 -0.34 Aortic root size; chr7:66748504 chr7:66395191~66395286:+ LUSC cis rs801193 0.66 rs1016265 ENSG00000222364.1 RNU6-96P -7.89 2.14e-14 2.08e-11 -0.4 -0.34 Aortic root size; chr7:66749580 chr7:66395191~66395286:+ LUSC cis rs1012068 0.581 rs5749339 ENSG00000236132.1 CTA-440B3.1 7.89 2.15e-14 2.09e-11 0.47 0.34 Chronic hepatitis C infection; chr22:31919749 chr22:31816379~31817491:- LUSC cis rs10129255 0.5 rs1024350 ENSG00000211970.3 IGHV4-61 -7.89 2.16e-14 2.1e-11 -0.21 -0.34 Kawasaki disease; chr14:106685105 chr14:106639119~106639657:- LUSC cis rs9487094 0.961 rs3807005 ENSG00000260273.1 RP11-425D10.10 7.89 2.16e-14 2.1e-11 0.42 0.34 Height; chr6:109469907 chr6:109382795~109383666:+ LUSC cis rs875971 0.862 rs6460290 ENSG00000222364.1 RNU6-96P 7.89 2.17e-14 2.11e-11 0.41 0.34 Aortic root size; chr7:66344119 chr7:66395191~66395286:+ LUSC cis rs10129255 0.913 rs28861466 ENSG00000211972.2 IGHV3-66 7.89 2.17e-14 2.11e-11 0.26 0.34 Kawasaki disease; chr14:106718572 chr14:106675017~106675544:- LUSC cis rs10129255 0.5 rs6576231 ENSG00000211970.3 IGHV4-61 -7.89 2.17e-14 2.11e-11 -0.22 -0.34 Kawasaki disease; chr14:106783693 chr14:106639119~106639657:- LUSC cis rs5769707 0.642 rs4824070 ENSG00000235111.1 RP1-29C18.8 -7.89 2.17e-14 2.11e-11 -0.43 -0.34 Monocyte percentage of white cells;Monocyte count; chr22:49637873 chr22:49612657~49615716:- LUSC cis rs9322193 0.923 rs35830138 ENSG00000223701.3 RAET1E-AS1 7.89 2.17e-14 2.11e-11 0.4 0.34 Lung cancer; chr6:149668635 chr6:149884431~149919508:+ LUSC cis rs6991838 0.771 rs13282323 ENSG00000200714.1 Y_RNA 7.89 2.18e-14 2.12e-11 0.41 0.34 Intelligence (multi-trait analysis); chr8:65560557 chr8:65592731~65592820:+ LUSC cis rs9487094 0.922 rs9885646 ENSG00000260273.1 RP11-425D10.10 7.89 2.19e-14 2.12e-11 0.42 0.34 Height; chr6:109421257 chr6:109382795~109383666:+ LUSC cis rs9322193 0.923 rs9689084 ENSG00000223701.3 RAET1E-AS1 7.89 2.19e-14 2.12e-11 0.39 0.34 Lung cancer; chr6:149639648 chr6:149884431~149919508:+ LUSC cis rs12439619 0.53 rs28883606 ENSG00000278603.1 RP13-608F4.5 7.89 2.2e-14 2.14e-11 0.41 0.34 Intelligence (multi-trait analysis); chr15:82216713 chr15:82472203~82472426:+ LUSC cis rs12439619 0.693 rs28665836 ENSG00000278603.1 RP13-608F4.5 7.89 2.2e-14 2.14e-11 0.41 0.34 Intelligence (multi-trait analysis); chr15:82218955 chr15:82472203~82472426:+ LUSC cis rs1185460 0.565 rs540261 ENSG00000271751.1 RP11-110I1.14 7.89 2.2e-14 2.14e-11 0.44 0.34 Coronary artery disease; chr11:119076924 chr11:119065263~119065677:- LUSC cis rs5769707 0.872 rs5770604 ENSG00000235111.1 RP1-29C18.8 -7.89 2.2e-14 2.14e-11 -0.39 -0.34 Monocyte percentage of white cells;Monocyte count; chr22:49637024 chr22:49612657~49615716:- LUSC cis rs11098499 0.954 rs10006706 ENSG00000249244.1 RP11-548H18.2 7.89 2.21e-14 2.15e-11 0.45 0.34 Corneal astigmatism; chr4:119487997 chr4:119391831~119395335:- LUSC cis rs11098499 0.697 rs4560394 ENSG00000249244.1 RP11-548H18.2 7.89 2.21e-14 2.15e-11 0.44 0.34 Corneal astigmatism; chr4:119392280 chr4:119391831~119395335:- LUSC cis rs2739330 0.587 rs4820571 ENSG00000099984.9 GSTT2 -7.89 2.22e-14 2.15e-11 -0.41 -0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23980123~23983911:+ LUSC cis rs875971 0.862 rs10276077 ENSG00000222364.1 RNU6-96P 7.88 2.22e-14 2.16e-11 0.41 0.34 Aortic root size; chr7:66263424 chr7:66395191~66395286:+ LUSC cis rs10129255 0.5 rs7157975 ENSG00000211970.3 IGHV4-61 -7.88 2.22e-14 2.16e-11 -0.22 -0.34 Kawasaki disease; chr14:106804049 chr14:106639119~106639657:- LUSC cis rs17507216 0.958 rs72751643 ENSG00000255769.6 GOLGA2P10 -7.88 2.22e-14 2.16e-11 -0.48 -0.34 Excessive daytime sleepiness; chr15:82559444 chr15:82472993~82513950:- LUSC cis rs4141404 0.757 rs5749272 ENSG00000236132.1 CTA-440B3.1 7.88 2.24e-14 2.17e-11 0.42 0.34 Paclitaxel-induced neuropathy; chr22:31434365 chr22:31816379~31817491:- LUSC cis rs9487094 0.614 rs13191444 ENSG00000260273.1 RP11-425D10.10 7.88 2.24e-14 2.18e-11 0.46 0.34 Height; chr6:109762861 chr6:109382795~109383666:+ LUSC cis rs9487094 0.567 rs13196280 ENSG00000260273.1 RP11-425D10.10 7.88 2.24e-14 2.18e-11 0.46 0.34 Height; chr6:109764163 chr6:109382795~109383666:+ LUSC cis rs55665837 1 rs3923294 ENSG00000251991.1 RNU7-49P 7.88 2.25e-14 2.18e-11 0.38 0.34 Vitamin D levels; chr11:14419856 chr11:14478892~14478953:+ LUSC cis rs875971 0.862 rs2909688 ENSG00000237310.1 GS1-124K5.4 7.88 2.26e-14 2.19e-11 0.36 0.34 Aortic root size; chr7:66376625 chr7:66493706~66495474:+ LUSC cis rs11098499 0.909 rs1546502 ENSG00000249244.1 RP11-548H18.2 7.88 2.26e-14 2.19e-11 0.45 0.34 Corneal astigmatism; chr4:119314743 chr4:119391831~119395335:- LUSC cis rs9322193 0.607 rs10457852 ENSG00000223701.3 RAET1E-AS1 7.88 2.26e-14 2.2e-11 0.43 0.34 Lung cancer; chr6:149880584 chr6:149884431~149919508:+ LUSC cis rs10129255 1 rs10129255 ENSG00000211972.2 IGHV3-66 -7.88 2.27e-14 2.2e-11 -0.26 -0.34 Kawasaki disease; chr14:106767970 chr14:106675017~106675544:- LUSC cis rs7772486 0.558 rs62435775 ENSG00000235652.6 RP11-545I5.3 7.88 2.27e-14 2.2e-11 0.36 0.34 Lobe attachment (rater-scored or self-reported); chr6:145815279 chr6:145799409~145886585:+ LUSC cis rs7044106 0.762 rs1530370 ENSG00000226752.6 PSMD5-AS1 -7.88 2.27e-14 2.2e-11 -0.39 -0.34 Hip circumference adjusted for BMI; chr9:120662274 chr9:120824828~120854385:+ LUSC cis rs17711722 0.565 rs4717276 ENSG00000224316.1 RP11-479O9.2 7.88 2.27e-14 2.2e-11 0.33 0.34 Calcium levels; chr7:65829754 chr7:65773620~65802067:+ LUSC cis rs7044106 0.762 rs7024046 ENSG00000226752.6 PSMD5-AS1 -7.88 2.28e-14 2.21e-11 -0.39 -0.34 Hip circumference adjusted for BMI; chr9:120656900 chr9:120824828~120854385:+ LUSC cis rs77204473 0.557 rs9971422 ENSG00000254851.1 RP11-109L13.1 7.88 2.28e-14 2.21e-11 0.66 0.34 Sum eosinophil basophil counts;Eosinophil counts; chr11:116966657 chr11:117135528~117138582:+ LUSC cis rs11098499 0.779 rs7699346 ENSG00000249244.1 RP11-548H18.2 7.88 2.28e-14 2.21e-11 0.44 0.34 Corneal astigmatism; chr4:119389387 chr4:119391831~119395335:- LUSC cis rs11098499 0.865 rs28634456 ENSG00000249244.1 RP11-548H18.2 7.88 2.31e-14 2.24e-11 0.45 0.34 Corneal astigmatism; chr4:119454623 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs78332141 ENSG00000249244.1 RP11-548H18.2 7.88 2.31e-14 2.24e-11 0.45 0.34 Corneal astigmatism; chr4:119454627 chr4:119391831~119395335:- LUSC cis rs10256972 0.9 rs7812072 ENSG00000229043.2 AC091729.9 -7.88 2.31e-14 2.24e-11 -0.4 -0.34 Endometriosis;Longevity; chr7:1014226 chr7:1160374~1165267:+ LUSC cis rs34779708 0.931 rs11010130 ENSG00000230534.5 RP11-297A16.2 7.88 2.33e-14 2.26e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35224379 chr10:35098006~35127020:- LUSC cis rs34779708 0.897 rs11010131 ENSG00000230534.5 RP11-297A16.2 7.88 2.33e-14 2.26e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35224388 chr10:35098006~35127020:- LUSC cis rs875971 0.792 rs6971752 ENSG00000222364.1 RNU6-96P 7.88 2.34e-14 2.26e-11 0.4 0.34 Aortic root size; chr7:66272999 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs10950033 ENSG00000222364.1 RNU6-96P 7.88 2.34e-14 2.26e-11 0.4 0.34 Aortic root size; chr7:66274686 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs11760844 ENSG00000222364.1 RNU6-96P 7.88 2.34e-14 2.26e-11 0.4 0.34 Aortic root size; chr7:66274896 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs4149461 ENSG00000222364.1 RNU6-96P 7.88 2.34e-14 2.26e-11 0.4 0.34 Aortic root size; chr7:66279745 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs4236208 ENSG00000222364.1 RNU6-96P 7.88 2.34e-14 2.26e-11 0.4 0.34 Aortic root size; chr7:66284091 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs10261398 ENSG00000222364.1 RNU6-96P 7.88 2.34e-14 2.26e-11 0.4 0.34 Aortic root size; chr7:66285177 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs10224872 ENSG00000222364.1 RNU6-96P 7.88 2.34e-14 2.26e-11 0.4 0.34 Aortic root size; chr7:66294786 chr7:66395191~66395286:+ LUSC cis rs9322193 0.962 rs4380763 ENSG00000223701.3 RAET1E-AS1 7.88 2.34e-14 2.27e-11 0.4 0.34 Lung cancer; chr6:149678086 chr6:149884431~149919508:+ LUSC cis rs8059260 0.604 rs12102345 ENSG00000274038.1 RP11-66H6.4 -7.88 2.36e-14 2.29e-11 -0.56 -0.34 Alcohol consumption over the past year; chr16:11053863 chr16:11056556~11057034:+ LUSC cis rs7811142 1 rs112317829 ENSG00000242294.5 STAG3L5P 7.88 2.37e-14 2.3e-11 0.27 0.34 Platelet count; chr7:100445550 chr7:100336079~100351900:+ LUSC cis rs7811142 0.943 rs28578163 ENSG00000242294.5 STAG3L5P 7.88 2.37e-14 2.3e-11 0.27 0.34 Platelet count; chr7:100447131 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs67239991 ENSG00000242294.5 STAG3L5P 7.88 2.37e-14 2.3e-11 0.27 0.34 Platelet count; chr7:100448881 chr7:100336079~100351900:+ LUSC cis rs2280018 0.526 rs2941257 ENSG00000260735.1 RP11-72I8.1 -7.88 2.37e-14 2.3e-11 -0.42 -0.34 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15072588 chr16:15094411~15109197:+ LUSC cis rs34779708 0.966 rs11010129 ENSG00000230534.5 RP11-297A16.2 7.88 2.37e-14 2.3e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35221894 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs4934737 ENSG00000230534.5 RP11-297A16.2 7.88 2.37e-14 2.3e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35223871 chr10:35098006~35127020:- LUSC cis rs694739 0.726 rs17857342 ENSG00000236935.1 AP003774.1 7.88 2.38e-14 2.3e-11 0.34 0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64371433 chr11:64325050~64329504:- LUSC cis rs189798 0.738 rs330908 ENSG00000254340.1 RP11-10A14.3 7.87 2.38e-14 2.3e-11 0.43 0.34 Myopia (pathological); chr8:9137656 chr8:9141424~9145435:+ LUSC cis rs7811142 0.83 rs77861211 ENSG00000242294.5 STAG3L5P 7.87 2.38e-14 2.3e-11 0.27 0.34 Platelet count; chr7:100364473 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs11769057 ENSG00000242294.5 STAG3L5P 7.87 2.38e-14 2.3e-11 0.27 0.34 Platelet count; chr7:100367038 chr7:100336079~100351900:+ LUSC cis rs7201929 1 rs12920514 ENSG00000259982.1 CDC37P1 -7.87 2.4e-14 2.32e-11 -0.46 -0.34 QT interval; chr16:28824579 chr16:28700294~28701540:- LUSC cis rs11098499 0.865 rs1112817 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119376645 chr4:119391831~119395335:- LUSC cis rs11098499 0.779 rs10016060 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119377257 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs10005644 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119377322 chr4:119391831~119395335:- LUSC cis rs11098499 0.697 rs10016448 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119377690 chr4:119391831~119395335:- LUSC cis rs11098499 0.657 rs9996569 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119377849 chr4:119391831~119395335:- LUSC cis rs11098499 0.908 rs11729050 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119378911 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs28429722 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119378938 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs10014845 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119379922 chr4:119391831~119395335:- LUSC cis rs11098499 0.779 rs7674500 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119382438 chr4:119391831~119395335:- LUSC cis rs11098499 0.697 rs4373140 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119386543 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs13113483 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119387884 chr4:119391831~119395335:- LUSC cis rs11098499 0.542 rs10440343 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119388632 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs28668716 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119388720 chr4:119391831~119395335:- LUSC cis rs11098499 0.542 rs7677836 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119389483 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs10002083 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119389997 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs10024844 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119390373 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs4345162 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119391804 chr4:119391831~119395335:- LUSC cis rs11098499 0.657 rs4463052 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119392103 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs13151285 ENSG00000249244.1 RP11-548H18.2 7.87 2.42e-14 2.34e-11 0.44 0.34 Corneal astigmatism; chr4:119393586 chr4:119391831~119395335:- LUSC cis rs6921919 0.832 rs17312661 ENSG00000216901.1 AL022393.7 7.87 2.43e-14 2.35e-11 0.5 0.34 Autism spectrum disorder or schizophrenia; chr6:28332559 chr6:28176188~28176674:+ LUSC cis rs10256972 0.521 rs7457418 ENSG00000229043.2 AC091729.9 -7.87 2.44e-14 2.36e-11 -0.39 -0.34 Endometriosis;Longevity; chr7:1070619 chr7:1160374~1165267:+ LUSC cis rs10463554 1 rs3776864 ENSG00000175749.11 EIF3KP1 7.87 2.45e-14 2.36e-11 0.4 0.34 Parkinson's disease; chr5:102992164 chr5:103032376~103033031:+ LUSC cis rs4660456 0.564 rs34320811 ENSG00000237899.1 RP4-739H11.3 -7.87 2.45e-14 2.37e-11 -0.48 -0.34 Platelet count; chr1:40763288 chr1:40669089~40687588:- LUSC cis rs1012068 0.662 rs11703779 ENSG00000236132.1 CTA-440B3.1 -7.87 2.46e-14 2.37e-11 -0.44 -0.34 Chronic hepatitis C infection; chr22:31926398 chr22:31816379~31817491:- LUSC cis rs55665837 1 rs12295723 ENSG00000251991.1 RNU7-49P 7.87 2.46e-14 2.37e-11 0.38 0.34 Vitamin D levels; chr11:14428655 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs12288873 ENSG00000251991.1 RNU7-49P 7.87 2.46e-14 2.37e-11 0.38 0.34 Vitamin D levels; chr11:14428919 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs12295888 ENSG00000251991.1 RNU7-49P 7.87 2.46e-14 2.37e-11 0.38 0.34 Vitamin D levels; chr11:14428985 chr11:14478892~14478953:+ LUSC cis rs10256972 0.869 rs4720158 ENSG00000229043.2 AC091729.9 -7.87 2.47e-14 2.38e-11 -0.39 -0.34 Endometriosis;Longevity; chr7:1000689 chr7:1160374~1165267:+ LUSC cis rs7772486 0.603 rs2223411 ENSG00000235652.6 RP11-545I5.3 -7.87 2.47e-14 2.38e-11 -0.36 -0.34 Lobe attachment (rater-scored or self-reported); chr6:145707631 chr6:145799409~145886585:+ LUSC cis rs2712381 0.517 rs62273237 ENSG00000277250.1 Metazoa_SRP -7.87 2.49e-14 2.39e-11 -0.39 -0.34 Monocyte count; chr3:128591264 chr3:128673681~128674021:- LUSC cis rs34779708 0.931 rs17591135 ENSG00000230534.5 RP11-297A16.2 7.87 2.49e-14 2.4e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35176262 chr10:35098006~35127020:- LUSC cis rs10129255 0.5 rs2027902 ENSG00000211970.3 IGHV4-61 -7.87 2.49e-14 2.4e-11 -0.22 -0.34 Kawasaki disease; chr14:106807157 chr14:106639119~106639657:- LUSC cis rs12439619 0.921 rs4778672 ENSG00000255769.6 GOLGA2P10 7.87 2.53e-14 2.44e-11 0.44 0.34 Intelligence (multi-trait analysis); chr15:82245013 chr15:82472993~82513950:- LUSC cis rs9322193 0.923 rs9505982 ENSG00000223701.3 RAET1E-AS1 7.87 2.54e-14 2.44e-11 0.39 0.34 Lung cancer; chr6:149618465 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs10747275 ENSG00000223701.3 RAET1E-AS1 7.87 2.54e-14 2.44e-11 0.39 0.34 Lung cancer; chr6:149622782 chr6:149884431~149919508:+ LUSC cis rs875971 0.862 rs2460432 ENSG00000222364.1 RNU6-96P 7.86 2.57e-14 2.47e-11 0.41 0.34 Aortic root size; chr7:66089398 chr7:66395191~66395286:+ LUSC cis rs34779708 0.931 rs12771399 ENSG00000230534.5 RP11-297A16.2 7.86 2.57e-14 2.47e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35163449 chr10:35098006~35127020:- LUSC cis rs9487094 0.778 rs11757877 ENSG00000260273.1 RP11-425D10.10 7.86 2.57e-14 2.47e-11 0.44 0.34 Height; chr6:109360679 chr6:109382795~109383666:+ LUSC cis rs992157 0.735 rs13392177 ENSG00000261338.2 RP11-378A13.1 -7.86 2.58e-14 2.48e-11 -0.34 -0.34 Colorectal cancer; chr2:218248233 chr2:218255319~218257366:+ LUSC cis rs1075265 0.547 rs41385746 ENSG00000233266.1 HMGB1P31 -7.86 2.59e-14 2.49e-11 -0.42 -0.34 Chronotype;Morning vs. evening chronotype; chr2:54077893 chr2:54051334~54051760:+ LUSC cis rs34779708 0.931 rs11010101 ENSG00000230534.5 RP11-297A16.2 7.86 2.59e-14 2.49e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35122117 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs11010102 ENSG00000230534.5 RP11-297A16.2 7.86 2.59e-14 2.49e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35122138 chr10:35098006~35127020:- LUSC cis rs11098499 0.954 rs12506546 ENSG00000249244.1 RP11-548H18.2 7.86 2.6e-14 2.5e-11 0.44 0.34 Corneal astigmatism; chr4:119380463 chr4:119391831~119395335:- LUSC cis rs7945705 0.902 rs7479407 ENSG00000254860.4 TMEM9B-AS1 -7.86 2.61e-14 2.51e-11 -0.37 -0.34 Hemoglobin concentration; chr11:9001874 chr11:8964675~8977527:+ LUSC cis rs801193 0.636 rs2659895 ENSG00000222364.1 RNU6-96P -7.86 2.62e-14 2.51e-11 -0.4 -0.34 Aortic root size; chr7:66731484 chr7:66395191~66395286:+ LUSC cis rs2412819 0.571 rs7174260 ENSG00000249839.1 AC011330.5 -7.86 2.62e-14 2.52e-11 -0.57 -0.34 Lung cancer; chr15:43751988 chr15:43663654~43684339:- LUSC cis rs1707322 1 rs10789486 ENSG00000280836.1 AL355480.1 -7.86 2.62e-14 2.52e-11 -0.4 -0.34 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45942995 chr1:45581219~45581321:- LUSC cis rs80285556 1 rs17661933 ENSG00000161643.11 SIGLEC16 -7.86 2.64e-14 2.53e-11 -0.72 -0.34 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50031263 chr19:49969673~49975814:+ LUSC cis rs7811142 1 rs6972167 ENSG00000242294.5 STAG3L5P 7.86 2.64e-14 2.53e-11 0.27 0.34 Platelet count; chr7:100482390 chr7:100336079~100351900:+ LUSC cis rs783540 0.632 rs17356528 ENSG00000276710.3 CSPG4P8 7.86 2.64e-14 2.53e-11 0.38 0.34 Schizophrenia; chr15:82636799 chr15:82459472~82477258:+ LUSC cis rs11098499 0.604 rs2389882 ENSG00000249244.1 RP11-548H18.2 7.86 2.66e-14 2.56e-11 0.44 0.34 Corneal astigmatism; chr4:119645578 chr4:119391831~119395335:- LUSC cis rs11098499 0.739 rs951570 ENSG00000245958.5 RP11-33B1.1 7.86 2.67e-14 2.56e-11 0.33 0.34 Corneal astigmatism; chr4:119229312 chr4:119454791~119552025:+ LUSC cis rs9322193 0.962 rs2065664 ENSG00000223701.3 RAET1E-AS1 7.86 2.67e-14 2.56e-11 0.38 0.34 Lung cancer; chr6:149762485 chr6:149884431~149919508:+ LUSC cis rs11098499 0.739 rs7441137 ENSG00000245958.5 RP11-33B1.1 7.86 2.67e-14 2.56e-11 0.33 0.34 Corneal astigmatism; chr4:119212066 chr4:119454791~119552025:+ LUSC cis rs11098499 0.739 rs4833612 ENSG00000245958.5 RP11-33B1.1 7.86 2.67e-14 2.56e-11 0.33 0.34 Corneal astigmatism; chr4:119226441 chr4:119454791~119552025:+ LUSC cis rs11098499 0.739 rs10013032 ENSG00000245958.5 RP11-33B1.1 7.86 2.67e-14 2.56e-11 0.33 0.34 Corneal astigmatism; chr4:119228264 chr4:119454791~119552025:+ LUSC cis rs4713118 0.662 rs149901 ENSG00000219392.1 RP1-265C24.5 -7.86 2.68e-14 2.57e-11 -0.46 -0.34 Parkinson's disease; chr6:27997725 chr6:28115628~28116551:+ LUSC cis rs7772486 0.536 rs9373467 ENSG00000235652.6 RP11-545I5.3 7.86 2.71e-14 2.6e-11 0.36 0.34 Lobe attachment (rater-scored or self-reported); chr6:145634469 chr6:145799409~145886585:+ LUSC cis rs875971 0.825 rs4587224 ENSG00000222364.1 RNU6-96P 7.86 2.72e-14 2.6e-11 0.41 0.34 Aortic root size; chr7:66271195 chr7:66395191~66395286:+ LUSC cis rs34779708 0.897 rs9665538 ENSG00000230534.5 RP11-297A16.2 7.86 2.73e-14 2.61e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35172110 chr10:35098006~35127020:- LUSC cis rs7811142 1 rs76913697 ENSG00000242294.5 STAG3L5P 7.86 2.73e-14 2.62e-11 0.27 0.34 Platelet count; chr7:100405149 chr7:100336079~100351900:+ LUSC cis rs380904 0.926 rs7842979 ENSG00000254859.1 RP11-661A12.5 -7.86 2.74e-14 2.62e-11 -0.46 -0.34 Venous thromboembolism (SNP x SNP interaction); chr8:143519726 chr8:143541973~143549729:- LUSC cis rs10129255 0.833 rs61997797 ENSG00000224373.3 IGHV4-59 7.86 2.74e-14 2.62e-11 0.19 0.34 Kawasaki disease; chr14:106815190 chr14:106627249~106627825:- LUSC cis rs875971 0.862 rs7786892 ENSG00000222364.1 RNU6-96P 7.85 2.75e-14 2.63e-11 0.41 0.34 Aortic root size; chr7:66163889 chr7:66395191~66395286:+ LUSC cis rs189798 0.807 rs12785 ENSG00000254340.1 RP11-10A14.3 7.85 2.75e-14 2.63e-11 0.46 0.34 Myopia (pathological); chr8:9137426 chr8:9141424~9145435:+ LUSC cis rs80285556 0.655 rs17311832 ENSG00000161643.11 SIGLEC16 7.85 2.75e-14 2.63e-11 0.79 0.34 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50022059 chr19:49969673~49975814:+ LUSC cis rs80285556 1 rs80314222 ENSG00000161643.11 SIGLEC16 7.85 2.75e-14 2.63e-11 0.79 0.34 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50022257 chr19:49969673~49975814:+ LUSC cis rs3823536 0.583 rs10156169 ENSG00000275106.1 RP11-309L24.10 -7.85 2.76e-14 2.64e-11 -0.47 -0.34 Sjögren's syndrome; chr7:129044517 chr7:128952527~128953316:- LUSC cis rs8072100 0.935 rs78551919 ENSG00000228782.6 CTD-2026D20.3 -7.85 2.77e-14 2.65e-11 -0.32 -0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47548636 chr17:47450568~47492492:- LUSC cis rs10256972 0.621 rs2363285 ENSG00000229043.2 AC091729.9 -7.85 2.78e-14 2.66e-11 -0.38 -0.34 Endometriosis;Longevity; chr7:1052008 chr7:1160374~1165267:+ LUSC cis rs34779708 0.966 rs11599606 ENSG00000230534.5 RP11-297A16.2 7.85 2.79e-14 2.67e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35117698 chr10:35098006~35127020:- LUSC cis rs875971 0.862 rs778686 ENSG00000237310.1 GS1-124K5.4 7.85 2.81e-14 2.69e-11 0.35 0.34 Aortic root size; chr7:66370923 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs778684 ENSG00000237310.1 GS1-124K5.4 7.85 2.81e-14 2.69e-11 0.35 0.34 Aortic root size; chr7:66371416 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs778680 ENSG00000237310.1 GS1-124K5.4 7.85 2.81e-14 2.69e-11 0.35 0.34 Aortic root size; chr7:66375427 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs11769079 ENSG00000237310.1 GS1-124K5.4 7.85 2.81e-14 2.69e-11 0.35 0.34 Aortic root size; chr7:66377141 chr7:66493706~66495474:+ LUSC cis rs7811142 0.83 rs7792525 ENSG00000242294.5 STAG3L5P 7.85 2.81e-14 2.69e-11 0.27 0.34 Platelet count; chr7:100374499 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs6945952 ENSG00000242294.5 STAG3L5P 7.85 2.81e-14 2.69e-11 0.27 0.34 Platelet count; chr7:100384152 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs73401450 ENSG00000242294.5 STAG3L5P 7.85 2.81e-14 2.69e-11 0.27 0.34 Platelet count; chr7:100384236 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs73401451 ENSG00000242294.5 STAG3L5P 7.85 2.81e-14 2.69e-11 0.27 0.34 Platelet count; chr7:100384272 chr7:100336079~100351900:+ LUSC cis rs55665837 1 rs11023224 ENSG00000251991.1 RNU7-49P 7.85 2.82e-14 2.7e-11 0.38 0.34 Vitamin D levels; chr11:14436193 chr11:14478892~14478953:+ LUSC cis rs55665837 0.961 rs11023226 ENSG00000251991.1 RNU7-49P 7.85 2.82e-14 2.7e-11 0.38 0.34 Vitamin D levels; chr11:14437271 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs11023227 ENSG00000251991.1 RNU7-49P 7.85 2.82e-14 2.7e-11 0.38 0.34 Vitamin D levels; chr11:14437541 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs10832264 ENSG00000251991.1 RNU7-49P 7.85 2.82e-14 2.7e-11 0.38 0.34 Vitamin D levels; chr11:14438436 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs11023229 ENSG00000251991.1 RNU7-49P 7.85 2.82e-14 2.7e-11 0.38 0.34 Vitamin D levels; chr11:14439455 chr11:14478892~14478953:+ LUSC cis rs11098499 0.71 rs6851130 ENSG00000245958.5 RP11-33B1.1 7.85 2.84e-14 2.71e-11 0.33 0.34 Corneal astigmatism; chr4:119212557 chr4:119454791~119552025:+ LUSC cis rs2108622 0.958 rs79400241 ENSG00000267453.5 AC004791.2 -7.85 2.85e-14 2.72e-11 -0.47 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15873592 chr19:15851993~15864904:- LUSC cis rs11155671 0.53 rs9371215 ENSG00000268592.3 RAET1E-AS1 7.85 2.86e-14 2.73e-11 0.42 0.34 Testicular germ cell tumor; chr6:149873162 chr6:149863494~149919507:+ LUSC cis rs875971 0.767 rs12668005 ENSG00000237310.1 GS1-124K5.4 7.85 2.87e-14 2.74e-11 0.36 0.34 Aortic root size; chr7:66444034 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs11765791 ENSG00000237310.1 GS1-124K5.4 7.85 2.87e-14 2.74e-11 0.36 0.34 Aortic root size; chr7:66471587 chr7:66493706~66495474:+ LUSC cis rs6782228 1 rs12635488 ENSG00000242551.2 POU5F1P6 7.85 2.88e-14 2.75e-11 0.44 0.34 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128633535 chr3:128674735~128677005:- LUSC cis rs6991838 0.806 rs4285523 ENSG00000272010.1 CTD-3025N20.3 7.85 2.9e-14 2.76e-11 0.38 0.34 Intelligence (multi-trait analysis); chr8:65552095 chr8:65591850~65592472:- LUSC cis rs875971 0.83 rs778711 ENSG00000237310.1 GS1-124K5.4 7.85 2.9e-14 2.76e-11 0.36 0.34 Aortic root size; chr7:66386670 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs1083554 ENSG00000237310.1 GS1-124K5.4 7.85 2.9e-14 2.76e-11 0.36 0.34 Aortic root size; chr7:66387354 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs778707 ENSG00000237310.1 GS1-124K5.4 7.85 2.9e-14 2.76e-11 0.36 0.34 Aortic root size; chr7:66392040 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs778705 ENSG00000237310.1 GS1-124K5.4 7.85 2.9e-14 2.76e-11 0.36 0.34 Aortic root size; chr7:66396128 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs778697 ENSG00000237310.1 GS1-124K5.4 7.85 2.9e-14 2.76e-11 0.36 0.34 Aortic root size; chr7:66405439 chr7:66493706~66495474:+ LUSC cis rs875971 0.798 rs7789615 ENSG00000237310.1 GS1-124K5.4 7.85 2.9e-14 2.76e-11 0.36 0.34 Aortic root size; chr7:66413674 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6978028 ENSG00000237310.1 GS1-124K5.4 7.85 2.9e-14 2.76e-11 0.36 0.34 Aortic root size; chr7:66421313 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6947339 ENSG00000237310.1 GS1-124K5.4 7.85 2.9e-14 2.76e-11 0.36 0.34 Aortic root size; chr7:66423483 chr7:66493706~66495474:+ LUSC cis rs11098499 0.954 rs1546505 ENSG00000249244.1 RP11-548H18.2 7.85 2.9e-14 2.77e-11 0.45 0.34 Corneal astigmatism; chr4:119320069 chr4:119391831~119395335:- LUSC cis rs3096299 0.967 rs753852 ENSG00000274627.1 RP11-104N10.2 7.85 2.94e-14 2.8e-11 0.31 0.34 Multiple myeloma (IgH translocation); chr16:89380011 chr16:89516797~89522217:+ LUSC cis rs3096299 0.967 rs753853 ENSG00000274627.1 RP11-104N10.2 7.85 2.94e-14 2.8e-11 0.31 0.34 Multiple myeloma (IgH translocation); chr16:89380117 chr16:89516797~89522217:+ LUSC cis rs9322193 0.884 rs62439836 ENSG00000223701.3 RAET1E-AS1 7.85 2.94e-14 2.8e-11 0.4 0.34 Lung cancer; chr6:149669173 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs4869812 ENSG00000223701.3 RAET1E-AS1 7.85 2.94e-14 2.8e-11 0.4 0.34 Lung cancer; chr6:149669447 chr6:149884431~149919508:+ LUSC cis rs7811142 0.83 rs7341507 ENSG00000242294.5 STAG3L5P 7.84 2.94e-14 2.8e-11 0.27 0.34 Platelet count; chr7:100353692 chr7:100336079~100351900:+ LUSC cis rs11098499 0.954 rs59394118 ENSG00000249244.1 RP11-548H18.2 7.84 2.95e-14 2.81e-11 0.44 0.34 Corneal astigmatism; chr4:119374396 chr4:119391831~119395335:- LUSC cis rs11098499 0.865 rs9996417 ENSG00000249244.1 RP11-548H18.2 7.84 2.95e-14 2.81e-11 0.44 0.34 Corneal astigmatism; chr4:119374707 chr4:119391831~119395335:- LUSC cis rs875971 0.862 rs949930 ENSG00000222364.1 RNU6-96P 7.84 2.95e-14 2.81e-11 0.4 0.34 Aortic root size; chr7:66301835 chr7:66395191~66395286:+ LUSC cis rs2745572 0.538 rs4587210 ENSG00000272279.1 RP11-157J24.2 7.84 2.95e-14 2.81e-11 0.44 0.34 Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure); chr6:1542956 chr6:1528364~1528911:- LUSC cis rs853679 0.567 rs6905380 ENSG00000216901.1 AL022393.7 7.84 2.99e-14 2.84e-11 0.41 0.34 Depression; chr6:28407125 chr6:28176188~28176674:+ LUSC cis rs7684253 0.548 rs13106200 ENSG00000269949.1 RP11-738E22.3 -7.84 2.99e-14 2.85e-11 -0.41 -0.34 Migraine; chr4:56852029 chr4:56960927~56961373:- LUSC cis rs34779708 0.966 rs34605125 ENSG00000230534.5 RP11-297A16.2 7.84 3.01e-14 2.87e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35122318 chr10:35098006~35127020:- LUSC cis rs11098499 0.909 rs11723839 ENSG00000249244.1 RP11-548H18.2 7.84 3.04e-14 2.89e-11 0.44 0.34 Corneal astigmatism; chr4:119378518 chr4:119391831~119395335:- LUSC cis rs1577917 0.545 rs9344548 ENSG00000203875.9 SNHG5 7.84 3.04e-14 2.9e-11 0.44 0.34 Response to antipsychotic treatment; chr6:85777619 chr6:85660950~85678736:- LUSC cis rs992157 0.71 rs6752254 ENSG00000261338.2 RP11-378A13.1 7.84 3.05e-14 2.9e-11 0.34 0.34 Colorectal cancer; chr2:218194020 chr2:218255319~218257366:+ LUSC cis rs9322193 0.923 rs12176034 ENSG00000223701.3 RAET1E-AS1 7.84 3.07e-14 2.92e-11 0.4 0.34 Lung cancer; chr6:149800557 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs4869750 ENSG00000223701.3 RAET1E-AS1 7.84 3.07e-14 2.92e-11 0.39 0.34 Lung cancer; chr6:149855996 chr6:149884431~149919508:+ LUSC cis rs10129255 0.576 rs2157616 ENSG00000211970.3 IGHV4-61 -7.84 3.07e-14 2.92e-11 -0.21 -0.34 Kawasaki disease; chr14:106767802 chr14:106639119~106639657:- LUSC cis rs4423214 0.65 rs4245442 ENSG00000254682.1 RP11-660L16.2 7.84 3.09e-14 2.94e-11 0.49 0.34 Vitamin D levels; chr11:71509863 chr11:71448674~71452157:+ LUSC cis rs11098499 0.954 rs17006190 ENSG00000249244.1 RP11-548H18.2 7.84 3.09e-14 2.94e-11 0.44 0.34 Corneal astigmatism; chr4:119497683 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs3733519 ENSG00000249244.1 RP11-548H18.2 7.84 3.09e-14 2.94e-11 0.44 0.34 Corneal astigmatism; chr4:119502293 chr4:119391831~119395335:- LUSC cis rs34779708 0.966 rs35146199 ENSG00000230534.5 RP11-297A16.2 7.84 3.11e-14 2.95e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35172011 chr10:35098006~35127020:- LUSC cis rs35160687 0.798 rs2367233 ENSG00000273080.1 RP11-301O19.1 -7.84 3.13e-14 2.98e-11 -0.33 -0.34 Night sleep phenotypes; chr2:86314543 chr2:86195590~86196049:+ LUSC cis rs1075265 0.597 rs11694711 ENSG00000233266.1 HMGB1P31 7.84 3.14e-14 2.98e-11 0.43 0.34 Chronotype;Morning vs. evening chronotype; chr2:53971924 chr2:54051334~54051760:+ LUSC cis rs6991838 0.778 rs11782837 ENSG00000272010.1 CTD-3025N20.3 7.84 3.14e-14 2.99e-11 0.38 0.34 Intelligence (multi-trait analysis); chr8:65550328 chr8:65591850~65592472:- LUSC cis rs11098499 0.78 rs7692994 ENSG00000245958.5 RP11-33B1.1 -7.83 3.16e-14 3e-11 -0.34 -0.34 Corneal astigmatism; chr4:119506334 chr4:119454791~119552025:+ LUSC cis rs34779708 0.966 rs12765038 ENSG00000230534.5 RP11-297A16.2 7.83 3.17e-14 3.01e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35127585 chr10:35098006~35127020:- LUSC cis rs11098499 0.954 rs10017371 ENSG00000249244.1 RP11-548H18.2 7.83 3.19e-14 3.03e-11 0.45 0.34 Corneal astigmatism; chr4:119372621 chr4:119391831~119395335:- LUSC cis rs875971 0.798 rs6460304 ENSG00000222364.1 RNU6-96P -7.83 3.2e-14 3.03e-11 -0.4 -0.34 Aortic root size; chr7:66499741 chr7:66395191~66395286:+ LUSC cis rs875971 0.798 rs12698522 ENSG00000237310.1 GS1-124K5.4 7.83 3.21e-14 3.04e-11 0.36 0.34 Aortic root size; chr7:66502354 chr7:66493706~66495474:+ LUSC cis rs875971 0.83 rs28714531 ENSG00000237310.1 GS1-124K5.4 7.83 3.21e-14 3.04e-11 0.36 0.34 Aortic root size; chr7:66503250 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs12698526 ENSG00000237310.1 GS1-124K5.4 7.83 3.21e-14 3.04e-11 0.36 0.34 Aortic root size; chr7:66504118 chr7:66493706~66495474:+ LUSC cis rs35955747 0.902 rs5997919 ENSG00000236132.1 CTA-440B3.1 7.83 3.21e-14 3.05e-11 0.41 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31227456 chr22:31816379~31817491:- LUSC cis rs4706831 0.647 rs627240 ENSG00000272129.1 RP11-250B2.6 -7.83 3.21e-14 3.05e-11 -0.41 -0.34 Joint mobility (Beighton score); chr6:80276168 chr6:80355424~80356859:+ LUSC cis rs11089937 0.589 rs4239891 ENSG00000211639.2 IGLV4-60 7.83 3.22e-14 3.05e-11 0.37 0.34 Periodontitis (PAL4Q3); chr22:22165674 chr22:22162199~22162681:+ LUSC cis rs7811142 0.887 rs35111986 ENSG00000242294.5 STAG3L5P 7.83 3.23e-14 3.07e-11 0.28 0.34 Platelet count; chr7:100402651 chr7:100336079~100351900:+ LUSC cis rs55665837 1 rs34382046 ENSG00000251991.1 RNU7-49P 7.83 3.24e-14 3.07e-11 0.38 0.34 Vitamin D levels; chr11:14429772 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs7945167 ENSG00000251991.1 RNU7-49P 7.83 3.24e-14 3.07e-11 0.38 0.34 Vitamin D levels; chr11:14430274 chr11:14478892~14478953:+ LUSC cis rs55665837 0.961 rs60622588 ENSG00000251991.1 RNU7-49P 7.83 3.24e-14 3.07e-11 0.38 0.34 Vitamin D levels; chr11:14435452 chr11:14478892~14478953:+ LUSC cis rs55665837 1 rs11023223 ENSG00000251991.1 RNU7-49P 7.83 3.24e-14 3.07e-11 0.38 0.34 Vitamin D levels; chr11:14435566 chr11:14478892~14478953:+ LUSC cis rs8040855 0.791 rs8042888 ENSG00000259295.5 CSPG4P12 -7.83 3.27e-14 3.1e-11 -0.42 -0.34 Bulimia nervosa; chr15:85152360 chr15:85191438~85213905:+ LUSC cis rs6903823 0.508 rs1150726 ENSG00000204709.4 LINC01556 7.83 3.3e-14 3.13e-11 0.41 0.34 Pulmonary function; chr6:28275265 chr6:28943877~28944537:+ LUSC cis rs11098499 0.955 rs11944880 ENSG00000249244.1 RP11-548H18.2 -7.83 3.3e-14 3.13e-11 -0.43 -0.34 Corneal astigmatism; chr4:119238179 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs12502423 ENSG00000249244.1 RP11-548H18.2 7.83 3.32e-14 3.14e-11 0.43 0.34 Corneal astigmatism; chr4:119503017 chr4:119391831~119395335:- LUSC cis rs9322193 0.576 rs7452592 ENSG00000216906.2 RP11-350J20.9 7.83 3.33e-14 3.15e-11 0.48 0.34 Lung cancer; chr6:149875445 chr6:149904243~149906418:+ LUSC cis rs35955747 0.869 rs8141987 ENSG00000236132.1 CTA-440B3.1 7.83 3.34e-14 3.17e-11 0.41 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31191169 chr22:31816379~31817491:- LUSC cis rs35955747 0.869 rs8142988 ENSG00000236132.1 CTA-440B3.1 7.83 3.34e-14 3.17e-11 0.41 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31191172 chr22:31816379~31817491:- LUSC cis rs2712431 0.554 rs2010054 ENSG00000277250.1 Metazoa_SRP -7.83 3.35e-14 3.17e-11 -0.39 -0.34 Monocyte chemoattractant protein-1 levels; chr3:128586459 chr3:128673681~128674021:- LUSC cis rs6991838 0.584 rs7842085 ENSG00000272010.1 CTD-3025N20.3 7.83 3.36e-14 3.18e-11 0.4 0.34 Intelligence (multi-trait analysis); chr8:65636787 chr8:65591850~65592472:- LUSC cis rs801193 0.66 rs2659897 ENSG00000222364.1 RNU6-96P 7.83 3.37e-14 3.19e-11 0.4 0.34 Aortic root size; chr7:66722728 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6945775 ENSG00000222364.1 RNU6-96P -7.83 3.37e-14 3.19e-11 -0.4 -0.34 Aortic root size; chr7:66503987 chr7:66395191~66395286:+ LUSC cis rs9322193 0.962 rs9688412 ENSG00000223701.3 RAET1E-AS1 -7.82 3.39e-14 3.2e-11 -0.39 -0.34 Lung cancer; chr6:149803147 chr6:149884431~149919508:+ LUSC cis rs9487094 1 rs9480933 ENSG00000260273.1 RP11-425D10.10 7.82 3.39e-14 3.21e-11 0.41 0.34 Height; chr6:109350188 chr6:109382795~109383666:+ LUSC cis rs1113500 0.541 rs6692571 ENSG00000226822.1 RP11-356N1.2 7.82 3.4e-14 3.22e-11 0.4 0.34 Growth-regulated protein alpha levels; chr1:108034062 chr1:108071482~108074519:+ LUSC cis rs11098499 0.739 rs9884728 ENSG00000245958.5 RP11-33B1.1 7.82 3.42e-14 3.23e-11 0.33 0.34 Corneal astigmatism; chr4:119205924 chr4:119454791~119552025:+ LUSC cis rs11098499 0.739 rs6534130 ENSG00000245958.5 RP11-33B1.1 7.82 3.42e-14 3.23e-11 0.33 0.34 Corneal astigmatism; chr4:119210184 chr4:119454791~119552025:+ LUSC cis rs694739 0.628 rs475032 ENSG00000236935.1 AP003774.1 -7.82 3.43e-14 3.24e-11 -0.33 -0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373265 chr11:64325050~64329504:- LUSC cis rs9322193 0.923 rs10782310 ENSG00000223701.3 RAET1E-AS1 7.82 3.43e-14 3.24e-11 0.39 0.34 Lung cancer; chr6:149622458 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs10782311 ENSG00000223701.3 RAET1E-AS1 7.82 3.43e-14 3.24e-11 0.39 0.34 Lung cancer; chr6:149622592 chr6:149884431~149919508:+ LUSC cis rs2929278 0.638 rs2016840 ENSG00000249839.1 AC011330.5 7.82 3.45e-14 3.26e-11 0.44 0.34 Schizophrenia; chr15:43919670 chr15:43663654~43684339:- LUSC cis rs2179367 0.919 rs4897124 ENSG00000231760.4 RP11-350J20.5 7.82 3.45e-14 3.26e-11 0.43 0.34 Dupuytren's disease; chr6:149442073 chr6:149796151~149826294:- LUSC cis rs34779708 0.733 rs11597184 ENSG00000230534.5 RP11-297A16.2 7.82 3.45e-14 3.26e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35108468 chr10:35098006~35127020:- LUSC cis rs1185460 0.565 rs657685 ENSG00000271751.1 RP11-110I1.14 7.82 3.46e-14 3.27e-11 0.42 0.34 Coronary artery disease; chr11:119042272 chr11:119065263~119065677:- LUSC cis rs2739330 0.627 rs9608219 ENSG00000099984.9 GSTT2 -7.82 3.48e-14 3.29e-11 -0.41 -0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23980123~23983911:+ LUSC cis rs9545047 0.716 rs9545061 ENSG00000227676.3 LINC01068 7.82 3.48e-14 3.29e-11 0.41 0.34 Schizophrenia; chr13:79310695 chr13:79566727~79571436:+ LUSC cis rs34779708 0.966 rs878264 ENSG00000230534.5 RP11-297A16.2 7.82 3.5e-14 3.31e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35151653 chr10:35098006~35127020:- LUSC cis rs10829156 0.699 rs10828879 ENSG00000240291.1 RP11-499P20.2 7.82 3.5e-14 3.31e-11 0.35 0.34 Sudden cardiac arrest; chr10:18546425 chr10:18513115~18545651:- LUSC cis rs7617773 0.817 rs9819094 ENSG00000228638.1 FCF1P2 -7.82 3.5e-14 3.31e-11 -0.38 -0.34 Coronary artery disease; chr3:48278068 chr3:48290793~48291375:- LUSC cis rs1185460 0.547 rs667584 ENSG00000271751.1 RP11-110I1.14 7.82 3.51e-14 3.31e-11 0.42 0.34 Coronary artery disease; chr11:119040834 chr11:119065263~119065677:- LUSC cis rs9487094 0.665 rs13207864 ENSG00000260273.1 RP11-425D10.10 7.82 3.53e-14 3.33e-11 0.45 0.34 Height; chr6:109708527 chr6:109382795~109383666:+ LUSC cis rs9322193 0.962 rs9322206 ENSG00000223701.3 RAET1E-AS1 7.82 3.54e-14 3.35e-11 0.39 0.34 Lung cancer; chr6:149641481 chr6:149884431~149919508:+ LUSC cis rs694739 0.595 rs11542299 ENSG00000236935.1 AP003774.1 7.82 3.55e-14 3.35e-11 0.33 0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64371333 chr11:64325050~64329504:- LUSC cis rs10129255 0.744 rs28517388 ENSG00000211972.2 IGHV3-66 7.82 3.55e-14 3.35e-11 0.27 0.34 Kawasaki disease; chr14:106704323 chr14:106675017~106675544:- LUSC cis rs7044106 0.615 rs10818470 ENSG00000226752.6 PSMD5-AS1 -7.82 3.55e-14 3.35e-11 -0.39 -0.34 Hip circumference adjusted for BMI; chr9:120596926 chr9:120824828~120854385:+ LUSC cis rs11089937 0.568 rs12159174 ENSG00000211639.2 IGLV4-60 7.82 3.55e-14 3.35e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22131639 chr22:22162199~22162681:+ LUSC cis rs11098499 0.865 rs4507344 ENSG00000249244.1 RP11-548H18.2 7.82 3.55e-14 3.35e-11 0.44 0.34 Corneal astigmatism; chr4:119386330 chr4:119391831~119395335:- LUSC cis rs11098499 0.644 rs10009566 ENSG00000245958.5 RP11-33B1.1 -7.82 3.56e-14 3.36e-11 -0.33 -0.34 Corneal astigmatism; chr4:119637453 chr4:119454791~119552025:+ LUSC cis rs11098499 0.954 rs10006525 ENSG00000249244.1 RP11-548H18.2 7.82 3.56e-14 3.36e-11 0.44 0.34 Corneal astigmatism; chr4:119487776 chr4:119391831~119395335:- LUSC cis rs5769707 0.837 rs5770599 ENSG00000235111.1 RP1-29C18.8 -7.82 3.56e-14 3.36e-11 -0.39 -0.34 Monocyte percentage of white cells;Monocyte count; chr22:49626333 chr22:49612657~49615716:- LUSC cis rs6700559 0.692 rs2809342 ENSG00000260088.1 RP11-92G12.3 -7.82 3.57e-14 3.37e-11 -0.42 -0.34 Coronary artery disease; chr1:200628522 chr1:200669507~200694250:+ LUSC cis rs34779708 0.966 rs17591857 ENSG00000230534.5 RP11-297A16.2 -7.82 3.57e-14 3.37e-11 -0.37 -0.34 Inflammatory bowel disease;Crohn's disease; chr10:35210115 chr10:35098006~35127020:- LUSC cis rs11098499 0.618 rs28491261 ENSG00000249244.1 RP11-548H18.2 7.82 3.57e-14 3.37e-11 0.44 0.34 Corneal astigmatism; chr4:119373745 chr4:119391831~119395335:- LUSC cis rs34779708 0.966 rs12762493 ENSG00000230534.5 RP11-297A16.2 7.82 3.58e-14 3.38e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35182945 chr10:35098006~35127020:- LUSC cis rs35955747 0.838 rs7285171 ENSG00000236132.1 CTA-440B3.1 7.82 3.59e-14 3.38e-11 0.41 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31202381 chr22:31816379~31817491:- LUSC cis rs35955747 0.84 rs9621221 ENSG00000236132.1 CTA-440B3.1 7.82 3.62e-14 3.41e-11 0.41 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31220183 chr22:31816379~31817491:- LUSC cis rs6496044 0.507 rs2467096 ENSG00000202081.1 RNU6-1280P -7.82 3.62e-14 3.41e-11 -0.38 -0.34 Interstitial lung disease; chr15:85667447 chr15:85651522~85651628:- LUSC cis rs34779708 0.897 rs16935880 ENSG00000230534.5 RP11-297A16.2 7.82 3.63e-14 3.42e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35126540 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs4934730 ENSG00000230534.5 RP11-297A16.2 7.82 3.63e-14 3.42e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35126627 chr10:35098006~35127020:- LUSC cis rs2739330 0.796 rs5760097 ENSG00000235689.1 AP000351.13 7.81 3.64e-14 3.43e-11 0.36 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:24006305~24008258:- LUSC cis rs875971 0.861 rs801215 ENSG00000237310.1 GS1-124K5.4 -7.81 3.64e-14 3.43e-11 -0.36 -0.34 Aortic root size; chr7:66546951 chr7:66493706~66495474:+ LUSC cis rs694739 0.892 rs647152 ENSG00000236935.1 AP003774.1 7.81 3.65e-14 3.44e-11 0.33 0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64341646 chr11:64325050~64329504:- LUSC cis rs801193 0.613 rs2659900 ENSG00000222364.1 RNU6-96P -7.81 3.66e-14 3.45e-11 -0.4 -0.34 Aortic root size; chr7:66719456 chr7:66395191~66395286:+ LUSC cis rs2739330 0.892 rs5751776 ENSG00000235689.1 AP000351.13 7.81 3.68e-14 3.46e-11 0.36 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:24006305~24008258:- LUSC cis rs875971 0.825 rs1129531 ENSG00000222364.1 RNU6-96P 7.81 3.68e-14 3.46e-11 0.41 0.34 Aortic root size; chr7:66154117 chr7:66395191~66395286:+ LUSC cis rs783540 0.5 rs783541 ENSG00000255769.6 GOLGA2P10 7.81 3.7e-14 3.48e-11 0.46 0.34 Schizophrenia; chr15:82586310 chr15:82472993~82513950:- LUSC cis rs9545047 0.716 rs9545067 ENSG00000227676.3 LINC01068 7.81 3.71e-14 3.49e-11 0.41 0.34 Schizophrenia; chr13:79323429 chr13:79566727~79571436:+ LUSC cis rs9545047 0.68 rs9574405 ENSG00000227676.3 LINC01068 7.81 3.71e-14 3.49e-11 0.41 0.34 Schizophrenia; chr13:79328943 chr13:79566727~79571436:+ LUSC cis rs7617773 0.817 rs936426 ENSG00000228638.1 FCF1P2 -7.81 3.72e-14 3.5e-11 -0.39 -0.34 Coronary artery disease; chr3:48173763 chr3:48290793~48291375:- LUSC cis rs10129255 0.957 rs4387509 ENSG00000211972.2 IGHV3-66 7.81 3.73e-14 3.51e-11 0.26 0.34 Kawasaki disease; chr14:106704386 chr14:106675017~106675544:- LUSC cis rs9322193 0.962 rs2275046 ENSG00000223701.3 RAET1E-AS1 7.81 3.73e-14 3.51e-11 0.39 0.34 Lung cancer; chr6:149835865 chr6:149884431~149919508:+ LUSC cis rs7811142 0.72 rs7795656 ENSG00000242294.5 STAG3L5P 7.81 3.74e-14 3.52e-11 0.27 0.34 Platelet count; chr7:100352674 chr7:100336079~100351900:+ LUSC cis rs4660456 0.913 rs4660449 ENSG00000237899.1 RP4-739H11.3 7.81 3.76e-14 3.54e-11 0.47 0.34 Platelet count; chr1:40739780 chr1:40669089~40687588:- LUSC cis rs10129255 0.872 rs8015406 ENSG00000224373.3 IGHV4-59 7.81 3.77e-14 3.54e-11 0.19 0.34 Kawasaki disease; chr14:106670611 chr14:106627249~106627825:- LUSC cis rs7772486 0.558 rs9376965 ENSG00000235652.6 RP11-545I5.3 7.81 3.77e-14 3.55e-11 0.36 0.34 Lobe attachment (rater-scored or self-reported); chr6:145808919 chr6:145799409~145886585:+ LUSC cis rs2739330 0.753 rs4822452 ENSG00000235689.1 AP000351.13 7.81 3.79e-14 3.56e-11 0.36 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:24006305~24008258:- LUSC cis rs1789 0.786 rs6449161 ENSG00000273133.1 RP11-799M12.2 -7.81 3.81e-14 3.58e-11 -0.47 -0.34 Blood protein levels; chr4:15691331 chr4:15563698~15564253:- LUSC cis rs5769707 0.935 rs1109320 ENSG00000235111.1 RP1-29C18.8 -7.81 3.83e-14 3.6e-11 -0.39 -0.34 Monocyte percentage of white cells;Monocyte count; chr22:49595458 chr22:49612657~49615716:- LUSC cis rs7201929 1 rs8061877 ENSG00000259982.1 CDC37P1 -7.81 3.85e-14 3.62e-11 -0.46 -0.34 QT interval; chr16:28845498 chr16:28700294~28701540:- LUSC cis rs1167827 0.68 rs1167796 ENSG00000127957.15 PMS2P3 7.81 3.85e-14 3.62e-11 0.31 0.34 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75543861 chr7:75502930~75528148:- LUSC cis rs10129255 0.828 rs10140989 ENSG00000224373.3 IGHV4-59 7.81 3.88e-14 3.64e-11 0.19 0.34 Kawasaki disease; chr14:106668657 chr14:106627249~106627825:- LUSC cis rs7811142 0.779 rs77370288 ENSG00000242294.5 STAG3L5P 7.8 3.91e-14 3.67e-11 0.27 0.34 Platelet count; chr7:100350274 chr7:100336079~100351900:+ LUSC cis rs4423214 0.61 rs3763856 ENSG00000254682.1 RP11-660L16.2 7.8 3.91e-14 3.67e-11 0.41 0.34 Vitamin D levels; chr11:71414299 chr11:71448674~71452157:+ LUSC cis rs875971 0.862 rs778702 ENSG00000222364.1 RNU6-96P -7.8 3.91e-14 3.67e-11 -0.4 -0.34 Aortic root size; chr7:66399848 chr7:66395191~66395286:+ LUSC cis rs1061377 1 rs4974931 ENSG00000249207.1 RP11-360F5.1 -7.8 3.92e-14 3.68e-11 -0.36 -0.34 Uric acid levels; chr4:39108896 chr4:39112677~39126818:- LUSC cis rs61160187 0.582 rs1021005 ENSG00000215032.2 GNL3LP1 7.8 3.93e-14 3.68e-11 0.42 0.34 Educational attainment (years of education);Educational attainment (college completion); chr5:60895633 chr5:60891935~60893577:- LUSC cis rs7044106 0.708 rs2416760 ENSG00000226752.6 PSMD5-AS1 -7.8 3.94e-14 3.69e-11 -0.38 -0.34 Hip circumference adjusted for BMI; chr9:120612361 chr9:120824828~120854385:+ LUSC cis rs11098499 0.863 rs13136462 ENSG00000245958.5 RP11-33B1.1 -7.8 3.95e-14 3.7e-11 -0.34 -0.34 Corneal astigmatism; chr4:119622018 chr4:119454791~119552025:+ LUSC cis rs7811142 0.83 rs11765869 ENSG00000242294.5 STAG3L5P 7.8 3.96e-14 3.71e-11 0.28 0.34 Platelet count; chr7:100367166 chr7:100336079~100351900:+ LUSC cis rs11089937 0.524 rs2877021 ENSG00000211639.2 IGLV4-60 7.8 3.96e-14 3.71e-11 0.36 0.34 Periodontitis (PAL4Q3); chr22:22165909 chr22:22162199~22162681:+ LUSC cis rs10129255 0.912 rs730099 ENSG00000211972.2 IGHV3-66 7.8 3.96e-14 3.71e-11 0.26 0.34 Kawasaki disease; chr14:106711838 chr14:106675017~106675544:- LUSC cis rs465969 0.744 rs3851228 ENSG00000255389.1 C6orf3 7.8 3.97e-14 3.72e-11 0.56 0.34 Psoriasis; chr6:111526988 chr6:111599875~111602295:+ LUSC cis rs875971 0.767 rs1643394 ENSG00000237310.1 GS1-124K5.4 7.8 3.98e-14 3.73e-11 0.35 0.34 Aortic root size; chr7:66371107 chr7:66493706~66495474:+ LUSC cis rs6991838 0.806 rs35024820 ENSG00000272010.1 CTD-3025N20.3 7.8 3.99e-14 3.73e-11 0.38 0.34 Intelligence (multi-trait analysis); chr8:65551296 chr8:65591850~65592472:- LUSC cis rs6496044 0.507 rs8034676 ENSG00000202081.1 RNU6-1280P 7.8 3.99e-14 3.74e-11 0.38 0.34 Interstitial lung disease; chr15:85616031 chr15:85651522~85651628:- LUSC cis rs12134133 0.752 rs6540874 ENSG00000274245.1 RP11-357P18.2 7.8 4.01e-14 3.75e-11 0.46 0.34 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207221638 chr1:207372559~207373252:+ LUSC cis rs6700559 0.692 rs4915447 ENSG00000260088.1 RP11-92G12.3 7.8 4.04e-14 3.78e-11 0.41 0.34 Coronary artery disease; chr1:200624340 chr1:200669507~200694250:+ LUSC cis rs3823536 0.583 rs2280714 ENSG00000275106.1 RP11-309L24.10 -7.8 4.04e-14 3.78e-11 -0.45 -0.34 Sjögren's syndrome; chr7:128954671 chr7:128952527~128953316:- LUSC cis rs3823536 0.583 rs10236569 ENSG00000275106.1 RP11-309L24.10 -7.8 4.04e-14 3.78e-11 -0.45 -0.34 Sjögren's syndrome; chr7:128957533 chr7:128952527~128953316:- LUSC cis rs17270561 0.723 rs12192635 ENSG00000272462.2 U91328.19 -7.8 4.06e-14 3.79e-11 -0.43 -0.34 Iron status biomarkers; chr6:25880679 chr6:25992662~26001775:+ LUSC cis rs2282300 0.739 rs1222219 ENSG00000254532.1 RP11-624D11.2 7.8 4.06e-14 3.8e-11 0.47 0.34 Morning vs. evening chronotype; chr11:30322798 chr11:30044058~30084343:- LUSC cis rs7044106 0.762 rs10818471 ENSG00000226752.6 PSMD5-AS1 -7.8 4.09e-14 3.83e-11 -0.39 -0.34 Hip circumference adjusted for BMI; chr9:120631767 chr9:120824828~120854385:+ LUSC cis rs11098499 0.954 rs6820115 ENSG00000245958.5 RP11-33B1.1 -7.8 4.1e-14 3.83e-11 -0.33 -0.34 Corneal astigmatism; chr4:119477027 chr4:119454791~119552025:+ LUSC cis rs875971 0.862 rs2420174 ENSG00000222364.1 RNU6-96P 7.8 4.1e-14 3.83e-11 0.4 0.34 Aortic root size; chr7:66180374 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs2420173 ENSG00000222364.1 RNU6-96P 7.8 4.1e-14 3.83e-11 0.4 0.34 Aortic root size; chr7:66180412 chr7:66395191~66395286:+ LUSC cis rs9326248 0.727 rs4938347 ENSG00000280143.1 AP000892.6 7.8 4.12e-14 3.85e-11 0.42 0.34 Blood protein levels; chr11:117151043 chr11:117204967~117210292:+ LUSC cis rs6991838 0.778 rs11779601 ENSG00000272010.1 CTD-3025N20.3 7.8 4.16e-14 3.88e-11 0.38 0.34 Intelligence (multi-trait analysis); chr8:65550241 chr8:65591850~65592472:- LUSC cis rs7811142 0.83 rs11771936 ENSG00000242294.5 STAG3L5P 7.8 4.16e-14 3.89e-11 0.27 0.34 Platelet count; chr7:100345660 chr7:100336079~100351900:+ LUSC cis rs875971 0.965 rs697968 ENSG00000222364.1 RNU6-96P 7.79 4.19e-14 3.91e-11 0.41 0.34 Aortic root size; chr7:66070046 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs1183245 ENSG00000222364.1 RNU6-96P 7.79 4.19e-14 3.91e-11 0.41 0.34 Aortic root size; chr7:66076198 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs1144895 ENSG00000222364.1 RNU6-96P 7.79 4.19e-14 3.91e-11 0.41 0.34 Aortic root size; chr7:66076320 chr7:66395191~66395286:+ LUSC cis rs875971 1 rs1144894 ENSG00000222364.1 RNU6-96P 7.79 4.19e-14 3.91e-11 0.41 0.34 Aortic root size; chr7:66077907 chr7:66395191~66395286:+ LUSC cis rs13113518 0.513 rs13132085 ENSG00000223305.1 RN7SKP30 -7.79 4.22e-14 3.94e-11 -0.41 -0.34 Height; chr4:55593918 chr4:55540502~55540835:- LUSC cis rs7772486 0.641 rs2253757 ENSG00000235652.6 RP11-545I5.3 7.79 4.24e-14 3.95e-11 0.36 0.34 Lobe attachment (rater-scored or self-reported); chr6:145878550 chr6:145799409~145886585:+ LUSC cis rs7044106 0.718 rs1960421 ENSG00000226752.6 PSMD5-AS1 -7.79 4.25e-14 3.96e-11 -0.39 -0.34 Hip circumference adjusted for BMI; chr9:120632616 chr9:120824828~120854385:+ LUSC cis rs3091242 0.934 rs686631 ENSG00000224183.1 SDHDP6 -7.79 4.26e-14 3.98e-11 -0.41 -0.34 Erythrocyte sedimentation rate; chr1:25393108 chr1:25294164~25294643:- LUSC cis rs200895692 1 rs200895692 ENSG00000227533.4 SLC2A1-AS1 7.79 4.27e-14 3.99e-11 0.47 0.34 Monocyte count; chr1:42956299 chr1:42959049~42983358:+ LUSC cis rs2282300 0.739 rs10835647 ENSG00000254532.1 RP11-624D11.2 7.79 4.28e-14 3.99e-11 0.46 0.34 Morning vs. evening chronotype; chr11:30291721 chr11:30044058~30084343:- LUSC cis rs7811142 1 rs60844404 ENSG00000242294.5 STAG3L5P 7.79 4.28e-14 3.99e-11 0.27 0.34 Platelet count; chr7:100482851 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs113738841 ENSG00000242294.5 STAG3L5P 7.79 4.28e-14 3.99e-11 0.27 0.34 Platelet count; chr7:100483683 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs11763511 ENSG00000242294.5 STAG3L5P 7.79 4.28e-14 3.99e-11 0.27 0.34 Platelet count; chr7:100484321 chr7:100336079~100351900:+ LUSC cis rs875971 0.798 rs57739047 ENSG00000222364.1 RNU6-96P -7.79 4.29e-14 4e-11 -0.4 -0.34 Aortic root size; chr7:66507579 chr7:66395191~66395286:+ LUSC cis rs875971 0.651 rs2420596 ENSG00000222364.1 RNU6-96P -7.79 4.3e-14 4.01e-11 -0.4 -0.34 Aortic root size; chr7:66450996 chr7:66395191~66395286:+ LUSC cis rs875971 0.52 rs2420597 ENSG00000222364.1 RNU6-96P -7.79 4.3e-14 4.01e-11 -0.4 -0.34 Aortic root size; chr7:66450999 chr7:66395191~66395286:+ LUSC cis rs11098499 0.566 rs17051356 ENSG00000249244.1 RP11-548H18.2 7.79 4.33e-14 4.03e-11 0.45 0.34 Corneal astigmatism; chr4:119664153 chr4:119391831~119395335:- LUSC cis rs11089937 0.568 rs12160318 ENSG00000211639.2 IGLV4-60 7.79 4.35e-14 4.05e-11 0.4 0.34 Periodontitis (PAL4Q3); chr22:22131627 chr22:22162199~22162681:+ LUSC cis rs9326248 0.768 rs4936366 ENSG00000280143.1 AP000892.6 7.79 4.36e-14 4.06e-11 0.41 0.34 Blood protein levels; chr11:117156169 chr11:117204967~117210292:+ LUSC cis rs131777 0.577 rs131748 ENSG00000205559.3 CHKB-AS1 7.79 4.36e-14 4.06e-11 0.4 0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586408 chr22:50583026~50583877:+ LUSC cis rs4713118 0.662 rs464312 ENSG00000219392.1 RP1-265C24.5 -7.79 4.36e-14 4.06e-11 -0.46 -0.34 Parkinson's disease; chr6:27999813 chr6:28115628~28116551:+ LUSC cis rs34779708 0.966 rs4294520 ENSG00000230534.5 RP11-297A16.2 7.79 4.36e-14 4.06e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35133578 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs34876468 ENSG00000230534.5 RP11-297A16.2 7.79 4.36e-14 4.06e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35135522 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs35814343 ENSG00000230534.5 RP11-297A16.2 7.79 4.36e-14 4.06e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35138786 chr10:35098006~35127020:- LUSC cis rs2283792 0.73 rs894095 ENSG00000228050.1 TOP3BP1 7.79 4.37e-14 4.07e-11 0.39 0.34 Multiple sclerosis; chr22:21928404 chr22:22223187~22224566:- LUSC cis rs172166 0.637 rs1233691 ENSG00000204709.4 LINC01556 7.79 4.37e-14 4.07e-11 0.43 0.34 Cardiac Troponin-T levels; chr6:28186119 chr6:28943877~28944537:+ LUSC cis rs172166 0.637 rs1225592 ENSG00000204709.4 LINC01556 7.79 4.38e-14 4.08e-11 0.43 0.34 Cardiac Troponin-T levels; chr6:28182464 chr6:28943877~28944537:+ LUSC cis rs172166 0.637 rs1225595 ENSG00000204709.4 LINC01556 7.79 4.38e-14 4.08e-11 0.43 0.34 Cardiac Troponin-T levels; chr6:28183562 chr6:28943877~28944537:+ LUSC cis rs8040855 0.93 rs6496767 ENSG00000259295.5 CSPG4P12 -7.79 4.4e-14 4.09e-11 -0.41 -0.34 Bulimia nervosa; chr15:85159522 chr15:85191438~85213905:+ LUSC cis rs6921919 0.832 rs17312661 ENSG00000204709.4 LINC01556 7.79 4.41e-14 4.11e-11 0.55 0.34 Autism spectrum disorder or schizophrenia; chr6:28332559 chr6:28943877~28944537:+ LUSC cis rs2286503 0.65 rs1990279 ENSG00000228649.7 AC005682.5 7.79 4.41e-14 4.11e-11 0.38 0.34 Fibrinogen; chr7:22851123 chr7:22854178~22861579:+ LUSC cis rs4423214 0.592 rs11233977 ENSG00000254682.1 RP11-660L16.2 -7.79 4.43e-14 4.12e-11 -0.57 -0.34 Vitamin D levels; chr11:71510559 chr11:71448674~71452157:+ LUSC cis rs9487094 1 rs9480953 ENSG00000260273.1 RP11-425D10.10 7.79 4.43e-14 4.12e-11 0.41 0.34 Height; chr6:109417941 chr6:109382795~109383666:+ LUSC cis rs875971 0.83 rs6976714 ENSG00000222364.1 RNU6-96P -7.79 4.44e-14 4.13e-11 -0.4 -0.34 Aortic root size; chr7:66426474 chr7:66395191~66395286:+ LUSC cis rs7044106 0.762 rs7357638 ENSG00000226752.6 PSMD5-AS1 -7.78 4.51e-14 4.2e-11 -0.39 -0.34 Hip circumference adjusted for BMI; chr9:120626926 chr9:120824828~120854385:+ LUSC cis rs80285556 1 rs80285556 ENSG00000161643.11 SIGLEC16 7.78 4.52e-14 4.2e-11 0.75 0.34 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50036913 chr19:49969673~49975814:+ LUSC cis rs11098499 0.78 rs12504773 ENSG00000245958.5 RP11-33B1.1 -7.78 4.52e-14 4.2e-11 -0.35 -0.34 Corneal astigmatism; chr4:119640994 chr4:119454791~119552025:+ LUSC cis rs9532669 0.926 rs9532657 ENSG00000176268.5 CYCSP34 -7.78 4.53e-14 4.21e-11 -0.33 -0.34 Cervical cancer; chr13:40918208 chr13:40863599~40863902:- LUSC cis rs9341808 0.617 rs9294170 ENSG00000272129.1 RP11-250B2.6 7.78 4.53e-14 4.21e-11 0.41 0.34 Sitting height ratio; chr6:80104363 chr6:80355424~80356859:+ LUSC cis rs6991838 0.778 rs11779602 ENSG00000272010.1 CTD-3025N20.3 7.78 4.59e-14 4.26e-11 0.38 0.34 Intelligence (multi-trait analysis); chr8:65550247 chr8:65591850~65592472:- LUSC cis rs992157 0.735 rs13430006 ENSG00000261338.2 RP11-378A13.1 -7.78 4.6e-14 4.27e-11 -0.35 -0.34 Colorectal cancer; chr2:218248366 chr2:218255319~218257366:+ LUSC cis rs4950322 0.517 rs114823926 ENSG00000278811.3 LINC00624 7.78 4.6e-14 4.28e-11 0.39 0.34 Protein quantitative trait loci; chr1:147281805 chr1:147258885~147517875:- LUSC cis rs10754283 0.871 rs72712569 ENSG00000231613.1 RP5-943J3.1 -7.78 4.61e-14 4.28e-11 -0.4 -0.34 Amyotrophic lateral sclerosis (sporadic); chr1:89660098 chr1:89788914~89790492:+ LUSC cis rs875971 0.756 rs4718328 ENSG00000222364.1 RNU6-96P 7.78 4.61e-14 4.28e-11 0.4 0.34 Aortic root size; chr7:66228350 chr7:66395191~66395286:+ LUSC cis rs7739264 0.602 rs2223362 ENSG00000237404.1 RP3-471C18.2 -7.78 4.63e-14 4.3e-11 -0.39 -0.34 Endometriosis; chr6:19777940 chr6:19689825~19753113:- LUSC cis rs875971 0.862 rs4718319 ENSG00000222364.1 RNU6-96P 7.78 4.64e-14 4.31e-11 0.4 0.34 Aortic root size; chr7:66187797 chr7:66395191~66395286:+ LUSC cis rs875971 0.723 rs28391294 ENSG00000222364.1 RNU6-96P 7.78 4.64e-14 4.31e-11 0.4 0.34 Aortic root size; chr7:66189328 chr7:66395191~66395286:+ LUSC cis rs875971 0.83 rs6967708 ENSG00000222364.1 RNU6-96P 7.78 4.64e-14 4.31e-11 0.4 0.34 Aortic root size; chr7:66192326 chr7:66395191~66395286:+ LUSC cis rs875971 0.895 rs7782806 ENSG00000222364.1 RNU6-96P 7.78 4.64e-14 4.31e-11 0.4 0.34 Aortic root size; chr7:66192910 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs880166 ENSG00000222364.1 RNU6-96P 7.78 4.64e-14 4.31e-11 0.4 0.34 Aortic root size; chr7:66205775 chr7:66395191~66395286:+ LUSC cis rs9487094 1 rs9487094 ENSG00000260273.1 RP11-425D10.10 7.78 4.66e-14 4.32e-11 0.41 0.34 Height; chr6:109420812 chr6:109382795~109383666:+ LUSC cis rs34779708 0.966 rs4934732 ENSG00000230534.5 RP11-297A16.2 7.78 4.66e-14 4.32e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35142756 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs2045917 ENSG00000230534.5 RP11-297A16.2 7.78 4.67e-14 4.33e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35129598 chr10:35098006~35127020:- LUSC cis rs992157 0.661 rs17653757 ENSG00000261338.2 RP11-378A13.1 7.78 4.68e-14 4.34e-11 0.34 0.34 Colorectal cancer; chr2:218244641 chr2:218255319~218257366:+ LUSC cis rs77204473 0.557 rs7111854 ENSG00000254851.1 RP11-109L13.1 7.78 4.68e-14 4.34e-11 0.65 0.34 Sum eosinophil basophil counts;Eosinophil counts; chr11:116906110 chr11:117135528~117138582:+ LUSC cis rs10129255 1 rs4612959 ENSG00000211972.2 IGHV3-66 7.78 4.69e-14 4.35e-11 0.26 0.34 Kawasaki disease; chr14:106767055 chr14:106675017~106675544:- LUSC cis rs992157 0.71 rs12996912 ENSG00000261338.2 RP11-378A13.1 7.78 4.69e-14 4.35e-11 0.34 0.34 Colorectal cancer; chr2:218245832 chr2:218255319~218257366:+ LUSC cis rs10129255 0.5 rs11628999 ENSG00000211970.3 IGHV4-61 -7.78 4.73e-14 4.38e-11 -0.21 -0.34 Kawasaki disease; chr14:106800208 chr14:106639119~106639657:- LUSC cis rs35955747 0.869 rs28715 ENSG00000236132.1 CTA-440B3.1 -7.78 4.8e-14 4.45e-11 -0.4 -0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31334183 chr22:31816379~31817491:- LUSC cis rs875971 0.83 rs6950137 ENSG00000222364.1 RNU6-96P -7.78 4.8e-14 4.45e-11 -0.4 -0.34 Aortic root size; chr7:66511623 chr7:66395191~66395286:+ LUSC cis rs9322193 0.923 rs14314 ENSG00000223701.3 RAET1E-AS1 7.77 4.81e-14 4.45e-11 0.39 0.34 Lung cancer; chr6:149820395 chr6:149884431~149919508:+ LUSC cis rs7811142 0.83 rs705866 ENSG00000242294.5 STAG3L5P 7.77 4.81e-14 4.46e-11 0.28 0.34 Platelet count; chr7:100367662 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs6965458 ENSG00000242294.5 STAG3L5P 7.77 4.81e-14 4.46e-11 0.28 0.34 Platelet count; chr7:100375779 chr7:100336079~100351900:+ LUSC cis rs904251 0.523 rs2776871 ENSG00000204110.6 RP1-153P14.8 -7.77 4.83e-14 4.47e-11 -0.32 -0.34 Cognitive performance; chr6:37513983 chr6:37507348~37535616:+ LUSC cis rs2282300 0.739 rs2225909 ENSG00000254532.1 RP11-624D11.2 -7.77 4.83e-14 4.48e-11 -0.47 -0.34 Morning vs. evening chronotype; chr11:30308197 chr11:30044058~30084343:- LUSC cis rs2282300 0.702 rs2211018 ENSG00000254532.1 RP11-624D11.2 -7.77 4.83e-14 4.48e-11 -0.47 -0.34 Morning vs. evening chronotype; chr11:30308532 chr11:30044058~30084343:- LUSC cis rs2282300 0.739 rs7926465 ENSG00000254532.1 RP11-624D11.2 -7.77 4.83e-14 4.48e-11 -0.47 -0.34 Morning vs. evening chronotype; chr11:30311469 chr11:30044058~30084343:- LUSC cis rs10129255 0.957 rs10138532 ENSG00000211972.2 IGHV3-66 7.77 4.84e-14 4.48e-11 0.26 0.34 Kawasaki disease; chr14:106803901 chr14:106675017~106675544:- LUSC cis rs4660456 0.913 rs3767951 ENSG00000237899.1 RP4-739H11.3 -7.77 4.84e-14 4.48e-11 -0.48 -0.34 Platelet count; chr1:40767359 chr1:40669089~40687588:- LUSC cis rs4950322 0.57 rs6703892 ENSG00000278811.3 LINC00624 7.77 4.85e-14 4.49e-11 0.38 0.34 Protein quantitative trait loci; chr1:147287627 chr1:147258885~147517875:- LUSC cis rs10129255 0.5 rs8004923 ENSG00000211970.3 IGHV4-61 -7.77 4.86e-14 4.5e-11 -0.21 -0.34 Kawasaki disease; chr14:106785926 chr14:106639119~106639657:- LUSC cis rs10129255 0.5 rs6576232 ENSG00000211970.3 IGHV4-61 -7.77 4.86e-14 4.5e-11 -0.21 -0.34 Kawasaki disease; chr14:106787090 chr14:106639119~106639657:- LUSC cis rs7811142 1 rs11766752 ENSG00000242294.5 STAG3L5P 7.77 4.86e-14 4.5e-11 0.27 0.34 Platelet count; chr7:100475669 chr7:100336079~100351900:+ LUSC cis rs9322193 0.884 rs1125 ENSG00000223701.3 RAET1E-AS1 7.77 4.88e-14 4.52e-11 0.41 0.34 Lung cancer; chr6:149658280 chr6:149884431~149919508:+ LUSC cis rs4423214 0.569 rs12806918 ENSG00000254682.1 RP11-660L16.2 7.77 4.89e-14 4.52e-11 0.41 0.34 Vitamin D levels; chr11:71407972 chr11:71448674~71452157:+ LUSC cis rs11098499 0.532 rs12512646 ENSG00000245958.5 RP11-33B1.1 -7.77 4.9e-14 4.54e-11 -0.35 -0.34 Corneal astigmatism; chr4:119664578 chr4:119454791~119552025:+ LUSC cis rs904251 0.523 rs1776454 ENSG00000204110.6 RP1-153P14.8 -7.77 4.92e-14 4.55e-11 -0.32 -0.34 Cognitive performance; chr6:37514323 chr6:37507348~37535616:+ LUSC cis rs9487094 1 rs9480955 ENSG00000260273.1 RP11-425D10.10 7.77 4.92e-14 4.55e-11 0.41 0.34 Height; chr6:109423330 chr6:109382795~109383666:+ LUSC cis rs9487094 1 rs9320287 ENSG00000260273.1 RP11-425D10.10 7.77 4.92e-14 4.55e-11 0.41 0.34 Height; chr6:109423487 chr6:109382795~109383666:+ LUSC cis rs7044106 0.762 rs1158553 ENSG00000226752.6 PSMD5-AS1 -7.77 4.92e-14 4.56e-11 -0.38 -0.34 Hip circumference adjusted for BMI; chr9:120638696 chr9:120824828~120854385:+ LUSC cis rs67180937 0.582 rs71524942 ENSG00000272750.1 RP11-378J18.8 -7.77 4.93e-14 4.56e-11 -0.38 -0.34 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222689650 chr1:222658867~222661512:- LUSC cis rs3823536 0.583 rs7800687 ENSG00000275106.1 RP11-309L24.10 -7.77 4.94e-14 4.57e-11 -0.45 -0.34 Sjögren's syndrome; chr7:128953665 chr7:128952527~128953316:- LUSC cis rs113835537 0.66 rs7116940 ENSG00000255517.5 CTD-3074O7.5 -7.77 4.95e-14 4.58e-11 -0.4 -0.34 Airway imaging phenotypes; chr11:66536424 chr11:66473490~66480233:- LUSC cis rs2739330 0.828 rs2877178 ENSG00000235689.1 AP000351.13 7.77 4.95e-14 4.58e-11 0.36 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:24006305~24008258:- LUSC cis rs34779708 0.966 rs12773647 ENSG00000230534.5 RP11-297A16.2 7.77 4.96e-14 4.59e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35151399 chr10:35098006~35127020:- LUSC cis rs7945705 0.818 rs2742552 ENSG00000254860.4 TMEM9B-AS1 7.77 4.97e-14 4.59e-11 0.37 0.34 Hemoglobin concentration; chr11:8855305 chr11:8964675~8977527:+ LUSC cis rs11089937 0.568 rs11089919 ENSG00000211639.2 IGLV4-60 7.77 4.98e-14 4.6e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22131648 chr22:22162199~22162681:+ LUSC cis rs11098499 0.78 rs7680914 ENSG00000245958.5 RP11-33B1.1 -7.77 4.99e-14 4.61e-11 -0.35 -0.34 Corneal astigmatism; chr4:119641898 chr4:119454791~119552025:+ LUSC cis rs875971 0.862 rs1695820 ENSG00000237310.1 GS1-124K5.4 7.77 5.01e-14 4.63e-11 0.35 0.34 Aortic root size; chr7:66379576 chr7:66493706~66495474:+ LUSC cis rs6496044 0.507 rs7175731 ENSG00000202081.1 RNU6-1280P -7.77 5.02e-14 4.63e-11 -0.38 -0.34 Interstitial lung disease; chr15:85611115 chr15:85651522~85651628:- LUSC cis rs6496044 0.507 rs1471455 ENSG00000202081.1 RNU6-1280P -7.77 5.02e-14 4.63e-11 -0.38 -0.34 Interstitial lung disease; chr15:85611496 chr15:85651522~85651628:- LUSC cis rs10129255 0.872 rs1858683 ENSG00000224373.3 IGHV4-59 7.77 5.04e-14 4.65e-11 0.19 0.34 Kawasaki disease; chr14:106670217 chr14:106627249~106627825:- LUSC cis rs6964833 0.554 rs2527366 ENSG00000277053.3 GTF2IP1 7.77 5.04e-14 4.66e-11 0.45 0.34 Menarche (age at onset); chr7:74684615 chr7:75185385~75237696:- LUSC cis rs875971 0.862 rs1695820 ENSG00000222364.1 RNU6-96P -7.77 5.06e-14 4.67e-11 -0.4 -0.34 Aortic root size; chr7:66379576 chr7:66395191~66395286:+ LUSC cis rs2282300 0.739 rs6484478 ENSG00000254532.1 RP11-624D11.2 -7.77 5.07e-14 4.68e-11 -0.47 -0.34 Morning vs. evening chronotype; chr11:30284893 chr11:30044058~30084343:- LUSC cis rs2282300 0.739 rs10742237 ENSG00000254532.1 RP11-624D11.2 -7.77 5.07e-14 4.68e-11 -0.47 -0.34 Morning vs. evening chronotype; chr11:30289112 chr11:30044058~30084343:- LUSC cis rs853679 0.567 rs1005126 ENSG00000216901.1 AL022393.7 7.77 5.1e-14 4.71e-11 0.42 0.34 Depression; chr6:28399846 chr6:28176188~28176674:+ LUSC cis rs17826219 0.789 rs4794873 ENSG00000263531.1 RP13-753N3.1 7.77 5.11e-14 4.71e-11 0.55 0.34 Body mass index; chr17:30421334 chr17:30863921~30864940:- LUSC cis rs12134133 0.752 rs6673080 ENSG00000274245.1 RP11-357P18.2 7.77 5.13e-14 4.73e-11 0.46 0.34 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207216859 chr1:207372559~207373252:+ LUSC cis rs1075265 0.554 rs10168293 ENSG00000233266.1 HMGB1P31 7.77 5.13e-14 4.73e-11 0.43 0.34 Chronotype;Morning vs. evening chronotype; chr2:53973793 chr2:54051334~54051760:+ LUSC cis rs11089937 0.626 rs9622968 ENSG00000211639.2 IGLV4-60 7.77 5.14e-14 4.74e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22144916 chr22:22162199~22162681:+ LUSC cis rs11089937 0.597 rs5757007 ENSG00000211639.2 IGLV4-60 7.76 5.16e-14 4.76e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22135167 chr22:22162199~22162681:+ LUSC cis rs11089937 0.626 rs4820337 ENSG00000211639.2 IGLV4-60 -7.76 5.25e-14 4.84e-11 -0.38 -0.34 Periodontitis (PAL4Q3); chr22:22164374 chr22:22162199~22162681:+ LUSC cis rs10129255 0.957 rs12590667 ENSG00000211970.3 IGHV4-61 7.76 5.27e-14 4.86e-11 0.23 0.34 Kawasaki disease; chr14:106779223 chr14:106639119~106639657:- LUSC cis rs10829156 0.66 rs10764587 ENSG00000240291.1 RP11-499P20.2 7.76 5.31e-14 4.89e-11 0.36 0.34 Sudden cardiac arrest; chr10:18548901 chr10:18513115~18545651:- LUSC cis rs2739330 0.828 rs5751770 ENSG00000235689.1 AP000351.13 7.76 5.34e-14 4.92e-11 0.36 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:24006305~24008258:- LUSC cis rs875971 0.862 rs4718330 ENSG00000222364.1 RNU6-96P 7.76 5.37e-14 4.94e-11 0.4 0.34 Aortic root size; chr7:66250256 chr7:66395191~66395286:+ LUSC cis rs34779708 0.966 rs2045918 ENSG00000230534.5 RP11-297A16.2 7.76 5.38e-14 4.95e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35129589 chr10:35098006~35127020:- LUSC cis rs11089937 0.54 rs2329931 ENSG00000211639.2 IGLV4-60 7.76 5.42e-14 4.99e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22131994 chr22:22162199~22162681:+ LUSC cis rs11089937 0.568 rs2876996 ENSG00000211639.2 IGLV4-60 7.76 5.42e-14 4.99e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22132006 chr22:22162199~22162681:+ LUSC cis rs7772486 0.597 rs2246132 ENSG00000235652.6 RP11-545I5.3 7.76 5.46e-14 5.02e-11 0.35 0.34 Lobe attachment (rater-scored or self-reported); chr6:145861379 chr6:145799409~145886585:+ LUSC cis rs8072100 0.934 rs8067286 ENSG00000228782.6 CTD-2026D20.3 -7.76 5.46e-14 5.02e-11 -0.32 -0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47517224 chr17:47450568~47492492:- LUSC cis rs9601248 0.838 rs2783130 ENSG00000227676.3 LINC01068 -7.75 5.53e-14 5.09e-11 -0.42 -0.34 Major depressive disorder; chr13:79596025 chr13:79566727~79571436:+ LUSC cis rs9601248 1 rs9601248 ENSG00000227676.3 LINC01068 -7.75 5.55e-14 5.1e-11 -0.39 -0.34 Major depressive disorder; chr13:79594869 chr13:79566727~79571436:+ LUSC cis rs9326248 0.861 rs4938348 ENSG00000280143.1 AP000892.6 7.75 5.55e-14 5.1e-11 0.42 0.34 Blood protein levels; chr11:117151161 chr11:117204967~117210292:+ LUSC cis rs6142102 0.602 rs932388 ENSG00000276073.1 RP5-1125A11.7 -7.75 5.57e-14 5.12e-11 -0.33 -0.34 Skin pigmentation; chr20:34069572 chr20:33985617~33988989:- LUSC cis rs875971 0.756 rs2901210 ENSG00000237310.1 GS1-124K5.4 -7.75 5.58e-14 5.13e-11 -0.35 -0.34 Aortic root size; chr7:66552518 chr7:66493706~66495474:+ LUSC cis rs875971 0.83 rs778715 ENSG00000222364.1 RNU6-96P -7.75 5.62e-14 5.16e-11 -0.4 -0.34 Aortic root size; chr7:66384222 chr7:66395191~66395286:+ LUSC cis rs875971 0.83 rs809025 ENSG00000222364.1 RNU6-96P -7.75 5.62e-14 5.16e-11 -0.4 -0.34 Aortic root size; chr7:66384832 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs1643375 ENSG00000222364.1 RNU6-96P -7.75 5.62e-14 5.16e-11 -0.4 -0.34 Aortic root size; chr7:66407690 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6962717 ENSG00000222364.1 RNU6-96P -7.75 5.62e-14 5.16e-11 -0.4 -0.34 Aortic root size; chr7:66418748 chr7:66395191~66395286:+ LUSC cis rs11098499 0.739 rs2203039 ENSG00000245958.5 RP11-33B1.1 7.75 5.63e-14 5.17e-11 0.33 0.34 Corneal astigmatism; chr4:119211192 chr4:119454791~119552025:+ LUSC cis rs875971 0.862 rs778724 ENSG00000237310.1 GS1-124K5.4 7.75 5.64e-14 5.18e-11 0.35 0.34 Aortic root size; chr7:66364304 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs11763189 ENSG00000237310.1 GS1-124K5.4 7.75 5.67e-14 5.2e-11 0.35 0.34 Aortic root size; chr7:66518542 chr7:66493706~66495474:+ LUSC cis rs10129255 0.957 rs8005468 ENSG00000211972.2 IGHV3-66 7.75 5.68e-14 5.21e-11 0.25 0.34 Kawasaki disease; chr14:106686431 chr14:106675017~106675544:- LUSC cis rs7945705 0.902 rs10769980 ENSG00000254860.4 TMEM9B-AS1 -7.75 5.69e-14 5.22e-11 -0.37 -0.34 Hemoglobin concentration; chr11:8992633 chr11:8964675~8977527:+ LUSC cis rs34779708 0.931 rs13377158 ENSG00000230534.5 RP11-297A16.2 -7.75 5.72e-14 5.24e-11 -0.37 -0.34 Inflammatory bowel disease;Crohn's disease; chr10:35081537 chr10:35098006~35127020:- LUSC cis rs440932 0.565 rs19334 ENSG00000254340.1 RP11-10A14.3 7.75 5.72e-14 5.24e-11 0.41 0.34 High light scatter reticulocyte percentage of red cells; chr8:9152396 chr8:9141424~9145435:+ LUSC cis rs2282300 0.739 rs7942129 ENSG00000254532.1 RP11-624D11.2 7.75 5.72e-14 5.24e-11 0.45 0.34 Morning vs. evening chronotype; chr11:30203145 chr11:30044058~30084343:- LUSC cis rs34779708 0.966 rs10827487 ENSG00000230534.5 RP11-297A16.2 7.75 5.72e-14 5.24e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35117950 chr10:35098006~35127020:- LUSC cis rs2935183 1 rs2935183 ENSG00000228782.6 CTD-2026D20.3 -7.75 5.73e-14 5.25e-11 -0.32 -0.34 Multiple sclerosis or amyotrophic lateral sclerosis; chr17:47530206 chr17:47450568~47492492:- LUSC cis rs11098499 0.954 rs11722872 ENSG00000249244.1 RP11-548H18.2 7.75 5.74e-14 5.26e-11 0.44 0.34 Corneal astigmatism; chr4:119311875 chr4:119391831~119395335:- LUSC cis rs853679 0.527 rs707907 ENSG00000204709.4 LINC01556 7.75 5.74e-14 5.26e-11 0.42 0.34 Depression; chr6:28323463 chr6:28943877~28944537:+ LUSC cis rs8081395 0.603 rs1292047 ENSG00000266992.1 DHX40P1 7.75 5.74e-14 5.27e-11 0.39 0.34 White blood cell count; chr17:59877805 chr17:59976009~60002384:- LUSC cis rs1865760 0.623 rs12216125 ENSG00000272462.2 U91328.19 -7.75 5.82e-14 5.33e-11 -0.38 -0.34 Height; chr6:25997230 chr6:25992662~26001775:+ LUSC cis rs4660456 0.913 rs2780953 ENSG00000237899.1 RP4-739H11.3 7.75 5.85e-14 5.35e-11 0.47 0.34 Platelet count; chr1:40694105 chr1:40669089~40687588:- LUSC cis rs12134133 0.752 rs6683677 ENSG00000274245.1 RP11-357P18.2 7.74 5.93e-14 5.43e-11 0.46 0.34 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207228335 chr1:207372559~207373252:+ LUSC cis rs11089937 0.597 rs4821772 ENSG00000211639.2 IGLV4-60 -7.74 5.93e-14 5.43e-11 -0.38 -0.34 Periodontitis (PAL4Q3); chr22:22131383 chr22:22162199~22162681:+ LUSC cis rs875971 0.651 rs2420596 ENSG00000237310.1 GS1-124K5.4 7.74 5.95e-14 5.44e-11 0.35 0.34 Aortic root size; chr7:66450996 chr7:66493706~66495474:+ LUSC cis rs875971 0.52 rs2420597 ENSG00000237310.1 GS1-124K5.4 7.74 5.95e-14 5.44e-11 0.35 0.34 Aortic root size; chr7:66450999 chr7:66493706~66495474:+ LUSC cis rs11168854 0.595 rs11168857 ENSG00000258017.1 RP11-386G11.10 -7.74 5.95e-14 5.44e-11 -0.44 -0.34 Body mass index; chr12:49096526 chr12:49127782~49147869:+ LUSC cis rs12280210 0.557 rs12284696 ENSG00000254851.1 RP11-109L13.1 7.74 5.95e-14 5.44e-11 0.64 0.34 Lobe attachment (rater-scored or self-reported); chr11:117008803 chr11:117135528~117138582:+ LUSC cis rs801193 0.636 rs10233806 ENSG00000222364.1 RNU6-96P 7.74 5.96e-14 5.45e-11 0.4 0.34 Aortic root size; chr7:66653261 chr7:66395191~66395286:+ LUSC cis rs9326248 0.813 rs474488 ENSG00000280143.1 AP000892.6 7.74 6e-14 5.48e-11 0.42 0.34 Blood protein levels; chr11:117198261 chr11:117204967~117210292:+ LUSC cis rs2282300 0.739 rs1933343 ENSG00000254532.1 RP11-624D11.2 -7.74 6.04e-14 5.53e-11 -0.46 -0.34 Morning vs. evening chronotype; chr11:30289445 chr11:30044058~30084343:- LUSC cis rs9487094 0.922 rs9487098 ENSG00000260273.1 RP11-425D10.10 7.74 6.05e-14 5.53e-11 0.41 0.34 Height; chr6:109422189 chr6:109382795~109383666:+ LUSC cis rs875971 0.862 rs11763189 ENSG00000222364.1 RNU6-96P -7.74 6.08e-14 5.56e-11 -0.4 -0.34 Aortic root size; chr7:66518542 chr7:66395191~66395286:+ LUSC cis rs12134133 1 rs10494890 ENSG00000274245.1 RP11-357P18.2 -7.74 6.09e-14 5.56e-11 -0.45 -0.34 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207251041 chr1:207372559~207373252:+ LUSC cis rs9322193 0.884 rs11155679 ENSG00000223701.3 RAET1E-AS1 7.74 6.09e-14 5.57e-11 0.41 0.34 Lung cancer; chr6:149758881 chr6:149884431~149919508:+ LUSC cis rs9326248 0.861 rs7120309 ENSG00000280143.1 AP000892.6 7.74 6.1e-14 5.57e-11 0.41 0.34 Blood protein levels; chr11:117172100 chr11:117204967~117210292:+ LUSC cis rs9326248 0.861 rs7120449 ENSG00000280143.1 AP000892.6 7.74 6.1e-14 5.57e-11 0.41 0.34 Blood protein levels; chr11:117172183 chr11:117204967~117210292:+ LUSC cis rs875971 0.862 rs13232191 ENSG00000237310.1 GS1-124K5.4 7.74 6.1e-14 5.57e-11 0.35 0.34 Aortic root size; chr7:66521661 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs35378740 ENSG00000237310.1 GS1-124K5.4 7.74 6.1e-14 5.57e-11 0.35 0.34 Aortic root size; chr7:66522725 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs10950043 ENSG00000237310.1 GS1-124K5.4 7.74 6.1e-14 5.57e-11 0.35 0.34 Aortic root size; chr7:66523623 chr7:66493706~66495474:+ LUSC cis rs875971 0.767 rs61348003 ENSG00000237310.1 GS1-124K5.4 7.74 6.1e-14 5.57e-11 0.35 0.34 Aortic root size; chr7:66540947 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs13536 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66554203 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs801209 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66554403 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs801206 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66556979 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs801204 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66557934 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs801203 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66558025 chr7:66493706~66495474:+ LUSC cis rs875971 0.825 rs801202 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66558942 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs801194 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66563508 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs2024192 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66576460 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6955837 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66578155 chr7:66493706~66495474:+ LUSC cis rs875971 0.825 rs10281499 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66583979 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs4718377 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66584691 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs10278014 ENSG00000237310.1 GS1-124K5.4 -7.74 6.1e-14 5.57e-11 -0.35 -0.34 Aortic root size; chr7:66586277 chr7:66493706~66495474:+ LUSC cis rs7945705 0.818 rs2653613 ENSG00000254860.4 TMEM9B-AS1 7.74 6.11e-14 5.58e-11 0.37 0.34 Hemoglobin concentration; chr11:8857558 chr11:8964675~8977527:+ LUSC cis rs7772486 0.597 rs2485631 ENSG00000235652.6 RP11-545I5.3 7.74 6.11e-14 5.58e-11 0.35 0.34 Lobe attachment (rater-scored or self-reported); chr6:145868941 chr6:145799409~145886585:+ LUSC cis rs11089937 0.568 rs12160317 ENSG00000211639.2 IGLV4-60 7.74 6.12e-14 5.59e-11 0.4 0.34 Periodontitis (PAL4Q3); chr22:22131619 chr22:22162199~22162681:+ LUSC cis rs1113500 0.614 rs61797342 ENSG00000226822.1 RP11-356N1.2 7.74 6.13e-14 5.6e-11 0.38 0.34 Growth-regulated protein alpha levels; chr1:108065763 chr1:108071482~108074519:+ LUSC cis rs34779708 0.966 rs6481941 ENSG00000230534.5 RP11-297A16.2 7.74 6.13e-14 5.6e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35151213 chr10:35098006~35127020:- LUSC cis rs10129255 0.5 rs8011115 ENSG00000211970.3 IGHV4-61 -7.74 6.14e-14 5.6e-11 -0.21 -0.34 Kawasaki disease; chr14:106786292 chr14:106639119~106639657:- LUSC cis rs875971 0.862 rs7783779 ENSG00000222364.1 RNU6-96P 7.74 6.15e-14 5.61e-11 0.4 0.34 Aortic root size; chr7:66331639 chr7:66395191~66395286:+ LUSC cis rs2282300 0.739 rs1933342 ENSG00000254532.1 RP11-624D11.2 -7.74 6.17e-14 5.63e-11 -0.46 -0.34 Morning vs. evening chronotype; chr11:30291278 chr11:30044058~30084343:- LUSC cis rs875971 0.83 rs778715 ENSG00000237310.1 GS1-124K5.4 7.74 6.17e-14 5.63e-11 0.35 0.34 Aortic root size; chr7:66384222 chr7:66493706~66495474:+ LUSC cis rs875971 0.83 rs809025 ENSG00000237310.1 GS1-124K5.4 7.74 6.17e-14 5.63e-11 0.35 0.34 Aortic root size; chr7:66384832 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs1643375 ENSG00000237310.1 GS1-124K5.4 7.74 6.17e-14 5.63e-11 0.35 0.34 Aortic root size; chr7:66407690 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6962717 ENSG00000237310.1 GS1-124K5.4 7.74 6.17e-14 5.63e-11 0.35 0.34 Aortic root size; chr7:66418748 chr7:66493706~66495474:+ LUSC cis rs4713118 0.629 rs203887 ENSG00000219392.1 RP1-265C24.5 -7.74 6.17e-14 5.63e-11 -0.5 -0.34 Parkinson's disease; chr6:28053491 chr6:28115628~28116551:+ LUSC cis rs10129255 0.5 rs10131875 ENSG00000211970.3 IGHV4-61 -7.74 6.19e-14 5.65e-11 -0.21 -0.34 Kawasaki disease; chr14:106792798 chr14:106639119~106639657:- LUSC cis rs4713118 0.629 rs203888 ENSG00000204709.4 LINC01556 7.74 6.2e-14 5.65e-11 0.45 0.34 Parkinson's disease; chr6:28053811 chr6:28943877~28944537:+ LUSC cis rs992157 0.71 rs56364928 ENSG00000261338.2 RP11-378A13.1 7.74 6.21e-14 5.66e-11 0.34 0.34 Colorectal cancer; chr2:218194335 chr2:218255319~218257366:+ LUSC cis rs10129255 0.5 rs1974468 ENSG00000211970.3 IGHV4-61 -7.74 6.21e-14 5.66e-11 -0.21 -0.34 Kawasaki disease; chr14:106686149 chr14:106639119~106639657:- LUSC cis rs17507216 0.958 rs28648832 ENSG00000255769.6 GOLGA2P10 -7.74 6.23e-14 5.68e-11 -0.47 -0.34 Excessive daytime sleepiness; chr15:82567642 chr15:82472993~82513950:- LUSC cis rs1930961 1 rs6004672 ENSG00000100058.11 CRYBB2P1 7.74 6.26e-14 5.7e-11 0.62 0.34 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25448105~25520854:+ LUSC cis rs4660456 0.913 rs556875 ENSG00000237899.1 RP4-739H11.3 -7.74 6.26e-14 5.7e-11 -0.47 -0.34 Platelet count; chr1:40688571 chr1:40669089~40687588:- LUSC cis rs875971 0.83 rs6976714 ENSG00000237310.1 GS1-124K5.4 7.74 6.27e-14 5.71e-11 0.35 0.34 Aortic root size; chr7:66426474 chr7:66493706~66495474:+ LUSC cis rs12439619 0.508 rs11856561 ENSG00000278603.1 RP13-608F4.5 7.74 6.29e-14 5.73e-11 0.42 0.34 Intelligence (multi-trait analysis); chr15:82161415 chr15:82472203~82472426:+ LUSC cis rs9545047 0.74 rs9574409 ENSG00000227676.3 LINC01068 7.74 6.3e-14 5.73e-11 0.41 0.34 Schizophrenia; chr13:79341844 chr13:79566727~79571436:+ LUSC cis rs9545047 0.68 rs7987769 ENSG00000227676.3 LINC01068 7.74 6.3e-14 5.73e-11 0.41 0.34 Schizophrenia; chr13:79343965 chr13:79566727~79571436:+ LUSC cis rs9545047 0.716 rs7327386 ENSG00000227676.3 LINC01068 7.74 6.3e-14 5.73e-11 0.41 0.34 Schizophrenia; chr13:79347901 chr13:79566727~79571436:+ LUSC cis rs875971 0.862 rs778702 ENSG00000237310.1 GS1-124K5.4 7.74 6.31e-14 5.75e-11 0.35 0.34 Aortic root size; chr7:66399848 chr7:66493706~66495474:+ LUSC cis rs66887589 0.592 rs28580295 ENSG00000245958.5 RP11-33B1.1 -7.74 6.32e-14 5.75e-11 -0.32 -0.34 Diastolic blood pressure; chr4:119357718 chr4:119454791~119552025:+ LUSC cis rs992157 0.71 rs12694432 ENSG00000261338.2 RP11-378A13.1 7.74 6.32e-14 5.76e-11 0.34 0.34 Colorectal cancer; chr2:218217607 chr2:218255319~218257366:+ LUSC cis rs8040855 0.894 rs6496770 ENSG00000259295.5 CSPG4P12 -7.74 6.35e-14 5.78e-11 -0.41 -0.34 Bulimia nervosa; chr15:85161890 chr15:85191438~85213905:+ LUSC cis rs10463554 0.963 rs62362546 ENSG00000175749.11 EIF3KP1 7.73 6.36e-14 5.79e-11 0.4 0.34 Parkinson's disease; chr5:103015615 chr5:103032376~103033031:+ LUSC cis rs992157 0.735 rs13388024 ENSG00000261338.2 RP11-378A13.1 7.73 6.36e-14 5.79e-11 0.34 0.34 Colorectal cancer; chr2:218233050 chr2:218255319~218257366:+ LUSC cis rs34375054 0.525 rs10846829 ENSG00000279233.1 RP11-158L12.4 7.73 6.37e-14 5.8e-11 0.31 0.34 Post bronchodilator FEV1/FVC ratio; chr12:125110512 chr12:125138245~125141711:+ LUSC cis rs992157 0.735 rs2271541 ENSG00000261338.2 RP11-378A13.1 7.73 6.38e-14 5.81e-11 0.34 0.34 Colorectal cancer; chr2:218217396 chr2:218255319~218257366:+ LUSC cis rs9326248 0.861 rs11216172 ENSG00000280143.1 AP000892.6 7.73 6.46e-14 5.88e-11 0.39 0.34 Blood protein levels; chr11:116879162 chr11:117204967~117210292:+ LUSC cis rs11098499 0.644 rs7676296 ENSG00000245958.5 RP11-33B1.1 -7.73 6.47e-14 5.88e-11 -0.33 -0.34 Corneal astigmatism; chr4:119634532 chr4:119454791~119552025:+ LUSC cis rs34779708 0.966 rs4934725 ENSG00000230534.5 RP11-297A16.2 7.73 6.47e-14 5.89e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35109308 chr10:35098006~35127020:- LUSC cis rs34779708 1 rs12769189 ENSG00000230534.5 RP11-297A16.2 7.73 6.47e-14 5.89e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35110740 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs12774834 ENSG00000230534.5 RP11-297A16.2 7.73 6.47e-14 5.89e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35111142 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs12775759 ENSG00000230534.5 RP11-297A16.2 7.73 6.47e-14 5.89e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35111255 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs34296409 ENSG00000230534.5 RP11-297A16.2 7.73 6.47e-14 5.89e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35115685 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs35777088 ENSG00000230534.5 RP11-297A16.2 7.73 6.47e-14 5.89e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35120120 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs11592567 ENSG00000230534.5 RP11-297A16.2 7.73 6.47e-14 5.89e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35120441 chr10:35098006~35127020:- LUSC cis rs7945705 0.747 rs2568045 ENSG00000254860.4 TMEM9B-AS1 7.73 6.48e-14 5.89e-11 0.37 0.34 Hemoglobin concentration; chr11:8982513 chr11:8964675~8977527:+ LUSC cis rs9487094 0.567 rs13198879 ENSG00000260273.1 RP11-425D10.10 7.73 6.5e-14 5.91e-11 0.44 0.34 Height; chr6:109769861 chr6:109382795~109383666:+ LUSC cis rs10463554 0.963 rs3776860 ENSG00000175749.11 EIF3KP1 7.73 6.51e-14 5.92e-11 0.4 0.34 Parkinson's disease; chr5:103014266 chr5:103032376~103033031:+ LUSC cis rs904251 0.523 rs9369005 ENSG00000204110.6 RP1-153P14.8 -7.73 6.52e-14 5.92e-11 -0.32 -0.34 Cognitive performance; chr6:37515333 chr6:37507348~37535616:+ LUSC cis rs7044106 0.648 rs2031369 ENSG00000226752.6 PSMD5-AS1 -7.73 6.52e-14 5.92e-11 -0.38 -0.34 Hip circumference adjusted for BMI; chr9:120598016 chr9:120824828~120854385:+ LUSC cis rs1930961 1 rs7285549 ENSG00000100058.11 CRYBB2P1 7.73 6.53e-14 5.93e-11 0.63 0.34 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25448105~25520854:+ LUSC cis rs8072100 1 rs4794048 ENSG00000228782.6 CTD-2026D20.3 7.73 6.53e-14 5.94e-11 0.31 0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47685707 chr17:47450568~47492492:- LUSC cis rs6142102 0.646 rs2223553 ENSG00000276073.1 RP5-1125A11.7 -7.73 6.54e-14 5.94e-11 -0.33 -0.34 Skin pigmentation; chr20:34121638 chr20:33985617~33988989:- LUSC cis rs4713118 0.869 rs7776351 ENSG00000219392.1 RP1-265C24.5 7.73 6.55e-14 5.95e-11 0.44 0.34 Parkinson's disease; chr6:27758952 chr6:28115628~28116551:+ LUSC cis rs801193 0.591 rs2707839 ENSG00000222364.1 RNU6-96P -7.73 6.57e-14 5.97e-11 -0.4 -0.34 Aortic root size; chr7:66728097 chr7:66395191~66395286:+ LUSC cis rs7772486 0.558 rs9497403 ENSG00000235652.6 RP11-545I5.3 -7.73 6.57e-14 5.97e-11 -0.36 -0.34 Lobe attachment (rater-scored or self-reported); chr6:145733559 chr6:145799409~145886585:+ LUSC cis rs7772486 0.727 rs2235481 ENSG00000235652.6 RP11-545I5.3 -7.73 6.57e-14 5.97e-11 -0.36 -0.34 Lobe attachment (rater-scored or self-reported); chr6:145735712 chr6:145799409~145886585:+ LUSC cis rs9322193 1 rs9377229 ENSG00000223701.3 RAET1E-AS1 7.73 6.65e-14 6.03e-11 0.38 0.34 Lung cancer; chr6:149607655 chr6:149884431~149919508:+ LUSC cis rs4950322 0.748 rs17360812 ENSG00000278811.3 LINC00624 -7.73 6.65e-14 6.03e-11 -0.39 -0.34 Protein quantitative trait loci; chr1:147355010 chr1:147258885~147517875:- LUSC cis rs2282300 0.739 rs1222211 ENSG00000254532.1 RP11-624D11.2 7.73 6.65e-14 6.04e-11 0.47 0.34 Morning vs. evening chronotype; chr11:30340692 chr11:30044058~30084343:- LUSC cis rs673078 0.607 rs61943391 ENSG00000275759.1 RP11-131L12.3 -7.73 6.69e-14 6.07e-11 -0.48 -0.34 Glucose homeostasis traits; chr12:118382603 chr12:118428281~118428870:+ LUSC cis rs9326248 0.861 rs4938352 ENSG00000280143.1 AP000892.6 7.73 6.7e-14 6.08e-11 0.41 0.34 Blood protein levels; chr11:117156765 chr11:117204967~117210292:+ LUSC cis rs6471393 1 rs6997642 ENSG00000253848.1 RP11-10N23.5 -7.73 6.71e-14 6.08e-11 -0.44 -0.34 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93703737 chr8:93741193~93744534:+ LUSC cis rs2282300 0.739 rs34951229 ENSG00000254532.1 RP11-624D11.2 7.73 6.73e-14 6.11e-11 0.46 0.34 Morning vs. evening chronotype; chr11:30243619 chr11:30044058~30084343:- LUSC cis rs11118620 0.853 rs12037861 ENSG00000238078.1 LINC01352 7.73 6.74e-14 6.11e-11 0.38 0.34 Heart failure; chr1:220864835 chr1:220829255~220832429:+ LUSC cis rs9322193 0.884 rs9371201 ENSG00000223701.3 RAET1E-AS1 7.73 6.74e-14 6.11e-11 0.41 0.34 Lung cancer; chr6:149823865 chr6:149884431~149919508:+ LUSC cis rs4706831 0.625 rs638056 ENSG00000272129.1 RP11-250B2.6 -7.73 6.75e-14 6.12e-11 -0.41 -0.34 Joint mobility (Beighton score); chr6:80271091 chr6:80355424~80356859:+ LUSC cis rs9487094 0.961 rs6911838 ENSG00000260273.1 RP11-425D10.10 7.73 6.75e-14 6.13e-11 0.41 0.34 Height; chr6:109478720 chr6:109382795~109383666:+ LUSC cis rs8177876 0.822 rs804902 ENSG00000261838.4 RP11-303E16.6 7.73 6.77e-14 6.14e-11 0.67 0.34 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81071360 chr16:81069854~81076598:+ LUSC cis rs875971 0.862 rs4368860 ENSG00000222364.1 RNU6-96P 7.73 6.79e-14 6.16e-11 0.4 0.34 Aortic root size; chr7:66143495 chr7:66395191~66395286:+ LUSC cis rs2282300 0.739 rs35229181 ENSG00000254532.1 RP11-624D11.2 7.73 6.81e-14 6.18e-11 0.46 0.34 Morning vs. evening chronotype; chr11:30220151 chr11:30044058~30084343:- LUSC cis rs2282300 0.739 rs34234618 ENSG00000254532.1 RP11-624D11.2 7.73 6.81e-14 6.18e-11 0.46 0.34 Morning vs. evening chronotype; chr11:30220154 chr11:30044058~30084343:- LUSC cis rs9322193 0.884 rs10872647 ENSG00000223701.3 RAET1E-AS1 7.72 6.82e-14 6.18e-11 0.41 0.34 Lung cancer; chr6:149758687 chr6:149884431~149919508:+ LUSC cis rs875971 0.83 rs6950137 ENSG00000237310.1 GS1-124K5.4 7.72 6.84e-14 6.2e-11 0.35 0.34 Aortic root size; chr7:66511623 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6945775 ENSG00000237310.1 GS1-124K5.4 7.72 6.86e-14 6.21e-11 0.35 0.34 Aortic root size; chr7:66503987 chr7:66493706~66495474:+ LUSC cis rs7811142 0.83 rs1063945 ENSG00000242294.5 STAG3L5P 7.72 6.86e-14 6.22e-11 0.27 0.34 Platelet count; chr7:100332824 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs11761253 ENSG00000242294.5 STAG3L5P 7.72 6.86e-14 6.22e-11 0.27 0.34 Platelet count; chr7:100341698 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs78256546 ENSG00000242294.5 STAG3L5P 7.72 6.88e-14 6.23e-11 0.27 0.34 Platelet count; chr7:100355347 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs41280971 ENSG00000242294.5 STAG3L5P 7.72 6.88e-14 6.23e-11 0.27 0.34 Platelet count; chr7:100356834 chr7:100336079~100351900:+ LUSC cis rs7945705 0.902 rs10769979 ENSG00000254860.4 TMEM9B-AS1 -7.72 6.88e-14 6.24e-11 -0.37 -0.34 Hemoglobin concentration; chr11:8989112 chr11:8964675~8977527:+ LUSC cis rs7811142 0.83 rs75636500 ENSG00000242294.5 STAG3L5P 7.72 6.9e-14 6.25e-11 0.28 0.34 Platelet count; chr7:100350034 chr7:100336079~100351900:+ LUSC cis rs11098499 0.532 rs4833624 ENSG00000245958.5 RP11-33B1.1 -7.72 6.9e-14 6.25e-11 -0.34 -0.34 Corneal astigmatism; chr4:119664342 chr4:119454791~119552025:+ LUSC cis rs5760092 0.572 rs738806 ENSG00000231271.1 AP000350.8 7.72 6.96e-14 6.3e-11 0.49 0.34 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23949918~23954042:+ LUSC cis rs6991838 0.831 rs4394432 ENSG00000200714.1 Y_RNA 7.72 7e-14 6.33e-11 0.4 0.34 Intelligence (multi-trait analysis); chr8:65560939 chr8:65592731~65592820:+ LUSC cis rs875971 0.798 rs6460304 ENSG00000237310.1 GS1-124K5.4 7.72 7.01e-14 6.34e-11 0.35 0.34 Aortic root size; chr7:66499741 chr7:66493706~66495474:+ LUSC cis rs9322193 0.962 rs7745915 ENSG00000223701.3 RAET1E-AS1 7.72 7.05e-14 6.38e-11 0.39 0.34 Lung cancer; chr6:149834111 chr6:149884431~149919508:+ LUSC cis rs4950322 0.58 rs972368 ENSG00000278811.3 LINC00624 7.72 7.06e-14 6.39e-11 0.35 0.34 Protein quantitative trait loci; chr1:147111142 chr1:147258885~147517875:- LUSC cis rs875971 0.862 rs13226170 ENSG00000237310.1 GS1-124K5.4 7.72 7.09e-14 6.41e-11 0.35 0.34 Aortic root size; chr7:66534311 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs2420611 ENSG00000237310.1 GS1-124K5.4 7.72 7.09e-14 6.41e-11 0.35 0.34 Aortic root size; chr7:66534333 chr7:66493706~66495474:+ LUSC cis rs6991838 0.806 rs35284121 ENSG00000272010.1 CTD-3025N20.3 7.72 7.11e-14 6.44e-11 0.38 0.34 Intelligence (multi-trait analysis); chr8:65551230 chr8:65591850~65592472:- LUSC cis rs6991838 0.751 rs35553155 ENSG00000272010.1 CTD-3025N20.3 7.72 7.11e-14 6.44e-11 0.38 0.34 Intelligence (multi-trait analysis); chr8:65551232 chr8:65591850~65592472:- LUSC cis rs10129255 0.828 rs10140989 ENSG00000211972.2 IGHV3-66 7.72 7.13e-14 6.45e-11 0.26 0.34 Kawasaki disease; chr14:106668657 chr14:106675017~106675544:- LUSC cis rs7684253 0.55 rs4566710 ENSG00000269949.1 RP11-738E22.3 -7.72 7.14e-14 6.46e-11 -0.41 -0.34 Migraine; chr4:56879297 chr4:56960927~56961373:- LUSC cis rs34779708 0.771 rs12098283 ENSG00000230534.5 RP11-297A16.2 7.72 7.15e-14 6.46e-11 0.38 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35189187 chr10:35098006~35127020:- LUSC cis rs875971 0.862 rs709596 ENSG00000237310.1 GS1-124K5.4 7.72 7.15e-14 6.46e-11 0.35 0.34 Aortic root size; chr7:66360926 chr7:66493706~66495474:+ LUSC cis rs11155671 0.53 rs9383940 ENSG00000268592.3 RAET1E-AS1 7.72 7.15e-14 6.47e-11 0.41 0.34 Testicular germ cell tumor; chr6:149904923 chr6:149863494~149919507:+ LUSC cis rs6471393 0.964 rs56282609 ENSG00000253848.1 RP11-10N23.5 7.72 7.16e-14 6.48e-11 0.44 0.34 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93737852 chr8:93741193~93744534:+ LUSC cis rs34779708 0.966 rs1057108 ENSG00000230534.5 RP11-297A16.2 7.72 7.2e-14 6.51e-11 0.37 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35196021 chr10:35098006~35127020:- LUSC cis rs11089937 0.597 rs9619812 ENSG00000211639.2 IGLV4-60 7.72 7.24e-14 6.54e-11 0.37 0.34 Periodontitis (PAL4Q3); chr22:22163945 chr22:22162199~22162681:+ LUSC cis rs673078 0.607 rs7309484 ENSG00000275759.1 RP11-131L12.3 -7.72 7.25e-14 6.55e-11 -0.48 -0.34 Glucose homeostasis traits; chr12:118400833 chr12:118428281~118428870:+ LUSC cis rs10129255 0.518 rs2006284 ENSG00000211970.3 IGHV4-61 -7.72 7.27e-14 6.57e-11 -0.21 -0.34 Kawasaki disease; chr14:106676185 chr14:106639119~106639657:- LUSC cis rs4713118 0.629 rs203888 ENSG00000219392.1 RP1-265C24.5 -7.72 7.29e-14 6.58e-11 -0.44 -0.34 Parkinson's disease; chr6:28053811 chr6:28115628~28116551:+ LUSC cis rs732716 0.74 rs62129356 ENSG00000267769.1 CTB-50L17.9 -7.71 7.31e-14 6.6e-11 -0.37 -0.34 Mean corpuscular volume; chr19:4400317 chr19:4454014~4455286:+ LUSC cis rs9487094 1 rs10872032 ENSG00000260273.1 RP11-425D10.10 7.71 7.31e-14 6.61e-11 0.4 0.34 Height; chr6:109355573 chr6:109382795~109383666:+ LUSC cis rs6471393 0.862 rs11994625 ENSG00000253848.1 RP11-10N23.5 7.71 7.34e-14 6.63e-11 0.44 0.34 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93760149 chr8:93741193~93744534:+ LUSC cis rs6471393 0.83 rs6981752 ENSG00000253848.1 RP11-10N23.5 7.71 7.34e-14 6.63e-11 0.44 0.34 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93761046 chr8:93741193~93744534:+ LUSC cis rs3091242 0.933 rs10903129 ENSG00000224183.1 SDHDP6 -7.71 7.34e-14 6.63e-11 -0.4 -0.34 Erythrocyte sedimentation rate; chr1:25442446 chr1:25294164~25294643:- LUSC cis rs9326248 0.813 rs4938350 ENSG00000280143.1 AP000892.6 7.71 7.35e-14 6.63e-11 0.41 0.34 Blood protein levels; chr11:117151560 chr11:117204967~117210292:+ LUSC cis rs9322193 0.566 rs6912330 ENSG00000223701.3 RAET1E-AS1 -7.71 7.41e-14 6.69e-11 -0.43 -0.34 Lung cancer; chr6:149908811 chr6:149884431~149919508:+ LUSC cis rs7772486 0.521 rs9485017 ENSG00000235652.6 RP11-545I5.3 7.71 7.43e-14 6.71e-11 0.35 0.34 Lobe attachment (rater-scored or self-reported); chr6:145702190 chr6:145799409~145886585:+ LUSC cis rs1012068 0.581 rs5753817 ENSG00000236132.1 CTA-440B3.1 -7.71 7.45e-14 6.72e-11 -0.46 -0.34 Chronic hepatitis C infection; chr22:31917741 chr22:31816379~31817491:- LUSC cis rs11089937 0.553 rs35336247 ENSG00000211639.2 IGLV4-60 7.71 7.46e-14 6.73e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22131593 chr22:22162199~22162681:+ LUSC cis rs11089937 0.553 rs34088081 ENSG00000211639.2 IGLV4-60 7.71 7.46e-14 6.73e-11 0.39 0.34 Periodontitis (PAL4Q3); chr22:22131601 chr22:22162199~22162681:+ LUSC cis rs2739330 0.828 rs5760108 ENSG00000235689.1 AP000351.13 7.71 7.46e-14 6.73e-11 0.36 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:24006305~24008258:- LUSC cis rs11089937 0.626 rs5757051 ENSG00000211639.2 IGLV4-60 -7.71 7.47e-14 6.74e-11 -0.37 -0.34 Periodontitis (PAL4Q3); chr22:22141753 chr22:22162199~22162681:+ LUSC cis rs9545047 0.716 rs9545063 ENSG00000227676.3 LINC01068 7.71 7.53e-14 6.79e-11 0.41 0.34 Schizophrenia; chr13:79316989 chr13:79566727~79571436:+ LUSC cis rs875971 0.862 rs801195 ENSG00000237310.1 GS1-124K5.4 -7.71 7.54e-14 6.8e-11 -0.35 -0.34 Aortic root size; chr7:66561128 chr7:66493706~66495474:+ LUSC cis rs4660456 0.871 rs7549789 ENSG00000237899.1 RP4-739H11.3 -7.71 7.57e-14 6.83e-11 -0.47 -0.34 Platelet count; chr1:40759362 chr1:40669089~40687588:- LUSC cis rs2282300 0.739 rs34855782 ENSG00000254532.1 RP11-624D11.2 7.71 7.59e-14 6.85e-11 0.45 0.34 Morning vs. evening chronotype; chr11:30203923 chr11:30044058~30084343:- LUSC cis rs17023223 0.537 rs10923756 ENSG00000231365.4 RP11-418J17.1 -7.71 7.6e-14 6.85e-11 -0.42 -0.34 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119132025 chr1:119140396~119275973:+ LUSC cis rs10129255 0.719 rs7156660 ENSG00000280411.1 IGHV1-69-2 -7.71 7.61e-14 6.86e-11 -0.23 -0.34 Kawasaki disease; chr14:106673171 chr14:106762092~106762588:- LUSC cis rs8072100 0.817 rs7213086 ENSG00000228782.6 CTD-2026D20.3 7.71 7.61e-14 6.86e-11 0.32 0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47674944 chr17:47450568~47492492:- LUSC cis rs4713118 0.662 rs469228 ENSG00000219392.1 RP1-265C24.5 -7.71 7.61e-14 6.86e-11 -0.45 -0.34 Parkinson's disease; chr6:28002926 chr6:28115628~28116551:+ LUSC cis rs4713118 0.54 rs469227 ENSG00000219392.1 RP1-265C24.5 -7.71 7.61e-14 6.86e-11 -0.45 -0.34 Parkinson's disease; chr6:28002927 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs149948 ENSG00000219392.1 RP1-265C24.5 -7.71 7.61e-14 6.86e-11 -0.45 -0.34 Parkinson's disease; chr6:28007039 chr6:28115628~28116551:+ LUSC cis rs12439619 1 rs12439619 ENSG00000276710.3 CSPG4P8 -7.71 7.65e-14 6.89e-11 -0.36 -0.34 Intelligence (multi-trait analysis); chr15:82254605 chr15:82459472~82477258:+ LUSC cis rs6921919 0.697 rs12180820 ENSG00000204709.4 LINC01556 -7.71 7.67e-14 6.91e-11 -0.43 -0.33 Autism spectrum disorder or schizophrenia; chr6:28348701 chr6:28943877~28944537:+ LUSC cis rs11098499 0.675 rs11098534 ENSG00000245958.5 RP11-33B1.1 -7.71 7.68e-14 6.92e-11 -0.33 -0.33 Corneal astigmatism; chr4:119635617 chr4:119454791~119552025:+ LUSC cis rs9326248 0.861 rs1871757 ENSG00000280143.1 AP000892.6 7.71 7.69e-14 6.93e-11 0.41 0.33 Blood protein levels; chr11:117159865 chr11:117204967~117210292:+ LUSC cis rs5753618 0.539 rs695438 ENSG00000236132.1 CTA-440B3.1 -7.71 7.71e-14 6.95e-11 -0.43 -0.33 Colorectal cancer; chr22:31415890 chr22:31816379~31817491:- LUSC cis rs9322193 0.607 rs9371228 ENSG00000223701.3 RAET1E-AS1 -7.71 7.71e-14 6.95e-11 -0.44 -0.33 Lung cancer; chr6:149921977 chr6:149884431~149919508:+ LUSC cis rs7811142 1 rs60257855 ENSG00000242294.5 STAG3L5P 7.71 7.72e-14 6.96e-11 0.27 0.33 Platelet count; chr7:100429157 chr7:100336079~100351900:+ LUSC cis rs66887589 0.66 rs4833613 ENSG00000245958.5 RP11-33B1.1 7.71 7.75e-14 6.98e-11 0.32 0.33 Diastolic blood pressure; chr4:119229001 chr4:119454791~119552025:+ LUSC cis rs5769707 0.839 rs73176988 ENSG00000235111.1 RP1-29C18.8 -7.71 7.75e-14 6.99e-11 -0.38 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49596001 chr22:49612657~49615716:- LUSC cis rs5769707 0.967 rs17182154 ENSG00000235111.1 RP1-29C18.8 -7.71 7.75e-14 6.99e-11 -0.38 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49596822 chr22:49612657~49615716:- LUSC cis rs673078 0.607 rs17512644 ENSG00000275759.1 RP11-131L12.3 -7.71 7.79e-14 7.01e-11 -0.48 -0.33 Glucose homeostasis traits; chr12:118359963 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs17512652 ENSG00000275759.1 RP11-131L12.3 -7.71 7.79e-14 7.01e-11 -0.48 -0.33 Glucose homeostasis traits; chr12:118361278 chr12:118428281~118428870:+ LUSC cis rs34779708 0.9 rs73262807 ENSG00000230534.5 RP11-297A16.2 7.71 7.81e-14 7.03e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35207458 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs11010125 ENSG00000230534.5 RP11-297A16.2 7.71 7.81e-14 7.03e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35214025 chr10:35098006~35127020:- LUSC cis rs2412819 0.52 rs17727763 ENSG00000249839.1 AC011330.5 -7.7 7.9e-14 7.11e-11 -0.61 -0.33 Lung cancer; chr15:43623873 chr15:43663654~43684339:- LUSC cis rs6142102 0.581 rs4911148 ENSG00000276073.1 RP5-1125A11.7 -7.7 7.9e-14 7.12e-11 -0.34 -0.33 Skin pigmentation; chr20:34080438 chr20:33985617~33988989:- LUSC cis rs6142102 0.602 rs4911402 ENSG00000276073.1 RP5-1125A11.7 -7.7 7.92e-14 7.13e-11 -0.34 -0.33 Skin pigmentation; chr20:34079839 chr20:33985617~33988989:- LUSC cis rs10740039 0.804 rs894384 ENSG00000254271.1 RP11-131N11.4 7.7 7.94e-14 7.15e-11 0.47 0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60692535 chr10:60734342~60741828:+ LUSC cis rs8072100 0.688 rs12602134 ENSG00000228782.6 CTD-2026D20.3 -7.7 7.95e-14 7.15e-11 -0.32 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47504770 chr17:47450568~47492492:- LUSC cis rs11098499 0.908 rs1002152 ENSG00000249244.1 RP11-548H18.2 7.7 7.95e-14 7.15e-11 0.43 0.33 Corneal astigmatism; chr4:119352232 chr4:119391831~119395335:- LUSC cis rs80285556 1 rs55914901 ENSG00000161643.11 SIGLEC16 7.7 7.96e-14 7.16e-11 0.71 0.33 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50025089 chr19:49969673~49975814:+ LUSC cis rs80285556 1 rs76812330 ENSG00000161643.11 SIGLEC16 7.7 7.96e-14 7.16e-11 0.71 0.33 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50028603 chr19:49969673~49975814:+ LUSC cis rs853679 0.567 rs1005126 ENSG00000204709.4 LINC01556 7.7 8.01e-14 7.2e-11 0.45 0.33 Depression; chr6:28399846 chr6:28943877~28944537:+ LUSC cis rs34779708 0.931 rs4934731 ENSG00000230534.5 RP11-297A16.2 7.7 8.04e-14 7.22e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35142708 chr10:35098006~35127020:- LUSC cis rs7945705 0.869 rs4909952 ENSG00000254860.4 TMEM9B-AS1 -7.7 8.06e-14 7.25e-11 -0.36 -0.33 Hemoglobin concentration; chr11:8942399 chr11:8964675~8977527:+ LUSC cis rs34779708 0.966 rs17500582 ENSG00000230534.5 RP11-297A16.2 7.7 8.07e-14 7.26e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35209860 chr10:35098006~35127020:- LUSC cis rs6496044 0.507 rs62022863 ENSG00000202081.1 RNU6-1280P -7.7 8.09e-14 7.27e-11 -0.38 -0.33 Interstitial lung disease; chr15:85618822 chr15:85651522~85651628:- LUSC cis rs8072100 1 rs11650372 ENSG00000228782.6 CTD-2026D20.3 7.7 8.12e-14 7.3e-11 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47644429 chr17:47450568~47492492:- LUSC cis rs875971 0.862 rs778686 ENSG00000222364.1 RNU6-96P -7.7 8.13e-14 7.3e-11 -0.4 -0.33 Aortic root size; chr7:66370923 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs778684 ENSG00000222364.1 RNU6-96P -7.7 8.13e-14 7.3e-11 -0.4 -0.33 Aortic root size; chr7:66371416 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs778680 ENSG00000222364.1 RNU6-96P -7.7 8.13e-14 7.3e-11 -0.4 -0.33 Aortic root size; chr7:66375427 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs11769079 ENSG00000222364.1 RNU6-96P -7.7 8.13e-14 7.3e-11 -0.4 -0.33 Aortic root size; chr7:66377141 chr7:66395191~66395286:+ LUSC cis rs2282300 0.739 rs1222208 ENSG00000254532.1 RP11-624D11.2 7.7 8.14e-14 7.31e-11 0.46 0.33 Morning vs. evening chronotype; chr11:30339830 chr11:30044058~30084343:- LUSC cis rs8072100 0.875 rs62073966 ENSG00000228782.6 CTD-2026D20.3 -7.7 8.19e-14 7.36e-11 -0.32 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47522647 chr17:47450568~47492492:- LUSC cis rs875971 0.862 rs9791712 ENSG00000237310.1 GS1-124K5.4 -7.7 8.25e-14 7.41e-11 -0.35 -0.33 Aortic root size; chr7:66640176 chr7:66493706~66495474:+ LUSC cis rs10740039 0.768 rs920646 ENSG00000254271.1 RP11-131N11.4 7.7 8.26e-14 7.41e-11 0.46 0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60703767 chr10:60734342~60741828:+ LUSC cis rs11098499 0.57 rs6832740 ENSG00000245958.5 RP11-33B1.1 -7.7 8.28e-14 7.44e-11 -0.33 -0.33 Corneal astigmatism; chr4:119624981 chr4:119454791~119552025:+ LUSC cis rs11098499 0.644 rs6855918 ENSG00000245958.5 RP11-33B1.1 -7.7 8.28e-14 7.44e-11 -0.33 -0.33 Corneal astigmatism; chr4:119625144 chr4:119454791~119552025:+ LUSC cis rs3096299 0.838 rs4785561 ENSG00000274627.1 RP11-104N10.2 7.7 8.29e-14 7.44e-11 0.29 0.33 Multiple myeloma (IgH translocation); chr16:89362644 chr16:89516797~89522217:+ LUSC cis rs10129255 1 rs10129407 ENSG00000211972.2 IGHV3-66 7.7 8.29e-14 7.44e-11 0.26 0.33 Kawasaki disease; chr14:106767956 chr14:106675017~106675544:- LUSC cis rs9322193 0.923 rs12211511 ENSG00000223701.3 RAET1E-AS1 7.7 8.29e-14 7.44e-11 0.38 0.33 Lung cancer; chr6:149745206 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9479810 ENSG00000223701.3 RAET1E-AS1 7.7 8.29e-14 7.44e-11 0.38 0.33 Lung cancer; chr6:149751359 chr6:149884431~149919508:+ LUSC cis rs9532669 0.963 rs9315794 ENSG00000176268.5 CYCSP34 7.7 8.3e-14 7.45e-11 0.33 0.33 Cervical cancer; chr13:40939489 chr13:40863599~40863902:- LUSC cis rs4713118 0.662 rs175954 ENSG00000219392.1 RP1-265C24.5 -7.7 8.32e-14 7.46e-11 -0.45 -0.33 Parkinson's disease; chr6:28043807 chr6:28115628~28116551:+ LUSC cis rs10129255 0.957 rs8009948 ENSG00000224373.3 IGHV4-59 7.7 8.33e-14 7.47e-11 0.19 0.33 Kawasaki disease; chr14:106805607 chr14:106627249~106627825:- LUSC cis rs9322193 0.923 rs7753812 ENSG00000223701.3 RAET1E-AS1 7.7 8.33e-14 7.47e-11 0.38 0.33 Lung cancer; chr6:149690150 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs12195866 ENSG00000223701.3 RAET1E-AS1 7.7 8.33e-14 7.47e-11 0.38 0.33 Lung cancer; chr6:149693334 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9285524 ENSG00000223701.3 RAET1E-AS1 7.7 8.33e-14 7.47e-11 0.38 0.33 Lung cancer; chr6:149694122 chr6:149884431~149919508:+ LUSC cis rs2282300 0.739 rs12577729 ENSG00000254532.1 RP11-624D11.2 7.7 8.34e-14 7.48e-11 0.46 0.33 Morning vs. evening chronotype; chr11:30235830 chr11:30044058~30084343:- LUSC cis rs2282300 0.739 rs34044331 ENSG00000254532.1 RP11-624D11.2 7.7 8.34e-14 7.48e-11 0.46 0.33 Morning vs. evening chronotype; chr11:30242939 chr11:30044058~30084343:- LUSC cis rs875971 0.862 rs709596 ENSG00000222364.1 RNU6-96P -7.69 8.41e-14 7.54e-11 -0.4 -0.33 Aortic root size; chr7:66360926 chr7:66395191~66395286:+ LUSC cis rs875971 0.755 rs10228885 ENSG00000222364.1 RNU6-96P 7.69 8.44e-14 7.57e-11 0.4 0.33 Aortic root size; chr7:66315542 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs3893216 ENSG00000222364.1 RNU6-96P 7.69 8.44e-14 7.57e-11 0.4 0.33 Aortic root size; chr7:66325720 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6958294 ENSG00000222364.1 RNU6-96P 7.69 8.44e-14 7.57e-11 0.4 0.33 Aortic root size; chr7:66329809 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs2088655 ENSG00000222364.1 RNU6-96P 7.69 8.44e-14 7.57e-11 0.4 0.33 Aortic root size; chr7:66330724 chr7:66395191~66395286:+ LUSC cis rs875971 0.895 rs10447522 ENSG00000222364.1 RNU6-96P 7.69 8.44e-14 7.57e-11 0.4 0.33 Aortic root size; chr7:66331087 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs2088653 ENSG00000222364.1 RNU6-96P 7.69 8.44e-14 7.57e-11 0.4 0.33 Aortic root size; chr7:66343621 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6460293 ENSG00000222364.1 RNU6-96P 7.69 8.44e-14 7.57e-11 0.4 0.33 Aortic root size; chr7:66345205 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs778736 ENSG00000222364.1 RNU6-96P -7.69 8.44e-14 7.57e-11 -0.4 -0.33 Aortic root size; chr7:66348861 chr7:66395191~66395286:+ LUSC cis rs11098499 1 rs11098500 ENSG00000249244.1 RP11-548H18.2 7.69 8.47e-14 7.59e-11 0.44 0.33 Corneal astigmatism; chr4:119298084 chr4:119391831~119395335:- LUSC cis rs9322193 0.961 rs4870144 ENSG00000223701.3 RAET1E-AS1 7.69 8.47e-14 7.59e-11 0.39 0.33 Lung cancer; chr6:149575540 chr6:149884431~149919508:+ LUSC cis rs8062405 0.69 rs4787458 ENSG00000259982.1 CDC37P1 7.69 8.48e-14 7.6e-11 0.43 0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28519966 chr16:28700294~28701540:- LUSC cis rs8081395 0.576 rs1292032 ENSG00000266992.1 DHX40P1 7.69 8.49e-14 7.61e-11 0.38 0.33 White blood cell count; chr17:59914982 chr17:59976009~60002384:- LUSC cis rs2739330 0.828 rs2154593 ENSG00000235689.1 AP000351.13 7.69 8.5e-14 7.61e-11 0.36 0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:24006305~24008258:- LUSC cis rs10463554 0.853 rs2432177 ENSG00000175749.11 EIF3KP1 7.69 8.52e-14 7.63e-11 0.39 0.33 Parkinson's disease; chr5:103236172 chr5:103032376~103033031:+ LUSC cis rs783540 0.656 rs783538 ENSG00000255769.6 GOLGA2P10 7.69 8.55e-14 7.66e-11 0.43 0.33 Schizophrenia; chr15:82584394 chr15:82472993~82513950:- LUSC cis rs34779708 0.966 rs7070427 ENSG00000230534.5 RP11-297A16.2 7.69 8.57e-14 7.67e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35196761 chr10:35098006~35127020:- LUSC cis rs10129255 0.879 rs7160512 ENSG00000224373.3 IGHV4-59 7.69 8.61e-14 7.71e-11 0.18 0.33 Kawasaki disease; chr14:106694574 chr14:106627249~106627825:- LUSC cis rs10129255 0.879 rs7159157 ENSG00000224373.3 IGHV4-59 7.69 8.61e-14 7.71e-11 0.18 0.33 Kawasaki disease; chr14:106694578 chr14:106627249~106627825:- LUSC cis rs875971 0.798 rs57739047 ENSG00000237310.1 GS1-124K5.4 7.69 8.64e-14 7.74e-11 0.35 0.33 Aortic root size; chr7:66507579 chr7:66493706~66495474:+ LUSC cis rs8072100 0.846 rs4264433 ENSG00000228782.6 CTD-2026D20.3 -7.69 8.67e-14 7.76e-11 -0.32 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47659909 chr17:47450568~47492492:- LUSC cis rs9322193 0.923 rs10872645 ENSG00000223701.3 RAET1E-AS1 7.69 8.71e-14 7.8e-11 0.38 0.33 Lung cancer; chr6:149742840 chr6:149884431~149919508:+ LUSC cis rs875971 0.895 rs4145009 ENSG00000237310.1 GS1-124K5.4 -7.69 8.72e-14 7.8e-11 -0.35 -0.33 Aortic root size; chr7:66261628 chr7:66493706~66495474:+ LUSC cis rs34779708 0.966 rs57081218 ENSG00000230534.5 RP11-297A16.2 7.69 8.76e-14 7.84e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35145680 chr10:35098006~35127020:- LUSC cis rs6782228 1 rs6775011 ENSG00000277250.1 Metazoa_SRP 7.69 8.81e-14 7.87e-11 0.41 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128677640 chr3:128673681~128674021:- LUSC cis rs9322193 0.961 rs9027 ENSG00000223701.3 RAET1E-AS1 7.69 8.82e-14 7.89e-11 0.38 0.33 Lung cancer; chr6:149594921 chr6:149884431~149919508:+ LUSC cis rs10463554 0.963 rs13340364 ENSG00000175749.11 EIF3KP1 7.69 8.83e-14 7.9e-11 0.4 0.33 Parkinson's disease; chr5:103003406 chr5:103032376~103033031:+ LUSC cis rs8059260 0.604 rs741177 ENSG00000274038.1 RP11-66H6.4 -7.69 8.87e-14 7.93e-11 -0.56 -0.33 Alcohol consumption over the past year; chr16:11051791 chr16:11056556~11057034:+ LUSC cis rs2283792 0.73 rs2083565 ENSG00000228050.1 TOP3BP1 7.69 8.88e-14 7.93e-11 0.39 0.33 Multiple sclerosis; chr22:21929985 chr22:22223187~22224566:- LUSC cis rs7811142 1 rs73161759 ENSG00000242294.5 STAG3L5P 7.69 8.89e-14 7.95e-11 0.27 0.33 Platelet count; chr7:100412371 chr7:100336079~100351900:+ LUSC cis rs7811142 0.945 rs6955362 ENSG00000242294.5 STAG3L5P 7.69 8.91e-14 7.96e-11 0.27 0.33 Platelet count; chr7:100458543 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs6975514 ENSG00000242294.5 STAG3L5P 7.69 8.91e-14 7.96e-11 0.27 0.33 Platelet count; chr7:100458597 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs11773661 ENSG00000242294.5 STAG3L5P 7.69 8.91e-14 7.96e-11 0.27 0.33 Platelet count; chr7:100475446 chr7:100336079~100351900:+ LUSC cis rs9545047 0.644 rs9318624 ENSG00000227676.3 LINC01068 7.69 8.94e-14 7.99e-11 0.41 0.33 Schizophrenia; chr13:79350915 chr13:79566727~79571436:+ LUSC cis rs189798 0.807 rs330909 ENSG00000254340.1 RP11-10A14.3 7.69 8.97e-14 8.01e-11 0.45 0.33 Myopia (pathological); chr8:9137877 chr8:9141424~9145435:+ LUSC cis rs11098499 0.532 rs4504231 ENSG00000245958.5 RP11-33B1.1 -7.69 8.99e-14 8.02e-11 -0.34 -0.33 Corneal astigmatism; chr4:119665736 chr4:119454791~119552025:+ LUSC cis rs1075232 1 rs12439239 ENSG00000215302.7 CTD-3092A11.1 -7.68 9.03e-14 8.07e-11 -0.74 -0.33 Survival in colorectal cancer (non-distant metastatic); chr15:31359515 chr15:30470779~30507623:+ LUSC cis rs9322193 0.884 rs10872648 ENSG00000223701.3 RAET1E-AS1 7.68 9.04e-14 8.07e-11 0.4 0.33 Lung cancer; chr6:149758699 chr6:149884431~149919508:+ LUSC cis rs9487094 0.744 rs13211604 ENSG00000260273.1 RP11-425D10.10 7.68 9.05e-14 8.08e-11 0.44 0.33 Height; chr6:109712525 chr6:109382795~109383666:+ LUSC cis rs7945705 0.902 rs7930026 ENSG00000254860.4 TMEM9B-AS1 -7.68 9.12e-14 8.14e-11 -0.37 -0.33 Hemoglobin concentration; chr11:8992092 chr11:8964675~8977527:+ LUSC cis rs61160187 0.548 rs17392014 ENSG00000215032.2 GNL3LP1 7.68 9.14e-14 8.15e-11 0.41 0.33 Educational attainment (years of education);Educational attainment (college completion); chr5:60869373 chr5:60891935~60893577:- LUSC cis rs61160187 0.582 rs4647150 ENSG00000215032.2 GNL3LP1 7.68 9.14e-14 8.15e-11 0.41 0.33 Educational attainment (years of education);Educational attainment (college completion); chr5:60874778 chr5:60891935~60893577:- LUSC cis rs853679 0.527 rs853683 ENSG00000204709.4 LINC01556 7.68 9.15e-14 8.16e-11 0.42 0.33 Depression; chr6:28327262 chr6:28943877~28944537:+ LUSC cis rs6471393 0.895 rs58103546 ENSG00000253848.1 RP11-10N23.5 7.68 9.16e-14 8.17e-11 0.43 0.33 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93749483 chr8:93741193~93744534:+ LUSC cis rs7044106 0.718 rs10616 ENSG00000226752.6 PSMD5-AS1 -7.68 9.22e-14 8.22e-11 -0.37 -0.33 Hip circumference adjusted for BMI; chr9:120601255 chr9:120824828~120854385:+ LUSC cis rs1930961 0.702 rs8141065 ENSG00000272977.1 CTA-390C10.10 7.68 9.25e-14 8.24e-11 0.65 0.33 Bipolar disorder with mood-incongruent psychosis; chr22:25489221 chr22:25476218~25479971:+ LUSC cis rs2980439 0.818 rs2948294 ENSG00000253893.2 FAM85B -7.68 9.25e-14 8.25e-11 -0.41 -0.33 Neuroticism; chr8:8237439 chr8:8167819~8226614:- LUSC cis rs7811142 0.83 rs3087502 ENSG00000242294.5 STAG3L5P 7.68 9.27e-14 8.26e-11 0.27 0.33 Platelet count; chr7:100357741 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs61735533 ENSG00000242294.5 STAG3L5P 7.68 9.27e-14 8.26e-11 0.27 0.33 Platelet count; chr7:100358243 chr7:100336079~100351900:+ LUSC cis rs7811142 0.83 rs11761426 ENSG00000242294.5 STAG3L5P 7.68 9.27e-14 8.26e-11 0.27 0.33 Platelet count; chr7:100359270 chr7:100336079~100351900:+ LUSC cis rs673078 0.607 rs61943388 ENSG00000275759.1 RP11-131L12.3 -7.68 9.28e-14 8.28e-11 -0.48 -0.33 Glucose homeostasis traits; chr12:118374590 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943389 ENSG00000275759.1 RP11-131L12.3 -7.68 9.28e-14 8.28e-11 -0.48 -0.33 Glucose homeostasis traits; chr12:118377467 chr12:118428281~118428870:+ LUSC cis rs35955747 0.807 rs9619169 ENSG00000236132.1 CTA-440B3.1 7.68 9.32e-14 8.31e-11 0.4 0.33 Neutrophil count;Sum basophil neutrophil counts; chr22:31141356 chr22:31816379~31817491:- LUSC cis rs35955747 0.902 rs131202 ENSG00000236132.1 CTA-440B3.1 -7.68 9.34e-14 8.32e-11 -0.4 -0.33 Neutrophil count;Sum basophil neutrophil counts; chr22:31313323 chr22:31816379~31817491:- LUSC cis rs11118620 0.81 rs1603047 ENSG00000238078.1 LINC01352 7.68 9.42e-14 8.39e-11 0.38 0.33 Heart failure; chr1:220849953 chr1:220829255~220832429:+ LUSC cis rs748404 0.697 rs493177 ENSG00000249839.1 AC011330.5 -7.68 9.42e-14 8.4e-11 -0.43 -0.33 Lung cancer; chr15:43251060 chr15:43663654~43684339:- LUSC cis rs7684253 0.548 rs922570 ENSG00000269949.1 RP11-738E22.3 -7.68 9.43e-14 8.4e-11 -0.4 -0.33 Migraine; chr4:56851192 chr4:56960927~56961373:- LUSC cis rs9322193 1 rs9322193 ENSG00000223701.3 RAET1E-AS1 7.68 9.53e-14 8.49e-11 0.38 0.33 Lung cancer; chr6:149598007 chr6:149884431~149919508:+ LUSC cis rs4950322 0.57 rs72691041 ENSG00000278811.3 LINC00624 7.68 9.61e-14 8.55e-11 0.38 0.33 Protein quantitative trait loci; chr1:147267084 chr1:147258885~147517875:- LUSC cis rs34779708 0.966 rs17591781 ENSG00000230534.5 RP11-297A16.2 7.68 9.61e-14 8.56e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35209610 chr10:35098006~35127020:- LUSC cis rs2117029 0.587 rs7958572 ENSG00000258017.1 RP11-386G11.10 -7.68 9.61e-14 8.56e-11 -0.42 -0.33 Intelligence (multi-trait analysis); chr12:49115658 chr12:49127782~49147869:+ LUSC cis rs9322193 0.607 rs6925151 ENSG00000223701.3 RAET1E-AS1 7.68 9.64e-14 8.58e-11 0.43 0.33 Lung cancer; chr6:149889587 chr6:149884431~149919508:+ LUSC cis rs34779708 0.931 rs4934724 ENSG00000230534.5 RP11-297A16.2 7.67 9.66e-14 8.6e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35104741 chr10:35098006~35127020:- LUSC cis rs2282300 0.653 rs67745574 ENSG00000254532.1 RP11-624D11.2 7.67 9.7e-14 8.63e-11 0.46 0.33 Morning vs. evening chronotype; chr11:30213292 chr11:30044058~30084343:- LUSC cis rs34779708 0.966 rs12775799 ENSG00000230534.5 RP11-297A16.2 7.67 9.71e-14 8.64e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35199336 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs11010122 ENSG00000230534.5 RP11-297A16.2 7.67 9.71e-14 8.64e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35204590 chr10:35098006~35127020:- LUSC cis rs8177876 0.749 rs2602407 ENSG00000261838.4 RP11-303E16.6 -7.67 9.75e-14 8.68e-11 -0.69 -0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81059141 chr16:81069854~81076598:+ LUSC cis rs4950322 0.57 rs945742 ENSG00000278811.3 LINC00624 7.67 9.76e-14 8.68e-11 0.38 0.33 Protein quantitative trait loci; chr1:147313437 chr1:147258885~147517875:- LUSC cis rs34779708 0.966 rs10508816 ENSG00000230534.5 RP11-297A16.2 7.67 9.77e-14 8.69e-11 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35171048 chr10:35098006~35127020:- LUSC cis rs7811142 0.775 rs1636980 ENSG00000242294.5 STAG3L5P -7.67 9.8e-14 8.71e-11 -0.27 -0.33 Platelet count; chr7:100341241 chr7:100336079~100351900:+ LUSC cis rs3091242 0.9 rs4649086 ENSG00000224183.1 SDHDP6 -7.67 9.83e-14 8.74e-11 -0.4 -0.33 Erythrocyte sedimentation rate; chr1:25452476 chr1:25294164~25294643:- LUSC cis rs7811142 1 rs11559117 ENSG00000242294.5 STAG3L5P 7.67 9.84e-14 8.75e-11 0.27 0.33 Platelet count; chr7:100478991 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs2406253 ENSG00000242294.5 STAG3L5P 7.67 9.84e-14 8.75e-11 0.27 0.33 Platelet count; chr7:100479650 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs4463351 ENSG00000242294.5 STAG3L5P 7.67 9.84e-14 8.75e-11 0.27 0.33 Platelet count; chr7:100480603 chr7:100336079~100351900:+ LUSC cis rs875971 1 rs1167411 ENSG00000222364.1 RNU6-96P 7.67 9.86e-14 8.77e-11 0.4 0.33 Aortic root size; chr7:66074277 chr7:66395191~66395286:+ LUSC cis rs10129255 1 rs10129319 ENSG00000211972.2 IGHV3-66 7.67 9.89e-14 8.79e-11 0.25 0.33 Kawasaki disease; chr14:106767996 chr14:106675017~106675544:- LUSC cis rs11098499 0.644 rs7693919 ENSG00000245958.5 RP11-33B1.1 -7.67 9.95e-14 8.84e-11 -0.33 -0.33 Corneal astigmatism; chr4:119619416 chr4:119454791~119552025:+ LUSC cis rs4950322 0.57 rs17356184 ENSG00000278811.3 LINC00624 7.67 9.95e-14 8.85e-11 0.38 0.33 Protein quantitative trait loci; chr1:147262943 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs80270233 ENSG00000278811.3 LINC00624 7.67 9.95e-14 8.85e-11 0.38 0.33 Protein quantitative trait loci; chr1:147263320 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs4950392 ENSG00000278811.3 LINC00624 7.67 9.95e-14 8.85e-11 0.38 0.33 Protein quantitative trait loci; chr1:147264889 chr1:147258885~147517875:- LUSC cis rs34779708 0.966 rs34776628 ENSG00000230534.5 RP11-297A16.2 7.67 9.98e-14 8.86e-11 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35137396 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs17499247 ENSG00000230534.5 RP11-297A16.2 7.67 9.98e-14 8.86e-11 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35137827 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs10827491 ENSG00000230534.5 RP11-297A16.2 7.67 9.98e-14 8.86e-11 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35138467 chr10:35098006~35127020:- LUSC cis rs7811142 0.83 rs28495773 ENSG00000242294.5 STAG3L5P 7.67 9.98e-14 8.86e-11 0.27 0.33 Platelet count; chr7:100345960 chr7:100336079~100351900:+ LUSC cis rs2179367 0.959 rs2262617 ENSG00000231760.4 RP11-350J20.5 7.67 9.98e-14 8.87e-11 0.43 0.33 Dupuytren's disease; chr6:149438590 chr6:149796151~149826294:- LUSC cis rs2282300 0.653 rs12800124 ENSG00000254532.1 RP11-624D11.2 7.67 9.99e-14 8.87e-11 0.46 0.33 Morning vs. evening chronotype; chr11:30218318 chr11:30044058~30084343:- LUSC cis rs2282300 0.696 rs12578061 ENSG00000254532.1 RP11-624D11.2 7.67 9.99e-14 8.87e-11 0.46 0.33 Morning vs. evening chronotype; chr11:30227818 chr11:30044058~30084343:- LUSC cis rs2282300 0.739 rs34224414 ENSG00000254532.1 RP11-624D11.2 7.67 9.99e-14 8.87e-11 0.46 0.33 Morning vs. evening chronotype; chr11:30229494 chr11:30044058~30084343:- LUSC cis rs10129255 0.912 rs61997792 ENSG00000224373.3 IGHV4-59 7.67 1.01e-13 8.94e-11 0.19 0.33 Kawasaki disease; chr14:106799304 chr14:106627249~106627825:- LUSC cis rs2337406 0.714 rs7152055 ENSG00000274576.2 IGHV2-70 -7.67 1.01e-13 8.94e-11 -0.35 -0.33 Alzheimer's disease (late onset); chr14:106818996 chr14:106770577~106771020:- LUSC cis rs9322193 0.516 rs1999632 ENSG00000223701.3 RAET1E-AS1 7.67 1.02e-13 9.04e-11 0.44 0.33 Lung cancer; chr6:149866737 chr6:149884431~149919508:+ LUSC cis rs11098499 0.865 rs11722183 ENSG00000249244.1 RP11-548H18.2 7.67 1.02e-13 9.07e-11 0.42 0.33 Corneal astigmatism; chr4:119359442 chr4:119391831~119395335:- LUSC cis rs875971 0.862 rs9791713 ENSG00000237310.1 GS1-124K5.4 -7.67 1.03e-13 9.12e-11 -0.35 -0.33 Aortic root size; chr7:66640211 chr7:66493706~66495474:+ LUSC cis rs3091242 0.933 rs11802413 ENSG00000224183.1 SDHDP6 7.66 1.03e-13 9.18e-11 0.41 0.33 Erythrocyte sedimentation rate; chr1:25434429 chr1:25294164~25294643:- LUSC cis rs7684253 0.548 rs13108002 ENSG00000269949.1 RP11-738E22.3 -7.66 1.04e-13 9.2e-11 -0.4 -0.33 Migraine; chr4:56852087 chr4:56960927~56961373:- LUSC cis rs10129255 0.872 rs10133674 ENSG00000280411.1 IGHV1-69-2 -7.66 1.04e-13 9.21e-11 -0.23 -0.33 Kawasaki disease; chr14:106692788 chr14:106762092~106762588:- LUSC cis rs10256972 0.967 rs7799110 ENSG00000229043.2 AC091729.9 -7.66 1.04e-13 9.24e-11 -0.39 -0.33 Endometriosis;Longevity; chr7:999429 chr7:1160374~1165267:+ LUSC cis rs9487094 0.567 rs11964864 ENSG00000260273.1 RP11-425D10.10 7.66 1.05e-13 9.28e-11 0.43 0.33 Height; chr6:109773423 chr6:109382795~109383666:+ LUSC cis rs9322193 0.884 rs2064521 ENSG00000223701.3 RAET1E-AS1 -7.66 1.05e-13 9.3e-11 -0.38 -0.33 Lung cancer; chr6:149625336 chr6:149884431~149919508:+ LUSC cis rs11098499 0.954 rs6849561 ENSG00000249244.1 RP11-548H18.2 -7.66 1.05e-13 9.31e-11 -0.44 -0.33 Corneal astigmatism; chr4:119488539 chr4:119391831~119395335:- LUSC cis rs6991838 0.778 rs13261559 ENSG00000272010.1 CTD-3025N20.3 7.66 1.05e-13 9.33e-11 0.37 0.33 Intelligence (multi-trait analysis); chr8:65549808 chr8:65591850~65592472:- LUSC cis rs6991838 0.778 rs7843697 ENSG00000272010.1 CTD-3025N20.3 7.66 1.05e-13 9.33e-11 0.37 0.33 Intelligence (multi-trait analysis); chr8:65550533 chr8:65591850~65592472:- LUSC cis rs6991838 0.778 rs7843724 ENSG00000272010.1 CTD-3025N20.3 7.66 1.05e-13 9.33e-11 0.37 0.33 Intelligence (multi-trait analysis); chr8:65550581 chr8:65591850~65592472:- LUSC cis rs34375054 0.525 rs12316499 ENSG00000279233.1 RP11-158L12.4 7.66 1.05e-13 9.34e-11 0.31 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125108772 chr12:125138245~125141711:+ LUSC cis rs7811142 1 rs11761725 ENSG00000242294.5 STAG3L5P 7.66 1.07e-13 9.44e-11 0.28 0.33 Platelet count; chr7:100442192 chr7:100336079~100351900:+ LUSC cis rs875971 0.825 rs28480509 ENSG00000237310.1 GS1-124K5.4 -7.66 1.07e-13 9.44e-11 -0.35 -0.33 Aortic root size; chr7:66634237 chr7:66493706~66495474:+ LUSC cis rs5769707 0.521 rs6009810 ENSG00000235111.1 RP1-29C18.8 -7.66 1.07e-13 9.45e-11 -0.42 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49665892 chr22:49612657~49615716:- LUSC cis rs875971 0.862 rs17747530 ENSG00000237310.1 GS1-124K5.4 7.66 1.07e-13 9.48e-11 0.35 0.33 Aortic root size; chr7:66529742 chr7:66493706~66495474:+ LUSC cis rs2282300 0.739 rs1616223 ENSG00000254532.1 RP11-624D11.2 7.66 1.07e-13 9.5e-11 0.46 0.33 Morning vs. evening chronotype; chr11:30317236 chr11:30044058~30084343:- LUSC cis rs2282300 0.739 rs1717772 ENSG00000254532.1 RP11-624D11.2 7.66 1.07e-13 9.5e-11 0.46 0.33 Morning vs. evening chronotype; chr11:30318586 chr11:30044058~30084343:- LUSC cis rs875971 0.893 rs62465470 ENSG00000222364.1 RNU6-96P 7.66 1.07e-13 9.5e-11 0.4 0.33 Aortic root size; chr7:66136231 chr7:66395191~66395286:+ LUSC cis rs9322193 0.962 rs1413655 ENSG00000223701.3 RAET1E-AS1 7.66 1.07e-13 9.5e-11 0.38 0.33 Lung cancer; chr6:149821815 chr6:149884431~149919508:+ LUSC cis rs9322193 0.926 rs9383546 ENSG00000223701.3 RAET1E-AS1 7.66 1.07e-13 9.5e-11 0.38 0.33 Lung cancer; chr6:149822743 chr6:149884431~149919508:+ LUSC cis rs2739330 0.892 rs4822455 ENSG00000235689.1 AP000351.13 7.66 1.08e-13 9.53e-11 0.35 0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:24006305~24008258:- LUSC cis rs67180937 0.921 rs35700460 ENSG00000272750.1 RP11-378J18.8 -7.66 1.08e-13 9.53e-11 -0.36 -0.33 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222638065 chr1:222658867~222661512:- LUSC cis rs131777 0.575 rs963980 ENSG00000205559.3 CHKB-AS1 -7.66 1.08e-13 9.55e-11 -0.42 -0.33 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50583688 chr22:50583026~50583877:+ LUSC cis rs1707322 1 rs7538978 ENSG00000280836.1 AL355480.1 7.66 1.08e-13 9.56e-11 0.38 0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46039382 chr1:45581219~45581321:- LUSC cis rs9601248 0.51 rs9601250 ENSG00000227676.3 LINC01068 7.66 1.08e-13 9.56e-11 0.44 0.33 Major depressive disorder; chr13:79614567 chr13:79566727~79571436:+ LUSC cis rs10463554 0.963 rs187427 ENSG00000175749.11 EIF3KP1 7.66 1.08e-13 9.56e-11 0.39 0.33 Parkinson's disease; chr5:103177102 chr5:103032376~103033031:+ LUSC cis rs9322193 0.962 rs17673294 ENSG00000223701.3 RAET1E-AS1 7.66 1.08e-13 9.57e-11 0.38 0.33 Lung cancer; chr6:149813857 chr6:149884431~149919508:+ LUSC cis rs4950322 0.57 rs17356219 ENSG00000278811.3 LINC00624 7.66 1.09e-13 9.59e-11 0.38 0.33 Protein quantitative trait loci; chr1:147265684 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs17356233 ENSG00000278811.3 LINC00624 7.66 1.09e-13 9.59e-11 0.38 0.33 Protein quantitative trait loci; chr1:147268843 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs17356240 ENSG00000278811.3 LINC00624 7.66 1.09e-13 9.59e-11 0.38 0.33 Protein quantitative trait loci; chr1:147269877 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs1999820 ENSG00000278811.3 LINC00624 7.66 1.09e-13 9.59e-11 0.38 0.33 Protein quantitative trait loci; chr1:147270329 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs4950316 ENSG00000278811.3 LINC00624 7.66 1.09e-13 9.59e-11 0.38 0.33 Protein quantitative trait loci; chr1:147273712 chr1:147258885~147517875:- LUSC cis rs10463554 0.927 rs34831 ENSG00000175749.11 EIF3KP1 7.66 1.09e-13 9.6e-11 0.4 0.33 Parkinson's disease; chr5:103108385 chr5:103032376~103033031:+ LUSC cis rs875971 0.862 rs908915 ENSG00000222364.1 RNU6-96P 7.66 1.09e-13 9.62e-11 0.4 0.33 Aortic root size; chr7:66149664 chr7:66395191~66395286:+ LUSC cis rs673078 0.607 rs7968011 ENSG00000275759.1 RP11-131L12.3 -7.66 1.1e-13 9.72e-11 -0.48 -0.33 Glucose homeostasis traits; chr12:118382001 chr12:118428281~118428870:+ LUSC cis rs9487094 0.813 rs12524502 ENSG00000260273.1 RP11-425D10.10 7.66 1.1e-13 9.72e-11 0.41 0.33 Height; chr6:109333018 chr6:109382795~109383666:+ LUSC cis rs4865169 0.791 rs11731868 ENSG00000269949.1 RP11-738E22.3 -7.66 1.1e-13 9.75e-11 -0.41 -0.33 Breast cancer; chr4:57029048 chr4:56960927~56961373:- LUSC cis rs875971 0.862 rs778724 ENSG00000222364.1 RNU6-96P -7.65 1.11e-13 9.81e-11 -0.4 -0.33 Aortic root size; chr7:66364304 chr7:66395191~66395286:+ LUSC cis rs7772486 0.558 rs702322 ENSG00000235652.6 RP11-545I5.3 -7.65 1.11e-13 9.84e-11 -0.35 -0.33 Lobe attachment (rater-scored or self-reported); chr6:145686030 chr6:145799409~145886585:+ LUSC cis rs7772486 0.558 rs2142978 ENSG00000235652.6 RP11-545I5.3 -7.65 1.11e-13 9.84e-11 -0.35 -0.33 Lobe attachment (rater-scored or self-reported); chr6:145690925 chr6:145799409~145886585:+ LUSC cis rs9322193 0.847 rs868375 ENSG00000223701.3 RAET1E-AS1 7.65 1.12e-13 9.84e-11 0.38 0.33 Lung cancer; chr6:149844905 chr6:149884431~149919508:+ LUSC cis rs6142102 0.625 rs6142068 ENSG00000276073.1 RP5-1125A11.7 7.65 1.12e-13 9.84e-11 0.33 0.33 Skin pigmentation; chr20:33969366 chr20:33985617~33988989:- LUSC cis rs367615 0.537 rs1965670 ENSG00000249476.1 CTD-2587M2.1 -7.65 1.12e-13 9.88e-11 -0.37 -0.33 Colorectal cancer (SNP x SNP interaction); chr5:109314097 chr5:109237120~109326369:- LUSC cis rs8072100 1 rs8072100 ENSG00000228782.6 CTD-2026D20.3 -7.65 1.12e-13 9.91e-11 -0.31 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47597321 chr17:47450568~47492492:- LUSC cis rs7811142 1 rs74460138 ENSG00000242294.5 STAG3L5P 7.65 1.13e-13 9.96e-11 0.27 0.33 Platelet count; chr7:100429716 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs6975729 ENSG00000242294.5 STAG3L5P 7.65 1.13e-13 9.96e-11 0.27 0.33 Platelet count; chr7:100430564 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs1073 ENSG00000242294.5 STAG3L5P 7.65 1.13e-13 9.96e-11 0.27 0.33 Platelet count; chr7:100433989 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs4989959 ENSG00000242294.5 STAG3L5P 7.65 1.13e-13 9.96e-11 0.27 0.33 Platelet count; chr7:100434665 chr7:100336079~100351900:+ LUSC cis rs7811142 0.887 rs4074838 ENSG00000242294.5 STAG3L5P 7.65 1.13e-13 9.96e-11 0.27 0.33 Platelet count; chr7:100435042 chr7:100336079~100351900:+ LUSC cis rs1577917 0.545 rs7755958 ENSG00000203875.9 SNHG5 7.65 1.13e-13 1e-10 0.44 0.33 Response to antipsychotic treatment; chr6:85778793 chr6:85660950~85678736:- LUSC cis rs9487094 0.71 rs10499052 ENSG00000260273.1 RP11-425D10.10 7.65 1.14e-13 1e-10 0.44 0.33 Height; chr6:109564272 chr6:109382795~109383666:+ LUSC cis rs801193 0.548 rs2659904 ENSG00000222364.1 RNU6-96P -7.65 1.14e-13 1e-10 -0.4 -0.33 Aortic root size; chr7:66713615 chr7:66395191~66395286:+ LUSC cis rs2019137 0.936 rs4849169 ENSG00000189223.12 PAX8-AS1 7.65 1.14e-13 1.01e-10 0.43 0.33 Lymphocyte counts; chr2:113196080 chr2:113211522~113276581:+ LUSC cis rs2019137 0.836 rs4848318 ENSG00000189223.12 PAX8-AS1 7.65 1.14e-13 1.01e-10 0.43 0.33 Lymphocyte counts; chr2:113196375 chr2:113211522~113276581:+ LUSC cis rs2019137 0.936 rs2241978 ENSG00000189223.12 PAX8-AS1 7.65 1.14e-13 1.01e-10 0.43 0.33 Lymphocyte counts; chr2:113196429 chr2:113211522~113276581:+ LUSC cis rs6142102 0.602 rs2300209 ENSG00000276073.1 RP5-1125A11.7 -7.65 1.15e-13 1.01e-10 -0.33 -0.33 Skin pigmentation; chr20:34055294 chr20:33985617~33988989:- LUSC cis rs2282300 0.739 rs1222215 ENSG00000254532.1 RP11-624D11.2 7.65 1.15e-13 1.01e-10 0.46 0.33 Morning vs. evening chronotype; chr11:30326049 chr11:30044058~30084343:- LUSC cis rs2282300 0.696 rs1222214 ENSG00000254532.1 RP11-624D11.2 7.65 1.15e-13 1.01e-10 0.46 0.33 Morning vs. evening chronotype; chr11:30326148 chr11:30044058~30084343:- LUSC cis rs1113500 0.541 rs11185240 ENSG00000226822.1 RP11-356N1.2 7.65 1.15e-13 1.01e-10 0.39 0.33 Growth-regulated protein alpha levels; chr1:108040188 chr1:108071482~108074519:+ LUSC cis rs1113500 0.541 rs11185241 ENSG00000226822.1 RP11-356N1.2 7.65 1.15e-13 1.01e-10 0.39 0.33 Growth-regulated protein alpha levels; chr1:108040403 chr1:108071482~108074519:+ LUSC cis rs10129255 0.957 rs8009948 ENSG00000211972.2 IGHV3-66 7.65 1.15e-13 1.02e-10 0.26 0.33 Kawasaki disease; chr14:106805607 chr14:106675017~106675544:- LUSC cis rs8072100 1 rs8065669 ENSG00000228782.6 CTD-2026D20.3 7.65 1.16e-13 1.02e-10 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47647630 chr17:47450568~47492492:- LUSC cis rs17023223 0.581 rs10923750 ENSG00000231365.4 RP11-418J17.1 -7.65 1.16e-13 1.02e-10 -0.42 -0.33 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119108172 chr1:119140396~119275973:+ LUSC cis rs11098499 0.644 rs3806808 ENSG00000245958.5 RP11-33B1.1 -7.65 1.16e-13 1.02e-10 -0.33 -0.33 Corneal astigmatism; chr4:119629930 chr4:119454791~119552025:+ LUSC cis rs875971 0.862 rs7809814 ENSG00000222364.1 RNU6-96P 7.65 1.16e-13 1.02e-10 0.4 0.33 Aortic root size; chr7:66150410 chr7:66395191~66395286:+ LUSC cis rs4950322 0.57 rs72691102 ENSG00000278811.3 LINC00624 7.65 1.16e-13 1.02e-10 0.38 0.33 Protein quantitative trait loci; chr1:147301189 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692904 ENSG00000278811.3 LINC00624 7.65 1.16e-13 1.02e-10 0.38 0.33 Protein quantitative trait loci; chr1:147301437 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692905 ENSG00000278811.3 LINC00624 7.65 1.16e-13 1.02e-10 0.38 0.33 Protein quantitative trait loci; chr1:147301560 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692907 ENSG00000278811.3 LINC00624 7.65 1.16e-13 1.02e-10 0.38 0.33 Protein quantitative trait loci; chr1:147301921 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692914 ENSG00000278811.3 LINC00624 7.65 1.16e-13 1.02e-10 0.38 0.33 Protein quantitative trait loci; chr1:147302946 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692917 ENSG00000278811.3 LINC00624 7.65 1.16e-13 1.02e-10 0.38 0.33 Protein quantitative trait loci; chr1:147304389 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs66580541 ENSG00000278811.3 LINC00624 7.65 1.16e-13 1.02e-10 0.38 0.33 Protein quantitative trait loci; chr1:147308828 chr1:147258885~147517875:- LUSC cis rs3823536 0.505 rs3925323 ENSG00000275106.1 RP11-309L24.10 -7.65 1.16e-13 1.02e-10 -0.44 -0.33 Sjögren's syndrome; chr7:128952187 chr7:128952527~128953316:- LUSC cis rs9326248 0.861 rs4938353 ENSG00000280143.1 AP000892.6 7.65 1.17e-13 1.03e-10 0.4 0.33 Blood protein levels; chr11:117175481 chr11:117204967~117210292:+ LUSC cis rs3091242 0.933 rs9438905 ENSG00000224183.1 SDHDP6 -7.65 1.17e-13 1.03e-10 -0.41 -0.33 Erythrocyte sedimentation rate; chr1:25437686 chr1:25294164~25294643:- LUSC cis rs2019137 0.936 rs3828188 ENSG00000189223.12 PAX8-AS1 7.65 1.17e-13 1.03e-10 0.43 0.33 Lymphocyte counts; chr2:113196670 chr2:113211522~113276581:+ LUSC cis rs2019137 0.936 rs3828189 ENSG00000189223.12 PAX8-AS1 7.65 1.17e-13 1.03e-10 0.43 0.33 Lymphocyte counts; chr2:113196919 chr2:113211522~113276581:+ LUSC cis rs7267979 0.753 rs404148 ENSG00000274973.1 RP13-401N8.7 -7.65 1.18e-13 1.03e-10 -0.34 -0.33 Liver enzyme levels (alkaline phosphatase); chr20:25467295 chr20:25845497~25845862:+ LUSC cis rs2282300 0.739 rs35883696 ENSG00000254532.1 RP11-624D11.2 7.65 1.18e-13 1.03e-10 0.45 0.33 Morning vs. evening chronotype; chr11:30224860 chr11:30044058~30084343:- LUSC cis rs875971 0.767 rs1643394 ENSG00000222364.1 RNU6-96P -7.65 1.18e-13 1.04e-10 -0.4 -0.33 Aortic root size; chr7:66371107 chr7:66395191~66395286:+ LUSC cis rs6471393 0.861 rs2976372 ENSG00000253848.1 RP11-10N23.5 -7.65 1.18e-13 1.04e-10 -0.41 -0.33 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93690797 chr8:93741193~93744534:+ LUSC cis rs2297363 1 rs2297363 ENSG00000213073.4 RP11-288H12.3 -7.65 1.18e-13 1.04e-10 -0.41 -0.33 Total cholesterol levels;Blood protein levels; chr6:160085430 chr6:160093082~160096212:+ LUSC cis rs11098499 0.954 rs6820115 ENSG00000249244.1 RP11-548H18.2 7.65 1.18e-13 1.04e-10 0.41 0.33 Corneal astigmatism; chr4:119477027 chr4:119391831~119395335:- LUSC cis rs9322193 0.962 rs12175575 ENSG00000223701.3 RAET1E-AS1 7.65 1.19e-13 1.04e-10 0.38 0.33 Lung cancer; chr6:149763351 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs4869966 ENSG00000223701.3 RAET1E-AS1 7.65 1.19e-13 1.04e-10 0.38 0.33 Lung cancer; chr6:149763714 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs1112730 ENSG00000223701.3 RAET1E-AS1 7.65 1.19e-13 1.04e-10 0.38 0.33 Lung cancer; chr6:149766383 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs1112729 ENSG00000223701.3 RAET1E-AS1 7.65 1.19e-13 1.04e-10 0.38 0.33 Lung cancer; chr6:149766491 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs10452626 ENSG00000223701.3 RAET1E-AS1 7.65 1.19e-13 1.04e-10 0.38 0.33 Lung cancer; chr6:149767481 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs62441303 ENSG00000223701.3 RAET1E-AS1 7.65 1.19e-13 1.04e-10 0.38 0.33 Lung cancer; chr6:149767547 chr6:149884431~149919508:+ LUSC cis rs34779708 0.931 rs7079498 ENSG00000230534.5 RP11-297A16.2 7.65 1.19e-13 1.04e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35086416 chr10:35098006~35127020:- LUSC cis rs7267979 0.738 rs2892409 ENSG00000274973.1 RP13-401N8.7 -7.64 1.19e-13 1.04e-10 -0.34 -0.33 Liver enzyme levels (alkaline phosphatase); chr20:25657502 chr20:25845497~25845862:+ LUSC cis rs34779708 0.966 rs7077242 ENSG00000230534.5 RP11-297A16.2 -7.64 1.19e-13 1.05e-10 -0.37 -0.33 Inflammatory bowel disease;Crohn's disease; chr10:35193037 chr10:35098006~35127020:- LUSC cis rs7811142 0.775 rs6946768 ENSG00000242294.5 STAG3L5P 7.64 1.2e-13 1.05e-10 0.28 0.33 Platelet count; chr7:100356770 chr7:100336079~100351900:+ LUSC cis rs3823536 0.583 rs1874327 ENSG00000275106.1 RP11-309L24.10 -7.64 1.2e-13 1.05e-10 -0.44 -0.33 Sjögren's syndrome; chr7:128945322 chr7:128952527~128953316:- LUSC cis rs6496044 0.507 rs410522 ENSG00000202081.1 RNU6-1280P -7.64 1.2e-13 1.06e-10 -0.38 -0.33 Interstitial lung disease; chr15:85663813 chr15:85651522~85651628:- LUSC cis rs34779708 0.966 rs4934736 ENSG00000230534.5 RP11-297A16.2 7.64 1.2e-13 1.06e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35207940 chr10:35098006~35127020:- LUSC cis rs673078 0.607 rs7299040 ENSG00000275759.1 RP11-131L12.3 -7.64 1.2e-13 1.06e-10 -0.48 -0.33 Glucose homeostasis traits; chr12:118380660 chr12:118428281~118428870:+ LUSC cis rs875971 0.862 rs10250544 ENSG00000222364.1 RNU6-96P 7.64 1.21e-13 1.06e-10 0.39 0.33 Aortic root size; chr7:66301574 chr7:66395191~66395286:+ LUSC cis rs1075232 1 rs12439239 ENSG00000270055.1 CTD-3092A11.2 -7.64 1.21e-13 1.06e-10 -0.65 -0.33 Survival in colorectal cancer (non-distant metastatic); chr15:31359515 chr15:30487963~30490313:+ LUSC cis rs7811142 1 rs73161762 ENSG00000242294.5 STAG3L5P 7.64 1.21e-13 1.06e-10 0.28 0.33 Platelet count; chr7:100417223 chr7:100336079~100351900:+ LUSC cis rs9322193 0.962 rs10872653 ENSG00000223701.3 RAET1E-AS1 7.64 1.21e-13 1.06e-10 0.38 0.33 Lung cancer; chr6:149778907 chr6:149884431~149919508:+ LUSC cis rs1113500 0.73 rs1781077 ENSG00000226822.1 RP11-356N1.2 -7.64 1.22e-13 1.07e-10 -0.33 -0.33 Growth-regulated protein alpha levels; chr1:108046967 chr1:108071482~108074519:+ LUSC cis rs2117029 0.561 rs7957983 ENSG00000258017.1 RP11-386G11.10 -7.64 1.23e-13 1.08e-10 -0.42 -0.33 Intelligence (multi-trait analysis); chr12:49115204 chr12:49127782~49147869:+ LUSC cis rs673078 0.607 rs61943392 ENSG00000275759.1 RP11-131L12.3 -7.64 1.23e-13 1.08e-10 -0.48 -0.33 Glucose homeostasis traits; chr12:118382618 chr12:118428281~118428870:+ LUSC cis rs7945705 0.869 rs2742471 ENSG00000254860.4 TMEM9B-AS1 7.64 1.23e-13 1.08e-10 0.37 0.33 Hemoglobin concentration; chr11:8982406 chr11:8964675~8977527:+ LUSC cis rs4950322 0.57 rs72691090 ENSG00000278811.3 LINC00624 7.64 1.23e-13 1.08e-10 0.38 0.33 Protein quantitative trait loci; chr1:147297884 chr1:147258885~147517875:- LUSC cis rs7811142 1 rs67471932 ENSG00000242294.5 STAG3L5P 7.64 1.24e-13 1.09e-10 0.27 0.33 Platelet count; chr7:100412362 chr7:100336079~100351900:+ LUSC cis rs1113500 0.614 rs12565953 ENSG00000226822.1 RP11-356N1.2 7.64 1.25e-13 1.09e-10 0.38 0.33 Growth-regulated protein alpha levels; chr1:108064465 chr1:108071482~108074519:+ LUSC cis rs34779708 0.897 rs7897827 ENSG00000230534.5 RP11-297A16.2 7.64 1.25e-13 1.1e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35097309 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs7913615 ENSG00000230534.5 RP11-297A16.2 7.64 1.25e-13 1.1e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35134029 chr10:35098006~35127020:- LUSC cis rs992157 0.735 rs10932765 ENSG00000261338.2 RP11-378A13.1 7.64 1.26e-13 1.1e-10 0.33 0.33 Colorectal cancer; chr2:218234761 chr2:218255319~218257366:+ LUSC cis rs150992 0.504 rs6878136 ENSG00000248489.1 CTD-2007H13.3 -7.64 1.26e-13 1.11e-10 -0.44 -0.33 Body mass index; chr5:99022487 chr5:98929171~98995013:+ LUSC cis rs9487094 0.744 rs13212535 ENSG00000260273.1 RP11-425D10.10 7.63 1.27e-13 1.11e-10 0.44 0.33 Height; chr6:109713188 chr6:109382795~109383666:+ LUSC cis rs2282300 0.702 rs4379811 ENSG00000254532.1 RP11-624D11.2 -7.63 1.27e-13 1.12e-10 -0.46 -0.33 Morning vs. evening chronotype; chr11:30273213 chr11:30044058~30084343:- LUSC cis rs2282300 0.739 rs3858428 ENSG00000254532.1 RP11-624D11.2 -7.63 1.27e-13 1.12e-10 -0.46 -0.33 Morning vs. evening chronotype; chr11:30275003 chr11:30044058~30084343:- LUSC cis rs11098499 0.739 rs9996382 ENSG00000245958.5 RP11-33B1.1 -7.63 1.28e-13 1.12e-10 -0.32 -0.33 Corneal astigmatism; chr4:119229857 chr4:119454791~119552025:+ LUSC cis rs10463554 0.892 rs13340345 ENSG00000175749.11 EIF3KP1 7.63 1.29e-13 1.13e-10 0.4 0.33 Parkinson's disease; chr5:103003518 chr5:103032376~103033031:+ LUSC cis rs875971 0.789 rs7808013 ENSG00000222364.1 RNU6-96P 7.63 1.29e-13 1.13e-10 0.4 0.33 Aortic root size; chr7:66606209 chr7:66395191~66395286:+ LUSC cis rs783540 0.656 rs783524 ENSG00000255769.6 GOLGA2P10 7.63 1.29e-13 1.13e-10 0.43 0.33 Schizophrenia; chr15:82615393 chr15:82472993~82513950:- LUSC cis rs6991838 0.584 rs2175810 ENSG00000200714.1 Y_RNA -7.63 1.3e-13 1.14e-10 -0.4 -0.33 Intelligence (multi-trait analysis); chr8:65643583 chr8:65592731~65592820:+ LUSC cis rs61160187 0.582 rs12516995 ENSG00000215032.2 GNL3LP1 7.63 1.31e-13 1.14e-10 0.41 0.33 Educational attainment (years of education);Educational attainment (college completion); chr5:61012447 chr5:60891935~60893577:- LUSC cis rs11089937 0.568 rs5756989 ENSG00000211639.2 IGLV4-60 7.63 1.31e-13 1.14e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22132415 chr22:22162199~22162681:+ LUSC cis rs4950322 0.57 rs17360443 ENSG00000278811.3 LINC00624 7.63 1.31e-13 1.15e-10 0.38 0.33 Protein quantitative trait loci; chr1:147279737 chr1:147258885~147517875:- LUSC cis rs875971 0.825 rs7384021 ENSG00000222364.1 RNU6-96P 7.63 1.31e-13 1.15e-10 0.4 0.33 Aortic root size; chr7:66612917 chr7:66395191~66395286:+ LUSC cis rs4423214 0.592 rs10898186 ENSG00000254682.1 RP11-660L16.2 -7.63 1.31e-13 1.15e-10 -0.55 -0.33 Vitamin D levels; chr11:71477754 chr11:71448674~71452157:+ LUSC cis rs3091242 0.904 rs6661533 ENSG00000224183.1 SDHDP6 -7.63 1.32e-13 1.15e-10 -0.41 -0.33 Erythrocyte sedimentation rate; chr1:25445224 chr1:25294164~25294643:- LUSC cis rs9322193 0.884 rs9688858 ENSG00000223701.3 RAET1E-AS1 7.63 1.32e-13 1.15e-10 0.38 0.33 Lung cancer; chr6:149637911 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9688750 ENSG00000223701.3 RAET1E-AS1 7.63 1.32e-13 1.15e-10 0.38 0.33 Lung cancer; chr6:149657633 chr6:149884431~149919508:+ LUSC cis rs7811142 1 rs67315960 ENSG00000242294.5 STAG3L5P 7.63 1.32e-13 1.15e-10 0.27 0.33 Platelet count; chr7:100417501 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs11763414 ENSG00000242294.5 STAG3L5P 7.63 1.32e-13 1.15e-10 0.27 0.33 Platelet count; chr7:100419221 chr7:100336079~100351900:+ LUSC cis rs853679 0.55 rs9295762 ENSG00000204709.4 LINC01556 -7.63 1.33e-13 1.16e-10 -0.45 -0.33 Depression; chr6:28187640 chr6:28943877~28944537:+ LUSC cis rs1865760 0.566 rs9366634 ENSG00000272462.2 U91328.19 -7.63 1.33e-13 1.16e-10 -0.36 -0.33 Height; chr6:26072168 chr6:25992662~26001775:+ LUSC cis rs10829156 0.699 rs1917209 ENSG00000240291.1 RP11-499P20.2 7.63 1.34e-13 1.17e-10 0.35 0.33 Sudden cardiac arrest; chr10:18543631 chr10:18513115~18545651:- LUSC cis rs2019137 0.936 rs731834 ENSG00000189223.12 PAX8-AS1 7.63 1.35e-13 1.18e-10 0.43 0.33 Lymphocyte counts; chr2:113199621 chr2:113211522~113276581:+ LUSC cis rs9532669 0.857 rs9525427 ENSG00000176268.5 CYCSP34 7.63 1.35e-13 1.18e-10 0.32 0.33 Cervical cancer; chr13:40918029 chr13:40863599~40863902:- LUSC cis rs2282300 0.739 rs1222216 ENSG00000254532.1 RP11-624D11.2 7.63 1.35e-13 1.18e-10 0.46 0.33 Morning vs. evening chronotype; chr11:30324505 chr11:30044058~30084343:- LUSC cis rs875971 0.862 rs1875057 ENSG00000222364.1 RNU6-96P 7.63 1.35e-13 1.18e-10 0.39 0.33 Aortic root size; chr7:66266868 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6960446 ENSG00000222364.1 RNU6-96P 7.63 1.35e-13 1.18e-10 0.39 0.33 Aortic root size; chr7:66268272 chr7:66395191~66395286:+ LUSC cis rs875971 0.789 rs10260426 ENSG00000222364.1 RNU6-96P 7.63 1.35e-13 1.18e-10 0.39 0.33 Aortic root size; chr7:66271055 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs10263690 ENSG00000222364.1 RNU6-96P 7.63 1.35e-13 1.18e-10 0.39 0.33 Aortic root size; chr7:66301466 chr7:66395191~66395286:+ LUSC cis rs2283792 0.73 rs2027790 ENSG00000228050.1 TOP3BP1 7.63 1.36e-13 1.19e-10 0.39 0.33 Multiple sclerosis; chr22:21933592 chr22:22223187~22224566:- LUSC cis rs783540 0.592 rs2567632 ENSG00000255769.6 GOLGA2P10 7.62 1.36e-13 1.19e-10 0.43 0.33 Schizophrenia; chr15:82616053 chr15:82472993~82513950:- LUSC cis rs4950322 0.57 rs2354428 ENSG00000278811.3 LINC00624 7.62 1.37e-13 1.19e-10 0.38 0.33 Protein quantitative trait loci; chr1:147277512 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72691054 ENSG00000278811.3 LINC00624 7.62 1.37e-13 1.19e-10 0.38 0.33 Protein quantitative trait loci; chr1:147277942 chr1:147258885~147517875:- LUSC cis rs11089937 0.626 rs9619800 ENSG00000211639.2 IGLV4-60 7.62 1.37e-13 1.19e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22141088 chr22:22162199~22162681:+ LUSC cis rs61160187 0.582 rs55814394 ENSG00000215032.2 GNL3LP1 7.62 1.37e-13 1.19e-10 0.41 0.33 Educational attainment (years of education);Educational attainment (college completion); chr5:61014107 chr5:60891935~60893577:- LUSC cis rs2282300 0.739 rs16920406 ENSG00000254532.1 RP11-624D11.2 7.62 1.37e-13 1.2e-10 0.45 0.33 Morning vs. evening chronotype; chr11:30194611 chr11:30044058~30084343:- LUSC cis rs2019137 0.905 rs2276561 ENSG00000189223.12 PAX8-AS1 7.62 1.38e-13 1.2e-10 0.43 0.33 Lymphocyte counts; chr2:113198794 chr2:113211522~113276581:+ LUSC cis rs2019137 0.936 rs2305133 ENSG00000189223.12 PAX8-AS1 7.62 1.38e-13 1.2e-10 0.43 0.33 Lymphocyte counts; chr2:113199244 chr2:113211522~113276581:+ LUSC cis rs2019137 0.936 rs12612729 ENSG00000189223.12 PAX8-AS1 7.62 1.38e-13 1.2e-10 0.43 0.33 Lymphocyte counts; chr2:113199471 chr2:113211522~113276581:+ LUSC cis rs10129255 0.957 rs61997760 ENSG00000211972.2 IGHV3-66 7.62 1.38e-13 1.21e-10 0.26 0.33 Kawasaki disease; chr14:106716993 chr14:106675017~106675544:- LUSC cis rs11098499 1 rs12506395 ENSG00000249244.1 RP11-548H18.2 7.62 1.38e-13 1.21e-10 0.43 0.33 Corneal astigmatism; chr4:119263939 chr4:119391831~119395335:- LUSC cis rs9322193 0.923 rs9322197 ENSG00000223701.3 RAET1E-AS1 7.62 1.39e-13 1.21e-10 0.38 0.33 Lung cancer; chr6:149622577 chr6:149884431~149919508:+ LUSC cis rs11118620 1 rs11118620 ENSG00000238078.1 LINC01352 7.62 1.4e-13 1.22e-10 0.38 0.33 Heart failure; chr1:220855166 chr1:220829255~220832429:+ LUSC cis rs4950322 0.57 rs4950409 ENSG00000278811.3 LINC00624 7.62 1.4e-13 1.22e-10 0.38 0.33 Protein quantitative trait loci; chr1:147335879 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692979 ENSG00000278811.3 LINC00624 7.62 1.4e-13 1.22e-10 0.38 0.33 Protein quantitative trait loci; chr1:147336094 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692980 ENSG00000278811.3 LINC00624 7.62 1.4e-13 1.22e-10 0.38 0.33 Protein quantitative trait loci; chr1:147337830 chr1:147258885~147517875:- LUSC cis rs875971 0.862 rs1983372 ENSG00000222364.1 RNU6-96P 7.62 1.4e-13 1.22e-10 0.39 0.33 Aortic root size; chr7:66146364 chr7:66395191~66395286:+ LUSC cis rs6142102 0.812 rs6120440 ENSG00000276073.1 RP5-1125A11.7 7.62 1.4e-13 1.22e-10 0.35 0.33 Skin pigmentation; chr20:33929779 chr20:33985617~33988989:- LUSC cis rs9322193 0.923 rs9371486 ENSG00000223701.3 RAET1E-AS1 7.62 1.4e-13 1.22e-10 0.4 0.33 Lung cancer; chr6:149832090 chr6:149884431~149919508:+ LUSC cis rs189798 1 rs189798 ENSG00000254340.1 RP11-10A14.3 -7.62 1.41e-13 1.22e-10 -0.43 -0.33 Myopia (pathological); chr8:9133067 chr8:9141424~9145435:+ LUSC cis rs9326248 0.861 rs4938343 ENSG00000280143.1 AP000892.6 7.62 1.41e-13 1.22e-10 0.42 0.33 Blood protein levels; chr11:117132812 chr11:117204967~117210292:+ LUSC cis rs7811142 1 rs66632384 ENSG00000242294.5 STAG3L5P 7.62 1.41e-13 1.22e-10 0.27 0.33 Platelet count; chr7:100421281 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs67163493 ENSG00000242294.5 STAG3L5P 7.62 1.41e-13 1.22e-10 0.27 0.33 Platelet count; chr7:100426215 chr7:100336079~100351900:+ LUSC cis rs7811142 0.943 rs73403312 ENSG00000242294.5 STAG3L5P 7.62 1.41e-13 1.22e-10 0.27 0.33 Platelet count; chr7:100426530 chr7:100336079~100351900:+ LUSC cis rs4950322 0.57 rs72692920 ENSG00000278811.3 LINC00624 7.62 1.41e-13 1.23e-10 0.38 0.33 Protein quantitative trait loci; chr1:147308501 chr1:147258885~147517875:- LUSC cis rs17711722 0.528 rs73138179 ENSG00000224316.1 RP11-479O9.2 7.62 1.42e-13 1.23e-10 0.33 0.33 Calcium levels; chr7:65829495 chr7:65773620~65802067:+ LUSC cis rs10466239 0.667 rs10899792 ENSG00000230555.2 RP11-517P14.2 7.62 1.42e-13 1.23e-10 0.54 0.33 Telomere length; chr10:43364722 chr10:43420738~43422100:+ LUSC cis rs875971 0.862 rs7796162 ENSG00000222364.1 RNU6-96P 7.62 1.42e-13 1.23e-10 0.39 0.33 Aortic root size; chr7:66280771 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs2901152 ENSG00000222364.1 RNU6-96P 7.62 1.42e-13 1.23e-10 0.39 0.33 Aortic root size; chr7:66300017 chr7:66395191~66395286:+ LUSC cis rs34779708 0.931 rs67976880 ENSG00000230534.5 RP11-297A16.2 7.62 1.42e-13 1.24e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35083333 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs72789687 ENSG00000230534.5 RP11-297A16.2 7.62 1.42e-13 1.24e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35083561 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs35997236 ENSG00000230534.5 RP11-297A16.2 7.62 1.42e-13 1.24e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35087762 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs4934719 ENSG00000230534.5 RP11-297A16.2 7.62 1.42e-13 1.24e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35087841 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs4934720 ENSG00000230534.5 RP11-297A16.2 7.62 1.42e-13 1.24e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35087872 chr10:35098006~35127020:- LUSC cis rs875971 0.862 rs3926380 ENSG00000222364.1 RNU6-96P 7.62 1.43e-13 1.24e-10 0.4 0.33 Aortic root size; chr7:66615658 chr7:66395191~66395286:+ LUSC cis rs875971 0.825 rs1860472 ENSG00000222364.1 RNU6-96P 7.62 1.43e-13 1.24e-10 0.4 0.33 Aortic root size; chr7:66617736 chr7:66395191~66395286:+ LUSC cis rs11089937 0.626 rs11704092 ENSG00000211639.2 IGLV4-60 7.62 1.43e-13 1.24e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22135815 chr22:22162199~22162681:+ LUSC cis rs4950322 0.634 rs7542951 ENSG00000278811.3 LINC00624 7.62 1.44e-13 1.25e-10 0.38 0.33 Protein quantitative trait loci; chr1:147340308 chr1:147258885~147517875:- LUSC cis rs4713118 0.513 rs149962 ENSG00000204709.4 LINC01556 7.62 1.44e-13 1.25e-10 0.42 0.33 Parkinson's disease; chr6:28048140 chr6:28943877~28944537:+ LUSC cis rs55794721 0.509 rs6699896 ENSG00000224183.1 SDHDP6 -7.62 1.44e-13 1.25e-10 -0.41 -0.33 Mean corpuscular volume;Plateletcrit; chr1:25436411 chr1:25294164~25294643:- LUSC cis rs9322193 0.962 rs3805748 ENSG00000223701.3 RAET1E-AS1 7.62 1.45e-13 1.25e-10 0.38 0.33 Lung cancer; chr6:149772542 chr6:149884431~149919508:+ LUSC cis rs9322193 0.736 rs10457851 ENSG00000223701.3 RAET1E-AS1 7.62 1.45e-13 1.25e-10 0.38 0.33 Lung cancer; chr6:149775216 chr6:149884431~149919508:+ LUSC cis rs9322193 0.886 rs10872652 ENSG00000223701.3 RAET1E-AS1 7.62 1.45e-13 1.25e-10 0.38 0.33 Lung cancer; chr6:149775303 chr6:149884431~149919508:+ LUSC cis rs9322193 0.886 rs12525871 ENSG00000223701.3 RAET1E-AS1 7.62 1.45e-13 1.25e-10 0.38 0.33 Lung cancer; chr6:149775882 chr6:149884431~149919508:+ LUSC cis rs9322193 0.886 rs17672976 ENSG00000223701.3 RAET1E-AS1 7.62 1.45e-13 1.25e-10 0.38 0.33 Lung cancer; chr6:149776207 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs2184369 ENSG00000223701.3 RAET1E-AS1 7.62 1.45e-13 1.25e-10 0.38 0.33 Lung cancer; chr6:149776681 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs2342861 ENSG00000223701.3 RAET1E-AS1 7.62 1.45e-13 1.25e-10 0.38 0.33 Lung cancer; chr6:149777561 chr6:149884431~149919508:+ LUSC cis rs9322193 0.926 rs2342860 ENSG00000223701.3 RAET1E-AS1 7.62 1.45e-13 1.25e-10 0.38 0.33 Lung cancer; chr6:149777641 chr6:149884431~149919508:+ LUSC cis rs1865760 0.686 rs12210098 ENSG00000272462.2 U91328.19 -7.62 1.45e-13 1.26e-10 -0.38 -0.33 Height; chr6:25963738 chr6:25992662~26001775:+ LUSC cis rs9322193 0.962 rs3763163 ENSG00000223701.3 RAET1E-AS1 7.62 1.45e-13 1.26e-10 0.38 0.33 Lung cancer; chr6:149819770 chr6:149884431~149919508:+ LUSC cis rs2282300 0.739 rs67670125 ENSG00000254532.1 RP11-624D11.2 7.62 1.45e-13 1.26e-10 0.45 0.33 Morning vs. evening chronotype; chr11:30193367 chr11:30044058~30084343:- LUSC cis rs1113500 0.614 rs1343192 ENSG00000226822.1 RP11-356N1.2 7.62 1.45e-13 1.26e-10 0.38 0.33 Growth-regulated protein alpha levels; chr1:108071266 chr1:108071482~108074519:+ LUSC cis rs875971 0.522 rs1617484 ENSG00000236529.1 RP13-254B10.1 7.62 1.46e-13 1.26e-10 0.35 0.33 Aortic root size; chr7:65998108 chr7:65840212~65840596:+ LUSC cis rs992157 0.735 rs12990082 ENSG00000261338.2 RP11-378A13.1 7.61 1.47e-13 1.28e-10 0.34 0.33 Colorectal cancer; chr2:218237609 chr2:218255319~218257366:+ LUSC cis rs4950322 0.57 rs72691097 ENSG00000278811.3 LINC00624 7.61 1.48e-13 1.28e-10 0.38 0.33 Protein quantitative trait loci; chr1:147299711 chr1:147258885~147517875:- LUSC cis rs853679 0.567 rs3799499 ENSG00000204709.4 LINC01556 7.61 1.48e-13 1.28e-10 0.45 0.33 Depression; chr6:28386473 chr6:28943877~28944537:+ LUSC cis rs34779708 0.931 rs34954932 ENSG00000230534.5 RP11-297A16.2 7.61 1.49e-13 1.29e-10 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35121879 chr10:35098006~35127020:- LUSC cis rs9487094 0.744 rs13204787 ENSG00000260273.1 RP11-425D10.10 7.61 1.49e-13 1.29e-10 0.44 0.33 Height; chr6:109618283 chr6:109382795~109383666:+ LUSC cis rs34779708 0.897 rs34481177 ENSG00000230534.5 RP11-297A16.2 7.61 1.49e-13 1.29e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35091985 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs11593858 ENSG00000230534.5 RP11-297A16.2 7.61 1.49e-13 1.29e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35092445 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs72789690 ENSG00000230534.5 RP11-297A16.2 7.61 1.49e-13 1.29e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35093889 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs68039650 ENSG00000230534.5 RP11-297A16.2 7.61 1.49e-13 1.29e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35096571 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs35136660 ENSG00000230534.5 RP11-297A16.2 7.61 1.49e-13 1.29e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35097045 chr10:35098006~35127020:- LUSC cis rs34779708 0.897 rs12764820 ENSG00000230534.5 RP11-297A16.2 7.61 1.49e-13 1.29e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35097393 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs67261877 ENSG00000230534.5 RP11-297A16.2 7.61 1.49e-13 1.29e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35097412 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs12768019 ENSG00000230534.5 RP11-297A16.2 7.61 1.49e-13 1.29e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35100915 chr10:35098006~35127020:- LUSC cis rs6142102 0.602 rs10485503 ENSG00000276073.1 RP5-1125A11.7 -7.61 1.5e-13 1.3e-10 -0.33 -0.33 Skin pigmentation; chr20:33970036 chr20:33985617~33988989:- LUSC cis rs61160187 0.582 rs62367903 ENSG00000215032.2 GNL3LP1 7.61 1.5e-13 1.3e-10 0.41 0.33 Educational attainment (years of education);Educational attainment (college completion); chr5:61023146 chr5:60891935~60893577:- LUSC cis rs3096299 0.9 rs744327 ENSG00000274627.1 RP11-104N10.2 7.61 1.5e-13 1.3e-10 0.3 0.33 Multiple myeloma (IgH translocation); chr16:89372862 chr16:89516797~89522217:+ LUSC cis rs9341808 0.621 rs2322627 ENSG00000272129.1 RP11-250B2.6 7.61 1.51e-13 1.3e-10 0.4 0.33 Sitting height ratio; chr6:80096624 chr6:80355424~80356859:+ LUSC cis rs2739330 0.652 rs2000469 ENSG00000231271.1 AP000350.8 7.61 1.52e-13 1.31e-10 0.45 0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23949918~23954042:+ LUSC cis rs172166 0.637 rs1225597 ENSG00000204709.4 LINC01556 7.61 1.52e-13 1.32e-10 0.43 0.33 Cardiac Troponin-T levels; chr6:28194309 chr6:28943877~28944537:+ LUSC cis rs7684253 0.548 rs62308071 ENSG00000269949.1 RP11-738E22.3 -7.61 1.52e-13 1.32e-10 -0.4 -0.33 Migraine; chr4:56850720 chr4:56960927~56961373:- LUSC cis rs7267979 0.789 rs62213729 ENSG00000274973.1 RP13-401N8.7 7.61 1.52e-13 1.32e-10 0.34 0.33 Liver enzyme levels (alkaline phosphatase); chr20:25382790 chr20:25845497~25845862:+ LUSC cis rs2739330 0.76 rs1002286 ENSG00000099984.9 GSTT2 7.61 1.53e-13 1.32e-10 0.4 0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23980123~23983911:+ LUSC cis rs1113500 0.565 rs1777455 ENSG00000226822.1 RP11-356N1.2 -7.61 1.53e-13 1.32e-10 -0.38 -0.33 Growth-regulated protein alpha levels; chr1:108047666 chr1:108071482~108074519:+ LUSC cis rs1823913 0.927 rs1454761 ENSG00000280083.1 RP11-317J9.1 -7.61 1.53e-13 1.33e-10 -0.41 -0.33 Obesity-related traits; chr2:191237092 chr2:191154118~191156070:- LUSC cis rs11089937 0.597 rs4821774 ENSG00000211639.2 IGLV4-60 7.61 1.54e-13 1.33e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22131536 chr22:22162199~22162681:+ LUSC cis rs7684446 1 rs7684446 ENSG00000273133.1 RP11-799M12.2 7.61 1.55e-13 1.34e-10 0.42 0.33 Red blood cell count; chr4:15591241 chr4:15563698~15564253:- LUSC cis rs1789 0.653 rs13142069 ENSG00000273133.1 RP11-799M12.2 7.61 1.55e-13 1.34e-10 0.42 0.33 Blood protein levels; chr4:15592069 chr4:15563698~15564253:- LUSC cis rs875971 0.895 rs12531677 ENSG00000222364.1 RNU6-96P 7.61 1.55e-13 1.34e-10 0.39 0.33 Aortic root size; chr7:66304099 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs7798630 ENSG00000222364.1 RNU6-96P 7.61 1.55e-13 1.34e-10 0.39 0.33 Aortic root size; chr7:66306492 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs11984115 ENSG00000222364.1 RNU6-96P 7.61 1.55e-13 1.34e-10 0.39 0.33 Aortic root size; chr7:66308872 chr7:66395191~66395286:+ LUSC cis rs6782228 1 rs35604103 ENSG00000277250.1 Metazoa_SRP 7.61 1.55e-13 1.34e-10 0.4 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128616009 chr3:128673681~128674021:- LUSC cis rs2337406 0.714 rs7145254 ENSG00000274576.2 IGHV2-70 -7.61 1.55e-13 1.34e-10 -0.35 -0.33 Alzheimer's disease (late onset); chr14:106817783 chr14:106770577~106771020:- LUSC cis rs8062405 0.69 rs762634 ENSG00000259982.1 CDC37P1 7.61 1.56e-13 1.35e-10 0.42 0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28592014 chr16:28700294~28701540:- LUSC cis rs62034325 0.697 rs710410 ENSG00000259982.1 CDC37P1 7.61 1.56e-13 1.35e-10 0.42 0.33 Body mass index; chr16:28592021 chr16:28700294~28701540:- LUSC cis rs7945705 0.902 rs2568059 ENSG00000254860.4 TMEM9B-AS1 7.6 1.57e-13 1.36e-10 0.36 0.33 Hemoglobin concentration; chr11:8862614 chr11:8964675~8977527:+ LUSC cis rs7945705 0.875 rs2653616 ENSG00000254860.4 TMEM9B-AS1 7.6 1.57e-13 1.36e-10 0.36 0.33 Hemoglobin concentration; chr11:8864345 chr11:8964675~8977527:+ LUSC cis rs7945705 0.935 rs2568061 ENSG00000254860.4 TMEM9B-AS1 7.6 1.57e-13 1.36e-10 0.36 0.33 Hemoglobin concentration; chr11:8864713 chr11:8964675~8977527:+ LUSC cis rs172166 0.769 rs149965 ENSG00000204709.4 LINC01556 7.6 1.58e-13 1.36e-10 0.42 0.33 Cardiac Troponin-T levels; chr6:28050911 chr6:28943877~28944537:+ LUSC cis rs61160187 0.582 rs10939879 ENSG00000215032.2 GNL3LP1 7.6 1.58e-13 1.36e-10 0.41 0.33 Educational attainment (years of education);Educational attainment (college completion); chr5:61019996 chr5:60891935~60893577:- LUSC cis rs11098499 0.644 rs34835603 ENSG00000245958.5 RP11-33B1.1 -7.6 1.59e-13 1.37e-10 -0.33 -0.33 Corneal astigmatism; chr4:119632273 chr4:119454791~119552025:+ LUSC cis rs11098499 0.615 rs28850368 ENSG00000245958.5 RP11-33B1.1 -7.6 1.59e-13 1.37e-10 -0.33 -0.33 Corneal astigmatism; chr4:119633158 chr4:119454791~119552025:+ LUSC cis rs875971 0.79 rs10257911 ENSG00000222364.1 RNU6-96P 7.6 1.59e-13 1.37e-10 0.39 0.33 Aortic root size; chr7:66278783 chr7:66395191~66395286:+ LUSC cis rs2179367 0.887 rs6570965 ENSG00000231760.4 RP11-350J20.5 7.6 1.59e-13 1.38e-10 0.42 0.33 Dupuytren's disease; chr6:149396340 chr6:149796151~149826294:- LUSC cis rs34779708 0.658 rs4934715 ENSG00000230534.5 RP11-297A16.2 7.6 1.61e-13 1.39e-10 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35076064 chr10:35098006~35127020:- LUSC cis rs1757171 0.504 rs11969056 ENSG00000204110.6 RP1-153P14.8 -7.6 1.61e-13 1.39e-10 -0.32 -0.33 Cognitive performance; chr6:37516509 chr6:37507348~37535616:+ LUSC cis rs9487094 0.677 rs35452836 ENSG00000260273.1 RP11-425D10.10 7.6 1.62e-13 1.39e-10 0.43 0.33 Height; chr6:109378243 chr6:109382795~109383666:+ LUSC cis rs875971 0.862 rs6971059 ENSG00000222364.1 RNU6-96P 7.6 1.62e-13 1.4e-10 0.39 0.33 Aortic root size; chr7:66602045 chr7:66395191~66395286:+ LUSC cis rs875971 0.825 rs66981195 ENSG00000222364.1 RNU6-96P 7.6 1.62e-13 1.4e-10 0.39 0.33 Aortic root size; chr7:66614048 chr7:66395191~66395286:+ LUSC cis rs4713118 0.662 rs149946 ENSG00000219392.1 RP1-265C24.5 7.6 1.62e-13 1.4e-10 0.46 0.33 Parkinson's disease; chr6:28002253 chr6:28115628~28116551:+ LUSC cis rs367615 0.552 rs2963024 ENSG00000249476.1 CTD-2587M2.1 -7.6 1.63e-13 1.4e-10 -0.37 -0.33 Colorectal cancer (SNP x SNP interaction); chr5:109395072 chr5:109237120~109326369:- LUSC cis rs11089937 0.539 rs6001075 ENSG00000211639.2 IGLV4-60 7.6 1.64e-13 1.41e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22133765 chr22:22162199~22162681:+ LUSC cis rs11089937 0.597 rs6001076 ENSG00000211639.2 IGLV4-60 7.6 1.64e-13 1.41e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22133873 chr22:22162199~22162681:+ LUSC cis rs11089937 0.597 rs5995560 ENSG00000211639.2 IGLV4-60 7.6 1.64e-13 1.41e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22133989 chr22:22162199~22162681:+ LUSC cis rs10829156 0.699 rs7911922 ENSG00000240291.1 RP11-499P20.2 7.6 1.64e-13 1.41e-10 0.35 0.33 Sudden cardiac arrest; chr10:18542768 chr10:18513115~18545651:- LUSC cis rs3091242 0.933 rs34006994 ENSG00000224183.1 SDHDP6 7.6 1.66e-13 1.43e-10 0.4 0.33 Erythrocyte sedimentation rate; chr1:25454177 chr1:25294164~25294643:- LUSC cis rs3091242 0.933 rs61775167 ENSG00000224183.1 SDHDP6 7.6 1.66e-13 1.43e-10 0.4 0.33 Erythrocyte sedimentation rate; chr1:25454402 chr1:25294164~25294643:- LUSC cis rs4950322 0.57 rs72691095 ENSG00000278811.3 LINC00624 7.6 1.66e-13 1.43e-10 0.38 0.33 Protein quantitative trait loci; chr1:147298305 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72691098 ENSG00000278811.3 LINC00624 7.6 1.66e-13 1.43e-10 0.38 0.33 Protein quantitative trait loci; chr1:147300142 chr1:147258885~147517875:- LUSC cis rs11089937 0.568 rs6001078 ENSG00000211639.2 IGLV4-60 7.6 1.67e-13 1.44e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22134365 chr22:22162199~22162681:+ LUSC cis rs7267979 0.702 rs449801 ENSG00000274973.1 RP13-401N8.7 -7.6 1.67e-13 1.44e-10 -0.34 -0.33 Liver enzyme levels (alkaline phosphatase); chr20:25511211 chr20:25845497~25845862:+ LUSC cis rs875971 0.83 rs12673450 ENSG00000222364.1 RNU6-96P -7.59 1.68e-13 1.44e-10 -0.4 -0.33 Aortic root size; chr7:66544233 chr7:66395191~66395286:+ LUSC cis rs17482078 0.959 rs13185488 ENSG00000248734.2 CTD-2260A17.1 7.59 1.69e-13 1.45e-10 0.39 0.33 Behcet's disease;Blood protein levels; chr5:96785480 chr5:96784777~96785999:+ LUSC cis rs17482078 0.959 rs13186739 ENSG00000248734.2 CTD-2260A17.1 7.59 1.69e-13 1.45e-10 0.39 0.33 Behcet's disease;Blood protein levels; chr5:96785539 chr5:96784777~96785999:+ LUSC cis rs4950322 0.57 rs72691093 ENSG00000278811.3 LINC00624 7.59 1.69e-13 1.45e-10 0.38 0.33 Protein quantitative trait loci; chr1:147297977 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs76236344 ENSG00000278811.3 LINC00624 7.59 1.69e-13 1.45e-10 0.38 0.33 Protein quantitative trait loci; chr1:147297989 chr1:147258885~147517875:- LUSC cis rs5753618 0.583 rs5749279 ENSG00000236132.1 CTA-440B3.1 -7.59 1.69e-13 1.46e-10 -0.43 -0.33 Colorectal cancer; chr22:31458223 chr22:31816379~31817491:- LUSC cis rs11089937 0.54 rs9622920 ENSG00000211639.2 IGLV4-60 -7.59 1.7e-13 1.46e-10 -0.36 -0.33 Periodontitis (PAL4Q3); chr22:22133024 chr22:22162199~22162681:+ LUSC cis rs875971 0.862 rs801195 ENSG00000222364.1 RNU6-96P 7.59 1.71e-13 1.47e-10 0.39 0.33 Aortic root size; chr7:66561128 chr7:66395191~66395286:+ LUSC cis rs6991838 0.806 rs13262793 ENSG00000272010.1 CTD-3025N20.3 7.59 1.71e-13 1.47e-10 0.37 0.33 Intelligence (multi-trait analysis); chr8:65549662 chr8:65591850~65592472:- LUSC cis rs10463554 1 rs12659870 ENSG00000175749.11 EIF3KP1 7.59 1.71e-13 1.47e-10 0.39 0.33 Parkinson's disease; chr5:103000867 chr5:103032376~103033031:+ LUSC cis rs10463554 0.963 rs1552916 ENSG00000175749.11 EIF3KP1 7.59 1.71e-13 1.47e-10 0.39 0.33 Parkinson's disease; chr5:103002036 chr5:103032376~103033031:+ LUSC cis rs1185460 0.546 rs592190 ENSG00000271751.1 RP11-110I1.14 7.59 1.71e-13 1.47e-10 0.43 0.33 Coronary artery disease; chr11:119084604 chr11:119065263~119065677:- LUSC cis rs1185460 0.546 rs589925 ENSG00000271751.1 RP11-110I1.14 7.59 1.71e-13 1.47e-10 0.43 0.33 Coronary artery disease; chr11:119084969 chr11:119065263~119065677:- LUSC cis rs17711722 0.585 rs6942660 ENSG00000224316.1 RP11-479O9.2 7.59 1.72e-13 1.47e-10 0.32 0.33 Calcium levels; chr7:65837419 chr7:65773620~65802067:+ LUSC cis rs11089937 0.626 rs9619811 ENSG00000211639.2 IGLV4-60 7.59 1.72e-13 1.47e-10 0.36 0.33 Periodontitis (PAL4Q3); chr22:22159186 chr22:22162199~22162681:+ LUSC cis rs11098499 0.526 rs10026625 ENSG00000245958.5 RP11-33B1.1 -7.59 1.73e-13 1.48e-10 -0.32 -0.33 Corneal astigmatism; chr4:119358981 chr4:119454791~119552025:+ LUSC cis rs55665837 1 rs10832254 ENSG00000251991.1 RNU7-49P 7.59 1.73e-13 1.48e-10 0.37 0.33 Vitamin D levels; chr11:14413152 chr11:14478892~14478953:+ LUSC cis rs11118620 0.81 rs4587570 ENSG00000238078.1 LINC01352 7.59 1.73e-13 1.49e-10 0.38 0.33 Heart failure; chr1:220860693 chr1:220829255~220832429:+ LUSC cis rs673078 0.607 rs7967900 ENSG00000275759.1 RP11-131L12.3 7.59 1.74e-13 1.49e-10 0.47 0.33 Glucose homeostasis traits; chr12:118381902 chr12:118428281~118428870:+ LUSC cis rs10129255 1 rs10134517 ENSG00000211972.2 IGHV3-66 7.59 1.74e-13 1.49e-10 0.25 0.33 Kawasaki disease; chr14:106718498 chr14:106675017~106675544:- LUSC cis rs4660456 0.913 rs656230 ENSG00000237899.1 RP4-739H11.3 7.59 1.74e-13 1.49e-10 0.47 0.33 Platelet count; chr1:40692701 chr1:40669089~40687588:- LUSC cis rs9322193 0.962 rs9397022 ENSG00000223701.3 RAET1E-AS1 7.59 1.74e-13 1.5e-10 0.38 0.33 Lung cancer; chr6:149812052 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9397357 ENSG00000223701.3 RAET1E-AS1 7.59 1.74e-13 1.5e-10 0.38 0.33 Lung cancer; chr6:149812465 chr6:149884431~149919508:+ LUSC cis rs1113500 0.541 rs9803640 ENSG00000226822.1 RP11-356N1.2 -7.59 1.75e-13 1.5e-10 -0.39 -0.33 Growth-regulated protein alpha levels; chr1:108033645 chr1:108071482~108074519:+ LUSC cis rs1185460 1 rs4614 ENSG00000271751.1 RP11-110I1.14 -7.59 1.76e-13 1.51e-10 -0.42 -0.33 Coronary artery disease; chr11:119081661 chr11:119065263~119065677:- LUSC cis rs465969 1 rs9387010 ENSG00000255389.1 C6orf3 7.59 1.76e-13 1.51e-10 0.6 0.33 Psoriasis; chr6:111384741 chr6:111599875~111602295:+ LUSC cis rs17711722 0.701 rs55773927 ENSG00000224316.1 RP11-479O9.2 7.59 1.76e-13 1.51e-10 0.32 0.33 Calcium levels; chr7:65872915 chr7:65773620~65802067:+ LUSC cis rs17711722 0.727 rs35850374 ENSG00000224316.1 RP11-479O9.2 7.59 1.76e-13 1.51e-10 0.32 0.33 Calcium levels; chr7:65892789 chr7:65773620~65802067:+ LUSC cis rs6142102 1 rs6142102 ENSG00000276073.1 RP5-1125A11.7 -7.59 1.76e-13 1.51e-10 -0.34 -0.33 Skin pigmentation; chr20:34116821 chr20:33985617~33988989:- LUSC cis rs801193 0.569 rs13226966 ENSG00000222364.1 RNU6-96P -7.59 1.77e-13 1.52e-10 -0.4 -0.33 Aortic root size; chr7:66768636 chr7:66395191~66395286:+ LUSC cis rs9322193 0.923 rs2342857 ENSG00000223701.3 RAET1E-AS1 7.59 1.77e-13 1.52e-10 0.38 0.33 Lung cancer; chr6:149809537 chr6:149884431~149919508:+ LUSC cis rs853679 0.567 rs13209596 ENSG00000204709.4 LINC01556 7.59 1.79e-13 1.53e-10 0.44 0.33 Depression; chr6:28428413 chr6:28943877~28944537:+ LUSC cis rs11089937 0.512 rs6001073 ENSG00000211639.2 IGLV4-60 7.59 1.79e-13 1.54e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22133650 chr22:22162199~22162681:+ LUSC cis rs2337406 0.714 rs115401799 ENSG00000274576.2 IGHV2-70 -7.58 1.8e-13 1.55e-10 -0.37 -0.33 Alzheimer's disease (late onset); chr14:106813739 chr14:106770577~106771020:- LUSC cis rs4713118 0.662 rs9393881 ENSG00000204709.4 LINC01556 7.58 1.81e-13 1.55e-10 0.45 0.33 Parkinson's disease; chr6:28055973 chr6:28943877~28944537:+ LUSC cis rs11123170 0.65 rs2289897 ENSG00000189223.12 PAX8-AS1 -7.58 1.81e-13 1.55e-10 -0.5 -0.33 Renal function-related traits (BUN); chr2:113219877 chr2:113211522~113276581:+ LUSC cis rs4713118 0.662 rs149900 ENSG00000204709.4 LINC01556 7.58 1.81e-13 1.55e-10 0.47 0.33 Parkinson's disease; chr6:28046819 chr6:28943877~28944537:+ LUSC cis rs11098499 0.644 rs28787668 ENSG00000245958.5 RP11-33B1.1 -7.58 1.81e-13 1.55e-10 -0.33 -0.33 Corneal astigmatism; chr4:119633532 chr4:119454791~119552025:+ LUSC cis rs6142102 0.602 rs68051854 ENSG00000276073.1 RP5-1125A11.7 -7.58 1.82e-13 1.56e-10 -0.33 -0.33 Skin pigmentation; chr20:34114150 chr20:33985617~33988989:- LUSC cis rs10129255 0.879 rs7160512 ENSG00000280411.1 IGHV1-69-2 -7.58 1.83e-13 1.57e-10 -0.23 -0.33 Kawasaki disease; chr14:106694574 chr14:106762092~106762588:- LUSC cis rs10129255 0.879 rs7159157 ENSG00000280411.1 IGHV1-69-2 -7.58 1.83e-13 1.57e-10 -0.23 -0.33 Kawasaki disease; chr14:106694578 chr14:106762092~106762588:- LUSC cis rs2980436 1 rs2980436 ENSG00000173295.6 FAM86B3P -7.58 1.84e-13 1.57e-10 -0.39 -0.33 Schizophrenia; chr8:8234503 chr8:8228595~8244865:+ LUSC cis rs4950322 0.543 rs4950318 ENSG00000278811.3 LINC00624 7.58 1.84e-13 1.57e-10 0.38 0.33 Protein quantitative trait loci; chr1:147316240 chr1:147258885~147517875:- LUSC cis rs4950322 0.543 rs4950319 ENSG00000278811.3 LINC00624 7.58 1.84e-13 1.57e-10 0.38 0.33 Protein quantitative trait loci; chr1:147316250 chr1:147258885~147517875:- LUSC cis rs4950322 0.543 rs4453096 ENSG00000278811.3 LINC00624 7.58 1.84e-13 1.57e-10 0.38 0.33 Protein quantitative trait loci; chr1:147316574 chr1:147258885~147517875:- LUSC cis rs9322193 0.962 rs9322220 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149782897 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs10214845 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149783124 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9767122 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149783553 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs1413654 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149783956 chr6:149884431~149919508:+ LUSC cis rs9322193 0.683 rs113281309 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149787289 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9688809 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149787920 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9689242 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149787970 chr6:149884431~149919508:+ LUSC cis rs9322193 1 rs9767077 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149788479 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9688938 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149788941 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9688940 ENSG00000223701.3 RAET1E-AS1 7.58 1.84e-13 1.58e-10 0.38 0.33 Lung cancer; chr6:149788977 chr6:149884431~149919508:+ LUSC cis rs875971 0.862 rs1968126 ENSG00000222364.1 RNU6-96P 7.58 1.85e-13 1.58e-10 0.39 0.33 Aortic root size; chr7:66592017 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6460306 ENSG00000222364.1 RNU6-96P 7.58 1.85e-13 1.58e-10 0.39 0.33 Aortic root size; chr7:66595806 chr7:66395191~66395286:+ LUSC cis rs34779708 0.966 rs12775548 ENSG00000230534.5 RP11-297A16.2 7.58 1.85e-13 1.58e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35190576 chr10:35098006~35127020:- LUSC cis rs4660456 0.913 rs552147 ENSG00000237899.1 RP4-739H11.3 -7.58 1.85e-13 1.58e-10 -0.48 -0.33 Platelet count; chr1:40689141 chr1:40669089~40687588:- LUSC cis rs9322193 0.566 rs4870118 ENSG00000223701.3 RAET1E-AS1 -7.58 1.86e-13 1.59e-10 -0.43 -0.33 Lung cancer; chr6:149923877 chr6:149884431~149919508:+ LUSC cis rs9322193 0.566 rs4869767 ENSG00000223701.3 RAET1E-AS1 -7.58 1.86e-13 1.59e-10 -0.43 -0.33 Lung cancer; chr6:149923974 chr6:149884431~149919508:+ LUSC cis rs9322193 0.566 rs4869768 ENSG00000223701.3 RAET1E-AS1 -7.58 1.86e-13 1.59e-10 -0.43 -0.33 Lung cancer; chr6:149924067 chr6:149884431~149919508:+ LUSC cis rs1823913 0.963 rs4146105 ENSG00000280083.1 RP11-317J9.1 -7.58 1.86e-13 1.59e-10 -0.41 -0.33 Obesity-related traits; chr2:191245240 chr2:191154118~191156070:- LUSC cis rs10028773 0.515 rs9994651 ENSG00000245958.5 RP11-33B1.1 -7.58 1.86e-13 1.59e-10 -0.33 -0.33 Educational attainment; chr4:119666648 chr4:119454791~119552025:+ LUSC cis rs9322193 0.962 rs1889473 ENSG00000223701.3 RAET1E-AS1 7.58 1.87e-13 1.6e-10 0.38 0.33 Lung cancer; chr6:149825485 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs1984111 ENSG00000223701.3 RAET1E-AS1 7.58 1.87e-13 1.6e-10 0.38 0.33 Lung cancer; chr6:149831720 chr6:149884431~149919508:+ LUSC cis rs875971 0.522 rs4718286 ENSG00000224316.1 RP11-479O9.2 7.58 1.87e-13 1.6e-10 0.32 0.33 Aortic root size; chr7:65827777 chr7:65773620~65802067:+ LUSC cis rs11098499 0.82 rs2389885 ENSG00000245958.5 RP11-33B1.1 -7.58 1.87e-13 1.6e-10 -0.34 -0.33 Corneal astigmatism; chr4:119612776 chr4:119454791~119552025:+ LUSC cis rs66887589 0.777 rs4643791 ENSG00000245958.5 RP11-33B1.1 7.58 1.89e-13 1.62e-10 0.31 0.33 Diastolic blood pressure; chr4:119344464 chr4:119454791~119552025:+ LUSC cis rs11089937 0.597 rs6001072 ENSG00000211639.2 IGLV4-60 7.58 1.89e-13 1.62e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22133629 chr22:22162199~22162681:+ LUSC cis rs6142102 0.602 rs4911399 ENSG00000276073.1 RP5-1125A11.7 -7.58 1.91e-13 1.63e-10 -0.32 -0.33 Skin pigmentation; chr20:34035612 chr20:33985617~33988989:- LUSC cis rs34779708 0.897 rs12830 ENSG00000230534.5 RP11-297A16.2 7.58 1.91e-13 1.63e-10 0.38 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35013777 chr10:35098006~35127020:- LUSC cis rs875971 0.756 rs2901210 ENSG00000222364.1 RNU6-96P 7.58 1.91e-13 1.63e-10 0.39 0.33 Aortic root size; chr7:66552518 chr7:66395191~66395286:+ LUSC cis rs34375054 0.525 rs7133864 ENSG00000279233.1 RP11-158L12.4 7.58 1.91e-13 1.63e-10 0.3 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125121634 chr12:125138245~125141711:+ LUSC cis rs9322193 0.962 rs9505974 ENSG00000223701.3 RAET1E-AS1 7.58 1.91e-13 1.63e-10 0.38 0.33 Lung cancer; chr6:149779294 chr6:149884431~149919508:+ LUSC cis rs9322193 0.926 rs9689036 ENSG00000223701.3 RAET1E-AS1 7.58 1.91e-13 1.63e-10 0.38 0.33 Lung cancer; chr6:149780563 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9322218 ENSG00000223701.3 RAET1E-AS1 7.58 1.91e-13 1.63e-10 0.38 0.33 Lung cancer; chr6:149782183 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9322219 ENSG00000223701.3 RAET1E-AS1 7.58 1.91e-13 1.63e-10 0.38 0.33 Lung cancer; chr6:149782263 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9322223 ENSG00000223701.3 RAET1E-AS1 7.58 1.91e-13 1.63e-10 0.38 0.33 Lung cancer; chr6:149801509 chr6:149884431~149919508:+ LUSC cis rs3930017 1 rs3930017 ENSG00000242435.1 UPK3BP1 7.58 1.92e-13 1.64e-10 0.35 0.33 Body mass index; chr7:77091265 chr7:77004662~77005774:+ LUSC cis rs4950322 0.57 rs17356492 ENSG00000278811.3 LINC00624 7.58 1.92e-13 1.64e-10 0.38 0.33 Protein quantitative trait loci; chr1:147296089 chr1:147258885~147517875:- LUSC cis rs9322193 0.607 rs9322229 ENSG00000223701.3 RAET1E-AS1 7.57 1.93e-13 1.64e-10 0.41 0.33 Lung cancer; chr6:149908949 chr6:149884431~149919508:+ LUSC cis rs11098499 0.644 rs3806808 ENSG00000249244.1 RP11-548H18.2 7.57 1.93e-13 1.65e-10 0.41 0.33 Corneal astigmatism; chr4:119629930 chr4:119391831~119395335:- LUSC cis rs7849270 0.879 rs6478866 ENSG00000268707.1 RP11-247A12.7 -7.57 1.94e-13 1.65e-10 -0.4 -0.33 Blood metabolite ratios; chr9:129133585 chr9:129170434~129170940:+ LUSC cis rs2282300 0.739 rs1765133 ENSG00000254532.1 RP11-624D11.2 7.57 1.94e-13 1.65e-10 0.46 0.33 Morning vs. evening chronotype; chr11:30317853 chr11:30044058~30084343:- LUSC cis rs9322193 0.962 rs4552 ENSG00000223701.3 RAET1E-AS1 7.57 1.94e-13 1.65e-10 0.38 0.33 Lung cancer; chr6:149811183 chr6:149884431~149919508:+ LUSC cis rs34375054 0.525 rs7133006 ENSG00000279233.1 RP11-158L12.4 7.57 1.95e-13 1.66e-10 0.3 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125121577 chr12:125138245~125141711:+ LUSC cis rs55794721 0.509 rs6699113 ENSG00000224183.1 SDHDP6 -7.57 1.96e-13 1.67e-10 -0.4 -0.33 Mean corpuscular volume;Plateletcrit; chr1:25451252 chr1:25294164~25294643:- LUSC cis rs9322193 0.962 rs13215691 ENSG00000223701.3 RAET1E-AS1 7.57 1.96e-13 1.67e-10 0.38 0.33 Lung cancer; chr6:149792666 chr6:149884431~149919508:+ LUSC cis rs11089937 0.597 rs4145535 ENSG00000211639.2 IGLV4-60 7.57 1.96e-13 1.67e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22143981 chr22:22162199~22162681:+ LUSC cis rs6782228 1 rs12495411 ENSG00000277250.1 Metazoa_SRP 7.57 1.96e-13 1.67e-10 0.4 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128676852 chr3:128673681~128674021:- LUSC cis rs2239557 0.529 rs2041185 ENSG00000259065.1 RP5-1021I20.1 7.57 1.96e-13 1.67e-10 0.41 0.33 Common traits (Other); chr14:73815387 chr14:73787360~73803270:+ LUSC cis rs4423214 0.559 rs10898228 ENSG00000254682.1 RP11-660L16.2 -7.57 1.99e-13 1.69e-10 -0.55 -0.33 Vitamin D levels; chr11:71517312 chr11:71448674~71452157:+ LUSC cis rs4950322 0.57 rs72691032 ENSG00000278811.3 LINC00624 7.57 1.99e-13 1.69e-10 0.38 0.33 Protein quantitative trait loci; chr1:147261120 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72691033 ENSG00000278811.3 LINC00624 7.57 1.99e-13 1.69e-10 0.38 0.33 Protein quantitative trait loci; chr1:147261267 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs111370771 ENSG00000278811.3 LINC00624 7.57 1.99e-13 1.69e-10 0.38 0.33 Protein quantitative trait loci; chr1:147261420 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs4301678 ENSG00000278811.3 LINC00624 7.57 1.99e-13 1.69e-10 0.38 0.33 Protein quantitative trait loci; chr1:147261907 chr1:147258885~147517875:- LUSC cis rs6921919 0.806 rs213230 ENSG00000204709.4 LINC01556 7.57 1.99e-13 1.7e-10 0.46 0.33 Autism spectrum disorder or schizophrenia; chr6:28362487 chr6:28943877~28944537:+ LUSC cis rs4950322 0.57 rs4950401 ENSG00000278811.3 LINC00624 7.57 2e-13 1.7e-10 0.38 0.33 Protein quantitative trait loci; chr1:147319571 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs4950402 ENSG00000278811.3 LINC00624 7.57 2e-13 1.7e-10 0.38 0.33 Protein quantitative trait loci; chr1:147319684 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs4950404 ENSG00000278811.3 LINC00624 7.57 2e-13 1.7e-10 0.38 0.33 Protein quantitative trait loci; chr1:147319834 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692953 ENSG00000278811.3 LINC00624 7.57 2e-13 1.7e-10 0.38 0.33 Protein quantitative trait loci; chr1:147321416 chr1:147258885~147517875:- LUSC cis rs9322193 0.962 rs4869730 ENSG00000223701.3 RAET1E-AS1 7.57 2.01e-13 1.71e-10 0.38 0.33 Lung cancer; chr6:149808187 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs11155689 ENSG00000223701.3 RAET1E-AS1 7.57 2.01e-13 1.71e-10 0.38 0.33 Lung cancer; chr6:149808470 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs2151913 ENSG00000223701.3 RAET1E-AS1 7.57 2.01e-13 1.71e-10 0.38 0.33 Lung cancer; chr6:149809506 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs933055 ENSG00000223701.3 RAET1E-AS1 7.57 2.01e-13 1.71e-10 0.38 0.33 Lung cancer; chr6:149809701 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs4869731 ENSG00000223701.3 RAET1E-AS1 7.57 2.01e-13 1.71e-10 0.38 0.33 Lung cancer; chr6:149810072 chr6:149884431~149919508:+ LUSC cis rs3091242 0.935 rs4233043 ENSG00000224183.1 SDHDP6 -7.57 2.02e-13 1.71e-10 -0.4 -0.33 Erythrocyte sedimentation rate; chr1:25438992 chr1:25294164~25294643:- LUSC cis rs3091242 0.933 rs11249250 ENSG00000224183.1 SDHDP6 -7.57 2.02e-13 1.71e-10 -0.4 -0.33 Erythrocyte sedimentation rate; chr1:25441118 chr1:25294164~25294643:- LUSC cis rs10463554 1 rs1593842 ENSG00000175749.11 EIF3KP1 7.57 2.02e-13 1.72e-10 0.38 0.33 Parkinson's disease; chr5:102999018 chr5:103032376~103033031:+ LUSC cis rs11098499 0.82 rs28535956 ENSG00000245958.5 RP11-33B1.1 7.57 2.03e-13 1.72e-10 0.34 0.33 Corneal astigmatism; chr4:119615703 chr4:119454791~119552025:+ LUSC cis rs875971 0.522 rs7784623 ENSG00000224316.1 RP11-479O9.2 7.57 2.04e-13 1.73e-10 0.32 0.33 Aortic root size; chr7:65930047 chr7:65773620~65802067:+ LUSC cis rs11098499 0.644 rs10012252 ENSG00000245958.5 RP11-33B1.1 -7.57 2.04e-13 1.73e-10 -0.33 -0.33 Corneal astigmatism; chr4:119637984 chr4:119454791~119552025:+ LUSC cis rs61160187 0.582 rs1479645 ENSG00000215032.2 GNL3LP1 7.57 2.05e-13 1.74e-10 0.41 0.33 Educational attainment (years of education);Educational attainment (college completion); chr5:61023904 chr5:60891935~60893577:- LUSC cis rs2739330 0.703 rs5760112 ENSG00000099984.9 GSTT2 -7.57 2.06e-13 1.74e-10 -0.4 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23980123~23983911:+ LUSC cis rs1113500 0.787 rs11185266 ENSG00000226822.1 RP11-356N1.2 7.56 2.07e-13 1.75e-10 0.33 0.33 Growth-regulated protein alpha levels; chr1:108100042 chr1:108071482~108074519:+ LUSC cis rs5769707 0.967 rs5769698 ENSG00000235111.1 RP1-29C18.8 -7.56 2.07e-13 1.76e-10 -0.37 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49604058 chr22:49612657~49615716:- LUSC cis rs9322193 0.923 rs11155683 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149779341 chr6:149884431~149919508:+ LUSC cis rs9322193 0.923 rs9372044 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149780867 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs11155685 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149781649 chr6:149884431~149919508:+ LUSC cis rs9322193 0.632 rs3828700 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149791033 chr6:149884431~149919508:+ LUSC cis rs9322193 0.926 rs3805751 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149791193 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs9689269 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149791861 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs62441335 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149792658 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs4816 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149793609 chr6:149884431~149919508:+ LUSC cis rs9322193 0.926 rs952166 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149798774 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs952165 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149798900 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs10872656 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149799444 chr6:149884431~149919508:+ LUSC cis rs9322193 0.926 rs9285525 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149801253 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs6914319 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149806304 chr6:149884431~149919508:+ LUSC cis rs9322193 0.884 rs2095375 ENSG00000223701.3 RAET1E-AS1 7.56 2.08e-13 1.76e-10 0.38 0.33 Lung cancer; chr6:149807037 chr6:149884431~149919508:+ LUSC cis rs875971 0.862 rs778720 ENSG00000237310.1 GS1-124K5.4 -7.56 2.08e-13 1.76e-10 -0.35 -0.33 Aortic root size; chr7:66381288 chr7:66493706~66495474:+ LUSC cis rs11098499 0.644 rs10009566 ENSG00000249244.1 RP11-548H18.2 7.56 2.08e-13 1.76e-10 0.41 0.33 Corneal astigmatism; chr4:119637453 chr4:119391831~119395335:- LUSC cis rs673078 0.607 rs61943404 ENSG00000275759.1 RP11-131L12.3 -7.56 2.08e-13 1.77e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118402062 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs7136676 ENSG00000275759.1 RP11-131L12.3 -7.56 2.08e-13 1.77e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118403605 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs17441033 ENSG00000275759.1 RP11-131L12.3 -7.56 2.08e-13 1.77e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118404101 chr12:118428281~118428870:+ LUSC cis rs673078 0.562 rs61943405 ENSG00000275759.1 RP11-131L12.3 -7.56 2.08e-13 1.77e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118405030 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943406 ENSG00000275759.1 RP11-131L12.3 -7.56 2.08e-13 1.77e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118405767 chr12:118428281~118428870:+ LUSC cis rs3823536 0.583 rs10954214 ENSG00000275106.1 RP11-309L24.10 -7.56 2.09e-13 1.77e-10 -0.44 -0.33 Sjögren's syndrome; chr7:128949579 chr7:128952527~128953316:- LUSC cis rs10129255 0.833 rs61997797 ENSG00000280411.1 IGHV1-69-2 -7.56 2.09e-13 1.77e-10 -0.23 -0.33 Kawasaki disease; chr14:106815190 chr14:106762092~106762588:- LUSC cis rs10129255 0.912 rs61997792 ENSG00000211972.2 IGHV3-66 7.56 2.09e-13 1.77e-10 0.26 0.33 Kawasaki disease; chr14:106799304 chr14:106675017~106675544:- LUSC cis rs7811142 1 rs7811142 ENSG00000242294.5 STAG3L5P 7.56 2.09e-13 1.77e-10 0.26 0.33 Platelet count; chr7:100467820 chr7:100336079~100351900:+ LUSC cis rs10129255 0.872 rs10133674 ENSG00000224373.3 IGHV4-59 7.56 2.1e-13 1.78e-10 0.18 0.33 Kawasaki disease; chr14:106692788 chr14:106627249~106627825:- LUSC cis rs9326248 0.861 rs7931335 ENSG00000280143.1 AP000892.6 7.56 2.11e-13 1.78e-10 0.4 0.33 Blood protein levels; chr11:117166089 chr11:117204967~117210292:+ LUSC cis rs875971 0.862 rs13232191 ENSG00000222364.1 RNU6-96P -7.56 2.11e-13 1.78e-10 -0.39 -0.33 Aortic root size; chr7:66521661 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs35378740 ENSG00000222364.1 RNU6-96P -7.56 2.11e-13 1.78e-10 -0.39 -0.33 Aortic root size; chr7:66522725 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs10950043 ENSG00000222364.1 RNU6-96P -7.56 2.11e-13 1.78e-10 -0.39 -0.33 Aortic root size; chr7:66523623 chr7:66395191~66395286:+ LUSC cis rs875971 0.767 rs61348003 ENSG00000222364.1 RNU6-96P -7.56 2.11e-13 1.78e-10 -0.39 -0.33 Aortic root size; chr7:66540947 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs13536 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66554203 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs801209 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66554403 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs801206 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66556979 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs801204 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66557934 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs801203 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66558025 chr7:66395191~66395286:+ LUSC cis rs875971 0.825 rs801202 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66558942 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs801194 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66563508 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs2024192 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66576460 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6955837 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66578155 chr7:66395191~66395286:+ LUSC cis rs875971 0.825 rs10281499 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66583979 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs4718377 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66584691 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs10278014 ENSG00000222364.1 RNU6-96P 7.56 2.11e-13 1.78e-10 0.39 0.33 Aortic root size; chr7:66586277 chr7:66395191~66395286:+ LUSC cis rs3091242 0.933 rs35497030 ENSG00000224183.1 SDHDP6 7.56 2.12e-13 1.79e-10 0.4 0.33 Erythrocyte sedimentation rate; chr1:25456575 chr1:25294164~25294643:- LUSC cis rs875971 0.862 rs1860469 ENSG00000237310.1 GS1-124K5.4 -7.56 2.12e-13 1.8e-10 -0.35 -0.33 Aortic root size; chr7:66641888 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs4718383 ENSG00000237310.1 GS1-124K5.4 -7.56 2.12e-13 1.8e-10 -0.35 -0.33 Aortic root size; chr7:66643422 chr7:66493706~66495474:+ LUSC cis rs13113518 0.678 rs7663650 ENSG00000223305.1 RN7SKP30 -7.56 2.13e-13 1.8e-10 -0.38 -0.33 Height; chr4:55364952 chr4:55540502~55540835:- LUSC cis rs9322193 0.962 rs6899661 ENSG00000223701.3 RAET1E-AS1 7.56 2.13e-13 1.8e-10 0.38 0.33 Lung cancer; chr6:149818093 chr6:149884431~149919508:+ LUSC cis rs4423214 0.592 rs11234027 ENSG00000254682.1 RP11-660L16.2 -7.56 2.13e-13 1.8e-10 -0.55 -0.33 Vitamin D levels; chr11:71523061 chr11:71448674~71452157:+ LUSC cis rs17482078 0.959 rs13154629 ENSG00000248734.2 CTD-2260A17.1 7.56 2.13e-13 1.81e-10 0.38 0.33 Behcet's disease;Blood protein levels; chr5:96786754 chr5:96784777~96785999:+ LUSC cis rs1757171 0.542 rs3818985 ENSG00000204110.6 RP1-153P14.8 -7.56 2.14e-13 1.81e-10 -0.32 -0.33 Cognitive performance; chr6:37516438 chr6:37507348~37535616:+ LUSC cis rs7945705 0.902 rs2016942 ENSG00000254860.4 TMEM9B-AS1 -7.56 2.14e-13 1.81e-10 -0.36 -0.33 Hemoglobin concentration; chr11:8917240 chr11:8964675~8977527:+ LUSC cis rs34779708 0.931 rs12773169 ENSG00000230534.5 RP11-297A16.2 7.56 2.15e-13 1.82e-10 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35077534 chr10:35098006~35127020:- LUSC cis rs7945705 0.818 rs1988708 ENSG00000254860.4 TMEM9B-AS1 7.56 2.16e-13 1.82e-10 0.36 0.33 Hemoglobin concentration; chr11:8861346 chr11:8964675~8977527:+ LUSC cis rs4950322 0.57 rs3737855 ENSG00000278811.3 LINC00624 7.56 2.16e-13 1.83e-10 0.38 0.33 Protein quantitative trait loci; chr1:147271257 chr1:147258885~147517875:- LUSC cis rs8072100 0.676 rs7221345 ENSG00000228782.6 CTD-2026D20.3 7.56 2.16e-13 1.83e-10 0.33 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47327778 chr17:47450568~47492492:- LUSC cis rs11089937 0.626 rs737840 ENSG00000211639.2 IGLV4-60 7.56 2.17e-13 1.83e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22162743 chr22:22162199~22162681:+ LUSC cis rs11089937 0.626 rs737841 ENSG00000211639.2 IGLV4-60 7.56 2.17e-13 1.83e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22162769 chr22:22162199~22162681:+ LUSC cis rs9322193 0.962 rs3805753 ENSG00000223701.3 RAET1E-AS1 7.56 2.18e-13 1.84e-10 0.38 0.33 Lung cancer; chr6:149795662 chr6:149884431~149919508:+ LUSC cis rs6142102 0.625 rs1883707 ENSG00000276073.1 RP5-1125A11.7 7.56 2.18e-13 1.84e-10 0.32 0.33 Skin pigmentation; chr20:33964781 chr20:33985617~33988989:- LUSC cis rs7811142 0.943 rs66958101 ENSG00000242294.5 STAG3L5P 7.56 2.18e-13 1.84e-10 0.26 0.33 Platelet count; chr7:100476397 chr7:100336079~100351900:+ LUSC cis rs35955747 0.869 rs9621216 ENSG00000236132.1 CTA-440B3.1 7.56 2.19e-13 1.85e-10 0.39 0.33 Neutrophil count;Sum basophil neutrophil counts; chr22:31194222 chr22:31816379~31817491:- LUSC cis rs1113500 0.73 rs1361829 ENSG00000226822.1 RP11-356N1.2 -7.56 2.2e-13 1.86e-10 -0.32 -0.33 Growth-regulated protein alpha levels; chr1:108051273 chr1:108071482~108074519:+ LUSC cis rs6964833 0.554 rs112506907 ENSG00000277053.3 GTF2IP1 -7.56 2.2e-13 1.86e-10 -0.44 -0.33 Menarche (age at onset); chr7:74654407 chr7:75185385~75237696:- LUSC cis rs9487094 0.961 rs11153171 ENSG00000260273.1 RP11-425D10.10 7.55 2.21e-13 1.86e-10 0.39 0.33 Height; chr6:109332622 chr6:109382795~109383666:+ LUSC cis rs4950322 0.571 rs4373796 ENSG00000278811.3 LINC00624 7.55 2.23e-13 1.88e-10 0.38 0.33 Protein quantitative trait loci; chr1:147316747 chr1:147258885~147517875:- LUSC cis rs4950322 0.543 rs4568882 ENSG00000278811.3 LINC00624 7.55 2.23e-13 1.88e-10 0.38 0.33 Protein quantitative trait loci; chr1:147316885 chr1:147258885~147517875:- LUSC cis rs4950322 0.543 rs2883323 ENSG00000278811.3 LINC00624 7.55 2.23e-13 1.88e-10 0.38 0.33 Protein quantitative trait loci; chr1:147316995 chr1:147258885~147517875:- LUSC cis rs4950322 0.543 rs2883324 ENSG00000278811.3 LINC00624 7.55 2.23e-13 1.88e-10 0.38 0.33 Protein quantitative trait loci; chr1:147317157 chr1:147258885~147517875:- LUSC cis rs172166 0.694 rs536704 ENSG00000204709.4 LINC01556 7.55 2.24e-13 1.89e-10 0.42 0.33 Cardiac Troponin-T levels; chr6:28124825 chr6:28943877~28944537:+ LUSC cis rs1823913 1 rs68014803 ENSG00000280083.1 RP11-317J9.1 -7.55 2.25e-13 1.9e-10 -0.41 -0.33 Obesity-related traits; chr2:191241877 chr2:191154118~191156070:- LUSC cis rs7811142 0.887 rs111972532 ENSG00000242294.5 STAG3L5P 7.55 2.25e-13 1.9e-10 0.27 0.33 Platelet count; chr7:100471465 chr7:100336079~100351900:+ LUSC cis rs875971 0.651 rs313829 ENSG00000164669.11 INTS4P1 7.55 2.26e-13 1.9e-10 0.38 0.33 Aortic root size; chr7:66087510 chr7:65141225~65234216:+ LUSC cis rs11089937 0.597 rs5757005 ENSG00000211639.2 IGLV4-60 7.55 2.26e-13 1.91e-10 0.38 0.33 Periodontitis (PAL4Q3); chr22:22134775 chr22:22162199~22162681:+ LUSC cis rs34779708 0.966 rs2045915 ENSG00000230534.5 RP11-297A16.2 7.55 2.27e-13 1.91e-10 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35129688 chr10:35098006~35127020:- LUSC cis rs8040855 0.659 rs8037886 ENSG00000259295.5 CSPG4P12 -7.55 2.28e-13 1.92e-10 -0.41 -0.33 Bulimia nervosa; chr15:85143533 chr15:85191438~85213905:+ LUSC cis rs34375054 0.525 rs7133614 ENSG00000279233.1 RP11-158L12.4 7.55 2.29e-13 1.93e-10 0.3 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125121411 chr12:125138245~125141711:+ LUSC cis rs2006771 0.74 rs8140312 ENSG00000236132.1 CTA-440B3.1 -7.55 2.29e-13 1.93e-10 -0.4 -0.33 Nonsyndromic cleft lip with cleft palate; chr22:31609608 chr22:31816379~31817491:- LUSC cis rs34779708 0.931 rs7920095 ENSG00000230534.5 RP11-297A16.2 7.55 2.29e-13 1.93e-10 0.38 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35014406 chr10:35098006~35127020:- LUSC cis rs2337406 0.714 rs7150993 ENSG00000274576.2 IGHV2-70 -7.55 2.3e-13 1.93e-10 -0.35 -0.33 Alzheimer's disease (late onset); chr14:106818515 chr14:106770577~106771020:- LUSC cis rs875971 0.522 rs9530 ENSG00000236529.1 RP13-254B10.1 7.55 2.3e-13 1.94e-10 0.35 0.33 Aortic root size; chr7:65960907 chr7:65840212~65840596:+ LUSC cis rs7617773 0.817 rs936427 ENSG00000228638.1 FCF1P2 7.55 2.3e-13 1.94e-10 0.38 0.33 Coronary artery disease; chr3:48259584 chr3:48290793~48291375:- LUSC cis rs4950322 0.542 rs72692942 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147318467 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs113498894 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147318880 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs4950399 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147319302 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs4950403 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147319723 chr1:147258885~147517875:- LUSC cis rs4950322 0.517 rs116479391 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147320940 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692963 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147331090 chr1:147258885~147517875:- LUSC cis rs4950322 0.518 rs72692965 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147332085 chr1:147258885~147517875:- LUSC cis rs4950322 0.518 rs72692968 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147332884 chr1:147258885~147517875:- LUSC cis rs4950322 0.518 rs72692970 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147332887 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692971 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147333088 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692973 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147333281 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692975 ENSG00000278811.3 LINC00624 7.55 2.3e-13 1.94e-10 0.38 0.33 Protein quantitative trait loci; chr1:147333506 chr1:147258885~147517875:- LUSC cis rs853679 0.567 rs2232427 ENSG00000204709.4 LINC01556 7.55 2.31e-13 1.94e-10 0.45 0.33 Depression; chr6:28391932 chr6:28943877~28944537:+ LUSC cis rs2108622 1 rs2108622 ENSG00000267453.5 AC004791.2 -7.55 2.32e-13 1.95e-10 -0.44 -0.33 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15879621 chr19:15851993~15864904:- LUSC cis rs4950322 0.57 rs4950315 ENSG00000278811.3 LINC00624 -7.55 2.33e-13 1.96e-10 -0.37 -0.33 Protein quantitative trait loci; chr1:147264433 chr1:147258885~147517875:- LUSC cis rs673078 0.607 rs17441075 ENSG00000275759.1 RP11-131L12.3 -7.55 2.34e-13 1.97e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118410542 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs965524 ENSG00000275759.1 RP11-131L12.3 -7.55 2.34e-13 1.97e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118412361 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs74685643 ENSG00000275759.1 RP11-131L12.3 -7.55 2.34e-13 1.97e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118412761 chr12:118428281~118428870:+ LUSC cis rs6452524 0.904 rs10076056 ENSG00000249664.1 CTD-2227C6.2 -7.55 2.34e-13 1.97e-10 -0.36 -0.33 Hypertension (SNP x SNP interaction); chr5:83161702 chr5:83012285~83013109:- LUSC cis rs9322193 0.962 rs3763162 ENSG00000223701.3 RAET1E-AS1 -7.55 2.35e-13 1.97e-10 -0.38 -0.33 Lung cancer; chr6:149819674 chr6:149884431~149919508:+ LUSC cis rs11089937 0.597 rs9619793 ENSG00000211639.2 IGLV4-60 7.55 2.35e-13 1.98e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22132952 chr22:22162199~22162681:+ LUSC cis rs17482078 0.959 rs35983588 ENSG00000248734.2 CTD-2260A17.1 7.55 2.35e-13 1.98e-10 0.37 0.33 Behcet's disease;Blood protein levels; chr5:96787726 chr5:96784777~96785999:+ LUSC cis rs4423214 0.592 rs7114252 ENSG00000254682.1 RP11-660L16.2 -7.55 2.35e-13 1.98e-10 -0.55 -0.33 Vitamin D levels; chr11:71526560 chr11:71448674~71452157:+ LUSC cis rs66887589 0.616 rs11732621 ENSG00000245958.5 RP11-33B1.1 -7.55 2.36e-13 1.98e-10 -0.31 -0.33 Diastolic blood pressure; chr4:119291728 chr4:119454791~119552025:+ LUSC cis rs172166 0.694 rs2791332 ENSG00000204709.4 LINC01556 7.54 2.37e-13 1.99e-10 0.43 0.33 Cardiac Troponin-T levels; chr6:28141010 chr6:28943877~28944537:+ LUSC cis rs875971 0.505 rs1723275 ENSG00000224316.1 RP11-479O9.2 -7.54 2.37e-13 1.99e-10 -0.32 -0.33 Aortic root size; chr7:66039646 chr7:65773620~65802067:+ LUSC cis rs11155671 0.53 rs4458704 ENSG00000268592.3 RAET1E-AS1 7.54 2.37e-13 2e-10 0.4 0.33 Testicular germ cell tumor; chr6:149911743 chr6:149863494~149919507:+ LUSC cis rs10129255 0.789 rs61997796 ENSG00000211972.2 IGHV3-66 7.54 2.38e-13 2e-10 0.25 0.33 Kawasaki disease; chr14:106813798 chr14:106675017~106675544:- LUSC cis rs11089937 0.597 rs5756991 ENSG00000211639.2 IGLV4-60 7.54 2.39e-13 2.01e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22132541 chr22:22162199~22162681:+ LUSC cis rs11089937 0.54 rs5756992 ENSG00000211639.2 IGLV4-60 7.54 2.39e-13 2.01e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22132636 chr22:22162199~22162681:+ LUSC cis rs11089937 0.597 rs9622919 ENSG00000211639.2 IGLV4-60 7.54 2.39e-13 2.01e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22132863 chr22:22162199~22162681:+ LUSC cis rs875971 0.862 rs17747530 ENSG00000222364.1 RNU6-96P -7.54 2.4e-13 2.01e-10 -0.39 -0.33 Aortic root size; chr7:66529742 chr7:66395191~66395286:+ LUSC cis rs34779708 0.931 rs12776390 ENSG00000230534.5 RP11-297A16.2 7.54 2.4e-13 2.02e-10 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35102607 chr10:35098006~35127020:- LUSC cis rs10129255 0.957 rs10150241 ENSG00000211972.2 IGHV3-66 -7.54 2.4e-13 2.02e-10 -0.25 -0.33 Kawasaki disease; chr14:106775945 chr14:106675017~106675544:- LUSC cis rs2282300 0.739 rs7925340 ENSG00000254532.1 RP11-624D11.2 -7.54 2.41e-13 2.02e-10 -0.45 -0.33 Morning vs. evening chronotype; chr11:30258861 chr11:30044058~30084343:- LUSC cis rs875971 0.505 rs1167385 ENSG00000224316.1 RP11-479O9.2 -7.54 2.41e-13 2.02e-10 -0.32 -0.33 Aortic root size; chr7:66048321 chr7:65773620~65802067:+ LUSC cis rs4718428 1 rs1830070 ENSG00000226824.5 RP4-756H11.3 -7.54 2.41e-13 2.03e-10 -0.4 -0.33 Corneal structure; chr7:66884684 chr7:66654538~66669855:+ LUSC cis rs8072100 0.539 rs36043200 ENSG00000228782.6 CTD-2026D20.3 -7.54 2.43e-13 2.04e-10 -0.32 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47552040 chr17:47450568~47492492:- LUSC cis rs875971 0.861 rs801215 ENSG00000222364.1 RNU6-96P 7.54 2.44e-13 2.05e-10 0.39 0.33 Aortic root size; chr7:66546951 chr7:66395191~66395286:+ LUSC cis rs55794721 0.509 rs7554255 ENSG00000224183.1 SDHDP6 -7.54 2.45e-13 2.06e-10 -0.4 -0.33 Mean corpuscular volume;Plateletcrit; chr1:25451615 chr1:25294164~25294643:- LUSC cis rs55794721 0.509 rs4649085 ENSG00000224183.1 SDHDP6 -7.54 2.45e-13 2.06e-10 -0.4 -0.33 Mean corpuscular volume;Plateletcrit; chr1:25452341 chr1:25294164~25294643:- LUSC cis rs673078 0.607 rs17441061 ENSG00000275759.1 RP11-131L12.3 -7.54 2.45e-13 2.06e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118409847 chr12:118428281~118428870:+ LUSC cis rs4950322 0.57 rs79810882 ENSG00000278811.3 LINC00624 7.54 2.45e-13 2.06e-10 0.37 0.33 Protein quantitative trait loci; chr1:147235575 chr1:147258885~147517875:- LUSC cis rs172166 0.694 rs1631552 ENSG00000204709.4 LINC01556 7.54 2.46e-13 2.07e-10 0.42 0.33 Cardiac Troponin-T levels; chr6:28121921 chr6:28943877~28944537:+ LUSC cis rs875971 0.825 rs59466412 ENSG00000222364.1 RNU6-96P 7.54 2.47e-13 2.07e-10 0.39 0.33 Aortic root size; chr7:66100371 chr7:66395191~66395286:+ LUSC cis rs34779708 0.966 rs1213392 ENSG00000230534.5 RP11-297A16.2 7.54 2.47e-13 2.07e-10 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35141357 chr10:35098006~35127020:- LUSC cis rs10129255 0.5 rs4774189 ENSG00000211970.3 IGHV4-61 -7.54 2.49e-13 2.09e-10 -0.21 -0.33 Kawasaki disease; chr14:106768275 chr14:106639119~106639657:- LUSC cis rs875971 0.798 rs12698522 ENSG00000222364.1 RNU6-96P -7.54 2.5e-13 2.09e-10 -0.39 -0.33 Aortic root size; chr7:66502354 chr7:66395191~66395286:+ LUSC cis rs875971 0.83 rs28714531 ENSG00000222364.1 RNU6-96P -7.54 2.5e-13 2.09e-10 -0.39 -0.33 Aortic root size; chr7:66503250 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs12698526 ENSG00000222364.1 RNU6-96P -7.54 2.5e-13 2.09e-10 -0.39 -0.33 Aortic root size; chr7:66504118 chr7:66395191~66395286:+ LUSC cis rs367615 0.506 rs246102 ENSG00000249476.1 CTD-2587M2.1 -7.54 2.5e-13 2.1e-10 -0.37 -0.33 Colorectal cancer (SNP x SNP interaction); chr5:109363994 chr5:109237120~109326369:- LUSC cis rs1075232 1 rs72722829 ENSG00000215302.7 CTD-3092A11.1 -7.54 2.5e-13 2.1e-10 -0.71 -0.33 Survival in colorectal cancer (non-distant metastatic); chr15:31346911 chr15:30470779~30507623:+ LUSC cis rs1075232 1 rs16956707 ENSG00000215302.7 CTD-3092A11.1 -7.54 2.5e-13 2.1e-10 -0.71 -0.33 Survival in colorectal cancer (non-distant metastatic); chr15:31349430 chr15:30470779~30507623:+ LUSC cis rs904251 0.523 rs10807184 ENSG00000204110.6 RP1-153P14.8 -7.54 2.5e-13 2.1e-10 -0.31 -0.33 Cognitive performance; chr6:37515937 chr6:37507348~37535616:+ LUSC cis rs904251 0.561 rs1757189 ENSG00000204110.6 RP1-153P14.8 -7.54 2.5e-13 2.1e-10 -0.31 -0.33 Cognitive performance; chr6:37515951 chr6:37507348~37535616:+ LUSC cis rs801193 0.569 rs10950050 ENSG00000222364.1 RNU6-96P -7.54 2.51e-13 2.11e-10 -0.38 -0.33 Aortic root size; chr7:66774601 chr7:66395191~66395286:+ LUSC cis rs8059260 0.668 rs8055893 ENSG00000274038.1 RP11-66H6.4 -7.54 2.52e-13 2.11e-10 -0.56 -0.33 Alcohol consumption over the past year; chr16:10977938 chr16:11056556~11057034:+ LUSC cis rs34779708 0.931 rs2384283 ENSG00000230534.5 RP11-297A16.2 7.54 2.52e-13 2.11e-10 0.38 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35037861 chr10:35098006~35127020:- LUSC cis rs875971 0.895 rs4145009 ENSG00000222364.1 RNU6-96P 7.54 2.53e-13 2.12e-10 0.4 0.33 Aortic root size; chr7:66261628 chr7:66395191~66395286:+ LUSC cis rs5769707 0.542 rs739242 ENSG00000235111.1 RP1-29C18.8 -7.53 2.56e-13 2.15e-10 -0.41 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49663468 chr22:49612657~49615716:- LUSC cis rs11089937 0.597 rs9619794 ENSG00000211639.2 IGLV4-60 7.53 2.57e-13 2.15e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22132999 chr22:22162199~22162681:+ LUSC cis rs4660456 0.913 rs6667368 ENSG00000237899.1 RP4-739H11.3 7.53 2.57e-13 2.15e-10 0.47 0.33 Platelet count; chr1:40694887 chr1:40669089~40687588:- LUSC cis rs1823913 1 rs13019004 ENSG00000280083.1 RP11-317J9.1 -7.53 2.59e-13 2.17e-10 -0.41 -0.33 Obesity-related traits; chr2:191245493 chr2:191154118~191156070:- LUSC cis rs4660456 0.913 rs657149 ENSG00000237899.1 RP4-739H11.3 7.53 2.59e-13 2.17e-10 0.47 0.33 Platelet count; chr1:40692486 chr1:40669089~40687588:- LUSC cis rs875971 0.862 rs6460307 ENSG00000237310.1 GS1-124K5.4 7.53 2.6e-13 2.18e-10 0.34 0.33 Aortic root size; chr7:66595884 chr7:66493706~66495474:+ LUSC cis rs11098499 0.644 rs10012252 ENSG00000249244.1 RP11-548H18.2 7.53 2.61e-13 2.18e-10 0.41 0.33 Corneal astigmatism; chr4:119637984 chr4:119391831~119395335:- LUSC cis rs2404602 0.684 rs57682236 ENSG00000259422.1 RP11-593F23.1 -7.53 2.62e-13 2.19e-10 -0.4 -0.33 Blood metabolite levels; chr15:76576137 chr15:76174891~76181486:- LUSC cis rs13113518 0.513 rs13147861 ENSG00000223305.1 RN7SKP30 7.53 2.62e-13 2.19e-10 0.4 0.33 Height; chr4:55611014 chr4:55540502~55540835:- LUSC cis rs7811142 1 rs11764818 ENSG00000242294.5 STAG3L5P 7.53 2.63e-13 2.2e-10 0.26 0.33 Platelet count; chr7:100445432 chr7:100336079~100351900:+ LUSC cis rs875971 0.522 rs1701760 ENSG00000224316.1 RP11-479O9.2 7.53 2.64e-13 2.2e-10 0.32 0.33 Aortic root size; chr7:66008701 chr7:65773620~65802067:+ LUSC cis rs4713118 0.513 rs149958 ENSG00000204709.4 LINC01556 7.53 2.64e-13 2.21e-10 0.42 0.33 Parkinson's disease; chr6:28045839 chr6:28943877~28944537:+ LUSC cis rs4713118 0.513 rs156738 ENSG00000204709.4 LINC01556 7.53 2.64e-13 2.21e-10 0.42 0.33 Parkinson's disease; chr6:28046247 chr6:28943877~28944537:+ LUSC cis rs801193 0.591 rs9986881 ENSG00000224316.1 RP11-479O9.2 7.53 2.65e-13 2.21e-10 0.32 0.33 Aortic root size; chr7:66708053 chr7:65773620~65802067:+ LUSC cis rs10170846 1 rs10170846 ENSG00000261428.2 RP11-16P6.1 -7.53 2.66e-13 2.23e-10 -0.39 -0.33 Schizophrenia (inflammation and infection response interaction); chr2:222652986 chr2:222566899~222569719:- LUSC cis rs7811142 1 rs2406255 ENSG00000242294.5 STAG3L5P 7.53 2.67e-13 2.23e-10 0.27 0.33 Platelet count; chr7:100456067 chr7:100336079~100351900:+ LUSC cis rs673078 0.607 rs61943385 ENSG00000275759.1 RP11-131L12.3 -7.53 2.68e-13 2.24e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118370339 chr12:118428281~118428870:+ LUSC cis rs11098499 0.73 rs12505735 ENSG00000245958.5 RP11-33B1.1 -7.53 2.68e-13 2.24e-10 -0.33 -0.33 Corneal astigmatism; chr4:119611801 chr4:119454791~119552025:+ LUSC cis rs34779708 0.931 rs7897457 ENSG00000230534.5 RP11-297A16.2 7.53 2.68e-13 2.24e-10 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35097112 chr10:35098006~35127020:- LUSC cis rs7811142 0.83 rs118119933 ENSG00000242294.5 STAG3L5P 7.53 2.69e-13 2.24e-10 0.28 0.33 Platelet count; chr7:100341427 chr7:100336079~100351900:+ LUSC cis rs6142102 0.58 rs6142101 ENSG00000276073.1 RP5-1125A11.7 -7.53 2.7e-13 2.26e-10 -0.33 -0.33 Skin pigmentation; chr20:34110039 chr20:33985617~33988989:- LUSC cis rs2404602 0.684 rs28895952 ENSG00000259422.1 RP11-593F23.1 -7.52 2.71e-13 2.26e-10 -0.39 -0.33 Blood metabolite levels; chr15:76564435 chr15:76174891~76181486:- LUSC cis rs9322193 0.962 rs9478848 ENSG00000223701.3 RAET1E-AS1 7.52 2.71e-13 2.27e-10 0.38 0.33 Lung cancer; chr6:149825080 chr6:149884431~149919508:+ LUSC cis rs8040855 0.825 rs4843021 ENSG00000259295.5 CSPG4P12 -7.52 2.72e-13 2.27e-10 -0.41 -0.33 Bulimia nervosa; chr15:85151317 chr15:85191438~85213905:+ LUSC cis rs7617773 0.78 rs6442111 ENSG00000228638.1 FCF1P2 -7.52 2.74e-13 2.29e-10 -0.39 -0.33 Coronary artery disease; chr3:48270570 chr3:48290793~48291375:- LUSC cis rs7617773 0.851 rs6775179 ENSG00000228638.1 FCF1P2 -7.52 2.74e-13 2.29e-10 -0.39 -0.33 Coronary artery disease; chr3:48271928 chr3:48290793~48291375:- LUSC cis rs66887589 0.592 rs62320740 ENSG00000245958.5 RP11-33B1.1 -7.52 2.76e-13 2.3e-10 -0.31 -0.33 Diastolic blood pressure; chr4:119358331 chr4:119454791~119552025:+ LUSC cis rs3091242 0.933 rs10903130 ENSG00000224183.1 SDHDP6 -7.52 2.76e-13 2.3e-10 -0.39 -0.33 Erythrocyte sedimentation rate; chr1:25442730 chr1:25294164~25294643:- LUSC cis rs3091242 0.933 rs11249251 ENSG00000224183.1 SDHDP6 -7.52 2.76e-13 2.3e-10 -0.39 -0.33 Erythrocyte sedimentation rate; chr1:25443697 chr1:25294164~25294643:- LUSC cis rs875971 0.862 rs778720 ENSG00000222364.1 RNU6-96P 7.52 2.76e-13 2.3e-10 0.39 0.33 Aortic root size; chr7:66381288 chr7:66395191~66395286:+ LUSC cis rs10129255 0.912 rs67410411 ENSG00000280411.1 IGHV1-69-2 -7.52 2.76e-13 2.31e-10 -0.23 -0.33 Kawasaki disease; chr14:106680324 chr14:106762092~106762588:- LUSC cis rs2188561 0.697 rs6947099 ENSG00000241764.3 AC002467.7 7.52 2.77e-13 2.31e-10 0.43 0.33 Alcohol consumption; chr7:107720471 chr7:107742817~107744581:- LUSC cis rs131777 0.547 rs131753 ENSG00000205559.3 CHKB-AS1 -7.52 2.78e-13 2.31e-10 -0.41 -0.33 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50584433 chr22:50583026~50583877:+ LUSC cis rs4950322 0.57 rs72692946 ENSG00000278811.3 LINC00624 7.52 2.8e-13 2.33e-10 0.38 0.33 Protein quantitative trait loci; chr1:147319966 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692948 ENSG00000278811.3 LINC00624 7.52 2.8e-13 2.33e-10 0.38 0.33 Protein quantitative trait loci; chr1:147320298 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs72692951 ENSG00000278811.3 LINC00624 7.52 2.8e-13 2.33e-10 0.38 0.33 Protein quantitative trait loci; chr1:147320551 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs77118461 ENSG00000278811.3 LINC00624 7.52 2.8e-13 2.33e-10 0.38 0.33 Protein quantitative trait loci; chr1:147320718 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs78681047 ENSG00000278811.3 LINC00624 7.52 2.8e-13 2.33e-10 0.38 0.33 Protein quantitative trait loci; chr1:147321013 chr1:147258885~147517875:- LUSC cis rs4950322 0.57 rs80070044 ENSG00000278811.3 LINC00624 7.52 2.8e-13 2.33e-10 0.38 0.33 Protein quantitative trait loci; chr1:147330238 chr1:147258885~147517875:- LUSC cis rs55665837 1 rs11023216 ENSG00000251991.1 RNU7-49P 7.52 2.81e-13 2.34e-10 0.37 0.33 Vitamin D levels; chr11:14415607 chr11:14478892~14478953:+ LUSC cis rs11098499 0.604 rs2389886 ENSG00000245958.5 RP11-33B1.1 -7.52 2.81e-13 2.34e-10 -0.34 -0.33 Corneal astigmatism; chr4:119649267 chr4:119454791~119552025:+ LUSC cis rs4713118 0.662 rs149970 ENSG00000219392.1 RP1-265C24.5 -7.52 2.81e-13 2.35e-10 -0.43 -0.33 Parkinson's disease; chr6:28012442 chr6:28115628~28116551:+ LUSC cis rs35955747 0.838 rs5997887 ENSG00000236132.1 CTA-440B3.1 7.52 2.82e-13 2.35e-10 0.4 0.33 Neutrophil count;Sum basophil neutrophil counts; chr22:31147211 chr22:31816379~31817491:- LUSC cis rs10129255 1 rs10141557 ENSG00000280411.1 IGHV1-69-2 -7.52 2.84e-13 2.36e-10 -0.24 -0.33 Kawasaki disease; chr14:106767990 chr14:106762092~106762588:- LUSC cis rs3091242 0.933 rs61775174 ENSG00000224183.1 SDHDP6 7.52 2.85e-13 2.37e-10 0.4 0.33 Erythrocyte sedimentation rate; chr1:25460822 chr1:25294164~25294643:- LUSC cis rs34779708 0.897 rs4934529 ENSG00000230534.5 RP11-297A16.2 7.52 2.85e-13 2.38e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35013448 chr10:35098006~35127020:- LUSC cis rs11089937 0.667 rs78549985 ENSG00000211639.2 IGLV4-60 7.52 2.86e-13 2.38e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22139152 chr22:22162199~22162681:+ LUSC cis rs2179367 0.887 rs506268 ENSG00000231760.4 RP11-350J20.5 7.52 2.87e-13 2.39e-10 0.42 0.33 Dupuytren's disease; chr6:149364481 chr6:149796151~149826294:- LUSC cis rs783540 0.681 rs1259178 ENSG00000255769.6 GOLGA2P10 7.52 2.87e-13 2.39e-10 0.43 0.33 Schizophrenia; chr15:82603127 chr15:82472993~82513950:- LUSC cis rs9322193 0.962 rs6903998 ENSG00000223701.3 RAET1E-AS1 7.52 2.87e-13 2.39e-10 0.38 0.33 Lung cancer; chr6:149831357 chr6:149884431~149919508:+ LUSC cis rs7267979 0.657 rs6107073 ENSG00000274973.1 RP13-401N8.7 -7.52 2.88e-13 2.4e-10 -0.34 -0.33 Liver enzyme levels (alkaline phosphatase); chr20:25735727 chr20:25845497~25845862:+ LUSC cis rs7267979 0.789 rs6083841 ENSG00000274973.1 RP13-401N8.7 7.52 2.89e-13 2.4e-10 0.33 0.33 Liver enzyme levels (alkaline phosphatase); chr20:25403928 chr20:25845497~25845862:+ LUSC cis rs7684253 0.587 rs9685436 ENSG00000269949.1 RP11-738E22.3 -7.51 2.93e-13 2.44e-10 -0.41 -0.33 Migraine; chr4:56881195 chr4:56960927~56961373:- LUSC cis rs8177876 0.658 rs2911158 ENSG00000261838.4 RP11-303E16.6 -7.51 2.94e-13 2.44e-10 -0.68 -0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81057652 chr16:81069854~81076598:+ LUSC cis rs433852 0.718 rs550455 ENSG00000232871.7 SEC1P -7.51 2.94e-13 2.44e-10 -0.41 -0.33 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48633258 chr19:48638071~48682245:+ LUSC cis rs2564921 0.73 rs2564929 ENSG00000242142.1 SERBP1P3 -7.51 2.94e-13 2.45e-10 -0.37 -0.33 Height; chr3:53084188 chr3:53064283~53065091:- LUSC cis rs2297363 1 rs13207901 ENSG00000213073.4 RP11-288H12.3 -7.51 2.97e-13 2.46e-10 -0.39 -0.33 Total cholesterol levels;Blood protein levels; chr6:160081428 chr6:160093082~160096212:+ LUSC cis rs6921919 0.583 rs9468355 ENSG00000216901.1 AL022393.7 7.51 2.97e-13 2.47e-10 0.39 0.33 Autism spectrum disorder or schizophrenia; chr6:28374100 chr6:28176188~28176674:+ LUSC cis rs760794 0.729 rs2206033 ENSG00000227116.1 RP3-471C18.1 -7.51 2.97e-13 2.47e-10 -0.36 -0.33 Endometriosis; chr6:19796647 chr6:19730427~19734567:- LUSC cis rs6142102 0.602 rs6142069 ENSG00000276073.1 RP5-1125A11.7 -7.51 2.99e-13 2.48e-10 -0.33 -0.33 Skin pigmentation; chr20:33972736 chr20:33985617~33988989:- LUSC cis rs875971 0.862 rs709609 ENSG00000222364.1 RNU6-96P 7.51 3e-13 2.49e-10 0.39 0.33 Aortic root size; chr7:66095574 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs1167399 ENSG00000222364.1 RNU6-96P 7.51 3e-13 2.49e-10 0.39 0.33 Aortic root size; chr7:66096890 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs57866200 ENSG00000222364.1 RNU6-96P 7.51 3e-13 2.49e-10 0.39 0.33 Aortic root size; chr7:66100405 chr7:66395191~66395286:+ LUSC cis rs801193 0.569 rs881285 ENSG00000237310.1 GS1-124K5.4 -7.51 3.01e-13 2.5e-10 -0.34 -0.33 Aortic root size; chr7:66654433 chr7:66493706~66495474:+ LUSC cis rs4713118 0.513 rs149959 ENSG00000204709.4 LINC01556 7.51 3.01e-13 2.5e-10 0.42 0.33 Parkinson's disease; chr6:28046076 chr6:28943877~28944537:+ LUSC cis rs875971 0.83 rs427973 ENSG00000222364.1 RNU6-96P -7.51 3.01e-13 2.5e-10 -0.39 -0.33 Aortic root size; chr7:66061661 chr7:66395191~66395286:+ LUSC cis rs7044106 0.537 rs10818474 ENSG00000226752.6 PSMD5-AS1 -7.51 3.02e-13 2.5e-10 -0.39 -0.33 Hip circumference adjusted for BMI; chr9:120727686 chr9:120824828~120854385:+ LUSC cis rs7945705 0.837 rs2742474 ENSG00000254860.4 TMEM9B-AS1 7.51 3.02e-13 2.5e-10 0.36 0.33 Hemoglobin concentration; chr11:8980542 chr11:8964675~8977527:+ LUSC cis rs17711722 0.701 rs781145 ENSG00000224316.1 RP11-479O9.2 7.51 3.03e-13 2.51e-10 0.31 0.33 Calcium levels; chr7:65975383 chr7:65773620~65802067:+ LUSC cis rs875971 0.862 rs10274883 ENSG00000237310.1 GS1-124K5.4 -7.51 3.03e-13 2.51e-10 -0.34 -0.33 Aortic root size; chr7:66651104 chr7:66493706~66495474:+ LUSC cis rs2739330 0.734 rs2000467 ENSG00000235689.1 AP000351.13 -7.51 3.04e-13 2.52e-10 -0.36 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:24006305~24008258:- LUSC cis rs2404602 0.684 rs2047504 ENSG00000259422.1 RP11-593F23.1 -7.51 3.08e-13 2.55e-10 -0.39 -0.33 Blood metabolite levels; chr15:76591175 chr15:76174891~76181486:- LUSC cis rs7267979 0.844 rs6050477 ENSG00000274973.1 RP13-401N8.7 7.51 3.1e-13 2.57e-10 0.34 0.33 Liver enzyme levels (alkaline phosphatase); chr20:25240911 chr20:25845497~25845862:+ LUSC cis rs9322193 0.962 rs9765929 ENSG00000223701.3 RAET1E-AS1 7.51 3.1e-13 2.57e-10 0.37 0.33 Lung cancer; chr6:149769680 chr6:149884431~149919508:+ LUSC cis rs55665837 1 rs11023214 ENSG00000251991.1 RNU7-49P 7.51 3.1e-13 2.57e-10 0.36 0.33 Vitamin D levels; chr11:14414713 chr11:14478892~14478953:+ LUSC cis rs17507216 0.667 rs13379724 ENSG00000278603.1 RP13-608F4.5 7.5 3.11e-13 2.58e-10 0.47 0.33 Excessive daytime sleepiness; chr15:82619892 chr15:82472203~82472426:+ LUSC cis rs673078 0.607 rs61943367 ENSG00000275759.1 RP11-131L12.3 -7.5 3.12e-13 2.58e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118366316 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943368 ENSG00000275759.1 RP11-131L12.3 -7.5 3.12e-13 2.58e-10 -0.47 -0.33 Glucose homeostasis traits; chr12:118366568 chr12:118428281~118428870:+ LUSC cis rs8040855 0.657 rs6496733 ENSG00000259295.5 CSPG4P12 -7.5 3.12e-13 2.58e-10 -0.4 -0.33 Bulimia nervosa; chr15:85129945 chr15:85191438~85213905:+ LUSC cis rs2179367 0.959 rs585022 ENSG00000231760.4 RP11-350J20.5 7.5 3.13e-13 2.59e-10 0.43 0.33 Dupuytren's disease; chr6:149432168 chr6:149796151~149826294:- LUSC cis rs875971 0.862 rs1167408 ENSG00000237310.1 GS1-124K5.4 -7.5 3.15e-13 2.61e-10 -0.34 -0.33 Aortic root size; chr7:66091121 chr7:66493706~66495474:+ LUSC cis rs875971 0.83 rs1167406 ENSG00000237310.1 GS1-124K5.4 -7.5 3.15e-13 2.61e-10 -0.34 -0.33 Aortic root size; chr7:66091949 chr7:66493706~66495474:+ LUSC cis rs875971 0.767 rs12668005 ENSG00000222364.1 RNU6-96P -7.5 3.15e-13 2.61e-10 -0.39 -0.33 Aortic root size; chr7:66444034 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs11765791 ENSG00000222364.1 RNU6-96P -7.5 3.15e-13 2.61e-10 -0.39 -0.33 Aortic root size; chr7:66471587 chr7:66395191~66395286:+ LUSC cis rs761746 0.577 rs5994431 ENSG00000236132.1 CTA-440B3.1 7.5 3.16e-13 2.61e-10 0.45 0.33 Intelligence; chr22:31814314 chr22:31816379~31817491:- LUSC cis rs7945705 0.783 rs11042125 ENSG00000254860.4 TMEM9B-AS1 7.5 3.16e-13 2.62e-10 0.35 0.33 Hemoglobin concentration; chr11:8916502 chr11:8964675~8977527:+ LUSC cis rs8081395 0.58 rs180515 ENSG00000266992.1 DHX40P1 7.5 3.16e-13 2.62e-10 0.38 0.33 White blood cell count; chr17:59946914 chr17:59976009~60002384:- LUSC cis rs9487094 1 rs35056702 ENSG00000260273.1 RP11-425D10.10 7.5 3.18e-13 2.63e-10 0.4 0.33 Height; chr6:109415123 chr6:109382795~109383666:+ LUSC cis rs1865760 1 rs3799371 ENSG00000272462.2 U91328.19 7.5 3.18e-13 2.63e-10 0.34 0.33 Height; chr6:25912588 chr6:25992662~26001775:+ LUSC cis rs875971 0.755 rs76288834 ENSG00000222364.1 RNU6-96P 7.5 3.18e-13 2.63e-10 0.39 0.33 Aortic root size; chr7:66604815 chr7:66395191~66395286:+ LUSC cis rs6782228 0.876 rs34198449 ENSG00000277250.1 Metazoa_SRP 7.5 3.18e-13 2.63e-10 0.4 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128662427 chr3:128673681~128674021:- LUSC cis rs9322193 0.962 rs2151912 ENSG00000223701.3 RAET1E-AS1 7.5 3.18e-13 2.63e-10 0.38 0.33 Lung cancer; chr6:149831772 chr6:149884431~149919508:+ LUSC cis rs7945705 0.837 rs10769981 ENSG00000254860.4 TMEM9B-AS1 -7.5 3.18e-13 2.63e-10 -0.37 -0.33 Hemoglobin concentration; chr11:9002913 chr11:8964675~8977527:+ LUSC cis rs2337406 0.5 rs57619050 ENSG00000274576.2 IGHV2-70 -7.5 3.19e-13 2.64e-10 -0.35 -0.33 Alzheimer's disease (late onset); chr14:106820074 chr14:106770577~106771020:- LUSC cis rs10129255 0.957 rs10136560 ENSG00000211972.2 IGHV3-66 7.5 3.19e-13 2.64e-10 0.25 0.33 Kawasaki disease; chr14:106787630 chr14:106675017~106675544:- LUSC cis rs6142102 0.602 rs11696338 ENSG00000276073.1 RP5-1125A11.7 -7.5 3.2e-13 2.64e-10 -0.33 -0.33 Skin pigmentation; chr20:34099805 chr20:33985617~33988989:- LUSC cis rs801193 0.569 rs3846973 ENSG00000237310.1 GS1-124K5.4 -7.5 3.21e-13 2.65e-10 -0.34 -0.33 Aortic root size; chr7:66655048 chr7:66493706~66495474:+ LUSC cis rs801193 0.569 rs2013908 ENSG00000237310.1 GS1-124K5.4 -7.5 3.21e-13 2.65e-10 -0.34 -0.33 Aortic root size; chr7:66656082 chr7:66493706~66495474:+ LUSC cis rs801193 0.569 rs6951302 ENSG00000237310.1 GS1-124K5.4 -7.5 3.21e-13 2.65e-10 -0.34 -0.33 Aortic root size; chr7:66667525 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6964437 ENSG00000237310.1 GS1-124K5.4 -7.5 3.22e-13 2.66e-10 -0.34 -0.33 Aortic root size; chr7:66221457 chr7:66493706~66495474:+ LUSC cis rs9322193 0.962 rs9689447 ENSG00000223701.3 RAET1E-AS1 7.5 3.23e-13 2.67e-10 0.38 0.33 Lung cancer; chr6:149789350 chr6:149884431~149919508:+ LUSC cis rs34779708 0.931 rs4934723 ENSG00000230534.5 RP11-297A16.2 7.5 3.23e-13 2.67e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35092835 chr10:35098006~35127020:- LUSC cis rs801193 0.548 rs2109297 ENSG00000237310.1 GS1-124K5.4 -7.5 3.24e-13 2.67e-10 -0.34 -0.33 Aortic root size; chr7:66657397 chr7:66493706~66495474:+ LUSC cis rs801193 0.591 rs721717 ENSG00000237310.1 GS1-124K5.4 -7.5 3.24e-13 2.67e-10 -0.34 -0.33 Aortic root size; chr7:66665305 chr7:66493706~66495474:+ LUSC cis rs9322193 0.736 rs3828701 ENSG00000223701.3 RAET1E-AS1 7.5 3.24e-13 2.68e-10 0.38 0.33 Lung cancer; chr6:149791063 chr6:149884431~149919508:+ LUSC cis rs9322193 0.736 rs3805750 ENSG00000223701.3 RAET1E-AS1 7.5 3.24e-13 2.68e-10 0.38 0.33 Lung cancer; chr6:149791065 chr6:149884431~149919508:+ LUSC cis rs10129255 0.912 rs8009135 ENSG00000211972.2 IGHV3-66 7.5 3.25e-13 2.68e-10 0.25 0.33 Kawasaki disease; chr14:106777528 chr14:106675017~106675544:- LUSC cis rs10129255 0.833 rs7156689 ENSG00000280411.1 IGHV1-69-2 -7.5 3.26e-13 2.69e-10 -0.23 -0.33 Kawasaki disease; chr14:106816039 chr14:106762092~106762588:- LUSC cis rs8072100 0.676 rs9905308 ENSG00000228782.6 CTD-2026D20.3 7.5 3.26e-13 2.69e-10 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47332020 chr17:47450568~47492492:- LUSC cis rs875971 0.793 rs460678 ENSG00000222364.1 RNU6-96P -7.5 3.27e-13 2.7e-10 -0.39 -0.33 Aortic root size; chr7:66062213 chr7:66395191~66395286:+ LUSC cis rs10129255 1 rs11627342 ENSG00000224373.3 IGHV4-59 7.5 3.27e-13 2.7e-10 0.19 0.33 Kawasaki disease; chr14:106675823 chr14:106627249~106627825:- LUSC cis rs4713118 0.699 rs200969 ENSG00000219392.1 RP1-265C24.5 -7.5 3.28e-13 2.71e-10 -0.46 -0.33 Parkinson's disease; chr6:27891675 chr6:28115628~28116551:+ LUSC cis rs6903823 0.508 rs1778484 ENSG00000204709.4 LINC01556 7.5 3.29e-13 2.72e-10 0.4 0.33 Pulmonary function; chr6:28273021 chr6:28943877~28944537:+ LUSC cis rs7945705 0.902 rs11042152 ENSG00000254860.4 TMEM9B-AS1 -7.5 3.31e-13 2.73e-10 -0.36 -0.33 Hemoglobin concentration; chr11:8999440 chr11:8964675~8977527:+ LUSC cis rs34375054 0.525 rs7136220 ENSG00000279233.1 RP11-158L12.4 7.5 3.31e-13 2.73e-10 0.3 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125118138 chr12:125138245~125141711:+ LUSC cis rs875971 0.825 rs6951503 ENSG00000222364.1 RNU6-96P 7.49 3.35e-13 2.76e-10 0.39 0.33 Aortic root size; chr7:66253949 chr7:66395191~66395286:+ LUSC cis rs875971 0.83 rs12673450 ENSG00000237310.1 GS1-124K5.4 7.49 3.36e-13 2.77e-10 0.35 0.33 Aortic root size; chr7:66544233 chr7:66493706~66495474:+ LUSC cis rs10754283 0.967 rs12058749 ENSG00000231613.1 RP5-943J3.1 7.49 3.36e-13 2.77e-10 0.37 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89640045 chr1:89788914~89790492:+ LUSC cis rs8177876 0.749 rs2911159 ENSG00000261838.4 RP11-303E16.6 -7.49 3.37e-13 2.78e-10 -0.67 -0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81057653 chr16:81069854~81076598:+ LUSC cis rs6991838 0.8 rs11786598 ENSG00000200714.1 Y_RNA -7.49 3.37e-13 2.78e-10 -0.39 -0.33 Intelligence (multi-trait analysis); chr8:65559944 chr8:65592731~65592820:+ LUSC cis rs875971 0.505 rs2462573 ENSG00000224316.1 RP11-479O9.2 -7.49 3.39e-13 2.79e-10 -0.31 -0.33 Aortic root size; chr7:66042405 chr7:65773620~65802067:+ LUSC cis rs6471393 1 rs6471393 ENSG00000253848.1 RP11-10N23.5 -7.49 3.42e-13 2.82e-10 -0.43 -0.33 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93703063 chr8:93741193~93744534:+ LUSC cis rs34779708 0.931 rs66887762 ENSG00000230534.5 RP11-297A16.2 7.49 3.43e-13 2.82e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35041649 chr10:35098006~35127020:- LUSC cis rs150992 0.537 rs1604450 ENSG00000248489.1 CTD-2007H13.3 -7.49 3.43e-13 2.83e-10 -0.43 -0.33 Body mass index; chr5:99036274 chr5:98929171~98995013:+ LUSC cis rs150992 0.504 rs7719649 ENSG00000248489.1 CTD-2007H13.3 7.49 3.43e-13 2.83e-10 0.43 0.33 Body mass index; chr5:99036711 chr5:98929171~98995013:+ LUSC cis rs1075265 0.87 rs6749817 ENSG00000233266.1 HMGB1P31 7.49 3.44e-13 2.83e-10 0.4 0.33 Chronotype;Morning vs. evening chronotype; chr2:54032396 chr2:54051334~54051760:+ LUSC cis rs9322193 0.607 rs12209310 ENSG00000223701.3 RAET1E-AS1 7.49 3.45e-13 2.84e-10 0.42 0.33 Lung cancer; chr6:149904882 chr6:149884431~149919508:+ LUSC cis rs3096299 0.874 rs3102342 ENSG00000274627.1 RP11-104N10.2 7.49 3.46e-13 2.85e-10 0.29 0.33 Multiple myeloma (IgH translocation); chr16:89385167 chr16:89516797~89522217:+ LUSC cis rs11098499 0.909 rs73842633 ENSG00000249244.1 RP11-548H18.2 7.49 3.48e-13 2.86e-10 0.44 0.33 Corneal astigmatism; chr4:119454309 chr4:119391831~119395335:- LUSC cis rs1113500 0.548 rs11185271 ENSG00000226822.1 RP11-356N1.2 7.49 3.49e-13 2.87e-10 0.38 0.33 Growth-regulated protein alpha levels; chr1:108117311 chr1:108071482~108074519:+ LUSC cis rs875971 0.505 rs1167386 ENSG00000224316.1 RP11-479O9.2 -7.49 3.5e-13 2.88e-10 -0.31 -0.33 Aortic root size; chr7:66048109 chr7:65773620~65802067:+ LUSC cis rs7847628 0.765 rs7026635 ENSG00000226752.6 PSMD5-AS1 7.49 3.51e-13 2.89e-10 0.42 0.33 Birth weight; chr9:120787749 chr9:120824828~120854385:+ LUSC cis rs2404602 0.684 rs965818 ENSG00000259422.1 RP11-593F23.1 -7.49 3.51e-13 2.89e-10 -0.39 -0.33 Blood metabolite levels; chr15:76574444 chr15:76174891~76181486:- LUSC cis rs11098499 0.866 rs7665125 ENSG00000249244.1 RP11-548H18.2 7.49 3.54e-13 2.91e-10 0.4 0.33 Corneal astigmatism; chr4:119480924 chr4:119391831~119395335:- LUSC cis rs8072100 0.905 rs9895274 ENSG00000228782.6 CTD-2026D20.3 7.49 3.54e-13 2.91e-10 0.31 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47461751 chr17:47450568~47492492:- LUSC cis rs2188561 1 rs2712208 ENSG00000241764.3 AC002467.7 7.48 3.56e-13 2.93e-10 0.44 0.33 Alcohol consumption; chr7:107703317 chr7:107742817~107744581:- LUSC cis rs1972460 0.506 rs62012050 ENSG00000276710.3 CSPG4P8 -7.48 3.56e-13 2.93e-10 -0.36 -0.33 Intelligence (multi-trait analysis); chr15:82239933 chr15:82459472~82477258:+ LUSC cis rs875971 0.522 rs6960048 ENSG00000224316.1 RP11-479O9.2 7.48 3.57e-13 2.93e-10 0.31 0.33 Aortic root size; chr7:65943052 chr7:65773620~65802067:+ LUSC cis rs380904 0.963 rs410822 ENSG00000254859.1 RP11-661A12.5 -7.48 3.57e-13 2.94e-10 -0.44 -0.33 Venous thromboembolism (SNP x SNP interaction); chr8:143492441 chr8:143541973~143549729:- LUSC cis rs9549367 0.707 rs9549353 ENSG00000269125.1 RP11-98F14.11 -7.48 3.6e-13 2.96e-10 -0.42 -0.33 Platelet distribution width; chr13:113189113 chr13:113165002~113165183:- LUSC cis rs8072100 0.967 rs12452315 ENSG00000228782.6 CTD-2026D20.3 -7.48 3.62e-13 2.98e-10 -0.31 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402080 chr17:47450568~47492492:- LUSC cis rs17507216 0.591 rs7163848 ENSG00000278603.1 RP13-608F4.5 7.48 3.63e-13 2.98e-10 0.5 0.33 Excessive daytime sleepiness; chr15:82729563 chr15:82472203~82472426:+ LUSC cis rs992157 0.643 rs10191283 ENSG00000261338.2 RP11-378A13.1 7.48 3.66e-13 3e-10 0.34 0.33 Colorectal cancer; chr2:218192032 chr2:218255319~218257366:+ LUSC cis rs9322193 0.884 rs2342858 ENSG00000223701.3 RAET1E-AS1 7.48 3.66e-13 3e-10 0.38 0.33 Lung cancer; chr6:149805967 chr6:149884431~149919508:+ LUSC cis rs34779708 0.931 rs7084196 ENSG00000230534.5 RP11-297A16.2 7.48 3.66e-13 3.01e-10 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35078233 chr10:35098006~35127020:- LUSC cis rs34779708 0.966 rs1148245 ENSG00000230534.5 RP11-297A16.2 7.48 3.69e-13 3.03e-10 0.36 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35222966 chr10:35098006~35127020:- LUSC cis rs9318086 0.648 rs35449605 ENSG00000205861.10 C1QTNF9B-AS1 -7.48 3.69e-13 3.03e-10 -0.41 -0.33 Myopia (pathological); chr13:23898443 chr13:23888889~23897263:+ LUSC cis rs2404602 0.684 rs8037847 ENSG00000259422.1 RP11-593F23.1 -7.48 3.7e-13 3.03e-10 -0.38 -0.33 Blood metabolite levels; chr15:76564210 chr15:76174891~76181486:- LUSC cis rs2404602 0.684 rs11072600 ENSG00000259422.1 RP11-593F23.1 -7.48 3.7e-13 3.03e-10 -0.38 -0.33 Blood metabolite levels; chr15:76575574 chr15:76174891~76181486:- LUSC cis rs8040855 0.69 rs8041189 ENSG00000259295.5 CSPG4P12 -7.48 3.7e-13 3.04e-10 -0.41 -0.33 Bulimia nervosa; chr15:85143096 chr15:85191438~85213905:+ LUSC cis rs6471393 0.964 rs1051914 ENSG00000253848.1 RP11-10N23.5 7.48 3.7e-13 3.04e-10 0.43 0.33 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93728838 chr8:93741193~93744534:+ LUSC cis rs7684253 0.587 rs4339274 ENSG00000269949.1 RP11-738E22.3 7.48 3.73e-13 3.06e-10 0.4 0.33 Migraine; chr4:56881468 chr4:56960927~56961373:- LUSC cis rs1075232 1 rs72722829 ENSG00000270055.1 CTD-3092A11.2 -7.48 3.74e-13 3.07e-10 -0.63 -0.33 Survival in colorectal cancer (non-distant metastatic); chr15:31346911 chr15:30487963~30490313:+ LUSC cis rs1075232 1 rs16956707 ENSG00000270055.1 CTD-3092A11.2 -7.48 3.74e-13 3.07e-10 -0.63 -0.33 Survival in colorectal cancer (non-distant metastatic); chr15:31349430 chr15:30487963~30490313:+ LUSC cis rs4423214 0.559 rs10898201 ENSG00000254682.1 RP11-660L16.2 -7.48 3.75e-13 3.07e-10 -0.52 -0.33 Vitamin D levels; chr11:71490481 chr11:71448674~71452157:+ LUSC cis rs113835537 0.597 rs57288351 ENSG00000255517.5 CTD-3074O7.5 -7.48 3.77e-13 3.09e-10 -0.38 -0.33 Airway imaging phenotypes; chr11:66540018 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs11227525 ENSG00000255517.5 CTD-3074O7.5 -7.48 3.77e-13 3.09e-10 -0.38 -0.33 Airway imaging phenotypes; chr11:66540594 chr11:66473490~66480233:- LUSC cis rs2404602 0.684 rs11072602 ENSG00000259422.1 RP11-593F23.1 -7.48 3.79e-13 3.11e-10 -0.39 -0.33 Blood metabolite levels; chr15:76581126 chr15:76174891~76181486:- LUSC cis rs7811142 0.666 rs28401739 ENSG00000242294.5 STAG3L5P 7.48 3.79e-13 3.11e-10 0.26 0.33 Platelet count; chr7:100308061 chr7:100336079~100351900:+ LUSC cis rs6142102 0.602 rs4911395 ENSG00000276073.1 RP5-1125A11.7 -7.48 3.81e-13 3.12e-10 -0.32 -0.33 Skin pigmentation; chr20:33992095 chr20:33985617~33988989:- LUSC cis rs2581828 0.618 rs7615099 ENSG00000242142.1 SERBP1P3 -7.47 3.82e-13 3.13e-10 -0.37 -0.33 Crohn's disease; chr3:53109885 chr3:53064283~53065091:- LUSC cis rs1113500 0.614 rs6677839 ENSG00000226822.1 RP11-356N1.2 -7.47 3.84e-13 3.15e-10 -0.36 -0.33 Growth-regulated protein alpha levels; chr1:108056719 chr1:108071482~108074519:+ LUSC cis rs11098499 1 rs35643470 ENSG00000249244.1 RP11-548H18.2 7.47 3.86e-13 3.16e-10 0.42 0.33 Corneal astigmatism; chr4:119263793 chr4:119391831~119395335:- LUSC cis rs9322193 0.607 rs12210822 ENSG00000223701.3 RAET1E-AS1 7.47 3.87e-13 3.17e-10 0.42 0.33 Lung cancer; chr6:149905356 chr6:149884431~149919508:+ LUSC cis rs950169 0.922 rs11635505 ENSG00000225151.9 GOLGA2P7 7.47 3.88e-13 3.18e-10 0.44 0.33 Schizophrenia; chr15:84553803 chr15:84199311~84230136:- LUSC cis rs34779708 0.931 rs4934721 ENSG00000230534.5 RP11-297A16.2 7.47 3.88e-13 3.18e-10 0.38 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35088787 chr10:35098006~35127020:- LUSC cis rs875971 0.862 rs13226170 ENSG00000222364.1 RNU6-96P -7.47 3.89e-13 3.18e-10 -0.39 -0.33 Aortic root size; chr7:66534311 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs2420611 ENSG00000222364.1 RNU6-96P -7.47 3.89e-13 3.18e-10 -0.39 -0.33 Aortic root size; chr7:66534333 chr7:66395191~66395286:+ LUSC cis rs4950322 0.542 rs3766519 ENSG00000278811.3 LINC00624 7.47 3.9e-13 3.19e-10 0.37 0.33 Protein quantitative trait loci; chr1:147214802 chr1:147258885~147517875:- LUSC cis rs10129255 0.5 rs2105989 ENSG00000211970.3 IGHV4-61 -7.47 3.9e-13 3.2e-10 -0.2 -0.33 Kawasaki disease; chr14:106682199 chr14:106639119~106639657:- LUSC cis rs34375054 0.525 rs1080910 ENSG00000279233.1 RP11-158L12.4 7.47 3.91e-13 3.2e-10 0.3 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125123946 chr12:125138245~125141711:+ LUSC cis rs12554020 0.786 rs78547192 ENSG00000227603.1 RP11-165J3.6 7.47 3.91e-13 3.2e-10 0.56 0.33 Schizophrenia; chr9:93597221 chr9:93435332~93437121:- LUSC cis rs992157 0.735 rs13393821 ENSG00000261338.2 RP11-378A13.1 7.47 3.93e-13 3.21e-10 0.33 0.33 Colorectal cancer; chr2:218212019 chr2:218255319~218257366:+ LUSC cis rs34779708 0.931 rs4934700 ENSG00000230534.5 RP11-297A16.2 7.47 3.94e-13 3.22e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35021914 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs4934697 ENSG00000230534.5 RP11-297A16.2 7.47 3.94e-13 3.23e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34998264 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs34087268 ENSG00000230534.5 RP11-297A16.2 7.47 3.96e-13 3.24e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35057796 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs58159560 ENSG00000230534.5 RP11-297A16.2 7.47 3.96e-13 3.24e-10 0.37 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35062321 chr10:35098006~35127020:- LUSC cis rs8072100 0.817 rs9892497 ENSG00000228782.6 CTD-2026D20.3 7.47 3.98e-13 3.25e-10 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47468553 chr17:47450568~47492492:- LUSC cis rs7945705 0.818 rs2742537 ENSG00000254860.4 TMEM9B-AS1 7.47 4.02e-13 3.28e-10 0.35 0.33 Hemoglobin concentration; chr11:8886842 chr11:8964675~8977527:+ LUSC cis rs4141404 0.787 rs11913992 ENSG00000236132.1 CTA-440B3.1 7.47 4.02e-13 3.29e-10 0.4 0.33 Paclitaxel-induced neuropathy; chr22:31189234 chr22:31816379~31817491:- LUSC cis rs875971 0.83 rs778711 ENSG00000222364.1 RNU6-96P -7.47 4.04e-13 3.3e-10 -0.39 -0.33 Aortic root size; chr7:66386670 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs1083554 ENSG00000222364.1 RNU6-96P -7.47 4.04e-13 3.3e-10 -0.39 -0.33 Aortic root size; chr7:66387354 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs778707 ENSG00000222364.1 RNU6-96P -7.47 4.04e-13 3.3e-10 -0.39 -0.33 Aortic root size; chr7:66392040 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs778705 ENSG00000222364.1 RNU6-96P -7.47 4.04e-13 3.3e-10 -0.39 -0.33 Aortic root size; chr7:66396128 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs778697 ENSG00000222364.1 RNU6-96P -7.47 4.04e-13 3.3e-10 -0.39 -0.33 Aortic root size; chr7:66405439 chr7:66395191~66395286:+ LUSC cis rs875971 0.798 rs7789615 ENSG00000222364.1 RNU6-96P -7.47 4.04e-13 3.3e-10 -0.39 -0.33 Aortic root size; chr7:66413674 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6978028 ENSG00000222364.1 RNU6-96P -7.47 4.04e-13 3.3e-10 -0.39 -0.33 Aortic root size; chr7:66421313 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6947339 ENSG00000222364.1 RNU6-96P -7.47 4.04e-13 3.3e-10 -0.39 -0.33 Aortic root size; chr7:66423483 chr7:66395191~66395286:+ LUSC cis rs13113518 0.729 rs12641881 ENSG00000249700.7 SRD5A3-AS1 7.47 4.04e-13 3.3e-10 0.41 0.33 Height; chr4:55401306 chr4:55363971~55395847:- LUSC cis rs4660456 0.913 rs2744808 ENSG00000237899.1 RP4-739H11.3 -7.47 4.04e-13 3.3e-10 -0.45 -0.33 Platelet count; chr1:40712271 chr1:40669089~40687588:- LUSC cis rs8081395 0.627 rs180536 ENSG00000266992.1 DHX40P1 7.47 4.06e-13 3.31e-10 0.38 0.33 White blood cell count; chr17:59919445 chr17:59976009~60002384:- LUSC cis rs7945705 0.747 rs2653605 ENSG00000254860.4 TMEM9B-AS1 7.46 4.08e-13 3.33e-10 0.36 0.33 Hemoglobin concentration; chr11:8971762 chr11:8964675~8977527:+ LUSC cis rs1823913 0.892 rs35596292 ENSG00000280083.1 RP11-317J9.1 -7.46 4.1e-13 3.35e-10 -0.4 -0.33 Obesity-related traits; chr2:191246890 chr2:191154118~191156070:- LUSC cis rs1823913 0.927 rs35530564 ENSG00000280083.1 RP11-317J9.1 -7.46 4.1e-13 3.35e-10 -0.4 -0.33 Obesity-related traits; chr2:191247324 chr2:191154118~191156070:- LUSC cis rs10935480 0.771 rs7634817 ENSG00000239445.4 ST3GAL6-AS1 7.46 4.11e-13 3.35e-10 0.4 0.33 Blood protein levels; chr3:98743681 chr3:98714330~98732651:- LUSC cis rs17711722 0.64 rs13237956 ENSG00000236529.1 RP13-254B10.1 7.46 4.12e-13 3.36e-10 0.34 0.33 Calcium levels; chr7:65853042 chr7:65840212~65840596:+ LUSC cis rs992157 0.71 rs7569907 ENSG00000261338.2 RP11-378A13.1 7.46 4.14e-13 3.38e-10 0.33 0.33 Colorectal cancer; chr2:218205828 chr2:218255319~218257366:+ LUSC cis rs9322193 0.566 rs12528243 ENSG00000223701.3 RAET1E-AS1 7.46 4.15e-13 3.39e-10 0.42 0.33 Lung cancer; chr6:149898491 chr6:149884431~149919508:+ LUSC cis rs9322193 0.607 rs915140 ENSG00000223701.3 RAET1E-AS1 7.46 4.15e-13 3.39e-10 0.42 0.33 Lung cancer; chr6:149899674 chr6:149884431~149919508:+ LUSC cis rs13056815 1 rs13056815 ENSG00000236132.1 CTA-440B3.1 7.46 4.15e-13 3.39e-10 0.39 0.33 Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr22:31272264 chr22:31816379~31817491:- LUSC cis rs992157 0.687 rs10206984 ENSG00000261338.2 RP11-378A13.1 7.46 4.17e-13 3.4e-10 0.33 0.33 Colorectal cancer; chr2:218202257 chr2:218255319~218257366:+ LUSC cis rs992157 0.697 rs13384682 ENSG00000261338.2 RP11-378A13.1 7.46 4.17e-13 3.4e-10 0.33 0.33 Colorectal cancer; chr2:218204414 chr2:218255319~218257366:+ LUSC cis rs4950322 0.542 rs56080828 ENSG00000278811.3 LINC00624 7.46 4.18e-13 3.41e-10 0.37 0.33 Protein quantitative trait loci; chr1:147183447 chr1:147258885~147517875:- LUSC cis rs17482078 0.959 rs2287987 ENSG00000248734.2 CTD-2260A17.1 7.46 4.2e-13 3.42e-10 0.37 0.33 Behcet's disease;Blood protein levels; chr5:96793832 chr5:96784777~96785999:+ LUSC cis rs17482078 0.959 rs13168673 ENSG00000248734.2 CTD-2260A17.1 7.46 4.2e-13 3.42e-10 0.37 0.33 Behcet's disease;Blood protein levels; chr5:96794486 chr5:96784777~96785999:+ LUSC cis rs1061377 0.748 rs11096977 ENSG00000249207.1 RP11-360F5.1 -7.46 4.2e-13 3.43e-10 -0.36 -0.33 Uric acid levels; chr4:39106186 chr4:39112677~39126818:- LUSC cis rs853679 0.527 rs213228 ENSG00000204709.4 LINC01556 7.46 4.21e-13 3.43e-10 0.42 0.33 Depression; chr6:28363475 chr6:28943877~28944537:+ LUSC cis rs2282300 0.667 rs10734405 ENSG00000254532.1 RP11-624D11.2 -7.46 4.21e-13 3.43e-10 -0.45 -0.33 Morning vs. evening chronotype; chr11:30252203 chr11:30044058~30084343:- LUSC cis rs1061377 0.748 rs6810770 ENSG00000249207.1 RP11-360F5.1 -7.46 4.21e-13 3.43e-10 -0.36 -0.33 Uric acid levels; chr4:39106545 chr4:39112677~39126818:- LUSC cis rs1061377 0.748 rs6812316 ENSG00000249207.1 RP11-360F5.1 -7.46 4.21e-13 3.43e-10 -0.36 -0.33 Uric acid levels; chr4:39106617 chr4:39112677~39126818:- LUSC cis rs875971 0.54 rs781152 ENSG00000236529.1 RP13-254B10.1 7.46 4.22e-13 3.44e-10 0.35 0.33 Aortic root size; chr7:66014585 chr7:65840212~65840596:+ LUSC cis rs17711722 0.727 rs781151 ENSG00000236529.1 RP13-254B10.1 7.46 4.22e-13 3.44e-10 0.35 0.33 Calcium levels; chr7:66014891 chr7:65840212~65840596:+ LUSC cis rs875971 0.79 rs10257911 ENSG00000237310.1 GS1-124K5.4 -7.46 4.23e-13 3.44e-10 -0.34 -0.33 Aortic root size; chr7:66278783 chr7:66493706~66495474:+ LUSC cis rs875971 0.522 rs4718285 ENSG00000236529.1 RP13-254B10.1 7.46 4.24e-13 3.46e-10 0.34 0.33 Aortic root size; chr7:65827018 chr7:65840212~65840596:+ LUSC cis rs34779708 0.966 rs4934735 ENSG00000230534.5 RP11-297A16.2 -7.46 4.25e-13 3.46e-10 -0.36 -0.33 Inflammatory bowel disease;Crohn's disease; chr10:35207802 chr10:35098006~35127020:- LUSC cis rs875971 0.825 rs6951503 ENSG00000237310.1 GS1-124K5.4 -7.46 4.26e-13 3.46e-10 -0.34 -0.33 Aortic root size; chr7:66253949 chr7:66493706~66495474:+ LUSC cis rs4950322 0.748 rs56392137 ENSG00000278811.3 LINC00624 7.46 4.26e-13 3.47e-10 0.38 0.33 Protein quantitative trait loci; chr1:147352450 chr1:147258885~147517875:- LUSC cis rs732716 0.785 rs62129354 ENSG00000267769.1 CTB-50L17.9 -7.46 4.26e-13 3.47e-10 -0.36 -0.33 Mean corpuscular volume; chr19:4396508 chr19:4454014~4455286:+ LUSC cis rs11089937 0.597 rs4821773 ENSG00000211639.2 IGLV4-60 7.46 4.26e-13 3.47e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22131434 chr22:22162199~22162681:+ LUSC cis rs673078 0.607 rs17440942 ENSG00000275759.1 RP11-131L12.3 7.46 4.28e-13 3.48e-10 0.47 0.33 Glucose homeostasis traits; chr12:118394030 chr12:118428281~118428870:+ LUSC cis rs8177876 0.749 rs12927828 ENSG00000261838.4 RP11-303E16.6 7.46 4.28e-13 3.48e-10 0.67 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81057019 chr16:81069854~81076598:+ LUSC cis rs6782228 1 rs11711038 ENSG00000277250.1 Metazoa_SRP 7.46 4.29e-13 3.49e-10 0.4 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128675467 chr3:128673681~128674021:- LUSC cis rs8072100 0.846 rs6503796 ENSG00000228782.6 CTD-2026D20.3 7.46 4.29e-13 3.49e-10 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47687883 chr17:47450568~47492492:- LUSC cis rs10256972 0.967 rs1881122 ENSG00000229043.2 AC091729.9 -7.46 4.29e-13 3.49e-10 -0.38 -0.33 Endometriosis;Longevity; chr7:1001310 chr7:1160374~1165267:+ LUSC cis rs7617773 0.78 rs11706277 ENSG00000228638.1 FCF1P2 -7.46 4.29e-13 3.49e-10 -0.41 -0.33 Coronary artery disease; chr3:48318943 chr3:48290793~48291375:- LUSC cis rs8072100 0.748 rs9912592 ENSG00000228782.6 CTD-2026D20.3 7.46 4.3e-13 3.5e-10 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47479579 chr17:47450568~47492492:- LUSC cis rs2337406 1 rs17113276 ENSG00000274576.2 IGHV2-70 7.46 4.3e-13 3.5e-10 0.37 0.33 Alzheimer's disease (late onset); chr14:106683485 chr14:106770577~106771020:- LUSC cis rs875971 0.862 rs1875057 ENSG00000237310.1 GS1-124K5.4 -7.46 4.31e-13 3.51e-10 -0.34 -0.33 Aortic root size; chr7:66266868 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6960446 ENSG00000237310.1 GS1-124K5.4 -7.46 4.31e-13 3.51e-10 -0.34 -0.33 Aortic root size; chr7:66268272 chr7:66493706~66495474:+ LUSC cis rs875971 0.789 rs10260426 ENSG00000237310.1 GS1-124K5.4 -7.46 4.31e-13 3.51e-10 -0.34 -0.33 Aortic root size; chr7:66271055 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs10263690 ENSG00000237310.1 GS1-124K5.4 -7.46 4.31e-13 3.51e-10 -0.34 -0.33 Aortic root size; chr7:66301466 chr7:66493706~66495474:+ LUSC cis rs6471393 0.964 rs2914952 ENSG00000253848.1 RP11-10N23.5 7.46 4.31e-13 3.51e-10 0.43 0.33 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93729524 chr8:93741193~93744534:+ LUSC cis rs783540 0.5 rs1313494 ENSG00000276710.3 CSPG4P8 7.46 4.32e-13 3.51e-10 0.39 0.33 Schizophrenia; chr15:82605530 chr15:82459472~82477258:+ LUSC cis rs7945705 0.935 rs2568062 ENSG00000254860.4 TMEM9B-AS1 7.46 4.33e-13 3.52e-10 0.36 0.33 Hemoglobin concentration; chr11:8866398 chr11:8964675~8977527:+ LUSC cis rs150992 0.504 rs7719562 ENSG00000248489.1 CTD-2007H13.3 -7.46 4.33e-13 3.52e-10 -0.43 -0.33 Body mass index; chr5:99029419 chr5:98929171~98995013:+ LUSC cis rs150992 0.504 rs4583911 ENSG00000248489.1 CTD-2007H13.3 -7.46 4.33e-13 3.52e-10 -0.43 -0.33 Body mass index; chr5:99031401 chr5:98929171~98995013:+ LUSC cis rs10129255 0.789 rs61997796 ENSG00000224373.3 IGHV4-59 7.46 4.34e-13 3.53e-10 0.19 0.33 Kawasaki disease; chr14:106813798 chr14:106627249~106627825:- LUSC cis rs6142102 1 rs6059673 ENSG00000276073.1 RP5-1125A11.7 -7.46 4.34e-13 3.53e-10 -0.35 -0.33 Skin pigmentation; chr20:34117755 chr20:33985617~33988989:- LUSC cis rs8072100 0.817 rs12449647 ENSG00000228782.6 CTD-2026D20.3 7.45 4.37e-13 3.55e-10 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47471592 chr17:47450568~47492492:- LUSC cis rs8072100 0.748 rs9908016 ENSG00000228782.6 CTD-2026D20.3 7.45 4.38e-13 3.56e-10 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47473995 chr17:47450568~47492492:- LUSC cis rs8072100 0.782 rs28507314 ENSG00000228782.6 CTD-2026D20.3 7.45 4.38e-13 3.56e-10 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47474036 chr17:47450568~47492492:- LUSC cis rs7811142 1 rs2897358 ENSG00000242294.5 STAG3L5P 7.45 4.38e-13 3.56e-10 0.26 0.33 Platelet count; chr7:100491017 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs60478351 ENSG00000242294.5 STAG3L5P 7.45 4.38e-13 3.56e-10 0.26 0.33 Platelet count; chr7:100491394 chr7:100336079~100351900:+ LUSC cis rs7811142 1 rs7787620 ENSG00000242294.5 STAG3L5P 7.45 4.38e-13 3.56e-10 0.26 0.33 Platelet count; chr7:100491611 chr7:100336079~100351900:+ LUSC cis rs35955747 0.869 rs5997909 ENSG00000236132.1 CTA-440B3.1 7.45 4.39e-13 3.57e-10 0.39 0.33 Neutrophil count;Sum basophil neutrophil counts; chr22:31195242 chr22:31816379~31817491:- LUSC cis rs9601248 0.841 rs9545146 ENSG00000227676.3 LINC01068 -7.45 4.41e-13 3.58e-10 -0.39 -0.33 Major depressive disorder; chr13:79601471 chr13:79566727~79571436:+ LUSC cis rs4950322 0.57 rs72691012 ENSG00000278811.3 LINC00624 7.45 4.42e-13 3.59e-10 0.36 0.33 Protein quantitative trait loci; chr1:147239751 chr1:147258885~147517875:- LUSC cis rs11089937 0.597 rs4821770 ENSG00000211639.2 IGLV4-60 7.45 4.43e-13 3.6e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22131281 chr22:22162199~22162681:+ LUSC cis rs11089937 0.568 rs4821771 ENSG00000211639.2 IGLV4-60 7.45 4.43e-13 3.6e-10 0.37 0.33 Periodontitis (PAL4Q3); chr22:22131287 chr22:22162199~22162681:+ LUSC cis rs11603023 0.805 rs687190 ENSG00000255239.1 AP002954.6 7.45 4.46e-13 3.62e-10 0.38 0.33 Cholesterol, total; chr11:118671674 chr11:118688039~118690600:- LUSC cis rs5769707 0.521 rs7285764 ENSG00000235111.1 RP1-29C18.8 -7.45 4.47e-13 3.63e-10 -0.41 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49664913 chr22:49612657~49615716:- LUSC cis rs5769707 0.521 rs9616715 ENSG00000235111.1 RP1-29C18.8 -7.45 4.47e-13 3.63e-10 -0.41 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49664934 chr22:49612657~49615716:- LUSC cis rs5769707 0.521 rs6009805 ENSG00000235111.1 RP1-29C18.8 -7.45 4.47e-13 3.63e-10 -0.41 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49665067 chr22:49612657~49615716:- LUSC cis rs5769707 0.521 rs6009807 ENSG00000235111.1 RP1-29C18.8 -7.45 4.47e-13 3.63e-10 -0.41 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49665274 chr22:49612657~49615716:- LUSC cis rs875971 0.862 rs2909688 ENSG00000222364.1 RNU6-96P -7.45 4.5e-13 3.65e-10 -0.39 -0.33 Aortic root size; chr7:66376625 chr7:66395191~66395286:+ LUSC cis rs7945705 0.935 rs10769971 ENSG00000254860.4 TMEM9B-AS1 -7.45 4.5e-13 3.65e-10 -0.36 -0.33 Hemoglobin concentration; chr11:8903729 chr11:8964675~8977527:+ LUSC cis rs2739330 0.76 rs5760095 ENSG00000099984.9 GSTT2 -7.45 4.5e-13 3.65e-10 -0.39 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23980123~23983911:+ LUSC cis rs4713118 0.662 rs149961 ENSG00000204709.4 LINC01556 7.45 4.51e-13 3.66e-10 0.46 0.32 Parkinson's disease; chr6:28047791 chr6:28943877~28944537:+ LUSC cis rs6782228 1 rs7429360 ENSG00000277250.1 Metazoa_SRP 7.45 4.53e-13 3.67e-10 0.4 0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128645954 chr3:128673681~128674021:- LUSC cis rs9487094 0.744 rs11964533 ENSG00000260273.1 RP11-425D10.10 7.45 4.53e-13 3.67e-10 0.43 0.32 Height; chr6:109737797 chr6:109382795~109383666:+ LUSC cis rs10256972 0.869 rs1007766 ENSG00000229043.2 AC091729.9 -7.45 4.53e-13 3.67e-10 -0.37 -0.32 Endometriosis;Longevity; chr7:995267 chr7:1160374~1165267:+ LUSC cis rs7267979 0.789 rs6083810 ENSG00000274973.1 RP13-401N8.7 7.45 4.54e-13 3.68e-10 0.33 0.32 Liver enzyme levels (alkaline phosphatase); chr20:25349123 chr20:25845497~25845862:+ LUSC cis rs8072100 0.967 rs9894905 ENSG00000228782.6 CTD-2026D20.3 7.45 4.55e-13 3.69e-10 0.31 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47408616 chr17:47450568~47492492:- LUSC cis rs9322193 0.962 rs7818 ENSG00000223701.3 RAET1E-AS1 7.45 4.58e-13 3.71e-10 0.36 0.32 Lung cancer; chr6:149810956 chr6:149884431~149919508:+ LUSC cis rs8072100 0.817 rs9905581 ENSG00000228782.6 CTD-2026D20.3 7.45 4.58e-13 3.71e-10 0.32 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469819 chr17:47450568~47492492:- LUSC cis rs10129255 1 rs8012033 ENSG00000280411.1 IGHV1-69-2 -7.45 4.59e-13 3.72e-10 -0.23 -0.32 Kawasaki disease; chr14:106678854 chr14:106762092~106762588:- LUSC cis rs10129255 0.912 rs8011090 ENSG00000280411.1 IGHV1-69-2 -7.45 4.59e-13 3.72e-10 -0.23 -0.32 Kawasaki disease; chr14:106678896 chr14:106762092~106762588:- LUSC cis rs9322193 0.886 rs4039600 ENSG00000223701.3 RAET1E-AS1 7.45 4.6e-13 3.73e-10 0.37 0.32 Lung cancer; chr6:149576319 chr6:149884431~149919508:+ LUSC cis rs875971 0.862 rs7796162 ENSG00000237310.1 GS1-124K5.4 -7.45 4.62e-13 3.74e-10 -0.34 -0.32 Aortic root size; chr7:66280771 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs2901152 ENSG00000237310.1 GS1-124K5.4 -7.45 4.62e-13 3.74e-10 -0.34 -0.32 Aortic root size; chr7:66300017 chr7:66493706~66495474:+ LUSC cis rs2280018 0.609 rs2941253 ENSG00000260735.1 RP11-72I8.1 -7.45 4.64e-13 3.76e-10 -0.39 -0.32 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15079889 chr16:15094411~15109197:+ LUSC cis rs9921338 0.54 rs2868410 ENSG00000263080.1 RP11-485G7.5 7.45 4.65e-13 3.77e-10 0.35 0.32 Vein graft stenosis in coronary artery bypass grafting; chr16:11334244 chr16:11341809~11345211:- LUSC cis rs1075232 1 rs12437749 ENSG00000270055.1 CTD-3092A11.2 -7.45 4.66e-13 3.78e-10 -0.62 -0.32 Survival in colorectal cancer (non-distant metastatic); chr15:31357685 chr15:30487963~30490313:+ LUSC cis rs875971 0.522 rs9530 ENSG00000224316.1 RP11-479O9.2 7.44 4.67e-13 3.78e-10 0.32 0.32 Aortic root size; chr7:65960907 chr7:65773620~65802067:+ LUSC cis rs875971 0.862 rs9791712 ENSG00000222364.1 RNU6-96P 7.44 4.71e-13 3.81e-10 0.39 0.32 Aortic root size; chr7:66640176 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6952182 ENSG00000222364.1 RNU6-96P 7.44 4.72e-13 3.82e-10 0.39 0.32 Aortic root size; chr7:66218330 chr7:66395191~66395286:+ LUSC cis rs8177876 0.749 rs11865207 ENSG00000261838.4 RP11-303E16.6 7.44 4.75e-13 3.85e-10 0.66 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81056055 chr16:81069854~81076598:+ LUSC cis rs5753618 0.504 rs5749295 ENSG00000236132.1 CTA-440B3.1 -7.44 4.78e-13 3.87e-10 -0.43 -0.32 Colorectal cancer; chr22:31536909 chr22:31816379~31817491:- LUSC cis rs11098499 0.675 rs11098534 ENSG00000249244.1 RP11-548H18.2 7.44 4.79e-13 3.88e-10 0.4 0.32 Corneal astigmatism; chr4:119635617 chr4:119391831~119395335:- LUSC cis rs10256972 0.933 rs35696159 ENSG00000229043.2 AC091729.9 -7.44 4.8e-13 3.88e-10 -0.38 -0.32 Endometriosis;Longevity; chr7:1007558 chr7:1160374~1165267:+ LUSC cis rs55794721 0.509 rs873308 ENSG00000224183.1 SDHDP6 7.44 4.81e-13 3.89e-10 0.39 0.32 Mean corpuscular volume;Plateletcrit; chr1:25432164 chr1:25294164~25294643:- LUSC cis rs8040855 0.756 rs12909477 ENSG00000259295.5 CSPG4P12 -7.44 4.83e-13 3.9e-10 -0.41 -0.32 Bulimia nervosa; chr15:85146644 chr15:85191438~85213905:+ LUSC cis rs4950322 0.542 rs3766520 ENSG00000278811.3 LINC00624 7.44 4.83e-13 3.91e-10 0.37 0.32 Protein quantitative trait loci; chr1:147214658 chr1:147258885~147517875:- LUSC cis rs10129255 1 rs61997605 ENSG00000280411.1 IGHV1-69-2 -7.44 4.84e-13 3.92e-10 -0.23 -0.32 Kawasaki disease; chr14:106678368 chr14:106762092~106762588:- LUSC cis rs8031584 0.697 rs798080 ENSG00000260382.1 RP11-540B6.2 -7.44 4.84e-13 3.92e-10 -0.44 -0.32 Huntington's disease progression; chr15:30829966 chr15:30882267~30883231:- LUSC cis rs10129255 0.701 rs2005643 ENSG00000211972.2 IGHV3-66 7.44 4.85e-13 3.92e-10 0.24 0.32 Kawasaki disease; chr14:106676288 chr14:106675017~106675544:- LUSC cis rs875971 0.862 rs709609 ENSG00000237310.1 GS1-124K5.4 -7.44 4.86e-13 3.93e-10 -0.34 -0.32 Aortic root size; chr7:66095574 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs1167399 ENSG00000237310.1 GS1-124K5.4 -7.44 4.86e-13 3.93e-10 -0.34 -0.32 Aortic root size; chr7:66096890 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs57866200 ENSG00000237310.1 GS1-124K5.4 -7.44 4.86e-13 3.93e-10 -0.34 -0.32 Aortic root size; chr7:66100405 chr7:66493706~66495474:+ LUSC cis rs11098499 0.604 rs10022185 ENSG00000245958.5 RP11-33B1.1 -7.44 4.89e-13 3.95e-10 -0.33 -0.32 Corneal astigmatism; chr4:119650610 chr4:119454791~119552025:+ LUSC cis rs10129255 0.957 rs2007467 ENSG00000211972.2 IGHV3-66 -7.44 4.92e-13 3.98e-10 -0.25 -0.32 Kawasaki disease; chr14:106771605 chr14:106675017~106675544:- LUSC cis rs875971 0.862 rs6964437 ENSG00000222364.1 RNU6-96P 7.44 4.93e-13 3.98e-10 0.39 0.32 Aortic root size; chr7:66221457 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs7783779 ENSG00000237310.1 GS1-124K5.4 -7.44 4.95e-13 4e-10 -0.34 -0.32 Aortic root size; chr7:66331639 chr7:66493706~66495474:+ LUSC cis rs11098499 0.82 rs13122709 ENSG00000250412.1 KLHL2P1 7.44 4.96e-13 4.01e-10 0.41 0.32 Corneal astigmatism; chr4:119634201 chr4:119334329~119378233:+ LUSC cis rs17711722 1 rs17711722 ENSG00000224316.1 RP11-479O9.2 -7.44 4.97e-13 4.02e-10 -0.31 -0.32 Calcium levels; chr7:65806210 chr7:65773620~65802067:+ LUSC cis rs1113500 0.524 rs12145813 ENSG00000226822.1 RP11-356N1.2 7.44 4.99e-13 4.03e-10 0.37 0.32 Growth-regulated protein alpha levels; chr1:108027282 chr1:108071482~108074519:+ LUSC cis rs35160687 0.871 rs2278105 ENSG00000273080.1 RP11-301O19.1 7.43 5.01e-13 4.04e-10 0.31 0.32 Night sleep phenotypes; chr2:86239393 chr2:86195590~86196049:+ LUSC cis rs34779708 0.931 rs59418206 ENSG00000230534.5 RP11-297A16.2 7.43 5.03e-13 4.06e-10 0.37 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35042696 chr10:35098006~35127020:- LUSC cis rs904251 0.522 rs882322 ENSG00000204110.6 RP1-153P14.8 -7.43 5.05e-13 4.07e-10 -0.31 -0.32 Cognitive performance; chr6:37516327 chr6:37507348~37535616:+ LUSC cis rs2739330 0.791 rs9612520 ENSG00000099984.9 GSTT2 -7.43 5.05e-13 4.07e-10 -0.39 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23980123~23983911:+ LUSC cis rs875971 0.522 rs709604 ENSG00000224316.1 RP11-479O9.2 -7.43 5.07e-13 4.09e-10 -0.31 -0.32 Aortic root size; chr7:66032447 chr7:65773620~65802067:+ LUSC cis rs7617773 0.779 rs11718329 ENSG00000228638.1 FCF1P2 -7.43 5.09e-13 4.11e-10 -0.38 -0.32 Coronary artery disease; chr3:48268338 chr3:48290793~48291375:- LUSC cis rs35955747 0.902 rs4820961 ENSG00000236132.1 CTA-440B3.1 7.43 5.12e-13 4.13e-10 0.38 0.32 Neutrophil count;Sum basophil neutrophil counts; chr22:31283463 chr22:31816379~31817491:- LUSC cis rs7811142 0.83 rs76798830 ENSG00000242294.5 STAG3L5P 7.43 5.13e-13 4.14e-10 0.28 0.32 Platelet count; chr7:100355205 chr7:100336079~100351900:+ LUSC cis rs801193 0.569 rs6978178 ENSG00000237310.1 GS1-124K5.4 -7.43 5.14e-13 4.15e-10 -0.34 -0.32 Aortic root size; chr7:66658097 chr7:66493706~66495474:+ LUSC cis rs4853012 0.838 rs12619982 ENSG00000257800.1 FNBP1P1 7.43 5.14e-13 4.15e-10 0.39 0.32 Gestational age at birth (maternal effect); chr2:74128895 chr2:74120680~74123218:+ LUSC cis rs2019137 0.936 rs902696 ENSG00000189223.12 PAX8-AS1 -7.43 5.15e-13 4.16e-10 -0.42 -0.32 Lymphocyte counts; chr2:113197302 chr2:113211522~113276581:+ LUSC cis rs2297363 0.841 rs13220323 ENSG00000213073.4 RP11-288H12.3 -7.43 5.16e-13 4.16e-10 -0.41 -0.32 Total cholesterol levels;Blood protein levels; chr6:160085723 chr6:160093082~160096212:+ LUSC cis rs6471393 0.83 rs57803852 ENSG00000253848.1 RP11-10N23.5 7.43 5.16e-13 4.16e-10 0.42 0.32 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93761156 chr8:93741193~93744534:+ LUSC cis rs4141404 0.818 rs5997897 ENSG00000236132.1 CTA-440B3.1 7.43 5.17e-13 4.17e-10 0.4 0.32 Paclitaxel-induced neuropathy; chr22:31174450 chr22:31816379~31817491:- LUSC cis rs853679 0.567 rs16894091 ENSG00000216901.1 AL022393.7 -7.43 5.21e-13 4.2e-10 -0.42 -0.32 Depression; chr6:28422360 chr6:28176188~28176674:+ LUSC cis rs7945705 0.935 rs2653567 ENSG00000254860.4 TMEM9B-AS1 7.43 5.23e-13 4.21e-10 0.36 0.32 Hemoglobin concentration; chr11:8868083 chr11:8964675~8977527:+ LUSC cis rs6142102 0.961 rs2268089 ENSG00000276073.1 RP5-1125A11.7 -7.43 5.24e-13 4.22e-10 -0.34 -0.32 Skin pigmentation; chr20:34079492 chr20:33985617~33988989:- LUSC cis rs992157 0.71 rs10167446 ENSG00000261338.2 RP11-378A13.1 7.43 5.24e-13 4.22e-10 0.33 0.32 Colorectal cancer; chr2:218192143 chr2:218255319~218257366:+ LUSC cis rs13113518 0.812 rs11945371 ENSG00000223305.1 RN7SKP30 7.43 5.25e-13 4.23e-10 0.39 0.32 Height; chr4:55409063 chr4:55540502~55540835:- LUSC cis rs875971 0.862 rs9791713 ENSG00000222364.1 RNU6-96P 7.43 5.25e-13 4.23e-10 0.39 0.32 Aortic root size; chr7:66640211 chr7:66395191~66395286:+ LUSC cis rs465969 1 rs34382476 ENSG00000255389.1 C6orf3 -7.43 5.26e-13 4.24e-10 -0.6 -0.32 Psoriasis; chr6:111423551 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs17090837 ENSG00000255389.1 C6orf3 -7.43 5.26e-13 4.24e-10 -0.6 -0.32 Psoriasis; chr6:111430650 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs35208445 ENSG00000255389.1 C6orf3 -7.43 5.26e-13 4.24e-10 -0.6 -0.32 Psoriasis; chr6:111434944 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs35248830 ENSG00000255389.1 C6orf3 -7.43 5.26e-13 4.24e-10 -0.6 -0.32 Psoriasis; chr6:111435547 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs35151650 ENSG00000255389.1 C6orf3 -7.43 5.26e-13 4.24e-10 -0.6 -0.32 Psoriasis; chr6:111436524 chr6:111599875~111602295:+ LUSC cis rs465969 0.744 rs34089926 ENSG00000255389.1 C6orf3 -7.43 5.26e-13 4.24e-10 -0.6 -0.32 Psoriasis; chr6:111439043 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs4580915 ENSG00000255389.1 C6orf3 -7.43 5.26e-13 4.24e-10 -0.6 -0.32 Psoriasis; chr6:111439561 chr6:111599875~111602295:+ LUSC cis rs10740039 0.804 rs1837950 ENSG00000254271.1 RP11-131N11.4 -7.43 5.27e-13 4.24e-10 -0.44 -0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60685207 chr10:60734342~60741828:+ LUSC cis rs10129255 1 rs8010605 ENSG00000280411.1 IGHV1-69-2 -7.43 5.27e-13 4.25e-10 -0.23 -0.32 Kawasaki disease; chr14:106678742 chr14:106762092~106762588:- LUSC cis rs17711722 0.675 rs6947132 ENSG00000224316.1 RP11-479O9.2 -7.43 5.28e-13 4.25e-10 -0.31 -0.32 Calcium levels; chr7:65808508 chr7:65773620~65802067:+ LUSC cis rs17023223 0.537 rs3936018 ENSG00000231365.4 RP11-418J17.1 -7.43 5.29e-13 4.26e-10 -0.44 -0.32 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119139747 chr1:119140396~119275973:+ LUSC cis rs801193 0.569 rs7800620 ENSG00000222364.1 RNU6-96P -7.43 5.29e-13 4.26e-10 -0.39 -0.32 Aortic root size; chr7:66758701 chr7:66395191~66395286:+ LUSC cis rs7617773 0.925 rs6442105 ENSG00000228638.1 FCF1P2 7.43 5.29e-13 4.26e-10 0.38 0.32 Coronary artery disease; chr3:48140836 chr3:48290793~48291375:- LUSC cis rs673078 0.607 rs4767669 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118390651 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs4767670 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118390737 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs950288 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118392201 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943399 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118393628 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs7137055 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118395030 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs7137184 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118395163 chr12:118428281~118428870:+ LUSC cis rs673078 0.562 rs4767672 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118397048 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs73205594 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118397168 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943400 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118398236 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943401 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118398527 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943402 ENSG00000275759.1 RP11-131L12.3 -7.43 5.3e-13 4.27e-10 -0.47 -0.32 Glucose homeostasis traits; chr12:118398808 chr12:118428281~118428870:+ LUSC cis rs875971 0.895 rs6460278 ENSG00000222364.1 RNU6-96P 7.43 5.32e-13 4.28e-10 0.39 0.32 Aortic root size; chr7:66197749 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs6460279 ENSG00000222364.1 RNU6-96P 7.43 5.32e-13 4.28e-10 0.39 0.32 Aortic root size; chr7:66197774 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs28491091 ENSG00000222364.1 RNU6-96P 7.43 5.32e-13 4.28e-10 0.39 0.32 Aortic root size; chr7:66204077 chr7:66395191~66395286:+ LUSC cis rs9318086 0.712 rs1886970 ENSG00000205861.10 C1QTNF9B-AS1 -7.43 5.34e-13 4.3e-10 -0.41 -0.32 Myopia (pathological); chr13:23866359 chr13:23888889~23897263:+ LUSC cis rs8177876 0.749 rs804885 ENSG00000261838.4 RP11-303E16.6 -7.42 5.39e-13 4.33e-10 -0.65 -0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81061758 chr16:81069854~81076598:+ LUSC cis rs17711722 1 rs17711722 ENSG00000236529.1 RP13-254B10.1 -7.42 5.39e-13 4.34e-10 -0.34 -0.32 Calcium levels; chr7:65806210 chr7:65840212~65840596:+ LUSC cis rs11098499 0.644 rs34835603 ENSG00000249244.1 RP11-548H18.2 7.42 5.42e-13 4.36e-10 0.4 0.32 Corneal astigmatism; chr4:119632273 chr4:119391831~119395335:- LUSC cis rs11098499 0.615 rs28850368 ENSG00000249244.1 RP11-548H18.2 7.42 5.42e-13 4.36e-10 0.4 0.32 Corneal astigmatism; chr4:119633158 chr4:119391831~119395335:- LUSC cis rs66887589 0.616 rs7659403 ENSG00000245958.5 RP11-33B1.1 -7.42 5.44e-13 4.38e-10 -0.31 -0.32 Diastolic blood pressure; chr4:119286099 chr4:119454791~119552025:+ LUSC cis rs7945705 0.875 rs2568065 ENSG00000254860.4 TMEM9B-AS1 7.42 5.46e-13 4.39e-10 0.35 0.32 Hemoglobin concentration; chr11:8868101 chr11:8964675~8977527:+ LUSC cis rs875971 0.522 rs4502988 ENSG00000236529.1 RP13-254B10.1 7.42 5.46e-13 4.39e-10 0.33 0.32 Aortic root size; chr7:65832759 chr7:65840212~65840596:+ LUSC cis rs2188561 1 rs2188561 ENSG00000241764.3 AC002467.7 7.42 5.47e-13 4.4e-10 0.44 0.32 Alcohol consumption; chr7:107695613 chr7:107742817~107744581:- LUSC cis rs875971 0.862 rs10250544 ENSG00000237310.1 GS1-124K5.4 -7.42 5.48e-13 4.4e-10 -0.34 -0.32 Aortic root size; chr7:66301574 chr7:66493706~66495474:+ LUSC cis rs9322193 0.926 rs9766562 ENSG00000223701.3 RAET1E-AS1 7.42 5.48e-13 4.41e-10 0.38 0.32 Lung cancer; chr6:149788709 chr6:149884431~149919508:+ LUSC cis rs673078 0.607 rs17440893 ENSG00000275759.1 RP11-131L12.3 -7.42 5.52e-13 4.44e-10 -0.46 -0.32 Glucose homeostasis traits; chr12:118362532 chr12:118428281~118428870:+ LUSC cis rs17507216 1 rs17158413 ENSG00000255769.6 GOLGA2P10 -7.42 5.52e-13 4.44e-10 -0.45 -0.32 Excessive daytime sleepiness; chr15:82566658 chr15:82472993~82513950:- LUSC cis rs875971 0.862 rs1167408 ENSG00000222364.1 RNU6-96P 7.42 5.53e-13 4.44e-10 0.39 0.32 Aortic root size; chr7:66091121 chr7:66395191~66395286:+ LUSC cis rs875971 0.83 rs1167406 ENSG00000222364.1 RNU6-96P 7.42 5.53e-13 4.44e-10 0.39 0.32 Aortic root size; chr7:66091949 chr7:66395191~66395286:+ LUSC cis rs17711722 0.727 rs2658585 ENSG00000224316.1 RP11-479O9.2 7.42 5.53e-13 4.44e-10 0.31 0.32 Calcium levels; chr7:65996954 chr7:65773620~65802067:+ LUSC cis rs11098499 0.863 rs1552095 ENSG00000250412.1 KLHL2P1 7.42 5.56e-13 4.46e-10 0.42 0.32 Corneal astigmatism; chr4:119539151 chr4:119334329~119378233:+ LUSC cis rs10129255 0.913 rs10140943 ENSG00000280411.1 IGHV1-69-2 -7.42 5.56e-13 4.47e-10 -0.23 -0.32 Kawasaki disease; chr14:106767441 chr14:106762092~106762588:- LUSC cis rs367615 0.552 rs3828603 ENSG00000249476.1 CTD-2587M2.1 -7.42 5.58e-13 4.48e-10 -0.37 -0.32 Colorectal cancer (SNP x SNP interaction); chr5:109376367 chr5:109237120~109326369:- LUSC cis rs17711722 0.64 rs13237956 ENSG00000224316.1 RP11-479O9.2 7.42 5.59e-13 4.49e-10 0.31 0.32 Calcium levels; chr7:65853042 chr7:65773620~65802067:+ LUSC cis rs10129255 0.957 rs10136817 ENSG00000211972.2 IGHV3-66 7.42 5.6e-13 4.5e-10 0.25 0.32 Kawasaki disease; chr14:106787730 chr14:106675017~106675544:- LUSC cis rs10129255 1 rs11621409 ENSG00000280411.1 IGHV1-69-2 -7.42 5.61e-13 4.5e-10 -0.23 -0.32 Kawasaki disease; chr14:106695603 chr14:106762092~106762588:- LUSC cis rs11098499 0.954 rs12510138 ENSG00000249244.1 RP11-548H18.2 7.42 5.62e-13 4.51e-10 0.42 0.32 Corneal astigmatism; chr4:119502780 chr4:119391831~119395335:- LUSC cis rs760794 0.765 rs7759616 ENSG00000227116.1 RP3-471C18.1 -7.42 5.63e-13 4.52e-10 -0.36 -0.32 Endometriosis; chr6:19794354 chr6:19730427~19734567:- LUSC cis rs494459 0.536 rs10790267 ENSG00000255422.1 AP002954.4 -7.42 5.64e-13 4.53e-10 -0.35 -0.32 Height; chr11:118856460 chr11:118704607~118750263:+ LUSC cis rs494459 0.536 rs11217067 ENSG00000255422.1 AP002954.4 -7.42 5.64e-13 4.53e-10 -0.35 -0.32 Height; chr11:118856623 chr11:118704607~118750263:+ LUSC cis rs10256972 0.967 rs4723338 ENSG00000229043.2 AC091729.9 -7.42 5.64e-13 4.53e-10 -0.37 -0.32 Endometriosis;Longevity; chr7:996605 chr7:1160374~1165267:+ LUSC cis rs10129255 0.646 rs55995061 ENSG00000224373.3 IGHV4-59 7.42 5.65e-13 4.54e-10 0.18 0.32 Kawasaki disease; chr14:106799309 chr14:106627249~106627825:- LUSC cis rs875971 0.862 rs10276077 ENSG00000237310.1 GS1-124K5.4 -7.42 5.65e-13 4.54e-10 -0.34 -0.32 Aortic root size; chr7:66263424 chr7:66493706~66495474:+ LUSC cis rs1865760 1 rs7770139 ENSG00000272462.2 U91328.19 -7.42 5.66e-13 4.55e-10 -0.35 -0.32 Height; chr6:25925595 chr6:25992662~26001775:+ LUSC cis rs783540 0.521 rs1259176 ENSG00000276710.3 CSPG4P8 7.42 5.66e-13 4.55e-10 0.39 0.32 Schizophrenia; chr15:82602149 chr15:82459472~82477258:+ LUSC cis rs7267979 0.789 rs6083820 ENSG00000274973.1 RP13-401N8.7 7.42 5.69e-13 4.56e-10 0.33 0.32 Liver enzyme levels (alkaline phosphatase); chr20:25373542 chr20:25845497~25845862:+ LUSC cis rs853679 0.55 rs1237875 ENSG00000204709.4 LINC01556 -7.42 5.69e-13 4.56e-10 -0.45 -0.32 Depression; chr6:28205232 chr6:28943877~28944537:+ LUSC cis rs17711722 0.675 rs6947132 ENSG00000236529.1 RP13-254B10.1 -7.42 5.69e-13 4.57e-10 -0.34 -0.32 Calcium levels; chr7:65808508 chr7:65840212~65840596:+ LUSC cis rs11089937 0.512 rs13054756 ENSG00000211639.2 IGLV4-60 7.42 5.7e-13 4.58e-10 0.37 0.32 Periodontitis (PAL4Q3); chr22:22130948 chr22:22162199~22162681:+ LUSC cis rs11089937 0.597 rs4821768 ENSG00000211639.2 IGLV4-60 7.42 5.7e-13 4.58e-10 0.37 0.32 Periodontitis (PAL4Q3); chr22:22131047 chr22:22162199~22162681:+ LUSC cis rs875971 0.516 rs6945322 ENSG00000236529.1 RP13-254B10.1 7.42 5.72e-13 4.59e-10 0.33 0.32 Aortic root size; chr7:65871069 chr7:65840212~65840596:+ LUSC cis rs875971 0.516 rs6945322 ENSG00000224316.1 RP11-479O9.2 7.41 5.74e-13 4.6e-10 0.31 0.32 Aortic root size; chr7:65871069 chr7:65773620~65802067:+ LUSC cis rs2179367 0.613 rs62426122 ENSG00000231760.4 RP11-350J20.5 7.41 5.78e-13 4.64e-10 0.44 0.32 Dupuytren's disease; chr6:149427449 chr6:149796151~149826294:- LUSC cis rs801193 0.569 rs4717315 ENSG00000222364.1 RNU6-96P -7.41 5.8e-13 4.65e-10 -0.39 -0.32 Aortic root size; chr7:66713338 chr7:66395191~66395286:+ LUSC cis rs1185460 0.565 rs10892325 ENSG00000271751.1 RP11-110I1.14 7.41 5.8e-13 4.65e-10 0.41 0.32 Coronary artery disease; chr11:119041992 chr11:119065263~119065677:- LUSC cis rs875971 0.505 rs6955582 ENSG00000224316.1 RP11-479O9.2 7.41 5.82e-13 4.66e-10 0.31 0.32 Aortic root size; chr7:65966699 chr7:65773620~65802067:+ LUSC cis rs9545047 0.716 rs9545108 ENSG00000227676.3 LINC01068 7.41 5.83e-13 4.67e-10 0.4 0.32 Schizophrenia; chr13:79411175 chr13:79566727~79571436:+ LUSC cis rs7849270 0.801 rs10819474 ENSG00000268707.1 RP11-247A12.7 -7.41 5.84e-13 4.68e-10 -0.37 -0.32 Blood metabolite ratios; chr9:129168215 chr9:129170434~129170940:+ LUSC cis rs875971 0.54 rs1723268 ENSG00000224316.1 RP11-479O9.2 7.41 5.85e-13 4.69e-10 0.31 0.32 Aortic root size; chr7:66008093 chr7:65773620~65802067:+ LUSC cis rs131777 0.575 rs131760 ENSG00000205559.3 CHKB-AS1 -7.41 5.86e-13 4.7e-10 -0.41 -0.32 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50573507 chr22:50583026~50583877:+ LUSC cis rs8062405 0.755 rs1074631 ENSG00000259982.1 CDC37P1 -7.41 5.89e-13 4.72e-10 -0.41 -0.32 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28542787 chr16:28700294~28701540:- LUSC cis rs10829156 0.625 rs7082235 ENSG00000240291.1 RP11-499P20.2 7.41 5.9e-13 4.73e-10 0.34 0.32 Sudden cardiac arrest; chr10:18536765 chr10:18513115~18545651:- LUSC cis rs2581828 0.659 rs4282053 ENSG00000242142.1 SERBP1P3 -7.41 5.91e-13 4.73e-10 -0.37 -0.32 Crohn's disease; chr3:53107949 chr3:53064283~53065091:- LUSC cis rs2581828 0.659 rs9845352 ENSG00000242142.1 SERBP1P3 -7.41 5.91e-13 4.73e-10 -0.37 -0.32 Crohn's disease; chr3:53108205 chr3:53064283~53065091:- LUSC cis rs2581828 0.659 rs9845484 ENSG00000242142.1 SERBP1P3 -7.41 5.91e-13 4.73e-10 -0.37 -0.32 Crohn's disease; chr3:53108240 chr3:53064283~53065091:- LUSC cis rs17711722 0.585 rs6942660 ENSG00000236529.1 RP13-254B10.1 7.41 5.91e-13 4.74e-10 0.33 0.32 Calcium levels; chr7:65837419 chr7:65840212~65840596:+ LUSC cis rs2510897 0.675 rs4936442 ENSG00000255422.1 AP002954.4 -7.41 5.93e-13 4.75e-10 -0.35 -0.32 Height; chr11:118857611 chr11:118704607~118750263:+ LUSC cis rs35160687 0.901 rs12472390 ENSG00000273080.1 RP11-301O19.1 7.41 5.95e-13 4.77e-10 0.31 0.32 Night sleep phenotypes; chr2:86247960 chr2:86195590~86196049:+ LUSC cis rs35160687 0.865 rs10189492 ENSG00000273080.1 RP11-301O19.1 7.41 5.97e-13 4.78e-10 0.31 0.32 Night sleep phenotypes; chr2:86251779 chr2:86195590~86196049:+ LUSC cis rs6867032 0.527 rs4975777 ENSG00000249731.1 RP11-259O2.3 -7.41 5.98e-13 4.78e-10 -0.39 -0.32 Gut microbiome composition (winter); chr5:1973210 chr5:1968094~1969013:+ LUSC cis rs801193 0.569 rs13242290 ENSG00000237310.1 GS1-124K5.4 -7.41 6e-13 4.8e-10 -0.34 -0.32 Aortic root size; chr7:66656898 chr7:66493706~66495474:+ LUSC cis rs9322193 0.566 rs5024811 ENSG00000223701.3 RAET1E-AS1 -7.41 6.02e-13 4.81e-10 -0.41 -0.32 Lung cancer; chr6:149924898 chr6:149884431~149919508:+ LUSC cis rs9487094 1 rs10080429 ENSG00000260273.1 RP11-425D10.10 7.41 6.02e-13 4.81e-10 0.39 0.32 Height; chr6:109416903 chr6:109382795~109383666:+ LUSC cis rs875971 0.522 rs4718285 ENSG00000224316.1 RP11-479O9.2 7.41 6.06e-13 4.85e-10 0.31 0.32 Aortic root size; chr7:65827018 chr7:65773620~65802067:+ LUSC cis rs440932 0.717 rs330944 ENSG00000254340.1 RP11-10A14.3 7.41 6.07e-13 4.85e-10 0.39 0.32 High light scatter reticulocyte percentage of red cells; chr8:9163783 chr8:9141424~9145435:+ LUSC cis rs6142102 0.961 rs6119447 ENSG00000276073.1 RP5-1125A11.7 -7.41 6.07e-13 4.85e-10 -0.34 -0.32 Skin pigmentation; chr20:34080770 chr20:33985617~33988989:- LUSC cis rs7044106 0.708 rs1324472 ENSG00000226752.6 PSMD5-AS1 -7.41 6.07e-13 4.86e-10 -0.36 -0.32 Hip circumference adjusted for BMI; chr9:120612832 chr9:120824828~120854385:+ LUSC cis rs9487094 0.645 rs34292461 ENSG00000260273.1 RP11-425D10.10 7.41 6.08e-13 4.86e-10 0.44 0.32 Height; chr6:109352277 chr6:109382795~109383666:+ LUSC cis rs2282300 0.739 rs1765139 ENSG00000254532.1 RP11-624D11.2 7.41 6.09e-13 4.86e-10 0.44 0.32 Morning vs. evening chronotype; chr11:30332178 chr11:30044058~30084343:- LUSC cis rs875971 0.522 rs4718286 ENSG00000236529.1 RP13-254B10.1 7.41 6.09e-13 4.87e-10 0.33 0.32 Aortic root size; chr7:65827777 chr7:65840212~65840596:+ LUSC cis rs9322193 0.962 rs35031906 ENSG00000223701.3 RAET1E-AS1 7.4 6.13e-13 4.9e-10 0.37 0.32 Lung cancer; chr6:149677438 chr6:149884431~149919508:+ LUSC cis rs2510897 0.675 rs4936442 ENSG00000255239.1 AP002954.6 7.4 6.14e-13 4.9e-10 0.36 0.32 Height; chr11:118857611 chr11:118688039~118690600:- LUSC cis rs465969 0.744 rs574056 ENSG00000255389.1 C6orf3 -7.4 6.14e-13 4.9e-10 -0.65 -0.32 Psoriasis; chr6:111305787 chr6:111599875~111602295:+ LUSC cis rs494459 0.536 rs57719838 ENSG00000255422.1 AP002954.4 -7.4 6.15e-13 4.91e-10 -0.34 -0.32 Height; chr11:118854014 chr11:118704607~118750263:+ LUSC cis rs1075232 1 rs12437749 ENSG00000215302.7 CTD-3092A11.1 -7.4 6.15e-13 4.91e-10 -0.69 -0.32 Survival in colorectal cancer (non-distant metastatic); chr15:31357685 chr15:30470779~30507623:+ LUSC cis rs875971 0.862 rs1968126 ENSG00000237310.1 GS1-124K5.4 -7.4 6.16e-13 4.92e-10 -0.34 -0.32 Aortic root size; chr7:66592017 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6460306 ENSG00000237310.1 GS1-124K5.4 -7.4 6.16e-13 4.92e-10 -0.34 -0.32 Aortic root size; chr7:66595806 chr7:66493706~66495474:+ LUSC cis rs34779708 0.931 rs11597392 ENSG00000230534.5 RP11-297A16.2 7.4 6.17e-13 4.93e-10 0.37 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34999647 chr10:35098006~35127020:- LUSC cis rs6867032 0.527 rs4246752 ENSG00000249731.1 RP11-259O2.3 -7.4 6.17e-13 4.93e-10 -0.39 -0.32 Gut microbiome composition (winter); chr5:1975461 chr5:1968094~1969013:+ LUSC cis rs10170846 0.8 rs10194743 ENSG00000261428.2 RP11-16P6.1 7.4 6.2e-13 4.95e-10 0.38 0.32 Schizophrenia (inflammation and infection response interaction); chr2:222653432 chr2:222566899~222569719:- LUSC cis rs2179367 0.887 rs2143076 ENSG00000231760.4 RP11-350J20.5 7.4 6.23e-13 4.97e-10 0.41 0.32 Dupuytren's disease; chr6:149425315 chr6:149796151~149826294:- LUSC cis rs34779708 0.931 rs2148482 ENSG00000230534.5 RP11-297A16.2 7.4 6.24e-13 4.98e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35059982 chr10:35098006~35127020:- LUSC cis rs950169 0.887 rs220333 ENSG00000259728.4 LINC00933 7.4 6.24e-13 4.98e-10 0.41 0.32 Schizophrenia; chr15:84547902 chr15:84570649~84580175:+ LUSC cis rs11098499 0.604 rs34278750 ENSG00000245958.5 RP11-33B1.1 -7.4 6.25e-13 4.99e-10 -0.33 -0.32 Corneal astigmatism; chr4:119649981 chr4:119454791~119552025:+ LUSC cis rs12439619 1 rs35152457 ENSG00000276710.3 CSPG4P8 -7.4 6.29e-13 5.02e-10 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82254207 chr15:82459472~82477258:+ LUSC cis rs2404602 0.684 rs2454451 ENSG00000259422.1 RP11-593F23.1 7.4 6.29e-13 5.02e-10 0.38 0.32 Blood metabolite levels; chr15:76569120 chr15:76174891~76181486:- LUSC cis rs172166 0.637 rs1233708 ENSG00000204709.4 LINC01556 7.4 6.31e-13 5.04e-10 0.41 0.32 Cardiac Troponin-T levels; chr6:28205441 chr6:28943877~28944537:+ LUSC cis rs528808 1 rs528808 ENSG00000279170.1 RP1-199J3.6 7.4 6.32e-13 5.05e-10 0.47 0.32 Age-related hearing impairment; chr6:99656413 chr6:99587611~99589898:+ LUSC cis rs34779708 0.931 rs10466072 ENSG00000230534.5 RP11-297A16.2 7.4 6.35e-13 5.07e-10 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35113828 chr10:35098006~35127020:- LUSC cis rs11763147 1 rs11763147 ENSG00000224316.1 RP11-479O9.2 -7.4 6.35e-13 5.07e-10 -0.31 -0.32 Corneal structure; chr7:65861834 chr7:65773620~65802067:+ LUSC cis rs6142102 0.961 rs6087557 ENSG00000276073.1 RP5-1125A11.7 -7.4 6.35e-13 5.07e-10 -0.34 -0.32 Skin pigmentation; chr20:34110469 chr20:33985617~33988989:- LUSC cis rs875971 0.825 rs59466412 ENSG00000237310.1 GS1-124K5.4 -7.4 6.37e-13 5.08e-10 -0.34 -0.32 Aortic root size; chr7:66100371 chr7:66493706~66495474:+ LUSC cis rs4713118 0.866 rs9468217 ENSG00000219392.1 RP1-265C24.5 -7.4 6.4e-13 5.1e-10 -0.44 -0.32 Parkinson's disease; chr6:27758688 chr6:28115628~28116551:+ LUSC cis rs2019137 0.967 rs902695 ENSG00000189223.12 PAX8-AS1 7.4 6.43e-13 5.13e-10 0.42 0.32 Lymphocyte counts; chr2:113197497 chr2:113211522~113276581:+ LUSC cis rs1061377 0.748 rs12649085 ENSG00000249207.1 RP11-360F5.1 -7.4 6.44e-13 5.13e-10 -0.35 -0.32 Uric acid levels; chr4:39106459 chr4:39112677~39126818:- LUSC cis rs875971 0.54 rs736270 ENSG00000236529.1 RP13-254B10.1 7.4 6.48e-13 5.16e-10 0.34 0.32 Aortic root size; chr7:65963835 chr7:65840212~65840596:+ LUSC cis rs11098499 0.78 rs7692994 ENSG00000249244.1 RP11-548H18.2 7.4 6.49e-13 5.17e-10 0.4 0.32 Corneal astigmatism; chr4:119506334 chr4:119391831~119395335:- LUSC cis rs1061377 1 rs6829450 ENSG00000249207.1 RP11-360F5.1 -7.4 6.52e-13 5.19e-10 -0.35 -0.32 Uric acid levels; chr4:39114721 chr4:39112677~39126818:- LUSC cis rs801193 0.591 rs4506088 ENSG00000222364.1 RNU6-96P 7.4 6.53e-13 5.2e-10 0.39 0.32 Aortic root size; chr7:66670470 chr7:66395191~66395286:+ LUSC cis rs10129255 0.957 rs28887506 ENSG00000211972.2 IGHV3-66 7.4 6.54e-13 5.21e-10 0.24 0.32 Kawasaki disease; chr14:106785589 chr14:106675017~106675544:- LUSC cis rs1075265 0.875 rs12616212 ENSG00000233266.1 HMGB1P31 7.39 6.55e-13 5.21e-10 0.41 0.32 Chronotype;Morning vs. evening chronotype; chr2:54039109 chr2:54051334~54051760:+ LUSC cis rs2188561 0.638 rs3735609 ENSG00000241764.3 AC002467.7 7.39 6.56e-13 5.23e-10 0.42 0.32 Alcohol consumption; chr7:107743299 chr7:107742817~107744581:- LUSC cis rs6142102 0.602 rs2268079 ENSG00000276073.1 RP5-1125A11.7 -7.39 6.57e-13 5.23e-10 -0.32 -0.32 Skin pigmentation; chr20:34008944 chr20:33985617~33988989:- LUSC cis rs34779708 0.931 rs34304999 ENSG00000230534.5 RP11-297A16.2 7.39 6.57e-13 5.23e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35076777 chr10:35098006~35127020:- LUSC cis rs3813579 0.654 rs4480821 ENSG00000261390.4 RP11-345M22.2 -7.39 6.58e-13 5.24e-10 -0.39 -0.32 Thyroid volume; chr16:79711416 chr16:79715232~79770563:- LUSC cis rs526231 0.578 rs35100629 ENSG00000175749.11 EIF3KP1 7.39 6.59e-13 5.25e-10 0.39 0.32 Primary biliary cholangitis; chr5:102910381 chr5:103032376~103033031:+ LUSC cis rs11098499 0.863 rs13136462 ENSG00000250412.1 KLHL2P1 7.39 6.6e-13 5.25e-10 0.4 0.32 Corneal astigmatism; chr4:119622018 chr4:119334329~119378233:+ LUSC cis rs801193 0.569 rs11772819 ENSG00000222364.1 RNU6-96P -7.39 6.6e-13 5.25e-10 -0.39 -0.32 Aortic root size; chr7:66752983 chr7:66395191~66395286:+ LUSC cis rs4950322 0.57 rs4593887 ENSG00000278811.3 LINC00624 7.39 6.63e-13 5.28e-10 0.36 0.32 Protein quantitative trait loci; chr1:147234246 chr1:147258885~147517875:- LUSC cis rs7621025 0.5 rs71630059 ENSG00000239213.4 NCK1-AS1 -7.39 6.63e-13 5.28e-10 -0.42 -0.32 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136862769 chr3:136841726~136862054:- LUSC cis rs9322193 0.923 rs12175504 ENSG00000223701.3 RAET1E-AS1 7.39 6.67e-13 5.3e-10 0.37 0.32 Lung cancer; chr6:149664079 chr6:149884431~149919508:+ LUSC cis rs9322193 0.962 rs62439843 ENSG00000223701.3 RAET1E-AS1 7.39 6.67e-13 5.3e-10 0.37 0.32 Lung cancer; chr6:149676521 chr6:149884431~149919508:+ LUSC cis rs875971 0.825 rs28480509 ENSG00000222364.1 RNU6-96P 7.39 6.67e-13 5.3e-10 0.39 0.32 Aortic root size; chr7:66634237 chr7:66395191~66395286:+ LUSC cis rs783540 0.542 rs62009945 ENSG00000255769.6 GOLGA2P10 7.39 6.68e-13 5.31e-10 0.43 0.32 Schizophrenia; chr15:82631205 chr15:82472993~82513950:- LUSC cis rs875971 0.522 rs34973832 ENSG00000224316.1 RP11-479O9.2 7.39 6.69e-13 5.32e-10 0.31 0.32 Aortic root size; chr7:65931217 chr7:65773620~65802067:+ LUSC cis rs1930961 1 rs6004673 ENSG00000100058.11 CRYBB2P1 7.39 6.71e-13 5.33e-10 0.57 0.32 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25448105~25520854:+ LUSC cis rs17023223 0.537 rs10923754 ENSG00000231365.4 RP11-418J17.1 -7.39 6.71e-13 5.34e-10 -0.41 -0.32 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119126017 chr1:119140396~119275973:+ LUSC cis rs6142102 1 rs4911409 ENSG00000276073.1 RP5-1125A11.7 -7.39 6.71e-13 5.34e-10 -0.33 -0.32 Skin pigmentation; chr20:34122904 chr20:33985617~33988989:- LUSC cis rs6142102 0.961 rs4911411 ENSG00000276073.1 RP5-1125A11.7 -7.39 6.71e-13 5.34e-10 -0.33 -0.32 Skin pigmentation; chr20:34128036 chr20:33985617~33988989:- LUSC cis rs10129255 0.957 rs8009948 ENSG00000280411.1 IGHV1-69-2 -7.39 6.75e-13 5.36e-10 -0.23 -0.32 Kawasaki disease; chr14:106805607 chr14:106762092~106762588:- LUSC cis rs11098499 0.566 rs7664440 ENSG00000245958.5 RP11-33B1.1 -7.39 6.75e-13 5.37e-10 -0.33 -0.32 Corneal astigmatism; chr4:119657385 chr4:119454791~119552025:+ LUSC cis rs35160687 0.901 rs12620833 ENSG00000273080.1 RP11-301O19.1 7.39 6.76e-13 5.37e-10 0.31 0.32 Night sleep phenotypes; chr2:86245747 chr2:86195590~86196049:+ LUSC cis rs7945705 0.902 rs2012696 ENSG00000254860.4 TMEM9B-AS1 -7.39 6.78e-13 5.39e-10 -0.35 -0.32 Hemoglobin concentration; chr11:8974271 chr11:8964675~8977527:+ LUSC cis rs3091242 0.933 rs7541095 ENSG00000224183.1 SDHDP6 -7.39 6.8e-13 5.4e-10 -0.39 -0.32 Erythrocyte sedimentation rate; chr1:25434800 chr1:25294164~25294643:- LUSC cis rs17482078 0.959 rs71630754 ENSG00000248734.2 CTD-2260A17.1 7.39 6.8e-13 5.41e-10 0.36 0.32 Behcet's disease;Blood protein levels; chr5:96791235 chr5:96784777~96785999:+ LUSC cis rs9549367 0.713 rs9549357 ENSG00000269125.1 RP11-98F14.11 -7.39 6.81e-13 5.41e-10 -0.41 -0.32 Platelet distribution width; chr13:113205807 chr13:113165002~113165183:- LUSC cis rs11098499 0.863 rs2127823 ENSG00000250412.1 KLHL2P1 7.39 6.85e-13 5.44e-10 0.4 0.32 Corneal astigmatism; chr4:119564515 chr4:119334329~119378233:+ LUSC cis rs875971 0.862 rs6971059 ENSG00000237310.1 GS1-124K5.4 -7.39 6.87e-13 5.46e-10 -0.34 -0.32 Aortic root size; chr7:66602045 chr7:66493706~66495474:+ LUSC cis rs875971 0.825 rs66981195 ENSG00000237310.1 GS1-124K5.4 -7.39 6.87e-13 5.46e-10 -0.34 -0.32 Aortic root size; chr7:66614048 chr7:66493706~66495474:+ LUSC cis rs172166 0.637 rs1071893 ENSG00000204709.4 LINC01556 7.39 6.87e-13 5.46e-10 0.41 0.32 Cardiac Troponin-T levels; chr6:28199857 chr6:28943877~28944537:+ LUSC cis rs1930961 1 rs997873 ENSG00000100058.11 CRYBB2P1 7.39 6.89e-13 5.47e-10 0.59 0.32 Bipolar disorder with mood-incongruent psychosis; chr22:25482315 chr22:25448105~25520854:+ LUSC cis rs1930961 1 rs997872 ENSG00000100058.11 CRYBB2P1 7.39 6.89e-13 5.47e-10 0.59 0.32 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25448105~25520854:+ LUSC cis rs1930961 1 rs6004671 ENSG00000100058.11 CRYBB2P1 7.39 6.89e-13 5.47e-10 0.59 0.32 Bipolar disorder with mood-incongruent psychosis; chr22:25483507 chr22:25448105~25520854:+ LUSC cis rs34779708 0.931 rs7908573 ENSG00000230534.5 RP11-297A16.2 7.39 6.89e-13 5.47e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35020585 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs17583009 ENSG00000230534.5 RP11-297A16.2 7.39 6.89e-13 5.47e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35031987 chr10:35098006~35127020:- LUSC cis rs34779708 0.898 rs11595898 ENSG00000230534.5 RP11-297A16.2 7.39 6.89e-13 5.47e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35037335 chr10:35098006~35127020:- LUSC cis rs66887589 0.616 rs11098497 ENSG00000245958.5 RP11-33B1.1 -7.39 6.89e-13 5.47e-10 -0.31 -0.32 Diastolic blood pressure; chr4:119265913 chr4:119454791~119552025:+ LUSC cis rs66887589 0.616 rs11098498 ENSG00000245958.5 RP11-33B1.1 -7.39 6.89e-13 5.47e-10 -0.31 -0.32 Diastolic blood pressure; chr4:119265964 chr4:119454791~119552025:+ LUSC cis rs10129255 0.957 rs8009464 ENSG00000211972.2 IGHV3-66 7.39 6.9e-13 5.48e-10 0.24 0.32 Kawasaki disease; chr14:106777611 chr14:106675017~106675544:- LUSC cis rs875971 0.825 rs7384021 ENSG00000237310.1 GS1-124K5.4 -7.39 6.92e-13 5.49e-10 -0.34 -0.32 Aortic root size; chr7:66612917 chr7:66493706~66495474:+ LUSC cis rs875971 0.83 rs587360 ENSG00000222364.1 RNU6-96P -7.39 6.93e-13 5.5e-10 -0.38 -0.32 Aortic root size; chr7:66057711 chr7:66395191~66395286:+ LUSC cis rs6142102 0.58 rs761233 ENSG00000276073.1 RP5-1125A11.7 -7.39 6.93e-13 5.5e-10 -0.32 -0.32 Skin pigmentation; chr20:33981080 chr20:33985617~33988989:- LUSC cis rs494459 0.536 rs10790267 ENSG00000255239.1 AP002954.6 7.39 6.97e-13 5.53e-10 0.36 0.32 Height; chr11:118856460 chr11:118688039~118690600:- LUSC cis rs494459 0.536 rs11217067 ENSG00000255239.1 AP002954.6 7.39 6.97e-13 5.53e-10 0.36 0.32 Height; chr11:118856623 chr11:118688039~118690600:- LUSC cis rs875971 0.8 rs427557 ENSG00000222364.1 RNU6-96P -7.39 6.98e-13 5.54e-10 -0.38 -0.32 Aortic root size; chr7:66054263 chr7:66395191~66395286:+ LUSC cis rs2404602 0.684 rs8029283 ENSG00000259422.1 RP11-593F23.1 -7.39 6.98e-13 5.54e-10 -0.38 -0.32 Blood metabolite levels; chr15:76544799 chr15:76174891~76181486:- LUSC cis rs875971 0.862 rs3926380 ENSG00000237310.1 GS1-124K5.4 -7.38 7.01e-13 5.56e-10 -0.34 -0.32 Aortic root size; chr7:66615658 chr7:66493706~66495474:+ LUSC cis rs875971 0.825 rs1860472 ENSG00000237310.1 GS1-124K5.4 -7.38 7.01e-13 5.56e-10 -0.34 -0.32 Aortic root size; chr7:66617736 chr7:66493706~66495474:+ LUSC cis rs6142102 0.886 rs6142098 ENSG00000276073.1 RP5-1125A11.7 -7.38 7.01e-13 5.56e-10 -0.34 -0.32 Skin pigmentation; chr20:34100488 chr20:33985617~33988989:- LUSC cis rs10754283 0.935 rs1934046 ENSG00000231613.1 RP5-943J3.1 -7.38 7.03e-13 5.57e-10 -0.37 -0.32 Amyotrophic lateral sclerosis (sporadic); chr1:89653731 chr1:89788914~89790492:+ LUSC cis rs4660456 0.869 rs616954 ENSG00000237899.1 RP4-739H11.3 7.38 7.05e-13 5.58e-10 0.48 0.32 Platelet count; chr1:40669947 chr1:40669089~40687588:- LUSC cis rs801193 0.569 rs2659908 ENSG00000222364.1 RNU6-96P -7.38 7.07e-13 5.6e-10 -0.39 -0.32 Aortic root size; chr7:66695835 chr7:66395191~66395286:+ LUSC cis rs801193 0.569 rs7782587 ENSG00000222364.1 RNU6-96P -7.38 7.07e-13 5.6e-10 -0.39 -0.32 Aortic root size; chr7:66701485 chr7:66395191~66395286:+ LUSC cis rs801193 0.527 rs2707837 ENSG00000222364.1 RNU6-96P -7.38 7.07e-13 5.6e-10 -0.39 -0.32 Aortic root size; chr7:66716086 chr7:66395191~66395286:+ LUSC cis rs6142102 0.923 rs4911379 ENSG00000276073.1 RP5-1125A11.7 -7.38 7.09e-13 5.61e-10 -0.34 -0.32 Skin pigmentation; chr20:33947499 chr20:33985617~33988989:- LUSC cis rs3091242 0.866 rs11249249 ENSG00000224183.1 SDHDP6 -7.38 7.13e-13 5.65e-10 -0.4 -0.32 Erythrocyte sedimentation rate; chr1:25431643 chr1:25294164~25294643:- LUSC cis rs61160187 0.582 rs12655209 ENSG00000215032.2 GNL3LP1 -7.38 7.14e-13 5.65e-10 -0.4 -0.32 Educational attainment (years of education);Educational attainment (college completion); chr5:61010225 chr5:60891935~60893577:- LUSC cis rs10129255 0.957 rs8014696 ENSG00000280411.1 IGHV1-69-2 7.38 7.19e-13 5.69e-10 0.22 0.32 Kawasaki disease; chr14:106769752 chr14:106762092~106762588:- LUSC cis rs172166 0.611 rs203883 ENSG00000204709.4 LINC01556 7.38 7.2e-13 5.7e-10 0.42 0.32 Cardiac Troponin-T levels; chr6:28110578 chr6:28943877~28944537:+ LUSC cis rs172166 0.611 rs203882 ENSG00000204709.4 LINC01556 7.38 7.2e-13 5.7e-10 0.42 0.32 Cardiac Troponin-T levels; chr6:28110724 chr6:28943877~28944537:+ LUSC cis rs172166 0.694 rs1770131 ENSG00000204709.4 LINC01556 7.38 7.2e-13 5.7e-10 0.42 0.32 Cardiac Troponin-T levels; chr6:28118635 chr6:28943877~28944537:+ LUSC cis rs748404 0.697 rs574065 ENSG00000249839.1 AC011330.5 7.38 7.2e-13 5.7e-10 0.42 0.32 Lung cancer; chr15:43258457 chr15:43663654~43684339:- LUSC cis rs9532669 0.963 rs4343141 ENSG00000176268.5 CYCSP34 7.38 7.21e-13 5.7e-10 0.31 0.32 Cervical cancer; chr13:40940497 chr13:40863599~40863902:- LUSC cis rs9532669 0.963 rs3887418 ENSG00000176268.5 CYCSP34 7.38 7.21e-13 5.7e-10 0.31 0.32 Cervical cancer; chr13:40940560 chr13:40863599~40863902:- LUSC cis rs3091242 0.9 rs1811832 ENSG00000224183.1 SDHDP6 -7.38 7.21e-13 5.71e-10 -0.4 -0.32 Erythrocyte sedimentation rate; chr1:25427074 chr1:25294164~25294643:- LUSC cis rs17711722 0.701 rs4467826 ENSG00000224316.1 RP11-479O9.2 7.38 7.23e-13 5.72e-10 0.31 0.32 Calcium levels; chr7:65903721 chr7:65773620~65802067:+ LUSC cis rs7811142 1 rs7794485 ENSG00000242294.5 STAG3L5P 7.38 7.27e-13 5.75e-10 0.27 0.32 Platelet count; chr7:100471313 chr7:100336079~100351900:+ LUSC cis rs12439619 0.508 rs11856561 ENSG00000276710.3 CSPG4P8 -7.38 7.28e-13 5.75e-10 -0.34 -0.32 Intelligence (multi-trait analysis); chr15:82161415 chr15:82459472~82477258:+ LUSC cis rs6142102 1 rs4911410 ENSG00000276073.1 RP5-1125A11.7 -7.38 7.28e-13 5.76e-10 -0.33 -0.32 Skin pigmentation; chr20:34123168 chr20:33985617~33988989:- LUSC cis rs10129255 0.518 rs10150460 ENSG00000224373.3 IGHV4-59 -7.38 7.31e-13 5.78e-10 -0.16 -0.32 Kawasaki disease; chr14:106677179 chr14:106627249~106627825:- LUSC cis rs34779708 0.931 rs72789609 ENSG00000230534.5 RP11-297A16.2 7.38 7.33e-13 5.79e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35017278 chr10:35098006~35127020:- LUSC cis rs9487094 0.71 rs71558370 ENSG00000260273.1 RP11-425D10.10 7.38 7.35e-13 5.81e-10 0.45 0.32 Height; chr6:109455700 chr6:109382795~109383666:+ LUSC cis rs6142102 0.602 rs4911396 ENSG00000276073.1 RP5-1125A11.7 -7.38 7.35e-13 5.81e-10 -0.32 -0.32 Skin pigmentation; chr20:33992139 chr20:33985617~33988989:- LUSC cis rs3091242 0.902 rs36003018 ENSG00000224183.1 SDHDP6 7.38 7.36e-13 5.81e-10 0.39 0.32 Erythrocyte sedimentation rate; chr1:25457827 chr1:25294164~25294643:- LUSC cis rs11098499 0.604 rs2389887 ENSG00000245958.5 RP11-33B1.1 -7.38 7.38e-13 5.83e-10 -0.33 -0.32 Corneal astigmatism; chr4:119649489 chr4:119454791~119552025:+ LUSC cis rs7945705 0.935 rs1883098 ENSG00000254860.4 TMEM9B-AS1 7.38 7.39e-13 5.84e-10 0.35 0.32 Hemoglobin concentration; chr11:8869047 chr11:8964675~8977527:+ LUSC cis rs8081395 0.627 rs12952730 ENSG00000266992.1 DHX40P1 7.38 7.4e-13 5.85e-10 0.37 0.32 White blood cell count; chr17:59901475 chr17:59976009~60002384:- LUSC cis rs10740039 0.768 rs7895268 ENSG00000254271.1 RP11-131N11.4 7.38 7.43e-13 5.87e-10 0.44 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60703479 chr10:60734342~60741828:+ LUSC cis rs4713118 0.699 rs200978 ENSG00000219392.1 RP1-265C24.5 -7.38 7.45e-13 5.88e-10 -0.46 -0.32 Parkinson's disease; chr6:27885390 chr6:28115628~28116551:+ LUSC cis rs801193 0.548 rs2659891 ENSG00000222364.1 RNU6-96P -7.37 7.49e-13 5.91e-10 -0.39 -0.32 Aortic root size; chr7:66736127 chr7:66395191~66395286:+ LUSC cis rs801193 0.548 rs7805152 ENSG00000222364.1 RNU6-96P -7.37 7.49e-13 5.91e-10 -0.39 -0.32 Aortic root size; chr7:66744266 chr7:66395191~66395286:+ LUSC cis rs172166 0.694 rs9295760 ENSG00000204709.4 LINC01556 7.37 7.5e-13 5.92e-10 0.42 0.32 Cardiac Troponin-T levels; chr6:28179607 chr6:28943877~28944537:+ LUSC cis rs875971 0.83 rs427575 ENSG00000222364.1 RNU6-96P -7.37 7.52e-13 5.94e-10 -0.38 -0.32 Aortic root size; chr7:66054232 chr7:66395191~66395286:+ LUSC cis rs7811142 1 rs67040465 ENSG00000242294.5 STAG3L5P 7.37 7.55e-13 5.96e-10 0.27 0.32 Platelet count; chr7:100485455 chr7:100336079~100351900:+ LUSC cis rs494459 0.504 rs7929520 ENSG00000255422.1 AP002954.4 -7.37 7.58e-13 5.98e-10 -0.34 -0.32 Height; chr11:118859432 chr11:118704607~118750263:+ LUSC cis rs6142102 0.602 rs1054534 ENSG00000276073.1 RP5-1125A11.7 -7.37 7.58e-13 5.98e-10 -0.32 -0.32 Skin pigmentation; chr20:34017521 chr20:33985617~33988989:- LUSC cis rs1113500 0.787 rs473704 ENSG00000226822.1 RP11-356N1.2 -7.37 7.59e-13 5.99e-10 -0.32 -0.32 Growth-regulated protein alpha levels; chr1:108094688 chr1:108071482~108074519:+ LUSC cis rs4950322 0.542 rs4950384 ENSG00000278811.3 LINC00624 7.37 7.59e-13 5.99e-10 0.36 0.32 Protein quantitative trait loci; chr1:147177310 chr1:147258885~147517875:- LUSC cis rs4718428 1 rs4718421 ENSG00000226824.5 RP4-756H11.3 -7.37 7.6e-13 5.99e-10 -0.39 -0.32 Corneal structure; chr7:66885313 chr7:66654538~66669855:+ LUSC cis rs4950322 0.57 rs72691004 ENSG00000278811.3 LINC00624 7.37 7.62e-13 6.01e-10 0.36 0.32 Protein quantitative trait loci; chr1:147234309 chr1:147258885~147517875:- LUSC cis rs2337406 0.714 rs8022729 ENSG00000274576.2 IGHV2-70 7.37 7.62e-13 6.01e-10 0.33 0.32 Alzheimer's disease (late onset); chr14:106816928 chr14:106770577~106771020:- LUSC cis rs10256972 1 rs10256972 ENSG00000229043.2 AC091729.9 7.37 7.63e-13 6.02e-10 0.37 0.32 Endometriosis;Longevity; chr7:999367 chr7:1160374~1165267:+ LUSC cis rs10754283 0.967 rs1934044 ENSG00000231613.1 RP5-943J3.1 -7.37 7.64e-13 6.03e-10 -0.36 -0.32 Amyotrophic lateral sclerosis (sporadic); chr1:89641942 chr1:89788914~89790492:+ LUSC cis rs9322193 0.962 rs35443312 ENSG00000223701.3 RAET1E-AS1 7.37 7.66e-13 6.04e-10 0.37 0.32 Lung cancer; chr6:149670625 chr6:149884431~149919508:+ LUSC cis rs150992 0.53 rs2927646 ENSG00000248489.1 CTD-2007H13.3 7.37 7.68e-13 6.06e-10 0.36 0.32 Body mass index; chr5:98989462 chr5:98929171~98995013:+ LUSC cis rs34779708 0.931 rs10437420 ENSG00000230534.5 RP11-297A16.2 -7.37 7.69e-13 6.06e-10 -0.36 -0.32 Inflammatory bowel disease;Crohn's disease; chr10:35046116 chr10:35098006~35127020:- LUSC cis rs4713118 0.513 rs202908 ENSG00000204709.4 LINC01556 7.37 7.69e-13 6.06e-10 0.4 0.32 Parkinson's disease; chr6:28043773 chr6:28943877~28944537:+ LUSC cis rs875971 0.862 rs10282433 ENSG00000237310.1 GS1-124K5.4 -7.37 7.7e-13 6.07e-10 -0.34 -0.32 Aortic root size; chr7:66256452 chr7:66493706~66495474:+ LUSC cis rs4713118 0.699 rs573179 ENSG00000219392.1 RP1-265C24.5 -7.37 7.7e-13 6.08e-10 -0.45 -0.32 Parkinson's disease; chr6:27881898 chr6:28115628~28116551:+ LUSC cis rs1113500 0.548 rs3853497 ENSG00000226822.1 RP11-356N1.2 7.37 7.71e-13 6.08e-10 0.37 0.32 Growth-regulated protein alpha levels; chr1:108114562 chr1:108071482~108074519:+ LUSC cis rs494459 0.536 rs11217065 ENSG00000255422.1 AP002954.4 -7.37 7.74e-13 6.1e-10 -0.34 -0.32 Height; chr11:118855938 chr11:118704607~118750263:+ LUSC cis rs875971 0.862 rs6944374 ENSG00000222364.1 RNU6-96P 7.37 7.8e-13 6.15e-10 0.38 0.32 Aortic root size; chr7:66221942 chr7:66395191~66395286:+ LUSC cis rs10129255 0.957 rs8009073 ENSG00000211972.2 IGHV3-66 7.37 7.83e-13 6.17e-10 0.24 0.32 Kawasaki disease; chr14:106777278 chr14:106675017~106675544:- LUSC cis rs2412819 0.571 rs6493090 ENSG00000249839.1 AC011330.5 7.37 7.84e-13 6.17e-10 0.51 0.32 Lung cancer; chr15:43792084 chr15:43663654~43684339:- LUSC cis rs4950322 0.57 rs7554833 ENSG00000278811.3 LINC00624 -7.37 7.84e-13 6.18e-10 -0.37 -0.32 Protein quantitative trait loci; chr1:147289362 chr1:147258885~147517875:- LUSC cis rs7617773 0.746 rs11713476 ENSG00000228638.1 FCF1P2 -7.37 7.85e-13 6.18e-10 -0.38 -0.32 Coronary artery disease; chr3:48333944 chr3:48290793~48291375:- LUSC cis rs6471393 0.893 rs2976350 ENSG00000253848.1 RP11-10N23.5 -7.37 7.86e-13 6.19e-10 -0.41 -0.32 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93716818 chr8:93741193~93744534:+ LUSC cis rs17482078 0.879 rs2124921 ENSG00000248734.2 CTD-2260A17.1 7.37 7.87e-13 6.2e-10 0.38 0.32 Behcet's disease;Blood protein levels; chr5:96783635 chr5:96784777~96785999:+ LUSC cis rs61160187 0.582 rs888799 ENSG00000215032.2 GNL3LP1 7.37 7.88e-13 6.21e-10 0.4 0.32 Educational attainment (years of education);Educational attainment (college completion); chr5:61049363 chr5:60891935~60893577:- LUSC cis rs61160187 0.548 rs1983484 ENSG00000215032.2 GNL3LP1 7.37 7.88e-13 6.21e-10 0.4 0.32 Educational attainment (years of education);Educational attainment (college completion); chr5:61050998 chr5:60891935~60893577:- LUSC cis rs875971 0.825 rs1000464 ENSG00000237310.1 GS1-124K5.4 -7.37 7.91e-13 6.23e-10 -0.34 -0.32 Aortic root size; chr7:66312922 chr7:66493706~66495474:+ LUSC cis rs1865760 1 rs6905887 ENSG00000272462.2 U91328.19 -7.37 7.92e-13 6.23e-10 -0.34 -0.32 Height; chr6:25911875 chr6:25992662~26001775:+ LUSC cis rs10129255 0.957 rs10136560 ENSG00000224373.3 IGHV4-59 7.37 7.92e-13 6.24e-10 0.18 0.32 Kawasaki disease; chr14:106787630 chr14:106627249~106627825:- LUSC cis rs2404602 0.684 rs4886816 ENSG00000259422.1 RP11-593F23.1 -7.37 7.93e-13 6.24e-10 -0.38 -0.32 Blood metabolite levels; chr15:76582366 chr15:76174891~76181486:- LUSC cis rs494459 0.536 rs34561290 ENSG00000255422.1 AP002954.4 -7.37 7.99e-13 6.29e-10 -0.34 -0.32 Height; chr11:118860890 chr11:118704607~118750263:+ LUSC cis rs494459 0.536 rs11217072 ENSG00000255422.1 AP002954.4 -7.37 7.99e-13 6.29e-10 -0.34 -0.32 Height; chr11:118861053 chr11:118704607~118750263:+ LUSC cis rs34779708 0.931 rs7923172 ENSG00000230534.5 RP11-297A16.2 7.37 7.99e-13 6.29e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35020439 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs3740083 ENSG00000230534.5 RP11-297A16.2 7.37 7.99e-13 6.29e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35031455 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs12261654 ENSG00000230534.5 RP11-297A16.2 7.37 7.99e-13 6.29e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35033096 chr10:35098006~35127020:- LUSC cis rs801193 0.569 rs11761542 ENSG00000222364.1 RNU6-96P -7.36 8.02e-13 6.31e-10 -0.39 -0.32 Aortic root size; chr7:66753209 chr7:66395191~66395286:+ LUSC cis rs3091242 0.933 rs35403885 ENSG00000224183.1 SDHDP6 7.36 8.04e-13 6.33e-10 0.39 0.32 Erythrocyte sedimentation rate; chr1:25458060 chr1:25294164~25294643:- LUSC cis rs494459 0.536 rs11217063 ENSG00000255422.1 AP002954.4 -7.36 8.1e-13 6.38e-10 -0.34 -0.32 Height; chr11:118855233 chr11:118704607~118750263:+ LUSC cis rs6991838 0.798 rs6994889 ENSG00000200714.1 Y_RNA 7.36 8.13e-13 6.39e-10 0.38 0.32 Intelligence (multi-trait analysis); chr8:65562547 chr8:65592731~65592820:+ LUSC cis rs34779708 0.966 rs2505639 ENSG00000230534.5 RP11-297A16.2 -7.36 8.14e-13 6.4e-10 -0.35 -0.32 Inflammatory bowel disease;Crohn's disease; chr10:35185493 chr10:35098006~35127020:- LUSC cis rs4950322 0.515 rs72691016 ENSG00000278811.3 LINC00624 7.36 8.17e-13 6.42e-10 0.36 0.32 Protein quantitative trait loci; chr1:147245375 chr1:147258885~147517875:- LUSC cis rs732716 0.785 rs9973266 ENSG00000267769.1 CTB-50L17.9 -7.36 8.18e-13 6.43e-10 -0.35 -0.32 Mean corpuscular volume; chr19:4392718 chr19:4454014~4455286:+ LUSC cis rs17711722 0.701 rs55773927 ENSG00000236529.1 RP13-254B10.1 7.36 8.18e-13 6.43e-10 0.33 0.32 Calcium levels; chr7:65872915 chr7:65840212~65840596:+ LUSC cis rs17711722 0.727 rs35850374 ENSG00000236529.1 RP13-254B10.1 7.36 8.18e-13 6.43e-10 0.33 0.32 Calcium levels; chr7:65892789 chr7:65840212~65840596:+ LUSC cis rs748404 0.723 rs565658 ENSG00000249839.1 AC011330.5 -7.36 8.19e-13 6.44e-10 -0.42 -0.32 Lung cancer; chr15:43264109 chr15:43663654~43684339:- LUSC cis rs2404602 0.684 rs157759 ENSG00000259422.1 RP11-593F23.1 7.36 8.23e-13 6.47e-10 0.38 0.32 Blood metabolite levels; chr15:76554649 chr15:76174891~76181486:- LUSC cis rs9601248 0.756 rs928640 ENSG00000227676.3 LINC01068 -7.36 8.24e-13 6.48e-10 -0.39 -0.32 Major depressive disorder; chr13:79603348 chr13:79566727~79571436:+ LUSC cis rs4713118 0.513 rs156739 ENSG00000204709.4 LINC01556 7.36 8.26e-13 6.49e-10 0.41 0.32 Parkinson's disease; chr6:28045632 chr6:28943877~28944537:+ LUSC cis rs17507216 0.628 rs8028130 ENSG00000278603.1 RP13-608F4.5 7.36 8.28e-13 6.5e-10 0.5 0.32 Excessive daytime sleepiness; chr15:82734974 chr15:82472203~82472426:+ LUSC cis rs875971 0.789 rs7808013 ENSG00000237310.1 GS1-124K5.4 -7.36 8.33e-13 6.55e-10 -0.34 -0.32 Aortic root size; chr7:66606209 chr7:66493706~66495474:+ LUSC cis rs2280018 0.526 rs2966129 ENSG00000260735.1 RP11-72I8.1 7.36 8.35e-13 6.56e-10 0.39 0.32 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059070 chr16:15094411~15109197:+ LUSC cis rs875971 0.862 rs6460282 ENSG00000222364.1 RNU6-96P 7.36 8.35e-13 6.56e-10 0.38 0.32 Aortic root size; chr7:66226259 chr7:66395191~66395286:+ LUSC cis rs9318086 0.673 rs7981928 ENSG00000205861.10 C1QTNF9B-AS1 -7.36 8.42e-13 6.61e-10 -0.41 -0.32 Myopia (pathological); chr13:23861041 chr13:23888889~23897263:+ LUSC cis rs4713118 0.911 rs9295746 ENSG00000219392.1 RP1-265C24.5 -7.36 8.44e-13 6.62e-10 -0.44 -0.32 Parkinson's disease; chr6:27762285 chr6:28115628~28116551:+ LUSC cis rs2188561 0.673 rs2712218 ENSG00000241764.3 AC002467.7 7.36 8.45e-13 6.63e-10 0.44 0.32 Alcohol consumption; chr7:107716314 chr7:107742817~107744581:- LUSC cis rs1865760 1 rs2071301 ENSG00000272462.2 U91328.19 -7.36 8.45e-13 6.63e-10 -0.34 -0.32 Height; chr6:25914035 chr6:25992662~26001775:+ LUSC cis rs4950322 0.57 rs17160051 ENSG00000278811.3 LINC00624 7.36 8.46e-13 6.64e-10 0.36 0.32 Protein quantitative trait loci; chr1:147255733 chr1:147258885~147517875:- LUSC cis rs17482078 0.959 rs2013717 ENSG00000248734.2 CTD-2260A17.1 7.36 8.5e-13 6.67e-10 0.36 0.32 Behcet's disease;Blood protein levels; chr5:96798472 chr5:96784777~96785999:+ LUSC cis rs17482078 0.918 rs2013671 ENSG00000248734.2 CTD-2260A17.1 7.36 8.5e-13 6.67e-10 0.36 0.32 Behcet's disease;Blood protein levels; chr5:96798580 chr5:96784777~96785999:+ LUSC cis rs17482078 0.959 rs2013633 ENSG00000248734.2 CTD-2260A17.1 7.36 8.5e-13 6.67e-10 0.36 0.32 Behcet's disease;Blood protein levels; chr5:96798603 chr5:96784777~96785999:+ LUSC cis rs11098499 0.863 rs10018280 ENSG00000250412.1 KLHL2P1 7.36 8.5e-13 6.67e-10 0.4 0.32 Corneal astigmatism; chr4:119556984 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs6534141 ENSG00000250412.1 KLHL2P1 7.36 8.5e-13 6.67e-10 0.4 0.32 Corneal astigmatism; chr4:119564068 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs3775858 ENSG00000250412.1 KLHL2P1 7.36 8.5e-13 6.67e-10 0.4 0.32 Corneal astigmatism; chr4:119564873 chr4:119334329~119378233:+ LUSC cis rs7811142 1 rs73405353 ENSG00000242294.5 STAG3L5P 7.36 8.56e-13 6.71e-10 0.27 0.32 Platelet count; chr7:100493592 chr7:100336079~100351900:+ LUSC cis rs875971 0.792 rs6971752 ENSG00000237310.1 GS1-124K5.4 -7.35 8.57e-13 6.72e-10 -0.33 -0.32 Aortic root size; chr7:66272999 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs10950033 ENSG00000237310.1 GS1-124K5.4 -7.35 8.57e-13 6.72e-10 -0.33 -0.32 Aortic root size; chr7:66274686 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs11760844 ENSG00000237310.1 GS1-124K5.4 -7.35 8.57e-13 6.72e-10 -0.33 -0.32 Aortic root size; chr7:66274896 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs4149461 ENSG00000237310.1 GS1-124K5.4 -7.35 8.57e-13 6.72e-10 -0.33 -0.32 Aortic root size; chr7:66279745 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs4236208 ENSG00000237310.1 GS1-124K5.4 -7.35 8.57e-13 6.72e-10 -0.33 -0.32 Aortic root size; chr7:66284091 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs10261398 ENSG00000237310.1 GS1-124K5.4 -7.35 8.57e-13 6.72e-10 -0.33 -0.32 Aortic root size; chr7:66285177 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs10224872 ENSG00000237310.1 GS1-124K5.4 -7.35 8.57e-13 6.72e-10 -0.33 -0.32 Aortic root size; chr7:66294786 chr7:66493706~66495474:+ LUSC cis rs10129255 0.879 rs7160512 ENSG00000211972.2 IGHV3-66 7.35 8.6e-13 6.74e-10 0.24 0.32 Kawasaki disease; chr14:106694574 chr14:106675017~106675544:- LUSC cis rs10129255 0.879 rs7159157 ENSG00000211972.2 IGHV3-66 7.35 8.6e-13 6.74e-10 0.24 0.32 Kawasaki disease; chr14:106694578 chr14:106675017~106675544:- LUSC cis rs904251 0.523 rs2797799 ENSG00000204110.6 RP1-153P14.8 -7.35 8.6e-13 6.75e-10 -0.3 -0.32 Cognitive performance; chr6:37515844 chr6:37507348~37535616:+ LUSC cis rs34779708 0.931 rs12268745 ENSG00000230534.5 RP11-297A16.2 7.35 8.64e-13 6.78e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35017061 chr10:35098006~35127020:- LUSC cis rs17482078 0.879 rs10050860 ENSG00000248734.2 CTD-2260A17.1 -7.35 8.66e-13 6.79e-10 -0.36 -0.32 Behcet's disease;Blood protein levels; chr5:96786506 chr5:96784777~96785999:+ LUSC cis rs9322193 0.923 rs2342765 ENSG00000268592.3 RAET1E-AS1 7.35 8.68e-13 6.8e-10 0.39 0.32 Lung cancer; chr6:149858873 chr6:149863494~149919507:+ LUSC cis rs2239557 0.5 rs7157723 ENSG00000259065.1 RP5-1021I20.1 7.35 8.69e-13 6.81e-10 0.39 0.32 Common traits (Other); chr14:73999497 chr14:73787360~73803270:+ LUSC cis rs10129255 0.957 rs10137980 ENSG00000211972.2 IGHV3-66 7.35 8.72e-13 6.83e-10 0.24 0.32 Kawasaki disease; chr14:106775735 chr14:106675017~106675544:- LUSC cis rs6904897 0.563 rs4896117 ENSG00000232876.1 CTA-212D2.2 7.35 8.77e-13 6.87e-10 0.39 0.32 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134908262 chr6:135055033~135060550:+ LUSC cis rs4660456 0.913 rs2780950 ENSG00000237899.1 RP4-739H11.3 7.35 8.78e-13 6.88e-10 0.47 0.32 Platelet count; chr1:40686937 chr1:40669089~40687588:- LUSC cis rs6907340 0.517 rs6939160 ENSG00000237404.1 RP3-471C18.2 -7.35 8.79e-13 6.88e-10 -0.42 -0.32 Endometriosis; chr6:19802086 chr6:19689825~19753113:- LUSC cis rs7617773 0.817 rs9830016 ENSG00000228638.1 FCF1P2 -7.35 8.8e-13 6.89e-10 -0.35 -0.32 Coronary artery disease; chr3:48241004 chr3:48290793~48291375:- LUSC cis rs875971 0.862 rs10274883 ENSG00000222364.1 RNU6-96P 7.35 8.8e-13 6.89e-10 0.38 0.32 Aortic root size; chr7:66651104 chr7:66395191~66395286:+ LUSC cis rs7617773 0.963 rs12495221 ENSG00000229759.1 MRPS18AP1 -7.35 8.81e-13 6.9e-10 -0.31 -0.32 Coronary artery disease; chr3:48137688 chr3:48256350~48256938:- LUSC cis rs2179367 0.887 rs2789488 ENSG00000231760.4 RP11-350J20.5 -7.35 8.82e-13 6.91e-10 -0.4 -0.32 Dupuytren's disease; chr6:149404154 chr6:149796151~149826294:- LUSC cis rs34779708 0.931 rs7099593 ENSG00000230534.5 RP11-297A16.2 7.35 8.83e-13 6.91e-10 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35077950 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs13376871 ENSG00000230534.5 RP11-297A16.2 7.35 8.83e-13 6.91e-10 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35080128 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs13376801 ENSG00000230534.5 RP11-297A16.2 7.35 8.83e-13 6.91e-10 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35081515 chr10:35098006~35127020:- LUSC cis rs9318086 0.712 rs3794339 ENSG00000205861.10 C1QTNF9B-AS1 -7.35 8.84e-13 6.92e-10 -0.4 -0.32 Myopia (pathological); chr13:23859926 chr13:23888889~23897263:+ LUSC cis rs55794721 0.509 rs12027135 ENSG00000224183.1 SDHDP6 -7.35 8.86e-13 6.93e-10 -0.39 -0.32 Mean corpuscular volume;Plateletcrit; chr1:25449242 chr1:25294164~25294643:- LUSC cis rs1075265 0.87 rs17268179 ENSG00000233266.1 HMGB1P31 7.35 8.89e-13 6.95e-10 0.41 0.32 Chronotype;Morning vs. evening chronotype; chr2:54036876 chr2:54051334~54051760:+ LUSC cis rs1075265 0.818 rs12713253 ENSG00000233266.1 HMGB1P31 7.35 8.89e-13 6.95e-10 0.41 0.32 Chronotype;Morning vs. evening chronotype; chr2:54037323 chr2:54051334~54051760:+ LUSC cis rs6921919 0.609 rs9461455 ENSG00000204709.4 LINC01556 7.35 8.91e-13 6.97e-10 0.42 0.32 Autism spectrum disorder or schizophrenia; chr6:28361954 chr6:28943877~28944537:+ LUSC cis rs4713118 0.513 rs156734 ENSG00000204709.4 LINC01556 7.35 8.92e-13 6.98e-10 0.4 0.32 Parkinson's disease; chr6:28039579 chr6:28943877~28944537:+ LUSC cis rs9921338 0.923 rs72771877 ENSG00000263080.1 RP11-485G7.5 7.35 8.96e-13 7.01e-10 0.39 0.32 Vein graft stenosis in coronary artery bypass grafting; chr16:11274759 chr16:11341809~11345211:- LUSC cis rs526231 0.578 rs3776870 ENSG00000175749.11 EIF3KP1 7.35 8.98e-13 7.02e-10 0.38 0.32 Primary biliary cholangitis; chr5:102959366 chr5:103032376~103033031:+ LUSC cis rs853679 0.628 rs9368560 ENSG00000204709.4 LINC01556 7.35 9e-13 7.03e-10 0.46 0.32 Depression; chr6:28192182 chr6:28943877~28944537:+ LUSC cis rs17482078 1 rs17482078 ENSG00000248734.2 CTD-2260A17.1 7.35 9.05e-13 7.07e-10 0.38 0.32 Behcet's disease;Blood protein levels; chr5:96783162 chr5:96784777~96785999:+ LUSC cis rs10129255 1 rs9324091 ENSG00000224373.3 IGHV4-59 7.35 9.05e-13 7.07e-10 0.18 0.32 Kawasaki disease; chr14:106676625 chr14:106627249~106627825:- LUSC cis rs875971 0.54 rs4717275 ENSG00000224316.1 RP11-479O9.2 -7.35 9.07e-13 7.09e-10 -0.31 -0.32 Aortic root size; chr7:65800193 chr7:65773620~65802067:+ LUSC cis rs801193 0.569 rs2707824 ENSG00000222364.1 RNU6-96P -7.35 9.11e-13 7.12e-10 -0.39 -0.32 Aortic root size; chr7:66724256 chr7:66395191~66395286:+ LUSC cis rs801193 0.569 rs2659893 ENSG00000222364.1 RNU6-96P -7.35 9.11e-13 7.12e-10 -0.39 -0.32 Aortic root size; chr7:66735006 chr7:66395191~66395286:+ LUSC cis rs801193 0.569 rs2659892 ENSG00000222364.1 RNU6-96P -7.35 9.11e-13 7.12e-10 -0.39 -0.32 Aortic root size; chr7:66735318 chr7:66395191~66395286:+ LUSC cis rs801193 0.569 rs2707847 ENSG00000222364.1 RNU6-96P -7.35 9.11e-13 7.12e-10 -0.39 -0.32 Aortic root size; chr7:66737884 chr7:66395191~66395286:+ LUSC cis rs4660456 0.826 rs507914 ENSG00000237899.1 RP4-739H11.3 7.35 9.14e-13 7.14e-10 0.47 0.32 Platelet count; chr1:40686529 chr1:40669089~40687588:- LUSC cis rs875971 0.755 rs76288834 ENSG00000237310.1 GS1-124K5.4 -7.34 9.17e-13 7.16e-10 -0.34 -0.32 Aortic root size; chr7:66604815 chr7:66493706~66495474:+ LUSC cis rs4423214 0.592 rs7120029 ENSG00000254682.1 RP11-660L16.2 -7.34 9.17e-13 7.16e-10 -0.53 -0.32 Vitamin D levels; chr11:71487911 chr11:71448674~71452157:+ LUSC cis rs35160687 1 rs35160687 ENSG00000273080.1 RP11-301O19.1 7.34 9.17e-13 7.17e-10 0.31 0.32 Night sleep phenotypes; chr2:86244991 chr2:86195590~86196049:+ LUSC cis rs801193 0.548 rs2109297 ENSG00000222364.1 RNU6-96P 7.34 9.18e-13 7.17e-10 0.38 0.32 Aortic root size; chr7:66657397 chr7:66395191~66395286:+ LUSC cis rs801193 0.591 rs721717 ENSG00000222364.1 RNU6-96P 7.34 9.18e-13 7.17e-10 0.38 0.32 Aortic root size; chr7:66665305 chr7:66395191~66395286:+ LUSC cis rs61160187 0.549 rs12518404 ENSG00000215032.2 GNL3LP1 7.34 9.18e-13 7.17e-10 0.4 0.32 Educational attainment (years of education);Educational attainment (college completion); chr5:61046169 chr5:60891935~60893577:- LUSC cis rs783540 0.632 rs17356528 ENSG00000255769.6 GOLGA2P10 7.34 9.19e-13 7.18e-10 0.42 0.32 Schizophrenia; chr15:82636799 chr15:82472993~82513950:- LUSC cis rs801193 0.569 rs2659907 ENSG00000222364.1 RNU6-96P -7.34 9.22e-13 7.2e-10 -0.39 -0.32 Aortic root size; chr7:66699045 chr7:66395191~66395286:+ LUSC cis rs61160187 0.582 rs28436304 ENSG00000215032.2 GNL3LP1 7.34 9.26e-13 7.23e-10 0.4 0.32 Educational attainment (years of education);Educational attainment (college completion); chr5:61038584 chr5:60891935~60893577:- LUSC cis rs11098499 0.82 rs11737395 ENSG00000250412.1 KLHL2P1 7.34 9.3e-13 7.26e-10 0.4 0.32 Corneal astigmatism; chr4:119599549 chr4:119334329~119378233:+ LUSC cis rs9487094 0.645 rs1322818 ENSG00000260273.1 RP11-425D10.10 7.34 9.31e-13 7.27e-10 0.43 0.32 Height; chr6:109369898 chr6:109382795~109383666:+ LUSC cis rs465969 0.744 rs71562296 ENSG00000255389.1 C6orf3 -7.34 9.32e-13 7.27e-10 -0.57 -0.32 Psoriasis; chr6:111521444 chr6:111599875~111602295:+ LUSC cis rs465969 0.744 rs6939657 ENSG00000255389.1 C6orf3 -7.34 9.32e-13 7.27e-10 -0.57 -0.32 Psoriasis; chr6:111521822 chr6:111599875~111602295:+ LUSC cis rs5769707 0.749 rs7286706 ENSG00000235111.1 RP1-29C18.8 -7.34 9.32e-13 7.27e-10 -0.38 -0.32 Monocyte percentage of white cells;Monocyte count; chr22:49664698 chr22:49612657~49615716:- LUSC cis rs6921919 0.583 rs7764722 ENSG00000204709.4 LINC01556 7.34 9.33e-13 7.28e-10 0.41 0.32 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28943877~28944537:+ LUSC cis rs8177876 0.822 rs4889231 ENSG00000261838.4 RP11-303E16.6 -7.34 9.33e-13 7.28e-10 -0.73 -0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080110 chr16:81069854~81076598:+ LUSC cis rs6907340 0.517 rs9465531 ENSG00000237404.1 RP3-471C18.2 -7.34 9.35e-13 7.3e-10 -0.43 -0.32 Endometriosis; chr6:19798418 chr6:19689825~19753113:- LUSC cis rs6142102 0.961 rs2284389 ENSG00000276073.1 RP5-1125A11.7 -7.34 9.36e-13 7.3e-10 -0.33 -0.32 Skin pigmentation; chr20:34069035 chr20:33985617~33988989:- LUSC cis rs465969 0.546 rs7772141 ENSG00000255389.1 C6orf3 7.34 9.36e-13 7.31e-10 0.61 0.32 Psoriasis; chr6:111472358 chr6:111599875~111602295:+ LUSC cis rs465969 0.793 rs7776047 ENSG00000255389.1 C6orf3 7.34 9.36e-13 7.31e-10 0.61 0.32 Psoriasis; chr6:111472391 chr6:111599875~111602295:+ LUSC cis rs6142102 0.625 rs4911138 ENSG00000276073.1 RP5-1125A11.7 -7.34 9.42e-13 7.35e-10 -0.32 -0.32 Skin pigmentation; chr20:33959893 chr20:33985617~33988989:- LUSC cis rs6142102 0.625 rs4243974 ENSG00000276073.1 RP5-1125A11.7 -7.34 9.42e-13 7.35e-10 -0.32 -0.32 Skin pigmentation; chr20:33960062 chr20:33985617~33988989:- LUSC cis rs6142102 0.625 rs6142061 ENSG00000276073.1 RP5-1125A11.7 -7.34 9.42e-13 7.35e-10 -0.32 -0.32 Skin pigmentation; chr20:33960529 chr20:33985617~33988989:- LUSC cis rs6142102 0.625 rs6142062 ENSG00000276073.1 RP5-1125A11.7 -7.34 9.42e-13 7.35e-10 -0.32 -0.32 Skin pigmentation; chr20:33960706 chr20:33985617~33988989:- LUSC cis rs6142102 0.625 rs6141432 ENSG00000276073.1 RP5-1125A11.7 -7.34 9.42e-13 7.35e-10 -0.32 -0.32 Skin pigmentation; chr20:33960791 chr20:33985617~33988989:- LUSC cis rs6142102 0.602 rs6141433 ENSG00000276073.1 RP5-1125A11.7 -7.34 9.42e-13 7.35e-10 -0.32 -0.32 Skin pigmentation; chr20:33961056 chr20:33985617~33988989:- LUSC cis rs17482078 0.959 rs13173167 ENSG00000248734.2 CTD-2260A17.1 7.34 9.42e-13 7.35e-10 0.36 0.32 Behcet's disease;Blood protein levels; chr5:96795780 chr5:96784777~96785999:+ LUSC cis rs17482078 0.959 rs10062964 ENSG00000248734.2 CTD-2260A17.1 7.34 9.46e-13 7.37e-10 0.36 0.32 Behcet's disease;Blood protein levels; chr5:96803363 chr5:96784777~96785999:+ LUSC cis rs1865760 1 rs7739966 ENSG00000272462.2 U91328.19 -7.34 9.48e-13 7.39e-10 -0.34 -0.32 Height; chr6:25905812 chr6:25992662~26001775:+ LUSC cis rs1865760 1 rs56118523 ENSG00000272462.2 U91328.19 -7.34 9.48e-13 7.39e-10 -0.34 -0.32 Height; chr6:25908747 chr6:25992662~26001775:+ LUSC cis rs1865760 1 rs12209482 ENSG00000272462.2 U91328.19 -7.34 9.48e-13 7.39e-10 -0.34 -0.32 Height; chr6:25909001 chr6:25992662~26001775:+ LUSC cis rs1865760 0.963 rs3846838 ENSG00000272462.2 U91328.19 -7.34 9.48e-13 7.39e-10 -0.34 -0.32 Height; chr6:25911547 chr6:25992662~26001775:+ LUSC cis rs1757171 0.542 rs1757186 ENSG00000204110.6 RP1-153P14.8 -7.34 9.48e-13 7.39e-10 -0.31 -0.32 Cognitive performance; chr6:37516335 chr6:37507348~37535616:+ LUSC cis rs12594515 0.548 rs12912226 ENSG00000273972.1 CTD-2306A12.1 -7.34 9.49e-13 7.39e-10 -0.4 -0.32 Weight;Waist circumference; chr15:45693510 chr15:45702640~45703183:+ LUSC cis rs2404602 0.647 rs12898810 ENSG00000259422.1 RP11-593F23.1 -7.34 9.51e-13 7.41e-10 -0.39 -0.32 Blood metabolite levels; chr15:76612397 chr15:76174891~76181486:- LUSC cis rs10129255 0.785 rs10150044 ENSG00000211972.2 IGHV3-66 7.34 9.53e-13 7.43e-10 0.24 0.32 Kawasaki disease; chr14:106775695 chr14:106675017~106675544:- LUSC cis rs10129255 0.957 rs10137980 ENSG00000224373.3 IGHV4-59 7.34 9.54e-13 7.43e-10 0.18 0.32 Kawasaki disease; chr14:106775735 chr14:106627249~106627825:- LUSC cis rs17711722 0.701 rs4467826 ENSG00000236529.1 RP13-254B10.1 7.34 9.57e-13 7.45e-10 0.33 0.32 Calcium levels; chr7:65903721 chr7:65840212~65840596:+ LUSC cis rs673078 0.607 rs2055534 ENSG00000275759.1 RP11-131L12.3 -7.34 9.57e-13 7.46e-10 -0.46 -0.32 Glucose homeostasis traits; chr12:118386527 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs56157623 ENSG00000275759.1 RP11-131L12.3 -7.34 9.57e-13 7.46e-10 -0.46 -0.32 Glucose homeostasis traits; chr12:118388162 chr12:118428281~118428870:+ LUSC cis rs2179367 0.887 rs2789492 ENSG00000231760.4 RP11-350J20.5 -7.34 9.57e-13 7.46e-10 -0.41 -0.32 Dupuytren's disease; chr6:149426243 chr6:149796151~149826294:- LUSC cis rs113835537 0.569 rs17496586 ENSG00000255517.5 CTD-3074O7.5 -7.34 9.58e-13 7.46e-10 -0.38 -0.32 Airway imaging phenotypes; chr11:66548041 chr11:66473490~66480233:- LUSC cis rs875971 0.895 rs12531677 ENSG00000237310.1 GS1-124K5.4 -7.34 9.58e-13 7.46e-10 -0.33 -0.32 Aortic root size; chr7:66304099 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs7798630 ENSG00000237310.1 GS1-124K5.4 -7.34 9.58e-13 7.46e-10 -0.33 -0.32 Aortic root size; chr7:66306492 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs11984115 ENSG00000237310.1 GS1-124K5.4 -7.34 9.58e-13 7.46e-10 -0.33 -0.32 Aortic root size; chr7:66308872 chr7:66493706~66495474:+ LUSC cis rs13113518 0.783 rs7690837 ENSG00000223305.1 RN7SKP30 7.34 9.63e-13 7.5e-10 0.39 0.32 Height; chr4:55575856 chr4:55540502~55540835:- LUSC cis rs9921338 0.961 rs4781055 ENSG00000263080.1 RP11-485G7.5 7.34 9.67e-13 7.53e-10 0.38 0.32 Vein graft stenosis in coronary artery bypass grafting; chr16:11275571 chr16:11341809~11345211:- LUSC cis rs17023223 0.553 rs72691108 ENSG00000231365.4 RP11-418J17.1 -7.34 9.67e-13 7.53e-10 -0.43 -0.32 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119219552 chr1:119140396~119275973:+ LUSC cis rs8177876 0.584 rs2602404 ENSG00000261838.4 RP11-303E16.6 -7.34 9.71e-13 7.56e-10 -0.65 -0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81056042 chr16:81069854~81076598:+ LUSC cis rs7044106 0.537 rs4434680 ENSG00000226752.6 PSMD5-AS1 -7.34 9.72e-13 7.56e-10 -0.4 -0.32 Hip circumference adjusted for BMI; chr9:120727410 chr9:120824828~120854385:+ LUSC cis rs11123170 0.65 rs2289897 ENSG00000274877.1 RP11-65I12.1 -7.34 9.72e-13 7.57e-10 -0.45 -0.32 Renal function-related traits (BUN); chr2:113219877 chr2:113237595~113240825:+ LUSC cis rs10129255 1 rs61997605 ENSG00000224373.3 IGHV4-59 7.34 9.74e-13 7.58e-10 0.18 0.32 Kawasaki disease; chr14:106678368 chr14:106627249~106627825:- LUSC cis rs11098499 0.863 rs3822195 ENSG00000250412.1 KLHL2P1 7.34 9.75e-13 7.59e-10 0.4 0.32 Corneal astigmatism; chr4:119550505 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs3775854 ENSG00000250412.1 KLHL2P1 7.34 9.75e-13 7.59e-10 0.4 0.32 Corneal astigmatism; chr4:119550816 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs2306457 ENSG00000250412.1 KLHL2P1 7.34 9.75e-13 7.59e-10 0.4 0.32 Corneal astigmatism; chr4:119551684 chr4:119334329~119378233:+ LUSC cis rs6142102 0.602 rs4911380 ENSG00000276073.1 RP5-1125A11.7 -7.34 9.76e-13 7.6e-10 -0.32 -0.32 Skin pigmentation; chr20:33958418 chr20:33985617~33988989:- LUSC cis rs10129255 1 rs10129319 ENSG00000224373.3 IGHV4-59 7.33 9.81e-13 7.63e-10 0.18 0.32 Kawasaki disease; chr14:106767996 chr14:106627249~106627825:- LUSC cis rs904251 0.523 rs2776872 ENSG00000204110.6 RP1-153P14.8 -7.33 9.82e-13 7.64e-10 -0.3 -0.32 Cognitive performance; chr6:37515011 chr6:37507348~37535616:+ LUSC cis rs904251 0.523 rs1757191 ENSG00000204110.6 RP1-153P14.8 -7.33 9.82e-13 7.64e-10 -0.3 -0.32 Cognitive performance; chr6:37515095 chr6:37507348~37535616:+ LUSC cis rs4713118 0.512 rs2622319 ENSG00000204709.4 LINC01556 7.33 9.82e-13 7.64e-10 0.42 0.32 Parkinson's disease; chr6:28152623 chr6:28943877~28944537:+ LUSC cis rs11098499 0.863 rs6853998 ENSG00000250412.1 KLHL2P1 7.33 9.84e-13 7.65e-10 0.4 0.32 Corneal astigmatism; chr4:119554705 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs6858777 ENSG00000250412.1 KLHL2P1 7.33 9.84e-13 7.65e-10 0.4 0.32 Corneal astigmatism; chr4:119554811 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs11731756 ENSG00000250412.1 KLHL2P1 7.33 9.84e-13 7.65e-10 0.4 0.32 Corneal astigmatism; chr4:119557541 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs34308924 ENSG00000250412.1 KLHL2P1 7.33 9.84e-13 7.65e-10 0.4 0.32 Corneal astigmatism; chr4:119560276 chr4:119334329~119378233:+ LUSC cis rs4950322 0.57 rs4950400 ENSG00000278811.3 LINC00624 -7.33 9.85e-13 7.66e-10 -0.37 -0.32 Protein quantitative trait loci; chr1:147319383 chr1:147258885~147517875:- LUSC cis rs6142102 0.625 rs4012234 ENSG00000276073.1 RP5-1125A11.7 -7.33 9.86e-13 7.67e-10 -0.32 -0.32 Skin pigmentation; chr20:33965241 chr20:33985617~33988989:- LUSC cis rs6142102 0.649 rs4911382 ENSG00000276073.1 RP5-1125A11.7 -7.33 9.86e-13 7.67e-10 -0.32 -0.32 Skin pigmentation; chr20:33965289 chr20:33985617~33988989:- LUSC cis rs4660456 0.871 rs669072 ENSG00000237899.1 RP4-739H11.3 7.33 9.87e-13 7.68e-10 0.47 0.32 Platelet count; chr1:40679946 chr1:40669089~40687588:- LUSC cis rs1865760 0.964 rs6932113 ENSG00000272462.2 U91328.19 -7.33 9.89e-13 7.69e-10 -0.34 -0.32 Height; chr6:25912870 chr6:25992662~26001775:+ LUSC cis rs7849270 0.801 rs10819475 ENSG00000268707.1 RP11-247A12.7 7.33 9.9e-13 7.7e-10 0.37 0.32 Blood metabolite ratios; chr9:129168561 chr9:129170434~129170940:+ LUSC cis rs17711722 0.701 rs781143 ENSG00000224316.1 RP11-479O9.2 7.33 9.93e-13 7.72e-10 0.31 0.32 Calcium levels; chr7:65974892 chr7:65773620~65802067:+ LUSC cis rs61160187 0.582 rs4700404 ENSG00000215032.2 GNL3LP1 7.33 9.97e-13 7.75e-10 0.4 0.32 Educational attainment (years of education);Educational attainment (college completion); chr5:61028769 chr5:60891935~60893577:- LUSC cis rs7811142 1 rs11769700 ENSG00000242294.5 STAG3L5P 7.33 9.97e-13 7.75e-10 0.26 0.32 Platelet count; chr7:100492426 chr7:100336079~100351900:+ LUSC cis rs11763147 1 rs11763147 ENSG00000236529.1 RP13-254B10.1 -7.33 9.98e-13 7.75e-10 -0.33 -0.32 Corneal structure; chr7:65861834 chr7:65840212~65840596:+ LUSC cis rs904251 0.504 rs1757188 ENSG00000204110.6 RP1-153P14.8 -7.33 9.98e-13 7.76e-10 -0.3 -0.32 Cognitive performance; chr6:37516032 chr6:37507348~37535616:+ LUSC cis rs9487094 0.813 rs6920962 ENSG00000260273.1 RP11-425D10.10 7.33 9.99e-13 7.77e-10 0.38 0.32 Height; chr6:109403287 chr6:109382795~109383666:+ LUSC cis rs1113500 0.509 rs17020915 ENSG00000226822.1 RP11-356N1.2 7.33 9.99e-13 7.77e-10 0.37 0.32 Growth-regulated protein alpha levels; chr1:108104384 chr1:108071482~108074519:+ LUSC cis rs853679 0.55 rs1233701 ENSG00000204709.4 LINC01556 -7.33 1e-12 7.77e-10 -0.43 -0.32 Depression; chr6:28200948 chr6:28943877~28944537:+ LUSC cis rs875971 0.755 rs10228885 ENSG00000237310.1 GS1-124K5.4 -7.33 1e-12 7.78e-10 -0.34 -0.32 Aortic root size; chr7:66315542 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs3893216 ENSG00000237310.1 GS1-124K5.4 -7.33 1e-12 7.78e-10 -0.34 -0.32 Aortic root size; chr7:66325720 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6958294 ENSG00000237310.1 GS1-124K5.4 -7.33 1e-12 7.78e-10 -0.34 -0.32 Aortic root size; chr7:66329809 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs2088655 ENSG00000237310.1 GS1-124K5.4 -7.33 1e-12 7.78e-10 -0.34 -0.32 Aortic root size; chr7:66330724 chr7:66493706~66495474:+ LUSC cis rs875971 0.895 rs10447522 ENSG00000237310.1 GS1-124K5.4 -7.33 1e-12 7.78e-10 -0.34 -0.32 Aortic root size; chr7:66331087 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs2088653 ENSG00000237310.1 GS1-124K5.4 -7.33 1e-12 7.78e-10 -0.34 -0.32 Aortic root size; chr7:66343621 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6460293 ENSG00000237310.1 GS1-124K5.4 -7.33 1e-12 7.78e-10 -0.34 -0.32 Aortic root size; chr7:66345205 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs778736 ENSG00000237310.1 GS1-124K5.4 7.33 1e-12 7.78e-10 0.34 0.32 Aortic root size; chr7:66348861 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs1167390 ENSG00000237310.1 GS1-124K5.4 -7.33 1e-12 7.79e-10 -0.33 -0.32 Aortic root size; chr7:66110906 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs35034167 ENSG00000237310.1 GS1-124K5.4 -7.33 1e-12 7.79e-10 -0.33 -0.32 Aortic root size; chr7:66115179 chr7:66493706~66495474:+ LUSC cis rs760794 0.729 rs6921786 ENSG00000227116.1 RP3-471C18.1 7.33 1e-12 7.8e-10 0.35 0.32 Endometriosis; chr6:19793785 chr6:19730427~19734567:- LUSC cis rs7849270 0.76 rs419636 ENSG00000268707.1 RP11-247A12.7 7.33 1e-12 7.8e-10 0.37 0.32 Blood metabolite ratios; chr9:129168998 chr9:129170434~129170940:+ LUSC cis rs11098499 0.644 rs7676296 ENSG00000249244.1 RP11-548H18.2 7.33 1.01e-12 7.81e-10 0.4 0.32 Corneal astigmatism; chr4:119634532 chr4:119391831~119395335:- LUSC cis rs8059260 0.604 rs9302458 ENSG00000274038.1 RP11-66H6.4 -7.33 1.01e-12 7.83e-10 -0.52 -0.32 Alcohol consumption over the past year; chr16:11050352 chr16:11056556~11057034:+ LUSC cis rs66887589 0.616 rs11731675 ENSG00000245958.5 RP11-33B1.1 -7.33 1.01e-12 7.84e-10 -0.31 -0.32 Diastolic blood pressure; chr4:119291359 chr4:119454791~119552025:+ LUSC cis rs7945705 0.967 rs10769973 ENSG00000254860.4 TMEM9B-AS1 -7.33 1.01e-12 7.84e-10 -0.36 -0.32 Hemoglobin concentration; chr11:8907068 chr11:8964675~8977527:+ LUSC cis rs1113500 0.548 rs9970655 ENSG00000226822.1 RP11-356N1.2 7.33 1.01e-12 7.85e-10 0.38 0.32 Growth-regulated protein alpha levels; chr1:108100915 chr1:108071482~108074519:+ LUSC cis rs875971 0.862 rs6460282 ENSG00000237310.1 GS1-124K5.4 -7.33 1.01e-12 7.87e-10 -0.34 -0.32 Aortic root size; chr7:66226259 chr7:66493706~66495474:+ LUSC cis rs172166 0.694 rs1225716 ENSG00000204709.4 LINC01556 7.33 1.01e-12 7.88e-10 0.42 0.32 Cardiac Troponin-T levels; chr6:28145968 chr6:28943877~28944537:+ LUSC cis rs2019137 0.868 rs6755639 ENSG00000274877.1 RP11-65I12.1 -7.33 1.02e-12 7.88e-10 -0.39 -0.32 Lymphocyte counts; chr2:113224233 chr2:113237595~113240825:+ LUSC cis rs9532669 0.926 rs1056820 ENSG00000176268.5 CYCSP34 7.33 1.02e-12 7.89e-10 0.31 0.32 Cervical cancer; chr13:40941150 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs9532678 ENSG00000176268.5 CYCSP34 7.33 1.02e-12 7.89e-10 0.31 0.32 Cervical cancer; chr13:40941862 chr13:40863599~40863902:- LUSC cis rs2117029 0.619 rs10747562 ENSG00000258017.1 RP11-386G11.10 -7.33 1.02e-12 7.89e-10 -0.41 -0.32 Intelligence (multi-trait analysis); chr12:49111401 chr12:49127782~49147869:+ LUSC cis rs2117029 0.619 rs11168862 ENSG00000258017.1 RP11-386G11.10 -7.33 1.02e-12 7.89e-10 -0.41 -0.32 Intelligence (multi-trait analysis); chr12:49112175 chr12:49127782~49147869:+ LUSC cis rs8031584 0.723 rs711224 ENSG00000260382.1 RP11-540B6.2 -7.33 1.02e-12 7.9e-10 -0.43 -0.32 Huntington's disease progression; chr15:30835718 chr15:30882267~30883231:- LUSC cis rs10463554 0.926 rs26433 ENSG00000175749.11 EIF3KP1 7.33 1.02e-12 7.95e-10 0.38 0.32 Parkinson's disease; chr5:103028154 chr5:103032376~103033031:+ LUSC cis rs1789 0.786 rs6414768 ENSG00000273133.1 RP11-799M12.2 -7.33 1.03e-12 7.96e-10 -0.44 -0.32 Blood protein levels; chr4:15693740 chr4:15563698~15564253:- LUSC cis rs494459 0.504 rs7929520 ENSG00000255239.1 AP002954.6 7.33 1.03e-12 8e-10 0.35 0.32 Height; chr11:118859432 chr11:118688039~118690600:- LUSC cis rs6142102 0.602 rs6141435 ENSG00000276073.1 RP5-1125A11.7 -7.33 1.03e-12 8.02e-10 -0.32 -0.32 Skin pigmentation; chr20:33963473 chr20:33985617~33988989:- LUSC cis rs6142102 0.625 rs1883706 ENSG00000276073.1 RP5-1125A11.7 -7.33 1.03e-12 8.02e-10 -0.32 -0.32 Skin pigmentation; chr20:33965071 chr20:33985617~33988989:- LUSC cis rs6142102 0.625 rs1883705 ENSG00000276073.1 RP5-1125A11.7 -7.33 1.03e-12 8.02e-10 -0.32 -0.32 Skin pigmentation; chr20:33965072 chr20:33985617~33988989:- LUSC cis rs6921919 0.551 rs13201753 ENSG00000204709.4 LINC01556 7.33 1.04e-12 8.05e-10 0.41 0.32 Autism spectrum disorder or schizophrenia; chr6:28363351 chr6:28943877~28944537:+ LUSC cis rs1865760 0.929 rs9358896 ENSG00000272462.2 U91328.19 -7.33 1.04e-12 8.06e-10 -0.35 -0.32 Height; chr6:25942969 chr6:25992662~26001775:+ LUSC cis rs875971 0.862 rs4718330 ENSG00000237310.1 GS1-124K5.4 -7.33 1.04e-12 8.06e-10 -0.33 -0.32 Aortic root size; chr7:66250256 chr7:66493706~66495474:+ LUSC cis rs7945705 0.905 rs2568054 ENSG00000254860.4 TMEM9B-AS1 7.33 1.04e-12 8.06e-10 0.35 0.32 Hemoglobin concentration; chr11:8854482 chr11:8964675~8977527:+ LUSC cis rs34779708 0.931 rs11010077 ENSG00000230534.5 RP11-297A16.2 -7.33 1.04e-12 8.08e-10 -0.35 -0.32 Inflammatory bowel disease;Crohn's disease; chr10:35039160 chr10:35098006~35127020:- LUSC cis rs11118620 0.622 rs11118618 ENSG00000272823.1 RP11-295M18.6 7.33 1.04e-12 8.1e-10 0.42 0.32 Heart failure; chr1:220838204 chr1:220828676~220829211:- LUSC cis rs9318086 0.624 rs9510909 ENSG00000205861.10 C1QTNF9B-AS1 -7.33 1.05e-12 8.11e-10 -0.4 -0.32 Myopia (pathological); chr13:23862621 chr13:23888889~23897263:+ LUSC cis rs9487094 0.553 rs13191995 ENSG00000260273.1 RP11-425D10.10 7.33 1.05e-12 8.11e-10 0.44 0.32 Height; chr6:109645257 chr6:109382795~109383666:+ LUSC cis rs10129255 0.785 rs10150044 ENSG00000224373.3 IGHV4-59 7.32 1.05e-12 8.12e-10 0.18 0.32 Kawasaki disease; chr14:106775695 chr14:106627249~106627825:- LUSC cis rs7267979 0.789 rs2260197 ENSG00000274973.1 RP13-401N8.7 -7.32 1.06e-12 8.18e-10 -0.33 -0.32 Liver enzyme levels (alkaline phosphatase); chr20:25303707 chr20:25845497~25845862:+ LUSC cis rs801193 0.569 rs881285 ENSG00000222364.1 RNU6-96P 7.32 1.06e-12 8.21e-10 0.38 0.32 Aortic root size; chr7:66654433 chr7:66395191~66395286:+ LUSC cis rs10129255 0.957 rs7493713 ENSG00000224373.3 IGHV4-59 7.32 1.06e-12 8.25e-10 0.18 0.32 Kawasaki disease; chr14:106783685 chr14:106627249~106627825:- LUSC cis rs10129255 0.912 rs35468694 ENSG00000224373.3 IGHV4-59 7.32 1.06e-12 8.25e-10 0.18 0.32 Kawasaki disease; chr14:106784199 chr14:106627249~106627825:- LUSC cis rs10129255 0.957 rs8019272 ENSG00000224373.3 IGHV4-59 7.32 1.06e-12 8.25e-10 0.18 0.32 Kawasaki disease; chr14:106784709 chr14:106627249~106627825:- LUSC cis rs1865760 1 rs9467636 ENSG00000272462.2 U91328.19 -7.32 1.07e-12 8.29e-10 -0.34 -0.32 Height; chr6:25919321 chr6:25992662~26001775:+ LUSC cis rs1865760 1 rs9358893 ENSG00000272462.2 U91328.19 -7.32 1.07e-12 8.29e-10 -0.34 -0.32 Height; chr6:25921533 chr6:25992662~26001775:+ LUSC cis rs1865760 1 rs3799372 ENSG00000272462.2 U91328.19 -7.32 1.07e-12 8.29e-10 -0.34 -0.32 Height; chr6:25922083 chr6:25992662~26001775:+ LUSC cis rs1865760 0.963 rs1540273 ENSG00000272462.2 U91328.19 -7.32 1.07e-12 8.29e-10 -0.34 -0.32 Height; chr6:25923930 chr6:25992662~26001775:+ LUSC cis rs1865760 1 rs9358895 ENSG00000272462.2 U91328.19 -7.32 1.07e-12 8.29e-10 -0.34 -0.32 Height; chr6:25924427 chr6:25992662~26001775:+ LUSC cis rs11098499 0.863 rs1010739 ENSG00000249244.1 RP11-548H18.2 7.32 1.07e-12 8.3e-10 0.41 0.32 Corneal astigmatism; chr4:119542316 chr4:119391831~119395335:- LUSC cis rs673078 0.607 rs17512763 ENSG00000275759.1 RP11-131L12.3 -7.32 1.07e-12 8.31e-10 -0.46 -0.32 Glucose homeostasis traits; chr12:118400974 chr12:118428281~118428870:+ LUSC cis rs6904897 0.563 rs6569976 ENSG00000232876.1 CTA-212D2.2 -7.32 1.07e-12 8.31e-10 -0.39 -0.32 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134903615 chr6:135055033~135060550:+ LUSC cis rs34779708 0.931 rs35886556 ENSG00000230534.5 RP11-297A16.2 7.32 1.08e-12 8.33e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35046057 chr10:35098006~35127020:- LUSC cis rs1865760 1 rs7757666 ENSG00000272462.2 U91328.19 -7.32 1.08e-12 8.33e-10 -0.34 -0.32 Height; chr6:25902398 chr6:25992662~26001775:+ LUSC cis rs950169 0.922 rs11630507 ENSG00000259728.4 LINC00933 7.32 1.08e-12 8.34e-10 0.41 0.32 Schizophrenia; chr15:84552494 chr15:84570649~84580175:+ LUSC cis rs34779708 0.966 rs12761675 ENSG00000230534.5 RP11-297A16.2 -7.32 1.08e-12 8.35e-10 -0.35 -0.32 Inflammatory bowel disease;Crohn's disease; chr10:35149409 chr10:35098006~35127020:- LUSC cis rs7621025 0.5 rs9845460 ENSG00000239213.4 NCK1-AS1 7.32 1.08e-12 8.36e-10 0.4 0.32 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136868275 chr3:136841726~136862054:- LUSC cis rs4718428 1 rs4718428 ENSG00000226824.5 RP4-756H11.3 -7.32 1.08e-12 8.38e-10 -0.38 -0.32 Corneal structure; chr7:66956459 chr7:66654538~66669855:+ LUSC cis rs7847628 0.566 rs10739575 ENSG00000226752.6 PSMD5-AS1 7.32 1.08e-12 8.39e-10 0.48 0.32 Birth weight; chr9:120843823 chr9:120824828~120854385:+ LUSC cis rs9549367 0.664 rs9549689 ENSG00000269125.1 RP11-98F14.11 -7.32 1.09e-12 8.43e-10 -0.42 -0.32 Platelet distribution width; chr13:113194073 chr13:113165002~113165183:- LUSC cis rs9549367 0.713 rs9549356 ENSG00000269125.1 RP11-98F14.11 -7.32 1.09e-12 8.43e-10 -0.42 -0.32 Platelet distribution width; chr13:113197319 chr13:113165002~113165183:- LUSC cis rs494459 0.536 rs34561290 ENSG00000255239.1 AP002954.6 7.32 1.09e-12 8.44e-10 0.35 0.32 Height; chr11:118860890 chr11:118688039~118690600:- LUSC cis rs494459 0.536 rs11217072 ENSG00000255239.1 AP002954.6 7.32 1.09e-12 8.44e-10 0.35 0.32 Height; chr11:118861053 chr11:118688039~118690600:- LUSC cis rs11098499 0.644 rs2389880 ENSG00000245958.5 RP11-33B1.1 -7.32 1.09e-12 8.44e-10 -0.32 -0.32 Corneal astigmatism; chr4:119638715 chr4:119454791~119552025:+ LUSC cis rs6142102 0.625 rs2050208 ENSG00000276073.1 RP5-1125A11.7 -7.32 1.09e-12 8.45e-10 -0.32 -0.32 Skin pigmentation; chr20:33955767 chr20:33985617~33988989:- LUSC cis rs4141404 0.818 rs6518737 ENSG00000236132.1 CTA-440B3.1 7.32 1.09e-12 8.45e-10 0.39 0.32 Paclitaxel-induced neuropathy; chr22:31186676 chr22:31816379~31817491:- LUSC cis rs875971 0.862 rs6952182 ENSG00000237310.1 GS1-124K5.4 -7.32 1.09e-12 8.45e-10 -0.33 -0.32 Aortic root size; chr7:66218330 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs1612452 ENSG00000237310.1 GS1-124K5.4 -7.32 1.1e-12 8.5e-10 -0.33 -0.32 Aortic root size; chr7:66108909 chr7:66493706~66495474:+ LUSC cis rs6142102 0.961 rs6120487 ENSG00000276073.1 RP5-1125A11.7 -7.32 1.1e-12 8.51e-10 -0.33 -0.32 Skin pigmentation; chr20:34034802 chr20:33985617~33988989:- LUSC cis rs801193 0.569 rs3846973 ENSG00000222364.1 RNU6-96P 7.32 1.11e-12 8.54e-10 0.38 0.32 Aortic root size; chr7:66655048 chr7:66395191~66395286:+ LUSC cis rs801193 0.569 rs2013908 ENSG00000222364.1 RNU6-96P 7.32 1.11e-12 8.54e-10 0.38 0.32 Aortic root size; chr7:66656082 chr7:66395191~66395286:+ LUSC cis rs801193 0.569 rs6951302 ENSG00000222364.1 RNU6-96P 7.32 1.11e-12 8.54e-10 0.38 0.32 Aortic root size; chr7:66667525 chr7:66395191~66395286:+ LUSC cis rs13113518 0.729 rs11133377 ENSG00000249700.7 SRD5A3-AS1 7.32 1.11e-12 8.56e-10 0.39 0.32 Height; chr4:55413708 chr4:55363971~55395847:- LUSC cis rs9487094 0.677 rs4428538 ENSG00000260273.1 RP11-425D10.10 7.32 1.11e-12 8.57e-10 0.44 0.32 Height; chr6:109409645 chr6:109382795~109383666:+ LUSC cis rs12216125 0.801 rs56107510 ENSG00000272462.2 U91328.19 -7.32 1.11e-12 8.58e-10 -0.37 -0.32 Iron status biomarkers; chr6:25987208 chr6:25992662~26001775:+ LUSC cis rs875971 0.522 rs4502988 ENSG00000224316.1 RP11-479O9.2 7.32 1.11e-12 8.59e-10 0.31 0.32 Aortic root size; chr7:65832759 chr7:65773620~65802067:+ LUSC cis rs11089937 0.568 rs5756988 ENSG00000211639.2 IGLV4-60 -7.32 1.12e-12 8.63e-10 -0.36 -0.32 Periodontitis (PAL4Q3); chr22:22132397 chr22:22162199~22162681:+ LUSC cis rs172166 0.694 rs1150666 ENSG00000204709.4 LINC01556 7.32 1.12e-12 8.63e-10 0.41 0.32 Cardiac Troponin-T levels; chr6:28156150 chr6:28943877~28944537:+ LUSC cis rs2412819 0.545 rs35822148 ENSG00000249839.1 AC011330.5 -7.31 1.12e-12 8.64e-10 -0.56 -0.32 Lung cancer; chr15:43808084 chr15:43663654~43684339:- LUSC cis rs56080343 0.808 rs1045552 ENSG00000275759.1 RP11-131L12.3 -7.31 1.12e-12 8.67e-10 -0.46 -0.32 Neuroticism; chr12:118417678 chr12:118428281~118428870:+ LUSC cis rs801193 0.591 rs4506088 ENSG00000237310.1 GS1-124K5.4 -7.31 1.13e-12 8.69e-10 -0.34 -0.32 Aortic root size; chr7:66670470 chr7:66493706~66495474:+ LUSC cis rs66887589 0.616 rs10032299 ENSG00000245958.5 RP11-33B1.1 -7.31 1.13e-12 8.69e-10 -0.3 -0.32 Diastolic blood pressure; chr4:119285264 chr4:119454791~119552025:+ LUSC cis rs67180937 0.645 rs2270707 ENSG00000272750.1 RP11-378J18.8 7.31 1.13e-12 8.73e-10 0.38 0.32 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222664252 chr1:222658867~222661512:- LUSC cis rs10129255 0.912 rs61997792 ENSG00000280411.1 IGHV1-69-2 -7.31 1.13e-12 8.74e-10 -0.23 -0.32 Kawasaki disease; chr14:106799304 chr14:106762092~106762588:- LUSC cis rs4950322 0.58 rs2083720 ENSG00000278811.3 LINC00624 7.31 1.14e-12 8.78e-10 0.35 0.32 Protein quantitative trait loci; chr1:147122296 chr1:147258885~147517875:- LUSC cis rs4950322 0.58 rs72706441 ENSG00000278811.3 LINC00624 7.31 1.14e-12 8.78e-10 0.35 0.32 Protein quantitative trait loci; chr1:147122601 chr1:147258885~147517875:- LUSC cis rs4950322 0.547 rs17355509 ENSG00000278811.3 LINC00624 7.31 1.14e-12 8.78e-10 0.35 0.32 Protein quantitative trait loci; chr1:147123139 chr1:147258885~147517875:- LUSC cis rs875971 0.522 rs2949690 ENSG00000224316.1 RP11-479O9.2 -7.31 1.14e-12 8.82e-10 -0.31 -0.32 Aortic root size; chr7:66018255 chr7:65773620~65802067:+ LUSC cis rs853679 0.657 rs1778483 ENSG00000204709.4 LINC01556 7.31 1.15e-12 8.86e-10 0.41 0.32 Depression; chr6:28273214 chr6:28943877~28944537:+ LUSC cis rs853679 0.657 rs1778482 ENSG00000204709.4 LINC01556 7.31 1.15e-12 8.86e-10 0.41 0.32 Depression; chr6:28273215 chr6:28943877~28944537:+ LUSC cis rs4660456 0.913 rs2223486 ENSG00000237899.1 RP4-739H11.3 -7.31 1.15e-12 8.88e-10 -0.45 -0.32 Platelet count; chr1:40693557 chr1:40669089~40687588:- LUSC cis rs875971 0.522 rs1701760 ENSG00000236529.1 RP13-254B10.1 7.31 1.15e-12 8.9e-10 0.33 0.32 Aortic root size; chr7:66008701 chr7:65840212~65840596:+ LUSC cis rs4660456 0.826 rs2744802 ENSG00000237899.1 RP4-739H11.3 7.31 1.16e-12 8.93e-10 0.46 0.32 Platelet count; chr1:40687577 chr1:40669089~40687588:- LUSC cis rs1113500 0.787 rs12047429 ENSG00000226822.1 RP11-356N1.2 7.31 1.16e-12 8.94e-10 0.32 0.32 Growth-regulated protein alpha levels; chr1:108090617 chr1:108071482~108074519:+ LUSC cis rs13113518 0.683 rs9761521 ENSG00000223305.1 RN7SKP30 7.31 1.16e-12 8.95e-10 0.38 0.32 Height; chr4:55363436 chr4:55540502~55540835:- LUSC cis rs4713118 0.513 rs149942 ENSG00000204709.4 LINC01556 7.31 1.16e-12 8.96e-10 0.4 0.32 Parkinson's disease; chr6:28033832 chr6:28943877~28944537:+ LUSC cis rs4713118 0.513 rs149945 ENSG00000204709.4 LINC01556 7.31 1.16e-12 8.96e-10 0.4 0.32 Parkinson's disease; chr6:28035075 chr6:28943877~28944537:+ LUSC cis rs6782228 1 rs11718130 ENSG00000242551.2 POU5F1P6 7.31 1.17e-12 9.01e-10 0.42 0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611184 chr3:128674735~128677005:- LUSC cis rs526231 0.578 rs17154825 ENSG00000175749.11 EIF3KP1 7.31 1.17e-12 9.03e-10 0.39 0.32 Primary biliary cholangitis; chr5:102910365 chr5:103032376~103033031:+ LUSC cis rs1865760 1 rs6910138 ENSG00000272462.2 U91328.19 -7.31 1.17e-12 9.03e-10 -0.34 -0.32 Height; chr6:25904124 chr6:25992662~26001775:+ LUSC cis rs1865760 1 rs6910174 ENSG00000272462.2 U91328.19 -7.31 1.17e-12 9.03e-10 -0.34 -0.32 Height; chr6:25904186 chr6:25992662~26001775:+ LUSC cis rs34779708 0.966 rs998658 ENSG00000230534.5 RP11-297A16.2 7.31 1.18e-12 9.09e-10 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35119726 chr10:35098006~35127020:- LUSC cis rs10129255 1 rs11621409 ENSG00000224373.3 IGHV4-59 7.31 1.19e-12 9.13e-10 0.18 0.32 Kawasaki disease; chr14:106695603 chr14:106627249~106627825:- LUSC cis rs2404602 0.647 rs11072631 ENSG00000259422.1 RP11-593F23.1 -7.31 1.19e-12 9.13e-10 -0.39 -0.32 Blood metabolite levels; chr15:76840568 chr15:76174891~76181486:- LUSC cis rs11098499 0.866 rs10518329 ENSG00000249244.1 RP11-548H18.2 7.31 1.19e-12 9.15e-10 0.39 0.32 Corneal astigmatism; chr4:119480680 chr4:119391831~119395335:- LUSC cis rs112744032 1 rs112744032 ENSG00000240350.2 AC017002.1 -7.31 1.19e-12 9.17e-10 -0.45 -0.32 Mean corpuscular hemoglobin; chr2:111521757 chr2:111491273~111570974:+ LUSC cis rs62162297 1 rs62162297 ENSG00000240350.2 AC017002.1 -7.31 1.19e-12 9.17e-10 -0.45 -0.32 Red blood cell count; chr2:111521758 chr2:111491273~111570974:+ LUSC cis rs11089937 0.568 rs35626600 ENSG00000211639.2 IGLV4-60 7.31 1.19e-12 9.18e-10 0.36 0.32 Periodontitis (PAL4Q3); chr22:22130811 chr22:22162199~22162681:+ LUSC cis rs11089937 0.539 rs34228957 ENSG00000211639.2 IGLV4-60 7.31 1.19e-12 9.18e-10 0.36 0.32 Periodontitis (PAL4Q3); chr22:22130838 chr22:22162199~22162681:+ LUSC cis rs34779708 0.931 rs34375045 ENSG00000230534.5 RP11-297A16.2 7.31 1.19e-12 9.18e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35073428 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs11596502 ENSG00000230534.5 RP11-297A16.2 7.31 1.2e-12 9.21e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35098259 chr10:35098006~35127020:- LUSC cis rs11098499 0.739 rs9996382 ENSG00000249244.1 RP11-548H18.2 7.3 1.2e-12 9.23e-10 0.39 0.32 Corneal astigmatism; chr4:119229857 chr4:119391831~119395335:- LUSC cis rs6142102 0.961 rs6120519 ENSG00000276073.1 RP5-1125A11.7 -7.3 1.21e-12 9.28e-10 -0.33 -0.32 Skin pigmentation; chr20:34100307 chr20:33985617~33988989:- LUSC cis rs34779708 0.931 rs1926556 ENSG00000230534.5 RP11-297A16.2 7.3 1.21e-12 9.29e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35055979 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs1926554 ENSG00000230534.5 RP11-297A16.2 7.3 1.21e-12 9.29e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35056041 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs4934710 ENSG00000230534.5 RP11-297A16.2 7.3 1.21e-12 9.29e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35061488 chr10:35098006~35127020:- LUSC cis rs34779708 0.897 rs35784065 ENSG00000230534.5 RP11-297A16.2 7.3 1.21e-12 9.29e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35064646 chr10:35098006~35127020:- LUSC cis rs748404 0.697 rs564946 ENSG00000249839.1 AC011330.5 -7.3 1.21e-12 9.31e-10 -0.42 -0.32 Lung cancer; chr15:43264074 chr15:43663654~43684339:- LUSC cis rs34779708 0.931 rs4934709 ENSG00000230534.5 RP11-297A16.2 -7.3 1.21e-12 9.33e-10 -0.35 -0.32 Inflammatory bowel disease;Crohn's disease; chr10:35050396 chr10:35098006~35127020:- LUSC cis rs875971 0.893 rs62465470 ENSG00000237310.1 GS1-124K5.4 -7.3 1.21e-12 9.33e-10 -0.33 -0.32 Aortic root size; chr7:66136231 chr7:66493706~66495474:+ LUSC cis rs950169 0.922 rs12915832 ENSG00000259728.4 LINC00933 7.3 1.21e-12 9.33e-10 0.41 0.32 Schizophrenia; chr15:84568226 chr15:84570649~84580175:+ LUSC cis rs17608059 0.524 rs9897978 ENSG00000141028.6 CDRT15P1 7.3 1.21e-12 9.34e-10 0.37 0.32 Temperament; chr17:13996939 chr17:14024514~14025488:+ LUSC cis rs10129255 0.957 rs10140904 ENSG00000211972.2 IGHV3-66 7.3 1.22e-12 9.36e-10 0.24 0.32 Kawasaki disease; chr14:106776558 chr14:106675017~106675544:- LUSC cis rs6142102 1 rs2378078 ENSG00000276073.1 RP5-1125A11.7 -7.3 1.22e-12 9.38e-10 -0.32 -0.32 Skin pigmentation; chr20:34126922 chr20:33985617~33988989:- LUSC cis rs34779708 0.75 rs35032841 ENSG00000230534.5 RP11-297A16.2 7.3 1.22e-12 9.4e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35023759 chr10:35098006~35127020:- LUSC cis rs34779708 0.742 rs35912711 ENSG00000230534.5 RP11-297A16.2 7.3 1.22e-12 9.4e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35024068 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs4934702 ENSG00000230534.5 RP11-297A16.2 7.3 1.22e-12 9.4e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35034146 chr10:35098006~35127020:- LUSC cis rs9326248 0.773 rs1060211 ENSG00000280143.1 AP000892.6 7.3 1.23e-12 9.42e-10 0.4 0.32 Blood protein levels; chr11:117169081 chr11:117204967~117210292:+ LUSC cis rs34779708 0.931 rs11597483 ENSG00000230534.5 RP11-297A16.2 7.3 1.23e-12 9.45e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34996189 chr10:35098006~35127020:- LUSC cis rs1075265 0.84 rs10084355 ENSG00000233266.1 HMGB1P31 7.3 1.23e-12 9.46e-10 0.4 0.32 Chronotype;Morning vs. evening chronotype; chr2:54021711 chr2:54051334~54051760:+ LUSC cis rs12594515 0.591 rs35554150 ENSG00000273972.1 CTD-2306A12.1 -7.3 1.23e-12 9.46e-10 -0.4 -0.32 Weight;Waist circumference; chr15:45698100 chr15:45702640~45703183:+ LUSC cis rs9921338 0.961 rs8060767 ENSG00000263080.1 RP11-485G7.5 7.3 1.23e-12 9.47e-10 0.38 0.32 Vein graft stenosis in coronary artery bypass grafting; chr16:11276741 chr16:11341809~11345211:- LUSC cis rs9322193 0.651 rs9322188 ENSG00000223701.3 RAET1E-AS1 -7.3 1.23e-12 9.48e-10 -0.37 -0.32 Lung cancer; chr6:149588355 chr6:149884431~149919508:+ LUSC cis rs2404602 0.647 rs55778276 ENSG00000259422.1 RP11-593F23.1 -7.3 1.24e-12 9.5e-10 -0.39 -0.32 Blood metabolite levels; chr15:76844249 chr15:76174891~76181486:- LUSC cis rs3091242 0.933 rs35530120 ENSG00000224183.1 SDHDP6 7.3 1.24e-12 9.52e-10 0.39 0.32 Erythrocyte sedimentation rate; chr1:25458960 chr1:25294164~25294643:- LUSC cis rs55665837 1 rs11023215 ENSG00000251991.1 RNU7-49P 7.3 1.24e-12 9.56e-10 0.36 0.32 Vitamin D levels; chr11:14415424 chr11:14478892~14478953:+ LUSC cis rs34779708 0.931 rs35848945 ENSG00000230534.5 RP11-297A16.2 7.3 1.25e-12 9.57e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34998633 chr10:35098006~35127020:- LUSC cis rs494459 0.536 rs11217065 ENSG00000255239.1 AP002954.6 7.3 1.25e-12 9.58e-10 0.35 0.32 Height; chr11:118855938 chr11:118688039~118690600:- LUSC cis rs10129255 1 rs8012033 ENSG00000224373.3 IGHV4-59 7.3 1.25e-12 9.6e-10 0.18 0.32 Kawasaki disease; chr14:106678854 chr14:106627249~106627825:- LUSC cis rs10129255 0.912 rs8011090 ENSG00000224373.3 IGHV4-59 7.3 1.25e-12 9.6e-10 0.18 0.32 Kawasaki disease; chr14:106678896 chr14:106627249~106627825:- LUSC cis rs34779708 0.931 rs12767414 ENSG00000230534.5 RP11-297A16.2 7.3 1.25e-12 9.63e-10 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35101265 chr10:35098006~35127020:- LUSC cis rs9921338 0.961 rs4780357 ENSG00000263080.1 RP11-485G7.5 7.3 1.26e-12 9.65e-10 0.38 0.32 Vein graft stenosis in coronary artery bypass grafting; chr16:11277114 chr16:11341809~11345211:- LUSC cis rs55665837 1 rs12804549 ENSG00000251991.1 RNU7-49P 7.3 1.26e-12 9.66e-10 0.35 0.32 Vitamin D levels; chr11:14416212 chr11:14478892~14478953:+ LUSC cis rs17711722 0.727 rs2658585 ENSG00000236529.1 RP13-254B10.1 7.3 1.26e-12 9.66e-10 0.33 0.32 Calcium levels; chr7:65996954 chr7:65840212~65840596:+ LUSC cis rs465969 1 rs78945802 ENSG00000255389.1 C6orf3 -7.3 1.26e-12 9.68e-10 -0.59 -0.32 Psoriasis; chr6:111407143 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs17072683 ENSG00000255389.1 C6orf3 -7.3 1.26e-12 9.68e-10 -0.59 -0.32 Psoriasis; chr6:111410007 chr6:111599875~111602295:+ LUSC cis rs875971 0.522 rs1617484 ENSG00000224316.1 RP11-479O9.2 7.3 1.27e-12 9.72e-10 0.31 0.32 Aortic root size; chr7:65998108 chr7:65773620~65802067:+ LUSC cis rs1113500 0.573 rs10748507 ENSG00000226822.1 RP11-356N1.2 7.3 1.27e-12 9.73e-10 0.37 0.32 Growth-regulated protein alpha levels; chr1:108088899 chr1:108071482~108074519:+ LUSC cis rs35160687 0.901 rs6714362 ENSG00000273080.1 RP11-301O19.1 -7.3 1.27e-12 9.75e-10 -0.31 -0.32 Night sleep phenotypes; chr2:86249465 chr2:86195590~86196049:+ LUSC cis rs1113500 0.805 rs11185248 ENSG00000226822.1 RP11-356N1.2 -7.3 1.27e-12 9.76e-10 -0.32 -0.32 Growth-regulated protein alpha levels; chr1:108068379 chr1:108071482~108074519:+ LUSC cis rs1113500 0.636 rs3853493 ENSG00000226822.1 RP11-356N1.2 7.3 1.27e-12 9.77e-10 0.32 0.32 Growth-regulated protein alpha levels; chr1:108094571 chr1:108071482~108074519:+ LUSC cis rs10129255 0.957 rs12589190 ENSG00000211972.2 IGHV3-66 7.3 1.28e-12 9.79e-10 0.24 0.32 Kawasaki disease; chr14:106783079 chr14:106675017~106675544:- LUSC cis rs10129255 0.957 rs10132367 ENSG00000224373.3 IGHV4-59 7.29 1.28e-12 9.82e-10 0.18 0.32 Kawasaki disease; chr14:106690981 chr14:106627249~106627825:- LUSC cis rs30380 0.69 rs2042381 ENSG00000248734.2 CTD-2260A17.1 7.29 1.28e-12 9.84e-10 0.33 0.32 Cerebrospinal fluid biomarker levels; chr5:96852963 chr5:96784777~96785999:+ LUSC cis rs465969 0.744 rs7758483 ENSG00000255389.1 C6orf3 -7.29 1.28e-12 9.84e-10 -0.6 -0.32 Psoriasis; chr6:111467945 chr6:111599875~111602295:+ LUSC cis rs465969 0.744 rs9400477 ENSG00000255389.1 C6orf3 7.29 1.28e-12 9.84e-10 0.6 0.32 Psoriasis; chr6:111469440 chr6:111599875~111602295:+ LUSC cis rs6991838 0.798 rs62507575 ENSG00000200714.1 Y_RNA 7.29 1.28e-12 9.84e-10 0.38 0.32 Intelligence (multi-trait analysis); chr8:65566486 chr8:65592731~65592820:+ LUSC cis rs34779708 0.931 rs7099036 ENSG00000230534.5 RP11-297A16.2 7.29 1.28e-12 9.85e-10 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35060646 chr10:35098006~35127020:- LUSC cis rs4713118 0.513 rs149954 ENSG00000204709.4 LINC01556 7.29 1.29e-12 9.86e-10 0.41 0.32 Parkinson's disease; chr6:28067468 chr6:28943877~28944537:+ LUSC cis rs8072100 0.79 rs11656856 ENSG00000228782.6 CTD-2026D20.3 -7.29 1.29e-12 9.87e-10 -0.31 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47637305 chr17:47450568~47492492:- LUSC cis rs13113518 0.729 rs13120134 ENSG00000249700.7 SRD5A3-AS1 7.29 1.29e-12 9.88e-10 0.39 0.32 Height; chr4:55415153 chr4:55363971~55395847:- LUSC cis rs1865760 1 rs3830057 ENSG00000272462.2 U91328.19 -7.29 1.29e-12 9.9e-10 -0.34 -0.32 Height; chr6:25918282 chr6:25992662~26001775:+ LUSC cis rs34779708 0.931 rs2384275 ENSG00000230534.5 RP11-297A16.2 7.29 1.29e-12 9.91e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35008214 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs2001893 ENSG00000230534.5 RP11-297A16.2 7.29 1.29e-12 9.91e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35011695 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs35317849 ENSG00000230534.5 RP11-297A16.2 7.29 1.29e-12 9.93e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34996793 chr10:35098006~35127020:- LUSC cis rs9532669 0.926 rs6560963 ENSG00000176268.5 CYCSP34 7.29 1.3e-12 9.93e-10 0.31 0.32 Cervical cancer; chr13:40871126 chr13:40863599~40863902:- LUSC cis rs34779708 0.931 rs10508815 ENSG00000230534.5 RP11-297A16.2 7.29 1.3e-12 9.95e-10 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35043693 chr10:35098006~35127020:- LUSC cis rs4713118 0.629 rs149899 ENSG00000204709.4 LINC01556 7.29 1.31e-12 1e-09 0.45 0.32 Parkinson's disease; chr6:28052201 chr6:28943877~28944537:+ LUSC cis rs4713118 0.629 rs172165 ENSG00000204709.4 LINC01556 7.29 1.31e-12 1e-09 0.45 0.32 Parkinson's disease; chr6:28053036 chr6:28943877~28944537:+ LUSC cis rs4713118 0.597 rs172166 ENSG00000204709.4 LINC01556 7.29 1.31e-12 1e-09 0.45 0.32 Parkinson's disease; chr6:28053042 chr6:28943877~28944537:+ LUSC cis rs11089937 0.512 rs34963809 ENSG00000211639.2 IGLV4-60 7.29 1.31e-12 1e-09 0.36 0.32 Periodontitis (PAL4Q3); chr22:22130737 chr22:22162199~22162681:+ LUSC cis rs875971 0.862 rs28470208 ENSG00000237310.1 GS1-124K5.4 -7.29 1.31e-12 1.01e-09 -0.33 -0.32 Aortic root size; chr7:66119713 chr7:66493706~66495474:+ LUSC cis rs494459 0.536 rs11217063 ENSG00000255239.1 AP002954.6 7.29 1.32e-12 1.01e-09 0.35 0.32 Height; chr11:118855233 chr11:118688039~118690600:- LUSC cis rs4713118 0.513 rs149944 ENSG00000204709.4 LINC01556 7.29 1.32e-12 1.01e-09 0.4 0.32 Parkinson's disease; chr6:28035040 chr6:28943877~28944537:+ LUSC cis rs150992 0.504 rs7723242 ENSG00000248489.1 CTD-2007H13.3 -7.29 1.32e-12 1.01e-09 -0.42 -0.32 Body mass index; chr5:99023408 chr5:98929171~98995013:+ LUSC cis rs6142102 0.962 rs2206448 ENSG00000276073.1 RP5-1125A11.7 -7.29 1.32e-12 1.01e-09 -0.33 -0.32 Skin pigmentation; chr20:34121719 chr20:33985617~33988989:- LUSC cis rs3779195 0.929 rs1635612 ENSG00000272950.1 RP11-307C18.1 7.29 1.33e-12 1.01e-09 0.53 0.32 Sex hormone-binding globulin levels; chr7:98385737 chr7:98322853~98323430:+ LUSC cis rs667920 0.573 rs9682783 ENSG00000239213.4 NCK1-AS1 7.29 1.33e-12 1.02e-09 0.4 0.32 Coronary artery disease; chr3:136820847 chr3:136841726~136862054:- LUSC cis rs7945705 0.934 rs1988709 ENSG00000254860.4 TMEM9B-AS1 -7.29 1.33e-12 1.02e-09 -0.35 -0.32 Hemoglobin concentration; chr11:8861343 chr11:8964675~8977527:+ LUSC cis rs875971 0.522 rs1917563 ENSG00000224316.1 RP11-479O9.2 -7.29 1.33e-12 1.02e-09 -0.3 -0.32 Aortic root size; chr7:65950660 chr7:65773620~65802067:+ LUSC cis rs875971 0.522 rs34973832 ENSG00000236529.1 RP13-254B10.1 7.29 1.34e-12 1.02e-09 0.33 0.32 Aortic root size; chr7:65931217 chr7:65840212~65840596:+ LUSC cis rs189798 0.807 rs330905 ENSG00000254340.1 RP11-10A14.3 7.29 1.34e-12 1.03e-09 0.41 0.32 Myopia (pathological); chr8:9136041 chr8:9141424~9145435:+ LUSC cis rs748404 0.697 rs555001 ENSG00000249839.1 AC011330.5 -7.29 1.34e-12 1.03e-09 -0.41 -0.32 Lung cancer; chr15:43253530 chr15:43663654~43684339:- LUSC cis rs748404 0.697 rs475261 ENSG00000249839.1 AC011330.5 -7.29 1.34e-12 1.03e-09 -0.41 -0.32 Lung cancer; chr15:43254258 chr15:43663654~43684339:- LUSC cis rs7250849 1 rs7250849 ENSG00000273837.1 LLNLR-470E3.1 7.29 1.35e-12 1.03e-09 0.51 0.32 Blood protein levels; chr19:51655063 chr19:51639478~51639931:- LUSC cis rs34779708 0.931 rs7923217 ENSG00000230534.5 RP11-297A16.2 7.29 1.35e-12 1.03e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35020661 chr10:35098006~35127020:- LUSC cis rs760794 0.533 rs2206034 ENSG00000227116.1 RP3-471C18.1 -7.29 1.35e-12 1.04e-09 -0.36 -0.32 Endometriosis; chr6:19796632 chr6:19730427~19734567:- LUSC cis rs8070463 0.515 rs11655943 ENSG00000228782.6 CTD-2026D20.3 7.29 1.36e-12 1.04e-09 0.3 0.32 Multiple sclerosis;Ankylosing spondylitis; chr17:47308274 chr17:47450568~47492492:- LUSC cis rs6907340 0.517 rs9465533 ENSG00000237404.1 RP3-471C18.2 -7.28 1.37e-12 1.05e-09 -0.42 -0.32 Endometriosis; chr6:19801477 chr6:19689825~19753113:- LUSC cis rs1113500 0.814 rs893983 ENSG00000226822.1 RP11-356N1.2 -7.28 1.37e-12 1.05e-09 -0.32 -0.32 Growth-regulated protein alpha levels; chr1:108087716 chr1:108071482~108074519:+ LUSC cis rs8059260 0.668 rs75811377 ENSG00000274038.1 RP11-66H6.4 -7.28 1.37e-12 1.05e-09 -0.55 -0.32 Alcohol consumption over the past year; chr16:11023451 chr16:11056556~11057034:+ LUSC cis rs875971 0.895 rs6460278 ENSG00000237310.1 GS1-124K5.4 -7.28 1.38e-12 1.05e-09 -0.33 -0.32 Aortic root size; chr7:66197749 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6460279 ENSG00000237310.1 GS1-124K5.4 -7.28 1.38e-12 1.05e-09 -0.33 -0.32 Aortic root size; chr7:66197774 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs28491091 ENSG00000237310.1 GS1-124K5.4 -7.28 1.38e-12 1.05e-09 -0.33 -0.32 Aortic root size; chr7:66204077 chr7:66493706~66495474:+ LUSC cis rs34779708 0.966 rs11010095 ENSG00000230534.5 RP11-297A16.2 7.28 1.38e-12 1.05e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35107020 chr10:35098006~35127020:- LUSC cis rs8072100 0.875 rs7208530 ENSG00000228782.6 CTD-2026D20.3 7.28 1.38e-12 1.06e-09 0.31 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47466741 chr17:47450568~47492492:- LUSC cis rs8072100 0.875 rs12451409 ENSG00000228782.6 CTD-2026D20.3 7.28 1.38e-12 1.06e-09 0.31 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47467490 chr17:47450568~47492492:- LUSC cis rs875971 0.862 rs2460432 ENSG00000237310.1 GS1-124K5.4 -7.28 1.39e-12 1.06e-09 -0.34 -0.32 Aortic root size; chr7:66089398 chr7:66493706~66495474:+ LUSC cis rs2739330 0.652 rs2000469 ENSG00000235689.1 AP000351.13 7.28 1.39e-12 1.06e-09 0.35 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:24006305~24008258:- LUSC cis rs1113500 0.548 rs3853495 ENSG00000226822.1 RP11-356N1.2 7.28 1.39e-12 1.07e-09 0.38 0.32 Growth-regulated protein alpha levels; chr1:108100623 chr1:108071482~108074519:+ LUSC cis rs13113518 0.783 rs12510400 ENSG00000223305.1 RN7SKP30 7.28 1.4e-12 1.07e-09 0.39 0.32 Height; chr4:55577294 chr4:55540502~55540835:- LUSC cis rs13113518 0.783 rs13111128 ENSG00000223305.1 RN7SKP30 7.28 1.4e-12 1.07e-09 0.39 0.32 Height; chr4:55578154 chr4:55540502~55540835:- LUSC cis rs8040855 0.603 rs10520585 ENSG00000259295.5 CSPG4P12 -7.28 1.4e-12 1.07e-09 -0.41 -0.32 Bulimia nervosa; chr15:85118275 chr15:85191438~85213905:+ LUSC cis rs673078 0.607 rs61943393 ENSG00000275759.1 RP11-131L12.3 -7.28 1.4e-12 1.07e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118383650 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs73205576 ENSG00000275759.1 RP11-131L12.3 -7.28 1.4e-12 1.07e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118384268 chr12:118428281~118428870:+ LUSC cis rs783540 0.521 rs1259176 ENSG00000255769.6 GOLGA2P10 7.28 1.4e-12 1.07e-09 0.44 0.32 Schizophrenia; chr15:82602149 chr15:82472993~82513950:- LUSC cis rs465969 1 rs13208890 ENSG00000255389.1 C6orf3 -7.28 1.41e-12 1.08e-09 -0.56 -0.32 Psoriasis; chr6:111500620 chr6:111599875~111602295:+ LUSC cis rs10129255 0.957 rs12590735 ENSG00000211972.2 IGHV3-66 7.28 1.41e-12 1.08e-09 0.24 0.32 Kawasaki disease; chr14:106779660 chr14:106675017~106675544:- LUSC cis rs6471393 0.798 rs62525169 ENSG00000253848.1 RP11-10N23.5 7.28 1.41e-12 1.08e-09 0.42 0.32 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93804169 chr8:93741193~93744534:+ LUSC cis rs7811142 1 rs6979335 ENSG00000242294.5 STAG3L5P 7.28 1.42e-12 1.08e-09 0.27 0.32 Platelet count; chr7:100492237 chr7:100336079~100351900:+ LUSC cis rs7945705 0.967 rs10769970 ENSG00000254860.4 TMEM9B-AS1 -7.28 1.42e-12 1.08e-09 -0.36 -0.32 Hemoglobin concentration; chr11:8896390 chr11:8964675~8977527:+ LUSC cis rs7945705 0.967 rs10840148 ENSG00000254860.4 TMEM9B-AS1 -7.28 1.42e-12 1.08e-09 -0.36 -0.32 Hemoglobin concentration; chr11:8901981 chr11:8964675~8977527:+ LUSC cis rs875971 0.862 rs10256544 ENSG00000222364.1 RNU6-96P -7.28 1.42e-12 1.08e-09 -0.38 -0.32 Aortic root size; chr7:66210141 chr7:66395191~66395286:+ LUSC cis rs10129255 0.719 rs7156660 ENSG00000211972.2 IGHV3-66 7.28 1.42e-12 1.09e-09 0.23 0.32 Kawasaki disease; chr14:106673171 chr14:106675017~106675544:- LUSC cis rs36423 0.528 rs1205066 ENSG00000266869.1 RP6-114E22.1 7.28 1.42e-12 1.09e-09 0.51 0.32 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71880340 chr14:71848606~71908430:+ LUSC cis rs673078 0.607 rs61943444 ENSG00000275759.1 RP11-131L12.3 -7.28 1.42e-12 1.09e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118421641 chr12:118428281~118428870:+ LUSC cis rs801193 0.569 rs13242290 ENSG00000222364.1 RNU6-96P 7.28 1.43e-12 1.09e-09 0.38 0.32 Aortic root size; chr7:66656898 chr7:66395191~66395286:+ LUSC cis rs11098499 0.82 rs2389885 ENSG00000250412.1 KLHL2P1 7.28 1.43e-12 1.09e-09 0.41 0.32 Corneal astigmatism; chr4:119612776 chr4:119334329~119378233:+ LUSC cis rs10129255 0.957 rs12589190 ENSG00000224373.3 IGHV4-59 7.28 1.43e-12 1.09e-09 0.18 0.32 Kawasaki disease; chr14:106783079 chr14:106627249~106627825:- LUSC cis rs8059260 0.668 rs4781029 ENSG00000274038.1 RP11-66H6.4 -7.28 1.43e-12 1.09e-09 -0.53 -0.32 Alcohol consumption over the past year; chr16:10983717 chr16:11056556~11057034:+ LUSC cis rs4423214 0.592 rs79634040 ENSG00000254682.1 RP11-660L16.2 -7.28 1.43e-12 1.09e-09 -0.54 -0.32 Vitamin D levels; chr11:71519123 chr11:71448674~71452157:+ LUSC cis rs11098499 0.863 rs2170276 ENSG00000250412.1 KLHL2P1 7.28 1.44e-12 1.1e-09 0.4 0.32 Corneal astigmatism; chr4:119564669 chr4:119334329~119378233:+ LUSC cis rs1865760 1 rs2071299 ENSG00000272462.2 U91328.19 -7.28 1.44e-12 1.1e-09 -0.34 -0.32 Height; chr6:25914573 chr6:25992662~26001775:+ LUSC cis rs1865760 1 rs2071298 ENSG00000272462.2 U91328.19 -7.28 1.44e-12 1.1e-09 -0.34 -0.32 Height; chr6:25914673 chr6:25992662~26001775:+ LUSC cis rs1865760 0.964 rs1324084 ENSG00000272462.2 U91328.19 -7.28 1.44e-12 1.1e-09 -0.34 -0.32 Height; chr6:25914906 chr6:25992662~26001775:+ LUSC cis rs7945705 0.935 rs11042102 ENSG00000254860.4 TMEM9B-AS1 -7.28 1.44e-12 1.1e-09 -0.35 -0.32 Hemoglobin concentration; chr11:8860617 chr11:8964675~8977527:+ LUSC cis rs10129255 0.957 rs6576233 ENSG00000224373.3 IGHV4-59 7.28 1.44e-12 1.1e-09 0.18 0.32 Kawasaki disease; chr14:106787239 chr14:106627249~106627825:- LUSC cis rs761746 0.542 rs7290856 ENSG00000236132.1 CTA-440B3.1 -7.28 1.44e-12 1.1e-09 -0.45 -0.32 Intelligence; chr22:31834930 chr22:31816379~31817491:- LUSC cis rs673078 0.607 rs61944669 ENSG00000275759.1 RP11-131L12.3 -7.28 1.44e-12 1.1e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118448530 chr12:118428281~118428870:+ LUSC cis rs6991838 0.733 rs13281981 ENSG00000200714.1 Y_RNA 7.28 1.45e-12 1.1e-09 0.38 0.32 Intelligence (multi-trait analysis); chr8:65611649 chr8:65592731~65592820:+ LUSC cis rs1865760 0.963 rs9356991 ENSG00000272462.2 U91328.19 -7.28 1.45e-12 1.1e-09 -0.34 -0.32 Height; chr6:25901530 chr6:25992662~26001775:+ LUSC cis rs11098499 0.644 rs28787668 ENSG00000249244.1 RP11-548H18.2 7.28 1.45e-12 1.1e-09 0.4 0.32 Corneal astigmatism; chr4:119633532 chr4:119391831~119395335:- LUSC cis rs8072100 0.512 rs9303533 ENSG00000228782.6 CTD-2026D20.3 7.28 1.45e-12 1.1e-09 0.3 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309174 chr17:47450568~47492492:- LUSC cis rs13113518 0.812 rs1522114 ENSG00000223305.1 RN7SKP30 7.28 1.45e-12 1.11e-09 0.39 0.32 Height; chr4:55489895 chr4:55540502~55540835:- LUSC cis rs783540 0.5 rs1313494 ENSG00000255769.6 GOLGA2P10 7.28 1.45e-12 1.11e-09 0.44 0.32 Schizophrenia; chr15:82605530 chr15:82472993~82513950:- LUSC cis rs2404602 0.684 rs12437981 ENSG00000259422.1 RP11-593F23.1 -7.28 1.46e-12 1.11e-09 -0.38 -0.32 Blood metabolite levels; chr15:76550060 chr15:76174891~76181486:- LUSC cis rs4423214 0.61 rs12793607 ENSG00000254682.1 RP11-660L16.2 -7.28 1.46e-12 1.11e-09 -0.38 -0.32 Vitamin D levels; chr11:71418270 chr11:71448674~71452157:+ LUSC cis rs6782228 1 rs35871360 ENSG00000277250.1 Metazoa_SRP 7.28 1.46e-12 1.11e-09 0.39 0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128617286 chr3:128673681~128674021:- LUSC cis rs10129255 1 rs11627342 ENSG00000280411.1 IGHV1-69-2 -7.27 1.47e-12 1.12e-09 -0.22 -0.32 Kawasaki disease; chr14:106675823 chr14:106762092~106762588:- LUSC cis rs113835537 0.597 rs3737525 ENSG00000255517.5 CTD-3074O7.5 -7.27 1.47e-12 1.12e-09 -0.37 -0.32 Airway imaging phenotypes; chr11:66538884 chr11:66473490~66480233:- LUSC cis rs17711722 0.565 rs4275112 ENSG00000236529.1 RP13-254B10.1 -7.27 1.47e-12 1.12e-09 -0.33 -0.32 Calcium levels; chr7:65733651 chr7:65840212~65840596:+ LUSC cis rs1075265 0.836 rs11687324 ENSG00000233266.1 HMGB1P31 7.27 1.47e-12 1.12e-09 0.41 0.32 Chronotype;Morning vs. evening chronotype; chr2:54046589 chr2:54051334~54051760:+ LUSC cis rs853679 0.55 rs1150692 ENSG00000204709.4 LINC01556 7.27 1.47e-12 1.12e-09 0.44 0.32 Depression; chr6:28206179 chr6:28943877~28944537:+ LUSC cis rs1757171 0.542 rs3818986 ENSG00000204110.6 RP1-153P14.8 -7.27 1.49e-12 1.13e-09 -0.31 -0.32 Cognitive performance; chr6:37516573 chr6:37507348~37535616:+ LUSC cis rs17023223 0.581 rs61808932 ENSG00000231365.4 RP11-418J17.1 -7.27 1.49e-12 1.13e-09 -0.42 -0.32 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119101197 chr1:119140396~119275973:+ LUSC cis rs9545047 0.716 rs418150 ENSG00000227676.3 LINC01068 -7.27 1.49e-12 1.13e-09 -0.38 -0.32 Schizophrenia; chr13:79432675 chr13:79566727~79571436:+ LUSC cis rs6142102 0.502 rs58393429 ENSG00000276073.1 RP5-1125A11.7 -7.27 1.49e-12 1.13e-09 -0.32 -0.32 Skin pigmentation; chr20:33957996 chr20:33985617~33988989:- LUSC cis rs950169 0.8 rs34302901 ENSG00000259728.4 LINC00933 7.27 1.5e-12 1.14e-09 0.4 0.32 Schizophrenia; chr15:84567712 chr15:84570649~84580175:+ LUSC cis rs1865760 1 rs1865760 ENSG00000272462.2 U91328.19 -7.27 1.51e-12 1.15e-09 -0.34 -0.32 Height; chr6:25916751 chr6:25992662~26001775:+ LUSC cis rs875971 0.522 rs7784623 ENSG00000236529.1 RP13-254B10.1 7.27 1.51e-12 1.15e-09 0.33 0.32 Aortic root size; chr7:65930047 chr7:65840212~65840596:+ LUSC cis rs875971 0.964 rs160635 ENSG00000222364.1 RNU6-96P -7.27 1.51e-12 1.15e-09 -0.38 -0.32 Aortic root size; chr7:66063931 chr7:66395191~66395286:+ LUSC cis rs11168854 0.93 rs10783302 ENSG00000258017.1 RP11-386G11.10 7.27 1.51e-12 1.15e-09 0.39 0.32 Body mass index; chr12:49104347 chr12:49127782~49147869:+ LUSC cis rs66887589 0.967 rs1480933 ENSG00000245958.5 RP11-33B1.1 -7.27 1.51e-12 1.15e-09 -0.3 -0.32 Diastolic blood pressure; chr4:119512093 chr4:119454791~119552025:+ LUSC cis rs10129255 0.5 rs10143242 ENSG00000224373.3 IGHV4-59 7.27 1.51e-12 1.15e-09 0.16 0.32 Kawasaki disease; chr14:106681814 chr14:106627249~106627825:- LUSC cis rs1823913 0.927 rs35092718 ENSG00000280083.1 RP11-317J9.1 -7.27 1.52e-12 1.16e-09 -0.39 -0.32 Obesity-related traits; chr2:191243882 chr2:191154118~191156070:- LUSC cis rs1075265 0.87 rs6724389 ENSG00000233266.1 HMGB1P31 7.27 1.52e-12 1.16e-09 0.4 0.32 Chronotype;Morning vs. evening chronotype; chr2:53985698 chr2:54051334~54051760:+ LUSC cis rs9322193 0.566 rs3922947 ENSG00000223701.3 RAET1E-AS1 -7.27 1.53e-12 1.16e-09 -0.41 -0.32 Lung cancer; chr6:149924856 chr6:149884431~149919508:+ LUSC cis rs4660456 0.912 rs658806 ENSG00000237899.1 RP4-739H11.3 7.27 1.53e-12 1.16e-09 0.47 0.32 Platelet count; chr1:40683312 chr1:40669089~40687588:- LUSC cis rs4660456 0.913 rs489222 ENSG00000237899.1 RP4-739H11.3 7.27 1.53e-12 1.16e-09 0.47 0.32 Platelet count; chr1:40683422 chr1:40669089~40687588:- LUSC cis rs4660456 0.871 rs671704 ENSG00000237899.1 RP4-739H11.3 7.27 1.53e-12 1.16e-09 0.47 0.32 Platelet count; chr1:40683974 chr1:40669089~40687588:- LUSC cis rs494459 0.536 rs57719838 ENSG00000255239.1 AP002954.6 7.27 1.53e-12 1.16e-09 0.35 0.32 Height; chr11:118854014 chr11:118688039~118690600:- LUSC cis rs11098499 0.604 rs17051352 ENSG00000245958.5 RP11-33B1.1 -7.27 1.53e-12 1.16e-09 -0.33 -0.32 Corneal astigmatism; chr4:119660272 chr4:119454791~119552025:+ LUSC cis rs465969 1 rs463543 ENSG00000255389.1 C6orf3 -7.27 1.53e-12 1.16e-09 -0.59 -0.32 Psoriasis; chr6:111346349 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs13213522 ENSG00000255389.1 C6orf3 -7.27 1.53e-12 1.16e-09 -0.59 -0.32 Psoriasis; chr6:111384138 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs17510761 ENSG00000255389.1 C6orf3 -7.27 1.53e-12 1.16e-09 -0.59 -0.32 Psoriasis; chr6:111387380 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs17510733 ENSG00000255389.1 C6orf3 -7.27 1.53e-12 1.16e-09 -0.59 -0.32 Psoriasis; chr6:111389715 chr6:111599875~111602295:+ LUSC cis rs875971 0.862 rs949930 ENSG00000237310.1 GS1-124K5.4 -7.27 1.54e-12 1.17e-09 -0.33 -0.32 Aortic root size; chr7:66301835 chr7:66493706~66495474:+ LUSC cis rs8396 1 rs4690909 ENSG00000271817.2 U3 -7.27 1.54e-12 1.17e-09 -0.31 -0.32 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158707999 chr4:158700691~158700909:+ LUSC cis rs904251 0.523 rs1776455 ENSG00000204110.6 RP1-153P14.8 -7.27 1.55e-12 1.18e-09 -0.3 -0.32 Cognitive performance; chr6:37515147 chr6:37507348~37535616:+ LUSC cis rs6782228 1 rs6801509 ENSG00000277250.1 Metazoa_SRP 7.27 1.55e-12 1.18e-09 0.39 0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128645426 chr3:128673681~128674021:- LUSC cis rs673078 0.607 rs73207504 ENSG00000275759.1 RP11-131L12.3 -7.27 1.55e-12 1.18e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118427914 chr12:118428281~118428870:+ LUSC cis rs4713118 0.513 rs1225591 ENSG00000204709.4 LINC01556 7.27 1.55e-12 1.18e-09 0.41 0.32 Parkinson's disease; chr6:28180974 chr6:28943877~28944537:+ LUSC cis rs875971 0.862 rs4368860 ENSG00000237310.1 GS1-124K5.4 -7.27 1.56e-12 1.18e-09 -0.33 -0.32 Aortic root size; chr7:66143495 chr7:66493706~66495474:+ LUSC cis rs4713118 0.662 rs175954 ENSG00000204709.4 LINC01556 7.27 1.56e-12 1.18e-09 0.44 0.32 Parkinson's disease; chr6:28043807 chr6:28943877~28944537:+ LUSC cis rs1113500 0.548 rs6583062 ENSG00000226822.1 RP11-356N1.2 7.27 1.56e-12 1.18e-09 0.37 0.32 Growth-regulated protein alpha levels; chr1:108113841 chr1:108071482~108074519:+ LUSC cis rs2337406 0.925 rs873533 ENSG00000274576.2 IGHV2-70 -7.27 1.56e-12 1.18e-09 -0.35 -0.32 Alzheimer's disease (late onset); chr14:106667442 chr14:106770577~106771020:- LUSC cis rs465969 0.744 rs36007392 ENSG00000255389.1 C6orf3 -7.27 1.56e-12 1.18e-09 -0.56 -0.32 Psoriasis; chr6:111509287 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs13197107 ENSG00000255389.1 C6orf3 -7.27 1.56e-12 1.18e-09 -0.56 -0.32 Psoriasis; chr6:111512031 chr6:111599875~111602295:+ LUSC cis rs465969 0.546 rs77990243 ENSG00000255389.1 C6orf3 -7.27 1.56e-12 1.18e-09 -0.56 -0.32 Psoriasis; chr6:111513183 chr6:111599875~111602295:+ LUSC cis rs7739264 0.563 rs9465516 ENSG00000227116.1 RP3-471C18.1 -7.26 1.56e-12 1.19e-09 -0.36 -0.32 Endometriosis; chr6:19771767 chr6:19730427~19734567:- LUSC cis rs7772486 0.597 rs7746618 ENSG00000235652.6 RP11-545I5.3 -7.26 1.56e-12 1.19e-09 -0.33 -0.32 Lobe attachment (rater-scored or self-reported); chr6:145960231 chr6:145799409~145886585:+ LUSC cis rs4853012 0.838 rs2177707 ENSG00000257800.1 FNBP1P1 7.26 1.57e-12 1.19e-09 0.38 0.32 Gestational age at birth (maternal effect); chr2:74129723 chr2:74120680~74123218:+ LUSC cis rs11603023 0.874 rs483598 ENSG00000255239.1 AP002954.6 7.26 1.57e-12 1.19e-09 0.37 0.32 Cholesterol, total; chr11:118638950 chr11:118688039~118690600:- LUSC cis rs9532669 0.89 rs4941999 ENSG00000176268.5 CYCSP34 7.26 1.57e-12 1.19e-09 0.31 0.32 Cervical cancer; chr13:40859926 chr13:40863599~40863902:- LUSC cis rs1113500 0.814 rs12039712 ENSG00000226822.1 RP11-356N1.2 7.26 1.57e-12 1.19e-09 0.32 0.32 Growth-regulated protein alpha levels; chr1:108098577 chr1:108071482~108074519:+ LUSC cis rs10129255 0.957 rs8014696 ENSG00000224373.3 IGHV4-59 -7.26 1.57e-12 1.19e-09 -0.18 -0.32 Kawasaki disease; chr14:106769752 chr14:106627249~106627825:- LUSC cis rs34779708 0.931 rs35388511 ENSG00000230534.5 RP11-297A16.2 7.26 1.58e-12 1.2e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35007688 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs34815241 ENSG00000230534.5 RP11-297A16.2 7.26 1.58e-12 1.2e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35007748 chr10:35098006~35127020:- LUSC cis rs66887589 0.777 rs10015883 ENSG00000245958.5 RP11-33B1.1 -7.26 1.58e-12 1.2e-09 -0.3 -0.32 Diastolic blood pressure; chr4:119346991 chr4:119454791~119552025:+ LUSC cis rs673078 0.607 rs7305647 ENSG00000275759.1 RP11-131L12.3 -7.26 1.58e-12 1.2e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118417761 chr12:118428281~118428870:+ LUSC cis rs75422866 0.51 rs75424057 ENSG00000274902.1 RP1-197B17.4 7.26 1.59e-12 1.2e-09 0.75 0.32 Pneumonia; chr12:47737294 chr12:47731908~47732351:+ LUSC cis rs875971 0.928 rs2036263 ENSG00000237310.1 GS1-124K5.4 -7.26 1.59e-12 1.2e-09 -0.33 -0.32 Aortic root size; chr7:66335210 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs10240949 ENSG00000237310.1 GS1-124K5.4 -7.26 1.59e-12 1.2e-09 -0.33 -0.32 Aortic root size; chr7:66339430 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs7782704 ENSG00000237310.1 GS1-124K5.4 -7.26 1.59e-12 1.2e-09 -0.33 -0.32 Aortic root size; chr7:66340379 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6959268 ENSG00000237310.1 GS1-124K5.4 -7.26 1.59e-12 1.2e-09 -0.33 -0.32 Aortic root size; chr7:66347979 chr7:66493706~66495474:+ LUSC cis rs7044106 0.537 rs10739573 ENSG00000226752.6 PSMD5-AS1 -7.26 1.59e-12 1.21e-09 -0.39 -0.32 Hip circumference adjusted for BMI; chr9:120727540 chr9:120824828~120854385:+ LUSC cis rs10129255 1 rs10129407 ENSG00000224373.3 IGHV4-59 7.26 1.6e-12 1.21e-09 0.18 0.32 Kawasaki disease; chr14:106767956 chr14:106627249~106627825:- LUSC cis rs9322193 0.962 rs4870048 ENSG00000223701.3 RAET1E-AS1 7.26 1.6e-12 1.21e-09 0.36 0.32 Lung cancer; chr6:149834324 chr6:149884431~149919508:+ LUSC cis rs875971 0.825 rs4587224 ENSG00000237310.1 GS1-124K5.4 -7.26 1.61e-12 1.22e-09 -0.33 -0.32 Aortic root size; chr7:66271195 chr7:66493706~66495474:+ LUSC cis rs9322193 0.607 rs7764677 ENSG00000223701.3 RAET1E-AS1 7.26 1.61e-12 1.22e-09 0.4 0.32 Lung cancer; chr6:149906197 chr6:149884431~149919508:+ LUSC cis rs673078 0.607 rs17441172 ENSG00000275759.1 RP11-131L12.3 7.26 1.61e-12 1.22e-09 0.46 0.32 Glucose homeostasis traits; chr12:118430456 chr12:118428281~118428870:+ LUSC cis rs875971 0.54 rs736270 ENSG00000224316.1 RP11-479O9.2 7.26 1.62e-12 1.23e-09 0.31 0.32 Aortic root size; chr7:65963835 chr7:65773620~65802067:+ LUSC cis rs9549367 0.713 rs2476328 ENSG00000269125.1 RP11-98F14.11 7.26 1.62e-12 1.23e-09 0.4 0.32 Platelet distribution width; chr13:113175036 chr13:113165002~113165183:- LUSC cis rs526231 0.578 rs10463553 ENSG00000175749.11 EIF3KP1 7.26 1.62e-12 1.23e-09 0.39 0.32 Primary biliary cholangitis; chr5:102913503 chr5:103032376~103033031:+ LUSC cis rs4237845 0.611 rs10877036 ENSG00000257159.1 RP11-58A17.3 -7.26 1.62e-12 1.23e-09 -0.38 -0.32 Intelligence (multi-trait analysis); chr12:57927867 chr12:57967058~57968399:+ LUSC cis rs1075265 0.87 rs1421617 ENSG00000233266.1 HMGB1P31 7.26 1.62e-12 1.23e-09 0.4 0.32 Chronotype;Morning vs. evening chronotype; chr2:54032995 chr2:54051334~54051760:+ LUSC cis rs10129255 0.83 rs61997609 ENSG00000280411.1 IGHV1-69-2 -7.26 1.62e-12 1.23e-09 -0.22 -0.32 Kawasaki disease; chr14:106692376 chr14:106762092~106762588:- LUSC cis rs17270561 0.887 rs12201170 ENSG00000272462.2 U91328.19 -7.26 1.63e-12 1.23e-09 -0.43 -0.32 Iron status biomarkers; chr6:25866019 chr6:25992662~26001775:+ LUSC cis rs2980439 0.846 rs2980437 ENSG00000173295.6 FAM86B3P -7.26 1.63e-12 1.23e-09 -0.35 -0.32 Neuroticism; chr8:8237241 chr8:8228595~8244865:+ LUSC cis rs3096299 0.933 rs3096297 ENSG00000274627.1 RP11-104N10.2 7.26 1.63e-12 1.24e-09 0.28 0.32 Multiple myeloma (IgH translocation); chr16:89386747 chr16:89516797~89522217:+ LUSC cis rs875971 0.522 rs1880556 ENSG00000236529.1 RP13-254B10.1 7.26 1.63e-12 1.24e-09 0.33 0.32 Aortic root size; chr7:65967557 chr7:65840212~65840596:+ LUSC cis rs10129255 0.957 rs10141052 ENSG00000211972.2 IGHV3-66 7.26 1.64e-12 1.24e-09 0.24 0.32 Kawasaki disease; chr14:106776528 chr14:106675017~106675544:- LUSC cis rs10129255 0.957 rs10141009 ENSG00000211972.2 IGHV3-66 7.26 1.64e-12 1.24e-09 0.24 0.32 Kawasaki disease; chr14:106776695 chr14:106675017~106675544:- LUSC cis rs2412819 0.571 rs4923964 ENSG00000249839.1 AC011330.5 7.26 1.64e-12 1.24e-09 0.5 0.32 Lung cancer; chr15:43722882 chr15:43663654~43684339:- LUSC cis rs6921919 0.583 rs2071965 ENSG00000204709.4 LINC01556 7.26 1.64e-12 1.24e-09 0.4 0.32 Autism spectrum disorder or schizophrenia; chr6:28435448 chr6:28943877~28944537:+ LUSC cis rs11603023 0.772 rs540800 ENSG00000255239.1 AP002954.6 7.26 1.64e-12 1.24e-09 0.38 0.32 Cholesterol, total; chr11:118694942 chr11:118688039~118690600:- LUSC cis rs875971 0.54 rs4717275 ENSG00000236529.1 RP13-254B10.1 -7.26 1.64e-12 1.24e-09 -0.33 -0.32 Aortic root size; chr7:65800193 chr7:65840212~65840596:+ LUSC cis rs1865760 0.964 rs3799373 ENSG00000272462.2 U91328.19 -7.26 1.66e-12 1.25e-09 -0.34 -0.32 Height; chr6:25928945 chr6:25992662~26001775:+ LUSC cis rs11123694 1 rs11123694 ENSG00000214184.3 AC012487.2 -7.26 1.66e-12 1.26e-09 -0.39 -0.32 Mean platelet volume; chr2:108448107 chr2:108507515~108534196:- LUSC cis rs35160687 0.901 rs6713456 ENSG00000273080.1 RP11-301O19.1 7.26 1.66e-12 1.26e-09 0.3 0.32 Night sleep phenotypes; chr2:86280530 chr2:86195590~86196049:+ LUSC cis rs61160187 0.61 rs4700397 ENSG00000215032.2 GNL3LP1 -7.26 1.66e-12 1.26e-09 -0.39 -0.32 Educational attainment (years of education);Educational attainment (college completion); chr5:60840135 chr5:60891935~60893577:- LUSC cis rs7772486 0.534 rs34541797 ENSG00000235652.6 RP11-545I5.3 7.26 1.67e-12 1.26e-09 0.33 0.32 Lobe attachment (rater-scored or self-reported); chr6:145884168 chr6:145799409~145886585:+ LUSC cis rs673078 0.607 rs73207564 ENSG00000275759.1 RP11-131L12.3 -7.25 1.67e-12 1.27e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118429566 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943447 ENSG00000275759.1 RP11-131L12.3 -7.25 1.67e-12 1.27e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118430598 chr12:118428281~118428870:+ LUSC cis rs17711722 0.653 rs2460421 ENSG00000224316.1 RP11-479O9.2 -7.25 1.67e-12 1.27e-09 -0.3 -0.32 Calcium levels; chr7:66026136 chr7:65773620~65802067:+ LUSC cis rs1113500 0.73 rs1781080 ENSG00000226822.1 RP11-356N1.2 -7.25 1.68e-12 1.27e-09 -0.31 -0.32 Growth-regulated protein alpha levels; chr1:108050793 chr1:108071482~108074519:+ LUSC cis rs10129255 0.912 rs67410411 ENSG00000224373.3 IGHV4-59 7.25 1.69e-12 1.28e-09 0.18 0.32 Kawasaki disease; chr14:106680324 chr14:106627249~106627825:- LUSC cis rs2404602 0.684 rs10851888 ENSG00000259422.1 RP11-593F23.1 -7.25 1.7e-12 1.28e-09 -0.38 -0.32 Blood metabolite levels; chr15:76610165 chr15:76174891~76181486:- LUSC cis rs748404 0.723 rs573169 ENSG00000249839.1 AC011330.5 -7.25 1.7e-12 1.28e-09 -0.41 -0.32 Lung cancer; chr15:43258383 chr15:43663654~43684339:- LUSC cis rs748404 0.697 rs524547 ENSG00000249839.1 AC011330.5 -7.25 1.7e-12 1.28e-09 -0.41 -0.32 Lung cancer; chr15:43258825 chr15:43663654~43684339:- LUSC cis rs34779708 0.931 rs4934524 ENSG00000230534.5 RP11-297A16.2 7.25 1.7e-12 1.28e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34981993 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs4934693 ENSG00000230534.5 RP11-297A16.2 7.25 1.7e-12 1.28e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34982916 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs11592404 ENSG00000230534.5 RP11-297A16.2 7.25 1.7e-12 1.28e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34984548 chr10:35098006~35127020:- LUSC cis rs2337406 1 rs11850709 ENSG00000274576.2 IGHV2-70 -7.25 1.7e-12 1.29e-09 -0.35 -0.32 Alzheimer's disease (late onset); chr14:106670844 chr14:106770577~106771020:- LUSC cis rs3750965 0.959 rs4930265 ENSG00000260895.1 RP11-554A11.7 7.25 1.7e-12 1.29e-09 0.37 0.32 Hair color; chr11:69088486 chr11:69103493~69109094:+ LUSC cis rs1113500 0.787 rs10881501 ENSG00000226822.1 RP11-356N1.2 7.25 1.7e-12 1.29e-09 0.32 0.32 Growth-regulated protein alpha levels; chr1:108099123 chr1:108071482~108074519:+ LUSC cis rs34779708 0.931 rs9663401 ENSG00000230534.5 RP11-297A16.2 7.25 1.71e-12 1.29e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34989921 chr10:35098006~35127020:- LUSC cis rs34779708 0.897 rs9787566 ENSG00000230534.5 RP11-297A16.2 7.25 1.71e-12 1.29e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34990527 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs4351760 ENSG00000230534.5 RP11-297A16.2 7.25 1.71e-12 1.29e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34991326 chr10:35098006~35127020:- LUSC cis rs34779708 0.898 rs4934695 ENSG00000230534.5 RP11-297A16.2 7.25 1.71e-12 1.29e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34991677 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs79749947 ENSG00000230534.5 RP11-297A16.2 7.25 1.72e-12 1.3e-09 0.36 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34988153 chr10:35098006~35127020:- LUSC cis rs10129255 0.917 rs8022493 ENSG00000224373.3 IGHV4-59 7.25 1.72e-12 1.3e-09 0.17 0.32 Kawasaki disease; chr14:106781820 chr14:106627249~106627825:- LUSC cis rs1113500 0.787 rs4571989 ENSG00000226822.1 RP11-356N1.2 7.25 1.73e-12 1.31e-09 0.32 0.32 Growth-regulated protein alpha levels; chr1:108088722 chr1:108071482~108074519:+ LUSC cis rs10129255 1 rs10129255 ENSG00000280411.1 IGHV1-69-2 7.25 1.74e-12 1.31e-09 0.22 0.32 Kawasaki disease; chr14:106767970 chr14:106762092~106762588:- LUSC cis rs673078 0.607 rs111607725 ENSG00000275759.1 RP11-131L12.3 -7.25 1.74e-12 1.32e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118442957 chr12:118428281~118428870:+ LUSC cis rs7309 0.935 rs11884495 ENSG00000227403.1 AC009299.3 -7.25 1.75e-12 1.32e-09 -0.4 -0.32 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161203458 chr2:161244739~161249050:+ LUSC cis rs9545047 0.716 rs8001795 ENSG00000227676.3 LINC01068 7.25 1.75e-12 1.32e-09 0.39 0.32 Schizophrenia; chr13:79421402 chr13:79566727~79571436:+ LUSC cis rs7309 0.935 rs1921309 ENSG00000227403.1 AC009299.3 -7.25 1.76e-12 1.33e-09 -0.4 -0.32 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161192464 chr2:161244739~161249050:+ LUSC cis rs1075265 0.87 rs1363062 ENSG00000233266.1 HMGB1P31 7.25 1.76e-12 1.33e-09 0.4 0.32 Chronotype;Morning vs. evening chronotype; chr2:54054625 chr2:54051334~54051760:+ LUSC cis rs7309 0.935 rs6432674 ENSG00000227403.1 AC009299.3 -7.25 1.76e-12 1.33e-09 -0.4 -0.32 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161168811 chr2:161244739~161249050:+ LUSC cis rs7309 0.81 rs11684253 ENSG00000227403.1 AC009299.3 -7.25 1.76e-12 1.33e-09 -0.4 -0.32 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161178025 chr2:161244739~161249050:+ LUSC cis rs853679 0.527 rs853693 ENSG00000204709.4 LINC01556 7.25 1.76e-12 1.33e-09 0.4 0.32 Depression; chr6:28314871 chr6:28943877~28944537:+ LUSC cis rs6921919 0.515 rs1339898 ENSG00000204709.4 LINC01556 7.25 1.78e-12 1.34e-09 0.39 0.32 Autism spectrum disorder or schizophrenia; chr6:28427729 chr6:28943877~28944537:+ LUSC cis rs1061377 0.674 rs34506243 ENSG00000249207.1 RP11-360F5.1 -7.25 1.78e-12 1.34e-09 -0.34 -0.32 Uric acid levels; chr4:39082702 chr4:39112677~39126818:- LUSC cis rs7945705 0.967 rs56316046 ENSG00000254860.4 TMEM9B-AS1 -7.24 1.78e-12 1.35e-09 -0.35 -0.32 Hemoglobin concentration; chr11:8855051 chr11:8964675~8977527:+ LUSC cis rs1113500 0.548 rs11185269 ENSG00000226822.1 RP11-356N1.2 7.24 1.79e-12 1.35e-09 0.37 0.32 Growth-regulated protein alpha levels; chr1:108105014 chr1:108071482~108074519:+ LUSC cis rs950169 0.881 rs34117475 ENSG00000225151.9 GOLGA2P7 -7.24 1.79e-12 1.35e-09 -0.44 -0.32 Schizophrenia; chr15:84565212 chr15:84199311~84230136:- LUSC cis rs8072100 0.544 rs9284377 ENSG00000228782.6 CTD-2026D20.3 7.24 1.79e-12 1.35e-09 0.3 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309046 chr17:47450568~47492492:- LUSC cis rs35160687 0.814 rs1863063 ENSG00000273080.1 RP11-301O19.1 7.24 1.79e-12 1.35e-09 0.3 0.32 Night sleep phenotypes; chr2:86291126 chr2:86195590~86196049:+ LUSC cis rs61160187 0.576 rs10805374 ENSG00000215032.2 GNL3LP1 7.24 1.8e-12 1.35e-09 0.4 0.32 Educational attainment (years of education);Educational attainment (college completion); chr5:61004078 chr5:60891935~60893577:- LUSC cis rs875971 0.54 rs1723268 ENSG00000236529.1 RP13-254B10.1 7.24 1.8e-12 1.36e-09 0.33 0.32 Aortic root size; chr7:66008093 chr7:65840212~65840596:+ LUSC cis rs10829156 0.66 rs7918933 ENSG00000240291.1 RP11-499P20.2 7.24 1.8e-12 1.36e-09 0.33 0.32 Sudden cardiac arrest; chr10:18517434 chr10:18513115~18545651:- LUSC cis rs4718428 1 rs12534637 ENSG00000226824.5 RP4-756H11.3 -7.24 1.81e-12 1.36e-09 -0.38 -0.32 Corneal structure; chr7:66862667 chr7:66654538~66669855:+ LUSC cis rs34779708 0.931 rs12240347 ENSG00000230534.5 RP11-297A16.2 7.24 1.82e-12 1.37e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35070547 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs4934533 ENSG00000230534.5 RP11-297A16.2 7.24 1.82e-12 1.37e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35070691 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs12248333 ENSG00000230534.5 RP11-297A16.2 7.24 1.82e-12 1.37e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35074049 chr10:35098006~35127020:- LUSC cis rs17711722 0.727 rs1880555 ENSG00000224316.1 RP11-479O9.2 7.24 1.82e-12 1.37e-09 0.3 0.32 Calcium levels; chr7:65967580 chr7:65773620~65802067:+ LUSC cis rs6142102 0.625 rs6141436 ENSG00000276073.1 RP5-1125A11.7 -7.24 1.82e-12 1.37e-09 -0.31 -0.32 Skin pigmentation; chr20:33966765 chr20:33985617~33988989:- LUSC cis rs4950322 0.542 rs28381210 ENSG00000278811.3 LINC00624 7.24 1.83e-12 1.37e-09 0.35 0.32 Protein quantitative trait loci; chr1:147201925 chr1:147258885~147517875:- LUSC cis rs34779708 0.931 rs2244100 ENSG00000230534.5 RP11-297A16.2 -7.24 1.83e-12 1.38e-09 -0.35 -0.32 Inflammatory bowel disease;Crohn's disease; chr10:35034708 chr10:35098006~35127020:- LUSC cis rs367615 0.552 rs2963023 ENSG00000249476.1 CTD-2587M2.1 -7.24 1.83e-12 1.38e-09 -0.36 -0.32 Colorectal cancer (SNP x SNP interaction); chr5:109394369 chr5:109237120~109326369:- LUSC cis rs9807989 0.507 rs1420097 ENSG00000234389.1 AC007278.3 -7.24 1.83e-12 1.38e-09 -0.3 -0.32 Asthma; chr2:102392894 chr2:102438713~102440475:+ LUSC cis rs12554020 0.892 rs75625893 ENSG00000227603.1 RP11-165J3.6 7.24 1.83e-12 1.38e-09 0.43 0.32 Schizophrenia; chr9:93605006 chr9:93435332~93437121:- LUSC cis rs34779708 0.931 rs6481935 ENSG00000230534.5 RP11-297A16.2 7.24 1.84e-12 1.38e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35054031 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs12242882 ENSG00000230534.5 RP11-297A16.2 7.24 1.84e-12 1.38e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35058932 chr10:35098006~35127020:- LUSC cis rs34779708 0.931 rs11010082 ENSG00000230534.5 RP11-297A16.2 7.24 1.84e-12 1.38e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35062227 chr10:35098006~35127020:- LUSC cis rs7621025 0.5 rs12629000 ENSG00000239213.4 NCK1-AS1 7.24 1.84e-12 1.38e-09 0.4 0.32 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136924729 chr3:136841726~136862054:- LUSC cis rs7621025 0.5 rs1965107 ENSG00000239213.4 NCK1-AS1 7.24 1.84e-12 1.38e-09 0.4 0.32 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136929801 chr3:136841726~136862054:- LUSC cis rs10129255 0.957 rs7493713 ENSG00000211972.2 IGHV3-66 7.24 1.85e-12 1.39e-09 0.23 0.32 Kawasaki disease; chr14:106783685 chr14:106675017~106675544:- LUSC cis rs10129255 0.912 rs35468694 ENSG00000211972.2 IGHV3-66 7.24 1.85e-12 1.39e-09 0.23 0.32 Kawasaki disease; chr14:106784199 chr14:106675017~106675544:- LUSC cis rs10129255 0.957 rs8019272 ENSG00000211972.2 IGHV3-66 7.24 1.85e-12 1.39e-09 0.23 0.32 Kawasaki disease; chr14:106784709 chr14:106675017~106675544:- LUSC cis rs77204473 0.793 rs11216206 ENSG00000254851.1 RP11-109L13.1 7.24 1.85e-12 1.39e-09 0.66 0.32 Sum eosinophil basophil counts;Eosinophil counts; chr11:116972709 chr11:117135528~117138582:+ LUSC cis rs7826238 0.566 rs2945886 ENSG00000253893.2 FAM85B -7.24 1.85e-12 1.39e-09 -0.38 -0.32 Systolic blood pressure; chr8:8290748 chr8:8167819~8226614:- LUSC cis rs526231 0.578 rs6876278 ENSG00000175749.11 EIF3KP1 7.24 1.85e-12 1.4e-09 0.39 0.32 Primary biliary cholangitis; chr5:102913842 chr5:103032376~103033031:+ LUSC cis rs9532669 0.926 rs2039119 ENSG00000176268.5 CYCSP34 -7.24 1.86e-12 1.4e-09 -0.32 -0.32 Cervical cancer; chr13:40872432 chr13:40863599~40863902:- LUSC cis rs11089937 0.667 rs10483108 ENSG00000211639.2 IGLV4-60 7.24 1.86e-12 1.4e-09 0.36 0.32 Periodontitis (PAL4Q3); chr22:22152664 chr22:22162199~22162681:+ LUSC cis rs10463554 0.853 rs246903 ENSG00000175749.11 EIF3KP1 7.24 1.86e-12 1.4e-09 0.38 0.32 Parkinson's disease; chr5:103253753 chr5:103032376~103033031:+ LUSC cis rs10129255 0.957 rs56134540 ENSG00000280411.1 IGHV1-69-2 -7.24 1.86e-12 1.4e-09 -0.22 -0.32 Kawasaki disease; chr14:106691290 chr14:106762092~106762588:- LUSC cis rs13113518 0.783 rs34534635 ENSG00000223305.1 RN7SKP30 7.24 1.86e-12 1.4e-09 0.39 0.32 Height; chr4:55573424 chr4:55540502~55540835:- LUSC cis rs35160687 0.814 rs7563887 ENSG00000273080.1 RP11-301O19.1 7.24 1.86e-12 1.4e-09 0.3 0.32 Night sleep phenotypes; chr2:86288998 chr2:86195590~86196049:+ LUSC cis rs875971 0.522 rs10807697 ENSG00000224316.1 RP11-479O9.2 7.24 1.87e-12 1.4e-09 0.3 0.32 Aortic root size; chr7:65951183 chr7:65773620~65802067:+ LUSC cis rs9322193 0.847 rs868375 ENSG00000268592.3 RAET1E-AS1 7.24 1.87e-12 1.41e-09 0.4 0.32 Lung cancer; chr6:149844905 chr6:149863494~149919507:+ LUSC cis rs11098499 0.863 rs2306456 ENSG00000250412.1 KLHL2P1 7.24 1.88e-12 1.41e-09 0.4 0.32 Corneal astigmatism; chr4:119551267 chr4:119334329~119378233:+ LUSC cis rs17482078 0.959 rs10074694 ENSG00000248734.2 CTD-2260A17.1 7.24 1.88e-12 1.41e-09 0.36 0.32 Behcet's disease;Blood protein levels; chr5:96801437 chr5:96784777~96785999:+ LUSC cis rs17482078 0.959 rs10074708 ENSG00000248734.2 CTD-2260A17.1 7.24 1.88e-12 1.41e-09 0.36 0.32 Behcet's disease;Blood protein levels; chr5:96801501 chr5:96784777~96785999:+ LUSC cis rs2455601 0.744 rs11042107 ENSG00000254860.4 TMEM9B-AS1 7.24 1.88e-12 1.42e-09 0.46 0.32 Schizophrenia; chr11:8884324 chr11:8964675~8977527:+ LUSC cis rs4713118 0.513 rs149950 ENSG00000204709.4 LINC01556 7.24 1.88e-12 1.42e-09 0.4 0.32 Parkinson's disease; chr6:28065261 chr6:28943877~28944537:+ LUSC cis rs4713118 0.513 rs149951 ENSG00000204709.4 LINC01556 7.24 1.88e-12 1.42e-09 0.4 0.32 Parkinson's disease; chr6:28065309 chr6:28943877~28944537:+ LUSC cis rs10129255 0.957 rs11847726 ENSG00000211972.2 IGHV3-66 7.24 1.89e-12 1.42e-09 0.23 0.32 Kawasaki disease; chr14:106779116 chr14:106675017~106675544:- LUSC cis rs55794721 0.509 rs11249248 ENSG00000224183.1 SDHDP6 -7.24 1.89e-12 1.42e-09 -0.39 -0.32 Mean corpuscular volume;Plateletcrit; chr1:25426560 chr1:25294164~25294643:- LUSC cis rs3091242 0.933 rs909833 ENSG00000224183.1 SDHDP6 -7.24 1.89e-12 1.42e-09 -0.39 -0.32 Erythrocyte sedimentation rate; chr1:25427649 chr1:25294164~25294643:- LUSC cis rs2282300 0.739 rs7952339 ENSG00000254532.1 RP11-624D11.2 -7.24 1.89e-12 1.42e-09 -0.43 -0.32 Morning vs. evening chronotype; chr11:30305797 chr11:30044058~30084343:- LUSC cis rs11098499 0.57 rs6832740 ENSG00000249244.1 RP11-548H18.2 7.24 1.89e-12 1.42e-09 0.39 0.32 Corneal astigmatism; chr4:119624981 chr4:119391831~119395335:- LUSC cis rs11098499 0.644 rs6855918 ENSG00000249244.1 RP11-548H18.2 7.24 1.89e-12 1.42e-09 0.39 0.32 Corneal astigmatism; chr4:119625144 chr4:119391831~119395335:- LUSC cis rs11098499 0.863 rs11947234 ENSG00000250412.1 KLHL2P1 7.24 1.9e-12 1.42e-09 0.4 0.32 Corneal astigmatism; chr4:119553704 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs11933966 ENSG00000250412.1 KLHL2P1 7.24 1.9e-12 1.42e-09 0.4 0.32 Corneal astigmatism; chr4:119555560 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs36040693 ENSG00000250412.1 KLHL2P1 7.24 1.9e-12 1.42e-09 0.4 0.32 Corneal astigmatism; chr4:119556461 chr4:119334329~119378233:+ LUSC cis rs4950322 0.857 rs72693002 ENSG00000278811.3 LINC00624 7.24 1.9e-12 1.43e-09 0.37 0.32 Protein quantitative trait loci; chr1:147357593 chr1:147258885~147517875:- LUSC cis rs4950322 0.857 rs72694703 ENSG00000278811.3 LINC00624 7.24 1.9e-12 1.43e-09 0.37 0.32 Protein quantitative trait loci; chr1:147358427 chr1:147258885~147517875:- LUSC cis rs34779708 0.931 rs4934711 ENSG00000230534.5 RP11-297A16.2 7.24 1.9e-12 1.43e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35071382 chr10:35098006~35127020:- LUSC cis rs4660456 0.827 rs617413 ENSG00000237899.1 RP4-739H11.3 7.24 1.91e-12 1.43e-09 0.47 0.32 Platelet count; chr1:40669846 chr1:40669089~40687588:- LUSC cis rs10129255 0.957 rs10142918 ENSG00000211972.2 IGHV3-66 7.23 1.91e-12 1.43e-09 0.23 0.32 Kawasaki disease; chr14:106782206 chr14:106675017~106675544:- LUSC cis rs10129255 0.957 rs10142859 ENSG00000211972.2 IGHV3-66 7.23 1.91e-12 1.43e-09 0.23 0.32 Kawasaki disease; chr14:106782238 chr14:106675017~106675544:- LUSC cis rs2337406 1 rs11849532 ENSG00000274576.2 IGHV2-70 -7.23 1.91e-12 1.44e-09 -0.35 -0.32 Alzheimer's disease (late onset); chr14:106669877 chr14:106770577~106771020:- LUSC cis rs9595066 0.715 rs9567366 ENSG00000227258.4 SMIM2-AS1 -7.23 1.91e-12 1.44e-09 -0.54 -0.32 Schizophrenia; chr13:44108837 chr13:44110451~44240517:+ LUSC cis rs9532669 0.926 rs7338617 ENSG00000176268.5 CYCSP34 7.23 1.91e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40870787 chr13:40863599~40863902:- LUSC cis rs9532669 0.857 rs6560961 ENSG00000176268.5 CYCSP34 7.23 1.91e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40870878 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs6560962 ENSG00000176268.5 CYCSP34 7.23 1.91e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40870948 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs3610 ENSG00000176268.5 CYCSP34 7.23 1.91e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40871334 chr13:40863599~40863902:- LUSC cis rs10740039 0.883 rs1442540 ENSG00000254271.1 RP11-131N11.4 -7.23 1.92e-12 1.44e-09 -0.43 -0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60653548 chr10:60734342~60741828:+ LUSC cis rs367615 0.552 rs2963022 ENSG00000249476.1 CTD-2587M2.1 -7.23 1.92e-12 1.44e-09 -0.36 -0.32 Colorectal cancer (SNP x SNP interaction); chr5:109391484 chr5:109237120~109326369:- LUSC cis rs10129255 0.957 rs8022165 ENSG00000224373.3 IGHV4-59 7.23 1.92e-12 1.44e-09 0.17 0.32 Kawasaki disease; chr14:106781682 chr14:106627249~106627825:- LUSC cis rs8040855 0.579 rs28521166 ENSG00000259295.5 CSPG4P12 -7.23 1.92e-12 1.44e-09 -0.36 -0.32 Bulimia nervosa; chr15:85184801 chr15:85191438~85213905:+ LUSC cis rs9532669 0.926 rs4942005 ENSG00000176268.5 CYCSP34 7.23 1.92e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40871636 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4942006 ENSG00000176268.5 CYCSP34 7.23 1.92e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40871862 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4942008 ENSG00000176268.5 CYCSP34 7.23 1.92e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40871989 chr13:40863599~40863902:- LUSC cis rs9532669 0.89 rs2039118 ENSG00000176268.5 CYCSP34 7.23 1.92e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40872260 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4356347 ENSG00000176268.5 CYCSP34 7.23 1.92e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40872516 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs7982346 ENSG00000176268.5 CYCSP34 7.23 1.92e-12 1.44e-09 0.31 0.32 Cervical cancer; chr13:40873273 chr13:40863599~40863902:- LUSC cis rs4237845 0.586 rs4760174 ENSG00000257159.1 RP11-58A17.3 7.23 1.93e-12 1.45e-09 0.39 0.32 Intelligence (multi-trait analysis); chr12:57926653 chr12:57967058~57968399:+ LUSC cis rs75422866 0.51 rs73105829 ENSG00000274902.1 RP1-197B17.4 7.23 1.93e-12 1.45e-09 0.74 0.32 Pneumonia; chr12:47734162 chr12:47731908~47732351:+ LUSC cis rs9532669 0.926 rs1055588 ENSG00000176268.5 CYCSP34 7.23 1.93e-12 1.45e-09 0.31 0.32 Cervical cancer; chr13:40871306 chr13:40863599~40863902:- LUSC cis rs673078 0.607 rs7132753 ENSG00000275759.1 RP11-131L12.3 -7.23 1.93e-12 1.45e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118420383 chr12:118428281~118428870:+ LUSC cis rs10129255 0.957 rs2013423 ENSG00000224373.3 IGHV4-59 7.23 1.94e-12 1.45e-09 0.18 0.32 Kawasaki disease; chr14:106690675 chr14:106627249~106627825:- LUSC cis rs4950322 0.802 rs72694705 ENSG00000278811.3 LINC00624 7.23 1.94e-12 1.46e-09 0.37 0.32 Protein quantitative trait loci; chr1:147362313 chr1:147258885~147517875:- LUSC cis rs4950322 0.857 rs55790545 ENSG00000278811.3 LINC00624 7.23 1.94e-12 1.46e-09 0.37 0.32 Protein quantitative trait loci; chr1:147366649 chr1:147258885~147517875:- LUSC cis rs4950322 0.857 rs7522219 ENSG00000278811.3 LINC00624 7.23 1.94e-12 1.46e-09 0.37 0.32 Protein quantitative trait loci; chr1:147366904 chr1:147258885~147517875:- LUSC cis rs9513627 0.573 rs12431100 ENSG00000280710.1 RP11-214F16.8 -7.23 1.94e-12 1.46e-09 -0.48 -0.32 Obesity-related traits; chr13:99532664 chr13:99498524~99501315:+ LUSC cis rs2412819 0.571 rs4923965 ENSG00000249839.1 AC011330.5 7.23 1.94e-12 1.46e-09 0.5 0.32 Lung cancer; chr15:43790232 chr15:43663654~43684339:- LUSC cis rs748404 0.589 rs62020616 ENSG00000249839.1 AC011330.5 -7.23 1.95e-12 1.46e-09 -0.55 -0.32 Lung cancer; chr15:43558554 chr15:43663654~43684339:- LUSC cis rs9928842 0.823 rs4888365 ENSG00000280152.1 RP11-331F4.5 7.23 1.95e-12 1.46e-09 0.39 0.32 Alcoholic chronic pancreatitis; chr16:75248349 chr16:75245994~75250077:- LUSC cis rs11098499 0.909 rs28555550 ENSG00000249244.1 RP11-548H18.2 7.23 1.95e-12 1.46e-09 0.41 0.32 Corneal astigmatism; chr4:119289885 chr4:119391831~119395335:- LUSC cis rs11098499 1 rs28419773 ENSG00000249244.1 RP11-548H18.2 7.23 1.95e-12 1.46e-09 0.41 0.32 Corneal astigmatism; chr4:119289906 chr4:119391831~119395335:- LUSC cis rs9928842 0.882 rs6564241 ENSG00000280152.1 RP11-331F4.5 7.23 1.96e-12 1.47e-09 0.41 0.32 Alcoholic chronic pancreatitis; chr16:75230076 chr16:75245994~75250077:- LUSC cis rs875971 0.522 rs2008188 ENSG00000224316.1 RP11-479O9.2 7.23 1.96e-12 1.47e-09 0.3 0.32 Aortic root size; chr7:65964026 chr7:65773620~65802067:+ LUSC cis rs11098499 0.863 rs9997631 ENSG00000250412.1 KLHL2P1 7.23 1.96e-12 1.47e-09 0.39 0.32 Corneal astigmatism; chr4:119548840 chr4:119334329~119378233:+ LUSC cis rs875971 0.505 rs6955582 ENSG00000236529.1 RP13-254B10.1 7.23 1.96e-12 1.47e-09 0.33 0.32 Aortic root size; chr7:65966699 chr7:65840212~65840596:+ LUSC cis rs2404602 0.684 rs1603860 ENSG00000259422.1 RP11-593F23.1 -7.23 1.97e-12 1.48e-09 -0.38 -0.32 Blood metabolite levels; chr15:76557250 chr15:76174891~76181486:- LUSC cis rs2412819 0.571 rs4644832 ENSG00000249839.1 AC011330.5 7.23 1.97e-12 1.48e-09 0.5 0.32 Lung cancer; chr15:43792507 chr15:43663654~43684339:- LUSC cis rs11098499 0.954 rs2389802 ENSG00000250412.1 KLHL2P1 7.23 1.98e-12 1.48e-09 0.4 0.32 Corneal astigmatism; chr4:119404577 chr4:119334329~119378233:+ LUSC cis rs1113500 0.614 rs11185243 ENSG00000226822.1 RP11-356N1.2 7.23 1.98e-12 1.49e-09 0.35 0.32 Growth-regulated protein alpha levels; chr1:108054519 chr1:108071482~108074519:+ LUSC cis rs12554020 0.681 rs80062429 ENSG00000227603.1 RP11-165J3.6 7.23 1.98e-12 1.49e-09 0.43 0.32 Schizophrenia; chr9:93608830 chr9:93435332~93437121:- LUSC cis rs7309 0.935 rs10930013 ENSG00000227403.1 AC009299.3 -7.23 1.99e-12 1.49e-09 -0.4 -0.32 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161213814 chr2:161244739~161249050:+ LUSC cis rs1075265 0.87 rs7569214 ENSG00000233266.1 HMGB1P31 7.23 2e-12 1.5e-09 0.39 0.32 Chronotype;Morning vs. evening chronotype; chr2:53989049 chr2:54051334~54051760:+ LUSC cis rs11098499 0.863 rs7669520 ENSG00000250412.1 KLHL2P1 7.23 2e-12 1.5e-09 0.4 0.32 Corneal astigmatism; chr4:119594123 chr4:119334329~119378233:+ LUSC cis rs10129255 0.646 rs55995061 ENSG00000280411.1 IGHV1-69-2 -7.23 2.01e-12 1.51e-09 -0.22 -0.32 Kawasaki disease; chr14:106799309 chr14:106762092~106762588:- LUSC cis rs748404 0.697 rs579651 ENSG00000249839.1 AC011330.5 -7.23 2.01e-12 1.51e-09 -0.41 -0.32 Lung cancer; chr15:43266178 chr15:43663654~43684339:- LUSC cis rs748404 0.697 rs473016 ENSG00000249839.1 AC011330.5 -7.23 2.01e-12 1.51e-09 -0.41 -0.32 Lung cancer; chr15:43266625 chr15:43663654~43684339:- LUSC cis rs748404 0.697 rs531910 ENSG00000249839.1 AC011330.5 -7.23 2.01e-12 1.51e-09 -0.41 -0.32 Lung cancer; chr15:43268409 chr15:43663654~43684339:- LUSC cis rs748404 0.697 rs491804 ENSG00000249839.1 AC011330.5 -7.23 2.01e-12 1.51e-09 -0.41 -0.32 Lung cancer; chr15:43268627 chr15:43663654~43684339:- LUSC cis rs748404 0.697 rs492743 ENSG00000249839.1 AC011330.5 -7.23 2.01e-12 1.51e-09 -0.41 -0.32 Lung cancer; chr15:43268747 chr15:43663654~43684339:- LUSC cis rs10129255 0.53 rs11624912 ENSG00000224373.3 IGHV4-59 7.23 2.01e-12 1.51e-09 0.16 0.32 Kawasaki disease; chr14:106673891 chr14:106627249~106627825:- LUSC cis rs9928842 0.722 rs1035540 ENSG00000280152.1 RP11-331F4.5 7.23 2.02e-12 1.51e-09 0.37 0.32 Alcoholic chronic pancreatitis; chr16:75244897 chr16:75245994~75250077:- LUSC cis rs950169 0.519 rs7237 ENSG00000259728.4 LINC00933 7.23 2.03e-12 1.52e-09 0.41 0.32 Schizophrenia; chr15:84643346 chr15:84570649~84580175:+ LUSC cis rs875971 0.756 rs4718328 ENSG00000237310.1 GS1-124K5.4 -7.23 2.03e-12 1.52e-09 -0.33 -0.32 Aortic root size; chr7:66228350 chr7:66493706~66495474:+ LUSC cis rs748404 0.666 rs12905220 ENSG00000249839.1 AC011330.5 -7.23 2.04e-12 1.52e-09 -0.53 -0.32 Lung cancer; chr15:43465641 chr15:43663654~43684339:- LUSC cis rs7267979 0.789 rs6076347 ENSG00000274973.1 RP13-401N8.7 7.22 2.04e-12 1.53e-09 0.33 0.32 Liver enzyme levels (alkaline phosphatase); chr20:25418154 chr20:25845497~25845862:+ LUSC cis rs7617773 0.963 rs9822496 ENSG00000228638.1 FCF1P2 -7.22 2.04e-12 1.53e-09 -0.36 -0.32 Coronary artery disease; chr3:48139843 chr3:48290793~48291375:- LUSC cis rs8040855 0.86 rs7172266 ENSG00000259295.5 CSPG4P12 -7.22 2.04e-12 1.53e-09 -0.39 -0.32 Bulimia nervosa; chr15:85172982 chr15:85191438~85213905:+ LUSC cis rs17711722 0.74 rs7809991 ENSG00000224316.1 RP11-479O9.2 7.22 2.05e-12 1.53e-09 0.3 0.32 Calcium levels; chr7:65941231 chr7:65773620~65802067:+ LUSC cis rs11098499 0.82 rs28535956 ENSG00000250412.1 KLHL2P1 -7.22 2.06e-12 1.54e-09 -0.4 -0.32 Corneal astigmatism; chr4:119615703 chr4:119334329~119378233:+ LUSC cis rs9545047 0.716 rs8002838 ENSG00000227676.3 LINC01068 7.22 2.06e-12 1.54e-09 0.39 0.32 Schizophrenia; chr13:79421681 chr13:79566727~79571436:+ LUSC cis rs9545047 0.669 rs9545113 ENSG00000227676.3 LINC01068 7.22 2.06e-12 1.54e-09 0.39 0.32 Schizophrenia; chr13:79422017 chr13:79566727~79571436:+ LUSC cis rs9545047 0.68 rs9545114 ENSG00000227676.3 LINC01068 7.22 2.06e-12 1.54e-09 0.39 0.32 Schizophrenia; chr13:79423744 chr13:79566727~79571436:+ LUSC cis rs9545047 0.716 rs586219 ENSG00000227676.3 LINC01068 -7.22 2.06e-12 1.54e-09 -0.39 -0.32 Schizophrenia; chr13:79425177 chr13:79566727~79571436:+ LUSC cis rs9545047 0.716 rs2265377 ENSG00000227676.3 LINC01068 -7.22 2.06e-12 1.54e-09 -0.39 -0.32 Schizophrenia; chr13:79425485 chr13:79566727~79571436:+ LUSC cis rs9545047 0.716 rs2265378 ENSG00000227676.3 LINC01068 -7.22 2.06e-12 1.54e-09 -0.39 -0.32 Schizophrenia; chr13:79425581 chr13:79566727~79571436:+ LUSC cis rs67180937 0.645 rs1909197 ENSG00000272750.1 RP11-378J18.8 -7.22 2.07e-12 1.55e-09 -0.38 -0.32 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222645879 chr1:222658867~222661512:- LUSC cis rs7945705 0.935 rs2653593 ENSG00000254860.4 TMEM9B-AS1 7.22 2.07e-12 1.55e-09 0.35 0.32 Hemoglobin concentration; chr11:8855770 chr11:8964675~8977527:+ LUSC cis rs10129255 0.957 rs2013423 ENSG00000280411.1 IGHV1-69-2 -7.22 2.08e-12 1.55e-09 -0.22 -0.32 Kawasaki disease; chr14:106690675 chr14:106762092~106762588:- LUSC cis rs9487094 0.553 rs11968891 ENSG00000260273.1 RP11-425D10.10 7.22 2.09e-12 1.56e-09 0.44 0.32 Height; chr6:109548647 chr6:109382795~109383666:+ LUSC cis rs6991838 0.765 rs4424306 ENSG00000200714.1 Y_RNA 7.22 2.09e-12 1.56e-09 0.37 0.32 Intelligence (multi-trait analysis); chr8:65618674 chr8:65592731~65592820:+ LUSC cis rs8072100 0.967 rs4338849 ENSG00000228782.6 CTD-2026D20.3 7.22 2.1e-12 1.57e-09 0.3 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47435117 chr17:47450568~47492492:- LUSC cis rs673078 0.607 rs7958551 ENSG00000275759.1 RP11-131L12.3 -7.22 2.1e-12 1.57e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118442585 chr12:118428281~118428870:+ LUSC cis rs35160687 0.901 rs17738096 ENSG00000273080.1 RP11-301O19.1 7.22 2.1e-12 1.57e-09 0.3 0.32 Night sleep phenotypes; chr2:86286770 chr2:86195590~86196049:+ LUSC cis rs3091242 0.933 rs1534954 ENSG00000224183.1 SDHDP6 -7.22 2.1e-12 1.57e-09 -0.39 -0.32 Erythrocyte sedimentation rate; chr1:25435433 chr1:25294164~25294643:- LUSC cis rs4950322 0.542 rs17159924 ENSG00000278811.3 LINC00624 7.22 2.11e-12 1.57e-09 0.35 0.32 Protein quantitative trait loci; chr1:147199463 chr1:147258885~147517875:- LUSC cis rs5769707 0.521 rs5769719 ENSG00000235111.1 RP1-29C18.8 -7.22 2.11e-12 1.57e-09 -0.4 -0.32 Monocyte percentage of white cells;Monocyte count; chr22:49668453 chr22:49612657~49615716:- LUSC cis rs5769707 0.521 rs5769720 ENSG00000235111.1 RP1-29C18.8 -7.22 2.11e-12 1.57e-09 -0.4 -0.32 Monocyte percentage of white cells;Monocyte count; chr22:49668485 chr22:49612657~49615716:- LUSC cis rs5769707 0.521 rs5770633 ENSG00000235111.1 RP1-29C18.8 -7.22 2.11e-12 1.57e-09 -0.4 -0.32 Monocyte percentage of white cells;Monocyte count; chr22:49668779 chr22:49612657~49615716:- LUSC cis rs3747113 1 rs35303215 ENSG00000128262.7 POM121L9P -7.22 2.11e-12 1.58e-09 -0.34 -0.32 Gut microbiome composition (summer); chr22:24405567 chr22:24251828~24265525:+ LUSC cis rs6921919 0.583 rs7764737 ENSG00000204709.4 LINC01556 7.22 2.12e-12 1.58e-09 0.4 0.32 Autism spectrum disorder or schizophrenia; chr6:28386838 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs9461458 ENSG00000204709.4 LINC01556 7.22 2.12e-12 1.58e-09 0.4 0.32 Autism spectrum disorder or schizophrenia; chr6:28388098 chr6:28943877~28944537:+ LUSC cis rs6921919 0.609 rs9468365 ENSG00000204709.4 LINC01556 7.22 2.12e-12 1.58e-09 0.4 0.32 Autism spectrum disorder or schizophrenia; chr6:28390189 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs1361385 ENSG00000204709.4 LINC01556 7.22 2.12e-12 1.58e-09 0.4 0.32 Autism spectrum disorder or schizophrenia; chr6:28390543 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs1416918 ENSG00000204709.4 LINC01556 7.22 2.12e-12 1.58e-09 0.4 0.32 Autism spectrum disorder or schizophrenia; chr6:28390558 chr6:28943877~28944537:+ LUSC cis rs11098499 0.604 rs12642411 ENSG00000245958.5 RP11-33B1.1 -7.22 2.12e-12 1.58e-09 -0.33 -0.32 Corneal astigmatism; chr4:119659370 chr4:119454791~119552025:+ LUSC cis rs1075265 0.729 rs7571086 ENSG00000233266.1 HMGB1P31 7.22 2.12e-12 1.59e-09 0.39 0.32 Chronotype;Morning vs. evening chronotype; chr2:54007899 chr2:54051334~54051760:+ LUSC cis rs10129255 0.957 rs10136817 ENSG00000224373.3 IGHV4-59 7.22 2.14e-12 1.6e-09 0.18 0.32 Kawasaki disease; chr14:106787730 chr14:106627249~106627825:- LUSC cis rs875971 0.522 rs709604 ENSG00000236529.1 RP13-254B10.1 -7.22 2.15e-12 1.6e-09 -0.33 -0.32 Aortic root size; chr7:66032447 chr7:65840212~65840596:+ LUSC cis rs1865760 1 rs3752421 ENSG00000272462.2 U91328.19 -7.22 2.15e-12 1.6e-09 -0.34 -0.32 Height; chr6:25918460 chr6:25992662~26001775:+ LUSC cis rs7429990 0.965 rs319686 ENSG00000229759.1 MRPS18AP1 7.22 2.16e-12 1.61e-09 0.33 0.32 Educational attainment (years of education); chr3:47888930 chr3:48256350~48256938:- LUSC cis rs6142102 1 rs6059672 ENSG00000276073.1 RP5-1125A11.7 -7.22 2.17e-12 1.62e-09 -0.34 -0.32 Skin pigmentation; chr20:34117662 chr20:33985617~33988989:- LUSC cis rs904251 0.523 rs914348 ENSG00000204110.6 RP1-153P14.8 -7.22 2.18e-12 1.62e-09 -0.3 -0.32 Cognitive performance; chr6:37516953 chr6:37507348~37535616:+ LUSC cis rs673078 0.607 rs4766900 ENSG00000275759.1 RP11-131L12.3 -7.21 2.18e-12 1.62e-09 -0.44 -0.32 Glucose homeostasis traits; chr12:118375139 chr12:118428281~118428870:+ LUSC cis rs10129255 0.956 rs10137268 ENSG00000224373.3 IGHV4-59 7.21 2.18e-12 1.63e-09 0.18 0.32 Kawasaki disease; chr14:106697402 chr14:106627249~106627825:- LUSC cis rs10129255 1 rs8010605 ENSG00000224373.3 IGHV4-59 7.21 2.19e-12 1.63e-09 0.18 0.32 Kawasaki disease; chr14:106678742 chr14:106627249~106627825:- LUSC cis rs494459 0.536 rs7103067 ENSG00000255239.1 AP002954.6 7.21 2.19e-12 1.64e-09 0.35 0.32 Height; chr11:118852670 chr11:118688039~118690600:- LUSC cis rs2739330 0.731 rs4822450 ENSG00000099984.9 GSTT2 -7.21 2.21e-12 1.65e-09 -0.37 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23980123~23983911:+ LUSC cis rs875971 0.862 rs1860469 ENSG00000222364.1 RNU6-96P 7.21 2.22e-12 1.65e-09 0.38 0.32 Aortic root size; chr7:66641888 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs4718383 ENSG00000222364.1 RNU6-96P 7.21 2.22e-12 1.65e-09 0.38 0.32 Aortic root size; chr7:66643422 chr7:66395191~66395286:+ LUSC cis rs34779708 0.931 rs4934704 ENSG00000230534.5 RP11-297A16.2 7.21 2.22e-12 1.65e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35043236 chr10:35098006~35127020:- LUSC cis rs2286503 1 rs1029740 ENSG00000228649.7 AC005682.5 7.21 2.23e-12 1.66e-09 0.35 0.32 Fibrinogen; chr7:22833967 chr7:22854178~22861579:+ LUSC cis rs673078 0.607 rs76809232 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118444979 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61944660 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118445326 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61944662 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118445520 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs4254101 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118445877 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs4622305 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118445912 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs2393418 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118445995 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs73207575 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118446711 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61944663 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118446886 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs73207577 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118447012 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs73207579 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118447123 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61944664 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118447145 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs7969871 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118447331 chr12:118428281~118428870:+ LUSC cis rs673078 0.56 rs7970361 ENSG00000275759.1 RP11-131L12.3 -7.21 2.23e-12 1.66e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118447723 chr12:118428281~118428870:+ LUSC cis rs4853012 0.838 rs4563249 ENSG00000257800.1 FNBP1P1 7.21 2.24e-12 1.67e-09 0.37 0.32 Gestational age at birth (maternal effect); chr2:74126889 chr2:74120680~74123218:+ LUSC cis rs34779708 0.931 rs2384287 ENSG00000230534.5 RP11-297A16.2 7.21 2.24e-12 1.67e-09 0.35 0.32 Inflammatory bowel disease;Crohn's disease; chr10:35051631 chr10:35098006~35127020:- LUSC cis rs673078 0.607 rs7958652 ENSG00000275759.1 RP11-131L12.3 -7.21 2.26e-12 1.68e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118442630 chr12:118428281~118428870:+ LUSC cis rs10129255 0.957 rs6576233 ENSG00000280411.1 IGHV1-69-2 -7.21 2.26e-12 1.68e-09 -0.22 -0.32 Kawasaki disease; chr14:106787239 chr14:106762092~106762588:- LUSC cis rs2455601 0.608 rs11042104 ENSG00000254860.4 TMEM9B-AS1 -7.21 2.26e-12 1.68e-09 -0.37 -0.32 Schizophrenia; chr11:8869377 chr11:8964675~8977527:+ LUSC cis rs9322193 0.923 rs2880436 ENSG00000268592.3 RAET1E-AS1 7.21 2.26e-12 1.69e-09 0.4 0.32 Lung cancer; chr6:149859123 chr6:149863494~149919507:+ LUSC cis rs10740039 0.768 rs10761549 ENSG00000254271.1 RP11-131N11.4 7.21 2.27e-12 1.69e-09 0.43 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60701902 chr10:60734342~60741828:+ LUSC cis rs10129255 0.957 rs1024349 ENSG00000280411.1 IGHV1-69-2 -7.21 2.27e-12 1.69e-09 -0.22 -0.32 Kawasaki disease; chr14:106689997 chr14:106762092~106762588:- LUSC cis rs1075265 0.836 rs1363063 ENSG00000233266.1 HMGB1P31 7.21 2.27e-12 1.69e-09 0.41 0.32 Chronotype;Morning vs. evening chronotype; chr2:54047433 chr2:54051334~54051760:+ LUSC cis rs10170846 0.924 rs3768973 ENSG00000261428.2 RP11-16P6.1 7.21 2.27e-12 1.69e-09 0.38 0.32 Schizophrenia (inflammation and infection response interaction); chr2:222571683 chr2:222566899~222569719:- LUSC cis rs4713118 0.513 rs149941 ENSG00000204709.4 LINC01556 7.21 2.27e-12 1.69e-09 0.4 0.32 Parkinson's disease; chr6:28033255 chr6:28943877~28944537:+ LUSC cis rs11098499 0.863 rs12498539 ENSG00000250412.1 KLHL2P1 7.21 2.28e-12 1.69e-09 0.39 0.32 Corneal astigmatism; chr4:119547215 chr4:119334329~119378233:+ LUSC cis rs10463554 0.927 rs34798 ENSG00000175749.11 EIF3KP1 7.21 2.28e-12 1.7e-09 0.43 0.32 Parkinson's disease; chr5:103090047 chr5:103032376~103033031:+ LUSC cis rs10028773 0.515 rs9994488 ENSG00000245958.5 RP11-33B1.1 -7.21 2.29e-12 1.7e-09 -0.31 -0.32 Educational attainment; chr4:119666626 chr4:119454791~119552025:+ LUSC cis rs10129255 0.957 rs10142918 ENSG00000224373.3 IGHV4-59 7.21 2.3e-12 1.71e-09 0.17 0.32 Kawasaki disease; chr14:106782206 chr14:106627249~106627825:- LUSC cis rs10129255 0.957 rs10142859 ENSG00000224373.3 IGHV4-59 7.21 2.3e-12 1.71e-09 0.17 0.32 Kawasaki disease; chr14:106782238 chr14:106627249~106627825:- LUSC cis rs10129255 0.957 rs8022165 ENSG00000211972.2 IGHV3-66 7.21 2.3e-12 1.71e-09 0.23 0.32 Kawasaki disease; chr14:106781682 chr14:106675017~106675544:- LUSC cis rs12554020 0.786 rs12551314 ENSG00000227603.1 RP11-165J3.6 7.21 2.31e-12 1.72e-09 0.43 0.32 Schizophrenia; chr9:93617515 chr9:93435332~93437121:- LUSC cis rs10754283 0.967 rs7546518 ENSG00000231613.1 RP5-943J3.1 7.21 2.31e-12 1.72e-09 0.35 0.32 Amyotrophic lateral sclerosis (sporadic); chr1:89644397 chr1:89788914~89790492:+ LUSC cis rs801193 0.569 rs6978178 ENSG00000222364.1 RNU6-96P 7.21 2.32e-12 1.72e-09 0.38 0.32 Aortic root size; chr7:66658097 chr7:66395191~66395286:+ LUSC cis rs73219805 1 rs1042992 ENSG00000228451.3 SDAD1P1 7.21 2.32e-12 1.72e-09 0.43 0.32 Schizophrenia; chr8:26411675 chr8:26379259~26382953:- LUSC cis rs11123170 0.64 rs931472 ENSG00000189223.12 PAX8-AS1 7.21 2.32e-12 1.73e-09 0.45 0.32 Renal function-related traits (BUN); chr2:113212371 chr2:113211522~113276581:+ LUSC cis rs10129255 0.957 rs10136817 ENSG00000280411.1 IGHV1-69-2 -7.2 2.33e-12 1.73e-09 -0.22 -0.32 Kawasaki disease; chr14:106787730 chr14:106762092~106762588:- LUSC cis rs4853012 0.838 rs72915068 ENSG00000257800.1 FNBP1P1 7.2 2.33e-12 1.73e-09 0.37 0.32 Gestational age at birth (maternal effect); chr2:74129058 chr2:74120680~74123218:+ LUSC cis rs10129255 0.957 rs2007467 ENSG00000224373.3 IGHV4-59 -7.2 2.34e-12 1.74e-09 -0.18 -0.32 Kawasaki disease; chr14:106771605 chr14:106627249~106627825:- LUSC cis rs6142102 0.886 rs4911147 ENSG00000276073.1 RP5-1125A11.7 -7.2 2.34e-12 1.74e-09 -0.34 -0.32 Skin pigmentation; chr20:34079801 chr20:33985617~33988989:- LUSC cis rs2282300 0.739 rs10835648 ENSG00000254532.1 RP11-624D11.2 -7.2 2.34e-12 1.74e-09 -0.43 -0.32 Morning vs. evening chronotype; chr11:30298959 chr11:30044058~30084343:- LUSC cis rs9921338 0.961 rs4780358 ENSG00000263080.1 RP11-485G7.5 7.2 2.35e-12 1.75e-09 0.37 0.32 Vein graft stenosis in coronary artery bypass grafting; chr16:11280355 chr16:11341809~11345211:- LUSC cis rs9543976 1 rs2031236 ENSG00000261553.4 RP11-29G8.3 -7.2 2.35e-12 1.75e-09 -0.57 -0.32 Diabetic retinopathy; chr13:75595641 chr13:75549773~75807120:+ LUSC cis rs3779195 0.929 rs2906184 ENSG00000272950.1 RP11-307C18.1 -7.2 2.35e-12 1.75e-09 -0.51 -0.32 Sex hormone-binding globulin levels; chr7:98310675 chr7:98322853~98323430:+ LUSC cis rs10754283 0.967 rs10922685 ENSG00000231613.1 RP5-943J3.1 7.2 2.37e-12 1.76e-09 0.36 0.32 Amyotrophic lateral sclerosis (sporadic); chr1:89652761 chr1:89788914~89790492:+ LUSC cis rs465969 1 rs35856111 ENSG00000255389.1 C6orf3 -7.2 2.37e-12 1.76e-09 -0.6 -0.32 Psoriasis; chr6:111452265 chr6:111599875~111602295:+ LUSC cis rs465969 0.744 rs13220692 ENSG00000255389.1 C6orf3 -7.2 2.37e-12 1.76e-09 -0.6 -0.32 Psoriasis; chr6:111455836 chr6:111599875~111602295:+ LUSC cis rs465969 0.793 rs7752225 ENSG00000255389.1 C6orf3 7.2 2.37e-12 1.76e-09 0.6 0.32 Psoriasis; chr6:111459412 chr6:111599875~111602295:+ LUSC cis rs9532669 0.926 rs4309270 ENSG00000176268.5 CYCSP34 7.2 2.37e-12 1.76e-09 0.31 0.32 Cervical cancer; chr13:40877827 chr13:40863599~40863902:- LUSC cis rs75422866 0.51 rs35784744 ENSG00000274902.1 RP1-197B17.4 7.2 2.38e-12 1.77e-09 0.73 0.32 Pneumonia; chr12:47729646 chr12:47731908~47732351:+ LUSC cis rs950169 0.922 rs67804993 ENSG00000259728.4 LINC00933 7.2 2.39e-12 1.77e-09 0.41 0.32 Schizophrenia; chr15:84560799 chr15:84570649~84580175:+ LUSC cis rs2404602 0.647 rs11072610 ENSG00000259422.1 RP11-593F23.1 -7.2 2.39e-12 1.77e-09 -0.38 -0.32 Blood metabolite levels; chr15:76638464 chr15:76174891~76181486:- LUSC cis rs10129255 0.518 rs2006284 ENSG00000224373.3 IGHV4-59 7.2 2.4e-12 1.78e-09 0.16 0.32 Kawasaki disease; chr14:106676185 chr14:106627249~106627825:- LUSC cis rs11098499 0.863 rs3822194 ENSG00000250412.1 KLHL2P1 7.2 2.4e-12 1.78e-09 0.39 0.32 Corneal astigmatism; chr4:119550493 chr4:119334329~119378233:+ LUSC cis rs10754283 0.934 rs10493829 ENSG00000231613.1 RP5-943J3.1 7.2 2.4e-12 1.78e-09 0.36 0.32 Amyotrophic lateral sclerosis (sporadic); chr1:89652274 chr1:89788914~89790492:+ LUSC cis rs11098499 0.82 rs6829903 ENSG00000250412.1 KLHL2P1 7.2 2.4e-12 1.78e-09 0.39 0.32 Corneal astigmatism; chr4:119585729 chr4:119334329~119378233:+ LUSC cis rs17711722 0.701 rs781143 ENSG00000236529.1 RP13-254B10.1 7.2 2.41e-12 1.79e-09 0.33 0.32 Calcium levels; chr7:65974892 chr7:65840212~65840596:+ LUSC cis rs66887589 0.616 rs1052633 ENSG00000245958.5 RP11-33B1.1 -7.2 2.42e-12 1.8e-09 -0.3 -0.32 Diastolic blood pressure; chr4:119294159 chr4:119454791~119552025:+ LUSC cis rs673078 0.607 rs61944670 ENSG00000275759.1 RP11-131L12.3 -7.2 2.43e-12 1.8e-09 -0.46 -0.32 Glucose homeostasis traits; chr12:118448697 chr12:118428281~118428870:+ LUSC cis rs2188561 0.697 rs3735607 ENSG00000241764.3 AC002467.7 7.2 2.43e-12 1.8e-09 0.41 0.32 Alcohol consumption; chr7:107743833 chr7:107742817~107744581:- LUSC cis rs673078 0.607 rs884844 ENSG00000275759.1 RP11-131L12.3 -7.2 2.43e-12 1.8e-09 -0.44 -0.32 Glucose homeostasis traits; chr12:118377033 chr12:118428281~118428870:+ LUSC cis rs10129255 1 rs10129407 ENSG00000280411.1 IGHV1-69-2 -7.2 2.43e-12 1.8e-09 -0.22 -0.32 Kawasaki disease; chr14:106767956 chr14:106762092~106762588:- LUSC cis rs12554020 0.892 rs76488437 ENSG00000227603.1 RP11-165J3.6 7.2 2.43e-12 1.81e-09 0.43 0.32 Schizophrenia; chr9:93605514 chr9:93435332~93437121:- LUSC cis rs7945705 0.935 rs11042103 ENSG00000254860.4 TMEM9B-AS1 -7.2 2.43e-12 1.81e-09 -0.35 -0.32 Hemoglobin concentration; chr11:8867153 chr11:8964675~8977527:+ LUSC cis rs11098499 0.863 rs9884402 ENSG00000250412.1 KLHL2P1 7.2 2.44e-12 1.81e-09 0.39 0.32 Corneal astigmatism; chr4:119568827 chr4:119334329~119378233:+ LUSC cis rs11098499 0.731 rs9995026 ENSG00000250412.1 KLHL2P1 7.2 2.44e-12 1.81e-09 0.39 0.32 Corneal astigmatism; chr4:119569344 chr4:119334329~119378233:+ LUSC cis rs875971 0.862 rs778734 ENSG00000237310.1 GS1-124K5.4 7.2 2.44e-12 1.81e-09 0.33 0.32 Aortic root size; chr7:66349862 chr7:66493706~66495474:+ LUSC cis rs9928842 0.882 rs9927264 ENSG00000280152.1 RP11-331F4.5 7.2 2.44e-12 1.81e-09 0.38 0.32 Alcoholic chronic pancreatitis; chr16:75226343 chr16:75245994~75250077:- LUSC cis rs10129255 0.957 rs1024349 ENSG00000224373.3 IGHV4-59 7.2 2.45e-12 1.82e-09 0.18 0.32 Kawasaki disease; chr14:106689997 chr14:106627249~106627825:- LUSC cis rs8177876 0.749 rs2549891 ENSG00000261838.4 RP11-303E16.6 -7.2 2.45e-12 1.82e-09 -0.7 -0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046761 chr16:81069854~81076598:+ LUSC cis rs11098499 0.954 rs9998585 ENSG00000250412.1 KLHL2P1 7.2 2.46e-12 1.82e-09 0.4 0.32 Corneal astigmatism; chr4:119475647 chr4:119334329~119378233:+ LUSC cis rs1113500 0.805 rs11185244 ENSG00000226822.1 RP11-356N1.2 7.2 2.47e-12 1.83e-09 0.31 0.32 Growth-regulated protein alpha levels; chr1:108058525 chr1:108071482~108074519:+ LUSC cis rs12439619 0.508 rs8042665 ENSG00000276710.3 CSPG4P8 -7.2 2.47e-12 1.83e-09 -0.33 -0.32 Intelligence (multi-trait analysis); chr15:82189008 chr15:82459472~82477258:+ LUSC cis rs10129255 0.957 rs10132367 ENSG00000280411.1 IGHV1-69-2 -7.2 2.47e-12 1.83e-09 -0.22 -0.32 Kawasaki disease; chr14:106690981 chr14:106762092~106762588:- LUSC cis rs6142102 0.538 rs6142058 ENSG00000276073.1 RP5-1125A11.7 -7.2 2.48e-12 1.84e-09 -0.31 -0.32 Skin pigmentation; chr20:33954995 chr20:33985617~33988989:- LUSC cis rs950169 0.84 rs62019457 ENSG00000259728.4 LINC00933 7.2 2.48e-12 1.84e-09 0.41 0.31 Schizophrenia; chr15:84558911 chr15:84570649~84580175:+ LUSC cis rs75422866 0.541 rs12425816 ENSG00000274902.1 RP1-197B17.4 7.19 2.5e-12 1.85e-09 0.74 0.31 Pneumonia; chr12:47731419 chr12:47731908~47732351:+ LUSC cis rs875971 0.862 rs11773628 ENSG00000237310.1 GS1-124K5.4 -7.19 2.5e-12 1.85e-09 -0.33 -0.31 Aortic root size; chr7:66517644 chr7:66493706~66495474:+ LUSC cis rs34779708 0.966 rs11010135 ENSG00000230534.5 RP11-297A16.2 7.19 2.51e-12 1.86e-09 0.36 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35229135 chr10:35098006~35127020:- LUSC cis rs875971 0.522 rs781144 ENSG00000236529.1 RP13-254B10.1 7.19 2.51e-12 1.86e-09 0.33 0.31 Aortic root size; chr7:65975357 chr7:65840212~65840596:+ LUSC cis rs875971 0.862 rs12537823 ENSG00000237310.1 GS1-124K5.4 7.19 2.51e-12 1.86e-09 0.33 0.31 Aortic root size; chr7:66255897 chr7:66493706~66495474:+ LUSC cis rs748404 0.666 rs12908460 ENSG00000249839.1 AC011330.5 -7.19 2.51e-12 1.86e-09 -0.53 -0.31 Lung cancer; chr15:43413472 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs2230451 ENSG00000249839.1 AC011330.5 -7.19 2.51e-12 1.86e-09 -0.53 -0.31 Lung cancer; chr15:43415610 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs62021180 ENSG00000249839.1 AC011330.5 -7.19 2.51e-12 1.86e-09 -0.53 -0.31 Lung cancer; chr15:43420139 chr15:43663654~43684339:- LUSC cis rs10129255 1 rs10129319 ENSG00000280411.1 IGHV1-69-2 -7.19 2.51e-12 1.86e-09 -0.22 -0.31 Kawasaki disease; chr14:106767996 chr14:106762092~106762588:- LUSC cis rs66887589 0.592 rs11731571 ENSG00000245958.5 RP11-33B1.1 -7.19 2.51e-12 1.86e-09 -0.3 -0.31 Diastolic blood pressure; chr4:119300030 chr4:119454791~119552025:+ LUSC cis rs465969 0.655 rs13203984 ENSG00000255389.1 C6orf3 -7.19 2.52e-12 1.86e-09 -0.58 -0.31 Psoriasis; chr6:111388538 chr6:111599875~111602295:+ LUSC cis rs2134046 0.555 rs11854483 ENSG00000278603.1 RP13-608F4.5 7.19 2.53e-12 1.87e-09 0.38 0.31 Cognitive ability; chr15:82267217 chr15:82472203~82472426:+ LUSC cis rs10129255 1 rs9324091 ENSG00000280411.1 IGHV1-69-2 -7.19 2.53e-12 1.87e-09 -0.22 -0.31 Kawasaki disease; chr14:106676625 chr14:106762092~106762588:- LUSC cis rs34779708 0.931 rs4007289 ENSG00000230534.5 RP11-297A16.2 7.19 2.53e-12 1.88e-09 0.35 0.31 Inflammatory bowel disease;Crohn's disease; chr10:34980862 chr10:35098006~35127020:- LUSC cis rs1789 0.706 rs7696938 ENSG00000273133.1 RP11-799M12.2 7.19 2.54e-12 1.88e-09 0.46 0.31 Blood protein levels; chr4:15701954 chr4:15563698~15564253:- LUSC cis rs9813712 0.571 rs9855426 ENSG00000228252.7 COL6A4P2 7.19 2.54e-12 1.88e-09 0.29 0.31 Response to amphetamines; chr3:130214475 chr3:130212823~130273806:+ LUSC cis rs10829156 0.66 rs7910506 ENSG00000240291.1 RP11-499P20.2 -7.19 2.55e-12 1.89e-09 -0.33 -0.31 Sudden cardiac arrest; chr10:18518128 chr10:18513115~18545651:- LUSC cis rs4141404 0.851 rs5749222 ENSG00000236132.1 CTA-440B3.1 7.19 2.55e-12 1.89e-09 0.41 0.31 Paclitaxel-induced neuropathy; chr22:31160773 chr22:31816379~31817491:- LUSC cis rs673078 0.607 rs61944661 ENSG00000275759.1 RP11-131L12.3 -7.19 2.55e-12 1.89e-09 -0.46 -0.31 Glucose homeostasis traits; chr12:118445514 chr12:118428281~118428870:+ LUSC cis rs1113500 0.814 rs1592282 ENSG00000226822.1 RP11-356N1.2 7.19 2.57e-12 1.9e-09 0.31 0.31 Growth-regulated protein alpha levels; chr1:108058743 chr1:108071482~108074519:+ LUSC cis rs853679 0.55 rs1233704 ENSG00000204709.4 LINC01556 -7.19 2.57e-12 1.91e-09 -0.42 -0.31 Depression; chr6:28199145 chr6:28943877~28944537:+ LUSC cis rs4713118 0.513 rs149989 ENSG00000204709.4 LINC01556 7.19 2.59e-12 1.92e-09 0.4 0.31 Parkinson's disease; chr6:28030406 chr6:28943877~28944537:+ LUSC cis rs10129255 0.917 rs8022493 ENSG00000211972.2 IGHV3-66 7.19 2.59e-12 1.92e-09 0.23 0.31 Kawasaki disease; chr14:106781820 chr14:106675017~106675544:- LUSC cis rs6471393 0.861 rs2976374 ENSG00000253848.1 RP11-10N23.5 7.19 2.6e-12 1.92e-09 0.39 0.31 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93691945 chr8:93741193~93744534:+ LUSC cis rs17711722 0.701 rs781145 ENSG00000236529.1 RP13-254B10.1 7.19 2.6e-12 1.92e-09 0.33 0.31 Calcium levels; chr7:65975383 chr7:65840212~65840596:+ LUSC cis rs10129255 0.957 rs12590799 ENSG00000224373.3 IGHV4-59 7.19 2.6e-12 1.93e-09 0.17 0.31 Kawasaki disease; chr14:106779713 chr14:106627249~106627825:- LUSC cis rs10129255 0.957 rs10136781 ENSG00000224373.3 IGHV4-59 7.19 2.6e-12 1.93e-09 0.17 0.31 Kawasaki disease; chr14:106780451 chr14:106627249~106627825:- LUSC cis rs875971 0.522 rs10807697 ENSG00000236529.1 RP13-254B10.1 7.19 2.6e-12 1.93e-09 0.33 0.31 Aortic root size; chr7:65951183 chr7:65840212~65840596:+ LUSC cis rs11098499 0.644 rs7693919 ENSG00000249244.1 RP11-548H18.2 7.19 2.61e-12 1.93e-09 0.39 0.31 Corneal astigmatism; chr4:119619416 chr4:119391831~119395335:- LUSC cis rs4853012 1 rs2280643 ENSG00000257800.1 FNBP1P1 7.19 2.62e-12 1.94e-09 0.38 0.31 Gestational age at birth (maternal effect); chr2:74131159 chr2:74120680~74123218:+ LUSC cis rs4853012 0.887 rs2280644 ENSG00000257800.1 FNBP1P1 7.19 2.62e-12 1.94e-09 0.38 0.31 Gestational age at birth (maternal effect); chr2:74131284 chr2:74120680~74123218:+ LUSC cis rs950169 0.509 rs71395455 ENSG00000259728.4 LINC00933 7.19 2.62e-12 1.94e-09 0.41 0.31 Schizophrenia; chr15:84610573 chr15:84570649~84580175:+ LUSC cis rs11089937 0.667 rs10483107 ENSG00000211639.2 IGLV4-60 7.19 2.65e-12 1.96e-09 0.36 0.31 Periodontitis (PAL4Q3); chr22:22151036 chr22:22162199~22162681:+ LUSC cis rs11089937 0.667 rs11704024 ENSG00000211639.2 IGLV4-60 7.19 2.65e-12 1.96e-09 0.36 0.31 Periodontitis (PAL4Q3); chr22:22151195 chr22:22162199~22162681:+ LUSC cis rs10129255 0.5 rs9324092 ENSG00000224373.3 IGHV4-59 -7.18 2.66e-12 1.97e-09 -0.16 -0.31 Kawasaki disease; chr14:106683806 chr14:106627249~106627825:- LUSC cis rs875971 0.522 rs6960048 ENSG00000236529.1 RP13-254B10.1 7.18 2.66e-12 1.97e-09 0.33 0.31 Aortic root size; chr7:65943052 chr7:65840212~65840596:+ LUSC cis rs9318086 0.663 rs2312295 ENSG00000205861.10 C1QTNF9B-AS1 -7.18 2.67e-12 1.97e-09 -0.39 -0.31 Myopia (pathological); chr13:23883605 chr13:23888889~23897263:+ LUSC cis rs2729354 0.514 rs1967179 ENSG00000265566.2 RN7SL605P -7.18 2.68e-12 1.98e-09 -0.36 -0.31 Blood protein levels; chr11:57581010 chr11:57528085~57528365:- LUSC cis rs9595066 1 rs9595066 ENSG00000227258.4 SMIM2-AS1 7.18 2.68e-12 1.98e-09 0.48 0.31 Schizophrenia; chr13:44132132 chr13:44110451~44240517:+ LUSC cis rs8031584 0.678 rs798125 ENSG00000260382.1 RP11-540B6.2 -7.18 2.68e-12 1.98e-09 -0.42 -0.31 Huntington's disease progression; chr15:30824597 chr15:30882267~30883231:- LUSC cis rs8040855 0.756 rs2342118 ENSG00000259295.5 CSPG4P12 -7.18 2.69e-12 1.99e-09 -0.39 -0.31 Bulimia nervosa; chr15:85149785 chr15:85191438~85213905:+ LUSC cis rs11098499 1 rs13116504 ENSG00000249244.1 RP11-548H18.2 7.18 2.7e-12 1.99e-09 0.41 0.31 Corneal astigmatism; chr4:119288257 chr4:119391831~119395335:- LUSC cis rs4713118 0.869 rs7773070 ENSG00000219392.1 RP1-265C24.5 -7.18 2.71e-12 2e-09 -0.41 -0.31 Parkinson's disease; chr6:27761048 chr6:28115628~28116551:+ LUSC cis rs875971 0.522 rs2008188 ENSG00000236529.1 RP13-254B10.1 7.18 2.72e-12 2.01e-09 0.33 0.31 Aortic root size; chr7:65964026 chr7:65840212~65840596:+ LUSC cis rs526231 0.578 rs17154821 ENSG00000175749.11 EIF3KP1 7.18 2.72e-12 2.01e-09 0.38 0.31 Primary biliary cholangitis; chr5:102905637 chr5:103032376~103033031:+ LUSC cis rs2739330 0.734 rs2000467 ENSG00000231271.1 AP000350.8 -7.18 2.73e-12 2.02e-09 -0.42 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23949918~23954042:+ LUSC cis rs875971 0.545 rs221986 ENSG00000164669.11 INTS4P1 7.18 2.74e-12 2.02e-09 0.38 0.31 Aortic root size; chr7:66105323 chr7:65141225~65234216:+ LUSC cis rs8177876 0.731 rs4889227 ENSG00000261838.4 RP11-303E16.6 -7.18 2.74e-12 2.02e-09 -0.72 -0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81075576 chr16:81069854~81076598:+ LUSC cis rs17711722 0.522 rs4642526 ENSG00000236529.1 RP13-254B10.1 7.18 2.75e-12 2.03e-09 0.33 0.31 Calcium levels; chr7:65751755 chr7:65840212~65840596:+ LUSC cis rs380904 1 rs12543128 ENSG00000254859.1 RP11-661A12.5 -7.18 2.75e-12 2.03e-09 -0.42 -0.31 Venous thromboembolism (SNP x SNP interaction); chr8:143512872 chr8:143541973~143549729:- LUSC cis rs6142102 0.625 rs4911384 ENSG00000276073.1 RP5-1125A11.7 -7.18 2.75e-12 2.03e-09 -0.31 -0.31 Skin pigmentation; chr20:33968001 chr20:33985617~33988989:- LUSC cis rs7617773 0.78 rs13090538 ENSG00000228638.1 FCF1P2 -7.18 2.76e-12 2.04e-09 -0.37 -0.31 Coronary artery disease; chr3:48329279 chr3:48290793~48291375:- LUSC cis rs10129255 1 rs10134517 ENSG00000224373.3 IGHV4-59 7.18 2.76e-12 2.04e-09 0.18 0.31 Kawasaki disease; chr14:106718498 chr14:106627249~106627825:- LUSC cis rs465969 1 rs34530632 ENSG00000255389.1 C6orf3 -7.18 2.77e-12 2.04e-09 -0.64 -0.31 Psoriasis; chr6:111455132 chr6:111599875~111602295:+ LUSC cis rs2188561 0.697 rs7782475 ENSG00000241764.3 AC002467.7 -7.18 2.77e-12 2.04e-09 -0.4 -0.31 Alcohol consumption; chr7:107745806 chr7:107742817~107744581:- LUSC cis rs4423214 0.535 rs1540129 ENSG00000254682.1 RP11-660L16.2 7.18 2.83e-12 2.09e-09 0.42 0.31 Vitamin D levels; chr11:71418477 chr11:71448674~71452157:+ LUSC cis rs9595066 0.941 rs9533777 ENSG00000227258.4 SMIM2-AS1 -7.17 2.84e-12 2.09e-09 -0.49 -0.31 Schizophrenia; chr13:44134584 chr13:44110451~44240517:+ LUSC cis rs7811142 0.779 rs111312383 ENSG00000242294.5 STAG3L5P 7.17 2.84e-12 2.09e-09 0.26 0.31 Platelet count; chr7:100307702 chr7:100336079~100351900:+ LUSC cis rs7811142 0.779 rs28680963 ENSG00000242294.5 STAG3L5P 7.17 2.84e-12 2.09e-09 0.26 0.31 Platelet count; chr7:100307852 chr7:100336079~100351900:+ LUSC cis rs875971 0.862 rs6460307 ENSG00000222364.1 RNU6-96P -7.17 2.85e-12 2.1e-09 -0.37 -0.31 Aortic root size; chr7:66595884 chr7:66395191~66395286:+ LUSC cis rs35955747 0.869 rs7286648 ENSG00000236132.1 CTA-440B3.1 -7.17 2.85e-12 2.1e-09 -0.37 -0.31 Neutrophil count;Sum basophil neutrophil counts; chr22:31143628 chr22:31816379~31817491:- LUSC cis rs9549367 0.713 rs9549681 ENSG00000269125.1 RP11-98F14.11 -7.17 2.85e-12 2.1e-09 -0.41 -0.31 Platelet distribution width; chr13:113175559 chr13:113165002~113165183:- LUSC cis rs673078 0.607 rs17513013 ENSG00000275759.1 RP11-131L12.3 -7.17 2.87e-12 2.11e-09 -0.46 -0.31 Glucose homeostasis traits; chr12:118442070 chr12:118428281~118428870:+ LUSC cis rs8040855 0.965 rs11073990 ENSG00000259295.5 CSPG4P12 7.17 2.87e-12 2.11e-09 0.37 0.31 Bulimia nervosa; chr15:85168070 chr15:85191438~85213905:+ LUSC cis rs9309473 0.948 rs10199224 ENSG00000163016.8 ALMS1P 7.17 2.87e-12 2.11e-09 0.38 0.31 Metabolite levels; chr2:73534319 chr2:73644919~73685576:+ LUSC cis rs875971 0.862 rs7809814 ENSG00000237310.1 GS1-124K5.4 -7.17 2.88e-12 2.12e-09 -0.33 -0.31 Aortic root size; chr7:66150410 chr7:66493706~66495474:+ LUSC cis rs7739264 0.602 rs6925511 ENSG00000227116.1 RP3-471C18.1 7.17 2.88e-12 2.12e-09 0.35 0.31 Endometriosis; chr6:19773322 chr6:19730427~19734567:- LUSC cis rs2282300 0.739 rs1222221 ENSG00000254532.1 RP11-624D11.2 7.17 2.89e-12 2.13e-09 0.42 0.31 Morning vs. evening chronotype; chr11:30321191 chr11:30044058~30084343:- LUSC cis rs10129255 0.957 rs11846893 ENSG00000224373.3 IGHV4-59 7.17 2.89e-12 2.13e-09 0.17 0.31 Kawasaki disease; chr14:106779068 chr14:106627249~106627825:- LUSC cis rs1113500 0.73 rs1618693 ENSG00000226822.1 RP11-356N1.2 -7.17 2.9e-12 2.13e-09 -0.31 -0.31 Growth-regulated protein alpha levels; chr1:108048961 chr1:108071482~108074519:+ LUSC cis rs1113500 0.698 rs1781078 ENSG00000226822.1 RP11-356N1.2 -7.17 2.9e-12 2.13e-09 -0.31 -0.31 Growth-regulated protein alpha levels; chr1:108049020 chr1:108071482~108074519:+ LUSC cis rs55794721 0.509 rs909834 ENSG00000224183.1 SDHDP6 -7.17 2.91e-12 2.14e-09 -0.39 -0.31 Mean corpuscular volume;Plateletcrit; chr1:25431505 chr1:25294164~25294643:- LUSC cis rs1075265 0.729 rs10201364 ENSG00000233266.1 HMGB1P31 7.17 2.92e-12 2.15e-09 0.39 0.31 Chronotype;Morning vs. evening chronotype; chr2:53990220 chr2:54051334~54051760:+ LUSC cis rs17711722 0.565 rs4717276 ENSG00000236529.1 RP13-254B10.1 7.17 2.92e-12 2.15e-09 0.33 0.31 Calcium levels; chr7:65829754 chr7:65840212~65840596:+ LUSC cis rs11098499 1 rs11726229 ENSG00000249244.1 RP11-548H18.2 7.17 2.92e-12 2.15e-09 0.41 0.31 Corneal astigmatism; chr4:119290425 chr4:119391831~119395335:- LUSC cis rs4865169 0.595 rs9998008 ENSG00000269949.1 RP11-738E22.3 7.17 2.93e-12 2.15e-09 0.39 0.31 Breast cancer; chr4:56899886 chr4:56960927~56961373:- LUSC cis rs4423214 0.547 rs11234030 ENSG00000254682.1 RP11-660L16.2 -7.17 2.93e-12 2.16e-09 -0.52 -0.31 Vitamin D levels; chr11:71525921 chr11:71448674~71452157:+ LUSC cis rs11098499 0.909 rs6842762 ENSG00000250412.1 KLHL2P1 7.17 2.94e-12 2.16e-09 0.4 0.31 Corneal astigmatism; chr4:119477081 chr4:119334329~119378233:+ LUSC cis rs12439619 0.53 rs7162177 ENSG00000276710.3 CSPG4P8 -7.17 2.94e-12 2.16e-09 -0.33 -0.31 Intelligence (multi-trait analysis); chr15:82181728 chr15:82459472~82477258:+ LUSC cis rs9549367 0.662 rs3818334 ENSG00000269125.1 RP11-98F14.11 -7.17 2.94e-12 2.16e-09 -0.41 -0.31 Platelet distribution width; chr13:113170860 chr13:113165002~113165183:- LUSC cis rs2946504 0.52 rs2272624 ENSG00000251468.2 RP11-369K16.1 -7.17 2.94e-12 2.16e-09 -0.37 -0.31 Type 2 diabetes; chr8:12952158 chr8:12958387~12962200:+ LUSC cis rs4713118 0.513 rs149955 ENSG00000204709.4 LINC01556 7.17 2.96e-12 2.17e-09 0.41 0.31 Parkinson's disease; chr6:28068447 chr6:28943877~28944537:+ LUSC cis rs1823913 0.927 rs13025919 ENSG00000280083.1 RP11-317J9.1 -7.17 2.96e-12 2.17e-09 -0.39 -0.31 Obesity-related traits; chr2:191260175 chr2:191154118~191156070:- LUSC cis rs11098499 0.604 rs2389882 ENSG00000245958.5 RP11-33B1.1 -7.17 2.97e-12 2.18e-09 -0.32 -0.31 Corneal astigmatism; chr4:119645578 chr4:119454791~119552025:+ LUSC cis rs875971 0.862 rs6460290 ENSG00000237310.1 GS1-124K5.4 -7.17 2.97e-12 2.18e-09 -0.33 -0.31 Aortic root size; chr7:66344119 chr7:66493706~66495474:+ LUSC cis rs1113500 0.73 rs1777456 ENSG00000226822.1 RP11-356N1.2 -7.17 2.98e-12 2.19e-09 -0.31 -0.31 Growth-regulated protein alpha levels; chr1:108045850 chr1:108071482~108074519:+ LUSC cis rs10754283 0.967 rs1320563 ENSG00000231613.1 RP5-943J3.1 7.17 2.98e-12 2.19e-09 0.36 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89655473 chr1:89788914~89790492:+ LUSC cis rs9532669 0.89 rs12865032 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40873801 chr13:40863599~40863902:- LUSC cis rs9532669 0.89 rs34123829 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40873808 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4488324 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40873864 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4288867 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40873880 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4415896 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40874001 chr13:40863599~40863902:- LUSC cis rs9532669 0.89 rs4415897 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40874035 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4389021 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40874209 chr13:40863599~40863902:- LUSC cis rs9532669 0.824 rs4628828 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40874369 chr13:40863599~40863902:- LUSC cis rs9532669 0.737 rs34354179 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40874424 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs9594445 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40874859 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs9594446 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40874863 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4402423 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40875010 chr13:40863599~40863902:- LUSC cis rs9532669 0.963 rs9532628 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40875172 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs9532629 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40875193 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs7491149 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40875216 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs9532630 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40875472 chr13:40863599~40863902:- LUSC cis rs9532669 0.89 rs4306385 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40875641 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4406939 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40876108 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4628824 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40876217 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs9532632 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40876309 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs9532633 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40876332 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs9532634 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40876369 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs9532635 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40876397 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs12428959 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40876638 chr13:40863599~40863902:- LUSC cis rs9532669 0.895 rs4942009 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40877243 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs4334153 ENSG00000176268.5 CYCSP34 7.17 2.98e-12 2.19e-09 0.31 0.31 Cervical cancer; chr13:40877737 chr13:40863599~40863902:- LUSC cis rs13113518 0.756 rs11939652 ENSG00000223305.1 RN7SKP30 7.17 2.99e-12 2.19e-09 0.38 0.31 Height; chr4:55532542 chr4:55540502~55540835:- LUSC cis rs4660456 1 rs4660456 ENSG00000237899.1 RP4-739H11.3 -7.17 3e-12 2.2e-09 -0.44 -0.31 Platelet count; chr1:40773839 chr1:40669089~40687588:- LUSC cis rs75422866 0.867 rs73113117 ENSG00000274902.1 RP1-197B17.4 7.17 3.01e-12 2.21e-09 0.8 0.31 Pneumonia; chr12:47617299 chr12:47731908~47732351:+ LUSC cis rs1823913 1 rs10445782 ENSG00000280083.1 RP11-317J9.1 7.17 3.02e-12 2.21e-09 0.38 0.31 Obesity-related traits; chr2:191236639 chr2:191154118~191156070:- LUSC cis rs9921338 0.961 rs66555362 ENSG00000263080.1 RP11-485G7.5 7.17 3.02e-12 2.21e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11294976 chr16:11341809~11345211:- LUSC cis rs875971 0.862 rs908915 ENSG00000237310.1 GS1-124K5.4 -7.17 3.02e-12 2.22e-09 -0.33 -0.31 Aortic root size; chr7:66149664 chr7:66493706~66495474:+ LUSC cis rs875971 0.571 rs160641 ENSG00000164669.11 INTS4P1 7.17 3.02e-12 2.22e-09 0.38 0.31 Aortic root size; chr7:66112359 chr7:65141225~65234216:+ LUSC cis rs853679 0.556 rs13200214 ENSG00000204709.4 LINC01556 7.16 3.03e-12 2.22e-09 0.67 0.31 Depression; chr6:28049472 chr6:28943877~28944537:+ LUSC cis rs2412819 0.597 rs2412821 ENSG00000249839.1 AC011330.5 -7.16 3.03e-12 2.22e-09 -0.5 -0.31 Lung cancer; chr15:43864966 chr15:43663654~43684339:- LUSC cis rs2412819 0.597 rs514311 ENSG00000249839.1 AC011330.5 -7.16 3.03e-12 2.22e-09 -0.5 -0.31 Lung cancer; chr15:43869376 chr15:43663654~43684339:- LUSC cis rs10754283 0.967 rs7523046 ENSG00000231613.1 RP5-943J3.1 7.16 3.03e-12 2.22e-09 0.35 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89643940 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs7523518 ENSG00000231613.1 RP5-943J3.1 7.16 3.03e-12 2.22e-09 0.35 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89644451 chr1:89788914~89790492:+ LUSC cis rs3091242 0.933 rs9438904 ENSG00000224183.1 SDHDP6 -7.16 3.04e-12 2.23e-09 -0.38 -0.31 Erythrocyte sedimentation rate; chr1:25430369 chr1:25294164~25294643:- LUSC cis rs17507216 0.667 rs72753916 ENSG00000278603.1 RP13-608F4.5 7.16 3.05e-12 2.24e-09 0.45 0.31 Excessive daytime sleepiness; chr15:82684001 chr15:82472203~82472426:+ LUSC cis rs12554020 0.892 rs75678521 ENSG00000227603.1 RP11-165J3.6 7.16 3.06e-12 2.24e-09 0.43 0.31 Schizophrenia; chr9:93600744 chr9:93435332~93437121:- LUSC cis rs6142102 0.923 rs3787230 ENSG00000276073.1 RP5-1125A11.7 -7.16 3.06e-12 2.24e-09 -0.32 -0.31 Skin pigmentation; chr20:34052466 chr20:33985617~33988989:- LUSC cis rs2404602 0.684 rs12591622 ENSG00000259422.1 RP11-593F23.1 -7.16 3.07e-12 2.25e-09 -0.38 -0.31 Blood metabolite levels; chr15:76638314 chr15:76174891~76181486:- LUSC cis rs4423214 0.592 rs10898191 ENSG00000254682.1 RP11-660L16.2 -7.16 3.07e-12 2.25e-09 -0.51 -0.31 Vitamin D levels; chr11:71483555 chr11:71448674~71452157:+ LUSC cis rs17711722 0.727 rs1880555 ENSG00000236529.1 RP13-254B10.1 7.16 3.07e-12 2.25e-09 0.32 0.31 Calcium levels; chr7:65967580 chr7:65840212~65840596:+ LUSC cis rs6142102 0.961 rs909884 ENSG00000276073.1 RP5-1125A11.7 -7.16 3.08e-12 2.26e-09 -0.33 -0.31 Skin pigmentation; chr20:34058257 chr20:33985617~33988989:- LUSC cis rs35160687 0.901 rs12472676 ENSG00000273080.1 RP11-301O19.1 7.16 3.09e-12 2.26e-09 0.3 0.31 Night sleep phenotypes; chr2:86283692 chr2:86195590~86196049:+ LUSC cis rs17711722 0.565 rs73372653 ENSG00000236529.1 RP13-254B10.1 7.16 3.1e-12 2.27e-09 0.33 0.31 Calcium levels; chr7:65977808 chr7:65840212~65840596:+ LUSC cis rs17711722 0.74 rs7809991 ENSG00000236529.1 RP13-254B10.1 7.16 3.1e-12 2.27e-09 0.32 0.31 Calcium levels; chr7:65941231 chr7:65840212~65840596:+ LUSC cis rs867371 0.502 rs8025964 ENSG00000276710.3 CSPG4P8 -7.16 3.11e-12 2.27e-09 -0.32 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82229429 chr15:82459472~82477258:+ LUSC cis rs36423 0.528 rs1205061 ENSG00000266869.1 RP6-114E22.1 7.16 3.11e-12 2.28e-09 0.48 0.31 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71882819 chr14:71848606~71908430:+ LUSC cis rs10129255 0.912 rs8009135 ENSG00000224373.3 IGHV4-59 7.16 3.13e-12 2.29e-09 0.18 0.31 Kawasaki disease; chr14:106777528 chr14:106627249~106627825:- LUSC cis rs8177876 0.749 rs804895 ENSG00000261838.4 RP11-303E16.6 -7.16 3.13e-12 2.29e-09 -0.7 -0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81066108 chr16:81069854~81076598:+ LUSC cis rs8040855 0.599 rs4643289 ENSG00000259295.5 CSPG4P12 -7.16 3.14e-12 2.29e-09 -0.35 -0.31 Bulimia nervosa; chr15:85183483 chr15:85191438~85213905:+ LUSC cis rs8177876 0.822 rs9925940 ENSG00000261838.4 RP11-303E16.6 7.16 3.14e-12 2.29e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077379 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs9925943 ENSG00000261838.4 RP11-303E16.6 7.16 3.14e-12 2.29e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077402 chr16:81069854~81076598:+ LUSC cis rs17023223 0.581 rs12064109 ENSG00000231365.4 RP11-418J17.1 -7.16 3.15e-12 2.3e-09 -0.42 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119099673 chr1:119140396~119275973:+ LUSC cis rs801193 1 rs10234018 ENSG00000224316.1 RP11-479O9.2 -7.16 3.17e-12 2.32e-09 -0.3 -0.31 Aortic root size; chr7:66681297 chr7:65773620~65802067:+ LUSC cis rs9921338 0.924 rs7193645 ENSG00000263080.1 RP11-485G7.5 7.16 3.17e-12 2.32e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11287179 chr16:11341809~11345211:- LUSC cis rs34375054 0.738 rs10773145 ENSG00000279233.1 RP11-158L12.4 -7.16 3.17e-12 2.32e-09 -0.28 -0.31 Post bronchodilator FEV1/FVC ratio; chr12:125141057 chr12:125138245~125141711:+ LUSC cis rs6142102 0.961 rs4911408 ENSG00000276073.1 RP5-1125A11.7 -7.16 3.17e-12 2.32e-09 -0.34 -0.31 Skin pigmentation; chr20:34112760 chr20:33985617~33988989:- LUSC cis rs875971 0.522 rs2949690 ENSG00000236529.1 RP13-254B10.1 -7.16 3.18e-12 2.32e-09 -0.32 -0.31 Aortic root size; chr7:66018255 chr7:65840212~65840596:+ LUSC cis rs673078 0.66 rs17512609 ENSG00000275759.1 RP11-131L12.3 -7.16 3.18e-12 2.32e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118354072 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs73207578 ENSG00000275759.1 RP11-131L12.3 -7.16 3.19e-12 2.34e-09 -0.46 -0.31 Glucose homeostasis traits; chr12:118447080 chr12:118428281~118428870:+ LUSC cis rs10129255 0.5 rs2105991 ENSG00000224373.3 IGHV4-59 7.16 3.19e-12 2.34e-09 0.15 0.31 Kawasaki disease; chr14:106682022 chr14:106627249~106627825:- LUSC cis rs465969 1 rs9400478 ENSG00000255389.1 C6orf3 7.16 3.21e-12 2.35e-09 0.62 0.31 Psoriasis; chr6:111478441 chr6:111599875~111602295:+ LUSC cis rs10129255 0.957 rs12590799 ENSG00000211972.2 IGHV3-66 7.16 3.22e-12 2.35e-09 0.23 0.31 Kawasaki disease; chr14:106779713 chr14:106675017~106675544:- LUSC cis rs10129255 0.957 rs10136781 ENSG00000211972.2 IGHV3-66 7.16 3.22e-12 2.35e-09 0.23 0.31 Kawasaki disease; chr14:106780451 chr14:106675017~106675544:- LUSC cis rs673078 0.607 rs61943443 ENSG00000275759.1 RP11-131L12.3 -7.15 3.24e-12 2.37e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118416602 chr12:118428281~118428870:+ LUSC cis rs2739330 0.76 rs5751760 ENSG00000099984.9 GSTT2 -7.15 3.24e-12 2.37e-09 -0.37 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23980123~23983911:+ LUSC cis rs8177876 0.686 rs804897 ENSG00000261838.4 RP11-303E16.6 -7.15 3.24e-12 2.37e-09 -0.71 -0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81067590 chr16:81069854~81076598:+ LUSC cis rs4713118 0.513 rs9368547 ENSG00000204709.4 LINC01556 7.15 3.24e-12 2.37e-09 0.39 0.31 Parkinson's disease; chr6:28060289 chr6:28943877~28944537:+ LUSC cis rs4713118 0.513 rs183244 ENSG00000204709.4 LINC01556 7.15 3.24e-12 2.37e-09 0.39 0.31 Parkinson's disease; chr6:28064060 chr6:28943877~28944537:+ LUSC cis rs3747113 0.865 rs9620384 ENSG00000128262.7 POM121L9P -7.15 3.24e-12 2.37e-09 -0.33 -0.31 Gut microbiome composition (summer); chr22:24379380 chr22:24251828~24265525:+ LUSC cis rs11089937 0.597 rs11704434 ENSG00000211639.2 IGLV4-60 7.15 3.25e-12 2.37e-09 0.37 0.31 Periodontitis (PAL4Q3); chr22:22131715 chr22:22162199~22162681:+ LUSC cis rs6142102 0.58 rs4911139 ENSG00000276073.1 RP5-1125A11.7 -7.15 3.25e-12 2.38e-09 -0.31 -0.31 Skin pigmentation; chr20:33963729 chr20:33985617~33988989:- LUSC cis rs6921919 0.583 rs7759191 ENSG00000204709.4 LINC01556 7.15 3.25e-12 2.38e-09 0.4 0.31 Autism spectrum disorder or schizophrenia; chr6:28385657 chr6:28943877~28944537:+ LUSC cis rs9921338 0.961 rs9936328 ENSG00000263080.1 RP11-485G7.5 7.15 3.26e-12 2.38e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11344364 chr16:11341809~11345211:- LUSC cis rs4141404 0.851 rs8135417 ENSG00000236132.1 CTA-440B3.1 7.15 3.26e-12 2.38e-09 0.4 0.31 Paclitaxel-induced neuropathy; chr22:31163269 chr22:31816379~31817491:- LUSC cis rs1075232 1 rs34959140 ENSG00000215302.7 CTD-3092A11.1 -7.15 3.26e-12 2.38e-09 -0.72 -0.31 Survival in colorectal cancer (non-distant metastatic); chr15:31433020 chr15:30470779~30507623:+ LUSC cis rs9487094 0.645 rs34533653 ENSG00000260273.1 RP11-425D10.10 7.15 3.28e-12 2.4e-09 0.44 0.31 Height; chr6:109479488 chr6:109382795~109383666:+ LUSC cis rs17507216 0.56 rs28493687 ENSG00000278603.1 RP13-608F4.5 7.15 3.29e-12 2.4e-09 0.38 0.31 Excessive daytime sleepiness; chr15:82560062 chr15:82472203~82472426:+ LUSC cis rs9532669 0.926 rs9532691 ENSG00000176268.5 CYCSP34 -7.15 3.29e-12 2.4e-09 -0.3 -0.31 Cervical cancer; chr13:40969358 chr13:40863599~40863902:- LUSC cis rs6890270 1 rs6890270 ENSG00000271828.1 CTD-2310F14.1 7.15 3.29e-12 2.4e-09 0.54 0.31 Breast cancer; chr5:56964779 chr5:56927874~56929573:+ LUSC cis rs3813579 0.679 rs4329928 ENSG00000261390.4 RP11-345M22.2 7.15 3.29e-12 2.4e-09 0.38 0.31 Thyroid volume; chr16:79713988 chr16:79715232~79770563:- LUSC cis rs10129255 0.957 rs10138532 ENSG00000280411.1 IGHV1-69-2 -7.15 3.3e-12 2.41e-09 -0.23 -0.31 Kawasaki disease; chr14:106803901 chr14:106762092~106762588:- LUSC cis rs10740039 1 rs10761541 ENSG00000254271.1 RP11-131N11.4 7.15 3.3e-12 2.41e-09 0.41 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60655383 chr10:60734342~60741828:+ LUSC cis rs2188561 0.697 rs2237679 ENSG00000241764.3 AC002467.7 7.15 3.3e-12 2.41e-09 0.41 0.31 Alcohol consumption; chr7:107693581 chr7:107742817~107744581:- LUSC cis rs34779708 0.931 rs2384289 ENSG00000230534.5 RP11-297A16.2 7.15 3.31e-12 2.42e-09 0.35 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35054597 chr10:35098006~35127020:- LUSC cis rs2404602 0.684 rs11854850 ENSG00000259422.1 RP11-593F23.1 -7.15 3.34e-12 2.44e-09 -0.37 -0.31 Blood metabolite levels; chr15:76552230 chr15:76174891~76181486:- LUSC cis rs9549367 0.713 rs576463 ENSG00000269125.1 RP11-98F14.11 7.15 3.34e-12 2.44e-09 0.38 0.31 Platelet distribution width; chr13:113192300 chr13:113165002~113165183:- LUSC cis rs9813712 0.571 rs11715351 ENSG00000228252.7 COL6A4P2 -7.15 3.35e-12 2.44e-09 -0.29 -0.31 Response to amphetamines; chr3:130214704 chr3:130212823~130273806:+ LUSC cis rs6142102 0.602 rs4911145 ENSG00000276073.1 RP5-1125A11.7 7.15 3.35e-12 2.45e-09 0.3 0.31 Skin pigmentation; chr20:34027417 chr20:33985617~33988989:- LUSC cis rs7739264 0.564 rs2223361 ENSG00000227116.1 RP3-471C18.1 -7.15 3.36e-12 2.45e-09 -0.35 -0.31 Endometriosis; chr6:19790578 chr6:19730427~19734567:- LUSC cis rs11098499 1 rs7659194 ENSG00000249244.1 RP11-548H18.2 7.15 3.36e-12 2.45e-09 0.4 0.31 Corneal astigmatism; chr4:119285992 chr4:119391831~119395335:- LUSC cis rs8177876 0.749 rs754429 ENSG00000261838.4 RP11-303E16.6 7.15 3.37e-12 2.45e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81062574 chr16:81069854~81076598:+ LUSC cis rs11098499 0.908 rs28559989 ENSG00000250412.1 KLHL2P1 7.15 3.39e-12 2.47e-09 0.4 0.31 Corneal astigmatism; chr4:119465472 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs28632018 ENSG00000250412.1 KLHL2P1 7.15 3.39e-12 2.47e-09 0.4 0.31 Corneal astigmatism; chr4:119465575 chr4:119334329~119378233:+ LUSC cis rs6142102 0.961 rs1055857 ENSG00000276073.1 RP5-1125A11.7 -7.15 3.39e-12 2.47e-09 -0.32 -0.31 Skin pigmentation; chr20:34026067 chr20:33985617~33988989:- LUSC cis rs6142102 0.625 rs9753690 ENSG00000276073.1 RP5-1125A11.7 -7.15 3.4e-12 2.48e-09 -0.31 -0.31 Skin pigmentation; chr20:33952995 chr20:33985617~33988989:- LUSC cis rs6142102 0.625 rs7263727 ENSG00000276073.1 RP5-1125A11.7 -7.15 3.4e-12 2.48e-09 -0.31 -0.31 Skin pigmentation; chr20:33953133 chr20:33985617~33988989:- LUSC cis rs10129255 0.518 rs7143784 ENSG00000224373.3 IGHV4-59 7.15 3.41e-12 2.48e-09 0.15 0.31 Kawasaki disease; chr14:106687277 chr14:106627249~106627825:- LUSC cis rs6142102 0.961 rs2284386 ENSG00000276073.1 RP5-1125A11.7 -7.15 3.42e-12 2.49e-09 -0.32 -0.31 Skin pigmentation; chr20:34056590 chr20:33985617~33988989:- LUSC cis rs9487094 0.744 rs13220304 ENSG00000260273.1 RP11-425D10.10 7.15 3.43e-12 2.5e-09 0.4 0.31 Height; chr6:109331033 chr6:109382795~109383666:+ LUSC cis rs6142102 0.625 rs4911381 ENSG00000276073.1 RP5-1125A11.7 7.15 3.43e-12 2.5e-09 0.31 0.31 Skin pigmentation; chr20:33962539 chr20:33985617~33988989:- LUSC cis rs6570726 0.577 rs406868 ENSG00000235652.6 RP11-545I5.3 7.15 3.43e-12 2.5e-09 0.33 0.31 Lobe attachment (rater-scored or self-reported); chr6:145488847 chr6:145799409~145886585:+ LUSC cis rs10754283 0.967 rs4658307 ENSG00000231613.1 RP5-943J3.1 7.15 3.43e-12 2.5e-09 0.36 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89652027 chr1:89788914~89790492:+ LUSC cis rs11428934 1 rs11428934 ENSG00000232871.7 SEC1P 7.15 3.44e-12 2.51e-09 0.4 0.31 Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts; chr19:48640988 chr19:48638071~48682245:+ LUSC cis rs9341808 0.527 rs7453746 ENSG00000272129.1 RP11-250B2.6 7.15 3.45e-12 2.51e-09 0.38 0.31 Sitting height ratio; chr6:80100296 chr6:80355424~80356859:+ LUSC cis rs3091242 0.933 rs12402120 ENSG00000224183.1 SDHDP6 -7.15 3.45e-12 2.51e-09 -0.39 -0.31 Erythrocyte sedimentation rate; chr1:25425141 chr1:25294164~25294643:- LUSC cis rs6471393 0.798 rs55680024 ENSG00000253848.1 RP11-10N23.5 7.14 3.46e-12 2.52e-09 0.42 0.31 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93836533 chr8:93741193~93744534:+ LUSC cis rs2179367 0.613 rs12207047 ENSG00000231760.4 RP11-350J20.5 7.14 3.46e-12 2.52e-09 0.43 0.31 Dupuytren's disease; chr6:149423496 chr6:149796151~149826294:- LUSC cis rs2179367 0.613 rs12207261 ENSG00000231760.4 RP11-350J20.5 7.14 3.46e-12 2.52e-09 0.43 0.31 Dupuytren's disease; chr6:149423722 chr6:149796151~149826294:- LUSC cis rs34779708 0.931 rs11010067 ENSG00000230534.5 RP11-297A16.2 -7.14 3.46e-12 2.52e-09 -0.35 -0.31 Inflammatory bowel disease;Crohn's disease; chr10:35006503 chr10:35098006~35127020:- LUSC cis rs4713118 0.513 rs149975 ENSG00000204709.4 LINC01556 7.14 3.46e-12 2.52e-09 0.4 0.31 Parkinson's disease; chr6:28018562 chr6:28943877~28944537:+ LUSC cis rs17711722 0.522 rs6957759 ENSG00000236529.1 RP13-254B10.1 7.14 3.47e-12 2.53e-09 0.33 0.31 Calcium levels; chr7:65806798 chr7:65840212~65840596:+ LUSC cis rs10754283 0.901 rs10922683 ENSG00000231613.1 RP5-943J3.1 7.14 3.48e-12 2.53e-09 0.36 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89650509 chr1:89788914~89790492:+ LUSC cis rs1865760 0.786 rs1436308 ENSG00000272462.2 U91328.19 -7.14 3.48e-12 2.53e-09 -0.34 -0.31 Height; chr6:25939339 chr6:25992662~26001775:+ LUSC cis rs35160687 0.901 rs12999029 ENSG00000273080.1 RP11-301O19.1 7.14 3.49e-12 2.54e-09 0.3 0.31 Night sleep phenotypes; chr2:86275790 chr2:86195590~86196049:+ LUSC cis rs35160687 0.901 rs67903513 ENSG00000273080.1 RP11-301O19.1 7.14 3.49e-12 2.54e-09 0.3 0.31 Night sleep phenotypes; chr2:86284976 chr2:86195590~86196049:+ LUSC cis rs34779708 0.868 rs2384352 ENSG00000230534.5 RP11-297A16.2 7.14 3.49e-12 2.54e-09 0.35 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35203904 chr10:35098006~35127020:- LUSC cis rs465969 1 rs4509157 ENSG00000255389.1 C6orf3 -7.14 3.5e-12 2.55e-09 -0.54 -0.31 Psoriasis; chr6:111513875 chr6:111599875~111602295:+ LUSC cis rs3091242 0.933 rs4649084 ENSG00000224183.1 SDHDP6 -7.14 3.5e-12 2.55e-09 -0.39 -0.31 Erythrocyte sedimentation rate; chr1:25426126 chr1:25294164~25294643:- LUSC cis rs10129255 1 rs4612959 ENSG00000280411.1 IGHV1-69-2 -7.14 3.5e-12 2.55e-09 -0.22 -0.31 Kawasaki disease; chr14:106767055 chr14:106762092~106762588:- LUSC cis rs853679 0.55 rs6901017 ENSG00000204709.4 LINC01556 7.14 3.5e-12 2.55e-09 0.43 0.31 Depression; chr6:28184805 chr6:28943877~28944537:+ LUSC cis rs4308124 0.708 rs28766030 ENSG00000227992.1 AC108463.2 -7.14 3.51e-12 2.55e-09 -0.42 -0.31 Vitiligo; chr2:111204852 chr2:111203964~111206215:- LUSC cis rs4308124 0.708 rs28871990 ENSG00000227992.1 AC108463.2 -7.14 3.51e-12 2.55e-09 -0.42 -0.31 Vitiligo; chr2:111204864 chr2:111203964~111206215:- LUSC cis rs4308124 0.708 rs67816163 ENSG00000227992.1 AC108463.2 -7.14 3.51e-12 2.55e-09 -0.42 -0.31 Vitiligo; chr2:111205733 chr2:111203964~111206215:- LUSC cis rs4308124 0.679 rs7600458 ENSG00000227992.1 AC108463.2 -7.14 3.51e-12 2.55e-09 -0.42 -0.31 Vitiligo; chr2:111206013 chr2:111203964~111206215:- LUSC cis rs8040855 1 rs8040855 ENSG00000259295.5 CSPG4P12 -7.14 3.52e-12 2.56e-09 -0.37 -0.31 Bulimia nervosa; chr15:85155976 chr15:85191438~85213905:+ LUSC cis rs2455601 0.608 rs16906256 ENSG00000254860.4 TMEM9B-AS1 7.14 3.52e-12 2.56e-09 0.37 0.31 Schizophrenia; chr11:8865550 chr11:8964675~8977527:+ LUSC cis rs2188561 0.697 rs2072064 ENSG00000241764.3 AC002467.7 7.14 3.52e-12 2.56e-09 0.41 0.31 Alcohol consumption; chr7:107694068 chr7:107742817~107744581:- LUSC cis rs6142102 0.961 rs1883524 ENSG00000276073.1 RP5-1125A11.7 -7.14 3.53e-12 2.57e-09 -0.32 -0.31 Skin pigmentation; chr20:34038301 chr20:33985617~33988989:- LUSC cis rs10129255 0.957 rs61997760 ENSG00000224373.3 IGHV4-59 7.14 3.55e-12 2.58e-09 0.18 0.31 Kawasaki disease; chr14:106716993 chr14:106627249~106627825:- LUSC cis rs7772486 0.597 rs6912351 ENSG00000235652.6 RP11-545I5.3 -7.14 3.56e-12 2.59e-09 -0.32 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145942935 chr6:145799409~145886585:+ LUSC cis rs853679 0.55 rs1225598 ENSG00000204709.4 LINC01556 7.14 3.58e-12 2.6e-09 0.44 0.31 Depression; chr6:28193021 chr6:28943877~28944537:+ LUSC cis rs34779708 0.966 rs10827492 ENSG00000230534.5 RP11-297A16.2 -7.14 3.58e-12 2.6e-09 -0.35 -0.31 Inflammatory bowel disease;Crohn's disease; chr10:35140897 chr10:35098006~35127020:- LUSC cis rs9532669 0.926 rs4270044 ENSG00000176268.5 CYCSP34 7.14 3.59e-12 2.61e-09 0.31 0.31 Cervical cancer; chr13:40877923 chr13:40863599~40863902:- LUSC cis rs9532669 0.926 rs11147824 ENSG00000176268.5 CYCSP34 7.14 3.59e-12 2.61e-09 0.31 0.31 Cervical cancer; chr13:40878183 chr13:40863599~40863902:- LUSC cis rs8177876 0.822 rs9923732 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077298 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs9933184 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077571 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs9926174 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077831 chr16:81069854~81076598:+ LUSC cis rs8177876 0.642 rs8052490 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078251 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs8056972 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078817 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs74437879 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078987 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs76948085 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079199 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs80315956 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079254 chr16:81069854~81076598:+ LUSC cis rs8177876 0.642 rs16954572 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079299 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs9929586 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079416 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs9938965 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079558 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs7204040 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079888 chr16:81069854~81076598:+ LUSC cis rs8177876 0.731 rs7188508 ENSG00000261838.4 RP11-303E16.6 7.14 3.59e-12 2.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080097 chr16:81069854~81076598:+ LUSC cis rs6142102 0.625 rs6142056 ENSG00000276073.1 RP5-1125A11.7 -7.14 3.6e-12 2.62e-09 -0.31 -0.31 Skin pigmentation; chr20:33953349 chr20:33985617~33988989:- LUSC cis rs2188561 0.697 rs10808154 ENSG00000241764.3 AC002467.7 7.14 3.6e-12 2.62e-09 0.41 0.31 Alcohol consumption; chr7:107745951 chr7:107742817~107744581:- LUSC cis rs13113518 0.812 rs2048564 ENSG00000223305.1 RN7SKP30 7.14 3.61e-12 2.62e-09 0.38 0.31 Height; chr4:55407965 chr4:55540502~55540835:- LUSC cis rs9549367 0.713 rs11620600 ENSG00000269125.1 RP11-98F14.11 -7.14 3.61e-12 2.62e-09 -0.41 -0.31 Platelet distribution width; chr13:113174776 chr13:113165002~113165183:- LUSC cis rs11603023 0.874 rs613243 ENSG00000255239.1 AP002954.6 7.14 3.61e-12 2.62e-09 0.37 0.31 Cholesterol, total; chr11:118643304 chr11:118688039~118690600:- LUSC cis rs11098499 1 rs11098499 ENSG00000249244.1 RP11-548H18.2 7.14 3.63e-12 2.64e-09 0.4 0.31 Corneal astigmatism; chr4:119266456 chr4:119391831~119395335:- LUSC cis rs12554020 0.786 rs78619366 ENSG00000227603.1 RP11-165J3.6 7.14 3.64e-12 2.64e-09 0.53 0.31 Schizophrenia; chr9:93590541 chr9:93435332~93437121:- LUSC cis rs12554020 0.579 rs78814851 ENSG00000227603.1 RP11-165J3.6 7.14 3.64e-12 2.64e-09 0.53 0.31 Schizophrenia; chr9:93590652 chr9:93435332~93437121:- LUSC cis rs10129255 0.957 rs56134540 ENSG00000224373.3 IGHV4-59 7.14 3.64e-12 2.64e-09 0.18 0.31 Kawasaki disease; chr14:106691290 chr14:106627249~106627825:- LUSC cis rs950169 0.922 rs67804993 ENSG00000225151.9 GOLGA2P7 -7.14 3.64e-12 2.64e-09 -0.43 -0.31 Schizophrenia; chr15:84560799 chr15:84199311~84230136:- LUSC cis rs4660456 0.913 rs569159 ENSG00000237899.1 RP4-739H11.3 -7.14 3.65e-12 2.64e-09 -0.44 -0.31 Platelet count; chr1:40701862 chr1:40669089~40687588:- LUSC cis rs11098499 0.908 rs71614449 ENSG00000250412.1 KLHL2P1 7.14 3.65e-12 2.65e-09 0.4 0.31 Corneal astigmatism; chr4:119465900 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs35063680 ENSG00000250412.1 KLHL2P1 7.14 3.65e-12 2.65e-09 0.4 0.31 Corneal astigmatism; chr4:119465947 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs34858317 ENSG00000250412.1 KLHL2P1 7.14 3.65e-12 2.65e-09 0.4 0.31 Corneal astigmatism; chr4:119465955 chr4:119334329~119378233:+ LUSC cis rs10129255 0.957 rs17113284 ENSG00000224373.3 IGHV4-59 -7.14 3.66e-12 2.65e-09 -0.17 -0.31 Kawasaki disease; chr14:106684476 chr14:106627249~106627825:- LUSC cis rs1823913 1 rs4853561 ENSG00000280083.1 RP11-317J9.1 7.14 3.66e-12 2.65e-09 0.38 0.31 Obesity-related traits; chr2:191242980 chr2:191154118~191156070:- LUSC cis rs1823913 1 rs6704784 ENSG00000280083.1 RP11-317J9.1 7.14 3.66e-12 2.65e-09 0.38 0.31 Obesity-related traits; chr2:191244832 chr2:191154118~191156070:- LUSC cis rs36423 0.528 rs1205063 ENSG00000266869.1 RP6-114E22.1 7.14 3.66e-12 2.66e-09 0.49 0.31 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71881828 chr14:71848606~71908430:+ LUSC cis rs4950322 0.634 rs4950415 ENSG00000278811.3 LINC00624 7.14 3.66e-12 2.66e-09 0.36 0.31 Protein quantitative trait loci; chr1:147350951 chr1:147258885~147517875:- LUSC cis rs10754283 0.934 rs6661282 ENSG00000231613.1 RP5-943J3.1 7.14 3.67e-12 2.66e-09 0.36 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89654433 chr1:89788914~89790492:+ LUSC cis rs6142102 0.625 rs6141431 ENSG00000276073.1 RP5-1125A11.7 -7.14 3.67e-12 2.66e-09 -0.31 -0.31 Skin pigmentation; chr20:33952508 chr20:33985617~33988989:- LUSC cis rs10129255 0.912 rs6576227 ENSG00000211972.2 IGHV3-66 7.14 3.67e-12 2.66e-09 0.23 0.31 Kawasaki disease; chr14:106778202 chr14:106675017~106675544:- LUSC cis rs10129255 0.957 rs6576228 ENSG00000211972.2 IGHV3-66 7.14 3.67e-12 2.66e-09 0.23 0.31 Kawasaki disease; chr14:106778401 chr14:106675017~106675544:- LUSC cis rs35160687 0.901 rs12714179 ENSG00000273080.1 RP11-301O19.1 7.14 3.67e-12 2.66e-09 0.3 0.31 Night sleep phenotypes; chr2:86287835 chr2:86195590~86196049:+ LUSC cis rs10129255 1 rs10129255 ENSG00000224373.3 IGHV4-59 -7.14 3.68e-12 2.67e-09 -0.18 -0.31 Kawasaki disease; chr14:106767970 chr14:106627249~106627825:- LUSC cis rs1865760 0.929 rs1816546 ENSG00000272462.2 U91328.19 -7.14 3.68e-12 2.67e-09 -0.34 -0.31 Height; chr6:25938024 chr6:25992662~26001775:+ LUSC cis rs17507216 0.591 rs7163848 ENSG00000255769.6 GOLGA2P10 -7.13 3.69e-12 2.67e-09 -0.48 -0.31 Excessive daytime sleepiness; chr15:82729563 chr15:82472993~82513950:- LUSC cis rs8062405 0.69 rs62034351 ENSG00000259982.1 CDC37P1 7.13 3.69e-12 2.67e-09 0.4 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554168 chr16:28700294~28701540:- LUSC cis rs6904897 0.538 rs4639353 ENSG00000232876.1 CTA-212D2.2 7.13 3.69e-12 2.67e-09 0.38 0.31 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134903190 chr6:135055033~135060550:+ LUSC cis rs8059260 0.604 rs741176 ENSG00000274038.1 RP11-66H6.4 7.13 3.69e-12 2.67e-09 0.5 0.31 Alcohol consumption over the past year; chr16:11051953 chr16:11056556~11057034:+ LUSC cis rs465969 1 rs459048 ENSG00000255389.1 C6orf3 -7.13 3.69e-12 2.68e-09 -0.59 -0.31 Psoriasis; chr6:111368429 chr6:111599875~111602295:+ LUSC cis rs465969 1 rs479343 ENSG00000255389.1 C6orf3 -7.13 3.69e-12 2.68e-09 -0.59 -0.31 Psoriasis; chr6:111369701 chr6:111599875~111602295:+ LUSC cis rs465969 0.744 rs458017 ENSG00000255389.1 C6orf3 -7.13 3.69e-12 2.68e-09 -0.59 -0.31 Psoriasis; chr6:111374888 chr6:111599875~111602295:+ LUSC cis rs6921919 0.583 rs7740351 ENSG00000204709.4 LINC01556 7.13 3.69e-12 2.68e-09 0.39 0.31 Autism spectrum disorder or schizophrenia; chr6:28431635 chr6:28943877~28944537:+ LUSC cis rs440932 1 rs378974 ENSG00000254340.1 RP11-10A14.3 7.13 3.7e-12 2.68e-09 0.39 0.31 High light scatter reticulocyte percentage of red cells; chr8:9169129 chr8:9141424~9145435:+ LUSC cis rs8072100 0.79 rs3760371 ENSG00000228782.6 CTD-2026D20.3 -7.13 3.7e-12 2.68e-09 -0.3 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47618548 chr17:47450568~47492492:- LUSC cis rs67180937 0.733 rs35725247 ENSG00000272750.1 RP11-378J18.8 -7.13 3.71e-12 2.69e-09 -0.35 -0.31 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222706825 chr1:222658867~222661512:- LUSC cis rs1930961 1 rs59226697 ENSG00000272977.1 CTA-390C10.10 -7.13 3.71e-12 2.69e-09 -0.71 -0.31 Bipolar disorder with mood-incongruent psychosis; chr22:25474070 chr22:25476218~25479971:+ LUSC cis rs9921338 0.961 rs6498185 ENSG00000263080.1 RP11-485G7.5 7.13 3.71e-12 2.69e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11350869 chr16:11341809~11345211:- LUSC cis rs172166 0.637 rs1233708 ENSG00000216901.1 AL022393.7 7.13 3.71e-12 2.69e-09 0.37 0.31 Cardiac Troponin-T levels; chr6:28205441 chr6:28176188~28176674:+ LUSC cis rs875971 0.522 rs781144 ENSG00000224316.1 RP11-479O9.2 7.13 3.72e-12 2.69e-09 0.3 0.31 Aortic root size; chr7:65975357 chr7:65773620~65802067:+ LUSC cis rs748404 0.697 rs513970 ENSG00000249839.1 AC011330.5 -7.13 3.72e-12 2.69e-09 -0.42 -0.31 Lung cancer; chr15:43287368 chr15:43663654~43684339:- LUSC cis rs17482078 0.959 rs10043309 ENSG00000248734.2 CTD-2260A17.1 7.13 3.73e-12 2.7e-09 0.35 0.31 Behcet's disease;Blood protein levels; chr5:96804163 chr5:96784777~96785999:+ LUSC cis rs17482078 0.959 rs10041240 ENSG00000248734.2 CTD-2260A17.1 7.13 3.73e-12 2.7e-09 0.35 0.31 Behcet's disease;Blood protein levels; chr5:96805037 chr5:96784777~96785999:+ LUSC cis rs6142102 0.625 rs6142051 ENSG00000276073.1 RP5-1125A11.7 -7.13 3.74e-12 2.71e-09 -0.31 -0.31 Skin pigmentation; chr20:33945212 chr20:33985617~33988989:- LUSC cis rs2739330 0.796 rs1006771 ENSG00000231271.1 AP000350.8 7.13 3.75e-12 2.71e-09 0.43 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23949918~23954042:+ LUSC cis rs9532669 0.926 rs4600337 ENSG00000176268.5 CYCSP34 7.13 3.76e-12 2.72e-09 0.31 0.31 Cervical cancer; chr13:40879564 chr13:40863599~40863902:- LUSC cis rs9318086 0.648 rs7331047 ENSG00000205861.10 C1QTNF9B-AS1 -7.13 3.76e-12 2.72e-09 -0.39 -0.31 Myopia (pathological); chr13:23893203 chr13:23888889~23897263:+ LUSC cis rs8031584 0.678 rs35098644 ENSG00000260382.1 RP11-540B6.2 7.13 3.77e-12 2.73e-09 0.43 0.31 Huntington's disease progression; chr15:30853237 chr15:30882267~30883231:- LUSC cis rs34779708 0.897 rs4934527 ENSG00000230534.5 RP11-297A16.2 7.13 3.78e-12 2.73e-09 0.35 0.31 Inflammatory bowel disease;Crohn's disease; chr10:34992190 chr10:35098006~35127020:- LUSC cis rs853679 0.55 rs1233707 ENSG00000204709.4 LINC01556 7.13 3.79e-12 2.74e-09 0.43 0.31 Depression; chr6:28205175 chr6:28943877~28944537:+ LUSC cis rs950169 0.922 rs11631096 ENSG00000259728.4 LINC00933 7.13 3.8e-12 2.74e-09 0.41 0.31 Schizophrenia; chr15:84557698 chr15:84570649~84580175:+ LUSC cis rs11690935 1 rs312918 ENSG00000228389.1 AC068039.4 7.13 3.81e-12 2.75e-09 0.36 0.31 Schizophrenia; chr2:171713077 chr2:171773482~171775844:+ LUSC cis rs11098499 0.644 rs10050092 ENSG00000249244.1 RP11-548H18.2 7.13 3.82e-12 2.76e-09 0.38 0.31 Corneal astigmatism; chr4:119610930 chr4:119391831~119395335:- LUSC cis rs8072100 0.79 rs6505048 ENSG00000228782.6 CTD-2026D20.3 -7.13 3.82e-12 2.76e-09 -0.3 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47597632 chr17:47450568~47492492:- LUSC cis rs1865760 0.566 rs9379821 ENSG00000272462.2 U91328.19 -7.13 3.82e-12 2.76e-09 -0.34 -0.31 Height; chr6:26054040 chr6:25992662~26001775:+ LUSC cis rs1865760 0.566 rs9358902 ENSG00000272462.2 U91328.19 -7.13 3.82e-12 2.76e-09 -0.34 -0.31 Height; chr6:26058342 chr6:25992662~26001775:+ LUSC cis rs2404602 0.684 rs4886819 ENSG00000259422.1 RP11-593F23.1 -7.13 3.82e-12 2.76e-09 -0.37 -0.31 Blood metabolite levels; chr15:76609357 chr15:76174891~76181486:- LUSC cis rs440932 0.757 rs330943 ENSG00000254340.1 RP11-10A14.3 7.13 3.82e-12 2.76e-09 0.39 0.31 High light scatter reticulocyte percentage of red cells; chr8:9163516 chr8:9141424~9145435:+ LUSC cis rs4308124 0.708 rs7585313 ENSG00000227992.1 AC108463.2 -7.13 3.82e-12 2.76e-09 -0.42 -0.31 Vitiligo; chr2:111217626 chr2:111203964~111206215:- LUSC cis rs2412819 0.571 rs528764 ENSG00000249839.1 AC011330.5 7.13 3.85e-12 2.78e-09 0.5 0.31 Lung cancer; chr15:43838650 chr15:43663654~43684339:- LUSC cis rs10129255 0.509 rs756583 ENSG00000211970.3 IGHV4-61 -7.13 3.85e-12 2.78e-09 -0.2 -0.31 Kawasaki disease; chr14:106680002 chr14:106639119~106639657:- LUSC cis rs8177876 0.731 rs76093926 ENSG00000261838.4 RP11-303E16.6 7.13 3.87e-12 2.79e-09 0.77 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078920 chr16:81069854~81076598:+ LUSC cis rs367615 0.552 rs10042721 ENSG00000249476.1 CTD-2587M2.1 -7.13 3.89e-12 2.81e-09 -0.36 -0.31 Colorectal cancer (SNP x SNP interaction); chr5:109378269 chr5:109237120~109326369:- LUSC cis rs10129255 0.913 rs28861466 ENSG00000280411.1 IGHV1-69-2 -7.13 3.9e-12 2.81e-09 -0.22 -0.31 Kawasaki disease; chr14:106718572 chr14:106762092~106762588:- LUSC cis rs10129255 0.83 rs61997609 ENSG00000224373.3 IGHV4-59 7.13 3.92e-12 2.83e-09 0.18 0.31 Kawasaki disease; chr14:106692376 chr14:106627249~106627825:- LUSC cis rs2946504 0.501 rs2977092 ENSG00000251468.2 RP11-369K16.1 -7.13 3.92e-12 2.83e-09 -0.37 -0.31 Type 2 diabetes; chr8:12949867 chr8:12958387~12962200:+ LUSC cis rs1865760 0.928 rs9295673 ENSG00000272462.2 U91328.19 -7.13 3.92e-12 2.83e-09 -0.33 -0.31 Height; chr6:25911866 chr6:25992662~26001775:+ LUSC cis rs4713118 0.662 rs9357060 ENSG00000204709.4 LINC01556 7.13 3.92e-12 2.83e-09 0.43 0.31 Parkinson's disease; chr6:28056708 chr6:28943877~28944537:+ LUSC cis rs4713118 0.662 rs9468271 ENSG00000204709.4 LINC01556 7.13 3.92e-12 2.83e-09 0.43 0.31 Parkinson's disease; chr6:28056792 chr6:28943877~28944537:+ LUSC cis rs4660456 0.913 rs2361651 ENSG00000237899.1 RP4-739H11.3 7.13 3.93e-12 2.83e-09 0.48 0.31 Platelet count; chr1:40764542 chr1:40669089~40687588:- LUSC cis rs5742933 0.779 rs1899025 ENSG00000253559.1 OSGEPL1-AS1 7.12 3.94e-12 2.84e-09 0.37 0.31 Ferritin levels; chr2:189784856 chr2:189762704~189765556:+ LUSC cis rs526231 0.578 rs6860588 ENSG00000175749.11 EIF3KP1 -7.12 3.94e-12 2.84e-09 -0.38 -0.31 Primary biliary cholangitis; chr5:102944598 chr5:103032376~103033031:+ LUSC cis rs1865760 0.566 rs9379825 ENSG00000272462.2 U91328.19 -7.12 3.94e-12 2.85e-09 -0.34 -0.31 Height; chr6:26083643 chr6:25992662~26001775:+ LUSC cis rs1865760 0.566 rs9467672 ENSG00000272462.2 U91328.19 -7.12 3.94e-12 2.85e-09 -0.34 -0.31 Height; chr6:26083676 chr6:25992662~26001775:+ LUSC cis rs1865760 0.566 rs9295688 ENSG00000272462.2 U91328.19 -7.12 3.94e-12 2.85e-09 -0.34 -0.31 Height; chr6:26083989 chr6:25992662~26001775:+ LUSC cis rs11098499 0.644 rs2389880 ENSG00000249244.1 RP11-548H18.2 7.12 3.95e-12 2.85e-09 0.39 0.31 Corneal astigmatism; chr4:119638715 chr4:119391831~119395335:- LUSC cis rs1075265 0.87 rs7569370 ENSG00000233266.1 HMGB1P31 7.12 3.96e-12 2.86e-09 0.4 0.31 Chronotype;Morning vs. evening chronotype; chr2:53989212 chr2:54051334~54051760:+ LUSC cis rs7772486 0.597 rs6570732 ENSG00000235652.6 RP11-545I5.3 -7.12 3.96e-12 2.86e-09 -0.32 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145924015 chr6:145799409~145886585:+ LUSC cis rs783540 0.609 rs803686 ENSG00000276710.3 CSPG4P8 7.12 3.96e-12 2.86e-09 0.37 0.31 Schizophrenia; chr15:82550590 chr15:82459472~82477258:+ LUSC cis rs8062405 0.723 rs4788077 ENSG00000259982.1 CDC37P1 7.12 3.97e-12 2.86e-09 0.4 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558443 chr16:28700294~28701540:- LUSC cis rs2581828 0.646 rs9867023 ENSG00000242142.1 SERBP1P3 7.12 3.98e-12 2.87e-09 0.35 0.31 Crohn's disease; chr3:53126116 chr3:53064283~53065091:- LUSC cis rs748404 0.666 rs12906481 ENSG00000249839.1 AC011330.5 -7.12 3.99e-12 2.87e-09 -0.53 -0.31 Lung cancer; chr15:43467356 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs35958032 ENSG00000249839.1 AC011330.5 -7.12 3.99e-12 2.87e-09 -0.53 -0.31 Lung cancer; chr15:43494397 chr15:43663654~43684339:- LUSC cis rs10129255 1 rs4612959 ENSG00000224373.3 IGHV4-59 7.12 3.99e-12 2.87e-09 0.18 0.31 Kawasaki disease; chr14:106767055 chr14:106627249~106627825:- LUSC cis rs6867032 0.57 rs13166888 ENSG00000249731.1 RP11-259O2.3 -7.12 3.99e-12 2.88e-09 -0.37 -0.31 Gut microbiome composition (winter); chr5:1982852 chr5:1968094~1969013:+ LUSC cis rs2581828 0.646 rs6769931 ENSG00000242142.1 SERBP1P3 -7.12 4e-12 2.88e-09 -0.35 -0.31 Crohn's disease; chr3:53126177 chr3:53064283~53065091:- LUSC cis rs2581828 0.646 rs6809973 ENSG00000242142.1 SERBP1P3 -7.12 4e-12 2.88e-09 -0.35 -0.31 Crohn's disease; chr3:53126200 chr3:53064283~53065091:- LUSC cis rs2581828 0.608 rs6769944 ENSG00000242142.1 SERBP1P3 -7.12 4e-12 2.88e-09 -0.35 -0.31 Crohn's disease; chr3:53126227 chr3:53064283~53065091:- LUSC cis rs2581828 0.646 rs9858469 ENSG00000242142.1 SERBP1P3 -7.12 4e-12 2.88e-09 -0.35 -0.31 Crohn's disease; chr3:53128390 chr3:53064283~53065091:- LUSC cis rs2581828 0.646 rs9820324 ENSG00000242142.1 SERBP1P3 -7.12 4e-12 2.88e-09 -0.35 -0.31 Crohn's disease; chr3:53128429 chr3:53064283~53065091:- LUSC cis rs17711722 0.522 rs62469933 ENSG00000236529.1 RP13-254B10.1 7.12 4e-12 2.89e-09 0.32 0.31 Calcium levels; chr7:65800652 chr7:65840212~65840596:+ LUSC cis rs2412819 0.571 rs2729494 ENSG00000249839.1 AC011330.5 7.12 4.01e-12 2.89e-09 0.5 0.31 Lung cancer; chr15:43837395 chr15:43663654~43684339:- LUSC cis rs66887589 0.592 rs2175383 ENSG00000245958.5 RP11-33B1.1 -7.12 4.01e-12 2.89e-09 -0.3 -0.31 Diastolic blood pressure; chr4:119294681 chr4:119454791~119552025:+ LUSC cis rs34779708 0.966 rs12257770 ENSG00000230534.5 RP11-297A16.2 7.12 4.02e-12 2.9e-09 0.34 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35228306 chr10:35098006~35127020:- LUSC cis rs4713118 0.588 rs200994 ENSG00000219392.1 RP1-265C24.5 7.12 4.02e-12 2.9e-09 0.42 0.31 Parkinson's disease; chr6:27846035 chr6:28115628~28116551:+ LUSC cis rs748404 0.723 rs512431 ENSG00000249839.1 AC011330.5 7.12 4.03e-12 2.9e-09 0.41 0.31 Lung cancer; chr15:43249741 chr15:43663654~43684339:- LUSC cis rs2297363 1 rs16888669 ENSG00000213073.4 RP11-288H12.3 -7.12 4.03e-12 2.9e-09 -0.39 -0.31 Total cholesterol levels;Blood protein levels; chr6:160082862 chr6:160093082~160096212:+ LUSC cis rs34779708 0.931 rs11010083 ENSG00000230534.5 RP11-297A16.2 7.12 4.03e-12 2.91e-09 0.35 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35062603 chr10:35098006~35127020:- LUSC cis rs6142102 0.517 rs6142046 ENSG00000276073.1 RP5-1125A11.7 -7.12 4.04e-12 2.91e-09 -0.31 -0.31 Skin pigmentation; chr20:33926255 chr20:33985617~33988989:- LUSC cis rs904251 0.6 rs1874736 ENSG00000204110.6 RP1-153P14.8 -7.12 4.05e-12 2.92e-09 -0.3 -0.31 Cognitive performance; chr6:37480218 chr6:37507348~37535616:+ LUSC cis rs7208859 0.673 rs423151 ENSG00000263603.1 CTD-2349P21.5 -7.12 4.05e-12 2.92e-09 -0.4 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30625268 chr17:30729469~30731202:+ LUSC cis rs875971 0.862 rs6460302 ENSG00000237310.1 GS1-124K5.4 7.12 4.05e-12 2.92e-09 0.32 0.31 Aortic root size; chr7:66495270 chr7:66493706~66495474:+ LUSC cis rs5742933 0.817 rs5742938 ENSG00000253559.1 OSGEPL1-AS1 7.12 4.05e-12 2.92e-09 0.37 0.31 Ferritin levels; chr2:189785232 chr2:189762704~189765556:+ LUSC cis rs7945705 0.967 rs34842234 ENSG00000254860.4 TMEM9B-AS1 -7.12 4.06e-12 2.92e-09 -0.34 -0.31 Hemoglobin concentration; chr11:8870347 chr11:8964675~8977527:+ LUSC cis rs7945705 0.967 rs7123861 ENSG00000254860.4 TMEM9B-AS1 -7.12 4.06e-12 2.92e-09 -0.34 -0.31 Hemoglobin concentration; chr11:8870776 chr11:8964675~8977527:+ LUSC cis rs638893 0.578 rs500254 ENSG00000278376.1 RP11-158I9.8 7.12 4.06e-12 2.92e-09 0.43 0.31 Vitiligo; chr11:118808071 chr11:118791254~118793137:+ LUSC cis rs4308124 0.708 rs56693625 ENSG00000227992.1 AC108463.2 -7.12 4.07e-12 2.93e-09 -0.42 -0.31 Vitiligo; chr2:111207578 chr2:111203964~111206215:- LUSC cis rs4308124 0.708 rs61358692 ENSG00000227992.1 AC108463.2 -7.12 4.07e-12 2.93e-09 -0.42 -0.31 Vitiligo; chr2:111207582 chr2:111203964~111206215:- LUSC cis rs1865760 0.566 rs2051544 ENSG00000272462.2 U91328.19 -7.12 4.07e-12 2.93e-09 -0.34 -0.31 Height; chr6:26070865 chr6:25992662~26001775:+ LUSC cis rs950169 0.686 rs12906474 ENSG00000259728.4 LINC00933 7.12 4.1e-12 2.95e-09 0.4 0.31 Schizophrenia; chr15:84566006 chr15:84570649~84580175:+ LUSC cis rs950169 0.81 rs2879976 ENSG00000259728.4 LINC00933 7.12 4.1e-12 2.95e-09 0.4 0.31 Schizophrenia; chr15:84566347 chr15:84570649~84580175:+ LUSC cis rs367615 0.506 rs2963021 ENSG00000249476.1 CTD-2587M2.1 7.12 4.11e-12 2.96e-09 0.34 0.31 Colorectal cancer (SNP x SNP interaction); chr5:109464664 chr5:109237120~109326369:- LUSC cis rs11098499 0.863 rs10019674 ENSG00000250412.1 KLHL2P1 -7.12 4.13e-12 2.97e-09 -0.4 -0.31 Corneal astigmatism; chr4:119522334 chr4:119334329~119378233:+ LUSC cis rs10129255 0.957 rs10136560 ENSG00000280411.1 IGHV1-69-2 -7.12 4.14e-12 2.98e-09 -0.22 -0.31 Kawasaki disease; chr14:106787630 chr14:106762092~106762588:- LUSC cis rs9545047 0.669 rs2095477 ENSG00000227676.3 LINC01068 -7.12 4.15e-12 2.98e-09 -0.39 -0.31 Schizophrenia; chr13:79427869 chr13:79566727~79571436:+ LUSC cis rs75422866 0.51 rs74733564 ENSG00000274902.1 RP1-197B17.4 7.12 4.15e-12 2.99e-09 0.72 0.31 Pneumonia; chr12:47724644 chr12:47731908~47732351:+ LUSC cis rs75422866 0.51 rs73105814 ENSG00000274902.1 RP1-197B17.4 7.12 4.15e-12 2.99e-09 0.72 0.31 Pneumonia; chr12:47725817 chr12:47731908~47732351:+ LUSC cis rs875971 0.505 rs1167385 ENSG00000236529.1 RP13-254B10.1 -7.12 4.16e-12 2.99e-09 -0.32 -0.31 Aortic root size; chr7:66048321 chr7:65840212~65840596:+ LUSC cis rs8072100 0.512 rs9674670 ENSG00000228782.6 CTD-2026D20.3 7.12 4.17e-12 3e-09 0.3 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47308791 chr17:47450568~47492492:- LUSC cis rs748404 0.666 rs16957715 ENSG00000249839.1 AC011330.5 -7.12 4.17e-12 3e-09 -0.52 -0.31 Lung cancer; chr15:43416539 chr15:43663654~43684339:- LUSC cis rs2412819 0.571 rs2930530 ENSG00000249839.1 AC011330.5 7.12 4.17e-12 3e-09 0.49 0.31 Lung cancer; chr15:43823268 chr15:43663654~43684339:- LUSC cis rs11123170 0.64 rs1015754 ENSG00000189223.12 PAX8-AS1 7.12 4.18e-12 3.01e-09 0.45 0.31 Renal function-related traits (BUN); chr2:113210413 chr2:113211522~113276581:+ LUSC cis rs35160687 0.787 rs10186289 ENSG00000273080.1 RP11-301O19.1 7.12 4.19e-12 3.01e-09 0.3 0.31 Night sleep phenotypes; chr2:86285865 chr2:86195590~86196049:+ LUSC cis rs10740039 0.804 rs894383 ENSG00000254271.1 RP11-131N11.4 7.12 4.19e-12 3.01e-09 0.43 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60683359 chr10:60734342~60741828:+ LUSC cis rs9549367 0.601 rs558869 ENSG00000269125.1 RP11-98F14.11 7.12 4.19e-12 3.01e-09 0.38 0.31 Platelet distribution width; chr13:113195618 chr13:113165002~113165183:- LUSC cis rs9549367 0.713 rs2480949 ENSG00000269125.1 RP11-98F14.11 7.12 4.19e-12 3.01e-09 0.38 0.31 Platelet distribution width; chr13:113198835 chr13:113165002~113165183:- LUSC cis rs2455601 0.608 rs10840137 ENSG00000254860.4 TMEM9B-AS1 7.12 4.19e-12 3.02e-09 0.37 0.31 Schizophrenia; chr11:8868532 chr11:8964675~8977527:+ LUSC cis rs10129255 0.957 rs11846893 ENSG00000211972.2 IGHV3-66 7.12 4.2e-12 3.02e-09 0.23 0.31 Kawasaki disease; chr14:106779068 chr14:106675017~106675544:- LUSC cis rs1012068 0.662 rs4820994 ENSG00000236132.1 CTA-440B3.1 -7.11 4.21e-12 3.03e-09 -0.41 -0.31 Chronic hepatitis C infection; chr22:31915633 chr22:31816379~31817491:- LUSC cis rs8177876 0.822 rs77475047 ENSG00000261838.4 RP11-303E16.6 7.11 4.22e-12 3.03e-09 0.78 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81073355 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs55939311 ENSG00000261838.4 RP11-303E16.6 7.11 4.22e-12 3.03e-09 0.78 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81075493 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs12444137 ENSG00000261838.4 RP11-303E16.6 7.11 4.22e-12 3.03e-09 0.78 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81076746 chr16:81069854~81076598:+ LUSC cis rs7945705 0.967 rs1569408 ENSG00000254860.4 TMEM9B-AS1 -7.11 4.22e-12 3.03e-09 -0.34 -0.31 Hemoglobin concentration; chr11:8888185 chr11:8964675~8977527:+ LUSC cis rs11098499 0.697 rs11941899 ENSG00000250412.1 KLHL2P1 7.11 4.23e-12 3.04e-09 0.4 0.31 Corneal astigmatism; chr4:119461603 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs7681978 ENSG00000250412.1 KLHL2P1 7.11 4.23e-12 3.04e-09 0.4 0.31 Corneal astigmatism; chr4:119462620 chr4:119334329~119378233:+ LUSC cis rs11098499 0.821 rs28665282 ENSG00000250412.1 KLHL2P1 7.11 4.23e-12 3.04e-09 0.4 0.31 Corneal astigmatism; chr4:119463031 chr4:119334329~119378233:+ LUSC cis rs11098499 0.738 rs10026493 ENSG00000250412.1 KLHL2P1 7.11 4.23e-12 3.04e-09 0.4 0.31 Corneal astigmatism; chr4:119463039 chr4:119334329~119378233:+ LUSC cis rs875971 0.505 rs1723275 ENSG00000236529.1 RP13-254B10.1 -7.11 4.24e-12 3.05e-09 -0.32 -0.31 Aortic root size; chr7:66039646 chr7:65840212~65840596:+ LUSC cis rs2404602 0.598 rs11634019 ENSG00000259422.1 RP11-593F23.1 -7.11 4.24e-12 3.05e-09 -0.39 -0.31 Blood metabolite levels; chr15:76342339 chr15:76174891~76181486:- LUSC cis rs442309 0.553 rs10995278 ENSG00000238280.1 RP11-436D10.3 -7.11 4.26e-12 3.06e-09 -0.38 -0.31 Vogt-Koyanagi-Harada syndrome; chr10:62694737 chr10:62793562~62805887:- LUSC cis rs9549367 0.713 rs9549352 ENSG00000269125.1 RP11-98F14.11 -7.11 4.27e-12 3.06e-09 -0.41 -0.31 Platelet distribution width; chr13:113178907 chr13:113165002~113165183:- LUSC cis rs2412819 0.571 rs2930529 ENSG00000249839.1 AC011330.5 7.11 4.28e-12 3.08e-09 0.49 0.31 Lung cancer; chr15:43819467 chr15:43663654~43684339:- LUSC cis rs1113500 0.836 rs1539553 ENSG00000226822.1 RP11-356N1.2 -7.11 4.29e-12 3.08e-09 -0.31 -0.31 Growth-regulated protein alpha levels; chr1:108047376 chr1:108071482~108074519:+ LUSC cis rs6921919 0.583 rs9468370 ENSG00000204709.4 LINC01556 7.11 4.31e-12 3.1e-09 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28401163 chr6:28943877~28944537:+ LUSC cis rs9309473 1 rs7580825 ENSG00000163016.8 ALMS1P 7.11 4.32e-12 3.1e-09 0.38 0.31 Metabolite levels; chr2:73408020 chr2:73644919~73685576:+ LUSC cis rs9309473 1 rs6755241 ENSG00000163016.8 ALMS1P 7.11 4.32e-12 3.1e-09 0.38 0.31 Metabolite levels; chr2:73414236 chr2:73644919~73685576:+ LUSC cis rs7617773 0.963 rs6766754 ENSG00000228638.1 FCF1P2 7.11 4.32e-12 3.1e-09 0.35 0.31 Coronary artery disease; chr3:48141099 chr3:48290793~48291375:- LUSC cis rs7617773 0.832 rs6775114 ENSG00000228638.1 FCF1P2 7.11 4.32e-12 3.1e-09 0.35 0.31 Coronary artery disease; chr3:48141130 chr3:48290793~48291375:- LUSC cis rs9322193 0.886 rs4870055 ENSG00000268592.3 RAET1E-AS1 7.11 4.33e-12 3.11e-09 0.39 0.31 Lung cancer; chr6:149848433 chr6:149863494~149919507:+ LUSC cis rs11098499 0.863 rs11098531 ENSG00000250412.1 KLHL2P1 7.11 4.33e-12 3.11e-09 0.39 0.31 Corneal astigmatism; chr4:119543846 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs28718422 ENSG00000250412.1 KLHL2P1 7.11 4.33e-12 3.11e-09 0.39 0.31 Corneal astigmatism; chr4:119545149 chr4:119334329~119378233:+ LUSC cis rs11098499 0.818 rs12498599 ENSG00000250412.1 KLHL2P1 7.11 4.33e-12 3.11e-09 0.39 0.31 Corneal astigmatism; chr4:119547348 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs10009626 ENSG00000250412.1 KLHL2P1 7.11 4.33e-12 3.11e-09 0.39 0.31 Corneal astigmatism; chr4:119548850 chr4:119334329~119378233:+ LUSC cis rs61160187 0.582 rs2898309 ENSG00000215032.2 GNL3LP1 7.11 4.34e-12 3.12e-09 0.39 0.31 Educational attainment (years of education);Educational attainment (college completion); chr5:60981546 chr5:60891935~60893577:- LUSC cis rs4423214 0.592 rs7130829 ENSG00000254682.1 RP11-660L16.2 -7.11 4.35e-12 3.12e-09 -0.51 -0.31 Vitamin D levels; chr11:71526656 chr11:71448674~71452157:+ LUSC cis rs34779708 0.931 rs11010132 ENSG00000230534.5 RP11-297A16.2 7.11 4.35e-12 3.12e-09 0.34 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35228337 chr10:35098006~35127020:- LUSC cis rs17023223 0.537 rs2645295 ENSG00000231365.4 RP11-418J17.1 -7.11 4.36e-12 3.13e-09 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119039825 chr1:119140396~119275973:+ LUSC cis rs6142102 0.961 rs2235596 ENSG00000276073.1 RP5-1125A11.7 7.11 4.37e-12 3.14e-09 0.32 0.31 Skin pigmentation; chr20:34096503 chr20:33985617~33988989:- LUSC cis rs9545047 0.716 rs416660 ENSG00000227676.3 LINC01068 -7.11 4.37e-12 3.14e-09 -0.38 -0.31 Schizophrenia; chr13:79432726 chr13:79566727~79571436:+ LUSC cis rs11098499 0.739 rs2203039 ENSG00000249244.1 RP11-548H18.2 -7.11 4.37e-12 3.14e-09 -0.39 -0.31 Corneal astigmatism; chr4:119211192 chr4:119391831~119395335:- LUSC cis rs9318086 0.648 rs4067969 ENSG00000205861.10 C1QTNF9B-AS1 -7.11 4.39e-12 3.15e-09 -0.4 -0.31 Myopia (pathological); chr13:23894981 chr13:23888889~23897263:+ LUSC cis rs1113500 0.73 rs1777457 ENSG00000226822.1 RP11-356N1.2 -7.11 4.4e-12 3.16e-09 -0.31 -0.31 Growth-regulated protein alpha levels; chr1:108045573 chr1:108071482~108074519:+ LUSC cis rs8059260 0.604 rs16957966 ENSG00000274038.1 RP11-66H6.4 -7.11 4.4e-12 3.16e-09 -0.5 -0.31 Alcohol consumption over the past year; chr16:11046280 chr16:11056556~11057034:+ LUSC cis rs10028773 0.546 rs13117947 ENSG00000245958.5 RP11-33B1.1 -7.11 4.41e-12 3.17e-09 -0.29 -0.31 Educational attainment; chr4:119335905 chr4:119454791~119552025:+ LUSC cis rs61160187 0.517 rs7709522 ENSG00000215032.2 GNL3LP1 7.11 4.42e-12 3.17e-09 0.39 0.31 Educational attainment (years of education);Educational attainment (college completion); chr5:61022188 chr5:60891935~60893577:- LUSC cis rs9532669 0.926 rs9525418 ENSG00000176268.5 CYCSP34 -7.11 4.43e-12 3.18e-09 -0.31 -0.31 Cervical cancer; chr13:40879081 chr13:40863599~40863902:- LUSC cis rs11157436 1 rs11157440 ENSG00000211813.2 TRAV34 7.11 4.43e-12 3.18e-09 0.36 0.31 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22181757 chr14:22207522~22208129:+ LUSC cis rs1823913 1 rs6749232 ENSG00000280083.1 RP11-317J9.1 7.11 4.44e-12 3.18e-09 0.37 0.31 Obesity-related traits; chr2:191250326 chr2:191154118~191156070:- LUSC cis rs494459 0.536 rs7103067 ENSG00000255422.1 AP002954.4 -7.11 4.45e-12 3.19e-09 -0.33 -0.31 Height; chr11:118852670 chr11:118704607~118750263:+ LUSC cis rs950169 0.922 rs4586394 ENSG00000225151.9 GOLGA2P7 7.11 4.46e-12 3.19e-09 0.43 0.31 Schizophrenia; chr15:84153633 chr15:84199311~84230136:- LUSC cis rs6782228 1 rs6782407 ENSG00000277250.1 Metazoa_SRP 7.11 4.48e-12 3.21e-09 0.39 0.31 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619905 chr3:128673681~128674021:- LUSC cis rs8177876 0.731 rs10514512 ENSG00000261838.4 RP11-303E16.6 7.11 4.49e-12 3.21e-09 0.77 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080350 chr16:81069854~81076598:+ LUSC cis rs6991838 0.831 rs11992528 ENSG00000200714.1 Y_RNA 7.1 4.5e-12 3.22e-09 0.36 0.31 Intelligence (multi-trait analysis); chr8:65561644 chr8:65592731~65592820:+ LUSC cis rs4803480 0.543 rs7257282 ENSG00000270164.1 LINC01480 -7.1 4.5e-12 3.22e-09 -0.27 -0.31 Schizophrenia; chr19:41536585 chr19:41535183~41536904:+ LUSC cis rs8062405 0.789 rs1968752 ENSG00000278665.1 RP11-666O2.4 7.1 4.5e-12 3.23e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620264 chr16:28599241~28601881:- LUSC cis rs1823913 1 rs11691372 ENSG00000280083.1 RP11-317J9.1 7.1 4.52e-12 3.24e-09 0.38 0.31 Obesity-related traits; chr2:191249952 chr2:191154118~191156070:- LUSC cis rs3747113 1 rs13056719 ENSG00000128262.7 POM121L9P -7.1 4.53e-12 3.24e-09 -0.34 -0.31 Gut microbiome composition (summer); chr22:24328131 chr22:24251828~24265525:+ LUSC cis rs6142102 0.961 rs4911146 ENSG00000276073.1 RP5-1125A11.7 -7.1 4.53e-12 3.24e-09 -0.33 -0.31 Skin pigmentation; chr20:34052241 chr20:33985617~33988989:- LUSC cis rs11098499 0.909 rs79026312 ENSG00000250412.1 KLHL2P1 7.1 4.53e-12 3.24e-09 0.4 0.31 Corneal astigmatism; chr4:119519522 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs35111518 ENSG00000250412.1 KLHL2P1 7.1 4.53e-12 3.24e-09 0.4 0.31 Corneal astigmatism; chr4:119519527 chr4:119334329~119378233:+ LUSC cis rs9309473 1 rs10179134 ENSG00000163016.8 ALMS1P 7.1 4.54e-12 3.25e-09 0.38 0.31 Metabolite levels; chr2:73410391 chr2:73644919~73685576:+ LUSC cis rs2188561 1 rs2712207 ENSG00000241764.3 AC002467.7 7.1 4.57e-12 3.27e-09 0.42 0.31 Alcohol consumption; chr7:107711672 chr7:107742817~107744581:- LUSC cis rs9921338 0.961 rs7198849 ENSG00000263080.1 RP11-485G7.5 7.1 4.57e-12 3.27e-09 0.35 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11279444 chr16:11341809~11345211:- LUSC cis rs6142102 0.961 rs4911401 ENSG00000276073.1 RP5-1125A11.7 -7.1 4.58e-12 3.28e-09 -0.33 -0.31 Skin pigmentation; chr20:34066756 chr20:33985617~33988989:- LUSC cis rs11098499 0.863 rs1552092 ENSG00000250412.1 KLHL2P1 7.1 4.58e-12 3.28e-09 0.39 0.31 Corneal astigmatism; chr4:119567341 chr4:119334329~119378233:+ LUSC cis rs2404602 0.71 rs2469541 ENSG00000259422.1 RP11-593F23.1 -7.1 4.6e-12 3.29e-09 -0.36 -0.31 Blood metabolite levels; chr15:76269777 chr15:76174891~76181486:- LUSC cis rs75422866 0.51 rs73105803 ENSG00000274902.1 RP1-197B17.4 7.1 4.61e-12 3.3e-09 0.72 0.31 Pneumonia; chr12:47722135 chr12:47731908~47732351:+ LUSC cis rs75422866 0.51 rs73105812 ENSG00000274902.1 RP1-197B17.4 7.1 4.61e-12 3.3e-09 0.72 0.31 Pneumonia; chr12:47724404 chr12:47731908~47732351:+ LUSC cis rs11098499 0.908 rs28499576 ENSG00000250412.1 KLHL2P1 7.1 4.61e-12 3.3e-09 0.39 0.31 Corneal astigmatism; chr4:119465522 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs11098532 ENSG00000250412.1 KLHL2P1 7.1 4.62e-12 3.3e-09 0.39 0.31 Corneal astigmatism; chr4:119569571 chr4:119334329~119378233:+ LUSC cis rs950169 0.922 rs8037078 ENSG00000225151.9 GOLGA2P7 7.1 4.62e-12 3.31e-09 0.43 0.31 Schizophrenia; chr15:84150119 chr15:84199311~84230136:- LUSC cis rs9309473 1 rs56672945 ENSG00000163016.8 ALMS1P 7.1 4.64e-12 3.32e-09 0.39 0.31 Metabolite levels; chr2:73395535 chr2:73644919~73685576:+ LUSC cis rs9309473 1 rs60844734 ENSG00000163016.8 ALMS1P 7.1 4.64e-12 3.32e-09 0.39 0.31 Metabolite levels; chr2:73396077 chr2:73644919~73685576:+ LUSC cis rs9309473 1 rs11899902 ENSG00000163016.8 ALMS1P 7.1 4.64e-12 3.32e-09 0.39 0.31 Metabolite levels; chr2:73404436 chr2:73644919~73685576:+ LUSC cis rs9309473 1 rs13428235 ENSG00000163016.8 ALMS1P 7.1 4.64e-12 3.32e-09 0.39 0.31 Metabolite levels; chr2:73406302 chr2:73644919~73685576:+ LUSC cis rs4660456 0.913 rs12040422 ENSG00000237899.1 RP4-739H11.3 7.1 4.65e-12 3.32e-09 0.46 0.31 Platelet count; chr1:40669239 chr1:40669089~40687588:- LUSC cis rs9545047 0.645 rs9635027 ENSG00000227676.3 LINC01068 7.1 4.65e-12 3.33e-09 0.38 0.31 Schizophrenia; chr13:79295538 chr13:79566727~79571436:+ LUSC cis rs853679 0.517 rs1904840 ENSG00000204709.4 LINC01556 7.1 4.65e-12 3.33e-09 0.45 0.31 Depression; chr6:28140454 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9368555 ENSG00000204709.4 LINC01556 7.1 4.65e-12 3.33e-09 0.45 0.31 Depression; chr6:28141189 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393893 ENSG00000204709.4 LINC01556 7.1 4.65e-12 3.33e-09 0.45 0.31 Depression; chr6:28141484 chr6:28943877~28944537:+ LUSC cis rs1113500 0.524 rs11185270 ENSG00000226822.1 RP11-356N1.2 7.1 4.65e-12 3.33e-09 0.35 0.31 Growth-regulated protein alpha levels; chr1:108111740 chr1:108071482~108074519:+ LUSC cis rs1113500 0.548 rs17020971 ENSG00000226822.1 RP11-356N1.2 7.1 4.65e-12 3.33e-09 0.35 0.31 Growth-regulated protein alpha levels; chr1:108112666 chr1:108071482~108074519:+ LUSC cis rs748404 0.697 rs554001 ENSG00000249839.1 AC011330.5 -7.1 4.67e-12 3.34e-09 -0.41 -0.31 Lung cancer; chr15:43259721 chr15:43663654~43684339:- LUSC cis rs10129255 0.957 rs10141052 ENSG00000224373.3 IGHV4-59 7.1 4.67e-12 3.34e-09 0.17 0.31 Kawasaki disease; chr14:106776528 chr14:106627249~106627825:- LUSC cis rs10129255 0.957 rs10141009 ENSG00000224373.3 IGHV4-59 7.1 4.67e-12 3.34e-09 0.17 0.31 Kawasaki disease; chr14:106776695 chr14:106627249~106627825:- LUSC cis rs9322193 0.923 rs12174035 ENSG00000223701.3 RAET1E-AS1 7.1 4.67e-12 3.34e-09 0.36 0.31 Lung cancer; chr6:149763311 chr6:149884431~149919508:+ LUSC cis rs4660456 0.913 rs2780952 ENSG00000237899.1 RP4-739H11.3 7.1 4.68e-12 3.34e-09 0.45 0.31 Platelet count; chr1:40689711 chr1:40669089~40687588:- LUSC cis rs9921338 0.887 rs9926136 ENSG00000263080.1 RP11-485G7.5 7.1 4.68e-12 3.35e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11343418 chr16:11341809~11345211:- LUSC cis rs8059260 0.736 rs3871209 ENSG00000274038.1 RP11-66H6.4 -7.1 4.71e-12 3.36e-09 -0.54 -0.31 Alcohol consumption over the past year; chr16:10962907 chr16:11056556~11057034:+ LUSC cis rs4308124 0.708 rs10179596 ENSG00000227992.1 AC108463.2 -7.1 4.73e-12 3.38e-09 -0.42 -0.31 Vitiligo; chr2:111212803 chr2:111203964~111206215:- LUSC cis rs4308124 0.708 rs6727313 ENSG00000227992.1 AC108463.2 -7.1 4.73e-12 3.38e-09 -0.42 -0.31 Vitiligo; chr2:111213963 chr2:111203964~111206215:- LUSC cis rs950169 0.922 rs12912934 ENSG00000259728.4 LINC00933 7.1 4.73e-12 3.38e-09 0.4 0.31 Schizophrenia; chr15:84571216 chr15:84570649~84580175:+ LUSC cis rs11098499 0.818 rs55825515 ENSG00000250412.1 KLHL2P1 7.1 4.74e-12 3.38e-09 0.39 0.31 Corneal astigmatism; chr4:119565247 chr4:119334329~119378233:+ LUSC cis rs6142102 0.961 rs4911407 ENSG00000276073.1 RP5-1125A11.7 -7.1 4.74e-12 3.39e-09 -0.33 -0.31 Skin pigmentation; chr20:34095759 chr20:33985617~33988989:- LUSC cis rs1075265 0.84 rs2884254 ENSG00000233266.1 HMGB1P31 7.1 4.74e-12 3.39e-09 0.38 0.31 Chronotype;Morning vs. evening chronotype; chr2:53979326 chr2:54051334~54051760:+ LUSC cis rs11098499 0.739 rs951570 ENSG00000249244.1 RP11-548H18.2 -7.1 4.75e-12 3.39e-09 -0.38 -0.31 Corneal astigmatism; chr4:119229312 chr4:119391831~119395335:- LUSC cis rs10129255 0.912 rs6576227 ENSG00000224373.3 IGHV4-59 7.1 4.75e-12 3.39e-09 0.17 0.31 Kawasaki disease; chr14:106778202 chr14:106627249~106627825:- LUSC cis rs10129255 0.957 rs6576228 ENSG00000224373.3 IGHV4-59 7.1 4.75e-12 3.39e-09 0.17 0.31 Kawasaki disease; chr14:106778401 chr14:106627249~106627825:- LUSC cis rs6142102 0.961 rs8123521 ENSG00000276073.1 RP5-1125A11.7 -7.1 4.77e-12 3.4e-09 -0.34 -0.31 Skin pigmentation; chr20:34081079 chr20:33985617~33988989:- LUSC cis rs3779195 0.929 rs10953259 ENSG00000272950.1 RP11-307C18.1 -7.1 4.77e-12 3.41e-09 -0.52 -0.31 Sex hormone-binding globulin levels; chr7:98383795 chr7:98322853~98323430:+ LUSC cis rs9545047 0.716 rs9530920 ENSG00000227676.3 LINC01068 7.09 4.79e-12 3.42e-09 0.39 0.31 Schizophrenia; chr13:79423254 chr13:79566727~79571436:+ LUSC cis rs17507216 0.628 rs17158396 ENSG00000278603.1 RP13-608F4.5 7.09 4.8e-12 3.43e-09 0.45 0.31 Excessive daytime sleepiness; chr15:82615688 chr15:82472203~82472426:+ LUSC cis rs904251 0.6 rs4714068 ENSG00000204110.6 RP1-153P14.8 -7.09 4.81e-12 3.43e-09 -0.3 -0.31 Cognitive performance; chr6:37487866 chr6:37507348~37535616:+ LUSC cis rs748404 0.666 rs72709850 ENSG00000249839.1 AC011330.5 -7.09 4.82e-12 3.44e-09 -0.52 -0.31 Lung cancer; chr15:43462486 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs34633582 ENSG00000249839.1 AC011330.5 -7.09 4.82e-12 3.44e-09 -0.52 -0.31 Lung cancer; chr15:43462683 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs36078097 ENSG00000249839.1 AC011330.5 -7.09 4.82e-12 3.44e-09 -0.52 -0.31 Lung cancer; chr15:43466209 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs7181783 ENSG00000249839.1 AC011330.5 -7.09 4.82e-12 3.44e-09 -0.52 -0.31 Lung cancer; chr15:43469723 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs35903301 ENSG00000249839.1 AC011330.5 -7.09 4.82e-12 3.44e-09 -0.52 -0.31 Lung cancer; chr15:43472332 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs34002293 ENSG00000249839.1 AC011330.5 -7.09 4.82e-12 3.44e-09 -0.52 -0.31 Lung cancer; chr15:43472401 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs34181131 ENSG00000249839.1 AC011330.5 -7.09 4.82e-12 3.44e-09 -0.52 -0.31 Lung cancer; chr15:43478527 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs7173383 ENSG00000249839.1 AC011330.5 -7.09 4.82e-12 3.44e-09 -0.52 -0.31 Lung cancer; chr15:43480838 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs12911740 ENSG00000249839.1 AC011330.5 -7.09 4.82e-12 3.44e-09 -0.52 -0.31 Lung cancer; chr15:43498254 chr15:43663654~43684339:- LUSC cis rs9309473 1 rs10207220 ENSG00000163016.8 ALMS1P 7.09 4.84e-12 3.45e-09 0.37 0.31 Metabolite levels; chr2:73557919 chr2:73644919~73685576:+ LUSC cis rs4950322 0.515 rs17160050 ENSG00000278811.3 LINC00624 7.09 4.84e-12 3.46e-09 0.34 0.31 Protein quantitative trait loci; chr1:147255558 chr1:147258885~147517875:- LUSC cis rs11123170 0.64 rs2863240 ENSG00000189223.12 PAX8-AS1 7.09 4.86e-12 3.46e-09 0.45 0.31 Renal function-related traits (BUN); chr2:113212539 chr2:113211522~113276581:+ LUSC cis rs1075265 0.84 rs805309 ENSG00000233266.1 HMGB1P31 7.09 4.86e-12 3.46e-09 0.38 0.31 Chronotype;Morning vs. evening chronotype; chr2:53968877 chr2:54051334~54051760:+ LUSC cis rs2188561 0.806 rs2712210 ENSG00000241764.3 AC002467.7 7.09 4.86e-12 3.47e-09 0.39 0.31 Alcohol consumption; chr7:107687407 chr7:107742817~107744581:- LUSC cis rs1865760 0.622 rs9295685 ENSG00000272462.2 U91328.19 -7.09 4.86e-12 3.47e-09 -0.34 -0.31 Height; chr6:26071497 chr6:25992662~26001775:+ LUSC cis rs11098499 0.954 rs10034623 ENSG00000250412.1 KLHL2P1 7.09 4.86e-12 3.47e-09 0.39 0.31 Corneal astigmatism; chr4:119476674 chr4:119334329~119378233:+ LUSC cis rs11123170 0.543 rs4849178 ENSG00000189223.12 PAX8-AS1 -7.09 4.87e-12 3.47e-09 -0.47 -0.31 Renal function-related traits (BUN); chr2:113225031 chr2:113211522~113276581:+ LUSC cis rs4141404 0.851 rs5997893 ENSG00000236132.1 CTA-440B3.1 7.09 4.87e-12 3.47e-09 0.4 0.31 Paclitaxel-induced neuropathy; chr22:31160117 chr22:31816379~31817491:- LUSC cis rs2903698 0.565 rs10009558 ENSG00000250735.4 RP11-567N4.3 7.09 4.9e-12 3.49e-09 0.35 0.31 Prion diseases; chr4:75522060 chr4:75401195~75423023:+ LUSC cis rs8031584 0.678 rs798127 ENSG00000260382.1 RP11-540B6.2 -7.09 4.9e-12 3.49e-09 -0.42 -0.31 Huntington's disease progression; chr15:30825200 chr15:30882267~30883231:- LUSC cis rs3829251 0.786 rs7103591 ENSG00000254682.1 RP11-660L16.2 -7.09 4.91e-12 3.5e-09 -0.51 -0.31 Vitamin D levels; chr11:71526573 chr11:71448674~71452157:+ LUSC cis rs8072100 0.79 rs7222225 ENSG00000228782.6 CTD-2026D20.3 -7.09 4.91e-12 3.5e-09 -0.3 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47616131 chr17:47450568~47492492:- LUSC cis rs6142102 0.961 rs2235597 ENSG00000276073.1 RP5-1125A11.7 -7.09 4.92e-12 3.51e-09 -0.33 -0.31 Skin pigmentation; chr20:34077808 chr20:33985617~33988989:- LUSC cis rs2337406 1 rs10459466 ENSG00000274576.2 IGHV2-70 -7.09 4.95e-12 3.52e-09 -0.34 -0.31 Alzheimer's disease (late onset); chr14:106689255 chr14:106770577~106771020:- LUSC cis rs9309473 1 rs6755217 ENSG00000163016.8 ALMS1P 7.09 4.95e-12 3.53e-09 0.38 0.31 Metabolite levels; chr2:73414157 chr2:73644919~73685576:+ LUSC cis rs2412819 0.571 rs678084 ENSG00000249839.1 AC011330.5 7.09 4.95e-12 3.53e-09 0.49 0.31 Lung cancer; chr15:43828361 chr15:43663654~43684339:- LUSC cis rs588177 0.613 rs3782101 ENSG00000236935.1 AP003774.1 -7.09 4.96e-12 3.53e-09 -0.29 -0.31 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells; chr11:64363808 chr11:64325050~64329504:- LUSC cis rs4713118 0.869 rs4713121 ENSG00000219392.1 RP1-265C24.5 -7.09 4.96e-12 3.53e-09 -0.41 -0.31 Parkinson's disease; chr6:27754285 chr6:28115628~28116551:+ LUSC cis rs8059260 0.736 rs78121798 ENSG00000274038.1 RP11-66H6.4 -7.09 5e-12 3.56e-09 -0.52 -0.31 Alcohol consumption over the past year; chr16:10984224 chr16:11056556~11057034:+ LUSC cis rs7739264 0.564 rs760794 ENSG00000227116.1 RP3-471C18.1 -7.09 5.02e-12 3.57e-09 -0.35 -0.31 Endometriosis; chr6:19790329 chr6:19730427~19734567:- LUSC cis rs4950322 1 rs72694720 ENSG00000278811.3 LINC00624 7.09 5.02e-12 3.58e-09 0.38 0.31 Protein quantitative trait loci; chr1:147371939 chr1:147258885~147517875:- LUSC cis rs10129255 0.957 rs8009464 ENSG00000224373.3 IGHV4-59 7.09 5.03e-12 3.58e-09 0.17 0.31 Kawasaki disease; chr14:106777611 chr14:106627249~106627825:- LUSC cis rs6142102 0.961 rs6059587 ENSG00000276073.1 RP5-1125A11.7 -7.09 5.05e-12 3.59e-09 -0.33 -0.31 Skin pigmentation; chr20:33955120 chr20:33985617~33988989:- LUSC cis rs875971 0.522 rs1917563 ENSG00000236529.1 RP13-254B10.1 -7.09 5.05e-12 3.6e-09 -0.32 -0.31 Aortic root size; chr7:65950660 chr7:65840212~65840596:+ LUSC cis rs4713118 0.629 rs203889 ENSG00000204709.4 LINC01556 7.09 5.06e-12 3.6e-09 0.43 0.31 Parkinson's disease; chr6:28053997 chr6:28943877~28944537:+ LUSC cis rs131777 0.577 rs5770928 ENSG00000205559.3 CHKB-AS1 -7.09 5.06e-12 3.6e-09 -0.4 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50590662 chr22:50583026~50583877:+ LUSC cis rs4950322 1 rs72694715 ENSG00000278811.3 LINC00624 7.09 5.07e-12 3.61e-09 0.38 0.31 Protein quantitative trait loci; chr1:147368468 chr1:147258885~147517875:- LUSC cis rs6921919 0.583 rs9468367 ENSG00000204709.4 LINC01556 7.09 5.07e-12 3.61e-09 0.4 0.31 Autism spectrum disorder or schizophrenia; chr6:28392469 chr6:28943877~28944537:+ LUSC cis rs172166 0.694 rs188105 ENSG00000204709.4 LINC01556 7.09 5.07e-12 3.61e-09 0.4 0.31 Cardiac Troponin-T levels; chr6:28103615 chr6:28943877~28944537:+ LUSC cis rs8072100 0.79 rs11079783 ENSG00000228782.6 CTD-2026D20.3 -7.09 5.08e-12 3.61e-09 -0.3 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47608650 chr17:47450568~47492492:- LUSC cis rs465969 1 rs459888 ENSG00000255389.1 C6orf3 7.09 5.1e-12 3.63e-09 0.56 0.31 Psoriasis; chr6:111329953 chr6:111599875~111602295:+ LUSC cis rs748404 0.697 rs471122 ENSG00000249839.1 AC011330.5 7.08 5.12e-12 3.64e-09 0.4 0.31 Lung cancer; chr15:43266376 chr15:43663654~43684339:- LUSC cis rs673078 0.607 rs882927 ENSG00000275759.1 RP11-131L12.3 -7.08 5.14e-12 3.66e-09 -0.43 -0.31 Glucose homeostasis traits; chr12:118406737 chr12:118428281~118428870:+ LUSC cis rs10740039 0.842 rs7080024 ENSG00000254271.1 RP11-131N11.4 -7.08 5.15e-12 3.66e-09 -0.42 -0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60632033 chr10:60734342~60741828:+ LUSC cis rs10080237 0.564 rs2490232 ENSG00000272129.1 RP11-250B2.6 -7.08 5.17e-12 3.67e-09 -0.38 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr6:80105085 chr6:80355424~80356859:+ LUSC cis rs11098499 0.909 rs2127821 ENSG00000250412.1 KLHL2P1 7.08 5.18e-12 3.68e-09 0.4 0.31 Corneal astigmatism; chr4:119473380 chr4:119334329~119378233:+ LUSC cis rs853679 0.769 rs7752608 ENSG00000204709.4 LINC01556 7.08 5.2e-12 3.69e-09 0.63 0.31 Depression; chr6:28333418 chr6:28943877~28944537:+ LUSC cis rs9318086 0.712 rs9510916 ENSG00000205861.10 C1QTNF9B-AS1 -7.08 5.21e-12 3.7e-09 -0.39 -0.31 Myopia (pathological); chr13:23868650 chr13:23888889~23897263:+ LUSC cis rs9309473 0.95 rs10178678 ENSG00000163016.8 ALMS1P 7.08 5.24e-12 3.72e-09 0.37 0.31 Metabolite levels; chr2:73535109 chr2:73644919~73685576:+ LUSC cis rs2903698 0.565 rs9307834 ENSG00000250735.4 RP11-567N4.3 7.08 5.25e-12 3.73e-09 0.35 0.31 Prion diseases; chr4:75528640 chr4:75401195~75423023:+ LUSC cis rs1930961 1 rs5996946 ENSG00000100058.11 CRYBB2P1 7.08 5.25e-12 3.73e-09 0.57 0.31 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25448105~25520854:+ LUSC cis rs1865760 1 rs9348698 ENSG00000272462.2 U91328.19 -7.08 5.26e-12 3.74e-09 -0.34 -0.31 Height; chr6:25929461 chr6:25992662~26001775:+ LUSC cis rs2188561 0.697 rs3735606 ENSG00000241764.3 AC002467.7 7.08 5.26e-12 3.74e-09 0.4 0.31 Alcohol consumption; chr7:107743864 chr7:107742817~107744581:- LUSC cis rs10129255 0.872 rs10133674 ENSG00000211972.2 IGHV3-66 7.08 5.27e-12 3.74e-09 0.23 0.31 Kawasaki disease; chr14:106692788 chr14:106675017~106675544:- LUSC cis rs75422866 0.867 rs35044089 ENSG00000274902.1 RP1-197B17.4 7.08 5.27e-12 3.74e-09 0.8 0.31 Pneumonia; chr12:47610881 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs78912815 ENSG00000274902.1 RP1-197B17.4 7.08 5.27e-12 3.74e-09 0.8 0.31 Pneumonia; chr12:47612065 chr12:47731908~47732351:+ LUSC cis rs9928842 0.882 rs9319481 ENSG00000280152.1 RP11-331F4.5 7.08 5.3e-12 3.76e-09 0.38 0.31 Alcoholic chronic pancreatitis; chr16:75225580 chr16:75245994~75250077:- LUSC cis rs2412819 0.597 rs541871 ENSG00000249839.1 AC011330.5 -7.08 5.32e-12 3.77e-09 -0.5 -0.31 Lung cancer; chr15:43868656 chr15:43663654~43684339:- LUSC cis rs2412819 0.571 rs495880 ENSG00000249839.1 AC011330.5 7.08 5.34e-12 3.79e-09 0.49 0.31 Lung cancer; chr15:43855067 chr15:43663654~43684339:- LUSC cis rs6142102 0.961 rs6059651 ENSG00000276073.1 RP5-1125A11.7 -7.08 5.37e-12 3.81e-09 -0.33 -0.31 Skin pigmentation; chr20:34057246 chr20:33985617~33988989:- LUSC cis rs8062405 0.755 rs56272201 ENSG00000259982.1 CDC37P1 7.08 5.38e-12 3.82e-09 0.39 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569364 chr16:28700294~28701540:- LUSC cis rs8062405 0.755 rs62034355 ENSG00000259982.1 CDC37P1 7.08 5.38e-12 3.82e-09 0.39 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569717 chr16:28700294~28701540:- LUSC cis rs11089937 0.637 rs988200 ENSG00000211639.2 IGLV4-60 7.08 5.39e-12 3.82e-09 0.36 0.31 Periodontitis (PAL4Q3); chr22:22154715 chr22:22162199~22162681:+ LUSC cis rs4308124 0.708 rs10178095 ENSG00000227992.1 AC108463.2 -7.08 5.4e-12 3.83e-09 -0.41 -0.31 Vitiligo; chr2:111214939 chr2:111203964~111206215:- LUSC cis rs228614 0.51 rs223438 ENSG00000230069.3 LRRC37A15P 7.08 5.4e-12 3.83e-09 0.32 0.31 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798584 chr4:102727274~102730721:- LUSC cis rs9318086 0.712 rs9510917 ENSG00000205861.10 C1QTNF9B-AS1 -7.08 5.41e-12 3.84e-09 -0.39 -0.31 Myopia (pathological); chr13:23868707 chr13:23888889~23897263:+ LUSC cis rs950169 0.922 rs6603022 ENSG00000225151.9 GOLGA2P7 7.08 5.41e-12 3.84e-09 0.43 0.31 Schizophrenia; chr15:84161418 chr15:84199311~84230136:- LUSC cis rs950169 0.922 rs4842941 ENSG00000225151.9 GOLGA2P7 7.08 5.41e-12 3.84e-09 0.43 0.31 Schizophrenia; chr15:84162560 chr15:84199311~84230136:- LUSC cis rs950169 0.922 rs12911223 ENSG00000225151.9 GOLGA2P7 7.08 5.41e-12 3.84e-09 0.43 0.31 Schizophrenia; chr15:84162919 chr15:84199311~84230136:- LUSC cis rs950169 0.845 rs4106951 ENSG00000225151.9 GOLGA2P7 -7.08 5.41e-12 3.84e-09 -0.43 -0.31 Schizophrenia; chr15:84164642 chr15:84199311~84230136:- LUSC cis rs8059260 0.668 rs16957894 ENSG00000274038.1 RP11-66H6.4 -7.08 5.41e-12 3.84e-09 -0.52 -0.31 Alcohol consumption over the past year; chr16:10996501 chr16:11056556~11057034:+ LUSC cis rs11690935 0.959 rs7597387 ENSG00000228389.1 AC068039.4 7.08 5.42e-12 3.84e-09 0.36 0.31 Schizophrenia; chr2:171720606 chr2:171773482~171775844:+ LUSC cis rs4950322 0.947 rs72694723 ENSG00000278811.3 LINC00624 7.08 5.42e-12 3.85e-09 0.38 0.31 Protein quantitative trait loci; chr1:147373174 chr1:147258885~147517875:- LUSC cis rs61160187 0.582 rs12652830 ENSG00000215032.2 GNL3LP1 7.08 5.42e-12 3.85e-09 0.39 0.31 Educational attainment (years of education);Educational attainment (college completion); chr5:60956655 chr5:60891935~60893577:- LUSC cis rs8059260 0.736 rs8049278 ENSG00000274038.1 RP11-66H6.4 -7.08 5.42e-12 3.85e-09 -0.54 -0.31 Alcohol consumption over the past year; chr16:10968766 chr16:11056556~11057034:+ LUSC cis rs673078 0.607 rs73207573 ENSG00000275759.1 RP11-131L12.3 -7.08 5.43e-12 3.85e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118444664 chr12:118428281~118428870:+ LUSC cis rs11123170 0.543 rs12472361 ENSG00000189223.12 PAX8-AS1 -7.08 5.43e-12 3.85e-09 -0.47 -0.31 Renal function-related traits (BUN); chr2:113223068 chr2:113211522~113276581:+ LUSC cis rs10129255 0.536 rs17113249 ENSG00000224373.3 IGHV4-59 7.08 5.44e-12 3.85e-09 0.15 0.31 Kawasaki disease; chr14:106678273 chr14:106627249~106627825:- LUSC cis rs11098499 1 rs58601355 ENSG00000249244.1 RP11-548H18.2 7.08 5.44e-12 3.86e-09 0.4 0.31 Corneal astigmatism; chr4:119265212 chr4:119391831~119395335:- LUSC cis rs4950322 0.748 rs17356680 ENSG00000278811.3 LINC00624 7.07 5.46e-12 3.87e-09 0.36 0.31 Protein quantitative trait loci; chr1:147354934 chr1:147258885~147517875:- LUSC cis rs9549367 0.713 rs1323315 ENSG00000269125.1 RP11-98F14.11 7.07 5.49e-12 3.89e-09 0.38 0.31 Platelet distribution width; chr13:113205344 chr13:113165002~113165183:- LUSC cis rs853679 0.517 rs1904841 ENSG00000204709.4 LINC01556 7.07 5.51e-12 3.9e-09 0.45 0.31 Depression; chr6:28140307 chr6:28943877~28944537:+ LUSC cis rs11098499 0.739 rs7441137 ENSG00000249244.1 RP11-548H18.2 -7.07 5.53e-12 3.92e-09 -0.38 -0.31 Corneal astigmatism; chr4:119212066 chr4:119391831~119395335:- LUSC cis rs11098499 0.739 rs4833612 ENSG00000249244.1 RP11-548H18.2 -7.07 5.53e-12 3.92e-09 -0.38 -0.31 Corneal astigmatism; chr4:119226441 chr4:119391831~119395335:- LUSC cis rs11098499 0.739 rs10013032 ENSG00000249244.1 RP11-548H18.2 -7.07 5.53e-12 3.92e-09 -0.38 -0.31 Corneal astigmatism; chr4:119228264 chr4:119391831~119395335:- LUSC cis rs8072100 0.79 rs34200664 ENSG00000228782.6 CTD-2026D20.3 -7.07 5.54e-12 3.92e-09 -0.3 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47667286 chr17:47450568~47492492:- LUSC cis rs8062405 0.824 rs28698667 ENSG00000278665.1 RP11-666O2.4 7.07 5.55e-12 3.93e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28521750 chr16:28599241~28601881:- LUSC cis rs8040855 0.579 rs6496797 ENSG00000259295.5 CSPG4P12 -7.07 5.57e-12 3.94e-09 -0.35 -0.31 Bulimia nervosa; chr15:85183624 chr15:85191438~85213905:+ LUSC cis rs4950322 0.515 rs76327075 ENSG00000278811.3 LINC00624 7.07 5.58e-12 3.95e-09 0.34 0.31 Protein quantitative trait loci; chr1:147246319 chr1:147258885~147517875:- LUSC cis rs4950322 0.515 rs11239958 ENSG00000278811.3 LINC00624 7.07 5.58e-12 3.95e-09 0.34 0.31 Protein quantitative trait loci; chr1:147247454 chr1:147258885~147517875:- LUSC cis rs4950322 0.515 rs12060046 ENSG00000278811.3 LINC00624 7.07 5.58e-12 3.95e-09 0.34 0.31 Protein quantitative trait loci; chr1:147249278 chr1:147258885~147517875:- LUSC cis rs761746 0.739 rs140078 ENSG00000236132.1 CTA-440B3.1 7.07 5.59e-12 3.96e-09 0.44 0.31 Intelligence; chr22:31714177 chr22:31816379~31817491:- LUSC cis rs11098499 0.909 rs7681214 ENSG00000250412.1 KLHL2P1 7.07 5.6e-12 3.96e-09 0.4 0.31 Corneal astigmatism; chr4:119464165 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs17046116 ENSG00000250412.1 KLHL2P1 7.07 5.6e-12 3.96e-09 0.4 0.31 Corneal astigmatism; chr4:119466104 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs17046118 ENSG00000250412.1 KLHL2P1 7.07 5.6e-12 3.96e-09 0.4 0.31 Corneal astigmatism; chr4:119466341 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs59732491 ENSG00000250412.1 KLHL2P1 7.07 5.6e-12 3.97e-09 0.39 0.31 Corneal astigmatism; chr4:119568433 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs11723090 ENSG00000250412.1 KLHL2P1 7.07 5.6e-12 3.97e-09 0.39 0.31 Corneal astigmatism; chr4:119569437 chr4:119334329~119378233:+ LUSC cis rs1113500 0.548 rs7541433 ENSG00000226822.1 RP11-356N1.2 7.07 5.61e-12 3.97e-09 0.35 0.31 Growth-regulated protein alpha levels; chr1:108103019 chr1:108071482~108074519:+ LUSC cis rs5742933 0.948 rs7592066 ENSG00000253559.1 OSGEPL1-AS1 7.07 5.61e-12 3.97e-09 0.37 0.31 Ferritin levels; chr2:189778792 chr2:189762704~189765556:+ LUSC cis rs5742933 0.779 rs7595020 ENSG00000253559.1 OSGEPL1-AS1 7.07 5.61e-12 3.97e-09 0.37 0.31 Ferritin levels; chr2:189778950 chr2:189762704~189765556:+ LUSC cis rs75422866 0.867 rs117388682 ENSG00000274902.1 RP1-197B17.4 7.07 5.61e-12 3.97e-09 0.8 0.31 Pneumonia; chr12:47599713 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs79113930 ENSG00000274902.1 RP1-197B17.4 7.07 5.61e-12 3.97e-09 0.8 0.31 Pneumonia; chr12:47600628 chr12:47731908~47732351:+ LUSC cis rs2297363 1 rs2282140 ENSG00000213073.4 RP11-288H12.3 -7.07 5.61e-12 3.97e-09 -0.39 -0.31 Total cholesterol levels;Blood protein levels; chr6:160073489 chr6:160093082~160096212:+ LUSC cis rs10129255 0.744 rs28517388 ENSG00000280411.1 IGHV1-69-2 -7.07 5.62e-12 3.97e-09 -0.23 -0.31 Kawasaki disease; chr14:106704323 chr14:106762092~106762588:- LUSC cis rs17507216 0.56 rs2871011 ENSG00000278603.1 RP13-608F4.5 7.07 5.63e-12 3.98e-09 0.38 0.31 Excessive daytime sleepiness; chr15:82560792 chr15:82472203~82472426:+ LUSC cis rs950169 0.922 rs4842940 ENSG00000225151.9 GOLGA2P7 7.07 5.63e-12 3.98e-09 0.43 0.31 Schizophrenia; chr15:84162473 chr15:84199311~84230136:- LUSC cis rs3747113 0.913 rs34999116 ENSG00000128262.7 POM121L9P -7.07 5.63e-12 3.98e-09 -0.33 -0.31 Gut microbiome composition (summer); chr22:24418657 chr22:24251828~24265525:+ LUSC cis rs673078 0.562 rs56347775 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118438002 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943451 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118438929 chr12:118428281~118428870:+ LUSC cis rs673078 0.518 rs61943452 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118438990 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943454 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118439140 chr12:118428281~118428870:+ LUSC cis rs673078 0.517 rs61943455 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118439414 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs73207566 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118439471 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs2393416 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118439968 chr12:118428281~118428870:+ LUSC cis rs673078 0.56 rs4406856 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118440094 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs4457791 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118440144 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943456 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118440326 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs17513006 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118440383 chr12:118428281~118428870:+ LUSC cis rs673078 0.56 rs61943457 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118440487 chr12:118428281~118428870:+ LUSC cis rs673078 0.562 rs55883417 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118440801 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs55842338 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118441259 chr12:118428281~118428870:+ LUSC cis rs673078 0.518 rs17441251 ENSG00000275759.1 RP11-131L12.3 -7.07 5.64e-12 3.99e-09 -0.45 -0.31 Glucose homeostasis traits; chr12:118441361 chr12:118428281~118428870:+ LUSC cis rs11157436 1 rs3811278 ENSG00000211813.2 TRAV34 7.07 5.64e-12 3.99e-09 0.35 0.31 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22186227 chr14:22207522~22208129:+ LUSC cis rs34779708 0.931 rs17582416 ENSG00000230534.5 RP11-297A16.2 7.07 5.65e-12 4e-09 0.34 0.31 Inflammatory bowel disease;Crohn's disease; chr10:34998722 chr10:35098006~35127020:- LUSC cis rs11098499 0.863 rs3775847 ENSG00000250412.1 KLHL2P1 7.07 5.67e-12 4.01e-09 0.39 0.31 Corneal astigmatism; chr4:119526487 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs3775848 ENSG00000250412.1 KLHL2P1 7.07 5.67e-12 4.01e-09 0.39 0.31 Corneal astigmatism; chr4:119526569 chr4:119334329~119378233:+ LUSC cis rs8059260 0.668 rs16957855 ENSG00000274038.1 RP11-66H6.4 -7.07 5.68e-12 4.01e-09 -0.52 -0.31 Alcohol consumption over the past year; chr16:10977116 chr16:11056556~11057034:+ LUSC cis rs61160187 0.549 rs62367879 ENSG00000215032.2 GNL3LP1 7.07 5.69e-12 4.02e-09 0.39 0.31 Educational attainment (years of education);Educational attainment (college completion); chr5:60996384 chr5:60891935~60893577:- LUSC cis rs6991838 0.765 rs10957358 ENSG00000200714.1 Y_RNA 7.07 5.71e-12 4.04e-09 0.36 0.31 Intelligence (multi-trait analysis); chr8:65590067 chr8:65592731~65592820:+ LUSC cis rs11098499 0.863 rs3733525 ENSG00000250412.1 KLHL2P1 7.07 5.72e-12 4.04e-09 0.39 0.31 Corneal astigmatism; chr4:119525893 chr4:119334329~119378233:+ LUSC cis rs8059260 0.736 rs7195509 ENSG00000274038.1 RP11-66H6.4 -7.07 5.75e-12 4.06e-09 -0.54 -0.31 Alcohol consumption over the past year; chr16:10951572 chr16:11056556~11057034:+ LUSC cis rs9921338 0.961 rs7195536 ENSG00000263080.1 RP11-485G7.5 7.07 5.77e-12 4.08e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11348171 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs7191093 ENSG00000263080.1 RP11-485G7.5 7.07 5.77e-12 4.08e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11348422 chr16:11341809~11345211:- LUSC cis rs950169 0.84 rs12905223 ENSG00000259728.4 LINC00933 7.07 5.78e-12 4.08e-09 0.4 0.31 Schizophrenia; chr15:84571037 chr15:84570649~84580175:+ LUSC cis rs4403732 1 rs4237333 ENSG00000230526.1 RP11-472G21.2 7.07 5.81e-12 4.11e-09 0.43 0.31 Coronary artery disease; chr10:71877468 chr10:71878356~71879107:+ LUSC cis rs1865760 0.892 rs2328903 ENSG00000272462.2 U91328.19 -7.07 5.82e-12 4.11e-09 -0.34 -0.31 Height; chr6:25935537 chr6:25992662~26001775:+ LUSC cis rs1865760 0.892 rs6456705 ENSG00000272462.2 U91328.19 -7.07 5.82e-12 4.11e-09 -0.34 -0.31 Height; chr6:25935828 chr6:25992662~26001775:+ LUSC cis rs11098499 0.954 rs11098525 ENSG00000250412.1 KLHL2P1 7.06 5.83e-12 4.12e-09 0.39 0.31 Corneal astigmatism; chr4:119468997 chr4:119334329~119378233:+ LUSC cis rs875971 0.505 rs1167386 ENSG00000236529.1 RP13-254B10.1 -7.06 5.85e-12 4.13e-09 -0.32 -0.31 Aortic root size; chr7:66048109 chr7:65840212~65840596:+ LUSC cis rs8040855 0.965 rs4843027 ENSG00000259295.5 CSPG4P12 -7.06 5.85e-12 4.13e-09 -0.36 -0.31 Bulimia nervosa; chr15:85171892 chr15:85191438~85213905:+ LUSC cis rs4803480 0.578 rs7252454 ENSG00000270164.1 LINC01480 -7.06 5.86e-12 4.14e-09 -0.27 -0.31 Schizophrenia; chr19:41527343 chr19:41535183~41536904:+ LUSC cis rs11603023 0.874 rs577396 ENSG00000255239.1 AP002954.6 7.06 5.87e-12 4.14e-09 0.36 0.31 Cholesterol, total; chr11:118628753 chr11:118688039~118690600:- LUSC cis rs11603023 0.874 rs11216934 ENSG00000255239.1 AP002954.6 7.06 5.87e-12 4.14e-09 0.36 0.31 Cholesterol, total; chr11:118630742 chr11:118688039~118690600:- LUSC cis rs11098499 0.562 rs58583086 ENSG00000249244.1 RP11-548H18.2 -7.06 5.87e-12 4.14e-09 -0.37 -0.31 Corneal astigmatism; chr4:119635207 chr4:119391831~119395335:- LUSC cis rs10466239 0.73 rs2245413 ENSG00000230555.2 RP11-517P14.2 -7.06 5.88e-12 4.15e-09 -0.49 -0.31 Telomere length; chr10:43355120 chr10:43420738~43422100:+ LUSC cis rs10129255 0.957 rs8009638 ENSG00000211972.2 IGHV3-66 7.06 5.89e-12 4.15e-09 0.24 0.31 Kawasaki disease; chr14:106777570 chr14:106675017~106675544:- LUSC cis rs6570726 0.791 rs378937 ENSG00000235652.6 RP11-545I5.3 7.06 5.89e-12 4.16e-09 0.3 0.31 Lobe attachment (rater-scored or self-reported); chr6:145513609 chr6:145799409~145886585:+ LUSC cis rs9921338 0.887 rs7189044 ENSG00000263080.1 RP11-485G7.5 7.06 5.91e-12 4.17e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11348339 chr16:11341809~11345211:- LUSC cis rs9494142 0.592 rs1547247 ENSG00000232876.1 CTA-212D2.2 -7.06 5.91e-12 4.17e-09 -0.41 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts; chr6:135069698 chr6:135055033~135060550:+ LUSC cis rs433852 0.718 rs386551 ENSG00000232871.7 SEC1P -7.06 5.91e-12 4.17e-09 -0.39 -0.31 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48635029 chr19:48638071~48682245:+ LUSC cis rs10129255 0.912 rs61996059 ENSG00000280411.1 IGHV1-69-2 -7.06 5.91e-12 4.17e-09 -0.22 -0.31 Kawasaki disease; chr14:106716897 chr14:106762092~106762588:- LUSC cis rs1075265 0.744 rs2909460 ENSG00000233266.1 HMGB1P31 7.06 5.92e-12 4.18e-09 0.38 0.31 Chronotype;Morning vs. evening chronotype; chr2:53967611 chr2:54051334~54051760:+ LUSC cis rs881375 0.967 rs1930778 ENSG00000226752.6 PSMD5-AS1 -7.06 5.93e-12 4.18e-09 -0.36 -0.31 Rheumatoid arthritis; chr9:120879091 chr9:120824828~120854385:+ LUSC cis rs801193 0.548 rs6975044 ENSG00000222364.1 RNU6-96P -7.06 5.94e-12 4.19e-09 -0.38 -0.31 Aortic root size; chr7:66762495 chr7:66395191~66395286:+ LUSC cis rs6471393 0.792 rs7839522 ENSG00000253848.1 RP11-10N23.5 -7.06 5.96e-12 4.2e-09 -0.41 -0.31 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93827906 chr8:93741193~93744534:+ LUSC cis rs8177376 0.906 rs8177380 ENSG00000254905.1 RP11-712L6.7 -7.06 5.96e-12 4.2e-09 -0.41 -0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126295671 chr11:126292922~126294254:- LUSC cis rs867371 0.519 rs1566560 ENSG00000276710.3 CSPG4P8 -7.06 6e-12 4.23e-09 -0.32 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82232116 chr15:82459472~82477258:+ LUSC cis rs867371 0.519 rs1566559 ENSG00000276710.3 CSPG4P8 -7.06 6e-12 4.23e-09 -0.32 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82232120 chr15:82459472~82477258:+ LUSC cis rs10463554 0.853 rs246902 ENSG00000175749.11 EIF3KP1 7.06 6e-12 4.23e-09 0.37 0.31 Parkinson's disease; chr5:103253553 chr5:103032376~103033031:+ LUSC cis rs113835537 0.529 rs17147644 ENSG00000255517.5 CTD-3074O7.5 -7.06 6.01e-12 4.24e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66489189 chr11:66473490~66480233:- LUSC cis rs1075265 0.811 rs805308 ENSG00000233266.1 HMGB1P31 7.06 6.02e-12 4.24e-09 0.38 0.31 Chronotype;Morning vs. evening chronotype; chr2:53967797 chr2:54051334~54051760:+ LUSC cis rs10129255 0.744 rs28517388 ENSG00000224373.3 IGHV4-59 7.06 6.03e-12 4.25e-09 0.18 0.31 Kawasaki disease; chr14:106704323 chr14:106627249~106627825:- LUSC cis rs12554020 0.579 rs79056932 ENSG00000227603.1 RP11-165J3.6 7.06 6.05e-12 4.26e-09 0.52 0.31 Schizophrenia; chr9:93585431 chr9:93435332~93437121:- LUSC cis rs9318086 0.648 rs9510927 ENSG00000205861.10 C1QTNF9B-AS1 -7.06 6.05e-12 4.26e-09 -0.39 -0.31 Myopia (pathological); chr13:23893502 chr13:23888889~23897263:+ LUSC cis rs2404602 0.647 rs11072628 ENSG00000259422.1 RP11-593F23.1 -7.06 6.06e-12 4.27e-09 -0.38 -0.31 Blood metabolite levels; chr15:76815420 chr15:76174891~76181486:- LUSC cis rs465969 0.744 rs13212489 ENSG00000255389.1 C6orf3 -7.06 6.07e-12 4.28e-09 -0.58 -0.31 Psoriasis; chr6:111536863 chr6:111599875~111602295:+ LUSC cis rs465969 0.744 rs76257900 ENSG00000255389.1 C6orf3 -7.06 6.07e-12 4.28e-09 -0.58 -0.31 Psoriasis; chr6:111537286 chr6:111599875~111602295:+ LUSC cis rs13113518 0.783 rs1586555 ENSG00000223305.1 RN7SKP30 7.06 6.08e-12 4.28e-09 0.38 0.31 Height; chr4:55587104 chr4:55540502~55540835:- LUSC cis rs1865760 0.927 rs6915834 ENSG00000272462.2 U91328.19 -7.06 6.08e-12 4.28e-09 -0.34 -0.31 Height; chr6:25935199 chr6:25992662~26001775:+ LUSC cis rs66887589 0.616 rs6822808 ENSG00000245958.5 RP11-33B1.1 -7.06 6.09e-12 4.29e-09 -0.3 -0.31 Diastolic blood pressure; chr4:119296210 chr4:119454791~119552025:+ LUSC cis rs9549367 0.713 rs56002882 ENSG00000269125.1 RP11-98F14.11 -7.06 6.09e-12 4.29e-09 -0.4 -0.31 Platelet distribution width; chr13:113176380 chr13:113165002~113165183:- LUSC cis rs113835537 0.529 rs7950407 ENSG00000255517.5 CTD-3074O7.5 -7.06 6.11e-12 4.3e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66490535 chr11:66473490~66480233:- LUSC cis rs13113518 0.812 rs11133385 ENSG00000223305.1 RN7SKP30 7.06 6.11e-12 4.3e-09 0.38 0.31 Height; chr4:55460485 chr4:55540502~55540835:- LUSC cis rs1075232 0.826 rs12438813 ENSG00000215302.7 CTD-3092A11.1 -7.06 6.12e-12 4.31e-09 -0.72 -0.31 Survival in colorectal cancer (non-distant metastatic); chr15:31413710 chr15:30470779~30507623:+ LUSC cis rs9921338 0.924 rs7204628 ENSG00000263080.1 RP11-485G7.5 7.06 6.15e-12 4.33e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11350715 chr16:11341809~11345211:- LUSC cis rs2337406 0.925 rs2011167 ENSG00000274576.2 IGHV2-70 -7.06 6.15e-12 4.33e-09 -0.34 -0.31 Alzheimer's disease (late onset); chr14:106680831 chr14:106770577~106771020:- LUSC cis rs6142102 0.625 rs4911137 ENSG00000276073.1 RP5-1125A11.7 -7.06 6.16e-12 4.33e-09 -0.31 -0.31 Skin pigmentation; chr20:33947657 chr20:33985617~33988989:- LUSC cis rs950169 0.922 rs11633075 ENSG00000259728.4 LINC00933 7.06 6.16e-12 4.33e-09 0.4 0.31 Schizophrenia; chr15:84570741 chr15:84570649~84580175:+ LUSC cis rs11098499 0.954 rs7436506 ENSG00000250412.1 KLHL2P1 7.06 6.16e-12 4.34e-09 0.39 0.31 Corneal astigmatism; chr4:119472614 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs12499324 ENSG00000250412.1 KLHL2P1 7.06 6.16e-12 4.34e-09 0.39 0.31 Corneal astigmatism; chr4:119472631 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs10008459 ENSG00000250412.1 KLHL2P1 7.06 6.16e-12 4.34e-09 0.39 0.31 Corneal astigmatism; chr4:119473076 chr4:119334329~119378233:+ LUSC cis rs11123170 0.543 rs4849180 ENSG00000189223.12 PAX8-AS1 -7.06 6.17e-12 4.34e-09 -0.47 -0.31 Renal function-related traits (BUN); chr2:113227609 chr2:113211522~113276581:+ LUSC cis rs10754283 0.901 rs10922684 ENSG00000231613.1 RP5-943J3.1 7.06 6.18e-12 4.35e-09 0.35 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89652375 chr1:89788914~89790492:+ LUSC cis rs992157 0.71 rs10169718 ENSG00000261338.2 RP11-378A13.1 -7.05 6.22e-12 4.37e-09 -0.32 -0.31 Colorectal cancer; chr2:218238857 chr2:218255319~218257366:+ LUSC cis rs875971 0.862 rs1983372 ENSG00000237310.1 GS1-124K5.4 -7.05 6.22e-12 4.38e-09 -0.32 -0.31 Aortic root size; chr7:66146364 chr7:66493706~66495474:+ LUSC cis rs6142102 0.961 rs4911405 ENSG00000276073.1 RP5-1125A11.7 -7.05 6.28e-12 4.41e-09 -0.33 -0.31 Skin pigmentation; chr20:34087161 chr20:33985617~33988989:- LUSC cis rs9309473 1 rs9653557 ENSG00000163016.8 ALMS1P 7.05 6.28e-12 4.42e-09 0.37 0.31 Metabolite levels; chr2:73568835 chr2:73644919~73685576:+ LUSC cis rs9309473 0.848 rs17009159 ENSG00000163016.8 ALMS1P 7.05 6.28e-12 4.42e-09 0.37 0.31 Metabolite levels; chr2:73570635 chr2:73644919~73685576:+ LUSC cis rs9309473 1 rs7586463 ENSG00000163016.8 ALMS1P 7.05 6.28e-12 4.42e-09 0.37 0.31 Metabolite levels; chr2:73571349 chr2:73644919~73685576:+ LUSC cis rs875971 0.862 rs4718319 ENSG00000237310.1 GS1-124K5.4 -7.05 6.3e-12 4.43e-09 -0.32 -0.31 Aortic root size; chr7:66187797 chr7:66493706~66495474:+ LUSC cis rs875971 0.723 rs28391294 ENSG00000237310.1 GS1-124K5.4 -7.05 6.3e-12 4.43e-09 -0.32 -0.31 Aortic root size; chr7:66189328 chr7:66493706~66495474:+ LUSC cis rs875971 0.83 rs6967708 ENSG00000237310.1 GS1-124K5.4 -7.05 6.3e-12 4.43e-09 -0.32 -0.31 Aortic root size; chr7:66192326 chr7:66493706~66495474:+ LUSC cis rs875971 0.895 rs7782806 ENSG00000237310.1 GS1-124K5.4 -7.05 6.3e-12 4.43e-09 -0.32 -0.31 Aortic root size; chr7:66192910 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs880166 ENSG00000237310.1 GS1-124K5.4 -7.05 6.3e-12 4.43e-09 -0.32 -0.31 Aortic root size; chr7:66205775 chr7:66493706~66495474:+ LUSC cis rs748404 0.697 rs1814323 ENSG00000249839.1 AC011330.5 7.05 6.3e-12 4.43e-09 0.41 0.31 Lung cancer; chr15:43271039 chr15:43663654~43684339:- LUSC cis rs4853012 0.887 rs2280642 ENSG00000257800.1 FNBP1P1 7.05 6.31e-12 4.44e-09 0.37 0.31 Gestational age at birth (maternal effect); chr2:74131125 chr2:74120680~74123218:+ LUSC cis rs17270561 1 rs12211184 ENSG00000272462.2 U91328.19 -7.05 6.31e-12 4.44e-09 -0.42 -0.31 Iron status biomarkers; chr6:25823546 chr6:25992662~26001775:+ LUSC cis rs9545047 0.716 rs314692 ENSG00000227676.3 LINC01068 -7.05 6.32e-12 4.44e-09 -0.38 -0.31 Schizophrenia; chr13:79433091 chr13:79566727~79571436:+ LUSC cis rs11907546 1 rs11907546 ENSG00000276073.1 RP5-1125A11.7 -7.05 6.32e-12 4.44e-09 -0.32 -0.31 Cancer (pleiotropy);Cancer; chr20:34131991 chr20:33985617~33988989:- LUSC cis rs465969 1 rs1407644 ENSG00000255389.1 C6orf3 7.05 6.33e-12 4.45e-09 0.59 0.31 Psoriasis; chr6:111480895 chr6:111599875~111602295:+ LUSC cis rs3750965 0.959 rs3376 ENSG00000260895.1 RP11-554A11.7 7.05 6.34e-12 4.45e-09 0.36 0.31 Hair color; chr11:69089212 chr11:69103493~69109094:+ LUSC cis rs3750965 0.959 rs2253658 ENSG00000260895.1 RP11-554A11.7 7.05 6.34e-12 4.45e-09 0.36 0.31 Hair color; chr11:69089336 chr11:69103493~69109094:+ LUSC cis rs17711722 0.51 rs11767457 ENSG00000236529.1 RP13-254B10.1 7.05 6.34e-12 4.45e-09 0.32 0.31 Calcium levels; chr7:65825628 chr7:65840212~65840596:+ LUSC cis rs75422866 0.51 rs73105818 ENSG00000274902.1 RP1-197B17.4 7.05 6.34e-12 4.46e-09 0.73 0.31 Pneumonia; chr12:47726538 chr12:47731908~47732351:+ LUSC cis rs526231 0.543 rs152123 ENSG00000175749.11 EIF3KP1 -7.05 6.35e-12 4.46e-09 -0.4 -0.31 Primary biliary cholangitis; chr5:103196218 chr5:103032376~103033031:+ LUSC cis rs881375 1 rs10760118 ENSG00000226752.6 PSMD5-AS1 -7.05 6.35e-12 4.46e-09 -0.36 -0.31 Rheumatoid arthritis; chr9:120879338 chr9:120824828~120854385:+ LUSC cis rs10129255 0.789 rs61997796 ENSG00000280411.1 IGHV1-69-2 -7.05 6.36e-12 4.47e-09 -0.22 -0.31 Kawasaki disease; chr14:106813798 chr14:106762092~106762588:- LUSC cis rs2455601 0.679 rs2653559 ENSG00000254860.4 TMEM9B-AS1 7.05 6.38e-12 4.48e-09 0.43 0.31 Schizophrenia; chr11:8878847 chr11:8964675~8977527:+ LUSC cis rs10129255 0.5 rs1024350 ENSG00000224373.3 IGHV4-59 7.05 6.38e-12 4.48e-09 0.15 0.31 Kawasaki disease; chr14:106685105 chr14:106627249~106627825:- LUSC cis rs853679 0.567 rs16894091 ENSG00000204709.4 LINC01556 -7.05 6.38e-12 4.48e-09 -0.44 -0.31 Depression; chr6:28422360 chr6:28943877~28944537:+ LUSC cis rs66887589 0.616 rs13113885 ENSG00000245958.5 RP11-33B1.1 -7.05 6.39e-12 4.48e-09 -0.3 -0.31 Diastolic blood pressure; chr4:119300021 chr4:119454791~119552025:+ LUSC cis rs442309 0.553 rs10995281 ENSG00000238280.1 RP11-436D10.3 -7.05 6.39e-12 4.49e-09 -0.38 -0.31 Vogt-Koyanagi-Harada syndrome; chr10:62707416 chr10:62793562~62805887:- LUSC cis rs11098499 0.71 rs6851130 ENSG00000249244.1 RP11-548H18.2 -7.05 6.4e-12 4.49e-09 -0.38 -0.31 Corneal astigmatism; chr4:119212557 chr4:119391831~119395335:- LUSC cis rs875971 0.862 rs2420174 ENSG00000237310.1 GS1-124K5.4 -7.05 6.4e-12 4.49e-09 -0.32 -0.31 Aortic root size; chr7:66180374 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs2420173 ENSG00000237310.1 GS1-124K5.4 -7.05 6.4e-12 4.49e-09 -0.32 -0.31 Aortic root size; chr7:66180412 chr7:66493706~66495474:+ LUSC cis rs853679 0.607 rs33932084 ENSG00000204709.4 LINC01556 7.05 6.41e-12 4.5e-09 0.62 0.31 Depression; chr6:28301047 chr6:28943877~28944537:+ LUSC cis rs9309473 1 rs13383871 ENSG00000163016.8 ALMS1P 7.05 6.42e-12 4.5e-09 0.38 0.31 Metabolite levels; chr2:73404651 chr2:73644919~73685576:+ LUSC cis rs66887589 0.616 rs6843509 ENSG00000245958.5 RP11-33B1.1 -7.05 6.43e-12 4.51e-09 -0.3 -0.31 Diastolic blood pressure; chr4:119299041 chr4:119454791~119552025:+ LUSC cis rs113835537 0.529 rs7943327 ENSG00000255517.5 CTD-3074O7.5 -7.05 6.43e-12 4.51e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66489110 chr11:66473490~66480233:- LUSC cis rs12216125 0.554 rs6942196 ENSG00000272462.2 U91328.19 -7.05 6.44e-12 4.52e-09 -0.33 -0.31 Iron status biomarkers; chr6:26072576 chr6:25992662~26001775:+ LUSC cis rs1865760 0.566 rs1539183 ENSG00000272462.2 U91328.19 -7.05 6.44e-12 4.52e-09 -0.33 -0.31 Height; chr6:26074823 chr6:25992662~26001775:+ LUSC cis rs11098499 0.562 rs13101722 ENSG00000249244.1 RP11-548H18.2 -7.05 6.44e-12 4.52e-09 -0.38 -0.31 Corneal astigmatism; chr4:119634820 chr4:119391831~119395335:- LUSC cis rs4713118 0.868 rs7756968 ENSG00000219392.1 RP1-265C24.5 -7.05 6.49e-12 4.55e-09 -0.43 -0.31 Parkinson's disease; chr6:27767175 chr6:28115628~28116551:+ LUSC cis rs2283792 0.765 rs34550586 ENSG00000228050.1 TOP3BP1 7.05 6.49e-12 4.55e-09 0.36 0.31 Multiple sclerosis; chr22:21791345 chr22:22223187~22224566:- LUSC cis rs75422866 0.51 rs73105819 ENSG00000274902.1 RP1-197B17.4 7.05 6.5e-12 4.56e-09 0.72 0.31 Pneumonia; chr12:47727190 chr12:47731908~47732351:+ LUSC cis rs10129255 0.957 rs10140904 ENSG00000224373.3 IGHV4-59 7.05 6.51e-12 4.56e-09 0.17 0.31 Kawasaki disease; chr14:106776558 chr14:106627249~106627825:- LUSC cis rs9545047 0.716 rs6563096 ENSG00000227676.3 LINC01068 -7.05 6.51e-12 4.57e-09 -0.38 -0.31 Schizophrenia; chr13:79284100 chr13:79566727~79571436:+ LUSC cis rs8059260 0.604 rs8052325 ENSG00000274038.1 RP11-66H6.4 -7.05 6.54e-12 4.59e-09 -0.5 -0.31 Alcohol consumption over the past year; chr16:11044121 chr16:11056556~11057034:+ LUSC cis rs748404 0.666 rs55801120 ENSG00000249839.1 AC011330.5 -7.05 6.56e-12 4.6e-09 -0.52 -0.31 Lung cancer; chr15:43495042 chr15:43663654~43684339:- LUSC cis rs950169 0.887 rs220333 ENSG00000225151.9 GOLGA2P7 -7.05 6.56e-12 4.6e-09 -0.42 -0.31 Schizophrenia; chr15:84547902 chr15:84199311~84230136:- LUSC cis rs853679 0.506 rs1150693 ENSG00000204709.4 LINC01556 7.05 6.58e-12 4.61e-09 0.43 0.31 Depression; chr6:28206812 chr6:28943877~28944537:+ LUSC cis rs8177876 0.822 rs1563077 ENSG00000261838.4 RP11-303E16.6 7.05 6.58e-12 4.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81073951 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs1563075 ENSG00000261838.4 RP11-303E16.6 7.05 6.58e-12 4.61e-09 0.71 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81074143 chr16:81069854~81076598:+ LUSC cis rs67180937 0.733 rs61824331 ENSG00000272750.1 RP11-378J18.8 -7.05 6.58e-12 4.62e-09 -0.34 -0.31 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222708030 chr1:222658867~222661512:- LUSC cis rs9928842 0.882 rs1107593 ENSG00000280152.1 RP11-331F4.5 7.05 6.61e-12 4.63e-09 0.38 0.31 Alcoholic chronic pancreatitis; chr16:75227431 chr16:75245994~75250077:- LUSC cis rs9928842 0.824 rs12924999 ENSG00000280152.1 RP11-331F4.5 7.05 6.61e-12 4.63e-09 0.38 0.31 Alcoholic chronic pancreatitis; chr16:75228527 chr16:75245994~75250077:- LUSC cis rs875971 0.505 rs2462573 ENSG00000236529.1 RP13-254B10.1 -7.04 6.65e-12 4.66e-09 -0.32 -0.31 Aortic root size; chr7:66042405 chr7:65840212~65840596:+ LUSC cis rs9309473 0.748 rs2421552 ENSG00000163016.8 ALMS1P 7.04 6.65e-12 4.66e-09 0.37 0.31 Metabolite levels; chr2:73531676 chr2:73644919~73685576:+ LUSC cis rs7945705 0.902 rs10743093 ENSG00000254860.4 TMEM9B-AS1 -7.04 6.66e-12 4.66e-09 -0.34 -0.31 Hemoglobin concentration; chr11:8847582 chr11:8964675~8977527:+ LUSC cis rs10754283 0.967 rs10737707 ENSG00000231613.1 RP5-943J3.1 7.04 6.66e-12 4.67e-09 0.35 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89653745 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs10737708 ENSG00000231613.1 RP5-943J3.1 7.04 6.66e-12 4.67e-09 0.35 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89654245 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs10801763 ENSG00000231613.1 RP5-943J3.1 7.04 6.66e-12 4.67e-09 0.35 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89655263 chr1:89788914~89790492:+ LUSC cis rs6142102 0.517 rs8119076 ENSG00000276073.1 RP5-1125A11.7 -7.04 6.68e-12 4.68e-09 -0.3 -0.31 Skin pigmentation; chr20:33937909 chr20:33985617~33988989:- LUSC cis rs6142102 0.517 rs6059577 ENSG00000276073.1 RP5-1125A11.7 -7.04 6.68e-12 4.68e-09 -0.3 -0.31 Skin pigmentation; chr20:33939880 chr20:33985617~33988989:- LUSC cis rs7250849 0.565 rs73052859 ENSG00000273837.1 LLNLR-470E3.1 -7.04 6.69e-12 4.68e-09 -0.42 -0.31 Blood protein levels; chr19:51661210 chr19:51639478~51639931:- LUSC cis rs7250849 0.565 rs73052861 ENSG00000273837.1 LLNLR-470E3.1 -7.04 6.69e-12 4.68e-09 -0.42 -0.31 Blood protein levels; chr19:51661217 chr19:51639478~51639931:- LUSC cis rs12554020 0.681 rs78792144 ENSG00000227603.1 RP11-165J3.6 7.04 6.69e-12 4.68e-09 0.52 0.31 Schizophrenia; chr9:93583725 chr9:93435332~93437121:- LUSC cis rs113835537 0.529 rs11227495 ENSG00000255517.5 CTD-3074O7.5 -7.04 6.71e-12 4.69e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66495772 chr11:66473490~66480233:- LUSC cis rs11098499 0.863 rs10004484 ENSG00000250412.1 KLHL2P1 7.04 6.75e-12 4.72e-09 0.39 0.31 Corneal astigmatism; chr4:119521273 chr4:119334329~119378233:+ LUSC cis rs8062405 0.824 rs4788083 ENSG00000278665.1 RP11-666O2.4 7.04 6.75e-12 4.72e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534128 chr16:28599241~28601881:- LUSC cis rs1865760 0.929 rs1436307 ENSG00000272462.2 U91328.19 -7.04 6.76e-12 4.73e-09 -0.34 -0.31 Height; chr6:25939495 chr6:25992662~26001775:+ LUSC cis rs1865760 0.892 rs9379806 ENSG00000272462.2 U91328.19 -7.04 6.76e-12 4.73e-09 -0.34 -0.31 Height; chr6:25940730 chr6:25992662~26001775:+ LUSC cis rs950169 0.84 rs62019457 ENSG00000225151.9 GOLGA2P7 -7.04 6.79e-12 4.75e-09 -0.43 -0.31 Schizophrenia; chr15:84558911 chr15:84199311~84230136:- LUSC cis rs2117029 0.555 rs2279596 ENSG00000258017.1 RP11-386G11.10 -7.04 6.8e-12 4.76e-09 -0.39 -0.31 Intelligence (multi-trait analysis); chr12:49104968 chr12:49127782~49147869:+ LUSC cis rs2404602 0.647 rs11631394 ENSG00000259422.1 RP11-593F23.1 -7.04 6.81e-12 4.76e-09 -0.36 -0.31 Blood metabolite levels; chr15:76680868 chr15:76174891~76181486:- LUSC cis rs6570726 0.577 rs441982 ENSG00000235652.6 RP11-545I5.3 7.04 6.82e-12 4.77e-09 0.32 0.31 Lobe attachment (rater-scored or self-reported); chr6:145521712 chr6:145799409~145886585:+ LUSC cis rs6142102 1 rs2143230 ENSG00000276073.1 RP5-1125A11.7 -7.04 6.84e-12 4.78e-09 -0.32 -0.31 Skin pigmentation; chr20:34136539 chr20:33985617~33988989:- LUSC cis rs6142102 0.961 rs2268088 ENSG00000276073.1 RP5-1125A11.7 -7.04 6.86e-12 4.79e-09 -0.33 -0.31 Skin pigmentation; chr20:34061258 chr20:33985617~33988989:- LUSC cis rs6142102 0.961 rs2284388 ENSG00000276073.1 RP5-1125A11.7 -7.04 6.86e-12 4.79e-09 -0.33 -0.31 Skin pigmentation; chr20:34067935 chr20:33985617~33988989:- LUSC cis rs75422866 0.51 rs73104197 ENSG00000274902.1 RP1-197B17.4 7.04 6.87e-12 4.8e-09 0.73 0.31 Pneumonia; chr12:47717273 chr12:47731908~47732351:+ LUSC cis rs1075265 0.783 rs805453 ENSG00000233266.1 HMGB1P31 7.04 6.88e-12 4.81e-09 0.38 0.31 Chronotype;Morning vs. evening chronotype; chr2:53955761 chr2:54051334~54051760:+ LUSC cis rs8177876 0.749 rs2287995 ENSG00000261838.4 RP11-303E16.6 7.04 6.89e-12 4.82e-09 0.7 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81061494 chr16:81069854~81076598:+ LUSC cis rs11089937 0.609 rs9622980 ENSG00000211639.2 IGLV4-60 7.04 6.91e-12 4.83e-09 0.36 0.31 Periodontitis (PAL4Q3); chr22:22149888 chr22:22162199~22162681:+ LUSC cis rs1198872 0.558 rs10929699 ENSG00000272275.1 RP11-791G15.2 -7.04 6.96e-12 4.86e-09 -0.45 -0.31 Cardiac Troponin-T levels; chr2:10778083 chr2:10767875~10770058:- LUSC cis rs748404 0.589 rs3862138 ENSG00000249839.1 AC011330.5 -7.04 6.97e-12 4.87e-09 -0.53 -0.31 Lung cancer; chr15:43523801 chr15:43663654~43684339:- LUSC cis rs1865760 0.566 rs9295686 ENSG00000272462.2 U91328.19 -7.04 6.97e-12 4.87e-09 -0.33 -0.31 Height; chr6:26081755 chr6:25992662~26001775:+ LUSC cis rs1865760 0.532 rs9295687 ENSG00000272462.2 U91328.19 -7.04 6.97e-12 4.87e-09 -0.33 -0.31 Height; chr6:26082482 chr6:25992662~26001775:+ LUSC cis rs1865760 0.566 rs4529296 ENSG00000272462.2 U91328.19 -7.04 6.97e-12 4.87e-09 -0.33 -0.31 Height; chr6:26082907 chr6:25992662~26001775:+ LUSC cis rs1865760 0.566 rs1971509 ENSG00000272462.2 U91328.19 -7.04 6.97e-12 4.87e-09 -0.33 -0.31 Height; chr6:26085549 chr6:25992662~26001775:+ LUSC cis rs1865760 0.532 rs2006736 ENSG00000272462.2 U91328.19 -7.04 6.97e-12 4.87e-09 -0.33 -0.31 Height; chr6:26085789 chr6:25992662~26001775:+ LUSC cis rs1865760 0.566 rs1800702 ENSG00000272462.2 U91328.19 -7.04 6.97e-12 4.87e-09 -0.33 -0.31 Height; chr6:26086235 chr6:25992662~26001775:+ LUSC cis rs1865760 0.566 rs2794720 ENSG00000272462.2 U91328.19 -7.04 6.97e-12 4.87e-09 -0.33 -0.31 Height; chr6:26086974 chr6:25992662~26001775:+ LUSC cis rs748404 0.666 rs10518812 ENSG00000249839.1 AC011330.5 7.04 6.98e-12 4.87e-09 0.52 0.31 Lung cancer; chr15:43360739 chr15:43663654~43684339:- LUSC cis rs34779708 0.897 rs4934716 ENSG00000230534.5 RP11-297A16.2 7.04 6.99e-12 4.88e-09 0.34 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35080371 chr10:35098006~35127020:- LUSC cis rs56145559 1 rs56145559 ENSG00000163016.8 ALMS1P 7.04 6.99e-12 4.88e-09 0.38 0.31 Schizophrenia; chr2:73396311 chr2:73644919~73685576:+ LUSC cis rs9813712 0.548 rs9880123 ENSG00000228252.7 COL6A4P2 -7.04 7.04e-12 4.91e-09 -0.29 -0.31 Response to amphetamines; chr3:130215275 chr3:130212823~130273806:+ LUSC cis rs8177876 0.749 rs79834398 ENSG00000261838.4 RP11-303E16.6 7.03 7.11e-12 4.96e-09 0.73 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81057033 chr16:81069854~81076598:+ LUSC cis rs11098499 0.863 rs34868248 ENSG00000250412.1 KLHL2P1 7.03 7.13e-12 4.97e-09 0.39 0.31 Corneal astigmatism; chr4:119521275 chr4:119334329~119378233:+ LUSC cis rs11098499 0.866 rs3756156 ENSG00000250412.1 KLHL2P1 7.03 7.14e-12 4.98e-09 0.38 0.31 Corneal astigmatism; chr4:119603686 chr4:119334329~119378233:+ LUSC cis rs367615 0.552 rs2115511 ENSG00000249476.1 CTD-2587M2.1 -7.03 7.15e-12 4.98e-09 -0.35 -0.31 Colorectal cancer (SNP x SNP interaction); chr5:109389702 chr5:109237120~109326369:- LUSC cis rs61160187 0.582 rs17419290 ENSG00000215032.2 GNL3LP1 -7.03 7.17e-12 4.99e-09 -0.39 -0.31 Educational attainment (years of education);Educational attainment (college completion); chr5:61012077 chr5:60891935~60893577:- LUSC cis rs3750965 0.959 rs11228490 ENSG00000260895.1 RP11-554A11.7 -7.03 7.18e-12 5e-09 -0.36 -0.31 Hair color; chr11:69093404 chr11:69103493~69109094:+ LUSC cis rs11098499 0.615 rs59867181 ENSG00000249244.1 RP11-548H18.2 -7.03 7.19e-12 5.01e-09 -0.37 -0.31 Corneal astigmatism; chr4:119635312 chr4:119391831~119395335:- LUSC cis rs11098499 0.562 rs2389879 ENSG00000249244.1 RP11-548H18.2 -7.03 7.19e-12 5.01e-09 -0.37 -0.31 Corneal astigmatism; chr4:119636529 chr4:119391831~119395335:- LUSC cis rs2337406 1 rs17095456 ENSG00000274576.2 IGHV2-70 -7.03 7.2e-12 5.01e-09 -0.34 -0.31 Alzheimer's disease (late onset); chr14:106676559 chr14:106770577~106771020:- LUSC cis rs35160687 0.901 rs35762338 ENSG00000273080.1 RP11-301O19.1 7.03 7.23e-12 5.03e-09 0.3 0.31 Night sleep phenotypes; chr2:86286430 chr2:86195590~86196049:+ LUSC cis rs4308124 0.708 rs6716091 ENSG00000227992.1 AC108463.2 -7.03 7.23e-12 5.04e-09 -0.41 -0.31 Vitiligo; chr2:111233556 chr2:111203964~111206215:- LUSC cis rs875971 0.545 rs4441996 ENSG00000164669.11 INTS4P1 7.03 7.26e-12 5.05e-09 0.37 0.31 Aortic root size; chr7:66123233 chr7:65141225~65234216:+ LUSC cis rs748404 0.697 rs501884 ENSG00000249839.1 AC011330.5 -7.03 7.27e-12 5.06e-09 -0.41 -0.31 Lung cancer; chr15:43261784 chr15:43663654~43684339:- LUSC cis rs748404 0.697 rs504417 ENSG00000249839.1 AC011330.5 -7.03 7.27e-12 5.06e-09 -0.41 -0.31 Lung cancer; chr15:43262028 chr15:43663654~43684339:- LUSC cis rs748404 0.723 rs560134 ENSG00000249839.1 AC011330.5 -7.03 7.27e-12 5.06e-09 -0.41 -0.31 Lung cancer; chr15:43263501 chr15:43663654~43684339:- LUSC cis rs11690935 0.959 rs10184866 ENSG00000228389.1 AC068039.4 7.03 7.28e-12 5.07e-09 0.36 0.31 Schizophrenia; chr2:171752446 chr2:171773482~171775844:+ LUSC cis rs8072100 0.512 rs3809863 ENSG00000228782.6 CTD-2026D20.3 7.03 7.29e-12 5.07e-09 0.29 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47307646 chr17:47450568~47492492:- LUSC cis rs11123170 0.569 rs1049137 ENSG00000189223.12 PAX8-AS1 -7.03 7.29e-12 5.07e-09 -0.47 -0.31 Renal function-related traits (BUN); chr2:113217533 chr2:113211522~113276581:+ LUSC cis rs904251 0.965 rs1317563 ENSG00000204110.6 RP1-153P14.8 -7.03 7.3e-12 5.08e-09 -0.3 -0.31 Cognitive performance; chr6:37484078 chr6:37507348~37535616:+ LUSC cis rs2404602 0.647 rs62026889 ENSG00000259422.1 RP11-593F23.1 -7.03 7.33e-12 5.1e-09 -0.36 -0.31 Blood metabolite levels; chr15:76625544 chr15:76174891~76181486:- LUSC cis rs11098499 0.82 rs28578366 ENSG00000250412.1 KLHL2P1 -7.03 7.33e-12 5.1e-09 -0.38 -0.31 Corneal astigmatism; chr4:119615750 chr4:119334329~119378233:+ LUSC cis rs9545047 0.716 rs643778 ENSG00000227676.3 LINC01068 -7.03 7.34e-12 5.1e-09 -0.38 -0.31 Schizophrenia; chr13:79423937 chr13:79566727~79571436:+ LUSC cis rs3747113 1 rs11703914 ENSG00000128262.7 POM121L9P -7.03 7.34e-12 5.11e-09 -0.33 -0.31 Gut microbiome composition (summer); chr22:24371634 chr22:24251828~24265525:+ LUSC cis rs801193 0.569 rs10950050 ENSG00000237310.1 GS1-124K5.4 7.03 7.36e-12 5.12e-09 0.32 0.31 Aortic root size; chr7:66774601 chr7:66493706~66495474:+ LUSC cis rs801193 0.569 rs7800620 ENSG00000237310.1 GS1-124K5.4 7.03 7.42e-12 5.15e-09 0.33 0.31 Aortic root size; chr7:66758701 chr7:66493706~66495474:+ LUSC cis rs9309473 0.898 rs10197755 ENSG00000163016.8 ALMS1P 7.03 7.42e-12 5.16e-09 0.37 0.31 Metabolite levels; chr2:73570496 chr2:73644919~73685576:+ LUSC cis rs6921919 0.609 rs1005127 ENSG00000204709.4 LINC01556 7.03 7.44e-12 5.17e-09 0.39 0.31 Autism spectrum disorder or schizophrenia; chr6:28399881 chr6:28943877~28944537:+ LUSC cis rs853679 0.515 rs4580862 ENSG00000204709.4 LINC01556 7.03 7.44e-12 5.17e-09 0.39 0.31 Depression; chr6:28399886 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs4357130 ENSG00000204709.4 LINC01556 7.03 7.44e-12 5.17e-09 0.39 0.31 Autism spectrum disorder or schizophrenia; chr6:28399906 chr6:28943877~28944537:+ LUSC cis rs9549367 0.713 rs556990 ENSG00000269125.1 RP11-98F14.11 7.03 7.45e-12 5.18e-09 0.38 0.31 Platelet distribution width; chr13:113190745 chr13:113165002~113165183:- LUSC cis rs11098499 0.863 rs6833334 ENSG00000250412.1 KLHL2P1 7.03 7.46e-12 5.18e-09 0.38 0.31 Corneal astigmatism; chr4:119583072 chr4:119334329~119378233:+ LUSC cis rs2188561 0.697 rs34986332 ENSG00000241764.3 AC002467.7 7.03 7.46e-12 5.18e-09 0.4 0.31 Alcohol consumption; chr7:107739010 chr7:107742817~107744581:- LUSC cis rs2188561 0.638 rs28690459 ENSG00000241764.3 AC002467.7 7.03 7.46e-12 5.18e-09 0.4 0.31 Alcohol consumption; chr7:107740258 chr7:107742817~107744581:- LUSC cis rs748404 0.666 rs7177146 ENSG00000249839.1 AC011330.5 -7.03 7.46e-12 5.18e-09 -0.53 -0.31 Lung cancer; chr15:43506110 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs12907870 ENSG00000249839.1 AC011330.5 -7.03 7.53e-12 5.23e-09 -0.52 -0.31 Lung cancer; chr15:43453971 chr15:43663654~43684339:- LUSC cis rs9309473 0.898 rs10185080 ENSG00000163016.8 ALMS1P 7.03 7.53e-12 5.23e-09 0.37 0.31 Metabolite levels; chr2:73570380 chr2:73644919~73685576:+ LUSC cis rs2297363 1 rs1130861 ENSG00000213073.4 RP11-288H12.3 -7.03 7.55e-12 5.24e-09 -0.39 -0.31 Total cholesterol levels;Blood protein levels; chr6:160090322 chr6:160093082~160096212:+ LUSC cis rs6921919 0.583 rs16894108 ENSG00000204709.4 LINC01556 7.02 7.56e-12 5.25e-09 0.39 0.31 Autism spectrum disorder or schizophrenia; chr6:28434013 chr6:28943877~28944537:+ LUSC cis rs35160687 0.901 rs13017338 ENSG00000273080.1 RP11-301O19.1 7.02 7.57e-12 5.26e-09 0.3 0.31 Night sleep phenotypes; chr2:86274430 chr2:86195590~86196049:+ LUSC cis rs7739264 0.564 rs760796 ENSG00000227116.1 RP3-471C18.1 -7.02 7.59e-12 5.27e-09 -0.35 -0.31 Endometriosis; chr6:19790156 chr6:19730427~19734567:- LUSC cis rs11123170 0.543 rs2166421 ENSG00000189223.12 PAX8-AS1 -7.02 7.59e-12 5.27e-09 -0.47 -0.31 Renal function-related traits (BUN); chr2:113232665 chr2:113211522~113276581:+ LUSC cis rs9921338 0.961 rs56010295 ENSG00000263080.1 RP11-485G7.5 7.02 7.6e-12 5.28e-09 0.36 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11285050 chr16:11341809~11345211:- LUSC cis rs2188561 0.697 rs739518 ENSG00000241764.3 AC002467.7 7.02 7.61e-12 5.28e-09 0.4 0.31 Alcohol consumption; chr7:107743682 chr7:107742817~107744581:- LUSC cis rs440932 1 rs365309 ENSG00000254340.1 RP11-10A14.3 -7.02 7.62e-12 5.29e-09 -0.38 -0.31 High light scatter reticulocyte percentage of red cells; chr8:9169430 chr8:9141424~9145435:+ LUSC cis rs8059260 0.736 rs7202408 ENSG00000274038.1 RP11-66H6.4 -7.02 7.62e-12 5.29e-09 -0.51 -0.31 Alcohol consumption over the past year; chr16:10984758 chr16:11056556~11057034:+ LUSC cis rs853679 0.55 rs1233699 ENSG00000204709.4 LINC01556 7.02 7.62e-12 5.29e-09 0.42 0.31 Depression; chr6:28201380 chr6:28943877~28944537:+ LUSC cis rs11098499 0.82 rs28394116 ENSG00000250412.1 KLHL2P1 7.02 7.67e-12 5.32e-09 0.38 0.31 Corneal astigmatism; chr4:119603128 chr4:119334329~119378233:+ LUSC cis rs10754283 0.967 rs10737706 ENSG00000231613.1 RP5-943J3.1 7.02 7.68e-12 5.33e-09 0.34 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89647020 chr1:89788914~89790492:+ LUSC cis rs11098499 0.863 rs3775843 ENSG00000250412.1 KLHL2P1 7.02 7.7e-12 5.34e-09 0.39 0.31 Corneal astigmatism; chr4:119506689 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs3775844 ENSG00000250412.1 KLHL2P1 7.02 7.7e-12 5.34e-09 0.39 0.31 Corneal astigmatism; chr4:119506878 chr4:119334329~119378233:+ LUSC cis rs35160687 0.901 rs10520415 ENSG00000273080.1 RP11-301O19.1 -7.02 7.7e-12 5.34e-09 -0.29 -0.31 Night sleep phenotypes; chr2:86271615 chr2:86195590~86196049:+ LUSC cis rs13113518 0.812 rs13107810 ENSG00000223305.1 RN7SKP30 7.02 7.7e-12 5.34e-09 0.38 0.31 Height; chr4:55542243 chr4:55540502~55540835:- LUSC cis rs11098499 0.954 rs7654587 ENSG00000250412.1 KLHL2P1 7.02 7.7e-12 5.34e-09 0.39 0.31 Corneal astigmatism; chr4:119467251 chr4:119334329~119378233:+ LUSC cis rs5742933 0.817 rs2033870 ENSG00000253559.1 OSGEPL1-AS1 -7.02 7.73e-12 5.36e-09 -0.37 -0.31 Ferritin levels; chr2:189739104 chr2:189762704~189765556:+ LUSC cis rs11098499 0.754 rs7672372 ENSG00000249244.1 RP11-548H18.2 7.02 7.73e-12 5.36e-09 0.39 0.31 Corneal astigmatism; chr4:119327251 chr4:119391831~119395335:- LUSC cis rs11098499 0.78 rs7680914 ENSG00000250412.1 KLHL2P1 7.02 7.75e-12 5.37e-09 0.39 0.31 Corneal astigmatism; chr4:119641898 chr4:119334329~119378233:+ LUSC cis rs34779708 0.931 rs2505631 ENSG00000230534.5 RP11-297A16.2 -7.02 7.81e-12 5.41e-09 -0.34 -0.31 Inflammatory bowel disease;Crohn's disease; chr10:35079457 chr10:35098006~35127020:- LUSC cis rs8062405 0.824 rs4788085 ENSG00000278665.1 RP11-666O2.4 7.02 7.81e-12 5.41e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523682 chr16:28599241~28601881:- LUSC cis rs8062405 0.824 rs28772958 ENSG00000278665.1 RP11-666O2.4 7.02 7.81e-12 5.41e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523984 chr16:28599241~28601881:- LUSC cis rs12554020 1 rs55846141 ENSG00000227603.1 RP11-165J3.6 7.02 7.81e-12 5.41e-09 0.47 0.31 Schizophrenia; chr9:93427679 chr9:93435332~93437121:- LUSC cis rs13113518 0.812 rs7667741 ENSG00000223305.1 RN7SKP30 7.02 7.82e-12 5.42e-09 0.38 0.31 Height; chr4:55544621 chr4:55540502~55540835:- LUSC cis rs6570726 0.62 rs367693 ENSG00000235652.6 RP11-545I5.3 7.02 7.86e-12 5.45e-09 0.32 0.31 Lobe attachment (rater-scored or self-reported); chr6:145494813 chr6:145799409~145886585:+ LUSC cis rs6142102 0.812 rs6059554 ENSG00000276073.1 RP5-1125A11.7 -7.02 7.9e-12 5.47e-09 -0.32 -0.31 Skin pigmentation; chr20:33926286 chr20:33985617~33988989:- LUSC cis rs12554020 0.786 rs16909150 ENSG00000227603.1 RP11-165J3.6 -7.02 7.92e-12 5.48e-09 -0.46 -0.31 Schizophrenia; chr9:93454464 chr9:93435332~93437121:- LUSC cis rs10129255 0.957 rs28887506 ENSG00000280411.1 IGHV1-69-2 -7.02 7.93e-12 5.49e-09 -0.21 -0.31 Kawasaki disease; chr14:106785589 chr14:106762092~106762588:- LUSC cis rs2188561 0.697 rs66560125 ENSG00000241764.3 AC002467.7 7.02 7.93e-12 5.49e-09 0.4 0.31 Alcohol consumption; chr7:107729589 chr7:107742817~107744581:- LUSC cis rs13113518 0.812 rs12500456 ENSG00000223305.1 RN7SKP30 7.02 7.94e-12 5.5e-09 0.37 0.31 Height; chr4:55561053 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs13116035 ENSG00000223305.1 RN7SKP30 7.02 7.94e-12 5.5e-09 0.37 0.31 Height; chr4:55561218 chr4:55540502~55540835:- LUSC cis rs1865760 1 rs2071297 ENSG00000272462.2 U91328.19 7.02 7.95e-12 5.5e-09 0.33 0.31 Height; chr6:25924285 chr6:25992662~26001775:+ LUSC cis rs11098499 0.863 rs13140391 ENSG00000250412.1 KLHL2P1 7.02 7.95e-12 5.51e-09 0.38 0.31 Corneal astigmatism; chr4:119582282 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs13140409 ENSG00000250412.1 KLHL2P1 7.02 7.95e-12 5.51e-09 0.38 0.31 Corneal astigmatism; chr4:119582305 chr4:119334329~119378233:+ LUSC cis rs748404 0.666 rs12899865 ENSG00000249839.1 AC011330.5 -7.02 8.01e-12 5.54e-09 -0.51 -0.31 Lung cancer; chr15:43448819 chr15:43663654~43684339:- LUSC cis rs8062405 0.824 rs240702 ENSG00000278665.1 RP11-666O2.4 7.02 8.01e-12 5.54e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28520032 chr16:28599241~28601881:- LUSC cis rs8177876 0.749 rs76892049 ENSG00000261838.4 RP11-303E16.6 7.02 8.02e-12 5.55e-09 0.73 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81055736 chr16:81069854~81076598:+ LUSC cis rs11098499 0.863 rs17050695 ENSG00000250412.1 KLHL2P1 7.02 8.03e-12 5.55e-09 0.36 0.31 Corneal astigmatism; chr4:119568372 chr4:119334329~119378233:+ LUSC cis rs13113518 0.51 rs11732723 ENSG00000249700.7 SRD5A3-AS1 -7.02 8.04e-12 5.56e-09 -0.34 -0.31 Height; chr4:55424391 chr4:55363971~55395847:- LUSC cis rs8177876 0.822 rs79926943 ENSG00000261838.4 RP11-303E16.6 7.02 8.05e-12 5.57e-09 0.75 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81072005 chr16:81069854~81076598:+ LUSC cis rs442309 0.553 rs7073430 ENSG00000238280.1 RP11-436D10.3 -7.01 8.06e-12 5.58e-09 -0.38 -0.31 Vogt-Koyanagi-Harada syndrome; chr10:62695121 chr10:62793562~62805887:- LUSC cis rs7829975 0.624 rs7823056 ENSG00000253893.2 FAM85B -7.01 8.09e-12 5.6e-09 -0.36 -0.31 Mood instability; chr8:8525195 chr8:8167819~8226614:- LUSC cis rs4308124 0.708 rs6749633 ENSG00000227992.1 AC108463.2 7.01 8.11e-12 5.61e-09 0.41 0.31 Vitiligo; chr2:111230439 chr2:111203964~111206215:- LUSC cis rs11098499 0.909 rs10026736 ENSG00000250412.1 KLHL2P1 7.01 8.11e-12 5.61e-09 0.4 0.31 Corneal astigmatism; chr4:119463167 chr4:119334329~119378233:+ LUSC cis rs1185460 0.546 rs7114961 ENSG00000271751.1 RP11-110I1.14 7.01 8.12e-12 5.61e-09 0.4 0.31 Coronary artery disease; chr11:119043677 chr11:119065263~119065677:- LUSC cis rs9549367 0.713 rs553316 ENSG00000269125.1 RP11-98F14.11 7.01 8.15e-12 5.63e-09 0.37 0.31 Platelet distribution width; chr13:113183701 chr13:113165002~113165183:- LUSC cis rs950169 0.922 rs11639244 ENSG00000225151.9 GOLGA2P7 -7.01 8.16e-12 5.64e-09 -0.43 -0.31 Schizophrenia; chr15:84163898 chr15:84199311~84230136:- LUSC cis rs4141404 0.737 rs5998067 ENSG00000236132.1 CTA-440B3.1 7.01 8.19e-12 5.66e-09 0.41 0.31 Paclitaxel-induced neuropathy; chr22:31647644 chr22:31816379~31817491:- LUSC cis rs8177876 0.642 rs10514513 ENSG00000261838.4 RP11-303E16.6 7.01 8.21e-12 5.67e-09 0.67 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080578 chr16:81069854~81076598:+ LUSC cis rs2412819 0.545 rs654276 ENSG00000249839.1 AC011330.5 7.01 8.21e-12 5.67e-09 0.51 0.31 Lung cancer; chr15:43798656 chr15:43663654~43684339:- LUSC cis rs7945705 0.902 rs1560569 ENSG00000254860.4 TMEM9B-AS1 7.01 8.22e-12 5.68e-09 0.33 0.31 Hemoglobin concentration; chr11:8918340 chr11:8964675~8977527:+ LUSC cis rs2179367 0.959 rs9285519 ENSG00000231760.4 RP11-350J20.5 7.01 8.23e-12 5.69e-09 0.4 0.31 Dupuytren's disease; chr6:149371799 chr6:149796151~149826294:- LUSC cis rs9545047 0.692 rs314694 ENSG00000227676.3 LINC01068 -7.01 8.24e-12 5.69e-09 -0.37 -0.31 Schizophrenia; chr13:79432467 chr13:79566727~79571436:+ LUSC cis rs10129255 0.957 rs2007467 ENSG00000280411.1 IGHV1-69-2 7.01 8.25e-12 5.7e-09 0.22 0.31 Kawasaki disease; chr14:106771605 chr14:106762092~106762588:- LUSC cis rs748404 0.697 rs530188 ENSG00000249839.1 AC011330.5 -7.01 8.26e-12 5.7e-09 -0.4 -0.31 Lung cancer; chr15:43253116 chr15:43663654~43684339:- LUSC cis rs748404 0.697 rs475227 ENSG00000249839.1 AC011330.5 -7.01 8.26e-12 5.7e-09 -0.4 -0.31 Lung cancer; chr15:43254248 chr15:43663654~43684339:- LUSC cis rs11098499 0.863 rs7664986 ENSG00000250412.1 KLHL2P1 7.01 8.26e-12 5.7e-09 0.39 0.31 Corneal astigmatism; chr4:119508797 chr4:119334329~119378233:+ LUSC cis rs11098499 0.818 rs10008791 ENSG00000250412.1 KLHL2P1 7.01 8.26e-12 5.7e-09 0.39 0.31 Corneal astigmatism; chr4:119510314 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs11736416 ENSG00000250412.1 KLHL2P1 7.01 8.26e-12 5.7e-09 0.39 0.31 Corneal astigmatism; chr4:119510506 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs3775845 ENSG00000250412.1 KLHL2P1 7.01 8.26e-12 5.7e-09 0.39 0.31 Corneal astigmatism; chr4:119511292 chr4:119334329~119378233:+ LUSC cis rs465969 1 rs7750803 ENSG00000255389.1 C6orf3 7.01 8.29e-12 5.73e-09 0.6 0.31 Psoriasis; chr6:111478910 chr6:111599875~111602295:+ LUSC cis rs189798 0.807 rs9949 ENSG00000254340.1 RP11-10A14.3 7.01 8.31e-12 5.73e-09 0.43 0.31 Myopia (pathological); chr8:9137002 chr8:9141424~9145435:+ LUSC cis rs1865760 1 rs6938233 ENSG00000272462.2 U91328.19 -7.01 8.31e-12 5.74e-09 -0.33 -0.31 Height; chr6:25913849 chr6:25992662~26001775:+ LUSC cis rs2412819 0.571 rs28410121 ENSG00000249839.1 AC011330.5 7.01 8.34e-12 5.76e-09 0.47 0.31 Lung cancer; chr15:43777831 chr15:43663654~43684339:- LUSC cis rs8031584 0.652 rs2691683 ENSG00000260382.1 RP11-540B6.2 -7.01 8.34e-12 5.76e-09 -0.42 -0.31 Huntington's disease progression; chr15:30842857 chr15:30882267~30883231:- LUSC cis rs6142102 0.58 rs9753679 ENSG00000276073.1 RP5-1125A11.7 -7.01 8.35e-12 5.76e-09 -0.3 -0.31 Skin pigmentation; chr20:33953054 chr20:33985617~33988989:- LUSC cis rs9309473 0.948 rs13392691 ENSG00000163016.8 ALMS1P 7.01 8.35e-12 5.76e-09 0.37 0.31 Metabolite levels; chr2:73521853 chr2:73644919~73685576:+ LUSC cis rs442309 0.553 rs10995299 ENSG00000238280.1 RP11-436D10.3 -7.01 8.35e-12 5.77e-09 -0.38 -0.31 Vogt-Koyanagi-Harada syndrome; chr10:62744443 chr10:62793562~62805887:- LUSC cis rs113835537 0.597 rs11227527 ENSG00000255517.5 CTD-3074O7.5 -7.01 8.35e-12 5.77e-09 -0.35 -0.31 Airway imaging phenotypes; chr11:66545555 chr11:66473490~66480233:- LUSC cis rs2188561 0.708 rs9718496 ENSG00000241764.3 AC002467.7 7.01 8.4e-12 5.8e-09 0.4 0.31 Alcohol consumption; chr7:107730187 chr7:107742817~107744581:- LUSC cis rs367615 0.552 rs2963025 ENSG00000249476.1 CTD-2587M2.1 -7.01 8.4e-12 5.8e-09 -0.35 -0.31 Colorectal cancer (SNP x SNP interaction); chr5:109397555 chr5:109237120~109326369:- LUSC cis rs1075265 0.783 rs6545376 ENSG00000233266.1 HMGB1P31 7.01 8.42e-12 5.81e-09 0.38 0.31 Chronotype;Morning vs. evening chronotype; chr2:53987685 chr2:54051334~54051760:+ LUSC cis rs11098499 0.657 rs71614442 ENSG00000250412.1 KLHL2P1 7.01 8.44e-12 5.82e-09 0.39 0.31 Corneal astigmatism; chr4:119458191 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs2892848 ENSG00000250412.1 KLHL2P1 7.01 8.44e-12 5.82e-09 0.39 0.31 Corneal astigmatism; chr4:119460186 chr4:119334329~119378233:+ LUSC cis rs11098499 0.865 rs9994730 ENSG00000250412.1 KLHL2P1 7.01 8.44e-12 5.82e-09 0.39 0.31 Corneal astigmatism; chr4:119460409 chr4:119334329~119378233:+ LUSC cis rs6471393 0.964 rs2914959 ENSG00000253848.1 RP11-10N23.5 7.01 8.46e-12 5.84e-09 0.41 0.31 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93727117 chr8:93741193~93744534:+ LUSC cis rs9921338 0.887 rs6498183 ENSG00000263080.1 RP11-485G7.5 7.01 8.48e-12 5.85e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11337051 chr16:11341809~11345211:- LUSC cis rs73219805 1 rs17310286 ENSG00000228451.3 SDAD1P1 7.01 8.5e-12 5.86e-09 0.44 0.31 Schizophrenia; chr8:26411516 chr8:26379259~26382953:- LUSC cis rs55665837 0.524 rs2882128 ENSG00000251991.1 RNU7-49P 7.01 8.5e-12 5.86e-09 0.35 0.31 Vitamin D levels; chr11:14393088 chr11:14478892~14478953:+ LUSC cis rs6867032 0.527 rs1017924 ENSG00000249731.1 RP11-259O2.3 7.01 8.51e-12 5.86e-09 0.36 0.31 Gut microbiome composition (winter); chr5:1976073 chr5:1968094~1969013:+ LUSC cis rs8072100 0.934 rs6504872 ENSG00000228782.6 CTD-2026D20.3 7.01 8.51e-12 5.87e-09 0.29 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47361586 chr17:47450568~47492492:- LUSC cis rs8031584 0.678 rs4779496 ENSG00000260382.1 RP11-540B6.2 7.01 8.52e-12 5.87e-09 0.42 0.31 Huntington's disease progression; chr15:30858851 chr15:30882267~30883231:- LUSC cis rs8031584 0.678 rs4779497 ENSG00000260382.1 RP11-540B6.2 7.01 8.52e-12 5.87e-09 0.42 0.31 Huntington's disease progression; chr15:30859162 chr15:30882267~30883231:- LUSC cis rs8031584 0.578 rs1088473 ENSG00000260382.1 RP11-540B6.2 -7.01 8.52e-12 5.87e-09 -0.42 -0.31 Huntington's disease progression; chr15:30847095 chr15:30882267~30883231:- LUSC cis rs7772486 0.754 rs2328709 ENSG00000235652.6 RP11-545I5.3 -7.01 8.53e-12 5.88e-09 -0.31 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145785683 chr6:145799409~145886585:+ LUSC cis rs2412819 0.571 rs12443084 ENSG00000249839.1 AC011330.5 7.01 8.53e-12 5.88e-09 0.48 0.31 Lung cancer; chr15:43748767 chr15:43663654~43684339:- LUSC cis rs2412819 0.571 rs10163069 ENSG00000249839.1 AC011330.5 7.01 8.53e-12 5.88e-09 0.48 0.31 Lung cancer; chr15:43755372 chr15:43663654~43684339:- LUSC cis rs12439619 0.508 rs8023960 ENSG00000276710.3 CSPG4P8 -7.01 8.53e-12 5.88e-09 -0.32 -0.31 Intelligence (multi-trait analysis); chr15:82206704 chr15:82459472~82477258:+ LUSC cis rs2404602 0.647 rs11072607 ENSG00000259422.1 RP11-593F23.1 -7.01 8.55e-12 5.89e-09 -0.36 -0.31 Blood metabolite levels; chr15:76616188 chr15:76174891~76181486:- LUSC cis rs3779195 0.697 rs13232861 ENSG00000272950.1 RP11-307C18.1 7.01 8.55e-12 5.89e-09 0.49 0.31 Sex hormone-binding globulin levels; chr7:98299769 chr7:98322853~98323430:+ LUSC cis rs11098499 0.754 rs1511017 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119329650 chr4:119391831~119395335:- LUSC cis rs11098499 0.789 rs12498994 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119329663 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs12507565 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119329966 chr4:119391831~119395335:- LUSC cis rs11098499 0.826 rs12511640 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119330093 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs1980026 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119330488 chr4:119391831~119395335:- LUSC cis rs11098499 0.722 rs28713555 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119330840 chr4:119391831~119395335:- LUSC cis rs11098499 0.743 rs11098501 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119330862 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs11098502 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119330908 chr4:119391831~119395335:- LUSC cis rs11098499 0.708 rs11732686 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119331175 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs11724409 ENSG00000249244.1 RP11-548H18.2 7.01 8.57e-12 5.9e-09 0.38 0.31 Corneal astigmatism; chr4:119331206 chr4:119391831~119395335:- LUSC cis rs13113518 0.783 rs6843722 ENSG00000223305.1 RN7SKP30 7.01 8.57e-12 5.9e-09 0.38 0.31 Height; chr4:55465165 chr4:55540502~55540835:- LUSC cis rs6142102 1 rs4911412 ENSG00000276073.1 RP5-1125A11.7 -7 8.6e-12 5.92e-09 -0.32 -0.31 Skin pigmentation; chr20:34128629 chr20:33985617~33988989:- LUSC cis rs11157436 1 rs61972228 ENSG00000211813.2 TRAV34 7 8.63e-12 5.94e-09 0.35 0.31 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22179460 chr14:22207522~22208129:+ LUSC cis rs11157436 1 rs12587157 ENSG00000211813.2 TRAV34 7 8.63e-12 5.94e-09 0.35 0.31 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22181476 chr14:22207522~22208129:+ LUSC cis rs12291225 0.535 rs12806025 ENSG00000251991.1 RNU7-49P 7 8.66e-12 5.96e-09 0.35 0.31 Sense of smell; chr11:14392271 chr11:14478892~14478953:+ LUSC cis rs801193 0.569 rs11761542 ENSG00000237310.1 GS1-124K5.4 7 8.66e-12 5.96e-09 0.32 0.31 Aortic root size; chr7:66753209 chr7:66493706~66495474:+ LUSC cis rs11098499 0.863 rs3822192 ENSG00000250412.1 KLHL2P1 7 8.7e-12 5.99e-09 0.39 0.31 Corneal astigmatism; chr4:119524565 chr4:119334329~119378233:+ LUSC cis rs6142102 0.961 rs1555075 ENSG00000276073.1 RP5-1125A11.7 -7 8.71e-12 5.99e-09 -0.32 -0.31 Skin pigmentation; chr20:34022595 chr20:33985617~33988989:- LUSC cis rs801193 0.569 rs11772819 ENSG00000237310.1 GS1-124K5.4 7 8.72e-12 6e-09 0.32 0.31 Aortic root size; chr7:66752983 chr7:66493706~66495474:+ LUSC cis rs4713118 0.955 rs9468200 ENSG00000219392.1 RP1-265C24.5 -7 8.75e-12 6.02e-09 -0.41 -0.31 Parkinson's disease; chr6:27715284 chr6:28115628~28116551:+ LUSC cis rs4713118 0.955 rs34752872 ENSG00000219392.1 RP1-265C24.5 -7 8.75e-12 6.02e-09 -0.41 -0.31 Parkinson's disease; chr6:27715465 chr6:28115628~28116551:+ LUSC cis rs12439619 0.739 rs4778988 ENSG00000276710.3 CSPG4P8 -7 8.76e-12 6.03e-09 -0.34 -0.31 Intelligence (multi-trait analysis); chr15:82247996 chr15:82459472~82477258:+ LUSC cis rs10129255 0.957 rs8009073 ENSG00000280411.1 IGHV1-69-2 -7 8.76e-12 6.03e-09 -0.22 -0.31 Kawasaki disease; chr14:106777278 chr14:106762092~106762588:- LUSC cis rs2404602 0.647 rs34103231 ENSG00000259422.1 RP11-593F23.1 -7 8.78e-12 6.04e-09 -0.37 -0.31 Blood metabolite levels; chr15:76620349 chr15:76174891~76181486:- LUSC cis rs8062405 0.964 rs62036614 ENSG00000278665.1 RP11-666O2.4 7 8.78e-12 6.04e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28813364 chr16:28599241~28601881:- LUSC cis rs12550612 0.614 rs4268128 ENSG00000253616.4 RP11-875O11.3 7 8.78e-12 6.04e-09 0.41 0.31 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23080343 chr8:23071377~23074488:- LUSC cis rs2404602 0.647 rs11852395 ENSG00000259422.1 RP11-593F23.1 -7 8.79e-12 6.04e-09 -0.37 -0.31 Blood metabolite levels; chr15:76795444 chr15:76174891~76181486:- LUSC cis rs1185460 0.546 rs2508948 ENSG00000271751.1 RP11-110I1.14 7 8.8e-12 6.05e-09 0.39 0.31 Coronary artery disease; chr11:119080932 chr11:119065263~119065677:- LUSC cis rs1865760 0.566 rs9348706 ENSG00000272462.2 U91328.19 -7 8.81e-12 6.06e-09 -0.33 -0.31 Height; chr6:26065253 chr6:25992662~26001775:+ LUSC cis rs9322193 0.607 rs4870078 ENSG00000223701.3 RAET1E-AS1 -7 8.84e-12 6.08e-09 -0.4 -0.31 Lung cancer; chr6:149880676 chr6:149884431~149919508:+ LUSC cis rs6921919 0.583 rs3800328 ENSG00000204709.4 LINC01556 7 8.85e-12 6.08e-09 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28423066 chr6:28943877~28944537:+ LUSC cis rs6921919 0.609 rs67211468 ENSG00000204709.4 LINC01556 7 8.85e-12 6.08e-09 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28424210 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs35560946 ENSG00000204709.4 LINC01556 7 8.85e-12 6.08e-09 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28427660 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs740622 ENSG00000204709.4 LINC01556 7 8.85e-12 6.08e-09 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28430514 chr6:28943877~28944537:+ LUSC cis rs7250849 0.565 rs73052857 ENSG00000273837.1 LLNLR-470E3.1 -7 8.85e-12 6.09e-09 -0.42 -0.31 Blood protein levels; chr19:51661182 chr19:51639478~51639931:- LUSC cis rs1865760 0.534 rs2032444 ENSG00000272462.2 U91328.19 -7 8.86e-12 6.09e-09 -0.36 -0.31 Height; chr6:26046516 chr6:25992662~26001775:+ LUSC cis rs853679 0.607 rs34878803 ENSG00000204709.4 LINC01556 7 8.88e-12 6.1e-09 0.64 0.31 Depression; chr6:28282402 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs34396849 ENSG00000204709.4 LINC01556 7 8.88e-12 6.1e-09 0.64 0.31 Depression; chr6:28283178 chr6:28943877~28944537:+ LUSC cis rs8059260 0.673 rs74985998 ENSG00000274038.1 RP11-66H6.4 -7 8.88e-12 6.1e-09 -0.54 -0.31 Alcohol consumption over the past year; chr16:10967208 chr16:11056556~11057034:+ LUSC cis rs2404602 0.647 rs12439141 ENSG00000259422.1 RP11-593F23.1 -7 8.91e-12 6.12e-09 -0.37 -0.31 Blood metabolite levels; chr15:76803082 chr15:76174891~76181486:- LUSC cis rs950169 0.922 rs11630760 ENSG00000259728.4 LINC00933 7 8.93e-12 6.14e-09 0.4 0.31 Schizophrenia; chr15:84570106 chr15:84570649~84580175:+ LUSC cis rs950169 0.887 rs71395453 ENSG00000259728.4 LINC00933 7 8.93e-12 6.14e-09 0.4 0.31 Schizophrenia; chr15:84570259 chr15:84570649~84580175:+ LUSC cis rs11098499 0.954 rs67265404 ENSG00000250412.1 KLHL2P1 7 8.94e-12 6.14e-09 0.39 0.31 Corneal astigmatism; chr4:119438115 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs71614422 ENSG00000250412.1 KLHL2P1 7 8.94e-12 6.14e-09 0.39 0.31 Corneal astigmatism; chr4:119438185 chr4:119334329~119378233:+ LUSC cis rs6142102 0.517 rs6142050 ENSG00000276073.1 RP5-1125A11.7 -7 8.94e-12 6.14e-09 -0.3 -0.31 Skin pigmentation; chr20:33939322 chr20:33985617~33988989:- LUSC cis rs113835537 0.735 rs519380 ENSG00000255517.5 CTD-3074O7.5 -7 8.96e-12 6.15e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66641938 chr11:66473490~66480233:- LUSC cis rs9921338 0.961 rs7206749 ENSG00000263080.1 RP11-485G7.5 7 8.98e-12 6.16e-09 0.36 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11283065 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs55707838 ENSG00000263080.1 RP11-485G7.5 7 8.98e-12 6.16e-09 0.36 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11284218 chr16:11341809~11345211:- LUSC cis rs526231 0.578 rs59323174 ENSG00000175749.11 EIF3KP1 7 8.98e-12 6.17e-09 0.37 0.31 Primary biliary cholangitis; chr5:102932165 chr5:103032376~103033031:+ LUSC cis rs2179367 0.959 rs9322178 ENSG00000231760.4 RP11-350J20.5 7 8.99e-12 6.17e-09 0.4 0.31 Dupuytren's disease; chr6:149372131 chr6:149796151~149826294:- LUSC cis rs131777 0.708 rs131749 ENSG00000205559.3 CHKB-AS1 7 8.99e-12 6.17e-09 0.39 0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586195 chr22:50583026~50583877:+ LUSC cis rs4660456 0.913 rs545218 ENSG00000237899.1 RP4-739H11.3 7 8.99e-12 6.18e-09 0.46 0.31 Platelet count; chr1:40675313 chr1:40669089~40687588:- LUSC cis rs1865760 0.82 rs9348697 ENSG00000272462.2 U91328.19 -7 9.02e-12 6.19e-09 -0.32 -0.31 Height; chr6:25890606 chr6:25992662~26001775:+ LUSC cis rs3750965 1 rs1466222 ENSG00000260895.1 RP11-554A11.7 7 9.02e-12 6.19e-09 0.36 0.31 Hair color; chr11:69065380 chr11:69103493~69109094:+ LUSC cis rs35160687 0.901 rs13020869 ENSG00000273080.1 RP11-301O19.1 7 9.03e-12 6.2e-09 0.3 0.31 Night sleep phenotypes; chr2:86296237 chr2:86195590~86196049:+ LUSC cis rs35160687 0.901 rs12714180 ENSG00000273080.1 RP11-301O19.1 7 9.03e-12 6.2e-09 0.3 0.31 Night sleep phenotypes; chr2:86298200 chr2:86195590~86196049:+ LUSC cis rs801193 0.569 rs2707824 ENSG00000237310.1 GS1-124K5.4 7 9.04e-12 6.2e-09 0.32 0.31 Aortic root size; chr7:66724256 chr7:66493706~66495474:+ LUSC cis rs801193 0.569 rs2659893 ENSG00000237310.1 GS1-124K5.4 7 9.04e-12 6.2e-09 0.32 0.31 Aortic root size; chr7:66735006 chr7:66493706~66495474:+ LUSC cis rs801193 0.569 rs2659892 ENSG00000237310.1 GS1-124K5.4 7 9.04e-12 6.2e-09 0.32 0.31 Aortic root size; chr7:66735318 chr7:66493706~66495474:+ LUSC cis rs801193 0.569 rs2707847 ENSG00000237310.1 GS1-124K5.4 7 9.04e-12 6.2e-09 0.32 0.31 Aortic root size; chr7:66737884 chr7:66493706~66495474:+ LUSC cis rs11098499 0.789 rs10212719 ENSG00000249244.1 RP11-548H18.2 7 9.08e-12 6.23e-09 0.38 0.31 Corneal astigmatism; chr4:119333282 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs17049949 ENSG00000249244.1 RP11-548H18.2 7 9.08e-12 6.23e-09 0.38 0.31 Corneal astigmatism; chr4:119334135 chr4:119391831~119395335:- LUSC cis rs2919917 0.915 rs3899796 ENSG00000254352.1 RP11-578O24.2 7 9.1e-12 6.24e-09 0.39 0.31 Lymphocyte counts; chr8:78655847 chr8:78723796~78724136:- LUSC cis rs801193 0.548 rs2659891 ENSG00000237310.1 GS1-124K5.4 7 9.1e-12 6.24e-09 0.32 0.31 Aortic root size; chr7:66736127 chr7:66493706~66495474:+ LUSC cis rs801193 0.548 rs7805152 ENSG00000237310.1 GS1-124K5.4 7 9.1e-12 6.24e-09 0.32 0.31 Aortic root size; chr7:66744266 chr7:66493706~66495474:+ LUSC cis rs11098499 0.505 rs75122014 ENSG00000250412.1 KLHL2P1 7 9.12e-12 6.26e-09 0.39 0.31 Corneal astigmatism; chr4:119441271 chr4:119334329~119378233:+ LUSC cis rs2739330 0.76 rs1007888 ENSG00000099984.9 GSTT2 -7 9.13e-12 6.26e-09 -0.36 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23980123~23983911:+ LUSC cis rs442309 0.553 rs7088592 ENSG00000238280.1 RP11-436D10.3 -6.99 9.18e-12 6.29e-09 -0.38 -0.31 Vogt-Koyanagi-Harada syndrome; chr10:62721530 chr10:62793562~62805887:- LUSC cis rs9660180 0.967 rs2272908 ENSG00000231050.1 RP1-140A9.1 -6.99 9.2e-12 6.3e-09 -0.3 -0.31 Body mass index; chr1:1790040 chr1:1891471~1892658:+ LUSC cis rs1075265 0.783 rs805450 ENSG00000233266.1 HMGB1P31 6.99 9.2e-12 6.3e-09 0.38 0.31 Chronotype;Morning vs. evening chronotype; chr2:53951772 chr2:54051334~54051760:+ LUSC cis rs13113518 0.783 rs2171618 ENSG00000223305.1 RN7SKP30 6.99 9.2e-12 6.31e-09 0.37 0.31 Height; chr4:55564241 chr4:55540502~55540835:- LUSC cis rs9660180 0.967 rs6603802 ENSG00000231050.1 RP1-140A9.1 6.99 9.24e-12 6.33e-09 0.31 0.31 Body mass index; chr1:1881082 chr1:1891471~1892658:+ LUSC cis rs11690935 1 rs6433311 ENSG00000228389.1 AC068039.4 -6.99 9.24e-12 6.33e-09 -0.36 -0.31 Schizophrenia; chr2:171692738 chr2:171773482~171775844:+ LUSC cis rs11690935 1 rs6757773 ENSG00000228389.1 AC068039.4 -6.99 9.24e-12 6.33e-09 -0.36 -0.31 Schizophrenia; chr2:171693120 chr2:171773482~171775844:+ LUSC cis rs11098499 0.908 rs11098527 ENSG00000250412.1 KLHL2P1 6.99 9.25e-12 6.34e-09 0.39 0.31 Corneal astigmatism; chr4:119478751 chr4:119334329~119378233:+ LUSC cis rs6504950 0.83 rs12936860 ENSG00000275710.1 RP11-257O5.4 6.99 9.26e-12 6.35e-09 0.38 0.31 Breast cancer; chr17:54952865 chr17:54964474~54964679:+ LUSC cis rs11157436 0.958 rs3811277 ENSG00000211813.2 TRAV34 6.99 9.27e-12 6.35e-09 0.34 0.31 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22190419 chr14:22207522~22208129:+ LUSC cis rs1865760 0.532 rs1061482 ENSG00000272462.2 U91328.19 -6.99 9.3e-12 6.37e-09 -0.33 -0.31 Height; chr6:26086471 chr6:25992662~26001775:+ LUSC cis rs11098499 0.615 rs59867181 ENSG00000245958.5 RP11-33B1.1 6.99 9.3e-12 6.37e-09 0.3 0.31 Corneal astigmatism; chr4:119635312 chr4:119454791~119552025:+ LUSC cis rs11098499 0.562 rs2389879 ENSG00000245958.5 RP11-33B1.1 6.99 9.3e-12 6.37e-09 0.3 0.31 Corneal astigmatism; chr4:119636529 chr4:119454791~119552025:+ LUSC cis rs6142102 0.812 rs4911375 ENSG00000276073.1 RP5-1125A11.7 -6.99 9.33e-12 6.39e-09 -0.32 -0.31 Skin pigmentation; chr20:33928216 chr20:33985617~33988989:- LUSC cis rs10129255 0.536 rs3944157 ENSG00000211970.3 IGHV4-61 -6.99 9.34e-12 6.39e-09 -0.19 -0.31 Kawasaki disease; chr14:106682286 chr14:106639119~106639657:- LUSC cis rs853679 0.607 rs67340775 ENSG00000204709.4 LINC01556 6.99 9.35e-12 6.4e-09 0.67 0.31 Depression; chr6:28336607 chr6:28943877~28944537:+ LUSC cis rs4950322 0.518 rs55697094 ENSG00000278811.3 LINC00624 6.99 9.35e-12 6.4e-09 0.33 0.31 Protein quantitative trait loci; chr1:147121205 chr1:147258885~147517875:- LUSC cis rs875971 0.516 rs6945322 ENSG00000164669.11 INTS4P1 -6.99 9.37e-12 6.42e-09 -0.33 -0.31 Aortic root size; chr7:65871069 chr7:65141225~65234216:+ LUSC cis rs367615 0.552 rs2416210 ENSG00000249476.1 CTD-2587M2.1 -6.99 9.39e-12 6.43e-09 -0.35 -0.31 Colorectal cancer (SNP x SNP interaction); chr5:109405436 chr5:109237120~109326369:- LUSC cis rs748404 0.697 rs546722 ENSG00000249839.1 AC011330.5 -6.99 9.41e-12 6.44e-09 -0.41 -0.31 Lung cancer; chr15:43288621 chr15:43663654~43684339:- LUSC cis rs4423214 0.592 rs10898193 ENSG00000254682.1 RP11-660L16.2 6.99 9.43e-12 6.45e-09 0.49 0.31 Vitamin D levels; chr11:71486037 chr11:71448674~71452157:+ LUSC cis rs2404602 0.647 rs11855296 ENSG00000259422.1 RP11-593F23.1 -6.99 9.43e-12 6.45e-09 -0.37 -0.31 Blood metabolite levels; chr15:76800621 chr15:76174891~76181486:- LUSC cis rs9309473 1 rs1114380 ENSG00000163016.8 ALMS1P 6.99 9.44e-12 6.46e-09 0.37 0.31 Metabolite levels; chr2:73577581 chr2:73644919~73685576:+ LUSC cis rs11603023 0.805 rs687190 ENSG00000255422.1 AP002954.4 -6.99 9.45e-12 6.47e-09 -0.35 -0.31 Cholesterol, total; chr11:118671674 chr11:118704607~118750263:+ LUSC cis rs11098499 0.954 rs11098526 ENSG00000250412.1 KLHL2P1 6.99 9.46e-12 6.47e-09 0.39 0.31 Corneal astigmatism; chr4:119469204 chr4:119334329~119378233:+ LUSC cis rs10740039 1 rs10761543 ENSG00000254271.1 RP11-131N11.4 6.99 9.49e-12 6.49e-09 0.42 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60655633 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs10761544 ENSG00000254271.1 RP11-131N11.4 6.99 9.49e-12 6.49e-09 0.42 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60655647 chr10:60734342~60741828:+ LUSC cis rs10740039 0.804 rs7900848 ENSG00000254271.1 RP11-131N11.4 6.99 9.49e-12 6.49e-09 0.42 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60655893 chr10:60734342~60741828:+ LUSC cis rs10740039 0.842 rs10821819 ENSG00000254271.1 RP11-131N11.4 6.99 9.49e-12 6.49e-09 0.42 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60658857 chr10:60734342~60741828:+ LUSC cis rs4718428 0.924 rs6971897 ENSG00000226824.5 RP4-756H11.3 -6.99 9.5e-12 6.5e-09 -0.37 -0.31 Corneal structure; chr7:66947787 chr7:66654538~66669855:+ LUSC cis rs8062405 1 rs62036616 ENSG00000278665.1 RP11-666O2.4 6.99 9.51e-12 6.51e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814986 chr16:28599241~28601881:- LUSC cis rs8062405 0.789 rs2106480 ENSG00000278665.1 RP11-666O2.4 6.99 9.51e-12 6.51e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28526650 chr16:28599241~28601881:- LUSC cis rs2286503 0.966 rs6949233 ENSG00000228649.7 AC005682.5 6.99 9.53e-12 6.52e-09 0.33 0.31 Fibrinogen; chr7:22818572 chr7:22854178~22861579:+ LUSC cis rs801193 0.569 rs35070132 ENSG00000222364.1 RNU6-96P -6.99 9.55e-12 6.53e-09 -0.37 -0.31 Aortic root size; chr7:66773096 chr7:66395191~66395286:+ LUSC cis rs35955747 0.778 rs9609263 ENSG00000236132.1 CTA-440B3.1 6.99 9.58e-12 6.55e-09 0.37 0.31 Neutrophil count;Sum basophil neutrophil counts; chr22:31349288 chr22:31816379~31817491:- LUSC cis rs9506514 0.509 rs9509294 ENSG00000222726.1 RNU2-7P -6.99 9.59e-12 6.56e-09 -0.34 -0.31 Coronary artery calcification; chr13:20600506 chr13:20612161~20612338:+ LUSC cis rs9549367 0.826 rs9549710 ENSG00000269125.1 RP11-98F14.11 -6.99 9.61e-12 6.57e-09 -0.38 -0.31 Platelet distribution width; chr13:113243750 chr13:113165002~113165183:- LUSC cis rs113835537 0.559 rs11227498 ENSG00000255517.5 CTD-3074O7.5 -6.99 9.69e-12 6.62e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66502243 chr11:66473490~66480233:- LUSC cis rs867371 0.502 rs28610286 ENSG00000276710.3 CSPG4P8 -6.99 9.69e-12 6.62e-09 -0.31 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82233314 chr15:82459472~82477258:+ LUSC cis rs10463554 0.857 rs3776871 ENSG00000175749.11 EIF3KP1 6.99 9.72e-12 6.64e-09 0.36 0.31 Parkinson's disease; chr5:102956507 chr5:103032376~103033031:+ LUSC cis rs7772486 0.719 rs2206141 ENSG00000235652.6 RP11-545I5.3 -6.99 9.76e-12 6.67e-09 -0.31 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145765056 chr6:145799409~145886585:+ LUSC cis rs7772486 0.654 rs6906402 ENSG00000235652.6 RP11-545I5.3 -6.99 9.76e-12 6.67e-09 -0.31 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145768171 chr6:145799409~145886585:+ LUSC cis rs8059260 0.736 rs7192171 ENSG00000274038.1 RP11-66H6.4 -6.99 9.77e-12 6.67e-09 -0.54 -0.31 Alcohol consumption over the past year; chr16:10955262 chr16:11056556~11057034:+ LUSC cis rs7772486 0.754 rs12199362 ENSG00000235652.6 RP11-545I5.3 6.98 9.84e-12 6.72e-09 0.3 0.31 Lobe attachment (rater-scored or self-reported); chr6:145797089 chr6:145799409~145886585:+ LUSC cis rs875971 0.522 rs4502988 ENSG00000164669.11 INTS4P1 -6.98 9.87e-12 6.74e-09 -0.33 -0.31 Aortic root size; chr7:65832759 chr7:65141225~65234216:+ LUSC cis rs11098499 0.566 rs17051356 ENSG00000245958.5 RP11-33B1.1 -6.98 9.91e-12 6.76e-09 -0.32 -0.31 Corneal astigmatism; chr4:119664153 chr4:119454791~119552025:+ LUSC cis rs7739264 0.544 rs6456266 ENSG00000227116.1 RP3-471C18.1 -6.98 9.92e-12 6.77e-09 -0.35 -0.31 Endometriosis; chr6:19791053 chr6:19730427~19734567:- LUSC cis rs6570726 0.557 rs403956 ENSG00000235652.6 RP11-545I5.3 6.98 9.96e-12 6.8e-09 0.32 0.31 Lobe attachment (rater-scored or self-reported); chr6:145508820 chr6:145799409~145886585:+ LUSC cis rs10754283 0.967 rs7552896 ENSG00000231613.1 RP5-943J3.1 6.98 1e-11 6.82e-09 0.35 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89637635 chr1:89788914~89790492:+ LUSC cis rs11098499 1 rs6849889 ENSG00000249244.1 RP11-548H18.2 6.98 1e-11 6.82e-09 0.4 0.31 Corneal astigmatism; chr4:119265193 chr4:119391831~119395335:- LUSC cis rs6921919 0.583 rs6908137 ENSG00000204709.4 LINC01556 6.98 1e-11 6.83e-09 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28402616 chr6:28943877~28944537:+ LUSC cis rs11098499 0.789 rs1980024 ENSG00000249244.1 RP11-548H18.2 6.98 1e-11 6.84e-09 0.38 0.31 Corneal astigmatism; chr4:119331892 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs34425882 ENSG00000249244.1 RP11-548H18.2 6.98 1e-11 6.84e-09 0.38 0.31 Corneal astigmatism; chr4:119332022 chr4:119391831~119395335:- LUSC cis rs2980439 0.818 rs2945249 ENSG00000173295.6 FAM86B3P 6.98 1e-11 6.84e-09 0.35 0.31 Neuroticism; chr8:8237204 chr8:8228595~8244865:+ LUSC cis rs8177876 0.749 rs2549896 ENSG00000261838.4 RP11-303E16.6 -6.98 1.01e-11 6.86e-09 -0.63 -0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81054334 chr16:81069854~81076598:+ LUSC cis rs10129255 0.957 rs8005468 ENSG00000280411.1 IGHV1-69-2 -6.98 1.01e-11 6.88e-09 -0.21 -0.31 Kawasaki disease; chr14:106686431 chr14:106762092~106762588:- LUSC cis rs9309473 0.948 rs11884776 ENSG00000163016.8 ALMS1P 6.98 1.01e-11 6.88e-09 0.36 0.31 Metabolite levels; chr2:73519796 chr2:73644919~73685576:+ LUSC cis rs11089937 0.626 rs2213161 ENSG00000211639.2 IGLV4-60 6.98 1.01e-11 6.88e-09 0.36 0.31 Periodontitis (PAL4Q3); chr22:22143005 chr22:22162199~22162681:+ LUSC cis rs11098499 0.865 rs10213221 ENSG00000249244.1 RP11-548H18.2 6.98 1.01e-11 6.88e-09 0.38 0.31 Corneal astigmatism; chr4:119334771 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs17009122 ENSG00000250412.1 KLHL2P1 6.98 1.01e-11 6.9e-09 0.39 0.31 Corneal astigmatism; chr4:119441248 chr4:119334329~119378233:+ LUSC cis rs11098499 0.78 rs12504773 ENSG00000250412.1 KLHL2P1 6.98 1.02e-11 6.92e-09 0.39 0.31 Corneal astigmatism; chr4:119640994 chr4:119334329~119378233:+ LUSC cis rs10740039 0.729 rs7091383 ENSG00000254271.1 RP11-131N11.4 6.98 1.02e-11 6.93e-09 0.42 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60676419 chr10:60734342~60741828:+ LUSC cis rs1865760 0.568 rs2032450 ENSG00000272462.2 U91328.19 -6.98 1.02e-11 6.93e-09 -0.33 -0.31 Height; chr6:25992886 chr6:25992662~26001775:+ LUSC cis rs1865760 0.713 rs2013063 ENSG00000272462.2 U91328.19 -6.98 1.02e-11 6.93e-09 -0.33 -0.31 Height; chr6:25993870 chr6:25992662~26001775:+ LUSC cis rs748404 0.697 rs572959 ENSG00000249839.1 AC011330.5 -6.98 1.02e-11 6.94e-09 -0.4 -0.31 Lung cancer; chr15:43258304 chr15:43663654~43684339:- LUSC cis rs7772486 0.754 rs2064185 ENSG00000235652.6 RP11-545I5.3 -6.98 1.02e-11 6.95e-09 -0.31 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145745678 chr6:145799409~145886585:+ LUSC cis rs11098499 0.954 rs13107475 ENSG00000250412.1 KLHL2P1 6.98 1.02e-11 6.98e-09 0.39 0.31 Corneal astigmatism; chr4:119471856 chr4:119334329~119378233:+ LUSC cis rs8177376 1 rs534804 ENSG00000254905.1 RP11-712L6.7 6.98 1.03e-11 7e-09 0.41 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126205873 chr11:126292922~126294254:- LUSC cis rs9322193 0.923 rs4869750 ENSG00000268592.3 RAET1E-AS1 6.98 1.03e-11 7.01e-09 0.38 0.31 Lung cancer; chr6:149855996 chr6:149863494~149919507:+ LUSC cis rs113835537 0.597 rs2305534 ENSG00000255517.5 CTD-3074O7.5 -6.98 1.03e-11 7.02e-09 -0.35 -0.31 Airway imaging phenotypes; chr11:66545732 chr11:66473490~66480233:- LUSC cis rs8177876 0.822 rs28672349 ENSG00000261838.4 RP11-303E16.6 6.98 1.03e-11 7.02e-09 0.7 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080768 chr16:81069854~81076598:+ LUSC cis rs950169 0.922 rs11631096 ENSG00000225151.9 GOLGA2P7 -6.98 1.03e-11 7.04e-09 -0.43 -0.31 Schizophrenia; chr15:84557698 chr15:84199311~84230136:- LUSC cis rs113835537 0.529 rs11821155 ENSG00000255517.5 CTD-3074O7.5 6.98 1.03e-11 7.05e-09 0.36 0.31 Airway imaging phenotypes; chr11:66478866 chr11:66473490~66480233:- LUSC cis rs875971 0.522 rs4718285 ENSG00000164669.11 INTS4P1 -6.98 1.04e-11 7.05e-09 -0.33 -0.31 Aortic root size; chr7:65827018 chr7:65141225~65234216:+ LUSC cis rs35160687 0.901 rs35281683 ENSG00000273080.1 RP11-301O19.1 6.98 1.04e-11 7.05e-09 0.3 0.31 Night sleep phenotypes; chr2:86299249 chr2:86195590~86196049:+ LUSC cis rs2404602 0.647 rs11072625 ENSG00000259422.1 RP11-593F23.1 6.98 1.04e-11 7.05e-09 0.37 0.31 Blood metabolite levels; chr15:76792643 chr15:76174891~76181486:- LUSC cis rs748404 0.697 rs1095389 ENSG00000249839.1 AC011330.5 -6.98 1.04e-11 7.06e-09 -0.41 -0.31 Lung cancer; chr15:43274473 chr15:43663654~43684339:- LUSC cis rs4713118 0.868 rs742047 ENSG00000219392.1 RP1-265C24.5 -6.98 1.04e-11 7.06e-09 -0.43 -0.31 Parkinson's disease; chr6:27771601 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs149946 ENSG00000204709.4 LINC01556 -6.98 1.04e-11 7.07e-09 -0.43 -0.31 Parkinson's disease; chr6:28002253 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393896 ENSG00000204709.4 LINC01556 6.98 1.04e-11 7.07e-09 0.43 0.31 Depression; chr6:28159925 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393897 ENSG00000204709.4 LINC01556 6.98 1.04e-11 7.07e-09 0.43 0.31 Depression; chr6:28159932 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs9461459 ENSG00000204709.4 LINC01556 6.98 1.04e-11 7.09e-09 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28394139 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs28360638 ENSG00000204709.4 LINC01556 6.98 1.04e-11 7.09e-09 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28394552 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs9468368 ENSG00000204709.4 LINC01556 6.98 1.04e-11 7.09e-09 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28397172 chr6:28943877~28944537:+ LUSC cis rs10740039 0.804 rs1372714 ENSG00000254271.1 RP11-131N11.4 6.97 1.05e-11 7.12e-09 0.42 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60686640 chr10:60734342~60741828:+ LUSC cis rs11098499 0.954 rs9993199 ENSG00000250412.1 KLHL2P1 -6.97 1.05e-11 7.13e-09 -0.38 -0.31 Corneal astigmatism; chr4:119471718 chr4:119334329~119378233:+ LUSC cis rs7772486 0.754 rs857881 ENSG00000235652.6 RP11-545I5.3 -6.97 1.05e-11 7.13e-09 -0.31 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145649657 chr6:145799409~145886585:+ LUSC cis rs4713118 0.513 rs149878 ENSG00000219392.1 RP1-265C24.5 -6.97 1.05e-11 7.15e-09 -0.39 -0.31 Parkinson's disease; chr6:27910960 chr6:28115628~28116551:+ LUSC cis rs2337406 0.925 rs873534 ENSG00000274576.2 IGHV2-70 -6.97 1.05e-11 7.15e-09 -0.35 -0.31 Alzheimer's disease (late onset); chr14:106667423 chr14:106770577~106771020:- LUSC cis rs2134046 0.587 rs11854289 ENSG00000278603.1 RP13-608F4.5 -6.97 1.05e-11 7.15e-09 -0.36 -0.31 Cognitive ability; chr15:82266461 chr15:82472203~82472426:+ LUSC cis rs12550612 0.561 rs11784599 ENSG00000253616.4 RP11-875O11.3 6.97 1.05e-11 7.15e-09 0.43 0.31 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23074609 chr8:23071377~23074488:- LUSC cis rs7772486 0.686 rs1292334 ENSG00000235652.6 RP11-545I5.3 6.97 1.06e-11 7.18e-09 0.3 0.31 Lobe attachment (rater-scored or self-reported); chr6:145647152 chr6:145799409~145886585:+ LUSC cis rs11098499 0.738 rs34566984 ENSG00000250412.1 KLHL2P1 6.97 1.06e-11 7.19e-09 0.39 0.31 Corneal astigmatism; chr4:119440115 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs9685777 ENSG00000250412.1 KLHL2P1 6.97 1.06e-11 7.19e-09 0.39 0.31 Corneal astigmatism; chr4:119444810 chr4:119334329~119378233:+ LUSC cis rs10246939 0.579 rs9640205 ENSG00000228775.6 WEE2-AS1 6.97 1.06e-11 7.21e-09 0.36 0.31 Bitter taste perception; chr7:141844400 chr7:141704338~141738346:- LUSC cis rs11157436 0.915 rs11622938 ENSG00000211813.2 TRAV34 6.97 1.07e-11 7.26e-09 0.35 0.31 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22183456 chr14:22207522~22208129:+ LUSC cis rs2404602 0.647 rs2404604 ENSG00000259422.1 RP11-593F23.1 -6.97 1.07e-11 7.28e-09 -0.38 -0.31 Blood metabolite levels; chr15:76698764 chr15:76174891~76181486:- LUSC cis rs7591472 1 rs7591472 ENSG00000183308.6 AC005037.3 6.97 1.07e-11 7.29e-09 0.5 0.31 Triptolide cytotoxicity; chr2:201025028 chr2:200963263~201009102:+ LUSC cis rs8040855 0.825 rs3964197 ENSG00000259295.5 CSPG4P12 6.97 1.07e-11 7.29e-09 0.37 0.31 Bulimia nervosa; chr15:85178681 chr15:85191438~85213905:+ LUSC cis rs61160187 0.582 rs726824 ENSG00000215032.2 GNL3LP1 6.97 1.07e-11 7.3e-09 0.39 0.31 Educational attainment (years of education);Educational attainment (college completion); chr5:61036989 chr5:60891935~60893577:- LUSC cis rs11098499 0.908 rs9995234 ENSG00000250412.1 KLHL2P1 6.97 1.08e-11 7.31e-09 0.4 0.31 Corneal astigmatism; chr4:119400672 chr4:119334329~119378233:+ LUSC cis rs2564921 0.57 rs3821831 ENSG00000242142.1 SERBP1P3 -6.97 1.08e-11 7.32e-09 -0.34 -0.31 Height; chr3:52819385 chr3:53064283~53065091:- LUSC cis rs11098499 0.874 rs13139045 ENSG00000249244.1 RP11-548H18.2 6.97 1.08e-11 7.32e-09 0.38 0.31 Corneal astigmatism; chr4:119247433 chr4:119391831~119395335:- LUSC cis rs853679 0.517 rs4713145 ENSG00000204709.4 LINC01556 6.97 1.08e-11 7.32e-09 0.43 0.31 Depression; chr6:28139049 chr6:28943877~28944537:+ LUSC cis rs6142102 0.847 rs4911413 ENSG00000276073.1 RP5-1125A11.7 -6.97 1.08e-11 7.32e-09 -0.32 -0.31 Skin pigmentation; chr20:34133969 chr20:33985617~33988989:- LUSC cis rs2903698 0.565 rs13103482 ENSG00000250735.4 RP11-567N4.3 6.97 1.08e-11 7.32e-09 0.34 0.31 Prion diseases; chr4:75518973 chr4:75401195~75423023:+ LUSC cis rs4713118 0.869 rs9468214 ENSG00000219392.1 RP1-265C24.5 -6.97 1.08e-11 7.33e-09 -0.39 -0.31 Parkinson's disease; chr6:27745520 chr6:28115628~28116551:+ LUSC cis rs2404602 0.672 rs35374222 ENSG00000259422.1 RP11-593F23.1 -6.97 1.08e-11 7.34e-09 -0.37 -0.31 Blood metabolite levels; chr15:76779053 chr15:76174891~76181486:- LUSC cis rs10740039 0.883 rs2393676 ENSG00000254271.1 RP11-131N11.4 6.97 1.08e-11 7.34e-09 0.42 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60630500 chr10:60734342~60741828:+ LUSC cis rs6125961 0.629 rs6125971 ENSG00000224397.4 LINC01272 6.97 1.08e-11 7.34e-09 0.32 0.31 Granulocyte percentage of myeloid white cells;Monocyte count; chr20:50299229 chr20:50267486~50279795:+ LUSC cis rs113835537 0.529 rs7950790 ENSG00000255517.5 CTD-3074O7.5 -6.97 1.08e-11 7.36e-09 -0.35 -0.31 Airway imaging phenotypes; chr11:66490582 chr11:66473490~66480233:- LUSC cis rs11157436 1 rs75648426 ENSG00000211813.2 TRAV34 6.97 1.09e-11 7.38e-09 0.35 0.31 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22184044 chr14:22207522~22208129:+ LUSC cis rs12554020 0.786 rs79469056 ENSG00000227603.1 RP11-165J3.6 6.97 1.09e-11 7.4e-09 0.46 0.31 Schizophrenia; chr9:93453807 chr9:93435332~93437121:- LUSC cis rs7621025 0.5 rs16844241 ENSG00000239213.4 NCK1-AS1 -6.97 1.09e-11 7.4e-09 -0.39 -0.31 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136916329 chr3:136841726~136862054:- LUSC cis rs2282300 0.956 rs1222212 ENSG00000254532.1 RP11-624D11.2 6.97 1.09e-11 7.41e-09 0.42 0.31 Morning vs. evening chronotype; chr11:30353096 chr11:30044058~30084343:- LUSC cis rs5742933 0.817 rs6738042 ENSG00000253559.1 OSGEPL1-AS1 6.97 1.09e-11 7.41e-09 0.37 0.31 Ferritin levels; chr2:189776958 chr2:189762704~189765556:+ LUSC cis rs9921338 0.923 rs7186455 ENSG00000263080.1 RP11-485G7.5 6.97 1.09e-11 7.42e-09 0.36 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11333891 chr16:11341809~11345211:- LUSC cis rs1075265 0.73 rs2111868 ENSG00000233266.1 HMGB1P31 6.97 1.09e-11 7.42e-09 0.38 0.31 Chronotype;Morning vs. evening chronotype; chr2:53958916 chr2:54051334~54051760:+ LUSC cis rs2179367 0.509 rs9485390 ENSG00000231760.4 RP11-350J20.5 6.97 1.09e-11 7.43e-09 0.42 0.31 Dupuytren's disease; chr6:149421004 chr6:149796151~149826294:- LUSC cis rs11098499 0.739 rs9884728 ENSG00000249244.1 RP11-548H18.2 -6.97 1.1e-11 7.45e-09 -0.38 -0.31 Corneal astigmatism; chr4:119205924 chr4:119391831~119395335:- LUSC cis rs11098499 0.739 rs6534130 ENSG00000249244.1 RP11-548H18.2 -6.97 1.1e-11 7.45e-09 -0.38 -0.31 Corneal astigmatism; chr4:119210184 chr4:119391831~119395335:- LUSC cis rs9545047 0.716 rs9545053 ENSG00000227676.3 LINC01068 6.97 1.1e-11 7.45e-09 0.37 0.31 Schizophrenia; chr13:79296079 chr13:79566727~79571436:+ LUSC cis rs8072100 0.967 rs8074149 ENSG00000228782.6 CTD-2026D20.3 -6.97 1.1e-11 7.46e-09 -0.29 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47506009 chr17:47450568~47492492:- LUSC cis rs9487094 0.677 rs13203636 ENSG00000260273.1 RP11-425D10.10 6.97 1.1e-11 7.46e-09 0.42 0.31 Height; chr6:109741085 chr6:109382795~109383666:+ LUSC cis rs13113518 0.812 rs2035691 ENSG00000223305.1 RN7SKP30 6.97 1.1e-11 7.46e-09 0.38 0.31 Height; chr4:55529786 chr4:55540502~55540835:- LUSC cis rs35160687 0.814 rs6547673 ENSG00000273080.1 RP11-301O19.1 6.97 1.1e-11 7.48e-09 0.29 0.31 Night sleep phenotypes; chr2:86301815 chr2:86195590~86196049:+ LUSC cis rs9532669 0.926 rs8002809 ENSG00000176268.5 CYCSP34 6.97 1.1e-11 7.49e-09 0.31 0.31 Cervical cancer; chr13:40872769 chr13:40863599~40863902:- LUSC cis rs9532669 0.929 rs7982421 ENSG00000176268.5 CYCSP34 6.97 1.1e-11 7.49e-09 0.31 0.31 Cervical cancer; chr13:40872776 chr13:40863599~40863902:- LUSC cis rs1865760 0.566 rs10807006 ENSG00000272462.2 U91328.19 -6.97 1.11e-11 7.5e-09 -0.33 -0.31 Height; chr6:26048524 chr6:25992662~26001775:+ LUSC cis rs1865760 0.566 rs7772312 ENSG00000272462.2 U91328.19 -6.97 1.11e-11 7.5e-09 -0.33 -0.31 Height; chr6:26049388 chr6:25992662~26001775:+ LUSC cis rs1865760 0.508 rs9379820 ENSG00000272462.2 U91328.19 -6.97 1.11e-11 7.5e-09 -0.33 -0.31 Height; chr6:26049696 chr6:25992662~26001775:+ LUSC cis rs875971 0.545 rs313828 ENSG00000164669.11 INTS4P1 6.97 1.11e-11 7.5e-09 0.38 0.31 Aortic root size; chr7:66087627 chr7:65141225~65234216:+ LUSC cis rs875971 0.571 rs160647 ENSG00000164669.11 INTS4P1 6.97 1.11e-11 7.5e-09 0.38 0.31 Aortic root size; chr7:66089365 chr7:65141225~65234216:+ LUSC cis rs875971 0.52 rs160645 ENSG00000164669.11 INTS4P1 6.97 1.11e-11 7.5e-09 0.38 0.31 Aortic root size; chr7:66091320 chr7:65141225~65234216:+ LUSC cis rs875971 0.789 rs28815324 ENSG00000164669.11 INTS4P1 6.97 1.11e-11 7.5e-09 0.38 0.31 Aortic root size; chr7:66100789 chr7:65141225~65234216:+ LUSC cis rs11098499 0.863 rs1155576 ENSG00000250412.1 KLHL2P1 6.97 1.11e-11 7.51e-09 0.39 0.31 Corneal astigmatism; chr4:119529004 chr4:119334329~119378233:+ LUSC cis rs11089937 0.667 rs9622981 ENSG00000211639.2 IGLV4-60 6.96 1.11e-11 7.55e-09 0.35 0.31 Periodontitis (PAL4Q3); chr22:22150100 chr22:22162199~22162681:+ LUSC cis rs17711722 0.64 rs13237956 ENSG00000164669.11 INTS4P1 -6.96 1.12e-11 7.56e-09 -0.33 -0.31 Calcium levels; chr7:65853042 chr7:65141225~65234216:+ LUSC cis rs1075265 0.783 rs805424 ENSG00000233266.1 HMGB1P31 6.96 1.12e-11 7.59e-09 0.38 0.31 Chronotype;Morning vs. evening chronotype; chr2:53901098 chr2:54051334~54051760:+ LUSC cis rs1865760 0.566 rs2032443 ENSG00000272462.2 U91328.19 -6.96 1.12e-11 7.59e-09 -0.33 -0.31 Height; chr6:26046574 chr6:25992662~26001775:+ LUSC cis rs11098499 0.909 rs1809406 ENSG00000250412.1 KLHL2P1 6.96 1.12e-11 7.6e-09 0.38 0.31 Corneal astigmatism; chr4:119455967 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs9994810 ENSG00000250412.1 KLHL2P1 6.96 1.12e-11 7.6e-09 0.38 0.31 Corneal astigmatism; chr4:119460435 chr4:119334329~119378233:+ LUSC cis rs11098499 0.697 rs10020027 ENSG00000250412.1 KLHL2P1 6.96 1.12e-11 7.6e-09 0.38 0.31 Corneal astigmatism; chr4:119460724 chr4:119334329~119378233:+ LUSC cis rs11098499 0.779 rs7356491 ENSG00000250412.1 KLHL2P1 6.96 1.12e-11 7.6e-09 0.38 0.31 Corneal astigmatism; chr4:119460819 chr4:119334329~119378233:+ LUSC cis rs673078 0.607 rs7304342 ENSG00000275759.1 RP11-131L12.3 -6.96 1.12e-11 7.61e-09 -0.43 -0.31 Glucose homeostasis traits; chr12:118390166 chr12:118428281~118428870:+ LUSC cis rs673078 0.615 rs61943397 ENSG00000275759.1 RP11-131L12.3 -6.96 1.12e-11 7.61e-09 -0.43 -0.31 Glucose homeostasis traits; chr12:118390996 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943398 ENSG00000275759.1 RP11-131L12.3 -6.96 1.12e-11 7.61e-09 -0.43 -0.31 Glucose homeostasis traits; chr12:118393280 chr12:118428281~118428870:+ LUSC cis rs9309473 1 rs7564890 ENSG00000163016.8 ALMS1P 6.96 1.12e-11 7.61e-09 0.37 0.31 Metabolite levels; chr2:73414725 chr2:73644919~73685576:+ LUSC cis rs2404602 0.647 rs35710279 ENSG00000259422.1 RP11-593F23.1 -6.96 1.12e-11 7.61e-09 -0.37 -0.31 Blood metabolite levels; chr15:76789893 chr15:76174891~76181486:- LUSC cis rs9921338 0.961 rs77552156 ENSG00000263080.1 RP11-485G7.5 6.96 1.13e-11 7.64e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11332542 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs4781069 ENSG00000263080.1 RP11-485G7.5 6.96 1.13e-11 7.64e-09 0.37 0.31 Vein graft stenosis in coronary artery bypass grafting; chr16:11334905 chr16:11341809~11345211:- LUSC cis rs875971 1 rs709597 ENSG00000237310.1 GS1-124K5.4 -6.96 1.13e-11 7.64e-09 -0.31 -0.31 Aortic root size; chr7:66360996 chr7:66493706~66495474:+ LUSC cis rs950169 0.686 rs12906474 ENSG00000225151.9 GOLGA2P7 -6.96 1.13e-11 7.65e-09 -0.42 -0.31 Schizophrenia; chr15:84566006 chr15:84199311~84230136:- LUSC cis rs950169 0.81 rs2879976 ENSG00000225151.9 GOLGA2P7 -6.96 1.13e-11 7.65e-09 -0.42 -0.31 Schizophrenia; chr15:84566347 chr15:84199311~84230136:- LUSC cis rs5742933 0.681 rs4525728 ENSG00000253559.1 OSGEPL1-AS1 6.96 1.13e-11 7.65e-09 0.37 0.31 Ferritin levels; chr2:189780324 chr2:189762704~189765556:+ LUSC cis rs9549367 0.789 rs3764125 ENSG00000269125.1 RP11-98F14.11 6.96 1.13e-11 7.66e-09 0.38 0.31 Platelet distribution width; chr13:113243334 chr13:113165002~113165183:- LUSC cis rs2412819 0.545 rs3862143 ENSG00000249839.1 AC011330.5 6.96 1.13e-11 7.66e-09 0.47 0.31 Lung cancer; chr15:43779282 chr15:43663654~43684339:- LUSC cis rs6772849 0.805 rs61159406 ENSG00000242551.2 POU5F1P6 -6.96 1.13e-11 7.67e-09 -0.34 -0.31 Monocyte percentage of white cells;Monocyte count; chr3:128617166 chr3:128674735~128677005:- LUSC cis rs6772849 0.805 rs13325747 ENSG00000242551.2 POU5F1P6 -6.96 1.13e-11 7.67e-09 -0.34 -0.31 Monocyte percentage of white cells;Monocyte count; chr3:128617180 chr3:128674735~128677005:- LUSC cis rs881375 1 rs1953126 ENSG00000226752.6 PSMD5-AS1 -6.96 1.14e-11 7.69e-09 -0.36 -0.31 Rheumatoid arthritis; chr9:120878222 chr9:120824828~120854385:+ LUSC cis rs3779195 0.86 rs12704986 ENSG00000272950.1 RP11-307C18.1 6.96 1.14e-11 7.69e-09 0.5 0.31 Sex hormone-binding globulin levels; chr7:98357118 chr7:98322853~98323430:+ LUSC cis rs3779195 0.858 rs3779196 ENSG00000272950.1 RP11-307C18.1 6.96 1.14e-11 7.69e-09 0.5 0.31 Sex hormone-binding globulin levels; chr7:98360794 chr7:98322853~98323430:+ LUSC cis rs3779195 0.789 rs6965424 ENSG00000272950.1 RP11-307C18.1 6.96 1.14e-11 7.69e-09 0.5 0.31 Sex hormone-binding globulin levels; chr7:98361813 chr7:98322853~98323430:+ LUSC cis rs6921919 0.583 rs16894060 ENSG00000204709.4 LINC01556 6.96 1.14e-11 7.69e-09 0.39 0.31 Autism spectrum disorder or schizophrenia; chr6:28394694 chr6:28943877~28944537:+ LUSC cis rs7772486 0.754 rs1415747 ENSG00000235652.6 RP11-545I5.3 6.96 1.14e-11 7.71e-09 0.31 0.31 Lobe attachment (rater-scored or self-reported); chr6:145756113 chr6:145799409~145886585:+ LUSC cis rs7487637 0.566 rs875023 ENSG00000276691.1 RP5-1057I20.5 -6.96 1.14e-11 7.72e-09 -0.36 -0.31 Mononucleosis; chr12:47800652 chr12:47788426~47788971:+ LUSC cis rs761746 0.577 rs5998136 ENSG00000236132.1 CTA-440B3.1 -6.96 1.14e-11 7.73e-09 -0.42 -0.31 Intelligence; chr22:31828687 chr22:31816379~31817491:- LUSC cis rs17270561 1 rs79867288 ENSG00000272462.2 U91328.19 -6.96 1.14e-11 7.74e-09 -0.42 -0.31 Iron status biomarkers; chr6:25828188 chr6:25992662~26001775:+ LUSC cis rs8040855 0.965 rs6496766 ENSG00000259295.5 CSPG4P12 -6.96 1.14e-11 7.75e-09 -0.36 -0.31 Bulimia nervosa; chr15:85159144 chr15:85191438~85213905:+ LUSC cis rs8040855 1 rs6496768 ENSG00000259295.5 CSPG4P12 -6.96 1.14e-11 7.75e-09 -0.36 -0.31 Bulimia nervosa; chr15:85159701 chr15:85191438~85213905:+ LUSC cis rs8031584 0.678 rs798086 ENSG00000260382.1 RP11-540B6.2 -6.96 1.14e-11 7.75e-09 -0.41 -0.31 Huntington's disease progression; chr15:30837008 chr15:30882267~30883231:- LUSC cis rs748404 0.666 rs7176923 ENSG00000249839.1 AC011330.5 -6.96 1.15e-11 7.76e-09 -0.54 -0.31 Lung cancer; chr15:43317679 chr15:43663654~43684339:- LUSC cis rs3096299 0.869 rs748941 ENSG00000274627.1 RP11-104N10.2 6.96 1.15e-11 7.77e-09 0.28 0.31 Multiple myeloma (IgH translocation); chr16:89374346 chr16:89516797~89522217:+ LUSC cis rs10129255 0.957 rs10140904 ENSG00000280411.1 IGHV1-69-2 -6.96 1.16e-11 7.86e-09 -0.21 -0.31 Kawasaki disease; chr14:106776558 chr14:106762092~106762588:- LUSC cis rs8072100 0.871 rs7206971 ENSG00000228782.6 CTD-2026D20.3 -6.96 1.16e-11 7.87e-09 -0.29 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47347749 chr17:47450568~47492492:- LUSC cis rs11098499 0.863 rs10013305 ENSG00000250412.1 KLHL2P1 6.96 1.16e-11 7.88e-09 0.39 0.31 Corneal astigmatism; chr4:119529269 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs3775849 ENSG00000250412.1 KLHL2P1 6.96 1.16e-11 7.88e-09 0.39 0.31 Corneal astigmatism; chr4:119529753 chr4:119334329~119378233:+ LUSC cis rs11098499 0.818 rs7688802 ENSG00000250412.1 KLHL2P1 6.96 1.16e-11 7.88e-09 0.39 0.31 Corneal astigmatism; chr4:119530513 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs7695620 ENSG00000250412.1 KLHL2P1 6.96 1.16e-11 7.88e-09 0.39 0.31 Corneal astigmatism; chr4:119531621 chr4:119334329~119378233:+ LUSC cis rs11098499 0.821 rs3775852 ENSG00000250412.1 KLHL2P1 6.96 1.16e-11 7.88e-09 0.39 0.31 Corneal astigmatism; chr4:119533401 chr4:119334329~119378233:+ LUSC cis rs11098499 0.82 rs6534140 ENSG00000250412.1 KLHL2P1 6.96 1.16e-11 7.88e-09 0.39 0.31 Corneal astigmatism; chr4:119534156 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs7657849 ENSG00000250412.1 KLHL2P1 6.96 1.16e-11 7.88e-09 0.39 0.31 Corneal astigmatism; chr4:119534339 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs10034450 ENSG00000250412.1 KLHL2P1 6.96 1.16e-11 7.88e-09 0.39 0.31 Corneal astigmatism; chr4:119534494 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs1480939 ENSG00000250412.1 KLHL2P1 6.96 1.16e-11 7.88e-09 0.39 0.31 Corneal astigmatism; chr4:119535772 chr4:119334329~119378233:+ LUSC cis rs9309473 1 rs6745368 ENSG00000163016.8 ALMS1P 6.96 1.17e-11 7.9e-09 0.37 0.31 Metabolite levels; chr2:73582847 chr2:73644919~73685576:+ LUSC cis rs11098499 0.909 rs10020034 ENSG00000250412.1 KLHL2P1 6.96 1.17e-11 7.9e-09 0.39 0.31 Corneal astigmatism; chr4:119373176 chr4:119334329~119378233:+ LUSC cis rs2581828 0.618 rs9828221 ENSG00000242142.1 SERBP1P3 -6.96 1.17e-11 7.9e-09 -0.37 -0.31 Crohn's disease; chr3:53132643 chr3:53064283~53065091:- LUSC cis rs7829975 0.688 rs6995407 ENSG00000253893.2 FAM85B -6.96 1.17e-11 7.92e-09 -0.36 -0.31 Mood instability; chr8:8527137 chr8:8167819~8226614:- LUSC cis rs11976180 1 rs6464574 ENSG00000170356.8 OR2A20P -6.96 1.17e-11 7.93e-09 -0.41 -0.31 Obesity-related traits; chr7:144051164 chr7:144250045~144252957:- LUSC cis rs867371 0.502 rs1846908 ENSG00000276710.3 CSPG4P8 -6.96 1.18e-11 7.95e-09 -0.31 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82230185 chr15:82459472~82477258:+ LUSC cis rs2665103 0.655 rs1501367 ENSG00000276710.3 CSPG4P8 -6.96 1.18e-11 7.95e-09 -0.31 -0.31 Intelligence (multi-trait analysis); chr15:82230475 chr15:82459472~82477258:+ LUSC cis rs1823913 1 rs1454749 ENSG00000280083.1 RP11-317J9.1 -6.96 1.18e-11 7.96e-09 -0.37 -0.31 Obesity-related traits; chr2:191240909 chr2:191154118~191156070:- LUSC cis rs11098499 0.954 rs6848389 ENSG00000250412.1 KLHL2P1 6.96 1.18e-11 7.98e-09 0.38 0.31 Corneal astigmatism; chr4:119481467 chr4:119334329~119378233:+ LUSC cis rs172166 0.694 rs203884 ENSG00000204709.4 LINC01556 6.96 1.18e-11 8e-09 0.4 0.31 Cardiac Troponin-T levels; chr6:28109596 chr6:28943877~28944537:+ LUSC cis rs3779195 0.627 rs6950023 ENSG00000272950.1 RP11-307C18.1 6.96 1.19e-11 8.01e-09 0.51 0.31 Sex hormone-binding globulin levels; chr7:98286323 chr7:98322853~98323430:+ LUSC cis rs3779195 0.627 rs6967728 ENSG00000272950.1 RP11-307C18.1 6.96 1.19e-11 8.01e-09 0.51 0.31 Sex hormone-binding globulin levels; chr7:98286325 chr7:98322853~98323430:+ LUSC cis rs8177876 0.822 rs12443549 ENSG00000261838.4 RP11-303E16.6 -6.96 1.19e-11 8.01e-09 -0.64 -0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81070596 chr16:81069854~81076598:+ LUSC cis rs113835537 0.529 rs2279864 ENSG00000255517.5 CTD-3074O7.5 -6.95 1.19e-11 8.02e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66480373 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs78999944 ENSG00000255517.5 CTD-3074O7.5 -6.95 1.19e-11 8.02e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66483757 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs11550299 ENSG00000255517.5 CTD-3074O7.5 -6.95 1.19e-11 8.02e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66486614 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs4930379 ENSG00000255517.5 CTD-3074O7.5 -6.95 1.19e-11 8.02e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66488203 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs4930183 ENSG00000255517.5 CTD-3074O7.5 -6.95 1.19e-11 8.02e-09 -0.36 -0.31 Airway imaging phenotypes; chr11:66488261 chr11:66473490~66480233:- LUSC cis rs36405 0.5 rs8011906 ENSG00000266869.1 RP6-114E22.1 -6.95 1.19e-11 8.02e-09 -0.37 -0.31 Yang-deficiency constitution; chr14:71893078 chr14:71848606~71908430:+ LUSC cis rs7849270 1 rs7855278 ENSG00000268707.1 RP11-247A12.7 6.95 1.19e-11 8.05e-09 0.37 0.31 Blood metabolite ratios; chr9:129159086 chr9:129170434~129170940:+ LUSC cis rs11098499 0.954 rs2389803 ENSG00000250412.1 KLHL2P1 -6.95 1.19e-11 8.06e-09 -0.39 -0.31 Corneal astigmatism; chr4:119472356 chr4:119334329~119378233:+ LUSC cis rs2404602 0.66 rs11852777 ENSG00000259422.1 RP11-593F23.1 -6.95 1.19e-11 8.06e-09 -0.36 -0.31 Blood metabolite levels; chr15:76637451 chr15:76174891~76181486:- LUSC cis rs10246939 0.579 rs35647444 ENSG00000228775.6 WEE2-AS1 6.95 1.2e-11 8.08e-09 0.36 0.31 Bitter taste perception; chr7:141833957 chr7:141704338~141738346:- LUSC cis rs66887589 0.777 rs2017058 ENSG00000245958.5 RP11-33B1.1 -6.95 1.2e-11 8.09e-09 -0.29 -0.31 Diastolic blood pressure; chr4:119336584 chr4:119454791~119552025:+ LUSC cis rs66887589 0.777 rs1814815 ENSG00000245958.5 RP11-33B1.1 -6.95 1.2e-11 8.09e-09 -0.29 -0.31 Diastolic blood pressure; chr4:119336936 chr4:119454791~119552025:+ LUSC cis rs10246939 0.543 rs9640359 ENSG00000228775.6 WEE2-AS1 6.95 1.2e-11 8.09e-09 0.36 0.31 Bitter taste perception; chr7:141844399 chr7:141704338~141738346:- LUSC cis rs7189233 0.531 rs3929 ENSG00000279344.1 RP11-44F14.7 -6.95 1.2e-11 8.12e-09 -0.27 -0.31 Intelligence (multi-trait analysis); chr16:53490396 chr16:53478957~53481550:- LUSC cis rs9318086 0.712 rs12875437 ENSG00000205861.10 C1QTNF9B-AS1 -6.95 1.21e-11 8.14e-09 -0.38 -0.31 Myopia (pathological); chr13:23879817 chr13:23888889~23897263:+ LUSC cis rs11098499 0.754 rs1849457 ENSG00000249244.1 RP11-548H18.2 6.95 1.21e-11 8.17e-09 0.38 0.31 Corneal astigmatism; chr4:119333200 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs7689729 ENSG00000249244.1 RP11-548H18.2 6.95 1.21e-11 8.18e-09 0.38 0.31 Corneal astigmatism; chr4:119335037 chr4:119391831~119395335:- LUSC cis rs10028773 0.7 rs7690338 ENSG00000249244.1 RP11-548H18.2 6.95 1.21e-11 8.18e-09 0.38 0.31 Educational attainment; chr4:119335313 chr4:119391831~119395335:- LUSC cis rs11098499 0.865 rs3956464 ENSG00000249244.1 RP11-548H18.2 6.95 1.21e-11 8.18e-09 0.38 0.31 Corneal astigmatism; chr4:119335609 chr4:119391831~119395335:- LUSC cis rs11098499 0.619 rs28502463 ENSG00000249244.1 RP11-548H18.2 6.95 1.21e-11 8.18e-09 0.38 0.31 Corneal astigmatism; chr4:119335868 chr4:119391831~119395335:- LUSC cis rs11098499 0.648 rs2002047 ENSG00000249244.1 RP11-548H18.2 6.95 1.21e-11 8.18e-09 0.38 0.31 Corneal astigmatism; chr4:119336073 chr4:119391831~119395335:- LUSC cis rs11098499 0.775 rs2002049 ENSG00000249244.1 RP11-548H18.2 6.95 1.21e-11 8.18e-09 0.38 0.31 Corneal astigmatism; chr4:119336262 chr4:119391831~119395335:- LUSC cis rs10754283 0.967 rs10754285 ENSG00000231613.1 RP5-943J3.1 6.95 1.21e-11 8.18e-09 0.36 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89651028 chr1:89788914~89790492:+ LUSC cis rs4950322 1 rs4950322 ENSG00000278811.3 LINC00624 -6.95 1.22e-11 8.2e-09 -0.37 -0.31 Protein quantitative trait loci; chr1:147383114 chr1:147258885~147517875:- LUSC cis rs875971 0.545 rs73136346 ENSG00000164669.11 INTS4P1 6.95 1.22e-11 8.2e-09 0.37 0.31 Aortic root size; chr7:66101095 chr7:65141225~65234216:+ LUSC cis rs1198872 0.571 rs902130 ENSG00000272275.1 RP11-791G15.2 -6.95 1.22e-11 8.2e-09 -0.43 -0.31 Cardiac Troponin-T levels; chr2:10770843 chr2:10767875~10770058:- LUSC cis rs8031584 0.678 rs8028173 ENSG00000260382.1 RP11-540B6.2 6.95 1.22e-11 8.24e-09 0.42 0.31 Huntington's disease progression; chr15:30863546 chr15:30882267~30883231:- LUSC cis rs8031584 0.706 rs2177670 ENSG00000260382.1 RP11-540B6.2 6.95 1.22e-11 8.24e-09 0.42 0.31 Huntington's disease progression; chr15:30865548 chr15:30882267~30883231:- LUSC cis rs8031584 0.678 rs36047941 ENSG00000260382.1 RP11-540B6.2 6.95 1.22e-11 8.24e-09 0.42 0.31 Huntington's disease progression; chr15:30867032 chr15:30882267~30883231:- LUSC cis rs11098499 0.588 rs6534149 ENSG00000249244.1 RP11-548H18.2 -6.95 1.22e-11 8.25e-09 -0.37 -0.31 Corneal astigmatism; chr4:119638137 chr4:119391831~119395335:- LUSC cis rs13113518 0.812 rs2035692 ENSG00000223305.1 RN7SKP30 6.95 1.23e-11 8.27e-09 0.37 0.31 Height; chr4:55528801 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs4507426 ENSG00000223305.1 RN7SKP30 6.95 1.23e-11 8.27e-09 0.37 0.31 Height; chr4:55529387 chr4:55540502~55540835:- LUSC cis rs8062405 0.755 rs17707300 ENSG00000278665.1 RP11-666O2.4 6.95 1.23e-11 8.29e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582026 chr16:28599241~28601881:- LUSC cis rs1062177 0.855 rs6892117 ENSG00000213433.5 RPLP1P6 6.95 1.23e-11 8.3e-09 0.36 0.31 Preschool internalizing problems; chr5:151885424 chr5:151765859~151766378:- LUSC cis rs7567389 0.74 rs4536600 ENSG00000236682.1 AC068282.3 -6.95 1.23e-11 8.31e-09 -0.42 -0.31 Self-rated health; chr2:127244996 chr2:127389130~127400580:+ LUSC cis rs7044106 0.69 rs10739569 ENSG00000226752.6 PSMD5-AS1 -6.95 1.24e-11 8.34e-09 -0.34 -0.31 Hip circumference adjusted for BMI; chr9:120598749 chr9:120824828~120854385:+ LUSC cis rs11098499 0.863 rs7699064 ENSG00000250412.1 KLHL2P1 -6.95 1.24e-11 8.34e-09 -0.39 -0.31 Corneal astigmatism; chr4:119507154 chr4:119334329~119378233:+ LUSC cis rs9660180 0.967 rs9660106 ENSG00000231050.1 RP1-140A9.1 6.95 1.24e-11 8.35e-09 0.3 0.31 Body mass index; chr1:1866508 chr1:1891471~1892658:+ LUSC cis rs748404 0.626 rs57938858 ENSG00000249839.1 AC011330.5 -6.95 1.24e-11 8.36e-09 -0.54 -0.31 Lung cancer; chr15:43520259 chr15:43663654~43684339:- LUSC cis rs8062405 0.824 rs153106 ENSG00000278665.1 RP11-666O2.4 6.95 1.25e-11 8.39e-09 0.31 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28515576 chr16:28599241~28601881:- LUSC cis rs2404602 0.647 rs11632765 ENSG00000259422.1 RP11-593F23.1 6.95 1.25e-11 8.41e-09 0.36 0.31 Blood metabolite levels; chr15:76681920 chr15:76174891~76181486:- LUSC cis rs950169 0.881 rs34117475 ENSG00000259728.4 LINC00933 6.95 1.25e-11 8.44e-09 0.39 0.31 Schizophrenia; chr15:84565212 chr15:84570649~84580175:+ LUSC cis rs904251 0.523 rs2776874 ENSG00000204110.6 RP1-153P14.8 -6.95 1.26e-11 8.45e-09 -0.29 -0.31 Cognitive performance; chr6:37515421 chr6:37507348~37535616:+ LUSC cis rs10740039 0.671 rs7919726 ENSG00000254271.1 RP11-131N11.4 6.95 1.26e-11 8.46e-09 0.42 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60689748 chr10:60734342~60741828:+ LUSC cis rs10740039 0.804 rs10821824 ENSG00000254271.1 RP11-131N11.4 6.95 1.26e-11 8.46e-09 0.42 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60690449 chr10:60734342~60741828:+ LUSC cis rs10262624 0.935 rs6966641 ENSG00000234286.1 AC006026.13 -6.95 1.26e-11 8.49e-09 -0.35 -0.31 Schizophrenia; chr7:23866979 chr7:23680195~23680786:- LUSC cis rs12554020 0.792 rs79419498 ENSG00000227603.1 RP11-165J3.6 6.95 1.26e-11 8.49e-09 0.47 0.31 Schizophrenia; chr9:93504701 chr9:93435332~93437121:- LUSC cis rs12439619 0.53 rs28883606 ENSG00000276710.3 CSPG4P8 -6.95 1.27e-11 8.51e-09 -0.31 -0.31 Intelligence (multi-trait analysis); chr15:82216713 chr15:82459472~82477258:+ LUSC cis rs12439619 0.693 rs28665836 ENSG00000276710.3 CSPG4P8 -6.95 1.27e-11 8.51e-09 -0.31 -0.31 Intelligence (multi-trait analysis); chr15:82218955 chr15:82459472~82477258:+ LUSC cis rs11098499 0.821 rs10032151 ENSG00000250412.1 KLHL2P1 6.94 1.27e-11 8.52e-09 0.39 0.31 Corneal astigmatism; chr4:119470473 chr4:119334329~119378233:+ LUSC cis rs11098499 0.865 rs10032158 ENSG00000250412.1 KLHL2P1 6.94 1.27e-11 8.52e-09 0.39 0.31 Corneal astigmatism; chr4:119470477 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs6838814 ENSG00000250412.1 KLHL2P1 6.94 1.27e-11 8.52e-09 0.39 0.31 Corneal astigmatism; chr4:119471288 chr4:119334329~119378233:+ LUSC cis rs2581828 0.618 rs9824325 ENSG00000242142.1 SERBP1P3 -6.94 1.27e-11 8.52e-09 -0.37 -0.31 Crohn's disease; chr3:53132494 chr3:53064283~53065091:- LUSC cis rs4660456 0.956 rs4660457 ENSG00000237899.1 RP4-739H11.3 -6.94 1.27e-11 8.53e-09 -0.43 -0.31 Platelet count; chr1:40774121 chr1:40669089~40687588:- LUSC cis rs8177376 1 rs563011 ENSG00000254905.1 RP11-712L6.7 -6.94 1.27e-11 8.56e-09 -0.39 -0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126281527 chr11:126292922~126294254:- LUSC cis rs875971 0.522 rs1880556 ENSG00000224316.1 RP11-479O9.2 6.94 1.27e-11 8.56e-09 0.3 0.31 Aortic root size; chr7:65967557 chr7:65773620~65802067:+ LUSC cis rs11118620 0.622 rs11118618 ENSG00000238078.1 LINC01352 6.94 1.27e-11 8.56e-09 0.37 0.31 Heart failure; chr1:220838204 chr1:220829255~220832429:+ LUSC cis rs9309473 0.948 rs10173534 ENSG00000163016.8 ALMS1P 6.94 1.28e-11 8.6e-09 0.37 0.31 Metabolite levels; chr2:73586305 chr2:73644919~73685576:+ LUSC cis rs8059260 0.736 rs77920180 ENSG00000274038.1 RP11-66H6.4 -6.94 1.29e-11 8.65e-09 -0.54 -0.3 Alcohol consumption over the past year; chr16:10949041 chr16:11056556~11057034:+ LUSC cis rs6921919 0.583 rs2027361 ENSG00000204709.4 LINC01556 6.94 1.29e-11 8.66e-09 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28420531 chr6:28943877~28944537:+ LUSC cis rs8031584 0.651 rs28664821 ENSG00000260382.1 RP11-540B6.2 -6.94 1.29e-11 8.67e-09 -0.4 -0.3 Huntington's disease progression; chr15:30880120 chr15:30882267~30883231:- LUSC cis rs11098499 0.863 rs12502389 ENSG00000250412.1 KLHL2P1 6.94 1.29e-11 8.68e-09 0.39 0.3 Corneal astigmatism; chr4:119533036 chr4:119334329~119378233:+ LUSC cis rs10740039 0.671 rs7913549 ENSG00000254271.1 RP11-131N11.4 6.94 1.3e-11 8.7e-09 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60658474 chr10:60734342~60741828:+ LUSC cis rs11098499 0.909 rs9759478 ENSG00000250412.1 KLHL2P1 6.94 1.3e-11 8.7e-09 0.39 0.3 Corneal astigmatism; chr4:119446843 chr4:119334329~119378233:+ LUSC cis rs12554020 0.892 rs7025805 ENSG00000227603.1 RP11-165J3.6 -6.94 1.3e-11 8.7e-09 -0.41 -0.3 Schizophrenia; chr9:93481463 chr9:93435332~93437121:- LUSC cis rs8040855 0.599 rs1964724 ENSG00000259295.5 CSPG4P12 -6.94 1.3e-11 8.72e-09 -0.34 -0.3 Bulimia nervosa; chr15:85183269 chr15:85191438~85213905:+ LUSC cis rs1865760 0.713 rs1130000 ENSG00000272462.2 U91328.19 -6.94 1.3e-11 8.73e-09 -0.32 -0.3 Height; chr6:25985168 chr6:25992662~26001775:+ LUSC cis rs9545047 0.716 rs314693 ENSG00000227676.3 LINC01068 -6.94 1.3e-11 8.74e-09 -0.37 -0.3 Schizophrenia; chr13:79432792 chr13:79566727~79571436:+ LUSC cis rs6921919 0.583 rs4642462 ENSG00000204709.4 LINC01556 6.94 1.3e-11 8.74e-09 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28421474 chr6:28943877~28944537:+ LUSC cis rs748404 0.666 rs35158584 ENSG00000249839.1 AC011330.5 -6.94 1.3e-11 8.75e-09 -0.52 -0.3 Lung cancer; chr15:43392876 chr15:43663654~43684339:- LUSC cis rs17270561 1 rs12200962 ENSG00000272462.2 U91328.19 -6.94 1.3e-11 8.76e-09 -0.42 -0.3 Iron status biomarkers; chr6:25828758 chr6:25992662~26001775:+ LUSC cis rs2581828 0.58 rs9872260 ENSG00000242142.1 SERBP1P3 -6.94 1.31e-11 8.78e-09 -0.37 -0.3 Crohn's disease; chr3:53136158 chr3:53064283~53065091:- LUSC cis rs7945705 0.87 rs10840142 ENSG00000254860.4 TMEM9B-AS1 -6.94 1.31e-11 8.82e-09 -0.34 -0.3 Hemoglobin concentration; chr11:8884531 chr11:8964675~8977527:+ LUSC cis rs2404602 0.647 rs12910081 ENSG00000259422.1 RP11-593F23.1 -6.94 1.32e-11 8.83e-09 -0.37 -0.3 Blood metabolite levels; chr15:76730618 chr15:76174891~76181486:- LUSC cis rs2404602 0.647 rs10851889 ENSG00000259422.1 RP11-593F23.1 -6.94 1.32e-11 8.83e-09 -0.37 -0.3 Blood metabolite levels; chr15:76730995 chr15:76174891~76181486:- LUSC cis rs11098499 0.863 rs1010740 ENSG00000250412.1 KLHL2P1 -6.94 1.32e-11 8.85e-09 -0.38 -0.3 Corneal astigmatism; chr4:119542254 chr4:119334329~119378233:+ LUSC cis rs6504950 0.8 rs17745183 ENSG00000275710.1 RP11-257O5.4 6.94 1.32e-11 8.86e-09 0.36 0.3 Breast cancer; chr17:54936234 chr17:54964474~54964679:+ LUSC cis rs2412819 0.597 rs7181912 ENSG00000249839.1 AC011330.5 6.94 1.32e-11 8.87e-09 0.47 0.3 Lung cancer; chr15:43770676 chr15:43663654~43684339:- LUSC cis rs8059260 0.668 rs75637865 ENSG00000274038.1 RP11-66H6.4 -6.94 1.33e-11 8.9e-09 -0.51 -0.3 Alcohol consumption over the past year; chr16:10982439 chr16:11056556~11057034:+ LUSC cis rs113835537 0.529 rs4930378 ENSG00000255517.5 CTD-3074O7.5 -6.94 1.33e-11 8.9e-09 -0.35 -0.3 Airway imaging phenotypes; chr11:66488044 chr11:66473490~66480233:- LUSC cis rs748404 0.666 rs72709879 ENSG00000249839.1 AC011330.5 -6.94 1.33e-11 8.9e-09 -0.53 -0.3 Lung cancer; chr15:43507777 chr15:43663654~43684339:- LUSC cis rs12291225 0.535 rs10832248 ENSG00000251991.1 RNU7-49P 6.94 1.33e-11 8.92e-09 0.35 0.3 Sense of smell; chr11:14391541 chr11:14478892~14478953:+ LUSC cis rs8062405 0.754 rs3859172 ENSG00000278665.1 RP11-666O2.4 6.94 1.33e-11 8.92e-09 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554837 chr16:28599241~28601881:- LUSC cis rs732716 0.785 rs34080966 ENSG00000267769.1 CTB-50L17.9 6.94 1.33e-11 8.92e-09 0.33 0.3 Mean corpuscular volume; chr19:4417848 chr19:4454014~4455286:+ LUSC cis rs950169 0.922 rs12915832 ENSG00000225151.9 GOLGA2P7 -6.94 1.33e-11 8.92e-09 -0.41 -0.3 Schizophrenia; chr15:84568226 chr15:84199311~84230136:- LUSC cis rs75422866 0.867 rs73111258 ENSG00000274902.1 RP1-197B17.4 6.94 1.33e-11 8.95e-09 0.79 0.3 Pneumonia; chr12:47597313 chr12:47731908~47732351:+ LUSC cis rs8040855 0.599 rs6496800 ENSG00000259295.5 CSPG4P12 -6.94 1.34e-11 8.95e-09 -0.34 -0.3 Bulimia nervosa; chr15:85185055 chr15:85191438~85213905:+ LUSC cis rs10740039 0.883 rs10761542 ENSG00000254271.1 RP11-131N11.4 6.94 1.34e-11 8.96e-09 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60655465 chr10:60734342~60741828:+ LUSC cis rs867371 1 rs13380317 ENSG00000255769.6 GOLGA2P10 6.94 1.34e-11 8.96e-09 0.36 0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82214449 chr15:82472993~82513950:- LUSC cis rs10759883 0.627 rs816672 ENSG00000175611.10 LINC00476 6.94 1.34e-11 8.97e-09 0.38 0.3 Nicotine dependence; chr9:95812171 chr9:95759231~95875977:- LUSC cis rs2404602 0.647 rs11633869 ENSG00000259422.1 RP11-593F23.1 6.94 1.34e-11 8.98e-09 0.35 0.3 Blood metabolite levels; chr15:76840981 chr15:76174891~76181486:- LUSC cis rs2412819 0.571 rs11070411 ENSG00000249839.1 AC011330.5 6.94 1.34e-11 8.98e-09 0.46 0.3 Lung cancer; chr15:43766436 chr15:43663654~43684339:- LUSC cis rs4972806 0.849 rs2857535 ENSG00000226363.3 HAGLROS -6.94 1.34e-11 8.99e-09 -0.37 -0.3 IgG glycosylation; chr2:176171483 chr2:176177717~176179008:+ LUSC cis rs4713118 0.662 rs9380045 ENSG00000204709.4 LINC01556 6.94 1.34e-11 8.99e-09 0.43 0.3 Parkinson's disease; chr6:28057501 chr6:28943877~28944537:+ LUSC cis rs4713118 0.616 rs9348789 ENSG00000204709.4 LINC01556 6.94 1.34e-11 8.99e-09 0.43 0.3 Parkinson's disease; chr6:28057708 chr6:28943877~28944537:+ LUSC cis rs4713118 0.662 rs9468274 ENSG00000204709.4 LINC01556 6.94 1.34e-11 8.99e-09 0.43 0.3 Parkinson's disease; chr6:28058299 chr6:28943877~28944537:+ LUSC cis rs4713118 0.662 rs9468275 ENSG00000204709.4 LINC01556 6.94 1.34e-11 8.99e-09 0.43 0.3 Parkinson's disease; chr6:28058358 chr6:28943877~28944537:+ LUSC cis rs4713118 0.662 rs9468276 ENSG00000204709.4 LINC01556 6.94 1.34e-11 8.99e-09 0.43 0.3 Parkinson's disease; chr6:28059910 chr6:28943877~28944537:+ LUSC cis rs4713118 0.662 rs9468277 ENSG00000204709.4 LINC01556 6.94 1.34e-11 8.99e-09 0.43 0.3 Parkinson's disease; chr6:28060612 chr6:28943877~28944537:+ LUSC cis rs4713118 0.662 rs9468278 ENSG00000204709.4 LINC01556 6.94 1.34e-11 8.99e-09 0.43 0.3 Parkinson's disease; chr6:28060704 chr6:28943877~28944537:+ LUSC cis rs4713118 0.662 rs13218430 ENSG00000204709.4 LINC01556 6.94 1.34e-11 8.99e-09 0.43 0.3 Parkinson's disease; chr6:28062059 chr6:28943877~28944537:+ LUSC cis rs875971 1 rs1167411 ENSG00000237310.1 GS1-124K5.4 -6.94 1.34e-11 8.99e-09 -0.32 -0.3 Aortic root size; chr7:66074277 chr7:66493706~66495474:+ LUSC cis rs6504950 0.8 rs72829484 ENSG00000275710.1 RP11-257O5.4 6.94 1.34e-11 8.99e-09 0.36 0.3 Breast cancer; chr17:54931919 chr17:54964474~54964679:+ LUSC cis rs6504622 0.702 rs3851792 ENSG00000262879.4 RP11-156P1.3 6.94 1.34e-11 9e-09 0.32 0.3 Orofacial clefts; chr17:46982458 chr17:46984045~47100323:- LUSC cis rs12550612 0.614 rs6983885 ENSG00000253616.4 RP11-875O11.3 6.94 1.35e-11 9.02e-09 0.42 0.3 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23087574 chr8:23071377~23074488:- LUSC cis rs1075265 0.749 rs805434 ENSG00000233266.1 HMGB1P31 6.94 1.35e-11 9.02e-09 0.39 0.3 Chronotype;Morning vs. evening chronotype; chr2:53836196 chr2:54051334~54051760:+ LUSC cis rs9921338 0.961 rs57579443 ENSG00000263080.1 RP11-485G7.5 6.94 1.35e-11 9.03e-09 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11349140 chr16:11341809~11345211:- LUSC cis rs2581828 0.618 rs6792345 ENSG00000242142.1 SERBP1P3 -6.93 1.35e-11 9.04e-09 -0.37 -0.3 Crohn's disease; chr3:53131178 chr3:53064283~53065091:- LUSC cis rs2581828 0.618 rs6792363 ENSG00000242142.1 SERBP1P3 -6.93 1.35e-11 9.04e-09 -0.37 -0.3 Crohn's disease; chr3:53131247 chr3:53064283~53065091:- LUSC cis rs2581828 0.618 rs6445565 ENSG00000242142.1 SERBP1P3 -6.93 1.35e-11 9.04e-09 -0.37 -0.3 Crohn's disease; chr3:53131448 chr3:53064283~53065091:- LUSC cis rs2581828 0.618 rs6784207 ENSG00000242142.1 SERBP1P3 -6.93 1.35e-11 9.04e-09 -0.37 -0.3 Crohn's disease; chr3:53133458 chr3:53064283~53065091:- LUSC cis rs113835537 0.529 rs10501397 ENSG00000255517.5 CTD-3074O7.5 -6.93 1.35e-11 9.05e-09 -0.35 -0.3 Airway imaging phenotypes; chr11:66505505 chr11:66473490~66480233:- LUSC cis rs11690935 0.921 rs6710698 ENSG00000228389.1 AC068039.4 6.93 1.35e-11 9.06e-09 0.36 0.3 Schizophrenia; chr2:171739568 chr2:171773482~171775844:+ LUSC cis rs881375 1 rs1609810 ENSG00000226752.6 PSMD5-AS1 -6.93 1.35e-11 9.06e-09 -0.36 -0.3 Rheumatoid arthritis; chr9:120880073 chr9:120824828~120854385:+ LUSC cis rs11098499 0.73 rs12505735 ENSG00000250412.1 KLHL2P1 6.93 1.35e-11 9.07e-09 0.37 0.3 Corneal astigmatism; chr4:119611801 chr4:119334329~119378233:+ LUSC cis rs10129255 0.912 rs730099 ENSG00000224373.3 IGHV4-59 6.93 1.36e-11 9.08e-09 0.17 0.3 Kawasaki disease; chr14:106711838 chr14:106627249~106627825:- LUSC cis rs10129255 0.917 rs7142373 ENSG00000280411.1 IGHV1-69-2 -6.93 1.36e-11 9.08e-09 -0.22 -0.3 Kawasaki disease; chr14:106708947 chr14:106762092~106762588:- LUSC cis rs853679 0.517 rs6922063 ENSG00000204709.4 LINC01556 6.93 1.36e-11 9.13e-09 0.43 0.3 Depression; chr6:28126588 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs2275508 ENSG00000204709.4 LINC01556 6.93 1.36e-11 9.13e-09 0.43 0.3 Depression; chr6:28126953 chr6:28943877~28944537:+ LUSC cis rs35160687 0.901 rs12622200 ENSG00000273080.1 RP11-301O19.1 -6.93 1.37e-11 9.15e-09 -0.29 -0.3 Night sleep phenotypes; chr2:86271472 chr2:86195590~86196049:+ LUSC cis rs4423214 0.592 rs10898211 ENSG00000254682.1 RP11-660L16.2 -6.93 1.37e-11 9.16e-09 -0.5 -0.3 Vitamin D levels; chr11:71499631 chr11:71448674~71452157:+ LUSC cis rs11098499 0.954 rs10518331 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.16e-09 0.39 0.3 Corneal astigmatism; chr4:119402440 chr4:119334329~119378233:+ LUSC cis rs2404602 0.647 rs12440511 ENSG00000259422.1 RP11-593F23.1 -6.93 1.37e-11 9.16e-09 -0.37 -0.3 Blood metabolite levels; chr15:76700794 chr15:76174891~76181486:- LUSC cis rs10129255 0.5 rs4774008 ENSG00000224373.3 IGHV4-59 6.93 1.37e-11 9.17e-09 0.15 0.3 Kawasaki disease; chr14:106681273 chr14:106627249~106627825:- LUSC cis rs2337406 1 rs4774173 ENSG00000274576.2 IGHV2-70 -6.93 1.37e-11 9.17e-09 -0.33 -0.3 Alzheimer's disease (late onset); chr14:106682029 chr14:106770577~106771020:- LUSC cis rs11098499 0.954 rs13133522 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119403269 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs35091806 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119404374 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs35165976 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119404475 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs3890049 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119405128 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs6846442 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119405168 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs71614438 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119450097 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs66506550 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119450290 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs7659501 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119450397 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs71629403 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119451412 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs28571712 ENSG00000250412.1 KLHL2P1 6.93 1.37e-11 9.19e-09 0.39 0.3 Corneal astigmatism; chr4:119454825 chr4:119334329~119378233:+ LUSC cis rs2117029 0.555 rs7958241 ENSG00000258017.1 RP11-386G11.10 6.93 1.37e-11 9.19e-09 0.38 0.3 Intelligence (multi-trait analysis); chr12:49115479 chr12:49127782~49147869:+ LUSC cis rs5753618 0.504 rs8138525 ENSG00000236132.1 CTA-440B3.1 6.93 1.38e-11 9.19e-09 0.43 0.3 Colorectal cancer; chr22:31615943 chr22:31816379~31817491:- LUSC cis rs11098499 0.954 rs1480931 ENSG00000250412.1 KLHL2P1 6.93 1.38e-11 9.21e-09 0.38 0.3 Corneal astigmatism; chr4:119474654 chr4:119334329~119378233:+ LUSC cis rs12554020 0.892 rs78046549 ENSG00000227603.1 RP11-165J3.6 6.93 1.38e-11 9.23e-09 0.47 0.3 Schizophrenia; chr9:93506196 chr9:93435332~93437121:- LUSC cis rs2117029 0.555 rs10747561 ENSG00000258017.1 RP11-386G11.10 -6.93 1.38e-11 9.23e-09 -0.38 -0.3 Intelligence (multi-trait analysis); chr12:49106726 chr12:49127782~49147869:+ LUSC cis rs8059260 0.736 rs16957836 ENSG00000274038.1 RP11-66H6.4 -6.93 1.38e-11 9.24e-09 -0.54 -0.3 Alcohol consumption over the past year; chr16:10959229 chr16:11056556~11057034:+ LUSC cis rs853679 0.517 rs17711344 ENSG00000204709.4 LINC01556 -6.93 1.38e-11 9.25e-09 -0.42 -0.3 Depression; chr6:28109824 chr6:28943877~28944537:+ LUSC cis rs11098499 0.863 rs10030660 ENSG00000250412.1 KLHL2P1 6.93 1.39e-11 9.27e-09 0.39 0.3 Corneal astigmatism; chr4:119515549 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs13149407 ENSG00000250412.1 KLHL2P1 6.93 1.39e-11 9.27e-09 0.39 0.3 Corneal astigmatism; chr4:119516670 chr4:119334329~119378233:+ LUSC cis rs11123170 0.543 rs35222158 ENSG00000189223.12 PAX8-AS1 -6.93 1.39e-11 9.27e-09 -0.46 -0.3 Renal function-related traits (BUN); chr2:113229052 chr2:113211522~113276581:+ LUSC cis rs9309473 1 rs11899740 ENSG00000163016.8 ALMS1P 6.93 1.39e-11 9.28e-09 0.37 0.3 Metabolite levels; chr2:73404084 chr2:73644919~73685576:+ LUSC cis rs301901 0.683 rs34485458 ENSG00000250155.1 CTD-2353F22.1 -6.93 1.39e-11 9.28e-09 -0.31 -0.3 Height; chr5:36861889 chr5:36666214~36725195:- LUSC cis rs8062405 0.756 rs151301 ENSG00000278665.1 RP11-666O2.4 6.93 1.39e-11 9.31e-09 0.31 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28485738 chr16:28599241~28601881:- LUSC cis rs801193 0.569 rs2659908 ENSG00000237310.1 GS1-124K5.4 6.93 1.4e-11 9.35e-09 0.32 0.3 Aortic root size; chr7:66695835 chr7:66493706~66495474:+ LUSC cis rs801193 0.569 rs7782587 ENSG00000237310.1 GS1-124K5.4 6.93 1.4e-11 9.35e-09 0.32 0.3 Aortic root size; chr7:66701485 chr7:66493706~66495474:+ LUSC cis rs801193 0.527 rs2707837 ENSG00000237310.1 GS1-124K5.4 6.93 1.4e-11 9.35e-09 0.32 0.3 Aortic root size; chr7:66716086 chr7:66493706~66495474:+ LUSC cis rs9318086 0.687 rs9507182 ENSG00000205861.10 C1QTNF9B-AS1 -6.93 1.4e-11 9.36e-09 -0.38 -0.3 Myopia (pathological); chr13:23868226 chr13:23888889~23897263:+ LUSC cis rs11123170 0.543 rs2863242 ENSG00000189223.12 PAX8-AS1 -6.93 1.4e-11 9.36e-09 -0.46 -0.3 Renal function-related traits (BUN); chr2:113231659 chr2:113211522~113276581:+ LUSC cis rs7250849 0.688 rs16982907 ENSG00000273837.1 LLNLR-470E3.1 -6.93 1.4e-11 9.38e-09 -0.39 -0.3 Blood protein levels; chr19:51659782 chr19:51639478~51639931:- LUSC cis rs11098499 0.588 rs2389874 ENSG00000249244.1 RP11-548H18.2 -6.93 1.41e-11 9.39e-09 -0.37 -0.3 Corneal astigmatism; chr4:119633836 chr4:119391831~119395335:- LUSC cis rs1113500 0.787 rs2336126 ENSG00000226822.1 RP11-356N1.2 6.93 1.41e-11 9.4e-09 0.33 0.3 Growth-regulated protein alpha levels; chr1:108098283 chr1:108071482~108074519:+ LUSC cis rs875971 0.965 rs697968 ENSG00000237310.1 GS1-124K5.4 -6.93 1.41e-11 9.4e-09 -0.32 -0.3 Aortic root size; chr7:66070046 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1183245 ENSG00000237310.1 GS1-124K5.4 -6.93 1.41e-11 9.4e-09 -0.32 -0.3 Aortic root size; chr7:66076198 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1144895 ENSG00000237310.1 GS1-124K5.4 -6.93 1.41e-11 9.4e-09 -0.32 -0.3 Aortic root size; chr7:66076320 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1144894 ENSG00000237310.1 GS1-124K5.4 -6.93 1.41e-11 9.4e-09 -0.32 -0.3 Aortic root size; chr7:66077907 chr7:66493706~66495474:+ LUSC cis rs10246939 0.543 rs9640204 ENSG00000228775.6 WEE2-AS1 6.93 1.41e-11 9.4e-09 0.36 0.3 Bitter taste perception; chr7:141844300 chr7:141704338~141738346:- LUSC cis rs801193 0.569 rs4717315 ENSG00000237310.1 GS1-124K5.4 6.93 1.41e-11 9.42e-09 0.32 0.3 Aortic root size; chr7:66713338 chr7:66493706~66495474:+ LUSC cis rs2337406 1 rs11845269 ENSG00000274576.2 IGHV2-70 -6.93 1.41e-11 9.42e-09 -0.32 -0.3 Alzheimer's disease (late onset); chr14:106683851 chr14:106770577~106771020:- LUSC cis rs4789693 0.518 rs6502117 ENSG00000265458.1 RP13-20L14.6 6.93 1.42e-11 9.45e-09 0.36 0.3 Glucocorticoid-induced osteonecrosis; chr17:82494716 chr17:82454273~82458521:- LUSC cis rs4308124 0.708 rs6747657 ENSG00000227992.1 AC108463.2 -6.93 1.42e-11 9.48e-09 -0.4 -0.3 Vitiligo; chr2:111245586 chr2:111203964~111206215:- LUSC cis rs2179367 0.568 rs9498358 ENSG00000231760.4 RP11-350J20.5 6.93 1.43e-11 9.52e-09 0.47 0.3 Dupuytren's disease; chr6:149458529 chr6:149796151~149826294:- LUSC cis rs2179367 0.6 rs58747890 ENSG00000231760.4 RP11-350J20.5 6.93 1.43e-11 9.52e-09 0.47 0.3 Dupuytren's disease; chr6:149459369 chr6:149796151~149826294:- LUSC cis rs34779708 0.931 rs2490663 ENSG00000230534.5 RP11-297A16.2 -6.93 1.43e-11 9.54e-09 -0.34 -0.3 Inflammatory bowel disease;Crohn's disease; chr10:35040807 chr10:35098006~35127020:- LUSC cis rs8177876 0.749 rs12444969 ENSG00000261838.4 RP11-303E16.6 6.93 1.43e-11 9.55e-09 0.75 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81050211 chr16:81069854~81076598:+ LUSC cis rs8059260 0.736 rs8059156 ENSG00000274038.1 RP11-66H6.4 -6.93 1.43e-11 9.55e-09 -0.54 -0.3 Alcohol consumption over the past year; chr16:10952135 chr16:11056556~11057034:+ LUSC cis rs8059260 0.736 rs8044180 ENSG00000274038.1 RP11-66H6.4 -6.93 1.43e-11 9.55e-09 -0.54 -0.3 Alcohol consumption over the past year; chr16:10952531 chr16:11056556~11057034:+ LUSC cis rs5742933 0.803 rs1233262 ENSG00000253559.1 OSGEPL1-AS1 -6.93 1.43e-11 9.55e-09 -0.37 -0.3 Ferritin levels; chr2:189793107 chr2:189762704~189765556:+ LUSC cis rs8177376 1 rs8177376 ENSG00000254905.1 RP11-712L6.7 6.93 1.43e-11 9.56e-09 0.4 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126293717 chr11:126292922~126294254:- LUSC cis rs9601248 0.756 rs2146592 ENSG00000227676.3 LINC01068 -6.93 1.44e-11 9.58e-09 -0.37 -0.3 Major depressive disorder; chr13:79606146 chr13:79566727~79571436:+ LUSC cis rs875971 0.545 rs313830 ENSG00000164669.11 INTS4P1 6.93 1.44e-11 9.59e-09 0.37 0.3 Aortic root size; chr7:66086944 chr7:65141225~65234216:+ LUSC cis rs8059260 0.668 rs16957839 ENSG00000274038.1 RP11-66H6.4 -6.92 1.44e-11 9.6e-09 -0.53 -0.3 Alcohol consumption over the past year; chr16:10962521 chr16:11056556~11057034:+ LUSC cis rs7811142 0.72 rs112622797 ENSG00000242294.5 STAG3L5P 6.92 1.44e-11 9.61e-09 0.26 0.3 Platelet count; chr7:100319793 chr7:100336079~100351900:+ LUSC cis rs6570726 0.599 rs455001 ENSG00000235652.6 RP11-545I5.3 6.92 1.44e-11 9.62e-09 0.32 0.3 Lobe attachment (rater-scored or self-reported); chr6:145533314 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs6570718 ENSG00000235652.6 RP11-545I5.3 -6.92 1.44e-11 9.63e-09 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145767307 chr6:145799409~145886585:+ LUSC cis rs55665837 0.583 rs78843135 ENSG00000251991.1 RNU7-49P 6.92 1.45e-11 9.64e-09 0.35 0.3 Vitamin D levels; chr11:14389708 chr11:14478892~14478953:+ LUSC cis rs8062405 0.824 rs7191618 ENSG00000278665.1 RP11-666O2.4 6.92 1.45e-11 9.64e-09 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554346 chr16:28599241~28601881:- LUSC cis rs875971 1 rs10244498 ENSG00000237310.1 GS1-124K5.4 6.92 1.45e-11 9.66e-09 0.31 0.3 Aortic root size; chr7:66651069 chr7:66493706~66495474:+ LUSC cis rs11098499 0.722 rs1814814 ENSG00000249244.1 RP11-548H18.2 6.92 1.45e-11 9.66e-09 0.37 0.3 Corneal astigmatism; chr4:119336969 chr4:119391831~119395335:- LUSC cis rs748404 0.697 rs493444 ENSG00000249839.1 AC011330.5 -6.92 1.45e-11 9.68e-09 -0.41 -0.3 Lung cancer; chr15:43274272 chr15:43663654~43684339:- LUSC cis rs11098499 0.562 rs13101722 ENSG00000245958.5 RP11-33B1.1 6.92 1.46e-11 9.7e-09 0.29 0.3 Corneal astigmatism; chr4:119634820 chr4:119454791~119552025:+ LUSC cis rs9921338 0.961 rs7187870 ENSG00000263080.1 RP11-485G7.5 6.92 1.46e-11 9.7e-09 0.37 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11338062 chr16:11341809~11345211:- LUSC cis rs853679 0.517 rs36078605 ENSG00000204709.4 LINC01556 6.92 1.46e-11 9.7e-09 0.43 0.3 Depression; chr6:28110254 chr6:28943877~28944537:+ LUSC cis rs12554020 0.892 rs76977206 ENSG00000227603.1 RP11-165J3.6 6.92 1.46e-11 9.72e-09 0.47 0.3 Schizophrenia; chr9:93518181 chr9:93435332~93437121:- LUSC cis rs12554020 0.786 rs883785 ENSG00000227603.1 RP11-165J3.6 6.92 1.46e-11 9.72e-09 0.47 0.3 Schizophrenia; chr9:93519841 chr9:93435332~93437121:- LUSC cis rs12554020 0.681 rs883783 ENSG00000227603.1 RP11-165J3.6 6.92 1.46e-11 9.72e-09 0.47 0.3 Schizophrenia; chr9:93519987 chr9:93435332~93437121:- LUSC cis rs6142102 0.778 rs6059555 ENSG00000276073.1 RP5-1125A11.7 -6.92 1.46e-11 9.73e-09 -0.32 -0.3 Skin pigmentation; chr20:33926518 chr20:33985617~33988989:- LUSC cis rs10178409 1 rs10178409 ENSG00000163016.8 ALMS1P 6.92 1.46e-11 9.73e-09 0.37 0.3 Urinary metabolites; chr2:73628380 chr2:73644919~73685576:+ LUSC cis rs6142102 0.778 rs4911374 ENSG00000276073.1 RP5-1125A11.7 -6.92 1.46e-11 9.75e-09 -0.32 -0.3 Skin pigmentation; chr20:33928195 chr20:33985617~33988989:- LUSC cis rs8040855 0.599 rs4577058 ENSG00000259295.5 CSPG4P12 -6.92 1.47e-11 9.76e-09 -0.34 -0.3 Bulimia nervosa; chr15:85183227 chr15:85191438~85213905:+ LUSC cis rs1823913 1 rs4853562 ENSG00000280083.1 RP11-317J9.1 6.92 1.47e-11 9.77e-09 0.37 0.3 Obesity-related traits; chr2:191253696 chr2:191154118~191156070:- LUSC cis rs9921338 0.961 rs72773825 ENSG00000263080.1 RP11-485G7.5 6.92 1.47e-11 9.79e-09 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11318591 chr16:11341809~11345211:- LUSC cis rs9309473 1 rs7582606 ENSG00000163016.8 ALMS1P 6.92 1.47e-11 9.8e-09 0.36 0.3 Metabolite levels; chr2:73586818 chr2:73644919~73685576:+ LUSC cis rs2404602 0.684 rs1011084 ENSG00000259422.1 RP11-593F23.1 -6.92 1.48e-11 9.82e-09 -0.37 -0.3 Blood metabolite levels; chr15:76715139 chr15:76174891~76181486:- LUSC cis rs2404602 0.647 rs11629727 ENSG00000259422.1 RP11-593F23.1 -6.92 1.48e-11 9.82e-09 -0.37 -0.3 Blood metabolite levels; chr15:76716697 chr15:76174891~76181486:- LUSC cis rs2404602 0.61 rs28823285 ENSG00000259422.1 RP11-593F23.1 -6.92 1.48e-11 9.83e-09 -0.36 -0.3 Blood metabolite levels; chr15:76758054 chr15:76174891~76181486:- LUSC cis rs10463554 0.892 rs2195272 ENSG00000175749.11 EIF3KP1 6.92 1.49e-11 9.93e-09 0.36 0.3 Parkinson's disease; chr5:102959800 chr5:103032376~103033031:+ LUSC cis rs9921338 0.961 rs7199821 ENSG00000263080.1 RP11-485G7.5 6.92 1.5e-11 9.95e-09 0.37 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11331154 chr16:11341809~11345211:- LUSC cis rs7772486 0.79 rs9403749 ENSG00000235652.6 RP11-545I5.3 6.92 1.5e-11 9.96e-09 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145841103 chr6:145799409~145886585:+ LUSC cis rs10262624 0.564 rs58051142 ENSG00000234286.1 AC006026.13 -6.92 1.5e-11 9.98e-09 -0.36 -0.3 Schizophrenia; chr7:23866047 chr7:23680195~23680786:- LUSC cis rs11098499 0.754 rs12513083 ENSG00000249244.1 RP11-548H18.2 6.92 1.5e-11 9.98e-09 0.38 0.3 Corneal astigmatism; chr4:119328457 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs12509621 ENSG00000249244.1 RP11-548H18.2 6.92 1.5e-11 9.98e-09 0.38 0.3 Corneal astigmatism; chr4:119328505 chr4:119391831~119395335:- LUSC cis rs10129255 0.957 rs10150241 ENSG00000280411.1 IGHV1-69-2 6.92 1.51e-11 1e-08 0.21 0.3 Kawasaki disease; chr14:106775945 chr14:106762092~106762588:- LUSC cis rs8018967 1 rs8018967 ENSG00000258695.2 RP3-414A15.2 -6.92 1.51e-11 1e-08 -0.36 -0.3 Blood metabolite ratios; chr14:73510230 chr14:73522878~73530610:+ LUSC cis rs761746 0.614 rs8141214 ENSG00000236132.1 CTA-440B3.1 -6.92 1.52e-11 1.01e-08 -0.43 -0.3 Intelligence; chr22:31800195 chr22:31816379~31817491:- LUSC cis rs61160187 0.556 rs62367862 ENSG00000215032.2 GNL3LP1 6.92 1.53e-11 1.02e-08 0.38 0.3 Educational attainment (years of education);Educational attainment (college completion); chr5:60973134 chr5:60891935~60893577:- LUSC cis rs11098499 0.863 rs1480940 ENSG00000250412.1 KLHL2P1 6.92 1.53e-11 1.02e-08 0.39 0.3 Corneal astigmatism; chr4:119536527 chr4:119334329~119378233:+ LUSC cis rs11098499 0.697 rs28655325 ENSG00000250412.1 KLHL2P1 6.91 1.54e-11 1.02e-08 0.38 0.3 Corneal astigmatism; chr4:119451844 chr4:119334329~119378233:+ LUSC cis rs9309473 1 rs7598396 ENSG00000163016.8 ALMS1P 6.91 1.54e-11 1.02e-08 0.36 0.3 Metabolite levels; chr2:73425500 chr2:73644919~73685576:+ LUSC cis rs950169 0.922 rs11638445 ENSG00000259728.4 LINC00933 6.91 1.54e-11 1.02e-08 0.41 0.3 Schizophrenia; chr15:84594463 chr15:84570649~84580175:+ LUSC cis rs1075265 0.749 rs6738369 ENSG00000233266.1 HMGB1P31 6.91 1.54e-11 1.02e-08 0.37 0.3 Chronotype;Morning vs. evening chronotype; chr2:53756547 chr2:54051334~54051760:+ LUSC cis rs6504950 0.76 rs17745189 ENSG00000275710.1 RP11-257O5.4 6.91 1.54e-11 1.03e-08 0.38 0.3 Breast cancer; chr17:54936619 chr17:54964474~54964679:+ LUSC cis rs9928842 0.941 rs8057145 ENSG00000280152.1 RP11-331F4.5 6.91 1.54e-11 1.03e-08 0.37 0.3 Alcoholic chronic pancreatitis; chr16:75222353 chr16:75245994~75250077:- LUSC cis rs8177376 1 rs7932766 ENSG00000254905.1 RP11-712L6.7 6.91 1.55e-11 1.03e-08 0.4 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126292967 chr11:126292922~126294254:- LUSC cis rs9309473 0.95 rs6740766 ENSG00000163016.8 ALMS1P 6.91 1.55e-11 1.03e-08 0.36 0.3 Metabolite levels; chr2:73553786 chr2:73644919~73685576:+ LUSC cis rs9309473 1 rs13431267 ENSG00000163016.8 ALMS1P 6.91 1.55e-11 1.03e-08 0.36 0.3 Metabolite levels; chr2:73555073 chr2:73644919~73685576:+ LUSC cis rs9309473 0.95 rs6735946 ENSG00000163016.8 ALMS1P 6.91 1.55e-11 1.03e-08 0.36 0.3 Metabolite levels; chr2:73562931 chr2:73644919~73685576:+ LUSC cis rs950169 0.922 rs11630507 ENSG00000225151.9 GOLGA2P7 -6.91 1.55e-11 1.03e-08 -0.42 -0.3 Schizophrenia; chr15:84552494 chr15:84199311~84230136:- LUSC cis rs732716 0.719 rs56088814 ENSG00000267769.1 CTB-50L17.9 -6.91 1.55e-11 1.03e-08 -0.34 -0.3 Mean corpuscular volume; chr19:4422181 chr19:4454014~4455286:+ LUSC cis rs9545047 0.704 rs9530904 ENSG00000227676.3 LINC01068 6.91 1.55e-11 1.03e-08 0.37 0.3 Schizophrenia; chr13:79370157 chr13:79566727~79571436:+ LUSC cis rs8062405 0.824 rs62034319 ENSG00000278665.1 RP11-666O2.4 6.91 1.55e-11 1.03e-08 0.31 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28520867 chr16:28599241~28601881:- LUSC cis rs13113518 0.507 rs11943456 ENSG00000249700.7 SRD5A3-AS1 6.91 1.56e-11 1.03e-08 0.33 0.3 Height; chr4:55410167 chr4:55363971~55395847:- LUSC cis rs66887589 0.72 rs11724758 ENSG00000245958.5 RP11-33B1.1 -6.91 1.56e-11 1.04e-08 -0.28 -0.3 Diastolic blood pressure; chr4:119318723 chr4:119454791~119552025:+ LUSC cis rs35160687 0.901 rs11127026 ENSG00000273080.1 RP11-301O19.1 6.91 1.56e-11 1.04e-08 0.29 0.3 Night sleep phenotypes; chr2:86304625 chr2:86195590~86196049:+ LUSC cis rs875971 0.862 rs7786892 ENSG00000237310.1 GS1-124K5.4 -6.91 1.57e-11 1.04e-08 -0.32 -0.3 Aortic root size; chr7:66163889 chr7:66493706~66495474:+ LUSC cis rs4713118 0.869 rs9283883 ENSG00000219392.1 RP1-265C24.5 -6.91 1.57e-11 1.04e-08 -0.39 -0.3 Parkinson's disease; chr6:27747691 chr6:28115628~28116551:+ LUSC cis rs10129255 0.957 rs4387509 ENSG00000280411.1 IGHV1-69-2 -6.91 1.57e-11 1.04e-08 -0.22 -0.3 Kawasaki disease; chr14:106704386 chr14:106762092~106762588:- LUSC cis rs10129255 0.956 rs10137268 ENSG00000280411.1 IGHV1-69-2 -6.91 1.58e-11 1.04e-08 -0.22 -0.3 Kawasaki disease; chr14:106697402 chr14:106762092~106762588:- LUSC cis rs11098499 0.738 rs34965784 ENSG00000250412.1 KLHL2P1 6.91 1.58e-11 1.05e-08 0.38 0.3 Corneal astigmatism; chr4:119440431 chr4:119334329~119378233:+ LUSC cis rs6570726 0.577 rs403345 ENSG00000235652.6 RP11-545I5.3 6.91 1.58e-11 1.05e-08 0.32 0.3 Lobe attachment (rater-scored or self-reported); chr6:145524035 chr6:145799409~145886585:+ LUSC cis rs11098499 0.863 rs1383533 ENSG00000250412.1 KLHL2P1 6.91 1.58e-11 1.05e-08 0.38 0.3 Corneal astigmatism; chr4:119513421 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs2291185 ENSG00000250412.1 KLHL2P1 6.91 1.58e-11 1.05e-08 0.38 0.3 Corneal astigmatism; chr4:119513678 chr4:119334329~119378233:+ LUSC cis rs4713118 0.621 rs9295756 ENSG00000204709.4 LINC01556 6.91 1.58e-11 1.05e-08 0.42 0.3 Parkinson's disease; chr6:28065618 chr6:28943877~28944537:+ LUSC cis rs9601248 0.711 rs9530937 ENSG00000227676.3 LINC01068 -6.91 1.58e-11 1.05e-08 -0.37 -0.3 Major depressive disorder; chr13:79603701 chr13:79566727~79571436:+ LUSC cis rs4950322 0.58 rs2014106 ENSG00000278811.3 LINC00624 6.91 1.58e-11 1.05e-08 0.33 0.3 Protein quantitative trait loci; chr1:147118499 chr1:147258885~147517875:- LUSC cis rs8177876 0.584 rs13185 ENSG00000261838.4 RP11-303E16.6 -6.91 1.59e-11 1.05e-08 -0.6 -0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046036 chr16:81069854~81076598:+ LUSC cis rs950169 0.922 rs62021167 ENSG00000259728.4 LINC00933 6.91 1.59e-11 1.05e-08 0.4 0.3 Schizophrenia; chr15:84574820 chr15:84570649~84580175:+ LUSC cis rs8062405 0.789 rs240704 ENSG00000278665.1 RP11-666O2.4 6.91 1.59e-11 1.06e-08 0.31 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28518628 chr16:28599241~28601881:- LUSC cis rs10463554 0.892 rs1898673 ENSG00000175749.11 EIF3KP1 6.91 1.6e-11 1.06e-08 0.36 0.3 Parkinson's disease; chr5:102957676 chr5:103032376~103033031:+ LUSC cis rs867371 1 rs13380319 ENSG00000255769.6 GOLGA2P10 -6.91 1.6e-11 1.06e-08 -0.37 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82214526 chr15:82472993~82513950:- LUSC cis rs6142102 0.923 rs6059635 ENSG00000276073.1 RP5-1125A11.7 -6.91 1.6e-11 1.06e-08 -0.31 -0.3 Skin pigmentation; chr20:34025687 chr20:33985617~33988989:- LUSC cis rs4423214 0.559 rs7949129 ENSG00000254682.1 RP11-660L16.2 -6.91 1.61e-11 1.07e-08 -0.5 -0.3 Vitamin D levels; chr11:71482089 chr11:71448674~71452157:+ LUSC cis rs10246939 0.543 rs10952509 ENSG00000228775.6 WEE2-AS1 6.91 1.61e-11 1.07e-08 0.38 0.3 Bitter taste perception; chr7:141890884 chr7:141704338~141738346:- LUSC cis rs11098499 0.863 rs3822190 ENSG00000250412.1 KLHL2P1 6.91 1.62e-11 1.07e-08 0.38 0.3 Corneal astigmatism; chr4:119506943 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs3822191 ENSG00000250412.1 KLHL2P1 6.91 1.62e-11 1.07e-08 0.38 0.3 Corneal astigmatism; chr4:119506946 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs3775841 ENSG00000250412.1 KLHL2P1 6.91 1.62e-11 1.07e-08 0.38 0.3 Corneal astigmatism; chr4:119504622 chr4:119334329~119378233:+ LUSC cis rs227275 0.556 rs223426 ENSG00000230069.3 LRRC37A15P -6.91 1.62e-11 1.07e-08 -0.32 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:102801330 chr4:102727274~102730721:- LUSC cis rs5742933 0.744 rs13002216 ENSG00000253559.1 OSGEPL1-AS1 6.91 1.63e-11 1.08e-08 0.36 0.3 Ferritin levels; chr2:189746358 chr2:189762704~189765556:+ LUSC cis rs875971 0.502 rs2946580 ENSG00000164669.11 INTS4P1 6.91 1.63e-11 1.08e-08 0.37 0.3 Aortic root size; chr7:66066855 chr7:65141225~65234216:+ LUSC cis rs11976180 1 rs1919951 ENSG00000170356.8 OR2A20P -6.9 1.64e-11 1.08e-08 -0.41 -0.3 Obesity-related traits; chr7:144071798 chr7:144250045~144252957:- LUSC cis rs35160687 0.901 rs12478575 ENSG00000273080.1 RP11-301O19.1 6.9 1.64e-11 1.08e-08 0.29 0.3 Night sleep phenotypes; chr2:86308191 chr2:86195590~86196049:+ LUSC cis rs11098499 0.754 rs4107728 ENSG00000249244.1 RP11-548H18.2 6.9 1.64e-11 1.08e-08 0.38 0.3 Corneal astigmatism; chr4:119332755 chr4:119391831~119395335:- LUSC cis rs8177876 0.749 rs78707250 ENSG00000261838.4 RP11-303E16.6 6.9 1.64e-11 1.08e-08 0.75 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046757 chr16:81069854~81076598:+ LUSC cis rs7772486 0.754 rs9386134 ENSG00000235652.6 RP11-545I5.3 6.9 1.65e-11 1.09e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145824372 chr6:145799409~145886585:+ LUSC cis rs673078 0.607 rs61944671 ENSG00000275759.1 RP11-131L12.3 -6.9 1.65e-11 1.09e-08 -0.45 -0.3 Glucose homeostasis traits; chr12:118450046 chr12:118428281~118428870:+ LUSC cis rs9549367 0.636 rs486407 ENSG00000269125.1 RP11-98F14.11 6.9 1.65e-11 1.09e-08 0.37 0.3 Platelet distribution width; chr13:113179185 chr13:113165002~113165183:- LUSC cis rs9549367 0.713 rs2476319 ENSG00000269125.1 RP11-98F14.11 6.9 1.65e-11 1.09e-08 0.37 0.3 Platelet distribution width; chr13:113182205 chr13:113165002~113165183:- LUSC cis rs1865760 0.713 rs6928951 ENSG00000272462.2 U91328.19 -6.9 1.66e-11 1.09e-08 -0.32 -0.3 Height; chr6:25995326 chr6:25992662~26001775:+ LUSC cis rs1075265 0.704 rs10181999 ENSG00000233266.1 HMGB1P31 6.9 1.66e-11 1.1e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54025360 chr2:54051334~54051760:+ LUSC cis rs1113500 0.787 rs10881502 ENSG00000226822.1 RP11-356N1.2 -6.9 1.66e-11 1.1e-08 -0.3 -0.3 Growth-regulated protein alpha levels; chr1:108099197 chr1:108071482~108074519:+ LUSC cis rs2739330 0.796 rs1006771 ENSG00000235689.1 AP000351.13 6.9 1.66e-11 1.1e-08 0.34 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:24006305~24008258:- LUSC cis rs10129255 0.957 rs11847726 ENSG00000280411.1 IGHV1-69-2 -6.9 1.66e-11 1.1e-08 -0.21 -0.3 Kawasaki disease; chr14:106779116 chr14:106762092~106762588:- LUSC cis rs17711722 0.701 rs55773927 ENSG00000164669.11 INTS4P1 -6.9 1.66e-11 1.1e-08 -0.33 -0.3 Calcium levels; chr7:65872915 chr7:65141225~65234216:+ LUSC cis rs17711722 0.727 rs35850374 ENSG00000164669.11 INTS4P1 -6.9 1.66e-11 1.1e-08 -0.33 -0.3 Calcium levels; chr7:65892789 chr7:65141225~65234216:+ LUSC cis rs9309473 0.848 rs9750915 ENSG00000163016.8 ALMS1P 6.9 1.67e-11 1.1e-08 0.36 0.3 Metabolite levels; chr2:73584753 chr2:73644919~73685576:+ LUSC cis rs11157436 0.958 rs2204963 ENSG00000211813.2 TRAV34 6.9 1.67e-11 1.1e-08 0.34 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22187871 chr14:22207522~22208129:+ LUSC cis rs11098499 0.779 rs28495013 ENSG00000250412.1 KLHL2P1 6.9 1.67e-11 1.1e-08 0.38 0.3 Corneal astigmatism; chr4:119454676 chr4:119334329~119378233:+ LUSC cis rs2404602 0.647 rs11637096 ENSG00000259422.1 RP11-593F23.1 -6.9 1.67e-11 1.11e-08 -0.37 -0.3 Blood metabolite levels; chr15:76638761 chr15:76174891~76181486:- LUSC cis rs442309 0.553 rs10761660 ENSG00000238280.1 RP11-436D10.3 -6.9 1.68e-11 1.11e-08 -0.38 -0.3 Vogt-Koyanagi-Harada syndrome; chr10:62756546 chr10:62793562~62805887:- LUSC cis rs10463554 0.892 rs3776874 ENSG00000175749.11 EIF3KP1 6.9 1.68e-11 1.11e-08 0.36 0.3 Parkinson's disease; chr5:102946613 chr5:103032376~103033031:+ LUSC cis rs10463554 0.857 rs3776873 ENSG00000175749.11 EIF3KP1 6.9 1.68e-11 1.11e-08 0.36 0.3 Parkinson's disease; chr5:102946768 chr5:103032376~103033031:+ LUSC cis rs9921338 1 rs8049173 ENSG00000263080.1 RP11-485G7.5 6.9 1.69e-11 1.11e-08 0.37 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11343025 chr16:11341809~11345211:- LUSC cis rs9921338 1 rs8055427 ENSG00000263080.1 RP11-485G7.5 6.9 1.69e-11 1.11e-08 0.37 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11343026 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs9936093 ENSG00000263080.1 RP11-485G7.5 6.9 1.69e-11 1.11e-08 0.37 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11343459 chr16:11341809~11345211:- LUSC cis rs1075265 0.744 rs10203576 ENSG00000233266.1 HMGB1P31 6.9 1.69e-11 1.11e-08 0.39 0.3 Chronotype;Morning vs. evening chronotype; chr2:54060939 chr2:54051334~54051760:+ LUSC cis rs11098499 0.863 rs13134665 ENSG00000250412.1 KLHL2P1 6.9 1.69e-11 1.12e-08 0.38 0.3 Corneal astigmatism; chr4:119505275 chr4:119334329~119378233:+ LUSC cis rs113835537 0.529 rs2305535 ENSG00000255517.5 CTD-3074O7.5 6.9 1.69e-11 1.12e-08 0.35 0.3 Airway imaging phenotypes; chr11:66504766 chr11:66473490~66480233:- LUSC cis rs710216 0.536 rs710221 ENSG00000227533.4 SLC2A1-AS1 6.9 1.69e-11 1.12e-08 0.33 0.3 Red cell distribution width; chr1:42948529 chr1:42959049~42983358:+ LUSC cis rs66887589 0.72 rs2036858 ENSG00000245958.5 RP11-33B1.1 -6.9 1.69e-11 1.12e-08 -0.29 -0.3 Diastolic blood pressure; chr4:119328082 chr4:119454791~119552025:+ LUSC cis rs113835537 0.559 rs11227497 ENSG00000255517.5 CTD-3074O7.5 -6.9 1.69e-11 1.12e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66501993 chr11:66473490~66480233:- LUSC cis rs11098499 0.908 rs7695996 ENSG00000250412.1 KLHL2P1 6.9 1.7e-11 1.12e-08 0.38 0.3 Corneal astigmatism; chr4:119400878 chr4:119334329~119378233:+ LUSC cis rs11098499 0.908 rs7696649 ENSG00000250412.1 KLHL2P1 6.9 1.7e-11 1.12e-08 0.38 0.3 Corneal astigmatism; chr4:119401022 chr4:119334329~119378233:+ LUSC cis rs853679 0.527 rs9461443 ENSG00000204709.4 LINC01556 6.9 1.7e-11 1.12e-08 0.41 0.3 Depression; chr6:28226851 chr6:28943877~28944537:+ LUSC cis rs9549367 0.789 rs9549361 ENSG00000269125.1 RP11-98F14.11 6.9 1.7e-11 1.12e-08 0.37 0.3 Platelet distribution width; chr13:113244015 chr13:113165002~113165183:- LUSC cis rs2581828 0.591 rs6445566 ENSG00000242142.1 SERBP1P3 -6.9 1.7e-11 1.12e-08 -0.37 -0.3 Crohn's disease; chr3:53131611 chr3:53064283~53065091:- LUSC cis rs2581828 0.618 rs13319872 ENSG00000242142.1 SERBP1P3 -6.9 1.7e-11 1.12e-08 -0.37 -0.3 Crohn's disease; chr3:53132082 chr3:53064283~53065091:- LUSC cis rs9487094 1 rs17070580 ENSG00000260273.1 RP11-425D10.10 -6.9 1.71e-11 1.13e-08 -0.37 -0.3 Height; chr6:109417511 chr6:109382795~109383666:+ LUSC cis rs10028773 0.7 rs7671797 ENSG00000249244.1 RP11-548H18.2 6.9 1.71e-11 1.13e-08 0.38 0.3 Educational attainment; chr4:119327002 chr4:119391831~119395335:- LUSC cis rs2284378 0.515 rs6059579 ENSG00000276073.1 RP5-1125A11.7 -6.9 1.71e-11 1.13e-08 -0.3 -0.3 Breast cancer; chr20:33940059 chr20:33985617~33988989:- LUSC cis rs2412819 0.571 rs2930531 ENSG00000249839.1 AC011330.5 6.9 1.71e-11 1.13e-08 0.48 0.3 Lung cancer; chr15:43829372 chr15:43663654~43684339:- LUSC cis rs1823913 1 rs4853461 ENSG00000280083.1 RP11-317J9.1 6.9 1.71e-11 1.13e-08 0.37 0.3 Obesity-related traits; chr2:191254572 chr2:191154118~191156070:- LUSC cis rs1823913 1 rs4853563 ENSG00000280083.1 RP11-317J9.1 6.9 1.71e-11 1.13e-08 0.37 0.3 Obesity-related traits; chr2:191254808 chr2:191154118~191156070:- LUSC cis rs10129255 1 rs10134517 ENSG00000280411.1 IGHV1-69-2 -6.9 1.71e-11 1.13e-08 -0.21 -0.3 Kawasaki disease; chr14:106718498 chr14:106762092~106762588:- LUSC cis rs7138300 0.526 rs17226898 ENSG00000257265.1 CTD-2021H9.1 6.9 1.71e-11 1.13e-08 0.33 0.3 Type 2 diabetes; chr12:71191963 chr12:71007773~71032083:- LUSC cis rs2337406 0.925 rs76288499 ENSG00000274576.2 IGHV2-70 -6.9 1.72e-11 1.13e-08 -0.32 -0.3 Alzheimer's disease (late onset); chr14:106686309 chr14:106770577~106771020:- LUSC cis rs875971 0.895 rs7788984 ENSG00000237310.1 GS1-124K5.4 6.9 1.72e-11 1.13e-08 0.31 0.3 Aortic root size; chr7:66450629 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1981798 ENSG00000237310.1 GS1-124K5.4 6.9 1.72e-11 1.13e-08 0.31 0.3 Aortic root size; chr7:66489916 chr7:66493706~66495474:+ LUSC cis rs9928842 0.882 rs8048956 ENSG00000280152.1 RP11-331F4.5 -6.9 1.72e-11 1.13e-08 -0.36 -0.3 Alcoholic chronic pancreatitis; chr16:75221068 chr16:75245994~75250077:- LUSC cis rs9322193 0.923 rs7769101 ENSG00000268592.3 RAET1E-AS1 6.9 1.72e-11 1.13e-08 0.39 0.3 Lung cancer; chr6:149848768 chr6:149863494~149919507:+ LUSC cis rs950169 0.922 rs11630760 ENSG00000225151.9 GOLGA2P7 -6.9 1.73e-11 1.14e-08 -0.42 -0.3 Schizophrenia; chr15:84570106 chr15:84199311~84230136:- LUSC cis rs950169 0.887 rs71395453 ENSG00000225151.9 GOLGA2P7 -6.9 1.73e-11 1.14e-08 -0.42 -0.3 Schizophrenia; chr15:84570259 chr15:84199311~84230136:- LUSC cis rs6570726 0.791 rs448939 ENSG00000235652.6 RP11-545I5.3 6.9 1.73e-11 1.14e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145487184 chr6:145799409~145886585:+ LUSC cis rs7945705 0.902 rs10743095 ENSG00000254860.4 TMEM9B-AS1 -6.9 1.73e-11 1.14e-08 -0.33 -0.3 Hemoglobin concentration; chr11:8915437 chr11:8964675~8977527:+ LUSC cis rs4950322 0.515 rs11239954 ENSG00000278811.3 LINC00624 6.9 1.74e-11 1.14e-08 0.32 0.3 Protein quantitative trait loci; chr1:147246045 chr1:147258885~147517875:- LUSC cis rs7250849 0.79 rs73052830 ENSG00000273837.1 LLNLR-470E3.1 -6.9 1.74e-11 1.14e-08 -0.49 -0.3 Blood protein levels; chr19:51657512 chr19:51639478~51639931:- LUSC cis rs10463554 0.892 rs10463988 ENSG00000175749.11 EIF3KP1 6.9 1.74e-11 1.15e-08 0.37 0.3 Parkinson's disease; chr5:102913595 chr5:103032376~103033031:+ LUSC cis rs34779708 0.897 rs7900480 ENSG00000230534.5 RP11-297A16.2 -6.89 1.75e-11 1.15e-08 -0.33 -0.3 Inflammatory bowel disease;Crohn's disease; chr10:35049771 chr10:35098006~35127020:- LUSC cis rs10754283 0.967 rs10801761 ENSG00000231613.1 RP5-943J3.1 6.89 1.75e-11 1.15e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89649710 chr1:89788914~89790492:+ LUSC cis rs1865760 0.713 rs7766342 ENSG00000272462.2 U91328.19 -6.89 1.75e-11 1.15e-08 -0.32 -0.3 Height; chr6:25990446 chr6:25992662~26001775:+ LUSC cis rs1865760 0.713 rs9461229 ENSG00000272462.2 U91328.19 -6.89 1.75e-11 1.15e-08 -0.32 -0.3 Height; chr6:25992051 chr6:25992662~26001775:+ LUSC cis rs6504950 0.8 rs12952253 ENSG00000275710.1 RP11-257O5.4 6.89 1.75e-11 1.15e-08 0.36 0.3 Breast cancer; chr17:54928355 chr17:54964474~54964679:+ LUSC cis rs6504950 0.8 rs7208123 ENSG00000275710.1 RP11-257O5.4 6.89 1.75e-11 1.15e-08 0.36 0.3 Breast cancer; chr17:54928978 chr17:54964474~54964679:+ LUSC cis rs10129255 0.957 rs12590735 ENSG00000280411.1 IGHV1-69-2 -6.89 1.75e-11 1.15e-08 -0.21 -0.3 Kawasaki disease; chr14:106779660 chr14:106762092~106762588:- LUSC cis rs748404 0.666 rs12906017 ENSG00000249839.1 AC011330.5 -6.89 1.75e-11 1.15e-08 -0.52 -0.3 Lung cancer; chr15:43504710 chr15:43663654~43684339:- LUSC cis rs5742933 0.817 rs1233299 ENSG00000253559.1 OSGEPL1-AS1 -6.89 1.75e-11 1.15e-08 -0.37 -0.3 Ferritin levels; chr2:189799912 chr2:189762704~189765556:+ LUSC cis rs10754283 0.967 rs6663363 ENSG00000231613.1 RP5-943J3.1 6.89 1.76e-11 1.16e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89651295 chr1:89788914~89790492:+ LUSC cis rs6504950 0.8 rs9891704 ENSG00000275710.1 RP11-257O5.4 6.89 1.76e-11 1.16e-08 0.35 0.3 Breast cancer; chr17:54933394 chr17:54964474~54964679:+ LUSC cis rs6504950 0.8 rs9900816 ENSG00000275710.1 RP11-257O5.4 6.89 1.76e-11 1.16e-08 0.35 0.3 Breast cancer; chr17:54934696 chr17:54964474~54964679:+ LUSC cis rs6504950 0.8 rs9907961 ENSG00000275710.1 RP11-257O5.4 6.89 1.76e-11 1.16e-08 0.35 0.3 Breast cancer; chr17:54935566 chr17:54964474~54964679:+ LUSC cis rs6142102 0.517 rs6059580 ENSG00000276073.1 RP5-1125A11.7 -6.89 1.76e-11 1.16e-08 -0.3 -0.3 Skin pigmentation; chr20:33940067 chr20:33985617~33988989:- LUSC cis rs9549367 0.713 rs9549682 ENSG00000269125.1 RP11-98F14.11 -6.89 1.76e-11 1.16e-08 -0.4 -0.3 Platelet distribution width; chr13:113175867 chr13:113165002~113165183:- LUSC cis rs3091242 0.933 rs932372 ENSG00000224183.1 SDHDP6 -6.89 1.76e-11 1.16e-08 -0.37 -0.3 Erythrocyte sedimentation rate; chr1:25428523 chr1:25294164~25294643:- LUSC cis rs7739264 0.602 rs9350179 ENSG00000227116.1 RP3-471C18.1 -6.89 1.77e-11 1.16e-08 -0.35 -0.3 Endometriosis; chr6:19763864 chr6:19730427~19734567:- LUSC cis rs11098499 0.618 rs35265692 ENSG00000250412.1 KLHL2P1 6.89 1.77e-11 1.16e-08 0.38 0.3 Corneal astigmatism; chr4:119403980 chr4:119334329~119378233:+ LUSC cis rs6142102 0.625 rs6142067 ENSG00000276073.1 RP5-1125A11.7 -6.89 1.77e-11 1.17e-08 -0.3 -0.3 Skin pigmentation; chr20:33968766 chr20:33985617~33988989:- LUSC cis rs11098499 0.562 rs58583086 ENSG00000245958.5 RP11-33B1.1 6.89 1.78e-11 1.17e-08 0.29 0.3 Corneal astigmatism; chr4:119635207 chr4:119454791~119552025:+ LUSC cis rs1865760 0.865 rs1541987 ENSG00000272462.2 U91328.19 6.89 1.78e-11 1.17e-08 0.32 0.3 Height; chr6:25950169 chr6:25992662~26001775:+ LUSC cis rs6570726 0.577 rs9497315 ENSG00000235652.6 RP11-545I5.3 -6.89 1.78e-11 1.17e-08 -0.32 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145470831 chr6:145799409~145886585:+ LUSC cis rs6921919 0.583 rs4254981 ENSG00000204709.4 LINC01556 6.89 1.78e-11 1.17e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28403625 chr6:28943877~28944537:+ LUSC cis rs6921919 0.525 rs6929825 ENSG00000204709.4 LINC01556 6.89 1.78e-11 1.17e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28411182 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs35599905 ENSG00000204709.4 LINC01556 6.89 1.78e-11 1.17e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28411886 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs1124131 ENSG00000204709.4 LINC01556 6.89 1.78e-11 1.17e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28412471 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs6899389 ENSG00000204709.4 LINC01556 6.89 1.78e-11 1.17e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28413363 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs6922374 ENSG00000204709.4 LINC01556 6.89 1.78e-11 1.17e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28413495 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs6899603 ENSG00000204709.4 LINC01556 6.89 1.78e-11 1.17e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28413528 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs6922429 ENSG00000204709.4 LINC01556 6.89 1.78e-11 1.17e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28413568 chr6:28943877~28944537:+ LUSC cis rs9309473 1 rs13432605 ENSG00000163016.8 ALMS1P 6.89 1.78e-11 1.17e-08 0.36 0.3 Metabolite levels; chr2:73583854 chr2:73644919~73685576:+ LUSC cis rs55726902 1 rs73107993 ENSG00000276691.1 RP5-1057I20.5 6.89 1.79e-11 1.17e-08 0.37 0.3 Allergic disease (asthma, hay fever or eczema); chr12:47802090 chr12:47788426~47788971:+ LUSC cis rs35160687 0.871 rs11127028 ENSG00000273080.1 RP11-301O19.1 6.89 1.79e-11 1.18e-08 0.29 0.3 Night sleep phenotypes; chr2:86310386 chr2:86195590~86196049:+ LUSC cis rs11098499 0.865 rs4001305 ENSG00000250412.1 KLHL2P1 6.89 1.79e-11 1.18e-08 0.38 0.3 Corneal astigmatism; chr4:119438081 chr4:119334329~119378233:+ LUSC cis rs9309473 1 rs9309473 ENSG00000163016.8 ALMS1P 6.89 1.79e-11 1.18e-08 0.36 0.3 Metabolite levels; chr2:73516855 chr2:73644919~73685576:+ LUSC cis rs7945705 0.87 rs4929922 ENSG00000254860.4 TMEM9B-AS1 6.89 1.8e-11 1.18e-08 0.34 0.3 Hemoglobin concentration; chr11:8954229 chr11:8964675~8977527:+ LUSC cis rs748404 0.589 rs62020612 ENSG00000249839.1 AC011330.5 -6.89 1.81e-11 1.19e-08 -0.52 -0.3 Lung cancer; chr15:43525881 chr15:43663654~43684339:- LUSC cis rs2188561 0.697 rs13224313 ENSG00000241764.3 AC002467.7 6.89 1.81e-11 1.19e-08 0.38 0.3 Alcohol consumption; chr7:107741907 chr7:107742817~107744581:- LUSC cis rs6991838 0.673 rs7462352 ENSG00000200714.1 Y_RNA 6.89 1.81e-11 1.19e-08 0.36 0.3 Intelligence (multi-trait analysis); chr8:65584378 chr8:65592731~65592820:+ LUSC cis rs875971 1 rs697970 ENSG00000237310.1 GS1-124K5.4 -6.89 1.81e-11 1.19e-08 -0.31 -0.3 Aortic root size; chr7:66095065 chr7:66493706~66495474:+ LUSC cis rs11763147 1 rs11763147 ENSG00000164669.11 INTS4P1 6.89 1.81e-11 1.19e-08 0.33 0.3 Corneal structure; chr7:65861834 chr7:65141225~65234216:+ LUSC cis rs7955901 0.691 rs11178602 ENSG00000257265.1 CTD-2021H9.1 -6.89 1.81e-11 1.19e-08 -0.33 -0.3 Type 2 diabetes; chr12:71097725 chr12:71007773~71032083:- LUSC cis rs11098499 0.738 rs28408407 ENSG00000250412.1 KLHL2P1 6.89 1.81e-11 1.19e-08 0.38 0.3 Corneal astigmatism; chr4:119454875 chr4:119334329~119378233:+ LUSC cis rs4950322 1 rs1806618 ENSG00000278811.3 LINC00624 6.89 1.81e-11 1.19e-08 0.36 0.3 Protein quantitative trait loci; chr1:147377075 chr1:147258885~147517875:- LUSC cis rs4950322 1 rs4448568 ENSG00000278811.3 LINC00624 6.89 1.81e-11 1.19e-08 0.36 0.3 Protein quantitative trait loci; chr1:147377296 chr1:147258885~147517875:- LUSC cis rs4950322 0.895 rs17356735 ENSG00000278811.3 LINC00624 6.89 1.81e-11 1.19e-08 0.36 0.3 Protein quantitative trait loci; chr1:147378328 chr1:147258885~147517875:- LUSC cis rs11976180 1 rs1320893 ENSG00000170356.8 OR2A20P -6.89 1.81e-11 1.19e-08 -0.41 -0.3 Obesity-related traits; chr7:144055019 chr7:144250045~144252957:- LUSC cis rs10740039 0.883 rs7898504 ENSG00000254271.1 RP11-131N11.4 6.89 1.81e-11 1.19e-08 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60658233 chr10:60734342~60741828:+ LUSC cis rs11098499 0.588 rs2389874 ENSG00000245958.5 RP11-33B1.1 6.89 1.82e-11 1.2e-08 0.29 0.3 Corneal astigmatism; chr4:119633836 chr4:119454791~119552025:+ LUSC cis rs9545047 0.716 rs9318638 ENSG00000227676.3 LINC01068 -6.89 1.82e-11 1.2e-08 -0.37 -0.3 Schizophrenia; chr13:79412018 chr13:79566727~79571436:+ LUSC cis rs875971 0.522 rs4718286 ENSG00000164669.11 INTS4P1 -6.89 1.83e-11 1.2e-08 -0.33 -0.3 Aortic root size; chr7:65827777 chr7:65141225~65234216:+ LUSC cis rs10129255 0.784 rs7147210 ENSG00000224373.3 IGHV4-59 6.89 1.83e-11 1.2e-08 0.18 0.3 Kawasaki disease; chr14:106705271 chr14:106627249~106627825:- LUSC cis rs10129255 0.826 rs7150693 ENSG00000224373.3 IGHV4-59 6.89 1.83e-11 1.2e-08 0.18 0.3 Kawasaki disease; chr14:106705382 chr14:106627249~106627825:- LUSC cis rs10129255 0.869 rs7150549 ENSG00000224373.3 IGHV4-59 6.89 1.83e-11 1.2e-08 0.18 0.3 Kawasaki disease; chr14:106705441 chr14:106627249~106627825:- LUSC cis rs4950322 0.542 rs17159914 ENSG00000278811.3 LINC00624 -6.89 1.83e-11 1.2e-08 -0.32 -0.3 Protein quantitative trait loci; chr1:147183226 chr1:147258885~147517875:- LUSC cis rs4950322 0.744 rs2353987 ENSG00000278811.3 LINC00624 6.89 1.83e-11 1.2e-08 0.34 0.3 Protein quantitative trait loci; chr1:147355845 chr1:147258885~147517875:- LUSC cis rs9326248 0.52 rs236919 ENSG00000280143.1 AP000892.6 6.89 1.83e-11 1.21e-08 0.31 0.3 Blood protein levels; chr11:117224645 chr11:117204967~117210292:+ LUSC cis rs1134634 1 rs1134634 ENSG00000273133.1 RP11-799M12.2 6.89 1.84e-11 1.21e-08 0.38 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15601446 chr4:15563698~15564253:- LUSC cis rs2946504 0.501 rs2946509 ENSG00000251468.2 RP11-369K16.1 -6.89 1.84e-11 1.21e-08 -0.36 -0.3 Type 2 diabetes; chr8:12950782 chr8:12958387~12962200:+ LUSC cis rs2919917 1 rs10093797 ENSG00000254352.1 RP11-578O24.2 6.89 1.84e-11 1.21e-08 0.38 0.3 Lymphocyte counts; chr8:78660478 chr8:78723796~78724136:- LUSC cis rs2179367 0.959 rs628488 ENSG00000231760.4 RP11-350J20.5 6.89 1.84e-11 1.21e-08 0.4 0.3 Dupuytren's disease; chr6:149398264 chr6:149796151~149826294:- LUSC cis rs9660180 0.967 rs6687065 ENSG00000231050.1 RP1-140A9.1 6.89 1.84e-11 1.21e-08 0.3 0.3 Body mass index; chr1:1847030 chr1:1891471~1892658:+ LUSC cis rs801193 0.636 rs10233806 ENSG00000237310.1 GS1-124K5.4 -6.89 1.85e-11 1.21e-08 -0.31 -0.3 Aortic root size; chr7:66653261 chr7:66493706~66495474:+ LUSC cis rs6142102 0.961 rs6088355 ENSG00000276073.1 RP5-1125A11.7 -6.89 1.85e-11 1.21e-08 -0.32 -0.3 Skin pigmentation; chr20:33958081 chr20:33985617~33988989:- LUSC cis rs11690935 0.959 rs7562356 ENSG00000228389.1 AC068039.4 6.89 1.85e-11 1.22e-08 0.35 0.3 Schizophrenia; chr2:171770101 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs1113389 ENSG00000228389.1 AC068039.4 6.89 1.85e-11 1.22e-08 0.35 0.3 Schizophrenia; chr2:171778855 chr2:171773482~171775844:+ LUSC cis rs2665103 0.715 rs7403041 ENSG00000278603.1 RP13-608F4.5 -6.89 1.86e-11 1.22e-08 -0.36 -0.3 Intelligence (multi-trait analysis); chr15:82287841 chr15:82472203~82472426:+ LUSC cis rs4713118 0.868 rs760587 ENSG00000219392.1 RP1-265C24.5 -6.89 1.86e-11 1.22e-08 -0.42 -0.3 Parkinson's disease; chr6:27772521 chr6:28115628~28116551:+ LUSC cis rs6142102 0.961 rs6059649 ENSG00000276073.1 RP5-1125A11.7 -6.88 1.86e-11 1.22e-08 -0.32 -0.3 Skin pigmentation; chr20:34056071 chr20:33985617~33988989:- LUSC cis rs881375 1 rs10818480 ENSG00000226752.6 PSMD5-AS1 -6.88 1.86e-11 1.22e-08 -0.35 -0.3 Rheumatoid arthritis; chr9:120880892 chr9:120824828~120854385:+ LUSC cis rs3750965 0.959 rs3168115 ENSG00000260895.1 RP11-554A11.7 -6.88 1.87e-11 1.23e-08 -0.35 -0.3 Hair color; chr11:69090622 chr11:69103493~69109094:+ LUSC cis rs875971 0.54 rs781152 ENSG00000224316.1 RP11-479O9.2 6.88 1.87e-11 1.23e-08 0.3 0.3 Aortic root size; chr7:66014585 chr7:65773620~65802067:+ LUSC cis rs17711722 0.727 rs781151 ENSG00000224316.1 RP11-479O9.2 6.88 1.87e-11 1.23e-08 0.3 0.3 Calcium levels; chr7:66014891 chr7:65773620~65802067:+ LUSC cis rs8072100 0.967 rs4239163 ENSG00000228782.6 CTD-2026D20.3 6.88 1.87e-11 1.23e-08 0.29 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47678588 chr17:47450568~47492492:- LUSC cis rs2929278 0.617 rs3986209 ENSG00000249839.1 AC011330.5 6.88 1.88e-11 1.23e-08 0.47 0.3 Schizophrenia; chr15:43758675 chr15:43663654~43684339:- LUSC cis rs6142102 0.961 rs4911144 ENSG00000276073.1 RP5-1125A11.7 -6.88 1.88e-11 1.23e-08 -0.32 -0.3 Skin pigmentation; chr20:34026565 chr20:33985617~33988989:- LUSC cis rs11690935 1 rs34542126 ENSG00000228389.1 AC068039.4 -6.88 1.88e-11 1.23e-08 -0.35 -0.3 Schizophrenia; chr2:171686195 chr2:171773482~171775844:+ LUSC cis rs6142102 0.961 rs2284387 ENSG00000276073.1 RP5-1125A11.7 -6.88 1.88e-11 1.23e-08 -0.32 -0.3 Skin pigmentation; chr20:34056782 chr20:33985617~33988989:- LUSC cis rs2297363 1 rs3777404 ENSG00000213073.4 RP11-288H12.3 -6.88 1.88e-11 1.24e-08 -0.38 -0.3 Total cholesterol levels;Blood protein levels; chr6:160077017 chr6:160093082~160096212:+ LUSC cis rs2404602 0.647 rs36114653 ENSG00000259422.1 RP11-593F23.1 -6.88 1.88e-11 1.24e-08 -0.37 -0.3 Blood metabolite levels; chr15:76733052 chr15:76174891~76181486:- LUSC cis rs10129255 0.784 rs7147210 ENSG00000280411.1 IGHV1-69-2 -6.88 1.89e-11 1.24e-08 -0.22 -0.3 Kawasaki disease; chr14:106705271 chr14:106762092~106762588:- LUSC cis rs10129255 0.826 rs7150693 ENSG00000280411.1 IGHV1-69-2 -6.88 1.89e-11 1.24e-08 -0.22 -0.3 Kawasaki disease; chr14:106705382 chr14:106762092~106762588:- LUSC cis rs10129255 0.869 rs7150549 ENSG00000280411.1 IGHV1-69-2 -6.88 1.89e-11 1.24e-08 -0.22 -0.3 Kawasaki disease; chr14:106705441 chr14:106762092~106762588:- LUSC cis rs783540 0.521 rs28719490 ENSG00000276710.3 CSPG4P8 -6.88 1.89e-11 1.24e-08 -0.35 -0.3 Schizophrenia; chr15:82720688 chr15:82459472~82477258:+ LUSC cis rs8072100 0.967 rs4239162 ENSG00000228782.6 CTD-2026D20.3 6.88 1.89e-11 1.24e-08 0.29 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47678444 chr17:47450568~47492492:- LUSC cis rs1075265 0.749 rs805436 ENSG00000233266.1 HMGB1P31 6.88 1.89e-11 1.24e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:53837843 chr2:54051334~54051760:+ LUSC cis rs17711722 0.528 rs73138179 ENSG00000236529.1 RP13-254B10.1 6.88 1.89e-11 1.24e-08 0.32 0.3 Calcium levels; chr7:65829495 chr7:65840212~65840596:+ LUSC cis rs7174755 0.637 rs10152713 ENSG00000260657.2 RP11-315D16.4 -6.88 1.89e-11 1.24e-08 -0.36 -0.3 Major depressive disorder; chr15:68179553 chr15:68267792~68277994:- LUSC cis rs7250849 0.736 rs12459542 ENSG00000273837.1 LLNLR-470E3.1 -6.88 1.9e-11 1.24e-08 -0.41 -0.3 Blood protein levels; chr19:51660025 chr19:51639478~51639931:- LUSC cis rs2179367 0.959 rs9390677 ENSG00000231760.4 RP11-350J20.5 6.88 1.9e-11 1.25e-08 0.4 0.3 Dupuytren's disease; chr6:149389361 chr6:149796151~149826294:- LUSC cis rs2337406 1 rs1961901 ENSG00000274576.2 IGHV2-70 -6.88 1.9e-11 1.25e-08 -0.33 -0.3 Alzheimer's disease (late onset); chr14:106680856 chr14:106770577~106771020:- LUSC cis rs2337406 1 rs4774172 ENSG00000274576.2 IGHV2-70 -6.88 1.9e-11 1.25e-08 -0.33 -0.3 Alzheimer's disease (late onset); chr14:106681320 chr14:106770577~106771020:- LUSC cis rs801193 0.569 rs13226966 ENSG00000237310.1 GS1-124K5.4 6.88 1.9e-11 1.25e-08 0.32 0.3 Aortic root size; chr7:66768636 chr7:66493706~66495474:+ LUSC cis rs8031584 0.706 rs798084 ENSG00000260382.1 RP11-540B6.2 6.88 1.91e-11 1.25e-08 0.41 0.3 Huntington's disease progression; chr15:30834732 chr15:30882267~30883231:- LUSC cis rs8177876 0.631 rs2549895 ENSG00000261838.4 RP11-303E16.6 -6.88 1.91e-11 1.25e-08 -0.59 -0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81052415 chr16:81069854~81076598:+ LUSC cis rs11157436 0.874 rs35951144 ENSG00000211813.2 TRAV34 6.88 1.92e-11 1.26e-08 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22149973 chr14:22207522~22208129:+ LUSC cis rs2337406 0.85 rs11849578 ENSG00000274576.2 IGHV2-70 -6.88 1.92e-11 1.26e-08 -0.35 -0.3 Alzheimer's disease (late onset); chr14:106670302 chr14:106770577~106771020:- LUSC cis rs9318086 0.648 rs78881146 ENSG00000205861.10 C1QTNF9B-AS1 -6.88 1.92e-11 1.26e-08 -0.39 -0.3 Myopia (pathological); chr13:23894565 chr13:23888889~23897263:+ LUSC cis rs748404 0.697 rs473554 ENSG00000249839.1 AC011330.5 -6.88 1.92e-11 1.26e-08 -0.4 -0.3 Lung cancer; chr15:43276009 chr15:43663654~43684339:- LUSC cis rs9921338 0.961 rs72773830 ENSG00000263080.1 RP11-485G7.5 6.88 1.93e-11 1.26e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11318966 chr16:11341809~11345211:- LUSC cis rs9921338 0.924 rs72773831 ENSG00000263080.1 RP11-485G7.5 6.88 1.93e-11 1.26e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11319070 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs72773832 ENSG00000263080.1 RP11-485G7.5 6.88 1.93e-11 1.26e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11319266 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs72773834 ENSG00000263080.1 RP11-485G7.5 6.88 1.93e-11 1.26e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11319436 chr16:11341809~11345211:- LUSC cis rs10800713 0.908 rs6686605 ENSG00000260088.1 RP11-92G12.3 -6.88 1.93e-11 1.26e-08 -0.43 -0.3 Tandem gait; chr1:200539440 chr1:200669507~200694250:+ LUSC cis rs1865760 0.929 rs12195653 ENSG00000272462.2 U91328.19 -6.88 1.93e-11 1.26e-08 -0.33 -0.3 Height; chr6:25958393 chr6:25992662~26001775:+ LUSC cis rs13113518 0.812 rs13140590 ENSG00000223305.1 RN7SKP30 6.88 1.93e-11 1.26e-08 0.37 0.3 Height; chr4:55548666 chr4:55540502~55540835:- LUSC cis rs11098499 0.754 rs7672778 ENSG00000249244.1 RP11-548H18.2 6.88 1.93e-11 1.26e-08 0.38 0.3 Corneal astigmatism; chr4:119327430 chr4:119391831~119395335:- LUSC cis rs1823913 1 rs1823913 ENSG00000280083.1 RP11-317J9.1 -6.88 1.93e-11 1.26e-08 -0.37 -0.3 Obesity-related traits; chr2:191253321 chr2:191154118~191156070:- LUSC cis rs34375054 0.526 rs883315 ENSG00000279233.1 RP11-158L12.4 6.88 1.94e-11 1.27e-08 0.3 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125192343 chr12:125138245~125141711:+ LUSC cis rs34375054 0.526 rs2343638 ENSG00000279233.1 RP11-158L12.4 6.88 1.94e-11 1.27e-08 0.3 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125192576 chr12:125138245~125141711:+ LUSC cis rs2179367 0.959 rs237034 ENSG00000231760.4 RP11-350J20.5 6.88 1.94e-11 1.27e-08 0.4 0.3 Dupuytren's disease; chr6:149390726 chr6:149796151~149826294:- LUSC cis rs5753618 0.583 rs71324184 ENSG00000236132.1 CTA-440B3.1 -6.88 1.94e-11 1.27e-08 -0.39 -0.3 Colorectal cancer; chr22:31356075 chr22:31816379~31817491:- LUSC cis rs3779195 0.697 rs1688606 ENSG00000272950.1 RP11-307C18.1 6.88 1.94e-11 1.27e-08 0.5 0.3 Sex hormone-binding globulin levels; chr7:98345539 chr7:98322853~98323430:+ LUSC cis rs867371 0.896 rs6495647 ENSG00000255769.6 GOLGA2P10 -6.88 1.94e-11 1.27e-08 -0.37 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82244708 chr15:82472993~82513950:- LUSC cis rs10129255 0.912 rs8009135 ENSG00000280411.1 IGHV1-69-2 -6.88 1.95e-11 1.27e-08 -0.21 -0.3 Kawasaki disease; chr14:106777528 chr14:106762092~106762588:- LUSC cis rs4950322 0.947 rs58671552 ENSG00000278811.3 LINC00624 6.88 1.95e-11 1.27e-08 0.37 0.3 Protein quantitative trait loci; chr1:147409534 chr1:147258885~147517875:- LUSC cis rs10129255 0.834 rs10139893 ENSG00000280411.1 IGHV1-69-2 -6.88 1.95e-11 1.28e-08 -0.22 -0.3 Kawasaki disease; chr14:106711377 chr14:106762092~106762588:- LUSC cis rs113835537 0.529 rs2305532 ENSG00000255517.5 CTD-3074O7.5 -6.88 1.97e-11 1.29e-08 -0.36 -0.3 Airway imaging phenotypes; chr11:66531123 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs2305533 ENSG00000255517.5 CTD-3074O7.5 -6.88 1.97e-11 1.29e-08 -0.36 -0.3 Airway imaging phenotypes; chr11:66531152 chr11:66473490~66480233:- LUSC cis rs2919917 1 rs3808619 ENSG00000254352.1 RP11-578O24.2 6.88 1.97e-11 1.29e-08 0.38 0.3 Lymphocyte counts; chr8:78665491 chr8:78723796~78724136:- LUSC cis rs6142102 1 rs12480839 ENSG00000276073.1 RP5-1125A11.7 -6.88 1.97e-11 1.29e-08 -0.31 -0.3 Skin pigmentation; chr20:34139624 chr20:33985617~33988989:- LUSC cis rs17711722 0.585 rs6942660 ENSG00000164669.11 INTS4P1 -6.88 1.97e-11 1.29e-08 -0.33 -0.3 Calcium levels; chr7:65837419 chr7:65141225~65234216:+ LUSC cis rs6142102 0.961 rs2056990 ENSG00000276073.1 RP5-1125A11.7 -6.88 1.97e-11 1.29e-08 -0.32 -0.3 Skin pigmentation; chr20:34035658 chr20:33985617~33988989:- LUSC cis rs875971 1 rs6979382 ENSG00000237310.1 GS1-124K5.4 6.88 1.98e-11 1.29e-08 0.31 0.3 Aortic root size; chr7:66421388 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs6961990 ENSG00000237310.1 GS1-124K5.4 6.88 1.98e-11 1.29e-08 0.31 0.3 Aortic root size; chr7:66423583 chr7:66493706~66495474:+ LUSC cis rs853679 0.542 rs6934769 ENSG00000204709.4 LINC01556 6.87 1.98e-11 1.3e-08 0.42 0.3 Depression; chr6:28123153 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs17711801 ENSG00000204709.4 LINC01556 6.87 1.98e-11 1.3e-08 0.42 0.3 Depression; chr6:28124529 chr6:28943877~28944537:+ LUSC cis rs4713118 0.527 rs9461433 ENSG00000204709.4 LINC01556 6.87 1.98e-11 1.3e-08 0.42 0.3 Parkinson's disease; chr6:28127394 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9468292 ENSG00000204709.4 LINC01556 6.87 1.98e-11 1.3e-08 0.42 0.3 Depression; chr6:28127577 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs1947863 ENSG00000204709.4 LINC01556 6.87 1.98e-11 1.3e-08 0.42 0.3 Depression; chr6:28131566 chr6:28943877~28944537:+ LUSC cis rs1865760 1 rs9393675 ENSG00000272462.2 U91328.19 -6.87 1.98e-11 1.3e-08 -0.33 -0.3 Height; chr6:25929888 chr6:25992662~26001775:+ LUSC cis rs7772486 0.754 rs6906258 ENSG00000235652.6 RP11-545I5.3 -6.87 1.98e-11 1.3e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145768220 chr6:145799409~145886585:+ LUSC cis rs853679 0.607 rs13211507 ENSG00000204709.4 LINC01556 6.87 1.99e-11 1.3e-08 0.62 0.3 Depression; chr6:28289600 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs34691223 ENSG00000204709.4 LINC01556 6.87 1.99e-11 1.3e-08 0.62 0.3 Depression; chr6:28290431 chr6:28943877~28944537:+ LUSC cis rs9309473 0.95 rs10198549 ENSG00000163016.8 ALMS1P 6.87 1.99e-11 1.3e-08 0.36 0.3 Metabolite levels; chr2:73567277 chr2:73644919~73685576:+ LUSC cis rs9309473 1 rs7583255 ENSG00000163016.8 ALMS1P 6.87 1.99e-11 1.3e-08 0.36 0.3 Metabolite levels; chr2:73570869 chr2:73644919~73685576:+ LUSC cis rs35160687 0.901 rs34048420 ENSG00000273080.1 RP11-301O19.1 6.87 1.99e-11 1.3e-08 0.29 0.3 Night sleep phenotypes; chr2:86302625 chr2:86195590~86196049:+ LUSC cis rs35160687 0.901 rs34069316 ENSG00000273080.1 RP11-301O19.1 6.87 1.99e-11 1.3e-08 0.29 0.3 Night sleep phenotypes; chr2:86302669 chr2:86195590~86196049:+ LUSC cis rs7772486 0.79 rs2249386 ENSG00000235652.6 RP11-545I5.3 6.87 1.99e-11 1.3e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145865475 chr6:145799409~145886585:+ LUSC cis rs11098499 0.754 rs10212714 ENSG00000249244.1 RP11-548H18.2 6.87 1.99e-11 1.3e-08 0.38 0.3 Corneal astigmatism; chr4:119333147 chr4:119391831~119395335:- LUSC cis rs6142102 0.812 rs6059558 ENSG00000276073.1 RP5-1125A11.7 -6.87 1.99e-11 1.3e-08 -0.32 -0.3 Skin pigmentation; chr20:33929024 chr20:33985617~33988989:- LUSC cis rs673078 0.607 rs61943403 ENSG00000275759.1 RP11-131L12.3 -6.87 1.99e-11 1.3e-08 -0.42 -0.3 Glucose homeostasis traits; chr12:118399887 chr12:118428281~118428870:+ LUSC cis rs9921338 0.961 rs8043692 ENSG00000263080.1 RP11-485G7.5 6.87 1.99e-11 1.3e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11333100 chr16:11341809~11345211:- LUSC cis rs9921338 0.923 rs6498181 ENSG00000263080.1 RP11-485G7.5 6.87 1.99e-11 1.3e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11333336 chr16:11341809~11345211:- LUSC cis rs9309473 1 rs10190219 ENSG00000163016.8 ALMS1P 6.87 2e-11 1.3e-08 0.36 0.3 Metabolite levels; chr2:73431203 chr2:73644919~73685576:+ LUSC cis rs6921919 0.583 rs6928771 ENSG00000204709.4 LINC01556 6.87 2e-11 1.31e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28407432 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs6928773 ENSG00000204709.4 LINC01556 6.87 2e-11 1.31e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28407433 chr6:28943877~28944537:+ LUSC cis rs7772486 0.754 rs9386132 ENSG00000235652.6 RP11-545I5.3 6.87 2.01e-11 1.31e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145819615 chr6:145799409~145886585:+ LUSC cis rs8177876 0.731 rs77145371 ENSG00000261838.4 RP11-303E16.6 6.87 2.01e-11 1.31e-08 0.69 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085055 chr16:81069854~81076598:+ LUSC cis rs8177876 0.908 rs80187824 ENSG00000261838.4 RP11-303E16.6 6.87 2.01e-11 1.31e-08 0.69 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085075 chr16:81069854~81076598:+ LUSC cis rs8177876 0.731 rs74882687 ENSG00000261838.4 RP11-303E16.6 6.87 2.01e-11 1.31e-08 0.69 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085315 chr16:81069854~81076598:+ LUSC cis rs8177876 0.642 rs76909932 ENSG00000261838.4 RP11-303E16.6 6.87 2.01e-11 1.31e-08 0.69 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085449 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs8177939 ENSG00000261838.4 RP11-303E16.6 6.87 2.01e-11 1.31e-08 0.69 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085591 chr16:81069854~81076598:+ LUSC cis rs8062405 0.756 rs151182 ENSG00000278665.1 RP11-666O2.4 6.87 2.01e-11 1.31e-08 0.31 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28484431 chr16:28599241~28601881:- LUSC cis rs9322193 0.923 rs9371207 ENSG00000268592.3 RAET1E-AS1 6.87 2.02e-11 1.32e-08 0.38 0.3 Lung cancer; chr6:149858087 chr6:149863494~149919507:+ LUSC cis rs172166 0.694 rs203876 ENSG00000204709.4 LINC01556 6.87 2.02e-11 1.32e-08 0.39 0.3 Cardiac Troponin-T levels; chr6:28078895 chr6:28943877~28944537:+ LUSC cis rs12554020 0.786 rs12554164 ENSG00000227603.1 RP11-165J3.6 6.87 2.02e-11 1.32e-08 0.46 0.3 Schizophrenia; chr9:93456677 chr9:93435332~93437121:- LUSC cis rs2834288 0.613 rs2834297 ENSG00000237945.6 LINC00649 -6.87 2.02e-11 1.32e-08 -0.3 -0.3 Gut microbiota (bacterial taxa); chr21:33910534 chr21:33915534~33977691:+ LUSC cis rs1075265 0.836 rs10208233 ENSG00000233266.1 HMGB1P31 6.87 2.02e-11 1.32e-08 0.4 0.3 Chronotype;Morning vs. evening chronotype; chr2:54066433 chr2:54051334~54051760:+ LUSC cis rs2903698 0.565 rs13152113 ENSG00000250735.4 RP11-567N4.3 6.87 2.02e-11 1.32e-08 0.34 0.3 Prion diseases; chr4:75465869 chr4:75401195~75423023:+ LUSC cis rs172166 0.694 rs203892 ENSG00000204709.4 LINC01556 6.87 2.03e-11 1.32e-08 0.39 0.3 Cardiac Troponin-T levels; chr6:28099418 chr6:28943877~28944537:+ LUSC cis rs12022452 0.822 rs6600343 ENSG00000238287.1 RP11-656D10.3 -6.87 2.03e-11 1.32e-08 -0.46 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr1:40562538 chr1:40493157~40508661:- LUSC cis rs6504950 0.745 rs12603899 ENSG00000275710.1 RP11-257O5.4 6.87 2.03e-11 1.32e-08 0.35 0.3 Breast cancer; chr17:54932737 chr17:54964474~54964679:+ LUSC cis rs35160687 0.901 rs12478653 ENSG00000273080.1 RP11-301O19.1 -6.87 2.03e-11 1.32e-08 -0.29 -0.3 Night sleep phenotypes; chr2:86308271 chr2:86195590~86196049:+ LUSC cis rs6921919 0.559 rs13210866 ENSG00000204709.4 LINC01556 6.87 2.03e-11 1.32e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28416065 chr6:28943877~28944537:+ LUSC cis rs6921919 0.609 rs36018474 ENSG00000204709.4 LINC01556 6.87 2.03e-11 1.32e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28417752 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs13201726 ENSG00000204709.4 LINC01556 6.87 2.03e-11 1.32e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28417774 chr6:28943877~28944537:+ LUSC cis rs10129255 0.912 rs61996059 ENSG00000224373.3 IGHV4-59 6.87 2.03e-11 1.33e-08 0.18 0.3 Kawasaki disease; chr14:106716897 chr14:106627249~106627825:- LUSC cis rs6570726 0.577 rs399502 ENSG00000235652.6 RP11-545I5.3 6.87 2.03e-11 1.33e-08 0.31 0.3 Lobe attachment (rater-scored or self-reported); chr6:145484738 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs6915718 ENSG00000235652.6 RP11-545I5.3 -6.87 2.04e-11 1.33e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145779540 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs973856 ENSG00000235652.6 RP11-545I5.3 -6.87 2.04e-11 1.33e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145460780 chr6:145799409~145886585:+ LUSC cis rs881375 0.935 rs7034390 ENSG00000226752.6 PSMD5-AS1 -6.87 2.04e-11 1.33e-08 -0.34 -0.3 Rheumatoid arthritis; chr9:120884210 chr9:120824828~120854385:+ LUSC cis rs8062405 0.823 rs7202948 ENSG00000278665.1 RP11-666O2.4 6.87 2.05e-11 1.34e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546968 chr16:28599241~28601881:- LUSC cis rs2337406 1 rs17113257 ENSG00000274576.2 IGHV2-70 -6.87 2.05e-11 1.34e-08 -0.32 -0.3 Alzheimer's disease (late onset); chr14:106679574 chr14:106770577~106771020:- LUSC cis rs8059260 0.736 rs80079627 ENSG00000274038.1 RP11-66H6.4 -6.87 2.06e-11 1.34e-08 -0.54 -0.3 Alcohol consumption over the past year; chr16:10948741 chr16:11056556~11057034:+ LUSC cis rs748404 0.666 rs60018990 ENSG00000249839.1 AC011330.5 -6.87 2.06e-11 1.34e-08 -0.51 -0.3 Lung cancer; chr15:43504606 chr15:43663654~43684339:- LUSC cis rs2903698 0.585 rs11944808 ENSG00000250735.4 RP11-567N4.3 6.87 2.06e-11 1.34e-08 0.34 0.3 Prion diseases; chr4:75437206 chr4:75401195~75423023:+ LUSC cis rs2903698 0.585 rs7662152 ENSG00000250735.4 RP11-567N4.3 6.87 2.06e-11 1.34e-08 0.34 0.3 Prion diseases; chr4:75437830 chr4:75401195~75423023:+ LUSC cis rs2903698 0.585 rs9994735 ENSG00000250735.4 RP11-567N4.3 6.87 2.06e-11 1.34e-08 0.34 0.3 Prion diseases; chr4:75438267 chr4:75401195~75423023:+ LUSC cis rs8059260 0.736 rs12149904 ENSG00000274038.1 RP11-66H6.4 -6.87 2.06e-11 1.35e-08 -0.5 -0.3 Alcohol consumption over the past year; chr16:10991789 chr16:11056556~11057034:+ LUSC cis rs2919917 1 rs1384804 ENSG00000254352.1 RP11-578O24.2 6.87 2.07e-11 1.35e-08 0.38 0.3 Lymphocyte counts; chr8:78659987 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs10093654 ENSG00000254352.1 RP11-578O24.2 6.87 2.07e-11 1.35e-08 0.38 0.3 Lymphocyte counts; chr8:78660360 chr8:78723796~78724136:- LUSC cis rs7772486 0.719 rs7753770 ENSG00000235652.6 RP11-545I5.3 -6.87 2.07e-11 1.35e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145745025 chr6:145799409~145886585:+ LUSC cis rs7772486 0.655 rs2142981 ENSG00000235652.6 RP11-545I5.3 -6.87 2.07e-11 1.35e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145750559 chr6:145799409~145886585:+ LUSC cis rs7772486 0.72 rs1890171 ENSG00000235652.6 RP11-545I5.3 -6.87 2.07e-11 1.35e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145750978 chr6:145799409~145886585:+ LUSC cis rs7772486 0.72 rs6570713 ENSG00000235652.6 RP11-545I5.3 -6.87 2.07e-11 1.35e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145753949 chr6:145799409~145886585:+ LUSC cis rs7772486 0.72 rs4896844 ENSG00000235652.6 RP11-545I5.3 -6.87 2.07e-11 1.35e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145754088 chr6:145799409~145886585:+ LUSC cis rs11690935 1 rs3795999 ENSG00000228389.1 AC068039.4 -6.87 2.07e-11 1.35e-08 -0.35 -0.3 Schizophrenia; chr2:171687973 chr2:171773482~171775844:+ LUSC cis rs10129255 0.957 rs12590667 ENSG00000211972.2 IGHV3-66 -6.87 2.07e-11 1.35e-08 -0.22 -0.3 Kawasaki disease; chr14:106779223 chr14:106675017~106675544:- LUSC cis rs11976180 1 rs2961134 ENSG00000170356.8 OR2A20P -6.87 2.08e-11 1.35e-08 -0.4 -0.3 Obesity-related traits; chr7:144073969 chr7:144250045~144252957:- LUSC cis rs66887589 0.748 rs28439855 ENSG00000245958.5 RP11-33B1.1 -6.87 2.08e-11 1.36e-08 -0.28 -0.3 Diastolic blood pressure; chr4:119341101 chr4:119454791~119552025:+ LUSC cis rs2188561 0.697 rs13242107 ENSG00000241764.3 AC002467.7 6.87 2.09e-11 1.36e-08 0.39 0.3 Alcohol consumption; chr7:107734800 chr7:107742817~107744581:- LUSC cis rs950169 0.8 rs34302901 ENSG00000225151.9 GOLGA2P7 -6.87 2.09e-11 1.36e-08 -0.41 -0.3 Schizophrenia; chr15:84567712 chr15:84199311~84230136:- LUSC cis rs1865760 0.929 rs2876693 ENSG00000272462.2 U91328.19 -6.87 2.09e-11 1.36e-08 -0.33 -0.3 Height; chr6:25954206 chr6:25992662~26001775:+ LUSC cis rs4853012 0.752 rs13413795 ENSG00000257800.1 FNBP1P1 6.87 2.09e-11 1.36e-08 0.35 0.3 Gestational age at birth (maternal effect); chr2:74122712 chr2:74120680~74123218:+ LUSC cis rs113835537 0.597 rs3825065 ENSG00000255517.5 CTD-3074O7.5 -6.87 2.1e-11 1.37e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66543540 chr11:66473490~66480233:- LUSC cis rs950169 0.922 rs12912934 ENSG00000225151.9 GOLGA2P7 -6.87 2.1e-11 1.37e-08 -0.42 -0.3 Schizophrenia; chr15:84571216 chr15:84199311~84230136:- LUSC cis rs172166 0.694 rs203893 ENSG00000204709.4 LINC01556 6.87 2.1e-11 1.37e-08 0.39 0.3 Cardiac Troponin-T levels; chr6:28094288 chr6:28943877~28944537:+ LUSC cis rs10129255 0.957 rs10150241 ENSG00000224373.3 IGHV4-59 -6.87 2.1e-11 1.37e-08 -0.17 -0.3 Kawasaki disease; chr14:106775945 chr14:106627249~106627825:- LUSC cis rs10129255 0.957 rs8009464 ENSG00000280411.1 IGHV1-69-2 -6.87 2.11e-11 1.37e-08 -0.21 -0.3 Kawasaki disease; chr14:106777611 chr14:106762092~106762588:- LUSC cis rs6921919 0.525 rs11760133 ENSG00000204709.4 LINC01556 6.87 2.11e-11 1.37e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28418962 chr6:28943877~28944537:+ LUSC cis rs7772486 0.754 rs10872580 ENSG00000235652.6 RP11-545I5.3 -6.86 2.11e-11 1.37e-08 -0.29 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145819145 chr6:145799409~145886585:+ LUSC cis rs5742933 0.803 rs1233302 ENSG00000253559.1 OSGEPL1-AS1 -6.86 2.11e-11 1.38e-08 -0.37 -0.3 Ferritin levels; chr2:189804154 chr2:189762704~189765556:+ LUSC cis rs9660180 0.967 rs11260623 ENSG00000231050.1 RP1-140A9.1 6.86 2.11e-11 1.38e-08 0.3 0.3 Body mass index; chr1:1850017 chr1:1891471~1892658:+ LUSC cis rs35160687 0.842 rs10200526 ENSG00000273080.1 RP11-301O19.1 6.86 2.12e-11 1.38e-08 0.29 0.3 Night sleep phenotypes; chr2:86300476 chr2:86195590~86196049:+ LUSC cis rs113835537 0.529 rs11824771 ENSG00000255517.5 CTD-3074O7.5 -6.86 2.12e-11 1.38e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66495079 chr11:66473490~66480233:- LUSC cis rs11098499 0.954 rs10017543 ENSG00000250412.1 KLHL2P1 6.86 2.12e-11 1.38e-08 0.38 0.3 Corneal astigmatism; chr4:119400265 chr4:119334329~119378233:+ LUSC cis rs8062405 0.72 rs9926245 ENSG00000278665.1 RP11-666O2.4 6.86 2.12e-11 1.38e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544385 chr16:28599241~28601881:- LUSC cis rs748404 0.666 rs34515241 ENSG00000249839.1 AC011330.5 -6.86 2.13e-11 1.38e-08 -0.52 -0.3 Lung cancer; chr15:43342011 chr15:43663654~43684339:- LUSC cis rs367615 0.506 rs1428932 ENSG00000249476.1 CTD-2587M2.1 -6.86 2.13e-11 1.39e-08 -0.34 -0.3 Colorectal cancer (SNP x SNP interaction); chr5:109456778 chr5:109237120~109326369:- LUSC cis rs17711722 0.653 rs2460421 ENSG00000236529.1 RP13-254B10.1 -6.86 2.13e-11 1.39e-08 -0.31 -0.3 Calcium levels; chr7:66026136 chr7:65840212~65840596:+ LUSC cis rs6504950 0.751 rs12937760 ENSG00000275710.1 RP11-257O5.4 6.86 2.13e-11 1.39e-08 0.38 0.3 Breast cancer; chr17:54938769 chr17:54964474~54964679:+ LUSC cis rs4865169 0.595 rs4865165 ENSG00000269949.1 RP11-738E22.3 -6.86 2.13e-11 1.39e-08 -0.37 -0.3 Breast cancer; chr4:56899380 chr4:56960927~56961373:- LUSC cis rs8072100 0.967 rs3760370 ENSG00000228782.6 CTD-2026D20.3 -6.86 2.14e-11 1.39e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47618466 chr17:47450568~47492492:- LUSC cis rs113835537 0.529 rs80100524 ENSG00000255517.5 CTD-3074O7.5 -6.86 2.14e-11 1.39e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66478465 chr11:66473490~66480233:- LUSC cis rs9309473 0.95 rs10169213 ENSG00000163016.8 ALMS1P 6.86 2.14e-11 1.39e-08 0.36 0.3 Metabolite levels; chr2:73560107 chr2:73644919~73685576:+ LUSC cis rs9309473 0.95 rs17009149 ENSG00000163016.8 ALMS1P 6.86 2.14e-11 1.39e-08 0.36 0.3 Metabolite levels; chr2:73563241 chr2:73644919~73685576:+ LUSC cis rs4803480 0.542 rs7255742 ENSG00000270164.1 LINC01480 -6.86 2.14e-11 1.39e-08 -0.25 -0.3 Schizophrenia; chr19:41543459 chr19:41535183~41536904:+ LUSC cis rs1865760 0.516 rs9393684 ENSG00000272462.2 U91328.19 -6.86 2.15e-11 1.4e-08 -0.32 -0.3 Height; chr6:26075303 chr6:25992662~26001775:+ LUSC cis rs6921919 0.525 rs16894095 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.37 0.3 Autism spectrum disorder or schizophrenia; chr6:28422453 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393891 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28111382 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9468286 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28111650 chr6:28943877~28944537:+ LUSC cis rs4713118 0.516 rs7739216 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Parkinson's disease; chr6:28112168 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs35512245 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28112175 chr6:28943877~28944537:+ LUSC cis rs853679 0.542 rs9393892 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28113616 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9380055 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28113851 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9368553 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28114487 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9368554 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28114933 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs4713137 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28115743 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9348793 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28116411 chr6:28943877~28944537:+ LUSC cis rs4713118 0.586 rs6905516 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Parkinson's disease; chr6:28118700 chr6:28943877~28944537:+ LUSC cis rs4713118 0.586 rs6905522 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Parkinson's disease; chr6:28118701 chr6:28943877~28944537:+ LUSC cis rs4713118 0.586 rs9468290 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Parkinson's disease; chr6:28119896 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs4711164 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28147378 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs4711165 ENSG00000204709.4 LINC01556 6.86 2.15e-11 1.4e-08 0.43 0.3 Depression; chr6:28147406 chr6:28943877~28944537:+ LUSC cis rs1865760 0.827 rs9295680 ENSG00000272462.2 U91328.19 -6.86 2.15e-11 1.4e-08 -0.32 -0.3 Height; chr6:25943875 chr6:25992662~26001775:+ LUSC cis rs1865760 0.827 rs9295681 ENSG00000272462.2 U91328.19 -6.86 2.15e-11 1.4e-08 -0.32 -0.3 Height; chr6:25943889 chr6:25992662~26001775:+ LUSC cis rs11098499 0.954 rs10017371 ENSG00000250412.1 KLHL2P1 6.86 2.15e-11 1.4e-08 0.39 0.3 Corneal astigmatism; chr4:119372621 chr4:119334329~119378233:+ LUSC cis rs367615 0.506 rs2914680 ENSG00000249476.1 CTD-2587M2.1 -6.86 2.16e-11 1.4e-08 -0.34 -0.3 Colorectal cancer (SNP x SNP interaction); chr5:109451445 chr5:109237120~109326369:- LUSC cis rs5742933 0.762 rs12992061 ENSG00000253559.1 OSGEPL1-AS1 6.86 2.16e-11 1.4e-08 0.36 0.3 Ferritin levels; chr2:189736026 chr2:189762704~189765556:+ LUSC cis rs55665837 0.559 rs11023209 ENSG00000251991.1 RNU7-49P 6.86 2.17e-11 1.41e-08 0.35 0.3 Vitamin D levels; chr11:14401054 chr11:14478892~14478953:+ LUSC cis rs172166 0.694 rs203877 ENSG00000204709.4 LINC01556 6.86 2.17e-11 1.41e-08 0.39 0.3 Cardiac Troponin-T levels; chr6:28080846 chr6:28943877~28944537:+ LUSC cis rs11690935 1 rs312925 ENSG00000228389.1 AC068039.4 6.86 2.18e-11 1.42e-08 0.35 0.3 Schizophrenia; chr2:171707412 chr2:171773482~171775844:+ LUSC cis rs2404602 0.611 rs2404734 ENSG00000259422.1 RP11-593F23.1 -6.86 2.18e-11 1.42e-08 -0.36 -0.3 Blood metabolite levels; chr15:76643824 chr15:76174891~76181486:- LUSC cis rs8040855 0.599 rs2342123 ENSG00000259295.5 CSPG4P12 6.86 2.18e-11 1.42e-08 0.33 0.3 Bulimia nervosa; chr15:85181918 chr15:85191438~85213905:+ LUSC cis rs17711722 0.701 rs4467826 ENSG00000164669.11 INTS4P1 -6.86 2.18e-11 1.42e-08 -0.33 -0.3 Calcium levels; chr7:65903721 chr7:65141225~65234216:+ LUSC cis rs61542988 1 rs61542988 ENSG00000228649.7 AC005682.5 6.86 2.19e-11 1.42e-08 0.35 0.3 Fibrinogen levels; chr7:22842672 chr7:22854178~22861579:+ LUSC cis rs6570726 0.62 rs12201226 ENSG00000235652.6 RP11-545I5.3 6.86 2.19e-11 1.42e-08 0.32 0.3 Lobe attachment (rater-scored or self-reported); chr6:145592283 chr6:145799409~145886585:+ LUSC cis rs10463554 0.892 rs66505956 ENSG00000175749.11 EIF3KP1 6.86 2.19e-11 1.42e-08 0.36 0.3 Parkinson's disease; chr5:102943853 chr5:103032376~103033031:+ LUSC cis rs748404 0.697 rs505249 ENSG00000249839.1 AC011330.5 -6.86 2.19e-11 1.42e-08 -0.4 -0.3 Lung cancer; chr15:43267762 chr15:43663654~43684339:- LUSC cis rs55665837 0.559 rs11023210 ENSG00000251991.1 RNU7-49P -6.86 2.19e-11 1.42e-08 -0.35 -0.3 Vitamin D levels; chr11:14401216 chr11:14478892~14478953:+ LUSC cis rs11690935 0.959 rs10497374 ENSG00000228389.1 AC068039.4 6.86 2.19e-11 1.42e-08 0.35 0.3 Schizophrenia; chr2:171784113 chr2:171773482~171775844:+ LUSC cis rs6570726 0.846 rs397311 ENSG00000235652.6 RP11-545I5.3 -6.86 2.2e-11 1.43e-08 -0.29 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145485565 chr6:145799409~145886585:+ LUSC cis rs35160687 0.901 rs10200186 ENSG00000273080.1 RP11-301O19.1 6.86 2.2e-11 1.43e-08 0.29 0.3 Night sleep phenotypes; chr2:86300300 chr2:86195590~86196049:+ LUSC cis rs748404 0.666 rs12911569 ENSG00000249839.1 AC011330.5 -6.86 2.21e-11 1.43e-08 -0.53 -0.3 Lung cancer; chr15:43305099 chr15:43663654~43684339:- LUSC cis rs748404 0.626 rs72707530 ENSG00000249839.1 AC011330.5 -6.86 2.21e-11 1.43e-08 -0.52 -0.3 Lung cancer; chr15:43353622 chr15:43663654~43684339:- LUSC cis rs8040855 0.599 rs6496791 ENSG00000259295.5 CSPG4P12 -6.86 2.21e-11 1.44e-08 -0.34 -0.3 Bulimia nervosa; chr15:85182428 chr15:85191438~85213905:+ LUSC cis rs4713118 0.621 rs10484403 ENSG00000204709.4 LINC01556 6.86 2.22e-11 1.44e-08 0.43 0.3 Parkinson's disease; chr6:28065745 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs6922169 ENSG00000204709.4 LINC01556 6.86 2.22e-11 1.44e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28415155 chr6:28943877~28944537:+ LUSC cis rs7250849 0.688 rs78019331 ENSG00000273837.1 LLNLR-470E3.1 -6.86 2.22e-11 1.44e-08 -0.4 -0.3 Blood protein levels; chr19:51658484 chr19:51639478~51639931:- LUSC cis rs11098499 0.863 rs1383532 ENSG00000250412.1 KLHL2P1 -6.86 2.22e-11 1.44e-08 -0.37 -0.3 Corneal astigmatism; chr4:119513249 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs28643450 ENSG00000249244.1 RP11-548H18.2 6.86 2.23e-11 1.44e-08 0.38 0.3 Corneal astigmatism; chr4:119324087 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs7672594 ENSG00000249244.1 RP11-548H18.2 6.86 2.23e-11 1.44e-08 0.38 0.3 Corneal astigmatism; chr4:119327388 chr4:119391831~119395335:- LUSC cis rs2337406 0.778 rs56965016 ENSG00000274576.2 IGHV2-70 -6.86 2.24e-11 1.45e-08 -0.34 -0.3 Alzheimer's disease (late onset); chr14:106656649 chr14:106770577~106771020:- LUSC cis rs11098499 0.754 rs2036860 ENSG00000249244.1 RP11-548H18.2 6.86 2.25e-11 1.46e-08 0.38 0.3 Corneal astigmatism; chr4:119327779 chr4:119391831~119395335:- LUSC cis rs5742933 0.652 rs10210345 ENSG00000253559.1 OSGEPL1-AS1 6.86 2.25e-11 1.46e-08 0.36 0.3 Ferritin levels; chr2:189754760 chr2:189762704~189765556:+ LUSC cis rs5742933 0.744 rs13009889 ENSG00000253559.1 OSGEPL1-AS1 6.86 2.25e-11 1.46e-08 0.36 0.3 Ferritin levels; chr2:189763842 chr2:189762704~189765556:+ LUSC cis rs8177876 0.642 rs56032321 ENSG00000261838.4 RP11-303E16.6 6.85 2.25e-11 1.46e-08 0.69 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81084301 chr16:81069854~81076598:+ LUSC cis rs748404 0.626 rs60367691 ENSG00000249839.1 AC011330.5 -6.85 2.26e-11 1.46e-08 -0.53 -0.3 Lung cancer; chr15:43559201 chr15:43663654~43684339:- LUSC cis rs3091242 0.933 rs926438 ENSG00000224183.1 SDHDP6 -6.85 2.26e-11 1.46e-08 -0.37 -0.3 Erythrocyte sedimentation rate; chr1:25427147 chr1:25294164~25294643:- LUSC cis rs227275 0.556 rs11731885 ENSG00000230069.3 LRRC37A15P -6.85 2.26e-11 1.46e-08 -0.32 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:103010913 chr4:102727274~102730721:- LUSC cis rs853679 0.546 rs71537572 ENSG00000204709.4 LINC01556 6.85 2.26e-11 1.47e-08 0.64 0.3 Depression; chr6:28002937 chr6:28943877~28944537:+ LUSC cis rs748404 0.666 rs7181545 ENSG00000249839.1 AC011330.5 -6.85 2.27e-11 1.47e-08 -0.53 -0.3 Lung cancer; chr15:43321363 chr15:43663654~43684339:- LUSC cis rs10129255 0.957 rs28887506 ENSG00000224373.3 IGHV4-59 6.85 2.28e-11 1.48e-08 0.17 0.3 Kawasaki disease; chr14:106785589 chr14:106627249~106627825:- LUSC cis rs11098499 0.865 rs2389809 ENSG00000250412.1 KLHL2P1 6.85 2.28e-11 1.48e-08 0.38 0.3 Corneal astigmatism; chr4:119456244 chr4:119334329~119378233:+ LUSC cis rs4713118 0.715 rs200480 ENSG00000216901.1 AL022393.7 6.85 2.29e-11 1.48e-08 0.32 0.3 Parkinson's disease; chr6:27805886 chr6:28176188~28176674:+ LUSC cis rs853679 0.607 rs34950484 ENSG00000204709.4 LINC01556 6.85 2.29e-11 1.49e-08 0.63 0.3 Depression; chr6:28310911 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs34661125 ENSG00000204709.4 LINC01556 6.85 2.29e-11 1.49e-08 0.63 0.3 Depression; chr6:28314117 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs13190888 ENSG00000204709.4 LINC01556 6.85 2.29e-11 1.49e-08 0.63 0.3 Depression; chr6:28318208 chr6:28943877~28944537:+ LUSC cis rs10129255 0.957 rs10142918 ENSG00000280411.1 IGHV1-69-2 -6.85 2.31e-11 1.49e-08 -0.21 -0.3 Kawasaki disease; chr14:106782206 chr14:106762092~106762588:- LUSC cis rs10129255 0.957 rs10142859 ENSG00000280411.1 IGHV1-69-2 -6.85 2.31e-11 1.49e-08 -0.21 -0.3 Kawasaki disease; chr14:106782238 chr14:106762092~106762588:- LUSC cis rs10246939 0.579 rs6969430 ENSG00000228775.6 WEE2-AS1 6.85 2.32e-11 1.5e-08 0.35 0.3 Bitter taste perception; chr7:141831340 chr7:141704338~141738346:- LUSC cis rs9309473 0.898 rs28879089 ENSG00000163016.8 ALMS1P 6.85 2.32e-11 1.5e-08 0.36 0.3 Metabolite levels; chr2:73585759 chr2:73644919~73685576:+ LUSC cis rs9309473 0.948 rs7603647 ENSG00000163016.8 ALMS1P 6.85 2.32e-11 1.5e-08 0.36 0.3 Metabolite levels; chr2:73590111 chr2:73644919~73685576:+ LUSC cis rs760794 0.577 rs17483277 ENSG00000237404.1 RP3-471C18.2 -6.85 2.33e-11 1.5e-08 -0.37 -0.3 Endometriosis; chr6:19790340 chr6:19689825~19753113:- LUSC cis rs1075265 0.749 rs805380 ENSG00000233266.1 HMGB1P31 6.85 2.33e-11 1.51e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:53867284 chr2:54051334~54051760:+ LUSC cis rs7739264 0.602 rs1121384 ENSG00000227116.1 RP3-471C18.1 -6.85 2.33e-11 1.51e-08 -0.34 -0.3 Endometriosis; chr6:19771276 chr6:19730427~19734567:- LUSC cis rs1075265 0.669 rs805317 ENSG00000233266.1 HMGB1P31 6.85 2.33e-11 1.51e-08 0.37 0.3 Chronotype;Morning vs. evening chronotype; chr2:53907867 chr2:54051334~54051760:+ LUSC cis rs1075265 0.692 rs805318 ENSG00000233266.1 HMGB1P31 6.85 2.33e-11 1.51e-08 0.37 0.3 Chronotype;Morning vs. evening chronotype; chr2:53907915 chr2:54051334~54051760:+ LUSC cis rs6597981 0.675 rs4963120 ENSG00000255142.1 AP006621.6 -6.85 2.33e-11 1.51e-08 -0.24 -0.3 Breast cancer; chr11:825777 chr11:781645~782105:+ LUSC cis rs8177876 0.822 rs56119129 ENSG00000261838.4 RP11-303E16.6 6.85 2.35e-11 1.52e-08 0.69 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81084661 chr16:81069854~81076598:+ LUSC cis rs853679 0.517 rs3757187 ENSG00000204709.4 LINC01556 6.85 2.35e-11 1.52e-08 0.43 0.3 Depression; chr6:28139876 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs3757185 ENSG00000204709.4 LINC01556 6.85 2.35e-11 1.52e-08 0.43 0.3 Depression; chr6:28139998 chr6:28943877~28944537:+ LUSC cis rs4950322 0.58 rs4950371 ENSG00000278811.3 LINC00624 6.85 2.35e-11 1.52e-08 0.34 0.3 Protein quantitative trait loci; chr1:147114243 chr1:147258885~147517875:- LUSC cis rs7772486 0.754 rs9390356 ENSG00000235652.6 RP11-545I5.3 -6.85 2.36e-11 1.53e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145797847 chr6:145799409~145886585:+ LUSC cis rs11098499 0.863 rs6835635 ENSG00000250412.1 KLHL2P1 6.85 2.37e-11 1.53e-08 0.37 0.3 Corneal astigmatism; chr4:119537712 chr4:119334329~119378233:+ LUSC cis rs950169 0.922 rs11633075 ENSG00000225151.9 GOLGA2P7 -6.85 2.38e-11 1.54e-08 -0.42 -0.3 Schizophrenia; chr15:84570741 chr15:84199311~84230136:- LUSC cis rs748404 0.666 rs7177892 ENSG00000249839.1 AC011330.5 -6.85 2.38e-11 1.54e-08 -0.53 -0.3 Lung cancer; chr15:43321171 chr15:43663654~43684339:- LUSC cis rs2404602 0.735 rs283789 ENSG00000259422.1 RP11-593F23.1 6.85 2.38e-11 1.54e-08 0.35 0.3 Blood metabolite levels; chr15:76485236 chr15:76174891~76181486:- LUSC cis rs72772090 0.539 rs17405676 ENSG00000248734.2 CTD-2260A17.1 -6.85 2.38e-11 1.54e-08 -0.41 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96846912 chr5:96784777~96785999:+ LUSC cis rs17270561 0.887 rs717551 ENSG00000272462.2 U91328.19 -6.85 2.38e-11 1.54e-08 -0.42 -0.3 Iron status biomarkers; chr6:25855396 chr6:25992662~26001775:+ LUSC cis rs4713118 0.824 rs9468225 ENSG00000219392.1 RP1-265C24.5 -6.85 2.39e-11 1.54e-08 -0.39 -0.3 Parkinson's disease; chr6:27777940 chr6:28115628~28116551:+ LUSC cis rs2404602 0.622 rs9635380 ENSG00000259422.1 RP11-593F23.1 -6.85 2.39e-11 1.54e-08 -0.37 -0.3 Blood metabolite levels; chr15:76811138 chr15:76174891~76181486:- LUSC cis rs6921919 0.583 rs740621 ENSG00000204709.4 LINC01556 6.85 2.4e-11 1.55e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28430010 chr6:28943877~28944537:+ LUSC cis rs1075265 0.73 rs11893270 ENSG00000233266.1 HMGB1P31 6.84 2.4e-11 1.55e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54019828 chr2:54051334~54051760:+ LUSC cis rs1823913 1 rs11681777 ENSG00000280083.1 RP11-317J9.1 6.84 2.4e-11 1.55e-08 0.37 0.3 Obesity-related traits; chr2:191256741 chr2:191154118~191156070:- LUSC cis rs1823913 1 rs4853564 ENSG00000280083.1 RP11-317J9.1 6.84 2.4e-11 1.55e-08 0.37 0.3 Obesity-related traits; chr2:191258939 chr2:191154118~191156070:- LUSC cis rs1823913 1 rs4853565 ENSG00000280083.1 RP11-317J9.1 6.84 2.4e-11 1.55e-08 0.37 0.3 Obesity-related traits; chr2:191259020 chr2:191154118~191156070:- LUSC cis rs1823913 1 rs4853462 ENSG00000280083.1 RP11-317J9.1 6.84 2.4e-11 1.55e-08 0.37 0.3 Obesity-related traits; chr2:191259078 chr2:191154118~191156070:- LUSC cis rs13113518 0.756 rs7658446 ENSG00000223305.1 RN7SKP30 6.84 2.4e-11 1.55e-08 0.37 0.3 Height; chr4:55495262 chr4:55540502~55540835:- LUSC cis rs2188561 0.615 rs13226711 ENSG00000241764.3 AC002467.7 6.84 2.4e-11 1.55e-08 0.4 0.3 Alcohol consumption; chr7:107754897 chr7:107742817~107744581:- LUSC cis rs6504950 0.83 rs12949538 ENSG00000275710.1 RP11-257O5.4 -6.84 2.4e-11 1.55e-08 -0.37 -0.3 Breast cancer; chr17:54933309 chr17:54964474~54964679:+ LUSC cis rs172166 0.637 rs1225597 ENSG00000216901.1 AL022393.7 6.84 2.4e-11 1.55e-08 0.36 0.3 Cardiac Troponin-T levels; chr6:28194309 chr6:28176188~28176674:+ LUSC cis rs9322193 0.576 rs7452592 ENSG00000223701.3 RAET1E-AS1 6.84 2.42e-11 1.56e-08 0.41 0.3 Lung cancer; chr6:149875445 chr6:149884431~149919508:+ LUSC cis rs8177876 0.749 rs2970076 ENSG00000261838.4 RP11-303E16.6 6.84 2.42e-11 1.56e-08 0.58 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81056211 chr16:81069854~81076598:+ LUSC cis rs2404602 0.647 rs11072616 ENSG00000259422.1 RP11-593F23.1 -6.84 2.42e-11 1.56e-08 -0.36 -0.3 Blood metabolite levels; chr15:76692928 chr15:76174891~76181486:- LUSC cis rs10246939 0.543 rs7786202 ENSG00000228775.6 WEE2-AS1 6.84 2.43e-11 1.57e-08 0.38 0.3 Bitter taste perception; chr7:141906099 chr7:141704338~141738346:- LUSC cis rs10463554 0.892 rs66759661 ENSG00000175749.11 EIF3KP1 6.84 2.43e-11 1.57e-08 0.36 0.3 Parkinson's disease; chr5:102925894 chr5:103032376~103033031:+ LUSC cis rs10129255 1 rs10141557 ENSG00000224373.3 IGHV4-59 6.84 2.43e-11 1.57e-08 0.17 0.3 Kawasaki disease; chr14:106767990 chr14:106627249~106627825:- LUSC cis rs6504950 0.8 rs9916547 ENSG00000275710.1 RP11-257O5.4 6.84 2.43e-11 1.57e-08 0.35 0.3 Breast cancer; chr17:54929529 chr17:54964474~54964679:+ LUSC cis rs6504950 0.8 rs8065361 ENSG00000275710.1 RP11-257O5.4 6.84 2.43e-11 1.57e-08 0.35 0.3 Breast cancer; chr17:54931492 chr17:54964474~54964679:+ LUSC cis rs2919917 1 rs1021156 ENSG00000254352.1 RP11-578O24.2 6.84 2.44e-11 1.57e-08 0.38 0.3 Lymphocyte counts; chr8:78663569 chr8:78723796~78724136:- LUSC cis rs61160187 0.582 rs1471488 ENSG00000215032.2 GNL3LP1 6.84 2.44e-11 1.57e-08 0.38 0.3 Educational attainment (years of education);Educational attainment (college completion); chr5:60990270 chr5:60891935~60893577:- LUSC cis rs748404 0.55 rs12912505 ENSG00000249839.1 AC011330.5 -6.84 2.44e-11 1.57e-08 -0.52 -0.3 Lung cancer; chr15:43525206 chr15:43663654~43684339:- LUSC cis rs748404 0.65 rs518234 ENSG00000249839.1 AC011330.5 -6.84 2.45e-11 1.58e-08 -0.4 -0.3 Lung cancer; chr15:43281223 chr15:43663654~43684339:- LUSC cis rs748404 0.65 rs518261 ENSG00000249839.1 AC011330.5 -6.84 2.45e-11 1.58e-08 -0.4 -0.3 Lung cancer; chr15:43281231 chr15:43663654~43684339:- LUSC cis rs34375054 0.738 rs3751181 ENSG00000279233.1 RP11-158L12.4 6.84 2.45e-11 1.58e-08 0.27 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125141989 chr12:125138245~125141711:+ LUSC cis rs16928809 0.52 rs74050440 ENSG00000183562.3 CTC-343N3.1 6.84 2.46e-11 1.59e-08 0.49 0.3 Bilirubin levels; chr11:2941213 chr11:2989863~2991344:+ LUSC cis rs172166 0.652 rs476167 ENSG00000204709.4 LINC01556 6.84 2.46e-11 1.59e-08 0.39 0.3 Cardiac Troponin-T levels; chr6:28098110 chr6:28943877~28944537:+ LUSC cis rs2179367 0.959 rs579789 ENSG00000231760.4 RP11-350J20.5 6.84 2.47e-11 1.59e-08 0.39 0.3 Dupuytren's disease; chr6:149358235 chr6:149796151~149826294:- LUSC cis rs526231 0.578 rs1898672 ENSG00000175749.11 EIF3KP1 -6.84 2.47e-11 1.59e-08 -0.35 -0.3 Primary biliary cholangitis; chr5:102958149 chr5:103032376~103033031:+ LUSC cis rs4423214 0.592 rs3829251 ENSG00000254682.1 RP11-660L16.2 -6.84 2.47e-11 1.59e-08 -0.49 -0.3 Vitamin D levels; chr11:71483513 chr11:71448674~71452157:+ LUSC cis rs853679 0.55 rs34477097 ENSG00000204709.4 LINC01556 6.84 2.48e-11 1.6e-08 0.4 0.3 Depression; chr6:28229408 chr6:28943877~28944537:+ LUSC cis rs6142102 0.923 rs2268078 ENSG00000276073.1 RP5-1125A11.7 -6.84 2.48e-11 1.6e-08 -0.32 -0.3 Skin pigmentation; chr20:34008898 chr20:33985617~33988989:- LUSC cis rs7772486 0.754 rs4896841 ENSG00000235652.6 RP11-545I5.3 -6.84 2.48e-11 1.6e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145720386 chr6:145799409~145886585:+ LUSC cis rs10129255 0.917 rs7142373 ENSG00000224373.3 IGHV4-59 6.84 2.48e-11 1.6e-08 0.17 0.3 Kawasaki disease; chr14:106708947 chr14:106627249~106627825:- LUSC cis rs11089937 0.626 rs4821784 ENSG00000211639.2 IGLV4-60 6.84 2.49e-11 1.6e-08 0.35 0.3 Periodontitis (PAL4Q3); chr22:22143513 chr22:22162199~22162681:+ LUSC cis rs2404602 0.647 rs11072618 ENSG00000259422.1 RP11-593F23.1 -6.84 2.49e-11 1.6e-08 -0.37 -0.3 Blood metabolite levels; chr15:76727001 chr15:76174891~76181486:- LUSC cis rs748404 0.65 rs556851 ENSG00000249839.1 AC011330.5 -6.84 2.49e-11 1.6e-08 -0.4 -0.3 Lung cancer; chr15:43279021 chr15:43663654~43684339:- LUSC cis rs748404 0.697 rs567357 ENSG00000249839.1 AC011330.5 -6.84 2.49e-11 1.6e-08 -0.4 -0.3 Lung cancer; chr15:43279192 chr15:43663654~43684339:- LUSC cis rs6142102 0.659 rs6057945 ENSG00000276073.1 RP5-1125A11.7 -6.84 2.49e-11 1.6e-08 -0.32 -0.3 Skin pigmentation; chr20:33929374 chr20:33985617~33988989:- LUSC cis rs3750965 0.806 rs7107680 ENSG00000260895.1 RP11-554A11.7 6.84 2.49e-11 1.61e-08 0.35 0.3 Hair color; chr11:69092426 chr11:69103493~69109094:+ LUSC cis rs9921338 0.961 rs72773829 ENSG00000263080.1 RP11-485G7.5 6.84 2.5e-11 1.61e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11318766 chr16:11341809~11345211:- LUSC cis rs2282300 0.956 rs1717779 ENSG00000254532.1 RP11-624D11.2 6.84 2.51e-11 1.61e-08 0.41 0.3 Morning vs. evening chronotype; chr11:30355151 chr11:30044058~30084343:- LUSC cis rs3750965 1 rs61881024 ENSG00000260895.1 RP11-554A11.7 6.84 2.51e-11 1.61e-08 0.36 0.3 Hair color; chr11:69070326 chr11:69103493~69109094:+ LUSC cis rs4713118 0.911 rs2394000 ENSG00000219392.1 RP1-265C24.5 -6.84 2.51e-11 1.62e-08 -0.4 -0.3 Parkinson's disease; chr6:27719212 chr6:28115628~28116551:+ LUSC cis rs4713118 0.955 rs9393847 ENSG00000219392.1 RP1-265C24.5 -6.84 2.51e-11 1.62e-08 -0.4 -0.3 Parkinson's disease; chr6:27720194 chr6:28115628~28116551:+ LUSC cis rs10754283 0.905 rs7519969 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89643162 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs7519971 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89643184 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs7546410 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89644256 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs7515375 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89644295 chr1:89788914~89790492:+ LUSC cis rs10754283 0.901 rs6663526 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89645303 chr1:89788914~89790492:+ LUSC cis rs10754283 0.934 rs7529653 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89646292 chr1:89788914~89790492:+ LUSC cis rs10754283 0.87 rs2390764 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89647268 chr1:89788914~89790492:+ LUSC cis rs10754283 0.901 rs4520403 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89647281 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs4658130 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89647888 chr1:89788914~89790492:+ LUSC cis rs10754283 0.934 rs10754284 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89648143 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs10801759 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89648186 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs10801760 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89648265 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs7528433 ENSG00000231613.1 RP5-943J3.1 6.84 2.51e-11 1.62e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89648512 chr1:89788914~89790492:+ LUSC cis rs17818399 0.597 rs13385693 ENSG00000279254.1 RP11-536C12.1 -6.84 2.51e-11 1.62e-08 -0.34 -0.3 Height; chr2:46640019 chr2:46668870~46670778:+ LUSC cis rs9318086 0.578 rs2077709 ENSG00000205861.10 C1QTNF9B-AS1 6.84 2.51e-11 1.62e-08 0.38 0.3 Myopia (pathological); chr13:23901934 chr13:23888889~23897263:+ LUSC cis rs10129255 0.957 rs7493713 ENSG00000280411.1 IGHV1-69-2 -6.84 2.51e-11 1.62e-08 -0.21 -0.3 Kawasaki disease; chr14:106783685 chr14:106762092~106762588:- LUSC cis rs10129255 0.912 rs35468694 ENSG00000280411.1 IGHV1-69-2 -6.84 2.51e-11 1.62e-08 -0.21 -0.3 Kawasaki disease; chr14:106784199 chr14:106762092~106762588:- LUSC cis rs10129255 0.957 rs8019272 ENSG00000280411.1 IGHV1-69-2 -6.84 2.51e-11 1.62e-08 -0.21 -0.3 Kawasaki disease; chr14:106784709 chr14:106762092~106762588:- LUSC cis rs9921338 0.961 rs72773833 ENSG00000263080.1 RP11-485G7.5 6.84 2.52e-11 1.62e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11319417 chr16:11341809~11345211:- LUSC cis rs11098499 0.779 rs80242894 ENSG00000250412.1 KLHL2P1 6.84 2.53e-11 1.63e-08 0.38 0.3 Corneal astigmatism; chr4:119454597 chr4:119334329~119378233:+ LUSC cis rs10754283 0.967 rs10922680 ENSG00000231613.1 RP5-943J3.1 -6.84 2.55e-11 1.64e-08 -0.34 -0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89635767 chr1:89788914~89790492:+ LUSC cis rs10740039 0.842 rs10761539 ENSG00000254271.1 RP11-131N11.4 6.84 2.55e-11 1.64e-08 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60649733 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs1442546 ENSG00000254271.1 RP11-131N11.4 6.84 2.55e-11 1.64e-08 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60650240 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs1442545 ENSG00000254271.1 RP11-131N11.4 6.84 2.55e-11 1.64e-08 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60650268 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs1975442 ENSG00000254271.1 RP11-131N11.4 6.84 2.55e-11 1.64e-08 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60651161 chr10:60734342~60741828:+ LUSC cis rs10740039 0.804 rs7094818 ENSG00000254271.1 RP11-131N11.4 6.84 2.55e-11 1.64e-08 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60652213 chr10:60734342~60741828:+ LUSC cis rs17507216 0.628 rs8028130 ENSG00000255769.6 GOLGA2P10 -6.84 2.55e-11 1.64e-08 -0.46 -0.3 Excessive daytime sleepiness; chr15:82734974 chr15:82472993~82513950:- LUSC cis rs10754283 0.934 rs6428563 ENSG00000231613.1 RP5-943J3.1 6.84 2.55e-11 1.64e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89646024 chr1:89788914~89790492:+ LUSC cis rs875971 0.825 rs1129531 ENSG00000237310.1 GS1-124K5.4 -6.84 2.55e-11 1.64e-08 -0.32 -0.3 Aortic root size; chr7:66154117 chr7:66493706~66495474:+ LUSC cis rs11690935 0.959 rs2674484 ENSG00000228389.1 AC068039.4 6.84 2.55e-11 1.64e-08 0.35 0.3 Schizophrenia; chr2:171718102 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs10206062 ENSG00000228389.1 AC068039.4 6.84 2.55e-11 1.64e-08 0.35 0.3 Schizophrenia; chr2:171720766 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs973889 ENSG00000228389.1 AC068039.4 6.84 2.55e-11 1.64e-08 0.35 0.3 Schizophrenia; chr2:171723444 chr2:171773482~171775844:+ LUSC cis rs9545047 0.704 rs3742120 ENSG00000227676.3 LINC01068 6.84 2.55e-11 1.64e-08 0.37 0.3 Schizophrenia; chr13:79386700 chr13:79566727~79571436:+ LUSC cis rs9545047 0.716 rs3742122 ENSG00000227676.3 LINC01068 6.84 2.55e-11 1.64e-08 0.37 0.3 Schizophrenia; chr13:79387061 chr13:79566727~79571436:+ LUSC cis rs801193 0.569 rs2659907 ENSG00000237310.1 GS1-124K5.4 6.83 2.56e-11 1.64e-08 0.32 0.3 Aortic root size; chr7:66699045 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1544549 ENSG00000237310.1 GS1-124K5.4 -6.83 2.56e-11 1.64e-08 -0.31 -0.3 Aortic root size; chr7:66625676 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs2420820 ENSG00000237310.1 GS1-124K5.4 -6.83 2.56e-11 1.64e-08 -0.31 -0.3 Aortic root size; chr7:66626920 chr7:66493706~66495474:+ LUSC cis rs440932 1 rs440932 ENSG00000254340.1 RP11-10A14.3 6.83 2.56e-11 1.65e-08 0.37 0.3 High light scatter reticulocyte percentage of red cells; chr8:9169419 chr8:9141424~9145435:+ LUSC cis rs10740039 0.804 rs4948424 ENSG00000254271.1 RP11-131N11.4 6.83 2.57e-11 1.65e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60681812 chr10:60734342~60741828:+ LUSC cis rs1865760 0.622 rs9968910 ENSG00000272462.2 U91328.19 -6.83 2.57e-11 1.65e-08 -0.35 -0.3 Height; chr6:26071867 chr6:25992662~26001775:+ LUSC cis rs1865760 0.622 rs10946807 ENSG00000272462.2 U91328.19 -6.83 2.57e-11 1.65e-08 -0.35 -0.3 Height; chr6:26079410 chr6:25992662~26001775:+ LUSC cis rs380904 0.552 rs10099003 ENSG00000254859.1 RP11-661A12.5 -6.83 2.58e-11 1.66e-08 -0.4 -0.3 Venous thromboembolism (SNP x SNP interaction); chr8:143563290 chr8:143541973~143549729:- LUSC cis rs10754283 0.967 rs6428559 ENSG00000231613.1 RP5-943J3.1 6.83 2.58e-11 1.66e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89633477 chr1:89788914~89790492:+ LUSC cis rs8062405 0.792 rs12446550 ENSG00000278665.1 RP11-666O2.4 6.83 2.6e-11 1.67e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28532060 chr16:28599241~28601881:- LUSC cis rs7714584 1 rs11741861 ENSG00000197083.10 ZNF300P1 -6.83 2.6e-11 1.67e-08 -0.55 -0.3 Crohn's disease; chr5:150898347 chr5:150930645~150946289:- LUSC cis rs4713118 0.869 rs6930992 ENSG00000219392.1 RP1-265C24.5 -6.83 2.61e-11 1.68e-08 -0.38 -0.3 Parkinson's disease; chr6:27744341 chr6:28115628~28116551:+ LUSC cis rs9309473 1 rs6740223 ENSG00000163016.8 ALMS1P 6.83 2.61e-11 1.68e-08 0.37 0.3 Metabolite levels; chr2:73426204 chr2:73644919~73685576:+ LUSC cis rs9309473 1 rs6707722 ENSG00000163016.8 ALMS1P 6.83 2.61e-11 1.68e-08 0.37 0.3 Metabolite levels; chr2:73427235 chr2:73644919~73685576:+ LUSC cis rs875971 0.83 rs4718358 ENSG00000237310.1 GS1-124K5.4 6.83 2.62e-11 1.68e-08 0.31 0.3 Aortic root size; chr7:66508681 chr7:66493706~66495474:+ LUSC cis rs8062405 0.754 rs62034323 ENSG00000278665.1 RP11-666O2.4 6.83 2.62e-11 1.68e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525152 chr16:28599241~28601881:- LUSC cis rs8062405 0.824 rs62034324 ENSG00000278665.1 RP11-666O2.4 6.83 2.62e-11 1.68e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525441 chr16:28599241~28601881:- LUSC cis rs8062405 0.824 rs62034326 ENSG00000278665.1 RP11-666O2.4 6.83 2.62e-11 1.68e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28527972 chr16:28599241~28601881:- LUSC cis rs8062405 0.824 rs4788084 ENSG00000278665.1 RP11-666O2.4 6.83 2.62e-11 1.68e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28528527 chr16:28599241~28601881:- LUSC cis rs853679 0.607 rs67662114 ENSG00000204709.4 LINC01556 6.83 2.62e-11 1.68e-08 0.65 0.3 Depression; chr6:27964523 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs13216117 ENSG00000204709.4 LINC01556 6.83 2.62e-11 1.68e-08 0.65 0.3 Depression; chr6:27970706 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs36101351 ENSG00000204709.4 LINC01556 6.83 2.62e-11 1.68e-08 0.65 0.3 Depression; chr6:27975591 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs28360499 ENSG00000204709.4 LINC01556 6.83 2.62e-11 1.68e-08 0.65 0.3 Depression; chr6:27977618 chr6:28943877~28944537:+ LUSC cis rs7772486 0.72 rs6901888 ENSG00000235652.6 RP11-545I5.3 -6.83 2.63e-11 1.69e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145702008 chr6:145799409~145886585:+ LUSC cis rs7772486 0.72 rs991507 ENSG00000235652.6 RP11-545I5.3 -6.83 2.63e-11 1.69e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145702473 chr6:145799409~145886585:+ LUSC cis rs11098499 0.863 rs6858592 ENSG00000250412.1 KLHL2P1 6.83 2.64e-11 1.69e-08 0.38 0.3 Corneal astigmatism; chr4:119537537 chr4:119334329~119378233:+ LUSC cis rs7772486 0.72 rs6931553 ENSG00000235652.6 RP11-545I5.3 -6.83 2.64e-11 1.69e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145791212 chr6:145799409~145886585:+ LUSC cis rs11089937 0.597 rs11704434 ENSG00000211638.2 IGLV8-61 -6.83 2.64e-11 1.69e-08 -0.33 -0.3 Periodontitis (PAL4Q3); chr22:22131715 chr22:22098700~22099212:+ LUSC cis rs875971 1 rs6958271 ENSG00000237310.1 GS1-124K5.4 6.83 2.64e-11 1.69e-08 0.31 0.3 Aortic root size; chr7:66514344 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs6958277 ENSG00000237310.1 GS1-124K5.4 6.83 2.64e-11 1.69e-08 0.31 0.3 Aortic root size; chr7:66514362 chr7:66493706~66495474:+ LUSC cis rs7772486 0.692 rs2265915 ENSG00000235652.6 RP11-545I5.3 6.83 2.64e-11 1.69e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145873196 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2253654 ENSG00000235652.6 RP11-545I5.3 6.83 2.64e-11 1.69e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145878309 chr6:145799409~145886585:+ LUSC cis rs6782228 1 rs11718130 ENSG00000277250.1 Metazoa_SRP 6.83 2.65e-11 1.7e-08 0.38 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611184 chr3:128673681~128674021:- LUSC cis rs1865760 0.566 rs9358904 ENSG00000272462.2 U91328.19 -6.83 2.65e-11 1.7e-08 -0.33 -0.3 Height; chr6:26068338 chr6:25992662~26001775:+ LUSC cis rs2337406 0.85 rs10131280 ENSG00000274576.2 IGHV2-70 -6.83 2.65e-11 1.7e-08 -0.33 -0.3 Alzheimer's disease (late onset); chr14:106665591 chr14:106770577~106771020:- LUSC cis rs10463554 0.927 rs62362489 ENSG00000175749.11 EIF3KP1 6.83 2.65e-11 1.7e-08 0.36 0.3 Parkinson's disease; chr5:102909841 chr5:103032376~103033031:+ LUSC cis rs10740039 0.842 rs7090892 ENSG00000254271.1 RP11-131N11.4 6.83 2.66e-11 1.7e-08 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60652093 chr10:60734342~60741828:+ LUSC cis rs17711722 0.523 rs365896 ENSG00000236529.1 RP13-254B10.1 -6.83 2.66e-11 1.71e-08 -0.31 -0.3 Calcium levels; chr7:66045710 chr7:65840212~65840596:+ LUSC cis rs11098499 0.954 rs10008392 ENSG00000250412.1 KLHL2P1 6.83 2.67e-11 1.71e-08 0.38 0.3 Corneal astigmatism; chr4:119397684 chr4:119334329~119378233:+ LUSC cis rs10754283 0.967 rs1934045 ENSG00000231613.1 RP5-943J3.1 -6.83 2.67e-11 1.71e-08 -0.34 -0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89642240 chr1:89788914~89790492:+ LUSC cis rs10463554 0.927 rs55641526 ENSG00000175749.11 EIF3KP1 6.83 2.67e-11 1.71e-08 0.36 0.3 Parkinson's disease; chr5:102915301 chr5:103032376~103033031:+ LUSC cis rs17818399 0.62 rs6544906 ENSG00000279254.1 RP11-536C12.1 -6.83 2.68e-11 1.72e-08 -0.34 -0.3 Height; chr2:46636733 chr2:46668870~46670778:+ LUSC cis rs950169 0.84 rs72748702 ENSG00000225151.9 GOLGA2P7 -6.83 2.68e-11 1.72e-08 -0.42 -0.3 Schizophrenia; chr15:84246494 chr15:84199311~84230136:- LUSC cis rs950169 0.922 rs4338765 ENSG00000225151.9 GOLGA2P7 -6.83 2.68e-11 1.72e-08 -0.42 -0.3 Schizophrenia; chr15:84248084 chr15:84199311~84230136:- LUSC cis rs6142102 0.961 rs2300204 ENSG00000276073.1 RP5-1125A11.7 -6.83 2.69e-11 1.72e-08 -0.31 -0.3 Skin pigmentation; chr20:34000967 chr20:33985617~33988989:- LUSC cis rs1865760 0.566 rs2032445 ENSG00000272462.2 U91328.19 -6.83 2.69e-11 1.72e-08 -0.32 -0.3 Height; chr6:26044584 chr6:25992662~26001775:+ LUSC cis rs5753618 0.504 rs9609329 ENSG00000236132.1 CTA-440B3.1 -6.83 2.69e-11 1.73e-08 -0.42 -0.3 Colorectal cancer; chr22:31570327 chr22:31816379~31817491:- LUSC cis rs1075265 0.73 rs7597189 ENSG00000233266.1 HMGB1P31 6.83 2.69e-11 1.73e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54014733 chr2:54051334~54051760:+ LUSC cis rs875971 0.964 rs6945019 ENSG00000237310.1 GS1-124K5.4 6.83 2.7e-11 1.73e-08 0.31 0.3 Aortic root size; chr7:66457471 chr7:66493706~66495474:+ LUSC cis rs4713118 0.587 rs61471148 ENSG00000204709.4 LINC01556 6.83 2.71e-11 1.73e-08 0.43 0.3 Parkinson's disease; chr6:28069254 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs4713148 ENSG00000204709.4 LINC01556 6.83 2.71e-11 1.74e-08 0.43 0.3 Depression; chr6:28148143 chr6:28943877~28944537:+ LUSC cis rs748404 0.666 rs7180812 ENSG00000249839.1 AC011330.5 -6.83 2.71e-11 1.74e-08 -0.51 -0.3 Lung cancer; chr15:43403033 chr15:43663654~43684339:- LUSC cis rs881375 0.967 rs10733648 ENSG00000226752.6 PSMD5-AS1 -6.83 2.71e-11 1.74e-08 -0.35 -0.3 Rheumatoid arthritis; chr9:120938501 chr9:120824828~120854385:+ LUSC cis rs7829975 0.688 rs13270194 ENSG00000253893.2 FAM85B -6.83 2.71e-11 1.74e-08 -0.35 -0.3 Mood instability; chr8:8520592 chr8:8167819~8226614:- LUSC cis rs2903698 0.519 rs28877578 ENSG00000250735.4 RP11-567N4.3 6.83 2.72e-11 1.74e-08 0.34 0.3 Prion diseases; chr4:75499766 chr4:75401195~75423023:+ LUSC cis rs10129255 0.5 rs1974468 ENSG00000224373.3 IGHV4-59 6.83 2.72e-11 1.74e-08 0.15 0.3 Kawasaki disease; chr14:106686149 chr14:106627249~106627825:- LUSC cis rs6782228 0.848 rs3935016 ENSG00000277250.1 Metazoa_SRP 6.82 2.72e-11 1.74e-08 0.37 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128701591 chr3:128673681~128674021:- LUSC cis rs6782228 0.848 rs6439141 ENSG00000277250.1 Metazoa_SRP 6.82 2.72e-11 1.74e-08 0.37 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128701691 chr3:128673681~128674021:- LUSC cis rs4950322 0.58 rs17355474 ENSG00000278811.3 LINC00624 6.82 2.72e-11 1.74e-08 0.33 0.3 Protein quantitative trait loci; chr1:147120541 chr1:147258885~147517875:- LUSC cis rs10463554 0.927 rs11952361 ENSG00000175749.11 EIF3KP1 6.82 2.73e-11 1.75e-08 0.36 0.3 Parkinson's disease; chr5:102952216 chr5:103032376~103033031:+ LUSC cis rs10129255 0.957 rs10141052 ENSG00000280411.1 IGHV1-69-2 -6.82 2.73e-11 1.75e-08 -0.21 -0.3 Kawasaki disease; chr14:106776528 chr14:106762092~106762588:- LUSC cis rs10129255 0.957 rs10141009 ENSG00000280411.1 IGHV1-69-2 -6.82 2.73e-11 1.75e-08 -0.21 -0.3 Kawasaki disease; chr14:106776695 chr14:106762092~106762588:- LUSC cis rs72772090 0.539 rs72773917 ENSG00000248734.2 CTD-2260A17.1 -6.82 2.73e-11 1.75e-08 -0.45 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96775598 chr5:96784777~96785999:+ LUSC cis rs8072100 0.935 rs4793978 ENSG00000228782.6 CTD-2026D20.3 -6.82 2.74e-11 1.75e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47620809 chr17:47450568~47492492:- LUSC cis rs10463554 0.927 rs6862616 ENSG00000175749.11 EIF3KP1 6.82 2.74e-11 1.75e-08 0.36 0.3 Parkinson's disease; chr5:102910334 chr5:103032376~103033031:+ LUSC cis rs1075265 0.749 rs805375 ENSG00000233266.1 HMGB1P31 6.82 2.74e-11 1.75e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:53863268 chr2:54051334~54051760:+ LUSC cis rs7267979 1 rs2856 ENSG00000274973.1 RP13-401N8.7 -6.82 2.75e-11 1.76e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25452900 chr20:25845497~25845862:+ LUSC cis rs748404 0.626 rs62019432 ENSG00000249839.1 AC011330.5 -6.82 2.75e-11 1.76e-08 -0.53 -0.3 Lung cancer; chr15:43316482 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs17723479 ENSG00000249839.1 AC011330.5 -6.82 2.75e-11 1.76e-08 -0.53 -0.3 Lung cancer; chr15:43322114 chr15:43663654~43684339:- LUSC cis rs4713118 0.826 rs2893929 ENSG00000219392.1 RP1-265C24.5 -6.82 2.75e-11 1.76e-08 -0.42 -0.3 Parkinson's disease; chr6:27770953 chr6:28115628~28116551:+ LUSC cis rs4713118 0.666 rs4140646 ENSG00000219392.1 RP1-265C24.5 -6.82 2.75e-11 1.76e-08 -0.42 -0.3 Parkinson's disease; chr6:27771022 chr6:28115628~28116551:+ LUSC cis rs4713118 0.666 rs2893930 ENSG00000219392.1 RP1-265C24.5 -6.82 2.75e-11 1.76e-08 -0.42 -0.3 Parkinson's disease; chr6:27771027 chr6:28115628~28116551:+ LUSC cis rs367615 0.506 rs2963013 ENSG00000249476.1 CTD-2587M2.1 -6.82 2.75e-11 1.76e-08 -0.33 -0.3 Colorectal cancer (SNP x SNP interaction); chr5:109440110 chr5:109237120~109326369:- LUSC cis rs6921919 0.583 rs11755942 ENSG00000204709.4 LINC01556 6.82 2.75e-11 1.76e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28401760 chr6:28943877~28944537:+ LUSC cis rs11157436 0.918 rs1983520 ENSG00000211813.2 TRAV34 6.82 2.75e-11 1.76e-08 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22150390 chr14:22207522~22208129:+ LUSC cis rs11157436 0.918 rs1983522 ENSG00000211813.2 TRAV34 6.82 2.75e-11 1.76e-08 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22150588 chr14:22207522~22208129:+ LUSC cis rs11690935 0.694 rs312921 ENSG00000228389.1 AC068039.4 6.82 2.76e-11 1.77e-08 0.35 0.3 Schizophrenia; chr2:171710715 chr2:171773482~171775844:+ LUSC cis rs2179367 0.959 rs4895788 ENSG00000231760.4 RP11-350J20.5 6.82 2.76e-11 1.77e-08 0.39 0.3 Dupuytren's disease; chr6:149426955 chr6:149796151~149826294:- LUSC cis rs9549367 0.789 rs12869947 ENSG00000269125.1 RP11-98F14.11 -6.82 2.77e-11 1.77e-08 -0.37 -0.3 Platelet distribution width; chr13:113241842 chr13:113165002~113165183:- LUSC cis rs72772090 0.539 rs72773942 ENSG00000248734.2 CTD-2260A17.1 -6.82 2.78e-11 1.78e-08 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96787663 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs11743410 ENSG00000248734.2 CTD-2260A17.1 -6.82 2.78e-11 1.78e-08 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96788750 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs11746534 ENSG00000248734.2 CTD-2260A17.1 -6.82 2.78e-11 1.78e-08 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789104 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs55773007 ENSG00000248734.2 CTD-2260A17.1 -6.82 2.78e-11 1.78e-08 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789215 chr5:96784777~96785999:+ LUSC cis rs8177876 0.749 rs75923695 ENSG00000261838.4 RP11-303E16.6 6.82 2.79e-11 1.78e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81060289 chr16:81069854~81076598:+ LUSC cis rs11098499 0.754 rs2036857 ENSG00000249244.1 RP11-548H18.2 6.82 2.79e-11 1.79e-08 0.38 0.3 Corneal astigmatism; chr4:119328085 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs2036856 ENSG00000249244.1 RP11-548H18.2 6.82 2.79e-11 1.79e-08 0.38 0.3 Corneal astigmatism; chr4:119328133 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs4443261 ENSG00000249244.1 RP11-548H18.2 6.82 2.79e-11 1.79e-08 0.38 0.3 Corneal astigmatism; chr4:119328146 chr4:119391831~119395335:- LUSC cis rs8177876 0.818 rs59177227 ENSG00000261838.4 RP11-303E16.6 6.82 2.8e-11 1.79e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081524 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs59685942 ENSG00000261838.4 RP11-303E16.6 6.82 2.8e-11 1.79e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081534 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs10514515 ENSG00000261838.4 RP11-303E16.6 6.82 2.8e-11 1.79e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081717 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs1410 ENSG00000261838.4 RP11-303E16.6 6.82 2.8e-11 1.79e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81082228 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs1412 ENSG00000261838.4 RP11-303E16.6 6.82 2.8e-11 1.79e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81082237 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs1414 ENSG00000261838.4 RP11-303E16.6 6.82 2.8e-11 1.79e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81082252 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs8177940 ENSG00000261838.4 RP11-303E16.6 6.82 2.8e-11 1.79e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81083789 chr16:81069854~81076598:+ LUSC cis rs8177876 0.73 rs76656387 ENSG00000261838.4 RP11-303E16.6 6.82 2.8e-11 1.79e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81083862 chr16:81069854~81076598:+ LUSC cis rs9549367 0.713 rs3024761 ENSG00000269125.1 RP11-98F14.11 6.82 2.8e-11 1.79e-08 0.39 0.3 Platelet distribution width; chr13:113169776 chr13:113165002~113165183:- LUSC cis rs11690935 0.959 rs6705200 ENSG00000228389.1 AC068039.4 6.82 2.81e-11 1.79e-08 0.35 0.3 Schizophrenia; chr2:171781090 chr2:171773482~171775844:+ LUSC cis rs10129255 0.785 rs10150044 ENSG00000280411.1 IGHV1-69-2 -6.82 2.81e-11 1.79e-08 -0.21 -0.3 Kawasaki disease; chr14:106775695 chr14:106762092~106762588:- LUSC cis rs950169 1 rs11638297 ENSG00000225151.9 GOLGA2P7 -6.82 2.81e-11 1.8e-08 -0.41 -0.3 Schizophrenia; chr15:84113665 chr15:84199311~84230136:- LUSC cis rs13113518 0.783 rs11943206 ENSG00000223305.1 RN7SKP30 6.82 2.82e-11 1.8e-08 0.36 0.3 Height; chr4:55570843 chr4:55540502~55540835:- LUSC cis rs853679 0.517 rs9380056 ENSG00000204709.4 LINC01556 6.82 2.82e-11 1.8e-08 0.42 0.3 Depression; chr6:28136698 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9380057 ENSG00000204709.4 LINC01556 6.82 2.82e-11 1.8e-08 0.42 0.3 Depression; chr6:28136856 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs6941992 ENSG00000204709.4 LINC01556 6.82 2.82e-11 1.8e-08 0.42 0.3 Depression; chr6:28138363 chr6:28943877~28944537:+ LUSC cis rs4713118 0.516 rs4713142 ENSG00000204709.4 LINC01556 6.82 2.82e-11 1.8e-08 0.42 0.3 Parkinson's disease; chr6:28138569 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs4713143 ENSG00000204709.4 LINC01556 6.82 2.82e-11 1.8e-08 0.42 0.3 Depression; chr6:28138981 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs4713144 ENSG00000204709.4 LINC01556 6.82 2.82e-11 1.8e-08 0.42 0.3 Depression; chr6:28139012 chr6:28943877~28944537:+ LUSC cis rs9928842 0.679 rs4888361 ENSG00000280152.1 RP11-331F4.5 6.82 2.83e-11 1.8e-08 0.36 0.3 Alcoholic chronic pancreatitis; chr16:75233778 chr16:75245994~75250077:- LUSC cis rs9318086 0.712 rs9318099 ENSG00000205861.10 C1QTNF9B-AS1 6.82 2.83e-11 1.8e-08 0.37 0.3 Myopia (pathological); chr13:23868323 chr13:23888889~23897263:+ LUSC cis rs10463554 0.892 rs1560040 ENSG00000175749.11 EIF3KP1 6.82 2.83e-11 1.81e-08 0.36 0.3 Parkinson's disease; chr5:102964363 chr5:103032376~103033031:+ LUSC cis rs227275 0.525 rs724446 ENSG00000230069.3 LRRC37A15P -6.82 2.83e-11 1.81e-08 -0.32 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:103010206 chr4:102727274~102730721:- LUSC cis rs9549367 0.713 rs3024776 ENSG00000269125.1 RP11-98F14.11 6.82 2.83e-11 1.81e-08 0.38 0.3 Platelet distribution width; chr13:113172761 chr13:113165002~113165183:- LUSC cis rs11157436 0.918 rs12586393 ENSG00000211813.2 TRAV34 6.82 2.84e-11 1.81e-08 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22150815 chr14:22207522~22208129:+ LUSC cis rs11157436 0.918 rs2178788 ENSG00000211813.2 TRAV34 6.82 2.84e-11 1.81e-08 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22150916 chr14:22207522~22208129:+ LUSC cis rs9309473 1 rs6705489 ENSG00000163016.8 ALMS1P 6.82 2.84e-11 1.81e-08 0.36 0.3 Metabolite levels; chr2:73421683 chr2:73644919~73685576:+ LUSC cis rs11098499 0.954 rs878373 ENSG00000250412.1 KLHL2P1 6.82 2.84e-11 1.81e-08 0.38 0.3 Corneal astigmatism; chr4:119316329 chr4:119334329~119378233:+ LUSC cis rs7772486 0.754 rs9497401 ENSG00000235652.6 RP11-545I5.3 -6.82 2.84e-11 1.81e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145730135 chr6:145799409~145886585:+ LUSC cis rs875971 1 rs7792762 ENSG00000237310.1 GS1-124K5.4 6.82 2.84e-11 1.81e-08 0.31 0.3 Aortic root size; chr7:66539151 chr7:66493706~66495474:+ LUSC cis rs10129255 0.828 rs10140989 ENSG00000280411.1 IGHV1-69-2 -6.82 2.84e-11 1.81e-08 -0.21 -0.3 Kawasaki disease; chr14:106668657 chr14:106762092~106762588:- LUSC cis rs8177876 0.822 rs8177950 ENSG00000261838.4 RP11-303E16.6 6.82 2.85e-11 1.82e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81083290 chr16:81069854~81076598:+ LUSC cis rs8177876 0.731 rs8177948 ENSG00000261838.4 RP11-303E16.6 6.82 2.85e-11 1.82e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81083315 chr16:81069854~81076598:+ LUSC cis rs13113518 0.812 rs1522114 ENSG00000272969.1 RP11-528I4.2 6.82 2.85e-11 1.82e-08 0.35 0.3 Height; chr4:55489895 chr4:55547112~55547889:+ LUSC cis rs8072100 0.701 rs10163469 ENSG00000228782.6 CTD-2026D20.3 -6.82 2.86e-11 1.82e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47610401 chr17:47450568~47492492:- LUSC cis rs748404 0.666 rs34591748 ENSG00000249839.1 AC011330.5 -6.82 2.86e-11 1.83e-08 -0.51 -0.3 Lung cancer; chr15:43334917 chr15:43663654~43684339:- LUSC cis rs10129255 0.872 rs8015406 ENSG00000280411.1 IGHV1-69-2 -6.82 2.86e-11 1.83e-08 -0.21 -0.3 Kawasaki disease; chr14:106670611 chr14:106762092~106762588:- LUSC cis rs11976180 1 rs2961120 ENSG00000170356.8 OR2A20P -6.82 2.86e-11 1.83e-08 -0.4 -0.3 Obesity-related traits; chr7:144059492 chr7:144250045~144252957:- LUSC cis rs62229266 0.839 rs11088335 ENSG00000231106.2 LINC01436 6.82 2.87e-11 1.83e-08 0.38 0.3 Mitral valve prolapse; chr21:36098037 chr21:36005338~36007838:+ LUSC cis rs4718428 0.96 rs6460317 ENSG00000226824.5 RP4-756H11.3 -6.82 2.87e-11 1.83e-08 -0.36 -0.3 Corneal structure; chr7:66925268 chr7:66654538~66669855:+ LUSC cis rs11098499 0.863 rs58452170 ENSG00000250412.1 KLHL2P1 6.82 2.88e-11 1.84e-08 0.38 0.3 Corneal astigmatism; chr4:119538519 chr4:119334329~119378233:+ LUSC cis rs748404 0.629 rs34657657 ENSG00000249839.1 AC011330.5 -6.82 2.88e-11 1.84e-08 -0.53 -0.3 Lung cancer; chr15:43315763 chr15:43663654~43684339:- LUSC cis rs875971 1 rs6957199 ENSG00000237310.1 GS1-124K5.4 6.82 2.88e-11 1.84e-08 0.31 0.3 Aortic root size; chr7:66513532 chr7:66493706~66495474:+ LUSC cis rs11098499 0.954 rs59394118 ENSG00000250412.1 KLHL2P1 6.82 2.89e-11 1.84e-08 0.38 0.3 Corneal astigmatism; chr4:119374396 chr4:119334329~119378233:+ LUSC cis rs11098499 0.865 rs9996417 ENSG00000250412.1 KLHL2P1 6.82 2.89e-11 1.84e-08 0.38 0.3 Corneal astigmatism; chr4:119374707 chr4:119334329~119378233:+ LUSC cis rs113835537 0.597 rs7116921 ENSG00000255517.5 CTD-3074O7.5 -6.82 2.89e-11 1.84e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66536383 chr11:66473490~66480233:- LUSC cis rs8177876 0.749 rs58144189 ENSG00000261838.4 RP11-303E16.6 6.82 2.89e-11 1.84e-08 0.7 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81064478 chr16:81069854~81076598:+ LUSC cis rs1823913 0.599 rs17412635 ENSG00000280083.1 RP11-317J9.1 6.82 2.89e-11 1.84e-08 0.35 0.3 Obesity-related traits; chr2:191294834 chr2:191154118~191156070:- LUSC cis rs113835537 0.627 rs11227534 ENSG00000255517.5 CTD-3074O7.5 -6.82 2.9e-11 1.84e-08 -0.34 -0.3 Airway imaging phenotypes; chr11:66568700 chr11:66473490~66480233:- LUSC cis rs13113518 0.812 rs6825774 ENSG00000223305.1 RN7SKP30 6.82 2.9e-11 1.85e-08 0.37 0.3 Height; chr4:55491150 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs3805153 ENSG00000223305.1 RN7SKP30 6.82 2.9e-11 1.85e-08 0.37 0.3 Height; chr4:55493557 chr4:55540502~55540835:- LUSC cis rs2282300 0.91 rs528292 ENSG00000254532.1 RP11-624D11.2 -6.81 2.9e-11 1.85e-08 -0.41 -0.3 Morning vs. evening chronotype; chr11:30368163 chr11:30044058~30084343:- LUSC cis rs2282300 0.956 rs594937 ENSG00000254532.1 RP11-624D11.2 -6.81 2.9e-11 1.85e-08 -0.41 -0.3 Morning vs. evening chronotype; chr11:30368585 chr11:30044058~30084343:- LUSC cis rs11155671 0.546 rs1999633 ENSG00000223701.3 RAET1E-AS1 6.81 2.91e-11 1.85e-08 0.38 0.3 Testicular germ cell tumor; chr6:149866576 chr6:149884431~149919508:+ LUSC cis rs10129255 0.957 rs4387509 ENSG00000224373.3 IGHV4-59 6.81 2.91e-11 1.85e-08 0.17 0.3 Kawasaki disease; chr14:106704386 chr14:106627249~106627825:- LUSC cis rs875971 0.964 rs60193905 ENSG00000237310.1 GS1-124K5.4 6.81 2.91e-11 1.85e-08 0.31 0.3 Aortic root size; chr7:66506273 chr7:66493706~66495474:+ LUSC cis rs875971 0.929 rs10950041 ENSG00000237310.1 GS1-124K5.4 6.81 2.91e-11 1.85e-08 0.31 0.3 Aortic root size; chr7:66508888 chr7:66493706~66495474:+ LUSC cis rs875971 0.929 rs6970860 ENSG00000237310.1 GS1-124K5.4 6.81 2.91e-11 1.85e-08 0.31 0.3 Aortic root size; chr7:66511647 chr7:66493706~66495474:+ LUSC cis rs8177376 0.861 rs4937119 ENSG00000254905.1 RP11-712L6.7 6.81 2.91e-11 1.85e-08 0.4 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126297825 chr11:126292922~126294254:- LUSC cis rs2665103 0.715 rs16973457 ENSG00000278603.1 RP13-608F4.5 6.81 2.91e-11 1.86e-08 0.35 0.3 Intelligence (multi-trait analysis); chr15:82271650 chr15:82472203~82472426:+ LUSC cis rs9921338 0.961 rs4390613 ENSG00000263080.1 RP11-485G7.5 -6.81 2.92e-11 1.86e-08 -0.36 -0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11328979 chr16:11341809~11345211:- LUSC cis rs2404602 0.735 rs4886798 ENSG00000259422.1 RP11-593F23.1 6.81 2.92e-11 1.86e-08 0.35 0.3 Blood metabolite levels; chr15:76380885 chr15:76174891~76181486:- LUSC cis rs9309473 1 rs7598419 ENSG00000163016.8 ALMS1P 6.81 2.92e-11 1.86e-08 0.36 0.3 Metabolite levels; chr2:73571096 chr2:73644919~73685576:+ LUSC cis rs7772486 0.754 rs9399567 ENSG00000235652.6 RP11-545I5.3 6.81 2.92e-11 1.86e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145826159 chr6:145799409~145886585:+ LUSC cis rs1061377 0.513 rs6840214 ENSG00000249207.1 RP11-360F5.1 6.81 2.92e-11 1.86e-08 0.36 0.3 Uric acid levels; chr4:39118999 chr4:39112677~39126818:- LUSC cis rs9309473 1 rs10169714 ENSG00000163016.8 ALMS1P 6.81 2.94e-11 1.87e-08 0.36 0.3 Metabolite levels; chr2:73581646 chr2:73644919~73685576:+ LUSC cis rs7772486 0.727 rs6941429 ENSG00000235652.6 RP11-545I5.3 6.81 2.94e-11 1.87e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145631147 chr6:145799409~145886585:+ LUSC cis rs61160187 0.582 rs7723901 ENSG00000215032.2 GNL3LP1 6.81 2.94e-11 1.87e-08 0.38 0.3 Educational attainment (years of education);Educational attainment (college completion); chr5:60977163 chr5:60891935~60893577:- LUSC cis rs7246657 1 rs12709812 ENSG00000276846.1 CTD-3220F14.3 -6.81 2.94e-11 1.87e-08 -0.46 -0.3 Coronary artery calcification; chr19:37303948 chr19:37314868~37315620:- LUSC cis rs6142102 0.923 rs6059586 ENSG00000276073.1 RP5-1125A11.7 -6.81 2.95e-11 1.87e-08 -0.31 -0.3 Skin pigmentation; chr20:33952695 chr20:33985617~33988989:- LUSC cis rs2739330 0.731 rs2000468 ENSG00000099984.9 GSTT2 -6.81 2.95e-11 1.88e-08 -0.35 -0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23980123~23983911:+ LUSC cis rs6700559 0.703 rs10919993 ENSG00000260088.1 RP11-92G12.3 6.81 2.95e-11 1.88e-08 0.38 0.3 Coronary artery disease; chr1:200658184 chr1:200669507~200694250:+ LUSC cis rs6782228 0.883 rs6439142 ENSG00000277250.1 Metazoa_SRP 6.81 2.96e-11 1.89e-08 0.37 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128701714 chr3:128673681~128674021:- LUSC cis rs2179367 0.959 rs489551 ENSG00000231760.4 RP11-350J20.5 6.81 2.96e-11 1.89e-08 0.39 0.3 Dupuytren's disease; chr6:149368321 chr6:149796151~149826294:- LUSC cis rs7772486 0.754 rs4895682 ENSG00000235652.6 RP11-545I5.3 -6.81 2.97e-11 1.89e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145741725 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs13214277 ENSG00000235652.6 RP11-545I5.3 6.81 2.97e-11 1.89e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145814989 chr6:145799409~145886585:+ LUSC cis rs4972806 0.849 rs2857541 ENSG00000226363.3 HAGLROS -6.81 2.97e-11 1.89e-08 -0.36 -0.3 IgG glycosylation; chr2:176164358 chr2:176177717~176179008:+ LUSC cis rs13113518 0.545 rs6810483 ENSG00000249700.7 SRD5A3-AS1 6.81 2.98e-11 1.89e-08 0.33 0.3 Height; chr4:55424406 chr4:55363971~55395847:- LUSC cis rs4950322 1 rs72694750 ENSG00000278811.3 LINC00624 6.81 2.98e-11 1.89e-08 0.36 0.3 Protein quantitative trait loci; chr1:147396856 chr1:147258885~147517875:- LUSC cis rs4950322 1 rs1986987 ENSG00000278811.3 LINC00624 6.81 2.98e-11 1.89e-08 0.36 0.3 Protein quantitative trait loci; chr1:147397553 chr1:147258885~147517875:- LUSC cis rs4950322 1 rs61230354 ENSG00000278811.3 LINC00624 6.81 2.98e-11 1.89e-08 0.36 0.3 Protein quantitative trait loci; chr1:147398161 chr1:147258885~147517875:- LUSC cis rs4950322 1 rs4950429 ENSG00000278811.3 LINC00624 6.81 2.98e-11 1.89e-08 0.36 0.3 Protein quantitative trait loci; chr1:147400227 chr1:147258885~147517875:- LUSC cis rs4950322 1 rs59498179 ENSG00000278811.3 LINC00624 6.81 2.98e-11 1.89e-08 0.36 0.3 Protein quantitative trait loci; chr1:147400417 chr1:147258885~147517875:- LUSC cis rs11098499 0.738 rs72918577 ENSG00000250412.1 KLHL2P1 6.81 2.99e-11 1.9e-08 0.38 0.3 Corneal astigmatism; chr4:119405546 chr4:119334329~119378233:+ LUSC cis rs875971 0.838 rs2173570 ENSG00000237310.1 GS1-124K5.4 -6.81 3e-11 1.91e-08 -0.31 -0.3 Aortic root size; chr7:66297976 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs6460296 ENSG00000237310.1 GS1-124K5.4 6.81 3e-11 1.91e-08 0.31 0.3 Aortic root size; chr7:66430152 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs4717292 ENSG00000237310.1 GS1-124K5.4 6.81 3e-11 1.91e-08 0.31 0.3 Aortic root size; chr7:66430611 chr7:66493706~66495474:+ LUSC cis rs5760092 0.755 rs4585126 ENSG00000235689.1 AP000351.13 -6.81 3.01e-11 1.92e-08 -0.36 -0.3 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:24006305~24008258:- LUSC cis rs6504622 0.755 rs36056466 ENSG00000262879.4 RP11-156P1.3 -6.81 3.02e-11 1.92e-08 -0.32 -0.3 Orofacial clefts; chr17:47006017 chr17:46984045~47100323:- LUSC cis rs11098499 0.913 rs56122576 ENSG00000250412.1 KLHL2P1 6.81 3.02e-11 1.92e-08 0.38 0.3 Corneal astigmatism; chr4:119208181 chr4:119334329~119378233:+ LUSC cis rs748404 0.626 rs62021176 ENSG00000249839.1 AC011330.5 -6.81 3.02e-11 1.92e-08 -0.51 -0.3 Lung cancer; chr15:43388014 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs16957680 ENSG00000249839.1 AC011330.5 -6.81 3.02e-11 1.92e-08 -0.51 -0.3 Lung cancer; chr15:43396207 chr15:43663654~43684339:- LUSC cis rs904251 0.58 rs62408367 ENSG00000204110.6 RP1-153P14.8 -6.81 3.03e-11 1.92e-08 -0.29 -0.3 Cognitive performance; chr6:37477037 chr6:37507348~37535616:+ LUSC cis rs6142102 0.961 rs2377957 ENSG00000276073.1 RP5-1125A11.7 -6.81 3.03e-11 1.92e-08 -0.31 -0.3 Skin pigmentation; chr20:33966667 chr20:33985617~33988989:- LUSC cis rs875971 0.895 rs4718349 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66444024 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs2420591 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66447394 chr7:66493706~66495474:+ LUSC cis rs875971 0.895 rs10755833 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66448930 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs12668936 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66449417 chr7:66493706~66495474:+ LUSC cis rs875971 0.895 rs1833495 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66456608 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs6945032 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66457499 chr7:66493706~66495474:+ LUSC cis rs875971 0.929 rs12673810 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66458866 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs35149210 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66464938 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs2042133 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66466935 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs2161065 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66467918 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs6961155 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66468308 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs7789768 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66473993 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs12698521 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66474502 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1363055 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66478288 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs9691480 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66479319 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs7789554 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66481051 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs4717300 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66482393 chr7:66493706~66495474:+ LUSC cis rs875971 0.895 rs1974769 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66485627 chr7:66493706~66495474:+ LUSC cis rs875971 0.895 rs6460300 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66487937 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs7803416 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66489212 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs1981799 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66490572 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs2277911 ENSG00000237310.1 GS1-124K5.4 6.81 3.03e-11 1.93e-08 0.31 0.3 Aortic root size; chr7:66493638 chr7:66493706~66495474:+ LUSC cis rs2919917 1 rs13269243 ENSG00000254352.1 RP11-578O24.2 6.81 3.04e-11 1.93e-08 0.38 0.3 Lymphocyte counts; chr8:78669501 chr8:78723796~78724136:- LUSC cis rs11098499 0.731 rs6846966 ENSG00000249244.1 RP11-548H18.2 6.81 3.04e-11 1.93e-08 0.38 0.3 Corneal astigmatism; chr4:119372053 chr4:119391831~119395335:- LUSC cis rs9928842 0.824 rs889515 ENSG00000280152.1 RP11-331F4.5 6.81 3.05e-11 1.93e-08 0.38 0.3 Alcoholic chronic pancreatitis; chr16:75217401 chr16:75245994~75250077:- LUSC cis rs11098499 0.913 rs10006304 ENSG00000250412.1 KLHL2P1 6.81 3.05e-11 1.93e-08 0.38 0.3 Corneal astigmatism; chr4:119203150 chr4:119334329~119378233:+ LUSC cis rs11089937 0.584 rs6001213 ENSG00000211639.2 IGLV4-60 6.81 3.05e-11 1.94e-08 0.31 0.3 Periodontitis (PAL4Q3); chr22:22182108 chr22:22162199~22162681:+ LUSC cis rs5742933 0.817 rs3816196 ENSG00000253559.1 OSGEPL1-AS1 6.81 3.05e-11 1.94e-08 0.36 0.3 Ferritin levels; chr2:189775749 chr2:189762704~189765556:+ LUSC cis rs4950322 0.542 rs115179956 ENSG00000278811.3 LINC00624 6.81 3.05e-11 1.94e-08 0.32 0.3 Protein quantitative trait loci; chr1:147172620 chr1:147258885~147517875:- LUSC cis rs12550612 0.614 rs11135696 ENSG00000253616.4 RP11-875O11.3 6.81 3.06e-11 1.94e-08 0.41 0.3 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23084410 chr8:23071377~23074488:- LUSC cis rs6142102 0.961 rs4911392 ENSG00000276073.1 RP5-1125A11.7 -6.81 3.06e-11 1.94e-08 -0.31 -0.3 Skin pigmentation; chr20:33982712 chr20:33985617~33988989:- LUSC cis rs6142102 0.961 rs4911393 ENSG00000276073.1 RP5-1125A11.7 -6.81 3.06e-11 1.94e-08 -0.31 -0.3 Skin pigmentation; chr20:33983120 chr20:33985617~33988989:- LUSC cis rs2739330 0.791 rs4822458 ENSG00000099984.9 GSTT2 -6.81 3.06e-11 1.95e-08 -0.35 -0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23980123~23983911:+ LUSC cis rs75422866 0.867 rs73113139 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47622826 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73113143 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47623060 chr12:47731908~47732351:+ LUSC cis rs75422866 0.717 rs73113159 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47631318 chr12:47731908~47732351:+ LUSC cis rs75422866 0.717 rs73113161 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47632361 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs117022227 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47633282 chr12:47731908~47732351:+ LUSC cis rs75422866 1 rs73102120 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47637280 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102125 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47637869 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs12426849 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47638975 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs117950951 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47639794 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs7954764 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47641136 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs12422974 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47644559 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102127 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47645341 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102140 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47647497 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102148 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47648013 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102151 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47648023 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs75568526 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47649718 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs116302411 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47649788 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102166 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47653769 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102168 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47654010 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102171 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47656077 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs76100981 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47660092 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102188 ENSG00000274902.1 RP1-197B17.4 6.81 3.07e-11 1.95e-08 0.77 0.3 Pneumonia; chr12:47662993 chr12:47731908~47732351:+ LUSC cis rs10129255 0.957 rs61997760 ENSG00000280411.1 IGHV1-69-2 -6.81 3.07e-11 1.95e-08 -0.21 -0.3 Kawasaki disease; chr14:106716993 chr14:106762092~106762588:- LUSC cis rs8177876 0.822 rs56166222 ENSG00000261838.4 RP11-303E16.6 6.81 3.09e-11 1.96e-08 0.73 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81067920 chr16:81069854~81076598:+ LUSC cis rs7267979 1 rs4815420 ENSG00000274973.1 RP13-401N8.7 6.8 3.09e-11 1.96e-08 0.3 0.3 Liver enzyme levels (alkaline phosphatase); chr20:25403343 chr20:25845497~25845862:+ LUSC cis rs6142102 0.646 rs2223553 ENSG00000275784.1 RP5-1125A11.6 -6.8 3.09e-11 1.96e-08 -0.33 -0.3 Skin pigmentation; chr20:34121638 chr20:33989480~33991818:- LUSC cis rs2179367 0.959 rs480034 ENSG00000231760.4 RP11-350J20.5 -6.8 3.09e-11 1.96e-08 -0.39 -0.3 Dupuytren's disease; chr6:149414294 chr6:149796151~149826294:- LUSC cis rs875971 0.895 rs12698520 ENSG00000237310.1 GS1-124K5.4 6.8 3.1e-11 1.96e-08 0.31 0.3 Aortic root size; chr7:66453720 chr7:66493706~66495474:+ LUSC cis rs5742933 0.857 rs11685425 ENSG00000253559.1 OSGEPL1-AS1 6.8 3.1e-11 1.96e-08 0.36 0.3 Ferritin levels; chr2:189747977 chr2:189762704~189765556:+ LUSC cis rs10129255 0.834 rs10139893 ENSG00000224373.3 IGHV4-59 6.8 3.1e-11 1.96e-08 0.17 0.3 Kawasaki disease; chr14:106711377 chr14:106627249~106627825:- LUSC cis rs1035539 1 rs1035539 ENSG00000280152.1 RP11-331F4.5 6.8 3.1e-11 1.96e-08 0.3 0.3 Alcoholic chronic pancreatitis; chr16:75242877 chr16:75245994~75250077:- LUSC cis rs2286503 1 rs2286498 ENSG00000228649.7 AC005682.5 -6.8 3.1e-11 1.96e-08 -0.32 -0.3 Fibrinogen; chr7:22817885 chr7:22854178~22861579:+ LUSC cis rs875971 0.522 rs6960048 ENSG00000164669.11 INTS4P1 -6.8 3.1e-11 1.97e-08 -0.33 -0.3 Aortic root size; chr7:65943052 chr7:65141225~65234216:+ LUSC cis rs2179367 0.959 rs9373592 ENSG00000231760.4 RP11-350J20.5 6.8 3.11e-11 1.97e-08 0.39 0.3 Dupuytren's disease; chr6:149412119 chr6:149796151~149826294:- LUSC cis rs11098499 0.618 rs28491261 ENSG00000250412.1 KLHL2P1 6.8 3.12e-11 1.98e-08 0.38 0.3 Corneal astigmatism; chr4:119373745 chr4:119334329~119378233:+ LUSC cis rs4141404 0.737 rs5998058 ENSG00000236132.1 CTA-440B3.1 -6.8 3.12e-11 1.98e-08 -0.42 -0.3 Paclitaxel-induced neuropathy; chr22:31610422 chr22:31816379~31817491:- LUSC cis rs10129255 0.872 rs1858683 ENSG00000280411.1 IGHV1-69-2 -6.8 3.13e-11 1.98e-08 -0.21 -0.3 Kawasaki disease; chr14:106670217 chr14:106762092~106762588:- LUSC cis rs801193 0.569 rs35070132 ENSG00000237310.1 GS1-124K5.4 6.8 3.13e-11 1.98e-08 0.32 0.3 Aortic root size; chr7:66773096 chr7:66493706~66495474:+ LUSC cis rs8040855 0.931 rs11855471 ENSG00000259295.5 CSPG4P12 -6.8 3.14e-11 1.99e-08 -0.35 -0.3 Bulimia nervosa; chr15:85175976 chr15:85191438~85213905:+ LUSC cis rs875971 1 rs2077593 ENSG00000237310.1 GS1-124K5.4 6.8 3.14e-11 1.99e-08 0.31 0.3 Aortic root size; chr7:66427543 chr7:66493706~66495474:+ LUSC cis rs1075265 0.68 rs6715488 ENSG00000233266.1 HMGB1P31 6.8 3.14e-11 1.99e-08 0.37 0.3 Chronotype;Morning vs. evening chronotype; chr2:54004130 chr2:54051334~54051760:+ LUSC cis rs9309473 1 rs10184268 ENSG00000163016.8 ALMS1P 6.8 3.15e-11 1.99e-08 0.37 0.3 Metabolite levels; chr2:73399916 chr2:73644919~73685576:+ LUSC cis rs11603023 0.967 rs4245184 ENSG00000255239.1 AP002954.6 -6.8 3.15e-11 1.99e-08 -0.35 -0.3 Cholesterol, total; chr11:118639844 chr11:118688039~118690600:- LUSC cis rs11603023 0.967 rs644273 ENSG00000255239.1 AP002954.6 -6.8 3.15e-11 1.99e-08 -0.35 -0.3 Cholesterol, total; chr11:118640634 chr11:118688039~118690600:- LUSC cis rs7246657 0.943 rs7408563 ENSG00000276846.1 CTD-3220F14.3 6.8 3.15e-11 2e-08 0.46 0.3 Coronary artery calcification; chr19:37317683 chr19:37314868~37315620:- LUSC cis rs8059260 0.736 rs113120936 ENSG00000274038.1 RP11-66H6.4 -6.8 3.16e-11 2e-08 -0.5 -0.3 Alcohol consumption over the past year; chr16:10989474 chr16:11056556~11057034:+ LUSC cis rs4713118 0.629 rs203890 ENSG00000204709.4 LINC01556 6.8 3.16e-11 2e-08 0.42 0.3 Parkinson's disease; chr6:28054470 chr6:28943877~28944537:+ LUSC cis rs904251 0.828 rs1757178 ENSG00000204110.6 RP1-153P14.8 6.8 3.17e-11 2.01e-08 0.28 0.3 Cognitive performance; chr6:37518534 chr6:37507348~37535616:+ LUSC cis rs9309473 1 rs11893881 ENSG00000163016.8 ALMS1P 6.8 3.17e-11 2.01e-08 0.36 0.3 Metabolite levels; chr2:73597246 chr2:73644919~73685576:+ LUSC cis rs7955901 0.638 rs10506626 ENSG00000257265.1 CTD-2021H9.1 -6.8 3.17e-11 2.01e-08 -0.34 -0.3 Type 2 diabetes; chr12:71135711 chr12:71007773~71032083:- LUSC cis rs8072100 0.967 rs4794001 ENSG00000228782.6 CTD-2026D20.3 6.8 3.18e-11 2.01e-08 0.28 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47643483 chr17:47450568~47492492:- LUSC cis rs7772486 0.79 rs2265474 ENSG00000235652.6 RP11-545I5.3 6.8 3.18e-11 2.01e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145860956 chr6:145799409~145886585:+ LUSC cis rs4713118 0.911 rs9461406 ENSG00000219392.1 RP1-265C24.5 6.8 3.19e-11 2.02e-08 0.41 0.3 Parkinson's disease; chr6:27751985 chr6:28115628~28116551:+ LUSC cis rs748404 0.697 rs530683 ENSG00000249839.1 AC011330.5 6.8 3.19e-11 2.02e-08 0.39 0.3 Lung cancer; chr15:43276801 chr15:43663654~43684339:- LUSC cis rs1075232 1 rs56396205 ENSG00000215302.7 CTD-3092A11.1 -6.8 3.2e-11 2.03e-08 -0.7 -0.3 Survival in colorectal cancer (non-distant metastatic); chr15:31386182 chr15:30470779~30507623:+ LUSC cis rs1075232 1 rs12438318 ENSG00000215302.7 CTD-3092A11.1 -6.8 3.2e-11 2.03e-08 -0.7 -0.3 Survival in colorectal cancer (non-distant metastatic); chr15:31388242 chr15:30470779~30507623:+ LUSC cis rs10740039 0.804 rs2028563 ENSG00000254271.1 RP11-131N11.4 -6.8 3.21e-11 2.03e-08 -0.41 -0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60677139 chr10:60734342~60741828:+ LUSC cis rs10759883 0.603 rs13299166 ENSG00000175611.10 LINC00476 6.8 3.22e-11 2.04e-08 0.35 0.3 Nicotine dependence; chr9:95833249 chr9:95759231~95875977:- LUSC cis rs72772090 0.539 rs111886458 ENSG00000248734.2 CTD-2260A17.1 -6.8 3.22e-11 2.04e-08 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789344 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs10515249 ENSG00000248734.2 CTD-2260A17.1 -6.8 3.22e-11 2.04e-08 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789556 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs72773947 ENSG00000248734.2 CTD-2260A17.1 -6.8 3.22e-11 2.04e-08 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789830 chr5:96784777~96785999:+ LUSC cis rs8177876 0.686 rs2602402 ENSG00000261838.4 RP11-303E16.6 6.8 3.23e-11 2.04e-08 0.55 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81052725 chr16:81069854~81076598:+ LUSC cis rs36405 0.5 rs11621704 ENSG00000266869.1 RP6-114E22.1 -6.8 3.24e-11 2.05e-08 -0.37 -0.3 Yang-deficiency constitution; chr14:71888476 chr14:71848606~71908430:+ LUSC cis rs36405 0.5 rs4622450 ENSG00000266869.1 RP6-114E22.1 -6.8 3.24e-11 2.05e-08 -0.37 -0.3 Yang-deficiency constitution; chr14:71889095 chr14:71848606~71908430:+ LUSC cis rs61160187 0.582 rs17332824 ENSG00000215032.2 GNL3LP1 -6.8 3.24e-11 2.05e-08 -0.37 -0.3 Educational attainment (years of education);Educational attainment (college completion); chr5:60870360 chr5:60891935~60893577:- LUSC cis rs12554020 0.686 rs77734990 ENSG00000227603.1 RP11-165J3.6 6.8 3.25e-11 2.06e-08 0.48 0.3 Schizophrenia; chr9:93561870 chr9:93435332~93437121:- LUSC cis rs12554020 0.686 rs56275034 ENSG00000227603.1 RP11-165J3.6 6.8 3.25e-11 2.06e-08 0.48 0.3 Schizophrenia; chr9:93563474 chr9:93435332~93437121:- LUSC cis rs7955901 0.638 rs11178651 ENSG00000257265.1 CTD-2021H9.1 6.8 3.26e-11 2.06e-08 0.34 0.3 Type 2 diabetes; chr12:71142377 chr12:71007773~71032083:- LUSC cis rs8177876 0.749 rs1035541 ENSG00000261838.4 RP11-303E16.6 6.8 3.27e-11 2.06e-08 0.7 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81065249 chr16:81069854~81076598:+ LUSC cis rs748404 1 rs17779494 ENSG00000249839.1 AC011330.5 6.8 3.27e-11 2.07e-08 0.46 0.3 Lung cancer; chr15:43287025 chr15:43663654~43684339:- LUSC cis rs9921338 0.961 rs7200667 ENSG00000263080.1 RP11-485G7.5 6.8 3.27e-11 2.07e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11346547 chr16:11341809~11345211:- LUSC cis rs9921338 0.924 rs7202024 ENSG00000263080.1 RP11-485G7.5 6.8 3.27e-11 2.07e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11346901 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs7206017 ENSG00000263080.1 RP11-485G7.5 6.8 3.27e-11 2.07e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11347004 chr16:11341809~11345211:- LUSC cis rs10754283 0.967 rs2002883 ENSG00000231613.1 RP5-943J3.1 6.8 3.28e-11 2.07e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89640279 chr1:89788914~89790492:+ LUSC cis rs10754283 0.934 rs1934043 ENSG00000231613.1 RP5-943J3.1 6.8 3.28e-11 2.07e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89641086 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs2185195 ENSG00000231613.1 RP5-943J3.1 6.8 3.28e-11 2.07e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89641138 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs6657988 ENSG00000231613.1 RP5-943J3.1 6.8 3.28e-11 2.07e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89641186 chr1:89788914~89790492:+ LUSC cis rs950169 0.84 rs12905223 ENSG00000225151.9 GOLGA2P7 -6.8 3.28e-11 2.07e-08 -0.41 -0.3 Schizophrenia; chr15:84571037 chr15:84199311~84230136:- LUSC cis rs748404 0.626 rs17780920 ENSG00000249839.1 AC011330.5 -6.8 3.28e-11 2.08e-08 -0.48 -0.3 Lung cancer; chr15:43370164 chr15:43663654~43684339:- LUSC cis rs9487094 0.645 rs12529505 ENSG00000260273.1 RP11-425D10.10 -6.8 3.29e-11 2.08e-08 -0.4 -0.3 Height; chr6:109625358 chr6:109382795~109383666:+ LUSC cis rs10246939 0.543 rs7802271 ENSG00000228775.6 WEE2-AS1 6.79 3.29e-11 2.08e-08 0.38 0.3 Bitter taste perception; chr7:141909624 chr7:141704338~141738346:- LUSC cis rs10246939 0.52 rs7782886 ENSG00000228775.6 WEE2-AS1 6.79 3.29e-11 2.08e-08 0.38 0.3 Bitter taste perception; chr7:141909958 chr7:141704338~141738346:- LUSC cis rs10246939 0.543 rs994808 ENSG00000228775.6 WEE2-AS1 6.79 3.29e-11 2.08e-08 0.38 0.3 Bitter taste perception; chr7:141911091 chr7:141704338~141738346:- LUSC cis rs10246939 0.543 rs7808421 ENSG00000228775.6 WEE2-AS1 6.79 3.29e-11 2.08e-08 0.38 0.3 Bitter taste perception; chr7:141911592 chr7:141704338~141738346:- LUSC cis rs10246939 0.543 rs7789123 ENSG00000228775.6 WEE2-AS1 6.79 3.29e-11 2.08e-08 0.38 0.3 Bitter taste perception; chr7:141911699 chr7:141704338~141738346:- LUSC cis rs10246939 0.543 rs11767119 ENSG00000228775.6 WEE2-AS1 6.79 3.29e-11 2.08e-08 0.38 0.3 Bitter taste perception; chr7:141912316 chr7:141704338~141738346:- LUSC cis rs10246939 0.543 rs11769089 ENSG00000228775.6 WEE2-AS1 6.79 3.29e-11 2.08e-08 0.38 0.3 Bitter taste perception; chr7:141914310 chr7:141704338~141738346:- LUSC cis rs7772486 0.641 rs9390374 ENSG00000235652.6 RP11-545I5.3 6.79 3.29e-11 2.08e-08 0.31 0.3 Lobe attachment (rater-scored or self-reported); chr6:146047039 chr6:145799409~145886585:+ LUSC cis rs6907340 0.513 rs6938418 ENSG00000237404.1 RP3-471C18.2 6.79 3.29e-11 2.08e-08 0.4 0.3 Endometriosis; chr6:19808802 chr6:19689825~19753113:- LUSC cis rs3750965 1 rs7950657 ENSG00000260895.1 RP11-554A11.7 6.79 3.3e-11 2.08e-08 0.35 0.3 Hair color; chr11:69067363 chr11:69103493~69109094:+ LUSC cis rs10129255 0.957 rs12590735 ENSG00000224373.3 IGHV4-59 6.79 3.3e-11 2.08e-08 0.16 0.3 Kawasaki disease; chr14:106779660 chr14:106627249~106627825:- LUSC cis rs17023223 0.537 rs2645292 ENSG00000231365.4 RP11-418J17.1 -6.79 3.3e-11 2.09e-08 -0.38 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119030571 chr1:119140396~119275973:+ LUSC cis rs7267979 1 rs6050565 ENSG00000274973.1 RP13-401N8.7 6.79 3.31e-11 2.09e-08 0.3 0.3 Liver enzyme levels (alkaline phosphatase); chr20:25366927 chr20:25845497~25845862:+ LUSC cis rs34779708 0.931 rs7079205 ENSG00000230534.5 RP11-297A16.2 6.79 3.31e-11 2.09e-08 0.34 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35035691 chr10:35098006~35127020:- LUSC cis rs6921919 0.583 rs2041230 ENSG00000204709.4 LINC01556 6.79 3.31e-11 2.09e-08 0.37 0.3 Autism spectrum disorder or schizophrenia; chr6:28397738 chr6:28943877~28944537:+ LUSC cis rs875971 1 rs12698523 ENSG00000237310.1 GS1-124K5.4 6.79 3.31e-11 2.09e-08 0.31 0.3 Aortic root size; chr7:66503126 chr7:66493706~66495474:+ LUSC cis rs7772486 0.754 rs4896838 ENSG00000235652.6 RP11-545I5.3 -6.79 3.32e-11 2.09e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145694315 chr6:145799409~145886585:+ LUSC cis rs10754283 0.967 rs6698273 ENSG00000231613.1 RP5-943J3.1 6.79 3.32e-11 2.09e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89641232 chr1:89788914~89790492:+ LUSC cis rs2337406 1 rs17113276 ENSG00000254174.1 IGHV1-12 -6.79 3.32e-11 2.1e-08 -0.32 -0.3 Alzheimer's disease (late onset); chr14:106683485 chr14:106122420~106122709:- LUSC cis rs10754283 0.967 rs10801757 ENSG00000231613.1 RP5-943J3.1 6.79 3.32e-11 2.1e-08 0.33 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89637521 chr1:89788914~89790492:+ LUSC cis rs113835537 0.597 rs11227523 ENSG00000255517.5 CTD-3074O7.5 -6.79 3.32e-11 2.1e-08 -0.34 -0.3 Airway imaging phenotypes; chr11:66538467 chr11:66473490~66480233:- LUSC cis rs7772486 0.754 rs9373475 ENSG00000235652.6 RP11-545I5.3 6.79 3.32e-11 2.1e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145805283 chr6:145799409~145886585:+ LUSC cis rs867371 1 rs2088858 ENSG00000255769.6 GOLGA2P10 -6.79 3.33e-11 2.1e-08 -0.37 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82182408 chr15:82472993~82513950:- LUSC cis rs867371 1 rs4778982 ENSG00000255769.6 GOLGA2P10 -6.79 3.33e-11 2.1e-08 -0.37 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82182931 chr15:82472993~82513950:- LUSC cis rs867371 1 rs2867579 ENSG00000255769.6 GOLGA2P10 -6.79 3.33e-11 2.1e-08 -0.37 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82183043 chr15:82472993~82513950:- LUSC cis rs867371 1 rs881308 ENSG00000255769.6 GOLGA2P10 -6.79 3.33e-11 2.1e-08 -0.37 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82183456 chr15:82472993~82513950:- LUSC cis rs5753618 0.529 rs5749298 ENSG00000236132.1 CTA-440B3.1 -6.79 3.33e-11 2.1e-08 -0.42 -0.3 Colorectal cancer; chr22:31545046 chr22:31816379~31817491:- LUSC cis rs12216125 0.549 rs9358905 ENSG00000272462.2 U91328.19 -6.79 3.34e-11 2.11e-08 -0.32 -0.3 Iron status biomarkers; chr6:26077611 chr6:25992662~26001775:+ LUSC cis rs11098499 1 rs6837898 ENSG00000250412.1 KLHL2P1 6.79 3.34e-11 2.11e-08 0.38 0.3 Corneal astigmatism; chr4:119257999 chr4:119334329~119378233:+ LUSC cis rs1823913 0.927 rs35339956 ENSG00000280083.1 RP11-317J9.1 -6.79 3.35e-11 2.11e-08 -0.38 -0.3 Obesity-related traits; chr2:191261668 chr2:191154118~191156070:- LUSC cis rs853679 0.517 rs9357065 ENSG00000204709.4 LINC01556 6.79 3.35e-11 2.11e-08 0.42 0.3 Depression; chr6:28161802 chr6:28943877~28944537:+ LUSC cis rs11098499 0.954 rs10006877 ENSG00000250412.1 KLHL2P1 6.79 3.37e-11 2.13e-08 0.38 0.3 Corneal astigmatism; chr4:119321638 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs7678400 ENSG00000250412.1 KLHL2P1 6.79 3.37e-11 2.13e-08 0.38 0.3 Corneal astigmatism; chr4:119540802 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs1480936 ENSG00000250412.1 KLHL2P1 6.79 3.37e-11 2.13e-08 0.38 0.3 Corneal astigmatism; chr4:119541706 chr4:119334329~119378233:+ LUSC cis rs17023223 0.537 rs17023171 ENSG00000231365.4 RP11-418J17.1 -6.79 3.38e-11 2.13e-08 -0.38 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119050645 chr1:119140396~119275973:+ LUSC cis rs75422866 0.867 rs73104103 ENSG00000274902.1 RP1-197B17.4 6.79 3.38e-11 2.13e-08 0.77 0.3 Pneumonia; chr12:47669604 chr12:47731908~47732351:+ LUSC cis rs2404602 0.684 rs1011083 ENSG00000259422.1 RP11-593F23.1 -6.79 3.38e-11 2.13e-08 -0.36 -0.3 Blood metabolite levels; chr15:76715186 chr15:76174891~76181486:- LUSC cis rs10740039 0.883 rs10821809 ENSG00000254271.1 RP11-131N11.4 6.79 3.38e-11 2.13e-08 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60637612 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs10761533 ENSG00000254271.1 RP11-131N11.4 6.79 3.38e-11 2.13e-08 0.42 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60638573 chr10:60734342~60741828:+ LUSC cis rs2179367 0.537 rs12192159 ENSG00000231760.4 RP11-350J20.5 6.79 3.39e-11 2.14e-08 0.45 0.3 Dupuytren's disease; chr6:149445969 chr6:149796151~149826294:- LUSC cis rs9326248 0.53 rs11216171 ENSG00000280143.1 AP000892.6 6.79 3.39e-11 2.14e-08 0.35 0.3 Blood protein levels; chr11:116878397 chr11:117204967~117210292:+ LUSC cis rs9549367 0.713 rs2146750 ENSG00000269125.1 RP11-98F14.11 6.79 3.39e-11 2.14e-08 0.38 0.3 Platelet distribution width; chr13:113168216 chr13:113165002~113165183:- LUSC cis rs10080237 0.564 rs2490224 ENSG00000272129.1 RP11-250B2.6 6.79 3.39e-11 2.14e-08 0.37 0.3 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr6:80100116 chr6:80355424~80356859:+ LUSC cis rs7772486 0.754 rs697053 ENSG00000235652.6 RP11-545I5.3 -6.79 3.4e-11 2.14e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145668671 chr6:145799409~145886585:+ LUSC cis rs10754283 0.901 rs10047070 ENSG00000231613.1 RP5-943J3.1 6.79 3.41e-11 2.15e-08 0.34 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89633156 chr1:89788914~89790492:+ LUSC cis rs10262624 0.901 rs6966655 ENSG00000234286.1 AC006026.13 -6.79 3.41e-11 2.15e-08 -0.35 -0.3 Schizophrenia; chr7:23867010 chr7:23680195~23680786:- LUSC cis rs3096299 0.748 rs3102339 ENSG00000274627.1 RP11-104N10.2 6.79 3.42e-11 2.16e-08 0.27 0.3 Multiple myeloma (IgH translocation); chr16:89376303 chr16:89516797~89522217:+ LUSC cis rs801193 0.548 rs6975044 ENSG00000237310.1 GS1-124K5.4 6.79 3.43e-11 2.16e-08 0.32 0.3 Aortic root size; chr7:66762495 chr7:66493706~66495474:+ LUSC cis rs11098499 0.955 rs56386062 ENSG00000250412.1 KLHL2P1 6.79 3.43e-11 2.16e-08 0.37 0.3 Corneal astigmatism; chr4:119233980 chr4:119334329~119378233:+ LUSC cis rs11098499 0.955 rs4145951 ENSG00000250412.1 KLHL2P1 6.79 3.43e-11 2.16e-08 0.37 0.3 Corneal astigmatism; chr4:119234662 chr4:119334329~119378233:+ LUSC cis rs11098499 0.955 rs35916640 ENSG00000250412.1 KLHL2P1 6.79 3.43e-11 2.16e-08 0.37 0.3 Corneal astigmatism; chr4:119234697 chr4:119334329~119378233:+ LUSC cis rs11098499 0.955 rs13114751 ENSG00000250412.1 KLHL2P1 6.79 3.43e-11 2.16e-08 0.37 0.3 Corneal astigmatism; chr4:119235462 chr4:119334329~119378233:+ LUSC cis rs11098499 0.913 rs35271032 ENSG00000250412.1 KLHL2P1 6.79 3.43e-11 2.16e-08 0.37 0.3 Corneal astigmatism; chr4:119235504 chr4:119334329~119378233:+ LUSC cis rs673078 0.571 rs17440823 ENSG00000275759.1 RP11-131L12.3 -6.79 3.44e-11 2.17e-08 -0.43 -0.3 Glucose homeostasis traits; chr12:118353023 chr12:118428281~118428870:+ LUSC cis rs17711722 0.701 rs781145 ENSG00000164669.11 INTS4P1 -6.79 3.45e-11 2.17e-08 -0.33 -0.3 Calcium levels; chr7:65975383 chr7:65141225~65234216:+ LUSC cis rs875971 0.964 rs697969 ENSG00000237310.1 GS1-124K5.4 -6.79 3.45e-11 2.17e-08 -0.31 -0.3 Aortic root size; chr7:66093491 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1182882 ENSG00000237310.1 GS1-124K5.4 -6.79 3.45e-11 2.17e-08 -0.31 -0.3 Aortic root size; chr7:66097076 chr7:66493706~66495474:+ LUSC cis rs75422866 0.867 rs73102195 ENSG00000274902.1 RP1-197B17.4 6.79 3.45e-11 2.17e-08 0.77 0.3 Pneumonia; chr12:47666309 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73102201 ENSG00000274902.1 RP1-197B17.4 6.79 3.45e-11 2.17e-08 0.77 0.3 Pneumonia; chr12:47669269 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73104104 ENSG00000274902.1 RP1-197B17.4 6.79 3.45e-11 2.17e-08 0.77 0.3 Pneumonia; chr12:47671986 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73104111 ENSG00000274902.1 RP1-197B17.4 6.79 3.45e-11 2.17e-08 0.77 0.3 Pneumonia; chr12:47673994 chr12:47731908~47732351:+ LUSC cis rs113835537 0.529 rs3741360 ENSG00000255517.5 CTD-3074O7.5 -6.79 3.45e-11 2.17e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66532877 chr11:66473490~66480233:- LUSC cis rs6504950 0.8 rs7209926 ENSG00000275710.1 RP11-257O5.4 -6.79 3.46e-11 2.18e-08 -0.36 -0.3 Breast cancer; chr17:54928963 chr17:54964474~54964679:+ LUSC cis rs11098499 0.913 rs13126596 ENSG00000250412.1 KLHL2P1 6.79 3.46e-11 2.18e-08 0.38 0.3 Corneal astigmatism; chr4:119219574 chr4:119334329~119378233:+ LUSC cis rs2179367 0.959 rs521845 ENSG00000231760.4 RP11-350J20.5 -6.79 3.47e-11 2.19e-08 -0.38 -0.3 Dupuytren's disease; chr6:149350562 chr6:149796151~149826294:- LUSC cis rs7246657 0.943 rs10424574 ENSG00000276846.1 CTD-3220F14.3 6.79 3.48e-11 2.19e-08 0.45 0.3 Coronary artery calcification; chr19:37347491 chr19:37314868~37315620:- LUSC cis rs1185460 0.546 rs17075 ENSG00000271751.1 RP11-110I1.14 6.79 3.49e-11 2.2e-08 0.38 0.3 Coronary artery disease; chr11:119088621 chr11:119065263~119065677:- LUSC cis rs8177876 0.822 rs4306521 ENSG00000261838.4 RP11-303E16.6 6.79 3.49e-11 2.2e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081288 chr16:81069854~81076598:+ LUSC cis rs8177876 0.822 rs4324142 ENSG00000261838.4 RP11-303E16.6 6.79 3.49e-11 2.2e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081298 chr16:81069854~81076598:+ LUSC cis rs8177876 0.642 rs4324143 ENSG00000261838.4 RP11-303E16.6 6.79 3.49e-11 2.2e-08 0.68 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081383 chr16:81069854~81076598:+ LUSC cis rs12439619 0.508 rs8032033 ENSG00000276710.3 CSPG4P8 -6.79 3.49e-11 2.2e-08 -0.31 -0.3 Intelligence (multi-trait analysis); chr15:82165555 chr15:82459472~82477258:+ LUSC cis rs9903692 0.865 rs7220520 ENSG00000278765.1 RP5-890E16.5 6.79 3.49e-11 2.2e-08 0.35 0.3 Pulse pressure; chr17:48090580 chr17:48066704~48067293:- LUSC cis rs2337406 1 rs11850600 ENSG00000274576.2 IGHV2-70 -6.78 3.51e-11 2.21e-08 -0.34 -0.3 Alzheimer's disease (late onset); chr14:106670765 chr14:106770577~106771020:- LUSC cis rs67311347 0.866 rs11712426 ENSG00000223797.4 ENTPD3-AS1 6.78 3.51e-11 2.21e-08 0.33 0.3 Renal cell carcinoma; chr3:40288831 chr3:40313802~40453329:- LUSC cis rs8031584 0.678 rs4779790 ENSG00000260382.1 RP11-540B6.2 6.78 3.52e-11 2.21e-08 0.41 0.3 Huntington's disease progression; chr15:30872392 chr15:30882267~30883231:- LUSC cis rs10129255 0.957 rs10137980 ENSG00000280411.1 IGHV1-69-2 -6.78 3.52e-11 2.22e-08 -0.21 -0.3 Kawasaki disease; chr14:106775735 chr14:106762092~106762588:- LUSC cis rs13113518 0.51 rs11732723 ENSG00000273257.1 RP11-177J6.1 -6.78 3.52e-11 2.22e-08 -0.36 -0.3 Height; chr4:55424391 chr4:55387949~55388271:+ LUSC cis rs10800713 0.908 rs6670625 ENSG00000260088.1 RP11-92G12.3 -6.78 3.53e-11 2.22e-08 -0.42 -0.3 Tandem gait; chr1:200587514 chr1:200669507~200694250:+ LUSC cis rs9309473 0.95 rs6756885 ENSG00000163016.8 ALMS1P 6.78 3.54e-11 2.23e-08 0.36 0.3 Metabolite levels; chr2:73578045 chr2:73644919~73685576:+ LUSC cis rs5742933 0.857 rs1233272 ENSG00000253559.1 OSGEPL1-AS1 -6.78 3.55e-11 2.23e-08 -0.37 -0.3 Ferritin levels; chr2:189814968 chr2:189762704~189765556:+ LUSC cis rs875971 0.505 rs6955582 ENSG00000164669.11 INTS4P1 -6.78 3.56e-11 2.24e-08 -0.33 -0.3 Aortic root size; chr7:65966699 chr7:65141225~65234216:+ LUSC cis rs13137105 0.864 rs34402235 ENSG00000250735.4 RP11-567N4.3 6.78 3.57e-11 2.25e-08 0.34 0.3 Response to tocilizumab in rheumatoid arthritis; chr4:75523046 chr4:75401195~75423023:+ LUSC cis rs227275 0.554 rs223425 ENSG00000230069.3 LRRC37A15P -6.78 3.58e-11 2.25e-08 -0.32 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:102802836 chr4:102727274~102730721:- LUSC cis rs2282300 0.956 rs2685286 ENSG00000254532.1 RP11-624D11.2 6.78 3.59e-11 2.26e-08 0.41 0.3 Morning vs. evening chronotype; chr11:30360041 chr11:30044058~30084343:- LUSC cis rs2282300 0.956 rs1717773 ENSG00000254532.1 RP11-624D11.2 6.78 3.59e-11 2.26e-08 0.41 0.3 Morning vs. evening chronotype; chr11:30361607 chr11:30044058~30084343:- LUSC cis rs10262624 0.967 rs13235406 ENSG00000234286.1 AC006026.13 -6.78 3.59e-11 2.26e-08 -0.35 -0.3 Schizophrenia; chr7:23879212 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs17347733 ENSG00000234286.1 AC006026.13 -6.78 3.6e-11 2.26e-08 -0.35 -0.3 Schizophrenia; chr7:23878891 chr7:23680195~23680786:- LUSC cis rs113835537 0.529 rs2277302 ENSG00000255517.5 CTD-3074O7.5 -6.78 3.61e-11 2.27e-08 -0.34 -0.3 Airway imaging phenotypes; chr11:66473411 chr11:66473490~66480233:- LUSC cis rs853679 0.517 rs1947862 ENSG00000204709.4 LINC01556 6.78 3.61e-11 2.27e-08 0.42 0.3 Depression; chr6:28137418 chr6:28943877~28944537:+ LUSC cis rs8072100 0.967 rs11656855 ENSG00000228782.6 CTD-2026D20.3 -6.78 3.61e-11 2.27e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47637289 chr17:47450568~47492492:- LUSC cis rs2455601 0.671 rs10840135 ENSG00000254860.4 TMEM9B-AS1 6.78 3.62e-11 2.27e-08 0.35 0.3 Schizophrenia; chr11:8858247 chr11:8964675~8977527:+ LUSC cis rs1075265 0.901 rs1118618 ENSG00000233266.1 HMGB1P31 6.78 3.62e-11 2.27e-08 0.4 0.3 Chronotype;Morning vs. evening chronotype; chr2:54099333 chr2:54051334~54051760:+ LUSC cis rs113835537 0.529 rs11227509 ENSG00000255517.5 CTD-3074O7.5 -6.78 3.62e-11 2.27e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66513723 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs11227510 ENSG00000255517.5 CTD-3074O7.5 -6.78 3.62e-11 2.27e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66513749 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs11227512 ENSG00000255517.5 CTD-3074O7.5 -6.78 3.62e-11 2.27e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66513820 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs2298806 ENSG00000255517.5 CTD-3074O7.5 -6.78 3.62e-11 2.27e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66514624 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs2276406 ENSG00000255517.5 CTD-3074O7.5 -6.78 3.62e-11 2.27e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66515786 chr11:66473490~66480233:- LUSC cis rs8072100 0.967 rs4289035 ENSG00000228782.6 CTD-2026D20.3 6.78 3.62e-11 2.27e-08 0.28 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47629845 chr17:47450568~47492492:- LUSC cis rs3779195 0.929 rs4268041 ENSG00000272950.1 RP11-307C18.1 -6.78 3.62e-11 2.28e-08 -0.46 -0.3 Sex hormone-binding globulin levels; chr7:98376226 chr7:98322853~98323430:+ LUSC cis rs11098499 0.58 rs12509234 ENSG00000250412.1 KLHL2P1 6.78 3.62e-11 2.28e-08 0.38 0.3 Corneal astigmatism; chr4:119398279 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs10014719 ENSG00000250412.1 KLHL2P1 6.78 3.62e-11 2.28e-08 0.38 0.3 Corneal astigmatism; chr4:119399560 chr4:119334329~119378233:+ LUSC cis rs875971 0.522 rs1917563 ENSG00000164669.11 INTS4P1 6.78 3.63e-11 2.28e-08 0.32 0.3 Aortic root size; chr7:65950660 chr7:65141225~65234216:+ LUSC cis rs7829975 0.688 rs7826654 ENSG00000253893.2 FAM85B -6.78 3.63e-11 2.28e-08 -0.35 -0.3 Mood instability; chr8:8521596 chr8:8167819~8226614:- LUSC cis rs7829975 0.688 rs7826660 ENSG00000253893.2 FAM85B -6.78 3.63e-11 2.28e-08 -0.35 -0.3 Mood instability; chr8:8521597 chr8:8167819~8226614:- LUSC cis rs7829975 0.688 rs7837587 ENSG00000253893.2 FAM85B -6.78 3.63e-11 2.28e-08 -0.35 -0.3 Mood instability; chr8:8521482 chr8:8167819~8226614:- LUSC cis rs13113518 0.812 rs4865001 ENSG00000223305.1 RN7SKP30 6.78 3.64e-11 2.29e-08 0.37 0.3 Height; chr4:55490176 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs4864543 ENSG00000223305.1 RN7SKP30 6.78 3.64e-11 2.29e-08 0.37 0.3 Height; chr4:55490228 chr4:55540502~55540835:- LUSC cis rs875971 1 rs778726 ENSG00000237310.1 GS1-124K5.4 6.78 3.65e-11 2.29e-08 0.31 0.3 Aortic root size; chr7:66363744 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs778723 ENSG00000237310.1 GS1-124K5.4 6.78 3.65e-11 2.29e-08 0.31 0.3 Aortic root size; chr7:66364510 chr7:66493706~66495474:+ LUSC cis rs875971 0.767 rs1695815 ENSG00000237310.1 GS1-124K5.4 6.78 3.65e-11 2.29e-08 0.31 0.3 Aortic root size; chr7:66366357 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs778685 ENSG00000237310.1 GS1-124K5.4 6.78 3.65e-11 2.29e-08 0.31 0.3 Aortic root size; chr7:66371189 chr7:66493706~66495474:+ LUSC cis rs875971 0.929 rs778682 ENSG00000237310.1 GS1-124K5.4 6.78 3.65e-11 2.29e-08 0.31 0.3 Aortic root size; chr7:66372947 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs11765965 ENSG00000237310.1 GS1-124K5.4 6.78 3.65e-11 2.29e-08 0.31 0.3 Aortic root size; chr7:66377234 chr7:66493706~66495474:+ LUSC cis rs228614 0.536 rs223437 ENSG00000230069.3 LRRC37A15P -6.78 3.65e-11 2.29e-08 -0.32 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798736 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223435 ENSG00000230069.3 LRRC37A15P -6.78 3.65e-11 2.29e-08 -0.32 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799826 chr4:102727274~102730721:- LUSC cis rs8072100 0.935 rs12943464 ENSG00000228782.6 CTD-2026D20.3 -6.78 3.66e-11 2.3e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47612985 chr17:47450568~47492492:- LUSC cis rs8062405 0.69 rs762634 ENSG00000278665.1 RP11-666O2.4 6.78 3.67e-11 2.3e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28592014 chr16:28599241~28601881:- LUSC cis rs62034325 0.697 rs710410 ENSG00000278665.1 RP11-666O2.4 6.78 3.67e-11 2.3e-08 0.3 0.3 Body mass index; chr16:28592021 chr16:28599241~28601881:- LUSC cis rs55726902 1 rs55726902 ENSG00000276691.1 RP5-1057I20.5 6.78 3.67e-11 2.3e-08 0.37 0.3 Allergic disease (asthma, hay fever or eczema); chr12:47803199 chr12:47788426~47788971:+ LUSC cis rs875971 1 rs7781698 ENSG00000237310.1 GS1-124K5.4 6.78 3.68e-11 2.31e-08 0.31 0.3 Aortic root size; chr7:66431325 chr7:66493706~66495474:+ LUSC cis rs7829975 0.688 rs6601703 ENSG00000253893.2 FAM85B -6.78 3.68e-11 2.31e-08 -0.35 -0.3 Mood instability; chr8:8522714 chr8:8167819~8226614:- LUSC cis rs9921338 0.961 rs8048768 ENSG00000263080.1 RP11-485G7.5 6.78 3.68e-11 2.31e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11302983 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs11074958 ENSG00000263080.1 RP11-485G7.5 6.78 3.68e-11 2.31e-08 0.36 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11303222 chr16:11341809~11345211:- LUSC cis rs7772486 0.754 rs9399561 ENSG00000235652.6 RP11-545I5.3 6.78 3.68e-11 2.31e-08 0.3 0.3 Lobe attachment (rater-scored or self-reported); chr6:145634551 chr6:145799409~145886585:+ LUSC cis rs10129255 0.957 rs11847726 ENSG00000224373.3 IGHV4-59 6.78 3.68e-11 2.31e-08 0.16 0.3 Kawasaki disease; chr14:106779116 chr14:106627249~106627825:- LUSC cis rs853679 0.517 rs6932109 ENSG00000280107.1 AL022393.9 6.78 3.69e-11 2.31e-08 0.37 0.3 Depression; chr6:28110525 chr6:28170845~28172521:+ LUSC cis rs7429990 0.965 rs319689 ENSG00000229759.1 MRPS18AP1 6.78 3.7e-11 2.32e-08 0.29 0.3 Educational attainment (years of education); chr3:47886677 chr3:48256350~48256938:- LUSC cis rs11098499 0.866 rs72676074 ENSG00000250412.1 KLHL2P1 6.78 3.7e-11 2.32e-08 0.38 0.3 Corneal astigmatism; chr4:119438686 chr4:119334329~119378233:+ LUSC cis rs1930961 1 rs6004669 ENSG00000100058.11 CRYBB2P1 6.78 3.7e-11 2.32e-08 0.55 0.3 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25448105~25520854:+ LUSC cis rs67180937 0.7 rs4282830 ENSG00000272750.1 RP11-378J18.8 -6.78 3.7e-11 2.32e-08 -0.33 -0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222738618 chr1:222658867~222661512:- LUSC cis rs367615 0.506 rs2914684 ENSG00000249476.1 CTD-2587M2.1 -6.78 3.7e-11 2.32e-08 -0.33 -0.3 Colorectal cancer (SNP x SNP interaction); chr5:109439409 chr5:109237120~109326369:- LUSC cis rs12554020 0.892 rs75775593 ENSG00000227603.1 RP11-165J3.6 6.78 3.71e-11 2.32e-08 0.48 0.3 Schizophrenia; chr9:93568611 chr9:93435332~93437121:- LUSC cis rs12554020 0.892 rs78816659 ENSG00000227603.1 RP11-165J3.6 6.78 3.71e-11 2.32e-08 0.48 0.3 Schizophrenia; chr9:93575141 chr9:93435332~93437121:- LUSC cis rs10800713 0.954 rs10800710 ENSG00000260088.1 RP11-92G12.3 -6.78 3.71e-11 2.33e-08 -0.41 -0.3 Tandem gait; chr1:200569240 chr1:200669507~200694250:+ LUSC cis rs10800713 0.954 rs10800711 ENSG00000260088.1 RP11-92G12.3 -6.78 3.71e-11 2.33e-08 -0.41 -0.3 Tandem gait; chr1:200569757 chr1:200669507~200694250:+ LUSC cis rs10800713 0.954 rs12092148 ENSG00000260088.1 RP11-92G12.3 -6.78 3.71e-11 2.33e-08 -0.41 -0.3 Tandem gait; chr1:200570655 chr1:200669507~200694250:+ LUSC cis rs10800713 0.826 rs11586257 ENSG00000260088.1 RP11-92G12.3 -6.78 3.71e-11 2.33e-08 -0.41 -0.3 Tandem gait; chr1:200572236 chr1:200669507~200694250:+ LUSC cis rs2179367 0.959 rs9373589 ENSG00000231760.4 RP11-350J20.5 6.78 3.71e-11 2.33e-08 0.39 0.3 Dupuytren's disease; chr6:149386152 chr6:149796151~149826294:- LUSC cis rs62229266 0.839 rs11702763 ENSG00000231106.2 LINC01436 6.78 3.73e-11 2.33e-08 0.39 0.3 Mitral valve prolapse; chr21:36098406 chr21:36005338~36007838:+ LUSC cis rs1865760 0.516 rs9295684 ENSG00000272462.2 U91328.19 -6.78 3.73e-11 2.34e-08 -0.32 -0.3 Height; chr6:26069441 chr6:25992662~26001775:+ LUSC cis rs10246939 0.543 rs12538701 ENSG00000228775.6 WEE2-AS1 6.78 3.73e-11 2.34e-08 0.38 0.3 Bitter taste perception; chr7:141893634 chr7:141704338~141738346:- LUSC cis rs4713118 0.621 rs4713132 ENSG00000204709.4 LINC01556 6.78 3.73e-11 2.34e-08 0.43 0.3 Parkinson's disease; chr6:28066257 chr6:28943877~28944537:+ LUSC cis rs4713118 0.621 rs4713133 ENSG00000204709.4 LINC01556 6.78 3.73e-11 2.34e-08 0.43 0.3 Parkinson's disease; chr6:28066263 chr6:28943877~28944537:+ LUSC cis rs4713118 0.621 rs4713134 ENSG00000204709.4 LINC01556 6.78 3.73e-11 2.34e-08 0.43 0.3 Parkinson's disease; chr6:28066343 chr6:28943877~28944537:+ LUSC cis rs2188561 0.697 rs7787927 ENSG00000241764.3 AC002467.7 6.77 3.73e-11 2.34e-08 0.39 0.3 Alcohol consumption; chr7:107763915 chr7:107742817~107744581:- LUSC cis rs13113518 0.812 rs56055342 ENSG00000223305.1 RN7SKP30 6.77 3.74e-11 2.34e-08 0.37 0.3 Height; chr4:55540928 chr4:55540502~55540835:- LUSC cis rs6504950 0.79 rs8076984 ENSG00000275710.1 RP11-257O5.4 6.77 3.74e-11 2.34e-08 0.37 0.3 Breast cancer; chr17:54958067 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs17745231 ENSG00000275710.1 RP11-257O5.4 6.77 3.74e-11 2.34e-08 0.37 0.3 Breast cancer; chr17:54959168 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs12938118 ENSG00000275710.1 RP11-257O5.4 6.77 3.74e-11 2.34e-08 0.37 0.3 Breast cancer; chr17:54959998 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs1802212 ENSG00000275710.1 RP11-257O5.4 6.77 3.74e-11 2.34e-08 0.37 0.3 Breast cancer; chr17:54961293 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs17817901 ENSG00000275710.1 RP11-257O5.4 6.77 3.74e-11 2.34e-08 0.37 0.3 Breast cancer; chr17:54961384 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs12150038 ENSG00000275710.1 RP11-257O5.4 6.77 3.74e-11 2.34e-08 0.37 0.3 Breast cancer; chr17:54964159 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs12951542 ENSG00000275710.1 RP11-257O5.4 6.77 3.74e-11 2.34e-08 0.37 0.3 Breast cancer; chr17:54964604 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs72831295 ENSG00000275710.1 RP11-257O5.4 6.77 3.74e-11 2.34e-08 0.37 0.3 Breast cancer; chr17:54966443 chr17:54964474~54964679:+ LUSC cis rs10800713 0.954 rs6660637 ENSG00000260088.1 RP11-92G12.3 -6.77 3.74e-11 2.34e-08 -0.42 -0.3 Tandem gait; chr1:200550893 chr1:200669507~200694250:+ LUSC cis rs10800713 0.954 rs10737572 ENSG00000260088.1 RP11-92G12.3 -6.77 3.74e-11 2.34e-08 -0.42 -0.3 Tandem gait; chr1:200552003 chr1:200669507~200694250:+ LUSC cis rs2404602 0.735 rs2468130 ENSG00000259422.1 RP11-593F23.1 -6.77 3.75e-11 2.35e-08 -0.35 -0.3 Blood metabolite levels; chr15:76504155 chr15:76174891~76181486:- LUSC cis rs9549367 0.713 rs4907599 ENSG00000269125.1 RP11-98F14.11 6.77 3.75e-11 2.35e-08 0.35 0.3 Platelet distribution width; chr13:113207127 chr13:113165002~113165183:- LUSC cis rs853679 0.607 rs13208096 ENSG00000204709.4 LINC01556 6.77 3.76e-11 2.35e-08 0.65 0.3 Depression; chr6:28257533 chr6:28943877~28944537:+ LUSC cis rs9532669 0.926 rs9525438 ENSG00000176268.5 CYCSP34 6.77 3.76e-11 2.35e-08 0.3 0.3 Cervical cancer; chr13:40964123 chr13:40863599~40863902:- LUSC cis rs11976180 1 rs2961118 ENSG00000170356.8 OR2A20P -6.77 3.76e-11 2.35e-08 -0.4 -0.3 Obesity-related traits; chr7:144058350 chr7:144250045~144252957:- LUSC cis rs113835537 0.529 rs75003264 ENSG00000255517.5 CTD-3074O7.5 -6.77 3.76e-11 2.35e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66488628 chr11:66473490~66480233:- LUSC cis rs10262624 0.935 rs4722283 ENSG00000234286.1 AC006026.13 6.77 3.77e-11 2.36e-08 0.35 0.3 Schizophrenia; chr7:23866595 chr7:23680195~23680786:- LUSC cis rs11098499 0.954 rs1546505 ENSG00000250412.1 KLHL2P1 6.77 3.77e-11 2.36e-08 0.39 0.3 Corneal astigmatism; chr4:119320069 chr4:119334329~119378233:+ LUSC cis rs12291225 0.585 rs10832246 ENSG00000251991.1 RNU7-49P 6.77 3.77e-11 2.36e-08 0.34 0.3 Sense of smell; chr11:14359282 chr11:14478892~14478953:+ LUSC cis rs17711722 0.727 rs2658585 ENSG00000164669.11 INTS4P1 -6.77 3.77e-11 2.36e-08 -0.33 -0.3 Calcium levels; chr7:65996954 chr7:65141225~65234216:+ LUSC cis rs4713118 0.869 rs9283880 ENSG00000219392.1 RP1-265C24.5 -6.77 3.78e-11 2.36e-08 -0.38 -0.3 Parkinson's disease; chr6:27747464 chr6:28115628~28116551:+ LUSC cis rs7955901 0.691 rs60903622 ENSG00000257265.1 CTD-2021H9.1 6.77 3.78e-11 2.36e-08 0.33 0.3 Type 2 diabetes; chr12:71097041 chr12:71007773~71032083:- LUSC cis rs11098499 0.754 rs1980025 ENSG00000249244.1 RP11-548H18.2 -6.77 3.78e-11 2.36e-08 -0.36 -0.3 Corneal astigmatism; chr4:119331651 chr4:119391831~119395335:- LUSC cis rs732716 0.785 rs56272533 ENSG00000267769.1 CTB-50L17.9 -6.77 3.78e-11 2.36e-08 -0.33 -0.3 Mean corpuscular volume; chr19:4420045 chr19:4454014~4455286:+ LUSC cis rs7955901 0.691 rs12831292 ENSG00000257265.1 CTD-2021H9.1 6.77 3.78e-11 2.37e-08 0.33 0.3 Type 2 diabetes; chr12:71096376 chr12:71007773~71032083:- LUSC cis rs8177876 0.822 rs10514514 ENSG00000261838.4 RP11-303E16.6 6.77 3.79e-11 2.37e-08 0.64 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081668 chr16:81069854~81076598:+ LUSC cis rs6772849 0.805 rs61159406 ENSG00000277250.1 Metazoa_SRP -6.77 3.8e-11 2.37e-08 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr3:128617166 chr3:128673681~128674021:- LUSC cis rs6772849 0.805 rs13325747 ENSG00000277250.1 Metazoa_SRP -6.77 3.8e-11 2.37e-08 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr3:128617180 chr3:128673681~128674021:- LUSC cis rs8040855 0.965 rs1961276 ENSG00000259295.5 CSPG4P12 6.77 3.8e-11 2.38e-08 0.34 0.3 Bulimia nervosa; chr15:85170986 chr15:85191438~85213905:+ LUSC cis rs4713118 0.868 rs2893928 ENSG00000219392.1 RP1-265C24.5 -6.77 3.81e-11 2.38e-08 -0.42 -0.3 Parkinson's disease; chr6:27770651 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9295758 ENSG00000204709.4 LINC01556 6.77 3.82e-11 2.39e-08 0.43 0.3 Depression; chr6:28152885 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs17774663 ENSG00000204709.4 LINC01556 6.77 3.82e-11 2.39e-08 0.43 0.3 Depression; chr6:28153120 chr6:28943877~28944537:+ LUSC cis rs11098499 0.955 rs13129661 ENSG00000250412.1 KLHL2P1 6.77 3.83e-11 2.39e-08 0.37 0.3 Corneal astigmatism; chr4:119231754 chr4:119334329~119378233:+ LUSC cis rs1075265 0.568 rs805416 ENSG00000233266.1 HMGB1P31 -6.77 3.83e-11 2.39e-08 -0.37 -0.3 Chronotype;Morning vs. evening chronotype; chr2:53898121 chr2:54051334~54051760:+ LUSC cis rs6570726 0.577 rs867056 ENSG00000235652.6 RP11-545I5.3 -6.77 3.83e-11 2.39e-08 -0.31 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145463669 chr6:145799409~145886585:+ LUSC cis rs9921338 0.961 rs7202814 ENSG00000263080.1 RP11-485G7.5 6.77 3.83e-11 2.39e-08 0.35 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11295917 chr16:11341809~11345211:- LUSC cis rs8031584 0.678 rs8035703 ENSG00000260382.1 RP11-540B6.2 6.77 3.83e-11 2.4e-08 0.41 0.3 Huntington's disease progression; chr15:30876269 chr15:30882267~30883231:- LUSC cis rs227275 0.555 rs223403 ENSG00000230069.3 LRRC37A15P -6.77 3.84e-11 2.4e-08 -0.32 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:102817086 chr4:102727274~102730721:- LUSC cis rs875971 1 rs6946143 ENSG00000237310.1 GS1-124K5.4 6.77 3.85e-11 2.4e-08 0.3 0.3 Aortic root size; chr7:66114735 chr7:66493706~66495474:+ LUSC cis rs113835537 0.529 rs11227501 ENSG00000255517.5 CTD-3074O7.5 -6.77 3.85e-11 2.4e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66506601 chr11:66473490~66480233:- LUSC cis rs875971 0.965 rs6971509 ENSG00000237310.1 GS1-124K5.4 -6.77 3.85e-11 2.4e-08 -0.31 -0.3 Aortic root size; chr7:66249983 chr7:66493706~66495474:+ LUSC cis rs2903698 0.585 rs7657576 ENSG00000250735.4 RP11-567N4.3 6.77 3.85e-11 2.41e-08 0.33 0.3 Prion diseases; chr4:75504175 chr4:75401195~75423023:+ LUSC cis rs11157436 0.958 rs6572313 ENSG00000211813.2 TRAV34 6.77 3.86e-11 2.41e-08 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22214070 chr14:22207522~22208129:+ LUSC cis rs3750965 0.959 rs4930264 ENSG00000260895.1 RP11-554A11.7 6.77 3.86e-11 2.41e-08 0.35 0.3 Hair color; chr11:69084713 chr11:69103493~69109094:+ LUSC cis rs7246657 0.941 rs10418729 ENSG00000276846.1 CTD-3220F14.3 6.77 3.86e-11 2.41e-08 0.46 0.3 Coronary artery calcification; chr19:37246163 chr19:37314868~37315620:- LUSC cis rs17608059 0.679 rs9898056 ENSG00000141028.6 CDRT15P1 -6.77 3.87e-11 2.42e-08 -0.33 -0.3 Temperament; chr17:14048649 chr17:14024514~14025488:+ LUSC cis rs227275 0.555 rs223402 ENSG00000230069.3 LRRC37A15P -6.77 3.88e-11 2.42e-08 -0.32 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:102817198 chr4:102727274~102730721:- LUSC cis rs4713118 0.662 rs156744 ENSG00000204709.4 LINC01556 6.77 3.88e-11 2.42e-08 0.41 0.3 Parkinson's disease; chr6:27999496 chr6:28943877~28944537:+ LUSC cis rs9903692 0.954 rs875065 ENSG00000278765.1 RP5-890E16.5 6.77 3.89e-11 2.43e-08 0.36 0.3 Pulse pressure; chr17:48062207 chr17:48066704~48067293:- LUSC cis rs9813712 0.597 rs1453255 ENSG00000228252.7 COL6A4P2 -6.77 3.9e-11 2.43e-08 -0.27 -0.3 Response to amphetamines; chr3:130258815 chr3:130212823~130273806:+ LUSC cis rs11690935 0.959 rs7608403 ENSG00000228389.1 AC068039.4 6.77 3.9e-11 2.43e-08 0.35 0.3 Schizophrenia; chr2:171790255 chr2:171773482~171775844:+ LUSC cis rs9326248 0.52 rs74830 ENSG00000280143.1 AP000892.6 -6.77 3.9e-11 2.44e-08 -0.31 -0.3 Blood protein levels; chr11:117219842 chr11:117204967~117210292:+ LUSC cis rs4713118 0.869 rs9461405 ENSG00000219392.1 RP1-265C24.5 -6.77 3.91e-11 2.44e-08 -0.38 -0.3 Parkinson's disease; chr6:27751596 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs9357066 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28162053 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9368556 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28163375 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9368557 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28163759 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9380059 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28164580 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9380060 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28164825 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs35227624 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28164948 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9380061 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28165025 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9368558 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28165528 chr6:28943877~28944537:+ LUSC cis rs4713118 0.587 rs9393899 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Parkinson's disease; chr6:28165750 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs4713150 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28168434 chr6:28943877~28944537:+ LUSC cis rs4713118 0.527 rs4713151 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Parkinson's disease; chr6:28168578 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393901 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28169019 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs3173443 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28169249 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs4713152 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28169676 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9348797 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28169755 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9380062 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28169791 chr6:28943877~28944537:+ LUSC cis rs853679 0.542 rs9380063 ENSG00000204709.4 LINC01556 6.77 3.91e-11 2.44e-08 0.42 0.3 Depression; chr6:28170075 chr6:28943877~28944537:+ LUSC cis rs2337406 1 rs17112416 ENSG00000274576.2 IGHV2-70 6.77 3.94e-11 2.46e-08 0.31 0.3 Alzheimer's disease (late onset); chr14:106686773 chr14:106770577~106771020:- LUSC cis rs17608059 0.71 rs8080167 ENSG00000141028.6 CDRT15P1 -6.77 3.94e-11 2.46e-08 -0.33 -0.3 Temperament; chr17:14046511 chr17:14024514~14025488:+ LUSC cis rs12554020 0.892 rs16909273 ENSG00000227603.1 RP11-165J3.6 6.77 3.95e-11 2.46e-08 0.47 0.3 Schizophrenia; chr9:93532820 chr9:93435332~93437121:- LUSC cis rs710216 0.536 rs710222 ENSG00000227533.4 SLC2A1-AS1 6.77 3.95e-11 2.46e-08 0.32 0.3 Red cell distribution width; chr1:42947982 chr1:42959049~42983358:+ LUSC cis rs1865760 0.534 rs72834629 ENSG00000272462.2 U91328.19 -6.77 3.96e-11 2.47e-08 -0.35 -0.3 Height; chr6:26022804 chr6:25992662~26001775:+ LUSC cis rs853679 0.607 rs13204012 ENSG00000204709.4 LINC01556 6.77 3.96e-11 2.47e-08 0.66 0.3 Depression; chr6:28233753 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs13205211 ENSG00000204709.4 LINC01556 6.77 3.96e-11 2.47e-08 0.66 0.3 Depression; chr6:28235278 chr6:28943877~28944537:+ LUSC cis rs11976180 1 rs2951360 ENSG00000170356.8 OR2A20P -6.77 3.96e-11 2.47e-08 -0.4 -0.3 Obesity-related traits; chr7:144060256 chr7:144250045~144252957:- LUSC cis rs71335811 1 rs71335811 ENSG00000232871.7 SEC1P -6.77 3.97e-11 2.47e-08 -0.38 -0.3 Myeloid white cell count; chr19:48626814 chr19:48638071~48682245:+ LUSC cis rs875971 0.964 rs6978429 ENSG00000237310.1 GS1-124K5.4 6.77 3.97e-11 2.47e-08 0.31 0.3 Aortic root size; chr7:66494889 chr7:66493706~66495474:+ LUSC cis rs875971 0.929 rs12535036 ENSG00000237310.1 GS1-124K5.4 6.77 3.97e-11 2.47e-08 0.31 0.3 Aortic root size; chr7:66499076 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs12533997 ENSG00000237310.1 GS1-124K5.4 6.77 3.97e-11 2.47e-08 0.31 0.3 Aortic root size; chr7:66500390 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs12532998 ENSG00000237310.1 GS1-124K5.4 6.77 3.97e-11 2.47e-08 0.31 0.3 Aortic root size; chr7:66502472 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs6970030 ENSG00000237310.1 GS1-124K5.4 6.77 3.97e-11 2.47e-08 0.31 0.3 Aortic root size; chr7:66503692 chr7:66493706~66495474:+ LUSC cis rs875971 0.928 rs6970357 ENSG00000237310.1 GS1-124K5.4 6.77 3.97e-11 2.47e-08 0.31 0.3 Aortic root size; chr7:66503891 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs3735148 ENSG00000237310.1 GS1-124K5.4 6.77 3.97e-11 2.47e-08 0.31 0.3 Aortic root size; chr7:66506022 chr7:66493706~66495474:+ LUSC cis rs17711722 1 rs17711722 ENSG00000164669.11 INTS4P1 6.77 3.97e-11 2.47e-08 0.33 0.3 Calcium levels; chr7:65806210 chr7:65141225~65234216:+ LUSC cis rs748404 0.697 rs546170 ENSG00000249839.1 AC011330.5 -6.76 3.98e-11 2.48e-08 -0.4 -0.3 Lung cancer; chr15:43272651 chr15:43663654~43684339:- LUSC cis rs673078 0.607 rs61943370 ENSG00000275759.1 RP11-131L12.3 -6.76 3.99e-11 2.49e-08 -0.41 -0.3 Glucose homeostasis traits; chr12:118369469 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs61943371 ENSG00000275759.1 RP11-131L12.3 -6.76 3.99e-11 2.49e-08 -0.41 -0.3 Glucose homeostasis traits; chr12:118369600 chr12:118428281~118428870:+ LUSC cis rs1823913 0.895 rs10931491 ENSG00000280083.1 RP11-317J9.1 6.76 3.99e-11 2.49e-08 0.36 0.3 Obesity-related traits; chr2:191256087 chr2:191154118~191156070:- LUSC cis rs113835537 0.529 rs11227502 ENSG00000255517.5 CTD-3074O7.5 -6.76 3.99e-11 2.49e-08 -0.35 -0.3 Airway imaging phenotypes; chr11:66506677 chr11:66473490~66480233:- LUSC cis rs3750965 1 rs731974 ENSG00000260895.1 RP11-554A11.7 6.76 3.99e-11 2.49e-08 0.35 0.3 Hair color; chr11:69079688 chr11:69103493~69109094:+ LUSC cis rs875971 1 rs2220626 ENSG00000237310.1 GS1-124K5.4 -6.76 4e-11 2.49e-08 -0.31 -0.3 Aortic root size; chr7:66081075 chr7:66493706~66495474:+ LUSC cis rs4423214 0.592 rs78300366 ENSG00000254682.1 RP11-660L16.2 -6.76 4e-11 2.49e-08 -0.49 -0.3 Vitamin D levels; chr11:71494468 chr11:71448674~71452157:+ LUSC cis rs10800713 0.862 rs7533417 ENSG00000260088.1 RP11-92G12.3 -6.76 4.01e-11 2.5e-08 -0.42 -0.3 Tandem gait; chr1:200558177 chr1:200669507~200694250:+ LUSC cis rs867371 1 rs8041924 ENSG00000255769.6 GOLGA2P10 -6.76 4.01e-11 2.5e-08 -0.37 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82181320 chr15:82472993~82513950:- LUSC cis rs11098499 0.535 rs7671759 ENSG00000249244.1 RP11-548H18.2 6.76 4.01e-11 2.5e-08 0.38 0.3 Corneal astigmatism; chr4:119326939 chr4:119391831~119395335:- LUSC cis rs2404602 0.647 rs907593 ENSG00000259422.1 RP11-593F23.1 -6.76 4.01e-11 2.5e-08 -0.37 -0.3 Blood metabolite levels; chr15:76904612 chr15:76174891~76181486:- LUSC cis rs1075265 0.73 rs7597188 ENSG00000233266.1 HMGB1P31 6.76 4.02e-11 2.5e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54014732 chr2:54051334~54051760:+ LUSC cis rs11098499 0.913 rs10010696 ENSG00000250412.1 KLHL2P1 6.76 4.02e-11 2.5e-08 0.38 0.3 Corneal astigmatism; chr4:119243148 chr4:119334329~119378233:+ LUSC cis rs10740039 0.883 rs10761538 ENSG00000254271.1 RP11-131N11.4 6.76 4.03e-11 2.51e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60649463 chr10:60734342~60741828:+ LUSC cis rs992157 0.764 rs10932774 ENSG00000261338.2 RP11-378A13.1 6.76 4.04e-11 2.51e-08 0.31 0.3 Colorectal cancer; chr2:218326846 chr2:218255319~218257366:+ LUSC cis rs17711722 0.675 rs6947132 ENSG00000164669.11 INTS4P1 6.76 4.04e-11 2.51e-08 0.33 0.3 Calcium levels; chr7:65808508 chr7:65141225~65234216:+ LUSC cis rs10129255 0.913 rs10140943 ENSG00000224373.3 IGHV4-59 6.76 4.04e-11 2.51e-08 0.17 0.3 Kawasaki disease; chr14:106767441 chr14:106627249~106627825:- LUSC cis rs8072100 0.875 rs9635762 ENSG00000228782.6 CTD-2026D20.3 -6.76 4.04e-11 2.52e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47571080 chr17:47450568~47492492:- LUSC cis rs8072100 0.967 rs4793842 ENSG00000228782.6 CTD-2026D20.3 -6.76 4.05e-11 2.52e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47594140 chr17:47450568~47492492:- LUSC cis rs8072100 0.967 rs8075411 ENSG00000228782.6 CTD-2026D20.3 -6.76 4.05e-11 2.52e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47599394 chr17:47450568~47492492:- LUSC cis rs4604732 0.631 rs12038793 ENSG00000227135.1 GCSAML-AS1 6.76 4.07e-11 2.53e-08 0.45 0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247460960 chr1:247524679~247526752:- LUSC cis rs2980439 0.818 rs2948294 ENSG00000173295.6 FAM86B3P 6.76 4.09e-11 2.54e-08 0.34 0.3 Neuroticism; chr8:8237439 chr8:8228595~8244865:+ LUSC cis rs1075265 0.783 rs805359 ENSG00000233266.1 HMGB1P31 6.76 4.09e-11 2.54e-08 0.36 0.3 Chronotype;Morning vs. evening chronotype; chr2:53935317 chr2:54051334~54051760:+ LUSC cis rs11089937 0.651 rs928894 ENSG00000211639.2 IGLV4-60 6.76 4.1e-11 2.55e-08 0.31 0.3 Periodontitis (PAL4Q3); chr22:22185882 chr22:22162199~22162681:+ LUSC cis rs8059260 0.736 rs16957872 ENSG00000274038.1 RP11-66H6.4 -6.76 4.11e-11 2.55e-08 -0.5 -0.3 Alcohol consumption over the past year; chr16:10988835 chr16:11056556~11057034:+ LUSC cis rs2179367 0.959 rs544947 ENSG00000231760.4 RP11-350J20.5 6.76 4.12e-11 2.56e-08 0.39 0.3 Dupuytren's disease; chr6:149402412 chr6:149796151~149826294:- LUSC cis rs9928842 1 rs7202566 ENSG00000280152.1 RP11-331F4.5 6.76 4.13e-11 2.57e-08 0.37 0.3 Alcoholic chronic pancreatitis; chr16:75213746 chr16:75245994~75250077:- LUSC cis rs8040855 0.579 rs4843029 ENSG00000259295.5 CSPG4P12 -6.76 4.13e-11 2.57e-08 -0.33 -0.3 Bulimia nervosa; chr15:85182164 chr15:85191438~85213905:+ LUSC cis rs10262624 0.967 rs10229233 ENSG00000234286.1 AC006026.13 -6.76 4.13e-11 2.57e-08 -0.34 -0.3 Schizophrenia; chr7:23867900 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs10245161 ENSG00000234286.1 AC006026.13 -6.76 4.13e-11 2.57e-08 -0.34 -0.3 Schizophrenia; chr7:23868073 chr7:23680195~23680786:- LUSC cis rs11690935 0.959 rs7355594 ENSG00000228389.1 AC068039.4 6.76 4.13e-11 2.57e-08 0.35 0.3 Schizophrenia; chr2:171782938 chr2:171773482~171775844:+ LUSC cis rs5769707 0.521 rs739244 ENSG00000235111.1 RP1-29C18.8 -6.76 4.15e-11 2.58e-08 -0.37 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49666510 chr22:49612657~49615716:- LUSC cis rs9921338 0.923 rs17233387 ENSG00000263080.1 RP11-485G7.5 6.76 4.15e-11 2.58e-08 0.31 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11295191 chr16:11341809~11345211:- LUSC cis rs875971 0.929 rs4122249 ENSG00000237310.1 GS1-124K5.4 6.76 4.16e-11 2.58e-08 0.31 0.3 Aortic root size; chr7:66455949 chr7:66493706~66495474:+ LUSC cis rs10740039 0.883 rs7920170 ENSG00000254271.1 RP11-131N11.4 6.76 4.16e-11 2.59e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60647766 chr10:60734342~60741828:+ LUSC cis rs6142102 0.924 rs6059662 ENSG00000276073.1 RP5-1125A11.7 6.76 4.17e-11 2.59e-08 0.33 0.3 Skin pigmentation; chr20:34087921 chr20:33985617~33988989:- LUSC cis rs227275 0.525 rs13117110 ENSG00000230069.3 LRRC37A15P -6.76 4.18e-11 2.6e-08 -0.32 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:103003981 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs13144033 ENSG00000230069.3 LRRC37A15P -6.76 4.18e-11 2.6e-08 -0.32 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:103004032 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs10029073 ENSG00000230069.3 LRRC37A15P -6.76 4.18e-11 2.6e-08 -0.32 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:103006991 chr4:102727274~102730721:- LUSC cis rs8059260 0.668 rs7198089 ENSG00000274038.1 RP11-66H6.4 -6.76 4.19e-11 2.6e-08 -0.51 -0.3 Alcohol consumption over the past year; chr16:11027199 chr16:11056556~11057034:+ LUSC cis rs10129255 0.5 rs11628999 ENSG00000224373.3 IGHV4-59 6.76 4.2e-11 2.6e-08 0.15 0.3 Kawasaki disease; chr14:106800208 chr14:106627249~106627825:- LUSC cis rs8040855 0.599 rs6496792 ENSG00000259295.5 CSPG4P12 -6.76 4.2e-11 2.6e-08 -0.33 -0.3 Bulimia nervosa; chr15:85182514 chr15:85191438~85213905:+ LUSC cis rs8040855 0.599 rs6496793 ENSG00000259295.5 CSPG4P12 -6.76 4.2e-11 2.6e-08 -0.33 -0.3 Bulimia nervosa; chr15:85182515 chr15:85191438~85213905:+ LUSC cis rs8040855 0.599 rs6496795 ENSG00000259295.5 CSPG4P12 -6.76 4.2e-11 2.6e-08 -0.33 -0.3 Bulimia nervosa; chr15:85182622 chr15:85191438~85213905:+ LUSC cis rs10129255 0.912 rs6576227 ENSG00000280411.1 IGHV1-69-2 -6.76 4.2e-11 2.61e-08 -0.21 -0.3 Kawasaki disease; chr14:106778202 chr14:106762092~106762588:- LUSC cis rs10129255 0.957 rs6576228 ENSG00000280411.1 IGHV1-69-2 -6.76 4.2e-11 2.61e-08 -0.21 -0.3 Kawasaki disease; chr14:106778401 chr14:106762092~106762588:- LUSC cis rs992157 0.71 rs12612347 ENSG00000261338.2 RP11-378A13.1 -6.76 4.2e-11 2.61e-08 -0.3 -0.3 Colorectal cancer; chr2:218192615 chr2:218255319~218257366:+ LUSC cis rs853679 0.55 rs1225599 ENSG00000204709.4 LINC01556 6.76 4.22e-11 2.61e-08 0.41 0.3 Depression; chr6:28197412 chr6:28943877~28944537:+ LUSC cis rs853679 0.574 rs1233705 ENSG00000204709.4 LINC01556 6.76 4.22e-11 2.61e-08 0.41 0.3 Depression; chr6:28198669 chr6:28943877~28944537:+ LUSC cis rs9309473 0.95 rs10189885 ENSG00000163016.8 ALMS1P 6.76 4.23e-11 2.62e-08 0.36 0.3 Metabolite levels; chr2:73649928 chr2:73644919~73685576:+ LUSC cis rs2404602 0.735 rs2461871 ENSG00000259422.1 RP11-593F23.1 -6.76 4.23e-11 2.62e-08 -0.35 -0.3 Blood metabolite levels; chr15:76530077 chr15:76174891~76181486:- LUSC cis rs113835537 0.529 rs57634456 ENSG00000255517.5 CTD-3074O7.5 -6.76 4.23e-11 2.62e-08 -0.34 -0.3 Airway imaging phenotypes; chr11:66483367 chr11:66473490~66480233:- LUSC cis rs8177876 0.57 rs11863158 ENSG00000261838.4 RP11-303E16.6 6.75 4.23e-11 2.63e-08 0.65 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81034525 chr16:81069854~81076598:+ LUSC cis rs853679 0.517 rs12332979 ENSG00000204709.4 LINC01556 6.75 4.24e-11 2.63e-08 0.42 0.3 Depression; chr6:28173770 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs67878650 ENSG00000204709.4 LINC01556 6.75 4.24e-11 2.63e-08 0.42 0.3 Depression; chr6:28174809 chr6:28943877~28944537:+ LUSC cis rs853679 0.569 rs9348798 ENSG00000204709.4 LINC01556 6.75 4.24e-11 2.63e-08 0.42 0.3 Depression; chr6:28175233 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9380065 ENSG00000204709.4 LINC01556 6.75 4.24e-11 2.63e-08 0.42 0.3 Depression; chr6:28176973 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9295761 ENSG00000204709.4 LINC01556 6.75 4.24e-11 2.63e-08 0.42 0.3 Depression; chr6:28180209 chr6:28943877~28944537:+ LUSC cis rs7246657 0.943 rs7258692 ENSG00000276846.1 CTD-3220F14.3 6.75 4.25e-11 2.63e-08 0.46 0.3 Coronary artery calcification; chr19:37327927 chr19:37314868~37315620:- LUSC cis rs7955901 0.691 rs11178601 ENSG00000257265.1 CTD-2021H9.1 6.75 4.25e-11 2.63e-08 0.33 0.3 Type 2 diabetes; chr12:71097575 chr12:71007773~71032083:- LUSC cis rs881375 0.933 rs4837804 ENSG00000226752.6 PSMD5-AS1 -6.75 4.25e-11 2.64e-08 -0.34 -0.3 Rheumatoid arthritis; chr9:120943026 chr9:120824828~120854385:+ LUSC cis rs881375 0.967 rs7039505 ENSG00000226752.6 PSMD5-AS1 -6.75 4.25e-11 2.64e-08 -0.34 -0.3 Rheumatoid arthritis; chr9:120943667 chr9:120824828~120854385:+ LUSC cis rs673078 0.607 rs11068926 ENSG00000275759.1 RP11-131L12.3 -6.75 4.26e-11 2.64e-08 -0.41 -0.3 Glucose homeostasis traits; chr12:118367320 chr12:118428281~118428870:+ LUSC cis rs7955901 0.658 rs12816762 ENSG00000257265.1 CTD-2021H9.1 6.75 4.26e-11 2.64e-08 0.33 0.3 Type 2 diabetes; chr12:71097837 chr12:71007773~71032083:- LUSC cis rs7955901 0.572 rs34952247 ENSG00000257265.1 CTD-2021H9.1 6.75 4.26e-11 2.64e-08 0.33 0.3 Type 2 diabetes; chr12:71098065 chr12:71007773~71032083:- LUSC cis rs1075232 1 rs9672214 ENSG00000215302.7 CTD-3092A11.1 -6.75 4.26e-11 2.64e-08 -0.7 -0.3 Survival in colorectal cancer (non-distant metastatic); chr15:31385572 chr15:30470779~30507623:+ LUSC cis rs4713118 0.662 rs9380046 ENSG00000204709.4 LINC01556 6.75 4.26e-11 2.64e-08 0.42 0.3 Parkinson's disease; chr6:28062721 chr6:28943877~28944537:+ LUSC cis rs9318086 0.712 rs9318100 ENSG00000205861.10 C1QTNF9B-AS1 6.75 4.27e-11 2.65e-08 0.37 0.3 Myopia (pathological); chr13:23868343 chr13:23888889~23897263:+ LUSC cis rs10129255 0.957 rs8022165 ENSG00000280411.1 IGHV1-69-2 -6.75 4.28e-11 2.65e-08 -0.2 -0.3 Kawasaki disease; chr14:106781682 chr14:106762092~106762588:- LUSC cis rs607541 0.85 rs2218309 ENSG00000259520.4 CTD-2651B20.3 -6.75 4.28e-11 2.65e-08 -0.59 -0.3 Obesity-related traits; chr15:45646463 chr15:45251580~45279251:- LUSC cis rs875971 0.54 rs35510581 ENSG00000236529.1 RP13-254B10.1 -6.75 4.29e-11 2.66e-08 -0.31 -0.3 Aortic root size; chr7:66113790 chr7:65840212~65840596:+ LUSC cis rs5753618 0.583 rs5753639 ENSG00000236132.1 CTA-440B3.1 6.75 4.29e-11 2.66e-08 0.39 0.3 Colorectal cancer; chr22:31474414 chr22:31816379~31817491:- LUSC cis rs13113518 0.812 rs6830409 ENSG00000223305.1 RN7SKP30 6.75 4.3e-11 2.67e-08 0.37 0.3 Height; chr4:55522229 chr4:55540502~55540835:- LUSC cis rs9322193 0.923 rs9766037 ENSG00000268592.3 RAET1E-AS1 6.75 4.3e-11 2.67e-08 0.37 0.3 Lung cancer; chr6:149616921 chr6:149863494~149919507:+ LUSC cis rs75422866 0.867 rs73104115 ENSG00000274902.1 RP1-197B17.4 6.75 4.31e-11 2.67e-08 0.77 0.3 Pneumonia; chr12:47684843 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73104116 ENSG00000274902.1 RP1-197B17.4 6.75 4.31e-11 2.67e-08 0.77 0.3 Pneumonia; chr12:47685023 chr12:47731908~47732351:+ LUSC cis rs867371 0.502 rs3759800 ENSG00000276710.3 CSPG4P8 6.75 4.31e-11 2.67e-08 0.3 0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82240622 chr15:82459472~82477258:+ LUSC cis rs11098499 0.913 rs68128210 ENSG00000250412.1 KLHL2P1 6.75 4.32e-11 2.67e-08 0.37 0.3 Corneal astigmatism; chr4:119216664 chr4:119334329~119378233:+ LUSC cis rs496547 0.756 rs562059 ENSG00000255239.1 AP002954.6 6.75 4.32e-11 2.67e-08 0.34 0.3 Hip minimal joint space width; chr11:118731349 chr11:118688039~118690600:- LUSC cis rs11098499 0.866 rs6847778 ENSG00000249244.1 RP11-548H18.2 6.75 4.33e-11 2.68e-08 0.38 0.3 Corneal astigmatism; chr4:119372427 chr4:119391831~119395335:- LUSC cis rs11098499 1 rs28374891 ENSG00000250412.1 KLHL2P1 6.75 4.33e-11 2.68e-08 0.37 0.3 Corneal astigmatism; chr4:119262395 chr4:119334329~119378233:+ LUSC cis rs8072100 0.967 rs7219303 ENSG00000228782.6 CTD-2026D20.3 -6.75 4.33e-11 2.68e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47660335 chr17:47450568~47492492:- LUSC cis rs875971 0.929 rs34406470 ENSG00000237310.1 GS1-124K5.4 6.75 4.33e-11 2.68e-08 0.31 0.3 Aortic root size; chr7:66464969 chr7:66493706~66495474:+ LUSC cis rs11098499 0.754 rs1980027 ENSG00000249244.1 RP11-548H18.2 6.75 4.34e-11 2.69e-08 0.37 0.3 Corneal astigmatism; chr4:119330422 chr4:119391831~119395335:- LUSC cis rs9326248 0.769 rs499910 ENSG00000280143.1 AP000892.6 6.75 4.35e-11 2.69e-08 0.35 0.3 Blood protein levels; chr11:116892318 chr11:117204967~117210292:+ LUSC cis rs950169 0.922 rs11633534 ENSG00000259728.4 LINC00933 6.75 4.35e-11 2.69e-08 0.39 0.3 Schizophrenia; chr15:84581411 chr15:84570649~84580175:+ LUSC cis rs950169 0.65 rs12902052 ENSG00000259728.4 LINC00933 6.75 4.35e-11 2.69e-08 0.39 0.3 Schizophrenia; chr15:84582607 chr15:84570649~84580175:+ LUSC cis rs4713118 0.824 rs2179095 ENSG00000219392.1 RP1-265C24.5 6.75 4.35e-11 2.69e-08 0.38 0.3 Parkinson's disease; chr6:27783079 chr6:28115628~28116551:+ LUSC cis rs6570726 0.599 rs4398765 ENSG00000235652.6 RP11-545I5.3 6.75 4.36e-11 2.7e-08 0.32 0.3 Lobe attachment (rater-scored or self-reported); chr6:145613870 chr6:145799409~145886585:+ LUSC cis rs748404 0.666 rs12913977 ENSG00000249839.1 AC011330.5 -6.75 4.36e-11 2.7e-08 -0.5 -0.3 Lung cancer; chr15:43438913 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs12914122 ENSG00000249839.1 AC011330.5 -6.75 4.36e-11 2.7e-08 -0.5 -0.3 Lung cancer; chr15:43438956 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs34697113 ENSG00000249839.1 AC011330.5 -6.75 4.36e-11 2.7e-08 -0.5 -0.3 Lung cancer; chr15:43442041 chr15:43663654~43684339:- LUSC cis rs11157436 1 rs2293731 ENSG00000211813.2 TRAV34 6.75 4.36e-11 2.7e-08 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22148880 chr14:22207522~22208129:+ LUSC cis rs10129255 0.957 rs12590667 ENSG00000224373.3 IGHV4-59 -6.75 4.37e-11 2.7e-08 -0.16 -0.3 Kawasaki disease; chr14:106779223 chr14:106627249~106627825:- LUSC cis rs12931792 0.748 rs11150585 ENSG00000183604.13 SMG1P5 6.75 4.37e-11 2.7e-08 0.33 0.3 Tonsillectomy; chr16:30172965 chr16:30267553~30335374:- LUSC cis rs228614 0.536 rs223477 ENSG00000230069.3 LRRC37A15P -6.75 4.38e-11 2.71e-08 -0.32 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769099 chr4:102727274~102730721:- LUSC cis rs17507216 0.718 rs7165690 ENSG00000255769.6 GOLGA2P10 -6.75 4.38e-11 2.71e-08 -0.45 -0.3 Excessive daytime sleepiness; chr15:82654804 chr15:82472993~82513950:- LUSC cis rs2455601 0.608 rs1368017 ENSG00000254860.4 TMEM9B-AS1 6.75 4.41e-11 2.72e-08 0.35 0.3 Schizophrenia; chr11:8845523 chr11:8964675~8977527:+ LUSC cis rs7772486 0.692 rs1577916 ENSG00000235652.6 RP11-545I5.3 -6.75 4.41e-11 2.73e-08 -0.29 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145748653 chr6:145799409~145886585:+ LUSC cis rs7772486 0.72 rs7752286 ENSG00000235652.6 RP11-545I5.3 -6.75 4.41e-11 2.73e-08 -0.29 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145751526 chr6:145799409~145886585:+ LUSC cis rs11098499 0.863 rs12508173 ENSG00000250412.1 KLHL2P1 6.75 4.41e-11 2.73e-08 0.38 0.3 Corneal astigmatism; chr4:119397371 chr4:119334329~119378233:+ LUSC cis rs11098499 0.908 rs12504149 ENSG00000250412.1 KLHL2P1 6.75 4.41e-11 2.73e-08 0.38 0.3 Corneal astigmatism; chr4:119397422 chr4:119334329~119378233:+ LUSC cis rs2919917 1 rs1466526 ENSG00000254352.1 RP11-578O24.2 -6.75 4.43e-11 2.74e-08 -0.37 -0.3 Lymphocyte counts; chr8:78643239 chr8:78723796~78724136:- LUSC cis rs1075265 0.704 rs9631059 ENSG00000233266.1 HMGB1P31 6.75 4.44e-11 2.75e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54015160 chr2:54051334~54051760:+ LUSC cis rs1075265 0.73 rs6711105 ENSG00000233266.1 HMGB1P31 6.75 4.44e-11 2.75e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54017775 chr2:54051334~54051760:+ LUSC cis rs1075265 0.704 rs6711217 ENSG00000233266.1 HMGB1P31 6.75 4.44e-11 2.75e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54017892 chr2:54051334~54051760:+ LUSC cis rs1075265 0.704 rs10084374 ENSG00000233266.1 HMGB1P31 6.75 4.44e-11 2.75e-08 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54022175 chr2:54051334~54051760:+ LUSC cis rs9309473 1 rs7594511 ENSG00000163016.8 ALMS1P 6.75 4.45e-11 2.75e-08 0.35 0.3 Metabolite levels; chr2:73454512 chr2:73644919~73685576:+ LUSC cis rs875971 0.895 rs3857684 ENSG00000237310.1 GS1-124K5.4 6.75 4.45e-11 2.75e-08 0.31 0.3 Aortic root size; chr7:66473171 chr7:66493706~66495474:+ LUSC cis rs10800713 0.954 rs10800712 ENSG00000260088.1 RP11-92G12.3 -6.75 4.45e-11 2.75e-08 -0.41 -0.3 Tandem gait; chr1:200576059 chr1:200669507~200694250:+ LUSC cis rs10800713 0.908 rs10919978 ENSG00000260088.1 RP11-92G12.3 -6.75 4.45e-11 2.75e-08 -0.41 -0.3 Tandem gait; chr1:200576923 chr1:200669507~200694250:+ LUSC cis rs10800713 0.954 rs4353125 ENSG00000260088.1 RP11-92G12.3 -6.75 4.45e-11 2.75e-08 -0.41 -0.3 Tandem gait; chr1:200582178 chr1:200669507~200694250:+ LUSC cis rs4950322 0.542 rs4950382 ENSG00000278811.3 LINC00624 6.75 4.46e-11 2.75e-08 0.32 0.3 Protein quantitative trait loci; chr1:147176645 chr1:147258885~147517875:- LUSC cis rs9309473 0.904 rs79145598 ENSG00000163016.8 ALMS1P 6.75 4.46e-11 2.76e-08 0.35 0.3 Metabolite levels; chr2:73594255 chr2:73644919~73685576:+ LUSC cis rs9309473 0.904 rs62149783 ENSG00000163016.8 ALMS1P 6.75 4.46e-11 2.76e-08 0.35 0.3 Metabolite levels; chr2:73594257 chr2:73644919~73685576:+ LUSC cis rs1865760 0.516 rs9358903 ENSG00000272462.2 U91328.19 -6.75 4.47e-11 2.76e-08 -0.32 -0.3 Height; chr6:26061721 chr6:25992662~26001775:+ LUSC cis rs1865760 0.516 rs9393683 ENSG00000272462.2 U91328.19 -6.75 4.47e-11 2.76e-08 -0.32 -0.3 Height; chr6:26065970 chr6:25992662~26001775:+ LUSC cis rs6142102 0.961 rs6057957 ENSG00000276073.1 RP5-1125A11.7 -6.75 4.48e-11 2.77e-08 -0.31 -0.3 Skin pigmentation; chr20:33962052 chr20:33985617~33988989:- LUSC cis rs9309473 1 rs6736866 ENSG00000163016.8 ALMS1P 6.75 4.49e-11 2.77e-08 0.36 0.3 Metabolite levels; chr2:73434858 chr2:73644919~73685576:+ LUSC cis rs881375 1 rs10760121 ENSG00000226752.6 PSMD5-AS1 -6.75 4.49e-11 2.77e-08 -0.34 -0.3 Rheumatoid arthritis; chr9:120885637 chr9:120824828~120854385:+ LUSC cis rs853679 0.517 rs9468298 ENSG00000204709.4 LINC01556 6.75 4.51e-11 2.78e-08 0.42 0.3 Depression; chr6:28154567 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9295759 ENSG00000204709.4 LINC01556 6.75 4.51e-11 2.78e-08 0.42 0.3 Depression; chr6:28156691 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9348796 ENSG00000204709.4 LINC01556 6.75 4.51e-11 2.78e-08 0.42 0.3 Depression; chr6:28158424 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs11552219 ENSG00000204709.4 LINC01556 6.75 4.51e-11 2.78e-08 0.42 0.3 Depression; chr6:28159056 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393895 ENSG00000204709.4 LINC01556 6.75 4.51e-11 2.78e-08 0.42 0.3 Depression; chr6:28159843 chr6:28943877~28944537:+ LUSC cis rs9921338 0.961 rs56136462 ENSG00000263080.1 RP11-485G7.5 6.74 4.51e-11 2.79e-08 0.35 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11321738 chr16:11341809~11345211:- LUSC cis rs853679 0.517 rs9348794 ENSG00000204709.4 LINC01556 6.74 4.53e-11 2.79e-08 0.43 0.3 Depression; chr6:28149979 chr6:28943877~28944537:+ LUSC cis rs5742933 0.817 rs1055091 ENSG00000253559.1 OSGEPL1-AS1 6.74 4.53e-11 2.79e-08 0.36 0.3 Ferritin levels; chr2:189770417 chr2:189762704~189765556:+ LUSC cis rs5742933 0.817 rs6942 ENSG00000253559.1 OSGEPL1-AS1 6.74 4.53e-11 2.79e-08 0.36 0.3 Ferritin levels; chr2:189771685 chr2:189762704~189765556:+ LUSC cis rs7772486 0.754 rs864148 ENSG00000235652.6 RP11-545I5.3 -6.74 4.53e-11 2.8e-08 -0.29 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145655539 chr6:145799409~145886585:+ LUSC cis rs1823913 1 rs1840377 ENSG00000280083.1 RP11-317J9.1 6.74 4.53e-11 2.8e-08 0.36 0.3 Obesity-related traits; chr2:191257992 chr2:191154118~191156070:- LUSC cis rs11098499 0.754 rs17595608 ENSG00000249244.1 RP11-548H18.2 6.74 4.53e-11 2.8e-08 0.37 0.3 Corneal astigmatism; chr4:119329351 chr4:119391831~119395335:- LUSC cis rs875971 0.522 rs1617484 ENSG00000164669.11 INTS4P1 -6.74 4.54e-11 2.8e-08 -0.33 -0.3 Aortic root size; chr7:65998108 chr7:65141225~65234216:+ LUSC cis rs11098499 0.863 rs3736115 ENSG00000250412.1 KLHL2P1 -6.74 4.54e-11 2.8e-08 -0.37 -0.3 Corneal astigmatism; chr4:119567548 chr4:119334329~119378233:+ LUSC cis rs1823913 0.927 rs56209234 ENSG00000280083.1 RP11-317J9.1 -6.74 4.54e-11 2.8e-08 -0.38 -0.3 Obesity-related traits; chr2:191261748 chr2:191154118~191156070:- LUSC cis rs6570726 0.599 rs9376951 ENSG00000235652.6 RP11-545I5.3 6.74 4.54e-11 2.8e-08 0.31 0.3 Lobe attachment (rater-scored or self-reported); chr6:145577775 chr6:145799409~145886585:+ LUSC cis rs113835537 0.597 rs2075792 ENSG00000255517.5 CTD-3074O7.5 -6.74 4.56e-11 2.81e-08 -0.34 -0.3 Airway imaging phenotypes; chr11:66567085 chr11:66473490~66480233:- LUSC cis rs9543976 1 rs73223968 ENSG00000261553.4 RP11-29G8.3 -6.74 4.57e-11 2.82e-08 -0.55 -0.3 Diabetic retinopathy; chr13:75567585 chr13:75549773~75807120:+ LUSC cis rs9543976 1 rs2296146 ENSG00000261553.4 RP11-29G8.3 -6.74 4.57e-11 2.82e-08 -0.55 -0.3 Diabetic retinopathy; chr13:75569436 chr13:75549773~75807120:+ LUSC cis rs875971 0.522 rs2008188 ENSG00000164669.11 INTS4P1 -6.74 4.57e-11 2.82e-08 -0.32 -0.3 Aortic root size; chr7:65964026 chr7:65141225~65234216:+ LUSC cis rs853679 0.517 rs9393898 ENSG00000204709.4 LINC01556 6.74 4.58e-11 2.82e-08 0.42 0.3 Depression; chr6:28162598 chr6:28943877~28944537:+ LUSC cis rs11603023 0.804 rs527619 ENSG00000255239.1 AP002954.6 -6.74 4.59e-11 2.83e-08 -0.36 -0.3 Cholesterol, total; chr11:118692577 chr11:118688039~118690600:- LUSC cis rs10740039 0.883 rs10994446 ENSG00000254271.1 RP11-131N11.4 6.74 4.59e-11 2.83e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60639433 chr10:60734342~60741828:+ LUSC cis rs6565180 0.525 rs1132812 ENSG00000183604.13 SMG1P5 6.74 4.6e-11 2.83e-08 0.33 0.3 Tonsillectomy; chr16:30186830 chr16:30267553~30335374:- LUSC cis rs9322193 0.962 rs7818 ENSG00000268592.3 RAET1E-AS1 6.74 4.61e-11 2.84e-08 0.36 0.3 Lung cancer; chr6:149810956 chr6:149863494~149919507:+ LUSC cis rs10129255 0.5 rs8022547 ENSG00000224373.3 IGHV4-59 6.74 4.61e-11 2.84e-08 0.15 0.3 Kawasaki disease; chr14:106781985 chr14:106627249~106627825:- LUSC cis rs10129255 0.5 rs8006888 ENSG00000224373.3 IGHV4-59 6.74 4.61e-11 2.84e-08 0.15 0.3 Kawasaki disease; chr14:106782219 chr14:106627249~106627825:- LUSC cis rs783540 0.609 rs803686 ENSG00000255769.6 GOLGA2P10 6.74 4.61e-11 2.84e-08 0.4 0.3 Schizophrenia; chr15:82550590 chr15:82472993~82513950:- LUSC cis rs11098499 0.955 rs13113112 ENSG00000250412.1 KLHL2P1 6.74 4.62e-11 2.85e-08 0.37 0.3 Corneal astigmatism; chr4:119234885 chr4:119334329~119378233:+ LUSC cis rs2404602 0.647 rs12904417 ENSG00000259422.1 RP11-593F23.1 6.74 4.62e-11 2.85e-08 0.35 0.3 Blood metabolite levels; chr15:76671811 chr15:76174891~76181486:- LUSC cis rs1012068 1 rs1012068 ENSG00000236132.1 CTA-440B3.1 -6.74 4.63e-11 2.85e-08 -0.4 -0.3 Chronic hepatitis C infection; chr22:31869917 chr22:31816379~31817491:- LUSC cis rs71403859 0.685 rs12444890 ENSG00000260886.1 TAT-AS1 6.74 4.63e-11 2.85e-08 0.48 0.3 Post bronchodilator FEV1; chr16:71602123 chr16:71565789~71578187:+ LUSC cis rs2919917 1 rs7839152 ENSG00000254352.1 RP11-578O24.2 6.74 4.64e-11 2.86e-08 0.37 0.3 Lymphocyte counts; chr8:78677777 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs28429528 ENSG00000254352.1 RP11-578O24.2 6.74 4.64e-11 2.86e-08 0.37 0.3 Lymphocyte counts; chr8:78678782 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs9298316 ENSG00000254352.1 RP11-578O24.2 6.74 4.64e-11 2.86e-08 0.37 0.3 Lymphocyte counts; chr8:78680191 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs7842142 ENSG00000254352.1 RP11-578O24.2 6.74 4.64e-11 2.86e-08 0.37 0.3 Lymphocyte counts; chr8:78681501 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs11785966 ENSG00000254352.1 RP11-578O24.2 6.74 4.64e-11 2.86e-08 0.37 0.3 Lymphocyte counts; chr8:78681851 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs10092335 ENSG00000254352.1 RP11-578O24.2 6.74 4.64e-11 2.86e-08 0.37 0.3 Lymphocyte counts; chr8:78686218 chr8:78723796~78724136:- LUSC cis rs2919917 0.956 rs10112388 ENSG00000254352.1 RP11-578O24.2 6.74 4.64e-11 2.86e-08 0.37 0.3 Lymphocyte counts; chr8:78691512 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs7001074 ENSG00000254352.1 RP11-578O24.2 6.74 4.64e-11 2.86e-08 0.37 0.3 Lymphocyte counts; chr8:78691689 chr8:78723796~78724136:- LUSC cis rs11603023 0.967 rs654423 ENSG00000255239.1 AP002954.6 -6.74 4.64e-11 2.86e-08 -0.35 -0.3 Cholesterol, total; chr11:118641039 chr11:118688039~118690600:- LUSC cis rs11155671 0.53 rs6557133 ENSG00000268592.3 RAET1E-AS1 6.74 4.66e-11 2.87e-08 0.37 0.3 Testicular germ cell tumor; chr6:149874248 chr6:149863494~149919507:+ LUSC cis rs3813579 0.568 rs4506909 ENSG00000261390.4 RP11-345M22.2 -6.74 4.66e-11 2.87e-08 -0.37 -0.3 Thyroid volume; chr16:79719622 chr16:79715232~79770563:- LUSC cis rs7772486 0.738 rs2246334 ENSG00000235652.6 RP11-545I5.3 6.74 4.67e-11 2.87e-08 0.29 0.3 Lobe attachment (rater-scored or self-reported); chr6:145862499 chr6:145799409~145886585:+ LUSC cis rs17711722 0.74 rs7809991 ENSG00000164669.11 INTS4P1 -6.74 4.67e-11 2.88e-08 -0.32 -0.3 Calcium levels; chr7:65941231 chr7:65141225~65234216:+ LUSC cis rs440932 0.798 rs330942 ENSG00000254340.1 RP11-10A14.3 6.74 4.68e-11 2.88e-08 0.36 0.3 High light scatter reticulocyte percentage of red cells; chr8:9162929 chr8:9141424~9145435:+ LUSC cis rs10129255 0.5 rs6576231 ENSG00000224373.3 IGHV4-59 6.74 4.68e-11 2.88e-08 0.15 0.3 Kawasaki disease; chr14:106783693 chr14:106627249~106627825:- LUSC cis rs9322193 0.847 rs4870054 ENSG00000268592.3 RAET1E-AS1 6.74 4.68e-11 2.88e-08 0.39 0.3 Lung cancer; chr6:149848402 chr6:149863494~149919507:+ LUSC cis rs853679 0.55 rs1150689 ENSG00000204709.4 LINC01556 6.74 4.68e-11 2.88e-08 0.41 0.3 Depression; chr6:28197321 chr6:28943877~28944537:+ LUSC cis rs7945705 0.869 rs11042154 ENSG00000254860.4 TMEM9B-AS1 6.74 4.69e-11 2.89e-08 0.34 0.3 Hemoglobin concentration; chr11:9008153 chr11:8964675~8977527:+ LUSC cis rs950169 0.922 rs11638445 ENSG00000225151.9 GOLGA2P7 -6.74 4.7e-11 2.89e-08 -0.43 -0.3 Schizophrenia; chr15:84594463 chr15:84199311~84230136:- LUSC cis rs34375054 0.672 rs58416336 ENSG00000279233.1 RP11-158L12.4 6.74 4.7e-11 2.89e-08 0.27 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125121882 chr12:125138245~125141711:+ LUSC cis rs10466239 0.73 rs2243492 ENSG00000230555.2 RP11-517P14.2 6.74 4.7e-11 2.9e-08 0.47 0.3 Telomere length; chr10:43353910 chr10:43420738~43422100:+ LUSC cis rs9309473 1 rs62151652 ENSG00000163016.8 ALMS1P 6.74 4.72e-11 2.9e-08 0.35 0.3 Metabolite levels; chr2:73473004 chr2:73644919~73685576:+ LUSC cis rs8062405 0.754 rs151179 ENSG00000278665.1 RP11-666O2.4 6.74 4.72e-11 2.91e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28475735 chr16:28599241~28601881:- LUSC cis rs11098499 1 rs10029750 ENSG00000250412.1 KLHL2P1 6.74 4.73e-11 2.91e-08 0.37 0.3 Corneal astigmatism; chr4:119251388 chr4:119334329~119378233:+ LUSC cis rs4950322 0.58 rs7515160 ENSG00000278811.3 LINC00624 6.74 4.74e-11 2.91e-08 0.32 0.3 Protein quantitative trait loci; chr1:147120714 chr1:147258885~147517875:- LUSC cis rs6142102 0.812 rs6120440 ENSG00000275784.1 RP5-1125A11.6 6.74 4.74e-11 2.92e-08 0.35 0.3 Skin pigmentation; chr20:33929779 chr20:33989480~33991818:- LUSC cis rs6504950 0.76 rs7214573 ENSG00000275710.1 RP11-257O5.4 6.74 4.75e-11 2.92e-08 0.37 0.3 Breast cancer; chr17:54929293 chr17:54964474~54964679:+ LUSC cis rs11976180 1 rs2961119 ENSG00000170356.8 OR2A20P -6.74 4.75e-11 2.93e-08 -0.4 -0.3 Obesity-related traits; chr7:144058759 chr7:144250045~144252957:- LUSC cis rs11098499 0.955 rs1511019 ENSG00000250412.1 KLHL2P1 6.74 4.76e-11 2.93e-08 0.37 0.3 Corneal astigmatism; chr4:119244852 chr4:119334329~119378233:+ LUSC cis rs11690935 1 rs11678984 ENSG00000228389.1 AC068039.4 -6.74 4.76e-11 2.93e-08 -0.35 -0.3 Schizophrenia; chr2:171679338 chr2:171773482~171775844:+ LUSC cis rs10129255 0.536 rs10142951 ENSG00000224373.3 IGHV4-59 6.74 4.76e-11 2.93e-08 0.15 0.3 Kawasaki disease; chr14:106782337 chr14:106627249~106627825:- LUSC cis rs465969 0.793 rs34288099 ENSG00000255389.1 C6orf3 -6.74 4.77e-11 2.93e-08 -0.45 -0.3 Psoriasis; chr6:111424034 chr6:111599875~111602295:+ LUSC cis rs4950322 0.542 rs1932977 ENSG00000278811.3 LINC00624 6.74 4.77e-11 2.94e-08 0.3 0.3 Protein quantitative trait loci; chr1:147217371 chr1:147258885~147517875:- LUSC cis rs673078 0.607 rs4442583 ENSG00000275759.1 RP11-131L12.3 -6.74 4.77e-11 2.94e-08 -0.41 -0.3 Glucose homeostasis traits; chr12:118367914 chr12:118428281~118428870:+ LUSC cis rs10129255 0.912 rs730099 ENSG00000280411.1 IGHV1-69-2 -6.74 4.78e-11 2.94e-08 -0.21 -0.3 Kawasaki disease; chr14:106711838 chr14:106762092~106762588:- LUSC cis rs5742933 0.75 rs10197331 ENSG00000253559.1 OSGEPL1-AS1 6.74 4.79e-11 2.94e-08 0.36 0.3 Ferritin levels; chr2:189768112 chr2:189762704~189765556:+ LUSC cis rs875971 0.522 rs10807697 ENSG00000164669.11 INTS4P1 -6.74 4.79e-11 2.95e-08 -0.32 -0.3 Aortic root size; chr7:65951183 chr7:65141225~65234216:+ LUSC cis rs2337406 0.925 rs10131226 ENSG00000274576.2 IGHV2-70 -6.74 4.79e-11 2.95e-08 -0.33 -0.3 Alzheimer's disease (late onset); chr14:106665764 chr14:106770577~106771020:- LUSC cis rs10754283 0.967 rs1317864 ENSG00000231613.1 RP5-943J3.1 6.73 4.81e-11 2.95e-08 0.33 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89639889 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs2390763 ENSG00000231613.1 RP5-943J3.1 6.73 4.81e-11 2.95e-08 0.33 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89640129 chr1:89788914~89790492:+ LUSC cis rs801193 1 rs10234018 ENSG00000236529.1 RP13-254B10.1 -6.73 4.81e-11 2.96e-08 -0.31 -0.3 Aortic root size; chr7:66681297 chr7:65840212~65840596:+ LUSC cis rs7772486 0.754 rs1415746 ENSG00000235652.6 RP11-545I5.3 -6.73 4.81e-11 2.96e-08 -0.29 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145755971 chr6:145799409~145886585:+ LUSC cis rs853679 0.607 rs34243448 ENSG00000204709.4 LINC01556 6.73 4.82e-11 2.96e-08 0.66 0.3 Depression; chr6:28225324 chr6:28943877~28944537:+ LUSC cis rs9660180 0.846 rs10907195 ENSG00000231050.1 RP1-140A9.1 -6.73 4.82e-11 2.96e-08 -0.3 -0.3 Body mass index; chr1:1781909 chr1:1891471~1892658:+ LUSC cis rs6921919 0.583 rs6907950 ENSG00000204709.4 LINC01556 6.73 4.83e-11 2.97e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28402469 chr6:28943877~28944537:+ LUSC cis rs228614 0.536 rs223484 ENSG00000230069.3 LRRC37A15P -6.73 4.85e-11 2.98e-08 -0.31 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102764314 chr4:102727274~102730721:- LUSC cis rs17711722 0.523 rs313812 ENSG00000226824.5 RP4-756H11.3 6.73 4.85e-11 2.98e-08 0.35 0.3 Calcium levels; chr7:66040056 chr7:66654538~66669855:+ LUSC cis rs9903692 0.954 rs2051821 ENSG00000278765.1 RP5-890E16.5 6.73 4.85e-11 2.98e-08 0.36 0.3 Pulse pressure; chr17:48066153 chr17:48066704~48067293:- LUSC cis rs8177876 0.658 rs75422577 ENSG00000261838.4 RP11-303E16.6 6.73 4.86e-11 2.98e-08 0.7 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81054561 chr16:81069854~81076598:+ LUSC cis rs6142102 0.886 rs6059583 ENSG00000276073.1 RP5-1125A11.7 -6.73 4.88e-11 3e-08 -0.32 -0.3 Skin pigmentation; chr20:33944308 chr20:33985617~33988989:- LUSC cis rs4713118 0.869 rs6901520 ENSG00000219392.1 RP1-265C24.5 -6.73 4.89e-11 3e-08 -0.38 -0.3 Parkinson's disease; chr6:27746796 chr6:28115628~28116551:+ LUSC cis rs4713118 0.869 rs9295743 ENSG00000219392.1 RP1-265C24.5 -6.73 4.89e-11 3e-08 -0.38 -0.3 Parkinson's disease; chr6:27747323 chr6:28115628~28116551:+ LUSC cis rs10740039 0.883 rs7918897 ENSG00000254271.1 RP11-131N11.4 6.73 4.9e-11 3.01e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60643754 chr10:60734342~60741828:+ LUSC cis rs10740039 0.804 rs7902456 ENSG00000254271.1 RP11-131N11.4 6.73 4.9e-11 3.01e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60643937 chr10:60734342~60741828:+ LUSC cis rs10740039 0.96 rs10761536 ENSG00000254271.1 RP11-131N11.4 6.73 4.9e-11 3.01e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60644657 chr10:60734342~60741828:+ LUSC cis rs10760123 1 rs10760123 ENSG00000226752.6 PSMD5-AS1 -6.73 4.9e-11 3.01e-08 -0.34 -0.3 Allergic disease (asthma, hay fever or eczema); chr9:120888256 chr9:120824828~120854385:+ LUSC cis rs881375 0.967 rs2270231 ENSG00000226752.6 PSMD5-AS1 -6.73 4.9e-11 3.01e-08 -0.34 -0.3 Rheumatoid arthritis; chr9:120888704 chr9:120824828~120854385:+ LUSC cis rs881375 1 rs881375 ENSG00000226752.6 PSMD5-AS1 -6.73 4.9e-11 3.01e-08 -0.34 -0.3 Rheumatoid arthritis; chr9:120890620 chr9:120824828~120854385:+ LUSC cis rs7772486 0.713 rs1986729 ENSG00000235652.6 RP11-545I5.3 6.73 4.91e-11 3.01e-08 0.29 0.3 Lobe attachment (rater-scored or self-reported); chr6:145873695 chr6:145799409~145886585:+ LUSC cis rs8177876 0.749 rs10459871 ENSG00000261838.4 RP11-303E16.6 6.73 4.92e-11 3.02e-08 0.64 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81059462 chr16:81069854~81076598:+ LUSC cis rs36405 0.5 rs2013781 ENSG00000266869.1 RP6-114E22.1 -6.73 4.92e-11 3.02e-08 -0.37 -0.3 Yang-deficiency constitution; chr14:71890603 chr14:71848606~71908430:+ LUSC cis rs67180937 0.733 rs17532708 ENSG00000272750.1 RP11-378J18.8 -6.73 4.92e-11 3.02e-08 -0.33 -0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222726085 chr1:222658867~222661512:- LUSC cis rs4423214 0.592 rs10898223 ENSG00000254682.1 RP11-660L16.2 -6.73 4.93e-11 3.03e-08 -0.5 -0.3 Vitamin D levels; chr11:71508218 chr11:71448674~71452157:+ LUSC cis rs2404602 0.647 rs1443115 ENSG00000259422.1 RP11-593F23.1 -6.73 4.94e-11 3.03e-08 -0.36 -0.3 Blood metabolite levels; chr15:76749488 chr15:76174891~76181486:- LUSC cis rs2404602 0.647 rs12898416 ENSG00000259422.1 RP11-593F23.1 -6.73 4.94e-11 3.03e-08 -0.36 -0.3 Blood metabolite levels; chr15:76749951 chr15:76174891~76181486:- LUSC cis rs2404602 0.647 rs12904149 ENSG00000259422.1 RP11-593F23.1 -6.73 4.94e-11 3.03e-08 -0.36 -0.3 Blood metabolite levels; chr15:76751311 chr15:76174891~76181486:- LUSC cis rs10129255 0.5 rs7157975 ENSG00000224373.3 IGHV4-59 6.73 4.95e-11 3.04e-08 0.15 0.3 Kawasaki disease; chr14:106804049 chr14:106627249~106627825:- LUSC cis rs10129255 0.518 rs11847766 ENSG00000224373.3 IGHV4-59 6.73 4.96e-11 3.04e-08 0.15 0.3 Kawasaki disease; chr14:106779186 chr14:106627249~106627825:- LUSC cis rs12931792 0.72 rs12102320 ENSG00000183604.13 SMG1P5 6.73 4.97e-11 3.05e-08 0.33 0.3 Tonsillectomy; chr16:30167195 chr16:30267553~30335374:- LUSC cis rs17711722 0.727 rs1880555 ENSG00000164669.11 INTS4P1 -6.73 4.98e-11 3.06e-08 -0.32 -0.3 Calcium levels; chr7:65967580 chr7:65141225~65234216:+ LUSC cis rs113835537 0.529 rs11227500 ENSG00000255517.5 CTD-3074O7.5 -6.73 4.98e-11 3.06e-08 -0.34 -0.3 Airway imaging phenotypes; chr11:66505762 chr11:66473490~66480233:- LUSC cis rs1075265 0.587 rs2542585 ENSG00000233266.1 HMGB1P31 6.73 5.02e-11 3.08e-08 0.37 0.3 Chronotype;Morning vs. evening chronotype; chr2:53786407 chr2:54051334~54051760:+ LUSC cis rs2919917 1 rs6980663 ENSG00000254352.1 RP11-578O24.2 6.73 5.02e-11 3.08e-08 0.37 0.3 Lymphocyte counts; chr8:78691589 chr8:78723796~78724136:- LUSC cis rs3747113 0.732 rs28360612 ENSG00000128262.7 POM121L9P -6.73 5.03e-11 3.08e-08 -0.32 -0.3 Gut microbiome composition (summer); chr22:24487250 chr22:24251828~24265525:+ LUSC cis rs9549367 0.713 rs4907598 ENSG00000269125.1 RP11-98F14.11 6.73 5.03e-11 3.08e-08 0.36 0.3 Platelet distribution width; chr13:113207071 chr13:113165002~113165183:- LUSC cis rs748404 0.626 rs35992154 ENSG00000249839.1 AC011330.5 -6.73 5.04e-11 3.09e-08 -0.51 -0.3 Lung cancer; chr15:43345669 chr15:43663654~43684339:- LUSC cis rs17711722 0.523 rs313812 ENSG00000236529.1 RP13-254B10.1 -6.73 5.04e-11 3.09e-08 -0.31 -0.3 Calcium levels; chr7:66040056 chr7:65840212~65840596:+ LUSC cis rs2404602 0.647 rs11072619 ENSG00000259422.1 RP11-593F23.1 -6.73 5.05e-11 3.09e-08 -0.35 -0.3 Blood metabolite levels; chr15:76750901 chr15:76174891~76181486:- LUSC cis rs2404602 0.647 rs11072620 ENSG00000259422.1 RP11-593F23.1 -6.73 5.05e-11 3.09e-08 -0.35 -0.3 Blood metabolite levels; chr15:76756429 chr15:76174891~76181486:- LUSC cis rs11098499 0.754 rs938056 ENSG00000249244.1 RP11-548H18.2 6.73 5.05e-11 3.09e-08 0.37 0.3 Corneal astigmatism; chr4:119316298 chr4:119391831~119395335:- LUSC cis rs748404 0.666 rs17780417 ENSG00000249839.1 AC011330.5 -6.73 5.05e-11 3.1e-08 -0.51 -0.3 Lung cancer; chr15:43347264 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs7181634 ENSG00000249839.1 AC011330.5 -6.73 5.05e-11 3.1e-08 -0.51 -0.3 Lung cancer; chr15:43351703 chr15:43663654~43684339:- LUSC cis rs4950322 0.58 rs17359629 ENSG00000278811.3 LINC00624 6.73 5.06e-11 3.1e-08 0.32 0.3 Protein quantitative trait loci; chr1:147121537 chr1:147258885~147517875:- LUSC cis rs10740039 0.734 rs10821815 ENSG00000254271.1 RP11-131N11.4 6.73 5.06e-11 3.1e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60644843 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs10994455 ENSG00000254271.1 RP11-131N11.4 6.73 5.06e-11 3.1e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60645589 chr10:60734342~60741828:+ LUSC cis rs10740039 0.96 rs10443928 ENSG00000254271.1 RP11-131N11.4 6.73 5.06e-11 3.1e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60645718 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs10443929 ENSG00000254271.1 RP11-131N11.4 6.73 5.06e-11 3.1e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60645852 chr10:60734342~60741828:+ LUSC cis rs10740039 0.842 rs7915540 ENSG00000254271.1 RP11-131N11.4 6.73 5.06e-11 3.1e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60646538 chr10:60734342~60741828:+ LUSC cis rs11098499 0.954 rs12505469 ENSG00000250412.1 KLHL2P1 6.73 5.06e-11 3.1e-08 0.37 0.3 Corneal astigmatism; chr4:119328430 chr4:119334329~119378233:+ LUSC cis rs853679 0.517 rs9283884 ENSG00000204709.4 LINC01556 -6.73 5.06e-11 3.1e-08 -0.42 -0.3 Depression; chr6:28167882 chr6:28943877~28944537:+ LUSC cis rs10740039 0.766 rs2119917 ENSG00000254271.1 RP11-131N11.4 6.73 5.07e-11 3.1e-08 0.4 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60677626 chr10:60734342~60741828:+ LUSC cis rs10463554 0.892 rs72783889 ENSG00000175749.11 EIF3KP1 6.73 5.07e-11 3.1e-08 0.36 0.3 Parkinson's disease; chr5:102938835 chr5:103032376~103033031:+ LUSC cis rs10463554 0.892 rs72783890 ENSG00000175749.11 EIF3KP1 6.73 5.07e-11 3.1e-08 0.36 0.3 Parkinson's disease; chr5:102938836 chr5:103032376~103033031:+ LUSC cis rs9903692 0.954 rs12936731 ENSG00000278765.1 RP5-890E16.5 6.73 5.07e-11 3.11e-08 0.36 0.3 Pulse pressure; chr17:48050997 chr17:48066704~48067293:- LUSC cis rs9903692 0.909 rs9899275 ENSG00000278765.1 RP5-890E16.5 6.73 5.07e-11 3.11e-08 0.36 0.3 Pulse pressure; chr17:48051953 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs12450620 ENSG00000278765.1 RP5-890E16.5 6.73 5.07e-11 3.11e-08 0.36 0.3 Pulse pressure; chr17:48052892 chr17:48066704~48067293:- LUSC cis rs1865760 0.929 rs9467646 ENSG00000272462.2 U91328.19 -6.73 5.08e-11 3.11e-08 -0.32 -0.3 Height; chr6:25957180 chr6:25992662~26001775:+ LUSC cis rs34375054 0.526 rs7302475 ENSG00000279233.1 RP11-158L12.4 6.73 5.09e-11 3.12e-08 0.29 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125193340 chr12:125138245~125141711:+ LUSC cis rs35160687 0.722 rs6728029 ENSG00000273080.1 RP11-301O19.1 -6.73 5.09e-11 3.12e-08 -0.28 -0.3 Night sleep phenotypes; chr2:86328258 chr2:86195590~86196049:+ LUSC cis rs11098499 0.954 rs7681544 ENSG00000250412.1 KLHL2P1 6.73 5.09e-11 3.12e-08 0.37 0.3 Corneal astigmatism; chr4:119490100 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs11940028 ENSG00000250412.1 KLHL2P1 6.73 5.09e-11 3.12e-08 0.37 0.3 Corneal astigmatism; chr4:119490752 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs11935596 ENSG00000250412.1 KLHL2P1 6.73 5.09e-11 3.12e-08 0.37 0.3 Corneal astigmatism; chr4:119491302 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs12507964 ENSG00000250412.1 KLHL2P1 6.73 5.09e-11 3.12e-08 0.37 0.3 Corneal astigmatism; chr4:119491906 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs11098530 ENSG00000250412.1 KLHL2P1 6.73 5.09e-11 3.12e-08 0.37 0.3 Corneal astigmatism; chr4:119491999 chr4:119334329~119378233:+ LUSC cis rs875971 1 rs937495 ENSG00000237310.1 GS1-124K5.4 -6.73 5.1e-11 3.12e-08 -0.31 -0.3 Aortic root size; chr7:66314811 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs2036264 ENSG00000237310.1 GS1-124K5.4 -6.73 5.1e-11 3.12e-08 -0.31 -0.3 Aortic root size; chr7:66334917 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs7783613 ENSG00000237310.1 GS1-124K5.4 -6.73 5.1e-11 3.12e-08 -0.31 -0.3 Aortic root size; chr7:66340274 chr7:66493706~66495474:+ LUSC cis rs8062405 0.721 rs151303 ENSG00000278665.1 RP11-666O2.4 6.73 5.11e-11 3.13e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28481189 chr16:28599241~28601881:- LUSC cis rs853679 0.607 rs35030260 ENSG00000204709.4 LINC01556 6.72 5.11e-11 3.13e-08 0.66 0.3 Depression; chr6:28337731 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs13217619 ENSG00000204709.4 LINC01556 6.72 5.11e-11 3.13e-08 0.66 0.3 Depression; chr6:28338894 chr6:28943877~28944537:+ LUSC cis rs2188561 0.697 rs12539555 ENSG00000241764.3 AC002467.7 6.72 5.12e-11 3.13e-08 0.39 0.3 Alcohol consumption; chr7:107764028 chr7:107742817~107744581:- LUSC cis rs9903692 0.909 rs8078125 ENSG00000278765.1 RP5-890E16.5 6.72 5.14e-11 3.15e-08 0.36 0.3 Pulse pressure; chr17:48068347 chr17:48066704~48067293:- LUSC cis rs950169 0.922 rs62021167 ENSG00000225151.9 GOLGA2P7 -6.72 5.14e-11 3.15e-08 -0.41 -0.3 Schizophrenia; chr15:84574820 chr15:84199311~84230136:- LUSC cis rs10129255 0.957 rs11846893 ENSG00000280411.1 IGHV1-69-2 -6.72 5.15e-11 3.15e-08 -0.2 -0.3 Kawasaki disease; chr14:106779068 chr14:106762092~106762588:- LUSC cis rs9921338 0.961 rs17605444 ENSG00000263080.1 RP11-485G7.5 6.72 5.16e-11 3.16e-08 0.35 0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11319732 chr16:11341809~11345211:- LUSC cis rs10129255 0.5 rs11627315 ENSG00000224373.3 IGHV4-59 6.72 5.16e-11 3.16e-08 0.15 0.3 Kawasaki disease; chr14:106802182 chr14:106627249~106627825:- LUSC cis rs11157436 0.958 rs17183356 ENSG00000211813.2 TRAV34 6.72 5.16e-11 3.16e-08 0.35 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22219101 chr14:22207522~22208129:+ LUSC cis rs2455601 0.608 rs59025804 ENSG00000254860.4 TMEM9B-AS1 6.72 5.16e-11 3.16e-08 0.35 0.3 Schizophrenia; chr11:8848754 chr11:8964675~8977527:+ LUSC cis rs801193 0.591 rs9986881 ENSG00000226824.5 RP4-756H11.3 -6.72 5.17e-11 3.16e-08 -0.35 -0.3 Aortic root size; chr7:66708053 chr7:66654538~66669855:+ LUSC cis rs8072100 0.967 rs8078880 ENSG00000228782.6 CTD-2026D20.3 -6.72 5.17e-11 3.16e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47599160 chr17:47450568~47492492:- LUSC cis rs2524005 1 rs2524005 ENSG00000281831.1 HCP5B 6.72 5.17e-11 3.16e-08 0.39 0.3 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29871895~29873783:- LUSC cis rs4604732 0.631 rs12091081 ENSG00000227135.1 GCSAML-AS1 -6.72 5.17e-11 3.16e-08 -0.45 -0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247459762 chr1:247524679~247526752:- LUSC cis rs11976180 1 rs2371244 ENSG00000170356.8 OR2A20P -6.72 5.17e-11 3.16e-08 -0.4 -0.3 Obesity-related traits; chr7:144060518 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs4726669 ENSG00000170356.8 OR2A20P -6.72 5.17e-11 3.16e-08 -0.4 -0.3 Obesity-related traits; chr7:144061098 chr7:144250045~144252957:- LUSC cis rs2404602 0.647 rs4312276 ENSG00000259422.1 RP11-593F23.1 -6.72 5.17e-11 3.16e-08 -0.35 -0.3 Blood metabolite levels; chr15:76872020 chr15:76174891~76181486:- LUSC cis rs5769707 0.967 rs2187891 ENSG00000235111.1 RP1-29C18.8 -6.72 5.18e-11 3.17e-08 -0.34 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49600446 chr22:49612657~49615716:- LUSC cis rs875971 0.965 rs10267430 ENSG00000237310.1 GS1-124K5.4 -6.72 5.18e-11 3.17e-08 -0.31 -0.3 Aortic root size; chr7:66278036 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs10257427 ENSG00000237310.1 GS1-124K5.4 -6.72 5.18e-11 3.17e-08 -0.31 -0.3 Aortic root size; chr7:66278221 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs10215948 ENSG00000237310.1 GS1-124K5.4 -6.72 5.18e-11 3.17e-08 -0.31 -0.3 Aortic root size; chr7:66282799 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs55748098 ENSG00000237310.1 GS1-124K5.4 -6.72 5.18e-11 3.17e-08 -0.31 -0.3 Aortic root size; chr7:66298631 chr7:66493706~66495474:+ LUSC cis rs881375 1 rs10117059 ENSG00000226752.6 PSMD5-AS1 -6.72 5.19e-11 3.17e-08 -0.34 -0.3 Rheumatoid arthritis; chr9:120891199 chr9:120824828~120854385:+ LUSC cis rs881375 1 rs4323544 ENSG00000226752.6 PSMD5-AS1 -6.72 5.2e-11 3.18e-08 -0.35 -0.3 Rheumatoid arthritis; chr9:120885099 chr9:120824828~120854385:+ LUSC cis rs4713118 0.824 rs742046 ENSG00000219392.1 RP1-265C24.5 -6.72 5.2e-11 3.18e-08 -0.38 -0.3 Parkinson's disease; chr6:27771475 chr6:28115628~28116551:+ LUSC cis rs228614 0.51 rs150893 ENSG00000230069.3 LRRC37A15P 6.72 5.2e-11 3.18e-08 0.31 0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102817075 chr4:102727274~102730721:- LUSC cis rs11098499 0.754 rs10518300 ENSG00000249244.1 RP11-548H18.2 -6.72 5.21e-11 3.18e-08 -0.38 -0.3 Corneal astigmatism; chr4:119328344 chr4:119391831~119395335:- LUSC cis rs13113518 0.783 rs11133389 ENSG00000223305.1 RN7SKP30 6.72 5.21e-11 3.18e-08 0.37 0.3 Height; chr4:55486718 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs2048564 ENSG00000249700.7 SRD5A3-AS1 6.72 5.21e-11 3.19e-08 0.35 0.3 Height; chr4:55407965 chr4:55363971~55395847:- LUSC cis rs61160187 0.75 rs1807017 ENSG00000215032.2 GNL3LP1 6.72 5.22e-11 3.19e-08 0.37 0.3 Educational attainment (years of education);Educational attainment (college completion); chr5:60831897 chr5:60891935~60893577:- LUSC cis rs1865760 0.865 rs9393677 ENSG00000272462.2 U91328.19 -6.72 5.22e-11 3.19e-08 -0.31 -0.3 Height; chr6:25945587 chr6:25992662~26001775:+ LUSC cis rs992157 0.71 rs6719789 ENSG00000261338.2 RP11-378A13.1 -6.72 5.23e-11 3.19e-08 -0.3 -0.3 Colorectal cancer; chr2:218193087 chr2:218255319~218257366:+ LUSC cis rs2408955 0.541 rs11168428 ENSG00000240399.1 RP1-228P16.1 -6.72 5.24e-11 3.2e-08 -0.3 -0.3 Glycated hemoglobin levels; chr12:48153345 chr12:48054813~48055591:- LUSC cis rs13113518 0.595 rs13120635 ENSG00000249700.7 SRD5A3-AS1 6.72 5.26e-11 3.21e-08 0.35 0.3 Height; chr4:55361200 chr4:55363971~55395847:- LUSC cis rs17711722 0.701 rs781143 ENSG00000164669.11 INTS4P1 -6.72 5.27e-11 3.22e-08 -0.32 -0.3 Calcium levels; chr7:65974892 chr7:65141225~65234216:+ LUSC cis rs17507216 0.681 rs28877110 ENSG00000255769.6 GOLGA2P10 -6.72 5.27e-11 3.22e-08 -0.45 -0.3 Excessive daytime sleepiness; chr15:82672111 chr15:82472993~82513950:- LUSC cis rs5742933 0.817 rs1233297 ENSG00000253559.1 OSGEPL1-AS1 -6.72 5.27e-11 3.22e-08 -0.36 -0.3 Ferritin levels; chr2:189829449 chr2:189762704~189765556:+ LUSC cis rs9309473 1 rs6753344 ENSG00000163016.8 ALMS1P -6.72 5.27e-11 3.22e-08 -0.36 -0.3 Metabolite levels; chr2:73426010 chr2:73644919~73685576:+ LUSC cis rs853679 0.517 rs9380058 ENSG00000204709.4 LINC01556 6.72 5.28e-11 3.22e-08 0.42 0.3 Depression; chr6:28159666 chr6:28943877~28944537:+ LUSC cis rs10129255 0.917 rs8022493 ENSG00000280411.1 IGHV1-69-2 -6.72 5.28e-11 3.22e-08 -0.2 -0.3 Kawasaki disease; chr14:106781820 chr14:106762092~106762588:- LUSC cis rs7267979 0.789 rs6050472 ENSG00000274973.1 RP13-401N8.7 -6.72 5.28e-11 3.22e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25239216 chr20:25845497~25845862:+ LUSC cis rs875971 0.558 rs4433015 ENSG00000236529.1 RP13-254B10.1 -6.72 5.29e-11 3.23e-08 -0.31 -0.3 Aortic root size; chr7:66174736 chr7:65840212~65840596:+ LUSC cis rs11098499 0.954 rs6857105 ENSG00000250412.1 KLHL2P1 6.72 5.31e-11 3.24e-08 0.38 0.3 Corneal astigmatism; chr4:119301143 chr4:119334329~119378233:+ LUSC cis rs4853012 0.775 rs12465641 ENSG00000257800.1 FNBP1P1 -6.72 5.34e-11 3.26e-08 -0.35 -0.3 Gestational age at birth (maternal effect); chr2:74110588 chr2:74120680~74123218:+ LUSC cis rs2404602 0.647 rs11631959 ENSG00000259422.1 RP11-593F23.1 -6.72 5.35e-11 3.26e-08 -0.35 -0.3 Blood metabolite levels; chr15:76747707 chr15:76174891~76181486:- LUSC cis rs2179367 0.92 rs638407 ENSG00000231760.4 RP11-350J20.5 6.72 5.35e-11 3.26e-08 0.38 0.3 Dupuytren's disease; chr6:149417214 chr6:149796151~149826294:- LUSC cis rs9660180 0.783 rs1107910 ENSG00000231050.1 RP1-140A9.1 6.72 5.36e-11 3.27e-08 0.3 0.3 Body mass index; chr1:1760882 chr1:1891471~1892658:+ LUSC cis rs7267979 0.933 rs11699203 ENSG00000274973.1 RP13-401N8.7 -6.72 5.36e-11 3.27e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25454533 chr20:25845497~25845862:+ LUSC cis rs7267979 0.933 rs6138571 ENSG00000274973.1 RP13-401N8.7 -6.72 5.36e-11 3.27e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25454752 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs416745 ENSG00000274973.1 RP13-401N8.7 -6.72 5.36e-11 3.27e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25458232 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs454723 ENSG00000274973.1 RP13-401N8.7 -6.72 5.36e-11 3.27e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25458292 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs448396 ENSG00000274973.1 RP13-401N8.7 -6.72 5.36e-11 3.27e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25459633 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs447722 ENSG00000274973.1 RP13-401N8.7 -6.72 5.36e-11 3.27e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25462874 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs422424 ENSG00000274973.1 RP13-401N8.7 -6.72 5.36e-11 3.27e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25464810 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs401166 ENSG00000274973.1 RP13-401N8.7 -6.72 5.36e-11 3.27e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25465672 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs404394 ENSG00000274973.1 RP13-401N8.7 -6.72 5.36e-11 3.27e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25467260 chr20:25845497~25845862:+ LUSC cis rs881375 0.933 rs7028641 ENSG00000226752.6 PSMD5-AS1 -6.72 5.37e-11 3.27e-08 -0.34 -0.3 Rheumatoid arthritis; chr9:120928863 chr9:120824828~120854385:+ LUSC cis rs875971 1 rs1167612 ENSG00000237310.1 GS1-124K5.4 -6.72 5.37e-11 3.28e-08 -0.31 -0.3 Aortic root size; chr7:66102989 chr7:66493706~66495474:+ LUSC cis rs10129255 0.5 rs8021941 ENSG00000224373.3 IGHV4-59 6.72 5.39e-11 3.28e-08 0.15 0.3 Kawasaki disease; chr14:106781490 chr14:106627249~106627825:- LUSC cis rs10129255 0.5 rs10142931 ENSG00000224373.3 IGHV4-59 6.72 5.39e-11 3.28e-08 0.15 0.3 Kawasaki disease; chr14:106782288 chr14:106627249~106627825:- LUSC cis rs6772849 0.83 rs7633674 ENSG00000242551.2 POU5F1P6 -6.72 5.39e-11 3.29e-08 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr3:128636183 chr3:128674735~128677005:- LUSC cis rs7580658 0.864 rs3088374 ENSG00000236682.1 AC068282.3 -6.72 5.39e-11 3.29e-08 -0.39 -0.3 Protein C levels; chr2:127304472 chr2:127389130~127400580:+ LUSC cis rs9309473 0.898 rs10201159 ENSG00000163016.8 ALMS1P 6.72 5.4e-11 3.29e-08 0.36 0.3 Metabolite levels; chr2:73631838 chr2:73644919~73685576:+ LUSC cis rs11098499 0.754 rs878376 ENSG00000249244.1 RP11-548H18.2 6.72 5.4e-11 3.29e-08 0.37 0.3 Corneal astigmatism; chr4:119316547 chr4:119391831~119395335:- LUSC cis rs11098499 0.789 rs9991166 ENSG00000249244.1 RP11-548H18.2 6.72 5.4e-11 3.29e-08 0.37 0.3 Corneal astigmatism; chr4:119316696 chr4:119391831~119395335:- LUSC cis rs11098499 0.708 rs10005237 ENSG00000249244.1 RP11-548H18.2 6.72 5.4e-11 3.29e-08 0.37 0.3 Corneal astigmatism; chr4:119316742 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs10213267 ENSG00000249244.1 RP11-548H18.2 6.72 5.4e-11 3.29e-08 0.37 0.3 Corneal astigmatism; chr4:119317919 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs10212775 ENSG00000249244.1 RP11-548H18.2 6.72 5.4e-11 3.29e-08 0.37 0.3 Corneal astigmatism; chr4:119318089 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs11732087 ENSG00000249244.1 RP11-548H18.2 6.72 5.4e-11 3.29e-08 0.37 0.3 Corneal astigmatism; chr4:119318676 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs2964 ENSG00000249244.1 RP11-548H18.2 6.72 5.4e-11 3.29e-08 0.37 0.3 Corneal astigmatism; chr4:119318976 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs1511025 ENSG00000249244.1 RP11-548H18.2 6.72 5.4e-11 3.29e-08 0.37 0.3 Corneal astigmatism; chr4:119319083 chr4:119391831~119395335:- LUSC cis rs10129255 0.957 rs12590799 ENSG00000280411.1 IGHV1-69-2 -6.72 5.4e-11 3.29e-08 -0.2 -0.3 Kawasaki disease; chr14:106779713 chr14:106762092~106762588:- LUSC cis rs10129255 0.957 rs10136781 ENSG00000280411.1 IGHV1-69-2 -6.72 5.4e-11 3.29e-08 -0.2 -0.3 Kawasaki disease; chr14:106780451 chr14:106762092~106762588:- LUSC cis rs4853012 0.838 rs4429500 ENSG00000257800.1 FNBP1P1 6.72 5.41e-11 3.3e-08 0.34 0.3 Gestational age at birth (maternal effect); chr2:74118209 chr2:74120680~74123218:+ LUSC cis rs5753618 0.561 rs5753609 ENSG00000236132.1 CTA-440B3.1 -6.72 5.41e-11 3.3e-08 -0.39 -0.3 Colorectal cancer; chr22:31423226 chr22:31816379~31817491:- LUSC cis rs526231 0.578 rs2112886 ENSG00000175749.11 EIF3KP1 -6.72 5.41e-11 3.3e-08 -0.36 -0.3 Primary biliary cholangitis; chr5:102915678 chr5:103032376~103033031:+ LUSC cis rs10129255 0.518 rs8009594 ENSG00000224373.3 IGHV4-59 6.72 5.43e-11 3.31e-08 0.15 0.3 Kawasaki disease; chr14:106777494 chr14:106627249~106627825:- LUSC cis rs10129255 0.518 rs8009612 ENSG00000224373.3 IGHV4-59 6.72 5.43e-11 3.31e-08 0.15 0.3 Kawasaki disease; chr14:106777510 chr14:106627249~106627825:- LUSC cis rs10129255 0.957 rs17113284 ENSG00000280411.1 IGHV1-69-2 6.72 5.43e-11 3.31e-08 0.2 0.3 Kawasaki disease; chr14:106684476 chr14:106762092~106762588:- LUSC cis rs7267979 0.932 rs424487 ENSG00000274973.1 RP13-401N8.7 -6.71 5.46e-11 3.32e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25487495 chr20:25845497~25845862:+ LUSC cis rs950169 1 rs12903820 ENSG00000259728.4 LINC00933 6.71 5.46e-11 3.33e-08 0.39 0.3 Schizophrenia; chr15:84055068 chr15:84570649~84580175:+ LUSC cis rs875971 1 rs3981131 ENSG00000237310.1 GS1-124K5.4 6.71 5.46e-11 3.33e-08 0.31 0.3 Aortic root size; chr7:66486690 chr7:66493706~66495474:+ LUSC cis rs9309473 1 rs7558944 ENSG00000163016.8 ALMS1P 6.71 5.47e-11 3.33e-08 0.35 0.3 Metabolite levels; chr2:73583782 chr2:73644919~73685576:+ LUSC cis rs11098499 0.955 rs35434465 ENSG00000250412.1 KLHL2P1 6.71 5.47e-11 3.33e-08 0.37 0.3 Corneal astigmatism; chr4:119248223 chr4:119334329~119378233:+ LUSC cis rs2404602 0.735 rs2461870 ENSG00000259422.1 RP11-593F23.1 -6.71 5.47e-11 3.33e-08 -0.34 -0.3 Blood metabolite levels; chr15:76521579 chr15:76174891~76181486:- LUSC cis rs5753618 0.504 rs5753659 ENSG00000236132.1 CTA-440B3.1 -6.71 5.48e-11 3.34e-08 -0.4 -0.3 Colorectal cancer; chr22:31497627 chr22:31816379~31817491:- LUSC cis rs10740039 0.842 rs10761537 ENSG00000254271.1 RP11-131N11.4 6.71 5.48e-11 3.34e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60649263 chr10:60734342~60741828:+ LUSC cis rs9903692 0.954 rs11651097 ENSG00000278765.1 RP5-890E16.5 6.71 5.49e-11 3.34e-08 0.36 0.3 Pulse pressure; chr17:48069677 chr17:48066704~48067293:- LUSC cis rs875971 0.522 rs781144 ENSG00000164669.11 INTS4P1 -6.71 5.5e-11 3.35e-08 -0.33 -0.3 Aortic root size; chr7:65975357 chr7:65141225~65234216:+ LUSC cis rs11089937 0.521 rs6001221 ENSG00000211639.2 IGLV4-60 6.71 5.5e-11 3.35e-08 0.3 0.3 Periodontitis (PAL4Q3); chr22:22185176 chr22:22162199~22162681:+ LUSC cis rs6142102 0.961 rs2284379 ENSG00000276073.1 RP5-1125A11.7 -6.71 5.5e-11 3.35e-08 -0.31 -0.3 Skin pigmentation; chr20:34006836 chr20:33985617~33988989:- LUSC cis rs760794 0.764 rs7764632 ENSG00000227116.1 RP3-471C18.1 -6.71 5.51e-11 3.35e-08 -0.35 -0.3 Endometriosis; chr6:19795354 chr6:19730427~19734567:- LUSC cis rs875971 1 rs4718357 ENSG00000237310.1 GS1-124K5.4 6.71 5.51e-11 3.36e-08 0.31 0.3 Aortic root size; chr7:66495891 chr7:66493706~66495474:+ LUSC cis rs2404602 0.647 rs10851892 ENSG00000259422.1 RP11-593F23.1 -6.71 5.51e-11 3.36e-08 -0.36 -0.3 Blood metabolite levels; chr15:76884150 chr15:76174891~76181486:- LUSC cis rs1865760 0.566 rs2858993 ENSG00000272462.2 U91328.19 -6.71 5.51e-11 3.36e-08 -0.32 -0.3 Height; chr6:26087628 chr6:25992662~26001775:+ LUSC cis rs950169 0.92 rs2135551 ENSG00000259728.4 LINC00933 6.71 5.52e-11 3.36e-08 0.39 0.3 Schizophrenia; chr15:84039099 chr15:84570649~84580175:+ LUSC cis rs950169 1 rs12902672 ENSG00000259728.4 LINC00933 6.71 5.52e-11 3.36e-08 0.39 0.3 Schizophrenia; chr15:84048234 chr15:84570649~84580175:+ LUSC cis rs7267979 1 rs6050626 ENSG00000274973.1 RP13-401N8.7 -6.71 5.53e-11 3.37e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25447625 chr20:25845497~25845862:+ LUSC cis rs4604732 0.536 rs61184655 ENSG00000227135.1 GCSAML-AS1 -6.71 5.54e-11 3.37e-08 -0.44 -0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247488040 chr1:247524679~247526752:- LUSC cis rs8072100 0.656 rs2610367 ENSG00000228782.6 CTD-2026D20.3 6.71 5.54e-11 3.37e-08 0.29 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47492449 chr17:47450568~47492492:- LUSC cis rs748404 0.666 rs16957730 ENSG00000249839.1 AC011330.5 -6.71 5.54e-11 3.37e-08 -0.5 -0.3 Lung cancer; chr15:43438288 chr15:43663654~43684339:- LUSC cis rs9903692 0.954 rs875066 ENSG00000278765.1 RP5-890E16.5 6.71 5.55e-11 3.38e-08 0.35 0.3 Pulse pressure; chr17:48062370 chr17:48066704~48067293:- LUSC cis rs10246939 0.543 rs11765106 ENSG00000228775.6 WEE2-AS1 6.71 5.56e-11 3.38e-08 0.38 0.3 Bitter taste perception; chr7:141902676 chr7:141704338~141738346:- LUSC cis rs761746 0.614 rs2108108 ENSG00000236132.1 CTA-440B3.1 -6.71 5.56e-11 3.38e-08 -0.42 -0.3 Intelligence; chr22:31785951 chr22:31816379~31817491:- LUSC cis rs11098499 0.954 rs17005535 ENSG00000250412.1 KLHL2P1 6.71 5.56e-11 3.38e-08 0.37 0.3 Corneal astigmatism; chr4:119490407 chr4:119334329~119378233:+ LUSC cis rs9318086 0.753 rs9553094 ENSG00000205861.10 C1QTNF9B-AS1 6.71 5.56e-11 3.38e-08 0.36 0.3 Myopia (pathological); chr13:23900474 chr13:23888889~23897263:+ LUSC cis rs10463554 0.818 rs2241564 ENSG00000175749.11 EIF3KP1 6.71 5.56e-11 3.38e-08 0.36 0.3 Parkinson's disease; chr5:102966547 chr5:103032376~103033031:+ LUSC cis rs13113518 0.507 rs4549456 ENSG00000249700.7 SRD5A3-AS1 6.71 5.57e-11 3.39e-08 0.33 0.3 Height; chr4:55398586 chr4:55363971~55395847:- LUSC cis rs17767294 0.612 rs9461424 ENSG00000219392.1 RP1-265C24.5 -6.71 5.57e-11 3.39e-08 -0.64 -0.3 Parkinson's disease; chr6:27951623 chr6:28115628~28116551:+ LUSC cis rs10129255 0.5 rs10131875 ENSG00000224373.3 IGHV4-59 6.71 5.58e-11 3.39e-08 0.15 0.3 Kawasaki disease; chr14:106792798 chr14:106627249~106627825:- LUSC cis rs2581828 0.618 rs1560332 ENSG00000242142.1 SERBP1P3 6.71 5.58e-11 3.39e-08 0.35 0.3 Crohn's disease; chr3:53130787 chr3:53064283~53065091:- LUSC cis rs8062405 1 rs72793811 ENSG00000278665.1 RP11-666O2.4 6.71 5.58e-11 3.39e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828071 chr16:28599241~28601881:- LUSC cis rs7772486 0.905 rs9373486 ENSG00000235652.6 RP11-545I5.3 -6.71 5.59e-11 3.4e-08 -0.29 -0.3 Lobe attachment (rater-scored or self-reported); chr6:146124888 chr6:145799409~145886585:+ LUSC cis rs10080237 0.564 rs2490230 ENSG00000272129.1 RP11-250B2.6 6.71 5.59e-11 3.4e-08 0.37 0.3 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr6:80102747 chr6:80355424~80356859:+ LUSC cis rs55665837 0.559 rs9667144 ENSG00000251991.1 RNU7-49P -6.71 5.6e-11 3.4e-08 -0.34 -0.3 Vitamin D levels; chr11:14399555 chr11:14478892~14478953:+ LUSC cis rs8031584 0.736 rs11635775 ENSG00000260382.1 RP11-540B6.2 6.71 5.6e-11 3.4e-08 0.41 0.3 Huntington's disease progression; chr15:30868437 chr15:30882267~30883231:- LUSC cis rs10800713 0.954 rs6427835 ENSG00000260088.1 RP11-92G12.3 -6.71 5.61e-11 3.41e-08 -0.41 -0.3 Tandem gait; chr1:200591725 chr1:200669507~200694250:+ LUSC cis rs9322193 0.884 rs7744105 ENSG00000268592.3 RAET1E-AS1 6.71 5.62e-11 3.42e-08 0.38 0.3 Lung cancer; chr6:149849308 chr6:149863494~149919507:+ LUSC cis rs10246939 0.543 rs35836873 ENSG00000228775.6 WEE2-AS1 6.71 5.62e-11 3.42e-08 0.34 0.3 Bitter taste perception; chr7:141844010 chr7:141704338~141738346:- LUSC cis rs10246939 0.543 rs9640358 ENSG00000228775.6 WEE2-AS1 6.71 5.62e-11 3.42e-08 0.34 0.3 Bitter taste perception; chr7:141844082 chr7:141704338~141738346:- LUSC cis rs11089937 0.597 rs4821774 ENSG00000211638.2 IGLV8-61 -6.71 5.62e-11 3.42e-08 -0.32 -0.3 Periodontitis (PAL4Q3); chr22:22131536 chr22:22098700~22099212:+ LUSC cis rs228614 0.51 rs223415 ENSG00000230069.3 LRRC37A15P -6.71 5.63e-11 3.42e-08 -0.31 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102811016 chr4:102727274~102730721:- LUSC cis rs853679 0.513 rs9468296 ENSG00000204709.4 LINC01556 6.71 5.63e-11 3.42e-08 0.43 0.3 Depression; chr6:28145952 chr6:28943877~28944537:+ LUSC cis rs8072100 0.87 rs10432035 ENSG00000228782.6 CTD-2026D20.3 -6.71 5.63e-11 3.42e-08 -0.28 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47547547 chr17:47450568~47492492:- LUSC cis rs10740039 0.883 rs7905018 ENSG00000254271.1 RP11-131N11.4 6.71 5.64e-11 3.43e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60647585 chr10:60734342~60741828:+ LUSC cis rs10129255 0.5 rs8004923 ENSG00000224373.3 IGHV4-59 6.71 5.66e-11 3.44e-08 0.15 0.3 Kawasaki disease; chr14:106785926 chr14:106627249~106627825:- LUSC cis rs10129255 0.5 rs6576232 ENSG00000224373.3 IGHV4-59 6.71 5.66e-11 3.44e-08 0.15 0.3 Kawasaki disease; chr14:106787090 chr14:106627249~106627825:- LUSC cis rs9322193 0.923 rs9767554 ENSG00000268592.3 RAET1E-AS1 6.71 5.66e-11 3.44e-08 0.37 0.3 Lung cancer; chr6:149616860 chr6:149863494~149919507:+ LUSC cis rs17507216 0.628 rs28607761 ENSG00000255769.6 GOLGA2P10 -6.71 5.67e-11 3.44e-08 -0.45 -0.3 Excessive daytime sleepiness; chr15:82715317 chr15:82472993~82513950:- LUSC cis rs7772486 0.754 rs6937661 ENSG00000235652.6 RP11-545I5.3 -6.71 5.67e-11 3.45e-08 -0.29 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145792163 chr6:145799409~145886585:+ LUSC cis rs853679 0.517 rs9468297 ENSG00000204709.4 LINC01556 6.71 5.68e-11 3.45e-08 0.42 0.3 Depression; chr6:28151096 chr6:28943877~28944537:+ LUSC cis rs875971 0.964 rs1643388 ENSG00000237310.1 GS1-124K5.4 6.71 5.68e-11 3.45e-08 0.3 0.3 Aortic root size; chr7:66379575 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs778722 ENSG00000237310.1 GS1-124K5.4 6.71 5.68e-11 3.45e-08 0.3 0.3 Aortic root size; chr7:66379841 chr7:66493706~66495474:+ LUSC cis rs11690935 0.959 rs12185567 ENSG00000228389.1 AC068039.4 -6.71 5.68e-11 3.45e-08 -0.34 -0.3 Schizophrenia; chr2:171704219 chr2:171773482~171775844:+ LUSC cis rs10754283 0.967 rs7513928 ENSG00000231613.1 RP5-943J3.1 6.71 5.68e-11 3.45e-08 0.33 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89639275 chr1:89788914~89790492:+ LUSC cis rs72772090 0.539 rs11750464 ENSG00000248734.2 CTD-2260A17.1 6.71 5.7e-11 3.46e-08 0.47 0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777327 chr5:96784777~96785999:+ LUSC cis rs1865760 0.865 rs2164485 ENSG00000272462.2 U91328.19 -6.71 5.71e-11 3.47e-08 -0.31 -0.3 Height; chr6:25951878 chr6:25992662~26001775:+ LUSC cis rs2337406 0.778 rs56658355 ENSG00000274576.2 IGHV2-70 -6.71 5.71e-11 3.47e-08 -0.33 -0.3 Alzheimer's disease (late onset); chr14:106662151 chr14:106770577~106771020:- LUSC cis rs228614 0.51 rs223397 ENSG00000230069.3 LRRC37A15P -6.71 5.71e-11 3.47e-08 -0.31 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102821494 chr4:102727274~102730721:- LUSC cis rs5742933 0.817 rs1233265 ENSG00000253559.1 OSGEPL1-AS1 -6.71 5.71e-11 3.47e-08 -0.36 -0.3 Ferritin levels; chr2:189796390 chr2:189762704~189765556:+ LUSC cis rs1075265 0.548 rs805448 ENSG00000233266.1 HMGB1P31 6.71 5.71e-11 3.47e-08 0.37 0.3 Chronotype;Morning vs. evening chronotype; chr2:53950055 chr2:54051334~54051760:+ LUSC cis rs8177376 1 rs8177365 ENSG00000254905.1 RP11-712L6.7 6.71 5.72e-11 3.47e-08 0.39 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126289965 chr11:126292922~126294254:- LUSC cis rs1075265 0.783 rs698858 ENSG00000233266.1 HMGB1P31 6.71 5.72e-11 3.47e-08 0.36 0.3 Chronotype;Morning vs. evening chronotype; chr2:53943333 chr2:54051334~54051760:+ LUSC cis rs7246657 0.941 rs12982333 ENSG00000276846.1 CTD-3220F14.3 6.71 5.73e-11 3.48e-08 0.46 0.3 Coronary artery calcification; chr19:37303822 chr19:37314868~37315620:- LUSC cis rs7246657 1 rs10426297 ENSG00000276846.1 CTD-3220F14.3 6.71 5.73e-11 3.48e-08 0.46 0.3 Coronary artery calcification; chr19:37307471 chr19:37314868~37315620:- LUSC cis rs7246657 1 rs1823061 ENSG00000276846.1 CTD-3220F14.3 6.71 5.73e-11 3.48e-08 0.46 0.3 Coronary artery calcification; chr19:37309724 chr19:37314868~37315620:- LUSC cis rs8062405 1 rs72793812 ENSG00000278665.1 RP11-666O2.4 6.71 5.73e-11 3.48e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28829060 chr16:28599241~28601881:- LUSC cis rs1823913 1 rs12623832 ENSG00000280083.1 RP11-317J9.1 6.71 5.73e-11 3.48e-08 0.36 0.3 Obesity-related traits; chr2:191260918 chr2:191154118~191156070:- LUSC cis rs9660180 0.967 rs6603803 ENSG00000231050.1 RP1-140A9.1 6.71 5.73e-11 3.48e-08 0.29 0.3 Body mass index; chr1:1881249 chr1:1891471~1892658:+ LUSC cis rs6142102 0.961 rs6088360 ENSG00000276073.1 RP5-1125A11.7 -6.71 5.74e-11 3.48e-08 -0.31 -0.3 Skin pigmentation; chr20:33969383 chr20:33985617~33988989:- LUSC cis rs881375 0.967 rs7864019 ENSG00000226752.6 PSMD5-AS1 -6.71 5.74e-11 3.48e-08 -0.34 -0.3 Rheumatoid arthritis; chr9:120930590 chr9:120824828~120854385:+ LUSC cis rs6782228 1 rs12635488 ENSG00000277250.1 Metazoa_SRP 6.71 5.74e-11 3.48e-08 0.37 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128633535 chr3:128673681~128674021:- LUSC cis rs8062405 1 rs62036622 ENSG00000278665.1 RP11-666O2.4 6.71 5.74e-11 3.48e-08 0.3 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28825882 chr16:28599241~28601881:- LUSC cis rs6504950 0.83 rs56175787 ENSG00000275710.1 RP11-257O5.4 6.71 5.76e-11 3.49e-08 0.37 0.3 Breast cancer; chr17:54940386 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs17817847 ENSG00000275710.1 RP11-257O5.4 6.71 5.76e-11 3.49e-08 0.37 0.3 Breast cancer; chr17:54940920 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs35097996 ENSG00000275710.1 RP11-257O5.4 6.71 5.76e-11 3.49e-08 0.37 0.3 Breast cancer; chr17:54944562 chr17:54964474~54964679:+ LUSC cis rs6504950 0.79 rs8066833 ENSG00000275710.1 RP11-257O5.4 6.71 5.76e-11 3.49e-08 0.37 0.3 Breast cancer; chr17:54948114 chr17:54964474~54964679:+ LUSC cis rs6504950 0.821 rs8066588 ENSG00000275710.1 RP11-257O5.4 6.71 5.76e-11 3.49e-08 0.37 0.3 Breast cancer; chr17:54948328 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs3087650 ENSG00000275710.1 RP11-257O5.4 6.71 5.76e-11 3.49e-08 0.37 0.3 Breast cancer; chr17:54951967 chr17:54964474~54964679:+ LUSC cis rs6504950 0.83 rs12937006 ENSG00000275710.1 RP11-257O5.4 6.71 5.76e-11 3.49e-08 0.37 0.3 Breast cancer; chr17:54953100 chr17:54964474~54964679:+ LUSC cis rs2280018 0.538 rs7404526 ENSG00000260735.1 RP11-72I8.1 -6.71 5.76e-11 3.5e-08 -0.35 -0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15035305 chr16:15094411~15109197:+ LUSC cis rs950169 0.922 rs17531523 ENSG00000259728.4 LINC00933 6.71 5.77e-11 3.5e-08 0.39 0.3 Schizophrenia; chr15:84589218 chr15:84570649~84580175:+ LUSC cis rs5753618 0.583 rs738657 ENSG00000236132.1 CTA-440B3.1 -6.71 5.77e-11 3.5e-08 -0.39 -0.3 Colorectal cancer; chr22:31445763 chr22:31816379~31817491:- LUSC cis rs7772486 0.754 rs2328707 ENSG00000235652.6 RP11-545I5.3 -6.71 5.78e-11 3.5e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145732362 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs1055212 ENSG00000235652.6 RP11-545I5.3 -6.71 5.78e-11 3.5e-08 -0.3 -0.3 Lobe attachment (rater-scored or self-reported); chr6:145737179 chr6:145799409~145886585:+ LUSC cis rs9549367 0.789 rs2287253 ENSG00000269125.1 RP11-98F14.11 6.71 5.78e-11 3.51e-08 0.37 0.3 Platelet distribution width; chr13:113236761 chr13:113165002~113165183:- LUSC cis rs2297363 1 rs3777399 ENSG00000213073.4 RP11-288H12.3 -6.71 5.78e-11 3.51e-08 -0.37 -0.3 Total cholesterol levels;Blood protein levels; chr6:160092761 chr6:160093082~160096212:+ LUSC cis rs1012068 0.96 rs12167583 ENSG00000236132.1 CTA-440B3.1 -6.7 5.79e-11 3.51e-08 -0.4 -0.3 Chronic hepatitis C infection; chr22:31873725 chr22:31816379~31817491:- LUSC cis rs7267979 1 rs6050590 ENSG00000274973.1 RP13-401N8.7 6.7 5.8e-11 3.51e-08 0.3 0.3 Liver enzyme levels (alkaline phosphatase); chr20:25404358 chr20:25845497~25845862:+ LUSC cis rs11098499 0.909 rs1546504 ENSG00000250412.1 KLHL2P1 6.7 5.8e-11 3.52e-08 0.38 0.3 Corneal astigmatism; chr4:119320024 chr4:119334329~119378233:+ LUSC cis rs11098499 0.588 rs6534149 ENSG00000245958.5 RP11-33B1.1 6.7 5.81e-11 3.52e-08 0.29 0.3 Corneal astigmatism; chr4:119638137 chr4:119454791~119552025:+ LUSC cis rs11098499 0.754 rs12506610 ENSG00000249244.1 RP11-548H18.2 6.7 5.81e-11 3.52e-08 0.37 0.3 Corneal astigmatism; chr4:119320504 chr4:119391831~119395335:- LUSC cis rs11098499 0.743 rs10003567 ENSG00000249244.1 RP11-548H18.2 6.7 5.81e-11 3.52e-08 0.37 0.3 Corneal astigmatism; chr4:119320519 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs10006259 ENSG00000249244.1 RP11-548H18.2 6.7 5.81e-11 3.52e-08 0.37 0.3 Corneal astigmatism; chr4:119320990 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs28652763 ENSG00000249244.1 RP11-548H18.2 6.7 5.81e-11 3.52e-08 0.37 0.3 Corneal astigmatism; chr4:119321157 chr4:119391831~119395335:- LUSC cis rs10262624 1 rs11767124 ENSG00000234286.1 AC006026.13 -6.7 5.81e-11 3.52e-08 -0.35 -0.3 Schizophrenia; chr7:23879461 chr7:23680195~23680786:- LUSC cis rs7250849 0.529 rs73052877 ENSG00000273837.1 LLNLR-470E3.1 -6.7 5.81e-11 3.52e-08 -0.38 -0.3 Blood protein levels; chr19:51662744 chr19:51639478~51639931:- LUSC cis rs228614 0.536 rs223418 ENSG00000230069.3 LRRC37A15P -6.7 5.82e-11 3.53e-08 -0.31 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102809336 chr4:102727274~102730721:- LUSC cis rs12554020 0.786 rs75395683 ENSG00000227603.1 RP11-165J3.6 6.7 5.82e-11 3.53e-08 0.47 0.3 Schizophrenia; chr9:93415128 chr9:93435332~93437121:- LUSC cis rs2179367 0.632 rs2341774 ENSG00000231760.4 RP11-350J20.5 6.7 5.82e-11 3.53e-08 0.42 0.3 Dupuytren's disease; chr6:149425014 chr6:149796151~149826294:- LUSC cis rs4713118 0.868 rs35069907 ENSG00000219392.1 RP1-265C24.5 -6.7 5.83e-11 3.53e-08 -0.4 -0.3 Parkinson's disease; chr6:27778913 chr6:28115628~28116551:+ LUSC cis rs875971 0.54 rs1723268 ENSG00000164669.11 INTS4P1 -6.7 5.83e-11 3.53e-08 -0.32 -0.3 Aortic root size; chr7:66008093 chr7:65141225~65234216:+ LUSC cis rs7772486 0.701 rs11155438 ENSG00000235652.6 RP11-545I5.3 6.7 5.84e-11 3.54e-08 0.29 0.3 Lobe attachment (rater-scored or self-reported); chr6:145628976 chr6:145799409~145886585:+ LUSC cis rs7772486 0.701 rs7772717 ENSG00000235652.6 RP11-545I5.3 6.7 5.84e-11 3.54e-08 0.29 0.3 Lobe attachment (rater-scored or self-reported); chr6:145633718 chr6:145799409~145886585:+ LUSC cis rs10129255 0.5 rs6576230 ENSG00000224373.3 IGHV4-59 6.7 5.85e-11 3.54e-08 0.15 0.3 Kawasaki disease; chr14:106778539 chr14:106627249~106627825:- LUSC cis rs10740039 0.842 rs7069157 ENSG00000254271.1 RP11-131N11.4 6.7 5.85e-11 3.54e-08 0.41 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60629475 chr10:60734342~60741828:+ LUSC cis rs228614 0.51 rs223405 ENSG00000230069.3 LRRC37A15P -6.7 5.85e-11 3.54e-08 -0.31 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102815894 chr4:102727274~102730721:- LUSC cis rs72772090 0.539 rs10515248 ENSG00000248734.2 CTD-2260A17.1 -6.7 5.86e-11 3.55e-08 -0.43 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776301 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs56213813 ENSG00000248734.2 CTD-2260A17.1 -6.7 5.86e-11 3.55e-08 -0.43 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776580 chr5:96784777~96785999:+ LUSC cis rs72772090 0.52 rs56325109 ENSG00000248734.2 CTD-2260A17.1 -6.7 5.86e-11 3.55e-08 -0.43 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776591 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs11747148 ENSG00000248734.2 CTD-2260A17.1 -6.7 5.86e-11 3.55e-08 -0.43 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777159 chr5:96784777~96785999:+ LUSC cis rs748404 1 rs12909095 ENSG00000249839.1 AC011330.5 -6.7 5.86e-11 3.55e-08 -0.46 -0.3 Lung cancer; chr15:43265944 chr15:43663654~43684339:- LUSC cis rs10129255 0.646 rs55995061 ENSG00000211972.2 IGHV3-66 6.7 5.86e-11 3.55e-08 0.22 0.3 Kawasaki disease; chr14:106799309 chr14:106675017~106675544:- LUSC cis rs950169 0.922 rs62028133 ENSG00000225151.9 GOLGA2P7 -6.7 5.86e-11 3.55e-08 -0.41 -0.3 Schizophrenia; chr15:84250623 chr15:84199311~84230136:- LUSC cis rs950169 0.723 rs17589320 ENSG00000225151.9 GOLGA2P7 -6.7 5.86e-11 3.55e-08 -0.41 -0.3 Schizophrenia; chr15:84251244 chr15:84199311~84230136:- LUSC cis rs6772849 0.93 rs6768344 ENSG00000242551.2 POU5F1P6 -6.7 5.87e-11 3.55e-08 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr3:128654713 chr3:128674735~128677005:- LUSC cis rs9322193 0.607 rs6557165 ENSG00000223701.3 RAET1E-AS1 -6.7 5.88e-11 3.56e-08 -0.37 -0.3 Lung cancer; chr6:149906883 chr6:149884431~149919508:+ LUSC cis rs10463554 0.892 rs6872442 ENSG00000175749.11 EIF3KP1 6.7 5.89e-11 3.56e-08 0.36 0.3 Parkinson's disease; chr5:102930818 chr5:103032376~103033031:+ LUSC cis rs10262624 0.901 rs6977550 ENSG00000234286.1 AC006026.13 -6.7 5.9e-11 3.57e-08 -0.35 -0.3 Schizophrenia; chr7:23865825 chr7:23680195~23680786:- LUSC cis rs2179367 0.959 rs652807 ENSG00000231760.4 RP11-350J20.5 -6.7 5.9e-11 3.57e-08 -0.38 -0.3 Dupuytren's disease; chr6:149416359 chr6:149796151~149826294:- LUSC cis rs228614 0.51 rs223434 ENSG00000230069.3 LRRC37A15P -6.7 5.9e-11 3.57e-08 -0.31 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799902 chr4:102727274~102730721:- LUSC cis rs2903698 0.565 rs13134862 ENSG00000250735.4 RP11-567N4.3 6.7 5.9e-11 3.57e-08 0.33 0.3 Prion diseases; chr4:75500686 chr4:75401195~75423023:+ LUSC cis rs228614 0.51 rs223443 ENSG00000230069.3 LRRC37A15P -6.7 5.9e-11 3.57e-08 -0.31 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793629 chr4:102727274~102730721:- LUSC cis rs9921338 0.961 rs12934968 ENSG00000263080.1 RP11-485G7.5 -6.7 5.91e-11 3.58e-08 -0.35 -0.3 Vein graft stenosis in coronary artery bypass grafting; chr16:11320209 chr16:11341809~11345211:- LUSC cis rs17818399 0.62 rs6739397 ENSG00000279254.1 RP11-536C12.1 -6.7 5.92e-11 3.58e-08 -0.32 -0.3 Height; chr2:46631182 chr2:46668870~46670778:+ LUSC cis rs11098499 0.954 rs6834796 ENSG00000250412.1 KLHL2P1 6.7 5.94e-11 3.59e-08 0.37 0.3 Corneal astigmatism; chr4:119493538 chr4:119334329~119378233:+ LUSC cis rs748404 0.666 rs55748552 ENSG00000249839.1 AC011330.5 -6.7 5.95e-11 3.6e-08 -0.51 -0.3 Lung cancer; chr15:43359428 chr15:43663654~43684339:- LUSC cis rs748404 0.63 rs35278805 ENSG00000249839.1 AC011330.5 -6.7 5.95e-11 3.6e-08 -0.51 -0.3 Lung cancer; chr15:43361124 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs35160541 ENSG00000249839.1 AC011330.5 -6.7 5.95e-11 3.6e-08 -0.51 -0.3 Lung cancer; chr15:43365601 chr15:43663654~43684339:- LUSC cis rs6142102 0.961 rs4911385 ENSG00000276073.1 RP5-1125A11.7 -6.7 5.96e-11 3.6e-08 -0.31 -0.3 Skin pigmentation; chr20:33970787 chr20:33985617~33988989:- LUSC cis rs228614 0.51 rs223451 ENSG00000230069.3 LRRC37A15P -6.7 5.98e-11 3.62e-08 -0.31 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791032 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223450 ENSG00000230069.3 LRRC37A15P -6.7 5.98e-11 3.62e-08 -0.31 -0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791052 chr4:102727274~102730721:- LUSC cis rs10129255 0.913 rs28861466 ENSG00000224373.3 IGHV4-59 6.7 5.99e-11 3.62e-08 0.17 0.3 Kawasaki disease; chr14:106718572 chr14:106627249~106627825:- LUSC cis rs11157436 0.958 rs61972229 ENSG00000211813.2 TRAV34 6.7 6e-11 3.63e-08 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22189754 chr14:22207522~22208129:+ LUSC cis rs875971 0.522 rs7784623 ENSG00000164669.11 INTS4P1 -6.7 6.01e-11 3.64e-08 -0.32 -0.3 Aortic root size; chr7:65930047 chr7:65141225~65234216:+ LUSC cis rs11157436 0.918 rs11157426 ENSG00000211813.2 TRAV34 6.7 6.02e-11 3.64e-08 0.32 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22153691 chr14:22207522~22208129:+ LUSC cis rs11157436 0.918 rs11157427 ENSG00000211813.2 TRAV34 6.7 6.02e-11 3.64e-08 0.32 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22154291 chr14:22207522~22208129:+ LUSC cis rs11157436 0.792 rs12433875 ENSG00000211813.2 TRAV34 6.7 6.02e-11 3.64e-08 0.32 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22154490 chr14:22207522~22208129:+ LUSC cis rs6683071 1 rs6683071 ENSG00000272750.1 RP11-378J18.8 -6.7 6.02e-11 3.64e-08 -0.37 -0.3 Cognitive performance; chr1:222750009 chr1:222658867~222661512:- LUSC cis rs7267979 0.866 rs437635 ENSG00000274973.1 RP13-401N8.7 -6.7 6.03e-11 3.64e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25476252 chr20:25845497~25845862:+ LUSC cis rs7267979 0.899 rs442834 ENSG00000274973.1 RP13-401N8.7 -6.7 6.03e-11 3.64e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25477460 chr20:25845497~25845862:+ LUSC cis rs7267979 0.932 rs417110 ENSG00000274973.1 RP13-401N8.7 -6.7 6.03e-11 3.64e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25477661 chr20:25845497~25845862:+ LUSC cis rs7267979 0.932 rs449703 ENSG00000274973.1 RP13-401N8.7 -6.7 6.03e-11 3.64e-08 -0.3 -0.3 Liver enzyme levels (alkaline phosphatase); chr20:25477923 chr20:25845497~25845862:+ LUSC cis rs113835537 0.529 rs11227515 ENSG00000255517.5 CTD-3074O7.5 -6.7 6.04e-11 3.65e-08 -0.34 -0.3 Airway imaging phenotypes; chr11:66519912 chr11:66473490~66480233:- LUSC cis rs1865760 0.566 rs3752420 ENSG00000272462.2 U91328.19 -6.7 6.06e-11 3.66e-08 -0.32 -0.3 Height; chr6:26026907 chr6:25992662~26001775:+ LUSC cis rs6142102 0.961 rs8119937 ENSG00000276073.1 RP5-1125A11.7 -6.7 6.07e-11 3.67e-08 -0.31 -0.3 Skin pigmentation; chr20:34057745 chr20:33985617~33988989:- LUSC cis rs10129255 0.536 rs10139058 ENSG00000211970.3 IGHV4-61 -6.7 6.07e-11 3.67e-08 -0.18 -0.3 Kawasaki disease; chr14:106685899 chr14:106639119~106639657:- LUSC cis rs2919917 1 rs10093127 ENSG00000254352.1 RP11-578O24.2 6.7 6.08e-11 3.67e-08 0.37 0.3 Lymphocyte counts; chr8:78686869 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs1872072 ENSG00000254352.1 RP11-578O24.2 6.7 6.08e-11 3.67e-08 0.37 0.3 Lymphocyte counts; chr8:78689185 chr8:78723796~78724136:- LUSC cis rs4950322 0.58 rs7514970 ENSG00000278811.3 LINC00624 6.7 6.08e-11 3.67e-08 0.32 0.3 Protein quantitative trait loci; chr1:147120516 chr1:147258885~147517875:- LUSC cis rs11157436 0.83 rs61972214 ENSG00000211813.2 TRAV34 6.7 6.1e-11 3.68e-08 0.32 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22152416 chr14:22207522~22208129:+ LUSC cis rs9309473 1 rs10187192 ENSG00000163016.8 ALMS1P 6.7 6.1e-11 3.68e-08 0.36 0.3 Metabolite levels; chr2:73486373 chr2:73644919~73685576:+ LUSC cis rs9309473 0.948 rs10183818 ENSG00000163016.8 ALMS1P 6.7 6.1e-11 3.68e-08 0.36 0.3 Metabolite levels; chr2:73487429 chr2:73644919~73685576:+ LUSC cis rs17711722 0.523 rs365896 ENSG00000226824.5 RP4-756H11.3 6.7 6.1e-11 3.68e-08 0.35 0.3 Calcium levels; chr7:66045710 chr7:66654538~66669855:+ LUSC cis rs6504950 0.83 rs8073158 ENSG00000275710.1 RP11-257O5.4 6.7 6.1e-11 3.68e-08 0.37 0.3 Breast cancer; chr17:54951254 chr17:54964474~54964679:+ LUSC cis rs10754283 0.967 rs4658302 ENSG00000231613.1 RP5-943J3.1 6.7 6.1e-11 3.69e-08 0.33 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89637777 chr1:89788914~89790492:+ LUSC cis rs11098499 0.754 rs12510269 ENSG00000249244.1 RP11-548H18.2 6.7 6.11e-11 3.69e-08 0.37 0.3 Corneal astigmatism; chr4:119320491 chr4:119391831~119395335:- LUSC cis rs11098499 0.954 rs10518328 ENSG00000250412.1 KLHL2P1 6.7 6.12e-11 3.7e-08 0.37 0.3 Corneal astigmatism; chr4:119480624 chr4:119334329~119378233:+ LUSC cis rs113835537 0.597 rs4576 ENSG00000255517.5 CTD-3074O7.5 -6.7 6.13e-11 3.7e-08 -0.33 -0.3 Airway imaging phenotypes; chr11:66563529 chr11:66473490~66480233:- LUSC cis rs853679 0.513 rs13437444 ENSG00000219392.1 RP1-265C24.5 -6.7 6.14e-11 3.71e-08 -0.45 -0.3 Depression; chr6:28103220 chr6:28115628~28116551:+ LUSC cis rs2948294 0.588 rs12544596 ENSG00000253893.2 FAM85B -6.7 6.15e-11 3.71e-08 -0.39 -0.3 Red cell distribution width; chr8:8258824 chr8:8167819~8226614:- LUSC cis rs732716 0.889 rs62129355 ENSG00000267769.1 CTB-50L17.9 -6.7 6.15e-11 3.71e-08 -0.31 -0.3 Mean corpuscular volume; chr19:4397037 chr19:4454014~4455286:+ LUSC cis rs12931792 0.687 rs8057425 ENSG00000183604.13 SMG1P5 6.7 6.15e-11 3.71e-08 0.33 0.3 Tonsillectomy; chr16:30171220 chr16:30267553~30335374:- LUSC cis rs9813712 0.571 rs9836814 ENSG00000228252.7 COL6A4P2 6.7 6.16e-11 3.72e-08 0.27 0.3 Response to amphetamines; chr3:130216054 chr3:130212823~130273806:+ LUSC cis rs6142102 0.625 rs1883707 ENSG00000275784.1 RP5-1125A11.6 6.7 6.16e-11 3.72e-08 0.32 0.3 Skin pigmentation; chr20:33964781 chr20:33989480~33991818:- LUSC cis rs6921919 0.583 rs3734563 ENSG00000204709.4 LINC01556 6.69 6.17e-11 3.72e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28381948 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs1591913 ENSG00000204709.4 LINC01556 6.69 6.17e-11 3.72e-08 0.38 0.3 Autism spectrum disorder or schizophrenia; chr6:28383951 chr6:28943877~28944537:+ LUSC cis rs748404 0.666 rs35326382 ENSG00000249839.1 AC011330.5 -6.69 6.18e-11 3.73e-08 -0.5 -0.3 Lung cancer; chr15:43338686 chr15:43663654~43684339:- LUSC cis rs9309473 0.95 rs6546854 ENSG00000163016.8 ALMS1P 6.69 6.18e-11 3.73e-08 0.35 0.3 Metabolite levels; chr2:73606907 chr2:73644919~73685576:+ LUSC cis rs3750965 1 rs3750965 ENSG00000260895.1 RP11-554A11.7 6.69 6.19e-11 3.73e-08 0.35 0.3 Hair color; chr11:69072692 chr11:69103493~69109094:+ LUSC cis rs11976180 1 rs2951363 ENSG00000170356.8 OR2A20P -6.69 6.19e-11 3.73e-08 -0.39 -0.3 Obesity-related traits; chr7:144057631 chr7:144250045~144252957:- LUSC cis rs2179367 0.6 rs9498356 ENSG00000231760.4 RP11-350J20.5 6.69 6.2e-11 3.74e-08 0.44 0.3 Dupuytren's disease; chr6:149443337 chr6:149796151~149826294:- LUSC cis rs13113518 0.776 rs13124436 ENSG00000223305.1 RN7SKP30 6.69 6.2e-11 3.74e-08 0.36 0.3 Height; chr4:55502504 chr4:55540502~55540835:- LUSC cis rs13113518 0.783 rs6843997 ENSG00000223305.1 RN7SKP30 6.69 6.2e-11 3.74e-08 0.36 0.3 Height; chr4:55508982 chr4:55540502~55540835:- LUSC cis rs1865760 0.865 rs4478388 ENSG00000272462.2 U91328.19 -6.69 6.21e-11 3.75e-08 -0.31 -0.3 Height; chr6:25953405 chr6:25992662~26001775:+ LUSC cis rs6142102 0.961 rs1319363 ENSG00000276073.1 RP5-1125A11.7 -6.69 6.22e-11 3.75e-08 -0.31 -0.3 Skin pigmentation; chr20:33954070 chr20:33985617~33988989:- LUSC cis rs950169 1 rs12916348 ENSG00000259728.4 LINC00933 6.69 6.22e-11 3.75e-08 0.39 0.3 Schizophrenia; chr15:84096775 chr15:84570649~84580175:+ LUSC cis rs8177376 0.953 rs4935964 ENSG00000254905.1 RP11-712L6.7 6.69 6.22e-11 3.75e-08 0.39 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126285289 chr11:126292922~126294254:- LUSC cis rs11098499 0.913 rs11098496 ENSG00000250412.1 KLHL2P1 6.69 6.24e-11 3.77e-08 0.37 0.29 Corneal astigmatism; chr4:119246311 chr4:119334329~119378233:+ LUSC cis rs11098499 0.955 rs35197422 ENSG00000250412.1 KLHL2P1 6.69 6.24e-11 3.77e-08 0.37 0.29 Corneal astigmatism; chr4:119248159 chr4:119334329~119378233:+ LUSC cis rs11098499 0.955 rs1511015 ENSG00000250412.1 KLHL2P1 6.69 6.24e-11 3.77e-08 0.37 0.29 Corneal astigmatism; chr4:119249318 chr4:119334329~119378233:+ LUSC cis rs10463554 0.853 rs2241565 ENSG00000175749.11 EIF3KP1 6.69 6.24e-11 3.77e-08 0.36 0.29 Parkinson's disease; chr5:102966233 chr5:103032376~103033031:+ LUSC cis rs6782228 0.848 rs6439140 ENSG00000277250.1 Metazoa_SRP 6.69 6.24e-11 3.77e-08 0.36 0.29 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128699917 chr3:128673681~128674021:- LUSC cis rs4713118 0.869 rs6902689 ENSG00000219392.1 RP1-265C24.5 -6.69 6.25e-11 3.77e-08 -0.37 -0.29 Parkinson's disease; chr6:27741662 chr6:28115628~28116551:+ LUSC cis rs4713118 0.824 rs7759217 ENSG00000219392.1 RP1-265C24.5 -6.69 6.26e-11 3.77e-08 -0.39 -0.29 Parkinson's disease; chr6:27762684 chr6:28115628~28116551:+ LUSC cis rs4713118 0.784 rs9468219 ENSG00000219392.1 RP1-265C24.5 -6.69 6.26e-11 3.77e-08 -0.39 -0.29 Parkinson's disease; chr6:27763976 chr6:28115628~28116551:+ LUSC cis rs6504950 0.8 rs35647022 ENSG00000275710.1 RP11-257O5.4 6.69 6.26e-11 3.78e-08 0.37 0.29 Breast cancer; chr17:54930710 chr17:54964474~54964679:+ LUSC cis rs72772090 0.539 rs10515247 ENSG00000248734.2 CTD-2260A17.1 -6.69 6.3e-11 3.79e-08 -0.43 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776022 chr5:96784777~96785999:+ LUSC cis rs7772486 0.686 rs857883 ENSG00000235652.6 RP11-545I5.3 -6.69 6.3e-11 3.79e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145648078 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs857882 ENSG00000235652.6 RP11-545I5.3 -6.69 6.3e-11 3.79e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145648580 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs857877 ENSG00000235652.6 RP11-545I5.3 -6.69 6.3e-11 3.79e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145655094 chr6:145799409~145886585:+ LUSC cis rs11089937 0.568 rs12160317 ENSG00000211638.2 IGLV8-61 -6.69 6.3e-11 3.79e-08 -0.32 -0.29 Periodontitis (PAL4Q3); chr22:22131619 chr22:22098700~22099212:+ LUSC cis rs12291225 0.585 rs12270374 ENSG00000251991.1 RNU7-49P 6.69 6.3e-11 3.79e-08 0.34 0.29 Sense of smell; chr11:14353533 chr11:14478892~14478953:+ LUSC cis rs2404602 0.735 rs2454454 ENSG00000259422.1 RP11-593F23.1 -6.69 6.33e-11 3.81e-08 -0.34 -0.29 Blood metabolite levels; chr15:76531306 chr15:76174891~76181486:- LUSC cis rs7246657 0.943 rs10426666 ENSG00000276846.1 CTD-3220F14.3 6.69 6.34e-11 3.81e-08 0.45 0.29 Coronary artery calcification; chr19:37337612 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs4969487 ENSG00000276846.1 CTD-3220F14.3 6.69 6.34e-11 3.81e-08 0.45 0.29 Coronary artery calcification; chr19:37340137 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs28402338 ENSG00000276846.1 CTD-3220F14.3 6.69 6.34e-11 3.81e-08 0.45 0.29 Coronary artery calcification; chr19:37343021 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs10417503 ENSG00000276846.1 CTD-3220F14.3 6.69 6.34e-11 3.81e-08 0.45 0.29 Coronary artery calcification; chr19:37351833 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs10403613 ENSG00000276846.1 CTD-3220F14.3 6.69 6.34e-11 3.81e-08 0.45 0.29 Coronary artery calcification; chr19:37353404 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs9304566 ENSG00000276846.1 CTD-3220F14.3 6.69 6.34e-11 3.81e-08 0.45 0.29 Coronary artery calcification; chr19:37354602 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs10422967 ENSG00000276846.1 CTD-3220F14.3 6.69 6.34e-11 3.81e-08 0.45 0.29 Coronary artery calcification; chr19:37359235 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs4417644 ENSG00000276846.1 CTD-3220F14.3 6.69 6.34e-11 3.81e-08 0.45 0.29 Coronary artery calcification; chr19:37361570 chr19:37314868~37315620:- LUSC cis rs6772849 0.93 rs4467479 ENSG00000242551.2 POU5F1P6 -6.69 6.35e-11 3.82e-08 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128650212 chr3:128674735~128677005:- LUSC cis rs6772849 0.93 rs12630379 ENSG00000242551.2 POU5F1P6 -6.69 6.35e-11 3.82e-08 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128651361 chr3:128674735~128677005:- LUSC cis rs950169 0.922 rs17531523 ENSG00000225151.9 GOLGA2P7 -6.69 6.36e-11 3.83e-08 -0.42 -0.29 Schizophrenia; chr15:84589218 chr15:84199311~84230136:- LUSC cis rs950169 0.922 rs11635505 ENSG00000259728.4 LINC00933 -6.69 6.37e-11 3.83e-08 -0.37 -0.29 Schizophrenia; chr15:84553803 chr15:84570649~84580175:+ LUSC cis rs7955901 0.691 rs36071486 ENSG00000257265.1 CTD-2021H9.1 6.69 6.37e-11 3.83e-08 0.33 0.29 Type 2 diabetes; chr12:71094051 chr12:71007773~71032083:- LUSC cis rs1012068 0.92 rs5994443 ENSG00000236132.1 CTA-440B3.1 -6.69 6.38e-11 3.84e-08 -0.39 -0.29 Chronic hepatitis C infection; chr22:31879367 chr22:31816379~31817491:- LUSC cis rs13113518 0.812 rs13140173 ENSG00000223305.1 RN7SKP30 6.69 6.38e-11 3.84e-08 0.36 0.29 Height; chr4:55527164 chr4:55540502~55540835:- LUSC cis rs875971 0.964 rs778721 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66380410 chr7:66493706~66495474:+ LUSC cis rs875971 0.929 rs778712 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66384991 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs778710 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66389847 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs778708 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66391332 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs778706 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66395437 chr7:66493706~66495474:+ LUSC cis rs875971 0.895 rs778700 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66401463 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs778699 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66403303 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs778696 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66405826 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs778694 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66406571 chr7:66493706~66495474:+ LUSC cis rs875971 0.929 rs778692 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66407462 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs4718343 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66409301 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs4718344 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66409394 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1968225 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66409786 chr7:66493706~66495474:+ LUSC cis rs875971 0.737 rs7803424 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66415618 chr7:66493706~66495474:+ LUSC cis rs875971 0.83 rs7799834 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66415707 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs6460295 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66417741 chr7:66493706~66495474:+ LUSC cis rs875971 0.964 rs6978721 ENSG00000237310.1 GS1-124K5.4 6.69 6.38e-11 3.84e-08 0.3 0.29 Aortic root size; chr7:66418217 chr7:66493706~66495474:+ LUSC cis rs6142102 0.923 rs6057961 ENSG00000276073.1 RP5-1125A11.7 -6.69 6.39e-11 3.84e-08 -0.31 -0.29 Skin pigmentation; chr20:33986005 chr20:33985617~33988989:- LUSC cis rs1075265 0.749 rs2357693 ENSG00000233266.1 HMGB1P31 6.69 6.4e-11 3.84e-08 0.37 0.29 Chronotype;Morning vs. evening chronotype; chr2:53735699 chr2:54051334~54051760:+ LUSC cis rs9309473 1 rs7576245 ENSG00000163016.8 ALMS1P 6.69 6.4e-11 3.85e-08 0.36 0.29 Metabolite levels; chr2:73602551 chr2:73644919~73685576:+ LUSC cis rs3747113 1 rs34949904 ENSG00000128262.7 POM121L9P -6.69 6.41e-11 3.85e-08 -0.31 -0.29 Gut microbiome composition (summer); chr22:24299330 chr22:24251828~24265525:+ LUSC cis rs11098499 0.955 rs6815725 ENSG00000250412.1 KLHL2P1 6.69 6.42e-11 3.86e-08 0.37 0.29 Corneal astigmatism; chr4:119237255 chr4:119334329~119378233:+ LUSC cis rs11098499 0.955 rs1551 ENSG00000250412.1 KLHL2P1 6.69 6.42e-11 3.86e-08 0.37 0.29 Corneal astigmatism; chr4:119237345 chr4:119334329~119378233:+ LUSC cis rs172166 0.694 rs203893 ENSG00000216901.1 AL022393.7 6.69 6.42e-11 3.86e-08 0.35 0.29 Cardiac Troponin-T levels; chr6:28094288 chr6:28176188~28176674:+ LUSC cis rs1322639 0.531 rs11751421 ENSG00000261039.2 RP11-417E7.2 6.69 6.44e-11 3.87e-08 0.34 0.29 Pulse pressure; chr6:169174898 chr6:169175304~169182740:- LUSC cis rs881375 1 rs6478484 ENSG00000226752.6 PSMD5-AS1 -6.69 6.44e-11 3.87e-08 -0.34 -0.29 Rheumatoid arthritis; chr9:120890102 chr9:120824828~120854385:+ LUSC cis rs2188561 0.697 rs4730258 ENSG00000241764.3 AC002467.7 6.69 6.44e-11 3.87e-08 0.38 0.29 Alcohol consumption; chr7:107755787 chr7:107742817~107744581:- LUSC cis rs7772486 0.594 rs6901864 ENSG00000235652.6 RP11-545I5.3 -6.69 6.46e-11 3.88e-08 -0.3 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145701914 chr6:145799409~145886585:+ LUSC cis rs904251 0.772 rs756202 ENSG00000204110.6 RP1-153P14.8 -6.69 6.48e-11 3.89e-08 -0.3 -0.29 Cognitive performance; chr6:37492574 chr6:37507348~37535616:+ LUSC cis rs4713118 0.869 rs6914924 ENSG00000219392.1 RP1-265C24.5 -6.69 6.48e-11 3.89e-08 -0.38 -0.29 Parkinson's disease; chr6:27743751 chr6:28115628~28116551:+ LUSC cis rs11098499 0.754 rs878372 ENSG00000249244.1 RP11-548H18.2 6.69 6.48e-11 3.89e-08 0.37 0.29 Corneal astigmatism; chr4:119317625 chr4:119391831~119395335:- LUSC cis rs10740039 0.883 rs1470237 ENSG00000254271.1 RP11-131N11.4 6.69 6.48e-11 3.89e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60653381 chr10:60734342~60741828:+ LUSC cis rs4713118 0.955 rs9380010 ENSG00000219392.1 RP1-265C24.5 -6.69 6.48e-11 3.89e-08 -0.39 -0.29 Parkinson's disease; chr6:27715793 chr6:28115628~28116551:+ LUSC cis rs4713118 0.955 rs9368528 ENSG00000219392.1 RP1-265C24.5 -6.69 6.48e-11 3.89e-08 -0.39 -0.29 Parkinson's disease; chr6:27716019 chr6:28115628~28116551:+ LUSC cis rs4713118 0.955 rs9380011 ENSG00000219392.1 RP1-265C24.5 -6.69 6.48e-11 3.89e-08 -0.39 -0.29 Parkinson's disease; chr6:27716145 chr6:28115628~28116551:+ LUSC cis rs4713118 0.955 rs9380012 ENSG00000219392.1 RP1-265C24.5 -6.69 6.48e-11 3.89e-08 -0.39 -0.29 Parkinson's disease; chr6:27716875 chr6:28115628~28116551:+ LUSC cis rs2404602 0.647 rs2404600 ENSG00000259422.1 RP11-593F23.1 -6.69 6.49e-11 3.89e-08 -0.36 -0.29 Blood metabolite levels; chr15:76881216 chr15:76174891~76181486:- LUSC cis rs13113518 0.783 rs12508367 ENSG00000223305.1 RN7SKP30 6.69 6.49e-11 3.9e-08 0.36 0.29 Height; chr4:55509442 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs2272073 ENSG00000223305.1 RN7SKP30 6.69 6.49e-11 3.9e-08 0.36 0.29 Height; chr4:55510177 chr4:55540502~55540835:- LUSC cis rs9921338 0.887 rs13330151 ENSG00000263080.1 RP11-485G7.5 6.69 6.54e-11 3.92e-08 0.37 0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11308542 chr16:11341809~11345211:- LUSC cis rs11690935 1 rs6721680 ENSG00000228389.1 AC068039.4 -6.69 6.55e-11 3.93e-08 -0.34 -0.29 Schizophrenia; chr2:171687403 chr2:171773482~171775844:+ LUSC cis rs10740039 0.883 rs10994468 ENSG00000254271.1 RP11-131N11.4 6.69 6.55e-11 3.93e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60666533 chr10:60734342~60741828:+ LUSC cis rs9322193 0.884 rs1108889 ENSG00000268592.3 RAET1E-AS1 6.69 6.56e-11 3.93e-08 0.38 0.29 Lung cancer; chr6:149845433 chr6:149863494~149919507:+ LUSC cis rs8062405 0.755 rs1074631 ENSG00000278665.1 RP11-666O2.4 -6.68 6.56e-11 3.94e-08 -0.3 -0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28542787 chr16:28599241~28601881:- LUSC cis rs8177376 1 rs73017350 ENSG00000254905.1 RP11-712L6.7 6.68 6.57e-11 3.94e-08 0.39 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126246064 chr11:126292922~126294254:- LUSC cis rs7487637 0.529 rs11168245 ENSG00000276691.1 RP5-1057I20.5 6.68 6.57e-11 3.94e-08 0.35 0.29 Mononucleosis; chr12:47810716 chr12:47788426~47788971:+ LUSC cis rs113835537 0.529 rs17496250 ENSG00000255517.5 CTD-3074O7.5 -6.68 6.57e-11 3.94e-08 -0.35 -0.29 Airway imaging phenotypes; chr11:66503303 chr11:66473490~66480233:- LUSC cis rs227275 0.525 rs11097796 ENSG00000230069.3 LRRC37A15P -6.68 6.57e-11 3.94e-08 -0.31 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:103002401 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs11097797 ENSG00000230069.3 LRRC37A15P -6.68 6.57e-11 3.94e-08 -0.31 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:103002507 chr4:102727274~102730721:- LUSC cis rs10129255 0.957 rs8009073 ENSG00000224373.3 IGHV4-59 6.68 6.58e-11 3.94e-08 0.17 0.29 Kawasaki disease; chr14:106777278 chr14:106627249~106627825:- LUSC cis rs1075265 0.62 rs10192626 ENSG00000233266.1 HMGB1P31 6.68 6.59e-11 3.95e-08 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:53760885 chr2:54051334~54051760:+ LUSC cis rs10129255 0.5 rs8014529 ENSG00000224373.3 IGHV4-59 6.68 6.59e-11 3.95e-08 0.15 0.29 Kawasaki disease; chr14:106784065 chr14:106627249~106627825:- LUSC cis rs2179367 0.881 rs2744432 ENSG00000231760.4 RP11-350J20.5 -6.68 6.59e-11 3.95e-08 -0.39 -0.29 Dupuytren's disease; chr6:149422735 chr6:149796151~149826294:- LUSC cis rs801193 1 rs13239306 ENSG00000224316.1 RP11-479O9.2 -6.68 6.6e-11 3.95e-08 -0.28 -0.29 Aortic root size; chr7:66671030 chr7:65773620~65802067:+ LUSC cis rs10800713 0.607 rs6682828 ENSG00000260088.1 RP11-92G12.3 -6.68 6.6e-11 3.96e-08 -0.37 -0.29 Tandem gait; chr1:200537968 chr1:200669507~200694250:+ LUSC cis rs7267979 1 rs11087520 ENSG00000274973.1 RP13-401N8.7 -6.68 6.61e-11 3.96e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25456191 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs397119 ENSG00000274973.1 RP13-401N8.7 -6.68 6.61e-11 3.96e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25459551 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6132835 ENSG00000274973.1 RP13-401N8.7 -6.68 6.61e-11 3.96e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25454031 chr20:25845497~25845862:+ LUSC cis rs8177376 1 rs674218 ENSG00000254905.1 RP11-712L6.7 6.68 6.62e-11 3.97e-08 0.39 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126239165 chr11:126292922~126294254:- LUSC cis rs10740039 0.883 rs7902632 ENSG00000254271.1 RP11-131N11.4 6.68 6.63e-11 3.97e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60643811 chr10:60734342~60741828:+ LUSC cis rs8059260 0.736 rs7192695 ENSG00000274038.1 RP11-66H6.4 -6.68 6.64e-11 3.98e-08 -0.48 -0.29 Alcohol consumption over the past year; chr16:11005395 chr16:11056556~11057034:+ LUSC cis rs9549367 0.826 rs35306827 ENSG00000269125.1 RP11-98F14.11 -6.68 6.64e-11 3.98e-08 -0.38 -0.29 Platelet distribution width; chr13:113214731 chr13:113165002~113165183:- LUSC cis rs10170846 0.893 rs1447108 ENSG00000261428.2 RP11-16P6.1 6.68 6.66e-11 3.99e-08 0.35 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222677512 chr2:222566899~222569719:- LUSC cis rs10170846 0.893 rs12614976 ENSG00000261428.2 RP11-16P6.1 6.68 6.66e-11 3.99e-08 0.35 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222678177 chr2:222566899~222569719:- LUSC cis rs6570726 0.791 rs1509214 ENSG00000235652.6 RP11-545I5.3 -6.68 6.67e-11 4e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145463470 chr6:145799409~145886585:+ LUSC cis rs7267979 1 rs398036 ENSG00000274973.1 RP13-401N8.7 -6.68 6.69e-11 4e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25459214 chr20:25845497~25845862:+ LUSC cis rs17818399 0.574 rs6544907 ENSG00000279254.1 RP11-536C12.1 -6.68 6.69e-11 4.01e-08 -0.33 -0.29 Height; chr2:46641180 chr2:46668870~46670778:+ LUSC cis rs10754283 0.84 rs6428560 ENSG00000231613.1 RP5-943J3.1 6.68 6.69e-11 4.01e-08 0.33 0.29 Amyotrophic lateral sclerosis (sporadic); chr1:89636903 chr1:89788914~89790492:+ LUSC cis rs7772486 0.79 rs2253768 ENSG00000235652.6 RP11-545I5.3 6.68 6.71e-11 4.02e-08 0.29 0.29 Lobe attachment (rater-scored or self-reported); chr6:145878786 chr6:145799409~145886585:+ LUSC cis rs17023223 0.537 rs10802075 ENSG00000231365.4 RP11-418J17.1 -6.68 6.71e-11 4.02e-08 -0.38 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119084604 chr1:119140396~119275973:+ LUSC cis rs10740039 0.883 rs7476720 ENSG00000254271.1 RP11-131N11.4 6.68 6.72e-11 4.02e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60650610 chr10:60734342~60741828:+ LUSC cis rs1075265 0.756 rs805367 ENSG00000233266.1 HMGB1P31 6.68 6.73e-11 4.03e-08 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:53943956 chr2:54051334~54051760:+ LUSC cis rs1075265 0.783 rs718872 ENSG00000233266.1 HMGB1P31 6.68 6.73e-11 4.03e-08 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:53946569 chr2:54051334~54051760:+ LUSC cis rs11098499 1 rs11098500 ENSG00000250412.1 KLHL2P1 6.68 6.73e-11 4.03e-08 0.37 0.29 Corneal astigmatism; chr4:119298084 chr4:119334329~119378233:+ LUSC cis rs10129255 0.957 rs6576233 ENSG00000211972.2 IGHV3-66 6.68 6.74e-11 4.03e-08 0.22 0.29 Kawasaki disease; chr14:106787239 chr14:106675017~106675544:- LUSC cis rs3747113 0.954 rs2298378 ENSG00000128262.7 POM121L9P -6.68 6.76e-11 4.04e-08 -0.31 -0.29 Gut microbiome composition (summer); chr22:24323637 chr22:24251828~24265525:+ LUSC cis rs13113518 0.812 rs12500601 ENSG00000223305.1 RN7SKP30 6.68 6.76e-11 4.05e-08 0.36 0.29 Height; chr4:55451489 chr4:55540502~55540835:- LUSC cis rs2665103 0.687 rs11633000 ENSG00000278603.1 RP13-608F4.5 6.68 6.77e-11 4.05e-08 0.35 0.29 Intelligence (multi-trait analysis); chr15:82269320 chr15:82472203~82472426:+ LUSC cis rs8177376 0.861 rs4340064 ENSG00000254905.1 RP11-712L6.7 6.68 6.79e-11 4.06e-08 0.39 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126242165 chr11:126292922~126294254:- LUSC cis rs1865760 0.532 rs2794719 ENSG00000272462.2 U91328.19 -6.68 6.79e-11 4.07e-08 -0.32 -0.29 Height; chr6:26088662 chr6:25992662~26001775:+ LUSC cis rs875971 0.964 rs778735 ENSG00000237310.1 GS1-124K5.4 6.68 6.81e-11 4.07e-08 0.3 0.29 Aortic root size; chr7:66349822 chr7:66493706~66495474:+ LUSC cis rs11157436 0.958 rs17183301 ENSG00000211813.2 TRAV34 6.68 6.82e-11 4.08e-08 0.33 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22190003 chr14:22207522~22208129:+ LUSC cis rs11690935 0.959 rs11897196 ENSG00000228389.1 AC068039.4 6.68 6.84e-11 4.09e-08 0.34 0.29 Schizophrenia; chr2:171729085 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs10207085 ENSG00000228389.1 AC068039.4 6.68 6.84e-11 4.09e-08 0.34 0.29 Schizophrenia; chr2:171729375 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs7604918 ENSG00000228389.1 AC068039.4 6.68 6.84e-11 4.09e-08 0.34 0.29 Schizophrenia; chr2:171731584 chr2:171773482~171775844:+ LUSC cis rs881375 0.933 rs7031096 ENSG00000226752.6 PSMD5-AS1 -6.68 6.84e-11 4.09e-08 -0.34 -0.29 Rheumatoid arthritis; chr9:120932664 chr9:120824828~120854385:+ LUSC cis rs881375 0.967 rs10739580 ENSG00000226752.6 PSMD5-AS1 -6.68 6.84e-11 4.09e-08 -0.34 -0.29 Rheumatoid arthritis; chr9:120933004 chr9:120824828~120854385:+ LUSC cis rs11098499 0.909 rs1546502 ENSG00000250412.1 KLHL2P1 6.68 6.86e-11 4.1e-08 0.38 0.29 Corneal astigmatism; chr4:119314743 chr4:119334329~119378233:+ LUSC cis rs17711722 0.503 rs453835 ENSG00000236529.1 RP13-254B10.1 -6.68 6.87e-11 4.11e-08 -0.31 -0.29 Calcium levels; chr7:66046172 chr7:65840212~65840596:+ LUSC cis rs9309473 1 rs11674602 ENSG00000163016.8 ALMS1P 6.68 6.88e-11 4.11e-08 0.36 0.29 Metabolite levels; chr2:73496058 chr2:73644919~73685576:+ LUSC cis rs4950322 0.518 rs56151278 ENSG00000278811.3 LINC00624 6.68 6.88e-11 4.12e-08 0.32 0.29 Protein quantitative trait loci; chr1:147117421 chr1:147258885~147517875:- LUSC cis rs4950322 0.518 rs4950306 ENSG00000278811.3 LINC00624 6.68 6.88e-11 4.12e-08 0.32 0.29 Protein quantitative trait loci; chr1:147117838 chr1:147258885~147517875:- LUSC cis rs71403859 0.803 rs10500562 ENSG00000260886.1 TAT-AS1 6.68 6.89e-11 4.12e-08 0.47 0.29 Post bronchodilator FEV1; chr16:71593828 chr16:71565789~71578187:+ LUSC cis rs950169 0.881 rs72750843 ENSG00000259728.4 LINC00933 6.68 6.89e-11 4.12e-08 0.4 0.29 Schizophrenia; chr15:84592552 chr15:84570649~84580175:+ LUSC cis rs2408955 0.504 rs11168441 ENSG00000240399.1 RP1-228P16.1 6.68 6.89e-11 4.12e-08 0.3 0.29 Glycated hemoglobin levels; chr12:48182271 chr12:48054813~48055591:- LUSC cis rs7267979 1 rs453329 ENSG00000274973.1 RP13-401N8.7 -6.68 6.9e-11 4.12e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25459957 chr20:25845497~25845862:+ LUSC cis rs8072100 0.935 rs8070759 ENSG00000228782.6 CTD-2026D20.3 -6.68 6.9e-11 4.12e-08 -0.28 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47561394 chr17:47450568~47492492:- LUSC cis rs8072100 0.764 rs2644349 ENSG00000228782.6 CTD-2026D20.3 -6.68 6.9e-11 4.13e-08 -0.28 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47564377 chr17:47450568~47492492:- LUSC cis rs11098499 0.78 rs10013652 ENSG00000249244.1 RP11-548H18.2 6.68 6.93e-11 4.14e-08 0.37 0.29 Corneal astigmatism; chr4:119371101 chr4:119391831~119395335:- LUSC cis rs881375 0.967 rs2239658 ENSG00000226752.6 PSMD5-AS1 -6.68 6.93e-11 4.14e-08 -0.34 -0.29 Rheumatoid arthritis; chr9:120909559 chr9:120824828~120854385:+ LUSC cis rs10740039 0.883 rs1837946 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60633676 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs1837945 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60633757 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs7089287 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60634006 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs7089720 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60634063 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs7093573 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60634611 chr10:60734342~60741828:+ LUSC cis rs10740039 0.804 rs7093882 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60634863 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs7097818 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60635106 chr10:60734342~60741828:+ LUSC cis rs10740039 0.842 rs2119913 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60635631 chr10:60734342~60741828:+ LUSC cis rs10740039 0.586 rs7068462 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60636240 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs7069814 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60637001 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs10740037 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60637747 chr10:60734342~60741828:+ LUSC cis rs10740039 0.804 rs10761531 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60638177 chr10:60734342~60741828:+ LUSC cis rs10740039 0.846 rs2165690 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60639609 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs2119912 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60639754 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs2119911 ENSG00000254271.1 RP11-131N11.4 6.68 6.94e-11 4.14e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60639808 chr10:60734342~60741828:+ LUSC cis rs2665103 0.61 rs56398167 ENSG00000276710.3 CSPG4P8 -6.68 6.95e-11 4.15e-08 -0.3 -0.29 Intelligence (multi-trait analysis); chr15:82237482 chr15:82459472~82477258:+ LUSC cis rs11098499 0.754 rs9991959 ENSG00000249244.1 RP11-548H18.2 -6.68 6.96e-11 4.15e-08 -0.36 -0.29 Corneal astigmatism; chr4:119332618 chr4:119391831~119395335:- LUSC cis rs35160687 0.623 rs2276625 ENSG00000273080.1 RP11-301O19.1 6.68 6.98e-11 4.17e-08 0.28 0.29 Night sleep phenotypes; chr2:86254712 chr2:86195590~86196049:+ LUSC cis rs6772849 0.93 rs55987729 ENSG00000242551.2 POU5F1P6 -6.68 6.98e-11 4.17e-08 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128621267 chr3:128674735~128677005:- LUSC cis rs10262624 1 rs13244265 ENSG00000234286.1 AC006026.13 -6.67 6.98e-11 4.17e-08 -0.34 -0.29 Schizophrenia; chr7:23878284 chr7:23680195~23680786:- LUSC cis rs10262624 0.967 rs35988560 ENSG00000234286.1 AC006026.13 -6.67 6.98e-11 4.17e-08 -0.34 -0.29 Schizophrenia; chr7:23878561 chr7:23680195~23680786:- LUSC cis rs867371 0.964 rs7169961 ENSG00000255769.6 GOLGA2P10 -6.67 6.99e-11 4.17e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82186588 chr15:82472993~82513950:- LUSC cis rs867371 1 rs6495643 ENSG00000255769.6 GOLGA2P10 -6.67 6.99e-11 4.17e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82186913 chr15:82472993~82513950:- LUSC cis rs9903692 0.954 rs7212202 ENSG00000278765.1 RP5-890E16.5 6.67 6.99e-11 4.18e-08 0.36 0.29 Pulse pressure; chr17:48055361 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs34750858 ENSG00000278765.1 RP5-890E16.5 6.67 6.99e-11 4.18e-08 0.36 0.29 Pulse pressure; chr17:48055575 chr17:48066704~48067293:- LUSC cis rs10129255 0.5 rs2105989 ENSG00000224373.3 IGHV4-59 6.67 7e-11 4.18e-08 0.14 0.29 Kawasaki disease; chr14:106682199 chr14:106627249~106627825:- LUSC cis rs9341808 0.527 rs2505946 ENSG00000272129.1 RP11-250B2.6 6.67 7.02e-11 4.19e-08 0.36 0.29 Sitting height ratio; chr6:80100966 chr6:80355424~80356859:+ LUSC cis rs6142102 0.961 rs4911390 ENSG00000276073.1 RP5-1125A11.7 -6.67 7.02e-11 4.19e-08 -0.31 -0.29 Skin pigmentation; chr20:33977401 chr20:33985617~33988989:- LUSC cis rs11089937 0.553 rs35336247 ENSG00000211638.2 IGLV8-61 -6.67 7.03e-11 4.2e-08 -0.32 -0.29 Periodontitis (PAL4Q3); chr22:22131593 chr22:22098700~22099212:+ LUSC cis rs11089937 0.553 rs34088081 ENSG00000211638.2 IGLV8-61 -6.67 7.03e-11 4.2e-08 -0.32 -0.29 Periodontitis (PAL4Q3); chr22:22131601 chr22:22098700~22099212:+ LUSC cis rs10129255 0.5 rs12101190 ENSG00000224373.3 IGHV4-59 6.67 7.04e-11 4.2e-08 0.15 0.29 Kawasaki disease; chr14:106784149 chr14:106627249~106627825:- LUSC cis rs10129255 0.518 rs8004895 ENSG00000224373.3 IGHV4-59 6.67 7.04e-11 4.2e-08 0.15 0.29 Kawasaki disease; chr14:106785139 chr14:106627249~106627825:- LUSC cis rs228614 0.51 rs223445 ENSG00000230069.3 LRRC37A15P -6.67 7.04e-11 4.2e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793337 chr4:102727274~102730721:- LUSC cis rs10262624 1 rs17347692 ENSG00000234286.1 AC006026.13 -6.67 7.05e-11 4.2e-08 -0.34 -0.29 Schizophrenia; chr7:23878748 chr7:23680195~23680786:- LUSC cis rs10129255 0.5 rs988134 ENSG00000224373.3 IGHV4-59 6.67 7.06e-11 4.21e-08 0.15 0.29 Kawasaki disease; chr14:106776698 chr14:106627249~106627825:- LUSC cis rs10129255 0.5 rs988133 ENSG00000224373.3 IGHV4-59 6.67 7.06e-11 4.21e-08 0.15 0.29 Kawasaki disease; chr14:106776724 chr14:106627249~106627825:- LUSC cis rs17507216 0.588 rs28864981 ENSG00000255769.6 GOLGA2P10 -6.67 7.06e-11 4.21e-08 -0.44 -0.29 Excessive daytime sleepiness; chr15:82695420 chr15:82472993~82513950:- LUSC cis rs9903692 0.954 rs12941295 ENSG00000278765.1 RP5-890E16.5 -6.67 7.06e-11 4.21e-08 -0.35 -0.29 Pulse pressure; chr17:48110825 chr17:48066704~48067293:- LUSC cis rs6496044 1 rs6496044 ENSG00000202081.1 RNU6-1280P 6.67 7.07e-11 4.21e-08 0.33 0.29 Interstitial lung disease; chr15:85524075 chr15:85651522~85651628:- LUSC cis rs10740039 0.883 rs7088404 ENSG00000254271.1 RP11-131N11.4 6.67 7.07e-11 4.22e-08 0.41 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60633320 chr10:60734342~60741828:+ LUSC cis rs4604732 0.536 rs12058821 ENSG00000227135.1 GCSAML-AS1 -6.67 7.08e-11 4.22e-08 -0.45 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247486349 chr1:247524679~247526752:- LUSC cis rs4604732 0.536 rs10925056 ENSG00000227135.1 GCSAML-AS1 -6.67 7.08e-11 4.22e-08 -0.45 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247487170 chr1:247524679~247526752:- LUSC cis rs11098499 0.739 rs10031033 ENSG00000249244.1 RP11-548H18.2 6.67 7.09e-11 4.23e-08 0.35 0.29 Corneal astigmatism; chr4:119230297 chr4:119391831~119395335:- LUSC cis rs10262624 1 rs10257777 ENSG00000234286.1 AC006026.13 -6.67 7.1e-11 4.23e-08 -0.34 -0.29 Schizophrenia; chr7:23871362 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs2106748 ENSG00000234286.1 AC006026.13 -6.67 7.1e-11 4.23e-08 -0.34 -0.29 Schizophrenia; chr7:23871694 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs2106747 ENSG00000234286.1 AC006026.13 -6.67 7.1e-11 4.23e-08 -0.34 -0.29 Schizophrenia; chr7:23871880 chr7:23680195~23680786:- LUSC cis rs13113518 0.812 rs6849474 ENSG00000223305.1 RN7SKP30 6.67 7.11e-11 4.24e-08 0.36 0.29 Height; chr4:55452295 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs4864996 ENSG00000223305.1 RN7SKP30 6.67 7.11e-11 4.24e-08 0.36 0.29 Height; chr4:55452921 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs2412648 ENSG00000223305.1 RN7SKP30 6.67 7.11e-11 4.24e-08 0.36 0.29 Height; chr4:55454900 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs12512737 ENSG00000223305.1 RN7SKP30 6.67 7.11e-11 4.24e-08 0.36 0.29 Height; chr4:55454938 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs13125984 ENSG00000223305.1 RN7SKP30 6.67 7.11e-11 4.24e-08 0.36 0.29 Height; chr4:55455102 chr4:55540502~55540835:- LUSC cis rs10463554 0.892 rs62362519 ENSG00000175749.11 EIF3KP1 6.67 7.12e-11 4.24e-08 0.35 0.29 Parkinson's disease; chr5:102965759 chr5:103032376~103033031:+ LUSC cis rs11089937 0.651 rs6001216 ENSG00000211639.2 IGLV4-60 6.67 7.13e-11 4.25e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22183755 chr22:22162199~22162681:+ LUSC cis rs11089937 0.651 rs6001217 ENSG00000211639.2 IGLV4-60 6.67 7.13e-11 4.25e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22183804 chr22:22162199~22162681:+ LUSC cis rs17023223 0.537 rs17023185 ENSG00000231365.4 RP11-418J17.1 -6.67 7.13e-11 4.25e-08 -0.38 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119068164 chr1:119140396~119275973:+ LUSC cis rs7267979 1 rs2424712 ENSG00000274973.1 RP13-401N8.7 -6.67 7.13e-11 4.25e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25436306 chr20:25845497~25845862:+ LUSC cis rs1012068 0.921 rs5994442 ENSG00000236132.1 CTA-440B3.1 -6.67 7.13e-11 4.25e-08 -0.4 -0.29 Chronic hepatitis C infection; chr22:31875946 chr22:31816379~31817491:- LUSC cis rs2665103 0.589 rs3858953 ENSG00000276710.3 CSPG4P8 -6.67 7.13e-11 4.25e-08 -0.3 -0.29 Intelligence (multi-trait analysis); chr15:82238049 chr15:82459472~82477258:+ LUSC cis rs10246939 0.579 rs12703413 ENSG00000228775.6 WEE2-AS1 -6.67 7.15e-11 4.26e-08 -0.35 -0.29 Bitter taste perception; chr7:141847047 chr7:141704338~141738346:- LUSC cis rs7487637 0.529 rs56389811 ENSG00000276691.1 RP5-1057I20.5 6.67 7.15e-11 4.26e-08 0.37 0.29 Mononucleosis; chr12:47811575 chr12:47788426~47788971:+ LUSC cis rs75422866 0.867 rs73104138 ENSG00000274902.1 RP1-197B17.4 6.67 7.15e-11 4.26e-08 0.77 0.29 Pneumonia; chr12:47692302 chr12:47731908~47732351:+ LUSC cis rs75422866 0.717 rs73104143 ENSG00000274902.1 RP1-197B17.4 6.67 7.15e-11 4.26e-08 0.77 0.29 Pneumonia; chr12:47693449 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73104144 ENSG00000274902.1 RP1-197B17.4 6.67 7.15e-11 4.26e-08 0.77 0.29 Pneumonia; chr12:47694390 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73104148 ENSG00000274902.1 RP1-197B17.4 6.67 7.15e-11 4.26e-08 0.77 0.29 Pneumonia; chr12:47696732 chr12:47731908~47732351:+ LUSC cis rs9309711 0.623 rs4641971 ENSG00000225234.1 TRAPPC12-AS1 6.67 7.15e-11 4.26e-08 0.34 0.29 Neurofibrillary tangles; chr2:3478086 chr2:3481242~3482409:- LUSC cis rs9322193 0.962 rs2065664 ENSG00000268592.3 RAET1E-AS1 6.67 7.16e-11 4.26e-08 0.36 0.29 Lung cancer; chr6:149762485 chr6:149863494~149919507:+ LUSC cis rs875971 0.651 rs313829 ENSG00000226824.5 RP4-756H11.3 6.67 7.16e-11 4.27e-08 0.37 0.29 Aortic root size; chr7:66087510 chr7:66654538~66669855:+ LUSC cis rs9549367 0.789 rs71446682 ENSG00000269125.1 RP11-98F14.11 -6.67 7.17e-11 4.27e-08 -0.36 -0.29 Platelet distribution width; chr13:113240594 chr13:113165002~113165183:- LUSC cis rs13113518 0.812 rs4865003 ENSG00000223305.1 RN7SKP30 6.67 7.17e-11 4.27e-08 0.36 0.29 Height; chr4:55514802 chr4:55540502~55540835:- LUSC cis rs875971 1 rs6956179 ENSG00000237310.1 GS1-124K5.4 -6.67 7.18e-11 4.27e-08 -0.31 -0.29 Aortic root size; chr7:66341672 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs10263935 ENSG00000224316.1 RP11-479O9.2 6.67 7.18e-11 4.27e-08 0.28 0.29 Aortic root size; chr7:66631041 chr7:65773620~65802067:+ LUSC cis rs950169 0.922 rs11633534 ENSG00000225151.9 GOLGA2P7 -6.67 7.18e-11 4.28e-08 -0.42 -0.29 Schizophrenia; chr15:84581411 chr15:84199311~84230136:- LUSC cis rs950169 0.65 rs12902052 ENSG00000225151.9 GOLGA2P7 -6.67 7.18e-11 4.28e-08 -0.42 -0.29 Schizophrenia; chr15:84582607 chr15:84199311~84230136:- LUSC cis rs2179367 0.959 rs536203 ENSG00000231760.4 RP11-350J20.5 6.67 7.19e-11 4.28e-08 0.38 0.29 Dupuytren's disease; chr6:149330128 chr6:149796151~149826294:- LUSC cis rs9928842 0.823 rs889514 ENSG00000280152.1 RP11-331F4.5 6.67 7.2e-11 4.28e-08 0.35 0.29 Alcoholic chronic pancreatitis; chr16:75238614 chr16:75245994~75250077:- LUSC cis rs11976180 1 rs1533266 ENSG00000170356.8 OR2A20P -6.67 7.2e-11 4.28e-08 -0.4 -0.29 Obesity-related traits; chr7:144069621 chr7:144250045~144252957:- LUSC cis rs12931792 0.782 rs6565176 ENSG00000183604.13 SMG1P5 6.67 7.2e-11 4.29e-08 0.33 0.29 Tonsillectomy; chr16:30163605 chr16:30267553~30335374:- LUSC cis rs11098499 0.954 rs6822679 ENSG00000250412.1 KLHL2P1 6.67 7.2e-11 4.29e-08 0.37 0.29 Corneal astigmatism; chr4:119481547 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs4577559 ENSG00000250412.1 KLHL2P1 6.67 7.2e-11 4.29e-08 0.37 0.29 Corneal astigmatism; chr4:119482888 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs7656252 ENSG00000250412.1 KLHL2P1 6.67 7.2e-11 4.29e-08 0.37 0.29 Corneal astigmatism; chr4:119483113 chr4:119334329~119378233:+ LUSC cis rs11098499 0.865 rs28845498 ENSG00000250412.1 KLHL2P1 6.67 7.2e-11 4.29e-08 0.37 0.29 Corneal astigmatism; chr4:119484031 chr4:119334329~119378233:+ LUSC cis rs11098499 0.865 rs28753180 ENSG00000250412.1 KLHL2P1 6.67 7.2e-11 4.29e-08 0.37 0.29 Corneal astigmatism; chr4:119484212 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs56270433 ENSG00000250412.1 KLHL2P1 6.67 7.2e-11 4.29e-08 0.37 0.29 Corneal astigmatism; chr4:119484875 chr4:119334329~119378233:+ LUSC cis rs9921338 0.961 rs9302459 ENSG00000263080.1 RP11-485G7.5 -6.67 7.2e-11 4.29e-08 -0.35 -0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11326482 chr16:11341809~11345211:- LUSC cis rs904251 0.772 rs10692 ENSG00000204110.6 RP1-153P14.8 -6.67 7.22e-11 4.3e-08 -0.3 -0.29 Cognitive performance; chr6:37483138 chr6:37507348~37535616:+ LUSC cis rs867371 1 rs7180584 ENSG00000255769.6 GOLGA2P10 -6.67 7.22e-11 4.3e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163493 chr15:82472993~82513950:- LUSC cis rs12554020 0.892 rs12551084 ENSG00000227603.1 RP11-165J3.6 6.67 7.22e-11 4.3e-08 0.47 0.29 Schizophrenia; chr9:93538013 chr9:93435332~93437121:- LUSC cis rs71403859 0.803 rs8063455 ENSG00000260886.1 TAT-AS1 6.67 7.23e-11 4.3e-08 0.48 0.29 Post bronchodilator FEV1; chr16:71566074 chr16:71565789~71578187:+ LUSC cis rs10246939 0.579 rs10464444 ENSG00000228775.6 WEE2-AS1 -6.67 7.26e-11 4.32e-08 -0.34 -0.29 Bitter taste perception; chr7:141832387 chr7:141704338~141738346:- LUSC cis rs5742933 0.857 rs1233284 ENSG00000253559.1 OSGEPL1-AS1 -6.67 7.26e-11 4.32e-08 -0.36 -0.29 Ferritin levels; chr2:189825045 chr2:189762704~189765556:+ LUSC cis rs5742933 0.817 rs1233288 ENSG00000253559.1 OSGEPL1-AS1 -6.67 7.26e-11 4.32e-08 -0.36 -0.29 Ferritin levels; chr2:189825999 chr2:189762704~189765556:+ LUSC cis rs10129255 0.5 rs59939897 ENSG00000224373.3 IGHV4-59 6.67 7.26e-11 4.32e-08 0.15 0.29 Kawasaki disease; chr14:106783414 chr14:106627249~106627825:- LUSC cis rs4950322 0.542 rs2883434 ENSG00000278811.3 LINC00624 6.67 7.27e-11 4.32e-08 0.31 0.29 Protein quantitative trait loci; chr1:147177505 chr1:147258885~147517875:- LUSC cis rs172166 0.637 rs1225592 ENSG00000216901.1 AL022393.7 6.67 7.27e-11 4.33e-08 0.34 0.29 Cardiac Troponin-T levels; chr6:28182464 chr6:28176188~28176674:+ LUSC cis rs172166 0.637 rs1225595 ENSG00000216901.1 AL022393.7 6.67 7.27e-11 4.33e-08 0.34 0.29 Cardiac Troponin-T levels; chr6:28183562 chr6:28176188~28176674:+ LUSC cis rs7955901 0.725 rs1512988 ENSG00000257265.1 CTD-2021H9.1 6.67 7.29e-11 4.33e-08 0.32 0.29 Type 2 diabetes; chr12:71061219 chr12:71007773~71032083:- LUSC cis rs10170846 0.861 rs7571732 ENSG00000261428.2 RP11-16P6.1 -6.67 7.3e-11 4.34e-08 -0.35 -0.29 Schizophrenia (inflammation and infection response interaction); chr2:222673597 chr2:222566899~222569719:- LUSC cis rs17507216 0.609 rs1431716 ENSG00000255769.6 GOLGA2P10 -6.67 7.31e-11 4.35e-08 -0.45 -0.29 Excessive daytime sleepiness; chr15:82676180 chr15:82472993~82513950:- LUSC cis rs1061377 1 rs6829450 ENSG00000249685.1 RP11-360F5.3 6.67 7.31e-11 4.35e-08 0.34 0.29 Uric acid levels; chr4:39114721 chr4:39133913~39135608:+ LUSC cis rs10129255 0.957 rs12589190 ENSG00000280411.1 IGHV1-69-2 -6.67 7.33e-11 4.35e-08 -0.2 -0.29 Kawasaki disease; chr14:106783079 chr14:106762092~106762588:- LUSC cis rs10129255 0.5 rs6576225 ENSG00000224373.3 IGHV4-59 6.67 7.33e-11 4.35e-08 0.15 0.29 Kawasaki disease; chr14:106778120 chr14:106627249~106627825:- LUSC cis rs10129255 0.5 rs6576226 ENSG00000224373.3 IGHV4-59 6.67 7.33e-11 4.35e-08 0.15 0.29 Kawasaki disease; chr14:106778135 chr14:106627249~106627825:- LUSC cis rs761746 0.577 rs2012150 ENSG00000236132.1 CTA-440B3.1 -6.67 7.33e-11 4.36e-08 -0.41 -0.29 Intelligence; chr22:31820153 chr22:31816379~31817491:- LUSC cis rs881375 0.967 rs7046108 ENSG00000226752.6 PSMD5-AS1 6.67 7.33e-11 4.36e-08 0.33 0.29 Rheumatoid arthritis; chr9:120898061 chr9:120824828~120854385:+ LUSC cis rs2665103 0.632 rs3902959 ENSG00000276710.3 CSPG4P8 -6.67 7.34e-11 4.36e-08 -0.3 -0.29 Intelligence (multi-trait analysis); chr15:82252586 chr15:82459472~82477258:+ LUSC cis rs7772486 0.754 rs4896839 ENSG00000235652.6 RP11-545I5.3 -6.67 7.35e-11 4.37e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145698553 chr6:145799409~145886585:+ LUSC cis rs10262624 0.935 rs8180700 ENSG00000234286.1 AC006026.13 -6.67 7.36e-11 4.37e-08 -0.34 -0.29 Schizophrenia; chr7:23870323 chr7:23680195~23680786:- LUSC cis rs11971779 0.553 rs36002669 ENSG00000273391.1 RP11-634H22.1 6.67 7.36e-11 4.37e-08 0.32 0.29 Diisocyanate-induced asthma; chr7:139428415 chr7:139359032~139359566:- LUSC cis rs36405 0.5 rs17178883 ENSG00000266869.1 RP6-114E22.1 6.67 7.36e-11 4.37e-08 0.36 0.29 Yang-deficiency constitution; chr14:71888874 chr14:71848606~71908430:+ LUSC cis rs7267979 0.932 rs417130 ENSG00000274973.1 RP13-401N8.7 -6.67 7.37e-11 4.38e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25477684 chr20:25845497~25845862:+ LUSC cis rs7267979 0.932 rs372678 ENSG00000274973.1 RP13-401N8.7 -6.67 7.37e-11 4.38e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25484612 chr20:25845497~25845862:+ LUSC cis rs2948294 0.588 rs7011221 ENSG00000253893.2 FAM85B -6.67 7.37e-11 4.38e-08 -0.38 -0.29 Red cell distribution width; chr8:8256724 chr8:8167819~8226614:- LUSC cis rs2948294 0.545 rs11776397 ENSG00000253893.2 FAM85B -6.67 7.37e-11 4.38e-08 -0.38 -0.29 Red cell distribution width; chr8:8257639 chr8:8167819~8226614:- LUSC cis rs7267979 1 rs3761117 ENSG00000274973.1 RP13-401N8.7 6.67 7.37e-11 4.38e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25407434 chr20:25845497~25845862:+ LUSC cis rs950169 1 rs62026530 ENSG00000259728.4 LINC00933 6.67 7.38e-11 4.39e-08 0.38 0.29 Schizophrenia; chr15:84107088 chr15:84570649~84580175:+ LUSC cis rs950169 0.881 rs150965 ENSG00000259728.4 LINC00933 6.67 7.4e-11 4.39e-08 0.39 0.29 Schizophrenia; chr15:84537296 chr15:84570649~84580175:+ LUSC cis rs9309473 0.847 rs13538 ENSG00000163016.8 ALMS1P 6.67 7.41e-11 4.4e-08 0.35 0.29 Metabolite levels; chr2:73641201 chr2:73644919~73685576:+ LUSC cis rs748404 0.666 rs12900259 ENSG00000249839.1 AC011330.5 -6.67 7.42e-11 4.4e-08 -0.5 -0.29 Lung cancer; chr15:43427369 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs34921640 ENSG00000249839.1 AC011330.5 -6.67 7.42e-11 4.4e-08 -0.5 -0.29 Lung cancer; chr15:43429187 chr15:43663654~43684339:- LUSC cis rs748404 0.666 rs62020574 ENSG00000249839.1 AC011330.5 -6.67 7.42e-11 4.4e-08 -0.5 -0.29 Lung cancer; chr15:43429380 chr15:43663654~43684339:- LUSC cis rs10129255 0.5 rs7161740 ENSG00000224373.3 IGHV4-59 6.67 7.42e-11 4.41e-08 0.15 0.29 Kawasaki disease; chr14:106776119 chr14:106627249~106627825:- LUSC cis rs10129255 0.556 rs6576222 ENSG00000224373.3 IGHV4-59 6.67 7.42e-11 4.41e-08 0.15 0.29 Kawasaki disease; chr14:106776442 chr14:106627249~106627825:- LUSC cis rs10129255 0.536 rs6576223 ENSG00000224373.3 IGHV4-59 6.67 7.42e-11 4.41e-08 0.15 0.29 Kawasaki disease; chr14:106776448 chr14:106627249~106627825:- LUSC cis rs9903692 0.954 rs8076380 ENSG00000278765.1 RP5-890E16.5 -6.67 7.43e-11 4.41e-08 -0.35 -0.29 Pulse pressure; chr17:48113028 chr17:48066704~48067293:- LUSC cis rs875971 0.898 rs6977501 ENSG00000237310.1 GS1-124K5.4 -6.66 7.44e-11 4.42e-08 -0.3 -0.29 Aortic root size; chr7:66228355 chr7:66493706~66495474:+ LUSC cis rs881375 0.9 rs1930786 ENSG00000226752.6 PSMD5-AS1 -6.66 7.44e-11 4.42e-08 -0.34 -0.29 Rheumatoid arthritis; chr9:120929191 chr9:120824828~120854385:+ LUSC cis rs1865760 0.786 rs2164487 ENSG00000272462.2 U91328.19 -6.66 7.44e-11 4.42e-08 -0.31 -0.29 Height; chr6:25950572 chr6:25992662~26001775:+ LUSC cis rs1865760 0.865 rs6929805 ENSG00000272462.2 U91328.19 -6.66 7.44e-11 4.42e-08 -0.31 -0.29 Height; chr6:25950606 chr6:25992662~26001775:+ LUSC cis rs11089937 0.616 rs66651705 ENSG00000211639.2 IGLV4-60 6.66 7.45e-11 4.42e-08 0.31 0.29 Periodontitis (PAL4Q3); chr22:22179973 chr22:22162199~22162681:+ LUSC cis rs7267979 0.932 rs449370 ENSG00000274973.1 RP13-401N8.7 6.66 7.47e-11 4.43e-08 0.3 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25470544 chr20:25845497~25845862:+ LUSC cis rs760794 0.577 rs7752808 ENSG00000237404.1 RP3-471C18.2 -6.66 7.47e-11 4.44e-08 -0.36 -0.29 Endometriosis; chr6:19792665 chr6:19689825~19753113:- LUSC cis rs2858942 0.602 rs1211375 ENSG00000268836.1 LA16c-OS12.2 -6.66 7.48e-11 4.44e-08 -0.3 -0.29 Mean corpuscular hemoglobin; chr16:190281 chr16:185748~186294:- LUSC cis rs228614 0.536 rs223475 ENSG00000230069.3 LRRC37A15P -6.66 7.49e-11 4.44e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771986 chr4:102727274~102730721:- LUSC cis rs228614 0.536 rs223474 ENSG00000230069.3 LRRC37A15P -6.66 7.49e-11 4.44e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102772007 chr4:102727274~102730721:- LUSC cis rs10246939 0.543 rs11767947 ENSG00000228775.6 WEE2-AS1 6.66 7.49e-11 4.44e-08 0.37 0.29 Bitter taste perception; chr7:141912821 chr7:141704338~141738346:- LUSC cis rs10246939 0.543 rs11765974 ENSG00000228775.6 WEE2-AS1 6.66 7.49e-11 4.44e-08 0.37 0.29 Bitter taste perception; chr7:141914390 chr7:141704338~141738346:- LUSC cis rs11976180 1 rs2951308 ENSG00000170356.8 OR2A20P 6.66 7.5e-11 4.45e-08 0.39 0.29 Obesity-related traits; chr7:144070056 chr7:144250045~144252957:- LUSC cis rs9309473 0.948 rs7607892 ENSG00000163016.8 ALMS1P 6.66 7.52e-11 4.46e-08 0.35 0.29 Metabolite levels; chr2:73591580 chr2:73644919~73685576:+ LUSC cis rs8062405 0.721 rs151181 ENSG00000278665.1 RP11-666O2.4 6.66 7.52e-11 4.46e-08 0.3 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28479196 chr16:28599241~28601881:- LUSC cis rs116095464 0.558 rs6878087 ENSG00000250848.1 CTD-2083E4.5 6.66 7.53e-11 4.46e-08 0.44 0.29 Breast cancer; chr5:223002 chr5:288833~290321:- LUSC cis rs10262624 0.935 rs6955884 ENSG00000234286.1 AC006026.13 -6.66 7.53e-11 4.46e-08 -0.35 -0.29 Schizophrenia; chr7:23865654 chr7:23680195~23680786:- LUSC cis rs9309473 0.95 rs13408433 ENSG00000163016.8 ALMS1P 6.66 7.53e-11 4.47e-08 0.35 0.29 Metabolite levels; chr2:73655945 chr2:73644919~73685576:+ LUSC cis rs7246657 0.943 rs34603719 ENSG00000276846.1 CTD-3220F14.3 6.66 7.54e-11 4.47e-08 0.46 0.29 Coronary artery calcification; chr19:37303626 chr19:37314868~37315620:- LUSC cis rs11098499 0.754 rs66900435 ENSG00000249244.1 RP11-548H18.2 6.66 7.54e-11 4.47e-08 0.37 0.29 Corneal astigmatism; chr4:119328270 chr4:119391831~119395335:- LUSC cis rs2404602 0.735 rs4886805 ENSG00000259422.1 RP11-593F23.1 6.66 7.57e-11 4.48e-08 0.35 0.29 Blood metabolite levels; chr15:76447043 chr15:76174891~76181486:- LUSC cis rs4718428 1 rs868961 ENSG00000226824.5 RP4-756H11.3 -6.66 7.57e-11 4.49e-08 -0.36 -0.29 Corneal structure; chr7:66972221 chr7:66654538~66669855:+ LUSC cis rs7267979 0.932 rs367666 ENSG00000274973.1 RP13-401N8.7 -6.66 7.58e-11 4.49e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25469182 chr20:25845497~25845862:+ LUSC cis rs9903692 0.789 rs12601675 ENSG00000278765.1 RP5-890E16.5 -6.66 7.6e-11 4.5e-08 -0.35 -0.29 Pulse pressure; chr17:48113566 chr17:48066704~48067293:- LUSC cis rs9903692 0.754 rs12602948 ENSG00000278765.1 RP5-890E16.5 -6.66 7.6e-11 4.5e-08 -0.35 -0.29 Pulse pressure; chr17:48113567 chr17:48066704~48067293:- LUSC cis rs2665103 0.715 rs11639440 ENSG00000278603.1 RP13-608F4.5 6.66 7.6e-11 4.5e-08 0.35 0.29 Intelligence (multi-trait analysis); chr15:82278705 chr15:82472203~82472426:+ LUSC cis rs1865760 0.865 rs9393678 ENSG00000272462.2 U91328.19 -6.66 7.6e-11 4.5e-08 -0.31 -0.29 Height; chr6:25945591 chr6:25992662~26001775:+ LUSC cis rs2337406 1 rs4774173 ENSG00000254174.1 IGHV1-12 6.66 7.61e-11 4.51e-08 0.3 0.29 Alzheimer's disease (late onset); chr14:106682029 chr14:106122420~106122709:- LUSC cis rs2153535 0.563 rs1737585 ENSG00000230939.1 RP11-314C16.1 6.66 7.61e-11 4.51e-08 0.35 0.29 Motion sickness; chr6:8536361 chr6:8784178~8785445:+ LUSC cis rs5753618 0.504 rs9606847 ENSG00000236132.1 CTA-440B3.1 -6.66 7.63e-11 4.52e-08 -0.42 -0.29 Colorectal cancer; chr22:31505803 chr22:31816379~31817491:- LUSC cis rs5753618 0.504 rs9606848 ENSG00000236132.1 CTA-440B3.1 -6.66 7.63e-11 4.52e-08 -0.42 -0.29 Colorectal cancer; chr22:31505881 chr22:31816379~31817491:- LUSC cis rs950169 0.959 rs12911210 ENSG00000225151.9 GOLGA2P7 -6.66 7.64e-11 4.53e-08 -0.41 -0.29 Schizophrenia; chr15:84123331 chr15:84199311~84230136:- LUSC cis rs8040855 0.599 rs8037195 ENSG00000259295.5 CSPG4P12 -6.66 7.66e-11 4.54e-08 -0.33 -0.29 Bulimia nervosa; chr15:85181455 chr15:85191438~85213905:+ LUSC cis rs7267979 0.966 rs8123949 ENSG00000274973.1 RP13-401N8.7 6.66 7.67e-11 4.54e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25407497 chr20:25845497~25845862:+ LUSC cis rs853679 0.517 rs35193936 ENSG00000204709.4 LINC01556 6.66 7.67e-11 4.54e-08 0.42 0.29 Depression; chr6:28108492 chr6:28943877~28944537:+ LUSC cis rs34375054 0.558 rs67041765 ENSG00000279233.1 RP11-158L12.4 6.66 7.67e-11 4.54e-08 0.29 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125188367 chr12:125138245~125141711:+ LUSC cis rs1865760 0.516 rs10807007 ENSG00000272462.2 U91328.19 -6.66 7.69e-11 4.55e-08 -0.31 -0.29 Height; chr6:26048703 chr6:25992662~26001775:+ LUSC cis rs1865760 0.516 rs9379819 ENSG00000272462.2 U91328.19 -6.66 7.69e-11 4.55e-08 -0.31 -0.29 Height; chr6:26049591 chr6:25992662~26001775:+ LUSC cis rs1865760 0.663 rs9379815 ENSG00000272462.2 U91328.19 -6.66 7.7e-11 4.56e-08 -0.31 -0.29 Height; chr6:25979888 chr6:25992662~26001775:+ LUSC cis rs17023223 0.537 rs2645302 ENSG00000231365.4 RP11-418J17.1 -6.66 7.72e-11 4.57e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119047775 chr1:119140396~119275973:+ LUSC cis rs7246657 1 rs35398388 ENSG00000276846.1 CTD-3220F14.3 6.66 7.73e-11 4.57e-08 0.46 0.29 Coronary artery calcification; chr19:37249456 chr19:37314868~37315620:- LUSC cis rs7246657 1 rs7247672 ENSG00000276846.1 CTD-3220F14.3 6.66 7.73e-11 4.57e-08 0.46 0.29 Coronary artery calcification; chr19:37253026 chr19:37314868~37315620:- LUSC cis rs7246657 1 rs8110011 ENSG00000276846.1 CTD-3220F14.3 6.66 7.73e-11 4.57e-08 0.46 0.29 Coronary artery calcification; chr19:37254911 chr19:37314868~37315620:- LUSC cis rs7246657 0.941 rs7259618 ENSG00000276846.1 CTD-3220F14.3 6.66 7.73e-11 4.57e-08 0.46 0.29 Coronary artery calcification; chr19:37259817 chr19:37314868~37315620:- LUSC cis rs9928842 1 rs9928842 ENSG00000280152.1 RP11-331F4.5 6.66 7.73e-11 4.57e-08 0.37 0.29 Alcoholic chronic pancreatitis; chr16:75208969 chr16:75245994~75250077:- LUSC cis rs11603023 0.967 rs7936556 ENSG00000255239.1 AP002954.6 -6.66 7.73e-11 4.58e-08 -0.34 -0.29 Cholesterol, total; chr11:118630582 chr11:118688039~118690600:- LUSC cis rs11089937 0.523 rs4821832 ENSG00000211639.2 IGLV4-60 6.66 7.75e-11 4.59e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22188499 chr22:22162199~22162681:+ LUSC cis rs6782228 0.883 rs11712115 ENSG00000277250.1 Metazoa_SRP 6.66 7.76e-11 4.59e-08 0.36 0.29 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128685426 chr3:128673681~128674021:- LUSC cis rs12550612 0.567 rs7834950 ENSG00000253616.4 RP11-875O11.3 6.66 7.76e-11 4.59e-08 0.4 0.29 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23084305 chr8:23071377~23074488:- LUSC cis rs9928842 0.771 rs8059190 ENSG00000280152.1 RP11-331F4.5 6.66 7.76e-11 4.59e-08 0.35 0.29 Alcoholic chronic pancreatitis; chr16:75226899 chr16:75245994~75250077:- LUSC cis rs75920871 0.588 rs7118591 ENSG00000254851.1 RP11-109L13.1 -6.66 7.78e-11 4.6e-08 -0.41 -0.29 Subjective well-being; chr11:117037741 chr11:117135528~117138582:+ LUSC cis rs4713118 0.955 rs9468201 ENSG00000219392.1 RP1-265C24.5 -6.66 7.78e-11 4.6e-08 -0.39 -0.29 Parkinson's disease; chr6:27719256 chr6:28115628~28116551:+ LUSC cis rs10256972 0.63 rs10282584 ENSG00000229043.2 AC091729.9 -6.66 7.79e-11 4.61e-08 -0.35 -0.29 Endometriosis;Longevity; chr7:1041806 chr7:1160374~1165267:+ LUSC cis rs11722779 0.935 rs3857200 ENSG00000230069.3 LRRC37A15P -6.66 7.82e-11 4.62e-08 -0.31 -0.29 Schizophrenia; chr4:103001864 chr4:102727274~102730721:- LUSC cis rs9318086 0.935 rs9553083 ENSG00000205861.10 C1QTNF9B-AS1 6.66 7.82e-11 4.63e-08 0.36 0.29 Myopia (pathological); chr13:23867386 chr13:23888889~23897263:+ LUSC cis rs4713118 0.547 rs2116981 ENSG00000204709.4 LINC01556 6.66 7.83e-11 4.63e-08 0.42 0.29 Parkinson's disease; chr6:28100173 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9368552 ENSG00000204709.4 LINC01556 6.66 7.83e-11 4.63e-08 0.42 0.29 Depression; chr6:28100648 chr6:28943877~28944537:+ LUSC cis rs853679 0.542 rs34131763 ENSG00000204709.4 LINC01556 6.66 7.83e-11 4.63e-08 0.42 0.29 Depression; chr6:28107222 chr6:28943877~28944537:+ LUSC cis rs9660180 0.934 rs12729990 ENSG00000231050.1 RP1-140A9.1 6.66 7.84e-11 4.63e-08 0.29 0.29 Body mass index; chr1:1880596 chr1:1891471~1892658:+ LUSC cis rs10754283 0.967 rs1953821 ENSG00000231613.1 RP5-943J3.1 6.66 7.85e-11 4.64e-08 0.33 0.29 Amyotrophic lateral sclerosis (sporadic); chr1:89641539 chr1:89788914~89790492:+ LUSC cis rs13113518 0.51 rs3749473 ENSG00000273257.1 RP11-177J6.1 6.66 7.85e-11 4.64e-08 0.36 0.29 Height; chr4:55428461 chr4:55387949~55388271:+ LUSC cis rs2665103 0.61 rs1972460 ENSG00000276710.3 CSPG4P8 -6.66 7.85e-11 4.64e-08 -0.29 -0.29 Intelligence (multi-trait analysis); chr15:82238289 chr15:82459472~82477258:+ LUSC cis rs11976180 1 rs1320894 ENSG00000170356.8 OR2A20P -6.66 7.86e-11 4.64e-08 -0.39 -0.29 Obesity-related traits; chr7:144054709 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs2951369 ENSG00000170356.8 OR2A20P -6.66 7.86e-11 4.64e-08 -0.39 -0.29 Obesity-related traits; chr7:144055545 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs2951368 ENSG00000170356.8 OR2A20P -6.66 7.86e-11 4.64e-08 -0.39 -0.29 Obesity-related traits; chr7:144055728 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs2961115 ENSG00000170356.8 OR2A20P -6.66 7.86e-11 4.64e-08 -0.39 -0.29 Obesity-related traits; chr7:144056278 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs2951364 ENSG00000170356.8 OR2A20P -6.66 7.86e-11 4.64e-08 -0.39 -0.29 Obesity-related traits; chr7:144057390 chr7:144250045~144252957:- LUSC cis rs950169 1 rs35297609 ENSG00000259728.4 LINC00933 6.66 7.86e-11 4.64e-08 0.38 0.29 Schizophrenia; chr15:84104144 chr15:84570649~84580175:+ LUSC cis rs7267979 0.966 rs2424714 ENSG00000274973.1 RP13-401N8.7 -6.66 7.86e-11 4.64e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25438045 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2424715 ENSG00000274973.1 RP13-401N8.7 -6.66 7.86e-11 4.64e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25439441 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050617 ENSG00000274973.1 RP13-401N8.7 -6.66 7.86e-11 4.64e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25441012 chr20:25845497~25845862:+ LUSC cis rs7267979 0.933 rs2387887 ENSG00000274973.1 RP13-401N8.7 -6.66 7.86e-11 4.64e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25446445 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6037121 ENSG00000274973.1 RP13-401N8.7 -6.66 7.86e-11 4.64e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25447675 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs1047171 ENSG00000274973.1 RP13-401N8.7 -6.66 7.86e-11 4.64e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25448150 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050629 ENSG00000274973.1 RP13-401N8.7 -6.66 7.86e-11 4.64e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25450044 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050630 ENSG00000274973.1 RP13-401N8.7 -6.66 7.86e-11 4.64e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25450109 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050632 ENSG00000274973.1 RP13-401N8.7 -6.66 7.86e-11 4.64e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25451965 chr20:25845497~25845862:+ LUSC cis rs4713118 0.621 rs9368548 ENSG00000204709.4 LINC01556 6.66 7.86e-11 4.64e-08 0.42 0.29 Parkinson's disease; chr6:28066959 chr6:28943877~28944537:+ LUSC cis rs10129255 0.957 rs8009638 ENSG00000224373.3 IGHV4-59 6.66 7.88e-11 4.66e-08 0.17 0.29 Kawasaki disease; chr14:106777570 chr14:106627249~106627825:- LUSC cis rs761746 0.584 rs62238892 ENSG00000236132.1 CTA-440B3.1 -6.66 7.9e-11 4.67e-08 -0.42 -0.29 Intelligence; chr22:31765563 chr22:31816379~31817491:- LUSC cis rs7267979 1 rs6083844 ENSG00000274973.1 RP13-401N8.7 6.65 7.93e-11 4.68e-08 0.3 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25406196 chr20:25845497~25845862:+ LUSC cis rs6142102 0.812 rs6059574 ENSG00000276073.1 RP5-1125A11.7 6.65 7.93e-11 4.68e-08 0.3 0.29 Skin pigmentation; chr20:33935366 chr20:33985617~33988989:- LUSC cis rs17507216 0.628 rs8032321 ENSG00000255769.6 GOLGA2P10 -6.65 7.94e-11 4.68e-08 -0.44 -0.29 Excessive daytime sleepiness; chr15:82698956 chr15:82472993~82513950:- LUSC cis rs17507216 0.628 rs8040488 ENSG00000255769.6 GOLGA2P10 -6.65 7.94e-11 4.68e-08 -0.44 -0.29 Excessive daytime sleepiness; chr15:82699081 chr15:82472993~82513950:- LUSC cis rs11098499 0.908 rs2017057 ENSG00000250412.1 KLHL2P1 6.65 7.94e-11 4.69e-08 0.37 0.29 Corneal astigmatism; chr4:119336556 chr4:119334329~119378233:+ LUSC cis rs853679 0.517 rs6932109 ENSG00000204709.4 LINC01556 -6.65 7.94e-11 4.69e-08 -0.41 -0.29 Depression; chr6:28110525 chr6:28943877~28944537:+ LUSC cis rs5742933 0.857 rs1233291 ENSG00000253559.1 OSGEPL1-AS1 -6.65 7.95e-11 4.69e-08 -0.36 -0.29 Ferritin levels; chr2:189826225 chr2:189762704~189765556:+ LUSC cis rs17818399 0.62 rs7598578 ENSG00000279254.1 RP11-536C12.1 -6.65 7.96e-11 4.7e-08 -0.32 -0.29 Height; chr2:46629946 chr2:46668870~46670778:+ LUSC cis rs17818399 0.62 rs1598517 ENSG00000279254.1 RP11-536C12.1 -6.65 7.96e-11 4.7e-08 -0.32 -0.29 Height; chr2:46630262 chr2:46668870~46670778:+ LUSC cis rs9903692 0.908 rs8066391 ENSG00000278765.1 RP5-890E16.5 -6.65 7.98e-11 4.71e-08 -0.35 -0.29 Pulse pressure; chr17:48117934 chr17:48066704~48067293:- LUSC cis rs9903692 0.908 rs11079809 ENSG00000278765.1 RP5-890E16.5 -6.65 7.98e-11 4.71e-08 -0.35 -0.29 Pulse pressure; chr17:48120859 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs3744346 ENSG00000278765.1 RP5-890E16.5 -6.65 7.98e-11 4.71e-08 -0.35 -0.29 Pulse pressure; chr17:48121514 chr17:48066704~48067293:- LUSC cis rs9903692 0.908 rs7222136 ENSG00000278765.1 RP5-890E16.5 -6.65 7.98e-11 4.71e-08 -0.35 -0.29 Pulse pressure; chr17:48122230 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs1010228 ENSG00000278765.1 RP5-890E16.5 -6.65 7.98e-11 4.71e-08 -0.35 -0.29 Pulse pressure; chr17:48122986 chr17:48066704~48067293:- LUSC cis rs17023223 0.537 rs1057991 ENSG00000231365.4 RP11-418J17.1 -6.65 7.98e-11 4.71e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119032547 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs1057990 ENSG00000231365.4 RP11-418J17.1 -6.65 7.98e-11 4.71e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119032609 chr1:119140396~119275973:+ LUSC cis rs56080343 0.688 rs10083190 ENSG00000275759.1 RP11-131L12.3 -6.65 8.03e-11 4.74e-08 -0.39 -0.29 Neuroticism; chr12:118365385 chr12:118428281~118428870:+ LUSC cis rs801193 0.935 rs11772264 ENSG00000224316.1 RP11-479O9.2 6.65 8.05e-11 4.75e-08 0.28 0.29 Aortic root size; chr7:66711400 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs7782320 ENSG00000224316.1 RP11-479O9.2 6.65 8.05e-11 4.75e-08 0.28 0.29 Aortic root size; chr7:66712111 chr7:65773620~65802067:+ LUSC cis rs11976180 1 rs1533268 ENSG00000170356.8 OR2A20P -6.65 8.05e-11 4.75e-08 -0.4 -0.29 Obesity-related traits; chr7:144069265 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs1533267 ENSG00000170356.8 OR2A20P -6.65 8.05e-11 4.75e-08 -0.4 -0.29 Obesity-related traits; chr7:144069347 chr7:144250045~144252957:- LUSC cis rs4713118 0.869 rs9283881 ENSG00000219392.1 RP1-265C24.5 -6.65 8.05e-11 4.75e-08 -0.38 -0.29 Parkinson's disease; chr6:27747476 chr6:28115628~28116551:+ LUSC cis rs4713118 0.869 rs9283882 ENSG00000219392.1 RP1-265C24.5 -6.65 8.05e-11 4.75e-08 -0.38 -0.29 Parkinson's disease; chr6:27747479 chr6:28115628~28116551:+ LUSC cis rs7250849 0.79 rs7259861 ENSG00000273837.1 LLNLR-470E3.1 -6.65 8.06e-11 4.75e-08 -0.45 -0.29 Blood protein levels; chr19:51657490 chr19:51639478~51639931:- LUSC cis rs10129255 0.518 rs10136903 ENSG00000224373.3 IGHV4-59 6.65 8.07e-11 4.76e-08 0.15 0.29 Kawasaki disease; chr14:106778866 chr14:106627249~106627825:- LUSC cis rs2903698 0.585 rs2867917 ENSG00000250735.4 RP11-567N4.3 6.65 8.08e-11 4.76e-08 0.32 0.29 Prion diseases; chr4:75435042 chr4:75401195~75423023:+ LUSC cis rs9545047 0.716 rs9565500 ENSG00000227676.3 LINC01068 -6.65 8.09e-11 4.77e-08 -0.37 -0.29 Schizophrenia; chr13:79433416 chr13:79566727~79571436:+ LUSC cis rs761746 0.543 rs5998122 ENSG00000236132.1 CTA-440B3.1 -6.65 8.1e-11 4.77e-08 -0.42 -0.29 Intelligence; chr22:31777067 chr22:31816379~31817491:- LUSC cis rs853679 0.607 rs13207345 ENSG00000204709.4 LINC01556 6.65 8.12e-11 4.78e-08 0.62 0.29 Depression; chr6:28297795 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs72854513 ENSG00000204709.4 LINC01556 6.65 8.12e-11 4.78e-08 0.62 0.29 Depression; chr6:28298177 chr6:28943877~28944537:+ LUSC cis rs7267979 1 rs2387884 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25398433 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6076345 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25401259 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs4813566 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25405829 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs4815421 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25405873 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2184000 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25415242 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs4815425 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25418240 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050599 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25419604 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050602 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25420567 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs6083855 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25424482 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs4815426 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25424550 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6115182 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25429623 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050609 ENSG00000274973.1 RP13-401N8.7 6.65 8.13e-11 4.78e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25431115 chr20:25845497~25845862:+ LUSC cis rs113835537 0.529 rs57207756 ENSG00000255517.5 CTD-3074O7.5 -6.65 8.13e-11 4.78e-08 -0.35 -0.29 Airway imaging phenotypes; chr11:66502889 chr11:66473490~66480233:- LUSC cis rs10129255 0.5 rs2027903 ENSG00000224373.3 IGHV4-59 6.65 8.14e-11 4.79e-08 0.15 0.29 Kawasaki disease; chr14:106807047 chr14:106627249~106627825:- LUSC cis rs17023223 0.537 rs7525871 ENSG00000231365.4 RP11-418J17.1 -6.65 8.16e-11 4.8e-08 -0.38 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119079271 chr1:119140396~119275973:+ LUSC cis rs1012068 0.695 rs5998152 ENSG00000236132.1 CTA-440B3.1 -6.65 8.17e-11 4.81e-08 -0.41 -0.29 Chronic hepatitis C infection; chr22:31867176 chr22:31816379~31817491:- LUSC cis rs9903692 0.954 rs1860866 ENSG00000278765.1 RP5-890E16.5 -6.65 8.19e-11 4.82e-08 -0.35 -0.29 Pulse pressure; chr17:48123669 chr17:48066704~48067293:- LUSC cis rs875971 0.522 rs34973832 ENSG00000164669.11 INTS4P1 -6.65 8.2e-11 4.83e-08 -0.32 -0.29 Aortic root size; chr7:65931217 chr7:65141225~65234216:+ LUSC cis rs10262624 1 rs10238070 ENSG00000234286.1 AC006026.13 -6.65 8.21e-11 4.83e-08 -0.34 -0.29 Schizophrenia; chr7:23870172 chr7:23680195~23680786:- LUSC cis rs7772486 0.754 rs702318 ENSG00000235652.6 RP11-545I5.3 -6.65 8.21e-11 4.83e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145684737 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs702319 ENSG00000235652.6 RP11-545I5.3 -6.65 8.21e-11 4.83e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145684981 chr6:145799409~145886585:+ LUSC cis rs10262624 1 rs2390847 ENSG00000234286.1 AC006026.13 -6.65 8.22e-11 4.84e-08 -0.34 -0.29 Schizophrenia; chr7:23872082 chr7:23680195~23680786:- LUSC cis rs7246657 0.941 rs67293224 ENSG00000276846.1 CTD-3220F14.3 6.65 8.23e-11 4.84e-08 0.46 0.29 Coronary artery calcification; chr19:37312346 chr19:37314868~37315620:- LUSC cis rs17023223 0.581 rs2765529 ENSG00000231365.4 RP11-418J17.1 -6.65 8.24e-11 4.85e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119039277 chr1:119140396~119275973:+ LUSC cis rs7267979 1 rs4815418 ENSG00000274973.1 RP13-401N8.7 6.65 8.24e-11 4.85e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25401575 chr20:25845497~25845862:+ LUSC cis rs4713118 0.869 rs10214440 ENSG00000219392.1 RP1-265C24.5 -6.65 8.26e-11 4.86e-08 -0.37 -0.29 Parkinson's disease; chr6:27734661 chr6:28115628~28116551:+ LUSC cis rs75920871 0.588 rs6589587 ENSG00000254851.1 RP11-109L13.1 6.65 8.29e-11 4.87e-08 0.41 0.29 Subjective well-being; chr11:117004622 chr11:117135528~117138582:+ LUSC cis rs75920871 0.588 rs7119185 ENSG00000254851.1 RP11-109L13.1 6.65 8.29e-11 4.87e-08 0.41 0.29 Subjective well-being; chr11:117015380 chr11:117135528~117138582:+ LUSC cis rs10754283 0.935 rs10801756 ENSG00000231613.1 RP5-943J3.1 6.65 8.32e-11 4.89e-08 0.33 0.29 Amyotrophic lateral sclerosis (sporadic); chr1:89636273 chr1:89788914~89790492:+ LUSC cis rs10754283 0.934 rs6684676 ENSG00000231613.1 RP5-943J3.1 6.65 8.32e-11 4.89e-08 0.33 0.29 Amyotrophic lateral sclerosis (sporadic); chr1:89636614 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs6428561 ENSG00000231613.1 RP5-943J3.1 6.65 8.32e-11 4.89e-08 0.33 0.29 Amyotrophic lateral sclerosis (sporadic); chr1:89637060 chr1:89788914~89790492:+ LUSC cis rs10754283 0.967 rs6428562 ENSG00000231613.1 RP5-943J3.1 6.65 8.32e-11 4.89e-08 0.33 0.29 Amyotrophic lateral sclerosis (sporadic); chr1:89637106 chr1:89788914~89790492:+ LUSC cis rs2179367 0.959 rs9377212 ENSG00000231760.4 RP11-350J20.5 6.65 8.33e-11 4.89e-08 0.38 0.29 Dupuytren's disease; chr6:149383765 chr6:149796151~149826294:- LUSC cis rs11098499 0.909 rs11723757 ENSG00000250412.1 KLHL2P1 6.65 8.33e-11 4.9e-08 0.37 0.29 Corneal astigmatism; chr4:119378514 chr4:119334329~119378233:+ LUSC cis rs6921919 0.515 rs1558205 ENSG00000204709.4 LINC01556 -6.65 8.33e-11 4.9e-08 -0.36 -0.29 Autism spectrum disorder or schizophrenia; chr6:28414485 chr6:28943877~28944537:+ LUSC cis rs875971 0.577 rs34888281 ENSG00000236529.1 RP13-254B10.1 -6.65 8.34e-11 4.9e-08 -0.31 -0.29 Aortic root size; chr7:66120784 chr7:65840212~65840596:+ LUSC cis rs442309 0.687 rs11815005 ENSG00000238280.1 RP11-436D10.3 -6.65 8.34e-11 4.9e-08 -0.35 -0.29 Vogt-Koyanagi-Harada syndrome; chr10:62696987 chr10:62793562~62805887:- LUSC cis rs4713118 0.824 rs9366702 ENSG00000219392.1 RP1-265C24.5 -6.65 8.35e-11 4.91e-08 -0.39 -0.29 Parkinson's disease; chr6:27766691 chr6:28115628~28116551:+ LUSC cis rs12554020 0.685 rs55893789 ENSG00000227603.1 RP11-165J3.6 6.65 8.35e-11 4.91e-08 0.45 0.29 Schizophrenia; chr9:93408608 chr9:93435332~93437121:- LUSC cis rs7772486 0.754 rs6932863 ENSG00000235652.6 RP11-545I5.3 -6.65 8.36e-11 4.91e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145700119 chr6:145799409~145886585:+ LUSC cis rs9309473 1 rs13398956 ENSG00000163016.8 ALMS1P 6.65 8.36e-11 4.91e-08 0.35 0.29 Metabolite levels; chr2:73493131 chr2:73644919~73685576:+ LUSC cis rs9309473 1 rs56154726 ENSG00000163016.8 ALMS1P 6.65 8.36e-11 4.91e-08 0.35 0.29 Metabolite levels; chr2:73494640 chr2:73644919~73685576:+ LUSC cis rs7246657 0.943 rs10415358 ENSG00000276846.1 CTD-3220F14.3 6.65 8.36e-11 4.91e-08 0.45 0.29 Coronary artery calcification; chr19:37317961 chr19:37314868~37315620:- LUSC cis rs17507216 0.628 rs4627310 ENSG00000255769.6 GOLGA2P10 -6.65 8.38e-11 4.92e-08 -0.44 -0.29 Excessive daytime sleepiness; chr15:82708330 chr15:82472993~82513950:- LUSC cis rs11098499 0.954 rs11729521 ENSG00000250412.1 KLHL2P1 6.65 8.38e-11 4.92e-08 0.37 0.29 Corneal astigmatism; chr4:119495633 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs11734241 ENSG00000250412.1 KLHL2P1 6.65 8.38e-11 4.92e-08 0.37 0.29 Corneal astigmatism; chr4:119495717 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs28685688 ENSG00000250412.1 KLHL2P1 6.65 8.38e-11 4.92e-08 0.37 0.29 Corneal astigmatism; chr4:119499179 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs7687843 ENSG00000250412.1 KLHL2P1 6.65 8.38e-11 4.92e-08 0.37 0.29 Corneal astigmatism; chr4:119500056 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs2306455 ENSG00000250412.1 KLHL2P1 6.65 8.38e-11 4.92e-08 0.37 0.29 Corneal astigmatism; chr4:119500814 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs10031483 ENSG00000250412.1 KLHL2P1 6.65 8.38e-11 4.92e-08 0.37 0.29 Corneal astigmatism; chr4:119501481 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs10031665 ENSG00000250412.1 KLHL2P1 6.65 8.38e-11 4.92e-08 0.37 0.29 Corneal astigmatism; chr4:119501697 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs3733523 ENSG00000250412.1 KLHL2P1 6.65 8.38e-11 4.92e-08 0.37 0.29 Corneal astigmatism; chr4:119502564 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs12508504 ENSG00000250412.1 KLHL2P1 6.65 8.39e-11 4.93e-08 0.36 0.29 Corneal astigmatism; chr4:119489452 chr4:119334329~119378233:+ LUSC cis rs11690935 0.959 rs10204501 ENSG00000228389.1 AC068039.4 6.65 8.39e-11 4.93e-08 0.34 0.29 Schizophrenia; chr2:171732355 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs10204502 ENSG00000228389.1 AC068039.4 6.65 8.39e-11 4.93e-08 0.34 0.29 Schizophrenia; chr2:171732356 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs10204622 ENSG00000228389.1 AC068039.4 6.65 8.39e-11 4.93e-08 0.34 0.29 Schizophrenia; chr2:171732472 chr2:171773482~171775844:+ LUSC cis rs5742933 0.857 rs1233282 ENSG00000253559.1 OSGEPL1-AS1 -6.65 8.4e-11 4.93e-08 -0.36 -0.29 Ferritin levels; chr2:189823518 chr2:189762704~189765556:+ LUSC cis rs10754283 0.967 rs10922679 ENSG00000231613.1 RP5-943J3.1 6.65 8.4e-11 4.94e-08 0.33 0.29 Amyotrophic lateral sclerosis (sporadic); chr1:89635366 chr1:89788914~89790492:+ LUSC cis rs2179367 0.959 rs562428 ENSG00000231760.4 RP11-350J20.5 6.65 8.41e-11 4.94e-08 0.38 0.29 Dupuytren's disease; chr6:149326389 chr6:149796151~149826294:- LUSC cis rs12554020 1 rs35540150 ENSG00000227603.1 RP11-165J3.6 6.64 8.42e-11 4.94e-08 0.47 0.29 Schizophrenia; chr9:93538572 chr9:93435332~93437121:- LUSC cis rs8062405 1 rs2008514 ENSG00000278665.1 RP11-666O2.4 -6.64 8.42e-11 4.94e-08 -0.29 -0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814284 chr16:28599241~28601881:- LUSC cis rs75920871 0.588 rs4548653 ENSG00000254851.1 RP11-109L13.1 6.64 8.42e-11 4.95e-08 0.41 0.29 Subjective well-being; chr11:117032600 chr11:117135528~117138582:+ LUSC cis rs4141404 0.74 rs9609301 ENSG00000236132.1 CTA-440B3.1 -6.64 8.43e-11 4.95e-08 -0.42 -0.29 Paclitaxel-induced neuropathy; chr22:31499954 chr22:31816379~31817491:- LUSC cis rs5753618 0.555 rs9609302 ENSG00000236132.1 CTA-440B3.1 -6.64 8.43e-11 4.95e-08 -0.42 -0.29 Colorectal cancer; chr22:31500001 chr22:31816379~31817491:- LUSC cis rs5753618 0.504 rs9609303 ENSG00000236132.1 CTA-440B3.1 -6.64 8.43e-11 4.95e-08 -0.42 -0.29 Colorectal cancer; chr22:31500323 chr22:31816379~31817491:- LUSC cis rs5753618 0.504 rs9606846 ENSG00000236132.1 CTA-440B3.1 -6.64 8.43e-11 4.95e-08 -0.42 -0.29 Colorectal cancer; chr22:31501585 chr22:31816379~31817491:- LUSC cis rs5753618 0.555 rs9609304 ENSG00000236132.1 CTA-440B3.1 -6.64 8.43e-11 4.95e-08 -0.42 -0.29 Colorectal cancer; chr22:31501809 chr22:31816379~31817491:- LUSC cis rs10262624 1 rs2023786 ENSG00000234286.1 AC006026.13 -6.64 8.43e-11 4.95e-08 -0.34 -0.29 Schizophrenia; chr7:23875534 chr7:23680195~23680786:- LUSC cis rs75422866 0.867 rs73104152 ENSG00000274902.1 RP1-197B17.4 6.64 8.44e-11 4.95e-08 0.77 0.29 Pneumonia; chr12:47699091 chr12:47731908~47732351:+ LUSC cis rs75422866 0.867 rs73104155 ENSG00000274902.1 RP1-197B17.4 6.64 8.44e-11 4.95e-08 0.77 0.29 Pneumonia; chr12:47700790 chr12:47731908~47732351:+ LUSC cis rs11690935 0.959 rs6709156 ENSG00000228389.1 AC068039.4 6.64 8.44e-11 4.96e-08 0.34 0.29 Schizophrenia; chr2:171735434 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs12692970 ENSG00000228389.1 AC068039.4 6.64 8.44e-11 4.96e-08 0.34 0.29 Schizophrenia; chr2:171737687 chr2:171773482~171775844:+ LUSC cis rs1823913 0.599 rs1823912 ENSG00000227542.1 AC092614.2 6.64 8.46e-11 4.96e-08 0.38 0.29 Obesity-related traits; chr2:191266388 chr2:191229165~191246172:- LUSC cis rs7267979 1 rs2387880 ENSG00000274973.1 RP13-401N8.7 6.64 8.46e-11 4.97e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25397151 chr20:25845497~25845862:+ LUSC cis rs10954213 0.525 rs11770589 ENSG00000275106.1 RP11-309L24.10 -6.64 8.47e-11 4.97e-08 -0.37 -0.29 Sjögren's syndrome; chr7:128949434 chr7:128952527~128953316:- LUSC cis rs4713118 0.868 rs10484401 ENSG00000219392.1 RP1-265C24.5 6.64 8.48e-11 4.97e-08 0.4 0.29 Parkinson's disease; chr6:27778811 chr6:28115628~28116551:+ LUSC cis rs442309 0.532 rs10995276 ENSG00000238280.1 RP11-436D10.3 6.64 8.48e-11 4.98e-08 0.37 0.29 Vogt-Koyanagi-Harada syndrome; chr10:62694301 chr10:62793562~62805887:- LUSC cis rs748404 0.697 rs498227 ENSG00000249839.1 AC011330.5 -6.64 8.49e-11 4.98e-08 -0.39 -0.29 Lung cancer; chr15:43280854 chr15:43663654~43684339:- LUSC cis rs9309473 0.95 rs1052162 ENSG00000163016.8 ALMS1P -6.64 8.52e-11 5e-08 -0.35 -0.29 Metabolite levels; chr2:73602245 chr2:73644919~73685576:+ LUSC cis rs867371 1 rs7173339 ENSG00000255769.6 GOLGA2P10 -6.64 8.53e-11 5e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82175253 chr15:82472993~82513950:- LUSC cis rs10262624 0.967 rs2390848 ENSG00000234286.1 AC006026.13 -6.64 8.53e-11 5.01e-08 -0.34 -0.29 Schizophrenia; chr7:23872755 chr7:23680195~23680786:- LUSC cis rs9309473 1 rs7572722 ENSG00000163016.8 ALMS1P 6.64 8.54e-11 5.01e-08 0.35 0.29 Metabolite levels; chr2:73497548 chr2:73644919~73685576:+ LUSC cis rs950169 0.544 rs2036949 ENSG00000259728.4 LINC00933 6.64 8.55e-11 5.01e-08 0.38 0.29 Schizophrenia; chr15:84620374 chr15:84570649~84580175:+ LUSC cis rs950169 0.922 rs2033284 ENSG00000225151.9 GOLGA2P7 -6.64 8.55e-11 5.02e-08 -0.41 -0.29 Schizophrenia; chr15:84391575 chr15:84199311~84230136:- LUSC cis rs3750965 1 rs7937006 ENSG00000260895.1 RP11-554A11.7 6.64 8.56e-11 5.02e-08 0.34 0.29 Hair color; chr11:69076464 chr11:69103493~69109094:+ LUSC cis rs9903692 0.908 rs9807087 ENSG00000278765.1 RP5-890E16.5 -6.64 8.57e-11 5.03e-08 -0.35 -0.29 Pulse pressure; chr17:48126776 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs7209730 ENSG00000278765.1 RP5-890E16.5 -6.64 8.57e-11 5.03e-08 -0.35 -0.29 Pulse pressure; chr17:48130137 chr17:48066704~48067293:- LUSC cis rs4789693 0.518 rs6502108 ENSG00000265458.1 RP13-20L14.6 -6.64 8.58e-11 5.03e-08 -0.34 -0.29 Glucocorticoid-induced osteonecrosis; chr17:82417023 chr17:82454273~82458521:- LUSC cis rs7246657 0.943 rs7255952 ENSG00000276846.1 CTD-3220F14.3 6.64 8.61e-11 5.05e-08 0.45 0.29 Coronary artery calcification; chr19:37497895 chr19:37314868~37315620:- LUSC cis rs4660456 0.504 rs491619 ENSG00000237899.1 RP4-739H11.3 6.64 8.61e-11 5.05e-08 0.43 0.29 Platelet count; chr1:40641688 chr1:40669089~40687588:- LUSC cis rs11089937 0.651 rs1543779 ENSG00000211639.2 IGLV4-60 -6.64 8.62e-11 5.05e-08 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22194092 chr22:22162199~22162681:+ LUSC cis rs9309473 0.898 rs6546851 ENSG00000163016.8 ALMS1P 6.64 8.62e-11 5.05e-08 0.36 0.29 Metabolite levels; chr2:73606156 chr2:73644919~73685576:+ LUSC cis rs9309473 0.948 rs2421577 ENSG00000163016.8 ALMS1P 6.64 8.62e-11 5.05e-08 0.36 0.29 Metabolite levels; chr2:73613871 chr2:73644919~73685576:+ LUSC cis rs13113518 0.51 rs10049561 ENSG00000249700.7 SRD5A3-AS1 6.64 8.62e-11 5.05e-08 0.32 0.29 Height; chr4:55426623 chr4:55363971~55395847:- LUSC cis rs853679 0.517 rs4713141 ENSG00000204709.4 LINC01556 6.64 8.64e-11 5.06e-08 0.41 0.29 Depression; chr6:28133900 chr6:28943877~28944537:+ LUSC cis rs9322193 0.923 rs10872649 ENSG00000268592.3 RAET1E-AS1 6.64 8.65e-11 5.07e-08 0.37 0.29 Lung cancer; chr6:149759454 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs10872650 ENSG00000268592.3 RAET1E-AS1 6.64 8.65e-11 5.07e-08 0.37 0.29 Lung cancer; chr6:149760959 chr6:149863494~149919507:+ LUSC cis rs11098499 0.866 rs11098506 ENSG00000249244.1 RP11-548H18.2 6.64 8.68e-11 5.08e-08 0.37 0.29 Corneal astigmatism; chr4:119363816 chr4:119391831~119395335:- LUSC cis rs113835537 0.529 rs117112180 ENSG00000255517.5 CTD-3074O7.5 -6.64 8.68e-11 5.08e-08 -0.35 -0.29 Airway imaging phenotypes; chr11:66525802 chr11:66473490~66480233:- LUSC cis rs6570726 0.599 rs426371 ENSG00000235652.6 RP11-545I5.3 -6.64 8.7e-11 5.1e-08 -0.31 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145565333 chr6:145799409~145886585:+ LUSC cis rs5753618 0.555 rs5749291 ENSG00000236132.1 CTA-440B3.1 -6.64 8.72e-11 5.1e-08 -0.42 -0.29 Colorectal cancer; chr22:31511537 chr22:31816379~31817491:- LUSC cis rs5753618 0.504 rs7284622 ENSG00000236132.1 CTA-440B3.1 -6.64 8.72e-11 5.1e-08 -0.42 -0.29 Colorectal cancer; chr22:31511999 chr22:31816379~31817491:- LUSC cis rs11098499 0.955 rs11931312 ENSG00000250412.1 KLHL2P1 6.64 8.73e-11 5.11e-08 0.36 0.29 Corneal astigmatism; chr4:119237868 chr4:119334329~119378233:+ LUSC cis rs7246657 0.943 rs7252325 ENSG00000276846.1 CTD-3220F14.3 6.64 8.74e-11 5.11e-08 0.45 0.29 Coronary artery calcification; chr19:37439743 chr19:37314868~37315620:- LUSC cis rs10262624 1 rs2023787 ENSG00000234286.1 AC006026.13 -6.64 8.74e-11 5.12e-08 -0.34 -0.29 Schizophrenia; chr7:23875521 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs17347505 ENSG00000234286.1 AC006026.13 -6.64 8.74e-11 5.12e-08 -0.34 -0.29 Schizophrenia; chr7:23875664 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs12671624 ENSG00000234286.1 AC006026.13 -6.64 8.74e-11 5.12e-08 -0.34 -0.29 Schizophrenia; chr7:23875794 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs12671584 ENSG00000234286.1 AC006026.13 -6.64 8.74e-11 5.12e-08 -0.34 -0.29 Schizophrenia; chr7:23875803 chr7:23680195~23680786:- LUSC cis rs7267979 0.966 rs2387882 ENSG00000274973.1 RP13-401N8.7 6.64 8.75e-11 5.12e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25398166 chr20:25845497~25845862:+ LUSC cis rs7189233 1 rs16952251 ENSG00000279344.1 RP11-44F14.7 6.64 8.77e-11 5.13e-08 0.26 0.29 Intelligence (multi-trait analysis); chr16:53449226 chr16:53478957~53481550:- LUSC cis rs5753618 0.504 rs5753671 ENSG00000236132.1 CTA-440B3.1 -6.64 8.82e-11 5.16e-08 -0.42 -0.29 Colorectal cancer; chr22:31514748 chr22:31816379~31817491:- LUSC cis rs11098499 0.575 rs907204 ENSG00000249244.1 RP11-548H18.2 6.64 8.83e-11 5.16e-08 0.37 0.29 Corneal astigmatism; chr4:119317499 chr4:119391831~119395335:- LUSC cis rs11098499 0.575 rs907205 ENSG00000249244.1 RP11-548H18.2 6.64 8.83e-11 5.16e-08 0.37 0.29 Corneal astigmatism; chr4:119317509 chr4:119391831~119395335:- LUSC cis rs2179367 0.959 rs537354 ENSG00000231760.4 RP11-350J20.5 6.64 8.84e-11 5.17e-08 0.38 0.29 Dupuytren's disease; chr6:149344801 chr6:149796151~149826294:- LUSC cis rs9549367 0.713 rs9549691 ENSG00000269125.1 RP11-98F14.11 -6.64 8.84e-11 5.17e-08 -0.37 -0.29 Platelet distribution width; chr13:113207292 chr13:113165002~113165183:- LUSC cis rs6142102 0.602 rs2268086 ENSG00000275784.1 RP5-1125A11.6 6.64 8.84e-11 5.17e-08 0.32 0.29 Skin pigmentation; chr20:34060932 chr20:33989480~33991818:- LUSC cis rs6142102 1 rs6059681 ENSG00000276073.1 RP5-1125A11.7 -6.64 8.84e-11 5.17e-08 -0.31 -0.29 Skin pigmentation; chr20:34135535 chr20:33985617~33988989:- LUSC cis rs1823913 0.599 rs13399251 ENSG00000227542.1 AC092614.2 6.64 8.84e-11 5.17e-08 0.37 0.29 Obesity-related traits; chr2:191268758 chr2:191229165~191246172:- LUSC cis rs10800713 0.954 rs6667081 ENSG00000260088.1 RP11-92G12.3 -6.64 8.84e-11 5.17e-08 -0.41 -0.29 Tandem gait; chr1:200593366 chr1:200669507~200694250:+ LUSC cis rs10800713 0.954 rs6673474 ENSG00000260088.1 RP11-92G12.3 -6.64 8.84e-11 5.17e-08 -0.41 -0.29 Tandem gait; chr1:200594991 chr1:200669507~200694250:+ LUSC cis rs6142102 0.812 rs2377955 ENSG00000276073.1 RP5-1125A11.7 -6.64 8.85e-11 5.17e-08 -0.31 -0.29 Skin pigmentation; chr20:33937564 chr20:33985617~33988989:- LUSC cis rs748404 0.666 rs34178146 ENSG00000249839.1 AC011330.5 -6.64 8.85e-11 5.18e-08 -0.5 -0.29 Lung cancer; chr15:43384406 chr15:43663654~43684339:- LUSC cis rs11089937 0.568 rs12160318 ENSG00000211638.2 IGLV8-61 -6.64 8.86e-11 5.18e-08 -0.32 -0.29 Periodontitis (PAL4Q3); chr22:22131627 chr22:22098700~22099212:+ LUSC cis rs748404 1 rs748404 ENSG00000249839.1 AC011330.5 -6.64 8.87e-11 5.19e-08 -0.46 -0.29 Lung cancer; chr15:43267033 chr15:43663654~43684339:- LUSC cis rs673078 0.615 rs56324376 ENSG00000275759.1 RP11-131L12.3 -6.64 8.89e-11 5.2e-08 -0.38 -0.29 Glucose homeostasis traits; chr12:118372134 chr12:118428281~118428870:+ LUSC cis rs783540 0.5 rs7178459 ENSG00000276710.3 CSPG4P8 -6.64 8.92e-11 5.21e-08 -0.34 -0.29 Schizophrenia; chr15:82729632 chr15:82459472~82477258:+ LUSC cis rs2903698 0.585 rs61334117 ENSG00000250735.4 RP11-567N4.3 6.64 8.92e-11 5.21e-08 0.33 0.29 Prion diseases; chr4:75453734 chr4:75401195~75423023:+ LUSC cis rs7267979 1 rs6050561 ENSG00000274973.1 RP13-401N8.7 6.64 8.94e-11 5.23e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25354219 chr20:25845497~25845862:+ LUSC cis rs9903692 0.954 rs8080662 ENSG00000278765.1 RP5-890E16.5 -6.64 8.94e-11 5.23e-08 -0.35 -0.29 Pulse pressure; chr17:48113457 chr17:48066704~48067293:- LUSC cis rs10740039 0.883 rs34168977 ENSG00000254271.1 RP11-131N11.4 6.64 8.94e-11 5.23e-08 0.4 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60632916 chr10:60734342~60741828:+ LUSC cis rs875971 0.867 rs1002053 ENSG00000237310.1 GS1-124K5.4 -6.64 8.95e-11 5.23e-08 -0.3 -0.29 Aortic root size; chr7:66333558 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs6460292 ENSG00000237310.1 GS1-124K5.4 -6.64 8.95e-11 5.23e-08 -0.3 -0.29 Aortic root size; chr7:66345088 chr7:66493706~66495474:+ LUSC cis rs10129255 0.536 rs8004835 ENSG00000211970.3 IGHV4-61 -6.64 8.95e-11 5.23e-08 -0.18 -0.29 Kawasaki disease; chr14:106686361 chr14:106639119~106639657:- LUSC cis rs801193 1 rs13239306 ENSG00000236529.1 RP13-254B10.1 -6.64 8.95e-11 5.23e-08 -0.3 -0.29 Aortic root size; chr7:66671030 chr7:65840212~65840596:+ LUSC cis rs11098499 0.604 rs2389887 ENSG00000250412.1 KLHL2P1 6.63 8.97e-11 5.24e-08 0.37 0.29 Corneal astigmatism; chr4:119649489 chr4:119334329~119378233:+ LUSC cis rs3750965 0.839 rs921670 ENSG00000260895.1 RP11-554A11.7 6.63 8.98e-11 5.25e-08 0.34 0.29 Hair color; chr11:69104171 chr11:69103493~69109094:+ LUSC cis rs5753618 0.583 rs8138596 ENSG00000236132.1 CTA-440B3.1 -6.63 8.98e-11 5.25e-08 -0.4 -0.29 Colorectal cancer; chr22:31390975 chr22:31816379~31817491:- LUSC cis rs10262624 1 rs9769098 ENSG00000234286.1 AC006026.13 -6.63 8.98e-11 5.25e-08 -0.34 -0.29 Schizophrenia; chr7:23877113 chr7:23680195~23680786:- LUSC cis rs10262624 0.967 rs12333669 ENSG00000234286.1 AC006026.13 -6.63 8.98e-11 5.25e-08 -0.34 -0.29 Schizophrenia; chr7:23877267 chr7:23680195~23680786:- LUSC cis rs10262624 0.935 rs10487596 ENSG00000234286.1 AC006026.13 -6.63 8.98e-11 5.25e-08 -0.34 -0.29 Schizophrenia; chr7:23877458 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs10950973 ENSG00000234286.1 AC006026.13 -6.63 8.98e-11 5.25e-08 -0.34 -0.29 Schizophrenia; chr7:23877658 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs10950974 ENSG00000234286.1 AC006026.13 -6.63 8.98e-11 5.25e-08 -0.34 -0.29 Schizophrenia; chr7:23877661 chr7:23680195~23680786:- LUSC cis rs10262624 1 rs10950975 ENSG00000234286.1 AC006026.13 -6.63 8.98e-11 5.25e-08 -0.34 -0.29 Schizophrenia; chr7:23877861 chr7:23680195~23680786:- LUSC cis rs10262624 0.967 rs13244145 ENSG00000234286.1 AC006026.13 -6.63 8.98e-11 5.25e-08 -0.34 -0.29 Schizophrenia; chr7:23878123 chr7:23680195~23680786:- LUSC cis rs113835537 0.529 rs3816492 ENSG00000255517.5 CTD-3074O7.5 -6.63 8.99e-11 5.25e-08 -0.35 -0.29 Airway imaging phenotypes; chr11:66529892 chr11:66473490~66480233:- LUSC cis rs9309473 0.847 rs4547554 ENSG00000163016.8 ALMS1P 6.63 9.01e-11 5.26e-08 0.35 0.29 Metabolite levels; chr2:73640735 chr2:73644919~73685576:+ LUSC cis rs2404602 0.647 rs7165053 ENSG00000259422.1 RP11-593F23.1 -6.63 9.01e-11 5.26e-08 -0.35 -0.29 Blood metabolite levels; chr15:76686577 chr15:76174891~76181486:- LUSC cis rs9322193 0.884 rs880245 ENSG00000268592.3 RAET1E-AS1 -6.63 9.02e-11 5.27e-08 -0.37 -0.29 Lung cancer; chr6:149846262 chr6:149863494~149919507:+ LUSC cis rs12554020 0.786 rs79804179 ENSG00000227603.1 RP11-165J3.6 6.63 9.02e-11 5.27e-08 0.47 0.29 Schizophrenia; chr9:93486200 chr9:93435332~93437121:- LUSC cis rs2404602 0.647 rs12913024 ENSG00000259422.1 RP11-593F23.1 -6.63 9.03e-11 5.27e-08 -0.36 -0.29 Blood metabolite levels; chr15:76852875 chr15:76174891~76181486:- LUSC cis rs853679 0.517 rs4713146 ENSG00000204709.4 LINC01556 6.63 9.06e-11 5.29e-08 0.42 0.29 Depression; chr6:28143758 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393894 ENSG00000204709.4 LINC01556 6.63 9.06e-11 5.29e-08 0.42 0.29 Depression; chr6:28144784 chr6:28943877~28944537:+ LUSC cis rs17023223 0.537 rs2645301 ENSG00000231365.4 RP11-418J17.1 -6.63 9.08e-11 5.3e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119047797 chr1:119140396~119275973:+ LUSC cis rs6504950 0.83 rs17817877 ENSG00000275710.1 RP11-257O5.4 6.63 9.08e-11 5.3e-08 0.36 0.29 Breast cancer; chr17:54957267 chr17:54964474~54964679:+ LUSC cis rs7246657 0.943 rs7259968 ENSG00000276846.1 CTD-3220F14.3 6.63 9.09e-11 5.31e-08 0.45 0.29 Coronary artery calcification; chr19:37320952 chr19:37314868~37315620:- LUSC cis rs12554020 0.786 rs12553389 ENSG00000227603.1 RP11-165J3.6 6.63 9.11e-11 5.32e-08 0.46 0.29 Schizophrenia; chr9:93500979 chr9:93435332~93437121:- LUSC cis rs12554020 0.786 rs78865387 ENSG00000227603.1 RP11-165J3.6 6.63 9.11e-11 5.32e-08 0.46 0.29 Schizophrenia; chr9:93501827 chr9:93435332~93437121:- LUSC cis rs2980436 1 rs2980436 ENSG00000253893.2 FAM85B 6.63 9.12e-11 5.32e-08 0.37 0.29 Schizophrenia; chr8:8234503 chr8:8167819~8226614:- LUSC cis rs9903692 0.779 rs2285863 ENSG00000278765.1 RP5-890E16.5 6.63 9.16e-11 5.34e-08 0.35 0.29 Pulse pressure; chr17:48048616 chr17:48066704~48067293:- LUSC cis rs2179367 0.632 rs2143075 ENSG00000231760.4 RP11-350J20.5 6.63 9.16e-11 5.35e-08 0.42 0.29 Dupuytren's disease; chr6:149425507 chr6:149796151~149826294:- LUSC cis rs10800713 0.866 rs6703783 ENSG00000260088.1 RP11-92G12.3 -6.63 9.16e-11 5.35e-08 -0.41 -0.29 Tandem gait; chr1:200544290 chr1:200669507~200694250:+ LUSC cis rs7250849 0.565 rs7255319 ENSG00000273837.1 LLNLR-470E3.1 6.63 9.17e-11 5.35e-08 0.38 0.29 Blood protein levels; chr19:51664653 chr19:51639478~51639931:- LUSC cis rs2404602 0.647 rs12910820 ENSG00000259422.1 RP11-593F23.1 -6.63 9.22e-11 5.38e-08 -0.35 -0.29 Blood metabolite levels; chr15:76730484 chr15:76174891~76181486:- LUSC cis rs10129255 0.556 rs8010005 ENSG00000224373.3 IGHV4-59 6.63 9.22e-11 5.38e-08 0.15 0.29 Kawasaki disease; chr14:106777987 chr14:106627249~106627825:- LUSC cis rs10129255 0.556 rs6576224 ENSG00000224373.3 IGHV4-59 6.63 9.22e-11 5.38e-08 0.15 0.29 Kawasaki disease; chr14:106777997 chr14:106627249~106627825:- LUSC cis rs10129255 0.518 rs8010020 ENSG00000224373.3 IGHV4-59 6.63 9.22e-11 5.38e-08 0.15 0.29 Kawasaki disease; chr14:106778016 chr14:106627249~106627825:- LUSC cis rs12908161 1 rs12905057 ENSG00000259728.4 LINC00933 6.63 9.23e-11 5.39e-08 0.38 0.29 Schizophrenia; chr15:84667534 chr15:84570649~84580175:+ LUSC cis rs950169 0.544 rs62021193 ENSG00000259728.4 LINC00933 6.63 9.24e-11 5.39e-08 0.37 0.29 Schizophrenia; chr15:84627352 chr15:84570649~84580175:+ LUSC cis rs10262624 0.935 rs6955725 ENSG00000234286.1 AC006026.13 -6.63 9.25e-11 5.4e-08 -0.35 -0.29 Schizophrenia; chr7:23865523 chr7:23680195~23680786:- LUSC cis rs113835537 0.559 rs74933537 ENSG00000255517.5 CTD-3074O7.5 -6.63 9.27e-11 5.4e-08 -0.34 -0.29 Airway imaging phenotypes; chr11:66507487 chr11:66473490~66480233:- LUSC cis rs6496044 0.963 rs11853972 ENSG00000202081.1 RNU6-1280P 6.63 9.28e-11 5.41e-08 0.33 0.29 Interstitial lung disease; chr15:85519209 chr15:85651522~85651628:- LUSC cis rs881375 1 rs6478486 ENSG00000226752.6 PSMD5-AS1 -6.63 9.28e-11 5.41e-08 -0.34 -0.29 Rheumatoid arthritis; chr9:120893051 chr9:120824828~120854385:+ LUSC cis rs7267979 1 rs6083813 ENSG00000274973.1 RP13-401N8.7 6.63 9.29e-11 5.41e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25357035 chr20:25845497~25845862:+ LUSC cis rs4604732 0.578 rs12038656 ENSG00000227135.1 GCSAML-AS1 -6.63 9.3e-11 5.42e-08 -0.44 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247460514 chr1:247524679~247526752:- LUSC cis rs10262624 1 rs10262624 ENSG00000234286.1 AC006026.13 -6.63 9.31e-11 5.43e-08 -0.34 -0.29 Schizophrenia; chr7:23876057 chr7:23680195~23680786:- LUSC cis rs10262624 0.967 rs7792734 ENSG00000234286.1 AC006026.13 -6.63 9.31e-11 5.43e-08 -0.34 -0.29 Schizophrenia; chr7:23876429 chr7:23680195~23680786:- LUSC cis rs9318086 0.901 rs7336730 ENSG00000205861.10 C1QTNF9B-AS1 6.63 9.31e-11 5.43e-08 0.36 0.29 Myopia (pathological); chr13:23877965 chr13:23888889~23897263:+ LUSC cis rs853679 0.517 rs16893666 ENSG00000204709.4 LINC01556 -6.63 9.35e-11 5.45e-08 -0.41 -0.29 Depression; chr6:28086929 chr6:28943877~28944537:+ LUSC cis rs4972806 0.814 rs2113560 ENSG00000226363.3 HAGLROS -6.63 9.36e-11 5.45e-08 -0.36 -0.29 IgG glycosylation; chr2:176166258 chr2:176177717~176179008:+ LUSC cis rs875971 0.522 rs2949690 ENSG00000164669.11 INTS4P1 6.63 9.36e-11 5.45e-08 0.32 0.29 Aortic root size; chr7:66018255 chr7:65141225~65234216:+ LUSC cis rs10875746 0.517 rs12721420 ENSG00000240399.1 RP1-228P16.1 -6.63 9.37e-11 5.46e-08 -0.38 -0.29 Longevity (90 years and older); chr12:47965011 chr12:48054813~48055591:- LUSC cis rs9376098 0.698 rs6929368 ENSG00000232876.1 CTA-212D2.2 6.63 9.41e-11 5.48e-08 0.35 0.29 Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells; chr6:135146587 chr6:135055033~135060550:+ LUSC cis rs2019137 0.868 rs3748916 ENSG00000274877.1 RP11-65I12.1 6.63 9.41e-11 5.48e-08 0.35 0.29 Lymphocyte counts; chr2:113226456 chr2:113237595~113240825:+ LUSC cis rs2919917 1 rs3736169 ENSG00000254352.1 RP11-578O24.2 6.63 9.41e-11 5.48e-08 0.37 0.29 Lymphocyte counts; chr8:78675620 chr8:78723796~78724136:- LUSC cis rs11690935 0.959 rs4668412 ENSG00000228389.1 AC068039.4 6.63 9.44e-11 5.5e-08 0.34 0.29 Schizophrenia; chr2:171763260 chr2:171773482~171775844:+ LUSC cis rs11098499 0.697 rs35280960 ENSG00000249244.1 RP11-548H18.2 6.63 9.44e-11 5.5e-08 0.37 0.29 Corneal astigmatism; chr4:119335904 chr4:119391831~119395335:- LUSC cis rs12291225 0.585 rs11023194 ENSG00000251991.1 RNU7-49P 6.63 9.44e-11 5.5e-08 0.33 0.29 Sense of smell; chr11:14348223 chr11:14478892~14478953:+ LUSC cis rs8177376 0.953 rs73017399 ENSG00000254905.1 RP11-712L6.7 6.63 9.45e-11 5.5e-08 0.41 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126316417 chr11:126292922~126294254:- LUSC cis rs2179367 0.919 rs577001 ENSG00000231760.4 RP11-350J20.5 6.63 9.46e-11 5.51e-08 0.38 0.29 Dupuytren's disease; chr6:149325172 chr6:149796151~149826294:- LUSC cis rs3747113 1 rs1041748 ENSG00000128262.7 POM121L9P -6.63 9.46e-11 5.51e-08 -0.31 -0.29 Gut microbiome composition (summer); chr22:24304886 chr22:24251828~24265525:+ LUSC cis rs71403859 0.73 rs12922775 ENSG00000260886.1 TAT-AS1 6.63 9.47e-11 5.51e-08 0.46 0.29 Post bronchodilator FEV1; chr16:71550451 chr16:71565789~71578187:+ LUSC cis rs9928842 0.941 rs1808427 ENSG00000280152.1 RP11-331F4.5 6.63 9.48e-11 5.52e-08 0.37 0.29 Alcoholic chronic pancreatitis; chr16:75207496 chr16:75245994~75250077:- LUSC cis rs16885979 1 rs12664791 ENSG00000224984.1 RP11-524H19.2 6.63 9.49e-11 5.52e-08 0.63 0.29 Daytime sleep phenotypes; chr6:54829547 chr6:54840118~54840855:- LUSC cis rs17023223 0.537 rs1325938 ENSG00000231365.4 RP11-418J17.1 -6.63 9.51e-11 5.53e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119040019 chr1:119140396~119275973:+ LUSC cis rs761746 0.579 rs5998126 ENSG00000236132.1 CTA-440B3.1 -6.63 9.52e-11 5.54e-08 -0.42 -0.29 Intelligence; chr22:31782416 chr22:31816379~31817491:- LUSC cis rs6772849 0.93 rs9813197 ENSG00000242551.2 POU5F1P6 -6.62 9.53e-11 5.54e-08 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128650261 chr3:128674735~128677005:- LUSC cis rs4713118 0.955 rs9393848 ENSG00000219392.1 RP1-265C24.5 -6.62 9.53e-11 5.55e-08 -0.39 -0.29 Parkinson's disease; chr6:27720590 chr6:28115628~28116551:+ LUSC cis rs950169 1 rs950169 ENSG00000259728.4 LINC00933 6.62 9.55e-11 5.56e-08 0.39 0.29 Schizophrenia; chr15:84037709 chr15:84570649~84580175:+ LUSC cis rs6700559 0.74 rs11582610 ENSG00000260088.1 RP11-92G12.3 6.62 9.57e-11 5.57e-08 0.37 0.29 Coronary artery disease; chr1:200675973 chr1:200669507~200694250:+ LUSC cis rs6700559 0.74 rs10919997 ENSG00000260088.1 RP11-92G12.3 6.62 9.57e-11 5.57e-08 0.37 0.29 Coronary artery disease; chr1:200677522 chr1:200669507~200694250:+ LUSC cis rs6700559 0.74 rs4072551 ENSG00000260088.1 RP11-92G12.3 6.62 9.57e-11 5.57e-08 0.37 0.29 Coronary artery disease; chr1:200679993 chr1:200669507~200694250:+ LUSC cis rs6700559 0.74 rs4072554 ENSG00000260088.1 RP11-92G12.3 6.62 9.57e-11 5.57e-08 0.37 0.29 Coronary artery disease; chr1:200680238 chr1:200669507~200694250:+ LUSC cis rs6700559 0.74 rs10919999 ENSG00000260088.1 RP11-92G12.3 6.62 9.57e-11 5.57e-08 0.37 0.29 Coronary artery disease; chr1:200680631 chr1:200669507~200694250:+ LUSC cis rs6700559 0.654 rs12061556 ENSG00000260088.1 RP11-92G12.3 6.62 9.57e-11 5.57e-08 0.37 0.29 Coronary artery disease; chr1:200681111 chr1:200669507~200694250:+ LUSC cis rs10129255 0.957 rs8005468 ENSG00000224373.3 IGHV4-59 6.62 9.58e-11 5.57e-08 0.16 0.29 Kawasaki disease; chr14:106686431 chr14:106627249~106627825:- LUSC cis rs7267979 1 rs6050598 ENSG00000274973.1 RP13-401N8.7 -6.62 9.59e-11 5.57e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25416621 chr20:25845497~25845862:+ LUSC cis rs11098499 0.526 rs10026625 ENSG00000249244.1 RP11-548H18.2 6.62 9.6e-11 5.58e-08 0.35 0.29 Corneal astigmatism; chr4:119358981 chr4:119391831~119395335:- LUSC cis rs9309473 0.95 rs2947860 ENSG00000163016.8 ALMS1P 6.62 9.61e-11 5.59e-08 0.35 0.29 Metabolite levels; chr2:73628259 chr2:73644919~73685576:+ LUSC cis rs853679 0.607 rs68188794 ENSG00000204709.4 LINC01556 6.62 9.61e-11 5.59e-08 0.65 0.29 Depression; chr6:28112999 chr6:28943877~28944537:+ LUSC cis rs11123170 0.543 rs2166421 ENSG00000274877.1 RP11-65I12.1 -6.62 9.61e-11 5.59e-08 -0.41 -0.29 Renal function-related traits (BUN); chr2:113232665 chr2:113237595~113240825:+ LUSC cis rs2286503 1 rs2286501 ENSG00000228649.7 AC005682.5 6.62 9.61e-11 5.59e-08 0.32 0.29 Fibrinogen; chr7:22817166 chr7:22854178~22861579:+ LUSC cis rs11098499 0.82 rs13128602 ENSG00000250412.1 KLHL2P1 -6.62 9.61e-11 5.59e-08 -0.36 -0.29 Corneal astigmatism; chr4:119538211 chr4:119334329~119378233:+ LUSC cis rs11089937 0.568 rs11089919 ENSG00000211638.2 IGLV8-61 -6.62 9.62e-11 5.59e-08 -0.32 -0.29 Periodontitis (PAL4Q3); chr22:22131648 chr22:22098700~22099212:+ LUSC cis rs11089937 0.523 rs4820352 ENSG00000211639.2 IGLV4-60 6.62 9.62e-11 5.59e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22189203 chr22:22162199~22162681:+ LUSC cis rs2028299 0.919 rs3759831 ENSG00000259677.1 RP11-493E3.1 6.62 9.63e-11 5.6e-08 0.37 0.29 Type 2 diabetes; chr15:89871410 chr15:89876540~89877285:+ LUSC cis rs442309 0.574 rs7895364 ENSG00000238280.1 RP11-436D10.3 -6.62 9.64e-11 5.6e-08 -0.36 -0.29 Vogt-Koyanagi-Harada syndrome; chr10:62725053 chr10:62793562~62805887:- LUSC cis rs9309473 0.95 rs13431529 ENSG00000163016.8 ALMS1P 6.62 9.66e-11 5.61e-08 0.35 0.29 Metabolite levels; chr2:73648914 chr2:73644919~73685576:+ LUSC cis rs2179367 0.92 rs560051 ENSG00000231760.4 RP11-350J20.5 6.62 9.69e-11 5.63e-08 0.38 0.29 Dupuytren's disease; chr6:149345841 chr6:149796151~149826294:- LUSC cis rs10262624 0.967 rs2188845 ENSG00000234286.1 AC006026.13 -6.62 9.69e-11 5.63e-08 -0.34 -0.29 Schizophrenia; chr7:23882391 chr7:23680195~23680786:- LUSC cis rs881375 1 rs7037140 ENSG00000226752.6 PSMD5-AS1 -6.62 9.69e-11 5.63e-08 -0.34 -0.29 Rheumatoid arthritis; chr9:120894049 chr9:120824828~120854385:+ LUSC cis rs2179367 0.959 rs540538 ENSG00000231760.4 RP11-350J20.5 6.62 9.69e-11 5.63e-08 0.38 0.29 Dupuytren's disease; chr6:149326808 chr6:149796151~149826294:- LUSC cis rs4950322 0.518 rs61838951 ENSG00000278811.3 LINC00624 6.62 9.7e-11 5.64e-08 0.31 0.29 Protein quantitative trait loci; chr1:147116081 chr1:147258885~147517875:- LUSC cis rs7246657 0.943 rs10420722 ENSG00000276846.1 CTD-3220F14.3 6.62 9.7e-11 5.64e-08 0.45 0.29 Coronary artery calcification; chr19:37482872 chr19:37314868~37315620:- LUSC cis rs3743266 0.507 rs34092508 ENSG00000245534.5 RORA-AS1 -6.62 9.71e-11 5.64e-08 -0.44 -0.29 Menarche (age at onset); chr15:60430780 chr15:60479178~60630637:+ LUSC cis rs11690935 0.959 rs10803863 ENSG00000228389.1 AC068039.4 -6.62 9.72e-11 5.64e-08 -0.34 -0.29 Schizophrenia; chr2:171678827 chr2:171773482~171775844:+ LUSC cis rs11123170 0.543 rs12472361 ENSG00000274877.1 RP11-65I12.1 -6.62 9.72e-11 5.65e-08 -0.41 -0.29 Renal function-related traits (BUN); chr2:113223068 chr2:113237595~113240825:+ LUSC cis rs801193 0.967 rs2707853 ENSG00000224316.1 RP11-479O9.2 6.62 9.72e-11 5.65e-08 0.28 0.29 Aortic root size; chr7:66749023 chr7:65773620~65802067:+ LUSC cis rs7246657 0.943 rs10407084 ENSG00000276846.1 CTD-3220F14.3 6.62 9.73e-11 5.65e-08 0.45 0.29 Coronary artery calcification; chr19:37416890 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs7252099 ENSG00000276846.1 CTD-3220F14.3 6.62 9.73e-11 5.65e-08 0.45 0.29 Coronary artery calcification; chr19:37442878 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs7255972 ENSG00000276846.1 CTD-3220F14.3 6.62 9.73e-11 5.65e-08 0.45 0.29 Coronary artery calcification; chr19:37442939 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs1015849 ENSG00000276846.1 CTD-3220F14.3 6.62 9.73e-11 5.65e-08 0.45 0.29 Coronary artery calcification; chr19:37455278 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs13343502 ENSG00000276846.1 CTD-3220F14.3 6.62 9.73e-11 5.65e-08 0.45 0.29 Coronary artery calcification; chr19:37471390 chr19:37314868~37315620:- LUSC cis rs6921919 0.583 rs1054372 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28368965 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs9468354 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28370024 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs7773051 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28372539 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs12697938 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28373322 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs13437294 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28373758 chr6:28943877~28944537:+ LUSC cis rs6921919 0.609 rs9468357 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28374276 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs34513104 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28375566 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs9461456 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28376039 chr6:28943877~28944537:+ LUSC cis rs6921919 0.525 rs9468360 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28376661 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs16894021 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28377249 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs11751693 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28377306 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs7749736 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28378254 chr6:28943877~28944537:+ LUSC cis rs6921919 0.525 rs9468361 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28378541 chr6:28943877~28944537:+ LUSC cis rs6921919 0.583 rs7775132 ENSG00000204709.4 LINC01556 6.62 9.75e-11 5.66e-08 0.38 0.29 Autism spectrum disorder or schizophrenia; chr6:28379236 chr6:28943877~28944537:+ LUSC cis rs4713118 0.955 rs9368529 ENSG00000219392.1 RP1-265C24.5 -6.62 9.76e-11 5.66e-08 -0.39 -0.29 Parkinson's disease; chr6:27716852 chr6:28115628~28116551:+ LUSC cis rs62432291 0.681 rs397476 ENSG00000235086.1 FNDC1-IT1 -6.62 9.76e-11 5.67e-08 -0.49 -0.29 Joint mobility (Beighton score); chr6:159218252 chr6:159240786~159243329:+ LUSC cis rs7246657 0.714 rs12972195 ENSG00000276846.1 CTD-3220F14.3 6.62 9.77e-11 5.67e-08 0.45 0.29 Coronary artery calcification; chr19:37261603 chr19:37314868~37315620:- LUSC cis rs881375 0.967 rs2416806 ENSG00000226752.6 PSMD5-AS1 -6.62 9.78e-11 5.67e-08 -0.33 -0.29 Rheumatoid arthritis; chr9:120928014 chr9:120824828~120854385:+ LUSC cis rs4713118 0.662 rs149947 ENSG00000204709.4 LINC01556 6.62 9.79e-11 5.68e-08 0.41 0.29 Parkinson's disease; chr6:28004655 chr6:28943877~28944537:+ LUSC cis rs916888 0.773 rs199448 ENSG00000261575.2 RP11-259G18.1 6.62 9.79e-11 5.68e-08 0.37 0.29 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46267037~46268694:+ LUSC cis rs2404602 0.735 rs2454450 ENSG00000259422.1 RP11-593F23.1 -6.62 9.79e-11 5.68e-08 -0.34 -0.29 Blood metabolite levels; chr15:76538895 chr15:76174891~76181486:- LUSC cis rs1876905 0.539 rs240980 ENSG00000255389.1 C6orf3 -6.62 9.79e-11 5.68e-08 -0.4 -0.29 Mean corpuscular hemoglobin; chr6:111288707 chr6:111599875~111602295:+ LUSC cis rs875971 1 rs6958484 ENSG00000237310.1 GS1-124K5.4 -6.62 9.79e-11 5.68e-08 -0.3 -0.29 Aortic root size; chr7:66134459 chr7:66493706~66495474:+ LUSC cis rs13113518 0.683 rs9761521 ENSG00000249700.7 SRD5A3-AS1 6.62 9.8e-11 5.68e-08 0.33 0.29 Height; chr4:55363436 chr4:55363971~55395847:- LUSC cis rs11089937 0.54 rs9622920 ENSG00000211638.2 IGLV8-61 6.62 9.8e-11 5.68e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22133024 chr22:22098700~22099212:+ LUSC cis rs4972806 0.849 rs1542180 ENSG00000226363.3 HAGLROS -6.62 9.8e-11 5.69e-08 -0.35 -0.29 IgG glycosylation; chr2:176164039 chr2:176177717~176179008:+ LUSC cis rs7267979 0.966 rs7270835 ENSG00000274973.1 RP13-401N8.7 -6.62 9.8e-11 5.69e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25454431 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6115191 ENSG00000274973.1 RP13-401N8.7 -6.62 9.8e-11 5.69e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25459842 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6107045 ENSG00000274973.1 RP13-401N8.7 -6.62 9.8e-11 5.69e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25461300 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6107046 ENSG00000274973.1 RP13-401N8.7 -6.62 9.8e-11 5.69e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25461413 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6107047 ENSG00000274973.1 RP13-401N8.7 -6.62 9.8e-11 5.69e-08 -0.3 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25461461 chr20:25845497~25845862:+ LUSC cis rs4308124 0.708 rs2137168 ENSG00000227992.1 AC108463.2 -6.62 9.81e-11 5.69e-08 -0.39 -0.29 Vitiligo; chr2:111228932 chr2:111203964~111206215:- LUSC cis rs11976180 1 rs2951354 ENSG00000170356.8 OR2A20P -6.62 9.82e-11 5.7e-08 -0.4 -0.29 Obesity-related traits; chr7:144063908 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs2961125 ENSG00000170356.8 OR2A20P -6.62 9.82e-11 5.7e-08 -0.4 -0.29 Obesity-related traits; chr7:144064677 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs2961126 ENSG00000170356.8 OR2A20P -6.62 9.82e-11 5.7e-08 -0.4 -0.29 Obesity-related traits; chr7:144065643 chr7:144250045~144252957:- LUSC cis rs11976180 0.953 rs2961127 ENSG00000170356.8 OR2A20P -6.62 9.82e-11 5.7e-08 -0.4 -0.29 Obesity-related traits; chr7:144065644 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs1919948 ENSG00000170356.8 OR2A20P -6.62 9.82e-11 5.7e-08 -0.4 -0.29 Obesity-related traits; chr7:144065750 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs2961128 ENSG00000170356.8 OR2A20P -6.62 9.82e-11 5.7e-08 -0.4 -0.29 Obesity-related traits; chr7:144066390 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs2371248 ENSG00000170356.8 OR2A20P -6.62 9.82e-11 5.7e-08 -0.4 -0.29 Obesity-related traits; chr7:144067096 chr7:144250045~144252957:- LUSC cis rs34375054 0.738 rs10846834 ENSG00000279233.1 RP11-158L12.4 6.62 9.83e-11 5.7e-08 0.26 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125141024 chr12:125138245~125141711:+ LUSC cis rs75422866 0.51 rs73104197 ENSG00000257433.4 RP1-197B17.3 6.62 9.84e-11 5.7e-08 0.64 0.29 Pneumonia; chr12:47717273 chr12:47706085~47742294:+ LUSC cis rs11690935 1 rs12053003 ENSG00000228389.1 AC068039.4 -6.62 9.84e-11 5.71e-08 -0.34 -0.29 Schizophrenia; chr2:171680840 chr2:171773482~171775844:+ LUSC cis rs4853012 0.838 rs59570457 ENSG00000257800.1 FNBP1P1 6.62 9.84e-11 5.71e-08 0.34 0.29 Gestational age at birth (maternal effect); chr2:74117155 chr2:74120680~74123218:+ LUSC cis rs11098499 0.954 rs12502423 ENSG00000250412.1 KLHL2P1 6.62 9.86e-11 5.71e-08 0.36 0.29 Corneal astigmatism; chr4:119503017 chr4:119334329~119378233:+ LUSC cis rs881375 0.967 rs1930781 ENSG00000226752.6 PSMD5-AS1 -6.62 9.88e-11 5.73e-08 -0.33 -0.29 Rheumatoid arthritis; chr9:120925556 chr9:120824828~120854385:+ LUSC cis rs10740039 0.846 rs10761529 ENSG00000254271.1 RP11-131N11.4 6.62 9.91e-11 5.74e-08 0.4 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60627052 chr10:60734342~60741828:+ LUSC cis rs11168351 1 rs11168351 ENSG00000240399.1 RP1-228P16.1 6.62 9.91e-11 5.74e-08 0.29 0.29 Bipolar disorder and schizophrenia; chr12:48009982 chr12:48054813~48055591:- LUSC cis rs7829975 0.593 rs2921051 ENSG00000253893.2 FAM85B -6.62 9.91e-11 5.74e-08 -0.34 -0.29 Mood instability; chr8:8462594 chr8:8167819~8226614:- LUSC cis rs8028182 0.537 rs4371118 ENSG00000260269.4 CTD-2323K18.1 -6.62 9.96e-11 5.76e-08 -0.42 -0.29 Sudden cardiac arrest; chr15:75606549 chr15:75527150~75601205:- LUSC cis rs7189233 1 rs62048520 ENSG00000279344.1 RP11-44F14.7 6.62 9.99e-11 5.79e-08 0.26 0.29 Intelligence (multi-trait analysis); chr16:53457183 chr16:53478957~53481550:- LUSC cis rs34375054 0.672 rs10400509 ENSG00000279233.1 RP11-158L12.4 6.62 1e-10 5.8e-08 0.26 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125107627 chr12:125138245~125141711:+ LUSC cis rs1865760 0.663 rs9467656 ENSG00000272462.2 U91328.19 -6.62 1e-10 5.8e-08 -0.3 -0.29 Height; chr6:25993331 chr6:25992662~26001775:+ LUSC cis rs9309473 0.95 rs11126412 ENSG00000163016.8 ALMS1P 6.62 1e-10 5.81e-08 0.36 0.29 Metabolite levels; chr2:73660507 chr2:73644919~73685576:+ LUSC cis rs17507216 0.671 rs28582623 ENSG00000255769.6 GOLGA2P10 -6.62 1e-10 5.82e-08 -0.44 -0.29 Excessive daytime sleepiness; chr15:82577381 chr15:82472993~82513950:- LUSC cis rs12554020 0.786 rs7035657 ENSG00000227603.1 RP11-165J3.6 -6.62 1e-10 5.82e-08 -0.37 -0.29 Schizophrenia; chr9:93434769 chr9:93435332~93437121:- LUSC cis rs17767294 0.612 rs9461425 ENSG00000219392.1 RP1-265C24.5 -6.62 1.01e-10 5.83e-08 -0.63 -0.29 Parkinson's disease; chr6:27951910 chr6:28115628~28116551:+ LUSC cis rs11089937 0.616 rs5757258 ENSG00000211639.2 IGLV4-60 6.62 1.01e-10 5.84e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22179648 chr22:22162199~22162681:+ LUSC cis rs4972806 0.849 rs2071581 ENSG00000226363.3 HAGLROS -6.62 1.01e-10 5.84e-08 -0.36 -0.29 IgG glycosylation; chr2:176161420 chr2:176177717~176179008:+ LUSC cis rs11098499 0.691 rs9996644 ENSG00000249244.1 RP11-548H18.2 6.62 1.01e-10 5.84e-08 0.37 0.29 Corneal astigmatism; chr4:119317722 chr4:119391831~119395335:- LUSC cis rs11098499 0.691 rs9996494 ENSG00000249244.1 RP11-548H18.2 6.62 1.01e-10 5.84e-08 0.37 0.29 Corneal astigmatism; chr4:119317725 chr4:119391831~119395335:- LUSC cis rs2903698 0.585 rs35820395 ENSG00000250735.4 RP11-567N4.3 6.62 1.01e-10 5.86e-08 0.33 0.29 Prion diseases; chr4:75455831 chr4:75401195~75423023:+ LUSC cis rs853679 0.517 rs2281588 ENSG00000204709.4 LINC01556 6.61 1.02e-10 5.88e-08 0.42 0.29 Depression; chr6:28104824 chr6:28943877~28944537:+ LUSC cis rs5753618 0.504 rs9609296 ENSG00000236132.1 CTA-440B3.1 -6.61 1.02e-10 5.89e-08 -0.41 -0.29 Colorectal cancer; chr22:31495798 chr22:31816379~31817491:- LUSC cis rs11690935 0.959 rs10166005 ENSG00000228389.1 AC068039.4 6.61 1.02e-10 5.9e-08 0.34 0.29 Schizophrenia; chr2:171750784 chr2:171773482~171775844:+ LUSC cis rs875971 0.965 rs9969301 ENSG00000237310.1 GS1-124K5.4 -6.61 1.02e-10 5.91e-08 -0.3 -0.29 Aortic root size; chr7:66316668 chr7:66493706~66495474:+ LUSC cis rs9322193 0.923 rs10782316 ENSG00000268592.3 RAET1E-AS1 6.61 1.02e-10 5.92e-08 0.37 0.29 Lung cancer; chr6:149752755 chr6:149863494~149919507:+ LUSC cis rs867371 1 rs8041868 ENSG00000255769.6 GOLGA2P10 -6.61 1.03e-10 5.93e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82179985 chr15:82472993~82513950:- LUSC cis rs35955747 0.722 rs5997898 ENSG00000236132.1 CTA-440B3.1 6.61 1.03e-10 5.94e-08 0.35 0.29 Neutrophil count;Sum basophil neutrophil counts; chr22:31176977 chr22:31816379~31817491:- LUSC cis rs228614 0.536 rs150898 ENSG00000230069.3 LRRC37A15P -6.61 1.03e-10 5.94e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769234 chr4:102727274~102730721:- LUSC cis rs950169 0.96 rs12905475 ENSG00000225151.9 GOLGA2P7 -6.61 1.03e-10 5.94e-08 -0.42 -0.29 Schizophrenia; chr15:84131743 chr15:84199311~84230136:- LUSC cis rs17818399 0.597 rs12104572 ENSG00000279254.1 RP11-536C12.1 -6.61 1.03e-10 5.95e-08 -0.32 -0.29 Height; chr2:46635327 chr2:46668870~46670778:+ LUSC cis rs12931792 0.782 rs12927190 ENSG00000183604.13 SMG1P5 6.61 1.03e-10 5.96e-08 0.33 0.29 Tonsillectomy; chr16:30158072 chr16:30267553~30335374:- LUSC cis rs7246657 0.943 rs8106839 ENSG00000276846.1 CTD-3220F14.3 6.61 1.03e-10 5.96e-08 0.45 0.29 Coronary artery calcification; chr19:37467573 chr19:37314868~37315620:- LUSC cis rs11603023 0.874 rs613243 ENSG00000255422.1 AP002954.4 -6.61 1.03e-10 5.96e-08 -0.33 -0.29 Cholesterol, total; chr11:118643304 chr11:118704607~118750263:+ LUSC cis rs13113518 0.812 rs11932712 ENSG00000223305.1 RN7SKP30 6.61 1.03e-10 5.97e-08 0.36 0.29 Height; chr4:55436423 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs12501746 ENSG00000223305.1 RN7SKP30 6.61 1.03e-10 5.97e-08 0.36 0.29 Height; chr4:55437438 chr4:55540502~55540835:- LUSC cis rs6142102 0.923 rs4911394 ENSG00000276073.1 RP5-1125A11.7 -6.61 1.04e-10 5.98e-08 -0.31 -0.29 Skin pigmentation; chr20:33989521 chr20:33985617~33988989:- LUSC cis rs8062405 0.895 rs56186137 ENSG00000278665.1 RP11-666O2.4 6.61 1.04e-10 5.99e-08 0.29 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814632 chr16:28599241~28601881:- LUSC cis rs6142102 0.961 rs6088361 ENSG00000276073.1 RP5-1125A11.7 -6.61 1.04e-10 5.99e-08 -0.3 -0.29 Skin pigmentation; chr20:33969520 chr20:33985617~33988989:- LUSC cis rs2404602 0.735 rs11637490 ENSG00000259422.1 RP11-593F23.1 -6.61 1.04e-10 6e-08 -0.34 -0.29 Blood metabolite levels; chr15:76467224 chr15:76174891~76181486:- LUSC cis rs7772486 0.754 rs9373476 ENSG00000235652.6 RP11-545I5.3 6.61 1.04e-10 6e-08 0.29 0.29 Lobe attachment (rater-scored or self-reported); chr6:145818605 chr6:145799409~145886585:+ LUSC cis rs228614 0.536 rs223478 ENSG00000230069.3 LRRC37A15P -6.61 1.04e-10 6e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102768648 chr4:102727274~102730721:- LUSC cis rs228614 0.509 rs223476 ENSG00000230069.3 LRRC37A15P -6.61 1.04e-10 6e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771000 chr4:102727274~102730721:- LUSC cis rs228614 0.509 rs150896 ENSG00000230069.3 LRRC37A15P -6.61 1.04e-10 6e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771186 chr4:102727274~102730721:- LUSC cis rs11976180 0.953 rs2951355 ENSG00000170356.8 OR2A20P -6.61 1.04e-10 6.01e-08 -0.4 -0.29 Obesity-related traits; chr7:144063469 chr7:144250045~144252957:- LUSC cis rs950169 0.881 rs150965 ENSG00000225151.9 GOLGA2P7 -6.61 1.04e-10 6.01e-08 -0.41 -0.29 Schizophrenia; chr15:84537296 chr15:84199311~84230136:- LUSC cis rs11089937 0.559 rs2330014 ENSG00000211638.2 IGLV8-61 -6.61 1.04e-10 6.02e-08 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22166155 chr22:22098700~22099212:+ LUSC cis rs1075265 0.722 rs7596349 ENSG00000233266.1 HMGB1P31 6.61 1.04e-10 6.02e-08 0.37 0.29 Chronotype;Morning vs. evening chronotype; chr2:53709123 chr2:54051334~54051760:+ LUSC cis rs8062405 0.964 rs11860513 ENSG00000278665.1 RP11-666O2.4 6.61 1.04e-10 6.03e-08 0.29 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814099 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs1987472 ENSG00000278665.1 RP11-666O2.4 6.61 1.04e-10 6.03e-08 0.29 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814456 chr16:28599241~28601881:- LUSC cis rs1865760 0.865 rs9467647 ENSG00000272462.2 U91328.19 -6.61 1.05e-10 6.04e-08 -0.31 -0.29 Height; chr6:25957414 chr6:25992662~26001775:+ LUSC cis rs1865760 0.865 rs10946800 ENSG00000272462.2 U91328.19 -6.61 1.05e-10 6.04e-08 -0.31 -0.29 Height; chr6:25957545 chr6:25992662~26001775:+ LUSC cis rs1823913 0.927 rs13013390 ENSG00000280083.1 RP11-317J9.1 -6.61 1.05e-10 6.05e-08 -0.35 -0.29 Obesity-related traits; chr2:191262001 chr2:191154118~191156070:- LUSC cis rs748404 1 rs66651343 ENSG00000249839.1 AC011330.5 -6.61 1.05e-10 6.06e-08 -0.45 -0.29 Lung cancer; chr15:43265806 chr15:43663654~43684339:- LUSC cis rs9322193 0.923 rs10872644 ENSG00000268592.3 RAET1E-AS1 6.61 1.05e-10 6.06e-08 0.37 0.29 Lung cancer; chr6:149741819 chr6:149863494~149919507:+ LUSC cis rs7772486 0.686 rs9403746 ENSG00000235652.6 RP11-545I5.3 -6.61 1.05e-10 6.07e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145782632 chr6:145799409~145886585:+ LUSC cis rs10463554 0.892 rs17154860 ENSG00000175749.11 EIF3KP1 6.61 1.05e-10 6.07e-08 0.34 0.29 Parkinson's disease; chr5:102955441 chr5:103032376~103033031:+ LUSC cis rs6142102 0.812 rs761236 ENSG00000276073.1 RP5-1125A11.7 -6.61 1.05e-10 6.07e-08 -0.31 -0.29 Skin pigmentation; chr20:33932245 chr20:33985617~33988989:- LUSC cis rs11976180 1 rs1540894 ENSG00000170356.8 OR2A20P -6.61 1.05e-10 6.08e-08 -0.39 -0.29 Obesity-related traits; chr7:144070583 chr7:144250045~144252957:- LUSC cis rs7772486 0.79 rs2485632 ENSG00000235652.6 RP11-545I5.3 6.61 1.05e-10 6.08e-08 0.29 0.29 Lobe attachment (rater-scored or self-reported); chr6:145872092 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2253307 ENSG00000235652.6 RP11-545I5.3 6.61 1.05e-10 6.08e-08 0.29 0.29 Lobe attachment (rater-scored or self-reported); chr6:145875045 chr6:145799409~145886585:+ LUSC cis rs6142102 0.602 rs4911380 ENSG00000275784.1 RP5-1125A11.6 -6.61 1.05e-10 6.08e-08 -0.32 -0.29 Skin pigmentation; chr20:33958418 chr20:33989480~33991818:- LUSC cis rs13113518 0.51 rs6828454 ENSG00000249700.7 SRD5A3-AS1 6.61 1.06e-10 6.09e-08 0.32 0.29 Height; chr4:55424329 chr4:55363971~55395847:- LUSC cis rs950169 0.845 rs4502182 ENSG00000225151.9 GOLGA2P7 -6.61 1.06e-10 6.1e-08 -0.41 -0.29 Schizophrenia; chr15:84254768 chr15:84199311~84230136:- LUSC cis rs11603023 0.804 rs527619 ENSG00000255422.1 AP002954.4 6.61 1.06e-10 6.1e-08 0.34 0.29 Cholesterol, total; chr11:118692577 chr11:118704607~118750263:+ LUSC cis rs6772849 0.93 rs1962040 ENSG00000242551.2 POU5F1P6 -6.61 1.06e-10 6.11e-08 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128605318 chr3:128674735~128677005:- LUSC cis rs113835537 0.529 rs11227503 ENSG00000255517.5 CTD-3074O7.5 -6.61 1.06e-10 6.11e-08 -0.34 -0.29 Airway imaging phenotypes; chr11:66507771 chr11:66473490~66480233:- LUSC cis rs4141404 0.561 rs5994376 ENSG00000236132.1 CTA-440B3.1 6.61 1.06e-10 6.11e-08 0.34 0.29 Paclitaxel-induced neuropathy; chr22:31167569 chr22:31816379~31817491:- LUSC cis rs11098499 0.954 rs6847248 ENSG00000250412.1 KLHL2P1 6.61 1.06e-10 6.11e-08 0.38 0.29 Corneal astigmatism; chr4:119304800 chr4:119334329~119378233:+ LUSC cis rs8177876 0.822 rs4324141 ENSG00000261838.4 RP11-303E16.6 -6.61 1.06e-10 6.12e-08 -0.64 -0.29 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081220 chr16:81069854~81076598:+ LUSC cis rs6772849 0.896 rs35535737 ENSG00000242551.2 POU5F1P6 -6.61 1.06e-10 6.12e-08 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128664563 chr3:128674735~128677005:- LUSC cis rs12554020 0.681 rs74816254 ENSG00000227603.1 RP11-165J3.6 6.61 1.06e-10 6.12e-08 0.47 0.29 Schizophrenia; chr9:93486661 chr9:93435332~93437121:- LUSC cis rs12554020 0.786 rs79068125 ENSG00000227603.1 RP11-165J3.6 6.61 1.06e-10 6.12e-08 0.47 0.29 Schizophrenia; chr9:93486957 chr9:93435332~93437121:- LUSC cis rs12554020 0.786 rs79330192 ENSG00000227603.1 RP11-165J3.6 6.61 1.06e-10 6.12e-08 0.47 0.29 Schizophrenia; chr9:93487542 chr9:93435332~93437121:- LUSC cis rs801193 0.967 rs34356500 ENSG00000224316.1 RP11-479O9.2 6.61 1.06e-10 6.12e-08 0.28 0.29 Aortic root size; chr7:66771620 chr7:65773620~65802067:+ LUSC cis rs1823913 0.599 rs7598639 ENSG00000227542.1 AC092614.2 6.61 1.06e-10 6.12e-08 0.38 0.29 Obesity-related traits; chr2:191267958 chr2:191229165~191246172:- LUSC cis rs11976180 1 rs6464573 ENSG00000170356.8 OR2A20P 6.61 1.06e-10 6.14e-08 0.38 0.29 Obesity-related traits; chr7:144051005 chr7:144250045~144252957:- LUSC cis rs4237845 1 rs4237845 ENSG00000257159.1 RP11-58A17.3 -6.61 1.07e-10 6.15e-08 -0.35 -0.29 Intelligence (multi-trait analysis); chr12:57908653 chr12:57967058~57968399:+ LUSC cis rs9921338 0.961 rs4356497 ENSG00000263080.1 RP11-485G7.5 -6.61 1.07e-10 6.17e-08 -0.35 -0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11320339 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs9937269 ENSG00000263080.1 RP11-485G7.5 -6.61 1.07e-10 6.17e-08 -0.35 -0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11322822 chr16:11341809~11345211:- LUSC cis rs9921338 1 rs9921338 ENSG00000263080.1 RP11-485G7.5 -6.61 1.07e-10 6.17e-08 -0.35 -0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11322982 chr16:11341809~11345211:- LUSC cis rs113835537 0.529 rs61561111 ENSG00000255517.5 CTD-3074O7.5 -6.61 1.07e-10 6.17e-08 -0.34 -0.29 Airway imaging phenotypes; chr11:66508452 chr11:66473490~66480233:- LUSC cis rs72772090 0.539 rs11739020 ENSG00000248734.2 CTD-2260A17.1 6.61 1.07e-10 6.18e-08 0.4 0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96778134 chr5:96784777~96785999:+ LUSC cis rs875971 1 rs6961717 ENSG00000237310.1 GS1-124K5.4 -6.61 1.07e-10 6.18e-08 -0.3 -0.29 Aortic root size; chr7:66122550 chr7:66493706~66495474:+ LUSC cis rs9309473 1 rs1534471 ENSG00000163016.8 ALMS1P 6.61 1.07e-10 6.19e-08 0.36 0.29 Metabolite levels; chr2:73420380 chr2:73644919~73685576:+ LUSC cis rs11098499 0.954 rs28572238 ENSG00000250412.1 KLHL2P1 6.61 1.08e-10 6.2e-08 0.37 0.29 Corneal astigmatism; chr4:119395531 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs28714195 ENSG00000250412.1 KLHL2P1 6.61 1.08e-10 6.2e-08 0.37 0.29 Corneal astigmatism; chr4:119395795 chr4:119334329~119378233:+ LUSC cis rs113835537 0.529 rs4542420 ENSG00000255517.5 CTD-3074O7.5 -6.61 1.08e-10 6.2e-08 -0.34 -0.29 Airway imaging phenotypes; chr11:66510139 chr11:66473490~66480233:- LUSC cis rs6142102 0.961 rs973409 ENSG00000276073.1 RP5-1125A11.7 -6.61 1.08e-10 6.2e-08 -0.31 -0.29 Skin pigmentation; chr20:33948558 chr20:33985617~33988989:- LUSC cis rs10262624 1 rs7792262 ENSG00000234286.1 AC006026.13 6.61 1.08e-10 6.2e-08 0.34 0.29 Schizophrenia; chr7:23876124 chr7:23680195~23680786:- LUSC cis rs172166 0.637 rs1233691 ENSG00000216901.1 AL022393.7 6.61 1.08e-10 6.21e-08 0.34 0.29 Cardiac Troponin-T levels; chr6:28186119 chr6:28176188~28176674:+ LUSC cis rs1865760 0.865 rs9467641 ENSG00000272462.2 U91328.19 -6.6 1.08e-10 6.21e-08 -0.31 -0.29 Height; chr6:25947008 chr6:25992662~26001775:+ LUSC cis rs7772486 0.719 rs702307 ENSG00000235652.6 RP11-545I5.3 -6.6 1.08e-10 6.23e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145672318 chr6:145799409~145886585:+ LUSC cis rs8177376 1 rs17656 ENSG00000254905.1 RP11-712L6.7 6.6 1.08e-10 6.23e-08 0.38 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126263287 chr11:126292922~126294254:- LUSC cis rs7772486 0.754 rs9390358 ENSG00000235652.6 RP11-545I5.3 6.6 1.08e-10 6.23e-08 0.29 0.29 Lobe attachment (rater-scored or self-reported); chr6:145824542 chr6:145799409~145886585:+ LUSC cis rs10129255 0.957 rs8009638 ENSG00000280411.1 IGHV1-69-2 -6.6 1.08e-10 6.23e-08 -0.21 -0.29 Kawasaki disease; chr14:106777570 chr14:106762092~106762588:- LUSC cis rs9903692 0.954 rs6847 ENSG00000278765.1 RP5-890E16.5 -6.6 1.08e-10 6.23e-08 -0.35 -0.29 Pulse pressure; chr17:48070445 chr17:48066704~48067293:- LUSC cis rs673078 0.607 rs59594854 ENSG00000275759.1 RP11-131L12.3 -6.6 1.08e-10 6.23e-08 -0.38 -0.29 Glucose homeostasis traits; chr12:118374000 chr12:118428281~118428870:+ LUSC cis rs7772486 0.625 rs9390355 ENSG00000235652.6 RP11-545I5.3 -6.6 1.08e-10 6.24e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145791806 chr6:145799409~145886585:+ LUSC cis rs7772486 0.658 rs4895683 ENSG00000235652.6 RP11-545I5.3 -6.6 1.08e-10 6.24e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145792518 chr6:145799409~145886585:+ LUSC cis rs7772486 0.625 rs2050027 ENSG00000235652.6 RP11-545I5.3 -6.6 1.08e-10 6.24e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145794977 chr6:145799409~145886585:+ LUSC cis rs11157436 0.958 rs12432733 ENSG00000211813.2 TRAV34 6.6 1.08e-10 6.24e-08 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22230741 chr14:22207522~22208129:+ LUSC cis rs6951245 0.935 rs113365567 ENSG00000224079.1 AC091729.7 -6.6 1.09e-10 6.26e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1069149 chr7:1074450~1078036:+ LUSC cis rs8177876 0.822 rs7185637 ENSG00000261838.4 RP11-303E16.6 -6.6 1.09e-10 6.27e-08 -0.59 -0.29 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81089551 chr16:81069854~81076598:+ LUSC cis rs12554020 1 rs4552973 ENSG00000227603.1 RP11-165J3.6 6.6 1.09e-10 6.28e-08 0.37 0.29 Schizophrenia; chr9:93539437 chr9:93435332~93437121:- LUSC cis rs875971 0.638 rs6960778 ENSG00000236529.1 RP13-254B10.1 -6.6 1.09e-10 6.28e-08 -0.3 -0.29 Aortic root size; chr7:66606610 chr7:65840212~65840596:+ LUSC cis rs4713118 0.869 rs6922574 ENSG00000219392.1 RP1-265C24.5 -6.6 1.09e-10 6.29e-08 -0.37 -0.29 Parkinson's disease; chr6:27725224 chr6:28115628~28116551:+ LUSC cis rs867371 0.502 rs7176926 ENSG00000276710.3 CSPG4P8 -6.6 1.09e-10 6.29e-08 -0.3 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82245753 chr15:82459472~82477258:+ LUSC cis rs867371 1 rs6495642 ENSG00000255769.6 GOLGA2P10 -6.6 1.09e-10 6.29e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82165156 chr15:82472993~82513950:- LUSC cis rs867371 0.502 rs2047679 ENSG00000276710.3 CSPG4P8 -6.6 1.09e-10 6.29e-08 -0.3 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82239540 chr15:82459472~82477258:+ LUSC cis rs950169 1 rs11638394 ENSG00000259728.4 LINC00933 6.6 1.1e-10 6.3e-08 0.38 0.29 Schizophrenia; chr15:84110176 chr15:84570649~84580175:+ LUSC cis rs950169 1 rs35658069 ENSG00000259728.4 LINC00933 6.6 1.1e-10 6.3e-08 0.38 0.29 Schizophrenia; chr15:84111394 chr15:84570649~84580175:+ LUSC cis rs7267979 0.932 rs431579 ENSG00000274973.1 RP13-401N8.7 -6.6 1.1e-10 6.3e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25489420 chr20:25845497~25845862:+ LUSC cis rs875971 0.522 rs709604 ENSG00000164669.11 INTS4P1 6.6 1.1e-10 6.3e-08 0.32 0.29 Aortic root size; chr7:66032447 chr7:65141225~65234216:+ LUSC cis rs8177376 1 rs671492 ENSG00000254905.1 RP11-712L6.7 6.6 1.1e-10 6.3e-08 0.39 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126280025 chr11:126292922~126294254:- LUSC cis rs8062405 1 rs8062405 ENSG00000278665.1 RP11-666O2.4 -6.6 1.1e-10 6.31e-08 -0.29 -0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826585 chr16:28599241~28601881:- LUSC cis rs11089937 0.651 rs2330015 ENSG00000211639.2 IGLV4-60 -6.6 1.1e-10 6.31e-08 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22182566 chr22:22162199~22162681:+ LUSC cis rs17023223 0.537 rs2765530 ENSG00000231365.4 RP11-418J17.1 -6.6 1.1e-10 6.32e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119041773 chr1:119140396~119275973:+ LUSC cis rs8177876 0.658 rs2970077 ENSG00000261838.4 RP11-303E16.6 6.6 1.1e-10 6.32e-08 0.61 0.29 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81041195 chr16:81069854~81076598:+ LUSC cis rs10740039 0.842 rs1442541 ENSG00000254271.1 RP11-131N11.4 6.6 1.1e-10 6.32e-08 0.4 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60626285 chr10:60734342~60741828:+ LUSC cis rs10740039 0.883 rs1867081 ENSG00000254271.1 RP11-131N11.4 6.6 1.1e-10 6.32e-08 0.4 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60626569 chr10:60734342~60741828:+ LUSC cis rs853679 0.607 rs35072899 ENSG00000204709.4 LINC01556 6.6 1.1e-10 6.33e-08 0.62 0.29 Depression; chr6:28313764 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs56075693 ENSG00000204709.4 LINC01556 6.6 1.1e-10 6.33e-08 0.62 0.29 Depression; chr6:28322551 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs34218844 ENSG00000204709.4 LINC01556 6.6 1.1e-10 6.33e-08 0.62 0.29 Depression; chr6:28322870 chr6:28943877~28944537:+ LUSC cis rs6142102 0.625 rs4911138 ENSG00000275784.1 RP5-1125A11.6 -6.6 1.1e-10 6.34e-08 -0.32 -0.29 Skin pigmentation; chr20:33959893 chr20:33989480~33991818:- LUSC cis rs6142102 0.625 rs4243974 ENSG00000275784.1 RP5-1125A11.6 -6.6 1.1e-10 6.34e-08 -0.32 -0.29 Skin pigmentation; chr20:33960062 chr20:33989480~33991818:- LUSC cis rs6142102 0.625 rs6142061 ENSG00000275784.1 RP5-1125A11.6 -6.6 1.1e-10 6.34e-08 -0.32 -0.29 Skin pigmentation; chr20:33960529 chr20:33989480~33991818:- LUSC cis rs6142102 0.625 rs6142062 ENSG00000275784.1 RP5-1125A11.6 -6.6 1.1e-10 6.34e-08 -0.32 -0.29 Skin pigmentation; chr20:33960706 chr20:33989480~33991818:- LUSC cis rs6142102 0.625 rs6141432 ENSG00000275784.1 RP5-1125A11.6 -6.6 1.1e-10 6.34e-08 -0.32 -0.29 Skin pigmentation; chr20:33960791 chr20:33989480~33991818:- LUSC cis rs6142102 0.602 rs6141433 ENSG00000275784.1 RP5-1125A11.6 -6.6 1.1e-10 6.34e-08 -0.32 -0.29 Skin pigmentation; chr20:33961056 chr20:33989480~33991818:- LUSC cis rs2404602 0.647 rs12440965 ENSG00000259422.1 RP11-593F23.1 -6.6 1.11e-10 6.35e-08 -0.35 -0.29 Blood metabolite levels; chr15:76666250 chr15:76174891~76181486:- LUSC cis rs11690935 0.959 rs13419987 ENSG00000228389.1 AC068039.4 6.6 1.11e-10 6.36e-08 0.34 0.29 Schizophrenia; chr2:171767404 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs10194102 ENSG00000228389.1 AC068039.4 6.6 1.11e-10 6.36e-08 0.34 0.29 Schizophrenia; chr2:171769633 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs11904009 ENSG00000228389.1 AC068039.4 6.6 1.11e-10 6.36e-08 0.34 0.29 Schizophrenia; chr2:171770833 chr2:171773482~171775844:+ LUSC cis rs673078 0.66 rs76842574 ENSG00000275759.1 RP11-131L12.3 -6.6 1.11e-10 6.38e-08 -0.38 -0.29 Glucose homeostasis traits; chr12:118371789 chr12:118428281~118428870:+ LUSC cis rs7246657 0.943 rs7253091 ENSG00000276846.1 CTD-3220F14.3 6.6 1.11e-10 6.38e-08 0.45 0.29 Coronary artery calcification; chr19:37476312 chr19:37314868~37315620:- LUSC cis rs75422866 0.51 rs73105818 ENSG00000257433.4 RP1-197B17.3 6.6 1.11e-10 6.38e-08 0.63 0.29 Pneumonia; chr12:47726538 chr12:47706085~47742294:+ LUSC cis rs7267979 0.966 rs6083817 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25363362 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050564 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25363595 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs6083818 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25365446 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs4815409 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25366061 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6037099 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25376240 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs4815414 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25381065 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6083825 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25385788 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs34645895 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25387737 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6115168 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25392255 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6037105 ENSG00000274973.1 RP13-401N8.7 6.6 1.11e-10 6.39e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25393563 chr20:25845497~25845862:+ LUSC cis rs8040855 0.557 rs9744503 ENSG00000259295.5 CSPG4P12 -6.6 1.12e-10 6.4e-08 -0.33 -0.29 Bulimia nervosa; chr15:85180986 chr15:85191438~85213905:+ LUSC cis rs11690935 0.921 rs10200608 ENSG00000228389.1 AC068039.4 6.6 1.12e-10 6.4e-08 0.34 0.29 Schizophrenia; chr2:171741419 chr2:171773482~171775844:+ LUSC cis rs6951245 0.832 rs79808627 ENSG00000224079.1 AC091729.7 -6.6 1.12e-10 6.4e-08 -0.47 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1052883 chr7:1074450~1078036:+ LUSC cis rs1823913 1 rs4853568 ENSG00000280083.1 RP11-317J9.1 6.6 1.12e-10 6.41e-08 0.36 0.29 Obesity-related traits; chr2:191261464 chr2:191154118~191156070:- LUSC cis rs2188561 0.697 rs6956243 ENSG00000241764.3 AC002467.7 6.6 1.12e-10 6.42e-08 0.38 0.29 Alcohol consumption; chr7:107748466 chr7:107742817~107744581:- LUSC cis rs6772849 0.896 rs4557179 ENSG00000242551.2 POU5F1P6 -6.6 1.12e-10 6.43e-08 -0.32 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128647883 chr3:128674735~128677005:- LUSC cis rs13113518 0.812 rs11945371 ENSG00000272969.1 RP11-528I4.2 6.6 1.12e-10 6.44e-08 0.33 0.29 Height; chr4:55409063 chr4:55547112~55547889:+ LUSC cis rs113835537 0.597 rs7939759 ENSG00000255517.5 CTD-3074O7.5 -6.6 1.12e-10 6.45e-08 -0.33 -0.29 Airway imaging phenotypes; chr11:66570493 chr11:66473490~66480233:- LUSC cis rs113835537 0.597 rs10896129 ENSG00000255517.5 CTD-3074O7.5 -6.6 1.12e-10 6.45e-08 -0.33 -0.29 Airway imaging phenotypes; chr11:66570829 chr11:66473490~66480233:- LUSC cis rs6142102 1 rs2378078 ENSG00000275784.1 RP5-1125A11.6 -6.6 1.12e-10 6.45e-08 -0.32 -0.29 Skin pigmentation; chr20:34126922 chr20:33989480~33991818:- LUSC cis rs9921338 0.54 rs2868409 ENSG00000263080.1 RP11-485G7.5 6.6 1.12e-10 6.45e-08 0.3 0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11323512 chr16:11341809~11345211:- LUSC cis rs7267979 1 rs422844 ENSG00000274973.1 RP13-401N8.7 -6.6 1.12e-10 6.45e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25464955 chr20:25845497~25845862:+ LUSC cis rs957448 1 rs2381882 ENSG00000253175.1 RP11-267M23.6 6.6 1.13e-10 6.45e-08 0.34 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94535496 chr8:94565036~94565715:+ LUSC cis rs5753618 0.555 rs5749286 ENSG00000236132.1 CTA-440B3.1 -6.6 1.13e-10 6.45e-08 -0.41 -0.29 Colorectal cancer; chr22:31504373 chr22:31816379~31817491:- LUSC cis rs66887589 0.616 rs11732621 ENSG00000249244.1 RP11-548H18.2 6.6 1.13e-10 6.45e-08 0.35 0.29 Diastolic blood pressure; chr4:119291728 chr4:119391831~119395335:- LUSC cis rs867371 1 rs11855089 ENSG00000255769.6 GOLGA2P10 -6.6 1.13e-10 6.46e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82154924 chr15:82472993~82513950:- LUSC cis rs7246657 0.943 rs10415024 ENSG00000276846.1 CTD-3220F14.3 6.6 1.13e-10 6.46e-08 0.45 0.29 Coronary artery calcification; chr19:37323822 chr19:37314868~37315620:- LUSC cis rs10129255 0.5 rs34326748 ENSG00000224373.3 IGHV4-59 6.6 1.13e-10 6.46e-08 0.15 0.29 Kawasaki disease; chr14:106782523 chr14:106627249~106627825:- LUSC cis rs10129255 0.5 rs10143385 ENSG00000224373.3 IGHV4-59 6.6 1.13e-10 6.46e-08 0.15 0.29 Kawasaki disease; chr14:106782559 chr14:106627249~106627825:- LUSC cis rs875971 1 rs6945843 ENSG00000237310.1 GS1-124K5.4 -6.6 1.13e-10 6.46e-08 -0.3 -0.29 Aortic root size; chr7:66269796 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs7807944 ENSG00000236529.1 RP13-254B10.1 -6.6 1.13e-10 6.46e-08 -0.3 -0.29 Aortic root size; chr7:66622208 chr7:65840212~65840596:+ LUSC cis rs7250849 0.565 rs11883221 ENSG00000273837.1 LLNLR-470E3.1 -6.6 1.13e-10 6.46e-08 -0.38 -0.29 Blood protein levels; chr19:51665579 chr19:51639478~51639931:- LUSC cis rs11098499 0.826 rs4472123 ENSG00000249244.1 RP11-548H18.2 6.6 1.13e-10 6.46e-08 0.37 0.29 Corneal astigmatism; chr4:119315475 chr4:119391831~119395335:- LUSC cis rs11098499 0.955 rs1397608 ENSG00000250412.1 KLHL2P1 6.6 1.13e-10 6.47e-08 0.36 0.29 Corneal astigmatism; chr4:119240589 chr4:119334329~119378233:+ LUSC cis rs11098499 0.955 rs7685268 ENSG00000250412.1 KLHL2P1 6.6 1.13e-10 6.47e-08 0.36 0.29 Corneal astigmatism; chr4:119241033 chr4:119334329~119378233:+ LUSC cis rs11098499 0.955 rs7684942 ENSG00000250412.1 KLHL2P1 6.6 1.13e-10 6.47e-08 0.36 0.29 Corneal astigmatism; chr4:119241046 chr4:119334329~119378233:+ LUSC cis rs853679 0.607 rs56189111 ENSG00000204709.4 LINC01556 6.6 1.13e-10 6.48e-08 0.61 0.29 Depression; chr6:28304196 chr6:28943877~28944537:+ LUSC cis rs9813712 0.571 rs9824426 ENSG00000228252.7 COL6A4P2 -6.6 1.13e-10 6.49e-08 -0.26 -0.29 Response to amphetamines; chr3:130226115 chr3:130212823~130273806:+ LUSC cis rs112990264 0.568 rs3006239 ENSG00000198468.6 FLVCR1-AS1 6.6 1.13e-10 6.49e-08 0.55 0.29 Itch intensity from mosquito bite; chr1:212812498 chr1:212852108~212858088:- LUSC cis rs1075232 1 rs72722861 ENSG00000215302.7 CTD-3092A11.1 -6.6 1.13e-10 6.5e-08 -0.69 -0.29 Survival in colorectal cancer (non-distant metastatic); chr15:31412085 chr15:30470779~30507623:+ LUSC cis rs875971 1 rs2087647 ENSG00000237310.1 GS1-124K5.4 -6.6 1.13e-10 6.5e-08 -0.3 -0.29 Aortic root size; chr7:66128201 chr7:66493706~66495474:+ LUSC cis rs11098499 0.954 rs10006706 ENSG00000250412.1 KLHL2P1 6.6 1.14e-10 6.5e-08 0.37 0.29 Corneal astigmatism; chr4:119487997 chr4:119334329~119378233:+ LUSC cis rs11098499 0.738 rs28687057 ENSG00000249244.1 RP11-548H18.2 6.6 1.14e-10 6.53e-08 0.36 0.29 Corneal astigmatism; chr4:119359657 chr4:119391831~119395335:- LUSC cis rs11098499 0.774 rs73842616 ENSG00000249244.1 RP11-548H18.2 6.6 1.14e-10 6.53e-08 0.36 0.29 Corneal astigmatism; chr4:119369528 chr4:119391831~119395335:- LUSC cis rs11098499 0.645 rs72676059 ENSG00000249244.1 RP11-548H18.2 6.6 1.14e-10 6.53e-08 0.36 0.29 Corneal astigmatism; chr4:119369673 chr4:119391831~119395335:- LUSC cis rs11098499 0.569 rs55845118 ENSG00000249244.1 RP11-548H18.2 6.6 1.14e-10 6.53e-08 0.36 0.29 Corneal astigmatism; chr4:119369758 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs7677068 ENSG00000249244.1 RP11-548H18.2 6.6 1.14e-10 6.53e-08 0.36 0.29 Corneal astigmatism; chr4:119370549 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs9991221 ENSG00000249244.1 RP11-548H18.2 6.6 1.14e-10 6.53e-08 0.36 0.29 Corneal astigmatism; chr4:119370952 chr4:119391831~119395335:- LUSC cis rs4713118 0.824 rs9468223 ENSG00000219392.1 RP1-265C24.5 -6.6 1.14e-10 6.53e-08 -0.38 -0.29 Parkinson's disease; chr6:27772887 chr6:28115628~28116551:+ LUSC cis rs1075265 0.704 rs805402 ENSG00000233266.1 HMGB1P31 6.6 1.14e-10 6.53e-08 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:53889212 chr2:54051334~54051760:+ LUSC cis rs7246657 0.882 rs13345148 ENSG00000276846.1 CTD-3220F14.3 6.6 1.14e-10 6.54e-08 0.45 0.29 Coronary artery calcification; chr19:37328729 chr19:37314868~37315620:- LUSC cis rs6700559 0.74 rs4437908 ENSG00000260088.1 RP11-92G12.3 6.59 1.15e-10 6.57e-08 0.37 0.29 Coronary artery disease; chr1:200679311 chr1:200669507~200694250:+ LUSC cis rs6142102 0.602 rs68051854 ENSG00000275784.1 RP5-1125A11.6 -6.59 1.15e-10 6.57e-08 -0.32 -0.29 Skin pigmentation; chr20:34114150 chr20:33989480~33991818:- LUSC cis rs6142102 0.961 rs1007090 ENSG00000276073.1 RP5-1125A11.7 -6.59 1.15e-10 6.58e-08 -0.31 -0.29 Skin pigmentation; chr20:33995065 chr20:33985617~33988989:- LUSC cis rs6142102 0.923 rs2284377 ENSG00000276073.1 RP5-1125A11.7 -6.59 1.15e-10 6.58e-08 -0.31 -0.29 Skin pigmentation; chr20:33998876 chr20:33985617~33988989:- LUSC cis rs6142102 0.961 rs2284378 ENSG00000276073.1 RP5-1125A11.7 -6.59 1.15e-10 6.58e-08 -0.31 -0.29 Skin pigmentation; chr20:34000289 chr20:33985617~33988989:- LUSC cis rs2300206 1 rs2300206 ENSG00000276073.1 RP5-1125A11.7 -6.59 1.15e-10 6.58e-08 -0.31 -0.29 Cancer (pleiotropy);Cancer; chr20:34002002 chr20:33985617~33988989:- LUSC cis rs6142102 0.961 rs2268080 ENSG00000276073.1 RP5-1125A11.7 -6.59 1.15e-10 6.58e-08 -0.31 -0.29 Skin pigmentation; chr20:34009910 chr20:33985617~33988989:- LUSC cis rs7267979 0.932 rs6037125 ENSG00000274973.1 RP13-401N8.7 -6.59 1.15e-10 6.58e-08 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25482746 chr20:25845497~25845862:+ LUSC cis rs496547 0.719 rs1790189 ENSG00000255239.1 AP002954.6 6.59 1.15e-10 6.59e-08 0.33 0.29 Hip minimal joint space width; chr11:118781617 chr11:118688039~118690600:- LUSC cis rs7429990 0.965 rs777015 ENSG00000229759.1 MRPS18AP1 6.59 1.15e-10 6.6e-08 0.29 0.29 Educational attainment (years of education); chr3:47895582 chr3:48256350~48256938:- LUSC cis rs4950322 0.547 rs61838945 ENSG00000278811.3 LINC00624 6.59 1.15e-10 6.6e-08 0.32 0.29 Protein quantitative trait loci; chr1:147111477 chr1:147258885~147517875:- LUSC cis rs4950322 0.563 rs6686480 ENSG00000278811.3 LINC00624 6.59 1.15e-10 6.6e-08 0.32 0.29 Protein quantitative trait loci; chr1:147111986 chr1:147258885~147517875:- LUSC cis rs4950322 0.563 rs6700783 ENSG00000278811.3 LINC00624 6.59 1.15e-10 6.6e-08 0.32 0.29 Protein quantitative trait loci; chr1:147111987 chr1:147258885~147517875:- LUSC cis rs9513627 0.512 rs9517759 ENSG00000280710.1 RP11-214F16.8 6.59 1.15e-10 6.6e-08 0.41 0.29 Obesity-related traits; chr13:99527854 chr13:99498524~99501315:+ LUSC cis rs2834288 0.613 rs2040113 ENSG00000237945.6 LINC00649 6.59 1.16e-10 6.61e-08 0.3 0.29 Gut microbiota (bacterial taxa); chr21:33908879 chr21:33915534~33977691:+ LUSC cis rs10829156 1 rs10829156 ENSG00000240291.1 RP11-499P20.2 6.59 1.16e-10 6.62e-08 0.32 0.29 Sudden cardiac arrest; chr10:18661626 chr10:18513115~18545651:- LUSC cis rs11976180 1 rs2951353 ENSG00000170356.8 OR2A20P -6.59 1.16e-10 6.63e-08 -0.4 -0.29 Obesity-related traits; chr7:144064023 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs2371247 ENSG00000170356.8 OR2A20P -6.59 1.16e-10 6.63e-08 -0.4 -0.29 Obesity-related traits; chr7:144067086 chr7:144250045~144252957:- LUSC cis rs11098499 0.954 rs1022145 ENSG00000250412.1 KLHL2P1 6.59 1.16e-10 6.63e-08 0.37 0.29 Corneal astigmatism; chr4:119309824 chr4:119334329~119378233:+ LUSC cis rs11690935 0.798 rs13018768 ENSG00000228389.1 AC068039.4 6.59 1.16e-10 6.64e-08 0.34 0.29 Schizophrenia; chr2:171742082 chr2:171773482~171775844:+ LUSC cis rs875971 0.66 rs7807930 ENSG00000236529.1 RP13-254B10.1 -6.59 1.16e-10 6.65e-08 -0.3 -0.29 Aortic root size; chr7:66622178 chr7:65840212~65840596:+ LUSC cis rs11690935 0.851 rs9808259 ENSG00000228389.1 AC068039.4 6.59 1.16e-10 6.65e-08 0.34 0.29 Schizophrenia; chr2:171792464 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs10167419 ENSG00000228389.1 AC068039.4 6.59 1.16e-10 6.65e-08 0.34 0.29 Schizophrenia; chr2:171793316 chr2:171773482~171775844:+ LUSC cis rs66887589 0.592 rs62320740 ENSG00000249244.1 RP11-548H18.2 6.59 1.16e-10 6.66e-08 0.35 0.29 Diastolic blood pressure; chr4:119358331 chr4:119391831~119395335:- LUSC cis rs6700559 0.545 rs12744758 ENSG00000260088.1 RP11-92G12.3 6.59 1.16e-10 6.66e-08 0.37 0.29 Coronary artery disease; chr1:200624010 chr1:200669507~200694250:+ LUSC cis rs875971 0.66 rs79009421 ENSG00000236529.1 RP13-254B10.1 -6.59 1.16e-10 6.66e-08 -0.3 -0.29 Aortic root size; chr7:66603522 chr7:65840212~65840596:+ LUSC cis rs7246657 0.943 rs2303131 ENSG00000276846.1 CTD-3220F14.3 6.59 1.16e-10 6.66e-08 0.45 0.29 Coronary artery calcification; chr19:37445123 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs1015848 ENSG00000276846.1 CTD-3220F14.3 6.59 1.16e-10 6.66e-08 0.45 0.29 Coronary artery calcification; chr19:37454372 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs4801759 ENSG00000276846.1 CTD-3220F14.3 6.59 1.16e-10 6.66e-08 0.45 0.29 Coronary artery calcification; chr19:37464083 chr19:37314868~37315620:- LUSC cis rs881375 0.967 rs2109896 ENSG00000226752.6 PSMD5-AS1 -6.59 1.16e-10 6.66e-08 -0.33 -0.29 Rheumatoid arthritis; chr9:120920828 chr9:120824828~120854385:+ LUSC cis rs950169 0.58 rs17598114 ENSG00000259728.4 LINC00933 6.59 1.16e-10 6.66e-08 0.37 0.29 Schizophrenia; chr15:84628086 chr15:84570649~84580175:+ LUSC cis rs9506514 0.509 rs9509279 ENSG00000222726.1 RNU2-7P 6.59 1.17e-10 6.66e-08 0.35 0.29 Coronary artery calcification; chr13:20559580 chr13:20612161~20612338:+ LUSC cis rs2282300 0.956 rs654710 ENSG00000254532.1 RP11-624D11.2 -6.59 1.17e-10 6.67e-08 -0.39 -0.29 Morning vs. evening chronotype; chr11:30372756 chr11:30044058~30084343:- LUSC cis rs6570726 0.905 rs421032 ENSG00000235652.6 RP11-545I5.3 6.59 1.17e-10 6.67e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145506635 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs9390329 ENSG00000235652.6 RP11-545I5.3 6.59 1.17e-10 6.67e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145506890 chr6:145799409~145886585:+ LUSC cis rs6570726 0.902 rs406979 ENSG00000235652.6 RP11-545I5.3 6.59 1.17e-10 6.67e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145517847 chr6:145799409~145886585:+ LUSC cis rs875971 0.502 rs1796227 ENSG00000226824.5 RP4-756H11.3 6.59 1.17e-10 6.68e-08 0.39 0.29 Aortic root size; chr7:66622032 chr7:66654538~66669855:+ LUSC cis rs9903692 0.909 rs11079806 ENSG00000278765.1 RP5-890E16.5 6.59 1.17e-10 6.68e-08 0.35 0.29 Pulse pressure; chr17:48065318 chr17:48066704~48067293:- LUSC cis rs11976180 1 rs2951372 ENSG00000170356.8 OR2A20P -6.59 1.18e-10 6.75e-08 -0.39 -0.29 Obesity-related traits; chr7:144052410 chr7:144250045~144252957:- LUSC cis rs10740039 0.883 rs1561850 ENSG00000254271.1 RP11-131N11.4 6.59 1.18e-10 6.75e-08 0.4 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60631583 chr10:60734342~60741828:+ LUSC cis rs867371 1 rs7181655 ENSG00000255769.6 GOLGA2P10 -6.59 1.18e-10 6.76e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163275 chr15:82472993~82513950:- LUSC cis rs10129255 0.5 rs988132 ENSG00000224373.3 IGHV4-59 6.59 1.18e-10 6.76e-08 0.15 0.29 Kawasaki disease; chr14:106776758 chr14:106627249~106627825:- LUSC cis rs2404602 0.647 rs12905181 ENSG00000259422.1 RP11-593F23.1 -6.59 1.19e-10 6.77e-08 -0.34 -0.29 Blood metabolite levels; chr15:76806090 chr15:76174891~76181486:- LUSC cis rs904251 0.772 rs2776906 ENSG00000204110.6 RP1-153P14.8 -6.59 1.19e-10 6.77e-08 -0.3 -0.29 Cognitive performance; chr6:37463981 chr6:37507348~37535616:+ LUSC cis rs9322193 0.923 rs9766004 ENSG00000268592.3 RAET1E-AS1 6.59 1.19e-10 6.77e-08 0.37 0.29 Lung cancer; chr6:149754363 chr6:149863494~149919507:+ LUSC cis rs11971779 0.68 rs6947215 ENSG00000273391.1 RP11-634H22.1 6.59 1.19e-10 6.78e-08 0.29 0.29 Diisocyanate-induced asthma; chr7:139341892 chr7:139359032~139359566:- LUSC cis rs875971 0.66 rs6460308 ENSG00000236529.1 RP13-254B10.1 -6.59 1.19e-10 6.79e-08 -0.3 -0.29 Aortic root size; chr7:66619753 chr7:65840212~65840596:+ LUSC cis rs1865760 0.827 rs9461227 ENSG00000272462.2 U91328.19 -6.59 1.19e-10 6.79e-08 -0.31 -0.29 Height; chr6:25960587 chr6:25992662~26001775:+ LUSC cis rs9309473 0.95 rs6546858 ENSG00000163016.8 ALMS1P 6.59 1.19e-10 6.8e-08 0.35 0.29 Metabolite levels; chr2:73611486 chr2:73644919~73685576:+ LUSC cis rs904251 0.802 rs2646933 ENSG00000204110.6 RP1-153P14.8 -6.59 1.19e-10 6.8e-08 -0.3 -0.29 Cognitive performance; chr6:37434294 chr6:37507348~37535616:+ LUSC cis rs4938330 0.512 rs4938327 ENSG00000254851.1 RP11-109L13.1 6.59 1.19e-10 6.8e-08 0.4 0.29 Blood protein levels; chr11:117036012 chr11:117135528~117138582:+ LUSC cis rs950169 1 rs1818950 ENSG00000259728.4 LINC00933 6.59 1.19e-10 6.81e-08 0.38 0.29 Schizophrenia; chr15:84053769 chr15:84570649~84580175:+ LUSC cis rs55720021 1 rs55720021 ENSG00000232871.7 SEC1P 6.59 1.2e-10 6.82e-08 0.37 0.29 Neutrophil percentage of white cells;Lymphocyte percentage of white cells; chr19:48640984 chr19:48638071~48682245:+ LUSC cis rs8062405 1 rs12446589 ENSG00000278665.1 RP11-666O2.4 6.59 1.2e-10 6.82e-08 0.3 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859641 chr16:28599241~28601881:- LUSC cis rs228614 0.536 rs223420 ENSG00000230069.3 LRRC37A15P -6.59 1.2e-10 6.83e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102806853 chr4:102727274~102730721:- LUSC cis rs172166 0.652 rs476167 ENSG00000216901.1 AL022393.7 6.59 1.2e-10 6.84e-08 0.34 0.29 Cardiac Troponin-T levels; chr6:28098110 chr6:28176188~28176674:+ LUSC cis rs11690935 0.959 rs7572215 ENSG00000228389.1 AC068039.4 6.59 1.2e-10 6.85e-08 0.34 0.29 Schizophrenia; chr2:171777718 chr2:171773482~171775844:+ LUSC cis rs867371 1 rs8037224 ENSG00000255769.6 GOLGA2P10 -6.59 1.2e-10 6.86e-08 -0.35 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82172189 chr15:82472993~82513950:- LUSC cis rs113835537 0.529 rs10896125 ENSG00000255517.5 CTD-3074O7.5 -6.59 1.2e-10 6.86e-08 -0.34 -0.29 Airway imaging phenotypes; chr11:66521262 chr11:66473490~66480233:- LUSC cis rs10246939 0.543 rs11765575 ENSG00000228775.6 WEE2-AS1 6.59 1.2e-10 6.87e-08 0.33 0.29 Bitter taste perception; chr7:141838168 chr7:141704338~141738346:- LUSC cis rs1075265 0.587 rs2949812 ENSG00000233266.1 HMGB1P31 6.59 1.21e-10 6.87e-08 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:53797190 chr2:54051334~54051760:+ LUSC cis rs5753618 0.504 rs5753661 ENSG00000236132.1 CTA-440B3.1 -6.59 1.21e-10 6.88e-08 -0.42 -0.29 Colorectal cancer; chr22:31503811 chr22:31816379~31817491:- LUSC cis rs730566 0.64 rs6442112 ENSG00000229759.1 MRPS18AP1 6.59 1.21e-10 6.88e-08 0.3 0.29 Prion diseases; chr3:48274544 chr3:48256350~48256938:- LUSC cis rs881375 0.933 rs2239657 ENSG00000226752.6 PSMD5-AS1 6.59 1.21e-10 6.89e-08 0.33 0.29 Rheumatoid arthritis; chr9:120909242 chr9:120824828~120854385:+ LUSC cis rs228614 0.536 rs223419 ENSG00000230069.3 LRRC37A15P -6.59 1.21e-10 6.89e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102808586 chr4:102727274~102730721:- LUSC cis rs867371 1 rs1501372 ENSG00000255769.6 GOLGA2P10 -6.59 1.21e-10 6.89e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82176114 chr15:82472993~82513950:- LUSC cis rs8177876 0.822 rs4889225 ENSG00000261838.4 RP11-303E16.6 -6.59 1.21e-10 6.9e-08 -0.63 -0.29 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81074891 chr16:81069854~81076598:+ LUSC cis rs11089937 0.597 rs4821773 ENSG00000211638.2 IGLV8-61 -6.59 1.21e-10 6.9e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22131434 chr22:22098700~22099212:+ LUSC cis rs2280018 0.963 rs11075255 ENSG00000260735.1 RP11-72I8.1 -6.59 1.21e-10 6.9e-08 -0.32 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15072375 chr16:15094411~15109197:+ LUSC cis rs4950322 0.542 rs12046706 ENSG00000278811.3 LINC00624 6.59 1.21e-10 6.91e-08 0.32 0.29 Protein quantitative trait loci; chr1:147189758 chr1:147258885~147517875:- LUSC cis rs2903698 0.585 rs6812261 ENSG00000250735.4 RP11-567N4.3 -6.59 1.21e-10 6.92e-08 -0.33 -0.29 Prion diseases; chr4:75431611 chr4:75401195~75423023:+ LUSC cis rs13113518 0.812 rs12649507 ENSG00000223305.1 RN7SKP30 -6.59 1.21e-10 6.92e-08 -0.35 -0.29 Height; chr4:55514317 chr4:55540502~55540835:- LUSC cis rs950169 0.58 rs11635597 ENSG00000259728.4 LINC00933 6.59 1.21e-10 6.92e-08 0.37 0.29 Schizophrenia; chr15:84622468 chr15:84570649~84580175:+ LUSC cis rs13113518 0.738 rs6849883 ENSG00000223305.1 RN7SKP30 6.59 1.21e-10 6.92e-08 0.35 0.29 Height; chr4:55387515 chr4:55540502~55540835:- LUSC cis rs867371 0.929 rs7176075 ENSG00000255769.6 GOLGA2P10 -6.59 1.22e-10 6.93e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82178998 chr15:82472993~82513950:- LUSC cis rs5753618 0.583 rs5749268 ENSG00000236132.1 CTA-440B3.1 -6.59 1.22e-10 6.93e-08 -0.4 -0.29 Colorectal cancer; chr22:31413166 chr22:31816379~31817491:- LUSC cis rs9326248 0.581 rs10892076 ENSG00000280143.1 AP000892.6 6.59 1.22e-10 6.93e-08 0.31 0.29 Blood protein levels; chr11:117118220 chr11:117204967~117210292:+ LUSC cis rs875971 1 rs709595 ENSG00000237310.1 GS1-124K5.4 6.59 1.22e-10 6.94e-08 0.3 0.29 Aortic root size; chr7:66352346 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs811880 ENSG00000237310.1 GS1-124K5.4 6.59 1.22e-10 6.94e-08 0.3 0.29 Aortic root size; chr7:66353659 chr7:66493706~66495474:+ LUSC cis rs950169 0.922 rs4842939 ENSG00000259728.4 LINC00933 -6.58 1.22e-10 6.95e-08 -0.35 -0.29 Schizophrenia; chr15:84159214 chr15:84570649~84580175:+ LUSC cis rs5753618 0.583 rs34545960 ENSG00000236132.1 CTA-440B3.1 -6.58 1.22e-10 6.96e-08 -0.4 -0.29 Colorectal cancer; chr22:31416476 chr22:31816379~31817491:- LUSC cis rs5753618 0.583 rs5749270 ENSG00000236132.1 CTA-440B3.1 -6.58 1.22e-10 6.96e-08 -0.4 -0.29 Colorectal cancer; chr22:31416867 chr22:31816379~31817491:- LUSC cis rs9549367 0.756 rs2302756 ENSG00000269125.1 RP11-98F14.11 6.58 1.22e-10 6.96e-08 0.36 0.29 Platelet distribution width; chr13:113245883 chr13:113165002~113165183:- LUSC cis rs6142102 0.961 rs6059596 ENSG00000276073.1 RP5-1125A11.7 -6.58 1.22e-10 6.97e-08 -0.31 -0.29 Skin pigmentation; chr20:33969313 chr20:33985617~33988989:- LUSC cis rs3747113 1 rs9624447 ENSG00000128262.7 POM121L9P -6.58 1.22e-10 6.97e-08 -0.31 -0.29 Gut microbiome composition (summer); chr22:24285587 chr22:24251828~24265525:+ LUSC cis rs1865760 0.663 rs9348704 ENSG00000272462.2 U91328.19 -6.58 1.22e-10 6.97e-08 -0.3 -0.29 Height; chr6:26000165 chr6:25992662~26001775:+ LUSC cis rs7246657 0.943 rs10405064 ENSG00000276846.1 CTD-3220F14.3 6.58 1.23e-10 6.98e-08 0.44 0.29 Coronary artery calcification; chr19:37370959 chr19:37314868~37315620:- LUSC cis rs673078 0.607 rs11068919 ENSG00000275759.1 RP11-131L12.3 -6.58 1.23e-10 6.98e-08 -0.39 -0.29 Glucose homeostasis traits; chr12:118354925 chr12:118428281~118428870:+ LUSC cis rs7772486 0.727 rs4896843 ENSG00000235652.6 RP11-545I5.3 -6.58 1.23e-10 6.99e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145742315 chr6:145799409~145886585:+ LUSC cis rs2286503 1 rs2286499 ENSG00000228649.7 AC005682.5 6.58 1.23e-10 6.99e-08 0.32 0.29 Fibrinogen; chr7:22817858 chr7:22854178~22861579:+ LUSC cis rs6142102 0.923 rs4911383 ENSG00000276073.1 RP5-1125A11.7 -6.58 1.23e-10 7e-08 -0.31 -0.29 Skin pigmentation; chr20:33967973 chr20:33985617~33988989:- LUSC cis rs8040855 0.894 rs4843023 ENSG00000259295.5 CSPG4P12 -6.58 1.24e-10 7.03e-08 -0.34 -0.29 Bulimia nervosa; chr15:85162641 chr15:85191438~85213905:+ LUSC cis rs10129255 0.556 rs9324093 ENSG00000211970.3 IGHV4-61 -6.58 1.24e-10 7.05e-08 -0.18 -0.29 Kawasaki disease; chr14:106683893 chr14:106639119~106639657:- LUSC cis rs2408955 0.521 rs10875749 ENSG00000240399.1 RP1-228P16.1 -6.58 1.24e-10 7.05e-08 -0.3 -0.29 Glycated hemoglobin levels; chr12:48138134 chr12:48054813~48055591:- LUSC cis rs9543976 1 rs7989568 ENSG00000261553.4 RP11-29G8.3 6.58 1.24e-10 7.05e-08 0.52 0.29 Diabetic retinopathy; chr13:75581428 chr13:75549773~75807120:+ LUSC cis rs867371 1 rs7166570 ENSG00000255769.6 GOLGA2P10 -6.58 1.24e-10 7.06e-08 -0.35 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82173880 chr15:82472993~82513950:- LUSC cis rs9309473 1 rs11903916 ENSG00000163016.8 ALMS1P 6.58 1.24e-10 7.06e-08 0.36 0.29 Metabolite levels; chr2:73588201 chr2:73644919~73685576:+ LUSC cis rs867371 1 rs1846911 ENSG00000255769.6 GOLGA2P10 -6.58 1.24e-10 7.07e-08 -0.36 -0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82176309 chr15:82472993~82513950:- LUSC cis rs11098499 0.687 rs71610270 ENSG00000249244.1 RP11-548H18.2 6.58 1.24e-10 7.08e-08 0.36 0.29 Corneal astigmatism; chr4:119366281 chr4:119391831~119395335:- LUSC cis rs12554020 0.579 rs74740549 ENSG00000227603.1 RP11-165J3.6 6.58 1.25e-10 7.09e-08 0.45 0.29 Schizophrenia; chr9:93480399 chr9:93435332~93437121:- LUSC cis rs11098499 0.663 rs9996501 ENSG00000249244.1 RP11-548H18.2 6.58 1.25e-10 7.1e-08 0.37 0.29 Corneal astigmatism; chr4:119317763 chr4:119391831~119395335:- LUSC cis rs11098499 0.697 rs28458294 ENSG00000249244.1 RP11-548H18.2 6.58 1.25e-10 7.1e-08 0.37 0.29 Corneal astigmatism; chr4:119317769 chr4:119391831~119395335:- LUSC cis rs11098499 0.663 rs28369503 ENSG00000249244.1 RP11-548H18.2 6.58 1.25e-10 7.1e-08 0.37 0.29 Corneal astigmatism; chr4:119317770 chr4:119391831~119395335:- LUSC cis rs13113518 0.756 rs11939652 ENSG00000249700.7 SRD5A3-AS1 6.58 1.25e-10 7.1e-08 0.34 0.29 Height; chr4:55532542 chr4:55363971~55395847:- LUSC cis rs1823913 0.599 rs6732976 ENSG00000227542.1 AC092614.2 -6.58 1.25e-10 7.1e-08 -0.37 -0.29 Obesity-related traits; chr2:191281004 chr2:191229165~191246172:- LUSC cis rs11098499 0.954 rs17006190 ENSG00000250412.1 KLHL2P1 6.58 1.25e-10 7.1e-08 0.36 0.29 Corneal astigmatism; chr4:119497683 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs3733519 ENSG00000250412.1 KLHL2P1 6.58 1.25e-10 7.1e-08 0.36 0.29 Corneal astigmatism; chr4:119502293 chr4:119334329~119378233:+ LUSC cis rs465969 1 rs465969 ENSG00000255389.1 C6orf3 -6.58 1.25e-10 7.11e-08 -0.48 -0.29 Psoriasis; chr6:111334327 chr6:111599875~111602295:+ LUSC cis rs13113518 0.841 rs7699867 ENSG00000223305.1 RN7SKP30 6.58 1.25e-10 7.11e-08 0.36 0.29 Height; chr4:55483718 chr4:55540502~55540835:- LUSC cis rs1075265 0.722 rs805374 ENSG00000233266.1 HMGB1P31 6.58 1.25e-10 7.13e-08 0.37 0.29 Chronotype;Morning vs. evening chronotype; chr2:53862720 chr2:54051334~54051760:+ LUSC cis rs8062405 1 rs12325113 ENSG00000278665.1 RP11-666O2.4 6.58 1.26e-10 7.17e-08 0.3 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28837347 chr16:28599241~28601881:- LUSC cis rs56163509 1 rs56163509 ENSG00000278665.1 RP11-666O2.4 6.58 1.26e-10 7.17e-08 0.3 0.29 Tonsillectomy;Mean corpuscular volume; chr16:28853150 chr16:28599241~28601881:- LUSC cis rs8062405 0.964 rs7187333 ENSG00000278665.1 RP11-666O2.4 6.58 1.26e-10 7.17e-08 0.3 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854595 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs62037369 ENSG00000278665.1 RP11-666O2.4 6.58 1.26e-10 7.17e-08 0.3 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28872520 chr16:28599241~28601881:- LUSC cis rs8062405 0.965 rs7359397 ENSG00000278665.1 RP11-666O2.4 6.58 1.26e-10 7.17e-08 0.3 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874338 chr16:28599241~28601881:- LUSC cis rs1865760 0.865 rs1436306 ENSG00000272462.2 U91328.19 -6.58 1.26e-10 7.17e-08 -0.31 -0.29 Height; chr6:25948193 chr6:25992662~26001775:+ LUSC cis rs67340775 0.541 rs200966 ENSG00000219392.1 RP1-265C24.5 -6.58 1.26e-10 7.17e-08 -0.45 -0.29 Lung cancer in ever smokers; chr6:27894374 chr6:28115628~28116551:+ LUSC cis rs875971 0.965 rs28682868 ENSG00000237310.1 GS1-124K5.4 -6.58 1.26e-10 7.18e-08 -0.3 -0.29 Aortic root size; chr7:66224822 chr7:66493706~66495474:+ LUSC cis rs34375054 0.641 rs34624329 ENSG00000279233.1 RP11-158L12.4 6.58 1.26e-10 7.18e-08 0.26 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125123482 chr12:125138245~125141711:+ LUSC cis rs11089937 0.597 rs9619794 ENSG00000211638.2 IGLV8-61 -6.58 1.26e-10 7.19e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22132999 chr22:22098700~22099212:+ LUSC cis rs72772090 0.539 rs11738115 ENSG00000248734.2 CTD-2260A17.1 6.58 1.26e-10 7.19e-08 0.41 0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777368 chr5:96784777~96785999:+ LUSC cis rs11089937 0.568 rs12159174 ENSG00000211638.2 IGLV8-61 -6.58 1.27e-10 7.22e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22131639 chr22:22098700~22099212:+ LUSC cis rs228614 0.51 rs223392 ENSG00000230069.3 LRRC37A15P -6.58 1.27e-10 7.22e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102824599 chr4:102727274~102730721:- LUSC cis rs227275 0.554 rs223390 ENSG00000230069.3 LRRC37A15P -6.58 1.27e-10 7.22e-08 -0.31 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102827640 chr4:102727274~102730721:- LUSC cis rs7246657 0.943 rs2126977 ENSG00000276846.1 CTD-3220F14.3 -6.58 1.27e-10 7.23e-08 -0.43 -0.29 Coronary artery calcification; chr19:37504845 chr19:37314868~37315620:- LUSC cis rs11722779 0.933 rs7695096 ENSG00000230069.3 LRRC37A15P -6.58 1.28e-10 7.24e-08 -0.31 -0.29 Schizophrenia; chr4:103011399 chr4:102727274~102730721:- LUSC cis rs875971 1 rs875971 ENSG00000237310.1 GS1-124K5.4 -6.58 1.28e-10 7.25e-08 -0.3 -0.29 Aortic root size; chr7:66152608 chr7:66493706~66495474:+ LUSC cis rs7772486 0.654 rs1011597 ENSG00000235652.6 RP11-545I5.3 -6.58 1.28e-10 7.25e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145754536 chr6:145799409~145886585:+ LUSC cis rs748404 0.666 rs7183708 ENSG00000249839.1 AC011330.5 -6.58 1.28e-10 7.26e-08 -0.49 -0.29 Lung cancer; chr15:43355226 chr15:43663654~43684339:- LUSC cis rs7772486 0.727 rs11155442 ENSG00000235652.6 RP11-545I5.3 6.58 1.28e-10 7.27e-08 0.29 0.29 Lobe attachment (rater-scored or self-reported); chr6:145819589 chr6:145799409~145886585:+ LUSC cis rs673078 0.607 rs17440956 ENSG00000275759.1 RP11-131L12.3 6.58 1.28e-10 7.27e-08 0.43 0.29 Glucose homeostasis traits; chr12:118394639 chr12:118428281~118428870:+ LUSC cis rs11976180 1 rs2961132 ENSG00000170356.8 OR2A20P -6.58 1.28e-10 7.27e-08 -0.39 -0.29 Obesity-related traits; chr7:144071035 chr7:144250045~144252957:- LUSC cis rs11690935 0.959 rs35391289 ENSG00000228389.1 AC068039.4 6.58 1.28e-10 7.29e-08 0.34 0.29 Schizophrenia; chr2:171778473 chr2:171773482~171775844:+ LUSC cis rs11123170 0.543 rs4849180 ENSG00000274877.1 RP11-65I12.1 -6.58 1.28e-10 7.29e-08 -0.41 -0.29 Renal function-related traits (BUN); chr2:113227609 chr2:113237595~113240825:+ LUSC cis rs7246657 0.943 rs28373708 ENSG00000276846.1 CTD-3220F14.3 6.58 1.28e-10 7.29e-08 0.45 0.29 Coronary artery calcification; chr19:37485757 chr19:37314868~37315620:- LUSC cis rs6991838 0.806 rs11781358 ENSG00000200714.1 Y_RNA 6.58 1.29e-10 7.3e-08 0.35 0.29 Intelligence (multi-trait analysis); chr8:65557691 chr8:65592731~65592820:+ LUSC cis rs11089937 0.568 rs6001078 ENSG00000211638.2 IGLV8-61 -6.58 1.29e-10 7.31e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22134365 chr22:22098700~22099212:+ LUSC cis rs7246657 0.882 rs59224125 ENSG00000276846.1 CTD-3220F14.3 6.58 1.29e-10 7.31e-08 0.44 0.29 Coronary artery calcification; chr19:37472303 chr19:37314868~37315620:- LUSC cis rs12931792 0.846 rs9924308 ENSG00000183604.13 SMG1P5 -6.58 1.29e-10 7.32e-08 -0.32 -0.29 Tonsillectomy; chr16:30143419 chr16:30267553~30335374:- LUSC cis rs748404 0.666 rs8027748 ENSG00000249839.1 AC011330.5 -6.58 1.29e-10 7.34e-08 -0.5 -0.29 Lung cancer; chr15:43447622 chr15:43663654~43684339:- LUSC cis rs4972806 0.849 rs2113561 ENSG00000226363.3 HAGLROS -6.57 1.3e-10 7.37e-08 -0.35 -0.29 IgG glycosylation; chr2:176166197 chr2:176177717~176179008:+ LUSC cis rs7772486 0.686 rs857880 ENSG00000235652.6 RP11-545I5.3 -6.57 1.3e-10 7.37e-08 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145649979 chr6:145799409~145886585:+ LUSC cis rs1823913 0.561 rs60479498 ENSG00000280083.1 RP11-317J9.1 -6.57 1.3e-10 7.38e-08 -0.34 -0.29 Obesity-related traits; chr2:191275197 chr2:191154118~191156070:- LUSC cis rs13113518 0.812 rs12500601 ENSG00000272969.1 RP11-528I4.2 6.57 1.3e-10 7.38e-08 0.34 0.29 Height; chr4:55451489 chr4:55547112~55547889:+ LUSC cis rs11089937 0.512 rs6001073 ENSG00000211638.2 IGLV8-61 -6.57 1.3e-10 7.39e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22133650 chr22:22098700~22099212:+ LUSC cis rs9318086 0.935 rs2025701 ENSG00000205861.10 C1QTNF9B-AS1 -6.57 1.3e-10 7.39e-08 -0.35 -0.29 Myopia (pathological); chr13:23866442 chr13:23888889~23897263:+ LUSC cis rs4141404 0.706 rs5753698 ENSG00000236132.1 CTA-440B3.1 -6.57 1.3e-10 7.4e-08 -0.4 -0.29 Paclitaxel-induced neuropathy; chr22:31574068 chr22:31816379~31817491:- LUSC cis rs875971 0.638 rs7793569 ENSG00000236529.1 RP13-254B10.1 -6.57 1.31e-10 7.42e-08 -0.3 -0.29 Aortic root size; chr7:66651646 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs6975195 ENSG00000236529.1 RP13-254B10.1 -6.57 1.31e-10 7.42e-08 -0.3 -0.29 Aortic root size; chr7:66659787 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs3857688 ENSG00000236529.1 RP13-254B10.1 -6.57 1.31e-10 7.42e-08 -0.3 -0.29 Aortic root size; chr7:66662819 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs2286684 ENSG00000236529.1 RP13-254B10.1 -6.57 1.31e-10 7.42e-08 -0.3 -0.29 Aortic root size; chr7:66664843 chr7:65840212~65840596:+ LUSC cis rs801193 0.935 rs2286683 ENSG00000236529.1 RP13-254B10.1 -6.57 1.31e-10 7.42e-08 -0.3 -0.29 Aortic root size; chr7:66664856 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs10274773 ENSG00000236529.1 RP13-254B10.1 -6.57 1.31e-10 7.42e-08 -0.3 -0.29 Aortic root size; chr7:66668591 chr7:65840212~65840596:+ LUSC cis rs10800713 0.826 rs6427834 ENSG00000260088.1 RP11-92G12.3 -6.57 1.31e-10 7.42e-08 -0.41 -0.29 Tandem gait; chr1:200561936 chr1:200669507~200694250:+ LUSC cis rs950169 0.922 rs12910334 ENSG00000225151.9 GOLGA2P7 -6.57 1.31e-10 7.42e-08 -0.41 -0.29 Schizophrenia; chr15:84403620 chr15:84199311~84230136:- LUSC cis rs4972806 0.814 rs966801 ENSG00000226363.3 HAGLROS -6.57 1.31e-10 7.42e-08 -0.35 -0.29 IgG glycosylation; chr2:176173099 chr2:176177717~176179008:+ LUSC cis rs10262624 1 rs4722286 ENSG00000234286.1 AC006026.13 6.57 1.31e-10 7.42e-08 0.33 0.29 Schizophrenia; chr7:23874005 chr7:23680195~23680786:- LUSC cis rs1865760 0.865 rs9467650 ENSG00000272462.2 U91328.19 -6.57 1.31e-10 7.43e-08 -0.31 -0.29 Height; chr6:25958007 chr6:25992662~26001775:+ LUSC cis rs1865760 0.865 rs9467651 ENSG00000272462.2 U91328.19 -6.57 1.31e-10 7.43e-08 -0.31 -0.29 Height; chr6:25958029 chr6:25992662~26001775:+ LUSC cis rs1865760 0.865 rs9467652 ENSG00000272462.2 U91328.19 -6.57 1.31e-10 7.43e-08 -0.31 -0.29 Height; chr6:25958899 chr6:25992662~26001775:+ LUSC cis rs10129255 0.518 rs12590732 ENSG00000224373.3 IGHV4-59 -6.57 1.31e-10 7.43e-08 -0.14 -0.29 Kawasaki disease; chr14:106779612 chr14:106627249~106627825:- LUSC cis rs7955901 0.638 rs73134417 ENSG00000257265.1 CTD-2021H9.1 6.57 1.32e-10 7.46e-08 0.32 0.29 Type 2 diabetes; chr12:71097071 chr12:71007773~71032083:- LUSC cis rs8072100 0.967 rs4794058 ENSG00000228782.6 CTD-2026D20.3 -6.57 1.32e-10 7.48e-08 -0.28 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47519732 chr17:47450568~47492492:- LUSC cis rs4728142 0.593 rs7808907 ENSG00000275106.1 RP11-309L24.10 6.57 1.32e-10 7.5e-08 0.35 0.29 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128944030 chr7:128952527~128953316:- LUSC cis rs10800713 0.954 rs4504918 ENSG00000260088.1 RP11-92G12.3 6.57 1.33e-10 7.52e-08 0.41 0.29 Tandem gait; chr1:200588639 chr1:200669507~200694250:+ LUSC cis rs13113518 0.51 rs3749473 ENSG00000249700.7 SRD5A3-AS1 6.57 1.33e-10 7.53e-08 0.32 0.29 Height; chr4:55428461 chr4:55363971~55395847:- LUSC cis rs8072100 0.967 rs7221548 ENSG00000228782.6 CTD-2026D20.3 -6.57 1.33e-10 7.53e-08 -0.28 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47505586 chr17:47450568~47492492:- LUSC cis rs5753618 0.504 rs5753669 ENSG00000236132.1 CTA-440B3.1 -6.57 1.33e-10 7.53e-08 -0.41 -0.29 Colorectal cancer; chr22:31509833 chr22:31816379~31817491:- LUSC cis rs13113518 0.812 rs11945371 ENSG00000249700.7 SRD5A3-AS1 6.57 1.33e-10 7.53e-08 0.33 0.29 Height; chr4:55409063 chr4:55363971~55395847:- LUSC cis rs17023223 0.537 rs2765531 ENSG00000231365.4 RP11-418J17.1 -6.57 1.33e-10 7.53e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119042874 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs1325940 ENSG00000231365.4 RP11-418J17.1 -6.57 1.33e-10 7.53e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119044064 chr1:119140396~119275973:+ LUSC cis rs227275 0.525 rs223462 ENSG00000230069.3 LRRC37A15P -6.57 1.33e-10 7.53e-08 -0.31 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102780661 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223459 ENSG00000230069.3 LRRC37A15P -6.57 1.33e-10 7.53e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102788229 chr4:102727274~102730721:- LUSC cis rs227275 0.588 rs223458 ENSG00000230069.3 LRRC37A15P -6.57 1.33e-10 7.53e-08 -0.31 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102788414 chr4:102727274~102730721:- LUSC cis rs1075265 0.783 rs805438 ENSG00000233266.1 HMGB1P31 6.57 1.33e-10 7.55e-08 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:53829051 chr2:54051334~54051760:+ LUSC cis rs2948294 0.524 rs13270062 ENSG00000253893.2 FAM85B -6.57 1.33e-10 7.55e-08 -0.38 -0.29 Red cell distribution width; chr8:8255128 chr8:8167819~8226614:- LUSC cis rs1075232 1 rs72722847 ENSG00000215302.7 CTD-3092A11.1 -6.57 1.34e-10 7.56e-08 -0.68 -0.29 Survival in colorectal cancer (non-distant metastatic); chr15:31390143 chr15:30470779~30507623:+ LUSC cis rs9549367 0.789 rs9549715 ENSG00000269125.1 RP11-98F14.11 -6.57 1.34e-10 7.57e-08 -0.36 -0.29 Platelet distribution width; chr13:113253926 chr13:113165002~113165183:- LUSC cis rs9549367 0.789 rs2302757 ENSG00000269125.1 RP11-98F14.11 -6.57 1.34e-10 7.57e-08 -0.36 -0.29 Platelet distribution width; chr13:113255025 chr13:113165002~113165183:- LUSC cis rs3779195 1 rs3779195 ENSG00000272950.1 RP11-307C18.1 -6.57 1.34e-10 7.58e-08 -0.49 -0.29 Sex hormone-binding globulin levels; chr7:98364050 chr7:98322853~98323430:+ LUSC cis rs12554020 0.786 rs56073019 ENSG00000227603.1 RP11-165J3.6 6.57 1.34e-10 7.58e-08 0.46 0.29 Schizophrenia; chr9:93491169 chr9:93435332~93437121:- LUSC cis rs12554020 0.786 rs75576302 ENSG00000227603.1 RP11-165J3.6 6.57 1.34e-10 7.58e-08 0.46 0.29 Schizophrenia; chr9:93492940 chr9:93435332~93437121:- LUSC cis rs12554020 0.786 rs76703294 ENSG00000227603.1 RP11-165J3.6 6.57 1.34e-10 7.58e-08 0.46 0.29 Schizophrenia; chr9:93493884 chr9:93435332~93437121:- LUSC cis rs957448 1 rs16916881 ENSG00000253175.1 RP11-267M23.6 6.57 1.34e-10 7.58e-08 0.34 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94554042 chr8:94565036~94565715:+ LUSC cis rs957448 1 rs12680965 ENSG00000253175.1 RP11-267M23.6 6.57 1.34e-10 7.58e-08 0.34 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94554069 chr8:94565036~94565715:+ LUSC cis rs11089937 0.616 rs5757247 ENSG00000211639.2 IGLV4-60 6.57 1.34e-10 7.6e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22177186 chr22:22162199~22162681:+ LUSC cis rs6683071 0.894 rs12073392 ENSG00000272750.1 RP11-378J18.8 -6.57 1.35e-10 7.63e-08 -0.37 -0.29 Cognitive performance; chr1:222753336 chr1:222658867~222661512:- LUSC cis rs881375 0.715 rs10985073 ENSG00000226752.6 PSMD5-AS1 -6.57 1.35e-10 7.63e-08 -0.32 -0.29 Rheumatoid arthritis; chr9:120881577 chr9:120824828~120854385:+ LUSC cis rs2337406 0.641 rs10133227 ENSG00000274576.2 IGHV2-70 6.57 1.35e-10 7.64e-08 0.31 0.29 Alzheimer's disease (late onset); chr14:106814260 chr14:106770577~106771020:- LUSC cis rs11098499 0.604 rs10022185 ENSG00000250412.1 KLHL2P1 6.57 1.35e-10 7.64e-08 0.37 0.29 Corneal astigmatism; chr4:119650610 chr4:119334329~119378233:+ LUSC cis rs13113518 0.812 rs12505880 ENSG00000223305.1 RN7SKP30 6.57 1.35e-10 7.64e-08 0.35 0.29 Height; chr4:55440988 chr4:55540502~55540835:- LUSC cis rs6142102 0.625 rs2050208 ENSG00000275784.1 RP5-1125A11.6 -6.57 1.35e-10 7.66e-08 -0.32 -0.29 Skin pigmentation; chr20:33955767 chr20:33989480~33991818:- LUSC cis rs6142102 0.961 rs4911389 ENSG00000276073.1 RP5-1125A11.7 -6.57 1.36e-10 7.67e-08 -0.31 -0.29 Skin pigmentation; chr20:33977235 chr20:33985617~33988989:- LUSC cis rs950169 0.96 rs35159785 ENSG00000225151.9 GOLGA2P7 -6.57 1.36e-10 7.67e-08 -0.41 -0.29 Schizophrenia; chr15:84135262 chr15:84199311~84230136:- LUSC cis rs9322193 0.884 rs9397036 ENSG00000268592.3 RAET1E-AS1 6.57 1.36e-10 7.68e-08 0.37 0.29 Lung cancer; chr6:149851787 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs9383864 ENSG00000268592.3 RAET1E-AS1 6.57 1.36e-10 7.68e-08 0.37 0.29 Lung cancer; chr6:149851969 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs9383865 ENSG00000268592.3 RAET1E-AS1 6.57 1.36e-10 7.68e-08 0.37 0.29 Lung cancer; chr6:149852043 chr6:149863494~149919507:+ LUSC cis rs9318086 0.904 rs9580769 ENSG00000205861.10 C1QTNF9B-AS1 6.57 1.36e-10 7.7e-08 0.35 0.29 Myopia (pathological); chr13:23865585 chr13:23888889~23897263:+ LUSC cis rs7520050 0.667 rs11211176 ENSG00000280836.1 AL355480.1 6.57 1.36e-10 7.71e-08 0.32 0.29 Reticulocyte count;Red blood cell count; chr1:45757414 chr1:45581219~45581321:- LUSC cis rs881375 0.933 rs1548784 ENSG00000226752.6 PSMD5-AS1 -6.57 1.36e-10 7.71e-08 -0.33 -0.29 Rheumatoid arthritis; chr9:120923002 chr9:120824828~120854385:+ LUSC cis rs2179367 0.632 rs55836833 ENSG00000231760.4 RP11-350J20.5 6.57 1.36e-10 7.71e-08 0.42 0.29 Dupuytren's disease; chr6:149403736 chr6:149796151~149826294:- LUSC cis rs11976180 0.569 rs12703565 ENSG00000170356.8 OR2A20P -6.57 1.36e-10 7.71e-08 -0.45 -0.29 Obesity-related traits; chr7:144057308 chr7:144250045~144252957:- LUSC cis rs1075265 0.575 rs2692531 ENSG00000233266.1 HMGB1P31 6.57 1.37e-10 7.72e-08 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:53776640 chr2:54051334~54051760:+ LUSC cis rs950169 1 rs35297609 ENSG00000225151.9 GOLGA2P7 -6.57 1.37e-10 7.73e-08 -0.4 -0.29 Schizophrenia; chr15:84104144 chr15:84199311~84230136:- LUSC cis rs783540 0.521 rs28719490 ENSG00000255769.6 GOLGA2P10 -6.57 1.37e-10 7.74e-08 -0.39 -0.29 Schizophrenia; chr15:82720688 chr15:82472993~82513950:- LUSC cis rs2179367 0.632 rs7349921 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149392727 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs60153446 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149393186 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs61259243 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149393457 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs62426115 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149393718 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs68080376 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149393873 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs763590 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149398831 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs17506789 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149399710 chr6:149796151~149826294:- LUSC cis rs2179367 0.586 rs34097428 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149399822 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs9498344 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149401053 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs12154153 ENSG00000231760.4 RP11-350J20.5 6.57 1.37e-10 7.75e-08 0.42 0.29 Dupuytren's disease; chr6:149401686 chr6:149796151~149826294:- LUSC cis rs7267979 1 rs6083828 ENSG00000274973.1 RP13-401N8.7 6.57 1.37e-10 7.75e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25389282 chr20:25845497~25845862:+ LUSC cis rs10463554 0.892 rs11952337 ENSG00000175749.11 EIF3KP1 6.57 1.37e-10 7.76e-08 0.35 0.29 Parkinson's disease; chr5:102928043 chr5:103032376~103033031:+ LUSC cis rs2404602 0.647 rs11634266 ENSG00000259422.1 RP11-593F23.1 -6.57 1.38e-10 7.77e-08 -0.34 -0.29 Blood metabolite levels; chr15:76801120 chr15:76174891~76181486:- LUSC cis rs2404602 0.647 rs7178250 ENSG00000259422.1 RP11-593F23.1 -6.57 1.38e-10 7.77e-08 -0.34 -0.29 Blood metabolite levels; chr15:76806766 chr15:76174891~76181486:- LUSC cis rs761746 0.579 rs5998121 ENSG00000236132.1 CTA-440B3.1 -6.57 1.38e-10 7.77e-08 -0.41 -0.29 Intelligence; chr22:31776381 chr22:31816379~31817491:- LUSC cis rs8059260 0.668 rs76212701 ENSG00000274038.1 RP11-66H6.4 -6.57 1.38e-10 7.77e-08 -0.49 -0.29 Alcohol consumption over the past year; chr16:11023634 chr16:11056556~11057034:+ LUSC cis rs2732480 0.538 rs2468943 ENSG00000240399.1 RP1-228P16.1 -6.57 1.38e-10 7.77e-08 -0.3 -0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48353466 chr12:48054813~48055591:- LUSC cis rs6772849 0.896 rs61112519 ENSG00000242551.2 POU5F1P6 -6.57 1.38e-10 7.77e-08 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128619333 chr3:128674735~128677005:- LUSC cis rs2019137 0.901 rs4849176 ENSG00000274877.1 RP11-65I12.1 6.57 1.38e-10 7.78e-08 0.35 0.29 Lymphocyte counts; chr2:113220359 chr2:113237595~113240825:+ LUSC cis rs7955901 0.691 rs11178599 ENSG00000257265.1 CTD-2021H9.1 6.57 1.38e-10 7.78e-08 0.32 0.29 Type 2 diabetes; chr12:71093985 chr12:71007773~71032083:- LUSC cis rs10829156 0.898 rs4748504 ENSG00000240291.1 RP11-499P20.2 6.57 1.38e-10 7.78e-08 0.31 0.29 Sudden cardiac arrest; chr10:18651868 chr10:18513115~18545651:- LUSC cis rs673078 0.607 rs4766899 ENSG00000275759.1 RP11-131L12.3 -6.57 1.38e-10 7.79e-08 -0.38 -0.29 Glucose homeostasis traits; chr12:118374888 chr12:118428281~118428870:+ LUSC cis rs10740039 0.883 rs7068934 ENSG00000254271.1 RP11-131N11.4 6.56 1.38e-10 7.79e-08 0.4 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60636490 chr10:60734342~60741828:+ LUSC cis rs6142102 0.961 rs761235 ENSG00000276073.1 RP5-1125A11.7 -6.56 1.38e-10 7.79e-08 -0.31 -0.29 Skin pigmentation; chr20:33946602 chr20:33985617~33988989:- LUSC cis rs2404602 0.622 rs11632670 ENSG00000259422.1 RP11-593F23.1 -6.56 1.38e-10 7.8e-08 -0.34 -0.29 Blood metabolite levels; chr15:76681714 chr15:76174891~76181486:- LUSC cis rs881375 0.902 rs2900180 ENSG00000226752.6 PSMD5-AS1 -6.56 1.38e-10 7.8e-08 -0.33 -0.29 Rheumatoid arthritis; chr9:120944104 chr9:120824828~120854385:+ LUSC cis rs783540 0.967 rs1269134 ENSG00000276710.3 CSPG4P8 6.56 1.38e-10 7.8e-08 0.31 0.29 Schizophrenia; chr15:82613877 chr15:82459472~82477258:+ LUSC cis rs11098499 0.754 rs12711071 ENSG00000249244.1 RP11-548H18.2 6.56 1.38e-10 7.81e-08 0.36 0.29 Corneal astigmatism; chr4:119319779 chr4:119391831~119395335:- LUSC cis rs9549367 0.789 rs7994324 ENSG00000269125.1 RP11-98F14.11 -6.56 1.39e-10 7.83e-08 -0.36 -0.29 Platelet distribution width; chr13:113252183 chr13:113165002~113165183:- LUSC cis rs9309473 0.95 rs6546849 ENSG00000163016.8 ALMS1P 6.56 1.39e-10 7.83e-08 0.35 0.29 Metabolite levels; chr2:73603910 chr2:73644919~73685576:+ LUSC cis rs9309473 0.851 rs6546850 ENSG00000163016.8 ALMS1P 6.56 1.39e-10 7.83e-08 0.35 0.29 Metabolite levels; chr2:73604020 chr2:73644919~73685576:+ LUSC cis rs9309473 0.898 rs6546852 ENSG00000163016.8 ALMS1P 6.56 1.39e-10 7.83e-08 0.35 0.29 Metabolite levels; chr2:73606304 chr2:73644919~73685576:+ LUSC cis rs9309473 0.95 rs6546853 ENSG00000163016.8 ALMS1P 6.56 1.39e-10 7.83e-08 0.35 0.29 Metabolite levels; chr2:73606612 chr2:73644919~73685576:+ LUSC cis rs6951245 0.872 rs76713558 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056230 chr7:1074450~1078036:+ LUSC cis rs6951245 0.748 rs79658522 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056241 chr7:1074450~1078036:+ LUSC cis rs6951245 0.935 rs76525951 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056377 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs79683221 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056503 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs78185801 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056731 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs80031817 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057157 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs78143408 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057210 chr7:1074450~1078036:+ LUSC cis rs6951245 0.938 rs78351779 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057387 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs11761941 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057547 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs11767527 ENSG00000224079.1 AC091729.7 -6.56 1.39e-10 7.83e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057758 chr7:1074450~1078036:+ LUSC cis rs9376098 0.698 rs9494155 ENSG00000232876.1 CTA-212D2.2 -6.56 1.39e-10 7.83e-08 -0.35 -0.29 Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells; chr6:135147753 chr6:135055033~135060550:+ LUSC cis rs881375 0.967 rs1860823 ENSG00000226752.6 PSMD5-AS1 -6.56 1.39e-10 7.84e-08 -0.33 -0.29 Rheumatoid arthritis; chr9:120897026 chr9:120824828~120854385:+ LUSC cis rs9322193 0.923 rs9480031 ENSG00000268592.3 RAET1E-AS1 6.56 1.39e-10 7.85e-08 0.37 0.29 Lung cancer; chr6:149758875 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9505823 ENSG00000268592.3 RAET1E-AS1 6.56 1.39e-10 7.85e-08 0.36 0.29 Lung cancer; chr6:149628899 chr6:149863494~149919507:+ LUSC cis rs11123170 0.543 rs4849178 ENSG00000274877.1 RP11-65I12.1 -6.56 1.39e-10 7.85e-08 -0.4 -0.29 Renal function-related traits (BUN); chr2:113225031 chr2:113237595~113240825:+ LUSC cis rs4950322 0.518 rs61838936 ENSG00000278811.3 LINC00624 6.56 1.39e-10 7.86e-08 0.32 0.29 Protein quantitative trait loci; chr1:147098422 chr1:147258885~147517875:- LUSC cis rs7727544 0.735 rs274559 ENSG00000233006.5 AC034220.3 -6.56 1.39e-10 7.86e-08 -0.28 -0.29 Blood metabolite levels; chr5:132384378 chr5:132311285~132369916:- LUSC cis rs992157 0.56 rs6436047 ENSG00000261338.2 RP11-378A13.1 6.56 1.39e-10 7.86e-08 0.29 0.29 Colorectal cancer; chr2:218244190 chr2:218255319~218257366:+ LUSC cis rs5760092 0.755 rs915589 ENSG00000235689.1 AP000351.13 -6.56 1.39e-10 7.87e-08 -0.36 -0.29 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:24006305~24008258:- LUSC cis rs7246657 0.943 rs1382357 ENSG00000276846.1 CTD-3220F14.3 6.56 1.4e-10 7.87e-08 0.45 0.29 Coronary artery calcification; chr19:37486707 chr19:37314868~37315620:- LUSC cis rs228614 0.51 rs223410 ENSG00000230069.3 LRRC37A15P -6.56 1.4e-10 7.87e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102813568 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs3774987 ENSG00000230069.3 LRRC37A15P -6.56 1.4e-10 7.9e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799709 chr4:102727274~102730721:- LUSC cis rs2404602 0.647 rs920712 ENSG00000259422.1 RP11-593F23.1 -6.56 1.4e-10 7.9e-08 -0.34 -0.29 Blood metabolite levels; chr15:76741593 chr15:76174891~76181486:- LUSC cis rs2280018 0.963 rs12928424 ENSG00000260735.1 RP11-72I8.1 -6.56 1.4e-10 7.91e-08 -0.32 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15056916 chr16:15094411~15109197:+ LUSC cis rs5742933 0.762 rs2033746 ENSG00000253559.1 OSGEPL1-AS1 6.56 1.4e-10 7.91e-08 0.35 0.29 Ferritin levels; chr2:189734726 chr2:189762704~189765556:+ LUSC cis rs748404 0.666 rs72709871 ENSG00000249839.1 AC011330.5 -6.56 1.4e-10 7.91e-08 -0.49 -0.29 Lung cancer; chr15:43499025 chr15:43663654~43684339:- LUSC cis rs10129255 0.5 rs4774189 ENSG00000224373.3 IGHV4-59 6.56 1.41e-10 7.94e-08 0.15 0.29 Kawasaki disease; chr14:106768275 chr14:106627249~106627825:- LUSC cis rs801193 0.66 rs2659897 ENSG00000237310.1 GS1-124K5.4 -6.56 1.41e-10 7.94e-08 -0.3 -0.29 Aortic root size; chr7:66722728 chr7:66493706~66495474:+ LUSC cis rs2408955 0.5 rs12816820 ENSG00000240399.1 RP1-228P16.1 6.56 1.41e-10 7.94e-08 0.29 0.29 Glycated hemoglobin levels; chr12:48164542 chr12:48054813~48055591:- LUSC cis rs1387259 0.57 rs12368659 ENSG00000240399.1 RP1-228P16.1 6.56 1.41e-10 7.94e-08 0.29 0.29 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48168516 chr12:48054813~48055591:- LUSC cis rs7246657 0.943 rs6508711 ENSG00000276846.1 CTD-3220F14.3 6.56 1.41e-10 7.95e-08 0.44 0.29 Coronary artery calcification; chr19:37324232 chr19:37314868~37315620:- LUSC cis rs7246657 0.882 rs6508716 ENSG00000276846.1 CTD-3220F14.3 6.56 1.41e-10 7.95e-08 0.44 0.29 Coronary artery calcification; chr19:37328108 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs7257672 ENSG00000276846.1 CTD-3220F14.3 6.56 1.41e-10 7.95e-08 0.44 0.29 Coronary artery calcification; chr19:37332957 chr19:37314868~37315620:- LUSC cis rs7246657 0.891 rs7257495 ENSG00000276846.1 CTD-3220F14.3 6.56 1.41e-10 7.95e-08 0.44 0.29 Coronary artery calcification; chr19:37332974 chr19:37314868~37315620:- LUSC cis rs853679 0.546 rs13195291 ENSG00000204709.4 LINC01556 6.56 1.41e-10 7.95e-08 0.64 0.29 Depression; chr6:28201463 chr6:28943877~28944537:+ LUSC cis rs10129255 0.5 rs2027902 ENSG00000224373.3 IGHV4-59 6.56 1.41e-10 7.96e-08 0.15 0.29 Kawasaki disease; chr14:106807157 chr14:106627249~106627825:- LUSC cis rs2404602 0.735 rs62028423 ENSG00000259422.1 RP11-593F23.1 -6.56 1.42e-10 8e-08 -0.33 -0.29 Blood metabolite levels; chr15:76462173 chr15:76174891~76181486:- LUSC cis rs17507216 0.718 rs28587782 ENSG00000255769.6 GOLGA2P10 -6.56 1.42e-10 8e-08 -0.43 -0.29 Excessive daytime sleepiness; chr15:82576881 chr15:82472993~82513950:- LUSC cis rs11089937 0.616 rs12484482 ENSG00000211639.2 IGLV4-60 6.56 1.43e-10 8.04e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22180158 chr22:22162199~22162681:+ LUSC cis rs2337406 1 rs11845269 ENSG00000254174.1 IGHV1-12 6.56 1.43e-10 8.04e-08 0.29 0.29 Alzheimer's disease (late onset); chr14:106683851 chr14:106122420~106122709:- LUSC cis rs75920871 0.545 rs7939934 ENSG00000254851.1 RP11-109L13.1 6.56 1.43e-10 8.04e-08 0.4 0.29 Subjective well-being; chr11:116990552 chr11:117135528~117138582:+ LUSC cis rs72772090 0.539 rs11750671 ENSG00000248734.2 CTD-2260A17.1 -6.56 1.43e-10 8.06e-08 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96852779 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs72775817 ENSG00000248734.2 CTD-2260A17.1 -6.56 1.43e-10 8.06e-08 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96855006 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs72775818 ENSG00000248734.2 CTD-2260A17.1 -6.56 1.43e-10 8.06e-08 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96857512 chr5:96784777~96785999:+ LUSC cis rs801193 0.761 rs2659888 ENSG00000236529.1 RP13-254B10.1 6.56 1.43e-10 8.06e-08 0.3 0.29 Aortic root size; chr7:66765184 chr7:65840212~65840596:+ LUSC cis rs6570726 0.935 rs392014 ENSG00000235652.6 RP11-545I5.3 6.56 1.43e-10 8.06e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145522555 chr6:145799409~145886585:+ LUSC cis rs8177376 1 rs657361 ENSG00000254905.1 RP11-712L6.7 6.56 1.43e-10 8.07e-08 0.39 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126241196 chr11:126292922~126294254:- LUSC cis rs8040855 0.597 rs994989 ENSG00000259295.5 CSPG4P12 6.56 1.44e-10 8.09e-08 0.37 0.29 Bulimia nervosa; chr15:85117485 chr15:85191438~85213905:+ LUSC cis rs9309473 0.66 rs62151564 ENSG00000163016.8 ALMS1P 6.56 1.44e-10 8.1e-08 0.42 0.29 Metabolite levels; chr2:73388321 chr2:73644919~73685576:+ LUSC cis rs228614 0.51 rs223455 ENSG00000230069.3 LRRC37A15P -6.56 1.44e-10 8.11e-08 -0.3 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789026 chr4:102727274~102730721:- LUSC cis rs10740039 0.883 rs10740038 ENSG00000254271.1 RP11-131N11.4 6.56 1.44e-10 8.11e-08 0.4 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60643479 chr10:60734342~60741828:+ LUSC cis rs1075232 1 rs4450360 ENSG00000215302.7 CTD-3092A11.1 -6.56 1.44e-10 8.13e-08 -0.68 -0.29 Survival in colorectal cancer (non-distant metastatic); chr15:31389827 chr15:30470779~30507623:+ LUSC cis rs11976180 1 rs13226728 ENSG00000170356.8 OR2A20P -6.56 1.45e-10 8.13e-08 -0.39 -0.29 Obesity-related traits; chr7:144049485 chr7:144250045~144252957:- LUSC cis rs8031584 0.723 rs11632229 ENSG00000260382.1 RP11-540B6.2 -6.56 1.45e-10 8.16e-08 -0.38 -0.29 Huntington's disease progression; chr15:30887331 chr15:30882267~30883231:- LUSC cis rs875971 0.66 rs12698534 ENSG00000236529.1 RP13-254B10.1 6.56 1.45e-10 8.17e-08 0.3 0.29 Aortic root size; chr7:66521858 chr7:65840212~65840596:+ LUSC cis rs8177376 0.953 rs529328 ENSG00000254905.1 RP11-712L6.7 6.56 1.45e-10 8.17e-08 0.39 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126263746 chr11:126292922~126294254:- LUSC cis rs4604732 0.536 rs12049066 ENSG00000227135.1 GCSAML-AS1 -6.56 1.45e-10 8.17e-08 -0.44 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247479353 chr1:247524679~247526752:- LUSC cis rs62432291 0.681 rs2932987 ENSG00000235086.1 FNDC1-IT1 6.56 1.45e-10 8.18e-08 0.47 0.29 Joint mobility (Beighton score); chr6:159234641 chr6:159240786~159243329:+ LUSC cis rs11089937 0.597 rs4821772 ENSG00000211638.2 IGLV8-61 6.56 1.45e-10 8.18e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22131383 chr22:22098700~22099212:+ LUSC cis rs853679 0.607 rs34662244 ENSG00000204709.4 LINC01556 6.56 1.46e-10 8.19e-08 0.64 0.29 Depression; chr6:28106103 chr6:28943877~28944537:+ LUSC cis rs35952432 1 rs35952432 ENSG00000204709.4 LINC01556 6.56 1.46e-10 8.19e-08 0.64 0.29 Lung cancer; chr6:28107123 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs13203816 ENSG00000204709.4 LINC01556 6.56 1.46e-10 8.19e-08 0.64 0.29 Depression; chr6:28111820 chr6:28943877~28944537:+ LUSC cis rs853679 0.546 rs34371502 ENSG00000204709.4 LINC01556 6.56 1.46e-10 8.19e-08 0.64 0.29 Depression; chr6:28113980 chr6:28943877~28944537:+ LUSC cis rs228614 0.51 rs223447 ENSG00000230069.3 LRRC37A15P -6.56 1.46e-10 8.19e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102792202 chr4:102727274~102730721:- LUSC cis rs11098499 0.954 rs59866101 ENSG00000250412.1 KLHL2P1 6.56 1.46e-10 8.21e-08 0.36 0.29 Corneal astigmatism; chr4:119375436 chr4:119334329~119378233:+ LUSC cis rs11098499 0.618 rs6858383 ENSG00000250412.1 KLHL2P1 6.56 1.46e-10 8.21e-08 0.36 0.29 Corneal astigmatism; chr4:119375617 chr4:119334329~119378233:+ LUSC cis rs11098499 0.697 rs6832410 ENSG00000250412.1 KLHL2P1 6.56 1.46e-10 8.21e-08 0.36 0.29 Corneal astigmatism; chr4:119375645 chr4:119334329~119378233:+ LUSC cis rs2179367 0.959 rs514839 ENSG00000231760.4 RP11-350J20.5 6.56 1.46e-10 8.21e-08 0.37 0.29 Dupuytren's disease; chr6:149327304 chr6:149796151~149826294:- LUSC cis rs227275 0.556 rs223449 ENSG00000230069.3 LRRC37A15P -6.56 1.46e-10 8.21e-08 -0.31 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102791180 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223446 ENSG00000230069.3 LRRC37A15P -6.56 1.46e-10 8.21e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793025 chr4:102727274~102730721:- LUSC cis rs6142102 0.778 rs6059581 ENSG00000276073.1 RP5-1125A11.7 -6.56 1.46e-10 8.22e-08 -0.31 -0.29 Skin pigmentation; chr20:33940582 chr20:33985617~33988989:- LUSC cis rs11089937 0.597 rs4821770 ENSG00000211638.2 IGLV8-61 -6.56 1.46e-10 8.22e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22131281 chr22:22098700~22099212:+ LUSC cis rs11089937 0.568 rs4821771 ENSG00000211638.2 IGLV8-61 -6.56 1.46e-10 8.22e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22131287 chr22:22098700~22099212:+ LUSC cis rs7246657 0.943 rs10415937 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.22e-08 0.43 0.29 Coronary artery calcification; chr19:37339162 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs10414904 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.22e-08 0.43 0.29 Coronary artery calcification; chr19:37339186 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs10417844 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.22e-08 0.43 0.29 Coronary artery calcification; chr19:37346685 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs1373991 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.22e-08 0.43 0.29 Coronary artery calcification; chr19:37348009 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs10405407 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.22e-08 0.43 0.29 Coronary artery calcification; chr19:37348262 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs12709813 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.22e-08 0.43 0.29 Coronary artery calcification; chr19:37354081 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs13345116 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.22e-08 0.43 0.29 Coronary artery calcification; chr19:37356196 chr19:37314868~37315620:- LUSC cis rs7246657 0.765 rs7247259 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.22e-08 0.43 0.29 Coronary artery calcification; chr19:37360188 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs3745765 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.22e-08 0.43 0.29 Coronary artery calcification; chr19:37363333 chr19:37314868~37315620:- LUSC cis rs881375 0.967 rs10739579 ENSG00000226752.6 PSMD5-AS1 -6.56 1.46e-10 8.23e-08 -0.33 -0.29 Rheumatoid arthritis; chr9:120932510 chr9:120824828~120854385:+ LUSC cis rs7246657 0.943 rs2045908 ENSG00000276846.1 CTD-3220F14.3 6.56 1.46e-10 8.23e-08 0.45 0.29 Coronary artery calcification; chr19:37488866 chr19:37314868~37315620:- LUSC cis rs1075265 0.722 rs2111623 ENSG00000233266.1 HMGB1P31 -6.56 1.47e-10 8.24e-08 -0.35 -0.29 Chronotype;Morning vs. evening chronotype; chr2:53757820 chr2:54051334~54051760:+ LUSC cis rs1322639 0.571 rs13204417 ENSG00000261039.2 RP11-417E7.2 6.55 1.47e-10 8.24e-08 0.34 0.29 Pulse pressure; chr6:169175260 chr6:169175304~169182740:- LUSC cis rs881375 0.967 rs7034492 ENSG00000226752.6 PSMD5-AS1 -6.55 1.47e-10 8.26e-08 -0.33 -0.29 Rheumatoid arthritis; chr9:120924933 chr9:120824828~120854385:+ LUSC cis rs10129255 0.518 rs28378320 ENSG00000224373.3 IGHV4-59 6.55 1.47e-10 8.26e-08 0.15 0.29 Kawasaki disease; chr14:106808609 chr14:106627249~106627825:- LUSC cis rs950169 1 rs12916348 ENSG00000225151.9 GOLGA2P7 -6.55 1.47e-10 8.28e-08 -0.4 -0.29 Schizophrenia; chr15:84096775 chr15:84199311~84230136:- LUSC cis rs801193 1 rs2659915 ENSG00000236529.1 RP13-254B10.1 6.55 1.47e-10 8.28e-08 0.29 0.29 Aortic root size; chr7:66688114 chr7:65840212~65840596:+ LUSC cis rs75920871 0.588 rs10892054 ENSG00000254851.1 RP11-109L13.1 6.55 1.47e-10 8.28e-08 0.4 0.29 Subjective well-being; chr11:116997505 chr11:117135528~117138582:+ LUSC cis rs75920871 0.588 rs10892055 ENSG00000254851.1 RP11-109L13.1 6.55 1.47e-10 8.28e-08 0.4 0.29 Subjective well-being; chr11:116997655 chr11:117135528~117138582:+ LUSC cis rs11089937 0.522 rs5757259 ENSG00000211639.2 IGLV4-60 6.55 1.48e-10 8.3e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22179649 chr22:22162199~22162681:+ LUSC cis rs9921338 0.961 rs11545336 ENSG00000263080.1 RP11-485G7.5 6.55 1.48e-10 8.32e-08 0.35 0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11345639 chr16:11341809~11345211:- LUSC cis rs11098499 0.779 rs7699346 ENSG00000250412.1 KLHL2P1 6.55 1.48e-10 8.33e-08 0.36 0.29 Corneal astigmatism; chr4:119389387 chr4:119334329~119378233:+ LUSC cis rs3002131 0.688 rs2936040 ENSG00000225265.1 TAF1A-AS1 -6.55 1.48e-10 8.34e-08 -0.4 -0.29 Interleukin-10 levels; chr1:222590319 chr1:222589825~222593032:+ LUSC cis rs13423976 0.663 rs7559097 ENSG00000231367.4 AC016995.3 -6.55 1.49e-10 8.36e-08 -0.36 -0.29 Gut microbiome composition (summer); chr2:38517625 chr2:38406719~38515740:- LUSC cis rs11089937 0.539 rs6001075 ENSG00000211638.2 IGLV8-61 -6.55 1.49e-10 8.38e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22133765 chr22:22098700~22099212:+ LUSC cis rs11089937 0.597 rs6001076 ENSG00000211638.2 IGLV8-61 -6.55 1.49e-10 8.38e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22133873 chr22:22098700~22099212:+ LUSC cis rs11089937 0.597 rs5995560 ENSG00000211638.2 IGLV8-61 -6.55 1.49e-10 8.38e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22133989 chr22:22098700~22099212:+ LUSC cis rs11690935 0.959 rs2292815 ENSG00000228389.1 AC068039.4 6.55 1.49e-10 8.38e-08 0.34 0.29 Schizophrenia; chr2:171730141 chr2:171773482~171775844:+ LUSC cis rs4853012 0.838 rs4452177 ENSG00000257800.1 FNBP1P1 6.55 1.5e-10 8.41e-08 0.33 0.29 Gestational age at birth (maternal effect); chr2:74118079 chr2:74120680~74123218:+ LUSC cis rs10829156 0.945 rs10741131 ENSG00000240291.1 RP11-499P20.2 6.55 1.5e-10 8.42e-08 0.33 0.29 Sudden cardiac arrest; chr10:18683130 chr10:18513115~18545651:- LUSC cis rs7189233 0.956 rs62048478 ENSG00000279344.1 RP11-44F14.7 6.55 1.5e-10 8.42e-08 0.26 0.29 Intelligence (multi-trait analysis); chr16:53395268 chr16:53478957~53481550:- LUSC cis rs638893 0.685 rs486651 ENSG00000278376.1 RP11-158I9.8 -6.55 1.5e-10 8.43e-08 -0.38 -0.29 Vitiligo; chr11:118779150 chr11:118791254~118793137:+ LUSC cis rs10740039 0.961 rs2083696 ENSG00000254271.1 RP11-131N11.4 6.55 1.5e-10 8.43e-08 0.38 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60656430 chr10:60734342~60741828:+ LUSC cis rs10740039 1 rs10821818 ENSG00000254271.1 RP11-131N11.4 6.55 1.5e-10 8.43e-08 0.38 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60657178 chr10:60734342~60741828:+ LUSC cis rs10740039 1 rs10761545 ENSG00000254271.1 RP11-131N11.4 6.55 1.5e-10 8.43e-08 0.38 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60658811 chr10:60734342~60741828:+ LUSC cis rs10463554 0.892 rs17154859 ENSG00000175749.11 EIF3KP1 -6.55 1.51e-10 8.46e-08 -0.34 -0.29 Parkinson's disease; chr5:102955208 chr5:103032376~103033031:+ LUSC cis rs4968361 0.892 rs11653976 ENSG00000266992.1 DHX40P1 -6.55 1.51e-10 8.46e-08 -0.47 -0.29 Schizophrenia; chr17:59439633 chr17:59976009~60002384:- LUSC cis rs783540 0.967 rs783526 ENSG00000276710.3 CSPG4P8 6.55 1.51e-10 8.48e-08 0.31 0.29 Schizophrenia; chr15:82617044 chr15:82459472~82477258:+ LUSC cis rs783540 0.967 rs783527 ENSG00000276710.3 CSPG4P8 6.55 1.51e-10 8.48e-08 0.31 0.29 Schizophrenia; chr15:82617096 chr15:82459472~82477258:+ LUSC cis rs6142102 0.625 rs4012234 ENSG00000275784.1 RP5-1125A11.6 -6.55 1.51e-10 8.49e-08 -0.32 -0.29 Skin pigmentation; chr20:33965241 chr20:33989480~33991818:- LUSC cis rs6142102 0.649 rs4911382 ENSG00000275784.1 RP5-1125A11.6 -6.55 1.51e-10 8.49e-08 -0.32 -0.29 Skin pigmentation; chr20:33965289 chr20:33989480~33991818:- LUSC cis rs11098499 0.955 rs1511018 ENSG00000250412.1 KLHL2P1 6.55 1.52e-10 8.51e-08 0.36 0.29 Corneal astigmatism; chr4:119240425 chr4:119334329~119378233:+ LUSC cis rs9309473 1 rs1881245 ENSG00000163016.8 ALMS1P 6.55 1.52e-10 8.51e-08 0.35 0.29 Metabolite levels; chr2:73422800 chr2:73644919~73685576:+ LUSC cis rs875971 0.638 rs7793569 ENSG00000224316.1 RP11-479O9.2 -6.55 1.52e-10 8.52e-08 -0.27 -0.29 Aortic root size; chr7:66651646 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs6975195 ENSG00000224316.1 RP11-479O9.2 -6.55 1.52e-10 8.52e-08 -0.27 -0.29 Aortic root size; chr7:66659787 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs3857688 ENSG00000224316.1 RP11-479O9.2 -6.55 1.52e-10 8.52e-08 -0.27 -0.29 Aortic root size; chr7:66662819 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs2286684 ENSG00000224316.1 RP11-479O9.2 -6.55 1.52e-10 8.52e-08 -0.27 -0.29 Aortic root size; chr7:66664843 chr7:65773620~65802067:+ LUSC cis rs801193 0.935 rs2286683 ENSG00000224316.1 RP11-479O9.2 -6.55 1.52e-10 8.52e-08 -0.27 -0.29 Aortic root size; chr7:66664856 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs10274773 ENSG00000224316.1 RP11-479O9.2 -6.55 1.52e-10 8.52e-08 -0.27 -0.29 Aortic root size; chr7:66668591 chr7:65773620~65802067:+ LUSC cis rs227275 0.554 rs223485 ENSG00000230069.3 LRRC37A15P -6.55 1.52e-10 8.54e-08 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102764018 chr4:102727274~102730721:- LUSC cis rs10829156 0.773 rs7909552 ENSG00000240291.1 RP11-499P20.2 6.55 1.53e-10 8.56e-08 0.31 0.29 Sudden cardiac arrest; chr10:18620407 chr10:18513115~18545651:- LUSC cis rs1865760 0.865 rs9467645 ENSG00000272462.2 U91328.19 -6.55 1.53e-10 8.56e-08 -0.31 -0.29 Height; chr6:25954948 chr6:25992662~26001775:+ LUSC cis rs66887589 0.616 rs6822808 ENSG00000249244.1 RP11-548H18.2 6.55 1.53e-10 8.57e-08 0.35 0.29 Diastolic blood pressure; chr4:119296210 chr4:119391831~119395335:- LUSC cis rs1075265 0.749 rs10203095 ENSG00000233266.1 HMGB1P31 6.55 1.53e-10 8.57e-08 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:53737150 chr2:54051334~54051760:+ LUSC cis rs2404602 0.735 rs2048856 ENSG00000259422.1 RP11-593F23.1 -6.55 1.53e-10 8.58e-08 -0.34 -0.29 Blood metabolite levels; chr15:76507742 chr15:76174891~76181486:- LUSC cis rs11089937 0.584 rs5757245 ENSG00000211639.2 IGLV4-60 6.55 1.53e-10 8.58e-08 0.3 0.29 Periodontitis (PAL4Q3); chr22:22176674 chr22:22162199~22162681:+ LUSC cis rs8072100 0.967 rs62076549 ENSG00000228782.6 CTD-2026D20.3 -6.55 1.53e-10 8.58e-08 -0.28 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47502189 chr17:47450568~47492492:- LUSC cis rs7267979 1 rs4815406 ENSG00000274973.1 RP13-401N8.7 6.55 1.53e-10 8.58e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25360680 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs6107031 ENSG00000274973.1 RP13-401N8.7 6.55 1.53e-10 8.58e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25370041 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6115159 ENSG00000274973.1 RP13-401N8.7 6.55 1.53e-10 8.58e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25370308 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs4813562 ENSG00000274973.1 RP13-401N8.7 6.55 1.53e-10 8.58e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25371952 chr20:25845497~25845862:+ LUSC cis rs7772486 0.764 rs7762562 ENSG00000235652.6 RP11-545I5.3 6.55 1.53e-10 8.59e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145837858 chr6:145799409~145886585:+ LUSC cis rs7772486 0.701 rs697056 ENSG00000235652.6 RP11-545I5.3 -6.55 1.53e-10 8.59e-08 -0.29 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145682761 chr6:145799409~145886585:+ LUSC cis rs9318086 0.935 rs9652080 ENSG00000205861.10 C1QTNF9B-AS1 6.55 1.53e-10 8.59e-08 0.35 0.29 Myopia (pathological); chr13:23861287 chr13:23888889~23897263:+ LUSC cis rs9318086 0.935 rs9652081 ENSG00000205861.10 C1QTNF9B-AS1 6.55 1.53e-10 8.59e-08 0.35 0.29 Myopia (pathological); chr13:23861371 chr13:23888889~23897263:+ LUSC cis rs66887589 0.592 rs28580295 ENSG00000249244.1 RP11-548H18.2 6.55 1.54e-10 8.61e-08 0.34 0.29 Diastolic blood pressure; chr4:119357718 chr4:119391831~119395335:- LUSC cis rs5753618 0.583 rs5753601 ENSG00000236132.1 CTA-440B3.1 -6.55 1.54e-10 8.61e-08 -0.4 -0.29 Colorectal cancer; chr22:31402273 chr22:31816379~31817491:- LUSC cis rs6142102 1 rs4911414 ENSG00000276073.1 RP5-1125A11.7 -6.55 1.54e-10 8.61e-08 -0.3 -0.29 Skin pigmentation; chr20:34141638 chr20:33985617~33988989:- LUSC cis rs748404 1 rs12911132 ENSG00000249839.1 AC011330.5 -6.55 1.54e-10 8.62e-08 -0.45 -0.29 Lung cancer; chr15:43268238 chr15:43663654~43684339:- LUSC cis rs9322193 0.847 rs12234128 ENSG00000268592.3 RAET1E-AS1 6.55 1.54e-10 8.62e-08 0.36 0.29 Lung cancer; chr6:149627553 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs57012784 ENSG00000268592.3 RAET1E-AS1 6.55 1.54e-10 8.62e-08 0.36 0.29 Lung cancer; chr6:149627691 chr6:149863494~149919507:+ LUSC cis rs6142102 0.602 rs6141435 ENSG00000275784.1 RP5-1125A11.6 -6.55 1.54e-10 8.63e-08 -0.32 -0.29 Skin pigmentation; chr20:33963473 chr20:33989480~33991818:- LUSC cis rs6142102 0.625 rs1883706 ENSG00000275784.1 RP5-1125A11.6 -6.55 1.54e-10 8.63e-08 -0.32 -0.29 Skin pigmentation; chr20:33965071 chr20:33989480~33991818:- LUSC cis rs6142102 0.625 rs1883705 ENSG00000275784.1 RP5-1125A11.6 -6.55 1.54e-10 8.63e-08 -0.32 -0.29 Skin pigmentation; chr20:33965072 chr20:33989480~33991818:- LUSC cis rs71403859 0.803 rs17282500 ENSG00000260886.1 TAT-AS1 6.55 1.54e-10 8.63e-08 0.46 0.29 Post bronchodilator FEV1; chr16:71599750 chr16:71565789~71578187:+ LUSC cis rs228614 0.51 rs223400 ENSG00000230069.3 LRRC37A15P -6.55 1.54e-10 8.63e-08 -0.31 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102820439 chr4:102727274~102730721:- LUSC cis rs881375 0.967 rs1860824 ENSG00000226752.6 PSMD5-AS1 -6.55 1.54e-10 8.63e-08 -0.33 -0.29 Rheumatoid arthritis; chr9:120897061 chr9:120824828~120854385:+ LUSC cis rs10246939 0.505 rs6967189 ENSG00000228775.6 WEE2-AS1 6.55 1.54e-10 8.64e-08 0.37 0.29 Bitter taste perception; chr7:141826220 chr7:141704338~141738346:- LUSC cis rs6142102 0.625 rs9753690 ENSG00000275784.1 RP5-1125A11.6 -6.55 1.54e-10 8.64e-08 -0.32 -0.29 Skin pigmentation; chr20:33952995 chr20:33989480~33991818:- LUSC cis rs6142102 0.625 rs7263727 ENSG00000275784.1 RP5-1125A11.6 -6.55 1.54e-10 8.64e-08 -0.32 -0.29 Skin pigmentation; chr20:33953133 chr20:33989480~33991818:- LUSC cis rs11123170 0.569 rs1049137 ENSG00000274877.1 RP11-65I12.1 -6.55 1.54e-10 8.64e-08 -0.4 -0.29 Renal function-related traits (BUN); chr2:113217533 chr2:113237595~113240825:+ LUSC cis rs1865760 0.865 rs1115920 ENSG00000272462.2 U91328.19 -6.55 1.54e-10 8.64e-08 -0.31 -0.29 Height; chr6:25953799 chr6:25992662~26001775:+ LUSC cis rs875971 0.522 rs1880556 ENSG00000164669.11 INTS4P1 -6.55 1.54e-10 8.64e-08 -0.32 -0.29 Aortic root size; chr7:65967557 chr7:65141225~65234216:+ LUSC cis rs1075232 0.826 rs12438813 ENSG00000270055.1 CTD-3092A11.2 -6.55 1.55e-10 8.65e-08 -0.6 -0.29 Survival in colorectal cancer (non-distant metastatic); chr15:31413710 chr15:30487963~30490313:+ LUSC cis rs4604732 0.631 rs34924545 ENSG00000227135.1 GCSAML-AS1 -6.55 1.55e-10 8.66e-08 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463590 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs34443739 ENSG00000227135.1 GCSAML-AS1 -6.55 1.55e-10 8.66e-08 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463611 chr1:247524679~247526752:- LUSC cis rs113835537 0.529 rs11227514 ENSG00000255517.5 CTD-3074O7.5 -6.55 1.55e-10 8.68e-08 -0.34 -0.29 Airway imaging phenotypes; chr11:66519156 chr11:66473490~66480233:- LUSC cis rs10740039 1 rs10740040 ENSG00000254271.1 RP11-131N11.4 6.55 1.55e-10 8.69e-08 0.38 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60654985 chr10:60734342~60741828:+ LUSC cis rs11098499 0.779 rs10011097 ENSG00000250412.1 KLHL2P1 6.55 1.55e-10 8.69e-08 0.36 0.29 Corneal astigmatism; chr4:119389204 chr4:119334329~119378233:+ LUSC cis rs9322193 0.923 rs11155677 ENSG00000268592.3 RAET1E-AS1 6.55 1.55e-10 8.69e-08 0.37 0.29 Lung cancer; chr6:149756953 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs9480009 ENSG00000268592.3 RAET1E-AS1 6.55 1.55e-10 8.69e-08 0.37 0.29 Lung cancer; chr6:149758502 chr6:149863494~149919507:+ LUSC cis rs62432291 0.681 rs436277 ENSG00000235086.1 FNDC1-IT1 6.55 1.55e-10 8.7e-08 0.49 0.29 Joint mobility (Beighton score); chr6:159213110 chr6:159240786~159243329:+ LUSC cis rs12554020 0.681 rs78759589 ENSG00000227603.1 RP11-165J3.6 6.55 1.55e-10 8.7e-08 0.45 0.29 Schizophrenia; chr9:93409518 chr9:93435332~93437121:- LUSC cis rs4853012 0.793 rs6707619 ENSG00000257800.1 FNBP1P1 6.55 1.55e-10 8.7e-08 0.33 0.29 Gestational age at birth (maternal effect); chr2:74117529 chr2:74120680~74123218:+ LUSC cis rs6142102 0.923 rs4911379 ENSG00000275784.1 RP5-1125A11.6 -6.55 1.56e-10 8.7e-08 -0.33 -0.29 Skin pigmentation; chr20:33947499 chr20:33989480~33991818:- LUSC cis rs11098499 0.866 rs12501602 ENSG00000249244.1 RP11-548H18.2 6.55 1.56e-10 8.71e-08 0.36 0.29 Corneal astigmatism; chr4:119366780 chr4:119391831~119395335:- LUSC cis rs673078 0.607 rs2036489 ENSG00000275759.1 RP11-131L12.3 -6.55 1.56e-10 8.72e-08 -0.38 -0.29 Glucose homeostasis traits; chr12:118364643 chr12:118428281~118428870:+ LUSC cis rs801193 0.967 rs2707853 ENSG00000236529.1 RP13-254B10.1 6.54 1.56e-10 8.73e-08 0.3 0.29 Aortic root size; chr7:66749023 chr7:65840212~65840596:+ LUSC cis rs2153535 0.563 rs1796687 ENSG00000230939.1 RP11-314C16.1 -6.54 1.56e-10 8.75e-08 -0.34 -0.29 Motion sickness; chr6:8535885 chr6:8784178~8785445:+ LUSC cis rs2286503 1 rs2286503 ENSG00000228649.7 AC005682.5 6.54 1.56e-10 8.75e-08 0.32 0.29 Fibrinogen; chr7:22816987 chr7:22854178~22861579:+ LUSC cis rs11098499 0.775 rs67281037 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119360002 chr4:119391831~119395335:- LUSC cis rs10028773 0.506 rs12374346 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Educational attainment; chr4:119360550 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs12374244 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119360817 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs12374352 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119360822 chr4:119391831~119395335:- LUSC cis rs11098499 0.775 rs10021601 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119361408 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs6857892 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119361541 chr4:119391831~119395335:- LUSC cis rs11098499 0.909 rs28581362 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119362393 chr4:119391831~119395335:- LUSC cis rs11098499 0.82 rs12503082 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119363162 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs12499602 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119363232 chr4:119391831~119395335:- LUSC cis rs11098499 0.774 rs11098505 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119363472 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs13105020 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119364533 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs6824111 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119364813 chr4:119391831~119395335:- LUSC cis rs11098499 0.779 rs10857066 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119365441 chr4:119391831~119395335:- LUSC cis rs11098499 0.775 rs10029303 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119365600 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs9995136 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119365690 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs13125526 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119366864 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs12513310 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119366884 chr4:119391831~119395335:- LUSC cis rs11098499 0.866 rs12510451 ENSG00000249244.1 RP11-548H18.2 6.54 1.57e-10 8.76e-08 0.36 0.29 Corneal astigmatism; chr4:119367988 chr4:119391831~119395335:- LUSC cis rs9309473 1 rs6711033 ENSG00000163016.8 ALMS1P 6.54 1.57e-10 8.77e-08 0.34 0.29 Metabolite levels; chr2:73519516 chr2:73644919~73685576:+ LUSC cis rs8177376 0.953 rs73017394 ENSG00000254905.1 RP11-712L6.7 6.54 1.57e-10 8.78e-08 0.4 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126311952 chr11:126292922~126294254:- LUSC cis rs7772486 0.658 rs9403737 ENSG00000235652.6 RP11-545I5.3 6.54 1.57e-10 8.79e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145641057 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs4896832 ENSG00000235652.6 RP11-545I5.3 6.54 1.57e-10 8.79e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145643015 chr6:145799409~145886585:+ LUSC cis rs62432291 0.681 rs385438 ENSG00000235086.1 FNDC1-IT1 -6.54 1.58e-10 8.8e-08 -0.49 -0.29 Joint mobility (Beighton score); chr6:159235181 chr6:159240786~159243329:+ LUSC cis rs853679 0.607 rs35902873 ENSG00000204709.4 LINC01556 6.54 1.58e-10 8.81e-08 0.64 0.29 Depression; chr6:28091171 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs13197574 ENSG00000204709.4 LINC01556 6.54 1.58e-10 8.81e-08 0.64 0.29 Depression; chr6:28092461 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs34166054 ENSG00000204709.4 LINC01556 6.54 1.58e-10 8.81e-08 0.64 0.29 Depression; chr6:28098023 chr6:28943877~28944537:+ LUSC cis rs11089937 0.597 rs5756991 ENSG00000211638.2 IGLV8-61 -6.54 1.58e-10 8.82e-08 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22132541 chr22:22098700~22099212:+ LUSC cis rs11089937 0.54 rs5756992 ENSG00000211638.2 IGLV8-61 -6.54 1.58e-10 8.82e-08 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22132636 chr22:22098700~22099212:+ LUSC cis rs11089937 0.597 rs9622919 ENSG00000211638.2 IGLV8-61 -6.54 1.58e-10 8.82e-08 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22132863 chr22:22098700~22099212:+ LUSC cis rs6570726 0.764 rs366673 ENSG00000235652.6 RP11-545I5.3 6.54 1.58e-10 8.82e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145493492 chr6:145799409~145886585:+ LUSC cis rs5753618 0.583 rs5753615 ENSG00000236132.1 CTA-440B3.1 -6.54 1.58e-10 8.82e-08 -0.4 -0.29 Colorectal cancer; chr22:31432041 chr22:31816379~31817491:- LUSC cis rs11089937 0.597 rs5757005 ENSG00000211638.2 IGLV8-61 -6.54 1.58e-10 8.82e-08 -0.31 -0.29 Periodontitis (PAL4Q3); chr22:22134775 chr22:22098700~22099212:+ LUSC cis rs1876905 0.539 rs240969 ENSG00000255389.1 C6orf3 -6.54 1.58e-10 8.83e-08 -0.39 -0.29 Mean corpuscular hemoglobin; chr6:111314605 chr6:111599875~111602295:+ LUSC cis rs8177876 0.822 rs7206814 ENSG00000261838.4 RP11-303E16.6 -6.54 1.58e-10 8.84e-08 -0.64 -0.29 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81074086 chr16:81069854~81076598:+ LUSC cis rs1865760 0.865 rs9467648 ENSG00000272462.2 U91328.19 -6.54 1.58e-10 8.85e-08 -0.3 -0.29 Height; chr6:25957705 chr6:25992662~26001775:+ LUSC cis rs11976180 0.517 rs6949375 ENSG00000170356.8 OR2A20P -6.54 1.59e-10 8.86e-08 -0.45 -0.29 Obesity-related traits; chr7:144076758 chr7:144250045~144252957:- LUSC cis rs7580658 0.724 rs7568261 ENSG00000236682.1 AC068282.3 -6.54 1.59e-10 8.86e-08 -0.38 -0.29 Protein C levels; chr2:127359748 chr2:127389130~127400580:+ LUSC cis rs6142102 0.625 rs6141431 ENSG00000275784.1 RP5-1125A11.6 -6.54 1.59e-10 8.88e-08 -0.32 -0.29 Skin pigmentation; chr20:33952508 chr20:33989480~33991818:- LUSC cis rs875971 0.638 rs6960778 ENSG00000224316.1 RP11-479O9.2 -6.54 1.59e-10 8.88e-08 -0.27 -0.29 Aortic root size; chr7:66606610 chr7:65773620~65802067:+ LUSC cis rs6142102 0.602 rs932388 ENSG00000275784.1 RP5-1125A11.6 -6.54 1.59e-10 8.88e-08 -0.32 -0.29 Skin pigmentation; chr20:34069572 chr20:33989480~33991818:- LUSC cis rs5753618 0.583 rs2273249 ENSG00000236132.1 CTA-440B3.1 -6.54 1.6e-10 8.91e-08 -0.4 -0.29 Colorectal cancer; chr22:31440500 chr22:31816379~31817491:- LUSC cis rs72772090 0.539 rs35898772 ENSG00000248734.2 CTD-2260A17.1 -6.54 1.6e-10 8.91e-08 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96843982 chr5:96784777~96785999:+ LUSC cis rs6951245 0.935 rs61910751 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1058259 chr7:1074450~1078036:+ LUSC cis rs6951245 0.872 rs77434655 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1058769 chr7:1074450~1078036:+ LUSC cis rs6951245 0.872 rs75398423 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1058778 chr7:1074450~1078036:+ LUSC cis rs6951245 0.872 rs112309216 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1060660 chr7:1074450~1078036:+ LUSC cis rs6951245 0.872 rs76161580 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1060671 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs76388414 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061058 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs77305932 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061225 chr7:1074450~1078036:+ LUSC cis rs6951245 0.872 rs11768486 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061654 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs11766526 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061797 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs76214082 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1062461 chr7:1074450~1078036:+ LUSC cis rs6951245 0.938 rs113642700 ENSG00000224079.1 AC091729.7 -6.54 1.6e-10 8.91e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1066018 chr7:1074450~1078036:+ LUSC cis rs4423214 0.592 rs11233933 ENSG00000254682.1 RP11-660L16.2 -6.54 1.6e-10 8.92e-08 -0.48 -0.29 Vitamin D levels; chr11:71499024 chr11:71448674~71452157:+ LUSC cis rs2179367 0.959 rs564961 ENSG00000231760.4 RP11-350J20.5 6.54 1.6e-10 8.93e-08 0.37 0.29 Dupuytren's disease; chr6:149336091 chr6:149796151~149826294:- LUSC cis rs2179367 0.959 rs504985 ENSG00000231760.4 RP11-350J20.5 6.54 1.6e-10 8.93e-08 0.37 0.29 Dupuytren's disease; chr6:149337842 chr6:149796151~149826294:- LUSC cis rs13113518 1 rs11133388 ENSG00000249700.7 SRD5A3-AS1 -6.54 1.61e-10 8.96e-08 -0.33 -0.29 Height; chr4:55477866 chr4:55363971~55395847:- LUSC cis rs950169 0.881 rs72750843 ENSG00000225151.9 GOLGA2P7 -6.54 1.61e-10 8.96e-08 -0.42 -0.29 Schizophrenia; chr15:84592552 chr15:84199311~84230136:- LUSC cis rs801193 0.844 rs2244022 ENSG00000224316.1 RP11-479O9.2 6.54 1.61e-10 8.97e-08 0.27 0.29 Aortic root size; chr7:66737443 chr7:65773620~65802067:+ LUSC cis rs6142102 0.625 rs6142056 ENSG00000275784.1 RP5-1125A11.6 -6.54 1.61e-10 8.97e-08 -0.32 -0.29 Skin pigmentation; chr20:33953349 chr20:33989480~33991818:- LUSC cis rs801193 0.761 rs2659888 ENSG00000224316.1 RP11-479O9.2 6.54 1.62e-10 9.02e-08 0.28 0.29 Aortic root size; chr7:66765184 chr7:65773620~65802067:+ LUSC cis rs7267979 0.966 rs3827014 ENSG00000274973.1 RP13-401N8.7 6.54 1.62e-10 9.02e-08 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25390923 chr20:25845497~25845862:+ LUSC cis rs801193 1 rs2659889 ENSG00000224316.1 RP11-479O9.2 6.54 1.62e-10 9.03e-08 0.28 0.29 Aortic root size; chr7:66752125 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs3800812 ENSG00000224316.1 RP11-479O9.2 6.54 1.62e-10 9.03e-08 0.28 0.29 Aortic root size; chr7:66758474 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs4279493 ENSG00000224316.1 RP11-479O9.2 6.54 1.62e-10 9.03e-08 0.28 0.29 Aortic root size; chr7:66761633 chr7:65773620~65802067:+ LUSC cis rs3743266 0.507 rs56261931 ENSG00000245534.5 RORA-AS1 -6.54 1.62e-10 9.03e-08 -0.43 -0.29 Menarche (age at onset); chr15:60439419 chr15:60479178~60630637:+ LUSC cis rs9309473 1 rs13421462 ENSG00000163016.8 ALMS1P 6.54 1.62e-10 9.04e-08 0.35 0.29 Metabolite levels; chr2:73492748 chr2:73644919~73685576:+ LUSC cis rs673078 0.607 rs4767671 ENSG00000275759.1 RP11-131L12.3 -6.54 1.62e-10 9.06e-08 -0.44 -0.29 Glucose homeostasis traits; chr12:118396038 chr12:118428281~118428870:+ LUSC cis rs8062405 0.754 rs149299 ENSG00000278665.1 RP11-666O2.4 6.54 1.62e-10 9.06e-08 0.3 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28473820 chr16:28599241~28601881:- LUSC cis rs904251 0.686 rs2776911 ENSG00000204110.6 RP1-153P14.8 -6.54 1.63e-10 9.06e-08 -0.32 -0.29 Cognitive performance; chr6:37472174 chr6:37507348~37535616:+ LUSC cis rs7429990 0.694 rs7645846 ENSG00000229759.1 MRPS18AP1 -6.54 1.63e-10 9.08e-08 -0.29 -0.29 Educational attainment (years of education); chr3:47740829 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs7637372 ENSG00000229759.1 MRPS18AP1 -6.54 1.63e-10 9.08e-08 -0.29 -0.29 Educational attainment (years of education); chr3:47750385 chr3:48256350~48256938:- LUSC cis rs6570726 0.967 rs373527 ENSG00000235652.6 RP11-545I5.3 6.54 1.64e-10 9.11e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145480725 chr6:145799409~145886585:+ LUSC cis rs6700559 0.565 rs12728040 ENSG00000260088.1 RP11-92G12.3 6.54 1.64e-10 9.12e-08 0.37 0.29 Coronary artery disease; chr1:200626751 chr1:200669507~200694250:+ LUSC cis rs11098499 0.754 rs1546503 ENSG00000249244.1 RP11-548H18.2 6.54 1.64e-10 9.12e-08 0.37 0.29 Corneal astigmatism; chr4:119320012 chr4:119391831~119395335:- LUSC cis rs11098499 0.708 rs1546506 ENSG00000249244.1 RP11-548H18.2 6.54 1.64e-10 9.12e-08 0.37 0.29 Corneal astigmatism; chr4:119320085 chr4:119391831~119395335:- LUSC cis rs6772849 0.93 rs13434160 ENSG00000242551.2 POU5F1P6 -6.54 1.64e-10 9.12e-08 -0.32 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128655927 chr3:128674735~128677005:- LUSC cis rs6772849 0.93 rs4857916 ENSG00000242551.2 POU5F1P6 -6.54 1.64e-10 9.12e-08 -0.32 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128657171 chr3:128674735~128677005:- LUSC cis rs9921338 0.961 rs4315353 ENSG00000263080.1 RP11-485G7.5 -6.54 1.64e-10 9.12e-08 -0.34 -0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11320303 chr16:11341809~11345211:- LUSC cis rs6700559 0.716 rs12140579 ENSG00000260088.1 RP11-92G12.3 6.54 1.64e-10 9.14e-08 0.37 0.29 Coronary artery disease; chr1:200655368 chr1:200669507~200694250:+ LUSC cis rs6782228 1 rs6782228 ENSG00000277250.1 Metazoa_SRP 6.54 1.64e-10 9.15e-08 0.35 0.29 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128604581 chr3:128673681~128674021:- LUSC cis rs172166 0.694 rs203893 ENSG00000219392.1 RP1-265C24.5 -6.54 1.64e-10 9.15e-08 -0.37 -0.29 Cardiac Troponin-T levels; chr6:28094288 chr6:28115628~28116551:+ LUSC cis rs9322193 0.923 rs62441284 ENSG00000268592.3 RAET1E-AS1 6.54 1.64e-10 9.15e-08 0.37 0.29 Lung cancer; chr6:149751542 chr6:149863494~149919507:+ LUSC cis rs11690935 1 rs1554166 ENSG00000228389.1 AC068039.4 6.54 1.64e-10 9.15e-08 0.34 0.29 Schizophrenia; chr2:171685099 chr2:171773482~171775844:+ LUSC cis rs6700559 0.74 rs4387211 ENSG00000260088.1 RP11-92G12.3 -6.54 1.65e-10 9.16e-08 -0.36 -0.29 Coronary artery disease; chr1:200676810 chr1:200669507~200694250:+ LUSC cis rs875971 0.545 rs316328 ENSG00000226824.5 RP4-756H11.3 6.54 1.65e-10 9.16e-08 0.36 0.29 Aortic root size; chr7:66143851 chr7:66654538~66669855:+ LUSC cis rs11098499 0.954 rs12506546 ENSG00000250412.1 KLHL2P1 6.54 1.65e-10 9.17e-08 0.37 0.29 Corneal astigmatism; chr4:119380463 chr4:119334329~119378233:+ LUSC cis rs4604732 0.631 rs12031721 ENSG00000227135.1 GCSAML-AS1 -6.54 1.65e-10 9.17e-08 -0.44 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247460471 chr1:247524679~247526752:- LUSC cis rs75920871 0.588 rs3181 ENSG00000254851.1 RP11-109L13.1 6.54 1.65e-10 9.18e-08 0.39 0.29 Subjective well-being; chr11:117036327 chr11:117135528~117138582:+ LUSC cis rs1823913 0.599 rs35892286 ENSG00000227542.1 AC092614.2 6.54 1.65e-10 9.19e-08 0.37 0.29 Obesity-related traits; chr2:191269010 chr2:191229165~191246172:- LUSC cis rs8062405 1 rs12443881 ENSG00000278665.1 RP11-666O2.4 6.54 1.65e-10 9.19e-08 0.29 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28830456 chr16:28599241~28601881:- LUSC cis rs783540 0.869 rs783521 ENSG00000276710.3 CSPG4P8 6.54 1.65e-10 9.2e-08 0.3 0.29 Schizophrenia; chr15:82611694 chr15:82459472~82477258:+ LUSC cis rs783540 0.835 rs783522 ENSG00000276710.3 CSPG4P8 6.54 1.65e-10 9.2e-08 0.3 0.29 Schizophrenia; chr15:82611862 chr15:82459472~82477258:+ LUSC cis rs9903692 1 rs9903692 ENSG00000278765.1 RP5-890E16.5 6.54 1.65e-10 9.2e-08 0.34 0.29 Pulse pressure; chr17:48196567 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs9909933 ENSG00000278765.1 RP5-890E16.5 6.54 1.65e-10 9.2e-08 0.34 0.29 Pulse pressure; chr17:48202870 chr17:48066704~48067293:- LUSC cis rs9903692 0.909 rs2325885 ENSG00000278765.1 RP5-890E16.5 6.54 1.65e-10 9.2e-08 0.34 0.29 Pulse pressure; chr17:48213013 chr17:48066704~48067293:- LUSC cis rs4713118 0.621 rs9295756 ENSG00000280107.1 AL022393.9 -6.54 1.66e-10 9.22e-08 -0.35 -0.29 Parkinson's disease; chr6:28065618 chr6:28170845~28172521:+ LUSC cis rs62432291 0.681 rs365045 ENSG00000235086.1 FNDC1-IT1 6.54 1.66e-10 9.22e-08 0.5 0.29 Joint mobility (Beighton score); chr6:159211218 chr6:159240786~159243329:+ LUSC cis rs8062405 0.789 rs1968752 ENSG00000259982.1 CDC37P1 6.53 1.66e-10 9.23e-08 0.35 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620264 chr16:28700294~28701540:- LUSC cis rs17023223 0.537 rs2794313 ENSG00000231365.4 RP11-418J17.1 -6.53 1.66e-10 9.25e-08 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119044817 chr1:119140396~119275973:+ LUSC cis rs13113518 0.812 rs7667741 ENSG00000249700.7 SRD5A3-AS1 6.53 1.67e-10 9.27e-08 0.34 0.29 Height; chr4:55544621 chr4:55363971~55395847:- LUSC cis rs3750965 0.919 rs12280942 ENSG00000260895.1 RP11-554A11.7 -6.53 1.67e-10 9.29e-08 -0.33 -0.29 Hair color; chr11:69092215 chr11:69103493~69109094:+ LUSC cis rs875971 0.502 rs2465121 ENSG00000226824.5 RP4-756H11.3 6.53 1.67e-10 9.3e-08 0.38 0.29 Aortic root size; chr7:66156017 chr7:66654538~66669855:+ LUSC cis rs1823913 0.637 rs979967 ENSG00000227542.1 AC092614.2 6.53 1.67e-10 9.3e-08 0.37 0.29 Obesity-related traits; chr2:191304695 chr2:191229165~191246172:- LUSC cis rs2903698 0.565 rs6835573 ENSG00000250735.4 RP11-567N4.3 6.53 1.67e-10 9.31e-08 0.32 0.29 Prion diseases; chr4:75511219 chr4:75401195~75423023:+ LUSC cis rs2919917 0.688 rs6993386 ENSG00000254352.1 RP11-578O24.2 -6.53 1.68e-10 9.33e-08 -0.33 -0.29 Lymphocyte counts; chr8:78741910 chr8:78723796~78724136:- LUSC cis rs6142102 0.962 rs2206448 ENSG00000275784.1 RP5-1125A11.6 -6.53 1.68e-10 9.33e-08 -0.33 -0.29 Skin pigmentation; chr20:34121719 chr20:33989480~33991818:- LUSC cis rs71403859 0.803 rs7203606 ENSG00000260886.1 TAT-AS1 6.53 1.68e-10 9.33e-08 0.45 0.29 Post bronchodilator FEV1; chr16:71556608 chr16:71565789~71578187:+ LUSC cis rs72772090 0.539 rs72773923 ENSG00000248734.2 CTD-2260A17.1 -6.53 1.68e-10 9.34e-08 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96781875 chr5:96784777~96785999:+ LUSC cis rs7580658 0.637 rs9636236 ENSG00000236682.1 AC068282.3 -6.53 1.68e-10 9.34e-08 -0.38 -0.29 Protein C levels; chr2:127225365 chr2:127389130~127400580:+ LUSC cis rs801193 0.844 rs732465 ENSG00000224316.1 RP11-479O9.2 6.53 1.68e-10 9.35e-08 0.27 0.29 Aortic root size; chr7:66533463 chr7:65773620~65802067:+ LUSC cis rs801193 0.773 rs801207 ENSG00000224316.1 RP11-479O9.2 -6.53 1.68e-10 9.35e-08 -0.27 -0.29 Aortic root size; chr7:66555603 chr7:65773620~65802067:+ LUSC cis rs875971 0.543 rs801191 ENSG00000224316.1 RP11-479O9.2 -6.53 1.68e-10 9.35e-08 -0.27 -0.29 Aortic root size; chr7:66567968 chr7:65773620~65802067:+ LUSC cis rs950169 1 rs62026530 ENSG00000225151.9 GOLGA2P7 -6.53 1.68e-10 9.35e-08 -0.4 -0.29 Schizophrenia; chr15:84107088 chr15:84199311~84230136:- LUSC cis rs875971 0.508 rs6947808 ENSG00000237310.1 GS1-124K5.4 -6.53 1.68e-10 9.35e-08 -0.29 -0.29 Aortic root size; chr7:66580095 chr7:66493706~66495474:+ LUSC cis rs5753618 0.504 rs8142121 ENSG00000236132.1 CTA-440B3.1 -6.53 1.68e-10 9.36e-08 -0.41 -0.29 Colorectal cancer; chr22:31486799 chr22:31816379~31817491:- LUSC cis rs11098499 0.865 rs4507344 ENSG00000250412.1 KLHL2P1 6.53 1.69e-10 9.37e-08 0.36 0.29 Corneal astigmatism; chr4:119386330 chr4:119334329~119378233:+ LUSC cis rs2404602 0.735 rs2436996 ENSG00000259422.1 RP11-593F23.1 -6.53 1.69e-10 9.38e-08 -0.34 -0.29 Blood metabolite levels; chr15:76525079 chr15:76174891~76181486:- LUSC cis rs6951245 1 rs74887741 ENSG00000224079.1 AC091729.7 -6.53 1.69e-10 9.38e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1071022 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs79617366 ENSG00000224079.1 AC091729.7 -6.53 1.69e-10 9.38e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1072322 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs111899361 ENSG00000224079.1 AC091729.7 -6.53 1.69e-10 9.38e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1072712 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs80212261 ENSG00000224079.1 AC091729.7 -6.53 1.69e-10 9.38e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1074376 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs77346188 ENSG00000224079.1 AC091729.7 -6.53 1.69e-10 9.38e-08 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1074387 chr7:1074450~1078036:+ LUSC cis rs8072100 0.967 rs8072644 ENSG00000228782.6 CTD-2026D20.3 -6.53 1.69e-10 9.41e-08 -0.27 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47575998 chr17:47450568~47492492:- LUSC cis rs2524005 1 rs2524005 ENSG00000176998.4 HCG4 -6.53 1.69e-10 9.41e-08 -0.37 -0.29 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29791753~29792750:- LUSC cis rs9322193 0.923 rs9689599 ENSG00000268592.3 RAET1E-AS1 6.53 1.7e-10 9.42e-08 0.36 0.29 Lung cancer; chr6:149631973 chr6:149863494~149919507:+ LUSC cis rs2919917 0.955 rs1441850 ENSG00000254352.1 RP11-578O24.2 -6.53 1.7e-10 9.42e-08 -0.36 -0.29 Lymphocyte counts; chr8:78745431 chr8:78723796~78724136:- LUSC cis rs8059260 0.736 rs7200623 ENSG00000274038.1 RP11-66H6.4 -6.53 1.7e-10 9.42e-08 -0.49 -0.29 Alcohol consumption over the past year; chr16:11001188 chr16:11056556~11057034:+ LUSC cis rs496547 0.756 rs562059 ENSG00000255422.1 AP002954.4 -6.53 1.7e-10 9.43e-08 -0.31 -0.29 Hip minimal joint space width; chr11:118731349 chr11:118704607~118750263:+ LUSC cis rs875971 0.66 rs7807944 ENSG00000224316.1 RP11-479O9.2 -6.53 1.7e-10 9.44e-08 -0.27 -0.29 Aortic root size; chr7:66622208 chr7:65773620~65802067:+ LUSC cis rs8062405 0.69 rs62034351 ENSG00000278665.1 RP11-666O2.4 6.53 1.7e-10 9.44e-08 0.3 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554168 chr16:28599241~28601881:- LUSC cis rs11976180 1 rs11976180 ENSG00000170356.8 OR2A20P -6.53 1.7e-10 9.45e-08 -0.39 -0.29 Obesity-related traits; chr7:144044487 chr7:144250045~144252957:- LUSC cis rs8059260 0.544 rs35347079 ENSG00000274038.1 RP11-66H6.4 -6.53 1.7e-10 9.45e-08 -0.51 -0.29 Alcohol consumption over the past year; chr16:11099696 chr16:11056556~11057034:+ LUSC cis rs113835537 0.559 rs57045447 ENSG00000255517.5 CTD-3074O7.5 -6.53 1.7e-10 9.45e-08 -0.33 -0.29 Airway imaging phenotypes; chr11:66572212 chr11:66473490~66480233:- LUSC cis rs875971 0.54 rs736270 ENSG00000164669.11 INTS4P1 -6.53 1.7e-10 9.46e-08 -0.32 -0.29 Aortic root size; chr7:65963835 chr7:65141225~65234216:+ LUSC cis rs875971 0.545 rs73142265 ENSG00000226824.5 RP4-756H11.3 -6.53 1.7e-10 9.46e-08 -0.38 -0.29 Aortic root size; chr7:66234510 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs2707845 ENSG00000224316.1 RP11-479O9.2 6.53 1.71e-10 9.47e-08 0.27 0.29 Aortic root size; chr7:66733811 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs2707850 ENSG00000224316.1 RP11-479O9.2 6.53 1.71e-10 9.47e-08 0.27 0.29 Aortic root size; chr7:66738883 chr7:65773620~65802067:+ LUSC cis rs801193 0.967 rs1110414 ENSG00000224316.1 RP11-479O9.2 6.53 1.71e-10 9.47e-08 0.27 0.29 Aortic root size; chr7:66740595 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs7783924 ENSG00000224316.1 RP11-479O9.2 6.53 1.71e-10 9.47e-08 0.27 0.29 Aortic root size; chr7:66744070 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs7789184 ENSG00000224316.1 RP11-479O9.2 6.53 1.71e-10 9.47e-08 0.27 0.29 Aortic root size; chr7:66745208 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs2707854 ENSG00000224316.1 RP11-479O9.2 6.53 1.71e-10 9.47e-08 0.27 0.29 Aortic root size; chr7:66747610 chr7:65773620~65802067:+ LUSC cis rs10759883 0.563 rs12345187 ENSG00000175611.10 LINC00476 6.53 1.71e-10 9.47e-08 0.33 0.29 Nicotine dependence; chr9:95906088 chr9:95759231~95875977:- LUSC cis rs17507216 0.718 rs4779034 ENSG00000255769.6 GOLGA2P10 -6.53 1.71e-10 9.47e-08 -0.43 -0.29 Excessive daytime sleepiness; chr15:82576799 chr15:82472993~82513950:- LUSC cis rs3813579 0.606 rs3813583 ENSG00000261390.4 RP11-345M22.2 -6.53 1.71e-10 9.48e-08 -0.35 -0.29 Thyroid volume; chr16:79721183 chr16:79715232~79770563:- LUSC cis rs875971 1 rs4718307 ENSG00000237310.1 GS1-124K5.4 -6.53 1.71e-10 9.48e-08 -0.3 -0.29 Aortic root size; chr7:66146001 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs7801282 ENSG00000237310.1 GS1-124K5.4 -6.53 1.71e-10 9.48e-08 -0.3 -0.29 Aortic root size; chr7:66148700 chr7:66493706~66495474:+ LUSC cis rs11098499 0.954 rs3733524 ENSG00000250412.1 KLHL2P1 6.53 1.71e-10 9.49e-08 0.36 0.29 Corneal astigmatism; chr4:119502574 chr4:119334329~119378233:+ LUSC cis rs875971 0.508 rs10950045 ENSG00000224316.1 RP11-479O9.2 -6.53 1.72e-10 9.52e-08 -0.27 -0.29 Aortic root size; chr7:66601386 chr7:65773620~65802067:+ LUSC cis rs801193 0.839 rs6968619 ENSG00000224316.1 RP11-479O9.2 -6.53 1.72e-10 9.52e-08 -0.27 -0.29 Aortic root size; chr7:66603880 chr7:65773620~65802067:+ LUSC cis rs801193 0.839 rs12534943 ENSG00000224316.1 RP11-479O9.2 -6.53 1.72e-10 9.52e-08 -0.27 -0.29 Aortic root size; chr7:66605533 chr7:65773620~65802067:+ LUSC cis rs801193 0.805 rs12532355 ENSG00000224316.1 RP11-479O9.2 -6.53 1.72e-10 9.52e-08 -0.27 -0.29 Aortic root size; chr7:66605597 chr7:65773620~65802067:+ LUSC cis rs9322193 0.923 rs1572229 ENSG00000268592.3 RAET1E-AS1 6.53 1.72e-10 9.52e-08 0.37 0.29 Lung cancer; chr6:149743841 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs10872646 ENSG00000268592.3 RAET1E-AS1 6.53 1.72e-10 9.52e-08 0.37 0.29 Lung cancer; chr6:149746539 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs12528279 ENSG00000268592.3 RAET1E-AS1 6.53 1.72e-10 9.52e-08 0.37 0.29 Lung cancer; chr6:149750892 chr6:149863494~149919507:+ LUSC cis rs9322193 0.809 rs9479808 ENSG00000268592.3 RAET1E-AS1 6.53 1.72e-10 9.52e-08 0.37 0.29 Lung cancer; chr6:149751328 chr6:149863494~149919507:+ LUSC cis rs13113518 0.756 rs12510275 ENSG00000223305.1 RN7SKP30 6.53 1.72e-10 9.53e-08 0.35 0.29 Height; chr4:55516548 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs12510327 ENSG00000223305.1 RN7SKP30 6.53 1.72e-10 9.53e-08 0.35 0.29 Height; chr4:55516744 chr4:55540502~55540835:- LUSC cis rs13113518 0.812 rs11939580 ENSG00000223305.1 RN7SKP30 6.53 1.72e-10 9.53e-08 0.35 0.29 Height; chr4:55517185 chr4:55540502~55540835:- LUSC cis rs801193 0.935 rs2659899 ENSG00000224316.1 RP11-479O9.2 6.53 1.72e-10 9.53e-08 0.27 0.29 Aortic root size; chr7:66721734 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs1553609 ENSG00000224316.1 RP11-479O9.2 6.53 1.72e-10 9.53e-08 0.27 0.29 Aortic root size; chr7:66732152 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs1553610 ENSG00000224316.1 RP11-479O9.2 6.53 1.72e-10 9.53e-08 0.27 0.29 Aortic root size; chr7:66732246 chr7:65773620~65802067:+ LUSC cis rs6142102 0.602 rs4911402 ENSG00000275784.1 RP5-1125A11.6 -6.53 1.72e-10 9.53e-08 -0.32 -0.29 Skin pigmentation; chr20:34079839 chr20:33989480~33991818:- LUSC cis rs7246657 0.943 rs4802766 ENSG00000276846.1 CTD-3220F14.3 6.53 1.72e-10 9.54e-08 0.44 0.29 Coronary artery calcification; chr19:37491031 chr19:37314868~37315620:- LUSC cis rs5753618 0.561 rs5749265 ENSG00000236132.1 CTA-440B3.1 -6.53 1.72e-10 9.54e-08 -0.4 -0.29 Colorectal cancer; chr22:31400911 chr22:31816379~31817491:- LUSC cis rs2408955 0.501 rs8716 ENSG00000240399.1 RP1-228P16.1 6.53 1.72e-10 9.55e-08 0.29 0.29 Glycated hemoglobin levels; chr12:48145699 chr12:48054813~48055591:- LUSC cis rs2408955 0.521 rs7301003 ENSG00000240399.1 RP1-228P16.1 6.53 1.72e-10 9.55e-08 0.29 0.29 Glycated hemoglobin levels; chr12:48156444 chr12:48054813~48055591:- LUSC cis rs8072100 0.902 rs12051716 ENSG00000228782.6 CTD-2026D20.3 -6.53 1.72e-10 9.56e-08 -0.27 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47505029 chr17:47450568~47492492:- LUSC cis rs801193 1 rs2659906 ENSG00000224316.1 RP11-479O9.2 6.53 1.72e-10 9.56e-08 0.27 0.29 Aortic root size; chr7:66700323 chr7:65773620~65802067:+ LUSC cis rs6142102 0.625 rs6142051 ENSG00000275784.1 RP5-1125A11.6 -6.53 1.72e-10 9.56e-08 -0.32 -0.29 Skin pigmentation; chr20:33945212 chr20:33989480~33991818:- LUSC cis rs4713118 0.513 rs149955 ENSG00000216901.1 AL022393.7 6.53 1.73e-10 9.58e-08 0.34 0.29 Parkinson's disease; chr6:28068447 chr6:28176188~28176674:+ LUSC cis rs11098499 0.954 rs11098524 ENSG00000249244.1 RP11-548H18.2 6.53 1.73e-10 9.59e-08 0.37 0.29 Corneal astigmatism; chr4:119468877 chr4:119391831~119395335:- LUSC cis rs11690935 0.959 rs6738445 ENSG00000228389.1 AC068039.4 -6.53 1.73e-10 9.59e-08 -0.34 -0.29 Schizophrenia; chr2:171743105 chr2:171773482~171775844:+ LUSC cis rs801193 1 rs2659915 ENSG00000224316.1 RP11-479O9.2 6.53 1.73e-10 9.6e-08 0.27 0.29 Aortic root size; chr7:66688114 chr7:65773620~65802067:+ LUSC cis rs9928842 0.771 rs4888363 ENSG00000280152.1 RP11-331F4.5 6.53 1.73e-10 9.6e-08 0.33 0.29 Alcoholic chronic pancreatitis; chr16:75243446 chr16:75245994~75250077:- LUSC cis rs75920871 0.528 rs4388921 ENSG00000254851.1 RP11-109L13.1 6.53 1.73e-10 9.6e-08 0.41 0.29 Subjective well-being; chr11:117106062 chr11:117135528~117138582:+ LUSC cis rs7246657 0.882 rs10422667 ENSG00000276846.1 CTD-3220F14.3 6.53 1.73e-10 9.61e-08 0.45 0.29 Coronary artery calcification; chr19:37446974 chr19:37314868~37315620:- LUSC cis rs496547 0.686 rs540180 ENSG00000255239.1 AP002954.6 6.53 1.73e-10 9.61e-08 0.32 0.29 Hip minimal joint space width; chr11:118782920 chr11:118688039~118690600:- LUSC cis rs1501911 0.509 rs34487 ENSG00000248489.1 CTD-2007H13.3 6.53 1.74e-10 9.63e-08 0.31 0.29 Lung function (FEV1/FVC); chr5:98872725 chr5:98929171~98995013:+ LUSC cis rs1501911 0.509 rs327786 ENSG00000248489.1 CTD-2007H13.3 6.53 1.74e-10 9.63e-08 0.31 0.29 Lung function (FEV1/FVC); chr5:98878301 chr5:98929171~98995013:+ LUSC cis rs875971 0.666 rs13242072 ENSG00000236529.1 RP13-254B10.1 -6.53 1.74e-10 9.63e-08 -0.3 -0.29 Aortic root size; chr7:66301001 chr7:65840212~65840596:+ LUSC cis rs875971 0.66 rs7807930 ENSG00000224316.1 RP11-479O9.2 -6.53 1.74e-10 9.66e-08 -0.27 -0.29 Aortic root size; chr7:66622178 chr7:65773620~65802067:+ LUSC cis rs7955901 0.673 rs1512989 ENSG00000257265.1 CTD-2021H9.1 6.53 1.74e-10 9.67e-08 0.32 0.29 Type 2 diabetes; chr12:71061394 chr12:71007773~71032083:- LUSC cis rs11098499 0.909 rs11723839 ENSG00000250412.1 KLHL2P1 6.53 1.75e-10 9.67e-08 0.36 0.29 Corneal astigmatism; chr4:119378518 chr4:119334329~119378233:+ LUSC cis rs6142102 0.581 rs4911148 ENSG00000275784.1 RP5-1125A11.6 -6.53 1.75e-10 9.69e-08 -0.32 -0.29 Skin pigmentation; chr20:34080438 chr20:33989480~33991818:- LUSC cis rs11098499 0.604 rs34278750 ENSG00000250412.1 KLHL2P1 6.53 1.75e-10 9.69e-08 0.36 0.29 Corneal astigmatism; chr4:119649981 chr4:119334329~119378233:+ LUSC cis rs801193 1 rs2659889 ENSG00000236529.1 RP13-254B10.1 6.53 1.75e-10 9.69e-08 0.3 0.29 Aortic root size; chr7:66752125 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs3800812 ENSG00000236529.1 RP13-254B10.1 6.53 1.75e-10 9.69e-08 0.3 0.29 Aortic root size; chr7:66758474 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs4279493 ENSG00000236529.1 RP13-254B10.1 6.53 1.75e-10 9.69e-08 0.3 0.29 Aortic root size; chr7:66761633 chr7:65840212~65840596:+ LUSC cis rs7246657 0.943 rs10409204 ENSG00000276846.1 CTD-3220F14.3 6.53 1.76e-10 9.72e-08 0.45 0.29 Coronary artery calcification; chr19:37426790 chr19:37314868~37315620:- LUSC cis rs867371 1 rs1174543 ENSG00000255769.6 GOLGA2P10 6.53 1.76e-10 9.72e-08 0.35 0.29 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82155732 chr15:82472993~82513950:- LUSC cis rs8059260 0.736 rs16957883 ENSG00000274038.1 RP11-66H6.4 -6.53 1.76e-10 9.73e-08 -0.48 -0.29 Alcohol consumption over the past year; chr16:10994788 chr16:11056556~11057034:+ LUSC cis rs875971 0.66 rs79009421 ENSG00000224316.1 RP11-479O9.2 -6.53 1.76e-10 9.73e-08 -0.27 -0.29 Aortic root size; chr7:66603522 chr7:65773620~65802067:+ LUSC cis rs2412819 0.571 rs514255 ENSG00000249839.1 AC011330.5 -6.53 1.76e-10 9.74e-08 -0.47 -0.29 Lung cancer; chr15:43893134 chr15:43663654~43684339:- LUSC cis rs7772486 0.875 rs2748501 ENSG00000235652.6 RP11-545I5.3 6.53 1.76e-10 9.74e-08 0.29 0.29 Lobe attachment (rater-scored or self-reported); chr6:145991122 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs371744 ENSG00000235652.6 RP11-545I5.3 6.53 1.76e-10 9.74e-08 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145519888 chr6:145799409~145886585:+ LUSC cis rs67180937 0.7 rs12043288 ENSG00000272750.1 RP11-378J18.8 -6.53 1.76e-10 9.75e-08 -0.32 -0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222732952 chr1:222658867~222661512:- LUSC cis rs7945705 0.967 rs10769968 ENSG00000254860.4 TMEM9B-AS1 -6.53 1.76e-10 9.75e-08 -0.32 -0.29 Hemoglobin concentration; chr11:8886036 chr11:8964675~8977527:+ LUSC cis rs4950322 0.58 rs17355419 ENSG00000278811.3 LINC00624 6.53 1.76e-10 9.75e-08 0.31 0.29 Protein quantitative trait loci; chr1:147110094 chr1:147258885~147517875:- LUSC cis rs4950322 0.58 rs72706428 ENSG00000278811.3 LINC00624 6.53 1.76e-10 9.75e-08 0.31 0.29 Protein quantitative trait loci; chr1:147110219 chr1:147258885~147517875:- LUSC cis rs4950322 0.563 rs61838944 ENSG00000278811.3 LINC00624 6.53 1.76e-10 9.75e-08 0.31 0.29 Protein quantitative trait loci; chr1:147110275 chr1:147258885~147517875:- LUSC cis rs12291225 0.545 rs11023187 ENSG00000251991.1 RNU7-49P 6.53 1.76e-10 9.75e-08 0.33 0.29 Sense of smell; chr11:14324013 chr11:14478892~14478953:+ LUSC cis rs2179367 0.553 rs7762222 ENSG00000231760.4 RP11-350J20.5 6.53 1.76e-10 9.75e-08 0.42 0.29 Dupuytren's disease; chr6:149444846 chr6:149796151~149826294:- LUSC cis rs72772090 0.539 rs55996659 ENSG00000248734.2 CTD-2260A17.1 -6.52 1.76e-10 9.77e-08 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96778446 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs11135480 ENSG00000248734.2 CTD-2260A17.1 -6.52 1.76e-10 9.77e-08 -0.44 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96774878 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs13601 ENSG00000248734.2 CTD-2260A17.1 -6.52 1.76e-10 9.77e-08 -0.44 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96774892 chr5:96784777~96785999:+ LUSC cis rs11089937 0.597 rs9619793 ENSG00000211638.2 IGLV8-61 -6.52 1.77e-10 9.77e-08 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22132952 chr22:22098700~22099212:+ LUSC cis rs7772486 0.686 rs9399564 ENSG00000235652.6 RP11-545I5.3 -6.52 1.77e-10 9.77e-08 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145757771 chr6:145799409~145886585:+ LUSC cis rs11976180 1 rs1919949 ENSG00000170356.8 OR2A20P -6.52 1.77e-10 9.78e-08 -0.39 -0.29 Obesity-related traits; chr7:144070630 chr7:144250045~144252957:- LUSC cis rs1823913 0.599 rs13035132 ENSG00000227542.1 AC092614.2 6.52 1.77e-10 9.78e-08 0.37 0.29 Obesity-related traits; chr2:191265275 chr2:191229165~191246172:- LUSC cis rs761746 0.577 rs131245 ENSG00000236132.1 CTA-440B3.1 -6.52 1.77e-10 9.78e-08 -0.42 -0.29 Intelligence; chr22:31730777 chr22:31816379~31817491:- LUSC cis rs9549367 0.789 rs12866090 ENSG00000269125.1 RP11-98F14.11 -6.52 1.77e-10 9.79e-08 -0.37 -0.29 Platelet distribution width; chr13:113215096 chr13:113165002~113165183:- LUSC cis rs875971 0.66 rs6460308 ENSG00000224316.1 RP11-479O9.2 -6.52 1.77e-10 9.79e-08 -0.27 -0.29 Aortic root size; chr7:66619753 chr7:65773620~65802067:+ LUSC cis rs8062405 1 rs7498555 ENSG00000278665.1 RP11-666O2.4 6.52 1.77e-10 9.8e-08 0.3 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28882250 chr16:28599241~28601881:- LUSC cis rs875971 0.638 rs6460305 ENSG00000236529.1 RP13-254B10.1 -6.52 1.77e-10 9.8e-08 -0.29 -0.29 Aortic root size; chr7:66595421 chr7:65840212~65840596:+ LUSC cis rs1113500 0.509 rs1619485 ENSG00000226822.1 RP11-356N1.2 -6.52 1.77e-10 9.81e-08 -0.3 -0.29 Growth-regulated protein alpha levels; chr1:108065725 chr1:108071482~108074519:+ LUSC cis rs11098499 0.865 rs28634456 ENSG00000250412.1 KLHL2P1 6.52 1.78e-10 9.82e-08 0.37 0.29 Corneal astigmatism; chr4:119454623 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs78332141 ENSG00000250412.1 KLHL2P1 6.52 1.78e-10 9.82e-08 0.37 0.29 Corneal astigmatism; chr4:119454627 chr4:119334329~119378233:+ LUSC cis rs2188561 0.666 rs13231387 ENSG00000241764.3 AC002467.7 6.52 1.78e-10 9.82e-08 0.38 0.29 Alcohol consumption; chr7:107749534 chr7:107742817~107744581:- LUSC cis rs11098499 0.566 rs7664440 ENSG00000250412.1 KLHL2P1 6.52 1.78e-10 9.82e-08 0.36 0.29 Corneal astigmatism; chr4:119657385 chr4:119334329~119378233:+ LUSC cis rs9322193 0.962 rs2342764 ENSG00000268592.3 RAET1E-AS1 6.52 1.78e-10 9.83e-08 0.37 0.29 Lung cancer; chr6:149835068 chr6:149863494~149919507:+ LUSC cis rs7580658 0.637 rs4662710 ENSG00000236682.1 AC068282.3 -6.52 1.78e-10 9.84e-08 -0.38 -0.29 Protein C levels; chr2:127219241 chr2:127389130~127400580:+ LUSC cis rs6142102 0.812 rs6059578 ENSG00000276073.1 RP5-1125A11.7 -6.52 1.78e-10 9.84e-08 -0.3 -0.29 Skin pigmentation; chr20:33939900 chr20:33985617~33988989:- LUSC cis rs3750965 0.92 rs10896420 ENSG00000260895.1 RP11-554A11.7 6.52 1.78e-10 9.85e-08 0.34 0.29 Hair color; chr11:69095579 chr11:69103493~69109094:+ LUSC cis rs3750965 0.92 rs10896421 ENSG00000260895.1 RP11-554A11.7 6.52 1.78e-10 9.85e-08 0.34 0.29 Hair color; chr11:69095580 chr11:69103493~69109094:+ LUSC cis rs875971 0.545 rs73378304 ENSG00000226824.5 RP4-756H11.3 -6.52 1.78e-10 9.86e-08 -0.37 -0.29 Aortic root size; chr7:66175760 chr7:66654538~66669855:+ LUSC cis rs875971 0.642 rs35526611 ENSG00000236529.1 RP13-254B10.1 -6.52 1.78e-10 9.86e-08 -0.29 -0.29 Aortic root size; chr7:66629021 chr7:65840212~65840596:+ LUSC cis rs9921338 0.886 rs4780363 ENSG00000263080.1 RP11-485G7.5 -6.52 1.78e-10 9.86e-08 -0.34 -0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11322034 chr16:11341809~11345211:- LUSC cis rs4713118 0.824 rs13211701 ENSG00000219392.1 RP1-265C24.5 -6.52 1.79e-10 9.87e-08 -0.37 -0.29 Parkinson's disease; chr6:27782300 chr6:28115628~28116551:+ LUSC cis rs4713118 0.824 rs9468229 ENSG00000219392.1 RP1-265C24.5 -6.52 1.79e-10 9.87e-08 -0.37 -0.29 Parkinson's disease; chr6:27782307 chr6:28115628~28116551:+ LUSC cis rs673078 0.607 rs10082823 ENSG00000275759.1 RP11-131L12.3 -6.52 1.79e-10 9.87e-08 -0.38 -0.29 Glucose homeostasis traits; chr12:118365386 chr12:118428281~118428870:+ LUSC cis rs9376098 0.698 rs6924521 ENSG00000232876.1 CTA-212D2.2 -6.52 1.79e-10 9.88e-08 -0.35 -0.29 Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells; chr6:135146277 chr6:135055033~135060550:+ LUSC cis rs4266144 0.569 rs729257 ENSG00000244515.1 KRT18P34 -6.52 1.79e-10 9.88e-08 -0.34 -0.29 Coronary artery disease; chr3:157111034 chr3:157162663~157163932:- LUSC cis rs875971 0.522 rs1968127 ENSG00000236529.1 RP13-254B10.1 -6.52 1.79e-10 9.89e-08 -0.29 -0.29 Aortic root size; chr7:66591816 chr7:65840212~65840596:+ LUSC cis rs2019137 1 rs2019137 ENSG00000274877.1 RP11-65I12.1 6.52 1.79e-10 9.89e-08 0.35 0.29 Lymphocyte counts; chr2:113216055 chr2:113237595~113240825:+ LUSC cis rs2019137 0.967 rs895412 ENSG00000274877.1 RP11-65I12.1 6.52 1.79e-10 9.89e-08 0.35 0.29 Lymphocyte counts; chr2:113216387 chr2:113237595~113240825:+ LUSC cis rs7955901 0.638 rs11178649 ENSG00000257265.1 CTD-2021H9.1 6.52 1.79e-10 9.89e-08 0.32 0.29 Type 2 diabetes; chr12:71139458 chr12:71007773~71032083:- LUSC cis rs801193 0.935 rs2659916 ENSG00000224316.1 RP11-479O9.2 6.52 1.79e-10 9.9e-08 0.27 0.29 Aortic root size; chr7:66686365 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs6958520 ENSG00000224316.1 RP11-479O9.2 6.52 1.79e-10 9.9e-08 0.27 0.29 Aortic root size; chr7:66686466 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs7788576 ENSG00000224316.1 RP11-479O9.2 -6.52 1.79e-10 9.9e-08 -0.27 -0.29 Aortic root size; chr7:66683315 chr7:65773620~65802067:+ LUSC cis rs957448 1 rs72674866 ENSG00000253175.1 RP11-267M23.6 6.52 1.79e-10 9.9e-08 0.34 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94564619 chr8:94565036~94565715:+ LUSC cis rs957448 1 rs55897841 ENSG00000253175.1 RP11-267M23.6 6.52 1.79e-10 9.9e-08 0.34 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94565042 chr8:94565036~94565715:+ LUSC cis rs7246657 0.943 rs10404602 ENSG00000276846.1 CTD-3220F14.3 6.52 1.79e-10 9.91e-08 0.44 0.29 Coronary artery calcification; chr19:37334731 chr19:37314868~37315620:- LUSC cis rs801193 1 rs11773829 ENSG00000224316.1 RP11-479O9.2 -6.52 1.8e-10 9.92e-08 -0.27 -0.29 Aortic root size; chr7:66676087 chr7:65773620~65802067:+ LUSC cis rs9921338 0.961 rs7626 ENSG00000263080.1 RP11-485G7.5 6.52 1.8e-10 9.92e-08 0.35 0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11351739 chr16:11341809~11345211:- LUSC cis rs9921338 0.961 rs7193278 ENSG00000263080.1 RP11-485G7.5 6.52 1.8e-10 9.92e-08 0.35 0.29 Vein graft stenosis in coronary artery bypass grafting; chr16:11351974 chr16:11341809~11345211:- LUSC cis rs6772849 0.796 rs9841521 ENSG00000242551.2 POU5F1P6 -6.52 1.8e-10 9.92e-08 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128673431 chr3:128674735~128677005:- LUSC cis rs11089937 0.568 rs5756989 ENSG00000211638.2 IGLV8-61 -6.52 1.8e-10 9.92e-08 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22132415 chr22:22098700~22099212:+ LUSC cis rs12908161 0.959 rs2175567 ENSG00000259728.4 LINC00933 6.52 1.8e-10 9.92e-08 0.37 0.29 Schizophrenia; chr15:84657715 chr15:84570649~84580175:+ LUSC cis rs875971 0.545 rs1796217 ENSG00000226824.5 RP4-756H11.3 6.52 1.8e-10 9.94e-08 0.38 0.29 Aortic root size; chr7:66620931 chr7:66654538~66669855:+ LUSC cis rs875971 0.508 rs6947808 ENSG00000224316.1 RP11-479O9.2 -6.52 1.8e-10 9.95e-08 -0.27 -0.29 Aortic root size; chr7:66580095 chr7:65773620~65802067:+ LUSC cis rs8072100 0.817 rs11869940 ENSG00000228782.6 CTD-2026D20.3 -6.52 1.8e-10 9.95e-08 -0.27 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47501069 chr17:47450568~47492492:- LUSC cis rs6772849 0.93 rs9873888 ENSG00000242551.2 POU5F1P6 -6.52 1.8e-10 9.96e-08 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128642144 chr3:128674735~128677005:- LUSC cis rs10740039 1 rs10994460 ENSG00000254271.1 RP11-131N11.4 6.52 1.81e-10 9.97e-08 0.38 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60659033 chr10:60734342~60741828:+ LUSC cis rs875971 0.638 rs35986979 ENSG00000236529.1 RP13-254B10.1 -6.52 1.81e-10 9.98e-08 -0.29 -0.29 Aortic root size; chr7:66624003 chr7:65840212~65840596:+ LUSC cis rs5760092 0.627 rs6519489 ENSG00000235689.1 AP000351.13 -6.52 1.81e-10 9.98e-08 -0.37 -0.29 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:24006305~24008258:- LUSC cis rs875971 0.66 rs10281080 ENSG00000236529.1 RP13-254B10.1 -6.52 1.81e-10 1e-07 -0.29 -0.29 Aortic root size; chr7:66577454 chr7:65840212~65840596:+ LUSC cis rs875971 0.66 rs10950044 ENSG00000236529.1 RP13-254B10.1 -6.52 1.81e-10 1e-07 -0.29 -0.29 Aortic root size; chr7:66577989 chr7:65840212~65840596:+ LUSC cis rs228614 0.509 rs223482 ENSG00000230069.3 LRRC37A15P -6.52 1.81e-10 1e-07 -0.3 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766051 chr4:102727274~102730721:- LUSC cis rs7580658 0.637 rs1566822 ENSG00000236682.1 AC068282.3 -6.52 1.81e-10 1e-07 -0.38 -0.29 Protein C levels; chr2:127229815 chr2:127389130~127400580:+ LUSC cis rs72772090 0.539 rs114006288 ENSG00000248734.2 CTD-2260A17.1 -6.52 1.82e-10 1.01e-07 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782300 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs72773932 ENSG00000248734.2 CTD-2260A17.1 -6.52 1.82e-10 1.01e-07 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782444 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs11750934 ENSG00000248734.2 CTD-2260A17.1 -6.52 1.82e-10 1.01e-07 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782783 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs11738810 ENSG00000248734.2 CTD-2260A17.1 -6.52 1.82e-10 1.01e-07 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96783351 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs11748519 ENSG00000248734.2 CTD-2260A17.1 -6.52 1.82e-10 1.01e-07 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96783624 chr5:96784777~96785999:+ LUSC cis rs7267979 0.966 rs6050567 ENSG00000274973.1 RP13-401N8.7 6.52 1.82e-10 1.01e-07 0.29 0.29 Liver enzyme levels (alkaline phosphatase); chr20:25373925 chr20:25845497~25845862:+ LUSC cis rs6969780 1 rs73071550 ENSG00000233429.8 HOTAIRM1 6.52 1.82e-10 1.01e-07 0.56 0.29 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27109480 chr7:27095647~27100265:+ LUSC cis rs6969780 1 rs6461985 ENSG00000233429.8 HOTAIRM1 6.52 1.82e-10 1.01e-07 0.56 0.29 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27111015 chr7:27095647~27100265:+ LUSC cis rs4713118 0.869 rs9366700 ENSG00000219392.1 RP1-265C24.5 -6.52 1.83e-10 1.01e-07 -0.36 -0.29 Parkinson's disease; chr6:27729172 chr6:28115628~28116551:+ LUSC cis rs4713118 0.869 rs6456802 ENSG00000219392.1 RP1-265C24.5 -6.52 1.83e-10 1.01e-07 -0.36 -0.29 Parkinson's disease; chr6:27730576 chr6:28115628~28116551:+ LUSC cis rs4713118 0.869 rs9393851 ENSG00000219392.1 RP1-265C24.5 -6.52 1.83e-10 1.01e-07 -0.36 -0.29 Parkinson's disease; chr6:27731802 chr6:28115628~28116551:+ LUSC cis rs4713118 0.869 rs9461400 ENSG00000219392.1 RP1-265C24.5 -6.52 1.83e-10 1.01e-07 -0.36 -0.29 Parkinson's disease; chr6:27732780 chr6:28115628~28116551:+ LUSC cis rs4713118 0.869 rs9295742 ENSG00000219392.1 RP1-265C24.5 -6.52 1.83e-10 1.01e-07 -0.36 -0.29 Parkinson's disease; chr6:27735053 chr6:28115628~28116551:+ LUSC cis rs4713118 0.869 rs9461401 ENSG00000219392.1 RP1-265C24.5 -6.52 1.83e-10 1.01e-07 -0.36 -0.29 Parkinson's disease; chr6:27735512 chr6:28115628~28116551:+ LUSC cis rs9903692 0.909 rs1468270 ENSG00000278765.1 RP5-890E16.5 6.52 1.83e-10 1.01e-07 0.35 0.29 Pulse pressure; chr17:48047829 chr17:48066704~48067293:- LUSC cis rs783540 0.967 rs1259183 ENSG00000276710.3 CSPG4P8 6.52 1.83e-10 1.01e-07 0.31 0.29 Schizophrenia; chr15:82610683 chr15:82459472~82477258:+ LUSC cis rs7267979 1 rs10966 ENSG00000274973.1 RP13-401N8.7 -6.52 1.83e-10 1.01e-07 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25302308 chr20:25845497~25845862:+ LUSC cis rs11098499 0.954 rs7437420 ENSG00000250412.1 KLHL2P1 6.52 1.83e-10 1.01e-07 0.36 0.29 Corneal astigmatism; chr4:119391748 chr4:119334329~119378233:+ LUSC cis rs9322193 0.884 rs7743823 ENSG00000268592.3 RAET1E-AS1 6.52 1.83e-10 1.01e-07 0.37 0.29 Lung cancer; chr6:149849744 chr6:149863494~149919507:+ LUSC cis rs62432291 0.681 rs400477 ENSG00000235086.1 FNDC1-IT1 6.52 1.83e-10 1.01e-07 0.47 0.29 Joint mobility (Beighton score); chr6:159214911 chr6:159240786~159243329:+ LUSC cis rs5753618 0.583 rs5753632 ENSG00000236132.1 CTA-440B3.1 -6.52 1.84e-10 1.01e-07 -0.39 -0.29 Colorectal cancer; chr22:31467111 chr22:31816379~31817491:- LUSC cis rs11123170 0.543 rs35222158 ENSG00000274877.1 RP11-65I12.1 -6.52 1.84e-10 1.01e-07 -0.4 -0.29 Renal function-related traits (BUN); chr2:113229052 chr2:113237595~113240825:+ LUSC cis rs950169 1 rs11638394 ENSG00000225151.9 GOLGA2P7 -6.52 1.84e-10 1.01e-07 -0.4 -0.29 Schizophrenia; chr15:84110176 chr15:84199311~84230136:- LUSC cis rs950169 1 rs35658069 ENSG00000225151.9 GOLGA2P7 -6.52 1.84e-10 1.01e-07 -0.4 -0.29 Schizophrenia; chr15:84111394 chr15:84199311~84230136:- LUSC cis rs72772090 0.539 rs56120748 ENSG00000248734.2 CTD-2260A17.1 -6.52 1.84e-10 1.01e-07 -0.44 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96774918 chr5:96784777~96785999:+ LUSC cis rs11690935 0.959 rs6722757 ENSG00000228389.1 AC068039.4 6.52 1.85e-10 1.02e-07 0.34 0.29 Schizophrenia; chr2:171735453 chr2:171773482~171775844:+ LUSC cis rs9660180 0.875 rs4648727 ENSG00000231050.1 RP1-140A9.1 -6.52 1.85e-10 1.02e-07 -0.3 -0.29 Body mass index; chr1:1844830 chr1:1891471~1892658:+ LUSC cis rs2919917 1 rs13280202 ENSG00000254352.1 RP11-578O24.2 -6.52 1.85e-10 1.02e-07 -0.37 -0.29 Lymphocyte counts; chr8:78700238 chr8:78723796~78724136:- LUSC cis rs6782228 1 rs34890930 ENSG00000277250.1 Metazoa_SRP 6.52 1.85e-10 1.02e-07 0.35 0.29 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128610380 chr3:128673681~128674021:- LUSC cis rs11976180 1 rs1919950 ENSG00000170356.8 OR2A20P -6.52 1.85e-10 1.02e-07 -0.39 -0.29 Obesity-related traits; chr7:144070805 chr7:144250045~144252957:- LUSC cis rs2337406 1 rs11850709 ENSG00000254174.1 IGHV1-12 6.52 1.85e-10 1.02e-07 0.3 0.29 Alzheimer's disease (late onset); chr14:106670844 chr14:106122420~106122709:- LUSC cis rs6570726 0.791 rs11155426 ENSG00000235652.6 RP11-545I5.3 6.52 1.85e-10 1.02e-07 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145495994 chr6:145799409~145886585:+ LUSC cis rs17023223 0.537 rs2765534 ENSG00000231365.4 RP11-418J17.1 -6.52 1.85e-10 1.02e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119055169 chr1:119140396~119275973:+ LUSC cis rs2903698 0.565 rs13137105 ENSG00000250735.4 RP11-567N4.3 6.52 1.86e-10 1.02e-07 0.32 0.29 Prion diseases; chr4:75491177 chr4:75401195~75423023:+ LUSC cis rs11098499 0.954 rs6849171 ENSG00000250412.1 KLHL2P1 6.52 1.86e-10 1.02e-07 0.36 0.29 Corneal astigmatism; chr4:119488394 chr4:119334329~119378233:+ LUSC cis rs8062405 0.558 rs231976 ENSG00000259982.1 CDC37P1 6.52 1.86e-10 1.03e-07 0.34 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534266 chr16:28700294~28701540:- LUSC cis rs1075265 0.901 rs7569743 ENSG00000233266.1 HMGB1P31 6.52 1.86e-10 1.03e-07 0.37 0.29 Chronotype;Morning vs. evening chronotype; chr2:54137806 chr2:54051334~54051760:+ LUSC cis rs6951245 0.935 rs79143504 ENSG00000224079.1 AC091729.7 -6.52 1.86e-10 1.03e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1070576 chr7:1074450~1078036:+ LUSC cis rs4604732 0.527 rs79329288 ENSG00000227135.1 GCSAML-AS1 -6.52 1.86e-10 1.03e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463211 chr1:247524679~247526752:- LUSC cis rs673078 0.562 rs61944668 ENSG00000275759.1 RP11-131L12.3 -6.52 1.86e-10 1.03e-07 -0.44 -0.29 Glucose homeostasis traits; chr12:118448446 chr12:118428281~118428870:+ LUSC cis rs30380 1 rs246454 ENSG00000248734.2 CTD-2260A17.1 6.52 1.86e-10 1.03e-07 0.28 0.29 Cerebrospinal fluid biomarker levels; chr5:96787561 chr5:96784777~96785999:+ LUSC cis rs801193 0.844 rs732465 ENSG00000237310.1 GS1-124K5.4 6.52 1.87e-10 1.03e-07 0.29 0.29 Aortic root size; chr7:66533463 chr7:66493706~66495474:+ LUSC cis rs801193 0.773 rs801207 ENSG00000237310.1 GS1-124K5.4 -6.52 1.87e-10 1.03e-07 -0.29 -0.29 Aortic root size; chr7:66555603 chr7:66493706~66495474:+ LUSC cis rs875971 0.543 rs801191 ENSG00000237310.1 GS1-124K5.4 -6.52 1.87e-10 1.03e-07 -0.29 -0.29 Aortic root size; chr7:66567968 chr7:66493706~66495474:+ LUSC cis rs7267979 0.966 rs6037097 ENSG00000274973.1 RP13-401N8.7 -6.52 1.87e-10 1.03e-07 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25366585 chr20:25845497~25845862:+ LUSC cis rs75422866 0.51 rs74733564 ENSG00000257433.4 RP1-197B17.3 6.52 1.87e-10 1.03e-07 0.62 0.29 Pneumonia; chr12:47724644 chr12:47706085~47742294:+ LUSC cis rs75422866 0.51 rs73105814 ENSG00000257433.4 RP1-197B17.3 6.52 1.87e-10 1.03e-07 0.62 0.29 Pneumonia; chr12:47725817 chr12:47706085~47742294:+ LUSC cis rs5753618 0.583 rs2899164 ENSG00000236132.1 CTA-440B3.1 -6.52 1.87e-10 1.03e-07 -0.4 -0.29 Colorectal cancer; chr22:31394303 chr22:31816379~31817491:- LUSC cis rs853679 0.517 rs868987 ENSG00000204709.4 LINC01556 -6.52 1.87e-10 1.03e-07 -0.4 -0.29 Depression; chr6:28142370 chr6:28943877~28944537:+ LUSC cis rs67180937 0.621 rs2378607 ENSG00000272750.1 RP11-378J18.8 -6.51 1.88e-10 1.03e-07 -0.31 -0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222746553 chr1:222658867~222661512:- LUSC cis rs7246657 0.943 rs8111782 ENSG00000276846.1 CTD-3220F14.3 6.51 1.88e-10 1.04e-07 0.44 0.29 Coronary artery calcification; chr19:37377002 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs10404920 ENSG00000276846.1 CTD-3220F14.3 6.51 1.88e-10 1.04e-07 0.44 0.29 Coronary artery calcification; chr19:37390654 chr19:37314868~37315620:- LUSC cis rs5742933 0.857 rs7571089 ENSG00000253559.1 OSGEPL1-AS1 6.51 1.89e-10 1.04e-07 0.34 0.29 Ferritin levels; chr2:189697067 chr2:189762704~189765556:+ LUSC cis rs957448 0.948 rs72674867 ENSG00000253175.1 RP11-267M23.6 6.51 1.89e-10 1.04e-07 0.34 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94565973 chr8:94565036~94565715:+ LUSC cis rs6570726 0.791 rs401331 ENSG00000235652.6 RP11-545I5.3 6.51 1.89e-10 1.04e-07 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145510272 chr6:145799409~145886585:+ LUSC cis rs7246657 1 rs1529957 ENSG00000276846.1 CTD-3220F14.3 6.51 1.89e-10 1.04e-07 0.45 0.29 Coronary artery calcification; chr19:37248899 chr19:37314868~37315620:- LUSC cis rs1823913 0.599 rs2124093 ENSG00000280083.1 RP11-317J9.1 -6.51 1.89e-10 1.04e-07 -0.34 -0.29 Obesity-related traits; chr2:191288280 chr2:191154118~191156070:- LUSC cis rs75422866 0.51 rs73105803 ENSG00000257433.4 RP1-197B17.3 6.51 1.89e-10 1.04e-07 0.62 0.29 Pneumonia; chr12:47722135 chr12:47706085~47742294:+ LUSC cis rs75422866 0.51 rs73105812 ENSG00000257433.4 RP1-197B17.3 6.51 1.89e-10 1.04e-07 0.62 0.29 Pneumonia; chr12:47724404 chr12:47706085~47742294:+ LUSC cis rs9322193 0.923 rs12660304 ENSG00000268592.3 RAET1E-AS1 6.51 1.89e-10 1.04e-07 0.36 0.29 Lung cancer; chr6:149739647 chr6:149863494~149919507:+ LUSC cis rs875971 0.619 rs10278371 ENSG00000224316.1 RP11-479O9.2 -6.51 1.9e-10 1.04e-07 -0.27 -0.29 Aortic root size; chr7:66586553 chr7:65773620~65802067:+ LUSC cis rs72772090 0.539 rs116360011 ENSG00000248734.2 CTD-2260A17.1 -6.51 1.9e-10 1.04e-07 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782093 chr5:96784777~96785999:+ LUSC cis rs55757919 1 rs55757919 ENSG00000237595.3 RP11-112L6.3 6.51 1.9e-10 1.04e-07 0.4 0.29 Monocyte percentage of white cells; chr20:50132011 chr20:50162765~50166102:- LUSC cis rs9399135 0.507 rs7766963 ENSG00000232876.1 CTA-212D2.2 6.51 1.9e-10 1.04e-07 0.34 0.29 Red blood cell count; chr6:135111745 chr6:135055033~135060550:+ LUSC cis rs228614 0.534 rs223387 ENSG00000230069.3 LRRC37A15P -6.51 1.9e-10 1.04e-07 -0.3 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102828359 chr4:102727274~102730721:- LUSC cis rs8177376 0.813 rs667627 ENSG00000254905.1 RP11-712L6.7 6.51 1.9e-10 1.05e-07 0.38 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126277802 chr11:126292922~126294254:- LUSC cis rs748404 0.706 rs35975365 ENSG00000249839.1 AC011330.5 -6.51 1.9e-10 1.05e-07 -0.52 -0.29 Lung cancer; chr15:43379347 chr15:43663654~43684339:- LUSC cis rs7955901 0.691 rs2088160 ENSG00000257265.1 CTD-2021H9.1 6.51 1.9e-10 1.05e-07 0.32 0.29 Type 2 diabetes; chr12:71090562 chr12:71007773~71032083:- LUSC cis rs13113518 0.51 rs6828454 ENSG00000273257.1 RP11-177J6.1 6.51 1.9e-10 1.05e-07 0.35 0.29 Height; chr4:55424329 chr4:55387949~55388271:+ LUSC cis rs6683071 1 rs2378606 ENSG00000272750.1 RP11-378J18.8 6.51 1.9e-10 1.05e-07 0.36 0.29 Cognitive performance; chr1:222746406 chr1:222658867~222661512:- LUSC cis rs875971 0.545 rs10261710 ENSG00000226824.5 RP4-756H11.3 -6.51 1.9e-10 1.05e-07 -0.38 -0.29 Aortic root size; chr7:66249202 chr7:66654538~66669855:+ LUSC cis rs11098499 0.954 rs3733520 ENSG00000250412.1 KLHL2P1 6.51 1.91e-10 1.05e-07 0.36 0.29 Corneal astigmatism; chr4:119502325 chr4:119334329~119378233:+ LUSC cis rs66887589 0.616 rs11731675 ENSG00000249244.1 RP11-548H18.2 6.51 1.91e-10 1.05e-07 0.35 0.29 Diastolic blood pressure; chr4:119291359 chr4:119391831~119395335:- LUSC cis rs8062405 0.723 rs35175818 ENSG00000278665.1 RP11-666O2.4 6.51 1.92e-10 1.05e-07 0.29 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597425 chr16:28599241~28601881:- LUSC cis rs9322193 0.847 rs62439808 ENSG00000268592.3 RAET1E-AS1 6.51 1.92e-10 1.06e-07 0.36 0.29 Lung cancer; chr6:149629690 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9322200 ENSG00000268592.3 RAET1E-AS1 6.51 1.92e-10 1.06e-07 0.36 0.29 Lung cancer; chr6:149630078 chr6:149863494~149919507:+ LUSC cis rs5753618 0.583 rs8141150 ENSG00000236132.1 CTA-440B3.1 -6.51 1.92e-10 1.06e-07 -0.4 -0.29 Colorectal cancer; chr22:31404350 chr22:31816379~31817491:- LUSC cis rs5753618 0.583 rs9606839 ENSG00000236132.1 CTA-440B3.1 -6.51 1.92e-10 1.06e-07 -0.4 -0.29 Colorectal cancer; chr22:31406724 chr22:31816379~31817491:- LUSC cis rs11089937 0.589 rs4239891 ENSG00000211638.2 IGLV8-61 -6.51 1.92e-10 1.06e-07 -0.29 -0.29 Periodontitis (PAL4Q3); chr22:22165674 chr22:22098700~22099212:+ LUSC cis rs55726902 0.761 rs2544030 ENSG00000276691.1 RP5-1057I20.5 6.51 1.92e-10 1.06e-07 0.32 0.29 Allergic disease (asthma, hay fever or eczema); chr12:47801668 chr12:47788426~47788971:+ LUSC cis rs6142102 0.602 rs2300209 ENSG00000275784.1 RP5-1125A11.6 -6.51 1.93e-10 1.06e-07 -0.31 -0.29 Skin pigmentation; chr20:34055294 chr20:33989480~33991818:- LUSC cis rs875971 0.66 rs12698534 ENSG00000224316.1 RP11-479O9.2 6.51 1.93e-10 1.06e-07 0.27 0.29 Aortic root size; chr7:66521858 chr7:65773620~65802067:+ LUSC cis rs7772486 0.686 rs702305 ENSG00000235652.6 RP11-545I5.3 -6.51 1.93e-10 1.06e-07 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145652704 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs857875 ENSG00000235652.6 RP11-545I5.3 -6.51 1.93e-10 1.06e-07 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145658897 chr6:145799409~145886585:+ LUSC cis rs9813712 0.571 rs6795143 ENSG00000228252.7 COL6A4P2 -6.51 1.94e-10 1.06e-07 -0.26 -0.29 Response to amphetamines; chr3:130224355 chr3:130212823~130273806:+ LUSC cis rs9813712 0.571 rs9289366 ENSG00000228252.7 COL6A4P2 -6.51 1.94e-10 1.06e-07 -0.26 -0.29 Response to amphetamines; chr3:130225267 chr3:130212823~130273806:+ LUSC cis rs9813712 0.571 rs9289367 ENSG00000228252.7 COL6A4P2 -6.51 1.94e-10 1.06e-07 -0.26 -0.29 Response to amphetamines; chr3:130225286 chr3:130212823~130273806:+ LUSC cis rs9813712 0.571 rs9289368 ENSG00000228252.7 COL6A4P2 -6.51 1.94e-10 1.06e-07 -0.26 -0.29 Response to amphetamines; chr3:130225562 chr3:130212823~130273806:+ LUSC cis rs9813712 0.571 rs6774141 ENSG00000228252.7 COL6A4P2 -6.51 1.94e-10 1.06e-07 -0.26 -0.29 Response to amphetamines; chr3:130225599 chr3:130212823~130273806:+ LUSC cis rs11690935 0.959 rs76324055 ENSG00000228389.1 AC068039.4 6.51 1.94e-10 1.06e-07 0.34 0.29 Schizophrenia; chr2:171763640 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs77280952 ENSG00000228389.1 AC068039.4 6.51 1.94e-10 1.06e-07 0.34 0.29 Schizophrenia; chr2:171763641 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs75922913 ENSG00000228389.1 AC068039.4 6.51 1.94e-10 1.06e-07 0.34 0.29 Schizophrenia; chr2:171763642 chr2:171773482~171775844:+ LUSC cis rs113835537 0.529 rs3892818 ENSG00000255517.5 CTD-3074O7.5 -6.51 1.94e-10 1.07e-07 -0.33 -0.29 Airway imaging phenotypes; chr11:66472720 chr11:66473490~66480233:- LUSC cis rs13113518 1 rs13113518 ENSG00000249700.7 SRD5A3-AS1 6.51 1.95e-10 1.07e-07 0.33 0.29 Height; chr4:55533481 chr4:55363971~55395847:- LUSC cis rs875971 1 rs6963646 ENSG00000237310.1 GS1-124K5.4 -6.51 1.95e-10 1.07e-07 -0.3 -0.29 Aortic root size; chr7:66220780 chr7:66493706~66495474:+ LUSC cis rs113835537 0.529 rs116867234 ENSG00000255517.5 CTD-3074O7.5 -6.51 1.95e-10 1.07e-07 -0.34 -0.29 Airway imaging phenotypes; chr11:66441553 chr11:66473490~66480233:- LUSC cis rs6142102 0.812 rs725478 ENSG00000276073.1 RP5-1125A11.7 6.51 1.95e-10 1.07e-07 0.3 0.29 Skin pigmentation; chr20:33930548 chr20:33985617~33988989:- LUSC cis rs2408955 0.521 rs10875753 ENSG00000240399.1 RP1-228P16.1 6.51 1.96e-10 1.07e-07 0.29 0.29 Glycated hemoglobin levels; chr12:48163358 chr12:48054813~48055591:- LUSC cis rs783540 0.934 rs783530 ENSG00000276710.3 CSPG4P8 6.51 1.96e-10 1.07e-07 0.31 0.29 Schizophrenia; chr15:82597799 chr15:82459472~82477258:+ LUSC cis rs172166 0.694 rs203877 ENSG00000216901.1 AL022393.7 6.51 1.96e-10 1.08e-07 0.34 0.29 Cardiac Troponin-T levels; chr6:28080846 chr6:28176188~28176674:+ LUSC cis rs11098499 0.865 rs1112817 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119376645 chr4:119334329~119378233:+ LUSC cis rs11098499 0.779 rs10016060 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119377257 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs10005644 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119377322 chr4:119334329~119378233:+ LUSC cis rs11098499 0.697 rs10016448 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119377690 chr4:119334329~119378233:+ LUSC cis rs11098499 0.657 rs9996569 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119377849 chr4:119334329~119378233:+ LUSC cis rs11098499 0.908 rs11729050 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119378911 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs28429722 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119378938 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs10014845 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119379922 chr4:119334329~119378233:+ LUSC cis rs11098499 0.779 rs7674500 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119382438 chr4:119334329~119378233:+ LUSC cis rs11098499 0.697 rs4373140 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119386543 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs13113483 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119387884 chr4:119334329~119378233:+ LUSC cis rs11098499 0.542 rs10440343 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119388632 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs28668716 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119388720 chr4:119334329~119378233:+ LUSC cis rs11098499 0.542 rs7677836 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119389483 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs10002083 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119389997 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs10024844 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119390373 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs4345162 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119391804 chr4:119334329~119378233:+ LUSC cis rs11098499 0.657 rs4463052 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119392103 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs13151285 ENSG00000250412.1 KLHL2P1 6.51 1.97e-10 1.08e-07 0.36 0.29 Corneal astigmatism; chr4:119393586 chr4:119334329~119378233:+ LUSC cis rs875971 0.66 rs10272357 ENSG00000236529.1 RP13-254B10.1 -6.51 1.97e-10 1.08e-07 -0.29 -0.29 Aortic root size; chr7:66598087 chr7:65840212~65840596:+ LUSC cis rs7955901 0.691 rs1960312 ENSG00000257265.1 CTD-2021H9.1 6.51 1.97e-10 1.08e-07 0.32 0.29 Type 2 diabetes; chr12:71087670 chr12:71007773~71032083:- LUSC cis rs9549367 0.789 rs12584813 ENSG00000269125.1 RP11-98F14.11 -6.51 1.97e-10 1.08e-07 -0.34 -0.29 Platelet distribution width; chr13:113241129 chr13:113165002~113165183:- LUSC cis rs7772486 0.623 rs735535 ENSG00000235652.6 RP11-545I5.3 -6.51 1.98e-10 1.08e-07 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145715693 chr6:145799409~145886585:+ LUSC cis rs7772486 0.566 rs735536 ENSG00000235652.6 RP11-545I5.3 -6.51 1.98e-10 1.08e-07 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145715696 chr6:145799409~145886585:+ LUSC cis rs17023223 0.537 rs61808892 ENSG00000231365.4 RP11-418J17.1 -6.51 1.98e-10 1.08e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119056584 chr1:119140396~119275973:+ LUSC cis rs11976180 1 rs7777389 ENSG00000170356.8 OR2A20P -6.51 1.98e-10 1.09e-07 -0.39 -0.29 Obesity-related traits; chr7:144047709 chr7:144250045~144252957:- LUSC cis rs11976180 1 rs67239267 ENSG00000170356.8 OR2A20P -6.51 1.98e-10 1.09e-07 -0.39 -0.29 Obesity-related traits; chr7:144048023 chr7:144250045~144252957:- LUSC cis rs3096299 0.802 rs3102336 ENSG00000274627.1 RP11-104N10.2 6.51 1.98e-10 1.09e-07 0.26 0.29 Multiple myeloma (IgH translocation); chr16:89375598 chr16:89516797~89522217:+ LUSC cis rs9322193 0.847 rs880246 ENSG00000268592.3 RAET1E-AS1 6.51 1.98e-10 1.09e-07 0.36 0.29 Lung cancer; chr6:149845972 chr6:149863494~149919507:+ LUSC cis rs66887589 0.616 rs10032299 ENSG00000249244.1 RP11-548H18.2 6.51 1.98e-10 1.09e-07 0.34 0.29 Diastolic blood pressure; chr4:119285264 chr4:119391831~119395335:- LUSC cis rs6951245 1 rs75488469 ENSG00000224079.1 AC091729.7 -6.51 1.98e-10 1.09e-07 -0.49 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1062486 chr7:1074450~1078036:+ LUSC cis rs442309 0.532 rs10995301 ENSG00000238280.1 RP11-436D10.3 6.51 1.99e-10 1.09e-07 0.36 0.29 Vogt-Koyanagi-Harada syndrome; chr10:62747535 chr10:62793562~62805887:- LUSC cis rs3750965 0.92 rs896978 ENSG00000260895.1 RP11-554A11.7 6.51 1.99e-10 1.09e-07 0.35 0.29 Hair color; chr11:69061461 chr11:69103493~69109094:+ LUSC cis rs113835537 0.529 rs57724777 ENSG00000255517.5 CTD-3074O7.5 -6.51 1.99e-10 1.09e-07 -0.34 -0.29 Airway imaging phenotypes; chr11:66468960 chr11:66473490~66480233:- LUSC cis rs11098499 0.954 rs12510138 ENSG00000250412.1 KLHL2P1 6.51 1.99e-10 1.09e-07 0.36 0.29 Corneal astigmatism; chr4:119502780 chr4:119334329~119378233:+ LUSC cis rs1823913 0.599 rs55786000 ENSG00000227542.1 AC092614.2 6.51 1.99e-10 1.09e-07 0.37 0.29 Obesity-related traits; chr2:191284500 chr2:191229165~191246172:- LUSC cis rs875971 0.619 rs2302918 ENSG00000236529.1 RP13-254B10.1 6.5 1.99e-10 1.09e-07 0.3 0.29 Aortic root size; chr7:66535945 chr7:65840212~65840596:+ LUSC cis rs12291225 0.546 rs12291662 ENSG00000251991.1 RNU7-49P 6.5 2e-10 1.09e-07 0.33 0.29 Sense of smell; chr11:14321403 chr11:14478892~14478953:+ LUSC cis rs6570726 0.967 rs403584 ENSG00000235652.6 RP11-545I5.3 6.5 2e-10 1.1e-07 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145485874 chr6:145799409~145886585:+ LUSC cis rs228614 0.51 rs223472 ENSG00000230069.3 LRRC37A15P -6.5 2e-10 1.1e-07 -0.3 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102774327 chr4:102727274~102730721:- LUSC cis rs1823913 0.599 rs17346412 ENSG00000227542.1 AC092614.2 6.5 2e-10 1.1e-07 0.37 0.29 Obesity-related traits; chr2:191285902 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs17412239 ENSG00000227542.1 AC092614.2 6.5 2e-10 1.1e-07 0.37 0.29 Obesity-related traits; chr2:191285937 chr2:191229165~191246172:- LUSC cis rs4950322 0.547 rs6660507 ENSG00000278811.3 LINC00624 6.5 2e-10 1.1e-07 0.31 0.29 Protein quantitative trait loci; chr1:147148574 chr1:147258885~147517875:- LUSC cis rs172166 0.694 rs203876 ENSG00000216901.1 AL022393.7 6.5 2e-10 1.1e-07 0.34 0.29 Cardiac Troponin-T levels; chr6:28078895 chr6:28176188~28176674:+ LUSC cis rs801193 1 rs62466793 ENSG00000224316.1 RP11-479O9.2 6.5 2e-10 1.1e-07 0.27 0.29 Aortic root size; chr7:66726530 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs62466794 ENSG00000224316.1 RP11-479O9.2 6.5 2e-10 1.1e-07 0.27 0.29 Aortic root size; chr7:66726592 chr7:65773620~65802067:+ LUSC cis rs1134634 0.52 rs7665390 ENSG00000273133.1 RP11-799M12.2 -6.5 2e-10 1.1e-07 -0.38 -0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15576115 chr4:15563698~15564253:- LUSC cis rs9549367 0.789 rs912012 ENSG00000269125.1 RP11-98F14.11 -6.5 2e-10 1.1e-07 -0.36 -0.29 Platelet distribution width; chr13:113231838 chr13:113165002~113165183:- LUSC cis rs113835537 0.529 rs79798028 ENSG00000255517.5 CTD-3074O7.5 -6.5 2.01e-10 1.1e-07 -0.33 -0.29 Airway imaging phenotypes; chr11:66431891 chr11:66473490~66480233:- LUSC cis rs13423976 0.572 rs11893988 ENSG00000231367.4 AC016995.3 6.5 2.01e-10 1.1e-07 0.37 0.29 Gut microbiome composition (summer); chr2:38515630 chr2:38406719~38515740:- LUSC cis rs496547 0.686 rs2508916 ENSG00000255239.1 AP002954.6 6.5 2.01e-10 1.1e-07 0.32 0.29 Hip minimal joint space width; chr11:118783942 chr11:118688039~118690600:- LUSC cis rs6496044 0.963 rs6496050 ENSG00000202081.1 RNU6-1280P 6.5 2.01e-10 1.1e-07 0.32 0.29 Interstitial lung disease; chr15:85526019 chr15:85651522~85651628:- LUSC cis rs1012068 0.881 rs5998168 ENSG00000236132.1 CTA-440B3.1 -6.5 2.02e-10 1.1e-07 -0.39 -0.29 Chronic hepatitis C infection; chr22:31901310 chr22:31816379~31817491:- LUSC cis rs4713118 0.621 rs10484403 ENSG00000280107.1 AL022393.9 -6.5 2.02e-10 1.11e-07 -0.36 -0.29 Parkinson's disease; chr6:28065745 chr6:28170845~28172521:+ LUSC cis rs4713118 0.866 rs2179094 ENSG00000219392.1 RP1-265C24.5 -6.5 2.02e-10 1.11e-07 -0.38 -0.29 Parkinson's disease; chr6:27774046 chr6:28115628~28116551:+ LUSC cis rs801193 1 rs7785213 ENSG00000236529.1 RP13-254B10.1 -6.5 2.03e-10 1.11e-07 -0.29 -0.29 Aortic root size; chr7:66673991 chr7:65840212~65840596:+ LUSC cis rs673078 0.607 rs8467 ENSG00000275759.1 RP11-131L12.3 -6.5 2.03e-10 1.11e-07 -0.4 -0.29 Glucose homeostasis traits; chr12:118417479 chr12:118428281~118428870:+ LUSC cis rs801193 1 rs7785213 ENSG00000224316.1 RP11-479O9.2 -6.5 2.03e-10 1.11e-07 -0.27 -0.29 Aortic root size; chr7:66673991 chr7:65773620~65802067:+ LUSC cis rs9903692 0.954 rs8065670 ENSG00000278765.1 RP5-890E16.5 -6.5 2.03e-10 1.11e-07 -0.34 -0.29 Pulse pressure; chr17:48096478 chr17:48066704~48067293:- LUSC cis rs9903692 0.908 rs12950402 ENSG00000278765.1 RP5-890E16.5 -6.5 2.03e-10 1.11e-07 -0.34 -0.29 Pulse pressure; chr17:48102752 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs11079808 ENSG00000278765.1 RP5-890E16.5 -6.5 2.03e-10 1.11e-07 -0.34 -0.29 Pulse pressure; chr17:48102870 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs4794448 ENSG00000278765.1 RP5-890E16.5 -6.5 2.03e-10 1.11e-07 -0.34 -0.29 Pulse pressure; chr17:48103445 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs68175794 ENSG00000278765.1 RP5-890E16.5 -6.5 2.03e-10 1.11e-07 -0.34 -0.29 Pulse pressure; chr17:48103742 chr17:48066704~48067293:- LUSC cis rs9903692 0.862 rs12943543 ENSG00000278765.1 RP5-890E16.5 -6.5 2.03e-10 1.11e-07 -0.34 -0.29 Pulse pressure; chr17:48104003 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs4794451 ENSG00000278765.1 RP5-890E16.5 -6.5 2.03e-10 1.11e-07 -0.34 -0.29 Pulse pressure; chr17:48107419 chr17:48066704~48067293:- LUSC cis rs9903692 0.862 rs4794453 ENSG00000278765.1 RP5-890E16.5 -6.5 2.03e-10 1.11e-07 -0.34 -0.29 Pulse pressure; chr17:48107564 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs8077860 ENSG00000278765.1 RP5-890E16.5 -6.5 2.03e-10 1.11e-07 -0.34 -0.29 Pulse pressure; chr17:48107973 chr17:48066704~48067293:- LUSC cis rs1113500 0.575 rs1781067 ENSG00000226822.1 RP11-356N1.2 6.5 2.03e-10 1.11e-07 0.28 0.29 Growth-regulated protein alpha levels; chr1:108025389 chr1:108071482~108074519:+ LUSC cis rs7955901 0.638 rs11178648 ENSG00000257265.1 CTD-2021H9.1 -6.5 2.04e-10 1.12e-07 -0.32 -0.29 Type 2 diabetes; chr12:71139430 chr12:71007773~71032083:- LUSC cis rs11089937 0.616 rs1076851 ENSG00000211639.2 IGLV4-60 6.5 2.04e-10 1.12e-07 0.3 0.29 Periodontitis (PAL4Q3); chr22:22177442 chr22:22162199~22162681:+ LUSC cis rs10740039 0.883 rs6479722 ENSG00000254271.1 RP11-131N11.4 6.5 2.04e-10 1.12e-07 0.38 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60657923 chr10:60734342~60741828:+ LUSC cis rs10740039 1 rs6479723 ENSG00000254271.1 RP11-131N11.4 6.5 2.04e-10 1.12e-07 0.38 0.29 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60658127 chr10:60734342~60741828:+ LUSC cis rs950169 0.92 rs2135551 ENSG00000225151.9 GOLGA2P7 -6.5 2.04e-10 1.12e-07 -0.4 -0.29 Schizophrenia; chr15:84039099 chr15:84199311~84230136:- LUSC cis rs950169 1 rs12902672 ENSG00000225151.9 GOLGA2P7 -6.5 2.04e-10 1.12e-07 -0.4 -0.29 Schizophrenia; chr15:84048234 chr15:84199311~84230136:- LUSC cis rs4713118 0.621 rs9295755 ENSG00000204709.4 LINC01556 -6.5 2.04e-10 1.12e-07 -0.41 -0.29 Parkinson's disease; chr6:28065396 chr6:28943877~28944537:+ LUSC cis rs11098499 0.697 rs4560394 ENSG00000250412.1 KLHL2P1 6.5 2.05e-10 1.12e-07 0.36 0.29 Corneal astigmatism; chr4:119392280 chr4:119334329~119378233:+ LUSC cis rs950169 0.58 rs17532346 ENSG00000259728.4 LINC00933 6.5 2.05e-10 1.12e-07 0.36 0.29 Schizophrenia; chr15:84628264 chr15:84570649~84580175:+ LUSC cis rs67340775 0.541 rs200968 ENSG00000219392.1 RP1-265C24.5 -6.5 2.05e-10 1.12e-07 -0.45 -0.29 Lung cancer in ever smokers; chr6:27891790 chr6:28115628~28116551:+ LUSC cis rs720475 1 rs720475 ENSG00000204959.4 ARHGEF34P -6.5 2.06e-10 1.12e-07 -0.36 -0.29 Breast cancer; chr7:144377836 chr7:144272445~144286966:- LUSC cis rs732716 0.785 rs11667543 ENSG00000267769.1 CTB-50L17.9 -6.5 2.06e-10 1.12e-07 -0.32 -0.29 Mean corpuscular volume; chr19:4374853 chr19:4454014~4455286:+ LUSC cis rs10170846 0.893 rs11692810 ENSG00000261428.2 RP11-16P6.1 -6.5 2.06e-10 1.13e-07 -0.34 -0.29 Schizophrenia (inflammation and infection response interaction); chr2:222679377 chr2:222566899~222569719:- LUSC cis rs673078 0.607 rs10850967 ENSG00000275759.1 RP11-131L12.3 -6.5 2.06e-10 1.13e-07 -0.38 -0.29 Glucose homeostasis traits; chr12:118380072 chr12:118428281~118428870:+ LUSC cis rs2919917 1 rs2919917 ENSG00000254352.1 RP11-578O24.2 -6.5 2.06e-10 1.13e-07 -0.36 -0.29 Lymphocyte counts; chr8:78745028 chr8:78723796~78724136:- LUSC cis rs7772486 0.624 rs6930154 ENSG00000235652.6 RP11-545I5.3 -6.5 2.07e-10 1.13e-07 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145704526 chr6:145799409~145886585:+ LUSC cis rs526231 0.578 rs10515337 ENSG00000175749.11 EIF3KP1 -6.5 2.07e-10 1.13e-07 -0.35 -0.29 Primary biliary cholangitis; chr5:102965664 chr5:103032376~103033031:+ LUSC cis rs67340775 0.541 rs200973 ENSG00000219392.1 RP1-265C24.5 -6.5 2.08e-10 1.14e-07 -0.44 -0.29 Lung cancer in ever smokers; chr6:27890643 chr6:28115628~28116551:+ LUSC cis rs9376098 0.698 rs7756303 ENSG00000232876.1 CTA-212D2.2 -6.5 2.08e-10 1.14e-07 -0.35 -0.29 Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells; chr6:135148846 chr6:135055033~135060550:+ LUSC cis rs12554020 0.892 rs6479494 ENSG00000227603.1 RP11-165J3.6 -6.5 2.09e-10 1.14e-07 -0.37 -0.29 Schizophrenia; chr9:93568217 chr9:93435332~93437121:- LUSC cis rs1823913 0.599 rs13001899 ENSG00000280083.1 RP11-317J9.1 -6.5 2.09e-10 1.14e-07 -0.34 -0.29 Obesity-related traits; chr2:191285442 chr2:191154118~191156070:- LUSC cis rs8177376 1 rs598169 ENSG00000254905.1 RP11-712L6.7 6.5 2.1e-10 1.14e-07 0.38 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126219158 chr11:126292922~126294254:- LUSC cis rs11089937 0.616 rs5750675 ENSG00000211639.2 IGLV4-60 6.5 2.1e-10 1.14e-07 0.3 0.29 Periodontitis (PAL4Q3); chr22:22179233 chr22:22162199~22162681:+ LUSC cis rs7267979 0.903 rs6050482 ENSG00000274973.1 RP13-401N8.7 -6.5 2.1e-10 1.14e-07 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25245691 chr20:25845497~25845862:+ LUSC cis rs950169 0.763 rs35372971 ENSG00000225151.9 GOLGA2P7 -6.5 2.1e-10 1.14e-07 -0.4 -0.29 Schizophrenia; chr15:84387097 chr15:84199311~84230136:- LUSC cis rs950169 0.881 rs4842852 ENSG00000225151.9 GOLGA2P7 -6.5 2.1e-10 1.14e-07 -0.41 -0.29 Schizophrenia; chr15:84387263 chr15:84199311~84230136:- LUSC cis rs950169 0.84 rs4842853 ENSG00000225151.9 GOLGA2P7 -6.5 2.1e-10 1.14e-07 -0.41 -0.29 Schizophrenia; chr15:84387606 chr15:84199311~84230136:- LUSC cis rs950169 0.922 rs4842946 ENSG00000225151.9 GOLGA2P7 -6.5 2.1e-10 1.14e-07 -0.41 -0.29 Schizophrenia; chr15:84387633 chr15:84199311~84230136:- LUSC cis rs950169 0.84 rs4842854 ENSG00000225151.9 GOLGA2P7 -6.5 2.1e-10 1.14e-07 -0.41 -0.29 Schizophrenia; chr15:84387641 chr15:84199311~84230136:- LUSC cis rs950169 0.84 rs2896002 ENSG00000225151.9 GOLGA2P7 -6.5 2.1e-10 1.14e-07 -0.41 -0.29 Schizophrenia; chr15:84390423 chr15:84199311~84230136:- LUSC cis rs950169 0.887 rs3860265 ENSG00000225151.9 GOLGA2P7 -6.5 2.1e-10 1.14e-07 -0.41 -0.29 Schizophrenia; chr15:84390487 chr15:84199311~84230136:- LUSC cis rs950169 0.724 rs11632668 ENSG00000225151.9 GOLGA2P7 -6.5 2.1e-10 1.14e-07 -0.41 -0.29 Schizophrenia; chr15:84393989 chr15:84199311~84230136:- LUSC cis rs950169 0.881 rs34591918 ENSG00000225151.9 GOLGA2P7 -6.5 2.1e-10 1.14e-07 -0.41 -0.29 Schizophrenia; chr15:84396135 chr15:84199311~84230136:- LUSC cis rs7267979 0.706 rs6037069 ENSG00000274973.1 RP13-401N8.7 -6.5 2.1e-10 1.15e-07 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25253530 chr20:25845497~25845862:+ LUSC cis rs10170846 0.861 rs6740452 ENSG00000261428.2 RP11-16P6.1 6.5 2.1e-10 1.15e-07 0.34 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222653733 chr2:222566899~222569719:- LUSC cis rs10170846 0.789 rs972650 ENSG00000261428.2 RP11-16P6.1 6.5 2.1e-10 1.15e-07 0.34 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222655568 chr2:222566899~222569719:- LUSC cis rs11089937 0.616 rs12484472 ENSG00000211639.2 IGLV4-60 6.5 2.11e-10 1.15e-07 0.3 0.29 Periodontitis (PAL4Q3); chr22:22180136 chr22:22162199~22162681:+ LUSC cis rs2280018 0.963 rs4985147 ENSG00000260735.1 RP11-72I8.1 -6.5 2.11e-10 1.15e-07 -0.32 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15074903 chr16:15094411~15109197:+ LUSC cis rs7246657 0.943 rs6508732 ENSG00000276846.1 CTD-3220F14.3 6.5 2.11e-10 1.15e-07 0.42 0.29 Coronary artery calcification; chr19:37509566 chr19:37314868~37315620:- LUSC cis rs4713118 0.739 rs2893931 ENSG00000219392.1 RP1-265C24.5 -6.5 2.11e-10 1.15e-07 -0.37 -0.29 Parkinson's disease; chr6:27780231 chr6:28115628~28116551:+ LUSC cis rs4713118 0.824 rs2092075 ENSG00000219392.1 RP1-265C24.5 -6.5 2.11e-10 1.15e-07 -0.37 -0.29 Parkinson's disease; chr6:27781551 chr6:28115628~28116551:+ LUSC cis rs1823913 0.599 rs34100174 ENSG00000227542.1 AC092614.2 6.5 2.12e-10 1.15e-07 0.37 0.29 Obesity-related traits; chr2:191283579 chr2:191229165~191246172:- LUSC cis rs172166 0.694 rs203876 ENSG00000219392.1 RP1-265C24.5 -6.49 2.12e-10 1.15e-07 -0.36 -0.29 Cardiac Troponin-T levels; chr6:28078895 chr6:28115628~28116551:+ LUSC cis rs71403859 0.73 rs17347255 ENSG00000260886.1 TAT-AS1 6.49 2.12e-10 1.16e-07 0.45 0.29 Post bronchodilator FEV1; chr16:71553322 chr16:71565789~71578187:+ LUSC cis rs904251 0.686 rs931649 ENSG00000204110.6 RP1-153P14.8 -6.49 2.12e-10 1.16e-07 -0.32 -0.29 Cognitive performance; chr6:37498303 chr6:37507348~37535616:+ LUSC cis rs9322193 0.923 rs9479494 ENSG00000268592.3 RAET1E-AS1 6.49 2.12e-10 1.16e-07 0.36 0.29 Lung cancer; chr6:149739108 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9800806 ENSG00000268592.3 RAET1E-AS1 6.49 2.12e-10 1.16e-07 0.36 0.29 Lung cancer; chr6:149740350 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9688517 ENSG00000268592.3 RAET1E-AS1 6.49 2.12e-10 1.16e-07 0.36 0.29 Lung cancer; chr6:149740655 chr6:149863494~149919507:+ LUSC cis rs11089937 0.597 rs6001072 ENSG00000211638.2 IGLV8-61 -6.49 2.12e-10 1.16e-07 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22133629 chr22:22098700~22099212:+ LUSC cis rs4604732 0.631 rs12080860 ENSG00000227135.1 GCSAML-AS1 -6.49 2.13e-10 1.16e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247459751 chr1:247524679~247526752:- LUSC cis rs227275 0.525 rs13150426 ENSG00000230069.3 LRRC37A15P -6.49 2.13e-10 1.16e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:103013743 chr4:102727274~102730721:- LUSC cis rs881375 0.967 rs2416805 ENSG00000226752.6 PSMD5-AS1 -6.49 2.13e-10 1.16e-07 -0.33 -0.29 Rheumatoid arthritis; chr9:120914204 chr9:120824828~120854385:+ LUSC cis rs1134634 0.52 rs4280724 ENSG00000273133.1 RP11-799M12.2 -6.49 2.14e-10 1.16e-07 -0.37 -0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15574128 chr4:15563698~15564253:- LUSC cis rs7246657 1 rs7246657 ENSG00000276846.1 CTD-3220F14.3 -6.49 2.14e-10 1.16e-07 -0.42 -0.29 Coronary artery calcification; chr19:37256206 chr19:37314868~37315620:- LUSC cis rs6951245 1 rs113146460 ENSG00000224079.1 AC091729.7 -6.49 2.14e-10 1.16e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1065528 chr7:1074450~1078036:+ LUSC cis rs6951245 0.935 rs61753396 ENSG00000224079.1 AC091729.7 -6.49 2.14e-10 1.16e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1065736 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs79327308 ENSG00000224079.1 AC091729.7 -6.49 2.14e-10 1.16e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1068505 chr7:1074450~1078036:+ LUSC cis rs9601248 0.756 rs9601252 ENSG00000227676.3 LINC01068 -6.49 2.14e-10 1.16e-07 -0.35 -0.29 Major depressive disorder; chr13:79615607 chr13:79566727~79571436:+ LUSC cis rs1823913 0.599 rs2124093 ENSG00000227542.1 AC092614.2 6.49 2.14e-10 1.16e-07 0.37 0.29 Obesity-related traits; chr2:191288280 chr2:191229165~191246172:- LUSC cis rs4500972 1 rs4500972 ENSG00000163016.8 ALMS1P 6.49 2.14e-10 1.16e-07 0.35 0.29 Glomerular filtration rate (creatinine); chr2:73540770 chr2:73644919~73685576:+ LUSC cis rs10829156 0.738 rs4748502 ENSG00000240291.1 RP11-499P20.2 6.49 2.14e-10 1.17e-07 0.31 0.29 Sudden cardiac arrest; chr10:18647032 chr10:18513115~18545651:- LUSC cis rs2153535 0.58 rs9406169 ENSG00000230939.1 RP11-314C16.1 -6.49 2.14e-10 1.17e-07 -0.34 -0.29 Motion sickness; chr6:8509237 chr6:8784178~8785445:+ LUSC cis rs7267979 0.932 rs2387891 ENSG00000274973.1 RP13-401N8.7 -6.49 2.15e-10 1.17e-07 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25489692 chr20:25845497~25845862:+ LUSC cis rs4604732 0.578 rs112449432 ENSG00000227135.1 GCSAML-AS1 -6.49 2.15e-10 1.17e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247460878 chr1:247524679~247526752:- LUSC cis rs11123170 0.543 rs2863242 ENSG00000274877.1 RP11-65I12.1 -6.49 2.16e-10 1.17e-07 -0.4 -0.29 Renal function-related traits (BUN); chr2:113231659 chr2:113237595~113240825:+ LUSC cis rs1823913 0.599 rs13002286 ENSG00000280083.1 RP11-317J9.1 6.49 2.16e-10 1.17e-07 0.34 0.29 Obesity-related traits; chr2:191285626 chr2:191154118~191156070:- LUSC cis rs6772849 0.93 rs12487604 ENSG00000242551.2 POU5F1P6 -6.49 2.16e-10 1.18e-07 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr3:128618232 chr3:128674735~128677005:- LUSC cis rs17507216 0.628 rs28371837 ENSG00000255769.6 GOLGA2P10 -6.49 2.16e-10 1.18e-07 -0.43 -0.29 Excessive daytime sleepiness; chr15:82714435 chr15:82472993~82513950:- LUSC cis rs72772090 0.634 rs17402639 ENSG00000248734.2 CTD-2260A17.1 -6.49 2.16e-10 1.18e-07 -0.41 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96771301 chr5:96784777~96785999:+ LUSC cis rs72772090 0.634 rs72773912 ENSG00000248734.2 CTD-2260A17.1 -6.49 2.16e-10 1.18e-07 -0.41 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96772097 chr5:96784777~96785999:+ LUSC cis rs1322639 0.614 rs9689800 ENSG00000261039.2 RP11-417E7.2 6.49 2.17e-10 1.18e-07 0.33 0.29 Pulse pressure; chr6:169172850 chr6:169175304~169182740:- LUSC cis rs4713118 0.513 rs149954 ENSG00000216901.1 AL022393.7 6.49 2.17e-10 1.18e-07 0.34 0.29 Parkinson's disease; chr6:28067468 chr6:28176188~28176674:+ LUSC cis rs6951245 1 rs77868187 ENSG00000224079.1 AC091729.7 -6.49 2.17e-10 1.18e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054332 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs11763793 ENSG00000224079.1 AC091729.7 -6.49 2.17e-10 1.18e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054706 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs11763835 ENSG00000224079.1 AC091729.7 -6.49 2.17e-10 1.18e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054877 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs78861357 ENSG00000224079.1 AC091729.7 -6.49 2.17e-10 1.18e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1055782 chr7:1074450~1078036:+ LUSC cis rs1823913 0.599 rs2168166 ENSG00000280083.1 RP11-317J9.1 -6.49 2.18e-10 1.18e-07 -0.34 -0.29 Obesity-related traits; chr2:191288063 chr2:191154118~191156070:- LUSC cis rs9549367 0.789 rs9549718 ENSG00000269125.1 RP11-98F14.11 -6.49 2.18e-10 1.18e-07 -0.36 -0.29 Platelet distribution width; chr13:113255508 chr13:113165002~113165183:- LUSC cis rs227275 0.525 rs2086499 ENSG00000230069.3 LRRC37A15P -6.49 2.18e-10 1.18e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:103008672 chr4:102727274~102730721:- LUSC cis rs950169 0.922 rs12906983 ENSG00000225151.9 GOLGA2P7 -6.49 2.18e-10 1.19e-07 -0.41 -0.29 Schizophrenia; chr15:84262270 chr15:84199311~84230136:- LUSC cis rs801193 1 rs10252765 ENSG00000236529.1 RP13-254B10.1 6.49 2.18e-10 1.19e-07 0.29 0.29 Aortic root size; chr7:66763745 chr7:65840212~65840596:+ LUSC cis rs638893 0.636 rs6421569 ENSG00000278376.1 RP11-158I9.8 -6.49 2.19e-10 1.19e-07 -0.4 -0.29 Vitiligo; chr11:118785066 chr11:118791254~118793137:+ LUSC cis rs875971 0.66 rs801192 ENSG00000224316.1 RP11-479O9.2 -6.49 2.19e-10 1.19e-07 -0.27 -0.29 Aortic root size; chr7:66566965 chr7:65773620~65802067:+ LUSC cis rs875971 0.66 rs801190 ENSG00000224316.1 RP11-479O9.2 -6.49 2.19e-10 1.19e-07 -0.27 -0.29 Aortic root size; chr7:66568046 chr7:65773620~65802067:+ LUSC cis rs875971 0.66 rs3857686 ENSG00000224316.1 RP11-479O9.2 -6.49 2.19e-10 1.19e-07 -0.27 -0.29 Aortic root size; chr7:66571204 chr7:65773620~65802067:+ LUSC cis rs875971 0.638 rs3898855 ENSG00000224316.1 RP11-479O9.2 -6.49 2.19e-10 1.19e-07 -0.27 -0.29 Aortic root size; chr7:66571411 chr7:65773620~65802067:+ LUSC cis rs875971 0.638 rs10278816 ENSG00000224316.1 RP11-479O9.2 -6.49 2.19e-10 1.19e-07 -0.27 -0.29 Aortic root size; chr7:66572000 chr7:65773620~65802067:+ LUSC cis rs875971 0.66 rs28698552 ENSG00000224316.1 RP11-479O9.2 6.49 2.19e-10 1.19e-07 0.27 0.29 Aortic root size; chr7:66540031 chr7:65773620~65802067:+ LUSC cis rs875971 0.66 rs62465434 ENSG00000224316.1 RP11-479O9.2 6.49 2.19e-10 1.19e-07 0.27 0.29 Aortic root size; chr7:66540165 chr7:65773620~65802067:+ LUSC cis rs875971 0.66 rs801211 ENSG00000224316.1 RP11-479O9.2 -6.49 2.19e-10 1.19e-07 -0.27 -0.29 Aortic root size; chr7:66550702 chr7:65773620~65802067:+ LUSC cis rs875971 0.638 rs801205 ENSG00000224316.1 RP11-479O9.2 -6.49 2.19e-10 1.19e-07 -0.27 -0.29 Aortic root size; chr7:66557157 chr7:65773620~65802067:+ LUSC cis rs875971 0.617 rs810400 ENSG00000224316.1 RP11-479O9.2 -6.49 2.19e-10 1.19e-07 -0.27 -0.29 Aortic root size; chr7:66557902 chr7:65773620~65802067:+ LUSC cis rs875971 1 rs11974264 ENSG00000237310.1 GS1-124K5.4 -6.49 2.2e-10 1.19e-07 -0.3 -0.29 Aortic root size; chr7:66182595 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1540651 ENSG00000237310.1 GS1-124K5.4 -6.49 2.2e-10 1.19e-07 -0.3 -0.29 Aortic root size; chr7:66185134 chr7:66493706~66495474:+ LUSC cis rs875971 0.619 rs12533585 ENSG00000224316.1 RP11-479O9.2 6.49 2.2e-10 1.19e-07 0.27 0.29 Aortic root size; chr7:66519618 chr7:65773620~65802067:+ LUSC cis rs2404602 0.647 rs907594 ENSG00000259422.1 RP11-593F23.1 -6.49 2.2e-10 1.19e-07 -0.34 -0.29 Blood metabolite levels; chr15:76905404 chr15:76174891~76181486:- LUSC cis rs881375 0.967 rs7875829 ENSG00000226752.6 PSMD5-AS1 -6.49 2.2e-10 1.2e-07 -0.33 -0.29 Rheumatoid arthritis; chr9:120898120 chr9:120824828~120854385:+ LUSC cis rs1865760 0.566 rs2032449 ENSG00000272462.2 U91328.19 -6.49 2.2e-10 1.2e-07 -0.31 -0.29 Height; chr6:26026371 chr6:25992662~26001775:+ LUSC cis rs881375 0.934 rs2159778 ENSG00000226752.6 PSMD5-AS1 -6.49 2.2e-10 1.2e-07 -0.33 -0.29 Rheumatoid arthritis; chr9:120915851 chr9:120824828~120854385:+ LUSC cis rs4604732 0.527 rs60444724 ENSG00000227135.1 GCSAML-AS1 -6.49 2.21e-10 1.2e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247459862 chr1:247524679~247526752:- LUSC cis rs7955901 0.691 rs2132242 ENSG00000257265.1 CTD-2021H9.1 6.49 2.21e-10 1.2e-07 0.32 0.29 Type 2 diabetes; chr12:71082476 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs1510944 ENSG00000257265.1 CTD-2021H9.1 6.49 2.21e-10 1.2e-07 0.32 0.29 Type 2 diabetes; chr12:71083820 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs11178594 ENSG00000257265.1 CTD-2021H9.1 6.49 2.21e-10 1.2e-07 0.32 0.29 Type 2 diabetes; chr12:71085115 chr12:71007773~71032083:- LUSC cis rs7189233 0.955 rs72801821 ENSG00000279344.1 RP11-44F14.7 6.49 2.21e-10 1.2e-07 0.26 0.29 Intelligence (multi-trait analysis); chr16:53445740 chr16:53478957~53481550:- LUSC cis rs11123170 0.529 rs112692022 ENSG00000189223.12 PAX8-AS1 -6.49 2.21e-10 1.2e-07 -0.45 -0.29 Renal function-related traits (BUN); chr2:113212605 chr2:113211522~113276581:+ LUSC cis rs7189233 0.955 rs72801817 ENSG00000279344.1 RP11-44F14.7 6.49 2.21e-10 1.2e-07 0.26 0.29 Intelligence (multi-trait analysis); chr16:53440656 chr16:53478957~53481550:- LUSC cis rs1823913 0.599 rs17412094 ENSG00000280083.1 RP11-317J9.1 -6.49 2.21e-10 1.2e-07 -0.33 -0.29 Obesity-related traits; chr2:191284202 chr2:191154118~191156070:- LUSC cis rs9322193 0.923 rs9322196 ENSG00000268592.3 RAET1E-AS1 6.49 2.22e-10 1.2e-07 0.36 0.29 Lung cancer; chr6:149619645 chr6:149863494~149919507:+ LUSC cis rs9601248 0.756 rs9601251 ENSG00000227676.3 LINC01068 -6.49 2.22e-10 1.2e-07 -0.35 -0.29 Major depressive disorder; chr13:79615582 chr13:79566727~79571436:+ LUSC cis rs7267979 1 rs2424704 ENSG00000274973.1 RP13-401N8.7 -6.49 2.22e-10 1.2e-07 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25293293 chr20:25845497~25845862:+ LUSC cis rs9309473 1 rs3813227 ENSG00000163016.8 ALMS1P -6.49 2.22e-10 1.21e-07 -0.35 -0.29 Metabolite levels; chr2:73424839 chr2:73644919~73685576:+ LUSC cis rs7246657 0.943 rs2081096 ENSG00000276846.1 CTD-3220F14.3 6.49 2.22e-10 1.21e-07 0.44 0.29 Coronary artery calcification; chr19:37473798 chr19:37314868~37315620:- LUSC cis rs7772486 0.754 rs702306 ENSG00000235652.6 RP11-545I5.3 -6.49 2.22e-10 1.21e-07 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145669893 chr6:145799409~145886585:+ LUSC cis rs2179367 0.6 rs9498352 ENSG00000231760.4 RP11-350J20.5 6.49 2.23e-10 1.21e-07 0.42 0.29 Dupuytren's disease; chr6:149439108 chr6:149796151~149826294:- LUSC cis rs2179367 0.6 rs9498353 ENSG00000231760.4 RP11-350J20.5 6.49 2.23e-10 1.21e-07 0.42 0.29 Dupuytren's disease; chr6:149439860 chr6:149796151~149826294:- LUSC cis rs9549367 0.713 rs3024764 ENSG00000269125.1 RP11-98F14.11 -6.49 2.23e-10 1.21e-07 -0.36 -0.29 Platelet distribution width; chr13:113170000 chr13:113165002~113165183:- LUSC cis rs13113518 0.678 rs13149568 ENSG00000223305.1 RN7SKP30 6.49 2.23e-10 1.21e-07 0.34 0.29 Height; chr4:55370412 chr4:55540502~55540835:- LUSC cis rs11098499 1 rs3749591 ENSG00000250412.1 KLHL2P1 6.49 2.23e-10 1.21e-07 0.36 0.29 Corneal astigmatism; chr4:119292875 chr4:119334329~119378233:+ LUSC cis rs801193 1 rs11773829 ENSG00000236529.1 RP13-254B10.1 -6.49 2.23e-10 1.21e-07 -0.29 -0.29 Aortic root size; chr7:66676087 chr7:65840212~65840596:+ LUSC cis rs442309 0.687 rs10995294 ENSG00000238280.1 RP11-436D10.3 -6.49 2.24e-10 1.21e-07 -0.35 -0.29 Vogt-Koyanagi-Harada syndrome; chr10:62723157 chr10:62793562~62805887:- LUSC cis rs3758785 0.621 rs7128673 ENSG00000255893.1 RP11-685N10.1 -6.49 2.24e-10 1.21e-07 -0.33 -0.29 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94453072 chr11:94472908~94473570:- LUSC cis rs950169 0.92 rs12915390 ENSG00000225151.9 GOLGA2P7 -6.49 2.24e-10 1.22e-07 -0.4 -0.29 Schizophrenia; chr15:84123317 chr15:84199311~84230136:- LUSC cis rs8059260 0.551 rs7187539 ENSG00000274038.1 RP11-66H6.4 -6.49 2.24e-10 1.22e-07 -0.48 -0.29 Alcohol consumption over the past year; chr16:10964900 chr16:11056556~11057034:+ LUSC cis rs992157 0.56 rs7578940 ENSG00000261338.2 RP11-378A13.1 -6.49 2.24e-10 1.22e-07 -0.29 -0.29 Colorectal cancer; chr2:218218595 chr2:218255319~218257366:+ LUSC cis rs783540 0.934 rs803747 ENSG00000276710.3 CSPG4P8 6.49 2.24e-10 1.22e-07 0.3 0.29 Schizophrenia; chr15:82589345 chr15:82459472~82477258:+ LUSC cis rs6700559 0.692 rs12126676 ENSG00000260088.1 RP11-92G12.3 6.49 2.24e-10 1.22e-07 0.36 0.29 Coronary artery disease; chr1:200631692 chr1:200669507~200694250:+ LUSC cis rs7246657 1 rs6508710 ENSG00000276846.1 CTD-3220F14.3 6.49 2.25e-10 1.22e-07 0.45 0.29 Coronary artery calcification; chr19:37258984 chr19:37314868~37315620:- LUSC cis rs6142102 0.58 rs9753679 ENSG00000275784.1 RP5-1125A11.6 -6.49 2.25e-10 1.22e-07 -0.31 -0.29 Skin pigmentation; chr20:33953054 chr20:33989480~33991818:- LUSC cis rs4713118 0.868 rs9468220 ENSG00000219392.1 RP1-265C24.5 6.48 2.25e-10 1.22e-07 0.39 0.29 Parkinson's disease; chr6:27765197 chr6:28115628~28116551:+ LUSC cis rs2337406 0.925 rs2011167 ENSG00000254174.1 IGHV1-12 6.48 2.25e-10 1.22e-07 0.29 0.29 Alzheimer's disease (late onset); chr14:106680831 chr14:106122420~106122709:- LUSC cis rs6951245 0.938 rs117729148 ENSG00000224079.1 AC091729.7 -6.48 2.26e-10 1.22e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1068895 chr7:1074450~1078036:+ LUSC cis rs875971 0.66 rs801192 ENSG00000236529.1 RP13-254B10.1 -6.48 2.26e-10 1.22e-07 -0.29 -0.29 Aortic root size; chr7:66566965 chr7:65840212~65840596:+ LUSC cis rs875971 0.66 rs801190 ENSG00000236529.1 RP13-254B10.1 -6.48 2.26e-10 1.22e-07 -0.29 -0.29 Aortic root size; chr7:66568046 chr7:65840212~65840596:+ LUSC cis rs875971 0.66 rs3857686 ENSG00000236529.1 RP13-254B10.1 -6.48 2.26e-10 1.22e-07 -0.29 -0.29 Aortic root size; chr7:66571204 chr7:65840212~65840596:+ LUSC cis rs875971 0.638 rs3898855 ENSG00000236529.1 RP13-254B10.1 -6.48 2.26e-10 1.22e-07 -0.29 -0.29 Aortic root size; chr7:66571411 chr7:65840212~65840596:+ LUSC cis rs875971 0.638 rs10278816 ENSG00000236529.1 RP13-254B10.1 -6.48 2.26e-10 1.22e-07 -0.29 -0.29 Aortic root size; chr7:66572000 chr7:65840212~65840596:+ LUSC cis rs7772486 0.641 rs2777485 ENSG00000235652.6 RP11-545I5.3 6.48 2.26e-10 1.23e-07 0.3 0.29 Lobe attachment (rater-scored or self-reported); chr6:146013241 chr6:145799409~145886585:+ LUSC cis rs72772090 0.539 rs11747179 ENSG00000248734.2 CTD-2260A17.1 -6.48 2.26e-10 1.23e-07 -0.43 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777265 chr5:96784777~96785999:+ LUSC cis rs4950322 0.58 rs7541393 ENSG00000278811.3 LINC00624 6.48 2.26e-10 1.23e-07 0.31 0.29 Protein quantitative trait loci; chr1:147117186 chr1:147258885~147517875:- LUSC cis rs72772090 0.539 rs17481856 ENSG00000248734.2 CTD-2260A17.1 -6.48 2.26e-10 1.23e-07 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96781104 chr5:96784777~96785999:+ LUSC cis rs7246657 0.943 rs10422074 ENSG00000276846.1 CTD-3220F14.3 6.48 2.26e-10 1.23e-07 0.44 0.29 Coronary artery calcification; chr19:37403334 chr19:37314868~37315620:- LUSC cis rs34375054 0.526 rs4412800 ENSG00000279233.1 RP11-158L12.4 -6.48 2.26e-10 1.23e-07 -0.27 -0.29 Post bronchodilator FEV1/FVC ratio; chr12:125190196 chr12:125138245~125141711:+ LUSC cis rs950169 0.84 rs62029595 ENSG00000225151.9 GOLGA2P7 -6.48 2.27e-10 1.23e-07 -0.4 -0.29 Schizophrenia; chr15:84400603 chr15:84199311~84230136:- LUSC cis rs10129255 0.536 rs6576201 ENSG00000211970.3 IGHV4-61 6.48 2.27e-10 1.23e-07 0.18 0.29 Kawasaki disease; chr14:106683696 chr14:106639119~106639657:- LUSC cis rs875971 0.66 rs28698552 ENSG00000236529.1 RP13-254B10.1 6.48 2.27e-10 1.23e-07 0.29 0.29 Aortic root size; chr7:66540031 chr7:65840212~65840596:+ LUSC cis rs875971 0.66 rs62465434 ENSG00000236529.1 RP13-254B10.1 6.48 2.27e-10 1.23e-07 0.29 0.29 Aortic root size; chr7:66540165 chr7:65840212~65840596:+ LUSC cis rs875971 0.66 rs801211 ENSG00000236529.1 RP13-254B10.1 -6.48 2.27e-10 1.23e-07 -0.29 -0.29 Aortic root size; chr7:66550702 chr7:65840212~65840596:+ LUSC cis rs875971 0.638 rs801205 ENSG00000236529.1 RP13-254B10.1 -6.48 2.27e-10 1.23e-07 -0.29 -0.29 Aortic root size; chr7:66557157 chr7:65840212~65840596:+ LUSC cis rs875971 0.617 rs810400 ENSG00000236529.1 RP13-254B10.1 -6.48 2.27e-10 1.23e-07 -0.29 -0.29 Aortic root size; chr7:66557902 chr7:65840212~65840596:+ LUSC cis rs6142102 1 rs4911409 ENSG00000275784.1 RP5-1125A11.6 -6.48 2.27e-10 1.23e-07 -0.33 -0.29 Skin pigmentation; chr20:34122904 chr20:33989480~33991818:- LUSC cis rs6142102 0.961 rs4911411 ENSG00000275784.1 RP5-1125A11.6 -6.48 2.27e-10 1.23e-07 -0.33 -0.29 Skin pigmentation; chr20:34128036 chr20:33989480~33991818:- LUSC cis rs10246939 0.543 rs9640357 ENSG00000228775.6 WEE2-AS1 6.48 2.27e-10 1.23e-07 0.33 0.29 Bitter taste perception; chr7:141843298 chr7:141704338~141738346:- LUSC cis rs13423976 0.631 rs4566347 ENSG00000231367.4 AC016995.3 6.48 2.27e-10 1.23e-07 0.37 0.29 Gut microbiome composition (summer); chr2:38515498 chr2:38406719~38515740:- LUSC cis rs2179367 0.6 rs11155654 ENSG00000231760.4 RP11-350J20.5 6.48 2.28e-10 1.23e-07 0.42 0.29 Dupuytren's disease; chr6:149442001 chr6:149796151~149826294:- LUSC cis rs72772090 0.539 rs11741100 ENSG00000248734.2 CTD-2260A17.1 -6.48 2.29e-10 1.24e-07 -0.43 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777541 chr5:96784777~96785999:+ LUSC cis rs10751647 0.804 rs3809112 ENSG00000251661.3 RP11-326C3.11 -6.48 2.29e-10 1.24e-07 -0.34 -0.29 Monocyte count; chr11:307036 chr11:318640~325631:+ LUSC cis rs17023223 0.537 rs2361272 ENSG00000231365.4 RP11-418J17.1 -6.48 2.29e-10 1.24e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119060794 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs1343723 ENSG00000231365.4 RP11-418J17.1 -6.48 2.29e-10 1.24e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119062431 chr1:119140396~119275973:+ LUSC cis rs7580658 0.637 rs3902960 ENSG00000236682.1 AC068282.3 -6.48 2.29e-10 1.24e-07 -0.38 -0.29 Protein C levels; chr2:127230666 chr2:127389130~127400580:+ LUSC cis rs172166 0.694 rs203877 ENSG00000219392.1 RP1-265C24.5 -6.48 2.29e-10 1.24e-07 -0.36 -0.29 Cardiac Troponin-T levels; chr6:28080846 chr6:28115628~28116551:+ LUSC cis rs1823913 0.599 rs17511410 ENSG00000280083.1 RP11-317J9.1 -6.48 2.3e-10 1.25e-07 -0.34 -0.29 Obesity-related traits; chr2:191278043 chr2:191154118~191156070:- LUSC cis rs17023223 0.537 rs2794310 ENSG00000231365.4 RP11-418J17.1 -6.48 2.3e-10 1.25e-07 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119019307 chr1:119140396~119275973:+ LUSC cis rs1075265 0.783 rs6708095 ENSG00000233266.1 HMGB1P31 6.48 2.3e-10 1.25e-07 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:53710365 chr2:54051334~54051760:+ LUSC cis rs11089937 0.524 rs2877021 ENSG00000211638.2 IGLV8-61 -6.48 2.3e-10 1.25e-07 -0.29 -0.29 Periodontitis (PAL4Q3); chr22:22165909 chr22:22098700~22099212:+ LUSC cis rs992157 0.56 rs7605980 ENSG00000261338.2 RP11-378A13.1 6.48 2.3e-10 1.25e-07 0.29 0.29 Colorectal cancer; chr2:218236146 chr2:218255319~218257366:+ LUSC cis rs4266144 0.563 rs61124401 ENSG00000244515.1 KRT18P34 -6.48 2.3e-10 1.25e-07 -0.41 -0.29 Coronary artery disease; chr3:157123130 chr3:157162663~157163932:- LUSC cis rs783540 0.967 rs34186444 ENSG00000276710.3 CSPG4P8 6.48 2.31e-10 1.25e-07 0.3 0.29 Schizophrenia; chr15:82618749 chr15:82459472~82477258:+ LUSC cis rs6142102 0.58 rs4911139 ENSG00000275784.1 RP5-1125A11.6 -6.48 2.31e-10 1.25e-07 -0.31 -0.29 Skin pigmentation; chr20:33963729 chr20:33989480~33991818:- LUSC cis rs732716 0.785 rs11085073 ENSG00000267769.1 CTB-50L17.9 6.48 2.31e-10 1.25e-07 0.31 0.29 Mean corpuscular volume; chr19:4375165 chr19:4454014~4455286:+ LUSC cis rs992157 0.56 rs4674275 ENSG00000261338.2 RP11-378A13.1 -6.48 2.31e-10 1.25e-07 -0.29 -0.29 Colorectal cancer; chr2:218233015 chr2:218255319~218257366:+ LUSC cis rs992157 0.585 rs62182795 ENSG00000261338.2 RP11-378A13.1 -6.48 2.31e-10 1.25e-07 -0.29 -0.29 Colorectal cancer; chr2:218235479 chr2:218255319~218257366:+ LUSC cis rs1823913 0.599 rs1378155 ENSG00000227542.1 AC092614.2 6.48 2.31e-10 1.25e-07 0.37 0.29 Obesity-related traits; chr2:191266610 chr2:191229165~191246172:- LUSC cis rs1823913 0.576 rs13011608 ENSG00000227542.1 AC092614.2 6.48 2.31e-10 1.25e-07 0.37 0.29 Obesity-related traits; chr2:191267097 chr2:191229165~191246172:- LUSC cis rs10129255 0.5 rs8011115 ENSG00000224373.3 IGHV4-59 6.48 2.31e-10 1.25e-07 0.14 0.29 Kawasaki disease; chr14:106786292 chr14:106627249~106627825:- LUSC cis rs6142102 1 rs6142102 ENSG00000275784.1 RP5-1125A11.6 -6.48 2.32e-10 1.25e-07 -0.33 -0.29 Skin pigmentation; chr20:34116821 chr20:33989480~33991818:- LUSC cis rs11690935 0.959 rs6745143 ENSG00000228389.1 AC068039.4 6.48 2.32e-10 1.25e-07 0.33 0.29 Schizophrenia; chr2:171793872 chr2:171773482~171775844:+ LUSC cis rs11690935 0.959 rs6758704 ENSG00000228389.1 AC068039.4 6.48 2.32e-10 1.25e-07 0.33 0.29 Schizophrenia; chr2:171798587 chr2:171773482~171775844:+ LUSC cis rs11098499 0.909 rs28884220 ENSG00000250412.1 KLHL2P1 6.48 2.33e-10 1.26e-07 0.36 0.29 Corneal astigmatism; chr4:119386056 chr4:119334329~119378233:+ LUSC cis rs11098499 0.909 rs28793658 ENSG00000250412.1 KLHL2P1 6.48 2.33e-10 1.26e-07 0.36 0.29 Corneal astigmatism; chr4:119386059 chr4:119334329~119378233:+ LUSC cis rs11690935 0.959 rs12692973 ENSG00000228389.1 AC068039.4 -6.48 2.33e-10 1.26e-07 -0.34 -0.29 Schizophrenia; chr2:171785547 chr2:171773482~171775844:+ LUSC cis rs801193 1 rs2003301 ENSG00000224316.1 RP11-479O9.2 -6.48 2.33e-10 1.26e-07 -0.27 -0.29 Aortic root size; chr7:66682669 chr7:65773620~65802067:+ LUSC cis rs9903692 0.954 rs4794441 ENSG00000278765.1 RP5-890E16.5 -6.48 2.33e-10 1.26e-07 -0.34 -0.29 Pulse pressure; chr17:48099094 chr17:48066704~48067293:- LUSC cis rs6142102 1 rs6059673 ENSG00000275784.1 RP5-1125A11.6 -6.48 2.33e-10 1.26e-07 -0.34 -0.29 Skin pigmentation; chr20:34117755 chr20:33989480~33991818:- LUSC cis rs2739330 0.76 rs5751761 ENSG00000099984.9 GSTT2 6.48 2.33e-10 1.26e-07 0.33 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23980123~23983911:+ LUSC cis rs9326248 0.501 rs4938351 ENSG00000280143.1 AP000892.6 6.48 2.33e-10 1.26e-07 0.3 0.29 Blood protein levels; chr11:117151636 chr11:117204967~117210292:+ LUSC cis rs10170846 0.861 rs12694582 ENSG00000261428.2 RP11-16P6.1 6.48 2.33e-10 1.26e-07 0.34 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222657236 chr2:222566899~222569719:- LUSC cis rs10170846 0.731 rs10180632 ENSG00000261428.2 RP11-16P6.1 6.48 2.33e-10 1.26e-07 0.34 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222661665 chr2:222566899~222569719:- LUSC cis rs10170846 0.8 rs10180462 ENSG00000261428.2 RP11-16P6.1 6.48 2.33e-10 1.26e-07 0.34 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222661666 chr2:222566899~222569719:- LUSC cis rs4604732 0.631 rs1106721 ENSG00000227135.1 GCSAML-AS1 -6.48 2.33e-10 1.26e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461374 chr1:247524679~247526752:- LUSC cis rs10129255 0.576 rs2157616 ENSG00000224373.3 IGHV4-59 6.48 2.34e-10 1.26e-07 0.14 0.29 Kawasaki disease; chr14:106767802 chr14:106627249~106627825:- LUSC cis rs1823913 0.622 rs55787447 ENSG00000280083.1 RP11-317J9.1 -6.48 2.34e-10 1.27e-07 -0.33 -0.29 Obesity-related traits; chr2:191288596 chr2:191154118~191156070:- LUSC cis rs853679 0.607 rs66886492 ENSG00000204709.4 LINC01556 6.48 2.34e-10 1.27e-07 0.64 0.29 Depression; chr6:28121953 chr6:28943877~28944537:+ LUSC cis rs853679 0.607 rs35345226 ENSG00000204709.4 LINC01556 6.48 2.34e-10 1.27e-07 0.64 0.29 Depression; chr6:28123802 chr6:28943877~28944537:+ LUSC cis rs10829156 0.898 rs7923072 ENSG00000240291.1 RP11-499P20.2 6.48 2.35e-10 1.27e-07 0.31 0.29 Sudden cardiac arrest; chr10:18649305 chr10:18513115~18545651:- LUSC cis rs957448 1 rs1992370 ENSG00000253175.1 RP11-267M23.6 6.48 2.35e-10 1.27e-07 0.34 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94546466 chr8:94565036~94565715:+ LUSC cis rs875971 0.66 rs10281080 ENSG00000224316.1 RP11-479O9.2 -6.48 2.35e-10 1.27e-07 -0.27 -0.29 Aortic root size; chr7:66577454 chr7:65773620~65802067:+ LUSC cis rs875971 0.66 rs10950044 ENSG00000224316.1 RP11-479O9.2 -6.48 2.35e-10 1.27e-07 -0.27 -0.29 Aortic root size; chr7:66577989 chr7:65773620~65802067:+ LUSC cis rs7246657 0.943 rs12981532 ENSG00000276846.1 CTD-3220F14.3 6.48 2.36e-10 1.27e-07 0.44 0.29 Coronary artery calcification; chr19:37398378 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs7246993 ENSG00000276846.1 CTD-3220F14.3 6.48 2.36e-10 1.27e-07 0.44 0.29 Coronary artery calcification; chr19:37399252 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs10413602 ENSG00000276846.1 CTD-3220F14.3 6.48 2.36e-10 1.27e-07 0.44 0.29 Coronary artery calcification; chr19:37400590 chr19:37314868~37315620:- LUSC cis rs2919917 1 rs2717547 ENSG00000254352.1 RP11-578O24.2 -6.48 2.36e-10 1.27e-07 -0.36 -0.29 Lymphocyte counts; chr8:78744754 chr8:78723796~78724136:- LUSC cis rs1075265 0.716 rs7573991 ENSG00000233266.1 HMGB1P31 6.48 2.36e-10 1.27e-07 0.35 0.29 Chronotype;Morning vs. evening chronotype; chr2:53726830 chr2:54051334~54051760:+ LUSC cis rs875971 0.522 rs1968127 ENSG00000224316.1 RP11-479O9.2 -6.48 2.36e-10 1.27e-07 -0.27 -0.29 Aortic root size; chr7:66591816 chr7:65773620~65802067:+ LUSC cis rs227275 0.525 rs4698874 ENSG00000230069.3 LRRC37A15P -6.48 2.36e-10 1.28e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:103009354 chr4:102727274~102730721:- LUSC cis rs11690935 0.918 rs11757 ENSG00000228389.1 AC068039.4 6.48 2.36e-10 1.28e-07 0.33 0.29 Schizophrenia; chr2:171784535 chr2:171773482~171775844:+ LUSC cis rs875971 0.508 rs10242423 ENSG00000224316.1 RP11-479O9.2 -6.48 2.36e-10 1.28e-07 -0.27 -0.29 Aortic root size; chr7:66594188 chr7:65773620~65802067:+ LUSC cis rs875971 0.508 rs10253883 ENSG00000224316.1 RP11-479O9.2 -6.48 2.36e-10 1.28e-07 -0.27 -0.29 Aortic root size; chr7:66596151 chr7:65773620~65802067:+ LUSC cis rs875971 0.66 rs801217 ENSG00000236529.1 RP13-254B10.1 -6.48 2.36e-10 1.28e-07 -0.29 -0.29 Aortic root size; chr7:66545590 chr7:65840212~65840596:+ LUSC cis rs875971 0.638 rs801216 ENSG00000236529.1 RP13-254B10.1 -6.48 2.36e-10 1.28e-07 -0.29 -0.29 Aortic root size; chr7:66546680 chr7:65840212~65840596:+ LUSC cis rs875971 0.66 rs13224319 ENSG00000236529.1 RP13-254B10.1 6.48 2.36e-10 1.28e-07 0.29 0.29 Aortic root size; chr7:66542376 chr7:65840212~65840596:+ LUSC cis rs2404602 0.647 rs11072636 ENSG00000259422.1 RP11-593F23.1 -6.48 2.37e-10 1.28e-07 -0.33 -0.29 Blood metabolite levels; chr15:76893445 chr15:76174891~76181486:- LUSC cis rs227275 0.525 rs4699046 ENSG00000230069.3 LRRC37A15P -6.48 2.37e-10 1.28e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:103004514 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs4699047 ENSG00000230069.3 LRRC37A15P -6.48 2.37e-10 1.28e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:103005385 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs28778380 ENSG00000230069.3 LRRC37A15P -6.48 2.37e-10 1.28e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:103006416 chr4:102727274~102730721:- LUSC cis rs875971 1 rs9986696 ENSG00000237310.1 GS1-124K5.4 -6.48 2.37e-10 1.28e-07 -0.3 -0.29 Aortic root size; chr7:66239589 chr7:66493706~66495474:+ LUSC cis rs9903692 0.866 rs11079807 ENSG00000278765.1 RP5-890E16.5 -6.48 2.37e-10 1.28e-07 -0.34 -0.29 Pulse pressure; chr17:48098685 chr17:48066704~48067293:- LUSC cis rs9903692 0.954 rs10853094 ENSG00000278765.1 RP5-890E16.5 -6.48 2.37e-10 1.28e-07 -0.34 -0.29 Pulse pressure; chr17:48098700 chr17:48066704~48067293:- LUSC cis rs11098499 0.865 rs11098513 ENSG00000250412.1 KLHL2P1 6.48 2.37e-10 1.28e-07 0.37 0.29 Corneal astigmatism; chr4:119394920 chr4:119334329~119378233:+ LUSC cis rs11976180 1 rs13243677 ENSG00000170356.8 OR2A20P -6.48 2.38e-10 1.28e-07 -0.38 -0.29 Obesity-related traits; chr7:144049479 chr7:144250045~144252957:- LUSC cis rs783540 0.967 rs783523 ENSG00000276710.3 CSPG4P8 -6.48 2.38e-10 1.28e-07 -0.3 -0.29 Schizophrenia; chr15:82614804 chr15:82459472~82477258:+ LUSC cis rs875971 0.638 rs6460305 ENSG00000224316.1 RP11-479O9.2 -6.48 2.38e-10 1.29e-07 -0.27 -0.29 Aortic root size; chr7:66595421 chr7:65773620~65802067:+ LUSC cis rs11098499 0.662 rs13108589 ENSG00000249244.1 RP11-548H18.2 6.48 2.39e-10 1.29e-07 0.36 0.29 Corneal astigmatism; chr4:119346947 chr4:119391831~119395335:- LUSC cis rs875971 0.619 rs10278371 ENSG00000236529.1 RP13-254B10.1 -6.47 2.39e-10 1.29e-07 -0.29 -0.29 Aortic root size; chr7:66586553 chr7:65840212~65840596:+ LUSC cis rs2903698 0.585 rs28520516 ENSG00000250735.4 RP11-567N4.3 6.47 2.4e-10 1.29e-07 0.32 0.29 Prion diseases; chr4:75431837 chr4:75401195~75423023:+ LUSC cis rs8059260 0.736 rs2302558 ENSG00000274038.1 RP11-66H6.4 -6.47 2.4e-10 1.29e-07 -0.48 -0.29 Alcohol consumption over the past year; chr16:10969154 chr16:11056556~11057034:+ LUSC cis rs9903692 0.954 rs7224014 ENSG00000278765.1 RP5-890E16.5 6.47 2.4e-10 1.3e-07 0.34 0.29 Pulse pressure; chr17:48073499 chr17:48066704~48067293:- LUSC cis rs4266144 0.544 rs7340627 ENSG00000244515.1 KRT18P34 -6.47 2.4e-10 1.3e-07 -0.34 -0.29 Coronary artery disease; chr3:157114604 chr3:157162663~157163932:- LUSC cis rs10246939 0.529 rs60165685 ENSG00000228775.6 WEE2-AS1 6.47 2.41e-10 1.3e-07 0.34 0.29 Bitter taste perception; chr7:141861190 chr7:141704338~141738346:- LUSC cis rs11089937 0.512 rs13054756 ENSG00000211638.2 IGLV8-61 -6.47 2.42e-10 1.31e-07 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22130948 chr22:22098700~22099212:+ LUSC cis rs11089937 0.597 rs4821768 ENSG00000211638.2 IGLV8-61 -6.47 2.42e-10 1.31e-07 -0.3 -0.29 Periodontitis (PAL4Q3); chr22:22131047 chr22:22098700~22099212:+ LUSC cis rs2382817 0.58 rs6756265 ENSG00000261338.2 RP11-378A13.1 -6.47 2.42e-10 1.31e-07 -0.29 -0.29 Crohn's disease;Ulcerative colitis;Inflammatory bowel disease; chr2:218230831 chr2:218255319~218257366:+ LUSC cis rs11722779 0.873 rs223384 ENSG00000230069.3 LRRC37A15P -6.47 2.42e-10 1.31e-07 -0.3 -0.29 Schizophrenia; chr4:102829976 chr4:102727274~102730721:- LUSC cis rs227275 0.554 rs223383 ENSG00000230069.3 LRRC37A15P -6.47 2.42e-10 1.31e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102830094 chr4:102727274~102730721:- LUSC cis rs881375 0.967 rs758959 ENSG00000226752.6 PSMD5-AS1 -6.47 2.42e-10 1.31e-07 -0.33 -0.29 Rheumatoid arthritis; chr9:120914421 chr9:120824828~120854385:+ LUSC cis rs75920871 0.588 rs721783 ENSG00000254851.1 RP11-109L13.1 6.47 2.43e-10 1.31e-07 0.39 0.29 Subjective well-being; chr11:117036733 chr11:117135528~117138582:+ LUSC cis rs496547 0.686 rs487728 ENSG00000255239.1 AP002954.6 6.47 2.43e-10 1.31e-07 0.32 0.29 Hip minimal joint space width; chr11:118750785 chr11:118688039~118690600:- LUSC cis rs6951245 0.938 rs112425403 ENSG00000224079.1 AC091729.7 -6.47 2.43e-10 1.31e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1031895 chr7:1074450~1078036:+ LUSC cis rs11098499 0.954 rs6849561 ENSG00000250412.1 KLHL2P1 -6.47 2.43e-10 1.31e-07 -0.37 -0.29 Corneal astigmatism; chr4:119488539 chr4:119334329~119378233:+ LUSC cis rs9543976 0.858 rs9530447 ENSG00000261553.4 RP11-29G8.3 6.47 2.43e-10 1.31e-07 0.52 0.29 Diabetic retinopathy; chr13:75592666 chr13:75549773~75807120:+ LUSC cis rs6969780 1 rs73071548 ENSG00000233429.8 HOTAIRM1 6.47 2.43e-10 1.31e-07 0.57 0.29 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27107811 chr7:27095647~27100265:+ LUSC cis rs227275 0.554 rs223467 ENSG00000230069.3 LRRC37A15P -6.47 2.43e-10 1.31e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102779721 chr4:102727274~102730721:- LUSC cis rs9549367 0.789 rs3850451 ENSG00000269125.1 RP11-98F14.11 -6.47 2.44e-10 1.31e-07 -0.36 -0.29 Platelet distribution width; chr13:113251498 chr13:113165002~113165183:- LUSC cis rs17023223 0.537 rs2361269 ENSG00000231365.4 RP11-418J17.1 -6.47 2.44e-10 1.31e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119059592 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs2645300 ENSG00000231365.4 RP11-418J17.1 -6.47 2.44e-10 1.31e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119060444 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs2361270 ENSG00000231365.4 RP11-418J17.1 -6.47 2.44e-10 1.31e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119060699 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs2361271 ENSG00000231365.4 RP11-418J17.1 -6.47 2.44e-10 1.31e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119060782 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs2361273 ENSG00000231365.4 RP11-418J17.1 -6.47 2.44e-10 1.31e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119061077 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs10923741 ENSG00000231365.4 RP11-418J17.1 -6.47 2.44e-10 1.31e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119061850 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs10802073 ENSG00000231365.4 RP11-418J17.1 -6.47 2.44e-10 1.31e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119062032 chr1:119140396~119275973:+ LUSC cis rs1075265 0.868 rs1877906 ENSG00000233266.1 HMGB1P31 6.47 2.44e-10 1.32e-07 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:54136700 chr2:54051334~54051760:+ LUSC cis rs7208859 0.778 rs6505219 ENSG00000263531.1 RP13-753N3.1 6.47 2.44e-10 1.32e-07 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30938603 chr17:30863921~30864940:- LUSC cis rs8062405 0.723 rs4788077 ENSG00000278665.1 RP11-666O2.4 6.47 2.45e-10 1.32e-07 0.29 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558443 chr16:28599241~28601881:- LUSC cis rs8031584 0.958 rs7176569 ENSG00000260382.1 RP11-540B6.2 -6.47 2.45e-10 1.32e-07 -0.38 -0.29 Huntington's disease progression; chr15:30952292 chr15:30882267~30883231:- LUSC cis rs17023223 0.509 rs6668960 ENSG00000231365.4 RP11-418J17.1 -6.47 2.45e-10 1.32e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119058189 chr1:119140396~119275973:+ LUSC cis rs6603134 0.502 rs10405588 ENSG00000267939.1 CTD-2325M2.1 -6.47 2.45e-10 1.32e-07 -0.31 -0.29 Blood protein levels; chr19:8038663 chr19:8008729~8016025:+ LUSC cis rs7945705 0.967 rs10840141 ENSG00000254860.4 TMEM9B-AS1 -6.47 2.46e-10 1.32e-07 -0.31 -0.29 Hemoglobin concentration; chr11:8880671 chr11:8964675~8977527:+ LUSC cis rs7945705 0.846 rs2742540 ENSG00000254860.4 TMEM9B-AS1 -6.47 2.46e-10 1.33e-07 -0.3 -0.29 Hemoglobin concentration; chr11:8877981 chr11:8964675~8977527:+ LUSC cis rs11690935 1 rs312924 ENSG00000228389.1 AC068039.4 -6.47 2.46e-10 1.33e-07 -0.32 -0.29 Schizophrenia; chr2:171707511 chr2:171773482~171775844:+ LUSC cis rs950169 0.922 rs11639244 ENSG00000259728.4 LINC00933 6.47 2.46e-10 1.33e-07 0.37 0.29 Schizophrenia; chr15:84163898 chr15:84570649~84580175:+ LUSC cis rs2337406 1 rs17113257 ENSG00000254174.1 IGHV1-12 6.47 2.47e-10 1.33e-07 0.29 0.29 Alzheimer's disease (late onset); chr14:106679574 chr14:106122420~106122709:- LUSC cis rs13113518 0.678 rs7663650 ENSG00000249700.7 SRD5A3-AS1 -6.47 2.48e-10 1.34e-07 -0.32 -0.29 Height; chr4:55364952 chr4:55363971~55395847:- LUSC cis rs881375 0.967 rs2109895 ENSG00000226752.6 PSMD5-AS1 -6.47 2.48e-10 1.34e-07 -0.33 -0.29 Rheumatoid arthritis; chr9:120915549 chr9:120824828~120854385:+ LUSC cis rs11157436 1 rs12587166 ENSG00000211813.2 TRAV34 6.47 2.48e-10 1.34e-07 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22165492 chr14:22207522~22208129:+ LUSC cis rs950169 0.887 rs35986397 ENSG00000225151.9 GOLGA2P7 -6.47 2.49e-10 1.34e-07 -0.4 -0.29 Schizophrenia; chr15:84400409 chr15:84199311~84230136:- LUSC cis rs11971779 0.616 rs10269683 ENSG00000273391.1 RP11-634H22.1 6.47 2.49e-10 1.34e-07 0.31 0.29 Diisocyanate-induced asthma; chr7:139416122 chr7:139359032~139359566:- LUSC cis rs7772486 0.622 rs1292333 ENSG00000235652.6 RP11-545I5.3 -6.47 2.49e-10 1.34e-07 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145661208 chr6:145799409~145886585:+ LUSC cis rs1056107 0.763 rs10759529 ENSG00000225513.1 RP11-165N19.2 -6.47 2.49e-10 1.34e-07 -0.31 -0.29 Colorectal cancer; chr9:112176651 chr9:112173522~112173971:- LUSC cis rs1061377 0.513 rs2712000 ENSG00000249207.1 RP11-360F5.1 -6.47 2.49e-10 1.34e-07 -0.34 -0.29 Uric acid levels; chr4:39135462 chr4:39112677~39126818:- LUSC cis rs9487094 0.744 rs12661287 ENSG00000260273.1 RP11-425D10.10 6.47 2.5e-10 1.34e-07 0.36 0.29 Height; chr6:109732047 chr6:109382795~109383666:+ LUSC cis rs62432291 0.681 rs420054 ENSG00000235086.1 FNDC1-IT1 -6.47 2.5e-10 1.35e-07 -0.48 -0.29 Joint mobility (Beighton score); chr6:159234052 chr6:159240786~159243329:+ LUSC cis rs1823913 0.622 rs55787447 ENSG00000227542.1 AC092614.2 6.47 2.5e-10 1.35e-07 0.37 0.29 Obesity-related traits; chr2:191288596 chr2:191229165~191246172:- LUSC cis rs7246657 0.943 rs2291004 ENSG00000276846.1 CTD-3220F14.3 6.47 2.52e-10 1.36e-07 0.44 0.29 Coronary artery calcification; chr19:37507050 chr19:37314868~37315620:- LUSC cis rs67340775 0.541 rs169287 ENSG00000219392.1 RP1-265C24.5 -6.47 2.52e-10 1.36e-07 -0.44 -0.29 Lung cancer in ever smokers; chr6:27886982 chr6:28115628~28116551:+ LUSC cis rs783540 0.933 rs2567636 ENSG00000276710.3 CSPG4P8 6.47 2.52e-10 1.36e-07 0.3 0.29 Schizophrenia; chr15:82594678 chr15:82459472~82477258:+ LUSC cis rs783540 0.967 rs2567635 ENSG00000276710.3 CSPG4P8 6.47 2.52e-10 1.36e-07 0.3 0.29 Schizophrenia; chr15:82593431 chr15:82459472~82477258:+ LUSC cis rs4972806 0.775 rs2857534 ENSG00000226363.3 HAGLROS -6.47 2.52e-10 1.36e-07 -0.35 -0.29 IgG glycosylation; chr2:176170948 chr2:176177717~176179008:+ LUSC cis rs67180937 0.621 rs2068814 ENSG00000272750.1 RP11-378J18.8 -6.47 2.52e-10 1.36e-07 -0.31 -0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222749659 chr1:222658867~222661512:- LUSC cis rs4713118 0.621 rs9295755 ENSG00000280107.1 AL022393.9 6.47 2.53e-10 1.36e-07 0.36 0.29 Parkinson's disease; chr6:28065396 chr6:28170845~28172521:+ LUSC cis rs4853012 0.838 rs72911122 ENSG00000257800.1 FNBP1P1 6.47 2.53e-10 1.36e-07 0.33 0.29 Gestational age at birth (maternal effect); chr2:74116992 chr2:74120680~74123218:+ LUSC cis rs8072100 0.79 rs1962307 ENSG00000228782.6 CTD-2026D20.3 6.47 2.53e-10 1.36e-07 0.28 0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47630505 chr17:47450568~47492492:- LUSC cis rs11098499 0.754 rs9999724 ENSG00000249244.1 RP11-548H18.2 6.47 2.53e-10 1.36e-07 0.36 0.29 Corneal astigmatism; chr4:119318789 chr4:119391831~119395335:- LUSC cis rs17507216 0.628 rs28737193 ENSG00000255769.6 GOLGA2P10 -6.47 2.53e-10 1.36e-07 -0.42 -0.29 Excessive daytime sleepiness; chr15:82701318 chr15:82472993~82513950:- LUSC cis rs853679 0.607 rs71559070 ENSG00000204709.4 LINC01556 6.47 2.53e-10 1.36e-07 0.63 0.29 Depression; chr6:28071151 chr6:28943877~28944537:+ LUSC cis rs1823913 0.599 rs35098152 ENSG00000280083.1 RP11-317J9.1 -6.47 2.53e-10 1.36e-07 -0.34 -0.29 Obesity-related traits; chr2:191286658 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs35150635 ENSG00000280083.1 RP11-317J9.1 -6.47 2.53e-10 1.36e-07 -0.34 -0.29 Obesity-related traits; chr2:191287303 chr2:191154118~191156070:- LUSC cis rs5742933 0.857 rs893784 ENSG00000253559.1 OSGEPL1-AS1 -6.47 2.53e-10 1.36e-07 -0.34 -0.29 Ferritin levels; chr2:189671557 chr2:189762704~189765556:+ LUSC cis rs7267979 0.932 rs6107052 ENSG00000274973.1 RP13-401N8.7 -6.47 2.54e-10 1.37e-07 -0.29 -0.29 Liver enzyme levels (alkaline phosphatase); chr20:25550202 chr20:25845497~25845862:+ LUSC cis rs6570726 0.818 rs437978 ENSG00000235652.6 RP11-545I5.3 6.47 2.54e-10 1.37e-07 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145487998 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs7773939 ENSG00000235652.6 RP11-545I5.3 -6.47 2.54e-10 1.37e-07 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145606248 chr6:145799409~145886585:+ LUSC cis rs227275 0.525 rs1383733 ENSG00000230069.3 LRRC37A15P -6.46 2.54e-10 1.37e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102995297 chr4:102727274~102730721:- LUSC cis rs8177376 0.953 rs3862627 ENSG00000254905.1 RP11-712L6.7 6.46 2.55e-10 1.37e-07 0.4 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126311697 chr11:126292922~126294254:- LUSC cis rs957448 1 rs60655325 ENSG00000253175.1 RP11-267M23.6 6.46 2.55e-10 1.37e-07 0.34 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94552606 chr8:94565036~94565715:+ LUSC cis rs957448 1 rs28817653 ENSG00000253175.1 RP11-267M23.6 6.46 2.55e-10 1.37e-07 0.34 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94557822 chr8:94565036~94565715:+ LUSC cis rs10800713 0.954 rs6665951 ENSG00000260088.1 RP11-92G12.3 -6.46 2.55e-10 1.37e-07 -0.39 -0.29 Tandem gait; chr1:200589235 chr1:200669507~200694250:+ LUSC cis rs11690935 0.959 rs7586207 ENSG00000228389.1 AC068039.4 6.46 2.55e-10 1.37e-07 0.33 0.29 Schizophrenia; chr2:171814584 chr2:171773482~171775844:+ LUSC cis rs875971 0.522 rs9530 ENSG00000164669.11 INTS4P1 -6.46 2.55e-10 1.37e-07 -0.32 -0.29 Aortic root size; chr7:65960907 chr7:65141225~65234216:+ LUSC cis rs11098499 0.604 rs12642411 ENSG00000250412.1 KLHL2P1 6.46 2.55e-10 1.37e-07 0.36 0.29 Corneal astigmatism; chr4:119659370 chr4:119334329~119378233:+ LUSC cis rs71403859 0.73 rs12931191 ENSG00000260886.1 TAT-AS1 -6.46 2.55e-10 1.37e-07 -0.45 -0.29 Post bronchodilator FEV1; chr16:71587470 chr16:71565789~71578187:+ LUSC cis rs2188561 0.697 rs12705421 ENSG00000241764.3 AC002467.7 6.46 2.55e-10 1.37e-07 0.38 0.29 Alcohol consumption; chr7:107760984 chr7:107742817~107744581:- LUSC cis rs5760092 0.755 rs915589 ENSG00000099984.9 GSTT2 6.46 2.55e-10 1.37e-07 0.41 0.29 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23980123~23983911:+ LUSC cis rs1823913 0.599 rs13001899 ENSG00000227542.1 AC092614.2 6.46 2.55e-10 1.37e-07 0.37 0.29 Obesity-related traits; chr2:191285442 chr2:191229165~191246172:- LUSC cis rs11098499 0.954 rs10006525 ENSG00000250412.1 KLHL2P1 6.46 2.56e-10 1.37e-07 0.36 0.29 Corneal astigmatism; chr4:119487776 chr4:119334329~119378233:+ LUSC cis rs950169 0.8 rs4842847 ENSG00000225151.9 GOLGA2P7 -6.46 2.56e-10 1.37e-07 -0.4 -0.29 Schizophrenia; chr15:84262447 chr15:84199311~84230136:- LUSC cis rs6570726 0.791 rs621382 ENSG00000235652.6 RP11-545I5.3 6.46 2.56e-10 1.38e-07 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145478008 chr6:145799409~145886585:+ LUSC cis rs9309473 0.95 rs11689588 ENSG00000163016.8 ALMS1P 6.46 2.56e-10 1.38e-07 0.35 0.29 Metabolite levels; chr2:73546564 chr2:73644919~73685576:+ LUSC cis rs6142102 0.58 rs6142101 ENSG00000275784.1 RP5-1125A11.6 -6.46 2.56e-10 1.38e-07 -0.32 -0.29 Skin pigmentation; chr20:34110039 chr20:33989480~33991818:- LUSC cis rs7246657 0.943 rs35540940 ENSG00000276846.1 CTD-3220F14.3 6.46 2.56e-10 1.38e-07 0.43 0.29 Coronary artery calcification; chr19:37517333 chr19:37314868~37315620:- LUSC cis rs113835537 0.529 rs75685325 ENSG00000255517.5 CTD-3074O7.5 -6.46 2.56e-10 1.38e-07 -0.34 -0.29 Airway imaging phenotypes; chr11:66467771 chr11:66473490~66480233:- LUSC cis rs11098499 0.564 rs11098507 ENSG00000249244.1 RP11-548H18.2 6.46 2.57e-10 1.38e-07 0.36 0.29 Corneal astigmatism; chr4:119367131 chr4:119391831~119395335:- LUSC cis rs673078 0.607 rs2062519 ENSG00000275759.1 RP11-131L12.3 -6.46 2.57e-10 1.38e-07 -0.38 -0.29 Glucose homeostasis traits; chr12:118367577 chr12:118428281~118428870:+ LUSC cis rs801193 0.66 rs2659914 ENSG00000237310.1 GS1-124K5.4 6.46 2.57e-10 1.38e-07 0.3 0.29 Aortic root size; chr7:66691927 chr7:66493706~66495474:+ LUSC cis rs853679 0.517 rs9283884 ENSG00000280107.1 AL022393.9 6.46 2.58e-10 1.39e-07 0.36 0.29 Depression; chr6:28167882 chr6:28170845~28172521:+ LUSC cis rs9549367 0.789 rs3861720 ENSG00000269125.1 RP11-98F14.11 -6.46 2.58e-10 1.39e-07 -0.36 -0.29 Platelet distribution width; chr13:113251783 chr13:113165002~113165183:- LUSC cis rs9549367 0.865 rs3861721 ENSG00000269125.1 RP11-98F14.11 -6.46 2.58e-10 1.39e-07 -0.36 -0.29 Platelet distribution width; chr13:113251994 chr13:113165002~113165183:- LUSC cis rs172166 0.694 rs203892 ENSG00000216901.1 AL022393.7 6.46 2.58e-10 1.39e-07 0.34 0.29 Cardiac Troponin-T levels; chr6:28099418 chr6:28176188~28176674:+ LUSC cis rs7955901 0.664 rs11178589 ENSG00000257265.1 CTD-2021H9.1 6.46 2.58e-10 1.39e-07 0.32 0.29 Type 2 diabetes; chr12:71078550 chr12:71007773~71032083:- LUSC cis rs8177376 1 rs655540 ENSG00000254905.1 RP11-712L6.7 6.46 2.59e-10 1.39e-07 0.38 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126281347 chr11:126292922~126294254:- LUSC cis rs9549367 0.789 rs9549711 ENSG00000269125.1 RP11-98F14.11 -6.46 2.59e-10 1.39e-07 -0.36 -0.29 Platelet distribution width; chr13:113246243 chr13:113165002~113165183:- LUSC cis rs9549367 0.737 rs9549712 ENSG00000269125.1 RP11-98F14.11 -6.46 2.59e-10 1.39e-07 -0.36 -0.29 Platelet distribution width; chr13:113248041 chr13:113165002~113165183:- LUSC cis rs9549367 0.774 rs9549364 ENSG00000269125.1 RP11-98F14.11 -6.46 2.59e-10 1.39e-07 -0.36 -0.29 Platelet distribution width; chr13:113249431 chr13:113165002~113165183:- LUSC cis rs9549367 0.737 rs11619691 ENSG00000269125.1 RP11-98F14.11 -6.46 2.59e-10 1.39e-07 -0.36 -0.29 Platelet distribution width; chr13:113250322 chr13:113165002~113165183:- LUSC cis rs9549367 0.826 rs9549713 ENSG00000269125.1 RP11-98F14.11 -6.46 2.59e-10 1.39e-07 -0.36 -0.29 Platelet distribution width; chr13:113250994 chr13:113165002~113165183:- LUSC cis rs10759883 0.651 rs816670 ENSG00000175611.10 LINC00476 -6.46 2.59e-10 1.39e-07 -0.34 -0.29 Nicotine dependence; chr9:95813152 chr9:95759231~95875977:- LUSC cis rs2337406 0.925 rs76288499 ENSG00000254174.1 IGHV1-12 6.46 2.59e-10 1.39e-07 0.29 0.29 Alzheimer's disease (late onset); chr14:106686309 chr14:106122420~106122709:- LUSC cis rs4604732 0.631 rs1106720 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461379 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs12039596 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461464 chr1:247524679~247526752:- LUSC cis rs4604732 0.578 rs12036417 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461503 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs12039642 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461596 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs75600450 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462190 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs74154672 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462323 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs74154673 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462327 chr1:247524679~247526752:- LUSC cis rs4604732 0.678 rs74154674 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462383 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs11490198 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462401 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs11490199 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462435 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs74154675 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462534 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs74154676 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462592 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs11490200 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462613 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs56704806 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462846 chr1:247524679~247526752:- LUSC cis rs4604732 0.588 rs74154678 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462900 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs11490201 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462960 chr1:247524679~247526752:- LUSC cis rs4604732 0.589 rs78689516 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247462972 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs76761880 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463075 chr1:247524679~247526752:- LUSC cis rs4604732 0.536 rs78019731 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463128 chr1:247524679~247526752:- LUSC cis rs4604732 0.527 rs77361748 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463173 chr1:247524679~247526752:- LUSC cis rs4604732 0.578 rs79203328 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463279 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs75320597 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463449 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs35046441 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463510 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs80319072 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463533 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs34330532 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463542 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs12036460 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463626 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs10925043 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463699 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs10925044 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463769 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs10802509 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463856 chr1:247524679~247526752:- LUSC cis rs4604732 0.631 rs7546720 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463927 chr1:247524679~247526752:- LUSC cis rs4604732 0.527 rs7539082 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463958 chr1:247524679~247526752:- LUSC cis rs4604732 0.578 rs7525209 ENSG00000227135.1 GCSAML-AS1 -6.46 2.6e-10 1.39e-07 -0.43 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247464102 chr1:247524679~247526752:- LUSC cis rs75422866 0.51 rs35784744 ENSG00000257433.4 RP1-197B17.3 6.46 2.6e-10 1.39e-07 0.61 0.29 Pneumonia; chr12:47729646 chr12:47706085~47742294:+ LUSC cis rs228614 0.509 rs223480 ENSG00000230069.3 LRRC37A15P -6.46 2.6e-10 1.39e-07 -0.3 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766881 chr4:102727274~102730721:- LUSC cis rs881375 0.967 rs876445 ENSG00000226752.6 PSMD5-AS1 -6.46 2.6e-10 1.4e-07 -0.33 -0.29 Rheumatoid arthritis; chr9:120914824 chr9:120824828~120854385:+ LUSC cis rs950169 1 rs12903820 ENSG00000225151.9 GOLGA2P7 -6.46 2.61e-10 1.4e-07 -0.4 -0.29 Schizophrenia; chr15:84055068 chr15:84199311~84230136:- LUSC cis rs11098499 0.954 rs13145352 ENSG00000249244.1 RP11-548H18.2 -6.46 2.61e-10 1.4e-07 -0.37 -0.29 Corneal astigmatism; chr4:119488808 chr4:119391831~119395335:- LUSC cis rs17023223 0.537 rs6662165 ENSG00000231365.4 RP11-418J17.1 -6.46 2.61e-10 1.4e-07 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119071448 chr1:119140396~119275973:+ LUSC cis rs11098499 1 rs35643470 ENSG00000250412.1 KLHL2P1 6.46 2.62e-10 1.4e-07 0.36 0.29 Corneal astigmatism; chr4:119263793 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs11722872 ENSG00000250412.1 KLHL2P1 6.46 2.62e-10 1.4e-07 0.37 0.29 Corneal astigmatism; chr4:119311875 chr4:119334329~119378233:+ LUSC cis rs801193 0.935 rs3800820 ENSG00000224316.1 RP11-479O9.2 -6.46 2.62e-10 1.4e-07 -0.27 -0.29 Aortic root size; chr7:66682191 chr7:65773620~65802067:+ LUSC cis rs7246657 0.943 rs9917081 ENSG00000276846.1 CTD-3220F14.3 6.46 2.62e-10 1.41e-07 0.44 0.29 Coronary artery calcification; chr19:37385714 chr19:37314868~37315620:- LUSC cis rs9549367 0.713 rs9577211 ENSG00000269125.1 RP11-98F14.11 -6.46 2.62e-10 1.41e-07 -0.36 -0.29 Platelet distribution width; chr13:113176404 chr13:113165002~113165183:- LUSC cis rs801193 1 rs2659912 ENSG00000224316.1 RP11-479O9.2 6.46 2.62e-10 1.41e-07 0.27 0.29 Aortic root size; chr7:66693012 chr7:65773620~65802067:+ LUSC cis rs75422866 0.51 rs73105819 ENSG00000257433.4 RP1-197B17.3 6.46 2.62e-10 1.41e-07 0.62 0.29 Pneumonia; chr12:47727190 chr12:47706085~47742294:+ LUSC cis rs11690935 0.959 rs3770451 ENSG00000228389.1 AC068039.4 6.46 2.63e-10 1.41e-07 0.33 0.29 Schizophrenia; chr2:171812205 chr2:171773482~171775844:+ LUSC cis rs8062405 0.895 rs62036658 ENSG00000278665.1 RP11-666O2.4 6.46 2.63e-10 1.41e-07 0.29 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28839050 chr16:28599241~28601881:- LUSC cis rs7246657 0.943 rs4803347 ENSG00000276846.1 CTD-3220F14.3 6.46 2.64e-10 1.41e-07 0.43 0.29 Coronary artery calcification; chr19:37357115 chr19:37314868~37315620:- LUSC cis rs6142102 0.625 rs6141436 ENSG00000275784.1 RP5-1125A11.6 -6.46 2.64e-10 1.42e-07 -0.31 -0.29 Skin pigmentation; chr20:33966765 chr20:33989480~33991818:- LUSC cis rs1823913 0.599 rs35098152 ENSG00000227542.1 AC092614.2 6.46 2.64e-10 1.42e-07 0.37 0.29 Obesity-related traits; chr2:191286658 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs35150635 ENSG00000227542.1 AC092614.2 6.46 2.64e-10 1.42e-07 0.37 0.29 Obesity-related traits; chr2:191287303 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs55786000 ENSG00000280083.1 RP11-317J9.1 -6.46 2.64e-10 1.42e-07 -0.33 -0.29 Obesity-related traits; chr2:191284500 chr2:191154118~191156070:- LUSC cis rs6952407 1 rs6952407 ENSG00000224316.1 RP11-479O9.2 -6.46 2.64e-10 1.42e-07 -0.27 -0.29 Cotinine glucuronidation; chr7:66580525 chr7:65773620~65802067:+ LUSC cis rs6142102 1 rs4911412 ENSG00000275784.1 RP5-1125A11.6 -6.46 2.65e-10 1.42e-07 -0.33 -0.29 Skin pigmentation; chr20:34128629 chr20:33989480~33991818:- LUSC cis rs853679 0.517 rs9393896 ENSG00000280107.1 AL022393.9 -6.46 2.65e-10 1.42e-07 -0.35 -0.29 Depression; chr6:28159925 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9393897 ENSG00000280107.1 AL022393.9 -6.46 2.65e-10 1.42e-07 -0.35 -0.29 Depression; chr6:28159932 chr6:28170845~28172521:+ LUSC cis rs2919917 0.614 rs10102877 ENSG00000254352.1 RP11-578O24.2 6.46 2.66e-10 1.43e-07 0.34 0.29 Lymphocyte counts; chr8:78686127 chr8:78723796~78724136:- LUSC cis rs7189233 0.955 rs11540358 ENSG00000279344.1 RP11-44F14.7 6.46 2.66e-10 1.43e-07 0.26 0.29 Intelligence (multi-trait analysis); chr16:53470031 chr16:53478957~53481550:- LUSC cis rs1012068 0.961 rs5994441 ENSG00000236132.1 CTA-440B3.1 -6.46 2.67e-10 1.43e-07 -0.39 -0.29 Chronic hepatitis C infection; chr22:31870560 chr22:31816379~31817491:- LUSC cis rs6714900 0.588 rs11675048 ENSG00000234896.1 OR7E62P -6.46 2.67e-10 1.43e-07 -0.38 -0.29 Blood protein levels; chr2:71065534 chr2:71055527~71056003:+ LUSC cis rs75920871 0.588 rs7101763 ENSG00000254851.1 RP11-109L13.1 6.46 2.67e-10 1.43e-07 0.4 0.29 Subjective well-being; chr11:117071269 chr11:117135528~117138582:+ LUSC cis rs5742933 0.857 rs2289226 ENSG00000253559.1 OSGEPL1-AS1 -6.46 2.68e-10 1.43e-07 -0.35 -0.29 Ferritin levels; chr2:189661479 chr2:189762704~189765556:+ LUSC cis rs9322193 0.923 rs9478291 ENSG00000268592.3 RAET1E-AS1 6.46 2.68e-10 1.43e-07 0.36 0.29 Lung cancer; chr6:149729434 chr6:149863494~149919507:+ LUSC cis rs67340775 0.541 rs200979 ENSG00000219392.1 RP1-265C24.5 -6.46 2.68e-10 1.44e-07 -0.45 -0.29 Lung cancer in ever smokers; chr6:27884579 chr6:28115628~28116551:+ LUSC cis rs783540 0.934 rs36109438 ENSG00000276710.3 CSPG4P8 6.46 2.68e-10 1.44e-07 0.3 0.29 Schizophrenia; chr15:82595709 chr15:82459472~82477258:+ LUSC cis rs875971 0.54 rs4717275 ENSG00000164669.11 INTS4P1 6.46 2.68e-10 1.44e-07 0.31 0.29 Aortic root size; chr7:65800193 chr7:65141225~65234216:+ LUSC cis rs6951245 1 rs75016635 ENSG00000224079.1 AC091729.7 -6.46 2.68e-10 1.44e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054485 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs113066613 ENSG00000224079.1 AC091729.7 -6.46 2.68e-10 1.44e-07 -0.5 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054492 chr7:1074450~1078036:+ LUSC cis rs11603023 0.967 rs494560 ENSG00000255239.1 AP002954.6 -6.46 2.68e-10 1.44e-07 -0.33 -0.29 Cholesterol, total; chr11:118650844 chr11:118688039~118690600:- LUSC cis rs7955901 0.725 rs11178583 ENSG00000257265.1 CTD-2021H9.1 6.46 2.68e-10 1.44e-07 0.32 0.29 Type 2 diabetes; chr12:71069764 chr12:71007773~71032083:- LUSC cis rs7955901 0.752 rs11178584 ENSG00000257265.1 CTD-2021H9.1 6.46 2.68e-10 1.44e-07 0.32 0.29 Type 2 diabetes; chr12:71070075 chr12:71007773~71032083:- LUSC cis rs13113518 0.812 rs13107810 ENSG00000272969.1 RP11-528I4.2 6.46 2.69e-10 1.44e-07 0.33 0.29 Height; chr4:55542243 chr4:55547112~55547889:+ LUSC cis rs442309 0.551 rs7083045 ENSG00000238280.1 RP11-436D10.3 -6.46 2.7e-10 1.44e-07 -0.35 -0.29 Vogt-Koyanagi-Harada syndrome; chr10:62780204 chr10:62793562~62805887:- LUSC cis rs875971 0.619 rs12533585 ENSG00000236529.1 RP13-254B10.1 6.45 2.7e-10 1.45e-07 0.29 0.29 Aortic root size; chr7:66519618 chr7:65840212~65840596:+ LUSC cis rs950169 0.887 rs12903946 ENSG00000225151.9 GOLGA2P7 -6.45 2.7e-10 1.45e-07 -0.4 -0.29 Schizophrenia; chr15:84399732 chr15:84199311~84230136:- LUSC cis rs950169 0.887 rs62029593 ENSG00000225151.9 GOLGA2P7 -6.45 2.7e-10 1.45e-07 -0.4 -0.29 Schizophrenia; chr15:84400482 chr15:84199311~84230136:- LUSC cis rs950169 0.81 rs62029594 ENSG00000225151.9 GOLGA2P7 -6.45 2.7e-10 1.45e-07 -0.4 -0.29 Schizophrenia; chr15:84400554 chr15:84199311~84230136:- LUSC cis rs950169 0.881 rs62029596 ENSG00000225151.9 GOLGA2P7 -6.45 2.7e-10 1.45e-07 -0.4 -0.29 Schizophrenia; chr15:84400736 chr15:84199311~84230136:- LUSC cis rs950169 0.881 rs4081123 ENSG00000225151.9 GOLGA2P7 -6.45 2.7e-10 1.45e-07 -0.4 -0.29 Schizophrenia; chr15:84401537 chr15:84199311~84230136:- LUSC cis rs950169 0.881 rs62029599 ENSG00000225151.9 GOLGA2P7 -6.45 2.7e-10 1.45e-07 -0.4 -0.29 Schizophrenia; chr15:84401867 chr15:84199311~84230136:- LUSC cis rs950169 0.8 rs4099846 ENSG00000225151.9 GOLGA2P7 -6.45 2.7e-10 1.45e-07 -0.4 -0.29 Schizophrenia; chr15:84402196 chr15:84199311~84230136:- LUSC cis rs875971 0.83 rs587360 ENSG00000179406.6 LINC00174 -6.45 2.7e-10 1.45e-07 -0.31 -0.29 Aortic root size; chr7:66057711 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs73142245 ENSG00000226824.5 RP4-756H11.3 -6.45 2.71e-10 1.45e-07 -0.38 -0.29 Aortic root size; chr7:66226662 chr7:66654538~66669855:+ LUSC cis rs228614 0.51 rs223463 ENSG00000230069.3 LRRC37A15P -6.45 2.71e-10 1.45e-07 -0.3 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780620 chr4:102727274~102730721:- LUSC cis rs11089937 0.616 rs11705598 ENSG00000211639.2 IGLV4-60 6.45 2.71e-10 1.45e-07 0.29 0.29 Periodontitis (PAL4Q3); chr22:22178837 chr22:22162199~22162681:+ LUSC cis rs172166 0.652 rs476167 ENSG00000219392.1 RP1-265C24.5 -6.45 2.71e-10 1.45e-07 -0.36 -0.29 Cardiac Troponin-T levels; chr6:28098110 chr6:28115628~28116551:+ LUSC cis rs801193 0.935 rs2659916 ENSG00000236529.1 RP13-254B10.1 6.45 2.71e-10 1.45e-07 0.29 0.29 Aortic root size; chr7:66686365 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs6958520 ENSG00000236529.1 RP13-254B10.1 6.45 2.71e-10 1.45e-07 0.29 0.29 Aortic root size; chr7:66686466 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs7788576 ENSG00000236529.1 RP13-254B10.1 -6.45 2.71e-10 1.45e-07 -0.29 -0.29 Aortic root size; chr7:66683315 chr7:65840212~65840596:+ LUSC cis rs11098499 0.754 rs714899 ENSG00000249244.1 RP11-548H18.2 6.45 2.72e-10 1.46e-07 0.36 0.29 Corneal astigmatism; chr4:119321880 chr4:119391831~119395335:- LUSC cis rs6142102 0.502 rs58393429 ENSG00000275784.1 RP5-1125A11.6 -6.45 2.72e-10 1.46e-07 -0.31 -0.29 Skin pigmentation; chr20:33957996 chr20:33989480~33991818:- LUSC cis rs113835537 0.502 rs7104378 ENSG00000255517.5 CTD-3074O7.5 -6.45 2.72e-10 1.46e-07 -0.33 -0.29 Airway imaging phenotypes; chr11:66449204 chr11:66473490~66480233:- LUSC cis rs13113518 0.51 rs10049561 ENSG00000273257.1 RP11-177J6.1 6.45 2.73e-10 1.46e-07 0.35 0.29 Height; chr4:55426623 chr4:55387949~55388271:+ LUSC cis rs4713118 0.629 rs149899 ENSG00000280107.1 AL022393.9 -6.45 2.73e-10 1.46e-07 -0.35 -0.29 Parkinson's disease; chr6:28052201 chr6:28170845~28172521:+ LUSC cis rs4713118 0.629 rs172165 ENSG00000280107.1 AL022393.9 -6.45 2.73e-10 1.46e-07 -0.35 -0.29 Parkinson's disease; chr6:28053036 chr6:28170845~28172521:+ LUSC cis rs4713118 0.597 rs172166 ENSG00000280107.1 AL022393.9 -6.45 2.73e-10 1.46e-07 -0.35 -0.29 Parkinson's disease; chr6:28053042 chr6:28170845~28172521:+ LUSC cis rs9549367 0.724 rs7985335 ENSG00000269125.1 RP11-98F14.11 6.45 2.73e-10 1.46e-07 0.34 0.29 Platelet distribution width; chr13:113214930 chr13:113165002~113165183:- LUSC cis rs17023223 0.537 rs2765542 ENSG00000231365.4 RP11-418J17.1 -6.45 2.74e-10 1.46e-07 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119017703 chr1:119140396~119275973:+ LUSC cis rs5742933 0.857 rs12471217 ENSG00000253559.1 OSGEPL1-AS1 6.45 2.74e-10 1.46e-07 0.34 0.29 Ferritin levels; chr2:189707337 chr2:189762704~189765556:+ LUSC cis rs9309711 0.643 rs4264589 ENSG00000225234.1 TRAPPC12-AS1 -6.45 2.75e-10 1.47e-07 -0.33 -0.29 Neurofibrillary tangles; chr2:3477327 chr2:3481242~3482409:- LUSC cis rs113835537 0.529 rs2279865 ENSG00000255517.5 CTD-3074O7.5 -6.45 2.75e-10 1.47e-07 -0.33 -0.29 Airway imaging phenotypes; chr11:66435554 chr11:66473490~66480233:- LUSC cis rs7189233 0.955 rs60420081 ENSG00000279344.1 RP11-44F14.7 6.45 2.75e-10 1.47e-07 0.25 0.29 Intelligence (multi-trait analysis); chr16:53486892 chr16:53478957~53481550:- LUSC cis rs11098499 0.863 rs6534139 ENSG00000250412.1 KLHL2P1 -6.45 2.75e-10 1.47e-07 -0.37 -0.29 Corneal astigmatism; chr4:119528301 chr4:119334329~119378233:+ LUSC cis rs7598759 0.527 rs7571691 ENSG00000181798.2 LINC00471 -6.45 2.75e-10 1.47e-07 -0.3 -0.29 Noise-induced hearing loss; chr2:231504690 chr2:231508426~231514339:- LUSC cis rs78487399 0.71 rs28470852 ENSG00000234936.1 AC010883.5 6.45 2.76e-10 1.48e-07 0.45 0.29 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43365861 chr2:43229573~43233394:+ LUSC cis rs11098499 0.604 rs2389886 ENSG00000250412.1 KLHL2P1 6.45 2.76e-10 1.48e-07 0.36 0.29 Corneal astigmatism; chr4:119649267 chr4:119334329~119378233:+ LUSC cis rs9549367 0.737 rs71446680 ENSG00000269125.1 RP11-98F14.11 -6.45 2.76e-10 1.48e-07 -0.36 -0.29 Platelet distribution width; chr13:113240532 chr13:113165002~113165183:- LUSC cis rs4950322 0.58 rs4950308 ENSG00000278811.3 LINC00624 6.45 2.76e-10 1.48e-07 0.31 0.29 Protein quantitative trait loci; chr1:147120092 chr1:147258885~147517875:- LUSC cis rs10759883 0.563 rs689738 ENSG00000175611.10 LINC00476 6.45 2.76e-10 1.48e-07 0.32 0.29 Nicotine dependence; chr9:95939738 chr9:95759231~95875977:- LUSC cis rs1823913 0.599 rs17346412 ENSG00000280083.1 RP11-317J9.1 -6.45 2.77e-10 1.48e-07 -0.33 -0.29 Obesity-related traits; chr2:191285902 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs17412239 ENSG00000280083.1 RP11-317J9.1 -6.45 2.77e-10 1.48e-07 -0.33 -0.29 Obesity-related traits; chr2:191285937 chr2:191154118~191156070:- LUSC cis rs11157436 0.918 rs1983518 ENSG00000211813.2 TRAV34 6.45 2.77e-10 1.48e-07 0.31 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22149336 chr14:22207522~22208129:+ LUSC cis rs673078 0.607 rs55929628 ENSG00000275759.1 RP11-131L12.3 -6.45 2.77e-10 1.48e-07 -0.43 -0.29 Glucose homeostasis traits; chr12:118371332 chr12:118428281~118428870:+ LUSC cis rs801193 1 rs10252765 ENSG00000224316.1 RP11-479O9.2 6.45 2.77e-10 1.48e-07 0.27 0.29 Aortic root size; chr7:66763745 chr7:65773620~65802067:+ LUSC cis rs11123170 0.64 rs931472 ENSG00000274877.1 RP11-65I12.1 6.45 2.77e-10 1.48e-07 0.38 0.29 Renal function-related traits (BUN); chr2:113212371 chr2:113237595~113240825:+ LUSC cis rs227275 0.554 rs223388 ENSG00000230069.3 LRRC37A15P -6.45 2.78e-10 1.49e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102828287 chr4:102727274~102730721:- LUSC cis rs227275 0.554 rs223386 ENSG00000230069.3 LRRC37A15P -6.45 2.78e-10 1.49e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102829111 chr4:102727274~102730721:- LUSC cis rs227275 0.554 rs223385 ENSG00000230069.3 LRRC37A15P -6.45 2.78e-10 1.49e-07 -0.3 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102829159 chr4:102727274~102730721:- LUSC cis rs875971 0.638 rs10249404 ENSG00000236529.1 RP13-254B10.1 -6.45 2.78e-10 1.49e-07 -0.29 -0.29 Aortic root size; chr7:66581737 chr7:65840212~65840596:+ LUSC cis rs35160687 0.644 rs10204589 ENSG00000273080.1 RP11-301O19.1 6.45 2.79e-10 1.49e-07 0.27 0.29 Night sleep phenotypes; chr2:86266100 chr2:86195590~86196049:+ LUSC cis rs2179367 0.632 rs12196656 ENSG00000231760.4 RP11-350J20.5 6.45 2.79e-10 1.49e-07 0.41 0.29 Dupuytren's disease; chr6:149383104 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs12211570 ENSG00000231760.4 RP11-350J20.5 6.45 2.79e-10 1.49e-07 0.41 0.29 Dupuytren's disease; chr6:149383616 chr6:149796151~149826294:- LUSC cis rs2179367 0.568 rs11155647 ENSG00000231760.4 RP11-350J20.5 6.45 2.79e-10 1.49e-07 0.41 0.29 Dupuytren's disease; chr6:149384499 chr6:149796151~149826294:- LUSC cis rs783540 0.934 rs803747 ENSG00000255769.6 GOLGA2P10 6.45 2.79e-10 1.49e-07 0.35 0.29 Schizophrenia; chr15:82589345 chr15:82472993~82513950:- LUSC cis rs875971 0.577 rs35072105 ENSG00000236529.1 RP13-254B10.1 -6.45 2.79e-10 1.49e-07 -0.3 -0.29 Aortic root size; chr7:66144830 chr7:65840212~65840596:+ LUSC cis rs881375 0.967 rs1930780 ENSG00000226752.6 PSMD5-AS1 -6.45 2.8e-10 1.49e-07 -0.33 -0.29 Rheumatoid arthritis; chr9:120923941 chr9:120824828~120854385:+ LUSC cis rs950169 0.919 rs17300292 ENSG00000259728.4 LINC00933 6.45 2.8e-10 1.5e-07 0.37 0.29 Schizophrenia; chr15:84093816 chr15:84570649~84580175:+ LUSC cis rs8177876 0.658 rs11150337 ENSG00000261838.4 RP11-303E16.6 6.45 2.8e-10 1.5e-07 0.64 0.29 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81035712 chr16:81069854~81076598:+ LUSC cis rs1075265 0.836 rs1421622 ENSG00000233266.1 HMGB1P31 -6.45 2.8e-10 1.5e-07 -0.36 -0.29 Chronotype;Morning vs. evening chronotype; chr2:54062644 chr2:54051334~54051760:+ LUSC cis rs17023223 0.537 rs2794312 ENSG00000231365.4 RP11-418J17.1 -6.45 2.8e-10 1.5e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119048423 chr1:119140396~119275973:+ LUSC cis rs17023223 0.537 rs2765532 ENSG00000231365.4 RP11-418J17.1 -6.45 2.8e-10 1.5e-07 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119048923 chr1:119140396~119275973:+ LUSC cis rs9326248 0.52 rs2735183 ENSG00000280143.1 AP000892.6 6.45 2.81e-10 1.5e-07 0.3 0.29 Blood protein levels; chr11:117144479 chr11:117204967~117210292:+ LUSC cis rs6570726 0.791 rs1509213 ENSG00000235652.6 RP11-545I5.3 -6.45 2.81e-10 1.5e-07 -0.28 -0.29 Lobe attachment (rater-scored or self-reported); chr6:145462224 chr6:145799409~145886585:+ LUSC cis rs6570726 0.967 rs439017 ENSG00000235652.6 RP11-545I5.3 6.45 2.81e-10 1.5e-07 0.28 0.29 Lobe attachment (rater-scored or self-reported); chr6:145484987 chr6:145799409~145886585:+ LUSC cis rs7246657 0.891 rs7253114 ENSG00000276846.1 CTD-3220F14.3 6.45 2.82e-10 1.5e-07 0.43 0.29 Coronary artery calcification; chr19:37497823 chr19:37314868~37315620:- LUSC cis rs11971779 0.68 rs4732370 ENSG00000273391.1 RP11-634H22.1 -6.45 2.82e-10 1.51e-07 -0.31 -0.29 Diisocyanate-induced asthma; chr7:139392494 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6978680 ENSG00000273391.1 RP11-634H22.1 -6.45 2.82e-10 1.51e-07 -0.31 -0.29 Diisocyanate-induced asthma; chr7:139427302 chr7:139359032~139359566:- LUSC cis rs442309 0.64 rs11597299 ENSG00000238280.1 RP11-436D10.3 -6.45 2.82e-10 1.51e-07 -0.35 -0.29 Vogt-Koyanagi-Harada syndrome; chr10:62706515 chr10:62793562~62805887:- LUSC cis rs442309 0.687 rs11599754 ENSG00000238280.1 RP11-436D10.3 -6.45 2.82e-10 1.51e-07 -0.35 -0.29 Vogt-Koyanagi-Harada syndrome; chr10:62706891 chr10:62793562~62805887:- LUSC cis rs1823913 0.599 rs2168166 ENSG00000227542.1 AC092614.2 6.45 2.82e-10 1.51e-07 0.36 0.29 Obesity-related traits; chr2:191288063 chr2:191229165~191246172:- LUSC cis rs2404602 0.735 rs2436994 ENSG00000259422.1 RP11-593F23.1 -6.45 2.82e-10 1.51e-07 -0.33 -0.29 Blood metabolite levels; chr15:76508722 chr15:76174891~76181486:- LUSC cis rs1823913 0.599 rs56328712 ENSG00000280083.1 RP11-317J9.1 -6.45 2.82e-10 1.51e-07 -0.34 -0.29 Obesity-related traits; chr2:191273807 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs55862924 ENSG00000280083.1 RP11-317J9.1 -6.45 2.82e-10 1.51e-07 -0.34 -0.29 Obesity-related traits; chr2:191273809 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs12989203 ENSG00000280083.1 RP11-317J9.1 -6.45 2.82e-10 1.51e-07 -0.34 -0.29 Obesity-related traits; chr2:191276617 chr2:191154118~191156070:- LUSC cis rs7772486 0.641 rs9390370 ENSG00000235652.6 RP11-545I5.3 6.45 2.82e-10 1.51e-07 0.3 0.29 Lobe attachment (rater-scored or self-reported); chr6:146036433 chr6:145799409~145886585:+ LUSC cis rs17023223 0.537 rs12081585 ENSG00000231365.4 RP11-418J17.1 -6.45 2.82e-10 1.51e-07 -0.37 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119073333 chr1:119140396~119275973:+ LUSC cis rs9322193 0.923 rs4870052 ENSG00000268592.3 RAET1E-AS1 6.45 2.82e-10 1.51e-07 0.37 0.29 Lung cancer; chr6:149839978 chr6:149863494~149919507:+ LUSC cis rs875971 0.66 rs3764903 ENSG00000236529.1 RP13-254B10.1 -6.45 2.82e-10 1.51e-07 -0.29 -0.29 Aortic root size; chr7:66633495 chr7:65840212~65840596:+ LUSC cis rs875971 0.66 rs1860470 ENSG00000236529.1 RP13-254B10.1 -6.45 2.82e-10 1.51e-07 -0.29 -0.29 Aortic root size; chr7:66638707 chr7:65840212~65840596:+ LUSC cis rs1134634 0.52 rs4280723 ENSG00000273133.1 RP11-799M12.2 6.45 2.83e-10 1.51e-07 0.37 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15574095 chr4:15563698~15564253:- LUSC cis rs8062405 0.755 rs56272201 ENSG00000278665.1 RP11-666O2.4 6.45 2.83e-10 1.51e-07 0.29 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569364 chr16:28599241~28601881:- LUSC cis rs8062405 0.755 rs62034355 ENSG00000278665.1 RP11-666O2.4 6.45 2.83e-10 1.51e-07 0.29 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569717 chr16:28599241~28601881:- LUSC cis rs1113500 0.527 rs1777482 ENSG00000226822.1 RP11-356N1.2 -6.45 2.83e-10 1.51e-07 -0.3 -0.29 Growth-regulated protein alpha levels; chr1:108068752 chr1:108071482~108074519:+ LUSC cis rs6504622 0.755 rs12942936 ENSG00000262879.4 RP11-156P1.3 -6.45 2.83e-10 1.51e-07 -0.31 -0.29 Orofacial clefts; chr17:47075062 chr17:46984045~47100323:- LUSC cis rs2337406 1 rs1961901 ENSG00000254174.1 IGHV1-12 6.45 2.83e-10 1.51e-07 0.29 0.29 Alzheimer's disease (late onset); chr14:106680856 chr14:106122420~106122709:- LUSC cis rs2337406 1 rs4774172 ENSG00000254174.1 IGHV1-12 6.45 2.83e-10 1.51e-07 0.29 0.29 Alzheimer's disease (late onset); chr14:106681320 chr14:106122420~106122709:- LUSC cis rs4853012 0.838 rs6707729 ENSG00000257800.1 FNBP1P1 6.45 2.83e-10 1.51e-07 0.33 0.29 Gestational age at birth (maternal effect); chr2:74117558 chr2:74120680~74123218:+ LUSC cis rs228614 0.543 rs223330 ENSG00000230069.3 LRRC37A15P -6.45 2.84e-10 1.51e-07 -0.3 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102872502 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223329 ENSG00000230069.3 LRRC37A15P -6.45 2.84e-10 1.51e-07 -0.3 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873031 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223324 ENSG00000230069.3 LRRC37A15P -6.45 2.84e-10 1.51e-07 -0.3 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102876177 chr4:102727274~102730721:- LUSC cis rs67180937 0.882 rs17163345 ENSG00000272750.1 RP11-378J18.8 -6.45 2.85e-10 1.52e-07 -0.31 -0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222632876 chr1:222658867~222661512:- LUSC cis rs13113518 0.557 rs13142096 ENSG00000249700.7 SRD5A3-AS1 6.45 2.85e-10 1.52e-07 0.35 0.29 Height; chr4:55566291 chr4:55363971~55395847:- LUSC cis rs10829156 0.679 rs4747352 ENSG00000240291.1 RP11-499P20.2 6.45 2.85e-10 1.52e-07 0.31 0.29 Sudden cardiac arrest; chr10:18539734 chr10:18513115~18545651:- LUSC cis rs1134634 0.52 rs11943107 ENSG00000273133.1 RP11-799M12.2 -6.45 2.85e-10 1.52e-07 -0.37 -0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15573042 chr4:15563698~15564253:- LUSC cis rs783540 0.967 rs783529 ENSG00000276710.3 CSPG4P8 6.45 2.85e-10 1.52e-07 0.3 0.28 Schizophrenia; chr15:82599231 chr15:82459472~82477258:+ LUSC cis rs2179367 0.632 rs6920383 ENSG00000231760.4 RP11-350J20.5 6.45 2.86e-10 1.53e-07 0.41 0.28 Dupuytren's disease; chr6:149356361 chr6:149796151~149826294:- LUSC cis rs9309473 1 rs7585004 ENSG00000163016.8 ALMS1P 6.45 2.86e-10 1.53e-07 0.35 0.28 Metabolite levels; chr2:73439517 chr2:73644919~73685576:+ LUSC cis rs10829156 0.945 rs8181345 ENSG00000240291.1 RP11-499P20.2 6.44 2.88e-10 1.53e-07 0.32 0.28 Sudden cardiac arrest; chr10:18678689 chr10:18513115~18545651:- LUSC cis rs7246657 0.943 rs7255785 ENSG00000276846.1 CTD-3220F14.3 6.44 2.88e-10 1.54e-07 0.44 0.28 Coronary artery calcification; chr19:37480781 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs7255996 ENSG00000276846.1 CTD-3220F14.3 6.44 2.88e-10 1.54e-07 0.44 0.28 Coronary artery calcification; chr19:37480797 chr19:37314868~37315620:- LUSC cis rs1823913 0.599 rs34100174 ENSG00000280083.1 RP11-317J9.1 -6.44 2.88e-10 1.54e-07 -0.33 -0.28 Obesity-related traits; chr2:191283579 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs34262638 ENSG00000280083.1 RP11-317J9.1 -6.44 2.88e-10 1.54e-07 -0.33 -0.28 Obesity-related traits; chr2:191279442 chr2:191154118~191156070:- LUSC cis rs35160687 0.901 rs7571424 ENSG00000273080.1 RP11-301O19.1 6.44 2.88e-10 1.54e-07 0.27 0.28 Night sleep phenotypes; chr2:86312037 chr2:86195590~86196049:+ LUSC cis rs875971 0.965 rs7794930 ENSG00000237310.1 GS1-124K5.4 -6.44 2.89e-10 1.54e-07 -0.3 -0.28 Aortic root size; chr7:66313559 chr7:66493706~66495474:+ LUSC cis rs2404602 0.662 rs908817 ENSG00000259422.1 RP11-593F23.1 -6.44 2.89e-10 1.54e-07 -0.33 -0.28 Blood metabolite levels; chr15:76346850 chr15:76174891~76181486:- LUSC cis rs8005677 0.611 rs11624528 ENSG00000279656.1 RP11-298I3.6 6.44 2.89e-10 1.54e-07 0.33 0.28 Cognitive ability (multi-trait analysis); chr14:22989947 chr14:23023083~23024217:- LUSC cis rs1075265 0.749 rs805379 ENSG00000233266.1 HMGB1P31 6.44 2.89e-10 1.54e-07 0.36 0.28 Chronotype;Morning vs. evening chronotype; chr2:53865847 chr2:54051334~54051760:+ LUSC cis rs950169 0.58 rs11634322 ENSG00000259728.4 LINC00933 6.44 2.89e-10 1.54e-07 0.37 0.28 Schizophrenia; chr15:84628978 chr15:84570649~84580175:+ LUSC cis rs8031584 0.678 rs3122 ENSG00000260382.1 RP11-540B6.2 -6.44 2.89e-10 1.54e-07 -0.39 -0.28 Huntington's disease progression; chr15:30878087 chr15:30882267~30883231:- LUSC cis rs6142102 0.602 rs11696338 ENSG00000275784.1 RP5-1125A11.6 -6.44 2.9e-10 1.55e-07 -0.31 -0.28 Skin pigmentation; chr20:34099805 chr20:33989480~33991818:- LUSC cis rs2903698 0.539 rs6858804 ENSG00000250735.4 RP11-567N4.3 6.44 2.9e-10 1.55e-07 0.32 0.28 Prion diseases; chr4:75433604 chr4:75401195~75423023:+ LUSC cis rs6570726 0.902 rs973855 ENSG00000235652.6 RP11-545I5.3 -6.44 2.91e-10 1.55e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145460714 chr6:145799409~145886585:+ LUSC cis rs7267979 0.966 rs2151144 ENSG00000274973.1 RP13-401N8.7 6.44 2.91e-10 1.55e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25434288 chr20:25845497~25845862:+ LUSC cis rs8062405 0.723 rs762633 ENSG00000278665.1 RP11-666O2.4 6.44 2.91e-10 1.55e-07 0.29 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597020 chr16:28599241~28601881:- LUSC cis rs1134634 0.52 rs741180 ENSG00000273133.1 RP11-799M12.2 -6.44 2.91e-10 1.55e-07 -0.38 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15561787 chr4:15563698~15564253:- LUSC cis rs7772486 0.641 rs67882056 ENSG00000235652.6 RP11-545I5.3 6.44 2.92e-10 1.55e-07 0.3 0.28 Lobe attachment (rater-scored or self-reported); chr6:146095165 chr6:145799409~145886585:+ LUSC cis rs4713118 0.621 rs9368548 ENSG00000280107.1 AL022393.9 -6.44 2.92e-10 1.55e-07 -0.36 -0.28 Parkinson's disease; chr6:28066959 chr6:28170845~28172521:+ LUSC cis rs11089937 0.522 rs2005239 ENSG00000211639.2 IGLV4-60 6.44 2.93e-10 1.56e-07 0.29 0.28 Periodontitis (PAL4Q3); chr22:22178083 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs743520 ENSG00000211639.2 IGLV4-60 6.44 2.93e-10 1.56e-07 0.29 0.28 Periodontitis (PAL4Q3); chr22:22178249 chr22:22162199~22162681:+ LUSC cis rs9549367 0.789 rs34989271 ENSG00000269125.1 RP11-98F14.11 -6.44 2.93e-10 1.56e-07 -0.35 -0.28 Platelet distribution width; chr13:113240452 chr13:113165002~113165183:- LUSC cis rs7267979 1 rs2387881 ENSG00000274973.1 RP13-401N8.7 6.44 2.94e-10 1.57e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25397536 chr20:25845497~25845862:+ LUSC cis rs6951245 0.882 rs11764817 ENSG00000224079.1 AC091729.7 -6.44 2.95e-10 1.57e-07 -0.44 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1024974 chr7:1074450~1078036:+ LUSC cis rs6921919 0.583 rs9468355 ENSG00000204709.4 LINC01556 6.44 2.95e-10 1.57e-07 0.37 0.28 Autism spectrum disorder or schizophrenia; chr6:28374100 chr6:28943877~28944537:+ LUSC cis rs7772486 0.72 rs4896837 ENSG00000235652.6 RP11-545I5.3 -6.44 2.95e-10 1.57e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145693032 chr6:145799409~145886585:+ LUSC cis rs12291225 0.585 rs10832242 ENSG00000251991.1 RNU7-49P -6.44 2.95e-10 1.57e-07 -0.32 -0.28 Sense of smell; chr11:14318958 chr11:14478892~14478953:+ LUSC cis rs13113518 0.812 rs7667741 ENSG00000272969.1 RP11-528I4.2 6.44 2.96e-10 1.57e-07 0.33 0.28 Height; chr4:55544621 chr4:55547112~55547889:+ LUSC cis rs34375054 0.66 rs900411 ENSG00000279233.1 RP11-158L12.4 6.44 2.97e-10 1.58e-07 0.27 0.28 Post bronchodilator FEV1/FVC ratio; chr12:125128293 chr12:125138245~125141711:+ LUSC cis rs113835537 0.529 rs17065 ENSG00000255517.5 CTD-3074O7.5 -6.44 2.97e-10 1.58e-07 -0.34 -0.28 Airway imaging phenotypes; chr11:66509564 chr11:66473490~66480233:- LUSC cis rs950169 0.919 rs12915589 ENSG00000259728.4 LINC00933 6.44 2.97e-10 1.58e-07 0.37 0.28 Schizophrenia; chr15:84065712 chr15:84570649~84580175:+ LUSC cis rs950169 0.959 rs66801143 ENSG00000259728.4 LINC00933 6.44 2.97e-10 1.58e-07 0.37 0.28 Schizophrenia; chr15:84067905 chr15:84570649~84580175:+ LUSC cis rs950169 1 rs35648189 ENSG00000259728.4 LINC00933 6.44 2.97e-10 1.58e-07 0.37 0.28 Schizophrenia; chr15:84071996 chr15:84570649~84580175:+ LUSC cis rs950169 0.92 rs17300048 ENSG00000259728.4 LINC00933 6.44 2.97e-10 1.58e-07 0.37 0.28 Schizophrenia; chr15:84080725 chr15:84570649~84580175:+ LUSC cis rs950169 1 rs1848093 ENSG00000259728.4 LINC00933 6.44 2.97e-10 1.58e-07 0.37 0.28 Schizophrenia; chr15:84086775 chr15:84570649~84580175:+ LUSC cis rs950169 1 rs12915234 ENSG00000259728.4 LINC00933 6.44 2.97e-10 1.58e-07 0.37 0.28 Schizophrenia; chr15:84089549 chr15:84570649~84580175:+ LUSC cis rs950169 1 rs34751999 ENSG00000259728.4 LINC00933 6.44 2.97e-10 1.58e-07 0.37 0.28 Schizophrenia; chr15:84089667 chr15:84570649~84580175:+ LUSC cis rs6570726 0.791 rs407887 ENSG00000235652.6 RP11-545I5.3 6.44 2.97e-10 1.58e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145522623 chr6:145799409~145886585:+ LUSC cis rs6570726 0.764 rs451108 ENSG00000235652.6 RP11-545I5.3 6.44 2.97e-10 1.58e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145523173 chr6:145799409~145886585:+ LUSC cis rs1823913 0.637 rs13382985 ENSG00000280083.1 RP11-317J9.1 6.44 2.97e-10 1.58e-07 0.32 0.28 Obesity-related traits; chr2:191306335 chr2:191154118~191156070:- LUSC cis rs9921338 0.923 rs4563054 ENSG00000263080.1 RP11-485G7.5 6.44 2.98e-10 1.58e-07 0.35 0.28 Vein graft stenosis in coronary artery bypass grafting; chr16:11353689 chr16:11341809~11345211:- LUSC cis rs1075265 0.935 rs6545384 ENSG00000233266.1 HMGB1P31 6.44 2.98e-10 1.59e-07 0.37 0.28 Chronotype;Morning vs. evening chronotype; chr2:54073927 chr2:54051334~54051760:+ LUSC cis rs113835537 0.529 rs60358007 ENSG00000255517.5 CTD-3074O7.5 -6.44 2.98e-10 1.59e-07 -0.34 -0.28 Airway imaging phenotypes; chr11:66454882 chr11:66473490~66480233:- LUSC cis rs875971 0.545 rs316316 ENSG00000226824.5 RP4-756H11.3 6.44 2.98e-10 1.59e-07 0.37 0.28 Aortic root size; chr7:66149270 chr7:66654538~66669855:+ LUSC cis rs10246939 0.544 rs6955562 ENSG00000228775.6 WEE2-AS1 6.44 2.98e-10 1.59e-07 0.35 0.28 Bitter taste perception; chr7:141886641 chr7:141704338~141738346:- LUSC cis rs227275 0.525 rs28445579 ENSG00000230069.3 LRRC37A15P -6.44 2.99e-10 1.59e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103016438 chr4:102727274~102730721:- LUSC cis rs6570726 1 rs436066 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.59e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145525991 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs447992 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145496048 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs425999 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145498234 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs387376 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145501429 chr6:145799409~145886585:+ LUSC cis rs6570726 0.764 rs1912023 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145503142 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs9376945 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145506944 chr6:145799409~145886585:+ LUSC cis rs6570726 0.755 rs451699 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145509458 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs401561 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145514781 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs405206 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145515737 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs374478 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145518886 chr6:145799409~145886585:+ LUSC cis rs6570726 1 rs441477 ENSG00000235652.6 RP11-545I5.3 6.44 3e-10 1.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145527107 chr6:145799409~145886585:+ LUSC cis rs17818399 0.548 rs1989720 ENSG00000279254.1 RP11-536C12.1 -6.44 3e-10 1.6e-07 -0.31 -0.28 Height; chr2:46627225 chr2:46668870~46670778:+ LUSC cis rs30380 0.922 rs246453 ENSG00000248734.2 CTD-2260A17.1 6.44 3.01e-10 1.6e-07 0.27 0.28 Cerebrospinal fluid biomarker levels; chr5:96787633 chr5:96784777~96785999:+ LUSC cis rs6570726 0.967 rs9403706 ENSG00000235652.6 RP11-545I5.3 -6.44 3.01e-10 1.6e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145474051 chr6:145799409~145886585:+ LUSC cis rs5753618 0.583 rs7293171 ENSG00000236132.1 CTA-440B3.1 -6.44 3.01e-10 1.6e-07 -0.39 -0.28 Colorectal cancer; chr22:31406338 chr22:31816379~31817491:- LUSC cis rs1823913 0.599 rs6732976 ENSG00000280083.1 RP11-317J9.1 6.44 3.02e-10 1.6e-07 0.33 0.28 Obesity-related traits; chr2:191281004 chr2:191154118~191156070:- LUSC cis rs5753618 0.607 rs5753621 ENSG00000236132.1 CTA-440B3.1 -6.44 3.02e-10 1.6e-07 -0.39 -0.28 Colorectal cancer; chr22:31451661 chr22:31816379~31817491:- LUSC cis rs2834288 0.959 rs2834294 ENSG00000237945.6 LINC00649 -6.44 3.02e-10 1.61e-07 -0.3 -0.28 Gut microbiota (bacterial taxa); chr21:33908326 chr21:33915534~33977691:+ LUSC cis rs853679 0.556 rs34588114 ENSG00000204709.4 LINC01556 6.44 3.02e-10 1.61e-07 0.62 0.28 Depression; chr6:28112850 chr6:28943877~28944537:+ LUSC cis rs5753618 0.554 rs5753648 ENSG00000236132.1 CTA-440B3.1 -6.44 3.02e-10 1.61e-07 -0.4 -0.28 Colorectal cancer; chr22:31483479 chr22:31816379~31817491:- LUSC cis rs13423976 0.631 rs7582463 ENSG00000231367.4 AC016995.3 -6.44 3.03e-10 1.61e-07 -0.36 -0.28 Gut microbiome composition (summer); chr2:38511226 chr2:38406719~38515740:- LUSC cis rs66486766 1 rs66486766 ENSG00000225151.9 GOLGA2P7 -6.44 3.03e-10 1.61e-07 -0.41 -0.28 Bipolar disorder lithium response (categorical) or schizophrenia; chr15:84137308 chr15:84199311~84230136:- LUSC cis rs394563 0.967 rs438852 ENSG00000231760.4 RP11-350J20.5 -6.44 3.05e-10 1.62e-07 -0.35 -0.28 Dupuytren's disease; chr6:149473397 chr6:149796151~149826294:- LUSC cis rs2276314 0.857 rs7237599 ENSG00000278986.1 RP11-723J4.3 -6.43 3.05e-10 1.62e-07 -0.34 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36059433 chr18:35972151~35973916:+ LUSC cis rs1075232 1 rs56396205 ENSG00000270055.1 CTD-3092A11.2 -6.43 3.05e-10 1.62e-07 -0.59 -0.28 Survival in colorectal cancer (non-distant metastatic); chr15:31386182 chr15:30487963~30490313:+ LUSC cis rs1075232 1 rs12438318 ENSG00000270055.1 CTD-3092A11.2 -6.43 3.05e-10 1.62e-07 -0.59 -0.28 Survival in colorectal cancer (non-distant metastatic); chr15:31388242 chr15:30487963~30490313:+ LUSC cis rs801193 0.66 rs4610622 ENSG00000237310.1 GS1-124K5.4 6.43 3.05e-10 1.62e-07 0.3 0.28 Aortic root size; chr7:66759510 chr7:66493706~66495474:+ LUSC cis rs7267979 1 rs6115153 ENSG00000274973.1 RP13-401N8.7 6.43 3.05e-10 1.62e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25344931 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs7268053 ENSG00000274973.1 RP13-401N8.7 6.43 3.05e-10 1.62e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25347650 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6083809 ENSG00000274973.1 RP13-401N8.7 6.43 3.05e-10 1.62e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25348673 chr20:25845497~25845862:+ LUSC cis rs8062405 0.755 rs4149398 ENSG00000278665.1 RP11-666O2.4 6.43 3.06e-10 1.62e-07 0.29 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597617 chr16:28599241~28601881:- LUSC cis rs4604732 0.588 rs12045675 ENSG00000227135.1 GCSAML-AS1 -6.43 3.06e-10 1.62e-07 -0.43 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247460613 chr1:247524679~247526752:- LUSC cis rs4604732 0.527 rs12031949 ENSG00000227135.1 GCSAML-AS1 -6.43 3.06e-10 1.62e-07 -0.43 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461161 chr1:247524679~247526752:- LUSC cis rs172166 0.611 rs203883 ENSG00000216901.1 AL022393.7 6.43 3.06e-10 1.62e-07 0.34 0.28 Cardiac Troponin-T levels; chr6:28110578 chr6:28176188~28176674:+ LUSC cis rs172166 0.611 rs203882 ENSG00000216901.1 AL022393.7 6.43 3.06e-10 1.62e-07 0.34 0.28 Cardiac Troponin-T levels; chr6:28110724 chr6:28176188~28176674:+ LUSC cis rs172166 0.694 rs1770131 ENSG00000216901.1 AL022393.7 6.43 3.06e-10 1.62e-07 0.34 0.28 Cardiac Troponin-T levels; chr6:28118635 chr6:28176188~28176674:+ LUSC cis rs13113518 0.729 rs12641881 ENSG00000273257.1 RP11-177J6.1 6.43 3.06e-10 1.62e-07 0.4 0.28 Height; chr4:55401306 chr4:55387949~55388271:+ LUSC cis rs4853012 0.838 rs60964317 ENSG00000257800.1 FNBP1P1 6.43 3.06e-10 1.62e-07 0.33 0.28 Gestational age at birth (maternal effect); chr2:74116296 chr2:74120680~74123218:+ LUSC cis rs2280018 1 rs2280017 ENSG00000260735.1 RP11-72I8.1 6.43 3.06e-10 1.63e-07 0.32 0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15057504 chr16:15094411~15109197:+ LUSC cis rs875971 0.545 rs1796219 ENSG00000226824.5 RP4-756H11.3 6.43 3.06e-10 1.63e-07 0.38 0.28 Aortic root size; chr7:66645977 chr7:66654538~66669855:+ LUSC cis rs35955747 0.749 rs2027982 ENSG00000236132.1 CTA-440B3.1 6.43 3.06e-10 1.63e-07 0.35 0.28 Neutrophil count;Sum basophil neutrophil counts; chr22:31197449 chr22:31816379~31817491:- LUSC cis rs957448 1 rs72674861 ENSG00000253175.1 RP11-267M23.6 6.43 3.06e-10 1.63e-07 0.33 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94550051 chr8:94565036~94565715:+ LUSC cis rs4853012 0.838 rs60705299 ENSG00000257800.1 FNBP1P1 6.43 3.07e-10 1.63e-07 0.33 0.28 Gestational age at birth (maternal effect); chr2:74118243 chr2:74120680~74123218:+ LUSC cis rs9309473 0.66 rs17349321 ENSG00000163016.8 ALMS1P 6.43 3.07e-10 1.63e-07 0.41 0.28 Metabolite levels; chr2:73416625 chr2:73644919~73685576:+ LUSC cis rs10246939 0.505 rs34726057 ENSG00000228775.6 WEE2-AS1 6.43 3.07e-10 1.63e-07 0.36 0.28 Bitter taste perception; chr7:141832117 chr7:141704338~141738346:- LUSC cis rs113835537 0.529 rs17580784 ENSG00000255517.5 CTD-3074O7.5 -6.43 3.08e-10 1.63e-07 -0.34 -0.28 Airway imaging phenotypes; chr11:66447388 chr11:66473490~66480233:- LUSC cis rs11089937 0.597 rs5757007 ENSG00000211638.2 IGLV8-61 -6.43 3.08e-10 1.63e-07 -0.3 -0.28 Periodontitis (PAL4Q3); chr22:22135167 chr22:22098700~22099212:+ LUSC cis rs2179367 0.632 rs12197598 ENSG00000231760.4 RP11-350J20.5 6.43 3.09e-10 1.64e-07 0.41 0.28 Dupuytren's disease; chr6:149385418 chr6:149796151~149826294:- LUSC cis rs1075265 0.589 rs2253760 ENSG00000233266.1 HMGB1P31 6.43 3.09e-10 1.64e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:53806851 chr2:54051334~54051760:+ LUSC cis rs10246939 0.505 rs10952508 ENSG00000228775.6 WEE2-AS1 6.43 3.09e-10 1.64e-07 0.36 0.28 Bitter taste perception; chr7:141879415 chr7:141704338~141738346:- LUSC cis rs11971779 0.666 rs6467847 ENSG00000273391.1 RP11-634H22.1 6.43 3.09e-10 1.64e-07 0.32 0.28 Diisocyanate-induced asthma; chr7:139394690 chr7:139359032~139359566:- LUSC cis rs875971 0.638 rs10249404 ENSG00000224316.1 RP11-479O9.2 -6.43 3.09e-10 1.64e-07 -0.27 -0.28 Aortic root size; chr7:66581737 chr7:65773620~65802067:+ LUSC cis rs11089937 0.616 rs4991798 ENSG00000211639.2 IGLV4-60 6.43 3.1e-10 1.64e-07 0.3 0.28 Periodontitis (PAL4Q3); chr22:22178915 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs4991799 ENSG00000211639.2 IGLV4-60 6.43 3.1e-10 1.64e-07 0.3 0.28 Periodontitis (PAL4Q3); chr22:22178938 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs4991800 ENSG00000211639.2 IGLV4-60 6.43 3.1e-10 1.64e-07 0.3 0.28 Periodontitis (PAL4Q3); chr22:22178942 chr22:22162199~22162681:+ LUSC cis rs932287 0.505 rs2742536 ENSG00000254860.4 TMEM9B-AS1 6.43 3.1e-10 1.64e-07 0.31 0.28 Colonoscopy-negative controls vs population controls; chr11:8888269 chr11:8964675~8977527:+ LUSC cis rs881375 0.967 rs7034653 ENSG00000226752.6 PSMD5-AS1 -6.43 3.1e-10 1.64e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120925094 chr9:120824828~120854385:+ LUSC cis rs7267979 1 rs6050631 ENSG00000274973.1 RP13-401N8.7 -6.43 3.1e-10 1.65e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25451113 chr20:25845497~25845862:+ LUSC cis rs881375 0.692 rs2072438 ENSG00000226752.6 PSMD5-AS1 -6.43 3.1e-10 1.65e-07 -0.31 -0.28 Rheumatoid arthritis; chr9:120889023 chr9:120824828~120854385:+ LUSC cis rs638893 0.588 rs529717 ENSG00000278376.1 RP11-158I9.8 -6.43 3.11e-10 1.65e-07 -0.38 -0.28 Vitiligo; chr11:118769372 chr11:118791254~118793137:+ LUSC cis rs638893 0.588 rs2508929 ENSG00000278376.1 RP11-158I9.8 -6.43 3.11e-10 1.65e-07 -0.38 -0.28 Vitiligo; chr11:118770742 chr11:118791254~118793137:+ LUSC cis rs638893 0.636 rs548167 ENSG00000278376.1 RP11-158I9.8 -6.43 3.11e-10 1.65e-07 -0.38 -0.28 Vitiligo; chr11:118777687 chr11:118791254~118793137:+ LUSC cis rs7772486 0.641 rs2748489 ENSG00000235652.6 RP11-545I5.3 6.43 3.11e-10 1.65e-07 0.3 0.28 Lobe attachment (rater-scored or self-reported); chr6:146010151 chr6:145799409~145886585:+ LUSC cis rs801193 0.967 rs2707849 ENSG00000224316.1 RP11-479O9.2 6.43 3.11e-10 1.65e-07 0.27 0.28 Aortic root size; chr7:66687725 chr7:65773620~65802067:+ LUSC cis rs801193 0.967 rs2707841 ENSG00000224316.1 RP11-479O9.2 6.43 3.11e-10 1.65e-07 0.27 0.28 Aortic root size; chr7:66692033 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs4717310 ENSG00000224316.1 RP11-479O9.2 6.43 3.11e-10 1.65e-07 0.27 0.28 Aortic root size; chr7:66696020 chr7:65773620~65802067:+ LUSC cis rs801193 0.844 rs7779971 ENSG00000224316.1 RP11-479O9.2 6.43 3.11e-10 1.65e-07 0.27 0.28 Aortic root size; chr7:66696803 chr7:65773620~65802067:+ LUSC cis rs8062405 0.723 rs62031562 ENSG00000278665.1 RP11-666O2.4 6.43 3.11e-10 1.65e-07 0.29 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28598008 chr16:28599241~28601881:- LUSC cis rs7267979 0.966 rs6050611 ENSG00000274973.1 RP13-401N8.7 -6.43 3.11e-10 1.65e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25433783 chr20:25845497~25845862:+ LUSC cis rs7267979 0.932 rs446649 ENSG00000274973.1 RP13-401N8.7 -6.43 3.12e-10 1.65e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25486723 chr20:25845497~25845862:+ LUSC cis rs8040855 0.547 rs17611171 ENSG00000259295.5 CSPG4P12 6.43 3.12e-10 1.65e-07 0.37 0.28 Bulimia nervosa; chr15:85029468 chr15:85191438~85213905:+ LUSC cis rs8040855 0.575 rs12912860 ENSG00000259295.5 CSPG4P12 6.43 3.12e-10 1.65e-07 0.37 0.28 Bulimia nervosa; chr15:85030267 chr15:85191438~85213905:+ LUSC cis rs6964833 0.554 rs112506907 ENSG00000123965.13 PMS2P5 6.43 3.12e-10 1.65e-07 0.41 0.28 Menarche (age at onset); chr7:74654407 chr7:74894116~74897835:+ LUSC cis rs7772486 0.686 rs1337841 ENSG00000235652.6 RP11-545I5.3 -6.43 3.12e-10 1.65e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145738351 chr6:145799409~145886585:+ LUSC cis rs7955901 0.638 rs3763978 ENSG00000257265.1 CTD-2021H9.1 6.43 3.13e-10 1.66e-07 0.32 0.28 Type 2 diabetes; chr12:71139754 chr12:71007773~71032083:- LUSC cis rs881375 0.715 rs10818482 ENSG00000226752.6 PSMD5-AS1 6.43 3.13e-10 1.66e-07 0.32 0.28 Rheumatoid arthritis; chr9:120885807 chr9:120824828~120854385:+ LUSC cis rs783540 0.967 rs1259183 ENSG00000255769.6 GOLGA2P10 6.43 3.13e-10 1.66e-07 0.35 0.28 Schizophrenia; chr15:82610683 chr15:82472993~82513950:- LUSC cis rs8072100 0.967 rs11079784 ENSG00000228782.6 CTD-2026D20.3 -6.43 3.13e-10 1.66e-07 -0.27 -0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47624914 chr17:47450568~47492492:- LUSC cis rs2276314 0.857 rs28540805 ENSG00000278986.1 RP11-723J4.3 -6.43 3.13e-10 1.66e-07 -0.36 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36062012 chr18:35972151~35973916:+ LUSC cis rs7772486 0.719 rs702317 ENSG00000235652.6 RP11-545I5.3 -6.43 3.14e-10 1.66e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145683874 chr6:145799409~145886585:+ LUSC cis rs7772486 0.72 rs702320 ENSG00000235652.6 RP11-545I5.3 -6.43 3.14e-10 1.66e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145685518 chr6:145799409~145886585:+ LUSC cis rs8177876 0.658 rs889516 ENSG00000261838.4 RP11-303E16.6 -6.43 3.14e-10 1.66e-07 -0.62 -0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81034943 chr16:81069854~81076598:+ LUSC cis rs4853012 0.941 rs60291089 ENSG00000257800.1 FNBP1P1 6.43 3.14e-10 1.67e-07 0.33 0.28 Gestational age at birth (maternal effect); chr2:74117763 chr2:74120680~74123218:+ LUSC cis rs4853012 0.838 rs58759652 ENSG00000257800.1 FNBP1P1 6.43 3.14e-10 1.67e-07 0.33 0.28 Gestational age at birth (maternal effect); chr2:74117775 chr2:74120680~74123218:+ LUSC cis rs7772486 0.686 rs4895684 ENSG00000235652.6 RP11-545I5.3 -6.43 3.15e-10 1.67e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145792887 chr6:145799409~145886585:+ LUSC cis rs673078 0.607 rs17441214 ENSG00000275759.1 RP11-131L12.3 -6.43 3.15e-10 1.67e-07 -0.43 -0.28 Glucose homeostasis traits; chr12:118436721 chr12:118428281~118428870:+ LUSC cis rs17023223 0.537 rs12086549 ENSG00000231365.4 RP11-418J17.1 6.43 3.15e-10 1.67e-07 0.37 0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119071714 chr1:119140396~119275973:+ LUSC cis rs6772849 0.83 rs4857917 ENSG00000242551.2 POU5F1P6 -6.43 3.15e-10 1.67e-07 -0.32 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128657335 chr3:128674735~128677005:- LUSC cis rs227275 0.554 rs223399 ENSG00000230069.3 LRRC37A15P -6.43 3.15e-10 1.67e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102820800 chr4:102727274~102730721:- LUSC cis rs7567389 0.704 rs4662714 ENSG00000236682.1 AC068282.3 6.43 3.15e-10 1.67e-07 0.39 0.28 Self-rated health; chr2:127237637 chr2:127389130~127400580:+ LUSC cis rs904251 0.686 rs1224128 ENSG00000204110.6 RP1-153P14.8 -6.43 3.15e-10 1.67e-07 -0.31 -0.28 Cognitive performance; chr6:37447900 chr6:37507348~37535616:+ LUSC cis rs62432291 0.681 rs445957 ENSG00000235086.1 FNDC1-IT1 -6.43 3.15e-10 1.67e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159241032 chr6:159240786~159243329:+ LUSC cis rs875971 0.66 rs13224319 ENSG00000224316.1 RP11-479O9.2 6.43 3.15e-10 1.67e-07 0.27 0.28 Aortic root size; chr7:66542376 chr7:65773620~65802067:+ LUSC cis rs875971 0.66 rs801217 ENSG00000224316.1 RP11-479O9.2 -6.43 3.15e-10 1.67e-07 -0.27 -0.28 Aortic root size; chr7:66545590 chr7:65773620~65802067:+ LUSC cis rs875971 0.638 rs801216 ENSG00000224316.1 RP11-479O9.2 -6.43 3.15e-10 1.67e-07 -0.27 -0.28 Aortic root size; chr7:66546680 chr7:65773620~65802067:+ LUSC cis rs227275 0.554 rs223409 ENSG00000230069.3 LRRC37A15P -6.43 3.16e-10 1.67e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102815023 chr4:102727274~102730721:- LUSC cis rs11098499 0.82 rs2389885 ENSG00000248280.1 RP11-33B1.2 6.43 3.16e-10 1.68e-07 0.35 0.28 Corneal astigmatism; chr4:119612776 chr4:119440561~119450157:- LUSC cis rs950169 0.959 rs12902070 ENSG00000225151.9 GOLGA2P7 -6.43 3.17e-10 1.68e-07 -0.4 -0.28 Schizophrenia; chr15:84124806 chr15:84199311~84230136:- LUSC cis rs7580658 0.637 rs9636235 ENSG00000236682.1 AC068282.3 -6.43 3.17e-10 1.68e-07 -0.38 -0.28 Protein C levels; chr2:127223975 chr2:127389130~127400580:+ LUSC cis rs875971 0.66 rs3764903 ENSG00000224316.1 RP11-479O9.2 -6.43 3.18e-10 1.68e-07 -0.27 -0.28 Aortic root size; chr7:66633495 chr7:65773620~65802067:+ LUSC cis rs875971 0.66 rs1860470 ENSG00000224316.1 RP11-479O9.2 -6.43 3.18e-10 1.68e-07 -0.27 -0.28 Aortic root size; chr7:66638707 chr7:65773620~65802067:+ LUSC cis rs4604732 0.536 rs4433437 ENSG00000227135.1 GCSAML-AS1 -6.43 3.18e-10 1.68e-07 -0.43 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247473278 chr1:247524679~247526752:- LUSC cis rs9928842 0.823 rs2870472 ENSG00000280152.1 RP11-331F4.5 6.43 3.18e-10 1.68e-07 0.33 0.28 Alcoholic chronic pancreatitis; chr16:75244943 chr16:75245994~75250077:- LUSC cis rs783540 0.934 rs783530 ENSG00000255769.6 GOLGA2P10 6.43 3.19e-10 1.69e-07 0.35 0.28 Schizophrenia; chr15:82597799 chr15:82472993~82513950:- LUSC cis rs2337406 1 rs17095456 ENSG00000254174.1 IGHV1-12 6.43 3.19e-10 1.69e-07 0.29 0.28 Alzheimer's disease (late onset); chr14:106676559 chr14:106122420~106122709:- LUSC cis rs9921338 0.886 rs3931015 ENSG00000263080.1 RP11-485G7.5 -6.43 3.19e-10 1.69e-07 -0.34 -0.28 Vein graft stenosis in coronary artery bypass grafting; chr16:11321782 chr16:11341809~11345211:- LUSC cis rs2239557 1 rs7157566 ENSG00000259065.1 RP5-1021I20.1 6.43 3.19e-10 1.69e-07 0.34 0.28 Common traits (Other); chr14:74182426 chr14:73787360~73803270:+ LUSC cis rs67340775 0.541 rs200975 ENSG00000219392.1 RP1-265C24.5 -6.43 3.2e-10 1.69e-07 -0.45 -0.28 Lung cancer in ever smokers; chr6:27887847 chr6:28115628~28116551:+ LUSC cis rs67340775 0.541 rs200974 ENSG00000219392.1 RP1-265C24.5 -6.43 3.2e-10 1.69e-07 -0.45 -0.28 Lung cancer in ever smokers; chr6:27888067 chr6:28115628~28116551:+ LUSC cis rs7250849 0.529 rs16982912 ENSG00000273837.1 LLNLR-470E3.1 -6.43 3.2e-10 1.69e-07 -0.35 -0.28 Blood protein levels; chr19:51661874 chr19:51639478~51639931:- LUSC cis rs4713118 0.662 rs156744 ENSG00000280107.1 AL022393.9 -6.43 3.2e-10 1.69e-07 -0.35 -0.28 Parkinson's disease; chr6:27999496 chr6:28170845~28172521:+ LUSC cis rs2404602 0.647 rs4886840 ENSG00000259422.1 RP11-593F23.1 -6.43 3.2e-10 1.69e-07 -0.33 -0.28 Blood metabolite levels; chr15:76886661 chr15:76174891~76181486:- LUSC cis rs17023223 0.537 rs56708249 ENSG00000231365.4 RP11-418J17.1 -6.43 3.2e-10 1.69e-07 -0.36 -0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119050582 chr1:119140396~119275973:+ LUSC cis rs5742933 0.817 rs11679767 ENSG00000253559.1 OSGEPL1-AS1 6.43 3.2e-10 1.69e-07 0.34 0.28 Ferritin levels; chr2:189681574 chr2:189762704~189765556:+ LUSC cis rs75920871 0.588 rs4938321 ENSG00000254851.1 RP11-109L13.1 6.43 3.21e-10 1.7e-07 0.39 0.28 Subjective well-being; chr11:116981791 chr11:117135528~117138582:+ LUSC cis rs228614 0.51 rs223452 ENSG00000230069.3 LRRC37A15P -6.43 3.21e-10 1.7e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102790277 chr4:102727274~102730721:- LUSC cis rs5760092 0.627 rs6519489 ENSG00000099984.9 GSTT2 6.43 3.21e-10 1.7e-07 0.42 0.28 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23980123~23983911:+ LUSC cis rs116095464 0.558 rs6872854 ENSG00000250848.1 CTD-2083E4.5 -6.43 3.22e-10 1.7e-07 -0.43 -0.28 Breast cancer; chr5:208923 chr5:288833~290321:- LUSC cis rs62432291 0.681 rs402388 ENSG00000235086.1 FNDC1-IT1 -6.43 3.22e-10 1.71e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159233962 chr6:159240786~159243329:+ LUSC cis rs62432291 0.764 rs436743 ENSG00000235086.1 FNDC1-IT1 -6.43 3.22e-10 1.71e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159234070 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs3003174 ENSG00000235086.1 FNDC1-IT1 -6.43 3.22e-10 1.71e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159234294 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs2501176 ENSG00000235086.1 FNDC1-IT1 -6.43 3.22e-10 1.71e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159234351 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs2501177 ENSG00000235086.1 FNDC1-IT1 -6.43 3.22e-10 1.71e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159234561 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs439126 ENSG00000235086.1 FNDC1-IT1 -6.43 3.22e-10 1.71e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159235600 chr6:159240786~159243329:+ LUSC cis rs2408955 0.522 rs4760612 ENSG00000240399.1 RP1-228P16.1 -6.43 3.23e-10 1.71e-07 -0.29 -0.28 Glycated hemoglobin levels; chr12:48028073 chr12:48054813~48055591:- LUSC cis rs2019137 0.936 rs3811059 ENSG00000274877.1 RP11-65I12.1 6.43 3.23e-10 1.71e-07 0.34 0.28 Lymphocyte counts; chr2:113204494 chr2:113237595~113240825:+ LUSC cis rs2019137 0.936 rs12620738 ENSG00000274877.1 RP11-65I12.1 6.43 3.23e-10 1.71e-07 0.34 0.28 Lymphocyte counts; chr2:113206162 chr2:113237595~113240825:+ LUSC cis rs367615 0.513 rs11741087 ENSG00000249476.1 CTD-2587M2.1 6.43 3.24e-10 1.71e-07 0.33 0.28 Colorectal cancer (SNP x SNP interaction); chr5:109472059 chr5:109237120~109326369:- LUSC cis rs1865760 0.625 rs9393681 ENSG00000272462.2 U91328.19 -6.43 3.24e-10 1.71e-07 -0.3 -0.28 Height; chr6:26008032 chr6:25992662~26001775:+ LUSC cis rs6142102 1 rs4911410 ENSG00000275784.1 RP5-1125A11.6 -6.42 3.24e-10 1.71e-07 -0.32 -0.28 Skin pigmentation; chr20:34123168 chr20:33989480~33991818:- LUSC cis rs4266144 0.544 rs6805781 ENSG00000244515.1 KRT18P34 6.42 3.24e-10 1.71e-07 0.33 0.28 Coronary artery disease; chr3:157112780 chr3:157162663~157163932:- LUSC cis rs1876905 0.539 rs457497 ENSG00000255389.1 C6orf3 -6.42 3.25e-10 1.72e-07 -0.38 -0.28 Mean corpuscular hemoglobin; chr6:111301346 chr6:111599875~111602295:+ LUSC cis rs2276314 0.857 rs28396546 ENSG00000278986.1 RP11-723J4.3 -6.42 3.25e-10 1.72e-07 -0.35 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36059061 chr18:35972151~35973916:+ LUSC cis rs1075265 0.749 rs2692518 ENSG00000233266.1 HMGB1P31 6.42 3.26e-10 1.72e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:53804746 chr2:54051334~54051760:+ LUSC cis rs783540 0.967 rs2567635 ENSG00000255769.6 GOLGA2P10 6.42 3.27e-10 1.73e-07 0.35 0.28 Schizophrenia; chr15:82593431 chr15:82472993~82513950:- LUSC cis rs783540 0.967 rs783526 ENSG00000255769.6 GOLGA2P10 6.42 3.27e-10 1.73e-07 0.35 0.28 Schizophrenia; chr15:82617044 chr15:82472993~82513950:- LUSC cis rs783540 0.967 rs783527 ENSG00000255769.6 GOLGA2P10 6.42 3.27e-10 1.73e-07 0.35 0.28 Schizophrenia; chr15:82617096 chr15:82472993~82513950:- LUSC cis rs1823913 0.599 rs13427761 ENSG00000227542.1 AC092614.2 -6.42 3.28e-10 1.73e-07 -0.36 -0.28 Obesity-related traits; chr2:191269256 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs10497713 ENSG00000280083.1 RP11-317J9.1 -6.42 3.29e-10 1.74e-07 -0.33 -0.28 Obesity-related traits; chr2:191279312 chr2:191154118~191156070:- LUSC cis rs2408955 0.522 rs4760679 ENSG00000240399.1 RP1-228P16.1 -6.42 3.29e-10 1.74e-07 -0.29 -0.28 Glycated hemoglobin levels; chr12:48067852 chr12:48054813~48055591:- LUSC cis rs228614 0.51 rs223362 ENSG00000230069.3 LRRC37A15P -6.42 3.29e-10 1.74e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102848077 chr4:102727274~102730721:- LUSC cis rs6496044 0.963 rs7165300 ENSG00000202081.1 RNU6-1280P 6.42 3.29e-10 1.74e-07 0.32 0.28 Interstitial lung disease; chr15:85526838 chr15:85651522~85651628:- LUSC cis rs17507216 0.718 rs17158403 ENSG00000255769.6 GOLGA2P10 -6.42 3.29e-10 1.74e-07 -0.43 -0.28 Excessive daytime sleepiness; chr15:82572478 chr15:82472993~82513950:- LUSC cis rs853679 0.517 rs1340004 ENSG00000204709.4 LINC01556 6.42 3.29e-10 1.74e-07 0.41 0.28 Depression; chr6:28135913 chr6:28943877~28944537:+ LUSC cis rs4423214 0.559 rs11234042 ENSG00000254682.1 RP11-660L16.2 -6.42 3.3e-10 1.74e-07 -0.48 -0.28 Vitamin D levels; chr11:71528040 chr11:71448674~71452157:+ LUSC cis rs7246657 0.943 rs4801803 ENSG00000276846.1 CTD-3220F14.3 -6.42 3.3e-10 1.74e-07 -0.44 -0.28 Coronary artery calcification; chr19:37476021 chr19:37314868~37315620:- LUSC cis rs1823913 0.599 rs67342262 ENSG00000280083.1 RP11-317J9.1 -6.42 3.3e-10 1.74e-07 -0.33 -0.28 Obesity-related traits; chr2:191295612 chr2:191154118~191156070:- LUSC cis rs7267979 1 rs6515651 ENSG00000274973.1 RP13-401N8.7 6.42 3.3e-10 1.74e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25433903 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2424716 ENSG00000274973.1 RP13-401N8.7 -6.42 3.3e-10 1.74e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25442902 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs761025 ENSG00000274973.1 RP13-401N8.7 -6.42 3.3e-10 1.74e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25446332 chr20:25845497~25845862:+ LUSC cis rs950169 0.58 rs4603535 ENSG00000259728.4 LINC00933 6.42 3.3e-10 1.74e-07 0.36 0.28 Schizophrenia; chr15:84630641 chr15:84570649~84580175:+ LUSC cis rs6951245 1 rs79443843 ENSG00000224079.1 AC091729.7 -6.42 3.31e-10 1.75e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1035609 chr7:1074450~1078036:+ LUSC cis rs875971 0.964 rs160635 ENSG00000237310.1 GS1-124K5.4 6.42 3.31e-10 1.75e-07 0.3 0.28 Aortic root size; chr7:66063931 chr7:66493706~66495474:+ LUSC cis rs66887589 0.775 rs6843229 ENSG00000245958.5 RP11-33B1.1 -6.42 3.32e-10 1.75e-07 -0.27 -0.28 Diastolic blood pressure; chr4:119502932 chr4:119454791~119552025:+ LUSC cis rs67180937 0.621 rs34885880 ENSG00000272750.1 RP11-378J18.8 -6.42 3.32e-10 1.75e-07 -0.31 -0.28 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222752593 chr1:222658867~222661512:- LUSC cis rs8062405 0.755 rs4788073 ENSG00000278665.1 RP11-666O2.4 6.42 3.33e-10 1.76e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28583228 chr16:28599241~28601881:- LUSC cis rs7580658 0.676 rs4662717 ENSG00000236682.1 AC068282.3 -6.42 3.33e-10 1.76e-07 -0.37 -0.28 Protein C levels; chr2:127255928 chr2:127389130~127400580:+ LUSC cis rs5753618 0.561 rs9609264 ENSG00000236132.1 CTA-440B3.1 -6.42 3.33e-10 1.76e-07 -0.38 -0.28 Colorectal cancer; chr22:31350733 chr22:31816379~31817491:- LUSC cis rs9309473 0.95 rs7596773 ENSG00000163016.8 ALMS1P 6.42 3.33e-10 1.76e-07 0.34 0.28 Metabolite levels; chr2:73618873 chr2:73644919~73685576:+ LUSC cis rs853679 0.546 rs35744819 ENSG00000204709.4 LINC01556 6.42 3.33e-10 1.76e-07 0.63 0.28 Depression; chr6:28350554 chr6:28943877~28944537:+ LUSC cis rs13113518 1 rs13122619 ENSG00000273257.1 RP11-177J6.1 6.42 3.34e-10 1.76e-07 0.36 0.28 Height; chr4:55479339 chr4:55387949~55388271:+ LUSC cis rs6772849 0.896 rs9816260 ENSG00000242551.2 POU5F1P6 -6.42 3.34e-10 1.76e-07 -0.32 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128633240 chr3:128674735~128677005:- LUSC cis rs75920871 0.588 rs4620758 ENSG00000254851.1 RP11-109L13.1 6.42 3.34e-10 1.76e-07 0.39 0.28 Subjective well-being; chr11:117075002 chr11:117135528~117138582:+ LUSC cis rs4713118 0.621 rs4713132 ENSG00000280107.1 AL022393.9 -6.42 3.34e-10 1.76e-07 -0.36 -0.28 Parkinson's disease; chr6:28066257 chr6:28170845~28172521:+ LUSC cis rs4713118 0.621 rs4713133 ENSG00000280107.1 AL022393.9 -6.42 3.34e-10 1.76e-07 -0.36 -0.28 Parkinson's disease; chr6:28066263 chr6:28170845~28172521:+ LUSC cis rs4713118 0.621 rs4713134 ENSG00000280107.1 AL022393.9 -6.42 3.34e-10 1.76e-07 -0.36 -0.28 Parkinson's disease; chr6:28066343 chr6:28170845~28172521:+ LUSC cis rs8062405 0.691 rs743590 ENSG00000278665.1 RP11-666O2.4 6.42 3.35e-10 1.77e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28596909 chr16:28599241~28601881:- LUSC cis rs2179367 0.632 rs9498338 ENSG00000231760.4 RP11-350J20.5 6.42 3.35e-10 1.77e-07 0.41 0.28 Dupuytren's disease; chr6:149376428 chr6:149796151~149826294:- LUSC cis rs7772486 0.686 rs9386131 ENSG00000235652.6 RP11-545I5.3 6.42 3.35e-10 1.77e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145800472 chr6:145799409~145886585:+ LUSC cis rs2919917 1 rs1054283 ENSG00000254352.1 RP11-578O24.2 6.42 3.35e-10 1.77e-07 0.35 0.28 Lymphocyte counts; chr8:78698475 chr8:78723796~78724136:- LUSC cis rs6504950 0.72 rs9914836 ENSG00000275710.1 RP11-257O5.4 6.42 3.35e-10 1.77e-07 0.35 0.28 Breast cancer; chr17:54920514 chr17:54964474~54964679:+ LUSC cis rs1075265 0.62 rs2542584 ENSG00000233266.1 HMGB1P31 6.42 3.36e-10 1.77e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:53782707 chr2:54051334~54051760:+ LUSC cis rs67311347 1 rs9874499 ENSG00000223797.4 ENTPD3-AS1 6.42 3.36e-10 1.77e-07 0.32 0.28 Renal cell carcinoma; chr3:40400417 chr3:40313802~40453329:- LUSC cis rs5742933 0.857 rs13021611 ENSG00000253559.1 OSGEPL1-AS1 6.42 3.36e-10 1.77e-07 0.34 0.28 Ferritin levels; chr2:189700038 chr2:189762704~189765556:+ LUSC cis rs66887589 0.967 rs3775842 ENSG00000245958.5 RP11-33B1.1 -6.42 3.37e-10 1.78e-07 -0.27 -0.28 Diastolic blood pressure; chr4:119506577 chr4:119454791~119552025:+ LUSC cis rs8072100 0.764 rs4794371 ENSG00000228782.6 CTD-2026D20.3 -6.42 3.37e-10 1.78e-07 -0.27 -0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47550327 chr17:47450568~47492492:- LUSC cis rs6603134 0.502 rs10406540 ENSG00000267939.1 CTD-2325M2.1 -6.42 3.38e-10 1.78e-07 -0.31 -0.28 Blood protein levels; chr19:8039113 chr19:8008729~8016025:+ LUSC cis rs783540 0.933 rs2567636 ENSG00000255769.6 GOLGA2P10 6.42 3.38e-10 1.78e-07 0.35 0.28 Schizophrenia; chr15:82594678 chr15:82472993~82513950:- LUSC cis rs75422866 0.867 rs73113117 ENSG00000257433.4 RP1-197B17.3 6.42 3.38e-10 1.78e-07 0.67 0.28 Pneumonia; chr12:47617299 chr12:47706085~47742294:+ LUSC cis rs1075265 0.704 rs805410 ENSG00000233266.1 HMGB1P31 6.42 3.39e-10 1.79e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:53893360 chr2:54051334~54051760:+ LUSC cis rs875971 0.505 rs1167385 ENSG00000164669.11 INTS4P1 6.42 3.39e-10 1.79e-07 0.31 0.28 Aortic root size; chr7:66048321 chr7:65141225~65234216:+ LUSC cis rs11098499 0.865 rs11722183 ENSG00000250412.1 KLHL2P1 6.42 3.39e-10 1.79e-07 0.35 0.28 Corneal astigmatism; chr4:119359442 chr4:119334329~119378233:+ LUSC cis rs1823913 0.599 rs4146103 ENSG00000227542.1 AC092614.2 6.42 3.4e-10 1.79e-07 0.36 0.28 Obesity-related traits; chr2:191272000 chr2:191229165~191246172:- LUSC cis rs6570726 0.818 rs399516 ENSG00000235652.6 RP11-545I5.3 6.42 3.4e-10 1.79e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145489713 chr6:145799409~145886585:+ LUSC cis rs6951245 1 rs884977 ENSG00000224079.1 AC091729.7 -6.42 3.4e-10 1.79e-07 -0.47 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1026774 chr7:1074450~1078036:+ LUSC cis rs801193 0.66 rs974239 ENSG00000237310.1 GS1-124K5.4 6.42 3.41e-10 1.8e-07 0.29 0.28 Aortic root size; chr7:66748504 chr7:66493706~66495474:+ LUSC cis rs801193 0.66 rs1016265 ENSG00000237310.1 GS1-124K5.4 6.42 3.41e-10 1.8e-07 0.29 0.28 Aortic root size; chr7:66749580 chr7:66493706~66495474:+ LUSC cis rs4713118 0.662 rs149970 ENSG00000280107.1 AL022393.9 -6.42 3.41e-10 1.8e-07 -0.33 -0.28 Parkinson's disease; chr6:28012442 chr6:28170845~28172521:+ LUSC cis rs66887589 0.934 rs4834792 ENSG00000249244.1 RP11-548H18.2 -6.42 3.41e-10 1.8e-07 -0.34 -0.28 Diastolic blood pressure; chr4:119634541 chr4:119391831~119395335:- LUSC cis rs4604732 0.578 rs12040725 ENSG00000227135.1 GCSAML-AS1 -6.42 3.42e-10 1.8e-07 -0.43 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247481395 chr1:247524679~247526752:- LUSC cis rs496547 0.719 rs472641 ENSG00000255239.1 AP002954.6 6.42 3.42e-10 1.8e-07 0.32 0.28 Hip minimal joint space width; chr11:118746835 chr11:118688039~118690600:- LUSC cis rs7267979 1 rs4815424 ENSG00000274973.1 RP13-401N8.7 6.42 3.43e-10 1.81e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25409648 chr20:25845497~25845862:+ LUSC cis rs17507216 0.718 rs7161977 ENSG00000255769.6 GOLGA2P10 -6.42 3.43e-10 1.81e-07 -0.44 -0.28 Excessive daytime sleepiness; chr15:82646782 chr15:82472993~82513950:- LUSC cis rs881375 0.9 rs1008383 ENSG00000226752.6 PSMD5-AS1 -6.42 3.43e-10 1.81e-07 -0.33 -0.28 Rheumatoid arthritis; chr9:120921301 chr9:120824828~120854385:+ LUSC cis rs7246657 0.943 rs6508733 ENSG00000276846.1 CTD-3220F14.3 6.42 3.43e-10 1.81e-07 0.43 0.28 Coronary artery calcification; chr19:37509646 chr19:37314868~37315620:- LUSC cis rs2179367 0.632 rs9498336 ENSG00000231760.4 RP11-350J20.5 6.42 3.43e-10 1.81e-07 0.41 0.28 Dupuytren's disease; chr6:149374208 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs1980774 ENSG00000231760.4 RP11-350J20.5 6.42 3.43e-10 1.81e-07 0.41 0.28 Dupuytren's disease; chr6:149375030 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs9498337 ENSG00000231760.4 RP11-350J20.5 6.42 3.43e-10 1.81e-07 0.41 0.28 Dupuytren's disease; chr6:149375970 chr6:149796151~149826294:- LUSC cis rs8059260 0.542 rs80000109 ENSG00000274038.1 RP11-66H6.4 -6.42 3.43e-10 1.81e-07 -0.48 -0.28 Alcohol consumption over the past year; chr16:11031457 chr16:11056556~11057034:+ LUSC cis rs2179367 0.632 rs12196750 ENSG00000231760.4 RP11-350J20.5 6.42 3.44e-10 1.81e-07 0.4 0.28 Dupuytren's disease; chr6:149413335 chr6:149796151~149826294:- LUSC cis rs1075232 1 rs9672214 ENSG00000270055.1 CTD-3092A11.2 -6.42 3.44e-10 1.81e-07 -0.59 -0.28 Survival in colorectal cancer (non-distant metastatic); chr15:31385572 chr15:30487963~30490313:+ LUSC cis rs6142102 0.538 rs6142058 ENSG00000275784.1 RP5-1125A11.6 -6.41 3.44e-10 1.81e-07 -0.31 -0.28 Skin pigmentation; chr20:33954995 chr20:33989480~33991818:- LUSC cis rs7772486 0.686 rs2328708 ENSG00000235652.6 RP11-545I5.3 -6.41 3.44e-10 1.81e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145774603 chr6:145799409~145886585:+ LUSC cis rs11098499 0.69 rs34818745 ENSG00000250412.1 KLHL2P1 6.41 3.44e-10 1.81e-07 0.36 0.28 Corneal astigmatism; chr4:119335900 chr4:119334329~119378233:+ LUSC cis rs9309711 0.643 rs10188449 ENSG00000225234.1 TRAPPC12-AS1 -6.41 3.45e-10 1.81e-07 -0.33 -0.28 Neurofibrillary tangles; chr2:3476595 chr2:3481242~3482409:- LUSC cis rs2337406 0.925 rs11851094 ENSG00000274576.2 IGHV2-70 -6.41 3.45e-10 1.82e-07 -0.3 -0.28 Alzheimer's disease (late onset); chr14:106688967 chr14:106770577~106771020:- LUSC cis rs6964833 0.554 rs2527366 ENSG00000123965.13 PMS2P5 -6.41 3.45e-10 1.82e-07 -0.41 -0.28 Menarche (age at onset); chr7:74684615 chr7:74894116~74897835:+ LUSC cis rs11089937 0.616 rs12484496 ENSG00000211639.2 IGLV4-60 -6.41 3.46e-10 1.82e-07 -0.29 -0.28 Periodontitis (PAL4Q3); chr22:22180296 chr22:22162199~22162681:+ LUSC cis rs227275 0.556 rs223398 ENSG00000230069.3 LRRC37A15P -6.41 3.47e-10 1.82e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102821256 chr4:102727274~102730721:- LUSC cis rs6504622 0.755 rs34774205 ENSG00000262879.4 RP11-156P1.3 -6.41 3.47e-10 1.83e-07 -0.3 -0.28 Orofacial clefts; chr17:47083453 chr17:46984045~47100323:- LUSC cis rs783540 0.843 rs28374463 ENSG00000276710.3 CSPG4P8 6.41 3.47e-10 1.83e-07 0.3 0.28 Schizophrenia; chr15:82630613 chr15:82459472~82477258:+ LUSC cis rs783540 0.5 rs7163840 ENSG00000255769.6 GOLGA2P10 6.41 3.47e-10 1.83e-07 0.38 0.28 Schizophrenia; chr15:82729551 chr15:82472993~82513950:- LUSC cis rs7246657 0.823 rs4802236 ENSG00000276846.1 CTD-3220F14.3 6.41 3.48e-10 1.83e-07 0.44 0.28 Coronary artery calcification; chr19:37428344 chr19:37314868~37315620:- LUSC cis rs801193 1 rs2420824 ENSG00000236529.1 RP13-254B10.1 -6.41 3.48e-10 1.83e-07 -0.29 -0.28 Aortic root size; chr7:66666129 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs2659906 ENSG00000236529.1 RP13-254B10.1 6.41 3.5e-10 1.84e-07 0.29 0.28 Aortic root size; chr7:66700323 chr7:65840212~65840596:+ LUSC cis rs8177376 0.953 rs73017385 ENSG00000254905.1 RP11-712L6.7 6.41 3.51e-10 1.84e-07 0.39 0.28 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126309680 chr11:126292922~126294254:- LUSC cis rs9903692 0.954 rs2240122 ENSG00000278765.1 RP5-890E16.5 6.41 3.51e-10 1.85e-07 0.34 0.28 Pulse pressure; chr17:48075197 chr17:48066704~48067293:- LUSC cis rs9903692 0.738 rs35202025 ENSG00000278765.1 RP5-890E16.5 6.41 3.51e-10 1.85e-07 0.34 0.28 Pulse pressure; chr17:48075355 chr17:48066704~48067293:- LUSC cis rs9549367 0.789 rs9549695 ENSG00000269125.1 RP11-98F14.11 6.41 3.52e-10 1.85e-07 0.35 0.28 Platelet distribution width; chr13:113220500 chr13:113165002~113165183:- LUSC cis rs11089937 0.512 rs34963809 ENSG00000211638.2 IGLV8-61 -6.41 3.52e-10 1.85e-07 -0.3 -0.28 Periodontitis (PAL4Q3); chr22:22130737 chr22:22098700~22099212:+ LUSC cis rs875971 0.642 rs35526611 ENSG00000224316.1 RP11-479O9.2 -6.41 3.52e-10 1.85e-07 -0.27 -0.28 Aortic root size; chr7:66629021 chr7:65773620~65802067:+ LUSC cis rs801193 0.636 rs2659895 ENSG00000237310.1 GS1-124K5.4 6.41 3.52e-10 1.85e-07 0.29 0.28 Aortic root size; chr7:66731484 chr7:66493706~66495474:+ LUSC cis rs957448 0.948 rs1470153 ENSG00000253175.1 RP11-267M23.6 6.41 3.52e-10 1.85e-07 0.33 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94514587 chr8:94565036~94565715:+ LUSC cis rs228614 0.509 rs223481 ENSG00000230069.3 LRRC37A15P -6.41 3.53e-10 1.86e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766860 chr4:102727274~102730721:- LUSC cis rs801193 1 rs2707845 ENSG00000236529.1 RP13-254B10.1 6.41 3.53e-10 1.86e-07 0.29 0.28 Aortic root size; chr7:66733811 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs2707850 ENSG00000236529.1 RP13-254B10.1 6.41 3.53e-10 1.86e-07 0.29 0.28 Aortic root size; chr7:66738883 chr7:65840212~65840596:+ LUSC cis rs801193 0.967 rs1110414 ENSG00000236529.1 RP13-254B10.1 6.41 3.53e-10 1.86e-07 0.29 0.28 Aortic root size; chr7:66740595 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs7783924 ENSG00000236529.1 RP13-254B10.1 6.41 3.53e-10 1.86e-07 0.29 0.28 Aortic root size; chr7:66744070 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs7789184 ENSG00000236529.1 RP13-254B10.1 6.41 3.53e-10 1.86e-07 0.29 0.28 Aortic root size; chr7:66745208 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs2707854 ENSG00000236529.1 RP13-254B10.1 6.41 3.53e-10 1.86e-07 0.29 0.28 Aortic root size; chr7:66747610 chr7:65840212~65840596:+ LUSC cis rs2179367 0.632 rs11155645 ENSG00000231760.4 RP11-350J20.5 6.41 3.53e-10 1.86e-07 0.41 0.28 Dupuytren's disease; chr6:149360056 chr6:149796151~149826294:- LUSC cis rs9309473 0.514 rs62149659 ENSG00000163016.8 ALMS1P 6.41 3.54e-10 1.86e-07 0.41 0.28 Metabolite levels; chr2:73358068 chr2:73644919~73685576:+ LUSC cis rs801193 0.935 rs2659899 ENSG00000236529.1 RP13-254B10.1 6.41 3.54e-10 1.86e-07 0.29 0.28 Aortic root size; chr7:66721734 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs1553609 ENSG00000236529.1 RP13-254B10.1 6.41 3.54e-10 1.86e-07 0.29 0.28 Aortic root size; chr7:66732152 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs1553610 ENSG00000236529.1 RP13-254B10.1 6.41 3.54e-10 1.86e-07 0.29 0.28 Aortic root size; chr7:66732246 chr7:65840212~65840596:+ LUSC cis rs6142102 0.602 rs4911399 ENSG00000275784.1 RP5-1125A11.6 -6.41 3.54e-10 1.86e-07 -0.31 -0.28 Skin pigmentation; chr20:34035612 chr20:33989480~33991818:- LUSC cis rs10170846 0.893 rs10932967 ENSG00000261428.2 RP11-16P6.1 6.41 3.55e-10 1.86e-07 0.34 0.28 Schizophrenia (inflammation and infection response interaction); chr2:222679392 chr2:222566899~222569719:- LUSC cis rs8062405 0.755 rs17640009 ENSG00000278665.1 RP11-666O2.4 6.41 3.55e-10 1.87e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28584379 chr16:28599241~28601881:- LUSC cis rs67180937 0.553 rs2936023 ENSG00000272750.1 RP11-378J18.8 6.41 3.55e-10 1.87e-07 0.36 0.28 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222656989 chr1:222658867~222661512:- LUSC cis rs11098499 1 rs12506395 ENSG00000250412.1 KLHL2P1 6.41 3.55e-10 1.87e-07 0.36 0.28 Corneal astigmatism; chr4:119263939 chr4:119334329~119378233:+ LUSC cis rs3096299 0.679 rs3102338 ENSG00000274627.1 RP11-104N10.2 6.41 3.55e-10 1.87e-07 0.26 0.28 Multiple myeloma (IgH translocation); chr16:89375842 chr16:89516797~89522217:+ LUSC cis rs2404602 0.647 rs35940181 ENSG00000259422.1 RP11-593F23.1 -6.41 3.55e-10 1.87e-07 -0.33 -0.28 Blood metabolite levels; chr15:76887678 chr15:76174891~76181486:- LUSC cis rs7955901 0.752 rs10879249 ENSG00000257265.1 CTD-2021H9.1 6.41 3.56e-10 1.87e-07 0.32 0.28 Type 2 diabetes; chr12:71070083 chr12:71007773~71032083:- LUSC cis rs2153535 0.58 rs4960433 ENSG00000230939.1 RP11-314C16.1 -6.41 3.58e-10 1.88e-07 -0.33 -0.28 Motion sickness; chr6:8523464 chr6:8784178~8785445:+ LUSC cis rs8177876 0.749 rs2278024 ENSG00000261838.4 RP11-303E16.6 6.41 3.58e-10 1.88e-07 0.69 0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81045628 chr16:81069854~81076598:+ LUSC cis rs875971 0.638 rs35986979 ENSG00000224316.1 RP11-479O9.2 -6.41 3.58e-10 1.88e-07 -0.27 -0.28 Aortic root size; chr7:66624003 chr7:65773620~65802067:+ LUSC cis rs8062405 0.723 rs113208333 ENSG00000278665.1 RP11-666O2.4 6.41 3.59e-10 1.89e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28594839 chr16:28599241~28601881:- LUSC cis rs6952407 1 rs6952407 ENSG00000236529.1 RP13-254B10.1 -6.41 3.59e-10 1.89e-07 -0.29 -0.28 Cotinine glucuronidation; chr7:66580525 chr7:65840212~65840596:+ LUSC cis rs1823913 0.526 rs36028476 ENSG00000280083.1 RP11-317J9.1 -6.41 3.6e-10 1.89e-07 -0.33 -0.28 Obesity-related traits; chr2:191300595 chr2:191154118~191156070:- LUSC cis rs7267979 0.966 rs2482918 ENSG00000274973.1 RP13-401N8.7 6.41 3.61e-10 1.9e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25431499 chr20:25845497~25845862:+ LUSC cis rs13113518 0.595 rs13120635 ENSG00000273257.1 RP11-177J6.1 6.41 3.61e-10 1.9e-07 0.38 0.28 Height; chr4:55361200 chr4:55387949~55388271:+ LUSC cis rs801193 1 rs2003301 ENSG00000236529.1 RP13-254B10.1 -6.41 3.61e-10 1.9e-07 -0.29 -0.28 Aortic root size; chr7:66682669 chr7:65840212~65840596:+ LUSC cis rs8040855 0.627 rs12909971 ENSG00000259295.5 CSPG4P12 6.41 3.61e-10 1.9e-07 0.35 0.28 Bulimia nervosa; chr15:85045767 chr15:85191438~85213905:+ LUSC cis rs9545047 0.716 rs943710 ENSG00000227676.3 LINC01068 6.41 3.61e-10 1.9e-07 0.35 0.28 Schizophrenia; chr13:79282987 chr13:79566727~79571436:+ LUSC cis rs10829156 0.898 rs7095666 ENSG00000240291.1 RP11-499P20.2 -6.41 3.62e-10 1.9e-07 -0.3 -0.28 Sudden cardiac arrest; chr10:18650538 chr10:18513115~18545651:- LUSC cis rs1075265 1 rs1075265 ENSG00000233266.1 HMGB1P31 6.41 3.63e-10 1.9e-07 0.36 0.28 Chronotype;Morning vs. evening chronotype; chr2:54127790 chr2:54051334~54051760:+ LUSC cis rs1075232 1 rs34959140 ENSG00000270055.1 CTD-3092A11.2 -6.41 3.63e-10 1.91e-07 -0.58 -0.28 Survival in colorectal cancer (non-distant metastatic); chr15:31433020 chr15:30487963~30490313:+ LUSC cis rs6951245 0.872 rs74360401 ENSG00000224079.1 AC091729.7 -6.41 3.64e-10 1.91e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1027767 chr7:1074450~1078036:+ LUSC cis rs6951245 0.935 rs118132455 ENSG00000224079.1 AC091729.7 -6.41 3.64e-10 1.91e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1028596 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs78628466 ENSG00000224079.1 AC091729.7 -6.41 3.64e-10 1.91e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1028817 chr7:1074450~1078036:+ LUSC cis rs2903698 0.585 rs28851837 ENSG00000250735.4 RP11-567N4.3 6.41 3.65e-10 1.91e-07 0.32 0.28 Prion diseases; chr4:75417356 chr4:75401195~75423023:+ LUSC cis rs11690935 0.959 rs4667694 ENSG00000228389.1 AC068039.4 6.41 3.65e-10 1.92e-07 0.33 0.28 Schizophrenia; chr2:171748889 chr2:171773482~171775844:+ LUSC cis rs8062405 0.755 rs55792032 ENSG00000278665.1 RP11-666O2.4 6.41 3.65e-10 1.92e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28588090 chr16:28599241~28601881:- LUSC cis rs875971 0.66 rs10215132 ENSG00000224316.1 RP11-479O9.2 -6.4 3.66e-10 1.92e-07 -0.27 -0.28 Aortic root size; chr7:66589419 chr7:65773620~65802067:+ LUSC cis rs6504622 0.721 rs11079748 ENSG00000262879.4 RP11-156P1.3 -6.4 3.66e-10 1.92e-07 -0.31 -0.28 Orofacial clefts; chr17:47055097 chr17:46984045~47100323:- LUSC cis rs9506514 0.509 rs9509294 ENSG00000238286.1 SLC35E1P1 -6.4 3.66e-10 1.92e-07 -0.31 -0.28 Coronary artery calcification; chr13:20600506 chr13:20607268~20608131:+ LUSC cis rs4950322 0.58 rs1813002 ENSG00000278811.3 LINC00624 6.4 3.66e-10 1.92e-07 0.3 0.28 Protein quantitative trait loci; chr1:147112579 chr1:147258885~147517875:- LUSC cis rs7772486 0.623 rs9485021 ENSG00000235652.6 RP11-545I5.3 -6.4 3.67e-10 1.92e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145747661 chr6:145799409~145886585:+ LUSC cis rs7772486 0.654 rs6928007 ENSG00000235652.6 RP11-545I5.3 -6.4 3.67e-10 1.92e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145753805 chr6:145799409~145886585:+ LUSC cis rs7267979 1 rs4815411 ENSG00000274973.1 RP13-401N8.7 6.4 3.67e-10 1.92e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25369587 chr20:25845497~25845862:+ LUSC cis rs673078 0.607 rs61943369 ENSG00000275759.1 RP11-131L12.3 -6.4 3.67e-10 1.92e-07 -0.38 -0.28 Glucose homeostasis traits; chr12:118368145 chr12:118428281~118428870:+ LUSC cis rs7429990 0.864 rs2047559 ENSG00000229759.1 MRPS18AP1 -6.4 3.68e-10 1.93e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47704695 chr3:48256350~48256938:- LUSC cis rs496547 0.686 rs524590 ENSG00000255239.1 AP002954.6 6.4 3.68e-10 1.93e-07 0.32 0.28 Hip minimal joint space width; chr11:118769354 chr11:118688039~118690600:- LUSC cis rs6603134 0.502 rs6603133 ENSG00000267939.1 CTD-2325M2.1 -6.4 3.68e-10 1.93e-07 -0.31 -0.28 Blood protein levels; chr19:8038352 chr19:8008729~8016025:+ LUSC cis rs1155848 0.571 rs7983556 ENSG00000227354.5 RBM26-AS1 6.4 3.69e-10 1.94e-07 0.53 0.28 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79608777 chr13:79406309~79424328:+ LUSC cis rs4853012 0.838 rs6715351 ENSG00000257800.1 FNBP1P1 6.4 3.69e-10 1.94e-07 0.33 0.28 Gestational age at birth (maternal effect); chr2:74118992 chr2:74120680~74123218:+ LUSC cis rs4853012 0.838 rs61521879 ENSG00000257800.1 FNBP1P1 6.4 3.69e-10 1.94e-07 0.33 0.28 Gestational age at birth (maternal effect); chr2:74119081 chr2:74120680~74123218:+ LUSC cis rs172166 0.694 rs188105 ENSG00000216901.1 AL022393.7 6.4 3.7e-10 1.94e-07 0.34 0.28 Cardiac Troponin-T levels; chr6:28103615 chr6:28176188~28176674:+ LUSC cis rs13113518 1 rs55699500 ENSG00000273257.1 RP11-177J6.1 6.4 3.7e-10 1.94e-07 0.37 0.28 Height; chr4:55540912 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs56362210 ENSG00000273257.1 RP11-177J6.1 6.4 3.7e-10 1.94e-07 0.37 0.28 Height; chr4:55540972 chr4:55387949~55388271:+ LUSC cis rs2179367 0.632 rs9498332 ENSG00000231760.4 RP11-350J20.5 6.4 3.7e-10 1.94e-07 0.41 0.28 Dupuytren's disease; chr6:149367490 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs9498333 ENSG00000231760.4 RP11-350J20.5 6.4 3.7e-10 1.94e-07 0.41 0.28 Dupuytren's disease; chr6:149368196 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs9498334 ENSG00000231760.4 RP11-350J20.5 6.4 3.7e-10 1.94e-07 0.41 0.28 Dupuytren's disease; chr6:149370902 chr6:149796151~149826294:- LUSC cis rs17023223 0.537 rs2645305 ENSG00000231365.4 RP11-418J17.1 -6.4 3.7e-10 1.94e-07 -0.36 -0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119018742 chr1:119140396~119275973:+ LUSC cis rs7267979 1 rs6037095 ENSG00000274973.1 RP13-401N8.7 6.4 3.7e-10 1.94e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25355051 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050562 ENSG00000274973.1 RP13-401N8.7 6.4 3.7e-10 1.94e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25355550 chr20:25845497~25845862:+ LUSC cis rs2404602 0.735 rs2957614 ENSG00000259422.1 RP11-593F23.1 6.4 3.71e-10 1.94e-07 0.33 0.28 Blood metabolite levels; chr15:76404294 chr15:76174891~76181486:- LUSC cis rs9322193 0.886 rs4870049 ENSG00000268592.3 RAET1E-AS1 6.4 3.71e-10 1.95e-07 0.37 0.28 Lung cancer; chr6:149837058 chr6:149863494~149919507:+ LUSC cis rs113835537 0.529 rs75683511 ENSG00000255517.5 CTD-3074O7.5 -6.4 3.71e-10 1.95e-07 -0.33 -0.28 Airway imaging phenotypes; chr11:66507555 chr11:66473490~66480233:- LUSC cis rs732716 0.785 rs56033249 ENSG00000267769.1 CTB-50L17.9 -6.4 3.71e-10 1.95e-07 -0.32 -0.28 Mean corpuscular volume; chr19:4369450 chr19:4454014~4455286:+ LUSC cis rs7772486 0.686 rs1569540 ENSG00000235652.6 RP11-545I5.3 -6.4 3.72e-10 1.95e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145747976 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs2142983 ENSG00000235652.6 RP11-545I5.3 -6.4 3.72e-10 1.95e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145748565 chr6:145799409~145886585:+ LUSC cis rs7306456 0.623 rs10902513 ENSG00000256576.2 RP13-977J11.2 6.4 3.72e-10 1.95e-07 0.32 0.28 Anti-saccade response; chr12:132208942 chr12:132186735~132189695:- LUSC cis rs875971 0.505 rs1167386 ENSG00000164669.11 INTS4P1 6.4 3.72e-10 1.95e-07 0.31 0.28 Aortic root size; chr7:66048109 chr7:65141225~65234216:+ LUSC cis rs6142102 0.961 rs6119447 ENSG00000275784.1 RP5-1125A11.6 -6.4 3.72e-10 1.95e-07 -0.33 -0.28 Skin pigmentation; chr20:34080770 chr20:33989480~33991818:- LUSC cis rs992157 0.56 rs6738394 ENSG00000261338.2 RP11-378A13.1 -6.4 3.73e-10 1.95e-07 -0.28 -0.28 Colorectal cancer; chr2:218245902 chr2:218255319~218257366:+ LUSC cis rs4853012 0.941 rs4852329 ENSG00000257800.1 FNBP1P1 6.4 3.73e-10 1.96e-07 0.36 0.28 Gestational age at birth (maternal effect); chr2:74127417 chr2:74120680~74123218:+ LUSC cis rs66887589 0.87 rs10518336 ENSG00000245958.5 RP11-33B1.1 -6.4 3.73e-10 1.96e-07 -0.27 -0.28 Diastolic blood pressure; chr4:119601779 chr4:119454791~119552025:+ LUSC cis rs1823913 0.637 rs6741454 ENSG00000227542.1 AC092614.2 -6.4 3.74e-10 1.96e-07 -0.36 -0.28 Obesity-related traits; chr2:191269520 chr2:191229165~191246172:- LUSC cis rs1823913 0.614 rs6755243 ENSG00000227542.1 AC092614.2 -6.4 3.74e-10 1.96e-07 -0.36 -0.28 Obesity-related traits; chr2:191269810 chr2:191229165~191246172:- LUSC cis rs875971 1 rs1565531 ENSG00000237310.1 GS1-124K5.4 -6.4 3.74e-10 1.96e-07 -0.29 -0.28 Aortic root size; chr7:66198126 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs11974219 ENSG00000237310.1 GS1-124K5.4 -6.4 3.74e-10 1.96e-07 -0.29 -0.28 Aortic root size; chr7:66182423 chr7:66493706~66495474:+ LUSC cis rs9549367 0.789 rs9549705 ENSG00000269125.1 RP11-98F14.11 -6.4 3.75e-10 1.96e-07 -0.36 -0.28 Platelet distribution width; chr13:113234111 chr13:113165002~113165183:- LUSC cis rs7739264 0.933 rs6925962 ENSG00000237404.1 RP3-471C18.2 6.4 3.75e-10 1.96e-07 0.32 0.28 Endometriosis; chr6:19776824 chr6:19689825~19753113:- LUSC cis rs4713118 0.955 rs9468203 ENSG00000219392.1 RP1-265C24.5 -6.4 3.75e-10 1.96e-07 -0.36 -0.28 Parkinson's disease; chr6:27720888 chr6:28115628~28116551:+ LUSC cis rs13113518 1 rs7660980 ENSG00000273257.1 RP11-177J6.1 -6.4 3.75e-10 1.96e-07 -0.36 -0.28 Height; chr4:55542948 chr4:55387949~55388271:+ LUSC cis rs8040855 0.627 rs11632658 ENSG00000259295.5 CSPG4P12 -6.4 3.75e-10 1.96e-07 -0.36 -0.28 Bulimia nervosa; chr15:85062982 chr15:85191438~85213905:+ LUSC cis rs875971 0.545 rs73142233 ENSG00000226824.5 RP4-756H11.3 -6.4 3.76e-10 1.97e-07 -0.37 -0.28 Aortic root size; chr7:66221293 chr7:66654538~66669855:+ LUSC cis rs7267979 0.966 rs2500417 ENSG00000274973.1 RP13-401N8.7 6.4 3.76e-10 1.97e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25402651 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2482911 ENSG00000274973.1 RP13-401N8.7 6.4 3.76e-10 1.97e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25414892 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2500436 ENSG00000274973.1 RP13-401N8.7 6.4 3.76e-10 1.97e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25425730 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6083856 ENSG00000274973.1 RP13-401N8.7 6.4 3.76e-10 1.97e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25426949 chr20:25845497~25845862:+ LUSC cis rs5742933 0.817 rs4667297 ENSG00000253559.1 OSGEPL1-AS1 6.4 3.77e-10 1.97e-07 0.34 0.28 Ferritin levels; chr2:189664270 chr2:189762704~189765556:+ LUSC cis rs5742933 0.711 rs12693551 ENSG00000253559.1 OSGEPL1-AS1 6.4 3.77e-10 1.97e-07 0.34 0.28 Ferritin levels; chr2:189664505 chr2:189762704~189765556:+ LUSC cis rs11846409 0.652 rs10143549 ENSG00000274576.2 IGHV2-70 -6.4 3.77e-10 1.97e-07 -0.29 -0.28 Rheumatic heart disease; chr14:106644643 chr14:106770577~106771020:- LUSC cis rs62432291 0.681 rs2932988 ENSG00000235086.1 FNDC1-IT1 -6.4 3.77e-10 1.98e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159234370 chr6:159240786~159243329:+ LUSC cis rs801193 1 rs2707836 ENSG00000224316.1 RP11-479O9.2 6.4 3.77e-10 1.98e-07 0.27 0.28 Aortic root size; chr7:66695448 chr7:65773620~65802067:+ LUSC cis rs853679 0.517 rs9357066 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28162053 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9368556 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28163375 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9368557 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28163759 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9380059 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28164580 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9380060 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28164825 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs35227624 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28164948 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9380061 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28165025 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9368558 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28165528 chr6:28170845~28172521:+ LUSC cis rs4713118 0.587 rs9393899 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Parkinson's disease; chr6:28165750 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs4713150 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28168434 chr6:28170845~28172521:+ LUSC cis rs4713118 0.527 rs4713151 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Parkinson's disease; chr6:28168578 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9393901 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28169019 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs3173443 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28169249 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs4713152 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28169676 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9348797 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28169755 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9380062 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28169791 chr6:28170845~28172521:+ LUSC cis rs853679 0.542 rs9380063 ENSG00000280107.1 AL022393.9 -6.4 3.78e-10 1.98e-07 -0.35 -0.28 Depression; chr6:28170075 chr6:28170845~28172521:+ LUSC cis rs801193 0.901 rs4273746 ENSG00000236529.1 RP13-254B10.1 -6.4 3.79e-10 1.98e-07 -0.3 -0.28 Aortic root size; chr7:66836124 chr7:65840212~65840596:+ LUSC cis rs11123170 0.529 rs1015753 ENSG00000189223.12 PAX8-AS1 -6.4 3.79e-10 1.98e-07 -0.44 -0.28 Renal function-related traits (BUN); chr2:113211226 chr2:113211522~113276581:+ LUSC cis rs7955901 0.725 rs7294409 ENSG00000257265.1 CTD-2021H9.1 6.4 3.79e-10 1.99e-07 0.32 0.28 Type 2 diabetes; chr12:71068410 chr12:71007773~71032083:- LUSC cis rs7955901 0.725 rs10879248 ENSG00000257265.1 CTD-2021H9.1 6.4 3.79e-10 1.99e-07 0.32 0.28 Type 2 diabetes; chr12:71069635 chr12:71007773~71032083:- LUSC cis rs6504622 0.755 rs12938690 ENSG00000262879.4 RP11-156P1.3 -6.4 3.8e-10 1.99e-07 -0.3 -0.28 Orofacial clefts; chr17:46997999 chr17:46984045~47100323:- LUSC cis rs7772486 0.754 rs697054 ENSG00000235652.6 RP11-545I5.3 6.4 3.8e-10 1.99e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145682634 chr6:145799409~145886585:+ LUSC cis rs7246657 0.943 rs713256 ENSG00000276846.1 CTD-3220F14.3 6.4 3.81e-10 1.99e-07 0.43 0.28 Coronary artery calcification; chr19:37374463 chr19:37314868~37315620:- LUSC cis rs228614 0.51 rs223378 ENSG00000230069.3 LRRC37A15P -6.4 3.81e-10 1.99e-07 -0.31 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102833488 chr4:102727274~102730721:- LUSC cis rs11976180 1 rs11975942 ENSG00000170356.8 OR2A20P -6.4 3.82e-10 2e-07 -0.39 -0.28 Obesity-related traits; chr7:144043487 chr7:144250045~144252957:- LUSC cis rs8059260 0.673 rs7188928 ENSG00000274038.1 RP11-66H6.4 -6.4 3.82e-10 2e-07 -0.47 -0.28 Alcohol consumption over the past year; chr16:10964896 chr16:11056556~11057034:+ LUSC cis rs7621025 0.5 rs4678275 ENSG00000239213.4 NCK1-AS1 6.4 3.82e-10 2e-07 0.35 0.28 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136934841 chr3:136841726~136862054:- LUSC cis rs1823913 0.637 rs4853569 ENSG00000227542.1 AC092614.2 -6.4 3.82e-10 2e-07 -0.36 -0.28 Obesity-related traits; chr2:191266970 chr2:191229165~191246172:- LUSC cis rs853679 0.517 rs12332979 ENSG00000280107.1 AL022393.9 -6.4 3.83e-10 2e-07 -0.35 -0.28 Depression; chr6:28173770 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs67878650 ENSG00000280107.1 AL022393.9 -6.4 3.83e-10 2e-07 -0.35 -0.28 Depression; chr6:28174809 chr6:28170845~28172521:+ LUSC cis rs853679 0.569 rs9348798 ENSG00000280107.1 AL022393.9 -6.4 3.83e-10 2e-07 -0.35 -0.28 Depression; chr6:28175233 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9380065 ENSG00000280107.1 AL022393.9 -6.4 3.83e-10 2e-07 -0.35 -0.28 Depression; chr6:28176973 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9295761 ENSG00000280107.1 AL022393.9 -6.4 3.83e-10 2e-07 -0.35 -0.28 Depression; chr6:28180209 chr6:28170845~28172521:+ LUSC cis rs2337406 1 rs3858878 ENSG00000274576.2 IGHV2-70 -6.4 3.83e-10 2e-07 -0.3 -0.28 Alzheimer's disease (late onset); chr14:106688061 chr14:106770577~106771020:- LUSC cis rs9309473 0.948 rs13391552 ENSG00000163016.8 ALMS1P 6.4 3.83e-10 2e-07 0.34 0.28 Metabolite levels; chr2:73591809 chr2:73644919~73685576:+ LUSC cis rs4853012 0.941 rs7571083 ENSG00000257800.1 FNBP1P1 6.4 3.83e-10 2e-07 0.35 0.28 Gestational age at birth (maternal effect); chr2:74115133 chr2:74120680~74123218:+ LUSC cis rs950169 0.84 rs62029595 ENSG00000259728.4 LINC00933 6.4 3.83e-10 2e-07 0.37 0.28 Schizophrenia; chr15:84400603 chr15:84570649~84580175:+ LUSC cis rs17507216 0.718 rs72751657 ENSG00000255769.6 GOLGA2P10 -6.4 3.84e-10 2.01e-07 -0.44 -0.28 Excessive daytime sleepiness; chr15:82581259 chr15:82472993~82513950:- LUSC cis rs950169 0.922 rs4842940 ENSG00000259728.4 LINC00933 -6.4 3.84e-10 2.01e-07 -0.36 -0.28 Schizophrenia; chr15:84162473 chr15:84570649~84580175:+ LUSC cis rs853679 0.517 rs9357065 ENSG00000280107.1 AL022393.9 -6.4 3.84e-10 2.01e-07 -0.35 -0.28 Depression; chr6:28161802 chr6:28170845~28172521:+ LUSC cis rs17772222 0.582 rs1288122 ENSG00000258789.1 RP11-507K2.3 6.4 3.85e-10 2.01e-07 0.31 0.28 Coronary artery calcification; chr14:88472736 chr14:88551597~88552493:+ LUSC cis rs9309473 0.606 rs1589576 ENSG00000163016.8 ALMS1P 6.4 3.85e-10 2.01e-07 0.38 0.28 Metabolite levels; chr2:73511677 chr2:73644919~73685576:+ LUSC cis rs227275 0.556 rs724447 ENSG00000230069.3 LRRC37A15P 6.4 3.85e-10 2.01e-07 0.3 0.28 Allergic disease (asthma, hay fever or eczema); chr4:103010149 chr4:102727274~102730721:- LUSC cis rs875971 0.66 rs1860468 ENSG00000236529.1 RP13-254B10.1 -6.4 3.85e-10 2.01e-07 -0.29 -0.28 Aortic root size; chr7:66642265 chr7:65840212~65840596:+ LUSC cis rs1075265 0.901 rs2048749 ENSG00000233266.1 HMGB1P31 6.4 3.85e-10 2.01e-07 0.36 0.28 Chronotype;Morning vs. evening chronotype; chr2:54130483 chr2:54051334~54051760:+ LUSC cis rs761746 0.614 rs5994427 ENSG00000236132.1 CTA-440B3.1 -6.4 3.85e-10 2.01e-07 -0.41 -0.28 Intelligence; chr22:31736590 chr22:31816379~31817491:- LUSC cis rs12908161 0.959 rs17598603 ENSG00000259728.4 LINC00933 -6.4 3.86e-10 2.02e-07 -0.36 -0.28 Schizophrenia; chr15:84656980 chr15:84570649~84580175:+ LUSC cis rs13113518 0.783 rs7690837 ENSG00000249700.7 SRD5A3-AS1 6.4 3.87e-10 2.02e-07 0.33 0.28 Height; chr4:55575856 chr4:55363971~55395847:- LUSC cis rs9549367 0.713 rs3024745 ENSG00000269125.1 RP11-98F14.11 -6.39 3.88e-10 2.03e-07 -0.37 -0.28 Platelet distribution width; chr13:113167284 chr13:113165002~113165183:- LUSC cis rs62432291 0.681 rs420137 ENSG00000235086.1 FNDC1-IT1 -6.39 3.89e-10 2.03e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159231899 chr6:159240786~159243329:+ LUSC cis rs853679 0.598 rs9380054 ENSG00000204709.4 LINC01556 6.39 3.89e-10 2.03e-07 0.4 0.28 Depression; chr6:28099759 chr6:28943877~28944537:+ LUSC cis rs673078 0.607 rs2036314 ENSG00000275759.1 RP11-131L12.3 -6.39 3.89e-10 2.03e-07 -0.38 -0.28 Glucose homeostasis traits; chr12:118367132 chr12:118428281~118428870:+ LUSC cis rs2919917 0.793 rs2625664 ENSG00000254352.1 RP11-578O24.2 6.39 3.9e-10 2.04e-07 0.35 0.28 Lymphocyte counts; chr8:78718373 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs1026920 ENSG00000254352.1 RP11-578O24.2 6.39 3.9e-10 2.04e-07 0.35 0.28 Lymphocyte counts; chr8:78719775 chr8:78723796~78724136:- LUSC cis rs2919917 1 rs2717538 ENSG00000254352.1 RP11-578O24.2 6.39 3.9e-10 2.04e-07 0.35 0.28 Lymphocyte counts; chr8:78720914 chr8:78723796~78724136:- LUSC cis rs9903692 0.954 rs2109984 ENSG00000278765.1 RP5-890E16.5 6.39 3.9e-10 2.04e-07 0.34 0.28 Pulse pressure; chr17:48093737 chr17:48066704~48067293:- LUSC cis rs7267979 0.934 rs4815423 ENSG00000274973.1 RP13-401N8.7 6.39 3.91e-10 2.04e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25406885 chr20:25845497~25845862:+ LUSC cis rs732716 0.785 rs55660045 ENSG00000267769.1 CTB-50L17.9 -6.39 3.91e-10 2.04e-07 -0.33 -0.28 Mean corpuscular volume; chr19:4425308 chr19:4454014~4455286:+ LUSC cis rs11157436 0.958 rs17255510 ENSG00000211813.2 TRAV34 -6.39 3.92e-10 2.04e-07 -0.3 -0.28 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22194962 chr14:22207522~22208129:+ LUSC cis rs867371 1 rs9944197 ENSG00000255769.6 GOLGA2P10 -6.39 3.92e-10 2.05e-07 -0.35 -0.28 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82158261 chr15:82472993~82513950:- LUSC cis rs7246657 0.943 rs10420430 ENSG00000276846.1 CTD-3220F14.3 6.39 3.92e-10 2.05e-07 0.44 0.28 Coronary artery calcification; chr19:37403292 chr19:37314868~37315620:- LUSC cis rs4266144 0.562 rs2086667 ENSG00000244515.1 KRT18P34 -6.39 3.92e-10 2.05e-07 -0.4 -0.28 Coronary artery disease; chr3:157118728 chr3:157162663~157163932:- LUSC cis rs72772090 0.539 rs72773922 ENSG00000248734.2 CTD-2260A17.1 -6.39 3.93e-10 2.05e-07 -0.41 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96780956 chr5:96784777~96785999:+ LUSC cis rs2408955 0.522 rs10875721 ENSG00000240399.1 RP1-228P16.1 -6.39 3.93e-10 2.05e-07 -0.29 -0.28 Glycated hemoglobin levels; chr12:48019810 chr12:48054813~48055591:- LUSC cis rs7739264 1 rs9358270 ENSG00000237404.1 RP3-471C18.2 -6.39 3.93e-10 2.05e-07 -0.32 -0.28 Endometriosis; chr6:19780353 chr6:19689825~19753113:- LUSC cis rs853679 0.517 rs2273564 ENSG00000204709.4 LINC01556 6.39 3.94e-10 2.05e-07 0.4 0.28 Depression; chr6:28089816 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs1853097 ENSG00000204709.4 LINC01556 6.39 3.94e-10 2.05e-07 0.4 0.28 Depression; chr6:28090857 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393888 ENSG00000204709.4 LINC01556 6.39 3.94e-10 2.05e-07 0.4 0.28 Depression; chr6:28091439 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs3734573 ENSG00000204709.4 LINC01556 6.39 3.94e-10 2.05e-07 0.4 0.28 Depression; chr6:28091659 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9357063 ENSG00000204709.4 LINC01556 6.39 3.94e-10 2.05e-07 0.4 0.28 Depression; chr6:28092227 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs3823180 ENSG00000204709.4 LINC01556 6.39 3.94e-10 2.05e-07 0.4 0.28 Depression; chr6:28093966 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9368551 ENSG00000204709.4 LINC01556 6.39 3.94e-10 2.05e-07 0.4 0.28 Depression; chr6:28094014 chr6:28943877~28944537:+ LUSC cis rs8177876 0.749 rs935942 ENSG00000261838.4 RP11-303E16.6 -6.39 3.94e-10 2.06e-07 -0.62 -0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078531 chr16:81069854~81076598:+ LUSC cis rs496547 0.686 rs591756 ENSG00000255239.1 AP002954.6 6.39 3.94e-10 2.06e-07 0.32 0.28 Hip minimal joint space width; chr11:118808172 chr11:118688039~118690600:- LUSC cis rs7267979 1 rs6107033 ENSG00000274973.1 RP13-401N8.7 6.39 3.94e-10 2.06e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25382955 chr20:25845497~25845862:+ LUSC cis rs875971 0.545 rs67397473 ENSG00000226824.5 RP4-756H11.3 -6.39 3.94e-10 2.06e-07 -0.37 -0.28 Aortic root size; chr7:66168318 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs10950027 ENSG00000226824.5 RP4-756H11.3 -6.39 3.94e-10 2.06e-07 -0.37 -0.28 Aortic root size; chr7:66169164 chr7:66654538~66669855:+ LUSC cis rs62432291 0.614 rs452112 ENSG00000235086.1 FNDC1-IT1 -6.39 3.95e-10 2.06e-07 -0.48 -0.28 Joint mobility (Beighton score); chr6:159236996 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs417719 ENSG00000235086.1 FNDC1-IT1 -6.39 3.95e-10 2.06e-07 -0.48 -0.28 Joint mobility (Beighton score); chr6:159237010 chr6:159240786~159243329:+ LUSC cis rs11089937 0.568 rs35626600 ENSG00000211638.2 IGLV8-61 -6.39 3.95e-10 2.06e-07 -0.3 -0.28 Periodontitis (PAL4Q3); chr22:22130811 chr22:22098700~22099212:+ LUSC cis rs11089937 0.539 rs34228957 ENSG00000211638.2 IGLV8-61 -6.39 3.95e-10 2.06e-07 -0.3 -0.28 Periodontitis (PAL4Q3); chr22:22130838 chr22:22098700~22099212:+ LUSC cis rs7772486 0.654 rs9376958 ENSG00000235652.6 RP11-545I5.3 -6.39 3.95e-10 2.06e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145701904 chr6:145799409~145886585:+ LUSC cis rs9322193 0.923 rs12529698 ENSG00000268592.3 RAET1E-AS1 6.39 3.95e-10 2.06e-07 0.36 0.28 Lung cancer; chr6:149650951 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs10747276 ENSG00000268592.3 RAET1E-AS1 6.39 3.96e-10 2.06e-07 0.36 0.28 Lung cancer; chr6:149758739 chr6:149863494~149919507:+ LUSC cis rs7267979 0.966 rs2263204 ENSG00000274973.1 RP13-401N8.7 6.39 3.96e-10 2.07e-07 0.29 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25397052 chr20:25845497~25845862:+ LUSC cis rs2919917 1 rs2919936 ENSG00000254352.1 RP11-578O24.2 6.39 3.96e-10 2.07e-07 0.35 0.28 Lymphocyte counts; chr8:78721772 chr8:78723796~78724136:- LUSC cis rs783540 0.967 rs17158390 ENSG00000276710.3 CSPG4P8 6.39 3.97e-10 2.07e-07 0.29 0.28 Schizophrenia; chr15:82624277 chr15:82459472~82477258:+ LUSC cis rs783540 0.967 rs2870966 ENSG00000276710.3 CSPG4P8 6.39 3.97e-10 2.07e-07 0.29 0.28 Schizophrenia; chr15:82626493 chr15:82459472~82477258:+ LUSC cis rs11603023 0.772 rs540800 ENSG00000255422.1 AP002954.4 -6.39 3.97e-10 2.07e-07 -0.32 -0.28 Cholesterol, total; chr11:118694942 chr11:118704607~118750263:+ LUSC cis rs66887589 0.87 rs2389875 ENSG00000249244.1 RP11-548H18.2 -6.39 3.97e-10 2.07e-07 -0.34 -0.28 Diastolic blood pressure; chr4:119635859 chr4:119391831~119395335:- LUSC cis rs7829975 0.593 rs2921077 ENSG00000253893.2 FAM85B -6.39 3.97e-10 2.07e-07 -0.32 -0.28 Mood instability; chr8:8446992 chr8:8167819~8226614:- LUSC cis rs1823913 0.637 rs10931493 ENSG00000227542.1 AC092614.2 6.39 3.98e-10 2.08e-07 0.36 0.28 Obesity-related traits; chr2:191288142 chr2:191229165~191246172:- LUSC cis rs7829975 0.688 rs7817376 ENSG00000253893.2 FAM85B 6.39 3.98e-10 2.08e-07 0.33 0.28 Mood instability; chr8:8523020 chr8:8167819~8226614:- LUSC cis rs2919917 0.688 rs3780003 ENSG00000254352.1 RP11-578O24.2 6.39 3.98e-10 2.08e-07 0.33 0.28 Lymphocyte counts; chr8:78696019 chr8:78723796~78724136:- LUSC cis rs7246657 0.722 rs16958863 ENSG00000276846.1 CTD-3220F14.3 6.39 3.99e-10 2.08e-07 0.39 0.28 Coronary artery calcification; chr19:37633334 chr19:37314868~37315620:- LUSC cis rs17023223 0.537 rs17023174 ENSG00000231365.4 RP11-418J17.1 -6.39 3.99e-10 2.08e-07 -0.36 -0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119050678 chr1:119140396~119275973:+ LUSC cis rs2404602 0.647 rs11072612 ENSG00000259422.1 RP11-593F23.1 -6.39 3.99e-10 2.08e-07 -0.34 -0.28 Blood metabolite levels; chr15:76668643 chr15:76174891~76181486:- LUSC cis rs6142102 0.961 rs2284389 ENSG00000275784.1 RP5-1125A11.6 -6.39 3.99e-10 2.08e-07 -0.32 -0.28 Skin pigmentation; chr20:34069035 chr20:33989480~33991818:- LUSC cis rs228614 0.51 rs65671 ENSG00000230069.3 LRRC37A15P -6.39 4e-10 2.08e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102801081 chr4:102727274~102730721:- LUSC cis rs8059260 0.542 rs11860851 ENSG00000274038.1 RP11-66H6.4 -6.39 4.01e-10 2.09e-07 -0.48 -0.28 Alcohol consumption over the past year; chr16:11033893 chr16:11056556~11057034:+ LUSC cis rs442309 0.687 rs10822057 ENSG00000238280.1 RP11-436D10.3 -6.39 4.01e-10 2.09e-07 -0.34 -0.28 Vogt-Koyanagi-Harada syndrome; chr10:62760391 chr10:62793562~62805887:- LUSC cis rs67311347 1 rs10510708 ENSG00000223797.4 ENTPD3-AS1 6.39 4.01e-10 2.09e-07 0.31 0.28 Renal cell carcinoma; chr3:40363279 chr3:40313802~40453329:- LUSC cis rs2276314 0.857 rs28651028 ENSG00000278986.1 RP11-723J4.3 -6.39 4.02e-10 2.09e-07 -0.34 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36058947 chr18:35972151~35973916:+ LUSC cis rs9309473 1 rs7607014 ENSG00000163016.8 ALMS1P -6.39 4.02e-10 2.1e-07 -0.33 -0.28 Metabolite levels; chr2:73503047 chr2:73644919~73685576:+ LUSC cis rs7246657 0.882 rs10412043 ENSG00000276846.1 CTD-3220F14.3 6.39 4.03e-10 2.1e-07 0.43 0.28 Coronary artery calcification; chr19:37335724 chr19:37314868~37315620:- LUSC cis rs17507216 0.628 rs4513065 ENSG00000255769.6 GOLGA2P10 -6.39 4.03e-10 2.1e-07 -0.43 -0.28 Excessive daytime sleepiness; chr15:82712096 chr15:82472993~82513950:- LUSC cis rs7267979 0.808 rs84816 ENSG00000274973.1 RP13-401N8.7 -6.39 4.04e-10 2.1e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25479283 chr20:25845497~25845862:+ LUSC cis rs875971 0.66 rs10272357 ENSG00000224316.1 RP11-479O9.2 -6.39 4.04e-10 2.11e-07 -0.27 -0.28 Aortic root size; chr7:66598087 chr7:65773620~65802067:+ LUSC cis rs992157 0.56 rs1514132 ENSG00000261338.2 RP11-378A13.1 -6.39 4.05e-10 2.11e-07 -0.28 -0.28 Colorectal cancer; chr2:218219359 chr2:218255319~218257366:+ LUSC cis rs992157 0.56 rs10932763 ENSG00000261338.2 RP11-378A13.1 -6.39 4.05e-10 2.11e-07 -0.28 -0.28 Colorectal cancer; chr2:218221140 chr2:218255319~218257366:+ LUSC cis rs992157 0.56 rs12992937 ENSG00000261338.2 RP11-378A13.1 -6.39 4.05e-10 2.11e-07 -0.28 -0.28 Colorectal cancer; chr2:218222349 chr2:218255319~218257366:+ LUSC cis rs992157 0.56 rs4674274 ENSG00000261338.2 RP11-378A13.1 -6.39 4.05e-10 2.11e-07 -0.28 -0.28 Colorectal cancer; chr2:218224408 chr2:218255319~218257366:+ LUSC cis rs467650 0.782 rs719246 ENSG00000248489.1 CTD-2007H13.3 -6.39 4.07e-10 2.12e-07 -0.32 -0.28 Venous thromboembolism (SNP x SNP interaction); chr5:98722220 chr5:98929171~98995013:+ LUSC cis rs7246657 0.943 rs7248733 ENSG00000276846.1 CTD-3220F14.3 6.39 4.07e-10 2.12e-07 0.42 0.28 Coronary artery calcification; chr19:37505459 chr19:37314868~37315620:- LUSC cis rs6951245 1 rs118059236 ENSG00000224079.1 AC091729.7 -6.39 4.07e-10 2.12e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1033566 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs113858334 ENSG00000224079.1 AC091729.7 -6.39 4.07e-10 2.12e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1033840 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs79765398 ENSG00000224079.1 AC091729.7 -6.39 4.07e-10 2.12e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1034128 chr7:1074450~1078036:+ LUSC cis rs8177376 1 rs692955 ENSG00000254905.1 RP11-712L6.7 6.39 4.07e-10 2.12e-07 0.38 0.28 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126214601 chr11:126292922~126294254:- LUSC cis rs875971 0.505 rs1723275 ENSG00000164669.11 INTS4P1 6.39 4.08e-10 2.12e-07 0.31 0.28 Aortic root size; chr7:66039646 chr7:65141225~65234216:+ LUSC cis rs950169 0.922 rs4586394 ENSG00000259728.4 LINC00933 -6.39 4.08e-10 2.13e-07 -0.37 -0.28 Schizophrenia; chr15:84153633 chr15:84570649~84580175:+ LUSC cis rs5753618 0.583 rs5753612 ENSG00000236132.1 CTA-440B3.1 -6.39 4.09e-10 2.13e-07 -0.39 -0.28 Colorectal cancer; chr22:31425493 chr22:31816379~31817491:- LUSC cis rs72772090 0.539 rs11749811 ENSG00000248734.2 CTD-2260A17.1 -6.39 4.09e-10 2.13e-07 -0.41 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96780221 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs67140788 ENSG00000248734.2 CTD-2260A17.1 -6.39 4.09e-10 2.13e-07 -0.41 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96780582 chr5:96784777~96785999:+ LUSC cis rs12291225 0.546 rs12795545 ENSG00000251991.1 RNU7-49P 6.39 4.09e-10 2.13e-07 0.32 0.28 Sense of smell; chr11:14334018 chr11:14478892~14478953:+ LUSC cis rs2919917 0.662 rs1483572 ENSG00000254352.1 RP11-578O24.2 6.39 4.1e-10 2.13e-07 0.33 0.28 Lymphocyte counts; chr8:78723008 chr8:78723796~78724136:- LUSC cis rs881375 0.715 rs7858209 ENSG00000226752.6 PSMD5-AS1 -6.39 4.1e-10 2.13e-07 -0.31 -0.28 Rheumatoid arthritis; chr9:120883482 chr9:120824828~120854385:+ LUSC cis rs881375 0.715 rs10760119 ENSG00000226752.6 PSMD5-AS1 -6.39 4.1e-10 2.13e-07 -0.31 -0.28 Rheumatoid arthritis; chr9:120883782 chr9:120824828~120854385:+ LUSC cis rs7955901 0.691 rs7295488 ENSG00000257265.1 CTD-2021H9.1 6.39 4.1e-10 2.14e-07 0.32 0.28 Type 2 diabetes; chr12:71058266 chr12:71007773~71032083:- LUSC cis rs496547 0.588 rs473298 ENSG00000255422.1 AP002954.4 -6.39 4.1e-10 2.14e-07 -0.3 -0.28 Hip minimal joint space width; chr11:118808678 chr11:118704607~118750263:+ LUSC cis rs9309711 0.689 rs4535075 ENSG00000225234.1 TRAPPC12-AS1 -6.39 4.11e-10 2.14e-07 -0.33 -0.28 Neurofibrillary tangles; chr2:3477945 chr2:3481242~3482409:- LUSC cis rs9309711 0.666 rs6767 ENSG00000225234.1 TRAPPC12-AS1 -6.39 4.11e-10 2.14e-07 -0.33 -0.28 Neurofibrillary tangles; chr2:3479434 chr2:3481242~3482409:- LUSC cis rs9309711 0.623 rs7569694 ENSG00000225234.1 TRAPPC12-AS1 -6.39 4.11e-10 2.14e-07 -0.33 -0.28 Neurofibrillary tangles; chr2:3479619 chr2:3481242~3482409:- LUSC cis rs7804306 1 rs73050915 ENSG00000233264.2 AC006042.8 6.39 4.11e-10 2.14e-07 0.58 0.28 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8010614 chr7:7980312~7982228:+ LUSC cis rs7267979 1 rs2482930 ENSG00000274973.1 RP13-401N8.7 6.39 4.11e-10 2.14e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25353479 chr20:25845497~25845862:+ LUSC cis rs4604732 0.631 rs60311891 ENSG00000227135.1 GCSAML-AS1 -6.39 4.12e-10 2.14e-07 -0.42 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247459825 chr1:247524679~247526752:- LUSC cis rs7955901 0.725 rs12366661 ENSG00000257265.1 CTD-2021H9.1 6.39 4.12e-10 2.14e-07 0.32 0.28 Type 2 diabetes; chr12:71067588 chr12:71007773~71032083:- LUSC cis rs17711722 0.565 rs4717276 ENSG00000226824.5 RP4-756H11.3 -6.39 4.12e-10 2.14e-07 -0.33 -0.28 Calcium levels; chr7:65829754 chr7:66654538~66669855:+ LUSC cis rs35160687 0.623 rs7569654 ENSG00000273080.1 RP11-301O19.1 -6.38 4.13e-10 2.15e-07 -0.27 -0.28 Night sleep phenotypes; chr2:86250899 chr2:86195590~86196049:+ LUSC cis rs172166 0.694 rs1631552 ENSG00000216901.1 AL022393.7 6.38 4.13e-10 2.15e-07 0.33 0.28 Cardiac Troponin-T levels; chr6:28121921 chr6:28176188~28176674:+ LUSC cis rs4713118 0.513 rs149950 ENSG00000219392.1 RP1-265C24.5 -6.38 4.13e-10 2.15e-07 -0.35 -0.28 Parkinson's disease; chr6:28065261 chr6:28115628~28116551:+ LUSC cis rs4713118 0.513 rs149951 ENSG00000219392.1 RP1-265C24.5 -6.38 4.13e-10 2.15e-07 -0.35 -0.28 Parkinson's disease; chr6:28065309 chr6:28115628~28116551:+ LUSC cis rs10027350 0.765 rs6838393 ENSG00000281501.1 SEPSECS-AS1 6.38 4.13e-10 2.15e-07 0.34 0.28 Childhood ear infection; chr4:25172629 chr4:25160641~25201440:+ LUSC cis rs8040855 0.597 rs12902942 ENSG00000259295.5 CSPG4P12 6.38 4.13e-10 2.15e-07 0.36 0.28 Bulimia nervosa; chr15:85041573 chr15:85191438~85213905:+ LUSC cis rs11971779 0.68 rs1133067 ENSG00000273391.1 RP11-634H22.1 6.38 4.14e-10 2.15e-07 0.31 0.28 Diisocyanate-induced asthma; chr7:139368323 chr7:139359032~139359566:- LUSC cis rs13423976 0.6 rs2373404 ENSG00000231367.4 AC016995.3 6.38 4.14e-10 2.15e-07 0.37 0.28 Gut microbiome composition (summer); chr2:38512959 chr2:38406719~38515740:- LUSC cis rs6772849 0.93 rs4857912 ENSG00000242551.2 POU5F1P6 -6.38 4.14e-10 2.16e-07 -0.31 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128610381 chr3:128674735~128677005:- LUSC cis rs10829156 0.945 rs10829199 ENSG00000240291.1 RP11-499P20.2 6.38 4.15e-10 2.16e-07 0.32 0.28 Sudden cardiac arrest; chr10:18679012 chr10:18513115~18545651:- LUSC cis rs62432291 0.681 rs7757530 ENSG00000235086.1 FNDC1-IT1 6.38 4.17e-10 2.17e-07 0.47 0.28 Joint mobility (Beighton score); chr6:159226897 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs418859 ENSG00000235086.1 FNDC1-IT1 6.38 4.17e-10 2.17e-07 0.47 0.28 Joint mobility (Beighton score); chr6:159228663 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs404435 ENSG00000235086.1 FNDC1-IT1 -6.38 4.17e-10 2.17e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159233455 chr6:159240786~159243329:+ LUSC cis rs62432291 0.614 rs370434 ENSG00000235086.1 FNDC1-IT1 -6.38 4.17e-10 2.17e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159233519 chr6:159240786~159243329:+ LUSC cis rs7772486 0.686 rs1004752 ENSG00000235652.6 RP11-545I5.3 -6.38 4.18e-10 2.17e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145716686 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs9390347 ENSG00000235652.6 RP11-545I5.3 -6.38 4.18e-10 2.17e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145723611 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs9390348 ENSG00000235652.6 RP11-545I5.3 -6.38 4.18e-10 2.17e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145723612 chr6:145799409~145886585:+ LUSC cis rs7772486 0.632 rs9386128 ENSG00000235652.6 RP11-545I5.3 -6.38 4.18e-10 2.17e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145727917 chr6:145799409~145886585:+ LUSC cis rs783540 0.967 rs34186444 ENSG00000255769.6 GOLGA2P10 6.38 4.18e-10 2.17e-07 0.35 0.28 Schizophrenia; chr15:82618749 chr15:82472993~82513950:- LUSC cis rs13423976 0.631 rs11888984 ENSG00000231367.4 AC016995.3 -6.38 4.18e-10 2.17e-07 -0.37 -0.28 Gut microbiome composition (summer); chr2:38517250 chr2:38406719~38515740:- LUSC cis rs801193 0.935 rs11772264 ENSG00000236529.1 RP13-254B10.1 6.38 4.18e-10 2.17e-07 0.29 0.28 Aortic root size; chr7:66711400 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs7782320 ENSG00000236529.1 RP13-254B10.1 6.38 4.18e-10 2.17e-07 0.29 0.28 Aortic root size; chr7:66712111 chr7:65840212~65840596:+ LUSC cis rs75422866 0.51 rs73105829 ENSG00000257433.4 RP1-197B17.3 6.38 4.18e-10 2.17e-07 0.61 0.28 Pneumonia; chr12:47734162 chr12:47706085~47742294:+ LUSC cis rs6570726 0.791 rs422099 ENSG00000235652.6 RP11-545I5.3 6.38 4.19e-10 2.18e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145485800 chr6:145799409~145886585:+ LUSC cis rs853679 0.517 rs9393890 ENSG00000204709.4 LINC01556 6.38 4.19e-10 2.18e-07 0.4 0.28 Depression; chr6:28096077 chr6:28943877~28944537:+ LUSC cis rs4266144 0.562 rs56357317 ENSG00000244515.1 KRT18P34 -6.38 4.19e-10 2.18e-07 -0.4 -0.28 Coronary artery disease; chr3:157117385 chr3:157162663~157163932:- LUSC cis rs61270009 0.955 rs12163987 ENSG00000247828.6 TMEM161B-AS1 6.38 4.19e-10 2.18e-07 0.34 0.28 Depressive symptoms; chr5:88276209 chr5:88268895~88436685:+ LUSC cis rs7772486 0.686 rs4896827 ENSG00000235652.6 RP11-545I5.3 6.38 4.2e-10 2.18e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145632202 chr6:145799409~145886585:+ LUSC cis rs2337406 1 rs10459466 ENSG00000254174.1 IGHV1-12 6.38 4.2e-10 2.18e-07 0.3 0.28 Alzheimer's disease (late onset); chr14:106689255 chr14:106122420~106122709:- LUSC cis rs9549367 0.756 rs2316463 ENSG00000269125.1 RP11-98F14.11 -6.38 4.2e-10 2.19e-07 -0.36 -0.28 Platelet distribution width; chr13:113247092 chr13:113165002~113165183:- LUSC cis rs783540 0.5 rs7178459 ENSG00000255769.6 GOLGA2P10 -6.38 4.21e-10 2.19e-07 -0.38 -0.28 Schizophrenia; chr15:82729632 chr15:82472993~82513950:- LUSC cis rs4713118 0.629 rs203889 ENSG00000280107.1 AL022393.9 -6.38 4.21e-10 2.19e-07 -0.34 -0.28 Parkinson's disease; chr6:28053997 chr6:28170845~28172521:+ LUSC cis rs875971 0.8 rs427557 ENSG00000179406.6 LINC00174 -6.38 4.22e-10 2.19e-07 -0.3 -0.28 Aortic root size; chr7:66054263 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs11770063 ENSG00000226824.5 RP4-756H11.3 -6.38 4.22e-10 2.19e-07 -0.37 -0.28 Aortic root size; chr7:66318029 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs3936065 ENSG00000226824.5 RP4-756H11.3 -6.38 4.22e-10 2.19e-07 -0.37 -0.28 Aortic root size; chr7:66325577 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs4718335 ENSG00000226824.5 RP4-756H11.3 -6.38 4.22e-10 2.19e-07 -0.37 -0.28 Aortic root size; chr7:66339619 chr7:66654538~66669855:+ LUSC cis rs761746 0.579 rs131253 ENSG00000236132.1 CTA-440B3.1 -6.38 4.22e-10 2.19e-07 -0.41 -0.28 Intelligence; chr22:31734696 chr22:31816379~31817491:- LUSC cis rs6860806 0.507 rs2631362 ENSG00000233006.5 AC034220.3 -6.38 4.22e-10 2.19e-07 -0.3 -0.28 Breast cancer; chr5:132371601 chr5:132311285~132369916:- LUSC cis rs6951245 1 rs11768761 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1030171 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs76833820 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1030642 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs28379681 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1030903 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs28399710 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1030995 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs28528096 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1031276 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs74369356 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1032075 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs77083167 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1032187 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs74347384 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1032804 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs78308415 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1032998 chr7:1074450~1078036:+ LUSC cis rs6951245 0.872 rs75493422 ENSG00000224079.1 AC091729.7 -6.38 4.22e-10 2.19e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1033254 chr7:1074450~1078036:+ LUSC cis rs783540 0.934 rs36109438 ENSG00000255769.6 GOLGA2P10 6.38 4.22e-10 2.19e-07 0.35 0.28 Schizophrenia; chr15:82595709 chr15:82472993~82513950:- LUSC cis rs7955901 0.725 rs11178579 ENSG00000257265.1 CTD-2021H9.1 6.38 4.23e-10 2.2e-07 0.32 0.28 Type 2 diabetes; chr12:71063424 chr12:71007773~71032083:- LUSC cis rs7955901 0.725 rs1874313 ENSG00000257265.1 CTD-2021H9.1 6.38 4.23e-10 2.2e-07 0.32 0.28 Type 2 diabetes; chr12:71064385 chr12:71007773~71032083:- LUSC cis rs1075265 0.756 rs805423 ENSG00000233266.1 HMGB1P31 6.38 4.24e-10 2.2e-07 0.34 0.28 Chronotype;Morning vs. evening chronotype; chr2:53899904 chr2:54051334~54051760:+ LUSC cis rs4803480 0.678 rs3745936 ENSG00000270164.1 LINC01480 -6.38 4.25e-10 2.21e-07 -0.23 -0.28 Schizophrenia; chr19:41586462 chr19:41535183~41536904:+ LUSC cis rs11098499 0.955 rs11944880 ENSG00000250412.1 KLHL2P1 -6.38 4.25e-10 2.21e-07 -0.35 -0.28 Corneal astigmatism; chr4:119238179 chr4:119334329~119378233:+ LUSC cis rs1134634 0.52 rs13121363 ENSG00000273133.1 RP11-799M12.2 6.38 4.25e-10 2.21e-07 0.37 0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15567369 chr4:15563698~15564253:- LUSC cis rs1134634 0.52 rs13116304 ENSG00000273133.1 RP11-799M12.2 6.38 4.25e-10 2.21e-07 0.37 0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15567523 chr4:15563698~15564253:- LUSC cis rs75920871 0.588 rs7112111 ENSG00000254851.1 RP11-109L13.1 6.38 4.25e-10 2.21e-07 0.39 0.28 Subjective well-being; chr11:117110142 chr11:117135528~117138582:+ LUSC cis rs1075265 0.54 rs2542587 ENSG00000233266.1 HMGB1P31 6.38 4.25e-10 2.21e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:53788839 chr2:54051334~54051760:+ LUSC cis rs1075265 0.563 rs2692537 ENSG00000233266.1 HMGB1P31 6.38 4.25e-10 2.21e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:53788840 chr2:54051334~54051760:+ LUSC cis rs4604732 0.574 rs111928142 ENSG00000227135.1 GCSAML-AS1 -6.38 4.26e-10 2.21e-07 -0.42 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461927 chr1:247524679~247526752:- LUSC cis rs801193 1 rs62466793 ENSG00000236529.1 RP13-254B10.1 6.38 4.26e-10 2.21e-07 0.29 0.28 Aortic root size; chr7:66726530 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs62466794 ENSG00000236529.1 RP13-254B10.1 6.38 4.26e-10 2.21e-07 0.29 0.28 Aortic root size; chr7:66726592 chr7:65840212~65840596:+ LUSC cis rs2404602 0.647 rs3812909 ENSG00000259422.1 RP11-593F23.1 -6.38 4.26e-10 2.21e-07 -0.33 -0.28 Blood metabolite levels; chr15:76883859 chr15:76174891~76181486:- LUSC cis rs7246657 0.943 rs4803229 ENSG00000276846.1 CTD-3220F14.3 6.38 4.27e-10 2.22e-07 0.43 0.28 Coronary artery calcification; chr19:37373780 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs4452075 ENSG00000276846.1 CTD-3220F14.3 6.38 4.27e-10 2.22e-07 0.43 0.28 Coronary artery calcification; chr19:37388687 chr19:37314868~37315620:- LUSC cis rs875971 0.83 rs427575 ENSG00000179406.6 LINC00174 -6.38 4.27e-10 2.22e-07 -0.3 -0.28 Aortic root size; chr7:66054232 chr7:66376044~66401338:- LUSC cis rs950169 1 rs11638297 ENSG00000259728.4 LINC00933 6.38 4.28e-10 2.22e-07 0.36 0.28 Schizophrenia; chr15:84113665 chr15:84570649~84580175:+ LUSC cis rs7772486 0.641 rs960385 ENSG00000235652.6 RP11-545I5.3 6.38 4.28e-10 2.22e-07 0.3 0.28 Lobe attachment (rater-scored or self-reported); chr6:146049938 chr6:145799409~145886585:+ LUSC cis rs881375 0.967 rs1014529 ENSG00000226752.6 PSMD5-AS1 -6.38 4.28e-10 2.22e-07 -0.33 -0.28 Rheumatoid arthritis; chr9:120922665 chr9:120824828~120854385:+ LUSC cis rs801193 1 rs2707856 ENSG00000224316.1 RP11-479O9.2 6.38 4.28e-10 2.22e-07 0.27 0.28 Aortic root size; chr7:66746023 chr7:65773620~65802067:+ LUSC cis rs1823913 0.637 rs12992372 ENSG00000280083.1 RP11-317J9.1 -6.38 4.29e-10 2.22e-07 -0.33 -0.28 Obesity-related traits; chr2:191289251 chr2:191154118~191156070:- LUSC cis rs881375 0.967 rs1008382 ENSG00000226752.6 PSMD5-AS1 -6.38 4.3e-10 2.23e-07 -0.33 -0.28 Rheumatoid arthritis; chr9:120918977 chr9:120824828~120854385:+ LUSC cis rs228614 0.51 rs223465 ENSG00000230069.3 LRRC37A15P -6.38 4.3e-10 2.23e-07 -0.29 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780174 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223464 ENSG00000230069.3 LRRC37A15P -6.38 4.3e-10 2.23e-07 -0.29 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780603 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223468 ENSG00000230069.3 LRRC37A15P -6.38 4.3e-10 2.23e-07 -0.29 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102779265 chr4:102727274~102730721:- LUSC cis rs1113500 0.575 rs1781070 ENSG00000226822.1 RP11-356N1.2 -6.38 4.3e-10 2.23e-07 -0.27 -0.28 Growth-regulated protein alpha levels; chr1:108027076 chr1:108071482~108074519:+ LUSC cis rs12439619 0.693 rs8034801 ENSG00000276710.3 CSPG4P8 -6.38 4.3e-10 2.23e-07 -0.33 -0.28 Intelligence (multi-trait analysis); chr15:82183996 chr15:82459472~82477258:+ LUSC cis rs875971 0.545 rs10950025 ENSG00000226824.5 RP4-756H11.3 -6.38 4.3e-10 2.23e-07 -0.37 -0.28 Aortic root size; chr7:66158946 chr7:66654538~66669855:+ LUSC cis rs875971 0.52 rs12666485 ENSG00000226824.5 RP4-756H11.3 -6.38 4.3e-10 2.23e-07 -0.37 -0.28 Aortic root size; chr7:66160135 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs67688847 ENSG00000226824.5 RP4-756H11.3 -6.38 4.3e-10 2.23e-07 -0.37 -0.28 Aortic root size; chr7:66161064 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs12673308 ENSG00000226824.5 RP4-756H11.3 -6.38 4.3e-10 2.23e-07 -0.37 -0.28 Aortic root size; chr7:66166374 chr7:66654538~66669855:+ LUSC cis rs957448 1 rs12679345 ENSG00000253175.1 RP11-267M23.6 6.38 4.31e-10 2.23e-07 0.33 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94552305 chr8:94565036~94565715:+ LUSC cis rs227275 0.524 rs223337 ENSG00000230069.3 LRRC37A15P -6.38 4.31e-10 2.23e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102865214 chr4:102727274~102730721:- LUSC cis rs7772486 0.686 rs9403739 ENSG00000235652.6 RP11-545I5.3 -6.38 4.31e-10 2.24e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145694221 chr6:145799409~145886585:+ LUSC cis rs9322193 0.923 rs10782315 ENSG00000268592.3 RAET1E-AS1 6.38 4.31e-10 2.24e-07 0.36 0.28 Lung cancer; chr6:149743093 chr6:149863494~149919507:+ LUSC cis rs2729354 0.502 rs2848641 ENSG00000265566.2 RN7SL605P -6.38 4.31e-10 2.24e-07 -0.35 -0.28 Blood protein levels; chr11:57495595 chr11:57528085~57528365:- LUSC cis rs10829156 0.898 rs6482565 ENSG00000240291.1 RP11-499P20.2 6.38 4.32e-10 2.24e-07 0.31 0.28 Sudden cardiac arrest; chr10:18611664 chr10:18513115~18545651:- LUSC cis rs228614 0.51 rs223470 ENSG00000230069.3 LRRC37A15P -6.38 4.32e-10 2.24e-07 -0.29 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102778004 chr4:102727274~102730721:- LUSC cis rs875971 0.862 rs10256544 ENSG00000179406.6 LINC00174 -6.38 4.32e-10 2.24e-07 -0.31 -0.28 Aortic root size; chr7:66210141 chr7:66376044~66401338:- LUSC cis rs7772486 0.624 rs9485018 ENSG00000235652.6 RP11-545I5.3 -6.38 4.33e-10 2.24e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145704595 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs2092263 ENSG00000235652.6 RP11-545I5.3 -6.38 4.33e-10 2.24e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145708551 chr6:145799409~145886585:+ LUSC cis rs950169 0.845 rs4106951 ENSG00000259728.4 LINC00933 6.38 4.33e-10 2.24e-07 0.36 0.28 Schizophrenia; chr15:84164642 chr15:84570649~84580175:+ LUSC cis rs950169 0.922 rs6603022 ENSG00000259728.4 LINC00933 -6.38 4.33e-10 2.24e-07 -0.36 -0.28 Schizophrenia; chr15:84161418 chr15:84570649~84580175:+ LUSC cis rs950169 0.922 rs4842941 ENSG00000259728.4 LINC00933 -6.38 4.33e-10 2.24e-07 -0.36 -0.28 Schizophrenia; chr15:84162560 chr15:84570649~84580175:+ LUSC cis rs950169 0.922 rs12911223 ENSG00000259728.4 LINC00933 -6.38 4.33e-10 2.24e-07 -0.36 -0.28 Schizophrenia; chr15:84162919 chr15:84570649~84580175:+ LUSC cis rs5742933 0.817 rs13035966 ENSG00000253559.1 OSGEPL1-AS1 6.38 4.33e-10 2.24e-07 0.34 0.28 Ferritin levels; chr2:189726507 chr2:189762704~189765556:+ LUSC cis rs11971779 0.68 rs7801613 ENSG00000273391.1 RP11-634H22.1 -6.38 4.33e-10 2.25e-07 -0.31 -0.28 Diisocyanate-induced asthma; chr7:139355181 chr7:139359032~139359566:- LUSC cis rs5753618 0.583 rs7285619 ENSG00000236132.1 CTA-440B3.1 -6.38 4.34e-10 2.25e-07 -0.39 -0.28 Colorectal cancer; chr22:31446568 chr22:31816379~31817491:- LUSC cis rs13113518 0.783 rs12510400 ENSG00000249700.7 SRD5A3-AS1 6.38 4.34e-10 2.25e-07 0.33 0.28 Height; chr4:55577294 chr4:55363971~55395847:- LUSC cis rs13113518 0.783 rs13111128 ENSG00000249700.7 SRD5A3-AS1 6.38 4.34e-10 2.25e-07 0.33 0.28 Height; chr4:55578154 chr4:55363971~55395847:- LUSC cis rs853679 0.517 rs9468298 ENSG00000280107.1 AL022393.9 -6.38 4.34e-10 2.25e-07 -0.35 -0.28 Depression; chr6:28154567 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9295759 ENSG00000280107.1 AL022393.9 -6.38 4.34e-10 2.25e-07 -0.35 -0.28 Depression; chr6:28156691 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9348796 ENSG00000280107.1 AL022393.9 -6.38 4.34e-10 2.25e-07 -0.35 -0.28 Depression; chr6:28158424 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs11552219 ENSG00000280107.1 AL022393.9 -6.38 4.34e-10 2.25e-07 -0.35 -0.28 Depression; chr6:28159056 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9393895 ENSG00000280107.1 AL022393.9 -6.38 4.34e-10 2.25e-07 -0.35 -0.28 Depression; chr6:28159843 chr6:28170845~28172521:+ LUSC cis rs6772849 0.93 rs9868579 ENSG00000242551.2 POU5F1P6 6.38 4.36e-10 2.26e-07 0.32 0.28 Monocyte percentage of white cells;Monocyte count; chr3:128632211 chr3:128674735~128677005:- LUSC cis rs2919917 1 rs2717539 ENSG00000254352.1 RP11-578O24.2 6.38 4.36e-10 2.26e-07 0.35 0.28 Lymphocyte counts; chr8:78716804 chr8:78723796~78724136:- LUSC cis rs6142102 0.961 rs2268089 ENSG00000275784.1 RP5-1125A11.6 -6.38 4.37e-10 2.26e-07 -0.33 -0.28 Skin pigmentation; chr20:34079492 chr20:33989480~33991818:- LUSC cis rs875971 0.619 rs2302918 ENSG00000224316.1 RP11-479O9.2 6.37 4.38e-10 2.27e-07 0.27 0.28 Aortic root size; chr7:66535945 chr7:65773620~65802067:+ LUSC cis rs442309 0.687 rs10822054 ENSG00000238280.1 RP11-436D10.3 -6.37 4.38e-10 2.27e-07 -0.34 -0.28 Vogt-Koyanagi-Harada syndrome; chr10:62720492 chr10:62793562~62805887:- LUSC cis rs1823913 0.599 rs34840299 ENSG00000227542.1 AC092614.2 6.37 4.39e-10 2.27e-07 0.36 0.28 Obesity-related traits; chr2:191280379 chr2:191229165~191246172:- LUSC cis rs783540 0.967 rs1269134 ENSG00000255769.6 GOLGA2P10 6.37 4.39e-10 2.27e-07 0.35 0.28 Schizophrenia; chr15:82613877 chr15:82472993~82513950:- LUSC cis rs733592 0.599 rs12819124 ENSG00000240399.1 RP1-228P16.1 6.37 4.39e-10 2.27e-07 0.27 0.28 Plateletcrit; chr12:48015271 chr12:48054813~48055591:- LUSC cis rs496547 0.557 rs516719 ENSG00000255239.1 AP002954.6 6.37 4.4e-10 2.28e-07 0.32 0.28 Hip minimal joint space width; chr11:118808736 chr11:118688039~118690600:- LUSC cis rs7267979 0.903 rs2500400 ENSG00000274973.1 RP13-401N8.7 6.37 4.41e-10 2.28e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25374069 chr20:25845497~25845862:+ LUSC cis rs9549367 0.789 rs9604040 ENSG00000269125.1 RP11-98F14.11 6.37 4.41e-10 2.28e-07 0.34 0.28 Platelet distribution width; chr13:113256297 chr13:113165002~113165183:- LUSC cis rs5753618 0.583 rs9606843 ENSG00000236132.1 CTA-440B3.1 -6.37 4.41e-10 2.28e-07 -0.39 -0.28 Colorectal cancer; chr22:31457385 chr22:31816379~31817491:- LUSC cis rs9309473 1 rs7584575 ENSG00000163016.8 ALMS1P 6.37 4.41e-10 2.28e-07 0.34 0.28 Metabolite levels; chr2:73439274 chr2:73644919~73685576:+ LUSC cis rs9516 0.544 rs664679 ENSG00000254974.1 RP11-702H23.2 6.37 4.41e-10 2.29e-07 0.28 0.28 Facial morphology (factor 15, philtrum width); chr11:74475254 chr11:74485580~74486051:- LUSC cis rs3002131 0.736 rs2936027 ENSG00000225265.1 TAF1A-AS1 -6.37 4.41e-10 2.29e-07 -0.4 -0.28 Interleukin-10 levels; chr1:222588974 chr1:222589825~222593032:+ LUSC cis rs1823913 0.599 rs17346475 ENSG00000227542.1 AC092614.2 -6.37 4.42e-10 2.29e-07 -0.36 -0.28 Obesity-related traits; chr2:191288488 chr2:191229165~191246172:- LUSC cis rs875971 0.502 rs6460311 ENSG00000226824.5 RP4-756H11.3 6.37 4.42e-10 2.29e-07 0.38 0.28 Aortic root size; chr7:66646886 chr7:66654538~66669855:+ LUSC cis rs13113518 0.812 rs13107810 ENSG00000249700.7 SRD5A3-AS1 6.37 4.43e-10 2.29e-07 0.33 0.28 Height; chr4:55542243 chr4:55363971~55395847:- LUSC cis rs801193 0.591 rs2707839 ENSG00000237310.1 GS1-124K5.4 6.37 4.43e-10 2.29e-07 0.29 0.28 Aortic root size; chr7:66728097 chr7:66493706~66495474:+ LUSC cis rs4423214 0.592 rs10898234 ENSG00000254682.1 RP11-660L16.2 -6.37 4.43e-10 2.29e-07 -0.47 -0.28 Vitamin D levels; chr11:71525638 chr11:71448674~71452157:+ LUSC cis rs7246657 0.943 rs10406177 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37417045 chr19:37314868~37315620:- LUSC cis rs7246657 0.882 rs28623164 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37422551 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs7252346 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37423780 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs2891699 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37429335 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs9676967 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37437187 chr19:37314868~37315620:- LUSC cis rs7246657 0.882 rs8112610 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37437828 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs7255407 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37443034 chr19:37314868~37315620:- LUSC cis rs7246657 0.941 rs7256130 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37443079 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs2112923 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37449425 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs3760825 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37454699 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs10420754 ENSG00000276846.1 CTD-3220F14.3 6.37 4.44e-10 2.3e-07 0.43 0.28 Coronary artery calcification; chr19:37468470 chr19:37314868~37315620:- LUSC cis rs11089937 0.825 rs5757012 ENSG00000211638.2 IGLV8-61 -6.37 4.44e-10 2.3e-07 -0.26 -0.28 Periodontitis (PAL4Q3); chr22:22135515 chr22:22098700~22099212:+ LUSC cis rs801193 0.935 rs3800820 ENSG00000236529.1 RP13-254B10.1 -6.37 4.44e-10 2.3e-07 -0.29 -0.28 Aortic root size; chr7:66682191 chr7:65840212~65840596:+ LUSC cis rs227275 0.525 rs11737544 ENSG00000230069.3 LRRC37A15P -6.37 4.44e-10 2.3e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102983877 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs6533052 ENSG00000230069.3 LRRC37A15P -6.37 4.44e-10 2.3e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102990624 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs3974485 ENSG00000230069.3 LRRC37A15P -6.37 4.44e-10 2.3e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102993283 chr4:102727274~102730721:- LUSC cis rs17023223 0.537 rs2765533 ENSG00000231365.4 RP11-418J17.1 -6.37 4.45e-10 2.3e-07 -0.35 -0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119054772 chr1:119140396~119275973:+ LUSC cis rs7267979 0.932 rs928121 ENSG00000274973.1 RP13-401N8.7 -6.37 4.45e-10 2.3e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25554182 chr20:25845497~25845862:+ LUSC cis rs6772849 0.93 rs68090762 ENSG00000242551.2 POU5F1P6 -6.37 4.46e-10 2.3e-07 -0.32 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128625064 chr3:128674735~128677005:- LUSC cis rs6142102 0.602 rs10485503 ENSG00000275784.1 RP5-1125A11.6 -6.37 4.46e-10 2.31e-07 -0.31 -0.28 Skin pigmentation; chr20:33970036 chr20:33989480~33991818:- LUSC cis rs11976180 1 rs11976037 ENSG00000170356.8 OR2A20P -6.37 4.47e-10 2.31e-07 -0.38 -0.28 Obesity-related traits; chr7:144043931 chr7:144250045~144252957:- LUSC cis rs673078 0.517 rs73205578 ENSG00000275759.1 RP11-131L12.3 -6.37 4.47e-10 2.31e-07 -0.43 -0.28 Glucose homeostasis traits; chr12:118385113 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs73205579 ENSG00000275759.1 RP11-131L12.3 -6.37 4.47e-10 2.31e-07 -0.43 -0.28 Glucose homeostasis traits; chr12:118385125 chr12:118428281~118428870:+ LUSC cis rs875971 0.502 rs11769702 ENSG00000226824.5 RP4-756H11.3 -6.37 4.48e-10 2.31e-07 -0.37 -0.28 Aortic root size; chr7:66255529 chr7:66654538~66669855:+ LUSC cis rs35160687 0.623 rs11127019 ENSG00000273080.1 RP11-301O19.1 -6.37 4.48e-10 2.32e-07 -0.27 -0.28 Night sleep phenotypes; chr2:86240495 chr2:86195590~86196049:+ LUSC cis rs801193 0.591 rs9986881 ENSG00000236529.1 RP13-254B10.1 6.37 4.48e-10 2.32e-07 0.3 0.28 Aortic root size; chr7:66708053 chr7:65840212~65840596:+ LUSC cis rs875971 0.545 rs75840613 ENSG00000237310.1 GS1-124K5.4 6.37 4.49e-10 2.32e-07 0.32 0.28 Aortic root size; chr7:66376399 chr7:66493706~66495474:+ LUSC cis rs4713118 0.513 rs9368547 ENSG00000219392.1 RP1-265C24.5 -6.37 4.49e-10 2.32e-07 -0.35 -0.28 Parkinson's disease; chr6:28060289 chr6:28115628~28116551:+ LUSC cis rs4713118 0.513 rs183244 ENSG00000219392.1 RP1-265C24.5 -6.37 4.49e-10 2.32e-07 -0.35 -0.28 Parkinson's disease; chr6:28064060 chr6:28115628~28116551:+ LUSC cis rs783540 0.967 rs55972423 ENSG00000276710.3 CSPG4P8 6.37 4.49e-10 2.32e-07 0.3 0.28 Schizophrenia; chr15:82590203 chr15:82459472~82477258:+ LUSC cis rs2179367 0.632 rs11155651 ENSG00000231760.4 RP11-350J20.5 6.37 4.5e-10 2.32e-07 0.4 0.28 Dupuytren's disease; chr6:149408146 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs7896 ENSG00000231760.4 RP11-350J20.5 6.37 4.5e-10 2.32e-07 0.4 0.28 Dupuytren's disease; chr6:149410340 chr6:149796151~149826294:- LUSC cis rs6860806 0.507 rs2631369 ENSG00000233006.5 AC034220.3 -6.37 4.5e-10 2.32e-07 -0.3 -0.28 Breast cancer; chr5:132369574 chr5:132311285~132369916:- LUSC cis rs274567 0.501 rs2631368 ENSG00000233006.5 AC034220.3 -6.37 4.5e-10 2.32e-07 -0.3 -0.28 Blood metabolite levels; chr5:132369605 chr5:132311285~132369916:- LUSC cis rs2404602 0.647 rs8025991 ENSG00000259422.1 RP11-593F23.1 -6.37 4.5e-10 2.32e-07 -0.33 -0.28 Blood metabolite levels; chr15:76862927 chr15:76174891~76181486:- LUSC cis rs7429990 0.965 rs1550914 ENSG00000228638.1 FCF1P2 -6.37 4.52e-10 2.33e-07 -0.32 -0.28 Educational attainment (years of education); chr3:47953678 chr3:48290793~48291375:- LUSC cis rs7567389 0.74 rs1604817 ENSG00000236682.1 AC068282.3 6.37 4.52e-10 2.33e-07 0.39 0.28 Self-rated health; chr2:127242345 chr2:127389130~127400580:+ LUSC cis rs1823913 0.599 rs17346475 ENSG00000280083.1 RP11-317J9.1 6.37 4.52e-10 2.34e-07 0.33 0.28 Obesity-related traits; chr2:191288488 chr2:191154118~191156070:- LUSC cis rs4713118 0.955 rs9468204 ENSG00000219392.1 RP1-265C24.5 -6.37 4.52e-10 2.34e-07 -0.37 -0.28 Parkinson's disease; chr6:27721030 chr6:28115628~28116551:+ LUSC cis rs1823913 0.599 rs13427761 ENSG00000280083.1 RP11-317J9.1 6.37 4.52e-10 2.34e-07 0.33 0.28 Obesity-related traits; chr2:191269256 chr2:191154118~191156070:- LUSC cis rs7580658 0.637 rs4560059 ENSG00000236682.1 AC068282.3 -6.37 4.53e-10 2.34e-07 -0.37 -0.28 Protein C levels; chr2:127214652 chr2:127389130~127400580:+ LUSC cis rs2408955 0.521 rs11168437 ENSG00000240399.1 RP1-228P16.1 6.37 4.53e-10 2.34e-07 0.29 0.28 Glycated hemoglobin levels; chr12:48172373 chr12:48054813~48055591:- LUSC cis rs11690935 0.959 rs66835971 ENSG00000228389.1 AC068039.4 6.37 4.53e-10 2.34e-07 0.33 0.28 Schizophrenia; chr2:171820949 chr2:171773482~171775844:+ LUSC cis rs5742933 0.725 rs1132360 ENSG00000253559.1 OSGEPL1-AS1 6.37 4.53e-10 2.34e-07 0.34 0.28 Ferritin levels; chr2:189661498 chr2:189762704~189765556:+ LUSC cis rs638893 0.636 rs6589687 ENSG00000278376.1 RP11-158I9.8 -6.37 4.54e-10 2.34e-07 -0.37 -0.28 Vitiligo; chr11:118744951 chr11:118791254~118793137:+ LUSC cis rs35160687 0.623 rs11689971 ENSG00000273080.1 RP11-301O19.1 -6.37 4.54e-10 2.35e-07 -0.27 -0.28 Night sleep phenotypes; chr2:86247348 chr2:86195590~86196049:+ LUSC cis rs35160687 0.623 rs11127021 ENSG00000273080.1 RP11-301O19.1 -6.37 4.54e-10 2.35e-07 -0.27 -0.28 Night sleep phenotypes; chr2:86247796 chr2:86195590~86196049:+ LUSC cis rs10246939 0.505 rs9640203 ENSG00000228775.6 WEE2-AS1 6.37 4.55e-10 2.35e-07 0.36 0.28 Bitter taste perception; chr7:141844295 chr7:141704338~141738346:- LUSC cis rs801193 1 rs2707836 ENSG00000236529.1 RP13-254B10.1 6.37 4.55e-10 2.35e-07 0.29 0.28 Aortic root size; chr7:66695448 chr7:65840212~65840596:+ LUSC cis rs11098499 0.722 rs7673476 ENSG00000249244.1 RP11-548H18.2 6.37 4.56e-10 2.35e-07 0.35 0.28 Corneal astigmatism; chr4:119327528 chr4:119391831~119395335:- LUSC cis rs6951245 0.882 rs56048221 ENSG00000224079.1 AC091729.7 -6.37 4.56e-10 2.36e-07 -0.45 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1052897 chr7:1074450~1078036:+ LUSC cis rs11690935 1 rs2138348 ENSG00000228389.1 AC068039.4 -6.37 4.56e-10 2.36e-07 -0.33 -0.28 Schizophrenia; chr2:171701662 chr2:171773482~171775844:+ LUSC cis rs853679 0.517 rs9380047 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28070115 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs7755442 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28071237 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs55747925 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28076559 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs34716816 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28078391 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9380049 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28080757 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9380050 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28080760 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393885 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28082231 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9393886 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28082261 chr6:28943877~28944537:+ LUSC cis rs4713118 0.515 rs9368549 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Parkinson's disease; chr6:28082269 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs56364346 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28082984 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9357061 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28083994 chr6:28943877~28944537:+ LUSC cis rs853679 0.517 rs9368550 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28084025 chr6:28943877~28944537:+ LUSC cis rs853679 0.542 rs2295594 ENSG00000204709.4 LINC01556 6.37 4.56e-10 2.36e-07 0.4 0.28 Depression; chr6:28085319 chr6:28943877~28944537:+ LUSC cis rs172166 0.769 rs149965 ENSG00000216901.1 AL022393.7 6.37 4.56e-10 2.36e-07 0.33 0.28 Cardiac Troponin-T levels; chr6:28050911 chr6:28176188~28176674:+ LUSC cis rs6714900 0.588 rs2287331 ENSG00000234896.1 OR7E62P -6.37 4.57e-10 2.36e-07 -0.38 -0.28 Blood protein levels; chr2:71067422 chr2:71055527~71056003:+ LUSC cis rs2404602 0.53 rs11072614 ENSG00000259422.1 RP11-593F23.1 -6.37 4.57e-10 2.36e-07 -0.35 -0.28 Blood metabolite levels; chr15:76674864 chr15:76174891~76181486:- LUSC cis rs11089937 0.857 rs5750578 ENSG00000211638.2 IGLV8-61 -6.37 4.58e-10 2.36e-07 -0.25 -0.28 Periodontitis (PAL4Q3); chr22:22136444 chr22:22098700~22099212:+ LUSC cis rs801193 0.569 rs10950050 ENSG00000179406.6 LINC00174 -6.37 4.58e-10 2.36e-07 -0.3 -0.28 Aortic root size; chr7:66774601 chr7:66376044~66401338:- LUSC cis rs1865760 0.566 rs3752419 ENSG00000272462.2 U91328.19 -6.37 4.59e-10 2.37e-07 -0.29 -0.28 Height; chr6:26027205 chr6:25992662~26001775:+ LUSC cis rs6772849 0.896 rs4857859 ENSG00000242551.2 POU5F1P6 -6.37 4.59e-10 2.37e-07 -0.32 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128629171 chr3:128674735~128677005:- LUSC cis rs12439619 0.846 rs62013464 ENSG00000276710.3 CSPG4P8 -6.37 4.59e-10 2.37e-07 -0.34 -0.28 Intelligence (multi-trait analysis); chr15:82288250 chr15:82459472~82477258:+ LUSC cis rs13113518 0.812 rs2035692 ENSG00000249700.7 SRD5A3-AS1 6.37 4.59e-10 2.37e-07 0.33 0.28 Height; chr4:55528801 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs4507426 ENSG00000249700.7 SRD5A3-AS1 6.37 4.59e-10 2.37e-07 0.33 0.28 Height; chr4:55529387 chr4:55363971~55395847:- LUSC cis rs7267979 1 rs4815408 ENSG00000274973.1 RP13-401N8.7 6.37 4.59e-10 2.37e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25366042 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs4813563 ENSG00000274973.1 RP13-401N8.7 6.37 4.59e-10 2.37e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25384704 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs6037103 ENSG00000274973.1 RP13-401N8.7 6.37 4.59e-10 2.37e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25388459 chr20:25845497~25845862:+ LUSC cis rs6142102 1 rs6059672 ENSG00000275784.1 RP5-1125A11.6 -6.37 4.61e-10 2.38e-07 -0.33 -0.28 Skin pigmentation; chr20:34117662 chr20:33989480~33991818:- LUSC cis rs7429990 0.833 rs2030596 ENSG00000229759.1 MRPS18AP1 -6.37 4.61e-10 2.38e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47701712 chr3:48256350~48256938:- LUSC cis rs2834288 0.608 rs2017190 ENSG00000273102.1 AP000569.9 6.37 4.61e-10 2.38e-07 0.32 0.28 Gut microbiota (bacterial taxa); chr21:33938609 chr21:33967101~33968573:- LUSC cis rs11690935 0.959 rs6433314 ENSG00000228389.1 AC068039.4 6.37 4.61e-10 2.38e-07 0.33 0.28 Schizophrenia; chr2:171804461 chr2:171773482~171775844:+ LUSC cis rs9549367 0.789 rs3794422 ENSG00000269125.1 RP11-98F14.11 -6.37 4.62e-10 2.38e-07 -0.36 -0.28 Platelet distribution width; chr13:113239415 chr13:113165002~113165183:- LUSC cis rs11690935 0.838 rs10432423 ENSG00000228389.1 AC068039.4 6.37 4.62e-10 2.38e-07 0.33 0.28 Schizophrenia; chr2:171896785 chr2:171773482~171775844:+ LUSC cis rs9322193 0.923 rs7753812 ENSG00000268592.3 RAET1E-AS1 6.37 4.62e-10 2.38e-07 0.36 0.28 Lung cancer; chr6:149690150 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs12195866 ENSG00000268592.3 RAET1E-AS1 6.37 4.62e-10 2.38e-07 0.36 0.28 Lung cancer; chr6:149693334 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9285524 ENSG00000268592.3 RAET1E-AS1 6.37 4.62e-10 2.38e-07 0.36 0.28 Lung cancer; chr6:149694122 chr6:149863494~149919507:+ LUSC cis rs9532669 0.926 rs7329302 ENSG00000176268.5 CYCSP34 -6.37 4.62e-10 2.38e-07 -0.29 -0.28 Cervical cancer; chr13:40962396 chr13:40863599~40863902:- LUSC cis rs66887589 0.934 rs2389873 ENSG00000249244.1 RP11-548H18.2 -6.37 4.62e-10 2.38e-07 -0.34 -0.28 Diastolic blood pressure; chr4:119633559 chr4:119391831~119395335:- LUSC cis rs4713118 0.662 rs149900 ENSG00000280107.1 AL022393.9 -6.37 4.63e-10 2.38e-07 -0.35 -0.28 Parkinson's disease; chr6:28046819 chr6:28170845~28172521:+ LUSC cis rs17818399 0.62 rs1080871 ENSG00000279254.1 RP11-536C12.1 -6.37 4.63e-10 2.39e-07 -0.31 -0.28 Height; chr2:46627569 chr2:46668870~46670778:+ LUSC cis rs10246939 0.579 rs58093678 ENSG00000228775.6 WEE2-AS1 6.37 4.64e-10 2.39e-07 0.33 0.28 Bitter taste perception; chr7:141856719 chr7:141704338~141738346:- LUSC cis rs13113518 0.812 rs56055342 ENSG00000249700.7 SRD5A3-AS1 6.37 4.64e-10 2.39e-07 0.33 0.28 Height; chr4:55540928 chr4:55363971~55395847:- LUSC cis rs9903692 0.954 rs9889470 ENSG00000278765.1 RP5-890E16.5 6.37 4.64e-10 2.39e-07 0.34 0.28 Pulse pressure; chr17:48233713 chr17:48066704~48067293:- LUSC cis rs783540 0.967 rs783529 ENSG00000255769.6 GOLGA2P10 6.37 4.64e-10 2.39e-07 0.35 0.28 Schizophrenia; chr15:82599231 chr15:82472993~82513950:- LUSC cis rs1823913 0.599 rs34840299 ENSG00000280083.1 RP11-317J9.1 -6.36 4.65e-10 2.4e-07 -0.33 -0.28 Obesity-related traits; chr2:191280379 chr2:191154118~191156070:- LUSC cis rs950169 1 rs1911155 ENSG00000225151.9 GOLGA2P7 -6.36 4.66e-10 2.4e-07 -0.4 -0.28 Schizophrenia; chr15:84118883 chr15:84199311~84230136:- LUSC cis rs9341808 0.935 rs9448894 ENSG00000272129.1 RP11-250B2.6 6.36 4.67e-10 2.4e-07 0.34 0.28 Sitting height ratio; chr6:80127536 chr6:80355424~80356859:+ LUSC cis rs227275 0.525 rs7688940 ENSG00000230069.3 LRRC37A15P -6.36 4.67e-10 2.41e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102994153 chr4:102727274~102730721:- LUSC cis rs1320333 0.772 rs111825088 ENSG00000233296.1 AC092159.2 6.36 4.68e-10 2.41e-07 0.47 0.28 Obesity-related traits; chr2:695785 chr2:677186~697371:+ LUSC cis rs875971 0.545 rs7787063 ENSG00000226824.5 RP4-756H11.3 -6.36 4.68e-10 2.41e-07 -0.37 -0.28 Aortic root size; chr7:66164012 chr7:66654538~66669855:+ LUSC cis rs8040855 0.627 rs12900012 ENSG00000259295.5 CSPG4P12 6.36 4.68e-10 2.41e-07 0.35 0.28 Bulimia nervosa; chr15:85046955 chr15:85191438~85213905:+ LUSC cis rs1056107 0.763 rs60623018 ENSG00000225513.1 RP11-165N19.2 -6.36 4.68e-10 2.41e-07 -0.31 -0.28 Colorectal cancer; chr9:112175922 chr9:112173522~112173971:- LUSC cis rs10829156 0.947 rs10764661 ENSG00000240291.1 RP11-499P20.2 6.36 4.68e-10 2.41e-07 0.31 0.28 Sudden cardiac arrest; chr10:18659018 chr10:18513115~18545651:- LUSC cis rs638893 0.53 rs1961138 ENSG00000278376.1 RP11-158I9.8 -6.36 4.69e-10 2.41e-07 -0.37 -0.28 Vitiligo; chr11:118748714 chr11:118791254~118793137:+ LUSC cis rs9376098 0.698 rs2050020 ENSG00000232876.1 CTA-212D2.2 -6.36 4.7e-10 2.42e-07 -0.35 -0.28 Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells; chr6:135142915 chr6:135055033~135060550:+ LUSC cis rs35160687 0.644 rs56394965 ENSG00000273080.1 RP11-301O19.1 -6.36 4.7e-10 2.42e-07 -0.27 -0.28 Night sleep phenotypes; chr2:86271226 chr2:86195590~86196049:+ LUSC cis rs875971 0.505 rs2462573 ENSG00000164669.11 INTS4P1 6.36 4.71e-10 2.42e-07 0.31 0.28 Aortic root size; chr7:66042405 chr7:65141225~65234216:+ LUSC cis rs2280018 1 rs2280018 ENSG00000260735.1 RP11-72I8.1 -6.36 4.71e-10 2.42e-07 -0.31 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15056976 chr16:15094411~15109197:+ LUSC cis rs6504622 0.677 rs12949446 ENSG00000262879.4 RP11-156P1.3 -6.36 4.71e-10 2.42e-07 -0.29 -0.28 Orofacial clefts; chr17:46994311 chr17:46984045~47100323:- LUSC cis rs6504622 0.693 rs12952596 ENSG00000262879.4 RP11-156P1.3 -6.36 4.71e-10 2.42e-07 -0.29 -0.28 Orofacial clefts; chr17:46994319 chr17:46984045~47100323:- LUSC cis rs11976180 1 rs2961144 ENSG00000170356.8 OR2A20P 6.36 4.72e-10 2.43e-07 0.37 0.28 Obesity-related traits; chr7:144050777 chr7:144250045~144252957:- LUSC cis rs6504622 0.721 rs8077021 ENSG00000262879.4 RP11-156P1.3 -6.36 4.72e-10 2.43e-07 -0.3 -0.28 Orofacial clefts; chr17:47061937 chr17:46984045~47100323:- LUSC cis rs3096299 0.606 rs4785573 ENSG00000274627.1 RP11-104N10.2 6.36 4.73e-10 2.43e-07 0.27 0.28 Multiple myeloma (IgH translocation); chr16:89498995 chr16:89516797~89522217:+ LUSC cis rs7955901 0.691 rs34349223 ENSG00000257265.1 CTD-2021H9.1 6.36 4.74e-10 2.44e-07 0.32 0.28 Type 2 diabetes; chr12:71115872 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs36021752 ENSG00000257265.1 CTD-2021H9.1 6.36 4.74e-10 2.44e-07 0.32 0.28 Type 2 diabetes; chr12:71116013 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs7295634 ENSG00000257265.1 CTD-2021H9.1 6.36 4.74e-10 2.44e-07 0.32 0.28 Type 2 diabetes; chr12:71116398 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs68192204 ENSG00000257265.1 CTD-2021H9.1 6.36 4.74e-10 2.44e-07 0.32 0.28 Type 2 diabetes; chr12:71117193 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs68134932 ENSG00000257265.1 CTD-2021H9.1 6.36 4.74e-10 2.44e-07 0.32 0.28 Type 2 diabetes; chr12:71117288 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs59590422 ENSG00000257265.1 CTD-2021H9.1 6.36 4.74e-10 2.44e-07 0.32 0.28 Type 2 diabetes; chr12:71117812 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs12818936 ENSG00000257265.1 CTD-2021H9.1 6.36 4.74e-10 2.44e-07 0.32 0.28 Type 2 diabetes; chr12:71124229 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs12817873 ENSG00000257265.1 CTD-2021H9.1 6.36 4.74e-10 2.44e-07 0.32 0.28 Type 2 diabetes; chr12:71124253 chr12:71007773~71032083:- LUSC cis rs7955901 0.664 rs11178634 ENSG00000257265.1 CTD-2021H9.1 6.36 4.74e-10 2.44e-07 0.32 0.28 Type 2 diabetes; chr12:71124549 chr12:71007773~71032083:- LUSC cis rs8059260 0.736 rs16957835 ENSG00000274038.1 RP11-66H6.4 -6.36 4.75e-10 2.44e-07 -0.47 -0.28 Alcohol consumption over the past year; chr16:10958198 chr16:11056556~11057034:+ LUSC cis rs1823913 0.599 rs4146103 ENSG00000280083.1 RP11-317J9.1 -6.36 4.75e-10 2.44e-07 -0.33 -0.28 Obesity-related traits; chr2:191272000 chr2:191154118~191156070:- LUSC cis rs8177876 0.822 rs16954582 ENSG00000261838.4 RP11-303E16.6 6.36 4.76e-10 2.45e-07 0.6 0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080552 chr16:81069854~81076598:+ LUSC cis rs875971 0.545 rs6970498 ENSG00000226824.5 RP4-756H11.3 -6.36 4.77e-10 2.45e-07 -0.37 -0.28 Aortic root size; chr7:66275908 chr7:66654538~66669855:+ LUSC cis rs116139393 0.656 rs10244591 ENSG00000187953.9 PMS2CL -6.36 4.77e-10 2.45e-07 -0.36 -0.28 Alzheimer's disease (APOE e4 interaction); chr7:6731467 chr7:6710128~6753862:+ LUSC cis rs7267979 1 rs7018 ENSG00000274973.1 RP13-401N8.7 -6.36 4.77e-10 2.45e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25297625 chr20:25845497~25845862:+ LUSC cis rs6142102 0.625 rs4911381 ENSG00000275784.1 RP5-1125A11.6 6.36 4.78e-10 2.46e-07 0.3 0.28 Skin pigmentation; chr20:33962539 chr20:33989480~33991818:- LUSC cis rs7772486 0.686 rs4896828 ENSG00000235652.6 RP11-545I5.3 6.36 4.79e-10 2.46e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145632203 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs6570701 ENSG00000235652.6 RP11-545I5.3 6.36 4.79e-10 2.46e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145632954 chr6:145799409~145886585:+ LUSC cis rs17711722 0.565 rs4275112 ENSG00000226824.5 RP4-756H11.3 6.36 4.8e-10 2.46e-07 0.33 0.28 Calcium levels; chr7:65733651 chr7:66654538~66669855:+ LUSC cis rs4713118 0.629 rs203890 ENSG00000280107.1 AL022393.9 -6.36 4.8e-10 2.47e-07 -0.35 -0.28 Parkinson's disease; chr6:28054470 chr6:28170845~28172521:+ LUSC cis rs1823913 0.599 rs1378156 ENSG00000280083.1 RP11-317J9.1 6.36 4.8e-10 2.47e-07 0.33 0.28 Obesity-related traits; chr2:191272466 chr2:191154118~191156070:- LUSC cis rs11157436 0.918 rs12437004 ENSG00000211813.2 TRAV34 6.36 4.82e-10 2.48e-07 0.3 0.28 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22149461 chr14:22207522~22208129:+ LUSC cis rs13113518 0.812 rs12500456 ENSG00000249700.7 SRD5A3-AS1 6.36 4.82e-10 2.48e-07 0.33 0.28 Height; chr4:55561053 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs13116035 ENSG00000249700.7 SRD5A3-AS1 6.36 4.82e-10 2.48e-07 0.33 0.28 Height; chr4:55561218 chr4:55363971~55395847:- LUSC cis rs62388641 0.547 rs9391923 ENSG00000272279.1 RP11-157J24.2 -6.36 4.83e-10 2.48e-07 -0.38 -0.28 Daytime sleep phenotypes; chr6:1554089 chr6:1528364~1528911:- LUSC cis rs853679 0.517 rs56310871 ENSG00000204709.4 LINC01556 6.36 4.83e-10 2.48e-07 0.4 0.28 Depression; chr6:28076704 chr6:28943877~28944537:+ LUSC cis rs11123170 0.529 rs35606997 ENSG00000189223.12 PAX8-AS1 -6.36 4.84e-10 2.49e-07 -0.43 -0.28 Renal function-related traits (BUN); chr2:113215773 chr2:113211522~113276581:+ LUSC cis rs8062405 0.755 rs2077031 ENSG00000278665.1 RP11-666O2.4 6.36 4.84e-10 2.49e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28591847 chr16:28599241~28601881:- LUSC cis rs4237845 0.967 rs4553410 ENSG00000257159.1 RP11-58A17.3 6.36 4.85e-10 2.49e-07 0.34 0.28 Intelligence (multi-trait analysis); chr12:57907428 chr12:57967058~57968399:+ LUSC cis rs950169 0.92 rs12915390 ENSG00000259728.4 LINC00933 6.36 4.85e-10 2.49e-07 0.37 0.28 Schizophrenia; chr15:84123317 chr15:84570649~84580175:+ LUSC cis rs227275 0.554 rs223454 ENSG00000230069.3 LRRC37A15P -6.36 4.85e-10 2.49e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102789773 chr4:102727274~102730721:- LUSC cis rs875971 0.545 rs316305 ENSG00000226824.5 RP4-756H11.3 6.36 4.85e-10 2.49e-07 0.37 0.28 Aortic root size; chr7:66152984 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs2460427 ENSG00000226824.5 RP4-756H11.3 6.36 4.85e-10 2.49e-07 0.37 0.28 Aortic root size; chr7:66154218 chr7:66654538~66669855:+ LUSC cis rs36405 0.5 rs2109273 ENSG00000266869.1 RP6-114E22.1 -6.36 4.85e-10 2.49e-07 -0.35 -0.28 Yang-deficiency constitution; chr14:71894247 chr14:71848606~71908430:+ LUSC cis rs6772849 0.93 rs7639400 ENSG00000242551.2 POU5F1P6 -6.36 4.85e-10 2.49e-07 -0.32 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128604513 chr3:128674735~128677005:- LUSC cis rs6951245 1 rs11763020 ENSG00000224079.1 AC091729.7 -6.36 4.86e-10 2.5e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1020652 chr7:1074450~1078036:+ LUSC cis rs10829156 0.732 rs7075678 ENSG00000240291.1 RP11-499P20.2 6.36 4.86e-10 2.5e-07 0.32 0.28 Sudden cardiac arrest; chr10:18585174 chr10:18513115~18545651:- LUSC cis rs6951245 1 rs6951245 ENSG00000224079.1 AC091729.7 -6.36 4.88e-10 2.5e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1018557 chr7:1074450~1078036:+ LUSC cis rs4604732 0.536 rs4925674 ENSG00000227135.1 GCSAML-AS1 -6.36 4.88e-10 2.51e-07 -0.41 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247473604 chr1:247524679~247526752:- LUSC cis rs62432291 0.681 rs1699442 ENSG00000235086.1 FNDC1-IT1 6.36 4.89e-10 2.51e-07 0.48 0.28 Joint mobility (Beighton score); chr6:159234886 chr6:159240786~159243329:+ LUSC cis rs11098499 1 rs13435802 ENSG00000250412.1 KLHL2P1 -6.36 4.89e-10 2.51e-07 -0.35 -0.28 Corneal astigmatism; chr4:119256805 chr4:119334329~119378233:+ LUSC cis rs875971 0.545 rs4441996 ENSG00000226824.5 RP4-756H11.3 6.36 4.89e-10 2.51e-07 0.37 0.28 Aortic root size; chr7:66123233 chr7:66654538~66669855:+ LUSC cis rs7772486 0.686 rs9376961 ENSG00000235652.6 RP11-545I5.3 6.36 4.89e-10 2.51e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145727601 chr6:145799409~145886585:+ LUSC cis rs6570726 0.967 rs413880 ENSG00000235652.6 RP11-545I5.3 6.36 4.9e-10 2.51e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145483686 chr6:145799409~145886585:+ LUSC cis rs442309 0.687 rs10995283 ENSG00000238280.1 RP11-436D10.3 -6.36 4.9e-10 2.51e-07 -0.34 -0.28 Vogt-Koyanagi-Harada syndrome; chr10:62714628 chr10:62793562~62805887:- LUSC cis rs442309 0.687 rs7084016 ENSG00000238280.1 RP11-436D10.3 -6.36 4.9e-10 2.51e-07 -0.34 -0.28 Vogt-Koyanagi-Harada syndrome; chr10:62720681 chr10:62793562~62805887:- LUSC cis rs9322193 0.847 rs9383844 ENSG00000268592.3 RAET1E-AS1 6.36 4.9e-10 2.51e-07 0.36 0.28 Lung cancer; chr6:149716268 chr6:149863494~149919507:+ LUSC cis rs2408955 0.561 rs9971924 ENSG00000240399.1 RP1-228P16.1 -6.36 4.9e-10 2.51e-07 -0.29 -0.28 Glycated hemoglobin levels; chr12:48086049 chr12:48054813~48055591:- LUSC cis rs801193 0.613 rs2659900 ENSG00000237310.1 GS1-124K5.4 6.36 4.9e-10 2.52e-07 0.29 0.28 Aortic root size; chr7:66719456 chr7:66493706~66495474:+ LUSC cis rs11690935 0.921 rs908670 ENSG00000228389.1 AC068039.4 6.36 4.9e-10 2.52e-07 0.33 0.28 Schizophrenia; chr2:171833670 chr2:171773482~171775844:+ LUSC cis rs30380 1 rs27710 ENSG00000248734.2 CTD-2260A17.1 -6.36 4.91e-10 2.52e-07 -0.26 -0.28 Cerebrospinal fluid biomarker levels; chr5:96790494 chr5:96784777~96785999:+ LUSC cis rs9903692 0.954 rs7217496 ENSG00000278765.1 RP5-890E16.5 6.36 4.91e-10 2.52e-07 0.34 0.28 Pulse pressure; chr17:48076840 chr17:48066704~48067293:- LUSC cis rs7267979 1 rs7020 ENSG00000274973.1 RP13-401N8.7 -6.36 4.92e-10 2.53e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25297964 chr20:25845497~25845862:+ LUSC cis rs9376098 0.698 rs6908307 ENSG00000232876.1 CTA-212D2.2 -6.36 4.92e-10 2.53e-07 -0.34 -0.28 Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells; chr6:135141542 chr6:135055033~135060550:+ LUSC cis rs2280018 0.581 rs7404524 ENSG00000260735.1 RP11-72I8.1 -6.36 4.93e-10 2.53e-07 -0.34 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15035301 chr16:15094411~15109197:+ LUSC cis rs9309711 0.621 rs12993215 ENSG00000225234.1 TRAPPC12-AS1 -6.36 4.93e-10 2.53e-07 -0.33 -0.28 Neurofibrillary tangles; chr2:3469956 chr2:3481242~3482409:- LUSC cis rs8040855 0.627 rs12909130 ENSG00000259295.5 CSPG4P12 6.35 4.93e-10 2.53e-07 0.35 0.28 Bulimia nervosa; chr15:85047270 chr15:85191438~85213905:+ LUSC cis rs11098499 0.908 rs1002152 ENSG00000250412.1 KLHL2P1 6.35 4.93e-10 2.53e-07 0.35 0.28 Corneal astigmatism; chr4:119352232 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs10213554 ENSG00000249244.1 RP11-548H18.2 -6.35 4.94e-10 2.53e-07 -0.35 -0.28 Corneal astigmatism; chr4:119339630 chr4:119391831~119395335:- LUSC cis rs6570726 0.791 rs398408 ENSG00000235652.6 RP11-545I5.3 6.35 4.94e-10 2.53e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145479884 chr6:145799409~145886585:+ LUSC cis rs1823913 0.599 rs13027086 ENSG00000227542.1 AC092614.2 6.35 4.94e-10 2.53e-07 0.36 0.28 Obesity-related traits; chr2:191294058 chr2:191229165~191246172:- LUSC cis rs10829156 0.57 rs7904365 ENSG00000240291.1 RP11-499P20.2 6.35 4.96e-10 2.54e-07 0.31 0.28 Sudden cardiac arrest; chr10:18542375 chr10:18513115~18545651:- LUSC cis rs1823913 0.599 rs17412094 ENSG00000227542.1 AC092614.2 6.35 4.96e-10 2.54e-07 0.36 0.28 Obesity-related traits; chr2:191284202 chr2:191229165~191246172:- LUSC cis rs11722779 0.935 rs11938650 ENSG00000230069.3 LRRC37A15P -6.35 4.96e-10 2.54e-07 -0.3 -0.28 Schizophrenia; chr4:103021639 chr4:102727274~102730721:- LUSC cis rs2919917 1 rs2369440 ENSG00000254352.1 RP11-578O24.2 6.35 4.96e-10 2.54e-07 0.34 0.28 Lymphocyte counts; chr8:78709474 chr8:78723796~78724136:- LUSC cis rs172166 0.611 rs203883 ENSG00000219392.1 RP1-265C24.5 -6.35 4.96e-10 2.54e-07 -0.36 -0.28 Cardiac Troponin-T levels; chr6:28110578 chr6:28115628~28116551:+ LUSC cis rs172166 0.611 rs203882 ENSG00000219392.1 RP1-265C24.5 -6.35 4.96e-10 2.54e-07 -0.36 -0.28 Cardiac Troponin-T levels; chr6:28110724 chr6:28115628~28116551:+ LUSC cis rs172166 0.694 rs1770131 ENSG00000219392.1 RP1-265C24.5 -6.35 4.96e-10 2.54e-07 -0.36 -0.28 Cardiac Troponin-T levels; chr6:28118635 chr6:28115628~28116551:+ LUSC cis rs67311347 1 rs7648952 ENSG00000223797.4 ENTPD3-AS1 -6.35 4.97e-10 2.55e-07 -0.31 -0.28 Renal cell carcinoma; chr3:40415547 chr3:40313802~40453329:- LUSC cis rs2153535 0.58 rs2327051 ENSG00000230939.1 RP11-314C16.1 6.35 4.97e-10 2.55e-07 0.33 0.28 Motion sickness; chr6:8440917 chr6:8784178~8785445:+ LUSC cis rs904251 0.772 rs1812186 ENSG00000204110.6 RP1-153P14.8 -6.35 4.99e-10 2.56e-07 -0.29 -0.28 Cognitive performance; chr6:37498140 chr6:37507348~37535616:+ LUSC cis rs4950322 0.547 rs56864370 ENSG00000278811.3 LINC00624 6.35 4.99e-10 2.56e-07 0.3 0.28 Protein quantitative trait loci; chr1:147111847 chr1:147258885~147517875:- LUSC cis rs2179367 0.632 rs11155650 ENSG00000231760.4 RP11-350J20.5 6.35 4.99e-10 2.56e-07 0.4 0.28 Dupuytren's disease; chr6:149407613 chr6:149796151~149826294:- LUSC cis rs2919917 0.915 rs2046339 ENSG00000254352.1 RP11-578O24.2 6.35 5e-10 2.56e-07 0.35 0.28 Lymphocyte counts; chr8:78724283 chr8:78723796~78724136:- LUSC cis rs11098499 0.698 rs4422403 ENSG00000249244.1 RP11-548H18.2 6.35 5e-10 2.56e-07 0.34 0.28 Corneal astigmatism; chr4:119337039 chr4:119391831~119395335:- LUSC cis rs853679 0.517 rs9366715 ENSG00000204709.4 LINC01556 6.35 5e-10 2.56e-07 0.4 0.28 Depression; chr6:28096855 chr6:28943877~28944537:+ LUSC cis rs6504950 0.72 rs9910653 ENSG00000275710.1 RP11-257O5.4 6.35 5e-10 2.57e-07 0.33 0.28 Breast cancer; chr17:54914907 chr17:54964474~54964679:+ LUSC cis rs66887589 0.87 rs10518336 ENSG00000249244.1 RP11-548H18.2 6.35 5.01e-10 2.57e-07 0.34 0.28 Diastolic blood pressure; chr4:119601779 chr4:119391831~119395335:- LUSC cis rs957448 1 rs72674852 ENSG00000253175.1 RP11-267M23.6 6.35 5.01e-10 2.57e-07 0.33 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94536523 chr8:94565036~94565715:+ LUSC cis rs957448 1 rs16916874 ENSG00000253175.1 RP11-267M23.6 6.35 5.01e-10 2.57e-07 0.33 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94537749 chr8:94565036~94565715:+ LUSC cis rs13113518 1 rs13113518 ENSG00000273257.1 RP11-177J6.1 6.35 5.01e-10 2.57e-07 0.36 0.28 Height; chr4:55533481 chr4:55387949~55388271:+ LUSC cis rs11971779 0.68 rs4732369 ENSG00000273391.1 RP11-634H22.1 6.35 5.02e-10 2.57e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139384427 chr7:139359032~139359566:- LUSC cis rs13113518 0.513 rs13132085 ENSG00000249700.7 SRD5A3-AS1 -6.35 5.02e-10 2.57e-07 -0.32 -0.28 Height; chr4:55593918 chr4:55363971~55395847:- LUSC cis rs13631 0.697 rs1018330 ENSG00000268996.3 MAN1B1-AS1 6.35 5.03e-10 2.58e-07 0.27 0.28 Cerebrospinal fluid biomarker levels; chr9:137085933 chr9:137084946~137086817:- LUSC cis rs9309473 0.95 rs73947808 ENSG00000163016.8 ALMS1P 6.35 5.04e-10 2.58e-07 0.34 0.28 Metabolite levels; chr2:73494123 chr2:73644919~73685576:+ LUSC cis rs9309711 0.666 rs6723101 ENSG00000225234.1 TRAPPC12-AS1 -6.35 5.04e-10 2.58e-07 -0.33 -0.28 Neurofibrillary tangles; chr2:3480672 chr2:3481242~3482409:- LUSC cis rs9309711 0.666 rs6723126 ENSG00000225234.1 TRAPPC12-AS1 -6.35 5.04e-10 2.58e-07 -0.33 -0.28 Neurofibrillary tangles; chr2:3480729 chr2:3481242~3482409:- LUSC cis rs227275 0.554 rs223395 ENSG00000230069.3 LRRC37A15P -6.35 5.05e-10 2.59e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102823801 chr4:102727274~102730721:- LUSC cis rs2919917 1 rs1483573 ENSG00000254352.1 RP11-578O24.2 6.35 5.05e-10 2.59e-07 0.35 0.28 Lymphocyte counts; chr8:78711382 chr8:78723796~78724136:- LUSC cis rs7267979 1 rs4815417 ENSG00000274973.1 RP13-401N8.7 6.35 5.06e-10 2.59e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25398890 chr20:25845497~25845862:+ LUSC cis rs66887589 0.592 rs2175383 ENSG00000249244.1 RP11-548H18.2 6.35 5.06e-10 2.59e-07 0.34 0.28 Diastolic blood pressure; chr4:119294681 chr4:119391831~119395335:- LUSC cis rs9309473 0.95 rs6745480 ENSG00000163016.8 ALMS1P 6.35 5.07e-10 2.6e-07 0.34 0.28 Metabolite levels; chr2:73612928 chr2:73644919~73685576:+ LUSC cis rs867371 1 rs1392976 ENSG00000255769.6 GOLGA2P10 6.35 5.07e-10 2.6e-07 0.34 0.28 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82153834 chr15:82472993~82513950:- LUSC cis rs228614 0.51 rs50034 ENSG00000230069.3 LRRC37A15P -6.35 5.08e-10 2.6e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102832214 chr4:102727274~102730721:- LUSC cis rs227275 0.556 rs223380 ENSG00000230069.3 LRRC37A15P -6.35 5.08e-10 2.6e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102833343 chr4:102727274~102730721:- LUSC cis rs227275 0.556 rs223379 ENSG00000230069.3 LRRC37A15P -6.35 5.08e-10 2.6e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102833434 chr4:102727274~102730721:- LUSC cis rs2286503 0.901 rs10950922 ENSG00000228649.7 AC005682.5 6.35 5.08e-10 2.6e-07 0.31 0.28 Fibrinogen; chr7:22814387 chr7:22854178~22861579:+ LUSC cis rs950169 0.541 rs10795 ENSG00000259728.4 LINC00933 6.35 5.08e-10 2.6e-07 0.36 0.28 Schizophrenia; chr15:84634066 chr15:84570649~84580175:+ LUSC cis rs950169 0.58 rs36126054 ENSG00000259728.4 LINC00933 6.35 5.08e-10 2.6e-07 0.36 0.28 Schizophrenia; chr15:84634492 chr15:84570649~84580175:+ LUSC cis rs950169 0.58 rs1061737 ENSG00000259728.4 LINC00933 6.35 5.08e-10 2.6e-07 0.36 0.28 Schizophrenia; chr15:84640559 chr15:84570649~84580175:+ LUSC cis rs7772486 0.686 rs1292337 ENSG00000235652.6 RP11-545I5.3 -6.35 5.09e-10 2.61e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145646671 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs857879 ENSG00000235652.6 RP11-545I5.3 -6.35 5.09e-10 2.61e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145652907 chr6:145799409~145886585:+ LUSC cis rs228614 0.536 rs223375 ENSG00000230069.3 LRRC37A15P -6.35 5.09e-10 2.61e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102836484 chr4:102727274~102730721:- LUSC cis rs7267979 0.966 rs2261795 ENSG00000274973.1 RP13-401N8.7 -6.35 5.1e-10 2.61e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25282500 chr20:25845497~25845862:+ LUSC cis rs1823913 0.599 rs67781530 ENSG00000280083.1 RP11-317J9.1 -6.35 5.11e-10 2.61e-07 -0.33 -0.28 Obesity-related traits; chr2:191295608 chr2:191154118~191156070:- LUSC cis rs7772486 0.686 rs6933161 ENSG00000235652.6 RP11-545I5.3 -6.35 5.11e-10 2.61e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145760233 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs9399565 ENSG00000235652.6 RP11-545I5.3 -6.35 5.11e-10 2.61e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145760770 chr6:145799409~145886585:+ LUSC cis rs4938330 0.681 rs12271169 ENSG00000254851.1 RP11-109L13.1 6.35 5.11e-10 2.62e-07 0.39 0.28 Blood protein levels; chr11:117109305 chr11:117135528~117138582:+ LUSC cis rs2919917 0.915 rs2953477 ENSG00000254352.1 RP11-578O24.2 6.35 5.12e-10 2.62e-07 0.35 0.28 Lymphocyte counts; chr8:78712370 chr8:78723796~78724136:- LUSC cis rs9322193 0.923 rs9383812 ENSG00000268592.3 RAET1E-AS1 6.35 5.12e-10 2.62e-07 0.36 0.28 Lung cancer; chr6:149712355 chr6:149863494~149919507:+ LUSC cis rs6951245 0.745 rs79788515 ENSG00000224079.1 AC091729.7 -6.35 5.13e-10 2.62e-07 -0.49 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061443 chr7:1074450~1078036:+ LUSC cis rs17772222 0.682 rs2297129 ENSG00000258789.1 RP11-507K2.3 -6.35 5.13e-10 2.62e-07 -0.31 -0.28 Coronary artery calcification; chr14:88469581 chr14:88551597~88552493:+ LUSC cis rs17772222 0.682 rs61542857 ENSG00000258789.1 RP11-507K2.3 -6.35 5.13e-10 2.62e-07 -0.31 -0.28 Coronary artery calcification; chr14:88470358 chr14:88551597~88552493:+ LUSC cis rs17772222 0.637 rs7161660 ENSG00000258789.1 RP11-507K2.3 -6.35 5.13e-10 2.62e-07 -0.31 -0.28 Coronary artery calcification; chr14:88471832 chr14:88551597~88552493:+ LUSC cis rs17772222 0.682 rs7141363 ENSG00000258789.1 RP11-507K2.3 -6.35 5.13e-10 2.62e-07 -0.31 -0.28 Coronary artery calcification; chr14:88471879 chr14:88551597~88552493:+ LUSC cis rs2408955 0.522 rs7139330 ENSG00000240399.1 RP1-228P16.1 -6.35 5.13e-10 2.63e-07 -0.29 -0.28 Glycated hemoglobin levels; chr12:48089701 chr12:48054813~48055591:- LUSC cis rs7429990 0.864 rs2140335 ENSG00000229759.1 MRPS18AP1 -6.35 5.14e-10 2.63e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47663625 chr3:48256350~48256938:- LUSC cis rs78487399 0.71 rs13408002 ENSG00000234936.1 AC010883.5 6.35 5.15e-10 2.63e-07 0.43 0.28 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43382888 chr2:43229573~43233394:+ LUSC cis rs875971 0.545 rs73146609 ENSG00000226824.5 RP4-756H11.3 -6.35 5.16e-10 2.64e-07 -0.37 -0.28 Aortic root size; chr7:66302477 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs2173571 ENSG00000226824.5 RP4-756H11.3 -6.35 5.16e-10 2.64e-07 -0.37 -0.28 Aortic root size; chr7:66305392 chr7:66654538~66669855:+ LUSC cis rs9903692 0.697 rs6504024 ENSG00000278765.1 RP5-890E16.5 6.35 5.16e-10 2.64e-07 0.34 0.28 Pulse pressure; chr17:48088224 chr17:48066704~48067293:- LUSC cis rs9903692 0.779 rs6504025 ENSG00000278765.1 RP5-890E16.5 6.35 5.16e-10 2.64e-07 0.34 0.28 Pulse pressure; chr17:48088711 chr17:48066704~48067293:- LUSC cis rs75422866 0.541 rs12425816 ENSG00000257433.4 RP1-197B17.3 6.35 5.16e-10 2.64e-07 0.61 0.28 Pneumonia; chr12:47731419 chr12:47706085~47742294:+ LUSC cis rs228614 0.536 rs150897 ENSG00000230069.3 LRRC37A15P -6.35 5.17e-10 2.64e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769309 chr4:102727274~102730721:- LUSC cis rs1061377 0.513 rs2566162 ENSG00000249207.1 RP11-360F5.1 -6.35 5.17e-10 2.64e-07 -0.34 -0.28 Uric acid levels; chr4:39126453 chr4:39112677~39126818:- LUSC cis rs875971 0.545 rs1796222 ENSG00000226824.5 RP4-756H11.3 6.35 5.17e-10 2.64e-07 0.37 0.28 Aortic root size; chr7:66592167 chr7:66654538~66669855:+ LUSC cis rs5753618 0.561 rs13054220 ENSG00000236132.1 CTA-440B3.1 -6.35 5.19e-10 2.65e-07 -0.38 -0.28 Colorectal cancer; chr22:31308506 chr22:31816379~31817491:- LUSC cis rs5753618 0.561 rs9609254 ENSG00000236132.1 CTA-440B3.1 -6.35 5.19e-10 2.65e-07 -0.38 -0.28 Colorectal cancer; chr22:31309956 chr22:31816379~31817491:- LUSC cis rs227275 0.554 rs223404 ENSG00000230069.3 LRRC37A15P -6.35 5.19e-10 2.65e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102816951 chr4:102727274~102730721:- LUSC cis rs6142102 0.625 rs4911137 ENSG00000275784.1 RP5-1125A11.6 -6.35 5.19e-10 2.65e-07 -0.31 -0.28 Skin pigmentation; chr20:33947657 chr20:33989480~33991818:- LUSC cis rs2919917 1 rs894221 ENSG00000254352.1 RP11-578O24.2 -6.35 5.2e-10 2.66e-07 -0.35 -0.28 Lymphocyte counts; chr8:78736822 chr8:78723796~78724136:- LUSC cis rs2732480 0.538 rs2468943 ENSG00000226413.2 OR8T1P -6.35 5.2e-10 2.66e-07 -0.36 -0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48353466 chr12:48442030~48442947:- LUSC cis rs496547 0.686 rs477014 ENSG00000255239.1 AP002954.6 6.35 5.21e-10 2.66e-07 0.31 0.28 Hip minimal joint space width; chr11:118808277 chr11:118688039~118690600:- LUSC cis rs4713118 0.513 rs149959 ENSG00000216901.1 AL022393.7 6.35 5.21e-10 2.66e-07 0.33 0.28 Parkinson's disease; chr6:28046076 chr6:28176188~28176674:+ LUSC cis rs172166 0.694 rs536704 ENSG00000216901.1 AL022393.7 6.35 5.21e-10 2.66e-07 0.33 0.28 Cardiac Troponin-T levels; chr6:28124825 chr6:28176188~28176674:+ LUSC cis rs67180937 0.504 rs3008625 ENSG00000272750.1 RP11-378J18.8 6.35 5.21e-10 2.66e-07 0.36 0.28 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222646680 chr1:222658867~222661512:- LUSC cis rs673078 0.607 rs7312555 ENSG00000275759.1 RP11-131L12.3 -6.35 5.24e-10 2.68e-07 -0.43 -0.28 Glucose homeostasis traits; chr12:118414120 chr12:118428281~118428870:+ LUSC cis rs957448 1 rs957447 ENSG00000253175.1 RP11-267M23.6 6.35 5.24e-10 2.68e-07 0.33 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94528995 chr8:94565036~94565715:+ LUSC cis rs761746 0.739 rs9621317 ENSG00000236132.1 CTA-440B3.1 -6.34 5.24e-10 2.68e-07 -0.41 -0.28 Intelligence; chr22:31698060 chr22:31816379~31817491:- LUSC cis rs7739264 0.602 rs2223362 ENSG00000227116.1 RP3-471C18.1 -6.34 5.26e-10 2.68e-07 -0.32 -0.28 Endometriosis; chr6:19777940 chr6:19730427~19734567:- LUSC cis rs227275 0.554 rs223421 ENSG00000230069.3 LRRC37A15P -6.34 5.26e-10 2.68e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102805861 chr4:102727274~102730721:- LUSC cis rs7246657 0.943 rs10405325 ENSG00000276846.1 CTD-3220F14.3 6.34 5.28e-10 2.7e-07 0.44 0.28 Coronary artery calcification; chr19:37392575 chr19:37314868~37315620:- LUSC cis rs13392177 0.672 rs1877715 ENSG00000261338.2 RP11-378A13.1 6.34 5.28e-10 2.7e-07 0.29 0.28 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218187823 chr2:218255319~218257366:+ LUSC cis rs7772486 0.686 rs9485019 ENSG00000235652.6 RP11-545I5.3 -6.34 5.28e-10 2.7e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145725245 chr6:145799409~145886585:+ LUSC cis rs9322193 0.923 rs4421206 ENSG00000268592.3 RAET1E-AS1 6.34 5.29e-10 2.7e-07 0.35 0.28 Lung cancer; chr6:149682891 chr6:149863494~149919507:+ LUSC cis rs11168351 0.864 rs10875743 ENSG00000240399.1 RP1-228P16.1 -6.34 5.29e-10 2.7e-07 -0.29 -0.28 Bipolar disorder and schizophrenia; chr12:48104630 chr12:48054813~48055591:- LUSC cis rs7267979 0.899 rs2179459 ENSG00000274973.1 RP13-401N8.7 -6.34 5.29e-10 2.7e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25475505 chr20:25845497~25845862:+ LUSC cis rs78487399 0.71 rs76215753 ENSG00000234936.1 AC010883.5 6.34 5.3e-10 2.7e-07 0.46 0.28 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43370003 chr2:43229573~43233394:+ LUSC cis rs2179367 0.586 rs9498341 ENSG00000231760.4 RP11-350J20.5 6.34 5.3e-10 2.7e-07 0.4 0.28 Dupuytren's disease; chr6:149379737 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs9498342 ENSG00000231760.4 RP11-350J20.5 6.34 5.3e-10 2.7e-07 0.4 0.28 Dupuytren's disease; chr6:149379806 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs12191079 ENSG00000231760.4 RP11-350J20.5 6.34 5.3e-10 2.7e-07 0.4 0.28 Dupuytren's disease; chr6:149380333 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs12204461 ENSG00000231760.4 RP11-350J20.5 6.34 5.3e-10 2.7e-07 0.4 0.28 Dupuytren's disease; chr6:149380399 chr6:149796151~149826294:- LUSC cis rs2337406 1 rs11849532 ENSG00000254174.1 IGHV1-12 6.34 5.3e-10 2.7e-07 0.3 0.28 Alzheimer's disease (late onset); chr14:106669877 chr14:106122420~106122709:- LUSC cis rs1075265 0.756 rs3821081 ENSG00000233266.1 HMGB1P31 -6.34 5.3e-10 2.7e-07 -0.34 -0.28 Chronotype;Morning vs. evening chronotype; chr2:53738252 chr2:54051334~54051760:+ LUSC cis rs1823913 0.599 rs56328712 ENSG00000227542.1 AC092614.2 6.34 5.3e-10 2.71e-07 0.36 0.28 Obesity-related traits; chr2:191273807 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs55862924 ENSG00000227542.1 AC092614.2 6.34 5.3e-10 2.71e-07 0.36 0.28 Obesity-related traits; chr2:191273809 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs12989203 ENSG00000227542.1 AC092614.2 6.34 5.3e-10 2.71e-07 0.36 0.28 Obesity-related traits; chr2:191276617 chr2:191229165~191246172:- LUSC cis rs7772486 0.714 rs1883365 ENSG00000235652.6 RP11-545I5.3 -6.34 5.31e-10 2.71e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145755613 chr6:145799409~145886585:+ LUSC cis rs227275 0.556 rs10015289 ENSG00000230069.3 LRRC37A15P -6.34 5.31e-10 2.71e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102984956 chr4:102727274~102730721:- LUSC cis rs227275 0.556 rs6852141 ENSG00000230069.3 LRRC37A15P -6.34 5.31e-10 2.71e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102986439 chr4:102727274~102730721:- LUSC cis rs228614 0.509 rs4455415 ENSG00000230069.3 LRRC37A15P -6.34 5.31e-10 2.71e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102993663 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs6853193 ENSG00000230069.3 LRRC37A15P -6.34 5.31e-10 2.71e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102994888 chr4:102727274~102730721:- LUSC cis rs9903692 0.954 rs9747001 ENSG00000278765.1 RP5-890E16.5 6.34 5.31e-10 2.71e-07 0.34 0.28 Pulse pressure; chr17:48077307 chr17:48066704~48067293:- LUSC cis rs950169 0.919 rs12915589 ENSG00000225151.9 GOLGA2P7 -6.34 5.32e-10 2.71e-07 -0.39 -0.28 Schizophrenia; chr15:84065712 chr15:84199311~84230136:- LUSC cis rs950169 0.959 rs66801143 ENSG00000225151.9 GOLGA2P7 -6.34 5.32e-10 2.71e-07 -0.39 -0.28 Schizophrenia; chr15:84067905 chr15:84199311~84230136:- LUSC cis rs950169 1 rs35648189 ENSG00000225151.9 GOLGA2P7 -6.34 5.32e-10 2.71e-07 -0.39 -0.28 Schizophrenia; chr15:84071996 chr15:84199311~84230136:- LUSC cis rs950169 0.92 rs17300048 ENSG00000225151.9 GOLGA2P7 -6.34 5.32e-10 2.71e-07 -0.39 -0.28 Schizophrenia; chr15:84080725 chr15:84199311~84230136:- LUSC cis rs950169 1 rs1848093 ENSG00000225151.9 GOLGA2P7 -6.34 5.32e-10 2.71e-07 -0.39 -0.28 Schizophrenia; chr15:84086775 chr15:84199311~84230136:- LUSC cis rs950169 1 rs12915234 ENSG00000225151.9 GOLGA2P7 -6.34 5.32e-10 2.71e-07 -0.39 -0.28 Schizophrenia; chr15:84089549 chr15:84199311~84230136:- LUSC cis rs950169 1 rs34751999 ENSG00000225151.9 GOLGA2P7 -6.34 5.32e-10 2.71e-07 -0.39 -0.28 Schizophrenia; chr15:84089667 chr15:84199311~84230136:- LUSC cis rs11123170 0.503 rs28679654 ENSG00000189223.12 PAX8-AS1 -6.34 5.32e-10 2.71e-07 -0.44 -0.28 Renal function-related traits (BUN); chr2:113210040 chr2:113211522~113276581:+ LUSC cis rs875971 0.545 rs6460281 ENSG00000226824.5 RP4-756H11.3 -6.34 5.32e-10 2.71e-07 -0.37 -0.28 Aortic root size; chr7:66216128 chr7:66654538~66669855:+ LUSC cis rs8062405 1 rs62036617 ENSG00000278665.1 RP11-666O2.4 6.34 5.33e-10 2.72e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28816177 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs4788095 ENSG00000278665.1 RP11-666O2.4 6.34 5.33e-10 2.72e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28820038 chr16:28599241~28601881:- LUSC cis rs8062405 0.964 rs72793809 ENSG00000278665.1 RP11-666O2.4 6.34 5.33e-10 2.72e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821061 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs62036620 ENSG00000278665.1 RP11-666O2.4 6.34 5.33e-10 2.72e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821776 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs62036621 ENSG00000278665.1 RP11-666O2.4 6.34 5.33e-10 2.72e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821978 chr16:28599241~28601881:- LUSC cis rs13113518 0.783 rs12504300 ENSG00000249700.7 SRD5A3-AS1 6.34 5.33e-10 2.72e-07 0.35 0.28 Height; chr4:55482360 chr4:55363971~55395847:- LUSC cis rs875971 0.545 rs316324 ENSG00000226824.5 RP4-756H11.3 6.34 5.34e-10 2.72e-07 0.37 0.28 Aortic root size; chr7:66145627 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs316323 ENSG00000226824.5 RP4-756H11.3 6.34 5.34e-10 2.72e-07 0.37 0.28 Aortic root size; chr7:66146002 chr7:66654538~66669855:+ LUSC cis rs9322193 0.923 rs56397000 ENSG00000268592.3 RAET1E-AS1 6.34 5.34e-10 2.72e-07 0.36 0.28 Lung cancer; chr6:149739347 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs9689702 ENSG00000268592.3 RAET1E-AS1 6.34 5.34e-10 2.72e-07 0.36 0.28 Lung cancer; chr6:149740720 chr6:149863494~149919507:+ LUSC cis rs4266144 0.544 rs13080798 ENSG00000244515.1 KRT18P34 -6.34 5.35e-10 2.73e-07 -0.33 -0.28 Coronary artery disease; chr3:157114612 chr3:157162663~157163932:- LUSC cis rs1876905 0.539 rs240985 ENSG00000255389.1 C6orf3 -6.34 5.36e-10 2.73e-07 -0.39 -0.28 Mean corpuscular hemoglobin; chr6:111263428 chr6:111599875~111602295:+ LUSC cis rs7714584 1 rs1000113 ENSG00000197083.10 ZNF300P1 6.34 5.37e-10 2.74e-07 0.5 0.28 Crohn's disease; chr5:150860514 chr5:150930645~150946289:- LUSC cis rs9322193 0.923 rs4870529 ENSG00000268592.3 RAET1E-AS1 6.34 5.37e-10 2.74e-07 0.35 0.28 Lung cancer; chr6:149716436 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9767309 ENSG00000268592.3 RAET1E-AS1 6.34 5.37e-10 2.74e-07 0.35 0.28 Lung cancer; chr6:149716807 chr6:149863494~149919507:+ LUSC cis rs7772486 0.79 rs7742333 ENSG00000235652.6 RP11-545I5.3 -6.34 5.37e-10 2.74e-07 -0.27 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145837893 chr6:145799409~145886585:+ LUSC cis rs5770917 1 rs3180872 ENSG00000273272.1 CTA-384D8.34 6.34 5.38e-10 2.74e-07 0.54 0.28 Narcolepsy; chr22:50578965 chr22:50542650~50543011:+ LUSC cis rs875971 1 rs11971949 ENSG00000237310.1 GS1-124K5.4 -6.34 5.38e-10 2.74e-07 -0.29 -0.28 Aortic root size; chr7:66161027 chr7:66493706~66495474:+ LUSC cis rs13423976 0.631 rs4670876 ENSG00000231367.4 AC016995.3 6.34 5.38e-10 2.74e-07 0.37 0.28 Gut microbiome composition (summer); chr2:38508948 chr2:38406719~38515740:- LUSC cis rs1823913 0.637 rs13382985 ENSG00000227542.1 AC092614.2 -6.34 5.39e-10 2.75e-07 -0.35 -0.28 Obesity-related traits; chr2:191306335 chr2:191229165~191246172:- LUSC cis rs4660456 0.542 rs850009 ENSG00000237899.1 RP4-739H11.3 6.34 5.41e-10 2.76e-07 0.41 0.28 Platelet count; chr1:40643593 chr1:40669089~40687588:- LUSC cis rs853679 0.517 rs9393887 ENSG00000204709.4 LINC01556 6.34 5.42e-10 2.76e-07 0.4 0.28 Depression; chr6:28091242 chr6:28943877~28944537:+ LUSC cis rs13423976 0.631 rs2373405 ENSG00000231367.4 AC016995.3 6.34 5.42e-10 2.76e-07 0.37 0.28 Gut microbiome composition (summer); chr2:38513072 chr2:38406719~38515740:- LUSC cis rs7829975 0.593 rs2921077 ENSG00000173295.6 FAM86B3P 6.34 5.42e-10 2.76e-07 0.3 0.28 Mood instability; chr8:8446992 chr8:8228595~8244865:+ LUSC cis rs7772486 0.743 rs9403742 ENSG00000235652.6 RP11-545I5.3 6.34 5.43e-10 2.76e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145739057 chr6:145799409~145886585:+ LUSC cis rs7267979 1 rs4815412 ENSG00000274973.1 RP13-401N8.7 -6.34 5.44e-10 2.77e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25369689 chr20:25845497~25845862:+ LUSC cis rs11971779 0.68 rs17691238 ENSG00000273391.1 RP11-634H22.1 -6.34 5.44e-10 2.77e-07 -0.3 -0.28 Diisocyanate-induced asthma; chr7:139367538 chr7:139359032~139359566:- LUSC cis rs2919917 1 rs7010897 ENSG00000254352.1 RP11-578O24.2 6.34 5.44e-10 2.77e-07 0.35 0.28 Lymphocyte counts; chr8:78708119 chr8:78723796~78724136:- LUSC cis rs442309 0.687 rs10822058 ENSG00000238280.1 RP11-436D10.3 -6.34 5.44e-10 2.77e-07 -0.34 -0.28 Vogt-Koyanagi-Harada syndrome; chr10:62763822 chr10:62793562~62805887:- LUSC cis rs6603134 0.502 rs10405582 ENSG00000267939.1 CTD-2325M2.1 -6.34 5.45e-10 2.77e-07 -0.31 -0.28 Blood protein levels; chr19:8038654 chr19:8008729~8016025:+ LUSC cis rs6603134 0.502 rs10406511 ENSG00000267939.1 CTD-2325M2.1 -6.34 5.45e-10 2.77e-07 -0.31 -0.28 Blood protein levels; chr19:8039061 chr19:8008729~8016025:+ LUSC cis rs6142102 0.625 rs4911384 ENSG00000275784.1 RP5-1125A11.6 -6.34 5.45e-10 2.78e-07 -0.31 -0.28 Skin pigmentation; chr20:33968001 chr20:33989480~33991818:- LUSC cis rs8059260 0.542 rs16957948 ENSG00000274038.1 RP11-66H6.4 -6.34 5.46e-10 2.78e-07 -0.47 -0.28 Alcohol consumption over the past year; chr16:11034208 chr16:11056556~11057034:+ LUSC cis rs17507216 0.671 rs4779035 ENSG00000255769.6 GOLGA2P10 -6.34 5.47e-10 2.78e-07 -0.43 -0.28 Excessive daytime sleepiness; chr15:82591686 chr15:82472993~82513950:- LUSC cis rs2834288 0.536 rs762356 ENSG00000273102.1 AP000569.9 6.34 5.47e-10 2.78e-07 0.31 0.28 Gut microbiota (bacterial taxa); chr21:33964582 chr21:33967101~33968573:- LUSC cis rs7772486 0.686 rs9403741 ENSG00000235652.6 RP11-545I5.3 -6.34 5.47e-10 2.79e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145709412 chr6:145799409~145886585:+ LUSC cis rs11168351 0.833 rs6580652 ENSG00000240399.1 RP1-228P16.1 -6.34 5.48e-10 2.79e-07 -0.29 -0.28 Bipolar disorder and schizophrenia; chr12:48053322 chr12:48054813~48055591:- LUSC cis rs1876905 0.539 rs240962 ENSG00000255389.1 C6orf3 -6.34 5.48e-10 2.79e-07 -0.38 -0.28 Mean corpuscular hemoglobin; chr6:111321243 chr6:111599875~111602295:+ LUSC cis rs11976180 1 rs2961117 ENSG00000170356.8 OR2A20P -6.34 5.48e-10 2.79e-07 -0.37 -0.28 Obesity-related traits; chr7:144058160 chr7:144250045~144252957:- LUSC cis rs1075265 0.791 rs1833498 ENSG00000233266.1 HMGB1P31 6.34 5.48e-10 2.79e-07 0.36 0.28 Chronotype;Morning vs. evening chronotype; chr2:54080801 chr2:54051334~54051760:+ LUSC cis rs881375 0.867 rs10818484 ENSG00000226752.6 PSMD5-AS1 -6.34 5.49e-10 2.79e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120898916 chr9:120824828~120854385:+ LUSC cis rs11098499 0.532 rs12512646 ENSG00000249244.1 RP11-548H18.2 6.34 5.49e-10 2.79e-07 0.36 0.28 Corneal astigmatism; chr4:119664578 chr4:119391831~119395335:- LUSC cis rs2919917 1 rs11986947 ENSG00000254352.1 RP11-578O24.2 6.34 5.5e-10 2.8e-07 0.35 0.28 Lymphocyte counts; chr8:78708957 chr8:78723796~78724136:- LUSC cis rs2286503 0.966 rs2286507 ENSG00000228649.7 AC005682.5 6.34 5.5e-10 2.8e-07 0.31 0.28 Fibrinogen; chr7:22815141 chr7:22854178~22861579:+ LUSC cis rs875971 0.628 rs6974355 ENSG00000236529.1 RP13-254B10.1 6.34 5.51e-10 2.8e-07 0.29 0.28 Aortic root size; chr7:66376994 chr7:65840212~65840596:+ LUSC cis rs9532669 0.926 rs9562254 ENSG00000176268.5 CYCSP34 -6.34 5.51e-10 2.8e-07 -0.28 -0.28 Cervical cancer; chr13:40960902 chr13:40863599~40863902:- LUSC cis rs2179367 0.632 rs10155766 ENSG00000231760.4 RP11-350J20.5 6.34 5.53e-10 2.81e-07 0.4 0.28 Dupuytren's disease; chr6:149364577 chr6:149796151~149826294:- LUSC cis rs172166 0.694 rs203892 ENSG00000219392.1 RP1-265C24.5 -6.34 5.53e-10 2.81e-07 -0.36 -0.28 Cardiac Troponin-T levels; chr6:28099418 chr6:28115628~28116551:+ LUSC cis rs6142102 0.812 rs761238 ENSG00000276073.1 RP5-1125A11.7 6.34 5.54e-10 2.82e-07 0.28 0.28 Skin pigmentation; chr20:33932182 chr20:33985617~33988989:- LUSC cis rs11123170 0.529 rs1015755 ENSG00000189223.12 PAX8-AS1 -6.34 5.54e-10 2.82e-07 -0.44 -0.28 Renal function-related traits (BUN); chr2:113210730 chr2:113211522~113276581:+ LUSC cis rs7267979 1 rs6138572 ENSG00000274973.1 RP13-401N8.7 -6.34 5.54e-10 2.82e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25455298 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6138575 ENSG00000274973.1 RP13-401N8.7 -6.34 5.54e-10 2.82e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25458316 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs11087521 ENSG00000274973.1 RP13-401N8.7 -6.34 5.54e-10 2.82e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25460012 chr20:25845497~25845862:+ LUSC cis rs12439619 0.508 rs17354842 ENSG00000276710.3 CSPG4P8 6.34 5.54e-10 2.82e-07 0.3 0.28 Intelligence (multi-trait analysis); chr15:82177259 chr15:82459472~82477258:+ LUSC cis rs11168351 0.864 rs12228750 ENSG00000240399.1 RP1-228P16.1 -6.33 5.57e-10 2.83e-07 -0.29 -0.28 Bipolar disorder and schizophrenia; chr12:48103214 chr12:48054813~48055591:- LUSC cis rs9438901 0.655 rs609320 ENSG00000261349.1 RP3-465N24.5 6.33 5.57e-10 2.83e-07 0.46 0.28 Red cell distribution width; chr1:25390874 chr1:25266102~25267136:- LUSC cis rs7955901 0.725 rs9325191 ENSG00000257265.1 CTD-2021H9.1 6.33 5.58e-10 2.84e-07 0.31 0.28 Type 2 diabetes; chr12:71062479 chr12:71007773~71032083:- LUSC cis rs7955901 0.673 rs10506623 ENSG00000257265.1 CTD-2021H9.1 6.33 5.58e-10 2.84e-07 0.31 0.28 Type 2 diabetes; chr12:71062678 chr12:71007773~71032083:- LUSC cis rs7955901 0.725 rs10879242 ENSG00000257265.1 CTD-2021H9.1 6.33 5.58e-10 2.84e-07 0.31 0.28 Type 2 diabetes; chr12:71062708 chr12:71007773~71032083:- LUSC cis rs7955901 0.725 rs10879243 ENSG00000257265.1 CTD-2021H9.1 6.33 5.58e-10 2.84e-07 0.31 0.28 Type 2 diabetes; chr12:71062727 chr12:71007773~71032083:- LUSC cis rs7955901 0.725 rs10879245 ENSG00000257265.1 CTD-2021H9.1 6.33 5.58e-10 2.84e-07 0.31 0.28 Type 2 diabetes; chr12:71063552 chr12:71007773~71032083:- LUSC cis rs7955901 0.725 rs1495375 ENSG00000257265.1 CTD-2021H9.1 6.33 5.58e-10 2.84e-07 0.31 0.28 Type 2 diabetes; chr12:71063953 chr12:71007773~71032083:- LUSC cis rs7955901 0.63 rs17226821 ENSG00000257265.1 CTD-2021H9.1 6.33 5.58e-10 2.84e-07 0.31 0.28 Type 2 diabetes; chr12:71065419 chr12:71007773~71032083:- LUSC cis rs1134634 0.52 rs28661857 ENSG00000273133.1 RP11-799M12.2 -6.33 5.58e-10 2.84e-07 -0.37 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15589842 chr4:15563698~15564253:- LUSC cis rs12554020 0.892 rs12341488 ENSG00000227603.1 RP11-165J3.6 6.33 5.6e-10 2.84e-07 0.37 0.28 Schizophrenia; chr9:93568889 chr9:93435332~93437121:- LUSC cis rs2439831 0.85 rs8042868 ENSG00000249839.1 AC011330.5 -6.33 5.6e-10 2.85e-07 -0.57 -0.28 Lung cancer in ever smokers; chr15:43647444 chr15:43663654~43684339:- LUSC cis rs10246939 0.505 rs892354 ENSG00000228775.6 WEE2-AS1 6.33 5.61e-10 2.85e-07 0.35 0.28 Bitter taste perception; chr7:141844934 chr7:141704338~141738346:- LUSC cis rs950169 0.922 rs8037078 ENSG00000259728.4 LINC00933 -6.33 5.62e-10 2.85e-07 -0.36 -0.28 Schizophrenia; chr15:84150119 chr15:84570649~84580175:+ LUSC cis rs5742933 0.744 rs12693557 ENSG00000253559.1 OSGEPL1-AS1 6.33 5.62e-10 2.86e-07 0.34 0.28 Ferritin levels; chr2:189726211 chr2:189762704~189765556:+ LUSC cis rs7955901 0.725 rs966583 ENSG00000257265.1 CTD-2021H9.1 6.33 5.62e-10 2.86e-07 0.32 0.28 Type 2 diabetes; chr12:71057787 chr12:71007773~71032083:- LUSC cis rs6570726 0.905 rs1355146 ENSG00000235652.6 RP11-545I5.3 -6.33 5.63e-10 2.86e-07 -0.27 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145460605 chr6:145799409~145886585:+ LUSC cis rs6570726 0.967 rs1396648 ENSG00000235652.6 RP11-545I5.3 -6.33 5.63e-10 2.86e-07 -0.27 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145464112 chr6:145799409~145886585:+ LUSC cis rs66887589 0.616 rs13113885 ENSG00000249244.1 RP11-548H18.2 6.33 5.63e-10 2.86e-07 0.34 0.28 Diastolic blood pressure; chr4:119300021 chr4:119391831~119395335:- LUSC cis rs227275 0.554 rs223424 ENSG00000230069.3 LRRC37A15P -6.33 5.64e-10 2.86e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102804177 chr4:102727274~102730721:- LUSC cis rs227275 0.524 rs223423 ENSG00000230069.3 LRRC37A15P -6.33 5.64e-10 2.86e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102804737 chr4:102727274~102730721:- LUSC cis rs7772486 0.754 rs9386133 ENSG00000235652.6 RP11-545I5.3 6.33 5.64e-10 2.86e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145820077 chr6:145799409~145886585:+ LUSC cis rs4713118 0.539 rs200988 ENSG00000219392.1 RP1-265C24.5 -6.33 5.64e-10 2.86e-07 -0.34 -0.28 Parkinson's disease; chr6:27851575 chr6:28115628~28116551:+ LUSC cis rs875971 0.54 rs781152 ENSG00000164669.11 INTS4P1 -6.33 5.64e-10 2.87e-07 -0.31 -0.28 Aortic root size; chr7:66014585 chr7:65141225~65234216:+ LUSC cis rs17711722 0.727 rs781151 ENSG00000164669.11 INTS4P1 -6.33 5.64e-10 2.87e-07 -0.31 -0.28 Calcium levels; chr7:66014891 chr7:65141225~65234216:+ LUSC cis rs7267979 0.932 rs4280527 ENSG00000274973.1 RP13-401N8.7 -6.33 5.65e-10 2.87e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25563378 chr20:25845497~25845862:+ LUSC cis rs75422866 0.867 rs73111258 ENSG00000257433.4 RP1-197B17.3 6.33 5.65e-10 2.87e-07 0.67 0.28 Pneumonia; chr12:47597313 chr12:47706085~47742294:+ LUSC cis rs13113518 0.783 rs2171618 ENSG00000249700.7 SRD5A3-AS1 6.33 5.66e-10 2.88e-07 0.33 0.28 Height; chr4:55564241 chr4:55363971~55395847:- LUSC cis rs875971 0.66 rs10263935 ENSG00000236529.1 RP13-254B10.1 6.33 5.66e-10 2.88e-07 0.29 0.28 Aortic root size; chr7:66631041 chr7:65840212~65840596:+ LUSC cis rs7267979 1 rs2500443 ENSG00000274973.1 RP13-401N8.7 6.33 5.67e-10 2.88e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25350806 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2482928 ENSG00000274973.1 RP13-401N8.7 6.33 5.67e-10 2.88e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25350894 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2500446 ENSG00000274973.1 RP13-401N8.7 6.33 5.67e-10 2.88e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25359028 chr20:25845497~25845862:+ LUSC cis rs496547 0.686 rs524590 ENSG00000255422.1 AP002954.4 -6.33 5.68e-10 2.88e-07 -0.3 -0.28 Hip minimal joint space width; chr11:118769354 chr11:118704607~118750263:+ LUSC cis rs7955901 0.725 rs3942254 ENSG00000257265.1 CTD-2021H9.1 6.33 5.68e-10 2.88e-07 0.31 0.28 Type 2 diabetes; chr12:71062091 chr12:71007773~71032083:- LUSC cis rs7772486 0.777 rs1546966 ENSG00000235652.6 RP11-545I5.3 6.33 5.69e-10 2.89e-07 0.29 0.28 Lobe attachment (rater-scored or self-reported); chr6:146064882 chr6:145799409~145886585:+ LUSC cis rs6700559 0.565 rs11807125 ENSG00000260088.1 RP11-92G12.3 6.33 5.7e-10 2.89e-07 0.36 0.28 Coronary artery disease; chr1:200623167 chr1:200669507~200694250:+ LUSC cis rs6504950 1 rs17745344 ENSG00000275710.1 RP11-257O5.4 6.33 5.7e-10 2.89e-07 0.35 0.28 Breast cancer; chr17:54970958 chr17:54964474~54964679:+ LUSC cis rs6570726 0.902 rs9390326 ENSG00000235652.6 RP11-545I5.3 -6.33 5.7e-10 2.89e-07 -0.27 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145470086 chr6:145799409~145886585:+ LUSC cis rs66887589 0.616 rs1052633 ENSG00000249244.1 RP11-548H18.2 6.33 5.7e-10 2.9e-07 0.34 0.28 Diastolic blood pressure; chr4:119294159 chr4:119391831~119395335:- LUSC cis rs875971 0.545 rs2707851 ENSG00000226824.5 RP4-756H11.3 6.33 5.71e-10 2.9e-07 0.37 0.28 Aortic root size; chr7:66624178 chr7:66654538~66669855:+ LUSC cis rs6142102 0.961 rs2284386 ENSG00000275784.1 RP5-1125A11.6 -6.33 5.72e-10 2.9e-07 -0.32 -0.28 Skin pigmentation; chr20:34056590 chr20:33989480~33991818:- LUSC cis rs10829156 0.538 rs61840846 ENSG00000240291.1 RP11-499P20.2 6.33 5.72e-10 2.9e-07 0.31 0.28 Sudden cardiac arrest; chr10:18606393 chr10:18513115~18545651:- LUSC cis rs761746 0.577 rs131244 ENSG00000236132.1 CTA-440B3.1 -6.33 5.72e-10 2.9e-07 -0.41 -0.28 Intelligence; chr22:31730577 chr22:31816379~31817491:- LUSC cis rs11690935 0.959 rs1474074 ENSG00000228389.1 AC068039.4 6.33 5.72e-10 2.9e-07 0.33 0.28 Schizophrenia; chr2:171803342 chr2:171773482~171775844:+ LUSC cis rs8040855 0.627 rs11634975 ENSG00000259295.5 CSPG4P12 6.33 5.73e-10 2.91e-07 0.35 0.28 Bulimia nervosa; chr15:85063247 chr15:85191438~85213905:+ LUSC cis rs5753618 0.561 rs9606830 ENSG00000236132.1 CTA-440B3.1 -6.33 5.74e-10 2.91e-07 -0.38 -0.28 Colorectal cancer; chr22:31321813 chr22:31816379~31817491:- LUSC cis rs7955901 0.699 rs1567740 ENSG00000257265.1 CTD-2021H9.1 6.33 5.76e-10 2.92e-07 0.31 0.28 Type 2 diabetes; chr12:71066301 chr12:71007773~71032083:- LUSC cis rs13113518 0.513 rs13132085 ENSG00000272969.1 RP11-528I4.2 -6.33 5.76e-10 2.92e-07 -0.32 -0.28 Height; chr4:55593918 chr4:55547112~55547889:+ LUSC cis rs227275 0.525 rs10032234 ENSG00000230069.3 LRRC37A15P -6.33 5.76e-10 2.92e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102980538 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs28845922 ENSG00000230069.3 LRRC37A15P -6.33 5.76e-10 2.92e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102981959 chr4:102727274~102730721:- LUSC cis rs228614 0.517 rs3886722 ENSG00000230069.3 LRRC37A15P -6.33 5.76e-10 2.92e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102983084 chr4:102727274~102730721:- LUSC cis rs10740039 1 rs10740039 ENSG00000254271.1 RP11-131N11.4 6.33 5.77e-10 2.92e-07 0.37 0.28 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60654924 chr10:60734342~60741828:+ LUSC cis rs9903692 0.909 rs12952163 ENSG00000278765.1 RP5-890E16.5 6.33 5.77e-10 2.92e-07 0.34 0.28 Pulse pressure; chr17:48082029 chr17:48066704~48067293:- LUSC cis rs9903692 0.648 rs35361214 ENSG00000278765.1 RP5-890E16.5 6.33 5.77e-10 2.92e-07 0.34 0.28 Pulse pressure; chr17:48087729 chr17:48066704~48067293:- LUSC cis rs7945705 0.791 rs7944560 ENSG00000254860.4 TMEM9B-AS1 -6.33 5.77e-10 2.93e-07 -0.32 -0.28 Hemoglobin concentration; chr11:8795729 chr11:8964675~8977527:+ LUSC cis rs7267979 1 rs6050544 ENSG00000274973.1 RP13-401N8.7 6.33 5.77e-10 2.93e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25339592 chr20:25845497~25845862:+ LUSC cis rs35160687 0.736 rs6746198 ENSG00000273080.1 RP11-301O19.1 -6.33 5.78e-10 2.93e-07 -0.26 -0.28 Night sleep phenotypes; chr2:86314990 chr2:86195590~86196049:+ LUSC cis rs227275 0.527 rs223338 ENSG00000230069.3 LRRC37A15P -6.33 5.78e-10 2.93e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102864959 chr4:102727274~102730721:- LUSC cis rs228614 0.536 rs223327 ENSG00000230069.3 LRRC37A15P -6.33 5.78e-10 2.93e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873560 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223326 ENSG00000230069.3 LRRC37A15P -6.33 5.78e-10 2.93e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873770 chr4:102727274~102730721:- LUSC cis rs7246657 0.943 rs1559229 ENSG00000276846.1 CTD-3220F14.3 6.33 5.79e-10 2.94e-07 0.42 0.28 Coronary artery calcification; chr19:37385295 chr19:37314868~37315620:- LUSC cis rs7246657 0.882 rs6508719 ENSG00000276846.1 CTD-3220F14.3 6.33 5.79e-10 2.94e-07 0.42 0.28 Coronary artery calcification; chr19:37386517 chr19:37314868~37315620:- LUSC cis rs5742933 0.857 rs10931430 ENSG00000253559.1 OSGEPL1-AS1 6.33 5.79e-10 2.94e-07 0.34 0.28 Ferritin levels; chr2:189677460 chr2:189762704~189765556:+ LUSC cis rs6951245 1 rs11764748 ENSG00000224079.1 AC091729.7 -6.33 5.8e-10 2.94e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054872 chr7:1074450~1078036:+ LUSC cis rs673078 0.607 rs6490177 ENSG00000275759.1 RP11-131L12.3 -6.33 5.8e-10 2.94e-07 -0.38 -0.28 Glucose homeostasis traits; chr12:118358280 chr12:118428281~118428870:+ LUSC cis rs17772222 0.63 rs816069 ENSG00000258789.1 RP11-507K2.3 6.33 5.81e-10 2.94e-07 0.31 0.28 Coronary artery calcification; chr14:88500992 chr14:88551597~88552493:+ LUSC cis rs8062405 1 rs4451951 ENSG00000278665.1 RP11-666O2.4 6.33 5.82e-10 2.95e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28824884 chr16:28599241~28601881:- LUSC cis rs11098499 0.604 rs2389882 ENSG00000250412.1 KLHL2P1 6.33 5.83e-10 2.96e-07 0.35 0.28 Corneal astigmatism; chr4:119645578 chr4:119334329~119378233:+ LUSC cis rs7739264 1 rs6456265 ENSG00000237404.1 RP3-471C18.2 -6.33 5.84e-10 2.96e-07 -0.32 -0.28 Endometriosis; chr6:19786719 chr6:19689825~19753113:- LUSC cis rs14027 0.921 rs2136374 ENSG00000279347.1 RP11-85I17.2 -6.33 5.85e-10 2.96e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119765046 chr8:119838736~119840385:- LUSC cis rs14027 0.881 rs4871578 ENSG00000279347.1 RP11-85I17.2 -6.33 5.85e-10 2.96e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119767615 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs10110601 ENSG00000279347.1 RP11-85I17.2 -6.33 5.85e-10 2.96e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119774866 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs1433951 ENSG00000279347.1 RP11-85I17.2 -6.33 5.85e-10 2.96e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119777362 chr8:119838736~119840385:- LUSC cis rs4713118 0.662 rs149901 ENSG00000204709.4 LINC01556 6.33 5.85e-10 2.96e-07 0.38 0.28 Parkinson's disease; chr6:27997725 chr6:28943877~28944537:+ LUSC cis rs14027 0.921 rs13261032 ENSG00000279347.1 RP11-85I17.2 -6.33 5.85e-10 2.96e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119733117 chr8:119838736~119840385:- LUSC cis rs1075265 0.553 rs2692532 ENSG00000233266.1 HMGB1P31 6.33 5.86e-10 2.97e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:53778962 chr2:54051334~54051760:+ LUSC cis rs7739264 0.829 rs6909973 ENSG00000237404.1 RP3-471C18.2 -6.33 5.88e-10 2.98e-07 -0.31 -0.28 Endometriosis; chr6:19734043 chr6:19689825~19753113:- LUSC cis rs853679 0.517 rs9393898 ENSG00000280107.1 AL022393.9 -6.33 5.88e-10 2.98e-07 -0.35 -0.28 Depression; chr6:28162598 chr6:28170845~28172521:+ LUSC cis rs11971779 0.68 rs7795520 ENSG00000273391.1 RP11-634H22.1 6.33 5.88e-10 2.98e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139394461 chr7:139359032~139359566:- LUSC cis rs4713118 0.662 rs9380045 ENSG00000280107.1 AL022393.9 -6.33 5.88e-10 2.98e-07 -0.34 -0.28 Parkinson's disease; chr6:28057501 chr6:28170845~28172521:+ LUSC cis rs4713118 0.616 rs9348789 ENSG00000280107.1 AL022393.9 -6.33 5.88e-10 2.98e-07 -0.34 -0.28 Parkinson's disease; chr6:28057708 chr6:28170845~28172521:+ LUSC cis rs4713118 0.662 rs9468274 ENSG00000280107.1 AL022393.9 -6.33 5.88e-10 2.98e-07 -0.34 -0.28 Parkinson's disease; chr6:28058299 chr6:28170845~28172521:+ LUSC cis rs4713118 0.662 rs9468275 ENSG00000280107.1 AL022393.9 -6.33 5.88e-10 2.98e-07 -0.34 -0.28 Parkinson's disease; chr6:28058358 chr6:28170845~28172521:+ LUSC cis rs4713118 0.662 rs9468276 ENSG00000280107.1 AL022393.9 -6.33 5.88e-10 2.98e-07 -0.34 -0.28 Parkinson's disease; chr6:28059910 chr6:28170845~28172521:+ LUSC cis rs4713118 0.662 rs9468277 ENSG00000280107.1 AL022393.9 -6.33 5.88e-10 2.98e-07 -0.34 -0.28 Parkinson's disease; chr6:28060612 chr6:28170845~28172521:+ LUSC cis rs4713118 0.662 rs9468278 ENSG00000280107.1 AL022393.9 -6.33 5.88e-10 2.98e-07 -0.34 -0.28 Parkinson's disease; chr6:28060704 chr6:28170845~28172521:+ LUSC cis rs4713118 0.662 rs13218430 ENSG00000280107.1 AL022393.9 -6.33 5.88e-10 2.98e-07 -0.34 -0.28 Parkinson's disease; chr6:28062059 chr6:28170845~28172521:+ LUSC cis rs950169 0.58 rs11633762 ENSG00000259728.4 LINC00933 6.33 5.88e-10 2.98e-07 0.36 0.28 Schizophrenia; chr15:84643921 chr15:84570649~84580175:+ LUSC cis rs9322193 0.962 rs12175575 ENSG00000268592.3 RAET1E-AS1 6.33 5.88e-10 2.98e-07 0.35 0.28 Lung cancer; chr6:149763351 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs4869966 ENSG00000268592.3 RAET1E-AS1 6.33 5.88e-10 2.98e-07 0.35 0.28 Lung cancer; chr6:149763714 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs1112730 ENSG00000268592.3 RAET1E-AS1 6.33 5.88e-10 2.98e-07 0.35 0.28 Lung cancer; chr6:149766383 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs1112729 ENSG00000268592.3 RAET1E-AS1 6.33 5.88e-10 2.98e-07 0.35 0.28 Lung cancer; chr6:149766491 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs10452626 ENSG00000268592.3 RAET1E-AS1 6.33 5.88e-10 2.98e-07 0.35 0.28 Lung cancer; chr6:149767481 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs62441303 ENSG00000268592.3 RAET1E-AS1 6.33 5.88e-10 2.98e-07 0.35 0.28 Lung cancer; chr6:149767547 chr6:149863494~149919507:+ LUSC cis rs7267979 0.933 rs1130694 ENSG00000274973.1 RP13-401N8.7 -6.33 5.89e-10 2.98e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25295661 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs13038834 ENSG00000274973.1 RP13-401N8.7 -6.33 5.9e-10 2.98e-07 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25460797 chr20:25845497~25845862:+ LUSC cis rs6142102 0.602 rs6142069 ENSG00000275784.1 RP5-1125A11.6 -6.33 5.9e-10 2.99e-07 -0.31 -0.28 Skin pigmentation; chr20:33972736 chr20:33989480~33991818:- LUSC cis rs116095464 0.619 rs2303741 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:218241 chr5:288833~290321:- LUSC cis rs116095464 0.614 rs56299325 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:220479 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs62346526 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:220499 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs56043030 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:220802 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs10067021 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:221375 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs9312977 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:221801 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6881920 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:222296 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6878061 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:222957 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6882584 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:223296 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs3213838 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:223775 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6555052 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:224153 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs61689490 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:224789 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs61492827 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:225659 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs56342538 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:225681 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6555055 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:226045 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6555056 ENSG00000250848.1 CTD-2083E4.5 -6.32 5.91e-10 2.99e-07 -0.42 -0.28 Breast cancer; chr5:226107 chr5:288833~290321:- LUSC cis rs13113518 0.812 rs13140590 ENSG00000272969.1 RP11-528I4.2 6.32 5.91e-10 2.99e-07 0.32 0.28 Height; chr4:55548666 chr4:55547112~55547889:+ LUSC cis rs853679 0.517 rs4713135 ENSG00000204709.4 LINC01556 6.32 5.92e-10 2.99e-07 0.39 0.28 Depression; chr6:28071808 chr6:28943877~28944537:+ LUSC cis rs957448 1 rs72674843 ENSG00000253175.1 RP11-267M23.6 6.32 5.92e-10 2.99e-07 0.33 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94520772 chr8:94565036~94565715:+ LUSC cis rs875971 0.66 rs2013222 ENSG00000236529.1 RP13-254B10.1 -6.32 5.93e-10 3e-07 -0.29 -0.28 Aortic root size; chr7:66570949 chr7:65840212~65840596:+ LUSC cis rs1075265 0.584 rs10164409 ENSG00000233266.1 HMGB1P31 6.32 5.93e-10 3e-07 0.34 0.28 Chronotype;Morning vs. evening chronotype; chr2:53940867 chr2:54051334~54051760:+ LUSC cis rs4950322 0.518 rs4950304 ENSG00000278811.3 LINC00624 6.32 5.93e-10 3e-07 0.3 0.28 Protein quantitative trait loci; chr1:147116685 chr1:147258885~147517875:- LUSC cis rs12908161 0.92 rs12904605 ENSG00000259728.4 LINC00933 6.32 5.93e-10 3e-07 0.36 0.28 Schizophrenia; chr15:84658188 chr15:84570649~84580175:+ LUSC cis rs11089937 0.616 rs4991801 ENSG00000211639.2 IGLV4-60 6.32 5.93e-10 3e-07 0.29 0.28 Periodontitis (PAL4Q3); chr22:22178958 chr22:22162199~22162681:+ LUSC cis rs9322193 0.923 rs10782317 ENSG00000268592.3 RAET1E-AS1 -6.32 5.95e-10 3.01e-07 -0.35 -0.28 Lung cancer; chr6:149753911 chr6:149863494~149919507:+ LUSC cis rs7429990 0.864 rs6806860 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47708218 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs6768699 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47711258 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs6786001 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47718500 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs12495204 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47720540 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs7618758 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47720993 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs7612219 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47739676 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs35148469 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47739873 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs17079785 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47743160 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs6442082 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47743991 chr3:48256350~48256938:- LUSC cis rs7429990 0.747 rs6442083 ENSG00000229759.1 MRPS18AP1 -6.32 5.95e-10 3.01e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47744305 chr3:48256350~48256938:- LUSC cis rs950169 0.58 rs11634320 ENSG00000259728.4 LINC00933 -6.32 5.95e-10 3.01e-07 -0.36 -0.28 Schizophrenia; chr15:84628952 chr15:84570649~84580175:+ LUSC cis rs7739264 1 rs7739264 ENSG00000237404.1 RP3-471C18.2 -6.32 5.96e-10 3.01e-07 -0.32 -0.28 Endometriosis; chr6:19785357 chr6:19689825~19753113:- LUSC cis rs14027 0.843 rs1828238 ENSG00000279347.1 RP11-85I17.2 6.32 5.96e-10 3.01e-07 0.26 0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119848105 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs1960438 ENSG00000279347.1 RP11-85I17.2 6.32 5.96e-10 3.01e-07 0.26 0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119848193 chr8:119838736~119840385:- LUSC cis rs131777 0.576 rs131758 ENSG00000205559.3 CHKB-AS1 -6.32 5.97e-10 3.02e-07 -0.35 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50578653 chr22:50583026~50583877:+ LUSC cis rs9322193 0.923 rs11155670 ENSG00000268592.3 RAET1E-AS1 6.32 5.98e-10 3.02e-07 0.36 0.28 Lung cancer; chr6:149644992 chr6:149863494~149919507:+ LUSC cis rs30380 1 rs151964 ENSG00000248734.2 CTD-2260A17.1 6.32 5.98e-10 3.02e-07 0.27 0.28 Cerebrospinal fluid biomarker levels; chr5:96787963 chr5:96784777~96785999:+ LUSC cis rs227275 0.554 rs223466 ENSG00000230069.3 LRRC37A15P -6.32 5.99e-10 3.02e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102780039 chr4:102727274~102730721:- LUSC cis rs11098499 0.909 rs73842633 ENSG00000250412.1 KLHL2P1 6.32 5.99e-10 3.03e-07 0.37 0.28 Corneal astigmatism; chr4:119454309 chr4:119334329~119378233:+ LUSC cis rs1823913 0.599 rs35892286 ENSG00000280083.1 RP11-317J9.1 -6.32 5.99e-10 3.03e-07 -0.33 -0.28 Obesity-related traits; chr2:191269010 chr2:191154118~191156070:- LUSC cis rs227275 0.525 rs223332 ENSG00000230069.3 LRRC37A15P -6.32 6e-10 3.03e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102869029 chr4:102727274~102730721:- LUSC cis rs11690935 0.959 rs3770452 ENSG00000228389.1 AC068039.4 6.32 6.01e-10 3.04e-07 0.33 0.28 Schizophrenia; chr2:171812172 chr2:171773482~171775844:+ LUSC cis rs1113500 0.73 rs1343203 ENSG00000226822.1 RP11-356N1.2 6.32 6.01e-10 3.04e-07 0.29 0.28 Growth-regulated protein alpha levels; chr1:108048560 chr1:108071482~108074519:+ LUSC cis rs9322193 0.923 rs7767622 ENSG00000268592.3 RAET1E-AS1 6.32 6.01e-10 3.04e-07 0.35 0.28 Lung cancer; chr6:149681766 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs3798761 ENSG00000268592.3 RAET1E-AS1 6.32 6.01e-10 3.04e-07 0.35 0.28 Lung cancer; chr6:149683643 chr6:149863494~149919507:+ LUSC cis rs7246657 0.943 rs8109632 ENSG00000276846.1 CTD-3220F14.3 6.32 6.02e-10 3.04e-07 0.42 0.28 Coronary artery calcification; chr19:37440223 chr19:37314868~37315620:- LUSC cis rs7429990 0.786 rs13064183 ENSG00000229759.1 MRPS18AP1 -6.32 6.03e-10 3.05e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47745405 chr3:48256350~48256938:- LUSC cis rs17711722 0.565 rs73372653 ENSG00000226824.5 RP4-756H11.3 -6.32 6.04e-10 3.05e-07 -0.34 -0.28 Calcium levels; chr7:65977808 chr7:66654538~66669855:+ LUSC cis rs950169 0.922 rs2033284 ENSG00000259728.4 LINC00933 6.32 6.05e-10 3.05e-07 0.37 0.28 Schizophrenia; chr15:84391575 chr15:84570649~84580175:+ LUSC cis rs801193 1 rs4717319 ENSG00000236529.1 RP13-254B10.1 6.32 6.05e-10 3.05e-07 0.29 0.28 Aortic root size; chr7:66777606 chr7:65840212~65840596:+ LUSC cis rs801193 0.904 rs4718403 ENSG00000236529.1 RP13-254B10.1 6.32 6.05e-10 3.05e-07 0.29 0.28 Aortic root size; chr7:66777742 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs3778909 ENSG00000236529.1 RP13-254B10.1 6.32 6.05e-10 3.05e-07 0.29 0.28 Aortic root size; chr7:66790659 chr7:65840212~65840596:+ LUSC cis rs2404602 0.647 rs4886837 ENSG00000259422.1 RP11-593F23.1 -6.32 6.06e-10 3.06e-07 -0.33 -0.28 Blood metabolite levels; chr15:76864076 chr15:76174891~76181486:- LUSC cis rs228614 0.51 rs223353 ENSG00000230069.3 LRRC37A15P -6.32 6.06e-10 3.06e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102854547 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223352 ENSG00000230069.3 LRRC37A15P -6.32 6.06e-10 3.06e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102855710 chr4:102727274~102730721:- LUSC cis rs801193 0.967 rs2707849 ENSG00000236529.1 RP13-254B10.1 6.32 6.06e-10 3.06e-07 0.29 0.28 Aortic root size; chr7:66687725 chr7:65840212~65840596:+ LUSC cis rs801193 0.967 rs2707841 ENSG00000236529.1 RP13-254B10.1 6.32 6.06e-10 3.06e-07 0.29 0.28 Aortic root size; chr7:66692033 chr7:65840212~65840596:+ LUSC cis rs801193 1 rs4717310 ENSG00000236529.1 RP13-254B10.1 6.32 6.06e-10 3.06e-07 0.29 0.28 Aortic root size; chr7:66696020 chr7:65840212~65840596:+ LUSC cis rs801193 0.844 rs7779971 ENSG00000236529.1 RP13-254B10.1 6.32 6.06e-10 3.06e-07 0.29 0.28 Aortic root size; chr7:66696803 chr7:65840212~65840596:+ LUSC cis rs2179367 0.632 rs9498335 ENSG00000231760.4 RP11-350J20.5 6.32 6.06e-10 3.06e-07 0.4 0.28 Dupuytren's disease; chr6:149372648 chr6:149796151~149826294:- LUSC cis rs8040855 0.627 rs11630697 ENSG00000259295.5 CSPG4P12 6.32 6.08e-10 3.07e-07 0.35 0.28 Bulimia nervosa; chr15:85063214 chr15:85191438~85213905:+ LUSC cis rs7267979 1 rs6076339 ENSG00000274973.1 RP13-401N8.7 6.32 6.08e-10 3.07e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25368076 chr20:25845497~25845862:+ LUSC cis rs760794 0.577 rs17483277 ENSG00000227116.1 RP3-471C18.1 -6.32 6.09e-10 3.07e-07 -0.34 -0.28 Endometriosis; chr6:19790340 chr6:19730427~19734567:- LUSC cis rs6772849 0.931 rs60825080 ENSG00000242551.2 POU5F1P6 -6.32 6.1e-10 3.08e-07 -0.32 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128665991 chr3:128674735~128677005:- LUSC cis rs6700559 0.595 rs11581339 ENSG00000260088.1 RP11-92G12.3 6.32 6.11e-10 3.08e-07 0.35 0.28 Coronary artery disease; chr1:200686105 chr1:200669507~200694250:+ LUSC cis rs801193 1 rs2707856 ENSG00000236529.1 RP13-254B10.1 6.32 6.11e-10 3.08e-07 0.29 0.28 Aortic root size; chr7:66746023 chr7:65840212~65840596:+ LUSC cis rs11971779 0.68 rs6467840 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139380655 chr7:139359032~139359566:- LUSC cis rs11971779 0.564 rs6467841 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139381346 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs7792752 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139381450 chr7:139359032~139359566:- LUSC cis rs11971779 0.616 rs6974907 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139383983 chr7:139359032~139359566:- LUSC cis rs11971779 0.584 rs10236055 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139385245 chr7:139359032~139359566:- LUSC cis rs11971779 0.584 rs6942519 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139385344 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6467843 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139385777 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs2355785 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139386237 chr7:139359032~139359566:- LUSC cis rs11971779 0.588 rs6972408 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139386728 chr7:139359032~139359566:- LUSC cis rs11971779 0.625 rs2355784 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139387747 chr7:139359032~139359566:- LUSC cis rs11971779 0.616 rs2883772 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139388010 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs28579232 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139388370 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs2355783 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139391133 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs111461944 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139393157 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs12154842 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139393738 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6467846 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139394639 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6467848 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139395459 chr7:139359032~139359566:- LUSC cis rs11971779 0.648 rs6467849 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139395766 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs1986447 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139397334 chr7:139359032~139359566:- LUSC cis rs11971779 0.59 rs9642120 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139399225 chr7:139359032~139359566:- LUSC cis rs11971779 0.618 rs9640925 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139400542 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs7804388 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139401667 chr7:139359032~139359566:- LUSC cis rs11971779 0.618 rs6943788 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139402951 chr7:139359032~139359566:- LUSC cis rs11971779 0.648 rs10085708 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139426208 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs7805767 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139426669 chr7:139359032~139359566:- LUSC cis rs11971779 0.648 rs6467852 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139427845 chr7:139359032~139359566:- LUSC cis rs11971779 0.616 rs7779314 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139427950 chr7:139359032~139359566:- LUSC cis rs11971779 0.715 rs7779390 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139428207 chr7:139359032~139359566:- LUSC cis rs11971779 0.584 rs34762928 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139428422 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs11760420 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139430022 chr7:139359032~139359566:- LUSC cis rs11971779 0.553 rs10228643 ENSG00000273391.1 RP11-634H22.1 6.32 6.11e-10 3.08e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139430674 chr7:139359032~139359566:- LUSC cis rs9322193 0.923 rs4354168 ENSG00000268592.3 RAET1E-AS1 6.32 6.12e-10 3.08e-07 0.36 0.28 Lung cancer; chr6:149696642 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs4455682 ENSG00000268592.3 RAET1E-AS1 6.32 6.12e-10 3.08e-07 0.36 0.28 Lung cancer; chr6:149700161 chr6:149863494~149919507:+ LUSC cis rs442309 0.687 rs10995282 ENSG00000238280.1 RP11-436D10.3 -6.32 6.12e-10 3.09e-07 -0.34 -0.28 Vogt-Koyanagi-Harada syndrome; chr10:62711531 chr10:62793562~62805887:- LUSC cis rs2408955 0.568 rs12099462 ENSG00000240399.1 RP1-228P16.1 -6.32 6.13e-10 3.09e-07 -0.29 -0.28 Glycated hemoglobin levels; chr12:48109321 chr12:48054813~48055591:- LUSC cis rs7267979 1 rs2258617 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25293682 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2257420 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25295254 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2258769 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25296044 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2258879 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25298577 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2257496 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25298679 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2258884 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25298903 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2259837 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25299569 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2259873 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25300145 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs11100 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25300548 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs1046073 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25300697 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2259926 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25301097 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2259928 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25301198 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2259956 ENSG00000274973.1 RP13-401N8.7 -6.32 6.14e-10 3.1e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25301797 chr20:25845497~25845862:+ LUSC cis rs75920871 0.588 rs1871756 ENSG00000254851.1 RP11-109L13.1 6.32 6.15e-10 3.1e-07 0.39 0.28 Subjective well-being; chr11:117082929 chr11:117135528~117138582:+ LUSC cis rs4713118 0.662 rs464312 ENSG00000280107.1 AL022393.9 -6.32 6.16e-10 3.11e-07 -0.34 -0.28 Parkinson's disease; chr6:27999813 chr6:28170845~28172521:+ LUSC cis rs7246657 0.943 rs13343471 ENSG00000276846.1 CTD-3220F14.3 6.32 6.18e-10 3.11e-07 0.44 0.28 Coronary artery calcification; chr19:37441228 chr19:37314868~37315620:- LUSC cis rs2404602 0.709 rs11072591 ENSG00000259422.1 RP11-593F23.1 6.32 6.19e-10 3.12e-07 0.32 0.28 Blood metabolite levels; chr15:76357221 chr15:76174891~76181486:- LUSC cis rs11089937 0.616 rs713644 ENSG00000211639.2 IGLV4-60 6.32 6.19e-10 3.12e-07 0.29 0.28 Periodontitis (PAL4Q3); chr22:22180747 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs713624 ENSG00000211639.2 IGLV4-60 6.32 6.19e-10 3.12e-07 0.29 0.28 Periodontitis (PAL4Q3); chr22:22180754 chr22:22162199~22162681:+ LUSC cis rs17711722 0.522 rs6957759 ENSG00000226824.5 RP4-756H11.3 -6.32 6.19e-10 3.12e-07 -0.33 -0.28 Calcium levels; chr7:65806798 chr7:66654538~66669855:+ LUSC cis rs61270009 1 rs61270009 ENSG00000247828.6 TMEM161B-AS1 6.32 6.2e-10 3.12e-07 0.34 0.28 Depressive symptoms; chr5:88280322 chr5:88268895~88436685:+ LUSC cis rs2408955 0.522 rs2051851 ENSG00000240399.1 RP1-228P16.1 -6.32 6.21e-10 3.13e-07 -0.29 -0.28 Glycated hemoglobin levels; chr12:48092157 chr12:48054813~48055591:- LUSC cis rs2408955 0.522 rs973398 ENSG00000240399.1 RP1-228P16.1 -6.32 6.21e-10 3.13e-07 -0.29 -0.28 Glycated hemoglobin levels; chr12:48097265 chr12:48054813~48055591:- LUSC cis rs9549367 0.789 rs12584008 ENSG00000269125.1 RP11-98F14.11 -6.32 6.21e-10 3.13e-07 -0.35 -0.28 Platelet distribution width; chr13:113226914 chr13:113165002~113165183:- LUSC cis rs13113518 0.756 rs11939652 ENSG00000272969.1 RP11-528I4.2 6.32 6.21e-10 3.13e-07 0.32 0.28 Height; chr4:55532542 chr4:55547112~55547889:+ LUSC cis rs6142102 0.517 rs8119076 ENSG00000275784.1 RP5-1125A11.6 -6.32 6.21e-10 3.13e-07 -0.31 -0.28 Skin pigmentation; chr20:33937909 chr20:33989480~33991818:- LUSC cis rs6142102 0.517 rs6059577 ENSG00000275784.1 RP5-1125A11.6 -6.32 6.21e-10 3.13e-07 -0.31 -0.28 Skin pigmentation; chr20:33939880 chr20:33989480~33991818:- LUSC cis rs853679 0.517 rs9393884 ENSG00000204709.4 LINC01556 6.32 6.21e-10 3.13e-07 0.39 0.28 Depression; chr6:28079011 chr6:28943877~28944537:+ LUSC cis rs62432291 0.614 rs420339 ENSG00000235086.1 FNDC1-IT1 -6.32 6.21e-10 3.13e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159236163 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs425906 ENSG00000235086.1 FNDC1-IT1 -6.32 6.21e-10 3.13e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159236543 chr6:159240786~159243329:+ LUSC cis rs1876905 0.539 rs241003 ENSG00000255389.1 C6orf3 -6.32 6.23e-10 3.14e-07 -0.39 -0.28 Mean corpuscular hemoglobin; chr6:111274934 chr6:111599875~111602295:+ LUSC cis rs7772486 0.754 rs702304 ENSG00000235652.6 RP11-545I5.3 -6.32 6.24e-10 3.14e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145669661 chr6:145799409~145886585:+ LUSC cis rs7772486 0.727 rs10447449 ENSG00000235652.6 RP11-545I5.3 6.32 6.25e-10 3.15e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145817571 chr6:145799409~145886585:+ LUSC cis rs9322193 0.884 rs7769115 ENSG00000268592.3 RAET1E-AS1 6.32 6.26e-10 3.15e-07 0.36 0.28 Lung cancer; chr6:149848796 chr6:149863494~149919507:+ LUSC cis rs761746 0.739 rs140081 ENSG00000236132.1 CTA-440B3.1 -6.32 6.26e-10 3.15e-07 -0.41 -0.28 Intelligence; chr22:31716475 chr22:31816379~31817491:- LUSC cis rs7267979 1 rs4815404 ENSG00000274973.1 RP13-401N8.7 6.32 6.26e-10 3.15e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25321209 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6083805 ENSG00000274973.1 RP13-401N8.7 6.32 6.26e-10 3.15e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25336720 chr20:25845497~25845862:+ LUSC cis rs10759883 0.651 rs7852346 ENSG00000175611.10 LINC00476 -6.32 6.26e-10 3.15e-07 -0.34 -0.28 Nicotine dependence; chr9:95786167 chr9:95759231~95875977:- LUSC cis rs875971 0.545 rs4718325 ENSG00000226824.5 RP4-756H11.3 -6.31 6.27e-10 3.16e-07 -0.37 -0.28 Aortic root size; chr7:66215323 chr7:66654538~66669855:+ LUSC cis rs7429990 0.864 rs3915654 ENSG00000229759.1 MRPS18AP1 -6.31 6.27e-10 3.16e-07 -0.27 -0.28 Educational attainment (years of education); chr3:47827132 chr3:48256350~48256938:- LUSC cis rs7267979 1 rs4815407 ENSG00000274973.1 RP13-401N8.7 6.31 6.28e-10 3.16e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25360842 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050566 ENSG00000274973.1 RP13-401N8.7 6.31 6.28e-10 3.16e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25370435 chr20:25845497~25845862:+ LUSC cis rs2732480 0.5 rs2450989 ENSG00000240399.1 RP1-228P16.1 -6.31 6.28e-10 3.16e-07 -0.29 -0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48259625 chr12:48054813~48055591:- LUSC cis rs950169 1 rs79318564 ENSG00000225151.9 GOLGA2P7 -6.31 6.29e-10 3.17e-07 -0.39 -0.28 Schizophrenia; chr15:84117398 chr15:84199311~84230136:- LUSC cis rs7772486 0.686 rs1292336 ENSG00000235652.6 RP11-545I5.3 -6.31 6.3e-10 3.17e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145646682 chr6:145799409~145886585:+ LUSC cis rs496547 0.721 rs2508570 ENSG00000255239.1 AP002954.6 6.31 6.3e-10 3.17e-07 0.31 0.28 Hip minimal joint space width; chr11:118807900 chr11:118688039~118690600:- LUSC cis rs1865760 0.588 rs9467658 ENSG00000272462.2 U91328.19 -6.31 6.3e-10 3.17e-07 -0.29 -0.28 Height; chr6:26010653 chr6:25992662~26001775:+ LUSC cis rs2834288 0.5 rs7283594 ENSG00000273102.1 AP000569.9 -6.31 6.32e-10 3.18e-07 -0.31 -0.28 Gut microbiota (bacterial taxa); chr21:33962798 chr21:33967101~33968573:- LUSC cis rs7772486 0.79 rs9485024 ENSG00000235652.6 RP11-545I5.3 -6.31 6.32e-10 3.18e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145821351 chr6:145799409~145886585:+ LUSC cis rs875971 0.545 rs73376401 ENSG00000226824.5 RP4-756H11.3 -6.31 6.33e-10 3.19e-07 -0.37 -0.28 Aortic root size; chr7:66174841 chr7:66654538~66669855:+ LUSC cis rs11971779 0.68 rs4732373 ENSG00000273391.1 RP11-634H22.1 6.31 6.34e-10 3.19e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139401789 chr7:139359032~139359566:- LUSC cis rs4853012 0.887 rs6737314 ENSG00000257800.1 FNBP1P1 6.31 6.35e-10 3.19e-07 0.34 0.28 Gestational age at birth (maternal effect); chr2:74112459 chr2:74120680~74123218:+ LUSC cis rs875971 0.508 rs10950045 ENSG00000237310.1 GS1-124K5.4 -6.31 6.36e-10 3.2e-07 -0.28 -0.28 Aortic root size; chr7:66601386 chr7:66493706~66495474:+ LUSC cis rs801193 0.839 rs6968619 ENSG00000237310.1 GS1-124K5.4 -6.31 6.36e-10 3.2e-07 -0.28 -0.28 Aortic root size; chr7:66603880 chr7:66493706~66495474:+ LUSC cis rs801193 0.839 rs12534943 ENSG00000237310.1 GS1-124K5.4 -6.31 6.36e-10 3.2e-07 -0.28 -0.28 Aortic root size; chr7:66605533 chr7:66493706~66495474:+ LUSC cis rs801193 0.805 rs12532355 ENSG00000237310.1 GS1-124K5.4 -6.31 6.36e-10 3.2e-07 -0.28 -0.28 Aortic root size; chr7:66605597 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs17138149 ENSG00000226824.5 RP4-756H11.3 -6.31 6.37e-10 3.2e-07 -0.36 -0.28 Aortic root size; chr7:66228193 chr7:66654538~66669855:+ LUSC cis rs4266144 0.592 rs1545854 ENSG00000244515.1 KRT18P34 6.31 6.37e-10 3.2e-07 0.39 0.28 Coronary artery disease; chr3:157122349 chr3:157162663~157163932:- LUSC cis rs9309473 0.615 rs62153183 ENSG00000163016.8 ALMS1P 6.31 6.37e-10 3.2e-07 0.41 0.28 Metabolite levels; chr2:73536239 chr2:73644919~73685576:+ LUSC cis rs9309473 0.615 rs74523560 ENSG00000163016.8 ALMS1P 6.31 6.37e-10 3.2e-07 0.41 0.28 Metabolite levels; chr2:73537058 chr2:73644919~73685576:+ LUSC cis rs228614 0.51 rs223412 ENSG00000230069.3 LRRC37A15P -6.31 6.38e-10 3.2e-07 -0.29 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102812443 chr4:102727274~102730721:- LUSC cis rs929843 1 rs929843 ENSG00000196696.11 PDXDC2P -6.31 6.39e-10 3.21e-07 -0.23 -0.28 Menarche (age at onset); chr16:70011845 chr16:69976297~70065948:- LUSC cis rs62432291 0.681 rs438853 ENSG00000235086.1 FNDC1-IT1 -6.31 6.39e-10 3.21e-07 -0.46 -0.28 Joint mobility (Beighton score); chr6:159209320 chr6:159240786~159243329:+ LUSC cis rs7772486 0.686 rs1415744 ENSG00000235652.6 RP11-545I5.3 6.31 6.39e-10 3.21e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145701395 chr6:145799409~145886585:+ LUSC cis rs13113518 0.812 rs12500686 ENSG00000249700.7 SRD5A3-AS1 6.31 6.4e-10 3.22e-07 0.35 0.28 Height; chr4:55457922 chr4:55363971~55395847:- LUSC cis rs3743266 0.507 rs9630426 ENSG00000245534.5 RORA-AS1 -6.31 6.4e-10 3.22e-07 -0.42 -0.28 Menarche (age at onset); chr15:60446854 chr15:60479178~60630637:+ LUSC cis rs7772486 0.79 rs7753833 ENSG00000235652.6 RP11-545I5.3 6.31 6.42e-10 3.22e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145840296 chr6:145799409~145886585:+ LUSC cis rs73173548 0.528 rs13161403 ENSG00000247828.6 TMEM161B-AS1 6.31 6.42e-10 3.23e-07 0.34 0.28 Macular telangiectasia type 2; chr5:88471144 chr5:88268895~88436685:+ LUSC cis rs78487399 0.71 rs78681698 ENSG00000234936.1 AC010883.5 6.31 6.43e-10 3.23e-07 0.45 0.28 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43371021 chr2:43229573~43233394:+ LUSC cis rs12439619 0.846 rs62010071 ENSG00000276710.3 CSPG4P8 -6.31 6.43e-10 3.23e-07 -0.34 -0.28 Intelligence (multi-trait analysis); chr15:82289442 chr15:82459472~82477258:+ LUSC cis rs7772486 0.686 rs9390349 ENSG00000235652.6 RP11-545I5.3 -6.31 6.44e-10 3.23e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145733294 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs2072911 ENSG00000235652.6 RP11-545I5.3 -6.31 6.44e-10 3.23e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145735665 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs400968 ENSG00000235652.6 RP11-545I5.3 6.31 6.45e-10 3.24e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145498582 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs391820 ENSG00000235652.6 RP11-545I5.3 6.31 6.45e-10 3.24e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145500148 chr6:145799409~145886585:+ LUSC cis rs6570726 0.875 rs1883407 ENSG00000235652.6 RP11-545I5.3 6.31 6.45e-10 3.24e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145502296 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs367612 ENSG00000235652.6 RP11-545I5.3 6.31 6.45e-10 3.24e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145507851 chr6:145799409~145886585:+ LUSC cis rs6570726 0.905 rs375692 ENSG00000235652.6 RP11-545I5.3 6.31 6.45e-10 3.24e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145519232 chr6:145799409~145886585:+ LUSC cis rs11098499 0.82 rs28578366 ENSG00000248280.1 RP11-33B1.2 -6.31 6.46e-10 3.25e-07 -0.33 -0.28 Corneal astigmatism; chr4:119615750 chr4:119440561~119450157:- LUSC cis rs2404602 0.622 rs11637296 ENSG00000259422.1 RP11-593F23.1 -6.31 6.47e-10 3.25e-07 -0.34 -0.28 Blood metabolite levels; chr15:76915544 chr15:76174891~76181486:- LUSC cis rs4237845 0.837 rs7963992 ENSG00000257159.1 RP11-58A17.3 6.31 6.47e-10 3.25e-07 0.33 0.28 Intelligence (multi-trait analysis); chr12:57902166 chr12:57967058~57968399:+ LUSC cis rs7267979 1 rs2500432 ENSG00000274973.1 RP13-401N8.7 -6.31 6.47e-10 3.25e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25309876 chr20:25845497~25845862:+ LUSC cis rs875971 0.545 rs13311962 ENSG00000226824.5 RP4-756H11.3 6.31 6.48e-10 3.25e-07 0.36 0.28 Aortic root size; chr7:66603142 chr7:66654538~66669855:+ LUSC cis rs12554020 0.786 rs16909158 ENSG00000227603.1 RP11-165J3.6 6.31 6.52e-10 3.27e-07 0.43 0.28 Schizophrenia; chr9:93457882 chr9:93435332~93437121:- LUSC cis rs151227923 1 rs151227923 ENSG00000273117.1 AC144652.1 6.31 6.53e-10 3.28e-07 0.31 0.28 Stem cell growth factor beta levels; chr7:155314854 chr7:155295918~155297541:- LUSC cis rs140365914 1 rs140365914 ENSG00000273117.1 AC144652.1 6.31 6.53e-10 3.28e-07 0.31 0.28 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr7:155314860 chr7:155295918~155297541:- LUSC cis rs875971 0.545 rs6460276 ENSG00000226824.5 RP4-756H11.3 -6.31 6.53e-10 3.28e-07 -0.36 -0.28 Aortic root size; chr7:66182290 chr7:66654538~66669855:+ LUSC cis rs7429990 0.864 rs11130144 ENSG00000229759.1 MRPS18AP1 -6.31 6.53e-10 3.28e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47626444 chr3:48256350~48256938:- LUSC cis rs8062405 0.964 rs78613234 ENSG00000278665.1 RP11-666O2.4 6.31 6.53e-10 3.28e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828104 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs62036624 ENSG00000278665.1 RP11-666O2.4 6.31 6.53e-10 3.28e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828609 chr16:28599241~28601881:- LUSC cis rs11098499 0.604 rs17051352 ENSG00000250412.1 KLHL2P1 6.31 6.54e-10 3.28e-07 0.36 0.28 Corneal astigmatism; chr4:119660272 chr4:119334329~119378233:+ LUSC cis rs7772486 0.686 rs2179323 ENSG00000235652.6 RP11-545I5.3 -6.31 6.55e-10 3.29e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145661650 chr6:145799409~145886585:+ LUSC cis rs14027 0.921 rs12542794 ENSG00000279347.1 RP11-85I17.2 -6.31 6.56e-10 3.29e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119826153 chr8:119838736~119840385:- LUSC cis rs875971 0.66 rs10215132 ENSG00000236529.1 RP13-254B10.1 -6.31 6.56e-10 3.29e-07 -0.29 -0.28 Aortic root size; chr7:66589419 chr7:65840212~65840596:+ LUSC cis rs9341808 0.935 rs2298307 ENSG00000272129.1 RP11-250B2.6 6.31 6.56e-10 3.29e-07 0.33 0.28 Sitting height ratio; chr6:80106579 chr6:80355424~80356859:+ LUSC cis rs1729407 0.695 rs1263176 ENSG00000254851.1 RP11-109L13.1 -6.31 6.56e-10 3.29e-07 -0.34 -0.28 Apolipoprotein A-IV levels; chr11:116819407 chr11:117135528~117138582:+ LUSC cis rs113835537 0.529 rs74869459 ENSG00000255517.5 CTD-3074O7.5 -6.31 6.58e-10 3.3e-07 -0.33 -0.28 Airway imaging phenotypes; chr11:66529098 chr11:66473490~66480233:- LUSC cis rs35160687 0.842 rs7593440 ENSG00000273080.1 RP11-301O19.1 -6.31 6.58e-10 3.3e-07 -0.26 -0.28 Night sleep phenotypes; chr2:86323534 chr2:86195590~86196049:+ LUSC cis rs35160687 0.814 rs4392258 ENSG00000273080.1 RP11-301O19.1 -6.31 6.58e-10 3.3e-07 -0.26 -0.28 Night sleep phenotypes; chr2:86325454 chr2:86195590~86196049:+ LUSC cis rs35160687 0.842 rs11685863 ENSG00000273080.1 RP11-301O19.1 -6.31 6.58e-10 3.3e-07 -0.26 -0.28 Night sleep phenotypes; chr2:86327361 chr2:86195590~86196049:+ LUSC cis rs4713118 0.662 rs149947 ENSG00000280107.1 AL022393.9 -6.31 6.6e-10 3.31e-07 -0.34 -0.28 Parkinson's disease; chr6:28004655 chr6:28170845~28172521:+ LUSC cis rs1198872 0.563 rs1106185 ENSG00000272275.1 RP11-791G15.2 6.31 6.6e-10 3.31e-07 0.39 0.28 Cardiac Troponin-T levels; chr2:10823444 chr2:10767875~10770058:- LUSC cis rs12439619 0.846 rs62012003 ENSG00000276710.3 CSPG4P8 -6.31 6.61e-10 3.31e-07 -0.33 -0.28 Intelligence (multi-trait analysis); chr15:82183236 chr15:82459472~82477258:+ LUSC cis rs10885396 1 rs10885396 ENSG00000233547.1 RP11-57H14.2 -6.31 6.61e-10 3.31e-07 -0.29 -0.28 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112951996 chr10:112950646~112951875:- LUSC cis rs6603134 0.502 rs6603132 ENSG00000267939.1 CTD-2325M2.1 -6.31 6.61e-10 3.31e-07 -0.31 -0.28 Blood protein levels; chr19:8037908 chr19:8008729~8016025:+ LUSC cis rs2404602 0.709 rs11072597 ENSG00000259422.1 RP11-593F23.1 -6.31 6.61e-10 3.32e-07 -0.33 -0.28 Blood metabolite levels; chr15:76471173 chr15:76174891~76181486:- LUSC cis rs2404602 0.735 rs11857327 ENSG00000259422.1 RP11-593F23.1 -6.31 6.61e-10 3.32e-07 -0.33 -0.28 Blood metabolite levels; chr15:76471922 chr15:76174891~76181486:- LUSC cis rs6603134 0.502 rs6603131 ENSG00000267939.1 CTD-2325M2.1 -6.31 6.61e-10 3.32e-07 -0.31 -0.28 Blood protein levels; chr19:8037873 chr19:8008729~8016025:+ LUSC cis rs881375 0.967 rs1008381 ENSG00000226752.6 PSMD5-AS1 -6.31 6.62e-10 3.32e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120918838 chr9:120824828~120854385:+ LUSC cis rs1823913 0.637 rs2883912 ENSG00000227542.1 AC092614.2 -6.31 6.62e-10 3.32e-07 -0.35 -0.28 Obesity-related traits; chr2:191284290 chr2:191229165~191246172:- LUSC cis rs11690935 0.959 rs6759575 ENSG00000228389.1 AC068039.4 6.31 6.62e-10 3.32e-07 0.33 0.28 Schizophrenia; chr2:171832558 chr2:171773482~171775844:+ LUSC cis rs904251 0.734 rs2797790 ENSG00000204110.6 RP1-153P14.8 6.31 6.63e-10 3.32e-07 0.29 0.28 Cognitive performance; chr6:37479299 chr6:37507348~37535616:+ LUSC cis rs638893 0.578 rs485901 ENSG00000278376.1 RP11-158I9.8 -6.31 6.63e-10 3.32e-07 -0.37 -0.28 Vitiligo; chr11:118751536 chr11:118791254~118793137:+ LUSC cis rs638893 0.578 rs580079 ENSG00000278376.1 RP11-158I9.8 -6.31 6.63e-10 3.32e-07 -0.37 -0.28 Vitiligo; chr11:118754900 chr11:118791254~118793137:+ LUSC cis rs950169 0.919 rs17300292 ENSG00000225151.9 GOLGA2P7 -6.31 6.63e-10 3.32e-07 -0.39 -0.28 Schizophrenia; chr15:84093816 chr15:84199311~84230136:- LUSC cis rs13113518 1 rs13122619 ENSG00000249700.7 SRD5A3-AS1 6.31 6.64e-10 3.33e-07 0.32 0.28 Height; chr4:55479339 chr4:55363971~55395847:- LUSC cis rs11157436 0.918 rs1076546 ENSG00000211813.2 TRAV34 6.31 6.65e-10 3.33e-07 0.3 0.28 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22159015 chr14:22207522~22208129:+ LUSC cis rs11098499 0.73 rs78971550 ENSG00000249244.1 RP11-548H18.2 6.3 6.68e-10 3.35e-07 0.35 0.28 Corneal astigmatism; chr4:119359886 chr4:119391831~119395335:- LUSC cis rs11098499 0.645 rs78422072 ENSG00000249244.1 RP11-548H18.2 6.3 6.68e-10 3.35e-07 0.35 0.28 Corneal astigmatism; chr4:119359887 chr4:119391831~119395335:- LUSC cis rs6142102 0.961 rs6120519 ENSG00000275784.1 RP5-1125A11.6 -6.3 6.69e-10 3.35e-07 -0.32 -0.28 Skin pigmentation; chr20:34100307 chr20:33989480~33991818:- LUSC cis rs13113518 0.934 rs11133397 ENSG00000249700.7 SRD5A3-AS1 6.3 6.69e-10 3.35e-07 0.32 0.28 Height; chr4:55534166 chr4:55363971~55395847:- LUSC cis rs13113518 0.934 rs11133398 ENSG00000249700.7 SRD5A3-AS1 6.3 6.69e-10 3.35e-07 0.32 0.28 Height; chr4:55534180 chr4:55363971~55395847:- LUSC cis rs496547 0.719 rs598373 ENSG00000255422.1 AP002954.4 -6.3 6.7e-10 3.36e-07 -0.31 -0.28 Hip minimal joint space width; chr11:118793668 chr11:118704607~118750263:+ LUSC cis rs783540 0.5 rs7163840 ENSG00000276710.3 CSPG4P8 6.3 6.71e-10 3.36e-07 0.33 0.28 Schizophrenia; chr15:82729551 chr15:82459472~82477258:+ LUSC cis rs11098499 0.954 rs4309825 ENSG00000250412.1 KLHL2P1 -6.3 6.71e-10 3.36e-07 -0.33 -0.28 Corneal astigmatism; chr4:119393726 chr4:119334329~119378233:+ LUSC cis rs7772486 0.727 rs12190966 ENSG00000235652.6 RP11-545I5.3 6.3 6.72e-10 3.37e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145825684 chr6:145799409~145886585:+ LUSC cis rs6142102 0.961 rs6087557 ENSG00000275784.1 RP5-1125A11.6 -6.3 6.72e-10 3.37e-07 -0.32 -0.28 Skin pigmentation; chr20:34110469 chr20:33989480~33991818:- LUSC cis rs11098499 1 rs13116504 ENSG00000250412.1 KLHL2P1 6.3 6.73e-10 3.37e-07 0.35 0.28 Corneal astigmatism; chr4:119288257 chr4:119334329~119378233:+ LUSC cis rs950880 0.71 rs3771150 ENSG00000234389.1 AC007278.3 -6.3 6.73e-10 3.37e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102444391 chr2:102438713~102440475:+ LUSC cis rs1075265 0.597 rs10490471 ENSG00000233266.1 HMGB1P31 6.3 6.74e-10 3.37e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:53769446 chr2:54051334~54051760:+ LUSC cis rs6142102 0.923 rs3787230 ENSG00000275784.1 RP5-1125A11.6 -6.3 6.74e-10 3.38e-07 -0.32 -0.28 Skin pigmentation; chr20:34052466 chr20:33989480~33991818:- LUSC cis rs853679 0.517 rs9380058 ENSG00000280107.1 AL022393.9 -6.3 6.75e-10 3.38e-07 -0.35 -0.28 Depression; chr6:28159666 chr6:28170845~28172521:+ LUSC cis rs10759883 0.627 rs816683 ENSG00000175611.10 LINC00476 -6.3 6.75e-10 3.38e-07 -0.33 -0.28 Nicotine dependence; chr9:95822819 chr9:95759231~95875977:- LUSC cis rs66887589 0.616 rs6843509 ENSG00000249244.1 RP11-548H18.2 6.3 6.77e-10 3.39e-07 0.34 0.28 Diastolic blood pressure; chr4:119299041 chr4:119391831~119395335:- LUSC cis rs1322639 0.614 rs4708414 ENSG00000261039.2 RP11-417E7.2 -6.3 6.78e-10 3.39e-07 -0.32 -0.28 Pulse pressure; chr6:169174049 chr6:169175304~169182740:- LUSC cis rs2179367 0.552 rs11155652 ENSG00000231760.4 RP11-350J20.5 6.3 6.78e-10 3.39e-07 0.39 0.28 Dupuytren's disease; chr6:149417849 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs12209364 ENSG00000231760.4 RP11-350J20.5 6.3 6.78e-10 3.39e-07 0.39 0.28 Dupuytren's disease; chr6:149418062 chr6:149796151~149826294:- LUSC cis rs2179367 0.537 rs6911411 ENSG00000231760.4 RP11-350J20.5 6.3 6.79e-10 3.4e-07 0.43 0.28 Dupuytren's disease; chr6:149366954 chr6:149796151~149826294:- LUSC cis rs496547 0.719 rs598373 ENSG00000255239.1 AP002954.6 6.3 6.79e-10 3.4e-07 0.32 0.28 Hip minimal joint space width; chr11:118793668 chr11:118688039~118690600:- LUSC cis rs11123170 0.64 rs2863240 ENSG00000274877.1 RP11-65I12.1 6.3 6.79e-10 3.4e-07 0.37 0.28 Renal function-related traits (BUN); chr2:113212539 chr2:113237595~113240825:+ LUSC cis rs62432291 0.681 rs388001 ENSG00000235086.1 FNDC1-IT1 -6.3 6.8e-10 3.4e-07 -0.46 -0.28 Joint mobility (Beighton score); chr6:159237427 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs447637 ENSG00000235086.1 FNDC1-IT1 -6.3 6.8e-10 3.4e-07 -0.46 -0.28 Joint mobility (Beighton score); chr6:159237694 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs378339 ENSG00000235086.1 FNDC1-IT1 -6.3 6.8e-10 3.4e-07 -0.46 -0.28 Joint mobility (Beighton score); chr6:159237820 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs419836 ENSG00000235086.1 FNDC1-IT1 -6.3 6.8e-10 3.4e-07 -0.46 -0.28 Joint mobility (Beighton score); chr6:159238449 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs450538 ENSG00000235086.1 FNDC1-IT1 -6.3 6.8e-10 3.4e-07 -0.46 -0.28 Joint mobility (Beighton score); chr6:159238491 chr6:159240786~159243329:+ LUSC cis rs62432291 0.764 rs433256 ENSG00000235086.1 FNDC1-IT1 -6.3 6.8e-10 3.4e-07 -0.46 -0.28 Joint mobility (Beighton score); chr6:159239073 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs429339 ENSG00000235086.1 FNDC1-IT1 -6.3 6.8e-10 3.4e-07 -0.46 -0.28 Joint mobility (Beighton score); chr6:159239116 chr6:159240786~159243329:+ LUSC cis rs17507216 0.718 rs72751662 ENSG00000255769.6 GOLGA2P10 -6.3 6.8e-10 3.4e-07 -0.43 -0.28 Excessive daytime sleepiness; chr15:82594705 chr15:82472993~82513950:- LUSC cis rs1823913 0.637 rs12624271 ENSG00000227542.1 AC092614.2 -6.3 6.82e-10 3.41e-07 -0.35 -0.28 Obesity-related traits; chr2:191288586 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs11686185 ENSG00000227542.1 AC092614.2 -6.3 6.82e-10 3.41e-07 -0.35 -0.28 Obesity-related traits; chr2:191289282 chr2:191229165~191246172:- LUSC cis rs35160687 0.842 rs10200619 ENSG00000273080.1 RP11-301O19.1 -6.3 6.82e-10 3.41e-07 -0.26 -0.28 Night sleep phenotypes; chr2:86321725 chr2:86195590~86196049:+ LUSC cis rs496547 0.654 rs688161 ENSG00000255239.1 AP002954.6 6.3 6.82e-10 3.41e-07 0.31 0.28 Hip minimal joint space width; chr11:118807001 chr11:118688039~118690600:- LUSC cis rs2286503 0.901 rs2286505 ENSG00000228649.7 AC005682.5 6.3 6.83e-10 3.42e-07 0.31 0.28 Fibrinogen; chr7:22815221 chr7:22854178~22861579:+ LUSC cis rs2834288 0.5 rs766423 ENSG00000273102.1 AP000569.9 6.3 6.84e-10 3.42e-07 0.31 0.28 Gut microbiota (bacterial taxa); chr21:33962711 chr21:33967101~33968573:- LUSC cis rs5753618 0.561 rs4603880 ENSG00000236132.1 CTA-440B3.1 -6.3 6.85e-10 3.43e-07 -0.38 -0.28 Colorectal cancer; chr22:31348735 chr22:31816379~31817491:- LUSC cis rs13113518 0.812 rs2035691 ENSG00000249700.7 SRD5A3-AS1 6.3 6.86e-10 3.43e-07 0.33 0.28 Height; chr4:55529786 chr4:55363971~55395847:- LUSC cis rs14027 0.921 rs12707880 ENSG00000279347.1 RP11-85I17.2 -6.3 6.86e-10 3.43e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119829051 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs12542706 ENSG00000279347.1 RP11-85I17.2 -6.3 6.86e-10 3.43e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119831539 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs10505374 ENSG00000279347.1 RP11-85I17.2 -6.3 6.86e-10 3.43e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119832350 chr8:119838736~119840385:- LUSC cis rs7429990 0.864 rs1403578 ENSG00000229759.1 MRPS18AP1 -6.3 6.87e-10 3.43e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47617997 chr3:48256350~48256938:- LUSC cis rs950169 0.8 rs4842847 ENSG00000259728.4 LINC00933 6.3 6.87e-10 3.43e-07 0.37 0.28 Schizophrenia; chr15:84262447 chr15:84570649~84580175:+ LUSC cis rs6142102 0.961 rs4911408 ENSG00000275784.1 RP5-1125A11.6 -6.3 6.87e-10 3.43e-07 -0.33 -0.28 Skin pigmentation; chr20:34112760 chr20:33989480~33991818:- LUSC cis rs9322193 0.923 rs2185352 ENSG00000268592.3 RAET1E-AS1 6.3 6.87e-10 3.43e-07 0.35 0.28 Lung cancer; chr6:149714640 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs12174349 ENSG00000268592.3 RAET1E-AS1 6.3 6.87e-10 3.43e-07 0.35 0.28 Lung cancer; chr6:149718012 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs2297932 ENSG00000268592.3 RAET1E-AS1 6.3 6.87e-10 3.43e-07 0.35 0.28 Lung cancer; chr6:149718225 chr6:149863494~149919507:+ LUSC cis rs8062405 0.69 rs4787458 ENSG00000278665.1 RP11-666O2.4 6.3 6.87e-10 3.44e-07 0.29 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28519966 chr16:28599241~28601881:- LUSC cis rs113835537 0.529 rs12099041 ENSG00000255517.5 CTD-3074O7.5 -6.3 6.87e-10 3.44e-07 -0.32 -0.28 Airway imaging phenotypes; chr11:66465302 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs7928882 ENSG00000255517.5 CTD-3074O7.5 -6.3 6.87e-10 3.44e-07 -0.32 -0.28 Airway imaging phenotypes; chr11:66467294 chr11:66473490~66480233:- LUSC cis rs113835537 0.529 rs57691879 ENSG00000255517.5 CTD-3074O7.5 -6.3 6.87e-10 3.44e-07 -0.32 -0.28 Airway imaging phenotypes; chr11:66469133 chr11:66473490~66480233:- LUSC cis rs9309473 0.514 rs62149630 ENSG00000163016.8 ALMS1P 6.3 6.88e-10 3.44e-07 0.4 0.28 Metabolite levels; chr2:73354627 chr2:73644919~73685576:+ LUSC cis rs30380 1 rs30187 ENSG00000248734.2 CTD-2260A17.1 6.3 6.88e-10 3.44e-07 0.27 0.28 Cerebrospinal fluid biomarker levels; chr5:96788627 chr5:96784777~96785999:+ LUSC cis rs6142102 0.602 rs4911395 ENSG00000275784.1 RP5-1125A11.6 -6.3 6.9e-10 3.45e-07 -0.31 -0.28 Skin pigmentation; chr20:33992095 chr20:33989480~33991818:- LUSC cis rs9322193 0.962 rs17673294 ENSG00000268592.3 RAET1E-AS1 6.3 6.91e-10 3.45e-07 0.35 0.28 Lung cancer; chr6:149813857 chr6:149863494~149919507:+ LUSC cis rs5742933 0.597 rs7568449 ENSG00000253559.1 OSGEPL1-AS1 6.3 6.91e-10 3.46e-07 0.34 0.28 Ferritin levels; chr2:189656328 chr2:189762704~189765556:+ LUSC cis rs1823913 0.599 rs12988037 ENSG00000280083.1 RP11-317J9.1 -6.3 6.92e-10 3.46e-07 -0.33 -0.28 Obesity-related traits; chr2:191306419 chr2:191154118~191156070:- LUSC cis rs7955901 0.691 rs1051344 ENSG00000257265.1 CTD-2021H9.1 6.3 6.92e-10 3.46e-07 0.32 0.28 Type 2 diabetes; chr12:71125316 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs11178637 ENSG00000257265.1 CTD-2021H9.1 6.3 6.92e-10 3.46e-07 0.32 0.28 Type 2 diabetes; chr12:71125713 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs7312420 ENSG00000257265.1 CTD-2021H9.1 6.3 6.92e-10 3.46e-07 0.32 0.28 Type 2 diabetes; chr12:71125768 chr12:71007773~71032083:- LUSC cis rs10246939 0.544 rs6957037 ENSG00000228775.6 WEE2-AS1 6.3 6.94e-10 3.47e-07 0.33 0.28 Bitter taste perception; chr7:141865557 chr7:141704338~141738346:- LUSC cis rs4713118 0.662 rs9357060 ENSG00000280107.1 AL022393.9 -6.3 6.95e-10 3.47e-07 -0.34 -0.28 Parkinson's disease; chr6:28056708 chr6:28170845~28172521:+ LUSC cis rs4713118 0.662 rs9468271 ENSG00000280107.1 AL022393.9 -6.3 6.95e-10 3.47e-07 -0.34 -0.28 Parkinson's disease; chr6:28056792 chr6:28170845~28172521:+ LUSC cis rs4604732 0.631 rs12038880 ENSG00000227135.1 GCSAML-AS1 -6.3 6.96e-10 3.48e-07 -0.42 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461301 chr1:247524679~247526752:- LUSC cis rs950169 1 rs950169 ENSG00000225151.9 GOLGA2P7 -6.3 6.96e-10 3.48e-07 -0.39 -0.28 Schizophrenia; chr15:84037709 chr15:84199311~84230136:- LUSC cis rs1823913 0.599 rs12988037 ENSG00000227542.1 AC092614.2 6.3 6.96e-10 3.48e-07 0.36 0.28 Obesity-related traits; chr2:191306419 chr2:191229165~191246172:- LUSC cis rs8031584 0.958 rs34294266 ENSG00000260382.1 RP11-540B6.2 6.3 6.97e-10 3.48e-07 0.38 0.28 Huntington's disease progression; chr15:30954637 chr15:30882267~30883231:- LUSC cis rs875971 0.508 rs10242423 ENSG00000237310.1 GS1-124K5.4 -6.3 6.97e-10 3.48e-07 -0.28 -0.28 Aortic root size; chr7:66594188 chr7:66493706~66495474:+ LUSC cis rs875971 0.508 rs10253883 ENSG00000237310.1 GS1-124K5.4 -6.3 6.97e-10 3.48e-07 -0.28 -0.28 Aortic root size; chr7:66596151 chr7:66493706~66495474:+ LUSC cis rs950169 0.959 rs12902070 ENSG00000259728.4 LINC00933 6.3 6.98e-10 3.49e-07 0.37 0.28 Schizophrenia; chr15:84124806 chr15:84570649~84580175:+ LUSC cis rs7772486 0.754 rs9497419 ENSG00000235652.6 RP11-545I5.3 6.3 6.99e-10 3.49e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145821473 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs6921073 ENSG00000235652.6 RP11-545I5.3 6.3 6.99e-10 3.49e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145823241 chr6:145799409~145886585:+ LUSC cis rs9322193 0.923 rs9800871 ENSG00000268592.3 RAET1E-AS1 6.3 6.99e-10 3.49e-07 0.35 0.28 Lung cancer; chr6:149644540 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs11155671 ENSG00000268592.3 RAET1E-AS1 6.3 6.99e-10 3.49e-07 0.35 0.28 Lung cancer; chr6:149650996 chr6:149863494~149919507:+ LUSC cis rs6142102 0.961 rs6059587 ENSG00000275784.1 RP5-1125A11.6 -6.3 6.99e-10 3.49e-07 -0.32 -0.28 Skin pigmentation; chr20:33955120 chr20:33989480~33991818:- LUSC cis rs7955901 0.691 rs4505155 ENSG00000257265.1 CTD-2021H9.1 6.3 6.99e-10 3.49e-07 0.31 0.28 Type 2 diabetes; chr12:71126561 chr12:71007773~71032083:- LUSC cis rs7955901 0.691 rs1355373 ENSG00000257265.1 CTD-2021H9.1 6.3 7e-10 3.49e-07 0.31 0.28 Type 2 diabetes; chr12:71113602 chr12:71007773~71032083:- LUSC cis rs6951245 1 rs78896566 ENSG00000224079.1 AC091729.7 -6.3 7e-10 3.5e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1040546 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs79422648 ENSG00000224079.1 AC091729.7 -6.3 7e-10 3.5e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1040605 chr7:1074450~1078036:+ LUSC cis rs6951245 0.872 rs113119264 ENSG00000224079.1 AC091729.7 -6.3 7e-10 3.5e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1040928 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs76804143 ENSG00000224079.1 AC091729.7 -6.3 7e-10 3.5e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1042385 chr7:1074450~1078036:+ LUSC cis rs1823913 0.637 rs897197 ENSG00000227542.1 AC092614.2 -6.3 7e-10 3.5e-07 -0.35 -0.28 Obesity-related traits; chr2:191281456 chr2:191229165~191246172:- LUSC cis rs9549367 0.789 rs34448227 ENSG00000269125.1 RP11-98F14.11 -6.3 7.01e-10 3.5e-07 -0.35 -0.28 Platelet distribution width; chr13:113230440 chr13:113165002~113165183:- LUSC cis rs11971779 0.527 rs1076349 ENSG00000273391.1 RP11-634H22.1 6.3 7.01e-10 3.5e-07 0.31 0.28 Diisocyanate-induced asthma; chr7:139441748 chr7:139359032~139359566:- LUSC cis rs11971779 0.65 rs4732380 ENSG00000273391.1 RP11-634H22.1 6.3 7.01e-10 3.5e-07 0.31 0.28 Diisocyanate-induced asthma; chr7:139442113 chr7:139359032~139359566:- LUSC cis rs11971779 0.715 rs6467853 ENSG00000273391.1 RP11-634H22.1 6.3 7.01e-10 3.5e-07 0.31 0.28 Diisocyanate-induced asthma; chr7:139442281 chr7:139359032~139359566:- LUSC cis rs11971779 0.715 rs6467854 ENSG00000273391.1 RP11-634H22.1 6.3 7.01e-10 3.5e-07 0.31 0.28 Diisocyanate-induced asthma; chr7:139442337 chr7:139359032~139359566:- LUSC cis rs7267979 1 rs2482937 ENSG00000274973.1 RP13-401N8.7 6.3 7.01e-10 3.5e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25360150 chr20:25845497~25845862:+ LUSC cis rs11971779 0.59 rs6467839 ENSG00000273391.1 RP11-634H22.1 6.3 7.01e-10 3.5e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139378044 chr7:139359032~139359566:- LUSC cis rs66887589 0.934 rs6817317 ENSG00000249244.1 RP11-548H18.2 -6.3 7.02e-10 3.5e-07 -0.33 -0.28 Diastolic blood pressure; chr4:119621672 chr4:119391831~119395335:- LUSC cis rs783540 0.967 rs783523 ENSG00000255769.6 GOLGA2P10 -6.3 7.02e-10 3.51e-07 -0.34 -0.28 Schizophrenia; chr15:82614804 chr15:82472993~82513950:- LUSC cis rs2337406 0.925 rs873533 ENSG00000254174.1 IGHV1-12 6.3 7.03e-10 3.51e-07 0.29 0.28 Alzheimer's disease (late onset); chr14:106667442 chr14:106122420~106122709:- LUSC cis rs228614 0.51 rs223358 ENSG00000230069.3 LRRC37A15P -6.3 7.04e-10 3.51e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102849637 chr4:102727274~102730721:- LUSC cis rs66887589 0.934 rs7672519 ENSG00000249244.1 RP11-548H18.2 -6.3 7.04e-10 3.51e-07 -0.33 -0.28 Diastolic blood pressure; chr4:119622957 chr4:119391831~119395335:- LUSC cis rs7772486 0.651 rs1292338 ENSG00000235652.6 RP11-545I5.3 -6.29 7.06e-10 3.52e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145646335 chr6:145799409~145886585:+ LUSC cis rs4713118 0.662 rs149901 ENSG00000280107.1 AL022393.9 -6.29 7.09e-10 3.54e-07 -0.34 -0.28 Parkinson's disease; chr6:27997725 chr6:28170845~28172521:+ LUSC cis rs9549367 0.789 rs6577031 ENSG00000269125.1 RP11-98F14.11 6.29 7.11e-10 3.55e-07 0.33 0.28 Platelet distribution width; chr13:113223868 chr13:113165002~113165183:- LUSC cis rs62432291 0.681 rs386818 ENSG00000235086.1 FNDC1-IT1 -6.29 7.11e-10 3.55e-07 -0.47 -0.28 Joint mobility (Beighton score); chr6:159239223 chr6:159240786~159243329:+ LUSC cis rs1823913 0.599 rs2124095 ENSG00000280083.1 RP11-317J9.1 -6.29 7.12e-10 3.55e-07 -0.33 -0.28 Obesity-related traits; chr2:191301728 chr2:191154118~191156070:- LUSC cis rs3096299 0.679 rs3096322 ENSG00000274627.1 RP11-104N10.2 -6.29 7.13e-10 3.56e-07 -0.25 -0.28 Multiple myeloma (IgH translocation); chr16:89374715 chr16:89516797~89522217:+ LUSC cis rs13113518 0.783 rs34534635 ENSG00000249700.7 SRD5A3-AS1 6.29 7.14e-10 3.56e-07 0.33 0.28 Height; chr4:55573424 chr4:55363971~55395847:- LUSC cis rs1075265 0.901 rs2112124 ENSG00000233266.1 HMGB1P31 6.29 7.14e-10 3.56e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:54137385 chr2:54051334~54051760:+ LUSC cis rs2665103 0.589 rs2134046 ENSG00000276710.3 CSPG4P8 -6.29 7.14e-10 3.56e-07 -0.29 -0.28 Intelligence (multi-trait analysis); chr15:82232203 chr15:82459472~82477258:+ LUSC cis rs30380 1 rs469758 ENSG00000248734.2 CTD-2260A17.1 6.29 7.16e-10 3.57e-07 0.27 0.28 Cerebrospinal fluid biomarker levels; chr5:96786011 chr5:96784777~96785999:+ LUSC cis rs6991838 0.806 rs11777025 ENSG00000200714.1 Y_RNA -6.29 7.16e-10 3.57e-07 -0.34 -0.28 Intelligence (multi-trait analysis); chr8:65551438 chr8:65592731~65592820:+ LUSC cis rs77972916 0.519 rs13411327 ENSG00000234936.1 AC010883.5 6.29 7.16e-10 3.57e-07 0.38 0.28 Granulocyte percentage of myeloid white cells; chr2:43288344 chr2:43229573~43233394:+ LUSC cis rs7772486 0.686 rs1011596 ENSG00000235652.6 RP11-545I5.3 6.29 7.17e-10 3.57e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145755297 chr6:145799409~145886585:+ LUSC cis rs10885396 0.967 rs7094463 ENSG00000233547.1 RP11-57H14.2 6.29 7.19e-10 3.58e-07 0.28 0.28 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112952224 chr10:112950646~112951875:- LUSC cis rs496547 0.686 rs487728 ENSG00000255422.1 AP002954.4 -6.29 7.19e-10 3.58e-07 -0.3 -0.28 Hip minimal joint space width; chr11:118750785 chr11:118704607~118750263:+ LUSC cis rs6860806 0.507 rs272872 ENSG00000233006.5 AC034220.3 -6.29 7.2e-10 3.59e-07 -0.29 -0.28 Breast cancer; chr5:132340171 chr5:132311285~132369916:- LUSC cis rs4713118 0.738 rs200465 ENSG00000219392.1 RP1-265C24.5 -6.29 7.2e-10 3.59e-07 -0.36 -0.28 Parkinson's disease; chr6:27789875 chr6:28115628~28116551:+ LUSC cis rs9549367 0.789 rs2302754 ENSG00000269125.1 RP11-98F14.11 6.29 7.21e-10 3.59e-07 0.34 0.28 Platelet distribution width; chr13:113244071 chr13:113165002~113165183:- LUSC cis rs783540 0.967 rs55972423 ENSG00000255769.6 GOLGA2P10 6.29 7.21e-10 3.6e-07 0.34 0.28 Schizophrenia; chr15:82590203 chr15:82472993~82513950:- LUSC cis rs950169 0.887 rs35986397 ENSG00000259728.4 LINC00933 6.29 7.21e-10 3.6e-07 0.37 0.28 Schizophrenia; chr15:84400409 chr15:84570649~84580175:+ LUSC cis rs6142102 0.961 rs6120487 ENSG00000275784.1 RP5-1125A11.6 -6.29 7.22e-10 3.6e-07 -0.32 -0.28 Skin pigmentation; chr20:34034802 chr20:33989480~33991818:- LUSC cis rs7772486 0.686 rs7739735 ENSG00000235652.6 RP11-545I5.3 6.29 7.22e-10 3.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145802400 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs7744014 ENSG00000235652.6 RP11-545I5.3 6.29 7.22e-10 3.6e-07 0.28 0.28 Lobe attachment (rater-scored or self-reported); chr6:145802682 chr6:145799409~145886585:+ LUSC cis rs496547 0.719 rs476246 ENSG00000255239.1 AP002954.6 -6.29 7.24e-10 3.61e-07 -0.31 -0.28 Hip minimal joint space width; chr11:118747211 chr11:118688039~118690600:- LUSC cis rs1075265 0.73 rs805392 ENSG00000233266.1 HMGB1P31 6.29 7.24e-10 3.61e-07 0.34 0.28 Chronotype;Morning vs. evening chronotype; chr2:53877594 chr2:54051334~54051760:+ LUSC cis rs61270009 0.955 rs10514299 ENSG00000247828.6 TMEM161B-AS1 6.29 7.24e-10 3.61e-07 0.33 0.28 Depressive symptoms; chr5:88367793 chr5:88268895~88436685:+ LUSC cis rs172166 0.637 rs1071893 ENSG00000216901.1 AL022393.7 6.29 7.24e-10 3.61e-07 0.33 0.28 Cardiac Troponin-T levels; chr6:28199857 chr6:28176188~28176674:+ LUSC cis rs13113518 0.841 rs11133400 ENSG00000273257.1 RP11-177J6.1 6.29 7.26e-10 3.62e-07 0.36 0.28 Height; chr4:55578787 chr4:55387949~55388271:+ LUSC cis rs2834288 0.7 rs2834299 ENSG00000273102.1 AP000569.9 -6.29 7.28e-10 3.62e-07 -0.32 -0.28 Gut microbiota (bacterial taxa); chr21:33912198 chr21:33967101~33968573:- LUSC cis rs1823913 0.599 rs34262638 ENSG00000227542.1 AC092614.2 6.29 7.28e-10 3.63e-07 0.36 0.28 Obesity-related traits; chr2:191279442 chr2:191229165~191246172:- LUSC cis rs761746 0.614 rs131250 ENSG00000236132.1 CTA-440B3.1 -6.29 7.28e-10 3.63e-07 -0.41 -0.28 Intelligence; chr22:31733617 chr22:31816379~31817491:- LUSC cis rs1823913 0.637 rs897197 ENSG00000280083.1 RP11-317J9.1 6.29 7.29e-10 3.63e-07 0.32 0.28 Obesity-related traits; chr2:191281456 chr2:191154118~191156070:- LUSC cis rs1075265 0.621 rs2542593 ENSG00000233266.1 HMGB1P31 6.29 7.29e-10 3.63e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:53804299 chr2:54051334~54051760:+ LUSC cis rs10829156 0.755 rs10732437 ENSG00000240291.1 RP11-499P20.2 6.29 7.29e-10 3.63e-07 0.31 0.28 Sudden cardiac arrest; chr10:18626973 chr10:18513115~18545651:- LUSC cis rs950169 0.58 rs35516100 ENSG00000259728.4 LINC00933 6.29 7.29e-10 3.63e-07 0.36 0.28 Schizophrenia; chr15:84652199 chr15:84570649~84580175:+ LUSC cis rs950169 0.58 rs62021208 ENSG00000259728.4 LINC00933 6.29 7.29e-10 3.63e-07 0.36 0.28 Schizophrenia; chr15:84653013 chr15:84570649~84580175:+ LUSC cis rs11098499 0.818 rs55825515 ENSG00000248280.1 RP11-33B1.2 6.29 7.29e-10 3.63e-07 0.34 0.28 Corneal astigmatism; chr4:119565247 chr4:119440561~119450157:- LUSC cis rs7955901 0.775 rs3844207 ENSG00000257265.1 CTD-2021H9.1 6.29 7.3e-10 3.63e-07 0.31 0.28 Type 2 diabetes; chr12:71131078 chr12:71007773~71032083:- LUSC cis rs3096299 0.566 rs4129126 ENSG00000274627.1 RP11-104N10.2 6.29 7.31e-10 3.64e-07 0.27 0.28 Multiple myeloma (IgH translocation); chr16:89495067 chr16:89516797~89522217:+ LUSC cis rs7429990 0.864 rs6442081 ENSG00000229759.1 MRPS18AP1 -6.29 7.32e-10 3.65e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47728890 chr3:48256350~48256938:- LUSC cis rs11098499 0.909 rs10017335 ENSG00000250412.1 KLHL2P1 -6.29 7.32e-10 3.65e-07 -0.35 -0.28 Corneal astigmatism; chr4:119460368 chr4:119334329~119378233:+ LUSC cis rs1865760 0.533 rs1408270 ENSG00000272462.2 U91328.19 -6.29 7.33e-10 3.65e-07 -0.33 -0.28 Height; chr6:25872956 chr6:25992662~26001775:+ LUSC cis rs10246939 0.579 rs13232651 ENSG00000228775.6 WEE2-AS1 6.29 7.33e-10 3.65e-07 0.33 0.28 Bitter taste perception; chr7:141862624 chr7:141704338~141738346:- LUSC cis rs3750965 0.92 rs4930644 ENSG00000260895.1 RP11-554A11.7 6.29 7.34e-10 3.65e-07 0.34 0.28 Hair color; chr11:69051629 chr11:69103493~69109094:+ LUSC cis rs1823913 0.599 rs13027086 ENSG00000280083.1 RP11-317J9.1 -6.29 7.34e-10 3.66e-07 -0.33 -0.28 Obesity-related traits; chr2:191294058 chr2:191154118~191156070:- LUSC cis rs853679 0.517 rs12174753 ENSG00000204709.4 LINC01556 6.29 7.35e-10 3.66e-07 0.39 0.28 Depression; chr6:28074687 chr6:28943877~28944537:+ LUSC cis rs1823913 0.637 rs2883912 ENSG00000280083.1 RP11-317J9.1 6.29 7.36e-10 3.66e-07 0.32 0.28 Obesity-related traits; chr2:191284290 chr2:191154118~191156070:- LUSC cis rs1075265 0.933 rs2287642 ENSG00000233266.1 HMGB1P31 6.29 7.37e-10 3.67e-07 0.36 0.28 Chronotype;Morning vs. evening chronotype; chr2:54108447 chr2:54051334~54051760:+ LUSC cis rs227275 0.524 rs150894 ENSG00000230069.3 LRRC37A15P -6.29 7.38e-10 3.67e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102811541 chr4:102727274~102730721:- LUSC cis rs1134634 0.52 rs2160044 ENSG00000273133.1 RP11-799M12.2 -6.29 7.38e-10 3.67e-07 -0.37 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15556720 chr4:15563698~15564253:- LUSC cis rs1823913 0.599 rs17511410 ENSG00000227542.1 AC092614.2 6.29 7.39e-10 3.68e-07 0.36 0.28 Obesity-related traits; chr2:191278043 chr2:191229165~191246172:- LUSC cis rs17772222 0.655 rs816072 ENSG00000258789.1 RP11-507K2.3 6.29 7.39e-10 3.68e-07 0.31 0.28 Coronary artery calcification; chr14:88484335 chr14:88551597~88552493:+ LUSC cis rs4713118 0.513 rs149962 ENSG00000216901.1 AL022393.7 6.29 7.41e-10 3.69e-07 0.32 0.28 Parkinson's disease; chr6:28048140 chr6:28176188~28176674:+ LUSC cis rs9322193 0.962 rs7745915 ENSG00000268592.3 RAET1E-AS1 6.29 7.41e-10 3.69e-07 0.35 0.28 Lung cancer; chr6:149834111 chr6:149863494~149919507:+ LUSC cis rs6991838 1 rs6991838 ENSG00000200714.1 Y_RNA -6.29 7.41e-10 3.69e-07 -0.32 -0.28 Intelligence (multi-trait analysis); chr8:65558727 chr8:65592731~65592820:+ LUSC cis rs10759883 0.627 rs816684 ENSG00000175611.10 LINC00476 -6.29 7.42e-10 3.69e-07 -0.33 -0.28 Nicotine dependence; chr9:95822707 chr9:95759231~95875977:- LUSC cis rs875971 0.545 rs17138156 ENSG00000226824.5 RP4-756H11.3 -6.29 7.42e-10 3.7e-07 -0.36 -0.28 Aortic root size; chr7:66249708 chr7:66654538~66669855:+ LUSC cis rs7267979 0.966 rs2261784 ENSG00000274973.1 RP13-401N8.7 -6.29 7.43e-10 3.7e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25281760 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2261785 ENSG00000274973.1 RP13-401N8.7 -6.29 7.43e-10 3.7e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25281767 chr20:25845497~25845862:+ LUSC cis rs9516 0.544 rs681179 ENSG00000254974.1 RP11-702H23.2 6.29 7.45e-10 3.71e-07 0.28 0.28 Facial morphology (factor 15, philtrum width); chr11:74475791 chr11:74485580~74486051:- LUSC cis rs8062405 0.755 rs4788074 ENSG00000278665.1 RP11-666O2.4 -6.29 7.45e-10 3.71e-07 -0.28 -0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582276 chr16:28599241~28601881:- LUSC cis rs17772222 0.651 rs12586714 ENSG00000258789.1 RP11-507K2.3 -6.29 7.45e-10 3.71e-07 -0.3 -0.28 Coronary artery calcification; chr14:88360497 chr14:88551597~88552493:+ LUSC cis rs7267979 1 rs2258066 ENSG00000274973.1 RP13-401N8.7 -6.29 7.46e-10 3.71e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25290690 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2258135 ENSG00000274973.1 RP13-401N8.7 -6.29 7.46e-10 3.71e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25291687 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2258201 ENSG00000274973.1 RP13-401N8.7 -6.29 7.46e-10 3.71e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25291854 chr20:25845497~25845862:+ LUSC cis rs875971 1 rs55962648 ENSG00000237310.1 GS1-124K5.4 -6.29 7.47e-10 3.72e-07 -0.29 -0.28 Aortic root size; chr7:66160764 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs2420168 ENSG00000237310.1 GS1-124K5.4 -6.29 7.47e-10 3.72e-07 -0.29 -0.28 Aortic root size; chr7:66165644 chr7:66493706~66495474:+ LUSC cis rs113835537 0.529 rs3819247 ENSG00000255517.5 CTD-3074O7.5 -6.29 7.47e-10 3.72e-07 -0.33 -0.28 Airway imaging phenotypes; chr11:66526308 chr11:66473490~66480233:- LUSC cis rs2404602 0.735 rs2280306 ENSG00000259422.1 RP11-593F23.1 -6.29 7.47e-10 3.72e-07 -0.32 -0.28 Blood metabolite levels; chr15:76359917 chr15:76174891~76181486:- LUSC cis rs801193 0.66 rs10950049 ENSG00000237310.1 GS1-124K5.4 6.29 7.48e-10 3.72e-07 0.29 0.28 Aortic root size; chr7:66765873 chr7:66493706~66495474:+ LUSC cis rs11690935 0.921 rs3770445 ENSG00000228389.1 AC068039.4 6.28 7.49e-10 3.73e-07 0.33 0.28 Schizophrenia; chr2:171852409 chr2:171773482~171775844:+ LUSC cis rs6504950 1 rs7222197 ENSG00000275710.1 RP11-257O5.4 -6.28 7.5e-10 3.73e-07 -0.34 -0.28 Breast cancer; chr17:54970138 chr17:54964474~54964679:+ LUSC cis rs4604732 0.631 rs1106719 ENSG00000227135.1 GCSAML-AS1 6.28 7.51e-10 3.73e-07 0.42 0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461411 chr1:247524679~247526752:- LUSC cis rs4713118 0.513 rs149989 ENSG00000219392.1 RP1-265C24.5 -6.28 7.51e-10 3.74e-07 -0.35 -0.28 Parkinson's disease; chr6:28030406 chr6:28115628~28116551:+ LUSC cis rs957448 1 rs1055800 ENSG00000253175.1 RP11-267M23.6 -6.28 7.52e-10 3.74e-07 -0.31 -0.28 Nonsyndromic cleft lip with cleft palate; chr8:94510810 chr8:94565036~94565715:+ LUSC cis rs67311347 1 rs11914297 ENSG00000223797.4 ENTPD3-AS1 6.28 7.53e-10 3.74e-07 0.32 0.28 Renal cell carcinoma; chr3:40368579 chr3:40313802~40453329:- LUSC cis rs13423976 0.586 rs12617556 ENSG00000231367.4 AC016995.3 6.28 7.53e-10 3.74e-07 0.36 0.28 Gut microbiome composition (summer); chr2:38514972 chr2:38406719~38515740:- LUSC cis rs2337406 1 rs74090714 ENSG00000274576.2 IGHV2-70 -6.28 7.53e-10 3.74e-07 -0.29 -0.28 Alzheimer's disease (late onset); chr14:106691225 chr14:106770577~106771020:- LUSC cis rs7772486 0.688 rs1884364 ENSG00000235652.6 RP11-545I5.3 6.28 7.53e-10 3.75e-07 0.29 0.28 Lobe attachment (rater-scored or self-reported); chr6:146016681 chr6:145799409~145886585:+ LUSC cis rs9309473 0.606 rs78941213 ENSG00000163016.8 ALMS1P 6.28 7.54e-10 3.75e-07 0.4 0.28 Metabolite levels; chr2:73658010 chr2:73644919~73685576:+ LUSC cis rs875971 0.545 rs2420456 ENSG00000226824.5 RP4-756H11.3 -6.28 7.55e-10 3.75e-07 -0.37 -0.28 Aortic root size; chr7:66280619 chr7:66654538~66669855:+ LUSC cis rs116095464 0.558 rs62347683 ENSG00000250848.1 CTD-2083E4.5 -6.28 7.55e-10 3.75e-07 -0.42 -0.28 Breast cancer; chr5:230216 chr5:288833~290321:- LUSC cis rs9322193 0.923 rs2297930 ENSG00000268592.3 RAET1E-AS1 6.28 7.55e-10 3.75e-07 0.35 0.28 Lung cancer; chr6:149718360 chr6:149863494~149919507:+ LUSC cis rs11603023 0.874 rs483598 ENSG00000255422.1 AP002954.4 -6.28 7.58e-10 3.76e-07 -0.31 -0.28 Cholesterol, total; chr11:118638950 chr11:118704607~118750263:+ LUSC cis rs7267979 0.933 rs2258728 ENSG00000274973.1 RP13-401N8.7 -6.28 7.58e-10 3.77e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25295707 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs1077889 ENSG00000274973.1 RP13-401N8.7 -6.28 7.58e-10 3.77e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25287257 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs3002702 ENSG00000274973.1 RP13-401N8.7 -6.28 7.58e-10 3.77e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25288284 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2257982 ENSG00000274973.1 RP13-401N8.7 -6.28 7.58e-10 3.77e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25288994 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2257985 ENSG00000274973.1 RP13-401N8.7 -6.28 7.58e-10 3.77e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25289107 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2257988 ENSG00000274973.1 RP13-401N8.7 -6.28 7.58e-10 3.77e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25289367 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2257432 ENSG00000274973.1 RP13-401N8.7 -6.28 7.58e-10 3.77e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25290450 chr20:25845497~25845862:+ LUSC cis rs1823913 0.637 rs921737 ENSG00000227542.1 AC092614.2 -6.28 7.58e-10 3.77e-07 -0.35 -0.28 Obesity-related traits; chr2:191286097 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs6736071 ENSG00000227542.1 AC092614.2 -6.28 7.58e-10 3.77e-07 -0.35 -0.28 Obesity-related traits; chr2:191287265 chr2:191229165~191246172:- LUSC cis rs2153535 0.58 rs7741403 ENSG00000230939.1 RP11-314C16.1 6.28 7.58e-10 3.77e-07 0.33 0.28 Motion sickness; chr6:8530345 chr6:8784178~8785445:+ LUSC cis rs172166 0.637 rs1225592 ENSG00000219392.1 RP1-265C24.5 -6.28 7.59e-10 3.77e-07 -0.35 -0.28 Cardiac Troponin-T levels; chr6:28182464 chr6:28115628~28116551:+ LUSC cis rs172166 0.637 rs1225595 ENSG00000219392.1 RP1-265C24.5 -6.28 7.59e-10 3.77e-07 -0.35 -0.28 Cardiac Troponin-T levels; chr6:28183562 chr6:28115628~28116551:+ LUSC cis rs783540 0.934 rs4779053 ENSG00000276710.3 CSPG4P8 -6.28 7.59e-10 3.77e-07 -0.3 -0.28 Schizophrenia; chr15:82702846 chr15:82459472~82477258:+ LUSC cis rs3743266 0.507 rs10162677 ENSG00000245534.5 RORA-AS1 -6.28 7.6e-10 3.77e-07 -0.42 -0.28 Menarche (age at onset); chr15:60456369 chr15:60479178~60630637:+ LUSC cis rs1823913 0.614 rs4853463 ENSG00000280083.1 RP11-317J9.1 6.28 7.61e-10 3.78e-07 0.32 0.28 Obesity-related traits; chr2:191278699 chr2:191154118~191156070:- LUSC cis rs14027 0.921 rs10109901 ENSG00000279347.1 RP11-85I17.2 -6.28 7.62e-10 3.78e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119817287 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs10109951 ENSG00000279347.1 RP11-85I17.2 -6.28 7.62e-10 3.78e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119817519 chr8:119838736~119840385:- LUSC cis rs14027 0.883 rs4871642 ENSG00000279347.1 RP11-85I17.2 -6.28 7.62e-10 3.78e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119818813 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs2634 ENSG00000279347.1 RP11-85I17.2 -6.28 7.62e-10 3.78e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119819869 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs4870955 ENSG00000279347.1 RP11-85I17.2 -6.28 7.62e-10 3.78e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119821929 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs34718068 ENSG00000279347.1 RP11-85I17.2 -6.28 7.62e-10 3.78e-07 -0.26 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119822368 chr8:119838736~119840385:- LUSC cis rs1823913 0.599 rs13015653 ENSG00000280083.1 RP11-317J9.1 -6.28 7.62e-10 3.78e-07 -0.33 -0.28 Obesity-related traits; chr2:191306813 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs12994212 ENSG00000280083.1 RP11-317J9.1 -6.28 7.62e-10 3.78e-07 -0.33 -0.28 Obesity-related traits; chr2:191306910 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs12994236 ENSG00000280083.1 RP11-317J9.1 -6.28 7.62e-10 3.78e-07 -0.33 -0.28 Obesity-related traits; chr2:191306991 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs35495506 ENSG00000280083.1 RP11-317J9.1 -6.28 7.62e-10 3.78e-07 -0.33 -0.28 Obesity-related traits; chr2:191307551 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs34691559 ENSG00000280083.1 RP11-317J9.1 -6.28 7.62e-10 3.78e-07 -0.33 -0.28 Obesity-related traits; chr2:191307688 chr2:191154118~191156070:- LUSC cis rs1823913 0.561 rs55790432 ENSG00000280083.1 RP11-317J9.1 -6.28 7.62e-10 3.78e-07 -0.33 -0.28 Obesity-related traits; chr2:191307722 chr2:191154118~191156070:- LUSC cis rs66887589 0.616 rs7659403 ENSG00000249244.1 RP11-548H18.2 6.28 7.62e-10 3.78e-07 0.33 0.28 Diastolic blood pressure; chr4:119286099 chr4:119391831~119395335:- LUSC cis rs11971779 0.688 rs8137 ENSG00000273391.1 RP11-634H22.1 -6.28 7.63e-10 3.79e-07 -0.3 -0.28 Diisocyanate-induced asthma; chr7:139419715 chr7:139359032~139359566:- LUSC cis rs6142102 0.886 rs6142098 ENSG00000275784.1 RP5-1125A11.6 -6.28 7.63e-10 3.79e-07 -0.32 -0.28 Skin pigmentation; chr20:34100488 chr20:33989480~33991818:- LUSC cis rs1823913 0.599 rs13399251 ENSG00000280083.1 RP11-317J9.1 -6.28 7.65e-10 3.79e-07 -0.33 -0.28 Obesity-related traits; chr2:191268758 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs1378162 ENSG00000280083.1 RP11-317J9.1 -6.28 7.65e-10 3.8e-07 -0.33 -0.28 Obesity-related traits; chr2:191298523 chr2:191154118~191156070:- LUSC cis rs172166 0.769 rs149965 ENSG00000219392.1 RP1-265C24.5 -6.28 7.66e-10 3.8e-07 -0.35 -0.28 Cardiac Troponin-T levels; chr6:28050911 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs149961 ENSG00000280107.1 AL022393.9 -6.28 7.66e-10 3.8e-07 -0.34 -0.28 Parkinson's disease; chr6:28047791 chr6:28170845~28172521:+ LUSC cis rs9322193 0.923 rs11155674 ENSG00000268592.3 RAET1E-AS1 6.28 7.66e-10 3.8e-07 0.35 0.28 Lung cancer; chr6:149711111 chr6:149863494~149919507:+ LUSC cis rs7429990 0.864 rs11130143 ENSG00000229759.1 MRPS18AP1 -6.28 7.67e-10 3.81e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47614943 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs6774170 ENSG00000229759.1 MRPS18AP1 -6.28 7.67e-10 3.81e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47615977 chr3:48256350~48256938:- LUSC cis rs17772222 0.655 rs1152376 ENSG00000258789.1 RP11-507K2.3 6.28 7.67e-10 3.81e-07 0.31 0.28 Coronary artery calcification; chr14:88495121 chr14:88551597~88552493:+ LUSC cis rs12554020 0.786 rs60076242 ENSG00000227603.1 RP11-165J3.6 6.28 7.69e-10 3.81e-07 0.37 0.28 Schizophrenia; chr9:93571634 chr9:93435332~93437121:- LUSC cis rs12554020 0.786 rs10429558 ENSG00000227603.1 RP11-165J3.6 6.28 7.69e-10 3.81e-07 0.37 0.28 Schizophrenia; chr9:93574508 chr9:93435332~93437121:- LUSC cis rs9322193 0.923 rs10782318 ENSG00000268592.3 RAET1E-AS1 6.28 7.7e-10 3.82e-07 0.35 0.28 Lung cancer; chr6:149754137 chr6:149863494~149919507:+ LUSC cis rs6504950 0.745 rs1962045 ENSG00000275710.1 RP11-257O5.4 6.28 7.71e-10 3.82e-07 0.34 0.28 Breast cancer; chr17:54918789 chr17:54964474~54964679:+ LUSC cis rs11971779 0.68 rs7779900 ENSG00000273391.1 RP11-634H22.1 6.28 7.72e-10 3.83e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139398241 chr7:139359032~139359566:- LUSC cis rs9322193 0.886 rs9718079 ENSG00000268592.3 RAET1E-AS1 6.28 7.73e-10 3.83e-07 0.36 0.28 Lung cancer; chr6:149645947 chr6:149863494~149919507:+ LUSC cis rs1823913 0.599 rs1454754 ENSG00000280083.1 RP11-317J9.1 -6.28 7.74e-10 3.84e-07 -0.33 -0.28 Obesity-related traits; chr2:191303562 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs13010441 ENSG00000280083.1 RP11-317J9.1 -6.28 7.74e-10 3.84e-07 -0.33 -0.28 Obesity-related traits; chr2:191303903 chr2:191154118~191156070:- LUSC cis rs881375 0.867 rs6478487 ENSG00000226752.6 PSMD5-AS1 -6.28 7.75e-10 3.84e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120910499 chr9:120824828~120854385:+ LUSC cis rs950169 0.922 rs4842939 ENSG00000225151.9 GOLGA2P7 6.28 7.75e-10 3.84e-07 0.35 0.28 Schizophrenia; chr15:84159214 chr15:84199311~84230136:- LUSC cis rs12439619 0.693 rs17269819 ENSG00000276710.3 CSPG4P8 -6.28 7.75e-10 3.84e-07 -0.32 -0.28 Intelligence (multi-trait analysis); chr15:82174660 chr15:82459472~82477258:+ LUSC cis rs228614 0.51 rs223349 ENSG00000230069.3 LRRC37A15P -6.28 7.75e-10 3.84e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102857277 chr4:102727274~102730721:- LUSC cis rs957448 1 rs2381885 ENSG00000253175.1 RP11-267M23.6 6.28 7.76e-10 3.85e-07 0.32 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94499974 chr8:94565036~94565715:+ LUSC cis rs957448 1 rs10956915 ENSG00000253175.1 RP11-267M23.6 6.28 7.76e-10 3.85e-07 0.32 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94502362 chr8:94565036~94565715:+ LUSC cis rs9322193 0.884 rs9322210 ENSG00000268592.3 RAET1E-AS1 6.28 7.77e-10 3.85e-07 0.35 0.28 Lung cancer; chr6:149695440 chr6:149863494~149919507:+ LUSC cis rs6142102 0.961 rs4911407 ENSG00000275784.1 RP5-1125A11.6 -6.28 7.78e-10 3.86e-07 -0.33 -0.28 Skin pigmentation; chr20:34095759 chr20:33989480~33991818:- LUSC cis rs7267979 0.966 rs6037083 ENSG00000274973.1 RP13-401N8.7 6.28 7.78e-10 3.86e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25309907 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2297496 ENSG00000274973.1 RP13-401N8.7 6.28 7.78e-10 3.86e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25315151 chr20:25845497~25845862:+ LUSC cis rs227275 0.554 rs223371 ENSG00000230069.3 LRRC37A15P -6.28 7.78e-10 3.86e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102838032 chr4:102727274~102730721:- LUSC cis rs227275 0.554 rs223381 ENSG00000230069.3 LRRC37A15P -6.28 7.79e-10 3.86e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102832578 chr4:102727274~102730721:- LUSC cis rs801193 0.967 rs2420827 ENSG00000236529.1 RP13-254B10.1 -6.28 7.79e-10 3.86e-07 -0.29 -0.28 Aortic root size; chr7:66682114 chr7:65840212~65840596:+ LUSC cis rs17772222 0.682 rs2274736 ENSG00000258789.1 RP11-507K2.3 -6.28 7.79e-10 3.86e-07 -0.31 -0.28 Coronary artery calcification; chr14:88472308 chr14:88551597~88552493:+ LUSC cis rs11123170 0.64 rs1015754 ENSG00000274877.1 RP11-65I12.1 6.28 7.79e-10 3.86e-07 0.37 0.28 Renal function-related traits (BUN); chr2:113210413 chr2:113237595~113240825:+ LUSC cis rs6142102 0.517 rs6142050 ENSG00000275784.1 RP5-1125A11.6 -6.28 7.79e-10 3.86e-07 -0.3 -0.28 Skin pigmentation; chr20:33939322 chr20:33989480~33991818:- LUSC cis rs172166 0.637 rs1071893 ENSG00000219392.1 RP1-265C24.5 -6.28 7.8e-10 3.87e-07 -0.35 -0.28 Cardiac Troponin-T levels; chr6:28199857 chr6:28115628~28116551:+ LUSC cis rs11722779 0.869 rs223350 ENSG00000230069.3 LRRC37A15P -6.28 7.81e-10 3.87e-07 -0.3 -0.28 Schizophrenia; chr4:102856899 chr4:102727274~102730721:- LUSC cis rs12554020 0.792 rs11975 ENSG00000227603.1 RP11-165J3.6 6.28 7.83e-10 3.88e-07 0.37 0.28 Schizophrenia; chr9:93565409 chr9:93435332~93437121:- LUSC cis rs12554020 0.892 rs7870210 ENSG00000227603.1 RP11-165J3.6 6.28 7.83e-10 3.88e-07 0.37 0.28 Schizophrenia; chr9:93569534 chr9:93435332~93437121:- LUSC cis rs12554020 0.892 rs7860098 ENSG00000227603.1 RP11-165J3.6 6.28 7.83e-10 3.88e-07 0.37 0.28 Schizophrenia; chr9:93569562 chr9:93435332~93437121:- LUSC cis rs1823913 0.599 rs13035132 ENSG00000280083.1 RP11-317J9.1 -6.28 7.83e-10 3.88e-07 -0.33 -0.28 Obesity-related traits; chr2:191265275 chr2:191154118~191156070:- LUSC cis rs2179367 0.6 rs1001305 ENSG00000231760.4 RP11-350J20.5 6.28 7.84e-10 3.88e-07 0.41 0.28 Dupuytren's disease; chr6:149436808 chr6:149796151~149826294:- LUSC cis rs8059260 0.604 rs9652600 ENSG00000274038.1 RP11-66H6.4 -6.28 7.85e-10 3.89e-07 -0.5 -0.28 Alcohol consumption over the past year; chr16:11080157 chr16:11056556~11057034:+ LUSC cis rs875971 0.545 rs66594357 ENSG00000226824.5 RP4-756H11.3 -6.28 7.86e-10 3.89e-07 -0.36 -0.28 Aortic root size; chr7:66327797 chr7:66654538~66669855:+ LUSC cis rs950169 0.881 rs4842852 ENSG00000259728.4 LINC00933 6.28 7.86e-10 3.89e-07 0.37 0.28 Schizophrenia; chr15:84387263 chr15:84570649~84580175:+ LUSC cis rs950169 0.84 rs4842853 ENSG00000259728.4 LINC00933 6.28 7.86e-10 3.89e-07 0.37 0.28 Schizophrenia; chr15:84387606 chr15:84570649~84580175:+ LUSC cis rs950169 0.922 rs4842946 ENSG00000259728.4 LINC00933 6.28 7.86e-10 3.89e-07 0.37 0.28 Schizophrenia; chr15:84387633 chr15:84570649~84580175:+ LUSC cis rs950169 0.84 rs4842854 ENSG00000259728.4 LINC00933 6.28 7.86e-10 3.89e-07 0.37 0.28 Schizophrenia; chr15:84387641 chr15:84570649~84580175:+ LUSC cis rs950169 0.84 rs2896002 ENSG00000259728.4 LINC00933 6.28 7.86e-10 3.89e-07 0.37 0.28 Schizophrenia; chr15:84390423 chr15:84570649~84580175:+ LUSC cis rs950169 0.887 rs3860265 ENSG00000259728.4 LINC00933 6.28 7.86e-10 3.89e-07 0.37 0.28 Schizophrenia; chr15:84390487 chr15:84570649~84580175:+ LUSC cis rs950169 0.724 rs11632668 ENSG00000259728.4 LINC00933 6.28 7.86e-10 3.89e-07 0.37 0.28 Schizophrenia; chr15:84393989 chr15:84570649~84580175:+ LUSC cis rs950169 0.881 rs34591918 ENSG00000259728.4 LINC00933 6.28 7.86e-10 3.89e-07 0.37 0.28 Schizophrenia; chr15:84396135 chr15:84570649~84580175:+ LUSC cis rs2404602 0.647 rs12903586 ENSG00000259422.1 RP11-593F23.1 -6.28 7.86e-10 3.89e-07 -0.32 -0.28 Blood metabolite levels; chr15:76875899 chr15:76174891~76181486:- LUSC cis rs4713118 0.662 rs9380046 ENSG00000280107.1 AL022393.9 -6.28 7.86e-10 3.89e-07 -0.34 -0.28 Parkinson's disease; chr6:28062721 chr6:28170845~28172521:+ LUSC cis rs61270009 0.955 rs12655529 ENSG00000247828.6 TMEM161B-AS1 6.28 7.87e-10 3.9e-07 0.32 0.28 Depressive symptoms; chr5:88280980 chr5:88268895~88436685:+ LUSC cis rs17270561 1 rs17270561 ENSG00000272462.2 U91328.19 6.28 7.87e-10 3.9e-07 0.37 0.28 Iron status biomarkers; chr6:25820211 chr6:25992662~26001775:+ LUSC cis rs11098499 0.532 rs4833624 ENSG00000249244.1 RP11-548H18.2 6.28 7.88e-10 3.9e-07 0.36 0.28 Corneal astigmatism; chr4:119664342 chr4:119391831~119395335:- LUSC cis rs13113518 0.812 rs6849474 ENSG00000272969.1 RP11-528I4.2 6.28 7.88e-10 3.9e-07 0.32 0.28 Height; chr4:55452295 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs4864996 ENSG00000272969.1 RP11-528I4.2 6.28 7.88e-10 3.9e-07 0.32 0.28 Height; chr4:55452921 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs2412648 ENSG00000272969.1 RP11-528I4.2 6.28 7.88e-10 3.9e-07 0.32 0.28 Height; chr4:55454900 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs12512737 ENSG00000272969.1 RP11-528I4.2 6.28 7.88e-10 3.9e-07 0.32 0.28 Height; chr4:55454938 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs13125984 ENSG00000272969.1 RP11-528I4.2 6.28 7.88e-10 3.9e-07 0.32 0.28 Height; chr4:55455102 chr4:55547112~55547889:+ LUSC cis rs1789 0.592 rs1558572 ENSG00000273133.1 RP11-799M12.2 -6.28 7.88e-10 3.9e-07 -0.4 -0.28 Blood protein levels; chr4:15537121 chr4:15563698~15564253:- LUSC cis rs5753618 0.561 rs2040533 ENSG00000236132.1 CTA-440B3.1 6.28 7.88e-10 3.9e-07 0.38 0.28 Colorectal cancer; chr22:31283124 chr22:31816379~31817491:- LUSC cis rs801193 0.967 rs3800823 ENSG00000236529.1 RP13-254B10.1 -6.28 7.89e-10 3.91e-07 -0.29 -0.28 Aortic root size; chr7:66682123 chr7:65840212~65840596:+ LUSC cis rs4713118 0.662 rs464312 ENSG00000204709.4 LINC01556 6.28 7.89e-10 3.91e-07 0.38 0.28 Parkinson's disease; chr6:27999813 chr6:28943877~28944537:+ LUSC cis rs67311347 1 rs9968170 ENSG00000223797.4 ENTPD3-AS1 -6.28 7.9e-10 3.91e-07 -0.32 -0.28 Renal cell carcinoma; chr3:40452783 chr3:40313802~40453329:- LUSC cis rs957448 1 rs1023767 ENSG00000253175.1 RP11-267M23.6 6.28 7.9e-10 3.91e-07 0.33 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94518741 chr8:94565036~94565715:+ LUSC cis rs6951245 0.872 rs75280240 ENSG00000224079.1 AC091729.7 -6.28 7.91e-10 3.92e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1018875 chr7:1074450~1078036:+ LUSC cis rs7267979 0.966 rs2261747 ENSG00000274973.1 RP13-401N8.7 -6.28 7.91e-10 3.92e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25281148 chr20:25845497~25845862:+ LUSC cis rs1876905 0.539 rs190246 ENSG00000255389.1 C6orf3 -6.28 7.92e-10 3.92e-07 -0.39 -0.28 Mean corpuscular hemoglobin; chr6:111277043 chr6:111599875~111602295:+ LUSC cis rs1134634 0.52 rs1473166 ENSG00000273133.1 RP11-799M12.2 -6.28 7.92e-10 3.92e-07 -0.37 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15555868 chr4:15563698~15564253:- LUSC cis rs12439619 0.768 rs28694364 ENSG00000276710.3 CSPG4P8 -6.28 7.94e-10 3.93e-07 -0.33 -0.28 Intelligence (multi-trait analysis); chr15:82208119 chr15:82459472~82477258:+ LUSC cis rs394563 0.967 rs420099 ENSG00000231760.4 RP11-350J20.5 6.28 7.95e-10 3.93e-07 0.35 0.28 Dupuytren's disease; chr6:149473154 chr6:149796151~149826294:- LUSC cis rs6504950 0.615 rs66898273 ENSG00000275710.1 RP11-257O5.4 6.27 7.95e-10 3.93e-07 0.34 0.28 Breast cancer; chr17:54916595 chr17:54964474~54964679:+ LUSC cis rs7267979 1 rs6076336 ENSG00000274973.1 RP13-401N8.7 6.27 7.96e-10 3.94e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25338576 chr20:25845497~25845862:+ LUSC cis rs2919917 1 rs2953475 ENSG00000254352.1 RP11-578O24.2 -6.27 7.96e-10 3.94e-07 -0.35 -0.28 Lymphocyte counts; chr8:78725903 chr8:78723796~78724136:- LUSC cis rs10829156 0.786 rs7093907 ENSG00000240291.1 RP11-499P20.2 6.27 7.96e-10 3.94e-07 0.31 0.28 Sudden cardiac arrest; chr10:18587225 chr10:18513115~18545651:- LUSC cis rs10829156 0.66 rs4338439 ENSG00000240291.1 RP11-499P20.2 6.27 7.96e-10 3.94e-07 0.31 0.28 Sudden cardiac arrest; chr10:18594220 chr10:18513115~18545651:- LUSC cis rs7267979 1 rs7343481 ENSG00000274973.1 RP13-401N8.7 6.27 7.98e-10 3.95e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25319477 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6115146 ENSG00000274973.1 RP13-401N8.7 6.27 7.98e-10 3.95e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25323871 chr20:25845497~25845862:+ LUSC cis rs7267979 0.934 rs6037085 ENSG00000274973.1 RP13-401N8.7 6.27 7.98e-10 3.95e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25324566 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs6050532 ENSG00000274973.1 RP13-401N8.7 6.27 7.98e-10 3.95e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25328157 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6083804 ENSG00000274973.1 RP13-401N8.7 6.27 7.98e-10 3.95e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25336424 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6050542 ENSG00000274973.1 RP13-401N8.7 6.27 7.98e-10 3.95e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25338243 chr20:25845497~25845862:+ LUSC cis rs6951245 0.832 rs10266519 ENSG00000224079.1 AC091729.7 -6.27 7.98e-10 3.95e-07 -0.45 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1103341 chr7:1074450~1078036:+ LUSC cis rs801193 1 rs2659909 ENSG00000236529.1 RP13-254B10.1 6.27 7.99e-10 3.95e-07 0.28 0.28 Aortic root size; chr7:66695292 chr7:65840212~65840596:+ LUSC cis rs13113518 0.812 rs13140590 ENSG00000249700.7 SRD5A3-AS1 6.27 8e-10 3.96e-07 0.32 0.28 Height; chr4:55548666 chr4:55363971~55395847:- LUSC cis rs6951245 0.935 rs11763765 ENSG00000224079.1 AC091729.7 -6.27 8.01e-10 3.96e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1020874 chr7:1074450~1078036:+ LUSC cis rs6951245 0.935 rs11766669 ENSG00000224079.1 AC091729.7 -6.27 8.01e-10 3.96e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1023957 chr7:1074450~1078036:+ LUSC cis rs6951245 0.935 rs79067319 ENSG00000224079.1 AC091729.7 -6.27 8.01e-10 3.96e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1025912 chr7:1074450~1078036:+ LUSC cis rs4713118 0.513 rs149959 ENSG00000219392.1 RP1-265C24.5 -6.27 8.02e-10 3.97e-07 -0.35 -0.28 Parkinson's disease; chr6:28046076 chr6:28115628~28116551:+ LUSC cis rs881375 0.933 rs7859805 ENSG00000226752.6 PSMD5-AS1 -6.27 8.03e-10 3.97e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120901845 chr9:120824828~120854385:+ LUSC cis rs881375 0.933 rs10818485 ENSG00000226752.6 PSMD5-AS1 -6.27 8.03e-10 3.97e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120905538 chr9:120824828~120854385:+ LUSC cis rs881375 0.967 rs10435843 ENSG00000226752.6 PSMD5-AS1 -6.27 8.03e-10 3.97e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120905755 chr9:120824828~120854385:+ LUSC cis rs881375 0.967 rs10435844 ENSG00000226752.6 PSMD5-AS1 -6.27 8.03e-10 3.97e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120905921 chr9:120824828~120854385:+ LUSC cis rs881375 0.967 rs7848332 ENSG00000226752.6 PSMD5-AS1 -6.27 8.03e-10 3.97e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120907218 chr9:120824828~120854385:+ LUSC cis rs4713118 0.513 rs149954 ENSG00000219392.1 RP1-265C24.5 -6.27 8.03e-10 3.97e-07 -0.35 -0.28 Parkinson's disease; chr6:28067468 chr6:28115628~28116551:+ LUSC cis rs9549367 0.789 rs34568744 ENSG00000269125.1 RP11-98F14.11 -6.27 8.03e-10 3.97e-07 -0.34 -0.28 Platelet distribution width; chr13:113240250 chr13:113165002~113165183:- LUSC cis rs9549367 0.789 rs57747440 ENSG00000269125.1 RP11-98F14.11 -6.27 8.03e-10 3.97e-07 -0.34 -0.28 Platelet distribution width; chr13:113240436 chr13:113165002~113165183:- LUSC cis rs9549367 0.789 rs71446679 ENSG00000269125.1 RP11-98F14.11 -6.27 8.03e-10 3.97e-07 -0.34 -0.28 Platelet distribution width; chr13:113240507 chr13:113165002~113165183:- LUSC cis rs9549367 0.789 rs2287248 ENSG00000269125.1 RP11-98F14.11 -6.27 8.05e-10 3.98e-07 -0.35 -0.28 Platelet distribution width; chr13:113234912 chr13:113165002~113165183:- LUSC cis rs9549367 0.789 rs2287251 ENSG00000269125.1 RP11-98F14.11 -6.27 8.05e-10 3.98e-07 -0.35 -0.28 Platelet distribution width; chr13:113235185 chr13:113165002~113165183:- LUSC cis rs7955901 0.725 rs7313668 ENSG00000257265.1 CTD-2021H9.1 6.27 8.05e-10 3.98e-07 0.31 0.28 Type 2 diabetes; chr12:71055741 chr12:71007773~71032083:- LUSC cis rs2732480 0.538 rs2468943 ENSG00000273765.1 RP11-370I10.11 -6.27 8.06e-10 3.98e-07 -0.32 -0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48353466 chr12:48360920~48361377:+ LUSC cis rs8005677 1 rs4982709 ENSG00000279656.1 RP11-298I3.6 6.27 8.06e-10 3.99e-07 0.32 0.28 Cognitive ability (multi-trait analysis); chr14:22925490 chr14:23023083~23024217:- LUSC cis rs11723261 0.621 rs61794960 ENSG00000275426.1 CH17-262A2.1 6.27 8.08e-10 3.99e-07 0.47 0.28 Immune response to smallpox vaccine (IL-6); chr4:156661 chr4:149738~150317:+ LUSC cis rs4663866 0.505 rs3739064 ENSG00000186235.9 AC016757.3 6.27 8.08e-10 3.99e-07 0.38 0.28 Irritable bowel syndrome; chr2:238267745 chr2:238224552~238231677:- LUSC cis rs17711722 0.522 rs62469933 ENSG00000226824.5 RP4-756H11.3 -6.27 8.08e-10 4e-07 -0.33 -0.28 Calcium levels; chr7:65800652 chr7:66654538~66669855:+ LUSC cis rs6142102 0.961 rs909884 ENSG00000275784.1 RP5-1125A11.6 -6.27 8.09e-10 4e-07 -0.33 -0.28 Skin pigmentation; chr20:34058257 chr20:33989480~33991818:- LUSC cis rs6504622 0.702 rs2316758 ENSG00000262879.4 RP11-156P1.3 -6.27 8.11e-10 4.01e-07 -0.29 -0.28 Orofacial clefts; chr17:46988999 chr17:46984045~47100323:- LUSC cis rs9549367 0.789 rs9549708 ENSG00000269125.1 RP11-98F14.11 -6.27 8.11e-10 4.01e-07 -0.35 -0.28 Platelet distribution width; chr13:113237573 chr13:113165002~113165183:- LUSC cis rs8177876 0.749 rs12927239 ENSG00000261838.4 RP11-303E16.6 6.27 8.11e-10 4.01e-07 0.59 0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81053883 chr16:81069854~81076598:+ LUSC cis rs4372836 0.964 rs4408686 ENSG00000226833.4 AC097724.3 -6.27 8.12e-10 4.01e-07 -0.32 -0.28 Body mass index; chr2:28717660 chr2:28708953~28736205:- LUSC cis rs62229266 0.626 rs2835268 ENSG00000231106.2 LINC01436 6.27 8.13e-10 4.02e-07 0.34 0.28 Mitral valve prolapse; chr21:36076838 chr21:36005338~36007838:+ LUSC cis rs6603134 0.502 rs10411185 ENSG00000267939.1 CTD-2325M2.1 -6.27 8.13e-10 4.02e-07 -0.3 -0.28 Blood protein levels; chr19:8038997 chr19:8008729~8016025:+ LUSC cis rs4713118 0.513 rs149958 ENSG00000216901.1 AL022393.7 6.27 8.14e-10 4.02e-07 0.33 0.28 Parkinson's disease; chr6:28045839 chr6:28176188~28176674:+ LUSC cis rs4713118 0.513 rs156738 ENSG00000216901.1 AL022393.7 6.27 8.14e-10 4.02e-07 0.33 0.28 Parkinson's disease; chr6:28046247 chr6:28176188~28176674:+ LUSC cis rs5753618 0.509 rs2079431 ENSG00000236132.1 CTA-440B3.1 6.27 8.17e-10 4.04e-07 0.38 0.28 Colorectal cancer; chr22:31168348 chr22:31816379~31817491:- LUSC cis rs1823913 0.599 rs58106487 ENSG00000227542.1 AC092614.2 6.27 8.18e-10 4.04e-07 0.36 0.28 Obesity-related traits; chr2:191292404 chr2:191229165~191246172:- LUSC cis rs9322193 0.923 rs9800736 ENSG00000268592.3 RAET1E-AS1 6.27 8.18e-10 4.04e-07 0.35 0.28 Lung cancer; chr6:149661281 chr6:149863494~149919507:+ LUSC cis rs12439619 0.81 rs28876157 ENSG00000276710.3 CSPG4P8 -6.27 8.18e-10 4.04e-07 -0.33 -0.28 Intelligence (multi-trait analysis); chr15:82216708 chr15:82459472~82477258:+ LUSC cis rs6991838 0.806 rs17302392 ENSG00000200714.1 Y_RNA 6.27 8.19e-10 4.05e-07 0.34 0.28 Intelligence (multi-trait analysis); chr8:65551073 chr8:65592731~65592820:+ LUSC cis rs6142102 0.625 rs6142068 ENSG00000275784.1 RP5-1125A11.6 6.27 8.19e-10 4.05e-07 0.3 0.28 Skin pigmentation; chr20:33969366 chr20:33989480~33991818:- LUSC cis rs6504950 1 rs7221223 ENSG00000275710.1 RP11-257O5.4 6.27 8.22e-10 4.06e-07 0.34 0.28 Breast cancer; chr17:54981646 chr17:54964474~54964679:+ LUSC cis rs14027 0.921 rs1567359 ENSG00000279347.1 RP11-85I17.2 -6.27 8.23e-10 4.06e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119778378 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs2043430 ENSG00000279347.1 RP11-85I17.2 -6.27 8.23e-10 4.06e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119779741 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs12543087 ENSG00000279347.1 RP11-85I17.2 -6.27 8.23e-10 4.06e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119784207 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs10101278 ENSG00000279347.1 RP11-85I17.2 -6.27 8.23e-10 4.06e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119784799 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs1976575 ENSG00000279347.1 RP11-85I17.2 -6.27 8.23e-10 4.06e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119788618 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs7837589 ENSG00000279347.1 RP11-85I17.2 -6.27 8.23e-10 4.06e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119789401 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs67905698 ENSG00000279347.1 RP11-85I17.2 -6.27 8.23e-10 4.06e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119792186 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs28756749 ENSG00000279347.1 RP11-85I17.2 -6.27 8.23e-10 4.06e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119803164 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs4871634 ENSG00000279347.1 RP11-85I17.2 -6.27 8.23e-10 4.06e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119806243 chr8:119838736~119840385:- LUSC cis rs35160687 0.712 rs1863057 ENSG00000273080.1 RP11-301O19.1 -6.27 8.25e-10 4.07e-07 -0.27 -0.28 Night sleep phenotypes; chr2:86274978 chr2:86195590~86196049:+ LUSC cis rs10829156 0.732 rs7100884 ENSG00000240291.1 RP11-499P20.2 6.27 8.25e-10 4.08e-07 0.31 0.28 Sudden cardiac arrest; chr10:18523768 chr10:18513115~18545651:- LUSC cis rs9322193 0.923 rs4870267 ENSG00000268592.3 RAET1E-AS1 6.27 8.25e-10 4.08e-07 0.35 0.28 Lung cancer; chr6:149671572 chr6:149863494~149919507:+ LUSC cis rs1823913 0.637 rs2067610 ENSG00000280083.1 RP11-317J9.1 -6.27 8.27e-10 4.08e-07 -0.33 -0.28 Obesity-related traits; chr2:191299251 chr2:191154118~191156070:- LUSC cis rs11846409 0.86 rs1858692 ENSG00000274576.2 IGHV2-70 6.27 8.28e-10 4.09e-07 0.3 0.28 Rheumatic heart disease; chr14:106622776 chr14:106770577~106771020:- LUSC cis rs7826238 0.539 rs2945891 ENSG00000253893.2 FAM85B -6.27 8.28e-10 4.09e-07 -0.33 -0.28 Systolic blood pressure; chr8:8297953 chr8:8167819~8226614:- LUSC cis rs7267979 1 rs7019 ENSG00000274973.1 RP13-401N8.7 -6.27 8.28e-10 4.09e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25297642 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2424710 ENSG00000274973.1 RP13-401N8.7 -6.27 8.28e-10 4.09e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25303250 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6115140 ENSG00000274973.1 RP13-401N8.7 -6.27 8.28e-10 4.09e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25304871 chr20:25845497~25845862:+ LUSC cis rs13423976 0.546 rs10184164 ENSG00000231367.4 AC016995.3 6.27 8.29e-10 4.09e-07 0.36 0.28 Gut microbiome composition (summer); chr2:38514411 chr2:38406719~38515740:- LUSC cis rs9322193 0.923 rs9688350 ENSG00000268592.3 RAET1E-AS1 6.27 8.31e-10 4.1e-07 0.35 0.28 Lung cancer; chr6:149730977 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9767652 ENSG00000268592.3 RAET1E-AS1 6.27 8.31e-10 4.1e-07 0.35 0.28 Lung cancer; chr6:149734502 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs10782314 ENSG00000268592.3 RAET1E-AS1 6.27 8.31e-10 4.1e-07 0.35 0.28 Lung cancer; chr6:149735527 chr6:149863494~149919507:+ LUSC cis rs1075265 0.589 rs2542571 ENSG00000233266.1 HMGB1P31 6.27 8.31e-10 4.1e-07 0.34 0.28 Chronotype;Morning vs. evening chronotype; chr2:53814846 chr2:54051334~54051760:+ LUSC cis rs6570726 0.818 rs412350 ENSG00000235652.6 RP11-545I5.3 6.27 8.33e-10 4.11e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145531273 chr6:145799409~145886585:+ LUSC cis rs11971779 0.616 rs6967932 ENSG00000273391.1 RP11-634H22.1 6.27 8.33e-10 4.11e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139337635 chr7:139359032~139359566:- LUSC cis rs875971 0.545 rs1547529 ENSG00000226824.5 RP4-756H11.3 -6.27 8.35e-10 4.12e-07 -0.36 -0.28 Aortic root size; chr7:66258859 chr7:66654538~66669855:+ LUSC cis rs9322193 0.962 rs2275046 ENSG00000268592.3 RAET1E-AS1 6.27 8.35e-10 4.12e-07 0.36 0.28 Lung cancer; chr6:149835865 chr6:149863494~149919507:+ LUSC cis rs4713118 0.699 rs200969 ENSG00000280107.1 AL022393.9 -6.27 8.36e-10 4.12e-07 -0.35 -0.28 Parkinson's disease; chr6:27891675 chr6:28170845~28172521:+ LUSC cis rs6142102 0.602 rs2268079 ENSG00000275784.1 RP5-1125A11.6 -6.27 8.37e-10 4.13e-07 -0.3 -0.28 Skin pigmentation; chr20:34008944 chr20:33989480~33991818:- LUSC cis rs34375054 0.526 rs34764657 ENSG00000279233.1 RP11-158L12.4 6.27 8.37e-10 4.13e-07 0.27 0.28 Post bronchodilator FEV1/FVC ratio; chr12:125195093 chr12:125138245~125141711:+ LUSC cis rs1075265 0.587 rs2949811 ENSG00000233266.1 HMGB1P31 6.27 8.39e-10 4.14e-07 0.34 0.28 Chronotype;Morning vs. evening chronotype; chr2:53797028 chr2:54051334~54051760:+ LUSC cis rs61270009 0.818 rs4916718 ENSG00000247828.6 TMEM161B-AS1 6.27 8.39e-10 4.14e-07 0.32 0.28 Depressive symptoms; chr5:88316825 chr5:88268895~88436685:+ LUSC cis rs67180937 0.774 rs3748626 ENSG00000272750.1 RP11-378J18.8 -6.27 8.39e-10 4.14e-07 -0.3 -0.28 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222629461 chr1:222658867~222661512:- LUSC cis rs11690935 1 rs35549875 ENSG00000228389.1 AC068039.4 -6.27 8.39e-10 4.14e-07 -0.33 -0.28 Schizophrenia; chr2:171675882 chr2:171773482~171775844:+ LUSC cis rs227275 0.554 rs223357 ENSG00000230069.3 LRRC37A15P -6.27 8.4e-10 4.14e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102851095 chr4:102727274~102730721:- LUSC cis rs17772222 0.682 rs1152377 ENSG00000258789.1 RP11-507K2.3 6.27 8.4e-10 4.14e-07 0.31 0.28 Coronary artery calcification; chr14:88496243 chr14:88551597~88552493:+ LUSC cis rs6142102 0.602 rs1054534 ENSG00000275784.1 RP5-1125A11.6 -6.27 8.4e-10 4.14e-07 -0.3 -0.28 Skin pigmentation; chr20:34017521 chr20:33989480~33991818:- LUSC cis rs1865760 0.566 rs9467663 ENSG00000272462.2 U91328.19 -6.27 8.41e-10 4.15e-07 -0.3 -0.28 Height; chr6:26021228 chr6:25992662~26001775:+ LUSC cis rs875971 0.545 rs1909508 ENSG00000237310.1 GS1-124K5.4 6.27 8.41e-10 4.15e-07 0.31 0.28 Aortic root size; chr7:66301366 chr7:66493706~66495474:+ LUSC cis rs7429990 0.864 rs12492915 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47636545 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs12636863 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47638629 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs7613934 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47640681 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs7621236 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47646677 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs7624474 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47647786 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs4858846 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47654591 chr3:48256350~48256938:- LUSC cis rs7429990 0.803 rs13081356 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47660067 chr3:48256350~48256938:- LUSC cis rs7429990 0.803 rs11130145 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47661780 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs11130146 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47666322 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs12633604 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47673308 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs6772301 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47682366 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs13063042 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47683825 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs2133601 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47692525 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs6792497 ENSG00000229759.1 MRPS18AP1 -6.27 8.41e-10 4.15e-07 -0.28 -0.28 Educational attainment (years of education); chr3:47693684 chr3:48256350~48256938:- LUSC cis rs2834288 0.535 rs9982605 ENSG00000273102.1 AP000569.9 6.27 8.42e-10 4.15e-07 0.31 0.28 Gut microbiota (bacterial taxa); chr21:33961205 chr21:33967101~33968573:- LUSC cis rs4950322 0.518 rs4950305 ENSG00000278811.3 LINC00624 6.27 8.42e-10 4.15e-07 0.3 0.28 Protein quantitative trait loci; chr1:147117711 chr1:147258885~147517875:- LUSC cis rs783540 0.843 rs28374463 ENSG00000255769.6 GOLGA2P10 6.27 8.43e-10 4.16e-07 0.34 0.28 Schizophrenia; chr15:82630613 chr15:82472993~82513950:- LUSC cis rs72772090 0.539 rs17481759 ENSG00000248734.2 CTD-2260A17.1 -6.26 8.43e-10 4.16e-07 -0.41 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96778991 chr5:96784777~96785999:+ LUSC cis rs9549367 1 rs9549367 ENSG00000269125.1 RP11-98F14.11 -6.26 8.44e-10 4.16e-07 -0.34 -0.28 Platelet distribution width; chr13:113257218 chr13:113165002~113165183:- LUSC cis rs67180937 0.553 rs2936020 ENSG00000272750.1 RP11-378J18.8 6.26 8.45e-10 4.16e-07 0.35 0.28 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222655754 chr1:222658867~222661512:- LUSC cis rs2179367 0.568 rs62426092 ENSG00000231760.4 RP11-350J20.5 6.26 8.45e-10 4.16e-07 0.4 0.28 Dupuytren's disease; chr6:149352720 chr6:149796151~149826294:- LUSC cis rs75422866 0.867 rs117388682 ENSG00000257433.4 RP1-197B17.3 6.26 8.45e-10 4.16e-07 0.66 0.28 Pneumonia; chr12:47599713 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs79113930 ENSG00000257433.4 RP1-197B17.3 6.26 8.45e-10 4.16e-07 0.66 0.28 Pneumonia; chr12:47600628 chr12:47706085~47742294:+ LUSC cis rs881375 0.715 rs11794516 ENSG00000226752.6 PSMD5-AS1 -6.26 8.46e-10 4.17e-07 -0.31 -0.28 Rheumatoid arthritis; chr9:120877952 chr9:120824828~120854385:+ LUSC cis rs4237845 0.773 rs6650217 ENSG00000257159.1 RP11-58A17.3 6.26 8.46e-10 4.17e-07 0.33 0.28 Intelligence (multi-trait analysis); chr12:57895289 chr12:57967058~57968399:+ LUSC cis rs4237845 0.773 rs6650218 ENSG00000257159.1 RP11-58A17.3 6.26 8.46e-10 4.17e-07 0.33 0.28 Intelligence (multi-trait analysis); chr12:57895295 chr12:57967058~57968399:+ LUSC cis rs4237845 0.742 rs6650219 ENSG00000257159.1 RP11-58A17.3 6.26 8.46e-10 4.17e-07 0.33 0.28 Intelligence (multi-trait analysis); chr12:57895317 chr12:57967058~57968399:+ LUSC cis rs496547 0.588 rs473298 ENSG00000255239.1 AP002954.6 6.26 8.46e-10 4.17e-07 0.31 0.28 Hip minimal joint space width; chr11:118808678 chr11:118688039~118690600:- LUSC cis rs1876905 0.539 rs240956 ENSG00000255389.1 C6orf3 -6.26 8.47e-10 4.17e-07 -0.37 -0.28 Mean corpuscular hemoglobin; chr6:111294848 chr6:111599875~111602295:+ LUSC cis rs2337406 1 rs11850600 ENSG00000254174.1 IGHV1-12 6.26 8.48e-10 4.18e-07 0.3 0.28 Alzheimer's disease (late onset); chr14:106670765 chr14:106122420~106122709:- LUSC cis rs2455601 0.507 rs7948452 ENSG00000254860.4 TMEM9B-AS1 6.26 8.48e-10 4.18e-07 0.32 0.28 Schizophrenia; chr11:8856157 chr11:8964675~8977527:+ LUSC cis rs8177876 0.822 rs8177959 ENSG00000261838.4 RP11-303E16.6 6.26 8.48e-10 4.18e-07 0.62 0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81082082 chr16:81069854~81076598:+ LUSC cis rs13423976 0.6 rs35776111 ENSG00000231367.4 AC016995.3 6.26 8.48e-10 4.18e-07 0.36 0.28 Gut microbiome composition (summer); chr2:38515087 chr2:38406719~38515740:- LUSC cis rs8005677 1 rs1043209 ENSG00000279656.1 RP11-298I3.6 -6.26 8.49e-10 4.18e-07 -0.32 -0.28 Cognitive ability (multi-trait analysis); chr14:22904777 chr14:23023083~23024217:- LUSC cis rs875971 0.545 rs67775320 ENSG00000226824.5 RP4-756H11.3 -6.26 8.5e-10 4.19e-07 -0.36 -0.28 Aortic root size; chr7:66193792 chr7:66654538~66669855:+ LUSC cis rs1823913 0.599 rs55685315 ENSG00000280083.1 RP11-317J9.1 -6.26 8.51e-10 4.19e-07 -0.32 -0.28 Obesity-related traits; chr2:191306451 chr2:191154118~191156070:- LUSC cis rs8072100 0.544 rs7214993 ENSG00000228782.6 CTD-2026D20.3 6.26 8.51e-10 4.19e-07 0.27 0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309431 chr17:47450568~47492492:- LUSC cis rs75422866 0.867 rs35044089 ENSG00000257433.4 RP1-197B17.3 6.26 8.52e-10 4.19e-07 0.66 0.28 Pneumonia; chr12:47610881 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs78912815 ENSG00000257433.4 RP1-197B17.3 6.26 8.52e-10 4.19e-07 0.66 0.28 Pneumonia; chr12:47612065 chr12:47706085~47742294:+ LUSC cis rs950169 0.922 rs62028133 ENSG00000259728.4 LINC00933 6.26 8.53e-10 4.2e-07 0.36 0.28 Schizophrenia; chr15:84250623 chr15:84570649~84580175:+ LUSC cis rs950169 0.723 rs17589320 ENSG00000259728.4 LINC00933 6.26 8.53e-10 4.2e-07 0.36 0.28 Schizophrenia; chr15:84251244 chr15:84570649~84580175:+ LUSC cis rs13113518 0.513 rs13147861 ENSG00000249700.7 SRD5A3-AS1 6.26 8.53e-10 4.2e-07 0.32 0.28 Height; chr4:55611014 chr4:55363971~55395847:- LUSC cis rs9322193 0.886 rs2065663 ENSG00000268592.3 RAET1E-AS1 6.26 8.53e-10 4.2e-07 0.36 0.28 Lung cancer; chr6:149760331 chr6:149863494~149919507:+ LUSC cis rs11722779 0.815 rs223347 ENSG00000230069.3 LRRC37A15P -6.26 8.57e-10 4.22e-07 -0.3 -0.28 Schizophrenia; chr4:102858815 chr4:102727274~102730721:- LUSC cis rs9549367 0.762 rs9549694 ENSG00000269125.1 RP11-98F14.11 -6.26 8.57e-10 4.22e-07 -0.34 -0.28 Platelet distribution width; chr13:113216196 chr13:113165002~113165183:- LUSC cis rs9322193 0.923 rs12174716 ENSG00000268592.3 RAET1E-AS1 6.26 8.58e-10 4.22e-07 0.35 0.28 Lung cancer; chr6:149644487 chr6:149863494~149919507:+ LUSC cis rs783540 0.934 rs10400906 ENSG00000276710.3 CSPG4P8 -6.26 8.59e-10 4.23e-07 -0.29 -0.28 Schizophrenia; chr15:82628387 chr15:82459472~82477258:+ LUSC cis rs7246657 0.882 rs4803539 ENSG00000276846.1 CTD-3220F14.3 6.26 8.59e-10 4.23e-07 0.42 0.28 Coronary artery calcification; chr19:37406620 chr19:37314868~37315620:- LUSC cis rs7246657 0.943 rs3803895 ENSG00000276846.1 CTD-3220F14.3 6.26 8.59e-10 4.23e-07 0.42 0.28 Coronary artery calcification; chr19:37407767 chr19:37314868~37315620:- LUSC cis rs61270009 0.955 rs34241164 ENSG00000247828.6 TMEM161B-AS1 6.26 8.61e-10 4.24e-07 0.33 0.28 Depressive symptoms; chr5:88293189 chr5:88268895~88436685:+ LUSC cis rs2404602 0.647 rs12903331 ENSG00000259422.1 RP11-593F23.1 -6.26 8.62e-10 4.24e-07 -0.32 -0.28 Blood metabolite levels; chr15:76875927 chr15:76174891~76181486:- LUSC cis rs11971779 0.616 rs6467836 ENSG00000273391.1 RP11-634H22.1 6.26 8.62e-10 4.24e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139338771 chr7:139359032~139359566:- LUSC cis rs875971 0.66 rs1860468 ENSG00000224316.1 RP11-479O9.2 -6.26 8.63e-10 4.24e-07 -0.27 -0.28 Aortic root size; chr7:66642265 chr7:65773620~65802067:+ LUSC cis rs8177876 0.822 rs7203546 ENSG00000261838.4 RP11-303E16.6 -6.26 8.63e-10 4.25e-07 -0.61 -0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81083317 chr16:81069854~81076598:+ LUSC cis rs2278034 0.578 rs881753 ENSG00000272792.1 RP11-141C7.4 6.26 8.63e-10 4.25e-07 0.26 0.28 Bronchopulmonary dysplasia; chr3:195879899 chr3:195639990~195640460:+ LUSC cis rs2732480 0.577 rs1489109 ENSG00000226413.2 OR8T1P 6.26 8.64e-10 4.25e-07 0.37 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344997 chr12:48442030~48442947:- LUSC cis rs2732480 0.577 rs1489108 ENSG00000226413.2 OR8T1P 6.26 8.64e-10 4.25e-07 0.37 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344998 chr12:48442030~48442947:- LUSC cis rs875971 0.571 rs160641 ENSG00000226824.5 RP4-756H11.3 6.26 8.65e-10 4.25e-07 0.36 0.28 Aortic root size; chr7:66112359 chr7:66654538~66669855:+ LUSC cis rs9309473 0.66 rs10496192 ENSG00000163016.8 ALMS1P 6.26 8.65e-10 4.25e-07 0.4 0.28 Metabolite levels; chr2:73452739 chr2:73644919~73685576:+ LUSC cis rs72772090 0.539 rs11740375 ENSG00000248734.2 CTD-2260A17.1 -6.26 8.65e-10 4.26e-07 -0.41 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777193 chr5:96784777~96785999:+ LUSC cis rs228614 0.51 rs223313 ENSG00000230069.3 LRRC37A15P -6.26 8.67e-10 4.27e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102886563 chr4:102727274~102730721:- LUSC cis rs801193 1 rs2659912 ENSG00000236529.1 RP13-254B10.1 6.26 8.68e-10 4.27e-07 0.28 0.28 Aortic root size; chr7:66693012 chr7:65840212~65840596:+ LUSC cis rs11098499 0.909 rs28555550 ENSG00000250412.1 KLHL2P1 6.26 8.68e-10 4.27e-07 0.35 0.28 Corneal astigmatism; chr4:119289885 chr4:119334329~119378233:+ LUSC cis rs11098499 1 rs28419773 ENSG00000250412.1 KLHL2P1 6.26 8.68e-10 4.27e-07 0.35 0.28 Corneal astigmatism; chr4:119289906 chr4:119334329~119378233:+ LUSC cis rs950169 0.84 rs72748702 ENSG00000259728.4 LINC00933 6.26 8.69e-10 4.27e-07 0.36 0.28 Schizophrenia; chr15:84246494 chr15:84570649~84580175:+ LUSC cis rs950169 0.922 rs4338765 ENSG00000259728.4 LINC00933 6.26 8.69e-10 4.27e-07 0.36 0.28 Schizophrenia; chr15:84248084 chr15:84570649~84580175:+ LUSC cis rs496547 0.719 rs472641 ENSG00000255422.1 AP002954.4 -6.26 8.69e-10 4.27e-07 -0.3 -0.28 Hip minimal joint space width; chr11:118746835 chr11:118704607~118750263:+ LUSC cis rs9487094 0.6 rs3799842 ENSG00000260273.1 RP11-425D10.10 6.26 8.69e-10 4.27e-07 0.33 0.28 Height; chr6:109471826 chr6:109382795~109383666:+ LUSC cis rs904251 0.647 rs2776908 ENSG00000204110.6 RP1-153P14.8 -6.26 8.7e-10 4.28e-07 -0.31 -0.28 Cognitive performance; chr6:37467081 chr6:37507348~37535616:+ LUSC cis rs1823913 0.599 rs58106487 ENSG00000280083.1 RP11-317J9.1 -6.26 8.71e-10 4.28e-07 -0.32 -0.28 Obesity-related traits; chr2:191292404 chr2:191154118~191156070:- LUSC cis rs6142102 0.961 rs4911401 ENSG00000275784.1 RP5-1125A11.6 -6.26 8.71e-10 4.28e-07 -0.32 -0.28 Skin pigmentation; chr20:34066756 chr20:33989480~33991818:- LUSC cis rs66887589 0.87 rs59590064 ENSG00000249244.1 RP11-548H18.2 -6.26 8.72e-10 4.29e-07 -0.33 -0.28 Diastolic blood pressure; chr4:119618598 chr4:119391831~119395335:- LUSC cis rs8059260 0.542 rs11860777 ENSG00000274038.1 RP11-66H6.4 -6.26 8.73e-10 4.29e-07 -0.46 -0.28 Alcohol consumption over the past year; chr16:11033718 chr16:11056556~11057034:+ LUSC cis rs11690935 0.959 rs12692974 ENSG00000228389.1 AC068039.4 6.26 8.74e-10 4.3e-07 0.33 0.28 Schizophrenia; chr2:171806746 chr2:171773482~171775844:+ LUSC cis rs748404 0.626 rs1814324 ENSG00000249839.1 AC011330.5 -6.26 8.75e-10 4.3e-07 -0.48 -0.28 Lung cancer; chr15:43314951 chr15:43663654~43684339:- LUSC cis rs875971 0.545 rs12671152 ENSG00000226824.5 RP4-756H11.3 -6.26 8.76e-10 4.3e-07 -0.37 -0.28 Aortic root size; chr7:66311140 chr7:66654538~66669855:+ LUSC cis rs10170846 0.861 rs4674677 ENSG00000261428.2 RP11-16P6.1 6.26 8.77e-10 4.31e-07 0.33 0.28 Schizophrenia (inflammation and infection response interaction); chr2:222664939 chr2:222566899~222569719:- LUSC cis rs1075265 0.692 rs805358 ENSG00000233266.1 HMGB1P31 6.26 8.78e-10 4.31e-07 0.34 0.28 Chronotype;Morning vs. evening chronotype; chr2:53934885 chr2:54051334~54051760:+ LUSC cis rs17023223 0.509 rs10923740 ENSG00000231365.4 RP11-418J17.1 -6.26 8.78e-10 4.31e-07 -0.36 -0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119057664 chr1:119140396~119275973:+ LUSC cis rs2179367 0.632 rs9322179 ENSG00000231760.4 RP11-350J20.5 6.26 8.79e-10 4.32e-07 0.39 0.28 Dupuytren's disease; chr6:149418664 chr6:149796151~149826294:- LUSC cis rs7267979 1 rs6050555 ENSG00000274973.1 RP13-401N8.7 6.26 8.79e-10 4.32e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25347907 chr20:25845497~25845862:+ LUSC cis rs853679 0.517 rs4713145 ENSG00000280107.1 AL022393.9 -6.26 8.79e-10 4.32e-07 -0.35 -0.28 Depression; chr6:28139049 chr6:28170845~28172521:+ LUSC cis rs227275 0.554 rs223422 ENSG00000230069.3 LRRC37A15P -6.26 8.79e-10 4.32e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102805616 chr4:102727274~102730721:- LUSC cis rs9326248 0.539 rs7120565 ENSG00000280143.1 AP000892.6 6.26 8.8e-10 4.32e-07 0.29 0.28 Blood protein levels; chr11:117172233 chr11:117204967~117210292:+ LUSC cis rs9322193 0.923 rs9689723 ENSG00000268592.3 RAET1E-AS1 6.26 8.81e-10 4.33e-07 0.35 0.28 Lung cancer; chr6:149655935 chr6:149863494~149919507:+ LUSC cis rs6504950 0.72 rs12602751 ENSG00000275710.1 RP11-257O5.4 6.26 8.82e-10 4.33e-07 0.32 0.28 Breast cancer; chr17:54916813 chr17:54964474~54964679:+ LUSC cis rs6504950 0.72 rs7216138 ENSG00000275710.1 RP11-257O5.4 6.26 8.82e-10 4.33e-07 0.32 0.28 Breast cancer; chr17:54918303 chr17:54964474~54964679:+ LUSC cis rs6969780 1 rs6948297 ENSG00000233429.8 HOTAIRM1 6.26 8.82e-10 4.33e-07 0.52 0.28 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27109785 chr7:27095647~27100265:+ LUSC cis rs13113518 0.966 rs11942472 ENSG00000273257.1 RP11-177J6.1 6.26 8.85e-10 4.35e-07 0.36 0.28 Height; chr4:55574959 chr4:55387949~55388271:+ LUSC cis rs11971779 0.68 rs11764236 ENSG00000273391.1 RP11-634H22.1 6.26 8.86e-10 4.35e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139433768 chr7:139359032~139359566:- LUSC cis rs11971779 0.648 rs66463279 ENSG00000273391.1 RP11-634H22.1 6.26 8.86e-10 4.35e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139433915 chr7:139359032~139359566:- LUSC cis rs67311347 0.955 rs6599100 ENSG00000223797.4 ENTPD3-AS1 6.26 8.86e-10 4.35e-07 0.31 0.28 Renal cell carcinoma; chr3:40405871 chr3:40313802~40453329:- LUSC cis rs1823913 0.599 rs13015653 ENSG00000227542.1 AC092614.2 6.26 8.89e-10 4.36e-07 0.36 0.28 Obesity-related traits; chr2:191306813 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs12994212 ENSG00000227542.1 AC092614.2 6.26 8.89e-10 4.36e-07 0.36 0.28 Obesity-related traits; chr2:191306910 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs12994236 ENSG00000227542.1 AC092614.2 6.26 8.89e-10 4.36e-07 0.36 0.28 Obesity-related traits; chr2:191306991 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs35495506 ENSG00000227542.1 AC092614.2 6.26 8.89e-10 4.36e-07 0.36 0.28 Obesity-related traits; chr2:191307551 chr2:191229165~191246172:- LUSC cis rs1823913 0.599 rs34691559 ENSG00000227542.1 AC092614.2 6.26 8.89e-10 4.36e-07 0.36 0.28 Obesity-related traits; chr2:191307688 chr2:191229165~191246172:- LUSC cis rs1823913 0.561 rs55790432 ENSG00000227542.1 AC092614.2 6.26 8.89e-10 4.36e-07 0.36 0.28 Obesity-related traits; chr2:191307722 chr2:191229165~191246172:- LUSC cis rs55726902 0.761 rs2544029 ENSG00000276691.1 RP5-1057I20.5 6.26 8.89e-10 4.36e-07 0.31 0.28 Allergic disease (asthma, hay fever or eczema); chr12:47801174 chr12:47788426~47788971:+ LUSC cis rs8062405 0.755 rs56209193 ENSG00000278665.1 RP11-666O2.4 6.26 8.9e-10 4.37e-07 0.28 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574315 chr16:28599241~28601881:- LUSC cis rs5753618 0.583 rs2273251 ENSG00000236132.1 CTA-440B3.1 -6.26 8.9e-10 4.37e-07 -0.38 -0.28 Colorectal cancer; chr22:31447581 chr22:31816379~31817491:- LUSC cis rs9322193 0.923 rs9800614 ENSG00000268592.3 RAET1E-AS1 6.26 8.9e-10 4.37e-07 0.35 0.28 Lung cancer; chr6:149644604 chr6:149863494~149919507:+ LUSC cis rs2153535 0.58 rs9378556 ENSG00000230939.1 RP11-314C16.1 -6.26 8.91e-10 4.37e-07 -0.33 -0.28 Motion sickness; chr6:8514462 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406171 ENSG00000230939.1 RP11-314C16.1 -6.26 8.91e-10 4.37e-07 -0.33 -0.28 Motion sickness; chr6:8515129 chr6:8784178~8785445:+ LUSC cis rs2153535 0.54 rs9378557 ENSG00000230939.1 RP11-314C16.1 -6.26 8.91e-10 4.37e-07 -0.33 -0.28 Motion sickness; chr6:8517148 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2143355 ENSG00000230939.1 RP11-314C16.1 -6.26 8.91e-10 4.37e-07 -0.33 -0.28 Motion sickness; chr6:8517623 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2143354 ENSG00000230939.1 RP11-314C16.1 -6.26 8.91e-10 4.37e-07 -0.33 -0.28 Motion sickness; chr6:8517674 chr6:8784178~8785445:+ LUSC cis rs227275 0.554 rs149576 ENSG00000230069.3 LRRC37A15P -6.26 8.91e-10 4.37e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102811411 chr4:102727274~102730721:- LUSC cis rs7829975 0.688 rs7827182 ENSG00000253893.2 FAM85B -6.26 8.93e-10 4.38e-07 -0.32 -0.28 Mood instability; chr8:8522961 chr8:8167819~8226614:- LUSC cis rs227275 0.531 rs223460 ENSG00000230069.3 LRRC37A15P -6.26 8.93e-10 4.38e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102782903 chr4:102727274~102730721:- LUSC cis rs1823913 0.637 rs4853465 ENSG00000227542.1 AC092614.2 -6.26 8.94e-10 4.39e-07 -0.35 -0.28 Obesity-related traits; chr2:191294768 chr2:191229165~191246172:- LUSC cis rs9549367 0.789 rs2287244 ENSG00000269125.1 RP11-98F14.11 6.25 8.95e-10 4.39e-07 0.33 0.28 Platelet distribution width; chr13:113232859 chr13:113165002~113165183:- LUSC cis rs227275 0.525 rs7672319 ENSG00000230069.3 LRRC37A15P -6.25 8.98e-10 4.4e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102990002 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs6533051 ENSG00000230069.3 LRRC37A15P -6.25 8.98e-10 4.4e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102990065 chr4:102727274~102730721:- LUSC cis rs1075265 0.868 rs4671872 ENSG00000233266.1 HMGB1P31 6.25 8.99e-10 4.41e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:54134035 chr2:54051334~54051760:+ LUSC cis rs6860806 0.507 rs272868 ENSG00000233006.5 AC034220.3 6.25 9.01e-10 4.42e-07 0.29 0.28 Breast cancer; chr5:132345058 chr5:132311285~132369916:- LUSC cis rs9326248 0.52 rs6589602 ENSG00000280143.1 AP000892.6 6.25 9.01e-10 4.42e-07 0.29 0.28 Blood protein levels; chr11:117166349 chr11:117204967~117210292:+ LUSC cis rs2919917 1 rs1545228 ENSG00000254352.1 RP11-578O24.2 -6.25 9.01e-10 4.42e-07 -0.35 -0.28 Lymphocyte counts; chr8:78732202 chr8:78723796~78724136:- LUSC cis rs6951245 1 rs78185558 ENSG00000224079.1 AC091729.7 -6.25 9.01e-10 4.42e-07 -0.47 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1050547 chr7:1074450~1078036:+ LUSC cis rs35160687 0.644 rs4832271 ENSG00000273080.1 RP11-301O19.1 -6.25 9.03e-10 4.42e-07 -0.26 -0.28 Night sleep phenotypes; chr2:86278204 chr2:86195590~86196049:+ LUSC cis rs35160687 0.644 rs28488524 ENSG00000273080.1 RP11-301O19.1 -6.25 9.03e-10 4.42e-07 -0.26 -0.28 Night sleep phenotypes; chr2:86284021 chr2:86195590~86196049:+ LUSC cis rs2337406 0.587 rs2516889 ENSG00000274576.2 IGHV2-70 6.25 9.03e-10 4.43e-07 0.29 0.28 Alzheimer's disease (late onset); chr14:106648903 chr14:106770577~106771020:- LUSC cis rs9341808 0.935 rs4706113 ENSG00000272129.1 RP11-250B2.6 6.25 9.03e-10 4.43e-07 0.33 0.28 Sitting height ratio; chr6:80129598 chr6:80355424~80356859:+ LUSC cis rs2153535 0.601 rs9393030 ENSG00000230939.1 RP11-314C16.1 -6.25 9.04e-10 4.43e-07 -0.33 -0.28 Motion sickness; chr6:8516256 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9328479 ENSG00000230939.1 RP11-314C16.1 -6.25 9.04e-10 4.43e-07 -0.33 -0.28 Motion sickness; chr6:8519413 chr6:8784178~8785445:+ LUSC cis rs4423214 0.559 rs10898203 ENSG00000254682.1 RP11-660L16.2 -6.25 9.04e-10 4.43e-07 -0.47 -0.28 Vitamin D levels; chr11:71492390 chr11:71448674~71452157:+ LUSC cis rs748404 0.666 rs66629206 ENSG00000249839.1 AC011330.5 -6.25 9.05e-10 4.44e-07 -0.48 -0.28 Lung cancer; chr15:43458804 chr15:43663654~43684339:- LUSC cis rs496547 0.686 rs2508916 ENSG00000255422.1 AP002954.4 -6.25 9.06e-10 4.44e-07 -0.3 -0.28 Hip minimal joint space width; chr11:118783942 chr11:118704607~118750263:+ LUSC cis rs801193 0.66 rs1962050 ENSG00000179406.6 LINC00174 6.25 9.07e-10 4.44e-07 0.29 0.28 Aortic root size; chr7:66775021 chr7:66376044~66401338:- LUSC cis rs950169 0.887 rs12903946 ENSG00000259728.4 LINC00933 6.25 9.09e-10 4.45e-07 0.37 0.28 Schizophrenia; chr15:84399732 chr15:84570649~84580175:+ LUSC cis rs950169 0.887 rs62029593 ENSG00000259728.4 LINC00933 6.25 9.09e-10 4.45e-07 0.37 0.28 Schizophrenia; chr15:84400482 chr15:84570649~84580175:+ LUSC cis rs950169 0.81 rs62029594 ENSG00000259728.4 LINC00933 6.25 9.09e-10 4.45e-07 0.37 0.28 Schizophrenia; chr15:84400554 chr15:84570649~84580175:+ LUSC cis rs950169 0.881 rs62029596 ENSG00000259728.4 LINC00933 6.25 9.09e-10 4.45e-07 0.37 0.28 Schizophrenia; chr15:84400736 chr15:84570649~84580175:+ LUSC cis rs950169 0.881 rs4081123 ENSG00000259728.4 LINC00933 6.25 9.09e-10 4.45e-07 0.37 0.28 Schizophrenia; chr15:84401537 chr15:84570649~84580175:+ LUSC cis rs950169 0.881 rs62029599 ENSG00000259728.4 LINC00933 6.25 9.09e-10 4.45e-07 0.37 0.28 Schizophrenia; chr15:84401867 chr15:84570649~84580175:+ LUSC cis rs950169 0.8 rs4099846 ENSG00000259728.4 LINC00933 6.25 9.09e-10 4.45e-07 0.37 0.28 Schizophrenia; chr15:84402196 chr15:84570649~84580175:+ LUSC cis rs9903692 0.657 rs1452665 ENSG00000278765.1 RP5-890E16.5 6.25 9.09e-10 4.45e-07 0.34 0.28 Pulse pressure; chr17:48219789 chr17:48066704~48067293:- LUSC cis rs13113518 0.507 rs4549456 ENSG00000223305.1 RN7SKP30 6.25 9.09e-10 4.45e-07 0.32 0.28 Height; chr4:55398586 chr4:55540502~55540835:- LUSC cis rs11722779 0.935 rs7676736 ENSG00000230069.3 LRRC37A15P -6.25 9.12e-10 4.47e-07 -0.29 -0.28 Schizophrenia; chr4:103016729 chr4:102727274~102730721:- LUSC cis rs1823913 0.561 rs60479498 ENSG00000227542.1 AC092614.2 6.25 9.12e-10 4.47e-07 0.36 0.28 Obesity-related traits; chr2:191275197 chr2:191229165~191246172:- LUSC cis rs6142102 0.886 rs4911147 ENSG00000275784.1 RP5-1125A11.6 -6.25 9.12e-10 4.47e-07 -0.33 -0.28 Skin pigmentation; chr20:34079801 chr20:33989480~33991818:- LUSC cis rs6142102 0.961 rs1055857 ENSG00000275784.1 RP5-1125A11.6 -6.25 9.15e-10 4.48e-07 -0.31 -0.28 Skin pigmentation; chr20:34026067 chr20:33989480~33991818:- LUSC cis rs1075265 0.756 rs809280 ENSG00000233266.1 HMGB1P31 6.25 9.17e-10 4.49e-07 0.33 0.28 Chronotype;Morning vs. evening chronotype; chr2:53921270 chr2:54051334~54051760:+ LUSC cis rs17023223 0.537 rs2794311 ENSG00000231365.4 RP11-418J17.1 6.25 9.17e-10 4.49e-07 0.34 0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119053326 chr1:119140396~119275973:+ LUSC cis rs7955901 0.691 rs7311994 ENSG00000257265.1 CTD-2021H9.1 6.25 9.17e-10 4.49e-07 0.31 0.28 Type 2 diabetes; chr12:71116475 chr12:71007773~71032083:- LUSC cis rs10759883 0.603 rs10985156 ENSG00000175611.10 LINC00476 6.25 9.21e-10 4.51e-07 0.33 0.28 Nicotine dependence; chr9:95831462 chr9:95759231~95875977:- LUSC cis rs673078 0.607 rs1060964 ENSG00000275759.1 RP11-131L12.3 -6.25 9.21e-10 4.51e-07 -0.39 -0.28 Glucose homeostasis traits; chr12:118414906 chr12:118428281~118428870:+ LUSC cis rs7429990 0.833 rs870622 ENSG00000229759.1 MRPS18AP1 -6.25 9.21e-10 4.51e-07 -0.27 -0.28 Educational attainment (years of education); chr3:47618683 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs868255 ENSG00000229759.1 MRPS18AP1 -6.25 9.21e-10 4.51e-07 -0.27 -0.28 Educational attainment (years of education); chr3:47619074 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs4858842 ENSG00000229759.1 MRPS18AP1 -6.25 9.21e-10 4.51e-07 -0.27 -0.28 Educational attainment (years of education); chr3:47619574 chr3:48256350~48256938:- LUSC cis rs7267979 0.816 rs409853 ENSG00000274973.1 RP13-401N8.7 -6.25 9.21e-10 4.51e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25525431 chr20:25845497~25845862:+ LUSC cis rs6951245 1 rs74652290 ENSG00000224079.1 AC091729.7 -6.25 9.22e-10 4.51e-07 -0.47 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1050473 chr7:1074450~1078036:+ LUSC cis rs13113518 0.51 rs6858749 ENSG00000273257.1 RP11-177J6.1 6.25 9.23e-10 4.52e-07 0.33 0.28 Height; chr4:55424270 chr4:55387949~55388271:+ LUSC cis rs7267979 0.816 rs405822 ENSG00000274973.1 RP13-401N8.7 -6.25 9.23e-10 4.52e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25520678 chr20:25845497~25845862:+ LUSC cis rs7267979 0.816 rs6138593 ENSG00000274973.1 RP13-401N8.7 -6.25 9.23e-10 4.52e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25523856 chr20:25845497~25845862:+ LUSC cis rs13113518 1 rs4864547 ENSG00000273257.1 RP11-177J6.1 6.25 9.24e-10 4.52e-07 0.35 0.28 Height; chr4:55538228 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs34648901 ENSG00000273257.1 RP11-177J6.1 6.25 9.24e-10 4.52e-07 0.35 0.28 Height; chr4:55541259 chr4:55387949~55388271:+ LUSC cis rs875971 0.508 rs10258739 ENSG00000224316.1 RP11-479O9.2 -6.25 9.25e-10 4.53e-07 -0.26 -0.28 Aortic root size; chr7:66597948 chr7:65773620~65802067:+ LUSC cis rs10829156 0.732 rs10828834 ENSG00000240291.1 RP11-499P20.2 6.25 9.27e-10 4.54e-07 0.3 0.28 Sudden cardiac arrest; chr10:18523505 chr10:18513115~18545651:- LUSC cis rs30380 1 rs30379 ENSG00000248734.2 CTD-2260A17.1 6.25 9.28e-10 4.54e-07 0.27 0.28 Cerebrospinal fluid biomarker levels; chr5:96786556 chr5:96784777~96785999:+ LUSC cis rs30380 1 rs30380 ENSG00000248734.2 CTD-2260A17.1 6.25 9.28e-10 4.54e-07 0.27 0.28 Cerebrospinal fluid biomarker levels; chr5:96786577 chr5:96784777~96785999:+ LUSC cis rs7772486 0.79 rs6570723 ENSG00000235652.6 RP11-545I5.3 6.25 9.29e-10 4.54e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145830094 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs6570724 ENSG00000235652.6 RP11-545I5.3 6.25 9.29e-10 4.54e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145830147 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs6917135 ENSG00000235652.6 RP11-545I5.3 6.25 9.29e-10 4.54e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145831290 chr6:145799409~145886585:+ LUSC cis rs17507216 0.718 rs4779033 ENSG00000255769.6 GOLGA2P10 6.25 9.29e-10 4.55e-07 0.42 0.28 Excessive daytime sleepiness; chr15:82576634 chr15:82472993~82513950:- LUSC cis rs13113518 0.812 rs11932712 ENSG00000272969.1 RP11-528I4.2 6.25 9.31e-10 4.55e-07 0.32 0.28 Height; chr4:55436423 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs12501746 ENSG00000272969.1 RP11-528I4.2 6.25 9.31e-10 4.55e-07 0.32 0.28 Height; chr4:55437438 chr4:55547112~55547889:+ LUSC cis rs2239557 1 rs11628710 ENSG00000259065.1 RP5-1021I20.1 -6.25 9.32e-10 4.56e-07 -0.33 -0.28 Common traits (Other); chr14:74182577 chr14:73787360~73803270:+ LUSC cis rs2179367 0.632 rs9498348 ENSG00000231760.4 RP11-350J20.5 6.25 9.32e-10 4.56e-07 0.39 0.28 Dupuytren's disease; chr6:149418352 chr6:149796151~149826294:- LUSC cis rs7267979 0.966 rs4813557 ENSG00000274973.1 RP13-401N8.7 6.25 9.33e-10 4.56e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25311909 chr20:25845497~25845862:+ LUSC cis rs2276314 0.857 rs28530656 ENSG00000278986.1 RP11-723J4.3 6.25 9.34e-10 4.57e-07 0.34 0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36008737 chr18:35972151~35973916:+ LUSC cis rs875971 1 rs9986696 ENSG00000179406.6 LINC00174 6.25 9.36e-10 4.58e-07 0.3 0.28 Aortic root size; chr7:66239589 chr7:66376044~66401338:- LUSC cis rs2919917 1 rs1441438 ENSG00000254352.1 RP11-578O24.2 -6.25 9.36e-10 4.58e-07 -0.34 -0.28 Lymphocyte counts; chr8:78729534 chr8:78723796~78724136:- LUSC cis rs4372836 0.964 rs55721532 ENSG00000226833.4 AC097724.3 -6.25 9.37e-10 4.58e-07 -0.32 -0.28 Body mass index; chr2:28716102 chr2:28708953~28736205:- LUSC cis rs13113518 1 rs13141049 ENSG00000249700.7 SRD5A3-AS1 6.25 9.37e-10 4.58e-07 0.32 0.28 Height; chr4:55535489 chr4:55363971~55395847:- LUSC cis rs8059260 0.542 rs7184915 ENSG00000274038.1 RP11-66H6.4 -6.25 9.37e-10 4.58e-07 -0.46 -0.28 Alcohol consumption over the past year; chr16:11034509 chr16:11056556~11057034:+ LUSC cis rs10246939 0.579 rs17133534 ENSG00000228775.6 WEE2-AS1 6.25 9.39e-10 4.59e-07 0.32 0.28 Bitter taste perception; chr7:141860855 chr7:141704338~141738346:- LUSC cis rs7208859 0.673 rs2470251 ENSG00000263603.1 CTD-2349P21.5 -6.25 9.39e-10 4.59e-07 -0.35 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30768043 chr17:30729469~30731202:+ LUSC cis rs1823913 0.599 rs1378155 ENSG00000280083.1 RP11-317J9.1 -6.25 9.4e-10 4.59e-07 -0.33 -0.28 Obesity-related traits; chr2:191266610 chr2:191154118~191156070:- LUSC cis rs1823913 0.576 rs13011608 ENSG00000280083.1 RP11-317J9.1 -6.25 9.4e-10 4.59e-07 -0.33 -0.28 Obesity-related traits; chr2:191267097 chr2:191154118~191156070:- LUSC cis rs9322193 0.962 rs9322206 ENSG00000268592.3 RAET1E-AS1 6.25 9.4e-10 4.6e-07 0.35 0.28 Lung cancer; chr6:149641481 chr6:149863494~149919507:+ LUSC cis rs5753618 0.504 rs9609297 ENSG00000236132.1 CTA-440B3.1 -6.25 9.4e-10 4.6e-07 -0.39 -0.28 Colorectal cancer; chr22:31497745 chr22:31816379~31817491:- LUSC cis rs1134634 0.52 rs2041671 ENSG00000273133.1 RP11-799M12.2 -6.25 9.41e-10 4.6e-07 -0.37 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15550575 chr4:15563698~15564253:- LUSC cis rs6991838 0.806 rs4285523 ENSG00000200714.1 Y_RNA 6.25 9.42e-10 4.6e-07 0.34 0.28 Intelligence (multi-trait analysis); chr8:65552095 chr8:65592731~65592820:+ LUSC cis rs10885396 0.967 rs7094871 ENSG00000233547.1 RP11-57H14.2 -6.25 9.43e-10 4.61e-07 -0.29 -0.28 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112952395 chr10:112950646~112951875:- LUSC cis rs1075265 0.73 rs4413193 ENSG00000233266.1 HMGB1P31 6.25 9.44e-10 4.61e-07 0.34 0.28 Chronotype;Morning vs. evening chronotype; chr2:53710901 chr2:54051334~54051760:+ LUSC cis rs172166 0.694 rs9295760 ENSG00000219392.1 RP1-265C24.5 -6.25 9.44e-10 4.61e-07 -0.35 -0.28 Cardiac Troponin-T levels; chr6:28179607 chr6:28115628~28116551:+ LUSC cis rs875971 0.545 rs1796226 ENSG00000226824.5 RP4-756H11.3 -6.25 9.44e-10 4.61e-07 -0.36 -0.28 Aortic root size; chr7:66622723 chr7:66654538~66669855:+ LUSC cis rs113835537 0.529 rs17495838 ENSG00000255517.5 CTD-3074O7.5 -6.25 9.44e-10 4.61e-07 -0.34 -0.28 Airway imaging phenotypes; chr11:66428794 chr11:66473490~66480233:- LUSC cis rs17507216 0.628 rs17158396 ENSG00000255769.6 GOLGA2P10 -6.25 9.46e-10 4.62e-07 -0.4 -0.28 Excessive daytime sleepiness; chr15:82615688 chr15:82472993~82513950:- LUSC cis rs783540 0.869 rs783521 ENSG00000255769.6 GOLGA2P10 6.25 9.48e-10 4.63e-07 0.33 0.28 Schizophrenia; chr15:82611694 chr15:82472993~82513950:- LUSC cis rs783540 0.835 rs783522 ENSG00000255769.6 GOLGA2P10 6.25 9.48e-10 4.63e-07 0.33 0.28 Schizophrenia; chr15:82611862 chr15:82472993~82513950:- LUSC cis rs853679 0.517 rs9380056 ENSG00000280107.1 AL022393.9 -6.25 9.48e-10 4.63e-07 -0.34 -0.28 Depression; chr6:28136698 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9380057 ENSG00000280107.1 AL022393.9 -6.25 9.48e-10 4.63e-07 -0.34 -0.28 Depression; chr6:28136856 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs6941992 ENSG00000280107.1 AL022393.9 -6.25 9.48e-10 4.63e-07 -0.34 -0.28 Depression; chr6:28138363 chr6:28170845~28172521:+ LUSC cis rs4713118 0.516 rs4713142 ENSG00000280107.1 AL022393.9 -6.25 9.48e-10 4.63e-07 -0.34 -0.28 Parkinson's disease; chr6:28138569 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs4713143 ENSG00000280107.1 AL022393.9 -6.25 9.48e-10 4.63e-07 -0.34 -0.28 Depression; chr6:28138981 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs4713144 ENSG00000280107.1 AL022393.9 -6.25 9.48e-10 4.63e-07 -0.34 -0.28 Depression; chr6:28139012 chr6:28170845~28172521:+ LUSC cis rs1075265 0.933 rs7562055 ENSG00000233266.1 HMGB1P31 6.24 9.51e-10 4.64e-07 0.36 0.28 Chronotype;Morning vs. evening chronotype; chr2:54112694 chr2:54051334~54051760:+ LUSC cis rs875971 0.545 rs2420612 ENSG00000226824.5 RP4-756H11.3 -6.24 9.53e-10 4.65e-07 -0.37 -0.28 Aortic root size; chr7:66536825 chr7:66654538~66669855:+ LUSC cis rs1823913 0.637 rs12624271 ENSG00000280083.1 RP11-317J9.1 6.24 9.54e-10 4.65e-07 0.32 0.28 Obesity-related traits; chr2:191288586 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs11686185 ENSG00000280083.1 RP11-317J9.1 6.24 9.54e-10 4.65e-07 0.32 0.28 Obesity-related traits; chr2:191289282 chr2:191154118~191156070:- LUSC cis rs875971 0.545 rs73150604 ENSG00000226824.5 RP4-756H11.3 -6.24 9.55e-10 4.66e-07 -0.37 -0.28 Aortic root size; chr7:66480545 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs11767262 ENSG00000226824.5 RP4-756H11.3 -6.24 9.55e-10 4.66e-07 -0.36 -0.28 Aortic root size; chr7:66302237 chr7:66654538~66669855:+ LUSC cis rs7772486 0.79 rs2253764 ENSG00000235652.6 RP11-545I5.3 6.24 9.55e-10 4.66e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145878745 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2253880 ENSG00000235652.6 RP11-545I5.3 6.24 9.55e-10 4.66e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145879638 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2814879 ENSG00000235652.6 RP11-545I5.3 6.24 9.55e-10 4.66e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145880607 chr6:145799409~145886585:+ LUSC cis rs172166 0.694 rs188105 ENSG00000219392.1 RP1-265C24.5 -6.24 9.56e-10 4.67e-07 -0.35 -0.28 Cardiac Troponin-T levels; chr6:28103615 chr6:28115628~28116551:+ LUSC cis rs75920871 0.588 rs1815789 ENSG00000254851.1 RP11-109L13.1 6.24 9.56e-10 4.67e-07 0.39 0.28 Subjective well-being; chr11:116964237 chr11:117135528~117138582:+ LUSC cis rs6570726 0.967 rs365515 ENSG00000235652.6 RP11-545I5.3 -6.24 9.58e-10 4.67e-07 -0.27 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145481697 chr6:145799409~145886585:+ LUSC cis rs4718428 0.705 rs13227468 ENSG00000226824.5 RP4-756H11.3 -6.24 9.59e-10 4.68e-07 -0.38 -0.28 Corneal structure; chr7:66968576 chr7:66654538~66669855:+ LUSC cis rs3743266 0.507 rs62003261 ENSG00000245534.5 RORA-AS1 -6.24 9.59e-10 4.68e-07 -0.42 -0.28 Menarche (age at onset); chr15:60469290 chr15:60479178~60630637:+ LUSC cis rs853679 1 rs6901575 ENSG00000219392.1 RP1-265C24.5 -6.24 9.59e-10 4.68e-07 -0.44 -0.28 Depression; chr6:28283207 chr6:28115628~28116551:+ LUSC cis rs67311347 0.866 rs2371183 ENSG00000223797.4 ENTPD3-AS1 -6.24 9.6e-10 4.68e-07 -0.31 -0.28 Renal cell carcinoma; chr3:40292756 chr3:40313802~40453329:- LUSC cis rs143626010 1 rs143626010 ENSG00000278665.1 RP11-666O2.4 6.24 9.62e-10 4.69e-07 0.28 0.28 Mosquito bite size; chr16:28528081 chr16:28599241~28601881:- LUSC cis rs13113518 0.507 rs4549456 ENSG00000273257.1 RP11-177J6.1 6.24 9.62e-10 4.69e-07 0.34 0.28 Height; chr4:55398586 chr4:55387949~55388271:+ LUSC cis rs7267979 0.932 rs1541061 ENSG00000274973.1 RP13-401N8.7 -6.24 9.67e-10 4.71e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25540421 chr20:25845497~25845862:+ LUSC cis rs7267979 0.932 rs6138600 ENSG00000274973.1 RP13-401N8.7 -6.24 9.67e-10 4.71e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25540710 chr20:25845497~25845862:+ LUSC cis rs7267979 0.899 rs2104734 ENSG00000274973.1 RP13-401N8.7 -6.24 9.67e-10 4.71e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25546032 chr20:25845497~25845862:+ LUSC cis rs6772849 0.93 rs4467479 ENSG00000277250.1 Metazoa_SRP -6.24 9.67e-10 4.72e-07 -0.3 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128650212 chr3:128673681~128674021:- LUSC cis rs6772849 0.93 rs12630379 ENSG00000277250.1 Metazoa_SRP -6.24 9.67e-10 4.72e-07 -0.3 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128651361 chr3:128673681~128674021:- LUSC cis rs7804306 0.826 rs58348680 ENSG00000233264.2 AC006042.8 6.24 9.69e-10 4.72e-07 0.57 0.28 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8005655 chr7:7980312~7982228:+ LUSC cis rs62103177 0.564 rs1715230 ENSG00000261126.6 RP11-795F19.1 6.24 9.7e-10 4.73e-07 0.34 0.28 Opioid sensitivity; chr18:80090098 chr18:80046900~80095482:+ LUSC cis rs4853012 0.887 rs7570950 ENSG00000257800.1 FNBP1P1 6.24 9.73e-10 4.74e-07 0.34 0.28 Gestational age at birth (maternal effect); chr2:74111815 chr2:74120680~74123218:+ LUSC cis rs1823913 0.637 rs2067610 ENSG00000227542.1 AC092614.2 6.24 9.74e-10 4.75e-07 0.36 0.28 Obesity-related traits; chr2:191299251 chr2:191229165~191246172:- LUSC cis rs496547 0.719 rs1790189 ENSG00000255422.1 AP002954.4 -6.24 9.75e-10 4.75e-07 -0.3 -0.28 Hip minimal joint space width; chr11:118781617 chr11:118704607~118750263:+ LUSC cis rs1134634 0.52 rs10025837 ENSG00000273133.1 RP11-799M12.2 -6.24 9.75e-10 4.75e-07 -0.37 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15548362 chr4:15563698~15564253:- LUSC cis rs7267979 0.934 rs2261115 ENSG00000274973.1 RP13-401N8.7 -6.24 9.76e-10 4.75e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25279171 chr20:25845497~25845862:+ LUSC cis rs2337406 0.81 rs7161739 ENSG00000254174.1 IGHV1-12 6.24 9.76e-10 4.75e-07 0.27 0.28 Alzheimer's disease (late onset); chr14:106776118 chr14:106122420~106122709:- LUSC cis rs442309 0.687 rs10822053 ENSG00000238280.1 RP11-436D10.3 6.24 9.76e-10 4.75e-07 0.34 0.28 Vogt-Koyanagi-Harada syndrome; chr10:62701075 chr10:62793562~62805887:- LUSC cis rs9660180 0.62 rs3817856 ENSG00000231050.1 RP1-140A9.1 -6.24 9.78e-10 4.76e-07 -0.28 -0.28 Body mass index; chr1:1732392 chr1:1891471~1892658:+ LUSC cis rs7267979 0.966 rs3002698 ENSG00000274973.1 RP13-401N8.7 6.24 9.78e-10 4.76e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25322743 chr20:25845497~25845862:+ LUSC cis rs1075265 0.901 rs9808326 ENSG00000233266.1 HMGB1P31 6.24 9.78e-10 4.77e-07 0.36 0.28 Chronotype;Morning vs. evening chronotype; chr2:54115971 chr2:54051334~54051760:+ LUSC cis rs638893 0.636 rs583213 ENSG00000278376.1 RP11-158I9.8 -6.24 9.79e-10 4.77e-07 -0.39 -0.28 Vitiligo; chr11:118798469 chr11:118791254~118793137:+ LUSC cis rs227275 0.556 rs7676765 ENSG00000230069.3 LRRC37A15P 6.24 9.81e-10 4.78e-07 0.29 0.28 Allergic disease (asthma, hay fever or eczema); chr4:103016776 chr4:102727274~102730721:- LUSC cis rs4713118 0.513 rs149975 ENSG00000219392.1 RP1-265C24.5 -6.24 9.81e-10 4.78e-07 -0.35 -0.28 Parkinson's disease; chr6:28018562 chr6:28115628~28116551:+ LUSC cis rs2028299 0.959 rs12594808 ENSG00000259677.1 RP11-493E3.1 6.24 9.81e-10 4.78e-07 0.35 0.28 Type 2 diabetes; chr15:89857652 chr15:89876540~89877285:+ LUSC cis rs7267979 1 rs4815405 ENSG00000274973.1 RP13-401N8.7 6.24 9.82e-10 4.78e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25336856 chr20:25845497~25845862:+ LUSC cis rs5742933 0.857 rs1437891 ENSG00000253559.1 OSGEPL1-AS1 -6.24 9.82e-10 4.78e-07 -0.33 -0.28 Ferritin levels; chr2:189697982 chr2:189762704~189765556:+ LUSC cis rs6951245 1 rs1997243 ENSG00000224079.1 AC091729.7 -6.24 9.83e-10 4.79e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1044141 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs77760339 ENSG00000224079.1 AC091729.7 -6.24 9.83e-10 4.79e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1044291 chr7:1074450~1078036:+ LUSC cis rs9506514 0.509 rs9509279 ENSG00000238286.1 SLC35E1P1 6.24 9.84e-10 4.79e-07 0.33 0.28 Coronary artery calcification; chr13:20559580 chr13:20607268~20608131:+ LUSC cis rs992157 0.661 rs10171839 ENSG00000261338.2 RP11-378A13.1 6.24 9.87e-10 4.81e-07 0.28 0.28 Colorectal cancer; chr2:218186591 chr2:218255319~218257366:+ LUSC cis rs9322193 0.923 rs9322209 ENSG00000268592.3 RAET1E-AS1 6.24 9.88e-10 4.81e-07 0.35 0.28 Lung cancer; chr6:149691226 chr6:149863494~149919507:+ LUSC cis rs6504622 0.755 rs7216950 ENSG00000262879.4 RP11-156P1.3 -6.24 9.89e-10 4.81e-07 -0.3 -0.28 Orofacial clefts; chr17:47011089 chr17:46984045~47100323:- LUSC cis rs13113518 0.841 rs11133400 ENSG00000249700.7 SRD5A3-AS1 6.24 9.9e-10 4.81e-07 0.32 0.28 Height; chr4:55578787 chr4:55363971~55395847:- LUSC cis rs11971779 0.618 rs10085814 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139379343 chr7:139359032~139359566:- LUSC cis rs11971779 0.715 rs10085527 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139379614 chr7:139359032~139359566:- LUSC cis rs11971779 0.65 rs10085842 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139379836 chr7:139359032~139359566:- LUSC cis rs11971779 0.648 rs28754644 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139380311 chr7:139359032~139359566:- LUSC cis rs11971779 0.715 rs6954219 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139380364 chr7:139359032~139359566:- LUSC cis rs11971779 0.648 rs7799165 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139400211 chr7:139359032~139359566:- LUSC cis rs11971779 0.523 rs10279160 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139406015 chr7:139359032~139359566:- LUSC cis rs11971779 0.59 rs4732374 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139406707 chr7:139359032~139359566:- LUSC cis rs11971779 0.648 rs9642121 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139407875 chr7:139359032~139359566:- LUSC cis rs11971779 0.715 rs7781459 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139409136 chr7:139359032~139359566:- LUSC cis rs11971779 0.584 rs7786469 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139409875 chr7:139359032~139359566:- LUSC cis rs11971779 0.584 rs17613864 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139410841 chr7:139359032~139359566:- LUSC cis rs11971779 0.555 rs4728466 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139411619 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs4732376 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139413278 chr7:139359032~139359566:- LUSC cis rs11971779 0.648 rs6974099 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139413820 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs10261557 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139414291 chr7:139359032~139359566:- LUSC cis rs11971779 0.553 rs11973507 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139414715 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs10265718 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139415322 chr7:139359032~139359566:- LUSC cis rs11971779 0.553 rs10085770 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139415603 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs2355788 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139417151 chr7:139359032~139359566:- LUSC cis rs11971779 0.618 rs3778931 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139417744 chr7:139359032~139359566:- LUSC cis rs11971779 0.616 rs10278377 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139418325 chr7:139359032~139359566:- LUSC cis rs11971779 0.618 rs13068 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139419395 chr7:139359032~139359566:- LUSC cis rs11971779 0.648 rs6946113 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139421380 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6946393 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139421423 chr7:139359032~139359566:- LUSC cis rs11971779 0.553 rs10269108 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139421586 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs10085901 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139424243 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs10085902 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139424359 chr7:139359032~139359566:- LUSC cis rs11971779 0.617 rs66652773 ENSG00000273391.1 RP11-634H22.1 6.24 9.9e-10 4.81e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139424827 chr7:139359032~139359566:- LUSC cis rs394563 1 rs394563 ENSG00000231760.4 RP11-350J20.5 6.24 9.92e-10 4.83e-07 0.34 0.28 Dupuytren's disease; chr6:149475878 chr6:149796151~149826294:- LUSC cis rs14027 0.921 rs16893140 ENSG00000279347.1 RP11-85I17.2 -6.24 9.95e-10 4.84e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119767007 chr8:119838736~119840385:- LUSC cis rs9322193 0.884 rs7450246 ENSG00000268592.3 RAET1E-AS1 6.24 9.96e-10 4.84e-07 0.35 0.28 Lung cancer; chr6:149702517 chr6:149863494~149919507:+ LUSC cis rs11971779 0.68 rs9683 ENSG00000273391.1 RP11-634H22.1 6.24 9.97e-10 4.85e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139422993 chr7:139359032~139359566:- LUSC cis rs12935418 0.83 rs12448368 ENSG00000261061.1 RP11-303E16.2 6.24 9.97e-10 4.85e-07 0.5 0.28 Mean corpuscular volume; chr16:81011342 chr16:81030770~81031485:+ LUSC cis rs12439619 0.693 rs28689861 ENSG00000276710.3 CSPG4P8 -6.24 9.97e-10 4.85e-07 -0.32 -0.28 Intelligence (multi-trait analysis); chr15:82206369 chr15:82459472~82477258:+ LUSC cis rs2243480 1 rs316322 ENSG00000226824.5 RP4-756H11.3 -6.24 9.98e-10 4.85e-07 -0.54 -0.28 Diabetic kidney disease; chr7:66146246 chr7:66654538~66669855:+ LUSC cis rs950169 1 rs1818950 ENSG00000225151.9 GOLGA2P7 -6.24 9.98e-10 4.85e-07 -0.39 -0.28 Schizophrenia; chr15:84053769 chr15:84199311~84230136:- LUSC cis rs10759883 0.563 rs589362 ENSG00000175611.10 LINC00476 6.24 9.98e-10 4.85e-07 0.32 0.28 Nicotine dependence; chr9:95966906 chr9:95759231~95875977:- LUSC cis rs13113518 0.702 rs78829811 ENSG00000249700.7 SRD5A3-AS1 6.24 9.99e-10 4.85e-07 0.32 0.28 Height; chr4:55558258 chr4:55363971~55395847:- LUSC cis rs13113518 0.702 rs75801206 ENSG00000249700.7 SRD5A3-AS1 6.24 9.99e-10 4.85e-07 0.32 0.28 Height; chr4:55558259 chr4:55363971~55395847:- LUSC cis rs13113518 0.702 rs34658078 ENSG00000249700.7 SRD5A3-AS1 6.24 9.99e-10 4.85e-07 0.32 0.28 Height; chr4:55558261 chr4:55363971~55395847:- LUSC cis rs875971 0.862 rs7786892 ENSG00000179406.6 LINC00174 6.24 9.99e-10 4.86e-07 0.3 0.28 Aortic root size; chr7:66163889 chr7:66376044~66401338:- LUSC cis rs987710 1 rs987710 ENSG00000211639.2 IGLV4-60 -6.24 1e-09 4.86e-07 -0.31 -0.28 Iron status biomarkers;Iron deficiency; chr22:22158022 chr22:22162199~22162681:+ LUSC cis rs394563 0.967 rs444784 ENSG00000231760.4 RP11-350J20.5 6.24 1e-09 4.87e-07 0.34 0.28 Dupuytren's disease; chr6:149477230 chr6:149796151~149826294:- LUSC cis rs9322193 0.884 rs2064521 ENSG00000268592.3 RAET1E-AS1 -6.24 1e-09 4.87e-07 -0.35 -0.28 Lung cancer; chr6:149625336 chr6:149863494~149919507:+ LUSC cis rs17023223 0.537 rs7532510 ENSG00000231365.4 RP11-418J17.1 -6.24 1e-09 4.88e-07 -0.35 -0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119051613 chr1:119140396~119275973:+ LUSC cis rs8031584 0.958 rs1043742 ENSG00000260382.1 RP11-540B6.2 6.24 1.01e-09 4.88e-07 0.37 0.28 Huntington's disease progression; chr15:30940378 chr15:30882267~30883231:- LUSC cis rs6951245 0.935 rs112554101 ENSG00000224079.1 AC091729.7 -6.24 1.01e-09 4.88e-07 -0.45 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1025899 chr7:1074450~1078036:+ LUSC cis rs7267979 0.933 rs2261109 ENSG00000274973.1 RP13-401N8.7 -6.24 1.01e-09 4.88e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25278564 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2261698 ENSG00000274973.1 RP13-401N8.7 -6.24 1.01e-09 4.88e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25279274 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2261720 ENSG00000274973.1 RP13-401N8.7 -6.24 1.01e-09 4.88e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25280005 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2227890 ENSG00000274973.1 RP13-401N8.7 -6.24 1.01e-09 4.88e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25280295 chr20:25845497~25845862:+ LUSC cis rs7267979 0.934 rs2261753 ENSG00000274973.1 RP13-401N8.7 -6.24 1.01e-09 4.88e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25281655 chr20:25845497~25845862:+ LUSC cis rs875971 0.825 rs1129531 ENSG00000179406.6 LINC00174 6.23 1.01e-09 4.89e-07 0.3 0.28 Aortic root size; chr7:66154117 chr7:66376044~66401338:- LUSC cis rs1320333 0.685 rs6710875 ENSG00000233296.1 AC092159.2 -6.23 1.01e-09 4.9e-07 -0.46 -0.28 Obesity-related traits; chr2:699976 chr2:677186~697371:+ LUSC cis rs6504950 0.745 rs35079296 ENSG00000275710.1 RP11-257O5.4 6.23 1.01e-09 4.9e-07 0.33 0.28 Breast cancer; chr17:54916849 chr17:54964474~54964679:+ LUSC cis rs6504950 0.72 rs9914596 ENSG00000275710.1 RP11-257O5.4 6.23 1.01e-09 4.9e-07 0.33 0.28 Breast cancer; chr17:54919190 chr17:54964474~54964679:+ LUSC cis rs7580658 0.637 rs4580338 ENSG00000236682.1 AC068282.3 -6.23 1.01e-09 4.9e-07 -0.37 -0.28 Protein C levels; chr2:127217361 chr2:127389130~127400580:+ LUSC cis rs5753618 0.561 rs715510 ENSG00000236132.1 CTA-440B3.1 6.23 1.01e-09 4.91e-07 0.37 0.28 Colorectal cancer; chr22:31294542 chr22:31816379~31817491:- LUSC cis rs5753618 0.561 rs737887 ENSG00000236132.1 CTA-440B3.1 6.23 1.01e-09 4.91e-07 0.37 0.28 Colorectal cancer; chr22:31300629 chr22:31816379~31817491:- LUSC cis rs5753618 0.561 rs4820963 ENSG00000236132.1 CTA-440B3.1 6.23 1.01e-09 4.91e-07 0.37 0.28 Colorectal cancer; chr22:31302180 chr22:31816379~31817491:- LUSC cis rs7267979 1 rs6050547 ENSG00000274973.1 RP13-401N8.7 6.23 1.01e-09 4.91e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25345376 chr20:25845497~25845862:+ LUSC cis rs227275 0.525 rs17215211 ENSG00000230069.3 LRRC37A15P -6.23 1.01e-09 4.91e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103025961 chr4:102727274~102730721:- LUSC cis rs853679 0.517 rs9348794 ENSG00000280107.1 AL022393.9 -6.23 1.01e-09 4.91e-07 -0.35 -0.28 Depression; chr6:28149979 chr6:28170845~28172521:+ LUSC cis rs1134634 0.52 rs73125606 ENSG00000273133.1 RP11-799M12.2 -6.23 1.01e-09 4.92e-07 -0.37 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15545691 chr4:15563698~15564253:- LUSC cis rs875971 0.522 rs1701760 ENSG00000164669.11 INTS4P1 -6.23 1.01e-09 4.92e-07 -0.3 -0.28 Aortic root size; chr7:66008701 chr7:65141225~65234216:+ LUSC cis rs6951245 0.935 rs78573577 ENSG00000224079.1 AC091729.7 -6.23 1.01e-09 4.92e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1049451 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs76129108 ENSG00000224079.1 AC091729.7 -6.23 1.01e-09 4.92e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1049523 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs78523927 ENSG00000224079.1 AC091729.7 -6.23 1.01e-09 4.92e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1049822 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs78158942 ENSG00000224079.1 AC091729.7 -6.23 1.01e-09 4.92e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1050804 chr7:1074450~1078036:+ LUSC cis rs853679 0.542 rs6934769 ENSG00000280107.1 AL022393.9 -6.23 1.01e-09 4.92e-07 -0.34 -0.28 Depression; chr6:28123153 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs17711801 ENSG00000280107.1 AL022393.9 -6.23 1.01e-09 4.92e-07 -0.34 -0.28 Depression; chr6:28124529 chr6:28170845~28172521:+ LUSC cis rs4713118 0.527 rs9461433 ENSG00000280107.1 AL022393.9 -6.23 1.01e-09 4.92e-07 -0.34 -0.28 Parkinson's disease; chr6:28127394 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9468292 ENSG00000280107.1 AL022393.9 -6.23 1.01e-09 4.92e-07 -0.34 -0.28 Depression; chr6:28127577 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs1947863 ENSG00000280107.1 AL022393.9 -6.23 1.01e-09 4.92e-07 -0.34 -0.28 Depression; chr6:28131566 chr6:28170845~28172521:+ LUSC cis rs950880 0.71 rs10490204 ENSG00000234389.1 AC007278.3 -6.23 1.01e-09 4.92e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102440074 chr2:102438713~102440475:+ LUSC cis rs6504950 1 rs17818028 ENSG00000275710.1 RP11-257O5.4 -6.23 1.01e-09 4.92e-07 -0.33 -0.28 Breast cancer; chr17:54985394 chr17:54964474~54964679:+ LUSC cis rs11690935 0.879 rs908671 ENSG00000228389.1 AC068039.4 6.23 1.01e-09 4.92e-07 0.33 0.28 Schizophrenia; chr2:171833755 chr2:171773482~171775844:+ LUSC cis rs17826219 0.561 rs11655876 ENSG00000266490.1 CTD-2349P21.9 6.23 1.02e-09 4.93e-07 0.33 0.28 Body mass index; chr17:30690132 chr17:30792372~30792833:+ LUSC cis rs1823913 0.637 rs10931493 ENSG00000280083.1 RP11-317J9.1 -6.23 1.02e-09 4.94e-07 -0.32 -0.28 Obesity-related traits; chr2:191288142 chr2:191154118~191156070:- LUSC cis rs433852 0.898 rs376524 ENSG00000232871.7 SEC1P -6.23 1.02e-09 4.94e-07 -0.39 -0.28 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48613181 chr19:48638071~48682245:+ LUSC cis rs433852 1 rs433852 ENSG00000232871.7 SEC1P -6.23 1.02e-09 4.94e-07 -0.39 -0.28 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48613847 chr19:48638071~48682245:+ LUSC cis rs9322193 0.923 rs10872651 ENSG00000268592.3 RAET1E-AS1 6.23 1.02e-09 4.94e-07 0.36 0.28 Lung cancer; chr6:149768273 chr6:149863494~149919507:+ LUSC cis rs6504622 0.755 rs11653838 ENSG00000262879.4 RP11-156P1.3 -6.23 1.02e-09 4.94e-07 -0.3 -0.28 Orofacial clefts; chr17:47006317 chr17:46984045~47100323:- LUSC cis rs1075265 0.563 rs2542588 ENSG00000233266.1 HMGB1P31 -6.23 1.02e-09 4.95e-07 -0.34 -0.28 Chronotype;Morning vs. evening chronotype; chr2:53791787 chr2:54051334~54051760:+ LUSC cis rs2337406 0.925 rs873534 ENSG00000254174.1 IGHV1-12 6.23 1.02e-09 4.96e-07 0.3 0.28 Alzheimer's disease (late onset); chr14:106667423 chr14:106122420~106122709:- LUSC cis rs853679 0.517 rs4713148 ENSG00000280107.1 AL022393.9 -6.23 1.02e-09 4.96e-07 -0.35 -0.28 Depression; chr6:28148143 chr6:28170845~28172521:+ LUSC cis rs13113518 0.934 rs11133397 ENSG00000273257.1 RP11-177J6.1 6.23 1.03e-09 4.98e-07 0.35 0.28 Height; chr4:55534166 chr4:55387949~55388271:+ LUSC cis rs13113518 0.934 rs11133398 ENSG00000273257.1 RP11-177J6.1 6.23 1.03e-09 4.98e-07 0.35 0.28 Height; chr4:55534180 chr4:55387949~55388271:+ LUSC cis rs7712401 0.601 rs246285 ENSG00000263432.2 RN7SL689P -6.23 1.03e-09 4.98e-07 -0.34 -0.28 Mean platelet volume; chr5:122909273 chr5:123022487~123022783:- LUSC cis rs1823913 0.637 rs10931497 ENSG00000227542.1 AC092614.2 -6.23 1.03e-09 4.98e-07 -0.35 -0.28 Obesity-related traits; chr2:191306254 chr2:191229165~191246172:- LUSC cis rs13113518 0.507 rs11943456 ENSG00000273257.1 RP11-177J6.1 6.23 1.03e-09 4.98e-07 0.34 0.28 Height; chr4:55410167 chr4:55387949~55388271:+ LUSC cis rs5770917 1 rs8137478 ENSG00000273272.1 CTA-384D8.34 6.23 1.03e-09 4.99e-07 0.54 0.28 Narcolepsy; chr22:50578867 chr22:50542650~50543011:+ LUSC cis rs5770917 1 rs762676 ENSG00000273272.1 CTA-384D8.34 6.23 1.03e-09 4.99e-07 0.54 0.28 Narcolepsy; chr22:50579365 chr22:50542650~50543011:+ LUSC cis rs2337406 0.587 rs2516886 ENSG00000274576.2 IGHV2-70 6.23 1.03e-09 5e-07 0.29 0.28 Alzheimer's disease (late onset); chr14:106649674 chr14:106770577~106771020:- LUSC cis rs6951245 1 rs113575110 ENSG00000224079.1 AC091729.7 -6.23 1.03e-09 5e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1044758 chr7:1074450~1078036:+ LUSC cis rs17818399 0.62 rs3087822 ENSG00000279254.1 RP11-536C12.1 6.23 1.03e-09 5.01e-07 0.3 0.28 Height; chr2:46624894 chr2:46668870~46670778:+ LUSC cis rs66887589 0.967 rs6844263 ENSG00000245958.5 RP11-33B1.1 -6.23 1.04e-09 5.02e-07 -0.26 -0.28 Diastolic blood pressure; chr4:119512652 chr4:119454791~119552025:+ LUSC cis rs7267979 1 rs1888997 ENSG00000274973.1 RP13-401N8.7 6.23 1.04e-09 5.02e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25318352 chr20:25845497~25845862:+ LUSC cis rs9549367 0.789 rs7338235 ENSG00000269125.1 RP11-98F14.11 -6.23 1.04e-09 5.02e-07 -0.35 -0.28 Platelet distribution width; chr13:113234373 chr13:113165002~113165183:- LUSC cis rs853679 0.517 rs4713141 ENSG00000280107.1 AL022393.9 -6.23 1.04e-09 5.02e-07 -0.34 -0.28 Depression; chr6:28133900 chr6:28170845~28172521:+ LUSC cis rs4639966 0.569 rs603486 ENSG00000255422.1 AP002954.4 -6.23 1.04e-09 5.03e-07 -0.3 -0.28 Systemic lupus erythematosus; chr11:118716638 chr11:118704607~118750263:+ LUSC cis rs881375 0.933 rs4837799 ENSG00000226752.6 PSMD5-AS1 -6.23 1.04e-09 5.03e-07 -0.32 -0.28 Rheumatoid arthritis; chr9:120906048 chr9:120824828~120854385:+ LUSC cis rs8177876 0.543 rs2317086 ENSG00000261838.4 RP11-303E16.6 -6.23 1.04e-09 5.03e-07 -0.64 -0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81104468 chr16:81069854~81076598:+ LUSC cis rs7772486 0.774 rs6930181 ENSG00000235652.6 RP11-545I5.3 -6.23 1.04e-09 5.03e-07 -0.27 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145859838 chr6:145799409~145886585:+ LUSC cis rs6671200 0.573 rs3820345 ENSG00000228852.5 RP11-57H12.5 -6.23 1.04e-09 5.03e-07 -0.36 -0.28 Stearic acid (18:0) levels; chr1:95247619 chr1:95243167~95278940:- LUSC cis rs6671200 0.688 rs4950024 ENSG00000228852.5 RP11-57H12.5 -6.23 1.04e-09 5.03e-07 -0.36 -0.28 Stearic acid (18:0) levels; chr1:95247943 chr1:95243167~95278940:- LUSC cis rs11722779 0.692 rs223414 ENSG00000230069.3 LRRC37A15P -6.23 1.04e-09 5.03e-07 -0.29 -0.28 Schizophrenia; chr4:102811688 chr4:102727274~102730721:- LUSC cis rs950880 0.71 rs4851570 ENSG00000234389.1 AC007278.3 -6.23 1.04e-09 5.03e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102389927 chr2:102438713~102440475:+ LUSC cis rs116095464 0.867 rs7726582 ENSG00000250848.1 CTD-2083E4.5 -6.23 1.04e-09 5.04e-07 -0.42 -0.28 Breast cancer; chr5:215234 chr5:288833~290321:- LUSC cis rs950880 0.71 rs7597017 ENSG00000234389.1 AC007278.3 -6.23 1.04e-09 5.04e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102445656 chr2:102438713~102440475:+ LUSC cis rs6951245 0.872 rs57068908 ENSG00000224079.1 AC091729.7 -6.23 1.04e-09 5.05e-07 -0.45 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1020448 chr7:1074450~1078036:+ LUSC cis rs9322193 0.924 rs9498382 ENSG00000268592.3 RAET1E-AS1 6.23 1.04e-09 5.05e-07 0.35 0.28 Lung cancer; chr6:149610982 chr6:149863494~149919507:+ LUSC cis rs7176527 0.784 rs62021162 ENSG00000229212.6 RP11-561C5.4 6.23 1.04e-09 5.05e-07 0.42 0.28 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84565602 chr15:85205440~85234795:- LUSC cis rs853679 0.517 rs4713135 ENSG00000280107.1 AL022393.9 -6.23 1.04e-09 5.06e-07 -0.34 -0.28 Depression; chr6:28071808 chr6:28170845~28172521:+ LUSC cis rs113835537 0.529 rs11227511 ENSG00000255517.5 CTD-3074O7.5 -6.23 1.04e-09 5.06e-07 -0.32 -0.28 Airway imaging phenotypes; chr11:66513773 chr11:66473490~66480233:- LUSC cis rs11846409 0.932 rs73378155 ENSG00000274576.2 IGHV2-70 -6.23 1.05e-09 5.06e-07 -0.29 -0.28 Rheumatic heart disease; chr14:106637840 chr14:106770577~106771020:- LUSC cis rs9921338 0.961 rs8056282 ENSG00000263080.1 RP11-485G7.5 6.23 1.05e-09 5.06e-07 0.34 0.28 Vein graft stenosis in coronary artery bypass grafting; chr16:11313379 chr16:11341809~11345211:- LUSC cis rs2404602 0.735 rs11857015 ENSG00000259422.1 RP11-593F23.1 -6.23 1.05e-09 5.07e-07 -0.32 -0.28 Blood metabolite levels; chr15:76357049 chr15:76174891~76181486:- LUSC cis rs13113518 0.729 rs11133377 ENSG00000273257.1 RP11-177J6.1 6.23 1.05e-09 5.07e-07 0.38 0.28 Height; chr4:55413708 chr4:55387949~55388271:+ LUSC cis rs30380 1 rs26510 ENSG00000248734.2 CTD-2260A17.1 6.23 1.05e-09 5.08e-07 0.26 0.28 Cerebrospinal fluid biomarker levels; chr5:96790207 chr5:96784777~96785999:+ LUSC cis rs7598759 0.548 rs1584462 ENSG00000181798.2 LINC00471 -6.23 1.05e-09 5.08e-07 -0.29 -0.28 Noise-induced hearing loss; chr2:231505087 chr2:231508426~231514339:- LUSC cis rs227275 0.554 rs223333 ENSG00000230069.3 LRRC37A15P -6.23 1.05e-09 5.09e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102868653 chr4:102727274~102730721:- LUSC cis rs228614 0.536 rs223325 ENSG00000230069.3 LRRC37A15P -6.23 1.05e-09 5.09e-07 -0.29 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102875751 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223328 ENSG00000230069.3 LRRC37A15P -6.23 1.05e-09 5.09e-07 -0.29 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873379 chr4:102727274~102730721:- LUSC cis rs6142102 0.961 rs1883524 ENSG00000275784.1 RP5-1125A11.6 -6.23 1.05e-09 5.09e-07 -0.32 -0.28 Skin pigmentation; chr20:34038301 chr20:33989480~33991818:- LUSC cis rs8177876 0.597 rs2317085 ENSG00000261838.4 RP11-303E16.6 -6.23 1.05e-09 5.09e-07 -0.64 -0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81104460 chr16:81069854~81076598:+ LUSC cis rs9322193 0.962 rs9688412 ENSG00000268592.3 RAET1E-AS1 -6.23 1.05e-09 5.09e-07 -0.35 -0.28 Lung cancer; chr6:149803147 chr6:149863494~149919507:+ LUSC cis rs5751168 0.527 rs408785 ENSG00000211654.2 IGLV5-37 6.23 1.05e-09 5.1e-07 0.37 0.28 Prostate cancer (SNP x SNP interaction); chr22:22485213 chr22:22427540~22428035:+ LUSC cis rs9549367 0.774 rs2287246 ENSG00000269125.1 RP11-98F14.11 -6.23 1.06e-09 5.1e-07 -0.35 -0.28 Platelet distribution width; chr13:113234813 chr13:113165002~113165183:- LUSC cis rs9549367 0.789 rs2287247 ENSG00000269125.1 RP11-98F14.11 -6.23 1.06e-09 5.1e-07 -0.35 -0.28 Platelet distribution width; chr13:113234898 chr13:113165002~113165183:- LUSC cis rs9487605 1 rs9487605 ENSG00000230177.1 RP5-1112D6.4 -6.23 1.06e-09 5.11e-07 -0.27 -0.28 Inflammatory skin disease; chr6:111261682 chr6:111277932~111278742:+ LUSC cis rs11846409 0.818 rs2516909 ENSG00000274576.2 IGHV2-70 6.23 1.06e-09 5.11e-07 0.29 0.28 Rheumatic heart disease; chr14:106630317 chr14:106770577~106771020:- LUSC cis rs7772486 0.875 rs10872583 ENSG00000235652.6 RP11-545I5.3 -6.23 1.06e-09 5.12e-07 -0.27 -0.28 Lobe attachment (rater-scored or self-reported); chr6:146075563 chr6:145799409~145886585:+ LUSC cis rs9322193 0.772 rs7738696 ENSG00000268592.3 RAET1E-AS1 6.23 1.06e-09 5.12e-07 0.35 0.28 Lung cancer; chr6:149848985 chr6:149863494~149919507:+ LUSC cis rs9549367 0.789 rs9549701 ENSG00000269125.1 RP11-98F14.11 -6.23 1.06e-09 5.12e-07 -0.35 -0.28 Platelet distribution width; chr13:113227438 chr13:113165002~113165183:- LUSC cis rs4713118 0.513 rs1225591 ENSG00000216901.1 AL022393.7 6.23 1.06e-09 5.12e-07 0.33 0.28 Parkinson's disease; chr6:28180974 chr6:28176188~28176674:+ LUSC cis rs227275 0.554 rs223359 ENSG00000230069.3 LRRC37A15P -6.23 1.06e-09 5.12e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102849422 chr4:102727274~102730721:- LUSC cis rs2153535 0.563 rs1737586 ENSG00000230939.1 RP11-314C16.1 -6.23 1.06e-09 5.13e-07 -0.33 -0.28 Motion sickness; chr6:8535664 chr6:8784178~8785445:+ LUSC cis rs3743266 0.507 rs11637887 ENSG00000245534.5 RORA-AS1 -6.23 1.06e-09 5.13e-07 -0.42 -0.28 Menarche (age at onset); chr15:60473017 chr15:60479178~60630637:+ LUSC cis rs875971 0.706 rs1643374 ENSG00000236529.1 RP13-254B10.1 6.23 1.06e-09 5.13e-07 0.29 0.28 Aortic root size; chr7:66407695 chr7:65840212~65840596:+ LUSC cis rs9326248 0.689 rs4516002 ENSG00000280143.1 AP000892.6 6.23 1.06e-09 5.13e-07 0.38 0.28 Blood protein levels; chr11:117128343 chr11:117204967~117210292:+ LUSC cis rs227275 0.556 rs12508069 ENSG00000230069.3 LRRC37A15P -6.23 1.06e-09 5.13e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102983598 chr4:102727274~102730721:- LUSC cis rs227275 0.527 rs12500379 ENSG00000230069.3 LRRC37A15P -6.23 1.06e-09 5.13e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102983665 chr4:102727274~102730721:- LUSC cis rs227275 0.556 rs9999303 ENSG00000230069.3 LRRC37A15P -6.23 1.06e-09 5.13e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102986881 chr4:102727274~102730721:- LUSC cis rs7772486 0.764 rs7745696 ENSG00000235652.6 RP11-545I5.3 6.23 1.06e-09 5.14e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145841693 chr6:145799409~145886585:+ LUSC cis rs6969780 0.915 rs10085570 ENSG00000233429.8 HOTAIRM1 -6.23 1.06e-09 5.14e-07 -0.45 -0.28 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27111569 chr7:27095647~27100265:+ LUSC cis rs11722779 0.81 rs223417 ENSG00000230069.3 LRRC37A15P -6.23 1.06e-09 5.14e-07 -0.29 -0.28 Schizophrenia; chr4:102810568 chr4:102727274~102730721:- LUSC cis rs11722779 0.805 rs223416 ENSG00000230069.3 LRRC37A15P -6.23 1.06e-09 5.14e-07 -0.29 -0.28 Schizophrenia; chr4:102810580 chr4:102727274~102730721:- LUSC cis rs11971779 0.68 rs17613690 ENSG00000273391.1 RP11-634H22.1 -6.23 1.06e-09 5.15e-07 -0.3 -0.28 Diisocyanate-induced asthma; chr7:139403655 chr7:139359032~139359566:- LUSC cis rs116095464 0.558 rs10043002 ENSG00000250848.1 CTD-2083E4.5 -6.23 1.06e-09 5.15e-07 -0.42 -0.28 Breast cancer; chr5:226638 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs62347678 ENSG00000250848.1 CTD-2083E4.5 -6.23 1.06e-09 5.15e-07 -0.42 -0.28 Breast cancer; chr5:227381 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs73031482 ENSG00000250848.1 CTD-2083E4.5 -6.23 1.06e-09 5.15e-07 -0.42 -0.28 Breast cancer; chr5:227479 chr5:288833~290321:- LUSC cis rs7772486 0.686 rs9390357 ENSG00000235652.6 RP11-545I5.3 6.23 1.07e-09 5.15e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145808211 chr6:145799409~145886585:+ LUSC cis rs61270009 0.955 rs4916898 ENSG00000247828.6 TMEM161B-AS1 6.23 1.07e-09 5.15e-07 0.32 0.28 Depressive symptoms; chr5:88290245 chr5:88268895~88436685:+ LUSC cis rs9322193 0.923 rs14314 ENSG00000268592.3 RAET1E-AS1 6.23 1.07e-09 5.16e-07 0.35 0.28 Lung cancer; chr6:149820395 chr6:149863494~149919507:+ LUSC cis rs875971 0.545 rs7783889 ENSG00000226824.5 RP4-756H11.3 -6.23 1.07e-09 5.16e-07 -0.36 -0.28 Aortic root size; chr7:66283366 chr7:66654538~66669855:+ LUSC cis rs4372836 1 rs4666119 ENSG00000226833.4 AC097724.3 6.22 1.07e-09 5.17e-07 0.32 0.28 Body mass index; chr2:28752824 chr2:28708953~28736205:- LUSC cis rs1823913 0.637 rs921737 ENSG00000280083.1 RP11-317J9.1 6.22 1.07e-09 5.17e-07 0.32 0.28 Obesity-related traits; chr2:191286097 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs6736071 ENSG00000280083.1 RP11-317J9.1 6.22 1.07e-09 5.17e-07 0.32 0.28 Obesity-related traits; chr2:191287265 chr2:191154118~191156070:- LUSC cis rs12554020 1 rs12335532 ENSG00000227603.1 RP11-165J3.6 6.22 1.07e-09 5.17e-07 0.34 0.28 Schizophrenia; chr9:93431673 chr9:93435332~93437121:- LUSC cis rs6504622 0.755 rs11079750 ENSG00000262879.4 RP11-156P1.3 -6.22 1.07e-09 5.17e-07 -0.3 -0.28 Orofacial clefts; chr17:47072149 chr17:46984045~47100323:- LUSC cis rs1823913 0.599 rs10497713 ENSG00000227542.1 AC092614.2 6.22 1.07e-09 5.18e-07 0.35 0.28 Obesity-related traits; chr2:191279312 chr2:191229165~191246172:- LUSC cis rs4664293 0.769 rs10171236 ENSG00000226266.5 AC009961.3 -6.22 1.07e-09 5.18e-07 -0.33 -0.28 Monocyte percentage of white cells; chr2:159729752 chr2:159670708~159712435:- LUSC cis rs13113518 1 rs11133388 ENSG00000273257.1 RP11-177J6.1 -6.22 1.07e-09 5.18e-07 -0.35 -0.28 Height; chr4:55477866 chr4:55387949~55388271:+ LUSC cis rs950880 0.71 rs11123927 ENSG00000234389.1 AC007278.3 -6.22 1.07e-09 5.18e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102442343 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs10490203 ENSG00000234389.1 AC007278.3 -6.22 1.07e-09 5.18e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102442777 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs4851583 ENSG00000234389.1 AC007278.3 -6.22 1.07e-09 5.18e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102443840 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs11694360 ENSG00000234389.1 AC007278.3 -6.22 1.07e-09 5.18e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102444687 chr2:102438713~102440475:+ LUSC cis rs61270009 0.913 rs357512 ENSG00000247828.6 TMEM161B-AS1 -6.22 1.07e-09 5.18e-07 -0.32 -0.28 Depressive symptoms; chr5:88222061 chr5:88268895~88436685:+ LUSC cis rs67311347 1 rs1119179 ENSG00000223797.4 ENTPD3-AS1 -6.22 1.07e-09 5.19e-07 -0.34 -0.28 Renal cell carcinoma; chr3:40383438 chr3:40313802~40453329:- LUSC cis rs9322193 0.847 rs12191643 ENSG00000268592.3 RAET1E-AS1 6.22 1.08e-09 5.21e-07 0.35 0.28 Lung cancer; chr6:149628912 chr6:149863494~149919507:+ LUSC cis rs3096299 0.967 rs2965932 ENSG00000274627.1 RP11-104N10.2 -6.22 1.08e-09 5.22e-07 -0.25 -0.28 Multiple myeloma (IgH translocation); chr16:89410643 chr16:89516797~89522217:+ LUSC cis rs9322193 0.884 rs2342858 ENSG00000268592.3 RAET1E-AS1 6.22 1.08e-09 5.22e-07 0.35 0.28 Lung cancer; chr6:149805967 chr6:149863494~149919507:+ LUSC cis rs7580658 0.75 rs6731176 ENSG00000236682.1 AC068282.3 -6.22 1.08e-09 5.23e-07 -0.35 -0.28 Protein C levels; chr2:127313427 chr2:127389130~127400580:+ LUSC cis rs7804306 0.826 rs73049252 ENSG00000233264.2 AC006042.8 6.22 1.08e-09 5.23e-07 0.56 0.28 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7976971 chr7:7980312~7982228:+ LUSC cis rs12908161 0.959 rs1051168 ENSG00000259728.4 LINC00933 6.22 1.08e-09 5.23e-07 0.35 0.28 Schizophrenia; chr15:84657289 chr15:84570649~84580175:+ LUSC cis rs11846409 0.932 rs74091721 ENSG00000274576.2 IGHV2-70 -6.22 1.08e-09 5.23e-07 -0.3 -0.28 Rheumatic heart disease; chr14:106638262 chr14:106770577~106771020:- LUSC cis rs2404602 0.735 rs11635463 ENSG00000259422.1 RP11-593F23.1 -6.22 1.08e-09 5.23e-07 -0.33 -0.28 Blood metabolite levels; chr15:76470645 chr15:76174891~76181486:- LUSC cis rs1061377 0.965 rs7669376 ENSG00000249685.1 RP11-360F5.3 6.22 1.09e-09 5.25e-07 0.32 0.28 Uric acid levels; chr4:39116717 chr4:39133913~39135608:+ LUSC cis rs9322193 0.923 rs1934534 ENSG00000268592.3 RAET1E-AS1 6.22 1.09e-09 5.25e-07 0.35 0.28 Lung cancer; chr6:149711896 chr6:149863494~149919507:+ LUSC cis rs6504950 1 rs9915183 ENSG00000275710.1 RP11-257O5.4 6.22 1.09e-09 5.27e-07 0.33 0.28 Breast cancer; chr17:54969776 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9895808 ENSG00000275710.1 RP11-257O5.4 6.22 1.09e-09 5.27e-07 0.33 0.28 Breast cancer; chr17:54971081 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9897447 ENSG00000275710.1 RP11-257O5.4 6.22 1.09e-09 5.27e-07 0.33 0.28 Breast cancer; chr17:54971108 chr17:54964474~54964679:+ LUSC cis rs7955901 0.746 rs4142883 ENSG00000257265.1 CTD-2021H9.1 6.22 1.09e-09 5.28e-07 0.31 0.28 Type 2 diabetes; chr12:71130802 chr12:71007773~71032083:- LUSC cis rs7955901 0.746 rs3844208 ENSG00000257265.1 CTD-2021H9.1 6.22 1.09e-09 5.28e-07 0.31 0.28 Type 2 diabetes; chr12:71131157 chr12:71007773~71032083:- LUSC cis rs875971 0.571 rs78668714 ENSG00000226824.5 RP4-756H11.3 -6.22 1.1e-09 5.29e-07 -0.37 -0.28 Aortic root size; chr7:66474464 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs7810213 ENSG00000226824.5 RP4-756H11.3 -6.22 1.1e-09 5.29e-07 -0.37 -0.28 Aortic root size; chr7:66481592 chr7:66654538~66669855:+ LUSC cis rs78487399 0.71 rs74616425 ENSG00000234936.1 AC010883.5 6.22 1.1e-09 5.29e-07 0.44 0.28 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43386443 chr2:43229573~43233394:+ LUSC cis rs172166 0.694 rs9295760 ENSG00000216901.1 AL022393.7 6.22 1.1e-09 5.29e-07 0.33 0.28 Cardiac Troponin-T levels; chr6:28179607 chr6:28176188~28176674:+ LUSC cis rs7267979 0.932 rs6115200 ENSG00000274973.1 RP13-401N8.7 -6.22 1.1e-09 5.29e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25506741 chr20:25845497~25845862:+ LUSC cis rs7267979 0.932 rs6138588 ENSG00000274973.1 RP13-401N8.7 -6.22 1.1e-09 5.29e-07 -0.28 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25506887 chr20:25845497~25845862:+ LUSC cis rs1823913 0.599 rs17414109 ENSG00000227542.1 AC092614.2 6.22 1.1e-09 5.3e-07 0.36 0.28 Obesity-related traits; chr2:191310675 chr2:191229165~191246172:- LUSC cis rs853679 0.517 rs3757187 ENSG00000280107.1 AL022393.9 -6.22 1.1e-09 5.31e-07 -0.34 -0.28 Depression; chr6:28139876 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs3757185 ENSG00000280107.1 AL022393.9 -6.22 1.1e-09 5.31e-07 -0.34 -0.28 Depression; chr6:28139998 chr6:28170845~28172521:+ LUSC cis rs875971 0.66 rs10215132 ENSG00000222364.1 RNU6-96P 6.22 1.1e-09 5.31e-07 0.32 0.28 Aortic root size; chr7:66589419 chr7:66395191~66395286:+ LUSC cis rs6991838 0.806 rs35024820 ENSG00000200714.1 Y_RNA 6.22 1.1e-09 5.31e-07 0.33 0.28 Intelligence (multi-trait analysis); chr8:65551296 chr8:65592731~65592820:+ LUSC cis rs7772486 0.79 rs2249147 ENSG00000235652.6 RP11-545I5.3 6.22 1.1e-09 5.32e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145863863 chr6:145799409~145886585:+ LUSC cis rs7955901 0.638 rs11178639 ENSG00000257265.1 CTD-2021H9.1 6.22 1.1e-09 5.32e-07 0.31 0.28 Type 2 diabetes; chr12:71126487 chr12:71007773~71032083:- LUSC cis rs6570726 0.934 rs9484995 ENSG00000235652.6 RP11-545I5.3 -6.22 1.11e-09 5.34e-07 -0.27 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145459978 chr6:145799409~145886585:+ LUSC cis rs227275 0.556 rs6842179 ENSG00000230069.3 LRRC37A15P -6.22 1.11e-09 5.34e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103018363 chr4:102727274~102730721:- LUSC cis rs1823913 0.599 rs17511445 ENSG00000227542.1 AC092614.2 -6.22 1.11e-09 5.35e-07 -0.35 -0.28 Obesity-related traits; chr2:191279831 chr2:191229165~191246172:- LUSC cis rs11971779 0.68 rs7785903 ENSG00000273391.1 RP11-634H22.1 6.22 1.11e-09 5.35e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139437897 chr7:139359032~139359566:- LUSC cis rs1823913 0.637 rs1470962 ENSG00000280083.1 RP11-317J9.1 6.22 1.11e-09 5.35e-07 0.32 0.28 Obesity-related traits; chr2:191270271 chr2:191154118~191156070:- LUSC cis rs116095464 0.614 rs10067482 ENSG00000250848.1 CTD-2083E4.5 -6.22 1.11e-09 5.36e-07 -0.41 -0.28 Breast cancer; chr5:219213 chr5:288833~290321:- LUSC cis rs1155848 0.571 rs6563125 ENSG00000227354.5 RBM26-AS1 6.22 1.11e-09 5.36e-07 0.51 0.28 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79630618 chr13:79406309~79424328:+ LUSC cis rs1155848 0.571 rs58739959 ENSG00000227354.5 RBM26-AS1 6.22 1.11e-09 5.36e-07 0.51 0.28 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79633468 chr13:79406309~79424328:+ LUSC cis rs9322193 0.923 rs9377230 ENSG00000268592.3 RAET1E-AS1 6.22 1.11e-09 5.36e-07 0.35 0.28 Lung cancer; chr6:149613607 chr6:149863494~149919507:+ LUSC cis rs6969780 0.778 rs11564055 ENSG00000233429.8 HOTAIRM1 6.22 1.11e-09 5.37e-07 0.53 0.28 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27105731 chr7:27095647~27100265:+ LUSC cis rs6969780 0.778 rs2428433 ENSG00000233429.8 HOTAIRM1 6.22 1.11e-09 5.37e-07 0.53 0.28 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27105898 chr7:27095647~27100265:+ LUSC cis rs6969780 0.778 rs2428434 ENSG00000233429.8 HOTAIRM1 6.22 1.11e-09 5.37e-07 0.53 0.28 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27106116 chr7:27095647~27100265:+ LUSC cis rs6969780 0.778 rs79619106 ENSG00000233429.8 HOTAIRM1 6.22 1.11e-09 5.37e-07 0.53 0.28 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27106709 chr7:27095647~27100265:+ LUSC cis rs2404602 0.735 rs4886495 ENSG00000259422.1 RP11-593F23.1 6.22 1.12e-09 5.37e-07 0.31 0.28 Blood metabolite levels; chr15:76446618 chr15:76174891~76181486:- LUSC cis rs227275 0.554 rs223367 ENSG00000230069.3 LRRC37A15P -6.22 1.12e-09 5.38e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102843836 chr4:102727274~102730721:- LUSC cis rs950169 0.58 rs11636189 ENSG00000259728.4 LINC00933 6.22 1.12e-09 5.38e-07 0.35 0.28 Schizophrenia; chr15:84650323 chr15:84570649~84580175:+ LUSC cis rs1075265 0.933 rs11888384 ENSG00000233266.1 HMGB1P31 6.22 1.12e-09 5.38e-07 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:54110984 chr2:54051334~54051760:+ LUSC cis rs6142102 0.961 rs6059651 ENSG00000275784.1 RP5-1125A11.6 -6.22 1.12e-09 5.4e-07 -0.32 -0.28 Skin pigmentation; chr20:34057246 chr20:33989480~33991818:- LUSC cis rs9322193 0.923 rs9689716 ENSG00000268592.3 RAET1E-AS1 6.22 1.12e-09 5.4e-07 0.35 0.28 Lung cancer; chr6:149655662 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9322207 ENSG00000268592.3 RAET1E-AS1 6.22 1.12e-09 5.4e-07 0.35 0.28 Lung cancer; chr6:149657185 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9968911 ENSG00000268592.3 RAET1E-AS1 6.22 1.12e-09 5.4e-07 0.35 0.28 Lung cancer; chr6:149657419 chr6:149863494~149919507:+ LUSC cis rs1075265 0.933 rs929734 ENSG00000233266.1 HMGB1P31 6.22 1.12e-09 5.41e-07 0.36 0.28 Chronotype;Morning vs. evening chronotype; chr2:54111158 chr2:54051334~54051760:+ LUSC cis rs11157436 0.918 rs3811285 ENSG00000211813.2 TRAV34 6.22 1.12e-09 5.41e-07 0.29 0.28 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22155322 chr14:22207522~22208129:+ LUSC cis rs116095464 0.558 rs2162870 ENSG00000250848.1 CTD-2083E4.5 -6.22 1.12e-09 5.41e-07 -0.42 -0.28 Breast cancer; chr5:228014 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs28729548 ENSG00000250848.1 CTD-2083E4.5 -6.22 1.12e-09 5.41e-07 -0.42 -0.28 Breast cancer; chr5:228910 chr5:288833~290321:- LUSC cis rs116095464 0.681 rs9687745 ENSG00000250848.1 CTD-2083E4.5 -6.22 1.12e-09 5.41e-07 -0.42 -0.28 Breast cancer; chr5:229194 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs9688136 ENSG00000250848.1 CTD-2083E4.5 -6.22 1.12e-09 5.41e-07 -0.42 -0.28 Breast cancer; chr5:229233 chr5:288833~290321:- LUSC cis rs116095464 0.51 rs55750776 ENSG00000250848.1 CTD-2083E4.5 -6.22 1.12e-09 5.41e-07 -0.42 -0.28 Breast cancer; chr5:230352 chr5:288833~290321:- LUSC cis rs116095464 0.764 rs10069197 ENSG00000250848.1 CTD-2083E4.5 -6.22 1.12e-09 5.41e-07 -0.42 -0.28 Breast cancer; chr5:230707 chr5:288833~290321:- LUSC cis rs116095464 0.867 rs10074958 ENSG00000250848.1 CTD-2083E4.5 -6.22 1.12e-09 5.41e-07 -0.42 -0.28 Breast cancer; chr5:230713 chr5:288833~290321:- LUSC cis rs172166 0.694 rs1631552 ENSG00000219392.1 RP1-265C24.5 -6.22 1.12e-09 5.41e-07 -0.35 -0.28 Cardiac Troponin-T levels; chr6:28121921 chr6:28115628~28116551:+ LUSC cis rs13113518 0.812 rs12500456 ENSG00000272969.1 RP11-528I4.2 6.22 1.12e-09 5.41e-07 0.31 0.28 Height; chr4:55561053 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs13116035 ENSG00000272969.1 RP11-528I4.2 6.22 1.12e-09 5.41e-07 0.31 0.28 Height; chr4:55561218 chr4:55547112~55547889:+ LUSC cis rs7772486 0.686 rs1337839 ENSG00000235652.6 RP11-545I5.3 -6.22 1.12e-09 5.42e-07 -0.28 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145689103 chr6:145799409~145886585:+ LUSC cis rs11089937 0.597 rs11089925 ENSG00000211638.2 IGLV8-61 -6.22 1.13e-09 5.42e-07 -0.29 -0.28 Periodontitis (PAL4Q3); chr22:22137267 chr22:22098700~22099212:+ LUSC cis rs6504622 0.755 rs4074249 ENSG00000262879.4 RP11-156P1.3 -6.22 1.13e-09 5.43e-07 -0.3 -0.28 Orofacial clefts; chr17:47072043 chr17:46984045~47100323:- LUSC cis rs11971779 0.68 rs2355786 ENSG00000273391.1 RP11-634H22.1 -6.22 1.13e-09 5.43e-07 -0.3 -0.28 Diisocyanate-induced asthma; chr7:139380876 chr7:139359032~139359566:- LUSC cis rs6772849 0.93 rs55987729 ENSG00000277250.1 Metazoa_SRP -6.22 1.13e-09 5.44e-07 -0.31 -0.28 Monocyte percentage of white cells;Monocyte count; chr3:128621267 chr3:128673681~128674021:- LUSC cis rs7955901 0.775 rs11178646 ENSG00000257265.1 CTD-2021H9.1 6.22 1.13e-09 5.44e-07 0.31 0.28 Type 2 diabetes; chr12:71135116 chr12:71007773~71032083:- LUSC cis rs7955901 0.775 rs67877703 ENSG00000257265.1 CTD-2021H9.1 6.22 1.13e-09 5.44e-07 0.31 0.28 Type 2 diabetes; chr12:71135566 chr12:71007773~71032083:- LUSC cis rs1061377 1 rs7685082 ENSG00000249685.1 RP11-360F5.3 6.22 1.13e-09 5.45e-07 0.32 0.28 Uric acid levels; chr4:39116472 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs7664078 ENSG00000249685.1 RP11-360F5.3 6.22 1.13e-09 5.45e-07 0.32 0.28 Uric acid levels; chr4:39116583 chr4:39133913~39135608:+ LUSC cis rs12554020 0.786 rs76640831 ENSG00000227603.1 RP11-165J3.6 6.22 1.13e-09 5.45e-07 0.42 0.28 Schizophrenia; chr9:93474133 chr9:93435332~93437121:- LUSC cis rs13113518 1 rs13152173 ENSG00000249700.7 SRD5A3-AS1 6.22 1.13e-09 5.45e-07 0.32 0.28 Height; chr4:55534788 chr4:55363971~55395847:- LUSC cis rs7684253 1 rs7684253 ENSG00000269949.1 RP11-738E22.3 6.22 1.13e-09 5.45e-07 0.33 0.28 Migraine; chr4:56861145 chr4:56960927~56961373:- LUSC cis rs2919917 1 rs2046338 ENSG00000254352.1 RP11-578O24.2 6.21 1.13e-09 5.46e-07 0.34 0.28 Lymphocyte counts; chr8:78723734 chr8:78723796~78724136:- LUSC cis rs9532669 0.926 rs9532689 ENSG00000176268.5 CYCSP34 6.21 1.13e-09 5.46e-07 0.27 0.28 Cervical cancer; chr13:40957990 chr13:40863599~40863902:- LUSC cis rs7955901 0.775 rs3844209 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71131351 chr12:71007773~71032083:- LUSC cis rs7955901 0.746 rs3896814 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71131490 chr12:71007773~71032083:- LUSC cis rs7955901 0.775 rs3851613 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71131943 chr12:71007773~71032083:- LUSC cis rs7955901 0.746 rs3851614 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71132167 chr12:71007773~71032083:- LUSC cis rs7955901 0.746 rs3851615 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71132284 chr12:71007773~71032083:- LUSC cis rs7955901 0.775 rs2270589 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71132507 chr12:71007773~71032083:- LUSC cis rs7955901 0.775 rs2270588 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71132634 chr12:71007773~71032083:- LUSC cis rs7955901 0.775 rs3816942 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71132929 chr12:71007773~71032083:- LUSC cis rs7955901 0.805 rs3851617 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71133430 chr12:71007773~71032083:- LUSC cis rs7955901 0.775 rs10784895 ENSG00000257265.1 CTD-2021H9.1 6.21 1.13e-09 5.46e-07 0.31 0.28 Type 2 diabetes; chr12:71134005 chr12:71007773~71032083:- LUSC cis rs9322193 0.926 rs9766562 ENSG00000268592.3 RAET1E-AS1 6.21 1.13e-09 5.46e-07 0.35 0.28 Lung cancer; chr6:149788709 chr6:149863494~149919507:+ LUSC cis rs10246939 0.544 rs2163953 ENSG00000228775.6 WEE2-AS1 6.21 1.14e-09 5.47e-07 0.33 0.28 Bitter taste perception; chr7:141867769 chr7:141704338~141738346:- LUSC cis rs17270561 0.639 rs9356989 ENSG00000272462.2 U91328.19 -6.21 1.14e-09 5.47e-07 -0.33 -0.28 Iron status biomarkers; chr6:25781722 chr6:25992662~26001775:+ LUSC cis rs2404602 0.622 rs1567671 ENSG00000259422.1 RP11-593F23.1 -6.21 1.14e-09 5.47e-07 -0.33 -0.28 Blood metabolite levels; chr15:76916859 chr15:76174891~76181486:- LUSC cis rs227275 0.554 rs223436 ENSG00000230069.3 LRRC37A15P -6.21 1.14e-09 5.47e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102798749 chr4:102727274~102730721:- LUSC cis rs2153535 0.542 rs9505465 ENSG00000230939.1 RP11-314C16.1 -6.21 1.14e-09 5.48e-07 -0.32 -0.28 Motion sickness; chr6:8510613 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7745043 ENSG00000230939.1 RP11-314C16.1 -6.21 1.14e-09 5.48e-07 -0.32 -0.28 Motion sickness; chr6:8513274 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406170 ENSG00000230939.1 RP11-314C16.1 -6.21 1.14e-09 5.48e-07 -0.32 -0.28 Motion sickness; chr6:8513920 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9379222 ENSG00000230939.1 RP11-314C16.1 -6.21 1.14e-09 5.48e-07 -0.32 -0.28 Motion sickness; chr6:8514555 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406172 ENSG00000230939.1 RP11-314C16.1 -6.21 1.14e-09 5.48e-07 -0.32 -0.28 Motion sickness; chr6:8515231 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406174 ENSG00000230939.1 RP11-314C16.1 -6.21 1.14e-09 5.48e-07 -0.32 -0.28 Motion sickness; chr6:8516531 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2143356 ENSG00000230939.1 RP11-314C16.1 -6.21 1.14e-09 5.48e-07 -0.32 -0.28 Motion sickness; chr6:8517442 chr6:8784178~8785445:+ LUSC cis rs9322193 0.923 rs17745062 ENSG00000268592.3 RAET1E-AS1 6.21 1.14e-09 5.48e-07 0.35 0.28 Lung cancer; chr6:149721079 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs62441279 ENSG00000268592.3 RAET1E-AS1 6.21 1.14e-09 5.48e-07 0.35 0.28 Lung cancer; chr6:149721194 chr6:149863494~149919507:+ LUSC cis rs2404602 0.735 rs1607017 ENSG00000259422.1 RP11-593F23.1 -6.21 1.14e-09 5.48e-07 -0.33 -0.28 Blood metabolite levels; chr15:76434124 chr15:76174891~76181486:- LUSC cis rs875971 0.862 rs6460302 ENSG00000179406.6 LINC00174 -6.21 1.14e-09 5.48e-07 -0.3 -0.28 Aortic root size; chr7:66495270 chr7:66376044~66401338:- LUSC cis rs11690935 0.959 rs6724337 ENSG00000228389.1 AC068039.4 6.21 1.14e-09 5.49e-07 0.32 0.28 Schizophrenia; chr2:171878819 chr2:171773482~171775844:+ LUSC cis rs6142102 0.961 rs4911405 ENSG00000275784.1 RP5-1125A11.6 -6.21 1.14e-09 5.49e-07 -0.33 -0.28 Skin pigmentation; chr20:34087161 chr20:33989480~33991818:- LUSC cis rs77204473 0.744 rs74882651 ENSG00000254851.1 RP11-109L13.1 6.21 1.14e-09 5.49e-07 0.69 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117114475 chr11:117135528~117138582:+ LUSC cis rs2179367 0.632 rs10872636 ENSG00000231760.4 RP11-350J20.5 6.21 1.14e-09 5.49e-07 0.39 0.28 Dupuytren's disease; chr6:149353678 chr6:149796151~149826294:- LUSC cis rs7665090 1 rs735404 ENSG00000230069.3 LRRC37A15P -6.21 1.14e-09 5.51e-07 -0.28 -0.28 Primary biliary cholangitis; chr4:102632508 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs4699049 ENSG00000230069.3 LRRC37A15P -6.21 1.15e-09 5.51e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103030467 chr4:102727274~102730721:- LUSC cis rs11722779 0.903 rs13130741 ENSG00000230069.3 LRRC37A15P -6.21 1.15e-09 5.51e-07 -0.29 -0.28 Schizophrenia; chr4:103035799 chr4:102727274~102730721:- LUSC cis rs2834288 0.575 rs2239564 ENSG00000273102.1 AP000569.9 -6.21 1.15e-09 5.51e-07 -0.32 -0.28 Gut microbiota (bacterial taxa); chr21:33908245 chr21:33967101~33968573:- LUSC cis rs227275 0.525 rs1080081 ENSG00000230069.3 LRRC37A15P -6.21 1.15e-09 5.52e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103029268 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs223377 ENSG00000230069.3 LRRC37A15P -6.21 1.15e-09 5.54e-07 -0.29 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102834919 chr4:102727274~102730721:- LUSC cis rs7429990 0.864 rs883663 ENSG00000229759.1 MRPS18AP1 -6.21 1.15e-09 5.54e-07 -0.27 -0.28 Educational attainment (years of education); chr3:47619306 chr3:48256350~48256938:- LUSC cis rs9322193 0.962 rs3805749 ENSG00000268592.3 RAET1E-AS1 6.21 1.15e-09 5.54e-07 0.36 0.28 Lung cancer; chr6:149772546 chr6:149863494~149919507:+ LUSC cis rs9322193 0.847 rs9505972 ENSG00000268592.3 RAET1E-AS1 6.21 1.15e-09 5.54e-07 0.36 0.28 Lung cancer; chr6:149775255 chr6:149863494~149919507:+ LUSC cis rs227275 0.554 rs223382 ENSG00000230069.3 LRRC37A15P -6.21 1.15e-09 5.54e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102831145 chr4:102727274~102730721:- LUSC cis rs77204473 0.744 rs74955808 ENSG00000254851.1 RP11-109L13.1 6.21 1.15e-09 5.55e-07 0.68 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117121969 chr11:117135528~117138582:+ LUSC cis rs2153535 0.58 rs2327067 ENSG00000230939.1 RP11-314C16.1 -6.21 1.16e-09 5.55e-07 -0.32 -0.28 Motion sickness; chr6:8518249 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs9328477 ENSG00000230939.1 RP11-314C16.1 -6.21 1.16e-09 5.55e-07 -0.32 -0.28 Motion sickness; chr6:8518876 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9328478 ENSG00000230939.1 RP11-314C16.1 -6.21 1.16e-09 5.55e-07 -0.32 -0.28 Motion sickness; chr6:8518950 chr6:8784178~8785445:+ LUSC cis rs875971 0.545 rs316306 ENSG00000226824.5 RP4-756H11.3 6.21 1.16e-09 5.57e-07 0.36 0.28 Aortic root size; chr7:66153687 chr7:66654538~66669855:+ LUSC cis rs9322193 0.962 rs9688750 ENSG00000268592.3 RAET1E-AS1 6.21 1.16e-09 5.58e-07 0.35 0.28 Lung cancer; chr6:149657633 chr6:149863494~149919507:+ LUSC cis rs7267979 1 rs8125868 ENSG00000274973.1 RP13-401N8.7 6.21 1.16e-09 5.58e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25343774 chr20:25845497~25845862:+ LUSC cis rs13113518 0.783 rs1586555 ENSG00000249700.7 SRD5A3-AS1 6.21 1.16e-09 5.58e-07 0.32 0.28 Height; chr4:55587104 chr4:55363971~55395847:- LUSC cis rs8062405 1 rs55991577 ENSG00000278665.1 RP11-666O2.4 6.21 1.16e-09 5.59e-07 0.27 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831704 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs56358680 ENSG00000278665.1 RP11-666O2.4 6.21 1.16e-09 5.59e-07 0.27 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831797 chr16:28599241~28601881:- LUSC cis rs34779708 0.766 rs35308730 ENSG00000230534.5 RP11-297A16.2 6.21 1.16e-09 5.59e-07 0.31 0.28 Inflammatory bowel disease;Crohn's disease; chr10:35260868 chr10:35098006~35127020:- LUSC cis rs34779708 0.736 rs34195979 ENSG00000230534.5 RP11-297A16.2 6.21 1.16e-09 5.59e-07 0.31 0.28 Inflammatory bowel disease;Crohn's disease; chr10:35260889 chr10:35098006~35127020:- LUSC cis rs7246657 0.943 rs4803460 ENSG00000276846.1 CTD-3220F14.3 6.21 1.16e-09 5.59e-07 0.42 0.28 Coronary artery calcification; chr19:37394326 chr19:37314868~37315620:- LUSC cis rs950169 0.845 rs4502182 ENSG00000259728.4 LINC00933 6.21 1.17e-09 5.61e-07 0.36 0.28 Schizophrenia; chr15:84254768 chr15:84570649~84580175:+ LUSC cis rs6951245 1 rs1881123 ENSG00000224079.1 AC091729.7 -6.21 1.17e-09 5.61e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1045070 chr7:1074450~1078036:+ LUSC cis rs6951245 0.872 rs77569514 ENSG00000224079.1 AC091729.7 -6.21 1.17e-09 5.61e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1045872 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs11770909 ENSG00000224079.1 AC091729.7 -6.21 1.17e-09 5.61e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1047080 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs74785791 ENSG00000224079.1 AC091729.7 -6.21 1.17e-09 5.61e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1048858 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs74366004 ENSG00000224079.1 AC091729.7 -6.21 1.17e-09 5.61e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1048994 chr7:1074450~1078036:+ LUSC cis rs6951245 1 rs77702926 ENSG00000224079.1 AC091729.7 -6.21 1.17e-09 5.61e-07 -0.48 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1049202 chr7:1074450~1078036:+ LUSC cis rs1322639 1 rs1322639 ENSG00000261039.2 RP11-417E7.2 6.21 1.17e-09 5.63e-07 0.36 0.28 Pulse pressure; chr6:169187008 chr6:169175304~169182740:- LUSC cis rs227275 0.554 rs223339 ENSG00000230069.3 LRRC37A15P -6.21 1.17e-09 5.63e-07 -0.29 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102864700 chr4:102727274~102730721:- LUSC cis rs9341808 0.935 rs9343974 ENSG00000272129.1 RP11-250B2.6 6.21 1.18e-09 5.64e-07 0.34 0.28 Sitting height ratio; chr6:80214928 chr6:80355424~80356859:+ LUSC cis rs3002131 0.688 rs3008650 ENSG00000225265.1 TAF1A-AS1 6.21 1.18e-09 5.64e-07 0.38 0.28 Interleukin-10 levels; chr1:222589873 chr1:222589825~222593032:+ LUSC cis rs5770917 1 rs762677 ENSG00000273272.1 CTA-384D8.34 6.21 1.18e-09 5.64e-07 0.54 0.28 Narcolepsy; chr22:50579284 chr22:50542650~50543011:+ LUSC cis rs9322193 0.962 rs10872653 ENSG00000268592.3 RAET1E-AS1 6.21 1.18e-09 5.65e-07 0.35 0.28 Lung cancer; chr6:149778907 chr6:149863494~149919507:+ LUSC cis rs7211079 0.879 rs72852522 ENSG00000279259.1 RP11-334C17.3 6.21 1.18e-09 5.65e-07 0.32 0.28 Myocardial infarction; chr17:80157691 chr17:80147250~80148596:+ LUSC cis rs875971 0.545 rs6979636 ENSG00000226824.5 RP4-756H11.3 -6.21 1.18e-09 5.66e-07 -0.37 -0.28 Aortic root size; chr7:66276638 chr7:66654538~66669855:+ LUSC cis rs957448 1 rs12543207 ENSG00000253175.1 RP11-267M23.6 6.21 1.18e-09 5.66e-07 0.32 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94485202 chr8:94565036~94565715:+ LUSC cis rs7955901 0.691 rs11178613 ENSG00000257265.1 CTD-2021H9.1 6.21 1.18e-09 5.66e-07 0.31 0.28 Type 2 diabetes; chr12:71111968 chr12:71007773~71032083:- LUSC cis rs5753618 0.561 rs5753543 ENSG00000236132.1 CTA-440B3.1 6.21 1.18e-09 5.66e-07 0.37 0.28 Colorectal cancer; chr22:31289472 chr22:31816379~31817491:- LUSC cis rs5753618 0.561 rs2413049 ENSG00000236132.1 CTA-440B3.1 6.21 1.18e-09 5.66e-07 0.37 0.28 Colorectal cancer; chr22:31290158 chr22:31816379~31817491:- LUSC cis rs227275 0.554 rs223314 ENSG00000230069.3 LRRC37A15P -6.21 1.18e-09 5.66e-07 -0.3 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102884642 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs7254 ENSG00000230069.3 LRRC37A15P -6.21 1.18e-09 5.66e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888488 chr4:102727274~102730721:- LUSC cis rs11722779 0.566 rs6822658 ENSG00000230069.3 LRRC37A15P -6.21 1.18e-09 5.66e-07 -0.3 -0.28 Schizophrenia; chr4:102891964 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs6823625 ENSG00000230069.3 LRRC37A15P -6.21 1.18e-09 5.66e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892437 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs6846762 ENSG00000230069.3 LRRC37A15P -6.21 1.18e-09 5.66e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892577 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs4699032 ENSG00000230069.3 LRRC37A15P -6.21 1.18e-09 5.66e-07 -0.3 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892724 chr4:102727274~102730721:- LUSC cis rs14027 0.921 rs2048239 ENSG00000279347.1 RP11-85I17.2 -6.21 1.18e-09 5.67e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119735701 chr8:119838736~119840385:- LUSC cis rs9322193 0.923 rs12211511 ENSG00000268592.3 RAET1E-AS1 6.21 1.18e-09 5.68e-07 0.34 0.28 Lung cancer; chr6:149745206 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9479810 ENSG00000268592.3 RAET1E-AS1 6.21 1.18e-09 5.68e-07 0.34 0.28 Lung cancer; chr6:149751359 chr6:149863494~149919507:+ LUSC cis rs7267979 1 rs2500424 ENSG00000274973.1 RP13-401N8.7 6.21 1.18e-09 5.68e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25411333 chr20:25845497~25845862:+ LUSC cis rs9322193 0.923 rs10872645 ENSG00000268592.3 RAET1E-AS1 6.21 1.19e-09 5.69e-07 0.34 0.28 Lung cancer; chr6:149742840 chr6:149863494~149919507:+ LUSC cis rs7826238 0.564 rs2921053 ENSG00000253893.2 FAM85B -6.21 1.19e-09 5.7e-07 -0.32 -0.28 Systolic blood pressure; chr8:8462453 chr8:8167819~8226614:- LUSC cis rs6142102 0.602 rs4911396 ENSG00000275784.1 RP5-1125A11.6 -6.21 1.19e-09 5.7e-07 -0.3 -0.28 Skin pigmentation; chr20:33992139 chr20:33989480~33991818:- LUSC cis rs13113518 0.729 rs13120134 ENSG00000273257.1 RP11-177J6.1 6.21 1.19e-09 5.7e-07 0.37 0.28 Height; chr4:55415153 chr4:55387949~55388271:+ LUSC cis rs17772222 0.651 rs1950280 ENSG00000258789.1 RP11-507K2.3 6.21 1.19e-09 5.7e-07 0.3 0.28 Coronary artery calcification; chr14:88366259 chr14:88551597~88552493:+ LUSC cis rs4604732 0.631 rs12031694 ENSG00000227135.1 GCSAML-AS1 -6.21 1.19e-09 5.71e-07 -0.41 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247460351 chr1:247524679~247526752:- LUSC cis rs853679 0.517 rs9380052 ENSG00000204709.4 LINC01556 6.21 1.19e-09 5.71e-07 0.39 0.28 Depression; chr6:28096845 chr6:28943877~28944537:+ LUSC cis rs6570726 0.967 rs9497316 ENSG00000235652.6 RP11-545I5.3 -6.21 1.19e-09 5.71e-07 -0.27 -0.28 Lobe attachment (rater-scored or self-reported); chr6:145471251 chr6:145799409~145886585:+ LUSC cis rs4814920 0.818 rs4813376 ENSG00000275142.1 RP5-999L4.2 6.21 1.19e-09 5.72e-07 0.43 0.28 Bipolar disorder (body mass index interaction); chr20:19870811 chr20:19871891~19872284:+ LUSC cis rs9322193 0.923 rs12205092 ENSG00000268592.3 RAET1E-AS1 6.21 1.19e-09 5.72e-07 0.35 0.28 Lung cancer; chr6:149761375 chr6:149863494~149919507:+ LUSC cis rs9322193 0.847 rs56103941 ENSG00000268592.3 RAET1E-AS1 6.21 1.19e-09 5.72e-07 0.35 0.28 Lung cancer; chr6:149816095 chr6:149863494~149919507:+ LUSC cis rs4237845 0.837 rs7954591 ENSG00000257159.1 RP11-58A17.3 6.21 1.19e-09 5.73e-07 0.33 0.28 Intelligence (multi-trait analysis); chr12:57905254 chr12:57967058~57968399:+ LUSC cis rs2834288 0.535 rs8129694 ENSG00000273102.1 AP000569.9 -6.21 1.19e-09 5.73e-07 -0.3 -0.28 Gut microbiota (bacterial taxa); chr21:33954795 chr21:33967101~33968573:- LUSC cis rs1056107 0.831 rs10125827 ENSG00000225513.1 RP11-165N19.2 6.21 1.2e-09 5.73e-07 0.3 0.28 Colorectal cancer; chr9:112182226 chr9:112173522~112173971:- LUSC cis rs14027 0.921 rs13257002 ENSG00000279347.1 RP11-85I17.2 -6.21 1.2e-09 5.74e-07 -0.25 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119757489 chr8:119838736~119840385:- LUSC cis rs7804306 0.826 rs73049300 ENSG00000233264.2 AC006042.8 6.21 1.2e-09 5.74e-07 0.57 0.28 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8002315 chr7:7980312~7982228:+ LUSC cis rs77204473 0.744 rs12420361 ENSG00000254851.1 RP11-109L13.1 6.21 1.2e-09 5.75e-07 0.69 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117123072 chr11:117135528~117138582:+ LUSC cis rs4814920 0.818 rs6035467 ENSG00000275142.1 RP5-999L4.2 -6.21 1.2e-09 5.75e-07 -0.47 -0.28 Bipolar disorder (body mass index interaction); chr20:19879602 chr20:19871891~19872284:+ LUSC cis rs12554020 0.786 rs78271342 ENSG00000227603.1 RP11-165J3.6 6.21 1.2e-09 5.75e-07 0.42 0.28 Schizophrenia; chr9:93468959 chr9:93435332~93437121:- LUSC cis rs9309473 0.606 rs77962988 ENSG00000163016.8 ALMS1P 6.21 1.2e-09 5.75e-07 0.4 0.28 Metabolite levels; chr2:73658963 chr2:73644919~73685576:+ LUSC cis rs11971779 0.588 rs2003531 ENSG00000273391.1 RP11-634H22.1 6.21 1.2e-09 5.76e-07 0.3 0.28 Diisocyanate-induced asthma; chr7:139441832 chr7:139359032~139359566:- LUSC cis rs1757171 0.534 rs2797793 ENSG00000204110.6 RP1-153P14.8 6.2 1.2e-09 5.76e-07 0.26 0.28 Cognitive performance; chr6:37509486 chr6:37507348~37535616:+ LUSC cis rs1823913 0.538 rs35311234 ENSG00000227542.1 AC092614.2 6.2 1.2e-09 5.77e-07 0.35 0.28 Obesity-related traits; chr2:191316952 chr2:191229165~191246172:- LUSC cis rs9322193 0.847 rs12210605 ENSG00000268592.3 RAET1E-AS1 6.2 1.2e-09 5.77e-07 0.35 0.28 Lung cancer; chr6:149817267 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9371199 ENSG00000268592.3 RAET1E-AS1 6.2 1.2e-09 5.77e-07 0.35 0.28 Lung cancer; chr6:149817526 chr6:149863494~149919507:+ LUSC cis rs11157436 0.602 rs17255447 ENSG00000211813.2 TRAV34 -6.2 1.21e-09 5.78e-07 -0.27 -0.28 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22167459 chr14:22207522~22208129:+ LUSC cis rs6991838 0.806 rs35284121 ENSG00000200714.1 Y_RNA 6.2 1.21e-09 5.78e-07 0.33 0.28 Intelligence (multi-trait analysis); chr8:65551230 chr8:65592731~65592820:+ LUSC cis rs6991838 0.751 rs35553155 ENSG00000200714.1 Y_RNA 6.2 1.21e-09 5.78e-07 0.33 0.28 Intelligence (multi-trait analysis); chr8:65551232 chr8:65592731~65592820:+ LUSC cis rs442309 0.551 rs10995305 ENSG00000238280.1 RP11-436D10.3 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Vogt-Koyanagi-Harada syndrome; chr10:62781150 chr10:62793562~62805887:- LUSC cis rs853679 0.517 rs9393891 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Depression; chr6:28111382 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9468286 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Depression; chr6:28111650 chr6:28170845~28172521:+ LUSC cis rs4713118 0.516 rs7739216 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Parkinson's disease; chr6:28112168 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs35512245 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Depression; chr6:28112175 chr6:28170845~28172521:+ LUSC cis rs853679 0.542 rs9393892 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Depression; chr6:28113616 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9380055 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Depression; chr6:28113851 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9368553 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Depression; chr6:28114487 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9368554 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Depression; chr6:28114933 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs4713137 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Depression; chr6:28115743 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9348793 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Depression; chr6:28116411 chr6:28170845~28172521:+ LUSC cis rs4713118 0.586 rs6905516 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Parkinson's disease; chr6:28118700 chr6:28170845~28172521:+ LUSC cis rs4713118 0.586 rs6905522 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Parkinson's disease; chr6:28118701 chr6:28170845~28172521:+ LUSC cis rs4713118 0.586 rs9468290 ENSG00000280107.1 AL022393.9 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 Parkinson's disease; chr6:28119896 chr6:28170845~28172521:+ LUSC cis rs720475 1 rs720475 ENSG00000170356.8 OR2A20P 6.2 1.21e-09 5.79e-07 0.39 0.28 Breast cancer; chr7:144377836 chr7:144250045~144252957:- LUSC cis rs440932 0.887 rs398801 ENSG00000254340.1 RP11-10A14.3 -6.2 1.21e-09 5.79e-07 -0.34 -0.28 High light scatter reticulocyte percentage of red cells; chr8:9174194 chr8:9141424~9145435:+ LUSC cis rs12908161 1 rs58416181 ENSG00000259728.4 LINC00933 6.2 1.21e-09 5.8e-07 0.36 0.28 Schizophrenia; chr15:84721230 chr15:84570649~84580175:+ LUSC cis rs79349575 0.783 rs4793991 ENSG00000270781.1 RP11-501C14.9 -6.2 1.21e-09 5.82e-07 -0.29 -0.28 Type 2 diabetes; chr17:48924439 chr17:48899131~48899748:+ LUSC cis rs79349575 0.715 rs62075844 ENSG00000270781.1 RP11-501C14.9 -6.2 1.21e-09 5.82e-07 -0.29 -0.28 Type 2 diabetes; chr17:48925027 chr17:48899131~48899748:+ LUSC cis rs79349575 0.749 rs957557 ENSG00000270781.1 RP11-501C14.9 -6.2 1.21e-09 5.82e-07 -0.29 -0.28 Type 2 diabetes; chr17:48925859 chr17:48899131~48899748:+ LUSC cis rs228614 0.51 rs223356 ENSG00000230069.3 LRRC37A15P -6.2 1.21e-09 5.82e-07 -0.29 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102852344 chr4:102727274~102730721:- LUSC cis rs7267979 0.509 rs6115218 ENSG00000274973.1 RP13-401N8.7 -6.2 1.21e-09 5.82e-07 -0.31 -0.28 Liver enzyme levels (alkaline phosphatase); chr20:25585849 chr20:25845497~25845862:+ LUSC cis rs8062405 1 rs62036626 ENSG00000278665.1 RP11-666O2.4 6.2 1.21e-09 5.82e-07 0.27 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28832963 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs62036657 ENSG00000278665.1 RP11-666O2.4 6.2 1.21e-09 5.82e-07 0.27 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833044 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs12444171 ENSG00000278665.1 RP11-666O2.4 6.2 1.21e-09 5.82e-07 0.27 0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833930 chr16:28599241~28601881:- LUSC cis rs4713118 0.662 rs469228 ENSG00000280107.1 AL022393.9 -6.2 1.22e-09 5.82e-07 -0.33 -0.28 Parkinson's disease; chr6:28002926 chr6:28170845~28172521:+ LUSC cis rs4713118 0.54 rs469227 ENSG00000280107.1 AL022393.9 -6.2 1.22e-09 5.82e-07 -0.33 -0.28 Parkinson's disease; chr6:28002927 chr6:28170845~28172521:+ LUSC cis rs4713118 0.662 rs149948 ENSG00000280107.1 AL022393.9 -6.2 1.22e-09 5.82e-07 -0.33 -0.28 Parkinson's disease; chr6:28007039 chr6:28170845~28172521:+ LUSC cis rs12908161 1 rs11638290 ENSG00000259728.4 LINC00933 6.2 1.22e-09 5.83e-07 0.36 0.28 Schizophrenia; chr15:84684405 chr15:84570649~84580175:+ LUSC cis rs12908161 0.959 rs34028043 ENSG00000259728.4 LINC00933 6.2 1.22e-09 5.83e-07 0.36 0.28 Schizophrenia; chr15:84688354 chr15:84570649~84580175:+ LUSC cis rs12908161 0.959 rs34784022 ENSG00000259728.4 LINC00933 6.2 1.22e-09 5.83e-07 0.36 0.28 Schizophrenia; chr15:84688675 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs12911736 ENSG00000259728.4 LINC00933 6.2 1.22e-09 5.83e-07 0.36 0.28 Schizophrenia; chr15:84696777 chr15:84570649~84580175:+ LUSC cis rs12908161 0.959 rs12908699 ENSG00000259728.4 LINC00933 6.2 1.22e-09 5.83e-07 0.36 0.28 Schizophrenia; chr15:84697172 chr15:84570649~84580175:+ LUSC cis rs496547 0.686 rs540180 ENSG00000255422.1 AP002954.4 -6.2 1.22e-09 5.84e-07 -0.3 -0.28 Hip minimal joint space width; chr11:118782920 chr11:118704607~118750263:+ LUSC cis rs950169 0.922 rs12910334 ENSG00000259728.4 LINC00933 6.2 1.22e-09 5.84e-07 0.36 0.28 Schizophrenia; chr15:84403620 chr15:84570649~84580175:+ LUSC cis rs67311347 1 rs9842564 ENSG00000223797.4 ENTPD3-AS1 -6.2 1.22e-09 5.85e-07 -0.3 -0.28 Renal cell carcinoma; chr3:40364319 chr3:40313802~40453329:- LUSC cis rs7138300 0.532 rs12833368 ENSG00000257265.1 CTD-2021H9.1 6.2 1.22e-09 5.85e-07 0.31 0.28 Type 2 diabetes; chr12:71135221 chr12:71007773~71032083:- LUSC cis rs13113518 0.783 rs2171618 ENSG00000272969.1 RP11-528I4.2 6.2 1.22e-09 5.86e-07 0.31 0.28 Height; chr4:55564241 chr4:55547112~55547889:+ LUSC cis rs72772090 0.634 rs17401901 ENSG00000248734.2 CTD-2260A17.1 -6.2 1.22e-09 5.86e-07 -0.39 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96756221 chr5:96784777~96785999:+ LUSC cis rs72772090 0.634 rs72773906 ENSG00000248734.2 CTD-2260A17.1 -6.2 1.22e-09 5.86e-07 -0.39 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96756570 chr5:96784777~96785999:+ LUSC cis rs950880 0.71 rs55645612 ENSG00000234389.1 AC007278.3 -6.2 1.22e-09 5.86e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102439201 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs56166614 ENSG00000234389.1 AC007278.3 -6.2 1.22e-09 5.86e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102439636 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs17027179 ENSG00000234389.1 AC007278.3 -6.2 1.22e-09 5.86e-07 -0.3 -0.28 Serum protein levels (sST2); chr2:102440699 chr2:102438713~102440475:+ LUSC cis rs7772486 0.79 rs1832362 ENSG00000235652.6 RP11-545I5.3 6.2 1.22e-09 5.86e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145858819 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs9376968 ENSG00000235652.6 RP11-545I5.3 6.2 1.22e-09 5.86e-07 0.27 0.28 Lobe attachment (rater-scored or self-reported); chr6:145859228 chr6:145799409~145886585:+ LUSC cis rs7617773 0.963 rs12495221 ENSG00000228638.1 FCF1P2 6.2 1.22e-09 5.86e-07 0.3 0.28 Coronary artery disease; chr3:48137688 chr3:48290793~48291375:- LUSC cis rs7267979 0.789 rs1983974 ENSG00000274973.1 RP13-401N8.7 6.2 1.23e-09 5.87e-07 0.28 0.28 Liver enzyme levels (alkaline phosphatase); chr20:25549983 chr20:25845497~25845862:+ LUSC cis rs761746 0.739 rs5998086 ENSG00000236132.1 CTA-440B3.1 -6.2 1.23e-09 5.88e-07 -0.39 -0.28 Intelligence; chr22:31684258 chr22:31816379~31817491:- LUSC cis rs17507216 0.718 rs72751675 ENSG00000255769.6 GOLGA2P10 -6.2 1.23e-09 5.88e-07 -0.43 -0.28 Excessive daytime sleepiness; chr15:82630452 chr15:82472993~82513950:- LUSC cis rs77204473 0.744 rs2306471 ENSG00000254851.1 RP11-109L13.1 6.2 1.23e-09 5.89e-07 0.66 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117145734 chr11:117135528~117138582:+ LUSC cis rs1823913 0.637 rs4853573 ENSG00000227542.1 AC092614.2 -6.2 1.23e-09 5.9e-07 -0.35 -0.27 Obesity-related traits; chr2:191295866 chr2:191229165~191246172:- LUSC cis rs1823913 0.614 rs4853466 ENSG00000227542.1 AC092614.2 -6.2 1.23e-09 5.9e-07 -0.35 -0.27 Obesity-related traits; chr2:191295943 chr2:191229165~191246172:- LUSC cis rs1387259 0.929 rs11168460 ENSG00000240399.1 RP1-228P16.1 6.2 1.23e-09 5.9e-07 0.29 0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48203582 chr12:48054813~48055591:- LUSC cis rs2732480 0.5 rs7297824 ENSG00000240399.1 RP1-228P16.1 6.2 1.23e-09 5.9e-07 0.29 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48204867 chr12:48054813~48055591:- LUSC cis rs6565180 0.507 rs4471699 ENSG00000183604.13 SMG1P5 -6.2 1.23e-09 5.9e-07 -0.3 -0.27 Tonsillectomy; chr16:30308986 chr16:30267553~30335374:- LUSC cis rs17772222 0.682 rs3783889 ENSG00000258789.1 RP11-507K2.3 -6.2 1.23e-09 5.9e-07 -0.3 -0.27 Coronary artery calcification; chr14:88475637 chr14:88551597~88552493:+ LUSC cis rs227275 0.525 rs6533050 ENSG00000230069.3 LRRC37A15P -6.2 1.24e-09 5.91e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102979044 chr4:102727274~102730721:- LUSC cis rs2665103 0.589 rs2134046 ENSG00000278603.1 RP13-608F4.5 6.2 1.24e-09 5.92e-07 0.34 0.27 Intelligence (multi-trait analysis); chr15:82232203 chr15:82472203~82472426:+ LUSC cis rs5753618 0.561 rs714909 ENSG00000236132.1 CTA-440B3.1 -6.2 1.24e-09 5.93e-07 -0.37 -0.27 Colorectal cancer; chr22:31345081 chr22:31816379~31817491:- LUSC cis rs875971 0.862 rs2420174 ENSG00000179406.6 LINC00174 6.2 1.24e-09 5.93e-07 0.3 0.27 Aortic root size; chr7:66180374 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs2420173 ENSG00000179406.6 LINC00174 6.2 1.24e-09 5.93e-07 0.3 0.27 Aortic root size; chr7:66180412 chr7:66376044~66401338:- LUSC cis rs6142102 0.812 rs6059554 ENSG00000275784.1 RP5-1125A11.6 -6.2 1.24e-09 5.94e-07 -0.32 -0.27 Skin pigmentation; chr20:33926286 chr20:33989480~33991818:- LUSC cis rs2404602 0.622 rs11632365 ENSG00000259422.1 RP11-593F23.1 -6.2 1.24e-09 5.94e-07 -0.35 -0.27 Blood metabolite levels; chr15:76846739 chr15:76174891~76181486:- LUSC cis rs6504950 1 rs9896044 ENSG00000275710.1 RP11-257O5.4 6.2 1.24e-09 5.94e-07 0.33 0.27 Breast cancer; chr17:54971181 chr17:54964474~54964679:+ LUSC cis rs12908161 1 rs62021219 ENSG00000259728.4 LINC00933 6.2 1.24e-09 5.94e-07 0.36 0.27 Schizophrenia; chr15:84712928 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs34900908 ENSG00000259728.4 LINC00933 6.2 1.24e-09 5.94e-07 0.36 0.27 Schizophrenia; chr15:84714368 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs35524990 ENSG00000259728.4 LINC00933 6.2 1.24e-09 5.94e-07 0.36 0.27 Schizophrenia; chr15:84714972 chr15:84570649~84580175:+ LUSC cis rs1823913 0.637 rs1470962 ENSG00000227542.1 AC092614.2 -6.2 1.24e-09 5.94e-07 -0.35 -0.27 Obesity-related traits; chr2:191270271 chr2:191229165~191246172:- LUSC cis rs12935418 0.83 rs12928638 ENSG00000261061.1 RP11-303E16.2 -6.2 1.24e-09 5.95e-07 -0.48 -0.27 Mean corpuscular volume; chr16:81016195 chr16:81030770~81031485:+ LUSC cis rs853679 0.769 rs7752448 ENSG00000204709.4 LINC01556 6.2 1.24e-09 5.95e-07 0.53 0.27 Depression; chr6:28333322 chr6:28943877~28944537:+ LUSC cis rs2243480 1 rs383402 ENSG00000226824.5 RP4-756H11.3 6.2 1.25e-09 5.98e-07 0.51 0.27 Diabetic kidney disease; chr7:66121666 chr7:66654538~66669855:+ LUSC cis rs72772090 0.539 rs72775810 ENSG00000248734.2 CTD-2260A17.1 -6.2 1.25e-09 5.98e-07 -0.4 -0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96849604 chr5:96784777~96785999:+ LUSC cis rs1823913 0.637 rs4853584 ENSG00000227542.1 AC092614.2 -6.2 1.25e-09 5.98e-07 -0.35 -0.27 Obesity-related traits; chr2:191310596 chr2:191229165~191246172:- LUSC cis rs3096299 0.606 rs2965946 ENSG00000274627.1 RP11-104N10.2 6.2 1.25e-09 5.98e-07 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89450204 chr16:89516797~89522217:+ LUSC cis rs5770917 1 rs3213445 ENSG00000273272.1 CTA-384D8.34 6.2 1.25e-09 5.98e-07 0.55 0.27 Narcolepsy; chr22:50577409 chr22:50542650~50543011:+ LUSC cis rs7208859 0.673 rs9907197 ENSG00000266490.1 CTD-2349P21.9 6.2 1.25e-09 5.98e-07 0.32 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30691245 chr17:30792372~30792833:+ LUSC cis rs7208859 0.673 rs9915963 ENSG00000266490.1 CTD-2349P21.9 6.2 1.25e-09 5.98e-07 0.32 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30692625 chr17:30792372~30792833:+ LUSC cis rs13113518 0.812 rs1522114 ENSG00000249700.7 SRD5A3-AS1 6.2 1.25e-09 5.99e-07 0.32 0.27 Height; chr4:55489895 chr4:55363971~55395847:- LUSC cis rs394563 0.901 rs448874 ENSG00000231760.4 RP11-350J20.5 6.2 1.25e-09 5.99e-07 0.34 0.27 Dupuytren's disease; chr6:149475831 chr6:149796151~149826294:- LUSC cis rs7772486 0.754 rs702323 ENSG00000235652.6 RP11-545I5.3 -6.2 1.25e-09 5.99e-07 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145687138 chr6:145799409~145886585:+ LUSC cis rs881375 0.9 rs2241003 ENSG00000226752.6 PSMD5-AS1 -6.2 1.26e-09 6e-07 -0.31 -0.27 Rheumatoid arthritis; chr9:120904499 chr9:120824828~120854385:+ LUSC cis rs7267979 1 rs2258563 ENSG00000274973.1 RP13-401N8.7 -6.2 1.26e-09 6.01e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25292799 chr20:25845497~25845862:+ LUSC cis rs4814920 0.756 rs6046400 ENSG00000275142.1 RP5-999L4.2 -6.2 1.26e-09 6.01e-07 -0.47 -0.27 Bipolar disorder (body mass index interaction); chr20:19878482 chr20:19871891~19872284:+ LUSC cis rs875971 0.545 rs7811204 ENSG00000226824.5 RP4-756H11.3 -6.2 1.26e-09 6.01e-07 -0.37 -0.27 Aortic root size; chr7:66387213 chr7:66654538~66669855:+ LUSC cis rs13113518 0.812 rs6830409 ENSG00000249700.7 SRD5A3-AS1 6.2 1.26e-09 6.02e-07 0.32 0.27 Height; chr4:55522229 chr4:55363971~55395847:- LUSC cis rs5760092 0.572 rs738806 ENSG00000235689.1 AP000351.13 6.2 1.26e-09 6.02e-07 0.33 0.27 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:24006305~24008258:- LUSC cis rs10129255 0.536 rs3944157 ENSG00000224373.3 IGHV4-59 6.2 1.26e-09 6.02e-07 0.14 0.27 Kawasaki disease; chr14:106682286 chr14:106627249~106627825:- LUSC cis rs6142102 0.961 rs2268088 ENSG00000275784.1 RP5-1125A11.6 -6.2 1.26e-09 6.03e-07 -0.32 -0.27 Skin pigmentation; chr20:34061258 chr20:33989480~33991818:- LUSC cis rs6142102 0.961 rs2284388 ENSG00000275784.1 RP5-1125A11.6 -6.2 1.26e-09 6.03e-07 -0.32 -0.27 Skin pigmentation; chr20:34067935 chr20:33989480~33991818:- LUSC cis rs9309473 0.615 rs62151562 ENSG00000163016.8 ALMS1P 6.2 1.26e-09 6.03e-07 0.39 0.27 Metabolite levels; chr2:73376412 chr2:73644919~73685576:+ LUSC cis rs7429990 0.864 rs4274776 ENSG00000229759.1 MRPS18AP1 6.2 1.26e-09 6.03e-07 0.28 0.27 Educational attainment (years of education); chr3:47605868 chr3:48256350~48256938:- LUSC cis rs1061377 0.513 rs2711994 ENSG00000249207.1 RP11-360F5.1 6.2 1.26e-09 6.03e-07 0.34 0.27 Uric acid levels; chr4:39148121 chr4:39112677~39126818:- LUSC cis rs6504622 0.721 rs7215903 ENSG00000262879.4 RP11-156P1.3 -6.2 1.27e-09 6.05e-07 -0.29 -0.27 Orofacial clefts; chr17:47097100 chr17:46984045~47100323:- LUSC cis rs227275 0.525 rs223461 ENSG00000230069.3 LRRC37A15P -6.2 1.27e-09 6.05e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102782372 chr4:102727274~102730721:- LUSC cis rs227275 0.554 rs223457 ENSG00000230069.3 LRRC37A15P -6.2 1.27e-09 6.05e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102788506 chr4:102727274~102730721:- LUSC cis rs853679 1 rs2799079 ENSG00000219392.1 RP1-265C24.5 -6.2 1.27e-09 6.05e-07 -0.42 -0.27 Depression; chr6:28267398 chr6:28115628~28116551:+ LUSC cis rs8031584 0.918 rs34331396 ENSG00000260382.1 RP11-540B6.2 6.2 1.27e-09 6.05e-07 0.38 0.27 Huntington's disease progression; chr15:30956533 chr15:30882267~30883231:- LUSC cis rs6860806 0.507 rs272883 ENSG00000233006.5 AC034220.3 6.2 1.27e-09 6.05e-07 0.29 0.27 Breast cancer; chr5:132333005 chr5:132311285~132369916:- LUSC cis rs6860806 0.507 rs272882 ENSG00000233006.5 AC034220.3 6.2 1.27e-09 6.05e-07 0.29 0.27 Breast cancer; chr5:132333468 chr5:132311285~132369916:- LUSC cis rs9903692 0.954 rs9899461 ENSG00000278765.1 RP5-890E16.5 -6.2 1.27e-09 6.06e-07 -0.34 -0.27 Pulse pressure; chr17:48051991 chr17:48066704~48067293:- LUSC cis rs7267979 1 rs2297497 ENSG00000274973.1 RP13-401N8.7 6.2 1.27e-09 6.06e-07 0.28 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25317273 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs12428 ENSG00000274973.1 RP13-401N8.7 6.2 1.27e-09 6.06e-07 0.28 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25453185 chr20:25845497~25845862:+ LUSC cis rs9813712 0.597 rs10934931 ENSG00000228252.7 COL6A4P2 -6.2 1.27e-09 6.07e-07 -0.25 -0.27 Response to amphetamines; chr3:130261365 chr3:130212823~130273806:+ LUSC cis rs9322193 0.884 rs9688699 ENSG00000268592.3 RAET1E-AS1 6.2 1.27e-09 6.07e-07 0.35 0.27 Lung cancer; chr6:149733680 chr6:149863494~149919507:+ LUSC cis rs8040855 0.627 rs4980357 ENSG00000259295.5 CSPG4P12 6.19 1.28e-09 6.09e-07 0.35 0.27 Bulimia nervosa; chr15:85064878 chr15:85191438~85213905:+ LUSC cis rs8040855 0.627 rs4980356 ENSG00000259295.5 CSPG4P12 6.19 1.28e-09 6.09e-07 0.35 0.27 Bulimia nervosa; chr15:85064901 chr15:85191438~85213905:+ LUSC cis rs1823913 0.599 rs1454754 ENSG00000227542.1 AC092614.2 6.19 1.28e-09 6.1e-07 0.36 0.27 Obesity-related traits; chr2:191303562 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs13010441 ENSG00000227542.1 AC092614.2 6.19 1.28e-09 6.1e-07 0.36 0.27 Obesity-related traits; chr2:191303903 chr2:191229165~191246172:- LUSC cis rs9322193 0.887 rs9767113 ENSG00000268592.3 RAET1E-AS1 6.19 1.28e-09 6.11e-07 0.35 0.27 Lung cancer; chr6:149718157 chr6:149863494~149919507:+ LUSC cis rs992157 0.56 rs12987130 ENSG00000261338.2 RP11-378A13.1 -6.19 1.28e-09 6.11e-07 -0.28 -0.27 Colorectal cancer; chr2:218240267 chr2:218255319~218257366:+ LUSC cis rs875971 1 rs55962648 ENSG00000179406.6 LINC00174 6.19 1.28e-09 6.13e-07 0.29 0.27 Aortic root size; chr7:66160764 chr7:66376044~66401338:- LUSC cis rs875971 1 rs2420168 ENSG00000179406.6 LINC00174 6.19 1.28e-09 6.13e-07 0.29 0.27 Aortic root size; chr7:66165644 chr7:66376044~66401338:- LUSC cis rs12908161 1 rs35316992 ENSG00000259728.4 LINC00933 6.19 1.29e-09 6.13e-07 0.36 0.27 Schizophrenia; chr15:84704902 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs4643294 ENSG00000259728.4 LINC00933 6.19 1.29e-09 6.13e-07 0.36 0.27 Schizophrenia; chr15:84707022 chr15:84570649~84580175:+ LUSC cis rs8177376 0.906 rs522486 ENSG00000254905.1 RP11-712L6.7 6.19 1.29e-09 6.14e-07 0.37 0.27 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126190054 chr11:126292922~126294254:- LUSC cis rs2732480 0.577 rs2732486 ENSG00000226413.2 OR8T1P 6.19 1.29e-09 6.15e-07 0.36 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344051 chr12:48442030~48442947:- LUSC cis rs2732480 0.517 rs2634676 ENSG00000226413.2 OR8T1P 6.19 1.29e-09 6.15e-07 0.36 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344453 chr12:48442030~48442947:- LUSC cis rs9322193 0.886 rs9485408 ENSG00000268592.3 RAET1E-AS1 6.19 1.29e-09 6.16e-07 0.35 0.27 Lung cancer; chr6:149618888 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs1080670 ENSG00000268592.3 RAET1E-AS1 6.19 1.29e-09 6.16e-07 0.35 0.27 Lung cancer; chr6:149620161 chr6:149863494~149919507:+ LUSC cis rs9322193 0.886 rs9322198 ENSG00000268592.3 RAET1E-AS1 6.19 1.29e-09 6.16e-07 0.35 0.27 Lung cancer; chr6:149623772 chr6:149863494~149919507:+ LUSC cis rs67311347 1 rs9829800 ENSG00000223797.4 ENTPD3-AS1 6.19 1.29e-09 6.17e-07 0.31 0.27 Renal cell carcinoma; chr3:40402436 chr3:40313802~40453329:- LUSC cis rs8062405 0.755 rs7186573 ENSG00000278665.1 RP11-666O2.4 6.19 1.29e-09 6.17e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576068 chr16:28599241~28601881:- LUSC cis rs1823913 0.538 rs35311234 ENSG00000280083.1 RP11-317J9.1 -6.19 1.3e-09 6.18e-07 -0.32 -0.27 Obesity-related traits; chr2:191316952 chr2:191154118~191156070:- LUSC cis rs10829156 0.741 rs9731044 ENSG00000240291.1 RP11-499P20.2 6.19 1.3e-09 6.19e-07 0.31 0.27 Sudden cardiac arrest; chr10:18605356 chr10:18513115~18545651:- LUSC cis rs853679 0.517 rs9295758 ENSG00000280107.1 AL022393.9 -6.19 1.3e-09 6.2e-07 -0.35 -0.27 Depression; chr6:28152885 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs17774663 ENSG00000280107.1 AL022393.9 -6.19 1.3e-09 6.2e-07 -0.35 -0.27 Depression; chr6:28153120 chr6:28170845~28172521:+ LUSC cis rs9309711 0.643 rs4535074 ENSG00000225234.1 TRAPPC12-AS1 -6.19 1.3e-09 6.2e-07 -0.32 -0.27 Neurofibrillary tangles; chr2:3477866 chr2:3481242~3482409:- LUSC cis rs1198872 0.563 rs1686497 ENSG00000272275.1 RP11-791G15.2 -6.19 1.3e-09 6.2e-07 -0.39 -0.27 Cardiac Troponin-T levels; chr2:10821058 chr2:10767875~10770058:- LUSC cis rs1823913 0.599 rs1823912 ENSG00000280083.1 RP11-317J9.1 -6.19 1.3e-09 6.21e-07 -0.32 -0.27 Obesity-related traits; chr2:191266388 chr2:191154118~191156070:- LUSC cis rs881375 0.933 rs7021206 ENSG00000226752.6 PSMD5-AS1 6.19 1.31e-09 6.22e-07 0.31 0.27 Rheumatoid arthritis; chr9:120921879 chr9:120824828~120854385:+ LUSC cis rs7267979 0.966 rs910996 ENSG00000274973.1 RP13-401N8.7 -6.19 1.31e-09 6.23e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25283560 chr20:25845497~25845862:+ LUSC cis rs496547 0.719 rs476246 ENSG00000255422.1 AP002954.4 6.19 1.31e-09 6.23e-07 0.3 0.27 Hip minimal joint space width; chr11:118747211 chr11:118704607~118750263:+ LUSC cis rs6772849 0.662 rs12494372 ENSG00000242551.2 POU5F1P6 -6.19 1.31e-09 6.24e-07 -0.33 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128682850 chr3:128674735~128677005:- LUSC cis rs67311347 0.868 rs10865895 ENSG00000223797.4 ENTPD3-AS1 6.19 1.31e-09 6.24e-07 0.3 0.27 Renal cell carcinoma; chr3:40337186 chr3:40313802~40453329:- LUSC cis rs2276314 1 rs9956938 ENSG00000278986.1 RP11-723J4.3 -6.19 1.31e-09 6.24e-07 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35987098 chr18:35972151~35973916:+ LUSC cis rs394563 0.967 rs369643 ENSG00000231760.4 RP11-350J20.5 6.19 1.31e-09 6.26e-07 0.34 0.27 Dupuytren's disease; chr6:149478662 chr6:149796151~149826294:- LUSC cis rs1823913 0.599 rs13002286 ENSG00000227542.1 AC092614.2 -6.19 1.31e-09 6.26e-07 -0.35 -0.27 Obesity-related traits; chr2:191285626 chr2:191229165~191246172:- LUSC cis rs11971779 0.68 rs6467837 ENSG00000273391.1 RP11-634H22.1 6.19 1.32e-09 6.26e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139338829 chr7:139359032~139359566:- LUSC cis rs1075232 1 rs72722861 ENSG00000270055.1 CTD-3092A11.2 -6.19 1.32e-09 6.27e-07 -0.58 -0.27 Survival in colorectal cancer (non-distant metastatic); chr15:31412085 chr15:30487963~30490313:+ LUSC cis rs853679 0.517 rs36078605 ENSG00000280107.1 AL022393.9 -6.19 1.32e-09 6.28e-07 -0.34 -0.27 Depression; chr6:28110254 chr6:28170845~28172521:+ LUSC cis rs1134634 0.52 rs73127647 ENSG00000273133.1 RP11-799M12.2 -6.19 1.32e-09 6.28e-07 -0.37 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15639969 chr4:15563698~15564253:- LUSC cis rs2243480 1 rs10807702 ENSG00000226824.5 RP4-756H11.3 -6.19 1.32e-09 6.28e-07 -0.52 -0.27 Diabetic kidney disease; chr7:66302856 chr7:66654538~66669855:+ LUSC cis rs4237845 0.837 rs7954957 ENSG00000257159.1 RP11-58A17.3 6.19 1.32e-09 6.28e-07 0.33 0.27 Intelligence (multi-trait analysis); chr12:57905467 chr12:57967058~57968399:+ LUSC cis rs875971 0.545 rs2279757 ENSG00000226824.5 RP4-756H11.3 -6.19 1.32e-09 6.29e-07 -0.37 -0.27 Aortic root size; chr7:66363676 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs11766183 ENSG00000226824.5 RP4-756H11.3 -6.19 1.32e-09 6.29e-07 -0.37 -0.27 Aortic root size; chr7:66374173 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs1065265 ENSG00000226824.5 RP4-756H11.3 -6.19 1.32e-09 6.29e-07 -0.37 -0.27 Aortic root size; chr7:66376216 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs6460298 ENSG00000237310.1 GS1-124K5.4 6.19 1.32e-09 6.29e-07 0.31 0.27 Aortic root size; chr7:66442783 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs75577046 ENSG00000237310.1 GS1-124K5.4 6.19 1.32e-09 6.29e-07 0.31 0.27 Aortic root size; chr7:66493729 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs3735147 ENSG00000237310.1 GS1-124K5.4 6.19 1.32e-09 6.29e-07 0.31 0.27 Aortic root size; chr7:66505541 chr7:66493706~66495474:+ LUSC cis rs17767294 0.612 rs12332927 ENSG00000219392.1 RP1-265C24.5 -6.19 1.32e-09 6.29e-07 -0.57 -0.27 Parkinson's disease; chr6:27987337 chr6:28115628~28116551:+ LUSC cis rs875971 1 rs11971949 ENSG00000179406.6 LINC00174 6.19 1.32e-09 6.29e-07 0.29 0.27 Aortic root size; chr7:66161027 chr7:66376044~66401338:- LUSC cis rs1823913 0.637 rs4853574 ENSG00000227542.1 AC092614.2 -6.19 1.32e-09 6.3e-07 -0.35 -0.27 Obesity-related traits; chr2:191296113 chr2:191229165~191246172:- LUSC cis rs9322193 0.923 rs3924871 ENSG00000268592.3 RAET1E-AS1 6.19 1.33e-09 6.31e-07 0.35 0.27 Lung cancer; chr6:149662080 chr6:149863494~149919507:+ LUSC cis rs1823913 0.599 rs13020656 ENSG00000280083.1 RP11-317J9.1 -6.19 1.33e-09 6.32e-07 -0.32 -0.27 Obesity-related traits; chr2:191314197 chr2:191154118~191156070:- LUSC cis rs11168351 0.75 rs11168366 ENSG00000240399.1 RP1-228P16.1 -6.19 1.33e-09 6.32e-07 -0.28 -0.27 Bipolar disorder and schizophrenia; chr12:48027990 chr12:48054813~48055591:- LUSC cis rs11159086 0.793 rs10136668 ENSG00000259005.1 RP3-449M8.6 6.19 1.33e-09 6.32e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74492183 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs10139029 ENSG00000259005.1 RP3-449M8.6 6.19 1.33e-09 6.32e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74492284 chr14:74474007~74474864:- LUSC cis rs5753618 0.539 rs4820962 ENSG00000236132.1 CTA-440B3.1 6.19 1.33e-09 6.33e-07 0.37 0.27 Colorectal cancer; chr22:31293965 chr22:31816379~31817491:- LUSC cis rs9322193 0.923 rs9767123 ENSG00000268592.3 RAET1E-AS1 6.19 1.33e-09 6.33e-07 0.35 0.27 Lung cancer; chr6:149660323 chr6:149863494~149919507:+ LUSC cis rs950169 0.887 rs220333 ENSG00000259295.5 CSPG4P12 6.19 1.33e-09 6.34e-07 0.36 0.27 Schizophrenia; chr15:84547902 chr15:85191438~85213905:+ LUSC cis rs7739264 0.829 rs2328436 ENSG00000237404.1 RP3-471C18.2 -6.19 1.33e-09 6.34e-07 -0.31 -0.27 Endometriosis; chr6:19736496 chr6:19689825~19753113:- LUSC cis rs9549367 0.789 rs9549699 ENSG00000269125.1 RP11-98F14.11 -6.19 1.34e-09 6.36e-07 -0.34 -0.27 Platelet distribution width; chr13:113223949 chr13:113165002~113165183:- LUSC cis rs950169 0.58 rs2271431 ENSG00000259728.4 LINC00933 6.19 1.34e-09 6.36e-07 0.35 0.27 Schizophrenia; chr15:84646233 chr15:84570649~84580175:+ LUSC cis rs875971 0.66 rs3764903 ENSG00000237310.1 GS1-124K5.4 -6.19 1.34e-09 6.37e-07 -0.28 -0.27 Aortic root size; chr7:66633495 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs1860470 ENSG00000237310.1 GS1-124K5.4 -6.19 1.34e-09 6.37e-07 -0.28 -0.27 Aortic root size; chr7:66638707 chr7:66493706~66495474:+ LUSC cis rs6504950 1 rs9902687 ENSG00000275710.1 RP11-257O5.4 6.19 1.34e-09 6.37e-07 0.33 0.27 Breast cancer; chr17:54971563 chr17:54964474~54964679:+ LUSC cis rs1134634 0.52 rs3822298 ENSG00000273133.1 RP11-799M12.2 -6.19 1.34e-09 6.37e-07 -0.37 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15554780 chr4:15563698~15564253:- LUSC cis rs7267979 0.789 rs4815429 ENSG00000274973.1 RP13-401N8.7 6.19 1.34e-09 6.37e-07 0.28 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25540975 chr20:25845497~25845862:+ LUSC cis rs2408955 0.522 rs11168408 ENSG00000240399.1 RP1-228P16.1 -6.19 1.34e-09 6.38e-07 -0.28 -0.27 Glycated hemoglobin levels; chr12:48104544 chr12:48054813~48055591:- LUSC cis rs957448 0.904 rs56302978 ENSG00000253175.1 RP11-267M23.6 6.19 1.34e-09 6.39e-07 0.32 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94505883 chr8:94565036~94565715:+ LUSC cis rs9322193 0.962 rs1413655 ENSG00000268592.3 RAET1E-AS1 6.19 1.35e-09 6.4e-07 0.35 0.27 Lung cancer; chr6:149821815 chr6:149863494~149919507:+ LUSC cis rs9322193 0.926 rs9383546 ENSG00000268592.3 RAET1E-AS1 6.19 1.35e-09 6.4e-07 0.35 0.27 Lung cancer; chr6:149822743 chr6:149863494~149919507:+ LUSC cis rs11971779 0.616 rs1862878 ENSG00000273391.1 RP11-634H22.1 6.19 1.35e-09 6.4e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139335168 chr7:139359032~139359566:- LUSC cis rs11155671 0.53 rs7763849 ENSG00000268592.3 RAET1E-AS1 6.19 1.35e-09 6.4e-07 0.36 0.27 Testicular germ cell tumor; chr6:149885244 chr6:149863494~149919507:+ LUSC cis rs7772486 0.686 rs9376956 ENSG00000235652.6 RP11-545I5.3 6.19 1.35e-09 6.41e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145628708 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs6570703 ENSG00000235652.6 RP11-545I5.3 6.19 1.35e-09 6.41e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145635916 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs6570705 ENSG00000235652.6 RP11-545I5.3 6.19 1.35e-09 6.41e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145640065 chr6:145799409~145886585:+ LUSC cis rs7772486 0.658 rs6570706 ENSG00000235652.6 RP11-545I5.3 6.19 1.35e-09 6.41e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145641786 chr6:145799409~145886585:+ LUSC cis rs172166 0.694 rs1150666 ENSG00000219392.1 RP1-265C24.5 -6.18 1.35e-09 6.42e-07 -0.35 -0.27 Cardiac Troponin-T levels; chr6:28156150 chr6:28115628~28116551:+ LUSC cis rs1865760 0.602 rs9467662 ENSG00000272462.2 U91328.19 -6.18 1.35e-09 6.43e-07 -0.3 -0.27 Height; chr6:26021099 chr6:25992662~26001775:+ LUSC cis rs7267979 1 rs6050573 ENSG00000274973.1 RP13-401N8.7 -6.18 1.35e-09 6.43e-07 -0.27 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25385429 chr20:25845497~25845862:+ LUSC cis rs4237845 0.742 rs3751330 ENSG00000257159.1 RP11-58A17.3 6.18 1.35e-09 6.43e-07 0.33 0.27 Intelligence (multi-trait analysis); chr12:57896443 chr12:57967058~57968399:+ LUSC cis rs11971779 0.68 rs6965212 ENSG00000273391.1 RP11-634H22.1 6.18 1.35e-09 6.44e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139341719 chr7:139359032~139359566:- LUSC cis rs9322193 0.962 rs4552 ENSG00000268592.3 RAET1E-AS1 6.18 1.35e-09 6.44e-07 0.35 0.27 Lung cancer; chr6:149811183 chr6:149863494~149919507:+ LUSC cis rs2732480 0.5 rs7315820 ENSG00000240399.1 RP1-228P16.1 6.18 1.35e-09 6.44e-07 0.29 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48205155 chr12:48054813~48055591:- LUSC cis rs4713118 0.513 rs149955 ENSG00000219392.1 RP1-265C24.5 -6.18 1.35e-09 6.44e-07 -0.35 -0.27 Parkinson's disease; chr6:28068447 chr6:28115628~28116551:+ LUSC cis rs4713118 0.662 rs149946 ENSG00000280107.1 AL022393.9 6.18 1.35e-09 6.44e-07 0.34 0.27 Parkinson's disease; chr6:28002253 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9468297 ENSG00000280107.1 AL022393.9 -6.18 1.35e-09 6.44e-07 -0.35 -0.27 Depression; chr6:28151096 chr6:28170845~28172521:+ LUSC cis rs6142102 0.923 rs6059586 ENSG00000275784.1 RP5-1125A11.6 -6.18 1.36e-09 6.44e-07 -0.31 -0.27 Skin pigmentation; chr20:33952695 chr20:33989480~33991818:- LUSC cis rs17023223 0.537 rs12072768 ENSG00000231365.4 RP11-418J17.1 -6.18 1.36e-09 6.45e-07 -0.34 -0.27 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119051295 chr1:119140396~119275973:+ LUSC cis rs13113518 0.812 rs2048564 ENSG00000272969.1 RP11-528I4.2 6.18 1.36e-09 6.46e-07 0.32 0.27 Height; chr4:55407965 chr4:55547112~55547889:+ LUSC cis rs881375 0.678 rs2269060 ENSG00000226752.6 PSMD5-AS1 -6.18 1.36e-09 6.47e-07 -0.3 -0.27 Rheumatoid arthritis; chr9:120921291 chr9:120824828~120854385:+ LUSC cis rs8177376 0.906 rs1613842 ENSG00000254905.1 RP11-712L6.7 6.18 1.37e-09 6.49e-07 0.37 0.27 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126326015 chr11:126292922~126294254:- LUSC cis rs9549367 0.789 rs9577218 ENSG00000269125.1 RP11-98F14.11 -6.18 1.37e-09 6.5e-07 -0.33 -0.27 Platelet distribution width; chr13:113240597 chr13:113165002~113165183:- LUSC cis rs12439619 0.846 rs7496227 ENSG00000276710.3 CSPG4P8 -6.18 1.37e-09 6.5e-07 -0.34 -0.27 Intelligence (multi-trait analysis); chr15:82275241 chr15:82459472~82477258:+ LUSC cis rs6504950 1 rs10468513 ENSG00000275710.1 RP11-257O5.4 6.18 1.37e-09 6.5e-07 0.33 0.27 Breast cancer; chr17:54985542 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs56348638 ENSG00000275710.1 RP11-257O5.4 6.18 1.37e-09 6.5e-07 0.33 0.27 Breast cancer; chr17:54987189 chr17:54964474~54964679:+ LUSC cis rs8062405 0.723 rs12445744 ENSG00000278665.1 RP11-666O2.4 6.18 1.37e-09 6.5e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28577074 chr16:28599241~28601881:- LUSC cis rs8062405 0.755 rs4787455 ENSG00000278665.1 RP11-666O2.4 6.18 1.37e-09 6.5e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28578134 chr16:28599241~28601881:- LUSC cis rs75422866 0.867 rs7304743 ENSG00000257433.4 RP1-197B17.3 -6.18 1.37e-09 6.5e-07 -0.61 -0.27 Pneumonia; chr12:47683658 chr12:47706085~47742294:+ LUSC cis rs6570726 0.846 rs1935616 ENSG00000235652.6 RP11-545I5.3 6.18 1.37e-09 6.5e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145622376 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs9376954 ENSG00000235652.6 RP11-545I5.3 6.18 1.37e-09 6.5e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145622601 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs9399559 ENSG00000235652.6 RP11-545I5.3 6.18 1.37e-09 6.5e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145624642 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs1045820 ENSG00000235652.6 RP11-545I5.3 6.18 1.37e-09 6.5e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145625944 chr6:145799409~145886585:+ LUSC cis rs2834288 0.645 rs2032313 ENSG00000273102.1 AP000569.9 6.18 1.37e-09 6.51e-07 0.29 0.27 Gut microbiota (bacterial taxa); chr21:33981946 chr21:33967101~33968573:- LUSC cis rs14027 0.921 rs7833112 ENSG00000279347.1 RP11-85I17.2 -6.18 1.37e-09 6.51e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119835842 chr8:119838736~119840385:- LUSC cis rs1729407 0.659 rs2542050 ENSG00000254851.1 RP11-109L13.1 -6.18 1.37e-09 6.51e-07 -0.34 -0.27 Apolipoprotein A-IV levels; chr11:116826401 chr11:117135528~117138582:+ LUSC cis rs7772486 0.558 rs2142980 ENSG00000235652.6 RP11-545I5.3 -6.18 1.37e-09 6.51e-07 -0.31 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145759543 chr6:145799409~145886585:+ LUSC cis rs9322193 0.923 rs55993747 ENSG00000268592.3 RAET1E-AS1 6.18 1.37e-09 6.51e-07 0.35 0.27 Lung cancer; chr6:149622016 chr6:149863494~149919507:+ LUSC cis rs1823913 0.599 rs13020656 ENSG00000227542.1 AC092614.2 6.18 1.37e-09 6.52e-07 0.35 0.27 Obesity-related traits; chr2:191314197 chr2:191229165~191246172:- LUSC cis rs7119038 0.509 rs11216956 ENSG00000255422.1 AP002954.4 6.18 1.37e-09 6.52e-07 0.36 0.27 Sjögren's syndrome; chr11:118704617 chr11:118704607~118750263:+ LUSC cis rs11168351 0.927 rs7971880 ENSG00000240399.1 RP1-228P16.1 6.18 1.37e-09 6.52e-07 0.28 0.27 Bipolar disorder and schizophrenia; chr12:47997272 chr12:48054813~48055591:- LUSC cis rs1865760 0.602 rs2157050 ENSG00000272462.2 U91328.19 -6.18 1.37e-09 6.52e-07 -0.3 -0.27 Height; chr6:26020203 chr6:25992662~26001775:+ LUSC cis rs11971779 0.584 rs6962029 ENSG00000273391.1 RP11-634H22.1 6.18 1.37e-09 6.52e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139349973 chr7:139359032~139359566:- LUSC cis rs9309711 0.666 rs4321399 ENSG00000225234.1 TRAPPC12-AS1 -6.18 1.37e-09 6.52e-07 -0.32 -0.27 Neurofibrillary tangles; chr2:3477888 chr2:3481242~3482409:- LUSC cis rs14027 0.921 rs3812463 ENSG00000279347.1 RP11-85I17.2 -6.18 1.37e-09 6.52e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119839860 chr8:119838736~119840385:- LUSC cis rs9322193 0.884 rs10782312 ENSG00000268592.3 RAET1E-AS1 6.18 1.37e-09 6.52e-07 0.35 0.27 Lung cancer; chr6:149622669 chr6:149863494~149919507:+ LUSC cis rs12439619 0.774 rs2867649 ENSG00000276710.3 CSPG4P8 -6.18 1.38e-09 6.54e-07 -0.33 -0.27 Intelligence (multi-trait analysis); chr15:82262331 chr15:82459472~82477258:+ LUSC cis rs12439619 0.846 rs28697264 ENSG00000276710.3 CSPG4P8 -6.18 1.38e-09 6.54e-07 -0.33 -0.27 Intelligence (multi-trait analysis); chr15:82265559 chr15:82459472~82477258:+ LUSC cis rs3750965 0.734 rs11604251 ENSG00000260895.1 RP11-554A11.7 -6.18 1.38e-09 6.57e-07 -0.33 -0.27 Hair color; chr11:69052961 chr11:69103493~69109094:+ LUSC cis rs13113518 1 rs13115828 ENSG00000249700.7 SRD5A3-AS1 6.18 1.38e-09 6.57e-07 0.31 0.27 Height; chr4:55551447 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs13136282 ENSG00000249700.7 SRD5A3-AS1 6.18 1.38e-09 6.57e-07 0.31 0.27 Height; chr4:55551845 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11934897 ENSG00000249700.7 SRD5A3-AS1 6.18 1.38e-09 6.57e-07 0.31 0.27 Height; chr4:55553396 chr4:55363971~55395847:- LUSC cis rs13113518 0.934 rs11932293 ENSG00000249700.7 SRD5A3-AS1 6.18 1.38e-09 6.57e-07 0.31 0.27 Height; chr4:55554025 chr4:55363971~55395847:- LUSC cis rs17772222 0.682 rs28371093 ENSG00000258789.1 RP11-507K2.3 -6.18 1.39e-09 6.58e-07 -0.3 -0.27 Coronary artery calcification; chr14:88486112 chr14:88551597~88552493:+ LUSC cis rs17772222 0.655 rs10150594 ENSG00000258789.1 RP11-507K2.3 -6.18 1.39e-09 6.58e-07 -0.3 -0.27 Coronary artery calcification; chr14:88489613 chr14:88551597~88552493:+ LUSC cis rs5753618 0.561 rs9606831 ENSG00000236132.1 CTA-440B3.1 -6.18 1.39e-09 6.58e-07 -0.37 -0.27 Colorectal cancer; chr22:31336526 chr22:31816379~31817491:- LUSC cis rs875971 0.508 rs10258739 ENSG00000237310.1 GS1-124K5.4 -6.18 1.39e-09 6.6e-07 -0.27 -0.27 Aortic root size; chr7:66597948 chr7:66493706~66495474:+ LUSC cis rs6504950 0.889 rs1156287 ENSG00000275710.1 RP11-257O5.4 -6.18 1.39e-09 6.6e-07 -0.34 -0.27 Breast cancer; chr17:54999438 chr17:54964474~54964679:+ LUSC cis rs28830936 1 rs17676742 ENSG00000250379.1 RP11-23P13.4 6.18 1.39e-09 6.61e-07 0.3 0.27 Diastolic blood pressure; chr15:41610850 chr15:41825099~41827936:- LUSC cis rs6142102 0.58 rs761233 ENSG00000275784.1 RP5-1125A11.6 -6.18 1.4e-09 6.62e-07 -0.3 -0.27 Skin pigmentation; chr20:33981080 chr20:33989480~33991818:- LUSC cis rs6969780 1 rs739734 ENSG00000233429.8 HOTAIRM1 6.18 1.4e-09 6.62e-07 0.53 0.27 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27119786 chr7:27095647~27100265:+ LUSC cis rs1075232 1 rs72722847 ENSG00000270055.1 CTD-3092A11.2 -6.18 1.4e-09 6.62e-07 -0.57 -0.27 Survival in colorectal cancer (non-distant metastatic); chr15:31390143 chr15:30487963~30490313:+ LUSC cis rs853679 0.517 rs9393884 ENSG00000280107.1 AL022393.9 -6.18 1.4e-09 6.63e-07 -0.34 -0.27 Depression; chr6:28079011 chr6:28170845~28172521:+ LUSC cis rs9549367 0.789 rs2316442 ENSG00000269125.1 RP11-98F14.11 -6.18 1.4e-09 6.63e-07 -0.35 -0.27 Platelet distribution width; chr13:113223173 chr13:113165002~113165183:- LUSC cis rs950880 0.71 rs11693955 ENSG00000234389.1 AC007278.3 -6.18 1.4e-09 6.64e-07 -0.3 -0.27 Serum protein levels (sST2); chr2:102412705 chr2:102438713~102440475:+ LUSC cis rs7772486 0.712 rs1292335 ENSG00000235652.6 RP11-545I5.3 6.18 1.4e-09 6.65e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145646741 chr6:145799409~145886585:+ LUSC cis rs227275 0.525 rs5028609 ENSG00000230069.3 LRRC37A15P -6.18 1.4e-09 6.65e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102959294 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs6815540 ENSG00000230069.3 LRRC37A15P -6.18 1.4e-09 6.65e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102959922 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs4698867 ENSG00000230069.3 LRRC37A15P -6.18 1.4e-09 6.65e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102961049 chr4:102727274~102730721:- LUSC cis rs11722779 0.658 rs6533044 ENSG00000230069.3 LRRC37A15P -6.18 1.4e-09 6.65e-07 -0.29 -0.27 Schizophrenia; chr4:102965261 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs7663876 ENSG00000230069.3 LRRC37A15P -6.18 1.4e-09 6.65e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102966174 chr4:102727274~102730721:- LUSC cis rs7208859 0.524 rs11653098 ENSG00000266490.1 CTD-2349P21.9 6.18 1.4e-09 6.65e-07 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30792372~30792833:+ LUSC cis rs1075265 0.87 rs10207537 ENSG00000233266.1 HMGB1P31 6.18 1.4e-09 6.65e-07 0.35 0.27 Chronotype;Morning vs. evening chronotype; chr2:54101700 chr2:54051334~54051760:+ LUSC cis rs5742933 0.597 rs6761923 ENSG00000253559.1 OSGEPL1-AS1 6.18 1.41e-09 6.67e-07 0.34 0.27 Ferritin levels; chr2:189642873 chr2:189762704~189765556:+ LUSC cis rs7772486 0.754 rs6570708 ENSG00000235652.6 RP11-545I5.3 -6.18 1.41e-09 6.68e-07 -0.28 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145668292 chr6:145799409~145886585:+ LUSC cis rs638893 0.636 rs7119702 ENSG00000278376.1 RP11-158I9.8 -6.18 1.41e-09 6.68e-07 -0.37 -0.27 Vitiligo; chr11:118736985 chr11:118791254~118793137:+ LUSC cis rs6772849 0.775 rs12486377 ENSG00000242551.2 POU5F1P6 -6.18 1.41e-09 6.69e-07 -0.33 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128696010 chr3:128674735~128677005:- LUSC cis rs6142102 0.961 rs8123521 ENSG00000275784.1 RP5-1125A11.6 -6.18 1.41e-09 6.69e-07 -0.33 -0.27 Skin pigmentation; chr20:34081079 chr20:33989480~33991818:- LUSC cis rs1075232 1 rs4450360 ENSG00000270055.1 CTD-3092A11.2 -6.18 1.41e-09 6.7e-07 -0.57 -0.27 Survival in colorectal cancer (non-distant metastatic); chr15:31389827 chr15:30487963~30490313:+ LUSC cis rs11971779 0.68 rs4077889 ENSG00000273391.1 RP11-634H22.1 6.18 1.41e-09 6.7e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139349168 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs11980313 ENSG00000273391.1 RP11-634H22.1 6.18 1.41e-09 6.7e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139349897 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6962186 ENSG00000273391.1 RP11-634H22.1 6.18 1.41e-09 6.7e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139350060 chr7:139359032~139359566:- LUSC cis rs6504950 1 rs28558726 ENSG00000275710.1 RP11-257O5.4 6.18 1.42e-09 6.7e-07 0.33 0.27 Breast cancer; chr17:54981315 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9892976 ENSG00000275710.1 RP11-257O5.4 6.18 1.42e-09 6.7e-07 0.33 0.27 Breast cancer; chr17:54982968 chr17:54964474~54964679:+ LUSC cis rs75920871 0.588 rs1815788 ENSG00000254851.1 RP11-109L13.1 6.18 1.42e-09 6.7e-07 0.38 0.27 Subjective well-being; chr11:116964255 chr11:117135528~117138582:+ LUSC cis rs11846409 0.86 rs1974470 ENSG00000274576.2 IGHV2-70 -6.18 1.42e-09 6.71e-07 -0.29 -0.27 Rheumatic heart disease; chr14:106621300 chr14:106770577~106771020:- LUSC cis rs8031584 0.872 rs11634761 ENSG00000260382.1 RP11-540B6.2 6.18 1.42e-09 6.72e-07 0.37 0.27 Huntington's disease progression; chr15:30950970 chr15:30882267~30883231:- LUSC cis rs853679 0.517 rs6922063 ENSG00000280107.1 AL022393.9 -6.18 1.42e-09 6.73e-07 -0.34 -0.27 Depression; chr6:28126588 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs2275508 ENSG00000280107.1 AL022393.9 -6.18 1.42e-09 6.73e-07 -0.34 -0.27 Depression; chr6:28126953 chr6:28170845~28172521:+ LUSC cis rs9322193 0.962 rs6899661 ENSG00000268592.3 RAET1E-AS1 6.18 1.42e-09 6.74e-07 0.34 0.27 Lung cancer; chr6:149818093 chr6:149863494~149919507:+ LUSC cis rs1823913 0.599 rs7598639 ENSG00000280083.1 RP11-317J9.1 -6.18 1.42e-09 6.74e-07 -0.32 -0.27 Obesity-related traits; chr2:191267958 chr2:191154118~191156070:- LUSC cis rs6504622 0.755 rs34038545 ENSG00000262879.4 RP11-156P1.3 -6.18 1.42e-09 6.74e-07 -0.29 -0.27 Orofacial clefts; chr17:47067541 chr17:46984045~47100323:- LUSC cis rs11971779 0.715 rs6943973 ENSG00000273391.1 RP11-634H22.1 6.18 1.42e-09 6.75e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139345147 chr7:139359032~139359566:- LUSC cis rs228614 0.51 rs223453 ENSG00000230069.3 LRRC37A15P -6.18 1.43e-09 6.77e-07 -0.29 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789895 chr4:102727274~102730721:- LUSC cis rs875971 0.83 rs427973 ENSG00000179406.6 LINC00174 -6.18 1.43e-09 6.78e-07 -0.3 -0.27 Aortic root size; chr7:66061661 chr7:66376044~66401338:- LUSC cis rs8059260 0.668 rs74423828 ENSG00000274038.1 RP11-66H6.4 -6.17 1.43e-09 6.79e-07 -0.48 -0.27 Alcohol consumption over the past year; chr16:10975574 chr16:11056556~11057034:+ LUSC cis rs9322193 0.962 rs6903998 ENSG00000268592.3 RAET1E-AS1 6.17 1.43e-09 6.79e-07 0.35 0.27 Lung cancer; chr6:149831357 chr6:149863494~149919507:+ LUSC cis rs875971 0.793 rs460678 ENSG00000179406.6 LINC00174 -6.17 1.44e-09 6.8e-07 -0.3 -0.27 Aortic root size; chr7:66062213 chr7:66376044~66401338:- LUSC cis rs11098499 0.566 rs17051356 ENSG00000250412.1 KLHL2P1 6.17 1.44e-09 6.8e-07 0.35 0.27 Corneal astigmatism; chr4:119664153 chr4:119334329~119378233:+ LUSC cis rs732716 0.853 rs62129349 ENSG00000267769.1 CTB-50L17.9 -6.17 1.44e-09 6.81e-07 -0.29 -0.27 Mean corpuscular volume; chr19:4385662 chr19:4454014~4455286:+ LUSC cis rs732716 0.889 rs11085074 ENSG00000267769.1 CTB-50L17.9 -6.17 1.44e-09 6.81e-07 -0.29 -0.27 Mean corpuscular volume; chr19:4386355 chr19:4454014~4455286:+ LUSC cis rs732716 0.889 rs55637375 ENSG00000267769.1 CTB-50L17.9 -6.17 1.44e-09 6.81e-07 -0.29 -0.27 Mean corpuscular volume; chr19:4386848 chr19:4454014~4455286:+ LUSC cis rs13113518 0.966 rs11942472 ENSG00000249700.7 SRD5A3-AS1 6.17 1.44e-09 6.81e-07 0.32 0.27 Height; chr4:55574959 chr4:55363971~55395847:- LUSC cis rs11089937 0.864 rs5757041 ENSG00000211638.2 IGLV8-61 -6.17 1.44e-09 6.82e-07 -0.25 -0.27 Periodontitis (PAL4Q3); chr22:22140538 chr22:22098700~22099212:+ LUSC cis rs9322193 0.923 rs9479094 ENSG00000268592.3 RAET1E-AS1 6.17 1.44e-09 6.82e-07 0.35 0.27 Lung cancer; chr6:149725083 chr6:149863494~149919507:+ LUSC cis rs9549367 0.826 rs2287249 ENSG00000269125.1 RP11-98F14.11 -6.17 1.45e-09 6.84e-07 -0.34 -0.27 Platelet distribution width; chr13:113235041 chr13:113165002~113165183:- LUSC cis rs13113518 0.812 rs11133385 ENSG00000272969.1 RP11-528I4.2 6.17 1.45e-09 6.84e-07 0.32 0.27 Height; chr4:55460485 chr4:55547112~55547889:+ LUSC cis rs4372836 0.964 rs11683296 ENSG00000226833.4 AC097724.3 -6.17 1.45e-09 6.85e-07 -0.32 -0.27 Body mass index; chr2:28702538 chr2:28708953~28736205:- LUSC cis rs950880 0.677 rs4851585 ENSG00000234389.1 AC007278.3 -6.17 1.45e-09 6.85e-07 -0.3 -0.27 Serum protein levels (sST2); chr2:102446294 chr2:102438713~102440475:+ LUSC cis rs16843372 0.599 rs10016 ENSG00000251491.2 OR7E28P -6.17 1.45e-09 6.85e-07 -0.3 -0.27 Obesity-related traits; chr2:158815930 chr2:158862311~158863285:+ LUSC cis rs875971 0.862 rs11773628 ENSG00000179406.6 LINC00174 6.17 1.45e-09 6.86e-07 0.29 0.27 Aortic root size; chr7:66517644 chr7:66376044~66401338:- LUSC cis rs9322193 0.923 rs9322208 ENSG00000268592.3 RAET1E-AS1 6.17 1.45e-09 6.86e-07 0.35 0.27 Lung cancer; chr6:149658547 chr6:149863494~149919507:+ LUSC cis rs11690935 0.921 rs7355523 ENSG00000228389.1 AC068039.4 6.17 1.45e-09 6.86e-07 0.32 0.27 Schizophrenia; chr2:171887911 chr2:171773482~171775844:+ LUSC cis rs8062405 0.755 rs62034325 ENSG00000278665.1 RP11-666O2.4 6.17 1.45e-09 6.86e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28527319 chr16:28599241~28601881:- LUSC cis rs9322193 0.962 rs3805752 ENSG00000268592.3 RAET1E-AS1 6.17 1.45e-09 6.86e-07 0.35 0.27 Lung cancer; chr6:149795490 chr6:149863494~149919507:+ LUSC cis rs801193 1 rs17566701 ENSG00000236529.1 RP13-254B10.1 6.17 1.45e-09 6.87e-07 0.29 0.27 Aortic root size; chr7:66728196 chr7:65840212~65840596:+ LUSC cis rs66887589 0.807 rs7694483 ENSG00000245958.5 RP11-33B1.1 -6.17 1.45e-09 6.87e-07 -0.26 -0.27 Diastolic blood pressure; chr4:119484774 chr4:119454791~119552025:+ LUSC cis rs875971 0.83 rs587360 ENSG00000237310.1 GS1-124K5.4 6.17 1.45e-09 6.88e-07 0.29 0.27 Aortic root size; chr7:66057711 chr7:66493706~66495474:+ LUSC cis rs1134634 0.52 rs4698403 ENSG00000273133.1 RP11-799M12.2 -6.17 1.46e-09 6.89e-07 -0.37 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15628204 chr4:15563698~15564253:- LUSC cis rs35160687 0.644 rs11676515 ENSG00000273080.1 RP11-301O19.1 -6.17 1.46e-09 6.89e-07 -0.27 -0.27 Night sleep phenotypes; chr2:86268934 chr2:86195590~86196049:+ LUSC cis rs11971779 0.68 rs4732379 ENSG00000273391.1 RP11-634H22.1 6.17 1.46e-09 6.89e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139438068 chr7:139359032~139359566:- LUSC cis rs61270009 0.955 rs895295 ENSG00000247828.6 TMEM161B-AS1 6.17 1.46e-09 6.89e-07 0.32 0.27 Depressive symptoms; chr5:88271529 chr5:88268895~88436685:+ LUSC cis rs61270009 0.913 rs16903040 ENSG00000247828.6 TMEM161B-AS1 6.17 1.46e-09 6.89e-07 0.32 0.27 Depressive symptoms; chr5:88273220 chr5:88268895~88436685:+ LUSC cis rs62388641 0.547 rs4513844 ENSG00000272279.1 RP11-157J24.2 -6.17 1.46e-09 6.89e-07 -0.36 -0.27 Daytime sleep phenotypes; chr6:1551747 chr6:1528364~1528911:- LUSC cis rs875971 0.862 rs4718319 ENSG00000179406.6 LINC00174 6.17 1.46e-09 6.89e-07 0.3 0.27 Aortic root size; chr7:66187797 chr7:66376044~66401338:- LUSC cis rs875971 0.723 rs28391294 ENSG00000179406.6 LINC00174 6.17 1.46e-09 6.89e-07 0.3 0.27 Aortic root size; chr7:66189328 chr7:66376044~66401338:- LUSC cis rs875971 0.83 rs6967708 ENSG00000179406.6 LINC00174 6.17 1.46e-09 6.89e-07 0.3 0.27 Aortic root size; chr7:66192326 chr7:66376044~66401338:- LUSC cis rs875971 0.895 rs7782806 ENSG00000179406.6 LINC00174 6.17 1.46e-09 6.89e-07 0.3 0.27 Aortic root size; chr7:66192910 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs880166 ENSG00000179406.6 LINC00174 6.17 1.46e-09 6.89e-07 0.3 0.27 Aortic root size; chr7:66205775 chr7:66376044~66401338:- LUSC cis rs72772090 0.634 rs10515246 ENSG00000248734.2 CTD-2260A17.1 -6.17 1.46e-09 6.9e-07 -0.39 -0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96763561 chr5:96784777~96785999:+ LUSC cis rs2303759 0.918 rs9749416 ENSG00000268686.1 AC010524.2 -6.17 1.46e-09 6.9e-07 -0.38 -0.27 Multiple sclerosis; chr19:49381748 chr19:49368705~49388081:- LUSC cis rs875971 1 rs11974219 ENSG00000179406.6 LINC00174 6.17 1.46e-09 6.9e-07 0.29 0.27 Aortic root size; chr7:66182423 chr7:66376044~66401338:- LUSC cis rs67311347 1 rs6599094 ENSG00000223797.4 ENTPD3-AS1 6.17 1.46e-09 6.9e-07 0.3 0.27 Renal cell carcinoma; chr3:40358102 chr3:40313802~40453329:- LUSC cis rs14027 0.843 rs6469849 ENSG00000279347.1 RP11-85I17.2 -6.17 1.46e-09 6.91e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119844929 chr8:119838736~119840385:- LUSC cis rs72772090 0.539 rs11747896 ENSG00000248734.2 CTD-2260A17.1 6.17 1.46e-09 6.92e-07 0.4 0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777693 chr5:96784777~96785999:+ LUSC cis rs875971 0.545 rs73148639 ENSG00000237310.1 GS1-124K5.4 6.17 1.47e-09 6.93e-07 0.31 0.27 Aortic root size; chr7:66390342 chr7:66493706~66495474:+ LUSC cis rs2337406 1 rs3858878 ENSG00000254174.1 IGHV1-12 6.17 1.47e-09 6.93e-07 0.27 0.27 Alzheimer's disease (late onset); chr14:106688061 chr14:106122420~106122709:- LUSC cis rs6504950 0.925 rs244317 ENSG00000275710.1 RP11-257O5.4 -6.17 1.47e-09 6.93e-07 -0.34 -0.27 Breast cancer; chr17:55139624 chr17:54964474~54964679:+ LUSC cis rs1075265 0.933 rs7607066 ENSG00000233266.1 HMGB1P31 6.17 1.47e-09 6.95e-07 0.35 0.27 Chronotype;Morning vs. evening chronotype; chr2:54110054 chr2:54051334~54051760:+ LUSC cis rs1823913 0.637 rs6741454 ENSG00000280083.1 RP11-317J9.1 6.17 1.47e-09 6.95e-07 0.32 0.27 Obesity-related traits; chr2:191269520 chr2:191154118~191156070:- LUSC cis rs1823913 0.614 rs6755243 ENSG00000280083.1 RP11-317J9.1 6.17 1.47e-09 6.95e-07 0.32 0.27 Obesity-related traits; chr2:191269810 chr2:191154118~191156070:- LUSC cis rs1823913 0.599 rs17414109 ENSG00000280083.1 RP11-317J9.1 -6.17 1.47e-09 6.96e-07 -0.32 -0.27 Obesity-related traits; chr2:191310675 chr2:191154118~191156070:- LUSC cis rs9322193 0.962 rs4869730 ENSG00000268592.3 RAET1E-AS1 6.17 1.47e-09 6.96e-07 0.35 0.27 Lung cancer; chr6:149808187 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs11155689 ENSG00000268592.3 RAET1E-AS1 6.17 1.47e-09 6.96e-07 0.35 0.27 Lung cancer; chr6:149808470 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs2151913 ENSG00000268592.3 RAET1E-AS1 6.17 1.47e-09 6.96e-07 0.35 0.27 Lung cancer; chr6:149809506 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs933055 ENSG00000268592.3 RAET1E-AS1 6.17 1.47e-09 6.96e-07 0.35 0.27 Lung cancer; chr6:149809701 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs4869731 ENSG00000268592.3 RAET1E-AS1 6.17 1.47e-09 6.96e-07 0.35 0.27 Lung cancer; chr6:149810072 chr6:149863494~149919507:+ LUSC cis rs8177376 0.906 rs1695739 ENSG00000254905.1 RP11-712L6.7 6.17 1.48e-09 6.97e-07 0.37 0.27 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126326280 chr11:126292922~126294254:- LUSC cis rs2153535 0.58 rs1328862 ENSG00000230939.1 RP11-314C16.1 -6.17 1.48e-09 6.99e-07 -0.32 -0.27 Motion sickness; chr6:8526448 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs1928183 ENSG00000230939.1 RP11-314C16.1 -6.17 1.48e-09 6.99e-07 -0.32 -0.27 Motion sickness; chr6:8529785 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6597337 ENSG00000230939.1 RP11-314C16.1 -6.17 1.48e-09 6.99e-07 -0.32 -0.27 Motion sickness; chr6:8531419 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1928184 ENSG00000230939.1 RP11-314C16.1 -6.17 1.48e-09 6.99e-07 -0.32 -0.27 Motion sickness; chr6:8531875 chr6:8784178~8785445:+ LUSC cis rs853679 1 rs853694 ENSG00000204709.4 LINC01556 6.17 1.48e-09 6.99e-07 0.45 0.27 Depression; chr6:28311323 chr6:28943877~28944537:+ LUSC cis rs9322193 0.923 rs57938011 ENSG00000268592.3 RAET1E-AS1 6.17 1.48e-09 7e-07 0.35 0.27 Lung cancer; chr6:149642969 chr6:149863494~149919507:+ LUSC cis rs6671200 0.607 rs3767313 ENSG00000228852.5 RP11-57H12.5 -6.17 1.49e-09 7.01e-07 -0.35 -0.27 Stearic acid (18:0) levels; chr1:95247241 chr1:95243167~95278940:- LUSC cis rs11722779 0.844 rs17033381 ENSG00000230069.3 LRRC37A15P -6.17 1.49e-09 7.05e-07 -0.29 -0.27 Schizophrenia; chr4:102974952 chr4:102727274~102730721:- LUSC cis rs227275 0.556 rs4699045 ENSG00000230069.3 LRRC37A15P -6.17 1.49e-09 7.05e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102977009 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs4596243 ENSG00000230069.3 LRRC37A15P -6.17 1.49e-09 7.05e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102964411 chr4:102727274~102730721:- LUSC cis rs2276314 0.802 rs58906216 ENSG00000278986.1 RP11-723J4.3 -6.17 1.49e-09 7.05e-07 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36050334 chr18:35972151~35973916:+ LUSC cis rs2276314 0.857 rs6507157 ENSG00000278986.1 RP11-723J4.3 -6.17 1.49e-09 7.05e-07 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36051740 chr18:35972151~35973916:+ LUSC cis rs1075265 0.933 rs7573491 ENSG00000233266.1 HMGB1P31 6.17 1.5e-09 7.06e-07 0.35 0.27 Chronotype;Morning vs. evening chronotype; chr2:54115875 chr2:54051334~54051760:+ LUSC cis rs1075265 0.933 rs2042143 ENSG00000233266.1 HMGB1P31 6.17 1.5e-09 7.06e-07 0.35 0.27 Chronotype;Morning vs. evening chronotype; chr2:54116377 chr2:54051334~54051760:+ LUSC cis rs6969780 1 rs6969780 ENSG00000233429.8 HOTAIRM1 6.17 1.5e-09 7.06e-07 0.52 0.27 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27119517 chr7:27095647~27100265:+ LUSC cis rs9322193 0.962 rs9322220 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149782897 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs10214845 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149783124 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9767122 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149783553 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs1413654 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149783956 chr6:149863494~149919507:+ LUSC cis rs9322193 0.683 rs113281309 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149787289 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9688809 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149787920 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9689242 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149787970 chr6:149863494~149919507:+ LUSC cis rs9322193 1 rs9767077 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149788479 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9688938 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149788941 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9688940 ENSG00000268592.3 RAET1E-AS1 6.17 1.5e-09 7.07e-07 0.35 0.27 Lung cancer; chr6:149788977 chr6:149863494~149919507:+ LUSC cis rs6504622 0.702 rs3851799 ENSG00000262879.4 RP11-156P1.3 -6.17 1.5e-09 7.07e-07 -0.28 -0.27 Orofacial clefts; chr17:46989122 chr17:46984045~47100323:- LUSC cis rs6504622 0.667 rs11653589 ENSG00000262879.4 RP11-156P1.3 -6.17 1.5e-09 7.07e-07 -0.28 -0.27 Orofacial clefts; chr17:46990299 chr17:46984045~47100323:- LUSC cis rs78487399 0.808 rs78886764 ENSG00000234936.1 AC010883.5 6.17 1.5e-09 7.07e-07 0.43 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43426360 chr2:43229573~43233394:+ LUSC cis rs1322639 1 rs9689079 ENSG00000261039.2 RP11-417E7.2 6.17 1.5e-09 7.07e-07 0.36 0.27 Pulse pressure; chr6:169187053 chr6:169175304~169182740:- LUSC cis rs78487399 0.71 rs79629200 ENSG00000234936.1 AC010883.5 6.17 1.5e-09 7.07e-07 0.44 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43375793 chr2:43229573~43233394:+ LUSC cis rs78487399 0.71 rs74469180 ENSG00000234936.1 AC010883.5 6.17 1.5e-09 7.07e-07 0.44 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43376228 chr2:43229573~43233394:+ LUSC cis rs78487399 0.71 rs78314405 ENSG00000234936.1 AC010883.5 6.17 1.5e-09 7.07e-07 0.44 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43377602 chr2:43229573~43233394:+ LUSC cis rs6142102 0.961 rs4911146 ENSG00000275784.1 RP5-1125A11.6 -6.17 1.5e-09 7.07e-07 -0.32 -0.27 Skin pigmentation; chr20:34052241 chr20:33989480~33991818:- LUSC cis rs1823913 0.637 rs4853579 ENSG00000227542.1 AC092614.2 -6.17 1.5e-09 7.08e-07 -0.35 -0.27 Obesity-related traits; chr2:191297413 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs12622194 ENSG00000227542.1 AC092614.2 -6.17 1.5e-09 7.08e-07 -0.35 -0.27 Obesity-related traits; chr2:191298680 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs13019567 ENSG00000227542.1 AC092614.2 -6.17 1.5e-09 7.08e-07 -0.35 -0.27 Obesity-related traits; chr2:191298736 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs1947456 ENSG00000227542.1 AC092614.2 -6.17 1.5e-09 7.08e-07 -0.35 -0.27 Obesity-related traits; chr2:191298759 chr2:191229165~191246172:- LUSC cis rs7955901 0.638 rs10879262 ENSG00000257265.1 CTD-2021H9.1 6.17 1.5e-09 7.08e-07 0.31 0.27 Type 2 diabetes; chr12:71128051 chr12:71007773~71032083:- LUSC cis rs9549367 0.789 rs2287250 ENSG00000269125.1 RP11-98F14.11 6.17 1.5e-09 7.08e-07 0.33 0.27 Platelet distribution width; chr13:113235160 chr13:113165002~113165183:- LUSC cis rs17772222 0.637 rs879932 ENSG00000258789.1 RP11-507K2.3 -6.17 1.5e-09 7.09e-07 -0.3 -0.27 Coronary artery calcification; chr14:88479247 chr14:88551597~88552493:+ LUSC cis rs5742933 0.597 rs12471663 ENSG00000253559.1 OSGEPL1-AS1 6.17 1.5e-09 7.09e-07 0.34 0.27 Ferritin levels; chr2:189642372 chr2:189762704~189765556:+ LUSC cis rs67311347 1 rs6801859 ENSG00000223797.4 ENTPD3-AS1 -6.17 1.5e-09 7.1e-07 -0.3 -0.27 Renal cell carcinoma; chr3:40451727 chr3:40313802~40453329:- LUSC cis rs7955901 0.638 rs12367470 ENSG00000257265.1 CTD-2021H9.1 6.17 1.51e-09 7.1e-07 0.31 0.27 Type 2 diabetes; chr12:71129027 chr12:71007773~71032083:- LUSC cis rs7955901 0.638 rs1051334 ENSG00000257265.1 CTD-2021H9.1 6.17 1.51e-09 7.1e-07 0.31 0.27 Type 2 diabetes; chr12:71129354 chr12:71007773~71032083:- LUSC cis rs7955901 0.638 rs11178644 ENSG00000257265.1 CTD-2021H9.1 6.17 1.51e-09 7.1e-07 0.31 0.27 Type 2 diabetes; chr12:71129761 chr12:71007773~71032083:- LUSC cis rs7955901 0.638 rs3844206 ENSG00000257265.1 CTD-2021H9.1 6.17 1.51e-09 7.1e-07 0.31 0.27 Type 2 diabetes; chr12:71130161 chr12:71007773~71032083:- LUSC cis rs8062405 0.755 rs12447461 ENSG00000278665.1 RP11-666O2.4 6.17 1.51e-09 7.1e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28571620 chr16:28599241~28601881:- LUSC cis rs8062405 0.755 rs111693583 ENSG00000278665.1 RP11-666O2.4 6.17 1.51e-09 7.1e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28572289 chr16:28599241~28601881:- LUSC cis rs1320333 0.772 rs17786111 ENSG00000233296.1 AC092159.2 6.17 1.51e-09 7.1e-07 0.46 0.27 Obesity-related traits; chr2:700562 chr2:677186~697371:+ LUSC cis rs17023223 0.537 rs12086 ENSG00000231365.4 RP11-418J17.1 -6.17 1.51e-09 7.11e-07 -0.37 -0.27 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119031237 chr1:119140396~119275973:+ LUSC cis rs2732480 0.5 rs12828309 ENSG00000240399.1 RP1-228P16.1 6.17 1.51e-09 7.11e-07 0.29 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48247377 chr12:48054813~48055591:- LUSC cis rs2028299 0.92 rs12594774 ENSG00000259677.1 RP11-493E3.1 6.17 1.51e-09 7.12e-07 0.36 0.27 Type 2 diabetes; chr15:89863652 chr15:89876540~89877285:+ LUSC cis rs6504622 0.634 rs8068715 ENSG00000262879.4 RP11-156P1.3 -6.17 1.51e-09 7.12e-07 -0.28 -0.27 Orofacial clefts; chr17:46991022 chr17:46984045~47100323:- LUSC cis rs6504622 0.514 rs60611133 ENSG00000262879.4 RP11-156P1.3 -6.17 1.51e-09 7.12e-07 -0.28 -0.27 Orofacial clefts; chr17:46993027 chr17:46984045~47100323:- LUSC cis rs6504622 0.702 rs3851796 ENSG00000262879.4 RP11-156P1.3 -6.17 1.51e-09 7.13e-07 -0.28 -0.27 Orofacial clefts; chr17:46983809 chr17:46984045~47100323:- LUSC cis rs7955901 0.638 rs3851610 ENSG00000257265.1 CTD-2021H9.1 6.17 1.51e-09 7.13e-07 0.31 0.27 Type 2 diabetes; chr12:71126820 chr12:71007773~71032083:- LUSC cis rs7955901 0.638 rs4115678 ENSG00000257265.1 CTD-2021H9.1 6.17 1.51e-09 7.13e-07 0.31 0.27 Type 2 diabetes; chr12:71127057 chr12:71007773~71032083:- LUSC cis rs7955901 0.588 rs11178642 ENSG00000257265.1 CTD-2021H9.1 6.17 1.51e-09 7.13e-07 0.31 0.27 Type 2 diabetes; chr12:71127465 chr12:71007773~71032083:- LUSC cis rs7189233 0.911 rs72801854 ENSG00000279344.1 RP11-44F14.7 6.17 1.51e-09 7.13e-07 0.25 0.27 Intelligence (multi-trait analysis); chr16:53483330 chr16:53478957~53481550:- LUSC cis rs66887589 0.592 rs11731571 ENSG00000249244.1 RP11-548H18.2 6.17 1.51e-09 7.13e-07 0.33 0.27 Diastolic blood pressure; chr4:119300030 chr4:119391831~119395335:- LUSC cis rs6969780 0.778 rs2465276 ENSG00000233429.8 HOTAIRM1 6.17 1.52e-09 7.14e-07 0.54 0.27 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27106098 chr7:27095647~27100265:+ LUSC cis rs6969780 0.778 rs61384251 ENSG00000233429.8 HOTAIRM1 6.17 1.52e-09 7.14e-07 0.54 0.27 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27106583 chr7:27095647~27100265:+ LUSC cis rs2581828 0.646 rs2564944 ENSG00000242142.1 SERBP1P3 6.17 1.52e-09 7.14e-07 0.31 0.27 Crohn's disease; chr3:53114439 chr3:53064283~53065091:- LUSC cis rs7267979 1 rs2257991 ENSG00000274973.1 RP13-401N8.7 6.17 1.52e-09 7.15e-07 0.28 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25289703 chr20:25845497~25845862:+ LUSC cis rs1729407 0.706 rs595049 ENSG00000254851.1 RP11-109L13.1 -6.17 1.52e-09 7.15e-07 -0.34 -0.27 Apolipoprotein A-IV levels; chr11:116828729 chr11:117135528~117138582:+ LUSC cis rs6504950 1 rs12940106 ENSG00000275710.1 RP11-257O5.4 6.17 1.52e-09 7.15e-07 0.34 0.27 Breast cancer; chr17:54990322 chr17:54964474~54964679:+ LUSC cis rs9322193 0.923 rs2297928 ENSG00000268592.3 RAET1E-AS1 6.17 1.52e-09 7.16e-07 0.35 0.27 Lung cancer; chr6:149718584 chr6:149863494~149919507:+ LUSC cis rs853679 1 rs853679 ENSG00000204709.4 LINC01556 6.16 1.52e-09 7.16e-07 0.46 0.27 Depression; chr6:28329086 chr6:28943877~28944537:+ LUSC cis rs853679 1 rs853678 ENSG00000204709.4 LINC01556 6.16 1.52e-09 7.16e-07 0.46 0.27 Depression; chr6:28329536 chr6:28943877~28944537:+ LUSC cis rs4372836 0.796 rs7580078 ENSG00000226833.4 AC097724.3 6.16 1.52e-09 7.16e-07 0.32 0.27 Body mass index; chr2:28774135 chr2:28708953~28736205:- LUSC cis rs957448 0.948 rs11992893 ENSG00000253175.1 RP11-267M23.6 6.16 1.52e-09 7.17e-07 0.32 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94508473 chr8:94565036~94565715:+ LUSC cis rs6504622 0.748 rs7215573 ENSG00000262879.4 RP11-156P1.3 -6.16 1.52e-09 7.18e-07 -0.29 -0.27 Orofacial clefts; chr17:47096887 chr17:46984045~47100323:- LUSC cis rs875971 0.8 rs427557 ENSG00000237310.1 GS1-124K5.4 6.16 1.52e-09 7.18e-07 0.29 0.27 Aortic root size; chr7:66054263 chr7:66493706~66495474:+ LUSC cis rs8062405 0.755 rs4787457 ENSG00000278665.1 RP11-666O2.4 6.16 1.52e-09 7.18e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544079 chr16:28599241~28601881:- LUSC cis rs8062405 0.755 rs4788080 ENSG00000278665.1 RP11-666O2.4 6.16 1.52e-09 7.18e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546760 chr16:28599241~28601881:- LUSC cis rs8062405 0.755 rs4787456 ENSG00000278665.1 RP11-666O2.4 6.16 1.52e-09 7.18e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548252 chr16:28599241~28601881:- LUSC cis rs875971 0.545 rs2279757 ENSG00000237310.1 GS1-124K5.4 6.16 1.52e-09 7.18e-07 0.32 0.27 Aortic root size; chr7:66363676 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs11766183 ENSG00000237310.1 GS1-124K5.4 6.16 1.52e-09 7.18e-07 0.32 0.27 Aortic root size; chr7:66374173 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs1065265 ENSG00000237310.1 GS1-124K5.4 6.16 1.52e-09 7.18e-07 0.32 0.27 Aortic root size; chr7:66376216 chr7:66493706~66495474:+ LUSC cis rs853679 0.517 rs17711344 ENSG00000280107.1 AL022393.9 6.16 1.53e-09 7.19e-07 0.33 0.27 Depression; chr6:28109824 chr6:28170845~28172521:+ LUSC cis rs8177376 0.906 rs240559 ENSG00000254905.1 RP11-712L6.7 6.16 1.53e-09 7.19e-07 0.38 0.27 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126321217 chr11:126292922~126294254:- LUSC cis rs4713118 0.662 rs9393881 ENSG00000280107.1 AL022393.9 -6.16 1.53e-09 7.2e-07 -0.33 -0.27 Parkinson's disease; chr6:28055973 chr6:28170845~28172521:+ LUSC cis rs6907340 0.517 rs9465531 ENSG00000227116.1 RP3-471C18.1 -6.16 1.53e-09 7.2e-07 -0.36 -0.27 Endometriosis; chr6:19798418 chr6:19730427~19734567:- LUSC cis rs227275 0.554 rs223363 ENSG00000230069.3 LRRC37A15P -6.16 1.53e-09 7.2e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102846182 chr4:102727274~102730721:- LUSC cis rs9322193 0.923 rs11155683 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149779341 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9372044 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149780867 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs11155685 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149781649 chr6:149863494~149919507:+ LUSC cis rs9322193 0.632 rs3828700 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149791033 chr6:149863494~149919507:+ LUSC cis rs9322193 0.926 rs3805751 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149791193 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9689269 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149791861 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs62441335 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149792658 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs4816 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149793609 chr6:149863494~149919507:+ LUSC cis rs9322193 0.926 rs952166 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149798774 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs952165 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149798900 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs10872656 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149799444 chr6:149863494~149919507:+ LUSC cis rs9322193 0.926 rs9285525 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149801253 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs6914319 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149806304 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs2095375 ENSG00000268592.3 RAET1E-AS1 6.16 1.53e-09 7.2e-07 0.34 0.27 Lung cancer; chr6:149807037 chr6:149863494~149919507:+ LUSC cis rs6772849 0.93 rs6768344 ENSG00000277250.1 Metazoa_SRP -6.16 1.53e-09 7.21e-07 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128654713 chr3:128673681~128674021:- LUSC cis rs35160687 0.644 rs4832264 ENSG00000273080.1 RP11-301O19.1 -6.16 1.53e-09 7.21e-07 -0.27 -0.27 Night sleep phenotypes; chr2:86259711 chr2:86195590~86196049:+ LUSC cis rs35160687 0.623 rs13005014 ENSG00000273080.1 RP11-301O19.1 -6.16 1.53e-09 7.21e-07 -0.27 -0.27 Night sleep phenotypes; chr2:86260093 chr2:86195590~86196049:+ LUSC cis rs35160687 0.644 rs4832265 ENSG00000273080.1 RP11-301O19.1 -6.16 1.53e-09 7.21e-07 -0.27 -0.27 Night sleep phenotypes; chr2:86261142 chr2:86195590~86196049:+ LUSC cis rs35160687 0.644 rs1863056 ENSG00000273080.1 RP11-301O19.1 -6.16 1.53e-09 7.21e-07 -0.27 -0.27 Night sleep phenotypes; chr2:86264122 chr2:86195590~86196049:+ LUSC cis rs1823913 0.614 rs12616167 ENSG00000227542.1 AC092614.2 -6.16 1.53e-09 7.22e-07 -0.35 -0.27 Obesity-related traits; chr2:191311274 chr2:191229165~191246172:- LUSC cis rs11722779 0.873 rs223346 ENSG00000230069.3 LRRC37A15P -6.16 1.54e-09 7.23e-07 -0.3 -0.27 Schizophrenia; chr4:102859339 chr4:102727274~102730721:- LUSC cis rs6570726 0.905 rs377143 ENSG00000235652.6 RP11-545I5.3 6.16 1.54e-09 7.24e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145513084 chr6:145799409~145886585:+ LUSC cis rs6142102 0.886 rs6059583 ENSG00000275784.1 RP5-1125A11.6 -6.16 1.54e-09 7.25e-07 -0.32 -0.27 Skin pigmentation; chr20:33944308 chr20:33989480~33991818:- LUSC cis rs1075265 0.548 rs2542575 ENSG00000233266.1 HMGB1P31 6.16 1.54e-09 7.25e-07 0.34 0.27 Chronotype;Morning vs. evening chronotype; chr2:53821221 chr2:54051334~54051760:+ LUSC cis rs1075265 0.568 rs2542577 ENSG00000233266.1 HMGB1P31 6.16 1.54e-09 7.25e-07 0.34 0.27 Chronotype;Morning vs. evening chronotype; chr2:53822111 chr2:54051334~54051760:+ LUSC cis rs13113518 0.812 rs12648271 ENSG00000249700.7 SRD5A3-AS1 6.16 1.55e-09 7.27e-07 0.34 0.27 Height; chr4:55501955 chr4:55363971~55395847:- LUSC cis rs1134634 0.52 rs4698408 ENSG00000273133.1 RP11-799M12.2 -6.16 1.55e-09 7.27e-07 -0.37 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15657425 chr4:15563698~15564253:- LUSC cis rs875971 0.83 rs427575 ENSG00000237310.1 GS1-124K5.4 6.16 1.55e-09 7.28e-07 0.29 0.27 Aortic root size; chr7:66054232 chr7:66493706~66495474:+ LUSC cis rs2404602 0.647 rs12914196 ENSG00000259422.1 RP11-593F23.1 -6.16 1.55e-09 7.28e-07 -0.33 -0.27 Blood metabolite levels; chr15:76649020 chr15:76174891~76181486:- LUSC cis rs11971779 0.68 rs7783619 ENSG00000273391.1 RP11-634H22.1 6.16 1.55e-09 7.29e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139376691 chr7:139359032~139359566:- LUSC cis rs1075265 0.655 rs13432632 ENSG00000233266.1 HMGB1P31 6.16 1.55e-09 7.29e-07 0.34 0.27 Chronotype;Morning vs. evening chronotype; chr2:53713586 chr2:54051334~54051760:+ LUSC cis rs2408955 0.522 rs6580650 ENSG00000240399.1 RP1-228P16.1 -6.16 1.56e-09 7.32e-07 -0.28 -0.27 Glycated hemoglobin levels; chr12:48024773 chr12:48054813~48055591:- LUSC cis rs7267979 1 rs2257808 ENSG00000274973.1 RP13-401N8.7 -6.16 1.56e-09 7.34e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25285814 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2257809 ENSG00000274973.1 RP13-401N8.7 -6.16 1.56e-09 7.34e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25285840 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2424700 ENSG00000274973.1 RP13-401N8.7 -6.16 1.56e-09 7.34e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25285877 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs910997 ENSG00000274973.1 RP13-401N8.7 -6.16 1.56e-09 7.34e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25286665 chr20:25845497~25845862:+ LUSC cis rs9322193 0.923 rs9800580 ENSG00000268592.3 RAET1E-AS1 6.16 1.56e-09 7.35e-07 0.34 0.27 Lung cancer; chr6:149632845 chr6:149863494~149919507:+ LUSC cis rs9322193 0.884 rs11155669 ENSG00000268592.3 RAET1E-AS1 6.16 1.56e-09 7.35e-07 0.34 0.27 Lung cancer; chr6:149633501 chr6:149863494~149919507:+ LUSC cis rs9322193 0.887 rs9505824 ENSG00000268592.3 RAET1E-AS1 6.16 1.56e-09 7.35e-07 0.34 0.27 Lung cancer; chr6:149633663 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9505826 ENSG00000268592.3 RAET1E-AS1 6.16 1.56e-09 7.35e-07 0.34 0.27 Lung cancer; chr6:149633912 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs9766886 ENSG00000268592.3 RAET1E-AS1 6.16 1.56e-09 7.35e-07 0.34 0.27 Lung cancer; chr6:149637048 chr6:149863494~149919507:+ LUSC cis rs7429990 0.833 rs6777632 ENSG00000229759.1 MRPS18AP1 -6.16 1.57e-09 7.35e-07 -0.27 -0.27 Educational attainment (years of education); chr3:47748775 chr3:48256350~48256938:- LUSC cis rs1823913 0.637 rs4613316 ENSG00000227542.1 AC092614.2 6.16 1.57e-09 7.36e-07 0.35 0.27 Obesity-related traits; chr2:191326074 chr2:191229165~191246172:- LUSC cis rs7429990 0.864 rs13086149 ENSG00000229759.1 MRPS18AP1 -6.16 1.57e-09 7.36e-07 -0.27 -0.27 Educational attainment (years of education); chr3:47784158 chr3:48256350~48256938:- LUSC cis rs12908161 1 rs17601029 ENSG00000259728.4 LINC00933 6.16 1.57e-09 7.37e-07 0.35 0.27 Schizophrenia; chr15:84804478 chr15:84570649~84580175:+ LUSC cis rs9322193 0.923 rs2342857 ENSG00000268592.3 RAET1E-AS1 6.16 1.57e-09 7.38e-07 0.34 0.27 Lung cancer; chr6:149809537 chr6:149863494~149919507:+ LUSC cis rs8062405 0.755 rs4788078 ENSG00000278665.1 RP11-666O2.4 6.16 1.57e-09 7.38e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548660 chr16:28599241~28601881:- LUSC cis rs7829975 0.623 rs10092965 ENSG00000253893.2 FAM85B -6.16 1.57e-09 7.38e-07 -0.32 -0.27 Mood instability; chr8:8515975 chr8:8167819~8226614:- LUSC cis rs14027 0.921 rs13270831 ENSG00000279347.1 RP11-85I17.2 -6.16 1.57e-09 7.39e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119755071 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs16893113 ENSG00000279347.1 RP11-85I17.2 -6.16 1.57e-09 7.39e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119756447 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs2326377 ENSG00000279347.1 RP11-85I17.2 -6.16 1.57e-09 7.39e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119756696 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs62526565 ENSG00000279347.1 RP11-85I17.2 -6.16 1.57e-09 7.39e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119759301 chr8:119838736~119840385:- LUSC cis rs1322639 0.697 rs12661910 ENSG00000261039.2 RP11-417E7.2 -6.16 1.57e-09 7.39e-07 -0.43 -0.27 Pulse pressure; chr6:169184293 chr6:169175304~169182740:- LUSC cis rs11971779 0.715 rs10265 ENSG00000273391.1 RP11-634H22.1 6.16 1.58e-09 7.4e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139341406 chr7:139359032~139359566:- LUSC cis rs5753618 0.519 rs5997939 ENSG00000236132.1 CTA-440B3.1 6.16 1.58e-09 7.4e-07 0.37 0.27 Colorectal cancer; chr22:31281144 chr22:31816379~31817491:- LUSC cis rs9435732 0.778 rs3738815 ENSG00000235241.1 RP11-108M9.5 6.16 1.58e-09 7.41e-07 0.38 0.27 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:16988207 chr1:16889095~16889602:+ LUSC cis rs6907340 0.517 rs6939160 ENSG00000227116.1 RP3-471C18.1 -6.16 1.58e-09 7.41e-07 -0.36 -0.27 Endometriosis; chr6:19802086 chr6:19730427~19734567:- LUSC cis rs6570726 1 rs374464 ENSG00000235652.6 RP11-545I5.3 6.16 1.58e-09 7.43e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145525543 chr6:145799409~145886585:+ LUSC cis rs6570726 1 rs450076 ENSG00000235652.6 RP11-545I5.3 6.16 1.58e-09 7.43e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145526519 chr6:145799409~145886585:+ LUSC cis rs950169 0.58 rs11630887 ENSG00000259728.4 LINC00933 6.16 1.58e-09 7.43e-07 0.35 0.27 Schizophrenia; chr15:84649784 chr15:84570649~84580175:+ LUSC cis rs66887589 0.934 rs7672519 ENSG00000248280.1 RP11-33B1.2 -6.16 1.58e-09 7.43e-07 -0.3 -0.27 Diastolic blood pressure; chr4:119622957 chr4:119440561~119450157:- LUSC cis rs7211079 0.912 rs4889831 ENSG00000279259.1 RP11-334C17.3 6.16 1.58e-09 7.44e-07 0.32 0.27 Myocardial infarction; chr17:80140854 chr17:80147250~80148596:+ LUSC cis rs9322193 0.962 rs3805753 ENSG00000268592.3 RAET1E-AS1 6.16 1.58e-09 7.44e-07 0.34 0.27 Lung cancer; chr6:149795662 chr6:149863494~149919507:+ LUSC cis rs6860806 0.507 rs272878 ENSG00000233006.5 AC034220.3 -6.16 1.58e-09 7.44e-07 -0.27 -0.27 Breast cancer; chr5:132336076 chr5:132311285~132369916:- LUSC cis rs1061377 1 rs7675782 ENSG00000249685.1 RP11-360F5.3 6.16 1.59e-09 7.44e-07 0.31 0.27 Uric acid levels; chr4:39120048 chr4:39133913~39135608:+ LUSC cis rs61270009 0.955 rs75214722 ENSG00000247828.6 TMEM161B-AS1 6.16 1.59e-09 7.45e-07 0.32 0.27 Depressive symptoms; chr5:88269908 chr5:88268895~88436685:+ LUSC cis rs13113518 0.51 rs6858749 ENSG00000249700.7 SRD5A3-AS1 6.16 1.59e-09 7.45e-07 0.3 0.27 Height; chr4:55424270 chr4:55363971~55395847:- LUSC cis rs801193 0.548 rs2659904 ENSG00000237310.1 GS1-124K5.4 6.16 1.59e-09 7.46e-07 0.29 0.27 Aortic root size; chr7:66713615 chr7:66493706~66495474:+ LUSC cis rs9322193 0.923 rs10782310 ENSG00000268592.3 RAET1E-AS1 6.16 1.59e-09 7.46e-07 0.34 0.27 Lung cancer; chr6:149622458 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs10782311 ENSG00000268592.3 RAET1E-AS1 6.16 1.59e-09 7.46e-07 0.34 0.27 Lung cancer; chr6:149622592 chr6:149863494~149919507:+ LUSC cis rs6142102 0.923 rs2268078 ENSG00000275784.1 RP5-1125A11.6 -6.16 1.59e-09 7.46e-07 -0.32 -0.27 Skin pigmentation; chr20:34008898 chr20:33989480~33991818:- LUSC cis rs66887589 0.934 rs6817317 ENSG00000248280.1 RP11-33B1.2 -6.16 1.59e-09 7.47e-07 -0.3 -0.27 Diastolic blood pressure; chr4:119621672 chr4:119440561~119450157:- LUSC cis rs853679 0.513 rs13437444 ENSG00000204709.4 LINC01556 6.16 1.6e-09 7.49e-07 0.42 0.27 Depression; chr6:28103220 chr6:28943877~28944537:+ LUSC cis rs13113518 1 rs4864549 ENSG00000249700.7 SRD5A3-AS1 6.16 1.6e-09 7.5e-07 0.31 0.27 Height; chr4:55554380 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs4865011 ENSG00000249700.7 SRD5A3-AS1 6.16 1.6e-09 7.5e-07 0.31 0.27 Height; chr4:55554456 chr4:55363971~55395847:- LUSC cis rs228614 0.51 rs6830407 ENSG00000230069.3 LRRC37A15P -6.16 1.6e-09 7.52e-07 -0.29 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102895366 chr4:102727274~102730721:- LUSC cis rs67180937 0.553 rs1498382 ENSG00000272750.1 RP11-378J18.8 6.16 1.6e-09 7.52e-07 0.35 0.27 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222641495 chr1:222658867~222661512:- LUSC cis rs875971 0.545 rs35459055 ENSG00000237310.1 GS1-124K5.4 6.16 1.61e-09 7.54e-07 0.31 0.27 Aortic root size; chr7:66479399 chr7:66493706~66495474:+ LUSC cis rs13113518 0.967 rs12507722 ENSG00000273257.1 RP11-177J6.1 6.15 1.61e-09 7.56e-07 0.35 0.27 Height; chr4:55536421 chr4:55387949~55388271:+ LUSC cis rs13113518 0.967 rs7696832 ENSG00000273257.1 RP11-177J6.1 6.15 1.61e-09 7.56e-07 0.35 0.27 Height; chr4:55537080 chr4:55387949~55388271:+ LUSC cis rs8031584 0.958 rs7168641 ENSG00000260382.1 RP11-540B6.2 6.15 1.61e-09 7.57e-07 0.37 0.27 Huntington's disease progression; chr15:30943249 chr15:30882267~30883231:- LUSC cis rs8031584 0.958 rs35256769 ENSG00000260382.1 RP11-540B6.2 6.15 1.61e-09 7.57e-07 0.37 0.27 Huntington's disease progression; chr15:30945573 chr15:30882267~30883231:- LUSC cis rs8031584 0.958 rs11629793 ENSG00000260382.1 RP11-540B6.2 6.15 1.61e-09 7.57e-07 0.37 0.27 Huntington's disease progression; chr15:30946220 chr15:30882267~30883231:- LUSC cis rs9322193 0.962 rs2151912 ENSG00000268592.3 RAET1E-AS1 6.15 1.62e-09 7.57e-07 0.35 0.27 Lung cancer; chr6:149831772 chr6:149863494~149919507:+ LUSC cis rs4604732 0.631 rs4411161 ENSG00000227135.1 GCSAML-AS1 -6.15 1.62e-09 7.58e-07 -0.4 -0.27 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247469072 chr1:247524679~247526752:- LUSC cis rs6772849 0.896 rs61112519 ENSG00000277250.1 Metazoa_SRP -6.15 1.62e-09 7.58e-07 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128619333 chr3:128673681~128674021:- LUSC cis rs1140227 0.502 rs10789304 ENSG00000235358.1 RP11-399E6.1 6.15 1.62e-09 7.58e-07 0.39 0.27 Intelligence (multi-trait analysis); chr1:41121740 chr1:41242373~41284861:+ LUSC cis rs7772486 0.79 rs1062068 ENSG00000235652.6 RP11-545I5.3 6.15 1.62e-09 7.6e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145886329 chr6:145799409~145886585:+ LUSC cis rs6504950 0.705 rs17745123 ENSG00000275710.1 RP11-257O5.4 6.15 1.62e-09 7.61e-07 0.33 0.27 Breast cancer; chr17:54910871 chr17:54964474~54964679:+ LUSC cis rs783540 0.967 rs17158390 ENSG00000255769.6 GOLGA2P10 6.15 1.62e-09 7.61e-07 0.33 0.27 Schizophrenia; chr15:82624277 chr15:82472993~82513950:- LUSC cis rs783540 0.967 rs2870966 ENSG00000255769.6 GOLGA2P10 6.15 1.62e-09 7.61e-07 0.33 0.27 Schizophrenia; chr15:82626493 chr15:82472993~82513950:- LUSC cis rs1322639 0.806 rs1322640 ENSG00000261039.2 RP11-417E7.2 6.15 1.62e-09 7.61e-07 0.37 0.27 Pulse pressure; chr6:169186792 chr6:169175304~169182740:- LUSC cis rs761746 0.705 rs10154390 ENSG00000236132.1 CTA-440B3.1 -6.15 1.62e-09 7.61e-07 -0.39 -0.27 Intelligence; chr22:31655103 chr22:31816379~31817491:- LUSC cis rs8040855 0.627 rs72757059 ENSG00000259295.5 CSPG4P12 6.15 1.63e-09 7.63e-07 0.35 0.27 Bulimia nervosa; chr15:85059918 chr15:85191438~85213905:+ LUSC cis rs5751168 0.736 rs5751179 ENSG00000211654.2 IGLV5-37 6.15 1.63e-09 7.63e-07 0.36 0.27 Prostate cancer (SNP x SNP interaction); chr22:22499665 chr22:22427540~22428035:+ LUSC cis rs1061377 1 rs2381284 ENSG00000249685.1 RP11-360F5.3 6.15 1.63e-09 7.64e-07 0.31 0.27 Uric acid levels; chr4:39117976 chr4:39133913~39135608:+ LUSC cis rs1075265 0.692 rs805361 ENSG00000233266.1 HMGB1P31 6.15 1.63e-09 7.65e-07 0.33 0.27 Chronotype;Morning vs. evening chronotype; chr2:53938709 chr2:54051334~54051760:+ LUSC cis rs3096299 0.606 rs2965960 ENSG00000274627.1 RP11-104N10.2 6.15 1.64e-09 7.66e-07 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89475387 chr16:89516797~89522217:+ LUSC cis rs9341808 0.905 rs3805903 ENSG00000272129.1 RP11-250B2.6 6.15 1.64e-09 7.66e-07 0.32 0.27 Sitting height ratio; chr6:80266112 chr6:80355424~80356859:+ LUSC cis rs853679 0.517 rs9366715 ENSG00000280107.1 AL022393.9 -6.15 1.64e-09 7.66e-07 -0.34 -0.27 Depression; chr6:28096855 chr6:28170845~28172521:+ LUSC cis rs66887589 0.934 rs2389873 ENSG00000248280.1 RP11-33B1.2 -6.15 1.64e-09 7.67e-07 -0.3 -0.27 Diastolic blood pressure; chr4:119633559 chr4:119440561~119450157:- LUSC cis rs6969780 0.778 rs2465275 ENSG00000233429.8 HOTAIRM1 6.15 1.64e-09 7.68e-07 0.54 0.27 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27105481 chr7:27095647~27100265:+ LUSC cis rs1823913 0.637 rs4853578 ENSG00000227542.1 AC092614.2 6.15 1.64e-09 7.68e-07 0.35 0.27 Obesity-related traits; chr2:191297215 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs4853577 ENSG00000227542.1 AC092614.2 -6.15 1.64e-09 7.68e-07 -0.35 -0.27 Obesity-related traits; chr2:191297118 chr2:191229165~191246172:- LUSC cis rs77204473 0.744 rs114221654 ENSG00000254851.1 RP11-109L13.1 6.15 1.64e-09 7.68e-07 0.68 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117109963 chr11:117135528~117138582:+ LUSC cis rs3096299 0.606 rs4785674 ENSG00000274627.1 RP11-104N10.2 6.15 1.64e-09 7.69e-07 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89470205 chr16:89516797~89522217:+ LUSC cis rs1134634 0.52 rs28528670 ENSG00000273133.1 RP11-799M12.2 -6.15 1.64e-09 7.69e-07 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15591295 chr4:15563698~15564253:- LUSC cis rs8062405 0.755 rs62034358 ENSG00000278665.1 RP11-666O2.4 6.15 1.64e-09 7.7e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576276 chr16:28599241~28601881:- LUSC cis rs8062405 0.755 rs12445823 ENSG00000278665.1 RP11-666O2.4 6.15 1.64e-09 7.7e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576728 chr16:28599241~28601881:- LUSC cis rs6142102 0.961 rs6088355 ENSG00000275784.1 RP5-1125A11.6 -6.15 1.65e-09 7.72e-07 -0.32 -0.27 Skin pigmentation; chr20:33958081 chr20:33989480~33991818:- LUSC cis rs13113518 1 rs13141049 ENSG00000273257.1 RP11-177J6.1 6.15 1.65e-09 7.72e-07 0.35 0.27 Height; chr4:55535489 chr4:55387949~55388271:+ LUSC cis rs6951245 0.744 rs10265758 ENSG00000224079.1 AC091729.7 -6.15 1.65e-09 7.72e-07 -0.43 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1132882 chr7:1074450~1078036:+ LUSC cis rs8177876 0.658 rs2278022 ENSG00000261838.4 RP11-303E16.6 6.15 1.65e-09 7.72e-07 0.66 0.27 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81043216 chr16:81069854~81076598:+ LUSC cis rs4853012 0.941 rs78128123 ENSG00000257800.1 FNBP1P1 6.15 1.65e-09 7.73e-07 0.35 0.27 Gestational age at birth (maternal effect); chr2:74120398 chr2:74120680~74123218:+ LUSC cis rs9322193 0.923 rs9688452 ENSG00000268592.3 RAET1E-AS1 6.15 1.65e-09 7.74e-07 0.35 0.27 Lung cancer; chr6:149658764 chr6:149863494~149919507:+ LUSC cis rs2439831 0.85 rs68079546 ENSG00000249839.1 AC011330.5 -6.15 1.65e-09 7.74e-07 -0.56 -0.27 Lung cancer in ever smokers; chr15:43844759 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs56909447 ENSG00000249839.1 AC011330.5 -6.15 1.65e-09 7.74e-07 -0.56 -0.27 Lung cancer in ever smokers; chr15:43845420 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs28476182 ENSG00000249839.1 AC011330.5 -6.15 1.65e-09 7.74e-07 -0.56 -0.27 Lung cancer in ever smokers; chr15:43847445 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs28696802 ENSG00000249839.1 AC011330.5 -6.15 1.65e-09 7.74e-07 -0.56 -0.27 Lung cancer in ever smokers; chr15:43848197 chr15:43663654~43684339:- LUSC cis rs5753618 0.561 rs2073857 ENSG00000236132.1 CTA-440B3.1 6.15 1.65e-09 7.74e-07 0.37 0.27 Colorectal cancer; chr22:31262295 chr22:31816379~31817491:- LUSC cis rs5753618 0.561 rs737684 ENSG00000236132.1 CTA-440B3.1 6.15 1.65e-09 7.74e-07 0.37 0.27 Colorectal cancer; chr22:31263841 chr22:31816379~31817491:- LUSC cis rs10759883 0.563 rs686048 ENSG00000175611.10 LINC00476 6.15 1.65e-09 7.74e-07 0.32 0.27 Nicotine dependence; chr9:95967100 chr9:95759231~95875977:- LUSC cis rs13113518 1 rs4864547 ENSG00000249700.7 SRD5A3-AS1 6.15 1.65e-09 7.74e-07 0.31 0.27 Height; chr4:55538228 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs34648901 ENSG00000249700.7 SRD5A3-AS1 6.15 1.65e-09 7.74e-07 0.31 0.27 Height; chr4:55541259 chr4:55363971~55395847:- LUSC cis rs2179367 0.632 rs9485384 ENSG00000231760.4 RP11-350J20.5 6.15 1.65e-09 7.74e-07 0.39 0.27 Dupuytren's disease; chr6:149328808 chr6:149796151~149826294:- LUSC cis rs1823913 0.637 rs4853583 ENSG00000280083.1 RP11-317J9.1 6.15 1.65e-09 7.75e-07 0.32 0.27 Obesity-related traits; chr2:191304648 chr2:191154118~191156070:- LUSC cis rs6142102 0.961 rs2235597 ENSG00000275784.1 RP5-1125A11.6 -6.15 1.66e-09 7.75e-07 -0.32 -0.27 Skin pigmentation; chr20:34077808 chr20:33989480~33991818:- LUSC cis rs7267979 0.966 rs2261790 ENSG00000274973.1 RP13-401N8.7 -6.15 1.66e-09 7.75e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25282153 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2261794 ENSG00000274973.1 RP13-401N8.7 -6.15 1.66e-09 7.75e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25282426 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2145126 ENSG00000274973.1 RP13-401N8.7 -6.15 1.66e-09 7.75e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25283012 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2257705 ENSG00000274973.1 RP13-401N8.7 -6.15 1.66e-09 7.75e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25284028 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2227892 ENSG00000274973.1 RP13-401N8.7 -6.15 1.66e-09 7.75e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25284178 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2257712 ENSG00000274973.1 RP13-401N8.7 -6.15 1.66e-09 7.75e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25284274 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2257461 ENSG00000274973.1 RP13-401N8.7 -6.15 1.66e-09 7.75e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25284918 chr20:25845497~25845862:+ LUSC cis rs7772486 0.686 rs9497395 ENSG00000235652.6 RP11-545I5.3 -6.15 1.66e-09 7.76e-07 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145692456 chr6:145799409~145886585:+ LUSC cis rs7246657 0.943 rs1035479 ENSG00000276846.1 CTD-3220F14.3 -6.15 1.66e-09 7.76e-07 -0.41 -0.27 Coronary artery calcification; chr19:37402398 chr19:37314868~37315620:- LUSC cis rs67180937 0.553 rs2088514 ENSG00000272750.1 RP11-378J18.8 -6.15 1.66e-09 7.77e-07 -0.34 -0.27 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222658030 chr1:222658867~222661512:- LUSC cis rs17772222 0.682 rs1864744 ENSG00000258789.1 RP11-507K2.3 6.15 1.66e-09 7.77e-07 0.31 0.27 Coronary artery calcification; chr14:88484662 chr14:88551597~88552493:+ LUSC cis rs66887589 0.774 rs9307477 ENSG00000245958.5 RP11-33B1.1 -6.15 1.66e-09 7.78e-07 -0.26 -0.27 Diastolic blood pressure; chr4:119500654 chr4:119454791~119552025:+ LUSC cis rs6700559 0.679 rs7520407 ENSG00000260088.1 RP11-92G12.3 6.15 1.66e-09 7.78e-07 0.34 0.27 Coronary artery disease; chr1:200686600 chr1:200669507~200694250:+ LUSC cis rs6700559 0.679 rs12076946 ENSG00000260088.1 RP11-92G12.3 6.15 1.66e-09 7.78e-07 0.34 0.27 Coronary artery disease; chr1:200693707 chr1:200669507~200694250:+ LUSC cis rs9545047 0.604 rs1324870 ENSG00000227676.3 LINC01068 -6.15 1.66e-09 7.79e-07 -0.33 -0.27 Schizophrenia; chr13:79297911 chr13:79566727~79571436:+ LUSC cis rs1061377 1 rs13182 ENSG00000249685.1 RP11-360F5.3 6.15 1.66e-09 7.79e-07 0.31 0.27 Uric acid levels; chr4:39121293 chr4:39133913~39135608:+ LUSC cis rs9549367 0.789 rs7999579 ENSG00000269125.1 RP11-98F14.11 -6.15 1.67e-09 7.79e-07 -0.34 -0.27 Platelet distribution width; chr13:113225043 chr13:113165002~113165183:- LUSC cis rs9549367 0.789 rs6577035 ENSG00000269125.1 RP11-98F14.11 -6.15 1.67e-09 7.79e-07 -0.34 -0.27 Platelet distribution width; chr13:113225683 chr13:113165002~113165183:- LUSC cis rs2028299 0.92 rs8027198 ENSG00000259677.1 RP11-493E3.1 6.15 1.67e-09 7.8e-07 0.35 0.27 Type 2 diabetes; chr15:89883457 chr15:89876540~89877285:+ LUSC cis rs73173548 0.502 rs34969608 ENSG00000247828.6 TMEM161B-AS1 6.15 1.67e-09 7.8e-07 0.33 0.27 Macular telangiectasia type 2; chr5:88448606 chr5:88268895~88436685:+ LUSC cis rs1134634 0.52 rs28419165 ENSG00000273133.1 RP11-799M12.2 -6.15 1.67e-09 7.8e-07 -0.37 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15587722 chr4:15563698~15564253:- LUSC cis rs7487637 0.529 rs11168244 ENSG00000276691.1 RP5-1057I20.5 6.15 1.67e-09 7.81e-07 0.32 0.27 Mononucleosis; chr12:47809158 chr12:47788426~47788971:+ LUSC cis rs1134634 0.52 rs28522268 ENSG00000273133.1 RP11-799M12.2 -6.15 1.67e-09 7.82e-07 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15601844 chr4:15563698~15564253:- LUSC cis rs6570726 0.791 rs9403729 ENSG00000235652.6 RP11-545I5.3 6.15 1.67e-09 7.82e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145585871 chr6:145799409~145886585:+ LUSC cis rs113835537 0.529 rs3179961 ENSG00000255517.5 CTD-3074O7.5 -6.15 1.68e-09 7.87e-07 -0.31 -0.27 Airway imaging phenotypes; chr11:66476983 chr11:66473490~66480233:- LUSC cis rs61270009 0.955 rs10942528 ENSG00000247828.6 TMEM161B-AS1 6.15 1.68e-09 7.87e-07 0.32 0.27 Depressive symptoms; chr5:88314098 chr5:88268895~88436685:+ LUSC cis rs61270009 0.913 rs13190179 ENSG00000247828.6 TMEM161B-AS1 6.15 1.68e-09 7.87e-07 0.32 0.27 Depressive symptoms; chr5:88314755 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs11738675 ENSG00000247828.6 TMEM161B-AS1 6.15 1.68e-09 7.87e-07 0.32 0.27 Depressive symptoms; chr5:88315360 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs60331678 ENSG00000247828.6 TMEM161B-AS1 6.15 1.68e-09 7.87e-07 0.32 0.27 Depressive symptoms; chr5:88315547 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs10462333 ENSG00000247828.6 TMEM161B-AS1 6.15 1.68e-09 7.87e-07 0.32 0.27 Depressive symptoms; chr5:88315871 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs6872897 ENSG00000247828.6 TMEM161B-AS1 6.15 1.68e-09 7.87e-07 0.32 0.27 Depressive symptoms; chr5:88322248 chr5:88268895~88436685:+ LUSC cis rs61270009 0.908 rs16903077 ENSG00000247828.6 TMEM161B-AS1 6.15 1.68e-09 7.87e-07 0.32 0.27 Depressive symptoms; chr5:88323008 chr5:88268895~88436685:+ LUSC cis rs13113518 0.812 rs12505880 ENSG00000272969.1 RP11-528I4.2 6.15 1.68e-09 7.88e-07 0.31 0.27 Height; chr4:55440988 chr4:55547112~55547889:+ LUSC cis rs9322193 0.923 rs9322197 ENSG00000268592.3 RAET1E-AS1 6.15 1.68e-09 7.88e-07 0.34 0.27 Lung cancer; chr6:149622577 chr6:149863494~149919507:+ LUSC cis rs11846409 0.872 rs74091715 ENSG00000274576.2 IGHV2-70 -6.15 1.69e-09 7.88e-07 -0.3 -0.27 Rheumatic heart disease; chr14:106637731 chr14:106770577~106771020:- LUSC cis rs17772222 0.682 rs8017689 ENSG00000258789.1 RP11-507K2.3 -6.15 1.69e-09 7.88e-07 -0.3 -0.27 Coronary artery calcification; chr14:88483442 chr14:88551597~88552493:+ LUSC cis rs1134634 0.52 rs10022610 ENSG00000273133.1 RP11-799M12.2 -6.15 1.69e-09 7.89e-07 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15635864 chr4:15563698~15564253:- LUSC cis rs7267979 1 rs6050559 ENSG00000274973.1 RP13-401N8.7 -6.15 1.69e-09 7.9e-07 -0.27 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25349279 chr20:25845497~25845862:+ LUSC cis rs11089937 0.568 rs5756988 ENSG00000211638.2 IGLV8-61 6.15 1.69e-09 7.9e-07 0.29 0.27 Periodontitis (PAL4Q3); chr22:22132397 chr22:22098700~22099212:+ LUSC cis rs875971 1 rs11974264 ENSG00000179406.6 LINC00174 6.15 1.69e-09 7.91e-07 0.29 0.27 Aortic root size; chr7:66182595 chr7:66376044~66401338:- LUSC cis rs875971 1 rs1540651 ENSG00000179406.6 LINC00174 6.15 1.69e-09 7.91e-07 0.29 0.27 Aortic root size; chr7:66185134 chr7:66376044~66401338:- LUSC cis rs1823913 0.614 rs11693878 ENSG00000227542.1 AC092614.2 -6.15 1.69e-09 7.91e-07 -0.35 -0.27 Obesity-related traits; chr2:191299399 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs10931494 ENSG00000227542.1 AC092614.2 -6.15 1.69e-09 7.91e-07 -0.35 -0.27 Obesity-related traits; chr2:191299442 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs10931495 ENSG00000227542.1 AC092614.2 -6.15 1.69e-09 7.91e-07 -0.35 -0.27 Obesity-related traits; chr2:191299447 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs12623156 ENSG00000227542.1 AC092614.2 -6.15 1.69e-09 7.91e-07 -0.35 -0.27 Obesity-related traits; chr2:191299661 chr2:191229165~191246172:- LUSC cis rs1061377 1 rs9990742 ENSG00000249685.1 RP11-360F5.3 6.15 1.69e-09 7.91e-07 0.31 0.27 Uric acid levels; chr4:39119794 chr4:39133913~39135608:+ LUSC cis rs227275 0.525 rs4623004 ENSG00000230069.3 LRRC37A15P -6.15 1.69e-09 7.91e-07 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:103000141 chr4:102727274~102730721:- LUSC cis rs1134634 0.52 rs872678 ENSG00000273133.1 RP11-799M12.2 -6.15 1.69e-09 7.92e-07 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15654075 chr4:15563698~15564253:- LUSC cis rs13113518 0.683 rs9761521 ENSG00000273257.1 RP11-177J6.1 6.15 1.69e-09 7.92e-07 0.34 0.27 Height; chr4:55363436 chr4:55387949~55388271:+ LUSC cis rs2283792 0.764 rs2298432 ENSG00000228050.1 TOP3BP1 6.15 1.69e-09 7.92e-07 0.32 0.27 Multiple sclerosis; chr22:21768900 chr22:22223187~22224566:- LUSC cis rs35160687 0.644 rs57270703 ENSG00000273080.1 RP11-301O19.1 -6.15 1.69e-09 7.92e-07 -0.26 -0.27 Night sleep phenotypes; chr2:86289750 chr2:86195590~86196049:+ LUSC cis rs35160687 0.644 rs2113615 ENSG00000273080.1 RP11-301O19.1 -6.15 1.69e-09 7.92e-07 -0.26 -0.27 Night sleep phenotypes; chr2:86290479 chr2:86195590~86196049:+ LUSC cis rs5753618 0.561 rs4141404 ENSG00000236132.1 CTA-440B3.1 6.15 1.7e-09 7.92e-07 0.37 0.27 Colorectal cancer; chr22:31279199 chr22:31816379~31817491:- LUSC cis rs5753618 0.561 rs1858821 ENSG00000236132.1 CTA-440B3.1 6.15 1.7e-09 7.92e-07 0.37 0.27 Colorectal cancer; chr22:31280468 chr22:31816379~31817491:- LUSC cis rs496547 0.686 rs591756 ENSG00000255422.1 AP002954.4 -6.15 1.7e-09 7.92e-07 -0.29 -0.27 Hip minimal joint space width; chr11:118808172 chr11:118704607~118750263:+ LUSC cis rs875971 0.545 rs6969224 ENSG00000226824.5 RP4-756H11.3 -6.15 1.7e-09 7.93e-07 -0.37 -0.27 Aortic root size; chr7:66370011 chr7:66654538~66669855:+ LUSC cis rs5753618 0.561 rs2078803 ENSG00000236132.1 CTA-440B3.1 6.15 1.7e-09 7.93e-07 0.37 0.27 Colorectal cancer; chr22:31256866 chr22:31816379~31817491:- LUSC cis rs11722779 0.935 rs6533046 ENSG00000230069.3 LRRC37A15P -6.15 1.7e-09 7.94e-07 -0.29 -0.27 Schizophrenia; chr4:102965917 chr4:102727274~102730721:- LUSC cis rs2337406 0.587 rs2583291 ENSG00000274576.2 IGHV2-70 6.15 1.7e-09 7.94e-07 0.29 0.27 Alzheimer's disease (late onset); chr14:106649293 chr14:106770577~106771020:- LUSC cis rs14027 0.921 rs7813651 ENSG00000279347.1 RP11-85I17.2 -6.15 1.7e-09 7.94e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119839119 chr8:119838736~119840385:- LUSC cis rs14027 0.921 rs35496588 ENSG00000279347.1 RP11-85I17.2 6.15 1.7e-09 7.94e-07 0.25 0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119842461 chr8:119838736~119840385:- LUSC cis rs10246939 0.553 rs34894166 ENSG00000228775.6 WEE2-AS1 6.15 1.7e-09 7.95e-07 0.32 0.27 Bitter taste perception; chr7:141852158 chr7:141704338~141738346:- LUSC cis rs10829156 0.898 rs10741120 ENSG00000240291.1 RP11-499P20.2 6.15 1.7e-09 7.96e-07 0.3 0.27 Sudden cardiac arrest; chr10:18641063 chr10:18513115~18545651:- LUSC cis rs77204473 0.744 rs12273536 ENSG00000254851.1 RP11-109L13.1 6.15 1.7e-09 7.96e-07 0.63 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117040255 chr11:117135528~117138582:+ LUSC cis rs10829156 0.796 rs6482567 ENSG00000240291.1 RP11-499P20.2 6.15 1.7e-09 7.96e-07 0.3 0.27 Sudden cardiac arrest; chr10:18625860 chr10:18513115~18545651:- LUSC cis rs881375 0.934 rs1468671 ENSG00000226752.6 PSMD5-AS1 -6.15 1.71e-09 7.97e-07 -0.32 -0.27 Rheumatoid arthritis; chr9:120895224 chr9:120824828~120854385:+ LUSC cis rs2337406 0.85 rs11849578 ENSG00000254174.1 IGHV1-12 6.15 1.71e-09 7.97e-07 0.3 0.27 Alzheimer's disease (late onset); chr14:106670302 chr14:106122420~106122709:- LUSC cis rs11846409 0.872 rs2956482 ENSG00000274576.2 IGHV2-70 6.14 1.71e-09 7.99e-07 0.28 0.27 Rheumatic heart disease; chr14:106630013 chr14:106770577~106771020:- LUSC cis rs8031584 0.918 rs35396566 ENSG00000260382.1 RP11-540B6.2 6.14 1.71e-09 8e-07 0.38 0.27 Huntington's disease progression; chr15:30970854 chr15:30882267~30883231:- LUSC cis rs9326248 0.581 rs4938331 ENSG00000280143.1 AP000892.6 6.14 1.71e-09 8e-07 0.28 0.27 Blood protein levels; chr11:117059966 chr11:117204967~117210292:+ LUSC cis rs9326248 0.51 rs4938332 ENSG00000280143.1 AP000892.6 6.14 1.71e-09 8e-07 0.28 0.27 Blood protein levels; chr11:117060082 chr11:117204967~117210292:+ LUSC cis rs9326248 0.559 rs4938334 ENSG00000280143.1 AP000892.6 6.14 1.71e-09 8e-07 0.28 0.27 Blood protein levels; chr11:117060326 chr11:117204967~117210292:+ LUSC cis rs9326248 0.581 rs6589590 ENSG00000280143.1 AP000892.6 6.14 1.71e-09 8e-07 0.28 0.27 Blood protein levels; chr11:117065365 chr11:117204967~117210292:+ LUSC cis rs992157 0.764 rs4672886 ENSG00000261338.2 RP11-378A13.1 -6.14 1.72e-09 8.01e-07 -0.29 -0.27 Colorectal cancer; chr2:218320822 chr2:218255319~218257366:+ LUSC cis rs7772486 0.686 rs9497380 ENSG00000235652.6 RP11-545I5.3 6.14 1.72e-09 8.02e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145634169 chr6:145799409~145886585:+ LUSC cis rs7267979 0.816 rs6037158 ENSG00000274973.1 RP13-401N8.7 -6.14 1.72e-09 8.02e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25614830 chr20:25845497~25845862:+ LUSC cis rs801193 1 rs2659915 ENSG00000237310.1 GS1-124K5.4 6.14 1.72e-09 8.03e-07 0.27 0.27 Aortic root size; chr7:66688114 chr7:66493706~66495474:+ LUSC cis rs13177755 1 rs13177755 ENSG00000247828.6 TMEM161B-AS1 6.14 1.72e-09 8.03e-07 0.32 0.27 Depressive symptoms (multi-trait analysis); chr5:88296420 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs13159835 ENSG00000247828.6 TMEM161B-AS1 6.14 1.72e-09 8.03e-07 0.32 0.27 Depressive symptoms; chr5:88305576 chr5:88268895~88436685:+ LUSC cis rs9549367 0.789 rs12584981 ENSG00000269125.1 RP11-98F14.11 -6.14 1.72e-09 8.04e-07 -0.34 -0.27 Platelet distribution width; chr13:113226871 chr13:113165002~113165183:- LUSC cis rs13113518 0.783 rs34534635 ENSG00000272969.1 RP11-528I4.2 6.14 1.72e-09 8.04e-07 0.31 0.27 Height; chr4:55573424 chr4:55547112~55547889:+ LUSC cis rs5770917 1 rs1056964 ENSG00000273272.1 CTA-384D8.34 6.14 1.72e-09 8.04e-07 0.53 0.27 Narcolepsy; chr22:50579047 chr22:50542650~50543011:+ LUSC cis rs9545047 0.604 rs9565487 ENSG00000227676.3 LINC01068 -6.14 1.72e-09 8.05e-07 -0.33 -0.27 Schizophrenia; chr13:79332742 chr13:79566727~79571436:+ LUSC cis rs35160687 0.644 rs4832272 ENSG00000273080.1 RP11-301O19.1 -6.14 1.73e-09 8.06e-07 -0.26 -0.27 Night sleep phenotypes; chr2:86289088 chr2:86195590~86196049:+ LUSC cis rs61270009 0.955 rs4916897 ENSG00000247828.6 TMEM161B-AS1 6.14 1.73e-09 8.06e-07 0.31 0.27 Depressive symptoms; chr5:88285771 chr5:88268895~88436685:+ LUSC cis rs1061377 0.965 rs3733275 ENSG00000249685.1 RP11-360F5.3 6.14 1.73e-09 8.07e-07 0.31 0.27 Uric acid levels; chr4:39121077 chr4:39133913~39135608:+ LUSC cis rs7267979 0.932 rs6132848 ENSG00000274973.1 RP13-401N8.7 -6.14 1.73e-09 8.07e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25581009 chr20:25845497~25845862:+ LUSC cis rs6504950 1 rs8082471 ENSG00000275710.1 RP11-257O5.4 6.14 1.73e-09 8.09e-07 0.33 0.27 Breast cancer; chr17:54990632 chr17:54964474~54964679:+ LUSC cis rs11098499 0.863 rs1010739 ENSG00000250412.1 KLHL2P1 6.14 1.74e-09 8.09e-07 0.34 0.27 Corneal astigmatism; chr4:119542316 chr4:119334329~119378233:+ LUSC cis rs2732480 0.577 rs2732481 ENSG00000226413.2 OR8T1P 6.14 1.74e-09 8.1e-07 0.36 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343202 chr12:48442030~48442947:- LUSC cis rs2732480 0.557 rs2732484 ENSG00000226413.2 OR8T1P 6.14 1.74e-09 8.1e-07 0.36 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343462 chr12:48442030~48442947:- LUSC cis rs2439831 1 rs7173487 ENSG00000249839.1 AC011330.5 -6.14 1.74e-09 8.11e-07 -0.52 -0.27 Lung cancer in ever smokers; chr15:43458041 chr15:43663654~43684339:- LUSC cis rs10759883 0.539 rs684455 ENSG00000175611.10 LINC00476 6.14 1.74e-09 8.11e-07 0.32 0.27 Nicotine dependence; chr9:95964061 chr9:95759231~95875977:- LUSC cis rs73173548 0.502 rs6885165 ENSG00000247828.6 TMEM161B-AS1 6.14 1.74e-09 8.12e-07 0.32 0.27 Macular telangiectasia type 2; chr5:88449705 chr5:88268895~88436685:+ LUSC cis rs2276314 0.857 rs8097597 ENSG00000278986.1 RP11-723J4.3 -6.14 1.74e-09 8.12e-07 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36039485 chr18:35972151~35973916:+ LUSC cis rs11603023 0.874 rs577396 ENSG00000255422.1 AP002954.4 -6.14 1.74e-09 8.12e-07 -0.31 -0.27 Cholesterol, total; chr11:118628753 chr11:118704607~118750263:+ LUSC cis rs11603023 0.874 rs11216934 ENSG00000255422.1 AP002954.4 -6.14 1.74e-09 8.12e-07 -0.31 -0.27 Cholesterol, total; chr11:118630742 chr11:118704607~118750263:+ LUSC cis rs496547 0.654 rs688161 ENSG00000255422.1 AP002954.4 -6.14 1.74e-09 8.12e-07 -0.29 -0.27 Hip minimal joint space width; chr11:118807001 chr11:118704607~118750263:+ LUSC cis rs67311347 1 rs11715214 ENSG00000223797.4 ENTPD3-AS1 6.14 1.74e-09 8.13e-07 0.31 0.27 Renal cell carcinoma; chr3:40361513 chr3:40313802~40453329:- LUSC cis rs67311347 1 rs9860162 ENSG00000223797.4 ENTPD3-AS1 6.14 1.74e-09 8.13e-07 0.31 0.27 Renal cell carcinoma; chr3:40362384 chr3:40313802~40453329:- LUSC cis rs5751168 0.646 rs362139 ENSG00000211654.2 IGLV5-37 6.14 1.74e-09 8.14e-07 0.36 0.27 Prostate cancer (SNP x SNP interaction); chr22:22507208 chr22:22427540~22428035:+ LUSC cis rs8031584 0.958 rs61997079 ENSG00000260382.1 RP11-540B6.2 6.14 1.74e-09 8.14e-07 0.37 0.27 Huntington's disease progression; chr15:30946068 chr15:30882267~30883231:- LUSC cis rs13113518 0.678 rs7663650 ENSG00000273257.1 RP11-177J6.1 -6.14 1.75e-09 8.14e-07 -0.33 -0.27 Height; chr4:55364952 chr4:55387949~55388271:+ LUSC cis rs1012068 0.924 rs5994449 ENSG00000236132.1 CTA-440B3.1 -6.14 1.75e-09 8.15e-07 -0.37 -0.27 Chronic hepatitis C infection; chr22:31908193 chr22:31816379~31817491:- LUSC cis rs8059260 0.542 rs7196077 ENSG00000274038.1 RP11-66H6.4 -6.14 1.75e-09 8.15e-07 -0.45 -0.27 Alcohol consumption over the past year; chr16:11033198 chr16:11056556~11057034:+ LUSC cis rs8072100 0.666 rs9913503 ENSG00000228782.6 CTD-2026D20.3 6.14 1.75e-09 8.16e-07 0.28 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47698964 chr17:47450568~47492492:- LUSC cis rs6504622 0.72 rs4968304 ENSG00000262879.4 RP11-156P1.3 -6.14 1.75e-09 8.18e-07 -0.29 -0.27 Orofacial clefts; chr17:47063235 chr17:46984045~47100323:- LUSC cis rs9309473 1 rs1403284 ENSG00000163016.8 ALMS1P -6.14 1.75e-09 8.18e-07 -0.33 -0.27 Metabolite levels; chr2:73499535 chr2:73644919~73685576:+ LUSC cis rs7189233 0.955 rs8044205 ENSG00000279344.1 RP11-44F14.7 6.14 1.76e-09 8.18e-07 0.25 0.27 Intelligence (multi-trait analysis); chr16:53481181 chr16:53478957~53481550:- LUSC cis rs7189233 0.955 rs8058684 ENSG00000279344.1 RP11-44F14.7 6.14 1.76e-09 8.18e-07 0.25 0.27 Intelligence (multi-trait analysis); chr16:53481206 chr16:53478957~53481550:- LUSC cis rs9309473 0.615 rs11680965 ENSG00000163016.8 ALMS1P 6.14 1.76e-09 8.19e-07 0.39 0.27 Metabolite levels; chr2:73498789 chr2:73644919~73685576:+ LUSC cis rs11089937 0.626 rs5757051 ENSG00000211638.2 IGLV8-61 6.14 1.76e-09 8.19e-07 0.28 0.27 Periodontitis (PAL4Q3); chr22:22141753 chr22:22098700~22099212:+ LUSC cis rs6504950 1 rs8080491 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54972508 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs6504948 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54972626 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs6504949 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54972772 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs8078550 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54976018 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9914732 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54977006 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9916642 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54977136 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9915832 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54977336 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9893306 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54977388 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs6504950 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54979110 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs6504951 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.19e-07 0.33 0.27 Breast cancer; chr17:54979614 chr17:54964474~54964679:+ LUSC cis rs7580658 0.75 rs4497825 ENSG00000236682.1 AC068282.3 -6.14 1.76e-09 8.19e-07 -0.35 -0.27 Protein C levels; chr2:127303477 chr2:127389130~127400580:+ LUSC cis rs6504950 1 rs16955471 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.2e-07 0.33 0.27 Breast cancer; chr17:54981446 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9891865 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.2e-07 0.33 0.27 Breast cancer; chr17:54982672 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9892173 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.2e-07 0.33 0.27 Breast cancer; chr17:54982853 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs1990674 ENSG00000275710.1 RP11-257O5.4 6.14 1.76e-09 8.2e-07 0.33 0.27 Breast cancer; chr17:54983714 chr17:54964474~54964679:+ LUSC cis rs2562456 0.874 rs2562408 ENSG00000268081.1 RP11-678G14.2 -6.14 1.76e-09 8.2e-07 -0.39 -0.27 Pain; chr19:21527079 chr19:21554640~21569237:- LUSC cis rs1823913 0.614 rs4853576 ENSG00000227542.1 AC092614.2 -6.14 1.76e-09 8.2e-07 -0.35 -0.27 Obesity-related traits; chr2:191296618 chr2:191229165~191246172:- LUSC cis rs11089937 0.929 rs5750624 ENSG00000211638.2 IGLV8-61 -6.14 1.76e-09 8.2e-07 -0.25 -0.27 Periodontitis (PAL4Q3); chr22:22165354 chr22:22098700~22099212:+ LUSC cis rs2153535 0.58 rs7743686 ENSG00000230939.1 RP11-314C16.1 -6.14 1.76e-09 8.21e-07 -0.32 -0.27 Motion sickness; chr6:8525878 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs718504 ENSG00000230939.1 RP11-314C16.1 -6.14 1.76e-09 8.21e-07 -0.32 -0.27 Motion sickness; chr6:8527279 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs9328487 ENSG00000230939.1 RP11-314C16.1 -6.14 1.76e-09 8.21e-07 -0.32 -0.27 Motion sickness; chr6:8529145 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9328488 ENSG00000230939.1 RP11-314C16.1 -6.14 1.76e-09 8.21e-07 -0.32 -0.27 Motion sickness; chr6:8529178 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs7775274 ENSG00000230939.1 RP11-314C16.1 -6.14 1.76e-09 8.21e-07 -0.32 -0.27 Motion sickness; chr6:8530070 chr6:8784178~8785445:+ LUSC cis rs2153535 0.623 rs6597338 ENSG00000230939.1 RP11-314C16.1 -6.14 1.76e-09 8.21e-07 -0.32 -0.27 Motion sickness; chr6:8533275 chr6:8784178~8785445:+ LUSC cis rs1061377 1 rs1560397 ENSG00000249685.1 RP11-360F5.3 6.14 1.76e-09 8.21e-07 0.31 0.27 Uric acid levels; chr4:39112265 chr4:39133913~39135608:+ LUSC cis rs1134634 0.52 rs56041141 ENSG00000273133.1 RP11-799M12.2 -6.14 1.76e-09 8.21e-07 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15598222 chr4:15563698~15564253:- LUSC cis rs6918586 0.658 rs198838 ENSG00000272462.2 U91328.19 6.14 1.76e-09 8.21e-07 0.29 0.27 Schizophrenia; chr6:26113112 chr6:25992662~26001775:+ LUSC cis rs7772486 0.686 rs4896833 ENSG00000235652.6 RP11-545I5.3 6.14 1.76e-09 8.22e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145644537 chr6:145799409~145886585:+ LUSC cis rs67311347 1 rs9849992 ENSG00000223797.4 ENTPD3-AS1 6.14 1.77e-09 8.24e-07 0.31 0.27 Renal cell carcinoma; chr3:40360649 chr3:40313802~40453329:- LUSC cis rs13113518 1 rs13116194 ENSG00000249700.7 SRD5A3-AS1 6.14 1.77e-09 8.24e-07 0.31 0.27 Height; chr4:55531150 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs13117836 ENSG00000249700.7 SRD5A3-AS1 6.14 1.77e-09 8.24e-07 0.31 0.27 Height; chr4:55531218 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs7668429 ENSG00000249700.7 SRD5A3-AS1 6.14 1.77e-09 8.24e-07 0.31 0.27 Height; chr4:55531811 chr4:55363971~55395847:- LUSC cis rs6504950 1 rs7219874 ENSG00000275710.1 RP11-257O5.4 6.14 1.77e-09 8.25e-07 0.33 0.27 Breast cancer; chr17:54988446 chr17:54964474~54964679:+ LUSC cis rs2276314 0.857 rs62101402 ENSG00000278986.1 RP11-723J4.3 -6.14 1.77e-09 8.25e-07 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36049472 chr18:35972151~35973916:+ LUSC cis rs6504622 0.755 rs4968253 ENSG00000262879.4 RP11-156P1.3 -6.14 1.77e-09 8.25e-07 -0.29 -0.27 Orofacial clefts; chr17:47093553 chr17:46984045~47100323:- LUSC cis rs116095464 0.558 rs2288459 ENSG00000250848.1 CTD-2083E4.5 -6.14 1.77e-09 8.25e-07 -0.41 -0.27 Breast cancer; chr5:231028 chr5:288833~290321:- LUSC cis rs6991838 0.725 rs6995134 ENSG00000200714.1 Y_RNA 6.14 1.77e-09 8.25e-07 0.33 0.27 Intelligence (multi-trait analysis); chr8:65555472 chr8:65592731~65592820:+ LUSC cis rs172166 0.694 rs536704 ENSG00000219392.1 RP1-265C24.5 -6.14 1.77e-09 8.26e-07 -0.35 -0.27 Cardiac Troponin-T levels; chr6:28124825 chr6:28115628~28116551:+ LUSC cis rs11089937 0.597 rs9619812 ENSG00000211638.2 IGLV8-61 -6.14 1.77e-09 8.26e-07 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22163945 chr22:22098700~22099212:+ LUSC cis rs8177876 0.749 rs11537 ENSG00000261838.4 RP11-303E16.6 6.14 1.78e-09 8.27e-07 0.62 0.27 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046894 chr16:81069854~81076598:+ LUSC cis rs1061377 1 rs9998481 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39117215 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs9998867 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39117542 chr4:39133913~39135608:+ LUSC cis rs7772486 0.79 rs9390365 ENSG00000235652.6 RP11-545I5.3 -6.14 1.78e-09 8.27e-07 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145914490 chr6:145799409~145886585:+ LUSC cis rs1061377 0.803 rs6857761 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39118353 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs9997089 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39119263 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs28465556 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39119569 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs10027813 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39119818 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs9990755 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39119819 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs7676008 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39120154 chr4:39133913~39135608:+ LUSC cis rs1061377 0.965 rs7677729 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39120370 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs7655122 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39120396 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs3796511 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39120586 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs3733274 ENSG00000249685.1 RP11-360F5.3 6.14 1.78e-09 8.27e-07 0.31 0.27 Uric acid levels; chr4:39120957 chr4:39133913~39135608:+ LUSC cis rs11971779 0.68 rs10229249 ENSG00000273391.1 RP11-634H22.1 6.14 1.78e-09 8.27e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139367764 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs11772026 ENSG00000273391.1 RP11-634H22.1 6.14 1.78e-09 8.27e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139367843 chr7:139359032~139359566:- LUSC cis rs11971779 0.616 rs1133068 ENSG00000273391.1 RP11-634H22.1 6.14 1.78e-09 8.27e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139368397 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6949599 ENSG00000273391.1 RP11-634H22.1 6.14 1.78e-09 8.27e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139369442 chr7:139359032~139359566:- LUSC cis rs11971779 0.616 rs6949963 ENSG00000273391.1 RP11-634H22.1 6.14 1.78e-09 8.27e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139369579 chr7:139359032~139359566:- LUSC cis rs11971779 0.555 rs6950143 ENSG00000273391.1 RP11-634H22.1 6.14 1.78e-09 8.27e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139369672 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs7788777 ENSG00000273391.1 RP11-634H22.1 6.14 1.78e-09 8.27e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139370447 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6963867 ENSG00000273391.1 RP11-634H22.1 6.14 1.78e-09 8.27e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139375218 chr7:139359032~139359566:- LUSC cis rs7739264 0.829 rs6456258 ENSG00000237404.1 RP3-471C18.2 6.14 1.78e-09 8.27e-07 0.3 0.27 Endometriosis; chr6:19747817 chr6:19689825~19753113:- LUSC cis rs7208859 0.623 rs7214570 ENSG00000266490.1 CTD-2349P21.9 6.14 1.78e-09 8.28e-07 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30820146 chr17:30792372~30792833:+ LUSC cis rs11098499 0.569 rs10023641 ENSG00000249244.1 RP11-548H18.2 6.14 1.78e-09 8.28e-07 0.33 0.27 Corneal astigmatism; chr4:119337255 chr4:119391831~119395335:- LUSC cis rs801193 0.844 rs2244022 ENSG00000236529.1 RP13-254B10.1 6.14 1.78e-09 8.28e-07 0.28 0.27 Aortic root size; chr7:66737443 chr7:65840212~65840596:+ LUSC cis rs7772486 0.79 rs9403756 ENSG00000235652.6 RP11-545I5.3 -6.14 1.78e-09 8.28e-07 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145936625 chr6:145799409~145886585:+ LUSC cis rs11971779 0.648 rs9656512 ENSG00000273391.1 RP11-634H22.1 6.14 1.78e-09 8.29e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139369300 chr7:139359032~139359566:- LUSC cis rs9322193 0.962 rs3805748 ENSG00000268592.3 RAET1E-AS1 6.14 1.78e-09 8.29e-07 0.34 0.27 Lung cancer; chr6:149772542 chr6:149863494~149919507:+ LUSC cis rs9322193 0.736 rs10457851 ENSG00000268592.3 RAET1E-AS1 6.14 1.78e-09 8.29e-07 0.34 0.27 Lung cancer; chr6:149775216 chr6:149863494~149919507:+ LUSC cis rs9322193 0.886 rs10872652 ENSG00000268592.3 RAET1E-AS1 6.14 1.78e-09 8.29e-07 0.34 0.27 Lung cancer; chr6:149775303 chr6:149863494~149919507:+ LUSC cis rs9322193 0.886 rs12525871 ENSG00000268592.3 RAET1E-AS1 6.14 1.78e-09 8.29e-07 0.34 0.27 Lung cancer; chr6:149775882 chr6:149863494~149919507:+ LUSC cis rs9322193 0.886 rs17672976 ENSG00000268592.3 RAET1E-AS1 6.14 1.78e-09 8.29e-07 0.34 0.27 Lung cancer; chr6:149776207 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs2184369 ENSG00000268592.3 RAET1E-AS1 6.14 1.78e-09 8.29e-07 0.34 0.27 Lung cancer; chr6:149776681 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs2342861 ENSG00000268592.3 RAET1E-AS1 6.14 1.78e-09 8.29e-07 0.34 0.27 Lung cancer; chr6:149777561 chr6:149863494~149919507:+ LUSC cis rs9322193 0.926 rs2342860 ENSG00000268592.3 RAET1E-AS1 6.14 1.78e-09 8.29e-07 0.34 0.27 Lung cancer; chr6:149777641 chr6:149863494~149919507:+ LUSC cis rs2179367 0.632 rs59820585 ENSG00000231760.4 RP11-350J20.5 6.14 1.78e-09 8.29e-07 0.39 0.27 Dupuytren's disease; chr6:149350249 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs56924465 ENSG00000231760.4 RP11-350J20.5 6.14 1.78e-09 8.29e-07 0.39 0.27 Dupuytren's disease; chr6:149350270 chr6:149796151~149826294:- LUSC cis rs10759883 0.539 rs649819 ENSG00000175611.10 LINC00476 6.14 1.78e-09 8.3e-07 0.32 0.27 Nicotine dependence; chr9:95969323 chr9:95759231~95875977:- LUSC cis rs1021993 0.545 rs6681466 ENSG00000231648.1 RP11-372M18.2 -6.14 1.78e-09 8.3e-07 -0.38 -0.27 Gut microbiome composition (winter); chr1:209355913 chr1:209367662~209379690:+ LUSC cis rs66887589 0.837 rs7661498 ENSG00000245958.5 RP11-33B1.1 -6.14 1.79e-09 8.3e-07 -0.26 -0.27 Diastolic blood pressure; chr4:119486953 chr4:119454791~119552025:+ LUSC cis rs9322193 0.962 rs7740784 ENSG00000268592.3 RAET1E-AS1 6.14 1.79e-09 8.31e-07 0.35 0.27 Lung cancer; chr6:149833364 chr6:149863494~149919507:+ LUSC cis rs6570726 0.935 rs447247 ENSG00000235652.6 RP11-545I5.3 6.14 1.79e-09 8.32e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145491542 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs369458 ENSG00000235652.6 RP11-545I5.3 6.14 1.79e-09 8.32e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145491673 chr6:145799409~145886585:+ LUSC cis rs1823913 0.637 rs1349938 ENSG00000227542.1 AC092614.2 -6.14 1.79e-09 8.32e-07 -0.35 -0.27 Obesity-related traits; chr2:191299970 chr2:191229165~191246172:- LUSC cis rs1823913 0.592 rs1349939 ENSG00000227542.1 AC092614.2 -6.14 1.79e-09 8.32e-07 -0.35 -0.27 Obesity-related traits; chr2:191300079 chr2:191229165~191246172:- LUSC cis rs8005677 1 rs4982712 ENSG00000279656.1 RP11-298I3.6 6.14 1.79e-09 8.33e-07 0.33 0.27 Cognitive ability (multi-trait analysis); chr14:22934519 chr14:23023083~23024217:- LUSC cis rs4713118 0.662 rs469228 ENSG00000204709.4 LINC01556 6.14 1.79e-09 8.34e-07 0.37 0.27 Parkinson's disease; chr6:28002926 chr6:28943877~28944537:+ LUSC cis rs4713118 0.54 rs469227 ENSG00000204709.4 LINC01556 6.14 1.79e-09 8.34e-07 0.37 0.27 Parkinson's disease; chr6:28002927 chr6:28943877~28944537:+ LUSC cis rs4713118 0.662 rs149948 ENSG00000204709.4 LINC01556 6.14 1.79e-09 8.34e-07 0.37 0.27 Parkinson's disease; chr6:28007039 chr6:28943877~28944537:+ LUSC cis rs881375 0.678 rs10760125 ENSG00000226752.6 PSMD5-AS1 -6.14 1.8e-09 8.35e-07 -0.3 -0.27 Rheumatoid arthritis; chr9:120900312 chr9:120824828~120854385:+ LUSC cis rs881375 0.654 rs10760126 ENSG00000226752.6 PSMD5-AS1 -6.14 1.8e-09 8.35e-07 -0.3 -0.27 Rheumatoid arthritis; chr9:120900340 chr9:120824828~120854385:+ LUSC cis rs881375 0.678 rs7031752 ENSG00000226752.6 PSMD5-AS1 -6.14 1.8e-09 8.35e-07 -0.3 -0.27 Rheumatoid arthritis; chr9:120901204 chr9:120824828~120854385:+ LUSC cis rs881375 0.678 rs4836834 ENSG00000226752.6 PSMD5-AS1 -6.14 1.8e-09 8.35e-07 -0.3 -0.27 Rheumatoid arthritis; chr9:120903623 chr9:120824828~120854385:+ LUSC cis rs881375 0.631 rs10739577 ENSG00000226752.6 PSMD5-AS1 -6.14 1.8e-09 8.35e-07 -0.3 -0.27 Rheumatoid arthritis; chr9:120906576 chr9:120824828~120854385:+ LUSC cis rs875971 0.545 rs10950029 ENSG00000226824.5 RP4-756H11.3 -6.14 1.8e-09 8.35e-07 -0.35 -0.27 Aortic root size; chr7:66169334 chr7:66654538~66669855:+ LUSC cis rs61270009 0.955 rs450202 ENSG00000247828.6 TMEM161B-AS1 -6.14 1.8e-09 8.37e-07 -0.32 -0.27 Depressive symptoms; chr5:88222635 chr5:88268895~88436685:+ LUSC cis rs228614 0.509 rs223486 ENSG00000230069.3 LRRC37A15P -6.14 1.8e-09 8.37e-07 -0.28 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102763796 chr4:102727274~102730721:- LUSC cis rs14027 0.883 rs28486074 ENSG00000279347.1 RP11-85I17.2 -6.14 1.8e-09 8.37e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119720762 chr8:119838736~119840385:- LUSC cis rs14027 0.842 rs28634937 ENSG00000279347.1 RP11-85I17.2 -6.14 1.8e-09 8.37e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119720877 chr8:119838736~119840385:- LUSC cis rs14027 0.883 rs35449013 ENSG00000279347.1 RP11-85I17.2 -6.14 1.8e-09 8.37e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119729239 chr8:119838736~119840385:- LUSC cis rs14027 0.705 rs13265683 ENSG00000279347.1 RP11-85I17.2 -6.14 1.8e-09 8.37e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119729926 chr8:119838736~119840385:- LUSC cis rs1823913 0.637 rs1378162 ENSG00000227542.1 AC092614.2 6.14 1.8e-09 8.37e-07 0.35 0.27 Obesity-related traits; chr2:191298523 chr2:191229165~191246172:- LUSC cis rs8072100 0.967 rs11871606 ENSG00000228782.6 CTD-2026D20.3 -6.14 1.8e-09 8.38e-07 -0.26 -0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47655408 chr17:47450568~47492492:- LUSC cis rs2732480 0.577 rs2634681 ENSG00000240399.1 RP1-228P16.1 -6.14 1.8e-09 8.38e-07 -0.28 -0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48339301 chr12:48054813~48055591:- LUSC cis rs4713118 0.699 rs200978 ENSG00000280107.1 AL022393.9 -6.14 1.81e-09 8.39e-07 -0.34 -0.27 Parkinson's disease; chr6:27885390 chr6:28170845~28172521:+ LUSC cis rs1075265 0.704 rs805405 ENSG00000233266.1 HMGB1P31 6.14 1.81e-09 8.4e-07 0.34 0.27 Chronotype;Morning vs. evening chronotype; chr2:53891014 chr2:54051334~54051760:+ LUSC cis rs17270561 0.525 rs10484432 ENSG00000272810.1 U91328.22 -6.14 1.81e-09 8.4e-07 -0.38 -0.27 Iron status biomarkers; chr6:26008648 chr6:26013241~26013757:+ LUSC cis rs7772486 0.79 rs3923579 ENSG00000235652.6 RP11-545I5.3 -6.14 1.81e-09 8.4e-07 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145909096 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs3924498 ENSG00000235652.6 RP11-545I5.3 -6.14 1.81e-09 8.4e-07 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145912202 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2247429 ENSG00000235652.6 RP11-545I5.3 6.14 1.81e-09 8.4e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145896633 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2247666 ENSG00000235652.6 RP11-545I5.3 6.14 1.81e-09 8.4e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145899273 chr6:145799409~145886585:+ LUSC cis rs2239557 0.961 rs11159061 ENSG00000259065.1 RP5-1021I20.1 -6.13 1.81e-09 8.42e-07 -0.33 -0.27 Common traits (Other); chr14:74089560 chr14:73787360~73803270:+ LUSC cis rs2239557 1 rs17096228 ENSG00000259065.1 RP5-1021I20.1 -6.13 1.81e-09 8.42e-07 -0.33 -0.27 Common traits (Other); chr14:74091966 chr14:73787360~73803270:+ LUSC cis rs9326248 0.731 rs90192 ENSG00000280143.1 AP000892.6 6.13 1.81e-09 8.43e-07 0.36 0.27 Blood protein levels; chr11:117188631 chr11:117204967~117210292:+ LUSC cis rs7598759 0.527 rs12987949 ENSG00000181798.2 LINC00471 -6.13 1.81e-09 8.43e-07 -0.29 -0.27 Noise-induced hearing loss; chr2:231502800 chr2:231508426~231514339:- LUSC cis rs72772090 0.539 rs111237997 ENSG00000248734.2 CTD-2260A17.1 -6.13 1.82e-09 8.43e-07 -0.4 -0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779249 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs3333 ENSG00000248734.2 CTD-2260A17.1 -6.13 1.82e-09 8.43e-07 -0.4 -0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779407 chr5:96784777~96785999:+ LUSC cis rs73173548 0.502 rs6865869 ENSG00000247828.6 TMEM161B-AS1 6.13 1.82e-09 8.43e-07 0.33 0.27 Macular telangiectasia type 2; chr5:88449645 chr5:88268895~88436685:+ LUSC cis rs75920871 0.588 rs1940626 ENSG00000254851.1 RP11-109L13.1 6.13 1.82e-09 8.43e-07 0.38 0.27 Subjective well-being; chr11:116957405 chr11:117135528~117138582:+ LUSC cis rs4713118 0.955 rs9393848 ENSG00000280107.1 AL022393.9 -6.13 1.82e-09 8.43e-07 -0.32 -0.27 Parkinson's disease; chr6:27720590 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs868987 ENSG00000280107.1 AL022393.9 6.13 1.82e-09 8.44e-07 0.34 0.27 Depression; chr6:28142370 chr6:28170845~28172521:+ LUSC cis rs4713118 0.699 rs573179 ENSG00000280107.1 AL022393.9 -6.13 1.82e-09 8.46e-07 -0.34 -0.27 Parkinson's disease; chr6:27881898 chr6:28170845~28172521:+ LUSC cis rs7267979 0.873 rs7453 ENSG00000274973.1 RP13-401N8.7 -6.13 1.82e-09 8.47e-07 -0.27 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25226438 chr20:25845497~25845862:+ LUSC cis rs7189233 0.911 rs8057808 ENSG00000279344.1 RP11-44F14.7 6.13 1.82e-09 8.47e-07 0.24 0.27 Intelligence (multi-trait analysis); chr16:53486701 chr16:53478957~53481550:- LUSC cis rs9322193 0.962 rs1889473 ENSG00000268592.3 RAET1E-AS1 6.13 1.82e-09 8.47e-07 0.35 0.27 Lung cancer; chr6:149825485 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs1984111 ENSG00000268592.3 RAET1E-AS1 6.13 1.82e-09 8.47e-07 0.35 0.27 Lung cancer; chr6:149831720 chr6:149863494~149919507:+ LUSC cis rs1134634 0.52 rs75099653 ENSG00000273133.1 RP11-799M12.2 -6.13 1.83e-09 8.48e-07 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15626397 chr4:15563698~15564253:- LUSC cis rs7189233 0.955 rs8054299 ENSG00000279344.1 RP11-44F14.7 -6.13 1.83e-09 8.48e-07 -0.24 -0.27 Intelligence (multi-trait analysis); chr16:53464743 chr16:53478957~53481550:- LUSC cis rs4237845 0.837 rs7971877 ENSG00000257159.1 RP11-58A17.3 6.13 1.83e-09 8.49e-07 0.33 0.27 Intelligence (multi-trait analysis); chr12:57893847 chr12:57967058~57968399:+ LUSC cis rs17270561 0.562 rs74293932 ENSG00000272810.1 U91328.22 -6.13 1.83e-09 8.49e-07 -0.38 -0.27 Iron status biomarkers; chr6:26014583 chr6:26013241~26013757:+ LUSC cis rs4853012 0.941 rs2421752 ENSG00000257800.1 FNBP1P1 6.13 1.83e-09 8.51e-07 0.34 0.27 Gestational age at birth (maternal effect); chr2:74114488 chr2:74120680~74123218:+ LUSC cis rs11157436 0.602 rs11157437 ENSG00000211813.2 TRAV34 6.13 1.84e-09 8.52e-07 0.27 0.27 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22169058 chr14:22207522~22208129:+ LUSC cis rs11157436 0.602 rs11157439 ENSG00000211813.2 TRAV34 6.13 1.84e-09 8.52e-07 0.27 0.27 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22171061 chr14:22207522~22208129:+ LUSC cis rs11157436 0.602 rs2331594 ENSG00000211813.2 TRAV34 6.13 1.84e-09 8.52e-07 0.27 0.27 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22171871 chr14:22207522~22208129:+ LUSC cis rs11157436 0.602 rs12588757 ENSG00000211813.2 TRAV34 6.13 1.84e-09 8.52e-07 0.27 0.27 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22172100 chr14:22207522~22208129:+ LUSC cis rs274567 0.55 rs272885 ENSG00000233006.5 AC034220.3 6.13 1.84e-09 8.52e-07 0.28 0.27 Blood metabolite levels; chr5:132332043 chr5:132311285~132369916:- LUSC cis rs7211079 0.917 rs4243251 ENSG00000279259.1 RP11-334C17.3 6.13 1.84e-09 8.52e-07 0.31 0.27 Myocardial infarction; chr17:80138811 chr17:80147250~80148596:+ LUSC cis rs66887589 0.967 rs2892869 ENSG00000249244.1 RP11-548H18.2 -6.13 1.84e-09 8.53e-07 -0.32 -0.27 Diastolic blood pressure; chr4:119600142 chr4:119391831~119395335:- LUSC cis rs61270009 0.955 rs4916899 ENSG00000247828.6 TMEM161B-AS1 6.13 1.84e-09 8.53e-07 0.3 0.27 Depressive symptoms; chr5:88292209 chr5:88268895~88436685:+ LUSC cis rs11907546 1 rs11907546 ENSG00000275784.1 RP5-1125A11.6 -6.13 1.84e-09 8.53e-07 -0.31 -0.27 Cancer (pleiotropy);Cancer; chr20:34131991 chr20:33989480~33991818:- LUSC cis rs5753618 0.583 rs5753631 ENSG00000236132.1 CTA-440B3.1 -6.13 1.84e-09 8.53e-07 -0.38 -0.27 Colorectal cancer; chr22:31467036 chr22:31816379~31817491:- LUSC cis rs17772222 0.839 rs2274735 ENSG00000258789.1 RP11-507K2.3 -6.13 1.84e-09 8.54e-07 -0.3 -0.27 Coronary artery calcification; chr14:88505414 chr14:88551597~88552493:+ LUSC cis rs11098499 1 rs11098499 ENSG00000250412.1 KLHL2P1 6.13 1.84e-09 8.54e-07 0.34 0.27 Corneal astigmatism; chr4:119266456 chr4:119334329~119378233:+ LUSC cis rs950880 0.645 rs4851006 ENSG00000234389.1 AC007278.3 -6.13 1.84e-09 8.55e-07 -0.3 -0.27 Serum protein levels (sST2); chr2:102408278 chr2:102438713~102440475:+ LUSC cis rs7246657 0.722 rs2972437 ENSG00000276846.1 CTD-3220F14.3 6.13 1.84e-09 8.55e-07 0.4 0.27 Coronary artery calcification; chr19:37719610 chr19:37314868~37315620:- LUSC cis rs3096299 0.702 rs2086825 ENSG00000274627.1 RP11-104N10.2 6.13 1.84e-09 8.55e-07 0.24 0.27 Multiple myeloma (IgH translocation); chr16:89405134 chr16:89516797~89522217:+ LUSC cis rs7772486 0.79 rs9376970 ENSG00000235652.6 RP11-545I5.3 -6.13 1.85e-09 8.57e-07 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145920336 chr6:145799409~145886585:+ LUSC cis rs2243480 1 rs316327 ENSG00000226824.5 RP4-756H11.3 6.13 1.85e-09 8.57e-07 0.5 0.27 Diabetic kidney disease; chr7:66144214 chr7:66654538~66669855:+ LUSC cis rs7772486 0.764 rs2265468 ENSG00000235652.6 RP11-545I5.3 6.13 1.85e-09 8.57e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145897210 chr6:145799409~145886585:+ LUSC cis rs17270561 0.779 rs1165200 ENSG00000272462.2 U91328.19 6.13 1.85e-09 8.58e-07 0.35 0.27 Iron status biomarkers; chr6:25874984 chr6:25992662~26001775:+ LUSC cis rs4141404 0.828 rs2413043 ENSG00000236132.1 CTA-440B3.1 6.13 1.85e-09 8.59e-07 0.37 0.27 Paclitaxel-induced neuropathy; chr22:31252590 chr22:31816379~31817491:- LUSC cis rs1134634 0.52 rs12645849 ENSG00000273133.1 RP11-799M12.2 -6.13 1.85e-09 8.59e-07 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15627457 chr4:15563698~15564253:- LUSC cis rs7804306 0.826 rs73049256 ENSG00000233264.2 AC006042.8 6.13 1.86e-09 8.62e-07 0.56 0.27 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7978858 chr7:7980312~7982228:+ LUSC cis rs7267979 0.934 rs2257464 ENSG00000274973.1 RP13-401N8.7 -6.13 1.86e-09 8.62e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25285236 chr20:25845497~25845862:+ LUSC cis rs2243480 0.901 rs12530490 ENSG00000226824.5 RP4-756H11.3 6.13 1.86e-09 8.62e-07 0.52 0.27 Diabetic kidney disease; chr7:66226660 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs7778911 ENSG00000226824.5 RP4-756H11.3 6.13 1.86e-09 8.62e-07 0.52 0.27 Diabetic kidney disease; chr7:66229519 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs1979823 ENSG00000226824.5 RP4-756H11.3 6.13 1.86e-09 8.62e-07 0.52 0.27 Diabetic kidney disease; chr7:66239626 chr7:66654538~66669855:+ LUSC cis rs35160687 0.644 rs11687392 ENSG00000273080.1 RP11-301O19.1 -6.13 1.86e-09 8.62e-07 -0.26 -0.27 Night sleep phenotypes; chr2:86275540 chr2:86195590~86196049:+ LUSC cis rs875971 0.502 rs2946580 ENSG00000226824.5 RP4-756H11.3 6.13 1.86e-09 8.63e-07 0.36 0.27 Aortic root size; chr7:66066855 chr7:66654538~66669855:+ LUSC cis rs6142102 0.625 rs6142067 ENSG00000275784.1 RP5-1125A11.6 -6.13 1.86e-09 8.63e-07 -0.3 -0.27 Skin pigmentation; chr20:33968766 chr20:33989480~33991818:- LUSC cis rs2179367 0.632 rs11155649 ENSG00000231760.4 RP11-350J20.5 6.13 1.86e-09 8.64e-07 0.39 0.27 Dupuytren's disease; chr6:149405830 chr6:149796151~149826294:- LUSC cis rs78487399 0.71 rs114510001 ENSG00000234936.1 AC010883.5 6.13 1.87e-09 8.64e-07 0.44 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43289949 chr2:43229573~43233394:+ LUSC cis rs853679 0.517 rs9380047 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28070115 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs7755442 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28071237 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs55747925 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28076559 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs34716816 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28078391 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9380049 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28080757 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9380050 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28080760 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9393885 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28082231 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9393886 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28082261 chr6:28170845~28172521:+ LUSC cis rs4713118 0.515 rs9368549 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Parkinson's disease; chr6:28082269 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs56364346 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28082984 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9357061 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28083994 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9368550 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28084025 chr6:28170845~28172521:+ LUSC cis rs853679 0.542 rs2295594 ENSG00000280107.1 AL022393.9 -6.13 1.87e-09 8.65e-07 -0.34 -0.27 Depression; chr6:28085319 chr6:28170845~28172521:+ LUSC cis rs1823913 0.637 rs12992372 ENSG00000227542.1 AC092614.2 6.13 1.87e-09 8.66e-07 0.35 0.27 Obesity-related traits; chr2:191289251 chr2:191229165~191246172:- LUSC cis rs79349575 0.783 rs62075838 ENSG00000270781.1 RP11-501C14.9 -6.13 1.87e-09 8.66e-07 -0.28 -0.27 Type 2 diabetes; chr17:48919070 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs62075839 ENSG00000270781.1 RP11-501C14.9 -6.13 1.87e-09 8.66e-07 -0.28 -0.27 Type 2 diabetes; chr17:48919072 chr17:48899131~48899748:+ LUSC cis rs875971 0.545 rs221986 ENSG00000226824.5 RP4-756H11.3 6.13 1.87e-09 8.66e-07 0.36 0.27 Aortic root size; chr7:66105323 chr7:66654538~66669855:+ LUSC cis rs9322193 0.886 rs9767555 ENSG00000268592.3 RAET1E-AS1 6.13 1.87e-09 8.67e-07 0.35 0.27 Lung cancer; chr6:149647022 chr6:149863494~149919507:+ LUSC cis rs6504622 0.755 rs7219544 ENSG00000262879.4 RP11-156P1.3 -6.13 1.87e-09 8.67e-07 -0.29 -0.27 Orofacial clefts; chr17:47089562 chr17:46984045~47100323:- LUSC cis rs66887589 0.87 rs59590064 ENSG00000248280.1 RP11-33B1.2 -6.13 1.87e-09 8.68e-07 -0.3 -0.27 Diastolic blood pressure; chr4:119618598 chr4:119440561~119450157:- LUSC cis rs2153535 0.58 rs6421948 ENSG00000230939.1 RP11-314C16.1 -6.13 1.87e-09 8.68e-07 -0.32 -0.27 Motion sickness; chr6:8530787 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6421949 ENSG00000230939.1 RP11-314C16.1 -6.13 1.87e-09 8.68e-07 -0.32 -0.27 Motion sickness; chr6:8531536 chr6:8784178~8785445:+ LUSC cis rs12439619 0.693 rs4778989 ENSG00000276710.3 CSPG4P8 -6.13 1.87e-09 8.68e-07 -0.33 -0.27 Intelligence (multi-trait analysis); chr15:82276963 chr15:82459472~82477258:+ LUSC cis rs1134634 0.52 rs10008889 ENSG00000273133.1 RP11-799M12.2 -6.13 1.88e-09 8.69e-07 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15622896 chr4:15563698~15564253:- LUSC cis rs2404602 0.735 rs4886493 ENSG00000259422.1 RP11-593F23.1 -6.13 1.88e-09 8.69e-07 -0.31 -0.27 Blood metabolite levels; chr15:76386685 chr15:76174891~76181486:- LUSC cis rs8062405 0.54 rs151226 ENSG00000259982.1 CDC37P1 6.13 1.88e-09 8.7e-07 0.33 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28538502 chr16:28700294~28701540:- LUSC cis rs7804306 0.826 rs73049270 ENSG00000233264.2 AC006042.8 6.13 1.88e-09 8.7e-07 0.56 0.27 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7982015 chr7:7980312~7982228:+ LUSC cis rs7804306 0.826 rs73049276 ENSG00000233264.2 AC006042.8 6.13 1.88e-09 8.7e-07 0.56 0.27 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7982385 chr7:7980312~7982228:+ LUSC cis rs17270561 0.636 rs2070642 ENSG00000272462.2 U91328.19 -6.13 1.88e-09 8.71e-07 -0.32 -0.27 Iron status biomarkers; chr6:25830984 chr6:25992662~26001775:+ LUSC cis rs1823913 0.614 rs4853463 ENSG00000227542.1 AC092614.2 -6.13 1.88e-09 8.71e-07 -0.34 -0.27 Obesity-related traits; chr2:191278699 chr2:191229165~191246172:- LUSC cis rs14027 0.883 rs13272852 ENSG00000279347.1 RP11-85I17.2 -6.13 1.88e-09 8.72e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119712921 chr8:119838736~119840385:- LUSC cis rs6671200 0.607 rs2147587 ENSG00000228852.5 RP11-57H12.5 -6.13 1.89e-09 8.73e-07 -0.35 -0.27 Stearic acid (18:0) levels; chr1:95249328 chr1:95243167~95278940:- LUSC cis rs2019137 0.936 rs4849169 ENSG00000274877.1 RP11-65I12.1 6.13 1.89e-09 8.75e-07 0.33 0.27 Lymphocyte counts; chr2:113196080 chr2:113237595~113240825:+ LUSC cis rs2019137 0.836 rs4848318 ENSG00000274877.1 RP11-65I12.1 6.13 1.89e-09 8.75e-07 0.33 0.27 Lymphocyte counts; chr2:113196375 chr2:113237595~113240825:+ LUSC cis rs2019137 0.936 rs2241978 ENSG00000274877.1 RP11-65I12.1 6.13 1.89e-09 8.75e-07 0.33 0.27 Lymphocyte counts; chr2:113196429 chr2:113237595~113240825:+ LUSC cis rs6918586 0.658 rs198826 ENSG00000272462.2 U91328.19 6.13 1.89e-09 8.75e-07 0.28 0.27 Schizophrenia; chr6:26120925 chr6:25992662~26001775:+ LUSC cis rs7267979 1 rs2424713 ENSG00000274973.1 RP13-401N8.7 -6.13 1.89e-09 8.75e-07 -0.27 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25437846 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2387885 ENSG00000274973.1 RP13-401N8.7 6.13 1.89e-09 8.75e-07 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25434588 chr20:25845497~25845862:+ LUSC cis rs4713118 0.513 rs149962 ENSG00000219392.1 RP1-265C24.5 -6.13 1.89e-09 8.77e-07 -0.34 -0.27 Parkinson's disease; chr6:28048140 chr6:28115628~28116551:+ LUSC cis rs11603023 0.967 rs494560 ENSG00000255422.1 AP002954.4 6.13 1.9e-09 8.77e-07 0.31 0.27 Cholesterol, total; chr11:118650844 chr11:118704607~118750263:+ LUSC cis rs875971 0.756 rs4718328 ENSG00000179406.6 LINC00174 6.13 1.9e-09 8.79e-07 0.29 0.27 Aortic root size; chr7:66228350 chr7:66376044~66401338:- LUSC cis rs17270561 0.609 rs1185976 ENSG00000272462.2 U91328.19 6.13 1.9e-09 8.8e-07 0.31 0.27 Iron status biomarkers; chr6:25822135 chr6:25992662~26001775:+ LUSC cis rs4834770 0.792 rs7676969 ENSG00000245958.5 RP11-33B1.1 -6.13 1.9e-09 8.81e-07 -0.27 -0.27 Blood protein levels; chr4:119252569 chr4:119454791~119552025:+ LUSC cis rs4834770 0.685 rs4496567 ENSG00000245958.5 RP11-33B1.1 -6.13 1.9e-09 8.81e-07 -0.27 -0.27 Blood protein levels; chr4:119254470 chr4:119454791~119552025:+ LUSC cis rs4834770 0.792 rs6823331 ENSG00000245958.5 RP11-33B1.1 -6.13 1.9e-09 8.81e-07 -0.27 -0.27 Blood protein levels; chr4:119259635 chr4:119454791~119552025:+ LUSC cis rs13113518 0.934 rs11935823 ENSG00000273257.1 RP11-177J6.1 6.13 1.91e-09 8.83e-07 0.35 0.27 Height; chr4:55589624 chr4:55387949~55388271:+ LUSC cis rs4713118 0.513 rs202908 ENSG00000219392.1 RP1-265C24.5 -6.13 1.91e-09 8.83e-07 -0.34 -0.27 Parkinson's disease; chr6:28043773 chr6:28115628~28116551:+ LUSC cis rs10246939 0.511 rs62475469 ENSG00000228775.6 WEE2-AS1 6.13 1.91e-09 8.84e-07 0.32 0.27 Bitter taste perception; chr7:141864846 chr7:141704338~141738346:- LUSC cis rs116095464 0.558 rs62347677 ENSG00000250848.1 CTD-2083E4.5 -6.13 1.91e-09 8.84e-07 -0.42 -0.27 Breast cancer; chr5:227338 chr5:288833~290321:- LUSC cis rs11089937 0.616 rs6001227 ENSG00000211639.2 IGLV4-60 6.13 1.91e-09 8.85e-07 0.29 0.27 Periodontitis (PAL4Q3); chr22:22187099 chr22:22162199~22162681:+ LUSC cis rs11971779 0.68 rs11765421 ENSG00000273391.1 RP11-634H22.1 6.13 1.91e-09 8.85e-07 0.3 0.27 Diisocyanate-induced asthma; chr7:139340348 chr7:139359032~139359566:- LUSC cis rs1823913 0.614 rs6434459 ENSG00000227542.1 AC092614.2 -6.13 1.91e-09 8.85e-07 -0.35 -0.27 Obesity-related traits; chr2:191300886 chr2:191229165~191246172:- LUSC cis rs1823913 0.592 rs7588555 ENSG00000227542.1 AC092614.2 -6.13 1.91e-09 8.85e-07 -0.35 -0.27 Obesity-related traits; chr2:191300912 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs4853581 ENSG00000227542.1 AC092614.2 -6.13 1.91e-09 8.85e-07 -0.35 -0.27 Obesity-related traits; chr2:191301533 chr2:191229165~191246172:- LUSC cis rs1823913 0.614 rs7565987 ENSG00000227542.1 AC092614.2 -6.13 1.91e-09 8.85e-07 -0.35 -0.27 Obesity-related traits; chr2:191301815 chr2:191229165~191246172:- LUSC cis rs1823913 0.614 rs1973067 ENSG00000227542.1 AC092614.2 -6.13 1.91e-09 8.85e-07 -0.35 -0.27 Obesity-related traits; chr2:191302021 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs1973068 ENSG00000227542.1 AC092614.2 -6.13 1.91e-09 8.85e-07 -0.35 -0.27 Obesity-related traits; chr2:191302227 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs7569231 ENSG00000227542.1 AC092614.2 -6.13 1.91e-09 8.85e-07 -0.35 -0.27 Obesity-related traits; chr2:191302373 chr2:191229165~191246172:- LUSC cis rs4713118 0.513 rs149941 ENSG00000219392.1 RP1-265C24.5 -6.13 1.92e-09 8.85e-07 -0.34 -0.27 Parkinson's disease; chr6:28033255 chr6:28115628~28116551:+ LUSC cis rs2153535 0.58 rs1410766 ENSG00000230939.1 RP11-314C16.1 -6.13 1.92e-09 8.86e-07 -0.32 -0.27 Motion sickness; chr6:8525127 chr6:8784178~8785445:+ LUSC cis rs11159086 0.793 rs10147316 ENSG00000259005.1 RP3-449M8.6 6.13 1.92e-09 8.86e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74475688 chr14:74474007~74474864:- LUSC cis rs11159086 0.838 rs10147963 ENSG00000259005.1 RP3-449M8.6 6.13 1.92e-09 8.86e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74476091 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs8021664 ENSG00000259005.1 RP3-449M8.6 6.13 1.92e-09 8.86e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74476592 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs10150696 ENSG00000259005.1 RP3-449M8.6 6.13 1.92e-09 8.86e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74476723 chr14:74474007~74474864:- LUSC cis rs7804306 0.826 rs73049290 ENSG00000233264.2 AC006042.8 6.12 1.92e-09 8.86e-07 0.55 0.27 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7992584 chr7:7980312~7982228:+ LUSC cis rs2337406 0.539 rs2583292 ENSG00000274576.2 IGHV2-70 -6.12 1.92e-09 8.87e-07 -0.29 -0.27 Alzheimer's disease (late onset); chr14:106649040 chr14:106770577~106771020:- LUSC cis rs7189233 1 rs7189819 ENSG00000279344.1 RP11-44F14.7 6.12 1.92e-09 8.87e-07 0.25 0.27 Intelligence (multi-trait analysis); chr16:53502433 chr16:53478957~53481550:- LUSC cis rs8031584 0.958 rs11637469 ENSG00000260382.1 RP11-540B6.2 6.12 1.92e-09 8.89e-07 0.37 0.27 Huntington's disease progression; chr15:30946580 chr15:30882267~30883231:- LUSC cis rs8031584 0.958 rs8034856 ENSG00000260382.1 RP11-540B6.2 6.12 1.92e-09 8.89e-07 0.37 0.27 Huntington's disease progression; chr15:30948754 chr15:30882267~30883231:- LUSC cis rs6907340 0.517 rs9465533 ENSG00000227116.1 RP3-471C18.1 -6.12 1.92e-09 8.89e-07 -0.36 -0.27 Endometriosis; chr6:19801477 chr6:19730427~19734567:- LUSC cis rs17826219 0.706 rs8075357 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Body mass index; chr17:30730179 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs59447372 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30730567 chr17:30792372~30792833:+ LUSC cis rs17826219 0.706 rs61643715 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Body mass index; chr17:30730744 chr17:30792372~30792833:+ LUSC cis rs17826219 0.636 rs8080829 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Body mass index; chr17:30731712 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs8079891 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30731845 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs73267858 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732719 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs56018041 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732967 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs56095789 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733152 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs11656844 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733579 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs11652533 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733583 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs11652631 ENSG00000266490.1 CTD-2349P21.9 6.12 1.92e-09 8.89e-07 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733748 chr17:30792372~30792833:+ LUSC cis rs9322193 0.923 rs9322204 ENSG00000268592.3 RAET1E-AS1 6.12 1.93e-09 8.89e-07 0.34 0.27 Lung cancer; chr6:149636047 chr6:149863494~149919507:+ LUSC cis rs13113518 1 rs13132420 ENSG00000223305.1 RN7SKP30 -6.12 1.93e-09 8.9e-07 -0.31 -0.27 Height; chr4:55526646 chr4:55540502~55540835:- LUSC cis rs9545047 0.532 rs9545079 ENSG00000227676.3 LINC01068 6.12 1.93e-09 8.93e-07 0.33 0.27 Schizophrenia; chr13:79346044 chr13:79566727~79571436:+ LUSC cis rs11089937 0.616 rs5995615 ENSG00000211639.2 IGLV4-60 6.12 1.94e-09 8.94e-07 0.29 0.27 Periodontitis (PAL4Q3); chr22:22185250 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs6001223 ENSG00000211639.2 IGLV4-60 6.12 1.94e-09 8.94e-07 0.29 0.27 Periodontitis (PAL4Q3); chr22:22185359 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs928895 ENSG00000211639.2 IGLV4-60 6.12 1.94e-09 8.94e-07 0.29 0.27 Periodontitis (PAL4Q3); chr22:22185915 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs928896 ENSG00000211639.2 IGLV4-60 6.12 1.94e-09 8.94e-07 0.29 0.27 Periodontitis (PAL4Q3); chr22:22185929 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs6001224 ENSG00000211639.2 IGLV4-60 6.12 1.94e-09 8.94e-07 0.29 0.27 Periodontitis (PAL4Q3); chr22:22186042 chr22:22162199~22162681:+ LUSC cis rs1021993 0.545 rs76438740 ENSG00000231648.1 RP11-372M18.2 -6.12 1.94e-09 8.95e-07 -0.39 -0.27 Gut microbiome composition (winter); chr1:209366381 chr1:209367662~209379690:+ LUSC cis rs7772486 0.654 rs4896829 ENSG00000235652.6 RP11-545I5.3 6.12 1.94e-09 8.95e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145632539 chr6:145799409~145886585:+ LUSC cis rs950880 0.71 rs11678975 ENSG00000234389.1 AC007278.3 -6.12 1.94e-09 8.96e-07 -0.3 -0.27 Serum protein levels (sST2); chr2:102427279 chr2:102438713~102440475:+ LUSC cis rs2153535 0.58 rs6914276 ENSG00000230939.1 RP11-314C16.1 6.12 1.94e-09 8.96e-07 0.32 0.27 Motion sickness; chr6:8450202 chr6:8784178~8785445:+ LUSC cis rs2276314 0.857 rs28431958 ENSG00000278986.1 RP11-723J4.3 -6.12 1.95e-09 8.98e-07 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35998438 chr18:35972151~35973916:+ LUSC cis rs13113518 0.812 rs13140173 ENSG00000249700.7 SRD5A3-AS1 6.12 1.95e-09 9e-07 0.32 0.27 Height; chr4:55527164 chr4:55363971~55395847:- LUSC cis rs11722779 0.869 rs223323 ENSG00000230069.3 LRRC37A15P -6.12 1.95e-09 9e-07 -0.29 -0.27 Schizophrenia; chr4:102878412 chr4:102727274~102730721:- LUSC cis rs6951245 1 rs80094748 ENSG00000224079.1 AC091729.7 -6.12 1.95e-09 9.01e-07 -0.47 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1064322 chr7:1074450~1078036:+ LUSC cis rs4372836 1 rs7562170 ENSG00000226833.4 AC097724.3 -6.12 1.96e-09 9.02e-07 -0.32 -0.27 Body mass index; chr2:28720650 chr2:28708953~28736205:- LUSC cis rs496547 0.721 rs2508570 ENSG00000255422.1 AP002954.4 -6.12 1.96e-09 9.02e-07 -0.29 -0.27 Hip minimal joint space width; chr11:118807900 chr11:118704607~118750263:+ LUSC cis rs801193 0.967 rs34356500 ENSG00000236529.1 RP13-254B10.1 6.12 1.96e-09 9.02e-07 0.28 0.27 Aortic root size; chr7:66771620 chr7:65840212~65840596:+ LUSC cis rs67311347 0.544 rs6769627 ENSG00000223797.4 ENTPD3-AS1 6.12 1.96e-09 9.03e-07 0.28 0.27 Renal cell carcinoma; chr3:40286354 chr3:40313802~40453329:- LUSC cis rs2439831 0.717 rs10518820 ENSG00000249839.1 AC011330.5 -6.12 1.96e-09 9.04e-07 -0.57 -0.27 Lung cancer in ever smokers; chr15:43596778 chr15:43663654~43684339:- LUSC cis rs11722779 0.935 rs7681629 ENSG00000230069.3 LRRC37A15P -6.12 1.96e-09 9.04e-07 -0.29 -0.27 Schizophrenia; chr4:102974407 chr4:102727274~102730721:- LUSC cis rs2276314 0.857 rs9960670 ENSG00000278986.1 RP11-723J4.3 -6.12 1.96e-09 9.05e-07 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35997749 chr18:35972151~35973916:+ LUSC cis rs11159086 0.793 rs9285594 ENSG00000259005.1 RP3-449M8.6 6.12 1.96e-09 9.05e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74489253 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs4903229 ENSG00000259005.1 RP3-449M8.6 6.12 1.96e-09 9.05e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74489865 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs8016972 ENSG00000259005.1 RP3-449M8.6 6.12 1.96e-09 9.05e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74491833 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs8015894 ENSG00000259005.1 RP3-449M8.6 6.12 1.96e-09 9.05e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74491917 chr14:74474007~74474864:- LUSC cis rs950169 0.922 rs12906983 ENSG00000259728.4 LINC00933 6.12 1.96e-09 9.05e-07 0.36 0.27 Schizophrenia; chr15:84262270 chr15:84570649~84580175:+ LUSC cis rs7267979 0.866 rs6138609 ENSG00000274973.1 RP13-401N8.7 -6.12 1.96e-09 9.06e-07 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25590349 chr20:25845497~25845862:+ LUSC cis rs61270009 0.955 rs16903057 ENSG00000247828.6 TMEM161B-AS1 6.12 1.96e-09 9.06e-07 0.33 0.27 Depressive symptoms; chr5:88292603 chr5:88268895~88436685:+ LUSC cis rs72772090 0.539 rs3335 ENSG00000248734.2 CTD-2260A17.1 -6.12 1.97e-09 9.07e-07 -0.4 -0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779366 chr5:96784777~96785999:+ LUSC cis rs72772090 0.539 rs3334 ENSG00000248734.2 CTD-2260A17.1 -6.12 1.97e-09 9.07e-07 -0.4 -0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779381 chr5:96784777~96785999:+ LUSC cis rs2732480 0.5 rs1552550 ENSG00000240399.1 RP1-228P16.1 6.12 1.97e-09 9.07e-07 0.29 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48249568 chr12:48054813~48055591:- LUSC cis rs2732480 0.5 rs2450991 ENSG00000240399.1 RP1-228P16.1 6.12 1.97e-09 9.07e-07 0.29 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48257838 chr12:48054813~48055591:- LUSC cis rs11676348 0.755 rs62183956 ENSG00000261338.2 RP11-378A13.1 6.12 1.97e-09 9.07e-07 0.26 0.27 Ulcerative colitis; chr2:218181399 chr2:218255319~218257366:+ LUSC cis rs7211079 0.917 rs8067991 ENSG00000279259.1 RP11-334C17.3 6.12 1.97e-09 9.09e-07 0.32 0.27 Myocardial infarction; chr17:80145503 chr17:80147250~80148596:+ LUSC cis rs7267979 0.873 rs6083853 ENSG00000274973.1 RP13-401N8.7 6.12 1.98e-09 9.11e-07 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25423905 chr20:25845497~25845862:+ LUSC cis rs7267979 0.934 rs2482913 ENSG00000274973.1 RP13-401N8.7 6.12 1.98e-09 9.11e-07 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25424450 chr20:25845497~25845862:+ LUSC cis rs9928842 0.882 rs4737 ENSG00000280152.1 RP11-331F4.5 -6.12 1.98e-09 9.11e-07 -0.34 -0.27 Alcoholic chronic pancreatitis; chr16:75204205 chr16:75245994~75250077:- LUSC cis rs875971 0.545 rs73136346 ENSG00000226824.5 RP4-756H11.3 6.12 1.98e-09 9.11e-07 0.36 0.27 Aortic root size; chr7:66101095 chr7:66654538~66669855:+ LUSC cis rs7955901 0.638 rs2270584 ENSG00000257265.1 CTD-2021H9.1 6.12 1.98e-09 9.11e-07 0.3 0.27 Type 2 diabetes; chr12:71138319 chr12:71007773~71032083:- LUSC cis rs875971 0.508 rs6947808 ENSG00000236529.1 RP13-254B10.1 -6.12 1.98e-09 9.11e-07 -0.27 -0.27 Aortic root size; chr7:66580095 chr7:65840212~65840596:+ LUSC cis rs67311347 0.955 rs12487955 ENSG00000223797.4 ENTPD3-AS1 6.12 1.98e-09 9.11e-07 0.31 0.27 Renal cell carcinoma; chr3:40371362 chr3:40313802~40453329:- LUSC cis rs1549118 0.669 rs11625414 ENSG00000239272.1 RPL21P10 6.12 1.98e-09 9.12e-07 0.32 0.27 Resting heart rate; chr14:77909001 chr14:77683202~77683989:- LUSC cis rs11159086 0.793 rs1860108 ENSG00000259005.1 RP3-449M8.6 6.12 1.98e-09 9.12e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74478562 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs11845370 ENSG00000259005.1 RP3-449M8.6 6.12 1.98e-09 9.12e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74481587 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs3784035 ENSG00000259005.1 RP3-449M8.6 6.12 1.98e-09 9.12e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74482221 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs12433382 ENSG00000259005.1 RP3-449M8.6 6.12 1.98e-09 9.12e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74482940 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs10148268 ENSG00000259005.1 RP3-449M8.6 6.12 1.98e-09 9.12e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74484261 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs11850070 ENSG00000259005.1 RP3-449M8.6 6.12 1.98e-09 9.12e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74487575 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs28378078 ENSG00000259005.1 RP3-449M8.6 6.12 1.98e-09 9.12e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74487940 chr14:74474007~74474864:- LUSC cis rs9341835 0.583 rs2753062 ENSG00000218048.2 RP3-407E4.4 6.12 1.98e-09 9.12e-07 0.31 0.27 Schizophrenia; chr6:63421905 chr6:63440766~63443580:+ LUSC cis rs3096299 0.702 rs2086824 ENSG00000274627.1 RP11-104N10.2 -6.12 1.98e-09 9.13e-07 -0.23 -0.27 Multiple myeloma (IgH translocation); chr16:89404838 chr16:89516797~89522217:+ LUSC cis rs7189233 0.955 rs7184800 ENSG00000279344.1 RP11-44F14.7 6.12 1.98e-09 9.13e-07 0.24 0.27 Intelligence (multi-trait analysis); chr16:53475219 chr16:53478957~53481550:- LUSC cis rs62432291 0.681 rs404461 ENSG00000235086.1 FNDC1-IT1 6.12 1.98e-09 9.14e-07 0.46 0.27 Joint mobility (Beighton score); chr6:159219677 chr6:159240786~159243329:+ LUSC cis rs2276314 0.857 rs4799408 ENSG00000278986.1 RP11-723J4.3 6.12 1.99e-09 9.15e-07 0.34 0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36009019 chr18:35972151~35973916:+ LUSC cis rs2404602 0.684 rs62026898 ENSG00000259422.1 RP11-593F23.1 -6.12 1.99e-09 9.15e-07 -0.32 -0.27 Blood metabolite levels; chr15:76652030 chr15:76174891~76181486:- LUSC cis rs875971 0.638 rs7793569 ENSG00000237310.1 GS1-124K5.4 -6.12 1.99e-09 9.15e-07 -0.27 -0.27 Aortic root size; chr7:66651646 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs6975195 ENSG00000237310.1 GS1-124K5.4 -6.12 1.99e-09 9.15e-07 -0.27 -0.27 Aortic root size; chr7:66659787 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs3857688 ENSG00000237310.1 GS1-124K5.4 -6.12 1.99e-09 9.15e-07 -0.27 -0.27 Aortic root size; chr7:66662819 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs2286684 ENSG00000237310.1 GS1-124K5.4 -6.12 1.99e-09 9.15e-07 -0.27 -0.27 Aortic root size; chr7:66664843 chr7:66493706~66495474:+ LUSC cis rs801193 0.935 rs2286683 ENSG00000237310.1 GS1-124K5.4 -6.12 1.99e-09 9.15e-07 -0.27 -0.27 Aortic root size; chr7:66664856 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs10274773 ENSG00000237310.1 GS1-124K5.4 -6.12 1.99e-09 9.15e-07 -0.27 -0.27 Aortic root size; chr7:66668591 chr7:66493706~66495474:+ LUSC cis rs11098499 1 rs7659194 ENSG00000250412.1 KLHL2P1 6.12 1.99e-09 9.17e-07 0.34 0.27 Corneal astigmatism; chr4:119285992 chr4:119334329~119378233:+ LUSC cis rs7829975 0.517 rs12542733 ENSG00000253893.2 FAM85B 6.12 1.99e-09 9.17e-07 0.3 0.27 Mood instability; chr8:8967348 chr8:8167819~8226614:- LUSC cis rs9322193 0.923 rs9505982 ENSG00000268592.3 RAET1E-AS1 6.12 1.99e-09 9.18e-07 0.34 0.27 Lung cancer; chr6:149618465 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs10747275 ENSG00000268592.3 RAET1E-AS1 6.12 1.99e-09 9.18e-07 0.34 0.27 Lung cancer; chr6:149622782 chr6:149863494~149919507:+ LUSC cis rs11971779 0.68 rs6954531 ENSG00000273391.1 RP11-634H22.1 6.12 1.99e-09 9.18e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139369960 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6954547 ENSG00000273391.1 RP11-634H22.1 6.12 1.99e-09 9.18e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139369988 chr7:139359032~139359566:- LUSC cis rs9309473 0.66 rs79370894 ENSG00000163016.8 ALMS1P 6.12 1.99e-09 9.18e-07 0.39 0.27 Metabolite levels; chr2:73456388 chr2:73644919~73685576:+ LUSC cis rs8031584 0.958 rs11293 ENSG00000260382.1 RP11-540B6.2 6.12 1.99e-09 9.19e-07 0.37 0.27 Huntington's disease progression; chr15:30942778 chr15:30882267~30883231:- LUSC cis rs7246657 0.678 rs2927740 ENSG00000276846.1 CTD-3220F14.3 -6.12 1.99e-09 9.19e-07 -0.4 -0.27 Coronary artery calcification; chr19:37650065 chr19:37314868~37315620:- LUSC cis rs6772849 0.93 rs13434160 ENSG00000277250.1 Metazoa_SRP -6.12 2e-09 9.19e-07 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128655927 chr3:128673681~128674021:- LUSC cis rs6772849 0.93 rs4857916 ENSG00000277250.1 Metazoa_SRP -6.12 2e-09 9.19e-07 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128657171 chr3:128673681~128674021:- LUSC cis rs14027 0.921 rs16893101 ENSG00000279347.1 RP11-85I17.2 -6.12 2e-09 9.19e-07 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119750669 chr8:119838736~119840385:- LUSC cis rs77972916 0.517 rs17406126 ENSG00000234936.1 AC010883.5 6.12 2e-09 9.21e-07 0.37 0.27 Granulocyte percentage of myeloid white cells; chr2:43319493 chr2:43229573~43233394:+ LUSC cis rs4372836 1 rs2276547 ENSG00000226833.4 AC097724.3 6.12 2e-09 9.21e-07 0.32 0.27 Body mass index; chr2:28752241 chr2:28708953~28736205:- LUSC cis rs6504950 1 rs9894529 ENSG00000275710.1 RP11-257O5.4 6.12 2e-09 9.23e-07 0.33 0.27 Breast cancer; chr17:54977885 chr17:54964474~54964679:+ LUSC cis rs12439619 0.846 rs62011975 ENSG00000276710.3 CSPG4P8 -6.12 2.01e-09 9.25e-07 -0.33 -0.27 Intelligence (multi-trait analysis); chr15:82159213 chr15:82459472~82477258:+ LUSC cis rs748404 0.556 rs574856 ENSG00000249839.1 AC011330.5 6.12 2.01e-09 9.26e-07 0.35 0.27 Lung cancer; chr15:43168636 chr15:43663654~43684339:- LUSC cis rs8031584 0.958 rs3512 ENSG00000260382.1 RP11-540B6.2 6.12 2.01e-09 9.27e-07 0.37 0.27 Huntington's disease progression; chr15:30942802 chr15:30882267~30883231:- LUSC cis rs853679 0.517 rs9393887 ENSG00000280107.1 AL022393.9 -6.12 2.01e-09 9.27e-07 -0.34 -0.27 Depression; chr6:28091242 chr6:28170845~28172521:+ LUSC cis rs11971779 0.68 rs10274480 ENSG00000273391.1 RP11-634H22.1 6.12 2.01e-09 9.27e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139367682 chr7:139359032~139359566:- LUSC cis rs7267979 1 rs2500418 ENSG00000274973.1 RP13-401N8.7 6.12 2.01e-09 9.27e-07 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25401632 chr20:25845497~25845862:+ LUSC cis rs2019137 0.936 rs3828188 ENSG00000274877.1 RP11-65I12.1 6.12 2.02e-09 9.28e-07 0.33 0.27 Lymphocyte counts; chr2:113196670 chr2:113237595~113240825:+ LUSC cis rs2019137 0.936 rs3828189 ENSG00000274877.1 RP11-65I12.1 6.12 2.02e-09 9.28e-07 0.33 0.27 Lymphocyte counts; chr2:113196919 chr2:113237595~113240825:+ LUSC cis rs8040855 0.627 rs35668291 ENSG00000259295.5 CSPG4P12 6.12 2.02e-09 9.3e-07 0.34 0.27 Bulimia nervosa; chr15:85109582 chr15:85191438~85213905:+ LUSC cis rs77204473 0.744 rs77171490 ENSG00000254851.1 RP11-109L13.1 6.12 2.02e-09 9.3e-07 0.65 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117168025 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs77678768 ENSG00000254851.1 RP11-109L13.1 6.12 2.02e-09 9.3e-07 0.65 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117169789 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs80353869 ENSG00000254851.1 RP11-109L13.1 6.12 2.02e-09 9.3e-07 0.65 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117177406 chr11:117135528~117138582:+ LUSC cis rs67311347 0.911 rs58282210 ENSG00000223797.4 ENTPD3-AS1 6.12 2.02e-09 9.3e-07 0.31 0.27 Renal cell carcinoma; chr3:40376452 chr3:40313802~40453329:- LUSC cis rs61270009 0.955 rs35300532 ENSG00000247828.6 TMEM161B-AS1 6.12 2.02e-09 9.31e-07 0.31 0.27 Depressive symptoms; chr5:88293219 chr5:88268895~88436685:+ LUSC cis rs11098499 0.82 rs11737395 ENSG00000248280.1 RP11-33B1.2 6.12 2.03e-09 9.32e-07 0.32 0.27 Corneal astigmatism; chr4:119599549 chr4:119440561~119450157:- LUSC cis rs6991838 0.778 rs11779602 ENSG00000200714.1 Y_RNA 6.12 2.03e-09 9.33e-07 0.33 0.27 Intelligence (multi-trait analysis); chr8:65550247 chr8:65592731~65592820:+ LUSC cis rs875971 0.545 rs313830 ENSG00000226824.5 RP4-756H11.3 6.12 2.03e-09 9.34e-07 0.36 0.27 Aortic root size; chr7:66086944 chr7:66654538~66669855:+ LUSC cis rs5753618 0.539 rs2228619 ENSG00000236132.1 CTA-440B3.1 6.11 2.03e-09 9.35e-07 0.37 0.27 Colorectal cancer; chr22:31267856 chr22:31816379~31817491:- LUSC cis rs9322193 0.962 rs3763162 ENSG00000268592.3 RAET1E-AS1 -6.11 2.03e-09 9.36e-07 -0.34 -0.27 Lung cancer; chr6:149819674 chr6:149863494~149919507:+ LUSC cis rs62103177 0.608 rs4799115 ENSG00000261126.6 RP11-795F19.1 -6.11 2.04e-09 9.36e-07 -0.35 -0.27 Opioid sensitivity; chr18:79976365 chr18:80046900~80095482:+ LUSC cis rs10829156 1 rs10829157 ENSG00000240291.1 RP11-499P20.2 6.11 2.04e-09 9.36e-07 0.3 0.27 Sudden cardiac arrest; chr10:18662534 chr10:18513115~18545651:- LUSC cis rs875971 0.66 rs10229345 ENSG00000236529.1 RP13-254B10.1 6.11 2.04e-09 9.37e-07 0.28 0.27 Aortic root size; chr7:66517181 chr7:65840212~65840596:+ LUSC cis rs11098499 1 rs11726229 ENSG00000250412.1 KLHL2P1 6.11 2.04e-09 9.38e-07 0.34 0.27 Corneal astigmatism; chr4:119290425 chr4:119334329~119378233:+ LUSC cis rs7189233 1 rs7194519 ENSG00000279344.1 RP11-44F14.7 6.11 2.04e-09 9.38e-07 0.25 0.27 Intelligence (multi-trait analysis); chr16:53501364 chr16:53478957~53481550:- LUSC cis rs8072100 0.727 rs4794052 ENSG00000228782.6 CTD-2026D20.3 6.11 2.04e-09 9.38e-07 0.27 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47691870 chr17:47450568~47492492:- LUSC cis rs8072100 0.701 rs4794053 ENSG00000228782.6 CTD-2026D20.3 6.11 2.04e-09 9.38e-07 0.27 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47692185 chr17:47450568~47492492:- LUSC cis rs11971779 0.68 rs7808740 ENSG00000273391.1 RP11-634H22.1 6.11 2.04e-09 9.39e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139344209 chr7:139359032~139359566:- LUSC cis rs950880 0.71 rs55883125 ENSG00000234389.1 AC007278.3 -6.11 2.04e-09 9.4e-07 -0.3 -0.27 Serum protein levels (sST2); chr2:102407871 chr2:102438713~102440475:+ LUSC cis rs172166 0.637 rs1225597 ENSG00000219392.1 RP1-265C24.5 -6.11 2.05e-09 9.4e-07 -0.35 -0.27 Cardiac Troponin-T levels; chr6:28194309 chr6:28115628~28116551:+ LUSC cis rs9322193 0.736 rs3828701 ENSG00000268592.3 RAET1E-AS1 6.11 2.05e-09 9.41e-07 0.34 0.27 Lung cancer; chr6:149791063 chr6:149863494~149919507:+ LUSC cis rs9322193 0.736 rs3805750 ENSG00000268592.3 RAET1E-AS1 6.11 2.05e-09 9.41e-07 0.34 0.27 Lung cancer; chr6:149791065 chr6:149863494~149919507:+ LUSC cis rs9545047 0.604 rs12865187 ENSG00000227676.3 LINC01068 -6.11 2.05e-09 9.41e-07 -0.33 -0.27 Schizophrenia; chr13:79316469 chr13:79566727~79571436:+ LUSC cis rs6570726 1 rs6570699 ENSG00000235652.6 RP11-545I5.3 6.11 2.05e-09 9.42e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145599596 chr6:145799409~145886585:+ LUSC cis rs10129255 0.536 rs10139058 ENSG00000224373.3 IGHV4-59 6.11 2.05e-09 9.42e-07 0.13 0.27 Kawasaki disease; chr14:106685899 chr14:106627249~106627825:- LUSC cis rs6772849 0.93 rs9813197 ENSG00000277250.1 Metazoa_SRP -6.11 2.05e-09 9.42e-07 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128650261 chr3:128673681~128674021:- LUSC cis rs853679 1 rs853676 ENSG00000204709.4 LINC01556 6.11 2.05e-09 9.44e-07 0.47 0.27 Depression; chr6:28331910 chr6:28943877~28944537:+ LUSC cis rs1823913 0.526 rs36028476 ENSG00000227542.1 AC092614.2 6.11 2.05e-09 9.44e-07 0.35 0.27 Obesity-related traits; chr2:191300595 chr2:191229165~191246172:- LUSC cis rs4713118 0.662 rs175954 ENSG00000280107.1 AL022393.9 -6.11 2.06e-09 9.45e-07 -0.33 -0.27 Parkinson's disease; chr6:28043807 chr6:28170845~28172521:+ LUSC cis rs77204473 0.744 rs12421425 ENSG00000254851.1 RP11-109L13.1 6.11 2.06e-09 9.45e-07 0.66 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117131244 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs17120367 ENSG00000254851.1 RP11-109L13.1 6.11 2.06e-09 9.45e-07 0.66 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117132112 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs17120370 ENSG00000254851.1 RP11-109L13.1 6.11 2.06e-09 9.45e-07 0.66 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117132672 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs74735277 ENSG00000254851.1 RP11-109L13.1 6.11 2.06e-09 9.45e-07 0.66 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117132702 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs75208249 ENSG00000254851.1 RP11-109L13.1 6.11 2.06e-09 9.45e-07 0.66 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117132907 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs12417098 ENSG00000254851.1 RP11-109L13.1 6.11 2.06e-09 9.45e-07 0.66 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117134137 chr11:117135528~117138582:+ LUSC cis rs950880 0.71 rs11123928 ENSG00000234389.1 AC007278.3 -6.11 2.06e-09 9.47e-07 -0.29 -0.27 Serum protein levels (sST2); chr2:102444826 chr2:102438713~102440475:+ LUSC cis rs957448 1 rs12678305 ENSG00000253175.1 RP11-267M23.6 6.11 2.06e-09 9.48e-07 0.32 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94508911 chr8:94565036~94565715:+ LUSC cis rs957448 1 rs1048029 ENSG00000253175.1 RP11-267M23.6 6.11 2.06e-09 9.48e-07 0.32 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94510149 chr8:94565036~94565715:+ LUSC cis rs957448 1 rs1055797 ENSG00000253175.1 RP11-267M23.6 6.11 2.06e-09 9.48e-07 0.32 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94511005 chr8:94565036~94565715:+ LUSC cis rs4713118 0.869 rs9348775 ENSG00000219392.1 RP1-265C24.5 -6.11 2.06e-09 9.48e-07 -0.35 -0.27 Parkinson's disease; chr6:27727550 chr6:28115628~28116551:+ LUSC cis rs9322193 0.923 rs9322214 ENSG00000268592.3 RAET1E-AS1 6.11 2.06e-09 9.48e-07 0.35 0.27 Lung cancer; chr6:149703986 chr6:149863494~149919507:+ LUSC cis rs8072100 0.782 rs62074054 ENSG00000228782.6 CTD-2026D20.3 6.11 2.07e-09 9.51e-07 0.27 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47694450 chr17:47450568~47492492:- LUSC cis rs8072100 0.666 rs6503804 ENSG00000228782.6 CTD-2026D20.3 6.11 2.07e-09 9.51e-07 0.27 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47695081 chr17:47450568~47492492:- LUSC cis rs11722779 0.844 rs223345 ENSG00000230069.3 LRRC37A15P -6.11 2.07e-09 9.51e-07 -0.29 -0.27 Schizophrenia; chr4:102859366 chr4:102727274~102730721:- LUSC cis rs11722779 0.873 rs223344 ENSG00000230069.3 LRRC37A15P -6.11 2.07e-09 9.51e-07 -0.29 -0.27 Schizophrenia; chr4:102859765 chr4:102727274~102730721:- LUSC cis rs11722779 0.775 rs223341 ENSG00000230069.3 LRRC37A15P -6.11 2.07e-09 9.51e-07 -0.29 -0.27 Schizophrenia; chr4:102862343 chr4:102727274~102730721:- LUSC cis rs950880 0.71 rs1035130 ENSG00000234389.1 AC007278.3 -6.11 2.07e-09 9.52e-07 -0.3 -0.27 Serum protein levels (sST2); chr2:102384942 chr2:102438713~102440475:+ LUSC cis rs8062405 1 rs62037364 ENSG00000278665.1 RP11-666O2.4 6.11 2.07e-09 9.53e-07 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857374 chr16:28599241~28601881:- LUSC cis rs2732480 0.5 rs11168464 ENSG00000240399.1 RP1-228P16.1 6.11 2.08e-09 9.54e-07 0.28 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48208332 chr12:48054813~48055591:- LUSC cis rs1387259 0.899 rs7307566 ENSG00000240399.1 RP1-228P16.1 6.11 2.08e-09 9.54e-07 0.28 0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48210899 chr12:48054813~48055591:- LUSC cis rs28830936 1 rs11629485 ENSG00000250379.1 RP11-23P13.4 6.11 2.08e-09 9.55e-07 0.29 0.27 Diastolic blood pressure; chr15:41612371 chr15:41825099~41827936:- LUSC cis rs6772849 0.775 rs66822528 ENSG00000242551.2 POU5F1P6 -6.11 2.08e-09 9.55e-07 -0.32 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128696254 chr3:128674735~128677005:- LUSC cis rs11159086 0.729 rs8015872 ENSG00000259005.1 RP3-449M8.6 6.11 2.08e-09 9.55e-07 0.4 0.27 Advanced glycation end-product levels; chr14:74475529 chr14:74474007~74474864:- LUSC cis rs853679 0.882 rs4713140 ENSG00000219392.1 RP1-265C24.5 -6.11 2.08e-09 9.56e-07 -0.45 -0.27 Depression; chr6:28129415 chr6:28115628~28116551:+ LUSC cis rs9549367 0.756 rs9603814 ENSG00000269125.1 RP11-98F14.11 6.11 2.08e-09 9.56e-07 0.32 0.27 Platelet distribution width; chr13:113246468 chr13:113165002~113165183:- LUSC cis rs1823913 0.637 rs6434461 ENSG00000227542.1 AC092614.2 -6.11 2.08e-09 9.57e-07 -0.35 -0.27 Obesity-related traits; chr2:191302661 chr2:191229165~191246172:- LUSC cis rs1823913 0.614 rs6434462 ENSG00000227542.1 AC092614.2 -6.11 2.08e-09 9.57e-07 -0.35 -0.27 Obesity-related traits; chr2:191302705 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs6750360 ENSG00000227542.1 AC092614.2 -6.11 2.08e-09 9.57e-07 -0.35 -0.27 Obesity-related traits; chr2:191303089 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs11677694 ENSG00000227542.1 AC092614.2 -6.11 2.08e-09 9.57e-07 -0.35 -0.27 Obesity-related traits; chr2:191303203 chr2:191229165~191246172:- LUSC cis rs1823913 0.571 rs6737307 ENSG00000227542.1 AC092614.2 -6.11 2.08e-09 9.57e-07 -0.35 -0.27 Obesity-related traits; chr2:191303247 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs4853582 ENSG00000227542.1 AC092614.2 -6.11 2.08e-09 9.57e-07 -0.35 -0.27 Obesity-related traits; chr2:191303483 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs35200176 ENSG00000227542.1 AC092614.2 -6.11 2.08e-09 9.57e-07 -0.35 -0.27 Obesity-related traits; chr2:191303534 chr2:191229165~191246172:- LUSC cis rs1823913 0.637 rs17348013 ENSG00000227542.1 AC092614.2 -6.11 2.08e-09 9.57e-07 -0.35 -0.27 Obesity-related traits; chr2:191303726 chr2:191229165~191246172:- LUSC cis rs6570726 0.791 rs952406 ENSG00000235652.6 RP11-545I5.3 6.11 2.09e-09 9.58e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145604480 chr6:145799409~145886585:+ LUSC cis rs11690935 0.921 rs4668414 ENSG00000228389.1 AC068039.4 6.11 2.09e-09 9.58e-07 0.32 0.27 Schizophrenia; chr2:171847781 chr2:171773482~171775844:+ LUSC cis rs1056107 0.933 rs10981350 ENSG00000225513.1 RP11-165N19.2 -6.11 2.09e-09 9.6e-07 -0.3 -0.27 Colorectal cancer; chr9:112304611 chr9:112173522~112173971:- LUSC cis rs783540 1 rs783531 ENSG00000255769.6 GOLGA2P10 6.11 2.09e-09 9.6e-07 0.33 0.27 Schizophrenia; chr15:82580370 chr15:82472993~82513950:- LUSC cis rs783540 0.934 rs783532 ENSG00000255769.6 GOLGA2P10 6.11 2.09e-09 9.6e-07 0.33 0.27 Schizophrenia; chr15:82580618 chr15:82472993~82513950:- LUSC cis rs1075265 0.626 rs805320 ENSG00000233266.1 HMGB1P31 6.11 2.09e-09 9.61e-07 0.33 0.27 Chronotype;Morning vs. evening chronotype; chr2:53911305 chr2:54051334~54051760:+ LUSC cis rs4718428 0.705 rs28648401 ENSG00000226824.5 RP4-756H11.3 -6.11 2.1e-09 9.62e-07 -0.37 -0.27 Corneal structure; chr7:66902145 chr7:66654538~66669855:+ LUSC cis rs4718428 0.607 rs66954441 ENSG00000226824.5 RP4-756H11.3 -6.11 2.1e-09 9.62e-07 -0.37 -0.27 Corneal structure; chr7:66904222 chr7:66654538~66669855:+ LUSC cis rs7772486 0.79 rs2254257 ENSG00000235652.6 RP11-545I5.3 6.11 2.1e-09 9.64e-07 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145882588 chr6:145799409~145886585:+ LUSC cis rs9309473 0.606 rs6759452 ENSG00000163016.8 ALMS1P 6.11 2.1e-09 9.65e-07 0.38 0.27 Metabolite levels; chr2:73651225 chr2:73644919~73685576:+ LUSC cis rs4713118 0.513 rs149958 ENSG00000219392.1 RP1-265C24.5 -6.11 2.1e-09 9.65e-07 -0.34 -0.27 Parkinson's disease; chr6:28045839 chr6:28115628~28116551:+ LUSC cis rs4713118 0.513 rs156738 ENSG00000219392.1 RP1-265C24.5 -6.11 2.1e-09 9.65e-07 -0.34 -0.27 Parkinson's disease; chr6:28046247 chr6:28115628~28116551:+ LUSC cis rs35160687 0.842 rs1863051 ENSG00000273080.1 RP11-301O19.1 6.11 2.11e-09 9.66e-07 0.25 0.27 Night sleep phenotypes; chr2:86332025 chr2:86195590~86196049:+ LUSC cis rs5753618 0.583 rs5753628 ENSG00000236132.1 CTA-440B3.1 -6.11 2.11e-09 9.67e-07 -0.38 -0.27 Colorectal cancer; chr22:31464336 chr22:31816379~31817491:- LUSC cis rs875971 0.508 rs10950045 ENSG00000236529.1 RP13-254B10.1 -6.11 2.11e-09 9.68e-07 -0.27 -0.27 Aortic root size; chr7:66601386 chr7:65840212~65840596:+ LUSC cis rs801193 0.839 rs6968619 ENSG00000236529.1 RP13-254B10.1 -6.11 2.11e-09 9.68e-07 -0.27 -0.27 Aortic root size; chr7:66603880 chr7:65840212~65840596:+ LUSC cis rs801193 0.839 rs12534943 ENSG00000236529.1 RP13-254B10.1 -6.11 2.11e-09 9.68e-07 -0.27 -0.27 Aortic root size; chr7:66605533 chr7:65840212~65840596:+ LUSC cis rs801193 0.805 rs12532355 ENSG00000236529.1 RP13-254B10.1 -6.11 2.11e-09 9.68e-07 -0.27 -0.27 Aortic root size; chr7:66605597 chr7:65840212~65840596:+ LUSC cis rs17772222 0.63 rs10873392 ENSG00000258789.1 RP11-507K2.3 6.11 2.11e-09 9.68e-07 0.3 0.27 Coronary artery calcification; chr14:88545124 chr14:88551597~88552493:+ LUSC cis rs1075265 0.783 rs805439 ENSG00000233266.1 HMGB1P31 6.11 2.11e-09 9.68e-07 0.34 0.27 Chronotype;Morning vs. evening chronotype; chr2:53829437 chr2:54051334~54051760:+ LUSC cis rs4852324 0.541 rs7568898 ENSG00000217702.2 RP11-287D1.4 6.11 2.11e-09 9.69e-07 0.57 0.27 Systemic lupus erythematosus; chr2:74044450 chr2:74130583~74135395:+ LUSC cis rs1387259 0.839 rs7486941 ENSG00000240399.1 RP1-228P16.1 -6.11 2.11e-09 9.7e-07 -0.27 -0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48184848 chr12:48054813~48055591:- LUSC cis rs4950322 0.518 rs11811023 ENSG00000278811.3 LINC00624 -6.11 2.12e-09 9.71e-07 -0.29 -0.27 Protein quantitative trait loci; chr1:147109536 chr1:147258885~147517875:- LUSC cis rs1823913 0.599 rs2124095 ENSG00000227542.1 AC092614.2 6.11 2.12e-09 9.71e-07 0.35 0.27 Obesity-related traits; chr2:191301728 chr2:191229165~191246172:- LUSC cis rs6570726 0.791 rs370112 ENSG00000235652.6 RP11-545I5.3 6.11 2.12e-09 9.71e-07 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145538717 chr6:145799409~145886585:+ LUSC cis rs13113518 1 rs13152173 ENSG00000273257.1 RP11-177J6.1 6.11 2.12e-09 9.71e-07 0.35 0.27 Height; chr4:55534788 chr4:55387949~55388271:+ LUSC cis rs783540 0.867 rs10906984 ENSG00000276710.3 CSPG4P8 -6.11 2.12e-09 9.72e-07 -0.29 -0.27 Schizophrenia; chr15:82697544 chr15:82459472~82477258:+ LUSC cis rs172166 0.694 rs1150666 ENSG00000216901.1 AL022393.7 6.11 2.12e-09 9.72e-07 0.32 0.27 Cardiac Troponin-T levels; chr6:28156150 chr6:28176188~28176674:+ LUSC cis rs11971779 0.648 rs4732367 ENSG00000273391.1 RP11-634H22.1 6.11 2.12e-09 9.72e-07 0.29 0.27 Diisocyanate-induced asthma; chr7:139343356 chr7:139359032~139359566:- LUSC cis rs2834288 0.7 rs6517196 ENSG00000273102.1 AP000569.9 -6.11 2.12e-09 9.73e-07 -0.31 -0.27 Gut microbiota (bacterial taxa); chr21:33905116 chr21:33967101~33968573:- LUSC cis rs227275 0.554 rs223442 ENSG00000230069.3 LRRC37A15P -6.11 2.13e-09 9.74e-07 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102793960 chr4:102727274~102730721:- LUSC cis rs227275 0.554 rs223441 ENSG00000230069.3 LRRC37A15P -6.11 2.13e-09 9.74e-07 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102794228 chr4:102727274~102730721:- LUSC cis rs2562456 0.917 rs2681389 ENSG00000268081.1 RP11-678G14.2 -6.11 2.13e-09 9.75e-07 -0.38 -0.27 Pain; chr19:21509773 chr19:21554640~21569237:- LUSC cis rs2562456 0.917 rs2681392 ENSG00000268081.1 RP11-678G14.2 -6.11 2.13e-09 9.75e-07 -0.38 -0.27 Pain; chr19:21513185 chr19:21554640~21569237:- LUSC cis rs8062405 0.722 rs3785354 ENSG00000278665.1 RP11-666O2.4 6.11 2.13e-09 9.75e-07 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28539346 chr16:28599241~28601881:- LUSC cis rs9309473 0.66 rs11686541 ENSG00000163016.8 ALMS1P 6.11 2.13e-09 9.75e-07 0.39 0.27 Metabolite levels; chr2:73477348 chr2:73644919~73685576:+ LUSC cis rs7772486 0.79 rs4075694 ENSG00000235652.6 RP11-545I5.3 -6.11 2.13e-09 9.76e-07 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145929972 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs9497434 ENSG00000235652.6 RP11-545I5.3 -6.11 2.13e-09 9.76e-07 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145939617 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs6924159 ENSG00000235652.6 RP11-545I5.3 -6.11 2.13e-09 9.76e-07 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145946737 chr6:145799409~145886585:+ LUSC cis rs2239557 1 rs2239557 ENSG00000259065.1 RP5-1021I20.1 -6.11 2.13e-09 9.77e-07 -0.33 -0.27 Common traits (Other); chr14:74085267 chr14:73787360~73803270:+ LUSC cis rs950880 0.71 rs3732123 ENSG00000234389.1 AC007278.3 -6.11 2.13e-09 9.77e-07 -0.29 -0.27 Serum protein levels (sST2); chr2:102401617 chr2:102438713~102440475:+ LUSC cis rs227275 0.554 rs150895 ENSG00000230069.3 LRRC37A15P -6.11 2.13e-09 9.77e-07 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102791432 chr4:102727274~102730721:- LUSC cis rs227275 0.586 rs223448 ENSG00000230069.3 LRRC37A15P -6.11 2.13e-09 9.77e-07 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102792189 chr4:102727274~102730721:- LUSC cis rs7267979 1 rs2482931 ENSG00000274973.1 RP13-401N8.7 6.11 2.14e-09 9.79e-07 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25353809 chr20:25845497~25845862:+ LUSC cis rs932287 0.54 rs4910442 ENSG00000254860.4 TMEM9B-AS1 -6.11 2.14e-09 9.79e-07 -0.31 -0.27 Colonoscopy-negative controls vs population controls; chr11:9022790 chr11:8964675~8977527:+ LUSC cis rs2732480 0.5 rs11168468 ENSG00000240399.1 RP1-228P16.1 6.11 2.14e-09 9.8e-07 0.28 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48218682 chr12:48054813~48055591:- LUSC cis rs1061377 0.513 rs2566166 ENSG00000249207.1 RP11-360F5.1 6.11 2.14e-09 9.8e-07 0.33 0.27 Uric acid levels; chr4:39148404 chr4:39112677~39126818:- LUSC cis rs4834770 0.765 rs1511016 ENSG00000245958.5 RP11-33B1.1 -6.11 2.14e-09 9.81e-07 -0.26 -0.27 Blood protein levels; chr4:119249200 chr4:119454791~119552025:+ LUSC cis rs9322193 0.923 rs9404048 ENSG00000268592.3 RAET1E-AS1 6.11 2.14e-09 9.81e-07 0.34 0.27 Lung cancer; chr6:149616188 chr6:149863494~149919507:+ LUSC cis rs7829975 0.623 rs7010753 ENSG00000253893.2 FAM85B -6.11 2.14e-09 9.81e-07 -0.32 -0.27 Mood instability; chr8:8516446 chr8:8167819~8226614:- LUSC cis rs7246657 0.722 rs2972438 ENSG00000276846.1 CTD-3220F14.3 6.11 2.14e-09 9.82e-07 0.4 0.27 Coronary artery calcification; chr19:37719946 chr19:37314868~37315620:- LUSC cis rs875971 0.545 rs6950988 ENSG00000237310.1 GS1-124K5.4 6.11 2.15e-09 9.84e-07 0.31 0.27 Aortic root size; chr7:66511428 chr7:66493706~66495474:+ LUSC cis rs11846409 0.86 rs73378154 ENSG00000274576.2 IGHV2-70 -6.11 2.15e-09 9.84e-07 -0.29 -0.27 Rheumatic heart disease; chr14:106637687 chr14:106770577~106771020:- LUSC cis rs11157436 0.602 rs4982569 ENSG00000211813.2 TRAV34 6.11 2.15e-09 9.86e-07 0.27 0.27 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22169716 chr14:22207522~22208129:+ LUSC cis rs75422866 0.867 rs7304743 ENSG00000274902.1 RP1-197B17.4 -6.1 2.15e-09 9.87e-07 -0.65 -0.27 Pneumonia; chr12:47683658 chr12:47731908~47732351:+ LUSC cis rs11098499 0.863 rs3822190 ENSG00000248280.1 RP11-33B1.2 6.1 2.16e-09 9.88e-07 0.33 0.27 Corneal astigmatism; chr4:119506943 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs3822191 ENSG00000248280.1 RP11-33B1.2 6.1 2.16e-09 9.88e-07 0.33 0.27 Corneal astigmatism; chr4:119506946 chr4:119440561~119450157:- LUSC cis rs11722779 0.873 rs6533041 ENSG00000230069.3 LRRC37A15P -6.1 2.16e-09 9.9e-07 -0.29 -0.27 Schizophrenia; chr4:102951615 chr4:102727274~102730721:- LUSC cis rs11722779 0.935 rs3857199 ENSG00000230069.3 LRRC37A15P -6.1 2.16e-09 9.9e-07 -0.29 -0.27 Schizophrenia; chr4:102957991 chr4:102727274~102730721:- LUSC cis rs6700559 0.565 rs2809341 ENSG00000260088.1 RP11-92G12.3 -6.1 2.16e-09 9.9e-07 -0.34 -0.27 Coronary artery disease; chr1:200628560 chr1:200669507~200694250:+ LUSC cis rs172166 0.637 rs1233691 ENSG00000219392.1 RP1-265C24.5 -6.1 2.16e-09 9.91e-07 -0.34 -0.27 Cardiac Troponin-T levels; chr6:28186119 chr6:28115628~28116551:+ LUSC cis rs2408955 0.522 rs3997 ENSG00000240399.1 RP1-228P16.1 -6.1 2.17e-09 9.92e-07 -0.28 -0.27 Glycated hemoglobin levels; chr12:48087804 chr12:48054813~48055591:- LUSC cis rs17507216 0.667 rs72753916 ENSG00000255769.6 GOLGA2P10 -6.1 2.17e-09 9.93e-07 -0.39 -0.27 Excessive daytime sleepiness; chr15:82684001 chr15:82472993~82513950:- LUSC cis rs17711722 0.522 rs4642526 ENSG00000226824.5 RP4-756H11.3 -6.1 2.17e-09 9.94e-07 -0.32 -0.27 Calcium levels; chr7:65751755 chr7:66654538~66669855:+ LUSC cis rs1134634 0.52 rs16892140 ENSG00000273133.1 RP11-799M12.2 -6.1 2.18e-09 9.96e-07 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15546927 chr4:15563698~15564253:- LUSC cis rs2732480 0.538 rs1387259 ENSG00000273765.1 RP11-370I10.11 -6.1 2.18e-09 9.96e-07 -0.32 -0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48309739 chr12:48360920~48361377:+ LUSC cis rs2179367 0.632 rs9498329 ENSG00000231760.4 RP11-350J20.5 6.1 2.18e-09 9.97e-07 0.38 0.27 Dupuytren's disease; chr6:149349941 chr6:149796151~149826294:- LUSC cis rs881375 0.678 rs9886724 ENSG00000226752.6 PSMD5-AS1 -6.1 2.18e-09 9.98e-07 -0.3 -0.27 Rheumatoid arthritis; chr9:120902741 chr9:120824828~120854385:+ LUSC cis rs950169 1 rs1911155 ENSG00000259728.4 LINC00933 6.1 2.18e-09 9.98e-07 0.36 0.27 Schizophrenia; chr15:84118883 chr15:84570649~84580175:+ LUSC cis rs116095464 0.558 rs10079760 ENSG00000250848.1 CTD-2083E4.5 -6.1 2.18e-09 9.98e-07 -0.41 -0.27 Breast cancer; chr5:230663 chr5:288833~290321:- LUSC cis rs7772486 0.79 rs7753696 ENSG00000235652.6 RP11-545I5.3 -6.1 2.19e-09 1e-06 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145957962 chr6:145799409~145886585:+ LUSC cis rs2404602 0.735 rs3765115 ENSG00000259422.1 RP11-593F23.1 -6.1 2.19e-09 1e-06 -0.31 -0.27 Blood metabolite levels; chr15:76381375 chr15:76174891~76181486:- LUSC cis rs6772849 0.896 rs4557179 ENSG00000277250.1 Metazoa_SRP -6.1 2.19e-09 1e-06 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128647883 chr3:128673681~128674021:- LUSC cis rs853679 0.517 rs56310871 ENSG00000280107.1 AL022393.9 -6.1 2.19e-09 1e-06 -0.33 -0.27 Depression; chr6:28076704 chr6:28170845~28172521:+ LUSC cis rs228614 0.51 rs170565 ENSG00000230069.3 LRRC37A15P -6.1 2.2e-09 1.01e-06 -0.29 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798277 chr4:102727274~102730721:- LUSC cis rs2153535 0.58 rs718502 ENSG00000230939.1 RP11-314C16.1 -6.1 2.2e-09 1.01e-06 -0.32 -0.27 Motion sickness; chr6:8527167 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs718503 ENSG00000230939.1 RP11-314C16.1 -6.1 2.2e-09 1.01e-06 -0.32 -0.27 Motion sickness; chr6:8527230 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6597335 ENSG00000230939.1 RP11-314C16.1 -6.1 2.2e-09 1.01e-06 -0.32 -0.27 Motion sickness; chr6:8527481 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9328486 ENSG00000230939.1 RP11-314C16.1 -6.1 2.2e-09 1.01e-06 -0.32 -0.27 Motion sickness; chr6:8527775 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2183112 ENSG00000230939.1 RP11-314C16.1 -6.1 2.2e-09 1.01e-06 -0.32 -0.27 Motion sickness; chr6:8527979 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs2143353 ENSG00000230939.1 RP11-314C16.1 -6.1 2.2e-09 1.01e-06 -0.32 -0.27 Motion sickness; chr6:8529878 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs2143352 ENSG00000230939.1 RP11-314C16.1 -6.1 2.2e-09 1.01e-06 -0.32 -0.27 Motion sickness; chr6:8530015 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs7741024 ENSG00000230939.1 RP11-314C16.1 -6.1 2.2e-09 1.01e-06 -0.32 -0.27 Motion sickness; chr6:8530080 chr6:8784178~8785445:+ LUSC cis rs11098499 0.863 rs7669520 ENSG00000248280.1 RP11-33B1.2 6.1 2.21e-09 1.01e-06 0.32 0.27 Corneal astigmatism; chr4:119594123 chr4:119440561~119450157:- LUSC cis rs6772849 0.775 rs9828414 ENSG00000242551.2 POU5F1P6 -6.1 2.21e-09 1.01e-06 -0.32 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128693874 chr3:128674735~128677005:- LUSC cis rs6772849 0.804 rs9832430 ENSG00000242551.2 POU5F1P6 -6.1 2.21e-09 1.01e-06 -0.32 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128694054 chr3:128674735~128677005:- LUSC cis rs1122900 1 rs1122900 ENSG00000250155.1 CTD-2353F22.1 6.1 2.21e-09 1.01e-06 0.27 0.27 Aggressive periodontitis; chr5:36689079 chr5:36666214~36725195:- LUSC cis rs9322193 0.923 rs9688861 ENSG00000268592.3 RAET1E-AS1 6.1 2.21e-09 1.01e-06 0.34 0.27 Lung cancer; chr6:149637924 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs7740278 ENSG00000268592.3 RAET1E-AS1 6.1 2.21e-09 1.01e-06 0.34 0.27 Lung cancer; chr6:149640116 chr6:149863494~149919507:+ LUSC cis rs9549367 0.712 rs2316443 ENSG00000269125.1 RP11-98F14.11 -6.1 2.21e-09 1.01e-06 -0.33 -0.27 Platelet distribution width; chr13:113210523 chr13:113165002~113165183:- LUSC cis rs9322193 0.962 rs9689447 ENSG00000268592.3 RAET1E-AS1 6.1 2.21e-09 1.01e-06 0.34 0.27 Lung cancer; chr6:149789350 chr6:149863494~149919507:+ LUSC cis rs7772486 0.79 rs4280983 ENSG00000235652.6 RP11-545I5.3 -6.1 2.21e-09 1.01e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145959654 chr6:145799409~145886585:+ LUSC cis rs11971779 0.553 rs7799742 ENSG00000273391.1 RP11-634H22.1 6.1 2.21e-09 1.01e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139367132 chr7:139359032~139359566:- LUSC cis rs7772486 0.79 rs6923545 ENSG00000235652.6 RP11-545I5.3 -6.1 2.21e-09 1.01e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145923607 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs6922507 ENSG00000235652.6 RP11-545I5.3 -6.1 2.21e-09 1.01e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145929019 chr6:145799409~145886585:+ LUSC cis rs35160687 0.712 rs2303359 ENSG00000273080.1 RP11-301O19.1 -6.1 2.22e-09 1.01e-06 -0.25 -0.27 Night sleep phenotypes; chr2:86251547 chr2:86195590~86196049:+ LUSC cis rs2276314 1 rs9304153 ENSG00000278986.1 RP11-723J4.3 -6.1 2.22e-09 1.01e-06 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35982187 chr18:35972151~35973916:+ LUSC cis rs2276314 1 rs9304154 ENSG00000278986.1 RP11-723J4.3 -6.1 2.22e-09 1.01e-06 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35982264 chr18:35972151~35973916:+ LUSC cis rs6142102 0.812 rs6059574 ENSG00000275784.1 RP5-1125A11.6 6.1 2.22e-09 1.01e-06 0.3 0.27 Skin pigmentation; chr20:33935366 chr20:33989480~33991818:- LUSC cis rs11846409 0.86 rs4774167 ENSG00000274576.2 IGHV2-70 -6.1 2.22e-09 1.01e-06 -0.29 -0.27 Rheumatic heart disease; chr14:106619987 chr14:106770577~106771020:- LUSC cis rs950169 1 rs79318564 ENSG00000259728.4 LINC00933 6.1 2.22e-09 1.02e-06 0.36 0.27 Schizophrenia; chr15:84117398 chr15:84570649~84580175:+ LUSC cis rs78487399 0.71 rs79165612 ENSG00000234936.1 AC010883.5 6.1 2.22e-09 1.02e-06 0.43 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43397113 chr2:43229573~43233394:+ LUSC cis rs1823913 0.66 rs1454752 ENSG00000227542.1 AC092614.2 -6.1 2.23e-09 1.02e-06 -0.35 -0.27 Obesity-related traits; chr2:191298668 chr2:191229165~191246172:- LUSC cis rs34792 0.637 rs2450356 ENSG00000207425.1 Y_RNA 6.1 2.23e-09 1.02e-06 0.35 0.27 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15477487 chr16:14915457~14915556:- LUSC cis rs1134634 0.52 rs7682586 ENSG00000273133.1 RP11-799M12.2 -6.1 2.23e-09 1.02e-06 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15624620 chr4:15563698~15564253:- LUSC cis rs2948294 0.588 rs4840913 ENSG00000253893.2 FAM85B -6.1 2.23e-09 1.02e-06 -0.35 -0.27 Red cell distribution width; chr8:8259384 chr8:8167819~8226614:- LUSC cis rs7955901 0.638 rs11178645 ENSG00000257265.1 CTD-2021H9.1 6.1 2.23e-09 1.02e-06 0.31 0.27 Type 2 diabetes; chr12:71129854 chr12:71007773~71032083:- LUSC cis rs13113518 0.812 rs56055342 ENSG00000272969.1 RP11-528I4.2 6.1 2.23e-09 1.02e-06 0.31 0.27 Height; chr4:55540928 chr4:55547112~55547889:+ LUSC cis rs7429990 0.833 rs883661 ENSG00000229759.1 MRPS18AP1 -6.1 2.23e-09 1.02e-06 -0.27 -0.27 Educational attainment (years of education); chr3:47618611 chr3:48256350~48256938:- LUSC cis rs7267979 0.932 rs6115215 ENSG00000274973.1 RP13-401N8.7 -6.1 2.23e-09 1.02e-06 -0.28 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25581864 chr20:25845497~25845862:+ LUSC cis rs6504950 0.925 rs244348 ENSG00000275710.1 RP11-257O5.4 6.1 2.23e-09 1.02e-06 0.33 0.27 Breast cancer; chr17:55118930 chr17:54964474~54964679:+ LUSC cis rs66887589 0.967 rs56173225 ENSG00000249244.1 RP11-548H18.2 -6.1 2.24e-09 1.02e-06 -0.32 -0.27 Diastolic blood pressure; chr4:119588817 chr4:119391831~119395335:- LUSC cis rs62432291 0.681 rs431205 ENSG00000235086.1 FNDC1-IT1 -6.1 2.24e-09 1.02e-06 -0.45 -0.27 Joint mobility (Beighton score); chr6:159241467 chr6:159240786~159243329:+ LUSC cis rs2276314 0.857 rs62101376 ENSG00000278986.1 RP11-723J4.3 -6.1 2.24e-09 1.02e-06 -0.35 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36002992 chr18:35972151~35973916:+ LUSC cis rs7189233 1 rs62048543 ENSG00000279344.1 RP11-44F14.7 6.1 2.24e-09 1.02e-06 0.25 0.27 Intelligence (multi-trait analysis); chr16:53500712 chr16:53478957~53481550:- LUSC cis rs9322193 0.962 rs9765929 ENSG00000268592.3 RAET1E-AS1 6.1 2.24e-09 1.02e-06 0.34 0.27 Lung cancer; chr6:149769680 chr6:149863494~149919507:+ LUSC cis rs9545047 0.604 rs9574406 ENSG00000227676.3 LINC01068 -6.1 2.24e-09 1.02e-06 -0.33 -0.27 Schizophrenia; chr13:79338982 chr13:79566727~79571436:+ LUSC cis rs7772486 0.659 rs9376957 ENSG00000235652.6 RP11-545I5.3 -6.1 2.24e-09 1.02e-06 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145689928 chr6:145799409~145886585:+ LUSC cis rs7772486 0.686 rs9497396 ENSG00000235652.6 RP11-545I5.3 -6.1 2.24e-09 1.02e-06 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145693827 chr6:145799409~145886585:+ LUSC cis rs638893 0.636 rs493720 ENSG00000278376.1 RP11-158I9.8 -6.1 2.24e-09 1.02e-06 -0.36 -0.27 Vitiligo; chr11:118733969 chr11:118791254~118793137:+ LUSC cis rs1134634 0.52 rs11932730 ENSG00000273133.1 RP11-799M12.2 6.1 2.25e-09 1.03e-06 0.35 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15564135 chr4:15563698~15564253:- LUSC cis rs875971 0.545 rs12670811 ENSG00000226824.5 RP4-756H11.3 -6.1 2.25e-09 1.03e-06 -0.35 -0.27 Aortic root size; chr7:66358032 chr7:66654538~66669855:+ LUSC cis rs8062405 1 rs80275162 ENSG00000278665.1 RP11-666O2.4 6.1 2.25e-09 1.03e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28852196 chr16:28599241~28601881:- LUSC cis rs8062405 0.755 rs7193402 ENSG00000278665.1 RP11-666O2.4 6.1 2.25e-09 1.03e-06 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574806 chr16:28599241~28601881:- LUSC cis rs227275 0.554 rs223334 ENSG00000230069.3 LRRC37A15P 6.1 2.25e-09 1.03e-06 0.29 0.27 Allergic disease (asthma, hay fever or eczema); chr4:102867054 chr4:102727274~102730721:- LUSC cis rs2842992 0.789 rs2475566 ENSG00000237927.1 RP3-393E18.2 -6.1 2.26e-09 1.03e-06 -0.4 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159727709 chr6:159586955~159589169:- LUSC cis rs7772486 0.79 rs9497431 ENSG00000235652.6 RP11-545I5.3 -6.1 2.26e-09 1.03e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145927041 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs7753092 ENSG00000235652.6 RP11-545I5.3 -6.1 2.26e-09 1.03e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145927727 chr6:145799409~145886585:+ LUSC cis rs227275 0.525 rs7685399 ENSG00000230069.3 LRRC37A15P -6.1 2.26e-09 1.03e-06 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102991926 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs2866417 ENSG00000230069.3 LRRC37A15P -6.1 2.26e-09 1.03e-06 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102993481 chr4:102727274~102730721:- LUSC cis rs1729407 0.814 rs2071521 ENSG00000254851.1 RP11-109L13.1 6.1 2.27e-09 1.03e-06 0.34 0.27 Apolipoprotein A-IV levels; chr11:116827132 chr11:117135528~117138582:+ LUSC cis rs853679 1 rs853685 ENSG00000204709.4 LINC01556 6.1 2.27e-09 1.04e-06 0.46 0.27 Depression; chr6:28321008 chr6:28943877~28944537:+ LUSC cis rs638893 0.636 rs526850 ENSG00000278376.1 RP11-158I9.8 -6.1 2.27e-09 1.04e-06 -0.36 -0.27 Vitiligo; chr11:118734418 chr11:118791254~118793137:+ LUSC cis rs8062405 0.625 rs8060365 ENSG00000278665.1 RP11-666O2.4 -6.1 2.28e-09 1.04e-06 -0.29 -0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28899988 chr16:28599241~28601881:- LUSC cis rs2243480 1 rs4718333 ENSG00000226824.5 RP4-756H11.3 6.1 2.28e-09 1.04e-06 0.52 0.27 Diabetic kidney disease; chr7:66307771 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs7792391 ENSG00000226824.5 RP4-756H11.3 6.1 2.28e-09 1.04e-06 0.52 0.27 Diabetic kidney disease; chr7:66308442 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs10247526 ENSG00000226824.5 RP4-756H11.3 6.1 2.28e-09 1.04e-06 0.52 0.27 Diabetic kidney disease; chr7:66315709 chr7:66654538~66669855:+ LUSC cis rs2243480 0.908 rs1532573 ENSG00000226824.5 RP4-756H11.3 6.1 2.28e-09 1.04e-06 0.52 0.27 Diabetic kidney disease; chr7:66333815 chr7:66654538~66669855:+ LUSC cis rs8062405 0.54 rs480400 ENSG00000259982.1 CDC37P1 6.1 2.28e-09 1.04e-06 0.33 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28563294 chr16:28700294~28701540:- LUSC cis rs2028299 0.92 rs4932265 ENSG00000259677.1 RP11-493E3.1 6.1 2.28e-09 1.04e-06 0.35 0.27 Type 2 diabetes; chr15:89880061 chr15:89876540~89877285:+ LUSC cis rs1061377 1 rs9996285 ENSG00000249685.1 RP11-360F5.3 6.09 2.28e-09 1.04e-06 0.3 0.27 Uric acid levels; chr4:39130556 chr4:39133913~39135608:+ LUSC cis rs4423214 0.524 rs4944046 ENSG00000254682.1 RP11-660L16.2 6.09 2.29e-09 1.04e-06 0.35 0.27 Vitamin D levels; chr11:71412748 chr11:71448674~71452157:+ LUSC cis rs8072100 0.701 rs8075566 ENSG00000228782.6 CTD-2026D20.3 6.09 2.29e-09 1.04e-06 0.27 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47693671 chr17:47450568~47492492:- LUSC cis rs9322193 0.923 rs55849538 ENSG00000268592.3 RAET1E-AS1 6.09 2.29e-09 1.04e-06 0.34 0.27 Lung cancer; chr6:149635330 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs4870509 ENSG00000268592.3 RAET1E-AS1 6.09 2.29e-09 1.04e-06 0.35 0.27 Lung cancer; chr6:149702212 chr6:149863494~149919507:+ LUSC cis rs6142102 0.961 rs1555075 ENSG00000275784.1 RP5-1125A11.6 -6.09 2.29e-09 1.04e-06 -0.31 -0.27 Skin pigmentation; chr20:34022595 chr20:33989480~33991818:- LUSC cis rs79349575 0.783 rs2088139 ENSG00000270781.1 RP11-501C14.9 -6.09 2.29e-09 1.04e-06 -0.28 -0.27 Type 2 diabetes; chr17:48922748 chr17:48899131~48899748:+ LUSC cis rs875971 0.545 rs1638724 ENSG00000226824.5 RP4-756H11.3 6.09 2.29e-09 1.04e-06 0.36 0.27 Aortic root size; chr7:66575494 chr7:66654538~66669855:+ LUSC cis rs13113518 0.812 rs12500601 ENSG00000249700.7 SRD5A3-AS1 6.09 2.3e-09 1.05e-06 0.32 0.27 Height; chr4:55451489 chr4:55363971~55395847:- LUSC cis rs11089937 0.597 rs5750579 ENSG00000211638.2 IGLV8-61 -6.09 2.3e-09 1.05e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22136581 chr22:22098700~22099212:+ LUSC cis rs11098499 0.644 rs10009566 ENSG00000250412.1 KLHL2P1 6.09 2.3e-09 1.05e-06 0.33 0.27 Corneal astigmatism; chr4:119637453 chr4:119334329~119378233:+ LUSC cis rs11971779 0.616 rs6965143 ENSG00000273391.1 RP11-634H22.1 6.09 2.3e-09 1.05e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139341862 chr7:139359032~139359566:- LUSC cis rs11971779 0.616 rs11771715 ENSG00000273391.1 RP11-634H22.1 6.09 2.3e-09 1.05e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139342750 chr7:139359032~139359566:- LUSC cis rs75422866 0.867 rs73113139 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47622826 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73113143 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47623060 chr12:47706085~47742294:+ LUSC cis rs75422866 0.717 rs73113159 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47631318 chr12:47706085~47742294:+ LUSC cis rs75422866 0.717 rs73113161 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47632361 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs117022227 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47633282 chr12:47706085~47742294:+ LUSC cis rs75422866 1 rs73102120 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47637280 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102125 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47637869 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs12426849 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47638975 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs117950951 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47639794 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs7954764 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47641136 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs12422974 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47644559 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102127 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47645341 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102140 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47647497 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102148 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47648013 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102151 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47648023 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs75568526 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47649718 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs116302411 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47649788 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102166 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47653769 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102168 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47654010 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102171 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47656077 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs76100981 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47660092 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102188 ENSG00000257433.4 RP1-197B17.3 6.09 2.3e-09 1.05e-06 0.65 0.27 Pneumonia; chr12:47662993 chr12:47706085~47742294:+ LUSC cis rs442309 0.812 rs448355 ENSG00000238280.1 RP11-436D10.3 -6.09 2.3e-09 1.05e-06 -0.35 -0.27 Vogt-Koyanagi-Harada syndrome; chr10:62772835 chr10:62793562~62805887:- LUSC cis rs66887589 0.934 rs41464847 ENSG00000248280.1 RP11-33B1.2 -6.09 2.3e-09 1.05e-06 -0.29 -0.27 Diastolic blood pressure; chr4:119611246 chr4:119440561~119450157:- LUSC cis rs8031584 1 rs35607976 ENSG00000260382.1 RP11-540B6.2 6.09 2.3e-09 1.05e-06 0.38 0.27 Huntington's disease progression; chr15:30985585 chr15:30882267~30883231:- LUSC cis rs11722779 0.903 rs6830193 ENSG00000230069.3 LRRC37A15P -6.09 2.3e-09 1.05e-06 -0.29 -0.27 Schizophrenia; chr4:102955457 chr4:102727274~102730721:- LUSC cis rs2337406 0.866 rs78462736 ENSG00000254174.1 IGHV1-12 6.09 2.3e-09 1.05e-06 0.26 0.27 Alzheimer's disease (late onset); chr14:106779942 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs8016203 ENSG00000254174.1 IGHV1-12 6.09 2.3e-09 1.05e-06 0.26 0.27 Alzheimer's disease (late onset); chr14:106780575 chr14:106122420~106122709:- LUSC cis rs7955901 0.638 rs2270586 ENSG00000257265.1 CTD-2021H9.1 6.09 2.31e-09 1.05e-06 0.31 0.27 Type 2 diabetes; chr12:71137859 chr12:71007773~71032083:- LUSC cis rs7955901 0.638 rs2270585 ENSG00000257265.1 CTD-2021H9.1 6.09 2.31e-09 1.05e-06 0.31 0.27 Type 2 diabetes; chr12:71137883 chr12:71007773~71032083:- LUSC cis rs61270009 0.955 rs780402 ENSG00000247828.6 TMEM161B-AS1 -6.09 2.31e-09 1.05e-06 -0.31 -0.27 Depressive symptoms; chr5:88244890 chr5:88268895~88436685:+ LUSC cis rs79349575 0.783 rs55771415 ENSG00000270781.1 RP11-501C14.9 -6.09 2.31e-09 1.05e-06 -0.28 -0.27 Type 2 diabetes; chr17:48922575 chr17:48899131~48899748:+ LUSC cis rs62103177 0.564 rs7228971 ENSG00000261126.6 RP11-795F19.1 -6.09 2.31e-09 1.05e-06 -0.34 -0.27 Opioid sensitivity; chr18:79978025 chr18:80046900~80095482:+ LUSC cis rs116095464 0.558 rs10052012 ENSG00000250848.1 CTD-2083E4.5 -6.09 2.31e-09 1.05e-06 -0.4 -0.27 Breast cancer; chr5:231793 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs10077076 ENSG00000250848.1 CTD-2083E4.5 -6.09 2.31e-09 1.05e-06 -0.4 -0.27 Breast cancer; chr5:231825 chr5:288833~290321:- LUSC cis rs801193 1 rs2420824 ENSG00000224316.1 RP11-479O9.2 -6.09 2.31e-09 1.05e-06 -0.26 -0.27 Aortic root size; chr7:66666129 chr7:65773620~65802067:+ LUSC cis rs950880 0.71 rs17027060 ENSG00000234389.1 AC007278.3 -6.09 2.31e-09 1.05e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102391107 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs66919607 ENSG00000234389.1 AC007278.3 -6.09 2.31e-09 1.05e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102392509 chr2:102438713~102440475:+ LUSC cis rs875971 0.862 rs1983372 ENSG00000179406.6 LINC00174 6.09 2.32e-09 1.05e-06 0.29 0.27 Aortic root size; chr7:66146364 chr7:66376044~66401338:- LUSC cis rs4372836 0.93 rs4233727 ENSG00000226833.4 AC097724.3 6.09 2.32e-09 1.06e-06 0.32 0.27 Body mass index; chr2:28754378 chr2:28708953~28736205:- LUSC cis rs875971 0.545 rs10950036 ENSG00000226824.5 RP4-756H11.3 -6.09 2.32e-09 1.06e-06 -0.35 -0.27 Aortic root size; chr7:66353241 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs73376394 ENSG00000226824.5 RP4-756H11.3 -6.09 2.32e-09 1.06e-06 -0.35 -0.27 Aortic root size; chr7:66172694 chr7:66654538~66669855:+ LUSC cis rs4372836 1 rs55835850 ENSG00000226833.4 AC097724.3 -6.09 2.32e-09 1.06e-06 -0.31 -0.27 Body mass index; chr2:28726430 chr2:28708953~28736205:- LUSC cis rs7772486 0.774 rs2748503 ENSG00000235652.6 RP11-545I5.3 6.09 2.33e-09 1.06e-06 0.28 0.27 Lobe attachment (rater-scored or self-reported); chr6:145973906 chr6:145799409~145886585:+ LUSC cis rs889398 0.967 rs244415 ENSG00000226232.7 RP11-419C5.2 6.09 2.33e-09 1.06e-06 0.26 0.27 Body mass index; chr16:69632780 chr16:69976388~69996188:- LUSC cis rs228614 0.51 rs223311 ENSG00000230069.3 LRRC37A15P -6.09 2.33e-09 1.06e-06 -0.29 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888757 chr4:102727274~102730721:- LUSC cis rs1729407 0.814 rs2542051 ENSG00000254851.1 RP11-109L13.1 6.09 2.33e-09 1.06e-06 0.33 0.27 Apolipoprotein A-IV levels; chr11:116827022 chr11:117135528~117138582:+ LUSC cis rs496547 0.557 rs516719 ENSG00000255422.1 AP002954.4 -6.09 2.33e-09 1.06e-06 -0.29 -0.27 Hip minimal joint space width; chr11:118808736 chr11:118704607~118750263:+ LUSC cis rs2408955 0.521 rs1476607 ENSG00000240399.1 RP1-228P16.1 -6.09 2.34e-09 1.06e-06 -0.28 -0.27 Glycated hemoglobin levels; chr12:48131021 chr12:48054813~48055591:- LUSC cis rs2153535 0.58 rs6927589 ENSG00000230939.1 RP11-314C16.1 6.09 2.34e-09 1.06e-06 0.32 0.27 Motion sickness; chr6:8456399 chr6:8784178~8785445:+ LUSC cis rs11159086 0.793 rs10139122 ENSG00000259005.1 RP3-449M8.6 6.09 2.34e-09 1.06e-06 0.4 0.27 Advanced glycation end-product levels; chr14:74492353 chr14:74474007~74474864:- LUSC cis rs801193 1 rs2420824 ENSG00000237310.1 GS1-124K5.4 -6.09 2.34e-09 1.06e-06 -0.27 -0.27 Aortic root size; chr7:66666129 chr7:66493706~66495474:+ LUSC cis rs7267979 0.899 rs6115213 ENSG00000274973.1 RP13-401N8.7 -6.09 2.34e-09 1.06e-06 -0.27 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25569736 chr20:25845497~25845862:+ LUSC cis rs11846409 0.521 rs10143547 ENSG00000274576.2 IGHV2-70 -6.09 2.34e-09 1.07e-06 -0.29 -0.27 Rheumatic heart disease; chr14:106644638 chr14:106770577~106771020:- LUSC cis rs17270561 0.609 rs1408271 ENSG00000272462.2 U91328.19 -6.09 2.35e-09 1.07e-06 -0.31 -0.27 Iron status biomarkers; chr6:25859393 chr6:25992662~26001775:+ LUSC cis rs66887589 0.807 rs13134517 ENSG00000245958.5 RP11-33B1.1 -6.09 2.35e-09 1.07e-06 -0.26 -0.27 Diastolic blood pressure; chr4:119484107 chr4:119454791~119552025:+ LUSC cis rs66887589 0.837 rs6534135 ENSG00000245958.5 RP11-33B1.1 -6.09 2.35e-09 1.07e-06 -0.26 -0.27 Diastolic blood pressure; chr4:119485147 chr4:119454791~119552025:+ LUSC cis rs61270009 0.955 rs13189889 ENSG00000247828.6 TMEM161B-AS1 6.09 2.35e-09 1.07e-06 0.32 0.27 Depressive symptoms; chr5:88365589 chr5:88268895~88436685:+ LUSC cis rs9322193 0.962 rs4380763 ENSG00000268592.3 RAET1E-AS1 6.09 2.35e-09 1.07e-06 0.35 0.27 Lung cancer; chr6:149678086 chr6:149863494~149919507:+ LUSC cis rs6991838 0.778 rs13261559 ENSG00000200714.1 Y_RNA 6.09 2.36e-09 1.07e-06 0.33 0.27 Intelligence (multi-trait analysis); chr8:65549808 chr8:65592731~65592820:+ LUSC cis rs6991838 0.778 rs7843697 ENSG00000200714.1 Y_RNA 6.09 2.36e-09 1.07e-06 0.33 0.27 Intelligence (multi-trait analysis); chr8:65550533 chr8:65592731~65592820:+ LUSC cis rs6991838 0.778 rs7843724 ENSG00000200714.1 Y_RNA 6.09 2.36e-09 1.07e-06 0.33 0.27 Intelligence (multi-trait analysis); chr8:65550581 chr8:65592731~65592820:+ LUSC cis rs2243480 1 rs1499613 ENSG00000226824.5 RP4-756H11.3 6.09 2.36e-09 1.07e-06 0.52 0.27 Diabetic kidney disease; chr7:66265873 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs1553174 ENSG00000226824.5 RP4-756H11.3 6.09 2.36e-09 1.07e-06 0.52 0.27 Diabetic kidney disease; chr7:66266207 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs10950032 ENSG00000226824.5 RP4-756H11.3 6.09 2.36e-09 1.07e-06 0.52 0.27 Diabetic kidney disease; chr7:66273604 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs6958420 ENSG00000226824.5 RP4-756H11.3 6.09 2.36e-09 1.07e-06 0.52 0.27 Diabetic kidney disease; chr7:66286184 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs1392104 ENSG00000226824.5 RP4-756H11.3 6.09 2.36e-09 1.07e-06 0.52 0.27 Diabetic kidney disease; chr7:66294120 chr7:66654538~66669855:+ LUSC cis rs227275 0.554 rs223316 ENSG00000230069.3 LRRC37A15P -6.09 2.36e-09 1.07e-06 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102881949 chr4:102727274~102730721:- LUSC cis rs950169 0.881 rs150965 ENSG00000259295.5 CSPG4P12 6.09 2.36e-09 1.07e-06 0.36 0.27 Schizophrenia; chr15:84537296 chr15:85191438~85213905:+ LUSC cis rs14027 0.921 rs6469852 ENSG00000279347.1 RP11-85I17.2 6.09 2.36e-09 1.07e-06 0.25 0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119848495 chr8:119838736~119840385:- LUSC cis rs11098499 0.863 rs13136462 ENSG00000248280.1 RP11-33B1.2 6.09 2.36e-09 1.07e-06 0.32 0.27 Corneal astigmatism; chr4:119622018 chr4:119440561~119450157:- LUSC cis rs2732480 0.538 rs1387260 ENSG00000273765.1 RP11-370I10.11 6.09 2.36e-09 1.07e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48309308 chr12:48360920~48361377:+ LUSC cis rs9545047 0.604 rs9574410 ENSG00000227676.3 LINC01068 -6.09 2.37e-09 1.07e-06 -0.32 -0.27 Schizophrenia; chr13:79343091 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs2274555 ENSG00000227676.3 LINC01068 -6.09 2.37e-09 1.07e-06 -0.32 -0.27 Schizophrenia; chr13:79344188 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9565491 ENSG00000227676.3 LINC01068 -6.09 2.37e-09 1.07e-06 -0.32 -0.27 Schizophrenia; chr13:79346037 chr13:79566727~79571436:+ LUSC cis rs8040855 0.627 rs62019482 ENSG00000259295.5 CSPG4P12 6.09 2.37e-09 1.07e-06 0.34 0.27 Bulimia nervosa; chr15:85071796 chr15:85191438~85213905:+ LUSC cis rs950880 0.71 rs2270298 ENSG00000234389.1 AC007278.3 -6.09 2.37e-09 1.08e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102375619 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs17027037 ENSG00000234389.1 AC007278.3 -6.09 2.37e-09 1.08e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102378424 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs2080289 ENSG00000234389.1 AC007278.3 -6.09 2.37e-09 1.08e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102378560 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs3821203 ENSG00000234389.1 AC007278.3 -6.09 2.37e-09 1.08e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102380412 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs3771162 ENSG00000234389.1 AC007278.3 -6.09 2.37e-09 1.08e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102380714 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs11465633 ENSG00000234389.1 AC007278.3 -6.09 2.37e-09 1.08e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102381273 chr2:102438713~102440475:+ LUSC cis rs2302464 1 rs12651052 ENSG00000214846.4 RP11-115L11.1 6.09 2.37e-09 1.08e-06 0.79 0.27 Cerebrospinal fluid biomarker levels; chr4:15726813 chr4:15730962~15731627:- LUSC cis rs2302464 1 rs56381553 ENSG00000214846.4 RP11-115L11.1 6.09 2.37e-09 1.08e-06 0.79 0.27 Cerebrospinal fluid biomarker levels; chr4:15726824 chr4:15730962~15731627:- LUSC cis rs2302464 1 rs12645513 ENSG00000214846.4 RP11-115L11.1 6.09 2.37e-09 1.08e-06 0.79 0.27 Cerebrospinal fluid biomarker levels; chr4:15727155 chr4:15730962~15731627:- LUSC cis rs2302464 1 rs58335439 ENSG00000214846.4 RP11-115L11.1 6.09 2.37e-09 1.08e-06 0.79 0.27 Cerebrospinal fluid biomarker levels; chr4:15727183 chr4:15730962~15731627:- LUSC cis rs2019137 0.936 rs731834 ENSG00000274877.1 RP11-65I12.1 6.09 2.37e-09 1.08e-06 0.32 0.27 Lymphocyte counts; chr2:113199621 chr2:113237595~113240825:+ LUSC cis rs11971779 0.715 rs6467856 ENSG00000273391.1 RP11-634H22.1 6.09 2.37e-09 1.08e-06 0.3 0.27 Diisocyanate-induced asthma; chr7:139442553 chr7:139359032~139359566:- LUSC cis rs10129255 0.556 rs9324093 ENSG00000224373.3 IGHV4-59 6.09 2.37e-09 1.08e-06 0.13 0.27 Kawasaki disease; chr14:106683893 chr14:106627249~106627825:- LUSC cis rs2439831 1 rs9920763 ENSG00000249839.1 AC011330.5 -6.09 2.38e-09 1.08e-06 -0.55 -0.27 Lung cancer in ever smokers; chr15:43468310 chr15:43663654~43684339:- LUSC cis rs853679 0.517 rs1947862 ENSG00000280107.1 AL022393.9 -6.09 2.38e-09 1.08e-06 -0.34 -0.27 Depression; chr6:28137418 chr6:28170845~28172521:+ LUSC cis rs13113518 0.738 rs6849883 ENSG00000273257.1 RP11-177J6.1 6.09 2.39e-09 1.08e-06 0.34 0.27 Height; chr4:55387515 chr4:55387949~55388271:+ LUSC cis rs1061377 1 rs1036036 ENSG00000249685.1 RP11-360F5.3 6.09 2.39e-09 1.08e-06 0.31 0.27 Uric acid levels; chr4:39111104 chr4:39133913~39135608:+ LUSC cis rs875971 0.66 rs1860468 ENSG00000237310.1 GS1-124K5.4 -6.09 2.39e-09 1.08e-06 -0.27 -0.27 Aortic root size; chr7:66642265 chr7:66493706~66495474:+ LUSC cis rs1387259 0.931 rs11168474 ENSG00000240399.1 RP1-228P16.1 6.09 2.39e-09 1.08e-06 0.29 0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48227601 chr12:48054813~48055591:- LUSC cis rs66887589 0.934 rs7681980 ENSG00000248280.1 RP11-33B1.2 -6.09 2.39e-09 1.08e-06 -0.3 -0.27 Diastolic blood pressure; chr4:119612068 chr4:119440561~119450157:- LUSC cis rs950880 0.71 rs66566526 ENSG00000234389.1 AC007278.3 -6.09 2.39e-09 1.08e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102431342 chr2:102438713~102440475:+ LUSC cis rs79349575 0.756 rs3848460 ENSG00000270781.1 RP11-501C14.9 6.09 2.4e-09 1.09e-06 0.28 0.27 Type 2 diabetes; chr17:48969752 chr17:48899131~48899748:+ LUSC cis rs9549367 0.774 rs9549696 ENSG00000269125.1 RP11-98F14.11 -6.09 2.4e-09 1.09e-06 -0.33 -0.27 Platelet distribution width; chr13:113220748 chr13:113165002~113165183:- LUSC cis rs71403859 0.614 rs12935422 ENSG00000260886.1 TAT-AS1 6.09 2.4e-09 1.09e-06 0.43 0.27 Post bronchodilator FEV1; chr16:71630322 chr16:71565789~71578187:+ LUSC cis rs66887589 0.934 rs7681980 ENSG00000249244.1 RP11-548H18.2 -6.09 2.41e-09 1.09e-06 -0.32 -0.27 Diastolic blood pressure; chr4:119612068 chr4:119391831~119395335:- LUSC cis rs7772486 0.84 rs2814864 ENSG00000235652.6 RP11-545I5.3 6.09 2.41e-09 1.09e-06 0.28 0.27 Lobe attachment (rater-scored or self-reported); chr6:146023910 chr6:145799409~145886585:+ LUSC cis rs9322193 0.884 rs9688794 ENSG00000268592.3 RAET1E-AS1 6.09 2.41e-09 1.09e-06 0.34 0.27 Lung cancer; chr6:149632121 chr6:149863494~149919507:+ LUSC cis rs853679 0.517 rs16893666 ENSG00000280107.1 AL022393.9 6.09 2.41e-09 1.09e-06 0.33 0.27 Depression; chr6:28086929 chr6:28170845~28172521:+ LUSC cis rs61270009 0.955 rs768705 ENSG00000247828.6 TMEM161B-AS1 6.09 2.41e-09 1.09e-06 0.31 0.27 Depressive symptoms; chr5:88272893 chr5:88268895~88436685:+ LUSC cis rs9322193 0.962 rs9478848 ENSG00000268592.3 RAET1E-AS1 6.09 2.42e-09 1.1e-06 0.34 0.27 Lung cancer; chr6:149825080 chr6:149863494~149919507:+ LUSC cis rs2153535 0.58 rs9328484 ENSG00000230939.1 RP11-314C16.1 -6.08 2.42e-09 1.1e-06 -0.32 -0.27 Motion sickness; chr6:8524610 chr6:8784178~8785445:+ LUSC cis rs13113518 0.967 rs12507722 ENSG00000249700.7 SRD5A3-AS1 6.08 2.42e-09 1.1e-06 0.31 0.27 Height; chr4:55536421 chr4:55363971~55395847:- LUSC cis rs13113518 0.967 rs7696832 ENSG00000249700.7 SRD5A3-AS1 6.08 2.42e-09 1.1e-06 0.31 0.27 Height; chr4:55537080 chr4:55363971~55395847:- LUSC cis rs496547 0.686 rs477014 ENSG00000255422.1 AP002954.4 -6.08 2.42e-09 1.1e-06 -0.29 -0.27 Hip minimal joint space width; chr11:118808277 chr11:118704607~118750263:+ LUSC cis rs2337406 0.85 rs4774179 ENSG00000254174.1 IGHV1-12 6.08 2.43e-09 1.1e-06 0.27 0.27 Alzheimer's disease (late onset); chr14:106700837 chr14:106122420~106122709:- LUSC cis rs6142102 0.961 rs6088361 ENSG00000275784.1 RP5-1125A11.6 -6.08 2.43e-09 1.1e-06 -0.31 -0.27 Skin pigmentation; chr20:33969520 chr20:33989480~33991818:- LUSC cis rs1198872 0.563 rs2005011 ENSG00000272275.1 RP11-791G15.2 -6.08 2.43e-09 1.1e-06 -0.38 -0.27 Cardiac Troponin-T levels; chr2:10823799 chr2:10767875~10770058:- LUSC cis rs1198872 0.563 rs2008967 ENSG00000272275.1 RP11-791G15.2 -6.08 2.43e-09 1.1e-06 -0.38 -0.27 Cardiac Troponin-T levels; chr2:10824167 chr2:10767875~10770058:- LUSC cis rs5753618 0.509 rs2413033 ENSG00000236132.1 CTA-440B3.1 6.08 2.43e-09 1.1e-06 0.37 0.27 Colorectal cancer; chr22:31178227 chr22:31816379~31817491:- LUSC cis rs35160687 0.623 rs1863060 ENSG00000273080.1 RP11-301O19.1 -6.08 2.44e-09 1.1e-06 -0.26 -0.27 Night sleep phenotypes; chr2:86284333 chr2:86195590~86196049:+ LUSC cis rs67180937 0.553 rs2133188 ENSG00000272750.1 RP11-378J18.8 6.08 2.44e-09 1.11e-06 0.34 0.27 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222640411 chr1:222658867~222661512:- LUSC cis rs2243480 1 rs958550 ENSG00000226824.5 RP4-756H11.3 6.08 2.44e-09 1.11e-06 0.53 0.27 Diabetic kidney disease; chr7:66170692 chr7:66654538~66669855:+ LUSC cis rs13113518 0.934 rs10866425 ENSG00000273257.1 RP11-177J6.1 6.08 2.44e-09 1.11e-06 0.35 0.27 Height; chr4:55582068 chr4:55387949~55388271:+ LUSC cis rs11971779 0.68 rs1862879 ENSG00000273391.1 RP11-634H22.1 6.08 2.44e-09 1.11e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139335205 chr7:139359032~139359566:- LUSC cis rs13113518 0.934 rs11935823 ENSG00000249700.7 SRD5A3-AS1 6.08 2.44e-09 1.11e-06 0.31 0.27 Height; chr4:55589624 chr4:55363971~55395847:- LUSC cis rs2153535 0.58 rs4140586 ENSG00000230939.1 RP11-314C16.1 -6.08 2.45e-09 1.11e-06 -0.32 -0.27 Motion sickness; chr6:8502959 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs4140585 ENSG00000230939.1 RP11-314C16.1 -6.08 2.45e-09 1.11e-06 -0.32 -0.27 Motion sickness; chr6:8503065 chr6:8784178~8785445:+ LUSC cis rs2019137 0.905 rs2276561 ENSG00000274877.1 RP11-65I12.1 6.08 2.45e-09 1.11e-06 0.32 0.27 Lymphocyte counts; chr2:113198794 chr2:113237595~113240825:+ LUSC cis rs2019137 0.936 rs2305133 ENSG00000274877.1 RP11-65I12.1 6.08 2.45e-09 1.11e-06 0.32 0.27 Lymphocyte counts; chr2:113199244 chr2:113237595~113240825:+ LUSC cis rs2019137 0.936 rs12612729 ENSG00000274877.1 RP11-65I12.1 6.08 2.45e-09 1.11e-06 0.32 0.27 Lymphocyte counts; chr2:113199471 chr2:113237595~113240825:+ LUSC cis rs2153535 0.58 rs7747306 ENSG00000230939.1 RP11-314C16.1 6.08 2.45e-09 1.11e-06 0.32 0.27 Motion sickness; chr6:8453430 chr6:8784178~8785445:+ LUSC cis rs11971779 0.648 rs10230407 ENSG00000273391.1 RP11-634H22.1 6.08 2.45e-09 1.11e-06 0.3 0.27 Diisocyanate-induced asthma; chr7:139419147 chr7:139359032~139359566:- LUSC cis rs11089937 0.555 rs6001226 ENSG00000211639.2 IGLV4-60 6.08 2.46e-09 1.11e-06 0.29 0.27 Periodontitis (PAL4Q3); chr22:22186888 chr22:22162199~22162681:+ LUSC cis rs6504950 1 rs9903146 ENSG00000275710.1 RP11-257O5.4 6.08 2.46e-09 1.11e-06 0.32 0.27 Breast cancer; chr17:54980386 chr17:54964474~54964679:+ LUSC cis rs6504950 0.962 rs9902950 ENSG00000275710.1 RP11-257O5.4 6.08 2.46e-09 1.11e-06 0.32 0.27 Breast cancer; chr17:54980403 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9903220 ENSG00000275710.1 RP11-257O5.4 6.08 2.46e-09 1.11e-06 0.32 0.27 Breast cancer; chr17:54980504 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9903444 ENSG00000275710.1 RP11-257O5.4 6.08 2.46e-09 1.11e-06 0.32 0.27 Breast cancer; chr17:54980532 chr17:54964474~54964679:+ LUSC cis rs6504950 1 rs9903825 ENSG00000275710.1 RP11-257O5.4 6.08 2.46e-09 1.11e-06 0.32 0.27 Breast cancer; chr17:54980553 chr17:54964474~54964679:+ LUSC cis rs8040855 0.627 rs12904238 ENSG00000259295.5 CSPG4P12 6.08 2.46e-09 1.11e-06 0.33 0.27 Bulimia nervosa; chr15:85096610 chr15:85191438~85213905:+ LUSC cis rs28830936 0.966 rs1918310 ENSG00000250379.1 RP11-23P13.4 6.08 2.46e-09 1.11e-06 0.29 0.27 Diastolic blood pressure; chr15:41773055 chr15:41825099~41827936:- LUSC cis rs13113518 0.934 rs10866425 ENSG00000249700.7 SRD5A3-AS1 6.08 2.46e-09 1.11e-06 0.31 0.27 Height; chr4:55582068 chr4:55363971~55395847:- LUSC cis rs34779708 0.741 rs34397613 ENSG00000230534.5 RP11-297A16.2 6.08 2.46e-09 1.11e-06 0.31 0.27 Inflammatory bowel disease;Crohn's disease; chr10:35261385 chr10:35098006~35127020:- LUSC cis rs14027 0.961 rs7017279 ENSG00000279347.1 RP11-85I17.2 6.08 2.46e-09 1.11e-06 0.25 0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119847580 chr8:119838736~119840385:- LUSC cis rs2834288 0.535 rs13049489 ENSG00000273102.1 AP000569.9 6.08 2.46e-09 1.12e-06 0.3 0.27 Gut microbiota (bacterial taxa); chr21:33961054 chr21:33967101~33968573:- LUSC cis rs34779708 0.733 rs7086715 ENSG00000230534.5 RP11-297A16.2 6.08 2.46e-09 1.12e-06 0.31 0.27 Inflammatory bowel disease;Crohn's disease; chr10:35252912 chr10:35098006~35127020:- LUSC cis rs9322193 0.923 rs12174035 ENSG00000268592.3 RAET1E-AS1 6.08 2.47e-09 1.12e-06 0.34 0.27 Lung cancer; chr6:149763311 chr6:149863494~149919507:+ LUSC cis rs66887589 0.967 rs7678973 ENSG00000249244.1 RP11-548H18.2 -6.08 2.47e-09 1.12e-06 -0.32 -0.27 Diastolic blood pressure; chr4:119590662 chr4:119391831~119395335:- LUSC cis rs2243480 1 rs10807701 ENSG00000226824.5 RP4-756H11.3 6.08 2.47e-09 1.12e-06 0.52 0.27 Diabetic kidney disease; chr7:66259699 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs1499614 ENSG00000226824.5 RP4-756H11.3 -6.08 2.47e-09 1.12e-06 -0.52 -0.27 Diabetic kidney disease; chr7:66265811 chr7:66654538~66669855:+ LUSC cis rs72928269 0.515 rs73472410 ENSG00000264263.1 RP11-671P2.1 6.08 2.47e-09 1.12e-06 0.43 0.27 Neuroticism; chr18:53895847 chr18:53480835~53568283:- LUSC cis rs12554020 0.582 rs75018698 ENSG00000227603.1 RP11-165J3.6 6.08 2.47e-09 1.12e-06 0.49 0.27 Schizophrenia; chr9:93647025 chr9:93435332~93437121:- LUSC cis rs6671200 0.607 rs6671408 ENSG00000228852.5 RP11-57H12.5 -6.08 2.47e-09 1.12e-06 -0.35 -0.27 Stearic acid (18:0) levels; chr1:95231535 chr1:95243167~95278940:- LUSC cis rs6671200 0.573 rs6666528 ENSG00000228852.5 RP11-57H12.5 -6.08 2.47e-09 1.12e-06 -0.35 -0.27 Stearic acid (18:0) levels; chr1:95231934 chr1:95243167~95278940:- LUSC cis rs6671200 0.541 rs3738170 ENSG00000228852.5 RP11-57H12.5 -6.08 2.47e-09 1.12e-06 -0.35 -0.27 Stearic acid (18:0) levels; chr1:95234048 chr1:95243167~95278940:- LUSC cis rs8062405 0.755 rs62034350 ENSG00000278665.1 RP11-666O2.4 6.08 2.47e-09 1.12e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28550935 chr16:28599241~28601881:- LUSC cis rs875971 0.965 rs28682868 ENSG00000179406.6 LINC00174 6.08 2.47e-09 1.12e-06 0.29 0.27 Aortic root size; chr7:66224822 chr7:66376044~66401338:- LUSC cis rs8072100 0.701 rs6503807 ENSG00000228782.6 CTD-2026D20.3 6.08 2.47e-09 1.12e-06 0.27 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47695566 chr17:47450568~47492492:- LUSC cis rs1823913 0.614 rs12616167 ENSG00000280083.1 RP11-317J9.1 6.08 2.48e-09 1.12e-06 0.32 0.27 Obesity-related traits; chr2:191311274 chr2:191154118~191156070:- LUSC cis rs801193 0.844 rs732465 ENSG00000236529.1 RP13-254B10.1 6.08 2.48e-09 1.12e-06 0.27 0.27 Aortic root size; chr7:66533463 chr7:65840212~65840596:+ LUSC cis rs801193 0.773 rs801207 ENSG00000236529.1 RP13-254B10.1 -6.08 2.48e-09 1.12e-06 -0.27 -0.27 Aortic root size; chr7:66555603 chr7:65840212~65840596:+ LUSC cis rs875971 0.543 rs801191 ENSG00000236529.1 RP13-254B10.1 -6.08 2.48e-09 1.12e-06 -0.27 -0.27 Aortic root size; chr7:66567968 chr7:65840212~65840596:+ LUSC cis rs7665090 0.967 rs6533022 ENSG00000230069.3 LRRC37A15P -6.08 2.48e-09 1.12e-06 -0.29 -0.27 Primary biliary cholangitis; chr4:102637794 chr4:102727274~102730721:- LUSC cis rs3747113 1 rs3747113 ENSG00000128262.7 POM121L9P 6.08 2.48e-09 1.12e-06 0.28 0.27 Gut microbiome composition (summer); chr22:24321550 chr22:24251828~24265525:+ LUSC cis rs4713118 0.911 rs2394000 ENSG00000280107.1 AL022393.9 -6.08 2.48e-09 1.12e-06 -0.32 -0.27 Parkinson's disease; chr6:27719212 chr6:28170845~28172521:+ LUSC cis rs4713118 0.955 rs9393847 ENSG00000280107.1 AL022393.9 -6.08 2.48e-09 1.12e-06 -0.32 -0.27 Parkinson's disease; chr6:27720194 chr6:28170845~28172521:+ LUSC cis rs7580658 0.711 rs12469035 ENSG00000236682.1 AC068282.3 -6.08 2.48e-09 1.12e-06 -0.36 -0.27 Protein C levels; chr2:127227341 chr2:127389130~127400580:+ LUSC cis rs4372836 0.828 rs6728459 ENSG00000226833.4 AC097724.3 6.08 2.48e-09 1.12e-06 0.32 0.27 Body mass index; chr2:28776470 chr2:28708953~28736205:- LUSC cis rs77204473 0.744 rs76883864 ENSG00000254851.1 RP11-109L13.1 6.08 2.49e-09 1.12e-06 0.68 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117181009 chr11:117135528~117138582:+ LUSC cis rs78487399 0.808 rs76282560 ENSG00000234936.1 AC010883.5 6.08 2.49e-09 1.12e-06 0.44 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43455496 chr2:43229573~43233394:+ LUSC cis rs7772486 0.811 rs2777475 ENSG00000235652.6 RP11-545I5.3 6.08 2.49e-09 1.13e-06 0.28 0.27 Lobe attachment (rater-scored or self-reported); chr6:145983467 chr6:145799409~145886585:+ LUSC cis rs2562456 0.917 rs2681377 ENSG00000268081.1 RP11-678G14.2 -6.08 2.49e-09 1.13e-06 -0.38 -0.27 Pain; chr19:21533718 chr19:21554640~21569237:- LUSC cis rs4718428 0.705 rs10267335 ENSG00000226824.5 RP4-756H11.3 -6.08 2.49e-09 1.13e-06 -0.37 -0.27 Corneal structure; chr7:66938233 chr7:66654538~66669855:+ LUSC cis rs172166 0.694 rs1225716 ENSG00000216901.1 AL022393.7 6.08 2.49e-09 1.13e-06 0.32 0.27 Cardiac Troponin-T levels; chr6:28145968 chr6:28176188~28176674:+ LUSC cis rs1862618 0.573 rs832532 ENSG00000271828.1 CTD-2310F14.1 6.08 2.49e-09 1.13e-06 0.42 0.27 Initial pursuit acceleration; chr5:56926111 chr5:56927874~56929573:+ LUSC cis rs12439619 0.693 rs9944185 ENSG00000276710.3 CSPG4P8 -6.08 2.49e-09 1.13e-06 -0.31 -0.27 Intelligence (multi-trait analysis); chr15:82157927 chr15:82459472~82477258:+ LUSC cis rs1501911 0.509 rs692759 ENSG00000248489.1 CTD-2007H13.3 -6.08 2.5e-09 1.13e-06 -0.31 -0.27 Lung function (FEV1/FVC); chr5:98856841 chr5:98929171~98995013:+ LUSC cis rs7772486 0.686 rs702314 ENSG00000235652.6 RP11-545I5.3 -6.08 2.5e-09 1.13e-06 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145682374 chr6:145799409~145886585:+ LUSC cis rs10759883 0.587 rs2405134 ENSG00000175611.10 LINC00476 -6.08 2.5e-09 1.13e-06 -0.34 -0.27 Nicotine dependence; chr9:95795179 chr9:95759231~95875977:- LUSC cis rs13113518 0.812 rs2035692 ENSG00000272969.1 RP11-528I4.2 6.08 2.5e-09 1.13e-06 0.31 0.27 Height; chr4:55528801 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs4507426 ENSG00000272969.1 RP11-528I4.2 6.08 2.5e-09 1.13e-06 0.31 0.27 Height; chr4:55529387 chr4:55547112~55547889:+ LUSC cis rs13113518 0.966 rs13144598 ENSG00000249700.7 SRD5A3-AS1 6.08 2.5e-09 1.13e-06 0.31 0.27 Height; chr4:55570311 chr4:55363971~55395847:- LUSC cis rs8062405 0.69 rs7187604 ENSG00000278665.1 RP11-666O2.4 6.08 2.5e-09 1.13e-06 0.28 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554632 chr16:28599241~28601881:- LUSC cis rs13113518 1 rs7660980 ENSG00000249700.7 SRD5A3-AS1 -6.08 2.5e-09 1.13e-06 -0.31 -0.27 Height; chr4:55542948 chr4:55363971~55395847:- LUSC cis rs875971 0.545 rs313828 ENSG00000226824.5 RP4-756H11.3 6.08 2.5e-09 1.13e-06 0.36 0.27 Aortic root size; chr7:66087627 chr7:66654538~66669855:+ LUSC cis rs875971 0.571 rs160647 ENSG00000226824.5 RP4-756H11.3 6.08 2.5e-09 1.13e-06 0.36 0.27 Aortic root size; chr7:66089365 chr7:66654538~66669855:+ LUSC cis rs875971 0.52 rs160645 ENSG00000226824.5 RP4-756H11.3 6.08 2.5e-09 1.13e-06 0.36 0.27 Aortic root size; chr7:66091320 chr7:66654538~66669855:+ LUSC cis rs875971 0.789 rs28815324 ENSG00000226824.5 RP4-756H11.3 6.08 2.5e-09 1.13e-06 0.36 0.27 Aortic root size; chr7:66100789 chr7:66654538~66669855:+ LUSC cis rs12439619 0.846 rs62012056 ENSG00000276710.3 CSPG4P8 -6.08 2.51e-09 1.13e-06 -0.33 -0.27 Intelligence (multi-trait analysis); chr15:82247278 chr15:82459472~82477258:+ LUSC cis rs11089937 0.616 rs5757244 ENSG00000211639.2 IGLV4-60 6.08 2.51e-09 1.13e-06 0.27 0.27 Periodontitis (PAL4Q3); chr22:22176637 chr22:22162199~22162681:+ LUSC cis rs7955901 0.691 rs2132241 ENSG00000257265.1 CTD-2021H9.1 -6.08 2.52e-09 1.14e-06 -0.31 -0.27 Type 2 diabetes; chr12:71110434 chr12:71007773~71032083:- LUSC cis rs9322193 0.884 rs9688858 ENSG00000268592.3 RAET1E-AS1 6.08 2.52e-09 1.14e-06 0.34 0.27 Lung cancer; chr6:149637911 chr6:149863494~149919507:+ LUSC cis rs7955901 0.638 rs4142884 ENSG00000257265.1 CTD-2021H9.1 6.08 2.52e-09 1.14e-06 0.31 0.27 Type 2 diabetes; chr12:71130693 chr12:71007773~71032083:- LUSC cis rs16843372 0.599 rs7603880 ENSG00000251491.2 OR7E28P -6.08 2.52e-09 1.14e-06 -0.29 -0.27 Obesity-related traits; chr2:158818293 chr2:158862311~158863285:+ LUSC cis rs7714584 1 rs11957134 ENSG00000197083.10 ZNF300P1 -6.08 2.52e-09 1.14e-06 -0.5 -0.27 Crohn's disease; chr5:150851388 chr5:150930645~150946289:- LUSC cis rs853679 1 rs853694 ENSG00000219392.1 RP1-265C24.5 -6.08 2.53e-09 1.14e-06 -0.44 -0.27 Depression; chr6:28311323 chr6:28115628~28116551:+ LUSC cis rs433852 0.904 rs8102492 ENSG00000232871.7 SEC1P 6.08 2.53e-09 1.14e-06 0.38 0.27 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48637552 chr19:48638071~48682245:+ LUSC cis rs7772486 0.654 rs702321 ENSG00000235652.6 RP11-545I5.3 -6.08 2.53e-09 1.14e-06 -0.27 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145685559 chr6:145799409~145886585:+ LUSC cis rs11971779 0.648 rs6947309 ENSG00000273391.1 RP11-634H22.1 6.08 2.54e-09 1.15e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139351084 chr7:139359032~139359566:- LUSC cis rs853679 0.517 rs9393890 ENSG00000280107.1 AL022393.9 -6.08 2.54e-09 1.15e-06 -0.34 -0.27 Depression; chr6:28096077 chr6:28170845~28172521:+ LUSC cis rs61270009 0.955 rs430943 ENSG00000247828.6 TMEM161B-AS1 -6.08 2.54e-09 1.15e-06 -0.32 -0.27 Depressive symptoms; chr5:88251306 chr5:88268895~88436685:+ LUSC cis rs13113518 0.702 rs78829811 ENSG00000273257.1 RP11-177J6.1 6.08 2.55e-09 1.15e-06 0.35 0.27 Height; chr4:55558258 chr4:55387949~55388271:+ LUSC cis rs13113518 0.702 rs75801206 ENSG00000273257.1 RP11-177J6.1 6.08 2.55e-09 1.15e-06 0.35 0.27 Height; chr4:55558259 chr4:55387949~55388271:+ LUSC cis rs13113518 0.702 rs34658078 ENSG00000273257.1 RP11-177J6.1 6.08 2.55e-09 1.15e-06 0.35 0.27 Height; chr4:55558261 chr4:55387949~55388271:+ LUSC cis rs6568401 0.508 rs4946685 ENSG00000219088.1 RP3-359N14.1 -6.08 2.55e-09 1.15e-06 -0.41 -0.27 Primary tooth development (time to first tooth eruption); chr6:105726315 chr6:105666326~105667998:+ LUSC cis rs78487399 0.71 rs77620935 ENSG00000234936.1 AC010883.5 6.08 2.55e-09 1.15e-06 0.43 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43446626 chr2:43229573~43233394:+ LUSC cis rs78487399 0.808 rs12105394 ENSG00000234936.1 AC010883.5 6.08 2.55e-09 1.15e-06 0.43 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43449651 chr2:43229573~43233394:+ LUSC cis rs78487399 0.808 rs76171330 ENSG00000234936.1 AC010883.5 6.08 2.55e-09 1.15e-06 0.43 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43450301 chr2:43229573~43233394:+ LUSC cis rs78487399 0.808 rs12105626 ENSG00000234936.1 AC010883.5 6.08 2.55e-09 1.15e-06 0.43 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43451620 chr2:43229573~43233394:+ LUSC cis rs35160687 0.644 rs1863061 ENSG00000273080.1 RP11-301O19.1 -6.08 2.55e-09 1.15e-06 -0.26 -0.27 Night sleep phenotypes; chr2:86285784 chr2:86195590~86196049:+ LUSC cis rs4713118 0.512 rs2622319 ENSG00000219392.1 RP1-265C24.5 -6.08 2.55e-09 1.15e-06 -0.35 -0.27 Parkinson's disease; chr6:28152623 chr6:28115628~28116551:+ LUSC cis rs2337406 0.587 rs10150642 ENSG00000274576.2 IGHV2-70 6.08 2.55e-09 1.15e-06 0.27 0.27 Alzheimer's disease (late onset); chr14:106647269 chr14:106770577~106771020:- LUSC cis rs5753618 0.509 rs5753500 ENSG00000236132.1 CTA-440B3.1 6.08 2.55e-09 1.15e-06 0.37 0.27 Colorectal cancer; chr22:31182893 chr22:31816379~31817491:- LUSC cis rs875971 0.893 rs62465470 ENSG00000179406.6 LINC00174 6.08 2.56e-09 1.15e-06 0.29 0.27 Aortic root size; chr7:66136231 chr7:66376044~66401338:- LUSC cis rs875971 0.666 rs13242072 ENSG00000237310.1 GS1-124K5.4 -6.08 2.56e-09 1.16e-06 -0.27 -0.27 Aortic root size; chr7:66301001 chr7:66493706~66495474:+ LUSC cis rs9322193 0.884 rs62439836 ENSG00000268592.3 RAET1E-AS1 6.08 2.56e-09 1.16e-06 0.34 0.27 Lung cancer; chr6:149669173 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs4869812 ENSG00000268592.3 RAET1E-AS1 6.08 2.56e-09 1.16e-06 0.34 0.27 Lung cancer; chr6:149669447 chr6:149863494~149919507:+ LUSC cis rs11098499 0.82 rs6829903 ENSG00000248280.1 RP11-33B1.2 6.07 2.56e-09 1.16e-06 0.32 0.27 Corneal astigmatism; chr4:119585729 chr4:119440561~119450157:- LUSC cis rs875971 0.666 rs13242072 ENSG00000224316.1 RP11-479O9.2 -6.07 2.56e-09 1.16e-06 -0.26 -0.27 Aortic root size; chr7:66301001 chr7:65773620~65802067:+ LUSC cis rs950880 0.71 rs55742125 ENSG00000234389.1 AC007278.3 -6.07 2.57e-09 1.16e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102403322 chr2:102438713~102440475:+ LUSC cis rs2732480 0.577 rs2634693 ENSG00000273765.1 RP11-370I10.11 6.07 2.57e-09 1.16e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48312715 chr12:48360920~48361377:+ LUSC cis rs2732480 0.577 rs2634691 ENSG00000273765.1 RP11-370I10.11 6.07 2.57e-09 1.16e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48314476 chr12:48360920~48361377:+ LUSC cis rs875971 0.545 rs73150604 ENSG00000237310.1 GS1-124K5.4 6.07 2.57e-09 1.16e-06 0.31 0.27 Aortic root size; chr7:66480545 chr7:66493706~66495474:+ LUSC cis rs12908161 1 rs12908161 ENSG00000259728.4 LINC00933 6.07 2.57e-09 1.16e-06 0.35 0.27 Schizophrenia; chr15:84664594 chr15:84570649~84580175:+ LUSC cis rs875971 0.545 rs1638724 ENSG00000237310.1 GS1-124K5.4 -6.07 2.57e-09 1.16e-06 -0.31 -0.27 Aortic root size; chr7:66575494 chr7:66493706~66495474:+ LUSC cis rs6142102 0.847 rs4911413 ENSG00000275784.1 RP5-1125A11.6 -6.07 2.57e-09 1.16e-06 -0.31 -0.27 Skin pigmentation; chr20:34133969 chr20:33989480~33991818:- LUSC cis rs66887589 0.934 rs56843000 ENSG00000249244.1 RP11-548H18.2 -6.07 2.58e-09 1.16e-06 -0.32 -0.27 Diastolic blood pressure; chr4:119595442 chr4:119391831~119395335:- LUSC cis rs875971 0.83 rs427973 ENSG00000237310.1 GS1-124K5.4 6.07 2.58e-09 1.16e-06 0.28 0.27 Aortic root size; chr7:66061661 chr7:66493706~66495474:+ LUSC cis rs4237845 0.804 rs10877034 ENSG00000257159.1 RP11-58A17.3 6.07 2.58e-09 1.16e-06 0.32 0.27 Intelligence (multi-trait analysis); chr12:57892661 chr12:57967058~57968399:+ LUSC cis rs67311347 0.955 rs9821036 ENSG00000223797.4 ENTPD3-AS1 6.07 2.58e-09 1.16e-06 0.3 0.27 Renal cell carcinoma; chr3:40337516 chr3:40313802~40453329:- LUSC cis rs6969780 0.908 rs6461987 ENSG00000233429.8 HOTAIRM1 6.07 2.58e-09 1.17e-06 0.52 0.27 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27127337 chr7:27095647~27100265:+ LUSC cis rs875971 0.898 rs6977501 ENSG00000179406.6 LINC00174 6.07 2.59e-09 1.17e-06 0.29 0.27 Aortic root size; chr7:66228355 chr7:66376044~66401338:- LUSC cis rs61270009 0.913 rs373845 ENSG00000247828.6 TMEM161B-AS1 -6.07 2.59e-09 1.17e-06 -0.32 -0.27 Depressive symptoms; chr5:88253893 chr5:88268895~88436685:+ LUSC cis rs801193 1 rs2055682 ENSG00000236529.1 RP13-254B10.1 6.07 2.59e-09 1.17e-06 0.28 0.27 Aortic root size; chr7:66795302 chr7:65840212~65840596:+ LUSC cis rs79349575 0.749 rs519537 ENSG00000270781.1 RP11-501C14.9 -6.07 2.59e-09 1.17e-06 -0.28 -0.27 Type 2 diabetes; chr17:48893778 chr17:48899131~48899748:+ LUSC cis rs11098499 0.863 rs3775841 ENSG00000248280.1 RP11-33B1.2 6.07 2.59e-09 1.17e-06 0.32 0.27 Corneal astigmatism; chr4:119504622 chr4:119440561~119450157:- LUSC cis rs6142102 0.527 rs1015362 ENSG00000276073.1 RP5-1125A11.7 6.07 2.59e-09 1.17e-06 0.28 0.27 Skin pigmentation; chr20:34150806 chr20:33985617~33988989:- LUSC cis rs9506514 0.722 rs4769124 ENSG00000222726.1 RNU2-7P 6.07 2.6e-09 1.17e-06 0.29 0.27 Coronary artery calcification; chr13:20652706 chr13:20612161~20612338:+ LUSC cis rs227275 0.526 rs223497 ENSG00000230069.3 LRRC37A15P -6.07 2.6e-09 1.17e-06 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102732819 chr4:102727274~102730721:- LUSC cis rs1876905 0.597 rs1150076 ENSG00000255389.1 C6orf3 6.07 2.6e-09 1.17e-06 0.36 0.27 Mean corpuscular hemoglobin; chr6:111227227 chr6:111599875~111602295:+ LUSC cis rs2404602 0.647 rs11072626 ENSG00000259422.1 RP11-593F23.1 -6.07 2.6e-09 1.17e-06 -0.33 -0.27 Blood metabolite levels; chr15:76798485 chr15:76174891~76181486:- LUSC cis rs1061377 0.722 rs34803689 ENSG00000249685.1 RP11-360F5.3 6.07 2.6e-09 1.17e-06 0.31 0.27 Uric acid levels; chr4:39116665 chr4:39133913~39135608:+ LUSC cis rs2404602 0.735 rs437131 ENSG00000259422.1 RP11-593F23.1 6.07 2.6e-09 1.17e-06 0.3 0.27 Blood metabolite levels; chr15:76488710 chr15:76174891~76181486:- LUSC cis rs2028299 0.959 rs2165069 ENSG00000259677.1 RP11-493E3.1 6.07 2.6e-09 1.17e-06 0.35 0.27 Type 2 diabetes; chr15:89863887 chr15:89876540~89877285:+ LUSC cis rs11971779 0.68 rs7805824 ENSG00000273391.1 RP11-634H22.1 -6.07 2.6e-09 1.17e-06 -0.29 -0.27 Diisocyanate-induced asthma; chr7:139426423 chr7:139359032~139359566:- LUSC cis rs61270009 0.955 rs13171573 ENSG00000247828.6 TMEM161B-AS1 6.07 2.61e-09 1.18e-06 0.32 0.27 Depressive symptoms; chr5:88383625 chr5:88268895~88436685:+ LUSC cis rs7267979 0.934 rs2500399 ENSG00000274973.1 RP13-401N8.7 6.07 2.61e-09 1.18e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25374058 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2500404 ENSG00000274973.1 RP13-401N8.7 6.07 2.61e-09 1.18e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25379122 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2500405 ENSG00000274973.1 RP13-401N8.7 6.07 2.61e-09 1.18e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25380190 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2482941 ENSG00000274973.1 RP13-401N8.7 6.07 2.61e-09 1.18e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25380580 chr20:25845497~25845862:+ LUSC cis rs7267979 0.903 rs2500423 ENSG00000274973.1 RP13-401N8.7 6.07 2.61e-09 1.18e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25394246 chr20:25845497~25845862:+ LUSC cis rs2243480 1 rs6964245 ENSG00000226824.5 RP4-756H11.3 6.07 2.61e-09 1.18e-06 0.52 0.27 Diabetic kidney disease; chr7:66253730 chr7:66654538~66669855:+ LUSC cis rs7267979 0.816 rs443009 ENSG00000274973.1 RP13-401N8.7 6.07 2.61e-09 1.18e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25519181 chr20:25845497~25845862:+ LUSC cis rs7772486 0.79 rs9403750 ENSG00000235652.6 RP11-545I5.3 6.07 2.61e-09 1.18e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145846626 chr6:145799409~145886585:+ LUSC cis rs875971 0.66 rs801217 ENSG00000222364.1 RNU6-96P 6.07 2.62e-09 1.18e-06 0.31 0.27 Aortic root size; chr7:66545590 chr7:66395191~66395286:+ LUSC cis rs875971 0.638 rs801216 ENSG00000222364.1 RNU6-96P 6.07 2.62e-09 1.18e-06 0.31 0.27 Aortic root size; chr7:66546680 chr7:66395191~66395286:+ LUSC cis rs875971 0.66 rs13224319 ENSG00000222364.1 RNU6-96P -6.07 2.62e-09 1.18e-06 -0.31 -0.27 Aortic root size; chr7:66542376 chr7:66395191~66395286:+ LUSC cis rs2842992 0.83 rs2025190 ENSG00000237927.1 RP3-393E18.2 -6.07 2.62e-09 1.18e-06 -0.4 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159717209 chr6:159586955~159589169:- LUSC cis rs13113518 0.783 rs1586555 ENSG00000272969.1 RP11-528I4.2 6.07 2.62e-09 1.18e-06 0.31 0.27 Height; chr4:55587104 chr4:55547112~55547889:+ LUSC cis rs75422866 0.867 rs73102195 ENSG00000257433.4 RP1-197B17.3 6.07 2.62e-09 1.18e-06 0.65 0.27 Pneumonia; chr12:47666309 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73102201 ENSG00000257433.4 RP1-197B17.3 6.07 2.62e-09 1.18e-06 0.65 0.27 Pneumonia; chr12:47669269 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73104104 ENSG00000257433.4 RP1-197B17.3 6.07 2.62e-09 1.18e-06 0.65 0.27 Pneumonia; chr12:47671986 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73104111 ENSG00000257433.4 RP1-197B17.3 6.07 2.62e-09 1.18e-06 0.65 0.27 Pneumonia; chr12:47673994 chr12:47706085~47742294:+ LUSC cis rs78487399 0.808 rs76993899 ENSG00000234936.1 AC010883.5 6.07 2.63e-09 1.18e-06 0.44 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43444018 chr2:43229573~43233394:+ LUSC cis rs9322193 0.81 rs62439811 ENSG00000268592.3 RAET1E-AS1 6.07 2.63e-09 1.18e-06 0.34 0.27 Lung cancer; chr6:149640416 chr6:149863494~149919507:+ LUSC cis rs6772849 0.93 rs1962040 ENSG00000277250.1 Metazoa_SRP -6.07 2.63e-09 1.18e-06 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128605318 chr3:128673681~128674021:- LUSC cis rs13113518 0.783 rs12510400 ENSG00000272969.1 RP11-528I4.2 6.07 2.63e-09 1.18e-06 0.31 0.27 Height; chr4:55577294 chr4:55547112~55547889:+ LUSC cis rs13113518 0.783 rs13111128 ENSG00000272969.1 RP11-528I4.2 6.07 2.63e-09 1.18e-06 0.31 0.27 Height; chr4:55578154 chr4:55547112~55547889:+ LUSC cis rs1387259 0.839 rs7487682 ENSG00000240399.1 RP1-228P16.1 -6.07 2.63e-09 1.19e-06 -0.28 -0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48185882 chr12:48054813~48055591:- LUSC cis rs5751168 0.564 rs5758473 ENSG00000211654.2 IGLV5-37 6.07 2.63e-09 1.19e-06 0.35 0.27 Prostate cancer (SNP x SNP interaction); chr22:22486819 chr22:22427540~22428035:+ LUSC cis rs875971 0.793 rs460678 ENSG00000237310.1 GS1-124K5.4 6.07 2.64e-09 1.19e-06 0.28 0.27 Aortic root size; chr7:66062213 chr7:66493706~66495474:+ LUSC cis rs2732480 0.577 rs1489109 ENSG00000273765.1 RP11-370I10.11 6.07 2.64e-09 1.19e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344997 chr12:48360920~48361377:+ LUSC cis rs2732480 0.577 rs1489108 ENSG00000273765.1 RP11-370I10.11 6.07 2.64e-09 1.19e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344998 chr12:48360920~48361377:+ LUSC cis rs4950322 0.518 rs61838938 ENSG00000278811.3 LINC00624 6.07 2.64e-09 1.19e-06 0.28 0.27 Protein quantitative trait loci; chr1:147105943 chr1:147258885~147517875:- LUSC cis rs4950322 0.529 rs11809327 ENSG00000278811.3 LINC00624 6.07 2.64e-09 1.19e-06 0.28 0.27 Protein quantitative trait loci; chr1:147106679 chr1:147258885~147517875:- LUSC cis rs4950322 0.563 rs11809328 ENSG00000278811.3 LINC00624 6.07 2.64e-09 1.19e-06 0.28 0.27 Protein quantitative trait loci; chr1:147106681 chr1:147258885~147517875:- LUSC cis rs875971 0.66 rs2013222 ENSG00000224316.1 RP11-479O9.2 -6.07 2.64e-09 1.19e-06 -0.26 -0.27 Aortic root size; chr7:66570949 chr7:65773620~65802067:+ LUSC cis rs1155848 0.571 rs6563127 ENSG00000227354.5 RBM26-AS1 6.07 2.65e-09 1.19e-06 0.5 0.27 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79642012 chr13:79406309~79424328:+ LUSC cis rs1823913 0.637 rs2356354 ENSG00000280083.1 RP11-317J9.1 6.07 2.65e-09 1.19e-06 0.31 0.27 Obesity-related traits; chr2:191270970 chr2:191154118~191156070:- LUSC cis rs10129255 0.957 rs12590667 ENSG00000280411.1 IGHV1-69-2 6.07 2.65e-09 1.19e-06 0.18 0.27 Kawasaki disease; chr14:106779223 chr14:106762092~106762588:- LUSC cis rs2732480 0.577 rs2732486 ENSG00000273765.1 RP11-370I10.11 6.07 2.65e-09 1.19e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344051 chr12:48360920~48361377:+ LUSC cis rs2732480 0.517 rs2634676 ENSG00000273765.1 RP11-370I10.11 6.07 2.65e-09 1.19e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344453 chr12:48360920~48361377:+ LUSC cis rs6969780 1 rs6973182 ENSG00000233429.8 HOTAIRM1 6.07 2.66e-09 1.2e-06 0.51 0.27 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27132702 chr7:27095647~27100265:+ LUSC cis rs8072100 0.837 rs62074055 ENSG00000228782.6 CTD-2026D20.3 6.07 2.66e-09 1.2e-06 0.25 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47694567 chr17:47450568~47492492:- LUSC cis rs6671200 0.607 rs2296308 ENSG00000228852.5 RP11-57H12.5 6.07 2.66e-09 1.2e-06 0.34 0.27 Stearic acid (18:0) levels; chr1:95244383 chr1:95243167~95278940:- LUSC cis rs1729407 0.565 rs2849173 ENSG00000254851.1 RP11-109L13.1 -6.07 2.67e-09 1.2e-06 -0.33 -0.27 Apolipoprotein A-IV levels; chr11:116826605 chr11:117135528~117138582:+ LUSC cis rs8062405 1 rs3088215 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28842675 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs28403629 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28843448 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs61737565 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844201 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs4788099 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844406 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs9972693 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28848481 chr16:28599241~28601881:- LUSC cis rs8062405 0.964 rs9972768 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850413 chr16:28599241~28601881:- LUSC cis rs8062405 0.965 rs62037363 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28853721 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs7205323 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854571 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs4788101 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28856483 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs62037365 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857641 chr16:28599241~28601881:- LUSC cis rs8062405 0.929 rs11150609 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859275 chr16:28599241~28601881:- LUSC cis rs8062405 0.737 rs11861132 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860539 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs11861174 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860668 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs4788102 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28862077 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs62037367 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863226 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs7198606 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863801 chr16:28599241~28601881:- LUSC cis rs8062405 0.929 rs11864750 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863883 chr16:28599241~28601881:- LUSC cis rs8062405 0.964 rs7193733 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28864161 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs8055982 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28869881 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs7498665 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28871920 chr16:28599241~28601881:- LUSC cis rs8062405 0.964 rs11864107 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874610 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs62037371 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878810 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs8055138 ENSG00000278665.1 RP11-666O2.4 6.07 2.67e-09 1.2e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28880144 chr16:28599241~28601881:- LUSC cis rs1823913 0.599 rs67342262 ENSG00000227542.1 AC092614.2 6.07 2.67e-09 1.2e-06 0.35 0.27 Obesity-related traits; chr2:191295612 chr2:191229165~191246172:- LUSC cis rs2179367 0.632 rs11155640 ENSG00000231760.4 RP11-350J20.5 6.07 2.67e-09 1.2e-06 0.38 0.27 Dupuytren's disease; chr6:149323648 chr6:149796151~149826294:- LUSC cis rs1061377 0.965 rs6833654 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39110701 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs1036037 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39111272 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs1036038 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39111383 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs1560396 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39112092 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs2381285 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39112775 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs2163272 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39112790 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs2163273 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39112835 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs62310332 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39112939 chr4:39133913~39135608:+ LUSC cis rs1061377 0.965 rs3796510 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39113309 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs10030904 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39113603 chr4:39133913~39135608:+ LUSC cis rs1061377 0.932 rs6855118 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39114322 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs6829234 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39114586 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs6812540 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39114803 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs10026775 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39115155 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs3733276 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39115291 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs3733277 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39115483 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs3733278 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39115615 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs3733279 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39115625 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs10018049 ENSG00000249685.1 RP11-360F5.3 6.07 2.67e-09 1.2e-06 0.31 0.27 Uric acid levels; chr4:39115781 chr4:39133913~39135608:+ LUSC cis rs7208859 0.623 rs9895785 ENSG00000266490.1 CTD-2349P21.9 -6.07 2.68e-09 1.2e-06 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780690 chr17:30792372~30792833:+ LUSC cis rs6142102 0.961 rs6059649 ENSG00000275784.1 RP5-1125A11.6 -6.07 2.68e-09 1.21e-06 -0.31 -0.27 Skin pigmentation; chr20:34056071 chr20:33989480~33991818:- LUSC cis rs853679 0.517 rs2273564 ENSG00000280107.1 AL022393.9 -6.07 2.68e-09 1.21e-06 -0.34 -0.27 Depression; chr6:28089816 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs1853097 ENSG00000280107.1 AL022393.9 -6.07 2.68e-09 1.21e-06 -0.34 -0.27 Depression; chr6:28090857 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9393888 ENSG00000280107.1 AL022393.9 -6.07 2.68e-09 1.21e-06 -0.34 -0.27 Depression; chr6:28091439 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs3734573 ENSG00000280107.1 AL022393.9 -6.07 2.68e-09 1.21e-06 -0.34 -0.27 Depression; chr6:28091659 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9357063 ENSG00000280107.1 AL022393.9 -6.07 2.68e-09 1.21e-06 -0.34 -0.27 Depression; chr6:28092227 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs3823180 ENSG00000280107.1 AL022393.9 -6.07 2.68e-09 1.21e-06 -0.34 -0.27 Depression; chr6:28093966 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9368551 ENSG00000280107.1 AL022393.9 -6.07 2.68e-09 1.21e-06 -0.34 -0.27 Depression; chr6:28094014 chr6:28170845~28172521:+ LUSC cis rs1075265 0.756 rs2542576 ENSG00000233266.1 HMGB1P31 6.07 2.69e-09 1.21e-06 0.33 0.27 Chronotype;Morning vs. evening chronotype; chr2:53821659 chr2:54051334~54051760:+ LUSC cis rs875971 0.862 rs28470208 ENSG00000179406.6 LINC00174 6.07 2.69e-09 1.21e-06 0.29 0.27 Aortic root size; chr7:66119713 chr7:66376044~66401338:- LUSC cis rs875971 1 rs6963646 ENSG00000179406.6 LINC00174 6.07 2.69e-09 1.21e-06 0.29 0.27 Aortic root size; chr7:66220780 chr7:66376044~66401338:- LUSC cis rs957448 0.796 rs72674824 ENSG00000253175.1 RP11-267M23.6 6.07 2.69e-09 1.21e-06 0.32 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94477053 chr8:94565036~94565715:+ LUSC cis rs75422866 0.764 rs73104177 ENSG00000274902.1 RP1-197B17.4 6.07 2.69e-09 1.21e-06 0.75 0.27 Pneumonia; chr12:47713550 chr12:47731908~47732351:+ LUSC cis rs13113518 0.545 rs6810483 ENSG00000273257.1 RP11-177J6.1 6.07 2.69e-09 1.21e-06 0.33 0.27 Height; chr4:55424406 chr4:55387949~55388271:+ LUSC cis rs4722166 0.541 rs1800795 ENSG00000179428.2 AC073072.5 -6.07 2.69e-09 1.21e-06 -0.33 -0.27 Lung cancer; chr7:22727026 chr7:22725395~22727620:- LUSC cis rs9435732 0.778 rs9435665 ENSG00000235241.1 RP11-108M9.5 6.07 2.7e-09 1.21e-06 0.39 0.27 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:16998042 chr1:16889095~16889602:+ LUSC cis rs10129255 0.509 rs756583 ENSG00000224373.3 IGHV4-59 6.07 2.7e-09 1.21e-06 0.13 0.27 Kawasaki disease; chr14:106680002 chr14:106627249~106627825:- LUSC cis rs6570726 0.935 rs413916 ENSG00000235652.6 RP11-545I5.3 6.07 2.7e-09 1.21e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145510264 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs6570700 ENSG00000235652.6 RP11-545I5.3 6.07 2.7e-09 1.21e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145610416 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs870491 ENSG00000235652.6 RP11-545I5.3 6.07 2.7e-09 1.21e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145612254 chr6:145799409~145886585:+ LUSC cis rs7189233 0.955 rs16952242 ENSG00000279344.1 RP11-44F14.7 6.07 2.7e-09 1.21e-06 0.24 0.27 Intelligence (multi-trait analysis); chr16:53440338 chr16:53478957~53481550:- LUSC cis rs4853012 0.887 rs77148265 ENSG00000257800.1 FNBP1P1 6.07 2.71e-09 1.22e-06 0.33 0.27 Gestational age at birth (maternal effect); chr2:74112392 chr2:74120680~74123218:+ LUSC cis rs6772849 0.804 rs4857920 ENSG00000242551.2 POU5F1P6 -6.07 2.71e-09 1.22e-06 -0.32 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128688780 chr3:128674735~128677005:- LUSC cis rs6142102 0.659 rs6057945 ENSG00000275784.1 RP5-1125A11.6 -6.07 2.71e-09 1.22e-06 -0.31 -0.27 Skin pigmentation; chr20:33929374 chr20:33989480~33991818:- LUSC cis rs1012068 0.924 rs5998173 ENSG00000236132.1 CTA-440B3.1 -6.07 2.71e-09 1.22e-06 -0.37 -0.27 Chronic hepatitis C infection; chr22:31909985 chr22:31816379~31817491:- LUSC cis rs10129255 0.646 rs55995061 ENSG00000211974.3 IGHV2-70 -6.07 2.71e-09 1.22e-06 -0.37 -0.27 Kawasaki disease; chr14:106799309 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs76871148 ENSG00000211974.3 IGHV2-70 -6.07 2.71e-09 1.22e-06 -0.37 -0.27 Alzheimer's disease (late onset); chr14:106799722 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs61521632 ENSG00000211974.3 IGHV2-70 -6.07 2.71e-09 1.22e-06 -0.37 -0.27 Alzheimer's disease (late onset); chr14:106801091 chr14:106723574~106724093:- LUSC cis rs11089937 0.963 rs5757098 ENSG00000211638.2 IGLV8-61 6.07 2.71e-09 1.22e-06 0.25 0.27 Periodontitis (PAL4Q3); chr22:22154322 chr22:22098700~22099212:+ LUSC cis rs2276314 0.857 rs16967327 ENSG00000278986.1 RP11-723J4.3 -6.07 2.71e-09 1.22e-06 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36007073 chr18:35972151~35973916:+ LUSC cis rs9322193 0.923 rs66516768 ENSG00000268592.3 RAET1E-AS1 6.07 2.71e-09 1.22e-06 0.34 0.27 Lung cancer; chr6:149671999 chr6:149863494~149919507:+ LUSC cis rs75422866 0.51 rs75424057 ENSG00000257433.4 RP1-197B17.3 6.06 2.72e-09 1.22e-06 0.59 0.27 Pneumonia; chr12:47737294 chr12:47706085~47742294:+ LUSC cis rs7246657 0.943 rs8109038 ENSG00000276846.1 CTD-3220F14.3 -6.06 2.72e-09 1.22e-06 -0.41 -0.27 Coronary artery calcification; chr19:37524807 chr19:37314868~37315620:- LUSC cis rs11168351 0.889 rs12817104 ENSG00000240399.1 RP1-228P16.1 6.06 2.72e-09 1.22e-06 0.28 0.27 Bipolar disorder and schizophrenia; chr12:47988790 chr12:48054813~48055591:- LUSC cis rs9549367 0.789 rs35569628 ENSG00000269125.1 RP11-98F14.11 -6.06 2.72e-09 1.22e-06 -0.33 -0.27 Platelet distribution width; chr13:113218398 chr13:113165002~113165183:- LUSC cis rs77204473 0.744 rs77661993 ENSG00000254851.1 RP11-109L13.1 6.06 2.72e-09 1.22e-06 0.65 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117139758 chr11:117135528~117138582:+ LUSC cis rs607541 1 rs675413 ENSG00000259520.4 CTD-2651B20.3 -6.06 2.73e-09 1.22e-06 -0.39 -0.27 Obesity-related traits; chr15:45644547 chr15:45251580~45279251:- LUSC cis rs11168351 0.927 rs10875716 ENSG00000240399.1 RP1-228P16.1 6.06 2.73e-09 1.23e-06 0.28 0.27 Bipolar disorder and schizophrenia; chr12:47995240 chr12:48054813~48055591:- LUSC cis rs875971 0.545 rs6969224 ENSG00000237310.1 GS1-124K5.4 6.06 2.73e-09 1.23e-06 0.31 0.27 Aortic root size; chr7:66370011 chr7:66493706~66495474:+ LUSC cis rs7267979 0.546 rs8115804 ENSG00000274973.1 RP13-401N8.7 6.06 2.73e-09 1.23e-06 0.29 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25458147 chr20:25845497~25845862:+ LUSC cis rs12554020 0.582 rs7033532 ENSG00000227603.1 RP11-165J3.6 6.06 2.74e-09 1.23e-06 0.48 0.27 Schizophrenia; chr9:93644962 chr9:93435332~93437121:- LUSC cis rs12554020 0.582 rs7038310 ENSG00000227603.1 RP11-165J3.6 6.06 2.74e-09 1.23e-06 0.48 0.27 Schizophrenia; chr9:93645638 chr9:93435332~93437121:- LUSC cis rs9322193 0.923 rs12176034 ENSG00000268592.3 RAET1E-AS1 6.06 2.74e-09 1.23e-06 0.35 0.27 Lung cancer; chr6:149800557 chr6:149863494~149919507:+ LUSC cis rs6142102 1 rs2143230 ENSG00000275784.1 RP5-1125A11.6 -6.06 2.74e-09 1.23e-06 -0.31 -0.27 Skin pigmentation; chr20:34136539 chr20:33989480~33991818:- LUSC cis rs6570726 0.935 rs906774 ENSG00000235652.6 RP11-545I5.3 6.06 2.74e-09 1.23e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145492634 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs366308 ENSG00000235652.6 RP11-545I5.3 6.06 2.74e-09 1.23e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145493396 chr6:145799409~145886585:+ LUSC cis rs5753618 0.561 rs5753521 ENSG00000236132.1 CTA-440B3.1 6.06 2.75e-09 1.23e-06 0.36 0.27 Colorectal cancer; chr22:31242041 chr22:31816379~31817491:- LUSC cis rs75422866 0.867 rs73104103 ENSG00000257433.4 RP1-197B17.3 6.06 2.75e-09 1.23e-06 0.64 0.27 Pneumonia; chr12:47669604 chr12:47706085~47742294:+ LUSC cis rs9549367 0.773 rs9549717 ENSG00000269125.1 RP11-98F14.11 -6.06 2.75e-09 1.23e-06 -0.32 -0.27 Platelet distribution width; chr13:113254512 chr13:113165002~113165183:- LUSC cis rs6772849 0.708 rs12491942 ENSG00000242551.2 POU5F1P6 -6.06 2.76e-09 1.24e-06 -0.32 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128702626 chr3:128674735~128677005:- LUSC cis rs2276314 0.857 rs62101379 ENSG00000278986.1 RP11-723J4.3 -6.06 2.76e-09 1.24e-06 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36004939 chr18:35972151~35973916:+ LUSC cis rs13113518 0.934 rs11935823 ENSG00000223305.1 RN7SKP30 6.06 2.76e-09 1.24e-06 0.33 0.27 Height; chr4:55589624 chr4:55540502~55540835:- LUSC cis rs950880 0.71 rs1135354 ENSG00000234389.1 AC007278.3 -6.06 2.76e-09 1.24e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102397842 chr2:102438713~102440475:+ LUSC cis rs1061377 0.513 rs2566163 ENSG00000249207.1 RP11-360F5.1 -6.06 2.76e-09 1.24e-06 -0.35 -0.27 Uric acid levels; chr4:39128345 chr4:39112677~39126818:- LUSC cis rs875971 0.862 rs908915 ENSG00000179406.6 LINC00174 6.06 2.76e-09 1.24e-06 0.29 0.27 Aortic root size; chr7:66149664 chr7:66376044~66401338:- LUSC cis rs11089937 0.626 rs4821784 ENSG00000211638.2 IGLV8-61 -6.06 2.77e-09 1.24e-06 -0.3 -0.27 Periodontitis (PAL4Q3); chr22:22143513 chr22:22098700~22099212:+ LUSC cis rs13113518 1 rs4865013 ENSG00000249700.7 SRD5A3-AS1 6.06 2.77e-09 1.24e-06 0.31 0.27 Height; chr4:55559957 chr4:55363971~55395847:- LUSC cis rs4718428 0.705 rs11028 ENSG00000226824.5 RP4-756H11.3 -6.06 2.77e-09 1.24e-06 -0.36 -0.27 Corneal structure; chr7:66811230 chr7:66654538~66669855:+ LUSC cis rs8040855 0.627 rs11637512 ENSG00000259295.5 CSPG4P12 6.06 2.77e-09 1.24e-06 0.34 0.27 Bulimia nervosa; chr15:85105528 chr15:85191438~85213905:+ LUSC cis rs8040855 0.627 rs17541051 ENSG00000259295.5 CSPG4P12 6.06 2.77e-09 1.24e-06 0.34 0.27 Bulimia nervosa; chr15:85106122 chr15:85191438~85213905:+ LUSC cis rs11723261 0.621 rs57013142 ENSG00000275426.1 CH17-262A2.1 6.06 2.77e-09 1.24e-06 0.46 0.27 Immune response to smallpox vaccine (IL-6); chr4:141956 chr4:149738~150317:+ LUSC cis rs11723261 0.564 rs61792258 ENSG00000275426.1 CH17-262A2.1 6.06 2.77e-09 1.24e-06 0.46 0.27 Immune response to smallpox vaccine (IL-6); chr4:143482 chr4:149738~150317:+ LUSC cis rs6142102 1 rs6059681 ENSG00000275784.1 RP5-1125A11.6 -6.06 2.77e-09 1.24e-06 -0.31 -0.27 Skin pigmentation; chr20:34135535 chr20:33989480~33991818:- LUSC cis rs1823913 0.637 rs4853465 ENSG00000280083.1 RP11-317J9.1 6.06 2.78e-09 1.24e-06 0.31 0.27 Obesity-related traits; chr2:191294768 chr2:191154118~191156070:- LUSC cis rs4141404 0.923 rs2413046 ENSG00000236132.1 CTA-440B3.1 6.06 2.78e-09 1.24e-06 0.37 0.27 Paclitaxel-induced neuropathy; chr22:31269923 chr22:31816379~31817491:- LUSC cis rs5753618 0.561 rs2413047 ENSG00000236132.1 CTA-440B3.1 6.06 2.78e-09 1.24e-06 0.37 0.27 Colorectal cancer; chr22:31270040 chr22:31816379~31817491:- LUSC cis rs6570726 0.935 rs384806 ENSG00000235652.6 RP11-545I5.3 6.06 2.78e-09 1.25e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145493753 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs385185 ENSG00000235652.6 RP11-545I5.3 6.06 2.78e-09 1.25e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145493856 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs384453 ENSG00000235652.6 RP11-545I5.3 6.06 2.78e-09 1.25e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145494009 chr6:145799409~145886585:+ LUSC cis rs227275 0.556 rs3886723 ENSG00000230069.3 LRRC37A15P -6.06 2.78e-09 1.25e-06 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102983013 chr4:102727274~102730721:- LUSC cis rs7246657 0.722 rs3101746 ENSG00000276846.1 CTD-3220F14.3 -6.06 2.79e-09 1.25e-06 -0.4 -0.27 Coronary artery calcification; chr19:37655499 chr19:37314868~37315620:- LUSC cis rs6570726 0.935 rs372378 ENSG00000235652.6 RP11-545I5.3 6.06 2.79e-09 1.25e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145495091 chr6:145799409~145886585:+ LUSC cis rs6570726 0.905 rs388728 ENSG00000235652.6 RP11-545I5.3 6.06 2.79e-09 1.25e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145495283 chr6:145799409~145886585:+ LUSC cis rs2243480 1 rs160652 ENSG00000226824.5 RP4-756H11.3 -6.06 2.79e-09 1.25e-06 -0.52 -0.27 Diabetic kidney disease; chr7:66073444 chr7:66654538~66669855:+ LUSC cis rs62432291 0.681 rs435521 ENSG00000235086.1 FNDC1-IT1 6.06 2.79e-09 1.25e-06 0.44 0.27 Joint mobility (Beighton score); chr6:159241606 chr6:159240786~159243329:+ LUSC cis rs881375 0.678 rs7021049 ENSG00000226752.6 PSMD5-AS1 -6.06 2.8e-09 1.25e-06 -0.3 -0.27 Rheumatoid arthritis; chr9:120921704 chr9:120824828~120854385:+ LUSC cis rs7772486 0.79 rs4896852 ENSG00000235652.6 RP11-545I5.3 -6.06 2.8e-09 1.25e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145963485 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs6912079 ENSG00000235652.6 RP11-545I5.3 6.06 2.8e-09 1.25e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145573813 chr6:145799409~145886585:+ LUSC cis rs7955901 0.775 rs3914135 ENSG00000257265.1 CTD-2021H9.1 6.06 2.8e-09 1.25e-06 0.3 0.27 Type 2 diabetes; chr12:71130511 chr12:71007773~71032083:- LUSC cis rs7955901 0.746 rs3851612 ENSG00000257265.1 CTD-2021H9.1 6.06 2.8e-09 1.25e-06 0.3 0.27 Type 2 diabetes; chr12:71131030 chr12:71007773~71032083:- LUSC cis rs79349575 0.783 rs4793992 ENSG00000270781.1 RP11-501C14.9 -6.06 2.8e-09 1.26e-06 -0.28 -0.27 Type 2 diabetes; chr17:48930845 chr17:48899131~48899748:+ LUSC cis rs2153535 0.563 rs7739249 ENSG00000230939.1 RP11-314C16.1 -6.06 2.8e-09 1.26e-06 -0.32 -0.27 Motion sickness; chr6:8534357 chr6:8784178~8785445:+ LUSC cis rs875971 0.862 rs4368860 ENSG00000179406.6 LINC00174 6.06 2.8e-09 1.26e-06 0.29 0.27 Aortic root size; chr7:66143495 chr7:66376044~66401338:- LUSC cis rs8062405 1 rs56404918 ENSG00000278665.1 RP11-666O2.4 6.06 2.81e-09 1.26e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835519 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs55719896 ENSG00000278665.1 RP11-666O2.4 6.06 2.81e-09 1.26e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835545 chr16:28599241~28601881:- LUSC cis rs8062405 1 rs55830740 ENSG00000278665.1 RP11-666O2.4 6.06 2.81e-09 1.26e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835828 chr16:28599241~28601881:- LUSC cis rs17270561 0.525 rs12201678 ENSG00000272810.1 U91328.22 -6.06 2.81e-09 1.26e-06 -0.37 -0.27 Iron status biomarkers; chr6:25978765 chr6:26013241~26013757:+ LUSC cis rs72627123 1 rs72627117 ENSG00000259065.1 RP5-1021I20.1 -6.06 2.81e-09 1.26e-06 -0.46 -0.27 Morning vs. evening chronotype; chr14:73888530 chr14:73787360~73803270:+ LUSC cis rs72627123 1 rs72627119 ENSG00000259065.1 RP5-1021I20.1 -6.06 2.81e-09 1.26e-06 -0.46 -0.27 Morning vs. evening chronotype; chr14:73889571 chr14:73787360~73803270:+ LUSC cis rs13113518 0.812 rs2035691 ENSG00000272969.1 RP11-528I4.2 6.06 2.82e-09 1.26e-06 0.31 0.27 Height; chr4:55529786 chr4:55547112~55547889:+ LUSC cis rs9549367 0.865 rs9549366 ENSG00000269125.1 RP11-98F14.11 -6.06 2.82e-09 1.26e-06 -0.33 -0.27 Platelet distribution width; chr13:113253330 chr13:113165002~113165183:- LUSC cis rs9549367 0.789 rs9577220 ENSG00000269125.1 RP11-98F14.11 -6.06 2.82e-09 1.26e-06 -0.33 -0.27 Platelet distribution width; chr13:113253980 chr13:113165002~113165183:- LUSC cis rs9549367 0.789 rs9549716 ENSG00000269125.1 RP11-98F14.11 -6.06 2.82e-09 1.26e-06 -0.33 -0.27 Platelet distribution width; chr13:113254164 chr13:113165002~113165183:- LUSC cis rs13113518 1 rs4865007 ENSG00000249700.7 SRD5A3-AS1 -6.06 2.82e-09 1.26e-06 -0.31 -0.27 Height; chr4:55537550 chr4:55363971~55395847:- LUSC cis rs853679 0.517 rs9380052 ENSG00000280107.1 AL022393.9 -6.06 2.82e-09 1.26e-06 -0.33 -0.27 Depression; chr6:28096845 chr6:28170845~28172521:+ LUSC cis rs9880192 0.516 rs2713575 ENSG00000242551.2 POU5F1P6 -6.06 2.82e-09 1.26e-06 -0.31 -0.27 White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts; chr3:128575512 chr3:128674735~128677005:- LUSC cis rs7189233 0.955 rs7189726 ENSG00000279344.1 RP11-44F14.7 6.06 2.82e-09 1.26e-06 0.24 0.27 Intelligence (multi-trait analysis); chr16:53463862 chr16:53478957~53481550:- LUSC cis rs79349575 0.721 rs9904645 ENSG00000270781.1 RP11-501C14.9 -6.06 2.83e-09 1.26e-06 -0.28 -0.27 Type 2 diabetes; chr17:48892303 chr17:48899131~48899748:+ LUSC cis rs11089937 0.626 rs9619811 ENSG00000211638.2 IGLV8-61 -6.06 2.83e-09 1.26e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22159186 chr22:22098700~22099212:+ LUSC cis rs11159086 1 rs4903233 ENSG00000259005.1 RP3-449M8.6 6.06 2.83e-09 1.27e-06 0.4 0.27 Advanced glycation end-product levels; chr14:74497291 chr14:74474007~74474864:- LUSC cis rs13113518 0.783 rs7690837 ENSG00000272969.1 RP11-528I4.2 6.06 2.83e-09 1.27e-06 0.31 0.27 Height; chr4:55575856 chr4:55547112~55547889:+ LUSC cis rs12908161 1 rs60957376 ENSG00000259728.4 LINC00933 6.06 2.83e-09 1.27e-06 0.35 0.27 Schizophrenia; chr15:84737561 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs11632465 ENSG00000259728.4 LINC00933 6.06 2.83e-09 1.27e-06 0.35 0.27 Schizophrenia; chr15:84738814 chr15:84570649~84580175:+ LUSC cis rs227275 0.525 rs3974604 ENSG00000230069.3 LRRC37A15P -6.06 2.84e-09 1.27e-06 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102928601 chr4:102727274~102730721:- LUSC cis rs78487399 0.808 rs17030855 ENSG00000234936.1 AC010883.5 6.06 2.84e-09 1.27e-06 0.42 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43462225 chr2:43229573~43233394:+ LUSC cis rs78487399 0.808 rs17030859 ENSG00000234936.1 AC010883.5 6.06 2.84e-09 1.27e-06 0.42 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43462765 chr2:43229573~43233394:+ LUSC cis rs62445005 1 rs62445005 ENSG00000211699.2 TRGV3 6.06 2.84e-09 1.27e-06 0.27 0.27 Shingles; chr7:38346957 chr7:38358512~38359162:- LUSC cis rs79349575 0.783 rs832410 ENSG00000270781.1 RP11-501C14.9 -6.06 2.85e-09 1.27e-06 -0.28 -0.27 Type 2 diabetes; chr17:48895503 chr17:48899131~48899748:+ LUSC cis rs62432291 0.681 rs423533 ENSG00000235086.1 FNDC1-IT1 -6.06 2.85e-09 1.27e-06 -0.45 -0.27 Joint mobility (Beighton score); chr6:159243484 chr6:159240786~159243329:+ LUSC cis rs7598759 0.548 rs1823328 ENSG00000181798.2 LINC00471 -6.06 2.85e-09 1.27e-06 -0.29 -0.27 Noise-induced hearing loss; chr2:231490473 chr2:231508426~231514339:- LUSC cis rs227275 0.554 rs223439 ENSG00000230069.3 LRRC37A15P -6.06 2.85e-09 1.28e-06 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102798377 chr4:102727274~102730721:- LUSC cis rs8072100 0.701 rs8078309 ENSG00000228782.6 CTD-2026D20.3 6.06 2.85e-09 1.28e-06 0.27 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47696706 chr17:47450568~47492492:- LUSC cis rs2337406 0.778 rs56965016 ENSG00000254174.1 IGHV1-12 6.06 2.86e-09 1.28e-06 0.29 0.27 Alzheimer's disease (late onset); chr14:106656649 chr14:106122420~106122709:- LUSC cis rs227275 0.556 rs28367331 ENSG00000230069.3 LRRC37A15P -6.06 2.86e-09 1.28e-06 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102900734 chr4:102727274~102730721:- LUSC cis rs2337406 0.866 rs2301536 ENSG00000211974.3 IGHV2-70 -6.06 2.86e-09 1.28e-06 -0.37 -0.27 Alzheimer's disease (late onset); chr14:106790636 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs7144369 ENSG00000211974.3 IGHV2-70 -6.06 2.86e-09 1.28e-06 -0.37 -0.27 Alzheimer's disease (late onset); chr14:106793065 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs78525520 ENSG00000211974.3 IGHV2-70 -6.06 2.86e-09 1.28e-06 -0.37 -0.27 Alzheimer's disease (late onset); chr14:106795643 chr14:106723574~106724093:- LUSC cis rs4372836 0.964 rs2045884 ENSG00000226833.4 AC097724.3 6.06 2.86e-09 1.28e-06 0.31 0.27 Body mass index; chr2:28741489 chr2:28708953~28736205:- LUSC cis rs4713118 0.513 rs149944 ENSG00000219392.1 RP1-265C24.5 -6.06 2.87e-09 1.28e-06 -0.33 -0.27 Parkinson's disease; chr6:28035040 chr6:28115628~28116551:+ LUSC cis rs9549367 0.789 rs2025247 ENSG00000269125.1 RP11-98F14.11 -6.06 2.87e-09 1.28e-06 -0.34 -0.27 Platelet distribution width; chr13:113228250 chr13:113165002~113165183:- LUSC cis rs7829975 0.564 rs2921060 ENSG00000253893.2 FAM85B 6.06 2.87e-09 1.28e-06 0.32 0.27 Mood instability; chr8:8460307 chr8:8167819~8226614:- LUSC cis rs7580658 0.637 rs12463909 ENSG00000236682.1 AC068282.3 6.06 2.88e-09 1.28e-06 0.35 0.27 Protein C levels; chr2:127214162 chr2:127389130~127400580:+ LUSC cis rs34779708 0.733 rs12254018 ENSG00000230534.5 RP11-297A16.2 6.05 2.88e-09 1.29e-06 0.31 0.27 Inflammatory bowel disease;Crohn's disease; chr10:35261713 chr10:35098006~35127020:- LUSC cis rs7712401 0.601 rs246268 ENSG00000263432.2 RN7SL689P 6.05 2.88e-09 1.29e-06 0.33 0.27 Mean platelet volume; chr5:122920647 chr5:123022487~123022783:- LUSC cis rs72772090 0.634 rs12186366 ENSG00000248734.2 CTD-2260A17.1 -6.05 2.89e-09 1.29e-06 -0.38 -0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96753146 chr5:96784777~96785999:+ LUSC cis rs8072100 0.701 rs2013383 ENSG00000228782.6 CTD-2026D20.3 6.05 2.89e-09 1.29e-06 0.27 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47713757 chr17:47450568~47492492:- LUSC cis rs6570726 0.967 rs418662 ENSG00000235652.6 RP11-545I5.3 6.05 2.89e-09 1.29e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145527696 chr6:145799409~145886585:+ LUSC cis rs5753618 0.539 rs1034588 ENSG00000236132.1 CTA-440B3.1 6.05 2.89e-09 1.29e-06 0.36 0.27 Colorectal cancer; chr22:31220315 chr22:31816379~31817491:- LUSC cis rs950169 0.922 rs11630507 ENSG00000259295.5 CSPG4P12 6.05 2.89e-09 1.29e-06 0.35 0.27 Schizophrenia; chr15:84552494 chr15:85191438~85213905:+ LUSC cis rs7772486 0.875 rs863820 ENSG00000235652.6 RP11-545I5.3 -6.05 2.89e-09 1.29e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:146026266 chr6:145799409~145886585:+ LUSC cis rs2243480 1 rs160655 ENSG00000226824.5 RP4-756H11.3 -6.05 2.89e-09 1.29e-06 -0.51 -0.27 Diabetic kidney disease; chr7:66068227 chr7:66654538~66669855:+ LUSC cis rs8062405 0.965 rs56040780 ENSG00000278665.1 RP11-666O2.4 6.05 2.9e-09 1.29e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850560 chr16:28599241~28601881:- LUSC cis rs1134634 0.52 rs7661102 ENSG00000273133.1 RP11-799M12.2 -6.05 2.9e-09 1.29e-06 -0.35 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15596914 chr4:15563698~15564253:- LUSC cis rs2834288 0.535 rs8132681 ENSG00000273102.1 AP000569.9 6.05 2.9e-09 1.29e-06 0.3 0.27 Gut microbiota (bacterial taxa); chr21:33950035 chr21:33967101~33968573:- LUSC cis rs2732480 0.577 rs2732481 ENSG00000273765.1 RP11-370I10.11 6.05 2.9e-09 1.29e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343202 chr12:48360920~48361377:+ LUSC cis rs2732480 0.557 rs2732484 ENSG00000273765.1 RP11-370I10.11 6.05 2.9e-09 1.29e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343462 chr12:48360920~48361377:+ LUSC cis rs6991838 0.778 rs11779601 ENSG00000200714.1 Y_RNA 6.05 2.91e-09 1.3e-06 0.32 0.27 Intelligence (multi-trait analysis); chr8:65550241 chr8:65592731~65592820:+ LUSC cis rs79349575 0.721 rs3744608 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48915871 chr17:48899131~48899748:+ LUSC cis rs79349575 0.745 rs170319 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48914169 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs318090 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48914390 chr17:48899131~48899748:+ LUSC cis rs79349575 0.651 rs4378658 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48916008 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs12453374 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48917484 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs12453394 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48917608 chr17:48899131~48899748:+ LUSC cis rs79349575 0.811 rs12601072 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48920636 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs28409394 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48920756 chr17:48899131~48899748:+ LUSC cis rs79349575 0.749 rs58838744 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48921540 chr17:48899131~48899748:+ LUSC cis rs79349575 0.811 rs60708039 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48922011 chr17:48899131~48899748:+ LUSC cis rs2842992 0.747 rs4709378 ENSG00000237927.1 RP3-393E18.2 -6.05 2.91e-09 1.3e-06 -0.41 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159806403 chr6:159586955~159589169:- LUSC cis rs79349575 0.783 rs17635252 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48929588 chr17:48899131~48899748:+ LUSC cis rs79349575 0.749 rs318093 ENSG00000270781.1 RP11-501C14.9 -6.05 2.91e-09 1.3e-06 -0.28 -0.27 Type 2 diabetes; chr17:48911992 chr17:48899131~48899748:+ LUSC cis rs11722779 0.935 rs3974481 ENSG00000230069.3 LRRC37A15P -6.05 2.91e-09 1.3e-06 -0.29 -0.27 Schizophrenia; chr4:102956834 chr4:102727274~102730721:- LUSC cis rs783540 0.934 rs1594511 ENSG00000276710.3 CSPG4P8 6.05 2.92e-09 1.3e-06 0.29 0.27 Schizophrenia; chr15:82638312 chr15:82459472~82477258:+ LUSC cis rs2834288 1 rs2834288 ENSG00000273102.1 AP000569.9 6.05 2.92e-09 1.3e-06 0.29 0.27 Gut microbiota (bacterial taxa); chr21:33892093 chr21:33967101~33968573:- LUSC cis rs10129255 0.536 rs8004835 ENSG00000224373.3 IGHV4-59 6.05 2.92e-09 1.3e-06 0.13 0.27 Kawasaki disease; chr14:106686361 chr14:106627249~106627825:- LUSC cis rs6928977 0.675 rs58761508 ENSG00000234084.1 RP3-388E23.2 6.05 2.92e-09 1.3e-06 0.22 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135514763 chr6:135301568~135307158:+ LUSC cis rs6928977 0.631 rs9385726 ENSG00000234084.1 RP3-388E23.2 6.05 2.92e-09 1.3e-06 0.22 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135515824 chr6:135301568~135307158:+ LUSC cis rs875971 0.862 rs7809814 ENSG00000179406.6 LINC00174 6.05 2.93e-09 1.31e-06 0.29 0.27 Aortic root size; chr7:66150410 chr7:66376044~66401338:- LUSC cis rs6504622 0.702 rs11079747 ENSG00000262879.4 RP11-156P1.3 -6.05 2.93e-09 1.31e-06 -0.28 -0.27 Orofacial clefts; chr17:47001484 chr17:46984045~47100323:- LUSC cis rs2404602 0.53 rs12915184 ENSG00000259422.1 RP11-593F23.1 -6.05 2.93e-09 1.31e-06 -0.34 -0.27 Blood metabolite levels; chr15:76673581 chr15:76174891~76181486:- LUSC cis rs4713118 0.513 rs1225591 ENSG00000219392.1 RP1-265C24.5 -6.05 2.94e-09 1.31e-06 -0.35 -0.27 Parkinson's disease; chr6:28180974 chr6:28115628~28116551:+ LUSC cis rs67311347 0.713 rs4974018 ENSG00000223797.4 ENTPD3-AS1 6.05 2.95e-09 1.31e-06 0.29 0.27 Renal cell carcinoma; chr3:40265928 chr3:40313802~40453329:- LUSC cis rs79349575 0.749 rs12601672 ENSG00000270781.1 RP11-501C14.9 -6.05 2.95e-09 1.31e-06 -0.28 -0.27 Type 2 diabetes; chr17:48929131 chr17:48899131~48899748:+ LUSC cis rs9322193 0.962 rs3763163 ENSG00000268592.3 RAET1E-AS1 6.05 2.95e-09 1.32e-06 0.34 0.27 Lung cancer; chr6:149819770 chr6:149863494~149919507:+ LUSC cis rs35160687 0.644 rs11127024 ENSG00000273080.1 RP11-301O19.1 -6.05 2.95e-09 1.32e-06 -0.26 -0.27 Night sleep phenotypes; chr2:86278330 chr2:86195590~86196049:+ LUSC cis rs2153535 0.541 rs945304 ENSG00000230939.1 RP11-314C16.1 -6.05 2.96e-09 1.32e-06 -0.32 -0.27 Motion sickness; chr6:8442659 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1889715 ENSG00000230939.1 RP11-314C16.1 -6.05 2.96e-09 1.32e-06 -0.32 -0.27 Motion sickness; chr6:8443242 chr6:8784178~8785445:+ LUSC cis rs875971 0.964 rs160635 ENSG00000179406.6 LINC00174 -6.05 2.96e-09 1.32e-06 -0.29 -0.27 Aortic root size; chr7:66063931 chr7:66376044~66401338:- LUSC cis rs875971 1 rs1565531 ENSG00000179406.6 LINC00174 6.05 2.96e-09 1.32e-06 0.29 0.27 Aortic root size; chr7:66198126 chr7:66376044~66401338:- LUSC cis rs8062405 1 rs8061590 ENSG00000278665.1 RP11-666O2.4 6.05 2.96e-09 1.32e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28883809 chr16:28599241~28601881:- LUSC cis rs7246657 0.722 rs2927739 ENSG00000276846.1 CTD-3220F14.3 -6.05 2.96e-09 1.32e-06 -0.4 -0.27 Coronary artery calcification; chr19:37658429 chr19:37314868~37315620:- LUSC cis rs7267979 0.668 rs4815398 ENSG00000274973.1 RP13-401N8.7 6.05 2.96e-09 1.32e-06 0.28 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25256702 chr20:25845497~25845862:+ LUSC cis rs9322193 0.923 rs35961297 ENSG00000268592.3 RAET1E-AS1 6.05 2.97e-09 1.32e-06 0.34 0.27 Lung cancer; chr6:149667929 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs35967444 ENSG00000268592.3 RAET1E-AS1 6.05 2.97e-09 1.32e-06 0.34 0.27 Lung cancer; chr6:149675588 chr6:149863494~149919507:+ LUSC cis rs9322193 0.923 rs62439842 ENSG00000268592.3 RAET1E-AS1 6.05 2.97e-09 1.32e-06 0.34 0.27 Lung cancer; chr6:149675847 chr6:149863494~149919507:+ LUSC cis rs11971779 0.523 rs10234578 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139353242 chr7:139359032~139359566:- LUSC cis rs11971779 0.616 rs7784192 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139354903 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs3924296 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139357181 chr7:139359032~139359566:- LUSC cis rs11971779 0.527 rs4379397 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139358639 chr7:139359032~139359566:- LUSC cis rs11971779 0.774 rs6467838 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139358755 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6961812 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139359062 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6962366 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139359121 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs3924445 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139359426 chr7:139359032~139359566:- LUSC cis rs11971779 0.585 rs3922848 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139361464 chr7:139359032~139359566:- LUSC cis rs11971779 0.59 rs6944104 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139366374 chr7:139359032~139359566:- LUSC cis rs11971779 0.616 rs6944244 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139366440 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs6962637 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139366604 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs7799598 ENSG00000273391.1 RP11-634H22.1 6.05 2.97e-09 1.32e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139367087 chr7:139359032~139359566:- LUSC cis rs4803480 0.935 rs758349 ENSG00000270164.1 LINC01480 -6.05 2.97e-09 1.32e-06 -0.24 -0.27 Schizophrenia; chr19:41578753 chr19:41535183~41536904:+ LUSC cis rs7429990 0.965 rs319686 ENSG00000228638.1 FCF1P2 -6.05 2.97e-09 1.33e-06 -0.32 -0.27 Educational attainment (years of education); chr3:47888930 chr3:48290793~48291375:- LUSC cis rs8031584 0.918 rs35784593 ENSG00000260382.1 RP11-540B6.2 6.05 2.98e-09 1.33e-06 0.37 0.27 Huntington's disease progression; chr15:30962385 chr15:30882267~30883231:- LUSC cis rs13113518 1 rs13116194 ENSG00000273257.1 RP11-177J6.1 6.05 2.98e-09 1.33e-06 0.34 0.27 Height; chr4:55531150 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs13117836 ENSG00000273257.1 RP11-177J6.1 6.05 2.98e-09 1.33e-06 0.34 0.27 Height; chr4:55531218 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs7668429 ENSG00000273257.1 RP11-177J6.1 6.05 2.98e-09 1.33e-06 0.34 0.27 Height; chr4:55531811 chr4:55387949~55388271:+ LUSC cis rs12908161 0.959 rs12906348 ENSG00000259728.4 LINC00933 6.05 2.98e-09 1.33e-06 0.35 0.27 Schizophrenia; chr15:84786190 chr15:84570649~84580175:+ LUSC cis rs12908161 0.959 rs34342559 ENSG00000259728.4 LINC00933 6.05 2.98e-09 1.33e-06 0.35 0.27 Schizophrenia; chr15:84788040 chr15:84570649~84580175:+ LUSC cis rs12908161 0.959 rs62019472 ENSG00000259728.4 LINC00933 6.05 2.98e-09 1.33e-06 0.35 0.27 Schizophrenia; chr15:84788262 chr15:84570649~84580175:+ LUSC cis rs12908161 0.959 rs35557864 ENSG00000259728.4 LINC00933 6.05 2.98e-09 1.33e-06 0.35 0.27 Schizophrenia; chr15:84788398 chr15:84570649~84580175:+ LUSC cis rs67311347 1 rs11129876 ENSG00000223797.4 ENTPD3-AS1 -6.05 2.98e-09 1.33e-06 -0.3 -0.27 Renal cell carcinoma; chr3:40360145 chr3:40313802~40453329:- LUSC cis rs36423 0.748 rs36388 ENSG00000266869.1 RP6-114E22.1 -6.05 2.99e-09 1.33e-06 -0.42 -0.27 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71898959 chr14:71848606~71908430:+ LUSC cis rs4372836 0.93 rs7607844 ENSG00000226833.4 AC097724.3 6.05 2.99e-09 1.33e-06 0.33 0.27 Body mass index; chr2:28748872 chr2:28708953~28736205:- LUSC cis rs3764021 0.527 rs10844503 ENSG00000256975.1 RP11-525E9.1 6.05 2.99e-09 1.33e-06 0.35 0.27 Type 1 diabetes; chr12:9701660 chr12:9506347~9508440:- LUSC cis rs11971779 0.648 rs59791374 ENSG00000273391.1 RP11-634H22.1 6.05 2.99e-09 1.33e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139432216 chr7:139359032~139359566:- LUSC cis rs11971779 0.59 rs59602547 ENSG00000273391.1 RP11-634H22.1 6.05 2.99e-09 1.33e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139432277 chr7:139359032~139359566:- LUSC cis rs67311347 0.911 rs9849224 ENSG00000223797.4 ENTPD3-AS1 6.05 3e-09 1.33e-06 0.3 0.27 Renal cell carcinoma; chr3:40351071 chr3:40313802~40453329:- LUSC cis rs1823913 0.599 rs1378156 ENSG00000227542.1 AC092614.2 -6.05 3e-09 1.34e-06 -0.35 -0.27 Obesity-related traits; chr2:191272466 chr2:191229165~191246172:- LUSC cis rs442309 0.551 rs1509966 ENSG00000238280.1 RP11-436D10.3 -6.05 3e-09 1.34e-06 -0.33 -0.27 Vogt-Koyanagi-Harada syndrome; chr10:62792847 chr10:62793562~62805887:- LUSC cis rs78487399 0.71 rs76675804 ENSG00000234936.1 AC010883.5 6.05 3e-09 1.34e-06 0.43 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43384744 chr2:43229573~43233394:+ LUSC cis rs9322193 0.962 rs9397022 ENSG00000268592.3 RAET1E-AS1 6.05 3.01e-09 1.34e-06 0.34 0.27 Lung cancer; chr6:149812052 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9397357 ENSG00000268592.3 RAET1E-AS1 6.05 3.01e-09 1.34e-06 0.34 0.27 Lung cancer; chr6:149812465 chr6:149863494~149919507:+ LUSC cis rs11089937 0.616 rs7286793 ENSG00000211639.2 IGLV4-60 6.05 3.01e-09 1.34e-06 0.29 0.27 Periodontitis (PAL4Q3); chr22:22182951 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs7291684 ENSG00000211639.2 IGLV4-60 6.05 3.01e-09 1.34e-06 0.29 0.27 Periodontitis (PAL4Q3); chr22:22183834 chr22:22162199~22162681:+ LUSC cis rs11089937 0.616 rs6001219 ENSG00000211639.2 IGLV4-60 6.05 3.01e-09 1.34e-06 0.29 0.27 Periodontitis (PAL4Q3); chr22:22184348 chr22:22162199~22162681:+ LUSC cis rs8005677 0.828 rs712486 ENSG00000279656.1 RP11-298I3.6 6.05 3.01e-09 1.34e-06 0.32 0.27 Cognitive ability (multi-trait analysis); chr14:22955832 chr14:23023083~23024217:- LUSC cis rs853679 0.517 rs12174753 ENSG00000280107.1 AL022393.9 -6.05 3.01e-09 1.34e-06 -0.33 -0.27 Depression; chr6:28074687 chr6:28170845~28172521:+ LUSC cis rs2243480 0.803 rs160649 ENSG00000226824.5 RP4-756H11.3 -6.05 3.02e-09 1.34e-06 -0.51 -0.27 Diabetic kidney disease; chr7:66078212 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs160648 ENSG00000226824.5 RP4-756H11.3 -6.05 3.02e-09 1.34e-06 -0.51 -0.27 Diabetic kidney disease; chr7:66078397 chr7:66654538~66669855:+ LUSC cis rs2337406 0.778 rs56658355 ENSG00000254174.1 IGHV1-12 6.05 3.02e-09 1.34e-06 0.29 0.27 Alzheimer's disease (late onset); chr14:106662151 chr14:106122420~106122709:- LUSC cis rs783540 0.934 rs10400906 ENSG00000255769.6 GOLGA2P10 -6.05 3.02e-09 1.34e-06 -0.32 -0.27 Schizophrenia; chr15:82628387 chr15:82472993~82513950:- LUSC cis rs11971779 0.68 rs4398844 ENSG00000273391.1 RP11-634H22.1 6.05 3.02e-09 1.35e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139358393 chr7:139359032~139359566:- LUSC cis rs950880 0.71 rs56258475 ENSG00000234389.1 AC007278.3 -6.05 3.03e-09 1.35e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102382852 chr2:102438713~102440475:+ LUSC cis rs2404602 0.735 rs11072598 ENSG00000259422.1 RP11-593F23.1 -6.05 3.03e-09 1.35e-06 -0.32 -0.27 Blood metabolite levels; chr15:76472447 chr15:76174891~76181486:- LUSC cis rs11846409 0.86 rs10150951 ENSG00000274576.2 IGHV2-70 -6.05 3.03e-09 1.35e-06 -0.27 -0.27 Rheumatic heart disease; chr14:106632988 chr14:106770577~106771020:- LUSC cis rs11846409 0.86 rs17112419 ENSG00000274576.2 IGHV2-70 -6.05 3.03e-09 1.35e-06 -0.27 -0.27 Rheumatic heart disease; chr14:106633260 chr14:106770577~106771020:- LUSC cis rs11846409 0.932 rs2583329 ENSG00000274576.2 IGHV2-70 6.05 3.03e-09 1.35e-06 0.27 0.27 Rheumatic heart disease; chr14:106632971 chr14:106770577~106771020:- LUSC cis rs6991838 0.778 rs11782837 ENSG00000200714.1 Y_RNA 6.05 3.04e-09 1.35e-06 0.33 0.27 Intelligence (multi-trait analysis); chr8:65550328 chr8:65592731~65592820:+ LUSC cis rs6860806 0.507 rs272880 ENSG00000233006.5 AC034220.3 6.05 3.04e-09 1.35e-06 0.28 0.27 Breast cancer; chr5:132334485 chr5:132311285~132369916:- LUSC cis rs5753618 0.539 rs737888 ENSG00000236132.1 CTA-440B3.1 6.05 3.04e-09 1.35e-06 0.36 0.27 Colorectal cancer; chr22:31215563 chr22:31816379~31817491:- LUSC cis rs2842992 0.83 rs1535475 ENSG00000237927.1 RP3-393E18.2 -6.05 3.04e-09 1.35e-06 -0.39 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159727903 chr6:159586955~159589169:- LUSC cis rs957448 1 rs7829886 ENSG00000253175.1 RP11-267M23.6 6.05 3.04e-09 1.35e-06 0.31 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94485160 chr8:94565036~94565715:+ LUSC cis rs6570726 0.935 rs453609 ENSG00000235652.6 RP11-545I5.3 6.05 3.05e-09 1.35e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145491196 chr6:145799409~145886585:+ LUSC cis rs11098499 0.863 rs3775843 ENSG00000248280.1 RP11-33B1.2 6.04 3.05e-09 1.36e-06 0.32 0.27 Corneal astigmatism; chr4:119506689 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs3775844 ENSG00000248280.1 RP11-33B1.2 6.04 3.05e-09 1.36e-06 0.32 0.27 Corneal astigmatism; chr4:119506878 chr4:119440561~119450157:- LUSC cis rs454422 0.812 rs13041190 ENSG00000275632.1 RP5-967N21.11 6.04 3.05e-09 1.36e-06 0.29 0.27 HIV-1 viral setpoint; chr20:5980812 chr20:6000418~6000941:+ LUSC cis rs1823913 0.637 rs4853569 ENSG00000280083.1 RP11-317J9.1 6.04 3.05e-09 1.36e-06 0.32 0.27 Obesity-related traits; chr2:191266970 chr2:191154118~191156070:- LUSC cis rs17270561 0.666 rs4712976 ENSG00000272462.2 U91328.19 -6.04 3.05e-09 1.36e-06 -0.31 -0.27 Iron status biomarkers; chr6:25841975 chr6:25992662~26001775:+ LUSC cis rs5753618 0.509 rs5749224 ENSG00000236132.1 CTA-440B3.1 6.04 3.05e-09 1.36e-06 0.37 0.27 Colorectal cancer; chr22:31162563 chr22:31816379~31817491:- LUSC cis rs2732480 0.557 rs2732441 ENSG00000273765.1 RP11-370I10.11 6.04 3.06e-09 1.36e-06 0.31 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48329541 chr12:48360920~48361377:+ LUSC cis rs2732480 0.577 rs2732448 ENSG00000273765.1 RP11-370I10.11 6.04 3.06e-09 1.36e-06 0.31 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48336817 chr12:48360920~48361377:+ LUSC cis rs73173548 0.502 rs76393802 ENSG00000247828.6 TMEM161B-AS1 6.04 3.06e-09 1.36e-06 0.32 0.27 Macular telangiectasia type 2; chr5:88455311 chr5:88268895~88436685:+ LUSC cis rs9545047 0.604 rs7322744 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79354070 chr13:79566727~79571436:+ LUSC cis rs13113518 1 rs55699500 ENSG00000249700.7 SRD5A3-AS1 6.04 3.06e-09 1.36e-06 0.31 0.27 Height; chr4:55540912 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs56362210 ENSG00000249700.7 SRD5A3-AS1 6.04 3.06e-09 1.36e-06 0.31 0.27 Height; chr4:55540972 chr4:55363971~55395847:- LUSC cis rs1021993 0.545 rs17014337 ENSG00000231648.1 RP11-372M18.2 -6.04 3.06e-09 1.36e-06 -0.39 -0.27 Gut microbiome composition (winter); chr1:209354120 chr1:209367662~209379690:+ LUSC cis rs13113518 0.783 rs11943206 ENSG00000249700.7 SRD5A3-AS1 6.04 3.06e-09 1.36e-06 0.31 0.27 Height; chr4:55570843 chr4:55363971~55395847:- LUSC cis rs9545047 0.604 rs7996652 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79341474 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9565488 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79341604 chr13:79566727~79571436:+ LUSC cis rs9545047 0.625 rs9565489 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79342106 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs3742117 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79342498 chr13:79566727~79571436:+ LUSC cis rs9545047 0.647 rs3742118 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79342838 chr13:79566727~79571436:+ LUSC cis rs9545047 0.625 rs7319320 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79343072 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs3752994 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79345076 chr13:79566727~79571436:+ LUSC cis rs9545047 0.567 rs4884129 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79346448 chr13:79566727~79571436:+ LUSC cis rs9545047 0.567 rs1410336 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79347598 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9565492 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79348554 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9318625 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79351429 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9530899 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79352461 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs7338677 ENSG00000227676.3 LINC01068 6.04 3.06e-09 1.36e-06 0.32 0.27 Schizophrenia; chr13:79352580 chr13:79566727~79571436:+ LUSC cis rs2153535 0.542 rs9393012 ENSG00000230939.1 RP11-314C16.1 -6.04 3.07e-09 1.36e-06 -0.32 -0.27 Motion sickness; chr6:8439576 chr6:8784178~8785445:+ LUSC cis rs11098499 0.863 rs7699064 ENSG00000248280.1 RP11-33B1.2 -6.04 3.08e-09 1.37e-06 -0.32 -0.27 Corneal astigmatism; chr4:119507154 chr4:119440561~119450157:- LUSC cis rs2337406 0.538 rs10141701 ENSG00000274576.2 IGHV2-70 -6.04 3.08e-09 1.37e-06 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106633467 chr14:106770577~106771020:- LUSC cis rs7772486 0.875 rs2814876 ENSG00000235652.6 RP11-545I5.3 6.04 3.08e-09 1.37e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145982894 chr6:145799409~145886585:+ LUSC cis rs17507216 0.667 rs13379724 ENSG00000255769.6 GOLGA2P10 -6.04 3.09e-09 1.37e-06 -0.39 -0.27 Excessive daytime sleepiness; chr15:82619892 chr15:82472993~82513950:- LUSC cis rs7567389 0.744 rs6430934 ENSG00000236682.1 AC068282.3 6.04 3.09e-09 1.37e-06 0.38 0.27 Self-rated health; chr2:127243257 chr2:127389130~127400580:+ LUSC cis rs7955901 0.638 rs10879261 ENSG00000257265.1 CTD-2021H9.1 6.04 3.1e-09 1.38e-06 0.3 0.27 Type 2 diabetes; chr12:71126981 chr12:71007773~71032083:- LUSC cis rs79349575 0.811 rs1057897 ENSG00000270781.1 RP11-501C14.9 -6.04 3.1e-09 1.38e-06 -0.28 -0.27 Type 2 diabetes; chr17:48928147 chr17:48899131~48899748:+ LUSC cis rs6142102 0.961 rs8119937 ENSG00000275784.1 RP5-1125A11.6 -6.04 3.1e-09 1.38e-06 -0.31 -0.27 Skin pigmentation; chr20:34057745 chr20:33989480~33991818:- LUSC cis rs875971 1 rs2087647 ENSG00000179406.6 LINC00174 6.04 3.1e-09 1.38e-06 0.29 0.27 Aortic root size; chr7:66128201 chr7:66376044~66401338:- LUSC cis rs62103177 0.565 rs473119 ENSG00000261126.6 RP11-795F19.1 -6.04 3.1e-09 1.38e-06 -0.34 -0.27 Opioid sensitivity; chr18:80091557 chr18:80046900~80095482:+ LUSC cis rs950880 0.645 rs56044378 ENSG00000234389.1 AC007278.3 -6.04 3.1e-09 1.38e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102448907 chr2:102438713~102440475:+ LUSC cis rs875971 0.528 rs801213 ENSG00000237310.1 GS1-124K5.4 -6.04 3.11e-09 1.38e-06 -0.31 -0.27 Aortic root size; chr7:66549931 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs801212 ENSG00000237310.1 GS1-124K5.4 -6.04 3.11e-09 1.38e-06 -0.31 -0.27 Aortic root size; chr7:66550643 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs801199 ENSG00000237310.1 GS1-124K5.4 -6.04 3.11e-09 1.38e-06 -0.31 -0.27 Aortic root size; chr7:66560286 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs1267814 ENSG00000237310.1 GS1-124K5.4 -6.04 3.11e-09 1.38e-06 -0.31 -0.27 Aortic root size; chr7:66579422 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs73152714 ENSG00000237310.1 GS1-124K5.4 6.04 3.11e-09 1.38e-06 0.31 0.27 Aortic root size; chr7:66534641 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs4718364 ENSG00000237310.1 GS1-124K5.4 6.04 3.11e-09 1.38e-06 0.31 0.27 Aortic root size; chr7:66536353 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs6961853 ENSG00000237310.1 GS1-124K5.4 6.04 3.11e-09 1.38e-06 0.31 0.27 Aortic root size; chr7:66537035 chr7:66493706~66495474:+ LUSC cis rs950880 0.744 rs3771156 ENSG00000234389.1 AC007278.3 -6.04 3.11e-09 1.38e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102420217 chr2:102438713~102440475:+ LUSC cis rs9928842 0.771 rs2870471 ENSG00000280152.1 RP11-331F4.5 -6.04 3.12e-09 1.39e-06 -0.3 -0.27 Alcoholic chronic pancreatitis; chr16:75240384 chr16:75245994~75250077:- LUSC cis rs4372836 1 rs4666118 ENSG00000226833.4 AC097724.3 6.04 3.12e-09 1.39e-06 0.31 0.27 Body mass index; chr2:28728832 chr2:28708953~28736205:- LUSC cis rs8062405 0.698 rs8046545 ENSG00000278665.1 RP11-666O2.4 -6.04 3.12e-09 1.39e-06 -0.28 -0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28903896 chr16:28599241~28601881:- LUSC cis rs8062405 0.698 rs10499 ENSG00000278665.1 RP11-666O2.4 -6.04 3.12e-09 1.39e-06 -0.28 -0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28904206 chr16:28599241~28601881:- LUSC cis rs2153535 0.58 rs9406167 ENSG00000230939.1 RP11-314C16.1 -6.04 3.13e-09 1.39e-06 -0.31 -0.27 Motion sickness; chr6:8502619 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6597334 ENSG00000230939.1 RP11-314C16.1 -6.04 3.13e-09 1.39e-06 -0.31 -0.27 Motion sickness; chr6:8504546 chr6:8784178~8785445:+ LUSC cis rs6142102 0.812 rs6059558 ENSG00000275784.1 RP5-1125A11.6 -6.04 3.13e-09 1.39e-06 -0.31 -0.27 Skin pigmentation; chr20:33929024 chr20:33989480~33991818:- LUSC cis rs875971 1 rs6958484 ENSG00000179406.6 LINC00174 6.04 3.13e-09 1.39e-06 0.29 0.27 Aortic root size; chr7:66134459 chr7:66376044~66401338:- LUSC cis rs7429990 0.864 rs13098128 ENSG00000229759.1 MRPS18AP1 -6.04 3.13e-09 1.39e-06 -0.27 -0.27 Educational attainment (years of education); chr3:47756066 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs7637950 ENSG00000229759.1 MRPS18AP1 -6.04 3.13e-09 1.39e-06 -0.27 -0.27 Educational attainment (years of education); chr3:47758204 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs6442085 ENSG00000229759.1 MRPS18AP1 -6.04 3.13e-09 1.39e-06 -0.27 -0.27 Educational attainment (years of education); chr3:47760080 chr3:48256350~48256938:- LUSC cis rs4372836 0.964 rs4665432 ENSG00000226833.4 AC097724.3 -6.04 3.14e-09 1.39e-06 -0.31 -0.27 Body mass index; chr2:28729160 chr2:28708953~28736205:- LUSC cis rs4372836 1 rs11688129 ENSG00000226833.4 AC097724.3 -6.04 3.14e-09 1.39e-06 -0.31 -0.27 Body mass index; chr2:28729715 chr2:28708953~28736205:- LUSC cis rs4372836 1 rs4549034 ENSG00000226833.4 AC097724.3 6.04 3.14e-09 1.39e-06 0.31 0.27 Body mass index; chr2:28749713 chr2:28708953~28736205:- LUSC cis rs4372836 1 rs4372836 ENSG00000226833.4 AC097724.3 6.04 3.14e-09 1.39e-06 0.31 0.27 Body mass index; chr2:28751017 chr2:28708953~28736205:- LUSC cis rs4372836 1 rs7598876 ENSG00000226833.4 AC097724.3 6.04 3.14e-09 1.39e-06 0.31 0.27 Body mass index; chr2:28751600 chr2:28708953~28736205:- LUSC cis rs66887589 0.934 rs12648182 ENSG00000245958.5 RP11-33B1.1 6.04 3.14e-09 1.39e-06 0.25 0.27 Diastolic blood pressure; chr4:119582736 chr4:119454791~119552025:+ LUSC cis rs2243480 1 rs1618893 ENSG00000226824.5 RP4-756H11.3 -6.04 3.14e-09 1.39e-06 -0.5 -0.27 Diabetic kidney disease; chr7:66631132 chr7:66654538~66669855:+ LUSC cis rs11098499 0.78 rs7680914 ENSG00000248280.1 RP11-33B1.2 6.04 3.15e-09 1.4e-06 0.33 0.27 Corneal astigmatism; chr4:119641898 chr4:119440561~119450157:- LUSC cis rs1823913 0.637 rs4853573 ENSG00000280083.1 RP11-317J9.1 6.04 3.15e-09 1.4e-06 0.31 0.27 Obesity-related traits; chr2:191295866 chr2:191154118~191156070:- LUSC cis rs1823913 0.614 rs4853466 ENSG00000280083.1 RP11-317J9.1 6.04 3.15e-09 1.4e-06 0.31 0.27 Obesity-related traits; chr2:191295943 chr2:191154118~191156070:- LUSC cis rs61270009 0.955 rs78909929 ENSG00000247828.6 TMEM161B-AS1 6.04 3.15e-09 1.4e-06 0.31 0.27 Depressive symptoms; chr5:88344154 chr5:88268895~88436685:+ LUSC cis rs67311347 0.713 rs9861194 ENSG00000223797.4 ENTPD3-AS1 6.04 3.15e-09 1.4e-06 0.29 0.27 Renal cell carcinoma; chr3:40267734 chr3:40313802~40453329:- LUSC cis rs35160687 0.623 rs35408390 ENSG00000273080.1 RP11-301O19.1 -6.04 3.15e-09 1.4e-06 -0.26 -0.27 Night sleep phenotypes; chr2:86244659 chr2:86195590~86196049:+ LUSC cis rs6142102 0.923 rs6059635 ENSG00000275784.1 RP5-1125A11.6 -6.04 3.16e-09 1.4e-06 -0.3 -0.27 Skin pigmentation; chr20:34025687 chr20:33989480~33991818:- LUSC cis rs875971 0.508 rs10242423 ENSG00000236529.1 RP13-254B10.1 -6.04 3.16e-09 1.4e-06 -0.27 -0.27 Aortic root size; chr7:66594188 chr7:65840212~65840596:+ LUSC cis rs875971 0.508 rs10253883 ENSG00000236529.1 RP13-254B10.1 -6.04 3.16e-09 1.4e-06 -0.27 -0.27 Aortic root size; chr7:66596151 chr7:65840212~65840596:+ LUSC cis rs7772486 0.875 rs2474356 ENSG00000235652.6 RP11-545I5.3 6.04 3.16e-09 1.4e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145975662 chr6:145799409~145886585:+ LUSC cis rs4718428 0.705 rs4718424 ENSG00000226824.5 RP4-756H11.3 -6.04 3.16e-09 1.4e-06 -0.36 -0.27 Corneal structure; chr7:66911108 chr7:66654538~66669855:+ LUSC cis rs2834288 0.7 rs731059 ENSG00000273102.1 AP000569.9 -6.04 3.16e-09 1.4e-06 -0.31 -0.27 Gut microbiota (bacterial taxa); chr21:33902813 chr21:33967101~33968573:- LUSC cis rs748404 0.706 rs57728767 ENSG00000249839.1 AC011330.5 -6.04 3.16e-09 1.4e-06 -0.48 -0.27 Lung cancer; chr15:43473639 chr15:43663654~43684339:- LUSC cis rs2337406 0.866 rs2301535 ENSG00000254174.1 IGHV1-12 6.04 3.16e-09 1.4e-06 0.27 0.27 Alzheimer's disease (late onset); chr14:106790663 chr14:106122420~106122709:- LUSC cis rs13113518 0.902 rs12505266 ENSG00000273257.1 RP11-177J6.1 6.04 3.16e-09 1.4e-06 0.34 0.27 Height; chr4:55546002 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs56154935 ENSG00000249700.7 SRD5A3-AS1 6.04 3.16e-09 1.4e-06 0.31 0.27 Height; chr4:55546378 chr4:55363971~55395847:- LUSC cis rs875971 0.528 rs801213 ENSG00000226824.5 RP4-756H11.3 6.04 3.17e-09 1.41e-06 0.35 0.27 Aortic root size; chr7:66549931 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs801212 ENSG00000226824.5 RP4-756H11.3 6.04 3.17e-09 1.41e-06 0.35 0.27 Aortic root size; chr7:66550643 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs801199 ENSG00000226824.5 RP4-756H11.3 6.04 3.17e-09 1.41e-06 0.35 0.27 Aortic root size; chr7:66560286 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs1267814 ENSG00000226824.5 RP4-756H11.3 6.04 3.17e-09 1.41e-06 0.35 0.27 Aortic root size; chr7:66579422 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs73152714 ENSG00000226824.5 RP4-756H11.3 -6.04 3.17e-09 1.41e-06 -0.35 -0.27 Aortic root size; chr7:66534641 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs4718364 ENSG00000226824.5 RP4-756H11.3 -6.04 3.17e-09 1.41e-06 -0.35 -0.27 Aortic root size; chr7:66536353 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs6961853 ENSG00000226824.5 RP4-756H11.3 -6.04 3.17e-09 1.41e-06 -0.35 -0.27 Aortic root size; chr7:66537035 chr7:66654538~66669855:+ LUSC cis rs227275 0.556 rs4235407 ENSG00000230069.3 LRRC37A15P -6.04 3.18e-09 1.41e-06 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102897427 chr4:102727274~102730721:- LUSC cis rs228614 0.51 rs4699033 ENSG00000230069.3 LRRC37A15P -6.04 3.18e-09 1.41e-06 -0.29 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102897577 chr4:102727274~102730721:- LUSC cis rs7189233 0.955 rs72801853 ENSG00000279344.1 RP11-44F14.7 6.04 3.18e-09 1.41e-06 0.24 0.27 Intelligence (multi-trait analysis); chr16:53482912 chr16:53478957~53481550:- LUSC cis rs6570726 0.846 rs7762536 ENSG00000235652.6 RP11-545I5.3 6.04 3.18e-09 1.41e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145602009 chr6:145799409~145886585:+ LUSC cis rs910316 0.836 rs6574212 ENSG00000279594.1 RP11-950C14.10 -6.04 3.18e-09 1.41e-06 -0.31 -0.27 Height; chr14:75204956 chr14:75011269~75012851:- LUSC cis rs1823913 0.599 rs17511445 ENSG00000280083.1 RP11-317J9.1 6.04 3.18e-09 1.41e-06 0.31 0.27 Obesity-related traits; chr2:191279831 chr2:191154118~191156070:- LUSC cis rs71403859 0.667 rs35538253 ENSG00000260886.1 TAT-AS1 6.04 3.19e-09 1.41e-06 0.42 0.27 Post bronchodilator FEV1; chr16:71644072 chr16:71565789~71578187:+ LUSC cis rs36405 0.5 rs8003168 ENSG00000266869.1 RP6-114E22.1 -6.04 3.19e-09 1.41e-06 -0.33 -0.27 Yang-deficiency constitution; chr14:71896671 chr14:71848606~71908430:+ LUSC cis rs7267979 0.844 rs35735333 ENSG00000274973.1 RP13-401N8.7 6.04 3.19e-09 1.41e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25356569 chr20:25845497~25845862:+ LUSC cis rs66887589 0.967 rs2892869 ENSG00000248280.1 RP11-33B1.2 -6.04 3.2e-09 1.42e-06 -0.3 -0.27 Diastolic blood pressure; chr4:119600142 chr4:119440561~119450157:- LUSC cis rs13113518 0.507 rs11943456 ENSG00000223305.1 RN7SKP30 6.04 3.2e-09 1.42e-06 0.31 0.27 Height; chr4:55410167 chr4:55540502~55540835:- LUSC cis rs73173548 0.502 rs6867204 ENSG00000247828.6 TMEM161B-AS1 6.04 3.2e-09 1.42e-06 0.32 0.27 Macular telangiectasia type 2; chr5:88446423 chr5:88268895~88436685:+ LUSC cis rs73173548 0.502 rs34933255 ENSG00000247828.6 TMEM161B-AS1 6.04 3.2e-09 1.42e-06 0.32 0.27 Macular telangiectasia type 2; chr5:88446492 chr5:88268895~88436685:+ LUSC cis rs12439619 0.846 rs62012059 ENSG00000276710.3 CSPG4P8 -6.04 3.2e-09 1.42e-06 -0.33 -0.27 Intelligence (multi-trait analysis); chr15:82251669 chr15:82459472~82477258:+ LUSC cis rs8040855 0.627 rs11632175 ENSG00000259295.5 CSPG4P12 6.04 3.2e-09 1.42e-06 0.34 0.27 Bulimia nervosa; chr15:85068449 chr15:85191438~85213905:+ LUSC cis rs11098499 0.82 rs28535956 ENSG00000248280.1 RP11-33B1.2 -6.04 3.2e-09 1.42e-06 -0.32 -0.27 Corneal astigmatism; chr4:119615703 chr4:119440561~119450157:- LUSC cis rs13113518 0.902 rs12505266 ENSG00000249700.7 SRD5A3-AS1 6.04 3.2e-09 1.42e-06 0.31 0.27 Height; chr4:55546002 chr4:55363971~55395847:- LUSC cis rs17772222 0.655 rs7160717 ENSG00000258789.1 RP11-507K2.3 -6.04 3.2e-09 1.42e-06 -0.3 -0.27 Coronary artery calcification; chr14:88498232 chr14:88551597~88552493:+ LUSC cis rs875971 0.54 rs35510581 ENSG00000237310.1 GS1-124K5.4 -6.04 3.21e-09 1.42e-06 -0.28 -0.27 Aortic root size; chr7:66113790 chr7:66493706~66495474:+ LUSC cis rs6570726 0.791 rs4332001 ENSG00000235652.6 RP11-545I5.3 6.04 3.21e-09 1.42e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145613705 chr6:145799409~145886585:+ LUSC cis rs11098499 0.866 rs3756156 ENSG00000248280.1 RP11-33B1.2 6.04 3.21e-09 1.42e-06 0.32 0.27 Corneal astigmatism; chr4:119603686 chr4:119440561~119450157:- LUSC cis rs1823913 0.637 rs6722183 ENSG00000227542.1 AC092614.2 -6.04 3.22e-09 1.43e-06 -0.34 -0.27 Obesity-related traits; chr2:191333203 chr2:191229165~191246172:- LUSC cis rs34779708 0.649 rs34421369 ENSG00000230534.5 RP11-297A16.2 6.04 3.22e-09 1.43e-06 0.31 0.27 Inflammatory bowel disease;Crohn's disease; chr10:35261347 chr10:35098006~35127020:- LUSC cis rs1823913 0.637 rs4853574 ENSG00000280083.1 RP11-317J9.1 6.04 3.23e-09 1.43e-06 0.31 0.27 Obesity-related traits; chr2:191296113 chr2:191154118~191156070:- LUSC cis rs9322193 0.923 rs35830138 ENSG00000268592.3 RAET1E-AS1 6.04 3.23e-09 1.43e-06 0.34 0.27 Lung cancer; chr6:149668635 chr6:149863494~149919507:+ LUSC cis rs4372836 1 rs34409160 ENSG00000226833.4 AC097724.3 -6.03 3.23e-09 1.43e-06 -0.32 -0.27 Body mass index; chr2:28720999 chr2:28708953~28736205:- LUSC cis rs67311347 1 rs7612015 ENSG00000223797.4 ENTPD3-AS1 6.03 3.23e-09 1.43e-06 0.3 0.27 Renal cell carcinoma; chr3:40358483 chr3:40313802~40453329:- LUSC cis rs10759883 0.627 rs816673 ENSG00000175611.10 LINC00476 -6.03 3.23e-09 1.43e-06 -0.32 -0.27 Nicotine dependence; chr9:95811134 chr9:95759231~95875977:- LUSC cis rs950880 0.71 rs56117144 ENSG00000234389.1 AC007278.3 -6.03 3.24e-09 1.44e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102458191 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs57081652 ENSG00000234389.1 AC007278.3 -6.03 3.24e-09 1.44e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102458921 chr2:102438713~102440475:+ LUSC cis rs875971 0.54 rs736270 ENSG00000237310.1 GS1-124K5.4 6.03 3.24e-09 1.44e-06 0.28 0.27 Aortic root size; chr7:65963835 chr7:66493706~66495474:+ LUSC cis rs9322193 0.962 rs9505974 ENSG00000268592.3 RAET1E-AS1 6.03 3.25e-09 1.44e-06 0.34 0.27 Lung cancer; chr6:149779294 chr6:149863494~149919507:+ LUSC cis rs9322193 0.926 rs9689036 ENSG00000268592.3 RAET1E-AS1 6.03 3.25e-09 1.44e-06 0.34 0.27 Lung cancer; chr6:149780563 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9322218 ENSG00000268592.3 RAET1E-AS1 6.03 3.25e-09 1.44e-06 0.34 0.27 Lung cancer; chr6:149782183 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9322219 ENSG00000268592.3 RAET1E-AS1 6.03 3.25e-09 1.44e-06 0.34 0.27 Lung cancer; chr6:149782263 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9322223 ENSG00000268592.3 RAET1E-AS1 6.03 3.25e-09 1.44e-06 0.34 0.27 Lung cancer; chr6:149801509 chr6:149863494~149919507:+ LUSC cis rs2243480 1 rs4718334 ENSG00000226824.5 RP4-756H11.3 6.03 3.25e-09 1.44e-06 0.51 0.27 Diabetic kidney disease; chr7:66324467 chr7:66654538~66669855:+ LUSC cis rs67311347 1 rs9834052 ENSG00000223797.4 ENTPD3-AS1 6.03 3.25e-09 1.44e-06 0.3 0.27 Renal cell carcinoma; chr3:40357569 chr3:40313802~40453329:- LUSC cis rs881375 0.678 rs10760129 ENSG00000226752.6 PSMD5-AS1 -6.03 3.25e-09 1.44e-06 -0.3 -0.27 Rheumatoid arthritis; chr9:120937905 chr9:120824828~120854385:+ LUSC cis rs2243480 1 rs4718317 ENSG00000226824.5 RP4-756H11.3 6.03 3.25e-09 1.44e-06 0.51 0.27 Diabetic kidney disease; chr7:66183914 chr7:66654538~66669855:+ LUSC cis rs8177876 0.642 rs4454990 ENSG00000261838.4 RP11-303E16.6 -6.03 3.26e-09 1.44e-06 -0.53 -0.27 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81106550 chr16:81069854~81076598:+ LUSC cis rs7615952 0.932 rs13325495 ENSG00000171084.14 FAM86JP 6.03 3.26e-09 1.44e-06 0.37 0.27 Blood pressure (smoking interaction); chr3:125918573 chr3:125916620~125930024:+ LUSC cis rs9545047 0.604 rs9565486 ENSG00000227676.3 LINC01068 -6.03 3.26e-09 1.44e-06 -0.32 -0.27 Schizophrenia; chr13:79317469 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9285310 ENSG00000227676.3 LINC01068 -6.03 3.26e-09 1.44e-06 -0.32 -0.27 Schizophrenia; chr13:79328340 chr13:79566727~79571436:+ LUSC cis rs9545047 0.625 rs9593391 ENSG00000227676.3 LINC01068 -6.03 3.26e-09 1.44e-06 -0.32 -0.27 Schizophrenia; chr13:79329168 chr13:79566727~79571436:+ LUSC cis rs11089937 0.626 rs5757056 ENSG00000211638.2 IGLV8-61 -6.03 3.26e-09 1.44e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22142491 chr22:22098700~22099212:+ LUSC cis rs14027 0.883 rs10087723 ENSG00000279347.1 RP11-85I17.2 -6.03 3.26e-09 1.44e-06 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119711014 chr8:119838736~119840385:- LUSC cis rs1134634 0.52 rs10034328 ENSG00000273133.1 RP11-799M12.2 -6.03 3.26e-09 1.44e-06 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15616764 chr4:15563698~15564253:- LUSC cis rs9545047 0.604 rs28579970 ENSG00000227676.3 LINC01068 -6.03 3.26e-09 1.44e-06 -0.32 -0.27 Schizophrenia; chr13:79308726 chr13:79566727~79571436:+ LUSC cis rs7657257 1 rs11931532 ENSG00000214846.4 RP11-115L11.1 6.03 3.27e-09 1.45e-06 0.67 0.27 Blood protein levels; chr4:15724143 chr4:15730962~15731627:- LUSC cis rs6750795 0.765 rs6742387 ENSG00000181798.2 LINC00471 -6.03 3.27e-09 1.45e-06 -0.29 -0.27 Height; chr2:231490121 chr2:231508426~231514339:- LUSC cis rs11089937 0.626 rs2213161 ENSG00000211638.2 IGLV8-61 -6.03 3.27e-09 1.45e-06 -0.29 -0.27 Periodontitis (PAL4Q3); chr22:22143005 chr22:22098700~22099212:+ LUSC cis rs2562456 0.917 rs10420016 ENSG00000268081.1 RP11-678G14.2 -6.03 3.27e-09 1.45e-06 -0.38 -0.27 Pain; chr19:21505800 chr19:21554640~21569237:- LUSC cis rs875971 0.628 rs6974355 ENSG00000237310.1 GS1-124K5.4 6.03 3.27e-09 1.45e-06 0.28 0.27 Aortic root size; chr7:66376994 chr7:66493706~66495474:+ LUSC cis rs2153535 0.58 rs915350 ENSG00000230939.1 RP11-314C16.1 -6.03 3.27e-09 1.45e-06 -0.32 -0.27 Motion sickness; chr6:8443253 chr6:8784178~8785445:+ LUSC cis rs881375 0.631 rs2416808 ENSG00000226752.6 PSMD5-AS1 -6.03 3.27e-09 1.45e-06 -0.3 -0.27 Rheumatoid arthritis; chr9:120944005 chr9:120824828~120854385:+ LUSC cis rs881375 0.678 rs10985102 ENSG00000226752.6 PSMD5-AS1 -6.03 3.27e-09 1.45e-06 -0.3 -0.27 Rheumatoid arthritis; chr9:120945219 chr9:120824828~120854385:+ LUSC cis rs950880 0.71 rs4851582 ENSG00000234389.1 AC007278.3 -6.03 3.27e-09 1.45e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102435098 chr2:102438713~102440475:+ LUSC cis rs11098499 0.78 rs7692994 ENSG00000248280.1 RP11-33B1.2 6.03 3.28e-09 1.45e-06 0.31 0.27 Corneal astigmatism; chr4:119506334 chr4:119440561~119450157:- LUSC cis rs11846409 0.932 rs60659763 ENSG00000274576.2 IGHV2-70 -6.03 3.28e-09 1.45e-06 -0.28 -0.27 Rheumatic heart disease; chr14:106634172 chr14:106770577~106771020:- LUSC cis rs11846409 0.932 rs57080270 ENSG00000274576.2 IGHV2-70 -6.03 3.28e-09 1.45e-06 -0.28 -0.27 Rheumatic heart disease; chr14:106634215 chr14:106770577~106771020:- LUSC cis rs7955901 0.638 rs3851611 ENSG00000257265.1 CTD-2021H9.1 6.03 3.29e-09 1.45e-06 0.3 0.27 Type 2 diabetes; chr12:71130262 chr12:71007773~71032083:- LUSC cis rs12935418 0.887 rs3743503 ENSG00000261061.1 RP11-303E16.2 -6.03 3.29e-09 1.45e-06 -0.53 -0.27 Mean corpuscular volume; chr16:81022836 chr16:81030770~81031485:+ LUSC cis rs36423 0.748 rs36387 ENSG00000266869.1 RP6-114E22.1 -6.03 3.29e-09 1.45e-06 -0.42 -0.27 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71900629 chr14:71848606~71908430:+ LUSC cis rs13113518 0.812 rs11133385 ENSG00000249700.7 SRD5A3-AS1 6.03 3.29e-09 1.46e-06 0.31 0.27 Height; chr4:55460485 chr4:55363971~55395847:- LUSC cis rs957448 1 rs56716157 ENSG00000253175.1 RP11-267M23.6 6.03 3.29e-09 1.46e-06 0.32 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94530644 chr8:94565036~94565715:+ LUSC cis rs2153535 0.58 rs1577467 ENSG00000230939.1 RP11-314C16.1 -6.03 3.3e-09 1.46e-06 -0.32 -0.27 Motion sickness; chr6:8444008 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1577468 ENSG00000230939.1 RP11-314C16.1 -6.03 3.3e-09 1.46e-06 -0.32 -0.27 Motion sickness; chr6:8444033 chr6:8784178~8785445:+ LUSC cis rs6504950 0.705 rs9899602 ENSG00000275710.1 RP11-257O5.4 -6.03 3.3e-09 1.46e-06 -0.32 -0.27 Breast cancer; chr17:54909547 chr17:54964474~54964679:+ LUSC cis rs75422866 0.867 rs73104115 ENSG00000257433.4 RP1-197B17.3 6.03 3.31e-09 1.46e-06 0.64 0.27 Pneumonia; chr12:47684843 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73104116 ENSG00000257433.4 RP1-197B17.3 6.03 3.31e-09 1.46e-06 0.64 0.27 Pneumonia; chr12:47685023 chr12:47706085~47742294:+ LUSC cis rs4660456 0.504 rs587963 ENSG00000237899.1 RP4-739H11.3 6.03 3.31e-09 1.46e-06 0.39 0.27 Platelet count; chr1:40640045 chr1:40669089~40687588:- LUSC cis rs14027 0.883 rs1469755 ENSG00000279347.1 RP11-85I17.2 -6.03 3.31e-09 1.47e-06 -0.25 -0.27 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119728107 chr8:119838736~119840385:- LUSC cis rs131777 0.545 rs131759 ENSG00000205559.3 CHKB-AS1 -6.03 3.32e-09 1.47e-06 -0.33 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50577052 chr22:50583026~50583877:+ LUSC cis rs2834288 0.7 rs731061 ENSG00000273102.1 AP000569.9 -6.03 3.32e-09 1.47e-06 -0.31 -0.27 Gut microbiota (bacterial taxa); chr21:33902937 chr21:33967101~33968573:- LUSC cis rs875971 0.545 rs6460298 ENSG00000226824.5 RP4-756H11.3 -6.03 3.32e-09 1.47e-06 -0.35 -0.27 Aortic root size; chr7:66442783 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs75577046 ENSG00000226824.5 RP4-756H11.3 -6.03 3.32e-09 1.47e-06 -0.35 -0.27 Aortic root size; chr7:66493729 chr7:66654538~66669855:+ LUSC cis rs875971 0.545 rs3735147 ENSG00000226824.5 RP4-756H11.3 -6.03 3.32e-09 1.47e-06 -0.35 -0.27 Aortic root size; chr7:66505541 chr7:66654538~66669855:+ LUSC cis rs12130219 1 rs12130219 ENSG00000237975.5 FLG-AS1 6.03 3.32e-09 1.47e-06 0.31 0.27 Inflammatory skin disease; chr1:152189630 chr1:152168125~152445456:+ LUSC cis rs7739264 0.796 rs9366314 ENSG00000237404.1 RP3-471C18.2 -6.03 3.32e-09 1.47e-06 -0.3 -0.27 Endometriosis; chr6:19742632 chr6:19689825~19753113:- LUSC cis rs9322193 0.923 rs9800686 ENSG00000268592.3 RAET1E-AS1 6.03 3.33e-09 1.47e-06 0.34 0.27 Lung cancer; chr6:149634464 chr6:149863494~149919507:+ LUSC cis rs853679 1 rs11965538 ENSG00000219392.1 RP1-265C24.5 -6.03 3.33e-09 1.47e-06 -0.43 -0.27 Depression; chr6:28272137 chr6:28115628~28116551:+ LUSC cis rs853679 0.882 rs2743555 ENSG00000219392.1 RP1-265C24.5 -6.03 3.33e-09 1.47e-06 -0.43 -0.27 Depression; chr6:28273304 chr6:28115628~28116551:+ LUSC cis rs638893 0.636 rs2186781 ENSG00000278376.1 RP11-158I9.8 -6.03 3.33e-09 1.47e-06 -0.36 -0.27 Vitiligo; chr11:118734738 chr11:118791254~118793137:+ LUSC cis rs6570726 0.791 rs4335004 ENSG00000235652.6 RP11-545I5.3 6.03 3.33e-09 1.47e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145583628 chr6:145799409~145886585:+ LUSC cis rs783540 1 rs783531 ENSG00000276710.3 CSPG4P8 6.03 3.33e-09 1.47e-06 0.28 0.27 Schizophrenia; chr15:82580370 chr15:82459472~82477258:+ LUSC cis rs783540 0.934 rs783532 ENSG00000276710.3 CSPG4P8 6.03 3.33e-09 1.47e-06 0.28 0.27 Schizophrenia; chr15:82580618 chr15:82459472~82477258:+ LUSC cis rs71403859 0.73 rs12923781 ENSG00000260886.1 TAT-AS1 6.03 3.34e-09 1.47e-06 0.44 0.27 Post bronchodilator FEV1; chr16:71619561 chr16:71565789~71578187:+ LUSC cis rs75422866 0.867 rs73104138 ENSG00000257433.4 RP1-197B17.3 6.03 3.34e-09 1.47e-06 0.65 0.27 Pneumonia; chr12:47692302 chr12:47706085~47742294:+ LUSC cis rs75422866 0.717 rs73104143 ENSG00000257433.4 RP1-197B17.3 6.03 3.34e-09 1.47e-06 0.65 0.27 Pneumonia; chr12:47693449 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73104144 ENSG00000257433.4 RP1-197B17.3 6.03 3.34e-09 1.47e-06 0.65 0.27 Pneumonia; chr12:47694390 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73104148 ENSG00000257433.4 RP1-197B17.3 6.03 3.34e-09 1.47e-06 0.65 0.27 Pneumonia; chr12:47696732 chr12:47706085~47742294:+ LUSC cis rs11089937 0.597 rs4145535 ENSG00000211638.2 IGLV8-61 -6.03 3.34e-09 1.47e-06 -0.29 -0.27 Periodontitis (PAL4Q3); chr22:22143981 chr22:22098700~22099212:+ LUSC cis rs12908161 0.96 rs34452033 ENSG00000259728.4 LINC00933 6.03 3.34e-09 1.47e-06 0.34 0.27 Schizophrenia; chr15:84678762 chr15:84570649~84580175:+ LUSC cis rs79349575 0.783 rs4255820 ENSG00000270781.1 RP11-501C14.9 -6.03 3.34e-09 1.47e-06 -0.28 -0.27 Type 2 diabetes; chr17:48919221 chr17:48899131~48899748:+ LUSC cis rs6772849 0.768 rs4521246 ENSG00000242551.2 POU5F1P6 6.03 3.34e-09 1.48e-06 0.32 0.27 Monocyte percentage of white cells;Monocyte count; chr3:128702323 chr3:128674735~128677005:- LUSC cis rs950880 0.71 rs11683700 ENSG00000234389.1 AC007278.3 -6.03 3.34e-09 1.48e-06 -0.3 -0.27 Serum protein levels (sST2); chr2:102380345 chr2:102438713~102440475:+ LUSC cis rs9545047 0.604 rs9530897 ENSG00000227676.3 LINC01068 6.03 3.35e-09 1.48e-06 0.32 0.27 Schizophrenia; chr13:79336420 chr13:79566727~79571436:+ LUSC cis rs12439619 0.693 rs7165536 ENSG00000276710.3 CSPG4P8 -6.03 3.35e-09 1.48e-06 -0.32 -0.27 Intelligence (multi-trait analysis); chr15:82273743 chr15:82459472~82477258:+ LUSC cis rs17772222 0.63 rs1344747 ENSG00000258789.1 RP11-507K2.3 6.03 3.35e-09 1.48e-06 0.3 0.27 Coronary artery calcification; chr14:88548091 chr14:88551597~88552493:+ LUSC cis rs7429990 0.864 rs11712464 ENSG00000229759.1 MRPS18AP1 6.03 3.35e-09 1.48e-06 0.27 0.27 Educational attainment (years of education); chr3:47724057 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs56376646 ENSG00000229759.1 MRPS18AP1 6.03 3.35e-09 1.48e-06 0.27 0.27 Educational attainment (years of education); chr3:47732588 chr3:48256350~48256938:- LUSC cis rs11098499 0.863 rs10019674 ENSG00000248280.1 RP11-33B1.2 -6.03 3.35e-09 1.48e-06 -0.32 -0.27 Corneal astigmatism; chr4:119522334 chr4:119440561~119450157:- LUSC cis rs11098499 0.644 rs3806808 ENSG00000250412.1 KLHL2P1 6.03 3.35e-09 1.48e-06 0.32 0.27 Corneal astigmatism; chr4:119629930 chr4:119334329~119378233:+ LUSC cis rs7208859 0.623 rs9915566 ENSG00000266490.1 CTD-2349P21.9 6.03 3.35e-09 1.48e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs55661352 ENSG00000266490.1 CTD-2349P21.9 6.03 3.36e-09 1.48e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30718610 chr17:30792372~30792833:+ LUSC cis rs13113518 0.812 rs4865003 ENSG00000249700.7 SRD5A3-AS1 6.03 3.36e-09 1.48e-06 0.31 0.27 Height; chr4:55514802 chr4:55363971~55395847:- LUSC cis rs17711722 0.503 rs453835 ENSG00000226824.5 RP4-756H11.3 6.03 3.36e-09 1.48e-06 0.32 0.27 Calcium levels; chr7:66046172 chr7:66654538~66669855:+ LUSC cis rs6504950 0.886 rs2787501 ENSG00000275710.1 RP11-257O5.4 6.03 3.36e-09 1.48e-06 0.31 0.27 Breast cancer; chr17:55016604 chr17:54964474~54964679:+ LUSC cis rs77204473 0.744 rs11216252 ENSG00000254851.1 RP11-109L13.1 6.03 3.36e-09 1.49e-06 0.63 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117057507 chr11:117135528~117138582:+ LUSC cis rs11098499 1 rs58601355 ENSG00000250412.1 KLHL2P1 6.03 3.37e-09 1.49e-06 0.34 0.27 Corneal astigmatism; chr4:119265212 chr4:119334329~119378233:+ LUSC cis rs8062405 0.558 rs151228 ENSG00000259982.1 CDC37P1 6.03 3.38e-09 1.49e-06 0.32 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28551705 chr16:28700294~28701540:- LUSC cis rs35160687 0.842 rs1863052 ENSG00000273080.1 RP11-301O19.1 6.03 3.38e-09 1.49e-06 0.25 0.27 Night sleep phenotypes; chr2:86332235 chr2:86195590~86196049:+ LUSC cis rs7598759 0.548 rs11686485 ENSG00000181798.2 LINC00471 -6.03 3.38e-09 1.49e-06 -0.29 -0.27 Noise-induced hearing loss; chr2:231495986 chr2:231508426~231514339:- LUSC cis rs875971 0.862 rs1167390 ENSG00000179406.6 LINC00174 6.03 3.38e-09 1.49e-06 0.29 0.27 Aortic root size; chr7:66110906 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs35034167 ENSG00000179406.6 LINC00174 6.03 3.38e-09 1.49e-06 0.29 0.27 Aortic root size; chr7:66115179 chr7:66376044~66401338:- LUSC cis rs9322193 0.923 rs9689084 ENSG00000268592.3 RAET1E-AS1 6.03 3.38e-09 1.49e-06 0.34 0.27 Lung cancer; chr6:149639648 chr6:149863494~149919507:+ LUSC cis rs35160687 0.623 rs4832263 ENSG00000273080.1 RP11-301O19.1 -6.03 3.39e-09 1.49e-06 -0.25 -0.27 Night sleep phenotypes; chr2:86258034 chr2:86195590~86196049:+ LUSC cis rs28830936 0.966 rs17678552 ENSG00000250379.1 RP11-23P13.4 6.03 3.39e-09 1.49e-06 0.29 0.27 Diastolic blood pressure; chr15:41773992 chr15:41825099~41827936:- LUSC cis rs78487399 0.808 rs17406646 ENSG00000234936.1 AC010883.5 6.03 3.39e-09 1.5e-06 0.43 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43451478 chr2:43229573~43233394:+ LUSC cis rs2153535 0.58 rs9505467 ENSG00000230939.1 RP11-314C16.1 -6.03 3.39e-09 1.5e-06 -0.31 -0.27 Motion sickness; chr6:8519986 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1360054 ENSG00000230939.1 RP11-314C16.1 -6.03 3.39e-09 1.5e-06 -0.31 -0.27 Motion sickness; chr6:8520144 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9328483 ENSG00000230939.1 RP11-314C16.1 -6.03 3.39e-09 1.5e-06 -0.31 -0.27 Motion sickness; chr6:8521062 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9393033 ENSG00000230939.1 RP11-314C16.1 -6.03 3.39e-09 1.5e-06 -0.31 -0.27 Motion sickness; chr6:8521213 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs6938688 ENSG00000230939.1 RP11-314C16.1 -6.03 3.39e-09 1.5e-06 -0.31 -0.27 Motion sickness; chr6:8521396 chr6:8784178~8785445:+ LUSC cis rs7267979 0.844 rs6076343 ENSG00000274973.1 RP13-401N8.7 6.03 3.4e-09 1.5e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25396027 chr20:25845497~25845862:+ LUSC cis rs875971 0.825 rs4587224 ENSG00000179406.6 LINC00174 6.03 3.4e-09 1.5e-06 0.29 0.27 Aortic root size; chr7:66271195 chr7:66376044~66401338:- LUSC cis rs9309473 0.615 rs62149774 ENSG00000163016.8 ALMS1P 6.03 3.4e-09 1.5e-06 0.39 0.27 Metabolite levels; chr2:73560525 chr2:73644919~73685576:+ LUSC cis rs4713118 0.513 rs149950 ENSG00000216901.1 AL022393.7 6.03 3.4e-09 1.5e-06 0.31 0.27 Parkinson's disease; chr6:28065261 chr6:28176188~28176674:+ LUSC cis rs4713118 0.513 rs149951 ENSG00000216901.1 AL022393.7 6.03 3.4e-09 1.5e-06 0.31 0.27 Parkinson's disease; chr6:28065309 chr6:28176188~28176674:+ LUSC cis rs875971 0.862 rs1612452 ENSG00000179406.6 LINC00174 6.03 3.41e-09 1.5e-06 0.29 0.27 Aortic root size; chr7:66108909 chr7:66376044~66401338:- LUSC cis rs7429990 0.864 rs11927129 ENSG00000229759.1 MRPS18AP1 6.03 3.41e-09 1.5e-06 0.27 0.27 Educational attainment (years of education); chr3:47745413 chr3:48256350~48256938:- LUSC cis rs4713118 0.868 rs10484401 ENSG00000280107.1 AL022393.9 6.03 3.41e-09 1.5e-06 0.32 0.27 Parkinson's disease; chr6:27778811 chr6:28170845~28172521:+ LUSC cis rs875971 0.558 rs4433015 ENSG00000224316.1 RP11-479O9.2 -6.02 3.42e-09 1.51e-06 -0.26 -0.27 Aortic root size; chr7:66174736 chr7:65773620~65802067:+ LUSC cis rs7772486 0.712 rs6570726 ENSG00000235652.6 RP11-545I5.3 6.02 3.42e-09 1.51e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145838324 chr6:145799409~145886585:+ LUSC cis rs2179367 0.632 rs62426068 ENSG00000231760.4 RP11-350J20.5 6.02 3.43e-09 1.51e-06 0.38 0.27 Dupuytren's disease; chr6:149325795 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs62426069 ENSG00000231760.4 RP11-350J20.5 6.02 3.43e-09 1.51e-06 0.38 0.27 Dupuytren's disease; chr6:149325804 chr6:149796151~149826294:- LUSC cis rs13113518 1 rs4864548 ENSG00000249700.7 SRD5A3-AS1 -6.02 3.43e-09 1.51e-06 -0.3 -0.27 Height; chr4:55547636 chr4:55363971~55395847:- LUSC cis rs2732480 0.577 rs2634680 ENSG00000273765.1 RP11-370I10.11 6.02 3.43e-09 1.51e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48340781 chr12:48360920~48361377:+ LUSC cis rs2732480 0.577 rs2634678 ENSG00000273765.1 RP11-370I10.11 6.02 3.43e-09 1.51e-06 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48341755 chr12:48360920~48361377:+ LUSC cis rs1876905 0.539 rs240958 ENSG00000255389.1 C6orf3 -6.02 3.43e-09 1.51e-06 -0.37 -0.27 Mean corpuscular hemoglobin; chr6:111298449 chr6:111599875~111602295:+ LUSC cis rs2581828 0.646 rs3796351 ENSG00000242142.1 SERBP1P3 6.02 3.44e-09 1.52e-06 0.32 0.27 Crohn's disease; chr3:53122049 chr3:53064283~53065091:- LUSC cis rs2562456 0.755 rs1879234 ENSG00000268081.1 RP11-678G14.2 -6.02 3.44e-09 1.52e-06 -0.38 -0.27 Pain; chr19:21521677 chr19:21554640~21569237:- LUSC cis rs2179367 0.543 rs9498328 ENSG00000231760.4 RP11-350J20.5 6.02 3.45e-09 1.52e-06 0.38 0.27 Dupuytren's disease; chr6:149348715 chr6:149796151~149826294:- LUSC cis rs6142102 0.961 rs4911144 ENSG00000275784.1 RP5-1125A11.6 -6.02 3.45e-09 1.52e-06 -0.31 -0.27 Skin pigmentation; chr20:34026565 chr20:33989480~33991818:- LUSC cis rs875971 0.597 rs11763224 ENSG00000226824.5 RP4-756H11.3 -6.02 3.45e-09 1.52e-06 -0.36 -0.27 Aortic root size; chr7:66518628 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs4718307 ENSG00000179406.6 LINC00174 6.02 3.45e-09 1.52e-06 0.29 0.27 Aortic root size; chr7:66146001 chr7:66376044~66401338:- LUSC cis rs875971 1 rs7801282 ENSG00000179406.6 LINC00174 6.02 3.45e-09 1.52e-06 0.29 0.27 Aortic root size; chr7:66148700 chr7:66376044~66401338:- LUSC cis rs7772486 0.743 rs62433835 ENSG00000235652.6 RP11-545I5.3 -6.02 3.45e-09 1.52e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145711552 chr6:145799409~145886585:+ LUSC cis rs7772486 0.743 rs2092262 ENSG00000235652.6 RP11-545I5.3 -6.02 3.45e-09 1.52e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145715969 chr6:145799409~145886585:+ LUSC cis rs7772486 0.682 rs1337840 ENSG00000235652.6 RP11-545I5.3 -6.02 3.45e-09 1.52e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145721422 chr6:145799409~145886585:+ LUSC cis rs9545047 0.588 rs9530894 ENSG00000227676.3 LINC01068 6.02 3.45e-09 1.52e-06 0.32 0.27 Schizophrenia; chr13:79334020 chr13:79566727~79571436:+ LUSC cis rs881375 0.678 rs10818488 ENSG00000226752.6 PSMD5-AS1 -6.02 3.45e-09 1.52e-06 -0.3 -0.27 Rheumatoid arthritis; chr9:120942809 chr9:120824828~120854385:+ LUSC cis rs11089937 0.626 rs9619800 ENSG00000211638.2 IGLV8-61 -6.02 3.45e-09 1.52e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22141088 chr22:22098700~22099212:+ LUSC cis rs13113518 1 rs7662966 ENSG00000249700.7 SRD5A3-AS1 6.02 3.45e-09 1.52e-06 0.31 0.27 Height; chr4:55548261 chr4:55363971~55395847:- LUSC cis rs6991838 0.806 rs13262793 ENSG00000200714.1 Y_RNA 6.02 3.45e-09 1.52e-06 0.32 0.27 Intelligence (multi-trait analysis); chr8:65549662 chr8:65592731~65592820:+ LUSC cis rs6772849 0.796 rs9841521 ENSG00000277250.1 Metazoa_SRP -6.02 3.46e-09 1.52e-06 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128673431 chr3:128673681~128674021:- LUSC cis rs875971 1 rs6961717 ENSG00000179406.6 LINC00174 6.02 3.46e-09 1.52e-06 0.28 0.27 Aortic root size; chr7:66122550 chr7:66376044~66401338:- LUSC cis rs9910055 0.762 rs11080007 ENSG00000267080.4 ASB16-AS1 6.02 3.47e-09 1.53e-06 0.24 0.27 Total body bone mineral density; chr17:44188074 chr17:44175973~44186717:- LUSC cis rs6142102 1 rs4911414 ENSG00000275784.1 RP5-1125A11.6 -6.02 3.47e-09 1.53e-06 -0.31 -0.27 Skin pigmentation; chr20:34141638 chr20:33989480~33991818:- LUSC cis rs11846409 0.932 rs74091728 ENSG00000274576.2 IGHV2-70 -6.02 3.47e-09 1.53e-06 -0.28 -0.27 Rheumatic heart disease; chr14:106638762 chr14:106770577~106771020:- LUSC cis rs904251 0.714 rs2776910 ENSG00000204110.6 RP1-153P14.8 -6.02 3.48e-09 1.53e-06 -0.29 -0.27 Cognitive performance; chr6:37468508 chr6:37507348~37535616:+ LUSC cis rs4713118 0.513 rs156739 ENSG00000219392.1 RP1-265C24.5 -6.02 3.48e-09 1.53e-06 -0.34 -0.27 Parkinson's disease; chr6:28045632 chr6:28115628~28116551:+ LUSC cis rs4713118 0.629 rs203887 ENSG00000204709.4 LINC01556 6.02 3.48e-09 1.53e-06 0.4 0.27 Parkinson's disease; chr6:28053491 chr6:28943877~28944537:+ LUSC cis rs2337406 0.866 rs7140974 ENSG00000211974.3 IGHV2-70 -6.02 3.48e-09 1.53e-06 -0.37 -0.27 Alzheimer's disease (late onset); chr14:106795976 chr14:106723574~106724093:- LUSC cis rs875971 0.545 rs6950988 ENSG00000226824.5 RP4-756H11.3 -6.02 3.48e-09 1.53e-06 -0.35 -0.27 Aortic root size; chr7:66511428 chr7:66654538~66669855:+ LUSC cis rs13113518 1 rs4864546 ENSG00000249700.7 SRD5A3-AS1 6.02 3.49e-09 1.53e-06 0.3 0.27 Height; chr4:55537960 chr4:55363971~55395847:- LUSC cis rs875971 1 rs875971 ENSG00000179406.6 LINC00174 6.02 3.49e-09 1.54e-06 0.29 0.27 Aortic root size; chr7:66152608 chr7:66376044~66401338:- LUSC cis rs6918586 0.658 rs198844 ENSG00000272462.2 U91328.19 -6.02 3.5e-09 1.54e-06 -0.28 -0.27 Schizophrenia; chr6:26108054 chr6:25992662~26001775:+ LUSC cis rs2732480 0.5 rs2450986 ENSG00000240399.1 RP1-228P16.1 6.02 3.5e-09 1.54e-06 0.29 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48267905 chr12:48054813~48055591:- LUSC cis rs1387259 0.929 rs2634666 ENSG00000240399.1 RP1-228P16.1 6.02 3.5e-09 1.54e-06 0.29 0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48269887 chr12:48054813~48055591:- LUSC cis rs1387259 0.929 rs2956703 ENSG00000240399.1 RP1-228P16.1 6.02 3.5e-09 1.54e-06 0.29 0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48276511 chr12:48054813~48055591:- LUSC cis rs1387259 0.931 rs1107654 ENSG00000240399.1 RP1-228P16.1 6.02 3.5e-09 1.54e-06 0.29 0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48287314 chr12:48054813~48055591:- LUSC cis rs9322193 0.923 rs12526675 ENSG00000268592.3 RAET1E-AS1 -6.02 3.5e-09 1.54e-06 -0.34 -0.27 Lung cancer; chr6:149729540 chr6:149863494~149919507:+ LUSC cis rs34779708 0.706 rs36027395 ENSG00000230534.5 RP11-297A16.2 6.02 3.5e-09 1.54e-06 0.31 0.27 Inflammatory bowel disease;Crohn's disease; chr10:35261395 chr10:35098006~35127020:- LUSC cis rs2834288 0.666 rs2834293 ENSG00000273102.1 AP000569.9 -6.02 3.5e-09 1.54e-06 -0.31 -0.27 Gut microbiota (bacterial taxa); chr21:33903905 chr21:33967101~33968573:- LUSC cis rs11089937 0.554 rs5995628 ENSG00000211639.2 IGLV4-60 6.02 3.5e-09 1.54e-06 0.3 0.27 Periodontitis (PAL4Q3); chr22:22194768 chr22:22162199~22162681:+ LUSC cis rs4713118 0.513 rs156734 ENSG00000219392.1 RP1-265C24.5 -6.02 3.5e-09 1.54e-06 -0.33 -0.27 Parkinson's disease; chr6:28039579 chr6:28115628~28116551:+ LUSC cis rs853679 0.517 rs35193936 ENSG00000280107.1 AL022393.9 -6.02 3.5e-09 1.54e-06 -0.34 -0.27 Depression; chr6:28108492 chr6:28170845~28172521:+ LUSC cis rs13113518 0.812 rs13140173 ENSG00000272969.1 RP11-528I4.2 6.02 3.5e-09 1.54e-06 0.31 0.27 Height; chr4:55527164 chr4:55547112~55547889:+ LUSC cis rs11690935 0.959 rs67204065 ENSG00000228389.1 AC068039.4 6.02 3.51e-09 1.54e-06 0.31 0.27 Schizophrenia; chr2:171816114 chr2:171773482~171775844:+ LUSC cis rs853679 0.517 rs4711164 ENSG00000280107.1 AL022393.9 -6.02 3.51e-09 1.54e-06 -0.34 -0.27 Depression; chr6:28147378 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs4711165 ENSG00000280107.1 AL022393.9 -6.02 3.51e-09 1.54e-06 -0.34 -0.27 Depression; chr6:28147406 chr6:28170845~28172521:+ LUSC cis rs2732480 0.557 rs2634682 ENSG00000273765.1 RP11-370I10.11 6.02 3.51e-09 1.55e-06 0.31 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48339160 chr12:48360920~48361377:+ LUSC cis rs801193 1 rs2659909 ENSG00000224316.1 RP11-479O9.2 6.02 3.52e-09 1.55e-06 0.25 0.27 Aortic root size; chr7:66695292 chr7:65773620~65802067:+ LUSC cis rs7772486 0.875 rs1331640 ENSG00000235652.6 RP11-545I5.3 6.02 3.52e-09 1.55e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:146106114 chr6:145799409~145886585:+ LUSC cis rs7429990 0.864 rs3772399 ENSG00000229759.1 MRPS18AP1 -6.02 3.52e-09 1.55e-06 -0.26 -0.27 Educational attainment (years of education); chr3:47826237 chr3:48256350~48256938:- LUSC cis rs67311347 1 rs2168111 ENSG00000223797.4 ENTPD3-AS1 6.02 3.52e-09 1.55e-06 0.3 0.27 Renal cell carcinoma; chr3:40353834 chr3:40313802~40453329:- LUSC cis rs66887589 0.967 rs7678973 ENSG00000248280.1 RP11-33B1.2 -6.02 3.52e-09 1.55e-06 -0.29 -0.27 Diastolic blood pressure; chr4:119590662 chr4:119440561~119450157:- LUSC cis rs6570726 0.643 rs9403735 ENSG00000235652.6 RP11-545I5.3 6.02 3.52e-09 1.55e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145615455 chr6:145799409~145886585:+ LUSC cis rs875971 0.545 rs17138149 ENSG00000179406.6 LINC00174 -6.02 3.53e-09 1.55e-06 -0.31 -0.27 Aortic root size; chr7:66228193 chr7:66376044~66401338:- LUSC cis rs6928977 0.637 rs9647635 ENSG00000234084.1 RP3-388E23.2 6.02 3.53e-09 1.55e-06 0.22 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135519918 chr6:135301568~135307158:+ LUSC cis rs11690935 0.851 rs7581072 ENSG00000228389.1 AC068039.4 6.02 3.53e-09 1.55e-06 0.31 0.27 Schizophrenia; chr2:171994938 chr2:171773482~171775844:+ LUSC cis rs17772222 0.63 rs12437422 ENSG00000258789.1 RP11-507K2.3 6.02 3.53e-09 1.55e-06 0.3 0.27 Coronary artery calcification; chr14:88529621 chr14:88551597~88552493:+ LUSC cis rs17772222 0.605 rs4899955 ENSG00000258789.1 RP11-507K2.3 6.02 3.53e-09 1.55e-06 0.3 0.27 Coronary artery calcification; chr14:88530381 chr14:88551597~88552493:+ LUSC cis rs17772222 0.63 rs4904454 ENSG00000258789.1 RP11-507K2.3 6.02 3.53e-09 1.55e-06 0.3 0.27 Coronary artery calcification; chr14:88537777 chr14:88551597~88552493:+ LUSC cis rs17772222 0.63 rs2033418 ENSG00000258789.1 RP11-507K2.3 6.02 3.53e-09 1.55e-06 0.3 0.27 Coronary artery calcification; chr14:88539331 chr14:88551597~88552493:+ LUSC cis rs1729407 0.709 rs2098453 ENSG00000254851.1 RP11-109L13.1 -6.02 3.53e-09 1.55e-06 -0.32 -0.27 Apolipoprotein A-IV levels; chr11:116825964 chr11:117135528~117138582:+ LUSC cis rs13392177 0.647 rs10932761 ENSG00000261338.2 RP11-378A13.1 -6.02 3.53e-09 1.55e-06 -0.27 -0.27 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218199668 chr2:218255319~218257366:+ LUSC cis rs2153535 0.542 rs6912740 ENSG00000230939.1 RP11-314C16.1 -6.02 3.53e-09 1.55e-06 -0.32 -0.27 Motion sickness; chr6:8439726 chr6:8784178~8785445:+ LUSC cis rs2153535 0.542 rs6905925 ENSG00000230939.1 RP11-314C16.1 -6.02 3.53e-09 1.55e-06 -0.32 -0.27 Motion sickness; chr6:8439797 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs6905934 ENSG00000230939.1 RP11-314C16.1 -6.02 3.53e-09 1.55e-06 -0.32 -0.27 Motion sickness; chr6:8439810 chr6:8784178~8785445:+ LUSC cis rs17270561 0.514 rs10946805 ENSG00000272810.1 U91328.22 -6.02 3.53e-09 1.55e-06 -0.36 -0.27 Iron status biomarkers; chr6:26077663 chr6:26013241~26013757:+ LUSC cis rs2276314 0.947 rs16967319 ENSG00000278986.1 RP11-723J4.3 -6.02 3.53e-09 1.55e-06 -0.34 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35993562 chr18:35972151~35973916:+ LUSC cis rs12908161 1 rs36033486 ENSG00000259728.4 LINC00933 6.02 3.53e-09 1.55e-06 0.34 0.27 Schizophrenia; chr15:84776461 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs62019469 ENSG00000259728.4 LINC00933 6.02 3.53e-09 1.55e-06 0.34 0.27 Schizophrenia; chr15:84777989 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs12908549 ENSG00000259728.4 LINC00933 6.02 3.53e-09 1.55e-06 0.34 0.27 Schizophrenia; chr15:84779120 chr15:84570649~84580175:+ LUSC cis rs7772486 0.875 rs6914813 ENSG00000235652.6 RP11-545I5.3 6.02 3.54e-09 1.55e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:146076662 chr6:145799409~145886585:+ LUSC cis rs7267979 1 rs2482940 ENSG00000274973.1 RP13-401N8.7 6.02 3.54e-09 1.56e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25369194 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2027003 ENSG00000274973.1 RP13-401N8.7 6.02 3.54e-09 1.56e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25369862 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs2027004 ENSG00000274973.1 RP13-401N8.7 6.02 3.54e-09 1.56e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25369982 chr20:25845497~25845862:+ LUSC cis rs2243480 1 rs6958289 ENSG00000226824.5 RP4-756H11.3 6.02 3.54e-09 1.56e-06 0.51 0.27 Diabetic kidney disease; chr7:66192124 chr7:66654538~66669855:+ LUSC cis rs2153535 0.58 rs2327050 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8440397 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs4404802 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8441819 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1932275 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8442100 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1932276 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8442360 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs915352 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8442533 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs915351 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8442560 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2327056 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8443072 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs3938660 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8443102 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs1855765 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8444092 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406143 ENSG00000230939.1 RP11-314C16.1 -6.02 3.55e-09 1.56e-06 -0.32 -0.27 Motion sickness; chr6:8444350 chr6:8784178~8785445:+ LUSC cis rs394563 0.663 rs415434 ENSG00000231760.4 RP11-350J20.5 6.02 3.55e-09 1.56e-06 0.33 0.27 Dupuytren's disease; chr6:149451509 chr6:149796151~149826294:- LUSC cis rs7208859 0.623 rs34756112 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs60724269 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs76633166 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs1061346 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs1061343 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs1061342 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs55938328 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs73269988 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs55961983 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30792372~30792833:+ LUSC cis rs7208859 0.673 rs9899525 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30792372~30792833:+ LUSC cis rs17826219 0.568 rs7213925 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Body mass index; chr17:30794616 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs11658945 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs11657990 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9911784 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9911997 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9890862 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs78071511 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs11650982 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs2035494 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs3794796 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9915546 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs8064686 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs11654035 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809408 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs11657369 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs8075341 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs73271842 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30792372~30792833:+ LUSC cis rs7208859 0.673 rs9895815 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30792372~30792833:+ LUSC cis rs7208859 0.673 rs8077116 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30792372~30792833:+ LUSC cis rs7208859 0.524 rs28760584 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30792372~30792833:+ LUSC cis rs17826219 0.706 rs73271850 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Body mass index; chr17:30815122 chr17:30792372~30792833:+ LUSC cis rs17826219 0.636 rs79565452 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Body mass index; chr17:30815823 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs7208088 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs7212991 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs28627615 ENSG00000266490.1 CTD-2349P21.9 6.02 3.55e-09 1.56e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30792372~30792833:+ LUSC cis rs13113518 0.783 rs6843722 ENSG00000272969.1 RP11-528I4.2 6.02 3.55e-09 1.56e-06 0.31 0.27 Height; chr4:55465165 chr4:55547112~55547889:+ LUSC cis rs11098499 0.863 rs7664986 ENSG00000248280.1 RP11-33B1.2 6.02 3.55e-09 1.56e-06 0.32 0.27 Corneal astigmatism; chr4:119508797 chr4:119440561~119450157:- LUSC cis rs11098499 0.818 rs10008791 ENSG00000248280.1 RP11-33B1.2 6.02 3.55e-09 1.56e-06 0.32 0.27 Corneal astigmatism; chr4:119510314 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs11736416 ENSG00000248280.1 RP11-33B1.2 6.02 3.55e-09 1.56e-06 0.32 0.27 Corneal astigmatism; chr4:119510506 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs3775845 ENSG00000248280.1 RP11-33B1.2 6.02 3.55e-09 1.56e-06 0.32 0.27 Corneal astigmatism; chr4:119511292 chr4:119440561~119450157:- LUSC cis rs9545047 0.604 rs1752649 ENSG00000227676.3 LINC01068 6.02 3.56e-09 1.56e-06 0.32 0.27 Schizophrenia; chr13:79331980 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs1749983 ENSG00000227676.3 LINC01068 6.02 3.56e-09 1.56e-06 0.32 0.27 Schizophrenia; chr13:79332077 chr13:79566727~79571436:+ LUSC cis rs9545047 0.567 rs1752648 ENSG00000227676.3 LINC01068 6.02 3.56e-09 1.56e-06 0.32 0.27 Schizophrenia; chr13:79332124 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs1752647 ENSG00000227676.3 LINC01068 6.02 3.56e-09 1.56e-06 0.32 0.27 Schizophrenia; chr13:79332741 chr13:79566727~79571436:+ LUSC cis rs9545047 0.532 rs1752646 ENSG00000227676.3 LINC01068 6.02 3.56e-09 1.56e-06 0.32 0.27 Schizophrenia; chr13:79332752 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs1749988 ENSG00000227676.3 LINC01068 6.02 3.56e-09 1.56e-06 0.32 0.27 Schizophrenia; chr13:79333103 chr13:79566727~79571436:+ LUSC cis rs6772849 0.901 rs9289330 ENSG00000242551.2 POU5F1P6 -6.02 3.56e-09 1.56e-06 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128592224 chr3:128674735~128677005:- LUSC cis rs7598759 0.548 rs11693738 ENSG00000181798.2 LINC00471 -6.02 3.56e-09 1.56e-06 -0.29 -0.27 Noise-induced hearing loss; chr2:231495773 chr2:231508426~231514339:- LUSC cis rs7580658 0.676 rs4150407 ENSG00000236682.1 AC068282.3 6.02 3.56e-09 1.56e-06 0.35 0.27 Protein C levels; chr2:127292055 chr2:127389130~127400580:+ LUSC cis rs9435732 0.725 rs10437047 ENSG00000235241.1 RP11-108M9.5 6.02 3.56e-09 1.56e-06 0.38 0.27 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:16994933 chr1:16889095~16889602:+ LUSC cis rs957448 1 rs72674855 ENSG00000253175.1 RP11-267M23.6 6.02 3.56e-09 1.56e-06 0.31 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94536706 chr8:94565036~94565715:+ LUSC cis rs66887589 0.967 rs59516282 ENSG00000245958.5 RP11-33B1.1 6.02 3.57e-09 1.57e-06 0.25 0.27 Diastolic blood pressure; chr4:119580861 chr4:119454791~119552025:+ LUSC cis rs79349575 0.756 rs4793605 ENSG00000270781.1 RP11-501C14.9 -6.02 3.57e-09 1.57e-06 -0.28 -0.27 Type 2 diabetes; chr17:48958507 chr17:48899131~48899748:+ LUSC cis rs2179367 0.632 rs12211357 ENSG00000231760.4 RP11-350J20.5 6.02 3.57e-09 1.57e-06 0.38 0.27 Dupuytren's disease; chr6:149331148 chr6:149796151~149826294:- LUSC cis rs79349575 0.783 rs12603969 ENSG00000270781.1 RP11-501C14.9 -6.02 3.57e-09 1.57e-06 -0.28 -0.27 Type 2 diabetes; chr17:48957057 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs12601955 ENSG00000270781.1 RP11-501C14.9 -6.02 3.57e-09 1.57e-06 -0.28 -0.27 Type 2 diabetes; chr17:48957058 chr17:48899131~48899748:+ LUSC cis rs79349575 0.594 rs62078375 ENSG00000270781.1 RP11-501C14.9 -6.02 3.57e-09 1.57e-06 -0.28 -0.27 Type 2 diabetes; chr17:48957612 chr17:48899131~48899748:+ LUSC cis rs1549118 0.669 rs11621178 ENSG00000239272.1 RPL21P10 6.02 3.57e-09 1.57e-06 0.32 0.27 Resting heart rate; chr14:77908885 chr14:77683202~77683989:- LUSC cis rs11971779 0.774 rs7785906 ENSG00000273391.1 RP11-634H22.1 6.02 3.57e-09 1.57e-06 0.31 0.27 Diisocyanate-induced asthma; chr7:139437906 chr7:139359032~139359566:- LUSC cis rs12908161 1 rs62019464 ENSG00000259728.4 LINC00933 6.02 3.58e-09 1.57e-06 0.34 0.27 Schizophrenia; chr15:84751238 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs11637142 ENSG00000259728.4 LINC00933 6.02 3.58e-09 1.57e-06 0.34 0.27 Schizophrenia; chr15:84752696 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs12910012 ENSG00000259728.4 LINC00933 6.02 3.58e-09 1.57e-06 0.34 0.27 Schizophrenia; chr15:84755431 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs12899981 ENSG00000259728.4 LINC00933 6.02 3.58e-09 1.57e-06 0.34 0.27 Schizophrenia; chr15:84759142 chr15:84570649~84580175:+ LUSC cis rs13113518 0.545 rs6810483 ENSG00000223305.1 RN7SKP30 6.02 3.58e-09 1.57e-06 0.31 0.27 Height; chr4:55424406 chr4:55540502~55540835:- LUSC cis rs1322639 0.697 rs12661910 ENSG00000223485.1 RP11-417E7.1 -6.02 3.59e-09 1.57e-06 -0.36 -0.27 Pulse pressure; chr6:169184293 chr6:169158092~169162924:- LUSC cis rs12908161 0.92 rs35738019 ENSG00000259728.4 LINC00933 6.02 3.59e-09 1.57e-06 0.35 0.27 Schizophrenia; chr15:84736979 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs34570071 ENSG00000259728.4 LINC00933 6.02 3.59e-09 1.57e-06 0.35 0.27 Schizophrenia; chr15:84736981 chr15:84570649~84580175:+ LUSC cis rs78487399 0.808 rs77377889 ENSG00000234936.1 AC010883.5 6.02 3.6e-09 1.58e-06 0.43 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43461185 chr2:43229573~43233394:+ LUSC cis rs75422866 0.867 rs73104152 ENSG00000257433.4 RP1-197B17.3 6.02 3.6e-09 1.58e-06 0.65 0.27 Pneumonia; chr12:47699091 chr12:47706085~47742294:+ LUSC cis rs75422866 0.867 rs73104155 ENSG00000257433.4 RP1-197B17.3 6.02 3.6e-09 1.58e-06 0.65 0.27 Pneumonia; chr12:47700790 chr12:47706085~47742294:+ LUSC cis rs6504622 0.693 rs12950276 ENSG00000262879.4 RP11-156P1.3 -6.02 3.6e-09 1.58e-06 -0.28 -0.27 Orofacial clefts; chr17:47095819 chr17:46984045~47100323:- LUSC cis rs6504622 0.755 rs12950699 ENSG00000262879.4 RP11-156P1.3 -6.02 3.6e-09 1.58e-06 -0.28 -0.27 Orofacial clefts; chr17:47096296 chr17:46984045~47100323:- LUSC cis rs6504950 0.888 rs2628315 ENSG00000275710.1 RP11-257O5.4 6.02 3.6e-09 1.58e-06 0.31 0.27 Breast cancer; chr17:55149261 chr17:54964474~54964679:+ LUSC cis rs5753618 0.561 rs2283879 ENSG00000236132.1 CTA-440B3.1 6.02 3.6e-09 1.58e-06 0.36 0.27 Colorectal cancer; chr22:31242462 chr22:31816379~31817491:- LUSC cis rs5753618 0.561 rs2283881 ENSG00000236132.1 CTA-440B3.1 6.02 3.6e-09 1.58e-06 0.36 0.27 Colorectal cancer; chr22:31242946 chr22:31816379~31817491:- LUSC cis rs17772222 0.682 rs4904452 ENSG00000258789.1 RP11-507K2.3 6.02 3.61e-09 1.58e-06 0.3 0.27 Coronary artery calcification; chr14:88517329 chr14:88551597~88552493:+ LUSC cis rs2153535 0.58 rs6920779 ENSG00000230939.1 RP11-314C16.1 -6.02 3.61e-09 1.58e-06 -0.32 -0.27 Motion sickness; chr6:8437391 chr6:8784178~8785445:+ LUSC cis rs8031584 0.918 rs34693097 ENSG00000260382.1 RP11-540B6.2 6.01 3.62e-09 1.59e-06 0.37 0.27 Huntington's disease progression; chr15:30961781 chr15:30882267~30883231:- LUSC cis rs227275 0.525 rs3974608 ENSG00000230069.3 LRRC37A15P -6.01 3.62e-09 1.59e-06 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102925641 chr4:102727274~102730721:- LUSC cis rs2842992 0.789 rs4709370 ENSG00000237927.1 RP3-393E18.2 -6.01 3.62e-09 1.59e-06 -0.4 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159789029 chr6:159586955~159589169:- LUSC cis rs61270009 0.738 rs12659772 ENSG00000247828.6 TMEM161B-AS1 6.01 3.62e-09 1.59e-06 0.32 0.27 Depressive symptoms; chr5:88451917 chr5:88268895~88436685:+ LUSC cis rs6142102 0.517 rs6142046 ENSG00000275784.1 RP5-1125A11.6 -6.01 3.63e-09 1.59e-06 -0.29 -0.27 Skin pigmentation; chr20:33926255 chr20:33989480~33991818:- LUSC cis rs2439831 1 rs2467426 ENSG00000249839.1 AC011330.5 -6.01 3.64e-09 1.59e-06 -0.51 -0.27 Lung cancer in ever smokers; chr15:43697320 chr15:43663654~43684339:- LUSC cis rs853679 0.699 rs9468318 ENSG00000204709.4 LINC01556 6.01 3.64e-09 1.59e-06 0.4 0.27 Depression; chr6:28241753 chr6:28943877~28944537:+ LUSC cis rs853679 0.76 rs9357067 ENSG00000204709.4 LINC01556 6.01 3.64e-09 1.59e-06 0.4 0.27 Depression; chr6:28242515 chr6:28943877~28944537:+ LUSC cis rs853679 0.76 rs967005 ENSG00000204709.4 LINC01556 6.01 3.64e-09 1.59e-06 0.4 0.27 Depression; chr6:28242910 chr6:28943877~28944537:+ LUSC cis rs7208859 0.623 rs7208441 ENSG00000266490.1 CTD-2349P21.9 6.01 3.64e-09 1.59e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30792372~30792833:+ LUSC cis rs5753618 0.539 rs5997933 ENSG00000236132.1 CTA-440B3.1 6.01 3.64e-09 1.59e-06 0.36 0.27 Colorectal cancer; chr22:31276766 chr22:31816379~31817491:- LUSC cis rs6570726 0.791 rs383841 ENSG00000235652.6 RP11-545I5.3 -6.01 3.64e-09 1.59e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145567193 chr6:145799409~145886585:+ LUSC cis rs2337406 1 rs61268362 ENSG00000254174.1 IGHV1-12 6.01 3.64e-09 1.6e-06 0.28 0.27 Alzheimer's disease (late onset); chr14:106697010 chr14:106122420~106122709:- LUSC cis rs11846409 0.932 rs61233250 ENSG00000274576.2 IGHV2-70 -6.01 3.65e-09 1.6e-06 -0.28 -0.27 Rheumatic heart disease; chr14:106634072 chr14:106770577~106771020:- LUSC cis rs7772486 0.875 rs865913 ENSG00000235652.6 RP11-545I5.3 6.01 3.65e-09 1.6e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145987738 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs2814873 ENSG00000235652.6 RP11-545I5.3 6.01 3.65e-09 1.6e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145987796 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs9403734 ENSG00000235652.6 RP11-545I5.3 6.01 3.65e-09 1.6e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145610323 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs2096201 ENSG00000235652.6 RP11-545I5.3 6.01 3.65e-09 1.6e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145613137 chr6:145799409~145886585:+ LUSC cis rs172166 0.694 rs203884 ENSG00000216901.1 AL022393.7 6.01 3.65e-09 1.6e-06 0.32 0.27 Cardiac Troponin-T levels; chr6:28109596 chr6:28176188~28176674:+ LUSC cis rs61270009 0.955 rs12659252 ENSG00000247828.6 TMEM161B-AS1 6.01 3.65e-09 1.6e-06 0.3 0.27 Depressive symptoms; chr5:88297472 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs6872223 ENSG00000247828.6 TMEM161B-AS1 6.01 3.65e-09 1.6e-06 0.3 0.27 Depressive symptoms; chr5:88306555 chr5:88268895~88436685:+ LUSC cis rs6570726 0.967 rs7772286 ENSG00000235652.6 RP11-545I5.3 -6.01 3.66e-09 1.6e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145609287 chr6:145799409~145886585:+ LUSC cis rs12908161 0.959 rs17534709 ENSG00000259728.4 LINC00933 6.01 3.66e-09 1.6e-06 0.35 0.27 Schizophrenia; chr15:84771166 chr15:84570649~84580175:+ LUSC cis rs6142102 0.961 rs2377957 ENSG00000275784.1 RP5-1125A11.6 -6.01 3.66e-09 1.6e-06 -0.3 -0.27 Skin pigmentation; chr20:33966667 chr20:33989480~33991818:- LUSC cis rs459571 0.959 rs2810491 ENSG00000235106.7 LINC00094 -6.01 3.66e-09 1.6e-06 -0.3 -0.27 Platelet distribution width; chr9:134058209 chr9:134025439~134034666:+ LUSC cis rs11098499 0.754 rs1814813 ENSG00000250412.1 KLHL2P1 -6.01 3.67e-09 1.61e-06 -0.32 -0.27 Corneal astigmatism; chr4:119337052 chr4:119334329~119378233:+ LUSC cis rs2732480 0.5 rs1387257 ENSG00000240399.1 RP1-228P16.1 6.01 3.67e-09 1.61e-06 0.28 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48242883 chr12:48054813~48055591:- LUSC cis rs11098499 0.82 rs28394116 ENSG00000248280.1 RP11-33B1.2 6.01 3.67e-09 1.61e-06 0.31 0.27 Corneal astigmatism; chr4:119603128 chr4:119440561~119450157:- LUSC cis rs11722779 0.844 rs3974602 ENSG00000230069.3 LRRC37A15P -6.01 3.67e-09 1.61e-06 -0.28 -0.27 Schizophrenia; chr4:102928840 chr4:102727274~102730721:- LUSC cis rs7267979 1 rs1888999 ENSG00000274973.1 RP13-401N8.7 -6.01 3.67e-09 1.61e-06 -0.27 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25311212 chr20:25845497~25845862:+ LUSC cis rs1134634 0.52 rs16892152 ENSG00000273133.1 RP11-799M12.2 -6.01 3.69e-09 1.61e-06 -0.37 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15559630 chr4:15563698~15564253:- LUSC cis rs6772849 0.93 rs4857914 ENSG00000242551.2 POU5F1P6 -6.01 3.69e-09 1.61e-06 -0.29 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128631841 chr3:128674735~128677005:- LUSC cis rs783540 0.843 rs9652567 ENSG00000276710.3 CSPG4P8 -6.01 3.7e-09 1.62e-06 -0.28 -0.27 Schizophrenia; chr15:82699762 chr15:82459472~82477258:+ LUSC cis rs783540 0.934 rs4779050 ENSG00000276710.3 CSPG4P8 -6.01 3.7e-09 1.62e-06 -0.28 -0.27 Schizophrenia; chr15:82699986 chr15:82459472~82477258:+ LUSC cis rs13113518 1 rs4864993 ENSG00000273257.1 RP11-177J6.1 6.01 3.7e-09 1.62e-06 0.35 0.27 Height; chr4:55450662 chr4:55387949~55388271:+ LUSC cis rs9326248 0.515 rs2727793 ENSG00000280143.1 AP000892.6 6.01 3.7e-09 1.62e-06 0.3 0.27 Blood protein levels; chr11:116812658 chr11:117204967~117210292:+ LUSC cis rs9640161 0.75 rs11769348 ENSG00000261305.1 RP4-584D14.7 -6.01 3.71e-09 1.62e-06 -0.38 -0.27 Blood protein levels;Circulating chemerin levels; chr7:150329664 chr7:150341771~150342607:+ LUSC cis rs9309473 0.606 rs62149777 ENSG00000163016.8 ALMS1P 6.01 3.73e-09 1.63e-06 0.38 0.27 Metabolite levels; chr2:73568237 chr2:73644919~73685576:+ LUSC cis rs7665090 0.934 rs35112949 ENSG00000230069.3 LRRC37A15P -6.01 3.74e-09 1.63e-06 -0.29 -0.27 Primary biliary cholangitis; chr4:102638473 chr4:102727274~102730721:- LUSC cis rs7665090 0.87 rs34349956 ENSG00000230069.3 LRRC37A15P -6.01 3.74e-09 1.63e-06 -0.29 -0.27 Primary biliary cholangitis; chr4:102638476 chr4:102727274~102730721:- LUSC cis rs957448 1 rs957448 ENSG00000253175.1 RP11-267M23.6 6.01 3.74e-09 1.64e-06 0.31 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94529074 chr8:94565036~94565715:+ LUSC cis rs7772486 0.84 rs2777478 ENSG00000235652.6 RP11-545I5.3 6.01 3.74e-09 1.64e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145987981 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs2814872 ENSG00000235652.6 RP11-545I5.3 6.01 3.74e-09 1.64e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145989098 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs854148 ENSG00000235652.6 RP11-545I5.3 6.01 3.74e-09 1.64e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145989843 chr6:145799409~145886585:+ LUSC cis rs8062405 0.723 rs4788079 ENSG00000278665.1 RP11-666O2.4 6.01 3.74e-09 1.64e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548042 chr16:28599241~28601881:- LUSC cis rs2980439 0.87 rs2945230 ENSG00000253893.2 FAM85B -6.01 3.75e-09 1.64e-06 -0.33 -0.27 Neuroticism; chr8:8252414 chr8:8167819~8226614:- LUSC cis rs73173548 0.502 rs12188494 ENSG00000247828.6 TMEM161B-AS1 6.01 3.76e-09 1.64e-06 0.32 0.27 Macular telangiectasia type 2; chr5:88447747 chr5:88268895~88436685:+ LUSC cis rs1198872 0.526 rs57282335 ENSG00000272275.1 RP11-791G15.2 -6.01 3.76e-09 1.64e-06 -0.4 -0.27 Cardiac Troponin-T levels; chr2:10788081 chr2:10767875~10770058:- LUSC cis rs6504950 0.705 rs9899545 ENSG00000275710.1 RP11-257O5.4 6.01 3.76e-09 1.64e-06 0.32 0.27 Breast cancer; chr17:54909484 chr17:54964474~54964679:+ LUSC cis rs61270009 0.955 rs1367233 ENSG00000247828.6 TMEM161B-AS1 6.01 3.76e-09 1.64e-06 0.31 0.27 Depressive symptoms; chr5:88301195 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs11740776 ENSG00000247828.6 TMEM161B-AS1 6.01 3.76e-09 1.64e-06 0.31 0.27 Depressive symptoms; chr5:88303489 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs4916717 ENSG00000247828.6 TMEM161B-AS1 6.01 3.76e-09 1.64e-06 0.31 0.27 Depressive symptoms; chr5:88305802 chr5:88268895~88436685:+ LUSC cis rs9545047 0.604 rs2876740 ENSG00000227676.3 LINC01068 -6.01 3.76e-09 1.64e-06 -0.32 -0.27 Schizophrenia; chr13:79409829 chr13:79566727~79571436:+ LUSC cis rs875971 0.862 rs6952182 ENSG00000179406.6 LINC00174 6.01 3.76e-09 1.64e-06 0.29 0.27 Aortic root size; chr7:66218330 chr7:66376044~66401338:- LUSC cis rs6142102 0.961 rs6057957 ENSG00000275784.1 RP5-1125A11.6 -6.01 3.77e-09 1.65e-06 -0.31 -0.27 Skin pigmentation; chr20:33962052 chr20:33989480~33991818:- LUSC cis rs9322193 0.962 rs13215691 ENSG00000268592.3 RAET1E-AS1 6.01 3.78e-09 1.65e-06 0.34 0.27 Lung cancer; chr6:149792666 chr6:149863494~149919507:+ LUSC cis rs17507216 0.56 rs28493687 ENSG00000255769.6 GOLGA2P10 -6.01 3.78e-09 1.65e-06 -0.32 -0.27 Excessive daytime sleepiness; chr15:82560062 chr15:82472993~82513950:- LUSC cis rs4372836 1 rs6710959 ENSG00000226833.4 AC097724.3 6.01 3.78e-09 1.65e-06 0.31 0.27 Body mass index; chr2:28735737 chr2:28708953~28736205:- LUSC cis rs4372836 1 rs4640348 ENSG00000226833.4 AC097724.3 6.01 3.78e-09 1.65e-06 0.31 0.27 Body mass index; chr2:28742613 chr2:28708953~28736205:- LUSC cis rs4372836 1 rs2169751 ENSG00000226833.4 AC097724.3 6.01 3.78e-09 1.65e-06 0.31 0.27 Body mass index; chr2:28743892 chr2:28708953~28736205:- LUSC cis rs4372836 0.93 rs7589860 ENSG00000226833.4 AC097724.3 6.01 3.78e-09 1.65e-06 0.31 0.27 Body mass index; chr2:28744782 chr2:28708953~28736205:- LUSC cis rs950880 0.71 rs11123929 ENSG00000234389.1 AC007278.3 -6.01 3.79e-09 1.65e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102450683 chr2:102438713~102440475:+ LUSC cis rs7267979 0.932 rs1985737 ENSG00000274973.1 RP13-401N8.7 -6.01 3.79e-09 1.65e-06 -0.27 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25610832 chr20:25845497~25845862:+ LUSC cis rs6570726 0.818 rs398812 ENSG00000235652.6 RP11-545I5.3 6.01 3.79e-09 1.65e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145496135 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs4896824 ENSG00000235652.6 RP11-545I5.3 6.01 3.79e-09 1.65e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145605912 chr6:145799409~145886585:+ LUSC cis rs61270009 0.955 rs12653830 ENSG00000247828.6 TMEM161B-AS1 6.01 3.79e-09 1.66e-06 0.3 0.27 Depressive symptoms; chr5:88353712 chr5:88268895~88436685:+ LUSC cis rs1075265 0.656 rs2542574 ENSG00000233266.1 HMGB1P31 6.01 3.8e-09 1.66e-06 0.33 0.27 Chronotype;Morning vs. evening chronotype; chr2:53820295 chr2:54051334~54051760:+ LUSC cis rs227275 0.556 rs4455413 ENSG00000230069.3 LRRC37A15P -6.01 3.8e-09 1.66e-06 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102971925 chr4:102727274~102730721:- LUSC cis rs6061231 0.837 rs6121558 ENSG00000273619.1 RP5-908M14.9 -6.01 3.8e-09 1.66e-06 -0.27 -0.27 Colorectal cancer; chr20:62386309 chr20:62386303~62386970:- LUSC cis rs4718428 0.672 rs13241598 ENSG00000226824.5 RP4-756H11.3 -6.01 3.8e-09 1.66e-06 -0.36 -0.27 Corneal structure; chr7:66835665 chr7:66654538~66669855:+ LUSC cis rs17270561 0.609 rs1892246 ENSG00000272462.2 U91328.19 -6.01 3.81e-09 1.66e-06 -0.31 -0.27 Iron status biomarkers; chr6:25764180 chr6:25992662~26001775:+ LUSC cis rs9309473 0.513 rs62149782 ENSG00000163016.8 ALMS1P 6.01 3.81e-09 1.66e-06 0.38 0.27 Metabolite levels; chr2:73591901 chr2:73644919~73685576:+ LUSC cis rs11157436 0.602 rs11157438 ENSG00000211813.2 TRAV34 6.01 3.81e-09 1.66e-06 0.26 0.27 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22169147 chr14:22207522~22208129:+ LUSC cis rs1056107 0.933 rs7047691 ENSG00000225513.1 RP11-165N19.2 -6.01 3.81e-09 1.66e-06 -0.29 -0.27 Colorectal cancer; chr9:112289887 chr9:112173522~112173971:- LUSC cis rs9435732 0.778 rs2076604 ENSG00000235241.1 RP11-108M9.5 6.01 3.82e-09 1.67e-06 0.38 0.27 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:16991570 chr1:16889095~16889602:+ LUSC cis rs7208859 0.623 rs56163556 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs8067338 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs4055105 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs73269923 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775553 chr17:30792372~30792833:+ LUSC cis rs7208859 0.562 rs8078897 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs8075163 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30792372~30792833:+ LUSC cis rs17826219 0.706 rs8075107 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Body mass index; chr17:30779631 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs7223209 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs7223404 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9916725 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9916727 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9914499 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs73269945 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9897728 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs1054400 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs1054397 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9890558 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9912283 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783355 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs12006 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs3752021 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs3752020 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9890855 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9893422 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9891166 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs73269974 ENSG00000266490.1 CTD-2349P21.9 6.01 3.82e-09 1.67e-06 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30792372~30792833:+ LUSC cis rs35160687 0.644 rs2367232 ENSG00000273080.1 RP11-301O19.1 -6.01 3.83e-09 1.67e-06 -0.26 -0.27 Night sleep phenotypes; chr2:86314368 chr2:86195590~86196049:+ LUSC cis rs1021993 0.545 rs17014375 ENSG00000231648.1 RP11-372M18.2 -6.01 3.83e-09 1.67e-06 -0.39 -0.27 Gut microbiome composition (winter); chr1:209370215 chr1:209367662~209379690:+ LUSC cis rs11089937 0.54 rs2329931 ENSG00000211638.2 IGLV8-61 -6.01 3.83e-09 1.67e-06 -0.29 -0.27 Periodontitis (PAL4Q3); chr22:22131994 chr22:22098700~22099212:+ LUSC cis rs11089937 0.568 rs2876996 ENSG00000211638.2 IGLV8-61 -6.01 3.83e-09 1.67e-06 -0.29 -0.27 Periodontitis (PAL4Q3); chr22:22132006 chr22:22098700~22099212:+ LUSC cis rs7772486 0.686 rs10872579 ENSG00000235652.6 RP11-545I5.3 6 3.83e-09 1.67e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145644876 chr6:145799409~145886585:+ LUSC cis rs1015362 0.869 rs6088411 ENSG00000276073.1 RP5-1125A11.7 6 3.83e-09 1.67e-06 0.28 0.27 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:34152101 chr20:33985617~33988989:- LUSC cis rs2834288 0.536 rs762357 ENSG00000273102.1 AP000569.9 6 3.84e-09 1.67e-06 0.29 0.27 Gut microbiota (bacterial taxa); chr21:33964695 chr21:33967101~33968573:- LUSC cis rs11098499 0.866 rs7665125 ENSG00000248280.1 RP11-33B1.2 6 3.84e-09 1.67e-06 0.31 0.27 Corneal astigmatism; chr4:119480924 chr4:119440561~119450157:- LUSC cis rs4713118 0.512 rs2622319 ENSG00000216901.1 AL022393.7 6 3.84e-09 1.67e-06 0.32 0.27 Parkinson's disease; chr6:28152623 chr6:28176188~28176674:+ LUSC cis rs950880 0.71 rs11681718 ENSG00000234389.1 AC007278.3 -6 3.84e-09 1.68e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102434684 chr2:102438713~102440475:+ LUSC cis rs2028299 0.879 rs8034631 ENSG00000259677.1 RP11-493E3.1 6 3.85e-09 1.68e-06 0.34 0.27 Type 2 diabetes; chr15:89879433 chr15:89876540~89877285:+ LUSC cis rs5753618 0.539 rs8135344 ENSG00000236132.1 CTA-440B3.1 6 3.85e-09 1.68e-06 0.36 0.27 Colorectal cancer; chr22:31275946 chr22:31816379~31817491:- LUSC cis rs875971 0.895 rs6460278 ENSG00000179406.6 LINC00174 6 3.85e-09 1.68e-06 0.29 0.27 Aortic root size; chr7:66197749 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6460279 ENSG00000179406.6 LINC00174 6 3.85e-09 1.68e-06 0.29 0.27 Aortic root size; chr7:66197774 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs28491091 ENSG00000179406.6 LINC00174 6 3.85e-09 1.68e-06 0.29 0.27 Aortic root size; chr7:66204077 chr7:66376044~66401338:- LUSC cis rs67311347 1 rs7636719 ENSG00000223797.4 ENTPD3-AS1 6 3.85e-09 1.68e-06 0.3 0.27 Renal cell carcinoma; chr3:40390593 chr3:40313802~40453329:- LUSC cis rs4718428 0.662 rs34577323 ENSG00000226824.5 RP4-756H11.3 -6 3.85e-09 1.68e-06 -0.36 -0.27 Corneal structure; chr7:66845054 chr7:66654538~66669855:+ LUSC cis rs1823913 0.599 rs55685315 ENSG00000227542.1 AC092614.2 6 3.85e-09 1.68e-06 0.34 0.27 Obesity-related traits; chr2:191306451 chr2:191229165~191246172:- LUSC cis rs67311347 0.869 rs9832311 ENSG00000223797.4 ENTPD3-AS1 6 3.86e-09 1.68e-06 0.3 0.27 Renal cell carcinoma; chr3:40339831 chr3:40313802~40453329:- LUSC cis rs11096990 0.634 rs4975002 ENSG00000249207.1 RP11-360F5.1 6 3.86e-09 1.68e-06 0.28 0.27 Cognitive function; chr4:39286733 chr4:39112677~39126818:- LUSC cis rs8059260 0.736 rs16957854 ENSG00000274038.1 RP11-66H6.4 -6 3.86e-09 1.68e-06 -0.48 -0.27 Alcohol consumption over the past year; chr16:10976466 chr16:11056556~11057034:+ LUSC cis rs2303759 0.676 rs10426452 ENSG00000268686.1 AC010524.2 -6 3.87e-09 1.68e-06 -0.36 -0.27 Multiple sclerosis; chr19:49404433 chr19:49368705~49388081:- LUSC cis rs1075265 0.704 rs13417926 ENSG00000233266.1 HMGB1P31 6 3.87e-09 1.68e-06 0.33 0.27 Chronotype;Morning vs. evening chronotype; chr2:53825520 chr2:54051334~54051760:+ LUSC cis rs11157436 0.602 rs11157435 ENSG00000211813.2 TRAV34 6 3.87e-09 1.69e-06 0.27 0.27 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22168888 chr14:22207522~22208129:+ LUSC cis rs66887589 0.627 rs3872807 ENSG00000249244.1 RP11-548H18.2 6 3.87e-09 1.69e-06 0.32 0.27 Diastolic blood pressure; chr4:119439096 chr4:119391831~119395335:- LUSC cis rs9549367 0.826 rs2302755 ENSG00000269125.1 RP11-98F14.11 -6 3.87e-09 1.69e-06 -0.32 -0.27 Platelet distribution width; chr13:113244104 chr13:113165002~113165183:- LUSC cis rs66887589 0.616 rs11098497 ENSG00000249244.1 RP11-548H18.2 6 3.88e-09 1.69e-06 0.32 0.27 Diastolic blood pressure; chr4:119265913 chr4:119391831~119395335:- LUSC cis rs66887589 0.616 rs11098498 ENSG00000249244.1 RP11-548H18.2 6 3.88e-09 1.69e-06 0.32 0.27 Diastolic blood pressure; chr4:119265964 chr4:119391831~119395335:- LUSC cis rs113835537 0.935 rs79496339 ENSG00000255517.5 CTD-3074O7.5 -6 3.89e-09 1.69e-06 -0.37 -0.27 Airway imaging phenotypes; chr11:66700298 chr11:66473490~66480233:- LUSC cis rs227275 0.556 rs6815526 ENSG00000230069.3 LRRC37A15P -6 3.89e-09 1.69e-06 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102899729 chr4:102727274~102730721:- LUSC cis rs227275 0.556 rs6824070 ENSG00000230069.3 LRRC37A15P -6 3.89e-09 1.69e-06 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102901676 chr4:102727274~102730721:- LUSC cis rs11722779 0.935 rs6856176 ENSG00000230069.3 LRRC37A15P -6 3.89e-09 1.69e-06 -0.29 -0.27 Schizophrenia; chr4:102902574 chr4:102727274~102730721:- LUSC cis rs227275 0.556 rs11722779 ENSG00000230069.3 LRRC37A15P -6 3.89e-09 1.69e-06 -0.29 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102906331 chr4:102727274~102730721:- LUSC cis rs77204473 0.744 rs2269399 ENSG00000254851.1 RP11-109L13.1 6 3.89e-09 1.69e-06 0.58 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117195637 chr11:117135528~117138582:+ LUSC cis rs11098499 0.863 rs2127823 ENSG00000248280.1 RP11-33B1.2 6 3.89e-09 1.69e-06 0.32 0.27 Corneal astigmatism; chr4:119564515 chr4:119440561~119450157:- LUSC cis rs1729407 0.649 rs2849176 ENSG00000254851.1 RP11-109L13.1 6 3.89e-09 1.69e-06 0.33 0.27 Apolipoprotein A-IV levels; chr11:116826205 chr11:117135528~117138582:+ LUSC cis rs17507216 0.56 rs2871011 ENSG00000255769.6 GOLGA2P10 -6 3.89e-09 1.7e-06 -0.32 -0.27 Excessive daytime sleepiness; chr15:82560792 chr15:82472993~82513950:- LUSC cis rs9341808 0.935 rs942381 ENSG00000272129.1 RP11-250B2.6 6 3.9e-09 1.7e-06 0.32 0.27 Sitting height ratio; chr6:80170433 chr6:80355424~80356859:+ LUSC cis rs875971 0.66 rs801217 ENSG00000237310.1 GS1-124K5.4 -6 3.9e-09 1.7e-06 -0.27 -0.27 Aortic root size; chr7:66545590 chr7:66493706~66495474:+ LUSC cis rs875971 0.638 rs801216 ENSG00000237310.1 GS1-124K5.4 -6 3.9e-09 1.7e-06 -0.27 -0.27 Aortic root size; chr7:66546680 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs13224319 ENSG00000237310.1 GS1-124K5.4 6 3.9e-09 1.7e-06 0.27 0.27 Aortic root size; chr7:66542376 chr7:66493706~66495474:+ LUSC cis rs6142102 0.961 rs761235 ENSG00000275784.1 RP5-1125A11.6 -6 3.91e-09 1.7e-06 -0.31 -0.27 Skin pigmentation; chr20:33946602 chr20:33989480~33991818:- LUSC cis rs6570726 1 rs444564 ENSG00000235652.6 RP11-545I5.3 6 3.91e-09 1.7e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145538659 chr6:145799409~145886585:+ LUSC cis rs35160687 0.644 rs36079379 ENSG00000273080.1 RP11-301O19.1 -6 3.91e-09 1.7e-06 -0.26 -0.27 Night sleep phenotypes; chr2:86318837 chr2:86195590~86196049:+ LUSC cis rs6570726 0.791 rs9399558 ENSG00000235652.6 RP11-545I5.3 6 3.92e-09 1.71e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145590594 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs9376953 ENSG00000235652.6 RP11-545I5.3 6 3.92e-09 1.71e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145591090 chr6:145799409~145886585:+ LUSC cis rs6570726 0.764 rs9403733 ENSG00000235652.6 RP11-545I5.3 6 3.92e-09 1.71e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145591175 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs13202312 ENSG00000235652.6 RP11-545I5.3 6 3.92e-09 1.71e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145591957 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs7765675 ENSG00000235652.6 RP11-545I5.3 6 3.92e-09 1.71e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145593941 chr6:145799409~145886585:+ LUSC cis rs6570726 0.738 rs6917199 ENSG00000235652.6 RP11-545I5.3 6 3.92e-09 1.71e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145597184 chr6:145799409~145886585:+ LUSC cis rs7208859 0.673 rs9907197 ENSG00000263603.1 CTD-2349P21.5 -6 3.92e-09 1.71e-06 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30691245 chr17:30729469~30731202:+ LUSC cis rs7208859 0.673 rs9915963 ENSG00000263603.1 CTD-2349P21.5 -6 3.92e-09 1.71e-06 -0.36 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30692625 chr17:30729469~30731202:+ LUSC cis rs6504950 0.85 rs2787507 ENSG00000275710.1 RP11-257O5.4 -6 3.92e-09 1.71e-06 -0.33 -0.27 Breast cancer; chr17:55050563 chr17:54964474~54964679:+ LUSC cis rs6504950 0.813 rs9889687 ENSG00000275710.1 RP11-257O5.4 -6 3.92e-09 1.71e-06 -0.33 -0.27 Breast cancer; chr17:55055050 chr17:54964474~54964679:+ LUSC cis rs6504950 0.85 rs17745534 ENSG00000275710.1 RP11-257O5.4 -6 3.92e-09 1.71e-06 -0.33 -0.27 Breast cancer; chr17:55060145 chr17:54964474~54964679:+ LUSC cis rs6504950 0.889 rs9303363 ENSG00000275710.1 RP11-257O5.4 -6 3.92e-09 1.71e-06 -0.33 -0.27 Breast cancer; chr17:55060613 chr17:54964474~54964679:+ LUSC cis rs1549118 0.527 rs13379143 ENSG00000239272.1 RPL21P10 6 3.93e-09 1.71e-06 0.31 0.27 Resting heart rate; chr14:77906749 chr14:77683202~77683989:- LUSC cis rs2732480 0.577 rs2634680 ENSG00000226413.2 OR8T1P 6 3.93e-09 1.71e-06 0.35 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48340781 chr12:48442030~48442947:- LUSC cis rs2732480 0.577 rs2634678 ENSG00000226413.2 OR8T1P 6 3.93e-09 1.71e-06 0.35 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48341755 chr12:48442030~48442947:- LUSC cis rs6142102 0.961 rs2056990 ENSG00000275784.1 RP5-1125A11.6 -6 3.93e-09 1.71e-06 -0.31 -0.27 Skin pigmentation; chr20:34035658 chr20:33989480~33991818:- LUSC cis rs2179367 0.6 rs9498354 ENSG00000231760.4 RP11-350J20.5 -6 3.93e-09 1.71e-06 -0.39 -0.27 Dupuytren's disease; chr6:149441715 chr6:149796151~149826294:- LUSC cis rs2732480 0.557 rs2732441 ENSG00000226413.2 OR8T1P 6 3.94e-09 1.71e-06 0.35 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48329541 chr12:48442030~48442947:- LUSC cis rs2732480 0.577 rs2732448 ENSG00000226413.2 OR8T1P 6 3.94e-09 1.71e-06 0.35 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48336817 chr12:48442030~48442947:- LUSC cis rs7772486 0.875 rs9322043 ENSG00000235652.6 RP11-545I5.3 6 3.94e-09 1.71e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:146031554 chr6:145799409~145886585:+ LUSC cis rs8005677 0.828 rs2295680 ENSG00000279656.1 RP11-298I3.6 -6 3.95e-09 1.72e-06 -0.31 -0.27 Cognitive ability (multi-trait analysis); chr14:22905226 chr14:23023083~23024217:- LUSC cis rs875971 0.66 rs28698552 ENSG00000222364.1 RNU6-96P -6 3.95e-09 1.72e-06 -0.3 -0.27 Aortic root size; chr7:66540031 chr7:66395191~66395286:+ LUSC cis rs875971 0.66 rs62465434 ENSG00000222364.1 RNU6-96P -6 3.95e-09 1.72e-06 -0.3 -0.27 Aortic root size; chr7:66540165 chr7:66395191~66395286:+ LUSC cis rs875971 0.66 rs801211 ENSG00000222364.1 RNU6-96P 6 3.95e-09 1.72e-06 0.3 0.27 Aortic root size; chr7:66550702 chr7:66395191~66395286:+ LUSC cis rs875971 0.638 rs801205 ENSG00000222364.1 RNU6-96P 6 3.95e-09 1.72e-06 0.3 0.27 Aortic root size; chr7:66557157 chr7:66395191~66395286:+ LUSC cis rs875971 0.617 rs810400 ENSG00000222364.1 RNU6-96P 6 3.95e-09 1.72e-06 0.3 0.27 Aortic root size; chr7:66557902 chr7:66395191~66395286:+ LUSC cis rs113835537 0.808 rs10896128 ENSG00000255517.5 CTD-3074O7.5 -6 3.95e-09 1.72e-06 -0.35 -0.27 Airway imaging phenotypes; chr11:66557058 chr11:66473490~66480233:- LUSC cis rs4718428 0.705 rs4717328 ENSG00000226824.5 RP4-756H11.3 -6 3.95e-09 1.72e-06 -0.36 -0.27 Corneal structure; chr7:66887678 chr7:66654538~66669855:+ LUSC cis rs227275 0.556 rs4699044 ENSG00000230069.3 LRRC37A15P -6 3.96e-09 1.72e-06 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102976939 chr4:102727274~102730721:- LUSC cis rs875971 0.66 rs12698534 ENSG00000222364.1 RNU6-96P -6 3.96e-09 1.72e-06 -0.31 -0.27 Aortic root size; chr7:66521858 chr7:66395191~66395286:+ LUSC cis rs2404602 1 rs12443137 ENSG00000259422.1 RP11-593F23.1 6 3.96e-09 1.72e-06 0.3 0.27 Blood metabolite levels; chr15:76548491 chr15:76174891~76181486:- LUSC cis rs11951515 0.508 rs10059993 ENSG00000249286.1 CTD-2210P15.2 6 3.96e-09 1.72e-06 0.31 0.27 Metabolite levels (X-11787); chr5:43598250 chr5:43586918~43588223:- LUSC cis rs4372836 0.893 rs745645 ENSG00000226833.4 AC097724.3 -6 3.97e-09 1.73e-06 -0.31 -0.27 Body mass index; chr2:28708705 chr2:28708953~28736205:- LUSC cis rs6740322 0.748 rs13420649 ENSG00000234936.1 AC010883.5 6 3.97e-09 1.73e-06 0.31 0.27 Coronary artery disease; chr2:43236498 chr2:43229573~43233394:+ LUSC cis rs3096299 0.606 rs8052103 ENSG00000274627.1 RP11-104N10.2 -6 3.97e-09 1.73e-06 -0.26 -0.27 Multiple myeloma (IgH translocation); chr16:89474835 chr16:89516797~89522217:+ LUSC cis rs2834288 0.666 rs762188 ENSG00000273102.1 AP000569.9 -6 3.97e-09 1.73e-06 -0.31 -0.27 Gut microbiota (bacterial taxa); chr21:33902206 chr21:33967101~33968573:- LUSC cis rs950880 0.71 rs56331791 ENSG00000234389.1 AC007278.3 -6 3.98e-09 1.73e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102431697 chr2:102438713~102440475:+ LUSC cis rs1865760 0.519 rs4360119 ENSG00000272462.2 U91328.19 -6 3.98e-09 1.73e-06 -0.32 -0.27 Height; chr6:25814846 chr6:25992662~26001775:+ LUSC cis rs12908161 0.92 rs35758837 ENSG00000259728.4 LINC00933 6 3.98e-09 1.73e-06 0.34 0.27 Schizophrenia; chr15:84768151 chr15:84570649~84580175:+ LUSC cis rs11098499 0.866 rs10518329 ENSG00000248280.1 RP11-33B1.2 6 3.98e-09 1.73e-06 0.3 0.27 Corneal astigmatism; chr4:119480680 chr4:119440561~119450157:- LUSC cis rs9545047 0.584 rs9565485 ENSG00000227676.3 LINC01068 -6 3.98e-09 1.73e-06 -0.32 -0.27 Schizophrenia; chr13:79307428 chr13:79566727~79571436:+ LUSC cis rs875971 0.545 rs75840613 ENSG00000226824.5 RP4-756H11.3 -6 3.98e-09 1.73e-06 -0.35 -0.27 Aortic root size; chr7:66376399 chr7:66654538~66669855:+ LUSC cis rs11971779 0.68 rs11768023 ENSG00000273391.1 RP11-634H22.1 6 3.98e-09 1.73e-06 0.29 0.27 Diisocyanate-induced asthma; chr7:139369649 chr7:139359032~139359566:- LUSC cis rs2562456 0.917 rs6511256 ENSG00000268081.1 RP11-678G14.2 -6 3.99e-09 1.73e-06 -0.38 -0.27 Pain; chr19:21510513 chr19:21554640~21569237:- LUSC cis rs7267979 0.844 rs4815413 ENSG00000274973.1 RP13-401N8.7 6 3.99e-09 1.73e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25378593 chr20:25845497~25845862:+ LUSC cis rs7267979 0.844 rs6083824 ENSG00000274973.1 RP13-401N8.7 6 3.99e-09 1.73e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25382421 chr20:25845497~25845862:+ LUSC cis rs17826219 0.561 rs11655876 ENSG00000263603.1 CTD-2349P21.5 -6 3.99e-09 1.73e-06 -0.36 -0.27 Body mass index; chr17:30690132 chr17:30729469~30731202:+ LUSC cis rs783540 0.934 rs4779053 ENSG00000255769.6 GOLGA2P10 -6 3.99e-09 1.74e-06 -0.33 -0.27 Schizophrenia; chr15:82702846 chr15:82472993~82513950:- LUSC cis rs6570726 0.791 rs6902404 ENSG00000235652.6 RP11-545I5.3 6 4e-09 1.74e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145584118 chr6:145799409~145886585:+ LUSC cis rs881375 0.678 rs10760130 ENSG00000226752.6 PSMD5-AS1 -6 4e-09 1.74e-06 -0.3 -0.27 Rheumatoid arthritis; chr9:120939712 chr9:120824828~120854385:+ LUSC cis rs71403859 0.667 rs12924650 ENSG00000260886.1 TAT-AS1 6 4e-09 1.74e-06 0.42 0.27 Post bronchodilator FEV1; chr16:71672005 chr16:71565789~71578187:+ LUSC cis rs2153535 0.58 rs6913100 ENSG00000230939.1 RP11-314C16.1 -6 4e-09 1.74e-06 -0.31 -0.27 Motion sickness; chr6:8456622 chr6:8784178~8785445:+ LUSC cis rs77204473 0.744 rs2239678 ENSG00000254851.1 RP11-109L13.1 6 4.01e-09 1.74e-06 0.64 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117199880 chr11:117135528~117138582:+ LUSC cis rs2243480 1 rs1546059 ENSG00000226824.5 RP4-756H11.3 6 4.01e-09 1.74e-06 0.51 0.27 Diabetic kidney disease; chr7:66189722 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs7804223 ENSG00000226824.5 RP4-756H11.3 6 4.01e-09 1.74e-06 0.51 0.27 Diabetic kidney disease; chr7:66199572 chr7:66654538~66669855:+ LUSC cis rs1729407 0.632 rs2071523 ENSG00000254851.1 RP11-109L13.1 -6 4.01e-09 1.74e-06 -0.33 -0.27 Apolipoprotein A-IV levels; chr11:116826628 chr11:117135528~117138582:+ LUSC cis rs2028299 0.839 rs2279848 ENSG00000259677.1 RP11-493E3.1 6 4.02e-09 1.75e-06 0.35 0.27 Type 2 diabetes; chr15:89901449 chr15:89876540~89877285:+ LUSC cis rs72627123 1 rs58204112 ENSG00000259065.1 RP5-1021I20.1 -6 4.02e-09 1.75e-06 -0.46 -0.27 Morning vs. evening chronotype; chr14:73892714 chr14:73787360~73803270:+ LUSC cis rs11098499 0.863 rs10018280 ENSG00000248280.1 RP11-33B1.2 6 4.02e-09 1.75e-06 0.32 0.27 Corneal astigmatism; chr4:119556984 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs6534141 ENSG00000248280.1 RP11-33B1.2 6 4.02e-09 1.75e-06 0.32 0.27 Corneal astigmatism; chr4:119564068 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs3775858 ENSG00000248280.1 RP11-33B1.2 6 4.02e-09 1.75e-06 0.32 0.27 Corneal astigmatism; chr4:119564873 chr4:119440561~119450157:- LUSC cis rs6504950 0.85 rs11658717 ENSG00000275710.1 RP11-257O5.4 -6 4.03e-09 1.75e-06 -0.32 -0.27 Breast cancer; chr17:54999625 chr17:54964474~54964679:+ LUSC cis rs2028299 0.919 rs12440156 ENSG00000259677.1 RP11-493E3.1 6 4.03e-09 1.75e-06 0.34 0.27 Type 2 diabetes; chr15:89877441 chr15:89876540~89877285:+ LUSC cis rs2337406 0.706 rs74090742 ENSG00000254174.1 IGHV1-12 6 4.03e-09 1.75e-06 0.27 0.27 Alzheimer's disease (late onset); chr14:106696601 chr14:106122420~106122709:- LUSC cis rs7772486 0.875 rs2814863 ENSG00000235652.6 RP11-545I5.3 -6 4.03e-09 1.75e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:146026163 chr6:145799409~145886585:+ LUSC cis rs7712401 0.601 rs30039 ENSG00000263432.2 RN7SL689P -6 4.03e-09 1.75e-06 -0.34 -0.27 Mean platelet volume; chr5:122941484 chr5:123022487~123022783:- LUSC cis rs6142102 0.59 rs6059691 ENSG00000276073.1 RP5-1125A11.7 6 4.04e-09 1.75e-06 0.28 0.27 Skin pigmentation; chr20:34149161 chr20:33985617~33988989:- LUSC cis rs9545047 0.567 rs9530896 ENSG00000227676.3 LINC01068 6 4.04e-09 1.75e-06 0.32 0.27 Schizophrenia; chr13:79335507 chr13:79566727~79571436:+ LUSC cis rs7580658 0.676 rs2174270 ENSG00000236682.1 AC068282.3 -6 4.04e-09 1.75e-06 -0.35 -0.27 Protein C levels; chr2:127248502 chr2:127389130~127400580:+ LUSC cis rs9322193 0.887 rs3734295 ENSG00000268592.3 RAET1E-AS1 6 4.04e-09 1.75e-06 0.35 0.27 Lung cancer; chr6:149593917 chr6:149863494~149919507:+ LUSC cis rs875971 0.66 rs801192 ENSG00000222364.1 RNU6-96P 6 4.04e-09 1.75e-06 0.3 0.27 Aortic root size; chr7:66566965 chr7:66395191~66395286:+ LUSC cis rs875971 0.66 rs801190 ENSG00000222364.1 RNU6-96P 6 4.04e-09 1.75e-06 0.3 0.27 Aortic root size; chr7:66568046 chr7:66395191~66395286:+ LUSC cis rs875971 0.66 rs3857686 ENSG00000222364.1 RNU6-96P 6 4.04e-09 1.75e-06 0.3 0.27 Aortic root size; chr7:66571204 chr7:66395191~66395286:+ LUSC cis rs875971 0.638 rs3898855 ENSG00000222364.1 RNU6-96P 6 4.04e-09 1.75e-06 0.3 0.27 Aortic root size; chr7:66571411 chr7:66395191~66395286:+ LUSC cis rs875971 0.638 rs10278816 ENSG00000222364.1 RNU6-96P 6 4.04e-09 1.75e-06 0.3 0.27 Aortic root size; chr7:66572000 chr7:66395191~66395286:+ LUSC cis rs910316 0.87 rs7147712 ENSG00000279594.1 RP11-950C14.10 -6 4.05e-09 1.76e-06 -0.3 -0.27 Height; chr14:75204004 chr14:75011269~75012851:- LUSC cis rs2280018 0.526 rs2966128 ENSG00000188599.16 NPIPP1 -6 4.05e-09 1.76e-06 -0.27 -0.27 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059532 chr16:15104312~15123498:- LUSC cis rs5753618 0.583 rs7287267 ENSG00000236132.1 CTA-440B3.1 -6 4.05e-09 1.76e-06 -0.35 -0.27 Colorectal cancer; chr22:31352429 chr22:31816379~31817491:- LUSC cis rs4604732 0.588 rs4356092 ENSG00000227135.1 GCSAML-AS1 -5.99 4.07e-09 1.76e-06 -0.38 -0.27 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247469366 chr1:247524679~247526752:- LUSC cis rs11089937 0.626 rs5757019 ENSG00000211638.2 IGLV8-61 -5.99 4.07e-09 1.77e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22136286 chr22:22098700~22099212:+ LUSC cis rs11846409 0.932 rs73378158 ENSG00000274576.2 IGHV2-70 -5.99 4.07e-09 1.77e-06 -0.27 -0.27 Rheumatic heart disease; chr14:106638433 chr14:106770577~106771020:- LUSC cis rs875971 0.545 rs7811204 ENSG00000237310.1 GS1-124K5.4 5.99 4.07e-09 1.77e-06 0.31 0.27 Aortic root size; chr7:66387213 chr7:66493706~66495474:+ LUSC cis rs11118620 0.535 rs1389750 ENSG00000257551.1 HLX-AS1 5.99 4.08e-09 1.77e-06 0.29 0.27 Heart failure; chr1:220866829 chr1:220832763~220880140:- LUSC cis rs12554020 0.681 rs76725109 ENSG00000227603.1 RP11-165J3.6 5.99 4.08e-09 1.77e-06 0.47 0.27 Schizophrenia; chr9:93639802 chr9:93435332~93437121:- LUSC cis rs12908161 0.96 rs62019463 ENSG00000259728.4 LINC00933 5.99 4.08e-09 1.77e-06 0.34 0.27 Schizophrenia; chr15:84744856 chr15:84570649~84580175:+ LUSC cis rs875971 0.862 rs12537823 ENSG00000179406.6 LINC00174 -5.99 4.09e-09 1.77e-06 -0.29 -0.27 Aortic root size; chr7:66255897 chr7:66376044~66401338:- LUSC cis rs61270009 0.955 rs2115884 ENSG00000247828.6 TMEM161B-AS1 5.99 4.09e-09 1.77e-06 0.31 0.27 Depressive symptoms; chr5:88358839 chr5:88268895~88436685:+ LUSC cis rs67311347 1 rs9865348 ENSG00000223797.4 ENTPD3-AS1 5.99 4.09e-09 1.78e-06 0.3 0.27 Renal cell carcinoma; chr3:40356167 chr3:40313802~40453329:- LUSC cis rs875971 0.66 rs10229345 ENSG00000237310.1 GS1-124K5.4 5.99 4.1e-09 1.78e-06 0.27 0.27 Aortic root size; chr7:66517181 chr7:66493706~66495474:+ LUSC cis rs227275 0.554 rs223439 ENSG00000246560.2 RP11-10L12.4 5.99 4.1e-09 1.78e-06 0.32 0.27 Allergic disease (asthma, hay fever or eczema); chr4:102798377 chr4:102828055~102844075:+ LUSC cis rs4713118 0.629 rs203888 ENSG00000280107.1 AL022393.9 -5.99 4.1e-09 1.78e-06 -0.31 -0.27 Parkinson's disease; chr6:28053811 chr6:28170845~28172521:+ LUSC cis rs9326248 0.574 rs1263173 ENSG00000280143.1 AP000892.6 5.99 4.1e-09 1.78e-06 0.29 0.27 Blood protein levels; chr11:116810292 chr11:117204967~117210292:+ LUSC cis rs7267979 1 rs2500448 ENSG00000274973.1 RP13-401N8.7 5.99 4.11e-09 1.78e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25423391 chr20:25845497~25845862:+ LUSC cis rs2302464 1 rs57326588 ENSG00000214846.4 RP11-115L11.1 5.99 4.11e-09 1.78e-06 0.74 0.27 Cerebrospinal fluid biomarker levels; chr4:15723813 chr4:15730962~15731627:- LUSC cis rs7246657 0.722 rs2927746 ENSG00000276846.1 CTD-3220F14.3 -5.99 4.11e-09 1.78e-06 -0.39 -0.27 Coronary artery calcification; chr19:37665669 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs2927747 ENSG00000276846.1 CTD-3220F14.3 -5.99 4.11e-09 1.78e-06 -0.39 -0.27 Coronary artery calcification; chr19:37668629 chr19:37314868~37315620:- LUSC cis rs7804306 0.826 rs113537684 ENSG00000233264.2 AC006042.8 5.99 4.11e-09 1.78e-06 0.54 0.27 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7985192 chr7:7980312~7982228:+ LUSC cis rs6504950 0.889 rs2628301 ENSG00000275710.1 RP11-257O5.4 -5.99 4.11e-09 1.78e-06 -0.33 -0.27 Breast cancer; chr17:55081912 chr17:54964474~54964679:+ LUSC cis rs4718428 0.705 rs3800817 ENSG00000226824.5 RP4-756H11.3 -5.99 4.11e-09 1.78e-06 -0.36 -0.27 Corneal structure; chr7:66798563 chr7:66654538~66669855:+ LUSC cis rs8040855 0.627 rs4843019 ENSG00000259295.5 CSPG4P12 -5.99 4.12e-09 1.78e-06 -0.33 -0.27 Bulimia nervosa; chr15:85101228 chr15:85191438~85213905:+ LUSC cis rs1823913 0.599 rs67781530 ENSG00000227542.1 AC092614.2 5.99 4.12e-09 1.78e-06 0.34 0.27 Obesity-related traits; chr2:191295608 chr2:191229165~191246172:- LUSC cis rs1061377 1 rs12499266 ENSG00000249685.1 RP11-360F5.3 -5.99 4.12e-09 1.79e-06 -0.3 -0.27 Uric acid levels; chr4:39118133 chr4:39133913~39135608:+ LUSC cis rs11089937 0.626 rs9622968 ENSG00000211638.2 IGLV8-61 -5.99 4.13e-09 1.79e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22144916 chr22:22098700~22099212:+ LUSC cis rs2276314 1 rs4799832 ENSG00000278986.1 RP11-723J4.3 -5.99 4.13e-09 1.79e-06 -0.33 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35979683 chr18:35972151~35973916:+ LUSC cis rs875971 0.862 rs4718330 ENSG00000179406.6 LINC00174 5.99 4.13e-09 1.79e-06 0.29 0.27 Aortic root size; chr7:66250256 chr7:66376044~66401338:- LUSC cis rs6504950 0.886 rs4794551 ENSG00000275710.1 RP11-257O5.4 -5.99 4.14e-09 1.79e-06 -0.32 -0.27 Breast cancer; chr17:54998066 chr17:54964474~54964679:+ LUSC cis rs28830936 1 rs28830936 ENSG00000250379.1 RP11-23P13.4 5.99 4.14e-09 1.79e-06 0.29 0.27 Diastolic blood pressure; chr15:41614210 chr15:41825099~41827936:- LUSC cis rs950169 0.686 rs12906474 ENSG00000259295.5 CSPG4P12 5.99 4.14e-09 1.79e-06 0.35 0.27 Schizophrenia; chr15:84566006 chr15:85191438~85213905:+ LUSC cis rs950169 0.81 rs2879976 ENSG00000259295.5 CSPG4P12 5.99 4.14e-09 1.79e-06 0.35 0.27 Schizophrenia; chr15:84566347 chr15:85191438~85213905:+ LUSC cis rs7246657 0.606 rs2972439 ENSG00000276846.1 CTD-3220F14.3 -5.99 4.14e-09 1.79e-06 -0.4 -0.27 Coronary artery calcification; chr19:37721680 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs2909100 ENSG00000276846.1 CTD-3220F14.3 -5.99 4.14e-09 1.79e-06 -0.4 -0.27 Coronary artery calcification; chr19:37721779 chr19:37314868~37315620:- LUSC cis rs11690935 0.851 rs6433319 ENSG00000228389.1 AC068039.4 5.99 4.14e-09 1.8e-06 0.3 0.27 Schizophrenia; chr2:171974442 chr2:171773482~171775844:+ LUSC cis rs4718428 0.705 rs12536410 ENSG00000226824.5 RP4-756H11.3 -5.99 4.15e-09 1.8e-06 -0.36 -0.27 Corneal structure; chr7:66789303 chr7:66654538~66669855:+ LUSC cis rs2337406 0.925 rs10131226 ENSG00000254174.1 IGHV1-12 5.99 4.15e-09 1.8e-06 0.28 0.27 Alzheimer's disease (late onset); chr14:106665764 chr14:106122420~106122709:- LUSC cis rs2153535 0.58 rs2327053 ENSG00000230939.1 RP11-314C16.1 -5.99 4.15e-09 1.8e-06 -0.32 -0.27 Motion sickness; chr6:8442894 chr6:8784178~8785445:+ LUSC cis rs17270561 0.609 rs1317817 ENSG00000272462.2 U91328.19 -5.99 4.15e-09 1.8e-06 -0.32 -0.27 Iron status biomarkers; chr6:25765149 chr6:25992662~26001775:+ LUSC cis rs4237845 0.804 rs11172372 ENSG00000257159.1 RP11-58A17.3 5.99 4.16e-09 1.8e-06 0.32 0.27 Intelligence (multi-trait analysis); chr12:57892490 chr12:57967058~57968399:+ LUSC cis rs7119038 0.509 rs10892257 ENSG00000255422.1 AP002954.4 5.99 4.16e-09 1.8e-06 0.35 0.27 Sjögren's syndrome; chr11:118708618 chr11:118704607~118750263:+ LUSC cis rs61270009 0.955 rs377958 ENSG00000247828.6 TMEM161B-AS1 -5.99 4.16e-09 1.8e-06 -0.31 -0.27 Depressive symptoms; chr5:88267571 chr5:88268895~88436685:+ LUSC cis rs61270009 0.913 rs402114 ENSG00000247828.6 TMEM161B-AS1 -5.99 4.16e-09 1.8e-06 -0.31 -0.27 Depressive symptoms; chr5:88268106 chr5:88268895~88436685:+ LUSC cis rs13113518 1 rs9312661 ENSG00000273257.1 RP11-177J6.1 5.99 4.17e-09 1.8e-06 0.34 0.27 Height; chr4:55476159 chr4:55387949~55388271:+ LUSC cis rs2404602 1 rs12594541 ENSG00000259422.1 RP11-593F23.1 5.99 4.17e-09 1.81e-06 0.3 0.27 Blood metabolite levels; chr15:76542027 chr15:76174891~76181486:- LUSC cis rs7181230 0.885 rs8026641 ENSG00000275636.1 RP11-521C20.5 -5.99 4.18e-09 1.81e-06 -0.32 -0.27 Dehydroepiandrosterone sulphate levels; chr15:40046660 chr15:40078892~40079347:+ LUSC cis rs4713118 0.513 rs156739 ENSG00000216901.1 AL022393.7 5.99 4.18e-09 1.81e-06 0.31 0.27 Parkinson's disease; chr6:28045632 chr6:28176188~28176674:+ LUSC cis rs7665090 1 rs2125211 ENSG00000230069.3 LRRC37A15P 5.99 4.19e-09 1.81e-06 0.29 0.27 Primary biliary cholangitis; chr4:102638719 chr4:102727274~102730721:- LUSC cis rs9910055 0.762 rs2240226 ENSG00000267080.4 ASB16-AS1 -5.99 4.19e-09 1.82e-06 -0.24 -0.27 Total body bone mineral density; chr17:44188850 chr17:44175973~44186717:- LUSC cis rs227275 0.554 rs223319 ENSG00000230069.3 LRRC37A15P -5.99 4.2e-09 1.82e-06 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102881157 chr4:102727274~102730721:- LUSC cis rs228614 0.509 rs223318 ENSG00000230069.3 LRRC37A15P -5.99 4.2e-09 1.82e-06 -0.28 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102881422 chr4:102727274~102730721:- LUSC cis rs227275 0.554 rs223315 ENSG00000230069.3 LRRC37A15P -5.99 4.2e-09 1.82e-06 -0.28 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102884286 chr4:102727274~102730721:- LUSC cis rs2337406 1 rs7145172 ENSG00000254174.1 IGHV1-12 5.99 4.2e-09 1.82e-06 0.27 0.27 Alzheimer's disease (late onset); chr14:106704924 chr14:106122420~106122709:- LUSC cis rs8059260 0.673 rs8056854 ENSG00000274038.1 RP11-66H6.4 -5.99 4.2e-09 1.82e-06 -0.5 -0.27 Alcohol consumption over the past year; chr16:10947858 chr16:11056556~11057034:+ LUSC cis rs1075265 0.933 rs7560947 ENSG00000233266.1 HMGB1P31 5.99 4.21e-09 1.82e-06 0.34 0.27 Chronotype;Morning vs. evening chronotype; chr2:54087473 chr2:54051334~54051760:+ LUSC cis rs889398 0.967 rs1437134 ENSG00000226232.7 RP11-419C5.2 -5.99 4.21e-09 1.82e-06 -0.25 -0.27 Body mass index; chr16:69696523 chr16:69976388~69996188:- LUSC cis rs6570726 1 rs1935615 ENSG00000235652.6 RP11-545I5.3 5.99 4.21e-09 1.82e-06 0.27 0.27 Lobe attachment (rater-scored or self-reported); chr6:145599981 chr6:145799409~145886585:+ LUSC cis rs62103177 0.525 rs4799117 ENSG00000261126.6 RP11-795F19.1 -5.99 4.22e-09 1.83e-06 -0.33 -0.27 Opioid sensitivity; chr18:79996604 chr18:80046900~80095482:+ LUSC cis rs7267979 0.933 rs2424708 ENSG00000274973.1 RP13-401N8.7 -5.99 4.23e-09 1.83e-06 -0.27 -0.27 Liver enzyme levels (alkaline phosphatase); chr20:25300762 chr20:25845497~25845862:+ LUSC cis rs6504950 1 rs9902718 ENSG00000275710.1 RP11-257O5.4 5.99 4.23e-09 1.83e-06 0.32 0.27 Breast cancer; chr17:54984261 chr17:54964474~54964679:+ LUSC cis rs2408955 0.542 rs7975632 ENSG00000240399.1 RP1-228P16.1 5.99 4.23e-09 1.83e-06 0.27 0.27 Glycated hemoglobin levels; chr12:48049265 chr12:48054813~48055591:- LUSC cis rs875971 0.66 rs801193 ENSG00000222364.1 RNU6-96P 5.99 4.23e-09 1.83e-06 0.3 0.27 Aortic root size; chr7:66565625 chr7:66395191~66395286:+ LUSC cis rs1823913 0.637 rs4853575 ENSG00000227542.1 AC092614.2 -5.99 4.23e-09 1.83e-06 -0.34 -0.27 Obesity-related traits; chr2:191296149 chr2:191229165~191246172:- LUSC cis rs7772486 0.686 rs9373473 ENSG00000235652.6 RP11-545I5.3 5.99 4.24e-09 1.83e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145761146 chr6:145799409~145886585:+ LUSC cis rs9545047 0.604 rs1007569 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79306752 chr13:79566727~79571436:+ LUSC cis rs9545047 0.584 rs4885626 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79309765 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs4885627 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79309786 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs4885628 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79309830 chr13:79566727~79571436:+ LUSC cis rs9545047 0.554 rs4885629 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79309855 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs1927506 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79311350 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs1409019 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79312431 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs7317343 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79312542 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs6563098 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79313102 chr13:79566727~79571436:+ LUSC cis rs9545047 0.532 rs1748768 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79313276 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs1748767 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79313381 chr13:79566727~79571436:+ LUSC cis rs9545047 0.567 rs1409018 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79313403 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs1410332 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79315171 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9545065 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79317034 chr13:79566727~79571436:+ LUSC cis rs9545047 0.625 rs1408657 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79329315 chr13:79566727~79571436:+ LUSC cis rs13113518 0.812 rs6830409 ENSG00000272969.1 RP11-528I4.2 5.99 4.24e-09 1.83e-06 0.31 0.27 Height; chr4:55522229 chr4:55547112~55547889:+ LUSC cis rs9545047 0.604 rs3818563 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79318587 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs3187338 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79320601 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9545068 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79324101 chr13:79566727~79571436:+ LUSC cis rs9545047 0.625 rs9318621 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79325662 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs7322167 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79325931 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9285309 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79326707 chr13:79566727~79571436:+ LUSC cis rs9545047 0.584 rs9545069 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79328065 chr13:79566727~79571436:+ LUSC cis rs9545047 0.647 rs7317416 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79328400 chr13:79566727~79571436:+ LUSC cis rs9545047 0.588 rs1408658 ENSG00000227676.3 LINC01068 5.99 4.24e-09 1.83e-06 0.32 0.27 Schizophrenia; chr13:79329294 chr13:79566727~79571436:+ LUSC cis rs2153535 0.601 rs4140584 ENSG00000230939.1 RP11-314C16.1 5.99 4.25e-09 1.83e-06 0.32 0.27 Motion sickness; chr6:8540381 chr6:8784178~8785445:+ LUSC cis rs8062405 0.679 rs72793818 ENSG00000278665.1 RP11-666O2.4 5.99 4.25e-09 1.84e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28881816 chr16:28599241~28601881:- LUSC cis rs6772849 0.901 rs9289330 ENSG00000277250.1 Metazoa_SRP -5.99 4.26e-09 1.84e-06 -0.29 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128592224 chr3:128673681~128674021:- LUSC cis rs2337406 1 rs74090714 ENSG00000254174.1 IGHV1-12 5.99 4.26e-09 1.84e-06 0.27 0.27 Alzheimer's disease (late onset); chr14:106691225 chr14:106122420~106122709:- LUSC cis rs950169 0.96 rs12905475 ENSG00000259728.4 LINC00933 5.99 4.26e-09 1.84e-06 0.36 0.27 Schizophrenia; chr15:84131743 chr15:84570649~84580175:+ LUSC cis rs11723261 0.509 rs61792240 ENSG00000275426.1 CH17-262A2.1 5.99 4.27e-09 1.85e-06 0.45 0.27 Immune response to smallpox vaccine (IL-6); chr4:134876 chr4:149738~150317:+ LUSC cis rs11098499 0.644 rs34835603 ENSG00000250412.1 KLHL2P1 5.99 4.27e-09 1.85e-06 0.32 0.27 Corneal astigmatism; chr4:119632273 chr4:119334329~119378233:+ LUSC cis rs11098499 0.615 rs28850368 ENSG00000250412.1 KLHL2P1 5.99 4.27e-09 1.85e-06 0.32 0.27 Corneal astigmatism; chr4:119633158 chr4:119334329~119378233:+ LUSC cis rs7246657 0.722 rs2909102 ENSG00000276846.1 CTD-3220F14.3 -5.99 4.28e-09 1.85e-06 -0.39 -0.27 Coronary artery calcification; chr19:37676463 chr19:37314868~37315620:- LUSC cis rs10759883 0.539 rs10117340 ENSG00000175611.10 LINC00476 -5.99 4.28e-09 1.85e-06 -0.31 -0.27 Nicotine dependence; chr9:96032530 chr9:95759231~95875977:- LUSC cis rs78487399 0.71 rs17030798 ENSG00000234936.1 AC010883.5 -5.99 4.28e-09 1.85e-06 -0.4 -0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43443044 chr2:43229573~43233394:+ LUSC cis rs6142102 1 rs12480839 ENSG00000275784.1 RP5-1125A11.6 -5.99 4.28e-09 1.85e-06 -0.31 -0.27 Skin pigmentation; chr20:34139624 chr20:33989480~33991818:- LUSC cis rs7267979 1 rs6083862 ENSG00000274973.1 RP13-401N8.7 5.99 4.29e-09 1.85e-06 0.26 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25430450 chr20:25845497~25845862:+ LUSC cis rs10027350 0.964 rs2302565 ENSG00000281501.1 SEPSECS-AS1 5.99 4.29e-09 1.85e-06 0.31 0.27 Childhood ear infection; chr4:25144685 chr4:25160641~25201440:+ LUSC cis rs17772222 0.701 rs845757 ENSG00000258789.1 RP11-507K2.3 5.99 4.29e-09 1.85e-06 0.3 0.27 Coronary artery calcification; chr14:88455372 chr14:88551597~88552493:+ LUSC cis rs17772222 0.675 rs845769 ENSG00000258789.1 RP11-507K2.3 5.99 4.29e-09 1.85e-06 0.3 0.27 Coronary artery calcification; chr14:88461455 chr14:88551597~88552493:+ LUSC cis rs6504950 0.72 rs9913784 ENSG00000275710.1 RP11-257O5.4 5.99 4.3e-09 1.85e-06 0.31 0.27 Breast cancer; chr17:54911710 chr17:54964474~54964679:+ LUSC cis rs17772222 0.682 rs7142053 ENSG00000258789.1 RP11-507K2.3 -5.98 4.3e-09 1.85e-06 -0.3 -0.27 Coronary artery calcification; chr14:88511594 chr14:88551597~88552493:+ LUSC cis rs17772222 0.63 rs12436642 ENSG00000258789.1 RP11-507K2.3 5.98 4.3e-09 1.85e-06 0.3 0.27 Coronary artery calcification; chr14:88559032 chr14:88551597~88552493:+ LUSC cis rs34779708 0.733 rs12249814 ENSG00000230534.5 RP11-297A16.2 5.98 4.3e-09 1.85e-06 0.3 0.27 Inflammatory bowel disease;Crohn's disease; chr10:35253829 chr10:35098006~35127020:- LUSC cis rs2243480 1 rs9769882 ENSG00000226824.5 RP4-756H11.3 5.98 4.3e-09 1.86e-06 0.51 0.27 Diabetic kidney disease; chr7:66177938 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs6966322 ENSG00000226824.5 RP4-756H11.3 5.98 4.3e-09 1.86e-06 0.51 0.27 Diabetic kidney disease; chr7:66181767 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs4145008 ENSG00000226824.5 RP4-756H11.3 5.98 4.3e-09 1.86e-06 0.51 0.27 Diabetic kidney disease; chr7:66182524 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs4718315 ENSG00000226824.5 RP4-756H11.3 5.98 4.3e-09 1.86e-06 0.51 0.27 Diabetic kidney disease; chr7:66183554 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs4718316 ENSG00000226824.5 RP4-756H11.3 5.98 4.3e-09 1.86e-06 0.51 0.27 Diabetic kidney disease; chr7:66183744 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs1873494 ENSG00000226824.5 RP4-756H11.3 5.98 4.3e-09 1.86e-06 0.51 0.27 Diabetic kidney disease; chr7:66184912 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs6959002 ENSG00000226824.5 RP4-756H11.3 5.98 4.3e-09 1.86e-06 0.51 0.27 Diabetic kidney disease; chr7:66185509 chr7:66654538~66669855:+ LUSC cis rs11690935 0.851 rs10174055 ENSG00000228389.1 AC068039.4 5.98 4.3e-09 1.86e-06 0.31 0.27 Schizophrenia; chr2:171993303 chr2:171773482~171775844:+ LUSC cis rs1134634 0.52 rs10003739 ENSG00000273133.1 RP11-799M12.2 -5.98 4.32e-09 1.86e-06 -0.35 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15617063 chr4:15563698~15564253:- LUSC cis rs66887589 0.934 rs4834792 ENSG00000248280.1 RP11-33B1.2 -5.98 4.32e-09 1.86e-06 -0.3 -0.27 Diastolic blood pressure; chr4:119634541 chr4:119440561~119450157:- LUSC cis rs1823913 0.637 rs10931497 ENSG00000280083.1 RP11-317J9.1 5.98 4.32e-09 1.86e-06 0.31 0.27 Obesity-related traits; chr2:191306254 chr2:191154118~191156070:- LUSC cis rs36423 0.748 rs36385 ENSG00000266869.1 RP6-114E22.1 -5.98 4.32e-09 1.86e-06 -0.41 -0.27 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71901594 chr14:71848606~71908430:+ LUSC cis rs36423 0.66 rs36384 ENSG00000266869.1 RP6-114E22.1 -5.98 4.32e-09 1.86e-06 -0.41 -0.27 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71901638 chr14:71848606~71908430:+ LUSC cis rs36423 0.702 rs36383 ENSG00000266869.1 RP6-114E22.1 -5.98 4.32e-09 1.86e-06 -0.41 -0.27 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71902385 chr14:71848606~71908430:+ LUSC cis rs36423 0.748 rs36381 ENSG00000266869.1 RP6-114E22.1 -5.98 4.32e-09 1.86e-06 -0.41 -0.27 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71903833 chr14:71848606~71908430:+ LUSC cis rs36423 0.748 rs36380 ENSG00000266869.1 RP6-114E22.1 -5.98 4.32e-09 1.86e-06 -0.41 -0.27 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71904545 chr14:71848606~71908430:+ LUSC cis rs8005677 1 rs10148215 ENSG00000279656.1 RP11-298I3.6 5.98 4.32e-09 1.86e-06 0.31 0.27 Cognitive ability (multi-trait analysis); chr14:22913136 chr14:23023083~23024217:- LUSC cis rs2019137 0.967 rs902695 ENSG00000274877.1 RP11-65I12.1 5.98 4.32e-09 1.86e-06 0.32 0.27 Lymphocyte counts; chr2:113197497 chr2:113237595~113240825:+ LUSC cis rs11098499 0.78 rs12504773 ENSG00000248280.1 RP11-33B1.2 5.98 4.32e-09 1.86e-06 0.32 0.27 Corneal astigmatism; chr4:119640994 chr4:119440561~119450157:- LUSC cis rs875971 0.66 rs10272357 ENSG00000222364.1 RNU6-96P 5.98 4.33e-09 1.87e-06 0.3 0.27 Aortic root size; chr7:66598087 chr7:66395191~66395286:+ LUSC cis rs4660456 0.504 rs587064 ENSG00000237899.1 RP4-739H11.3 5.98 4.33e-09 1.87e-06 0.39 0.27 Platelet count; chr1:40640238 chr1:40669089~40687588:- LUSC cis rs17826219 0.636 rs12946563 ENSG00000266490.1 CTD-2349P21.9 5.98 4.35e-09 1.87e-06 0.32 0.27 Body mass index; chr17:30776148 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs8068645 ENSG00000266490.1 CTD-2349P21.9 5.98 4.35e-09 1.87e-06 0.32 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777324 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs55811708 ENSG00000266490.1 CTD-2349P21.9 5.98 4.35e-09 1.87e-06 0.32 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777713 chr17:30792372~30792833:+ LUSC cis rs13113518 1 rs13115828 ENSG00000273257.1 RP11-177J6.1 5.98 4.35e-09 1.87e-06 0.34 0.27 Height; chr4:55551447 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs13136282 ENSG00000273257.1 RP11-177J6.1 5.98 4.35e-09 1.87e-06 0.34 0.27 Height; chr4:55551845 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11934897 ENSG00000273257.1 RP11-177J6.1 5.98 4.35e-09 1.87e-06 0.34 0.27 Height; chr4:55553396 chr4:55387949~55388271:+ LUSC cis rs13113518 0.934 rs11932293 ENSG00000273257.1 RP11-177J6.1 5.98 4.35e-09 1.87e-06 0.34 0.27 Height; chr4:55554025 chr4:55387949~55388271:+ LUSC cis rs73173548 0.528 rs68019847 ENSG00000247828.6 TMEM161B-AS1 5.98 4.35e-09 1.87e-06 0.32 0.27 Macular telangiectasia type 2; chr5:88446795 chr5:88268895~88436685:+ LUSC cis rs7119038 0.509 rs11216960 ENSG00000255422.1 AP002954.4 5.98 4.35e-09 1.87e-06 0.35 0.27 Sjögren's syndrome; chr11:118707164 chr11:118704607~118750263:+ LUSC cis rs7119038 0.509 rs10892256 ENSG00000255422.1 AP002954.4 5.98 4.35e-09 1.87e-06 0.35 0.27 Sjögren's syndrome; chr11:118707996 chr11:118704607~118750263:+ LUSC cis rs10759883 0.563 rs689761 ENSG00000175611.10 LINC00476 -5.98 4.36e-09 1.88e-06 -0.3 -0.27 Nicotine dependence; chr9:95970902 chr9:95759231~95875977:- LUSC cis rs2028299 0.919 rs8026131 ENSG00000259677.1 RP11-493E3.1 5.98 4.37e-09 1.88e-06 0.34 0.27 Type 2 diabetes; chr15:89874767 chr15:89876540~89877285:+ LUSC cis rs2028299 0.879 rs986505 ENSG00000259677.1 RP11-493E3.1 5.98 4.37e-09 1.88e-06 0.34 0.27 Type 2 diabetes; chr15:89875181 chr15:89876540~89877285:+ LUSC cis rs9549367 0.756 rs3861723 ENSG00000269125.1 RP11-98F14.11 -5.98 4.38e-09 1.88e-06 -0.32 -0.27 Platelet distribution width; chr13:113256612 chr13:113165002~113165183:- LUSC cis rs7772486 0.743 rs1292339 ENSG00000235652.6 RP11-545I5.3 -5.98 4.38e-09 1.89e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145645950 chr6:145799409~145886585:+ LUSC cis rs79349575 0.783 rs903567 ENSG00000270781.1 RP11-501C14.9 -5.98 4.38e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48902956 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs62075818 ENSG00000270781.1 RP11-501C14.9 -5.98 4.38e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48904965 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs9912829 ENSG00000270781.1 RP11-501C14.9 -5.98 4.38e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48905387 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs62075820 ENSG00000270781.1 RP11-501C14.9 -5.98 4.38e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48905809 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs4294857 ENSG00000270781.1 RP11-501C14.9 -5.98 4.38e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48906029 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs61576918 ENSG00000270781.1 RP11-501C14.9 -5.98 4.38e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48908231 chr17:48899131~48899748:+ LUSC cis rs6570726 0.935 rs449377 ENSG00000235652.6 RP11-545I5.3 5.98 4.38e-09 1.89e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145531301 chr6:145799409~145886585:+ LUSC cis rs66887589 0.967 rs56173225 ENSG00000248280.1 RP11-33B1.2 -5.98 4.38e-09 1.89e-06 -0.29 -0.27 Diastolic blood pressure; chr4:119588817 chr4:119440561~119450157:- LUSC cis rs875971 0.66 rs801193 ENSG00000236529.1 RP13-254B10.1 -5.98 4.38e-09 1.89e-06 -0.27 -0.27 Aortic root size; chr7:66565625 chr7:65840212~65840596:+ LUSC cis rs2337406 0.866 rs7153964 ENSG00000211974.3 IGHV2-70 -5.98 4.38e-09 1.89e-06 -0.36 -0.27 Alzheimer's disease (late onset); chr14:106790480 chr14:106723574~106724093:- LUSC cis rs881375 0.678 rs3761846 ENSG00000226752.6 PSMD5-AS1 -5.98 4.39e-09 1.89e-06 -0.3 -0.27 Rheumatoid arthritis; chr9:120927319 chr9:120824828~120854385:+ LUSC cis rs10759883 0.627 rs12343734 ENSG00000175611.10 LINC00476 5.98 4.39e-09 1.89e-06 0.31 0.27 Nicotine dependence; chr9:95847873 chr9:95759231~95875977:- LUSC cis rs79349575 0.594 rs1985785 ENSG00000270781.1 RP11-501C14.9 -5.98 4.39e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48890426 chr17:48899131~48899748:+ LUSC cis rs79349575 0.685 rs1124829 ENSG00000270781.1 RP11-501C14.9 -5.98 4.39e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48890435 chr17:48899131~48899748:+ LUSC cis rs79349575 0.721 rs1008834 ENSG00000270781.1 RP11-501C14.9 -5.98 4.39e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48890646 chr17:48899131~48899748:+ LUSC cis rs79349575 0.87 rs12941262 ENSG00000270781.1 RP11-501C14.9 -5.98 4.39e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48889675 chr17:48899131~48899748:+ LUSC cis rs79349575 0.778 rs12950328 ENSG00000270781.1 RP11-501C14.9 -5.98 4.39e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48889699 chr17:48899131~48899748:+ LUSC cis rs79349575 0.729 rs62075824 ENSG00000270781.1 RP11-501C14.9 -5.98 4.4e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48909317 chr17:48899131~48899748:+ LUSC cis rs79349575 0.749 rs46521 ENSG00000270781.1 RP11-501C14.9 -5.98 4.4e-09 1.89e-06 -0.28 -0.27 Type 2 diabetes; chr17:48911167 chr17:48899131~48899748:+ LUSC cis rs11971779 0.68 rs6960876 ENSG00000273391.1 RP11-634H22.1 -5.98 4.4e-09 1.89e-06 -0.29 -0.27 Diisocyanate-induced asthma; chr7:139427430 chr7:139359032~139359566:- LUSC cis rs2337406 0.866 rs2027901 ENSG00000211974.3 IGHV2-70 -5.98 4.4e-09 1.9e-06 -0.36 -0.27 Alzheimer's disease (late onset); chr14:106807164 chr14:106723574~106724093:- LUSC cis rs9341835 0.709 rs4358600 ENSG00000218048.2 RP3-407E4.4 5.98 4.4e-09 1.9e-06 0.31 0.27 Schizophrenia; chr6:63443314 chr6:63440766~63443580:+ LUSC cis rs2732480 0.577 rs2732479 ENSG00000273765.1 RP11-370I10.11 5.98 4.41e-09 1.9e-06 0.31 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342477 chr12:48360920~48361377:+ LUSC cis rs2732480 0.537 rs1061986 ENSG00000273765.1 RP11-370I10.11 5.98 4.41e-09 1.9e-06 0.31 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342656 chr12:48360920~48361377:+ LUSC cis rs2732480 0.577 rs2732479 ENSG00000226413.2 OR8T1P 5.98 4.41e-09 1.9e-06 0.35 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342477 chr12:48442030~48442947:- LUSC cis rs2732480 0.537 rs1061986 ENSG00000226413.2 OR8T1P 5.98 4.41e-09 1.9e-06 0.35 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342656 chr12:48442030~48442947:- LUSC cis rs6570726 0.935 rs419847 ENSG00000235652.6 RP11-545I5.3 5.98 4.41e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145506142 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs419850 ENSG00000235652.6 RP11-545I5.3 5.98 4.41e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145506145 chr6:145799409~145886585:+ LUSC cis rs2834288 0.535 rs881228 ENSG00000273102.1 AP000569.9 5.98 4.41e-09 1.9e-06 0.3 0.27 Gut microbiota (bacterial taxa); chr21:33950387 chr21:33967101~33968573:- LUSC cis rs9326248 0.581 rs6589582 ENSG00000280143.1 AP000892.6 5.98 4.42e-09 1.9e-06 0.28 0.27 Blood protein levels; chr11:116958484 chr11:117204967~117210292:+ LUSC cis rs6570726 0.935 rs12663204 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145497237 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs12663205 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145497242 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs12663211 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145497291 chr6:145799409~145886585:+ LUSC cis rs6570726 0.934 rs430003 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145498370 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs395948 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145499049 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs452552 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145499645 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs451349 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145499758 chr6:145799409~145886585:+ LUSC cis rs6570726 0.905 rs406799 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145500701 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs1883406 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145502069 chr6:145799409~145886585:+ LUSC cis rs6570726 0.87 rs370653 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145502506 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs391524 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145502708 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs429306 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145505880 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs428659 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145505903 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs411641 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145506396 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs376991 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145506937 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs379164 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145507957 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs401888 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145510399 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs414646 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145510549 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs454614 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145511497 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs411468 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145511656 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs425731 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145513015 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs421690 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145513458 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs399169 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145515217 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs422540 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145516679 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs408723 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145517399 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs425717 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145517484 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs409121 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145518657 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs424263 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145518937 chr6:145799409~145886585:+ LUSC cis rs6570726 0.905 rs419575 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145519038 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs409725 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145519204 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs386823 ENSG00000235652.6 RP11-545I5.3 5.98 4.42e-09 1.9e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145520229 chr6:145799409~145886585:+ LUSC cis rs496547 0.756 rs562059 ENSG00000278376.1 RP11-158I9.8 -5.98 4.42e-09 1.9e-06 -0.24 -0.27 Hip minimal joint space width; chr11:118731349 chr11:118791254~118793137:+ LUSC cis rs2665103 0.61 rs56398167 ENSG00000278603.1 RP13-608F4.5 5.98 4.42e-09 1.9e-06 0.32 0.27 Intelligence (multi-trait analysis); chr15:82237482 chr15:82472203~82472426:+ LUSC cis rs881375 0.678 rs10760128 ENSG00000226752.6 PSMD5-AS1 -5.98 4.43e-09 1.9e-06 -0.3 -0.27 Rheumatoid arthritis; chr9:120934047 chr9:120824828~120854385:+ LUSC cis rs11089937 0.895 rs5756985 ENSG00000211638.2 IGLV8-61 -5.98 4.43e-09 1.91e-06 -0.25 -0.27 Periodontitis (PAL4Q3); chr22:22131847 chr22:22098700~22099212:+ LUSC cis rs9322193 1 rs58189451 ENSG00000268592.3 RAET1E-AS1 5.98 4.44e-09 1.91e-06 0.34 0.27 Lung cancer; chr6:149600252 chr6:149863494~149919507:+ LUSC cis rs62025270 0.547 rs338540 ENSG00000202081.1 RNU6-1280P 5.98 4.44e-09 1.91e-06 0.32 0.27 Idiopathic pulmonary fibrosis; chr15:85652500 chr15:85651522~85651628:- LUSC cis rs9545047 0.604 rs9574411 ENSG00000227676.3 LINC01068 -5.98 4.44e-09 1.91e-06 -0.32 -0.27 Schizophrenia; chr13:79354342 chr13:79566727~79571436:+ LUSC cis rs62103177 0.525 rs4283293 ENSG00000261126.6 RP11-795F19.1 -5.98 4.45e-09 1.91e-06 -0.33 -0.27 Opioid sensitivity; chr18:79999582 chr18:80046900~80095482:+ LUSC cis rs12908161 1 rs17600551 ENSG00000259728.4 LINC00933 5.98 4.45e-09 1.91e-06 0.34 0.27 Schizophrenia; chr15:84776027 chr15:84570649~84580175:+ LUSC cis rs11089937 0.626 rs737840 ENSG00000211638.2 IGLV8-61 -5.98 4.45e-09 1.91e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22162743 chr22:22098700~22099212:+ LUSC cis rs11089937 0.626 rs737841 ENSG00000211638.2 IGLV8-61 -5.98 4.45e-09 1.91e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22162769 chr22:22098700~22099212:+ LUSC cis rs2283792 0.812 rs240066 ENSG00000224086.5 LL22NC03-86G7.1 5.98 4.45e-09 1.91e-06 0.23 0.27 Multiple sclerosis; chr22:21938623 chr22:21938293~21977632:+ LUSC cis rs875971 0.571 rs78668714 ENSG00000237310.1 GS1-124K5.4 5.98 4.46e-09 1.92e-06 0.31 0.27 Aortic root size; chr7:66474464 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs7810213 ENSG00000237310.1 GS1-124K5.4 5.98 4.46e-09 1.92e-06 0.31 0.27 Aortic root size; chr7:66481592 chr7:66493706~66495474:+ LUSC cis rs8005677 1 rs11157930 ENSG00000279656.1 RP11-298I3.6 5.98 4.46e-09 1.92e-06 0.32 0.27 Cognitive ability (multi-trait analysis); chr14:22933962 chr14:23023083~23024217:- LUSC cis rs8005677 0.962 rs11157931 ENSG00000279656.1 RP11-298I3.6 5.98 4.46e-09 1.92e-06 0.32 0.27 Cognitive ability (multi-trait analysis); chr14:22933984 chr14:23023083~23024217:- LUSC cis rs11722779 0.787 rs6533040 ENSG00000230069.3 LRRC37A15P -5.98 4.46e-09 1.92e-06 -0.29 -0.27 Schizophrenia; chr4:102951421 chr4:102727274~102730721:- LUSC cis rs950880 0.668 rs3732126 ENSG00000234389.1 AC007278.3 -5.98 4.46e-09 1.92e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102397502 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs3732125 ENSG00000234389.1 AC007278.3 -5.98 4.46e-09 1.92e-06 -0.29 -0.27 Serum protein levels (sST2); chr2:102397503 chr2:102438713~102440475:+ LUSC cis rs9545047 0.604 rs9530895 ENSG00000227676.3 LINC01068 5.98 4.47e-09 1.92e-06 0.32 0.27 Schizophrenia; chr13:79334877 chr13:79566727~79571436:+ LUSC cis rs2404602 0.647 rs10152247 ENSG00000259422.1 RP11-593F23.1 -5.98 4.47e-09 1.92e-06 -0.31 -0.27 Blood metabolite levels; chr15:76649911 chr15:76174891~76181486:- LUSC cis rs6570726 0.791 rs12208812 ENSG00000235652.6 RP11-545I5.3 5.98 4.48e-09 1.92e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145579788 chr6:145799409~145886585:+ LUSC cis rs71403859 0.667 rs12149264 ENSG00000260886.1 TAT-AS1 5.98 4.48e-09 1.92e-06 0.41 0.27 Post bronchodilator FEV1; chr16:71687018 chr16:71565789~71578187:+ LUSC cis rs8062405 0.755 rs4788076 ENSG00000278665.1 RP11-666O2.4 5.98 4.5e-09 1.93e-06 0.27 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558684 chr16:28599241~28601881:- LUSC cis rs6671200 0.541 rs7555339 ENSG00000228852.5 RP11-57H12.5 -5.98 4.5e-09 1.93e-06 -0.35 -0.27 Stearic acid (18:0) levels; chr1:95226023 chr1:95243167~95278940:- LUSC cis rs2153535 0.58 rs6912374 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8456190 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs6908504 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8456545 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7755284 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8457246 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7769020 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8457491 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9392220 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8457713 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9379206 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8457788 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs9379207 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8457953 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9393016 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8458340 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs4960421 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8459059 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs4960422 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8459076 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7742794 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8459490 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9505448 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8459571 chr6:8784178~8785445:+ LUSC cis rs7246657 0.654 rs10407568 ENSG00000276846.1 CTD-3220F14.3 5.98 4.5e-09 1.93e-06 0.39 0.27 Coronary artery calcification; chr19:37632108 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs10409605 ENSG00000276846.1 CTD-3220F14.3 5.98 4.5e-09 1.93e-06 0.39 0.27 Coronary artery calcification; chr19:37632236 chr19:37314868~37315620:- LUSC cis rs4950322 0.57 rs11800580 ENSG00000278811.3 LINC00624 -5.98 4.5e-09 1.93e-06 -0.3 -0.27 Protein quantitative trait loci; chr1:147261053 chr1:147258885~147517875:- LUSC cis rs2153535 0.58 rs5001130 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8442065 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2327057 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8443086 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1577466 ENSG00000230939.1 RP11-314C16.1 -5.98 4.5e-09 1.93e-06 -0.31 -0.27 Motion sickness; chr6:8443959 chr6:8784178~8785445:+ LUSC cis rs2732480 0.577 rs2732466 ENSG00000273765.1 RP11-370I10.11 5.98 4.51e-09 1.93e-06 0.31 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48338676 chr12:48360920~48361377:+ LUSC cis rs2179367 0.632 rs9485389 ENSG00000231760.4 RP11-350J20.5 -5.98 4.51e-09 1.94e-06 -0.38 -0.27 Dupuytren's disease; chr6:149420078 chr6:149796151~149826294:- LUSC cis rs6671200 0.607 rs3753872 ENSG00000228852.5 RP11-57H12.5 -5.98 4.51e-09 1.94e-06 -0.35 -0.27 Stearic acid (18:0) levels; chr1:95233628 chr1:95243167~95278940:- LUSC cis rs9341835 0.679 rs9344137 ENSG00000218048.2 RP3-407E4.4 5.98 4.51e-09 1.94e-06 0.31 0.27 Schizophrenia; chr6:63447059 chr6:63440766~63443580:+ LUSC cis rs875971 0.964 rs778721 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66380410 chr7:66376044~66401338:- LUSC cis rs875971 0.929 rs778712 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66384991 chr7:66376044~66401338:- LUSC cis rs875971 1 rs778710 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66389847 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs778708 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66391332 chr7:66376044~66401338:- LUSC cis rs875971 1 rs778706 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66395437 chr7:66376044~66401338:- LUSC cis rs875971 0.895 rs778700 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66401463 chr7:66376044~66401338:- LUSC cis rs875971 1 rs778699 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66403303 chr7:66376044~66401338:- LUSC cis rs875971 1 rs778696 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66405826 chr7:66376044~66401338:- LUSC cis rs875971 1 rs778694 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66406571 chr7:66376044~66401338:- LUSC cis rs875971 0.929 rs778692 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66407462 chr7:66376044~66401338:- LUSC cis rs875971 1 rs4718343 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66409301 chr7:66376044~66401338:- LUSC cis rs875971 1 rs4718344 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66409394 chr7:66376044~66401338:- LUSC cis rs875971 1 rs1968225 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66409786 chr7:66376044~66401338:- LUSC cis rs875971 0.737 rs7803424 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66415618 chr7:66376044~66401338:- LUSC cis rs875971 0.83 rs7799834 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66415707 chr7:66376044~66401338:- LUSC cis rs875971 1 rs6460295 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66417741 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs6978721 ENSG00000179406.6 LINC00174 -5.98 4.51e-09 1.94e-06 -0.28 -0.27 Aortic root size; chr7:66418217 chr7:66376044~66401338:- LUSC cis rs11098499 0.644 rs10012252 ENSG00000250412.1 KLHL2P1 5.98 4.51e-09 1.94e-06 0.32 0.27 Corneal astigmatism; chr4:119637984 chr4:119334329~119378233:+ LUSC cis rs7829975 0.593 rs2921051 ENSG00000173295.6 FAM86B3P 5.98 4.51e-09 1.94e-06 0.29 0.27 Mood instability; chr8:8462594 chr8:8228595~8244865:+ LUSC cis rs2412819 0.559 rs8040336 ENSG00000249839.1 AC011330.5 -5.98 4.52e-09 1.94e-06 -0.32 -0.27 Lung cancer; chr15:43761419 chr15:43663654~43684339:- LUSC cis rs9910055 0.718 rs2526022 ENSG00000267080.4 ASB16-AS1 -5.98 4.52e-09 1.94e-06 -0.24 -0.27 Total body bone mineral density; chr17:44135848 chr17:44175973~44186717:- LUSC cis rs9910055 0.762 rs2526021 ENSG00000267080.4 ASB16-AS1 -5.98 4.52e-09 1.94e-06 -0.24 -0.27 Total body bone mineral density; chr17:44135979 chr17:44175973~44186717:- LUSC cis rs61270009 0.955 rs11743103 ENSG00000247828.6 TMEM161B-AS1 -5.98 4.52e-09 1.94e-06 -0.31 -0.27 Depressive symptoms; chr5:88380145 chr5:88268895~88436685:+ LUSC cis rs11971779 0.68 rs10229358 ENSG00000273391.1 RP11-634H22.1 -5.98 4.53e-09 1.94e-06 -0.29 -0.27 Diisocyanate-induced asthma; chr7:139367799 chr7:139359032~139359566:- LUSC cis rs853679 0.517 rs1904840 ENSG00000280107.1 AL022393.9 -5.98 4.53e-09 1.94e-06 -0.34 -0.27 Depression; chr6:28140454 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9368555 ENSG00000280107.1 AL022393.9 -5.98 4.53e-09 1.94e-06 -0.34 -0.27 Depression; chr6:28141189 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9393893 ENSG00000280107.1 AL022393.9 -5.98 4.53e-09 1.94e-06 -0.34 -0.27 Depression; chr6:28141484 chr6:28170845~28172521:+ LUSC cis rs11971779 0.838 rs4728468 ENSG00000273391.1 RP11-634H22.1 5.98 4.53e-09 1.94e-06 0.3 0.27 Diisocyanate-induced asthma; chr7:139438232 chr7:139359032~139359566:- LUSC cis rs7267979 0.844 rs869358 ENSG00000274973.1 RP13-401N8.7 5.98 4.54e-09 1.95e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25394038 chr20:25845497~25845862:+ LUSC cis rs2153535 0.58 rs6597318 ENSG00000230939.1 RP11-314C16.1 -5.98 4.54e-09 1.95e-06 -0.31 -0.27 Motion sickness; chr6:8437056 chr6:8784178~8785445:+ LUSC cis rs11098499 0.863 rs3822195 ENSG00000248280.1 RP11-33B1.2 5.98 4.54e-09 1.95e-06 0.32 0.27 Corneal astigmatism; chr4:119550505 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs3775854 ENSG00000248280.1 RP11-33B1.2 5.98 4.54e-09 1.95e-06 0.32 0.27 Corneal astigmatism; chr4:119550816 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs2306457 ENSG00000248280.1 RP11-33B1.2 5.98 4.54e-09 1.95e-06 0.32 0.27 Corneal astigmatism; chr4:119551684 chr4:119440561~119450157:- LUSC cis rs2732480 0.557 rs2634682 ENSG00000226413.2 OR8T1P 5.98 4.55e-09 1.95e-06 0.35 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48339160 chr12:48442030~48442947:- LUSC cis rs4713118 0.955 rs9468200 ENSG00000280107.1 AL022393.9 -5.97 4.55e-09 1.95e-06 -0.32 -0.27 Parkinson's disease; chr6:27715284 chr6:28170845~28172521:+ LUSC cis rs4713118 0.955 rs34752872 ENSG00000280107.1 AL022393.9 -5.97 4.55e-09 1.95e-06 -0.32 -0.27 Parkinson's disease; chr6:27715465 chr6:28170845~28172521:+ LUSC cis rs5751168 0.57 rs2051488 ENSG00000211654.2 IGLV5-37 5.97 4.56e-09 1.96e-06 0.34 0.27 Prostate cancer (SNP x SNP interaction); chr22:22492858 chr22:22427540~22428035:+ LUSC cis rs11098499 1 rs6849889 ENSG00000250412.1 KLHL2P1 5.97 4.57e-09 1.96e-06 0.33 0.27 Corneal astigmatism; chr4:119265193 chr4:119334329~119378233:+ LUSC cis rs9326248 0.581 rs10892053 ENSG00000280143.1 AP000892.6 5.97 4.57e-09 1.96e-06 0.28 0.27 Blood protein levels; chr11:116986287 chr11:117204967~117210292:+ LUSC cis rs5751168 0.527 rs2236730 ENSG00000211654.2 IGLV5-37 5.97 4.57e-09 1.96e-06 0.35 0.27 Prostate cancer (SNP x SNP interaction); chr22:22488793 chr22:22427540~22428035:+ LUSC cis rs760794 0.577 rs7752808 ENSG00000227116.1 RP3-471C18.1 -5.97 4.58e-09 1.96e-06 -0.33 -0.27 Endometriosis; chr6:19792665 chr6:19730427~19734567:- LUSC cis rs6142102 0.961 rs2300204 ENSG00000275784.1 RP5-1125A11.6 -5.97 4.58e-09 1.96e-06 -0.31 -0.27 Skin pigmentation; chr20:34000967 chr20:33989480~33991818:- LUSC cis rs875971 0.545 rs35459055 ENSG00000226824.5 RP4-756H11.3 -5.97 4.58e-09 1.96e-06 -0.35 -0.27 Aortic root size; chr7:66479399 chr7:66654538~66669855:+ LUSC cis rs227275 0.554 rs223436 ENSG00000246560.2 RP11-10L12.4 5.97 4.58e-09 1.96e-06 0.32 0.27 Allergic disease (asthma, hay fever or eczema); chr4:102798749 chr4:102828055~102844075:+ LUSC cis rs2243480 1 rs2420170 ENSG00000226824.5 RP4-756H11.3 5.97 4.59e-09 1.97e-06 0.51 0.27 Diabetic kidney disease; chr7:66191066 chr7:66654538~66669855:+ LUSC cis rs1320333 0.772 rs2903491 ENSG00000233296.1 AC092159.2 5.97 4.59e-09 1.97e-06 0.45 0.27 Obesity-related traits; chr2:686688 chr2:677186~697371:+ LUSC cis rs6142102 0.961 rs2235596 ENSG00000275784.1 RP5-1125A11.6 5.97 4.6e-09 1.97e-06 0.3 0.27 Skin pigmentation; chr20:34096503 chr20:33989480~33991818:- LUSC cis rs950169 0.96 rs35159785 ENSG00000259728.4 LINC00933 5.97 4.6e-09 1.97e-06 0.35 0.27 Schizophrenia; chr15:84135262 chr15:84570649~84580175:+ LUSC cis rs2243480 0.711 rs2460426 ENSG00000226824.5 RP4-756H11.3 5.97 4.6e-09 1.97e-06 0.51 0.27 Diabetic kidney disease; chr7:66158142 chr7:66654538~66669855:+ LUSC cis rs7772486 0.875 rs2814875 ENSG00000235652.6 RP11-545I5.3 5.97 4.61e-09 1.97e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145984674 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs2814874 ENSG00000235652.6 RP11-545I5.3 5.97 4.61e-09 1.97e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145984759 chr6:145799409~145886585:+ LUSC cis rs2153535 0.541 rs9405386 ENSG00000230939.1 RP11-314C16.1 -5.97 4.61e-09 1.97e-06 -0.31 -0.27 Motion sickness; chr6:8457834 chr6:8784178~8785445:+ LUSC cis rs1008375 1 rs11727312 ENSG00000249502.1 AC006160.5 -5.97 4.61e-09 1.97e-06 -0.25 -0.27 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17667562 chr4:17587467~17614571:- LUSC cis rs6570726 0.791 rs11155433 ENSG00000235652.6 RP11-545I5.3 -5.97 4.62e-09 1.98e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145586695 chr6:145799409~145886585:+ LUSC cis rs875971 0.964 rs1643388 ENSG00000179406.6 LINC00174 -5.97 4.62e-09 1.98e-06 -0.28 -0.27 Aortic root size; chr7:66379575 chr7:66376044~66401338:- LUSC cis rs875971 1 rs778722 ENSG00000179406.6 LINC00174 -5.97 4.62e-09 1.98e-06 -0.28 -0.27 Aortic root size; chr7:66379841 chr7:66376044~66401338:- LUSC cis rs75422866 0.541 rs12425816 ENSG00000276691.1 RP5-1057I20.5 5.97 4.62e-09 1.98e-06 0.46 0.27 Pneumonia; chr12:47731419 chr12:47788426~47788971:+ LUSC cis rs2243480 1 rs2420171 ENSG00000226824.5 RP4-756H11.3 5.97 4.63e-09 1.98e-06 0.51 0.27 Diabetic kidney disease; chr7:66172773 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs6974723 ENSG00000226824.5 RP4-756H11.3 5.97 4.63e-09 1.98e-06 0.51 0.27 Diabetic kidney disease; chr7:66172952 chr7:66654538~66669855:+ LUSC cis rs9549367 0.713 rs3024769 ENSG00000269125.1 RP11-98F14.11 5.97 4.64e-09 1.99e-06 0.32 0.27 Platelet distribution width; chr13:113171287 chr13:113165002~113165183:- LUSC cis rs11089937 0.626 rs11704092 ENSG00000211638.2 IGLV8-61 -5.97 4.64e-09 1.99e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22135815 chr22:22098700~22099212:+ LUSC cis rs2179367 0.632 rs66672129 ENSG00000231760.4 RP11-350J20.5 5.97 4.64e-09 1.99e-06 0.38 0.27 Dupuytren's disease; chr6:149334387 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs9498322 ENSG00000231760.4 RP11-350J20.5 5.97 4.64e-09 1.99e-06 0.38 0.27 Dupuytren's disease; chr6:149335950 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs9498323 ENSG00000231760.4 RP11-350J20.5 5.97 4.64e-09 1.99e-06 0.38 0.27 Dupuytren's disease; chr6:149336077 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs12204793 ENSG00000231760.4 RP11-350J20.5 5.97 4.64e-09 1.99e-06 0.38 0.27 Dupuytren's disease; chr6:149340102 chr6:149796151~149826294:- LUSC cis rs6142102 0.961 rs2284387 ENSG00000275784.1 RP5-1125A11.6 -5.97 4.64e-09 1.99e-06 -0.31 -0.27 Skin pigmentation; chr20:34056782 chr20:33989480~33991818:- LUSC cis rs7826238 0.535 rs2979179 ENSG00000253893.2 FAM85B -5.97 4.65e-09 1.99e-06 -0.31 -0.27 Systolic blood pressure; chr8:8462519 chr8:8167819~8226614:- LUSC cis rs4372836 0.897 rs6707130 ENSG00000226833.4 AC097724.3 5.97 4.65e-09 1.99e-06 0.31 0.27 Body mass index; chr2:28750410 chr2:28708953~28736205:- LUSC cis rs2980439 0.607 rs2980419 ENSG00000253893.2 FAM85B -5.97 4.65e-09 1.99e-06 -0.33 -0.27 Neuroticism; chr8:8256619 chr8:8167819~8226614:- LUSC cis rs7772486 0.875 rs854146 ENSG00000235652.6 RP11-545I5.3 5.97 4.66e-09 1.99e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:146019897 chr6:145799409~145886585:+ LUSC cis rs12908161 1 rs35726233 ENSG00000259728.4 LINC00933 5.97 4.66e-09 1.99e-06 0.34 0.27 Schizophrenia; chr15:84794569 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs35960805 ENSG00000259728.4 LINC00933 5.97 4.66e-09 1.99e-06 0.34 0.27 Schizophrenia; chr15:84800749 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs12912388 ENSG00000259728.4 LINC00933 5.97 4.66e-09 1.99e-06 0.34 0.27 Schizophrenia; chr15:84801319 chr15:84570649~84580175:+ LUSC cis rs13113518 0.812 rs6849474 ENSG00000249700.7 SRD5A3-AS1 5.97 4.66e-09 2e-06 0.31 0.27 Height; chr4:55452295 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs4864996 ENSG00000249700.7 SRD5A3-AS1 5.97 4.66e-09 2e-06 0.31 0.27 Height; chr4:55452921 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs2412648 ENSG00000249700.7 SRD5A3-AS1 5.97 4.66e-09 2e-06 0.31 0.27 Height; chr4:55454900 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs12512737 ENSG00000249700.7 SRD5A3-AS1 5.97 4.66e-09 2e-06 0.31 0.27 Height; chr4:55454938 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs13125984 ENSG00000249700.7 SRD5A3-AS1 5.97 4.66e-09 2e-06 0.31 0.27 Height; chr4:55455102 chr4:55363971~55395847:- LUSC cis rs2404602 0.735 rs11632222 ENSG00000259422.1 RP11-593F23.1 -5.97 4.66e-09 2e-06 -0.31 -0.27 Blood metabolite levels; chr15:76420586 chr15:76174891~76181486:- LUSC cis rs13113518 0.812 rs12649507 ENSG00000249700.7 SRD5A3-AS1 -5.97 4.67e-09 2e-06 -0.31 -0.27 Height; chr4:55514317 chr4:55363971~55395847:- LUSC cis rs9322193 0.887 rs3777949 ENSG00000268592.3 RAET1E-AS1 5.97 4.68e-09 2e-06 0.34 0.27 Lung cancer; chr6:149596021 chr6:149863494~149919507:+ LUSC cis rs1823913 0.562 rs17347499 ENSG00000280083.1 RP11-317J9.1 -5.97 4.68e-09 2e-06 -0.32 -0.27 Obesity-related traits; chr2:191301116 chr2:191154118~191156070:- LUSC cis rs2404602 0.735 rs11638767 ENSG00000259422.1 RP11-593F23.1 -5.97 4.69e-09 2.01e-06 -0.31 -0.27 Blood metabolite levels; chr15:76363597 chr15:76174891~76181486:- LUSC cis rs881375 0.702 rs3761847 ENSG00000226752.6 PSMD5-AS1 -5.97 4.69e-09 2.01e-06 -0.29 -0.27 Rheumatoid arthritis; chr9:120927961 chr9:120824828~120854385:+ LUSC cis rs6772849 0.775 rs67105978 ENSG00000242551.2 POU5F1P6 -5.97 4.71e-09 2.01e-06 -0.32 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128696337 chr3:128674735~128677005:- LUSC cis rs4718428 0.705 rs68168107 ENSG00000226824.5 RP4-756H11.3 -5.97 4.71e-09 2.01e-06 -0.36 -0.27 Corneal structure; chr7:66790251 chr7:66654538~66669855:+ LUSC cis rs6671200 0.607 rs10874908 ENSG00000228852.5 RP11-57H12.5 -5.97 4.71e-09 2.01e-06 -0.35 -0.27 Stearic acid (18:0) levels; chr1:95238595 chr1:95243167~95278940:- LUSC cis rs11690935 0.851 rs6731562 ENSG00000228389.1 AC068039.4 5.97 4.71e-09 2.01e-06 0.3 0.27 Schizophrenia; chr2:171941742 chr2:171773482~171775844:+ LUSC cis rs11690935 0.851 rs10201430 ENSG00000228389.1 AC068039.4 5.97 4.71e-09 2.01e-06 0.3 0.27 Schizophrenia; chr2:171956715 chr2:171773482~171775844:+ LUSC cis rs7772486 0.754 rs697055 ENSG00000235652.6 RP11-545I5.3 5.97 4.72e-09 2.02e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145682654 chr6:145799409~145886585:+ LUSC cis rs2834288 0.535 rs4816468 ENSG00000273102.1 AP000569.9 5.97 4.73e-09 2.02e-06 0.29 0.27 Gut microbiota (bacterial taxa); chr21:33952235 chr21:33967101~33968573:- LUSC cis rs761746 0.739 rs5998072 ENSG00000236132.1 CTA-440B3.1 -5.97 4.73e-09 2.02e-06 -0.38 -0.27 Intelligence; chr22:31652388 chr22:31816379~31817491:- LUSC cis rs2732480 0.577 rs2732457 ENSG00000240399.1 RP1-228P16.1 -5.97 4.73e-09 2.02e-06 -0.28 -0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48364596 chr12:48054813~48055591:- LUSC cis rs853679 0.76 rs9295768 ENSG00000204709.4 LINC01556 5.97 4.73e-09 2.02e-06 0.4 0.27 Depression; chr6:28241324 chr6:28943877~28944537:+ LUSC cis rs2019137 0.936 rs902696 ENSG00000274877.1 RP11-65I12.1 -5.97 4.73e-09 2.02e-06 -0.32 -0.27 Lymphocyte counts; chr2:113197302 chr2:113237595~113240825:+ LUSC cis rs72627123 1 rs72627120 ENSG00000259065.1 RP5-1021I20.1 -5.97 4.74e-09 2.02e-06 -0.46 -0.27 Morning vs. evening chronotype; chr14:73896777 chr14:73787360~73803270:+ LUSC cis rs17270561 0.609 rs1317816 ENSG00000272462.2 U91328.19 -5.97 4.74e-09 2.03e-06 -0.31 -0.27 Iron status biomarkers; chr6:25765162 chr6:25992662~26001775:+ LUSC cis rs4713118 0.955 rs9380010 ENSG00000280107.1 AL022393.9 -5.97 4.75e-09 2.03e-06 -0.32 -0.27 Parkinson's disease; chr6:27715793 chr6:28170845~28172521:+ LUSC cis rs4713118 0.955 rs9368528 ENSG00000280107.1 AL022393.9 -5.97 4.75e-09 2.03e-06 -0.32 -0.27 Parkinson's disease; chr6:27716019 chr6:28170845~28172521:+ LUSC cis rs4713118 0.955 rs9380011 ENSG00000280107.1 AL022393.9 -5.97 4.75e-09 2.03e-06 -0.32 -0.27 Parkinson's disease; chr6:27716145 chr6:28170845~28172521:+ LUSC cis rs4713118 0.955 rs9380012 ENSG00000280107.1 AL022393.9 -5.97 4.75e-09 2.03e-06 -0.32 -0.27 Parkinson's disease; chr6:27716875 chr6:28170845~28172521:+ LUSC cis rs2153535 0.58 rs4960411 ENSG00000230939.1 RP11-314C16.1 -5.97 4.75e-09 2.03e-06 -0.31 -0.27 Motion sickness; chr6:8437998 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs4960412 ENSG00000230939.1 RP11-314C16.1 -5.97 4.75e-09 2.03e-06 -0.31 -0.27 Motion sickness; chr6:8438028 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs4960413 ENSG00000230939.1 RP11-314C16.1 -5.97 4.75e-09 2.03e-06 -0.31 -0.27 Motion sickness; chr6:8438233 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs4960414 ENSG00000230939.1 RP11-314C16.1 -5.97 4.75e-09 2.03e-06 -0.31 -0.27 Motion sickness; chr6:8438308 chr6:8784178~8785445:+ LUSC cis rs17772222 0.565 rs845759 ENSG00000258789.1 RP11-507K2.3 5.97 4.75e-09 2.03e-06 0.29 0.27 Coronary artery calcification; chr14:88415538 chr14:88551597~88552493:+ LUSC cis rs7665090 1 rs4013 ENSG00000230069.3 LRRC37A15P -5.97 4.76e-09 2.03e-06 -0.27 -0.27 Primary biliary cholangitis; chr4:102631656 chr4:102727274~102730721:- LUSC cis rs12908161 0.959 rs11637728 ENSG00000259728.4 LINC00933 5.97 4.76e-09 2.03e-06 0.35 0.27 Schizophrenia; chr15:84660161 chr15:84570649~84580175:+ LUSC cis rs11722779 0.838 rs3974494 ENSG00000230069.3 LRRC37A15P -5.97 4.76e-09 2.03e-06 -0.28 -0.27 Schizophrenia; chr4:102945323 chr4:102727274~102730721:- LUSC cis rs35740288 0.77 rs35348278 ENSG00000202081.1 RNU6-1280P 5.97 4.76e-09 2.03e-06 0.32 0.27 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85657109 chr15:85651522~85651628:- LUSC cis rs853679 0.76 rs9368563 ENSG00000204709.4 LINC01556 5.97 4.77e-09 2.04e-06 0.4 0.27 Depression; chr6:28240780 chr6:28943877~28944537:+ LUSC cis rs17270561 0.697 rs9366633 ENSG00000272462.2 U91328.19 -5.97 4.77e-09 2.04e-06 -0.31 -0.27 Iron status biomarkers; chr6:25837826 chr6:25992662~26001775:+ LUSC cis rs875971 0.929 rs34406470 ENSG00000179406.6 LINC00174 -5.97 4.77e-09 2.04e-06 -0.28 -0.27 Aortic root size; chr7:66464969 chr7:66376044~66401338:- LUSC cis rs2153535 0.601 rs2327091 ENSG00000230939.1 RP11-314C16.1 -5.97 4.77e-09 2.04e-06 -0.32 -0.27 Motion sickness; chr6:8540136 chr6:8784178~8785445:+ LUSC cis rs78487399 0.71 rs11899863 ENSG00000234936.1 AC010883.5 5.97 4.77e-09 2.04e-06 0.41 0.27 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43391680 chr2:43229573~43233394:+ LUSC cis rs9545047 0.547 rs2876739 ENSG00000227676.3 LINC01068 5.97 4.78e-09 2.04e-06 0.32 0.27 Schizophrenia; chr13:79299057 chr13:79566727~79571436:+ LUSC cis rs9545047 0.567 rs7988331 ENSG00000227676.3 LINC01068 5.97 4.78e-09 2.04e-06 0.32 0.27 Schizophrenia; chr13:79299745 chr13:79566727~79571436:+ LUSC cis rs28830936 1 rs4923905 ENSG00000250379.1 RP11-23P13.4 5.97 4.78e-09 2.04e-06 0.28 0.27 Diastolic blood pressure; chr15:41617691 chr15:41825099~41827936:- LUSC cis rs73173548 0.502 rs13180798 ENSG00000247828.6 TMEM161B-AS1 5.97 4.78e-09 2.04e-06 0.32 0.27 Macular telangiectasia type 2; chr5:88425633 chr5:88268895~88436685:+ LUSC cis rs73173548 0.502 rs13163266 ENSG00000247828.6 TMEM161B-AS1 5.97 4.78e-09 2.04e-06 0.32 0.27 Macular telangiectasia type 2; chr5:88425703 chr5:88268895~88436685:+ LUSC cis rs73173548 0.502 rs13180932 ENSG00000247828.6 TMEM161B-AS1 5.97 4.78e-09 2.04e-06 0.32 0.27 Macular telangiectasia type 2; chr5:88425720 chr5:88268895~88436685:+ LUSC cis rs4713118 0.513 rs202908 ENSG00000216901.1 AL022393.7 5.97 4.78e-09 2.04e-06 0.31 0.27 Parkinson's disease; chr6:28043773 chr6:28176188~28176674:+ LUSC cis rs2665103 0.589 rs3858953 ENSG00000278603.1 RP13-608F4.5 5.97 4.78e-09 2.04e-06 0.32 0.27 Intelligence (multi-trait analysis); chr15:82238049 chr15:82472203~82472426:+ LUSC cis rs9545047 0.604 rs9545054 ENSG00000227676.3 LINC01068 5.97 4.78e-09 2.04e-06 0.32 0.27 Schizophrenia; chr13:79298833 chr13:79566727~79571436:+ LUSC cis rs7665090 0.967 rs4019 ENSG00000230069.3 LRRC37A15P -5.97 4.78e-09 2.04e-06 -0.27 -0.27 Primary biliary cholangitis; chr4:102631673 chr4:102727274~102730721:- LUSC cis rs950880 0.71 rs2287035 ENSG00000234389.1 AC007278.3 -5.97 4.79e-09 2.04e-06 -0.28 -0.27 Serum protein levels (sST2); chr2:102394070 chr2:102438713~102440475:+ LUSC cis rs6570726 0.846 rs6570698 ENSG00000235652.6 RP11-545I5.3 5.97 4.79e-09 2.04e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145597499 chr6:145799409~145886585:+ LUSC cis rs7246657 0.722 rs16958861 ENSG00000276846.1 CTD-3220F14.3 5.97 4.79e-09 2.05e-06 0.39 0.27 Coronary artery calcification; chr19:37633278 chr19:37314868~37315620:- LUSC cis rs2404602 0.698 rs12909656 ENSG00000259422.1 RP11-593F23.1 -5.97 4.81e-09 2.05e-06 -0.31 -0.27 Blood metabolite levels; chr15:76372037 chr15:76174891~76181486:- LUSC cis rs875971 0.545 rs1909508 ENSG00000224316.1 RP11-479O9.2 5.97 4.81e-09 2.05e-06 0.28 0.27 Aortic root size; chr7:66301366 chr7:65773620~65802067:+ LUSC cis rs17772222 0.56 rs3742681 ENSG00000258789.1 RP11-507K2.3 5.97 4.81e-09 2.05e-06 0.3 0.27 Coronary artery calcification; chr14:88554903 chr14:88551597~88552493:+ LUSC cis rs858267 0.661 rs7786708 ENSG00000230658.1 KLHL7-AS1 -5.97 4.81e-09 2.05e-06 -0.72 -0.27 Blood protein levels; chr7:23075797 chr7:23101228~23105703:- LUSC cis rs7772486 0.79 rs3924499 ENSG00000235652.6 RP11-545I5.3 -5.97 4.81e-09 2.05e-06 -0.26 -0.27 Lobe attachment (rater-scored or self-reported); chr6:145911842 chr6:145799409~145886585:+ LUSC cis rs2284378 0.506 rs6142059 ENSG00000276073.1 RP5-1125A11.7 -5.96 4.83e-09 2.06e-06 -0.26 -0.27 Breast cancer; chr20:33956521 chr20:33985617~33988989:- LUSC cis rs4660456 0.572 rs1008204 ENSG00000237899.1 RP4-739H11.3 5.96 4.83e-09 2.06e-06 0.33 0.27 Platelet count; chr1:40700189 chr1:40669089~40687588:- LUSC cis rs8040855 0.658 rs11634877 ENSG00000259295.5 CSPG4P12 5.96 4.83e-09 2.06e-06 0.34 0.27 Bulimia nervosa; chr15:85068246 chr15:85191438~85213905:+ LUSC cis rs34779708 0.733 rs7070778 ENSG00000230534.5 RP11-297A16.2 5.96 4.84e-09 2.07e-06 0.3 0.27 Inflammatory bowel disease;Crohn's disease; chr10:35252760 chr10:35098006~35127020:- LUSC cis rs6142102 0.961 rs4911392 ENSG00000275784.1 RP5-1125A11.6 -5.96 4.85e-09 2.07e-06 -0.3 -0.27 Skin pigmentation; chr20:33982712 chr20:33989480~33991818:- LUSC cis rs6142102 0.961 rs4911393 ENSG00000275784.1 RP5-1125A11.6 -5.96 4.85e-09 2.07e-06 -0.3 -0.27 Skin pigmentation; chr20:33983120 chr20:33989480~33991818:- LUSC cis rs6570726 0.791 rs12208019 ENSG00000235652.6 RP11-545I5.3 5.96 4.85e-09 2.07e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145614436 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs11155435 ENSG00000235652.6 RP11-545I5.3 5.96 4.85e-09 2.07e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145617409 chr6:145799409~145886585:+ LUSC cis rs6772849 0.83 rs4857917 ENSG00000277250.1 Metazoa_SRP -5.96 4.85e-09 2.07e-06 -0.29 -0.27 Monocyte percentage of white cells;Monocyte count; chr3:128657335 chr3:128673681~128674021:- LUSC cis rs4713118 0.513 rs9368547 ENSG00000216901.1 AL022393.7 5.96 4.85e-09 2.07e-06 0.31 0.27 Parkinson's disease; chr6:28060289 chr6:28176188~28176674:+ LUSC cis rs4713118 0.513 rs183244 ENSG00000216901.1 AL022393.7 5.96 4.85e-09 2.07e-06 0.31 0.27 Parkinson's disease; chr6:28064060 chr6:28176188~28176674:+ LUSC cis rs6860806 0.531 rs272888 ENSG00000233006.5 AC034220.3 5.96 4.85e-09 2.07e-06 0.28 0.27 Breast cancer; chr5:132329730 chr5:132311285~132369916:- LUSC cis rs2562456 0.917 rs2562466 ENSG00000268081.1 RP11-678G14.2 -5.96 4.86e-09 2.07e-06 -0.38 -0.27 Pain; chr19:21531402 chr19:21554640~21569237:- LUSC cis rs2562456 0.917 rs2562468 ENSG00000268081.1 RP11-678G14.2 -5.96 4.86e-09 2.07e-06 -0.38 -0.27 Pain; chr19:21532048 chr19:21554640~21569237:- LUSC cis rs2562456 0.917 rs2562471 ENSG00000268081.1 RP11-678G14.2 -5.96 4.86e-09 2.07e-06 -0.38 -0.27 Pain; chr19:21533017 chr19:21554640~21569237:- LUSC cis rs13113518 0.756 rs12510275 ENSG00000249700.7 SRD5A3-AS1 5.96 4.86e-09 2.07e-06 0.31 0.27 Height; chr4:55516548 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs12510327 ENSG00000249700.7 SRD5A3-AS1 5.96 4.86e-09 2.07e-06 0.31 0.27 Height; chr4:55516744 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs11939580 ENSG00000249700.7 SRD5A3-AS1 5.96 4.86e-09 2.07e-06 0.31 0.27 Height; chr4:55517185 chr4:55363971~55395847:- LUSC cis rs7911264 0.739 rs7914814 ENSG00000236493.2 EIF2S2P3 5.96 4.86e-09 2.07e-06 0.31 0.27 Inflammatory bowel disease; chr10:92623193 chr10:92668745~92669743:- LUSC cis rs2404602 0.622 rs4886506 ENSG00000259422.1 RP11-593F23.1 5.96 4.86e-09 2.07e-06 0.31 0.27 Blood metabolite levels; chr15:76914936 chr15:76174891~76181486:- LUSC cis rs11098499 0.954 rs6820115 ENSG00000248280.1 RP11-33B1.2 5.96 4.87e-09 2.08e-06 0.31 0.27 Corneal astigmatism; chr4:119477027 chr4:119440561~119450157:- LUSC cis rs881375 0.678 rs1930782 ENSG00000226752.6 PSMD5-AS1 -5.96 4.89e-09 2.08e-06 -0.29 -0.27 Rheumatoid arthritis; chr9:120925627 chr9:120824828~120854385:+ LUSC cis rs9309711 0.922 rs11679058 ENSG00000225234.1 TRAPPC12-AS1 -5.96 4.89e-09 2.08e-06 -0.36 -0.27 Neurofibrillary tangles; chr2:3480042 chr2:3481242~3482409:- LUSC cis rs75422866 0.51 rs73105829 ENSG00000276691.1 RP5-1057I20.5 5.96 4.89e-09 2.08e-06 0.46 0.27 Pneumonia; chr12:47734162 chr12:47788426~47788971:+ LUSC cis rs6570726 0.846 rs6919684 ENSG00000235652.6 RP11-545I5.3 5.96 4.89e-09 2.09e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145562665 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs6899900 ENSG00000235652.6 RP11-545I5.3 5.96 4.89e-09 2.09e-06 0.26 0.27 Lobe attachment (rater-scored or self-reported); chr6:145562737 chr6:145799409~145886585:+ LUSC cis rs12468226 0.872 rs115187557 ENSG00000272966.1 RP11-686O6.1 5.96 4.91e-09 2.09e-06 0.43 0.27 Urate levels; chr2:202495351 chr2:202336739~202337200:+ LUSC cis rs4713118 0.955 rs9468201 ENSG00000280107.1 AL022393.9 -5.96 4.91e-09 2.09e-06 -0.32 -0.27 Parkinson's disease; chr6:27719256 chr6:28170845~28172521:+ LUSC cis rs17772222 0.682 rs28482235 ENSG00000258789.1 RP11-507K2.3 -5.96 4.91e-09 2.09e-06 -0.29 -0.27 Coronary artery calcification; chr14:88472857 chr14:88551597~88552493:+ LUSC cis rs77204473 0.744 rs2306472 ENSG00000254851.1 RP11-109L13.1 5.96 4.91e-09 2.09e-06 0.6 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117187346 chr11:117135528~117138582:+ LUSC cis rs11089937 0.568 rs59356111 ENSG00000211638.2 IGLV8-61 -5.96 4.91e-09 2.09e-06 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22136175 chr22:22098700~22099212:+ LUSC cis rs11098499 0.863 rs6853998 ENSG00000248280.1 RP11-33B1.2 5.96 4.91e-09 2.09e-06 0.32 0.27 Corneal astigmatism; chr4:119554705 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs6858777 ENSG00000248280.1 RP11-33B1.2 5.96 4.91e-09 2.09e-06 0.32 0.27 Corneal astigmatism; chr4:119554811 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs11731756 ENSG00000248280.1 RP11-33B1.2 5.96 4.91e-09 2.09e-06 0.32 0.27 Corneal astigmatism; chr4:119557541 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs34308924 ENSG00000248280.1 RP11-33B1.2 5.96 4.91e-09 2.09e-06 0.32 0.27 Corneal astigmatism; chr4:119560276 chr4:119440561~119450157:- LUSC cis rs67311347 0.955 rs4973999 ENSG00000223797.4 ENTPD3-AS1 5.96 4.91e-09 2.09e-06 0.29 0.27 Renal cell carcinoma; chr3:40418892 chr3:40313802~40453329:- LUSC cis rs11098499 0.863 rs9884402 ENSG00000248280.1 RP11-33B1.2 5.96 4.91e-09 2.09e-06 0.31 0.27 Corneal astigmatism; chr4:119568827 chr4:119440561~119450157:- LUSC cis rs11098499 0.731 rs9995026 ENSG00000248280.1 RP11-33B1.2 5.96 4.91e-09 2.09e-06 0.31 0.27 Corneal astigmatism; chr4:119569344 chr4:119440561~119450157:- LUSC cis rs11846409 1 rs11846409 ENSG00000274576.2 IGHV2-70 -5.96 4.91e-09 2.09e-06 -0.28 -0.27 Rheumatic heart disease; chr14:106645692 chr14:106770577~106771020:- LUSC cis rs228614 0.514 rs59550147 ENSG00000230069.3 LRRC37A15P -5.96 4.92e-09 2.1e-06 -0.28 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102914239 chr4:102727274~102730721:- LUSC cis rs12908161 0.959 rs3748376 ENSG00000259728.4 LINC00933 5.96 4.92e-09 2.1e-06 0.35 0.27 Schizophrenia; chr15:84785121 chr15:84570649~84580175:+ LUSC cis rs1823913 0.614 rs6434459 ENSG00000280083.1 RP11-317J9.1 5.96 4.92e-09 2.1e-06 0.31 0.27 Obesity-related traits; chr2:191300886 chr2:191154118~191156070:- LUSC cis rs1823913 0.592 rs7588555 ENSG00000280083.1 RP11-317J9.1 5.96 4.92e-09 2.1e-06 0.31 0.27 Obesity-related traits; chr2:191300912 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs4853581 ENSG00000280083.1 RP11-317J9.1 5.96 4.92e-09 2.1e-06 0.31 0.27 Obesity-related traits; chr2:191301533 chr2:191154118~191156070:- LUSC cis rs1823913 0.614 rs7565987 ENSG00000280083.1 RP11-317J9.1 5.96 4.92e-09 2.1e-06 0.31 0.27 Obesity-related traits; chr2:191301815 chr2:191154118~191156070:- LUSC cis rs1823913 0.614 rs1973067 ENSG00000280083.1 RP11-317J9.1 5.96 4.92e-09 2.1e-06 0.31 0.27 Obesity-related traits; chr2:191302021 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs1973068 ENSG00000280083.1 RP11-317J9.1 5.96 4.92e-09 2.1e-06 0.31 0.27 Obesity-related traits; chr2:191302227 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs7569231 ENSG00000280083.1 RP11-317J9.1 5.96 4.92e-09 2.1e-06 0.31 0.27 Obesity-related traits; chr2:191302373 chr2:191154118~191156070:- LUSC cis rs1320333 0.772 rs2867116 ENSG00000233296.1 AC092159.2 5.96 4.92e-09 2.1e-06 0.45 0.27 Obesity-related traits; chr2:682363 chr2:677186~697371:+ LUSC cis rs1185460 0.546 rs549893 ENSG00000271751.1 RP11-110I1.14 5.96 4.93e-09 2.1e-06 0.33 0.27 Coronary artery disease; chr11:119089022 chr11:119065263~119065677:- LUSC cis rs66486766 1 rs66486766 ENSG00000259728.4 LINC00933 5.96 4.93e-09 2.1e-06 0.35 0.27 Bipolar disorder lithium response (categorical) or schizophrenia; chr15:84137308 chr15:84570649~84580175:+ LUSC cis rs12468226 1 rs6739198 ENSG00000272966.1 RP11-686O6.1 5.96 4.93e-09 2.1e-06 0.43 0.27 Urate levels; chr2:202492273 chr2:202336739~202337200:+ LUSC cis rs11603023 0.967 rs4245184 ENSG00000255422.1 AP002954.4 5.96 4.93e-09 2.1e-06 0.3 0.27 Cholesterol, total; chr11:118639844 chr11:118704607~118750263:+ LUSC cis rs11603023 0.967 rs644273 ENSG00000255422.1 AP002954.4 5.96 4.93e-09 2.1e-06 0.3 0.27 Cholesterol, total; chr11:118640634 chr11:118704607~118750263:+ LUSC cis rs34779708 0.677 rs112355105 ENSG00000230534.5 RP11-297A16.2 5.96 4.94e-09 2.1e-06 0.3 0.27 Inflammatory bowel disease;Crohn's disease; chr10:35261366 chr10:35098006~35127020:- LUSC cis rs8040855 0.627 rs11631548 ENSG00000259295.5 CSPG4P12 5.96 4.94e-09 2.1e-06 0.34 0.27 Bulimia nervosa; chr15:85076017 chr15:85191438~85213905:+ LUSC cis rs2337406 0.85 rs8014460 ENSG00000254174.1 IGHV1-12 5.96 4.94e-09 2.1e-06 0.27 0.27 Alzheimer's disease (late onset); chr14:106697140 chr14:106122420~106122709:- LUSC cis rs7555523 0.83 rs4656460 ENSG00000224358.1 RP11-466F5.8 -5.96 4.95e-09 2.11e-06 -0.36 -0.27 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165703130 chr1:165768929~165775176:+ LUSC cis rs61270009 0.955 rs4916905 ENSG00000247828.6 TMEM161B-AS1 5.96 4.95e-09 2.11e-06 0.3 0.27 Depressive symptoms; chr5:88362244 chr5:88268895~88436685:+ LUSC cis rs17818399 0.888 rs2346419 ENSG00000279254.1 RP11-536C12.1 -5.96 4.96e-09 2.11e-06 -0.32 -0.27 Height; chr2:46617930 chr2:46668870~46670778:+ LUSC cis rs7267979 0.932 rs6115214 ENSG00000274973.1 RP13-401N8.7 5.96 4.97e-09 2.11e-06 0.27 0.27 Liver enzyme levels (alkaline phosphatase); chr20:25576790 chr20:25845497~25845862:+ LUSC cis rs9910055 0.762 rs2631299 ENSG00000267080.4 ASB16-AS1 -5.96 4.97e-09 2.12e-06 -0.24 -0.27 Total body bone mineral density; chr17:44142405 chr17:44175973~44186717:- LUSC cis rs2276314 1 rs56050783 ENSG00000278986.1 RP11-723J4.3 -5.96 4.98e-09 2.12e-06 -0.33 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35973828 chr18:35972151~35973916:+ LUSC cis rs2276314 1 rs58054756 ENSG00000278986.1 RP11-723J4.3 -5.96 4.98e-09 2.12e-06 -0.33 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35974090 chr18:35972151~35973916:+ LUSC cis rs77204473 0.744 rs10892067 ENSG00000254851.1 RP11-109L13.1 5.96 4.99e-09 2.12e-06 0.62 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117057046 chr11:117135528~117138582:+ LUSC cis rs2153535 0.601 rs2327054 ENSG00000230939.1 RP11-314C16.1 -5.96 4.99e-09 2.12e-06 -0.32 -0.27 Motion sickness; chr6:8442897 chr6:8784178~8785445:+ LUSC cis rs2153535 0.623 rs2327055 ENSG00000230939.1 RP11-314C16.1 -5.96 4.99e-09 2.12e-06 -0.32 -0.27 Motion sickness; chr6:8442912 chr6:8784178~8785445:+ LUSC cis rs79349575 0.756 rs2291726 ENSG00000270781.1 RP11-501C14.9 5.96 5e-09 2.13e-06 0.28 0.27 Type 2 diabetes; chr17:48961892 chr17:48899131~48899748:+ LUSC cis rs875971 0.706 rs1643374 ENSG00000237310.1 GS1-124K5.4 5.96 5e-09 2.13e-06 0.27 0.27 Aortic root size; chr7:66407695 chr7:66493706~66495474:+ LUSC cis rs1021993 0.545 rs77070927 ENSG00000231648.1 RP11-372M18.2 -5.96 5e-09 2.13e-06 -0.39 -0.27 Gut microbiome composition (winter); chr1:209356960 chr1:209367662~209379690:+ LUSC cis rs6570726 0.791 rs6918814 ENSG00000235652.6 RP11-545I5.3 5.96 5.01e-09 2.13e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145584892 chr6:145799409~145886585:+ LUSC cis rs7429990 0.864 rs12635438 ENSG00000229759.1 MRPS18AP1 5.96 5.01e-09 2.13e-06 0.27 0.26 Educational attainment (years of education); chr3:47693210 chr3:48256350~48256938:- LUSC cis rs732716 0.813 rs760369 ENSG00000267769.1 CTB-50L17.9 5.96 5.02e-09 2.13e-06 0.28 0.26 Mean corpuscular volume; chr19:4449290 chr19:4454014~4455286:+ LUSC cis rs17772222 0.701 rs1627444 ENSG00000258789.1 RP11-507K2.3 5.96 5.02e-09 2.13e-06 0.29 0.26 Coronary artery calcification; chr14:88413784 chr14:88551597~88552493:+ LUSC cis rs6772849 0.93 rs4857914 ENSG00000277250.1 Metazoa_SRP -5.96 5.02e-09 2.13e-06 -0.29 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128631841 chr3:128673681~128674021:- LUSC cis rs2404602 0.552 rs11630185 ENSG00000259422.1 RP11-593F23.1 -5.96 5.02e-09 2.13e-06 -0.34 -0.26 Blood metabolite levels; chr15:76667442 chr15:76174891~76181486:- LUSC cis rs66887589 1 rs66887589 ENSG00000248280.1 RP11-33B1.2 -5.96 5.04e-09 2.14e-06 -0.29 -0.26 Diastolic blood pressure; chr4:119588124 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs17050695 ENSG00000248280.1 RP11-33B1.2 5.96 5.04e-09 2.14e-06 0.3 0.26 Corneal astigmatism; chr4:119568372 chr4:119440561~119450157:- LUSC cis rs13113518 0.902 rs12642716 ENSG00000273257.1 RP11-177J6.1 5.96 5.04e-09 2.14e-06 0.34 0.26 Height; chr4:55479996 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs12501636 ENSG00000273257.1 RP11-177J6.1 5.96 5.04e-09 2.14e-06 0.34 0.26 Height; chr4:55482317 chr4:55387949~55388271:+ LUSC cis rs61270009 0.955 rs780397 ENSG00000247828.6 TMEM161B-AS1 -5.96 5.05e-09 2.15e-06 -0.31 -0.26 Depressive symptoms; chr5:88233841 chr5:88268895~88436685:+ LUSC cis rs61270009 0.874 rs780403 ENSG00000247828.6 TMEM161B-AS1 -5.96 5.05e-09 2.15e-06 -0.31 -0.26 Depressive symptoms; chr5:88244989 chr5:88268895~88436685:+ LUSC cis rs9545047 0.604 rs7981067 ENSG00000227676.3 LINC01068 5.96 5.05e-09 2.15e-06 0.32 0.26 Schizophrenia; chr13:79341254 chr13:79566727~79571436:+ LUSC cis rs442309 0.551 rs10822056 ENSG00000238280.1 RP11-436D10.3 -5.96 5.05e-09 2.15e-06 -0.32 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62754351 chr10:62793562~62805887:- LUSC cis rs783540 0.934 rs1594511 ENSG00000255769.6 GOLGA2P10 5.96 5.06e-09 2.15e-06 0.33 0.26 Schizophrenia; chr15:82638312 chr15:82472993~82513950:- LUSC cis rs6142102 0.778 rs4911374 ENSG00000275784.1 RP5-1125A11.6 -5.96 5.06e-09 2.15e-06 -0.31 -0.26 Skin pigmentation; chr20:33928195 chr20:33989480~33991818:- LUSC cis rs7665090 0.875 rs6813687 ENSG00000230069.3 LRRC37A15P -5.96 5.06e-09 2.15e-06 -0.28 -0.26 Primary biliary cholangitis; chr4:102634455 chr4:102727274~102730721:- LUSC cis rs2732480 0.538 rs2732462 ENSG00000273765.1 RP11-370I10.11 5.96 5.07e-09 2.15e-06 0.31 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48302601 chr12:48360920~48361377:+ LUSC cis rs1021993 0.545 rs58017268 ENSG00000231648.1 RP11-372M18.2 -5.96 5.07e-09 2.16e-06 -0.4 -0.26 Gut microbiome composition (winter); chr1:209366729 chr1:209367662~209379690:+ LUSC cis rs11098499 0.575 rs9996586 ENSG00000249244.1 RP11-548H18.2 5.96 5.08e-09 2.16e-06 0.32 0.26 Corneal astigmatism; chr4:119405787 chr4:119391831~119395335:- LUSC cis rs11098499 0.644 rs3986377 ENSG00000249244.1 RP11-548H18.2 5.96 5.09e-09 2.16e-06 0.33 0.26 Corneal astigmatism; chr4:119339115 chr4:119391831~119395335:- LUSC cis rs10028773 0.556 rs4473640 ENSG00000249244.1 RP11-548H18.2 5.96 5.09e-09 2.16e-06 0.33 0.26 Educational attainment; chr4:119339282 chr4:119391831~119395335:- LUSC cis rs75422866 0.51 rs73105819 ENSG00000276691.1 RP5-1057I20.5 5.95 5.1e-09 2.17e-06 0.46 0.26 Pneumonia; chr12:47727190 chr12:47788426~47788971:+ LUSC cis rs2276314 1 rs1540042 ENSG00000278986.1 RP11-723J4.3 -5.95 5.1e-09 2.17e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35975273 chr18:35972151~35973916:+ LUSC cis rs2303759 0.918 rs10405465 ENSG00000268686.1 AC010524.2 -5.95 5.1e-09 2.17e-06 -0.36 -0.26 Multiple sclerosis; chr19:49366041 chr19:49368705~49388081:- LUSC cis rs73173548 0.502 rs34743961 ENSG00000247828.6 TMEM161B-AS1 5.95 5.11e-09 2.17e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88435952 chr5:88268895~88436685:+ LUSC cis rs7772486 0.79 rs2814880 ENSG00000235652.6 RP11-545I5.3 5.95 5.11e-09 2.17e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145887801 chr6:145799409~145886585:+ LUSC cis rs2834288 0.535 rs7275560 ENSG00000273102.1 AP000569.9 -5.95 5.12e-09 2.17e-06 -0.29 -0.26 Gut microbiota (bacterial taxa); chr21:33956140 chr21:33967101~33968573:- LUSC cis rs11846409 0.587 rs1806881 ENSG00000274576.2 IGHV2-70 5.95 5.12e-09 2.17e-06 0.28 0.26 Rheumatic heart disease; chr14:106650770 chr14:106770577~106771020:- LUSC cis rs875971 0.545 rs73148639 ENSG00000226824.5 RP4-756H11.3 -5.95 5.13e-09 2.18e-06 -0.35 -0.26 Aortic root size; chr7:66390342 chr7:66654538~66669855:+ LUSC cis rs2834288 0.535 rs2834306 ENSG00000273102.1 AP000569.9 -5.95 5.13e-09 2.18e-06 -0.29 -0.26 Gut microbiota (bacterial taxa); chr21:33957563 chr21:33967101~33968573:- LUSC cis rs1823913 0.637 rs4853575 ENSG00000280083.1 RP11-317J9.1 5.95 5.13e-09 2.18e-06 0.31 0.26 Obesity-related traits; chr2:191296149 chr2:191154118~191156070:- LUSC cis rs9549367 0.789 rs3764124 ENSG00000269125.1 RP11-98F14.11 -5.95 5.13e-09 2.18e-06 -0.32 -0.26 Platelet distribution width; chr13:113243006 chr13:113165002~113165183:- LUSC cis rs1387259 0.79 rs2732445 ENSG00000240399.1 RP1-228P16.1 5.95 5.14e-09 2.18e-06 0.28 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48251750 chr12:48054813~48055591:- LUSC cis rs2732480 0.5 rs2932093 ENSG00000240399.1 RP1-228P16.1 5.95 5.14e-09 2.18e-06 0.28 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48254488 chr12:48054813~48055591:- LUSC cis rs6570726 0.738 rs7746330 ENSG00000235652.6 RP11-545I5.3 5.95 5.15e-09 2.19e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145578121 chr6:145799409~145886585:+ LUSC cis rs904251 0.698 rs2646926 ENSG00000204110.6 RP1-153P14.8 -5.95 5.15e-09 2.19e-06 -0.27 -0.26 Cognitive performance; chr6:37457212 chr6:37507348~37535616:+ LUSC cis rs7267979 0.816 rs422148 ENSG00000274973.1 RP13-401N8.7 -5.95 5.15e-09 2.19e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25531968 chr20:25845497~25845862:+ LUSC cis rs71403859 0.614 rs12447033 ENSG00000260886.1 TAT-AS1 5.95 5.15e-09 2.19e-06 0.4 0.26 Post bronchodilator FEV1; chr16:71549752 chr16:71565789~71578187:+ LUSC cis rs7267979 0.873 rs6037062 ENSG00000274973.1 RP13-401N8.7 -5.95 5.16e-09 2.19e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25222256 chr20:25845497~25845862:+ LUSC cis rs875971 0.597 rs11763224 ENSG00000237310.1 GS1-124K5.4 5.95 5.18e-09 2.2e-06 0.31 0.26 Aortic root size; chr7:66518628 chr7:66493706~66495474:+ LUSC cis rs8059260 0.696 rs2110354 ENSG00000274038.1 RP11-66H6.4 -5.95 5.18e-09 2.2e-06 -0.38 -0.26 Alcohol consumption over the past year; chr16:11013635 chr16:11056556~11057034:+ LUSC cis rs1823913 0.637 rs6434461 ENSG00000280083.1 RP11-317J9.1 5.95 5.18e-09 2.2e-06 0.31 0.26 Obesity-related traits; chr2:191302661 chr2:191154118~191156070:- LUSC cis rs1823913 0.614 rs6434462 ENSG00000280083.1 RP11-317J9.1 5.95 5.18e-09 2.2e-06 0.31 0.26 Obesity-related traits; chr2:191302705 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs6750360 ENSG00000280083.1 RP11-317J9.1 5.95 5.18e-09 2.2e-06 0.31 0.26 Obesity-related traits; chr2:191303089 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs11677694 ENSG00000280083.1 RP11-317J9.1 5.95 5.18e-09 2.2e-06 0.31 0.26 Obesity-related traits; chr2:191303203 chr2:191154118~191156070:- LUSC cis rs1823913 0.571 rs6737307 ENSG00000280083.1 RP11-317J9.1 5.95 5.18e-09 2.2e-06 0.31 0.26 Obesity-related traits; chr2:191303247 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs4853582 ENSG00000280083.1 RP11-317J9.1 5.95 5.18e-09 2.2e-06 0.31 0.26 Obesity-related traits; chr2:191303483 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs35200176 ENSG00000280083.1 RP11-317J9.1 5.95 5.18e-09 2.2e-06 0.31 0.26 Obesity-related traits; chr2:191303534 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs17348013 ENSG00000280083.1 RP11-317J9.1 5.95 5.18e-09 2.2e-06 0.31 0.26 Obesity-related traits; chr2:191303726 chr2:191154118~191156070:- LUSC cis rs950880 0.677 rs17027087 ENSG00000234389.1 AC007278.3 -5.95 5.19e-09 2.2e-06 -0.29 -0.26 Serum protein levels (sST2); chr2:102399458 chr2:102438713~102440475:+ LUSC cis rs6772849 0.93 rs12487604 ENSG00000277250.1 Metazoa_SRP -5.95 5.19e-09 2.2e-06 -0.3 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128618232 chr3:128673681~128674021:- LUSC cis rs6570726 0.935 rs419854 ENSG00000235652.6 RP11-545I5.3 5.95 5.19e-09 2.2e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145522949 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs365658 ENSG00000235652.6 RP11-545I5.3 5.95 5.19e-09 2.2e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145523452 chr6:145799409~145886585:+ LUSC cis rs2243480 1 rs4718269 ENSG00000226824.5 RP4-756H11.3 5.95 5.19e-09 2.2e-06 0.49 0.26 Diabetic kidney disease; chr7:65735810 chr7:66654538~66669855:+ LUSC cis rs6969780 0.915 rs11983200 ENSG00000233429.8 HOTAIRM1 5.95 5.19e-09 2.2e-06 0.52 0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27146977 chr7:27095647~27100265:+ LUSC cis rs4366055 1 rs4366055 ENSG00000253175.1 RP11-267M23.6 5.95 5.19e-09 2.2e-06 0.3 0.26 Body mass index; chr8:94495100 chr8:94565036~94565715:+ LUSC cis rs6142102 0.602 rs4911145 ENSG00000275784.1 RP5-1125A11.6 5.95 5.2e-09 2.2e-06 0.28 0.26 Skin pigmentation; chr20:34027417 chr20:33989480~33991818:- LUSC cis rs17507216 0.518 rs1877240 ENSG00000278603.1 RP13-608F4.5 5.95 5.2e-09 2.21e-06 0.44 0.26 Excessive daytime sleepiness; chr15:82770126 chr15:82472203~82472426:+ LUSC cis rs13113518 0.966 rs13144598 ENSG00000273257.1 RP11-177J6.1 5.95 5.2e-09 2.21e-06 0.34 0.26 Height; chr4:55570311 chr4:55387949~55388271:+ LUSC cis rs2337406 0.587 rs10129888 ENSG00000274576.2 IGHV2-70 -5.95 5.21e-09 2.21e-06 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106647421 chr14:106770577~106771020:- LUSC cis rs11098499 0.954 rs6820115 ENSG00000250412.1 KLHL2P1 5.95 5.21e-09 2.21e-06 0.32 0.26 Corneal astigmatism; chr4:119477027 chr4:119334329~119378233:+ LUSC cis rs7267979 1 rs2482919 ENSG00000274973.1 RP13-401N8.7 5.95 5.21e-09 2.21e-06 0.27 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25319120 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs6037086 ENSG00000274973.1 RP13-401N8.7 5.95 5.21e-09 2.21e-06 0.27 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25325702 chr20:25845497~25845862:+ LUSC cis rs13113518 0.966 rs11942472 ENSG00000223305.1 RN7SKP30 5.95 5.21e-09 2.21e-06 0.32 0.26 Height; chr4:55574959 chr4:55540502~55540835:- LUSC cis rs13113518 0.841 rs11133400 ENSG00000223305.1 RN7SKP30 5.95 5.22e-09 2.21e-06 0.32 0.26 Height; chr4:55578787 chr4:55540502~55540835:- LUSC cis rs748404 0.556 rs7166467 ENSG00000249839.1 AC011330.5 5.95 5.22e-09 2.21e-06 0.34 0.26 Lung cancer; chr15:43148324 chr15:43663654~43684339:- LUSC cis rs875971 0.66 rs801193 ENSG00000224316.1 RP11-479O9.2 -5.95 5.22e-09 2.21e-06 -0.25 -0.26 Aortic root size; chr7:66565625 chr7:65773620~65802067:+ LUSC cis rs950880 0.71 rs17027006 ENSG00000234389.1 AC007278.3 5.95 5.23e-09 2.22e-06 0.28 0.26 Serum protein levels (sST2); chr2:102348872 chr2:102438713~102440475:+ LUSC cis rs7712401 0.601 rs246322 ENSG00000263432.2 RN7SL689P -5.95 5.23e-09 2.22e-06 -0.33 -0.26 Mean platelet volume; chr5:122971574 chr5:123022487~123022783:- LUSC cis rs67311347 0.955 rs4974067 ENSG00000223797.4 ENTPD3-AS1 5.95 5.24e-09 2.22e-06 0.29 0.26 Renal cell carcinoma; chr3:40333060 chr3:40313802~40453329:- LUSC cis rs1864400 0.605 rs12360493 ENSG00000273008.1 RP11-351D16.3 5.95 5.24e-09 2.22e-06 0.29 0.26 Hirschsprung disease; chr10:43223165 chr10:43136824~43138334:- LUSC cis rs11098499 0.675 rs11098534 ENSG00000250412.1 KLHL2P1 5.95 5.26e-09 2.23e-06 0.32 0.26 Corneal astigmatism; chr4:119635617 chr4:119334329~119378233:+ LUSC cis rs77204473 0.744 rs3781985 ENSG00000254851.1 RP11-109L13.1 5.95 5.26e-09 2.23e-06 0.6 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117194350 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs11606480 ENSG00000254851.1 RP11-109L13.1 5.95 5.26e-09 2.23e-06 0.6 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117194817 chr11:117135528~117138582:+ LUSC cis rs2276314 0.857 rs56230698 ENSG00000278986.1 RP11-723J4.3 -5.95 5.26e-09 2.23e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36048922 chr18:35972151~35973916:+ LUSC cis rs17507216 1 rs17356118 ENSG00000276710.3 CSPG4P8 -5.95 5.27e-09 2.23e-06 -0.31 -0.26 Excessive daytime sleepiness; chr15:82569149 chr15:82459472~82477258:+ LUSC cis rs172166 0.694 rs203884 ENSG00000219392.1 RP1-265C24.5 -5.95 5.28e-09 2.23e-06 -0.34 -0.26 Cardiac Troponin-T levels; chr6:28109596 chr6:28115628~28116551:+ LUSC cis rs7246657 0.765 rs10402455 ENSG00000276846.1 CTD-3220F14.3 5.95 5.28e-09 2.24e-06 0.43 0.26 Coronary artery calcification; chr19:37237805 chr19:37314868~37315620:- LUSC cis rs6565180 0.963 rs4787642 ENSG00000183604.13 SMG1P5 -5.95 5.29e-09 2.24e-06 -0.32 -0.26 Tonsillectomy; chr16:30348087 chr16:30267553~30335374:- LUSC cis rs2732480 0.557 rs923397 ENSG00000273765.1 RP11-370I10.11 5.95 5.29e-09 2.24e-06 0.31 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48326609 chr12:48360920~48361377:+ LUSC cis rs2732480 0.557 rs2409004 ENSG00000273765.1 RP11-370I10.11 5.95 5.29e-09 2.24e-06 0.31 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48327668 chr12:48360920~48361377:+ LUSC cis rs2732480 0.577 rs2450994 ENSG00000273765.1 RP11-370I10.11 5.95 5.29e-09 2.24e-06 0.31 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48328049 chr12:48360920~48361377:+ LUSC cis rs2404602 0.647 rs3812908 ENSG00000259422.1 RP11-593F23.1 5.95 5.29e-09 2.24e-06 0.31 0.26 Blood metabolite levels; chr15:76883817 chr15:76174891~76181486:- LUSC cis rs2243480 1 rs2465120 ENSG00000226824.5 RP4-756H11.3 -5.95 5.29e-09 2.24e-06 -0.51 -0.26 Diabetic kidney disease; chr7:66155987 chr7:66654538~66669855:+ LUSC cis rs2243480 0.908 rs2460431 ENSG00000226824.5 RP4-756H11.3 5.95 5.29e-09 2.24e-06 0.51 0.26 Diabetic kidney disease; chr7:66157859 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs4718309 ENSG00000226824.5 RP4-756H11.3 5.95 5.29e-09 2.24e-06 0.51 0.26 Diabetic kidney disease; chr7:66162777 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs6460274 ENSG00000226824.5 RP4-756H11.3 5.95 5.29e-09 2.24e-06 0.51 0.26 Diabetic kidney disease; chr7:66163497 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs7787230 ENSG00000226824.5 RP4-756H11.3 5.95 5.29e-09 2.24e-06 0.51 0.26 Diabetic kidney disease; chr7:66164112 chr7:66654538~66669855:+ LUSC cis rs2243480 0.711 rs2420172 ENSG00000226824.5 RP4-756H11.3 5.95 5.29e-09 2.24e-06 0.51 0.26 Diabetic kidney disease; chr7:66170354 chr7:66654538~66669855:+ LUSC cis rs11722779 0.844 rs10003326 ENSG00000230069.3 LRRC37A15P -5.95 5.3e-09 2.24e-06 -0.28 -0.26 Schizophrenia; chr4:102948193 chr4:102727274~102730721:- LUSC cis rs149313 0.901 rs697976 ENSG00000248734.2 CTD-2260A17.1 5.95 5.31e-09 2.25e-06 0.25 0.26 Blood protein levels; chr5:96733063 chr5:96784777~96785999:+ LUSC cis rs35160687 0.644 rs1863058 ENSG00000273080.1 RP11-301O19.1 -5.95 5.31e-09 2.25e-06 -0.25 -0.26 Night sleep phenotypes; chr2:86282144 chr2:86195590~86196049:+ LUSC cis rs11722779 0.838 rs4533776 ENSG00000230069.3 LRRC37A15P -5.95 5.31e-09 2.25e-06 -0.28 -0.26 Schizophrenia; chr4:102912732 chr4:102727274~102730721:- LUSC cis rs67180937 0.553 rs3008629 ENSG00000272750.1 RP11-378J18.8 5.95 5.32e-09 2.25e-06 0.34 0.26 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222662588 chr1:222658867~222661512:- LUSC cis rs227275 0.554 rs9307281 ENSG00000230069.3 LRRC37A15P -5.95 5.32e-09 2.25e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102934971 chr4:102727274~102730721:- LUSC cis rs11722779 0.903 rs6533037 ENSG00000230069.3 LRRC37A15P -5.95 5.32e-09 2.25e-06 -0.28 -0.26 Schizophrenia; chr4:102935865 chr4:102727274~102730721:- LUSC cis rs11722779 0.903 rs4530634 ENSG00000230069.3 LRRC37A15P -5.95 5.32e-09 2.25e-06 -0.28 -0.26 Schizophrenia; chr4:102937924 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs7676943 ENSG00000230069.3 LRRC37A15P -5.95 5.32e-09 2.25e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102938135 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs6419160 ENSG00000230069.3 LRRC37A15P -5.95 5.32e-09 2.25e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102938648 chr4:102727274~102730721:- LUSC cis rs761746 0.739 rs5994420 ENSG00000236132.1 CTA-440B3.1 -5.95 5.32e-09 2.25e-06 -0.38 -0.26 Intelligence; chr22:31674765 chr22:31816379~31817491:- LUSC cis rs7267979 1 rs884613 ENSG00000274973.1 RP13-401N8.7 5.95 5.32e-09 2.25e-06 0.27 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25307869 chr20:25845497~25845862:+ LUSC cis rs7267979 1 rs1888998 ENSG00000274973.1 RP13-401N8.7 5.95 5.32e-09 2.25e-06 0.27 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25311190 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2500433 ENSG00000274973.1 RP13-401N8.7 5.95 5.32e-09 2.25e-06 0.27 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25315699 chr20:25845497~25845862:+ LUSC cis rs7267979 0.966 rs2482948 ENSG00000274973.1 RP13-401N8.7 5.95 5.32e-09 2.25e-06 0.27 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25315863 chr20:25845497~25845862:+ LUSC cis rs7657257 1 rs16892283 ENSG00000214846.4 RP11-115L11.1 5.95 5.32e-09 2.25e-06 0.69 0.26 Blood protein levels; chr4:15729911 chr4:15730962~15731627:- LUSC cis rs1056107 0.931 rs7033486 ENSG00000225513.1 RP11-165N19.2 5.95 5.34e-09 2.26e-06 0.29 0.26 Colorectal cancer; chr9:112248027 chr9:112173522~112173971:- LUSC cis rs6570726 0.791 rs10457788 ENSG00000235652.6 RP11-545I5.3 5.95 5.34e-09 2.26e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145600000 chr6:145799409~145886585:+ LUSC cis rs6504950 0.85 rs2541242 ENSG00000275710.1 RP11-257O5.4 -5.95 5.34e-09 2.26e-06 -0.33 -0.26 Breast cancer; chr17:55012326 chr17:54964474~54964679:+ LUSC cis rs6772849 0.768 rs4521246 ENSG00000277250.1 Metazoa_SRP 5.95 5.35e-09 2.26e-06 0.31 0.26 Monocyte percentage of white cells;Monocyte count; chr3:128702323 chr3:128673681~128674021:- LUSC cis rs11098499 0.73 rs12505735 ENSG00000248280.1 RP11-33B1.2 5.95 5.35e-09 2.26e-06 0.31 0.26 Corneal astigmatism; chr4:119611801 chr4:119440561~119450157:- LUSC cis rs881375 0.678 rs7037195 ENSG00000226752.6 PSMD5-AS1 -5.95 5.35e-09 2.26e-06 -0.29 -0.26 Rheumatoid arthritis; chr9:120921722 chr9:120824828~120854385:+ LUSC cis rs2153535 0.623 rs2152346 ENSG00000230939.1 RP11-314C16.1 -5.95 5.35e-09 2.26e-06 -0.31 -0.26 Motion sickness; chr6:8454419 chr6:8784178~8785445:+ LUSC cis rs2153535 0.562 rs6901765 ENSG00000230939.1 RP11-314C16.1 -5.95 5.35e-09 2.26e-06 -0.31 -0.26 Motion sickness; chr6:8455203 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs9502715 ENSG00000230939.1 RP11-314C16.1 -5.95 5.35e-09 2.26e-06 -0.31 -0.26 Motion sickness; chr6:8455476 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6912193 ENSG00000230939.1 RP11-314C16.1 -5.95 5.35e-09 2.26e-06 -0.31 -0.26 Motion sickness; chr6:8456073 chr6:8784178~8785445:+ LUSC cis rs9545047 0.604 rs1980883 ENSG00000227676.3 LINC01068 -5.95 5.36e-09 2.27e-06 -0.32 -0.26 Schizophrenia; chr13:79310629 chr13:79566727~79571436:+ LUSC cis rs7665090 1 rs7664828 ENSG00000230069.3 LRRC37A15P -5.95 5.36e-09 2.27e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102630219 chr4:102727274~102730721:- LUSC cis rs7665090 0.967 rs7690123 ENSG00000230069.3 LRRC37A15P -5.95 5.36e-09 2.27e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102630602 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs7665659 ENSG00000230069.3 LRRC37A15P -5.95 5.36e-09 2.27e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102630661 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs7665854 ENSG00000230069.3 LRRC37A15P -5.95 5.36e-09 2.27e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102630752 chr4:102727274~102730721:- LUSC cis rs7665090 0.846 rs7690700 ENSG00000230069.3 LRRC37A15P -5.95 5.36e-09 2.27e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102630911 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs13112557 ENSG00000230069.3 LRRC37A15P -5.95 5.36e-09 2.27e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102631096 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs12644381 ENSG00000230069.3 LRRC37A15P -5.95 5.36e-09 2.27e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102631273 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs1054037 ENSG00000230069.3 LRRC37A15P -5.95 5.36e-09 2.27e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102631552 chr4:102727274~102730721:- LUSC cis rs1823913 0.637 rs1349938 ENSG00000280083.1 RP11-317J9.1 5.95 5.37e-09 2.27e-06 0.31 0.26 Obesity-related traits; chr2:191299970 chr2:191154118~191156070:- LUSC cis rs1823913 0.592 rs1349939 ENSG00000280083.1 RP11-317J9.1 5.95 5.37e-09 2.27e-06 0.31 0.26 Obesity-related traits; chr2:191300079 chr2:191154118~191156070:- LUSC cis rs761746 0.739 rs131233 ENSG00000236132.1 CTA-440B3.1 -5.95 5.37e-09 2.27e-06 -0.4 -0.26 Intelligence; chr22:31721114 chr22:31816379~31817491:- LUSC cis rs5770917 1 rs3213446 ENSG00000273272.1 CTA-384D8.34 5.95 5.38e-09 2.28e-06 0.53 0.26 Narcolepsy; chr22:50577245 chr22:50542650~50543011:+ LUSC cis rs12468226 1 rs75040639 ENSG00000272966.1 RP11-686O6.1 5.95 5.39e-09 2.28e-06 0.43 0.26 Urate levels; chr2:202486973 chr2:202336739~202337200:+ LUSC cis rs1387259 0.859 rs2054905 ENSG00000240399.1 RP1-228P16.1 5.95 5.39e-09 2.28e-06 0.28 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48294168 chr12:48054813~48055591:- LUSC cis rs2732480 0.5 rs2732461 ENSG00000240399.1 RP1-228P16.1 5.95 5.39e-09 2.28e-06 0.28 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48299019 chr12:48054813~48055591:- LUSC cis rs116095464 0.558 rs7708182 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:234673 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs10058428 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:235493 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs10036253 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:238404 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs10076655 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:239349 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs10057492 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:239388 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs28418643 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:240744 chr5:288833~290321:- LUSC cis rs116095464 0.614 rs62344339 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:252880 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs9687898 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:253837 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs9688045 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:253920 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs112343653 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:257059 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs73024831 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:257077 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs62344345 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:257305 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs57335027 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:262792 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6869925 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:263921 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6875291 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:264077 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6866776 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:264380 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs6874745 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:264412 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs7715108 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:264546 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs7730700 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:264598 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs10057674 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:266698 chr5:288833~290321:- LUSC cis rs116095464 0.558 rs1812843 ENSG00000250848.1 CTD-2083E4.5 -5.94 5.4e-09 2.28e-06 -0.39 -0.26 Breast cancer; chr5:267543 chr5:288833~290321:- LUSC cis rs4718428 0.705 rs62465692 ENSG00000226824.5 RP4-756H11.3 -5.94 5.41e-09 2.28e-06 -0.36 -0.26 Corneal structure; chr7:66830758 chr7:66654538~66669855:+ LUSC cis rs14027 0.921 rs13262434 ENSG00000279347.1 RP11-85I17.2 -5.94 5.41e-09 2.28e-06 -0.25 -0.26 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119733423 chr8:119838736~119840385:- LUSC cis rs12130219 1 rs1552994 ENSG00000237975.5 FLG-AS1 5.94 5.41e-09 2.28e-06 0.31 0.26 Inflammatory skin disease; chr1:152198985 chr1:152168125~152445456:+ LUSC cis rs12130219 1 rs12733173 ENSG00000237975.5 FLG-AS1 5.94 5.41e-09 2.28e-06 0.31 0.26 Inflammatory skin disease; chr1:152201496 chr1:152168125~152445456:+ LUSC cis rs8062405 0.965 rs8049439 ENSG00000278665.1 RP11-666O2.4 5.94 5.41e-09 2.28e-06 0.26 0.26 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826194 chr16:28599241~28601881:- LUSC cis rs1823913 0.614 rs11693878 ENSG00000280083.1 RP11-317J9.1 5.94 5.42e-09 2.29e-06 0.31 0.26 Obesity-related traits; chr2:191299399 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs10931494 ENSG00000280083.1 RP11-317J9.1 5.94 5.42e-09 2.29e-06 0.31 0.26 Obesity-related traits; chr2:191299442 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs10931495 ENSG00000280083.1 RP11-317J9.1 5.94 5.42e-09 2.29e-06 0.31 0.26 Obesity-related traits; chr2:191299447 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs12623156 ENSG00000280083.1 RP11-317J9.1 5.94 5.42e-09 2.29e-06 0.31 0.26 Obesity-related traits; chr2:191299661 chr2:191154118~191156070:- LUSC cis rs11159086 1 rs8006958 ENSG00000259005.1 RP3-449M8.6 5.94 5.42e-09 2.29e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74478148 chr14:74474007~74474864:- LUSC cis rs77204473 0.744 rs12419178 ENSG00000254851.1 RP11-109L13.1 5.94 5.42e-09 2.29e-06 0.6 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117180202 chr11:117135528~117138582:+ LUSC cis rs6570726 0.935 rs432086 ENSG00000235652.6 RP11-545I5.3 -5.94 5.43e-09 2.29e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145520457 chr6:145799409~145886585:+ LUSC cis rs16843372 0.562 rs34525522 ENSG00000251491.2 OR7E28P -5.94 5.43e-09 2.29e-06 -0.29 -0.26 Obesity-related traits; chr2:158837311 chr2:158862311~158863285:+ LUSC cis rs853679 0.76 rs2299029 ENSG00000204709.4 LINC01556 5.94 5.43e-09 2.29e-06 0.39 0.26 Depression; chr6:28231053 chr6:28943877~28944537:+ LUSC cis rs13113518 1 rs4865007 ENSG00000273257.1 RP11-177J6.1 -5.94 5.44e-09 2.29e-06 -0.34 -0.26 Height; chr4:55537550 chr4:55387949~55388271:+ LUSC cis rs2834288 0.7 rs2409502 ENSG00000273102.1 AP000569.9 -5.94 5.44e-09 2.3e-06 -0.3 -0.26 Gut microbiota (bacterial taxa); chr21:33902431 chr21:33967101~33968573:- LUSC cis rs8005677 0.926 rs34344888 ENSG00000279656.1 RP11-298I3.6 5.94 5.45e-09 2.3e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22918376 chr14:23023083~23024217:- LUSC cis rs8005677 0.962 rs34917191 ENSG00000279656.1 RP11-298I3.6 5.94 5.45e-09 2.3e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22918419 chr14:23023083~23024217:- LUSC cis rs8005677 1 rs2295683 ENSG00000279656.1 RP11-298I3.6 5.94 5.45e-09 2.3e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22919173 chr14:23023083~23024217:- LUSC cis rs8005677 1 rs4981449 ENSG00000279656.1 RP11-298I3.6 5.94 5.45e-09 2.3e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22919662 chr14:23023083~23024217:- LUSC cis rs67311347 1 rs17078511 ENSG00000223797.4 ENTPD3-AS1 5.94 5.45e-09 2.3e-06 0.3 0.26 Renal cell carcinoma; chr3:40354763 chr3:40313802~40453329:- LUSC cis rs875971 0.862 rs6964437 ENSG00000179406.6 LINC00174 5.94 5.45e-09 2.3e-06 0.28 0.26 Aortic root size; chr7:66221457 chr7:66376044~66401338:- LUSC cis rs2179367 0.632 rs9498321 ENSG00000231760.4 RP11-350J20.5 5.94 5.46e-09 2.3e-06 0.38 0.26 Dupuytren's disease; chr6:149322573 chr6:149796151~149826294:- LUSC cis rs77204473 0.744 rs2046149 ENSG00000254851.1 RP11-109L13.1 5.94 5.47e-09 2.3e-06 0.6 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117183993 chr11:117135528~117138582:+ LUSC cis rs1134634 0.52 rs4393989 ENSG00000273133.1 RP11-799M12.2 -5.94 5.48e-09 2.31e-06 -0.35 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15614276 chr4:15563698~15564253:- LUSC cis rs11098499 0.863 rs2170276 ENSG00000248280.1 RP11-33B1.2 5.94 5.48e-09 2.31e-06 0.32 0.26 Corneal astigmatism; chr4:119564669 chr4:119440561~119450157:- LUSC cis rs4713118 0.955 rs9468204 ENSG00000280107.1 AL022393.9 -5.94 5.49e-09 2.31e-06 -0.31 -0.26 Parkinson's disease; chr6:27721030 chr6:28170845~28172521:+ LUSC cis rs11089937 0.667 rs9622981 ENSG00000211638.2 IGLV8-61 -5.94 5.5e-09 2.32e-06 -0.28 -0.26 Periodontitis (PAL4Q3); chr22:22150100 chr22:22098700~22099212:+ LUSC cis rs66887589 0.807 rs9799664 ENSG00000249244.1 RP11-548H18.2 5.94 5.5e-09 2.32e-06 0.31 0.26 Diastolic blood pressure; chr4:119405523 chr4:119391831~119395335:- LUSC cis rs113835537 0.935 rs76228630 ENSG00000255517.5 CTD-3074O7.5 -5.94 5.51e-09 2.32e-06 -0.36 -0.26 Airway imaging phenotypes; chr11:66691205 chr11:66473490~66480233:- LUSC cis rs2276314 0.857 rs28435069 ENSG00000278986.1 RP11-723J4.3 -5.94 5.52e-09 2.32e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36048512 chr18:35972151~35973916:+ LUSC cis rs2276314 0.857 rs8087539 ENSG00000278986.1 RP11-723J4.3 -5.94 5.52e-09 2.32e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36051574 chr18:35972151~35973916:+ LUSC cis rs12908161 1 rs12903134 ENSG00000259728.4 LINC00933 5.94 5.52e-09 2.33e-06 0.34 0.26 Schizophrenia; chr15:84794468 chr15:84570649~84580175:+ LUSC cis rs8059260 0.604 rs34215426 ENSG00000274038.1 RP11-66H6.4 -5.94 5.52e-09 2.33e-06 -0.46 -0.26 Alcohol consumption over the past year; chr16:11113614 chr16:11056556~11057034:+ LUSC cis rs8059260 0.736 rs8046423 ENSG00000274038.1 RP11-66H6.4 -5.94 5.52e-09 2.33e-06 -0.51 -0.26 Alcohol consumption over the past year; chr16:10964016 chr16:11056556~11057034:+ LUSC cis rs1021993 0.545 rs4844815 ENSG00000231648.1 RP11-372M18.2 -5.94 5.53e-09 2.33e-06 -0.37 -0.26 Gut microbiome composition (winter); chr1:209356309 chr1:209367662~209379690:+ LUSC cis rs875971 0.545 rs73376401 ENSG00000224316.1 RP11-479O9.2 5.94 5.53e-09 2.33e-06 0.28 0.26 Aortic root size; chr7:66174841 chr7:65773620~65802067:+ LUSC cis rs2153535 0.58 rs6597332 ENSG00000230939.1 RP11-314C16.1 -5.94 5.53e-09 2.33e-06 -0.31 -0.26 Motion sickness; chr6:8504515 chr6:8784178~8785445:+ LUSC cis rs35740288 0.77 rs11630286 ENSG00000202081.1 RNU6-1280P 5.94 5.54e-09 2.33e-06 0.32 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85659298 chr15:85651522~85651628:- LUSC cis rs6570726 1 rs404229 ENSG00000235652.6 RP11-545I5.3 5.94 5.54e-09 2.33e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145547064 chr6:145799409~145886585:+ LUSC cis rs17270561 0.609 rs4712968 ENSG00000272462.2 U91328.19 -5.94 5.55e-09 2.34e-06 -0.31 -0.26 Iron status biomarkers; chr6:25760116 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs7769908 ENSG00000272462.2 U91328.19 -5.94 5.55e-09 2.34e-06 -0.31 -0.26 Iron status biomarkers; chr6:25760311 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs7770037 ENSG00000272462.2 U91328.19 -5.94 5.55e-09 2.34e-06 -0.31 -0.26 Iron status biomarkers; chr6:25760363 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs9348695 ENSG00000272462.2 U91328.19 -5.94 5.55e-09 2.34e-06 -0.31 -0.26 Iron status biomarkers; chr6:25762782 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs2000350 ENSG00000272462.2 U91328.19 -5.94 5.55e-09 2.34e-06 -0.31 -0.26 Iron status biomarkers; chr6:25762926 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs1318016 ENSG00000272462.2 U91328.19 -5.94 5.55e-09 2.34e-06 -0.31 -0.26 Iron status biomarkers; chr6:25764476 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs1892245 ENSG00000272462.2 U91328.19 -5.94 5.55e-09 2.34e-06 -0.31 -0.26 Iron status biomarkers; chr6:25764605 chr6:25992662~26001775:+ LUSC cis rs17270561 0.583 rs6937800 ENSG00000272462.2 U91328.19 -5.94 5.55e-09 2.34e-06 -0.31 -0.26 Iron status biomarkers; chr6:25765715 chr6:25992662~26001775:+ LUSC cis rs4604732 0.631 rs4436425 ENSG00000227135.1 GCSAML-AS1 -5.94 5.55e-09 2.34e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247469021 chr1:247524679~247526752:- LUSC cis rs13113518 1 rs56154935 ENSG00000273257.1 RP11-177J6.1 5.94 5.55e-09 2.34e-06 0.34 0.26 Height; chr4:55546378 chr4:55387949~55388271:+ LUSC cis rs4713118 0.547 rs2116981 ENSG00000280107.1 AL022393.9 -5.94 5.57e-09 2.34e-06 -0.33 -0.26 Parkinson's disease; chr6:28100173 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9368552 ENSG00000280107.1 AL022393.9 -5.94 5.57e-09 2.34e-06 -0.33 -0.26 Depression; chr6:28100648 chr6:28170845~28172521:+ LUSC cis rs853679 0.542 rs34131763 ENSG00000280107.1 AL022393.9 -5.94 5.57e-09 2.34e-06 -0.33 -0.26 Depression; chr6:28107222 chr6:28170845~28172521:+ LUSC cis rs11603023 0.967 rs654423 ENSG00000255422.1 AP002954.4 5.94 5.57e-09 2.34e-06 0.3 0.26 Cholesterol, total; chr11:118641039 chr11:118704607~118750263:+ LUSC cis rs7772486 0.806 rs2253648 ENSG00000235652.6 RP11-545I5.3 5.94 5.57e-09 2.34e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145878160 chr6:145799409~145886585:+ LUSC cis rs761746 0.739 rs131225 ENSG00000236132.1 CTA-440B3.1 -5.94 5.57e-09 2.35e-06 -0.39 -0.26 Intelligence; chr22:31717863 chr22:31816379~31817491:- LUSC cis rs4372836 0.964 rs4665431 ENSG00000226833.4 AC097724.3 -5.94 5.59e-09 2.35e-06 -0.31 -0.26 Body mass index; chr2:28715302 chr2:28708953~28736205:- LUSC cis rs11846409 0.872 rs2516914 ENSG00000274576.2 IGHV2-70 5.94 5.59e-09 2.35e-06 0.27 0.26 Rheumatic heart disease; chr14:106629835 chr14:106770577~106771020:- LUSC cis rs17270561 0.609 rs2000351 ENSG00000272462.2 U91328.19 -5.94 5.6e-09 2.36e-06 -0.31 -0.26 Iron status biomarkers; chr6:25759555 chr6:25992662~26001775:+ LUSC cis rs875971 0.862 rs6460282 ENSG00000179406.6 LINC00174 5.94 5.6e-09 2.36e-06 0.29 0.26 Aortic root size; chr7:66226259 chr7:66376044~66401338:- LUSC cis rs2732480 0.557 rs923397 ENSG00000226413.2 OR8T1P 5.94 5.6e-09 2.36e-06 0.34 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48326609 chr12:48442030~48442947:- LUSC cis rs2732480 0.557 rs2409004 ENSG00000226413.2 OR8T1P 5.94 5.6e-09 2.36e-06 0.34 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48327668 chr12:48442030~48442947:- LUSC cis rs2732480 0.577 rs2450994 ENSG00000226413.2 OR8T1P 5.94 5.6e-09 2.36e-06 0.34 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48328049 chr12:48442030~48442947:- LUSC cis rs6570726 0.791 rs443628 ENSG00000235652.6 RP11-545I5.3 5.94 5.6e-09 2.36e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145562348 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs6915094 ENSG00000235652.6 RP11-545I5.3 5.94 5.6e-09 2.36e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145562404 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs365869 ENSG00000235652.6 RP11-545I5.3 5.94 5.6e-09 2.36e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145563615 chr6:145799409~145886585:+ LUSC cis rs8177876 0.642 rs12445303 ENSG00000261838.4 RP11-303E16.6 -5.94 5.6e-09 2.36e-06 -0.59 -0.26 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081968 chr16:81069854~81076598:+ LUSC cis rs4789693 1 rs4789693 ENSG00000265458.1 RP13-20L14.6 5.94 5.61e-09 2.36e-06 0.32 0.26 Glucocorticoid-induced osteonecrosis; chr17:82463994 chr17:82454273~82458521:- LUSC cis rs6772849 0.83 rs7633674 ENSG00000277250.1 Metazoa_SRP -5.94 5.62e-09 2.36e-06 -0.29 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128636183 chr3:128673681~128674021:- LUSC cis rs6504950 0.888 rs244320 ENSG00000275710.1 RP11-257O5.4 5.94 5.62e-09 2.36e-06 0.31 0.26 Breast cancer; chr17:55145559 chr17:54964474~54964679:+ LUSC cis rs7772486 0.79 rs1062067 ENSG00000235652.6 RP11-545I5.3 5.94 5.62e-09 2.36e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145886427 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2256998 ENSG00000235652.6 RP11-545I5.3 5.94 5.62e-09 2.36e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145886521 chr6:145799409~145886585:+ LUSC cis rs2834288 0.535 rs7278341 ENSG00000273102.1 AP000569.9 5.94 5.62e-09 2.36e-06 0.29 0.26 Gut microbiota (bacterial taxa); chr21:33961692 chr21:33967101~33968573:- LUSC cis rs2834288 0.535 rs7279183 ENSG00000273102.1 AP000569.9 5.94 5.62e-09 2.36e-06 0.29 0.26 Gut microbiota (bacterial taxa); chr21:33961701 chr21:33967101~33968573:- LUSC cis rs77204473 0.744 rs11216253 ENSG00000254851.1 RP11-109L13.1 5.94 5.62e-09 2.36e-06 0.63 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117057509 chr11:117135528~117138582:+ LUSC cis rs6570726 0.935 rs397418 ENSG00000235652.6 RP11-545I5.3 5.94 5.63e-09 2.37e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145521226 chr6:145799409~145886585:+ LUSC cis rs2243480 1 rs431076 ENSG00000226824.5 RP4-756H11.3 -5.94 5.64e-09 2.37e-06 -0.51 -0.26 Diabetic kidney disease; chr7:66135333 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs2257790 ENSG00000226824.5 RP4-756H11.3 -5.94 5.64e-09 2.37e-06 -0.51 -0.26 Diabetic kidney disease; chr7:66135463 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs2460422 ENSG00000226824.5 RP4-756H11.3 -5.94 5.64e-09 2.37e-06 -0.51 -0.26 Diabetic kidney disease; chr7:66136518 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs316334 ENSG00000226824.5 RP4-756H11.3 -5.94 5.64e-09 2.37e-06 -0.51 -0.26 Diabetic kidney disease; chr7:66137139 chr7:66654538~66669855:+ LUSC cis rs34779708 0.702 rs7087150 ENSG00000230534.5 RP11-297A16.2 5.94 5.66e-09 2.38e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35253210 chr10:35098006~35127020:- LUSC cis rs7267979 0.74 rs2259961 ENSG00000274973.1 RP13-401N8.7 -5.94 5.66e-09 2.38e-06 -0.26 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25301990 chr20:25845497~25845862:+ LUSC cis rs7267979 0.844 rs2474780 ENSG00000274973.1 RP13-401N8.7 -5.94 5.66e-09 2.38e-06 -0.26 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25305199 chr20:25845497~25845862:+ LUSC cis rs4713118 0.955 rs9368529 ENSG00000280107.1 AL022393.9 -5.94 5.66e-09 2.38e-06 -0.31 -0.26 Parkinson's disease; chr6:27716852 chr6:28170845~28172521:+ LUSC cis rs79349575 0.783 rs17708633 ENSG00000270781.1 RP11-501C14.9 -5.94 5.67e-09 2.38e-06 -0.27 -0.26 Type 2 diabetes; chr17:48934258 chr17:48899131~48899748:+ LUSC cis rs6907340 0.513 rs6938418 ENSG00000227116.1 RP3-471C18.1 5.94 5.67e-09 2.38e-06 0.35 0.26 Endometriosis; chr6:19808802 chr6:19730427~19734567:- LUSC cis rs8005677 1 rs1951119 ENSG00000279656.1 RP11-298I3.6 5.94 5.68e-09 2.39e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22919117 chr14:23023083~23024217:- LUSC cis rs61270009 0.955 rs11748798 ENSG00000247828.6 TMEM161B-AS1 5.94 5.69e-09 2.39e-06 0.31 0.26 Depressive symptoms; chr5:88354925 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs11740836 ENSG00000247828.6 TMEM161B-AS1 5.94 5.69e-09 2.39e-06 0.31 0.26 Depressive symptoms; chr5:88356311 chr5:88268895~88436685:+ LUSC cis rs61270009 0.913 rs13154590 ENSG00000247828.6 TMEM161B-AS1 5.94 5.69e-09 2.39e-06 0.31 0.26 Depressive symptoms; chr5:88357208 chr5:88268895~88436685:+ LUSC cis rs1823913 0.637 rs4853579 ENSG00000280083.1 RP11-317J9.1 5.94 5.69e-09 2.39e-06 0.31 0.26 Obesity-related traits; chr2:191297413 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs12622194 ENSG00000280083.1 RP11-317J9.1 5.94 5.69e-09 2.39e-06 0.31 0.26 Obesity-related traits; chr2:191298680 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs13019567 ENSG00000280083.1 RP11-317J9.1 5.94 5.69e-09 2.39e-06 0.31 0.26 Obesity-related traits; chr2:191298736 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs1947456 ENSG00000280083.1 RP11-317J9.1 5.94 5.69e-09 2.39e-06 0.31 0.26 Obesity-related traits; chr2:191298759 chr2:191154118~191156070:- LUSC cis rs11098499 0.863 rs9997631 ENSG00000248280.1 RP11-33B1.2 5.94 5.69e-09 2.39e-06 0.31 0.26 Corneal astigmatism; chr4:119548840 chr4:119440561~119450157:- LUSC cis rs11098499 1 rs1011054 ENSG00000249244.1 RP11-548H18.2 -5.94 5.69e-09 2.39e-06 -0.34 -0.26 Corneal astigmatism; chr4:119281232 chr4:119391831~119395335:- LUSC cis rs7267979 0.816 rs404775 ENSG00000274973.1 RP13-401N8.7 -5.94 5.69e-09 2.39e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25500481 chr20:25845497~25845862:+ LUSC cis rs7267979 0.816 rs374701 ENSG00000274973.1 RP13-401N8.7 -5.94 5.69e-09 2.39e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25502980 chr20:25845497~25845862:+ LUSC cis rs2243480 1 rs316326 ENSG00000226824.5 RP4-756H11.3 -5.94 5.69e-09 2.39e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66144466 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs316325 ENSG00000226824.5 RP4-756H11.3 -5.94 5.69e-09 2.39e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66144531 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs316321 ENSG00000226824.5 RP4-756H11.3 -5.94 5.69e-09 2.39e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66146626 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs316318 ENSG00000226824.5 RP4-756H11.3 -5.94 5.69e-09 2.39e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66147917 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs316317 ENSG00000226824.5 RP4-756H11.3 -5.94 5.69e-09 2.39e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66148650 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs316304 ENSG00000226824.5 RP4-756H11.3 -5.94 5.69e-09 2.39e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66151907 chr7:66654538~66669855:+ LUSC cis rs9309711 0.621 rs7586472 ENSG00000225234.1 TRAPPC12-AS1 -5.94 5.7e-09 2.39e-06 -0.31 -0.26 Neurofibrillary tangles; chr2:3469899 chr2:3481242~3482409:- LUSC cis rs2153535 0.58 rs7761937 ENSG00000230939.1 RP11-314C16.1 -5.94 5.7e-09 2.39e-06 -0.31 -0.26 Motion sickness; chr6:8459201 chr6:8784178~8785445:+ LUSC cis rs9545047 0.604 rs9530900 ENSG00000227676.3 LINC01068 5.94 5.71e-09 2.4e-06 0.32 0.26 Schizophrenia; chr13:79355048 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9530901 ENSG00000227676.3 LINC01068 5.94 5.71e-09 2.4e-06 0.32 0.26 Schizophrenia; chr13:79355191 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs4328330 ENSG00000227676.3 LINC01068 5.94 5.71e-09 2.4e-06 0.32 0.26 Schizophrenia; chr13:79355503 chr13:79566727~79571436:+ LUSC cis rs9545047 0.567 rs4497554 ENSG00000227676.3 LINC01068 5.94 5.71e-09 2.4e-06 0.32 0.26 Schizophrenia; chr13:79355651 chr13:79566727~79571436:+ LUSC cis rs113835537 0.866 rs59566349 ENSG00000255517.5 CTD-3074O7.5 -5.94 5.71e-09 2.4e-06 -0.36 -0.26 Airway imaging phenotypes; chr11:66598523 chr11:66473490~66480233:- LUSC cis rs875971 0.965 rs6971509 ENSG00000179406.6 LINC00174 5.94 5.71e-09 2.4e-06 0.28 0.26 Aortic root size; chr7:66249983 chr7:66376044~66401338:- LUSC cis rs79349575 0.783 rs4399576 ENSG00000270781.1 RP11-501C14.9 -5.94 5.71e-09 2.4e-06 -0.27 -0.26 Type 2 diabetes; chr17:48932473 chr17:48899131~48899748:+ LUSC cis rs79349575 0.687 rs12602179 ENSG00000270781.1 RP11-501C14.9 -5.94 5.71e-09 2.4e-06 -0.27 -0.26 Type 2 diabetes; chr17:48932672 chr17:48899131~48899748:+ LUSC cis rs11295209 1 rs11295209 ENSG00000245958.5 RP11-33B1.1 5.93 5.72e-09 2.4e-06 0.25 0.26 Plateletcrit; chr4:119559079 chr4:119454791~119552025:+ LUSC cis rs34779708 0.733 rs11010146 ENSG00000230534.5 RP11-297A16.2 5.93 5.73e-09 2.4e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35252633 chr10:35098006~35127020:- LUSC cis rs875971 0.545 rs2420456 ENSG00000237310.1 GS1-124K5.4 5.93 5.74e-09 2.41e-06 0.3 0.26 Aortic root size; chr7:66280619 chr7:66493706~66495474:+ LUSC cis rs2243480 0.831 rs57294491 ENSG00000226824.5 RP4-756H11.3 5.93 5.74e-09 2.41e-06 0.51 0.26 Diabetic kidney disease; chr7:66219914 chr7:66654538~66669855:+ LUSC cis rs7772486 0.79 rs11760 ENSG00000235652.6 RP11-545I5.3 5.93 5.75e-09 2.41e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145884837 chr6:145799409~145886585:+ LUSC cis rs13113518 0.783 rs6843722 ENSG00000249700.7 SRD5A3-AS1 5.93 5.75e-09 2.41e-06 0.31 0.26 Height; chr4:55465165 chr4:55363971~55395847:- LUSC cis rs1075265 0.568 rs3095756 ENSG00000233266.1 HMGB1P31 5.93 5.75e-09 2.41e-06 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:53822332 chr2:54051334~54051760:+ LUSC cis rs61270009 0.955 rs454830 ENSG00000247828.6 TMEM161B-AS1 -5.93 5.75e-09 2.41e-06 -0.32 -0.26 Depressive symptoms; chr5:88254678 chr5:88268895~88436685:+ LUSC cis rs763121 0.853 rs138712 ENSG00000273076.1 RP3-508I15.22 5.93 5.76e-09 2.41e-06 0.26 0.26 Menopause (age at onset); chr22:38745595 chr22:38743495~38743910:+ LUSC cis rs227275 0.525 rs7698608 ENSG00000230069.3 LRRC37A15P -5.93 5.76e-09 2.42e-06 -0.27 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:103016817 chr4:102727274~102730721:- LUSC cis rs6142102 0.778 rs6059555 ENSG00000275784.1 RP5-1125A11.6 -5.93 5.76e-09 2.42e-06 -0.31 -0.26 Skin pigmentation; chr20:33926518 chr20:33989480~33991818:- LUSC cis rs2337406 1 rs61268362 ENSG00000274576.2 IGHV2-70 -5.93 5.76e-09 2.42e-06 -0.29 -0.26 Alzheimer's disease (late onset); chr14:106697010 chr14:106770577~106771020:- LUSC cis rs6570726 0.791 rs9322029 ENSG00000235652.6 RP11-545I5.3 5.93 5.76e-09 2.42e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145585547 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs9403730 ENSG00000235652.6 RP11-545I5.3 5.93 5.76e-09 2.42e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145586097 chr6:145799409~145886585:+ LUSC cis rs2153535 0.58 rs4587214 ENSG00000230939.1 RP11-314C16.1 -5.93 5.77e-09 2.42e-06 -0.31 -0.26 Motion sickness; chr6:8453886 chr6:8784178~8785445:+ LUSC cis rs394563 0.602 rs409099 ENSG00000231760.4 RP11-350J20.5 5.93 5.77e-09 2.42e-06 0.32 0.26 Dupuytren's disease; chr6:149445727 chr6:149796151~149826294:- LUSC cis rs79349575 0.783 rs9747646 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48939520 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs62075852 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48939814 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs12601858 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48940115 chr17:48899131~48899748:+ LUSC cis rs79349575 0.715 rs55724082 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48940517 chr17:48899131~48899748:+ LUSC cis rs79349575 0.749 rs8182364 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48940663 chr17:48899131~48899748:+ LUSC cis rs79349575 0.681 rs56080003 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48941687 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs4793995 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48942037 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs4793996 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48942235 chr17:48899131~48899748:+ LUSC cis rs79349575 0.715 rs4793997 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48942310 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs4793998 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48942537 chr17:48899131~48899748:+ LUSC cis rs79349575 0.749 rs2270574 ENSG00000270781.1 RP11-501C14.9 -5.93 5.78e-09 2.42e-06 -0.27 -0.26 Type 2 diabetes; chr17:48944908 chr17:48899131~48899748:+ LUSC cis rs9309473 0.66 rs11679594 ENSG00000163016.8 ALMS1P 5.93 5.79e-09 2.43e-06 0.38 0.26 Metabolite levels; chr2:73552380 chr2:73644919~73685576:+ LUSC cis rs875971 0.66 rs7807930 ENSG00000237310.1 GS1-124K5.4 -5.93 5.79e-09 2.43e-06 -0.27 -0.26 Aortic root size; chr7:66622178 chr7:66493706~66495474:+ LUSC cis rs875971 0.619 rs12533585 ENSG00000222364.1 RNU6-96P -5.93 5.79e-09 2.43e-06 -0.3 -0.26 Aortic root size; chr7:66519618 chr7:66395191~66395286:+ LUSC cis rs875971 0.66 rs6460308 ENSG00000237310.1 GS1-124K5.4 -5.93 5.79e-09 2.43e-06 -0.27 -0.26 Aortic root size; chr7:66619753 chr7:66493706~66495474:+ LUSC cis rs783540 1 rs1259180 ENSG00000255769.6 GOLGA2P10 5.93 5.79e-09 2.43e-06 0.32 0.26 Schizophrenia; chr15:82575930 chr15:82472993~82513950:- LUSC cis rs2153535 0.58 rs2327064 ENSG00000230939.1 RP11-314C16.1 -5.93 5.8e-09 2.43e-06 -0.31 -0.26 Motion sickness; chr6:8453819 chr6:8784178~8785445:+ LUSC cis rs394563 0.602 rs409111 ENSG00000231760.4 RP11-350J20.5 5.93 5.8e-09 2.43e-06 0.32 0.26 Dupuytren's disease; chr6:149445724 chr6:149796151~149826294:- LUSC cis rs4604732 0.588 rs4925552 ENSG00000227135.1 GCSAML-AS1 -5.93 5.8e-09 2.43e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247468447 chr1:247524679~247526752:- LUSC cis rs875971 0.66 rs79009421 ENSG00000237310.1 GS1-124K5.4 -5.93 5.8e-09 2.43e-06 -0.27 -0.26 Aortic root size; chr7:66603522 chr7:66493706~66495474:+ LUSC cis rs79349575 0.783 rs4794000 ENSG00000270781.1 RP11-501C14.9 -5.93 5.8e-09 2.43e-06 -0.27 -0.26 Type 2 diabetes; chr17:48945393 chr17:48899131~48899748:+ LUSC cis rs78487399 0.808 rs76684055 ENSG00000234936.1 AC010883.5 5.93 5.81e-09 2.44e-06 0.42 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43438804 chr2:43229573~43233394:+ LUSC cis rs2337406 0.866 rs4774019 ENSG00000211974.3 IGHV2-70 -5.93 5.81e-09 2.44e-06 -0.36 -0.26 Alzheimer's disease (late onset); chr14:106805386 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs58850145 ENSG00000211974.3 IGHV2-70 -5.93 5.81e-09 2.44e-06 -0.36 -0.26 Alzheimer's disease (late onset); chr14:106806185 chr14:106723574~106724093:- LUSC cis rs9322193 0.962 rs4870048 ENSG00000268592.3 RAET1E-AS1 5.93 5.81e-09 2.44e-06 0.33 0.26 Lung cancer; chr6:149834324 chr6:149863494~149919507:+ LUSC cis rs71403859 0.502 rs12927006 ENSG00000260886.1 TAT-AS1 5.93 5.82e-09 2.44e-06 0.4 0.26 Post bronchodilator FEV1; chr16:71516008 chr16:71565789~71578187:+ LUSC cis rs113835537 0.529 rs11227499 ENSG00000255517.5 CTD-3074O7.5 -5.93 5.82e-09 2.44e-06 -0.28 -0.26 Airway imaging phenotypes; chr11:66505353 chr11:66473490~66480233:- LUSC cis rs77204473 0.744 rs3213459 ENSG00000254851.1 RP11-109L13.1 5.93 5.82e-09 2.44e-06 0.6 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117191773 chr11:117135528~117138582:+ LUSC cis rs72627123 1 rs45559033 ENSG00000259065.1 RP5-1021I20.1 -5.93 5.83e-09 2.44e-06 -0.46 -0.26 Morning vs. evening chronotype; chr14:73874421 chr14:73787360~73803270:+ LUSC cis rs9309473 0.606 rs79234109 ENSG00000163016.8 ALMS1P 5.93 5.84e-09 2.45e-06 0.39 0.26 Metabolite levels; chr2:73621227 chr2:73644919~73685576:+ LUSC cis rs79349575 0.756 rs2643361 ENSG00000270781.1 RP11-501C14.9 -5.93 5.84e-09 2.45e-06 -0.28 -0.26 Type 2 diabetes; chr17:48900100 chr17:48899131~48899748:+ LUSC cis rs79349575 0.749 rs2546491 ENSG00000270781.1 RP11-501C14.9 -5.93 5.84e-09 2.45e-06 -0.28 -0.26 Type 2 diabetes; chr17:48900554 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs962272 ENSG00000270781.1 RP11-501C14.9 -5.93 5.84e-09 2.45e-06 -0.28 -0.26 Type 2 diabetes; chr17:48900921 chr17:48899131~48899748:+ LUSC cis rs2337406 0.866 rs2301536 ENSG00000254174.1 IGHV1-12 5.93 5.85e-09 2.45e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106790636 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs7144369 ENSG00000254174.1 IGHV1-12 5.93 5.85e-09 2.45e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106793065 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs78525520 ENSG00000254174.1 IGHV1-12 5.93 5.85e-09 2.45e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106795643 chr14:106122420~106122709:- LUSC cis rs875971 0.66 rs7807944 ENSG00000237310.1 GS1-124K5.4 -5.93 5.85e-09 2.45e-06 -0.27 -0.26 Aortic root size; chr7:66622208 chr7:66493706~66495474:+ LUSC cis rs7267979 0.844 rs6083845 ENSG00000274973.1 RP13-401N8.7 5.93 5.85e-09 2.45e-06 0.26 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25407454 chr20:25845497~25845862:+ LUSC cis rs7267979 0.844 rs6083851 ENSG00000274973.1 RP13-401N8.7 5.93 5.85e-09 2.45e-06 0.26 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25420599 chr20:25845497~25845862:+ LUSC cis rs7267979 0.844 rs4423675 ENSG00000274973.1 RP13-401N8.7 5.93 5.85e-09 2.45e-06 0.26 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25422142 chr20:25845497~25845862:+ LUSC cis rs7829975 0.623 rs10087493 ENSG00000253893.2 FAM85B 5.93 5.85e-09 2.45e-06 0.31 0.26 Mood instability; chr8:8516047 chr8:8167819~8226614:- LUSC cis rs79349575 0.783 rs318095 ENSG00000270781.1 RP11-501C14.9 -5.93 5.85e-09 2.45e-06 -0.28 -0.26 Type 2 diabetes; chr17:48897372 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs318096 ENSG00000270781.1 RP11-501C14.9 -5.93 5.85e-09 2.45e-06 -0.28 -0.26 Type 2 diabetes; chr17:48898008 chr17:48899131~48899748:+ LUSC cis rs79349575 0.777 rs28517720 ENSG00000270781.1 RP11-501C14.9 -5.93 5.85e-09 2.45e-06 -0.28 -0.26 Type 2 diabetes; chr17:48899394 chr17:48899131~48899748:+ LUSC cis rs11098499 0.739 rs9996382 ENSG00000250412.1 KLHL2P1 5.93 5.87e-09 2.46e-06 0.32 0.26 Corneal astigmatism; chr4:119229857 chr4:119334329~119378233:+ LUSC cis rs2337406 0.587 rs916547 ENSG00000274576.2 IGHV2-70 -5.93 5.87e-09 2.46e-06 -0.29 -0.26 Alzheimer's disease (late onset); chr14:106646735 chr14:106770577~106771020:- LUSC cis rs12554020 0.582 rs112401922 ENSG00000227603.1 RP11-165J3.6 5.93 5.88e-09 2.46e-06 0.46 0.26 Schizophrenia; chr9:93661517 chr9:93435332~93437121:- LUSC cis rs5742933 0.557 rs6756571 ENSG00000253559.1 OSGEPL1-AS1 5.93 5.89e-09 2.47e-06 0.32 0.26 Ferritin levels; chr2:189640971 chr2:189762704~189765556:+ LUSC cis rs2179367 0.632 rs55826712 ENSG00000231760.4 RP11-350J20.5 5.93 5.89e-09 2.47e-06 0.38 0.26 Dupuytren's disease; chr6:149344716 chr6:149796151~149826294:- LUSC cis rs7267979 0.903 rs2474769 ENSG00000274973.1 RP13-401N8.7 -5.93 5.89e-09 2.47e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25268089 chr20:25845497~25845862:+ LUSC cis rs2732480 0.577 rs2634684 ENSG00000226413.2 OR8T1P -5.93 5.9e-09 2.47e-06 -0.34 -0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48337092 chr12:48442030~48442947:- LUSC cis rs13113518 1 rs3805148 ENSG00000273257.1 RP11-177J6.1 5.93 5.91e-09 2.47e-06 0.34 0.26 Height; chr4:55440643 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11133380 ENSG00000273257.1 RP11-177J6.1 5.93 5.91e-09 2.47e-06 0.34 0.26 Height; chr4:55441110 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs12510110 ENSG00000273257.1 RP11-177J6.1 5.93 5.91e-09 2.47e-06 0.34 0.26 Height; chr4:55441567 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs12510990 ENSG00000273257.1 RP11-177J6.1 5.93 5.91e-09 2.47e-06 0.34 0.26 Height; chr4:55441907 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs3805149 ENSG00000273257.1 RP11-177J6.1 5.93 5.91e-09 2.47e-06 0.34 0.26 Height; chr4:55442184 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11945370 ENSG00000273257.1 RP11-177J6.1 5.93 5.91e-09 2.47e-06 0.34 0.26 Height; chr4:55442875 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs12647677 ENSG00000273257.1 RP11-177J6.1 5.93 5.91e-09 2.47e-06 0.34 0.26 Height; chr4:55444253 chr4:55387949~55388271:+ LUSC cis rs13113518 0.902 rs3805150 ENSG00000273257.1 RP11-177J6.1 5.93 5.91e-09 2.47e-06 0.34 0.26 Height; chr4:55446869 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs4864990 ENSG00000273257.1 RP11-177J6.1 5.93 5.91e-09 2.47e-06 0.34 0.26 Height; chr4:55447523 chr4:55387949~55388271:+ LUSC cis rs7714584 1 rs12652003 ENSG00000197083.10 ZNF300P1 5.93 5.92e-09 2.48e-06 0.5 0.26 Crohn's disease; chr5:150852383 chr5:150930645~150946289:- LUSC cis rs9910055 0.762 rs184478 ENSG00000267080.4 ASB16-AS1 5.93 5.92e-09 2.48e-06 0.24 0.26 Total body bone mineral density; chr17:44132383 chr17:44175973~44186717:- LUSC cis rs6772849 0.896 rs35535737 ENSG00000277250.1 Metazoa_SRP -5.93 5.92e-09 2.48e-06 -0.29 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128664563 chr3:128673681~128674021:- LUSC cis rs1865760 0.519 rs2275904 ENSG00000272462.2 U91328.19 -5.93 5.93e-09 2.48e-06 -0.32 -0.26 Height; chr6:25767857 chr6:25992662~26001775:+ LUSC cis rs875971 0.619 rs12533585 ENSG00000237310.1 GS1-124K5.4 5.93 5.93e-09 2.48e-06 0.27 0.26 Aortic root size; chr7:66519618 chr7:66493706~66495474:+ LUSC cis rs1499614 1 rs2707840 ENSG00000226824.5 RP4-756H11.3 -5.93 5.93e-09 2.48e-06 -0.51 -0.26 Gout; chr7:66693028 chr7:66654538~66669855:+ LUSC cis rs73173548 0.502 rs34394411 ENSG00000247828.6 TMEM161B-AS1 5.93 5.94e-09 2.49e-06 0.32 0.26 Macular telangiectasia type 2; chr5:88436903 chr5:88268895~88436685:+ LUSC cis rs12935418 0.832 rs79957369 ENSG00000261061.1 RP11-303E16.2 -5.93 5.94e-09 2.49e-06 -0.51 -0.26 Mean corpuscular volume; chr16:81025654 chr16:81030770~81031485:+ LUSC cis rs5753618 0.539 rs2106294 ENSG00000236132.1 CTA-440B3.1 5.93 5.94e-09 2.49e-06 0.35 0.26 Colorectal cancer; chr22:31249773 chr22:31816379~31817491:- LUSC cis rs875971 0.862 rs778702 ENSG00000179406.6 LINC00174 -5.93 5.95e-09 2.49e-06 -0.28 -0.26 Aortic root size; chr7:66399848 chr7:66376044~66401338:- LUSC cis rs13113518 1 rs11133381 ENSG00000273257.1 RP11-177J6.1 5.93 5.95e-09 2.49e-06 0.34 0.26 Height; chr4:55450812 chr4:55387949~55388271:+ LUSC cis rs2337406 0.925 rs11851094 ENSG00000254174.1 IGHV1-12 5.93 5.95e-09 2.49e-06 0.27 0.26 Alzheimer's disease (late onset); chr14:106688967 chr14:106122420~106122709:- LUSC cis rs6772849 0.93 rs68090762 ENSG00000277250.1 Metazoa_SRP -5.93 5.95e-09 2.49e-06 -0.29 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128625064 chr3:128673681~128674021:- LUSC cis rs7267979 0.903 rs2474766 ENSG00000274973.1 RP13-401N8.7 -5.93 5.96e-09 2.49e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25265517 chr20:25845497~25845862:+ LUSC cis rs801193 1 rs7785213 ENSG00000237310.1 GS1-124K5.4 -5.93 5.97e-09 2.5e-06 -0.27 -0.26 Aortic root size; chr7:66673991 chr7:66493706~66495474:+ LUSC cis rs11157436 0.602 rs1894371 ENSG00000211813.2 TRAV34 -5.93 5.98e-09 2.5e-06 -0.26 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22166799 chr14:22207522~22208129:+ LUSC cis rs6570726 0.791 rs4896820 ENSG00000235652.6 RP11-545I5.3 5.93 5.98e-09 2.5e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145573821 chr6:145799409~145886585:+ LUSC cis rs6570726 0.764 rs4896821 ENSG00000235652.6 RP11-545I5.3 5.93 5.98e-09 2.5e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145575045 chr6:145799409~145886585:+ LUSC cis rs13113518 1 rs4864546 ENSG00000273257.1 RP11-177J6.1 5.93 5.98e-09 2.5e-06 0.33 0.26 Height; chr4:55537960 chr4:55387949~55388271:+ LUSC cis rs11098499 0.863 rs13134665 ENSG00000248280.1 RP11-33B1.2 5.93 5.98e-09 2.5e-06 0.32 0.26 Corneal astigmatism; chr4:119505275 chr4:119440561~119450157:- LUSC cis rs62103177 0.608 rs613847 ENSG00000261126.6 RP11-795F19.1 -5.93 5.99e-09 2.51e-06 -0.33 -0.26 Opioid sensitivity; chr18:80087736 chr18:80046900~80095482:+ LUSC cis rs62103177 0.525 rs612913 ENSG00000261126.6 RP11-795F19.1 -5.93 5.99e-09 2.51e-06 -0.33 -0.26 Opioid sensitivity; chr18:80087974 chr18:80046900~80095482:+ LUSC cis rs66887589 0.56 rs9684327 ENSG00000249244.1 RP11-548H18.2 5.93 6e-09 2.51e-06 0.31 0.26 Diastolic blood pressure; chr4:119444286 chr4:119391831~119395335:- LUSC cis rs2732480 0.557 rs2732454 ENSG00000273765.1 RP11-370I10.11 5.93 6.01e-09 2.51e-06 0.3 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48325894 chr12:48360920~48361377:+ LUSC cis rs2153535 0.563 rs6942177 ENSG00000230939.1 RP11-314C16.1 5.93 6.01e-09 2.51e-06 0.31 0.26 Motion sickness; chr6:8534227 chr6:8784178~8785445:+ LUSC cis rs13113518 1 rs12651640 ENSG00000273257.1 RP11-177J6.1 5.93 6.01e-09 2.51e-06 0.34 0.26 Height; chr4:55454154 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs1554483 ENSG00000273257.1 RP11-177J6.1 5.93 6.01e-09 2.51e-06 0.34 0.26 Height; chr4:55455650 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs1464490 ENSG00000273257.1 RP11-177J6.1 5.93 6.01e-09 2.51e-06 0.34 0.26 Height; chr4:55456620 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs10517346 ENSG00000273257.1 RP11-177J6.1 5.93 6.01e-09 2.51e-06 0.34 0.26 Height; chr4:55457027 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11133384 ENSG00000273257.1 RP11-177J6.1 5.93 6.01e-09 2.51e-06 0.34 0.26 Height; chr4:55457086 chr4:55387949~55388271:+ LUSC cis rs2276314 0.857 rs6507158 ENSG00000278986.1 RP11-723J4.3 -5.93 6.01e-09 2.51e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36056103 chr18:35972151~35973916:+ LUSC cis rs2153535 0.601 rs9502719 ENSG00000230939.1 RP11-314C16.1 -5.93 6.02e-09 2.52e-06 -0.32 -0.26 Motion sickness; chr6:8540799 chr6:8784178~8785445:+ LUSC cis rs2153535 0.547 rs9502720 ENSG00000230939.1 RP11-314C16.1 -5.93 6.02e-09 2.52e-06 -0.32 -0.26 Motion sickness; chr6:8541129 chr6:8784178~8785445:+ LUSC cis rs4803480 1 rs7255679 ENSG00000270164.1 LINC01480 -5.93 6.03e-09 2.52e-06 -0.23 -0.26 Schizophrenia; chr19:41557611 chr19:41535183~41536904:+ LUSC cis rs2337406 0.85 rs10131280 ENSG00000254174.1 IGHV1-12 5.93 6.04e-09 2.52e-06 0.28 0.26 Alzheimer's disease (late onset); chr14:106665591 chr14:106122420~106122709:- LUSC cis rs6504950 0.886 rs12449538 ENSG00000275710.1 RP11-257O5.4 -5.93 6.04e-09 2.52e-06 -0.3 -0.26 Breast cancer; chr17:55033760 chr17:54964474~54964679:+ LUSC cis rs875971 0.619 rs10278371 ENSG00000237310.1 GS1-124K5.4 -5.92 6.05e-09 2.53e-06 -0.26 -0.26 Aortic root size; chr7:66586553 chr7:66493706~66495474:+ LUSC cis rs7772486 0.806 rs7740785 ENSG00000235652.6 RP11-545I5.3 5.92 6.05e-09 2.53e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145850163 chr6:145799409~145886585:+ LUSC cis rs5742933 0.597 rs6756913 ENSG00000253559.1 OSGEPL1-AS1 5.92 6.05e-09 2.53e-06 0.32 0.26 Ferritin levels; chr2:189641040 chr2:189762704~189765556:+ LUSC cis rs16843372 0.599 rs13393279 ENSG00000251491.2 OR7E28P -5.92 6.06e-09 2.53e-06 -0.29 -0.26 Obesity-related traits; chr2:158819216 chr2:158862311~158863285:+ LUSC cis rs6570726 0.791 rs6902410 ENSG00000235652.6 RP11-545I5.3 5.92 6.06e-09 2.53e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145584125 chr6:145799409~145886585:+ LUSC cis rs875971 0.638 rs10249404 ENSG00000237310.1 GS1-124K5.4 -5.92 6.06e-09 2.53e-06 -0.26 -0.26 Aortic root size; chr7:66581737 chr7:66493706~66495474:+ LUSC cis rs950169 0.84 rs62029595 ENSG00000259295.5 CSPG4P12 5.92 6.06e-09 2.53e-06 0.35 0.26 Schizophrenia; chr15:84400603 chr15:85191438~85213905:+ LUSC cis rs1056107 0.966 rs7869209 ENSG00000225513.1 RP11-165N19.2 -5.92 6.07e-09 2.53e-06 -0.29 -0.26 Colorectal cancer; chr9:112301133 chr9:112173522~112173971:- LUSC cis rs11971779 0.68 rs2355787 ENSG00000273391.1 RP11-634H22.1 -5.92 6.07e-09 2.53e-06 -0.28 -0.26 Diisocyanate-induced asthma; chr7:139405182 chr7:139359032~139359566:- LUSC cis rs79349575 0.783 rs62078370 ENSG00000270781.1 RP11-501C14.9 -5.92 6.07e-09 2.54e-06 -0.28 -0.26 Type 2 diabetes; chr17:48949474 chr17:48899131~48899748:+ LUSC cis rs7772486 0.79 rs6926657 ENSG00000235652.6 RP11-545I5.3 -5.92 6.07e-09 2.54e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145934658 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs9376971 ENSG00000235652.6 RP11-545I5.3 -5.92 6.07e-09 2.54e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145938369 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs4314514 ENSG00000235652.6 RP11-545I5.3 -5.92 6.07e-09 2.54e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145938874 chr6:145799409~145886585:+ LUSC cis rs7772486 0.72 rs9403757 ENSG00000235652.6 RP11-545I5.3 -5.92 6.07e-09 2.54e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145940135 chr6:145799409~145886585:+ LUSC cis rs2337406 1 rs75651733 ENSG00000254174.1 IGHV1-12 5.92 6.07e-09 2.54e-06 0.27 0.26 Alzheimer's disease (late onset); chr14:106701309 chr14:106122420~106122709:- LUSC cis rs12554020 0.582 rs74842678 ENSG00000227603.1 RP11-165J3.6 5.92 6.08e-09 2.54e-06 0.46 0.26 Schizophrenia; chr9:93658926 chr9:93435332~93437121:- LUSC cis rs2439831 1 rs28628574 ENSG00000249839.1 AC011330.5 -5.92 6.08e-09 2.54e-06 -0.52 -0.26 Lung cancer in ever smokers; chr15:43509840 chr15:43663654~43684339:- LUSC cis rs61270009 0.955 rs11748768 ENSG00000247828.6 TMEM161B-AS1 5.92 6.08e-09 2.54e-06 0.3 0.26 Depressive symptoms; chr5:88354818 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs11750391 ENSG00000247828.6 TMEM161B-AS1 5.92 6.08e-09 2.54e-06 0.3 0.26 Depressive symptoms; chr5:88356255 chr5:88268895~88436685:+ LUSC cis rs1075265 0.605 rs805418 ENSG00000233266.1 HMGB1P31 5.92 6.08e-09 2.54e-06 0.32 0.26 Chronotype;Morning vs. evening chronotype; chr2:53898634 chr2:54051334~54051760:+ LUSC cis rs442309 0.812 rs224090 ENSG00000238280.1 RP11-436D10.3 5.92 6.08e-09 2.54e-06 0.33 0.26 Vogt-Koyanagi-Harada syndrome; chr10:62781559 chr10:62793562~62805887:- LUSC cis rs79349575 0.783 rs58591767 ENSG00000270781.1 RP11-501C14.9 -5.92 6.1e-09 2.55e-06 -0.28 -0.26 Type 2 diabetes; chr17:48948714 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs59270107 ENSG00000270781.1 RP11-501C14.9 -5.92 6.1e-09 2.55e-06 -0.28 -0.26 Type 2 diabetes; chr17:48948823 chr17:48899131~48899748:+ LUSC cis rs4718428 0.705 rs4718422 ENSG00000226824.5 RP4-756H11.3 -5.92 6.1e-09 2.55e-06 -0.36 -0.26 Corneal structure; chr7:66894282 chr7:66654538~66669855:+ LUSC cis rs4718428 0.705 rs13231140 ENSG00000226824.5 RP4-756H11.3 -5.92 6.1e-09 2.55e-06 -0.36 -0.26 Corneal structure; chr7:66896631 chr7:66654538~66669855:+ LUSC cis rs8031584 0.679 rs34017474 ENSG00000260382.1 RP11-540B6.2 5.92 6.1e-09 2.55e-06 0.35 0.26 Huntington's disease progression; chr15:30938408 chr15:30882267~30883231:- LUSC cis rs867371 1 rs867370 ENSG00000255769.6 GOLGA2P10 5.92 6.11e-09 2.55e-06 0.32 0.26 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82145921 chr15:82472993~82513950:- LUSC cis rs867371 1 rs867371 ENSG00000255769.6 GOLGA2P10 5.92 6.11e-09 2.55e-06 0.32 0.26 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82146005 chr15:82472993~82513950:- LUSC cis rs2562456 0.874 rs9304986 ENSG00000268081.1 RP11-678G14.2 -5.92 6.11e-09 2.55e-06 -0.38 -0.26 Pain; chr19:21499260 chr19:21554640~21569237:- LUSC cis rs2562456 0.917 rs2650805 ENSG00000268081.1 RP11-678G14.2 -5.92 6.11e-09 2.55e-06 -0.38 -0.26 Pain; chr19:21505137 chr19:21554640~21569237:- LUSC cis rs9341835 0.772 rs4710254 ENSG00000218048.2 RP3-407E4.4 5.92 6.12e-09 2.55e-06 0.31 0.26 Schizophrenia; chr6:63427704 chr6:63440766~63443580:+ LUSC cis rs8040855 0.627 rs1532776 ENSG00000259295.5 CSPG4P12 5.92 6.13e-09 2.56e-06 0.34 0.26 Bulimia nervosa; chr15:85081383 chr15:85191438~85213905:+ LUSC cis rs11089937 0.616 rs4145537 ENSG00000211639.2 IGLV4-60 -5.92 6.14e-09 2.56e-06 -0.29 -0.26 Periodontitis (PAL4Q3); chr22:22182550 chr22:22162199~22162681:+ LUSC cis rs2243480 0.764 rs2460423 ENSG00000226824.5 RP4-756H11.3 -5.92 6.14e-09 2.56e-06 -0.51 -0.26 Diabetic kidney disease; chr7:66136229 chr7:66654538~66669855:+ LUSC cis rs4604732 1 rs4604732 ENSG00000227135.1 GCSAML-AS1 5.92 6.14e-09 2.56e-06 0.37 0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247460570 chr1:247524679~247526752:- LUSC cis rs4372836 0.928 rs55836936 ENSG00000226833.4 AC097724.3 -5.92 6.14e-09 2.56e-06 -0.3 -0.26 Body mass index; chr2:28699967 chr2:28708953~28736205:- LUSC cis rs13113518 0.812 rs11932712 ENSG00000249700.7 SRD5A3-AS1 5.92 6.15e-09 2.57e-06 0.31 0.26 Height; chr4:55436423 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs12501746 ENSG00000249700.7 SRD5A3-AS1 5.92 6.15e-09 2.57e-06 0.31 0.26 Height; chr4:55437438 chr4:55363971~55395847:- LUSC cis rs1056107 0.931 rs2418199 ENSG00000225513.1 RP11-165N19.2 -5.92 6.16e-09 2.57e-06 -0.29 -0.26 Colorectal cancer; chr9:112242888 chr9:112173522~112173971:- LUSC cis rs75422866 0.867 rs7303895 ENSG00000257433.4 RP1-197B17.3 5.92 6.16e-09 2.57e-06 0.59 0.26 Pneumonia; chr12:47683290 chr12:47706085~47742294:+ LUSC cis rs10759883 0.627 rs10818746 ENSG00000175611.10 LINC00476 5.92 6.17e-09 2.57e-06 0.31 0.26 Nicotine dependence; chr9:95848031 chr9:95759231~95875977:- LUSC cis rs10759883 0.627 rs10985769 ENSG00000175611.10 LINC00476 5.92 6.17e-09 2.57e-06 0.31 0.26 Nicotine dependence; chr9:95848094 chr9:95759231~95875977:- LUSC cis rs7829975 0.54 rs2976909 ENSG00000173295.6 FAM86B3P -5.92 6.18e-09 2.58e-06 -0.29 -0.26 Mood instability; chr8:8489180 chr8:8228595~8244865:+ LUSC cis rs1056107 0.966 rs1538770 ENSG00000225513.1 RP11-165N19.2 -5.92 6.18e-09 2.58e-06 -0.29 -0.26 Colorectal cancer; chr9:112300069 chr9:112173522~112173971:- LUSC cis rs77972916 0.609 rs72790903 ENSG00000234936.1 AC010883.5 5.92 6.18e-09 2.58e-06 0.38 0.26 Granulocyte percentage of myeloid white cells; chr2:43334846 chr2:43229573~43233394:+ LUSC cis rs75422866 0.764 rs73104184 ENSG00000274902.1 RP1-197B17.4 5.92 6.19e-09 2.58e-06 0.76 0.26 Pneumonia; chr12:47715623 chr12:47731908~47732351:+ LUSC cis rs75422866 0.764 rs73104188 ENSG00000274902.1 RP1-197B17.4 5.92 6.19e-09 2.58e-06 0.76 0.26 Pneumonia; chr12:47715885 chr12:47731908~47732351:+ LUSC cis rs8059260 0.736 rs77599345 ENSG00000274038.1 RP11-66H6.4 -5.92 6.19e-09 2.58e-06 -0.5 -0.26 Alcohol consumption over the past year; chr16:10964707 chr16:11056556~11057034:+ LUSC cis rs6772849 0.768 rs9820741 ENSG00000242551.2 POU5F1P6 -5.92 6.19e-09 2.58e-06 -0.31 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128697237 chr3:128674735~128677005:- LUSC cis rs1021993 0.597 rs17014323 ENSG00000231648.1 RP11-372M18.2 -5.92 6.19e-09 2.58e-06 -0.38 -0.26 Gut microbiome composition (winter); chr1:209340507 chr1:209367662~209379690:+ LUSC cis rs66887589 0.934 rs56843000 ENSG00000245958.5 RP11-33B1.1 5.92 6.2e-09 2.58e-06 0.25 0.26 Diastolic blood pressure; chr4:119595442 chr4:119454791~119552025:+ LUSC cis rs2404602 0.552 rs11634428 ENSG00000259422.1 RP11-593F23.1 -5.92 6.2e-09 2.58e-06 -0.34 -0.26 Blood metabolite levels; chr15:76792241 chr15:76174891~76181486:- LUSC cis rs3169166 0.5 rs12909123 ENSG00000259562.2 RP11-762H8.2 -5.92 6.2e-09 2.58e-06 -0.21 -0.26 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78267501 chr15:78290527~78291221:- LUSC cis rs61270009 0.955 rs12514004 ENSG00000247828.6 TMEM161B-AS1 5.92 6.21e-09 2.59e-06 0.3 0.26 Depressive symptoms; chr5:88269979 chr5:88268895~88436685:+ LUSC cis rs1823913 0.637 rs4853577 ENSG00000280083.1 RP11-317J9.1 5.92 6.21e-09 2.59e-06 0.31 0.26 Obesity-related traits; chr2:191297118 chr2:191154118~191156070:- LUSC cis rs1823913 0.637 rs4853578 ENSG00000280083.1 RP11-317J9.1 -5.92 6.21e-09 2.59e-06 -0.31 -0.26 Obesity-related traits; chr2:191297215 chr2:191154118~191156070:- LUSC cis rs2378497 0.564 rs115883774 ENSG00000232679.1 RP11-400N13.3 5.92 6.21e-09 2.59e-06 0.28 0.26 Serum thyroid-stimulating hormone levels; chr1:221986970 chr1:222041705~222064763:- LUSC cis rs11098499 0.866 rs7665125 ENSG00000250412.1 KLHL2P1 5.92 6.21e-09 2.59e-06 0.32 0.26 Corneal astigmatism; chr4:119480924 chr4:119334329~119378233:+ LUSC cis rs875971 0.505 rs1723275 ENSG00000179406.6 LINC00174 5.92 6.21e-09 2.59e-06 0.28 0.26 Aortic root size; chr7:66039646 chr7:66376044~66401338:- LUSC cis rs2439831 0.85 rs3816792 ENSG00000249839.1 AC011330.5 5.92 6.21e-09 2.59e-06 0.53 0.26 Lung cancer in ever smokers; chr15:43824788 chr15:43663654~43684339:- LUSC cis rs2276314 1 rs8086395 ENSG00000278986.1 RP11-723J4.3 -5.92 6.22e-09 2.59e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35984629 chr18:35972151~35973916:+ LUSC cis rs1075265 0.669 rs805330 ENSG00000233266.1 HMGB1P31 5.92 6.22e-09 2.59e-06 0.32 0.26 Chronotype;Morning vs. evening chronotype; chr2:53921194 chr2:54051334~54051760:+ LUSC cis rs2439831 0.702 rs8033995 ENSG00000249839.1 AC011330.5 -5.92 6.22e-09 2.59e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43721311 chr15:43663654~43684339:- LUSC cis rs7580658 0.676 rs58475809 ENSG00000236682.1 AC068282.3 -5.92 6.23e-09 2.6e-06 -0.34 -0.26 Protein C levels; chr2:127245074 chr2:127389130~127400580:+ LUSC cis rs9309473 0.528 rs79799178 ENSG00000163016.8 ALMS1P 5.92 6.24e-09 2.6e-06 0.38 0.26 Metabolite levels; chr2:73564108 chr2:73644919~73685576:+ LUSC cis rs62025270 0.547 rs1026722 ENSG00000202081.1 RNU6-1280P 5.92 6.24e-09 2.6e-06 0.32 0.26 Idiopathic pulmonary fibrosis; chr15:85576168 chr15:85651522~85651628:- LUSC cis rs12439619 0.846 rs28470877 ENSG00000276710.3 CSPG4P8 -5.92 6.25e-09 2.6e-06 -0.32 -0.26 Intelligence (multi-trait analysis); chr15:82245797 chr15:82459472~82477258:+ LUSC cis rs66887589 1 rs66887589 ENSG00000245958.5 RP11-33B1.1 5.92 6.25e-09 2.6e-06 0.25 0.26 Diastolic blood pressure; chr4:119588124 chr4:119454791~119552025:+ LUSC cis rs72627123 1 rs72627122 ENSG00000259065.1 RP5-1021I20.1 -5.92 6.25e-09 2.6e-06 -0.46 -0.26 Morning vs. evening chronotype; chr14:73901533 chr14:73787360~73803270:+ LUSC cis rs7772486 0.782 rs7747576 ENSG00000235652.6 RP11-545I5.3 -5.92 6.25e-09 2.6e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145956691 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs9399571 ENSG00000235652.6 RP11-545I5.3 -5.92 6.25e-09 2.6e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145960925 chr6:145799409~145886585:+ LUSC cis rs9341835 0.772 rs9449233 ENSG00000218048.2 RP3-407E4.4 5.92 6.25e-09 2.6e-06 0.31 0.26 Schizophrenia; chr6:63428329 chr6:63440766~63443580:+ LUSC cis rs9322193 1 rs9377229 ENSG00000268592.3 RAET1E-AS1 5.92 6.26e-09 2.61e-06 0.33 0.26 Lung cancer; chr6:149607655 chr6:149863494~149919507:+ LUSC cis rs13113518 1 rs13133579 ENSG00000273257.1 RP11-177J6.1 5.92 6.26e-09 2.61e-06 0.34 0.26 Height; chr4:55459921 chr4:55387949~55388271:+ LUSC cis rs13113518 0.902 rs11133386 ENSG00000273257.1 RP11-177J6.1 5.92 6.26e-09 2.61e-06 0.34 0.26 Height; chr4:55461320 chr4:55387949~55388271:+ LUSC cis rs875971 0.577 rs34888281 ENSG00000164669.11 INTS4P1 5.92 6.26e-09 2.61e-06 0.29 0.26 Aortic root size; chr7:66120784 chr7:65141225~65234216:+ LUSC cis rs11098499 0.863 rs6833334 ENSG00000248280.1 RP11-33B1.2 5.92 6.27e-09 2.61e-06 0.31 0.26 Corneal astigmatism; chr4:119583072 chr4:119440561~119450157:- LUSC cis rs11089937 0.616 rs4991802 ENSG00000211639.2 IGLV4-60 5.92 6.27e-09 2.61e-06 0.27 0.26 Periodontitis (PAL4Q3); chr22:22179031 chr22:22162199~22162681:+ LUSC cis rs10246939 0.505 rs13236432 ENSG00000228775.6 WEE2-AS1 5.92 6.27e-09 2.61e-06 0.33 0.26 Bitter taste perception; chr7:141850980 chr7:141704338~141738346:- LUSC cis rs9545047 0.604 rs9318623 ENSG00000227676.3 LINC01068 -5.92 6.27e-09 2.61e-06 -0.32 -0.26 Schizophrenia; chr13:79346913 chr13:79566727~79571436:+ LUSC cis rs9545047 0.564 rs7998837 ENSG00000227676.3 LINC01068 -5.92 6.27e-09 2.61e-06 -0.32 -0.26 Schizophrenia; chr13:79349190 chr13:79566727~79571436:+ LUSC cis rs12908161 0.96 rs17599989 ENSG00000259728.4 LINC00933 5.92 6.27e-09 2.61e-06 0.34 0.26 Schizophrenia; chr15:84742305 chr15:84570649~84580175:+ LUSC cis rs7555523 0.83 rs6426936 ENSG00000224358.1 RP11-466F5.8 5.92 6.27e-09 2.61e-06 0.33 0.26 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165715470 chr1:165768929~165775176:+ LUSC cis rs875971 0.642 rs35526611 ENSG00000222364.1 RNU6-96P 5.92 6.27e-09 2.61e-06 0.3 0.26 Aortic root size; chr7:66629021 chr7:66395191~66395286:+ LUSC cis rs6570726 0.791 rs427128 ENSG00000235652.6 RP11-545I5.3 5.92 6.28e-09 2.62e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145544781 chr6:145799409~145886585:+ LUSC cis rs6504950 0.813 rs244321 ENSG00000275710.1 RP11-257O5.4 5.92 6.29e-09 2.62e-06 0.31 0.26 Breast cancer; chr17:55146637 chr17:54964474~54964679:+ LUSC cis rs13113518 0.783 rs11133389 ENSG00000272969.1 RP11-528I4.2 5.92 6.29e-09 2.62e-06 0.31 0.26 Height; chr4:55486718 chr4:55547112~55547889:+ LUSC cis rs875971 0.638 rs6460305 ENSG00000237310.1 GS1-124K5.4 -5.92 6.29e-09 2.62e-06 -0.26 -0.26 Aortic root size; chr7:66595421 chr7:66493706~66495474:+ LUSC cis rs11159086 1 rs4899514 ENSG00000259005.1 RP3-449M8.6 -5.92 6.3e-09 2.62e-06 -0.42 -0.26 Advanced glycation end-product levels; chr14:74473467 chr14:74474007~74474864:- LUSC cis rs875971 0.522 rs1968127 ENSG00000237310.1 GS1-124K5.4 -5.92 6.3e-09 2.62e-06 -0.26 -0.26 Aortic root size; chr7:66591816 chr7:66493706~66495474:+ LUSC cis rs7772486 0.79 rs2265917 ENSG00000235652.6 RP11-545I5.3 5.92 6.3e-09 2.62e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145891149 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2265469 ENSG00000235652.6 RP11-545I5.3 5.92 6.3e-09 2.62e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145897913 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2265918 ENSG00000235652.6 RP11-545I5.3 5.92 6.3e-09 2.62e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145898028 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2265472 ENSG00000235652.6 RP11-545I5.3 5.92 6.3e-09 2.62e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145899622 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs2265919 ENSG00000235652.6 RP11-545I5.3 5.92 6.3e-09 2.62e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145900617 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs9403755 ENSG00000235652.6 RP11-545I5.3 -5.92 6.3e-09 2.62e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145910334 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs4435956 ENSG00000235652.6 RP11-545I5.3 -5.92 6.3e-09 2.62e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145911267 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs6926076 ENSG00000235652.6 RP11-545I5.3 -5.92 6.3e-09 2.62e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145911668 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs6917482 ENSG00000235652.6 RP11-545I5.3 -5.92 6.3e-09 2.62e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145922445 chr6:145799409~145886585:+ LUSC cis rs7772486 0.754 rs4566902 ENSG00000235652.6 RP11-545I5.3 -5.92 6.3e-09 2.62e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145922992 chr6:145799409~145886585:+ LUSC cis rs875971 0.522 rs1968127 ENSG00000222364.1 RNU6-96P 5.92 6.31e-09 2.63e-06 0.3 0.26 Aortic root size; chr7:66591816 chr7:66395191~66395286:+ LUSC cis rs4660456 0.596 rs1534956 ENSG00000237899.1 RP4-739H11.3 5.92 6.31e-09 2.63e-06 0.33 0.26 Platelet count; chr1:40720771 chr1:40669089~40687588:- LUSC cis rs875971 0.638 rs6960778 ENSG00000237310.1 GS1-124K5.4 -5.92 6.31e-09 2.63e-06 -0.27 -0.26 Aortic root size; chr7:66606610 chr7:66493706~66495474:+ LUSC cis rs7772486 0.875 rs2814877 ENSG00000235652.6 RP11-545I5.3 5.92 6.31e-09 2.63e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145978627 chr6:145799409~145886585:+ LUSC cis rs78487399 0.71 rs72879290 ENSG00000234936.1 AC010883.5 5.92 6.31e-09 2.63e-06 0.4 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43406129 chr2:43229573~43233394:+ LUSC cis rs7739264 0.542 rs9460403 ENSG00000237404.1 RP3-471C18.2 -5.92 6.32e-09 2.63e-06 -0.29 -0.26 Endometriosis; chr6:19707864 chr6:19689825~19753113:- LUSC cis rs2732480 0.577 rs1489109 ENSG00000240399.1 RP1-228P16.1 5.92 6.32e-09 2.63e-06 0.29 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344997 chr12:48054813~48055591:- LUSC cis rs2732480 0.577 rs1489108 ENSG00000240399.1 RP1-228P16.1 5.92 6.32e-09 2.63e-06 0.29 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344998 chr12:48054813~48055591:- LUSC cis rs17772222 0.63 rs930181 ENSG00000258789.1 RP11-507K2.3 5.92 6.33e-09 2.64e-06 0.29 0.26 Coronary artery calcification; chr14:88552364 chr14:88551597~88552493:+ LUSC cis rs7739264 0.591 rs1016251 ENSG00000237404.1 RP3-471C18.2 -5.92 6.33e-09 2.64e-06 -0.29 -0.26 Endometriosis; chr6:19706530 chr6:19689825~19753113:- LUSC cis rs13113518 0.812 rs2048564 ENSG00000273257.1 RP11-177J6.1 5.92 6.33e-09 2.64e-06 0.34 0.26 Height; chr4:55407965 chr4:55387949~55388271:+ LUSC cis rs2153535 0.58 rs2143357 ENSG00000230939.1 RP11-314C16.1 -5.92 6.34e-09 2.64e-06 -0.31 -0.26 Motion sickness; chr6:8496963 chr6:8784178~8785445:+ LUSC cis rs7267979 0.966 rs2482923 ENSG00000274973.1 RP13-401N8.7 5.92 6.34e-09 2.64e-06 0.27 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25328345 chr20:25845497~25845862:+ LUSC cis rs14027 0.921 rs2289011 ENSG00000279347.1 RP11-85I17.2 5.92 6.35e-09 2.64e-06 0.24 0.26 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119744768 chr8:119838736~119840385:- LUSC cis rs1075265 0.756 rs698854 ENSG00000233266.1 HMGB1P31 5.92 6.35e-09 2.64e-06 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:53826784 chr2:54051334~54051760:+ LUSC cis rs9435732 0.832 rs2076602 ENSG00000235241.1 RP11-108M9.5 5.92 6.35e-09 2.64e-06 0.38 0.26 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:16996703 chr1:16889095~16889602:+ LUSC cis rs13113518 1 rs7662966 ENSG00000273257.1 RP11-177J6.1 5.92 6.35e-09 2.64e-06 0.33 0.26 Height; chr4:55548261 chr4:55387949~55388271:+ LUSC cis rs9287719 0.674 rs759399 ENSG00000234818.1 AC092687.5 -5.92 6.35e-09 2.64e-06 -0.3 -0.26 Prostate cancer; chr2:10656757 chr2:10589166~10604830:+ LUSC cis rs7267979 0.816 rs6076358 ENSG00000274973.1 RP13-401N8.7 5.92 6.36e-09 2.64e-06 0.26 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25538767 chr20:25845497~25845862:+ LUSC cis rs875971 0.638 rs35986979 ENSG00000222364.1 RNU6-96P 5.92 6.36e-09 2.65e-06 0.3 0.26 Aortic root size; chr7:66624003 chr7:66395191~66395286:+ LUSC cis rs13113518 0.812 rs12500686 ENSG00000273257.1 RP11-177J6.1 5.92 6.36e-09 2.65e-06 0.37 0.26 Height; chr4:55457922 chr4:55387949~55388271:+ LUSC cis rs4660456 0.504 rs2744805 ENSG00000237899.1 RP4-739H11.3 5.92 6.36e-09 2.65e-06 0.4 0.26 Platelet count; chr1:40654827 chr1:40669089~40687588:- LUSC cis rs5770917 1 rs2073605 ENSG00000273272.1 CTA-384D8.34 5.92 6.36e-09 2.65e-06 0.53 0.26 Narcolepsy; chr22:50570421 chr22:50542650~50543011:+ LUSC cis rs9611519 0.929 rs4820423 ENSG00000235513.1 RP4-756G23.5 5.92 6.37e-09 2.65e-06 0.31 0.26 Neuroticism; chr22:41034334 chr22:41209122~41217627:- LUSC cis rs10129255 0.646 rs55995061 ENSG00000254174.1 IGHV1-12 5.92 6.38e-09 2.65e-06 0.26 0.26 Kawasaki disease; chr14:106799309 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs76871148 ENSG00000254174.1 IGHV1-12 5.92 6.38e-09 2.65e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106799722 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs61521632 ENSG00000254174.1 IGHV1-12 5.92 6.38e-09 2.65e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106801091 chr14:106122420~106122709:- LUSC cis rs875971 0.66 rs10281080 ENSG00000237310.1 GS1-124K5.4 -5.92 6.38e-09 2.65e-06 -0.26 -0.26 Aortic root size; chr7:66577454 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs10950044 ENSG00000237310.1 GS1-124K5.4 -5.92 6.38e-09 2.65e-06 -0.26 -0.26 Aortic root size; chr7:66577989 chr7:66493706~66495474:+ LUSC cis rs7267979 1 rs2482927 ENSG00000274973.1 RP13-401N8.7 5.92 6.39e-09 2.66e-06 0.27 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25346515 chr20:25845497~25845862:+ LUSC cis rs227275 0.556 rs6821173 ENSG00000230069.3 LRRC37A15P -5.92 6.39e-09 2.66e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102966404 chr4:102727274~102730721:- LUSC cis rs7208859 0.573 rs56031503 ENSG00000266490.1 CTD-2349P21.9 5.92 6.39e-09 2.66e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30792372~30792833:+ LUSC cis rs9341835 0.74 rs9294215 ENSG00000218048.2 RP3-407E4.4 5.91 6.4e-09 2.66e-06 0.31 0.26 Schizophrenia; chr6:63441866 chr6:63440766~63443580:+ LUSC cis rs7429990 0.965 rs319689 ENSG00000228638.1 FCF1P2 -5.91 6.4e-09 2.66e-06 -0.3 -0.26 Educational attainment (years of education); chr3:47886677 chr3:48290793~48291375:- LUSC cis rs227275 0.554 rs223466 ENSG00000246560.2 RP11-10L12.4 5.91 6.41e-09 2.67e-06 0.32 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102780039 chr4:102828055~102844075:+ LUSC cis rs11089937 0.597 rs5757027 ENSG00000211638.2 IGLV8-61 -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22137683 chr22:22098700~22099212:+ LUSC cis rs11089937 0.626 rs5757028 ENSG00000211638.2 IGLV8-61 -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22137699 chr22:22098700~22099212:+ LUSC cis rs11089937 0.597 rs2213156 ENSG00000211638.2 IGLV8-61 -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22137852 chr22:22098700~22099212:+ LUSC cis rs11089937 0.626 rs2213157 ENSG00000211638.2 IGLV8-61 -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22137997 chr22:22098700~22099212:+ LUSC cis rs11089937 0.626 rs9622955 ENSG00000211638.2 IGLV8-61 -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22138343 chr22:22098700~22099212:+ LUSC cis rs11089937 0.626 rs4821781 ENSG00000211638.2 IGLV8-61 -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22138845 chr22:22098700~22099212:+ LUSC cis rs11089937 0.626 rs5750589 ENSG00000211638.2 IGLV8-61 -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22139655 chr22:22098700~22099212:+ LUSC cis rs11089937 0.626 rs5757038 ENSG00000211638.2 IGLV8-61 -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22140149 chr22:22098700~22099212:+ LUSC cis rs62229266 0.626 rs7280896 ENSG00000231106.2 LINC01436 5.91 6.41e-09 2.67e-06 0.33 0.26 Mitral valve prolapse; chr21:36088608 chr21:36005338~36007838:+ LUSC cis rs11089937 0.626 rs5757017 ENSG00000211638.2 IGLV8-61 -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22135947 chr22:22098700~22099212:+ LUSC cis rs7665090 0.967 rs6812747 ENSG00000230069.3 LRRC37A15P -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102634260 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs6839064 ENSG00000230069.3 LRRC37A15P -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102634519 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs2272695 ENSG00000230069.3 LRRC37A15P -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102634646 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs2272696 ENSG00000230069.3 LRRC37A15P -5.91 6.41e-09 2.67e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102634664 chr4:102727274~102730721:- LUSC cis rs875971 0.862 rs10276077 ENSG00000179406.6 LINC00174 5.91 6.42e-09 2.67e-06 0.28 0.26 Aortic root size; chr7:66263424 chr7:66376044~66401338:- LUSC cis rs4718428 0.672 rs12530806 ENSG00000226824.5 RP4-756H11.3 -5.91 6.42e-09 2.67e-06 -0.36 -0.26 Corneal structure; chr7:66925737 chr7:66654538~66669855:+ LUSC cis rs67311347 0.544 rs2887965 ENSG00000223797.4 ENTPD3-AS1 -5.91 6.43e-09 2.67e-06 -0.27 -0.26 Renal cell carcinoma; chr3:40292663 chr3:40313802~40453329:- LUSC cis rs7246657 0.722 rs2972447 ENSG00000276846.1 CTD-3220F14.3 -5.91 6.43e-09 2.67e-06 -0.38 -0.26 Coronary artery calcification; chr19:37638835 chr19:37314868~37315620:- LUSC cis rs7246657 0.678 rs2972446 ENSG00000276846.1 CTD-3220F14.3 -5.91 6.43e-09 2.67e-06 -0.38 -0.26 Coronary artery calcification; chr19:37638992 chr19:37314868~37315620:- LUSC cis rs2562456 0.874 rs2562417 ENSG00000268081.1 RP11-678G14.2 -5.91 6.44e-09 2.67e-06 -0.38 -0.26 Pain; chr19:21528400 chr19:21554640~21569237:- LUSC cis rs875971 0.862 rs10282433 ENSG00000179406.6 LINC00174 5.91 6.45e-09 2.68e-06 0.28 0.26 Aortic root size; chr7:66256452 chr7:66376044~66401338:- LUSC cis rs801193 0.844 rs2244022 ENSG00000237310.1 GS1-124K5.4 5.91 6.45e-09 2.68e-06 0.26 0.26 Aortic root size; chr7:66737443 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs10281080 ENSG00000222364.1 RNU6-96P 5.91 6.45e-09 2.68e-06 0.3 0.26 Aortic root size; chr7:66577454 chr7:66395191~66395286:+ LUSC cis rs875971 0.66 rs10950044 ENSG00000222364.1 RNU6-96P 5.91 6.45e-09 2.68e-06 0.3 0.26 Aortic root size; chr7:66577989 chr7:66395191~66395286:+ LUSC cis rs2284378 0.515 rs6059579 ENSG00000275784.1 RP5-1125A11.6 -5.91 6.45e-09 2.68e-06 -0.29 -0.26 Breast cancer; chr20:33940059 chr20:33989480~33991818:- LUSC cis rs2153535 0.58 rs7743418 ENSG00000230939.1 RP11-314C16.1 -5.91 6.45e-09 2.68e-06 -0.31 -0.26 Motion sickness; chr6:8437895 chr6:8784178~8785445:+ LUSC cis rs11096990 0.634 rs2062229 ENSG00000249207.1 RP11-360F5.1 -5.91 6.45e-09 2.68e-06 -0.28 -0.26 Cognitive function; chr4:39285146 chr4:39112677~39126818:- LUSC cis rs11846409 0.932 rs10151046 ENSG00000274576.2 IGHV2-70 -5.91 6.46e-09 2.68e-06 -0.27 -0.26 Rheumatic heart disease; chr14:106633095 chr14:106770577~106771020:- LUSC cis rs11690935 0.885 rs6725388 ENSG00000228389.1 AC068039.4 5.91 6.46e-09 2.68e-06 0.3 0.26 Schizophrenia; chr2:171873505 chr2:171773482~171775844:+ LUSC cis rs1823913 0.637 rs4853584 ENSG00000280083.1 RP11-317J9.1 5.91 6.46e-09 2.68e-06 0.31 0.26 Obesity-related traits; chr2:191310596 chr2:191154118~191156070:- LUSC cis rs11098499 0.604 rs12642411 ENSG00000248280.1 RP11-33B1.2 5.91 6.47e-09 2.69e-06 0.32 0.26 Corneal astigmatism; chr4:119659370 chr4:119440561~119450157:- LUSC cis rs950169 0.8 rs34302901 ENSG00000259295.5 CSPG4P12 5.91 6.47e-09 2.69e-06 0.34 0.26 Schizophrenia; chr15:84567712 chr15:85191438~85213905:+ LUSC cis rs1061377 1 rs4974931 ENSG00000249685.1 RP11-360F5.3 5.91 6.48e-09 2.69e-06 0.3 0.26 Uric acid levels; chr4:39108896 chr4:39133913~39135608:+ LUSC cis rs7665090 1 rs2272697 ENSG00000230069.3 LRRC37A15P -5.91 6.48e-09 2.69e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102634835 chr4:102727274~102730721:- LUSC cis rs9532669 0.926 rs7799 ENSG00000176268.5 CYCSP34 5.91 6.48e-09 2.69e-06 0.27 0.26 Cervical cancer; chr13:40958916 chr13:40863599~40863902:- LUSC cis rs6772849 0.93 rs9873888 ENSG00000277250.1 Metazoa_SRP -5.91 6.5e-09 2.7e-06 -0.29 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128642144 chr3:128673681~128674021:- LUSC cis rs8005677 1 rs8014936 ENSG00000279656.1 RP11-298I3.6 5.91 6.5e-09 2.7e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22905936 chr14:23023083~23024217:- LUSC cis rs8005677 1 rs8016061 ENSG00000279656.1 RP11-298I3.6 5.91 6.5e-09 2.7e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22906600 chr14:23023083~23024217:- LUSC cis rs8005677 1 rs8005677 ENSG00000279656.1 RP11-298I3.6 5.91 6.5e-09 2.7e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22907469 chr14:23023083~23024217:- LUSC cis rs875971 0.792 rs6971752 ENSG00000179406.6 LINC00174 5.91 6.5e-09 2.7e-06 0.28 0.26 Aortic root size; chr7:66272999 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs10950033 ENSG00000179406.6 LINC00174 5.91 6.5e-09 2.7e-06 0.28 0.26 Aortic root size; chr7:66274686 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs11760844 ENSG00000179406.6 LINC00174 5.91 6.5e-09 2.7e-06 0.28 0.26 Aortic root size; chr7:66274896 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs4149461 ENSG00000179406.6 LINC00174 5.91 6.5e-09 2.7e-06 0.28 0.26 Aortic root size; chr7:66279745 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs4236208 ENSG00000179406.6 LINC00174 5.91 6.5e-09 2.7e-06 0.28 0.26 Aortic root size; chr7:66284091 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs10261398 ENSG00000179406.6 LINC00174 5.91 6.5e-09 2.7e-06 0.28 0.26 Aortic root size; chr7:66285177 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs10224872 ENSG00000179406.6 LINC00174 5.91 6.5e-09 2.7e-06 0.28 0.26 Aortic root size; chr7:66294786 chr7:66376044~66401338:- LUSC cis rs2153535 0.58 rs6905237 ENSG00000230939.1 RP11-314C16.1 -5.91 6.5e-09 2.7e-06 -0.32 -0.26 Motion sickness; chr6:8471557 chr6:8784178~8785445:+ LUSC cis rs2153535 0.542 rs4440510 ENSG00000230939.1 RP11-314C16.1 -5.91 6.5e-09 2.7e-06 -0.32 -0.26 Motion sickness; chr6:8471585 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs1414347 ENSG00000230939.1 RP11-314C16.1 -5.91 6.5e-09 2.7e-06 -0.32 -0.26 Motion sickness; chr6:8471598 chr6:8784178~8785445:+ LUSC cis rs13113518 1 rs13113518 ENSG00000223305.1 RN7SKP30 5.91 6.5e-09 2.7e-06 0.32 0.26 Height; chr4:55533481 chr4:55540502~55540835:- LUSC cis rs11089937 0.609 rs9622980 ENSG00000211638.2 IGLV8-61 -5.91 6.51e-09 2.7e-06 -0.29 -0.26 Periodontitis (PAL4Q3); chr22:22149888 chr22:22098700~22099212:+ LUSC cis rs2276314 0.762 rs3826600 ENSG00000278986.1 RP11-723J4.3 -5.91 6.52e-09 2.71e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36029090 chr18:35972151~35973916:+ LUSC cis rs2179367 0.632 rs9498325 ENSG00000231760.4 RP11-350J20.5 5.91 6.52e-09 2.71e-06 0.37 0.26 Dupuytren's disease; chr6:149345993 chr6:149796151~149826294:- LUSC cis rs2179367 0.632 rs9498326 ENSG00000231760.4 RP11-350J20.5 5.91 6.52e-09 2.71e-06 0.37 0.26 Dupuytren's disease; chr6:149346112 chr6:149796151~149826294:- LUSC cis rs875971 1 rs778726 ENSG00000179406.6 LINC00174 -5.91 6.52e-09 2.71e-06 -0.28 -0.26 Aortic root size; chr7:66363744 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs778723 ENSG00000179406.6 LINC00174 -5.91 6.52e-09 2.71e-06 -0.28 -0.26 Aortic root size; chr7:66364510 chr7:66376044~66401338:- LUSC cis rs875971 0.767 rs1695815 ENSG00000179406.6 LINC00174 -5.91 6.52e-09 2.71e-06 -0.28 -0.26 Aortic root size; chr7:66366357 chr7:66376044~66401338:- LUSC cis rs875971 1 rs778685 ENSG00000179406.6 LINC00174 -5.91 6.52e-09 2.71e-06 -0.28 -0.26 Aortic root size; chr7:66371189 chr7:66376044~66401338:- LUSC cis rs875971 0.929 rs778682 ENSG00000179406.6 LINC00174 -5.91 6.52e-09 2.71e-06 -0.28 -0.26 Aortic root size; chr7:66372947 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs11765965 ENSG00000179406.6 LINC00174 -5.91 6.52e-09 2.71e-06 -0.28 -0.26 Aortic root size; chr7:66377234 chr7:66376044~66401338:- LUSC cis rs7267979 0.868 rs6138550 ENSG00000274973.1 RP13-401N8.7 -5.91 6.53e-09 2.71e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25242794 chr20:25845497~25845862:+ LUSC cis rs7267979 0.903 rs6050481 ENSG00000274973.1 RP13-401N8.7 -5.91 6.53e-09 2.71e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25243944 chr20:25845497~25845862:+ LUSC cis rs7267979 0.834 rs6115100 ENSG00000274973.1 RP13-401N8.7 -5.91 6.53e-09 2.71e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25245302 chr20:25845497~25845862:+ LUSC cis rs7772486 0.875 rs9322044 ENSG00000235652.6 RP11-545I5.3 5.91 6.53e-09 2.71e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146048472 chr6:145799409~145886585:+ LUSC cis rs113835537 0.935 rs1127145 ENSG00000255517.5 CTD-3074O7.5 -5.91 6.53e-09 2.71e-06 -0.36 -0.26 Airway imaging phenotypes; chr11:66605834 chr11:66473490~66480233:- LUSC cis rs13113518 0.812 rs7667741 ENSG00000273257.1 RP11-177J6.1 5.91 6.53e-09 2.71e-06 0.34 0.26 Height; chr4:55544621 chr4:55387949~55388271:+ LUSC cis rs875971 0.638 rs6460305 ENSG00000222364.1 RNU6-96P 5.91 6.54e-09 2.71e-06 0.3 0.26 Aortic root size; chr7:66595421 chr7:66395191~66395286:+ LUSC cis rs9322193 0.924 rs9322189 ENSG00000268592.3 RAET1E-AS1 5.91 6.54e-09 2.71e-06 0.34 0.26 Lung cancer; chr6:149588797 chr6:149863494~149919507:+ LUSC cis rs7208859 0.623 rs28556733 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30729469~30731202:+ LUSC cis rs17826219 0.5 rs28452421 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Body mass index; chr17:30756962 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs28433704 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30729469~30731202:+ LUSC cis rs7208859 0.573 rs28779471 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs11658022 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758341 chr17:30729469~30731202:+ LUSC cis rs17826219 0.5 rs61685770 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Body mass index; chr17:30758695 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs57486336 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30729469~30731202:+ LUSC cis rs17826219 0.706 rs55764512 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Body mass index; chr17:30758740 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs12103440 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs12103508 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30729469~30731202:+ LUSC cis rs7208859 0.524 rs11653605 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs11657777 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs73269913 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs7217984 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.54e-09 2.71e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30729469~30731202:+ LUSC cis rs11846409 0.86 rs4774166 ENSG00000274576.2 IGHV2-70 -5.91 6.55e-09 2.72e-06 -0.28 -0.26 Rheumatic heart disease; chr14:106619598 chr14:106770577~106771020:- LUSC cis rs1056107 0.931 rs7852473 ENSG00000225513.1 RP11-165N19.2 -5.91 6.55e-09 2.72e-06 -0.29 -0.26 Colorectal cancer; chr9:112245751 chr9:112173522~112173971:- LUSC cis rs7772486 0.875 rs12194437 ENSG00000235652.6 RP11-545I5.3 5.91 6.57e-09 2.72e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146090304 chr6:145799409~145886585:+ LUSC cis rs11971779 0.68 rs10271297 ENSG00000273391.1 RP11-634H22.1 5.91 6.57e-09 2.72e-06 0.28 0.26 Diisocyanate-induced asthma; chr7:139367564 chr7:139359032~139359566:- LUSC cis rs13113518 1 rs4864995 ENSG00000273257.1 RP11-177J6.1 5.91 6.57e-09 2.73e-06 0.34 0.26 Height; chr4:55452853 chr4:55387949~55388271:+ LUSC cis rs2404602 0.735 rs12906143 ENSG00000259422.1 RP11-593F23.1 -5.91 6.58e-09 2.73e-06 -0.31 -0.26 Blood metabolite levels; chr15:76417182 chr15:76174891~76181486:- LUSC cis rs638893 0.947 rs515707 ENSG00000278376.1 RP11-158I9.8 -5.91 6.58e-09 2.73e-06 -0.33 -0.26 Vitiligo; chr11:118814772 chr11:118791254~118793137:+ LUSC cis rs638893 0.898 rs587816 ENSG00000278376.1 RP11-158I9.8 -5.91 6.58e-09 2.73e-06 -0.33 -0.26 Vitiligo; chr11:118819162 chr11:118791254~118793137:+ LUSC cis rs35160687 0.644 rs17738058 ENSG00000273080.1 RP11-301O19.1 -5.91 6.58e-09 2.73e-06 -0.25 -0.26 Night sleep phenotypes; chr2:86286080 chr2:86195590~86196049:+ LUSC cis rs1320333 0.772 rs2867136 ENSG00000233296.1 AC092159.2 -5.91 6.58e-09 2.73e-06 -0.44 -0.26 Obesity-related traits; chr2:701455 chr2:677186~697371:+ LUSC cis rs992157 0.56 rs6436048 ENSG00000261338.2 RP11-378A13.1 5.91 6.59e-09 2.73e-06 0.27 0.26 Colorectal cancer; chr2:218244310 chr2:218255319~218257366:+ LUSC cis rs2179367 0.632 rs11155642 ENSG00000231760.4 RP11-350J20.5 5.91 6.6e-09 2.73e-06 0.37 0.26 Dupuytren's disease; chr6:149332984 chr6:149796151~149826294:- LUSC cis rs7665090 1 rs7677509 ENSG00000230069.3 LRRC37A15P -5.91 6.61e-09 2.74e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102628849 chr4:102727274~102730721:- LUSC cis rs7665090 0.967 rs7699231 ENSG00000230069.3 LRRC37A15P -5.91 6.61e-09 2.74e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102628918 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs7699678 ENSG00000230069.3 LRRC37A15P -5.91 6.61e-09 2.74e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102628939 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs11724614 ENSG00000230069.3 LRRC37A15P -5.91 6.61e-09 2.74e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102629091 chr4:102727274~102730721:- LUSC cis rs7267979 1 rs2258719 ENSG00000274973.1 RP13-401N8.7 -5.91 6.61e-09 2.74e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25295207 chr20:25845497~25845862:+ LUSC cis rs11098499 0.71 rs4145952 ENSG00000249244.1 RP11-548H18.2 5.91 6.62e-09 2.74e-06 0.32 0.26 Corneal astigmatism; chr4:119234651 chr4:119391831~119395335:- LUSC cis rs7772486 0.875 rs2180192 ENSG00000235652.6 RP11-545I5.3 5.91 6.62e-09 2.74e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146001148 chr6:145799409~145886585:+ LUSC cis rs2153535 0.58 rs1414342 ENSG00000230939.1 RP11-314C16.1 -5.91 6.64e-09 2.75e-06 -0.31 -0.26 Motion sickness; chr6:8462319 chr6:8784178~8785445:+ LUSC cis rs2153535 0.521 rs6939827 ENSG00000230939.1 RP11-314C16.1 -5.91 6.65e-09 2.76e-06 -0.31 -0.26 Motion sickness; chr6:8461127 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9393019 ENSG00000230939.1 RP11-314C16.1 -5.91 6.65e-09 2.76e-06 -0.31 -0.26 Motion sickness; chr6:8461858 chr6:8784178~8785445:+ LUSC cis rs7182621 0.639 rs1561048 ENSG00000259363.4 CTD-2054N24.2 -5.91 6.65e-09 2.76e-06 -0.32 -0.26 Colonoscopy-negative controls vs population controls; chr15:99875369 chr15:99807023~99877148:+ LUSC cis rs4604732 0.536 rs12037221 ENSG00000227135.1 GCSAML-AS1 -5.91 6.65e-09 2.76e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247467910 chr1:247524679~247526752:- LUSC cis rs4604732 0.536 rs12074913 ENSG00000227135.1 GCSAML-AS1 -5.91 6.65e-09 2.76e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247468305 chr1:247524679~247526752:- LUSC cis rs4604732 0.588 rs4925551 ENSG00000227135.1 GCSAML-AS1 -5.91 6.65e-09 2.76e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247468422 chr1:247524679~247526752:- LUSC cis rs11846409 0.86 rs74091720 ENSG00000274576.2 IGHV2-70 -5.91 6.66e-09 2.76e-06 -0.27 -0.26 Rheumatic heart disease; chr14:106638192 chr14:106770577~106771020:- LUSC cis rs6504950 0.854 rs244322 ENSG00000275710.1 RP11-257O5.4 5.91 6.66e-09 2.76e-06 0.31 0.26 Breast cancer; chr17:55147398 chr17:54964474~54964679:+ LUSC cis rs8005677 0.828 rs8016027 ENSG00000279656.1 RP11-298I3.6 5.91 6.66e-09 2.76e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22950944 chr14:23023083~23024217:- LUSC cis rs853679 1 rs853685 ENSG00000219392.1 RP1-265C24.5 -5.91 6.67e-09 2.76e-06 -0.44 -0.26 Depression; chr6:28321008 chr6:28115628~28116551:+ LUSC cis rs881375 0.678 rs1014530 ENSG00000226752.6 PSMD5-AS1 -5.91 6.67e-09 2.76e-06 -0.29 -0.26 Rheumatoid arthritis; chr9:120922814 chr9:120824828~120854385:+ LUSC cis rs783540 0.867 rs10906984 ENSG00000255769.6 GOLGA2P10 -5.91 6.67e-09 2.76e-06 -0.32 -0.26 Schizophrenia; chr15:82697544 chr15:82472993~82513950:- LUSC cis rs875971 0.577 rs34888281 ENSG00000237310.1 GS1-124K5.4 -5.91 6.68e-09 2.76e-06 -0.27 -0.26 Aortic root size; chr7:66120784 chr7:66493706~66495474:+ LUSC cis rs8091660 0.624 rs2175565 ENSG00000278983.1 RP11-426J5.3 -5.91 6.68e-09 2.77e-06 -0.38 -0.26 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48553481 chr18:48564795~48568342:+ LUSC cis rs2153535 0.563 rs1796688 ENSG00000230939.1 RP11-314C16.1 -5.91 6.69e-09 2.77e-06 -0.31 -0.26 Motion sickness; chr6:8536190 chr6:8784178~8785445:+ LUSC cis rs2153535 0.526 rs1796689 ENSG00000230939.1 RP11-314C16.1 -5.91 6.69e-09 2.77e-06 -0.31 -0.26 Motion sickness; chr6:8536200 chr6:8784178~8785445:+ LUSC cis rs7429990 0.864 rs883662 ENSG00000229759.1 MRPS18AP1 5.91 6.69e-09 2.77e-06 0.27 0.26 Educational attainment (years of education); chr3:47619342 chr3:48256350~48256938:- LUSC cis rs2028299 0.879 rs7163629 ENSG00000259677.1 RP11-493E3.1 5.91 6.69e-09 2.77e-06 0.34 0.26 Type 2 diabetes; chr15:89873508 chr15:89876540~89877285:+ LUSC cis rs55894132 1 rs55894132 ENSG00000279656.1 RP11-298I3.6 5.91 6.7e-09 2.77e-06 0.31 0.26 Intelligence (multi-trait analysis); chr14:22939628 chr14:23023083~23024217:- LUSC cis rs11846409 0.932 rs2015469 ENSG00000274576.2 IGHV2-70 -5.91 6.71e-09 2.78e-06 -0.26 -0.26 Rheumatic heart disease; chr14:106631857 chr14:106770577~106771020:- LUSC cis rs2153535 0.541 rs1414353 ENSG00000230939.1 RP11-314C16.1 -5.91 6.71e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8485409 chr6:8784178~8785445:+ LUSC cis rs2153535 0.525 rs1335644 ENSG00000230939.1 RP11-314C16.1 -5.91 6.71e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8487808 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9393025 ENSG00000230939.1 RP11-314C16.1 -5.91 6.71e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8490385 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1414340 ENSG00000230939.1 RP11-314C16.1 -5.91 6.71e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8490906 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1335628 ENSG00000230939.1 RP11-314C16.1 -5.91 6.71e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8491509 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6597330 ENSG00000230939.1 RP11-314C16.1 -5.91 6.71e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8491843 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6941771 ENSG00000230939.1 RP11-314C16.1 -5.91 6.71e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8494219 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6937186 ENSG00000230939.1 RP11-314C16.1 -5.91 6.71e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8494260 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6921036 ENSG00000230939.1 RP11-314C16.1 -5.91 6.72e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8455167 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6926759 ENSG00000230939.1 RP11-314C16.1 -5.91 6.72e-09 2.78e-06 -0.31 -0.26 Motion sickness; chr6:8455943 chr6:8784178~8785445:+ LUSC cis rs925255 0.774 rs7562 ENSG00000270210.1 RP11-373D23.3 -5.91 6.72e-09 2.78e-06 -0.29 -0.26 Inflammatory bowel disease;Crohn's disease; chr2:28412873 chr2:28425945~28426719:+ LUSC cis rs875971 0.545 rs4718348 ENSG00000226824.5 RP4-756H11.3 -5.91 6.73e-09 2.78e-06 -0.35 -0.26 Aortic root size; chr7:66441589 chr7:66654538~66669855:+ LUSC cis rs7772486 0.743 rs111332144 ENSG00000235652.6 RP11-545I5.3 -5.91 6.73e-09 2.78e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145735545 chr6:145799409~145886585:+ LUSC cis rs853679 0.55 rs1233704 ENSG00000280107.1 AL022393.9 5.91 6.73e-09 2.78e-06 0.31 0.26 Depression; chr6:28199145 chr6:28170845~28172521:+ LUSC cis rs2404602 0.552 rs11636612 ENSG00000259422.1 RP11-593F23.1 -5.91 6.73e-09 2.79e-06 -0.34 -0.26 Blood metabolite levels; chr15:76667189 chr15:76174891~76181486:- LUSC cis rs62432291 0.681 rs433786 ENSG00000235086.1 FNDC1-IT1 -5.91 6.74e-09 2.79e-06 -0.46 -0.26 Joint mobility (Beighton score); chr6:159244914 chr6:159240786~159243329:+ LUSC cis rs2732480 0.557 rs2732454 ENSG00000226413.2 OR8T1P 5.91 6.74e-09 2.79e-06 0.34 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48325894 chr12:48442030~48442947:- LUSC cis rs875971 0.66 rs79009421 ENSG00000222364.1 RNU6-96P 5.91 6.75e-09 2.79e-06 0.3 0.26 Aortic root size; chr7:66603522 chr7:66395191~66395286:+ LUSC cis rs11159086 1 rs4899516 ENSG00000259005.1 RP3-449M8.6 5.91 6.75e-09 2.79e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74492825 chr14:74474007~74474864:- LUSC cis rs67311347 0.956 rs11714871 ENSG00000223797.4 ENTPD3-AS1 5.91 6.76e-09 2.79e-06 0.3 0.26 Renal cell carcinoma; chr3:40387447 chr3:40313802~40453329:- LUSC cis rs67311347 1 rs2305521 ENSG00000223797.4 ENTPD3-AS1 5.91 6.76e-09 2.79e-06 0.3 0.26 Renal cell carcinoma; chr3:40387692 chr3:40313802~40453329:- LUSC cis rs1387259 0.859 rs2054905 ENSG00000273765.1 RP11-370I10.11 5.91 6.76e-09 2.79e-06 0.31 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48294168 chr12:48360920~48361377:+ LUSC cis rs2732480 0.5 rs2732461 ENSG00000273765.1 RP11-370I10.11 5.91 6.76e-09 2.79e-06 0.31 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48299019 chr12:48360920~48361377:+ LUSC cis rs7208859 0.623 rs73269916 ENSG00000263603.1 CTD-2349P21.5 -5.91 6.76e-09 2.8e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30729469~30731202:+ LUSC cis rs11089937 0.626 rs5757011 ENSG00000211638.2 IGLV8-61 -5.91 6.77e-09 2.8e-06 -0.28 -0.26 Periodontitis (PAL4Q3); chr22:22135336 chr22:22098700~22099212:+ LUSC cis rs6772849 0.896 rs4857859 ENSG00000277250.1 Metazoa_SRP -5.9 6.77e-09 2.8e-06 -0.29 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128629171 chr3:128673681~128674021:- LUSC cis rs13113518 1 rs4864549 ENSG00000273257.1 RP11-177J6.1 5.9 6.78e-09 2.8e-06 0.33 0.26 Height; chr4:55554380 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs4865011 ENSG00000273257.1 RP11-177J6.1 5.9 6.78e-09 2.8e-06 0.33 0.26 Height; chr4:55554456 chr4:55387949~55388271:+ LUSC cis rs116095464 0.558 rs6866632 ENSG00000250848.1 CTD-2083E4.5 -5.9 6.78e-09 2.81e-06 -0.39 -0.26 Breast cancer; chr5:264314 chr5:288833~290321:- LUSC cis rs8005677 1 rs1956881 ENSG00000279656.1 RP11-298I3.6 5.9 6.79e-09 2.81e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22924860 chr14:23023083~23024217:- LUSC cis rs2337406 0.866 rs7153964 ENSG00000254174.1 IGHV1-12 5.9 6.8e-09 2.81e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106790480 chr14:106122420~106122709:- LUSC cis rs1056107 0.931 rs7019056 ENSG00000225513.1 RP11-165N19.2 -5.9 6.8e-09 2.81e-06 -0.29 -0.26 Colorectal cancer; chr9:112248160 chr9:112173522~112173971:- LUSC cis rs875971 0.545 rs7783889 ENSG00000237310.1 GS1-124K5.4 5.9 6.82e-09 2.82e-06 0.3 0.26 Aortic root size; chr7:66283366 chr7:66493706~66495474:+ LUSC cis rs4803480 1 rs4803480 ENSG00000270164.1 LINC01480 -5.9 6.82e-09 2.82e-06 -0.23 -0.26 Schizophrenia; chr19:41559909 chr19:41535183~41536904:+ LUSC cis rs11098499 0.863 rs2306456 ENSG00000248280.1 RP11-33B1.2 5.9 6.82e-09 2.82e-06 0.31 0.26 Corneal astigmatism; chr4:119551267 chr4:119440561~119450157:- LUSC cis rs950169 0.959 rs12911210 ENSG00000259728.4 LINC00933 5.9 6.83e-09 2.82e-06 0.34 0.26 Schizophrenia; chr15:84123331 chr15:84570649~84580175:+ LUSC cis rs6502050 0.871 rs7226049 ENSG00000266654.1 RP11-1376P16.1 5.9 6.84e-09 2.83e-06 0.26 0.26 Life satisfaction; chr17:82113173 chr17:82160056~82160452:+ LUSC cis rs13113518 1 rs11726198 ENSG00000249700.7 SRD5A3-AS1 5.9 6.84e-09 2.83e-06 0.3 0.26 Height; chr4:55523835 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs7675109 ENSG00000249700.7 SRD5A3-AS1 5.9 6.84e-09 2.83e-06 0.3 0.26 Height; chr4:55525589 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs4865005 ENSG00000249700.7 SRD5A3-AS1 5.9 6.84e-09 2.83e-06 0.3 0.26 Height; chr4:55525781 chr4:55363971~55395847:- LUSC cis rs35160687 0.644 rs11680025 ENSG00000273080.1 RP11-301O19.1 -5.9 6.84e-09 2.83e-06 -0.25 -0.26 Night sleep phenotypes; chr2:86318215 chr2:86195590~86196049:+ LUSC cis rs34779708 0.733 rs7083266 ENSG00000230534.5 RP11-297A16.2 5.9 6.85e-09 2.83e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35252704 chr10:35098006~35127020:- LUSC cis rs9341835 0.74 rs10755410 ENSG00000218048.2 RP3-407E4.4 5.9 6.85e-09 2.83e-06 0.3 0.26 Schizophrenia; chr6:63440784 chr6:63440766~63443580:+ LUSC cis rs7772486 0.79 rs2254283 ENSG00000235652.6 RP11-545I5.3 5.9 6.85e-09 2.83e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145883153 chr6:145799409~145886585:+ LUSC cis rs853679 0.517 rs1904841 ENSG00000280107.1 AL022393.9 -5.9 6.85e-09 2.83e-06 -0.33 -0.26 Depression; chr6:28140307 chr6:28170845~28172521:+ LUSC cis rs34779708 0.766 rs7913451 ENSG00000230534.5 RP11-297A16.2 5.9 6.86e-09 2.83e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35262597 chr10:35098006~35127020:- LUSC cis rs11098499 0.863 rs1552092 ENSG00000248280.1 RP11-33B1.2 5.9 6.86e-09 2.84e-06 0.32 0.26 Corneal astigmatism; chr4:119567341 chr4:119440561~119450157:- LUSC cis rs875971 0.66 rs801192 ENSG00000237310.1 GS1-124K5.4 -5.9 6.87e-09 2.84e-06 -0.26 -0.26 Aortic root size; chr7:66566965 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs801190 ENSG00000237310.1 GS1-124K5.4 -5.9 6.87e-09 2.84e-06 -0.26 -0.26 Aortic root size; chr7:66568046 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs3857686 ENSG00000237310.1 GS1-124K5.4 -5.9 6.87e-09 2.84e-06 -0.26 -0.26 Aortic root size; chr7:66571204 chr7:66493706~66495474:+ LUSC cis rs875971 0.638 rs3898855 ENSG00000237310.1 GS1-124K5.4 -5.9 6.87e-09 2.84e-06 -0.26 -0.26 Aortic root size; chr7:66571411 chr7:66493706~66495474:+ LUSC cis rs875971 0.638 rs10278816 ENSG00000237310.1 GS1-124K5.4 -5.9 6.87e-09 2.84e-06 -0.26 -0.26 Aortic root size; chr7:66572000 chr7:66493706~66495474:+ LUSC cis rs5753618 0.509 rs5997902 ENSG00000236132.1 CTA-440B3.1 5.9 6.87e-09 2.84e-06 0.36 0.26 Colorectal cancer; chr22:31187021 chr22:31816379~31817491:- LUSC cis rs8177876 0.749 rs2278025 ENSG00000261838.4 RP11-303E16.6 -5.9 6.88e-09 2.84e-06 -0.6 -0.26 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81045636 chr16:81069854~81076598:+ LUSC cis rs7267979 0.789 rs4815400 ENSG00000274973.1 RP13-401N8.7 5.9 6.88e-09 2.84e-06 0.26 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25311924 chr20:25845497~25845862:+ LUSC cis rs6570726 0.689 rs411785 ENSG00000235652.6 RP11-545I5.3 5.9 6.89e-09 2.85e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145567262 chr6:145799409~145886585:+ LUSC cis rs2276314 0.947 rs4799831 ENSG00000278986.1 RP11-723J4.3 -5.9 6.89e-09 2.85e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35974812 chr18:35972151~35973916:+ LUSC cis rs227275 0.525 rs10028116 ENSG00000230069.3 LRRC37A15P -5.9 6.89e-09 2.85e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102931421 chr4:102727274~102730721:- LUSC cis rs2732480 0.577 rs2732486 ENSG00000240399.1 RP1-228P16.1 5.9 6.89e-09 2.85e-06 0.29 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344051 chr12:48054813~48055591:- LUSC cis rs2732480 0.517 rs2634676 ENSG00000240399.1 RP1-228P16.1 5.9 6.89e-09 2.85e-06 0.29 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344453 chr12:48054813~48055591:- LUSC cis rs28830936 1 rs17677991 ENSG00000250379.1 RP11-23P13.4 5.9 6.89e-09 2.85e-06 0.28 0.26 Diastolic blood pressure; chr15:41740185 chr15:41825099~41827936:- LUSC cis rs28830936 1 rs12440747 ENSG00000250379.1 RP11-23P13.4 5.9 6.89e-09 2.85e-06 0.28 0.26 Diastolic blood pressure; chr15:41744492 chr15:41825099~41827936:- LUSC cis rs6570726 0.935 rs384519 ENSG00000235652.6 RP11-545I5.3 5.9 6.89e-09 2.85e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145524881 chr6:145799409~145886585:+ LUSC cis rs9341835 0.74 rs7763834 ENSG00000218048.2 RP3-407E4.4 5.9 6.91e-09 2.85e-06 0.3 0.26 Schizophrenia; chr6:63439452 chr6:63440766~63443580:+ LUSC cis rs9341835 0.681 rs9352960 ENSG00000218048.2 RP3-407E4.4 5.9 6.91e-09 2.85e-06 0.3 0.26 Schizophrenia; chr6:63440521 chr6:63440766~63443580:+ LUSC cis rs6671200 0.573 rs3738171 ENSG00000228852.5 RP11-57H12.5 -5.9 6.91e-09 2.85e-06 -0.35 -0.26 Stearic acid (18:0) levels; chr1:95234038 chr1:95243167~95278940:- LUSC cis rs875971 1 rs4718357 ENSG00000179406.6 LINC00174 -5.9 6.91e-09 2.85e-06 -0.28 -0.26 Aortic root size; chr7:66495891 chr7:66376044~66401338:- LUSC cis rs875971 0.66 rs6460308 ENSG00000222364.1 RNU6-96P 5.9 6.91e-09 2.85e-06 0.3 0.26 Aortic root size; chr7:66619753 chr7:66395191~66395286:+ LUSC cis rs61142792 0.59 rs747861 ENSG00000249109.1 RP11-1026M7.2 -5.9 6.92e-09 2.86e-06 -0.5 -0.26 Alzheimer disease and age of onset; chr5:177610396 chr5:177782197~177794396:+ LUSC cis rs6570726 0.935 rs377130 ENSG00000235652.6 RP11-545I5.3 5.9 6.92e-09 2.86e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145515496 chr6:145799409~145886585:+ LUSC cis rs13113518 0.934 rs10866425 ENSG00000223305.1 RN7SKP30 5.9 6.93e-09 2.86e-06 0.32 0.26 Height; chr4:55582068 chr4:55540502~55540835:- LUSC cis rs6951245 0.872 rs11768895 ENSG00000224079.1 AC091729.7 -5.9 6.93e-09 2.86e-06 -0.43 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1024055 chr7:1074450~1078036:+ LUSC cis rs4713118 0.513 rs156734 ENSG00000216901.1 AL022393.7 5.9 6.93e-09 2.86e-06 0.3 0.26 Parkinson's disease; chr6:28039579 chr6:28176188~28176674:+ LUSC cis rs7267979 0.844 rs6115188 ENSG00000274973.1 RP13-401N8.7 -5.9 6.93e-09 2.86e-06 -0.26 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25451534 chr20:25845497~25845862:+ LUSC cis rs11098499 0.863 rs12498539 ENSG00000248280.1 RP11-33B1.2 5.9 6.94e-09 2.86e-06 0.31 0.26 Corneal astigmatism; chr4:119547215 chr4:119440561~119450157:- LUSC cis rs875971 0.66 rs10229345 ENSG00000224316.1 RP11-479O9.2 5.9 6.94e-09 2.87e-06 0.25 0.26 Aortic root size; chr7:66517181 chr7:65773620~65802067:+ LUSC cis rs889398 0.967 rs12599391 ENSG00000226232.7 RP11-419C5.2 -5.9 6.95e-09 2.87e-06 -0.25 -0.26 Body mass index; chr16:69571446 chr16:69976388~69996188:- LUSC cis rs875971 0.66 rs7807930 ENSG00000222364.1 RNU6-96P 5.9 6.95e-09 2.87e-06 0.3 0.26 Aortic root size; chr7:66622178 chr7:66395191~66395286:+ LUSC cis rs77972916 0.609 rs72790907 ENSG00000234936.1 AC010883.5 5.9 6.96e-09 2.87e-06 0.38 0.26 Granulocyte percentage of myeloid white cells; chr2:43348056 chr2:43229573~43233394:+ LUSC cis rs73173548 0.502 rs71639111 ENSG00000247828.6 TMEM161B-AS1 5.9 6.96e-09 2.87e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88428788 chr5:88268895~88436685:+ LUSC cis rs77204473 0.744 rs12281009 ENSG00000254851.1 RP11-109L13.1 5.9 6.96e-09 2.87e-06 0.58 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117162243 chr11:117135528~117138582:+ LUSC cis rs9322193 0.923 rs62439840 ENSG00000268592.3 RAET1E-AS1 5.9 6.97e-09 2.88e-06 0.34 0.26 Lung cancer; chr6:149674639 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs9393175 ENSG00000268592.3 RAET1E-AS1 5.9 6.97e-09 2.88e-06 0.34 0.26 Lung cancer; chr6:149677587 chr6:149863494~149919507:+ LUSC cis rs17772222 0.63 rs2778936 ENSG00000258789.1 RP11-507K2.3 5.9 6.97e-09 2.88e-06 0.29 0.26 Coronary artery calcification; chr14:88505959 chr14:88551597~88552493:+ LUSC cis rs61160187 0.604 rs7704338 ENSG00000215032.2 GNL3LP1 5.9 6.97e-09 2.88e-06 0.33 0.26 Educational attainment (years of education);Educational attainment (college completion); chr5:60690328 chr5:60891935~60893577:- LUSC cis rs61160187 0.604 rs7719611 ENSG00000215032.2 GNL3LP1 5.9 6.97e-09 2.88e-06 0.33 0.26 Educational attainment (years of education);Educational attainment (college completion); chr5:60692720 chr5:60891935~60893577:- LUSC cis rs2243480 1 rs1638734 ENSG00000226824.5 RP4-756H11.3 -5.9 6.98e-09 2.88e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66632552 chr7:66654538~66669855:+ LUSC cis rs7772486 0.84 rs11155451 ENSG00000235652.6 RP11-545I5.3 5.9 6.98e-09 2.88e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146101388 chr6:145799409~145886585:+ LUSC cis rs28830936 1 rs9672360 ENSG00000250379.1 RP11-23P13.4 5.9 6.98e-09 2.88e-06 0.28 0.26 Diastolic blood pressure; chr15:41620213 chr15:41825099~41827936:- LUSC cis rs7119038 0.509 rs10892258 ENSG00000255422.1 AP002954.4 -5.9 6.99e-09 2.88e-06 -0.34 -0.26 Sjögren's syndrome; chr11:118709156 chr11:118704607~118750263:+ LUSC cis rs2337406 0.866 rs7140974 ENSG00000254174.1 IGHV1-12 5.9 6.99e-09 2.88e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106795976 chr14:106122420~106122709:- LUSC cis rs2153535 0.607 rs9502722 ENSG00000230939.1 RP11-314C16.1 -5.9 6.99e-09 2.89e-06 -0.32 -0.26 Motion sickness; chr6:8541250 chr6:8784178~8785445:+ LUSC cis rs2337406 0.866 rs78462736 ENSG00000211974.3 IGHV2-70 -5.9 7e-09 2.89e-06 -0.35 -0.26 Alzheimer's disease (late onset); chr14:106779942 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs8016203 ENSG00000211974.3 IGHV2-70 -5.9 7e-09 2.89e-06 -0.35 -0.26 Alzheimer's disease (late onset); chr14:106780575 chr14:106723574~106724093:- LUSC cis rs79349575 0.749 rs1057902 ENSG00000270781.1 RP11-501C14.9 -5.9 7e-09 2.89e-06 -0.27 -0.26 Type 2 diabetes; chr17:48928226 chr17:48899131~48899748:+ LUSC cis rs61270009 0.955 rs10462472 ENSG00000247828.6 TMEM161B-AS1 5.9 7e-09 2.89e-06 0.31 0.26 Depressive symptoms; chr5:88346652 chr5:88268895~88436685:+ LUSC cis rs77204473 0.744 rs2170317 ENSG00000254851.1 RP11-109L13.1 5.9 7e-09 2.89e-06 0.58 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117200024 chr11:117135528~117138582:+ LUSC cis rs7772486 0.774 rs2247571 ENSG00000235652.6 RP11-545I5.3 5.9 7.01e-09 2.89e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145898397 chr6:145799409~145886585:+ LUSC cis rs6570726 0.818 rs9390338 ENSG00000235652.6 RP11-545I5.3 5.9 7.04e-09 2.9e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145587129 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs6570693 ENSG00000235652.6 RP11-545I5.3 5.9 7.04e-09 2.9e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145589705 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs6570694 ENSG00000235652.6 RP11-545I5.3 5.9 7.04e-09 2.9e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145590068 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs6570695 ENSG00000235652.6 RP11-545I5.3 5.9 7.04e-09 2.9e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145590150 chr6:145799409~145886585:+ LUSC cis rs6570726 0.764 rs9386125 ENSG00000235652.6 RP11-545I5.3 5.9 7.04e-09 2.9e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145590541 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs9373466 ENSG00000235652.6 RP11-545I5.3 5.9 7.04e-09 2.9e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145590880 chr6:145799409~145886585:+ LUSC cis rs6504622 0.818 rs28451958 ENSG00000262879.4 RP11-156P1.3 5.9 7.04e-09 2.9e-06 0.27 0.26 Orofacial clefts; chr17:46968528 chr17:46984045~47100323:- LUSC cis rs11098499 0.863 rs3822194 ENSG00000248280.1 RP11-33B1.2 5.9 7.04e-09 2.9e-06 0.31 0.26 Corneal astigmatism; chr4:119550493 chr4:119440561~119450157:- LUSC cis rs6142102 0.812 rs4911375 ENSG00000275784.1 RP5-1125A11.6 -5.9 7.04e-09 2.9e-06 -0.3 -0.26 Skin pigmentation; chr20:33928216 chr20:33989480~33991818:- LUSC cis rs8040855 0.627 rs3816105 ENSG00000259295.5 CSPG4P12 5.9 7.04e-09 2.9e-06 0.33 0.26 Bulimia nervosa; chr15:85097680 chr15:85191438~85213905:+ LUSC cis rs8040855 0.627 rs2304418 ENSG00000259295.5 CSPG4P12 5.9 7.04e-09 2.9e-06 0.33 0.26 Bulimia nervosa; chr15:85097752 chr15:85191438~85213905:+ LUSC cis rs875971 1 rs12698523 ENSG00000179406.6 LINC00174 -5.9 7.04e-09 2.9e-06 -0.28 -0.26 Aortic root size; chr7:66503126 chr7:66376044~66401338:- LUSC cis rs9326248 0.581 rs10892061 ENSG00000280143.1 AP000892.6 5.9 7.04e-09 2.9e-06 0.27 0.26 Blood protein levels; chr11:117015398 chr11:117204967~117210292:+ LUSC cis rs1061377 1 rs4974997 ENSG00000249685.1 RP11-360F5.3 5.9 7.04e-09 2.9e-06 0.31 0.26 Uric acid levels; chr4:39109151 chr4:39133913~39135608:+ LUSC cis rs875971 1 rs3981131 ENSG00000179406.6 LINC00174 -5.9 7.04e-09 2.9e-06 -0.28 -0.26 Aortic root size; chr7:66486690 chr7:66376044~66401338:- LUSC cis rs34375054 0.66 rs12578446 ENSG00000279233.1 RP11-158L12.4 5.9 7.05e-09 2.91e-06 0.25 0.26 Post bronchodilator FEV1/FVC ratio; chr12:125121341 chr12:125138245~125141711:+ LUSC cis rs7267979 0.844 rs2424703 ENSG00000274973.1 RP13-401N8.7 -5.9 7.05e-09 2.91e-06 -0.26 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25289488 chr20:25845497~25845862:+ LUSC cis rs6142102 0.961 rs1319363 ENSG00000275784.1 RP5-1125A11.6 -5.9 7.05e-09 2.91e-06 -0.31 -0.26 Skin pigmentation; chr20:33954070 chr20:33989480~33991818:- LUSC cis rs875971 0.66 rs7807944 ENSG00000222364.1 RNU6-96P 5.9 7.05e-09 2.91e-06 0.3 0.26 Aortic root size; chr7:66622208 chr7:66395191~66395286:+ LUSC cis rs11690935 0.885 rs7602037 ENSG00000228389.1 AC068039.4 5.9 7.06e-09 2.91e-06 0.3 0.26 Schizophrenia; chr2:171961268 chr2:171773482~171775844:+ LUSC cis rs1075265 0.756 rs2160931 ENSG00000233266.1 HMGB1P31 5.9 7.06e-09 2.91e-06 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:53712411 chr2:54051334~54051760:+ LUSC cis rs875971 0.508 rs10258739 ENSG00000236529.1 RP13-254B10.1 -5.9 7.06e-09 2.91e-06 -0.26 -0.26 Aortic root size; chr7:66597948 chr7:65840212~65840596:+ LUSC cis rs2179367 0.632 rs9498324 ENSG00000231760.4 RP11-350J20.5 5.9 7.06e-09 2.91e-06 0.37 0.26 Dupuytren's disease; chr6:149338973 chr6:149796151~149826294:- LUSC cis rs149313 1 rs149313 ENSG00000248734.2 CTD-2260A17.1 -5.9 7.07e-09 2.91e-06 -0.25 -0.26 Blood protein levels; chr5:96734501 chr5:96784777~96785999:+ LUSC cis rs72627123 1 rs59363432 ENSG00000259065.1 RP5-1021I20.1 -5.9 7.07e-09 2.91e-06 -0.45 -0.26 Morning vs. evening chronotype; chr14:73930842 chr14:73787360~73803270:+ LUSC cis rs11098499 0.82 rs13122709 ENSG00000248280.1 RP11-33B1.2 5.9 7.08e-09 2.92e-06 0.32 0.26 Corneal astigmatism; chr4:119634201 chr4:119440561~119450157:- LUSC cis rs2337406 0.866 rs2301535 ENSG00000211974.3 IGHV2-70 -5.9 7.08e-09 2.92e-06 -0.37 -0.26 Alzheimer's disease (late onset); chr14:106790663 chr14:106723574~106724093:- LUSC cis rs11098499 0.863 rs59732491 ENSG00000248280.1 RP11-33B1.2 5.9 7.09e-09 2.92e-06 0.31 0.26 Corneal astigmatism; chr4:119568433 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs11723090 ENSG00000248280.1 RP11-33B1.2 5.9 7.09e-09 2.92e-06 0.31 0.26 Corneal astigmatism; chr4:119569437 chr4:119440561~119450157:- LUSC cis rs8059260 0.668 rs7199305 ENSG00000274038.1 RP11-66H6.4 5.9 7.09e-09 2.92e-06 0.45 0.26 Alcohol consumption over the past year; chr16:11006476 chr16:11056556~11057034:+ LUSC cis rs36423 0.748 rs28138 ENSG00000266869.1 RP6-114E22.1 -5.9 7.11e-09 2.93e-06 -0.41 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71891970 chr14:71848606~71908430:+ LUSC cis rs7772486 0.817 rs2144477 ENSG00000235652.6 RP11-545I5.3 5.9 7.11e-09 2.93e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146085112 chr6:145799409~145886585:+ LUSC cis rs11098499 0.863 rs13140391 ENSG00000248280.1 RP11-33B1.2 5.9 7.12e-09 2.93e-06 0.31 0.26 Corneal astigmatism; chr4:119582282 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs13140409 ENSG00000248280.1 RP11-33B1.2 5.9 7.12e-09 2.93e-06 0.31 0.26 Corneal astigmatism; chr4:119582305 chr4:119440561~119450157:- LUSC cis rs12554020 0.582 rs12555927 ENSG00000227603.1 RP11-165J3.6 5.9 7.12e-09 2.93e-06 0.46 0.26 Schizophrenia; chr9:93666800 chr9:93435332~93437121:- LUSC cis rs4713118 0.513 rs149942 ENSG00000219392.1 RP1-265C24.5 -5.9 7.12e-09 2.93e-06 -0.33 -0.26 Parkinson's disease; chr6:28033832 chr6:28115628~28116551:+ LUSC cis rs4713118 0.513 rs149945 ENSG00000219392.1 RP1-265C24.5 -5.9 7.12e-09 2.93e-06 -0.33 -0.26 Parkinson's disease; chr6:28035075 chr6:28115628~28116551:+ LUSC cis rs17772222 0.545 rs1758846 ENSG00000258789.1 RP11-507K2.3 5.9 7.13e-09 2.93e-06 0.29 0.26 Coronary artery calcification; chr14:88449288 chr14:88551597~88552493:+ LUSC cis rs2280018 0.526 rs1510148 ENSG00000188599.16 NPIPP1 -5.9 7.13e-09 2.93e-06 -0.26 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15073522 chr16:15104312~15123498:- LUSC cis rs10759883 0.587 rs6478977 ENSG00000175611.10 LINC00476 -5.9 7.13e-09 2.94e-06 -0.31 -0.26 Nicotine dependence; chr9:95797994 chr9:95759231~95875977:- LUSC cis rs11089937 0.667 rs78549985 ENSG00000211638.2 IGLV8-61 -5.9 7.14e-09 2.94e-06 -0.28 -0.26 Periodontitis (PAL4Q3); chr22:22139152 chr22:22098700~22099212:+ LUSC cis rs1061377 1 rs1061377 ENSG00000249685.1 RP11-360F5.3 5.9 7.15e-09 2.94e-06 0.3 0.26 Uric acid levels; chr4:39123130 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs13109200 ENSG00000249685.1 RP11-360F5.3 5.9 7.15e-09 2.94e-06 0.3 0.26 Uric acid levels; chr4:39124396 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs13144374 ENSG00000249685.1 RP11-360F5.3 5.9 7.15e-09 2.94e-06 0.3 0.26 Uric acid levels; chr4:39128859 chr4:39133913~39135608:+ LUSC cis rs1823913 0.562 rs17347499 ENSG00000227542.1 AC092614.2 5.9 7.15e-09 2.94e-06 0.34 0.26 Obesity-related traits; chr2:191301116 chr2:191229165~191246172:- LUSC cis rs875971 0.66 rs801211 ENSG00000237310.1 GS1-124K5.4 -5.9 7.15e-09 2.94e-06 -0.26 -0.26 Aortic root size; chr7:66550702 chr7:66493706~66495474:+ LUSC cis rs875971 0.638 rs801205 ENSG00000237310.1 GS1-124K5.4 -5.9 7.15e-09 2.94e-06 -0.26 -0.26 Aortic root size; chr7:66557157 chr7:66493706~66495474:+ LUSC cis rs875971 0.617 rs810400 ENSG00000237310.1 GS1-124K5.4 -5.9 7.15e-09 2.94e-06 -0.26 -0.26 Aortic root size; chr7:66557902 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs28698552 ENSG00000237310.1 GS1-124K5.4 5.9 7.15e-09 2.94e-06 0.26 0.26 Aortic root size; chr7:66540031 chr7:66493706~66495474:+ LUSC cis rs875971 0.66 rs62465434 ENSG00000237310.1 GS1-124K5.4 5.9 7.15e-09 2.94e-06 0.26 0.26 Aortic root size; chr7:66540165 chr7:66493706~66495474:+ LUSC cis rs6867032 0.834 rs10043083 ENSG00000249731.1 RP11-259O2.3 -5.9 7.15e-09 2.94e-06 -0.29 -0.26 Gut microbiome composition (winter); chr5:1995573 chr5:1968094~1969013:+ LUSC cis rs2153535 0.584 rs9502723 ENSG00000230939.1 RP11-314C16.1 -5.9 7.15e-09 2.94e-06 -0.32 -0.26 Motion sickness; chr6:8541271 chr6:8784178~8785445:+ LUSC cis rs227275 0.525 rs13113923 ENSG00000230069.3 LRRC37A15P -5.9 7.15e-09 2.94e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102918936 chr4:102727274~102730721:- LUSC cis rs11723261 0.621 rs11733385 ENSG00000275426.1 CH17-262A2.1 5.9 7.16e-09 2.95e-06 0.44 0.26 Immune response to smallpox vaccine (IL-6); chr4:146677 chr4:149738~150317:+ LUSC cis rs11723261 0.546 rs4315728 ENSG00000275426.1 CH17-262A2.1 5.9 7.16e-09 2.95e-06 0.44 0.26 Immune response to smallpox vaccine (IL-6); chr4:147237 chr4:149738~150317:+ LUSC cis rs7714584 1 rs1428555 ENSG00000197083.10 ZNF300P1 -5.89 7.17e-09 2.95e-06 -0.46 -0.26 Crohn's disease; chr5:150877829 chr5:150930645~150946289:- LUSC cis rs6952407 1 rs6952407 ENSG00000237310.1 GS1-124K5.4 -5.89 7.18e-09 2.95e-06 -0.26 -0.26 Cotinine glucuronidation; chr7:66580525 chr7:66493706~66495474:+ LUSC cis rs1823913 0.614 rs4853576 ENSG00000280083.1 RP11-317J9.1 5.89 7.18e-09 2.95e-06 0.31 0.26 Obesity-related traits; chr2:191296618 chr2:191154118~191156070:- LUSC cis rs7772486 0.875 rs9403764 ENSG00000235652.6 RP11-545I5.3 5.89 7.19e-09 2.96e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146039446 chr6:145799409~145886585:+ LUSC cis rs2071303 0.836 rs198835 ENSG00000272462.2 U91328.19 -5.89 7.2e-09 2.96e-06 -0.28 -0.26 Intelligence (multi-trait analysis); chr6:26113766 chr6:25992662~26001775:+ LUSC cis rs227275 0.554 rs149576 ENSG00000246560.2 RP11-10L12.4 5.89 7.2e-09 2.96e-06 0.32 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102811411 chr4:102828055~102844075:+ LUSC cis rs6860806 0.507 rs183898 ENSG00000233006.5 AC034220.3 -5.89 7.2e-09 2.96e-06 -0.28 -0.26 Breast cancer; chr5:132381210 chr5:132311285~132369916:- LUSC cis rs7246657 0.722 rs2972458 ENSG00000276846.1 CTD-3220F14.3 -5.89 7.21e-09 2.96e-06 -0.39 -0.26 Coronary artery calcification; chr19:37644502 chr19:37314868~37315620:- LUSC cis rs2732480 0.5 rs12829841 ENSG00000240399.1 RP1-228P16.1 5.89 7.21e-09 2.96e-06 0.28 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48234956 chr12:48054813~48055591:- LUSC cis rs2732480 0.523 rs34286639 ENSG00000240399.1 RP1-228P16.1 5.89 7.21e-09 2.96e-06 0.28 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48235261 chr12:48054813~48055591:- LUSC cis rs3764021 0.527 rs10844427 ENSG00000256975.1 RP11-525E9.1 5.89 7.21e-09 2.96e-06 0.34 0.26 Type 1 diabetes; chr12:9681798 chr12:9506347~9508440:- LUSC cis rs1823913 0.637 rs4853583 ENSG00000227542.1 AC092614.2 -5.89 7.21e-09 2.97e-06 -0.33 -0.26 Obesity-related traits; chr2:191304648 chr2:191229165~191246172:- LUSC cis rs2153535 0.563 rs3117071 ENSG00000230939.1 RP11-314C16.1 -5.89 7.21e-09 2.97e-06 -0.31 -0.26 Motion sickness; chr6:8537675 chr6:8784178~8785445:+ LUSC cis rs7208859 0.524 rs73988172 ENSG00000263603.1 CTD-2349P21.5 -5.89 7.22e-09 2.97e-06 -0.37 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30729469~30731202:+ LUSC cis rs2276314 0.947 rs3898595 ENSG00000278986.1 RP11-723J4.3 -5.89 7.22e-09 2.97e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35985922 chr18:35972151~35973916:+ LUSC cis rs2276314 1 rs4799834 ENSG00000278986.1 RP11-723J4.3 -5.89 7.22e-09 2.97e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35986280 chr18:35972151~35973916:+ LUSC cis rs875971 0.505 rs1167386 ENSG00000179406.6 LINC00174 5.89 7.23e-09 2.97e-06 0.28 0.26 Aortic root size; chr7:66048109 chr7:66376044~66401338:- LUSC cis rs875971 0.638 rs10249404 ENSG00000222364.1 RNU6-96P 5.89 7.23e-09 2.97e-06 0.3 0.26 Aortic root size; chr7:66581737 chr7:66395191~66395286:+ LUSC cis rs28830936 1 rs17678138 ENSG00000250379.1 RP11-23P13.4 5.89 7.23e-09 2.97e-06 0.28 0.26 Diastolic blood pressure; chr15:41750869 chr15:41825099~41827936:- LUSC cis rs2834288 0.535 rs881229 ENSG00000273102.1 AP000569.9 5.89 7.24e-09 2.97e-06 0.29 0.26 Gut microbiota (bacterial taxa); chr21:33950417 chr21:33967101~33968573:- LUSC cis rs2243480 1 rs316332 ENSG00000226824.5 RP4-756H11.3 -5.89 7.24e-09 2.98e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66139312 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs316330 ENSG00000226824.5 RP4-756H11.3 -5.89 7.24e-09 2.98e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66140385 chr7:66654538~66669855:+ LUSC cis rs2367970 0.57 rs7123583 ENSG00000254851.1 RP11-109L13.1 5.89 7.26e-09 2.98e-06 0.35 0.26 HDL cholesterol; chr11:116729305 chr11:117135528~117138582:+ LUSC cis rs7520050 0.645 rs1768809 ENSG00000280836.1 AL355480.1 5.89 7.27e-09 2.99e-06 0.28 0.26 Reticulocyte count;Red blood cell count; chr1:46037164 chr1:45581219~45581321:- LUSC cis rs950169 0.922 rs11631096 ENSG00000259295.5 CSPG4P12 5.89 7.27e-09 2.99e-06 0.35 0.26 Schizophrenia; chr15:84557698 chr15:85191438~85213905:+ LUSC cis rs7665090 0.875 rs6813322 ENSG00000230069.3 LRRC37A15P -5.89 7.27e-09 2.99e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102634462 chr4:102727274~102730721:- LUSC cis rs9910055 0.762 rs4239142 ENSG00000267080.4 ASB16-AS1 5.89 7.28e-09 2.99e-06 0.24 0.26 Total body bone mineral density; chr17:44128508 chr17:44175973~44186717:- LUSC cis rs7772486 0.742 rs4896851 ENSG00000235652.6 RP11-545I5.3 -5.89 7.29e-09 2.99e-06 -0.27 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145957823 chr6:145799409~145886585:+ LUSC cis rs7945705 0.806 rs12224436 ENSG00000254860.4 TMEM9B-AS1 -5.89 7.29e-09 2.99e-06 -0.3 -0.26 Hemoglobin concentration; chr11:8794278 chr11:8964675~8977527:+ LUSC cis rs13113518 1 rs13108499 ENSG00000249700.7 SRD5A3-AS1 5.89 7.29e-09 3e-06 0.3 0.26 Height; chr4:55526514 chr4:55363971~55395847:- LUSC cis rs2179367 0.6 rs9498355 ENSG00000231760.4 RP11-350J20.5 -5.89 7.29e-09 3e-06 -0.39 -0.26 Dupuytren's disease; chr6:149442274 chr6:149796151~149826294:- LUSC cis rs6568401 0.6 rs1508361 ENSG00000219088.1 RP3-359N14.1 -5.89 7.3e-09 3e-06 -0.37 -0.26 Primary tooth development (time to first tooth eruption); chr6:105729410 chr6:105666326~105667998:+ LUSC cis rs2337406 0.866 rs7152038 ENSG00000254174.1 IGHV1-12 5.89 7.3e-09 3e-06 0.25 0.26 Alzheimer's disease (late onset); chr14:106778230 chr14:106122420~106122709:- LUSC cis rs10759883 0.58 rs10818738 ENSG00000175611.10 LINC00476 5.89 7.31e-09 3e-06 0.31 0.26 Nicotine dependence; chr9:95846938 chr9:95759231~95875977:- LUSC cis rs13113518 0.812 rs4865001 ENSG00000272969.1 RP11-528I4.2 5.89 7.31e-09 3e-06 0.3 0.26 Height; chr4:55490176 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs4864543 ENSG00000272969.1 RP11-528I4.2 5.89 7.31e-09 3e-06 0.3 0.26 Height; chr4:55490228 chr4:55547112~55547889:+ LUSC cis rs4803480 0.935 rs1476769 ENSG00000270164.1 LINC01480 -5.89 7.31e-09 3e-06 -0.23 -0.26 Schizophrenia; chr19:41577925 chr19:41535183~41536904:+ LUSC cis rs4803480 0.873 rs1476770 ENSG00000270164.1 LINC01480 -5.89 7.31e-09 3e-06 -0.23 -0.26 Schizophrenia; chr19:41578033 chr19:41535183~41536904:+ LUSC cis rs13113518 0.756 rs7658446 ENSG00000272969.1 RP11-528I4.2 5.89 7.31e-09 3e-06 0.3 0.26 Height; chr4:55495262 chr4:55547112~55547889:+ LUSC cis rs6772849 0.931 rs60825080 ENSG00000277250.1 Metazoa_SRP -5.89 7.31e-09 3e-06 -0.29 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128665991 chr3:128673681~128674021:- LUSC cis rs7208859 0.623 rs8082537 ENSG00000266490.1 CTD-2349P21.9 5.89 7.31e-09 3e-06 0.31 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30688914 chr17:30792372~30792833:+ LUSC cis rs11098499 0.691 rs10010355 ENSG00000249244.1 RP11-548H18.2 5.89 7.33e-09 3.01e-06 0.32 0.26 Corneal astigmatism; chr4:119339888 chr4:119391831~119395335:- LUSC cis rs11098499 0.691 rs9307471 ENSG00000249244.1 RP11-548H18.2 5.89 7.33e-09 3.01e-06 0.32 0.26 Corneal astigmatism; chr4:119340107 chr4:119391831~119395335:- LUSC cis rs7246657 0.722 rs2909098 ENSG00000276846.1 CTD-3220F14.3 -5.89 7.33e-09 3.01e-06 -0.39 -0.26 Coronary artery calcification; chr19:37713347 chr19:37314868~37315620:- LUSC cis rs5770917 1 rs2073604 ENSG00000273272.1 CTA-384D8.34 5.89 7.33e-09 3.01e-06 0.52 0.26 Narcolepsy; chr22:50570496 chr22:50542650~50543011:+ LUSC cis rs1075265 0.811 rs805322 ENSG00000233266.1 HMGB1P31 -5.89 7.34e-09 3.01e-06 -0.32 -0.26 Chronotype;Morning vs. evening chronotype; chr2:53912758 chr2:54051334~54051760:+ LUSC cis rs11971779 0.68 rs10242419 ENSG00000273391.1 RP11-634H22.1 -5.89 7.36e-09 3.02e-06 -0.28 -0.26 Diisocyanate-induced asthma; chr7:139404634 chr7:139359032~139359566:- LUSC cis rs394563 0.967 rs447025 ENSG00000231760.4 RP11-350J20.5 5.89 7.36e-09 3.02e-06 0.33 0.26 Dupuytren's disease; chr6:149477992 chr6:149796151~149826294:- LUSC cis rs7772486 0.875 rs10457793 ENSG00000235652.6 RP11-545I5.3 5.89 7.36e-09 3.02e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146094267 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs10457794 ENSG00000235652.6 RP11-545I5.3 5.89 7.36e-09 3.02e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146094472 chr6:145799409~145886585:+ LUSC cis rs34375054 0.573 rs12579211 ENSG00000279233.1 RP11-158L12.4 5.89 7.37e-09 3.03e-06 0.29 0.26 Post bronchodilator FEV1/FVC ratio; chr12:125163206 chr12:125138245~125141711:+ LUSC cis rs875971 0.66 rs12698534 ENSG00000237310.1 GS1-124K5.4 5.89 7.37e-09 3.03e-06 0.26 0.26 Aortic root size; chr7:66521858 chr7:66493706~66495474:+ LUSC cis rs7555523 0.83 rs1547725 ENSG00000224358.1 RP11-466F5.8 -5.89 7.37e-09 3.03e-06 -0.36 -0.26 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165701721 chr1:165768929~165775176:+ LUSC cis rs11098499 0.863 rs11098532 ENSG00000248280.1 RP11-33B1.2 5.89 7.37e-09 3.03e-06 0.31 0.26 Corneal astigmatism; chr4:119569571 chr4:119440561~119450157:- LUSC cis rs116139393 0.536 rs13247186 ENSG00000187953.9 PMS2CL -5.89 7.38e-09 3.03e-06 -0.34 -0.26 Alzheimer's disease (APOE e4 interaction); chr7:6729524 chr7:6710128~6753862:+ LUSC cis rs8040855 0.627 rs4842863 ENSG00000259295.5 CSPG4P12 5.89 7.38e-09 3.03e-06 0.33 0.26 Bulimia nervosa; chr15:85098974 chr15:85191438~85213905:+ LUSC cis rs11098499 0.863 rs11947234 ENSG00000248280.1 RP11-33B1.2 5.89 7.38e-09 3.03e-06 0.31 0.26 Corneal astigmatism; chr4:119553704 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs11933966 ENSG00000248280.1 RP11-33B1.2 5.89 7.38e-09 3.03e-06 0.31 0.26 Corneal astigmatism; chr4:119555560 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs36040693 ENSG00000248280.1 RP11-33B1.2 5.89 7.38e-09 3.03e-06 0.31 0.26 Corneal astigmatism; chr4:119556461 chr4:119440561~119450157:- LUSC cis rs11295209 1 rs11295209 ENSG00000248280.1 RP11-33B1.2 -5.89 7.39e-09 3.03e-06 -0.29 -0.26 Plateletcrit; chr4:119559079 chr4:119440561~119450157:- LUSC cis rs2408955 0.715 rs1793957 ENSG00000240399.1 RP1-228P16.1 5.89 7.41e-09 3.04e-06 0.26 0.26 Glycated hemoglobin levels; chr12:47999041 chr12:48054813~48055591:- LUSC cis rs853679 0.882 rs9461432 ENSG00000219392.1 RP1-265C24.5 -5.89 7.41e-09 3.04e-06 -0.45 -0.26 Depression; chr6:28119105 chr6:28115628~28116551:+ LUSC cis rs9341835 0.772 rs9294206 ENSG00000218048.2 RP3-407E4.4 5.89 7.41e-09 3.04e-06 0.3 0.26 Schizophrenia; chr6:63431296 chr6:63440766~63443580:+ LUSC cis rs2153535 0.601 rs9505472 ENSG00000230939.1 RP11-314C16.1 -5.89 7.42e-09 3.04e-06 -0.32 -0.26 Motion sickness; chr6:8538532 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs9505473 ENSG00000230939.1 RP11-314C16.1 -5.89 7.42e-09 3.04e-06 -0.32 -0.26 Motion sickness; chr6:8538544 chr6:8784178~8785445:+ LUSC cis rs36423 0.557 rs36457 ENSG00000266869.1 RP6-114E22.1 -5.89 7.42e-09 3.05e-06 -0.36 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71864157 chr14:71848606~71908430:+ LUSC cis rs6570726 0.846 rs439035 ENSG00000235652.6 RP11-545I5.3 5.89 7.43e-09 3.05e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145566854 chr6:145799409~145886585:+ LUSC cis rs875971 0.545 rs4718348 ENSG00000237310.1 GS1-124K5.4 5.89 7.43e-09 3.05e-06 0.3 0.26 Aortic root size; chr7:66441589 chr7:66493706~66495474:+ LUSC cis rs73173548 0.502 rs12653074 ENSG00000247828.6 TMEM161B-AS1 5.89 7.43e-09 3.05e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88452920 chr5:88268895~88436685:+ LUSC cis rs7772486 0.846 rs866473 ENSG00000235652.6 RP11-545I5.3 5.89 7.44e-09 3.05e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146032278 chr6:145799409~145886585:+ LUSC cis rs9322193 0.884 rs62439837 ENSG00000268592.3 RAET1E-AS1 5.89 7.44e-09 3.05e-06 0.34 0.26 Lung cancer; chr6:149670380 chr6:149863494~149919507:+ LUSC cis rs875971 0.964 rs6978429 ENSG00000179406.6 LINC00174 -5.89 7.44e-09 3.05e-06 -0.28 -0.26 Aortic root size; chr7:66494889 chr7:66376044~66401338:- LUSC cis rs875971 0.929 rs12535036 ENSG00000179406.6 LINC00174 -5.89 7.44e-09 3.05e-06 -0.28 -0.26 Aortic root size; chr7:66499076 chr7:66376044~66401338:- LUSC cis rs875971 1 rs12533997 ENSG00000179406.6 LINC00174 -5.89 7.44e-09 3.05e-06 -0.28 -0.26 Aortic root size; chr7:66500390 chr7:66376044~66401338:- LUSC cis rs875971 1 rs12532998 ENSG00000179406.6 LINC00174 -5.89 7.44e-09 3.05e-06 -0.28 -0.26 Aortic root size; chr7:66502472 chr7:66376044~66401338:- LUSC cis rs875971 1 rs6970030 ENSG00000179406.6 LINC00174 -5.89 7.44e-09 3.05e-06 -0.28 -0.26 Aortic root size; chr7:66503692 chr7:66376044~66401338:- LUSC cis rs875971 0.928 rs6970357 ENSG00000179406.6 LINC00174 -5.89 7.44e-09 3.05e-06 -0.28 -0.26 Aortic root size; chr7:66503891 chr7:66376044~66401338:- LUSC cis rs875971 1 rs3735148 ENSG00000179406.6 LINC00174 -5.89 7.44e-09 3.05e-06 -0.28 -0.26 Aortic root size; chr7:66506022 chr7:66376044~66401338:- LUSC cis rs638893 0.898 rs577121 ENSG00000278376.1 RP11-158I9.8 -5.89 7.45e-09 3.05e-06 -0.33 -0.26 Vitiligo; chr11:118819841 chr11:118791254~118793137:+ LUSC cis rs9322193 0.923 rs12175504 ENSG00000268592.3 RAET1E-AS1 5.89 7.45e-09 3.05e-06 0.33 0.26 Lung cancer; chr6:149664079 chr6:149863494~149919507:+ LUSC cis rs9322193 0.962 rs62439843 ENSG00000268592.3 RAET1E-AS1 5.89 7.45e-09 3.05e-06 0.33 0.26 Lung cancer; chr6:149676521 chr6:149863494~149919507:+ LUSC cis rs9601248 0.627 rs2146593 ENSG00000227354.5 RBM26-AS1 5.89 7.45e-09 3.05e-06 0.29 0.26 Major depressive disorder; chr13:79605977 chr13:79406309~79424328:+ LUSC cis rs30380 1 rs27529 ENSG00000248734.2 CTD-2260A17.1 5.89 7.46e-09 3.06e-06 0.25 0.26 Cerebrospinal fluid biomarker levels; chr5:96790605 chr5:96784777~96785999:+ LUSC cis rs6570726 0.791 rs11759979 ENSG00000235652.6 RP11-545I5.3 5.89 7.47e-09 3.06e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145597745 chr6:145799409~145886585:+ LUSC cis rs2834288 0.535 rs8128135 ENSG00000273102.1 AP000569.9 5.89 7.47e-09 3.06e-06 0.3 0.26 Gut microbiota (bacterial taxa); chr21:33934821 chr21:33967101~33968573:- LUSC cis rs8005677 1 rs8006396 ENSG00000279656.1 RP11-298I3.6 5.89 7.47e-09 3.06e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22911641 chr14:23023083~23024217:- LUSC cis rs8005677 1 rs4981446 ENSG00000279656.1 RP11-298I3.6 5.89 7.47e-09 3.06e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22912204 chr14:23023083~23024217:- LUSC cis rs8005677 1 rs4982706 ENSG00000279656.1 RP11-298I3.6 5.89 7.47e-09 3.06e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22912488 chr14:23023083~23024217:- LUSC cis rs875971 0.545 rs35459055 ENSG00000224316.1 RP11-479O9.2 5.89 7.48e-09 3.07e-06 0.28 0.26 Aortic root size; chr7:66479399 chr7:65773620~65802067:+ LUSC cis rs11846409 0.932 rs56167903 ENSG00000274576.2 IGHV2-70 -5.89 7.49e-09 3.07e-06 -0.26 -0.26 Rheumatic heart disease; chr14:106632070 chr14:106770577~106771020:- LUSC cis rs2153535 0.58 rs9505454 ENSG00000230939.1 RP11-314C16.1 -5.89 7.49e-09 3.07e-06 -0.31 -0.26 Motion sickness; chr6:8478299 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs9505456 ENSG00000230939.1 RP11-314C16.1 -5.89 7.49e-09 3.07e-06 -0.31 -0.26 Motion sickness; chr6:8478768 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9505458 ENSG00000230939.1 RP11-314C16.1 -5.89 7.49e-09 3.07e-06 -0.31 -0.26 Motion sickness; chr6:8478982 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9379215 ENSG00000230939.1 RP11-314C16.1 -5.89 7.49e-09 3.07e-06 -0.31 -0.26 Motion sickness; chr6:8480992 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6597326 ENSG00000230939.1 RP11-314C16.1 -5.89 7.49e-09 3.07e-06 -0.31 -0.26 Motion sickness; chr6:8481786 chr6:8784178~8785445:+ LUSC cis rs9813712 0.595 rs1453238 ENSG00000228252.7 COL6A4P2 5.89 7.5e-09 3.08e-06 0.25 0.26 Response to amphetamines; chr3:130290494 chr3:130212823~130273806:+ LUSC cis rs7580658 0.724 rs71414745 ENSG00000236682.1 AC068282.3 -5.89 7.51e-09 3.08e-06 -0.34 -0.26 Protein C levels; chr2:127235012 chr2:127389130~127400580:+ LUSC cis rs6570726 0.791 rs440477 ENSG00000235652.6 RP11-545I5.3 5.89 7.51e-09 3.08e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145533052 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs385729 ENSG00000235652.6 RP11-545I5.3 5.89 7.51e-09 3.08e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145534329 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs9376975 ENSG00000235652.6 RP11-545I5.3 5.89 7.52e-09 3.08e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146034445 chr6:145799409~145886585:+ LUSC cis rs7772486 0.846 rs9376976 ENSG00000235652.6 RP11-545I5.3 5.89 7.52e-09 3.08e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146034469 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs7761033 ENSG00000235652.6 RP11-545I5.3 5.89 7.52e-09 3.08e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146034970 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs9403763 ENSG00000235652.6 RP11-545I5.3 5.89 7.52e-09 3.08e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146036519 chr6:145799409~145886585:+ LUSC cis rs4722166 0.508 rs1474348 ENSG00000179428.2 AC073072.5 -5.89 7.52e-09 3.08e-06 -0.32 -0.26 Lung cancer; chr7:22728289 chr7:22725395~22727620:- LUSC cis rs2028299 0.919 rs7174878 ENSG00000259677.1 RP11-493E3.1 5.89 7.56e-09 3.1e-06 0.34 0.26 Type 2 diabetes; chr15:89891656 chr15:89876540~89877285:+ LUSC cis rs1075265 0.73 rs7601692 ENSG00000233266.1 HMGB1P31 5.88 7.58e-09 3.1e-06 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:53705532 chr2:54051334~54051760:+ LUSC cis rs8040855 0.627 rs12913859 ENSG00000259295.5 CSPG4P12 5.88 7.58e-09 3.1e-06 0.33 0.26 Bulimia nervosa; chr15:85095187 chr15:85191438~85213905:+ LUSC cis rs7772486 0.79 rs1854900 ENSG00000235652.6 RP11-545I5.3 5.88 7.59e-09 3.11e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146010246 chr6:145799409~145886585:+ LUSC cis rs2276314 0.802 rs9963714 ENSG00000278986.1 RP11-723J4.3 -5.88 7.59e-09 3.11e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36012093 chr18:35972151~35973916:+ LUSC cis rs2276314 0.802 rs4799838 ENSG00000278986.1 RP11-723J4.3 -5.88 7.59e-09 3.11e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36017567 chr18:35972151~35973916:+ LUSC cis rs2276314 0.748 rs4799839 ENSG00000278986.1 RP11-723J4.3 -5.88 7.59e-09 3.11e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36017568 chr18:35972151~35973916:+ LUSC cis rs2276314 0.857 rs28375959 ENSG00000278986.1 RP11-723J4.3 -5.88 7.59e-09 3.11e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36021571 chr18:35972151~35973916:+ LUSC cis rs853679 0.599 rs202906 ENSG00000204709.4 LINC01556 -5.88 7.61e-09 3.12e-06 -0.43 -0.26 Depression; chr6:28043874 chr6:28943877~28944537:+ LUSC cis rs67311347 0.955 rs2123999 ENSG00000223797.4 ENTPD3-AS1 5.88 7.61e-09 3.12e-06 0.29 0.26 Renal cell carcinoma; chr3:40337247 chr3:40313802~40453329:- LUSC cis rs853679 1 rs2799077 ENSG00000219392.1 RP1-265C24.5 -5.88 7.62e-09 3.12e-06 -0.42 -0.26 Depression; chr6:28266819 chr6:28115628~28116551:+ LUSC cis rs2842992 0.714 rs2475564 ENSG00000237927.1 RP3-393E18.2 -5.88 7.63e-09 3.12e-06 -0.4 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159702641 chr6:159586955~159589169:- LUSC cis rs2842992 0.747 rs4709379 ENSG00000237927.1 RP3-393E18.2 -5.88 7.63e-09 3.12e-06 -0.41 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159806498 chr6:159586955~159589169:- LUSC cis rs12439619 0.705 rs17354185 ENSG00000276710.3 CSPG4P8 5.88 7.64e-09 3.13e-06 0.33 0.26 Intelligence (multi-trait analysis); chr15:82133829 chr15:82459472~82477258:+ LUSC cis rs13113518 0.841 rs7699867 ENSG00000272969.1 RP11-528I4.2 5.88 7.64e-09 3.13e-06 0.3 0.26 Height; chr4:55483718 chr4:55547112~55547889:+ LUSC cis rs7580658 0.724 rs6712213 ENSG00000236682.1 AC068282.3 -5.88 7.65e-09 3.13e-06 -0.35 -0.26 Protein C levels; chr2:127240654 chr2:127389130~127400580:+ LUSC cis rs1823913 0.637 rs4613316 ENSG00000280083.1 RP11-317J9.1 -5.88 7.66e-09 3.13e-06 -0.31 -0.26 Obesity-related traits; chr2:191326074 chr2:191154118~191156070:- LUSC cis rs4718428 0.672 rs36038499 ENSG00000226824.5 RP4-756H11.3 -5.88 7.66e-09 3.14e-06 -0.36 -0.26 Corneal structure; chr7:66824628 chr7:66654538~66669855:+ LUSC cis rs2276314 1 rs2276314 ENSG00000278986.1 RP11-723J4.3 5.88 7.67e-09 3.14e-06 0.33 0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35977503 chr18:35972151~35973916:+ LUSC cis rs7772486 0.875 rs13198450 ENSG00000235652.6 RP11-545I5.3 5.88 7.68e-09 3.14e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146049388 chr6:145799409~145886585:+ LUSC cis rs13113518 0.812 rs6825774 ENSG00000272969.1 RP11-528I4.2 5.88 7.68e-09 3.14e-06 0.3 0.26 Height; chr4:55491150 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs3805153 ENSG00000272969.1 RP11-528I4.2 5.88 7.68e-09 3.14e-06 0.3 0.26 Height; chr4:55493557 chr4:55547112~55547889:+ LUSC cis rs274567 0.501 rs274571 ENSG00000233006.5 AC034220.3 -5.88 7.69e-09 3.15e-06 -0.28 -0.26 Blood metabolite levels; chr5:132376433 chr5:132311285~132369916:- LUSC cis rs71403859 0.73 rs12927768 ENSG00000260886.1 TAT-AS1 5.88 7.7e-09 3.15e-06 0.41 0.26 Post bronchodilator FEV1; chr16:71611360 chr16:71565789~71578187:+ LUSC cis rs13113518 0.783 rs12508367 ENSG00000272969.1 RP11-528I4.2 5.88 7.7e-09 3.15e-06 0.3 0.26 Height; chr4:55509442 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs2272073 ENSG00000272969.1 RP11-528I4.2 5.88 7.7e-09 3.15e-06 0.3 0.26 Height; chr4:55510177 chr4:55547112~55547889:+ LUSC cis rs28830936 1 rs9672298 ENSG00000250379.1 RP11-23P13.4 5.88 7.7e-09 3.15e-06 0.28 0.26 Diastolic blood pressure; chr15:41620170 chr15:41825099~41827936:- LUSC cis rs11098499 0.954 rs6848389 ENSG00000248280.1 RP11-33B1.2 5.88 7.72e-09 3.16e-06 0.31 0.26 Corneal astigmatism; chr4:119481467 chr4:119440561~119450157:- LUSC cis rs9640161 0.75 rs11538922 ENSG00000261305.1 RP4-584D14.7 5.88 7.72e-09 3.16e-06 0.38 0.26 Blood protein levels;Circulating chemerin levels; chr7:150338094 chr7:150341771~150342607:+ LUSC cis rs2153535 0.563 rs1737584 ENSG00000230939.1 RP11-314C16.1 -5.88 7.72e-09 3.16e-06 -0.31 -0.26 Motion sickness; chr6:8536509 chr6:8784178~8785445:+ LUSC cis rs1061377 1 rs12646251 ENSG00000249685.1 RP11-360F5.3 5.88 7.72e-09 3.16e-06 0.3 0.26 Uric acid levels; chr4:39132751 chr4:39133913~39135608:+ LUSC cis rs9813712 0.595 rs1993217 ENSG00000228252.7 COL6A4P2 -5.88 7.73e-09 3.16e-06 -0.25 -0.26 Response to amphetamines; chr3:130284832 chr3:130212823~130273806:+ LUSC cis rs62432291 0.681 rs3003173 ENSG00000235086.1 FNDC1-IT1 -5.88 7.73e-09 3.16e-06 -0.46 -0.26 Joint mobility (Beighton score); chr6:159244660 chr6:159240786~159243329:+ LUSC cis rs9309473 0.606 rs62149804 ENSG00000163016.8 ALMS1P 5.88 7.75e-09 3.17e-06 0.38 0.26 Metabolite levels; chr2:73609879 chr2:73644919~73685576:+ LUSC cis rs875971 1 rs6460296 ENSG00000179406.6 LINC00174 -5.88 7.75e-09 3.17e-06 -0.28 -0.26 Aortic root size; chr7:66430152 chr7:66376044~66401338:- LUSC cis rs875971 1 rs4717292 ENSG00000179406.6 LINC00174 -5.88 7.75e-09 3.17e-06 -0.28 -0.26 Aortic root size; chr7:66430611 chr7:66376044~66401338:- LUSC cis rs9545047 0.716 rs7140027 ENSG00000227676.3 LINC01068 5.88 7.75e-09 3.17e-06 0.33 0.26 Schizophrenia; chr13:79281162 chr13:79566727~79571436:+ LUSC cis rs11098499 0.863 rs1383533 ENSG00000248280.1 RP11-33B1.2 5.88 7.75e-09 3.17e-06 0.31 0.26 Corneal astigmatism; chr4:119513421 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs2291185 ENSG00000248280.1 RP11-33B1.2 5.88 7.75e-09 3.17e-06 0.31 0.26 Corneal astigmatism; chr4:119513678 chr4:119440561~119450157:- LUSC cis rs7665090 1 rs1054029 ENSG00000230069.3 LRRC37A15P -5.88 7.76e-09 3.17e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102631896 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs3194585 ENSG00000230069.3 LRRC37A15P -5.88 7.76e-09 3.17e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102631933 chr4:102727274~102730721:- LUSC cis rs783540 0.934 rs8043401 ENSG00000276710.3 CSPG4P8 -5.88 7.78e-09 3.18e-06 -0.28 -0.26 Schizophrenia; chr15:82687507 chr15:82459472~82477258:+ LUSC cis rs4660456 0.572 rs7519348 ENSG00000237899.1 RP4-739H11.3 -5.88 7.78e-09 3.18e-06 -0.32 -0.26 Platelet count; chr1:40694532 chr1:40669089~40687588:- LUSC cis rs950880 0.71 rs2287034 ENSG00000234389.1 AC007278.3 5.88 7.78e-09 3.18e-06 0.28 0.26 Serum protein levels (sST2); chr2:102394128 chr2:102438713~102440475:+ LUSC cis rs7772486 0.846 rs9373482 ENSG00000235652.6 RP11-545I5.3 5.88 7.78e-09 3.18e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146041987 chr6:145799409~145886585:+ LUSC cis rs2276314 0.857 rs3737474 ENSG00000278986.1 RP11-723J4.3 -5.88 7.78e-09 3.18e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36033632 chr18:35972151~35973916:+ LUSC cis rs7429990 0.828 rs11712152 ENSG00000229759.1 MRPS18AP1 5.88 7.81e-09 3.19e-06 0.27 0.26 Educational attainment (years of education); chr3:47655314 chr3:48256350~48256938:- LUSC cis rs72627123 1 rs17093141 ENSG00000259065.1 RP5-1021I20.1 -5.88 7.81e-09 3.19e-06 -0.46 -0.26 Morning vs. evening chronotype; chr14:73860200 chr14:73787360~73803270:+ LUSC cis rs7772486 0.875 rs2748482 ENSG00000235652.6 RP11-545I5.3 5.88 7.82e-09 3.2e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146015396 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs1331637 ENSG00000235652.6 RP11-545I5.3 5.88 7.82e-09 3.2e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146015951 chr6:145799409~145886585:+ LUSC cis rs9322193 1 rs9377228 ENSG00000268592.3 RAET1E-AS1 5.88 7.83e-09 3.2e-06 0.33 0.26 Lung cancer; chr6:149600862 chr6:149863494~149919507:+ LUSC cis rs7772486 0.875 rs7739371 ENSG00000235652.6 RP11-545I5.3 5.88 7.83e-09 3.2e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146103217 chr6:145799409~145886585:+ LUSC cis rs36423 0.748 rs36395 ENSG00000266869.1 RP6-114E22.1 -5.88 7.83e-09 3.2e-06 -0.4 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71895714 chr14:71848606~71908430:+ LUSC cis rs36423 0.748 rs36394 ENSG00000266869.1 RP6-114E22.1 -5.88 7.83e-09 3.2e-06 -0.4 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71895899 chr14:71848606~71908430:+ LUSC cis rs36423 0.702 rs36393 ENSG00000266869.1 RP6-114E22.1 -5.88 7.83e-09 3.2e-06 -0.4 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71896009 chr14:71848606~71908430:+ LUSC cis rs36423 0.748 rs36392 ENSG00000266869.1 RP6-114E22.1 -5.88 7.83e-09 3.2e-06 -0.4 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71896044 chr14:71848606~71908430:+ LUSC cis rs13113518 0.776 rs13124436 ENSG00000272969.1 RP11-528I4.2 5.88 7.84e-09 3.2e-06 0.3 0.26 Height; chr4:55502504 chr4:55547112~55547889:+ LUSC cis rs13113518 0.783 rs6843997 ENSG00000272969.1 RP11-528I4.2 5.88 7.84e-09 3.2e-06 0.3 0.26 Height; chr4:55508982 chr4:55547112~55547889:+ LUSC cis rs1056107 0.933 rs12376681 ENSG00000225513.1 RP11-165N19.2 -5.88 7.85e-09 3.2e-06 -0.29 -0.26 Colorectal cancer; chr9:112297115 chr9:112173522~112173971:- LUSC cis rs875971 0.545 rs17138156 ENSG00000224316.1 RP11-479O9.2 5.88 7.85e-09 3.21e-06 0.28 0.26 Aortic root size; chr7:66249708 chr7:65773620~65802067:+ LUSC cis rs2303759 0.918 rs7251704 ENSG00000268686.1 AC010524.2 -5.88 7.86e-09 3.21e-06 -0.37 -0.26 Multiple sclerosis; chr19:49387616 chr19:49368705~49388081:- LUSC cis rs2303759 0.874 rs10411630 ENSG00000268686.1 AC010524.2 -5.88 7.86e-09 3.21e-06 -0.37 -0.26 Multiple sclerosis; chr19:49388057 chr19:49368705~49388081:- LUSC cis rs6740322 0.748 rs13402621 ENSG00000234936.1 AC010883.5 5.88 7.87e-09 3.21e-06 0.3 0.26 Coronary artery disease; chr2:43231472 chr2:43229573~43233394:+ LUSC cis rs17826219 0.706 rs57698184 ENSG00000266490.1 CTD-2349P21.9 5.88 7.87e-09 3.21e-06 0.32 0.26 Body mass index; chr17:30737900 chr17:30792372~30792833:+ LUSC cis rs2153535 0.601 rs2015281 ENSG00000230939.1 RP11-314C16.1 -5.88 7.87e-09 3.21e-06 -0.31 -0.26 Motion sickness; chr6:8539440 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs9505474 ENSG00000230939.1 RP11-314C16.1 -5.88 7.87e-09 3.21e-06 -0.31 -0.26 Motion sickness; chr6:8539561 chr6:8784178~8785445:+ LUSC cis rs13113518 1 rs3749474 ENSG00000273257.1 RP11-177J6.1 5.88 7.89e-09 3.22e-06 0.34 0.26 Height; chr4:55434518 chr4:55387949~55388271:+ LUSC cis rs2153535 0.58 rs6597325 ENSG00000230939.1 RP11-314C16.1 -5.88 7.9e-09 3.22e-06 -0.31 -0.26 Motion sickness; chr6:8460820 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6918391 ENSG00000230939.1 RP11-314C16.1 -5.88 7.9e-09 3.22e-06 -0.31 -0.26 Motion sickness; chr6:8460945 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9379210 ENSG00000230939.1 RP11-314C16.1 -5.88 7.9e-09 3.22e-06 -0.31 -0.26 Motion sickness; chr6:8461695 chr6:8784178~8785445:+ LUSC cis rs9341835 0.772 rs6919709 ENSG00000218048.2 RP3-407E4.4 5.88 7.9e-09 3.22e-06 0.31 0.26 Schizophrenia; chr6:63429951 chr6:63440766~63443580:+ LUSC cis rs2439831 0.85 rs10438303 ENSG00000249839.1 AC011330.5 -5.88 7.9e-09 3.22e-06 -0.52 -0.26 Lung cancer in ever smokers; chr15:43724219 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs12441127 ENSG00000249839.1 AC011330.5 -5.88 7.9e-09 3.22e-06 -0.52 -0.26 Lung cancer in ever smokers; chr15:43728977 chr15:43663654~43684339:- LUSC cis rs7267979 0.789 rs9927 ENSG00000274973.1 RP13-401N8.7 -5.88 7.9e-09 3.22e-06 -0.26 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25296608 chr20:25845497~25845862:+ LUSC cis rs1862618 0.573 rs185220 ENSG00000271828.1 CTD-2310F14.1 5.88 7.91e-09 3.23e-06 0.42 0.26 Initial pursuit acceleration; chr5:56909530 chr5:56927874~56929573:+ LUSC cis rs875971 0.638 rs6960778 ENSG00000222364.1 RNU6-96P 5.88 7.92e-09 3.23e-06 0.3 0.26 Aortic root size; chr7:66606610 chr7:66395191~66395286:+ LUSC cis rs9309711 0.961 rs11678655 ENSG00000225234.1 TRAPPC12-AS1 -5.88 7.92e-09 3.23e-06 -0.35 -0.26 Neurofibrillary tangles; chr2:3472463 chr2:3481242~3482409:- LUSC cis rs9309711 0.961 rs11675119 ENSG00000225234.1 TRAPPC12-AS1 -5.88 7.92e-09 3.23e-06 -0.35 -0.26 Neurofibrillary tangles; chr2:3472651 chr2:3481242~3482409:- LUSC cis rs6570726 0.935 rs421268 ENSG00000235652.6 RP11-545I5.3 5.88 7.93e-09 3.23e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145524422 chr6:145799409~145886585:+ LUSC cis rs11971779 0.941 rs7802779 ENSG00000273391.1 RP11-634H22.1 5.88 7.93e-09 3.24e-06 0.31 0.26 Diisocyanate-induced asthma; chr7:139437833 chr7:139359032~139359566:- LUSC cis rs2337406 1 rs75651733 ENSG00000274576.2 IGHV2-70 -5.88 7.94e-09 3.24e-06 -0.29 -0.26 Alzheimer's disease (late onset); chr14:106701309 chr14:106770577~106771020:- LUSC cis rs875971 1 rs2077593 ENSG00000179406.6 LINC00174 -5.88 7.94e-09 3.24e-06 -0.28 -0.26 Aortic root size; chr7:66427543 chr7:66376044~66401338:- LUSC cis rs61270009 0.863 rs6452782 ENSG00000247828.6 TMEM161B-AS1 5.88 7.94e-09 3.24e-06 0.3 0.26 Depressive symptoms; chr5:88376887 chr5:88268895~88436685:+ LUSC cis rs4713118 0.955 rs9468203 ENSG00000280107.1 AL022393.9 -5.88 7.95e-09 3.24e-06 -0.3 -0.26 Parkinson's disease; chr6:27720888 chr6:28170845~28172521:+ LUSC cis rs2274273 0.84 rs7144737 ENSG00000258413.1 RP11-665C16.6 -5.88 7.95e-09 3.24e-06 -0.32 -0.26 Protein biomarker; chr14:55356228 chr14:55262767~55272075:- LUSC cis rs2337406 0.929 rs11847182 ENSG00000274576.2 IGHV2-70 -5.88 7.95e-09 3.24e-06 -0.29 -0.26 Alzheimer's disease (late onset); chr14:106697724 chr14:106770577~106771020:- LUSC cis rs9399135 0.517 rs1883354 ENSG00000232876.1 CTA-212D2.2 5.88 7.96e-09 3.25e-06 0.32 0.26 Red blood cell count; chr6:135136403 chr6:135055033~135060550:+ LUSC cis rs67311347 0.955 rs6764102 ENSG00000223797.4 ENTPD3-AS1 5.88 7.96e-09 3.25e-06 0.29 0.26 Renal cell carcinoma; chr3:40336662 chr3:40313802~40453329:- LUSC cis rs1061377 1 rs1982009 ENSG00000249685.1 RP11-360F5.3 5.88 7.97e-09 3.25e-06 0.3 0.26 Uric acid levels; chr4:39123253 chr4:39133913~39135608:+ LUSC cis rs1061377 0.965 rs1138494 ENSG00000249685.1 RP11-360F5.3 5.88 7.97e-09 3.25e-06 0.3 0.26 Uric acid levels; chr4:39123315 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs2890659 ENSG00000249685.1 RP11-360F5.3 5.88 7.97e-09 3.25e-06 0.3 0.26 Uric acid levels; chr4:39125401 chr4:39133913~39135608:+ LUSC cis rs1061377 0.965 rs1046655 ENSG00000249685.1 RP11-360F5.3 5.88 7.97e-09 3.25e-06 0.3 0.26 Uric acid levels; chr4:39126127 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs7694760 ENSG00000249685.1 RP11-360F5.3 5.88 7.97e-09 3.25e-06 0.3 0.26 Uric acid levels; chr4:39126481 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs34771104 ENSG00000249685.1 RP11-360F5.3 5.88 7.97e-09 3.25e-06 0.3 0.26 Uric acid levels; chr4:39127432 chr4:39133913~39135608:+ LUSC cis rs1061377 0.932 rs35464499 ENSG00000249685.1 RP11-360F5.3 5.88 7.97e-09 3.25e-06 0.3 0.26 Uric acid levels; chr4:39127670 chr4:39133913~39135608:+ LUSC cis rs1061377 0.965 rs11728058 ENSG00000249685.1 RP11-360F5.3 5.88 7.97e-09 3.25e-06 0.3 0.26 Uric acid levels; chr4:39128224 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs17508864 ENSG00000249685.1 RP11-360F5.3 5.88 7.97e-09 3.25e-06 0.3 0.26 Uric acid levels; chr4:39129025 chr4:39133913~39135608:+ LUSC cis rs2153535 0.58 rs7763190 ENSG00000230939.1 RP11-314C16.1 -5.88 7.98e-09 3.25e-06 -0.31 -0.26 Motion sickness; chr6:8483964 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs1414352 ENSG00000230939.1 RP11-314C16.1 -5.88 7.98e-09 3.25e-06 -0.31 -0.26 Motion sickness; chr6:8485314 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1577471 ENSG00000230939.1 RP11-314C16.1 -5.88 7.98e-09 3.25e-06 -0.31 -0.26 Motion sickness; chr6:8485672 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1120392 ENSG00000230939.1 RP11-314C16.1 -5.88 7.98e-09 3.25e-06 -0.31 -0.26 Motion sickness; chr6:8486820 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1335641 ENSG00000230939.1 RP11-314C16.1 -5.88 7.98e-09 3.25e-06 -0.31 -0.26 Motion sickness; chr6:8487627 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1335643 ENSG00000230939.1 RP11-314C16.1 -5.88 7.98e-09 3.25e-06 -0.31 -0.26 Motion sickness; chr6:8487788 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9378554 ENSG00000230939.1 RP11-314C16.1 -5.88 7.98e-09 3.25e-06 -0.31 -0.26 Motion sickness; chr6:8488235 chr6:8784178~8785445:+ LUSC cis rs7208859 0.524 rs77498725 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs73267865 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737186 chr17:30792372~30792833:+ LUSC cis rs7208859 0.524 rs59923796 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30792372~30792833:+ LUSC cis rs17826219 0.5 rs57005940 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Body mass index; chr17:30739311 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs73267872 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30792372~30792833:+ LUSC cis rs17826219 0.706 rs9893922 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Body mass index; chr17:30741407 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs56812022 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30792372~30792833:+ LUSC cis rs7208859 0.524 rs57670615 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30792372~30792833:+ LUSC cis rs17826219 0.5 rs2874724 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Body mass index; chr17:30745415 chr17:30792372~30792833:+ LUSC cis rs17826219 0.568 rs9898097 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Body mass index; chr17:30745654 chr17:30792372~30792833:+ LUSC cis rs17826219 0.5 rs9891256 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Body mass index; chr17:30745674 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9911490 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs7503542 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs7503335 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs11656278 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs6505207 ENSG00000266490.1 CTD-2349P21.9 5.88 8e-09 3.26e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30792372~30792833:+ LUSC cis rs62388641 0.547 rs2317966 ENSG00000272279.1 RP11-157J24.2 -5.88 8e-09 3.26e-06 -0.34 -0.26 Daytime sleep phenotypes; chr6:1550651 chr6:1528364~1528911:- LUSC cis rs79349575 0.756 rs937301 ENSG00000270781.1 RP11-501C14.9 5.87 8.02e-09 3.26e-06 0.27 0.26 Type 2 diabetes; chr17:48968914 chr17:48899131~48899748:+ LUSC cis rs875971 0.545 rs6979636 ENSG00000237310.1 GS1-124K5.4 5.87 8.03e-09 3.27e-06 0.3 0.26 Aortic root size; chr7:66276638 chr7:66493706~66495474:+ LUSC cis rs2153535 0.58 rs7743995 ENSG00000230939.1 RP11-314C16.1 -5.87 8.04e-09 3.27e-06 -0.31 -0.26 Motion sickness; chr6:8495979 chr6:8784178~8785445:+ LUSC cis rs11089937 0.929 rs5757155 ENSG00000211638.2 IGLV8-61 -5.87 8.05e-09 3.28e-06 -0.24 -0.26 Periodontitis (PAL4Q3); chr22:22165378 chr22:22098700~22099212:+ LUSC cis rs227275 0.525 rs223461 ENSG00000246560.2 RP11-10L12.4 5.87 8.05e-09 3.28e-06 0.32 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102782372 chr4:102828055~102844075:+ LUSC cis rs227275 0.554 rs223457 ENSG00000246560.2 RP11-10L12.4 5.87 8.05e-09 3.28e-06 0.32 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102788506 chr4:102828055~102844075:+ LUSC cis rs9326248 0.581 rs7120706 ENSG00000280143.1 AP000892.6 -5.87 8.08e-09 3.29e-06 -0.27 -0.26 Blood protein levels; chr11:116959371 chr11:117204967~117210292:+ LUSC cis rs7772486 0.846 rs1331636 ENSG00000235652.6 RP11-545I5.3 5.87 8.08e-09 3.29e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146017690 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs1929523 ENSG00000235652.6 RP11-545I5.3 5.87 8.08e-09 3.29e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146018853 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs2224120 ENSG00000235652.6 RP11-545I5.3 5.87 8.08e-09 3.29e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146022144 chr6:145799409~145886585:+ LUSC cis rs442309 0.846 rs224143 ENSG00000238280.1 RP11-436D10.3 -5.87 8.1e-09 3.3e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62718076 chr10:62793562~62805887:- LUSC cis rs9907295 0.688 rs2526327 ENSG00000270977.1 AC015849.16 5.87 8.1e-09 3.3e-06 0.29 0.26 Fibroblast growth factor basic levels; chr17:35929902 chr17:35893707~35911023:- LUSC cis rs2404602 0.735 rs1607015 ENSG00000259422.1 RP11-593F23.1 -5.87 8.1e-09 3.3e-06 -0.31 -0.26 Blood metabolite levels; chr15:76410088 chr15:76174891~76181486:- LUSC cis rs8062405 1 rs3888190 ENSG00000278665.1 RP11-666O2.4 5.87 8.11e-09 3.3e-06 0.26 0.26 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878165 chr16:28599241~28601881:- LUSC cis rs4237845 0.844 rs7306124 ENSG00000257159.1 RP11-58A17.3 5.87 8.12e-09 3.3e-06 0.33 0.26 Intelligence (multi-trait analysis); chr12:57909566 chr12:57967058~57968399:+ LUSC cis rs17361889 0.711 rs73056339 ENSG00000224683.1 RPL36AP29 5.87 8.12e-09 3.3e-06 0.32 0.26 Pediatric bone mineral content (hip); chr7:16131751 chr7:16208945~16209265:+ LUSC cis rs11159086 0.793 rs12432412 ENSG00000259005.1 RP3-449M8.6 5.87 8.12e-09 3.3e-06 0.39 0.26 Advanced glycation end-product levels; chr14:74474294 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs1029700 ENSG00000259005.1 RP3-449M8.6 5.87 8.12e-09 3.3e-06 0.39 0.26 Advanced glycation end-product levels; chr14:74474309 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs1029699 ENSG00000259005.1 RP3-449M8.6 5.87 8.12e-09 3.3e-06 0.39 0.26 Advanced glycation end-product levels; chr14:74474790 chr14:74474007~74474864:- LUSC cis rs2243480 0.901 rs73148097 ENSG00000226824.5 RP4-756H11.3 -5.87 8.12e-09 3.3e-06 -0.52 -0.26 Diabetic kidney disease; chr7:65966800 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs35820085 ENSG00000226824.5 RP4-756H11.3 -5.87 8.12e-09 3.3e-06 -0.52 -0.26 Diabetic kidney disease; chr7:65977771 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs906134 ENSG00000226824.5 RP4-756H11.3 -5.87 8.12e-09 3.3e-06 -0.52 -0.26 Diabetic kidney disease; chr7:65979301 chr7:66654538~66669855:+ LUSC cis rs6918586 0.658 rs198803 ENSG00000272462.2 U91328.19 -5.87 8.12e-09 3.3e-06 -0.28 -0.26 Schizophrenia; chr6:26134824 chr6:25992662~26001775:+ LUSC cis rs198389 0.589 rs535107 ENSG00000242349.4 NPPA-AS1 5.87 8.12e-09 3.3e-06 0.25 0.26 B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome; chr1:11829411 chr1:11841017~11848079:+ LUSC cis rs11098499 0.954 rs878373 ENSG00000248280.1 RP11-33B1.2 5.87 8.13e-09 3.3e-06 0.32 0.26 Corneal astigmatism; chr4:119316329 chr4:119440561~119450157:- LUSC cis rs4372836 0.964 rs56240884 ENSG00000226833.4 AC097724.3 -5.87 8.14e-09 3.31e-06 -0.31 -0.26 Body mass index; chr2:28717288 chr2:28708953~28736205:- LUSC cis rs6570726 0.791 rs10872577 ENSG00000235652.6 RP11-545I5.3 5.87 8.14e-09 3.31e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145579424 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs6570692 ENSG00000235652.6 RP11-545I5.3 5.87 8.14e-09 3.31e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145583265 chr6:145799409~145886585:+ LUSC cis rs2153535 0.58 rs6905242 ENSG00000230939.1 RP11-314C16.1 -5.87 8.15e-09 3.31e-06 -0.31 -0.26 Motion sickness; chr6:8471566 chr6:8784178~8785445:+ LUSC cis rs2739330 0.76 rs5751761 ENSG00000228039.3 KB-1125A3.10 -5.87 8.16e-09 3.32e-06 -0.32 -0.26 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23963780~23964374:+ LUSC cis rs13113518 0.966 rs11133396 ENSG00000249700.7 SRD5A3-AS1 5.87 8.16e-09 3.32e-06 0.3 0.26 Height; chr4:55524246 chr4:55363971~55395847:- LUSC cis rs8031584 0.697 rs8036176 ENSG00000260382.1 RP11-540B6.2 5.87 8.16e-09 3.32e-06 0.37 0.26 Huntington's disease progression; chr15:30883066 chr15:30882267~30883231:- LUSC cis rs763121 0.962 rs138703 ENSG00000273076.1 RP3-508I15.22 5.87 8.17e-09 3.32e-06 0.24 0.26 Menopause (age at onset); chr22:38736743 chr22:38743495~38743910:+ LUSC cis rs9545047 0.604 rs7988784 ENSG00000227676.3 LINC01068 -5.87 8.17e-09 3.32e-06 -0.31 -0.26 Schizophrenia; chr13:79335337 chr13:79566727~79571436:+ LUSC cis rs4372836 1 rs11690423 ENSG00000226833.4 AC097724.3 -5.87 8.17e-09 3.32e-06 -0.31 -0.26 Body mass index; chr2:28728671 chr2:28708953~28736205:- LUSC cis rs4372836 1 rs72782294 ENSG00000226833.4 AC097724.3 -5.87 8.17e-09 3.32e-06 -0.31 -0.26 Body mass index; chr2:28730524 chr2:28708953~28736205:- LUSC cis rs17772222 0.63 rs7146241 ENSG00000258789.1 RP11-507K2.3 5.87 8.17e-09 3.32e-06 0.29 0.26 Coronary artery calcification; chr14:88551622 chr14:88551597~88552493:+ LUSC cis rs1061377 1 rs9999327 ENSG00000249685.1 RP11-360F5.3 5.87 8.17e-09 3.32e-06 0.3 0.26 Uric acid levels; chr4:39110111 chr4:39133913~39135608:+ LUSC cis rs2153535 0.58 rs4365970 ENSG00000230939.1 RP11-314C16.1 5.87 8.18e-09 3.32e-06 0.31 0.26 Motion sickness; chr6:8453580 chr6:8784178~8785445:+ LUSC cis rs11159086 0.941 rs11846588 ENSG00000259005.1 RP3-449M8.6 5.87 8.18e-09 3.33e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74505398 chr14:74474007~74474864:- LUSC cis rs3738443 0.868 rs61839994 ENSG00000259865.1 RP11-488L18.10 5.87 8.21e-09 3.34e-06 0.28 0.26 Alcohol dependence; chr1:247195479 chr1:247187281~247188526:- LUSC cis rs3738443 0.868 rs7536883 ENSG00000259865.1 RP11-488L18.10 5.87 8.21e-09 3.34e-06 0.28 0.26 Alcohol dependence; chr1:247196266 chr1:247187281~247188526:- LUSC cis rs11089937 0.963 rs2073454 ENSG00000211638.2 IGLV8-61 -5.87 8.21e-09 3.34e-06 -0.24 -0.26 Periodontitis (PAL4Q3); chr22:22163086 chr22:22098700~22099212:+ LUSC cis rs875971 0.642 rs35526611 ENSG00000237310.1 GS1-124K5.4 -5.87 8.21e-09 3.34e-06 -0.26 -0.26 Aortic root size; chr7:66629021 chr7:66493706~66495474:+ LUSC cis rs17826219 0.706 rs28469200 ENSG00000266490.1 CTD-2349P21.9 5.87 8.23e-09 3.34e-06 0.32 0.26 Body mass index; chr17:30806554 chr17:30792372~30792833:+ LUSC cis rs1499614 1 rs2659913 ENSG00000226824.5 RP4-756H11.3 -5.87 8.23e-09 3.34e-06 -0.5 -0.26 Gout; chr7:66692349 chr7:66654538~66669855:+ LUSC cis rs1499614 1 rs2659911 ENSG00000226824.5 RP4-756H11.3 -5.87 8.23e-09 3.34e-06 -0.5 -0.26 Gout; chr7:66693433 chr7:66654538~66669855:+ LUSC cis rs1499614 1 rs2707838 ENSG00000226824.5 RP4-756H11.3 -5.87 8.23e-09 3.34e-06 -0.5 -0.26 Gout; chr7:66694214 chr7:66654538~66669855:+ LUSC cis rs1499614 1 rs60326618 ENSG00000226824.5 RP4-756H11.3 -5.87 8.23e-09 3.34e-06 -0.5 -0.26 Gout; chr7:66701371 chr7:66654538~66669855:+ LUSC cis rs1499614 1 rs2707830 ENSG00000226824.5 RP4-756H11.3 -5.87 8.23e-09 3.34e-06 -0.5 -0.26 Gout; chr7:66702658 chr7:66654538~66669855:+ LUSC cis rs1499614 1 rs2707828 ENSG00000226824.5 RP4-756H11.3 -5.87 8.23e-09 3.34e-06 -0.5 -0.26 Gout; chr7:66706390 chr7:66654538~66669855:+ LUSC cis rs1499614 0.803 rs1922723 ENSG00000226824.5 RP4-756H11.3 -5.87 8.23e-09 3.34e-06 -0.5 -0.26 Gout; chr7:66710076 chr7:66654538~66669855:+ LUSC cis rs1499614 1 rs2659903 ENSG00000226824.5 RP4-756H11.3 -5.87 8.23e-09 3.34e-06 -0.5 -0.26 Gout; chr7:66715944 chr7:66654538~66669855:+ LUSC cis rs1499614 1 rs2141924 ENSG00000226824.5 RP4-756H11.3 -5.87 8.23e-09 3.34e-06 -0.5 -0.26 Gout; chr7:66721259 chr7:66654538~66669855:+ LUSC cis rs7208859 0.573 rs7214313 ENSG00000266490.1 CTD-2349P21.9 5.87 8.23e-09 3.34e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30792372~30792833:+ LUSC cis rs875971 0.619 rs2302918 ENSG00000237310.1 GS1-124K5.4 5.87 8.23e-09 3.34e-06 0.27 0.26 Aortic root size; chr7:66535945 chr7:66493706~66495474:+ LUSC cis rs9322193 0.851 rs9322194 ENSG00000268592.3 RAET1E-AS1 5.87 8.24e-09 3.34e-06 0.34 0.26 Lung cancer; chr6:149599113 chr6:149863494~149919507:+ LUSC cis rs17826219 0.568 rs2626985 ENSG00000266490.1 CTD-2349P21.9 5.87 8.24e-09 3.34e-06 0.32 0.26 Body mass index; chr17:30750419 chr17:30792372~30792833:+ LUSC cis rs875971 1 rs6979382 ENSG00000179406.6 LINC00174 -5.87 8.24e-09 3.35e-06 -0.28 -0.26 Aortic root size; chr7:66421388 chr7:66376044~66401338:- LUSC cis rs875971 1 rs6961990 ENSG00000179406.6 LINC00174 -5.87 8.24e-09 3.35e-06 -0.28 -0.26 Aortic root size; chr7:66423583 chr7:66376044~66401338:- LUSC cis rs367615 0.679 rs10070786 ENSG00000249476.1 CTD-2587M2.1 5.87 8.25e-09 3.35e-06 0.31 0.26 Colorectal cancer (SNP x SNP interaction); chr5:109479380 chr5:109237120~109326369:- LUSC cis rs2243480 1 rs1796220 ENSG00000226824.5 RP4-756H11.3 -5.87 8.25e-09 3.35e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66597113 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs2707831 ENSG00000226824.5 RP4-756H11.3 -5.87 8.25e-09 3.35e-06 -0.5 -0.26 Diabetic kidney disease; chr7:66597524 chr7:66654538~66669855:+ LUSC cis rs73173548 0.557 rs71580759 ENSG00000247828.6 TMEM161B-AS1 5.87 8.25e-09 3.35e-06 0.32 0.26 Macular telangiectasia type 2; chr5:88474306 chr5:88268895~88436685:+ LUSC cis rs227275 0.554 rs223395 ENSG00000246560.2 RP11-10L12.4 5.87 8.25e-09 3.35e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102823801 chr4:102828055~102844075:+ LUSC cis rs6951245 0.608 rs10252234 ENSG00000224079.1 AC091729.7 -5.87 8.25e-09 3.35e-06 -0.35 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1074745 chr7:1074450~1078036:+ LUSC cis rs1075265 0.68 rs805396 ENSG00000233266.1 HMGB1P31 5.87 8.25e-09 3.35e-06 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:53882314 chr2:54051334~54051760:+ LUSC cis rs1056107 0.897 rs10817298 ENSG00000225513.1 RP11-165N19.2 -5.87 8.26e-09 3.35e-06 -0.29 -0.26 Colorectal cancer; chr9:112244396 chr9:112173522~112173971:- LUSC cis rs3764021 0.527 rs10844537 ENSG00000256975.1 RP11-525E9.1 5.87 8.27e-09 3.35e-06 0.35 0.26 Type 1 diabetes; chr12:9709528 chr12:9506347~9508440:- LUSC cis rs875971 0.895 rs4718349 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66444024 chr7:66376044~66401338:- LUSC cis rs875971 1 rs2420591 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66447394 chr7:66376044~66401338:- LUSC cis rs875971 0.895 rs10755833 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66448930 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs12668936 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66449417 chr7:66376044~66401338:- LUSC cis rs875971 0.895 rs1833495 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66456608 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs6945032 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66457499 chr7:66376044~66401338:- LUSC cis rs875971 0.929 rs12673810 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66458866 chr7:66376044~66401338:- LUSC cis rs875971 1 rs35149210 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66464938 chr7:66376044~66401338:- LUSC cis rs875971 1 rs2042133 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66466935 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs2161065 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66467918 chr7:66376044~66401338:- LUSC cis rs875971 1 rs6961155 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66468308 chr7:66376044~66401338:- LUSC cis rs875971 1 rs7789768 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66473993 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs12698521 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66474502 chr7:66376044~66401338:- LUSC cis rs875971 1 rs1363055 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66478288 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs9691480 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66479319 chr7:66376044~66401338:- LUSC cis rs875971 1 rs7789554 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66481051 chr7:66376044~66401338:- LUSC cis rs875971 1 rs4717300 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66482393 chr7:66376044~66401338:- LUSC cis rs875971 0.895 rs1974769 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66485627 chr7:66376044~66401338:- LUSC cis rs875971 0.895 rs6460300 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66487937 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs7803416 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66489212 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs1981799 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66490572 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs2277911 ENSG00000179406.6 LINC00174 -5.87 8.27e-09 3.36e-06 -0.28 -0.26 Aortic root size; chr7:66493638 chr7:66376044~66401338:- LUSC cis rs2919917 0.915 rs10957897 ENSG00000254352.1 RP11-578O24.2 5.87 8.29e-09 3.36e-06 0.33 0.26 Lymphocyte counts; chr8:78695658 chr8:78723796~78724136:- LUSC cis rs7181230 0.922 rs4924410 ENSG00000275636.1 RP11-521C20.5 -5.87 8.29e-09 3.36e-06 -0.32 -0.26 Dehydroepiandrosterone sulphate levels; chr15:40047293 chr15:40078892~40079347:+ LUSC cis rs7829975 0.514 rs2920991 ENSG00000253893.2 FAM85B -5.87 8.29e-09 3.36e-06 -0.3 -0.26 Mood instability; chr8:8401607 chr8:8167819~8226614:- LUSC cis rs2834288 0.7 rs731060 ENSG00000273102.1 AP000569.9 -5.87 8.29e-09 3.36e-06 -0.3 -0.26 Gut microbiota (bacterial taxa); chr21:33902624 chr21:33967101~33968573:- LUSC cis rs1021993 0.545 rs55684110 ENSG00000231648.1 RP11-372M18.2 -5.87 8.3e-09 3.37e-06 -0.38 -0.26 Gut microbiome composition (winter); chr1:209368487 chr1:209367662~209379690:+ LUSC cis rs1800795 0.901 rs2069833 ENSG00000179428.2 AC073072.5 -5.87 8.3e-09 3.37e-06 -0.32 -0.26 Cerebrospinal fluid clusterin levels in APOEe4- carriers; chr7:22728045 chr7:22725395~22727620:- LUSC cis rs2028299 0.92 rs11638138 ENSG00000259677.1 RP11-493E3.1 -5.87 8.31e-09 3.37e-06 -0.33 -0.26 Type 2 diabetes; chr15:89885523 chr15:89876540~89877285:+ LUSC cis rs853679 0.598 rs9380054 ENSG00000280107.1 AL022393.9 -5.87 8.33e-09 3.38e-06 -0.33 -0.26 Depression; chr6:28099759 chr6:28170845~28172521:+ LUSC cis rs4722166 0.63 rs2091115 ENSG00000179428.2 AC073072.5 -5.87 8.33e-09 3.38e-06 -0.31 -0.26 Lung cancer; chr7:22770547 chr7:22725395~22727620:- LUSC cis rs875971 0.545 rs2420612 ENSG00000237310.1 GS1-124K5.4 5.87 8.34e-09 3.38e-06 0.3 0.26 Aortic root size; chr7:66536825 chr7:66493706~66495474:+ LUSC cis rs6142102 0.812 rs761236 ENSG00000275784.1 RP5-1125A11.6 -5.87 8.37e-09 3.39e-06 -0.3 -0.26 Skin pigmentation; chr20:33932245 chr20:33989480~33991818:- LUSC cis rs10800713 0.56 rs10919967 ENSG00000260088.1 RP11-92G12.3 5.87 8.38e-09 3.4e-06 0.39 0.26 Tandem gait; chr1:200533543 chr1:200669507~200694250:+ LUSC cis rs34792 0.688 rs13339072 ENSG00000207425.1 Y_RNA -5.87 8.38e-09 3.4e-06 -0.35 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15504090 chr16:14915457~14915556:- LUSC cis rs28830936 0.966 rs3179542 ENSG00000250379.1 RP11-23P13.4 5.87 8.4e-09 3.41e-06 0.28 0.26 Diastolic blood pressure; chr15:41825925 chr15:41825099~41827936:- LUSC cis rs13113518 1 rs11133388 ENSG00000223305.1 RN7SKP30 -5.87 8.41e-09 3.41e-06 -0.31 -0.26 Height; chr4:55477866 chr4:55540502~55540835:- LUSC cis rs2153535 0.58 rs1119690 ENSG00000230939.1 RP11-314C16.1 -5.87 8.42e-09 3.41e-06 -0.31 -0.26 Motion sickness; chr6:8460427 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1119689 ENSG00000230939.1 RP11-314C16.1 -5.87 8.42e-09 3.41e-06 -0.31 -0.26 Motion sickness; chr6:8460521 chr6:8784178~8785445:+ LUSC cis rs9287719 0.674 rs10929690 ENSG00000234818.1 AC092687.5 -5.87 8.42e-09 3.41e-06 -0.29 -0.26 Prostate cancer; chr2:10665848 chr2:10589166~10604830:+ LUSC cis rs853679 0.76 rs9393910 ENSG00000204709.4 LINC01556 5.87 8.42e-09 3.41e-06 0.39 0.26 Depression; chr6:28240414 chr6:28943877~28944537:+ LUSC cis rs1499614 1 rs1638731 ENSG00000226824.5 RP4-756H11.3 -5.87 8.44e-09 3.42e-06 -0.5 -0.26 Gout; chr7:66679692 chr7:66654538~66669855:+ LUSC cis rs1499614 1 rs1882655 ENSG00000226824.5 RP4-756H11.3 5.87 8.44e-09 3.42e-06 0.5 0.26 Gout; chr7:66682070 chr7:66654538~66669855:+ LUSC cis rs1499614 0.831 rs3800822 ENSG00000226824.5 RP4-756H11.3 5.87 8.44e-09 3.42e-06 0.5 0.26 Gout; chr7:66682162 chr7:66654538~66669855:+ LUSC cis rs875971 0.825 rs1000464 ENSG00000179406.6 LINC00174 5.87 8.45e-09 3.42e-06 0.28 0.26 Aortic root size; chr7:66312922 chr7:66376044~66401338:- LUSC cis rs77204473 0.744 rs11606672 ENSG00000254851.1 RP11-109L13.1 5.87 8.46e-09 3.43e-06 0.59 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117185343 chr11:117135528~117138582:+ LUSC cis rs9287719 0.674 rs11691060 ENSG00000234818.1 AC092687.5 -5.87 8.46e-09 3.43e-06 -0.29 -0.26 Prostate cancer; chr2:10686935 chr2:10589166~10604830:+ LUSC cis rs9287719 0.674 rs11684157 ENSG00000234818.1 AC092687.5 -5.87 8.46e-09 3.43e-06 -0.29 -0.26 Prostate cancer; chr2:10687031 chr2:10589166~10604830:+ LUSC cis rs9287719 0.674 rs1387566 ENSG00000234818.1 AC092687.5 -5.87 8.46e-09 3.43e-06 -0.29 -0.26 Prostate cancer; chr2:10688524 chr2:10589166~10604830:+ LUSC cis rs4713118 0.513 rs149944 ENSG00000216901.1 AL022393.7 5.87 8.46e-09 3.43e-06 0.3 0.26 Parkinson's disease; chr6:28035040 chr6:28176188~28176674:+ LUSC cis rs2439831 0.85 rs28858500 ENSG00000249839.1 AC011330.5 -5.87 8.46e-09 3.43e-06 -0.54 -0.26 Lung cancer in ever smokers; chr15:43864744 chr15:43663654~43684339:- LUSC cis rs13113518 1 rs4864548 ENSG00000273257.1 RP11-177J6.1 -5.87 8.46e-09 3.43e-06 -0.33 -0.26 Height; chr4:55547636 chr4:55387949~55388271:+ LUSC cis rs1823913 0.637 rs6722183 ENSG00000280083.1 RP11-317J9.1 5.86 8.49e-09 3.44e-06 0.31 0.26 Obesity-related traits; chr2:191333203 chr2:191154118~191156070:- LUSC cis rs9813712 0.595 rs1901787 ENSG00000228252.7 COL6A4P2 5.86 8.49e-09 3.44e-06 0.25 0.26 Response to amphetamines; chr3:130288678 chr3:130212823~130273806:+ LUSC cis rs9813712 0.547 rs6807290 ENSG00000228252.7 COL6A4P2 5.86 8.49e-09 3.44e-06 0.25 0.26 Response to amphetamines; chr3:130297952 chr3:130212823~130273806:+ LUSC cis rs6991838 0.593 rs7011464 ENSG00000272010.1 CTD-3025N20.3 -5.86 8.5e-09 3.44e-06 -0.32 -0.26 Intelligence (multi-trait analysis); chr8:65723052 chr8:65591850~65592472:- LUSC cis rs875971 0.895 rs3857684 ENSG00000179406.6 LINC00174 -5.86 8.5e-09 3.44e-06 -0.28 -0.26 Aortic root size; chr7:66473171 chr7:66376044~66401338:- LUSC cis rs6142102 0.924 rs6059662 ENSG00000275784.1 RP5-1125A11.6 5.86 8.51e-09 3.45e-06 0.32 0.26 Skin pigmentation; chr20:34087921 chr20:33989480~33991818:- LUSC cis rs10759883 0.603 rs10760262 ENSG00000175611.10 LINC00476 5.86 8.52e-09 3.45e-06 0.31 0.26 Nicotine dependence; chr9:95850234 chr9:95759231~95875977:- LUSC cis rs61270009 0.955 rs11741675 ENSG00000247828.6 TMEM161B-AS1 5.86 8.52e-09 3.45e-06 0.3 0.26 Depressive symptoms; chr5:88332984 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs4916904 ENSG00000247828.6 TMEM161B-AS1 5.86 8.52e-09 3.45e-06 0.3 0.26 Depressive symptoms; chr5:88338780 chr5:88268895~88436685:+ LUSC cis rs11971779 0.68 rs4728465 ENSG00000273391.1 RP11-634H22.1 5.86 8.52e-09 3.45e-06 0.28 0.26 Diisocyanate-induced asthma; chr7:139384315 chr7:139359032~139359566:- LUSC cis rs11971779 0.715 rs55714903 ENSG00000273391.1 RP11-634H22.1 5.86 8.52e-09 3.45e-06 0.28 0.26 Diisocyanate-induced asthma; chr7:139389844 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs66491565 ENSG00000273391.1 RP11-634H22.1 5.86 8.52e-09 3.45e-06 0.28 0.26 Diisocyanate-induced asthma; chr7:139404231 chr7:139359032~139359566:- LUSC cis rs13113518 0.756 rs7658446 ENSG00000249700.7 SRD5A3-AS1 5.86 8.52e-09 3.45e-06 0.31 0.26 Height; chr4:55495262 chr4:55363971~55395847:- LUSC cis rs11089937 0.929 rs2236727 ENSG00000211638.2 IGLV8-61 -5.86 8.53e-09 3.45e-06 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22156654 chr22:22098700~22099212:+ LUSC cis rs12554020 0.582 rs79565493 ENSG00000227603.1 RP11-165J3.6 5.86 8.55e-09 3.46e-06 0.47 0.26 Schizophrenia; chr9:93634820 chr9:93435332~93437121:- LUSC cis rs12554020 0.582 rs74421510 ENSG00000227603.1 RP11-165J3.6 5.86 8.55e-09 3.46e-06 0.47 0.26 Schizophrenia; chr9:93634872 chr9:93435332~93437121:- LUSC cis rs853679 1 rs6905391 ENSG00000219392.1 RP1-265C24.5 -5.86 8.55e-09 3.46e-06 -0.41 -0.26 Depression; chr6:28294909 chr6:28115628~28116551:+ LUSC cis rs3764021 0.527 rs3764022 ENSG00000256975.1 RP11-525E9.1 5.86 8.55e-09 3.46e-06 0.34 0.26 Type 1 diabetes; chr12:9680928 chr12:9506347~9508440:- LUSC cis rs9341835 0.772 rs9344090 ENSG00000218048.2 RP3-407E4.4 5.86 8.55e-09 3.46e-06 0.3 0.26 Schizophrenia; chr6:63425925 chr6:63440766~63443580:+ LUSC cis rs2276314 1 rs62101367 ENSG00000278986.1 RP11-723J4.3 -5.86 8.56e-09 3.46e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35970921 chr18:35972151~35973916:+ LUSC cis rs1167827 1 rs1167827 ENSG00000278416.1 PMS2L2 5.86 8.56e-09 3.46e-06 0.34 0.26 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75533848 chr7:75344015~75359550:- LUSC cis rs9545047 0.604 rs12875039 ENSG00000227676.3 LINC01068 -5.86 8.56e-09 3.47e-06 -0.31 -0.26 Schizophrenia; chr13:79327449 chr13:79566727~79571436:+ LUSC cis rs1075265 0.626 rs805412 ENSG00000233266.1 HMGB1P31 5.86 8.57e-09 3.47e-06 0.32 0.26 Chronotype;Morning vs. evening chronotype; chr2:53893683 chr2:54051334~54051760:+ LUSC cis rs875971 0.895 rs12698520 ENSG00000179406.6 LINC00174 -5.86 8.57e-09 3.47e-06 -0.28 -0.26 Aortic root size; chr7:66453720 chr7:66376044~66401338:- LUSC cis rs4713118 0.911 rs9461406 ENSG00000280107.1 AL022393.9 5.86 8.58e-09 3.47e-06 0.32 0.26 Parkinson's disease; chr6:27751985 chr6:28170845~28172521:+ LUSC cis rs6142102 0.812 rs6059578 ENSG00000275784.1 RP5-1125A11.6 -5.86 8.58e-09 3.47e-06 -0.31 -0.26 Skin pigmentation; chr20:33939900 chr20:33989480~33991818:- LUSC cis rs875971 0.545 rs6460281 ENSG00000237310.1 GS1-124K5.4 5.86 8.58e-09 3.47e-06 0.3 0.26 Aortic root size; chr7:66216128 chr7:66493706~66495474:+ LUSC cis rs783540 1 rs1259180 ENSG00000276710.3 CSPG4P8 5.86 8.59e-09 3.47e-06 0.28 0.26 Schizophrenia; chr15:82575930 chr15:82459472~82477258:+ LUSC cis rs61270009 0.955 rs4916719 ENSG00000247828.6 TMEM161B-AS1 5.86 8.59e-09 3.48e-06 0.3 0.26 Depressive symptoms; chr5:88327844 chr5:88268895~88436685:+ LUSC cis rs875971 0.638 rs35986979 ENSG00000237310.1 GS1-124K5.4 -5.86 8.6e-09 3.48e-06 -0.26 -0.26 Aortic root size; chr7:66624003 chr7:66493706~66495474:+ LUSC cis rs12130219 1 rs34428306 ENSG00000237975.5 FLG-AS1 5.86 8.61e-09 3.48e-06 0.3 0.26 Inflammatory skin disease; chr1:152211840 chr1:152168125~152445456:+ LUSC cis rs17507216 0.958 rs28648832 ENSG00000276710.3 CSPG4P8 -5.86 8.61e-09 3.48e-06 -0.31 -0.26 Excessive daytime sleepiness; chr15:82567642 chr15:82459472~82477258:+ LUSC cis rs11603023 0.967 rs7936556 ENSG00000255422.1 AP002954.4 5.86 8.61e-09 3.48e-06 0.29 0.26 Cholesterol, total; chr11:118630582 chr11:118704607~118750263:+ LUSC cis rs77972916 0.561 rs4372955 ENSG00000234936.1 AC010883.5 5.86 8.61e-09 3.48e-06 0.35 0.26 Granulocyte percentage of myeloid white cells; chr2:43339007 chr2:43229573~43233394:+ LUSC cis rs13113518 0.812 rs12505880 ENSG00000249700.7 SRD5A3-AS1 5.86 8.62e-09 3.48e-06 0.3 0.26 Height; chr4:55440988 chr4:55363971~55395847:- LUSC cis rs2834288 0.536 rs8129513 ENSG00000273102.1 AP000569.9 5.86 8.64e-09 3.49e-06 0.29 0.26 Gut microbiota (bacterial taxa); chr21:33952615 chr21:33967101~33968573:- LUSC cis rs2153535 0.547 rs9505475 ENSG00000230939.1 RP11-314C16.1 -5.86 8.64e-09 3.49e-06 -0.31 -0.26 Motion sickness; chr6:8542657 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs6906170 ENSG00000230939.1 RP11-314C16.1 -5.86 8.64e-09 3.49e-06 -0.31 -0.26 Motion sickness; chr6:8542895 chr6:8784178~8785445:+ LUSC cis rs875971 1 rs10244498 ENSG00000179406.6 LINC00174 -5.86 8.65e-09 3.5e-06 -0.28 -0.26 Aortic root size; chr7:66651069 chr7:66376044~66401338:- LUSC cis rs7772486 0.713 rs2328704 ENSG00000235652.6 RP11-545I5.3 -5.86 8.66e-09 3.5e-06 -0.26 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145699358 chr6:145799409~145886585:+ LUSC cis rs875971 1 rs6946143 ENSG00000179406.6 LINC00174 -5.86 8.67e-09 3.51e-06 -0.27 -0.26 Aortic root size; chr7:66114735 chr7:66376044~66401338:- LUSC cis rs71403859 0.667 rs12920890 ENSG00000260886.1 TAT-AS1 5.86 8.68e-09 3.51e-06 0.42 0.26 Post bronchodilator FEV1; chr16:71753685 chr16:71565789~71578187:+ LUSC cis rs34779708 0.733 rs16935945 ENSG00000230534.5 RP11-297A16.2 5.86 8.68e-09 3.51e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35251392 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs12777960 ENSG00000230534.5 RP11-297A16.2 5.86 8.68e-09 3.51e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35252098 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs60553075 ENSG00000230534.5 RP11-297A16.2 5.86 8.68e-09 3.51e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35253534 chr10:35098006~35127020:- LUSC cis rs6570726 0.791 rs7755253 ENSG00000235652.6 RP11-545I5.3 5.86 8.68e-09 3.51e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145537757 chr6:145799409~145886585:+ LUSC cis rs9611519 0.929 rs9611465 ENSG00000235513.1 RP4-756G23.5 5.86 8.69e-09 3.51e-06 0.3 0.26 Neuroticism; chr22:41030135 chr22:41209122~41217627:- LUSC cis rs9611519 0.929 rs9611466 ENSG00000235513.1 RP4-756G23.5 5.86 8.69e-09 3.51e-06 0.3 0.26 Neuroticism; chr22:41030295 chr22:41209122~41217627:- LUSC cis rs11690935 0.885 rs6727017 ENSG00000228389.1 AC068039.4 5.86 8.69e-09 3.51e-06 0.3 0.26 Schizophrenia; chr2:171910337 chr2:171773482~171775844:+ LUSC cis rs7712401 0.601 rs30029 ENSG00000263432.2 RN7SL689P -5.86 8.69e-09 3.51e-06 -0.32 -0.26 Mean platelet volume; chr5:122947475 chr5:123022487~123022783:- LUSC cis rs9309711 0.961 rs11692184 ENSG00000225234.1 TRAPPC12-AS1 -5.86 8.7e-09 3.52e-06 -0.34 -0.26 Neurofibrillary tangles; chr2:3476939 chr2:3481242~3482409:- LUSC cis rs1056107 0.898 rs7021564 ENSG00000225513.1 RP11-165N19.2 -5.86 8.71e-09 3.52e-06 -0.29 -0.26 Colorectal cancer; chr9:112240034 chr9:112173522~112173971:- LUSC cis rs9326248 0.581 rs10892063 ENSG00000280143.1 AP000892.6 5.86 8.71e-09 3.52e-06 0.27 0.26 Blood protein levels; chr11:117025439 chr11:117204967~117210292:+ LUSC cis rs9326248 0.559 rs10892064 ENSG00000280143.1 AP000892.6 5.86 8.71e-09 3.52e-06 0.27 0.26 Blood protein levels; chr11:117025837 chr11:117204967~117210292:+ LUSC cis rs9326248 0.539 rs10892065 ENSG00000280143.1 AP000892.6 5.86 8.71e-09 3.52e-06 0.27 0.26 Blood protein levels; chr11:117026308 chr11:117204967~117210292:+ LUSC cis rs875971 0.965 rs10267430 ENSG00000179406.6 LINC00174 5.86 8.71e-09 3.52e-06 0.28 0.26 Aortic root size; chr7:66278036 chr7:66376044~66401338:- LUSC cis rs875971 1 rs10257427 ENSG00000179406.6 LINC00174 5.86 8.71e-09 3.52e-06 0.28 0.26 Aortic root size; chr7:66278221 chr7:66376044~66401338:- LUSC cis rs875971 1 rs10215948 ENSG00000179406.6 LINC00174 5.86 8.71e-09 3.52e-06 0.28 0.26 Aortic root size; chr7:66282799 chr7:66376044~66401338:- LUSC cis rs875971 0.964 rs55748098 ENSG00000179406.6 LINC00174 5.86 8.71e-09 3.52e-06 0.28 0.26 Aortic root size; chr7:66298631 chr7:66376044~66401338:- LUSC cis rs875971 0.505 rs2462573 ENSG00000179406.6 LINC00174 5.86 8.71e-09 3.52e-06 0.27 0.26 Aortic root size; chr7:66042405 chr7:66376044~66401338:- LUSC cis rs2404602 1 rs2056544 ENSG00000259422.1 RP11-593F23.1 5.86 8.71e-09 3.52e-06 0.3 0.26 Blood metabolite levels; chr15:76533662 chr15:76174891~76181486:- LUSC cis rs867371 0.82 rs12443224 ENSG00000278603.1 RP13-608F4.5 5.86 8.72e-09 3.52e-06 0.32 0.26 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82203269 chr15:82472203~82472426:+ LUSC cis rs13113518 1 rs2279458 ENSG00000249700.7 SRD5A3-AS1 5.86 8.72e-09 3.52e-06 0.31 0.26 Height; chr4:55562653 chr4:55363971~55395847:- LUSC cis rs11089937 0.609 rs2213158 ENSG00000211638.2 IGLV8-61 -5.86 8.73e-09 3.53e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22138099 chr22:22098700~22099212:+ LUSC cis rs11089937 0.637 rs2213159 ENSG00000211638.2 IGLV8-61 -5.86 8.73e-09 3.53e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22138100 chr22:22098700~22099212:+ LUSC cis rs9341835 0.772 rs9341841 ENSG00000218048.2 RP3-407E4.4 5.86 8.74e-09 3.53e-06 0.3 0.26 Schizophrenia; chr6:63425105 chr6:63440766~63443580:+ LUSC cis rs2276314 1 rs1789513 ENSG00000278986.1 RP11-723J4.3 5.86 8.74e-09 3.53e-06 0.33 0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35965667 chr18:35972151~35973916:+ LUSC cis rs6504950 0.695 rs9904377 ENSG00000275710.1 RP11-257O5.4 5.86 8.75e-09 3.53e-06 0.3 0.26 Breast cancer; chr17:54908621 chr17:54964474~54964679:+ LUSC cis rs13113518 0.902 rs12642716 ENSG00000249700.7 SRD5A3-AS1 5.86 8.75e-09 3.53e-06 0.3 0.26 Height; chr4:55479996 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs12501636 ENSG00000249700.7 SRD5A3-AS1 5.86 8.75e-09 3.53e-06 0.3 0.26 Height; chr4:55482317 chr4:55363971~55395847:- LUSC cis rs66887589 0.934 rs56843000 ENSG00000248280.1 RP11-33B1.2 -5.86 8.75e-09 3.53e-06 -0.29 -0.26 Diastolic blood pressure; chr4:119595442 chr4:119440561~119450157:- LUSC cis rs75422866 0.51 rs75424057 ENSG00000276691.1 RP5-1057I20.5 5.86 8.75e-09 3.54e-06 0.46 0.26 Pneumonia; chr12:47737294 chr12:47788426~47788971:+ LUSC cis rs8072100 0.713 rs11079776 ENSG00000228782.6 CTD-2026D20.3 5.86 8.77e-09 3.54e-06 0.26 0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469527 chr17:47450568~47492492:- LUSC cis rs1021993 0.545 rs1507331 ENSG00000231648.1 RP11-372M18.2 -5.86 8.77e-09 3.54e-06 -0.38 -0.26 Gut microbiome composition (winter); chr1:209343552 chr1:209367662~209379690:+ LUSC cis rs11098499 0.588 rs6534149 ENSG00000248280.1 RP11-33B1.2 -5.86 8.78e-09 3.55e-06 -0.3 -0.26 Corneal astigmatism; chr4:119638137 chr4:119440561~119450157:- LUSC cis rs79349575 0.783 rs11079844 ENSG00000270781.1 RP11-501C14.9 -5.86 8.8e-09 3.55e-06 -0.27 -0.26 Type 2 diabetes; chr17:48950972 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs62078372 ENSG00000270781.1 RP11-501C14.9 -5.86 8.8e-09 3.55e-06 -0.27 -0.26 Type 2 diabetes; chr17:48951627 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs12602933 ENSG00000270781.1 RP11-501C14.9 -5.86 8.8e-09 3.55e-06 -0.27 -0.26 Type 2 diabetes; chr17:48951918 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs4794003 ENSG00000270781.1 RP11-501C14.9 -5.86 8.8e-09 3.55e-06 -0.27 -0.26 Type 2 diabetes; chr17:48952542 chr17:48899131~48899748:+ LUSC cis rs79349575 0.783 rs12602746 ENSG00000270781.1 RP11-501C14.9 -5.86 8.8e-09 3.55e-06 -0.27 -0.26 Type 2 diabetes; chr17:48954379 chr17:48899131~48899748:+ LUSC cis rs12554020 0.582 rs77133953 ENSG00000227603.1 RP11-165J3.6 5.86 8.8e-09 3.55e-06 0.47 0.26 Schizophrenia; chr9:93635287 chr9:93435332~93437121:- LUSC cis rs1056107 0.866 rs12351043 ENSG00000225513.1 RP11-165N19.2 -5.86 8.81e-09 3.56e-06 -0.29 -0.26 Colorectal cancer; chr9:112241012 chr9:112173522~112173971:- LUSC cis rs1056107 0.931 rs7864927 ENSG00000225513.1 RP11-165N19.2 -5.86 8.81e-09 3.56e-06 -0.29 -0.26 Colorectal cancer; chr9:112241713 chr9:112173522~112173971:- LUSC cis rs79349575 0.783 rs15563 ENSG00000270781.1 RP11-501C14.9 -5.86 8.81e-09 3.56e-06 -0.27 -0.26 Type 2 diabetes; chr17:48927831 chr17:48899131~48899748:+ LUSC cis rs9322193 0.962 rs35443312 ENSG00000268592.3 RAET1E-AS1 5.86 8.81e-09 3.56e-06 0.33 0.26 Lung cancer; chr6:149670625 chr6:149863494~149919507:+ LUSC cis rs875971 0.838 rs2173570 ENSG00000179406.6 LINC00174 5.86 8.81e-09 3.56e-06 0.28 0.26 Aortic root size; chr7:66297976 chr7:66376044~66401338:- LUSC cis rs10759883 0.627 rs10125109 ENSG00000175611.10 LINC00476 -5.86 8.83e-09 3.56e-06 -0.31 -0.26 Nicotine dependence; chr9:95799228 chr9:95759231~95875977:- LUSC cis rs11089937 0.616 rs5995616 ENSG00000211639.2 IGLV4-60 -5.86 8.84e-09 3.57e-06 -0.28 -0.26 Periodontitis (PAL4Q3); chr22:22186667 chr22:22162199~22162681:+ LUSC cis rs75422866 0.51 rs35784744 ENSG00000276691.1 RP5-1057I20.5 5.86 8.84e-09 3.57e-06 0.45 0.26 Pneumonia; chr12:47729646 chr12:47788426~47788971:+ LUSC cis rs1056107 0.931 rs10759541 ENSG00000225513.1 RP11-165N19.2 -5.86 8.84e-09 3.57e-06 -0.29 -0.26 Colorectal cancer; chr9:112243277 chr9:112173522~112173971:- LUSC cis rs1056107 0.931 rs7032120 ENSG00000225513.1 RP11-165N19.2 -5.86 8.84e-09 3.57e-06 -0.29 -0.26 Colorectal cancer; chr9:112243865 chr9:112173522~112173971:- LUSC cis rs7208859 0.623 rs8067035 ENSG00000266490.1 CTD-2349P21.9 5.86 8.84e-09 3.57e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30792372~30792833:+ LUSC cis rs1056107 0.933 rs3808879 ENSG00000225513.1 RP11-165N19.2 -5.86 8.85e-09 3.57e-06 -0.29 -0.26 Colorectal cancer; chr9:112299198 chr9:112173522~112173971:- LUSC cis rs67311347 1 rs951560 ENSG00000223797.4 ENTPD3-AS1 5.86 8.85e-09 3.57e-06 0.29 0.26 Renal cell carcinoma; chr3:40421980 chr3:40313802~40453329:- LUSC cis rs2732480 0.538 rs2732462 ENSG00000240399.1 RP1-228P16.1 5.86 8.85e-09 3.57e-06 0.28 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48302601 chr12:48054813~48055591:- LUSC cis rs227275 0.554 rs223404 ENSG00000246560.2 RP11-10L12.4 5.86 8.85e-09 3.57e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102816951 chr4:102828055~102844075:+ LUSC cis rs2028299 0.839 rs3844575 ENSG00000259677.1 RP11-493E3.1 5.86 8.86e-09 3.57e-06 0.34 0.26 Type 2 diabetes; chr15:89900515 chr15:89876540~89877285:+ LUSC cis rs2028299 0.839 rs2279849 ENSG00000259677.1 RP11-493E3.1 5.86 8.86e-09 3.57e-06 0.34 0.26 Type 2 diabetes; chr15:89901407 chr15:89876540~89877285:+ LUSC cis rs2337406 0.587 rs10139664 ENSG00000274576.2 IGHV2-70 -5.86 8.86e-09 3.57e-06 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106647254 chr14:106770577~106771020:- LUSC cis rs79349575 0.783 rs56046215 ENSG00000270781.1 RP11-501C14.9 -5.86 8.86e-09 3.57e-06 -0.27 -0.26 Type 2 diabetes; chr17:48931395 chr17:48899131~48899748:+ LUSC cis rs6570726 0.818 rs952405 ENSG00000235652.6 RP11-545I5.3 5.86 8.86e-09 3.58e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145604816 chr6:145799409~145886585:+ LUSC cis rs2153535 0.584 rs9502721 ENSG00000230939.1 RP11-314C16.1 -5.86 8.87e-09 3.58e-06 -0.31 -0.26 Motion sickness; chr6:8541146 chr6:8784178~8785445:+ LUSC cis rs6918586 0.658 rs198829 ENSG00000272462.2 U91328.19 -5.86 8.87e-09 3.58e-06 -0.27 -0.26 Schizophrenia; chr6:26118665 chr6:25992662~26001775:+ LUSC cis rs6918586 0.658 rs198828 ENSG00000272462.2 U91328.19 -5.86 8.87e-09 3.58e-06 -0.27 -0.26 Schizophrenia; chr6:26119231 chr6:25992662~26001775:+ LUSC cis rs34779708 0.733 rs3853672 ENSG00000230534.5 RP11-297A16.2 5.86 8.87e-09 3.58e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35260678 chr10:35098006~35127020:- LUSC cis rs950880 0.71 rs4140785 ENSG00000234389.1 AC007278.3 -5.86 8.88e-09 3.58e-06 -0.28 -0.26 Serum protein levels (sST2); chr2:102472057 chr2:102438713~102440475:+ LUSC cis rs2153535 0.601 rs1737581 ENSG00000230939.1 RP11-314C16.1 -5.86 8.88e-09 3.58e-06 -0.31 -0.26 Motion sickness; chr6:8538905 chr6:8784178~8785445:+ LUSC cis rs875971 0.505 rs1167385 ENSG00000179406.6 LINC00174 5.86 8.88e-09 3.58e-06 0.28 0.26 Aortic root size; chr7:66048321 chr7:66376044~66401338:- LUSC cis rs2153535 0.58 rs9505455 ENSG00000230939.1 RP11-314C16.1 -5.86 8.91e-09 3.6e-06 -0.31 -0.26 Motion sickness; chr6:8478389 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9379216 ENSG00000230939.1 RP11-314C16.1 -5.86 8.91e-09 3.6e-06 -0.31 -0.26 Motion sickness; chr6:8481002 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7450817 ENSG00000230939.1 RP11-314C16.1 -5.86 8.91e-09 3.6e-06 -0.31 -0.26 Motion sickness; chr6:8481188 chr6:8784178~8785445:+ LUSC cis rs2153535 0.56 rs2210798 ENSG00000230939.1 RP11-314C16.1 -5.86 8.91e-09 3.6e-06 -0.31 -0.26 Motion sickness; chr6:8481289 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6597327 ENSG00000230939.1 RP11-314C16.1 -5.86 8.91e-09 3.6e-06 -0.31 -0.26 Motion sickness; chr6:8481924 chr6:8784178~8785445:+ LUSC cis rs8031584 1 rs1474380 ENSG00000260382.1 RP11-540B6.2 5.86 8.92e-09 3.6e-06 0.35 0.26 Huntington's disease progression; chr15:30977032 chr15:30882267~30883231:- LUSC cis rs227275 0.554 rs223399 ENSG00000246560.2 RP11-10L12.4 5.86 8.92e-09 3.6e-06 0.32 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102820800 chr4:102828055~102844075:+ LUSC cis rs6671200 1 rs62625008 ENSG00000228852.5 RP11-57H12.5 5.86 8.93e-09 3.6e-06 0.44 0.26 Stearic acid (18:0) levels; chr1:95237026 chr1:95243167~95278940:- LUSC cis rs6671200 0.92 rs35403759 ENSG00000228852.5 RP11-57H12.5 5.86 8.93e-09 3.6e-06 0.44 0.26 Stearic acid (18:0) levels; chr1:95237334 chr1:95243167~95278940:- LUSC cis rs1056107 1 rs1056107 ENSG00000225513.1 RP11-165N19.2 -5.86 8.94e-09 3.6e-06 -0.29 -0.26 Colorectal cancer; chr9:112324847 chr9:112173522~112173971:- LUSC cis rs2337406 0.778 rs58113768 ENSG00000254174.1 IGHV1-12 5.86 8.95e-09 3.61e-06 0.27 0.26 Alzheimer's disease (late onset); chr14:106700213 chr14:106122420~106122709:- LUSC cis rs4713118 0.868 rs9468220 ENSG00000280107.1 AL022393.9 5.86 8.95e-09 3.61e-06 0.32 0.26 Parkinson's disease; chr6:27765197 chr6:28170845~28172521:+ LUSC cis rs3738443 0.768 rs6668154 ENSG00000259865.1 RP11-488L18.10 5.85 8.97e-09 3.61e-06 0.28 0.26 Alcohol dependence; chr1:247187981 chr1:247187281~247188526:- LUSC cis rs3738443 0.768 rs6665647 ENSG00000259865.1 RP11-488L18.10 5.85 8.97e-09 3.61e-06 0.28 0.26 Alcohol dependence; chr1:247188127 chr1:247187281~247188526:- LUSC cis rs3738443 0.817 rs1115202 ENSG00000259865.1 RP11-488L18.10 5.85 8.97e-09 3.61e-06 0.28 0.26 Alcohol dependence; chr1:247189878 chr1:247187281~247188526:- LUSC cis rs17507216 0.591 rs7163848 ENSG00000276710.3 CSPG4P8 -5.85 8.98e-09 3.62e-06 -0.34 -0.26 Excessive daytime sleepiness; chr15:82729563 chr15:82459472~82477258:+ LUSC cis rs11089937 0.597 rs5757026 ENSG00000211638.2 IGLV8-61 -5.85 8.98e-09 3.62e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22137556 chr22:22098700~22099212:+ LUSC cis rs11089937 0.597 rs5750582 ENSG00000211638.2 IGLV8-61 -5.85 8.98e-09 3.62e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22137690 chr22:22098700~22099212:+ LUSC cis rs78487399 0.71 rs57696714 ENSG00000234936.1 AC010883.5 5.85 8.99e-09 3.62e-06 0.4 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43399382 chr2:43229573~43233394:+ LUSC cis rs78487399 0.71 rs57381820 ENSG00000234936.1 AC010883.5 5.85 8.99e-09 3.62e-06 0.4 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43399529 chr2:43229573~43233394:+ LUSC cis rs78487399 0.71 rs72879276 ENSG00000234936.1 AC010883.5 5.85 8.99e-09 3.62e-06 0.4 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43399962 chr2:43229573~43233394:+ LUSC cis rs1876905 0.539 rs240987 ENSG00000255389.1 C6orf3 5.85 9e-09 3.63e-06 0.35 0.26 Mean corpuscular hemoglobin; chr6:111268552 chr6:111599875~111602295:+ LUSC cis rs10759883 0.627 rs11998982 ENSG00000175611.10 LINC00476 5.85 9e-09 3.63e-06 0.31 0.26 Nicotine dependence; chr9:95851142 chr9:95759231~95875977:- LUSC cis rs14027 1 rs14027 ENSG00000279347.1 RP11-85I17.2 -5.85 9e-09 3.63e-06 -0.24 -0.26 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119834349 chr8:119838736~119840385:- LUSC cis rs442309 0.846 rs224050 ENSG00000238280.1 RP11-436D10.3 5.85 9.01e-09 3.63e-06 0.33 0.26 Vogt-Koyanagi-Harada syndrome; chr10:62733462 chr10:62793562~62805887:- LUSC cis rs875971 0.964 rs6945019 ENSG00000179406.6 LINC00174 -5.85 9.01e-09 3.63e-06 -0.28 -0.26 Aortic root size; chr7:66457471 chr7:66376044~66401338:- LUSC cis rs12554020 0.582 rs55783552 ENSG00000227603.1 RP11-165J3.6 5.85 9.02e-09 3.64e-06 0.47 0.26 Schizophrenia; chr9:93637205 chr9:93435332~93437121:- LUSC cis rs12554020 0.582 rs80228675 ENSG00000227603.1 RP11-165J3.6 5.85 9.02e-09 3.64e-06 0.47 0.26 Schizophrenia; chr9:93637918 chr9:93435332~93437121:- LUSC cis rs12554020 0.582 rs79391190 ENSG00000227603.1 RP11-165J3.6 5.85 9.02e-09 3.64e-06 0.47 0.26 Schizophrenia; chr9:93637992 chr9:93435332~93437121:- LUSC cis rs4660456 0.597 rs7518568 ENSG00000237899.1 RP4-739H11.3 5.85 9.02e-09 3.64e-06 0.32 0.26 Platelet count; chr1:40708508 chr1:40669089~40687588:- LUSC cis rs6918586 0.616 rs198836 ENSG00000272462.2 U91328.19 -5.85 9.03e-09 3.64e-06 -0.27 -0.26 Schizophrenia; chr6:26113388 chr6:25992662~26001775:+ LUSC cis rs4789693 0.938 rs8078595 ENSG00000265458.1 RP13-20L14.6 5.85 9.03e-09 3.64e-06 0.32 0.26 Glucocorticoid-induced osteonecrosis; chr17:82469112 chr17:82454273~82458521:- LUSC cis rs875971 0.545 rs6460281 ENSG00000224316.1 RP11-479O9.2 5.85 9.07e-09 3.65e-06 0.28 0.26 Aortic root size; chr7:66216128 chr7:65773620~65802067:+ LUSC cis rs1021993 0.545 rs79950910 ENSG00000231648.1 RP11-372M18.2 -5.85 9.07e-09 3.66e-06 -0.38 -0.26 Gut microbiome composition (winter); chr1:209344553 chr1:209367662~209379690:+ LUSC cis rs7772486 0.764 rs2265471 ENSG00000235652.6 RP11-545I5.3 5.85 9.08e-09 3.66e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145899114 chr6:145799409~145886585:+ LUSC cis rs875971 1 rs709597 ENSG00000179406.6 LINC00174 5.85 9.08e-09 3.66e-06 0.28 0.26 Aortic root size; chr7:66360996 chr7:66376044~66401338:- LUSC cis rs8005677 1 rs7145494 ENSG00000279656.1 RP11-298I3.6 5.85 9.09e-09 3.66e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22930581 chr14:23023083~23024217:- LUSC cis rs8005677 1 rs7155857 ENSG00000279656.1 RP11-298I3.6 5.85 9.09e-09 3.66e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22930850 chr14:23023083~23024217:- LUSC cis rs8005677 0.962 rs8003934 ENSG00000279656.1 RP11-298I3.6 5.85 9.09e-09 3.66e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22931933 chr14:23023083~23024217:- LUSC cis rs2153535 0.526 rs9406179 ENSG00000230939.1 RP11-314C16.1 -5.85 9.09e-09 3.66e-06 -0.31 -0.26 Motion sickness; chr6:8537991 chr6:8784178~8785445:+ LUSC cis rs875971 0.545 rs11767262 ENSG00000237310.1 GS1-124K5.4 5.85 9.1e-09 3.66e-06 0.29 0.26 Aortic root size; chr7:66302237 chr7:66493706~66495474:+ LUSC cis rs78487399 0.71 rs7607777 ENSG00000234936.1 AC010883.5 5.85 9.1e-09 3.66e-06 0.4 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43402792 chr2:43229573~43233394:+ LUSC cis rs2562456 0.917 rs2650804 ENSG00000268081.1 RP11-678G14.2 5.85 9.11e-09 3.67e-06 0.36 0.26 Pain; chr19:21497382 chr19:21554640~21569237:- LUSC cis rs6860806 0.507 rs2631364 ENSG00000233006.5 AC034220.3 -5.85 9.11e-09 3.67e-06 -0.28 -0.26 Breast cancer; chr5:132371222 chr5:132311285~132369916:- LUSC cis rs6860806 0.531 rs2631359 ENSG00000233006.5 AC034220.3 -5.85 9.11e-09 3.67e-06 -0.28 -0.26 Breast cancer; chr5:132372200 chr5:132311285~132369916:- LUSC cis rs8059260 0.736 rs76818150 ENSG00000274038.1 RP11-66H6.4 -5.85 9.11e-09 3.67e-06 -0.51 -0.26 Alcohol consumption over the past year; chr16:10955006 chr16:11056556~11057034:+ LUSC cis rs867371 1 rs8042464 ENSG00000255769.6 GOLGA2P10 -5.85 9.12e-09 3.67e-06 -0.32 -0.26 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82173195 chr15:82472993~82513950:- LUSC cis rs2276314 1 rs4799835 ENSG00000278986.1 RP11-723J4.3 -5.85 9.13e-09 3.68e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35991305 chr18:35972151~35973916:+ LUSC cis rs9326248 0.689 rs236916 ENSG00000280143.1 AP000892.6 -5.85 9.16e-09 3.69e-06 -0.36 -0.26 Blood protein levels; chr11:117218912 chr11:117204967~117210292:+ LUSC cis rs6918586 0.658 rs198843 ENSG00000272462.2 U91328.19 -5.85 9.16e-09 3.69e-06 -0.27 -0.26 Schizophrenia; chr6:26110086 chr6:25992662~26001775:+ LUSC cis rs8177876 0.596 rs2317087 ENSG00000261838.4 RP11-303E16.6 -5.85 9.17e-09 3.69e-06 -0.64 -0.26 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81104753 chr16:81069854~81076598:+ LUSC cis rs1823913 0.599 rs17412635 ENSG00000227542.1 AC092614.2 -5.85 9.18e-09 3.69e-06 -0.33 -0.26 Obesity-related traits; chr2:191294834 chr2:191229165~191246172:- LUSC cis rs72627123 1 rs72627138 ENSG00000259065.1 RP5-1021I20.1 -5.85 9.18e-09 3.69e-06 -0.45 -0.26 Morning vs. evening chronotype; chr14:73935197 chr14:73787360~73803270:+ LUSC cis rs6918586 0.616 rs1056314 ENSG00000272462.2 U91328.19 5.85 9.18e-09 3.69e-06 0.27 0.26 Schizophrenia; chr6:26114425 chr6:25992662~26001775:+ LUSC cis rs9545047 0.604 rs2182873 ENSG00000227676.3 LINC01068 5.85 9.19e-09 3.7e-06 0.31 0.26 Schizophrenia; chr13:79356846 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs2025913 ENSG00000227676.3 LINC01068 5.85 9.19e-09 3.7e-06 0.31 0.26 Schizophrenia; chr13:79357315 chr13:79566727~79571436:+ LUSC cis rs1061377 1 rs3796509 ENSG00000249685.1 RP11-360F5.3 5.85 9.2e-09 3.7e-06 0.3 0.26 Uric acid levels; chr4:39108566 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs4974998 ENSG00000249685.1 RP11-360F5.3 5.85 9.2e-09 3.7e-06 0.3 0.26 Uric acid levels; chr4:39109129 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs7673299 ENSG00000249685.1 RP11-360F5.3 5.85 9.2e-09 3.7e-06 0.3 0.26 Uric acid levels; chr4:39109138 chr4:39133913~39135608:+ LUSC cis rs75920871 0.588 rs6589580 ENSG00000254851.1 RP11-109L13.1 5.85 9.2e-09 3.7e-06 0.37 0.26 Subjective well-being; chr11:116949157 chr11:117135528~117138582:+ LUSC cis rs11846409 0.932 rs60917084 ENSG00000274576.2 IGHV2-70 -5.85 9.21e-09 3.7e-06 -0.28 -0.26 Rheumatic heart disease; chr14:106634621 chr14:106770577~106771020:- LUSC cis rs2337406 0.85 rs75196489 ENSG00000254174.1 IGHV1-12 5.85 9.21e-09 3.7e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106699438 chr14:106122420~106122709:- LUSC cis rs2337406 1 rs79452530 ENSG00000254174.1 IGHV1-12 5.85 9.21e-09 3.7e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106699992 chr14:106122420~106122709:- LUSC cis rs889398 0.874 rs2917677 ENSG00000226232.7 RP11-419C5.2 5.85 9.21e-09 3.7e-06 0.25 0.26 Body mass index; chr16:69716946 chr16:69976388~69996188:- LUSC cis rs6918586 0.658 rs198809 ENSG00000272462.2 U91328.19 -5.85 9.21e-09 3.7e-06 -0.27 -0.26 Schizophrenia; chr6:26128538 chr6:25992662~26001775:+ LUSC cis rs442309 0.812 rs224092 ENSG00000238280.1 RP11-436D10.3 -5.85 9.21e-09 3.71e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62781644 chr10:62793562~62805887:- LUSC cis rs875971 0.66 rs2013222 ENSG00000237310.1 GS1-124K5.4 -5.85 9.22e-09 3.71e-06 -0.26 -0.26 Aortic root size; chr7:66570949 chr7:66493706~66495474:+ LUSC cis rs5742933 0.817 rs7591929 ENSG00000253559.1 OSGEPL1-AS1 5.85 9.22e-09 3.71e-06 0.32 0.26 Ferritin levels; chr2:189778531 chr2:189762704~189765556:+ LUSC cis rs11098499 0.739 rs2203039 ENSG00000250412.1 KLHL2P1 -5.85 9.22e-09 3.71e-06 -0.31 -0.26 Corneal astigmatism; chr4:119211192 chr4:119334329~119378233:+ LUSC cis rs3764021 0.506 rs10844468 ENSG00000256975.1 RP11-525E9.1 5.85 9.23e-09 3.71e-06 0.34 0.26 Type 1 diabetes; chr12:9690799 chr12:9506347~9508440:- LUSC cis rs6671200 1 rs34396223 ENSG00000228852.5 RP11-57H12.5 5.85 9.25e-09 3.72e-06 0.43 0.26 Stearic acid (18:0) levels; chr1:95232272 chr1:95243167~95278940:- LUSC cis rs6570726 0.935 rs436212 ENSG00000235652.6 RP11-545I5.3 5.85 9.25e-09 3.72e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145528264 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs414222 ENSG00000235652.6 RP11-545I5.3 5.85 9.25e-09 3.72e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145529346 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs385134 ENSG00000235652.6 RP11-545I5.3 5.85 9.25e-09 3.72e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145529869 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs415590 ENSG00000235652.6 RP11-545I5.3 5.85 9.25e-09 3.72e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145530108 chr6:145799409~145886585:+ LUSC cis rs875971 0.545 rs1909508 ENSG00000226824.5 RP4-756H11.3 -5.85 9.28e-09 3.73e-06 -0.34 -0.26 Aortic root size; chr7:66301366 chr7:66654538~66669855:+ LUSC cis rs2834288 0.734 rs1557269 ENSG00000273102.1 AP000569.9 -5.85 9.28e-09 3.73e-06 -0.3 -0.26 Gut microbiota (bacterial taxa); chr21:33894091 chr21:33967101~33968573:- LUSC cis rs2337406 0.778 rs58113768 ENSG00000274576.2 IGHV2-70 -5.85 9.28e-09 3.73e-06 -0.28 -0.26 Alzheimer's disease (late onset); chr14:106700213 chr14:106770577~106771020:- LUSC cis rs34787248 1 rs34787248 ENSG00000204709.4 LINC01556 5.85 9.29e-09 3.73e-06 0.39 0.26 Autism spectrum disorder or schizophrenia; chr6:28230108 chr6:28943877~28944537:+ LUSC cis rs17361889 0.685 rs111795100 ENSG00000224683.1 RPL36AP29 5.85 9.29e-09 3.74e-06 0.32 0.26 Pediatric bone mineral content (hip); chr7:16112093 chr7:16208945~16209265:+ LUSC cis rs72627123 0.867 rs17094076 ENSG00000259065.1 RP5-1021I20.1 -5.85 9.29e-09 3.74e-06 -0.45 -0.26 Morning vs. evening chronotype; chr14:73933789 chr14:73787360~73803270:+ LUSC cis rs6740322 0.696 rs10188539 ENSG00000234936.1 AC010883.5 5.85 9.29e-09 3.74e-06 0.31 0.26 Coronary artery disease; chr2:43257536 chr2:43229573~43233394:+ LUSC cis rs5753618 0.509 rs5997912 ENSG00000236132.1 CTA-440B3.1 5.85 9.33e-09 3.75e-06 0.35 0.26 Colorectal cancer; chr22:31197875 chr22:31816379~31817491:- LUSC cis rs36423 0.748 rs36399 ENSG00000266869.1 RP6-114E22.1 -5.85 9.34e-09 3.75e-06 -0.4 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71893616 chr14:71848606~71908430:+ LUSC cis rs36423 0.748 rs36398 ENSG00000266869.1 RP6-114E22.1 -5.85 9.34e-09 3.75e-06 -0.4 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71893710 chr14:71848606~71908430:+ LUSC cis rs4964805 0.594 rs4981036 ENSG00000257681.1 RP11-341G23.4 5.85 9.34e-09 3.76e-06 0.29 0.26 Attention deficit hyperactivity disorder; chr12:103770566 chr12:103746315~103768858:- LUSC cis rs4964805 0.594 rs10861095 ENSG00000257681.1 RP11-341G23.4 5.85 9.34e-09 3.76e-06 0.29 0.26 Attention deficit hyperactivity disorder; chr12:103771609 chr12:103746315~103768858:- LUSC cis rs4964805 0.505 rs4981032 ENSG00000257681.1 RP11-341G23.4 5.85 9.34e-09 3.76e-06 0.29 0.26 Attention deficit hyperactivity disorder; chr12:103772086 chr12:103746315~103768858:- LUSC cis rs4964805 0.594 rs9132 ENSG00000257681.1 RP11-341G23.4 5.85 9.34e-09 3.76e-06 0.29 0.26 Attention deficit hyperactivity disorder; chr12:103772465 chr12:103746315~103768858:- LUSC cis rs875971 0.862 rs10256544 ENSG00000237310.1 GS1-124K5.4 5.85 9.34e-09 3.76e-06 0.28 0.26 Aortic root size; chr7:66210141 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6460290 ENSG00000179406.6 LINC00174 5.85 9.37e-09 3.77e-06 0.28 0.26 Aortic root size; chr7:66344119 chr7:66376044~66401338:- LUSC cis rs2732480 0.5 rs2450989 ENSG00000273765.1 RP11-370I10.11 -5.85 9.39e-09 3.77e-06 -0.3 -0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48259625 chr12:48360920~48361377:+ LUSC cis rs8059260 0.935 rs7203687 ENSG00000274038.1 RP11-66H6.4 -5.85 9.39e-09 3.77e-06 -0.37 -0.26 Alcohol consumption over the past year; chr16:11013063 chr16:11056556~11057034:+ LUSC cis rs6860806 0.507 rs273912 ENSG00000233006.5 AC034220.3 -5.85 9.39e-09 3.77e-06 -0.27 -0.26 Breast cancer; chr5:132325656 chr5:132311285~132369916:- LUSC cis rs11098499 0.908 rs9995234 ENSG00000248280.1 RP11-33B1.2 5.85 9.4e-09 3.78e-06 0.33 0.26 Corneal astigmatism; chr4:119400672 chr4:119440561~119450157:- LUSC cis rs7397814 0.558 rs4764447 ENSG00000255753.1 RP11-22B23.2 -5.85 9.4e-09 3.78e-06 -0.25 -0.26 IgG glycosylation; chr12:9426513 chr12:9314402~9316173:- LUSC cis rs6504950 0.85 rs2628309 ENSG00000275710.1 RP11-257O5.4 -5.85 9.4e-09 3.78e-06 -0.32 -0.26 Breast cancer; chr17:55038058 chr17:54964474~54964679:+ LUSC cis rs7804306 0.826 rs17566854 ENSG00000233264.2 AC006042.8 5.85 9.41e-09 3.78e-06 0.52 0.26 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7993887 chr7:7980312~7982228:+ LUSC cis rs7772486 0.875 rs2474353 ENSG00000235652.6 RP11-545I5.3 5.85 9.43e-09 3.79e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146002747 chr6:145799409~145886585:+ LUSC cis rs801193 1 rs10234018 ENSG00000222364.1 RNU6-96P 5.85 9.43e-09 3.79e-06 0.3 0.26 Aortic root size; chr7:66681297 chr7:66395191~66395286:+ LUSC cis rs8018967 0.622 rs2041073 ENSG00000258695.2 RP3-414A15.2 5.85 9.43e-09 3.79e-06 0.29 0.26 Blood metabolite ratios; chr14:73505831 chr14:73522878~73530610:+ LUSC cis rs2439831 0.85 rs28504496 ENSG00000249839.1 AC011330.5 -5.85 9.43e-09 3.79e-06 -0.52 -0.26 Lung cancer in ever smokers; chr15:43724685 chr15:43663654~43684339:- LUSC cis rs66887589 0.87 rs2389875 ENSG00000248280.1 RP11-33B1.2 -5.85 9.44e-09 3.79e-06 -0.29 -0.26 Diastolic blood pressure; chr4:119635859 chr4:119440561~119450157:- LUSC cis rs2842992 0.789 rs10945635 ENSG00000237927.1 RP3-393E18.2 -5.85 9.45e-09 3.8e-06 -0.39 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159793455 chr6:159586955~159589169:- LUSC cis rs227275 0.524 rs150894 ENSG00000246560.2 RP11-10L12.4 5.85 9.46e-09 3.8e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102811541 chr4:102828055~102844075:+ LUSC cis rs9326248 0.581 rs11216242 ENSG00000280143.1 AP000892.6 5.85 9.46e-09 3.8e-06 0.27 0.26 Blood protein levels; chr11:117030833 chr11:117204967~117210292:+ LUSC cis rs9326248 0.581 rs12804122 ENSG00000280143.1 AP000892.6 5.85 9.46e-09 3.8e-06 0.27 0.26 Blood protein levels; chr11:117031900 chr11:117204967~117210292:+ LUSC cis rs7555523 0.887 rs4657471 ENSG00000224358.1 RP11-466F5.8 -5.85 9.46e-09 3.8e-06 -0.33 -0.26 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165717636 chr1:165768929~165775176:+ LUSC cis rs6570726 0.935 rs454370 ENSG00000235652.6 RP11-545I5.3 5.85 9.46e-09 3.8e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145525593 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs416987 ENSG00000235652.6 RP11-545I5.3 5.85 9.46e-09 3.8e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145525869 chr6:145799409~145886585:+ LUSC cis rs6570726 0.905 rs452770 ENSG00000235652.6 RP11-545I5.3 5.85 9.46e-09 3.8e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145526026 chr6:145799409~145886585:+ LUSC cis rs4372836 0.964 rs17007191 ENSG00000226833.4 AC097724.3 -5.85 9.47e-09 3.8e-06 -0.31 -0.26 Body mass index; chr2:28709636 chr2:28708953~28736205:- LUSC cis rs6570726 0.935 rs442254 ENSG00000235652.6 RP11-545I5.3 5.85 9.48e-09 3.8e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145527982 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs441575 ENSG00000235652.6 RP11-545I5.3 5.85 9.48e-09 3.8e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145528069 chr6:145799409~145886585:+ LUSC cis rs6860806 0.531 rs274556 ENSG00000233006.5 AC034220.3 -5.85 9.48e-09 3.8e-06 -0.29 -0.26 Breast cancer; chr5:132386383 chr5:132311285~132369916:- LUSC cis rs875971 0.862 rs949930 ENSG00000179406.6 LINC00174 5.84 9.48e-09 3.81e-06 0.28 0.26 Aortic root size; chr7:66301835 chr7:66376044~66401338:- LUSC cis rs8031584 0.918 rs1425292 ENSG00000260382.1 RP11-540B6.2 5.84 9.49e-09 3.81e-06 0.36 0.26 Huntington's disease progression; chr15:30993219 chr15:30882267~30883231:- LUSC cis rs7829975 0.755 rs3789849 ENSG00000253893.2 FAM85B -5.84 9.49e-09 3.81e-06 -0.31 -0.26 Mood instability; chr8:8829544 chr8:8167819~8226614:- LUSC cis rs6504950 0.886 rs2787500 ENSG00000275710.1 RP11-257O5.4 -5.84 9.5e-09 3.81e-06 -0.3 -0.26 Breast cancer; chr17:55092445 chr17:54964474~54964679:+ LUSC cis rs2337406 0.85 rs4774179 ENSG00000274576.2 IGHV2-70 -5.84 9.51e-09 3.82e-06 -0.28 -0.26 Alzheimer's disease (late onset); chr14:106700837 chr14:106770577~106771020:- LUSC cis rs4489787 1 rs12298871 ENSG00000240399.1 RP1-228P16.1 5.84 9.52e-09 3.82e-06 0.43 0.26 Prostate cancer (SNP x SNP interaction); chr12:48395194 chr12:48054813~48055591:- LUSC cis rs1387259 0.929 rs11168484 ENSG00000240399.1 RP1-228P16.1 5.84 9.53e-09 3.82e-06 0.28 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48239806 chr12:48054813~48055591:- LUSC cis rs853679 0.76 rs9468317 ENSG00000204709.4 LINC01556 5.84 9.54e-09 3.83e-06 0.38 0.26 Depression; chr6:28230678 chr6:28943877~28944537:+ LUSC cis rs274567 0.501 rs581968 ENSG00000233006.5 AC034220.3 -5.84 9.54e-09 3.83e-06 -0.28 -0.26 Blood metabolite levels; chr5:132374510 chr5:132311285~132369916:- LUSC cis rs2337406 0.866 rs79901786 ENSG00000254174.1 IGHV1-12 5.84 9.54e-09 3.83e-06 0.25 0.26 Alzheimer's disease (late onset); chr14:106777623 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs7152809 ENSG00000254174.1 IGHV1-12 5.84 9.54e-09 3.83e-06 0.25 0.26 Alzheimer's disease (late onset); chr14:106778385 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs7152832 ENSG00000254174.1 IGHV1-12 5.84 9.54e-09 3.83e-06 0.25 0.26 Alzheimer's disease (late onset); chr14:106778427 chr14:106122420~106122709:- LUSC cis rs228614 0.51 rs223453 ENSG00000246560.2 RP11-10L12.4 5.84 9.54e-09 3.83e-06 0.31 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789895 chr4:102828055~102844075:+ LUSC cis rs35160687 0.688 rs4832033 ENSG00000273080.1 RP11-301O19.1 -5.84 9.54e-09 3.83e-06 -0.24 -0.26 Night sleep phenotypes; chr2:86281640 chr2:86195590~86196049:+ LUSC cis rs13113518 0.812 rs6825774 ENSG00000249700.7 SRD5A3-AS1 5.84 9.55e-09 3.83e-06 0.31 0.26 Height; chr4:55491150 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs3805153 ENSG00000249700.7 SRD5A3-AS1 5.84 9.55e-09 3.83e-06 0.31 0.26 Height; chr4:55493557 chr4:55363971~55395847:- LUSC cis rs6142102 0.961 rs4911385 ENSG00000275784.1 RP5-1125A11.6 -5.84 9.55e-09 3.83e-06 -0.3 -0.26 Skin pigmentation; chr20:33970787 chr20:33989480~33991818:- LUSC cis rs6570726 0.902 rs4895678 ENSG00000235652.6 RP11-545I5.3 5.84 9.55e-09 3.83e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145614374 chr6:145799409~145886585:+ LUSC cis rs240993 0.809 rs11153277 ENSG00000230177.1 RP5-1112D6.4 -5.84 9.55e-09 3.83e-06 -0.26 -0.26 Inflammatory skin disease;Psoriasis; chr6:111259358 chr6:111277932~111278742:+ LUSC cis rs6671200 0.607 rs3767315 ENSG00000228852.5 RP11-57H12.5 -5.84 9.56e-09 3.83e-06 -0.34 -0.26 Stearic acid (18:0) levels; chr1:95240416 chr1:95243167~95278940:- LUSC cis rs9326248 0.581 rs10892048 ENSG00000280143.1 AP000892.6 5.84 9.56e-09 3.83e-06 0.27 0.26 Blood protein levels; chr11:116943880 chr11:117204967~117210292:+ LUSC cis rs2337406 0.81 rs7161739 ENSG00000211974.3 IGHV2-70 -5.84 9.56e-09 3.84e-06 -0.35 -0.26 Alzheimer's disease (late onset); chr14:106776118 chr14:106723574~106724093:- LUSC cis rs2439831 0.85 rs28413704 ENSG00000249839.1 AC011330.5 -5.84 9.57e-09 3.84e-06 -0.54 -0.26 Lung cancer in ever smokers; chr15:43856229 chr15:43663654~43684339:- LUSC cis rs9640161 0.75 rs73170185 ENSG00000261305.1 RP4-584D14.7 5.84 9.58e-09 3.84e-06 0.38 0.26 Blood protein levels;Circulating chemerin levels; chr7:150333102 chr7:150341771~150342607:+ LUSC cis rs2153535 0.58 rs1414344 ENSG00000230939.1 RP11-314C16.1 -5.84 9.58e-09 3.84e-06 -0.31 -0.26 Motion sickness; chr6:8471132 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2152348 ENSG00000230939.1 RP11-314C16.1 -5.84 9.58e-09 3.84e-06 -0.31 -0.26 Motion sickness; chr6:8474068 chr6:8784178~8785445:+ LUSC cis rs875971 0.545 rs10950036 ENSG00000237310.1 GS1-124K5.4 5.84 9.58e-09 3.84e-06 0.3 0.26 Aortic root size; chr7:66353241 chr7:66493706~66495474:+ LUSC cis rs2337406 0.929 rs11847182 ENSG00000254174.1 IGHV1-12 5.84 9.59e-09 3.84e-06 0.27 0.26 Alzheimer's disease (late onset); chr14:106697724 chr14:106122420~106122709:- LUSC cis rs3764021 0.527 rs10844456 ENSG00000256975.1 RP11-525E9.1 5.84 9.61e-09 3.85e-06 0.34 0.26 Type 1 diabetes; chr12:9689319 chr12:9506347~9508440:- LUSC cis rs8031584 0.918 rs34095794 ENSG00000260382.1 RP11-540B6.2 5.84 9.61e-09 3.85e-06 0.35 0.26 Huntington's disease progression; chr15:30977488 chr15:30882267~30883231:- LUSC cis rs6570726 0.935 rs430561 ENSG00000235652.6 RP11-545I5.3 5.84 9.62e-09 3.86e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145492004 chr6:145799409~145886585:+ LUSC cis rs73173548 0.528 rs80083342 ENSG00000247828.6 TMEM161B-AS1 5.84 9.63e-09 3.86e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88476921 chr5:88268895~88436685:+ LUSC cis rs2153535 0.505 rs1737583 ENSG00000230939.1 RP11-314C16.1 -5.84 9.63e-09 3.86e-06 -0.31 -0.26 Motion sickness; chr6:8536579 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7341381 ENSG00000230939.1 RP11-314C16.1 -5.84 9.63e-09 3.86e-06 -0.31 -0.26 Motion sickness; chr6:8470304 chr6:8784178~8785445:+ LUSC cis rs13113518 1 rs13133579 ENSG00000249700.7 SRD5A3-AS1 5.84 9.64e-09 3.86e-06 0.3 0.26 Height; chr4:55459921 chr4:55363971~55395847:- LUSC cis rs13113518 0.902 rs11133386 ENSG00000249700.7 SRD5A3-AS1 5.84 9.64e-09 3.86e-06 0.3 0.26 Height; chr4:55461320 chr4:55363971~55395847:- LUSC cis rs35160687 0.712 rs11675942 ENSG00000273080.1 RP11-301O19.1 -5.84 9.64e-09 3.87e-06 -0.24 -0.26 Night sleep phenotypes; chr2:86280565 chr2:86195590~86196049:+ LUSC cis rs8031584 0.918 rs61997138 ENSG00000260382.1 RP11-540B6.2 5.84 9.66e-09 3.87e-06 0.35 0.26 Huntington's disease progression; chr15:30978573 chr15:30882267~30883231:- LUSC cis rs875971 0.577 rs35072105 ENSG00000237310.1 GS1-124K5.4 -5.84 9.66e-09 3.87e-06 -0.27 -0.26 Aortic root size; chr7:66144830 chr7:66493706~66495474:+ LUSC cis rs2276314 0.857 rs62101393 ENSG00000278986.1 RP11-723J4.3 -5.84 9.66e-09 3.87e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36012205 chr18:35972151~35973916:+ LUSC cis rs2276314 0.857 rs62101394 ENSG00000278986.1 RP11-723J4.3 -5.84 9.66e-09 3.87e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36012336 chr18:35972151~35973916:+ LUSC cis rs2276314 0.857 rs4799409 ENSG00000278986.1 RP11-723J4.3 -5.84 9.66e-09 3.87e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36012639 chr18:35972151~35973916:+ LUSC cis rs2732480 0.577 rs2732481 ENSG00000240399.1 RP1-228P16.1 5.84 9.66e-09 3.87e-06 0.28 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343202 chr12:48054813~48055591:- LUSC cis rs2732480 0.557 rs2732484 ENSG00000240399.1 RP1-228P16.1 5.84 9.66e-09 3.87e-06 0.28 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343462 chr12:48054813~48055591:- LUSC cis rs9545047 0.716 rs7333904 ENSG00000227676.3 LINC01068 5.84 9.66e-09 3.87e-06 0.33 0.26 Schizophrenia; chr13:79281413 chr13:79566727~79571436:+ LUSC cis rs34792 0.554 rs12933773 ENSG00000207425.1 Y_RNA -5.84 9.69e-09 3.89e-06 -0.37 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15529325 chr16:14915457~14915556:- LUSC cis rs2276314 0.857 rs28379448 ENSG00000278986.1 RP11-723J4.3 -5.84 9.71e-09 3.89e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36024401 chr18:35972151~35973916:+ LUSC cis rs1056107 0.898 rs943620 ENSG00000225513.1 RP11-165N19.2 -5.84 9.72e-09 3.9e-06 -0.29 -0.26 Colorectal cancer; chr9:112231228 chr9:112173522~112173971:- LUSC cis rs9910055 0.762 rs1135215 ENSG00000267080.4 ASB16-AS1 -5.84 9.72e-09 3.9e-06 -0.24 -0.26 Total body bone mineral density; chr17:44176151 chr17:44175973~44186717:- LUSC cis rs9910055 0.718 rs7212854 ENSG00000267080.4 ASB16-AS1 -5.84 9.72e-09 3.9e-06 -0.24 -0.26 Total body bone mineral density; chr17:44177049 chr17:44175973~44186717:- LUSC cis rs8031584 0.918 rs61997139 ENSG00000260382.1 RP11-540B6.2 5.84 9.73e-09 3.9e-06 0.35 0.26 Huntington's disease progression; chr15:30981399 chr15:30882267~30883231:- LUSC cis rs113835537 0.935 rs79106199 ENSG00000255517.5 CTD-3074O7.5 -5.84 9.74e-09 3.9e-06 -0.35 -0.26 Airway imaging phenotypes; chr11:66653047 chr11:66473490~66480233:- LUSC cis rs13113518 0.738 rs6849883 ENSG00000249700.7 SRD5A3-AS1 5.84 9.75e-09 3.91e-06 0.3 0.26 Height; chr4:55387515 chr4:55363971~55395847:- LUSC cis rs2276314 0.857 rs72883058 ENSG00000278986.1 RP11-723J4.3 -5.84 9.76e-09 3.91e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36032954 chr18:35972151~35973916:+ LUSC cis rs6860806 0.507 rs272892 ENSG00000233006.5 AC034220.3 5.84 9.77e-09 3.91e-06 0.28 0.26 Breast cancer; chr5:132328656 chr5:132311285~132369916:- LUSC cis rs75422866 0.51 rs73105818 ENSG00000276691.1 RP5-1057I20.5 5.84 9.78e-09 3.92e-06 0.46 0.26 Pneumonia; chr12:47726538 chr12:47788426~47788971:+ LUSC cis rs28830936 0.967 rs9672671 ENSG00000250379.1 RP11-23P13.4 5.84 9.78e-09 3.92e-06 0.28 0.26 Diastolic blood pressure; chr15:41624877 chr15:41825099~41827936:- LUSC cis rs950169 0.84 rs72748702 ENSG00000259295.5 CSPG4P12 5.84 9.78e-09 3.92e-06 0.34 0.26 Schizophrenia; chr15:84246494 chr15:85191438~85213905:+ LUSC cis rs950169 0.922 rs4338765 ENSG00000259295.5 CSPG4P12 5.84 9.78e-09 3.92e-06 0.34 0.26 Schizophrenia; chr15:84248084 chr15:85191438~85213905:+ LUSC cis rs227275 0.525 rs4699037 ENSG00000230069.3 LRRC37A15P -5.84 9.79e-09 3.92e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102957010 chr4:102727274~102730721:- LUSC cis rs227275 0.556 rs3857198 ENSG00000230069.3 LRRC37A15P -5.84 9.79e-09 3.92e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102957720 chr4:102727274~102730721:- LUSC cis rs227275 0.525 rs4699039 ENSG00000230069.3 LRRC37A15P -5.84 9.79e-09 3.92e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102958354 chr4:102727274~102730721:- LUSC cis rs9326248 0.581 rs10892072 ENSG00000280143.1 AP000892.6 5.84 9.79e-09 3.92e-06 0.27 0.26 Blood protein levels; chr11:117089597 chr11:117204967~117210292:+ LUSC cis rs7772486 0.875 rs2777476 ENSG00000235652.6 RP11-545I5.3 5.84 9.8e-09 3.92e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146023888 chr6:145799409~145886585:+ LUSC cis rs9341835 0.772 rs9294196 ENSG00000218048.2 RP3-407E4.4 -5.84 9.8e-09 3.93e-06 -0.3 -0.26 Schizophrenia; chr6:63425288 chr6:63440766~63443580:+ LUSC cis rs13113518 0.783 rs11133389 ENSG00000249700.7 SRD5A3-AS1 5.84 9.8e-09 3.93e-06 0.31 0.26 Height; chr4:55486718 chr4:55363971~55395847:- LUSC cis rs3750965 0.575 rs3018691 ENSG00000260895.1 RP11-554A11.7 5.84 9.81e-09 3.93e-06 0.3 0.26 Hair color; chr11:69117075 chr11:69103493~69109094:+ LUSC cis rs6969780 1 rs929249 ENSG00000233429.8 HOTAIRM1 5.84 9.81e-09 3.93e-06 0.5 0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27127918 chr7:27095647~27100265:+ LUSC cis rs2153535 0.58 rs2225766 ENSG00000230939.1 RP11-314C16.1 -5.84 9.83e-09 3.93e-06 -0.31 -0.26 Motion sickness; chr6:8481600 chr6:8784178~8785445:+ LUSC cis rs7772486 0.875 rs13204280 ENSG00000235652.6 RP11-545I5.3 5.84 9.83e-09 3.94e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146094232 chr6:145799409~145886585:+ LUSC cis rs7208859 0.562 rs11650923 ENSG00000266490.1 CTD-2349P21.9 5.84 9.84e-09 3.94e-06 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30681149 chr17:30792372~30792833:+ LUSC cis rs7267979 0.727 rs4815431 ENSG00000274973.1 RP13-401N8.7 5.84 9.85e-09 3.94e-06 0.26 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25551769 chr20:25845497~25845862:+ LUSC cis rs113835537 0.627 rs4630309 ENSG00000255517.5 CTD-3074O7.5 5.84 9.86e-09 3.95e-06 0.33 0.26 Airway imaging phenotypes; chr11:66565601 chr11:66473490~66480233:- LUSC cis rs2153535 0.541 rs6923558 ENSG00000230939.1 RP11-314C16.1 -5.84 9.86e-09 3.95e-06 -0.31 -0.26 Motion sickness; chr6:8461234 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1577470 ENSG00000230939.1 RP11-314C16.1 -5.84 9.86e-09 3.95e-06 -0.31 -0.26 Motion sickness; chr6:8462193 chr6:8784178~8785445:+ LUSC cis rs875971 0.545 rs1547529 ENSG00000224316.1 RP11-479O9.2 5.84 9.86e-09 3.95e-06 0.28 0.26 Aortic root size; chr7:66258859 chr7:65773620~65802067:+ LUSC cis rs2303759 0.918 rs4802597 ENSG00000268686.1 AC010524.2 -5.84 9.86e-09 3.95e-06 -0.35 -0.26 Multiple sclerosis; chr19:49368828 chr19:49368705~49388081:- LUSC cis rs4718428 0.705 rs12698547 ENSG00000226824.5 RP4-756H11.3 -5.84 9.87e-09 3.95e-06 -0.35 -0.26 Corneal structure; chr7:66813271 chr7:66654538~66669855:+ LUSC cis rs2153535 0.58 rs6921964 ENSG00000230939.1 RP11-314C16.1 -5.84 9.88e-09 3.95e-06 -0.31 -0.26 Motion sickness; chr6:8446162 chr6:8784178~8785445:+ LUSC cis rs748404 0.556 rs10851414 ENSG00000249839.1 AC011330.5 5.84 9.88e-09 3.95e-06 0.34 0.26 Lung cancer; chr15:43141734 chr15:43663654~43684339:- LUSC cis rs6860806 0.531 rs272887 ENSG00000233006.5 AC034220.3 5.84 9.88e-09 3.95e-06 0.28 0.26 Breast cancer; chr5:132330020 chr5:132311285~132369916:- LUSC cis rs13113518 0.812 rs12649507 ENSG00000272969.1 RP11-528I4.2 -5.84 9.89e-09 3.96e-06 -0.3 -0.26 Height; chr4:55514317 chr4:55547112~55547889:+ LUSC cis rs240993 0.715 rs7776346 ENSG00000230177.1 RP5-1112D6.4 5.84 9.89e-09 3.96e-06 0.28 0.26 Inflammatory skin disease;Psoriasis; chr6:111540162 chr6:111277932~111278742:+ LUSC cis rs2243480 1 rs422164 ENSG00000226824.5 RP4-756H11.3 -5.84 9.89e-09 3.96e-06 -0.49 -0.26 Diabetic kidney disease; chr7:66121618 chr7:66654538~66669855:+ LUSC cis rs1056107 0.933 rs4979099 ENSG00000225513.1 RP11-165N19.2 -5.84 9.9e-09 3.96e-06 -0.28 -0.26 Colorectal cancer; chr9:112319336 chr9:112173522~112173971:- LUSC cis rs2028299 1 rs4932148 ENSG00000259677.1 RP11-493E3.1 5.84 9.9e-09 3.96e-06 0.33 0.26 Type 2 diabetes; chr15:89851124 chr15:89876540~89877285:+ LUSC cis rs875971 0.66 rs10272357 ENSG00000237310.1 GS1-124K5.4 -5.84 9.91e-09 3.96e-06 -0.26 -0.26 Aortic root size; chr7:66598087 chr7:66493706~66495474:+ LUSC cis rs875971 1 rs1167612 ENSG00000179406.6 LINC00174 5.84 9.92e-09 3.97e-06 0.28 0.26 Aortic root size; chr7:66102989 chr7:66376044~66401338:- LUSC cis rs599083 0.793 rs314750 ENSG00000212093.1 AP000807.1 -5.84 9.92e-09 3.97e-06 -0.3 -0.26 Bone mineral density (spine); chr11:68414560 chr11:68506083~68506166:- LUSC cis rs2028299 0.92 rs4932261 ENSG00000259677.1 RP11-493E3.1 5.84 9.93e-09 3.97e-06 0.34 0.26 Type 2 diabetes; chr15:89887164 chr15:89876540~89877285:+ LUSC cis rs2297363 1 rs3777411 ENSG00000213073.4 RP11-288H12.3 -5.84 9.93e-09 3.97e-06 -0.3 -0.26 Total cholesterol levels;Blood protein levels; chr6:160055913 chr6:160093082~160096212:+ LUSC cis rs950169 0.922 rs12915832 ENSG00000259295.5 CSPG4P12 5.84 9.94e-09 3.97e-06 0.34 0.26 Schizophrenia; chr15:84568226 chr15:85191438~85213905:+ LUSC cis rs957448 0.554 rs12541408 ENSG00000253704.1 RP11-267M23.4 5.84 9.94e-09 3.97e-06 0.29 0.26 Nonsyndromic cleft lip with cleft palate; chr8:94573579 chr8:94553722~94569745:+ LUSC cis rs875971 0.862 rs778724 ENSG00000179406.6 LINC00174 -5.84 9.95e-09 3.98e-06 -0.28 -0.26 Aortic root size; chr7:66364304 chr7:66376044~66401338:- LUSC cis rs9611519 0.929 rs12484477 ENSG00000235513.1 RP4-756G23.5 5.84 9.95e-09 3.98e-06 0.3 0.26 Neuroticism; chr22:41033080 chr22:41209122~41217627:- LUSC cis rs673078 0.607 rs7307393 ENSG00000275759.1 RP11-131L12.3 -5.84 9.97e-09 3.99e-06 -0.4 -0.26 Glucose homeostasis traits; chr12:118308537 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs17440669 ENSG00000275759.1 RP11-131L12.3 -5.84 9.97e-09 3.99e-06 -0.4 -0.26 Glucose homeostasis traits; chr12:118310397 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs7309671 ENSG00000275759.1 RP11-131L12.3 -5.84 9.97e-09 3.99e-06 -0.4 -0.26 Glucose homeostasis traits; chr12:118313188 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs17512525 ENSG00000275759.1 RP11-131L12.3 -5.84 9.97e-09 3.99e-06 -0.4 -0.26 Glucose homeostasis traits; chr12:118315467 chr12:118428281~118428870:+ LUSC cis rs673078 0.607 rs17440774 ENSG00000275759.1 RP11-131L12.3 -5.84 9.97e-09 3.99e-06 -0.4 -0.26 Glucose homeostasis traits; chr12:118316155 chr12:118428281~118428870:+ LUSC cis rs853679 0.825 rs8180562 ENSG00000219392.1 RP1-265C24.5 -5.84 9.97e-09 3.99e-06 -0.44 -0.26 Depression; chr6:28173682 chr6:28115628~28116551:+ LUSC cis rs853679 0.882 rs9380064 ENSG00000219392.1 RP1-265C24.5 -5.84 9.97e-09 3.99e-06 -0.44 -0.26 Depression; chr6:28175340 chr6:28115628~28116551:+ LUSC cis rs442309 0.875 rs382424 ENSG00000238280.1 RP11-436D10.3 -5.84 9.98e-09 3.99e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62730014 chr10:62793562~62805887:- LUSC cis rs6772849 0.901 rs9849126 ENSG00000242551.2 POU5F1P6 5.84 9.98e-09 3.99e-06 0.3 0.26 Monocyte percentage of white cells;Monocyte count; chr3:128593226 chr3:128674735~128677005:- LUSC cis rs270601 0.913 rs273916 ENSG00000233006.5 AC034220.3 5.84 9.99e-09 3.99e-06 0.28 0.26 Acylcarnitine levels; chr5:132324137 chr5:132311285~132369916:- LUSC cis rs2276314 0.857 rs9304155 ENSG00000278986.1 RP11-723J4.3 -5.84 9.99e-09 3.99e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36005747 chr18:35972151~35973916:+ LUSC cis rs4865169 0.934 rs3796531 ENSG00000269949.1 RP11-738E22.3 -5.84 1e-08 4e-06 -0.32 -0.26 Breast cancer; chr4:56984680 chr4:56960927~56961373:- LUSC cis rs2153535 0.58 rs1577472 ENSG00000230939.1 RP11-314C16.1 -5.84 1e-08 4e-06 -0.31 -0.26 Motion sickness; chr6:8485982 chr6:8784178~8785445:+ LUSC cis rs2153535 0.542 rs1120393 ENSG00000230939.1 RP11-314C16.1 -5.84 1e-08 4e-06 -0.31 -0.26 Motion sickness; chr6:8486657 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406165 ENSG00000230939.1 RP11-314C16.1 -5.84 1e-08 4e-06 -0.31 -0.26 Motion sickness; chr6:8488604 chr6:8784178~8785445:+ LUSC cis rs2153535 0.563 rs4428546 ENSG00000230939.1 RP11-314C16.1 -5.84 1e-08 4e-06 -0.31 -0.26 Motion sickness; chr6:8490143 chr6:8784178~8785445:+ LUSC cis rs2153535 0.505 rs1335629 ENSG00000230939.1 RP11-314C16.1 -5.84 1e-08 4e-06 -0.31 -0.26 Motion sickness; chr6:8491630 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs763376 ENSG00000230939.1 RP11-314C16.1 -5.84 1e-08 4e-06 -0.31 -0.26 Motion sickness; chr6:8492543 chr6:8784178~8785445:+ LUSC cis rs17826219 0.706 rs2322197 ENSG00000266490.1 CTD-2349P21.9 5.84 1e-08 4e-06 0.32 0.26 Body mass index; chr17:30778787 chr17:30792372~30792833:+ LUSC cis rs60065504 1 rs60065504 ENSG00000251022.5 THAP9-AS1 -5.84 1e-08 4e-06 -0.3 -0.26 Lymphocyte percentage of white cells; chr4:82964057 chr4:82893009~82900960:- LUSC cis rs2337406 1 rs17112416 ENSG00000254174.1 IGHV1-12 -5.84 1e-08 4e-06 -0.26 -0.26 Alzheimer's disease (late onset); chr14:106686773 chr14:106122420~106122709:- LUSC cis rs1021993 0.545 rs7548184 ENSG00000231648.1 RP11-372M18.2 -5.84 1e-08 4e-06 -0.39 -0.26 Gut microbiome composition (winter); chr1:209358255 chr1:209367662~209379690:+ LUSC cis rs6671200 0.607 rs7528790 ENSG00000228852.5 RP11-57H12.5 -5.84 1e-08 4e-06 -0.34 -0.26 Stearic acid (18:0) levels; chr1:95243518 chr1:95243167~95278940:- LUSC cis rs1729407 0.625 rs2727789 ENSG00000254851.1 RP11-109L13.1 -5.84 1e-08 4e-06 -0.31 -0.26 Apolipoprotein A-IV levels; chr11:116826171 chr11:117135528~117138582:+ LUSC cis rs8005677 0.828 rs12589539 ENSG00000279656.1 RP11-298I3.6 5.84 1e-08 4e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22927471 chr14:23023083~23024217:- LUSC cis rs2337406 0.587 rs11624678 ENSG00000274576.2 IGHV2-70 5.84 1e-08 4e-06 0.28 0.26 Alzheimer's disease (late onset); chr14:106650408 chr14:106770577~106771020:- LUSC cis rs2337406 0.866 rs988130 ENSG00000254174.1 IGHV1-12 5.83 1e-08 4.01e-06 0.25 0.26 Alzheimer's disease (late onset); chr14:106777154 chr14:106122420~106122709:- LUSC cis rs2732480 0.577 rs2732466 ENSG00000226413.2 OR8T1P 5.83 1e-08 4.01e-06 0.34 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48338676 chr12:48442030~48442947:- LUSC cis rs8040855 0.559 rs6496801 ENSG00000259774.1 RP11-182J1.13 -5.83 1e-08 4.01e-06 -0.32 -0.26 Bulimia nervosa; chr15:85185168 chr15:84422618~84425882:+ LUSC cis rs875971 0.54 rs35510581 ENSG00000164669.11 INTS4P1 5.83 1.01e-08 4.02e-06 0.29 0.26 Aortic root size; chr7:66113790 chr7:65141225~65234216:+ LUSC cis rs2153535 0.58 rs1115079 ENSG00000230939.1 RP11-314C16.1 -5.83 1.01e-08 4.03e-06 -0.31 -0.26 Motion sickness; chr6:8449382 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1115078 ENSG00000230939.1 RP11-314C16.1 -5.83 1.01e-08 4.03e-06 -0.31 -0.26 Motion sickness; chr6:8449405 chr6:8784178~8785445:+ LUSC cis rs10759883 0.563 rs671058 ENSG00000175611.10 LINC00476 5.83 1.01e-08 4.03e-06 0.3 0.26 Nicotine dependence; chr9:95931728 chr9:95759231~95875977:- LUSC cis rs6969780 0.915 rs4722657 ENSG00000233429.8 HOTAIRM1 -5.83 1.01e-08 4.03e-06 -0.44 -0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27118137 chr7:27095647~27100265:+ LUSC cis rs875971 0.577 rs34888281 ENSG00000224316.1 RP11-479O9.2 -5.83 1.01e-08 4.03e-06 -0.26 -0.26 Aortic root size; chr7:66120784 chr7:65773620~65802067:+ LUSC cis rs17772222 0.727 rs3179969 ENSG00000258789.1 RP11-507K2.3 -5.83 1.01e-08 4.03e-06 -0.29 -0.26 Coronary artery calcification; chr14:88396185 chr14:88551597~88552493:+ LUSC cis rs7208859 0.573 rs7223803 ENSG00000266490.1 CTD-2349P21.9 5.83 1.01e-08 4.03e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750175 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs55814012 ENSG00000266490.1 CTD-2349P21.9 5.83 1.01e-08 4.03e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750679 chr17:30792372~30792833:+ LUSC cis rs17826219 0.5 rs2449749 ENSG00000266490.1 CTD-2349P21.9 5.83 1.01e-08 4.03e-06 0.32 0.26 Body mass index; chr17:30751280 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9894709 ENSG00000266490.1 CTD-2349P21.9 5.83 1.01e-08 4.03e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751436 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9896603 ENSG00000266490.1 CTD-2349P21.9 5.83 1.01e-08 4.03e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751494 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs8078656 ENSG00000266490.1 CTD-2349P21.9 5.83 1.01e-08 4.03e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753953 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs8080882 ENSG00000266490.1 CTD-2349P21.9 5.83 1.01e-08 4.03e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30754128 chr17:30792372~30792833:+ LUSC cis rs6142102 0.961 rs2284379 ENSG00000275784.1 RP5-1125A11.6 -5.83 1.01e-08 4.04e-06 -0.31 -0.26 Skin pigmentation; chr20:34006836 chr20:33989480~33991818:- LUSC cis rs73173548 0.502 rs71639110 ENSG00000247828.6 TMEM161B-AS1 5.83 1.01e-08 4.05e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88422222 chr5:88268895~88436685:+ LUSC cis rs875971 0.505 rs1167386 ENSG00000222364.1 RNU6-96P 5.83 1.01e-08 4.05e-06 0.3 0.26 Aortic root size; chr7:66048109 chr7:66395191~66395286:+ LUSC cis rs17270561 0.609 rs1165181 ENSG00000272462.2 U91328.19 -5.83 1.01e-08 4.05e-06 -0.3 -0.26 Iron status biomarkers; chr6:25825162 chr6:25992662~26001775:+ LUSC cis rs7580658 0.676 rs12465955 ENSG00000236682.1 AC068282.3 -5.83 1.02e-08 4.05e-06 -0.34 -0.26 Protein C levels; chr2:127249498 chr2:127389130~127400580:+ LUSC cis rs2337406 0.866 rs112089985 ENSG00000280411.1 IGHV1-69-2 -5.83 1.02e-08 4.05e-06 -0.23 -0.26 Alzheimer's disease (late onset); chr14:106780074 chr14:106762092~106762588:- LUSC cis rs227275 0.554 rs223442 ENSG00000246560.2 RP11-10L12.4 5.83 1.02e-08 4.05e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102793960 chr4:102828055~102844075:+ LUSC cis rs227275 0.554 rs223441 ENSG00000246560.2 RP11-10L12.4 5.83 1.02e-08 4.05e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102794228 chr4:102828055~102844075:+ LUSC cis rs8031584 0.918 rs61997140 ENSG00000260382.1 RP11-540B6.2 5.83 1.02e-08 4.05e-06 0.35 0.26 Huntington's disease progression; chr15:30985109 chr15:30882267~30883231:- LUSC cis rs227275 0.586 rs223448 ENSG00000246560.2 RP11-10L12.4 5.83 1.02e-08 4.06e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102792189 chr4:102828055~102844075:+ LUSC cis rs11159086 1 rs8006958 ENSG00000270000.1 RP3-449M8.9 5.83 1.02e-08 4.06e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74478148 chr14:74471930~74472360:- LUSC cis rs853679 0.882 rs4713139 ENSG00000219392.1 RP1-265C24.5 -5.83 1.02e-08 4.06e-06 -0.43 -0.26 Depression; chr6:28124907 chr6:28115628~28116551:+ LUSC cis rs853679 0.882 rs3757188 ENSG00000219392.1 RP1-265C24.5 -5.83 1.02e-08 4.06e-06 -0.43 -0.26 Depression; chr6:28139579 chr6:28115628~28116551:+ LUSC cis rs4489787 0.892 rs4448729 ENSG00000240399.1 RP1-228P16.1 -5.83 1.02e-08 4.06e-06 -0.43 -0.26 Prostate cancer (SNP x SNP interaction); chr12:48428545 chr12:48054813~48055591:- LUSC cis rs8005677 0.798 rs4536383 ENSG00000279656.1 RP11-298I3.6 5.83 1.02e-08 4.06e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22941717 chr14:23023083~23024217:- LUSC cis rs8005677 0.828 rs34584578 ENSG00000279656.1 RP11-298I3.6 5.83 1.02e-08 4.06e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22942481 chr14:23023083~23024217:- LUSC cis rs11123170 0.529 rs112692022 ENSG00000274877.1 RP11-65I12.1 -5.83 1.02e-08 4.06e-06 -0.37 -0.26 Renal function-related traits (BUN); chr2:113212605 chr2:113237595~113240825:+ LUSC cis rs7772486 0.875 rs2748485 ENSG00000235652.6 RP11-545I5.3 5.83 1.02e-08 4.06e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146011285 chr6:145799409~145886585:+ LUSC cis rs11098499 0.739 rs951570 ENSG00000250412.1 KLHL2P1 -5.83 1.02e-08 4.07e-06 -0.31 -0.26 Corneal astigmatism; chr4:119229312 chr4:119334329~119378233:+ LUSC cis rs34779708 0.733 rs61449529 ENSG00000230534.5 RP11-297A16.2 5.83 1.02e-08 4.07e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35254986 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs59287215 ENSG00000230534.5 RP11-297A16.2 5.83 1.02e-08 4.07e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35255066 chr10:35098006~35127020:- LUSC cis rs34779708 0.702 rs35969476 ENSG00000230534.5 RP11-297A16.2 5.83 1.02e-08 4.07e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35255390 chr10:35098006~35127020:- LUSC cis rs9326248 0.581 rs7106437 ENSG00000280143.1 AP000892.6 5.83 1.02e-08 4.07e-06 0.27 0.26 Blood protein levels; chr11:117121360 chr11:117204967~117210292:+ LUSC cis rs17270561 0.609 rs3778272 ENSG00000272462.2 U91328.19 -5.83 1.02e-08 4.07e-06 -0.3 -0.26 Iron status biomarkers; chr6:25767433 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs2275905 ENSG00000272462.2 U91328.19 -5.83 1.02e-08 4.07e-06 -0.3 -0.26 Iron status biomarkers; chr6:25767878 chr6:25992662~26001775:+ LUSC cis rs7772486 0.743 rs9376955 ENSG00000235652.6 RP11-545I5.3 5.83 1.02e-08 4.07e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145628268 chr6:145799409~145886585:+ LUSC cis rs7772486 0.805 rs4896831 ENSG00000235652.6 RP11-545I5.3 5.83 1.02e-08 4.07e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145638345 chr6:145799409~145886585:+ LUSC cis rs6504950 0.886 rs2541236 ENSG00000275710.1 RP11-257O5.4 -5.83 1.02e-08 4.07e-06 -0.32 -0.26 Breast cancer; chr17:55082471 chr17:54964474~54964679:+ LUSC cis rs7555523 0.887 rs4657477 ENSG00000224358.1 RP11-466F5.8 -5.83 1.02e-08 4.08e-06 -0.32 -0.26 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165766938 chr1:165768929~165775176:+ LUSC cis rs801193 1 rs2707856 ENSG00000222364.1 RNU6-96P -5.83 1.02e-08 4.08e-06 -0.3 -0.26 Aortic root size; chr7:66746023 chr7:66395191~66395286:+ LUSC cis rs66887589 0.934 rs12648182 ENSG00000249244.1 RP11-548H18.2 -5.83 1.02e-08 4.08e-06 -0.31 -0.26 Diastolic blood pressure; chr4:119582736 chr4:119391831~119395335:- LUSC cis rs6918586 0.658 rs198830 ENSG00000272462.2 U91328.19 -5.83 1.02e-08 4.08e-06 -0.27 -0.26 Schizophrenia; chr6:26118018 chr6:25992662~26001775:+ LUSC cis rs4865169 0.811 rs6841086 ENSG00000269949.1 RP11-738E22.3 5.83 1.02e-08 4.08e-06 0.32 0.26 Breast cancer; chr4:57037102 chr4:56960927~56961373:- LUSC cis rs13113518 0.812 rs4865001 ENSG00000249700.7 SRD5A3-AS1 5.83 1.03e-08 4.09e-06 0.31 0.26 Height; chr4:55490176 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs4864543 ENSG00000249700.7 SRD5A3-AS1 5.83 1.03e-08 4.09e-06 0.31 0.26 Height; chr4:55490228 chr4:55363971~55395847:- LUSC cis rs10759883 0.627 rs10985499 ENSG00000175611.10 LINC00476 5.83 1.03e-08 4.09e-06 0.3 0.26 Nicotine dependence; chr9:95840724 chr9:95759231~95875977:- LUSC cis rs13113518 1 rs1047354 ENSG00000273257.1 RP11-177J6.1 5.83 1.03e-08 4.09e-06 0.33 0.26 Height; chr4:55429416 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs1056547 ENSG00000273257.1 RP11-177J6.1 5.83 1.03e-08 4.09e-06 0.33 0.26 Height; chr4:55430596 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs1056545 ENSG00000273257.1 RP11-177J6.1 5.83 1.03e-08 4.09e-06 0.33 0.26 Height; chr4:55430730 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs5863 ENSG00000273257.1 RP11-177J6.1 5.83 1.03e-08 4.09e-06 0.33 0.26 Height; chr4:55430740 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs6828570 ENSG00000273257.1 RP11-177J6.1 5.83 1.03e-08 4.09e-06 0.33 0.26 Height; chr4:55431595 chr4:55387949~55388271:+ LUSC cis rs4372836 1 rs6707848 ENSG00000226833.4 AC097724.3 5.83 1.03e-08 4.09e-06 0.3 0.26 Body mass index; chr2:28765217 chr2:28708953~28736205:- LUSC cis rs875971 0.83 rs778715 ENSG00000179406.6 LINC00174 -5.83 1.03e-08 4.1e-06 -0.28 -0.26 Aortic root size; chr7:66384222 chr7:66376044~66401338:- LUSC cis rs875971 0.83 rs809025 ENSG00000179406.6 LINC00174 -5.83 1.03e-08 4.1e-06 -0.28 -0.26 Aortic root size; chr7:66384832 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs1643375 ENSG00000179406.6 LINC00174 -5.83 1.03e-08 4.1e-06 -0.28 -0.26 Aortic root size; chr7:66407690 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6962717 ENSG00000179406.6 LINC00174 -5.83 1.03e-08 4.1e-06 -0.28 -0.26 Aortic root size; chr7:66418748 chr7:66376044~66401338:- LUSC cis rs34779708 0.801 rs12246600 ENSG00000230534.5 RP11-297A16.2 5.83 1.03e-08 4.1e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35249193 chr10:35098006~35127020:- LUSC cis rs34779708 0.801 rs12098720 ENSG00000230534.5 RP11-297A16.2 5.83 1.03e-08 4.1e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35249755 chr10:35098006~35127020:- LUSC cis rs34779708 0.801 rs34592588 ENSG00000230534.5 RP11-297A16.2 5.83 1.03e-08 4.1e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35251206 chr10:35098006~35127020:- LUSC cis rs13113518 1 rs4864994 ENSG00000273257.1 RP11-177J6.1 5.83 1.03e-08 4.1e-06 0.34 0.26 Height; chr4:55451955 chr4:55387949~55388271:+ LUSC cis rs10759883 0.539 rs10115110 ENSG00000175611.10 LINC00476 5.83 1.03e-08 4.1e-06 0.31 0.26 Nicotine dependence; chr9:96033023 chr9:95759231~95875977:- LUSC cis rs11846409 0.799 rs10467899 ENSG00000274576.2 IGHV2-70 -5.83 1.03e-08 4.11e-06 -0.27 -0.26 Rheumatic heart disease; chr14:106644012 chr14:106770577~106771020:- LUSC cis rs227275 0.554 rs150895 ENSG00000246560.2 RP11-10L12.4 5.83 1.03e-08 4.11e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102791432 chr4:102828055~102844075:+ LUSC cis rs11971779 0.648 rs6967836 ENSG00000273391.1 RP11-634H22.1 5.83 1.03e-08 4.12e-06 0.28 0.26 Diisocyanate-induced asthma; chr7:139395198 chr7:139359032~139359566:- LUSC cis rs11971779 0.68 rs4728467 ENSG00000273391.1 RP11-634H22.1 5.83 1.03e-08 4.12e-06 0.29 0.26 Diisocyanate-induced asthma; chr7:139435816 chr7:139359032~139359566:- LUSC cis rs7208859 0.623 rs9898084 ENSG00000266490.1 CTD-2349P21.9 5.83 1.04e-08 4.12e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30792372~30792833:+ LUSC cis rs6504950 0.888 rs244319 ENSG00000275710.1 RP11-257O5.4 5.83 1.04e-08 4.13e-06 0.3 0.26 Breast cancer; chr17:55145513 chr17:54964474~54964679:+ LUSC cis rs11159086 1 rs58384818 ENSG00000259005.1 RP3-449M8.6 5.83 1.04e-08 4.13e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74487045 chr14:74474007~74474864:- LUSC cis rs11159086 1 rs17100588 ENSG00000259005.1 RP3-449M8.6 5.83 1.04e-08 4.13e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74487624 chr14:74474007~74474864:- LUSC cis rs6142102 0.812 rs761238 ENSG00000275784.1 RP5-1125A11.6 5.83 1.04e-08 4.13e-06 0.29 0.26 Skin pigmentation; chr20:33932182 chr20:33989480~33991818:- LUSC cis rs11098499 0.863 rs11098531 ENSG00000248280.1 RP11-33B1.2 5.83 1.04e-08 4.13e-06 0.31 0.26 Corneal astigmatism; chr4:119543846 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs28718422 ENSG00000248280.1 RP11-33B1.2 5.83 1.04e-08 4.13e-06 0.31 0.26 Corneal astigmatism; chr4:119545149 chr4:119440561~119450157:- LUSC cis rs11098499 0.818 rs12498599 ENSG00000248280.1 RP11-33B1.2 5.83 1.04e-08 4.13e-06 0.31 0.26 Corneal astigmatism; chr4:119547348 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs10009626 ENSG00000248280.1 RP11-33B1.2 5.83 1.04e-08 4.13e-06 0.31 0.26 Corneal astigmatism; chr4:119548850 chr4:119440561~119450157:- LUSC cis rs227275 0.527 rs223308 ENSG00000230069.3 LRRC37A15P -5.83 1.04e-08 4.13e-06 -0.28 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102891342 chr4:102727274~102730721:- LUSC cis rs8072100 0.738 rs9895509 ENSG00000228782.6 CTD-2026D20.3 -5.83 1.04e-08 4.14e-06 -0.26 -0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47472252 chr17:47450568~47492492:- LUSC cis rs6142102 0.812 rs2377955 ENSG00000275784.1 RP5-1125A11.6 -5.83 1.04e-08 4.14e-06 -0.3 -0.26 Skin pigmentation; chr20:33937564 chr20:33989480~33991818:- LUSC cis rs875971 0.545 rs6460298 ENSG00000224316.1 RP11-479O9.2 5.83 1.04e-08 4.14e-06 0.28 0.26 Aortic root size; chr7:66442783 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs75577046 ENSG00000224316.1 RP11-479O9.2 5.83 1.04e-08 4.14e-06 0.28 0.26 Aortic root size; chr7:66493729 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs3735147 ENSG00000224316.1 RP11-479O9.2 5.83 1.04e-08 4.14e-06 0.28 0.26 Aortic root size; chr7:66505541 chr7:65773620~65802067:+ LUSC cis rs13113518 0.812 rs56055342 ENSG00000273257.1 RP11-177J6.1 5.83 1.04e-08 4.14e-06 0.34 0.26 Height; chr4:55540928 chr4:55387949~55388271:+ LUSC cis rs950880 0.71 rs17027071 ENSG00000234389.1 AC007278.3 -5.83 1.04e-08 4.15e-06 -0.28 -0.26 Serum protein levels (sST2); chr2:102396214 chr2:102438713~102440475:+ LUSC cis rs13113518 0.812 rs4865003 ENSG00000272969.1 RP11-528I4.2 5.83 1.04e-08 4.15e-06 0.3 0.26 Height; chr4:55514802 chr4:55547112~55547889:+ LUSC cis rs6504950 0.72 rs28564882 ENSG00000275710.1 RP11-257O5.4 5.83 1.04e-08 4.15e-06 0.31 0.26 Breast cancer; chr17:54912237 chr17:54964474~54964679:+ LUSC cis rs7267979 0.816 rs376742 ENSG00000274973.1 RP13-401N8.7 -5.83 1.04e-08 4.15e-06 -0.26 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25506781 chr20:25845497~25845862:+ LUSC cis rs34779708 0.643 rs4275563 ENSG00000230534.5 RP11-297A16.2 5.83 1.04e-08 4.15e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35256358 chr10:35098006~35127020:- LUSC cis rs11157436 0.509 rs12589104 ENSG00000211813.2 TRAV34 5.83 1.04e-08 4.15e-06 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22167754 chr14:22207522~22208129:+ LUSC cis rs4713118 0.587 rs61471148 ENSG00000280107.1 AL022393.9 -5.83 1.04e-08 4.15e-06 -0.33 -0.26 Parkinson's disease; chr6:28069254 chr6:28170845~28172521:+ LUSC cis rs9341808 0.667 rs3828753 ENSG00000272129.1 RP11-250B2.6 5.83 1.04e-08 4.16e-06 0.32 0.26 Sitting height ratio; chr6:80203029 chr6:80355424~80356859:+ LUSC cis rs28830936 1 rs17678767 ENSG00000250379.1 RP11-23P13.4 5.83 1.04e-08 4.16e-06 0.28 0.26 Diastolic blood pressure; chr15:41804224 chr15:41825099~41827936:- LUSC cis rs28830936 1 rs4924575 ENSG00000250379.1 RP11-23P13.4 5.83 1.04e-08 4.16e-06 0.28 0.26 Diastolic blood pressure; chr15:41804728 chr15:41825099~41827936:- LUSC cis rs7665090 0.51 rs223498 ENSG00000230069.3 LRRC37A15P 5.83 1.04e-08 4.16e-06 0.28 0.26 Primary biliary cholangitis; chr4:102730805 chr4:102727274~102730721:- LUSC cis rs7246657 0.722 rs2287229 ENSG00000276846.1 CTD-3220F14.3 -5.83 1.04e-08 4.16e-06 -0.39 -0.26 Coronary artery calcification; chr19:37697751 chr19:37314868~37315620:- LUSC cis rs6918586 1 rs198806 ENSG00000272462.2 U91328.19 -5.83 1.05e-08 4.16e-06 -0.28 -0.26 Schizophrenia; chr6:26133388 chr6:25992662~26001775:+ LUSC cis rs9376098 0.698 rs7774081 ENSG00000232876.1 CTA-212D2.2 -5.83 1.05e-08 4.17e-06 -0.32 -0.26 Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells; chr6:135139861 chr6:135055033~135060550:+ LUSC cis rs62025270 0.547 rs338536 ENSG00000202081.1 RNU6-1280P -5.83 1.05e-08 4.17e-06 -0.32 -0.26 Idiopathic pulmonary fibrosis; chr15:85654009 chr15:85651522~85651628:- LUSC cis rs2153535 0.58 rs1119688 ENSG00000230939.1 RP11-314C16.1 -5.83 1.05e-08 4.17e-06 -0.31 -0.26 Motion sickness; chr6:8460617 chr6:8784178~8785445:+ LUSC cis rs853679 0.55 rs6901017 ENSG00000280107.1 AL022393.9 -5.83 1.05e-08 4.17e-06 -0.32 -0.26 Depression; chr6:28184805 chr6:28170845~28172521:+ LUSC cis rs72627123 1 rs72627123 ENSG00000259065.1 RP5-1021I20.1 -5.83 1.05e-08 4.17e-06 -0.45 -0.26 Morning vs. evening chronotype; chr14:73901628 chr14:73787360~73803270:+ LUSC cis rs7208859 0.623 rs11657662 ENSG00000266490.1 CTD-2349P21.9 -5.83 1.05e-08 4.17e-06 -0.32 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749329 chr17:30792372~30792833:+ LUSC cis rs875971 0.505 rs6955582 ENSG00000179406.6 LINC00174 -5.83 1.05e-08 4.17e-06 -0.27 -0.26 Aortic root size; chr7:65966699 chr7:66376044~66401338:- LUSC cis rs6918586 0.636 rs198816 ENSG00000272462.2 U91328.19 -5.83 1.05e-08 4.17e-06 -0.27 -0.26 Schizophrenia; chr6:26126956 chr6:25992662~26001775:+ LUSC cis rs6918586 0.658 rs198814 ENSG00000272462.2 U91328.19 -5.83 1.05e-08 4.17e-06 -0.27 -0.26 Schizophrenia; chr6:26127531 chr6:25992662~26001775:+ LUSC cis rs6740322 0.748 rs6732337 ENSG00000234936.1 AC010883.5 -5.83 1.05e-08 4.18e-06 -0.31 -0.26 Coronary artery disease; chr2:43235683 chr2:43229573~43233394:+ LUSC cis rs11159086 1 rs3759745 ENSG00000259005.1 RP3-449M8.6 5.83 1.05e-08 4.18e-06 0.39 0.26 Advanced glycation end-product levels; chr14:74495967 chr14:74474007~74474864:- LUSC cis rs4865169 0.967 rs10023088 ENSG00000269949.1 RP11-738E22.3 5.83 1.05e-08 4.18e-06 0.32 0.26 Breast cancer; chr4:57018269 chr4:56960927~56961373:- LUSC cis rs5753618 0.509 rs5997913 ENSG00000236132.1 CTA-440B3.1 5.83 1.05e-08 4.18e-06 0.35 0.26 Colorectal cancer; chr22:31197973 chr22:31816379~31817491:- LUSC cis rs9341808 0.591 rs7741013 ENSG00000272129.1 RP11-250B2.6 5.83 1.05e-08 4.18e-06 0.32 0.26 Sitting height ratio; chr6:80206613 chr6:80355424~80356859:+ LUSC cis rs875971 0.83 rs4718358 ENSG00000179406.6 LINC00174 -5.83 1.05e-08 4.18e-06 -0.28 -0.26 Aortic root size; chr7:66508681 chr7:66376044~66401338:- LUSC cis rs875971 0.895 rs7788984 ENSG00000179406.6 LINC00174 -5.83 1.05e-08 4.19e-06 -0.28 -0.26 Aortic root size; chr7:66450629 chr7:66376044~66401338:- LUSC cis rs875971 1 rs1981798 ENSG00000179406.6 LINC00174 -5.83 1.05e-08 4.19e-06 -0.28 -0.26 Aortic root size; chr7:66489916 chr7:66376044~66401338:- LUSC cis rs4604732 0.812 rs6663238 ENSG00000227135.1 GCSAML-AS1 5.83 1.05e-08 4.19e-06 0.36 0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461669 chr1:247524679~247526752:- LUSC cis rs2732480 0.577 rs2732457 ENSG00000226413.2 OR8T1P -5.83 1.05e-08 4.19e-06 -0.33 -0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48364596 chr12:48442030~48442947:- LUSC cis rs34779708 0.733 rs7087099 ENSG00000230534.5 RP11-297A16.2 5.83 1.05e-08 4.19e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35253054 chr10:35098006~35127020:- LUSC cis rs73173548 0.502 rs74429030 ENSG00000247828.6 TMEM161B-AS1 5.83 1.05e-08 4.19e-06 0.32 0.26 Macular telangiectasia type 2; chr5:88474689 chr5:88268895~88436685:+ LUSC cis rs11159086 1 rs12433848 ENSG00000259005.1 RP3-449M8.6 5.83 1.05e-08 4.19e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74497570 chr14:74474007~74474864:- LUSC cis rs2404602 0.646 rs3764245 ENSG00000259422.1 RP11-593F23.1 5.83 1.05e-08 4.19e-06 0.31 0.26 Blood metabolite levels; chr15:76930835 chr15:76174891~76181486:- LUSC cis rs2153535 0.58 rs1319169 ENSG00000230939.1 RP11-314C16.1 -5.83 1.05e-08 4.2e-06 -0.31 -0.26 Motion sickness; chr6:8464223 chr6:8784178~8785445:+ LUSC cis rs1345301 1 rs1420093 ENSG00000234389.1 AC007278.3 -5.83 1.06e-08 4.2e-06 -0.25 -0.26 Waist circumference; chr2:102253998 chr2:102438713~102440475:+ LUSC cis rs1345301 1 rs10200410 ENSG00000234389.1 AC007278.3 -5.83 1.06e-08 4.2e-06 -0.25 -0.26 Waist circumference; chr2:102254411 chr2:102438713~102440475:+ LUSC cis rs11089937 0.597 rs5757024 ENSG00000211638.2 IGLV8-61 -5.83 1.06e-08 4.2e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22137415 chr22:22098700~22099212:+ LUSC cis rs4237845 0.591 rs4760344 ENSG00000257159.1 RP11-58A17.3 5.83 1.06e-08 4.2e-06 0.34 0.26 Intelligence (multi-trait analysis); chr12:57927000 chr12:57967058~57968399:+ LUSC cis rs1061377 1 rs7685468 ENSG00000249685.1 RP11-360F5.3 5.83 1.06e-08 4.2e-06 0.3 0.26 Uric acid levels; chr4:39116649 chr4:39133913~39135608:+ LUSC cis rs6570726 0.738 rs4495284 ENSG00000235652.6 RP11-545I5.3 5.83 1.06e-08 4.2e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145595481 chr6:145799409~145886585:+ LUSC cis rs1061377 1 rs28607301 ENSG00000249685.1 RP11-360F5.3 5.83 1.06e-08 4.2e-06 0.29 0.26 Uric acid levels; chr4:39136460 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs36090629 ENSG00000249685.1 RP11-360F5.3 5.83 1.06e-08 4.2e-06 0.29 0.26 Uric acid levels; chr4:39137195 chr4:39133913~39135608:+ LUSC cis rs1061377 0.87 rs73238544 ENSG00000249685.1 RP11-360F5.3 5.83 1.06e-08 4.2e-06 0.29 0.26 Uric acid levels; chr4:39137343 chr4:39133913~39135608:+ LUSC cis rs2842992 0.789 rs4235925 ENSG00000237927.1 RP3-393E18.2 -5.83 1.06e-08 4.21e-06 -0.39 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159781828 chr6:159586955~159589169:- LUSC cis rs2179367 0.586 rs62426088 ENSG00000231760.4 RP11-350J20.5 5.83 1.06e-08 4.21e-06 0.37 0.26 Dupuytren's disease; chr6:149339301 chr6:149796151~149826294:- LUSC cis rs79349575 0.721 rs4794004 ENSG00000270781.1 RP11-501C14.9 -5.83 1.06e-08 4.21e-06 -0.27 -0.26 Type 2 diabetes; chr17:48961109 chr17:48899131~48899748:+ LUSC cis rs2153535 0.58 rs1832101 ENSG00000230939.1 RP11-314C16.1 -5.83 1.06e-08 4.21e-06 -0.31 -0.26 Motion sickness; chr6:8459944 chr6:8784178~8785445:+ LUSC cis rs270601 0.77 rs1007602 ENSG00000233006.5 AC034220.3 5.83 1.06e-08 4.21e-06 0.26 0.26 Acylcarnitine levels; chr5:132266473 chr5:132311285~132369916:- LUSC cis rs270601 0.71 rs4705852 ENSG00000233006.5 AC034220.3 5.83 1.06e-08 4.21e-06 0.26 0.26 Acylcarnitine levels; chr5:132267114 chr5:132311285~132369916:- LUSC cis rs13113518 0.776 rs13124436 ENSG00000249700.7 SRD5A3-AS1 5.82 1.06e-08 4.22e-06 0.3 0.26 Height; chr4:55502504 chr4:55363971~55395847:- LUSC cis rs13113518 0.783 rs6843997 ENSG00000249700.7 SRD5A3-AS1 5.82 1.06e-08 4.22e-06 0.3 0.26 Height; chr4:55508982 chr4:55363971~55395847:- LUSC cis rs875971 0.862 rs1695820 ENSG00000179406.6 LINC00174 -5.82 1.06e-08 4.22e-06 -0.28 -0.26 Aortic root size; chr7:66379576 chr7:66376044~66401338:- LUSC cis rs6570726 0.846 rs453834 ENSG00000235652.6 RP11-545I5.3 5.82 1.06e-08 4.22e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145565125 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs409553 ENSG00000235652.6 RP11-545I5.3 5.82 1.06e-08 4.22e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145565827 chr6:145799409~145886585:+ LUSC cis rs6570726 0.846 rs371186 ENSG00000235652.6 RP11-545I5.3 5.82 1.06e-08 4.22e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145565835 chr6:145799409~145886585:+ LUSC cis rs2153535 0.541 rs4637688 ENSG00000230939.1 RP11-314C16.1 -5.82 1.06e-08 4.22e-06 -0.31 -0.26 Motion sickness; chr6:8446268 chr6:8784178~8785445:+ LUSC cis rs2903698 0.585 rs6535429 ENSG00000250735.4 RP11-567N4.3 -5.82 1.06e-08 4.23e-06 -0.3 -0.26 Prion diseases; chr4:75425326 chr4:75401195~75423023:+ LUSC cis rs442309 0.807 rs224069 ENSG00000238280.1 RP11-436D10.3 -5.82 1.07e-08 4.23e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62748366 chr10:62793562~62805887:- LUSC cis rs5753618 0.509 rs4820951 ENSG00000236132.1 CTA-440B3.1 5.82 1.07e-08 4.23e-06 0.35 0.26 Colorectal cancer; chr22:31190262 chr22:31816379~31817491:- LUSC cis rs5753618 0.509 rs5749229 ENSG00000236132.1 CTA-440B3.1 5.82 1.07e-08 4.23e-06 0.35 0.26 Colorectal cancer; chr22:31191232 chr22:31816379~31817491:- LUSC cis rs4141404 0.787 rs4820042 ENSG00000236132.1 CTA-440B3.1 5.82 1.07e-08 4.23e-06 0.35 0.26 Paclitaxel-induced neuropathy; chr22:31193070 chr22:31816379~31817491:- LUSC cis rs459571 0.959 rs455381 ENSG00000235106.7 LINC00094 5.82 1.07e-08 4.24e-06 0.3 0.26 Platelet distribution width; chr9:134040455 chr9:134025439~134034666:+ LUSC cis rs9595066 0.627 rs4942287 ENSG00000227258.4 SMIM2-AS1 -5.82 1.07e-08 4.24e-06 -0.4 -0.26 Schizophrenia; chr13:44160560 chr13:44110451~44240517:+ LUSC cis rs113835537 0.935 rs75863187 ENSG00000255517.5 CTD-3074O7.5 -5.82 1.07e-08 4.24e-06 -0.35 -0.26 Airway imaging phenotypes; chr11:66675990 chr11:66473490~66480233:- LUSC cis rs4604732 0.588 rs7549495 ENSG00000227135.1 GCSAML-AS1 -5.82 1.07e-08 4.24e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247464504 chr1:247524679~247526752:- LUSC cis rs4604732 0.536 rs76191272 ENSG00000227135.1 GCSAML-AS1 -5.82 1.07e-08 4.24e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247464753 chr1:247524679~247526752:- LUSC cis rs4604732 0.536 rs7528219 ENSG00000227135.1 GCSAML-AS1 -5.82 1.07e-08 4.24e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247465005 chr1:247524679~247526752:- LUSC cis rs4604732 0.588 rs7549955 ENSG00000227135.1 GCSAML-AS1 -5.82 1.07e-08 4.24e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247465019 chr1:247524679~247526752:- LUSC cis rs4604732 0.588 rs7552443 ENSG00000227135.1 GCSAML-AS1 -5.82 1.07e-08 4.24e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247465281 chr1:247524679~247526752:- LUSC cis rs4604732 0.588 rs7552461 ENSG00000227135.1 GCSAML-AS1 -5.82 1.07e-08 4.24e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247465342 chr1:247524679~247526752:- LUSC cis rs4604732 0.588 rs6677477 ENSG00000227135.1 GCSAML-AS1 -5.82 1.07e-08 4.24e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247466109 chr1:247524679~247526752:- LUSC cis rs4372836 1 rs6547872 ENSG00000226833.4 AC097724.3 5.82 1.07e-08 4.24e-06 0.3 0.26 Body mass index; chr2:28755208 chr2:28708953~28736205:- LUSC cis rs1499614 0.901 rs2178742 ENSG00000226824.5 RP4-756H11.3 -5.82 1.07e-08 4.24e-06 -0.5 -0.26 Gout; chr7:66732812 chr7:66654538~66669855:+ LUSC cis rs6504950 0.889 rs2541245 ENSG00000275710.1 RP11-257O5.4 -5.82 1.07e-08 4.25e-06 -0.32 -0.26 Breast cancer; chr17:55023839 chr17:54964474~54964679:+ LUSC cis rs6504950 0.889 rs2787505 ENSG00000275710.1 RP11-257O5.4 -5.82 1.07e-08 4.25e-06 -0.32 -0.26 Breast cancer; chr17:55030071 chr17:54964474~54964679:+ LUSC cis rs2153535 0.601 rs330105 ENSG00000230939.1 RP11-314C16.1 -5.82 1.07e-08 4.25e-06 -0.31 -0.26 Motion sickness; chr6:8543748 chr6:8784178~8785445:+ LUSC cis rs2613964 1 rs2613964 ENSG00000240057.4 RP11-572M11.4 -5.82 1.07e-08 4.25e-06 -0.29 -0.26 Pediatric bone mineral content (spine);Pediatric bone mineral density (spine); chr3:113141933 chr3:113019532~113183301:+ LUSC cis rs673078 0.66 rs61945180 ENSG00000275759.1 RP11-131L12.3 -5.82 1.07e-08 4.26e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118216335 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs61945181 ENSG00000275759.1 RP11-131L12.3 -5.82 1.07e-08 4.26e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118216651 chr12:118428281~118428870:+ LUSC cis rs113835537 0.935 rs117131621 ENSG00000255517.5 CTD-3074O7.5 -5.82 1.07e-08 4.26e-06 -0.35 -0.26 Airway imaging phenotypes; chr11:66654863 chr11:66473490~66480233:- LUSC cis rs113835537 0.935 rs57043177 ENSG00000255517.5 CTD-3074O7.5 -5.82 1.07e-08 4.26e-06 -0.35 -0.26 Airway imaging phenotypes; chr11:66655676 chr11:66473490~66480233:- LUSC cis rs2153535 0.542 rs915353 ENSG00000230939.1 RP11-314C16.1 -5.82 1.07e-08 4.26e-06 -0.31 -0.26 Motion sickness; chr6:8440137 chr6:8784178~8785445:+ LUSC cis rs6918586 0.594 rs198842 ENSG00000272462.2 U91328.19 -5.82 1.07e-08 4.27e-06 -0.27 -0.26 Schizophrenia; chr6:26111220 chr6:25992662~26001775:+ LUSC cis rs6918586 0.658 rs198840 ENSG00000272462.2 U91328.19 -5.82 1.07e-08 4.27e-06 -0.27 -0.26 Schizophrenia; chr6:26111936 chr6:25992662~26001775:+ LUSC cis rs6860806 0.507 rs270601 ENSG00000233006.5 AC034220.3 5.82 1.07e-08 4.27e-06 0.27 0.26 Breast cancer; chr5:132321304 chr5:132311285~132369916:- LUSC cis rs801193 1 rs11773829 ENSG00000222364.1 RNU6-96P 5.82 1.07e-08 4.27e-06 0.3 0.26 Aortic root size; chr7:66676087 chr7:66395191~66395286:+ LUSC cis rs6142102 0.923 rs6057961 ENSG00000275784.1 RP5-1125A11.6 -5.82 1.08e-08 4.27e-06 -0.3 -0.26 Skin pigmentation; chr20:33986005 chr20:33989480~33991818:- LUSC cis rs34779708 0.733 rs4007271 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35257683 chr10:35098006~35127020:- LUSC cis rs34779708 0.702 rs4007272 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35257931 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs4934740 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35258213 chr10:35098006~35127020:- LUSC cis rs34779708 0.702 rs4244995 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35258247 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs4244997 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35258326 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs4298846 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35258452 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs4391768 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35258667 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs7914468 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35259143 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs7914560 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35259171 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs4444023 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35259426 chr10:35098006~35127020:- LUSC cis rs34779708 0.733 rs12243593 ENSG00000230534.5 RP11-297A16.2 5.82 1.08e-08 4.28e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35260117 chr10:35098006~35127020:- LUSC cis rs116095464 0.51 rs7714944 ENSG00000250848.1 CTD-2083E4.5 -5.82 1.08e-08 4.28e-06 -0.37 -0.26 Breast cancer; chr5:231650 chr5:288833~290321:- LUSC cis rs783540 0.869 rs783533 ENSG00000276710.3 CSPG4P8 5.82 1.08e-08 4.28e-06 0.26 0.26 Schizophrenia; chr15:82581437 chr15:82459472~82477258:+ LUSC cis rs367615 0.679 rs11241021 ENSG00000249476.1 CTD-2587M2.1 5.82 1.08e-08 4.29e-06 0.31 0.26 Colorectal cancer (SNP x SNP interaction); chr5:109476389 chr5:109237120~109326369:- LUSC cis rs7772486 0.84 rs2474355 ENSG00000235652.6 RP11-545I5.3 5.82 1.08e-08 4.29e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145991404 chr6:145799409~145886585:+ LUSC cis rs853679 0.882 rs9468300 ENSG00000219392.1 RP1-265C24.5 -5.82 1.08e-08 4.29e-06 -0.44 -0.26 Depression; chr6:28159062 chr6:28115628~28116551:+ LUSC cis rs11971779 0.715 rs7787398 ENSG00000273391.1 RP11-634H22.1 5.82 1.08e-08 4.29e-06 0.28 0.26 Diisocyanate-induced asthma; chr7:139377100 chr7:139359032~139359566:- LUSC cis rs11098499 0.71 rs6851130 ENSG00000250412.1 KLHL2P1 -5.82 1.08e-08 4.29e-06 -0.31 -0.26 Corneal astigmatism; chr4:119212557 chr4:119334329~119378233:+ LUSC cis rs13113518 0.783 rs12508367 ENSG00000249700.7 SRD5A3-AS1 5.82 1.08e-08 4.29e-06 0.3 0.26 Height; chr4:55509442 chr4:55363971~55395847:- LUSC cis rs13113518 0.812 rs2272073 ENSG00000249700.7 SRD5A3-AS1 5.82 1.08e-08 4.29e-06 0.3 0.26 Height; chr4:55510177 chr4:55363971~55395847:- LUSC cis rs75422866 0.867 rs7303895 ENSG00000274902.1 RP1-197B17.4 5.82 1.08e-08 4.3e-06 0.63 0.26 Pneumonia; chr12:47683290 chr12:47731908~47732351:+ LUSC cis rs11098499 0.739 rs7441137 ENSG00000250412.1 KLHL2P1 -5.82 1.08e-08 4.3e-06 -0.31 -0.26 Corneal astigmatism; chr4:119212066 chr4:119334329~119378233:+ LUSC cis rs11098499 0.739 rs4833612 ENSG00000250412.1 KLHL2P1 -5.82 1.08e-08 4.3e-06 -0.31 -0.26 Corneal astigmatism; chr4:119226441 chr4:119334329~119378233:+ LUSC cis rs11098499 0.739 rs10013032 ENSG00000250412.1 KLHL2P1 -5.82 1.08e-08 4.3e-06 -0.31 -0.26 Corneal astigmatism; chr4:119228264 chr4:119334329~119378233:+ LUSC cis rs10759883 0.563 rs690056 ENSG00000175611.10 LINC00476 5.82 1.08e-08 4.3e-06 0.31 0.26 Nicotine dependence; chr9:95938704 chr9:95759231~95875977:- LUSC cis rs6928977 0.66 rs2757643 ENSG00000234084.1 RP3-388E23.2 -5.82 1.09e-08 4.31e-06 -0.2 -0.26 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135440095 chr6:135301568~135307158:+ LUSC cis rs875971 0.545 rs17138156 ENSG00000237310.1 GS1-124K5.4 5.82 1.09e-08 4.31e-06 0.29 0.26 Aortic root size; chr7:66249708 chr7:66493706~66495474:+ LUSC cis rs16843372 0.599 rs10207728 ENSG00000251491.2 OR7E28P -5.82 1.09e-08 4.32e-06 -0.28 -0.26 Obesity-related traits; chr2:158819604 chr2:158862311~158863285:+ LUSC cis rs7829975 0.514 rs2976926 ENSG00000253893.2 FAM85B -5.82 1.09e-08 4.32e-06 -0.3 -0.26 Mood instability; chr8:8404114 chr8:8167819~8226614:- LUSC cis rs73173548 0.502 rs34634636 ENSG00000247828.6 TMEM161B-AS1 5.82 1.09e-08 4.32e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88435989 chr5:88268895~88436685:+ LUSC cis rs270601 0.77 rs4361510 ENSG00000233006.5 AC034220.3 5.82 1.09e-08 4.32e-06 0.26 0.26 Acylcarnitine levels; chr5:132263954 chr5:132311285~132369916:- LUSC cis rs11098499 0.739 rs9884728 ENSG00000250412.1 KLHL2P1 -5.82 1.09e-08 4.32e-06 -0.31 -0.26 Corneal astigmatism; chr4:119205924 chr4:119334329~119378233:+ LUSC cis rs11098499 0.739 rs6534130 ENSG00000250412.1 KLHL2P1 -5.82 1.09e-08 4.32e-06 -0.31 -0.26 Corneal astigmatism; chr4:119210184 chr4:119334329~119378233:+ LUSC cis rs13392177 0.66 rs12988046 ENSG00000261338.2 RP11-378A13.1 -5.82 1.09e-08 4.32e-06 -0.27 -0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218209081 chr2:218255319~218257366:+ LUSC cis rs7772486 0.846 rs7755440 ENSG00000235652.6 RP11-545I5.3 5.82 1.09e-08 4.33e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146054770 chr6:145799409~145886585:+ LUSC cis rs34779708 0.733 rs12240638 ENSG00000230534.5 RP11-297A16.2 5.82 1.09e-08 4.33e-06 0.3 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35253682 chr10:35098006~35127020:- LUSC cis rs9341808 1 rs1359239 ENSG00000272129.1 RP11-250B2.6 5.82 1.09e-08 4.33e-06 0.31 0.26 Sitting height ratio; chr6:80246429 chr6:80355424~80356859:+ LUSC cis rs6504950 0.85 rs2628308 ENSG00000275710.1 RP11-257O5.4 -5.82 1.09e-08 4.34e-06 -0.31 -0.26 Breast cancer; chr17:55046212 chr17:54964474~54964679:+ LUSC cis rs78487399 0.808 rs17030890 ENSG00000234936.1 AC010883.5 5.82 1.09e-08 4.34e-06 0.41 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43476953 chr2:43229573~43233394:+ LUSC cis rs875971 0.545 rs12670811 ENSG00000224316.1 RP11-479O9.2 5.82 1.09e-08 4.34e-06 0.28 0.26 Aortic root size; chr7:66358032 chr7:65773620~65802067:+ LUSC cis rs2134046 0.587 rs11854289 ENSG00000255769.6 GOLGA2P10 5.82 1.09e-08 4.34e-06 0.3 0.26 Cognitive ability; chr15:82266461 chr15:82472993~82513950:- LUSC cis rs66887589 0.72 rs2036858 ENSG00000249244.1 RP11-548H18.2 5.82 1.1e-08 4.34e-06 0.31 0.26 Diastolic blood pressure; chr4:119328082 chr4:119391831~119395335:- LUSC cis rs17507216 1 rs3850610 ENSG00000276710.3 CSPG4P8 5.82 1.1e-08 4.34e-06 0.3 0.26 Excessive daytime sleepiness; chr15:82552642 chr15:82459472~82477258:+ LUSC cis rs2274273 0.805 rs28660594 ENSG00000258413.1 RP11-665C16.6 -5.82 1.1e-08 4.35e-06 -0.31 -0.26 Protein biomarker; chr14:55379456 chr14:55262767~55272075:- LUSC cis rs673078 0.607 rs16948230 ENSG00000275759.1 RP11-131L12.3 -5.82 1.1e-08 4.35e-06 -0.38 -0.26 Glucose homeostasis traits; chr12:118277086 chr12:118428281~118428870:+ LUSC cis rs1056107 0.863 rs7041663 ENSG00000225513.1 RP11-165N19.2 -5.82 1.1e-08 4.35e-06 -0.29 -0.26 Colorectal cancer; chr9:112240538 chr9:112173522~112173971:- LUSC cis rs1056107 0.898 rs1831118 ENSG00000225513.1 RP11-165N19.2 -5.82 1.1e-08 4.35e-06 -0.29 -0.26 Colorectal cancer; chr9:112240552 chr9:112173522~112173971:- LUSC cis rs36423 0.748 rs36386 ENSG00000266869.1 RP6-114E22.1 5.82 1.1e-08 4.36e-06 0.39 0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71901187 chr14:71848606~71908430:+ LUSC cis rs1021993 0.587 rs78609792 ENSG00000231648.1 RP11-372M18.2 -5.82 1.1e-08 4.36e-06 -0.38 -0.26 Gut microbiome composition (winter); chr1:209372669 chr1:209367662~209379690:+ LUSC cis rs9341835 0.772 rs9294202 ENSG00000218048.2 RP3-407E4.4 5.82 1.1e-08 4.36e-06 0.3 0.26 Schizophrenia; chr6:63429049 chr6:63440766~63443580:+ LUSC cis rs67180937 0.553 rs3002148 ENSG00000272750.1 RP11-378J18.8 5.82 1.1e-08 4.36e-06 0.33 0.26 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222637575 chr1:222658867~222661512:- LUSC cis rs3764021 0.527 rs11052426 ENSG00000256975.1 RP11-525E9.1 5.82 1.1e-08 4.36e-06 0.34 0.26 Type 1 diabetes; chr12:9688330 chr12:9506347~9508440:- LUSC cis rs3764021 0.527 rs17806710 ENSG00000256975.1 RP11-525E9.1 5.82 1.1e-08 4.36e-06 0.34 0.26 Type 1 diabetes; chr12:9688368 chr12:9506347~9508440:- LUSC cis rs853679 0.599 rs149949 ENSG00000204709.4 LINC01556 5.82 1.1e-08 4.36e-06 0.43 0.26 Depression; chr6:28043738 chr6:28943877~28944537:+ LUSC cis rs35160687 0.644 rs4832274 ENSG00000273080.1 RP11-301O19.1 -5.82 1.1e-08 4.36e-06 -0.25 -0.26 Night sleep phenotypes; chr2:86301961 chr2:86195590~86196049:+ LUSC cis rs875971 0.862 rs709596 ENSG00000179406.6 LINC00174 -5.82 1.1e-08 4.36e-06 -0.28 -0.26 Aortic root size; chr7:66360926 chr7:66376044~66401338:- LUSC cis rs26949 0.554 rs11742421 ENSG00000215032.2 GNL3LP1 5.82 1.1e-08 4.37e-06 0.32 0.26 Intelligence (multi-trait analysis); chr5:60681590 chr5:60891935~60893577:- LUSC cis rs2153535 0.58 rs1932283 ENSG00000230939.1 RP11-314C16.1 -5.82 1.1e-08 4.37e-06 -0.31 -0.26 Motion sickness; chr6:8477428 chr6:8784178~8785445:+ LUSC cis rs6570726 1 rs405622 ENSG00000235652.6 RP11-545I5.3 5.82 1.1e-08 4.37e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145550761 chr6:145799409~145886585:+ LUSC cis rs6570726 1 rs455109 ENSG00000235652.6 RP11-545I5.3 5.82 1.1e-08 4.37e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145551529 chr6:145799409~145886585:+ LUSC cis rs11846409 0.932 rs28378201 ENSG00000274576.2 IGHV2-70 -5.82 1.1e-08 4.37e-06 -0.27 -0.26 Rheumatic heart disease; chr14:106637262 chr14:106770577~106771020:- LUSC cis rs11089937 0.857 rs5750580 ENSG00000211638.2 IGLV8-61 -5.82 1.1e-08 4.38e-06 -0.24 -0.26 Periodontitis (PAL4Q3); chr22:22137471 chr22:22098700~22099212:+ LUSC cis rs9326248 0.581 rs10502222 ENSG00000280143.1 AP000892.6 5.82 1.11e-08 4.38e-06 0.27 0.26 Blood protein levels; chr11:116963014 chr11:117204967~117210292:+ LUSC cis rs9326248 0.559 rs10892052 ENSG00000280143.1 AP000892.6 5.82 1.11e-08 4.38e-06 0.27 0.26 Blood protein levels; chr11:116963597 chr11:117204967~117210292:+ LUSC cis rs6570726 0.846 rs6914304 ENSG00000235652.6 RP11-545I5.3 5.82 1.11e-08 4.39e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145599881 chr6:145799409~145886585:+ LUSC cis rs2842992 0.747 rs1547093 ENSG00000237927.1 RP3-393E18.2 -5.82 1.11e-08 4.39e-06 -0.38 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159784959 chr6:159586955~159589169:- LUSC cis rs7267979 0.932 rs13040655 ENSG00000274973.1 RP13-401N8.7 -5.82 1.11e-08 4.39e-06 -0.27 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25601561 chr20:25845497~25845862:+ LUSC cis rs2276314 1 rs2298716 ENSG00000278986.1 RP11-723J4.3 -5.82 1.11e-08 4.39e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35972635 chr18:35972151~35973916:+ LUSC cis rs801193 1 rs2659915 ENSG00000222364.1 RNU6-96P -5.82 1.11e-08 4.39e-06 -0.3 -0.26 Aortic root size; chr7:66688114 chr7:66395191~66395286:+ LUSC cis rs6918586 0.557 rs198827 ENSG00000272462.2 U91328.19 -5.82 1.11e-08 4.39e-06 -0.27 -0.26 Schizophrenia; chr6:26120774 chr6:25992662~26001775:+ LUSC cis rs78773383 0.505 rs10033019 ENSG00000249207.1 RP11-360F5.1 5.82 1.11e-08 4.39e-06 0.3 0.26 Mean corpuscular volume;Mean corpuscular hemoglobin; chr4:39390320 chr4:39112677~39126818:- LUSC cis rs6683071 0.688 rs3811465 ENSG00000272750.1 RP11-378J18.8 -5.82 1.11e-08 4.4e-06 -0.35 -0.26 Cognitive performance; chr1:222712777 chr1:222658867~222661512:- LUSC cis rs7246657 0.722 rs2075284 ENSG00000276846.1 CTD-3220F14.3 -5.82 1.11e-08 4.41e-06 -0.39 -0.26 Coronary artery calcification; chr19:37698715 chr19:37314868~37315620:- LUSC cis rs13434995 0.513 rs11732481 ENSG00000249700.7 SRD5A3-AS1 5.82 1.11e-08 4.41e-06 0.33 0.26 Adiponectin levels; chr4:55570212 chr4:55363971~55395847:- LUSC cis rs1061377 0.76 rs7678457 ENSG00000249685.1 RP11-360F5.3 5.82 1.11e-08 4.41e-06 0.3 0.26 Uric acid levels; chr4:39136041 chr4:39133913~39135608:+ LUSC cis rs8040855 0.576 rs62022528 ENSG00000259295.5 CSPG4P12 5.82 1.11e-08 4.41e-06 0.35 0.26 Bulimia nervosa; chr15:84992030 chr15:85191438~85213905:+ LUSC cis rs889398 0.933 rs244418 ENSG00000226232.7 RP11-419C5.2 5.82 1.11e-08 4.41e-06 0.25 0.26 Body mass index; chr16:69588859 chr16:69976388~69996188:- LUSC cis rs6142102 0.517 rs6059580 ENSG00000275784.1 RP5-1125A11.6 -5.82 1.12e-08 4.42e-06 -0.29 -0.26 Skin pigmentation; chr20:33940067 chr20:33989480~33991818:- LUSC cis rs6860806 0.507 rs635620 ENSG00000233006.5 AC034220.3 -5.82 1.12e-08 4.42e-06 -0.28 -0.26 Breast cancer; chr5:132384571 chr5:132311285~132369916:- LUSC cis rs6860806 0.507 rs635619 ENSG00000233006.5 AC034220.3 -5.82 1.12e-08 4.42e-06 -0.28 -0.26 Breast cancer; chr5:132384573 chr5:132311285~132369916:- LUSC cis rs10510102 0.608 rs4486560 ENSG00000226864.1 ATE1-AS1 5.82 1.12e-08 4.42e-06 0.38 0.26 Breast cancer; chr10:121844840 chr10:121928312~121951965:+ LUSC cis rs2153535 0.56 rs9379214 ENSG00000230939.1 RP11-314C16.1 -5.82 1.12e-08 4.42e-06 -0.31 -0.26 Motion sickness; chr6:8480637 chr6:8784178~8785445:+ LUSC cis rs6570726 0.967 rs373704 ENSG00000235652.6 RP11-545I5.3 5.82 1.12e-08 4.42e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145539482 chr6:145799409~145886585:+ LUSC cis rs1056107 0.737 rs7041381 ENSG00000225513.1 RP11-165N19.2 -5.82 1.12e-08 4.42e-06 -0.28 -0.26 Colorectal cancer; chr9:112309799 chr9:112173522~112173971:- LUSC cis rs35160687 0.712 rs6738585 ENSG00000273080.1 RP11-301O19.1 -5.82 1.12e-08 4.43e-06 -0.24 -0.26 Night sleep phenotypes; chr2:86283161 chr2:86195590~86196049:+ LUSC cis rs35160687 0.712 rs6725234 ENSG00000273080.1 RP11-301O19.1 -5.82 1.12e-08 4.43e-06 -0.24 -0.26 Night sleep phenotypes; chr2:86283165 chr2:86195590~86196049:+ LUSC cis rs2153535 0.58 rs9505457 ENSG00000230939.1 RP11-314C16.1 -5.82 1.12e-08 4.43e-06 -0.31 -0.26 Motion sickness; chr6:8478909 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2225765 ENSG00000230939.1 RP11-314C16.1 -5.82 1.12e-08 4.43e-06 -0.31 -0.26 Motion sickness; chr6:8481552 chr6:8784178~8785445:+ LUSC cis rs72627123 1 rs17093474 ENSG00000259065.1 RP5-1021I20.1 -5.82 1.12e-08 4.43e-06 -0.43 -0.26 Morning vs. evening chronotype; chr14:73875710 chr14:73787360~73803270:+ LUSC cis rs13113518 1 rs4865013 ENSG00000273257.1 RP11-177J6.1 5.82 1.12e-08 4.43e-06 0.33 0.26 Height; chr4:55559957 chr4:55387949~55388271:+ LUSC cis rs442309 0.783 rs224095 ENSG00000238280.1 RP11-436D10.3 -5.82 1.12e-08 4.44e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62782299 chr10:62793562~62805887:- LUSC cis rs66887589 0.967 rs1155577 ENSG00000245958.5 RP11-33B1.1 5.82 1.12e-08 4.44e-06 0.24 0.26 Diastolic blood pressure; chr4:119528655 chr4:119454791~119552025:+ LUSC cis rs6142102 0.961 rs4911390 ENSG00000275784.1 RP5-1125A11.6 -5.81 1.12e-08 4.44e-06 -0.3 -0.26 Skin pigmentation; chr20:33977401 chr20:33989480~33991818:- LUSC cis rs13113518 1 rs13108499 ENSG00000273257.1 RP11-177J6.1 5.81 1.12e-08 4.44e-06 0.33 0.26 Height; chr4:55526514 chr4:55387949~55388271:+ LUSC cis rs7772486 0.875 rs9403768 ENSG00000235652.6 RP11-545I5.3 5.81 1.12e-08 4.45e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146085322 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs6938972 ENSG00000235652.6 RP11-545I5.3 5.81 1.12e-08 4.45e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146089472 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs9403770 ENSG00000235652.6 RP11-545I5.3 5.81 1.12e-08 4.45e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146102198 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs11155452 ENSG00000235652.6 RP11-545I5.3 5.81 1.12e-08 4.45e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146103495 chr6:145799409~145886585:+ LUSC cis rs11971779 0.688 rs1862880 ENSG00000273391.1 RP11-634H22.1 5.81 1.12e-08 4.45e-06 0.3 0.26 Diisocyanate-induced asthma; chr7:139335354 chr7:139359032~139359566:- LUSC cis rs55692468 0.539 rs4664110 ENSG00000213197.3 AC012066.1 -5.81 1.12e-08 4.45e-06 -0.3 -0.26 Intraocular pressure; chr2:152461900 chr2:152389937~152390630:+ LUSC cis rs2337406 0.866 rs988131 ENSG00000254174.1 IGHV1-12 5.81 1.13e-08 4.45e-06 0.24 0.26 Alzheimer's disease (late onset); chr14:106776833 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs8005518 ENSG00000254174.1 IGHV1-12 5.81 1.13e-08 4.45e-06 0.24 0.26 Alzheimer's disease (late onset); chr14:106777009 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs57684263 ENSG00000254174.1 IGHV1-12 5.81 1.13e-08 4.45e-06 0.24 0.26 Alzheimer's disease (late onset); chr14:106777263 chr14:106122420~106122709:- LUSC cis rs270601 0.77 rs61352298 ENSG00000233006.5 AC034220.3 5.81 1.13e-08 4.46e-06 0.26 0.26 Acylcarnitine levels; chr5:132264896 chr5:132311285~132369916:- LUSC cis rs270601 0.739 rs1979981 ENSG00000233006.5 AC034220.3 5.81 1.13e-08 4.46e-06 0.26 0.26 Acylcarnitine levels; chr5:132266027 chr5:132311285~132369916:- LUSC cis rs2337406 0.714 rs117798641 ENSG00000254174.1 IGHV1-12 5.81 1.13e-08 4.46e-06 0.25 0.26 Alzheimer's disease (late onset); chr14:106777984 chr14:106122420~106122709:- LUSC cis rs16843372 0.562 rs10174267 ENSG00000251491.2 OR7E28P -5.81 1.13e-08 4.47e-06 -0.28 -0.26 Obesity-related traits; chr2:158824629 chr2:158862311~158863285:+ LUSC cis rs6570726 0.791 rs6923074 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145572196 chr6:145799409~145886585:+ LUSC cis rs6570726 0.755 rs2092296 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145572548 chr6:145799409~145886585:+ LUSC cis rs6570726 0.755 rs2092297 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145572629 chr6:145799409~145886585:+ LUSC cis rs6570726 0.755 rs2103633 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145572885 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs9373463 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145573626 chr6:145799409~145886585:+ LUSC cis rs6570726 0.764 rs9322028 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145574661 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs12205752 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145574982 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs9390336 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145575687 chr6:145799409~145886585:+ LUSC cis rs6570726 0.738 rs6925594 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145577318 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs11155432 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145577625 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs6913727 ENSG00000235652.6 RP11-545I5.3 5.81 1.13e-08 4.47e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145578690 chr6:145799409~145886585:+ LUSC cis rs1056107 0.933 rs10981354 ENSG00000225513.1 RP11-165N19.2 -5.81 1.13e-08 4.47e-06 -0.29 -0.26 Colorectal cancer; chr9:112308436 chr9:112173522~112173971:- LUSC cis rs11971779 0.938 rs11981688 ENSG00000273391.1 RP11-634H22.1 5.81 1.13e-08 4.47e-06 0.32 0.26 Diisocyanate-induced asthma; chr7:139404149 chr7:139359032~139359566:- LUSC cis rs442309 0.967 rs224031 ENSG00000238280.1 RP11-436D10.3 -5.81 1.13e-08 4.47e-06 -0.31 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62761596 chr10:62793562~62805887:- LUSC cis rs2274273 0.87 rs8013713 ENSG00000258413.1 RP11-665C16.6 5.81 1.13e-08 4.47e-06 0.31 0.26 Protein biomarker; chr14:55374534 chr14:55262767~55272075:- LUSC cis rs4718428 0.705 rs4717331 ENSG00000226824.5 RP4-756H11.3 -5.81 1.13e-08 4.47e-06 -0.35 -0.26 Corneal structure; chr7:66913899 chr7:66654538~66669855:+ LUSC cis rs11098499 0.644 rs28787668 ENSG00000250412.1 KLHL2P1 5.81 1.13e-08 4.48e-06 0.32 0.26 Corneal astigmatism; chr4:119633532 chr4:119334329~119378233:+ LUSC cis rs763121 0.925 rs5757251 ENSG00000273076.1 RP3-508I15.22 5.81 1.13e-08 4.48e-06 0.25 0.26 Menopause (age at onset); chr22:38704123 chr22:38743495~38743910:+ LUSC cis rs1056107 0.933 rs10739341 ENSG00000225513.1 RP11-165N19.2 -5.81 1.13e-08 4.48e-06 -0.28 -0.26 Colorectal cancer; chr9:112310497 chr9:112173522~112173971:- LUSC cis rs28830936 1 rs112896623 ENSG00000250379.1 RP11-23P13.4 5.81 1.13e-08 4.48e-06 0.28 0.26 Diastolic blood pressure; chr15:41709647 chr15:41825099~41827936:- LUSC cis rs13113518 0.966 rs1474271 ENSG00000273257.1 RP11-177J6.1 5.81 1.13e-08 4.48e-06 0.33 0.26 Height; chr4:55435912 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11937487 ENSG00000273257.1 RP11-177J6.1 5.81 1.13e-08 4.48e-06 0.33 0.26 Height; chr4:55436576 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs3805146 ENSG00000273257.1 RP11-177J6.1 5.81 1.13e-08 4.48e-06 0.33 0.26 Height; chr4:55436985 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11133378 ENSG00000273257.1 RP11-177J6.1 5.81 1.13e-08 4.48e-06 0.33 0.26 Height; chr4:55439472 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11942279 ENSG00000273257.1 RP11-177J6.1 5.81 1.13e-08 4.48e-06 0.33 0.26 Height; chr4:55439652 chr4:55387949~55388271:+ LUSC cis rs875971 0.54 rs781152 ENSG00000237310.1 GS1-124K5.4 5.81 1.13e-08 4.48e-06 0.27 0.26 Aortic root size; chr7:66014585 chr7:66493706~66495474:+ LUSC cis rs17711722 0.727 rs781151 ENSG00000237310.1 GS1-124K5.4 5.81 1.13e-08 4.48e-06 0.27 0.26 Calcium levels; chr7:66014891 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs6460276 ENSG00000224316.1 RP11-479O9.2 5.81 1.13e-08 4.48e-06 0.28 0.26 Aortic root size; chr7:66182290 chr7:65773620~65802067:+ LUSC cis rs5742933 0.557 rs1233276 ENSG00000253559.1 OSGEPL1-AS1 -5.81 1.13e-08 4.49e-06 -0.35 -0.26 Ferritin levels; chr2:189820056 chr2:189762704~189765556:+ LUSC cis rs9549367 0.756 rs9549702 ENSG00000269125.1 RP11-98F14.11 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Platelet distribution width; chr13:113227630 chr13:113165002~113165183:- LUSC cis rs875971 0.545 rs67775320 ENSG00000224316.1 RP11-479O9.2 5.81 1.14e-08 4.49e-06 0.28 0.26 Aortic root size; chr7:66193792 chr7:65773620~65802067:+ LUSC cis rs78487399 0.71 rs74382177 ENSG00000234936.1 AC010883.5 5.81 1.14e-08 4.49e-06 0.41 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43300918 chr2:43229573~43233394:+ LUSC cis rs9326248 0.581 rs11216267 ENSG00000280143.1 AP000892.6 5.81 1.14e-08 4.49e-06 0.27 0.26 Blood protein levels; chr11:117081676 chr11:117204967~117210292:+ LUSC cis rs8005677 1 rs2295685 ENSG00000279656.1 RP11-298I3.6 5.81 1.14e-08 4.49e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22928944 chr14:23023083~23024217:- LUSC cis rs11098499 0.644 rs7676296 ENSG00000250412.1 KLHL2P1 5.81 1.14e-08 4.49e-06 0.31 0.26 Corneal astigmatism; chr4:119634532 chr4:119334329~119378233:+ LUSC cis rs2153535 0.562 rs9379211 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8463694 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs965706 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8464475 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1335636 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8464814 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs986060 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8465195 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9393021 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8465890 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406161 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8465911 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9405390 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8465976 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9405391 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8466315 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406163 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8466409 chr6:8784178~8785445:+ LUSC cis rs2153535 0.504 rs9405393 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8467199 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2184584 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8468174 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs7774752 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8468745 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1034272 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8469102 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9505450 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8469669 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406164 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8469815 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7341201 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8470037 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7341206 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8470256 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7341383 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8470401 chr6:8784178~8785445:+ LUSC cis rs2153535 0.504 rs9328472 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8470615 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1414345 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8471304 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1414348 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8471707 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1414349 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8472057 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1414350 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8472098 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9392224 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8472381 chr6:8784178~8785445:+ LUSC cis rs2153535 0.542 rs9378553 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8472399 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs1855768 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8472736 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1932281 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8473532 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6900007 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8473802 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2184585 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8473935 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6902001 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8476822 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs4960423 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8476977 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1932282 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.49e-06 -0.31 -0.26 Motion sickness; chr6:8477097 chr6:8784178~8785445:+ LUSC cis rs62103177 0.608 rs34383580 ENSG00000261126.6 RP11-795F19.1 -5.81 1.14e-08 4.5e-06 -0.32 -0.26 Opioid sensitivity; chr18:80074960 chr18:80046900~80095482:+ LUSC cis rs62103177 0.608 rs551643 ENSG00000261126.6 RP11-795F19.1 -5.81 1.14e-08 4.5e-06 -0.32 -0.26 Opioid sensitivity; chr18:80081068 chr18:80046900~80095482:+ LUSC cis rs2153535 0.546 rs1335640 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.5e-06 -0.31 -0.26 Motion sickness; chr6:8485092 chr6:8784178~8785445:+ LUSC cis rs607541 1 rs675876 ENSG00000259520.4 CTD-2651B20.3 -5.81 1.14e-08 4.5e-06 -0.39 -0.26 Obesity-related traits; chr15:45644658 chr15:45251580~45279251:- LUSC cis rs607541 0.85 rs675890 ENSG00000259520.4 CTD-2651B20.3 -5.81 1.14e-08 4.5e-06 -0.39 -0.26 Obesity-related traits; chr15:45644666 chr15:45251580~45279251:- LUSC cis rs875971 0.545 rs12671152 ENSG00000237310.1 GS1-124K5.4 5.81 1.14e-08 4.5e-06 0.3 0.26 Aortic root size; chr7:66311140 chr7:66493706~66495474:+ LUSC cis rs2834288 0.959 rs2834294 ENSG00000273102.1 AP000569.9 -5.81 1.14e-08 4.5e-06 -0.28 -0.26 Gut microbiota (bacterial taxa); chr21:33908326 chr21:33967101~33968573:- LUSC cis rs2739330 0.732 rs5760175 ENSG00000228039.3 KB-1125A3.10 5.81 1.14e-08 4.5e-06 0.32 0.26 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23963780~23964374:+ LUSC cis rs2439831 0.702 rs16977724 ENSG00000249839.1 AC011330.5 -5.81 1.14e-08 4.51e-06 -0.55 -0.26 Lung cancer in ever smokers; chr15:43859101 chr15:43663654~43684339:- LUSC cis rs9549367 0.789 rs6577034 ENSG00000269125.1 RP11-98F14.11 -5.81 1.14e-08 4.51e-06 -0.31 -0.26 Platelet distribution width; chr13:113225586 chr13:113165002~113165183:- LUSC cis rs853679 1 rs6905391 ENSG00000204709.4 LINC01556 5.81 1.14e-08 4.51e-06 0.41 0.26 Depression; chr6:28294909 chr6:28943877~28944537:+ LUSC cis rs875971 1 rs6957199 ENSG00000179406.6 LINC00174 -5.81 1.14e-08 4.51e-06 -0.28 -0.26 Aortic root size; chr7:66513532 chr7:66376044~66401338:- LUSC cis rs28830936 1 rs17734856 ENSG00000250379.1 RP11-23P13.4 5.81 1.14e-08 4.51e-06 0.28 0.26 Diastolic blood pressure; chr15:41752962 chr15:41825099~41827936:- LUSC cis rs7181230 0.848 rs75509561 ENSG00000275636.1 RP11-521C20.5 5.81 1.14e-08 4.51e-06 0.33 0.26 Dehydroepiandrosterone sulphate levels; chr15:40041268 chr15:40078892~40079347:+ LUSC cis rs77204473 0.744 rs2301174 ENSG00000254851.1 RP11-109L13.1 5.81 1.14e-08 4.52e-06 0.6 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117192993 chr11:117135528~117138582:+ LUSC cis rs2153535 0.58 rs7341382 ENSG00000230939.1 RP11-314C16.1 -5.81 1.14e-08 4.52e-06 -0.31 -0.26 Motion sickness; chr6:8470316 chr6:8784178~8785445:+ LUSC cis rs6918586 0.658 rs198837 ENSG00000272462.2 U91328.19 5.81 1.14e-08 4.52e-06 0.27 0.26 Schizophrenia; chr6:26113170 chr6:25992662~26001775:+ LUSC cis rs13113518 0.966 rs13108409 ENSG00000249700.7 SRD5A3-AS1 5.81 1.15e-08 4.52e-06 0.3 0.26 Height; chr4:55520278 chr4:55363971~55395847:- LUSC cis rs11723261 0.621 rs3829 ENSG00000275426.1 CH17-262A2.1 5.81 1.15e-08 4.53e-06 0.43 0.26 Immune response to smallpox vaccine (IL-6); chr4:141070 chr4:149738~150317:+ LUSC cis rs2243480 1 rs56291018 ENSG00000226824.5 RP4-756H11.3 -5.81 1.15e-08 4.54e-06 -0.51 -0.26 Diabetic kidney disease; chr7:65925352 chr7:66654538~66669855:+ LUSC cis rs1823913 0.637 rs2356354 ENSG00000227542.1 AC092614.2 -5.81 1.15e-08 4.54e-06 -0.33 -0.26 Obesity-related traits; chr2:191270970 chr2:191229165~191246172:- LUSC cis rs228614 0.51 rs223438 ENSG00000248971.2 KRT8P46 5.81 1.15e-08 4.54e-06 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798584 chr4:102728746~102730171:- LUSC cis rs6969780 1 rs1801085 ENSG00000233429.8 HOTAIRM1 5.81 1.15e-08 4.54e-06 0.49 0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27128971 chr7:27095647~27100265:+ LUSC cis rs638893 1 rs583905 ENSG00000278376.1 RP11-158I9.8 -5.81 1.15e-08 4.55e-06 -0.33 -0.26 Vitiligo; chr11:118825199 chr11:118791254~118793137:+ LUSC cis rs2153535 0.58 rs7753192 ENSG00000230939.1 RP11-314C16.1 -5.81 1.15e-08 4.55e-06 -0.31 -0.26 Motion sickness; chr6:8482404 chr6:8784178~8785445:+ LUSC cis rs442309 1 rs224148 ENSG00000238280.1 RP11-436D10.3 -5.81 1.15e-08 4.55e-06 -0.31 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62726879 chr10:62793562~62805887:- LUSC cis rs17572109 0.666 rs4674297 ENSG00000261338.2 RP11-378A13.1 5.81 1.15e-08 4.55e-06 0.3 0.26 Platelet count;Platelet distribution width;Mean platelet volume; chr2:218364424 chr2:218255319~218257366:+ LUSC cis rs2276314 0.857 rs28791905 ENSG00000278986.1 RP11-723J4.3 -5.81 1.15e-08 4.56e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36022250 chr18:35972151~35973916:+ LUSC cis rs2136613 0.751 rs1509955 ENSG00000238280.1 RP11-436D10.3 -5.81 1.15e-08 4.56e-06 -0.33 -0.26 Selective IgA deficiency; chr10:62843559 chr10:62793562~62805887:- LUSC cis rs2276314 1 rs16967317 ENSG00000278986.1 RP11-723J4.3 -5.81 1.16e-08 4.56e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35993437 chr18:35972151~35973916:+ LUSC cis rs526231 0.578 rs6867392 ENSG00000175749.11 EIF3KP1 5.81 1.16e-08 4.57e-06 0.31 0.26 Primary biliary cholangitis; chr5:102946183 chr5:103032376~103033031:+ LUSC cis rs11951515 0.508 rs6860493 ENSG00000249286.1 CTD-2210P15.2 5.81 1.16e-08 4.58e-06 0.3 0.26 Metabolite levels (X-11787); chr5:43602611 chr5:43586918~43588223:- LUSC cis rs11023332 0.832 rs10832289 ENSG00000251991.1 RNU7-49P -5.81 1.16e-08 4.58e-06 -0.28 -0.26 Vitamin D levels;Adiponectin levels; chr11:14647950 chr11:14478892~14478953:+ LUSC cis rs227275 0.554 rs223409 ENSG00000246560.2 RP11-10L12.4 5.81 1.16e-08 4.58e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102815023 chr4:102828055~102844075:+ LUSC cis rs2562456 0.917 rs9304987 ENSG00000268081.1 RP11-678G14.2 -5.81 1.16e-08 4.58e-06 -0.36 -0.26 Pain; chr19:21499472 chr19:21554640~21569237:- LUSC cis rs6860806 0.507 rs274572 ENSG00000233006.5 AC034220.3 -5.81 1.16e-08 4.58e-06 -0.28 -0.26 Breast cancer; chr5:132375225 chr5:132311285~132369916:- LUSC cis rs9435732 1 rs9435732 ENSG00000235241.1 RP11-108M9.5 5.81 1.16e-08 4.59e-06 0.32 0.26 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:16981663 chr1:16889095~16889602:+ LUSC cis rs1729407 0.706 rs1268354 ENSG00000254851.1 RP11-109L13.1 -5.81 1.16e-08 4.59e-06 -0.31 -0.26 Apolipoprotein A-IV levels; chr11:116819862 chr11:117135528~117138582:+ LUSC cis rs4604732 0.588 rs9943231 ENSG00000227135.1 GCSAML-AS1 -5.81 1.16e-08 4.59e-06 -0.38 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247466527 chr1:247524679~247526752:- LUSC cis rs442309 0.749 rs224109 ENSG00000238280.1 RP11-436D10.3 -5.81 1.16e-08 4.59e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62790311 chr10:62793562~62805887:- LUSC cis rs9990333 1 rs9990333 ENSG00000252174.1 RNU7-18P 5.81 1.16e-08 4.59e-06 0.27 0.26 Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation); chr3:196100334 chr3:196072819~196072880:+ LUSC cis rs62103177 0.525 rs10438902 ENSG00000261126.6 RP11-795F19.1 -5.81 1.16e-08 4.59e-06 -0.32 -0.26 Opioid sensitivity; chr18:79985640 chr18:80046900~80095482:+ LUSC cis rs6918586 0.615 rs198841 ENSG00000272462.2 U91328.19 -5.81 1.16e-08 4.59e-06 -0.27 -0.26 Schizophrenia; chr6:26111443 chr6:25992662~26001775:+ LUSC cis rs17772222 0.682 rs28711639 ENSG00000258789.1 RP11-507K2.3 -5.81 1.17e-08 4.6e-06 -0.29 -0.26 Coronary artery calcification; chr14:88482277 chr14:88551597~88552493:+ LUSC cis rs1044826 0.518 rs295488 ENSG00000272656.1 RP11-219D15.3 5.81 1.17e-08 4.6e-06 0.29 0.26 Obesity-related traits; chr3:139520481 chr3:139349024~139349371:- LUSC cis rs77204473 0.744 rs2046150 ENSG00000254851.1 RP11-109L13.1 5.81 1.17e-08 4.6e-06 0.61 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117182717 chr11:117135528~117138582:+ LUSC cis rs1021993 0.597 rs10494921 ENSG00000231648.1 RP11-372M18.2 -5.81 1.17e-08 4.6e-06 -0.37 -0.26 Gut microbiome composition (winter); chr1:209340156 chr1:209367662~209379690:+ LUSC cis rs8005677 1 rs4982710 ENSG00000279656.1 RP11-298I3.6 5.81 1.17e-08 4.6e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22929693 chr14:23023083~23024217:- LUSC cis rs17270561 0.562 rs12199626 ENSG00000272810.1 U91328.22 -5.81 1.17e-08 4.6e-06 -0.36 -0.26 Iron status biomarkers; chr6:26013376 chr6:26013241~26013757:+ LUSC cis rs496547 0.719 rs598373 ENSG00000278376.1 RP11-158I9.8 -5.81 1.17e-08 4.6e-06 -0.24 -0.26 Hip minimal joint space width; chr11:118793668 chr11:118791254~118793137:+ LUSC cis rs11098499 0.954 rs10006877 ENSG00000248280.1 RP11-33B1.2 5.81 1.17e-08 4.6e-06 0.31 0.26 Corneal astigmatism; chr4:119321638 chr4:119440561~119450157:- LUSC cis rs7665090 1 rs735405 ENSG00000230069.3 LRRC37A15P -5.81 1.17e-08 4.61e-06 -0.26 -0.26 Primary biliary cholangitis; chr4:102632759 chr4:102727274~102730721:- LUSC cis rs73186030 0.546 rs55780469 ENSG00000272758.4 RP11-299J3.8 5.81 1.17e-08 4.61e-06 0.38 0.26 Serum parathyroid hormone levels; chr3:122388590 chr3:122416207~122443180:+ LUSC cis rs13113518 1 rs4865007 ENSG00000223305.1 RN7SKP30 -5.81 1.17e-08 4.62e-06 -0.31 -0.26 Height; chr4:55537550 chr4:55540502~55540835:- LUSC cis rs7665090 1 rs1077358 ENSG00000230069.3 LRRC37A15P -5.81 1.17e-08 4.62e-06 -0.26 -0.26 Primary biliary cholangitis; chr4:102632769 chr4:102727274~102730721:- LUSC cis rs7772486 0.681 rs9390343 ENSG00000235652.6 RP11-545I5.3 -5.81 1.17e-08 4.62e-06 -0.25 -0.26 Lobe attachment (rater-scored or self-reported); chr6:145689391 chr6:145799409~145886585:+ LUSC cis rs6860806 0.507 rs582490 ENSG00000233006.5 AC034220.3 -5.81 1.17e-08 4.62e-06 -0.28 -0.26 Breast cancer; chr5:132374403 chr5:132311285~132369916:- LUSC cis rs11089937 0.626 rs5757013 ENSG00000211638.2 IGLV8-61 -5.81 1.17e-08 4.62e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22135544 chr22:22098700~22099212:+ LUSC cis rs7189233 0.91 rs3809634 ENSG00000279344.1 RP11-44F14.7 5.81 1.17e-08 4.62e-06 0.23 0.26 Intelligence (multi-trait analysis); chr16:53504245 chr16:53478957~53481550:- LUSC cis rs2028299 0.879 rs3803534 ENSG00000259677.1 RP11-493E3.1 5.81 1.17e-08 4.63e-06 0.34 0.26 Type 2 diabetes; chr15:89898638 chr15:89876540~89877285:+ LUSC cis rs6570726 0.935 rs407721 ENSG00000235652.6 RP11-545I5.3 5.81 1.17e-08 4.63e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145550218 chr6:145799409~145886585:+ LUSC cis rs4664293 0.631 rs13019272 ENSG00000226266.5 AC009961.3 -5.81 1.17e-08 4.63e-06 -0.31 -0.26 Monocyte percentage of white cells; chr2:159802352 chr2:159670708~159712435:- LUSC cis rs1061377 1 rs1897136 ENSG00000249685.1 RP11-360F5.3 5.81 1.18e-08 4.63e-06 0.29 0.26 Uric acid levels; chr4:39131242 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs1897137 ENSG00000249685.1 RP11-360F5.3 5.81 1.18e-08 4.63e-06 0.29 0.26 Uric acid levels; chr4:39131387 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs35437629 ENSG00000249685.1 RP11-360F5.3 5.81 1.18e-08 4.63e-06 0.29 0.26 Uric acid levels; chr4:39131712 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs7657926 ENSG00000249685.1 RP11-360F5.3 5.81 1.18e-08 4.63e-06 0.29 0.26 Uric acid levels; chr4:39132443 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs7681116 ENSG00000249685.1 RP11-360F5.3 5.81 1.18e-08 4.63e-06 0.29 0.26 Uric acid levels; chr4:39133015 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs11096982 ENSG00000249685.1 RP11-360F5.3 5.81 1.18e-08 4.63e-06 0.29 0.26 Uric acid levels; chr4:39133247 chr4:39133913~39135608:+ LUSC cis rs1061377 1 rs11727875 ENSG00000249685.1 RP11-360F5.3 5.81 1.18e-08 4.63e-06 0.29 0.26 Uric acid levels; chr4:39133699 chr4:39133913~39135608:+ LUSC cis rs1061377 0.965 rs10018622 ENSG00000249685.1 RP11-360F5.3 5.81 1.18e-08 4.63e-06 0.29 0.26 Uric acid levels; chr4:39133944 chr4:39133913~39135608:+ LUSC cis rs2404602 0.735 rs12903874 ENSG00000259422.1 RP11-593F23.1 -5.81 1.18e-08 4.64e-06 -0.3 -0.26 Blood metabolite levels; chr15:76400977 chr15:76174891~76181486:- LUSC cis rs6570726 1 rs386678 ENSG00000235652.6 RP11-545I5.3 5.81 1.18e-08 4.64e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145547874 chr6:145799409~145886585:+ LUSC cis rs6772849 0.708 rs12491942 ENSG00000277250.1 Metazoa_SRP -5.81 1.18e-08 4.64e-06 -0.3 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128702626 chr3:128673681~128674021:- LUSC cis rs11159086 1 rs4903232 ENSG00000259005.1 RP3-449M8.6 5.81 1.18e-08 4.65e-06 0.39 0.26 Advanced glycation end-product levels; chr14:74496585 chr14:74474007~74474864:- LUSC cis rs67311347 1 rs4973997 ENSG00000223797.4 ENTPD3-AS1 5.81 1.18e-08 4.65e-06 0.29 0.26 Renal cell carcinoma; chr3:40418654 chr3:40313802~40453329:- LUSC cis rs1008375 1 rs2058338 ENSG00000249502.1 AC006160.5 5.81 1.18e-08 4.66e-06 0.26 0.26 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17676977 chr4:17587467~17614571:- LUSC cis rs9545047 0.604 rs9601217 ENSG00000227676.3 LINC01068 -5.81 1.18e-08 4.66e-06 -0.31 -0.26 Schizophrenia; chr13:79359797 chr13:79566727~79571436:+ LUSC cis rs2274273 0.837 rs10141552 ENSG00000258413.1 RP11-665C16.6 5.81 1.18e-08 4.67e-06 0.31 0.26 Protein biomarker; chr14:55279373 chr14:55262767~55272075:- LUSC cis rs801193 0.66 rs2659897 ENSG00000179406.6 LINC00174 5.81 1.18e-08 4.67e-06 0.28 0.26 Aortic root size; chr7:66722728 chr7:66376044~66401338:- LUSC cis rs61270009 0.955 rs2305104 ENSG00000247828.6 TMEM161B-AS1 -5.81 1.19e-08 4.67e-06 -0.29 -0.26 Depressive symptoms; chr5:88324853 chr5:88268895~88436685:+ LUSC cis rs113835537 0.866 rs59320108 ENSG00000255517.5 CTD-3074O7.5 -5.8 1.19e-08 4.68e-06 -0.35 -0.26 Airway imaging phenotypes; chr11:66598525 chr11:66473490~66480233:- LUSC cis rs67180937 0.553 rs11485123 ENSG00000272750.1 RP11-378J18.8 -5.8 1.19e-08 4.68e-06 -0.35 -0.26 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222704833 chr1:222658867~222661512:- LUSC cis rs3169166 0.5 rs3813575 ENSG00000259562.2 RP11-762H8.2 5.8 1.19e-08 4.68e-06 0.2 0.26 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78268400 chr15:78290527~78291221:- LUSC cis rs28830936 0.966 rs17733613 ENSG00000250379.1 RP11-23P13.4 5.8 1.19e-08 4.69e-06 0.28 0.26 Diastolic blood pressure; chr15:41625387 chr15:41825099~41827936:- LUSC cis rs875971 0.545 rs66594357 ENSG00000237310.1 GS1-124K5.4 5.8 1.19e-08 4.69e-06 0.29 0.26 Aortic root size; chr7:66327797 chr7:66493706~66495474:+ LUSC cis rs11159086 1 rs58384818 ENSG00000270000.1 RP3-449M8.9 5.8 1.19e-08 4.69e-06 0.41 0.26 Advanced glycation end-product levels; chr14:74487045 chr14:74471930~74472360:- LUSC cis rs11159086 1 rs17100588 ENSG00000270000.1 RP3-449M8.9 5.8 1.19e-08 4.69e-06 0.41 0.26 Advanced glycation end-product levels; chr14:74487624 chr14:74471930~74472360:- LUSC cis rs72627123 0.881 rs28548133 ENSG00000259065.1 RP5-1021I20.1 5.8 1.19e-08 4.69e-06 0.43 0.26 Morning vs. evening chronotype; chr14:73842451 chr14:73787360~73803270:+ LUSC cis rs6860806 0.507 rs156322 ENSG00000233006.5 AC034220.3 5.8 1.19e-08 4.69e-06 0.28 0.26 Breast cancer; chr5:132318232 chr5:132311285~132369916:- LUSC cis rs10759883 0.539 rs7847393 ENSG00000175611.10 LINC00476 5.8 1.19e-08 4.7e-06 0.31 0.26 Nicotine dependence; chr9:96033431 chr9:95759231~95875977:- LUSC cis rs875971 0.545 rs1547529 ENSG00000237310.1 GS1-124K5.4 5.8 1.19e-08 4.7e-06 0.29 0.26 Aortic root size; chr7:66258859 chr7:66493706~66495474:+ LUSC cis rs9549367 0.789 rs9549365 ENSG00000269125.1 RP11-98F14.11 5.8 1.19e-08 4.7e-06 0.31 0.26 Platelet distribution width; chr13:113253077 chr13:113165002~113165183:- LUSC cis rs11971779 0.838 rs11764161 ENSG00000273391.1 RP11-634H22.1 5.8 1.19e-08 4.7e-06 0.3 0.26 Diisocyanate-induced asthma; chr7:139430452 chr7:139359032~139359566:- LUSC cis rs7772486 0.875 rs6934467 ENSG00000235652.6 RP11-545I5.3 5.8 1.19e-08 4.7e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146089393 chr6:145799409~145886585:+ LUSC cis rs2439831 0.85 rs7168158 ENSG00000249839.1 AC011330.5 -5.8 1.19e-08 4.7e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43758178 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs7174208 ENSG00000249839.1 AC011330.5 -5.8 1.19e-08 4.7e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43760484 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs12101756 ENSG00000249839.1 AC011330.5 -5.8 1.19e-08 4.7e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43761689 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs12442129 ENSG00000249839.1 AC011330.5 -5.8 1.19e-08 4.7e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43763658 chr15:43663654~43684339:- LUSC cis rs2439831 0.702 rs7175032 ENSG00000249839.1 AC011330.5 -5.8 1.19e-08 4.7e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43768038 chr15:43663654~43684339:- LUSC cis rs1823913 0.637 rs979967 ENSG00000280083.1 RP11-317J9.1 -5.8 1.2e-08 4.71e-06 -0.3 -0.26 Obesity-related traits; chr2:191304695 chr2:191154118~191156070:- LUSC cis rs7267979 0.816 rs390123 ENSG00000274973.1 RP13-401N8.7 -5.8 1.2e-08 4.71e-06 -0.26 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25499469 chr20:25845497~25845862:+ LUSC cis rs7246657 0.722 rs2927742 ENSG00000276846.1 CTD-3220F14.3 -5.8 1.2e-08 4.72e-06 -0.39 -0.26 Coronary artery calcification; chr19:37642717 chr19:37314868~37315620:- LUSC cis rs875971 0.522 rs6960048 ENSG00000179406.6 LINC00174 -5.8 1.2e-08 4.72e-06 -0.27 -0.26 Aortic root size; chr7:65943052 chr7:66376044~66401338:- LUSC cis rs10800713 0.56 rs10800706 ENSG00000260088.1 RP11-92G12.3 -5.8 1.2e-08 4.73e-06 -0.41 -0.26 Tandem gait; chr1:200526967 chr1:200669507~200694250:+ LUSC cis rs72627123 1 rs7148538 ENSG00000259065.1 RP5-1021I20.1 -5.8 1.2e-08 4.73e-06 -0.44 -0.26 Morning vs. evening chronotype; chr14:73925639 chr14:73787360~73803270:+ LUSC cis rs4664293 0.51 rs72961735 ENSG00000226266.5 AC009961.3 5.8 1.2e-08 4.73e-06 0.31 0.26 Monocyte percentage of white cells; chr2:159708009 chr2:159670708~159712435:- LUSC cis rs6570726 0.967 rs450973 ENSG00000235652.6 RP11-545I5.3 5.8 1.2e-08 4.73e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145541929 chr6:145799409~145886585:+ LUSC cis rs442309 0.583 rs10995307 ENSG00000238280.1 RP11-436D10.3 5.8 1.2e-08 4.73e-06 0.31 0.26 Vogt-Koyanagi-Harada syndrome; chr10:62792482 chr10:62793562~62805887:- LUSC cis rs9322193 0.886 rs4039600 ENSG00000268592.3 RAET1E-AS1 5.8 1.2e-08 4.73e-06 0.33 0.26 Lung cancer; chr6:149576319 chr6:149863494~149919507:+ LUSC cis rs2562456 1 rs2562456 ENSG00000268081.1 RP11-678G14.2 5.8 1.2e-08 4.74e-06 0.35 0.26 Pain; chr19:21483408 chr19:21554640~21569237:- LUSC cis rs7826238 0.509 rs2948288 ENSG00000253893.2 FAM85B -5.8 1.21e-08 4.74e-06 -0.31 -0.26 Systolic blood pressure; chr8:8257782 chr8:8167819~8226614:- LUSC cis rs1322639 0.614 rs6908401 ENSG00000223485.1 RP11-417E7.1 5.8 1.21e-08 4.74e-06 0.34 0.26 Pulse pressure; chr6:169164621 chr6:169158092~169162924:- LUSC cis rs875971 1 rs1167411 ENSG00000179406.6 LINC00174 5.8 1.21e-08 4.75e-06 0.28 0.26 Aortic root size; chr7:66074277 chr7:66376044~66401338:- LUSC cis rs853679 1 rs9986596 ENSG00000204709.4 LINC01556 5.8 1.21e-08 4.75e-06 0.43 0.26 Depression; chr6:28251883 chr6:28943877~28944537:+ LUSC cis rs9506514 0.712 rs11838795 ENSG00000222726.1 RNU2-7P 5.8 1.21e-08 4.75e-06 0.28 0.26 Coronary artery calcification; chr13:20684189 chr13:20612161~20612338:+ LUSC cis rs6951245 1 rs2363286 ENSG00000224079.1 AC091729.7 -5.8 1.21e-08 4.75e-06 -0.42 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1051989 chr7:1074450~1078036:+ LUSC cis rs1345301 1 rs12470560 ENSG00000234389.1 AC007278.3 -5.8 1.21e-08 4.75e-06 -0.25 -0.26 Waist circumference; chr2:102252380 chr2:102438713~102440475:+ LUSC cis rs1345301 1 rs12474199 ENSG00000234389.1 AC007278.3 -5.8 1.21e-08 4.75e-06 -0.25 -0.26 Waist circumference; chr2:102252520 chr2:102438713~102440475:+ LUSC cis rs7911264 0.739 rs6583827 ENSG00000236493.2 EIF2S2P3 5.8 1.21e-08 4.75e-06 0.3 0.26 Inflammatory bowel disease; chr10:92598266 chr10:92668745~92669743:- LUSC cis rs7911264 0.739 rs7096101 ENSG00000236493.2 EIF2S2P3 5.8 1.21e-08 4.75e-06 0.3 0.26 Inflammatory bowel disease; chr10:92603171 chr10:92668745~92669743:- LUSC cis rs7911264 0.739 rs10786050 ENSG00000236493.2 EIF2S2P3 5.8 1.21e-08 4.75e-06 0.3 0.26 Inflammatory bowel disease; chr10:92607473 chr10:92668745~92669743:- LUSC cis rs28830936 0.966 rs4924576 ENSG00000250379.1 RP11-23P13.4 5.8 1.21e-08 4.76e-06 0.28 0.26 Diastolic blood pressure; chr15:41827395 chr15:41825099~41827936:- LUSC cis rs28830936 0.934 rs4923915 ENSG00000250379.1 RP11-23P13.4 5.8 1.21e-08 4.76e-06 0.28 0.26 Diastolic blood pressure; chr15:41827408 chr15:41825099~41827936:- LUSC cis rs66887589 0.967 rs13104219 ENSG00000249244.1 RP11-548H18.2 5.8 1.21e-08 4.76e-06 0.31 0.26 Diastolic blood pressure; chr4:119517019 chr4:119391831~119395335:- LUSC cis rs2439831 0.702 rs7171750 ENSG00000249839.1 AC011330.5 -5.8 1.21e-08 4.76e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43733660 chr15:43663654~43684339:- LUSC cis rs7246657 0.722 rs1291 ENSG00000276846.1 CTD-3220F14.3 -5.8 1.21e-08 4.77e-06 -0.39 -0.26 Coronary artery calcification; chr19:37738477 chr19:37314868~37315620:- LUSC cis rs13113518 0.966 rs7677952 ENSG00000273257.1 RP11-177J6.1 5.8 1.21e-08 4.77e-06 0.33 0.26 Height; chr4:55425312 chr4:55387949~55388271:+ LUSC cis rs4803480 0.935 rs9304595 ENSG00000270164.1 LINC01480 5.8 1.21e-08 4.77e-06 0.23 0.26 Schizophrenia; chr19:41571639 chr19:41535183~41536904:+ LUSC cis rs10759883 0.612 rs816675 ENSG00000175611.10 LINC00476 -5.8 1.21e-08 4.77e-06 -0.31 -0.26 Nicotine dependence; chr9:95806799 chr9:95759231~95875977:- LUSC cis rs10759883 0.627 rs816674 ENSG00000175611.10 LINC00476 -5.8 1.21e-08 4.77e-06 -0.31 -0.26 Nicotine dependence; chr9:95807835 chr9:95759231~95875977:- LUSC cis rs7615952 0.551 rs6438945 ENSG00000171084.14 FAM86JP 5.8 1.21e-08 4.77e-06 0.35 0.26 Blood pressure (smoking interaction); chr3:125915630 chr3:125916620~125930024:+ LUSC cis rs7615952 0.673 rs7632557 ENSG00000171084.14 FAM86JP 5.8 1.21e-08 4.77e-06 0.35 0.26 Blood pressure (smoking interaction); chr3:125916038 chr3:125916620~125930024:+ LUSC cis rs7615952 0.932 rs9841157 ENSG00000171084.14 FAM86JP 5.8 1.21e-08 4.77e-06 0.35 0.26 Blood pressure (smoking interaction); chr3:125916812 chr3:125916620~125930024:+ LUSC cis rs7615952 0.551 rs12695470 ENSG00000171084.14 FAM86JP 5.8 1.21e-08 4.77e-06 0.35 0.26 Blood pressure (smoking interaction); chr3:125916875 chr3:125916620~125930024:+ LUSC cis rs2439831 0.85 rs11070408 ENSG00000249839.1 AC011330.5 -5.8 1.22e-08 4.78e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43742590 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs28718261 ENSG00000249839.1 AC011330.5 -5.8 1.22e-08 4.78e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43751595 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs28595038 ENSG00000249839.1 AC011330.5 -5.8 1.22e-08 4.78e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43752661 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs10163054 ENSG00000249839.1 AC011330.5 -5.8 1.22e-08 4.78e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43755440 chr15:43663654~43684339:- LUSC cis rs13137105 0.72 rs3775531 ENSG00000250735.4 RP11-567N4.3 -5.8 1.22e-08 4.78e-06 -0.29 -0.26 Response to tocilizumab in rheumatoid arthritis; chr4:75482854 chr4:75401195~75423023:+ LUSC cis rs10759883 0.563 rs10819668 ENSG00000175611.10 LINC00476 5.8 1.22e-08 4.78e-06 0.3 0.26 Nicotine dependence; chr9:95959848 chr9:95759231~95875977:- LUSC cis rs4713118 0.588 rs200994 ENSG00000280107.1 AL022393.9 5.8 1.22e-08 4.79e-06 0.31 0.26 Parkinson's disease; chr6:27846035 chr6:28170845~28172521:+ LUSC cis rs2153535 0.58 rs4451187 ENSG00000230939.1 RP11-314C16.1 -5.8 1.22e-08 4.79e-06 -0.31 -0.26 Motion sickness; chr6:8473677 chr6:8784178~8785445:+ LUSC cis rs2153535 0.504 rs4493781 ENSG00000230939.1 RP11-314C16.1 -5.8 1.22e-08 4.79e-06 -0.31 -0.26 Motion sickness; chr6:8473708 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs5026687 ENSG00000230939.1 RP11-314C16.1 -5.8 1.22e-08 4.79e-06 -0.31 -0.26 Motion sickness; chr6:8473724 chr6:8784178~8785445:+ LUSC cis rs7246657 0.722 rs10402671 ENSG00000276846.1 CTD-3220F14.3 5.8 1.22e-08 4.79e-06 0.38 0.26 Coronary artery calcification; chr19:37626185 chr19:37314868~37315620:- LUSC cis rs875971 0.964 rs60193905 ENSG00000179406.6 LINC00174 -5.8 1.22e-08 4.79e-06 -0.28 -0.26 Aortic root size; chr7:66506273 chr7:66376044~66401338:- LUSC cis rs875971 0.929 rs10950041 ENSG00000179406.6 LINC00174 -5.8 1.22e-08 4.79e-06 -0.28 -0.26 Aortic root size; chr7:66508888 chr7:66376044~66401338:- LUSC cis rs875971 0.929 rs6970860 ENSG00000179406.6 LINC00174 -5.8 1.22e-08 4.79e-06 -0.28 -0.26 Aortic root size; chr7:66511647 chr7:66376044~66401338:- LUSC cis rs6142102 0.961 rs973409 ENSG00000275784.1 RP5-1125A11.6 -5.8 1.22e-08 4.8e-06 -0.3 -0.26 Skin pigmentation; chr20:33948558 chr20:33989480~33991818:- LUSC cis rs13113518 0.783 rs11943206 ENSG00000272969.1 RP11-528I4.2 5.8 1.22e-08 4.8e-06 0.29 0.26 Height; chr4:55570843 chr4:55547112~55547889:+ LUSC cis rs9640161 0.75 rs4395803 ENSG00000261305.1 RP4-584D14.7 5.8 1.22e-08 4.8e-06 0.38 0.26 Blood protein levels;Circulating chemerin levels; chr7:150328278 chr7:150341771~150342607:+ LUSC cis rs875971 0.522 rs781144 ENSG00000179406.6 LINC00174 -5.8 1.22e-08 4.8e-06 -0.28 -0.26 Aortic root size; chr7:65975357 chr7:66376044~66401338:- LUSC cis rs1823913 0.66 rs1454752 ENSG00000280083.1 RP11-317J9.1 5.8 1.22e-08 4.8e-06 0.31 0.26 Obesity-related traits; chr2:191298668 chr2:191154118~191156070:- LUSC cis rs6772849 0.896 rs9816260 ENSG00000277250.1 Metazoa_SRP -5.8 1.22e-08 4.81e-06 -0.29 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128633240 chr3:128673681~128674021:- LUSC cis rs10483853 0.525 rs10138789 ENSG00000258695.2 RP3-414A15.2 -5.8 1.22e-08 4.81e-06 -0.36 -0.26 Coronary artery calcification; chr14:73497574 chr14:73522878~73530610:+ LUSC cis rs732716 0.785 rs62130979 ENSG00000267769.1 CTB-50L17.9 -5.8 1.22e-08 4.81e-06 -0.31 -0.26 Mean corpuscular volume; chr19:4432447 chr19:4454014~4455286:+ LUSC cis rs875971 1 rs6945843 ENSG00000179406.6 LINC00174 5.8 1.22e-08 4.81e-06 0.28 0.26 Aortic root size; chr7:66269796 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs6970498 ENSG00000237310.1 GS1-124K5.4 5.8 1.23e-08 4.81e-06 0.3 0.26 Aortic root size; chr7:66275908 chr7:66493706~66495474:+ LUSC cis rs11098499 0.532 rs4504231 ENSG00000249244.1 RP11-548H18.2 5.8 1.23e-08 4.81e-06 0.33 0.26 Corneal astigmatism; chr4:119665736 chr4:119391831~119395335:- LUSC cis rs7712401 0.601 rs152039 ENSG00000263432.2 RN7SL689P 5.8 1.23e-08 4.81e-06 0.32 0.26 Mean platelet volume; chr5:122884970 chr5:123022487~123022783:- LUSC cis rs459571 0.916 rs467303 ENSG00000235106.7 LINC00094 5.8 1.23e-08 4.82e-06 0.29 0.26 Platelet distribution width; chr9:134039713 chr9:134025439~134034666:+ LUSC cis rs6504950 0.889 rs1484769 ENSG00000275710.1 RP11-257O5.4 -5.8 1.23e-08 4.82e-06 -0.31 -0.26 Breast cancer; chr17:55089290 chr17:54964474~54964679:+ LUSC cis rs9506514 0.722 rs10400670 ENSG00000222726.1 RNU2-7P 5.8 1.23e-08 4.82e-06 0.28 0.26 Coronary artery calcification; chr13:20679350 chr13:20612161~20612338:+ LUSC cis rs2337406 0.85 rs8014460 ENSG00000274576.2 IGHV2-70 -5.8 1.23e-08 4.83e-06 -0.28 -0.26 Alzheimer's disease (late onset); chr14:106697140 chr14:106770577~106771020:- LUSC cis rs17711722 0.701 rs781145 ENSG00000179406.6 LINC00174 -5.8 1.23e-08 4.83e-06 -0.27 -0.26 Calcium levels; chr7:65975383 chr7:66376044~66401338:- LUSC cis rs7208859 0.524 rs60114476 ENSG00000266490.1 CTD-2349P21.9 5.8 1.23e-08 4.84e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30792372~30792833:+ LUSC cis rs7208859 0.524 rs8065744 ENSG00000266490.1 CTD-2349P21.9 5.8 1.23e-08 4.84e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30792372~30792833:+ LUSC cis rs17826219 0.706 rs8071236 ENSG00000266490.1 CTD-2349P21.9 5.8 1.23e-08 4.84e-06 0.32 0.26 Body mass index; chr17:30772984 chr17:30792372~30792833:+ LUSC cis rs17826219 0.636 rs2449770 ENSG00000266490.1 CTD-2349P21.9 5.8 1.23e-08 4.84e-06 0.32 0.26 Body mass index; chr17:30774046 chr17:30792372~30792833:+ LUSC cis rs7208859 0.524 rs59913838 ENSG00000266490.1 CTD-2349P21.9 5.8 1.23e-08 4.84e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30792372~30792833:+ LUSC cis rs227275 0.554 rs223467 ENSG00000246560.2 RP11-10L12.4 5.8 1.23e-08 4.84e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102779721 chr4:102828055~102844075:+ LUSC cis rs2303759 0.676 rs7248378 ENSG00000268686.1 AC010524.2 -5.8 1.23e-08 4.85e-06 -0.34 -0.26 Multiple sclerosis; chr19:49404887 chr19:49368705~49388081:- LUSC cis rs7772486 0.875 rs9373485 ENSG00000235652.6 RP11-545I5.3 5.8 1.24e-08 4.85e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146080293 chr6:145799409~145886585:+ LUSC cis rs2028299 0.92 rs10852123 ENSG00000259677.1 RP11-493E3.1 5.8 1.24e-08 4.85e-06 0.34 0.26 Type 2 diabetes; chr15:89885662 chr15:89876540~89877285:+ LUSC cis rs12554020 0.681 rs75519210 ENSG00000227603.1 RP11-165J3.6 5.8 1.24e-08 4.85e-06 0.45 0.26 Schizophrenia; chr9:93661448 chr9:93435332~93437121:- LUSC cis rs801193 0.901 rs4273746 ENSG00000237310.1 GS1-124K5.4 -5.8 1.24e-08 4.85e-06 -0.27 -0.26 Aortic root size; chr7:66836124 chr7:66493706~66495474:+ LUSC cis rs9341835 0.741 rs6929702 ENSG00000218048.2 RP3-407E4.4 5.8 1.24e-08 4.86e-06 0.3 0.26 Schizophrenia; chr6:63434209 chr6:63440766~63443580:+ LUSC cis rs11723261 0.582 rs11735742 ENSG00000275426.1 CH17-262A2.1 -5.8 1.24e-08 4.86e-06 -0.38 -0.26 Immune response to smallpox vaccine (IL-6); chr4:148766 chr4:149738~150317:+ LUSC cis rs12468226 1 rs76284304 ENSG00000272966.1 RP11-686O6.1 5.8 1.24e-08 4.86e-06 0.42 0.26 Urate levels; chr2:202427116 chr2:202336739~202337200:+ LUSC cis rs801193 0.591 rs4506088 ENSG00000179406.6 LINC00174 5.8 1.24e-08 4.86e-06 0.28 0.26 Aortic root size; chr7:66670470 chr7:66376044~66401338:- LUSC cis rs131777 0.545 rs140514 ENSG00000205559.3 CHKB-AS1 -5.8 1.24e-08 4.86e-06 -0.32 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50580150 chr22:50583026~50583877:+ LUSC cis rs9611519 0.78 rs9611528 ENSG00000235513.1 RP4-756G23.5 5.8 1.24e-08 4.87e-06 0.29 0.26 Neuroticism; chr22:41252498 chr22:41209122~41217627:- LUSC cis rs2337406 0.789 rs60000589 ENSG00000280411.1 IGHV1-69-2 -5.8 1.24e-08 4.88e-06 -0.23 -0.26 Alzheimer's disease (late onset); chr14:106782459 chr14:106762092~106762588:- LUSC cis rs6951245 0.786 rs77943789 ENSG00000224079.1 AC091729.7 -5.8 1.24e-08 4.88e-06 -0.42 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1100522 chr7:1074450~1078036:+ LUSC cis rs6570726 0.791 rs1280276 ENSG00000235652.6 RP11-545I5.3 5.8 1.24e-08 4.88e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145571214 chr6:145799409~145886585:+ LUSC cis rs875971 1 rs709595 ENSG00000179406.6 LINC00174 -5.8 1.25e-08 4.88e-06 -0.28 -0.26 Aortic root size; chr7:66352346 chr7:66376044~66401338:- LUSC cis rs875971 1 rs811880 ENSG00000179406.6 LINC00174 -5.8 1.25e-08 4.88e-06 -0.28 -0.26 Aortic root size; chr7:66353659 chr7:66376044~66401338:- LUSC cis rs10027350 0.857 rs3796793 ENSG00000281501.1 SEPSECS-AS1 5.8 1.25e-08 4.88e-06 0.31 0.26 Childhood ear infection; chr4:25142945 chr4:25160641~25201440:+ LUSC cis rs2274273 0.84 rs6573013 ENSG00000258413.1 RP11-665C16.6 -5.8 1.25e-08 4.89e-06 -0.31 -0.26 Protein biomarker; chr14:55269155 chr14:55262767~55272075:- LUSC cis rs783540 0.869 rs783533 ENSG00000255769.6 GOLGA2P10 5.8 1.25e-08 4.89e-06 0.3 0.26 Schizophrenia; chr15:82581437 chr15:82472993~82513950:- LUSC cis rs763121 0.853 rs1056610 ENSG00000273076.1 RP3-508I15.22 -5.8 1.25e-08 4.89e-06 -0.25 -0.26 Menopause (age at onset); chr22:38684073 chr22:38743495~38743910:+ LUSC cis rs2243480 1 rs34560516 ENSG00000226824.5 RP4-756H11.3 -5.8 1.25e-08 4.9e-06 -0.5 -0.26 Diabetic kidney disease; chr7:65939105 chr7:66654538~66669855:+ LUSC cis rs1008375 0.966 rs3775927 ENSG00000249502.1 AC006160.5 -5.8 1.25e-08 4.9e-06 -0.26 -0.26 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17598271 chr4:17587467~17614571:- LUSC cis rs2524005 1 rs2524005 ENSG00000227766.1 HCG4P5 -5.8 1.25e-08 4.9e-06 -0.38 -0.26 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29942075~29943067:- LUSC cis rs2243480 1 rs316329 ENSG00000226824.5 RP4-756H11.3 -5.8 1.25e-08 4.9e-06 -0.48 -0.26 Diabetic kidney disease; chr7:66143429 chr7:66654538~66669855:+ LUSC cis rs7945705 0.791 rs6484484 ENSG00000254860.4 TMEM9B-AS1 -5.8 1.25e-08 4.91e-06 -0.28 -0.26 Hemoglobin concentration; chr11:8795659 chr11:8964675~8977527:+ LUSC cis rs6570726 0.818 rs437147 ENSG00000235652.6 RP11-545I5.3 5.8 1.25e-08 4.91e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145554287 chr6:145799409~145886585:+ LUSC cis rs875971 0.54 rs35510581 ENSG00000222364.1 RNU6-96P 5.8 1.25e-08 4.91e-06 0.3 0.26 Aortic root size; chr7:66113790 chr7:66395191~66395286:+ LUSC cis rs9326248 0.559 rs12808524 ENSG00000280143.1 AP000892.6 5.8 1.25e-08 4.91e-06 0.27 0.26 Blood protein levels; chr11:117020277 chr11:117204967~117210292:+ LUSC cis rs1729407 0.786 rs5096 ENSG00000254851.1 RP11-109L13.1 -5.79 1.25e-08 4.91e-06 -0.31 -0.26 Apolipoprotein A-IV levels; chr11:116822379 chr11:117135528~117138582:+ LUSC cis rs853679 0.76 rs11962305 ENSG00000204709.4 LINC01556 5.79 1.25e-08 4.92e-06 0.39 0.26 Depression; chr6:28232159 chr6:28943877~28944537:+ LUSC cis rs17270561 0.609 rs9358887 ENSG00000272462.2 U91328.19 -5.79 1.26e-08 4.92e-06 -0.3 -0.26 Iron status biomarkers; chr6:25759178 chr6:25992662~26001775:+ LUSC cis rs875971 0.545 rs75840613 ENSG00000224316.1 RP11-479O9.2 5.79 1.26e-08 4.92e-06 0.28 0.26 Aortic root size; chr7:66376399 chr7:65773620~65802067:+ LUSC cis rs11098499 0.644 rs17517414 ENSG00000249244.1 RP11-548H18.2 5.79 1.26e-08 4.93e-06 0.32 0.26 Corneal astigmatism; chr4:119340946 chr4:119391831~119395335:- LUSC cis rs66887589 0.967 rs7678973 ENSG00000245958.5 RP11-33B1.1 5.79 1.26e-08 4.93e-06 0.24 0.26 Diastolic blood pressure; chr4:119590662 chr4:119454791~119552025:+ LUSC cis rs442309 0.846 rs224131 ENSG00000238280.1 RP11-436D10.3 -5.79 1.26e-08 4.94e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62705334 chr10:62793562~62805887:- LUSC cis rs35160687 0.644 rs4832036 ENSG00000273080.1 RP11-301O19.1 -5.79 1.26e-08 4.94e-06 -0.25 -0.26 Night sleep phenotypes; chr2:86324179 chr2:86195590~86196049:+ LUSC cis rs35160687 0.644 rs4610056 ENSG00000273080.1 RP11-301O19.1 -5.79 1.26e-08 4.94e-06 -0.25 -0.26 Night sleep phenotypes; chr2:86326127 chr2:86195590~86196049:+ LUSC cis rs35160687 0.644 rs7595785 ENSG00000273080.1 RP11-301O19.1 -5.79 1.26e-08 4.94e-06 -0.25 -0.26 Night sleep phenotypes; chr2:86329282 chr2:86195590~86196049:+ LUSC cis rs11089937 0.626 rs10483106 ENSG00000211639.2 IGLV4-60 5.79 1.26e-08 4.94e-06 0.31 0.26 Periodontitis (PAL4Q3); chr22:22149240 chr22:22162199~22162681:+ LUSC cis rs72627123 1 rs2302139 ENSG00000259065.1 RP5-1021I20.1 -5.79 1.26e-08 4.94e-06 -0.43 -0.26 Morning vs. evening chronotype; chr14:73896232 chr14:73787360~73803270:+ LUSC cis rs34375054 0.624 rs73233307 ENSG00000279233.1 RP11-158L12.4 5.79 1.26e-08 4.95e-06 0.26 0.26 Post bronchodilator FEV1/FVC ratio; chr12:125191327 chr12:125138245~125141711:+ LUSC cis rs34375054 0.624 rs12580033 ENSG00000279233.1 RP11-158L12.4 5.79 1.26e-08 4.95e-06 0.26 0.26 Post bronchodilator FEV1/FVC ratio; chr12:125191537 chr12:125138245~125141711:+ LUSC cis rs11098499 0.57 rs6832740 ENSG00000250412.1 KLHL2P1 5.79 1.26e-08 4.95e-06 0.31 0.26 Corneal astigmatism; chr4:119624981 chr4:119334329~119378233:+ LUSC cis rs11098499 0.644 rs6855918 ENSG00000250412.1 KLHL2P1 5.79 1.26e-08 4.95e-06 0.31 0.26 Corneal astigmatism; chr4:119625144 chr4:119334329~119378233:+ LUSC cis rs8177876 0.658 rs12456 ENSG00000261838.4 RP11-303E16.6 5.79 1.26e-08 4.95e-06 0.57 0.26 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81031454 chr16:81069854~81076598:+ LUSC cis rs4722166 0.63 rs13311155 ENSG00000179428.2 AC073072.5 -5.79 1.26e-08 4.95e-06 -0.32 -0.26 Lung cancer; chr7:22750170 chr7:22725395~22727620:- LUSC cis rs4722166 0.63 rs13311199 ENSG00000179428.2 AC073072.5 -5.79 1.26e-08 4.95e-06 -0.32 -0.26 Lung cancer; chr7:22750174 chr7:22725395~22727620:- LUSC cis rs7665090 1 rs4579121 ENSG00000230069.3 LRRC37A15P -5.79 1.27e-08 4.96e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102637012 chr4:102727274~102730721:- LUSC cis rs7665090 0.934 rs6533020 ENSG00000230069.3 LRRC37A15P -5.79 1.27e-08 4.96e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102637648 chr4:102727274~102730721:- LUSC cis rs7665090 0.934 rs6533021 ENSG00000230069.3 LRRC37A15P -5.79 1.27e-08 4.96e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102637696 chr4:102727274~102730721:- LUSC cis rs6928977 0.66 rs9373131 ENSG00000234084.1 RP3-388E23.2 5.79 1.27e-08 4.97e-06 0.2 0.26 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135478786 chr6:135301568~135307158:+ LUSC cis rs73173548 0.502 rs13185071 ENSG00000247828.6 TMEM161B-AS1 5.79 1.27e-08 4.97e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88429895 chr5:88268895~88436685:+ LUSC cis rs73173548 0.502 rs4601863 ENSG00000247828.6 TMEM161B-AS1 5.79 1.27e-08 4.97e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88433804 chr5:88268895~88436685:+ LUSC cis rs8005677 0.828 rs35085068 ENSG00000279656.1 RP11-298I3.6 5.79 1.27e-08 4.97e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22940700 chr14:23023083~23024217:- LUSC cis rs8005677 0.828 rs57822749 ENSG00000279656.1 RP11-298I3.6 5.79 1.27e-08 4.97e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22940758 chr14:23023083~23024217:- LUSC cis rs2337406 0.866 rs8003852 ENSG00000254174.1 IGHV1-12 5.79 1.27e-08 4.97e-06 0.24 0.26 Alzheimer's disease (late onset); chr14:106776648 chr14:106122420~106122709:- LUSC cis rs3738443 0.868 rs60698393 ENSG00000259865.1 RP11-488L18.10 5.79 1.27e-08 4.97e-06 0.28 0.26 Alcohol dependence; chr1:247198135 chr1:247187281~247188526:- LUSC cis rs875971 0.545 rs4441996 ENSG00000237310.1 GS1-124K5.4 -5.79 1.27e-08 4.97e-06 -0.29 -0.26 Aortic root size; chr7:66123233 chr7:66493706~66495474:+ LUSC cis rs11157436 0.581 rs17255433 ENSG00000211813.2 TRAV34 5.79 1.27e-08 4.98e-06 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22167051 chr14:22207522~22208129:+ LUSC cis rs11157436 0.602 rs17255440 ENSG00000211813.2 TRAV34 5.79 1.27e-08 4.98e-06 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22167297 chr14:22207522~22208129:+ LUSC cis rs6918586 0.681 rs198831 ENSG00000272462.2 U91328.19 -5.79 1.27e-08 4.98e-06 -0.27 -0.26 Schizophrenia; chr6:26116768 chr6:25992662~26001775:+ LUSC cis rs2842992 0.789 rs6908680 ENSG00000237927.1 RP3-393E18.2 -5.79 1.27e-08 4.98e-06 -0.39 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159797177 chr6:159586955~159589169:- LUSC cis rs73186030 0.546 rs73188320 ENSG00000272758.4 RP11-299J3.8 5.79 1.27e-08 4.99e-06 0.38 0.26 Serum parathyroid hormone levels; chr3:122391694 chr3:122416207~122443180:+ LUSC cis rs875971 0.545 rs4718325 ENSG00000237310.1 GS1-124K5.4 5.79 1.27e-08 4.99e-06 0.3 0.26 Aortic root size; chr7:66215323 chr7:66493706~66495474:+ LUSC cis rs61270009 0.955 rs410354 ENSG00000247828.6 TMEM161B-AS1 -5.79 1.27e-08 4.99e-06 -0.29 -0.26 Depressive symptoms; chr5:88254467 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs780404 ENSG00000247828.6 TMEM161B-AS1 -5.79 1.27e-08 4.99e-06 -0.29 -0.26 Depressive symptoms; chr5:88256675 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs375514 ENSG00000247828.6 TMEM161B-AS1 -5.79 1.27e-08 4.99e-06 -0.29 -0.26 Depressive symptoms; chr5:88259477 chr5:88268895~88436685:+ LUSC cis rs113835537 0.877 rs77239910 ENSG00000255517.5 CTD-3074O7.5 -5.79 1.28e-08 5e-06 -0.35 -0.26 Airway imaging phenotypes; chr11:66562168 chr11:66473490~66480233:- LUSC cis rs13113518 0.783 rs7690837 ENSG00000273257.1 RP11-177J6.1 5.79 1.28e-08 5e-06 0.33 0.26 Height; chr4:55575856 chr4:55387949~55388271:+ LUSC cis rs2153535 0.58 rs2327062 ENSG00000230939.1 RP11-314C16.1 -5.79 1.28e-08 5e-06 -0.31 -0.26 Motion sickness; chr6:8453625 chr6:8784178~8785445:+ LUSC cis rs6504950 0.85 rs11079143 ENSG00000275710.1 RP11-257O5.4 -5.79 1.28e-08 5.01e-06 -0.32 -0.26 Breast cancer; chr17:55005761 chr17:54964474~54964679:+ LUSC cis rs8059260 0.736 rs79361721 ENSG00000274038.1 RP11-66H6.4 -5.79 1.28e-08 5.01e-06 -0.49 -0.26 Alcohol consumption over the past year; chr16:10968082 chr16:11056556~11057034:+ LUSC cis rs2243480 1 rs316313 ENSG00000226824.5 RP4-756H11.3 -5.79 1.28e-08 5.01e-06 -0.49 -0.26 Diabetic kidney disease; chr7:66128561 chr7:66654538~66669855:+ LUSC cis rs9910055 0.762 rs7213436 ENSG00000267080.4 ASB16-AS1 5.79 1.28e-08 5.01e-06 0.24 0.26 Total body bone mineral density; chr17:44174795 chr17:44175973~44186717:- LUSC cis rs7772486 0.875 rs9390377 ENSG00000235652.6 RP11-545I5.3 5.79 1.28e-08 5.01e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146065796 chr6:145799409~145886585:+ LUSC cis rs4713118 0.513 rs149942 ENSG00000216901.1 AL022393.7 5.79 1.28e-08 5.01e-06 0.3 0.26 Parkinson's disease; chr6:28033832 chr6:28176188~28176674:+ LUSC cis rs4713118 0.513 rs149945 ENSG00000216901.1 AL022393.7 5.79 1.28e-08 5.01e-06 0.3 0.26 Parkinson's disease; chr6:28035075 chr6:28176188~28176674:+ LUSC cis rs2276314 0.857 rs59649576 ENSG00000278986.1 RP11-723J4.3 -5.79 1.28e-08 5.02e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36036112 chr18:35972151~35973916:+ LUSC cis rs7665090 1 rs2866413 ENSG00000230069.3 LRRC37A15P -5.79 1.28e-08 5.02e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102635920 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs4547797 ENSG00000230069.3 LRRC37A15P -5.79 1.28e-08 5.02e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102636035 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs2866414 ENSG00000230069.3 LRRC37A15P -5.79 1.28e-08 5.02e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102636062 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs2903283 ENSG00000230069.3 LRRC37A15P -5.79 1.28e-08 5.02e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102636596 chr4:102727274~102730721:- LUSC cis rs442309 0.846 rs224130 ENSG00000238280.1 RP11-436D10.3 -5.79 1.28e-08 5.02e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62705211 chr10:62793562~62805887:- LUSC cis rs172166 0.637 rs1233708 ENSG00000219392.1 RP1-265C24.5 -5.79 1.28e-08 5.02e-06 -0.33 -0.26 Cardiac Troponin-T levels; chr6:28205441 chr6:28115628~28116551:+ LUSC cis rs6683071 0.688 rs2936049 ENSG00000272750.1 RP11-378J18.8 5.79 1.29e-08 5.03e-06 0.35 0.26 Cognitive performance; chr1:222684825 chr1:222658867~222661512:- LUSC cis rs910316 0.737 rs175084 ENSG00000279594.1 RP11-950C14.10 -5.79 1.29e-08 5.03e-06 -0.3 -0.26 Height; chr14:75052472 chr14:75011269~75012851:- LUSC cis rs12922040 0.701 rs12149912 ENSG00000263335.1 AF001548.5 -5.79 1.29e-08 5.03e-06 -0.32 -0.26 Serum uric acid levels in response to allopurinol in gout; chr16:15774798 chr16:15726674~15732993:+ LUSC cis rs853679 0.545 rs35949109 ENSG00000204709.4 LINC01556 5.79 1.29e-08 5.03e-06 0.46 0.26 Depression; chr6:28058148 chr6:28943877~28944537:+ LUSC cis rs2243480 1 rs56016656 ENSG00000226824.5 RP4-756H11.3 -5.79 1.29e-08 5.04e-06 -0.51 -0.26 Diabetic kidney disease; chr7:65918494 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs36033484 ENSG00000226824.5 RP4-756H11.3 -5.79 1.29e-08 5.04e-06 -0.51 -0.26 Diabetic kidney disease; chr7:65925571 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs34193460 ENSG00000226824.5 RP4-756H11.3 -5.79 1.29e-08 5.04e-06 -0.51 -0.26 Diabetic kidney disease; chr7:65928123 chr7:66654538~66669855:+ LUSC cis rs6570726 1 rs951143 ENSG00000235652.6 RP11-545I5.3 5.79 1.29e-08 5.04e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145611440 chr6:145799409~145886585:+ LUSC cis rs17270561 0.636 rs9348696 ENSG00000272462.2 U91328.19 -5.79 1.29e-08 5.04e-06 -0.3 -0.26 Iron status biomarkers; chr6:25781710 chr6:25992662~26001775:+ LUSC cis rs2179367 0.632 rs9285520 ENSG00000231760.4 RP11-350J20.5 -5.79 1.29e-08 5.05e-06 -0.36 -0.26 Dupuytren's disease; chr6:149372001 chr6:149796151~149826294:- LUSC cis rs9341835 0.74 rs4710255 ENSG00000218048.2 RP3-407E4.4 5.79 1.29e-08 5.05e-06 0.3 0.26 Schizophrenia; chr6:63446363 chr6:63440766~63443580:+ LUSC cis rs11971779 0.752 rs4732371 ENSG00000273391.1 RP11-634H22.1 5.79 1.29e-08 5.05e-06 0.28 0.26 Diisocyanate-induced asthma; chr7:139392571 chr7:139359032~139359566:- LUSC cis rs801193 0.569 rs4717315 ENSG00000179406.6 LINC00174 -5.79 1.3e-08 5.07e-06 -0.28 -0.26 Aortic root size; chr7:66713338 chr7:66376044~66401338:- LUSC cis rs28830936 1 rs28754734 ENSG00000250379.1 RP11-23P13.4 5.79 1.3e-08 5.07e-06 0.28 0.26 Diastolic blood pressure; chr15:41800954 chr15:41825099~41827936:- LUSC cis rs28830936 1 rs11632424 ENSG00000250379.1 RP11-23P13.4 5.79 1.3e-08 5.07e-06 0.28 0.26 Diastolic blood pressure; chr15:41803153 chr15:41825099~41827936:- LUSC cis rs1021993 0.545 rs17014370 ENSG00000231648.1 RP11-372M18.2 -5.79 1.3e-08 5.07e-06 -0.37 -0.26 Gut microbiome composition (winter); chr1:209366746 chr1:209367662~209379690:+ LUSC cis rs66887589 0.774 rs9307477 ENSG00000248280.1 RP11-33B1.2 5.79 1.3e-08 5.08e-06 0.29 0.26 Diastolic blood pressure; chr4:119500654 chr4:119440561~119450157:- LUSC cis rs9322193 1 rs9399693 ENSG00000268592.3 RAET1E-AS1 5.79 1.3e-08 5.08e-06 0.33 0.26 Lung cancer; chr6:149612718 chr6:149863494~149919507:+ LUSC cis rs9326248 0.603 rs7396061 ENSG00000280143.1 AP000892.6 5.79 1.3e-08 5.08e-06 0.26 0.26 Blood protein levels; chr11:116880158 chr11:117204967~117210292:+ LUSC cis rs801193 0.935 rs3800820 ENSG00000222364.1 RNU6-96P 5.79 1.3e-08 5.08e-06 0.3 0.26 Aortic root size; chr7:66682191 chr7:66395191~66395286:+ LUSC cis rs2439831 0.702 rs9989313 ENSG00000249839.1 AC011330.5 -5.79 1.3e-08 5.08e-06 -0.53 -0.26 Lung cancer in ever smokers; chr15:43860619 chr15:43663654~43684339:- LUSC cis rs11159086 1 rs3759745 ENSG00000270000.1 RP3-449M8.9 5.79 1.3e-08 5.09e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74495967 chr14:74471930~74472360:- LUSC cis rs442309 0.812 rs224135 ENSG00000238280.1 RP11-436D10.3 -5.79 1.3e-08 5.09e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62707042 chr10:62793562~62805887:- LUSC cis rs71403859 0.502 rs35394108 ENSG00000260886.1 TAT-AS1 5.79 1.3e-08 5.09e-06 0.39 0.26 Post bronchodilator FEV1; chr16:71506736 chr16:71565789~71578187:+ LUSC cis rs66887589 0.934 rs12648182 ENSG00000248280.1 RP11-33B1.2 -5.79 1.31e-08 5.1e-06 -0.28 -0.26 Diastolic blood pressure; chr4:119582736 chr4:119440561~119450157:- LUSC cis rs11208659 1 rs12135802 ENSG00000224570.1 RP11-430H12.2 -5.79 1.31e-08 5.1e-06 -0.61 -0.26 Obesity (early onset extreme); chr1:65526457 chr1:65576129~65578380:- LUSC cis rs9341835 0.709 rs9359467 ENSG00000218048.2 RP3-407E4.4 5.79 1.31e-08 5.1e-06 0.3 0.26 Schizophrenia; chr6:63445070 chr6:63440766~63443580:+ LUSC cis rs2562456 0.792 rs2562398 ENSG00000268081.1 RP11-678G14.2 -5.79 1.31e-08 5.1e-06 -0.37 -0.26 Pain; chr19:21540147 chr19:21554640~21569237:- LUSC cis rs2153535 0.546 rs9378559 ENSG00000230939.1 RP11-314C16.1 -5.79 1.31e-08 5.11e-06 -0.31 -0.26 Motion sickness; chr6:8538825 chr6:8784178~8785445:+ LUSC cis rs7208859 0.623 rs8082537 ENSG00000263603.1 CTD-2349P21.5 -5.79 1.31e-08 5.11e-06 -0.35 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30688914 chr17:30729469~30731202:+ LUSC cis rs6502050 0.835 rs4789754 ENSG00000266654.1 RP11-1376P16.1 -5.79 1.31e-08 5.11e-06 -0.25 -0.26 Life satisfaction; chr17:82134065 chr17:82160056~82160452:+ LUSC cis rs13113518 0.934 rs11133397 ENSG00000223305.1 RN7SKP30 5.79 1.31e-08 5.11e-06 0.31 0.26 Height; chr4:55534166 chr4:55540502~55540835:- LUSC cis rs13113518 0.934 rs11133398 ENSG00000223305.1 RN7SKP30 5.79 1.31e-08 5.11e-06 0.31 0.26 Height; chr4:55534180 chr4:55540502~55540835:- LUSC cis rs875971 0.522 rs709604 ENSG00000179406.6 LINC00174 5.79 1.31e-08 5.11e-06 0.27 0.26 Aortic root size; chr7:66032447 chr7:66376044~66401338:- LUSC cis rs7246657 0.722 rs2291002 ENSG00000276846.1 CTD-3220F14.3 5.79 1.31e-08 5.11e-06 0.38 0.26 Coronary artery calcification; chr19:37543024 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs10404031 ENSG00000276846.1 CTD-3220F14.3 5.79 1.31e-08 5.11e-06 0.38 0.26 Coronary artery calcification; chr19:37545052 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs10406379 ENSG00000276846.1 CTD-3220F14.3 5.79 1.31e-08 5.11e-06 0.38 0.26 Coronary artery calcification; chr19:37545823 chr19:37314868~37315620:- LUSC cis rs3738443 0.868 rs61840048 ENSG00000259865.1 RP11-488L18.10 5.79 1.31e-08 5.11e-06 0.27 0.26 Alcohol dependence; chr1:247199829 chr1:247187281~247188526:- LUSC cis rs66887589 1 rs66887589 ENSG00000249244.1 RP11-548H18.2 -5.79 1.31e-08 5.12e-06 -0.31 -0.26 Diastolic blood pressure; chr4:119588124 chr4:119391831~119395335:- LUSC cis rs1056107 0.931 rs7027240 ENSG00000225513.1 RP11-165N19.2 -5.79 1.31e-08 5.12e-06 -0.29 -0.26 Colorectal cancer; chr9:112258733 chr9:112173522~112173971:- LUSC cis rs875971 0.545 rs73148639 ENSG00000224316.1 RP11-479O9.2 5.79 1.31e-08 5.12e-06 0.28 0.26 Aortic root size; chr7:66390342 chr7:65773620~65802067:+ LUSC cis rs8005677 0.798 rs4982713 ENSG00000279656.1 RP11-298I3.6 5.79 1.31e-08 5.12e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22934893 chr14:23023083~23024217:- LUSC cis rs8005677 0.798 rs35615180 ENSG00000279656.1 RP11-298I3.6 5.79 1.31e-08 5.12e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22935180 chr14:23023083~23024217:- LUSC cis rs2153535 0.58 rs1932284 ENSG00000230939.1 RP11-314C16.1 -5.79 1.31e-08 5.12e-06 -0.31 -0.26 Motion sickness; chr6:8477461 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1932285 ENSG00000230939.1 RP11-314C16.1 -5.79 1.31e-08 5.12e-06 -0.31 -0.26 Motion sickness; chr6:8477486 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7775909 ENSG00000230939.1 RP11-314C16.1 -5.79 1.31e-08 5.12e-06 -0.31 -0.26 Motion sickness; chr6:8477545 chr6:8784178~8785445:+ LUSC cis rs6860806 0.507 rs273915 ENSG00000233006.5 AC034220.3 5.79 1.31e-08 5.13e-06 0.27 0.26 Breast cancer; chr5:132324426 chr5:132311285~132369916:- LUSC cis rs12439619 0.921 rs56042848 ENSG00000276710.3 CSPG4P8 -5.79 1.31e-08 5.13e-06 -0.29 -0.26 Intelligence (multi-trait analysis); chr15:82235244 chr15:82459472~82477258:+ LUSC cis rs6928977 0.675 rs7750586 ENSG00000234084.1 RP3-388E23.2 5.79 1.31e-08 5.13e-06 0.21 0.26 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135506535 chr6:135301568~135307158:+ LUSC cis rs673078 0.66 rs17440433 ENSG00000275759.1 RP11-131L12.3 -5.79 1.32e-08 5.14e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118201507 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs17512219 ENSG00000275759.1 RP11-131L12.3 -5.79 1.32e-08 5.14e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118211468 chr12:118428281~118428870:+ LUSC cis rs6142102 0.923 rs4911383 ENSG00000275784.1 RP5-1125A11.6 -5.79 1.32e-08 5.14e-06 -0.3 -0.26 Skin pigmentation; chr20:33967973 chr20:33989480~33991818:- LUSC cis rs67180937 0.542 rs61824282 ENSG00000272750.1 RP11-378J18.8 -5.79 1.32e-08 5.14e-06 -0.26 -0.26 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222647869 chr1:222658867~222661512:- LUSC cis rs2732480 0.5 rs2450986 ENSG00000273765.1 RP11-370I10.11 5.79 1.32e-08 5.15e-06 0.3 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48267905 chr12:48360920~48361377:+ LUSC cis rs1387259 0.929 rs2634666 ENSG00000273765.1 RP11-370I10.11 5.79 1.32e-08 5.15e-06 0.3 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48269887 chr12:48360920~48361377:+ LUSC cis rs1387259 0.929 rs2956703 ENSG00000273765.1 RP11-370I10.11 5.79 1.32e-08 5.15e-06 0.3 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48276511 chr12:48360920~48361377:+ LUSC cis rs1387259 0.931 rs1107654 ENSG00000273765.1 RP11-370I10.11 5.79 1.32e-08 5.15e-06 0.3 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48287314 chr12:48360920~48361377:+ LUSC cis rs2439831 0.85 rs61390361 ENSG00000249839.1 AC011330.5 -5.79 1.32e-08 5.15e-06 -0.54 -0.26 Lung cancer in ever smokers; chr15:43867644 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs11856795 ENSG00000249839.1 AC011330.5 -5.79 1.32e-08 5.15e-06 -0.54 -0.26 Lung cancer in ever smokers; chr15:43868384 chr15:43663654~43684339:- LUSC cis rs2136613 0.751 rs10995328 ENSG00000238280.1 RP11-436D10.3 -5.79 1.32e-08 5.16e-06 -0.32 -0.26 Selective IgA deficiency; chr10:62842848 chr10:62793562~62805887:- LUSC cis rs11159086 1 rs17100451 ENSG00000259005.1 RP3-449M8.6 5.79 1.32e-08 5.16e-06 0.39 0.26 Advanced glycation end-product levels; chr14:74476210 chr14:74474007~74474864:- LUSC cis rs10759883 0.563 rs623438 ENSG00000175611.10 LINC00476 5.79 1.32e-08 5.16e-06 0.31 0.26 Nicotine dependence; chr9:95938114 chr9:95759231~95875977:- LUSC cis rs11690935 0.921 rs7594711 ENSG00000228389.1 AC068039.4 5.79 1.32e-08 5.16e-06 0.3 0.26 Schizophrenia; chr2:172030734 chr2:171773482~171775844:+ LUSC cis rs1075265 0.563 rs2692536 ENSG00000233266.1 HMGB1P31 5.79 1.32e-08 5.17e-06 0.32 0.26 Chronotype;Morning vs. evening chronotype; chr2:53788266 chr2:54051334~54051760:+ LUSC cis rs13113518 0.967 rs4340844 ENSG00000273257.1 RP11-177J6.1 5.79 1.32e-08 5.17e-06 0.33 0.26 Height; chr4:55462689 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs1522112 ENSG00000273257.1 RP11-177J6.1 5.79 1.32e-08 5.17e-06 0.33 0.26 Height; chr4:55463606 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs4864997 ENSG00000273257.1 RP11-177J6.1 5.79 1.32e-08 5.17e-06 0.33 0.26 Height; chr4:55466010 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs960152 ENSG00000273257.1 RP11-177J6.1 5.79 1.32e-08 5.17e-06 0.33 0.26 Height; chr4:55467308 chr4:55387949~55388271:+ LUSC cis rs13113518 0.967 rs12644948 ENSG00000273257.1 RP11-177J6.1 5.79 1.32e-08 5.17e-06 0.33 0.26 Height; chr4:55470266 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs3805151 ENSG00000273257.1 RP11-177J6.1 5.79 1.32e-08 5.17e-06 0.33 0.26 Height; chr4:55470874 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs13118237 ENSG00000273257.1 RP11-177J6.1 5.79 1.32e-08 5.17e-06 0.33 0.26 Height; chr4:55474259 chr4:55387949~55388271:+ LUSC cis rs2153535 0.58 rs1932280 ENSG00000230939.1 RP11-314C16.1 -5.79 1.32e-08 5.17e-06 -0.31 -0.26 Motion sickness; chr6:8473421 chr6:8784178~8785445:+ LUSC cis rs875971 0.505 rs2462573 ENSG00000222364.1 RNU6-96P 5.78 1.33e-08 5.17e-06 0.3 0.26 Aortic root size; chr7:66042405 chr7:66395191~66395286:+ LUSC cis rs7181230 0.848 rs7497289 ENSG00000275636.1 RP11-521C20.5 5.78 1.33e-08 5.18e-06 0.33 0.26 Dehydroepiandrosterone sulphate levels; chr15:40041456 chr15:40078892~40079347:+ LUSC cis rs7181230 0.848 rs1010879 ENSG00000275636.1 RP11-521C20.5 5.78 1.33e-08 5.18e-06 0.33 0.26 Dehydroepiandrosterone sulphate levels; chr15:40041714 chr15:40078892~40079347:+ LUSC cis rs783540 1 rs11631963 ENSG00000276710.3 CSPG4P8 -5.78 1.33e-08 5.18e-06 -0.27 -0.26 Schizophrenia; chr15:82649451 chr15:82459472~82477258:+ LUSC cis rs12468226 1 rs2350809 ENSG00000272966.1 RP11-686O6.1 5.78 1.33e-08 5.18e-06 0.42 0.26 Urate levels; chr2:202464210 chr2:202336739~202337200:+ LUSC cis rs8031584 0.918 rs3817498 ENSG00000260382.1 RP11-540B6.2 5.78 1.33e-08 5.19e-06 0.36 0.26 Huntington's disease progression; chr15:30976578 chr15:30882267~30883231:- LUSC cis rs442309 0.846 rs224145 ENSG00000238280.1 RP11-436D10.3 -5.78 1.33e-08 5.19e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62718695 chr10:62793562~62805887:- LUSC cis rs2153535 0.58 rs6938071 ENSG00000230939.1 RP11-314C16.1 -5.78 1.33e-08 5.19e-06 -0.31 -0.26 Motion sickness; chr6:8464612 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs9406160 ENSG00000230939.1 RP11-314C16.1 -5.78 1.33e-08 5.19e-06 -0.31 -0.26 Motion sickness; chr6:8464674 chr6:8784178~8785445:+ LUSC cis rs8059260 0.668 rs7206753 ENSG00000274038.1 RP11-66H6.4 -5.78 1.33e-08 5.2e-06 -0.41 -0.26 Alcohol consumption over the past year; chr16:10974987 chr16:11056556~11057034:+ LUSC cis rs442309 0.846 rs224133 ENSG00000238280.1 RP11-436D10.3 -5.78 1.33e-08 5.2e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62706743 chr10:62793562~62805887:- LUSC cis rs442309 0.819 rs224134 ENSG00000238280.1 RP11-436D10.3 -5.78 1.33e-08 5.2e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62706867 chr10:62793562~62805887:- LUSC cis rs7772486 0.846 rs9403767 ENSG00000235652.6 RP11-545I5.3 5.78 1.33e-08 5.2e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146081250 chr6:145799409~145886585:+ LUSC cis rs2153535 0.58 rs2327061 ENSG00000230939.1 RP11-314C16.1 -5.78 1.33e-08 5.2e-06 -0.3 -0.26 Motion sickness; chr6:8446998 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7453115 ENSG00000230939.1 RP11-314C16.1 -5.78 1.33e-08 5.2e-06 -0.3 -0.26 Motion sickness; chr6:8447028 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6910742 ENSG00000230939.1 RP11-314C16.1 -5.78 1.33e-08 5.2e-06 -0.3 -0.26 Motion sickness; chr6:8448095 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7767780 ENSG00000230939.1 RP11-314C16.1 -5.78 1.33e-08 5.2e-06 -0.3 -0.26 Motion sickness; chr6:8453229 chr6:8784178~8785445:+ LUSC cis rs73186030 0.546 rs55857899 ENSG00000272758.4 RP11-299J3.8 5.78 1.34e-08 5.2e-06 0.38 0.26 Serum parathyroid hormone levels; chr3:122390705 chr3:122416207~122443180:+ LUSC cis rs2243480 0.803 rs55700941 ENSG00000226824.5 RP4-756H11.3 -5.78 1.34e-08 5.21e-06 -0.51 -0.26 Diabetic kidney disease; chr7:65924813 chr7:66654538~66669855:+ LUSC cis rs228614 0.51 rs170565 ENSG00000246560.2 RP11-10L12.4 5.78 1.34e-08 5.21e-06 0.31 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798277 chr4:102828055~102844075:+ LUSC cis rs11089937 0.626 rs4820337 ENSG00000211638.2 IGLV8-61 5.78 1.34e-08 5.22e-06 0.27 0.26 Periodontitis (PAL4Q3); chr22:22164374 chr22:22098700~22099212:+ LUSC cis rs2408955 0.561 rs11168365 ENSG00000240399.1 RP1-228P16.1 -5.78 1.34e-08 5.22e-06 -0.26 -0.26 Glycated hemoglobin levels; chr12:48027989 chr12:48054813~48055591:- LUSC cis rs16843372 0.599 rs10182297 ENSG00000251491.2 OR7E28P -5.78 1.34e-08 5.23e-06 -0.28 -0.26 Obesity-related traits; chr2:158822240 chr2:158862311~158863285:+ LUSC cis rs16843372 0.599 rs10184861 ENSG00000251491.2 OR7E28P -5.78 1.34e-08 5.23e-06 -0.28 -0.26 Obesity-related traits; chr2:158822249 chr2:158862311~158863285:+ LUSC cis rs801193 0.569 rs6978178 ENSG00000179406.6 LINC00174 5.78 1.34e-08 5.23e-06 0.28 0.26 Aortic root size; chr7:66658097 chr7:66376044~66401338:- LUSC cis rs8005677 1 rs8006409 ENSG00000279656.1 RP11-298I3.6 5.78 1.34e-08 5.24e-06 0.3 0.26 Cognitive ability (multi-trait analysis); chr14:22927302 chr14:23023083~23024217:- LUSC cis rs7772486 0.817 rs12198065 ENSG00000235652.6 RP11-545I5.3 5.78 1.34e-08 5.24e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146064150 chr6:145799409~145886585:+ LUSC cis rs8177876 0.584 rs2549899 ENSG00000261838.4 RP11-303E16.6 -5.78 1.35e-08 5.24e-06 -0.51 -0.26 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81055267 chr16:81069854~81076598:+ LUSC cis rs6918586 0.658 rs198813 ENSG00000272462.2 U91328.19 -5.78 1.35e-08 5.24e-06 -0.27 -0.26 Schizophrenia; chr6:26127998 chr6:25992662~26001775:+ LUSC cis rs673078 0.66 rs16948234 ENSG00000275759.1 RP11-131L12.3 5.78 1.35e-08 5.24e-06 0.38 0.26 Glucose homeostasis traits; chr12:118282464 chr12:118428281~118428870:+ LUSC cis rs13113518 0.678 rs13149568 ENSG00000273257.1 RP11-177J6.1 5.78 1.35e-08 5.25e-06 0.33 0.26 Height; chr4:55370412 chr4:55387949~55388271:+ LUSC cis rs10129255 0.536 rs6576201 ENSG00000224373.3 IGHV4-59 -5.78 1.35e-08 5.25e-06 -0.13 -0.26 Kawasaki disease; chr14:106683696 chr14:106627249~106627825:- LUSC cis rs17772222 0.682 rs10132554 ENSG00000258789.1 RP11-507K2.3 -5.78 1.35e-08 5.25e-06 -0.28 -0.26 Coronary artery calcification; chr14:88473090 chr14:88551597~88552493:+ LUSC cis rs2337406 0.706 rs74090742 ENSG00000274576.2 IGHV2-70 -5.78 1.35e-08 5.25e-06 -0.28 -0.26 Alzheimer's disease (late onset); chr14:106696601 chr14:106770577~106771020:- LUSC cis rs8059260 1 rs8057540 ENSG00000274038.1 RP11-66H6.4 -5.78 1.35e-08 5.25e-06 -0.42 -0.26 Alcohol consumption over the past year; chr16:10951985 chr16:11056556~11057034:+ LUSC cis rs875971 0.545 rs73142233 ENSG00000237310.1 GS1-124K5.4 5.78 1.35e-08 5.26e-06 0.3 0.26 Aortic root size; chr7:66221293 chr7:66493706~66495474:+ LUSC cis rs2834288 0.7 rs11088263 ENSG00000273102.1 AP000569.9 -5.78 1.35e-08 5.26e-06 -0.3 -0.26 Gut microbiota (bacterial taxa); chr21:33918486 chr21:33967101~33968573:- LUSC cis rs2153535 0.542 rs915354 ENSG00000230939.1 RP11-314C16.1 -5.78 1.35e-08 5.26e-06 -0.31 -0.26 Motion sickness; chr6:8440124 chr6:8784178~8785445:+ LUSC cis rs9322193 0.887 rs11155662 ENSG00000268592.3 RAET1E-AS1 5.78 1.35e-08 5.26e-06 0.34 0.26 Lung cancer; chr6:149592731 chr6:149863494~149919507:+ LUSC cis rs11690935 0.918 rs12692978 ENSG00000228389.1 AC068039.4 5.78 1.35e-08 5.26e-06 0.31 0.26 Schizophrenia; chr2:171869471 chr2:171773482~171775844:+ LUSC cis rs2842992 0.83 rs2758313 ENSG00000237927.1 RP3-393E18.2 -5.78 1.35e-08 5.27e-06 -0.37 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159733067 chr6:159586955~159589169:- LUSC cis rs2276314 1 rs4573997 ENSG00000278986.1 RP11-723J4.3 -5.78 1.36e-08 5.28e-06 -0.32 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35972605 chr18:35972151~35973916:+ LUSC cis rs8040855 0.627 rs17540307 ENSG00000259295.5 CSPG4P12 5.78 1.36e-08 5.29e-06 0.33 0.26 Bulimia nervosa; chr15:85090614 chr15:85191438~85213905:+ LUSC cis rs2243480 1 rs466983 ENSG00000226824.5 RP4-756H11.3 -5.78 1.36e-08 5.29e-06 -0.51 -0.26 Diabetic kidney disease; chr7:66055509 chr7:66654538~66669855:+ LUSC cis rs13113518 1 rs10462032 ENSG00000249700.7 SRD5A3-AS1 5.78 1.36e-08 5.29e-06 0.3 0.26 Height; chr4:55479069 chr4:55363971~55395847:- LUSC cis rs227275 0.554 rs223424 ENSG00000246560.2 RP11-10L12.4 5.78 1.36e-08 5.3e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102804177 chr4:102828055~102844075:+ LUSC cis rs227275 0.524 rs223423 ENSG00000246560.2 RP11-10L12.4 5.78 1.36e-08 5.3e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102804737 chr4:102828055~102844075:+ LUSC cis rs7665090 1 rs6810869 ENSG00000230069.3 LRRC37A15P -5.78 1.36e-08 5.3e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102637357 chr4:102727274~102730721:- LUSC cis rs7772486 0.846 rs2748499 ENSG00000235652.6 RP11-545I5.3 5.78 1.36e-08 5.3e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145993866 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs2748498 ENSG00000235652.6 RP11-545I5.3 5.78 1.36e-08 5.3e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145998030 chr6:145799409~145886585:+ LUSC cis rs6772849 0.93 rs7639400 ENSG00000277250.1 Metazoa_SRP -5.78 1.36e-08 5.3e-06 -0.28 -0.26 Monocyte percentage of white cells;Monocyte count; chr3:128604513 chr3:128673681~128674021:- LUSC cis rs77972916 0.561 rs13411629 ENSG00000234936.1 AC010883.5 5.78 1.36e-08 5.3e-06 0.35 0.26 Granulocyte percentage of myeloid white cells; chr2:43339851 chr2:43229573~43233394:+ LUSC cis rs875971 0.867 rs1002053 ENSG00000179406.6 LINC00174 5.78 1.36e-08 5.31e-06 0.28 0.26 Aortic root size; chr7:66333558 chr7:66376044~66401338:- LUSC cis rs875971 1 rs6460292 ENSG00000179406.6 LINC00174 5.78 1.36e-08 5.31e-06 0.28 0.26 Aortic root size; chr7:66345088 chr7:66376044~66401338:- LUSC cis rs875971 0.505 rs1723275 ENSG00000222364.1 RNU6-96P 5.78 1.36e-08 5.31e-06 0.3 0.26 Aortic root size; chr7:66039646 chr7:66395191~66395286:+ LUSC cis rs6504622 0.875 rs3851786 ENSG00000262879.4 RP11-156P1.3 5.78 1.37e-08 5.32e-06 0.27 0.26 Orofacial clefts; chr17:46969566 chr17:46984045~47100323:- LUSC cis rs61270009 0.863 rs35339529 ENSG00000247828.6 TMEM161B-AS1 5.78 1.37e-08 5.32e-06 0.3 0.26 Depressive symptoms; chr5:88360284 chr5:88268895~88436685:+ LUSC cis rs642803 0.591 rs620088 ENSG00000255557.1 RP11-770G2.2 -5.78 1.37e-08 5.32e-06 -0.32 -0.26 Urate levels; chr11:65741515 chr11:65745729~65771585:+ LUSC cis rs12554020 0.504 rs74369348 ENSG00000227603.1 RP11-165J3.6 5.78 1.37e-08 5.32e-06 0.45 0.26 Schizophrenia; chr9:93664902 chr9:93435332~93437121:- LUSC cis rs12554020 0.582 rs76863038 ENSG00000227603.1 RP11-165J3.6 5.78 1.37e-08 5.32e-06 0.45 0.26 Schizophrenia; chr9:93666143 chr9:93435332~93437121:- LUSC cis rs12554020 0.582 rs56310424 ENSG00000227603.1 RP11-165J3.6 5.78 1.37e-08 5.32e-06 0.45 0.26 Schizophrenia; chr9:93666313 chr9:93435332~93437121:- LUSC cis rs12554020 0.504 rs12551694 ENSG00000227603.1 RP11-165J3.6 5.78 1.37e-08 5.32e-06 0.45 0.26 Schizophrenia; chr9:93666619 chr9:93435332~93437121:- LUSC cis rs228614 0.51 rs150893 ENSG00000246560.2 RP11-10L12.4 -5.78 1.37e-08 5.33e-06 -0.31 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102817075 chr4:102828055~102844075:+ LUSC cis rs881375 0.678 rs10118357 ENSG00000226752.6 PSMD5-AS1 -5.78 1.37e-08 5.33e-06 -0.28 -0.26 Rheumatoid arthritis; chr9:120917790 chr9:120824828~120854385:+ LUSC cis rs7246657 0.722 rs10417576 ENSG00000276846.1 CTD-3220F14.3 5.78 1.37e-08 5.34e-06 0.38 0.26 Coronary artery calcification; chr19:37628311 chr19:37314868~37315620:- LUSC cis rs2834288 0.7 rs2834298 ENSG00000273102.1 AP000569.9 -5.78 1.37e-08 5.34e-06 -0.29 -0.26 Gut microbiota (bacterial taxa); chr21:33911251 chr21:33967101~33968573:- LUSC cis rs801193 0.548 rs2659891 ENSG00000179406.6 LINC00174 -5.78 1.37e-08 5.34e-06 -0.28 -0.26 Aortic root size; chr7:66736127 chr7:66376044~66401338:- LUSC cis rs801193 0.548 rs7805152 ENSG00000179406.6 LINC00174 -5.78 1.37e-08 5.34e-06 -0.28 -0.26 Aortic root size; chr7:66744266 chr7:66376044~66401338:- LUSC cis rs13113518 1 rs10462032 ENSG00000273257.1 RP11-177J6.1 5.78 1.38e-08 5.36e-06 0.33 0.26 Height; chr4:55479069 chr4:55387949~55388271:+ LUSC cis rs35160687 0.712 rs12052607 ENSG00000273080.1 RP11-301O19.1 -5.78 1.38e-08 5.36e-06 -0.24 -0.26 Night sleep phenotypes; chr2:86279394 chr2:86195590~86196049:+ LUSC cis rs35160687 0.712 rs1863059 ENSG00000273080.1 RP11-301O19.1 -5.78 1.38e-08 5.36e-06 -0.24 -0.26 Night sleep phenotypes; chr2:86282265 chr2:86195590~86196049:+ LUSC cis rs801193 0.569 rs13226966 ENSG00000179406.6 LINC00174 -5.78 1.38e-08 5.37e-06 -0.28 -0.26 Aortic root size; chr7:66768636 chr7:66376044~66401338:- LUSC cis rs10759883 0.539 rs10988817 ENSG00000175611.10 LINC00476 5.78 1.38e-08 5.37e-06 0.3 0.26 Nicotine dependence; chr9:95960364 chr9:95759231~95875977:- LUSC cis rs853679 0.517 rs4713146 ENSG00000280107.1 AL022393.9 -5.78 1.38e-08 5.37e-06 -0.33 -0.26 Depression; chr6:28143758 chr6:28170845~28172521:+ LUSC cis rs853679 0.517 rs9393894 ENSG00000280107.1 AL022393.9 -5.78 1.38e-08 5.37e-06 -0.33 -0.26 Depression; chr6:28144784 chr6:28170845~28172521:+ LUSC cis rs6714900 0.53 rs13010446 ENSG00000234896.1 OR7E62P -5.78 1.38e-08 5.37e-06 -0.35 -0.26 Blood protein levels; chr2:71063957 chr2:71055527~71056003:+ LUSC cis rs763121 0.925 rs1056661 ENSG00000273076.1 RP3-508I15.22 5.78 1.38e-08 5.38e-06 0.24 0.26 Menopause (age at onset); chr22:38684240 chr22:38743495~38743910:+ LUSC cis rs988913 0.706 rs1155749 ENSG00000224984.1 RP11-524H19.2 5.78 1.38e-08 5.38e-06 0.27 0.26 Menarche (age at onset); chr6:54865585 chr6:54840118~54840855:- LUSC cis rs11690935 0.885 rs6752812 ENSG00000228389.1 AC068039.4 5.78 1.38e-08 5.38e-06 0.3 0.26 Schizophrenia; chr2:171986588 chr2:171773482~171775844:+ LUSC cis rs17507216 1 rs17507216 ENSG00000276710.3 CSPG4P8 5.78 1.38e-08 5.38e-06 0.31 0.26 Excessive daytime sleepiness; chr15:82558175 chr15:82459472~82477258:+ LUSC cis rs853679 0.517 rs2281588 ENSG00000280107.1 AL022393.9 -5.78 1.39e-08 5.39e-06 -0.33 -0.26 Depression; chr6:28104824 chr6:28170845~28172521:+ LUSC cis rs9813712 0.571 rs9866568 ENSG00000228252.7 COL6A4P2 -5.78 1.39e-08 5.39e-06 -0.25 -0.26 Response to amphetamines; chr3:130297539 chr3:130212823~130273806:+ LUSC cis rs6142102 0.961 rs6088360 ENSG00000275784.1 RP5-1125A11.6 -5.78 1.39e-08 5.39e-06 -0.3 -0.26 Skin pigmentation; chr20:33969383 chr20:33989480~33991818:- LUSC cis rs8059260 0.877 rs6498146 ENSG00000274038.1 RP11-66H6.4 5.78 1.39e-08 5.39e-06 0.37 0.26 Alcohol consumption over the past year; chr16:11012850 chr16:11056556~11057034:+ LUSC cis rs6969780 0.632 rs11762730 ENSG00000233429.8 HOTAIRM1 -5.78 1.39e-08 5.4e-06 -0.39 -0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27150779 chr7:27095647~27100265:+ LUSC cis rs875971 0.862 rs6945775 ENSG00000179406.6 LINC00174 -5.78 1.39e-08 5.4e-06 -0.28 -0.26 Aortic root size; chr7:66503987 chr7:66376044~66401338:- LUSC cis rs28830936 0.966 rs62002090 ENSG00000250379.1 RP11-23P13.4 5.78 1.39e-08 5.4e-06 0.28 0.26 Diastolic blood pressure; chr15:41800128 chr15:41825099~41827936:- LUSC cis rs673078 0.66 rs61945212 ENSG00000275759.1 RP11-131L12.3 -5.78 1.39e-08 5.41e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118252351 chr12:118428281~118428870:+ LUSC cis rs7829975 0.514 rs2979151 ENSG00000253893.2 FAM85B 5.78 1.39e-08 5.41e-06 0.3 0.26 Mood instability; chr8:8400509 chr8:8167819~8226614:- LUSC cis rs11846409 0.86 rs59055020 ENSG00000274576.2 IGHV2-70 -5.78 1.39e-08 5.41e-06 -0.26 -0.26 Rheumatic heart disease; chr14:106631573 chr14:106770577~106771020:- LUSC cis rs8177876 0.749 rs10459872 ENSG00000261838.4 RP11-303E16.6 -5.78 1.39e-08 5.42e-06 -0.54 -0.26 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81061346 chr16:81069854~81076598:+ LUSC cis rs875971 0.862 rs10274883 ENSG00000179406.6 LINC00174 5.78 1.39e-08 5.42e-06 0.28 0.26 Aortic root size; chr7:66651104 chr7:66376044~66401338:- LUSC cis rs889398 0.967 rs7359336 ENSG00000226232.7 RP11-419C5.2 -5.78 1.4e-08 5.42e-06 -0.25 -0.26 Body mass index; chr16:69699557 chr16:69976388~69996188:- LUSC cis rs11971779 0.793 rs11764426 ENSG00000273391.1 RP11-634H22.1 5.78 1.4e-08 5.42e-06 0.29 0.26 Diisocyanate-induced asthma; chr7:139339304 chr7:139359032~139359566:- LUSC cis rs2439831 0.85 rs7169988 ENSG00000249839.1 AC011330.5 -5.78 1.4e-08 5.43e-06 -0.51 -0.26 Lung cancer in ever smokers; chr15:43768237 chr15:43663654~43684339:- LUSC cis rs801193 1 rs17566701 ENSG00000224316.1 RP11-479O9.2 5.78 1.4e-08 5.43e-06 0.25 0.26 Aortic root size; chr7:66728196 chr7:65773620~65802067:+ LUSC cis rs9326248 0.581 rs7120515 ENSG00000280143.1 AP000892.6 5.78 1.4e-08 5.43e-06 0.27 0.26 Blood protein levels; chr11:117121210 chr11:117204967~117210292:+ LUSC cis rs950169 0.509 rs71395455 ENSG00000225151.9 GOLGA2P7 -5.78 1.4e-08 5.43e-06 -0.36 -0.26 Schizophrenia; chr15:84610573 chr15:84199311~84230136:- LUSC cis rs853679 1 rs1419183 ENSG00000219392.1 RP1-265C24.5 -5.78 1.4e-08 5.43e-06 -0.41 -0.26 Depression; chr6:28275017 chr6:28115628~28116551:+ LUSC cis rs36423 0.748 rs36401 ENSG00000266869.1 RP6-114E22.1 -5.77 1.4e-08 5.44e-06 -0.4 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71893031 chr14:71848606~71908430:+ LUSC cis rs3750965 0.575 rs3892895 ENSG00000260895.1 RP11-554A11.7 -5.77 1.4e-08 5.44e-06 -0.29 -0.26 Hair color; chr11:69117287 chr11:69103493~69109094:+ LUSC cis rs11098499 0.722 rs17595727 ENSG00000249244.1 RP11-548H18.2 -5.77 1.4e-08 5.44e-06 -0.32 -0.26 Corneal astigmatism; chr4:119340919 chr4:119391831~119395335:- LUSC cis rs13113518 0.756 rs11939652 ENSG00000273257.1 RP11-177J6.1 5.77 1.4e-08 5.45e-06 0.33 0.26 Height; chr4:55532542 chr4:55387949~55388271:+ LUSC cis rs910316 0.737 rs175080 ENSG00000279594.1 RP11-950C14.10 -5.77 1.4e-08 5.45e-06 -0.3 -0.26 Height; chr14:75047125 chr14:75011269~75012851:- LUSC cis rs7829975 0.593 rs2921061 ENSG00000173295.6 FAM86B3P 5.77 1.41e-08 5.46e-06 0.28 0.26 Mood instability; chr8:8460105 chr8:8228595~8244865:+ LUSC cis rs3738443 0.817 rs61839996 ENSG00000259865.1 RP11-488L18.10 5.77 1.41e-08 5.46e-06 0.28 0.26 Alcohol dependence; chr1:247197571 chr1:247187281~247188526:- LUSC cis rs801193 1 rs2659909 ENSG00000237310.1 GS1-124K5.4 5.77 1.41e-08 5.46e-06 0.26 0.26 Aortic root size; chr7:66695292 chr7:66493706~66495474:+ LUSC cis rs2028299 0.92 rs1866476 ENSG00000259677.1 RP11-493E3.1 5.77 1.41e-08 5.47e-06 0.33 0.26 Type 2 diabetes; chr15:89885311 chr15:89876540~89877285:+ LUSC cis rs7119038 0.509 rs11216961 ENSG00000255422.1 AP002954.4 5.77 1.41e-08 5.48e-06 0.34 0.26 Sjögren's syndrome; chr11:118709629 chr11:118704607~118750263:+ LUSC cis rs496547 0.52 rs11216963 ENSG00000255422.1 AP002954.4 5.77 1.41e-08 5.48e-06 0.34 0.26 Hip minimal joint space width; chr11:118710105 chr11:118704607~118750263:+ LUSC cis rs7615952 0.932 rs13065725 ENSG00000171084.14 FAM86JP 5.77 1.41e-08 5.49e-06 0.35 0.26 Blood pressure (smoking interaction); chr3:125913446 chr3:125916620~125930024:+ LUSC cis rs875971 0.66 rs2013222 ENSG00000222364.1 RNU6-96P 5.77 1.41e-08 5.49e-06 0.29 0.26 Aortic root size; chr7:66570949 chr7:66395191~66395286:+ LUSC cis rs7267979 1 rs2482943 ENSG00000274973.1 RP13-401N8.7 5.77 1.41e-08 5.49e-06 0.26 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25399957 chr20:25845497~25845862:+ LUSC cis rs6928977 0.675 rs9399148 ENSG00000234084.1 RP3-388E23.2 5.77 1.41e-08 5.49e-06 0.21 0.26 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135523221 chr6:135301568~135307158:+ LUSC cis rs13113518 0.841 rs7699867 ENSG00000249700.7 SRD5A3-AS1 5.77 1.42e-08 5.49e-06 0.3 0.26 Height; chr4:55483718 chr4:55363971~55395847:- LUSC cis rs2665103 0.61 rs1972460 ENSG00000278603.1 RP13-608F4.5 5.77 1.42e-08 5.49e-06 0.3 0.26 Intelligence (multi-trait analysis); chr15:82238289 chr15:82472203~82472426:+ LUSC cis rs881375 0.678 rs10739581 ENSG00000226752.6 PSMD5-AS1 -5.77 1.42e-08 5.5e-06 -0.29 -0.26 Rheumatoid arthritis; chr9:120934593 chr9:120824828~120854385:+ LUSC cis rs10759883 0.627 rs10760261 ENSG00000175611.10 LINC00476 5.77 1.42e-08 5.51e-06 0.3 0.26 Nicotine dependence; chr9:95850229 chr9:95759231~95875977:- LUSC cis rs2153535 0.58 rs9406158 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8463919 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1335637 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8464868 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9406162 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8465963 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9393022 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8466355 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs9392222 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8467416 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs6932434 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8467446 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1034273 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8467912 chr6:8784178~8785445:+ LUSC cis rs2153535 0.541 rs9328471 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8468609 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs9505451 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8469717 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9393023 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8469761 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1414346 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8471341 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1932279 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8473420 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2152347 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8474048 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9379213 ENSG00000230939.1 RP11-314C16.1 -5.77 1.42e-08 5.51e-06 -0.31 -0.26 Motion sickness; chr6:8474712 chr6:8784178~8785445:+ LUSC cis rs1499614 0.803 rs1796229 ENSG00000226824.5 RP4-756H11.3 -5.77 1.42e-08 5.51e-06 -0.49 -0.26 Gout; chr7:66654674 chr7:66654538~66669855:+ LUSC cis rs1499614 0.901 rs3936 ENSG00000226824.5 RP4-756H11.3 -5.77 1.42e-08 5.51e-06 -0.49 -0.26 Gout; chr7:66661502 chr7:66654538~66669855:+ LUSC cis rs11098499 0.909 rs1546504 ENSG00000248280.1 RP11-33B1.2 5.77 1.42e-08 5.51e-06 0.32 0.26 Corneal astigmatism; chr4:119320024 chr4:119440561~119450157:- LUSC cis rs801193 1 rs4717319 ENSG00000222364.1 RNU6-96P -5.77 1.42e-08 5.52e-06 -0.3 -0.26 Aortic root size; chr7:66777606 chr7:66395191~66395286:+ LUSC cis rs801193 0.904 rs4718403 ENSG00000222364.1 RNU6-96P -5.77 1.42e-08 5.52e-06 -0.3 -0.26 Aortic root size; chr7:66777742 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs3778909 ENSG00000222364.1 RNU6-96P -5.77 1.42e-08 5.52e-06 -0.3 -0.26 Aortic root size; chr7:66790659 chr7:66395191~66395286:+ LUSC cis rs9341835 0.608 rs2076874 ENSG00000218048.2 RP3-407E4.4 5.77 1.42e-08 5.52e-06 0.29 0.26 Schizophrenia; chr6:63443786 chr6:63440766~63443580:+ LUSC cis rs761746 0.695 rs3804087 ENSG00000236132.1 CTA-440B3.1 5.77 1.42e-08 5.52e-06 0.37 0.26 Intelligence; chr22:31683317 chr22:31816379~31817491:- LUSC cis rs673078 0.615 rs16948204 ENSG00000275759.1 RP11-131L12.3 -5.77 1.42e-08 5.52e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118258252 chr12:118428281~118428870:+ LUSC cis rs875971 0.619 rs10278371 ENSG00000222364.1 RNU6-96P 5.77 1.42e-08 5.52e-06 0.29 0.26 Aortic root size; chr7:66586553 chr7:66395191~66395286:+ LUSC cis rs9287719 0.674 rs6432130 ENSG00000234818.1 AC092687.5 -5.77 1.42e-08 5.52e-06 -0.29 -0.26 Prostate cancer; chr2:10681431 chr2:10589166~10604830:+ LUSC cis rs2243480 1 rs34970380 ENSG00000226824.5 RP4-756H11.3 -5.77 1.43e-08 5.53e-06 -0.51 -0.26 Diabetic kidney disease; chr7:65966506 chr7:66654538~66669855:+ LUSC cis rs2842992 0.789 rs7765490 ENSG00000237927.1 RP3-393E18.2 -5.77 1.43e-08 5.53e-06 -0.38 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159783294 chr6:159586955~159589169:- LUSC cis rs801193 0.935 rs2659916 ENSG00000222364.1 RNU6-96P -5.77 1.43e-08 5.53e-06 -0.3 -0.26 Aortic root size; chr7:66686365 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs6958520 ENSG00000222364.1 RNU6-96P -5.77 1.43e-08 5.53e-06 -0.3 -0.26 Aortic root size; chr7:66686466 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs7788576 ENSG00000222364.1 RNU6-96P 5.77 1.43e-08 5.53e-06 0.3 0.26 Aortic root size; chr7:66683315 chr7:66395191~66395286:+ LUSC cis rs12468226 1 rs74766638 ENSG00000272966.1 RP11-686O6.1 5.77 1.43e-08 5.54e-06 0.42 0.26 Urate levels; chr2:202445168 chr2:202336739~202337200:+ LUSC cis rs9341808 0.667 rs2505929 ENSG00000272129.1 RP11-250B2.6 5.77 1.43e-08 5.55e-06 0.32 0.26 Sitting height ratio; chr6:80124491 chr6:80355424~80356859:+ LUSC cis rs763121 0.888 rs2235229 ENSG00000273076.1 RP3-508I15.22 5.77 1.43e-08 5.56e-06 0.24 0.26 Menopause (age at onset); chr22:38728907 chr22:38743495~38743910:+ LUSC cis rs875971 0.928 rs2036263 ENSG00000179406.6 LINC00174 5.77 1.44e-08 5.56e-06 0.28 0.26 Aortic root size; chr7:66335210 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs10240949 ENSG00000179406.6 LINC00174 5.77 1.44e-08 5.56e-06 0.28 0.26 Aortic root size; chr7:66339430 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs7782704 ENSG00000179406.6 LINC00174 5.77 1.44e-08 5.56e-06 0.28 0.26 Aortic root size; chr7:66340379 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6959268 ENSG00000179406.6 LINC00174 5.77 1.44e-08 5.56e-06 0.28 0.26 Aortic root size; chr7:66347979 chr7:66376044~66401338:- LUSC cis rs11722779 0.692 rs223414 ENSG00000246560.2 RP11-10L12.4 5.77 1.44e-08 5.57e-06 0.31 0.26 Schizophrenia; chr4:102811688 chr4:102828055~102844075:+ LUSC cis rs4372836 0.929 rs11675572 ENSG00000226833.4 AC097724.3 -5.77 1.44e-08 5.58e-06 -0.31 -0.26 Body mass index; chr2:28708510 chr2:28708953~28736205:- LUSC cis rs8059260 0.932 rs7186166 ENSG00000274038.1 RP11-66H6.4 -5.77 1.44e-08 5.58e-06 -0.37 -0.26 Alcohol consumption over the past year; chr16:11011577 chr16:11056556~11057034:+ LUSC cis rs2337406 0.866 rs74092520 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106779632 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs4583128 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106780669 chr14:106762092~106762588:- LUSC cis rs2337406 0.929 rs12050200 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106780983 chr14:106762092~106762588:- LUSC cis rs2337406 0.852 rs12050239 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781132 chr14:106762092~106762588:- LUSC cis rs2337406 0.929 rs59263250 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781183 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs58083017 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781256 chr14:106762092~106762588:- LUSC cis rs2337406 0.789 rs60390024 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781327 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs74092532 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781363 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs74092534 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781364 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs74092535 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781722 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs74092537 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781883 chr14:106762092~106762588:- LUSC cis rs2337406 0.81 rs74092538 ENSG00000280411.1 IGHV1-69-2 -5.77 1.44e-08 5.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781942 chr14:106762092~106762588:- LUSC cis rs13113518 0.967 rs4340844 ENSG00000249700.7 SRD5A3-AS1 5.77 1.44e-08 5.58e-06 0.3 0.26 Height; chr4:55462689 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs1522112 ENSG00000249700.7 SRD5A3-AS1 5.77 1.44e-08 5.58e-06 0.3 0.26 Height; chr4:55463606 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs4864997 ENSG00000249700.7 SRD5A3-AS1 5.77 1.44e-08 5.58e-06 0.3 0.26 Height; chr4:55466010 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs960152 ENSG00000249700.7 SRD5A3-AS1 5.77 1.44e-08 5.58e-06 0.3 0.26 Height; chr4:55467308 chr4:55363971~55395847:- LUSC cis rs13113518 0.967 rs12644948 ENSG00000249700.7 SRD5A3-AS1 5.77 1.44e-08 5.58e-06 0.3 0.26 Height; chr4:55470266 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs3805151 ENSG00000249700.7 SRD5A3-AS1 5.77 1.44e-08 5.58e-06 0.3 0.26 Height; chr4:55470874 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs13118237 ENSG00000249700.7 SRD5A3-AS1 5.77 1.44e-08 5.58e-06 0.3 0.26 Height; chr4:55474259 chr4:55363971~55395847:- LUSC cis rs75920871 0.528 rs983567 ENSG00000254851.1 RP11-109L13.1 5.77 1.44e-08 5.58e-06 0.35 0.26 Subjective well-being; chr11:116912884 chr11:117135528~117138582:+ LUSC cis rs2136613 0.751 rs10761667 ENSG00000238280.1 RP11-436D10.3 -5.77 1.44e-08 5.59e-06 -0.32 -0.26 Selective IgA deficiency; chr10:62849038 chr10:62793562~62805887:- LUSC cis rs11089937 0.626 rs5757014 ENSG00000211638.2 IGLV8-61 -5.77 1.44e-08 5.59e-06 -0.27 -0.26 Periodontitis (PAL4Q3); chr22:22135612 chr22:22098700~22099212:+ LUSC cis rs875971 0.83 rs6976714 ENSG00000179406.6 LINC00174 -5.77 1.44e-08 5.59e-06 -0.28 -0.26 Aortic root size; chr7:66426474 chr7:66376044~66401338:- LUSC cis rs11971779 0.941 rs7800795 ENSG00000273391.1 RP11-634H22.1 5.77 1.44e-08 5.59e-06 0.32 0.26 Diisocyanate-induced asthma; chr7:139395602 chr7:139359032~139359566:- LUSC cis rs9545047 0.584 rs7995243 ENSG00000227676.3 LINC01068 -5.77 1.45e-08 5.6e-06 -0.31 -0.26 Schizophrenia; chr13:79358645 chr13:79566727~79571436:+ LUSC cis rs13113518 1 rs4864999 ENSG00000273257.1 RP11-177J6.1 5.77 1.45e-08 5.6e-06 0.33 0.26 Height; chr4:55476736 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs12506788 ENSG00000273257.1 RP11-177J6.1 5.77 1.45e-08 5.6e-06 0.33 0.26 Height; chr4:55477426 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs10517344 ENSG00000273257.1 RP11-177J6.1 5.77 1.45e-08 5.6e-06 0.33 0.26 Height; chr4:55477545 chr4:55387949~55388271:+ LUSC cis rs6504622 0.702 rs3851798 ENSG00000262879.4 RP11-156P1.3 5.77 1.45e-08 5.61e-06 0.27 0.26 Orofacial clefts; chr17:46988901 chr17:46984045~47100323:- LUSC cis rs12468226 1 rs79919139 ENSG00000272966.1 RP11-686O6.1 5.77 1.45e-08 5.61e-06 0.42 0.26 Urate levels; chr2:202382786 chr2:202336739~202337200:+ LUSC cis rs4865169 1 rs4865169 ENSG00000269949.1 RP11-738E22.3 -5.77 1.45e-08 5.61e-06 -0.32 -0.26 Breast cancer; chr4:57013626 chr4:56960927~56961373:- LUSC cis rs1823913 0.637 rs11688994 ENSG00000280083.1 RP11-317J9.1 -5.77 1.45e-08 5.62e-06 -0.29 -0.26 Obesity-related traits; chr2:191266242 chr2:191154118~191156070:- LUSC cis rs7208859 0.623 rs122898 ENSG00000266490.1 CTD-2349P21.9 -5.77 1.45e-08 5.62e-06 -0.31 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30578236 chr17:30792372~30792833:+ LUSC cis rs11159086 1 rs8006909 ENSG00000270000.1 RP3-449M8.9 5.77 1.45e-08 5.62e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74478085 chr14:74471930~74472360:- LUSC cis rs801193 1 rs2003301 ENSG00000222364.1 RNU6-96P 5.77 1.45e-08 5.62e-06 0.3 0.26 Aortic root size; chr7:66682669 chr7:66395191~66395286:+ LUSC cis rs13434995 0.513 rs6554285 ENSG00000249700.7 SRD5A3-AS1 5.77 1.46e-08 5.63e-06 0.32 0.26 Adiponectin levels; chr4:55533953 chr4:55363971~55395847:- LUSC cis rs9880192 0.516 rs2713575 ENSG00000277250.1 Metazoa_SRP -5.77 1.46e-08 5.64e-06 -0.29 -0.26 White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts; chr3:128575512 chr3:128673681~128674021:- LUSC cis rs7429990 0.864 rs1464614 ENSG00000229759.1 MRPS18AP1 5.77 1.46e-08 5.64e-06 0.25 0.26 Educational attainment (years of education); chr3:47612885 chr3:48256350~48256938:- LUSC cis rs13113518 0.783 rs12510400 ENSG00000273257.1 RP11-177J6.1 5.77 1.46e-08 5.64e-06 0.33 0.26 Height; chr4:55577294 chr4:55387949~55388271:+ LUSC cis rs13113518 0.783 rs13111128 ENSG00000273257.1 RP11-177J6.1 5.77 1.46e-08 5.64e-06 0.33 0.26 Height; chr4:55578154 chr4:55387949~55388271:+ LUSC cis rs6969780 1 rs1548497 ENSG00000233429.8 HOTAIRM1 -5.77 1.46e-08 5.65e-06 -0.49 -0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27134697 chr7:27095647~27100265:+ LUSC cis rs7739264 0.591 rs6926312 ENSG00000237404.1 RP3-471C18.2 -5.77 1.46e-08 5.65e-06 -0.29 -0.26 Endometriosis; chr6:19712062 chr6:19689825~19753113:- LUSC cis rs1823913 0.637 rs11688994 ENSG00000227542.1 AC092614.2 5.77 1.46e-08 5.65e-06 0.32 0.26 Obesity-related traits; chr2:191266242 chr2:191229165~191246172:- LUSC cis rs13113518 1 rs3749474 ENSG00000249700.7 SRD5A3-AS1 5.77 1.46e-08 5.65e-06 0.3 0.26 Height; chr4:55434518 chr4:55363971~55395847:- LUSC cis rs17826219 0.568 rs11658027 ENSG00000266490.1 CTD-2349P21.9 -5.77 1.46e-08 5.65e-06 -0.31 -0.26 Body mass index; chr17:30767864 chr17:30792372~30792833:+ LUSC cis rs36423 0.748 rs36408 ENSG00000266869.1 RP6-114E22.1 -5.77 1.46e-08 5.66e-06 -0.4 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71890558 chr14:71848606~71908430:+ LUSC cis rs11846409 0.932 rs28617526 ENSG00000274576.2 IGHV2-70 -5.77 1.46e-08 5.66e-06 -0.27 -0.26 Rheumatic heart disease; chr14:106637322 chr14:106770577~106771020:- LUSC cis rs8059260 0.604 rs34573672 ENSG00000274038.1 RP11-66H6.4 -5.77 1.46e-08 5.66e-06 -0.45 -0.26 Alcohol consumption over the past year; chr16:11111882 chr16:11056556~11057034:+ LUSC cis rs875971 0.545 rs67775320 ENSG00000237310.1 GS1-124K5.4 5.77 1.46e-08 5.66e-06 0.29 0.26 Aortic root size; chr7:66193792 chr7:66493706~66495474:+ LUSC cis rs12468226 1 rs76528043 ENSG00000272966.1 RP11-686O6.1 5.77 1.46e-08 5.66e-06 0.42 0.26 Urate levels; chr2:202466116 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs74508472 ENSG00000272966.1 RP11-686O6.1 5.77 1.46e-08 5.66e-06 0.42 0.26 Urate levels; chr2:202517290 chr2:202336739~202337200:+ LUSC cis rs7267979 0.868 rs6138546 ENSG00000274973.1 RP13-401N8.7 -5.77 1.46e-08 5.66e-06 -0.26 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25235898 chr20:25845497~25845862:+ LUSC cis rs2337406 0.866 rs61419485 ENSG00000211974.3 IGHV2-70 -5.77 1.47e-08 5.67e-06 -0.34 -0.26 Alzheimer's disease (late onset); chr14:106783374 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs8015361 ENSG00000211974.3 IGHV2-70 -5.77 1.47e-08 5.67e-06 -0.34 -0.26 Alzheimer's disease (late onset); chr14:106783991 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs74090151 ENSG00000211974.3 IGHV2-70 -5.77 1.47e-08 5.67e-06 -0.34 -0.26 Alzheimer's disease (late onset); chr14:106785377 chr14:106723574~106724093:- LUSC cis rs28830936 0.841 rs4923914 ENSG00000250379.1 RP11-23P13.4 5.77 1.47e-08 5.68e-06 0.28 0.26 Diastolic blood pressure; chr15:41827405 chr15:41825099~41827936:- LUSC cis rs875971 0.965 rs9969301 ENSG00000179406.6 LINC00174 5.77 1.47e-08 5.68e-06 0.28 0.26 Aortic root size; chr7:66316668 chr7:66376044~66401338:- LUSC cis rs11971779 0.646 rs58682779 ENSG00000273391.1 RP11-634H22.1 5.77 1.47e-08 5.69e-06 0.32 0.26 Diisocyanate-induced asthma; chr7:139399966 chr7:139359032~139359566:- LUSC cis rs875971 0.54 rs35510581 ENSG00000224316.1 RP11-479O9.2 -5.77 1.47e-08 5.69e-06 -0.25 -0.26 Aortic root size; chr7:66113790 chr7:65773620~65802067:+ LUSC cis rs10759883 0.587 rs10818899 ENSG00000175611.10 LINC00476 5.77 1.47e-08 5.69e-06 0.31 0.26 Nicotine dependence; chr9:95860129 chr9:95759231~95875977:- LUSC cis rs875971 0.66 rs3764903 ENSG00000222364.1 RNU6-96P 5.77 1.47e-08 5.7e-06 0.3 0.26 Aortic root size; chr7:66633495 chr7:66395191~66395286:+ LUSC cis rs875971 0.66 rs1860470 ENSG00000222364.1 RNU6-96P 5.77 1.47e-08 5.7e-06 0.3 0.26 Aortic root size; chr7:66638707 chr7:66395191~66395286:+ LUSC cis rs1056107 0.931 rs10759540 ENSG00000225513.1 RP11-165N19.2 -5.77 1.47e-08 5.7e-06 -0.28 -0.26 Colorectal cancer; chr9:112239394 chr9:112173522~112173971:- LUSC cis rs77204473 0.744 rs75890305 ENSG00000254851.1 RP11-109L13.1 5.77 1.48e-08 5.7e-06 0.6 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117049253 chr11:117135528~117138582:+ LUSC cis rs8059260 1 rs6498138 ENSG00000274038.1 RP11-66H6.4 5.77 1.48e-08 5.71e-06 0.41 0.26 Alcohol consumption over the past year; chr16:10951421 chr16:11056556~11057034:+ LUSC cis rs7208859 0.623 rs7219712 ENSG00000266490.1 CTD-2349P21.9 5.77 1.48e-08 5.71e-06 0.32 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753552 chr17:30792372~30792833:+ LUSC cis rs11098499 0.604 rs2389887 ENSG00000248280.1 RP11-33B1.2 5.77 1.48e-08 5.71e-06 0.31 0.26 Corneal astigmatism; chr4:119649489 chr4:119440561~119450157:- LUSC cis rs1075265 0.901 rs1058320 ENSG00000233266.1 HMGB1P31 5.77 1.48e-08 5.71e-06 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:54085016 chr2:54051334~54051760:+ LUSC cis rs1056107 0.902 rs10124118 ENSG00000225513.1 RP11-165N19.2 -5.77 1.48e-08 5.72e-06 -0.28 -0.26 Colorectal cancer; chr9:112240354 chr9:112173522~112173971:- LUSC cis rs6460942 0.597 rs13232817 ENSG00000226690.5 AC005281.1 5.76 1.48e-08 5.73e-06 0.51 0.26 Coronary artery disease; chr7:12512283 chr7:12496429~12541910:+ LUSC cis rs8059260 0.736 rs113433437 ENSG00000274038.1 RP11-66H6.4 -5.76 1.48e-08 5.73e-06 -0.5 -0.26 Alcohol consumption over the past year; chr16:10959438 chr16:11056556~11057034:+ LUSC cis rs2276314 0.793 rs77590522 ENSG00000278986.1 RP11-723J4.3 -5.76 1.48e-08 5.73e-06 -0.33 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36049447 chr18:35972151~35973916:+ LUSC cis rs7246657 0.722 rs2972430 ENSG00000276846.1 CTD-3220F14.3 -5.76 1.49e-08 5.74e-06 -0.39 -0.26 Coronary artery calcification; chr19:37691210 chr19:37314868~37315620:- LUSC cis rs8072100 0.57 rs9905073 ENSG00000228782.6 CTD-2026D20.3 5.76 1.49e-08 5.74e-06 0.26 0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47390930 chr17:47450568~47492492:- LUSC cis rs13434995 0.513 rs972446 ENSG00000249700.7 SRD5A3-AS1 5.76 1.49e-08 5.74e-06 0.32 0.26 Adiponectin levels; chr4:55569581 chr4:55363971~55395847:- LUSC cis rs442309 0.812 rs224123 ENSG00000238280.1 RP11-436D10.3 -5.76 1.49e-08 5.74e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62691473 chr10:62793562~62805887:- LUSC cis rs875971 0.545 rs7783889 ENSG00000224316.1 RP11-479O9.2 5.76 1.49e-08 5.74e-06 0.27 0.26 Aortic root size; chr7:66283366 chr7:65773620~65802067:+ LUSC cis rs6142102 0.961 rs6059596 ENSG00000275784.1 RP5-1125A11.6 -5.76 1.49e-08 5.75e-06 -0.3 -0.26 Skin pigmentation; chr20:33969313 chr20:33989480~33991818:- LUSC cis rs7772486 0.875 rs6913797 ENSG00000235652.6 RP11-545I5.3 5.76 1.49e-08 5.75e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:146092622 chr6:145799409~145886585:+ LUSC cis rs6502050 0.799 rs9675196 ENSG00000266654.1 RP11-1376P16.1 -5.76 1.49e-08 5.76e-06 -0.25 -0.26 Life satisfaction; chr17:82138779 chr17:82160056~82160452:+ LUSC cis rs7772486 0.875 rs7767660 ENSG00000235652.6 RP11-545I5.3 5.76 1.49e-08 5.76e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146115414 chr6:145799409~145886585:+ LUSC cis rs875971 0.929 rs4122249 ENSG00000179406.6 LINC00174 -5.76 1.49e-08 5.76e-06 -0.27 -0.26 Aortic root size; chr7:66455949 chr7:66376044~66401338:- LUSC cis rs801193 0.548 rs2109297 ENSG00000179406.6 LINC00174 5.76 1.49e-08 5.76e-06 0.28 0.26 Aortic root size; chr7:66657397 chr7:66376044~66401338:- LUSC cis rs801193 0.591 rs721717 ENSG00000179406.6 LINC00174 5.76 1.49e-08 5.76e-06 0.28 0.26 Aortic root size; chr7:66665305 chr7:66376044~66401338:- LUSC cis rs950169 0.922 rs12910334 ENSG00000259295.5 CSPG4P12 5.76 1.49e-08 5.77e-06 0.34 0.26 Schizophrenia; chr15:84403620 chr15:85191438~85213905:+ LUSC cis rs75422866 0.51 rs73104197 ENSG00000276691.1 RP5-1057I20.5 5.76 1.5e-08 5.77e-06 0.45 0.26 Pneumonia; chr12:47717273 chr12:47788426~47788971:+ LUSC cis rs10759883 0.627 rs10818574 ENSG00000175611.10 LINC00476 5.76 1.5e-08 5.78e-06 0.3 0.26 Nicotine dependence; chr9:95836685 chr9:95759231~95875977:- LUSC cis rs875971 0.571 rs160641 ENSG00000237310.1 GS1-124K5.4 -5.76 1.5e-08 5.78e-06 -0.29 -0.26 Aortic root size; chr7:66112359 chr7:66493706~66495474:+ LUSC cis rs2404602 0.735 rs56246286 ENSG00000259422.1 RP11-593F23.1 -5.76 1.5e-08 5.78e-06 -0.3 -0.26 Blood metabolite levels; chr15:76398390 chr15:76174891~76181486:- LUSC cis rs6142102 0.961 rs1007090 ENSG00000275784.1 RP5-1125A11.6 -5.76 1.5e-08 5.78e-06 -0.3 -0.26 Skin pigmentation; chr20:33995065 chr20:33989480~33991818:- LUSC cis rs6142102 0.923 rs2284377 ENSG00000275784.1 RP5-1125A11.6 -5.76 1.5e-08 5.78e-06 -0.3 -0.26 Skin pigmentation; chr20:33998876 chr20:33989480~33991818:- LUSC cis rs6142102 0.961 rs2284378 ENSG00000275784.1 RP5-1125A11.6 -5.76 1.5e-08 5.78e-06 -0.3 -0.26 Skin pigmentation; chr20:34000289 chr20:33989480~33991818:- LUSC cis rs2300206 1 rs2300206 ENSG00000275784.1 RP5-1125A11.6 -5.76 1.5e-08 5.78e-06 -0.3 -0.26 Cancer (pleiotropy);Cancer; chr20:34002002 chr20:33989480~33991818:- LUSC cis rs6142102 0.961 rs2268080 ENSG00000275784.1 RP5-1125A11.6 -5.76 1.5e-08 5.78e-06 -0.3 -0.26 Skin pigmentation; chr20:34009910 chr20:33989480~33991818:- LUSC cis rs875971 1 rs2220626 ENSG00000179406.6 LINC00174 5.76 1.5e-08 5.8e-06 0.28 0.26 Aortic root size; chr7:66081075 chr7:66376044~66401338:- LUSC cis rs8177876 0.658 rs77874075 ENSG00000261838.4 RP11-303E16.6 5.76 1.5e-08 5.8e-06 0.62 0.26 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81032734 chr16:81069854~81076598:+ LUSC cis rs442309 0.783 rs224111 ENSG00000238280.1 RP11-436D10.3 5.76 1.5e-08 5.8e-06 0.32 0.26 Vogt-Koyanagi-Harada syndrome; chr10:62792250 chr10:62793562~62805887:- LUSC cis rs4964805 0.505 rs15918 ENSG00000257681.1 RP11-341G23.4 5.76 1.5e-08 5.8e-06 0.29 0.26 Attention deficit hyperactivity disorder; chr12:103773246 chr12:103746315~103768858:- LUSC cis rs875971 0.66 rs10263935 ENSG00000237310.1 GS1-124K5.4 5.76 1.5e-08 5.8e-06 0.26 0.26 Aortic root size; chr7:66631041 chr7:66493706~66495474:+ LUSC cis rs9322193 0.607 rs3798763 ENSG00000268592.3 RAET1E-AS1 5.76 1.51e-08 5.81e-06 0.37 0.26 Lung cancer; chr6:149889964 chr6:149863494~149919507:+ LUSC cis rs9322193 0.607 rs12204653 ENSG00000268592.3 RAET1E-AS1 5.76 1.51e-08 5.81e-06 0.37 0.26 Lung cancer; chr6:149891885 chr6:149863494~149919507:+ LUSC cis rs1499614 1 rs1267818 ENSG00000226824.5 RP4-756H11.3 -5.76 1.51e-08 5.81e-06 -0.49 -0.26 Gout; chr7:66642037 chr7:66654538~66669855:+ LUSC cis rs9341835 0.772 rs9294197 ENSG00000218048.2 RP3-407E4.4 5.76 1.51e-08 5.81e-06 0.3 0.26 Schizophrenia; chr6:63425743 chr6:63440766~63443580:+ LUSC cis rs9341835 0.74 rs9294198 ENSG00000218048.2 RP3-407E4.4 5.76 1.51e-08 5.81e-06 0.3 0.26 Schizophrenia; chr6:63427088 chr6:63440766~63443580:+ LUSC cis rs6918586 1 rs198811 ENSG00000272462.2 U91328.19 5.76 1.51e-08 5.82e-06 0.27 0.26 Schizophrenia; chr6:26128218 chr6:25992662~26001775:+ LUSC cis rs673078 0.607 rs61946067 ENSG00000275759.1 RP11-131L12.3 -5.76 1.51e-08 5.82e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118303152 chr12:118428281~118428870:+ LUSC cis rs240993 0.812 rs9487668 ENSG00000230177.1 RP5-1112D6.4 5.76 1.51e-08 5.82e-06 0.31 0.26 Inflammatory skin disease;Psoriasis; chr6:111553466 chr6:111277932~111278742:+ LUSC cis rs7739264 0.566 rs7740281 ENSG00000237404.1 RP3-471C18.2 -5.76 1.51e-08 5.82e-06 -0.28 -0.26 Endometriosis; chr6:19705891 chr6:19689825~19753113:- LUSC cis rs750134 1 rs74939224 ENSG00000257221.1 RP11-689B22.2 -5.76 1.51e-08 5.82e-06 -0.4 -0.26 Low high density lipoprotein cholesterol levels; chr12:108657192 chr12:108628687~108641318:+ LUSC cis rs67311347 1 rs9875245 ENSG00000223797.4 ENTPD3-AS1 5.76 1.51e-08 5.83e-06 0.3 0.26 Renal cell carcinoma; chr3:40400789 chr3:40313802~40453329:- LUSC cis rs67311347 1 rs954589 ENSG00000223797.4 ENTPD3-AS1 5.76 1.51e-08 5.83e-06 0.3 0.26 Renal cell carcinoma; chr3:40403054 chr3:40313802~40453329:- LUSC cis rs4604732 0.642 rs4489599 ENSG00000227135.1 GCSAML-AS1 5.76 1.51e-08 5.83e-06 0.35 0.26 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247471911 chr1:247524679~247526752:- LUSC cis rs6565180 0.962 rs35480350 ENSG00000183604.13 SMG1P5 -5.76 1.51e-08 5.83e-06 -0.32 -0.26 Tonsillectomy; chr16:30354718 chr16:30267553~30335374:- LUSC cis rs4237845 0.68 rs10877033 ENSG00000257159.1 RP11-58A17.3 5.76 1.52e-08 5.84e-06 0.31 0.26 Intelligence (multi-trait analysis); chr12:57889948 chr12:57967058~57968399:+ LUSC cis rs66887589 0.774 rs9307477 ENSG00000249244.1 RP11-548H18.2 5.76 1.52e-08 5.84e-06 0.31 0.26 Diastolic blood pressure; chr4:119500654 chr4:119391831~119395335:- LUSC cis rs11159086 1 rs17100451 ENSG00000270000.1 RP3-449M8.9 5.76 1.52e-08 5.85e-06 0.4 0.26 Advanced glycation end-product levels; chr14:74476210 chr14:74471930~74472360:- LUSC cis rs2337406 0.85 rs75196489 ENSG00000274576.2 IGHV2-70 -5.76 1.52e-08 5.85e-06 -0.28 -0.26 Alzheimer's disease (late onset); chr14:106699438 chr14:106770577~106771020:- LUSC cis rs2337406 1 rs79452530 ENSG00000274576.2 IGHV2-70 -5.76 1.52e-08 5.85e-06 -0.28 -0.26 Alzheimer's disease (late onset); chr14:106699992 chr14:106770577~106771020:- LUSC cis rs4803480 0.872 rs2058149 ENSG00000270164.1 LINC01480 -5.76 1.52e-08 5.85e-06 -0.23 -0.26 Schizophrenia; chr19:41580312 chr19:41535183~41536904:+ LUSC cis rs875971 0.825 rs6951503 ENSG00000179406.6 LINC00174 5.76 1.52e-08 5.85e-06 0.28 0.26 Aortic root size; chr7:66253949 chr7:66376044~66401338:- LUSC cis rs6570726 1 rs373778 ENSG00000235652.6 RP11-545I5.3 5.76 1.52e-08 5.86e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145552116 chr6:145799409~145886585:+ LUSC cis rs13113518 0.783 rs34534635 ENSG00000273257.1 RP11-177J6.1 5.76 1.52e-08 5.87e-06 0.33 0.26 Height; chr4:55573424 chr4:55387949~55388271:+ LUSC cis rs35160687 0.712 rs11674249 ENSG00000273080.1 RP11-301O19.1 -5.76 1.52e-08 5.87e-06 -0.24 -0.26 Night sleep phenotypes; chr2:86270283 chr2:86195590~86196049:+ LUSC cis rs2834288 0.653 rs4817600 ENSG00000273102.1 AP000569.9 5.76 1.53e-08 5.88e-06 0.3 0.26 Gut microbiota (bacterial taxa); chr21:33925224 chr21:33967101~33968573:- LUSC cis rs11098499 0.863 rs3822192 ENSG00000248280.1 RP11-33B1.2 5.76 1.53e-08 5.88e-06 0.31 0.26 Corneal astigmatism; chr4:119524565 chr4:119440561~119450157:- LUSC cis rs801193 0.569 rs2659908 ENSG00000179406.6 LINC00174 -5.76 1.53e-08 5.89e-06 -0.28 -0.26 Aortic root size; chr7:66695835 chr7:66376044~66401338:- LUSC cis rs801193 0.569 rs7782587 ENSG00000179406.6 LINC00174 -5.76 1.53e-08 5.89e-06 -0.28 -0.26 Aortic root size; chr7:66701485 chr7:66376044~66401338:- LUSC cis rs801193 0.527 rs2707837 ENSG00000179406.6 LINC00174 -5.76 1.53e-08 5.89e-06 -0.28 -0.26 Aortic root size; chr7:66716086 chr7:66376044~66401338:- LUSC cis rs9322193 0.607 rs4869755 ENSG00000268592.3 RAET1E-AS1 5.76 1.53e-08 5.89e-06 0.37 0.26 Lung cancer; chr6:149886347 chr6:149863494~149919507:+ LUSC cis rs9322193 0.639 rs4869756 ENSG00000268592.3 RAET1E-AS1 5.76 1.53e-08 5.89e-06 0.37 0.26 Lung cancer; chr6:149886360 chr6:149863494~149919507:+ LUSC cis rs8059260 1 rs7205474 ENSG00000274038.1 RP11-66H6.4 -5.76 1.53e-08 5.9e-06 -0.42 -0.26 Alcohol consumption over the past year; chr16:10949556 chr16:11056556~11057034:+ LUSC cis rs8059260 0.877 rs111352543 ENSG00000274038.1 RP11-66H6.4 -5.76 1.53e-08 5.9e-06 -0.42 -0.26 Alcohol consumption over the past year; chr16:10949603 chr16:11056556~11057034:+ LUSC cis rs12468226 1 rs12468226 ENSG00000272966.1 RP11-686O6.1 5.76 1.53e-08 5.9e-06 0.42 0.26 Urate levels; chr2:202472278 chr2:202336739~202337200:+ LUSC cis rs6570726 0.764 rs448258 ENSG00000235652.6 RP11-545I5.3 5.76 1.53e-08 5.9e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145548009 chr6:145799409~145886585:+ LUSC cis rs7665090 1 rs9996834 ENSG00000230069.3 LRRC37A15P -5.76 1.53e-08 5.9e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102636372 chr4:102727274~102730721:- LUSC cis rs875971 0.798 rs6460304 ENSG00000179406.6 LINC00174 -5.76 1.53e-08 5.91e-06 -0.28 -0.26 Aortic root size; chr7:66499741 chr7:66376044~66401338:- LUSC cis rs8177876 0.822 rs8043855 ENSG00000261838.4 RP11-303E16.6 5.76 1.53e-08 5.91e-06 0.49 0.26 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81089256 chr16:81069854~81076598:+ LUSC cis rs1800795 0.652 rs7802307 ENSG00000179428.2 AC073072.5 -5.76 1.53e-08 5.91e-06 -0.32 -0.26 Cerebrospinal fluid clusterin levels in APOEe4- carriers; chr7:22726814 chr7:22725395~22727620:- LUSC cis rs950880 0.71 rs55927292 ENSG00000234389.1 AC007278.3 -5.76 1.54e-08 5.91e-06 -0.28 -0.26 Serum protein levels (sST2); chr2:102348401 chr2:102438713~102440475:+ LUSC cis rs7772486 0.875 rs10457792 ENSG00000235652.6 RP11-545I5.3 5.76 1.54e-08 5.91e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146091279 chr6:145799409~145886585:+ LUSC cis rs875971 0.651 rs2420596 ENSG00000179406.6 LINC00174 -5.76 1.54e-08 5.91e-06 -0.28 -0.26 Aortic root size; chr7:66450996 chr7:66376044~66401338:- LUSC cis rs875971 0.52 rs2420597 ENSG00000179406.6 LINC00174 -5.76 1.54e-08 5.91e-06 -0.28 -0.26 Aortic root size; chr7:66450999 chr7:66376044~66401338:- LUSC cis rs35160687 0.712 rs7560886 ENSG00000273080.1 RP11-301O19.1 -5.76 1.54e-08 5.92e-06 -0.24 -0.26 Night sleep phenotypes; chr2:86265907 chr2:86195590~86196049:+ LUSC cis rs875971 0.862 rs778686 ENSG00000179406.6 LINC00174 -5.76 1.54e-08 5.92e-06 -0.28 -0.26 Aortic root size; chr7:66370923 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs778684 ENSG00000179406.6 LINC00174 -5.76 1.54e-08 5.92e-06 -0.28 -0.26 Aortic root size; chr7:66371416 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs778680 ENSG00000179406.6 LINC00174 -5.76 1.54e-08 5.92e-06 -0.28 -0.26 Aortic root size; chr7:66375427 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs11769079 ENSG00000179406.6 LINC00174 -5.76 1.54e-08 5.92e-06 -0.28 -0.26 Aortic root size; chr7:66377141 chr7:66376044~66401338:- LUSC cis rs2337406 0.866 rs111881598 ENSG00000211974.3 IGHV2-70 -5.76 1.54e-08 5.93e-06 -0.34 -0.26 Alzheimer's disease (late onset); chr14:106783113 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs61164979 ENSG00000211974.3 IGHV2-70 -5.76 1.54e-08 5.93e-06 -0.34 -0.26 Alzheimer's disease (late onset); chr14:106783133 chr14:106723574~106724093:- LUSC cis rs9907295 1 rs11653282 ENSG00000270977.1 AC015849.16 -5.76 1.54e-08 5.94e-06 -0.32 -0.26 Fibroblast growth factor basic levels; chr17:35909742 chr17:35893707~35911023:- LUSC cis rs6570726 0.935 rs380883 ENSG00000235652.6 RP11-545I5.3 5.76 1.54e-08 5.94e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145501856 chr6:145799409~145886585:+ LUSC cis rs2439831 0.702 rs3759791 ENSG00000249839.1 AC011330.5 -5.76 1.55e-08 5.95e-06 -0.52 -0.26 Lung cancer in ever smokers; chr15:43798600 chr15:43663654~43684339:- LUSC cis rs7657257 1 rs4321629 ENSG00000214846.4 RP11-115L11.1 5.76 1.55e-08 5.95e-06 0.68 0.26 Blood protein levels; chr4:15730757 chr4:15730962~15731627:- LUSC cis rs7657257 1 rs10516290 ENSG00000214846.4 RP11-115L11.1 5.76 1.55e-08 5.95e-06 0.68 0.26 Blood protein levels; chr4:15730833 chr4:15730962~15731627:- LUSC cis rs2302464 1 rs10516291 ENSG00000214846.4 RP11-115L11.1 5.76 1.55e-08 5.95e-06 0.68 0.26 Cerebrospinal fluid biomarker levels; chr4:15731168 chr4:15730962~15731627:- LUSC cis rs673078 0.66 rs7303417 ENSG00000275759.1 RP11-131L12.3 -5.76 1.55e-08 5.96e-06 -0.38 -0.26 Glucose homeostasis traits; chr12:118258859 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs7965350 ENSG00000275759.1 RP11-131L12.3 -5.76 1.55e-08 5.96e-06 -0.38 -0.26 Glucose homeostasis traits; chr12:118266710 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs17433217 ENSG00000275759.1 RP11-131L12.3 -5.76 1.55e-08 5.96e-06 -0.38 -0.26 Glucose homeostasis traits; chr12:118269076 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs73205526 ENSG00000275759.1 RP11-131L12.3 -5.76 1.55e-08 5.96e-06 -0.38 -0.26 Glucose homeostasis traits; chr12:118273172 chr12:118428281~118428870:+ LUSC cis rs66887589 0.967 rs59516282 ENSG00000249244.1 RP11-548H18.2 -5.76 1.55e-08 5.96e-06 -0.3 -0.26 Diastolic blood pressure; chr4:119580861 chr4:119391831~119395335:- LUSC cis rs8062405 1 rs7187776 ENSG00000278665.1 RP11-666O2.4 5.76 1.55e-08 5.96e-06 0.26 0.26 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28846324 chr16:28599241~28601881:- LUSC cis rs6683071 0.643 rs35507977 ENSG00000272750.1 RP11-378J18.8 -5.76 1.55e-08 5.97e-06 -0.34 -0.26 Cognitive performance; chr1:222700776 chr1:222658867~222661512:- LUSC cis rs875971 0.545 rs6460276 ENSG00000237310.1 GS1-124K5.4 5.76 1.55e-08 5.97e-06 0.29 0.26 Aortic root size; chr7:66182290 chr7:66493706~66495474:+ LUSC cis rs950027 0.538 rs635205 ENSG00000259520.4 CTD-2651B20.3 -5.76 1.55e-08 5.97e-06 -0.3 -0.26 Response to fenofibrate (adiponectin levels); chr15:45656186 chr15:45251580~45279251:- LUSC cis rs6570726 0.791 rs9373464 ENSG00000235652.6 RP11-545I5.3 5.76 1.55e-08 5.98e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145586031 chr6:145799409~145886585:+ LUSC cis rs783540 0.967 rs1864699 ENSG00000276710.3 CSPG4P8 -5.76 1.56e-08 5.99e-06 -0.27 -0.26 Schizophrenia; chr15:82654567 chr15:82459472~82477258:+ LUSC cis rs13113518 1 rs9312661 ENSG00000223305.1 RN7SKP30 5.76 1.56e-08 5.99e-06 0.31 0.26 Height; chr4:55476159 chr4:55540502~55540835:- LUSC cis rs66887589 0.72 rs11724758 ENSG00000249244.1 RP11-548H18.2 5.76 1.56e-08 5.99e-06 0.3 0.26 Diastolic blood pressure; chr4:119318723 chr4:119391831~119395335:- LUSC cis rs875971 0.545 rs67397473 ENSG00000237310.1 GS1-124K5.4 5.76 1.56e-08 5.99e-06 0.29 0.26 Aortic root size; chr7:66168318 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs10950027 ENSG00000237310.1 GS1-124K5.4 5.76 1.56e-08 5.99e-06 0.29 0.26 Aortic root size; chr7:66169164 chr7:66493706~66495474:+ LUSC cis rs607541 0.764 rs629466 ENSG00000259520.4 CTD-2651B20.3 -5.76 1.56e-08 6e-06 -0.4 -0.26 Obesity-related traits; chr15:45642547 chr15:45251580~45279251:- LUSC cis rs607541 0.764 rs629880 ENSG00000259520.4 CTD-2651B20.3 -5.76 1.56e-08 6e-06 -0.4 -0.26 Obesity-related traits; chr15:45642612 chr15:45251580~45279251:- LUSC cis rs9322193 0.962 rs35031906 ENSG00000268592.3 RAET1E-AS1 5.76 1.56e-08 6.01e-06 0.32 0.26 Lung cancer; chr6:149677438 chr6:149863494~149919507:+ LUSC cis rs13113518 0.756 rs12510275 ENSG00000272969.1 RP11-528I4.2 5.76 1.56e-08 6.02e-06 0.3 0.26 Height; chr4:55516548 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs12510327 ENSG00000272969.1 RP11-528I4.2 5.76 1.56e-08 6.02e-06 0.3 0.26 Height; chr4:55516744 chr4:55547112~55547889:+ LUSC cis rs13113518 0.812 rs11939580 ENSG00000272969.1 RP11-528I4.2 5.76 1.56e-08 6.02e-06 0.3 0.26 Height; chr4:55517185 chr4:55547112~55547889:+ LUSC cis rs6504950 0.889 rs2541237 ENSG00000275710.1 RP11-257O5.4 -5.75 1.57e-08 6.02e-06 -0.31 -0.26 Breast cancer; chr17:55086676 chr17:54964474~54964679:+ LUSC cis rs10759883 0.563 rs690286 ENSG00000175611.10 LINC00476 5.75 1.57e-08 6.02e-06 0.31 0.26 Nicotine dependence; chr9:96034685 chr9:95759231~95875977:- LUSC cis rs5770917 1 rs17848459 ENSG00000273272.1 CTA-384D8.34 5.75 1.57e-08 6.02e-06 0.53 0.26 Narcolepsy; chr22:50573882 chr22:50542650~50543011:+ LUSC cis rs5770917 1 rs12627787 ENSG00000273272.1 CTA-384D8.34 5.75 1.57e-08 6.02e-06 0.53 0.26 Narcolepsy; chr22:50573952 chr22:50542650~50543011:+ LUSC cis rs875971 0.862 rs778720 ENSG00000179406.6 LINC00174 5.75 1.57e-08 6.03e-06 0.28 0.26 Aortic root size; chr7:66381288 chr7:66376044~66401338:- LUSC cis rs7712401 0.601 rs27976 ENSG00000263432.2 RN7SL689P -5.75 1.57e-08 6.03e-06 -0.32 -0.26 Mean platelet volume; chr5:122870765 chr5:123022487~123022783:- LUSC cis rs34792 0.554 rs4597346 ENSG00000207425.1 Y_RNA -5.75 1.57e-08 6.03e-06 -0.36 -0.26 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15529889 chr16:14915457~14915556:- LUSC cis rs77204473 0.549 rs12280210 ENSG00000280143.1 AP000892.6 -5.75 1.57e-08 6.04e-06 -0.4 -0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117069733 chr11:117204967~117210292:+ LUSC cis rs875971 0.862 rs778734 ENSG00000179406.6 LINC00174 -5.75 1.57e-08 6.05e-06 -0.28 -0.26 Aortic root size; chr7:66349862 chr7:66376044~66401338:- LUSC cis rs12908161 0.853 rs12912342 ENSG00000259728.4 LINC00933 5.75 1.57e-08 6.05e-06 0.31 0.26 Schizophrenia; chr15:84704985 chr15:84570649~84580175:+ LUSC cis rs9322193 0.961 rs9027 ENSG00000268592.3 RAET1E-AS1 5.75 1.58e-08 6.06e-06 0.32 0.26 Lung cancer; chr6:149594921 chr6:149863494~149919507:+ LUSC cis rs875971 0.628 rs6974355 ENSG00000224316.1 RP11-479O9.2 5.75 1.58e-08 6.07e-06 0.25 0.26 Aortic root size; chr7:66376994 chr7:65773620~65802067:+ LUSC cis rs875971 0.862 rs11763189 ENSG00000179406.6 LINC00174 -5.75 1.58e-08 6.07e-06 -0.28 -0.26 Aortic root size; chr7:66518542 chr7:66376044~66401338:- LUSC cis rs367615 0.918 rs10070104 ENSG00000249476.1 CTD-2587M2.1 -5.75 1.58e-08 6.09e-06 -0.33 -0.26 Colorectal cancer (SNP x SNP interaction); chr5:109530737 chr5:109237120~109326369:- LUSC cis rs875971 0.825 rs59466412 ENSG00000179406.6 LINC00174 5.75 1.59e-08 6.09e-06 0.28 0.26 Aortic root size; chr7:66100371 chr7:66376044~66401338:- LUSC cis rs4372836 0.964 rs2293553 ENSG00000226833.4 AC097724.3 -5.75 1.59e-08 6.1e-06 -0.3 -0.26 Body mass index; chr2:28709418 chr2:28708953~28736205:- LUSC cis rs9341808 0.667 rs2490239 ENSG00000272129.1 RP11-250B2.6 5.75 1.59e-08 6.1e-06 0.32 0.26 Sitting height ratio; chr6:80116572 chr6:80355424~80356859:+ LUSC cis rs4964805 0.672 rs11111757 ENSG00000257681.1 RP11-341G23.4 5.75 1.59e-08 6.1e-06 0.29 0.26 Attention deficit hyperactivity disorder; chr12:103766984 chr12:103746315~103768858:- LUSC cis rs12468226 1 rs16839149 ENSG00000272966.1 RP11-686O6.1 5.75 1.59e-08 6.1e-06 0.42 0.26 Urate levels; chr2:202427621 chr2:202336739~202337200:+ LUSC cis rs950169 0.84 rs62019457 ENSG00000259295.5 CSPG4P12 5.75 1.59e-08 6.1e-06 0.34 0.26 Schizophrenia; chr15:84558911 chr15:85191438~85213905:+ LUSC cis rs957448 0.687 rs10104041 ENSG00000253175.1 RP11-267M23.6 5.75 1.59e-08 6.1e-06 0.29 0.26 Nonsyndromic cleft lip with cleft palate; chr8:94559374 chr8:94565036~94565715:+ LUSC cis rs227275 0.554 rs223422 ENSG00000246560.2 RP11-10L12.4 5.75 1.59e-08 6.1e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102805616 chr4:102828055~102844075:+ LUSC cis rs13113518 1 rs11726198 ENSG00000273257.1 RP11-177J6.1 5.75 1.59e-08 6.1e-06 0.33 0.26 Height; chr4:55523835 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs7675109 ENSG00000273257.1 RP11-177J6.1 5.75 1.59e-08 6.1e-06 0.33 0.26 Height; chr4:55525589 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs4865005 ENSG00000273257.1 RP11-177J6.1 5.75 1.59e-08 6.1e-06 0.33 0.26 Height; chr4:55525781 chr4:55387949~55388271:+ LUSC cis rs7246657 0.722 rs6508736 ENSG00000276846.1 CTD-3220F14.3 5.75 1.59e-08 6.1e-06 0.38 0.26 Coronary artery calcification; chr19:37570855 chr19:37314868~37315620:- LUSC cis rs853679 1 rs853676 ENSG00000219392.1 RP1-265C24.5 -5.75 1.59e-08 6.11e-06 -0.44 -0.26 Depression; chr6:28331910 chr6:28115628~28116551:+ LUSC cis rs17507216 0.958 rs72751643 ENSG00000276710.3 CSPG4P8 -5.75 1.59e-08 6.11e-06 -0.31 -0.26 Excessive daytime sleepiness; chr15:82559444 chr15:82459472~82477258:+ LUSC cis rs2136613 0.533 rs1412554 ENSG00000238280.1 RP11-436D10.3 5.75 1.59e-08 6.12e-06 0.31 0.26 Selective IgA deficiency; chr10:62850180 chr10:62793562~62805887:- LUSC cis rs2028299 1 rs1371135 ENSG00000259677.1 RP11-493E3.1 5.75 1.6e-08 6.13e-06 0.32 0.26 Type 2 diabetes; chr15:89848038 chr15:89876540~89877285:+ LUSC cis rs2153535 0.58 rs4639392 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8446314 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1832100 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8446723 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2327058 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8446785 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs2327059 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8446838 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2184582 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8447560 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs2184583 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8447575 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9505446 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8448458 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs1335633 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8448567 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6597322 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8449719 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs962590 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8450666 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs5001324 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8451371 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs5001322 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8451375 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs969422 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8451547 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs969421 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8451716 chr6:8784178~8785445:+ LUSC cis rs2153535 0.601 rs969420 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8451733 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7741456 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8452191 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7742689 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8452200 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7767756 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8453195 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs7767926 ENSG00000230939.1 RP11-314C16.1 -5.75 1.6e-08 6.13e-06 -0.3 -0.26 Motion sickness; chr6:8453324 chr6:8784178~8785445:+ LUSC cis rs9601248 0.627 rs2146593 ENSG00000227676.3 LINC01068 5.75 1.6e-08 6.13e-06 0.32 0.26 Major depressive disorder; chr13:79605977 chr13:79566727~79571436:+ LUSC cis rs8005677 0.828 rs4981451 ENSG00000279656.1 RP11-298I3.6 5.75 1.6e-08 6.13e-06 0.31 0.26 Cognitive ability (multi-trait analysis); chr14:22941072 chr14:23023083~23024217:- LUSC cis rs801193 0.967 rs3800823 ENSG00000237310.1 GS1-124K5.4 -5.75 1.6e-08 6.14e-06 -0.26 -0.26 Aortic root size; chr7:66682123 chr7:66493706~66495474:+ LUSC cis rs2337406 0.538 rs2015470 ENSG00000274576.2 IGHV2-70 -5.75 1.6e-08 6.14e-06 -0.25 -0.26 Alzheimer's disease (late onset); chr14:106631885 chr14:106770577~106771020:- LUSC cis rs673078 0.66 rs75752792 ENSG00000275759.1 RP11-131L12.3 -5.75 1.61e-08 6.17e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118187005 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs75571641 ENSG00000275759.1 RP11-131L12.3 -5.75 1.61e-08 6.17e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118187012 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs17512177 ENSG00000275759.1 RP11-131L12.3 -5.75 1.61e-08 6.17e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118192335 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs17512198 ENSG00000275759.1 RP11-131L12.3 -5.75 1.61e-08 6.17e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118194217 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs10507286 ENSG00000275759.1 RP11-131L12.3 -5.75 1.61e-08 6.17e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118197101 chr12:118428281~118428870:+ LUSC cis rs7772486 0.875 rs10457796 ENSG00000235652.6 RP11-545I5.3 5.75 1.61e-08 6.17e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146094951 chr6:145799409~145886585:+ LUSC cis rs224278 0.51 rs1888967 ENSG00000238280.1 RP11-436D10.3 -5.75 1.61e-08 6.18e-06 -0.33 -0.26 Ewing sarcoma; chr10:62819700 chr10:62793562~62805887:- LUSC cis rs801193 0.967 rs2420827 ENSG00000237310.1 GS1-124K5.4 -5.75 1.61e-08 6.19e-06 -0.26 -0.26 Aortic root size; chr7:66682114 chr7:66493706~66495474:+ LUSC cis rs6570726 0.764 rs9399553 ENSG00000235652.6 RP11-545I5.3 5.75 1.61e-08 6.19e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145552528 chr6:145799409~145886585:+ LUSC cis rs875971 0.619 rs2302918 ENSG00000222364.1 RNU6-96P -5.75 1.61e-08 6.19e-06 -0.3 -0.26 Aortic root size; chr7:66535945 chr7:66395191~66395286:+ LUSC cis rs67311347 1 rs9332450 ENSG00000223797.4 ENTPD3-AS1 -5.75 1.62e-08 6.2e-06 -0.28 -0.26 Renal cell carcinoma; chr3:40416550 chr3:40313802~40453329:- LUSC cis rs2404602 0.552 rs4886823 ENSG00000259422.1 RP11-593F23.1 -5.75 1.62e-08 6.2e-06 -0.32 -0.26 Blood metabolite levels; chr15:76673061 chr15:76174891~76181486:- LUSC cis rs801193 0.569 rs2707824 ENSG00000179406.6 LINC00174 -5.75 1.62e-08 6.21e-06 -0.28 -0.26 Aortic root size; chr7:66724256 chr7:66376044~66401338:- LUSC cis rs801193 0.569 rs2659893 ENSG00000179406.6 LINC00174 -5.75 1.62e-08 6.21e-06 -0.28 -0.26 Aortic root size; chr7:66735006 chr7:66376044~66401338:- LUSC cis rs801193 0.569 rs2659892 ENSG00000179406.6 LINC00174 -5.75 1.62e-08 6.21e-06 -0.28 -0.26 Aortic root size; chr7:66735318 chr7:66376044~66401338:- LUSC cis rs801193 0.569 rs2707847 ENSG00000179406.6 LINC00174 -5.75 1.62e-08 6.21e-06 -0.28 -0.26 Aortic root size; chr7:66737884 chr7:66376044~66401338:- LUSC cis rs2153535 0.601 rs9379224 ENSG00000230939.1 RP11-314C16.1 -5.75 1.62e-08 6.21e-06 -0.31 -0.26 Motion sickness; chr6:8538180 chr6:8784178~8785445:+ LUSC cis rs62025270 0.547 rs386346 ENSG00000202081.1 RNU6-1280P -5.75 1.62e-08 6.21e-06 -0.31 -0.26 Idiopathic pulmonary fibrosis; chr15:85651328 chr15:85651522~85651628:- LUSC cis rs13434995 0.513 rs2130040 ENSG00000249700.7 SRD5A3-AS1 5.75 1.62e-08 6.22e-06 0.32 0.26 Adiponectin levels; chr4:55564036 chr4:55363971~55395847:- LUSC cis rs442309 0.846 rs224072 ENSG00000238280.1 RP11-436D10.3 -5.75 1.63e-08 6.23e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62748961 chr10:62793562~62805887:- LUSC cis rs61270009 0.955 rs12657757 ENSG00000247828.6 TMEM161B-AS1 -5.75 1.63e-08 6.24e-06 -0.31 -0.26 Depressive symptoms; chr5:88280952 chr5:88268895~88436685:+ LUSC cis rs17270561 0.636 rs1185977 ENSG00000272462.2 U91328.19 -5.75 1.63e-08 6.24e-06 -0.3 -0.26 Iron status biomarkers; chr6:25828826 chr6:25992662~26001775:+ LUSC cis rs4718428 0.705 rs13220977 ENSG00000226824.5 RP4-756H11.3 5.75 1.63e-08 6.24e-06 0.35 0.26 Corneal structure; chr7:66872661 chr7:66654538~66669855:+ LUSC cis rs642803 0.613 rs565427 ENSG00000255557.1 RP11-770G2.2 -5.75 1.63e-08 6.25e-06 -0.32 -0.26 Urate levels; chr11:65765354 chr11:65745729~65771585:+ LUSC cis rs2842992 0.789 rs4709376 ENSG00000237927.1 RP3-393E18.2 -5.75 1.63e-08 6.25e-06 -0.39 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159805305 chr6:159586955~159589169:- LUSC cis rs801193 0.569 rs881285 ENSG00000179406.6 LINC00174 5.75 1.63e-08 6.25e-06 0.28 0.26 Aortic root size; chr7:66654433 chr7:66376044~66401338:- LUSC cis rs11157436 0.602 rs1894370 ENSG00000211813.2 TRAV34 5.75 1.64e-08 6.27e-06 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22166764 chr14:22207522~22208129:+ LUSC cis rs950880 0.614 rs60038017 ENSG00000234389.1 AC007278.3 -5.75 1.64e-08 6.27e-06 -0.27 -0.26 Serum protein levels (sST2); chr2:102459541 chr2:102438713~102440475:+ LUSC cis rs801193 0.66 rs2659914 ENSG00000179406.6 LINC00174 -5.75 1.64e-08 6.27e-06 -0.27 -0.26 Aortic root size; chr7:66691927 chr7:66376044~66401338:- LUSC cis rs11098499 0.588 rs2389874 ENSG00000248280.1 RP11-33B1.2 -5.75 1.64e-08 6.27e-06 -0.29 -0.26 Corneal astigmatism; chr4:119633836 chr4:119440561~119450157:- LUSC cis rs78487399 0.71 rs80147536 ENSG00000234936.1 AC010883.5 5.75 1.64e-08 6.27e-06 0.41 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43470889 chr2:43229573~43233394:+ LUSC cis rs78487399 0.808 rs75135247 ENSG00000234936.1 AC010883.5 5.75 1.64e-08 6.27e-06 0.41 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43472260 chr2:43229573~43233394:+ LUSC cis rs875971 0.789 rs7808013 ENSG00000179406.6 LINC00174 5.75 1.64e-08 6.28e-06 0.28 0.26 Aortic root size; chr7:66606209 chr7:66376044~66401338:- LUSC cis rs2842992 0.789 rs2295901 ENSG00000237927.1 RP3-393E18.2 -5.75 1.64e-08 6.28e-06 -0.38 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159780263 chr6:159586955~159589169:- LUSC cis rs2842992 0.789 rs3818300 ENSG00000237927.1 RP3-393E18.2 -5.75 1.64e-08 6.28e-06 -0.38 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159780645 chr6:159586955~159589169:- LUSC cis rs4722166 0.508 rs2069832 ENSG00000179428.2 AC073072.5 -5.75 1.64e-08 6.28e-06 -0.32 -0.26 Lung cancer; chr7:22727814 chr7:22725395~22727620:- LUSC cis rs9640161 0.75 rs3735169 ENSG00000261305.1 RP4-584D14.7 5.75 1.64e-08 6.28e-06 0.37 0.26 Blood protein levels;Circulating chemerin levels; chr7:150337289 chr7:150341771~150342607:+ LUSC cis rs11157436 0.602 rs12587826 ENSG00000211813.2 TRAV34 5.75 1.64e-08 6.3e-06 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22166305 chr14:22207522~22208129:+ LUSC cis rs5770917 1 rs115743514 ENSG00000273272.1 CTA-384D8.34 5.75 1.64e-08 6.3e-06 0.53 0.26 Narcolepsy; chr22:50573504 chr22:50542650~50543011:+ LUSC cis rs7246657 1 rs34544865 ENSG00000276846.1 CTD-3220F14.3 5.75 1.64e-08 6.3e-06 0.42 0.26 Coronary artery calcification; chr19:37310340 chr19:37314868~37315620:- LUSC cis rs61270009 0.955 rs12657776 ENSG00000247828.6 TMEM161B-AS1 5.75 1.65e-08 6.3e-06 0.29 0.26 Depressive symptoms; chr5:88365776 chr5:88268895~88436685:+ LUSC cis rs8177376 0.727 rs601985 ENSG00000254905.1 RP11-712L6.7 5.75 1.65e-08 6.3e-06 0.34 0.26 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126327662 chr11:126292922~126294254:- LUSC cis rs12554020 0.582 rs3829059 ENSG00000227603.1 RP11-165J3.6 5.75 1.65e-08 6.3e-06 0.45 0.26 Schizophrenia; chr9:93668874 chr9:93435332~93437121:- LUSC cis rs2337406 1 rs17113331 ENSG00000274576.2 IGHV2-70 -5.75 1.65e-08 6.32e-06 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106703843 chr14:106770577~106771020:- LUSC cis rs9611519 0.929 rs9611469 ENSG00000235513.1 RP4-756G23.5 5.75 1.65e-08 6.32e-06 0.3 0.26 Neuroticism; chr22:41037315 chr22:41209122~41217627:- LUSC cis rs67311347 1 rs17078916 ENSG00000223797.4 ENTPD3-AS1 5.75 1.65e-08 6.32e-06 0.29 0.26 Renal cell carcinoma; chr3:40403947 chr3:40313802~40453329:- LUSC cis rs7829975 0.514 rs2945873 ENSG00000253893.2 FAM85B -5.75 1.65e-08 6.33e-06 -0.3 -0.26 Mood instability; chr8:8402935 chr8:8167819~8226614:- LUSC cis rs7772486 0.875 rs1331639 ENSG00000235652.6 RP11-545I5.3 -5.75 1.65e-08 6.33e-06 -0.25 -0.26 Lobe attachment (rater-scored or self-reported); chr6:146110733 chr6:145799409~145886585:+ LUSC cis rs853679 1 rs1778508 ENSG00000219392.1 RP1-265C24.5 5.74 1.66e-08 6.34e-06 0.4 0.26 Depression; chr6:28262103 chr6:28115628~28116551:+ LUSC cis rs7772486 0.846 rs6908063 ENSG00000235652.6 RP11-545I5.3 5.74 1.66e-08 6.34e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146082482 chr6:145799409~145886585:+ LUSC cis rs7804306 1 rs13225545 ENSG00000233264.2 AC006042.8 5.74 1.66e-08 6.34e-06 0.45 0.26 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8027509 chr7:7980312~7982228:+ LUSC cis rs539514 0.516 rs2273996 ENSG00000261105.4 LMO7-AS1 -5.74 1.66e-08 6.34e-06 -0.31 -0.26 Type 1 diabetes; chr13:75836589 chr13:75604700~75635994:- LUSC cis rs7246657 0.663 rs4803287 ENSG00000276846.1 CTD-3220F14.3 5.74 1.66e-08 6.35e-06 0.37 0.26 Coronary artery calcification; chr19:37588534 chr19:37314868~37315620:- LUSC cis rs3738443 0.868 rs7551871 ENSG00000259865.1 RP11-488L18.10 5.74 1.66e-08 6.35e-06 0.26 0.26 Alcohol dependence; chr1:247199888 chr1:247187281~247188526:- LUSC cis rs875971 0.83 rs6950137 ENSG00000179406.6 LINC00174 -5.74 1.66e-08 6.35e-06 -0.28 -0.26 Aortic root size; chr7:66511623 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs709609 ENSG00000179406.6 LINC00174 5.74 1.66e-08 6.36e-06 0.28 0.26 Aortic root size; chr7:66095574 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs1167399 ENSG00000179406.6 LINC00174 5.74 1.66e-08 6.36e-06 0.28 0.26 Aortic root size; chr7:66096890 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs57866200 ENSG00000179406.6 LINC00174 5.74 1.66e-08 6.36e-06 0.28 0.26 Aortic root size; chr7:66100405 chr7:66376044~66401338:- LUSC cis rs2919917 0.628 rs10109359 ENSG00000254352.1 RP11-578O24.2 5.74 1.66e-08 6.36e-06 0.35 0.26 Lymphocyte counts; chr8:78694369 chr8:78723796~78724136:- LUSC cis rs7665090 1 rs11727546 ENSG00000230069.3 LRRC37A15P -5.74 1.66e-08 6.36e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102636507 chr4:102727274~102730721:- LUSC cis rs13113518 0.966 rs11133396 ENSG00000273257.1 RP11-177J6.1 5.74 1.66e-08 6.36e-06 0.33 0.26 Height; chr4:55524246 chr4:55387949~55388271:+ LUSC cis rs875971 0.505 rs1167385 ENSG00000222364.1 RNU6-96P 5.74 1.67e-08 6.37e-06 0.3 0.26 Aortic root size; chr7:66048321 chr7:66395191~66395286:+ LUSC cis rs6918586 0.636 rs198817 ENSG00000272462.2 U91328.19 -5.74 1.67e-08 6.37e-06 -0.27 -0.26 Schizophrenia; chr6:26126296 chr6:25992662~26001775:+ LUSC cis rs2153535 0.58 rs9406159 ENSG00000230939.1 RP11-314C16.1 -5.74 1.67e-08 6.37e-06 -0.31 -0.26 Motion sickness; chr6:8464626 chr6:8784178~8785445:+ LUSC cis rs13113518 1 rs4864548 ENSG00000272969.1 RP11-528I4.2 -5.74 1.67e-08 6.37e-06 -0.29 -0.26 Height; chr4:55547636 chr4:55547112~55547889:+ LUSC cis rs11157436 0.602 rs928955 ENSG00000211813.2 TRAV34 5.74 1.67e-08 6.38e-06 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22166273 chr14:22207522~22208129:+ LUSC cis rs13113518 0.812 rs11945371 ENSG00000273257.1 RP11-177J6.1 5.74 1.67e-08 6.38e-06 0.33 0.26 Height; chr4:55409063 chr4:55387949~55388271:+ LUSC cis rs783540 0.843 rs9652567 ENSG00000255769.6 GOLGA2P10 -5.74 1.67e-08 6.39e-06 -0.31 -0.26 Schizophrenia; chr15:82699762 chr15:82472993~82513950:- LUSC cis rs783540 0.934 rs4779050 ENSG00000255769.6 GOLGA2P10 -5.74 1.67e-08 6.39e-06 -0.31 -0.26 Schizophrenia; chr15:82699986 chr15:82472993~82513950:- LUSC cis rs9549367 0.826 rs1885688 ENSG00000269125.1 RP11-98F14.11 -5.74 1.67e-08 6.39e-06 -0.31 -0.26 Platelet distribution width; chr13:113239922 chr13:113165002~113165183:- LUSC cis rs459571 0.92 rs460154 ENSG00000235106.7 LINC00094 5.74 1.67e-08 6.39e-06 0.28 0.26 Platelet distribution width; chr9:134044187 chr9:134025439~134034666:+ LUSC cis rs67311347 1 rs12488805 ENSG00000223797.4 ENTPD3-AS1 5.74 1.67e-08 6.39e-06 0.3 0.26 Renal cell carcinoma; chr3:40381378 chr3:40313802~40453329:- LUSC cis rs9640161 0.75 rs11764936 ENSG00000261305.1 RP4-584D14.7 5.74 1.67e-08 6.4e-06 0.37 0.26 Blood protein levels;Circulating chemerin levels; chr7:150328826 chr7:150341771~150342607:+ LUSC cis rs2243480 1 rs316312 ENSG00000226824.5 RP4-756H11.3 -5.74 1.67e-08 6.4e-06 -0.48 -0.26 Diabetic kidney disease; chr7:66131504 chr7:66654538~66669855:+ LUSC cis rs6683071 0.688 rs3008637 ENSG00000272750.1 RP11-378J18.8 5.74 1.68e-08 6.41e-06 0.34 0.26 Cognitive performance; chr1:222684427 chr1:222658867~222661512:- LUSC cis rs783540 1 rs7496954 ENSG00000276710.3 CSPG4P8 -5.74 1.68e-08 6.41e-06 -0.27 -0.26 Schizophrenia; chr15:82676784 chr15:82459472~82477258:+ LUSC cis rs1122900 1 rs56039629 ENSG00000250155.1 CTD-2353F22.1 5.74 1.68e-08 6.41e-06 0.25 0.26 Aggressive periodontitis; chr5:36683801 chr5:36666214~36725195:- LUSC cis rs36423 0.748 rs36415 ENSG00000266869.1 RP6-114E22.1 -5.74 1.68e-08 6.41e-06 -0.4 -0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71888958 chr14:71848606~71908430:+ LUSC cis rs7429990 0.828 rs55823596 ENSG00000229759.1 MRPS18AP1 5.74 1.68e-08 6.42e-06 0.26 0.26 Educational attainment (years of education); chr3:47758541 chr3:48256350~48256938:- LUSC cis rs7429990 0.864 rs4858853 ENSG00000229759.1 MRPS18AP1 5.74 1.68e-08 6.42e-06 0.26 0.26 Educational attainment (years of education); chr3:47760605 chr3:48256350~48256938:- LUSC cis rs34779708 0.733 rs7081597 ENSG00000230534.5 RP11-297A16.2 5.74 1.68e-08 6.43e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35257403 chr10:35098006~35127020:- LUSC cis rs9326248 0.52 rs1446105 ENSG00000280143.1 AP000892.6 5.74 1.68e-08 6.43e-06 0.27 0.26 Blood protein levels; chr11:116927828 chr11:117204967~117210292:+ LUSC cis rs10759883 0.549 rs816680 ENSG00000175611.10 LINC00476 -5.74 1.69e-08 6.44e-06 -0.31 -0.26 Nicotine dependence; chr9:95804111 chr9:95759231~95875977:- LUSC cis rs1021993 0.597 rs79455200 ENSG00000231648.1 RP11-372M18.2 -5.74 1.69e-08 6.45e-06 -0.38 -0.26 Gut microbiome composition (winter); chr1:209334422 chr1:209367662~209379690:+ LUSC cis rs1021993 0.597 rs17014320 ENSG00000231648.1 RP11-372M18.2 -5.74 1.69e-08 6.45e-06 -0.38 -0.26 Gut microbiome composition (winter); chr1:209338828 chr1:209367662~209379690:+ LUSC cis rs61160187 0.667 rs7722373 ENSG00000215032.2 GNL3LP1 5.74 1.69e-08 6.45e-06 0.32 0.26 Educational attainment (years of education);Educational attainment (college completion); chr5:60951988 chr5:60891935~60893577:- LUSC cis rs642803 0.551 rs1308020 ENSG00000255557.1 RP11-770G2.2 -5.74 1.69e-08 6.45e-06 -0.31 -0.26 Urate levels; chr11:65730087 chr11:65745729~65771585:+ LUSC cis rs7665090 0.87 rs227361 ENSG00000230069.3 LRRC37A15P -5.74 1.69e-08 6.46e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102665820 chr4:102727274~102730721:- LUSC cis rs7246657 0.722 rs2909093 ENSG00000276846.1 CTD-3220F14.3 -5.74 1.69e-08 6.46e-06 -0.38 -0.26 Coronary artery calcification; chr19:37708561 chr19:37314868~37315620:- LUSC cis rs10759883 0.539 rs10988755 ENSG00000175611.10 LINC00476 5.74 1.69e-08 6.46e-06 0.3 0.26 Nicotine dependence; chr9:95944085 chr9:95759231~95875977:- LUSC cis rs10759883 0.587 rs603947 ENSG00000175611.10 LINC00476 5.74 1.69e-08 6.46e-06 0.3 0.26 Nicotine dependence; chr9:95944647 chr9:95759231~95875977:- LUSC cis rs10759883 0.563 rs7847983 ENSG00000175611.10 LINC00476 5.74 1.69e-08 6.46e-06 0.3 0.26 Nicotine dependence; chr9:95948046 chr9:95759231~95875977:- LUSC cis rs10759883 0.563 rs10819650 ENSG00000175611.10 LINC00476 5.74 1.69e-08 6.46e-06 0.3 0.26 Nicotine dependence; chr9:95951161 chr9:95759231~95875977:- LUSC cis rs10759883 0.563 rs10760679 ENSG00000175611.10 LINC00476 5.74 1.69e-08 6.46e-06 0.3 0.26 Nicotine dependence; chr9:95951511 chr9:95759231~95875977:- LUSC cis rs4372836 0.964 rs4531886 ENSG00000226833.4 AC097724.3 -5.74 1.69e-08 6.47e-06 -0.3 -0.26 Body mass index; chr2:28695098 chr2:28708953~28736205:- LUSC cis rs875971 0.545 rs6950988 ENSG00000224316.1 RP11-479O9.2 5.74 1.7e-08 6.47e-06 0.27 0.26 Aortic root size; chr7:66511428 chr7:65773620~65802067:+ LUSC cis rs853679 1 rs68141011 ENSG00000204709.4 LINC01556 5.74 1.7e-08 6.47e-06 0.43 0.26 Depression; chr6:28250019 chr6:28943877~28944537:+ LUSC cis rs853679 1 rs13200462 ENSG00000204709.4 LINC01556 5.74 1.7e-08 6.47e-06 0.43 0.26 Depression; chr6:28250421 chr6:28943877~28944537:+ LUSC cis rs7267979 0.966 rs2257233 ENSG00000274973.1 RP13-401N8.7 5.74 1.7e-08 6.47e-06 0.26 0.26 Liver enzyme levels (alkaline phosphatase); chr20:25285348 chr20:25845497~25845862:+ LUSC cis rs910316 0.737 rs175424 ENSG00000279594.1 RP11-950C14.10 -5.74 1.7e-08 6.47e-06 -0.3 -0.26 Height; chr14:75159554 chr14:75011269~75012851:- LUSC cis rs910316 0.763 rs2080201 ENSG00000279594.1 RP11-950C14.10 -5.74 1.7e-08 6.47e-06 -0.3 -0.26 Height; chr14:75163269 chr14:75011269~75012851:- LUSC cis rs72627123 1 rs2302138 ENSG00000259065.1 RP5-1021I20.1 -5.74 1.7e-08 6.48e-06 -0.45 -0.26 Morning vs. evening chronotype; chr14:73896602 chr14:73787360~73803270:+ LUSC cis rs673078 0.66 rs58113338 ENSG00000275759.1 RP11-131L12.3 -5.74 1.7e-08 6.48e-06 -0.38 -0.26 Glucose homeostasis traits; chr12:118251335 chr12:118428281~118428870:+ LUSC cis rs13113518 1 rs1047354 ENSG00000249700.7 SRD5A3-AS1 5.74 1.7e-08 6.48e-06 0.3 0.26 Height; chr4:55429416 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs1056547 ENSG00000249700.7 SRD5A3-AS1 5.74 1.7e-08 6.48e-06 0.3 0.26 Height; chr4:55430596 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs1056545 ENSG00000249700.7 SRD5A3-AS1 5.74 1.7e-08 6.48e-06 0.3 0.26 Height; chr4:55430730 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs5863 ENSG00000249700.7 SRD5A3-AS1 5.74 1.7e-08 6.48e-06 0.3 0.26 Height; chr4:55430740 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs6828570 ENSG00000249700.7 SRD5A3-AS1 5.74 1.7e-08 6.48e-06 0.3 0.26 Height; chr4:55431595 chr4:55363971~55395847:- LUSC cis rs11098499 0.863 rs10004484 ENSG00000248280.1 RP11-33B1.2 5.74 1.7e-08 6.48e-06 0.31 0.26 Corneal astigmatism; chr4:119521273 chr4:119440561~119450157:- LUSC cis rs7555523 0.779 rs2790049 ENSG00000224358.1 RP11-466F5.8 -5.74 1.7e-08 6.49e-06 -0.33 -0.26 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165774286 chr1:165768929~165775176:+ LUSC cis rs6969780 0.915 rs12666919 ENSG00000233429.8 HOTAIRM1 -5.74 1.7e-08 6.49e-06 -0.43 -0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27149879 chr7:27095647~27100265:+ LUSC cis rs2153535 0.58 rs6941670 ENSG00000230939.1 RP11-314C16.1 -5.74 1.7e-08 6.5e-06 -0.3 -0.26 Motion sickness; chr6:8446113 chr6:8784178~8785445:+ LUSC cis rs11159086 0.793 rs9285594 ENSG00000270000.1 RP3-449M8.9 5.74 1.7e-08 6.5e-06 0.38 0.26 Advanced glycation end-product levels; chr14:74489253 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs4903229 ENSG00000270000.1 RP3-449M8.9 5.74 1.7e-08 6.5e-06 0.38 0.26 Advanced glycation end-product levels; chr14:74489865 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs8016972 ENSG00000270000.1 RP3-449M8.9 5.74 1.7e-08 6.5e-06 0.38 0.26 Advanced glycation end-product levels; chr14:74491833 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs8015894 ENSG00000270000.1 RP3-449M8.9 5.74 1.7e-08 6.5e-06 0.38 0.26 Advanced glycation end-product levels; chr14:74491917 chr14:74471930~74472360:- LUSC cis rs875971 0.825 rs7384021 ENSG00000179406.6 LINC00174 5.74 1.7e-08 6.5e-06 0.28 0.26 Aortic root size; chr7:66612917 chr7:66376044~66401338:- LUSC cis rs3738443 0.868 rs4351686 ENSG00000259865.1 RP11-488L18.10 5.74 1.71e-08 6.51e-06 0.28 0.26 Alcohol dependence; chr1:247190028 chr1:247187281~247188526:- LUSC cis rs2028299 0.92 rs2118847 ENSG00000259677.1 RP11-493E3.1 5.74 1.71e-08 6.51e-06 0.33 0.26 Type 2 diabetes; chr15:89865615 chr15:89876540~89877285:+ LUSC cis rs6504950 0.889 rs2628305 ENSG00000275710.1 RP11-257O5.4 5.74 1.71e-08 6.51e-06 0.31 0.26 Breast cancer; chr17:55063066 chr17:54964474~54964679:+ LUSC cis rs7772486 0.79 rs2250387 ENSG00000235652.6 RP11-545I5.3 5.74 1.71e-08 6.52e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145884097 chr6:145799409~145886585:+ LUSC cis rs28830936 0.966 rs2303518 ENSG00000250379.1 RP11-23P13.4 5.74 1.71e-08 6.52e-06 0.27 0.26 Diastolic blood pressure; chr15:41817777 chr15:41825099~41827936:- LUSC cis rs2439831 0.85 rs28413881 ENSG00000249839.1 AC011330.5 -5.74 1.71e-08 6.53e-06 -0.53 -0.26 Lung cancer in ever smokers; chr15:43881901 chr15:43663654~43684339:- LUSC cis rs7804306 1 rs35143180 ENSG00000233264.2 AC006042.8 5.74 1.71e-08 6.53e-06 0.45 0.26 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8017141 chr7:7980312~7982228:+ LUSC cis rs2732480 0.538 rs1387260 ENSG00000240399.1 RP1-228P16.1 5.74 1.71e-08 6.54e-06 0.28 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48309308 chr12:48054813~48055591:- LUSC cis rs7772486 0.738 rs75288066 ENSG00000235652.6 RP11-545I5.3 5.74 1.72e-08 6.56e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145998250 chr6:145799409~145886585:+ LUSC cis rs7772486 0.738 rs9485039 ENSG00000235652.6 RP11-545I5.3 5.74 1.72e-08 6.56e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145998251 chr6:145799409~145886585:+ LUSC cis rs7772486 0.713 rs79248977 ENSG00000235652.6 RP11-545I5.3 5.74 1.72e-08 6.56e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145998252 chr6:145799409~145886585:+ LUSC cis rs13113518 1 rs4864549 ENSG00000223305.1 RN7SKP30 5.74 1.72e-08 6.56e-06 0.31 0.26 Height; chr4:55554380 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs4865011 ENSG00000223305.1 RN7SKP30 5.74 1.72e-08 6.56e-06 0.31 0.26 Height; chr4:55554456 chr4:55540502~55540835:- LUSC cis rs950880 0.71 rs3821204 ENSG00000234389.1 AC007278.3 -5.74 1.72e-08 6.56e-06 -0.28 -0.26 Serum protein levels (sST2); chr2:102343821 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs12469506 ENSG00000234389.1 AC007278.3 -5.74 1.72e-08 6.56e-06 -0.28 -0.26 Serum protein levels (sST2); chr2:102349411 chr2:102438713~102440475:+ LUSC cis rs7772486 0.875 rs9322045 ENSG00000235652.6 RP11-545I5.3 5.74 1.72e-08 6.56e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146063814 chr6:145799409~145886585:+ LUSC cis rs2834288 0.535 rs4816469 ENSG00000273102.1 AP000569.9 5.74 1.72e-08 6.57e-06 0.28 0.26 Gut microbiota (bacterial taxa); chr21:33952321 chr21:33967101~33968573:- LUSC cis rs5770917 1 rs2269385 ENSG00000273272.1 CTA-384D8.34 5.74 1.72e-08 6.57e-06 0.53 0.26 Narcolepsy; chr22:50572510 chr22:50542650~50543011:+ LUSC cis rs5770917 1 rs2269384 ENSG00000273272.1 CTA-384D8.34 5.74 1.72e-08 6.57e-06 0.53 0.26 Narcolepsy; chr22:50572686 chr22:50542650~50543011:+ LUSC cis rs875971 0.545 rs10261710 ENSG00000237310.1 GS1-124K5.4 5.74 1.72e-08 6.58e-06 0.3 0.26 Aortic root size; chr7:66249202 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs3926380 ENSG00000179406.6 LINC00174 5.74 1.73e-08 6.58e-06 0.28 0.26 Aortic root size; chr7:66615658 chr7:66376044~66401338:- LUSC cis rs875971 0.825 rs1860472 ENSG00000179406.6 LINC00174 5.74 1.73e-08 6.58e-06 0.28 0.26 Aortic root size; chr7:66617736 chr7:66376044~66401338:- LUSC cis rs6683071 0.738 rs2030076 ENSG00000272750.1 RP11-378J18.8 -5.74 1.73e-08 6.58e-06 -0.34 -0.26 Cognitive performance; chr1:222701624 chr1:222658867~222661512:- LUSC cis rs950880 0.677 rs56224165 ENSG00000234389.1 AC007278.3 -5.74 1.73e-08 6.58e-06 -0.28 -0.26 Serum protein levels (sST2); chr2:102308763 chr2:102438713~102440475:+ LUSC cis rs2337406 0.929 rs12050233 ENSG00000280411.1 IGHV1-69-2 -5.74 1.73e-08 6.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781123 chr14:106762092~106762588:- LUSC cis rs2337406 0.852 rs12050466 ENSG00000280411.1 IGHV1-69-2 -5.74 1.73e-08 6.58e-06 -0.22 -0.26 Alzheimer's disease (late onset); chr14:106781131 chr14:106762092~106762588:- LUSC cis rs113835537 0.935 rs11550057 ENSG00000255517.5 CTD-3074O7.5 -5.74 1.73e-08 6.58e-06 -0.35 -0.26 Airway imaging phenotypes; chr11:66625409 chr11:66473490~66480233:- LUSC cis rs113835537 0.935 rs15969 ENSG00000255517.5 CTD-3074O7.5 -5.74 1.73e-08 6.58e-06 -0.35 -0.26 Airway imaging phenotypes; chr11:66626916 chr11:66473490~66480233:- LUSC cis rs2842992 0.83 rs2758312 ENSG00000237927.1 RP3-393E18.2 -5.74 1.73e-08 6.58e-06 -0.37 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159732420 chr6:159586955~159589169:- LUSC cis rs2274273 0.804 rs28428911 ENSG00000258413.1 RP11-665C16.6 -5.74 1.73e-08 6.59e-06 -0.31 -0.26 Protein biomarker; chr14:55376878 chr14:55262767~55272075:- LUSC cis rs442309 0.846 rs224125 ENSG00000238280.1 RP11-436D10.3 -5.74 1.73e-08 6.6e-06 -0.33 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62694329 chr10:62793562~62805887:- LUSC cis rs12554020 0.582 rs76499753 ENSG00000227603.1 RP11-165J3.6 5.74 1.73e-08 6.6e-06 0.45 0.26 Schizophrenia; chr9:93670155 chr9:93435332~93437121:- LUSC cis rs12554020 0.582 rs1963 ENSG00000227603.1 RP11-165J3.6 5.74 1.73e-08 6.6e-06 0.45 0.26 Schizophrenia; chr9:93670315 chr9:93435332~93437121:- LUSC cis rs12554020 0.582 rs76244171 ENSG00000227603.1 RP11-165J3.6 5.74 1.73e-08 6.6e-06 0.45 0.26 Schizophrenia; chr9:93673473 chr9:93435332~93437121:- LUSC cis rs12554020 0.582 rs74921118 ENSG00000227603.1 RP11-165J3.6 5.74 1.73e-08 6.6e-06 0.45 0.26 Schizophrenia; chr9:93675241 chr9:93435332~93437121:- LUSC cis rs5753618 0.509 rs1034589 ENSG00000236132.1 CTA-440B3.1 5.74 1.73e-08 6.6e-06 0.35 0.26 Colorectal cancer; chr22:31183247 chr22:31816379~31817491:- LUSC cis rs875971 0.862 rs1875057 ENSG00000179406.6 LINC00174 5.74 1.73e-08 6.61e-06 0.28 0.26 Aortic root size; chr7:66266868 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6960446 ENSG00000179406.6 LINC00174 5.74 1.73e-08 6.61e-06 0.28 0.26 Aortic root size; chr7:66268272 chr7:66376044~66401338:- LUSC cis rs875971 0.789 rs10260426 ENSG00000179406.6 LINC00174 5.74 1.73e-08 6.61e-06 0.28 0.26 Aortic root size; chr7:66271055 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs10263690 ENSG00000179406.6 LINC00174 5.74 1.73e-08 6.61e-06 0.28 0.26 Aortic root size; chr7:66301466 chr7:66376044~66401338:- LUSC cis rs13113518 0.966 rs11133387 ENSG00000249700.7 SRD5A3-AS1 5.74 1.74e-08 6.61e-06 0.3 0.26 Height; chr4:55475130 chr4:55363971~55395847:- LUSC cis rs7772486 0.875 rs10457795 ENSG00000235652.6 RP11-545I5.3 5.74 1.74e-08 6.61e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146094529 chr6:145799409~145886585:+ LUSC cis rs7665090 0.846 rs4496586 ENSG00000230069.3 LRRC37A15P -5.74 1.74e-08 6.61e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102636154 chr4:102727274~102730721:- LUSC cis rs875971 1 rs937495 ENSG00000179406.6 LINC00174 5.74 1.74e-08 6.61e-06 0.27 0.26 Aortic root size; chr7:66314811 chr7:66376044~66401338:- LUSC cis rs875971 1 rs2036264 ENSG00000179406.6 LINC00174 5.74 1.74e-08 6.61e-06 0.27 0.26 Aortic root size; chr7:66334917 chr7:66376044~66401338:- LUSC cis rs875971 1 rs7783613 ENSG00000179406.6 LINC00174 5.74 1.74e-08 6.61e-06 0.27 0.26 Aortic root size; chr7:66340274 chr7:66376044~66401338:- LUSC cis rs7208859 0.524 rs60114476 ENSG00000263603.1 CTD-2349P21.5 -5.74 1.74e-08 6.62e-06 -0.36 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30729469~30731202:+ LUSC cis rs7208859 0.524 rs8065744 ENSG00000263603.1 CTD-2349P21.5 -5.74 1.74e-08 6.62e-06 -0.36 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30729469~30731202:+ LUSC cis rs17826219 0.706 rs8071236 ENSG00000263603.1 CTD-2349P21.5 -5.74 1.74e-08 6.62e-06 -0.36 -0.26 Body mass index; chr17:30772984 chr17:30729469~30731202:+ LUSC cis rs17826219 0.636 rs2449770 ENSG00000263603.1 CTD-2349P21.5 -5.74 1.74e-08 6.62e-06 -0.36 -0.26 Body mass index; chr17:30774046 chr17:30729469~30731202:+ LUSC cis rs7208859 0.524 rs59913838 ENSG00000263603.1 CTD-2349P21.5 -5.74 1.74e-08 6.62e-06 -0.36 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30729469~30731202:+ LUSC cis rs853679 1 rs7740487 ENSG00000204709.4 LINC01556 5.74 1.74e-08 6.63e-06 0.43 0.26 Depression; chr6:28248708 chr6:28943877~28944537:+ LUSC cis rs7246657 0.722 rs8100646 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37617042 chr19:37314868~37315620:- LUSC cis rs801193 0.569 rs3846973 ENSG00000179406.6 LINC00174 5.74 1.75e-08 6.65e-06 0.28 0.26 Aortic root size; chr7:66655048 chr7:66376044~66401338:- LUSC cis rs801193 0.569 rs2013908 ENSG00000179406.6 LINC00174 5.74 1.75e-08 6.65e-06 0.28 0.26 Aortic root size; chr7:66656082 chr7:66376044~66401338:- LUSC cis rs801193 0.569 rs6951302 ENSG00000179406.6 LINC00174 5.74 1.75e-08 6.65e-06 0.28 0.26 Aortic root size; chr7:66667525 chr7:66376044~66401338:- LUSC cis rs11846409 0.86 rs61686131 ENSG00000274576.2 IGHV2-70 -5.74 1.75e-08 6.65e-06 -0.26 -0.26 Rheumatic heart disease; chr14:106631568 chr14:106770577~106771020:- LUSC cis rs7246657 0.722 rs954504 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37554492 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs8110865 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37556485 chr19:37314868~37315620:- LUSC cis rs7246657 0.678 rs4802024 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37561291 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs4802029 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37564710 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs28512414 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37565672 chr19:37314868~37315620:- LUSC cis rs7246657 0.55 rs9941475 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37573615 chr19:37314868~37315620:- LUSC cis rs7246657 0.765 rs4803262 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37575858 chr19:37314868~37315620:- LUSC cis rs7246657 0.712 rs4803263 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37575880 chr19:37314868~37315620:- LUSC cis rs7246657 0.663 rs10408619 ENSG00000276846.1 CTD-3220F14.3 5.74 1.75e-08 6.65e-06 0.38 0.26 Coronary artery calcification; chr19:37579573 chr19:37314868~37315620:- LUSC cis rs116095464 0.558 rs1541822 ENSG00000250848.1 CTD-2083E4.5 5.73 1.75e-08 6.66e-06 0.39 0.26 Breast cancer; chr5:269119 chr5:288833~290321:- LUSC cis rs2337406 1 rs17113331 ENSG00000254174.1 IGHV1-12 5.73 1.75e-08 6.66e-06 0.26 0.26 Alzheimer's disease (late onset); chr14:106703843 chr14:106122420~106122709:- LUSC cis rs35542019 1 rs35542019 ENSG00000273102.1 AP000569.9 5.73 1.75e-08 6.66e-06 0.28 0.26 Hemoglobin concentration;Hematocrit;Red blood cell count; chr21:33974555 chr21:33967101~33968573:- LUSC cis rs6565180 0.962 rs6565182 ENSG00000183604.13 SMG1P5 -5.73 1.75e-08 6.67e-06 -0.31 -0.26 Tonsillectomy; chr16:30363060 chr16:30267553~30335374:- LUSC cis rs11159086 0.793 rs10147316 ENSG00000270000.1 RP3-449M8.9 5.73 1.75e-08 6.67e-06 0.38 0.26 Advanced glycation end-product levels; chr14:74475688 chr14:74471930~74472360:- LUSC cis rs11159086 0.838 rs10147963 ENSG00000270000.1 RP3-449M8.9 5.73 1.75e-08 6.67e-06 0.38 0.26 Advanced glycation end-product levels; chr14:74476091 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs8021664 ENSG00000270000.1 RP3-449M8.9 5.73 1.75e-08 6.67e-06 0.38 0.26 Advanced glycation end-product levels; chr14:74476592 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs10150696 ENSG00000270000.1 RP3-449M8.9 5.73 1.75e-08 6.67e-06 0.38 0.26 Advanced glycation end-product levels; chr14:74476723 chr14:74471930~74472360:- LUSC cis rs875971 0.545 rs73146609 ENSG00000237310.1 GS1-124K5.4 5.73 1.75e-08 6.67e-06 0.29 0.26 Aortic root size; chr7:66302477 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs2173571 ENSG00000237310.1 GS1-124K5.4 5.73 1.75e-08 6.67e-06 0.29 0.26 Aortic root size; chr7:66305392 chr7:66493706~66495474:+ LUSC cis rs910316 0.737 rs175510 ENSG00000279594.1 RP11-950C14.10 -5.73 1.76e-08 6.68e-06 -0.3 -0.26 Height; chr14:75058136 chr14:75011269~75012851:- LUSC cis rs9813712 0.595 rs1453240 ENSG00000228252.7 COL6A4P2 -5.73 1.76e-08 6.68e-06 -0.24 -0.26 Response to amphetamines; chr3:130282849 chr3:130212823~130273806:+ LUSC cis rs11690935 0.885 rs10202823 ENSG00000228389.1 AC068039.4 5.73 1.76e-08 6.68e-06 0.3 0.26 Schizophrenia; chr2:171923622 chr2:171773482~171775844:+ LUSC cis rs2404602 1 rs12148786 ENSG00000259422.1 RP11-593F23.1 5.73 1.76e-08 6.69e-06 0.29 0.26 Blood metabolite levels; chr15:76508021 chr15:76174891~76181486:- LUSC cis rs6928977 0.675 rs7759971 ENSG00000234084.1 RP3-388E23.2 -5.73 1.76e-08 6.69e-06 -0.21 -0.26 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135425746 chr6:135301568~135307158:+ LUSC cis rs12468226 0.935 rs75597391 ENSG00000272966.1 RP11-686O6.1 5.73 1.76e-08 6.69e-06 0.42 0.26 Urate levels; chr2:202398850 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs12472408 ENSG00000272966.1 RP11-686O6.1 5.73 1.76e-08 6.69e-06 0.42 0.26 Urate levels; chr2:202413973 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs115170232 ENSG00000272966.1 RP11-686O6.1 5.73 1.76e-08 6.69e-06 0.42 0.26 Urate levels; chr2:202416790 chr2:202336739~202337200:+ LUSC cis rs2337406 0.866 rs988130 ENSG00000211974.3 IGHV2-70 -5.73 1.76e-08 6.69e-06 -0.33 -0.26 Alzheimer's disease (late onset); chr14:106777154 chr14:106723574~106724093:- LUSC cis rs5770917 1 rs1557503 ENSG00000273272.1 CTA-384D8.34 5.73 1.76e-08 6.69e-06 0.52 0.26 Narcolepsy; chr22:50574643 chr22:50542650~50543011:+ LUSC cis rs3096299 0.617 rs2353030 ENSG00000274627.1 RP11-104N10.2 -5.73 1.76e-08 6.7e-06 -0.22 -0.26 Multiple myeloma (IgH translocation); chr16:89339419 chr16:89516797~89522217:+ LUSC cis rs75920871 0.557 rs7123336 ENSG00000254851.1 RP11-109L13.1 5.73 1.76e-08 6.7e-06 0.35 0.26 Subjective well-being; chr11:116912103 chr11:117135528~117138582:+ LUSC cis rs3738443 0.817 rs6698690 ENSG00000259865.1 RP11-488L18.10 5.73 1.76e-08 6.71e-06 0.27 0.26 Alcohol dependence; chr1:247199176 chr1:247187281~247188526:- LUSC cis rs7772486 0.817 rs9322047 ENSG00000235652.6 RP11-545I5.3 5.73 1.76e-08 6.71e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146079258 chr6:145799409~145886585:+ LUSC cis rs8005677 0.962 rs10130756 ENSG00000279656.1 RP11-298I3.6 5.73 1.77e-08 6.71e-06 0.3 0.26 Cognitive ability (multi-trait analysis); chr14:22927391 chr14:23023083~23024217:- LUSC cis rs875971 0.545 rs4718348 ENSG00000224316.1 RP11-479O9.2 5.73 1.77e-08 6.72e-06 0.28 0.26 Aortic root size; chr7:66441589 chr7:65773620~65802067:+ LUSC cis rs673078 0.66 rs73205531 ENSG00000275759.1 RP11-131L12.3 -5.73 1.77e-08 6.72e-06 -0.39 -0.26 Glucose homeostasis traits; chr12:118282063 chr12:118428281~118428870:+ LUSC cis rs78487399 0.71 rs75330033 ENSG00000234936.1 AC010883.5 5.73 1.77e-08 6.74e-06 0.41 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43470584 chr2:43229573~43233394:+ LUSC cis rs9640161 0.711 rs55881542 ENSG00000261305.1 RP4-584D14.7 5.73 1.77e-08 6.74e-06 0.37 0.26 Blood protein levels;Circulating chemerin levels; chr7:150328645 chr7:150341771~150342607:+ LUSC cis rs950880 0.71 rs3771172 ENSG00000234389.1 AC007278.3 -5.73 1.78e-08 6.76e-06 -0.28 -0.26 Serum protein levels (sST2); chr2:102369352 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs2160202 ENSG00000234389.1 AC007278.3 -5.73 1.78e-08 6.76e-06 -0.28 -0.26 Serum protein levels (sST2); chr2:102369694 chr2:102438713~102440475:+ LUSC cis rs7829975 0.501 rs2980769 ENSG00000173295.6 FAM86B3P 5.73 1.78e-08 6.76e-06 0.28 0.26 Mood instability; chr8:8462781 chr8:8228595~8244865:+ LUSC cis rs7829975 0.509 rs2945269 ENSG00000253893.2 FAM85B -5.73 1.78e-08 6.76e-06 -0.31 -0.26 Mood instability; chr8:8258056 chr8:8167819~8226614:- LUSC cis rs73173548 0.502 rs10505857 ENSG00000247828.6 TMEM161B-AS1 5.73 1.78e-08 6.76e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88420376 chr5:88268895~88436685:+ LUSC cis rs2842992 0.672 rs4708845 ENSG00000237927.1 RP3-393E18.2 -5.73 1.78e-08 6.77e-06 -0.38 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159798569 chr6:159586955~159589169:- LUSC cis rs2842992 0.789 rs2342446 ENSG00000237927.1 RP3-393E18.2 -5.73 1.78e-08 6.77e-06 -0.38 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159799655 chr6:159586955~159589169:- LUSC cis rs2842992 0.789 rs2146163 ENSG00000237927.1 RP3-393E18.2 -5.73 1.78e-08 6.77e-06 -0.38 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159803314 chr6:159586955~159589169:- LUSC cis rs2842992 0.789 rs9364536 ENSG00000237927.1 RP3-393E18.2 -5.73 1.78e-08 6.77e-06 -0.38 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159804527 chr6:159586955~159589169:- LUSC cis rs1056107 0.933 rs12554866 ENSG00000225513.1 RP11-165N19.2 5.73 1.78e-08 6.77e-06 0.29 0.26 Colorectal cancer; chr9:112201066 chr9:112173522~112173971:- LUSC cis rs228614 0.51 rs223468 ENSG00000246560.2 RP11-10L12.4 5.73 1.79e-08 6.78e-06 0.31 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102779265 chr4:102828055~102844075:+ LUSC cis rs7119038 0.629 rs10892271 ENSG00000255422.1 AP002954.4 5.73 1.79e-08 6.78e-06 0.34 0.26 Sjögren's syndrome; chr11:118727835 chr11:118704607~118750263:+ LUSC cis rs10028773 0.666 rs12498657 ENSG00000249244.1 RP11-548H18.2 5.73 1.79e-08 6.79e-06 0.32 0.26 Educational attainment; chr4:119341711 chr4:119391831~119395335:- LUSC cis rs13113518 0.812 rs13107810 ENSG00000273257.1 RP11-177J6.1 5.73 1.79e-08 6.8e-06 0.33 0.26 Height; chr4:55542243 chr4:55387949~55388271:+ LUSC cis rs228614 0.51 rs223465 ENSG00000246560.2 RP11-10L12.4 5.73 1.79e-08 6.8e-06 0.31 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780174 chr4:102828055~102844075:+ LUSC cis rs228614 0.51 rs223464 ENSG00000246560.2 RP11-10L12.4 5.73 1.79e-08 6.8e-06 0.31 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780603 chr4:102828055~102844075:+ LUSC cis rs11168936 1 rs11168936 ENSG00000258017.1 RP11-386G11.10 -5.73 1.79e-08 6.8e-06 -0.3 -0.26 Cancer (pleiotropy); chr12:49251457 chr12:49127782~49147869:+ LUSC cis rs1008375 1 rs17507481 ENSG00000249502.1 AC006160.5 -5.73 1.79e-08 6.8e-06 -0.25 -0.26 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17618443 chr4:17587467~17614571:- LUSC cis rs6570726 0.764 rs4263604 ENSG00000235652.6 RP11-545I5.3 5.73 1.79e-08 6.8e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145595561 chr6:145799409~145886585:+ LUSC cis rs227275 0.554 rs223388 ENSG00000246560.2 RP11-10L12.4 5.73 1.79e-08 6.8e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102828287 chr4:102828055~102844075:+ LUSC cis rs227275 0.554 rs223386 ENSG00000246560.2 RP11-10L12.4 5.73 1.79e-08 6.8e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102829111 chr4:102828055~102844075:+ LUSC cis rs227275 0.554 rs223385 ENSG00000246560.2 RP11-10L12.4 5.73 1.79e-08 6.8e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102829159 chr4:102828055~102844075:+ LUSC cis rs228614 0.51 rs223470 ENSG00000246560.2 RP11-10L12.4 5.73 1.79e-08 6.81e-06 0.31 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102778004 chr4:102828055~102844075:+ LUSC cis rs6558530 0.73 rs7014327 ENSG00000253982.1 CTD-2336O2.1 5.73 1.8e-08 6.82e-06 0.3 0.26 Systolic blood pressure; chr8:1775886 chr8:1761990~1764502:- LUSC cis rs13113518 0.513 rs13147861 ENSG00000272969.1 RP11-528I4.2 5.73 1.8e-08 6.82e-06 0.29 0.26 Height; chr4:55611014 chr4:55547112~55547889:+ LUSC cis rs1729951 0.575 rs361237 ENSG00000261758.1 RP11-102M11.2 5.73 1.8e-08 6.83e-06 0.23 0.26 Neuroticism; chr3:136983572 chr3:136752630~136755780:+ LUSC cis rs801193 0.591 rs2707839 ENSG00000179406.6 LINC00174 -5.73 1.8e-08 6.83e-06 -0.27 -0.26 Aortic root size; chr7:66728097 chr7:66376044~66401338:- LUSC cis rs13392177 0.684 rs11695527 ENSG00000261338.2 RP11-378A13.1 5.73 1.8e-08 6.83e-06 0.26 0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218203380 chr2:218255319~218257366:+ LUSC cis rs4964805 0.594 rs4964830 ENSG00000257681.1 RP11-341G23.4 -5.73 1.8e-08 6.83e-06 -0.29 -0.26 Attention deficit hyperactivity disorder; chr12:103775130 chr12:103746315~103768858:- LUSC cis rs13113518 0.557 rs13142096 ENSG00000273257.1 RP11-177J6.1 5.73 1.8e-08 6.84e-06 0.35 0.26 Height; chr4:55566291 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs7677952 ENSG00000249700.7 SRD5A3-AS1 5.73 1.8e-08 6.84e-06 0.3 0.26 Height; chr4:55425312 chr4:55363971~55395847:- LUSC cis rs950169 0.922 rs62021167 ENSG00000259295.5 CSPG4P12 5.73 1.8e-08 6.85e-06 0.34 0.26 Schizophrenia; chr15:84574820 chr15:85191438~85213905:+ LUSC cis rs6570726 0.846 rs446031 ENSG00000235652.6 RP11-545I5.3 5.73 1.8e-08 6.85e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145564456 chr6:145799409~145886585:+ LUSC cis rs732716 0.819 rs12459919 ENSG00000267769.1 CTB-50L17.9 -5.73 1.8e-08 6.85e-06 -0.3 -0.26 Mean corpuscular volume; chr19:4434506 chr19:4454014~4455286:+ LUSC cis rs910316 0.763 rs175057 ENSG00000279594.1 RP11-950C14.10 -5.73 1.81e-08 6.85e-06 -0.31 -0.26 Height; chr14:75022929 chr14:75011269~75012851:- LUSC cis rs875971 0.545 rs73376401 ENSG00000237310.1 GS1-124K5.4 5.73 1.81e-08 6.86e-06 0.29 0.26 Aortic root size; chr7:66174841 chr7:66493706~66495474:+ LUSC cis rs9322193 1 rs9322193 ENSG00000268592.3 RAET1E-AS1 5.73 1.81e-08 6.86e-06 0.32 0.26 Lung cancer; chr6:149598007 chr6:149863494~149919507:+ LUSC cis rs7772486 0.875 rs11755334 ENSG00000235652.6 RP11-545I5.3 5.73 1.81e-08 6.86e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146078161 chr6:145799409~145886585:+ LUSC cis rs6928977 0.66 rs2614263 ENSG00000234084.1 RP3-388E23.2 5.73 1.81e-08 6.86e-06 0.2 0.26 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135459579 chr6:135301568~135307158:+ LUSC cis rs17772222 0.74 rs10143744 ENSG00000258789.1 RP11-507K2.3 -5.73 1.81e-08 6.87e-06 -0.29 -0.26 Coronary artery calcification; chr14:88508073 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs1999177 ENSG00000258789.1 RP11-507K2.3 -5.73 1.81e-08 6.87e-06 -0.29 -0.26 Coronary artery calcification; chr14:88508298 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs1999176 ENSG00000258789.1 RP11-507K2.3 -5.73 1.81e-08 6.87e-06 -0.29 -0.26 Coronary artery calcification; chr14:88508371 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs1864746 ENSG00000258789.1 RP11-507K2.3 -5.73 1.81e-08 6.87e-06 -0.29 -0.26 Coronary artery calcification; chr14:88508455 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs1864747 ENSG00000258789.1 RP11-507K2.3 -5.73 1.81e-08 6.87e-06 -0.29 -0.26 Coronary artery calcification; chr14:88508523 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs7151164 ENSG00000258789.1 RP11-507K2.3 -5.73 1.81e-08 6.87e-06 -0.29 -0.26 Coronary artery calcification; chr14:88509329 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs12433026 ENSG00000258789.1 RP11-507K2.3 -5.73 1.81e-08 6.87e-06 -0.29 -0.26 Coronary artery calcification; chr14:88509495 chr14:88551597~88552493:+ LUSC cis rs227275 0.554 rs223421 ENSG00000246560.2 RP11-10L12.4 5.73 1.81e-08 6.87e-06 0.31 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102805861 chr4:102828055~102844075:+ LUSC cis rs13113518 0.966 rs11133387 ENSG00000273257.1 RP11-177J6.1 5.73 1.81e-08 6.87e-06 0.33 0.26 Height; chr4:55475130 chr4:55387949~55388271:+ LUSC cis rs34779708 0.733 rs3936502 ENSG00000230534.5 RP11-297A16.2 5.73 1.81e-08 6.87e-06 0.29 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35260290 chr10:35098006~35127020:- LUSC cis rs4372836 0.894 rs55877710 ENSG00000226833.4 AC097724.3 -5.73 1.81e-08 6.88e-06 -0.3 -0.26 Body mass index; chr2:28706442 chr2:28708953~28736205:- LUSC cis rs4372836 0.929 rs55883854 ENSG00000226833.4 AC097724.3 -5.73 1.81e-08 6.88e-06 -0.3 -0.26 Body mass index; chr2:28706675 chr2:28708953~28736205:- LUSC cis rs1499614 1 rs1267817 ENSG00000226824.5 RP4-756H11.3 -5.73 1.82e-08 6.89e-06 -0.49 -0.26 Gout; chr7:66645053 chr7:66654538~66669855:+ LUSC cis rs875971 1 rs6956179 ENSG00000179406.6 LINC00174 5.73 1.82e-08 6.89e-06 0.28 0.26 Aortic root size; chr7:66341672 chr7:66376044~66401338:- LUSC cis rs73173548 0.502 rs10942532 ENSG00000247828.6 TMEM161B-AS1 5.73 1.82e-08 6.9e-06 0.3 0.26 Macular telangiectasia type 2; chr5:88462015 chr5:88268895~88436685:+ LUSC cis rs9309711 0.922 rs13385119 ENSG00000225234.1 TRAPPC12-AS1 -5.73 1.82e-08 6.9e-06 -0.34 -0.26 Neurofibrillary tangles; chr2:3480750 chr2:3481242~3482409:- LUSC cis rs9813712 0.595 rs1453239 ENSG00000228252.7 COL6A4P2 -5.73 1.82e-08 6.9e-06 -0.24 -0.26 Response to amphetamines; chr3:130288915 chr3:130212823~130273806:+ LUSC cis rs9813712 0.523 rs9866942 ENSG00000228252.7 COL6A4P2 -5.73 1.82e-08 6.9e-06 -0.24 -0.26 Response to amphetamines; chr3:130297796 chr3:130212823~130273806:+ LUSC cis rs7208859 0.623 rs9898084 ENSG00000263603.1 CTD-2349P21.5 -5.73 1.83e-08 6.92e-06 -0.36 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30729469~30731202:+ LUSC cis rs17270561 0.609 rs9393655 ENSG00000272462.2 U91328.19 -5.73 1.83e-08 6.92e-06 -0.3 -0.26 Iron status biomarkers; chr6:25711110 chr6:25992662~26001775:+ LUSC cis rs875971 1 rs6958271 ENSG00000179406.6 LINC00174 -5.73 1.83e-08 6.92e-06 -0.27 -0.26 Aortic root size; chr7:66514344 chr7:66376044~66401338:- LUSC cis rs875971 1 rs6958277 ENSG00000179406.6 LINC00174 -5.73 1.83e-08 6.92e-06 -0.27 -0.26 Aortic root size; chr7:66514362 chr7:66376044~66401338:- LUSC cis rs73173548 0.502 rs12659818 ENSG00000247828.6 TMEM161B-AS1 5.73 1.83e-08 6.94e-06 0.31 0.26 Macular telangiectasia type 2; chr5:88451964 chr5:88268895~88436685:+ LUSC cis rs4713118 0.662 rs149970 ENSG00000204709.4 LINC01556 5.73 1.84e-08 6.96e-06 0.34 0.26 Parkinson's disease; chr6:28012442 chr6:28943877~28944537:+ LUSC cis rs875971 0.79 rs10257911 ENSG00000179406.6 LINC00174 5.73 1.84e-08 6.96e-06 0.27 0.26 Aortic root size; chr7:66278783 chr7:66376044~66401338:- LUSC cis rs2302464 1 rs73123607 ENSG00000214846.4 RP11-115L11.1 5.73 1.84e-08 6.98e-06 0.68 0.26 Cerebrospinal fluid biomarker levels; chr4:15725058 chr4:15730962~15731627:- LUSC cis rs2302464 1 rs6844968 ENSG00000214846.4 RP11-115L11.1 5.73 1.84e-08 6.98e-06 0.68 0.26 Cerebrospinal fluid biomarker levels; chr4:15725641 chr4:15730962~15731627:- LUSC cis rs6565180 0.962 rs11642676 ENSG00000183604.13 SMG1P5 -5.73 1.84e-08 6.98e-06 -0.31 -0.26 Tonsillectomy; chr16:30360334 chr16:30267553~30335374:- LUSC cis rs73173548 0.502 rs12187348 ENSG00000247828.6 TMEM161B-AS1 5.73 1.84e-08 6.98e-06 0.29 0.26 Macular telangiectasia type 2; chr5:88424724 chr5:88268895~88436685:+ LUSC cis rs4489787 1 rs4489787 ENSG00000240399.1 RP1-228P16.1 5.72 1.85e-08 7e-06 0.42 0.26 Prostate cancer (SNP x SNP interaction); chr12:48417317 chr12:48054813~48055591:- LUSC cis rs4489787 1 rs12231229 ENSG00000240399.1 RP1-228P16.1 -5.72 1.85e-08 7e-06 -0.42 -0.26 Prostate cancer (SNP x SNP interaction); chr12:48416125 chr12:48054813~48055591:- LUSC cis rs4489787 1 rs17122979 ENSG00000240399.1 RP1-228P16.1 -5.72 1.85e-08 7e-06 -0.42 -0.26 Prostate cancer (SNP x SNP interaction); chr12:48419914 chr12:48054813~48055591:- LUSC cis rs9545047 0.604 rs9545082 ENSG00000227676.3 LINC01068 5.72 1.85e-08 7e-06 0.31 0.26 Schizophrenia; chr13:79358994 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs7332913 ENSG00000227676.3 LINC01068 5.72 1.85e-08 7e-06 0.31 0.26 Schizophrenia; chr13:79359149 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9545083 ENSG00000227676.3 LINC01068 5.72 1.85e-08 7e-06 0.31 0.26 Schizophrenia; chr13:79360695 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs7322756 ENSG00000227676.3 LINC01068 5.72 1.85e-08 7e-06 0.31 0.26 Schizophrenia; chr13:79361120 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs7324006 ENSG00000227676.3 LINC01068 5.72 1.85e-08 7e-06 0.31 0.26 Schizophrenia; chr13:79361225 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs7322673 ENSG00000227676.3 LINC01068 5.72 1.85e-08 7e-06 0.31 0.26 Schizophrenia; chr13:79361266 chr13:79566727~79571436:+ LUSC cis rs950169 0.922 rs67804993 ENSG00000259295.5 CSPG4P12 5.72 1.85e-08 7e-06 0.34 0.26 Schizophrenia; chr15:84560799 chr15:85191438~85213905:+ LUSC cis rs13113518 0.966 rs4864544 ENSG00000249700.7 SRD5A3-AS1 5.72 1.85e-08 7e-06 0.29 0.26 Height; chr4:55515292 chr4:55363971~55395847:- LUSC cis rs801193 0.569 rs7800620 ENSG00000179406.6 LINC00174 -5.72 1.85e-08 7.01e-06 -0.28 -0.26 Aortic root size; chr7:66758701 chr7:66376044~66401338:- LUSC cis rs7665090 1 rs5026473 ENSG00000230069.3 LRRC37A15P -5.72 1.85e-08 7.01e-06 -0.27 -0.26 Primary biliary cholangitis; chr4:102633636 chr4:102727274~102730721:- LUSC cis rs1008375 0.966 rs2315553 ENSG00000249502.1 AC006160.5 -5.72 1.85e-08 7.02e-06 -0.25 -0.26 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17625709 chr4:17587467~17614571:- LUSC cis rs13113518 1 rs4864542 ENSG00000249700.7 SRD5A3-AS1 -5.72 1.86e-08 7.03e-06 -0.3 -0.26 Height; chr4:55487920 chr4:55363971~55395847:- LUSC cis rs2919917 0.666 rs10957898 ENSG00000254352.1 RP11-578O24.2 -5.72 1.86e-08 7.03e-06 -0.33 -0.26 Lymphocyte counts; chr8:78705078 chr8:78723796~78724136:- LUSC cis rs9341808 0.667 rs1575541 ENSG00000272129.1 RP11-250B2.6 5.72 1.86e-08 7.03e-06 0.32 0.26 Sitting height ratio; chr6:80207768 chr6:80355424~80356859:+ LUSC cis rs67311347 1 rs1466237 ENSG00000223797.4 ENTPD3-AS1 5.72 1.86e-08 7.03e-06 0.28 0.26 Renal cell carcinoma; chr3:40420535 chr3:40313802~40453329:- LUSC cis rs2243480 1 rs2707844 ENSG00000226824.5 RP4-756H11.3 -5.72 1.86e-08 7.03e-06 -0.49 -0.26 Diabetic kidney disease; chr7:66594522 chr7:66654538~66669855:+ LUSC cis rs875971 0.964 rs778735 ENSG00000179406.6 LINC00174 -5.72 1.86e-08 7.03e-06 -0.27 -0.26 Aortic root size; chr7:66349822 chr7:66376044~66401338:- LUSC cis rs673078 0.607 rs56080343 ENSG00000275759.1 RP11-131L12.3 -5.72 1.86e-08 7.03e-06 -0.34 -0.26 Glucose homeostasis traits; chr12:118439113 chr12:118428281~118428870:+ LUSC cis rs801193 0.967 rs2707849 ENSG00000222364.1 RNU6-96P -5.72 1.86e-08 7.03e-06 -0.29 -0.26 Aortic root size; chr7:66687725 chr7:66395191~66395286:+ LUSC cis rs801193 0.967 rs2707841 ENSG00000222364.1 RNU6-96P -5.72 1.86e-08 7.03e-06 -0.29 -0.26 Aortic root size; chr7:66692033 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs4717310 ENSG00000222364.1 RNU6-96P -5.72 1.86e-08 7.03e-06 -0.29 -0.26 Aortic root size; chr7:66696020 chr7:66395191~66395286:+ LUSC cis rs801193 0.844 rs7779971 ENSG00000222364.1 RNU6-96P -5.72 1.86e-08 7.03e-06 -0.29 -0.26 Aortic root size; chr7:66696803 chr7:66395191~66395286:+ LUSC cis rs7246657 0.722 rs958305 ENSG00000276846.1 CTD-3220F14.3 -5.72 1.86e-08 7.03e-06 -0.39 -0.26 Coronary artery calcification; chr19:37698539 chr19:37314868~37315620:- LUSC cis rs66887589 0.967 rs2892869 ENSG00000245958.5 RP11-33B1.1 5.72 1.86e-08 7.04e-06 0.24 0.26 Diastolic blood pressure; chr4:119600142 chr4:119454791~119552025:+ LUSC cis rs2243480 1 rs387676 ENSG00000226824.5 RP4-756H11.3 -5.72 1.86e-08 7.04e-06 -0.48 -0.26 Diabetic kidney disease; chr7:66133233 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs13310597 ENSG00000226824.5 RP4-756H11.3 -5.72 1.86e-08 7.04e-06 -0.48 -0.26 Diabetic kidney disease; chr7:66133553 chr7:66654538~66669855:+ LUSC cis rs875971 0.798 rs57739047 ENSG00000179406.6 LINC00174 -5.72 1.87e-08 7.06e-06 -0.28 -0.26 Aortic root size; chr7:66507579 chr7:66376044~66401338:- LUSC cis rs11098499 0.863 rs6534139 ENSG00000248280.1 RP11-33B1.2 -5.72 1.87e-08 7.06e-06 -0.32 -0.26 Corneal astigmatism; chr4:119528301 chr4:119440561~119450157:- LUSC cis rs7945705 0.52 rs1984791 ENSG00000254860.4 TMEM9B-AS1 -5.72 1.87e-08 7.06e-06 -0.29 -0.26 Hemoglobin concentration; chr11:9013480 chr11:8964675~8977527:+ LUSC cis rs442309 0.846 rs382412 ENSG00000238280.1 RP11-436D10.3 -5.72 1.87e-08 7.06e-06 -0.32 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62730004 chr10:62793562~62805887:- LUSC cis rs875971 0.862 rs7796162 ENSG00000179406.6 LINC00174 5.72 1.87e-08 7.07e-06 0.27 0.26 Aortic root size; chr7:66280771 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs2901152 ENSG00000179406.6 LINC00174 5.72 1.87e-08 7.07e-06 0.27 0.26 Aortic root size; chr7:66300017 chr7:66376044~66401338:- LUSC cis rs11971779 0.715 rs11772771 ENSG00000273391.1 RP11-634H22.1 5.72 1.87e-08 7.07e-06 0.28 0.26 Diisocyanate-induced asthma; chr7:139374057 chr7:139359032~139359566:- LUSC cis rs11159086 0.793 rs17100414 ENSG00000259005.1 RP3-449M8.6 5.72 1.87e-08 7.07e-06 0.38 0.26 Advanced glycation end-product levels; chr14:74467918 chr14:74474007~74474864:- LUSC cis rs875971 0.545 rs73152714 ENSG00000224316.1 RP11-479O9.2 5.72 1.87e-08 7.07e-06 0.27 0.26 Aortic root size; chr7:66534641 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs4718364 ENSG00000224316.1 RP11-479O9.2 5.72 1.87e-08 7.07e-06 0.27 0.26 Aortic root size; chr7:66536353 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs6961853 ENSG00000224316.1 RP11-479O9.2 5.72 1.87e-08 7.07e-06 0.27 0.26 Aortic root size; chr7:66537035 chr7:65773620~65802067:+ LUSC cis rs875971 0.528 rs801213 ENSG00000224316.1 RP11-479O9.2 -5.72 1.87e-08 7.07e-06 -0.27 -0.26 Aortic root size; chr7:66549931 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs801212 ENSG00000224316.1 RP11-479O9.2 -5.72 1.87e-08 7.07e-06 -0.27 -0.26 Aortic root size; chr7:66550643 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs801199 ENSG00000224316.1 RP11-479O9.2 -5.72 1.87e-08 7.07e-06 -0.27 -0.26 Aortic root size; chr7:66560286 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs1267814 ENSG00000224316.1 RP11-479O9.2 -5.72 1.87e-08 7.07e-06 -0.27 -0.26 Aortic root size; chr7:66579422 chr7:65773620~65802067:+ LUSC cis rs950880 0.71 rs3771171 ENSG00000234389.1 AC007278.3 -5.72 1.87e-08 7.07e-06 -0.28 -0.26 Serum protein levels (sST2); chr2:102369490 chr2:102438713~102440475:+ LUSC cis rs1056107 0.931 rs7867823 ENSG00000225513.1 RP11-165N19.2 -5.72 1.87e-08 7.07e-06 -0.28 -0.26 Colorectal cancer; chr9:112245813 chr9:112173522~112173971:- LUSC cis rs2153535 0.58 rs2184586 ENSG00000230939.1 RP11-314C16.1 -5.72 1.87e-08 7.09e-06 -0.31 -0.26 Motion sickness; chr6:8473949 chr6:8784178~8785445:+ LUSC cis rs801193 1 rs7788576 ENSG00000237310.1 GS1-124K5.4 -5.72 1.88e-08 7.09e-06 -0.26 -0.26 Aortic root size; chr7:66683315 chr7:66493706~66495474:+ LUSC cis rs801193 0.935 rs2659916 ENSG00000237310.1 GS1-124K5.4 5.72 1.88e-08 7.09e-06 0.26 0.26 Aortic root size; chr7:66686365 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs6958520 ENSG00000237310.1 GS1-124K5.4 5.72 1.88e-08 7.09e-06 0.26 0.26 Aortic root size; chr7:66686466 chr7:66493706~66495474:+ LUSC cis rs66887589 0.967 rs56173225 ENSG00000245958.5 RP11-33B1.1 5.72 1.88e-08 7.09e-06 0.24 0.26 Diastolic blood pressure; chr4:119588817 chr4:119454791~119552025:+ LUSC cis rs7429990 0.965 rs777015 ENSG00000228638.1 FCF1P2 -5.72 1.88e-08 7.1e-06 -0.29 -0.26 Educational attainment (years of education); chr3:47895582 chr3:48290793~48291375:- LUSC cis rs875971 0.965 rs697968 ENSG00000179406.6 LINC00174 5.72 1.88e-08 7.11e-06 0.28 0.26 Aortic root size; chr7:66070046 chr7:66376044~66401338:- LUSC cis rs875971 1 rs1183245 ENSG00000179406.6 LINC00174 5.72 1.88e-08 7.11e-06 0.28 0.26 Aortic root size; chr7:66076198 chr7:66376044~66401338:- LUSC cis rs875971 1 rs1144895 ENSG00000179406.6 LINC00174 5.72 1.88e-08 7.11e-06 0.28 0.26 Aortic root size; chr7:66076320 chr7:66376044~66401338:- LUSC cis rs875971 1 rs1144894 ENSG00000179406.6 LINC00174 5.72 1.88e-08 7.11e-06 0.28 0.26 Aortic root size; chr7:66077907 chr7:66376044~66401338:- LUSC cis rs9341835 0.608 rs2800017 ENSG00000218048.2 RP3-407E4.4 -5.72 1.88e-08 7.12e-06 -0.29 -0.26 Schizophrenia; chr6:63448172 chr6:63440766~63443580:+ LUSC cis rs875971 0.545 rs73142233 ENSG00000224316.1 RP11-479O9.2 5.72 1.88e-08 7.12e-06 0.28 0.26 Aortic root size; chr7:66221293 chr7:65773620~65802067:+ LUSC cis rs1021993 0.545 rs4844809 ENSG00000231648.1 RP11-372M18.2 -5.72 1.89e-08 7.13e-06 -0.36 -0.26 Gut microbiome composition (winter); chr1:209346427 chr1:209367662~209379690:+ LUSC cis rs853679 0.76 rs11967137 ENSG00000204709.4 LINC01556 5.72 1.89e-08 7.14e-06 0.38 0.26 Depression; chr6:28231986 chr6:28943877~28944537:+ LUSC cis rs867371 0.722 rs8033050 ENSG00000255769.6 GOLGA2P10 -5.72 1.89e-08 7.14e-06 -0.32 -0.26 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82269648 chr15:82472993~82513950:- LUSC cis rs11123170 0.529 rs1015753 ENSG00000274877.1 RP11-65I12.1 -5.72 1.89e-08 7.15e-06 -0.36 -0.26 Renal function-related traits (BUN); chr2:113211226 chr2:113237595~113240825:+ LUSC cis rs2404602 0.575 rs11072611 ENSG00000259422.1 RP11-593F23.1 5.72 1.89e-08 7.15e-06 0.31 0.26 Blood metabolite levels; chr15:76655642 chr15:76174891~76181486:- LUSC cis rs6570726 0.764 rs9403731 ENSG00000235652.6 RP11-545I5.3 5.72 1.89e-08 7.15e-06 0.26 0.26 Lobe attachment (rater-scored or self-reported); chr6:145586801 chr6:145799409~145886585:+ LUSC cis rs867371 0.656 rs2665103 ENSG00000278603.1 RP13-608F4.5 -5.72 1.89e-08 7.16e-06 -0.3 -0.26 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82140374 chr15:82472203~82472426:+ LUSC cis rs13113518 1 rs4865004 ENSG00000249700.7 SRD5A3-AS1 5.72 1.89e-08 7.16e-06 0.29 0.26 Height; chr4:55515118 chr4:55363971~55395847:- LUSC cis rs2919917 0.628 rs13265305 ENSG00000254352.1 RP11-578O24.2 5.72 1.89e-08 7.16e-06 0.34 0.26 Lymphocyte counts; chr8:78656575 chr8:78723796~78724136:- LUSC cis rs6570726 0.791 rs408443 ENSG00000235652.6 RP11-545I5.3 5.72 1.89e-08 7.16e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145553507 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs436156 ENSG00000235652.6 RP11-545I5.3 5.72 1.89e-08 7.16e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145553737 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs436498 ENSG00000235652.6 RP11-545I5.3 5.72 1.89e-08 7.16e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:145555211 chr6:145799409~145886585:+ LUSC cis rs8059260 0.544 rs7205916 ENSG00000274038.1 RP11-66H6.4 -5.72 1.9e-08 7.17e-06 -0.41 -0.26 Alcohol consumption over the past year; chr16:11095399 chr16:11056556~11057034:+ LUSC cis rs73186030 0.546 rs73188388 ENSG00000272758.4 RP11-299J3.8 5.72 1.9e-08 7.19e-06 0.37 0.26 Serum parathyroid hormone levels; chr3:122399229 chr3:122416207~122443180:+ LUSC cis rs875971 0.545 rs17138149 ENSG00000237310.1 GS1-124K5.4 5.72 1.9e-08 7.19e-06 0.29 0.26 Aortic root size; chr7:66228193 chr7:66493706~66495474:+ LUSC cis rs9309711 0.922 rs13431788 ENSG00000225234.1 TRAPPC12-AS1 -5.72 1.9e-08 7.19e-06 -0.34 -0.26 Neurofibrillary tangles; chr2:3479141 chr2:3481242~3482409:- LUSC cis rs78487399 0.71 rs76857293 ENSG00000234936.1 AC010883.5 5.72 1.91e-08 7.2e-06 0.4 0.26 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43364537 chr2:43229573~43233394:+ LUSC cis rs801193 0.967 rs2707849 ENSG00000237310.1 GS1-124K5.4 5.72 1.91e-08 7.2e-06 0.26 0.26 Aortic root size; chr7:66687725 chr7:66493706~66495474:+ LUSC cis rs801193 0.967 rs2707841 ENSG00000237310.1 GS1-124K5.4 5.72 1.91e-08 7.2e-06 0.26 0.26 Aortic root size; chr7:66692033 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs4717310 ENSG00000237310.1 GS1-124K5.4 5.72 1.91e-08 7.2e-06 0.26 0.26 Aortic root size; chr7:66696020 chr7:66493706~66495474:+ LUSC cis rs801193 0.844 rs7779971 ENSG00000237310.1 GS1-124K5.4 5.72 1.91e-08 7.2e-06 0.26 0.26 Aortic root size; chr7:66696803 chr7:66493706~66495474:+ LUSC cis rs11971779 0.793 rs11772447 ENSG00000273391.1 RP11-634H22.1 5.72 1.91e-08 7.21e-06 0.29 0.26 Diisocyanate-induced asthma; chr7:139348843 chr7:139359032~139359566:- LUSC cis rs801193 0.904 rs4718405 ENSG00000236529.1 RP13-254B10.1 5.72 1.91e-08 7.22e-06 0.27 0.26 Aortic root size; chr7:66789659 chr7:65840212~65840596:+ LUSC cis rs4964805 0.641 rs11111755 ENSG00000257681.1 RP11-341G23.4 5.72 1.91e-08 7.22e-06 0.29 0.26 Attention deficit hyperactivity disorder; chr12:103765889 chr12:103746315~103768858:- LUSC cis rs4964805 0.641 rs10861094 ENSG00000257681.1 RP11-341G23.4 5.72 1.91e-08 7.22e-06 0.29 0.26 Attention deficit hyperactivity disorder; chr12:103765938 chr12:103746315~103768858:- LUSC cis rs1056107 0.933 rs943621 ENSG00000225513.1 RP11-165N19.2 -5.72 1.91e-08 7.22e-06 -0.28 -0.26 Colorectal cancer; chr9:112231510 chr9:112173522~112173971:- LUSC cis rs2562456 0.917 rs11085463 ENSG00000268081.1 RP11-678G14.2 5.72 1.92e-08 7.24e-06 0.35 0.26 Pain; chr19:21568500 chr19:21554640~21569237:- LUSC cis rs7267979 0.78 rs6050679 ENSG00000274973.1 RP13-401N8.7 -5.72 1.92e-08 7.25e-06 -0.26 -0.26 Liver enzyme levels (alkaline phosphatase); chr20:25557191 chr20:25845497~25845862:+ LUSC cis rs11098499 0.687 rs71610270 ENSG00000248280.1 RP11-33B1.2 5.72 1.92e-08 7.26e-06 0.3 0.26 Corneal astigmatism; chr4:119366281 chr4:119440561~119450157:- LUSC cis rs1075265 0.933 rs918357 ENSG00000233266.1 HMGB1P31 5.72 1.92e-08 7.26e-06 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:54108826 chr2:54051334~54051760:+ LUSC cis rs875971 0.522 rs1917563 ENSG00000237310.1 GS1-124K5.4 -5.72 1.92e-08 7.26e-06 -0.26 -0.26 Aortic root size; chr7:65950660 chr7:66493706~66495474:+ LUSC cis rs77972916 0.561 rs17406174 ENSG00000234936.1 AC010883.5 5.72 1.92e-08 7.26e-06 0.35 0.26 Granulocyte percentage of myeloid white cells; chr2:43330345 chr2:43229573~43233394:+ LUSC cis rs77972916 0.518 rs55877805 ENSG00000234936.1 AC010883.5 5.72 1.92e-08 7.26e-06 0.35 0.26 Granulocyte percentage of myeloid white cells; chr2:43330458 chr2:43229573~43233394:+ LUSC cis rs77972916 0.561 rs72788900 ENSG00000234936.1 AC010883.5 5.72 1.92e-08 7.26e-06 0.35 0.26 Granulocyte percentage of myeloid white cells; chr2:43331948 chr2:43229573~43233394:+ LUSC cis rs66887589 0.775 rs6843229 ENSG00000249244.1 RP11-548H18.2 5.72 1.92e-08 7.26e-06 0.3 0.26 Diastolic blood pressure; chr4:119502932 chr4:119391831~119395335:- LUSC cis rs7772486 0.875 rs6570736 ENSG00000235652.6 RP11-545I5.3 5.72 1.92e-08 7.27e-06 0.25 0.26 Lobe attachment (rater-scored or self-reported); chr6:146067184 chr6:145799409~145886585:+ LUSC cis rs9611519 0.929 rs4820425 ENSG00000235513.1 RP4-756G23.5 5.72 1.93e-08 7.27e-06 0.3 0.26 Neuroticism; chr22:41035338 chr22:41209122~41217627:- LUSC cis rs867371 0.762 rs12905578 ENSG00000255769.6 GOLGA2P10 5.72 1.93e-08 7.28e-06 0.32 0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82288923 chr15:82472993~82513950:- LUSC cis rs9341835 0.584 rs1741801 ENSG00000218048.2 RP3-407E4.4 5.72 1.93e-08 7.28e-06 0.29 0.25 Schizophrenia; chr6:63435470 chr6:63440766~63443580:+ LUSC cis rs77972916 0.611 rs61552842 ENSG00000234936.1 AC010883.5 5.72 1.93e-08 7.28e-06 0.32 0.25 Granulocyte percentage of myeloid white cells; chr2:43356897 chr2:43229573~43233394:+ LUSC cis rs73173548 0.528 rs6872276 ENSG00000247828.6 TMEM161B-AS1 5.72 1.93e-08 7.29e-06 0.31 0.25 Macular telangiectasia type 2; chr5:88473903 chr5:88268895~88436685:+ LUSC cis rs1008375 0.966 rs11733730 ENSG00000249502.1 AC006160.5 -5.72 1.93e-08 7.29e-06 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17623586 chr4:17587467~17614571:- LUSC cis rs6570726 0.791 rs9497357 ENSG00000235652.6 RP11-545I5.3 5.72 1.93e-08 7.29e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145591752 chr6:145799409~145886585:+ LUSC cis rs13113518 0.783 rs12504300 ENSG00000273257.1 RP11-177J6.1 5.72 1.93e-08 7.29e-06 0.35 0.25 Height; chr4:55482360 chr4:55387949~55388271:+ LUSC cis rs6570726 0.818 rs9399555 ENSG00000235652.6 RP11-545I5.3 5.72 1.93e-08 7.29e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145556418 chr6:145799409~145886585:+ LUSC cis rs394563 0.69 rs237009 ENSG00000231760.4 RP11-350J20.5 5.72 1.93e-08 7.3e-06 0.31 0.25 Dupuytren's disease; chr6:149438416 chr6:149796151~149826294:- LUSC cis rs6504950 0.888 rs244294 ENSG00000275710.1 RP11-257O5.4 5.72 1.93e-08 7.3e-06 0.3 0.25 Breast cancer; chr17:55151182 chr17:54964474~54964679:+ LUSC cis rs875971 0.767 rs1643394 ENSG00000179406.6 LINC00174 -5.72 1.94e-08 7.31e-06 -0.28 -0.25 Aortic root size; chr7:66371107 chr7:66376044~66401338:- LUSC cis rs11159086 0.793 rs1860108 ENSG00000270000.1 RP3-449M8.9 5.72 1.94e-08 7.31e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74478562 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs11845370 ENSG00000270000.1 RP3-449M8.9 5.72 1.94e-08 7.31e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74481587 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs3784035 ENSG00000270000.1 RP3-449M8.9 5.72 1.94e-08 7.31e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74482221 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs12433382 ENSG00000270000.1 RP3-449M8.9 5.72 1.94e-08 7.31e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74482940 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs10148268 ENSG00000270000.1 RP3-449M8.9 5.72 1.94e-08 7.31e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74484261 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs11850070 ENSG00000270000.1 RP3-449M8.9 5.72 1.94e-08 7.31e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74487575 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs28378078 ENSG00000270000.1 RP3-449M8.9 5.72 1.94e-08 7.31e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74487940 chr14:74471930~74472360:- LUSC cis rs75920871 0.528 rs7930264 ENSG00000254851.1 RP11-109L13.1 5.72 1.94e-08 7.31e-06 0.35 0.25 Subjective well-being; chr11:117000050 chr11:117135528~117138582:+ LUSC cis rs11951515 0.508 rs10065689 ENSG00000249286.1 CTD-2210P15.2 5.72 1.94e-08 7.32e-06 0.3 0.25 Metabolite levels (X-11787); chr5:43604156 chr5:43586918~43588223:- LUSC cis rs1387259 0.931 rs11168474 ENSG00000273765.1 RP11-370I10.11 5.72 1.94e-08 7.32e-06 0.29 0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48227601 chr12:48360920~48361377:+ LUSC cis rs801193 1 rs2003301 ENSG00000237310.1 GS1-124K5.4 -5.72 1.94e-08 7.33e-06 -0.26 -0.25 Aortic root size; chr7:66682669 chr7:66493706~66495474:+ LUSC cis rs950880 0.71 rs67723747 ENSG00000234389.1 AC007278.3 -5.72 1.95e-08 7.34e-06 -0.28 -0.25 Serum protein levels (sST2); chr2:102353347 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs56386507 ENSG00000234389.1 AC007278.3 -5.72 1.95e-08 7.34e-06 -0.28 -0.25 Serum protein levels (sST2); chr2:102354705 chr2:102438713~102440475:+ LUSC cis rs13113518 1 rs4864999 ENSG00000249700.7 SRD5A3-AS1 5.72 1.95e-08 7.34e-06 0.3 0.25 Height; chr4:55476736 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs12506788 ENSG00000249700.7 SRD5A3-AS1 5.72 1.95e-08 7.34e-06 0.3 0.25 Height; chr4:55477426 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs10517344 ENSG00000249700.7 SRD5A3-AS1 5.72 1.95e-08 7.34e-06 0.3 0.25 Height; chr4:55477545 chr4:55363971~55395847:- LUSC cis rs875971 0.66 rs801193 ENSG00000237310.1 GS1-124K5.4 -5.72 1.95e-08 7.34e-06 -0.25 -0.25 Aortic root size; chr7:66565625 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs2659912 ENSG00000222364.1 RNU6-96P -5.72 1.95e-08 7.35e-06 -0.29 -0.25 Aortic root size; chr7:66693012 chr7:66395191~66395286:+ LUSC cis rs6142102 0.651 rs1015361 ENSG00000276073.1 RP5-1125A11.7 5.71 1.95e-08 7.37e-06 0.27 0.25 Skin pigmentation; chr20:34150880 chr20:33985617~33988989:- LUSC cis rs6683071 0.643 rs34433664 ENSG00000272750.1 RP11-378J18.8 -5.71 1.96e-08 7.37e-06 -0.35 -0.25 Cognitive performance; chr1:222709607 chr1:222658867~222661512:- LUSC cis rs35740288 0.77 rs11633893 ENSG00000202081.1 RNU6-1280P -5.71 1.96e-08 7.38e-06 -0.31 -0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85605207 chr15:85651522~85651628:- LUSC cis rs1345301 1 rs1345302 ENSG00000234389.1 AC007278.3 -5.71 1.96e-08 7.38e-06 -0.24 -0.25 Waist circumference; chr2:102256909 chr2:102438713~102440475:+ LUSC cis rs1345301 1 rs13431601 ENSG00000234389.1 AC007278.3 -5.71 1.96e-08 7.38e-06 -0.24 -0.25 Waist circumference; chr2:102257253 chr2:102438713~102440475:+ LUSC cis rs875971 0.862 rs10250544 ENSG00000179406.6 LINC00174 5.71 1.96e-08 7.4e-06 0.27 0.25 Aortic root size; chr7:66301574 chr7:66376044~66401338:- LUSC cis rs16843372 0.576 rs10184397 ENSG00000251491.2 OR7E28P -5.71 1.97e-08 7.42e-06 -0.28 -0.25 Obesity-related traits; chr2:158838730 chr2:158862311~158863285:+ LUSC cis rs2337406 0.866 rs8012619 ENSG00000211974.3 IGHV2-70 -5.71 1.97e-08 7.42e-06 -0.34 -0.25 Alzheimer's disease (late onset); chr14:106793907 chr14:106723574~106724093:- LUSC cis rs11295209 1 rs11295209 ENSG00000249244.1 RP11-548H18.2 -5.71 1.97e-08 7.42e-06 -0.3 -0.25 Plateletcrit; chr4:119559079 chr4:119391831~119395335:- LUSC cis rs2919917 0.628 rs2887482 ENSG00000254352.1 RP11-578O24.2 5.71 1.98e-08 7.44e-06 0.34 0.25 Lymphocyte counts; chr8:78659633 chr8:78723796~78724136:- LUSC cis rs2919917 0.628 rs1905364 ENSG00000254352.1 RP11-578O24.2 5.71 1.98e-08 7.44e-06 0.34 0.25 Lymphocyte counts; chr8:78660244 chr8:78723796~78724136:- LUSC cis rs13113518 1 rs12651640 ENSG00000249700.7 SRD5A3-AS1 5.71 1.98e-08 7.44e-06 0.3 0.25 Height; chr4:55454154 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs1554483 ENSG00000249700.7 SRD5A3-AS1 5.71 1.98e-08 7.44e-06 0.3 0.25 Height; chr4:55455650 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs1464490 ENSG00000249700.7 SRD5A3-AS1 5.71 1.98e-08 7.44e-06 0.3 0.25 Height; chr4:55456620 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs10517346 ENSG00000249700.7 SRD5A3-AS1 5.71 1.98e-08 7.44e-06 0.3 0.25 Height; chr4:55457027 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11133384 ENSG00000249700.7 SRD5A3-AS1 5.71 1.98e-08 7.44e-06 0.3 0.25 Height; chr4:55457086 chr4:55363971~55395847:- LUSC cis rs2243480 1 rs73150014 ENSG00000226824.5 RP4-756H11.3 -5.71 1.98e-08 7.45e-06 -0.5 -0.25 Diabetic kidney disease; chr7:65985932 chr7:66654538~66669855:+ LUSC cis rs75920871 0.528 rs11216240 ENSG00000254851.1 RP11-109L13.1 5.71 1.98e-08 7.45e-06 0.35 0.25 Subjective well-being; chr11:117028532 chr11:117135528~117138582:+ LUSC cis rs75920871 0.528 rs11216241 ENSG00000254851.1 RP11-109L13.1 5.71 1.98e-08 7.45e-06 0.35 0.25 Subjective well-being; chr11:117028533 chr11:117135528~117138582:+ LUSC cis rs75920871 0.528 rs11600552 ENSG00000254851.1 RP11-109L13.1 5.71 1.98e-08 7.45e-06 0.35 0.25 Subjective well-being; chr11:117030231 chr11:117135528~117138582:+ LUSC cis rs75920871 0.528 rs7941428 ENSG00000254851.1 RP11-109L13.1 5.71 1.98e-08 7.45e-06 0.35 0.25 Subjective well-being; chr11:117032668 chr11:117135528~117138582:+ LUSC cis rs17826219 0.568 rs2626985 ENSG00000263603.1 CTD-2349P21.5 -5.71 1.98e-08 7.46e-06 -0.36 -0.25 Body mass index; chr17:30750419 chr17:30729469~30731202:+ LUSC cis rs11098499 0.863 rs1155576 ENSG00000248280.1 RP11-33B1.2 5.71 1.98e-08 7.46e-06 0.31 0.25 Corneal astigmatism; chr4:119529004 chr4:119440561~119450157:- LUSC cis rs13113518 1 rs6847529 ENSG00000249700.7 SRD5A3-AS1 5.71 1.98e-08 7.46e-06 0.29 0.25 Height; chr4:55518776 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs6822740 ENSG00000249700.7 SRD5A3-AS1 5.71 1.98e-08 7.46e-06 0.29 0.25 Height; chr4:55518922 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs3762837 ENSG00000249700.7 SRD5A3-AS1 5.71 1.98e-08 7.46e-06 0.29 0.25 Height; chr4:55511198 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs13141049 ENSG00000223305.1 RN7SKP30 5.71 1.98e-08 7.47e-06 0.31 0.25 Height; chr4:55535489 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs4864542 ENSG00000273257.1 RP11-177J6.1 -5.71 1.98e-08 7.47e-06 -0.33 -0.25 Height; chr4:55487920 chr4:55387949~55388271:+ LUSC cis rs783540 0.835 rs8030185 ENSG00000276710.3 CSPG4P8 -5.71 1.99e-08 7.48e-06 -0.27 -0.25 Schizophrenia; chr15:82722785 chr15:82459472~82477258:+ LUSC cis rs17711722 0.701 rs781143 ENSG00000179406.6 LINC00174 -5.71 1.99e-08 7.49e-06 -0.27 -0.25 Calcium levels; chr7:65974892 chr7:66376044~66401338:- LUSC cis rs8177876 0.597 rs1048194 ENSG00000261838.4 RP11-303E16.6 -5.71 1.99e-08 7.49e-06 -0.6 -0.25 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81031097 chr16:81069854~81076598:+ LUSC cis rs910316 1 rs4899544 ENSG00000279594.1 RP11-950C14.10 5.71 1.99e-08 7.49e-06 0.29 0.25 Height; chr14:75079853 chr14:75011269~75012851:- LUSC cis rs910316 1 rs4903279 ENSG00000279594.1 RP11-950C14.10 5.71 1.99e-08 7.49e-06 0.29 0.25 Height; chr14:75079880 chr14:75011269~75012851:- LUSC cis rs875971 0.895 rs12531677 ENSG00000179406.6 LINC00174 5.71 1.99e-08 7.49e-06 0.27 0.25 Aortic root size; chr7:66304099 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs7798630 ENSG00000179406.6 LINC00174 5.71 1.99e-08 7.49e-06 0.27 0.25 Aortic root size; chr7:66306492 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs11984115 ENSG00000179406.6 LINC00174 5.71 1.99e-08 7.49e-06 0.27 0.25 Aortic root size; chr7:66308872 chr7:66376044~66401338:- LUSC cis rs9341808 0.591 rs6454147 ENSG00000272129.1 RP11-250B2.6 5.71 1.99e-08 7.5e-06 0.32 0.25 Sitting height ratio; chr6:80206611 chr6:80355424~80356859:+ LUSC cis rs2842992 0.747 rs733319 ENSG00000237927.1 RP3-393E18.2 -5.71 1.99e-08 7.5e-06 -0.39 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159800443 chr6:159586955~159589169:- LUSC cis rs4489787 1 rs10875804 ENSG00000240399.1 RP1-228P16.1 -5.71 1.99e-08 7.5e-06 -0.44 -0.25 Prostate cancer (SNP x SNP interaction); chr12:48391191 chr12:48054813~48055591:- LUSC cis rs2439831 0.85 rs7179388 ENSG00000249839.1 AC011330.5 -5.71 1.99e-08 7.5e-06 -0.53 -0.25 Lung cancer in ever smokers; chr15:43831747 chr15:43663654~43684339:- LUSC cis rs950880 0.71 rs12470867 ENSG00000234389.1 AC007278.3 -5.71 1.99e-08 7.5e-06 -0.28 -0.25 Serum protein levels (sST2); chr2:102309906 chr2:102438713~102440475:+ LUSC cis rs7246657 0.639 rs3112434 ENSG00000276846.1 CTD-3220F14.3 -5.71 1.99e-08 7.5e-06 -0.39 -0.25 Coronary artery calcification; chr19:37707247 chr19:37314868~37315620:- LUSC cis rs6504950 0.889 rs1484776 ENSG00000275710.1 RP11-257O5.4 -5.71 1.99e-08 7.51e-06 -0.31 -0.25 Breast cancer; chr17:55034022 chr17:54964474~54964679:+ LUSC cis rs6568401 0.6 rs9386465 ENSG00000219088.1 RP3-359N14.1 -5.71 2e-08 7.51e-06 -0.39 -0.25 Primary tooth development (time to first tooth eruption); chr6:105714510 chr6:105666326~105667998:+ LUSC cis rs7208859 0.623 rs426434 ENSG00000266490.1 CTD-2349P21.9 5.71 2e-08 7.51e-06 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30598335 chr17:30792372~30792833:+ LUSC cis rs2153535 0.58 rs2327060 ENSG00000230939.1 RP11-314C16.1 -5.71 2e-08 7.53e-06 -0.3 -0.25 Motion sickness; chr6:8446878 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs6929206 ENSG00000230939.1 RP11-314C16.1 -5.71 2e-08 7.53e-06 -0.3 -0.25 Motion sickness; chr6:8447728 chr6:8784178~8785445:+ LUSC cis rs2842992 0.789 rs9355748 ENSG00000237927.1 RP3-393E18.2 -5.71 2e-08 7.54e-06 -0.38 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159773850 chr6:159586955~159589169:- LUSC cis rs875971 0.545 rs73142245 ENSG00000237310.1 GS1-124K5.4 5.71 2e-08 7.54e-06 0.29 0.25 Aortic root size; chr7:66226662 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs10950029 ENSG00000237310.1 GS1-124K5.4 5.71 2e-08 7.54e-06 0.28 0.25 Aortic root size; chr7:66169334 chr7:66493706~66495474:+ LUSC cis rs77204473 0.744 rs74420345 ENSG00000254851.1 RP11-109L13.1 5.71 2.01e-08 7.54e-06 0.64 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117092561 chr11:117135528~117138582:+ LUSC cis rs11690935 0.885 rs6750058 ENSG00000228389.1 AC068039.4 5.71 2.01e-08 7.55e-06 0.3 0.25 Schizophrenia; chr2:171930399 chr2:171773482~171775844:+ LUSC cis rs17772222 0.63 rs8017811 ENSG00000258789.1 RP11-507K2.3 5.71 2.01e-08 7.55e-06 0.28 0.25 Coronary artery calcification; chr14:88534559 chr14:88551597~88552493:+ LUSC cis rs6918586 0.658 rs13161 ENSG00000272462.2 U91328.19 -5.71 2.01e-08 7.55e-06 -0.27 -0.25 Schizophrenia; chr6:26114474 chr6:25992662~26001775:+ LUSC cis rs875971 0.66 rs10215132 ENSG00000237310.1 GS1-124K5.4 -5.71 2.01e-08 7.56e-06 -0.26 -0.25 Aortic root size; chr7:66589419 chr7:66493706~66495474:+ LUSC cis rs875971 0.862 rs6971059 ENSG00000179406.6 LINC00174 5.71 2.01e-08 7.57e-06 0.28 0.25 Aortic root size; chr7:66602045 chr7:66376044~66401338:- LUSC cis rs875971 0.825 rs66981195 ENSG00000179406.6 LINC00174 5.71 2.01e-08 7.57e-06 0.28 0.25 Aortic root size; chr7:66614048 chr7:66376044~66401338:- LUSC cis rs875971 0.577 rs34888281 ENSG00000222364.1 RNU6-96P 5.71 2.01e-08 7.57e-06 0.3 0.25 Aortic root size; chr7:66120784 chr7:66395191~66395286:+ LUSC cis rs853679 1 rs853679 ENSG00000219392.1 RP1-265C24.5 -5.71 2.01e-08 7.57e-06 -0.43 -0.25 Depression; chr6:28329086 chr6:28115628~28116551:+ LUSC cis rs853679 1 rs853678 ENSG00000219392.1 RP1-265C24.5 -5.71 2.01e-08 7.57e-06 -0.43 -0.25 Depression; chr6:28329536 chr6:28115628~28116551:+ LUSC cis rs9549367 0.789 rs7317558 ENSG00000269125.1 RP11-98F14.11 -5.71 2.01e-08 7.58e-06 -0.31 -0.25 Platelet distribution width; chr13:113239311 chr13:113165002~113165183:- LUSC cis rs13113518 1 rs6838882 ENSG00000249700.7 SRD5A3-AS1 5.71 2.02e-08 7.58e-06 0.3 0.25 Height; chr4:55489310 chr4:55363971~55395847:- LUSC cis rs2243480 1 rs464895 ENSG00000226824.5 RP4-756H11.3 -5.71 2.02e-08 7.59e-06 -0.51 -0.25 Diabetic kidney disease; chr7:66062119 chr7:66654538~66669855:+ LUSC cis rs801193 1 rs11773829 ENSG00000237310.1 GS1-124K5.4 -5.71 2.02e-08 7.59e-06 -0.26 -0.25 Aortic root size; chr7:66676087 chr7:66493706~66495474:+ LUSC cis rs2919917 0.628 rs13267679 ENSG00000254352.1 RP11-578O24.2 -5.71 2.02e-08 7.59e-06 -0.35 -0.25 Lymphocyte counts; chr8:78711603 chr8:78723796~78724136:- LUSC cis rs6142102 0.778 rs6059581 ENSG00000275784.1 RP5-1125A11.6 -5.71 2.02e-08 7.6e-06 -0.3 -0.25 Skin pigmentation; chr20:33940582 chr20:33989480~33991818:- LUSC cis rs13434995 0.513 rs550144 ENSG00000249700.7 SRD5A3-AS1 5.71 2.02e-08 7.6e-06 0.32 0.25 Adiponectin levels; chr4:55415317 chr4:55363971~55395847:- LUSC cis rs11123170 0.529 rs1015755 ENSG00000274877.1 RP11-65I12.1 -5.71 2.02e-08 7.61e-06 -0.37 -0.25 Renal function-related traits (BUN); chr2:113210730 chr2:113237595~113240825:+ LUSC cis rs944990 0.576 rs10821126 ENSG00000227603.1 RP11-165J3.6 5.71 2.02e-08 7.61e-06 0.25 0.25 Body mass index; chr9:93436451 chr9:93435332~93437121:- LUSC cis rs944990 0.576 rs10992731 ENSG00000227603.1 RP11-165J3.6 5.71 2.02e-08 7.61e-06 0.25 0.25 Body mass index; chr9:93436816 chr9:93435332~93437121:- LUSC cis rs6565180 0.791 rs4247355 ENSG00000183604.13 SMG1P5 5.71 2.03e-08 7.62e-06 0.31 0.25 Tonsillectomy; chr16:30380778 chr16:30267553~30335374:- LUSC cis rs9399135 0.517 rs1041478 ENSG00000232876.1 CTA-212D2.2 -5.71 2.03e-08 7.62e-06 -0.31 -0.25 Red blood cell count; chr6:135130059 chr6:135055033~135060550:+ LUSC cis rs875971 0.54 rs1723268 ENSG00000237310.1 GS1-124K5.4 5.71 2.03e-08 7.62e-06 0.26 0.25 Aortic root size; chr7:66008093 chr7:66493706~66495474:+ LUSC cis rs673078 0.66 rs76621503 ENSG00000275759.1 RP11-131L12.3 -5.71 2.03e-08 7.63e-06 -0.39 -0.25 Glucose homeostasis traits; chr12:118179370 chr12:118428281~118428870:+ LUSC cis rs9649213 0.593 rs6465683 ENSG00000272950.1 RP11-307C18.1 5.71 2.03e-08 7.64e-06 0.33 0.25 Prostate cancer (SNP x SNP interaction); chr7:98396780 chr7:98322853~98323430:+ LUSC cis rs801193 0.569 rs11772819 ENSG00000179406.6 LINC00174 -5.71 2.03e-08 7.64e-06 -0.28 -0.25 Aortic root size; chr7:66752983 chr7:66376044~66401338:- LUSC cis rs17270561 0.609 rs1937131 ENSG00000272462.2 U91328.19 5.71 2.04e-08 7.65e-06 0.3 0.25 Iron status biomarkers; chr6:25744603 chr6:25992662~26001775:+ LUSC cis rs763121 0.925 rs4821815 ENSG00000273076.1 RP3-508I15.22 5.71 2.04e-08 7.65e-06 0.25 0.25 Menopause (age at onset); chr22:38709702 chr22:38743495~38743910:+ LUSC cis rs61270009 0.955 rs4916907 ENSG00000247828.6 TMEM161B-AS1 5.71 2.04e-08 7.66e-06 0.29 0.25 Depressive symptoms; chr5:88364163 chr5:88268895~88436685:+ LUSC cis rs7208859 0.573 rs216443 ENSG00000266490.1 CTD-2349P21.9 5.71 2.04e-08 7.67e-06 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604853 chr17:30792372~30792833:+ LUSC cis rs6570726 0.935 rs368848 ENSG00000235652.6 RP11-545I5.3 5.71 2.04e-08 7.68e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145534145 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs374000 ENSG00000235652.6 RP11-545I5.3 5.71 2.04e-08 7.68e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145534154 chr6:145799409~145886585:+ LUSC cis rs9910055 0.676 rs11079983 ENSG00000267080.4 ASB16-AS1 -5.71 2.04e-08 7.68e-06 -0.23 -0.25 Total body bone mineral density; chr17:44120802 chr17:44175973~44186717:- LUSC cis rs11971779 0.941 rs1127424 ENSG00000273391.1 RP11-634H22.1 5.71 2.05e-08 7.69e-06 0.32 0.25 Diisocyanate-induced asthma; chr7:139422914 chr7:139359032~139359566:- LUSC cis rs1729407 0.786 rs5100 ENSG00000254851.1 RP11-109L13.1 -5.71 2.05e-08 7.7e-06 -0.31 -0.25 Apolipoprotein A-IV levels; chr11:116821978 chr11:117135528~117138582:+ LUSC cis rs9341835 0.584 rs2622307 ENSG00000218048.2 RP3-407E4.4 5.71 2.05e-08 7.71e-06 0.29 0.25 Schizophrenia; chr6:63442144 chr6:63440766~63443580:+ LUSC cis rs9341835 0.584 rs2096346 ENSG00000218048.2 RP3-407E4.4 5.71 2.05e-08 7.71e-06 0.29 0.25 Schizophrenia; chr6:63443109 chr6:63440766~63443580:+ LUSC cis rs875971 1 rs697970 ENSG00000179406.6 LINC00174 5.71 2.05e-08 7.71e-06 0.27 0.25 Aortic root size; chr7:66095065 chr7:66376044~66401338:- LUSC cis rs228614 0.51 rs223412 ENSG00000246560.2 RP11-10L12.4 5.71 2.06e-08 7.73e-06 0.31 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102812443 chr4:102828055~102844075:+ LUSC cis rs875971 0.545 rs2420456 ENSG00000224316.1 RP11-479O9.2 5.71 2.06e-08 7.73e-06 0.27 0.25 Aortic root size; chr7:66280619 chr7:65773620~65802067:+ LUSC cis rs13113518 1 rs13115828 ENSG00000223305.1 RN7SKP30 5.71 2.06e-08 7.73e-06 0.31 0.25 Height; chr4:55551447 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs13136282 ENSG00000223305.1 RN7SKP30 5.71 2.06e-08 7.73e-06 0.31 0.25 Height; chr4:55551845 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs11934897 ENSG00000223305.1 RN7SKP30 5.71 2.06e-08 7.73e-06 0.31 0.25 Height; chr4:55553396 chr4:55540502~55540835:- LUSC cis rs13113518 0.934 rs11932293 ENSG00000223305.1 RN7SKP30 5.71 2.06e-08 7.73e-06 0.31 0.25 Height; chr4:55554025 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs13152173 ENSG00000223305.1 RN7SKP30 5.71 2.06e-08 7.73e-06 0.31 0.25 Height; chr4:55534788 chr4:55540502~55540835:- LUSC cis rs7267979 0.844 rs2257649 ENSG00000274973.1 RP13-401N8.7 -5.71 2.06e-08 7.73e-06 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25282821 chr20:25845497~25845862:+ LUSC cis rs783540 0.934 rs8043401 ENSG00000255769.6 GOLGA2P10 -5.71 2.06e-08 7.73e-06 -0.31 -0.25 Schizophrenia; chr15:82687507 chr15:82472993~82513950:- LUSC cis rs783540 1 rs11637433 ENSG00000276710.3 CSPG4P8 -5.7 2.06e-08 7.74e-06 -0.27 -0.25 Schizophrenia; chr15:82652585 chr15:82459472~82477258:+ LUSC cis rs17711722 0.528 rs73138179 ENSG00000226824.5 RP4-756H11.3 -5.7 2.06e-08 7.74e-06 -0.31 -0.25 Calcium levels; chr7:65829495 chr7:66654538~66669855:+ LUSC cis rs8059260 1 rs8059260 ENSG00000274038.1 RP11-66H6.4 -5.7 2.06e-08 7.75e-06 -0.41 -0.25 Alcohol consumption over the past year; chr16:10966294 chr16:11056556~11057034:+ LUSC cis rs10759883 0.627 rs10760189 ENSG00000175611.10 LINC00476 5.7 2.06e-08 7.75e-06 0.31 0.25 Nicotine dependence; chr9:95838543 chr9:95759231~95875977:- LUSC cis rs2562456 0.876 rs2681370 ENSG00000268081.1 RP11-678G14.2 5.7 2.06e-08 7.75e-06 0.36 0.25 Pain; chr19:21554036 chr19:21554640~21569237:- LUSC cis rs2562456 0.876 rs11668606 ENSG00000268081.1 RP11-678G14.2 5.7 2.06e-08 7.75e-06 0.36 0.25 Pain; chr19:21554618 chr19:21554640~21569237:- LUSC cis rs2562456 0.876 rs2681395 ENSG00000268081.1 RP11-678G14.2 5.7 2.06e-08 7.75e-06 0.36 0.25 Pain; chr19:21555338 chr19:21554640~21569237:- LUSC cis rs11722779 0.901 rs28674656 ENSG00000230069.3 LRRC37A15P -5.7 2.06e-08 7.75e-06 -0.27 -0.25 Schizophrenia; chr4:102944396 chr4:102727274~102730721:- LUSC cis rs34375054 0.573 rs12581367 ENSG00000279233.1 RP11-158L12.4 5.7 2.07e-08 7.76e-06 0.28 0.25 Post bronchodilator FEV1/FVC ratio; chr12:125170095 chr12:125138245~125141711:+ LUSC cis rs8177376 0.834 rs12287976 ENSG00000254905.1 RP11-712L6.7 5.7 2.07e-08 7.77e-06 0.32 0.25 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126302693 chr11:126292922~126294254:- LUSC cis rs7945705 0.846 rs4929911 ENSG00000254860.4 TMEM9B-AS1 -5.7 2.07e-08 7.77e-06 -0.29 -0.25 Hemoglobin concentration; chr11:8794948 chr11:8964675~8977527:+ LUSC cis rs2442825 0.508 rs2648545 ENSG00000206573.7 THUMPD3-AS1 -5.7 2.07e-08 7.77e-06 -0.22 -0.25 Cerebrospinal fluid clusterin levels; chr3:9347539 chr3:9349689~9398579:- LUSC cis rs66887589 0.776 rs10518337 ENSG00000248280.1 RP11-33B1.2 -5.7 2.07e-08 7.77e-06 -0.29 -0.25 Diastolic blood pressure; chr4:119653719 chr4:119440561~119450157:- LUSC cis rs11159086 1 rs8006909 ENSG00000259005.1 RP3-449M8.6 5.7 2.07e-08 7.78e-06 0.39 0.25 Advanced glycation end-product levels; chr14:74478085 chr14:74474007~74474864:- LUSC cis rs875971 0.545 rs10950036 ENSG00000224316.1 RP11-479O9.2 5.7 2.07e-08 7.79e-06 0.27 0.25 Aortic root size; chr7:66353241 chr7:65773620~65802067:+ LUSC cis rs9640161 0.711 rs3735170 ENSG00000261305.1 RP4-584D14.7 5.7 2.08e-08 7.79e-06 0.37 0.25 Blood protein levels;Circulating chemerin levels; chr7:150337095 chr7:150341771~150342607:+ LUSC cis rs875971 0.862 rs1167408 ENSG00000179406.6 LINC00174 5.7 2.08e-08 7.79e-06 0.28 0.25 Aortic root size; chr7:66091121 chr7:66376044~66401338:- LUSC cis rs875971 0.83 rs1167406 ENSG00000179406.6 LINC00174 5.7 2.08e-08 7.79e-06 0.28 0.25 Aortic root size; chr7:66091949 chr7:66376044~66401338:- LUSC cis rs6570726 0.935 rs369214 ENSG00000235652.6 RP11-545I5.3 5.7 2.08e-08 7.79e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145535573 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs390252 ENSG00000235652.6 RP11-545I5.3 5.7 2.08e-08 7.79e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145535760 chr6:145799409~145886585:+ LUSC cis rs6565180 0.926 rs4787643 ENSG00000183604.13 SMG1P5 5.7 2.08e-08 7.79e-06 0.31 0.25 Tonsillectomy; chr16:30382339 chr16:30267553~30335374:- LUSC cis rs6565180 0.926 rs4788409 ENSG00000183604.13 SMG1P5 5.7 2.08e-08 7.79e-06 0.31 0.25 Tonsillectomy; chr16:30382450 chr16:30267553~30335374:- LUSC cis rs172166 0.694 rs1225716 ENSG00000219392.1 RP1-265C24.5 -5.7 2.08e-08 7.8e-06 -0.33 -0.25 Cardiac Troponin-T levels; chr6:28145968 chr6:28115628~28116551:+ LUSC cis rs7208859 0.673 rs423151 ENSG00000266490.1 CTD-2349P21.9 5.7 2.08e-08 7.8e-06 0.28 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30625268 chr17:30792372~30792833:+ LUSC cis rs2243480 1 rs160633 ENSG00000226824.5 RP4-756H11.3 -5.7 2.08e-08 7.8e-06 -0.49 -0.25 Diabetic kidney disease; chr7:66063241 chr7:66654538~66669855:+ LUSC cis rs673078 0.66 rs7970481 ENSG00000275759.1 RP11-131L12.3 -5.7 2.08e-08 7.8e-06 -0.38 -0.25 Glucose homeostasis traits; chr12:118242112 chr12:118428281~118428870:+ LUSC cis rs2274273 0.87 rs10139000 ENSG00000258413.1 RP11-665C16.6 -5.7 2.08e-08 7.81e-06 -0.31 -0.25 Protein biomarker; chr14:55383158 chr14:55262767~55272075:- LUSC cis rs853679 0.513 rs9468296 ENSG00000280107.1 AL022393.9 -5.7 2.08e-08 7.82e-06 -0.32 -0.25 Depression; chr6:28145952 chr6:28170845~28172521:+ LUSC cis rs11123170 0.529 rs35606997 ENSG00000274877.1 RP11-65I12.1 -5.7 2.09e-08 7.82e-06 -0.36 -0.25 Renal function-related traits (BUN); chr2:113215773 chr2:113237595~113240825:+ LUSC cis rs6504622 0.905 rs3851787 ENSG00000262879.4 RP11-156P1.3 5.7 2.09e-08 7.83e-06 0.27 0.25 Orofacial clefts; chr17:46969616 chr17:46984045~47100323:- LUSC cis rs17270561 0.609 rs9358886 ENSG00000272462.2 U91328.19 -5.7 2.09e-08 7.85e-06 -0.31 -0.25 Iron status biomarkers; chr6:25758025 chr6:25992662~26001775:+ LUSC cis rs875971 0.522 rs1880556 ENSG00000179406.6 LINC00174 -5.7 2.09e-08 7.85e-06 -0.27 -0.25 Aortic root size; chr7:65967557 chr7:66376044~66401338:- LUSC cis rs2136613 0.751 rs224307 ENSG00000238280.1 RP11-436D10.3 5.7 2.09e-08 7.85e-06 0.32 0.25 Selective IgA deficiency; chr10:62841675 chr10:62793562~62805887:- LUSC cis rs2136613 0.751 rs224308 ENSG00000238280.1 RP11-436D10.3 5.7 2.09e-08 7.85e-06 0.32 0.25 Selective IgA deficiency; chr10:62843007 chr10:62793562~62805887:- LUSC cis rs11690935 0.851 rs7573003 ENSG00000228389.1 AC068039.4 5.7 2.09e-08 7.85e-06 0.29 0.25 Schizophrenia; chr2:171884905 chr2:171773482~171775844:+ LUSC cis rs2919917 0.628 rs6997255 ENSG00000254352.1 RP11-578O24.2 5.7 2.09e-08 7.86e-06 0.34 0.25 Lymphocyte counts; chr8:78694850 chr8:78723796~78724136:- LUSC cis rs2919917 0.628 rs7017898 ENSG00000254352.1 RP11-578O24.2 5.7 2.09e-08 7.86e-06 0.34 0.25 Lymphocyte counts; chr8:78697147 chr8:78723796~78724136:- LUSC cis rs7772486 0.875 rs7766463 ENSG00000235652.6 RP11-545I5.3 5.7 2.1e-08 7.86e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:146043317 chr6:145799409~145886585:+ LUSC cis rs7665090 1 rs2866406 ENSG00000230069.3 LRRC37A15P -5.7 2.1e-08 7.87e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102632862 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs2866407 ENSG00000230069.3 LRRC37A15P -5.7 2.1e-08 7.87e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102632951 chr4:102727274~102730721:- LUSC cis rs7665090 1 rs2866408 ENSG00000230069.3 LRRC37A15P -5.7 2.1e-08 7.87e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102632956 chr4:102727274~102730721:- LUSC cis rs55665837 0.539 rs10500804 ENSG00000251991.1 RNU7-49P 5.7 2.1e-08 7.87e-06 0.29 0.25 Vitamin D levels; chr11:14888727 chr11:14478892~14478953:+ LUSC cis rs9326248 0.581 rs7120963 ENSG00000280143.1 AP000892.6 -5.7 2.1e-08 7.87e-06 -0.26 -0.25 Blood protein levels; chr11:116959545 chr11:117204967~117210292:+ LUSC cis rs35160687 0.644 rs10165626 ENSG00000273080.1 RP11-301O19.1 -5.7 2.1e-08 7.87e-06 -0.24 -0.25 Night sleep phenotypes; chr2:86309584 chr2:86195590~86196049:+ LUSC cis rs7665090 0.967 rs13106325 ENSG00000230069.3 LRRC37A15P -5.7 2.1e-08 7.88e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633835 chr4:102727274~102730721:- LUSC cis rs7267979 1 rs7267979 ENSG00000274973.1 RP13-401N8.7 -5.7 2.1e-08 7.89e-06 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25317451 chr20:25845497~25845862:+ LUSC cis rs2153535 0.505 rs9405395 ENSG00000230939.1 RP11-314C16.1 -5.7 2.1e-08 7.89e-06 -0.31 -0.25 Motion sickness; chr6:8468389 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9392223 ENSG00000230939.1 RP11-314C16.1 -5.7 2.1e-08 7.89e-06 -0.31 -0.25 Motion sickness; chr6:8468417 chr6:8784178~8785445:+ LUSC cis rs7665090 1 rs12498722 ENSG00000230069.3 LRRC37A15P -5.7 2.11e-08 7.89e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633365 chr4:102727274~102730721:- LUSC cis rs2243480 1 rs419603 ENSG00000226824.5 RP4-756H11.3 -5.7 2.11e-08 7.89e-06 -0.47 -0.25 Diabetic kidney disease; chr7:66132354 chr7:66654538~66669855:+ LUSC cis rs7665090 1 rs5026472 ENSG00000230069.3 LRRC37A15P -5.7 2.11e-08 7.9e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633616 chr4:102727274~102730721:- LUSC cis rs6951245 0.678 rs4724725 ENSG00000224079.1 AC091729.7 -5.7 2.11e-08 7.9e-06 -0.43 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1175115 chr7:1074450~1078036:+ LUSC cis rs4865169 0.934 rs12650737 ENSG00000269949.1 RP11-738E22.3 -5.7 2.11e-08 7.91e-06 -0.31 -0.25 Breast cancer; chr4:57026309 chr4:56960927~56961373:- LUSC cis rs2742234 0.541 rs11238490 ENSG00000273008.1 RP11-351D16.3 5.7 2.11e-08 7.91e-06 0.29 0.25 Hirschsprung disease; chr10:43252150 chr10:43136824~43138334:- LUSC cis rs750134 1 rs12578143 ENSG00000257221.1 RP11-689B22.2 -5.7 2.11e-08 7.91e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108669500 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs77103653 ENSG00000257221.1 RP11-689B22.2 -5.7 2.11e-08 7.91e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108671385 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs1861638 ENSG00000257221.1 RP11-689B22.2 -5.7 2.11e-08 7.91e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108671681 chr12:108628687~108641318:+ LUSC cis rs9341835 0.642 rs1723535 ENSG00000218048.2 RP3-407E4.4 5.7 2.11e-08 7.91e-06 0.29 0.25 Schizophrenia; chr6:63426981 chr6:63440766~63443580:+ LUSC cis rs11971779 0.715 rs10954646 ENSG00000273391.1 RP11-634H22.1 -5.7 2.11e-08 7.92e-06 -0.26 -0.25 Diisocyanate-induced asthma; chr7:139376323 chr7:139359032~139359566:- LUSC cis rs55665837 0.539 rs10766196 ENSG00000251991.1 RNU7-49P 5.7 2.12e-08 7.93e-06 0.29 0.25 Vitamin D levels; chr11:14891585 chr11:14478892~14478953:+ LUSC cis rs2404602 0.583 rs12898415 ENSG00000259422.1 RP11-593F23.1 5.7 2.12e-08 7.94e-06 0.29 0.25 Blood metabolite levels; chr15:76281891 chr15:76174891~76181486:- LUSC cis rs875971 0.558 rs4433015 ENSG00000222364.1 RNU6-96P 5.7 2.12e-08 7.94e-06 0.3 0.25 Aortic root size; chr7:66174736 chr7:66395191~66395286:+ LUSC cis rs1729407 0.741 rs1263177 ENSG00000254851.1 RP11-109L13.1 -5.7 2.12e-08 7.95e-06 -0.31 -0.25 Apolipoprotein A-IV levels; chr11:116819996 chr11:117135528~117138582:+ LUSC cis rs7665090 0.936 rs5026474 ENSG00000230069.3 LRRC37A15P -5.7 2.12e-08 7.96e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633653 chr4:102727274~102730721:- LUSC cis rs6570726 0.875 rs373313 ENSG00000235652.6 RP11-545I5.3 5.7 2.13e-08 7.96e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145536655 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs380433 ENSG00000235652.6 RP11-545I5.3 5.7 2.13e-08 7.96e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145538465 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs367643 ENSG00000235652.6 RP11-545I5.3 5.7 2.13e-08 7.96e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145538466 chr6:145799409~145886585:+ LUSC cis rs1707322 0.691 rs61784799 ENSG00000234329.1 RP11-767N6.2 -5.7 2.13e-08 7.96e-06 -0.28 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45712076 chr1:45651039~45651826:- LUSC cis rs7665090 1 rs5026476 ENSG00000230069.3 LRRC37A15P -5.7 2.13e-08 7.96e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633753 chr4:102727274~102730721:- LUSC cis rs8059260 1 rs6498139 ENSG00000274038.1 RP11-66H6.4 -5.7 2.13e-08 7.97e-06 -0.42 -0.25 Alcohol consumption over the past year; chr16:10954066 chr16:11056556~11057034:+ LUSC cis rs853679 0.723 rs9366718 ENSG00000204709.4 LINC01556 5.7 2.13e-08 7.98e-06 0.38 0.25 Depression; chr6:28237724 chr6:28943877~28944537:+ LUSC cis rs9341835 0.772 rs4445042 ENSG00000218048.2 RP3-407E4.4 5.7 2.13e-08 7.98e-06 0.3 0.25 Schizophrenia; chr6:63430092 chr6:63440766~63443580:+ LUSC cis rs8059260 1 rs7185978 ENSG00000274038.1 RP11-66H6.4 -5.7 2.13e-08 7.98e-06 -0.42 -0.25 Alcohol consumption over the past year; chr16:10954417 chr16:11056556~11057034:+ LUSC cis rs7665090 0.967 rs13106304 ENSG00000230069.3 LRRC37A15P -5.7 2.13e-08 7.99e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633818 chr4:102727274~102730721:- LUSC cis rs1075265 0.73 rs805391 ENSG00000233266.1 HMGB1P31 -5.7 2.13e-08 7.99e-06 -0.31 -0.25 Chronotype;Morning vs. evening chronotype; chr2:53877181 chr2:54051334~54051760:+ LUSC cis rs7772486 0.743 rs9390344 ENSG00000235652.6 RP11-545I5.3 -5.7 2.14e-08 8e-06 -0.25 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145691619 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs441290 ENSG00000235652.6 RP11-545I5.3 5.7 2.14e-08 8.01e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145562047 chr6:145799409~145886585:+ LUSC cis rs673078 0.66 rs56708462 ENSG00000275759.1 RP11-131L12.3 -5.7 2.14e-08 8.01e-06 -0.38 -0.25 Glucose homeostasis traits; chr12:118284135 chr12:118428281~118428870:+ LUSC cis rs17711722 0.653 rs2460421 ENSG00000164669.11 INTS4P1 5.7 2.14e-08 8.01e-06 0.27 0.25 Calcium levels; chr7:66026136 chr7:65141225~65234216:+ LUSC cis rs3738443 0.83 rs58405512 ENSG00000259865.1 RP11-488L18.10 5.7 2.15e-08 8.03e-06 0.27 0.25 Alcohol dependence; chr1:247198454 chr1:247187281~247188526:- LUSC cis rs8177876 0.642 rs12445303 ENSG00000261061.1 RP11-303E16.2 5.7 2.15e-08 8.04e-06 0.56 0.25 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081968 chr16:81030770~81031485:+ LUSC cis rs801193 1 rs10252765 ENSG00000222364.1 RNU6-96P -5.7 2.15e-08 8.04e-06 -0.29 -0.25 Aortic root size; chr7:66763745 chr7:66395191~66395286:+ LUSC cis rs10759883 0.627 rs10739622 ENSG00000175611.10 LINC00476 5.7 2.15e-08 8.04e-06 0.3 0.25 Nicotine dependence; chr9:95852889 chr9:95759231~95875977:- LUSC cis rs10759883 0.627 rs10760269 ENSG00000175611.10 LINC00476 5.7 2.15e-08 8.04e-06 0.3 0.25 Nicotine dependence; chr9:95852897 chr9:95759231~95875977:- LUSC cis rs2842992 0.83 rs752779 ENSG00000237927.1 RP3-393E18.2 -5.7 2.15e-08 8.05e-06 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159712925 chr6:159586955~159589169:- LUSC cis rs2842992 0.83 rs2025189 ENSG00000237927.1 RP3-393E18.2 -5.7 2.15e-08 8.05e-06 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159716486 chr6:159586955~159589169:- LUSC cis rs2842992 0.83 rs2495279 ENSG00000237927.1 RP3-393E18.2 -5.7 2.15e-08 8.05e-06 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159717764 chr6:159586955~159589169:- LUSC cis rs11098499 0.604 rs34278750 ENSG00000248280.1 RP11-33B1.2 5.7 2.15e-08 8.05e-06 0.31 0.25 Corneal astigmatism; chr4:119649981 chr4:119440561~119450157:- LUSC cis rs34375054 0.573 rs12811438 ENSG00000279233.1 RP11-158L12.4 5.7 2.15e-08 8.06e-06 0.28 0.25 Post bronchodilator FEV1/FVC ratio; chr12:125168944 chr12:125138245~125141711:+ LUSC cis rs13113518 1 rs9312661 ENSG00000249700.7 SRD5A3-AS1 5.7 2.16e-08 8.07e-06 0.29 0.25 Height; chr4:55476159 chr4:55363971~55395847:- LUSC cis rs875971 0.545 rs10950025 ENSG00000237310.1 GS1-124K5.4 5.7 2.16e-08 8.07e-06 0.29 0.25 Aortic root size; chr7:66158946 chr7:66493706~66495474:+ LUSC cis rs875971 0.52 rs12666485 ENSG00000237310.1 GS1-124K5.4 5.7 2.16e-08 8.07e-06 0.29 0.25 Aortic root size; chr7:66160135 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs67688847 ENSG00000237310.1 GS1-124K5.4 5.7 2.16e-08 8.07e-06 0.29 0.25 Aortic root size; chr7:66161064 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs12673308 ENSG00000237310.1 GS1-124K5.4 5.7 2.16e-08 8.07e-06 0.29 0.25 Aortic root size; chr7:66166374 chr7:66493706~66495474:+ LUSC cis rs7208859 0.623 rs56378576 ENSG00000266490.1 CTD-2349P21.9 5.7 2.16e-08 8.08e-06 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30683102 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs35916850 ENSG00000266490.1 CTD-2349P21.9 5.7 2.16e-08 8.08e-06 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30684155 chr17:30792372~30792833:+ LUSC cis rs2842992 0.709 rs1853257 ENSG00000237927.1 RP3-393E18.2 -5.7 2.16e-08 8.08e-06 -0.38 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159791678 chr6:159586955~159589169:- LUSC cis rs62025270 0.547 rs8035496 ENSG00000202081.1 RNU6-1280P -5.7 2.16e-08 8.09e-06 -0.31 -0.25 Idiopathic pulmonary fibrosis; chr15:85591101 chr15:85651522~85651628:- LUSC cis rs2153535 0.58 rs7748455 ENSG00000230939.1 RP11-314C16.1 -5.7 2.16e-08 8.09e-06 -0.3 -0.25 Motion sickness; chr6:8453392 chr6:8784178~8785445:+ LUSC cis rs13113518 1 rs13116194 ENSG00000223305.1 RN7SKP30 5.7 2.16e-08 8.09e-06 0.31 0.25 Height; chr4:55531150 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs13117836 ENSG00000223305.1 RN7SKP30 5.7 2.16e-08 8.09e-06 0.31 0.25 Height; chr4:55531218 chr4:55540502~55540835:- LUSC cis rs13113518 0.966 rs7668429 ENSG00000223305.1 RN7SKP30 5.7 2.16e-08 8.09e-06 0.31 0.25 Height; chr4:55531811 chr4:55540502~55540835:- LUSC cis rs6969780 0.915 rs7341470 ENSG00000233429.8 HOTAIRM1 -5.7 2.17e-08 8.1e-06 -0.44 -0.25 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27145223 chr7:27095647~27100265:+ LUSC cis rs875971 0.862 rs6460307 ENSG00000179406.6 LINC00174 -5.7 2.17e-08 8.1e-06 -0.27 -0.25 Aortic root size; chr7:66595884 chr7:66376044~66401338:- LUSC cis rs4865169 0.871 rs9918067 ENSG00000269949.1 RP11-738E22.3 -5.7 2.17e-08 8.11e-06 -0.31 -0.25 Breast cancer; chr4:57004378 chr4:56960927~56961373:- LUSC cis rs11722779 0.873 rs223384 ENSG00000246560.2 RP11-10L12.4 5.7 2.17e-08 8.11e-06 0.31 0.25 Schizophrenia; chr4:102829976 chr4:102828055~102844075:+ LUSC cis rs227275 0.554 rs223383 ENSG00000246560.2 RP11-10L12.4 5.7 2.17e-08 8.11e-06 0.31 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102830094 chr4:102828055~102844075:+ LUSC cis rs4834770 1 rs878375 ENSG00000245958.5 RP11-33B1.1 -5.7 2.17e-08 8.12e-06 -0.24 -0.25 Blood protein levels; chr4:119316419 chr4:119454791~119552025:+ LUSC cis rs172166 0.694 rs2791332 ENSG00000216901.1 AL022393.7 5.7 2.17e-08 8.12e-06 0.3 0.25 Cardiac Troponin-T levels; chr6:28141010 chr6:28176188~28176674:+ LUSC cis rs9813712 0.595 rs6439226 ENSG00000228252.7 COL6A4P2 5.7 2.17e-08 8.13e-06 0.24 0.25 Response to amphetamines; chr3:130283686 chr3:130212823~130273806:+ LUSC cis rs13434995 0.513 rs7665846 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.32 0.25 Adiponectin levels; chr4:55573078 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs3805148 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.29 0.25 Height; chr4:55440643 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11133380 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.29 0.25 Height; chr4:55441110 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs12510110 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.29 0.25 Height; chr4:55441567 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs12510990 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.29 0.25 Height; chr4:55441907 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs3805149 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.29 0.25 Height; chr4:55442184 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11945370 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.29 0.25 Height; chr4:55442875 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs12647677 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.29 0.25 Height; chr4:55444253 chr4:55363971~55395847:- LUSC cis rs13113518 0.902 rs3805150 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.29 0.25 Height; chr4:55446869 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs4864990 ENSG00000249700.7 SRD5A3-AS1 5.7 2.17e-08 8.13e-06 0.29 0.25 Height; chr4:55447523 chr4:55363971~55395847:- LUSC cis rs34375054 0.624 rs7132026 ENSG00000279233.1 RP11-158L12.4 -5.7 2.18e-08 8.13e-06 -0.25 -0.25 Post bronchodilator FEV1/FVC ratio; chr12:125193550 chr12:125138245~125141711:+ LUSC cis rs11098499 0.604 rs2389886 ENSG00000248280.1 RP11-33B1.2 5.69 2.18e-08 8.14e-06 0.31 0.25 Corneal astigmatism; chr4:119649267 chr4:119440561~119450157:- LUSC cis rs6504950 0.72 rs2877634 ENSG00000275710.1 RP11-257O5.4 5.69 2.18e-08 8.15e-06 0.29 0.25 Breast cancer; chr17:54910184 chr17:54964474~54964679:+ LUSC cis rs17772222 0.63 rs7141608 ENSG00000258789.1 RP11-507K2.3 5.69 2.18e-08 8.15e-06 0.28 0.25 Coronary artery calcification; chr14:88514045 chr14:88551597~88552493:+ LUSC cis rs459571 0.959 rs416390 ENSG00000235106.7 LINC00094 -5.69 2.18e-08 8.16e-06 -0.28 -0.25 Platelet distribution width; chr9:134043427 chr9:134025439~134034666:+ LUSC cis rs875971 0.545 rs67397473 ENSG00000224316.1 RP11-479O9.2 5.69 2.19e-08 8.17e-06 0.27 0.25 Aortic root size; chr7:66168318 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs10950027 ENSG00000224316.1 RP11-479O9.2 5.69 2.19e-08 8.17e-06 0.27 0.25 Aortic root size; chr7:66169164 chr7:65773620~65802067:+ LUSC cis rs7119038 0.509 rs10892259 ENSG00000255422.1 AP002954.4 5.69 2.19e-08 8.17e-06 0.34 0.25 Sjögren's syndrome; chr11:118712293 chr11:118704607~118750263:+ LUSC cis rs11992186 0.505 rs7845203 ENSG00000253893.2 FAM85B -5.69 2.19e-08 8.17e-06 -0.3 -0.25 Neuroticism; chr8:8287918 chr8:8167819~8226614:- LUSC cis rs2834288 0.734 rs8126669 ENSG00000273102.1 AP000569.9 -5.69 2.19e-08 8.17e-06 -0.3 -0.25 Gut microbiota (bacterial taxa); chr21:33895836 chr21:33967101~33968573:- LUSC cis rs2562456 0.682 rs11085464 ENSG00000268081.1 RP11-678G14.2 5.69 2.19e-08 8.17e-06 0.36 0.25 Pain; chr19:21568976 chr19:21554640~21569237:- LUSC cis rs2562456 0.876 rs11085467 ENSG00000268081.1 RP11-678G14.2 5.69 2.19e-08 8.17e-06 0.36 0.25 Pain; chr19:21569041 chr19:21554640~21569237:- LUSC cis rs2179367 0.632 rs997682 ENSG00000231760.4 RP11-350J20.5 -5.69 2.19e-08 8.17e-06 -0.36 -0.25 Dupuytren's disease; chr6:149345484 chr6:149796151~149826294:- LUSC cis rs7267979 0.868 rs6138553 ENSG00000274973.1 RP13-401N8.7 -5.69 2.19e-08 8.18e-06 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25258597 chr20:25845497~25845862:+ LUSC cis rs2439831 0.85 rs16950562 ENSG00000249839.1 AC011330.5 -5.69 2.19e-08 8.18e-06 -0.49 -0.25 Lung cancer in ever smokers; chr15:43744166 chr15:43663654~43684339:- LUSC cis rs2742234 0.504 rs7093409 ENSG00000273008.1 RP11-351D16.3 5.69 2.19e-08 8.18e-06 0.27 0.25 Hirschsprung disease; chr10:43244619 chr10:43136824~43138334:- LUSC cis rs875971 0.545 rs73378304 ENSG00000179406.6 LINC00174 -5.69 2.19e-08 8.18e-06 -0.29 -0.25 Aortic root size; chr7:66175760 chr7:66376044~66401338:- LUSC cis rs9341835 0.584 rs2622286 ENSG00000218048.2 RP3-407E4.4 5.69 2.19e-08 8.19e-06 0.29 0.25 Schizophrenia; chr6:63440162 chr6:63440766~63443580:+ LUSC cis rs13113518 1 rs11724094 ENSG00000223305.1 RN7SKP30 5.69 2.19e-08 8.2e-06 0.31 0.25 Height; chr4:55501479 chr4:55540502~55540835:- LUSC cis rs28830936 1 rs12441300 ENSG00000250379.1 RP11-23P13.4 5.69 2.2e-08 8.21e-06 0.27 0.25 Diastolic blood pressure; chr15:41810647 chr15:41825099~41827936:- LUSC cis rs2439831 0.867 rs3101443 ENSG00000249839.1 AC011330.5 -5.69 2.21e-08 8.23e-06 -0.48 -0.25 Lung cancer in ever smokers; chr15:43620174 chr15:43663654~43684339:- LUSC cis rs459571 1 rs456207 ENSG00000235106.7 LINC00094 5.69 2.21e-08 8.24e-06 0.28 0.25 Platelet distribution width; chr9:134046018 chr9:134025439~134034666:+ LUSC cis rs11098499 0.954 rs13145352 ENSG00000250412.1 KLHL2P1 -5.69 2.21e-08 8.24e-06 -0.32 -0.25 Corneal astigmatism; chr4:119488808 chr4:119334329~119378233:+ LUSC cis rs11098499 0.863 rs3775847 ENSG00000248280.1 RP11-33B1.2 5.69 2.21e-08 8.24e-06 0.31 0.25 Corneal astigmatism; chr4:119526487 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs3775848 ENSG00000248280.1 RP11-33B1.2 5.69 2.21e-08 8.24e-06 0.31 0.25 Corneal astigmatism; chr4:119526569 chr4:119440561~119450157:- LUSC cis rs801193 0.967 rs3800823 ENSG00000224316.1 RP11-479O9.2 -5.69 2.21e-08 8.24e-06 -0.25 -0.25 Aortic root size; chr7:66682123 chr7:65773620~65802067:+ LUSC cis rs11098499 0.562 rs58583086 ENSG00000248280.1 RP11-33B1.2 -5.69 2.21e-08 8.25e-06 -0.29 -0.25 Corneal astigmatism; chr4:119635207 chr4:119440561~119450157:- LUSC cis rs6860806 0.507 rs270608 ENSG00000233006.5 AC034220.3 5.69 2.21e-08 8.25e-06 0.27 0.25 Breast cancer; chr5:132312713 chr5:132311285~132369916:- LUSC cis rs7829975 0.514 rs2920991 ENSG00000173295.6 FAM86B3P 5.69 2.21e-08 8.25e-06 0.28 0.25 Mood instability; chr8:8401607 chr8:8228595~8244865:+ LUSC cis rs9545047 0.604 rs1028770 ENSG00000227676.3 LINC01068 -5.69 2.21e-08 8.26e-06 -0.3 -0.25 Schizophrenia; chr13:79297346 chr13:79566727~79571436:+ LUSC cis rs13113518 0.729 rs13120134 ENSG00000223305.1 RN7SKP30 5.69 2.21e-08 8.26e-06 0.33 0.25 Height; chr4:55415153 chr4:55540502~55540835:- LUSC cis rs11971779 0.838 rs58074268 ENSG00000273391.1 RP11-634H22.1 5.69 2.21e-08 8.26e-06 0.29 0.25 Diisocyanate-induced asthma; chr7:139424179 chr7:139359032~139359566:- LUSC cis rs11951515 0.508 rs67261887 ENSG00000249286.1 CTD-2210P15.2 5.69 2.22e-08 8.27e-06 0.3 0.25 Metabolite levels (X-11787); chr5:43612339 chr5:43586918~43588223:- LUSC cis rs750134 1 rs12580445 ENSG00000257221.1 RP11-689B22.2 -5.69 2.22e-08 8.27e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108681581 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs56389244 ENSG00000257221.1 RP11-689B22.2 -5.69 2.22e-08 8.27e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108683396 chr12:108628687~108641318:+ LUSC cis rs9326248 0.581 rs7121898 ENSG00000280143.1 AP000892.6 5.69 2.22e-08 8.27e-06 0.27 0.25 Blood protein levels; chr11:116926130 chr11:117204967~117210292:+ LUSC cis rs3198697 1 rs3198697 ENSG00000207425.1 Y_RNA 5.69 2.22e-08 8.28e-06 0.3 0.25 Triglycerides; chr16:15036083 chr16:14915457~14915556:- LUSC cis rs673078 0.66 rs17512574 ENSG00000275759.1 RP11-131L12.3 -5.69 2.22e-08 8.29e-06 -0.35 -0.25 Glucose homeostasis traits; chr12:118350198 chr12:118428281~118428870:+ LUSC cis rs11159086 0.941 rs12434836 ENSG00000270000.1 RP3-449M8.9 5.69 2.22e-08 8.29e-06 0.4 0.25 Advanced glycation end-product levels; chr14:74468887 chr14:74471930~74472360:- LUSC cis rs2302464 1 rs6835705 ENSG00000214846.4 RP11-115L11.1 -5.69 2.22e-08 8.29e-06 -0.66 -0.25 Cerebrospinal fluid biomarker levels; chr4:15736747 chr4:15730962~15731627:- LUSC cis rs11098499 0.604 rs10022185 ENSG00000248280.1 RP11-33B1.2 5.69 2.22e-08 8.3e-06 0.31 0.25 Corneal astigmatism; chr4:119650610 chr4:119440561~119450157:- LUSC cis rs11098499 0.722 rs10006192 ENSG00000249244.1 RP11-548H18.2 5.69 2.22e-08 8.3e-06 0.32 0.25 Corneal astigmatism; chr4:119341867 chr4:119391831~119395335:- LUSC cis rs11098499 0.615 rs28551750 ENSG00000249244.1 RP11-548H18.2 5.69 2.22e-08 8.3e-06 0.32 0.25 Corneal astigmatism; chr4:119343746 chr4:119391831~119395335:- LUSC cis rs17711722 0.51 rs11767457 ENSG00000226824.5 RP4-756H11.3 -5.69 2.23e-08 8.3e-06 -0.3 -0.25 Calcium levels; chr7:65825628 chr7:66654538~66669855:+ LUSC cis rs66887589 0.967 rs59516282 ENSG00000248280.1 RP11-33B1.2 -5.69 2.23e-08 8.3e-06 -0.28 -0.25 Diastolic blood pressure; chr4:119580861 chr4:119440561~119450157:- LUSC cis rs6772849 0.662 rs12494372 ENSG00000277250.1 Metazoa_SRP -5.69 2.23e-08 8.31e-06 -0.3 -0.25 Monocyte percentage of white cells;Monocyte count; chr3:128682850 chr3:128673681~128674021:- LUSC cis rs6928977 0.66 rs2614267 ENSG00000234084.1 RP3-388E23.2 5.69 2.23e-08 8.32e-06 0.2 0.25 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135455340 chr6:135301568~135307158:+ LUSC cis rs13113518 1 rs13133579 ENSG00000223305.1 RN7SKP30 5.69 2.23e-08 8.33e-06 0.31 0.25 Height; chr4:55459921 chr4:55540502~55540835:- LUSC cis rs13113518 0.902 rs11133386 ENSG00000223305.1 RN7SKP30 5.69 2.23e-08 8.33e-06 0.31 0.25 Height; chr4:55461320 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs4864995 ENSG00000249700.7 SRD5A3-AS1 5.69 2.24e-08 8.35e-06 0.29 0.25 Height; chr4:55452853 chr4:55363971~55395847:- LUSC cis rs6570726 0.905 rs442435 ENSG00000235652.6 RP11-545I5.3 5.69 2.24e-08 8.35e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145494423 chr6:145799409~145886585:+ LUSC cis rs6570726 0.905 rs396492 ENSG00000235652.6 RP11-545I5.3 5.69 2.24e-08 8.35e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145495044 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs7757387 ENSG00000235652.6 RP11-545I5.3 5.69 2.24e-08 8.35e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145495590 chr6:145799409~145886585:+ LUSC cis rs853679 0.55 rs9295762 ENSG00000280107.1 AL022393.9 5.69 2.24e-08 8.36e-06 0.3 0.25 Depression; chr6:28187640 chr6:28170845~28172521:+ LUSC cis rs1930961 0.85 rs5996945 ENSG00000272942.1 CTA-246H3.12 5.69 2.24e-08 8.36e-06 0.43 0.25 Bipolar disorder with mood-incongruent psychosis; chr22:25479606 chr22:25434324~25435070:- LUSC cis rs7208859 0.573 rs55661352 ENSG00000263603.1 CTD-2349P21.5 -5.69 2.24e-08 8.36e-06 -0.36 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30718610 chr17:30729469~30731202:+ LUSC cis rs2243480 1 rs4718270 ENSG00000226824.5 RP4-756H11.3 -5.69 2.25e-08 8.37e-06 -0.49 -0.25 Diabetic kidney disease; chr7:65737415 chr7:66654538~66669855:+ LUSC cis rs950169 0.922 rs62028133 ENSG00000259295.5 CSPG4P12 5.69 2.25e-08 8.38e-06 0.34 0.25 Schizophrenia; chr15:84250623 chr15:85191438~85213905:+ LUSC cis rs950169 0.723 rs17589320 ENSG00000259295.5 CSPG4P12 5.69 2.25e-08 8.38e-06 0.34 0.25 Schizophrenia; chr15:84251244 chr15:85191438~85213905:+ LUSC cis rs56751865 1 rs56751865 ENSG00000254851.1 RP11-109L13.1 5.69 2.25e-08 8.39e-06 0.6 0.25 Lobe attachment (rater scored); chr11:117066155 chr11:117135528~117138582:+ LUSC cis rs7772486 0.875 rs2814869 ENSG00000235652.6 RP11-545I5.3 5.69 2.25e-08 8.39e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145994373 chr6:145799409~145886585:+ LUSC cis rs4372836 1 rs2169748 ENSG00000226833.4 AC097724.3 -5.69 2.25e-08 8.39e-06 -0.3 -0.25 Body mass index; chr2:28734887 chr2:28708953~28736205:- LUSC cis rs9659323 0.67 rs61808898 ENSG00000231365.4 RP11-418J17.1 -5.69 2.25e-08 8.39e-06 -0.3 -0.25 Body mass index; chr1:119096232 chr1:119140396~119275973:+ LUSC cis rs4664293 0.51 rs72961751 ENSG00000226266.5 AC009961.3 5.69 2.25e-08 8.4e-06 0.3 0.25 Monocyte percentage of white cells; chr2:159738067 chr2:159670708~159712435:- LUSC cis rs71403859 0.502 rs36122765 ENSG00000260886.1 TAT-AS1 5.69 2.26e-08 8.4e-06 0.39 0.25 Post bronchodilator FEV1; chr16:71470280 chr16:71565789~71578187:+ LUSC cis rs71403859 0.502 rs12927456 ENSG00000260886.1 TAT-AS1 5.69 2.26e-08 8.4e-06 0.39 0.25 Post bronchodilator FEV1; chr16:71471803 chr16:71565789~71578187:+ LUSC cis rs801193 1 rs7785213 ENSG00000222364.1 RNU6-96P 5.69 2.26e-08 8.4e-06 0.29 0.25 Aortic root size; chr7:66673991 chr7:66395191~66395286:+ LUSC cis rs875971 0.964 rs697969 ENSG00000179406.6 LINC00174 5.69 2.26e-08 8.41e-06 0.27 0.25 Aortic root size; chr7:66093491 chr7:66376044~66401338:- LUSC cis rs875971 1 rs1182882 ENSG00000179406.6 LINC00174 5.69 2.26e-08 8.41e-06 0.27 0.25 Aortic root size; chr7:66097076 chr7:66376044~66401338:- LUSC cis rs8005677 1 rs1956880 ENSG00000279656.1 RP11-298I3.6 5.69 2.26e-08 8.41e-06 0.3 0.25 Cognitive ability (multi-trait analysis); chr14:22924798 chr14:23023083~23024217:- LUSC cis rs7246657 0.722 rs4802051 ENSG00000276846.1 CTD-3220F14.3 5.69 2.26e-08 8.42e-06 0.38 0.25 Coronary artery calcification; chr19:37581427 chr19:37314868~37315620:- LUSC cis rs7246657 0.663 rs4803276 ENSG00000276846.1 CTD-3220F14.3 5.69 2.26e-08 8.42e-06 0.38 0.25 Coronary artery calcification; chr19:37581429 chr19:37314868~37315620:- LUSC cis rs801193 0.761 rs2659888 ENSG00000222364.1 RNU6-96P -5.69 2.26e-08 8.42e-06 -0.29 -0.25 Aortic root size; chr7:66765184 chr7:66395191~66395286:+ LUSC cis rs7267979 0.833 rs6138556 ENSG00000274973.1 RP13-401N8.7 -5.69 2.26e-08 8.42e-06 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25262674 chr20:25845497~25845862:+ LUSC cis rs35160687 0.712 rs11691726 ENSG00000273080.1 RP11-301O19.1 -5.69 2.26e-08 8.42e-06 -0.24 -0.25 Night sleep phenotypes; chr2:86267147 chr2:86195590~86196049:+ LUSC cis rs875971 0.545 rs7787063 ENSG00000224316.1 RP11-479O9.2 5.69 2.26e-08 8.42e-06 0.27 0.25 Aortic root size; chr7:66164012 chr7:65773620~65802067:+ LUSC cis rs11159086 0.729 rs8015872 ENSG00000270000.1 RP3-449M8.9 5.69 2.26e-08 8.42e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74475529 chr14:74471930~74472360:- LUSC cis rs17772222 0.74 rs7143642 ENSG00000258789.1 RP11-507K2.3 -5.69 2.26e-08 8.43e-06 -0.29 -0.25 Coronary artery calcification; chr14:88507616 chr14:88551597~88552493:+ LUSC cis rs7665090 1 rs2866409 ENSG00000230069.3 LRRC37A15P -5.69 2.27e-08 8.44e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633104 chr4:102727274~102730721:- LUSC cis rs9506514 0.722 rs11147813 ENSG00000222726.1 RNU2-7P 5.69 2.27e-08 8.45e-06 0.28 0.25 Coronary artery calcification; chr13:20684419 chr13:20612161~20612338:+ LUSC cis rs2276314 1 rs2298715 ENSG00000278986.1 RP11-723J4.3 -5.69 2.27e-08 8.45e-06 -0.32 -0.25 Endometriosis;Drug-induced torsades de pointes; chr18:35972462 chr18:35972151~35973916:+ LUSC cis rs7246657 0.722 rs8103647 ENSG00000276846.1 CTD-3220F14.3 5.69 2.27e-08 8.45e-06 0.38 0.25 Coronary artery calcification; chr19:37609551 chr19:37314868~37315620:- LUSC cis rs1930961 1 rs6004669 ENSG00000272942.1 CTA-246H3.12 -5.69 2.27e-08 8.47e-06 -0.43 -0.25 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25434324~25435070:- LUSC cis rs459571 0.959 rs392134 ENSG00000235106.7 LINC00094 5.69 2.28e-08 8.47e-06 0.29 0.25 Platelet distribution width; chr9:134043886 chr9:134025439~134034666:+ LUSC cis rs459571 0.92 rs455073 ENSG00000235106.7 LINC00094 5.69 2.28e-08 8.47e-06 0.29 0.25 Platelet distribution width; chr9:134044019 chr9:134025439~134034666:+ LUSC cis rs4834770 1 rs878374 ENSG00000245958.5 RP11-33B1.1 -5.69 2.28e-08 8.47e-06 -0.25 -0.25 Blood protein levels; chr4:119316409 chr4:119454791~119552025:+ LUSC cis rs11723261 0.582 rs61792238 ENSG00000275426.1 CH17-262A2.1 5.69 2.28e-08 8.48e-06 0.43 0.25 Immune response to smallpox vaccine (IL-6); chr4:112398 chr4:149738~150317:+ LUSC cis rs750134 1 rs75258935 ENSG00000257221.1 RP11-689B22.2 -5.69 2.28e-08 8.48e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108659436 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs78091339 ENSG00000257221.1 RP11-689B22.2 -5.69 2.28e-08 8.48e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108662916 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs78894088 ENSG00000257221.1 RP11-689B22.2 -5.69 2.28e-08 8.48e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108663673 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs750133 ENSG00000257221.1 RP11-689B22.2 -5.69 2.28e-08 8.48e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108667009 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs1079088 ENSG00000257221.1 RP11-689B22.2 -5.69 2.28e-08 8.48e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108667755 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs1861639 ENSG00000257221.1 RP11-689B22.2 -5.69 2.28e-08 8.48e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108668422 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs10507230 ENSG00000257221.1 RP11-689B22.2 -5.69 2.28e-08 8.48e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108668645 chr12:108628687~108641318:+ LUSC cis rs750134 0.892 rs12423307 ENSG00000257221.1 RP11-689B22.2 -5.69 2.28e-08 8.48e-06 -0.39 -0.25 Low high density lipoprotein cholesterol levels; chr12:108668905 chr12:108628687~108641318:+ LUSC cis rs11159086 0.793 rs28612392 ENSG00000259005.1 RP3-449M8.6 5.69 2.28e-08 8.48e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74467894 chr14:74474007~74474864:- LUSC cis rs11159086 0.793 rs11625502 ENSG00000259005.1 RP3-449M8.6 5.69 2.28e-08 8.48e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74468309 chr14:74474007~74474864:- LUSC cis rs227275 0.531 rs223460 ENSG00000246560.2 RP11-10L12.4 5.69 2.28e-08 8.49e-06 0.31 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102782903 chr4:102828055~102844075:+ LUSC cis rs11098499 0.562 rs13101722 ENSG00000248280.1 RP11-33B1.2 -5.69 2.28e-08 8.49e-06 -0.29 -0.25 Corneal astigmatism; chr4:119634820 chr4:119440561~119450157:- LUSC cis rs13113518 1 rs13132420 ENSG00000272969.1 RP11-528I4.2 -5.69 2.29e-08 8.5e-06 -0.28 -0.25 Height; chr4:55526646 chr4:55547112~55547889:+ LUSC cis rs8072100 0.575 rs1221385 ENSG00000228782.6 CTD-2026D20.3 5.69 2.29e-08 8.51e-06 0.26 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47450208 chr17:47450568~47492492:- LUSC cis rs227275 0.525 rs9917919 ENSG00000230069.3 LRRC37A15P -5.69 2.29e-08 8.52e-06 -0.27 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102918497 chr4:102727274~102730721:- LUSC cis rs11098499 0.644 rs7693919 ENSG00000250412.1 KLHL2P1 5.69 2.29e-08 8.52e-06 0.31 0.25 Corneal astigmatism; chr4:119619416 chr4:119334329~119378233:+ LUSC cis rs73186030 0.546 rs67931976 ENSG00000272758.4 RP11-299J3.8 5.69 2.29e-08 8.52e-06 0.36 0.25 Serum parathyroid hormone levels; chr3:122386868 chr3:122416207~122443180:+ LUSC cis rs73186030 0.546 rs73188327 ENSG00000272758.4 RP11-299J3.8 5.69 2.29e-08 8.52e-06 0.37 0.25 Serum parathyroid hormone levels; chr3:122394819 chr3:122416207~122443180:+ LUSC cis rs910316 0.967 rs1071989 ENSG00000279594.1 RP11-950C14.10 5.69 2.29e-08 8.52e-06 0.29 0.25 Height; chr14:75097956 chr14:75011269~75012851:- LUSC cis rs910316 1 rs9805979 ENSG00000279594.1 RP11-950C14.10 5.69 2.29e-08 8.52e-06 0.29 0.25 Height; chr14:75099506 chr14:75011269~75012851:- LUSC cis rs6570726 0.791 rs446362 ENSG00000235652.6 RP11-545I5.3 5.69 2.29e-08 8.53e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145557580 chr6:145799409~145886585:+ LUSC cis rs2136613 0.751 rs224309 ENSG00000238280.1 RP11-436D10.3 5.69 2.29e-08 8.53e-06 0.32 0.25 Selective IgA deficiency; chr10:62848544 chr10:62793562~62805887:- LUSC cis rs11722779 0.838 rs6821247 ENSG00000230069.3 LRRC37A15P -5.69 2.29e-08 8.53e-06 -0.27 -0.25 Schizophrenia; chr4:102913483 chr4:102727274~102730721:- LUSC cis rs2732480 0.538 rs1387259 ENSG00000240399.1 RP1-228P16.1 -5.69 2.29e-08 8.53e-06 -0.27 -0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48309739 chr12:48054813~48055591:- LUSC cis rs7829975 0.501 rs2980769 ENSG00000253893.2 FAM85B -5.69 2.29e-08 8.53e-06 -0.3 -0.25 Mood instability; chr8:8462781 chr8:8167819~8226614:- LUSC cis rs17818399 0.817 rs17767994 ENSG00000279254.1 RP11-536C12.1 5.69 2.3e-08 8.53e-06 0.31 0.25 Height; chr2:46632940 chr2:46668870~46670778:+ LUSC cis rs442309 1 rs224149 ENSG00000238280.1 RP11-436D10.3 -5.69 2.3e-08 8.54e-06 -0.3 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62727313 chr10:62793562~62805887:- LUSC cis rs442309 1 rs224150 ENSG00000238280.1 RP11-436D10.3 -5.69 2.3e-08 8.54e-06 -0.3 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62728327 chr10:62793562~62805887:- LUSC cis rs442309 1 rs190113 ENSG00000238280.1 RP11-436D10.3 -5.69 2.3e-08 8.54e-06 -0.3 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62728463 chr10:62793562~62805887:- LUSC cis rs8040855 0.627 rs11632899 ENSG00000259295.5 CSPG4P12 5.68 2.3e-08 8.56e-06 0.31 0.25 Bulimia nervosa; chr15:85057609 chr15:85191438~85213905:+ LUSC cis rs2732480 0.5 rs7966829 ENSG00000240399.1 RP1-228P16.1 5.68 2.3e-08 8.56e-06 0.27 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48221820 chr12:48054813~48055591:- LUSC cis rs2028299 0.959 rs12912009 ENSG00000259677.1 RP11-493E3.1 5.68 2.3e-08 8.56e-06 0.32 0.25 Type 2 diabetes; chr15:89885916 chr15:89876540~89877285:+ LUSC cis rs875971 0.545 rs7787063 ENSG00000237310.1 GS1-124K5.4 5.68 2.3e-08 8.56e-06 0.29 0.25 Aortic root size; chr7:66164012 chr7:66493706~66495474:+ LUSC cis rs459571 0.959 rs461462 ENSG00000235106.7 LINC00094 5.68 2.31e-08 8.57e-06 0.28 0.25 Platelet distribution width; chr9:134046150 chr9:134025439~134034666:+ LUSC cis rs875971 0.502 rs11769702 ENSG00000237310.1 GS1-124K5.4 5.68 2.31e-08 8.57e-06 0.29 0.25 Aortic root size; chr7:66255529 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs11770063 ENSG00000237310.1 GS1-124K5.4 5.68 2.31e-08 8.58e-06 0.29 0.25 Aortic root size; chr7:66318029 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs3936065 ENSG00000237310.1 GS1-124K5.4 5.68 2.31e-08 8.58e-06 0.29 0.25 Aortic root size; chr7:66325577 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs4718335 ENSG00000237310.1 GS1-124K5.4 5.68 2.31e-08 8.58e-06 0.29 0.25 Aortic root size; chr7:66339619 chr7:66493706~66495474:+ LUSC cis rs7829975 0.582 rs6983150 ENSG00000253893.2 FAM85B 5.68 2.31e-08 8.58e-06 0.29 0.25 Mood instability; chr8:8934916 chr8:8167819~8226614:- LUSC cis rs9640161 0.75 rs11765644 ENSG00000261305.1 RP4-584D14.7 5.68 2.31e-08 8.58e-06 0.37 0.25 Blood protein levels;Circulating chemerin levels; chr7:150329250 chr7:150341771~150342607:+ LUSC cis rs2732480 0.577 rs2732457 ENSG00000273765.1 RP11-370I10.11 -5.68 2.31e-08 8.59e-06 -0.29 -0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48364596 chr12:48360920~48361377:+ LUSC cis rs763121 0.925 rs9611008 ENSG00000273076.1 RP3-508I15.22 5.68 2.31e-08 8.59e-06 0.25 0.25 Menopause (age at onset); chr22:38702782 chr22:38743495~38743910:+ LUSC cis rs889398 0.935 rs1364063 ENSG00000226232.7 RP11-419C5.2 5.68 2.31e-08 8.59e-06 0.24 0.25 Body mass index; chr16:69554669 chr16:69976388~69996188:- LUSC cis rs2274273 0.87 rs17741542 ENSG00000258413.1 RP11-665C16.6 5.68 2.31e-08 8.59e-06 0.31 0.25 Protein biomarker; chr14:55339143 chr14:55262767~55272075:- LUSC cis rs11676348 0.846 rs7607437 ENSG00000261338.2 RP11-378A13.1 -5.68 2.31e-08 8.6e-06 -0.24 -0.25 Ulcerative colitis; chr2:218143669 chr2:218255319~218257366:+ LUSC cis rs875971 0.522 rs1701760 ENSG00000237310.1 GS1-124K5.4 5.68 2.32e-08 8.6e-06 0.26 0.25 Aortic root size; chr7:66008701 chr7:66493706~66495474:+ LUSC cis rs7246657 0.722 rs35863684 ENSG00000276846.1 CTD-3220F14.3 5.68 2.32e-08 8.61e-06 0.37 0.25 Coronary artery calcification; chr19:37618876 chr19:37314868~37315620:- LUSC cis rs1322639 0.574 rs9689193 ENSG00000261039.2 RP11-417E7.2 -5.68 2.32e-08 8.62e-06 -0.42 -0.25 Pulse pressure; chr6:169187979 chr6:169175304~169182740:- LUSC cis rs35160687 0.623 rs718292 ENSG00000273080.1 RP11-301O19.1 5.68 2.32e-08 8.63e-06 0.24 0.25 Night sleep phenotypes; chr2:86246617 chr2:86195590~86196049:+ LUSC cis rs66887589 0.967 rs6844263 ENSG00000249244.1 RP11-548H18.2 5.68 2.32e-08 8.63e-06 0.3 0.25 Diastolic blood pressure; chr4:119512652 chr4:119391831~119395335:- LUSC cis rs9640161 0.673 rs11773351 ENSG00000261305.1 RP4-584D14.7 5.68 2.32e-08 8.63e-06 0.37 0.25 Blood protein levels;Circulating chemerin levels; chr7:150333874 chr7:150341771~150342607:+ LUSC cis rs2283792 0.935 rs9610375 ENSG00000228050.1 TOP3BP1 5.68 2.32e-08 8.63e-06 0.29 0.25 Multiple sclerosis; chr22:21832804 chr22:22223187~22224566:- LUSC cis rs2153535 0.58 rs1855769 ENSG00000230939.1 RP11-314C16.1 -5.68 2.32e-08 8.63e-06 -0.3 -0.25 Motion sickness; chr6:8472862 chr6:8784178~8785445:+ LUSC cis rs7267979 0.718 rs2983489 ENSG00000274973.1 RP13-401N8.7 -5.68 2.33e-08 8.65e-06 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25263484 chr20:25845497~25845862:+ LUSC cis rs7267979 0.727 rs2474765 ENSG00000274973.1 RP13-401N8.7 -5.68 2.33e-08 8.65e-06 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25265314 chr20:25845497~25845862:+ LUSC cis rs7267979 0.764 rs2474767 ENSG00000274973.1 RP13-401N8.7 -5.68 2.33e-08 8.65e-06 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25266097 chr20:25845497~25845862:+ LUSC cis rs2562456 0.876 rs62110163 ENSG00000268081.1 RP11-678G14.2 5.68 2.33e-08 8.65e-06 0.36 0.25 Pain; chr19:21546020 chr19:21554640~21569237:- LUSC cis rs875971 0.862 rs2909688 ENSG00000179406.6 LINC00174 -5.68 2.33e-08 8.65e-06 -0.27 -0.25 Aortic root size; chr7:66376625 chr7:66376044~66401338:- LUSC cis rs7615952 0.8 rs11915699 ENSG00000171084.14 FAM86JP 5.68 2.33e-08 8.66e-06 0.34 0.25 Blood pressure (smoking interaction); chr3:125913841 chr3:125916620~125930024:+ LUSC cis rs6504622 0.902 rs7216991 ENSG00000262879.4 RP11-156P1.3 -5.68 2.33e-08 8.66e-06 -0.27 -0.25 Orofacial clefts; chr17:46974887 chr17:46984045~47100323:- LUSC cis rs6568401 0.6 rs2400127 ENSG00000219088.1 RP3-359N14.1 -5.68 2.33e-08 8.66e-06 -0.39 -0.25 Primary tooth development (time to first tooth eruption); chr6:105715318 chr6:105666326~105667998:+ LUSC cis rs8062405 0.54 rs193628 ENSG00000259982.1 CDC37P1 -5.68 2.34e-08 8.67e-06 -0.31 -0.25 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28570821 chr16:28700294~28701540:- LUSC cis rs801193 1 rs2707836 ENSG00000237310.1 GS1-124K5.4 5.68 2.34e-08 8.68e-06 0.26 0.25 Aortic root size; chr7:66695448 chr7:66493706~66495474:+ LUSC cis rs9545047 0.511 rs1624537 ENSG00000227676.3 LINC01068 5.68 2.34e-08 8.68e-06 0.31 0.25 Schizophrenia; chr13:79411686 chr13:79566727~79571436:+ LUSC cis rs875971 0.545 rs73142265 ENSG00000224316.1 RP11-479O9.2 5.68 2.34e-08 8.68e-06 0.27 0.25 Aortic root size; chr7:66234510 chr7:65773620~65802067:+ LUSC cis rs75920871 0.528 rs7124872 ENSG00000254851.1 RP11-109L13.1 -5.68 2.34e-08 8.68e-06 -0.35 -0.25 Subjective well-being; chr11:117057235 chr11:117135528~117138582:+ LUSC cis rs6061231 1 rs11908473 ENSG00000273619.1 RP5-908M14.9 -5.68 2.34e-08 8.69e-06 -0.25 -0.25 Colorectal cancer; chr20:62382714 chr20:62386303~62386970:- LUSC cis rs2842992 0.789 rs9365093 ENSG00000237927.1 RP3-393E18.2 -5.68 2.34e-08 8.69e-06 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159754787 chr6:159586955~159589169:- LUSC cis rs6142102 0.923 rs4911394 ENSG00000275784.1 RP5-1125A11.6 -5.68 2.34e-08 8.7e-06 -0.3 -0.25 Skin pigmentation; chr20:33989521 chr20:33989480~33991818:- LUSC cis rs6860806 0.507 rs273917 ENSG00000233006.5 AC034220.3 5.68 2.35e-08 8.7e-06 0.27 0.25 Breast cancer; chr5:132323925 chr5:132311285~132369916:- LUSC cis rs6504622 0.875 rs28553405 ENSG00000262879.4 RP11-156P1.3 5.68 2.35e-08 8.71e-06 0.26 0.25 Orofacial clefts; chr17:46968529 chr17:46984045~47100323:- LUSC cis rs1008375 0.9 rs6812675 ENSG00000249502.1 AC006160.5 -5.68 2.35e-08 8.71e-06 -0.26 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17595926 chr4:17587467~17614571:- LUSC cis rs1008375 0.9 rs4698625 ENSG00000249502.1 AC006160.5 -5.68 2.35e-08 8.71e-06 -0.26 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17597877 chr4:17587467~17614571:- LUSC cis rs67340775 0.541 rs200966 ENSG00000280107.1 AL022393.9 -5.68 2.35e-08 8.72e-06 -0.35 -0.25 Lung cancer in ever smokers; chr6:27894374 chr6:28170845~28172521:+ LUSC cis rs13113518 1 rs11133381 ENSG00000249700.7 SRD5A3-AS1 5.68 2.35e-08 8.72e-06 0.29 0.25 Height; chr4:55450812 chr4:55363971~55395847:- LUSC cis rs6772849 0.775 rs9828414 ENSG00000277250.1 Metazoa_SRP -5.68 2.35e-08 8.74e-06 -0.29 -0.25 Monocyte percentage of white cells;Monocyte count; chr3:128693874 chr3:128673681~128674021:- LUSC cis rs6772849 0.804 rs9832430 ENSG00000277250.1 Metazoa_SRP -5.68 2.35e-08 8.74e-06 -0.29 -0.25 Monocyte percentage of white cells;Monocyte count; chr3:128694054 chr3:128673681~128674021:- LUSC cis rs7246657 0.722 rs1564206 ENSG00000276846.1 CTD-3220F14.3 5.68 2.35e-08 8.74e-06 0.38 0.25 Coronary artery calcification; chr19:37549174 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs1564208 ENSG00000276846.1 CTD-3220F14.3 5.68 2.35e-08 8.74e-06 0.38 0.25 Coronary artery calcification; chr19:37550319 chr19:37314868~37315620:- LUSC cis rs9659323 0.64 rs11800444 ENSG00000231365.4 RP11-418J17.1 -5.68 2.36e-08 8.74e-06 -0.29 -0.25 Body mass index; chr1:119097052 chr1:119140396~119275973:+ LUSC cis rs17270561 0.887 rs9358870 ENSG00000272462.2 U91328.19 -5.68 2.36e-08 8.74e-06 -0.35 -0.25 Iron status biomarkers; chr6:25718982 chr6:25992662~26001775:+ LUSC cis rs13113518 1 rs4865013 ENSG00000223305.1 RN7SKP30 5.68 2.36e-08 8.75e-06 0.3 0.25 Height; chr4:55559957 chr4:55540502~55540835:- LUSC cis rs11971779 0.816 rs11979272 ENSG00000273391.1 RP11-634H22.1 5.68 2.36e-08 8.76e-06 0.32 0.25 Diisocyanate-induced asthma; chr7:139389323 chr7:139359032~139359566:- LUSC cis rs62103177 0.608 rs8088089 ENSG00000261126.6 RP11-795F19.1 -5.68 2.37e-08 8.78e-06 -0.32 -0.25 Opioid sensitivity; chr18:80073851 chr18:80046900~80095482:+ LUSC cis rs17772222 0.74 rs10138139 ENSG00000258789.1 RP11-507K2.3 -5.68 2.37e-08 8.78e-06 -0.29 -0.25 Coronary artery calcification; chr14:88510027 chr14:88551597~88552493:+ LUSC cis rs950880 0.71 rs873022 ENSG00000234389.1 AC007278.3 -5.68 2.37e-08 8.78e-06 -0.28 -0.25 Serum protein levels (sST2); chr2:102339223 chr2:102438713~102440475:+ LUSC cis rs10759883 0.627 rs690633 ENSG00000175611.10 LINC00476 5.68 2.37e-08 8.78e-06 0.29 0.25 Nicotine dependence; chr9:95867894 chr9:95759231~95875977:- LUSC cis rs673078 0.66 rs17440364 ENSG00000275759.1 RP11-131L12.3 -5.68 2.37e-08 8.78e-06 -0.38 -0.25 Glucose homeostasis traits; chr12:118186613 chr12:118428281~118428870:+ LUSC cis rs12908161 0.683 rs12903256 ENSG00000259728.4 LINC00933 5.68 2.37e-08 8.79e-06 0.3 0.25 Schizophrenia; chr15:84764910 chr15:84570649~84580175:+ LUSC cis rs12468226 1 rs7597156 ENSG00000272966.1 RP11-686O6.1 5.68 2.38e-08 8.81e-06 0.39 0.25 Urate levels; chr2:202329339 chr2:202336739~202337200:+ LUSC cis rs924712 1 rs924712 ENSG00000224984.1 RP11-524H19.2 -5.68 2.38e-08 8.82e-06 -0.26 -0.25 Breast cancer; chr6:54862053 chr6:54840118~54840855:- LUSC cis rs6570726 0.811 rs375873 ENSG00000235652.6 RP11-545I5.3 5.68 2.38e-08 8.82e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145491235 chr6:145799409~145886585:+ LUSC cis rs6570726 0.875 rs368744 ENSG00000235652.6 RP11-545I5.3 5.68 2.38e-08 8.82e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145491486 chr6:145799409~145886585:+ LUSC cis rs10759883 0.627 rs689697 ENSG00000175611.10 LINC00476 5.68 2.38e-08 8.83e-06 0.3 0.25 Nicotine dependence; chr9:95876560 chr9:95759231~95875977:- LUSC cis rs6928977 0.66 rs2757647 ENSG00000234084.1 RP3-388E23.2 5.68 2.38e-08 8.83e-06 0.2 0.25 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135446416 chr6:135301568~135307158:+ LUSC cis rs11098499 0.863 rs3733525 ENSG00000248280.1 RP11-33B1.2 5.68 2.38e-08 8.84e-06 0.31 0.25 Corneal astigmatism; chr4:119525893 chr4:119440561~119450157:- LUSC cis rs17361889 0.738 rs17288304 ENSG00000224683.1 RPL36AP29 5.68 2.38e-08 8.84e-06 0.31 0.25 Pediatric bone mineral content (hip); chr7:16153112 chr7:16208945~16209265:+ LUSC cis rs7829975 0.514 rs2976929 ENSG00000253893.2 FAM85B -5.68 2.39e-08 8.84e-06 -0.29 -0.25 Mood instability; chr8:8401202 chr8:8167819~8226614:- LUSC cis rs6570726 0.902 rs396681 ENSG00000235652.6 RP11-545I5.3 5.68 2.39e-08 8.84e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145532467 chr6:145799409~145886585:+ LUSC cis rs9611519 0.964 rs2179744 ENSG00000235513.1 RP4-756G23.5 5.68 2.39e-08 8.84e-06 0.3 0.25 Neuroticism; chr22:41225710 chr22:41209122~41217627:- LUSC cis rs2028299 0.879 rs4932262 ENSG00000259677.1 RP11-493E3.1 5.68 2.39e-08 8.85e-06 0.34 0.25 Type 2 diabetes; chr15:89896365 chr15:89876540~89877285:+ LUSC cis rs2028299 0.879 rs4932263 ENSG00000259677.1 RP11-493E3.1 5.68 2.39e-08 8.85e-06 0.34 0.25 Type 2 diabetes; chr15:89896395 chr15:89876540~89877285:+ LUSC cis rs2243480 1 rs2961102 ENSG00000226824.5 RP4-756H11.3 -5.68 2.39e-08 8.85e-06 -0.49 -0.25 Diabetic kidney disease; chr7:65959671 chr7:66654538~66669855:+ LUSC cis rs801193 0.569 rs11761542 ENSG00000179406.6 LINC00174 -5.68 2.39e-08 8.85e-06 -0.28 -0.25 Aortic root size; chr7:66753209 chr7:66376044~66401338:- LUSC cis rs9322193 0.961 rs2064520 ENSG00000268592.3 RAET1E-AS1 5.68 2.39e-08 8.86e-06 0.32 0.25 Lung cancer; chr6:149603650 chr6:149863494~149919507:+ LUSC cis rs950169 0.84 rs12905223 ENSG00000259295.5 CSPG4P12 5.68 2.39e-08 8.87e-06 0.33 0.25 Schizophrenia; chr15:84571037 chr15:85191438~85213905:+ LUSC cis rs6142102 0.812 rs725478 ENSG00000275784.1 RP5-1125A11.6 5.68 2.4e-08 8.88e-06 0.29 0.25 Skin pigmentation; chr20:33930548 chr20:33989480~33991818:- LUSC cis rs2337406 0.5 rs7152934 ENSG00000280411.1 IGHV1-69-2 -5.68 2.4e-08 8.89e-06 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106778702 chr14:106762092~106762588:- LUSC cis rs42490 1 rs218905 ENSG00000251136.7 RP11-37B2.1 -5.68 2.4e-08 8.89e-06 -0.22 -0.25 Leprosy; chr8:89723661 chr8:89609409~89757727:- LUSC cis rs7829975 0.582 rs6982832 ENSG00000253893.2 FAM85B 5.68 2.4e-08 8.89e-06 0.29 0.25 Mood instability; chr8:8934707 chr8:8167819~8226614:- LUSC cis rs17711722 0.653 rs2460421 ENSG00000237310.1 GS1-124K5.4 -5.68 2.4e-08 8.9e-06 -0.25 -0.25 Calcium levels; chr7:66026136 chr7:66493706~66495474:+ LUSC cis rs10759883 0.627 rs12349742 ENSG00000175611.10 LINC00476 5.68 2.4e-08 8.9e-06 0.3 0.25 Nicotine dependence; chr9:95857698 chr9:95759231~95875977:- LUSC cis rs10759883 0.58 rs2026031 ENSG00000175611.10 LINC00476 5.68 2.4e-08 8.9e-06 0.3 0.25 Nicotine dependence; chr9:95859068 chr9:95759231~95875977:- LUSC cis rs9326248 0.581 rs10790167 ENSG00000280143.1 AP000892.6 5.68 2.41e-08 8.92e-06 0.27 0.25 Blood protein levels; chr11:116930227 chr11:117204967~117210292:+ LUSC cis rs17772222 0.74 rs10138309 ENSG00000258789.1 RP11-507K2.3 -5.68 2.41e-08 8.92e-06 -0.29 -0.25 Coronary artery calcification; chr14:88510352 chr14:88551597~88552493:+ LUSC cis rs2243480 0.908 rs4718273 ENSG00000226824.5 RP4-756H11.3 5.68 2.41e-08 8.93e-06 0.49 0.25 Diabetic kidney disease; chr7:65751112 chr7:66654538~66669855:+ LUSC cis rs13392177 0.66 rs62185964 ENSG00000261338.2 RP11-378A13.1 -5.68 2.41e-08 8.93e-06 -0.26 -0.25 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218209022 chr2:218255319~218257366:+ LUSC cis rs13392177 0.684 rs62185965 ENSG00000261338.2 RP11-378A13.1 -5.68 2.41e-08 8.93e-06 -0.26 -0.25 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218209056 chr2:218255319~218257366:+ LUSC cis rs950880 0.71 rs3732129 ENSG00000234389.1 AC007278.3 -5.68 2.41e-08 8.93e-06 -0.28 -0.25 Serum protein levels (sST2); chr2:102341072 chr2:102438713~102440475:+ LUSC cis rs673078 0.571 rs7954330 ENSG00000275759.1 RP11-131L12.3 -5.68 2.42e-08 8.95e-06 -0.39 -0.25 Glucose homeostasis traits; chr12:118275284 chr12:118428281~118428870:+ LUSC cis rs1061377 1 rs35116118 ENSG00000249685.1 RP11-360F5.3 5.68 2.42e-08 8.95e-06 0.29 0.25 Uric acid levels; chr4:39127293 chr4:39133913~39135608:+ LUSC cis rs2243480 1 rs1404147 ENSG00000232559.3 GS1-124K5.12 5.68 2.42e-08 8.96e-06 0.47 0.25 Diabetic kidney disease; chr7:65799537 chr7:66554588~66576923:- LUSC cis rs4141404 0.673 rs1968023 ENSG00000236132.1 CTA-440B3.1 5.68 2.42e-08 8.96e-06 0.37 0.25 Paclitaxel-induced neuropathy; chr22:31546784 chr22:31816379~31817491:- LUSC cis rs2153535 0.526 rs7748404 ENSG00000230939.1 RP11-314C16.1 -5.68 2.42e-08 8.96e-06 -0.31 -0.25 Motion sickness; chr6:8472267 chr6:8784178~8785445:+ LUSC cis rs9322193 0.961 rs9767713 ENSG00000268592.3 RAET1E-AS1 5.68 2.42e-08 8.96e-06 0.33 0.25 Lung cancer; chr6:149588241 chr6:149863494~149919507:+ LUSC cis rs2732480 1 rs2732480 ENSG00000240399.1 RP1-228P16.1 -5.68 2.43e-08 8.98e-06 -0.25 -0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342520 chr12:48054813~48055591:- LUSC cis rs4834770 1 rs4336213 ENSG00000245958.5 RP11-33B1.1 -5.68 2.43e-08 8.99e-06 -0.25 -0.25 Blood protein levels; chr4:119315314 chr4:119454791~119552025:+ LUSC cis rs875971 0.545 rs73376394 ENSG00000237310.1 GS1-124K5.4 5.67 2.43e-08 8.99e-06 0.29 0.25 Aortic root size; chr7:66172694 chr7:66493706~66495474:+ LUSC cis rs4964805 0.594 rs10861096 ENSG00000257681.1 RP11-341G23.4 5.67 2.43e-08 8.99e-06 0.28 0.25 Attention deficit hyperactivity disorder; chr12:103775578 chr12:103746315~103768858:- LUSC cis rs13113518 1 rs13115828 ENSG00000272969.1 RP11-528I4.2 5.67 2.43e-08 8.99e-06 0.29 0.25 Height; chr4:55551447 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs13136282 ENSG00000272969.1 RP11-528I4.2 5.67 2.43e-08 8.99e-06 0.29 0.25 Height; chr4:55551845 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs11934897 ENSG00000272969.1 RP11-528I4.2 5.67 2.43e-08 8.99e-06 0.29 0.25 Height; chr4:55553396 chr4:55547112~55547889:+ LUSC cis rs13113518 0.934 rs11932293 ENSG00000272969.1 RP11-528I4.2 5.67 2.43e-08 8.99e-06 0.29 0.25 Height; chr4:55554025 chr4:55547112~55547889:+ LUSC cis rs4789693 0.938 rs4789694 ENSG00000265458.1 RP13-20L14.6 -5.67 2.43e-08 8.99e-06 -0.31 -0.25 Glucocorticoid-induced osteonecrosis; chr17:82470223 chr17:82454273~82458521:- LUSC cis rs67311347 1 rs2276868 ENSG00000223797.4 ENTPD3-AS1 -5.67 2.43e-08 9e-06 -0.28 -0.25 Renal cell carcinoma; chr3:40457354 chr3:40313802~40453329:- LUSC cis rs875971 0.862 rs6944374 ENSG00000179406.6 LINC00174 5.67 2.44e-08 9.01e-06 0.27 0.25 Aortic root size; chr7:66221942 chr7:66376044~66401338:- LUSC cis rs801193 0.967 rs2707853 ENSG00000222364.1 RNU6-96P -5.67 2.44e-08 9.01e-06 -0.29 -0.25 Aortic root size; chr7:66749023 chr7:66395191~66395286:+ LUSC cis rs12439619 0.883 rs62012045 ENSG00000276710.3 CSPG4P8 -5.67 2.44e-08 9.01e-06 -0.29 -0.25 Intelligence (multi-trait analysis); chr15:82229366 chr15:82459472~82477258:+ LUSC cis rs11098499 0.644 rs2389880 ENSG00000250412.1 KLHL2P1 5.67 2.44e-08 9.01e-06 0.31 0.25 Corneal astigmatism; chr4:119638715 chr4:119334329~119378233:+ LUSC cis rs6570726 0.791 rs392612 ENSG00000235652.6 RP11-545I5.3 -5.67 2.45e-08 9.05e-06 -0.25 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145560450 chr6:145799409~145886585:+ LUSC cis rs4141404 0.512 rs1018490 ENSG00000236132.1 CTA-440B3.1 -5.67 2.45e-08 9.06e-06 -0.33 -0.25 Paclitaxel-induced neuropathy; chr22:31600639 chr22:31816379~31817491:- LUSC cis rs2153535 0.58 rs7766852 ENSG00000230939.1 RP11-314C16.1 -5.67 2.45e-08 9.06e-06 -0.3 -0.25 Motion sickness; chr6:8472184 chr6:8784178~8785445:+ LUSC cis rs2337406 0.5 rs7152934 ENSG00000254174.1 IGHV1-12 5.67 2.45e-08 9.06e-06 0.24 0.25 Alzheimer's disease (late onset); chr14:106778702 chr14:106122420~106122709:- LUSC cis rs910316 0.967 rs4903292 ENSG00000279594.1 RP11-950C14.10 5.67 2.45e-08 9.06e-06 0.29 0.25 Height; chr14:75189542 chr14:75011269~75012851:- LUSC cis rs801193 0.569 rs2659907 ENSG00000179406.6 LINC00174 -5.67 2.45e-08 9.07e-06 -0.28 -0.25 Aortic root size; chr7:66699045 chr7:66376044~66401338:- LUSC cis rs7945705 0.875 rs10769957 ENSG00000254860.4 TMEM9B-AS1 5.67 2.46e-08 9.08e-06 0.28 0.25 Hemoglobin concentration; chr11:8787469 chr11:8964675~8977527:+ LUSC cis rs3764021 0.527 rs10844380 ENSG00000256975.1 RP11-525E9.1 5.67 2.46e-08 9.09e-06 0.33 0.25 Type 1 diabetes; chr12:9670678 chr12:9506347~9508440:- LUSC cis rs8040855 0.694 rs12908400 ENSG00000259295.5 CSPG4P12 5.67 2.46e-08 9.09e-06 0.31 0.25 Bulimia nervosa; chr15:85029945 chr15:85191438~85213905:+ LUSC cis rs8040855 0.644 rs4635318 ENSG00000259774.1 RP11-182J1.13 -5.67 2.46e-08 9.1e-06 -0.3 -0.25 Bulimia nervosa; chr15:85183506 chr15:84422618~84425882:+ LUSC cis rs4852324 0.536 rs6721042 ENSG00000217702.2 RP11-287D1.4 5.67 2.46e-08 9.1e-06 0.71 0.25 Systemic lupus erythematosus; chr2:73990156 chr2:74130583~74135395:+ LUSC cis rs801193 0.636 rs2659895 ENSG00000179406.6 LINC00174 -5.67 2.46e-08 9.11e-06 -0.27 -0.25 Aortic root size; chr7:66731484 chr7:66376044~66401338:- LUSC cis rs12908161 1 rs35808647 ENSG00000259728.4 LINC00933 5.67 2.46e-08 9.11e-06 0.33 0.25 Schizophrenia; chr15:84834210 chr15:84570649~84580175:+ LUSC cis rs13113518 0.966 rs13108409 ENSG00000273257.1 RP11-177J6.1 5.67 2.47e-08 9.11e-06 0.32 0.25 Height; chr4:55520278 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs7660980 ENSG00000272969.1 RP11-528I4.2 -5.67 2.47e-08 9.12e-06 -0.29 -0.25 Height; chr4:55542948 chr4:55547112~55547889:+ LUSC cis rs7804306 1 rs12702689 ENSG00000233264.2 AC006042.8 5.67 2.47e-08 9.12e-06 0.44 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8046767 chr7:7980312~7982228:+ LUSC cis rs17772222 0.582 rs12050316 ENSG00000258789.1 RP11-507K2.3 -5.67 2.47e-08 9.12e-06 -0.27 -0.25 Coronary artery calcification; chr14:88522097 chr14:88551597~88552493:+ LUSC cis rs1056107 0.831 rs7856158 ENSG00000225513.1 RP11-165N19.2 5.67 2.47e-08 9.12e-06 0.28 0.25 Colorectal cancer; chr9:112188892 chr9:112173522~112173971:- LUSC cis rs6918586 0.636 rs198857 ENSG00000272462.2 U91328.19 -5.67 2.47e-08 9.14e-06 -0.27 -0.25 Schizophrenia; chr6:26102189 chr6:25992662~26001775:+ LUSC cis rs6918586 0.658 rs198856 ENSG00000272462.2 U91328.19 -5.67 2.47e-08 9.14e-06 -0.27 -0.25 Schizophrenia; chr6:26102480 chr6:25992662~26001775:+ LUSC cis rs6918586 0.658 rs198854 ENSG00000272462.2 U91328.19 -5.67 2.47e-08 9.14e-06 -0.27 -0.25 Schizophrenia; chr6:26103829 chr6:25992662~26001775:+ LUSC cis rs11098499 0.615 rs59867181 ENSG00000248280.1 RP11-33B1.2 -5.67 2.48e-08 9.15e-06 -0.29 -0.25 Corneal astigmatism; chr4:119635312 chr4:119440561~119450157:- LUSC cis rs11098499 0.562 rs2389879 ENSG00000248280.1 RP11-33B1.2 -5.67 2.48e-08 9.15e-06 -0.29 -0.25 Corneal astigmatism; chr4:119636529 chr4:119440561~119450157:- LUSC cis rs7665090 0.967 rs5026469 ENSG00000230069.3 LRRC37A15P -5.67 2.48e-08 9.15e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633556 chr4:102727274~102730721:- LUSC cis rs7665090 0.967 rs5026470 ENSG00000230069.3 LRRC37A15P -5.67 2.48e-08 9.15e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633565 chr4:102727274~102730721:- LUSC cis rs7665090 0.967 rs5026471 ENSG00000230069.3 LRRC37A15P -5.67 2.48e-08 9.15e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633576 chr4:102727274~102730721:- LUSC cis rs75920871 0.528 rs3886960 ENSG00000254851.1 RP11-109L13.1 5.67 2.48e-08 9.17e-06 0.34 0.25 Subjective well-being; chr11:117054274 chr11:117135528~117138582:+ LUSC cis rs75920871 0.528 rs723955 ENSG00000254851.1 RP11-109L13.1 5.67 2.48e-08 9.17e-06 0.34 0.25 Subjective well-being; chr11:117054326 chr11:117135528~117138582:+ LUSC cis rs75920871 0.528 rs7108912 ENSG00000254851.1 RP11-109L13.1 5.67 2.48e-08 9.17e-06 0.34 0.25 Subjective well-being; chr11:117055280 chr11:117135528~117138582:+ LUSC cis rs2337406 1 rs7145172 ENSG00000274576.2 IGHV2-70 -5.67 2.48e-08 9.17e-06 -0.27 -0.25 Alzheimer's disease (late onset); chr14:106704924 chr14:106770577~106771020:- LUSC cis rs7208859 0.573 rs7223803 ENSG00000263603.1 CTD-2349P21.5 -5.67 2.48e-08 9.17e-06 -0.36 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750175 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs55814012 ENSG00000263603.1 CTD-2349P21.5 -5.67 2.48e-08 9.17e-06 -0.36 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750679 chr17:30729469~30731202:+ LUSC cis rs17826219 0.5 rs2449749 ENSG00000263603.1 CTD-2349P21.5 -5.67 2.48e-08 9.17e-06 -0.36 -0.25 Body mass index; chr17:30751280 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9894709 ENSG00000263603.1 CTD-2349P21.5 -5.67 2.48e-08 9.17e-06 -0.36 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751436 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9896603 ENSG00000263603.1 CTD-2349P21.5 -5.67 2.48e-08 9.17e-06 -0.36 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751494 chr17:30729469~30731202:+ LUSC cis rs7208859 0.573 rs8078656 ENSG00000263603.1 CTD-2349P21.5 -5.67 2.48e-08 9.17e-06 -0.36 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753953 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs8080882 ENSG00000263603.1 CTD-2349P21.5 -5.67 2.48e-08 9.17e-06 -0.36 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30754128 chr17:30729469~30731202:+ LUSC cis rs7615952 0.932 rs11922218 ENSG00000171084.14 FAM86JP 5.67 2.48e-08 9.18e-06 0.34 0.25 Blood pressure (smoking interaction); chr3:125912446 chr3:125916620~125930024:+ LUSC cis rs7615952 0.866 rs11922276 ENSG00000171084.14 FAM86JP 5.67 2.48e-08 9.18e-06 0.34 0.25 Blood pressure (smoking interaction); chr3:125912483 chr3:125916620~125930024:+ LUSC cis rs9309711 0.883 rs13429373 ENSG00000225234.1 TRAPPC12-AS1 -5.67 2.48e-08 9.18e-06 -0.34 -0.25 Neurofibrillary tangles; chr2:3473243 chr2:3481242~3482409:- LUSC cis rs6860806 0.507 rs272891 ENSG00000233006.5 AC034220.3 5.67 2.48e-08 9.18e-06 0.27 0.25 Breast cancer; chr5:132328701 chr5:132311285~132369916:- LUSC cis rs2404602 1 rs2896954 ENSG00000259422.1 RP11-593F23.1 5.67 2.49e-08 9.18e-06 0.29 0.25 Blood metabolite levels; chr15:76559351 chr15:76174891~76181486:- LUSC cis rs2404602 1 rs2404741 ENSG00000259422.1 RP11-593F23.1 5.67 2.49e-08 9.18e-06 0.29 0.25 Blood metabolite levels; chr15:76559394 chr15:76174891~76181486:- LUSC cis rs2404602 1 rs2404740 ENSG00000259422.1 RP11-593F23.1 5.67 2.49e-08 9.18e-06 0.29 0.25 Blood metabolite levels; chr15:76559802 chr15:76174891~76181486:- LUSC cis rs1008375 0.9 rs1003413 ENSG00000249502.1 AC006160.5 5.67 2.49e-08 9.18e-06 0.25 0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17580819 chr4:17587467~17614571:- LUSC cis rs950880 0.71 rs1474309 ENSG00000234389.1 AC007278.3 -5.67 2.49e-08 9.19e-06 -0.27 -0.25 Serum protein levels (sST2); chr2:102474542 chr2:102438713~102440475:+ LUSC cis rs875971 0.577 rs35072105 ENSG00000222364.1 RNU6-96P 5.67 2.49e-08 9.19e-06 0.3 0.25 Aortic root size; chr7:66144830 chr7:66395191~66395286:+ LUSC cis rs2337406 0.789 rs112027230 ENSG00000211974.3 IGHV2-70 -5.67 2.49e-08 9.2e-06 -0.36 -0.25 Alzheimer's disease (late onset); chr14:106810329 chr14:106723574~106724093:- LUSC cis rs496547 0.557 rs516719 ENSG00000278376.1 RP11-158I9.8 -5.67 2.49e-08 9.2e-06 -0.23 -0.25 Hip minimal joint space width; chr11:118808736 chr11:118791254~118793137:+ LUSC cis rs783540 1 rs11631963 ENSG00000255769.6 GOLGA2P10 -5.67 2.49e-08 9.21e-06 -0.31 -0.25 Schizophrenia; chr15:82649451 chr15:82472993~82513950:- LUSC cis rs7712401 0.715 rs13163098 ENSG00000263432.2 RN7SL689P -5.67 2.5e-08 9.21e-06 -0.33 -0.25 Mean platelet volume; chr5:123010841 chr5:123022487~123022783:- LUSC cis rs7712401 0.715 rs13164161 ENSG00000263432.2 RN7SL689P -5.67 2.5e-08 9.21e-06 -0.33 -0.25 Mean platelet volume; chr5:123011202 chr5:123022487~123022783:- LUSC cis rs9525916 0.967 rs9533775 ENSG00000227258.4 SMIM2-AS1 -5.67 2.5e-08 9.22e-06 -0.3 -0.25 Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction); chr13:44123820 chr13:44110451~44240517:+ LUSC cis rs6570726 0.846 rs426874 ENSG00000235652.6 RP11-545I5.3 5.67 2.5e-08 9.22e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145559494 chr6:145799409~145886585:+ LUSC cis rs2153535 0.58 rs9378551 ENSG00000230939.1 RP11-314C16.1 -5.67 2.5e-08 9.22e-06 -0.3 -0.25 Motion sickness; chr6:8463511 chr6:8784178~8785445:+ LUSC cis rs2153535 0.58 rs9378552 ENSG00000230939.1 RP11-314C16.1 -5.67 2.5e-08 9.22e-06 -0.3 -0.25 Motion sickness; chr6:8463515 chr6:8784178~8785445:+ LUSC cis rs459571 0.959 rs465535 ENSG00000235106.7 LINC00094 5.67 2.5e-08 9.22e-06 0.28 0.25 Platelet distribution width; chr9:134045783 chr9:134025439~134034666:+ LUSC cis rs7665090 0.936 rs2866412 ENSG00000230069.3 LRRC37A15P -5.67 2.5e-08 9.22e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633193 chr4:102727274~102730721:- LUSC cis rs66887589 0.967 rs13104219 ENSG00000245958.5 RP11-33B1.1 -5.67 2.5e-08 9.22e-06 -0.24 -0.25 Diastolic blood pressure; chr4:119517019 chr4:119454791~119552025:+ LUSC cis rs367615 0.661 rs9326773 ENSG00000249476.1 CTD-2587M2.1 5.67 2.5e-08 9.24e-06 0.3 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109497822 chr5:109237120~109326369:- LUSC cis rs8040855 0.627 rs12905036 ENSG00000259295.5 CSPG4P12 5.67 2.5e-08 9.24e-06 0.32 0.25 Bulimia nervosa; chr15:85094557 chr15:85191438~85213905:+ LUSC cis rs11159086 0.793 rs10136668 ENSG00000270000.1 RP3-449M8.9 5.67 2.5e-08 9.24e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74492183 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs10139029 ENSG00000270000.1 RP3-449M8.9 5.67 2.5e-08 9.24e-06 0.38 0.25 Advanced glycation end-product levels; chr14:74492284 chr14:74471930~74472360:- LUSC cis rs7674212 0.556 rs223401 ENSG00000246560.2 RP11-10L12.4 5.67 2.5e-08 9.24e-06 0.32 0.25 Type 2 diabetes; chr4:102817815 chr4:102828055~102844075:+ LUSC cis rs2404602 0.575 rs11633309 ENSG00000259422.1 RP11-593F23.1 -5.67 2.51e-08 9.25e-06 -0.32 -0.25 Blood metabolite levels; chr15:76670008 chr15:76174891~76181486:- LUSC cis rs2274273 0.87 rs3783652 ENSG00000258413.1 RP11-665C16.6 -5.67 2.51e-08 9.25e-06 -0.31 -0.25 Protein biomarker; chr14:55387490 chr14:55262767~55272075:- LUSC cis rs73173548 0.502 rs4451795 ENSG00000247828.6 TMEM161B-AS1 5.67 2.51e-08 9.25e-06 0.28 0.25 Macular telangiectasia type 2; chr5:88422879 chr5:88268895~88436685:+ LUSC cis rs442309 0.875 rs192004 ENSG00000238280.1 RP11-436D10.3 -5.67 2.51e-08 9.25e-06 -0.31 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62745965 chr10:62793562~62805887:- LUSC cis rs11159086 1 rs4903232 ENSG00000270000.1 RP3-449M8.9 5.67 2.51e-08 9.26e-06 0.39 0.25 Advanced glycation end-product levels; chr14:74496585 chr14:74471930~74472360:- LUSC cis rs227275 0.554 rs223454 ENSG00000246560.2 RP11-10L12.4 5.67 2.51e-08 9.27e-06 0.3 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102789773 chr4:102828055~102844075:+ LUSC cis rs12712135 0.706 rs6543114 ENSG00000234389.1 AC007278.3 -5.67 2.51e-08 9.27e-06 -0.28 -0.25 Blood protein levels; chr2:102309534 chr2:102438713~102440475:+ LUSC cis rs11971779 0.793 rs4728464 ENSG00000273391.1 RP11-634H22.1 -5.67 2.52e-08 9.28e-06 -0.28 -0.25 Diisocyanate-induced asthma; chr7:139332924 chr7:139359032~139359566:- LUSC cis rs1021993 0.597 rs4844807 ENSG00000231648.1 RP11-372M18.2 -5.67 2.52e-08 9.29e-06 -0.37 -0.25 Gut microbiome composition (winter); chr1:209337769 chr1:209367662~209379690:+ LUSC cis rs9341808 0.69 rs2505932 ENSG00000272129.1 RP11-250B2.6 5.67 2.52e-08 9.29e-06 0.31 0.25 Sitting height ratio; chr6:80129535 chr6:80355424~80356859:+ LUSC cis rs950880 0.71 rs17027230 ENSG00000234389.1 AC007278.3 -5.67 2.52e-08 9.29e-06 -0.27 -0.25 Serum protein levels (sST2); chr2:102462870 chr2:102438713~102440475:+ LUSC cis rs7945705 0.774 rs6486060 ENSG00000254860.4 TMEM9B-AS1 -5.67 2.52e-08 9.3e-06 -0.29 -0.25 Hemoglobin concentration; chr11:9003083 chr11:8964675~8977527:+ LUSC cis rs8396 1 rs8396 ENSG00000271817.2 U3 -5.67 2.53e-08 9.31e-06 -0.24 -0.25 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158709665 chr4:158700691~158700909:+ LUSC cis rs801193 1 rs2707836 ENSG00000222364.1 RNU6-96P -5.67 2.53e-08 9.33e-06 -0.29 -0.25 Aortic root size; chr7:66695448 chr7:66395191~66395286:+ LUSC cis rs9322193 0.607 rs10457852 ENSG00000268592.3 RAET1E-AS1 5.67 2.53e-08 9.34e-06 0.35 0.25 Lung cancer; chr6:149880584 chr6:149863494~149919507:+ LUSC cis rs1876905 0.597 rs191631 ENSG00000255389.1 C6orf3 5.67 2.54e-08 9.35e-06 0.35 0.25 Mean corpuscular hemoglobin; chr6:111226862 chr6:111599875~111602295:+ LUSC cis rs2739330 0.761 rs5760176 ENSG00000228039.3 KB-1125A3.10 -5.67 2.54e-08 9.37e-06 -0.31 -0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23963780~23964374:+ LUSC cis rs41294858 1 rs75375208 ENSG00000232876.1 CTA-212D2.2 -5.67 2.54e-08 9.37e-06 -0.49 -0.25 Red blood cell count; chr6:135081951 chr6:135055033~135060550:+ LUSC cis rs16843372 0.562 rs10194836 ENSG00000251491.2 OR7E28P -5.67 2.55e-08 9.38e-06 -0.28 -0.25 Obesity-related traits; chr2:158838428 chr2:158862311~158863285:+ LUSC cis rs12935418 1 rs2602431 ENSG00000261838.4 RP11-303E16.6 -5.67 2.55e-08 9.38e-06 -0.44 -0.25 Mean corpuscular volume; chr16:81037092 chr16:81069854~81076598:+ LUSC cis rs11098499 0.78 rs10013652 ENSG00000248280.1 RP11-33B1.2 5.67 2.55e-08 9.39e-06 0.29 0.25 Corneal astigmatism; chr4:119371101 chr4:119440561~119450157:- LUSC cis rs783540 0.967 rs4779044 ENSG00000276710.3 CSPG4P8 -5.67 2.55e-08 9.39e-06 -0.27 -0.25 Schizophrenia; chr15:82670601 chr15:82459472~82477258:+ LUSC cis rs875971 0.522 rs2949690 ENSG00000179406.6 LINC00174 5.67 2.55e-08 9.4e-06 0.27 0.25 Aortic root size; chr7:66018255 chr7:66376044~66401338:- LUSC cis rs6570726 0.935 rs408768 ENSG00000235652.6 RP11-545I5.3 5.67 2.55e-08 9.41e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145550599 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs400329 ENSG00000235652.6 RP11-545I5.3 5.67 2.55e-08 9.41e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145558306 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs414600 ENSG00000235652.6 RP11-545I5.3 5.67 2.55e-08 9.41e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145558470 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs435671 ENSG00000235652.6 RP11-545I5.3 5.67 2.55e-08 9.41e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145560079 chr6:145799409~145886585:+ LUSC cis rs6570726 0.764 rs367065 ENSG00000235652.6 RP11-545I5.3 5.67 2.55e-08 9.41e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145561173 chr6:145799409~145886585:+ LUSC cis rs2337406 0.789 rs12050392 ENSG00000280411.1 IGHV1-69-2 -5.67 2.55e-08 9.41e-06 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106779073 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs74092505 ENSG00000280411.1 IGHV1-69-2 -5.67 2.55e-08 9.41e-06 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106779163 chr14:106762092~106762588:- LUSC cis rs2337406 0.789 rs74092507 ENSG00000280411.1 IGHV1-69-2 -5.67 2.55e-08 9.41e-06 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106779174 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs74092511 ENSG00000280411.1 IGHV1-69-2 -5.67 2.55e-08 9.41e-06 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106779234 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs74092512 ENSG00000280411.1 IGHV1-69-2 -5.67 2.55e-08 9.41e-06 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106779306 chr14:106762092~106762588:- LUSC cis rs2337406 0.789 rs74092514 ENSG00000280411.1 IGHV1-69-2 -5.67 2.55e-08 9.41e-06 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106779385 chr14:106762092~106762588:- LUSC cis rs77204473 0.744 rs79955870 ENSG00000254851.1 RP11-109L13.1 5.67 2.56e-08 9.42e-06 0.6 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117066645 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs11216261 ENSG00000254851.1 RP11-109L13.1 5.67 2.56e-08 9.42e-06 0.6 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117069494 chr11:117135528~117138582:+ LUSC cis rs2337406 0.789 rs12050392 ENSG00000254174.1 IGHV1-12 5.67 2.56e-08 9.42e-06 0.24 0.25 Alzheimer's disease (late onset); chr14:106779073 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs74092505 ENSG00000254174.1 IGHV1-12 5.67 2.56e-08 9.42e-06 0.24 0.25 Alzheimer's disease (late onset); chr14:106779163 chr14:106122420~106122709:- LUSC cis rs2337406 0.789 rs74092507 ENSG00000254174.1 IGHV1-12 5.67 2.56e-08 9.42e-06 0.24 0.25 Alzheimer's disease (late onset); chr14:106779174 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs74092511 ENSG00000254174.1 IGHV1-12 5.67 2.56e-08 9.42e-06 0.24 0.25 Alzheimer's disease (late onset); chr14:106779234 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs74092512 ENSG00000254174.1 IGHV1-12 5.67 2.56e-08 9.42e-06 0.24 0.25 Alzheimer's disease (late onset); chr14:106779306 chr14:106122420~106122709:- LUSC cis rs2337406 0.789 rs74092514 ENSG00000254174.1 IGHV1-12 5.67 2.56e-08 9.42e-06 0.24 0.25 Alzheimer's disease (late onset); chr14:106779385 chr14:106122420~106122709:- LUSC cis rs957448 0.698 rs116348949 ENSG00000253175.1 RP11-267M23.6 5.67 2.56e-08 9.43e-06 0.28 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94557488 chr8:94565036~94565715:+ LUSC cis rs875971 0.571 rs160641 ENSG00000224316.1 RP11-479O9.2 -5.67 2.56e-08 9.44e-06 -0.27 -0.25 Aortic root size; chr7:66112359 chr7:65773620~65802067:+ LUSC cis rs7772486 0.875 rs1331644 ENSG00000235652.6 RP11-545I5.3 5.66 2.57e-08 9.45e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:146077524 chr6:145799409~145886585:+ LUSC cis rs7083 0.935 rs523366 ENSG00000254851.1 RP11-109L13.1 5.66 2.57e-08 9.47e-06 0.32 0.25 Blood protein levels; chr11:117248836 chr11:117135528~117138582:+ LUSC cis rs7674212 0.556 rs6533039 ENSG00000246560.2 RP11-10L12.4 5.66 2.57e-08 9.48e-06 0.33 0.25 Type 2 diabetes; chr4:102938381 chr4:102828055~102844075:+ LUSC cis rs875971 0.545 rs1638724 ENSG00000224316.1 RP11-479O9.2 -5.66 2.57e-08 9.48e-06 -0.27 -0.25 Aortic root size; chr7:66575494 chr7:65773620~65802067:+ LUSC cis rs13392177 0.66 rs10932762 ENSG00000261338.2 RP11-378A13.1 -5.66 2.57e-08 9.48e-06 -0.26 -0.25 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218211490 chr2:218255319~218257366:+ LUSC cis rs442309 0.812 rs224089 ENSG00000238280.1 RP11-436D10.3 -5.66 2.57e-08 9.48e-06 -0.32 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62780161 chr10:62793562~62805887:- LUSC cis rs7267979 0.903 rs6115109 ENSG00000274973.1 RP13-401N8.7 -5.66 2.57e-08 9.48e-06 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25259031 chr20:25845497~25845862:+ LUSC cis rs66887589 0.967 rs1155577 ENSG00000249244.1 RP11-548H18.2 -5.66 2.58e-08 9.48e-06 -0.3 -0.25 Diastolic blood pressure; chr4:119528655 chr4:119391831~119395335:- LUSC cis rs7772486 0.875 rs1412081 ENSG00000235652.6 RP11-545I5.3 5.66 2.58e-08 9.49e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:146088597 chr6:145799409~145886585:+ LUSC cis rs11951515 0.508 rs7706431 ENSG00000249286.1 CTD-2210P15.2 5.66 2.58e-08 9.51e-06 0.3 0.25 Metabolite levels (X-11787); chr5:43582321 chr5:43586918~43588223:- LUSC cis rs11098499 0.575 rs9996586 ENSG00000248280.1 RP11-33B1.2 5.66 2.59e-08 9.55e-06 0.28 0.25 Corneal astigmatism; chr4:119405787 chr4:119440561~119450157:- LUSC cis rs6504950 0.925 rs244358 ENSG00000275710.1 RP11-257O5.4 5.66 2.6e-08 9.56e-06 0.31 0.25 Breast cancer; chr17:55114870 chr17:54964474~54964679:+ LUSC cis rs1322639 0.618 rs9505942 ENSG00000261039.2 RP11-417E7.2 -5.66 2.6e-08 9.56e-06 -0.41 -0.25 Pulse pressure; chr6:169191698 chr6:169175304~169182740:- LUSC cis rs7181230 0.848 rs62004114 ENSG00000275636.1 RP11-521C20.5 5.66 2.6e-08 9.58e-06 0.32 0.25 Dehydroepiandrosterone sulphate levels; chr15:40041154 chr15:40078892~40079347:+ LUSC cis rs1823913 0.549 rs4516458 ENSG00000280083.1 RP11-317J9.1 -5.66 2.6e-08 9.58e-06 -0.31 -0.25 Obesity-related traits; chr2:191325177 chr2:191154118~191156070:- LUSC cis rs932287 0.536 rs10840160 ENSG00000254860.4 TMEM9B-AS1 5.66 2.6e-08 9.58e-06 0.29 0.25 Colonoscopy-negative controls vs population controls; chr11:9031989 chr11:8964675~8977527:+ LUSC cis rs367615 0.704 rs60538082 ENSG00000249476.1 CTD-2587M2.1 5.66 2.61e-08 9.59e-06 0.3 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109493400 chr5:109237120~109326369:- LUSC cis rs7267979 0.844 rs6107027 ENSG00000274973.1 RP13-401N8.7 -5.66 2.61e-08 9.59e-06 -0.25 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25307996 chr20:25845497~25845862:+ LUSC cis rs7955901 0.904 rs7138300 ENSG00000257265.1 CTD-2021H9.1 -5.66 2.61e-08 9.59e-06 -0.28 -0.25 Type 2 diabetes; chr12:71045809 chr12:71007773~71032083:- LUSC cis rs875971 0.516 rs6945322 ENSG00000179406.6 LINC00174 -5.66 2.61e-08 9.59e-06 -0.27 -0.25 Aortic root size; chr7:65871069 chr7:66376044~66401338:- LUSC cis rs62432291 0.681 rs294913 ENSG00000235086.1 FNDC1-IT1 -5.66 2.61e-08 9.6e-06 -0.46 -0.25 Joint mobility (Beighton score); chr6:159246195 chr6:159240786~159243329:+ LUSC cis rs62432291 0.681 rs294912 ENSG00000235086.1 FNDC1-IT1 -5.66 2.61e-08 9.6e-06 -0.46 -0.25 Joint mobility (Beighton score); chr6:159246305 chr6:159240786~159243329:+ LUSC cis rs2274273 0.84 rs72715769 ENSG00000258413.1 RP11-665C16.6 -5.66 2.61e-08 9.6e-06 -0.31 -0.25 Protein biomarker; chr14:55295711 chr14:55262767~55272075:- LUSC cis rs2274273 0.87 rs66696758 ENSG00000258413.1 RP11-665C16.6 -5.66 2.61e-08 9.6e-06 -0.31 -0.25 Protein biomarker; chr14:55299791 chr14:55262767~55272075:- LUSC cis rs2274273 0.87 rs7153645 ENSG00000258413.1 RP11-665C16.6 -5.66 2.61e-08 9.6e-06 -0.31 -0.25 Protein biomarker; chr14:55304800 chr14:55262767~55272075:- LUSC cis rs7772486 0.875 rs2207785 ENSG00000235652.6 RP11-545I5.3 5.66 2.61e-08 9.6e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:146011648 chr6:145799409~145886585:+ LUSC cis rs6502050 0.805 rs6502057 ENSG00000266654.1 RP11-1376P16.1 5.66 2.61e-08 9.61e-06 0.25 0.25 Life satisfaction; chr17:82124184 chr17:82160056~82160452:+ LUSC cis rs1387259 0.69 rs1601985 ENSG00000226413.2 OR8T1P 5.66 2.62e-08 9.63e-06 0.32 0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48368131 chr12:48442030~48442947:- LUSC cis rs11673344 0.734 rs320887 ENSG00000226686.6 LINC01535 -5.66 2.62e-08 9.63e-06 -0.33 -0.25 Obesity-related traits; chr19:37202536 chr19:37251912~37265535:+ LUSC cis rs13113518 0.966 rs13144598 ENSG00000223305.1 RN7SKP30 5.66 2.62e-08 9.63e-06 0.31 0.25 Height; chr4:55570311 chr4:55540502~55540835:- LUSC cis rs599083 0.829 rs23691 ENSG00000212093.1 AP000807.1 -5.66 2.62e-08 9.64e-06 -0.29 -0.25 Bone mineral density (spine); chr11:68411200 chr11:68506083~68506166:- LUSC cis rs599083 0.829 rs314751 ENSG00000212093.1 AP000807.1 -5.66 2.62e-08 9.64e-06 -0.29 -0.25 Bone mineral density (spine); chr11:68412092 chr11:68506083~68506166:- LUSC cis rs11098499 0.863 rs34868248 ENSG00000248280.1 RP11-33B1.2 5.66 2.62e-08 9.65e-06 0.31 0.25 Corneal astigmatism; chr4:119521275 chr4:119440561~119450157:- LUSC cis rs2562456 0.917 rs6511253 ENSG00000268081.1 RP11-678G14.2 -5.66 2.62e-08 9.65e-06 -0.35 -0.25 Pain; chr19:21495996 chr19:21554640~21569237:- LUSC cis rs6844153 0.877 rs10939146 ENSG00000240005.4 RP11-293A21.1 -5.66 2.63e-08 9.65e-06 -0.4 -0.25 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26978399 chr4:26859806~26860599:- LUSC cis rs2243480 0.706 rs6460257 ENSG00000226824.5 RP4-756H11.3 -5.66 2.63e-08 9.66e-06 -0.43 -0.25 Diabetic kidney disease; chr7:65731813 chr7:66654538~66669855:+ LUSC cis rs6772849 0.804 rs4857920 ENSG00000277250.1 Metazoa_SRP -5.66 2.63e-08 9.66e-06 -0.29 -0.25 Monocyte percentage of white cells;Monocyte count; chr3:128688780 chr3:128673681~128674021:- LUSC cis rs2302464 1 rs73123625 ENSG00000214846.4 RP11-115L11.1 5.66 2.63e-08 9.66e-06 0.71 0.25 Cerebrospinal fluid biomarker levels; chr4:15727550 chr4:15730962~15731627:- LUSC cis rs889398 0.933 rs6499240 ENSG00000226232.7 RP11-419C5.2 -5.66 2.63e-08 9.66e-06 -0.25 -0.25 Body mass index; chr16:69653009 chr16:69976388~69996188:- LUSC cis rs394563 0.81 rs480870 ENSG00000231760.4 RP11-350J20.5 5.66 2.63e-08 9.67e-06 0.32 0.25 Dupuytren's disease; chr6:149463682 chr6:149796151~149826294:- LUSC cis rs73173548 0.502 rs13165211 ENSG00000247828.6 TMEM161B-AS1 5.66 2.63e-08 9.67e-06 0.3 0.25 Macular telangiectasia type 2; chr5:88443772 chr5:88268895~88436685:+ LUSC cis rs3758785 0.737 rs12270338 ENSG00000255893.1 RP11-685N10.1 5.66 2.64e-08 9.69e-06 0.33 0.25 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94414298 chr11:94472908~94473570:- LUSC cis rs12291225 0.679 rs11605531 ENSG00000251991.1 RNU7-49P 5.66 2.64e-08 9.69e-06 0.31 0.25 Sense of smell; chr11:14270048 chr11:14478892~14478953:+ LUSC cis rs763512 0.532 rs3110626 ENSG00000276054.1 RP11-378E13.3 -5.66 2.64e-08 9.7e-06 -0.31 -0.25 3-hydroxypropylmercapturic acid levels in smokers; chr17:37536300 chr17:37386886~37387926:+ LUSC cis rs801193 1 rs10252765 ENSG00000237310.1 GS1-124K5.4 5.66 2.64e-08 9.71e-06 0.26 0.25 Aortic root size; chr7:66763745 chr7:66493706~66495474:+ LUSC cis rs6570726 0.791 rs418701 ENSG00000235652.6 RP11-545I5.3 5.66 2.64e-08 9.71e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145568856 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs1280275 ENSG00000235652.6 RP11-545I5.3 5.66 2.64e-08 9.71e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145571266 chr6:145799409~145886585:+ LUSC cis rs6570726 0.791 rs6900040 ENSG00000235652.6 RP11-545I5.3 5.66 2.64e-08 9.71e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145571998 chr6:145799409~145886585:+ LUSC cis rs2303759 0.881 rs10412811 ENSG00000268686.1 AC010524.2 -5.66 2.64e-08 9.71e-06 -0.35 -0.25 Multiple sclerosis; chr19:49381238 chr19:49368705~49388081:- LUSC cis rs9928842 0.664 rs8053265 ENSG00000280152.1 RP11-331F4.5 5.66 2.65e-08 9.72e-06 0.3 0.25 Alcoholic chronic pancreatitis; chr16:75187953 chr16:75245994~75250077:- LUSC cis rs35740288 0.694 rs17618909 ENSG00000202081.1 RNU6-1280P 5.66 2.65e-08 9.72e-06 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85552231 chr15:85651522~85651628:- LUSC cis rs875971 0.522 rs7784623 ENSG00000179406.6 LINC00174 -5.66 2.65e-08 9.73e-06 -0.27 -0.25 Aortic root size; chr7:65930047 chr7:66376044~66401338:- LUSC cis rs7772486 0.701 rs2244308 ENSG00000235652.6 RP11-545I5.3 5.66 2.65e-08 9.73e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145892570 chr6:145799409~145886585:+ LUSC cis rs9309473 0.66 rs56131703 ENSG00000163016.8 ALMS1P 5.66 2.65e-08 9.74e-06 0.37 0.25 Metabolite levels; chr2:73620133 chr2:73644919~73685576:+ LUSC cis rs11951515 0.508 rs7705166 ENSG00000249286.1 CTD-2210P15.2 5.66 2.65e-08 9.74e-06 0.3 0.25 Metabolite levels (X-11787); chr5:43587346 chr5:43586918~43588223:- LUSC cis rs801193 0.636 rs10233806 ENSG00000179406.6 LINC00174 5.66 2.66e-08 9.76e-06 0.27 0.25 Aortic root size; chr7:66653261 chr7:66376044~66401338:- LUSC cis rs11168351 0.926 rs10875719 ENSG00000240399.1 RP1-228P16.1 5.66 2.66e-08 9.76e-06 0.25 0.25 Bipolar disorder and schizophrenia; chr12:48017375 chr12:48054813~48055591:- LUSC cis rs6570726 0.791 rs1935612 ENSG00000235652.6 RP11-545I5.3 5.66 2.66e-08 9.76e-06 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145584954 chr6:145799409~145886585:+ LUSC cis rs11098499 0.863 rs1552095 ENSG00000248280.1 RP11-33B1.2 5.66 2.66e-08 9.76e-06 0.31 0.25 Corneal astigmatism; chr4:119539151 chr4:119440561~119450157:- LUSC cis rs12554020 0.786 rs12349299 ENSG00000227603.1 RP11-165J3.6 5.66 2.66e-08 9.78e-06 0.35 0.25 Schizophrenia; chr9:93412482 chr9:93435332~93437121:- LUSC cis rs673078 0.66 rs61943535 ENSG00000275759.1 RP11-131L12.3 -5.66 2.66e-08 9.78e-06 -0.38 -0.25 Glucose homeostasis traits; chr12:118168307 chr12:118428281~118428870:+ LUSC cis rs73186030 0.546 rs67818421 ENSG00000272758.4 RP11-299J3.8 5.66 2.67e-08 9.78e-06 0.36 0.25 Serum parathyroid hormone levels; chr3:122389871 chr3:122416207~122443180:+ LUSC cis rs113835537 0.877 rs57127845 ENSG00000255517.5 CTD-3074O7.5 -5.66 2.67e-08 9.79e-06 -0.35 -0.25 Airway imaging phenotypes; chr11:66550854 chr11:66473490~66480233:- LUSC cis rs9659323 0.67 rs12096179 ENSG00000231365.4 RP11-418J17.1 -5.66 2.67e-08 9.8e-06 -0.29 -0.25 Body mass index; chr1:119093100 chr1:119140396~119275973:+ LUSC cis rs7712401 0.601 rs2126935 ENSG00000263432.2 RN7SL689P -5.66 2.67e-08 9.81e-06 -0.32 -0.25 Mean platelet volume; chr5:122977876 chr5:123022487~123022783:- LUSC cis rs4713118 0.513 rs149989 ENSG00000216901.1 AL022393.7 5.66 2.67e-08 9.81e-06 0.29 0.25 Parkinson's disease; chr6:28030406 chr6:28176188~28176674:+ LUSC cis rs11098499 0.954 rs6847248 ENSG00000248280.1 RP11-33B1.2 5.66 2.67e-08 9.81e-06 0.32 0.25 Corneal astigmatism; chr4:119304800 chr4:119440561~119450157:- LUSC cis rs6969780 1 rs6976129 ENSG00000233429.8 HOTAIRM1 5.66 2.67e-08 9.81e-06 0.49 0.25 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27138127 chr7:27095647~27100265:+ LUSC cis rs77204473 0.744 rs2238005 ENSG00000254851.1 RP11-109L13.1 5.66 2.68e-08 9.82e-06 0.62 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117217366 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs2239009 ENSG00000254851.1 RP11-109L13.1 5.66 2.68e-08 9.82e-06 0.62 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117219006 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs78628783 ENSG00000254851.1 RP11-109L13.1 5.66 2.68e-08 9.82e-06 0.62 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117221335 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs80351364 ENSG00000254851.1 RP11-109L13.1 5.66 2.68e-08 9.82e-06 0.62 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117221678 chr11:117135528~117138582:+ LUSC cis rs9341808 0.667 rs3805919 ENSG00000272129.1 RP11-250B2.6 5.66 2.68e-08 9.82e-06 0.31 0.25 Sitting height ratio; chr6:80197092 chr6:80355424~80356859:+ LUSC cis rs11098499 0.566 rs7664440 ENSG00000248280.1 RP11-33B1.2 5.66 2.68e-08 9.82e-06 0.31 0.25 Corneal astigmatism; chr4:119657385 chr4:119440561~119450157:- LUSC cis rs34792 0.554 rs28393495 ENSG00000207425.1 Y_RNA -5.66 2.68e-08 9.83e-06 -0.35 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15516406 chr16:14915457~14915556:- LUSC cis rs11079757 0.604 rs72823425 ENSG00000262879.4 RP11-156P1.3 5.66 2.68e-08 9.83e-06 0.32 0.25 Erythema nodosum in inflammatory bowel disease; chr17:47111303 chr17:46984045~47100323:- LUSC cis rs1528149 0.504 rs10227232 ENSG00000224683.1 RPL36AP29 -5.66 2.68e-08 9.85e-06 -0.29 -0.25 Sitting height ratio; chr7:16138475 chr7:16208945~16209265:+ LUSC cis rs875971 0.545 rs12670811 ENSG00000237310.1 GS1-124K5.4 5.66 2.69e-08 9.85e-06 0.29 0.25 Aortic root size; chr7:66358032 chr7:66493706~66495474:+ LUSC cis rs16843372 0.599 rs10172746 ENSG00000251491.2 OR7E28P -5.66 2.69e-08 9.86e-06 -0.28 -0.25 Obesity-related traits; chr2:158819586 chr2:158862311~158863285:+ LUSC cis rs801193 0.66 rs10950049 ENSG00000179406.6 LINC00174 -5.66 2.69e-08 9.87e-06 -0.27 -0.25 Aortic root size; chr7:66765873 chr7:66376044~66401338:- LUSC cis rs7804306 0.826 rs35567393 ENSG00000233264.2 AC006042.8 5.66 2.69e-08 9.87e-06 0.44 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8033938 chr7:7980312~7982228:+ LUSC cis rs7804306 1 rs34156160 ENSG00000233264.2 AC006042.8 5.66 2.69e-08 9.87e-06 0.44 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8043155 chr7:7980312~7982228:+ LUSC cis rs7804306 1 rs35641104 ENSG00000233264.2 AC006042.8 5.66 2.69e-08 9.87e-06 0.44 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8046289 chr7:7980312~7982228:+ LUSC cis rs11690935 0.843 rs9784123 ENSG00000228389.1 AC068039.4 5.66 2.69e-08 9.88e-06 0.3 0.25 Schizophrenia; chr2:171928495 chr2:171773482~171775844:+ LUSC cis rs2919917 0.628 rs979564 ENSG00000254352.1 RP11-578O24.2 5.66 2.69e-08 9.88e-06 0.34 0.25 Lymphocyte counts; chr8:78663924 chr8:78723796~78724136:- LUSC cis rs5751168 0.765 rs450981 ENSG00000211654.2 IGLV5-37 5.66 2.69e-08 9.88e-06 0.41 0.25 Prostate cancer (SNP x SNP interaction); chr22:22483141 chr22:22427540~22428035:+ LUSC cis rs7665090 0.905 rs2866410 ENSG00000230069.3 LRRC37A15P -5.66 2.7e-08 9.88e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633178 chr4:102727274~102730721:- LUSC cis rs7665090 0.936 rs2866411 ENSG00000230069.3 LRRC37A15P -5.66 2.7e-08 9.88e-06 -0.26 -0.25 Primary biliary cholangitis; chr4:102633183 chr4:102727274~102730721:- LUSC cis rs9910055 0.747 rs2905981 ENSG00000267080.4 ASB16-AS1 -5.66 2.7e-08 9.89e-06 -0.23 -0.25 Total body bone mineral density; chr17:44161257 chr17:44175973~44186717:- LUSC cis rs4713118 0.869 rs6922574 ENSG00000280107.1 AL022393.9 -5.66 2.7e-08 9.89e-06 -0.29 -0.25 Parkinson's disease; chr6:27725224 chr6:28170845~28172521:+ LUSC cis rs950880 0.71 rs12905 ENSG00000234389.1 AC007278.3 -5.66 2.7e-08 9.89e-06 -0.27 -0.25 Serum protein levels (sST2); chr2:102343547 chr2:102438713~102440475:+ LUSC cis rs6565180 1 rs12930787 ENSG00000183604.13 SMG1P5 -5.66 2.7e-08 9.9e-06 -0.31 -0.25 Tonsillectomy; chr16:30369982 chr16:30267553~30335374:- LUSC cis rs13113518 0.967 rs4340844 ENSG00000223305.1 RN7SKP30 5.66 2.7e-08 9.9e-06 0.31 0.25 Height; chr4:55462689 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs1522112 ENSG00000223305.1 RN7SKP30 5.66 2.7e-08 9.9e-06 0.31 0.25 Height; chr4:55463606 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs4864997 ENSG00000223305.1 RN7SKP30 5.66 2.7e-08 9.9e-06 0.31 0.25 Height; chr4:55466010 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs960152 ENSG00000223305.1 RN7SKP30 5.66 2.7e-08 9.9e-06 0.31 0.25 Height; chr4:55467308 chr4:55540502~55540835:- LUSC cis rs13113518 0.967 rs12644948 ENSG00000223305.1 RN7SKP30 5.66 2.7e-08 9.9e-06 0.31 0.25 Height; chr4:55470266 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs3805151 ENSG00000223305.1 RN7SKP30 5.66 2.7e-08 9.9e-06 0.31 0.25 Height; chr4:55470874 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs13118237 ENSG00000223305.1 RN7SKP30 5.66 2.7e-08 9.9e-06 0.31 0.25 Height; chr4:55474259 chr4:55540502~55540835:- LUSC cis rs3764021 1 rs3764021 ENSG00000256975.1 RP11-525E9.1 5.66 2.7e-08 9.91e-06 0.29 0.25 Type 1 diabetes; chr12:9681032 chr12:9506347~9508440:- LUSC cis rs3764021 0.527 rs12227655 ENSG00000256975.1 RP11-525E9.1 5.66 2.7e-08 9.91e-06 0.34 0.25 Type 1 diabetes; chr12:9715652 chr12:9506347~9508440:- LUSC cis rs3764021 0.506 rs12228641 ENSG00000256975.1 RP11-525E9.1 5.66 2.7e-08 9.91e-06 0.34 0.25 Type 1 diabetes; chr12:9715680 chr12:9506347~9508440:- LUSC cis rs4664293 0.51 rs12469374 ENSG00000226266.5 AC009961.3 5.66 2.71e-08 9.92e-06 0.3 0.25 Monocyte percentage of white cells; chr2:159720393 chr2:159670708~159712435:- LUSC cis rs11159086 1 rs4899516 ENSG00000270000.1 RP3-449M8.9 5.66 2.71e-08 9.92e-06 0.4 0.25 Advanced glycation end-product levels; chr14:74492825 chr14:74471930~74472360:- LUSC cis rs875971 0.545 rs73142245 ENSG00000224316.1 RP11-479O9.2 5.66 2.71e-08 9.93e-06 0.27 0.25 Aortic root size; chr7:66226662 chr7:65773620~65802067:+ LUSC cis rs2439831 0.717 rs28495368 ENSG00000249839.1 AC011330.5 -5.65 2.71e-08 9.93e-06 -0.48 -0.25 Lung cancer in ever smokers; chr15:43603444 chr15:43663654~43684339:- LUSC cis rs875971 0.756 rs2901210 ENSG00000179406.6 LINC00174 5.65 2.71e-08 9.93e-06 0.27 0.25 Aortic root size; chr7:66552518 chr7:66376044~66401338:- LUSC cis rs2243480 1 rs778729 ENSG00000226824.5 RP4-756H11.3 -5.65 2.71e-08 9.93e-06 -0.49 -0.25 Diabetic kidney disease; chr7:66359432 chr7:66654538~66669855:+ LUSC cis rs783540 1 rs11637433 ENSG00000255769.6 GOLGA2P10 -5.65 2.71e-08 9.94e-06 -0.31 -0.25 Schizophrenia; chr15:82652585 chr15:82472993~82513950:- LUSC cis rs10462794 0.661 rs12517672 ENSG00000260763.1 RP11-445O3.3 -5.65 2.71e-08 9.94e-06 -0.33 -0.25 DNA methylation (variation); chr5:4520378 chr5:4436850~4440259:- LUSC cis rs2243480 1 rs57057549 ENSG00000226824.5 RP4-756H11.3 -5.65 2.72e-08 9.95e-06 -0.49 -0.25 Diabetic kidney disease; chr7:65940751 chr7:66654538~66669855:+ LUSC cis rs2243480 0.808 rs12698508 ENSG00000226824.5 RP4-756H11.3 -5.65 2.72e-08 9.95e-06 -0.49 -0.25 Diabetic kidney disease; chr7:65946971 chr7:66654538~66669855:+ LUSC cis rs801193 0.935 rs11772264 ENSG00000237310.1 GS1-124K5.4 5.65 2.72e-08 9.96e-06 0.25 0.25 Aortic root size; chr7:66711400 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs7782320 ENSG00000237310.1 GS1-124K5.4 5.65 2.72e-08 9.96e-06 0.25 0.25 Aortic root size; chr7:66712111 chr7:66493706~66495474:+ LUSC cis rs932287 0.666 rs10840161 ENSG00000254860.4 TMEM9B-AS1 -5.65 2.72e-08 9.96e-06 -0.28 -0.25 Colonoscopy-negative controls vs population controls; chr11:9032277 chr11:8964675~8977527:+ LUSC cis rs875971 0.522 rs9530 ENSG00000179406.6 LINC00174 -5.65 2.72e-08 9.97e-06 -0.27 -0.25 Aortic root size; chr7:65960907 chr7:66376044~66401338:- LUSC cis rs801193 0.967 rs2420827 ENSG00000224316.1 RP11-479O9.2 -5.65 2.72e-08 9.98e-06 -0.25 -0.25 Aortic root size; chr7:66682114 chr7:65773620~65802067:+ LUSC cis rs66887589 0.66 rs4833613 ENSG00000249244.1 RP11-548H18.2 -5.65 2.73e-08 9.99e-06 -0.3 -0.25 Diastolic blood pressure; chr4:119229001 chr4:119391831~119395335:- LUSC cis rs13113518 0.967 rs12507722 ENSG00000223305.1 RN7SKP30 5.65 2.73e-08 1e-05 0.3 0.25 Height; chr4:55536421 chr4:55540502~55540835:- LUSC cis rs13113518 0.967 rs7696832 ENSG00000223305.1 RN7SKP30 5.65 2.73e-08 1e-05 0.3 0.25 Height; chr4:55537080 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs4864547 ENSG00000223305.1 RN7SKP30 5.65 2.73e-08 1e-05 0.3 0.25 Height; chr4:55538228 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs34648901 ENSG00000223305.1 RN7SKP30 5.65 2.73e-08 1e-05 0.3 0.25 Height; chr4:55541259 chr4:55540502~55540835:- LUSC cis rs7246657 0.722 rs10410588 ENSG00000276846.1 CTD-3220F14.3 5.65 2.73e-08 1e-05 0.38 0.25 Coronary artery calcification; chr19:37551508 chr19:37314868~37315620:- LUSC cis rs61270009 0.908 rs780405 ENSG00000247828.6 TMEM161B-AS1 -5.65 2.73e-08 1e-05 -0.29 -0.25 Depressive symptoms; chr5:88260522 chr5:88268895~88436685:+ LUSC cis rs10759883 0.627 rs12000073 ENSG00000175611.10 LINC00476 5.65 2.73e-08 1e-05 0.3 0.25 Nicotine dependence; chr9:95853844 chr9:95759231~95875977:- LUSC cis rs875971 0.825 rs28480509 ENSG00000179406.6 LINC00174 5.65 2.73e-08 1e-05 0.27 0.25 Aortic root size; chr7:66634237 chr7:66376044~66401338:- LUSC cis rs11951515 0.508 rs6898866 ENSG00000249286.1 CTD-2210P15.2 5.65 2.74e-08 1e-05 0.29 0.25 Metabolite levels (X-11787); chr5:43586273 chr5:43586918~43588223:- LUSC cis rs7176527 1 rs3762168 ENSG00000229212.6 RP11-561C5.4 5.65 2.74e-08 1e-05 0.4 0.25 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84599416 chr15:85205440~85234795:- LUSC cis rs9341808 0.667 rs2322632 ENSG00000272129.1 RP11-250B2.6 5.65 2.74e-08 1e-05 0.31 0.25 Sitting height ratio; chr6:80135891 chr6:80355424~80356859:+ LUSC cis rs17711722 0.701 rs55773927 ENSG00000179406.6 LINC00174 -5.65 2.74e-08 1e-05 -0.27 -0.25 Calcium levels; chr7:65872915 chr7:66376044~66401338:- LUSC cis rs17711722 0.727 rs35850374 ENSG00000179406.6 LINC00174 -5.65 2.74e-08 1e-05 -0.27 -0.25 Calcium levels; chr7:65892789 chr7:66376044~66401338:- LUSC cis rs875971 0.522 rs1617484 ENSG00000237310.1 GS1-124K5.4 5.65 2.75e-08 1e-05 0.26 0.25 Aortic root size; chr7:65998108 chr7:66493706~66495474:+ LUSC cis rs28830936 0.934 rs3959569 ENSG00000250379.1 RP11-23P13.4 5.65 2.75e-08 1.01e-05 0.27 0.25 Diastolic blood pressure; chr15:41823549 chr15:41825099~41827936:- LUSC cis rs7804306 1 rs35425218 ENSG00000233264.2 AC006042.8 5.65 2.75e-08 1.01e-05 0.41 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7977124 chr7:7980312~7982228:+ LUSC cis rs9649213 0.574 rs7791321 ENSG00000272950.1 RP11-307C18.1 5.65 2.76e-08 1.01e-05 0.33 0.25 Prostate cancer (SNP x SNP interaction); chr7:98314813 chr7:98322853~98323430:+ LUSC cis rs910316 0.737 rs175499 ENSG00000279594.1 RP11-950C14.10 -5.65 2.76e-08 1.01e-05 -0.29 -0.25 Height; chr14:75069224 chr14:75011269~75012851:- LUSC cis rs1345301 0.905 rs2310243 ENSG00000234389.1 AC007278.3 -5.65 2.76e-08 1.01e-05 -0.24 -0.25 Waist circumference; chr2:102261100 chr2:102438713~102440475:+ LUSC cis rs801193 0.569 rs13242290 ENSG00000179406.6 LINC00174 5.65 2.76e-08 1.01e-05 0.27 0.25 Aortic root size; chr7:66656898 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs1968126 ENSG00000179406.6 LINC00174 5.65 2.77e-08 1.01e-05 0.27 0.25 Aortic root size; chr7:66592017 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6460306 ENSG00000179406.6 LINC00174 5.65 2.77e-08 1.01e-05 0.27 0.25 Aortic root size; chr7:66595806 chr7:66376044~66401338:- LUSC cis rs950880 0.71 rs17027258 ENSG00000234389.1 AC007278.3 -5.65 2.77e-08 1.01e-05 -0.27 -0.25 Serum protein levels (sST2); chr2:102475081 chr2:102438713~102440475:+ LUSC cis rs17772222 0.74 rs10150311 ENSG00000258789.1 RP11-507K2.3 -5.65 2.77e-08 1.01e-05 -0.28 -0.25 Coronary artery calcification; chr14:88510128 chr14:88551597~88552493:+ LUSC cis rs7772486 0.875 rs9399573 ENSG00000235652.6 RP11-545I5.3 5.65 2.77e-08 1.01e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:146082119 chr6:145799409~145886585:+ LUSC cis rs16843372 0.599 rs11688793 ENSG00000251491.2 OR7E28P -5.65 2.77e-08 1.01e-05 -0.28 -0.25 Obesity-related traits; chr2:158823354 chr2:158862311~158863285:+ LUSC cis rs950880 0.71 rs56043441 ENSG00000234389.1 AC007278.3 -5.65 2.77e-08 1.01e-05 -0.27 -0.25 Serum protein levels (sST2); chr2:102470923 chr2:102438713~102440475:+ LUSC cis rs950880 0.71 rs17027255 ENSG00000234389.1 AC007278.3 -5.65 2.77e-08 1.01e-05 -0.27 -0.25 Serum protein levels (sST2); chr2:102473668 chr2:102438713~102440475:+ LUSC cis rs75920871 0.528 rs7128772 ENSG00000254851.1 RP11-109L13.1 5.65 2.77e-08 1.01e-05 0.35 0.25 Subjective well-being; chr11:117018695 chr11:117135528~117138582:+ LUSC cis rs75920871 0.528 rs10466590 ENSG00000254851.1 RP11-109L13.1 5.65 2.77e-08 1.01e-05 0.35 0.25 Subjective well-being; chr11:117023697 chr11:117135528~117138582:+ LUSC cis rs7555523 0.887 rs4657475 ENSG00000224358.1 RP11-466F5.8 -5.65 2.78e-08 1.02e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165717938 chr1:165768929~165775176:+ LUSC cis rs7208859 0.573 rs8070182 ENSG00000266490.1 CTD-2349P21.9 5.65 2.78e-08 1.02e-05 0.3 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30792372~30792833:+ LUSC cis rs9659323 0.67 rs12095067 ENSG00000231365.4 RP11-418J17.1 -5.65 2.78e-08 1.02e-05 -0.29 -0.25 Body mass index; chr1:119093110 chr1:119140396~119275973:+ LUSC cis rs67311347 1 rs13324109 ENSG00000223797.4 ENTPD3-AS1 5.65 2.78e-08 1.02e-05 0.28 0.25 Renal cell carcinoma; chr3:40419276 chr3:40313802~40453329:- LUSC cis rs459571 0.876 rs2520095 ENSG00000235106.7 LINC00094 5.65 2.78e-08 1.02e-05 0.28 0.25 Platelet distribution width; chr9:134054446 chr9:134025439~134034666:+ LUSC cis rs11159086 0.793 rs10139122 ENSG00000270000.1 RP3-449M8.9 5.65 2.78e-08 1.02e-05 0.38 0.25 Advanced glycation end-product levels; chr14:74492353 chr14:74471930~74472360:- LUSC cis rs6570726 0.935 rs434298 ENSG00000235652.6 RP11-545I5.3 5.65 2.79e-08 1.02e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145525737 chr6:145799409~145886585:+ LUSC cis rs2562456 0.917 rs2650793 ENSG00000268081.1 RP11-678G14.2 -5.65 2.79e-08 1.02e-05 -0.36 -0.25 Pain; chr19:21493313 chr19:21554640~21569237:- LUSC cis rs11971779 0.793 rs11543827 ENSG00000273391.1 RP11-634H22.1 5.65 2.79e-08 1.02e-05 0.29 0.25 Diisocyanate-induced asthma; chr7:139347947 chr7:139359032~139359566:- LUSC cis rs2439831 0.867 rs11856184 ENSG00000249839.1 AC011330.5 -5.65 2.8e-08 1.02e-05 -0.48 -0.25 Lung cancer in ever smokers; chr15:43626964 chr15:43663654~43684339:- LUSC cis rs2439831 0.867 rs2927072 ENSG00000249839.1 AC011330.5 -5.65 2.8e-08 1.02e-05 -0.48 -0.25 Lung cancer in ever smokers; chr15:43630200 chr15:43663654~43684339:- LUSC cis rs2439831 0.867 rs2920781 ENSG00000249839.1 AC011330.5 -5.65 2.8e-08 1.02e-05 -0.48 -0.25 Lung cancer in ever smokers; chr15:43632484 chr15:43663654~43684339:- LUSC cis rs2439831 0.764 rs2447193 ENSG00000249839.1 AC011330.5 -5.65 2.8e-08 1.02e-05 -0.48 -0.25 Lung cancer in ever smokers; chr15:43637535 chr15:43663654~43684339:- LUSC cis rs2439831 0.867 rs2447211 ENSG00000249839.1 AC011330.5 -5.65 2.8e-08 1.02e-05 -0.48 -0.25 Lung cancer in ever smokers; chr15:43644153 chr15:43663654~43684339:- LUSC cis rs2439831 0.571 rs2470121 ENSG00000249839.1 AC011330.5 -5.65 2.8e-08 1.02e-05 -0.48 -0.25 Lung cancer in ever smokers; chr15:43645420 chr15:43663654~43684339:- LUSC cis rs1075265 0.722 rs2287639 ENSG00000233266.1 HMGB1P31 5.65 2.8e-08 1.02e-05 0.31 0.25 Chronotype;Morning vs. evening chronotype; chr2:54138959 chr2:54051334~54051760:+ LUSC cis rs889398 0.967 rs244417 ENSG00000226232.7 RP11-419C5.2 5.65 2.8e-08 1.02e-05 0.24 0.25 Body mass index; chr16:69629616 chr16:69976388~69996188:- LUSC cis rs9545047 0.604 rs7987193 ENSG00000227676.3 LINC01068 -5.65 2.8e-08 1.02e-05 -0.31 -0.25 Schizophrenia; chr13:79408449 chr13:79566727~79571436:+ LUSC cis rs75920871 0.623 rs7928320 ENSG00000254851.1 RP11-109L13.1 5.65 2.8e-08 1.02e-05 0.6 0.25 Subjective well-being; chr11:117072037 chr11:117135528~117138582:+ LUSC cis rs950169 0.763 rs35372971 ENSG00000259728.4 LINC00933 5.65 2.8e-08 1.02e-05 0.33 0.25 Schizophrenia; chr15:84387097 chr15:84570649~84580175:+ LUSC cis rs1876905 0.539 rs62420362 ENSG00000255389.1 C6orf3 5.65 2.8e-08 1.02e-05 0.35 0.25 Mean corpuscular hemoglobin; chr6:111224167 chr6:111599875~111602295:+ LUSC cis rs17826219 0.568 rs11658027 ENSG00000263603.1 CTD-2349P21.5 5.65 2.8e-08 1.02e-05 0.35 0.25 Body mass index; chr17:30767864 chr17:30729469~30731202:+ LUSC cis rs9649213 0.593 rs62478233 ENSG00000272950.1 RP11-307C18.1 5.65 2.8e-08 1.02e-05 0.33 0.25 Prostate cancer (SNP x SNP interaction); chr7:98393780 chr7:98322853~98323430:+ LUSC cis rs875971 0.545 rs316316 ENSG00000224316.1 RP11-479O9.2 -5.65 2.81e-08 1.03e-05 -0.27 -0.25 Aortic root size; chr7:66149270 chr7:65773620~65802067:+ LUSC cis rs5770917 1 rs2269381 ENSG00000273272.1 CTA-384D8.34 5.65 2.81e-08 1.03e-05 0.54 0.25 Narcolepsy; chr22:50581640 chr22:50542650~50543011:+ LUSC cis rs66887589 0.807 rs13134517 ENSG00000248280.1 RP11-33B1.2 5.65 2.81e-08 1.03e-05 0.28 0.25 Diastolic blood pressure; chr4:119484107 chr4:119440561~119450157:- LUSC cis rs66887589 0.837 rs6534135 ENSG00000248280.1 RP11-33B1.2 5.65 2.81e-08 1.03e-05 0.28 0.25 Diastolic blood pressure; chr4:119485147 chr4:119440561~119450157:- LUSC cis rs7246657 0.663 rs9304568 ENSG00000276846.1 CTD-3220F14.3 5.65 2.81e-08 1.03e-05 0.37 0.25 Coronary artery calcification; chr19:37563606 chr19:37314868~37315620:- LUSC cis rs783540 1 rs698500 ENSG00000255769.6 GOLGA2P10 5.65 2.81e-08 1.03e-05 0.31 0.25 Schizophrenia; chr15:82569019 chr15:82472993~82513950:- LUSC cis rs4938303 0.718 rs3212282 ENSG00000254851.1 RP11-109L13.1 -5.65 2.82e-08 1.03e-05 -0.39 -0.25 Triglycerides; chr11:116731229 chr11:117135528~117138582:+ LUSC cis rs7182621 0.546 rs12906587 ENSG00000259363.4 CTD-2054N24.2 5.65 2.82e-08 1.03e-05 0.32 0.25 Colonoscopy-negative controls vs population controls; chr15:99837114 chr15:99807023~99877148:+ LUSC cis rs13113518 1 rs2279458 ENSG00000223305.1 RN7SKP30 5.65 2.82e-08 1.03e-05 0.31 0.25 Height; chr4:55562653 chr4:55540502~55540835:- LUSC cis rs66887589 0.807 rs13134517 ENSG00000249244.1 RP11-548H18.2 5.65 2.82e-08 1.03e-05 0.3 0.25 Diastolic blood pressure; chr4:119484107 chr4:119391831~119395335:- LUSC cis rs66887589 0.837 rs6534135 ENSG00000249244.1 RP11-548H18.2 5.65 2.82e-08 1.03e-05 0.3 0.25 Diastolic blood pressure; chr4:119485147 chr4:119391831~119395335:- LUSC cis rs6918586 1 rs6918586 ENSG00000272462.2 U91328.19 5.65 2.82e-08 1.03e-05 0.27 0.25 Schizophrenia; chr6:26097156 chr6:25992662~26001775:+ LUSC cis rs9341808 0.667 rs2490251 ENSG00000272129.1 RP11-250B2.6 5.65 2.82e-08 1.03e-05 0.31 0.25 Sitting height ratio; chr6:80185447 chr6:80355424~80356859:+ LUSC cis rs7665090 1 rs735403 ENSG00000230069.3 LRRC37A15P 5.65 2.83e-08 1.03e-05 0.25 0.25 Primary biliary cholangitis; chr4:102632386 chr4:102727274~102730721:- LUSC cis rs783540 1 rs7496954 ENSG00000255769.6 GOLGA2P10 -5.65 2.83e-08 1.03e-05 -0.31 -0.25 Schizophrenia; chr15:82676784 chr15:82472993~82513950:- LUSC cis rs6504950 0.785 rs2628304 ENSG00000275710.1 RP11-257O5.4 -5.65 2.83e-08 1.03e-05 -0.31 -0.25 Breast cancer; chr17:55079828 chr17:54964474~54964679:+ LUSC cis rs17818399 0.708 rs1531133 ENSG00000279254.1 RP11-536C12.1 -5.65 2.83e-08 1.03e-05 -0.27 -0.25 Height; chr2:46616492 chr2:46668870~46670778:+ LUSC cis rs910316 0.737 rs398896 ENSG00000279594.1 RP11-950C14.10 -5.65 2.83e-08 1.03e-05 -0.29 -0.25 Height; chr14:75016124 chr14:75011269~75012851:- LUSC cis rs2919917 0.628 rs1021157 ENSG00000254352.1 RP11-578O24.2 5.65 2.83e-08 1.03e-05 0.34 0.25 Lymphocyte counts; chr8:78662938 chr8:78723796~78724136:- LUSC cis rs11123170 0.542 rs28522253 ENSG00000189223.12 PAX8-AS1 -5.65 2.83e-08 1.03e-05 -0.4 -0.25 Renal function-related traits (BUN); chr2:113209810 chr2:113211522~113276581:+ LUSC cis rs11159086 1 rs11626856 ENSG00000270000.1 RP3-449M8.9 5.65 2.83e-08 1.03e-05 0.4 0.25 Advanced glycation end-product levels; chr14:74469665 chr14:74471930~74472360:- LUSC cis rs9907295 0.688 rs2251660 ENSG00000270977.1 AC015849.16 -5.65 2.83e-08 1.03e-05 -0.27 -0.25 Fibroblast growth factor basic levels; chr17:35925533 chr17:35893707~35911023:- LUSC cis rs910316 1 rs4903281 ENSG00000279594.1 RP11-950C14.10 5.65 2.84e-08 1.03e-05 0.28 0.25 Height; chr14:75087658 chr14:75011269~75012851:- LUSC cis rs6951245 0.882 rs10252404 ENSG00000224079.1 AC091729.7 -5.65 2.84e-08 1.04e-05 -0.42 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1169971 chr7:1074450~1078036:+ LUSC cis rs13434995 0.588 rs114571142 ENSG00000249700.7 SRD5A3-AS1 -5.65 2.84e-08 1.04e-05 -0.32 -0.25 Adiponectin levels; chr4:55412991 chr4:55363971~55395847:- LUSC cis rs7208859 0.623 rs28556733 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30792372~30792833:+ LUSC cis rs17826219 0.5 rs28452421 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Body mass index; chr17:30756962 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs28433704 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30792372~30792833:+ LUSC cis rs7208859 0.573 rs28779471 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs11658022 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758341 chr17:30792372~30792833:+ LUSC cis rs17826219 0.5 rs61685770 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Body mass index; chr17:30758695 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs57486336 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30792372~30792833:+ LUSC cis rs17826219 0.706 rs55764512 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Body mass index; chr17:30758740 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs12103440 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs12103508 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30792372~30792833:+ LUSC cis rs7208859 0.524 rs11653605 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs11657777 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs73269913 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs7217984 ENSG00000266490.1 CTD-2349P21.9 5.65 2.84e-08 1.04e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30792372~30792833:+ LUSC cis rs1930961 1 rs5996946 ENSG00000272942.1 CTA-246H3.12 -5.65 2.84e-08 1.04e-05 -0.43 -0.25 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25434324~25435070:- LUSC cis rs875971 0.545 rs10950029 ENSG00000179406.6 LINC00174 -5.65 2.84e-08 1.04e-05 -0.29 -0.25 Aortic root size; chr7:66169334 chr7:66376044~66401338:- LUSC cis rs62103177 0.525 rs4799116 ENSG00000261126.6 RP11-795F19.1 -5.65 2.85e-08 1.04e-05 -0.3 -0.25 Opioid sensitivity; chr18:79976735 chr18:80046900~80095482:+ LUSC cis rs3738443 0.868 rs56029850 ENSG00000259865.1 RP11-488L18.10 5.65 2.85e-08 1.04e-05 0.26 0.25 Alcohol dependence; chr1:247201027 chr1:247187281~247188526:- LUSC cis rs3738443 0.868 rs55643126 ENSG00000259865.1 RP11-488L18.10 5.65 2.85e-08 1.04e-05 0.26 0.25 Alcohol dependence; chr1:247201042 chr1:247187281~247188526:- LUSC cis rs7804306 1 rs35009545 ENSG00000233264.2 AC006042.8 5.65 2.85e-08 1.04e-05 0.45 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8037223 chr7:7980312~7982228:+ LUSC cis rs11723261 0.582 rs4634177 ENSG00000275426.1 CH17-262A2.1 5.65 2.85e-08 1.04e-05 0.39 0.25 Immune response to smallpox vaccine (IL-6); chr4:143055 chr4:149738~150317:+ LUSC cis rs910316 0.687 rs11627442 ENSG00000279594.1 RP11-950C14.10 -5.65 2.85e-08 1.04e-05 -0.29 -0.25 Height; chr14:75202946 chr14:75011269~75012851:- LUSC cis rs62025270 0.547 rs416916 ENSG00000202081.1 RNU6-1280P -5.65 2.85e-08 1.04e-05 -0.31 -0.25 Idiopathic pulmonary fibrosis; chr15:85649185 chr15:85651522~85651628:- LUSC cis rs875971 0.545 rs66594357 ENSG00000224316.1 RP11-479O9.2 5.65 2.85e-08 1.04e-05 0.27 0.25 Aortic root size; chr7:66327797 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs67397473 ENSG00000179406.6 LINC00174 -5.65 2.85e-08 1.04e-05 -0.3 -0.25 Aortic root size; chr7:66168318 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs10950027 ENSG00000179406.6 LINC00174 -5.65 2.85e-08 1.04e-05 -0.3 -0.25 Aortic root size; chr7:66169164 chr7:66376044~66401338:- LUSC cis rs28830936 1 rs11070343 ENSG00000250379.1 RP11-23P13.4 5.65 2.86e-08 1.04e-05 0.27 0.25 Diastolic blood pressure; chr15:41647948 chr15:41825099~41827936:- LUSC cis rs8062405 0.656 rs7189927 ENSG00000278665.1 RP11-666O2.4 -5.64 2.86e-08 1.04e-05 -0.26 -0.25 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28902466 chr16:28599241~28601881:- LUSC cis rs13392177 0.647 rs6718220 ENSG00000261338.2 RP11-378A13.1 -5.64 2.87e-08 1.04e-05 -0.26 -0.25 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218201795 chr2:218255319~218257366:+ LUSC cis rs6142102 0.651 rs6119463 ENSG00000276073.1 RP5-1125A11.7 5.64 2.87e-08 1.04e-05 0.27 0.25 Skin pigmentation; chr20:34149412 chr20:33985617~33988989:- LUSC cis rs36423 0.748 rs36391 ENSG00000266869.1 RP6-114E22.1 -5.64 2.87e-08 1.04e-05 -0.39 -0.25 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71898402 chr14:71848606~71908430:+ LUSC cis rs9649213 0.593 rs56286037 ENSG00000272950.1 RP11-307C18.1 5.64 2.87e-08 1.05e-05 0.33 0.25 Prostate cancer (SNP x SNP interaction); chr7:98390210 chr7:98322853~98323430:+ LUSC cis rs1008375 0.966 rs6449313 ENSG00000249502.1 AC006160.5 -5.64 2.87e-08 1.05e-05 -0.24 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17586697 chr4:17587467~17614571:- LUSC cis rs67311347 1 rs9854493 ENSG00000223797.4 ENTPD3-AS1 5.64 2.87e-08 1.05e-05 0.29 0.25 Renal cell carcinoma; chr3:40382131 chr3:40313802~40453329:- LUSC cis rs67311347 0.956 rs9817233 ENSG00000223797.4 ENTPD3-AS1 5.64 2.87e-08 1.05e-05 0.29 0.25 Renal cell carcinoma; chr3:40384127 chr3:40313802~40453329:- LUSC cis rs2842992 0.789 rs2277072 ENSG00000237927.1 RP3-393E18.2 -5.64 2.87e-08 1.05e-05 -0.38 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159761813 chr6:159586955~159589169:- LUSC cis rs27524 0.734 rs27037 ENSG00000248734.2 CTD-2260A17.1 5.64 2.87e-08 1.05e-05 0.26 0.25 Hodgkin's lymphoma;Psoriasis; chr5:96758990 chr5:96784777~96785999:+ LUSC cis rs4713118 0.868 rs35069907 ENSG00000280107.1 AL022393.9 -5.64 2.88e-08 1.05e-05 -0.31 -0.25 Parkinson's disease; chr6:27778913 chr6:28170845~28172521:+ LUSC cis rs2303759 0.709 rs8102658 ENSG00000268686.1 AC010524.2 -5.64 2.88e-08 1.05e-05 -0.37 -0.25 Multiple sclerosis; chr19:49325598 chr19:49368705~49388081:- LUSC cis rs2303759 0.709 rs8102574 ENSG00000268686.1 AC010524.2 -5.64 2.88e-08 1.05e-05 -0.37 -0.25 Multiple sclerosis; chr19:49325640 chr19:49368705~49388081:- LUSC cis rs13113518 1 rs4864549 ENSG00000272969.1 RP11-528I4.2 5.64 2.88e-08 1.05e-05 0.28 0.25 Height; chr4:55554380 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs4865011 ENSG00000272969.1 RP11-528I4.2 5.64 2.88e-08 1.05e-05 0.28 0.25 Height; chr4:55554456 chr4:55547112~55547889:+ LUSC cis rs9611519 1 rs5758268 ENSG00000235513.1 RP4-756G23.5 5.64 2.88e-08 1.05e-05 0.3 0.25 Neuroticism; chr22:41226415 chr22:41209122~41217627:- LUSC cis rs9309711 0.666 rs11127429 ENSG00000225234.1 TRAPPC12-AS1 -5.64 2.89e-08 1.05e-05 -0.3 -0.25 Neurofibrillary tangles; chr2:3481453 chr2:3481242~3482409:- LUSC cis rs9309711 0.666 rs11127430 ENSG00000225234.1 TRAPPC12-AS1 -5.64 2.89e-08 1.05e-05 -0.3 -0.25 Neurofibrillary tangles; chr2:3481471 chr2:3481242~3482409:- LUSC cis rs7083 1 rs512188 ENSG00000254851.1 RP11-109L13.1 -5.64 2.89e-08 1.05e-05 -0.31 -0.25 Blood protein levels; chr11:117255994 chr11:117135528~117138582:+ LUSC cis rs67180937 0.631 rs1909195 ENSG00000272750.1 RP11-378J18.8 -5.64 2.89e-08 1.05e-05 -0.3 -0.25 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222623985 chr1:222658867~222661512:- LUSC cis rs17772222 0.74 rs61975276 ENSG00000258789.1 RP11-507K2.3 -5.64 2.89e-08 1.05e-05 -0.29 -0.25 Coronary artery calcification; chr14:88511193 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs61975277 ENSG00000258789.1 RP11-507K2.3 -5.64 2.89e-08 1.05e-05 -0.29 -0.25 Coronary artery calcification; chr14:88511202 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs61975278 ENSG00000258789.1 RP11-507K2.3 -5.64 2.89e-08 1.05e-05 -0.29 -0.25 Coronary artery calcification; chr14:88511223 chr14:88551597~88552493:+ LUSC cis rs7246657 0.722 rs968073 ENSG00000276846.1 CTD-3220F14.3 -5.64 2.89e-08 1.05e-05 -0.38 -0.25 Coronary artery calcification; chr19:37701120 chr19:37314868~37315620:- LUSC cis rs6570726 0.902 rs373321 ENSG00000235652.6 RP11-545I5.3 5.64 2.9e-08 1.05e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145533014 chr6:145799409~145886585:+ LUSC cis rs6570726 0.967 rs374728 ENSG00000235652.6 RP11-545I5.3 5.64 2.9e-08 1.05e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145533462 chr6:145799409~145886585:+ LUSC cis rs496547 0.686 rs591756 ENSG00000278376.1 RP11-158I9.8 -5.64 2.9e-08 1.05e-05 -0.23 -0.25 Hip minimal joint space width; chr11:118808172 chr11:118791254~118793137:+ LUSC cis rs8040855 0.658 rs12909111 ENSG00000259295.5 CSPG4P12 5.64 2.9e-08 1.05e-05 0.31 0.25 Bulimia nervosa; chr15:85061095 chr15:85191438~85213905:+ LUSC cis rs853679 0.527 rs9461443 ENSG00000219392.1 RP1-265C24.5 -5.64 2.9e-08 1.06e-05 -0.34 -0.25 Depression; chr6:28226851 chr6:28115628~28116551:+ LUSC cis rs4372836 1 rs7579277 ENSG00000226833.4 AC097724.3 5.64 2.91e-08 1.06e-05 0.29 0.25 Body mass index; chr2:28773429 chr2:28708953~28736205:- LUSC cis rs1075265 0.901 rs7591194 ENSG00000233266.1 HMGB1P31 -5.64 2.91e-08 1.06e-05 -0.32 -0.25 Chronotype;Morning vs. evening chronotype; chr2:54086699 chr2:54051334~54051760:+ LUSC cis rs34375054 0.573 rs12831151 ENSG00000279233.1 RP11-158L12.4 5.64 2.91e-08 1.06e-05 0.28 0.25 Post bronchodilator FEV1/FVC ratio; chr12:125171717 chr12:125138245~125141711:+ LUSC cis rs6570726 0.791 rs365747 ENSG00000235652.6 RP11-545I5.3 5.64 2.91e-08 1.06e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145545648 chr6:145799409~145886585:+ LUSC cis rs17507216 0.628 rs8028130 ENSG00000276710.3 CSPG4P8 -5.64 2.92e-08 1.06e-05 -0.34 -0.25 Excessive daytime sleepiness; chr15:82734974 chr15:82459472~82477258:+ LUSC cis rs9341808 1 rs9341808 ENSG00000272129.1 RP11-250B2.6 5.64 2.92e-08 1.06e-05 0.3 0.25 Sitting height ratio; chr6:80243540 chr6:80355424~80356859:+ LUSC cis rs496547 0.686 rs477014 ENSG00000278376.1 RP11-158I9.8 -5.64 2.92e-08 1.06e-05 -0.23 -0.25 Hip minimal joint space width; chr11:118808277 chr11:118791254~118793137:+ LUSC cis rs11098499 0.661 rs10015965 ENSG00000249244.1 RP11-548H18.2 5.64 2.92e-08 1.06e-05 0.31 0.25 Corneal astigmatism; chr4:119347082 chr4:119391831~119395335:- LUSC cis rs11098499 0.535 rs10005542 ENSG00000249244.1 RP11-548H18.2 5.64 2.92e-08 1.06e-05 0.31 0.25 Corneal astigmatism; chr4:119347147 chr4:119391831~119395335:- LUSC cis rs442309 0.846 rs224127 ENSG00000238280.1 RP11-436D10.3 -5.64 2.92e-08 1.06e-05 -0.31 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62701513 chr10:62793562~62805887:- LUSC cis rs77204473 0.744 rs11216265 ENSG00000254851.1 RP11-109L13.1 5.64 2.92e-08 1.06e-05 0.61 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117076464 chr11:117135528~117138582:+ LUSC cis rs2028299 0.92 rs2043880 ENSG00000259677.1 RP11-493E3.1 5.64 2.93e-08 1.06e-05 0.33 0.25 Type 2 diabetes; chr15:89889294 chr15:89876540~89877285:+ LUSC cis rs875971 0.545 rs10950025 ENSG00000224316.1 RP11-479O9.2 5.64 2.93e-08 1.06e-05 0.27 0.25 Aortic root size; chr7:66158946 chr7:65773620~65802067:+ LUSC cis rs875971 0.52 rs12666485 ENSG00000224316.1 RP11-479O9.2 5.64 2.93e-08 1.06e-05 0.27 0.25 Aortic root size; chr7:66160135 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs67688847 ENSG00000224316.1 RP11-479O9.2 5.64 2.93e-08 1.06e-05 0.27 0.25 Aortic root size; chr7:66161064 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs12673308 ENSG00000224316.1 RP11-479O9.2 5.64 2.93e-08 1.06e-05 0.27 0.25 Aortic root size; chr7:66166374 chr7:65773620~65802067:+ LUSC cis rs12468226 1 rs116635509 ENSG00000272966.1 RP11-686O6.1 5.64 2.93e-08 1.07e-05 0.41 0.25 Urate levels; chr2:202460027 chr2:202336739~202337200:+ LUSC cis rs2554380 0.657 rs4530091 ENSG00000230373.7 GOLGA6L5P -5.64 2.93e-08 1.07e-05 -0.26 -0.25 Height; chr15:83814026 chr15:84507885~84516814:- LUSC cis rs1789 0.503 rs13133213 ENSG00000273133.1 RP11-799M12.2 -5.64 2.94e-08 1.07e-05 -0.31 -0.25 Blood protein levels; chr4:15645171 chr4:15563698~15564253:- LUSC cis rs875971 0.522 rs2949690 ENSG00000222364.1 RNU6-96P 5.64 2.94e-08 1.07e-05 0.29 0.25 Aortic root size; chr7:66018255 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs2659906 ENSG00000237310.1 GS1-124K5.4 5.64 2.94e-08 1.07e-05 0.25 0.25 Aortic root size; chr7:66700323 chr7:66493706~66495474:+ LUSC cis rs394563 0.775 rs420430 ENSG00000231760.4 RP11-350J20.5 5.64 2.94e-08 1.07e-05 0.32 0.25 Dupuytren's disease; chr6:149464403 chr6:149796151~149826294:- LUSC cis rs394563 0.775 rs448420 ENSG00000231760.4 RP11-350J20.5 5.64 2.94e-08 1.07e-05 0.32 0.25 Dupuytren's disease; chr6:149464666 chr6:149796151~149826294:- LUSC cis rs6570726 0.967 rs441364 ENSG00000235652.6 RP11-545I5.3 5.64 2.94e-08 1.07e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145532526 chr6:145799409~145886585:+ LUSC cis rs394563 0.775 rs412894 ENSG00000231760.4 RP11-350J20.5 5.64 2.94e-08 1.07e-05 0.32 0.25 Dupuytren's disease; chr6:149460039 chr6:149796151~149826294:- LUSC cis rs394563 0.717 rs548848 ENSG00000231760.4 RP11-350J20.5 5.64 2.94e-08 1.07e-05 0.32 0.25 Dupuytren's disease; chr6:149460873 chr6:149796151~149826294:- LUSC cis rs394563 0.775 rs399673 ENSG00000231760.4 RP11-350J20.5 5.64 2.94e-08 1.07e-05 0.32 0.25 Dupuytren's disease; chr6:149462085 chr6:149796151~149826294:- LUSC cis rs10759883 0.563 rs682682 ENSG00000175611.10 LINC00476 5.64 2.95e-08 1.07e-05 0.3 0.25 Nicotine dependence; chr9:95939980 chr9:95759231~95875977:- LUSC cis rs10759883 0.563 rs694230 ENSG00000175611.10 LINC00476 5.64 2.95e-08 1.07e-05 0.3 0.25 Nicotine dependence; chr9:95954227 chr9:95759231~95875977:- LUSC cis rs875971 0.545 rs316305 ENSG00000237310.1 GS1-124K5.4 -5.64 2.95e-08 1.07e-05 -0.29 -0.25 Aortic root size; chr7:66152984 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs2460427 ENSG00000237310.1 GS1-124K5.4 -5.64 2.95e-08 1.07e-05 -0.29 -0.25 Aortic root size; chr7:66154218 chr7:66493706~66495474:+ LUSC cis rs853679 1 rs1778511 ENSG00000219392.1 RP1-265C24.5 5.64 2.95e-08 1.07e-05 0.41 0.25 Depression; chr6:28261633 chr6:28115628~28116551:+ LUSC cis rs2404602 1 rs12594212 ENSG00000259422.1 RP11-593F23.1 5.64 2.95e-08 1.07e-05 0.29 0.25 Blood metabolite levels; chr15:76509673 chr15:76174891~76181486:- LUSC cis rs35740288 0.77 rs11636185 ENSG00000202081.1 RNU6-1280P 5.64 2.95e-08 1.07e-05 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85639887 chr15:85651522~85651628:- LUSC cis rs35740288 0.77 rs12898597 ENSG00000202081.1 RNU6-1280P 5.64 2.95e-08 1.07e-05 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85646688 chr15:85651522~85651628:- LUSC cis rs2562456 0.761 rs35008138 ENSG00000268081.1 RP11-678G14.2 5.64 2.96e-08 1.07e-05 0.36 0.25 Pain; chr19:21548822 chr19:21554640~21569237:- LUSC cis rs2562456 0.833 rs2681388 ENSG00000268081.1 RP11-678G14.2 5.64 2.96e-08 1.07e-05 0.36 0.25 Pain; chr19:21549451 chr19:21554640~21569237:- LUSC cis rs11098499 0.863 rs6858592 ENSG00000248280.1 RP11-33B1.2 5.64 2.96e-08 1.07e-05 0.31 0.25 Corneal astigmatism; chr4:119537537 chr4:119440561~119450157:- LUSC cis rs11676348 0.811 rs13027120 ENSG00000261338.2 RP11-378A13.1 5.64 2.96e-08 1.08e-05 0.24 0.25 Ulcerative colitis; chr2:218156191 chr2:218255319~218257366:+ LUSC cis rs2562456 0.834 rs2173727 ENSG00000268081.1 RP11-678G14.2 -5.64 2.96e-08 1.08e-05 -0.36 -0.25 Pain; chr19:21491155 chr19:21554640~21569237:- LUSC cis rs801193 1 rs2659912 ENSG00000237310.1 GS1-124K5.4 5.64 2.96e-08 1.08e-05 0.25 0.25 Aortic root size; chr7:66693012 chr7:66493706~66495474:+ LUSC cis rs944990 0.557 rs10821155 ENSG00000227603.1 RP11-165J3.6 5.64 2.96e-08 1.08e-05 0.24 0.25 Body mass index; chr9:93541996 chr9:93435332~93437121:- LUSC cis rs75920871 0.528 rs7935913 ENSG00000254851.1 RP11-109L13.1 -5.64 2.96e-08 1.08e-05 -0.34 -0.25 Subjective well-being; chr11:117073632 chr11:117135528~117138582:+ LUSC cis rs875971 0.545 rs10950029 ENSG00000224316.1 RP11-479O9.2 5.64 2.97e-08 1.08e-05 0.26 0.25 Aortic root size; chr7:66169334 chr7:65773620~65802067:+ LUSC cis rs6570726 0.846 rs372904 ENSG00000235652.6 RP11-545I5.3 5.64 2.97e-08 1.08e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145566289 chr6:145799409~145886585:+ LUSC cis rs2337406 0.929 rs12050233 ENSG00000254174.1 IGHV1-12 5.64 2.97e-08 1.08e-05 0.24 0.25 Alzheimer's disease (late onset); chr14:106781123 chr14:106122420~106122709:- LUSC cis rs2337406 0.852 rs12050466 ENSG00000254174.1 IGHV1-12 5.64 2.97e-08 1.08e-05 0.24 0.25 Alzheimer's disease (late onset); chr14:106781131 chr14:106122420~106122709:- LUSC cis rs7555523 0.779 rs6662839 ENSG00000224358.1 RP11-466F5.8 -5.64 2.97e-08 1.08e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165753409 chr1:165768929~165775176:+ LUSC cis rs9640161 0.789 rs2373751 ENSG00000261305.1 RP4-584D14.7 5.64 2.97e-08 1.08e-05 0.37 0.25 Blood protein levels;Circulating chemerin levels; chr7:150324510 chr7:150341771~150342607:+ LUSC cis rs10759883 0.627 rs690528 ENSG00000175611.10 LINC00476 5.64 2.98e-08 1.08e-05 0.3 0.25 Nicotine dependence; chr9:95876006 chr9:95759231~95875977:- LUSC cis rs2562456 0.561 rs12610883 ENSG00000268081.1 RP11-678G14.2 5.64 2.98e-08 1.08e-05 0.36 0.25 Pain; chr19:21567257 chr19:21554640~21569237:- LUSC cis rs2562456 0.837 rs11085462 ENSG00000268081.1 RP11-678G14.2 5.64 2.98e-08 1.08e-05 0.36 0.25 Pain; chr19:21567449 chr19:21554640~21569237:- LUSC cis rs7727544 0.735 rs274558 ENSG00000233006.5 AC034220.3 -5.64 2.98e-08 1.08e-05 -0.25 -0.25 Blood metabolite levels; chr5:132385482 chr5:132311285~132369916:- LUSC cis rs7727544 0.735 rs274557 ENSG00000233006.5 AC034220.3 -5.64 2.98e-08 1.08e-05 -0.25 -0.25 Blood metabolite levels; chr5:132385512 chr5:132311285~132369916:- LUSC cis rs71403859 0.73 rs17356206 ENSG00000260886.1 TAT-AS1 5.64 2.98e-08 1.08e-05 0.41 0.25 Post bronchodilator FEV1; chr16:71702456 chr16:71565789~71578187:+ LUSC cis rs853679 0.769 rs17720293 ENSG00000204709.4 LINC01556 5.64 2.98e-08 1.08e-05 0.47 0.25 Depression; chr6:28246920 chr6:28943877~28944537:+ LUSC cis rs6570726 0.791 rs370654 ENSG00000235652.6 RP11-545I5.3 5.64 2.99e-08 1.08e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145557869 chr6:145799409~145886585:+ LUSC cis rs12935418 1 rs62054589 ENSG00000261838.4 RP11-303E16.6 5.64 2.99e-08 1.08e-05 0.47 0.25 Mean corpuscular volume; chr16:81035143 chr16:81069854~81076598:+ LUSC cis rs875971 0.862 rs778736 ENSG00000179406.6 LINC00174 -5.64 2.99e-08 1.08e-05 -0.27 -0.25 Aortic root size; chr7:66348861 chr7:66376044~66401338:- LUSC cis rs875971 0.755 rs10228885 ENSG00000179406.6 LINC00174 5.64 2.99e-08 1.08e-05 0.27 0.25 Aortic root size; chr7:66315542 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs3893216 ENSG00000179406.6 LINC00174 5.64 2.99e-08 1.08e-05 0.27 0.25 Aortic root size; chr7:66325720 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6958294 ENSG00000179406.6 LINC00174 5.64 2.99e-08 1.08e-05 0.27 0.25 Aortic root size; chr7:66329809 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs2088655 ENSG00000179406.6 LINC00174 5.64 2.99e-08 1.08e-05 0.27 0.25 Aortic root size; chr7:66330724 chr7:66376044~66401338:- LUSC cis rs875971 0.895 rs10447522 ENSG00000179406.6 LINC00174 5.64 2.99e-08 1.08e-05 0.27 0.25 Aortic root size; chr7:66331087 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs2088653 ENSG00000179406.6 LINC00174 5.64 2.99e-08 1.08e-05 0.27 0.25 Aortic root size; chr7:66343621 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6460293 ENSG00000179406.6 LINC00174 5.64 2.99e-08 1.08e-05 0.27 0.25 Aortic root size; chr7:66345205 chr7:66376044~66401338:- LUSC cis rs7246657 0.722 rs10412510 ENSG00000276846.1 CTD-3220F14.3 5.64 2.99e-08 1.08e-05 0.37 0.25 Coronary artery calcification; chr19:37585043 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs3829688 ENSG00000276846.1 CTD-3220F14.3 5.64 2.99e-08 1.08e-05 0.37 0.25 Coronary artery calcification; chr19:37586199 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs13744 ENSG00000276846.1 CTD-3220F14.3 5.64 2.99e-08 1.08e-05 0.37 0.25 Coronary artery calcification; chr19:37587011 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs10403173 ENSG00000276846.1 CTD-3220F14.3 5.64 2.99e-08 1.08e-05 0.37 0.25 Coronary artery calcification; chr19:37587779 chr19:37314868~37315620:- LUSC cis rs7246657 0.679 rs12461113 ENSG00000276846.1 CTD-3220F14.3 5.64 2.99e-08 1.08e-05 0.37 0.25 Coronary artery calcification; chr19:37592287 chr19:37314868~37315620:- LUSC cis rs7246657 0.639 rs12459015 ENSG00000276846.1 CTD-3220F14.3 5.64 2.99e-08 1.08e-05 0.37 0.25 Coronary artery calcification; chr19:37592288 chr19:37314868~37315620:- LUSC cis rs11690935 0.843 rs9784070 ENSG00000228389.1 AC068039.4 5.64 2.99e-08 1.08e-05 0.3 0.25 Schizophrenia; chr2:171928497 chr2:171773482~171775844:+ LUSC cis rs28830936 0.966 rs890498 ENSG00000250379.1 RP11-23P13.4 5.64 2.99e-08 1.09e-05 0.27 0.25 Diastolic blood pressure; chr15:41819100 chr15:41825099~41827936:- LUSC cis rs12935418 0.733 rs12448615 ENSG00000261061.1 RP11-303E16.2 -5.64 2.99e-08 1.09e-05 -0.44 -0.25 Mean corpuscular volume; chr16:80947132 chr16:81030770~81031485:+ LUSC cis rs9640161 0.702 rs1962004 ENSG00000261305.1 RP4-584D14.7 5.64 2.99e-08 1.09e-05 0.37 0.25 Blood protein levels;Circulating chemerin levels; chr7:150323292 chr7:150341771~150342607:+ LUSC cis rs801193 1 rs2659889 ENSG00000222364.1 RNU6-96P -5.64 3e-08 1.09e-05 -0.29 -0.25 Aortic root size; chr7:66752125 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs3800812 ENSG00000222364.1 RNU6-96P -5.64 3e-08 1.09e-05 -0.29 -0.25 Aortic root size; chr7:66758474 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs4279493 ENSG00000222364.1 RNU6-96P -5.64 3e-08 1.09e-05 -0.29 -0.25 Aortic root size; chr7:66761633 chr7:66395191~66395286:+ LUSC cis rs875971 0.522 rs709604 ENSG00000222364.1 RNU6-96P 5.64 3e-08 1.09e-05 0.29 0.25 Aortic root size; chr7:66032447 chr7:66395191~66395286:+ LUSC cis rs13113518 0.966 rs11133387 ENSG00000223305.1 RN7SKP30 5.64 3e-08 1.09e-05 0.31 0.25 Height; chr4:55475130 chr4:55540502~55540835:- LUSC cis rs6504950 0.924 rs2628316 ENSG00000275710.1 RP11-257O5.4 -5.64 3e-08 1.09e-05 -0.29 -0.25 Breast cancer; chr17:55142476 chr17:54964474~54964679:+ LUSC cis rs867371 0.762 rs1846910 ENSG00000255769.6 GOLGA2P10 -5.64 3.01e-08 1.09e-05 -0.32 -0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82279439 chr15:82472993~82513950:- LUSC cis rs11098499 0.909 rs10020034 ENSG00000248280.1 RP11-33B1.2 5.64 3.01e-08 1.09e-05 0.3 0.25 Corneal astigmatism; chr4:119373176 chr4:119440561~119450157:- LUSC cis rs2303759 0.918 rs2288480 ENSG00000268686.1 AC010524.2 -5.64 3.01e-08 1.09e-05 -0.35 -0.25 Multiple sclerosis; chr19:49363759 chr19:49368705~49388081:- LUSC cis rs2303759 1 rs2303759 ENSG00000268686.1 AC010524.2 -5.64 3.01e-08 1.09e-05 -0.35 -0.25 Multiple sclerosis; chr19:49365794 chr19:49368705~49388081:- LUSC cis rs2303759 0.918 rs1054770 ENSG00000268686.1 AC010524.2 -5.64 3.01e-08 1.09e-05 -0.35 -0.25 Multiple sclerosis; chr19:49374858 chr19:49368705~49388081:- LUSC cis rs6991838 0.593 rs953593 ENSG00000272010.1 CTD-3025N20.3 -5.64 3.01e-08 1.09e-05 -0.31 -0.25 Intelligence (multi-trait analysis); chr8:65719737 chr8:65591850~65592472:- LUSC cis rs7208859 0.573 rs8070182 ENSG00000263603.1 CTD-2349P21.5 -5.64 3.02e-08 1.09e-05 -0.34 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30729469~30731202:+ LUSC cis rs6435862 0.636 rs717548 ENSG00000229267.2 AC072062.1 5.64 3.02e-08 1.09e-05 0.3 0.25 Neuroblastoma (high-risk); chr2:214812181 chr2:214810229~214963274:+ LUSC cis rs41294858 1 rs113033196 ENSG00000232876.1 CTA-212D2.2 -5.64 3.02e-08 1.09e-05 -0.48 -0.25 Red blood cell count; chr6:135082789 chr6:135055033~135060550:+ LUSC cis rs41294858 0.908 rs79562575 ENSG00000232876.1 CTA-212D2.2 -5.64 3.02e-08 1.09e-05 -0.48 -0.25 Red blood cell count; chr6:135082974 chr6:135055033~135060550:+ LUSC cis rs270601 0.955 rs273911 ENSG00000233006.5 AC034220.3 5.64 3.02e-08 1.09e-05 0.27 0.25 Acylcarnitine levels; chr5:132325833 chr5:132311285~132369916:- LUSC cis rs950169 0.887 rs35986397 ENSG00000259295.5 CSPG4P12 5.63 3.02e-08 1.1e-05 0.34 0.25 Schizophrenia; chr15:84400409 chr15:85191438~85213905:+ LUSC cis rs7208859 0.623 rs73269916 ENSG00000266490.1 CTD-2349P21.9 5.63 3.02e-08 1.1e-05 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30792372~30792833:+ LUSC cis rs4372836 1 rs11127188 ENSG00000226833.4 AC097724.3 5.63 3.03e-08 1.1e-05 0.29 0.25 Body mass index; chr2:28749986 chr2:28708953~28736205:- LUSC cis rs910316 0.763 rs4556 ENSG00000279594.1 RP11-950C14.10 5.63 3.03e-08 1.1e-05 0.29 0.25 Height; chr14:75009368 chr14:75011269~75012851:- LUSC cis rs1320333 0.772 rs17786120 ENSG00000233296.1 AC092159.2 5.63 3.03e-08 1.1e-05 0.42 0.25 Obesity-related traits; chr2:700580 chr2:677186~697371:+ LUSC cis rs7267979 0.833 rs4619688 ENSG00000274973.1 RP13-401N8.7 -5.63 3.04e-08 1.1e-05 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25263465 chr20:25845497~25845862:+ LUSC cis rs55665837 0.539 rs12794714 ENSG00000251991.1 RNU7-49P 5.63 3.04e-08 1.1e-05 0.29 0.25 Vitamin D levels; chr11:14892029 chr11:14478892~14478953:+ LUSC cis rs2919917 0.628 rs2625663 ENSG00000254352.1 RP11-578O24.2 5.63 3.04e-08 1.1e-05 0.33 0.25 Lymphocyte counts; chr8:78718106 chr8:78723796~78724136:- LUSC cis rs4722166 0.603 rs7801406 ENSG00000179428.2 AC073072.5 -5.63 3.04e-08 1.1e-05 -0.31 -0.25 Lung cancer; chr7:22748655 chr7:22725395~22727620:- LUSC cis rs11098499 0.863 rs10013305 ENSG00000248280.1 RP11-33B1.2 5.63 3.04e-08 1.1e-05 0.3 0.25 Corneal astigmatism; chr4:119529269 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs3775849 ENSG00000248280.1 RP11-33B1.2 5.63 3.04e-08 1.1e-05 0.3 0.25 Corneal astigmatism; chr4:119529753 chr4:119440561~119450157:- LUSC cis rs11098499 0.818 rs7688802 ENSG00000248280.1 RP11-33B1.2 5.63 3.04e-08 1.1e-05 0.3 0.25 Corneal astigmatism; chr4:119530513 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs7695620 ENSG00000248280.1 RP11-33B1.2 5.63 3.04e-08 1.1e-05 0.3 0.25 Corneal astigmatism; chr4:119531621 chr4:119440561~119450157:- LUSC cis rs11098499 0.821 rs3775852 ENSG00000248280.1 RP11-33B1.2 5.63 3.04e-08 1.1e-05 0.3 0.25 Corneal astigmatism; chr4:119533401 chr4:119440561~119450157:- LUSC cis rs11098499 0.82 rs6534140 ENSG00000248280.1 RP11-33B1.2 5.63 3.04e-08 1.1e-05 0.3 0.25 Corneal astigmatism; chr4:119534156 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs7657849 ENSG00000248280.1 RP11-33B1.2 5.63 3.04e-08 1.1e-05 0.3 0.25 Corneal astigmatism; chr4:119534339 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs10034450 ENSG00000248280.1 RP11-33B1.2 5.63 3.04e-08 1.1e-05 0.3 0.25 Corneal astigmatism; chr4:119534494 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs1480939 ENSG00000248280.1 RP11-33B1.2 5.63 3.04e-08 1.1e-05 0.3 0.25 Corneal astigmatism; chr4:119535772 chr4:119440561~119450157:- LUSC cis rs875971 0.545 rs11767262 ENSG00000224316.1 RP11-479O9.2 5.63 3.05e-08 1.1e-05 0.27 0.25 Aortic root size; chr7:66302237 chr7:65773620~65802067:+ LUSC cis rs7208859 0.623 rs7219712 ENSG00000263603.1 CTD-2349P21.5 -5.63 3.05e-08 1.1e-05 -0.36 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753552 chr17:30729469~30731202:+ LUSC cis rs7555523 0.887 rs7518099 ENSG00000224358.1 RP11-466F5.8 -5.63 3.05e-08 1.1e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165767643 chr1:165768929~165775176:+ LUSC cis rs66887589 0.934 rs41464847 ENSG00000249244.1 RP11-548H18.2 -5.63 3.05e-08 1.1e-05 -0.29 -0.25 Diastolic blood pressure; chr4:119611246 chr4:119391831~119395335:- LUSC cis rs910316 0.789 rs175457 ENSG00000279594.1 RP11-950C14.10 -5.63 3.05e-08 1.11e-05 -0.29 -0.25 Height; chr14:75117804 chr14:75011269~75012851:- LUSC cis rs9326248 0.59 rs2542063 ENSG00000280143.1 AP000892.6 5.63 3.05e-08 1.11e-05 0.28 0.25 Blood protein levels; chr11:116814051 chr11:117204967~117210292:+ LUSC cis rs73173548 0.528 rs34182576 ENSG00000247828.6 TMEM161B-AS1 5.63 3.06e-08 1.11e-05 0.3 0.25 Macular telangiectasia type 2; chr5:88438321 chr5:88268895~88436685:+ LUSC cis rs17826219 0.706 rs28469200 ENSG00000263603.1 CTD-2349P21.5 -5.63 3.06e-08 1.11e-05 -0.35 -0.25 Body mass index; chr17:30806554 chr17:30729469~30731202:+ LUSC cis rs66887589 0.56 rs9684327 ENSG00000248280.1 RP11-33B1.2 5.63 3.06e-08 1.11e-05 0.28 0.25 Diastolic blood pressure; chr4:119444286 chr4:119440561~119450157:- LUSC cis rs11159086 1 rs4899514 ENSG00000270000.1 RP3-449M8.9 -5.63 3.07e-08 1.11e-05 -0.41 -0.25 Advanced glycation end-product levels; chr14:74473467 chr14:74471930~74472360:- LUSC cis rs2842992 0.83 rs2842966 ENSG00000237927.1 RP3-393E18.2 -5.63 3.07e-08 1.11e-05 -0.36 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159720560 chr6:159586955~159589169:- LUSC cis rs13113518 0.966 rs1474271 ENSG00000249700.7 SRD5A3-AS1 5.63 3.07e-08 1.11e-05 0.29 0.25 Height; chr4:55435912 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11937487 ENSG00000249700.7 SRD5A3-AS1 5.63 3.07e-08 1.11e-05 0.29 0.25 Height; chr4:55436576 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs3805146 ENSG00000249700.7 SRD5A3-AS1 5.63 3.07e-08 1.11e-05 0.29 0.25 Height; chr4:55436985 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11133378 ENSG00000249700.7 SRD5A3-AS1 5.63 3.07e-08 1.11e-05 0.29 0.25 Height; chr4:55439472 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11942279 ENSG00000249700.7 SRD5A3-AS1 5.63 3.07e-08 1.11e-05 0.29 0.25 Height; chr4:55439652 chr4:55363971~55395847:- LUSC cis rs4718428 0.705 rs4718430 ENSG00000226824.5 RP4-756H11.3 -5.63 3.07e-08 1.11e-05 -0.35 -0.25 Corneal structure; chr7:66967037 chr7:66654538~66669855:+ LUSC cis rs8177376 0.861 rs604255 ENSG00000254905.1 RP11-712L6.7 5.63 3.07e-08 1.11e-05 0.35 0.25 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126327131 chr11:126292922~126294254:- LUSC cis rs6570726 0.764 rs376257 ENSG00000235652.6 RP11-545I5.3 5.63 3.07e-08 1.11e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145541813 chr6:145799409~145886585:+ LUSC cis rs6570726 0.693 rs450921 ENSG00000235652.6 RP11-545I5.3 5.63 3.07e-08 1.11e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145543124 chr6:145799409~145886585:+ LUSC cis rs950169 0.887 rs12903946 ENSG00000259295.5 CSPG4P12 5.63 3.07e-08 1.11e-05 0.34 0.25 Schizophrenia; chr15:84399732 chr15:85191438~85213905:+ LUSC cis rs950169 0.887 rs62029593 ENSG00000259295.5 CSPG4P12 5.63 3.07e-08 1.11e-05 0.34 0.25 Schizophrenia; chr15:84400482 chr15:85191438~85213905:+ LUSC cis rs950169 0.81 rs62029594 ENSG00000259295.5 CSPG4P12 5.63 3.07e-08 1.11e-05 0.34 0.25 Schizophrenia; chr15:84400554 chr15:85191438~85213905:+ LUSC cis rs950169 0.881 rs62029596 ENSG00000259295.5 CSPG4P12 5.63 3.07e-08 1.11e-05 0.34 0.25 Schizophrenia; chr15:84400736 chr15:85191438~85213905:+ LUSC cis rs950169 0.881 rs4081123 ENSG00000259295.5 CSPG4P12 5.63 3.07e-08 1.11e-05 0.34 0.25 Schizophrenia; chr15:84401537 chr15:85191438~85213905:+ LUSC cis rs950169 0.881 rs62029599 ENSG00000259295.5 CSPG4P12 5.63 3.07e-08 1.11e-05 0.34 0.25 Schizophrenia; chr15:84401867 chr15:85191438~85213905:+ LUSC cis rs950169 0.8 rs4099846 ENSG00000259295.5 CSPG4P12 5.63 3.07e-08 1.11e-05 0.34 0.25 Schizophrenia; chr15:84402196 chr15:85191438~85213905:+ LUSC cis rs2439831 0.85 rs12441861 ENSG00000249839.1 AC011330.5 -5.63 3.08e-08 1.11e-05 -0.49 -0.25 Lung cancer in ever smokers; chr15:43768685 chr15:43663654~43684339:- LUSC cis rs6504622 0.818 rs9910899 ENSG00000262879.4 RP11-156P1.3 5.63 3.08e-08 1.11e-05 0.27 0.25 Orofacial clefts; chr17:46956976 chr17:46984045~47100323:- LUSC cis rs6504622 0.818 rs9912794 ENSG00000262879.4 RP11-156P1.3 5.63 3.08e-08 1.11e-05 0.27 0.25 Orofacial clefts; chr17:46957075 chr17:46984045~47100323:- LUSC cis rs71403859 0.502 rs34015581 ENSG00000260886.1 TAT-AS1 5.63 3.08e-08 1.11e-05 0.38 0.25 Post bronchodilator FEV1; chr16:71474326 chr16:71565789~71578187:+ LUSC cis rs11159086 1 rs11159086 ENSG00000259005.1 RP3-449M8.6 5.63 3.08e-08 1.11e-05 0.37 0.25 Advanced glycation end-product levels; chr14:74495572 chr14:74474007~74474864:- LUSC cis rs801193 0.935 rs11772264 ENSG00000222364.1 RNU6-96P -5.63 3.08e-08 1.11e-05 -0.29 -0.25 Aortic root size; chr7:66711400 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs7782320 ENSG00000222364.1 RNU6-96P -5.63 3.08e-08 1.11e-05 -0.29 -0.25 Aortic root size; chr7:66712111 chr7:66395191~66395286:+ LUSC cis rs11098499 0.908 rs2017057 ENSG00000248280.1 RP11-33B1.2 5.63 3.08e-08 1.11e-05 0.3 0.25 Corneal astigmatism; chr4:119336556 chr4:119440561~119450157:- LUSC cis rs7674212 0.507 rs223322 ENSG00000246560.2 RP11-10L12.4 5.63 3.09e-08 1.12e-05 0.33 0.25 Type 2 diabetes; chr4:102879037 chr4:102828055~102844075:+ LUSC cis rs801193 0.613 rs2659900 ENSG00000179406.6 LINC00174 -5.63 3.09e-08 1.12e-05 -0.27 -0.25 Aortic root size; chr7:66719456 chr7:66376044~66401338:- LUSC cis rs7267979 0.903 rs6115118 ENSG00000274973.1 RP13-401N8.7 -5.63 3.09e-08 1.12e-05 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25266098 chr20:25845497~25845862:+ LUSC cis rs7267979 0.903 rs1118963 ENSG00000274973.1 RP13-401N8.7 -5.63 3.09e-08 1.12e-05 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25266813 chr20:25845497~25845862:+ LUSC cis rs8072100 0.713 rs2136750 ENSG00000228782.6 CTD-2026D20.3 5.63 3.1e-08 1.12e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47378734 chr17:47450568~47492492:- LUSC cis rs8072100 0.713 rs9807106 ENSG00000228782.6 CTD-2026D20.3 5.63 3.1e-08 1.12e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47379736 chr17:47450568~47492492:- LUSC cis rs8072100 0.607 rs9894594 ENSG00000228782.6 CTD-2026D20.3 5.63 3.1e-08 1.12e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47384017 chr17:47450568~47492492:- LUSC cis rs950880 0.71 rs3771177 ENSG00000234389.1 AC007278.3 -5.63 3.1e-08 1.12e-05 -0.27 -0.25 Serum protein levels (sST2); chr2:102339400 chr2:102438713~102440475:+ LUSC cis rs67311347 1 rs17078941 ENSG00000223797.4 ENTPD3-AS1 -5.63 3.1e-08 1.12e-05 -0.29 -0.25 Renal cell carcinoma; chr3:40409397 chr3:40313802~40453329:- LUSC cis rs73173548 0.502 rs4423262 ENSG00000247828.6 TMEM161B-AS1 5.63 3.1e-08 1.12e-05 0.29 0.25 Macular telangiectasia type 2; chr5:88438609 chr5:88268895~88436685:+ LUSC cis rs910316 0.763 rs175490 ENSG00000279594.1 RP11-950C14.10 5.63 3.1e-08 1.12e-05 0.29 0.25 Height; chr14:75078982 chr14:75011269~75012851:- LUSC cis rs11763147 1 rs11763147 ENSG00000237310.1 GS1-124K5.4 -5.63 3.1e-08 1.12e-05 -0.25 -0.25 Corneal structure; chr7:65861834 chr7:66493706~66495474:+ LUSC cis rs7119038 0.509 rs11216964 ENSG00000255422.1 AP002954.4 5.63 3.1e-08 1.12e-05 0.33 0.25 Sjögren's syndrome; chr11:118711186 chr11:118704607~118750263:+ LUSC cis rs801193 0.967 rs2707853 ENSG00000237310.1 GS1-124K5.4 5.63 3.1e-08 1.12e-05 0.25 0.25 Aortic root size; chr7:66749023 chr7:66493706~66495474:+ LUSC cis rs13113518 1 rs11724094 ENSG00000249700.7 SRD5A3-AS1 5.63 3.11e-08 1.12e-05 0.29 0.25 Height; chr4:55501479 chr4:55363971~55395847:- LUSC cis rs9341808 0.667 rs742833 ENSG00000272129.1 RP11-250B2.6 5.63 3.11e-08 1.12e-05 0.31 0.25 Sitting height ratio; chr6:80211729 chr6:80355424~80356859:+ LUSC cis rs4372836 0.964 rs34627117 ENSG00000226833.4 AC097724.3 -5.63 3.11e-08 1.12e-05 -0.3 -0.25 Body mass index; chr2:28707610 chr2:28708953~28736205:- LUSC cis rs950169 0.763 rs35372971 ENSG00000259295.5 CSPG4P12 5.63 3.11e-08 1.12e-05 0.34 0.25 Schizophrenia; chr15:84387097 chr15:85191438~85213905:+ LUSC cis rs801193 0.935 rs2659899 ENSG00000222364.1 RNU6-96P -5.63 3.11e-08 1.12e-05 -0.29 -0.25 Aortic root size; chr7:66721734 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs1553609 ENSG00000222364.1 RNU6-96P -5.63 3.11e-08 1.12e-05 -0.29 -0.25 Aortic root size; chr7:66732152 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs1553610 ENSG00000222364.1 RNU6-96P -5.63 3.11e-08 1.12e-05 -0.29 -0.25 Aortic root size; chr7:66732246 chr7:66395191~66395286:+ LUSC cis rs73173548 0.502 rs7726289 ENSG00000247828.6 TMEM161B-AS1 5.63 3.12e-08 1.13e-05 0.3 0.25 Macular telangiectasia type 2; chr5:88437392 chr5:88268895~88436685:+ LUSC cis rs7182621 0.546 rs11632596 ENSG00000259363.4 CTD-2054N24.2 -5.63 3.12e-08 1.13e-05 -0.33 -0.25 Colonoscopy-negative controls vs population controls; chr15:99834385 chr15:99807023~99877148:+ LUSC cis rs950880 0.71 rs17027166 ENSG00000234389.1 AC007278.3 -5.63 3.12e-08 1.13e-05 -0.27 -0.25 Serum protein levels (sST2); chr2:102438960 chr2:102438713~102440475:+ LUSC cis rs9341808 0.935 rs2322633 ENSG00000272129.1 RP11-250B2.6 -5.63 3.12e-08 1.13e-05 -0.3 -0.25 Sitting height ratio; chr6:80136272 chr6:80355424~80356859:+ LUSC cis rs801193 1 rs17566701 ENSG00000237310.1 GS1-124K5.4 5.63 3.12e-08 1.13e-05 0.26 0.25 Aortic root size; chr7:66728196 chr7:66493706~66495474:+ LUSC cis rs853679 0.55 rs1225598 ENSG00000280107.1 AL022393.9 -5.63 3.12e-08 1.13e-05 -0.31 -0.25 Depression; chr6:28193021 chr6:28170845~28172521:+ LUSC cis rs6951245 0.638 rs74976697 ENSG00000224079.1 AC091729.7 -5.63 3.12e-08 1.13e-05 -0.4 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1120869 chr7:1074450~1078036:+ LUSC cis rs10446497 0.61 rs12497046 ENSG00000272359.1 U4 5.63 3.12e-08 1.13e-05 0.3 0.25 Schizophrenia; chr3:196816775 chr3:196747192~196747324:- LUSC cis rs2243480 1 rs4149468 ENSG00000226824.5 RP4-756H11.3 -5.63 3.12e-08 1.13e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66360703 chr7:66654538~66669855:+ LUSC cis rs2243480 0.901 rs778687 ENSG00000226824.5 RP4-756H11.3 -5.63 3.12e-08 1.13e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66370832 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs778679 ENSG00000226824.5 RP4-756H11.3 -5.63 3.12e-08 1.13e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66375924 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs778704 ENSG00000226824.5 RP4-756H11.3 -5.63 3.12e-08 1.13e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66398480 chr7:66654538~66669855:+ LUSC cis rs2243480 0.901 rs778693 ENSG00000226824.5 RP4-756H11.3 -5.63 3.12e-08 1.13e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66407358 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs778691 ENSG00000226824.5 RP4-756H11.3 -5.63 3.12e-08 1.13e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66408105 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs13235972 ENSG00000226824.5 RP4-756H11.3 -5.63 3.12e-08 1.13e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66418618 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs34192067 ENSG00000226824.5 RP4-756H11.3 -5.63 3.12e-08 1.13e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66422670 chr7:66654538~66669855:+ LUSC cis rs2243480 0.901 rs34807232 ENSG00000226824.5 RP4-756H11.3 -5.63 3.12e-08 1.13e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66500146 chr7:66654538~66669855:+ LUSC cis rs11098499 0.954 rs4309825 ENSG00000248280.1 RP11-33B1.2 -5.63 3.12e-08 1.13e-05 -0.29 -0.25 Corneal astigmatism; chr4:119393726 chr4:119440561~119450157:- LUSC cis rs2742234 0.541 rs10793426 ENSG00000273008.1 RP11-351D16.3 5.63 3.13e-08 1.13e-05 0.29 0.25 Hirschsprung disease; chr10:43249832 chr10:43136824~43138334:- LUSC cis rs13113518 1 rs4864993 ENSG00000249700.7 SRD5A3-AS1 5.63 3.13e-08 1.13e-05 0.29 0.25 Height; chr4:55450662 chr4:55363971~55395847:- LUSC cis rs988913 0.706 rs4715489 ENSG00000224984.1 RP11-524H19.2 5.63 3.13e-08 1.13e-05 0.27 0.25 Menarche (age at onset); chr6:54868167 chr6:54840118~54840855:- LUSC cis rs2134046 0.555 rs11854483 ENSG00000255769.6 GOLGA2P10 -5.63 3.13e-08 1.13e-05 -0.3 -0.25 Cognitive ability; chr15:82267217 chr15:82472993~82513950:- LUSC cis rs75920871 0.528 rs7109649 ENSG00000254851.1 RP11-109L13.1 5.63 3.14e-08 1.13e-05 0.34 0.25 Subjective well-being; chr11:117072828 chr11:117135528~117138582:+ LUSC cis rs75920871 0.528 rs1531706 ENSG00000254851.1 RP11-109L13.1 5.63 3.14e-08 1.13e-05 0.34 0.25 Subjective well-being; chr11:117073236 chr11:117135528~117138582:+ LUSC cis rs13113518 1 rs13114841 ENSG00000249700.7 SRD5A3-AS1 5.63 3.14e-08 1.13e-05 0.29 0.25 Height; chr4:55485974 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs939823 ENSG00000249700.7 SRD5A3-AS1 5.63 3.14e-08 1.13e-05 0.29 0.25 Height; chr4:55487368 chr4:55363971~55395847:- LUSC cis rs11723261 0.582 rs6599293 ENSG00000275426.1 CH17-262A2.1 5.63 3.14e-08 1.13e-05 0.39 0.25 Immune response to smallpox vaccine (IL-6); chr4:139246 chr4:149738~150317:+ LUSC cis rs459571 0.92 rs433402 ENSG00000235106.7 LINC00094 5.63 3.14e-08 1.13e-05 0.29 0.25 Platelet distribution width; chr9:134033505 chr9:134025439~134034666:+ LUSC cis rs2562456 0.724 rs58001930 ENSG00000268081.1 RP11-678G14.2 5.63 3.14e-08 1.13e-05 0.36 0.25 Pain; chr19:21560061 chr19:21554640~21569237:- LUSC cis rs496547 0.719 rs476246 ENSG00000278376.1 RP11-158I9.8 5.63 3.15e-08 1.14e-05 0.23 0.25 Hip minimal joint space width; chr11:118747211 chr11:118791254~118793137:+ LUSC cis rs801193 1 rs2707845 ENSG00000237310.1 GS1-124K5.4 5.63 3.15e-08 1.14e-05 0.25 0.25 Aortic root size; chr7:66733811 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs2707850 ENSG00000237310.1 GS1-124K5.4 5.63 3.15e-08 1.14e-05 0.25 0.25 Aortic root size; chr7:66738883 chr7:66493706~66495474:+ LUSC cis rs801193 0.967 rs1110414 ENSG00000237310.1 GS1-124K5.4 5.63 3.15e-08 1.14e-05 0.25 0.25 Aortic root size; chr7:66740595 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs7783924 ENSG00000237310.1 GS1-124K5.4 5.63 3.15e-08 1.14e-05 0.25 0.25 Aortic root size; chr7:66744070 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs7789184 ENSG00000237310.1 GS1-124K5.4 5.63 3.15e-08 1.14e-05 0.25 0.25 Aortic root size; chr7:66745208 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs2707854 ENSG00000237310.1 GS1-124K5.4 5.63 3.15e-08 1.14e-05 0.25 0.25 Aortic root size; chr7:66747610 chr7:66493706~66495474:+ LUSC cis rs2243480 0.901 rs35823062 ENSG00000226824.5 RP4-756H11.3 -5.63 3.15e-08 1.14e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66500834 chr7:66654538~66669855:+ LUSC cis rs732716 0.785 rs62130978 ENSG00000267769.1 CTB-50L17.9 -5.63 3.15e-08 1.14e-05 -0.3 -0.25 Mean corpuscular volume; chr19:4429010 chr19:4454014~4455286:+ LUSC cis rs853679 1 rs1936365 ENSG00000204709.4 LINC01556 -5.63 3.15e-08 1.14e-05 -0.39 -0.25 Depression; chr6:28300675 chr6:28943877~28944537:+ LUSC cis rs7772486 0.875 rs969694 ENSG00000235652.6 RP11-545I5.3 5.63 3.15e-08 1.14e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:146073519 chr6:145799409~145886585:+ LUSC cis rs66887589 0.967 rs3775842 ENSG00000249244.1 RP11-548H18.2 5.63 3.16e-08 1.14e-05 0.3 0.25 Diastolic blood pressure; chr4:119506577 chr4:119391831~119395335:- LUSC cis rs2439831 0.85 rs28524541 ENSG00000249839.1 AC011330.5 -5.63 3.16e-08 1.14e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43832633 chr15:43663654~43684339:- LUSC cis rs75920871 0.512 rs6589583 ENSG00000254851.1 RP11-109L13.1 5.63 3.16e-08 1.14e-05 0.35 0.25 Subjective well-being; chr11:116993050 chr11:117135528~117138582:+ LUSC cis rs17711722 0.727 rs2658585 ENSG00000179406.6 LINC00174 -5.63 3.16e-08 1.14e-05 -0.27 -0.25 Calcium levels; chr7:65996954 chr7:66376044~66401338:- LUSC cis rs7772486 0.817 rs2748491 ENSG00000235652.6 RP11-545I5.3 5.63 3.16e-08 1.14e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:146006623 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs2777483 ENSG00000235652.6 RP11-545I5.3 5.63 3.16e-08 1.14e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:146008099 chr6:145799409~145886585:+ LUSC cis rs875971 0.545 rs4718325 ENSG00000224316.1 RP11-479O9.2 5.63 3.16e-08 1.14e-05 0.27 0.25 Aortic root size; chr7:66215323 chr7:65773620~65802067:+ LUSC cis rs801193 1 rs2707845 ENSG00000222364.1 RNU6-96P -5.63 3.17e-08 1.14e-05 -0.29 -0.25 Aortic root size; chr7:66733811 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs2707850 ENSG00000222364.1 RNU6-96P -5.63 3.17e-08 1.14e-05 -0.29 -0.25 Aortic root size; chr7:66738883 chr7:66395191~66395286:+ LUSC cis rs801193 0.967 rs1110414 ENSG00000222364.1 RNU6-96P -5.63 3.17e-08 1.14e-05 -0.29 -0.25 Aortic root size; chr7:66740595 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs7783924 ENSG00000222364.1 RNU6-96P -5.63 3.17e-08 1.14e-05 -0.29 -0.25 Aortic root size; chr7:66744070 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs7789184 ENSG00000222364.1 RNU6-96P -5.63 3.17e-08 1.14e-05 -0.29 -0.25 Aortic root size; chr7:66745208 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs2707854 ENSG00000222364.1 RNU6-96P -5.63 3.17e-08 1.14e-05 -0.29 -0.25 Aortic root size; chr7:66747610 chr7:66395191~66395286:+ LUSC cis rs2742234 0.541 rs10899786 ENSG00000273008.1 RP11-351D16.3 5.63 3.17e-08 1.14e-05 0.29 0.25 Hirschsprung disease; chr10:43249135 chr10:43136824~43138334:- LUSC cis rs10027350 0.927 rs1035091 ENSG00000281501.1 SEPSECS-AS1 5.63 3.17e-08 1.14e-05 0.29 0.25 Childhood ear infection; chr4:25150252 chr4:25160641~25201440:+ LUSC cis rs673078 0.615 rs61943528 ENSG00000275759.1 RP11-131L12.3 -5.63 3.17e-08 1.14e-05 -0.38 -0.25 Glucose homeostasis traits; chr12:118163134 chr12:118428281~118428870:+ LUSC cis rs442309 0.875 rs224062 ENSG00000238280.1 RP11-436D10.3 -5.63 3.18e-08 1.15e-05 -0.32 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62743036 chr10:62793562~62805887:- LUSC cis rs2439831 0.85 rs3742982 ENSG00000249839.1 AC011330.5 -5.63 3.18e-08 1.15e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43884483 chr15:43663654~43684339:- LUSC cis rs6565180 1 rs11646130 ENSG00000183604.13 SMG1P5 -5.63 3.18e-08 1.15e-05 -0.31 -0.25 Tonsillectomy; chr16:30365638 chr16:30267553~30335374:- LUSC cis rs11690935 0.788 rs10201053 ENSG00000228389.1 AC068039.4 5.63 3.18e-08 1.15e-05 0.29 0.25 Schizophrenia; chr2:172024653 chr2:171773482~171775844:+ LUSC cis rs11673344 0.642 rs55926714 ENSG00000226686.6 LINC01535 5.63 3.19e-08 1.15e-05 0.32 0.25 Obesity-related traits; chr19:37307974 chr19:37251912~37265535:+ LUSC cis rs2280018 0.526 rs2941257 ENSG00000188599.16 NPIPP1 -5.63 3.19e-08 1.15e-05 -0.25 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15072588 chr16:15104312~15123498:- LUSC cis rs2303759 0.83 rs7257053 ENSG00000268686.1 AC010524.2 -5.63 3.19e-08 1.15e-05 -0.35 -0.25 Multiple sclerosis; chr19:49391199 chr19:49368705~49388081:- LUSC cis rs875971 0.545 rs17138149 ENSG00000224316.1 RP11-479O9.2 5.63 3.19e-08 1.15e-05 0.27 0.25 Aortic root size; chr7:66228193 chr7:65773620~65802067:+ LUSC cis rs950169 0.922 rs11633075 ENSG00000259295.5 CSPG4P12 5.63 3.19e-08 1.15e-05 0.33 0.25 Schizophrenia; chr15:84570741 chr15:85191438~85213905:+ LUSC cis rs17270561 0.636 rs9379782 ENSG00000272462.2 U91328.19 -5.63 3.19e-08 1.15e-05 -0.3 -0.25 Iron status biomarkers; chr6:25714795 chr6:25992662~26001775:+ LUSC cis rs2274273 0.773 rs10147765 ENSG00000258413.1 RP11-665C16.6 -5.62 3.19e-08 1.15e-05 -0.31 -0.25 Protein biomarker; chr14:55361108 chr14:55262767~55272075:- LUSC cis rs910316 0.763 rs1548807 ENSG00000279594.1 RP11-950C14.10 5.62 3.19e-08 1.15e-05 0.29 0.25 Height; chr14:75012879 chr14:75011269~75012851:- LUSC cis rs801193 0.935 rs2659899 ENSG00000237310.1 GS1-124K5.4 5.62 3.19e-08 1.15e-05 0.25 0.25 Aortic root size; chr7:66721734 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs1553609 ENSG00000237310.1 GS1-124K5.4 5.62 3.19e-08 1.15e-05 0.25 0.25 Aortic root size; chr7:66732152 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs1553610 ENSG00000237310.1 GS1-124K5.4 5.62 3.19e-08 1.15e-05 0.25 0.25 Aortic root size; chr7:66732246 chr7:66493706~66495474:+ LUSC cis rs72627123 0.737 rs2240632 ENSG00000259065.1 RP5-1021I20.1 -5.62 3.19e-08 1.15e-05 -0.44 -0.25 Morning vs. evening chronotype; chr14:73904463 chr14:73787360~73803270:+ LUSC cis rs72627123 1 rs72627129 ENSG00000259065.1 RP5-1021I20.1 -5.62 3.19e-08 1.15e-05 -0.44 -0.25 Morning vs. evening chronotype; chr14:73908102 chr14:73787360~73803270:+ LUSC cis rs72627123 1 rs72627130 ENSG00000259065.1 RP5-1021I20.1 -5.62 3.19e-08 1.15e-05 -0.44 -0.25 Morning vs. evening chronotype; chr14:73908194 chr14:73787360~73803270:+ LUSC cis rs16843372 0.599 rs2138386 ENSG00000251491.2 OR7E28P -5.62 3.2e-08 1.15e-05 -0.28 -0.25 Obesity-related traits; chr2:158827374 chr2:158862311~158863285:+ LUSC cis rs1387259 0.723 rs2732488 ENSG00000226413.2 OR8T1P 5.62 3.2e-08 1.15e-05 0.32 0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48377661 chr12:48442030~48442947:- LUSC cis rs1387259 0.758 rs2634670 ENSG00000226413.2 OR8T1P 5.62 3.2e-08 1.15e-05 0.32 0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48378094 chr12:48442030~48442947:- LUSC cis rs6504950 0.889 rs2628296 ENSG00000275710.1 RP11-257O5.4 -5.62 3.2e-08 1.15e-05 -0.3 -0.25 Breast cancer; chr17:55089134 chr17:54964474~54964679:+ LUSC cis rs9487051 0.872 rs9400269 ENSG00000219700.1 PTCHD3P3 5.62 3.2e-08 1.15e-05 0.27 0.25 Reticulocyte fraction of red cells; chr6:109284862 chr6:109288571~109290503:- LUSC cis rs2243480 1 rs1723270 ENSG00000226824.5 RP4-756H11.3 -5.62 3.2e-08 1.15e-05 -0.49 -0.25 Diabetic kidney disease; chr7:66004843 chr7:66654538~66669855:+ LUSC cis rs8059260 0.604 rs12929596 ENSG00000274038.1 RP11-66H6.4 -5.62 3.2e-08 1.15e-05 -0.44 -0.25 Alcohol consumption over the past year; chr16:11105495 chr16:11056556~11057034:+ LUSC cis rs7267979 0.932 rs2260997 ENSG00000274973.1 RP13-401N8.7 5.62 3.21e-08 1.15e-05 0.25 0.25 Liver enzyme levels (alkaline phosphatase); chr20:25275630 chr20:25845497~25845862:+ LUSC cis rs7555523 0.887 rs2790053 ENSG00000224358.1 RP11-466F5.8 -5.62 3.21e-08 1.16e-05 -0.32 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165768467 chr1:165768929~165775176:+ LUSC cis rs7555523 0.778 rs2790052 ENSG00000224358.1 RP11-466F5.8 -5.62 3.21e-08 1.16e-05 -0.32 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165769226 chr1:165768929~165775176:+ LUSC cis rs11159086 0.793 rs11621693 ENSG00000259005.1 RP3-449M8.6 5.62 3.21e-08 1.16e-05 0.38 0.25 Advanced glycation end-product levels; chr14:74472631 chr14:74474007~74474864:- LUSC cis rs6951245 0.678 rs28600085 ENSG00000224079.1 AC091729.7 -5.62 3.21e-08 1.16e-05 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1130000 chr7:1074450~1078036:+ LUSC cis rs853679 0.55 rs1233701 ENSG00000280107.1 AL022393.9 5.62 3.22e-08 1.16e-05 0.3 0.25 Depression; chr6:28200948 chr6:28170845~28172521:+ LUSC cis rs11098499 0.691 rs9995716 ENSG00000249244.1 RP11-548H18.2 5.62 3.22e-08 1.16e-05 0.31 0.25 Corneal astigmatism; chr4:119343841 chr4:119391831~119395335:- LUSC cis rs61270009 0.955 rs34148755 ENSG00000247828.6 TMEM161B-AS1 5.62 3.22e-08 1.16e-05 0.3 0.25 Depressive symptoms; chr5:88394130 chr5:88268895~88436685:+ LUSC cis rs7665090 1 rs3733202 ENSG00000230069.3 LRRC37A15P -5.62 3.23e-08 1.16e-05 -0.26 -0.25 Primary biliary cholangitis; chr4:102635704 chr4:102727274~102730721:- LUSC cis rs77204473 0.744 rs117901629 ENSG00000254851.1 RP11-109L13.1 5.62 3.23e-08 1.16e-05 0.65 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117008963 chr11:117135528~117138582:+ LUSC cis rs8005677 0.828 rs3794452 ENSG00000279656.1 RP11-298I3.6 5.62 3.23e-08 1.16e-05 0.3 0.25 Cognitive ability (multi-trait analysis); chr14:22917473 chr14:23023083~23024217:- LUSC cis rs8005677 0.828 rs4981450 ENSG00000279656.1 RP11-298I3.6 5.62 3.23e-08 1.16e-05 0.3 0.25 Cognitive ability (multi-trait analysis); chr14:22920095 chr14:23023083~23024217:- LUSC cis rs950169 0.649 rs12911612 ENSG00000259728.4 LINC00933 5.62 3.23e-08 1.16e-05 0.35 0.25 Schizophrenia; chr15:84022262 chr15:84570649~84580175:+ LUSC cis rs950169 0.649 rs12905952 ENSG00000259728.4 LINC00933 5.62 3.23e-08 1.16e-05 0.35 0.25 Schizophrenia; chr15:84022509 chr15:84570649~84580175:+ LUSC cis rs950169 0.61 rs34529571 ENSG00000259728.4 LINC00933 5.62 3.23e-08 1.16e-05 0.35 0.25 Schizophrenia; chr15:84023055 chr15:84570649~84580175:+ LUSC cis rs5753618 0.561 rs4820043 ENSG00000236132.1 CTA-440B3.1 5.62 3.23e-08 1.16e-05 0.34 0.25 Colorectal cancer; chr22:31251108 chr22:31816379~31817491:- LUSC cis rs2842992 0.83 rs1475123 ENSG00000237927.1 RP3-393E18.2 -5.62 3.23e-08 1.16e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159756975 chr6:159586955~159589169:- LUSC cis rs950169 0.922 rs11635505 ENSG00000259295.5 CSPG4P12 -5.62 3.24e-08 1.16e-05 -0.32 -0.25 Schizophrenia; chr15:84553803 chr15:85191438~85213905:+ LUSC cis rs7739264 0.591 rs9366312 ENSG00000237404.1 RP3-471C18.2 5.62 3.24e-08 1.17e-05 0.28 0.25 Endometriosis; chr6:19708250 chr6:19689825~19753113:- LUSC cis rs66887589 0.627 rs3872807 ENSG00000248280.1 RP11-33B1.2 5.62 3.24e-08 1.17e-05 0.28 0.25 Diastolic blood pressure; chr4:119439096 chr4:119440561~119450157:- LUSC cis rs875971 0.638 rs7793569 ENSG00000222364.1 RNU6-96P 5.62 3.24e-08 1.17e-05 0.29 0.25 Aortic root size; chr7:66651646 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs6975195 ENSG00000222364.1 RNU6-96P 5.62 3.24e-08 1.17e-05 0.29 0.25 Aortic root size; chr7:66659787 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs3857688 ENSG00000222364.1 RNU6-96P 5.62 3.24e-08 1.17e-05 0.29 0.25 Aortic root size; chr7:66662819 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs2286684 ENSG00000222364.1 RNU6-96P 5.62 3.24e-08 1.17e-05 0.29 0.25 Aortic root size; chr7:66664843 chr7:66395191~66395286:+ LUSC cis rs801193 0.935 rs2286683 ENSG00000222364.1 RNU6-96P 5.62 3.24e-08 1.17e-05 0.29 0.25 Aortic root size; chr7:66664856 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs10274773 ENSG00000222364.1 RNU6-96P 5.62 3.24e-08 1.17e-05 0.29 0.25 Aortic root size; chr7:66668591 chr7:66395191~66395286:+ LUSC cis rs11098499 0.954 rs12505469 ENSG00000248280.1 RP11-33B1.2 5.62 3.25e-08 1.17e-05 0.3 0.25 Corneal astigmatism; chr4:119328430 chr4:119440561~119450157:- LUSC cis rs4237845 0.788 rs6581157 ENSG00000257159.1 RP11-58A17.3 5.62 3.25e-08 1.17e-05 0.31 0.25 Intelligence (multi-trait analysis); chr12:57895010 chr12:57967058~57968399:+ LUSC cis rs9640161 0.742 rs2159235 ENSG00000261305.1 RP4-584D14.7 5.62 3.25e-08 1.17e-05 0.34 0.25 Blood protein levels;Circulating chemerin levels; chr7:150320139 chr7:150341771~150342607:+ LUSC cis rs7804306 0.826 rs67343471 ENSG00000233264.2 AC006042.8 5.62 3.25e-08 1.17e-05 0.48 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7979532 chr7:7980312~7982228:+ LUSC cis rs2337406 0.866 rs4280141 ENSG00000280411.1 IGHV1-69-2 5.62 3.25e-08 1.17e-05 0.21 0.25 Alzheimer's disease (late onset); chr14:106780476 chr14:106762092~106762588:- LUSC cis rs2903698 0.651 rs9998576 ENSG00000250735.4 RP11-567N4.3 5.62 3.25e-08 1.17e-05 0.29 0.25 Prion diseases; chr4:75473655 chr4:75401195~75423023:+ LUSC cis rs16843372 0.562 rs28523325 ENSG00000251491.2 OR7E28P -5.62 3.26e-08 1.17e-05 -0.28 -0.25 Obesity-related traits; chr2:158820839 chr2:158862311~158863285:+ LUSC cis rs2739330 0.731 rs5751792 ENSG00000228039.3 KB-1125A3.10 5.62 3.26e-08 1.17e-05 0.31 0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23963780~23964374:+ LUSC cis rs801193 1 rs2659906 ENSG00000222364.1 RNU6-96P -5.62 3.26e-08 1.17e-05 -0.29 -0.25 Aortic root size; chr7:66700323 chr7:66395191~66395286:+ LUSC cis rs875971 0.862 rs13226170 ENSG00000179406.6 LINC00174 -5.62 3.26e-08 1.17e-05 -0.27 -0.25 Aortic root size; chr7:66534311 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs2420611 ENSG00000179406.6 LINC00174 -5.62 3.26e-08 1.17e-05 -0.27 -0.25 Aortic root size; chr7:66534333 chr7:66376044~66401338:- LUSC cis rs4237845 0.735 rs11172375 ENSG00000257159.1 RP11-58A17.3 5.62 3.26e-08 1.17e-05 0.31 0.25 Intelligence (multi-trait analysis); chr12:57897791 chr12:57967058~57968399:+ LUSC cis rs16843372 0.563 rs13403565 ENSG00000251491.2 OR7E28P -5.62 3.26e-08 1.17e-05 -0.27 -0.25 Obesity-related traits; chr2:158827692 chr2:158862311~158863285:+ LUSC cis rs9545047 0.519 rs8001281 ENSG00000227676.3 LINC01068 5.62 3.26e-08 1.17e-05 0.31 0.25 Schizophrenia; chr13:79410707 chr13:79566727~79571436:+ LUSC cis rs6918586 0.658 rs198819 ENSG00000272462.2 U91328.19 -5.62 3.26e-08 1.17e-05 -0.26 -0.25 Schizophrenia; chr6:26124202 chr6:25992662~26001775:+ LUSC cis rs11159086 0.793 rs12432412 ENSG00000270000.1 RP3-449M8.9 5.62 3.27e-08 1.18e-05 0.38 0.25 Advanced glycation end-product levels; chr14:74474294 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs1029700 ENSG00000270000.1 RP3-449M8.9 5.62 3.27e-08 1.18e-05 0.38 0.25 Advanced glycation end-product levels; chr14:74474309 chr14:74471930~74472360:- LUSC cis rs11159086 0.793 rs1029699 ENSG00000270000.1 RP3-449M8.9 5.62 3.27e-08 1.18e-05 0.38 0.25 Advanced glycation end-product levels; chr14:74474790 chr14:74471930~74472360:- LUSC cis rs2742234 0.59 rs2505557 ENSG00000273008.1 RP11-351D16.3 -5.62 3.27e-08 1.18e-05 -0.29 -0.25 Hirschsprung disease; chr10:43170568 chr10:43136824~43138334:- LUSC cis rs950169 0.922 rs11630760 ENSG00000259295.5 CSPG4P12 5.62 3.27e-08 1.18e-05 0.33 0.25 Schizophrenia; chr15:84570106 chr15:85191438~85213905:+ LUSC cis rs950169 0.887 rs71395453 ENSG00000259295.5 CSPG4P12 5.62 3.27e-08 1.18e-05 0.33 0.25 Schizophrenia; chr15:84570259 chr15:85191438~85213905:+ LUSC cis rs801193 1 rs62466793 ENSG00000237310.1 GS1-124K5.4 5.62 3.27e-08 1.18e-05 0.25 0.25 Aortic root size; chr7:66726530 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs62466794 ENSG00000237310.1 GS1-124K5.4 5.62 3.27e-08 1.18e-05 0.25 0.25 Aortic root size; chr7:66726592 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs6460281 ENSG00000179406.6 LINC00174 -5.62 3.28e-08 1.18e-05 -0.3 -0.25 Aortic root size; chr7:66216128 chr7:66376044~66401338:- LUSC cis rs17826219 0.636 rs12946563 ENSG00000263603.1 CTD-2349P21.5 -5.62 3.28e-08 1.18e-05 -0.35 -0.25 Body mass index; chr17:30776148 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs8068645 ENSG00000263603.1 CTD-2349P21.5 -5.62 3.28e-08 1.18e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777324 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs55811708 ENSG00000263603.1 CTD-2349P21.5 -5.62 3.28e-08 1.18e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777713 chr17:30729469~30731202:+ LUSC cis rs2337406 0.866 rs78462736 ENSG00000280411.1 IGHV1-69-2 -5.62 3.28e-08 1.18e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106779942 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs8016203 ENSG00000280411.1 IGHV1-69-2 -5.62 3.28e-08 1.18e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106780575 chr14:106762092~106762588:- LUSC cis rs17711722 0.701 rs781145 ENSG00000222364.1 RNU6-96P -5.62 3.28e-08 1.18e-05 -0.29 -0.25 Calcium levels; chr7:65975383 chr7:66395191~66395286:+ LUSC cis rs6502050 0.835 rs8077772 ENSG00000266654.1 RP11-1376P16.1 5.62 3.29e-08 1.18e-05 0.25 0.25 Life satisfaction; chr17:82159344 chr17:82160056~82160452:+ LUSC cis rs853679 1 rs1679709 ENSG00000219392.1 RP1-265C24.5 5.62 3.29e-08 1.18e-05 0.41 0.25 Depression; chr6:28260564 chr6:28115628~28116551:+ LUSC cis rs7674212 0.507 rs223317 ENSG00000246560.2 RP11-10L12.4 5.62 3.29e-08 1.18e-05 0.32 0.25 Type 2 diabetes; chr4:102881667 chr4:102828055~102844075:+ LUSC cis rs2742234 0.541 rs11238479 ENSG00000273008.1 RP11-351D16.3 5.62 3.29e-08 1.18e-05 0.29 0.25 Hirschsprung disease; chr10:43221975 chr10:43136824~43138334:- LUSC cis rs801193 0.66 rs4610622 ENSG00000179406.6 LINC00174 -5.62 3.29e-08 1.18e-05 -0.27 -0.25 Aortic root size; chr7:66759510 chr7:66376044~66401338:- LUSC cis rs1008375 0.966 rs2286773 ENSG00000249502.1 AC006160.5 -5.62 3.29e-08 1.18e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17614591 chr4:17587467~17614571:- LUSC cis rs77204473 0.744 rs11216270 ENSG00000254851.1 RP11-109L13.1 5.62 3.29e-08 1.18e-05 0.61 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117082928 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs2368149 ENSG00000254851.1 RP11-109L13.1 5.62 3.29e-08 1.18e-05 0.61 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117085218 chr11:117135528~117138582:+ LUSC cis rs950169 0.881 rs4842852 ENSG00000259295.5 CSPG4P12 5.62 3.29e-08 1.18e-05 0.34 0.25 Schizophrenia; chr15:84387263 chr15:85191438~85213905:+ LUSC cis rs950169 0.84 rs4842853 ENSG00000259295.5 CSPG4P12 5.62 3.29e-08 1.18e-05 0.34 0.25 Schizophrenia; chr15:84387606 chr15:85191438~85213905:+ LUSC cis rs950169 0.922 rs4842946 ENSG00000259295.5 CSPG4P12 5.62 3.29e-08 1.18e-05 0.34 0.25 Schizophrenia; chr15:84387633 chr15:85191438~85213905:+ LUSC cis rs950169 0.84 rs4842854 ENSG00000259295.5 CSPG4P12 5.62 3.29e-08 1.18e-05 0.34 0.25 Schizophrenia; chr15:84387641 chr15:85191438~85213905:+ LUSC cis rs950169 0.84 rs2896002 ENSG00000259295.5 CSPG4P12 5.62 3.29e-08 1.18e-05 0.34 0.25 Schizophrenia; chr15:84390423 chr15:85191438~85213905:+ LUSC cis rs950169 0.887 rs3860265 ENSG00000259295.5 CSPG4P12 5.62 3.29e-08 1.18e-05 0.34 0.25 Schizophrenia; chr15:84390487 chr15:85191438~85213905:+ LUSC cis rs950169 0.724 rs11632668 ENSG00000259295.5 CSPG4P12 5.62 3.29e-08 1.18e-05 0.34 0.25 Schizophrenia; chr15:84393989 chr15:85191438~85213905:+ LUSC cis rs950169 0.881 rs34591918 ENSG00000259295.5 CSPG4P12 5.62 3.29e-08 1.18e-05 0.34 0.25 Schizophrenia; chr15:84396135 chr15:85191438~85213905:+ LUSC cis rs6570726 0.791 rs7765687 ENSG00000235652.6 RP11-545I5.3 5.62 3.3e-08 1.18e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145593964 chr6:145799409~145886585:+ LUSC cis rs11098499 0.863 rs1383532 ENSG00000248280.1 RP11-33B1.2 -5.62 3.3e-08 1.18e-05 -0.3 -0.25 Corneal astigmatism; chr4:119513249 chr4:119440561~119450157:- LUSC cis rs2439831 0.85 rs7181039 ENSG00000249839.1 AC011330.5 -5.62 3.3e-08 1.19e-05 -0.52 -0.25 Lung cancer in ever smokers; chr15:43886914 chr15:43663654~43684339:- LUSC cis rs442309 0.875 rs224068 ENSG00000238280.1 RP11-436D10.3 -5.62 3.3e-08 1.19e-05 -0.31 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62748340 chr10:62793562~62805887:- LUSC cis rs2243480 0.803 rs423187 ENSG00000226824.5 RP4-756H11.3 -5.62 3.3e-08 1.19e-05 -0.5 -0.25 Diabetic kidney disease; chr7:66044512 chr7:66654538~66669855:+ LUSC cis rs34792 0.554 rs12919246 ENSG00000207425.1 Y_RNA -5.62 3.3e-08 1.19e-05 -0.35 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15533103 chr16:14915457~14915556:- LUSC cis rs6504622 0.818 rs9898527 ENSG00000262879.4 RP11-156P1.3 5.62 3.3e-08 1.19e-05 0.26 0.25 Orofacial clefts; chr17:46958844 chr17:46984045~47100323:- LUSC cis rs6504622 0.791 rs61671555 ENSG00000262879.4 RP11-156P1.3 5.62 3.3e-08 1.19e-05 0.26 0.25 Orofacial clefts; chr17:46960491 chr17:46984045~47100323:- LUSC cis rs13434995 0.513 rs2412658 ENSG00000249700.7 SRD5A3-AS1 5.62 3.3e-08 1.19e-05 0.32 0.25 Adiponectin levels; chr4:55577050 chr4:55363971~55395847:- LUSC cis rs28830936 0.966 rs28680296 ENSG00000250379.1 RP11-23P13.4 5.62 3.31e-08 1.19e-05 0.27 0.25 Diastolic blood pressure; chr15:41829340 chr15:41825099~41827936:- LUSC cis rs75422866 0.51 rs73105803 ENSG00000276691.1 RP5-1057I20.5 5.62 3.31e-08 1.19e-05 0.43 0.25 Pneumonia; chr12:47722135 chr12:47788426~47788971:+ LUSC cis rs75422866 0.51 rs73105812 ENSG00000276691.1 RP5-1057I20.5 5.62 3.31e-08 1.19e-05 0.43 0.25 Pneumonia; chr12:47724404 chr12:47788426~47788971:+ LUSC cis rs853679 0.517 rs1340004 ENSG00000280107.1 AL022393.9 -5.62 3.31e-08 1.19e-05 -0.32 -0.25 Depression; chr6:28135913 chr6:28170845~28172521:+ LUSC cis rs10759883 0.627 rs689986 ENSG00000175611.10 LINC00476 5.62 3.31e-08 1.19e-05 0.3 0.25 Nicotine dependence; chr9:95866867 chr9:95759231~95875977:- LUSC cis rs8005677 0.828 rs12437151 ENSG00000279656.1 RP11-298I3.6 5.62 3.32e-08 1.19e-05 0.3 0.25 Cognitive ability (multi-trait analysis); chr14:22903704 chr14:23023083~23024217:- LUSC cis rs75920871 0.528 rs11216244 ENSG00000254851.1 RP11-109L13.1 5.62 3.32e-08 1.19e-05 0.34 0.25 Subjective well-being; chr11:117042014 chr11:117135528~117138582:+ LUSC cis rs2337406 0.866 rs4774019 ENSG00000280411.1 IGHV1-69-2 -5.62 3.32e-08 1.19e-05 -0.23 -0.25 Alzheimer's disease (late onset); chr14:106805386 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs58850145 ENSG00000280411.1 IGHV1-69-2 -5.62 3.32e-08 1.19e-05 -0.23 -0.25 Alzheimer's disease (late onset); chr14:106806185 chr14:106762092~106762588:- LUSC cis rs62432291 0.681 rs378547 ENSG00000235086.1 FNDC1-IT1 5.62 3.33e-08 1.19e-05 0.43 0.25 Joint mobility (Beighton score); chr6:159241493 chr6:159240786~159243329:+ LUSC cis rs11089937 0.667 rs10483107 ENSG00000211638.2 IGLV8-61 -5.62 3.33e-08 1.2e-05 -0.27 -0.25 Periodontitis (PAL4Q3); chr22:22151036 chr22:22098700~22099212:+ LUSC cis rs11089937 0.667 rs11704024 ENSG00000211638.2 IGLV8-61 -5.62 3.33e-08 1.2e-05 -0.27 -0.25 Periodontitis (PAL4Q3); chr22:22151195 chr22:22098700~22099212:+ LUSC cis rs2404602 1 rs6495206 ENSG00000259422.1 RP11-593F23.1 5.62 3.33e-08 1.2e-05 0.28 0.25 Blood metabolite levels; chr15:76578622 chr15:76174891~76181486:- LUSC cis rs2404602 1 rs1117367 ENSG00000259422.1 RP11-593F23.1 5.62 3.33e-08 1.2e-05 0.28 0.25 Blood metabolite levels; chr15:76579989 chr15:76174891~76181486:- LUSC cis rs3738443 1 rs61839991 ENSG00000259865.1 RP11-488L18.10 5.62 3.33e-08 1.2e-05 0.28 0.25 Alcohol dependence; chr1:247186284 chr1:247187281~247188526:- LUSC cis rs3738443 0.953 rs56065612 ENSG00000259865.1 RP11-488L18.10 5.62 3.33e-08 1.2e-05 0.28 0.25 Alcohol dependence; chr1:247194812 chr1:247187281~247188526:- LUSC cis rs1008375 0.686 rs34338142 ENSG00000249502.1 AC006160.5 -5.62 3.34e-08 1.2e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17624551 chr4:17587467~17614571:- LUSC cis rs910316 1 rs3742780 ENSG00000279594.1 RP11-950C14.10 5.62 3.34e-08 1.2e-05 0.29 0.25 Height; chr14:75038305 chr14:75011269~75012851:- LUSC cis rs910316 1 rs10140851 ENSG00000279594.1 RP11-950C14.10 5.62 3.34e-08 1.2e-05 0.29 0.25 Height; chr14:75045909 chr14:75011269~75012851:- LUSC cis rs9311474 0.713 rs352166 ENSG00000243224.1 RP5-1157M23.2 -5.62 3.35e-08 1.2e-05 -0.24 -0.25 Electroencephalogram traits; chr3:52204661 chr3:52239258~52241097:+ LUSC cis rs11098499 0.909 rs79026312 ENSG00000248280.1 RP11-33B1.2 5.62 3.35e-08 1.2e-05 0.31 0.25 Corneal astigmatism; chr4:119519522 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs35111518 ENSG00000248280.1 RP11-33B1.2 5.62 3.35e-08 1.2e-05 0.31 0.25 Corneal astigmatism; chr4:119519527 chr4:119440561~119450157:- LUSC cis rs442309 0.807 rs224029 ENSG00000238280.1 RP11-436D10.3 -5.62 3.35e-08 1.2e-05 -0.31 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62759539 chr10:62793562~62805887:- LUSC cis rs17772222 0.74 rs10150986 ENSG00000258789.1 RP11-507K2.3 -5.62 3.36e-08 1.2e-05 -0.28 -0.25 Coronary artery calcification; chr14:88517326 chr14:88551597~88552493:+ LUSC cis rs4722166 0.63 rs12537614 ENSG00000179428.2 AC073072.5 -5.62 3.36e-08 1.2e-05 -0.3 -0.25 Lung cancer; chr7:22749932 chr7:22725395~22727620:- LUSC cis rs9341808 0.667 rs7745301 ENSG00000272129.1 RP11-250B2.6 5.62 3.37e-08 1.21e-05 0.31 0.25 Sitting height ratio; chr6:80212844 chr6:80355424~80356859:+ LUSC cis rs2834288 0.7 rs2834292 ENSG00000273102.1 AP000569.9 -5.61 3.37e-08 1.21e-05 -0.29 -0.25 Gut microbiota (bacterial taxa); chr21:33901909 chr21:33967101~33968573:- LUSC cis rs2439831 0.571 rs689883 ENSG00000249839.1 AC011330.5 -5.61 3.37e-08 1.21e-05 -0.47 -0.25 Lung cancer in ever smokers; chr15:43520398 chr15:43663654~43684339:- LUSC cis rs2742234 0.59 rs2257767 ENSG00000273008.1 RP11-351D16.3 -5.61 3.37e-08 1.21e-05 -0.29 -0.25 Hirschsprung disease; chr10:43162363 chr10:43136824~43138334:- LUSC cis rs67311347 1 rs73076046 ENSG00000223797.4 ENTPD3-AS1 5.61 3.37e-08 1.21e-05 0.29 0.25 Renal cell carcinoma; chr3:40406233 chr3:40313802~40453329:- LUSC cis rs198389 0.617 rs503040 ENSG00000242349.4 NPPA-AS1 -5.61 3.38e-08 1.21e-05 -0.24 -0.25 B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome; chr1:11830638 chr1:11841017~11848079:+ LUSC cis rs7429990 0.833 rs2293226 ENSG00000229759.1 MRPS18AP1 5.61 3.38e-08 1.21e-05 0.25 0.25 Educational attainment (years of education); chr3:47585292 chr3:48256350~48256938:- LUSC cis rs9813712 0.818 rs16845853 ENSG00000228252.7 COL6A4P2 5.61 3.38e-08 1.21e-05 0.25 0.25 Response to amphetamines; chr3:130229587 chr3:130212823~130273806:+ LUSC cis rs2136613 0.751 rs224310 ENSG00000238280.1 RP11-436D10.3 5.61 3.38e-08 1.21e-05 0.32 0.25 Selective IgA deficiency; chr10:62851821 chr10:62793562~62805887:- LUSC cis rs2136613 0.751 rs224311 ENSG00000238280.1 RP11-436D10.3 5.61 3.38e-08 1.21e-05 0.32 0.25 Selective IgA deficiency; chr10:62854429 chr10:62793562~62805887:- LUSC cis rs116095464 0.558 rs7714335 ENSG00000250848.1 CTD-2083E4.5 -5.61 3.38e-08 1.21e-05 -0.39 -0.25 Breast cancer; chr5:263398 chr5:288833~290321:- LUSC cis rs9910055 1 rs2071167 ENSG00000267080.4 ASB16-AS1 5.61 3.38e-08 1.21e-05 0.23 0.25 Total body bone mineral density; chr17:44210151 chr17:44175973~44186717:- LUSC cis rs1008375 0.931 rs2315558 ENSG00000249502.1 AC006160.5 -5.61 3.38e-08 1.21e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17672935 chr4:17587467~17614571:- LUSC cis rs75422866 0.51 rs74733564 ENSG00000276691.1 RP5-1057I20.5 5.61 3.39e-08 1.21e-05 0.43 0.25 Pneumonia; chr12:47724644 chr12:47788426~47788971:+ LUSC cis rs75422866 0.51 rs73105814 ENSG00000276691.1 RP5-1057I20.5 5.61 3.39e-08 1.21e-05 0.43 0.25 Pneumonia; chr12:47725817 chr12:47788426~47788971:+ LUSC cis rs2439831 0.85 rs9944216 ENSG00000249839.1 AC011330.5 5.61 3.39e-08 1.22e-05 0.52 0.25 Lung cancer in ever smokers; chr15:43868575 chr15:43663654~43684339:- LUSC cis rs853679 0.55 rs1233699 ENSG00000280107.1 AL022393.9 -5.61 3.39e-08 1.22e-05 -0.3 -0.25 Depression; chr6:28201380 chr6:28170845~28172521:+ LUSC cis rs7267979 0.903 rs6115101 ENSG00000274973.1 RP13-401N8.7 -5.61 3.4e-08 1.22e-05 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25248928 chr20:25845497~25845862:+ LUSC cis rs7267979 0.868 rs6107019 ENSG00000274973.1 RP13-401N8.7 -5.61 3.4e-08 1.22e-05 -0.26 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25253349 chr20:25845497~25845862:+ LUSC cis rs2337406 0.866 rs74092520 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106779632 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs4583128 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106780669 chr14:106122420~106122709:- LUSC cis rs2337406 0.929 rs12050200 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106780983 chr14:106122420~106122709:- LUSC cis rs2337406 0.852 rs12050239 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106781132 chr14:106122420~106122709:- LUSC cis rs2337406 0.929 rs59263250 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106781183 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs58083017 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106781256 chr14:106122420~106122709:- LUSC cis rs2337406 0.789 rs60390024 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106781327 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs74092532 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106781363 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs74092534 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106781364 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs74092535 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106781722 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs74092537 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106781883 chr14:106122420~106122709:- LUSC cis rs2337406 0.81 rs74092538 ENSG00000254174.1 IGHV1-12 5.61 3.42e-08 1.22e-05 0.23 0.25 Alzheimer's disease (late onset); chr14:106781942 chr14:106122420~106122709:- LUSC cis rs8031584 0.781 rs4779498 ENSG00000260382.1 RP11-540B6.2 5.61 3.42e-08 1.22e-05 0.33 0.25 Huntington's disease progression; chr15:30885273 chr15:30882267~30883231:- LUSC cis rs2274273 0.84 rs1045002 ENSG00000258413.1 RP11-665C16.6 -5.61 3.42e-08 1.22e-05 -0.31 -0.25 Protein biomarker; chr14:55351799 chr14:55262767~55272075:- LUSC cis rs77204473 0.744 rs116861530 ENSG00000254851.1 RP11-109L13.1 5.61 3.42e-08 1.22e-05 0.62 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117091945 chr11:117135528~117138582:+ LUSC cis rs4237845 0.788 rs1962047 ENSG00000257159.1 RP11-58A17.3 5.61 3.42e-08 1.22e-05 0.31 0.25 Intelligence (multi-trait analysis); chr12:57898924 chr12:57967058~57968399:+ LUSC cis rs6844153 0.823 rs12642922 ENSG00000240005.4 RP11-293A21.1 -5.61 3.42e-08 1.22e-05 -0.39 -0.25 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:27025996 chr4:26859806~26860599:- LUSC cis rs6504950 0.732 rs244373 ENSG00000275710.1 RP11-257O5.4 -5.61 3.42e-08 1.23e-05 -0.29 -0.25 Breast cancer; chr17:55107588 chr17:54964474~54964679:+ LUSC cis rs6504950 0.924 rs187242 ENSG00000275710.1 RP11-257O5.4 5.61 3.42e-08 1.23e-05 0.29 0.25 Breast cancer; chr17:55115585 chr17:54964474~54964679:+ LUSC cis rs13113518 1 rs13146987 ENSG00000249700.7 SRD5A3-AS1 5.61 3.43e-08 1.23e-05 0.29 0.25 Height; chr4:55491628 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs7677085 ENSG00000249700.7 SRD5A3-AS1 5.61 3.43e-08 1.23e-05 0.29 0.25 Height; chr4:55495801 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs12510681 ENSG00000249700.7 SRD5A3-AS1 5.61 3.43e-08 1.23e-05 0.29 0.25 Height; chr4:55496737 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs12500162 ENSG00000249700.7 SRD5A3-AS1 5.61 3.43e-08 1.23e-05 0.29 0.25 Height; chr4:55496933 chr4:55363971~55395847:- LUSC cis rs1008375 0.897 rs1006723 ENSG00000249502.1 AC006160.5 -5.61 3.43e-08 1.23e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17616901 chr4:17587467~17614571:- LUSC cis rs12935418 0.83 rs7188549 ENSG00000261061.1 RP11-303E16.2 -5.61 3.43e-08 1.23e-05 -0.43 -0.25 Mean corpuscular volume; chr16:81016371 chr16:81030770~81031485:+ LUSC cis rs910316 0.763 rs12588981 ENSG00000279594.1 RP11-950C14.10 5.61 3.44e-08 1.23e-05 0.29 0.25 Height; chr14:74993858 chr14:75011269~75012851:- LUSC cis rs1528149 0.504 rs6943936 ENSG00000224683.1 RPL36AP29 -5.61 3.44e-08 1.23e-05 -0.29 -0.25 Sitting height ratio; chr7:16128648 chr7:16208945~16209265:+ LUSC cis rs42490 0.873 rs218903 ENSG00000251136.7 RP11-37B2.1 -5.61 3.45e-08 1.23e-05 -0.22 -0.25 Leprosy; chr8:89721458 chr8:89609409~89757727:- LUSC cis rs11123170 0.503 rs28679654 ENSG00000274877.1 RP11-65I12.1 -5.61 3.45e-08 1.23e-05 -0.36 -0.25 Renal function-related traits (BUN); chr2:113210040 chr2:113237595~113240825:+ LUSC cis rs11159086 0.793 rs1029701 ENSG00000259005.1 RP3-449M8.6 5.61 3.45e-08 1.23e-05 0.37 0.25 Advanced glycation end-product levels; chr14:74474112 chr14:74474007~74474864:- LUSC cis rs763121 0.925 rs1043312 ENSG00000273076.1 RP3-508I15.22 5.61 3.45e-08 1.23e-05 0.24 0.25 Menopause (age at onset); chr22:38735722 chr22:38743495~38743910:+ LUSC cis rs13113518 1 rs6838882 ENSG00000273257.1 RP11-177J6.1 5.61 3.45e-08 1.23e-05 0.32 0.25 Height; chr4:55489310 chr4:55387949~55388271:+ LUSC cis rs7712401 0.601 rs154502 ENSG00000263432.2 RN7SL689P 5.61 3.45e-08 1.23e-05 0.31 0.25 Mean platelet volume; chr5:122871351 chr5:123022487~123022783:- LUSC cis rs28830936 0.966 rs3743024 ENSG00000250379.1 RP11-23P13.4 5.61 3.45e-08 1.23e-05 0.27 0.25 Diastolic blood pressure; chr15:41826773 chr15:41825099~41827936:- LUSC cis rs875971 0.862 rs9791713 ENSG00000179406.6 LINC00174 5.61 3.46e-08 1.24e-05 0.27 0.25 Aortic root size; chr7:66640211 chr7:66376044~66401338:- LUSC cis rs6918586 0.658 rs1572982 ENSG00000272462.2 U91328.19 5.61 3.47e-08 1.24e-05 0.26 0.25 Schizophrenia; chr6:26094139 chr6:25992662~26001775:+ LUSC cis rs748404 0.601 rs489964 ENSG00000249839.1 AC011330.5 5.61 3.47e-08 1.24e-05 0.32 0.25 Lung cancer; chr15:43225356 chr15:43663654~43684339:- LUSC cis rs2439831 0.557 rs13329084 ENSG00000249839.1 AC011330.5 5.61 3.47e-08 1.24e-05 0.54 0.25 Lung cancer in ever smokers; chr15:43858865 chr15:43663654~43684339:- LUSC cis rs75920871 0.528 rs12279066 ENSG00000254851.1 RP11-109L13.1 5.61 3.47e-08 1.24e-05 0.34 0.25 Subjective well-being; chr11:117043193 chr11:117135528~117138582:+ LUSC cis rs2439831 0.867 rs12443102 ENSG00000249839.1 AC011330.5 -5.61 3.48e-08 1.24e-05 -0.48 -0.25 Lung cancer in ever smokers; chr15:43639905 chr15:43663654~43684339:- LUSC cis rs270601 0.77 rs932019 ENSG00000233006.5 AC034220.3 5.61 3.48e-08 1.24e-05 0.25 0.25 Acylcarnitine levels; chr5:132263677 chr5:132311285~132369916:- LUSC cis rs459571 0.959 rs2520100 ENSG00000235106.7 LINC00094 5.61 3.48e-08 1.24e-05 0.28 0.25 Platelet distribution width; chr9:134053015 chr9:134025439~134034666:+ LUSC cis rs875971 0.706 rs1643374 ENSG00000224316.1 RP11-479O9.2 5.61 3.49e-08 1.25e-05 0.24 0.25 Aortic root size; chr7:66407695 chr7:65773620~65802067:+ LUSC cis rs28830936 0.934 rs28401754 ENSG00000250379.1 RP11-23P13.4 5.61 3.49e-08 1.25e-05 0.27 0.25 Diastolic blood pressure; chr15:41824705 chr15:41825099~41827936:- LUSC cis rs9322193 0.884 rs1125 ENSG00000268592.3 RAET1E-AS1 5.61 3.49e-08 1.25e-05 0.33 0.25 Lung cancer; chr6:149658280 chr6:149863494~149919507:+ LUSC cis rs875971 0.522 rs1917563 ENSG00000179406.6 LINC00174 5.61 3.5e-08 1.25e-05 0.26 0.25 Aortic root size; chr7:65950660 chr7:66376044~66401338:- LUSC cis rs66887589 0.807 rs9799664 ENSG00000245958.5 RP11-33B1.1 -5.61 3.5e-08 1.25e-05 -0.24 -0.25 Diastolic blood pressure; chr4:119405523 chr4:119454791~119552025:+ LUSC cis rs1008375 1 rs2215450 ENSG00000249502.1 AC006160.5 -5.61 3.5e-08 1.25e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17673771 chr4:17587467~17614571:- LUSC cis rs17772222 0.74 rs61984675 ENSG00000258789.1 RP11-507K2.3 -5.61 3.5e-08 1.25e-05 -0.29 -0.25 Coronary artery calcification; chr14:88511236 chr14:88551597~88552493:+ LUSC cis rs13113518 1 rs4864547 ENSG00000272969.1 RP11-528I4.2 5.61 3.51e-08 1.25e-05 0.28 0.25 Height; chr4:55538228 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs34648901 ENSG00000272969.1 RP11-528I4.2 5.61 3.51e-08 1.25e-05 0.28 0.25 Height; chr4:55541259 chr4:55547112~55547889:+ LUSC cis rs2842992 0.83 rs2273819 ENSG00000237927.1 RP3-393E18.2 -5.61 3.51e-08 1.25e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159762293 chr6:159586955~159589169:- LUSC cis rs875971 0.545 rs316324 ENSG00000237310.1 GS1-124K5.4 -5.61 3.51e-08 1.25e-05 -0.28 -0.25 Aortic root size; chr7:66145627 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs316323 ENSG00000237310.1 GS1-124K5.4 -5.61 3.51e-08 1.25e-05 -0.28 -0.25 Aortic root size; chr7:66146002 chr7:66493706~66495474:+ LUSC cis rs2842992 0.673 rs6930904 ENSG00000237927.1 RP3-393E18.2 -5.61 3.51e-08 1.25e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159796401 chr6:159586955~159589169:- LUSC cis rs9341808 0.905 rs9343977 ENSG00000272129.1 RP11-250B2.6 5.61 3.51e-08 1.25e-05 0.3 0.25 Sitting height ratio; chr6:80257284 chr6:80355424~80356859:+ LUSC cis rs2562456 0.876 rs11085465 ENSG00000268081.1 RP11-678G14.2 -5.61 3.52e-08 1.26e-05 -0.35 -0.25 Pain; chr19:21568988 chr19:21554640~21569237:- LUSC cis rs801193 0.66 rs974239 ENSG00000179406.6 LINC00174 -5.61 3.52e-08 1.26e-05 -0.27 -0.25 Aortic root size; chr7:66748504 chr7:66376044~66401338:- LUSC cis rs801193 0.66 rs1016265 ENSG00000179406.6 LINC00174 -5.61 3.52e-08 1.26e-05 -0.27 -0.25 Aortic root size; chr7:66749580 chr7:66376044~66401338:- LUSC cis rs2742234 0.541 rs10793427 ENSG00000273008.1 RP11-351D16.3 5.61 3.52e-08 1.26e-05 0.29 0.25 Hirschsprung disease; chr10:43251995 chr10:43136824~43138334:- LUSC cis rs4372836 0.681 rs9309664 ENSG00000226833.4 AC097724.3 -5.61 3.52e-08 1.26e-05 -0.27 -0.25 Body mass index; chr2:28716760 chr2:28708953~28736205:- LUSC cis rs11722779 0.81 rs223417 ENSG00000246560.2 RP11-10L12.4 5.61 3.53e-08 1.26e-05 0.3 0.25 Schizophrenia; chr4:102810568 chr4:102828055~102844075:+ LUSC cis rs11722779 0.805 rs223416 ENSG00000246560.2 RP11-10L12.4 5.61 3.53e-08 1.26e-05 0.3 0.25 Schizophrenia; chr4:102810580 chr4:102828055~102844075:+ LUSC cis rs67180937 0.677 rs17011666 ENSG00000272750.1 RP11-378J18.8 -5.61 3.53e-08 1.26e-05 -0.3 -0.25 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222625623 chr1:222658867~222661512:- LUSC cis rs28830936 0.966 rs2277535 ENSG00000250379.1 RP11-23P13.4 5.61 3.53e-08 1.26e-05 0.27 0.25 Diastolic blood pressure; chr15:41827513 chr15:41825099~41827936:- LUSC cis rs28830936 0.966 rs8025714 ENSG00000250379.1 RP11-23P13.4 5.61 3.53e-08 1.26e-05 0.27 0.25 Diastolic blood pressure; chr15:41827959 chr15:41825099~41827936:- LUSC cis rs66887589 0.967 rs3775842 ENSG00000248280.1 RP11-33B1.2 5.61 3.53e-08 1.26e-05 0.28 0.25 Diastolic blood pressure; chr4:119506577 chr4:119440561~119450157:- LUSC cis rs7208859 0.623 rs122898 ENSG00000263603.1 CTD-2349P21.5 5.61 3.53e-08 1.26e-05 0.34 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30578236 chr17:30729469~30731202:+ LUSC cis rs2136613 0.533 rs10761668 ENSG00000238280.1 RP11-436D10.3 -5.61 3.54e-08 1.26e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62849983 chr10:62793562~62805887:- LUSC cis rs11690935 0.788 rs6715929 ENSG00000228389.1 AC068039.4 5.61 3.54e-08 1.26e-05 0.27 0.25 Schizophrenia; chr2:172012600 chr2:171773482~171775844:+ LUSC cis rs17826219 0.706 rs2322197 ENSG00000263603.1 CTD-2349P21.5 -5.61 3.55e-08 1.26e-05 -0.35 -0.25 Body mass index; chr17:30778787 chr17:30729469~30731202:+ LUSC cis rs2136613 0.533 rs10740090 ENSG00000238280.1 RP11-436D10.3 -5.61 3.55e-08 1.27e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62850027 chr10:62793562~62805887:- LUSC cis rs957448 0.561 rs71532325 ENSG00000253704.1 RP11-267M23.4 5.61 3.55e-08 1.27e-05 0.29 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94615738 chr8:94553722~94569745:+ LUSC cis rs11096990 0.634 rs7564 ENSG00000249207.1 RP11-360F5.1 5.61 3.55e-08 1.27e-05 0.26 0.25 Cognitive function; chr4:39285702 chr4:39112677~39126818:- LUSC cis rs8177876 0.822 rs56198248 ENSG00000261838.4 RP11-303E16.6 5.61 3.55e-08 1.27e-05 0.66 0.25 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81074869 chr16:81069854~81076598:+ LUSC cis rs950169 0.845 rs4502182 ENSG00000259295.5 CSPG4P12 5.61 3.55e-08 1.27e-05 0.33 0.25 Schizophrenia; chr15:84254768 chr15:85191438~85213905:+ LUSC cis rs1322639 0.614 rs6925201 ENSG00000223485.1 RP11-417E7.1 5.61 3.55e-08 1.27e-05 0.34 0.25 Pulse pressure; chr6:169163262 chr6:169158092~169162924:- LUSC cis rs13113518 0.967 rs12507722 ENSG00000272969.1 RP11-528I4.2 5.61 3.55e-08 1.27e-05 0.28 0.25 Height; chr4:55536421 chr4:55547112~55547889:+ LUSC cis rs13113518 0.967 rs7696832 ENSG00000272969.1 RP11-528I4.2 5.61 3.55e-08 1.27e-05 0.28 0.25 Height; chr4:55537080 chr4:55547112~55547889:+ LUSC cis rs6543140 0.964 rs62154972 ENSG00000234389.1 AC007278.3 5.6 3.56e-08 1.27e-05 0.26 0.25 Blood protein levels; chr2:102432278 chr2:102438713~102440475:+ LUSC cis rs1075265 0.518 rs13414393 ENSG00000233266.1 HMGB1P31 5.6 3.56e-08 1.27e-05 0.32 0.25 Chronotype;Morning vs. evening chronotype; chr2:54048025 chr2:54051334~54051760:+ LUSC cis rs11159086 1 rs12433848 ENSG00000270000.1 RP3-449M8.9 5.6 3.56e-08 1.27e-05 0.39 0.25 Advanced glycation end-product levels; chr14:74497570 chr14:74471930~74472360:- LUSC cis rs4718428 0.705 rs2901311 ENSG00000226824.5 RP4-756H11.3 -5.6 3.56e-08 1.27e-05 -0.35 -0.25 Corneal structure; chr7:66950082 chr7:66654538~66669855:+ LUSC cis rs875971 0.83 rs778711 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.27 -0.25 Aortic root size; chr7:66386670 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs1083554 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.27 -0.25 Aortic root size; chr7:66387354 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs778707 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.27 -0.25 Aortic root size; chr7:66392040 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs778705 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.27 -0.25 Aortic root size; chr7:66396128 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs778697 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.27 -0.25 Aortic root size; chr7:66405439 chr7:66376044~66401338:- LUSC cis rs875971 0.798 rs7789615 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.27 -0.25 Aortic root size; chr7:66413674 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6978028 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.27 -0.25 Aortic root size; chr7:66421313 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6947339 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.27 -0.25 Aortic root size; chr7:66423483 chr7:66376044~66401338:- LUSC cis rs6504622 0.875 rs4968250 ENSG00000262879.4 RP11-156P1.3 5.6 3.56e-08 1.27e-05 0.26 0.25 Orofacial clefts; chr17:46967985 chr17:46984045~47100323:- LUSC cis rs75422866 0.764 rs73104177 ENSG00000257433.4 RP1-197B17.3 5.6 3.56e-08 1.27e-05 0.64 0.25 Pneumonia; chr12:47713550 chr12:47706085~47742294:+ LUSC cis rs875971 0.545 rs10950025 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.29 -0.25 Aortic root size; chr7:66158946 chr7:66376044~66401338:- LUSC cis rs875971 0.52 rs12666485 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.29 -0.25 Aortic root size; chr7:66160135 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs67688847 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.29 -0.25 Aortic root size; chr7:66161064 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs12673308 ENSG00000179406.6 LINC00174 -5.6 3.56e-08 1.27e-05 -0.29 -0.25 Aortic root size; chr7:66166374 chr7:66376044~66401338:- LUSC cis rs13113518 1 rs2279458 ENSG00000273257.1 RP11-177J6.1 5.6 3.56e-08 1.27e-05 0.32 0.25 Height; chr4:55562653 chr4:55387949~55388271:+ LUSC cis rs9341808 0.628 rs9294172 ENSG00000272129.1 RP11-250B2.6 5.6 3.57e-08 1.27e-05 0.31 0.25 Sitting height ratio; chr6:80208844 chr6:80355424~80356859:+ LUSC cis rs875971 0.862 rs9791712 ENSG00000179406.6 LINC00174 5.6 3.57e-08 1.27e-05 0.27 0.25 Aortic root size; chr7:66640176 chr7:66376044~66401338:- LUSC cis rs17772222 1 rs17772064 ENSG00000258789.1 RP11-507K2.3 -5.6 3.57e-08 1.27e-05 -0.29 -0.25 Coronary artery calcification; chr14:88356527 chr14:88551597~88552493:+ LUSC cis rs7208859 0.623 rs9915566 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.58e-08 1.27e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30729469~30731202:+ LUSC cis rs11098499 0.78 rs7692994 ENSG00000250412.1 KLHL2P1 5.6 3.58e-08 1.28e-05 0.31 0.25 Corneal astigmatism; chr4:119506334 chr4:119334329~119378233:+ LUSC cis rs875971 0.522 rs4718285 ENSG00000179406.6 LINC00174 -5.6 3.58e-08 1.28e-05 -0.26 -0.25 Aortic root size; chr7:65827018 chr7:66376044~66401338:- LUSC cis rs4722166 0.604 rs2390715 ENSG00000179428.2 AC073072.5 -5.6 3.59e-08 1.28e-05 -0.31 -0.25 Lung cancer; chr7:22744259 chr7:22725395~22727620:- LUSC cis rs4722166 0.63 rs4722169 ENSG00000179428.2 AC073072.5 -5.6 3.59e-08 1.28e-05 -0.31 -0.25 Lung cancer; chr7:22745800 chr7:22725395~22727620:- LUSC cis rs4722166 0.598 rs4722171 ENSG00000179428.2 AC073072.5 -5.6 3.59e-08 1.28e-05 -0.31 -0.25 Lung cancer; chr7:22746098 chr7:22725395~22727620:- LUSC cis rs11123170 0.542 rs11123169 ENSG00000189223.12 PAX8-AS1 5.6 3.59e-08 1.28e-05 0.34 0.25 Renal function-related traits (BUN); chr2:113209498 chr2:113211522~113276581:+ LUSC cis rs42490 1 rs218929 ENSG00000251136.7 RP11-37B2.1 -5.6 3.59e-08 1.28e-05 -0.22 -0.25 Leprosy; chr8:89739091 chr8:89609409~89757727:- LUSC cis rs10759883 0.539 rs966217 ENSG00000175611.10 LINC00476 5.6 3.59e-08 1.28e-05 0.29 0.25 Nicotine dependence; chr9:95943247 chr9:95759231~95875977:- LUSC cis rs2742234 0.518 rs1254967 ENSG00000273008.1 RP11-351D16.3 5.6 3.6e-08 1.28e-05 0.29 0.25 Hirschsprung disease; chr10:43194943 chr10:43136824~43138334:- LUSC cis rs6061231 1 rs13043313 ENSG00000273619.1 RP5-908M14.9 -5.6 3.6e-08 1.28e-05 -0.24 -0.25 Colorectal cancer; chr20:62383213 chr20:62386303~62386970:- LUSC cis rs34779708 0.801 rs12255409 ENSG00000230534.5 RP11-297A16.2 5.6 3.6e-08 1.28e-05 0.29 0.25 Inflammatory bowel disease;Crohn's disease; chr10:35246497 chr10:35098006~35127020:- LUSC cis rs66887589 0.837 rs7661498 ENSG00000249244.1 RP11-548H18.2 5.6 3.6e-08 1.28e-05 0.3 0.25 Diastolic blood pressure; chr4:119486953 chr4:119391831~119395335:- LUSC cis rs71403859 0.502 rs8051974 ENSG00000260886.1 TAT-AS1 5.6 3.6e-08 1.28e-05 0.37 0.25 Post bronchodilator FEV1; chr16:71454868 chr16:71565789~71578187:+ LUSC cis rs801193 0.935 rs3800820 ENSG00000237310.1 GS1-124K5.4 -5.6 3.6e-08 1.28e-05 -0.25 -0.25 Aortic root size; chr7:66682191 chr7:66493706~66495474:+ LUSC cis rs75920871 0.528 rs10082609 ENSG00000254851.1 RP11-109L13.1 5.6 3.61e-08 1.28e-05 0.34 0.25 Subjective well-being; chr11:117078358 chr11:117135528~117138582:+ LUSC cis rs910316 0.737 rs175077 ENSG00000279594.1 RP11-950C14.10 -5.6 3.61e-08 1.29e-05 -0.29 -0.25 Height; chr14:75040172 chr14:75011269~75012851:- LUSC cis rs2562456 0.876 rs11085468 ENSG00000268081.1 RP11-678G14.2 5.6 3.62e-08 1.29e-05 0.35 0.25 Pain; chr19:21569087 chr19:21554640~21569237:- LUSC cis rs950169 0.922 rs12912934 ENSG00000259295.5 CSPG4P12 5.6 3.63e-08 1.29e-05 0.33 0.25 Schizophrenia; chr15:84571216 chr15:85191438~85213905:+ LUSC cis rs17270561 0.609 rs9348692 ENSG00000272462.2 U91328.19 -5.6 3.63e-08 1.29e-05 -0.3 -0.25 Iron status biomarkers; chr6:25720584 chr6:25992662~26001775:+ LUSC cis rs7208859 0.623 rs34756112 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30729469~30731202:+ LUSC cis rs7208859 0.573 rs60724269 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs76633166 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs1061346 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs1061343 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs1061342 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs55938328 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs73269988 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs55961983 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30729469~30731202:+ LUSC cis rs7208859 0.673 rs9899525 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30729469~30731202:+ LUSC cis rs17826219 0.568 rs7213925 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Body mass index; chr17:30794616 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs11658945 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs11657990 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9911784 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9911997 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9890862 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs78071511 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs11650982 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs2035494 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs3794796 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9915546 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30729469~30731202:+ LUSC cis rs7208859 0.573 rs8064686 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30729469~30731202:+ LUSC cis rs7208859 0.573 rs11654035 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809408 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs11657369 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs8075341 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs73271842 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30729469~30731202:+ LUSC cis rs7208859 0.673 rs9895815 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30729469~30731202:+ LUSC cis rs7208859 0.673 rs8077116 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30729469~30731202:+ LUSC cis rs7208859 0.524 rs28760584 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30729469~30731202:+ LUSC cis rs17826219 0.706 rs73271850 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Body mass index; chr17:30815122 chr17:30729469~30731202:+ LUSC cis rs17826219 0.636 rs79565452 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Body mass index; chr17:30815823 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs7208088 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs7212991 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs28627615 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.63e-08 1.29e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30729469~30731202:+ LUSC cis rs1021993 0.597 rs1395753 ENSG00000231648.1 RP11-372M18.2 -5.6 3.63e-08 1.29e-05 -0.36 -0.25 Gut microbiome composition (winter); chr1:209317182 chr1:209367662~209379690:+ LUSC cis rs34792 0.688 rs153783 ENSG00000207425.1 Y_RNA 5.6 3.64e-08 1.29e-05 0.33 0.25 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15508509 chr16:14915457~14915556:- LUSC cis rs9322193 0.607 rs12527391 ENSG00000268592.3 RAET1E-AS1 5.6 3.64e-08 1.29e-05 0.36 0.25 Lung cancer; chr6:149882156 chr6:149863494~149919507:+ LUSC cis rs496547 0.654 rs688161 ENSG00000278376.1 RP11-158I9.8 -5.6 3.64e-08 1.29e-05 -0.23 -0.25 Hip minimal joint space width; chr11:118807001 chr11:118791254~118793137:+ LUSC cis rs7955901 0.837 rs10748169 ENSG00000257265.1 CTD-2021H9.1 -5.6 3.64e-08 1.3e-05 -0.28 -0.25 Type 2 diabetes; chr12:71023076 chr12:71007773~71032083:- LUSC cis rs13113518 1 rs4864999 ENSG00000223305.1 RN7SKP30 5.6 3.64e-08 1.3e-05 0.3 0.25 Height; chr4:55476736 chr4:55540502~55540835:- LUSC cis rs13113518 0.966 rs12506788 ENSG00000223305.1 RN7SKP30 5.6 3.64e-08 1.3e-05 0.3 0.25 Height; chr4:55477426 chr4:55540502~55540835:- LUSC cis rs13113518 0.966 rs10517344 ENSG00000223305.1 RN7SKP30 5.6 3.64e-08 1.3e-05 0.3 0.25 Height; chr4:55477545 chr4:55540502~55540835:- LUSC cis rs17772222 0.74 rs7160647 ENSG00000258789.1 RP11-507K2.3 -5.6 3.64e-08 1.3e-05 -0.28 -0.25 Coronary artery calcification; chr14:88507340 chr14:88551597~88552493:+ LUSC cis rs4332428 0.649 rs80261559 ENSG00000239148.1 U8 -5.6 3.64e-08 1.3e-05 -0.29 -0.25 Height; chr10:4940020 chr10:5004710~5004842:+ LUSC cis rs7555523 0.887 rs4656461 ENSG00000224358.1 RP11-466F5.8 -5.6 3.64e-08 1.3e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165717968 chr1:165768929~165775176:+ LUSC cis rs7714584 1 rs13361189 ENSG00000197083.10 ZNF300P1 5.6 3.65e-08 1.3e-05 0.42 0.25 Crohn's disease; chr5:150843825 chr5:150930645~150946289:- LUSC cis rs2742234 0.59 rs2435337 ENSG00000273008.1 RP11-351D16.3 -5.6 3.65e-08 1.3e-05 -0.29 -0.25 Hirschsprung disease; chr10:43166388 chr10:43136824~43138334:- LUSC cis rs9322193 0.607 rs4870078 ENSG00000268592.3 RAET1E-AS1 -5.6 3.65e-08 1.3e-05 -0.36 -0.25 Lung cancer; chr6:149880676 chr6:149863494~149919507:+ LUSC cis rs2243480 1 rs313803 ENSG00000226824.5 RP4-756H11.3 -5.6 3.65e-08 1.3e-05 -0.49 -0.25 Diabetic kidney disease; chr7:66049744 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs313802 ENSG00000226824.5 RP4-756H11.3 -5.6 3.65e-08 1.3e-05 -0.49 -0.25 Diabetic kidney disease; chr7:66051386 chr7:66654538~66669855:+ LUSC cis rs2243480 0.803 rs403089 ENSG00000226824.5 RP4-756H11.3 -5.6 3.65e-08 1.3e-05 -0.49 -0.25 Diabetic kidney disease; chr7:66052736 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs458291 ENSG00000226824.5 RP4-756H11.3 -5.6 3.65e-08 1.3e-05 -0.49 -0.25 Diabetic kidney disease; chr7:66055492 chr7:66654538~66669855:+ LUSC cis rs2337406 0.866 rs988130 ENSG00000280411.1 IGHV1-69-2 -5.6 3.65e-08 1.3e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106777154 chr14:106762092~106762588:- LUSC cis rs13113518 1 rs56154935 ENSG00000272969.1 RP11-528I4.2 5.6 3.66e-08 1.3e-05 0.28 0.25 Height; chr4:55546378 chr4:55547112~55547889:+ LUSC cis rs10462794 0.661 rs12517115 ENSG00000260763.1 RP11-445O3.3 -5.6 3.66e-08 1.3e-05 -0.32 -0.25 DNA methylation (variation); chr5:4520107 chr5:4436850~4440259:- LUSC cis rs9649213 0.593 rs6465682 ENSG00000272950.1 RP11-307C18.1 5.6 3.66e-08 1.3e-05 0.33 0.25 Prostate cancer (SNP x SNP interaction); chr7:98387105 chr7:98322853~98323430:+ LUSC cis rs35740288 0.77 rs11631386 ENSG00000202081.1 RNU6-1280P 5.6 3.66e-08 1.3e-05 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85648764 chr15:85651522~85651628:- LUSC cis rs6502050 0.835 rs7221451 ENSG00000266654.1 RP11-1376P16.1 -5.6 3.67e-08 1.3e-05 -0.25 -0.25 Life satisfaction; chr17:82131909 chr17:82160056~82160452:+ LUSC cis rs13113518 0.729 rs12641881 ENSG00000223305.1 RN7SKP30 5.6 3.67e-08 1.3e-05 0.33 0.25 Height; chr4:55401306 chr4:55540502~55540835:- LUSC cis rs2337406 0.704 rs1858679 ENSG00000274576.2 IGHV2-70 -5.6 3.67e-08 1.3e-05 -0.27 -0.25 Alzheimer's disease (late onset); chr14:106706726 chr14:106770577~106771020:- LUSC cis rs2742234 0.541 rs61845684 ENSG00000273008.1 RP11-351D16.3 5.6 3.67e-08 1.31e-05 0.29 0.25 Hirschsprung disease; chr10:43249535 chr10:43136824~43138334:- LUSC cis rs642803 0.613 rs489574 ENSG00000255557.1 RP11-770G2.2 -5.6 3.67e-08 1.31e-05 -0.31 -0.25 Urate levels; chr11:65775268 chr11:65745729~65771585:+ LUSC cis rs1789 0.592 rs1125378 ENSG00000273133.1 RP11-799M12.2 -5.6 3.67e-08 1.31e-05 -0.37 -0.25 Blood protein levels; chr4:15538867 chr4:15563698~15564253:- LUSC cis rs8005677 0.828 rs2295682 ENSG00000279656.1 RP11-298I3.6 5.6 3.68e-08 1.31e-05 0.29 0.25 Cognitive ability (multi-trait analysis); chr14:22905653 chr14:23023083~23024217:- LUSC cis rs7826238 0.539 rs2945891 ENSG00000173295.6 FAM86B3P 5.6 3.68e-08 1.31e-05 0.28 0.25 Systolic blood pressure; chr8:8297953 chr8:8228595~8244865:+ LUSC cis rs7580658 0.724 rs12623948 ENSG00000236682.1 AC068282.3 -5.6 3.68e-08 1.31e-05 -0.33 -0.25 Protein C levels; chr2:127243766 chr2:127389130~127400580:+ LUSC cis rs17711722 0.701 rs4467826 ENSG00000179406.6 LINC00174 -5.6 3.68e-08 1.31e-05 -0.26 -0.25 Calcium levels; chr7:65903721 chr7:66376044~66401338:- LUSC cis rs11159086 0.793 rs1029703 ENSG00000259005.1 RP3-449M8.6 5.6 3.68e-08 1.31e-05 0.37 0.25 Advanced glycation end-product levels; chr14:74473899 chr14:74474007~74474864:- LUSC cis rs801193 1 rs2659889 ENSG00000237310.1 GS1-124K5.4 5.6 3.69e-08 1.31e-05 0.25 0.25 Aortic root size; chr7:66752125 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs3800812 ENSG00000237310.1 GS1-124K5.4 5.6 3.69e-08 1.31e-05 0.25 0.25 Aortic root size; chr7:66758474 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs4279493 ENSG00000237310.1 GS1-124K5.4 5.6 3.69e-08 1.31e-05 0.25 0.25 Aortic root size; chr7:66761633 chr7:66493706~66495474:+ LUSC cis rs4834770 1 rs4834770 ENSG00000245958.5 RP11-33B1.1 -5.6 3.69e-08 1.31e-05 -0.24 -0.25 Blood protein levels; chr4:119320694 chr4:119454791~119552025:+ LUSC cis rs17711722 0.64 rs13237956 ENSG00000179406.6 LINC00174 -5.6 3.69e-08 1.31e-05 -0.26 -0.25 Calcium levels; chr7:65853042 chr7:66376044~66401338:- LUSC cis rs11951515 0.508 rs1366410 ENSG00000249286.1 CTD-2210P15.2 5.6 3.7e-08 1.31e-05 0.29 0.25 Metabolite levels (X-11787); chr5:43601508 chr5:43586918~43588223:- LUSC cis rs910316 0.763 rs175435 ENSG00000279594.1 RP11-950C14.10 5.6 3.7e-08 1.32e-05 0.29 0.25 Height; chr14:75145322 chr14:75011269~75012851:- LUSC cis rs673078 0.571 rs61945220 ENSG00000275759.1 RP11-131L12.3 -5.6 3.71e-08 1.32e-05 -0.39 -0.25 Glucose homeostasis traits; chr12:118272924 chr12:118428281~118428870:+ LUSC cis rs673078 0.571 rs61945221 ENSG00000275759.1 RP11-131L12.3 -5.6 3.71e-08 1.32e-05 -0.39 -0.25 Glucose homeostasis traits; chr12:118272926 chr12:118428281~118428870:+ LUSC cis rs17818399 0.633 rs2242033 ENSG00000279254.1 RP11-536C12.1 -5.6 3.71e-08 1.32e-05 -0.27 -0.25 Height; chr2:46615271 chr2:46668870~46670778:+ LUSC cis rs73173548 0.528 rs34857793 ENSG00000247828.6 TMEM161B-AS1 5.6 3.71e-08 1.32e-05 0.3 0.25 Macular telangiectasia type 2; chr5:88467749 chr5:88268895~88436685:+ LUSC cis rs4713118 0.869 rs6902689 ENSG00000280107.1 AL022393.9 -5.6 3.71e-08 1.32e-05 -0.28 -0.25 Parkinson's disease; chr6:27741662 chr6:28170845~28172521:+ LUSC cis rs4713118 0.513 rs149975 ENSG00000216901.1 AL022393.7 5.6 3.71e-08 1.32e-05 0.29 0.25 Parkinson's disease; chr6:28018562 chr6:28176188~28176674:+ LUSC cis rs8133932 0.701 rs7276114 ENSG00000280604.1 PCBP3-OT1 -5.6 3.72e-08 1.32e-05 -0.32 -0.25 Schizophrenia; chr21:45881273 chr21:45914296~45919483:+ LUSC cis rs6700559 0.74 rs6663322 ENSG00000260088.1 RP11-92G12.3 5.6 3.72e-08 1.32e-05 0.3 0.25 Coronary artery disease; chr1:200680741 chr1:200669507~200694250:+ LUSC cis rs35740288 0.77 rs56092539 ENSG00000202081.1 RNU6-1280P 5.6 3.72e-08 1.32e-05 0.3 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85639281 chr15:85651522~85651628:- LUSC cis rs41294858 1 rs76267242 ENSG00000232876.1 CTA-212D2.2 -5.6 3.72e-08 1.32e-05 -0.48 -0.25 Red blood cell count; chr6:135096322 chr6:135055033~135060550:+ LUSC cis rs17826219 0.706 rs57698184 ENSG00000263603.1 CTD-2349P21.5 -5.6 3.72e-08 1.32e-05 -0.35 -0.25 Body mass index; chr17:30737900 chr17:30729469~30731202:+ LUSC cis rs783540 0.967 rs1864699 ENSG00000255769.6 GOLGA2P10 -5.6 3.72e-08 1.32e-05 -0.3 -0.25 Schizophrenia; chr15:82654567 chr15:82472993~82513950:- LUSC cis rs7772486 0.875 rs2777481 ENSG00000235652.6 RP11-545I5.3 5.6 3.73e-08 1.32e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145988900 chr6:145799409~145886585:+ LUSC cis rs4972806 0.739 rs10834 ENSG00000226363.3 HAGLROS -5.6 3.73e-08 1.32e-05 -0.31 -0.25 IgG glycosylation; chr2:176177359 chr2:176177717~176179008:+ LUSC cis rs4964805 0.549 rs2292682 ENSG00000257681.1 RP11-341G23.4 5.6 3.73e-08 1.32e-05 0.29 0.25 Attention deficit hyperactivity disorder; chr12:103762742 chr12:103746315~103768858:- LUSC cis rs17361889 0.711 rs17287882 ENSG00000224683.1 RPL36AP29 5.6 3.73e-08 1.32e-05 0.31 0.25 Pediatric bone mineral content (hip); chr7:16139249 chr7:16208945~16209265:+ LUSC cis rs6683071 0.501 rs3002146 ENSG00000272750.1 RP11-378J18.8 5.6 3.74e-08 1.33e-05 0.32 0.25 Cognitive performance; chr1:222636066 chr1:222658867~222661512:- LUSC cis rs67180937 0.553 rs1391557 ENSG00000272750.1 RP11-378J18.8 5.6 3.74e-08 1.33e-05 0.32 0.25 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222636274 chr1:222658867~222661512:- LUSC cis rs875971 0.522 rs6960048 ENSG00000222364.1 RNU6-96P -5.6 3.74e-08 1.33e-05 -0.29 -0.25 Aortic root size; chr7:65943052 chr7:66395191~66395286:+ LUSC cis rs9640161 0.636 rs56190213 ENSG00000261305.1 RP4-584D14.7 5.6 3.74e-08 1.33e-05 0.37 0.25 Blood protein levels;Circulating chemerin levels; chr7:150328631 chr7:150341771~150342607:+ LUSC cis rs35160687 0.712 rs11127020 ENSG00000273080.1 RP11-301O19.1 -5.6 3.75e-08 1.33e-05 -0.24 -0.25 Night sleep phenotypes; chr2:86247421 chr2:86195590~86196049:+ LUSC cis rs2732480 0.577 rs2634693 ENSG00000226413.2 OR8T1P 5.6 3.75e-08 1.33e-05 0.33 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48312715 chr12:48442030~48442947:- LUSC cis rs2732480 0.577 rs2634691 ENSG00000226413.2 OR8T1P 5.6 3.75e-08 1.33e-05 0.33 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48314476 chr12:48442030~48442947:- LUSC cis rs9611519 1 rs5758267 ENSG00000235513.1 RP4-756G23.5 -5.6 3.75e-08 1.33e-05 -0.29 -0.25 Neuroticism; chr22:41223346 chr22:41209122~41217627:- LUSC cis rs227275 0.554 rs223363 ENSG00000246560.2 RP11-10L12.4 5.6 3.75e-08 1.33e-05 0.3 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102846182 chr4:102828055~102844075:+ LUSC cis rs459571 1 rs459571 ENSG00000235106.7 LINC00094 5.59 3.75e-08 1.33e-05 0.28 0.25 Platelet distribution width; chr9:134047504 chr9:134025439~134034666:+ LUSC cis rs75920871 0.528 rs1531707 ENSG00000254851.1 RP11-109L13.1 5.59 3.75e-08 1.33e-05 0.34 0.25 Subjective well-being; chr11:117073996 chr11:117135528~117138582:+ LUSC cis rs75920871 0.528 rs12274388 ENSG00000254851.1 RP11-109L13.1 5.59 3.75e-08 1.33e-05 0.34 0.25 Subjective well-being; chr11:117075522 chr11:117135528~117138582:+ LUSC cis rs11089937 0.626 rs10483106 ENSG00000211638.2 IGLV8-61 -5.59 3.76e-08 1.33e-05 -0.28 -0.25 Periodontitis (PAL4Q3); chr22:22149240 chr22:22098700~22099212:+ LUSC cis rs651907 0.535 rs13085776 ENSG00000244119.1 PDCL3P4 5.59 3.76e-08 1.33e-05 0.22 0.25 Colorectal cancer; chr3:101786663 chr3:101712472~101713191:+ LUSC cis rs7826238 0.524 rs2921055 ENSG00000253893.2 FAM85B -5.59 3.76e-08 1.33e-05 -0.3 -0.25 Systolic blood pressure; chr8:8461832 chr8:8167819~8226614:- LUSC cis rs875971 0.522 rs4718286 ENSG00000179406.6 LINC00174 -5.59 3.76e-08 1.33e-05 -0.26 -0.25 Aortic root size; chr7:65827777 chr7:66376044~66401338:- LUSC cis rs2282300 1 rs12799529 ENSG00000254532.1 RP11-624D11.2 5.59 3.76e-08 1.33e-05 0.35 0.25 Morning vs. evening chronotype; chr11:30387005 chr11:30044058~30084343:- LUSC cis rs875971 0.545 rs316316 ENSG00000237310.1 GS1-124K5.4 -5.59 3.76e-08 1.33e-05 -0.28 -0.25 Aortic root size; chr7:66149270 chr7:66493706~66495474:+ LUSC cis rs7208859 0.623 rs7208441 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.76e-08 1.33e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30729469~30731202:+ LUSC cis rs867371 0.502 rs2047679 ENSG00000278603.1 RP13-608F4.5 5.59 3.77e-08 1.34e-05 0.3 0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82239540 chr15:82472203~82472426:+ LUSC cis rs67311347 0.544 rs7644643 ENSG00000223797.4 ENTPD3-AS1 -5.59 3.77e-08 1.34e-05 -0.26 -0.25 Renal cell carcinoma; chr3:40308718 chr3:40313802~40453329:- LUSC cis rs73186030 0.546 rs9857972 ENSG00000272758.4 RP11-299J3.8 5.59 3.77e-08 1.34e-05 0.36 0.25 Serum parathyroid hormone levels; chr3:122390602 chr3:122416207~122443180:+ LUSC cis rs367615 0.704 rs55956735 ENSG00000249476.1 CTD-2587M2.1 5.59 3.77e-08 1.34e-05 0.29 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109509341 chr5:109237120~109326369:- LUSC cis rs2337406 0.789 rs60000589 ENSG00000211974.3 IGHV2-70 -5.59 3.78e-08 1.34e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106782459 chr14:106723574~106724093:- LUSC cis rs673078 0.66 rs61945183 ENSG00000275759.1 RP11-131L12.3 -5.59 3.78e-08 1.34e-05 -0.38 -0.25 Glucose homeostasis traits; chr12:118221966 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs16948193 ENSG00000275759.1 RP11-131L12.3 -5.59 3.78e-08 1.34e-05 -0.38 -0.25 Glucose homeostasis traits; chr12:118227115 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs61945187 ENSG00000275759.1 RP11-131L12.3 -5.59 3.78e-08 1.34e-05 -0.38 -0.25 Glucose homeostasis traits; chr12:118228989 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs61945190 ENSG00000275759.1 RP11-131L12.3 -5.59 3.78e-08 1.34e-05 -0.38 -0.25 Glucose homeostasis traits; chr12:118231345 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs7977403 ENSG00000275759.1 RP11-131L12.3 -5.59 3.78e-08 1.34e-05 -0.38 -0.25 Glucose homeostasis traits; chr12:118233446 chr12:118428281~118428870:+ LUSC cis rs13113518 0.812 rs2035692 ENSG00000273257.1 RP11-177J6.1 5.59 3.78e-08 1.34e-05 0.32 0.25 Height; chr4:55528801 chr4:55387949~55388271:+ LUSC cis rs13113518 0.812 rs4507426 ENSG00000273257.1 RP11-177J6.1 5.59 3.78e-08 1.34e-05 0.32 0.25 Height; chr4:55529387 chr4:55387949~55388271:+ LUSC cis rs11098499 0.738 rs28687057 ENSG00000248280.1 RP11-33B1.2 5.59 3.78e-08 1.34e-05 0.29 0.25 Corneal astigmatism; chr4:119359657 chr4:119440561~119450157:- LUSC cis rs11098499 0.774 rs73842616 ENSG00000248280.1 RP11-33B1.2 5.59 3.78e-08 1.34e-05 0.29 0.25 Corneal astigmatism; chr4:119369528 chr4:119440561~119450157:- LUSC cis rs11098499 0.645 rs72676059 ENSG00000248280.1 RP11-33B1.2 5.59 3.78e-08 1.34e-05 0.29 0.25 Corneal astigmatism; chr4:119369673 chr4:119440561~119450157:- LUSC cis rs11098499 0.569 rs55845118 ENSG00000248280.1 RP11-33B1.2 5.59 3.78e-08 1.34e-05 0.29 0.25 Corneal astigmatism; chr4:119369758 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs7677068 ENSG00000248280.1 RP11-33B1.2 5.59 3.78e-08 1.34e-05 0.29 0.25 Corneal astigmatism; chr4:119370549 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs9991221 ENSG00000248280.1 RP11-33B1.2 5.59 3.78e-08 1.34e-05 0.29 0.25 Corneal astigmatism; chr4:119370952 chr4:119440561~119450157:- LUSC cis rs9322193 0.961 rs9285521 ENSG00000268592.3 RAET1E-AS1 5.59 3.78e-08 1.34e-05 0.32 0.25 Lung cancer; chr6:149585576 chr6:149863494~149919507:+ LUSC cis rs853679 1 rs1679732 ENSG00000204709.4 LINC01556 -5.59 3.79e-08 1.34e-05 -0.41 -0.25 Depression; chr6:28253486 chr6:28943877~28944537:+ LUSC cis rs7520050 0.966 rs6429582 ENSG00000280836.1 AL355480.1 -5.59 3.79e-08 1.34e-05 -0.26 -0.25 Reticulocyte count;Red blood cell count; chr1:45856171 chr1:45581219~45581321:- LUSC cis rs11673344 0.642 rs12462487 ENSG00000226686.6 LINC01535 5.59 3.79e-08 1.34e-05 0.32 0.25 Obesity-related traits; chr19:37311211 chr19:37251912~37265535:+ LUSC cis rs9487051 0.872 rs1111865 ENSG00000219700.1 PTCHD3P3 -5.59 3.8e-08 1.35e-05 -0.27 -0.25 Reticulocyte fraction of red cells; chr6:109289660 chr6:109288571~109290503:- LUSC cis rs875971 0.862 rs17747530 ENSG00000179406.6 LINC00174 -5.59 3.8e-08 1.35e-05 -0.27 -0.25 Aortic root size; chr7:66529742 chr7:66376044~66401338:- LUSC cis rs11723261 0.582 rs6830247 ENSG00000275426.1 CH17-262A2.1 5.59 3.8e-08 1.35e-05 0.38 0.25 Immune response to smallpox vaccine (IL-6); chr4:156885 chr4:149738~150317:+ LUSC cis rs2243480 1 rs781150 ENSG00000226824.5 RP4-756H11.3 -5.59 3.8e-08 1.35e-05 -0.49 -0.25 Diabetic kidney disease; chr7:66015986 chr7:66654538~66669855:+ LUSC cis rs9640161 0.75 rs3800780 ENSG00000261305.1 RP4-584D14.7 5.59 3.8e-08 1.35e-05 0.37 0.25 Blood protein levels;Circulating chemerin levels; chr7:150330195 chr7:150341771~150342607:+ LUSC cis rs1499614 1 rs2707832 ENSG00000226824.5 RP4-756H11.3 -5.59 3.81e-08 1.35e-05 -0.47 -0.25 Gout; chr7:66671562 chr7:66654538~66669855:+ LUSC cis rs10027350 1 rs10027350 ENSG00000281501.1 SEPSECS-AS1 5.59 3.81e-08 1.35e-05 0.29 0.25 Childhood ear infection; chr4:25130872 chr4:25160641~25201440:+ LUSC cis rs14027 0.883 rs13255850 ENSG00000279347.1 RP11-85I17.2 -5.59 3.81e-08 1.35e-05 -0.23 -0.25 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119705923 chr8:119838736~119840385:- LUSC cis rs13113518 0.702 rs78829811 ENSG00000272969.1 RP11-528I4.2 5.59 3.81e-08 1.35e-05 0.28 0.25 Height; chr4:55558258 chr4:55547112~55547889:+ LUSC cis rs13113518 0.702 rs75801206 ENSG00000272969.1 RP11-528I4.2 5.59 3.81e-08 1.35e-05 0.28 0.25 Height; chr4:55558259 chr4:55547112~55547889:+ LUSC cis rs13113518 0.702 rs34658078 ENSG00000272969.1 RP11-528I4.2 5.59 3.81e-08 1.35e-05 0.28 0.25 Height; chr4:55558261 chr4:55547112~55547889:+ LUSC cis rs28830936 1 rs17677199 ENSG00000250379.1 RP11-23P13.4 5.59 3.81e-08 1.35e-05 0.27 0.25 Diastolic blood pressure; chr15:41662415 chr15:41825099~41827936:- LUSC cis rs28830936 1 rs11637341 ENSG00000250379.1 RP11-23P13.4 5.59 3.81e-08 1.35e-05 0.27 0.25 Diastolic blood pressure; chr15:41663627 chr15:41825099~41827936:- LUSC cis rs17361889 0.671 rs4282466 ENSG00000224683.1 RPL36AP29 5.59 3.81e-08 1.35e-05 0.3 0.25 Pediatric bone mineral content (hip); chr7:16111878 chr7:16208945~16209265:+ LUSC cis rs13113518 1 rs13114841 ENSG00000273257.1 RP11-177J6.1 5.59 3.82e-08 1.35e-05 0.32 0.25 Height; chr4:55485974 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs939823 ENSG00000273257.1 RP11-177J6.1 5.59 3.82e-08 1.35e-05 0.32 0.25 Height; chr4:55487368 chr4:55387949~55388271:+ LUSC cis rs1528149 0.504 rs1527215 ENSG00000224683.1 RPL36AP29 -5.59 3.82e-08 1.35e-05 -0.29 -0.25 Sitting height ratio; chr7:16127184 chr7:16208945~16209265:+ LUSC cis rs228614 0.51 rs65671 ENSG00000246560.2 RP11-10L12.4 5.59 3.82e-08 1.35e-05 0.3 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102801081 chr4:102828055~102844075:+ LUSC cis rs2742234 0.554 rs1270015 ENSG00000273008.1 RP11-351D16.3 5.59 3.82e-08 1.35e-05 0.29 0.25 Hirschsprung disease; chr10:43202792 chr10:43136824~43138334:- LUSC cis rs2243480 1 rs160633 ENSG00000164669.11 INTS4P1 5.59 3.82e-08 1.35e-05 0.45 0.25 Diabetic kidney disease; chr7:66063241 chr7:65141225~65234216:+ LUSC cis rs875971 0.895 rs4145009 ENSG00000179406.6 LINC00174 5.59 3.83e-08 1.36e-05 0.27 0.25 Aortic root size; chr7:66261628 chr7:66376044~66401338:- LUSC cis rs4639966 0.589 rs480958 ENSG00000255239.1 AP002954.6 5.59 3.83e-08 1.36e-05 0.29 0.25 Systemic lupus erythematosus; chr11:118707281 chr11:118688039~118690600:- LUSC cis rs17711722 0.675 rs6947132 ENSG00000179406.6 LINC00174 5.59 3.83e-08 1.36e-05 0.26 0.25 Calcium levels; chr7:65808508 chr7:66376044~66401338:- LUSC cis rs4664293 0.51 rs2042781 ENSG00000226266.5 AC009961.3 5.59 3.83e-08 1.36e-05 0.3 0.25 Monocyte percentage of white cells; chr2:159789899 chr2:159670708~159712435:- LUSC cis rs7208859 0.524 rs77498725 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30729469~30731202:+ LUSC cis rs7208859 0.573 rs73267865 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737186 chr17:30729469~30731202:+ LUSC cis rs7208859 0.524 rs59923796 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30729469~30731202:+ LUSC cis rs17826219 0.5 rs57005940 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Body mass index; chr17:30739311 chr17:30729469~30731202:+ LUSC cis rs7208859 0.573 rs73267872 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30729469~30731202:+ LUSC cis rs17826219 0.706 rs9893922 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Body mass index; chr17:30741407 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs56812022 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30729469~30731202:+ LUSC cis rs7208859 0.524 rs57670615 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30729469~30731202:+ LUSC cis rs17826219 0.5 rs2874724 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Body mass index; chr17:30745415 chr17:30729469~30731202:+ LUSC cis rs17826219 0.568 rs9898097 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Body mass index; chr17:30745654 chr17:30729469~30731202:+ LUSC cis rs17826219 0.5 rs9891256 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Body mass index; chr17:30745674 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9911490 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs7503542 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs7503335 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30729469~30731202:+ LUSC cis rs7208859 0.573 rs11656278 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs6505207 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.83e-08 1.36e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30729469~30731202:+ LUSC cis rs2337406 0.866 rs79901786 ENSG00000211974.3 IGHV2-70 -5.59 3.84e-08 1.36e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106777623 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs7152809 ENSG00000211974.3 IGHV2-70 -5.59 3.84e-08 1.36e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106778385 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs7152832 ENSG00000211974.3 IGHV2-70 -5.59 3.84e-08 1.36e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106778427 chr14:106723574~106724093:- LUSC cis rs13113518 1 rs4864542 ENSG00000223305.1 RN7SKP30 -5.59 3.84e-08 1.36e-05 -0.31 -0.25 Height; chr4:55487920 chr4:55540502~55540835:- LUSC cis rs1075265 0.722 rs1877907 ENSG00000233266.1 HMGB1P31 5.59 3.84e-08 1.36e-05 0.31 0.25 Chronotype;Morning vs. evening chronotype; chr2:54137118 chr2:54051334~54051760:+ LUSC cis rs2153535 0.601 rs7738877 ENSG00000230939.1 RP11-314C16.1 -5.59 3.84e-08 1.36e-05 -0.3 -0.25 Motion sickness; chr6:8541997 chr6:8784178~8785445:+ LUSC cis rs7911264 0.739 rs10882091 ENSG00000236493.2 EIF2S2P3 5.59 3.84e-08 1.36e-05 0.29 0.25 Inflammatory bowel disease; chr10:92614620 chr10:92668745~92669743:- LUSC cis rs7772486 0.597 rs9285508 ENSG00000235652.6 RP11-545I5.3 -5.59 3.84e-08 1.36e-05 -0.28 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145941561 chr6:145799409~145886585:+ LUSC cis rs1008375 0.933 rs4698637 ENSG00000249502.1 AC006160.5 -5.59 3.85e-08 1.36e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17631220 chr4:17587467~17614571:- LUSC cis rs8062405 0.728 rs9931989 ENSG00000278665.1 RP11-666O2.4 -5.59 3.85e-08 1.36e-05 -0.26 -0.25 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28894763 chr16:28599241~28601881:- LUSC cis rs1707322 0.752 rs4660880 ENSG00000234329.1 RP11-767N6.2 5.59 3.85e-08 1.36e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645368 chr1:45651039~45651826:- LUSC cis rs66887589 0.807 rs7694483 ENSG00000248280.1 RP11-33B1.2 5.59 3.86e-08 1.36e-05 0.28 0.25 Diastolic blood pressure; chr4:119484774 chr4:119440561~119450157:- LUSC cis rs875971 0.54 rs781152 ENSG00000179406.6 LINC00174 -5.59 3.86e-08 1.36e-05 -0.27 -0.25 Aortic root size; chr7:66014585 chr7:66376044~66401338:- LUSC cis rs17711722 0.727 rs781151 ENSG00000179406.6 LINC00174 -5.59 3.86e-08 1.36e-05 -0.27 -0.25 Calcium levels; chr7:66014891 chr7:66376044~66401338:- LUSC cis rs442309 0.875 rs224147 ENSG00000238280.1 RP11-436D10.3 5.59 3.86e-08 1.37e-05 0.3 0.25 Vogt-Koyanagi-Harada syndrome; chr10:62726055 chr10:62793562~62805887:- LUSC cis rs2337406 0.866 rs7152038 ENSG00000211974.3 IGHV2-70 -5.59 3.87e-08 1.37e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106778230 chr14:106723574~106724093:- LUSC cis rs6452524 0.618 rs3899556 ENSG00000248112.1 RP11-78C3.1 5.59 3.87e-08 1.37e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83067862 chr5:82919376~82921119:- LUSC cis rs2439831 0.867 rs2447208 ENSG00000249839.1 AC011330.5 -5.59 3.87e-08 1.37e-05 -0.48 -0.25 Lung cancer in ever smokers; chr15:43641697 chr15:43663654~43684339:- LUSC cis rs8059260 0.604 rs35715760 ENSG00000274038.1 RP11-66H6.4 -5.59 3.88e-08 1.37e-05 -0.43 -0.25 Alcohol consumption over the past year; chr16:11102091 chr16:11056556~11057034:+ LUSC cis rs17711722 0.585 rs6942660 ENSG00000179406.6 LINC00174 -5.59 3.88e-08 1.37e-05 -0.26 -0.25 Calcium levels; chr7:65837419 chr7:66376044~66401338:- LUSC cis rs853679 0.55 rs1233707 ENSG00000280107.1 AL022393.9 -5.59 3.88e-08 1.37e-05 -0.3 -0.25 Depression; chr6:28205175 chr6:28170845~28172521:+ LUSC cis rs1345301 1 rs1345301 ENSG00000234389.1 AC007278.3 -5.59 3.88e-08 1.37e-05 -0.24 -0.25 Waist circumference; chr2:102259127 chr2:102438713~102440475:+ LUSC cis rs1345301 1 rs11686567 ENSG00000234389.1 AC007278.3 -5.59 3.88e-08 1.37e-05 -0.24 -0.25 Waist circumference; chr2:102260149 chr2:102438713~102440475:+ LUSC cis rs1345301 0.935 rs11691721 ENSG00000234389.1 AC007278.3 -5.59 3.88e-08 1.37e-05 -0.24 -0.25 Waist circumference; chr2:102260219 chr2:102438713~102440475:+ LUSC cis rs7208859 0.623 rs56163556 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs8067338 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30729469~30731202:+ LUSC cis rs7208859 0.573 rs4055105 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs73269923 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775553 chr17:30729469~30731202:+ LUSC cis rs7208859 0.562 rs8078897 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs8075163 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30729469~30731202:+ LUSC cis rs17826219 0.706 rs8075107 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Body mass index; chr17:30779631 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs7223209 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs7223404 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9916725 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9916727 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9914499 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs73269945 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9897728 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs1054400 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs1054397 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9890558 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9912283 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783355 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs12006 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs3752021 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs3752020 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9890855 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9893422 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs9891166 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30729469~30731202:+ LUSC cis rs7208859 0.623 rs73269974 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.88e-08 1.37e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30729469~30731202:+ LUSC cis rs6683071 0.54 rs1391558 ENSG00000272750.1 RP11-378J18.8 5.59 3.89e-08 1.37e-05 0.34 0.25 Cognitive performance; chr1:222674687 chr1:222658867~222661512:- LUSC cis rs875971 0.545 rs73142265 ENSG00000237310.1 GS1-124K5.4 5.59 3.89e-08 1.37e-05 0.29 0.25 Aortic root size; chr7:66234510 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs316305 ENSG00000224316.1 RP11-479O9.2 -5.59 3.89e-08 1.37e-05 -0.27 -0.25 Aortic root size; chr7:66152984 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs2460427 ENSG00000224316.1 RP11-479O9.2 -5.59 3.89e-08 1.37e-05 -0.27 -0.25 Aortic root size; chr7:66154218 chr7:65773620~65802067:+ LUSC cis rs13113518 0.729 rs13120134 ENSG00000272969.1 RP11-528I4.2 5.59 3.89e-08 1.37e-05 0.3 0.25 Height; chr4:55415153 chr4:55547112~55547889:+ LUSC cis rs2243480 1 rs35432774 ENSG00000226824.5 RP4-756H11.3 -5.59 3.89e-08 1.37e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65928032 chr7:66654538~66669855:+ LUSC cis rs875971 0.862 rs7783779 ENSG00000179406.6 LINC00174 5.59 3.89e-08 1.38e-05 0.27 0.25 Aortic root size; chr7:66331639 chr7:66376044~66401338:- LUSC cis rs11098499 0.909 rs10026736 ENSG00000248280.1 RP11-33B1.2 5.59 3.9e-08 1.38e-05 0.31 0.25 Corneal astigmatism; chr4:119463167 chr4:119440561~119450157:- LUSC cis rs4722166 0.63 rs12700390 ENSG00000179428.2 AC073072.5 -5.59 3.9e-08 1.38e-05 -0.31 -0.25 Lung cancer; chr7:22737510 chr7:22725395~22727620:- LUSC cis rs4722166 0.63 rs12700391 ENSG00000179428.2 AC073072.5 -5.59 3.9e-08 1.38e-05 -0.31 -0.25 Lung cancer; chr7:22737708 chr7:22725395~22727620:- LUSC cis rs4722166 0.63 rs7781534 ENSG00000179428.2 AC073072.5 -5.59 3.9e-08 1.38e-05 -0.31 -0.25 Lung cancer; chr7:22738973 chr7:22725395~22727620:- LUSC cis rs4722166 0.63 rs1581497 ENSG00000179428.2 AC073072.5 -5.59 3.9e-08 1.38e-05 -0.31 -0.25 Lung cancer; chr7:22739884 chr7:22725395~22727620:- LUSC cis rs4722166 0.63 rs1829927 ENSG00000179428.2 AC073072.5 -5.59 3.9e-08 1.38e-05 -0.31 -0.25 Lung cancer; chr7:22740299 chr7:22725395~22727620:- LUSC cis rs6772849 0.775 rs66822528 ENSG00000277250.1 Metazoa_SRP -5.59 3.9e-08 1.38e-05 -0.29 -0.25 Monocyte percentage of white cells;Monocyte count; chr3:128696254 chr3:128673681~128674021:- LUSC cis rs13113518 1 rs6858803 ENSG00000249700.7 SRD5A3-AS1 5.59 3.9e-08 1.38e-05 0.29 0.25 Height; chr4:55484534 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs7662966 ENSG00000272969.1 RP11-528I4.2 5.59 3.9e-08 1.38e-05 0.28 0.25 Height; chr4:55548261 chr4:55547112~55547889:+ LUSC cis rs11098499 0.908 rs28499576 ENSG00000248280.1 RP11-33B1.2 5.59 3.91e-08 1.38e-05 0.3 0.25 Corneal astigmatism; chr4:119465522 chr4:119440561~119450157:- LUSC cis rs113835537 0.877 rs3867132 ENSG00000255517.5 CTD-3074O7.5 -5.59 3.91e-08 1.38e-05 -0.35 -0.25 Airway imaging phenotypes; chr11:66541798 chr11:66473490~66480233:- LUSC cis rs875971 0.522 rs7784623 ENSG00000222364.1 RNU6-96P -5.59 3.91e-08 1.38e-05 -0.29 -0.25 Aortic root size; chr7:65930047 chr7:66395191~66395286:+ LUSC cis rs2732480 0.5 rs11168468 ENSG00000273765.1 RP11-370I10.11 5.59 3.91e-08 1.38e-05 0.29 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48218682 chr12:48360920~48361377:+ LUSC cis rs2337406 0.866 rs11488879 ENSG00000280411.1 IGHV1-69-2 -5.59 3.91e-08 1.38e-05 -0.23 -0.25 Alzheimer's disease (late onset); chr14:106786097 chr14:106762092~106762588:- LUSC cis rs34375054 0.573 rs12581813 ENSG00000279233.1 RP11-158L12.4 5.59 3.92e-08 1.38e-05 0.28 0.25 Post bronchodilator FEV1/FVC ratio; chr12:125171856 chr12:125138245~125141711:+ LUSC cis rs67311347 1 rs9817142 ENSG00000223797.4 ENTPD3-AS1 5.59 3.92e-08 1.38e-05 0.29 0.25 Renal cell carcinoma; chr3:40384283 chr3:40313802~40453329:- LUSC cis rs9659323 0.67 rs10157346 ENSG00000231365.4 RP11-418J17.1 -5.59 3.92e-08 1.38e-05 -0.29 -0.25 Body mass index; chr1:119090924 chr1:119140396~119275973:+ LUSC cis rs7955901 1 rs7955901 ENSG00000257265.1 CTD-2021H9.1 -5.59 3.92e-08 1.38e-05 -0.27 -0.25 Type 2 diabetes; chr12:71039513 chr12:71007773~71032083:- LUSC cis rs2919917 0.628 rs7010299 ENSG00000254352.1 RP11-578O24.2 5.59 3.93e-08 1.39e-05 0.33 0.25 Lymphocyte counts; chr8:78707786 chr8:78723796~78724136:- LUSC cis rs61270009 0.955 rs12515274 ENSG00000247828.6 TMEM161B-AS1 5.59 3.93e-08 1.39e-05 0.29 0.25 Depressive symptoms; chr5:88359845 chr5:88268895~88436685:+ LUSC cis rs1823874 0.581 rs11855419 ENSG00000182397.13 DNM1P46 5.59 3.93e-08 1.39e-05 0.29 0.25 IgG glycosylation; chr15:99787275 chr15:99790156~99806927:- LUSC cis rs17711722 1 rs17711722 ENSG00000179406.6 LINC00174 5.59 3.93e-08 1.39e-05 0.26 0.25 Calcium levels; chr7:65806210 chr7:66376044~66401338:- LUSC cis rs9322193 0.884 rs11155675 ENSG00000268592.3 RAET1E-AS1 5.59 3.93e-08 1.39e-05 0.33 0.25 Lung cancer; chr6:149742883 chr6:149863494~149919507:+ LUSC cis rs11098499 0.865 rs10213221 ENSG00000250412.1 KLHL2P1 5.59 3.94e-08 1.39e-05 0.3 0.25 Corneal astigmatism; chr4:119334771 chr4:119334329~119378233:+ LUSC cis rs7208859 0.573 rs7214313 ENSG00000263603.1 CTD-2349P21.5 -5.59 3.94e-08 1.39e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30729469~30731202:+ LUSC cis rs7712401 0.601 rs144597 ENSG00000263432.2 RN7SL689P 5.59 3.94e-08 1.39e-05 0.31 0.25 Mean platelet volume; chr5:122887537 chr5:123022487~123022783:- LUSC cis rs34792 0.525 rs12708795 ENSG00000207425.1 Y_RNA -5.59 3.95e-08 1.39e-05 -0.35 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15533861 chr16:14915457~14915556:- LUSC cis rs2562456 0.793 rs7259708 ENSG00000268081.1 RP11-678G14.2 5.59 3.95e-08 1.39e-05 0.36 0.25 Pain; chr19:21567846 chr19:21554640~21569237:- LUSC cis rs944990 0.557 rs952288 ENSG00000227603.1 RP11-165J3.6 5.59 3.95e-08 1.39e-05 0.24 0.25 Body mass index; chr9:93502629 chr9:93435332~93437121:- LUSC cis rs2111504 0.583 rs10853921 ENSG00000267213.4 AC007773.2 -5.59 3.95e-08 1.39e-05 -0.32 -0.25 Bipolar disorder; chr19:32370899 chr19:32390050~32405560:- LUSC cis rs2732480 0.538 rs1387260 ENSG00000226413.2 OR8T1P 5.59 3.95e-08 1.39e-05 0.33 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48309308 chr12:48442030~48442947:- LUSC cis rs6565180 0.888 rs12447833 ENSG00000183604.13 SMG1P5 5.59 3.96e-08 1.39e-05 0.31 0.25 Tonsillectomy; chr16:30378993 chr16:30267553~30335374:- LUSC cis rs801193 0.761 rs2659888 ENSG00000237310.1 GS1-124K5.4 5.59 3.96e-08 1.4e-05 0.25 0.25 Aortic root size; chr7:66765184 chr7:66493706~66495474:+ LUSC cis rs11098499 0.954 rs11098525 ENSG00000248280.1 RP11-33B1.2 5.59 3.96e-08 1.4e-05 0.3 0.25 Corneal astigmatism; chr4:119468997 chr4:119440561~119450157:- LUSC cis rs875971 0.66 rs1860468 ENSG00000222364.1 RNU6-96P 5.59 3.96e-08 1.4e-05 0.29 0.25 Aortic root size; chr7:66642265 chr7:66395191~66395286:+ LUSC cis rs11098499 0.909 rs1546502 ENSG00000248280.1 RP11-33B1.2 5.58 3.96e-08 1.4e-05 0.31 0.25 Corneal astigmatism; chr4:119314743 chr4:119440561~119450157:- LUSC cis rs1021993 0.545 rs74155473 ENSG00000231648.1 RP11-372M18.2 -5.58 3.96e-08 1.4e-05 -0.36 -0.25 Gut microbiome composition (winter); chr1:209372518 chr1:209367662~209379690:+ LUSC cis rs673078 0.607 rs17512483 ENSG00000275759.1 RP11-131L12.3 5.58 3.96e-08 1.4e-05 0.38 0.25 Glucose homeostasis traits; chr12:118312380 chr12:118428281~118428870:+ LUSC cis rs17711722 0.727 rs2658585 ENSG00000237310.1 GS1-124K5.4 5.58 3.96e-08 1.4e-05 0.26 0.25 Calcium levels; chr7:65996954 chr7:66493706~66495474:+ LUSC cis rs17711722 0.74 rs7809991 ENSG00000179406.6 LINC00174 -5.58 3.97e-08 1.4e-05 -0.26 -0.25 Calcium levels; chr7:65941231 chr7:66376044~66401338:- LUSC cis rs910316 0.763 rs175450 ENSG00000279594.1 RP11-950C14.10 -5.58 3.97e-08 1.4e-05 -0.29 -0.25 Height; chr14:75123637 chr14:75011269~75012851:- LUSC cis rs7712401 0.601 rs2910136 ENSG00000263432.2 RN7SL689P -5.58 3.97e-08 1.4e-05 -0.31 -0.25 Mean platelet volume; chr5:122918322 chr5:123022487~123022783:- LUSC cis rs950169 0.881 rs34117475 ENSG00000259295.5 CSPG4P12 5.58 3.97e-08 1.4e-05 0.33 0.25 Schizophrenia; chr15:84565212 chr15:85191438~85213905:+ LUSC cis rs6502050 0.835 rs12051747 ENSG00000266654.1 RP11-1376P16.1 -5.58 3.97e-08 1.4e-05 -0.25 -0.25 Life satisfaction; chr17:82156938 chr17:82160056~82160452:+ LUSC cis rs11098499 0.775 rs67281037 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119360002 chr4:119440561~119450157:- LUSC cis rs10028773 0.506 rs12374346 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Educational attainment; chr4:119360550 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs12374244 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119360817 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs12374352 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119360822 chr4:119440561~119450157:- LUSC cis rs11098499 0.775 rs10021601 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119361408 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs6857892 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119361541 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs28581362 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119362393 chr4:119440561~119450157:- LUSC cis rs11098499 0.82 rs12503082 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119363162 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs12499602 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119363232 chr4:119440561~119450157:- LUSC cis rs11098499 0.774 rs11098505 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119363472 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs13105020 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119364533 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs6824111 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119364813 chr4:119440561~119450157:- LUSC cis rs11098499 0.779 rs10857066 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119365441 chr4:119440561~119450157:- LUSC cis rs11098499 0.775 rs10029303 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119365600 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs9995136 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119365690 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs13125526 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119366864 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs12513310 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119366884 chr4:119440561~119450157:- LUSC cis rs11098499 0.866 rs12510451 ENSG00000248280.1 RP11-33B1.2 5.58 3.98e-08 1.4e-05 0.29 0.25 Corneal astigmatism; chr4:119367988 chr4:119440561~119450157:- LUSC cis rs8005677 0.798 rs4982711 ENSG00000279656.1 RP11-298I3.6 5.58 3.98e-08 1.4e-05 0.3 0.25 Cognitive ability (multi-trait analysis); chr14:22929781 chr14:23023083~23024217:- LUSC cis rs7829975 0.514 rs2976929 ENSG00000173295.6 FAM86B3P 5.58 3.98e-08 1.4e-05 0.27 0.25 Mood instability; chr8:8401202 chr8:8228595~8244865:+ LUSC cis rs2337406 0.866 rs111881598 ENSG00000280411.1 IGHV1-69-2 -5.58 3.98e-08 1.4e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106783113 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs61164979 ENSG00000280411.1 IGHV1-69-2 -5.58 3.98e-08 1.4e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106783133 chr14:106762092~106762588:- LUSC cis rs2303759 0.918 rs8107548 ENSG00000268686.1 AC010524.2 -5.58 3.98e-08 1.4e-05 -0.34 -0.25 Multiple sclerosis; chr19:49367386 chr19:49368705~49388081:- LUSC cis rs2742234 0.59 rs1254960 ENSG00000273008.1 RP11-351D16.3 5.58 3.99e-08 1.4e-05 0.28 0.25 Hirschsprung disease; chr10:43204209 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs1254959 ENSG00000273008.1 RP11-351D16.3 5.58 3.99e-08 1.4e-05 0.28 0.25 Hirschsprung disease; chr10:43205531 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs1254958 ENSG00000273008.1 RP11-351D16.3 5.58 3.99e-08 1.4e-05 0.28 0.25 Hirschsprung disease; chr10:43206695 chr10:43136824~43138334:- LUSC cis rs4713118 0.513 rs149941 ENSG00000216901.1 AL022393.7 5.58 3.99e-08 1.4e-05 0.29 0.25 Parkinson's disease; chr6:28033255 chr6:28176188~28176674:+ LUSC cis rs6570726 0.935 rs387965 ENSG00000235652.6 RP11-545I5.3 5.58 3.99e-08 1.4e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145548230 chr6:145799409~145886585:+ LUSC cis rs17711722 0.727 rs1880555 ENSG00000179406.6 LINC00174 -5.58 3.99e-08 1.41e-05 -0.26 -0.25 Calcium levels; chr7:65967580 chr7:66376044~66401338:- LUSC cis rs77204473 0.744 rs80273401 ENSG00000254851.1 RP11-109L13.1 5.58 4e-08 1.41e-05 0.62 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117037990 chr11:117135528~117138582:+ LUSC cis rs13113518 1 rs4864548 ENSG00000223305.1 RN7SKP30 -5.58 4e-08 1.41e-05 -0.3 -0.25 Height; chr4:55547636 chr4:55540502~55540835:- LUSC cis rs11159086 0.793 rs1029702 ENSG00000259005.1 RP3-449M8.6 5.58 4e-08 1.41e-05 0.37 0.25 Advanced glycation end-product levels; chr14:74473909 chr14:74474007~74474864:- LUSC cis rs9890032 0.581 rs62070592 ENSG00000266490.1 CTD-2349P21.9 5.58 4.01e-08 1.41e-05 0.21 0.25 Hip circumference adjusted for BMI; chr17:30695531 chr17:30792372~30792833:+ LUSC cis rs11098499 0.863 rs7678400 ENSG00000248280.1 RP11-33B1.2 5.58 4.01e-08 1.41e-05 0.3 0.25 Corneal astigmatism; chr4:119540802 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs1480936 ENSG00000248280.1 RP11-33B1.2 5.58 4.01e-08 1.41e-05 0.3 0.25 Corneal astigmatism; chr4:119541706 chr4:119440561~119450157:- LUSC cis rs228614 0.509 rs223481 ENSG00000246560.2 RP11-10L12.4 5.58 4.02e-08 1.41e-05 0.3 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766860 chr4:102828055~102844075:+ LUSC cis rs2739330 0.76 rs5760095 ENSG00000228039.3 KB-1125A3.10 5.58 4.02e-08 1.41e-05 0.32 0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23963780~23964374:+ LUSC cis rs2236295 0.597 rs7477765 ENSG00000238280.1 RP11-436D10.3 -5.58 4.02e-08 1.41e-05 -0.32 -0.25 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks); chr10:62831984 chr10:62793562~62805887:- LUSC cis rs7555523 0.887 rs4657476 ENSG00000224358.1 RP11-466F5.8 5.58 4.02e-08 1.42e-05 0.31 0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165763424 chr1:165768929~165775176:+ LUSC cis rs867371 0.502 rs7176926 ENSG00000278603.1 RP13-608F4.5 5.58 4.03e-08 1.42e-05 0.3 0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82245753 chr15:82472203~82472426:+ LUSC cis rs72627123 1 rs72627124 ENSG00000259065.1 RP5-1021I20.1 -5.58 4.03e-08 1.42e-05 -0.44 -0.25 Morning vs. evening chronotype; chr14:73902425 chr14:73787360~73803270:+ LUSC cis rs72627123 1 rs72627125 ENSG00000259065.1 RP5-1021I20.1 -5.58 4.03e-08 1.42e-05 -0.44 -0.25 Morning vs. evening chronotype; chr14:73902920 chr14:73787360~73803270:+ LUSC cis rs72627123 1 rs72627127 ENSG00000259065.1 RP5-1021I20.1 -5.58 4.03e-08 1.42e-05 -0.44 -0.25 Morning vs. evening chronotype; chr14:73903395 chr14:73787360~73803270:+ LUSC cis rs853679 0.55 rs1225599 ENSG00000280107.1 AL022393.9 -5.58 4.03e-08 1.42e-05 -0.3 -0.25 Depression; chr6:28197412 chr6:28170845~28172521:+ LUSC cis rs853679 0.574 rs1233705 ENSG00000280107.1 AL022393.9 -5.58 4.03e-08 1.42e-05 -0.3 -0.25 Depression; chr6:28198669 chr6:28170845~28172521:+ LUSC cis rs11098499 0.618 rs28491261 ENSG00000248280.1 RP11-33B1.2 5.58 4.03e-08 1.42e-05 0.3 0.25 Corneal astigmatism; chr4:119373745 chr4:119440561~119450157:- LUSC cis rs9907295 0.818 rs9303692 ENSG00000270977.1 AC015849.16 5.58 4.03e-08 1.42e-05 0.3 0.25 Fibroblast growth factor basic levels; chr17:35861492 chr17:35893707~35911023:- LUSC cis rs875971 0.522 rs34973832 ENSG00000179406.6 LINC00174 -5.58 4.04e-08 1.42e-05 -0.26 -0.25 Aortic root size; chr7:65931217 chr7:66376044~66401338:- LUSC cis rs8042680 0.522 rs12595616 ENSG00000214432.8 AC068831.10 5.58 4.04e-08 1.42e-05 0.29 0.25 Type 2 diabetes; chr15:91020283 chr15:91022619~91036611:+ LUSC cis rs4722166 0.573 rs35436671 ENSG00000179428.2 AC073072.5 -5.58 4.04e-08 1.42e-05 -0.31 -0.25 Lung cancer; chr7:22735889 chr7:22725395~22727620:- LUSC cis rs75422866 0.85 rs73111210 ENSG00000274902.1 RP1-197B17.4 5.58 4.04e-08 1.42e-05 0.69 0.25 Pneumonia; chr12:47576949 chr12:47731908~47732351:+ LUSC cis rs4964805 0.58 rs10861097 ENSG00000257681.1 RP11-341G23.4 5.58 4.04e-08 1.42e-05 0.28 0.25 Attention deficit hyperactivity disorder; chr12:103776696 chr12:103746315~103768858:- LUSC cis rs6543140 0.929 rs11465700 ENSG00000234389.1 AC007278.3 5.58 4.04e-08 1.42e-05 0.26 0.25 Blood protein levels; chr2:102441208 chr2:102438713~102440475:+ LUSC cis rs2337406 0.539 rs2583290 ENSG00000274576.2 IGHV2-70 5.58 4.04e-08 1.42e-05 0.26 0.25 Alzheimer's disease (late onset); chr14:106650277 chr14:106770577~106771020:- LUSC cis rs4964805 0.612 rs11111758 ENSG00000257681.1 RP11-341G23.4 5.58 4.05e-08 1.42e-05 0.28 0.25 Attention deficit hyperactivity disorder; chr12:103767306 chr12:103746315~103768858:- LUSC cis rs11676348 0.755 rs1008562 ENSG00000261338.2 RP11-378A13.1 5.58 4.05e-08 1.42e-05 0.24 0.25 Ulcerative colitis; chr2:218162249 chr2:218255319~218257366:+ LUSC cis rs66887589 0.807 rs7694483 ENSG00000249244.1 RP11-548H18.2 5.58 4.05e-08 1.42e-05 0.3 0.25 Diastolic blood pressure; chr4:119484774 chr4:119391831~119395335:- LUSC cis rs28830936 0.966 rs2241522 ENSG00000250379.1 RP11-23P13.4 5.58 4.06e-08 1.43e-05 0.27 0.25 Diastolic blood pressure; chr15:41835536 chr15:41825099~41827936:- LUSC cis rs2919917 0.628 rs12680932 ENSG00000254352.1 RP11-578O24.2 -5.58 4.06e-08 1.43e-05 -0.35 -0.25 Lymphocyte counts; chr8:78685516 chr8:78723796~78724136:- LUSC cis rs950169 0.8 rs4842847 ENSG00000259295.5 CSPG4P12 5.58 4.06e-08 1.43e-05 0.34 0.25 Schizophrenia; chr15:84262447 chr15:85191438~85213905:+ LUSC cis rs9545047 0.604 rs7983344 ENSG00000227676.3 LINC01068 -5.58 4.06e-08 1.43e-05 -0.3 -0.25 Schizophrenia; chr13:79299295 chr13:79566727~79571436:+ LUSC cis rs3002131 0.522 rs2936031 ENSG00000225265.1 TAF1A-AS1 -5.58 4.06e-08 1.43e-05 -0.37 -0.25 Interleukin-10 levels; chr1:222582910 chr1:222589825~222593032:+ LUSC cis rs367615 0.704 rs72802966 ENSG00000249476.1 CTD-2587M2.1 5.58 4.07e-08 1.43e-05 0.28 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109511053 chr5:109237120~109326369:- LUSC cis rs367615 0.704 rs7726991 ENSG00000249476.1 CTD-2587M2.1 5.58 4.07e-08 1.43e-05 0.28 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109511733 chr5:109237120~109326369:- LUSC cis rs367615 0.704 rs72804385 ENSG00000249476.1 CTD-2587M2.1 5.58 4.07e-08 1.43e-05 0.28 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109512442 chr5:109237120~109326369:- LUSC cis rs2337406 0.866 rs988131 ENSG00000211974.3 IGHV2-70 -5.58 4.07e-08 1.43e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106776833 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs8005518 ENSG00000211974.3 IGHV2-70 -5.58 4.07e-08 1.43e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106777009 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs57684263 ENSG00000211974.3 IGHV2-70 -5.58 4.07e-08 1.43e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106777263 chr14:106723574~106724093:- LUSC cis rs10028773 0.515 rs9994488 ENSG00000249244.1 RP11-548H18.2 5.58 4.07e-08 1.43e-05 0.31 0.25 Educational attainment; chr4:119666626 chr4:119391831~119395335:- LUSC cis rs442309 0.875 rs224064 ENSG00000238280.1 RP11-436D10.3 -5.58 4.07e-08 1.43e-05 -0.31 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62744452 chr10:62793562~62805887:- LUSC cis rs2919917 0.628 rs10113703 ENSG00000254352.1 RP11-578O24.2 5.58 4.08e-08 1.43e-05 0.33 0.25 Lymphocyte counts; chr8:78688404 chr8:78723796~78724136:- LUSC cis rs4964805 0.594 rs3751204 ENSG00000257681.1 RP11-341G23.4 5.58 4.08e-08 1.43e-05 0.28 0.25 Attention deficit hyperactivity disorder; chr12:103777677 chr12:103746315~103768858:- LUSC cis rs12908161 1 rs35630683 ENSG00000259728.4 LINC00933 5.58 4.08e-08 1.43e-05 0.33 0.25 Schizophrenia; chr15:84806000 chr15:84570649~84580175:+ LUSC cis rs35828350 1 rs35828350 ENSG00000259728.4 LINC00933 5.58 4.08e-08 1.43e-05 0.33 0.25 Autism spectrum disorder or schizophrenia; chr15:84812610 chr15:84570649~84580175:+ LUSC cis rs12908161 1 rs56864281 ENSG00000259728.4 LINC00933 5.58 4.08e-08 1.43e-05 0.33 0.25 Schizophrenia; chr15:84814418 chr15:84570649~84580175:+ LUSC cis rs2274273 0.87 rs11625001 ENSG00000258413.1 RP11-665C16.6 -5.58 4.08e-08 1.44e-05 -0.3 -0.25 Protein biomarker; chr14:55291442 chr14:55262767~55272075:- LUSC cis rs2274273 0.805 rs11628437 ENSG00000258413.1 RP11-665C16.6 -5.58 4.08e-08 1.44e-05 -0.3 -0.25 Protein biomarker; chr14:55308750 chr14:55262767~55272075:- LUSC cis rs11159086 0.793 rs1029701 ENSG00000270000.1 RP3-449M8.9 5.58 4.09e-08 1.44e-05 0.37 0.25 Advanced glycation end-product levels; chr14:74474112 chr14:74471930~74472360:- LUSC cis rs6452524 0.618 rs4266384 ENSG00000248112.1 RP11-78C3.1 5.58 4.09e-08 1.44e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83080872 chr5:82919376~82921119:- LUSC cis rs7712401 0.715 rs401226 ENSG00000263432.2 RN7SL689P -5.58 4.09e-08 1.44e-05 -0.32 -0.25 Mean platelet volume; chr5:123012031 chr5:123022487~123022783:- LUSC cis rs7712401 0.715 rs395981 ENSG00000263432.2 RN7SL689P -5.58 4.09e-08 1.44e-05 -0.32 -0.25 Mean platelet volume; chr5:123012216 chr5:123022487~123022783:- LUSC cis rs7712401 0.715 rs424247 ENSG00000263432.2 RN7SL689P -5.58 4.09e-08 1.44e-05 -0.32 -0.25 Mean platelet volume; chr5:123012298 chr5:123022487~123022783:- LUSC cis rs7712401 0.715 rs424262 ENSG00000263432.2 RN7SL689P -5.58 4.09e-08 1.44e-05 -0.32 -0.25 Mean platelet volume; chr5:123012317 chr5:123022487~123022783:- LUSC cis rs7665090 1 rs6821119 ENSG00000230069.3 LRRC37A15P -5.58 4.09e-08 1.44e-05 -0.26 -0.25 Primary biliary cholangitis; chr4:102634076 chr4:102727274~102730721:- LUSC cis rs7665090 0.934 rs6844332 ENSG00000230069.3 LRRC37A15P -5.58 4.09e-08 1.44e-05 -0.26 -0.25 Primary biliary cholangitis; chr4:102634095 chr4:102727274~102730721:- LUSC cis rs7665090 0.967 rs6821133 ENSG00000230069.3 LRRC37A15P -5.58 4.09e-08 1.44e-05 -0.26 -0.25 Primary biliary cholangitis; chr4:102634096 chr4:102727274~102730721:- LUSC cis rs13030978 0.505 rs72916554 ENSG00000280083.1 RP11-317J9.1 -5.58 4.1e-08 1.44e-05 -0.31 -0.25 Liver enzyme levels (gamma-glutamyl transferase); chr2:191330532 chr2:191154118~191156070:- LUSC cis rs11971779 0.793 rs4732366 ENSG00000273391.1 RP11-634H22.1 5.58 4.1e-08 1.44e-05 0.28 0.25 Diisocyanate-induced asthma; chr7:139343099 chr7:139359032~139359566:- LUSC cis rs9341835 0.618 rs1779747 ENSG00000218048.2 RP3-407E4.4 -5.58 4.1e-08 1.44e-05 -0.27 -0.25 Schizophrenia; chr6:63431195 chr6:63440766~63443580:+ LUSC cis rs2243480 1 rs937108 ENSG00000226824.5 RP4-756H11.3 -5.58 4.1e-08 1.44e-05 -0.49 -0.25 Diabetic kidney disease; chr7:65963465 chr7:66654538~66669855:+ LUSC cis rs4713118 0.866 rs9468217 ENSG00000280107.1 AL022393.9 -5.58 4.11e-08 1.44e-05 -0.3 -0.25 Parkinson's disease; chr6:27758688 chr6:28170845~28172521:+ LUSC cis rs2842992 0.747 rs9365095 ENSG00000237927.1 RP3-393E18.2 -5.58 4.11e-08 1.44e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159771896 chr6:159586955~159589169:- LUSC cis rs2842992 0.789 rs7758895 ENSG00000237927.1 RP3-393E18.2 -5.58 4.11e-08 1.44e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159772433 chr6:159586955~159589169:- LUSC cis rs2842992 0.789 rs4276525 ENSG00000237927.1 RP3-393E18.2 -5.58 4.11e-08 1.44e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159772580 chr6:159586955~159589169:- LUSC cis rs1008375 0.932 rs6449315 ENSG00000249502.1 AC006160.5 -5.58 4.11e-08 1.44e-05 -0.24 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17588596 chr4:17587467~17614571:- LUSC cis rs61270009 0.955 rs454693 ENSG00000247828.6 TMEM161B-AS1 5.58 4.12e-08 1.45e-05 0.28 0.25 Depressive symptoms; chr5:88248396 chr5:88268895~88436685:+ LUSC cis rs11676348 0.755 rs13410318 ENSG00000261338.2 RP11-378A13.1 5.58 4.12e-08 1.45e-05 0.24 0.25 Ulcerative colitis; chr2:218158187 chr2:218255319~218257366:+ LUSC cis rs240993 0.516 rs241004 ENSG00000230177.1 RP5-1112D6.4 -5.58 4.12e-08 1.45e-05 -0.29 -0.25 Inflammatory skin disease;Psoriasis; chr6:111275341 chr6:111277932~111278742:+ LUSC cis rs6502050 0.835 rs8067875 ENSG00000266654.1 RP11-1376P16.1 -5.58 4.13e-08 1.45e-05 -0.25 -0.25 Life satisfaction; chr17:82134902 chr17:82160056~82160452:+ LUSC cis rs7674212 0.507 rs223361 ENSG00000246560.2 RP11-10L12.4 5.58 4.13e-08 1.45e-05 0.32 0.25 Type 2 diabetes; chr4:102848147 chr4:102828055~102844075:+ LUSC cis rs875971 0.545 rs316306 ENSG00000237310.1 GS1-124K5.4 -5.58 4.13e-08 1.45e-05 -0.28 -0.25 Aortic root size; chr7:66153687 chr7:66493706~66495474:+ LUSC cis rs8059260 0.736 rs74391397 ENSG00000274038.1 RP11-66H6.4 -5.58 4.13e-08 1.45e-05 -0.46 -0.25 Alcohol consumption over the past year; chr16:10975570 chr16:11056556~11057034:+ LUSC cis rs30380 0.69 rs2216752 ENSG00000248734.2 CTD-2260A17.1 -5.58 4.14e-08 1.45e-05 -0.27 -0.25 Cerebrospinal fluid biomarker levels; chr5:96849764 chr5:96784777~96785999:+ LUSC cis rs77683187 1 rs77683187 ENSG00000254851.1 RP11-109L13.1 5.58 4.14e-08 1.45e-05 0.6 0.25 Breast cancer; chr11:117214494 chr11:117135528~117138582:+ LUSC cis rs801193 1 rs62466793 ENSG00000222364.1 RNU6-96P -5.58 4.14e-08 1.45e-05 -0.29 -0.25 Aortic root size; chr7:66726530 chr7:66395191~66395286:+ LUSC cis rs801193 1 rs62466794 ENSG00000222364.1 RNU6-96P -5.58 4.14e-08 1.45e-05 -0.29 -0.25 Aortic root size; chr7:66726592 chr7:66395191~66395286:+ LUSC cis rs11098499 0.554 rs2175381 ENSG00000249244.1 RP11-548H18.2 5.58 4.14e-08 1.45e-05 0.31 0.25 Corneal astigmatism; chr4:119344812 chr4:119391831~119395335:- LUSC cis rs11098499 0.599 rs3864142 ENSG00000249244.1 RP11-548H18.2 5.58 4.14e-08 1.45e-05 0.31 0.25 Corneal astigmatism; chr4:119345036 chr4:119391831~119395335:- LUSC cis rs11098499 0.605 rs6833140 ENSG00000249244.1 RP11-548H18.2 5.58 4.14e-08 1.45e-05 0.31 0.25 Corneal astigmatism; chr4:119345667 chr4:119391831~119395335:- LUSC cis rs875971 0.522 rs2008188 ENSG00000179406.6 LINC00174 -5.58 4.14e-08 1.45e-05 -0.26 -0.25 Aortic root size; chr7:65964026 chr7:66376044~66401338:- LUSC cis rs6570726 0.764 rs9403726 ENSG00000235652.6 RP11-545I5.3 5.58 4.15e-08 1.46e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145580550 chr6:145799409~145886585:+ LUSC cis rs11096990 0.634 rs6531703 ENSG00000249207.1 RP11-360F5.1 5.58 4.15e-08 1.46e-05 0.26 0.25 Cognitive function; chr4:39281786 chr4:39112677~39126818:- LUSC cis rs6860806 0.507 rs270606 ENSG00000233006.5 AC034220.3 5.58 4.15e-08 1.46e-05 0.26 0.25 Breast cancer; chr5:132315174 chr5:132311285~132369916:- LUSC cis rs2337406 0.866 rs2027901 ENSG00000254174.1 IGHV1-12 5.58 4.15e-08 1.46e-05 0.25 0.25 Alzheimer's disease (late onset); chr14:106807164 chr14:106122420~106122709:- LUSC cis rs10759883 0.627 rs700962 ENSG00000175611.10 LINC00476 -5.58 4.15e-08 1.46e-05 -0.29 -0.25 Nicotine dependence; chr9:95815766 chr9:95759231~95875977:- LUSC cis rs875971 0.545 rs6460276 ENSG00000179406.6 LINC00174 -5.58 4.16e-08 1.46e-05 -0.29 -0.25 Aortic root size; chr7:66182290 chr7:66376044~66401338:- LUSC cis rs67340775 0.541 rs200973 ENSG00000280107.1 AL022393.9 -5.58 4.16e-08 1.46e-05 -0.34 -0.25 Lung cancer in ever smokers; chr6:27890643 chr6:28170845~28172521:+ LUSC cis rs380904 0.519 rs12541790 ENSG00000254859.1 RP11-661A12.5 -5.58 4.16e-08 1.46e-05 -0.36 -0.25 Venous thromboembolism (SNP x SNP interaction); chr8:143561151 chr8:143541973~143549729:- LUSC cis rs17361889 0.711 rs1120230 ENSG00000224683.1 RPL36AP29 5.58 4.17e-08 1.46e-05 0.3 0.25 Pediatric bone mineral content (hip); chr7:16110992 chr7:16208945~16209265:+ LUSC cis rs2439831 0.85 rs7183809 ENSG00000249839.1 AC011330.5 -5.58 4.17e-08 1.46e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43828670 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs3759790 ENSG00000249839.1 AC011330.5 -5.58 4.17e-08 1.46e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43828832 chr15:43663654~43684339:- LUSC cis rs202072 0.729 rs202038 ENSG00000272379.1 RP1-257A7.5 -5.58 4.18e-08 1.47e-05 -0.38 -0.25 HIV-1 viral setpoint; chr6:13288416 chr6:13290018~13290490:- LUSC cis rs13113518 1 rs13141049 ENSG00000272969.1 RP11-528I4.2 5.58 4.18e-08 1.47e-05 0.28 0.25 Height; chr4:55535489 chr4:55547112~55547889:+ LUSC cis rs11089937 0.585 rs6001229 ENSG00000211639.2 IGLV4-60 -5.58 4.18e-08 1.47e-05 -0.26 -0.25 Periodontitis (PAL4Q3); chr22:22187693 chr22:22162199~22162681:+ LUSC cis rs4964805 0.549 rs11111752 ENSG00000257681.1 RP11-341G23.4 5.57 4.19e-08 1.47e-05 0.29 0.25 Attention deficit hyperactivity disorder; chr12:103762774 chr12:103746315~103768858:- LUSC cis rs4964805 0.549 rs1976256 ENSG00000257681.1 RP11-341G23.4 5.57 4.19e-08 1.47e-05 0.29 0.25 Attention deficit hyperactivity disorder; chr12:103763121 chr12:103746315~103768858:- LUSC cis rs17270561 0.609 rs1937127 ENSG00000272462.2 U91328.19 5.57 4.19e-08 1.47e-05 0.29 0.25 Iron status biomarkers; chr6:25769644 chr6:25992662~26001775:+ LUSC cis rs11098499 0.604 rs17051352 ENSG00000248280.1 RP11-33B1.2 5.57 4.19e-08 1.47e-05 0.31 0.25 Corneal astigmatism; chr4:119660272 chr4:119440561~119450157:- LUSC cis rs13434995 0.513 rs6851971 ENSG00000249700.7 SRD5A3-AS1 5.57 4.19e-08 1.47e-05 0.3 0.25 Adiponectin levels; chr4:55561897 chr4:55363971~55395847:- LUSC cis rs12935418 0.83 rs7195459 ENSG00000261061.1 RP11-303E16.2 -5.57 4.19e-08 1.47e-05 -0.43 -0.25 Mean corpuscular volume; chr16:81016376 chr16:81030770~81031485:+ LUSC cis rs12468226 1 rs76021735 ENSG00000272966.1 RP11-686O6.1 5.57 4.2e-08 1.47e-05 0.41 0.25 Urate levels; chr2:202511476 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs57080353 ENSG00000272966.1 RP11-686O6.1 5.57 4.2e-08 1.47e-05 0.41 0.25 Urate levels; chr2:202511824 chr2:202336739~202337200:+ LUSC cis rs12468226 0.81 rs3736578 ENSG00000272966.1 RP11-686O6.1 5.57 4.2e-08 1.47e-05 0.41 0.25 Urate levels; chr2:202519989 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs116439150 ENSG00000272966.1 RP11-686O6.1 5.57 4.2e-08 1.47e-05 0.41 0.25 Urate levels; chr2:202523814 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs12467409 ENSG00000272966.1 RP11-686O6.1 5.57 4.2e-08 1.47e-05 0.41 0.25 Urate levels; chr2:202529625 chr2:202336739~202337200:+ LUSC cis rs12468226 0.81 rs77090459 ENSG00000272966.1 RP11-686O6.1 5.57 4.2e-08 1.47e-05 0.41 0.25 Urate levels; chr2:202542132 chr2:202336739~202337200:+ LUSC cis rs10462794 0.661 rs57263812 ENSG00000260763.1 RP11-445O3.3 -5.57 4.2e-08 1.47e-05 -0.33 -0.25 DNA methylation (variation); chr5:4521178 chr5:4436850~4440259:- LUSC cis rs4713118 0.868 rs760587 ENSG00000280107.1 AL022393.9 -5.57 4.2e-08 1.47e-05 -0.31 -0.25 Parkinson's disease; chr6:27772521 chr6:28170845~28172521:+ LUSC cis rs8005677 0.77 rs56180741 ENSG00000279656.1 RP11-298I3.6 5.57 4.2e-08 1.47e-05 0.29 0.25 Cognitive ability (multi-trait analysis); chr14:22908037 chr14:23023083~23024217:- LUSC cis rs77204473 0.744 rs12970 ENSG00000254851.1 RP11-109L13.1 5.57 4.2e-08 1.47e-05 0.6 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117203393 chr11:117135528~117138582:+ LUSC cis rs34792 0.678 rs153787 ENSG00000207425.1 Y_RNA 5.57 4.2e-08 1.47e-05 0.33 0.25 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15499916 chr16:14915457~14915556:- LUSC cis rs4938330 0.739 rs11216266 ENSG00000254851.1 RP11-109L13.1 5.57 4.2e-08 1.47e-05 0.34 0.25 Blood protein levels; chr11:117079434 chr11:117135528~117138582:+ LUSC cis rs75920871 0.748 rs7106662 ENSG00000254851.1 RP11-109L13.1 5.57 4.2e-08 1.47e-05 0.34 0.25 Subjective well-being; chr11:117080669 chr11:117135528~117138582:+ LUSC cis rs1008375 0.966 rs28441502 ENSG00000249502.1 AC006160.5 -5.57 4.2e-08 1.47e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17596761 chr4:17587467~17614571:- LUSC cis rs12468226 1 rs7565875 ENSG00000272966.1 RP11-686O6.1 5.57 4.21e-08 1.47e-05 0.41 0.25 Urate levels; chr2:202516412 chr2:202336739~202337200:+ LUSC cis rs875971 0.522 rs10807697 ENSG00000179406.6 LINC00174 -5.57 4.21e-08 1.48e-05 -0.26 -0.25 Aortic root size; chr7:65951183 chr7:66376044~66401338:- LUSC cis rs6928977 0.714 rs11154801 ENSG00000234084.1 RP3-388E23.2 -5.57 4.21e-08 1.48e-05 -0.21 -0.25 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135418217 chr6:135301568~135307158:+ LUSC cis rs3738443 0.904 rs61840000 ENSG00000259865.1 RP11-488L18.10 5.57 4.21e-08 1.48e-05 0.27 0.25 Alcohol dependence; chr1:247199027 chr1:247187281~247188526:- LUSC cis rs7208859 0.623 rs8067035 ENSG00000263603.1 CTD-2349P21.5 -5.57 4.22e-08 1.48e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30729469~30731202:+ LUSC cis rs5760092 0.755 rs4585126 ENSG00000099984.9 GSTT2 5.57 4.22e-08 1.48e-05 0.35 0.25 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23980123~23983911:+ LUSC cis rs638893 1 rs638893 ENSG00000278376.1 RP11-158I9.8 -5.57 4.22e-08 1.48e-05 -0.32 -0.25 Vitiligo; chr11:118827828 chr11:118791254~118793137:+ LUSC cis rs7555523 0.943 rs4537525 ENSG00000224358.1 RP11-466F5.8 -5.57 4.22e-08 1.48e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165741852 chr1:165768929~165775176:+ LUSC cis rs7555523 0.887 rs4269750 ENSG00000224358.1 RP11-466F5.8 -5.57 4.22e-08 1.48e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165742273 chr1:165768929~165775176:+ LUSC cis rs7555523 0.887 rs10918274 ENSG00000224358.1 RP11-466F5.8 -5.57 4.22e-08 1.48e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165745179 chr1:165768929~165775176:+ LUSC cis rs9322193 0.923 rs9371486 ENSG00000268592.3 RAET1E-AS1 5.57 4.23e-08 1.48e-05 0.33 0.25 Lung cancer; chr6:149832090 chr6:149863494~149919507:+ LUSC cis rs875971 0.545 rs2707851 ENSG00000237310.1 GS1-124K5.4 -5.57 4.23e-08 1.48e-05 -0.28 -0.25 Aortic root size; chr7:66624178 chr7:66493706~66495474:+ LUSC cis rs10462794 0.661 rs16873561 ENSG00000260763.1 RP11-445O3.3 -5.57 4.24e-08 1.49e-05 -0.33 -0.25 DNA methylation (variation); chr5:4521189 chr5:4436850~4440259:- LUSC cis rs2337406 0.866 rs61419485 ENSG00000280411.1 IGHV1-69-2 -5.57 4.24e-08 1.49e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106783374 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs8015361 ENSG00000280411.1 IGHV1-69-2 -5.57 4.24e-08 1.49e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106783991 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs74090151 ENSG00000280411.1 IGHV1-69-2 -5.57 4.24e-08 1.49e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106785377 chr14:106762092~106762588:- LUSC cis rs7208859 0.524 rs11653098 ENSG00000263603.1 CTD-2349P21.5 -5.57 4.24e-08 1.49e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30729469~30731202:+ LUSC cis rs9318086 0.776 rs1326130 ENSG00000205861.10 C1QTNF9B-AS1 -5.57 4.24e-08 1.49e-05 -0.3 -0.25 Myopia (pathological); chr13:23873525 chr13:23888889~23897263:+ LUSC cis rs13113518 1 rs6858803 ENSG00000273257.1 RP11-177J6.1 5.57 4.25e-08 1.49e-05 0.32 0.25 Height; chr4:55484534 chr4:55387949~55388271:+ LUSC cis rs6570726 0.72 rs412623 ENSG00000235652.6 RP11-545I5.3 5.57 4.25e-08 1.49e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145562121 chr6:145799409~145886585:+ LUSC cis rs7555523 0.887 rs2814471 ENSG00000224358.1 RP11-466F5.8 -5.57 4.25e-08 1.49e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165770361 chr1:165768929~165775176:+ LUSC cis rs11098499 0.863 rs12502389 ENSG00000248280.1 RP11-33B1.2 5.57 4.25e-08 1.49e-05 0.3 0.25 Corneal astigmatism; chr4:119533036 chr4:119440561~119450157:- LUSC cis rs17361889 0.633 rs17359183 ENSG00000224683.1 RPL36AP29 5.57 4.25e-08 1.49e-05 0.3 0.25 Pediatric bone mineral content (hip); chr7:16123149 chr7:16208945~16209265:+ LUSC cis rs17361889 0.711 rs17359294 ENSG00000224683.1 RPL36AP29 5.57 4.25e-08 1.49e-05 0.3 0.25 Pediatric bone mineral content (hip); chr7:16124889 chr7:16208945~16209265:+ LUSC cis rs910316 0.591 rs7157158 ENSG00000279594.1 RP11-950C14.10 5.57 4.25e-08 1.49e-05 0.29 0.25 Height; chr14:74990535 chr14:75011269~75012851:- LUSC cis rs7520050 0.807 rs72688483 ENSG00000280836.1 AL355480.1 -5.57 4.26e-08 1.49e-05 -0.28 -0.25 Reticulocyte count;Red blood cell count; chr1:45683537 chr1:45581219~45581321:- LUSC cis rs11673344 0.642 rs12462708 ENSG00000226686.6 LINC01535 -5.57 4.26e-08 1.49e-05 -0.31 -0.25 Obesity-related traits; chr19:37306676 chr19:37251912~37265535:+ LUSC cis rs17711722 0.522 rs62469933 ENSG00000228409.4 CCT6P1 -5.57 4.26e-08 1.49e-05 -0.19 -0.25 Calcium levels; chr7:65800652 chr7:65751142~65763354:+ LUSC cis rs9640161 0.789 rs10282458 ENSG00000261305.1 RP4-584D14.7 5.57 4.26e-08 1.49e-05 0.36 0.25 Blood protein levels;Circulating chemerin levels; chr7:150348213 chr7:150341771~150342607:+ LUSC cis rs67311347 0.544 rs2123998 ENSG00000223797.4 ENTPD3-AS1 -5.57 4.26e-08 1.49e-05 -0.26 -0.25 Renal cell carcinoma; chr3:40317514 chr3:40313802~40453329:- LUSC cis rs2562456 0.958 rs2562508 ENSG00000268081.1 RP11-678G14.2 -5.57 4.26e-08 1.49e-05 -0.35 -0.25 Pain; chr19:21543479 chr19:21554640~21569237:- LUSC cis rs875971 0.545 rs316328 ENSG00000224316.1 RP11-479O9.2 -5.57 4.26e-08 1.49e-05 -0.25 -0.25 Aortic root size; chr7:66143851 chr7:65773620~65802067:+ LUSC cis rs1823913 0.549 rs4465792 ENSG00000280083.1 RP11-317J9.1 -5.57 4.26e-08 1.49e-05 -0.31 -0.25 Obesity-related traits; chr2:191328884 chr2:191154118~191156070:- LUSC cis rs10028773 0.6 rs4001390 ENSG00000249244.1 RP11-548H18.2 5.57 4.27e-08 1.5e-05 0.31 0.25 Educational attainment; chr4:119344628 chr4:119391831~119395335:- LUSC cis rs11098499 0.691 rs2136911 ENSG00000249244.1 RP11-548H18.2 5.57 4.27e-08 1.5e-05 0.31 0.25 Corneal astigmatism; chr4:119344704 chr4:119391831~119395335:- LUSC cis rs11098499 0.779 rs6815934 ENSG00000249244.1 RP11-548H18.2 5.57 4.27e-08 1.5e-05 0.31 0.25 Corneal astigmatism; chr4:119346155 chr4:119391831~119395335:- LUSC cis rs10028773 0.568 rs6838457 ENSG00000249244.1 RP11-548H18.2 5.57 4.27e-08 1.5e-05 0.31 0.25 Educational attainment; chr4:119346212 chr4:119391831~119395335:- LUSC cis rs9549367 0.789 rs8001506 ENSG00000269125.1 RP11-98F14.11 -5.57 4.27e-08 1.5e-05 -0.3 -0.25 Platelet distribution width; chr13:113212839 chr13:113165002~113165183:- LUSC cis rs66887589 0.967 rs6844263 ENSG00000248280.1 RP11-33B1.2 5.57 4.27e-08 1.5e-05 0.28 0.25 Diastolic blood pressure; chr4:119512652 chr4:119440561~119450157:- LUSC cis rs6504950 0.679 rs2628298 ENSG00000275710.1 RP11-257O5.4 -5.57 4.27e-08 1.5e-05 -0.33 -0.25 Breast cancer; chr17:55086117 chr17:54964474~54964679:+ LUSC cis rs9611519 0.828 rs9611460 ENSG00000235513.1 RP4-756G23.5 5.57 4.29e-08 1.5e-05 0.3 0.25 Neuroticism; chr22:41022293 chr22:41209122~41217627:- LUSC cis rs2732480 0.967 rs2732469 ENSG00000240399.1 RP1-228P16.1 5.57 4.29e-08 1.5e-05 0.25 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48319149 chr12:48054813~48055591:- LUSC cis rs6951245 0.744 rs10265736 ENSG00000224079.1 AC091729.7 -5.57 4.29e-08 1.5e-05 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1132829 chr7:1074450~1078036:+ LUSC cis rs2337406 0.704 rs1858679 ENSG00000254174.1 IGHV1-12 5.57 4.29e-08 1.5e-05 0.26 0.25 Alzheimer's disease (late onset); chr14:106706726 chr14:106122420~106122709:- LUSC cis rs910316 1 rs10143132 ENSG00000279594.1 RP11-950C14.10 5.57 4.29e-08 1.5e-05 0.28 0.25 Height; chr14:75059147 chr14:75011269~75012851:- LUSC cis rs3738443 0.868 rs12569042 ENSG00000259865.1 RP11-488L18.10 5.57 4.3e-08 1.5e-05 0.26 0.25 Alcohol dependence; chr1:247203078 chr1:247187281~247188526:- LUSC cis rs2842992 0.715 rs2277073 ENSG00000237927.1 RP3-393E18.2 -5.57 4.3e-08 1.51e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159761717 chr6:159586955~159589169:- LUSC cis rs77204473 0.744 rs76567973 ENSG00000254851.1 RP11-109L13.1 5.57 4.31e-08 1.51e-05 0.62 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117100045 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs78135964 ENSG00000254851.1 RP11-109L13.1 5.57 4.31e-08 1.51e-05 0.62 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117100961 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs76942203 ENSG00000254851.1 RP11-109L13.1 5.57 4.31e-08 1.51e-05 0.62 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117102531 chr11:117135528~117138582:+ LUSC cis rs4604732 0.642 rs10925047 ENSG00000227135.1 GCSAML-AS1 -5.57 4.31e-08 1.51e-05 -0.35 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247476841 chr1:247524679~247526752:- LUSC cis rs9309711 0.922 rs13399524 ENSG00000225234.1 TRAPPC12-AS1 -5.57 4.31e-08 1.51e-05 -0.33 -0.25 Neurofibrillary tangles; chr2:3476435 chr2:3481242~3482409:- LUSC cis rs875971 0.545 rs73378304 ENSG00000237310.1 GS1-124K5.4 5.57 4.31e-08 1.51e-05 0.28 0.25 Aortic root size; chr7:66175760 chr7:66493706~66495474:+ LUSC cis rs2303759 0.543 rs7255778 ENSG00000268686.1 AC010524.2 -5.57 4.31e-08 1.51e-05 -0.34 -0.25 Multiple sclerosis; chr19:49403351 chr19:49368705~49388081:- LUSC cis rs12468226 0.872 rs1061157 ENSG00000272966.1 RP11-686O6.1 5.57 4.32e-08 1.51e-05 0.41 0.25 Urate levels; chr2:202556476 chr2:202336739~202337200:+ LUSC cis rs957448 0.554 rs12682601 ENSG00000253704.1 RP11-267M23.4 5.57 4.32e-08 1.51e-05 0.29 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94582492 chr8:94553722~94569745:+ LUSC cis rs2880765 0.631 rs55767890 ENSG00000202081.1 RNU6-1280P 5.57 4.33e-08 1.51e-05 0.28 0.25 Coronary artery disease; chr15:85460911 chr15:85651522~85651628:- LUSC cis rs11846409 0.652 rs10143549 ENSG00000211974.3 IGHV2-70 -5.57 4.33e-08 1.51e-05 -0.34 -0.25 Rheumatic heart disease; chr14:106644643 chr14:106723574~106724093:- LUSC cis rs6772849 0.901 rs9849126 ENSG00000277250.1 Metazoa_SRP 5.57 4.33e-08 1.52e-05 0.28 0.25 Monocyte percentage of white cells;Monocyte count; chr3:128593226 chr3:128673681~128674021:- LUSC cis rs11159086 0.941 rs12434836 ENSG00000259005.1 RP3-449M8.6 5.57 4.33e-08 1.52e-05 0.39 0.25 Advanced glycation end-product levels; chr14:74468887 chr14:74474007~74474864:- LUSC cis rs2274273 0.934 rs10137307 ENSG00000258413.1 RP11-665C16.6 -5.57 4.34e-08 1.52e-05 -0.3 -0.25 Protein biomarker; chr14:55378467 chr14:55262767~55272075:- LUSC cis rs910316 1 rs7303 ENSG00000279594.1 RP11-950C14.10 5.57 4.34e-08 1.52e-05 0.28 0.25 Height; chr14:75053362 chr14:75011269~75012851:- LUSC cis rs1528149 0.504 rs1990364 ENSG00000224683.1 RPL36AP29 5.57 4.34e-08 1.52e-05 0.29 0.25 Sitting height ratio; chr7:16129300 chr7:16208945~16209265:+ LUSC cis rs113835537 0.935 rs117480267 ENSG00000255517.5 CTD-3074O7.5 -5.57 4.34e-08 1.52e-05 -0.34 -0.25 Airway imaging phenotypes; chr11:66631125 chr11:66473490~66480233:- LUSC cis rs13113518 0.934 rs3805155 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55497842 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs7686261 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55500224 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11729220 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55501629 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11133390 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55501726 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11133391 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55501788 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs13133484 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55504176 chr4:55363971~55395847:- LUSC cis rs13113518 0.934 rs13127906 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55504201 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs6849433 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55506498 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs12501327 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55507248 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs11133392 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55507729 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs6838305 ENSG00000249700.7 SRD5A3-AS1 5.57 4.35e-08 1.52e-05 0.29 0.25 Height; chr4:55508587 chr4:55363971~55395847:- LUSC cis rs2136613 0.751 rs10761666 ENSG00000238280.1 RP11-436D10.3 -5.57 4.35e-08 1.52e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62848601 chr10:62793562~62805887:- LUSC cis rs2337406 0.866 rs4774019 ENSG00000254174.1 IGHV1-12 5.57 4.35e-08 1.52e-05 0.25 0.25 Alzheimer's disease (late onset); chr14:106805386 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs58850145 ENSG00000254174.1 IGHV1-12 5.57 4.35e-08 1.52e-05 0.25 0.25 Alzheimer's disease (late onset); chr14:106806185 chr14:106122420~106122709:- LUSC cis rs673078 0.607 rs17441172 ENSG00000275409.1 RP11-131L12.4 5.57 4.35e-08 1.52e-05 0.35 0.25 Glucose homeostasis traits; chr12:118430456 chr12:118430147~118430699:+ LUSC cis rs7772486 0.79 rs10223507 ENSG00000235652.6 RP11-545I5.3 -5.57 4.36e-08 1.52e-05 -0.24 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145964068 chr6:145799409~145886585:+ LUSC cis rs13113518 1 rs13152173 ENSG00000272969.1 RP11-528I4.2 5.57 4.36e-08 1.52e-05 0.28 0.25 Height; chr4:55534788 chr4:55547112~55547889:+ LUSC cis rs875971 0.522 rs781144 ENSG00000222364.1 RNU6-96P -5.57 4.36e-08 1.53e-05 -0.29 -0.25 Aortic root size; chr7:65975357 chr7:66395191~66395286:+ LUSC cis rs240993 0.516 rs240981 ENSG00000230177.1 RP5-1112D6.4 -5.57 4.37e-08 1.53e-05 -0.29 -0.25 Inflammatory skin disease;Psoriasis; chr6:111289990 chr6:111277932~111278742:+ LUSC cis rs6502050 0.749 rs7209948 ENSG00000266654.1 RP11-1376P16.1 5.57 4.37e-08 1.53e-05 0.25 0.25 Life satisfaction; chr17:82128928 chr17:82160056~82160452:+ LUSC cis rs910316 0.763 rs175036 ENSG00000279594.1 RP11-950C14.10 -5.57 4.37e-08 1.53e-05 -0.29 -0.25 Height; chr14:74997592 chr14:75011269~75012851:- LUSC cis rs875971 0.862 rs13232191 ENSG00000179406.6 LINC00174 -5.57 4.37e-08 1.53e-05 -0.27 -0.25 Aortic root size; chr7:66521661 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs35378740 ENSG00000179406.6 LINC00174 -5.57 4.37e-08 1.53e-05 -0.27 -0.25 Aortic root size; chr7:66522725 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs10950043 ENSG00000179406.6 LINC00174 -5.57 4.37e-08 1.53e-05 -0.27 -0.25 Aortic root size; chr7:66523623 chr7:66376044~66401338:- LUSC cis rs875971 0.767 rs61348003 ENSG00000179406.6 LINC00174 -5.57 4.37e-08 1.53e-05 -0.27 -0.25 Aortic root size; chr7:66540947 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs13536 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66554203 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs801209 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66554403 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs801206 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66556979 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs801204 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66557934 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs801203 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66558025 chr7:66376044~66401338:- LUSC cis rs875971 0.825 rs801202 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66558942 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs801194 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66563508 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs2024192 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66576460 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs6955837 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66578155 chr7:66376044~66401338:- LUSC cis rs875971 0.825 rs10281499 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66583979 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs4718377 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66584691 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs10278014 ENSG00000179406.6 LINC00174 5.57 4.37e-08 1.53e-05 0.27 0.25 Aortic root size; chr7:66586277 chr7:66376044~66401338:- LUSC cis rs7829975 0.514 rs2945873 ENSG00000173295.6 FAM86B3P 5.57 4.38e-08 1.53e-05 0.27 0.25 Mood instability; chr8:8402935 chr8:8228595~8244865:+ LUSC cis rs11098499 0.954 rs7654587 ENSG00000248280.1 RP11-33B1.2 5.57 4.38e-08 1.53e-05 0.3 0.25 Corneal astigmatism; chr4:119467251 chr4:119440561~119450157:- LUSC cis rs380904 0.519 rs1377663 ENSG00000254859.1 RP11-661A12.5 -5.57 4.38e-08 1.53e-05 -0.36 -0.25 Venous thromboembolism (SNP x SNP interaction); chr8:143562617 chr8:143541973~143549729:- LUSC cis rs2337406 0.636 rs74090069 ENSG00000254174.1 IGHV1-12 5.57 4.38e-08 1.53e-05 0.24 0.25 Alzheimer's disease (late onset); chr14:106777532 chr14:106122420~106122709:- LUSC cis rs2337406 0.866 rs74090071 ENSG00000254174.1 IGHV1-12 5.57 4.38e-08 1.53e-05 0.24 0.25 Alzheimer's disease (late onset); chr14:106777533 chr14:106122420~106122709:- LUSC cis rs61270009 0.955 rs13172095 ENSG00000247828.6 TMEM161B-AS1 -5.57 4.38e-08 1.53e-05 -0.28 -0.25 Depressive symptoms; chr5:88295130 chr5:88268895~88436685:+ LUSC cis rs1387259 0.79 rs2732445 ENSG00000273765.1 RP11-370I10.11 5.57 4.39e-08 1.53e-05 0.29 0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48251750 chr12:48360920~48361377:+ LUSC cis rs2732480 0.5 rs2932093 ENSG00000273765.1 RP11-370I10.11 5.57 4.39e-08 1.53e-05 0.29 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48254488 chr12:48360920~48361377:+ LUSC cis rs13113518 0.902 rs12503578 ENSG00000249700.7 SRD5A3-AS1 5.57 4.39e-08 1.53e-05 0.29 0.25 Height; chr4:55509367 chr4:55363971~55395847:- LUSC cis rs13113518 0.966 rs3828480 ENSG00000249700.7 SRD5A3-AS1 5.57 4.39e-08 1.53e-05 0.29 0.25 Height; chr4:55510352 chr4:55363971~55395847:- LUSC cis rs2243480 0.831 rs7806717 ENSG00000226824.5 RP4-756H11.3 5.57 4.39e-08 1.53e-05 0.48 0.25 Diabetic kidney disease; chr7:65928187 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs34136756 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65916269 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs78803505 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65917585 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs34933526 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65918212 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs34577383 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65920739 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs6949812 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65922114 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs55895244 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65922691 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs6970243 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65923503 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs7794661 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65924743 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs7795242 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65925107 chr7:66654538~66669855:+ LUSC cis rs2243480 0.708 rs35310401 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65925372 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs35058610 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65925938 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs2177703 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65926730 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs56985706 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65929575 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs60683927 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65929781 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs58062456 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65929865 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs34529418 ENSG00000226824.5 RP4-756H11.3 -5.57 4.39e-08 1.53e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65938222 chr7:66654538~66669855:+ LUSC cis rs67340775 0.541 rs169287 ENSG00000280107.1 AL022393.9 -5.57 4.39e-08 1.53e-05 -0.34 -0.25 Lung cancer in ever smokers; chr6:27886982 chr6:28170845~28172521:+ LUSC cis rs9309711 0.772 rs9309715 ENSG00000225234.1 TRAPPC12-AS1 5.57 4.4e-08 1.54e-05 0.33 0.25 Neurofibrillary tangles; chr2:3488547 chr2:3481242~3482409:- LUSC cis rs3764021 0.527 rs10772062 ENSG00000256975.1 RP11-525E9.1 5.57 4.4e-08 1.54e-05 0.33 0.25 Type 1 diabetes; chr12:9712561 chr12:9506347~9508440:- LUSC cis rs13434995 0.513 rs6554282 ENSG00000249700.7 SRD5A3-AS1 5.57 4.4e-08 1.54e-05 0.31 0.25 Adiponectin levels; chr4:55519812 chr4:55363971~55395847:- LUSC cis rs8040855 0.658 rs4842864 ENSG00000259295.5 CSPG4P12 5.57 4.4e-08 1.54e-05 0.3 0.25 Bulimia nervosa; chr15:85101315 chr15:85191438~85213905:+ LUSC cis rs8072100 0.713 rs4968228 ENSG00000228782.6 CTD-2026D20.3 5.57 4.41e-08 1.54e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47420182 chr17:47450568~47492492:- LUSC cis rs1707322 0.752 rs4660313 ENSG00000234329.1 RP11-767N6.2 -5.56 4.42e-08 1.54e-05 -0.26 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645169 chr1:45651039~45651826:- LUSC cis rs6740322 0.748 rs1549723 ENSG00000234936.1 AC010883.5 5.56 4.42e-08 1.54e-05 0.3 0.25 Coronary artery disease; chr2:43233375 chr2:43229573~43233394:+ LUSC cis rs17772222 1 rs61977049 ENSG00000258789.1 RP11-507K2.3 -5.56 4.42e-08 1.54e-05 -0.29 -0.25 Coronary artery calcification; chr14:88360656 chr14:88551597~88552493:+ LUSC cis rs17772222 1 rs12587386 ENSG00000258789.1 RP11-507K2.3 -5.56 4.42e-08 1.54e-05 -0.29 -0.25 Coronary artery calcification; chr14:88361420 chr14:88551597~88552493:+ LUSC cis rs13113518 0.902 rs12505266 ENSG00000223305.1 RN7SKP30 5.56 4.42e-08 1.54e-05 0.3 0.25 Height; chr4:55546002 chr4:55540502~55540835:- LUSC cis rs2337406 0.714 rs117798641 ENSG00000211974.3 IGHV2-70 -5.56 4.42e-08 1.54e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106777984 chr14:106723574~106724093:- LUSC cis rs1707322 0.721 rs11211165 ENSG00000234329.1 RP11-767N6.2 5.56 4.43e-08 1.54e-05 0.27 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692234 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs11211166 ENSG00000234329.1 RP11-767N6.2 5.56 4.43e-08 1.54e-05 0.27 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692270 chr1:45651039~45651826:- LUSC cis rs6772849 0.93 rs4857912 ENSG00000277250.1 Metazoa_SRP -5.56 4.43e-08 1.55e-05 -0.27 -0.25 Monocyte percentage of white cells;Monocyte count; chr3:128610381 chr3:128673681~128674021:- LUSC cis rs4814920 0.818 rs4813377 ENSG00000275142.1 RP5-999L4.2 -5.56 4.43e-08 1.55e-05 -0.37 -0.25 Bipolar disorder (body mass index interaction); chr20:19870822 chr20:19871891~19872284:+ LUSC cis rs7181230 0.885 rs9919974 ENSG00000275636.1 RP11-521C20.5 5.56 4.43e-08 1.55e-05 0.31 0.25 Dehydroepiandrosterone sulphate levels; chr15:40045261 chr15:40078892~40079347:+ LUSC cis rs13113518 0.812 rs2035691 ENSG00000273257.1 RP11-177J6.1 5.56 4.43e-08 1.55e-05 0.32 0.25 Height; chr4:55529786 chr4:55387949~55388271:+ LUSC cis rs7267979 0.744 rs6050463 ENSG00000274973.1 RP13-401N8.7 -5.56 4.44e-08 1.55e-05 -0.25 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25228354 chr20:25845497~25845862:+ LUSC cis rs6460942 0.659 rs13247187 ENSG00000226690.5 AC005281.1 5.56 4.44e-08 1.55e-05 0.49 0.25 Coronary artery disease; chr7:12512225 chr7:12496429~12541910:+ LUSC cis rs28830936 0.934 rs2412641 ENSG00000250379.1 RP11-23P13.4 5.56 4.44e-08 1.55e-05 0.27 0.25 Diastolic blood pressure; chr15:41832201 chr15:41825099~41827936:- LUSC cis rs28830936 0.966 rs11635067 ENSG00000250379.1 RP11-23P13.4 5.56 4.44e-08 1.55e-05 0.27 0.25 Diastolic blood pressure; chr15:41832475 chr15:41825099~41827936:- LUSC cis rs28830936 0.966 rs1531140 ENSG00000250379.1 RP11-23P13.4 5.56 4.44e-08 1.55e-05 0.27 0.25 Diastolic blood pressure; chr15:41833036 chr15:41825099~41827936:- LUSC cis rs4713118 0.869 rs10214440 ENSG00000280107.1 AL022393.9 -5.56 4.45e-08 1.55e-05 -0.28 -0.25 Parkinson's disease; chr6:27734661 chr6:28170845~28172521:+ LUSC cis rs61270009 0.731 rs13189022 ENSG00000247828.6 TMEM161B-AS1 5.56 4.45e-08 1.55e-05 0.3 0.25 Depressive symptoms; chr5:88445017 chr5:88268895~88436685:+ LUSC cis rs116095464 1 rs56095714 ENSG00000277812.1 AC021087.1 5.56 4.45e-08 1.55e-05 0.63 0.25 Breast cancer; chr5:311141 chr5:262769~262881:+ LUSC cis rs13113518 1 rs56154935 ENSG00000223305.1 RN7SKP30 5.56 4.45e-08 1.55e-05 0.3 0.25 Height; chr4:55546378 chr4:55540502~55540835:- LUSC cis rs6504950 0.924 rs244342 ENSG00000275710.1 RP11-257O5.4 5.56 4.45e-08 1.55e-05 0.28 0.25 Breast cancer; chr17:55121046 chr17:54964474~54964679:+ LUSC cis rs875971 0.545 rs316305 ENSG00000179406.6 LINC00174 5.56 4.45e-08 1.55e-05 0.29 0.25 Aortic root size; chr7:66152984 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs2460427 ENSG00000179406.6 LINC00174 5.56 4.45e-08 1.55e-05 0.29 0.25 Aortic root size; chr7:66154218 chr7:66376044~66401338:- LUSC cis rs6502050 0.805 rs7406858 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82122747 chr17:82160056~82160452:+ LUSC cis rs6502050 0.777 rs6502058 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82124624 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs6502059 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82125010 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs9646397 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82125658 chr17:82160056~82160452:+ LUSC cis rs6502050 0.723 rs11657069 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82125933 chr17:82160056~82160452:+ LUSC cis rs6502050 0.723 rs11650635 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82125940 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs7405738 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82126351 chr17:82160056~82160452:+ LUSC cis rs6502050 0.805 rs7406682 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82126492 chr17:82160056~82160452:+ LUSC cis rs6502050 0.769 rs11658272 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82126720 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs11658335 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82126945 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs34673303 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82127268 chr17:82160056~82160452:+ LUSC cis rs6502050 0.805 rs62078303 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82127334 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs7213172 ENSG00000266654.1 RP11-1376P16.1 5.56 4.45e-08 1.55e-05 0.25 0.25 Life satisfaction; chr17:82127827 chr17:82160056~82160452:+ LUSC cis rs16843372 0.576 rs10190307 ENSG00000251491.2 OR7E28P -5.56 4.45e-08 1.55e-05 -0.27 -0.25 Obesity-related traits; chr2:158839676 chr2:158862311~158863285:+ LUSC cis rs496547 0.721 rs2508570 ENSG00000278376.1 RP11-158I9.8 -5.56 4.45e-08 1.55e-05 -0.23 -0.25 Hip minimal joint space width; chr11:118807900 chr11:118791254~118793137:+ LUSC cis rs4938303 0.671 rs2008915 ENSG00000254851.1 RP11-109L13.1 -5.56 4.46e-08 1.55e-05 -0.38 -0.25 Triglycerides; chr11:116732418 chr11:117135528~117138582:+ LUSC cis rs9322193 0.884 rs11155679 ENSG00000268592.3 RAET1E-AS1 5.56 4.46e-08 1.55e-05 0.33 0.25 Lung cancer; chr6:149758881 chr6:149863494~149919507:+ LUSC cis rs11723261 0.621 rs6599306 ENSG00000275426.1 CH17-262A2.1 -5.56 4.46e-08 1.55e-05 -0.41 -0.25 Immune response to smallpox vaccine (IL-6); chr4:149655 chr4:149738~150317:+ LUSC cis rs7772486 0.754 rs4360151 ENSG00000235652.6 RP11-545I5.3 -5.56 4.46e-08 1.55e-05 -0.24 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145933943 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs9791313 ENSG00000235652.6 RP11-545I5.3 -5.56 4.46e-08 1.55e-05 -0.24 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145945036 chr6:145799409~145886585:+ LUSC cis rs875971 0.862 rs801195 ENSG00000179406.6 LINC00174 5.56 4.46e-08 1.55e-05 0.27 0.25 Aortic root size; chr7:66561128 chr7:66376044~66401338:- LUSC cis rs367615 0.704 rs11747622 ENSG00000249476.1 CTD-2587M2.1 5.56 4.46e-08 1.55e-05 0.28 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109509019 chr5:109237120~109326369:- LUSC cis rs875971 0.502 rs2465121 ENSG00000237310.1 GS1-124K5.4 -5.56 4.46e-08 1.56e-05 -0.29 -0.25 Aortic root size; chr7:66156017 chr7:66493706~66495474:+ LUSC cis rs13434995 0.513 rs7665286 ENSG00000249700.7 SRD5A3-AS1 5.56 4.47e-08 1.56e-05 0.31 0.25 Adiponectin levels; chr4:55578765 chr4:55363971~55395847:- LUSC cis rs6750795 0.502 rs11685196 ENSG00000181798.2 LINC00471 -5.56 4.47e-08 1.56e-05 -0.26 -0.25 Height; chr2:231516587 chr2:231508426~231514339:- LUSC cis rs13113518 0.934 rs11133397 ENSG00000272969.1 RP11-528I4.2 5.56 4.47e-08 1.56e-05 0.28 0.25 Height; chr4:55534166 chr4:55547112~55547889:+ LUSC cis rs13113518 0.934 rs11133398 ENSG00000272969.1 RP11-528I4.2 5.56 4.47e-08 1.56e-05 0.28 0.25 Height; chr4:55534180 chr4:55547112~55547889:+ LUSC cis rs910316 0.712 rs175037 ENSG00000279594.1 RP11-950C14.10 -5.56 4.47e-08 1.56e-05 -0.29 -0.25 Height; chr14:74998335 chr14:75011269~75012851:- LUSC cis rs6452524 0.618 rs1478487 ENSG00000248112.1 RP11-78C3.1 5.56 4.48e-08 1.56e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83080900 chr5:82919376~82921119:- LUSC cis rs67311347 0.826 rs9863679 ENSG00000223797.4 ENTPD3-AS1 5.56 4.48e-08 1.56e-05 0.29 0.25 Renal cell carcinoma; chr3:40398123 chr3:40313802~40453329:- LUSC cis rs67311347 1 rs7634375 ENSG00000223797.4 ENTPD3-AS1 5.56 4.48e-08 1.56e-05 0.29 0.25 Renal cell carcinoma; chr3:40390455 chr3:40313802~40453329:- LUSC cis rs2439831 0.85 rs28564774 ENSG00000249839.1 AC011330.5 -5.56 4.49e-08 1.56e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43833277 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs7169322 ENSG00000249839.1 AC011330.5 -5.56 4.49e-08 1.56e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43838816 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs28707214 ENSG00000249839.1 AC011330.5 -5.56 4.49e-08 1.56e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43839425 chr15:43663654~43684339:- LUSC cis rs17361889 0.711 rs1978253 ENSG00000224683.1 RPL36AP29 5.56 4.49e-08 1.56e-05 0.31 0.25 Pediatric bone mineral content (hip); chr7:16151114 chr7:16208945~16209265:+ LUSC cis rs6142102 0.961 rs4911389 ENSG00000275784.1 RP5-1125A11.6 -5.56 4.49e-08 1.56e-05 -0.29 -0.25 Skin pigmentation; chr20:33977235 chr20:33989480~33991818:- LUSC cis rs4237845 0.78 rs3751331 ENSG00000257159.1 RP11-58A17.3 5.56 4.49e-08 1.56e-05 0.31 0.25 Intelligence (multi-trait analysis); chr12:57896495 chr12:57967058~57968399:+ LUSC cis rs673078 0.66 rs7973455 ENSG00000275759.1 RP11-131L12.3 -5.56 4.49e-08 1.56e-05 -0.37 -0.25 Glucose homeostasis traits; chr12:118247490 chr12:118428281~118428870:+ LUSC cis rs7208859 0.573 rs56031503 ENSG00000263603.1 CTD-2349P21.5 -5.56 4.49e-08 1.57e-05 -0.35 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30729469~30731202:+ LUSC cis rs944990 0.597 rs4607675 ENSG00000227603.1 RP11-165J3.6 5.56 4.49e-08 1.57e-05 0.24 0.25 Body mass index; chr9:93454127 chr9:93435332~93437121:- LUSC cis rs17270561 0.666 rs1937129 ENSG00000272462.2 U91328.19 -5.56 4.5e-08 1.57e-05 -0.28 -0.25 Iron status biomarkers; chr6:25788904 chr6:25992662~26001775:+ LUSC cis rs6918586 0.615 rs198824 ENSG00000272462.2 U91328.19 -5.56 4.5e-08 1.57e-05 -0.26 -0.25 Schizophrenia; chr6:26122555 chr6:25992662~26001775:+ LUSC cis rs6918586 0.658 rs198821 ENSG00000272462.2 U91328.19 -5.56 4.5e-08 1.57e-05 -0.26 -0.25 Schizophrenia; chr6:26123401 chr6:25992662~26001775:+ LUSC cis rs6759004 1 rs6759004 ENSG00000183308.6 AC005037.3 5.56 4.5e-08 1.57e-05 0.44 0.25 Triptolide cytotoxicity; chr2:201139953 chr2:200963263~201009102:+ LUSC cis rs11098499 0.863 rs1480940 ENSG00000248280.1 RP11-33B1.2 5.56 4.5e-08 1.57e-05 0.3 0.25 Corneal astigmatism; chr4:119536527 chr4:119440561~119450157:- LUSC cis rs7772486 0.875 rs854145 ENSG00000235652.6 RP11-545I5.3 5.56 4.5e-08 1.57e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146028514 chr6:145799409~145886585:+ LUSC cis rs234043 1 rs234051 ENSG00000223387.5 RP11-408H1.3 -5.56 4.5e-08 1.57e-05 -0.28 -0.25 Renal cell carcinoma; chr3:172593922 chr3:172560888~172595607:- LUSC cis rs2562456 0.754 rs55771551 ENSG00000268081.1 RP11-678G14.2 5.56 4.51e-08 1.57e-05 0.35 0.25 Pain; chr19:21563578 chr19:21554640~21569237:- LUSC cis rs875971 0.54 rs1723268 ENSG00000179406.6 LINC00174 -5.56 4.51e-08 1.57e-05 -0.26 -0.25 Aortic root size; chr7:66008093 chr7:66376044~66401338:- LUSC cis rs9828933 0.938 rs2578011 ENSG00000280620.1 SCAANT1 5.56 4.51e-08 1.57e-05 0.37 0.25 Type 2 diabetes; chr3:64019143 chr3:63911518~63911772:- LUSC cis rs35160687 0.712 rs9677502 ENSG00000273080.1 RP11-301O19.1 -5.56 4.52e-08 1.57e-05 -0.23 -0.25 Night sleep phenotypes; chr2:86253815 chr2:86195590~86196049:+ LUSC cis rs944990 0.597 rs4744245 ENSG00000227603.1 RP11-165J3.6 5.56 4.52e-08 1.57e-05 0.24 0.25 Body mass index; chr9:93480372 chr9:93435332~93437121:- LUSC cis rs1555322 0.53 rs6060341 ENSG00000126005.14 MMP24-AS1 5.56 4.52e-08 1.57e-05 0.35 0.25 Attention deficit hyperactivity disorder; chr20:35275830 chr20:35216462~35278131:- LUSC cis rs3738443 0.868 rs6660351 ENSG00000259865.1 RP11-488L18.10 5.56 4.52e-08 1.58e-05 0.27 0.25 Alcohol dependence; chr1:247184526 chr1:247187281~247188526:- LUSC cis rs13113518 0.902 rs12505266 ENSG00000272969.1 RP11-528I4.2 5.56 4.52e-08 1.58e-05 0.28 0.25 Height; chr4:55546002 chr4:55547112~55547889:+ LUSC cis rs4489787 1 rs2705126 ENSG00000240399.1 RP1-228P16.1 5.56 4.53e-08 1.58e-05 0.4 0.25 Prostate cancer (SNP x SNP interaction); chr12:48488779 chr12:48054813~48055591:- LUSC cis rs1345301 1 rs13405355 ENSG00000234389.1 AC007278.3 -5.56 4.53e-08 1.58e-05 -0.24 -0.25 Waist circumference; chr2:102261746 chr2:102438713~102440475:+ LUSC cis rs875971 0.545 rs73376394 ENSG00000224316.1 RP11-479O9.2 5.56 4.53e-08 1.58e-05 0.27 0.25 Aortic root size; chr7:66172694 chr7:65773620~65802067:+ LUSC cis rs6570726 1 rs1935617 ENSG00000235652.6 RP11-545I5.3 5.56 4.53e-08 1.58e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145622190 chr6:145799409~145886585:+ LUSC cis rs77204473 0.557 rs9971422 ENSG00000280143.1 AP000892.6 -5.56 4.54e-08 1.58e-05 -0.41 -0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:116966657 chr11:117204967~117210292:+ LUSC cis rs7804306 0.826 rs56073406 ENSG00000233264.2 AC006042.8 5.56 4.54e-08 1.58e-05 0.48 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7981025 chr7:7980312~7982228:+ LUSC cis rs7176527 1 rs7176527 ENSG00000229212.6 RP11-561C5.4 5.56 4.54e-08 1.58e-05 0.39 0.25 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84597563 chr15:85205440~85234795:- LUSC cis rs1707322 0.721 rs4559551 ENSG00000234329.1 RP11-767N6.2 5.56 4.54e-08 1.58e-05 0.27 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701861 chr1:45651039~45651826:- LUSC cis rs7555523 1 rs7555523 ENSG00000224358.1 RP11-466F5.8 -5.56 4.54e-08 1.58e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165749742 chr1:165768929~165775176:+ LUSC cis rs9326248 0.648 rs11216257 ENSG00000280143.1 AP000892.6 5.56 4.54e-08 1.58e-05 0.31 0.25 Blood protein levels; chr11:117061845 chr11:117204967~117210292:+ LUSC cis rs875971 0.508 rs10258739 ENSG00000222364.1 RNU6-96P 5.56 4.54e-08 1.58e-05 0.28 0.25 Aortic root size; chr7:66597948 chr7:66395191~66395286:+ LUSC cis rs875971 0.755 rs76288834 ENSG00000179406.6 LINC00174 5.56 4.55e-08 1.58e-05 0.27 0.25 Aortic root size; chr7:66604815 chr7:66376044~66401338:- LUSC cis rs2880765 0.566 rs55899824 ENSG00000202081.1 RNU6-1280P 5.56 4.55e-08 1.59e-05 0.28 0.25 Coronary artery disease; chr15:85460860 chr15:85651522~85651628:- LUSC cis rs11098499 0.954 rs12508504 ENSG00000248280.1 RP11-33B1.2 5.56 4.56e-08 1.59e-05 0.29 0.25 Corneal astigmatism; chr4:119489452 chr4:119440561~119450157:- LUSC cis rs4604732 0.642 rs6426252 ENSG00000227135.1 GCSAML-AS1 -5.56 4.56e-08 1.59e-05 -0.34 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247476585 chr1:247524679~247526752:- LUSC cis rs75920871 0.528 rs7484045 ENSG00000254851.1 RP11-109L13.1 5.56 4.56e-08 1.59e-05 0.34 0.25 Subjective well-being; chr11:117076174 chr11:117135528~117138582:+ LUSC cis rs6543140 0.964 rs6748390 ENSG00000234389.1 AC007278.3 5.56 4.57e-08 1.59e-05 0.26 0.25 Blood protein levels; chr2:102445715 chr2:102438713~102440475:+ LUSC cis rs75920871 0.502 rs7124996 ENSG00000254851.1 RP11-109L13.1 5.56 4.57e-08 1.59e-05 0.34 0.25 Subjective well-being; chr11:117057290 chr11:117135528~117138582:+ LUSC cis rs957448 0.748 rs12680342 ENSG00000253175.1 RP11-267M23.6 5.56 4.57e-08 1.59e-05 0.31 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94347410 chr8:94565036~94565715:+ LUSC cis rs7945705 0.776 rs2316865 ENSG00000254860.4 TMEM9B-AS1 -5.56 4.57e-08 1.59e-05 -0.29 -0.25 Hemoglobin concentration; chr11:8793923 chr11:8964675~8977527:+ LUSC cis rs459571 0.959 rs2073818 ENSG00000235106.7 LINC00094 5.56 4.57e-08 1.59e-05 0.28 0.25 Platelet distribution width; chr9:134053540 chr9:134025439~134034666:+ LUSC cis rs17772222 1 rs7145588 ENSG00000258789.1 RP11-507K2.3 -5.56 4.58e-08 1.59e-05 -0.29 -0.25 Coronary artery calcification; chr14:88360452 chr14:88551597~88552493:+ LUSC cis rs7955901 0.904 rs1512991 ENSG00000257265.1 CTD-2021H9.1 -5.56 4.58e-08 1.59e-05 -0.27 -0.25 Type 2 diabetes; chr12:71028988 chr12:71007773~71032083:- LUSC cis rs2732480 0.577 rs2732466 ENSG00000240399.1 RP1-228P16.1 5.56 4.58e-08 1.59e-05 0.27 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48338676 chr12:48054813~48055591:- LUSC cis rs4664293 0.51 rs1968343 ENSG00000226266.5 AC009961.3 5.56 4.58e-08 1.59e-05 0.28 0.25 Monocyte percentage of white cells; chr2:159712247 chr2:159670708~159712435:- LUSC cis rs910316 1 rs12589376 ENSG00000279594.1 RP11-950C14.10 5.56 4.58e-08 1.59e-05 0.28 0.25 Height; chr14:75094449 chr14:75011269~75012851:- LUSC cis rs7772486 0.79 rs2247206 ENSG00000235652.6 RP11-545I5.3 5.56 4.58e-08 1.59e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145895048 chr6:145799409~145886585:+ LUSC cis rs7772486 0.764 rs2247211 ENSG00000235652.6 RP11-545I5.3 5.56 4.58e-08 1.59e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145895243 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs9497425 ENSG00000235652.6 RP11-545I5.3 -5.56 4.58e-08 1.59e-05 -0.24 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145913061 chr6:145799409~145886585:+ LUSC cis rs7772486 0.79 rs9497427 ENSG00000235652.6 RP11-545I5.3 -5.56 4.58e-08 1.59e-05 -0.24 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145917166 chr6:145799409~145886585:+ LUSC cis rs7772486 0.764 rs9399569 ENSG00000235652.6 RP11-545I5.3 -5.56 4.58e-08 1.59e-05 -0.24 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145921806 chr6:145799409~145886585:+ LUSC cis rs6740322 0.748 rs6544636 ENSG00000234936.1 AC010883.5 5.56 4.58e-08 1.59e-05 0.3 0.25 Coronary artery disease; chr2:43260347 chr2:43229573~43233394:+ LUSC cis rs1528149 0.504 rs6968537 ENSG00000224683.1 RPL36AP29 -5.56 4.59e-08 1.6e-05 -0.29 -0.25 Sitting height ratio; chr7:16129083 chr7:16208945~16209265:+ LUSC cis rs875971 0.502 rs2946580 ENSG00000224316.1 RP11-479O9.2 -5.56 4.59e-08 1.6e-05 -0.27 -0.25 Aortic root size; chr7:66066855 chr7:65773620~65802067:+ LUSC cis rs11098499 0.863 rs10030660 ENSG00000248280.1 RP11-33B1.2 5.56 4.59e-08 1.6e-05 0.3 0.25 Corneal astigmatism; chr4:119515549 chr4:119440561~119450157:- LUSC cis rs11098499 0.863 rs13149407 ENSG00000248280.1 RP11-33B1.2 5.56 4.59e-08 1.6e-05 0.3 0.25 Corneal astigmatism; chr4:119516670 chr4:119440561~119450157:- LUSC cis rs34792 0.688 rs153785 ENSG00000207425.1 Y_RNA 5.56 4.59e-08 1.6e-05 0.34 0.25 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15499435 chr16:14915457~14915556:- LUSC cis rs2439831 0.85 rs28513374 ENSG00000249839.1 AC011330.5 -5.56 4.6e-08 1.6e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43833297 chr15:43663654~43684339:- LUSC cis rs673078 0.66 rs73205512 ENSG00000275759.1 RP11-131L12.3 -5.56 4.61e-08 1.6e-05 -0.37 -0.25 Glucose homeostasis traits; chr12:118235770 chr12:118428281~118428870:+ LUSC cis rs673078 0.66 rs61945206 ENSG00000275759.1 RP11-131L12.3 -5.56 4.61e-08 1.6e-05 -0.37 -0.25 Glucose homeostasis traits; chr12:118238295 chr12:118428281~118428870:+ LUSC cis rs1021993 0.545 rs1507336 ENSG00000231648.1 RP11-372M18.2 -5.56 4.62e-08 1.61e-05 -0.38 -0.25 Gut microbiome composition (winter); chr1:209375580 chr1:209367662~209379690:+ LUSC cis rs11690935 0.802 rs34636594 ENSG00000228389.1 AC068039.4 5.56 4.62e-08 1.61e-05 0.3 0.25 Schizophrenia; chr2:172046366 chr2:171773482~171775844:+ LUSC cis rs11096990 0.551 rs2060005 ENSG00000249207.1 RP11-360F5.1 -5.56 4.63e-08 1.61e-05 -0.27 -0.25 Cognitive function; chr4:39160901 chr4:39112677~39126818:- LUSC cis rs1061377 0.501 rs62308278 ENSG00000249207.1 RP11-360F5.1 -5.56 4.63e-08 1.61e-05 -0.27 -0.25 Uric acid levels; chr4:39161038 chr4:39112677~39126818:- LUSC cis rs6867032 0.695 rs3902820 ENSG00000249731.1 RP11-259O2.3 -5.56 4.64e-08 1.61e-05 -0.27 -0.25 Gut microbiome composition (winter); chr5:2000216 chr5:1968094~1969013:+ LUSC cis rs2136613 0.751 rs1397030 ENSG00000238280.1 RP11-436D10.3 -5.56 4.64e-08 1.61e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62838746 chr10:62793562~62805887:- LUSC cis rs17270561 0.666 rs12209856 ENSG00000272462.2 U91328.19 -5.56 4.64e-08 1.61e-05 -0.29 -0.25 Iron status biomarkers; chr6:25793445 chr6:25992662~26001775:+ LUSC cis rs5770917 1 rs2269382 ENSG00000273272.1 CTA-384D8.34 5.56 4.64e-08 1.61e-05 0.54 0.25 Narcolepsy; chr22:50580482 chr22:50542650~50543011:+ LUSC cis rs13113518 1 rs7662966 ENSG00000223305.1 RN7SKP30 5.56 4.65e-08 1.62e-05 0.3 0.25 Height; chr4:55548261 chr4:55540502~55540835:- LUSC cis rs7804306 0.826 rs12113109 ENSG00000233264.2 AC006042.8 5.56 4.65e-08 1.62e-05 0.41 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7979920 chr7:7980312~7982228:+ LUSC cis rs1930961 1 rs7285549 ENSG00000272942.1 CTA-246H3.12 -5.55 4.66e-08 1.62e-05 -0.43 -0.25 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25434324~25435070:- LUSC cis rs1021993 0.545 rs1006316 ENSG00000231648.1 RP11-372M18.2 -5.55 4.66e-08 1.62e-05 -0.36 -0.25 Gut microbiome composition (winter); chr1:209377116 chr1:209367662~209379690:+ LUSC cis rs910316 0.763 rs175016 ENSG00000279594.1 RP11-950C14.10 -5.55 4.66e-08 1.62e-05 -0.29 -0.25 Height; chr14:74992930 chr14:75011269~75012851:- LUSC cis rs853679 0.55 rs1150689 ENSG00000280107.1 AL022393.9 -5.55 4.66e-08 1.62e-05 -0.3 -0.25 Depression; chr6:28197321 chr6:28170845~28172521:+ LUSC cis rs12291225 0.639 rs61883858 ENSG00000251991.1 RNU7-49P 5.55 4.67e-08 1.62e-05 0.3 0.25 Sense of smell; chr11:14273162 chr11:14478892~14478953:+ LUSC cis rs12291225 0.679 rs11023170 ENSG00000251991.1 RNU7-49P 5.55 4.67e-08 1.62e-05 0.3 0.25 Sense of smell; chr11:14273363 chr11:14478892~14478953:+ LUSC cis rs12291225 0.679 rs11023172 ENSG00000251991.1 RNU7-49P 5.55 4.67e-08 1.62e-05 0.3 0.25 Sense of smell; chr11:14273821 chr11:14478892~14478953:+ LUSC cis rs11098499 0.954 rs1546505 ENSG00000248280.1 RP11-33B1.2 5.55 4.67e-08 1.62e-05 0.31 0.25 Corneal astigmatism; chr4:119320069 chr4:119440561~119450157:- LUSC cis rs8005677 0.798 rs61977741 ENSG00000279656.1 RP11-298I3.6 5.55 4.67e-08 1.62e-05 0.29 0.25 Cognitive ability (multi-trait analysis); chr14:22931770 chr14:23023083~23024217:- LUSC cis rs66887589 0.807 rs9799664 ENSG00000248280.1 RP11-33B1.2 5.55 4.68e-08 1.62e-05 0.28 0.25 Diastolic blood pressure; chr4:119405523 chr4:119440561~119450157:- LUSC cis rs4604732 0.642 rs10802514 ENSG00000227135.1 GCSAML-AS1 -5.55 4.68e-08 1.62e-05 -0.34 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247474447 chr1:247524679~247526752:- LUSC cis rs2404602 1 rs2120107 ENSG00000259422.1 RP11-593F23.1 5.55 4.68e-08 1.63e-05 0.27 0.25 Blood metabolite levels; chr15:76577448 chr15:76174891~76181486:- LUSC cis rs17361889 0.671 rs73071825 ENSG00000224683.1 RPL36AP29 5.55 4.69e-08 1.63e-05 0.3 0.25 Pediatric bone mineral content (hip); chr7:16109442 chr7:16208945~16209265:+ LUSC cis rs6502050 0.805 rs11077970 ENSG00000266654.1 RP11-1376P16.1 5.55 4.69e-08 1.63e-05 0.25 0.25 Life satisfaction; chr17:82128040 chr17:82160056~82160452:+ LUSC cis rs6502050 0.777 rs7406162 ENSG00000266654.1 RP11-1376P16.1 5.55 4.69e-08 1.63e-05 0.25 0.25 Life satisfaction; chr17:82128510 chr17:82160056~82160452:+ LUSC cis rs6502050 0.777 rs4625783 ENSG00000266654.1 RP11-1376P16.1 5.55 4.69e-08 1.63e-05 0.25 0.25 Life satisfaction; chr17:82128519 chr17:82160056~82160452:+ LUSC cis rs35740288 0.929 rs11635081 ENSG00000202081.1 RNU6-1280P 5.55 4.69e-08 1.63e-05 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85761029 chr15:85651522~85651628:- LUSC cis rs2243480 1 rs1039664 ENSG00000226824.5 RP4-756H11.3 -5.55 4.7e-08 1.63e-05 -0.49 -0.25 Diabetic kidney disease; chr7:65984729 chr7:66654538~66669855:+ LUSC cis rs2834288 0.734 rs8126592 ENSG00000273102.1 AP000569.9 -5.55 4.7e-08 1.63e-05 -0.29 -0.25 Gut microbiota (bacterial taxa); chr21:33895961 chr21:33967101~33968573:- LUSC cis rs9611519 1 rs4820433 ENSG00000235513.1 RP4-756G23.5 5.55 4.7e-08 1.63e-05 0.29 0.25 Neuroticism; chr22:41211061 chr22:41209122~41217627:- LUSC cis rs9611519 1 rs3818003 ENSG00000235513.1 RP4-756G23.5 5.55 4.7e-08 1.63e-05 0.29 0.25 Neuroticism; chr22:41213686 chr22:41209122~41217627:- LUSC cis rs2404602 1 rs12441433 ENSG00000259422.1 RP11-593F23.1 5.55 4.7e-08 1.63e-05 0.28 0.25 Blood metabolite levels; chr15:76523674 chr15:76174891~76181486:- LUSC cis rs875971 0.545 rs221986 ENSG00000224316.1 RP11-479O9.2 -5.55 4.71e-08 1.63e-05 -0.27 -0.25 Aortic root size; chr7:66105323 chr7:65773620~65802067:+ LUSC cis rs2404602 0.583 rs12907668 ENSG00000259422.1 RP11-593F23.1 5.55 4.71e-08 1.63e-05 0.28 0.25 Blood metabolite levels; chr15:76297426 chr15:76174891~76181486:- LUSC cis rs638893 1 rs73005500 ENSG00000278376.1 RP11-158I9.8 5.55 4.71e-08 1.63e-05 0.33 0.25 Vitiligo; chr11:118826666 chr11:118791254~118793137:+ LUSC cis rs1387259 0.759 rs7960122 ENSG00000226413.2 OR8T1P -5.55 4.71e-08 1.64e-05 -0.32 -0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48383217 chr12:48442030~48442947:- LUSC cis rs4834770 1 rs10034579 ENSG00000245958.5 RP11-33B1.1 -5.55 4.71e-08 1.64e-05 -0.24 -0.25 Blood protein levels; chr4:119322874 chr4:119454791~119552025:+ LUSC cis rs1056107 0.897 rs7851129 ENSG00000225513.1 RP11-165N19.2 -5.55 4.72e-08 1.64e-05 -0.27 -0.25 Colorectal cancer; chr9:112193127 chr9:112173522~112173971:- LUSC cis rs11971779 0.818 rs12056045 ENSG00000273391.1 RP11-634H22.1 5.55 4.72e-08 1.64e-05 0.31 0.25 Diisocyanate-induced asthma; chr7:139340684 chr7:139359032~139359566:- LUSC cis rs853679 1 rs735765 ENSG00000219392.1 RP1-265C24.5 -5.55 4.73e-08 1.64e-05 -0.44 -0.25 Depression; chr6:28202519 chr6:28115628~28116551:+ LUSC cis rs8072100 0.713 rs3871595 ENSG00000228782.6 CTD-2026D20.3 5.55 4.73e-08 1.64e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47434022 chr17:47450568~47492492:- LUSC cis rs8072100 0.713 rs9899859 ENSG00000228782.6 CTD-2026D20.3 5.55 4.73e-08 1.64e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47435683 chr17:47450568~47492492:- LUSC cis rs8072100 0.713 rs1912486 ENSG00000228782.6 CTD-2026D20.3 5.55 4.73e-08 1.64e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47437801 chr17:47450568~47492492:- LUSC cis rs8072100 0.667 rs1912485 ENSG00000228782.6 CTD-2026D20.3 5.55 4.73e-08 1.64e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47438312 chr17:47450568~47492492:- LUSC cis rs2274273 0.84 rs11626751 ENSG00000258413.1 RP11-665C16.6 -5.55 4.73e-08 1.64e-05 -0.3 -0.25 Protein biomarker; chr14:55368509 chr14:55262767~55272075:- LUSC cis rs7772486 0.79 rs9497435 ENSG00000235652.6 RP11-545I5.3 -5.55 4.74e-08 1.64e-05 -0.24 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145944204 chr6:145799409~145886585:+ LUSC cis rs11971779 0.941 rs6954453 ENSG00000273391.1 RP11-634H22.1 5.55 4.74e-08 1.64e-05 0.31 0.25 Diisocyanate-induced asthma; chr7:139347048 chr7:139359032~139359566:- LUSC cis rs11971779 0.941 rs4732368 ENSG00000273391.1 RP11-634H22.1 5.55 4.74e-08 1.64e-05 0.31 0.25 Diisocyanate-induced asthma; chr7:139349461 chr7:139359032~139359566:- LUSC cis rs11096990 0.656 rs3733284 ENSG00000249207.1 RP11-360F5.1 5.55 4.74e-08 1.64e-05 0.26 0.25 Cognitive function; chr4:39299714 chr4:39112677~39126818:- LUSC cis rs77204473 0.744 rs12273545 ENSG00000254851.1 RP11-109L13.1 5.55 4.74e-08 1.64e-05 0.58 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117040296 chr11:117135528~117138582:+ LUSC cis rs77204473 0.744 rs77999164 ENSG00000254851.1 RP11-109L13.1 5.55 4.74e-08 1.64e-05 0.58 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117041401 chr11:117135528~117138582:+ LUSC cis rs2980439 0.557 rs2976876 ENSG00000253893.2 FAM85B -5.55 4.74e-08 1.65e-05 -0.3 -0.25 Neuroticism; chr8:8461340 chr8:8167819~8226614:- LUSC cis rs2274273 0.84 rs10136596 ENSG00000258413.1 RP11-665C16.6 -5.55 4.74e-08 1.65e-05 -0.3 -0.25 Protein biomarker; chr14:55370055 chr14:55262767~55272075:- LUSC cis rs75920871 0.528 rs10892071 ENSG00000254851.1 RP11-109L13.1 5.55 4.75e-08 1.65e-05 0.34 0.25 Subjective well-being; chr11:117083849 chr11:117135528~117138582:+ LUSC cis rs2153535 0.504 rs5001323 ENSG00000230939.1 RP11-314C16.1 -5.55 4.75e-08 1.65e-05 -0.29 -0.25 Motion sickness; chr6:8451372 chr6:8784178~8785445:+ LUSC cis rs910316 1 rs12879542 ENSG00000279594.1 RP11-950C14.10 5.55 4.75e-08 1.65e-05 0.28 0.25 Height; chr14:75040822 chr14:75011269~75012851:- LUSC cis rs910316 1 rs4903275 ENSG00000279594.1 RP11-950C14.10 5.55 4.75e-08 1.65e-05 0.28 0.25 Height; chr14:75045806 chr14:75011269~75012851:- LUSC cis rs13113518 0.729 rs11133377 ENSG00000272969.1 RP11-528I4.2 5.55 4.75e-08 1.65e-05 0.3 0.25 Height; chr4:55413708 chr4:55547112~55547889:+ LUSC cis rs6502050 0.835 rs12450189 ENSG00000266654.1 RP11-1376P16.1 -5.55 4.76e-08 1.65e-05 -0.25 -0.25 Life satisfaction; chr17:82137252 chr17:82160056~82160452:+ LUSC cis rs6502050 0.634 rs11077973 ENSG00000266654.1 RP11-1376P16.1 -5.55 4.76e-08 1.65e-05 -0.25 -0.25 Life satisfaction; chr17:82137315 chr17:82160056~82160452:+ LUSC cis rs4625783 0.583 rs11077974 ENSG00000266654.1 RP11-1376P16.1 -5.55 4.76e-08 1.65e-05 -0.25 -0.25 Blood metabolite levels; chr17:82137317 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs6502065 ENSG00000266654.1 RP11-1376P16.1 -5.55 4.76e-08 1.65e-05 -0.25 -0.25 Life satisfaction; chr17:82137766 chr17:82160056~82160452:+ LUSC cis rs6502050 0.731 rs35156322 ENSG00000266654.1 RP11-1376P16.1 -5.55 4.76e-08 1.65e-05 -0.25 -0.25 Life satisfaction; chr17:82138447 chr17:82160056~82160452:+ LUSC cis rs11098499 0.954 rs11098526 ENSG00000248280.1 RP11-33B1.2 5.55 4.76e-08 1.65e-05 0.3 0.25 Corneal astigmatism; chr4:119469204 chr4:119440561~119450157:- LUSC cis rs7181230 0.885 rs3923235 ENSG00000275636.1 RP11-521C20.5 5.55 4.76e-08 1.65e-05 0.31 0.25 Dehydroepiandrosterone sulphate levels; chr15:40078920 chr15:40078892~40079347:+ LUSC cis rs875971 0.798 rs12698522 ENSG00000179406.6 LINC00174 -5.55 4.76e-08 1.65e-05 -0.27 -0.25 Aortic root size; chr7:66502354 chr7:66376044~66401338:- LUSC cis rs875971 0.83 rs28714531 ENSG00000179406.6 LINC00174 -5.55 4.76e-08 1.65e-05 -0.27 -0.25 Aortic root size; chr7:66503250 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs12698526 ENSG00000179406.6 LINC00174 -5.55 4.76e-08 1.65e-05 -0.27 -0.25 Aortic root size; chr7:66504118 chr7:66376044~66401338:- LUSC cis rs7657257 1 rs12643722 ENSG00000214846.4 RP11-115L11.1 5.55 4.76e-08 1.65e-05 0.7 0.25 Blood protein levels; chr4:15728480 chr4:15730962~15731627:- LUSC cis rs7657257 1 rs12640554 ENSG00000214846.4 RP11-115L11.1 5.55 4.76e-08 1.65e-05 0.7 0.25 Blood protein levels; chr4:15728484 chr4:15730962~15731627:- LUSC cis rs2302464 1 rs111541714 ENSG00000214846.4 RP11-115L11.1 5.55 4.76e-08 1.65e-05 0.7 0.25 Cerebrospinal fluid biomarker levels; chr4:15728782 chr4:15730962~15731627:- LUSC cis rs2302464 1 rs73125993 ENSG00000214846.4 RP11-115L11.1 5.55 4.76e-08 1.65e-05 0.7 0.25 Cerebrospinal fluid biomarker levels; chr4:15728890 chr4:15730962~15731627:- LUSC cis rs6772849 0.93 rs9868579 ENSG00000277250.1 Metazoa_SRP 5.55 4.77e-08 1.65e-05 0.27 0.25 Monocyte percentage of white cells;Monocyte count; chr3:128632211 chr3:128673681~128674021:- LUSC cis rs11603023 0.625 rs633683 ENSG00000255239.1 AP002954.6 5.55 4.77e-08 1.65e-05 0.29 0.25 Cholesterol, total; chr11:118634025 chr11:118688039~118690600:- LUSC cis rs16843372 0.576 rs10175732 ENSG00000251491.2 OR7E28P -5.55 4.77e-08 1.65e-05 -0.27 -0.25 Obesity-related traits; chr2:158839775 chr2:158862311~158863285:+ LUSC cis rs28830936 1 rs2577960 ENSG00000250379.1 RP11-23P13.4 -5.55 4.77e-08 1.66e-05 -0.27 -0.25 Diastolic blood pressure; chr15:41736156 chr15:41825099~41827936:- LUSC cis rs1707322 0.685 rs11211177 ENSG00000234329.1 RP11-767N6.2 5.55 4.78e-08 1.66e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760677 chr1:45651039~45651826:- LUSC cis rs853679 1 rs1936365 ENSG00000219392.1 RP1-265C24.5 5.55 4.78e-08 1.66e-05 0.38 0.25 Depression; chr6:28300675 chr6:28115628~28116551:+ LUSC cis rs2337406 0.789 rs9324095 ENSG00000211974.3 IGHV2-70 -5.55 4.78e-08 1.66e-05 -0.33 -0.25 Alzheimer's disease (late onset); chr14:106795885 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs58154560 ENSG00000211974.3 IGHV2-70 -5.55 4.78e-08 1.66e-05 -0.33 -0.25 Alzheimer's disease (late onset); chr14:106799601 chr14:106723574~106724093:- LUSC cis rs7955901 0.837 rs11178531 ENSG00000257265.1 CTD-2021H9.1 -5.55 4.78e-08 1.66e-05 -0.27 -0.25 Type 2 diabetes; chr12:71014910 chr12:71007773~71032083:- LUSC cis rs11098499 0.954 rs59394118 ENSG00000248280.1 RP11-33B1.2 5.55 4.78e-08 1.66e-05 0.3 0.25 Corneal astigmatism; chr4:119374396 chr4:119440561~119450157:- LUSC cis rs11098499 0.865 rs9996417 ENSG00000248280.1 RP11-33B1.2 5.55 4.78e-08 1.66e-05 0.3 0.25 Corneal astigmatism; chr4:119374707 chr4:119440561~119450157:- LUSC cis rs7267979 0.866 rs2424698 ENSG00000274973.1 RP13-401N8.7 -5.55 4.78e-08 1.66e-05 -0.25 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25275470 chr20:25845497~25845862:+ LUSC cis rs2732480 0.577 rs2732479 ENSG00000240399.1 RP1-228P16.1 5.55 4.78e-08 1.66e-05 0.27 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342477 chr12:48054813~48055591:- LUSC cis rs2732480 0.537 rs1061986 ENSG00000240399.1 RP1-228P16.1 5.55 4.78e-08 1.66e-05 0.27 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342656 chr12:48054813~48055591:- LUSC cis rs442309 0.841 rs377859 ENSG00000238280.1 RP11-436D10.3 -5.55 4.78e-08 1.66e-05 -0.31 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62756305 chr10:62793562~62805887:- LUSC cis rs17772222 0.653 rs1346996 ENSG00000258789.1 RP11-507K2.3 -5.55 4.79e-08 1.66e-05 -0.28 -0.25 Coronary artery calcification; chr14:88507174 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs7160471 ENSG00000258789.1 RP11-507K2.3 -5.55 4.79e-08 1.66e-05 -0.28 -0.25 Coronary artery calcification; chr14:88507241 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs9323830 ENSG00000258789.1 RP11-507K2.3 -5.55 4.79e-08 1.66e-05 -0.28 -0.25 Coronary artery calcification; chr14:88507260 chr14:88551597~88552493:+ LUSC cis rs35740288 0.929 rs1978391 ENSG00000202081.1 RNU6-1280P -5.55 4.79e-08 1.66e-05 -0.31 -0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85768464 chr15:85651522~85651628:- LUSC cis rs9322193 0.884 rs10872647 ENSG00000268592.3 RAET1E-AS1 5.55 4.79e-08 1.66e-05 0.33 0.25 Lung cancer; chr6:149758687 chr6:149863494~149919507:+ LUSC cis rs3823536 0.5 rs4728144 ENSG00000275106.1 RP11-309L24.10 -5.55 4.79e-08 1.66e-05 -0.31 -0.25 Sjögren's syndrome; chr7:129000280 chr7:128952527~128953316:- LUSC cis rs2243480 1 rs3885839 ENSG00000226824.5 RP4-756H11.3 -5.55 4.79e-08 1.66e-05 -0.49 -0.25 Diabetic kidney disease; chr7:65825416 chr7:66654538~66669855:+ LUSC cis rs75422866 0.85 rs73111212 ENSG00000274902.1 RP1-197B17.4 5.55 4.8e-08 1.66e-05 0.69 0.25 Pneumonia; chr12:47577638 chr12:47731908~47732351:+ LUSC cis rs75422866 0.85 rs73111216 ENSG00000274902.1 RP1-197B17.4 5.55 4.8e-08 1.66e-05 0.69 0.25 Pneumonia; chr12:47577671 chr12:47731908~47732351:+ LUSC cis rs75422866 0.85 rs73111217 ENSG00000274902.1 RP1-197B17.4 5.55 4.8e-08 1.66e-05 0.69 0.25 Pneumonia; chr12:47577693 chr12:47731908~47732351:+ LUSC cis rs442309 0.875 rs224066 ENSG00000238280.1 RP11-436D10.3 -5.55 4.8e-08 1.66e-05 -0.3 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62746419 chr10:62793562~62805887:- LUSC cis rs2243480 1 rs35542501 ENSG00000226824.5 RP4-756H11.3 -5.55 4.8e-08 1.66e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65966228 chr7:66654538~66669855:+ LUSC cis rs2243480 0.711 rs1626926 ENSG00000226824.5 RP4-756H11.3 -5.55 4.8e-08 1.66e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65970805 chr7:66654538~66669855:+ LUSC cis rs2243480 0.708 rs781141 ENSG00000226824.5 RP4-756H11.3 -5.55 4.8e-08 1.66e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65973566 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs781142 ENSG00000226824.5 RP4-756H11.3 -5.55 4.8e-08 1.66e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65973791 chr7:66654538~66669855:+ LUSC cis rs1008375 0.966 rs3775923 ENSG00000249502.1 AC006160.5 -5.55 4.8e-08 1.66e-05 -0.24 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17584002 chr4:17587467~17614571:- LUSC cis rs2742234 0.59 rs2503864 ENSG00000273008.1 RP11-351D16.3 -5.55 4.8e-08 1.66e-05 -0.28 -0.25 Hirschsprung disease; chr10:43171319 chr10:43136824~43138334:- LUSC cis rs2742234 0.59 rs2503863 ENSG00000273008.1 RP11-351D16.3 -5.55 4.8e-08 1.66e-05 -0.28 -0.25 Hirschsprung disease; chr10:43171950 chr10:43136824~43138334:- LUSC cis rs2742234 0.59 rs2435383 ENSG00000273008.1 RP11-351D16.3 -5.55 4.8e-08 1.66e-05 -0.28 -0.25 Hirschsprung disease; chr10:43180223 chr10:43136824~43138334:- LUSC cis rs7712401 0.623 rs426877 ENSG00000263432.2 RN7SL689P -5.55 4.8e-08 1.66e-05 -0.32 -0.25 Mean platelet volume; chr5:122978940 chr5:123022487~123022783:- LUSC cis rs77204473 0.744 rs12418705 ENSG00000254851.1 RP11-109L13.1 5.55 4.8e-08 1.66e-05 0.61 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117213680 chr11:117135528~117138582:+ LUSC cis rs10027350 0.964 rs10026230 ENSG00000281501.1 SEPSECS-AS1 5.55 4.81e-08 1.67e-05 0.29 0.25 Childhood ear infection; chr4:25135784 chr4:25160641~25201440:+ LUSC cis rs77972916 0.505 rs6753197 ENSG00000234936.1 AC010883.5 5.55 4.81e-08 1.67e-05 0.3 0.25 Granulocyte percentage of myeloid white cells; chr2:43300823 chr2:43229573~43233394:+ LUSC cis rs2439831 0.85 rs28590651 ENSG00000249839.1 AC011330.5 -5.55 4.81e-08 1.67e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43820818 chr15:43663654~43684339:- LUSC cis rs6502050 0.765 rs55905076 ENSG00000266654.1 RP11-1376P16.1 -5.55 4.81e-08 1.67e-05 -0.25 -0.25 Life satisfaction; chr17:82147565 chr17:82160056~82160452:+ LUSC cis rs7712401 0.601 rs246320 ENSG00000263432.2 RN7SL689P 5.55 4.81e-08 1.67e-05 0.32 0.25 Mean platelet volume; chr5:122972886 chr5:123022487~123022783:- LUSC cis rs459571 0.959 rs456205 ENSG00000235106.7 LINC00094 5.55 4.82e-08 1.67e-05 0.28 0.25 Platelet distribution width; chr9:134046024 chr9:134025439~134034666:+ LUSC cis rs62103177 0.535 rs62101568 ENSG00000261126.6 RP11-795F19.1 5.55 4.82e-08 1.67e-05 0.32 0.25 Opioid sensitivity; chr18:80176788 chr18:80046900~80095482:+ LUSC cis rs35740288 0.685 rs12899481 ENSG00000202081.1 RNU6-1280P 5.55 4.82e-08 1.67e-05 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85765739 chr15:85651522~85651628:- LUSC cis rs6570726 0.791 rs6914203 ENSG00000235652.6 RP11-545I5.3 5.55 4.83e-08 1.67e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145578839 chr6:145799409~145886585:+ LUSC cis rs10462794 0.661 rs4702801 ENSG00000260763.1 RP11-445O3.3 -5.55 4.83e-08 1.67e-05 -0.33 -0.25 DNA methylation (variation); chr5:4522715 chr5:4436850~4440259:- LUSC cis rs2136613 0.751 rs10995324 ENSG00000238280.1 RP11-436D10.3 5.55 4.83e-08 1.67e-05 0.3 0.25 Selective IgA deficiency; chr10:62838233 chr10:62793562~62805887:- LUSC cis rs228614 0.534 rs223387 ENSG00000246560.2 RP11-10L12.4 5.55 4.84e-08 1.67e-05 0.3 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102828359 chr4:102828055~102844075:+ LUSC cis rs17818399 0.781 rs12105006 ENSG00000279254.1 RP11-536C12.1 5.55 4.84e-08 1.68e-05 0.3 0.25 Height; chr2:46635447 chr2:46668870~46670778:+ LUSC cis rs42490 0.966 rs2644033 ENSG00000251136.7 RP11-37B2.1 5.55 4.84e-08 1.68e-05 0.22 0.25 Leprosy; chr8:89739196 chr8:89609409~89757727:- LUSC cis rs7181230 0.885 rs4924413 ENSG00000275636.1 RP11-521C20.5 5.55 4.84e-08 1.68e-05 0.31 0.25 Dehydroepiandrosterone sulphate levels; chr15:40056496 chr15:40078892~40079347:+ LUSC cis rs11098499 0.866 rs11098506 ENSG00000248280.1 RP11-33B1.2 5.55 4.85e-08 1.68e-05 0.29 0.25 Corneal astigmatism; chr4:119363816 chr4:119440561~119450157:- LUSC cis rs9611519 1 rs2273085 ENSG00000235513.1 RP4-756G23.5 5.55 4.85e-08 1.68e-05 0.29 0.25 Neuroticism; chr22:41219372 chr22:41209122~41217627:- LUSC cis rs875971 0.545 rs1796226 ENSG00000237310.1 GS1-124K5.4 5.55 4.85e-08 1.68e-05 0.28 0.25 Aortic root size; chr7:66622723 chr7:66493706~66495474:+ LUSC cis rs853679 0.513 rs13437444 ENSG00000280107.1 AL022393.9 -5.55 4.86e-08 1.68e-05 -0.34 -0.25 Depression; chr6:28103220 chr6:28170845~28172521:+ LUSC cis rs9450351 0.744 rs9450294 ENSG00000203875.9 SNHG5 -5.55 4.86e-08 1.68e-05 -0.56 -0.25 Interferon gamma-induced protein 10 levels; chr6:85540712 chr6:85660950~85678736:- LUSC cis rs42490 1 rs2735873 ENSG00000251136.7 RP11-37B2.1 5.55 4.86e-08 1.68e-05 0.22 0.25 Leprosy; chr8:89737748 chr8:89609409~89757727:- LUSC cis rs10462794 0.661 rs62343555 ENSG00000260763.1 RP11-445O3.3 -5.55 4.87e-08 1.68e-05 -0.33 -0.25 DNA methylation (variation); chr5:4522357 chr5:4436850~4440259:- LUSC cis rs2562456 0.917 rs2681376 ENSG00000268081.1 RP11-678G14.2 -5.55 4.87e-08 1.69e-05 -0.35 -0.25 Pain; chr19:21532723 chr19:21554640~21569237:- LUSC cis rs1322639 0.614 rs6925201 ENSG00000261039.2 RP11-417E7.2 5.55 4.87e-08 1.69e-05 0.39 0.25 Pulse pressure; chr6:169163262 chr6:169175304~169182740:- LUSC cis rs2919917 0.628 rs6981103 ENSG00000254352.1 RP11-578O24.2 5.55 4.87e-08 1.69e-05 0.34 0.25 Lymphocyte counts; chr8:78691702 chr8:78723796~78724136:- LUSC cis rs6570726 0.967 rs6903252 ENSG00000235652.6 RP11-545I5.3 5.55 4.87e-08 1.69e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145601641 chr6:145799409~145886585:+ LUSC cis rs4803480 0.872 rs10420470 ENSG00000270164.1 LINC01480 -5.55 4.87e-08 1.69e-05 -0.22 -0.25 Schizophrenia; chr19:41567075 chr19:41535183~41536904:+ LUSC cis rs2980439 0.557 rs2921056 ENSG00000253893.2 FAM85B -5.55 4.88e-08 1.69e-05 -0.3 -0.25 Neuroticism; chr8:8461672 chr8:8167819~8226614:- LUSC cis rs875971 0.545 rs4441996 ENSG00000224316.1 RP11-479O9.2 -5.55 4.88e-08 1.69e-05 -0.26 -0.25 Aortic root size; chr7:66123233 chr7:65773620~65802067:+ LUSC cis rs13113518 0.678 rs13149568 ENSG00000249700.7 SRD5A3-AS1 5.55 4.89e-08 1.69e-05 0.28 0.25 Height; chr4:55370412 chr4:55363971~55395847:- LUSC cis rs11673344 0.58 rs320881 ENSG00000226686.6 LINC01535 5.55 4.89e-08 1.69e-05 0.32 0.25 Obesity-related traits; chr19:37246948 chr19:37251912~37265535:+ LUSC cis rs9545047 0.604 rs1616547 ENSG00000227676.3 LINC01068 5.55 4.89e-08 1.69e-05 0.31 0.25 Schizophrenia; chr13:79411901 chr13:79566727~79571436:+ LUSC cis rs1707322 0.682 rs12037459 ENSG00000234329.1 RP11-767N6.2 5.55 4.9e-08 1.7e-05 0.27 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629287 chr1:45651039~45651826:- LUSC cis rs875971 0.545 rs2420456 ENSG00000179406.6 LINC00174 -5.55 4.9e-08 1.7e-05 -0.29 -0.25 Aortic root size; chr7:66280619 chr7:66376044~66401338:- LUSC cis rs2562456 0.755 rs2914646 ENSG00000268081.1 RP11-678G14.2 -5.55 4.91e-08 1.7e-05 -0.36 -0.25 Pain; chr19:21454359 chr19:21554640~21569237:- LUSC cis rs7712401 0.623 rs30043 ENSG00000263432.2 RN7SL689P 5.55 4.91e-08 1.7e-05 0.31 0.25 Mean platelet volume; chr5:122936598 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs185009 ENSG00000263432.2 RN7SL689P 5.55 4.91e-08 1.7e-05 0.31 0.25 Mean platelet volume; chr5:122938072 chr5:123022487~123022783:- LUSC cis rs7712401 0.541 rs42537 ENSG00000263432.2 RN7SL689P 5.55 4.91e-08 1.7e-05 0.31 0.25 Mean platelet volume; chr5:122938993 chr5:123022487~123022783:- LUSC cis rs7712401 0.58 rs185008 ENSG00000263432.2 RN7SL689P 5.55 4.91e-08 1.7e-05 0.31 0.25 Mean platelet volume; chr5:122939039 chr5:123022487~123022783:- LUSC cis rs7712401 0.58 rs30041 ENSG00000263432.2 RN7SL689P 5.55 4.91e-08 1.7e-05 0.31 0.25 Mean platelet volume; chr5:122939658 chr5:123022487~123022783:- LUSC cis rs7555523 0.887 rs2251768 ENSG00000224358.1 RP11-466F5.8 -5.54 4.91e-08 1.7e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165769074 chr1:165768929~165775176:+ LUSC cis rs875971 0.545 rs316324 ENSG00000224316.1 RP11-479O9.2 -5.54 4.91e-08 1.7e-05 -0.26 -0.25 Aortic root size; chr7:66145627 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs316323 ENSG00000224316.1 RP11-479O9.2 -5.54 4.91e-08 1.7e-05 -0.26 -0.25 Aortic root size; chr7:66146002 chr7:65773620~65802067:+ LUSC cis rs17772222 0.74 rs4390529 ENSG00000258789.1 RP11-507K2.3 -5.54 4.92e-08 1.7e-05 -0.28 -0.25 Coronary artery calcification; chr14:88510853 chr14:88551597~88552493:+ LUSC cis rs17772222 0.771 rs4516145 ENSG00000258789.1 RP11-507K2.3 -5.54 4.92e-08 1.7e-05 -0.28 -0.25 Coronary artery calcification; chr14:88510953 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs4594187 ENSG00000258789.1 RP11-507K2.3 -5.54 4.92e-08 1.7e-05 -0.28 -0.25 Coronary artery calcification; chr14:88511071 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs4514599 ENSG00000258789.1 RP11-507K2.3 -5.54 4.92e-08 1.7e-05 -0.28 -0.25 Coronary artery calcification; chr14:88511083 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs73317739 ENSG00000258789.1 RP11-507K2.3 -5.54 4.92e-08 1.7e-05 -0.28 -0.25 Coronary artery calcification; chr14:88511400 chr14:88551597~88552493:+ LUSC cis rs2742234 0.541 rs10793422 ENSG00000273008.1 RP11-351D16.3 5.54 4.92e-08 1.7e-05 0.28 0.25 Hirschsprung disease; chr10:43208426 chr10:43136824~43138334:- LUSC cis rs7772486 0.79 rs2254288 ENSG00000235652.6 RP11-545I5.3 5.54 4.92e-08 1.7e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145883334 chr6:145799409~145886585:+ LUSC cis rs13113518 0.513 rs13147861 ENSG00000273257.1 RP11-177J6.1 5.54 4.92e-08 1.7e-05 0.32 0.25 Height; chr4:55611014 chr4:55387949~55388271:+ LUSC cis rs2337406 0.5 rs7152934 ENSG00000211974.3 IGHV2-70 -5.54 4.92e-08 1.7e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106778702 chr14:106723574~106724093:- LUSC cis rs13113518 1 rs4864994 ENSG00000249700.7 SRD5A3-AS1 5.54 4.92e-08 1.7e-05 0.29 0.25 Height; chr4:55451955 chr4:55363971~55395847:- LUSC cis rs2439831 0.867 rs935901 ENSG00000249839.1 AC011330.5 -5.54 4.92e-08 1.7e-05 -0.52 -0.25 Lung cancer in ever smokers; chr15:43359058 chr15:43663654~43684339:- LUSC cis rs17711722 0.653 rs2460421 ENSG00000179406.6 LINC00174 5.54 4.93e-08 1.7e-05 0.26 0.25 Calcium levels; chr7:66026136 chr7:66376044~66401338:- LUSC cis rs367615 0.704 rs7705399 ENSG00000249476.1 CTD-2587M2.1 5.54 4.93e-08 1.7e-05 0.28 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109514650 chr5:109237120~109326369:- LUSC cis rs11098499 0.754 rs1511017 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119329650 chr4:119334329~119378233:+ LUSC cis rs11098499 0.789 rs12498994 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119329663 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs12507565 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119329966 chr4:119334329~119378233:+ LUSC cis rs11098499 0.826 rs12511640 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119330093 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs1980026 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119330488 chr4:119334329~119378233:+ LUSC cis rs11098499 0.722 rs28713555 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119330840 chr4:119334329~119378233:+ LUSC cis rs11098499 0.743 rs11098501 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119330862 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs11098502 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119330908 chr4:119334329~119378233:+ LUSC cis rs11098499 0.708 rs11732686 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119331175 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs11724409 ENSG00000250412.1 KLHL2P1 5.54 4.93e-08 1.71e-05 0.3 0.25 Corneal astigmatism; chr4:119331206 chr4:119334329~119378233:+ LUSC cis rs2274273 0.87 rs10139083 ENSG00000258413.1 RP11-665C16.6 -5.54 4.94e-08 1.71e-05 -0.3 -0.25 Protein biomarker; chr14:55316017 chr14:55262767~55272075:- LUSC cis rs2274273 0.87 rs10145203 ENSG00000258413.1 RP11-665C16.6 -5.54 4.94e-08 1.71e-05 -0.3 -0.25 Protein biomarker; chr14:55317740 chr14:55262767~55272075:- LUSC cis rs3738443 0.83 rs6684181 ENSG00000259865.1 RP11-488L18.10 5.54 4.94e-08 1.71e-05 0.27 0.25 Alcohol dependence; chr1:247184669 chr1:247187281~247188526:- LUSC cis rs6142102 0.651 rs6059692 ENSG00000276073.1 RP5-1125A11.7 5.54 4.94e-08 1.71e-05 0.27 0.25 Skin pigmentation; chr20:34158397 chr20:33985617~33988989:- LUSC cis rs10462794 1 rs13358031 ENSG00000260763.1 RP11-445O3.3 -5.54 4.94e-08 1.71e-05 -0.31 -0.25 DNA methylation (variation); chr5:4477152 chr5:4436850~4440259:- LUSC cis rs13113518 1 rs11133388 ENSG00000272969.1 RP11-528I4.2 -5.54 4.95e-08 1.71e-05 -0.28 -0.25 Height; chr4:55477866 chr4:55547112~55547889:+ LUSC cis rs7829975 0.617 rs4841071 ENSG00000253893.2 FAM85B -5.54 4.96e-08 1.71e-05 -0.28 -0.25 Mood instability; chr8:8933634 chr8:8167819~8226614:- LUSC cis rs394563 0.69 rs237010 ENSG00000231760.4 RP11-350J20.5 5.54 4.96e-08 1.71e-05 0.3 0.25 Dupuytren's disease; chr6:149437614 chr6:149796151~149826294:- LUSC cis rs9611519 0.929 rs73174657 ENSG00000235513.1 RP4-756G23.5 5.54 4.96e-08 1.72e-05 0.29 0.25 Neuroticism; chr22:41038154 chr22:41209122~41217627:- LUSC cis rs9611519 0.929 rs9611474 ENSG00000235513.1 RP4-756G23.5 5.54 4.96e-08 1.72e-05 0.29 0.25 Neuroticism; chr22:41038854 chr22:41209122~41217627:- LUSC cis rs5770917 1 rs5770924 ENSG00000273272.1 CTA-384D8.34 5.54 4.96e-08 1.72e-05 0.54 0.25 Narcolepsy; chr22:50586113 chr22:50542650~50543011:+ LUSC cis rs2919917 0.628 rs2717540 ENSG00000254352.1 RP11-578O24.2 5.54 4.96e-08 1.72e-05 0.34 0.25 Lymphocyte counts; chr8:78710128 chr8:78723796~78724136:- LUSC cis rs6502050 0.805 rs7503095 ENSG00000266654.1 RP11-1376P16.1 -5.54 4.98e-08 1.72e-05 -0.25 -0.25 Life satisfaction; chr17:82149478 chr17:82160056~82160452:+ LUSC cis rs7712401 0.601 rs34233716 ENSG00000263432.2 RN7SL689P -5.54 4.98e-08 1.72e-05 -0.32 -0.25 Mean platelet volume; chr5:122980670 chr5:123022487~123022783:- LUSC cis rs7804306 1 rs13222718 ENSG00000233264.2 AC006042.8 5.54 4.98e-08 1.72e-05 0.41 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7974690 chr7:7980312~7982228:+ LUSC cis rs7804306 1 rs34438930 ENSG00000233264.2 AC006042.8 5.54 4.98e-08 1.72e-05 0.41 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7974740 chr7:7980312~7982228:+ LUSC cis rs763121 0.853 rs138709 ENSG00000273076.1 RP3-508I15.22 5.54 4.98e-08 1.72e-05 0.25 0.25 Menopause (age at onset); chr22:38743211 chr22:38743495~38743910:+ LUSC cis rs875971 0.502 rs11769702 ENSG00000224316.1 RP11-479O9.2 5.54 4.98e-08 1.72e-05 0.27 0.25 Aortic root size; chr7:66255529 chr7:65773620~65802067:+ LUSC cis rs7712401 0.601 rs40818 ENSG00000263432.2 RN7SL689P 5.54 4.98e-08 1.72e-05 0.31 0.25 Mean platelet volume; chr5:122959378 chr5:123022487~123022783:- LUSC cis rs3002131 0.604 rs3008644 ENSG00000225265.1 TAF1A-AS1 -5.54 4.98e-08 1.72e-05 -0.36 -0.25 Interleukin-10 levels; chr1:222577402 chr1:222589825~222593032:+ LUSC cis rs875971 1 rs7781698 ENSG00000179406.6 LINC00174 -5.54 4.99e-08 1.72e-05 -0.27 -0.25 Aortic root size; chr7:66431325 chr7:66376044~66401338:- LUSC cis rs9326248 0.581 rs12225187 ENSG00000280143.1 AP000892.6 5.54 4.99e-08 1.72e-05 0.26 0.25 Blood protein levels; chr11:116922515 chr11:117204967~117210292:+ LUSC cis rs61270009 0.955 rs17548339 ENSG00000247828.6 TMEM161B-AS1 5.54 4.99e-08 1.72e-05 0.29 0.25 Depressive symptoms; chr5:88391761 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs16903122 ENSG00000247828.6 TMEM161B-AS1 5.54 4.99e-08 1.72e-05 0.29 0.25 Depressive symptoms; chr5:88397744 chr5:88268895~88436685:+ LUSC cis rs2404602 0.583 rs12908334 ENSG00000259422.1 RP11-593F23.1 5.54 4.99e-08 1.72e-05 0.28 0.25 Blood metabolite levels; chr15:76289251 chr15:76174891~76181486:- LUSC cis rs9309711 0.621 rs11127428 ENSG00000225234.1 TRAPPC12-AS1 -5.54 4.99e-08 1.72e-05 -0.3 -0.25 Neurofibrillary tangles; chr2:3467375 chr2:3481242~3482409:- LUSC cis rs42490 0.966 rs218932 ENSG00000251136.7 RP11-37B2.1 -5.54 4.99e-08 1.73e-05 -0.22 -0.25 Leprosy; chr8:89740725 chr8:89609409~89757727:- LUSC cis rs42490 0.966 rs2735878 ENSG00000251136.7 RP11-37B2.1 -5.54 4.99e-08 1.73e-05 -0.22 -0.25 Leprosy; chr8:89742720 chr8:89609409~89757727:- LUSC cis rs11098499 0.863 rs58452170 ENSG00000248280.1 RP11-33B1.2 5.54 5e-08 1.73e-05 0.3 0.25 Corneal astigmatism; chr4:119538519 chr4:119440561~119450157:- LUSC cis rs2742234 0.541 rs1059484 ENSG00000273008.1 RP11-351D16.3 -5.54 5e-08 1.73e-05 -0.28 -0.25 Hirschsprung disease; chr10:43184352 chr10:43136824~43138334:- LUSC cis rs2742234 0.59 rs2505553 ENSG00000273008.1 RP11-351D16.3 -5.54 5e-08 1.73e-05 -0.28 -0.25 Hirschsprung disease; chr10:43185803 chr10:43136824~43138334:- LUSC cis rs2742234 0.59 rs2435376 ENSG00000273008.1 RP11-351D16.3 -5.54 5e-08 1.73e-05 -0.28 -0.25 Hirschsprung disease; chr10:43189515 chr10:43136824~43138334:- LUSC cis rs2742234 0.579 rs2503881 ENSG00000273008.1 RP11-351D16.3 -5.54 5e-08 1.73e-05 -0.28 -0.25 Hirschsprung disease; chr10:43190578 chr10:43136824~43138334:- LUSC cis rs2742234 0.59 rs2115817 ENSG00000273008.1 RP11-351D16.3 -5.54 5e-08 1.73e-05 -0.28 -0.25 Hirschsprung disease; chr10:43191104 chr10:43136824~43138334:- LUSC cis rs2742234 0.59 rs1254965 ENSG00000273008.1 RP11-351D16.3 5.54 5e-08 1.73e-05 0.28 0.25 Hirschsprung disease; chr10:43194405 chr10:43136824~43138334:- LUSC cis rs2742234 0.503 rs1254968 ENSG00000273008.1 RP11-351D16.3 5.54 5e-08 1.73e-05 0.28 0.25 Hirschsprung disease; chr10:43196243 chr10:43136824~43138334:- LUSC cis rs62355901 0.509 rs116154674 ENSG00000271828.1 CTD-2310F14.1 5.54 5e-08 1.73e-05 0.5 0.25 Breast cancer; chr5:56710833 chr5:56927874~56929573:+ LUSC cis rs910316 0.789 rs12894419 ENSG00000279594.1 RP11-950C14.10 5.54 5e-08 1.73e-05 0.29 0.25 Height; chr14:75005099 chr14:75011269~75012851:- LUSC cis rs7712401 0.54 rs416763 ENSG00000263432.2 RN7SL689P -5.54 5e-08 1.73e-05 -0.32 -0.25 Mean platelet volume; chr5:122981546 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs35339188 ENSG00000263432.2 RN7SL689P -5.54 5e-08 1.73e-05 -0.32 -0.25 Mean platelet volume; chr5:122981990 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs36099390 ENSG00000263432.2 RN7SL689P -5.54 5e-08 1.73e-05 -0.32 -0.25 Mean platelet volume; chr5:122982024 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs35157167 ENSG00000263432.2 RN7SL689P -5.54 5e-08 1.73e-05 -0.32 -0.25 Mean platelet volume; chr5:122982506 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs396941 ENSG00000263432.2 RN7SL689P -5.54 5e-08 1.73e-05 -0.32 -0.25 Mean platelet volume; chr5:122982570 chr5:123022487~123022783:- LUSC cis rs7712401 0.58 rs439739 ENSG00000263432.2 RN7SL689P -5.54 5e-08 1.73e-05 -0.32 -0.25 Mean platelet volume; chr5:122982726 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs371604 ENSG00000263432.2 RN7SL689P -5.54 5e-08 1.73e-05 -0.32 -0.25 Mean platelet volume; chr5:122982737 chr5:123022487~123022783:- LUSC cis rs6502050 0.731 rs34796376 ENSG00000266654.1 RP11-1376P16.1 -5.54 5e-08 1.73e-05 -0.25 -0.25 Life satisfaction; chr17:82158759 chr17:82160056~82160452:+ LUSC cis rs6502050 0.528 rs12942561 ENSG00000266654.1 RP11-1376P16.1 -5.54 5e-08 1.73e-05 -0.25 -0.25 Life satisfaction; chr17:82158763 chr17:82160056~82160452:+ LUSC cis rs6502050 0.529 rs35585236 ENSG00000266654.1 RP11-1376P16.1 -5.54 5e-08 1.73e-05 -0.25 -0.25 Life satisfaction; chr17:82158765 chr17:82160056~82160452:+ LUSC cis rs6502050 0.805 rs11651863 ENSG00000266654.1 RP11-1376P16.1 5.54 5.01e-08 1.73e-05 0.25 0.25 Life satisfaction; chr17:82126663 chr17:82160056~82160452:+ LUSC cis rs13434995 0.513 rs6554291 ENSG00000249700.7 SRD5A3-AS1 -5.54 5.01e-08 1.73e-05 -0.31 -0.25 Adiponectin levels; chr4:55571204 chr4:55363971~55395847:- LUSC cis rs13434995 0.513 rs7683997 ENSG00000249700.7 SRD5A3-AS1 5.54 5.01e-08 1.73e-05 0.31 0.25 Adiponectin levels; chr4:55581272 chr4:55363971~55395847:- LUSC cis rs763121 0.962 rs909564 ENSG00000273076.1 RP3-508I15.22 5.54 5.01e-08 1.73e-05 0.24 0.25 Menopause (age at onset); chr22:38730503 chr22:38743495~38743910:+ LUSC cis rs2742234 0.59 rs2503848 ENSG00000273008.1 RP11-351D16.3 -5.54 5.01e-08 1.73e-05 -0.28 -0.25 Hirschsprung disease; chr10:43177337 chr10:43136824~43138334:- LUSC cis rs4713118 0.868 rs7756968 ENSG00000280107.1 AL022393.9 -5.54 5.02e-08 1.73e-05 -0.31 -0.25 Parkinson's disease; chr6:27767175 chr6:28170845~28172521:+ LUSC cis rs7555523 0.83 rs6660601 ENSG00000224358.1 RP11-466F5.8 -5.54 5.03e-08 1.74e-05 -0.32 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165726618 chr1:165768929~165775176:+ LUSC cis rs673078 0.66 rs7962185 ENSG00000275759.1 RP11-131L12.3 -5.54 5.03e-08 1.74e-05 -0.37 -0.25 Glucose homeostasis traits; chr12:118287842 chr12:118428281~118428870:+ LUSC cis rs853679 1 rs6901575 ENSG00000204709.4 LINC01556 5.54 5.03e-08 1.74e-05 0.4 0.25 Depression; chr6:28283207 chr6:28943877~28944537:+ LUSC cis rs77204473 1 rs17120177 ENSG00000254851.1 RP11-109L13.1 5.54 5.03e-08 1.74e-05 0.65 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:116956653 chr11:117135528~117138582:+ LUSC cis rs2732480 0.577 rs2634684 ENSG00000273765.1 RP11-370I10.11 -5.54 5.03e-08 1.74e-05 -0.29 -0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48337092 chr12:48360920~48361377:+ LUSC cis rs13113518 0.702 rs78829811 ENSG00000223305.1 RN7SKP30 5.54 5.03e-08 1.74e-05 0.3 0.25 Height; chr4:55558258 chr4:55540502~55540835:- LUSC cis rs13113518 0.702 rs75801206 ENSG00000223305.1 RN7SKP30 5.54 5.03e-08 1.74e-05 0.3 0.25 Height; chr4:55558259 chr4:55540502~55540835:- LUSC cis rs13113518 0.702 rs34658078 ENSG00000223305.1 RN7SKP30 5.54 5.03e-08 1.74e-05 0.3 0.25 Height; chr4:55558261 chr4:55540502~55540835:- LUSC cis rs42490 0.934 rs218925 ENSG00000251136.7 RP11-37B2.1 -5.54 5.04e-08 1.74e-05 -0.22 -0.25 Leprosy; chr8:89737352 chr8:89609409~89757727:- LUSC cis rs11096990 0.656 rs3796513 ENSG00000249207.1 RP11-360F5.1 5.54 5.04e-08 1.74e-05 0.26 0.25 Cognitive function; chr4:39289462 chr4:39112677~39126818:- LUSC cis rs11096990 0.656 rs2123027 ENSG00000249207.1 RP11-360F5.1 5.54 5.04e-08 1.74e-05 0.26 0.25 Cognitive function; chr4:39289493 chr4:39112677~39126818:- LUSC cis rs11096990 0.634 rs10029074 ENSG00000249207.1 RP11-360F5.1 5.54 5.04e-08 1.74e-05 0.26 0.25 Cognitive function; chr4:39290882 chr4:39112677~39126818:- LUSC cis rs11096990 0.634 rs1564710 ENSG00000249207.1 RP11-360F5.1 5.54 5.04e-08 1.74e-05 0.26 0.25 Cognitive function; chr4:39291178 chr4:39112677~39126818:- LUSC cis rs11096990 0.634 rs2839765 ENSG00000249207.1 RP11-360F5.1 5.54 5.04e-08 1.74e-05 0.26 0.25 Cognitive function; chr4:39293933 chr4:39112677~39126818:- LUSC cis rs11096990 0.634 rs6531706 ENSG00000249207.1 RP11-360F5.1 5.54 5.04e-08 1.74e-05 0.26 0.25 Cognitive function; chr4:39294547 chr4:39112677~39126818:- LUSC cis rs11096990 0.656 rs4580661 ENSG00000249207.1 RP11-360F5.1 5.54 5.04e-08 1.74e-05 0.26 0.25 Cognitive function; chr4:39294730 chr4:39112677~39126818:- LUSC cis rs11096990 0.634 rs6815855 ENSG00000249207.1 RP11-360F5.1 5.54 5.04e-08 1.74e-05 0.26 0.25 Cognitive function; chr4:39294926 chr4:39112677~39126818:- LUSC cis rs11096990 0.656 rs9993224 ENSG00000249207.1 RP11-360F5.1 5.54 5.04e-08 1.74e-05 0.26 0.25 Cognitive function; chr4:39298578 chr4:39112677~39126818:- LUSC cis rs42490 1 rs1003843 ENSG00000251136.7 RP11-37B2.1 -5.54 5.05e-08 1.74e-05 -0.21 -0.25 Leprosy; chr8:89727252 chr8:89609409~89757727:- LUSC cis rs11089937 0.637 rs988200 ENSG00000211638.2 IGLV8-61 -5.54 5.05e-08 1.74e-05 -0.27 -0.25 Periodontitis (PAL4Q3); chr22:22154715 chr22:22098700~22099212:+ LUSC cis rs11159086 1 rs11159087 ENSG00000259005.1 RP3-449M8.6 5.54 5.05e-08 1.74e-05 0.37 0.25 Advanced glycation end-product levels; chr14:74504671 chr14:74474007~74474864:- LUSC cis rs910316 0.789 rs175444 ENSG00000279594.1 RP11-950C14.10 -5.54 5.05e-08 1.74e-05 -0.29 -0.25 Height; chr14:75135079 chr14:75011269~75012851:- LUSC cis rs9659323 0.67 rs17023223 ENSG00000231365.4 RP11-418J17.1 -5.54 5.05e-08 1.74e-05 -0.29 -0.25 Body mass index; chr1:119088551 chr1:119140396~119275973:+ LUSC cis rs6543140 0.964 rs4851010 ENSG00000234389.1 AC007278.3 -5.54 5.05e-08 1.74e-05 -0.26 -0.25 Blood protein levels; chr2:102439667 chr2:102438713~102440475:+ LUSC cis rs9402743 0.67 rs7769840 ENSG00000234084.1 RP3-388E23.2 5.54 5.06e-08 1.74e-05 0.2 0.25 Systemic lupus erythematosus; chr6:135605412 chr6:135301568~135307158:+ LUSC cis rs1008375 0.9 rs4698622 ENSG00000249502.1 AC006160.5 -5.54 5.06e-08 1.74e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17587934 chr4:17587467~17614571:- LUSC cis rs7674212 0.507 rs223471 ENSG00000246560.2 RP11-10L12.4 5.54 5.06e-08 1.75e-05 0.32 0.25 Type 2 diabetes; chr4:102777629 chr4:102828055~102844075:+ LUSC cis rs7804306 1 rs715377 ENSG00000233264.2 AC006042.8 5.54 5.06e-08 1.75e-05 0.4 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7980303 chr7:7980312~7982228:+ LUSC cis rs875971 0.54 rs1723268 ENSG00000222364.1 RNU6-96P -5.54 5.07e-08 1.75e-05 -0.29 -0.25 Aortic root size; chr7:66008093 chr7:66395191~66395286:+ LUSC cis rs11098499 0.866 rs6847778 ENSG00000248280.1 RP11-33B1.2 5.54 5.07e-08 1.75e-05 0.29 0.25 Corneal astigmatism; chr4:119372427 chr4:119440561~119450157:- LUSC cis rs6504950 0.925 rs2787497 ENSG00000275710.1 RP11-257O5.4 -5.54 5.07e-08 1.75e-05 -0.31 -0.25 Breast cancer; chr17:55098850 chr17:54964474~54964679:+ LUSC cis rs2903698 0.651 rs1841933 ENSG00000250735.4 RP11-567N4.3 5.54 5.08e-08 1.75e-05 0.28 0.25 Prion diseases; chr4:75477348 chr4:75401195~75423023:+ LUSC cis rs42490 1 rs218907 ENSG00000251136.7 RP11-37B2.1 -5.54 5.08e-08 1.75e-05 -0.22 -0.25 Leprosy; chr8:89728164 chr8:89609409~89757727:- LUSC cis rs9611519 0.78 rs5751072 ENSG00000235513.1 RP4-756G23.5 5.54 5.09e-08 1.76e-05 0.28 0.25 Neuroticism; chr22:41260505 chr22:41209122~41217627:- LUSC cis rs172166 0.694 rs2791332 ENSG00000219392.1 RP1-265C24.5 -5.54 5.1e-08 1.76e-05 -0.32 -0.25 Cardiac Troponin-T levels; chr6:28141010 chr6:28115628~28116551:+ LUSC cis rs6860806 0.507 rs274570 ENSG00000233006.5 AC034220.3 -5.54 5.1e-08 1.76e-05 -0.28 -0.25 Breast cancer; chr5:132377534 chr5:132311285~132369916:- LUSC cis rs8133932 0.668 rs3788226 ENSG00000280604.1 PCBP3-OT1 -5.54 5.1e-08 1.76e-05 -0.36 -0.25 Schizophrenia; chr21:45880201 chr21:45914296~45919483:+ LUSC cis rs7181230 0.885 rs28736699 ENSG00000275636.1 RP11-521C20.5 5.54 5.1e-08 1.76e-05 0.31 0.25 Dehydroepiandrosterone sulphate levels; chr15:40055234 chr15:40078892~40079347:+ LUSC cis rs6969780 0.915 rs4722659 ENSG00000233429.8 HOTAIRM1 -5.54 5.1e-08 1.76e-05 -0.42 -0.25 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27127131 chr7:27095647~27100265:+ LUSC cis rs6969780 0.915 rs3801320 ENSG00000233429.8 HOTAIRM1 5.54 5.1e-08 1.76e-05 0.42 0.25 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27124745 chr7:27095647~27100265:+ LUSC cis rs367615 0.918 rs10051855 ENSG00000249476.1 CTD-2587M2.1 5.54 5.12e-08 1.76e-05 0.33 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109524257 chr5:109237120~109326369:- LUSC cis rs14027 0.883 rs10102038 ENSG00000279347.1 RP11-85I17.2 -5.54 5.12e-08 1.76e-05 -0.23 -0.25 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119702544 chr8:119838736~119840385:- LUSC cis rs14027 0.883 rs35660840 ENSG00000279347.1 RP11-85I17.2 -5.54 5.12e-08 1.76e-05 -0.23 -0.25 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119704351 chr8:119838736~119840385:- LUSC cis rs14027 0.883 rs1433953 ENSG00000279347.1 RP11-85I17.2 -5.54 5.12e-08 1.76e-05 -0.23 -0.25 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119704754 chr8:119838736~119840385:- LUSC cis rs12554020 0.786 rs3893381 ENSG00000227603.1 RP11-165J3.6 -5.54 5.12e-08 1.76e-05 -0.36 -0.25 Schizophrenia; chr9:93519576 chr9:93435332~93437121:- LUSC cis rs6502050 0.835 rs55679819 ENSG00000266654.1 RP11-1376P16.1 -5.54 5.13e-08 1.77e-05 -0.25 -0.25 Life satisfaction; chr17:82147574 chr17:82160056~82160452:+ LUSC cis rs11089937 0.667 rs10483108 ENSG00000211638.2 IGLV8-61 -5.54 5.14e-08 1.77e-05 -0.27 -0.25 Periodontitis (PAL4Q3); chr22:22152664 chr22:22098700~22099212:+ LUSC cis rs12439619 0.921 rs4778672 ENSG00000276710.3 CSPG4P8 5.54 5.15e-08 1.77e-05 0.28 0.25 Intelligence (multi-trait analysis); chr15:82245013 chr15:82459472~82477258:+ LUSC cis rs11098499 0.821 rs10032151 ENSG00000248280.1 RP11-33B1.2 5.54 5.15e-08 1.77e-05 0.3 0.25 Corneal astigmatism; chr4:119470473 chr4:119440561~119450157:- LUSC cis rs11098499 0.865 rs10032158 ENSG00000248280.1 RP11-33B1.2 5.54 5.15e-08 1.77e-05 0.3 0.25 Corneal astigmatism; chr4:119470477 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs6838814 ENSG00000248280.1 RP11-33B1.2 5.54 5.15e-08 1.77e-05 0.3 0.25 Corneal astigmatism; chr4:119471288 chr4:119440561~119450157:- LUSC cis rs1823913 0.513 rs4334520 ENSG00000280083.1 RP11-317J9.1 -5.54 5.15e-08 1.77e-05 -0.31 -0.25 Obesity-related traits; chr2:191329200 chr2:191154118~191156070:- LUSC cis rs11098499 0.697 rs11941899 ENSG00000248280.1 RP11-33B1.2 5.54 5.15e-08 1.77e-05 0.3 0.25 Corneal astigmatism; chr4:119461603 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs7681978 ENSG00000248280.1 RP11-33B1.2 5.54 5.15e-08 1.77e-05 0.3 0.25 Corneal astigmatism; chr4:119462620 chr4:119440561~119450157:- LUSC cis rs11098499 0.821 rs28665282 ENSG00000248280.1 RP11-33B1.2 5.54 5.15e-08 1.77e-05 0.3 0.25 Corneal astigmatism; chr4:119463031 chr4:119440561~119450157:- LUSC cis rs11098499 0.738 rs10026493 ENSG00000248280.1 RP11-33B1.2 5.54 5.15e-08 1.77e-05 0.3 0.25 Corneal astigmatism; chr4:119463039 chr4:119440561~119450157:- LUSC cis rs67311347 1 rs12494022 ENSG00000223797.4 ENTPD3-AS1 5.54 5.16e-08 1.78e-05 0.29 0.25 Renal cell carcinoma; chr3:40385161 chr3:40313802~40453329:- LUSC cis rs367615 0.704 rs4286723 ENSG00000249476.1 CTD-2587M2.1 5.54 5.16e-08 1.78e-05 0.29 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109500258 chr5:109237120~109326369:- LUSC cis rs1412337 0.52 rs10918946 ENSG00000227777.1 RP4-738P11.3 -5.54 5.17e-08 1.78e-05 -0.34 -0.25 Morbidity-free survival; chr1:168641295 chr1:168542737~168543354:+ LUSC cis rs6772849 0.775 rs67105978 ENSG00000277250.1 Metazoa_SRP -5.54 5.17e-08 1.78e-05 -0.29 -0.25 Monocyte percentage of white cells;Monocyte count; chr3:128696337 chr3:128673681~128674021:- LUSC cis rs875971 0.767 rs12668005 ENSG00000179406.6 LINC00174 -5.54 5.18e-08 1.78e-05 -0.27 -0.25 Aortic root size; chr7:66444034 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs11765791 ENSG00000179406.6 LINC00174 -5.54 5.18e-08 1.78e-05 -0.27 -0.25 Aortic root size; chr7:66471587 chr7:66376044~66401338:- LUSC cis rs7772486 0.727 rs10223508 ENSG00000235652.6 RP11-545I5.3 -5.53 5.19e-08 1.79e-05 -0.24 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145964069 chr6:145799409~145886585:+ LUSC cis rs148406912 1 rs148406912 ENSG00000280143.1 AP000892.6 -5.53 5.19e-08 1.79e-05 -0.41 -0.25 Lobe attachment (rater-scored or self-reported); chr11:116967001 chr11:117204967~117210292:+ LUSC cis rs35740288 0.929 rs11073537 ENSG00000202081.1 RNU6-1280P 5.53 5.19e-08 1.79e-05 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85769450 chr15:85651522~85651628:- LUSC cis rs42490 0.966 rs218908 ENSG00000251136.7 RP11-37B2.1 -5.53 5.19e-08 1.79e-05 -0.22 -0.25 Leprosy; chr8:89728886 chr8:89609409~89757727:- LUSC cis rs42490 1 rs218913 ENSG00000251136.7 RP11-37B2.1 -5.53 5.19e-08 1.79e-05 -0.22 -0.25 Leprosy; chr8:89732206 chr8:89609409~89757727:- LUSC cis rs42490 0.966 rs218914 ENSG00000251136.7 RP11-37B2.1 -5.53 5.19e-08 1.79e-05 -0.22 -0.25 Leprosy; chr8:89733130 chr8:89609409~89757727:- LUSC cis rs2933343 0.903 rs2638846 ENSG00000231305.3 RP11-723O4.2 5.53 5.19e-08 1.79e-05 0.26 0.25 IgG glycosylation; chr3:128868320 chr3:128861313~128871540:- LUSC cis rs875971 0.862 rs2460432 ENSG00000179406.6 LINC00174 5.53 5.19e-08 1.79e-05 0.27 0.25 Aortic root size; chr7:66089398 chr7:66376044~66401338:- LUSC cis rs7911264 0.703 rs7894183 ENSG00000236493.2 EIF2S2P3 5.53 5.19e-08 1.79e-05 0.29 0.25 Inflammatory bowel disease; chr10:92622283 chr10:92668745~92669743:- LUSC cis rs801193 1 rs2659909 ENSG00000222364.1 RNU6-96P -5.53 5.19e-08 1.79e-05 -0.28 -0.25 Aortic root size; chr7:66695292 chr7:66395191~66395286:+ LUSC cis rs6772849 0.768 rs9820741 ENSG00000277250.1 Metazoa_SRP -5.53 5.2e-08 1.79e-05 -0.29 -0.25 Monocyte percentage of white cells;Monocyte count; chr3:128697237 chr3:128673681~128674021:- LUSC cis rs17772222 0.696 rs28666030 ENSG00000258789.1 RP11-507K2.3 -5.53 5.21e-08 1.79e-05 -0.28 -0.25 Coronary artery calcification; chr14:88511463 chr14:88551597~88552493:+ LUSC cis rs17772222 0.74 rs28493481 ENSG00000258789.1 RP11-507K2.3 -5.53 5.21e-08 1.79e-05 -0.28 -0.25 Coronary artery calcification; chr14:88511491 chr14:88551597~88552493:+ LUSC cis rs11098499 0.754 rs7689729 ENSG00000250412.1 KLHL2P1 5.53 5.21e-08 1.79e-05 0.3 0.25 Corneal astigmatism; chr4:119335037 chr4:119334329~119378233:+ LUSC cis rs10028773 0.7 rs7690338 ENSG00000250412.1 KLHL2P1 5.53 5.21e-08 1.79e-05 0.3 0.25 Educational attainment; chr4:119335313 chr4:119334329~119378233:+ LUSC cis rs11098499 0.865 rs3956464 ENSG00000250412.1 KLHL2P1 5.53 5.21e-08 1.79e-05 0.3 0.25 Corneal astigmatism; chr4:119335609 chr4:119334329~119378233:+ LUSC cis rs11098499 0.619 rs28502463 ENSG00000250412.1 KLHL2P1 5.53 5.21e-08 1.79e-05 0.3 0.25 Corneal astigmatism; chr4:119335868 chr4:119334329~119378233:+ LUSC cis rs11098499 0.648 rs2002047 ENSG00000250412.1 KLHL2P1 5.53 5.21e-08 1.79e-05 0.3 0.25 Corneal astigmatism; chr4:119336073 chr4:119334329~119378233:+ LUSC cis rs11098499 0.775 rs2002049 ENSG00000250412.1 KLHL2P1 5.53 5.21e-08 1.79e-05 0.3 0.25 Corneal astigmatism; chr4:119336262 chr4:119334329~119378233:+ LUSC cis rs2903698 0.521 rs10026125 ENSG00000250735.4 RP11-567N4.3 5.53 5.21e-08 1.79e-05 0.28 0.25 Prion diseases; chr4:75504304 chr4:75401195~75423023:+ LUSC cis rs6504950 0.924 rs244353 ENSG00000275710.1 RP11-257O5.4 -5.53 5.21e-08 1.79e-05 -0.28 -0.25 Breast cancer; chr17:55117408 chr17:54964474~54964679:+ LUSC cis rs11098499 0.731 rs6846966 ENSG00000248280.1 RP11-33B1.2 5.53 5.22e-08 1.79e-05 0.29 0.25 Corneal astigmatism; chr4:119372053 chr4:119440561~119450157:- LUSC cis rs3738443 0.953 rs61839997 ENSG00000259865.1 RP11-488L18.10 5.53 5.22e-08 1.8e-05 0.27 0.25 Alcohol dependence; chr1:247197867 chr1:247187281~247188526:- LUSC cis rs1707322 0.638 rs1707302 ENSG00000280836.1 AL355480.1 5.53 5.22e-08 1.8e-05 0.3 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46135245 chr1:45581219~45581321:- LUSC cis rs6061231 0.724 rs1570027 ENSG00000273619.1 RP5-908M14.9 -5.53 5.23e-08 1.8e-05 -0.27 -0.25 Colorectal cancer; chr20:62393540 chr20:62386303~62386970:- LUSC cis rs2732480 0.577 rs2634680 ENSG00000240399.1 RP1-228P16.1 5.53 5.23e-08 1.8e-05 0.27 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48340781 chr12:48054813~48055591:- LUSC cis rs2732480 0.577 rs2634678 ENSG00000240399.1 RP1-228P16.1 5.53 5.23e-08 1.8e-05 0.27 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48341755 chr12:48054813~48055591:- LUSC cis rs4664293 0.801 rs7607143 ENSG00000226266.5 AC009961.3 -5.53 5.23e-08 1.8e-05 -0.29 -0.25 Monocyte percentage of white cells; chr2:159728250 chr2:159670708~159712435:- LUSC cis rs4664293 0.833 rs10170336 ENSG00000226266.5 AC009961.3 -5.53 5.23e-08 1.8e-05 -0.29 -0.25 Monocyte percentage of white cells; chr2:159732832 chr2:159670708~159712435:- LUSC cis rs875971 0.54 rs4717275 ENSG00000237310.1 GS1-124K5.4 -5.53 5.23e-08 1.8e-05 -0.25 -0.25 Aortic root size; chr7:65800193 chr7:66493706~66495474:+ LUSC cis rs2842992 0.83 rs2758352 ENSG00000237927.1 RP3-393E18.2 -5.53 5.23e-08 1.8e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159701889 chr6:159586955~159589169:- LUSC cis rs13113518 1 rs4865007 ENSG00000272969.1 RP11-528I4.2 -5.53 5.23e-08 1.8e-05 -0.28 -0.25 Height; chr4:55537550 chr4:55547112~55547889:+ LUSC cis rs1021993 0.545 rs79212878 ENSG00000231648.1 RP11-372M18.2 -5.53 5.23e-08 1.8e-05 -0.37 -0.25 Gut microbiome composition (winter); chr1:209374072 chr1:209367662~209379690:+ LUSC cis rs1021993 0.545 rs80311419 ENSG00000231648.1 RP11-372M18.2 -5.53 5.23e-08 1.8e-05 -0.37 -0.25 Gut microbiome composition (winter); chr1:209374073 chr1:209367662~209379690:+ LUSC cis rs1008375 0.866 rs2109518 ENSG00000249502.1 AC006160.5 -5.53 5.23e-08 1.8e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17570539 chr4:17587467~17614571:- LUSC cis rs7829975 0.742 rs1533059 ENSG00000253893.2 FAM85B 5.53 5.24e-08 1.8e-05 0.3 0.25 Mood instability; chr8:8827443 chr8:8167819~8226614:- LUSC cis rs875971 0.545 rs13311962 ENSG00000237310.1 GS1-124K5.4 -5.53 5.24e-08 1.8e-05 -0.28 -0.25 Aortic root size; chr7:66603142 chr7:66493706~66495474:+ LUSC cis rs6061231 1 rs67941642 ENSG00000273619.1 RP5-908M14.9 -5.53 5.24e-08 1.8e-05 -0.24 -0.25 Colorectal cancer; chr20:62383052 chr20:62386303~62386970:- LUSC cis rs2842992 0.714 rs2495278 ENSG00000237927.1 RP3-393E18.2 -5.53 5.24e-08 1.8e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159702642 chr6:159586955~159589169:- LUSC cis rs12291225 0.679 rs4757245 ENSG00000251991.1 RNU7-49P 5.53 5.25e-08 1.8e-05 0.3 0.25 Sense of smell; chr11:14276326 chr11:14478892~14478953:+ LUSC cis rs11723261 0.582 rs3747693 ENSG00000275426.1 CH17-262A2.1 5.53 5.25e-08 1.81e-05 0.39 0.25 Immune response to smallpox vaccine (IL-6); chr4:124493 chr4:149738~150317:+ LUSC cis rs7911264 0.739 rs7071905 ENSG00000236493.2 EIF2S2P3 5.53 5.25e-08 1.81e-05 0.29 0.25 Inflammatory bowel disease; chr10:92626365 chr10:92668745~92669743:- LUSC cis rs7911264 0.739 rs10882094 ENSG00000236493.2 EIF2S2P3 5.53 5.25e-08 1.81e-05 0.29 0.25 Inflammatory bowel disease; chr10:92627919 chr10:92668745~92669743:- LUSC cis rs10050311 0.79 rs17751557 ENSG00000251411.1 RP11-397E7.4 -5.53 5.25e-08 1.81e-05 -0.33 -0.25 Insulin-related traits; chr4:86913454 chr4:86913266~86914817:- LUSC cis rs4604732 0.603 rs10925051 ENSG00000227135.1 GCSAML-AS1 -5.53 5.26e-08 1.81e-05 -0.34 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247478532 chr1:247524679~247526752:- LUSC cis rs2744375 0.6 rs2744371 ENSG00000234115.2 RP11-288G3.4 5.53 5.26e-08 1.81e-05 0.29 0.25 Resting heart rate; chr6:7553941 chr6:7516600~7517840:- LUSC cis rs2732480 0.538 rs2732462 ENSG00000226413.2 OR8T1P 5.53 5.26e-08 1.81e-05 0.32 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48302601 chr12:48442030~48442947:- LUSC cis rs875971 0.505 rs1167386 ENSG00000237310.1 GS1-124K5.4 -5.53 5.26e-08 1.81e-05 -0.25 -0.25 Aortic root size; chr7:66048109 chr7:66493706~66495474:+ LUSC cis rs4722166 0.63 rs6461667 ENSG00000179428.2 AC073072.5 -5.53 5.27e-08 1.81e-05 -0.31 -0.25 Lung cancer; chr7:22757124 chr7:22725395~22727620:- LUSC cis rs910316 0.737 rs175048 ENSG00000279594.1 RP11-950C14.10 -5.53 5.27e-08 1.81e-05 -0.28 -0.25 Height; chr14:75013191 chr14:75011269~75012851:- LUSC cis rs66887589 0.837 rs7661498 ENSG00000248280.1 RP11-33B1.2 5.53 5.28e-08 1.81e-05 0.28 0.25 Diastolic blood pressure; chr4:119486953 chr4:119440561~119450157:- LUSC cis rs6452524 0.618 rs10051445 ENSG00000248112.1 RP11-78C3.1 5.53 5.28e-08 1.82e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83060280 chr5:82919376~82921119:- LUSC cis rs6452524 0.618 rs6867727 ENSG00000248112.1 RP11-78C3.1 5.53 5.28e-08 1.82e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83061333 chr5:82919376~82921119:- LUSC cis rs6452524 0.618 rs7723639 ENSG00000248112.1 RP11-78C3.1 5.53 5.28e-08 1.82e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83062610 chr5:82919376~82921119:- LUSC cis rs875971 0.545 rs10261710 ENSG00000179406.6 LINC00174 -5.53 5.28e-08 1.82e-05 -0.3 -0.25 Aortic root size; chr7:66249202 chr7:66376044~66401338:- LUSC cis rs367615 0.679 rs4259216 ENSG00000249476.1 CTD-2587M2.1 5.53 5.29e-08 1.82e-05 0.29 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109506116 chr5:109237120~109326369:- LUSC cis rs2274273 0.837 rs59871474 ENSG00000258413.1 RP11-665C16.6 -5.53 5.29e-08 1.82e-05 -0.3 -0.25 Protein biomarker; chr14:55312645 chr14:55262767~55272075:- LUSC cis rs2665103 0.632 rs3902959 ENSG00000278603.1 RP13-608F4.5 5.53 5.29e-08 1.82e-05 0.3 0.25 Intelligence (multi-trait analysis); chr15:82252586 chr15:82472203~82472426:+ LUSC cis rs4834770 1 rs6823963 ENSG00000245958.5 RP11-33B1.1 -5.53 5.3e-08 1.82e-05 -0.24 -0.25 Blood protein levels; chr4:119321009 chr4:119454791~119552025:+ LUSC cis rs4834770 1 rs4834771 ENSG00000245958.5 RP11-33B1.1 -5.53 5.3e-08 1.82e-05 -0.24 -0.25 Blood protein levels; chr4:119321617 chr4:119454791~119552025:+ LUSC cis rs4834770 1 rs1397613 ENSG00000245958.5 RP11-33B1.1 -5.53 5.3e-08 1.82e-05 -0.24 -0.25 Blood protein levels; chr4:119321774 chr4:119454791~119552025:+ LUSC cis rs4834770 1 rs6857641 ENSG00000245958.5 RP11-33B1.1 -5.53 5.3e-08 1.82e-05 -0.24 -0.25 Blood protein levels; chr4:119322356 chr4:119454791~119552025:+ LUSC cis rs4834770 1 rs2282688 ENSG00000245958.5 RP11-33B1.1 -5.53 5.3e-08 1.82e-05 -0.24 -0.25 Blood protein levels; chr4:119322567 chr4:119454791~119552025:+ LUSC cis rs2742234 0.554 rs1254963 ENSG00000273008.1 RP11-351D16.3 5.53 5.3e-08 1.82e-05 0.28 0.25 Hirschsprung disease; chr10:43200638 chr10:43136824~43138334:- LUSC cis rs7712401 0.645 rs154497 ENSG00000263432.2 RN7SL689P 5.53 5.3e-08 1.82e-05 0.3 0.25 Mean platelet volume; chr5:122885725 chr5:123022487~123022783:- LUSC cis rs910316 0.763 rs13712 ENSG00000279594.1 RP11-950C14.10 5.53 5.31e-08 1.82e-05 0.28 0.25 Height; chr14:75017109 chr14:75011269~75012851:- LUSC cis rs9309711 0.961 rs35067331 ENSG00000225234.1 TRAPPC12-AS1 -5.53 5.31e-08 1.82e-05 -0.33 -0.25 Neurofibrillary tangles; chr2:3470314 chr2:3481242~3482409:- LUSC cis rs6504950 0.925 rs181727 ENSG00000275710.1 RP11-257O5.4 5.53 5.31e-08 1.83e-05 0.3 0.25 Breast cancer; chr17:55113634 chr17:54964474~54964679:+ LUSC cis rs875971 0.861 rs801215 ENSG00000179406.6 LINC00174 5.53 5.32e-08 1.83e-05 0.27 0.25 Aortic root size; chr7:66546951 chr7:66376044~66401338:- LUSC cis rs442309 0.875 rs224067 ENSG00000238280.1 RP11-436D10.3 5.53 5.32e-08 1.83e-05 0.3 0.25 Vogt-Koyanagi-Harada syndrome; chr10:62747211 chr10:62793562~62805887:- LUSC cis rs67311347 1 rs11714032 ENSG00000223797.4 ENTPD3-AS1 5.53 5.32e-08 1.83e-05 0.29 0.25 Renal cell carcinoma; chr3:40390114 chr3:40313802~40453329:- LUSC cis rs9640161 0.711 rs3800781 ENSG00000261305.1 RP4-584D14.7 5.53 5.32e-08 1.83e-05 0.36 0.25 Blood protein levels;Circulating chemerin levels; chr7:150330235 chr7:150341771~150342607:+ LUSC cis rs2136613 0.533 rs7093716 ENSG00000238280.1 RP11-436D10.3 -5.53 5.32e-08 1.83e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62847717 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs7097383 ENSG00000238280.1 RP11-436D10.3 -5.53 5.32e-08 1.83e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62848279 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10740088 ENSG00000238280.1 RP11-436D10.3 -5.53 5.32e-08 1.83e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62849651 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10740089 ENSG00000238280.1 RP11-436D10.3 -5.53 5.32e-08 1.83e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62849674 chr10:62793562~62805887:- LUSC cis rs910316 0.737 rs108622 ENSG00000279594.1 RP11-950C14.10 -5.53 5.33e-08 1.83e-05 -0.29 -0.25 Height; chr14:75015205 chr14:75011269~75012851:- LUSC cis rs910316 0.737 rs424120 ENSG00000279594.1 RP11-950C14.10 -5.53 5.33e-08 1.83e-05 -0.29 -0.25 Height; chr14:75016125 chr14:75011269~75012851:- LUSC cis rs875971 0.545 rs221986 ENSG00000237310.1 GS1-124K5.4 -5.53 5.34e-08 1.83e-05 -0.28 -0.25 Aortic root size; chr7:66105323 chr7:66493706~66495474:+ LUSC cis rs638893 0.636 rs61901411 ENSG00000278376.1 RP11-158I9.8 5.53 5.34e-08 1.84e-05 0.37 0.25 Vitiligo; chr11:118794615 chr11:118791254~118793137:+ LUSC cis rs2243480 1 rs1723269 ENSG00000226824.5 RP4-756H11.3 -5.53 5.35e-08 1.84e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66007799 chr7:66654538~66669855:+ LUSC cis rs2337406 0.866 rs4773949 ENSG00000280411.1 IGHV1-69-2 5.53 5.35e-08 1.84e-05 0.22 0.25 Alzheimer's disease (late onset); chr14:106808070 chr14:106762092~106762588:- LUSC cis rs6570726 0.935 rs388394 ENSG00000235652.6 RP11-545I5.3 5.53 5.35e-08 1.84e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145531553 chr6:145799409~145886585:+ LUSC cis rs6504950 1 rs9892848 ENSG00000275710.1 RP11-257O5.4 5.53 5.36e-08 1.84e-05 0.31 0.25 Breast cancer; chr17:54982414 chr17:54964474~54964679:+ LUSC cis rs2280018 0.526 rs2966129 ENSG00000188599.16 NPIPP1 5.53 5.37e-08 1.84e-05 0.25 0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059070 chr16:15104312~15123498:- LUSC cis rs72627123 1 rs72627126 ENSG00000259065.1 RP5-1021I20.1 -5.53 5.37e-08 1.84e-05 -0.43 -0.25 Morning vs. evening chronotype; chr14:73903321 chr14:73787360~73803270:+ LUSC cis rs801193 1 rs2707856 ENSG00000237310.1 GS1-124K5.4 5.53 5.37e-08 1.84e-05 0.25 0.25 Aortic root size; chr7:66746023 chr7:66493706~66495474:+ LUSC cis rs2179367 0.568 rs6932778 ENSG00000231760.4 RP11-350J20.5 5.53 5.37e-08 1.84e-05 0.37 0.25 Dupuytren's disease; chr6:149328293 chr6:149796151~149826294:- LUSC cis rs7083 1 rs535602 ENSG00000254851.1 RP11-109L13.1 5.53 5.37e-08 1.84e-05 0.32 0.25 Blood protein levels; chr11:117237059 chr11:117135528~117138582:+ LUSC cis rs2337406 0.789 rs12050392 ENSG00000211974.3 IGHV2-70 -5.53 5.37e-08 1.84e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106779073 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs74092505 ENSG00000211974.3 IGHV2-70 -5.53 5.37e-08 1.84e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106779163 chr14:106723574~106724093:- LUSC cis rs2337406 0.789 rs74092507 ENSG00000211974.3 IGHV2-70 -5.53 5.37e-08 1.84e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106779174 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs74092511 ENSG00000211974.3 IGHV2-70 -5.53 5.37e-08 1.84e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106779234 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs74092512 ENSG00000211974.3 IGHV2-70 -5.53 5.37e-08 1.84e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106779306 chr14:106723574~106724093:- LUSC cis rs2337406 0.789 rs74092514 ENSG00000211974.3 IGHV2-70 -5.53 5.37e-08 1.84e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106779385 chr14:106723574~106724093:- LUSC cis rs11098499 0.909 rs1809406 ENSG00000248280.1 RP11-33B1.2 5.53 5.38e-08 1.85e-05 0.3 0.25 Corneal astigmatism; chr4:119455967 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs9994810 ENSG00000248280.1 RP11-33B1.2 5.53 5.38e-08 1.85e-05 0.3 0.25 Corneal astigmatism; chr4:119460435 chr4:119440561~119450157:- LUSC cis rs11098499 0.697 rs10020027 ENSG00000248280.1 RP11-33B1.2 5.53 5.38e-08 1.85e-05 0.3 0.25 Corneal astigmatism; chr4:119460724 chr4:119440561~119450157:- LUSC cis rs11098499 0.779 rs7356491 ENSG00000248280.1 RP11-33B1.2 5.53 5.38e-08 1.85e-05 0.3 0.25 Corneal astigmatism; chr4:119460819 chr4:119440561~119450157:- LUSC cis rs7714584 1 rs931058 ENSG00000197083.10 ZNF300P1 5.53 5.38e-08 1.85e-05 0.49 0.25 Crohn's disease; chr5:150954136 chr5:150930645~150946289:- LUSC cis rs9611519 0.929 rs926914 ENSG00000235513.1 RP4-756G23.5 5.53 5.38e-08 1.85e-05 0.3 0.25 Neuroticism; chr22:41022150 chr22:41209122~41217627:- LUSC cis rs875971 0.505 rs1723275 ENSG00000237310.1 GS1-124K5.4 -5.53 5.38e-08 1.85e-05 -0.25 -0.25 Aortic root size; chr7:66039646 chr7:66493706~66495474:+ LUSC cis rs9910055 0.762 rs2526020 ENSG00000267080.4 ASB16-AS1 -5.53 5.39e-08 1.85e-05 -0.22 -0.25 Total body bone mineral density; chr17:44139220 chr17:44175973~44186717:- LUSC cis rs7772486 0.875 rs1125461 ENSG00000235652.6 RP11-545I5.3 5.53 5.39e-08 1.85e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:146096517 chr6:145799409~145886585:+ LUSC cis rs7829975 0.564 rs2921060 ENSG00000173295.6 FAM86B3P -5.53 5.39e-08 1.85e-05 -0.27 -0.25 Mood instability; chr8:8460307 chr8:8228595~8244865:+ LUSC cis rs950169 0.579 rs11633088 ENSG00000259728.4 LINC00933 -5.53 5.4e-08 1.85e-05 -0.34 -0.25 Schizophrenia; chr15:84003429 chr15:84570649~84580175:+ LUSC cis rs2919917 0.554 rs2086755 ENSG00000254352.1 RP11-578O24.2 5.53 5.4e-08 1.85e-05 0.34 0.25 Lymphocyte counts; chr8:78701809 chr8:78723796~78724136:- LUSC cis rs11079757 0.681 rs34811916 ENSG00000262879.4 RP11-156P1.3 5.53 5.4e-08 1.85e-05 0.29 0.25 Erythema nodosum in inflammatory bowel disease; chr17:47111431 chr17:46984045~47100323:- LUSC cis rs875971 0.545 rs67775320 ENSG00000179406.6 LINC00174 -5.53 5.4e-08 1.85e-05 -0.29 -0.25 Aortic root size; chr7:66193792 chr7:66376044~66401338:- LUSC cis rs7945705 0.875 rs10769955 ENSG00000254860.4 TMEM9B-AS1 -5.53 5.4e-08 1.85e-05 -0.28 -0.25 Hemoglobin concentration; chr11:8763100 chr11:8964675~8977527:+ LUSC cis rs1322639 0.614 rs6925188 ENSG00000223485.1 RP11-417E7.1 -5.53 5.4e-08 1.85e-05 -0.35 -0.25 Pulse pressure; chr6:169163242 chr6:169158092~169162924:- LUSC cis rs875971 0.545 rs73378304 ENSG00000224316.1 RP11-479O9.2 5.53 5.4e-08 1.85e-05 0.26 0.25 Aortic root size; chr7:66175760 chr7:65773620~65802067:+ LUSC cis rs1062177 0.756 rs2964592 ENSG00000213433.5 RPLP1P6 5.53 5.4e-08 1.85e-05 0.31 0.25 Preschool internalizing problems; chr5:151736127 chr5:151765859~151766378:- LUSC cis rs7665090 1 rs7665090 ENSG00000230069.3 LRRC37A15P 5.53 5.41e-08 1.86e-05 0.25 0.25 Primary biliary cholangitis; chr4:102630446 chr4:102727274~102730721:- LUSC cis rs875971 0.545 rs7787063 ENSG00000179406.6 LINC00174 -5.53 5.41e-08 1.86e-05 -0.29 -0.25 Aortic root size; chr7:66164012 chr7:66376044~66401338:- LUSC cis rs891378 0.793 rs12021745 ENSG00000274245.1 RP11-357P18.2 5.53 5.41e-08 1.86e-05 0.33 0.25 Spherical equivalent (joint analysis main effects and education interaction); chr1:207293254 chr1:207372559~207373252:+ LUSC cis rs9322193 0.923 rs9767105 ENSG00000268592.3 RAET1E-AS1 5.53 5.42e-08 1.86e-05 0.31 0.25 Lung cancer; chr6:149659591 chr6:149863494~149919507:+ LUSC cis rs6452524 0.618 rs2306336 ENSG00000248112.1 RP11-78C3.1 5.53 5.42e-08 1.86e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83064964 chr5:82919376~82921119:- LUSC cis rs6452524 0.589 rs6882386 ENSG00000248112.1 RP11-78C3.1 5.53 5.42e-08 1.86e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83065555 chr5:82919376~82921119:- LUSC cis rs6452524 0.618 rs6860752 ENSG00000248112.1 RP11-78C3.1 5.53 5.42e-08 1.86e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83065587 chr5:82919376~82921119:- LUSC cis rs2732480 0.5 rs12829841 ENSG00000273765.1 RP11-370I10.11 5.53 5.42e-08 1.86e-05 0.28 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48234956 chr12:48360920~48361377:+ LUSC cis rs2732480 0.523 rs34286639 ENSG00000273765.1 RP11-370I10.11 5.53 5.42e-08 1.86e-05 0.28 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48235261 chr12:48360920~48361377:+ LUSC cis rs35740288 0.862 rs11637444 ENSG00000202081.1 RNU6-1280P 5.53 5.42e-08 1.86e-05 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85767957 chr15:85651522~85651628:- LUSC cis rs11098499 0.722 rs10025925 ENSG00000249244.1 RP11-548H18.2 5.53 5.42e-08 1.86e-05 0.3 0.25 Corneal astigmatism; chr4:119350589 chr4:119391831~119395335:- LUSC cis rs11098499 0.731 rs10015579 ENSG00000249244.1 RP11-548H18.2 5.53 5.42e-08 1.86e-05 0.3 0.25 Corneal astigmatism; chr4:119350647 chr4:119391831~119395335:- LUSC cis rs2834288 0.734 rs9984514 ENSG00000273102.1 AP000569.9 5.53 5.42e-08 1.86e-05 0.28 0.25 Gut microbiota (bacterial taxa); chr21:33892370 chr21:33967101~33968573:- LUSC cis rs5770917 1 rs5770922 ENSG00000273272.1 CTA-384D8.34 5.53 5.43e-08 1.86e-05 0.54 0.25 Narcolepsy; chr22:50584979 chr22:50542650~50543011:+ LUSC cis rs442309 0.875 rs224061 ENSG00000238280.1 RP11-436D10.3 -5.53 5.43e-08 1.86e-05 -0.31 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62742409 chr10:62793562~62805887:- LUSC cis rs2993535 0.749 rs2358439 ENSG00000233626.2 RP11-565J7.1 -5.53 5.44e-08 1.86e-05 -0.52 -0.25 Hip circumference adjusted for BMI; chr1:212074153 chr1:211936249~211936634:+ LUSC cis rs7772486 0.875 rs9322046 ENSG00000235652.6 RP11-545I5.3 5.53 5.44e-08 1.86e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146072489 chr6:145799409~145886585:+ LUSC cis rs67311347 1 rs9822644 ENSG00000223797.4 ENTPD3-AS1 5.53 5.44e-08 1.87e-05 0.29 0.25 Renal cell carcinoma; chr3:40385118 chr3:40313802~40453329:- LUSC cis rs1707322 0.686 rs1250 ENSG00000234329.1 RP11-767N6.2 5.53 5.45e-08 1.87e-05 0.28 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628355 chr1:45651039~45651826:- LUSC cis rs8062405 0.698 rs7188071 ENSG00000278665.1 RP11-666O2.4 -5.53 5.45e-08 1.87e-05 -0.26 -0.25 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28906323 chr16:28599241~28601881:- LUSC cis rs853679 0.599 rs149990 ENSG00000204709.4 LINC01556 5.53 5.45e-08 1.87e-05 0.42 0.25 Depression; chr6:28030480 chr6:28943877~28944537:+ LUSC cis rs910316 1 rs7156328 ENSG00000279594.1 RP11-950C14.10 5.53 5.45e-08 1.87e-05 0.28 0.25 Height; chr14:75066238 chr14:75011269~75012851:- LUSC cis rs910316 1 rs12435391 ENSG00000279594.1 RP11-950C14.10 5.53 5.45e-08 1.87e-05 0.28 0.25 Height; chr14:75135034 chr14:75011269~75012851:- LUSC cis rs2274273 0.87 rs67514154 ENSG00000258413.1 RP11-665C16.6 -5.53 5.45e-08 1.87e-05 -0.3 -0.25 Protein biomarker; chr14:55300664 chr14:55262767~55272075:- LUSC cis rs11159086 1 rs11626856 ENSG00000259005.1 RP3-449M8.6 5.52 5.47e-08 1.87e-05 0.38 0.25 Advanced glycation end-product levels; chr14:74469665 chr14:74474007~74474864:- LUSC cis rs442309 0.875 rs224146 ENSG00000238280.1 RP11-436D10.3 -5.52 5.48e-08 1.88e-05 -0.3 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62723179 chr10:62793562~62805887:- LUSC cis rs950880 0.71 rs11693204 ENSG00000234389.1 AC007278.3 -5.52 5.49e-08 1.88e-05 -0.27 -0.25 Serum protein levels (sST2); chr2:102319514 chr2:102438713~102440475:+ LUSC cis rs6502050 0.723 rs11650633 ENSG00000266654.1 RP11-1376P16.1 5.52 5.49e-08 1.88e-05 0.25 0.25 Life satisfaction; chr17:82125931 chr17:82160056~82160452:+ LUSC cis rs10027350 0.964 rs3756208 ENSG00000281501.1 SEPSECS-AS1 5.52 5.49e-08 1.88e-05 0.29 0.25 Childhood ear infection; chr4:25132047 chr4:25160641~25201440:+ LUSC cis rs7246657 0.551 rs11084873 ENSG00000276846.1 CTD-3220F14.3 5.52 5.49e-08 1.88e-05 0.39 0.25 Coronary artery calcification; chr19:37093008 chr19:37314868~37315620:- LUSC cis rs7246657 0.551 rs12978093 ENSG00000276846.1 CTD-3220F14.3 5.52 5.49e-08 1.88e-05 0.39 0.25 Coronary artery calcification; chr19:37093514 chr19:37314868~37315620:- LUSC cis rs8072100 0.713 rs2292346 ENSG00000228782.6 CTD-2026D20.3 5.52 5.49e-08 1.88e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47378107 chr17:47450568~47492492:- LUSC cis rs8072100 0.666 rs9913014 ENSG00000228782.6 CTD-2026D20.3 5.52 5.49e-08 1.88e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47382823 chr17:47450568~47492492:- LUSC cis rs2439831 0.85 rs3862142 ENSG00000249839.1 AC011330.5 -5.52 5.49e-08 1.88e-05 -0.5 -0.25 Lung cancer in ever smokers; chr15:43772608 chr15:43663654~43684339:- LUSC cis rs2439831 0.702 rs2788 ENSG00000249839.1 AC011330.5 -5.52 5.49e-08 1.88e-05 -0.5 -0.25 Lung cancer in ever smokers; chr15:43772688 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs2277531 ENSG00000249839.1 AC011330.5 -5.52 5.49e-08 1.88e-05 -0.5 -0.25 Lung cancer in ever smokers; chr15:43776871 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs28891769 ENSG00000249839.1 AC011330.5 -5.52 5.49e-08 1.88e-05 -0.5 -0.25 Lung cancer in ever smokers; chr15:43780662 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs28578398 ENSG00000249839.1 AC011330.5 -5.52 5.49e-08 1.88e-05 -0.5 -0.25 Lung cancer in ever smokers; chr15:43782848 chr15:43663654~43684339:- LUSC cis rs6969780 0.722 rs983185 ENSG00000233429.8 HOTAIRM1 -5.52 5.5e-08 1.88e-05 -0.37 -0.25 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27148988 chr7:27095647~27100265:+ LUSC cis rs1707322 0.686 rs2991977 ENSG00000234329.1 RP11-767N6.2 -5.52 5.5e-08 1.88e-05 -0.27 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45588011 chr1:45651039~45651826:- LUSC cis rs1707322 0.656 rs2991981 ENSG00000234329.1 RP11-767N6.2 -5.52 5.5e-08 1.88e-05 -0.27 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45591472 chr1:45651039~45651826:- LUSC cis rs2337406 0.866 rs8003852 ENSG00000280411.1 IGHV1-69-2 -5.52 5.5e-08 1.88e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106776648 chr14:106762092~106762588:- LUSC cis rs2739330 0.731 rs4822450 ENSG00000228039.3 KB-1125A3.10 5.52 5.5e-08 1.88e-05 0.31 0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23963780~23964374:+ LUSC cis rs7712401 0.58 rs42536 ENSG00000263432.2 RN7SL689P 5.52 5.5e-08 1.88e-05 0.31 0.25 Mean platelet volume; chr5:122940728 chr5:123022487~123022783:- LUSC cis rs4722166 0.63 rs4722168 ENSG00000179428.2 AC073072.5 -5.52 5.5e-08 1.88e-05 -0.3 -0.25 Lung cancer; chr7:22739383 chr7:22725395~22727620:- LUSC cis rs2439831 0.85 rs3736180 ENSG00000249839.1 AC011330.5 -5.52 5.51e-08 1.89e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43814426 chr15:43663654~43684339:- LUSC cis rs2439831 0.85 rs28684672 ENSG00000249839.1 AC011330.5 -5.52 5.51e-08 1.89e-05 -0.51 -0.25 Lung cancer in ever smokers; chr15:43815464 chr15:43663654~43684339:- LUSC cis rs7927592 0.546 rs497261 ENSG00000212093.1 AP000807.1 5.52 5.52e-08 1.89e-05 0.29 0.25 Total body bone mineral density; chr11:68424776 chr11:68506083~68506166:- LUSC cis rs7927592 0.546 rs599083 ENSG00000212093.1 AP000807.1 5.52 5.52e-08 1.89e-05 0.29 0.25 Total body bone mineral density; chr11:68424878 chr11:68506083~68506166:- LUSC cis rs2921073 0.509 rs2976931 ENSG00000253893.2 FAM85B -5.52 5.52e-08 1.89e-05 -0.29 -0.25 Parkinson's disease; chr8:8399807 chr8:8167819~8226614:- LUSC cis rs11098499 0.909 rs7681214 ENSG00000248280.1 RP11-33B1.2 5.52 5.52e-08 1.89e-05 0.3 0.25 Corneal astigmatism; chr4:119464165 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs17046116 ENSG00000248280.1 RP11-33B1.2 5.52 5.52e-08 1.89e-05 0.3 0.25 Corneal astigmatism; chr4:119466104 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs17046118 ENSG00000248280.1 RP11-33B1.2 5.52 5.52e-08 1.89e-05 0.3 0.25 Corneal astigmatism; chr4:119466341 chr4:119440561~119450157:- LUSC cis rs17270561 0.609 rs1317510 ENSG00000272462.2 U91328.19 -5.52 5.52e-08 1.89e-05 -0.29 -0.25 Iron status biomarkers; chr6:25778696 chr6:25992662~26001775:+ LUSC cis rs875971 0.522 rs2008188 ENSG00000237310.1 GS1-124K5.4 5.52 5.52e-08 1.89e-05 0.25 0.25 Aortic root size; chr7:65964026 chr7:66493706~66495474:+ LUSC cis rs2404602 0.591 rs11635162 ENSG00000259422.1 RP11-593F23.1 -5.52 5.53e-08 1.89e-05 -0.31 -0.25 Blood metabolite levels; chr15:76658764 chr15:76174891~76181486:- LUSC cis rs67311347 0.911 rs9863737 ENSG00000223797.4 ENTPD3-AS1 5.52 5.53e-08 1.89e-05 0.28 0.25 Renal cell carcinoma; chr3:40398345 chr3:40313802~40453329:- LUSC cis rs2337406 0.714 rs117798641 ENSG00000280411.1 IGHV1-69-2 -5.52 5.54e-08 1.89e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106777984 chr14:106762092~106762588:- LUSC cis rs875971 0.522 rs4718286 ENSG00000222364.1 RNU6-96P -5.52 5.54e-08 1.89e-05 -0.29 -0.25 Aortic root size; chr7:65827777 chr7:66395191~66395286:+ LUSC cis rs2136613 0.533 rs7089121 ENSG00000238280.1 RP11-436D10.3 -5.52 5.54e-08 1.9e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62846850 chr10:62793562~62805887:- LUSC cis rs17270561 0.666 rs4712971 ENSG00000272462.2 U91328.19 -5.52 5.56e-08 1.9e-05 -0.3 -0.25 Iron status biomarkers; chr6:25771672 chr6:25992662~26001775:+ LUSC cis rs2274273 0.87 rs11851169 ENSG00000258413.1 RP11-665C16.6 -5.52 5.56e-08 1.9e-05 -0.3 -0.25 Protein biomarker; chr14:55349214 chr14:55262767~55272075:- LUSC cis rs2274273 0.805 rs28612464 ENSG00000258413.1 RP11-665C16.6 -5.52 5.56e-08 1.9e-05 -0.3 -0.25 Protein biomarker; chr14:55349693 chr14:55262767~55272075:- LUSC cis rs2274273 0.773 rs28430823 ENSG00000258413.1 RP11-665C16.6 -5.52 5.56e-08 1.9e-05 -0.3 -0.25 Protein biomarker; chr14:55349842 chr14:55262767~55272075:- LUSC cis rs2274273 0.87 rs17741831 ENSG00000258413.1 RP11-665C16.6 -5.52 5.56e-08 1.9e-05 -0.3 -0.25 Protein biomarker; chr14:55349997 chr14:55262767~55272075:- LUSC cis rs673078 0.66 rs16948197 ENSG00000275759.1 RP11-131L12.3 5.52 5.57e-08 1.9e-05 0.37 0.25 Glucose homeostasis traits; chr12:118239135 chr12:118428281~118428870:+ LUSC cis rs7246657 0.722 rs12979640 ENSG00000276846.1 CTD-3220F14.3 -5.52 5.57e-08 1.9e-05 -0.37 -0.25 Coronary artery calcification; chr19:37688255 chr19:37314868~37315620:- LUSC cis rs2243480 1 rs402418 ENSG00000226824.5 RP4-756H11.3 -5.52 5.57e-08 1.9e-05 -0.49 -0.25 Diabetic kidney disease; chr7:66044482 chr7:66654538~66669855:+ LUSC cis rs889398 0.9 rs4783722 ENSG00000226232.7 RP11-419C5.2 5.52 5.58e-08 1.91e-05 0.24 0.25 Body mass index; chr16:69548009 chr16:69976388~69996188:- LUSC cis rs12819124 0.502 rs10875718 ENSG00000240399.1 RP1-228P16.1 5.52 5.58e-08 1.91e-05 0.25 0.25 Glycated hemoglobin levels; chr12:48017319 chr12:48054813~48055591:- LUSC cis rs4332428 0.881 rs34702521 ENSG00000239148.1 U8 -5.52 5.59e-08 1.91e-05 -0.28 -0.25 Height; chr10:4939583 chr10:5004710~5004842:+ LUSC cis rs875971 0.522 rs10807697 ENSG00000237310.1 GS1-124K5.4 5.52 5.59e-08 1.91e-05 0.25 0.25 Aortic root size; chr7:65951183 chr7:66493706~66495474:+ LUSC cis rs910316 0.967 rs8013444 ENSG00000279594.1 RP11-950C14.10 -5.52 5.6e-08 1.91e-05 -0.28 -0.25 Height; chr14:75195278 chr14:75011269~75012851:- LUSC cis rs750134 0.786 rs78063826 ENSG00000257221.1 RP11-689B22.2 -5.52 5.6e-08 1.91e-05 -0.37 -0.25 Low high density lipoprotein cholesterol levels; chr12:108638656 chr12:108628687~108641318:+ LUSC cis rs750134 0.786 rs56067627 ENSG00000257221.1 RP11-689B22.2 -5.52 5.6e-08 1.91e-05 -0.37 -0.25 Low high density lipoprotein cholesterol levels; chr12:108639503 chr12:108628687~108641318:+ LUSC cis rs750134 1 rs12581716 ENSG00000257221.1 RP11-689B22.2 -5.52 5.6e-08 1.91e-05 -0.37 -0.25 Low high density lipoprotein cholesterol levels; chr12:108642825 chr12:108628687~108641318:+ LUSC cis rs17270561 0.636 rs1575535 ENSG00000272462.2 U91328.19 -5.52 5.6e-08 1.91e-05 -0.28 -0.25 Iron status biomarkers; chr6:25809681 chr6:25992662~26001775:+ LUSC cis rs10462794 0.853 rs1562825 ENSG00000260763.1 RP11-445O3.3 -5.52 5.6e-08 1.91e-05 -0.32 -0.25 DNA methylation (variation); chr5:4510870 chr5:4436850~4440259:- LUSC cis rs1008375 0.9 rs12650220 ENSG00000249502.1 AC006160.5 -5.52 5.6e-08 1.91e-05 -0.24 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17593742 chr4:17587467~17614571:- LUSC cis rs4604234 0.518 rs73463537 ENSG00000272129.1 RP11-250B2.6 -5.52 5.6e-08 1.91e-05 -0.54 -0.25 Cancer; chr6:80275314 chr6:80355424~80356859:+ LUSC cis rs2243480 1 rs313809 ENSG00000226824.5 RP4-756H11.3 -5.52 5.6e-08 1.91e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66034996 chr7:66654538~66669855:+ LUSC cis rs875971 0.522 rs1617484 ENSG00000179406.6 LINC00174 -5.52 5.6e-08 1.91e-05 -0.26 -0.25 Aortic root size; chr7:65998108 chr7:66376044~66401338:- LUSC cis rs801193 0.548 rs2659904 ENSG00000179406.6 LINC00174 -5.52 5.6e-08 1.91e-05 -0.27 -0.25 Aortic root size; chr7:66713615 chr7:66376044~66401338:- LUSC cis rs77204473 0.744 rs17120344 ENSG00000254851.1 RP11-109L13.1 -5.52 5.61e-08 1.92e-05 -0.61 -0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117125629 chr11:117135528~117138582:+ LUSC cis rs13434995 0.513 rs880358 ENSG00000249700.7 SRD5A3-AS1 -5.52 5.61e-08 1.92e-05 -0.32 -0.25 Adiponectin levels; chr4:55410311 chr4:55363971~55395847:- LUSC cis rs13434995 0.513 rs17776975 ENSG00000249700.7 SRD5A3-AS1 -5.52 5.61e-08 1.92e-05 -0.32 -0.25 Adiponectin levels; chr4:55410728 chr4:55363971~55395847:- LUSC cis rs13113518 1 rs13146987 ENSG00000273257.1 RP11-177J6.1 5.52 5.62e-08 1.92e-05 0.32 0.25 Height; chr4:55491628 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs7677085 ENSG00000273257.1 RP11-177J6.1 5.52 5.62e-08 1.92e-05 0.32 0.25 Height; chr4:55495801 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs12510681 ENSG00000273257.1 RP11-177J6.1 5.52 5.62e-08 1.92e-05 0.32 0.25 Height; chr4:55496737 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs12500162 ENSG00000273257.1 RP11-177J6.1 5.52 5.62e-08 1.92e-05 0.32 0.25 Height; chr4:55496933 chr4:55387949~55388271:+ LUSC cis rs7712401 0.601 rs154500 ENSG00000263432.2 RN7SL689P 5.52 5.62e-08 1.92e-05 0.3 0.25 Mean platelet volume; chr5:122876296 chr5:123022487~123022783:- LUSC cis rs1729951 0.575 rs168635 ENSG00000261758.1 RP11-102M11.2 5.52 5.62e-08 1.92e-05 0.23 0.25 Neuroticism; chr3:136980236 chr3:136752630~136755780:+ LUSC cis rs6502050 0.777 rs11077969 ENSG00000266654.1 RP11-1376P16.1 5.52 5.63e-08 1.92e-05 0.25 0.25 Life satisfaction; chr17:82127757 chr17:82160056~82160452:+ LUSC cis rs6918586 0.658 rs198822 ENSG00000272462.2 U91328.19 -5.52 5.63e-08 1.92e-05 -0.26 -0.25 Schizophrenia; chr6:26123311 chr6:25992662~26001775:+ LUSC cis rs17711722 0.585 rs6942660 ENSG00000222364.1 RNU6-96P -5.52 5.63e-08 1.92e-05 -0.29 -0.25 Calcium levels; chr7:65837419 chr7:66395191~66395286:+ LUSC cis rs2842992 0.872 rs2758315 ENSG00000237927.1 RP3-393E18.2 -5.52 5.63e-08 1.92e-05 -0.36 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159737608 chr6:159586955~159589169:- LUSC cis rs1322639 0.614 rs6900964 ENSG00000223485.1 RP11-417E7.1 -5.52 5.64e-08 1.92e-05 -0.34 -0.25 Pulse pressure; chr6:169166668 chr6:169158092~169162924:- LUSC cis rs7555523 0.887 rs6696454 ENSG00000224358.1 RP11-466F5.8 -5.52 5.64e-08 1.93e-05 -0.31 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165738686 chr1:165768929~165775176:+ LUSC cis rs853679 0.55 rs1237875 ENSG00000280107.1 AL022393.9 5.52 5.64e-08 1.93e-05 0.3 0.25 Depression; chr6:28205232 chr6:28170845~28172521:+ LUSC cis rs7665090 1 rs10027437 ENSG00000230069.3 LRRC37A15P -5.52 5.64e-08 1.93e-05 -0.26 -0.25 Primary biliary cholangitis; chr4:102636094 chr4:102727274~102730721:- LUSC cis rs202072 0.652 rs453695 ENSG00000272379.1 RP1-257A7.5 -5.52 5.65e-08 1.93e-05 -0.41 -0.25 HIV-1 viral setpoint; chr6:13262274 chr6:13290018~13290490:- LUSC cis rs910316 1 rs10873275 ENSG00000279594.1 RP11-950C14.10 5.52 5.65e-08 1.93e-05 0.28 0.25 Height; chr14:75064757 chr14:75011269~75012851:- LUSC cis rs875971 0.545 rs12671152 ENSG00000224316.1 RP11-479O9.2 5.52 5.65e-08 1.93e-05 0.27 0.25 Aortic root size; chr7:66311140 chr7:65773620~65802067:+ LUSC cis rs2613964 0.504 rs1903431 ENSG00000240057.4 RP11-572M11.4 -5.52 5.66e-08 1.93e-05 -0.26 -0.25 Pediatric bone mineral content (spine);Pediatric bone mineral density (spine); chr3:113133810 chr3:113019532~113183301:+ LUSC cis rs67311347 1 rs11720360 ENSG00000223797.4 ENTPD3-AS1 5.52 5.66e-08 1.93e-05 0.29 0.25 Renal cell carcinoma; chr3:40406906 chr3:40313802~40453329:- LUSC cis rs11098499 0.954 rs12502423 ENSG00000248280.1 RP11-33B1.2 5.52 5.66e-08 1.93e-05 0.29 0.25 Corneal astigmatism; chr4:119503017 chr4:119440561~119450157:- LUSC cis rs11098499 0.564 rs11098507 ENSG00000248280.1 RP11-33B1.2 5.52 5.67e-08 1.93e-05 0.29 0.25 Corneal astigmatism; chr4:119367131 chr4:119440561~119450157:- LUSC cis rs11098499 0.754 rs1814813 ENSG00000248280.1 RP11-33B1.2 -5.52 5.67e-08 1.93e-05 -0.28 -0.25 Corneal astigmatism; chr4:119337052 chr4:119440561~119450157:- LUSC cis rs7772486 0.875 rs2777484 ENSG00000235652.6 RP11-545I5.3 5.52 5.67e-08 1.94e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146013026 chr6:145799409~145886585:+ LUSC cis rs2919917 0.628 rs1384803 ENSG00000254352.1 RP11-578O24.2 -5.52 5.67e-08 1.94e-05 -0.33 -0.25 Lymphocyte counts; chr8:78669393 chr8:78723796~78724136:- LUSC cis rs35160687 0.644 rs4832276 ENSG00000273080.1 RP11-301O19.1 5.52 5.68e-08 1.94e-05 0.24 0.25 Night sleep phenotypes; chr2:86317895 chr2:86195590~86196049:+ LUSC cis rs12935418 1 rs62054589 ENSG00000261061.1 RP11-303E16.2 -5.52 5.69e-08 1.94e-05 -0.46 -0.25 Mean corpuscular volume; chr16:81035143 chr16:81030770~81031485:+ LUSC cis rs7772486 0.875 rs9399572 ENSG00000235652.6 RP11-545I5.3 5.52 5.69e-08 1.94e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146041809 chr6:145799409~145886585:+ LUSC cis rs7772486 0.817 rs9386145 ENSG00000235652.6 RP11-545I5.3 5.52 5.69e-08 1.94e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146042383 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs9390372 ENSG00000235652.6 RP11-545I5.3 5.52 5.69e-08 1.94e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146042502 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs9373483 ENSG00000235652.6 RP11-545I5.3 5.52 5.69e-08 1.94e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146043058 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs7766595 ENSG00000235652.6 RP11-545I5.3 5.52 5.69e-08 1.94e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146043371 chr6:145799409~145886585:+ LUSC cis rs9311474 0.652 rs411457 ENSG00000243224.1 RP5-1157M23.2 5.52 5.69e-08 1.94e-05 0.24 0.25 Electroencephalogram traits; chr3:52194134 chr3:52239258~52241097:+ LUSC cis rs11096990 0.679 rs6531707 ENSG00000249207.1 RP11-360F5.1 5.52 5.69e-08 1.94e-05 0.26 0.25 Cognitive function; chr4:39296064 chr4:39112677~39126818:- LUSC cis rs875971 0.545 rs1796217 ENSG00000179406.6 LINC00174 5.52 5.69e-08 1.94e-05 0.29 0.25 Aortic root size; chr7:66620931 chr7:66376044~66401338:- LUSC cis rs910316 0.737 rs175049 ENSG00000279594.1 RP11-950C14.10 -5.52 5.7e-08 1.94e-05 -0.29 -0.25 Height; chr14:75014665 chr14:75011269~75012851:- LUSC cis rs6452524 0.618 rs1871203 ENSG00000248112.1 RP11-78C3.1 5.52 5.7e-08 1.94e-05 0.27 0.25 Hypertension (SNP x SNP interaction); chr5:83059567 chr5:82919376~82921119:- LUSC cis rs453301 0.686 rs6601280 ENSG00000254340.1 RP11-10A14.3 5.52 5.7e-08 1.94e-05 0.32 0.25 Joint mobility (Beighton score); chr8:9051726 chr8:9141424~9145435:+ LUSC cis rs442309 0.875 rs224063 ENSG00000238280.1 RP11-436D10.3 5.52 5.7e-08 1.94e-05 0.3 0.25 Vogt-Koyanagi-Harada syndrome; chr10:62743589 chr10:62793562~62805887:- LUSC cis rs4728142 0.738 rs3807306 ENSG00000275106.1 RP11-309L24.10 5.52 5.7e-08 1.94e-05 0.31 0.25 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128940626 chr7:128952527~128953316:- LUSC cis rs13434995 0.513 rs1979604 ENSG00000249700.7 SRD5A3-AS1 5.52 5.7e-08 1.95e-05 0.31 0.25 Adiponectin levels; chr4:55552588 chr4:55363971~55395847:- LUSC cis rs13434995 0.513 rs1979605 ENSG00000249700.7 SRD5A3-AS1 5.52 5.7e-08 1.95e-05 0.31 0.25 Adiponectin levels; chr4:55552706 chr4:55363971~55395847:- LUSC cis rs13434995 0.537 rs4865012 ENSG00000249700.7 SRD5A3-AS1 5.52 5.7e-08 1.95e-05 0.31 0.25 Adiponectin levels; chr4:55554619 chr4:55363971~55395847:- LUSC cis rs7829975 0.514 rs2976926 ENSG00000173295.6 FAM86B3P 5.52 5.71e-08 1.95e-05 0.27 0.25 Mood instability; chr8:8404114 chr8:8228595~8244865:+ LUSC cis rs35160687 0.712 rs2303358 ENSG00000273080.1 RP11-301O19.1 -5.52 5.71e-08 1.95e-05 -0.23 -0.25 Night sleep phenotypes; chr2:86251541 chr2:86195590~86196049:+ LUSC cis rs35160687 0.712 rs4832030 ENSG00000273080.1 RP11-301O19.1 -5.52 5.71e-08 1.95e-05 -0.23 -0.25 Night sleep phenotypes; chr2:86251746 chr2:86195590~86196049:+ LUSC cis rs35160687 0.712 rs12988844 ENSG00000273080.1 RP11-301O19.1 -5.52 5.71e-08 1.95e-05 -0.23 -0.25 Night sleep phenotypes; chr2:86251912 chr2:86195590~86196049:+ LUSC cis rs35160687 0.712 rs17438687 ENSG00000273080.1 RP11-301O19.1 -5.52 5.71e-08 1.95e-05 -0.23 -0.25 Night sleep phenotypes; chr2:86252164 chr2:86195590~86196049:+ LUSC cis rs853679 1 rs1679732 ENSG00000219392.1 RP1-265C24.5 5.52 5.72e-08 1.95e-05 0.4 0.25 Depression; chr6:28253486 chr6:28115628~28116551:+ LUSC cis rs2921073 0.509 rs2976931 ENSG00000173295.6 FAM86B3P 5.52 5.72e-08 1.95e-05 0.27 0.25 Parkinson's disease; chr8:8399807 chr8:8228595~8244865:+ LUSC cis rs853679 0.599 rs149943 ENSG00000204709.4 LINC01556 5.52 5.72e-08 1.95e-05 0.42 0.25 Depression; chr6:28034610 chr6:28943877~28944537:+ LUSC cis rs11098499 0.575 rs9996586 ENSG00000245958.5 RP11-33B1.1 -5.52 5.72e-08 1.95e-05 -0.23 -0.25 Corneal astigmatism; chr4:119405787 chr4:119454791~119552025:+ LUSC cis rs1707322 0.656 rs3014210 ENSG00000234329.1 RP11-767N6.2 -5.52 5.72e-08 1.95e-05 -0.27 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45600936 chr1:45651039~45651826:- LUSC cis rs875971 0.505 rs1167385 ENSG00000237310.1 GS1-124K5.4 -5.52 5.73e-08 1.95e-05 -0.25 -0.25 Aortic root size; chr7:66048321 chr7:66493706~66495474:+ LUSC cis rs13434995 0.513 rs6846764 ENSG00000249700.7 SRD5A3-AS1 5.52 5.74e-08 1.96e-05 0.31 0.25 Adiponectin levels; chr4:55557322 chr4:55363971~55395847:- LUSC cis rs13434995 0.513 rs6853506 ENSG00000249700.7 SRD5A3-AS1 5.52 5.74e-08 1.96e-05 0.31 0.25 Adiponectin levels; chr4:55558207 chr4:55363971~55395847:- LUSC cis rs78487399 0.614 rs10166376 ENSG00000234936.1 AC010883.5 5.52 5.74e-08 1.96e-05 0.36 0.25 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43395333 chr2:43229573~43233394:+ LUSC cis rs6723108 0.517 rs6430543 ENSG00000224043.6 CCNT2-AS1 5.52 5.74e-08 1.96e-05 0.3 0.25 Type 2 diabetes; chr2:134844839 chr2:134735464~134918710:- LUSC cis rs4713118 0.869 rs9468214 ENSG00000280107.1 AL022393.9 -5.52 5.75e-08 1.96e-05 -0.28 -0.25 Parkinson's disease; chr6:27745520 chr6:28170845~28172521:+ LUSC cis rs9611519 0.894 rs13053242 ENSG00000235513.1 RP4-756G23.5 5.52 5.75e-08 1.96e-05 0.29 0.25 Neuroticism; chr22:41063482 chr22:41209122~41217627:- LUSC cis rs9322193 0.884 rs9371201 ENSG00000268592.3 RAET1E-AS1 5.52 5.75e-08 1.96e-05 0.33 0.25 Lung cancer; chr6:149823865 chr6:149863494~149919507:+ LUSC cis rs1167827 0.805 rs809439 ENSG00000278416.1 PMS2L2 -5.52 5.75e-08 1.96e-05 -0.34 -0.25 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75531992 chr7:75344015~75359550:- LUSC cis rs2404602 0.569 rs2469249 ENSG00000259422.1 RP11-593F23.1 -5.52 5.75e-08 1.96e-05 -0.31 -0.25 Blood metabolite levels; chr15:76479721 chr15:76174891~76181486:- LUSC cis rs12468226 1 rs7597469 ENSG00000272966.1 RP11-686O6.1 5.52 5.75e-08 1.96e-05 0.4 0.25 Urate levels; chr2:202329547 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs113877751 ENSG00000272966.1 RP11-686O6.1 5.52 5.75e-08 1.96e-05 0.4 0.25 Urate levels; chr2:202329998 chr2:202336739~202337200:+ LUSC cis rs12468226 0.935 rs113021930 ENSG00000272966.1 RP11-686O6.1 5.52 5.75e-08 1.96e-05 0.4 0.25 Urate levels; chr2:202330448 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs113491584 ENSG00000272966.1 RP11-686O6.1 5.52 5.75e-08 1.96e-05 0.4 0.25 Urate levels; chr2:202331724 chr2:202336739~202337200:+ LUSC cis rs7555523 0.887 rs10800155 ENSG00000224358.1 RP11-466F5.8 -5.52 5.75e-08 1.96e-05 -0.3 -0.25 Glaucoma (high intraocular pressure);Intraocular pressure; chr1:165754533 chr1:165768929~165775176:+ LUSC cis rs4713118 0.911 rs9295746 ENSG00000280107.1 AL022393.9 -5.52 5.76e-08 1.96e-05 -0.3 -0.25 Parkinson's disease; chr6:27762285 chr6:28170845~28172521:+ LUSC cis rs2274273 0.84 rs943590 ENSG00000258413.1 RP11-665C16.6 -5.52 5.76e-08 1.96e-05 -0.3 -0.25 Protein biomarker; chr14:55271878 chr14:55262767~55272075:- LUSC cis rs875971 0.545 rs73136346 ENSG00000224316.1 RP11-479O9.2 -5.52 5.76e-08 1.96e-05 -0.27 -0.25 Aortic root size; chr7:66101095 chr7:65773620~65802067:+ LUSC cis rs11098499 0.954 rs3733524 ENSG00000248280.1 RP11-33B1.2 5.52 5.76e-08 1.96e-05 0.3 0.25 Corneal astigmatism; chr4:119502574 chr4:119440561~119450157:- LUSC cis rs66887589 0.967 rs13104219 ENSG00000248280.1 RP11-33B1.2 5.52 5.76e-08 1.96e-05 0.28 0.25 Diastolic blood pressure; chr4:119517019 chr4:119440561~119450157:- LUSC cis rs62184315 0.638 rs12475694 ENSG00000253559.1 OSGEPL1-AS1 5.51 5.77e-08 1.96e-05 0.29 0.25 Alcohol dependence (age at onset); chr2:189907882 chr2:189762704~189765556:+ LUSC cis rs3758785 0.623 rs13447720 ENSG00000255893.1 RP11-685N10.1 -5.51 5.77e-08 1.97e-05 -0.33 -0.25 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94432160 chr11:94472908~94473570:- LUSC cis rs8072100 0.713 rs8074451 ENSG00000228782.6 CTD-2026D20.3 5.51 5.77e-08 1.97e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47400207 chr17:47450568~47492492:- LUSC cis rs853679 1 rs1679709 ENSG00000204709.4 LINC01556 -5.51 5.78e-08 1.97e-05 -0.4 -0.25 Depression; chr6:28260564 chr6:28943877~28944537:+ LUSC cis rs13113518 0.812 rs13140590 ENSG00000273257.1 RP11-177J6.1 5.51 5.78e-08 1.97e-05 0.32 0.25 Height; chr4:55548666 chr4:55387949~55388271:+ LUSC cis rs875971 0.545 rs316306 ENSG00000179406.6 LINC00174 5.51 5.78e-08 1.97e-05 0.29 0.25 Aortic root size; chr7:66153687 chr7:66376044~66401338:- LUSC cis rs7267979 1 rs2474777 ENSG00000274973.1 RP13-401N8.7 -5.51 5.78e-08 1.97e-05 -0.25 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25291997 chr20:25845497~25845862:+ LUSC cis rs875971 0.505 rs2462573 ENSG00000237310.1 GS1-124K5.4 -5.51 5.78e-08 1.97e-05 -0.25 -0.25 Aortic root size; chr7:66042405 chr7:66493706~66495474:+ LUSC cis rs9341808 0.667 rs12209624 ENSG00000272129.1 RP11-250B2.6 5.51 5.79e-08 1.97e-05 0.31 0.25 Sitting height ratio; chr6:80209416 chr6:80355424~80356859:+ LUSC cis rs6502050 0.842 rs8080305 ENSG00000266654.1 RP11-1376P16.1 5.51 5.8e-08 1.98e-05 0.25 0.25 Life satisfaction; chr17:82116640 chr17:82160056~82160452:+ LUSC cis rs6502050 0.871 rs8066137 ENSG00000266654.1 RP11-1376P16.1 5.51 5.81e-08 1.98e-05 0.25 0.25 Life satisfaction; chr17:82116440 chr17:82160056~82160452:+ LUSC cis rs889398 0.967 rs35967356 ENSG00000226232.7 RP11-419C5.2 5.51 5.82e-08 1.98e-05 0.24 0.25 Body mass index; chr16:69547451 chr16:69976388~69996188:- LUSC cis rs11159086 1 rs4903233 ENSG00000270000.1 RP3-449M8.9 5.51 5.83e-08 1.98e-05 0.38 0.25 Advanced glycation end-product levels; chr14:74497291 chr14:74471930~74472360:- LUSC cis rs7182621 0.512 rs34151878 ENSG00000182397.13 DNM1P46 5.51 5.83e-08 1.98e-05 0.34 0.25 Colonoscopy-negative controls vs population controls; chr15:99869179 chr15:99790156~99806927:- LUSC cis rs7800244 0.541 rs73097426 ENSG00000146666.5 LINC00525 -5.51 5.84e-08 1.99e-05 -0.35 -0.25 Hepatitis C induced liver fibrosis; chr7:47765018 chr7:47761476~47766772:+ LUSC cis rs910316 0.687 rs175059 ENSG00000279594.1 RP11-950C14.10 -5.51 5.84e-08 1.99e-05 -0.28 -0.25 Height; chr14:75023964 chr14:75011269~75012851:- LUSC cis rs2439831 0.85 rs2957637 ENSG00000249839.1 AC011330.5 -5.51 5.84e-08 1.99e-05 -0.47 -0.25 Lung cancer in ever smokers; chr15:43658920 chr15:43663654~43684339:- LUSC cis rs2645424 0.602 rs3779663 ENSG00000255046.1 RP11-297N6.4 -5.51 5.84e-08 1.99e-05 -0.27 -0.25 Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular); chr8:11813853 chr8:11797928~11802568:- LUSC cis rs889398 0.616 rs35808754 ENSG00000226232.7 RP11-419C5.2 5.51 5.85e-08 1.99e-05 0.24 0.25 Body mass index; chr16:69737807 chr16:69976388~69996188:- LUSC cis rs2243480 1 rs1964692 ENSG00000226824.5 RP4-756H11.3 -5.51 5.85e-08 1.99e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65989196 chr7:66654538~66669855:+ LUSC cis rs4372836 0.636 rs4665434 ENSG00000226833.4 AC097724.3 5.51 5.85e-08 1.99e-05 0.27 0.25 Body mass index; chr2:28753537 chr2:28708953~28736205:- LUSC cis rs748404 0.533 rs11632120 ENSG00000249839.1 AC011330.5 5.51 5.86e-08 1.99e-05 0.31 0.25 Lung cancer; chr15:43123175 chr15:43663654~43684339:- LUSC cis rs13434995 0.513 rs9993599 ENSG00000249700.7 SRD5A3-AS1 5.51 5.86e-08 1.99e-05 0.31 0.25 Adiponectin levels; chr4:55586798 chr4:55363971~55395847:- LUSC cis rs17270561 0.609 rs1892248 ENSG00000272462.2 U91328.19 -5.51 5.87e-08 2e-05 -0.29 -0.25 Iron status biomarkers; chr6:25768686 chr6:25992662~26001775:+ LUSC cis rs11098499 0.754 rs7672372 ENSG00000250412.1 KLHL2P1 5.51 5.87e-08 2e-05 0.3 0.25 Corneal astigmatism; chr4:119327251 chr4:119334329~119378233:+ LUSC cis rs9341808 0.714 rs9448911 ENSG00000272129.1 RP11-250B2.6 5.51 5.88e-08 2e-05 0.3 0.25 Sitting height ratio; chr6:80204142 chr6:80355424~80356859:+ LUSC cis rs7083 1 rs619772 ENSG00000254851.1 RP11-109L13.1 5.51 5.89e-08 2e-05 0.3 0.25 Blood protein levels; chr11:117268120 chr11:117135528~117138582:+ LUSC cis rs7083 1 rs493139 ENSG00000254851.1 RP11-109L13.1 5.51 5.89e-08 2e-05 0.3 0.25 Blood protein levels; chr11:117275233 chr11:117135528~117138582:+ LUSC cis rs11098499 0.789 rs10212719 ENSG00000250412.1 KLHL2P1 5.51 5.89e-08 2e-05 0.3 0.25 Corneal astigmatism; chr4:119333282 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs17049949 ENSG00000250412.1 KLHL2P1 5.51 5.89e-08 2e-05 0.3 0.25 Corneal astigmatism; chr4:119334135 chr4:119334329~119378233:+ LUSC cis rs2732480 0.577 rs2634681 ENSG00000226413.2 OR8T1P -5.51 5.89e-08 2e-05 -0.31 -0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48339301 chr12:48442030~48442947:- LUSC cis rs910316 0.737 rs175065 ENSG00000279594.1 RP11-950C14.10 -5.51 5.89e-08 2.01e-05 -0.28 -0.25 Height; chr14:75028280 chr14:75011269~75012851:- LUSC cis rs11098499 0.789 rs1980024 ENSG00000250412.1 KLHL2P1 5.51 5.9e-08 2.01e-05 0.3 0.25 Corneal astigmatism; chr4:119331892 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs34425882 ENSG00000250412.1 KLHL2P1 5.51 5.9e-08 2.01e-05 0.3 0.25 Corneal astigmatism; chr4:119332022 chr4:119334329~119378233:+ LUSC cis rs7927592 0.546 rs683978 ENSG00000212093.1 AP000807.1 5.51 5.9e-08 2.01e-05 0.29 0.25 Total body bone mineral density; chr11:68424953 chr11:68506083~68506166:- LUSC cis rs9611519 0.929 rs71327107 ENSG00000235513.1 RP4-756G23.5 5.51 5.9e-08 2.01e-05 0.3 0.25 Neuroticism; chr22:41022225 chr22:41209122~41217627:- LUSC cis rs17711722 0.675 rs6947132 ENSG00000222364.1 RNU6-96P 5.51 5.91e-08 2.01e-05 0.29 0.25 Calcium levels; chr7:65808508 chr7:66395191~66395286:+ LUSC cis rs17361889 0.671 rs987932 ENSG00000224683.1 RPL36AP29 5.51 5.91e-08 2.01e-05 0.3 0.25 Pediatric bone mineral content (hip); chr7:16114696 chr7:16208945~16209265:+ LUSC cis rs17361889 0.632 rs987934 ENSG00000224683.1 RPL36AP29 5.51 5.91e-08 2.01e-05 0.3 0.25 Pediatric bone mineral content (hip); chr7:16115124 chr7:16208945~16209265:+ LUSC cis rs950169 0.649 rs12911612 ENSG00000225151.9 GOLGA2P7 -5.51 5.92e-08 2.01e-05 -0.37 -0.25 Schizophrenia; chr15:84022262 chr15:84199311~84230136:- LUSC cis rs950169 0.649 rs12905952 ENSG00000225151.9 GOLGA2P7 -5.51 5.92e-08 2.01e-05 -0.37 -0.25 Schizophrenia; chr15:84022509 chr15:84199311~84230136:- LUSC cis rs950169 0.61 rs34529571 ENSG00000225151.9 GOLGA2P7 -5.51 5.92e-08 2.01e-05 -0.37 -0.25 Schizophrenia; chr15:84023055 chr15:84199311~84230136:- LUSC cis rs12291225 0.679 rs11238 ENSG00000251991.1 RNU7-49P -5.51 5.93e-08 2.02e-05 -0.3 -0.25 Sense of smell; chr11:14266582 chr11:14478892~14478953:+ LUSC cis rs8072100 0.905 rs11651766 ENSG00000228782.6 CTD-2026D20.3 5.51 5.94e-08 2.02e-05 0.23 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47497565 chr17:47450568~47492492:- LUSC cis rs8072100 0.905 rs9901869 ENSG00000228782.6 CTD-2026D20.3 5.51 5.94e-08 2.02e-05 0.23 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47497840 chr17:47450568~47492492:- LUSC cis rs11098499 0.754 rs12513083 ENSG00000250412.1 KLHL2P1 5.51 5.94e-08 2.02e-05 0.3 0.25 Corneal astigmatism; chr4:119328457 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs12509621 ENSG00000250412.1 KLHL2P1 5.51 5.94e-08 2.02e-05 0.3 0.25 Corneal astigmatism; chr4:119328505 chr4:119334329~119378233:+ LUSC cis rs66887589 0.56 rs9684327 ENSG00000245958.5 RP11-33B1.1 -5.51 5.94e-08 2.02e-05 -0.23 -0.25 Diastolic blood pressure; chr4:119444286 chr4:119454791~119552025:+ LUSC cis rs4604732 0.642 rs4266925 ENSG00000227135.1 GCSAML-AS1 -5.51 5.95e-08 2.02e-05 -0.34 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247475863 chr1:247524679~247526752:- LUSC cis rs750134 0.901 rs12424287 ENSG00000257221.1 RP11-689B22.2 -5.51 5.95e-08 2.02e-05 -0.36 -0.25 Low high density lipoprotein cholesterol levels; chr12:108833174 chr12:108628687~108641318:+ LUSC cis rs1387259 0.929 rs11168460 ENSG00000273765.1 RP11-370I10.11 5.51 5.96e-08 2.02e-05 0.28 0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48203582 chr12:48360920~48361377:+ LUSC cis rs2732480 0.5 rs7297824 ENSG00000273765.1 RP11-370I10.11 5.51 5.96e-08 2.02e-05 0.28 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48204867 chr12:48360920~48361377:+ LUSC cis rs6570726 0.935 rs110289 ENSG00000235652.6 RP11-545I5.3 5.51 5.96e-08 2.02e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145544040 chr6:145799409~145886585:+ LUSC cis rs6570726 0.875 rs12524077 ENSG00000235652.6 RP11-545I5.3 5.51 5.96e-08 2.02e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145545197 chr6:145799409~145886585:+ LUSC cis rs6570726 0.875 rs416243 ENSG00000235652.6 RP11-545I5.3 5.51 5.96e-08 2.02e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145546945 chr6:145799409~145886585:+ LUSC cis rs7182621 0.512 rs12903892 ENSG00000182397.13 DNM1P46 5.51 5.96e-08 2.02e-05 0.34 0.25 Colonoscopy-negative controls vs population controls; chr15:99869662 chr15:99790156~99806927:- LUSC cis rs875971 0.545 rs313828 ENSG00000224316.1 RP11-479O9.2 -5.51 5.97e-08 2.03e-05 -0.27 -0.25 Aortic root size; chr7:66087627 chr7:65773620~65802067:+ LUSC cis rs875971 0.571 rs160647 ENSG00000224316.1 RP11-479O9.2 -5.51 5.97e-08 2.03e-05 -0.27 -0.25 Aortic root size; chr7:66089365 chr7:65773620~65802067:+ LUSC cis rs875971 0.52 rs160645 ENSG00000224316.1 RP11-479O9.2 -5.51 5.97e-08 2.03e-05 -0.27 -0.25 Aortic root size; chr7:66091320 chr7:65773620~65802067:+ LUSC cis rs875971 0.789 rs28815324 ENSG00000224316.1 RP11-479O9.2 -5.51 5.97e-08 2.03e-05 -0.27 -0.25 Aortic root size; chr7:66100789 chr7:65773620~65802067:+ LUSC cis rs2274273 0.84 rs10150760 ENSG00000258413.1 RP11-665C16.6 5.51 5.98e-08 2.03e-05 0.3 0.25 Protein biomarker; chr14:55354830 chr14:55262767~55272075:- LUSC cis rs889398 0.935 rs244420 ENSG00000226232.7 RP11-419C5.2 5.51 5.98e-08 2.03e-05 0.24 0.25 Body mass index; chr16:69624093 chr16:69976388~69996188:- LUSC cis rs1008375 0.898 rs9998130 ENSG00000249502.1 AC006160.5 -5.51 5.99e-08 2.03e-05 -0.24 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17592282 chr4:17587467~17614571:- LUSC cis rs6969780 0.915 rs2107063 ENSG00000233429.8 HOTAIRM1 -5.51 5.99e-08 2.03e-05 -0.42 -0.25 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27127727 chr7:27095647~27100265:+ LUSC cis rs7772486 0.875 rs2224121 ENSG00000235652.6 RP11-545I5.3 5.51 5.99e-08 2.04e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146022078 chr6:145799409~145886585:+ LUSC cis rs6570726 0.905 rs430248 ENSG00000235652.6 RP11-545I5.3 5.51 5.99e-08 2.04e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145552968 chr6:145799409~145886585:+ LUSC cis rs6570726 0.935 rs406343 ENSG00000235652.6 RP11-545I5.3 5.51 5.99e-08 2.04e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145553252 chr6:145799409~145886585:+ LUSC cis rs6502050 0.799 rs8069827 ENSG00000266654.1 RP11-1376P16.1 -5.51 5.99e-08 2.04e-05 -0.25 -0.25 Life satisfaction; chr17:82131292 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs8065981 ENSG00000266654.1 RP11-1376P16.1 -5.51 5.99e-08 2.04e-05 -0.25 -0.25 Life satisfaction; chr17:82133517 chr17:82160056~82160452:+ LUSC cis rs7712401 0.601 rs415534 ENSG00000263432.2 RN7SL689P -5.51 5.99e-08 2.04e-05 -0.32 -0.25 Mean platelet volume; chr5:122989606 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs442911 ENSG00000263432.2 RN7SL689P -5.51 5.99e-08 2.04e-05 -0.32 -0.25 Mean platelet volume; chr5:122989856 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs425573 ENSG00000263432.2 RN7SL689P -5.51 5.99e-08 2.04e-05 -0.32 -0.25 Mean platelet volume; chr5:122990313 chr5:123022487~123022783:- LUSC cis rs7712401 0.562 rs364723 ENSG00000263432.2 RN7SL689P -5.51 5.99e-08 2.04e-05 -0.32 -0.25 Mean platelet volume; chr5:122990769 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs35847506 ENSG00000263432.2 RN7SL689P -5.51 5.99e-08 2.04e-05 -0.32 -0.25 Mean platelet volume; chr5:122991413 chr5:123022487~123022783:- LUSC cis rs6570726 0.791 rs379040 ENSG00000235652.6 RP11-545I5.3 5.51 6e-08 2.04e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145567899 chr6:145799409~145886585:+ LUSC cis rs66887589 0.776 rs10518337 ENSG00000249244.1 RP11-548H18.2 -5.51 6e-08 2.04e-05 -0.3 -0.25 Diastolic blood pressure; chr4:119653719 chr4:119391831~119395335:- LUSC cis rs4713118 0.868 rs742047 ENSG00000280107.1 AL022393.9 -5.51 6.01e-08 2.04e-05 -0.3 -0.25 Parkinson's disease; chr6:27771601 chr6:28170845~28172521:+ LUSC cis rs34375054 0.624 rs12826658 ENSG00000279233.1 RP11-158L12.4 5.51 6.01e-08 2.04e-05 0.24 0.25 Post bronchodilator FEV1/FVC ratio; chr12:125195691 chr12:125138245~125141711:+ LUSC cis rs34375054 0.624 rs12832525 ENSG00000279233.1 RP11-158L12.4 5.51 6.01e-08 2.04e-05 0.24 0.25 Post bronchodilator FEV1/FVC ratio; chr12:125195820 chr12:125138245~125141711:+ LUSC cis rs17711722 1 rs17711722 ENSG00000222364.1 RNU6-96P 5.51 6.02e-08 2.04e-05 0.29 0.25 Calcium levels; chr7:65806210 chr7:66395191~66395286:+ LUSC cis rs6570726 0.935 rs585292 ENSG00000235652.6 RP11-545I5.3 5.51 6.02e-08 2.04e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145541092 chr6:145799409~145886585:+ LUSC cis rs6570726 0.837 rs419991 ENSG00000235652.6 RP11-545I5.3 5.51 6.02e-08 2.04e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:145543076 chr6:145799409~145886585:+ LUSC cis rs910316 0.737 rs175043 ENSG00000279594.1 RP11-950C14.10 -5.51 6.02e-08 2.04e-05 -0.29 -0.25 Height; chr14:75005100 chr14:75011269~75012851:- LUSC cis rs910316 0.763 rs175044 ENSG00000279594.1 RP11-950C14.10 -5.51 6.02e-08 2.04e-05 -0.29 -0.25 Height; chr14:75005406 chr14:75011269~75012851:- LUSC cis rs7772486 0.79 rs9497424 ENSG00000235652.6 RP11-545I5.3 -5.51 6.02e-08 2.04e-05 -0.24 -0.25 Lobe attachment (rater-scored or self-reported); chr6:145904135 chr6:145799409~145886585:+ LUSC cis rs2708377 0.789 rs3911150 ENSG00000247157.5 LINC01252 -5.51 6.02e-08 2.04e-05 -0.4 -0.25 Bitter taste perception; chr12:11049649 chr12:11548030~11590369:+ LUSC cis rs875971 0.577 rs35072105 ENSG00000224316.1 RP11-479O9.2 -5.51 6.03e-08 2.05e-05 -0.24 -0.25 Aortic root size; chr7:66144830 chr7:65773620~65802067:+ LUSC cis rs6867032 0.834 rs4526149 ENSG00000249731.1 RP11-259O2.3 -5.51 6.03e-08 2.05e-05 -0.27 -0.25 Gut microbiome composition (winter); chr5:1990052 chr5:1968094~1969013:+ LUSC cis rs889398 0.802 rs8051168 ENSG00000226232.7 RP11-419C5.2 -5.51 6.03e-08 2.05e-05 -0.24 -0.25 Body mass index; chr16:69853371 chr16:69976388~69996188:- LUSC cis rs2732480 0.5 rs2450989 ENSG00000226413.2 OR8T1P -5.51 6.04e-08 2.05e-05 -0.31 -0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48259625 chr12:48442030~48442947:- LUSC cis rs1009115 0.528 rs4725086 ENSG00000272328.1 RP4-594A5.1 -5.51 6.05e-08 2.05e-05 -0.3 -0.25 Post bronchodilator FEV1; chr7:8358937 chr7:8303741~8341343:+ LUSC cis rs7712401 0.601 rs454617 ENSG00000263432.2 RN7SL689P -5.51 6.05e-08 2.05e-05 -0.32 -0.25 Mean platelet volume; chr5:122986232 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs442427 ENSG00000263432.2 RN7SL689P -5.51 6.05e-08 2.05e-05 -0.32 -0.25 Mean platelet volume; chr5:122986570 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs397731 ENSG00000263432.2 RN7SL689P -5.51 6.05e-08 2.05e-05 -0.32 -0.25 Mean platelet volume; chr5:122987264 chr5:123022487~123022783:- LUSC cis rs7712401 0.58 rs35902490 ENSG00000263432.2 RN7SL689P -5.51 6.05e-08 2.05e-05 -0.32 -0.25 Mean platelet volume; chr5:122987703 chr5:123022487~123022783:- LUSC cis rs7712401 0.562 rs383638 ENSG00000263432.2 RN7SL689P -5.51 6.05e-08 2.05e-05 -0.32 -0.25 Mean platelet volume; chr5:122988983 chr5:123022487~123022783:- LUSC cis rs7712401 0.562 rs62377399 ENSG00000263432.2 RN7SL689P -5.51 6.05e-08 2.05e-05 -0.32 -0.25 Mean platelet volume; chr5:122988984 chr5:123022487~123022783:- LUSC cis rs2337406 0.866 rs8012619 ENSG00000254174.1 IGHV1-12 5.51 6.05e-08 2.05e-05 0.24 0.25 Alzheimer's disease (late onset); chr14:106793907 chr14:106122420~106122709:- LUSC cis rs12291225 0.679 rs11369 ENSG00000251991.1 RNU7-49P 5.51 6.05e-08 2.05e-05 0.3 0.25 Sense of smell; chr11:14266550 chr11:14478892~14478953:+ LUSC cis rs875971 0.545 rs316306 ENSG00000224316.1 RP11-479O9.2 -5.51 6.05e-08 2.05e-05 -0.26 -0.25 Aortic root size; chr7:66153687 chr7:65773620~65802067:+ LUSC cis rs2842992 0.75 rs2758354 ENSG00000237927.1 RP3-393E18.2 -5.51 6.06e-08 2.05e-05 -0.37 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159704822 chr6:159586955~159589169:- LUSC cis rs4713118 0.869 rs9366700 ENSG00000280107.1 AL022393.9 -5.51 6.06e-08 2.06e-05 -0.28 -0.25 Parkinson's disease; chr6:27729172 chr6:28170845~28172521:+ LUSC cis rs4713118 0.869 rs6456802 ENSG00000280107.1 AL022393.9 -5.51 6.06e-08 2.06e-05 -0.28 -0.25 Parkinson's disease; chr6:27730576 chr6:28170845~28172521:+ LUSC cis rs4713118 0.869 rs9393851 ENSG00000280107.1 AL022393.9 -5.51 6.06e-08 2.06e-05 -0.28 -0.25 Parkinson's disease; chr6:27731802 chr6:28170845~28172521:+ LUSC cis rs4713118 0.869 rs9461400 ENSG00000280107.1 AL022393.9 -5.51 6.06e-08 2.06e-05 -0.28 -0.25 Parkinson's disease; chr6:27732780 chr6:28170845~28172521:+ LUSC cis rs4713118 0.869 rs9295742 ENSG00000280107.1 AL022393.9 -5.51 6.06e-08 2.06e-05 -0.28 -0.25 Parkinson's disease; chr6:27735053 chr6:28170845~28172521:+ LUSC cis rs4713118 0.869 rs9461401 ENSG00000280107.1 AL022393.9 -5.51 6.06e-08 2.06e-05 -0.28 -0.25 Parkinson's disease; chr6:27735512 chr6:28170845~28172521:+ LUSC cis rs2243480 1 rs35396113 ENSG00000226824.5 RP4-756H11.3 -5.51 6.07e-08 2.06e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66030474 chr7:66654538~66669855:+ LUSC cis rs4834770 0.746 rs2389747 ENSG00000249244.1 RP11-548H18.2 5.51 6.07e-08 2.06e-05 0.3 0.25 Blood protein levels; chr4:119314947 chr4:119391831~119395335:- LUSC cis rs4834770 0.717 rs1022146 ENSG00000249244.1 RP11-548H18.2 5.51 6.07e-08 2.06e-05 0.3 0.25 Blood protein levels; chr4:119314948 chr4:119391831~119395335:- LUSC cis rs910316 0.967 rs175432 ENSG00000279594.1 RP11-950C14.10 -5.51 6.07e-08 2.06e-05 -0.28 -0.25 Height; chr14:75148543 chr14:75011269~75012851:- LUSC cis rs7712401 0.601 rs385547 ENSG00000263432.2 RN7SL689P -5.51 6.07e-08 2.06e-05 -0.32 -0.25 Mean platelet volume; chr5:122986138 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs436546 ENSG00000263432.2 RN7SL689P -5.51 6.07e-08 2.06e-05 -0.32 -0.25 Mean platelet volume; chr5:122987095 chr5:123022487~123022783:- LUSC cis rs1876905 0.68 rs354527 ENSG00000255389.1 C6orf3 5.51 6.08e-08 2.06e-05 0.34 0.25 Mean corpuscular hemoglobin; chr6:111217390 chr6:111599875~111602295:+ LUSC cis rs4604732 0.603 rs4546958 ENSG00000227135.1 GCSAML-AS1 -5.51 6.08e-08 2.06e-05 -0.34 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247476176 chr1:247524679~247526752:- LUSC cis rs4604732 0.642 rs7515859 ENSG00000227135.1 GCSAML-AS1 -5.51 6.08e-08 2.06e-05 -0.34 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247476755 chr1:247524679~247526752:- LUSC cis rs4604732 0.642 rs7549312 ENSG00000227135.1 GCSAML-AS1 -5.51 6.08e-08 2.06e-05 -0.34 -0.25 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247476776 chr1:247524679~247526752:- LUSC cis rs8059260 0.935 rs9928255 ENSG00000274038.1 RP11-66H6.4 -5.51 6.08e-08 2.06e-05 -0.36 -0.25 Alcohol consumption over the past year; chr16:11027408 chr16:11056556~11057034:+ LUSC cis rs763121 0.925 rs17032 ENSG00000273076.1 RP3-508I15.22 5.51 6.08e-08 2.06e-05 0.24 0.25 Menopause (age at onset); chr22:38734838 chr22:38743495~38743910:+ LUSC cis rs66887589 0.627 rs3872807 ENSG00000245958.5 RP11-33B1.1 -5.5 6.08e-08 2.06e-05 -0.23 -0.25 Diastolic blood pressure; chr4:119439096 chr4:119454791~119552025:+ LUSC cis rs8133932 0.736 rs4819159 ENSG00000280604.1 PCBP3-OT1 5.5 6.08e-08 2.06e-05 0.33 0.25 Schizophrenia; chr21:45865691 chr21:45914296~45919483:+ LUSC cis rs7267979 0.753 rs400357 ENSG00000274973.1 RP13-401N8.7 -5.5 6.09e-08 2.07e-05 -0.25 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25498422 chr20:25845497~25845862:+ LUSC cis rs853679 0.628 rs9368560 ENSG00000280107.1 AL022393.9 -5.5 6.09e-08 2.07e-05 -0.31 -0.25 Depression; chr6:28192182 chr6:28170845~28172521:+ LUSC cis rs9611519 1 rs5758264 ENSG00000235513.1 RP4-756G23.5 5.5 6.1e-08 2.07e-05 0.29 0.25 Neuroticism; chr22:41220280 chr22:41209122~41217627:- LUSC cis rs2404602 1 rs4886818 ENSG00000259422.1 RP11-593F23.1 5.5 6.1e-08 2.07e-05 0.28 0.25 Blood metabolite levels; chr15:76588598 chr15:76174891~76181486:- LUSC cis rs2404602 1 rs11072603 ENSG00000259422.1 RP11-593F23.1 5.5 6.1e-08 2.07e-05 0.28 0.25 Blood metabolite levels; chr15:76588797 chr15:76174891~76181486:- LUSC cis rs13113518 0.902 rs12642716 ENSG00000223305.1 RN7SKP30 5.5 6.1e-08 2.07e-05 0.3 0.25 Height; chr4:55479996 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs12501636 ENSG00000223305.1 RN7SKP30 5.5 6.1e-08 2.07e-05 0.3 0.25 Height; chr4:55482317 chr4:55540502~55540835:- LUSC cis rs2842992 0.83 rs1853259 ENSG00000237927.1 RP3-393E18.2 5.5 6.1e-08 2.07e-05 0.36 0.25 Age-related macular degeneration (geographic atrophy); chr6:159726409 chr6:159586955~159589169:- LUSC cis rs2842992 0.789 rs2842969 ENSG00000237927.1 RP3-393E18.2 -5.5 6.1e-08 2.07e-05 -0.36 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159724332 chr6:159586955~159589169:- LUSC cis rs2337406 0.866 rs988131 ENSG00000280411.1 IGHV1-69-2 -5.5 6.11e-08 2.07e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106776833 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs8005518 ENSG00000280411.1 IGHV1-69-2 -5.5 6.11e-08 2.07e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106777009 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs57684263 ENSG00000280411.1 IGHV1-69-2 -5.5 6.11e-08 2.07e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106777263 chr14:106762092~106762588:- LUSC cis rs13113518 0.966 rs4864544 ENSG00000273257.1 RP11-177J6.1 5.5 6.11e-08 2.07e-05 0.31 0.25 Height; chr4:55515292 chr4:55387949~55388271:+ LUSC cis rs9907295 1 rs11657908 ENSG00000270977.1 AC015849.16 -5.5 6.11e-08 2.07e-05 -0.35 -0.25 Fibroblast growth factor basic levels; chr17:35908993 chr17:35893707~35911023:- LUSC cis rs13434995 0.513 rs2171617 ENSG00000249700.7 SRD5A3-AS1 5.5 6.12e-08 2.07e-05 0.32 0.25 Adiponectin levels; chr4:55591023 chr4:55363971~55395847:- LUSC cis rs2439831 0.702 rs28699233 ENSG00000249839.1 AC011330.5 -5.5 6.12e-08 2.07e-05 -0.53 -0.25 Lung cancer in ever smokers; chr15:43830668 chr15:43663654~43684339:- LUSC cis rs7246657 0.722 rs1531549 ENSG00000276846.1 CTD-3220F14.3 5.5 6.13e-08 2.08e-05 0.37 0.25 Coronary artery calcification; chr19:37597108 chr19:37314868~37315620:- LUSC cis rs7246657 0.722 rs1975937 ENSG00000276846.1 CTD-3220F14.3 5.5 6.13e-08 2.08e-05 0.37 0.25 Coronary artery calcification; chr19:37601031 chr19:37314868~37315620:- LUSC cis rs1008375 0.966 rs2191504 ENSG00000249502.1 AC006160.5 -5.5 6.14e-08 2.08e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17673969 chr4:17587467~17614571:- LUSC cis rs1008375 1 rs1121091 ENSG00000249502.1 AC006160.5 -5.5 6.14e-08 2.08e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17674763 chr4:17587467~17614571:- LUSC cis rs1008375 1 rs1121089 ENSG00000249502.1 AC006160.5 -5.5 6.14e-08 2.08e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17674853 chr4:17587467~17614571:- LUSC cis rs1008375 1 rs2315560 ENSG00000249502.1 AC006160.5 -5.5 6.14e-08 2.08e-05 -0.25 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17675682 chr4:17587467~17614571:- LUSC cis rs4366055 1 rs4366055 ENSG00000253704.1 RP11-267M23.4 5.5 6.14e-08 2.08e-05 0.29 0.25 Body mass index; chr8:94495100 chr8:94553722~94569745:+ LUSC cis rs2243480 0.803 rs423187 ENSG00000164669.11 INTS4P1 5.5 6.15e-08 2.08e-05 0.45 0.25 Diabetic kidney disease; chr7:66044512 chr7:65141225~65234216:+ LUSC cis rs8031584 0.541 rs1983459 ENSG00000260382.1 RP11-540B6.2 5.5 6.15e-08 2.08e-05 0.32 0.25 Huntington's disease progression; chr15:30916546 chr15:30882267~30883231:- LUSC cis rs4141404 0.512 rs2070274 ENSG00000236132.1 CTA-440B3.1 5.5 6.16e-08 2.08e-05 0.32 0.25 Paclitaxel-induced neuropathy; chr22:31603237 chr22:31816379~31817491:- LUSC cis rs7712401 0.601 rs154501 ENSG00000263432.2 RN7SL689P 5.5 6.16e-08 2.09e-05 0.3 0.25 Mean platelet volume; chr5:122875899 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs246271 ENSG00000263432.2 RN7SL689P 5.5 6.16e-08 2.09e-05 0.3 0.25 Mean platelet volume; chr5:122877127 chr5:123022487~123022783:- LUSC cis rs2274273 0.84 rs66486619 ENSG00000258413.1 RP11-665C16.6 -5.5 6.16e-08 2.09e-05 -0.3 -0.25 Protein biomarker; chr14:55402837 chr14:55262767~55272075:- LUSC cis rs8177876 0.731 rs79546329 ENSG00000261838.4 RP11-303E16.6 5.5 6.16e-08 2.09e-05 0.64 0.25 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81103636 chr16:81069854~81076598:+ LUSC cis rs8177876 0.731 rs12448806 ENSG00000261838.4 RP11-303E16.6 5.5 6.16e-08 2.09e-05 0.64 0.25 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81104597 chr16:81069854~81076598:+ LUSC cis rs9545047 0.584 rs1886494 ENSG00000227676.3 LINC01068 -5.5 6.17e-08 2.09e-05 -0.3 -0.25 Schizophrenia; chr13:79403005 chr13:79566727~79571436:+ LUSC cis rs7712401 0.601 rs34707663 ENSG00000263432.2 RN7SL689P -5.5 6.18e-08 2.09e-05 -0.32 -0.25 Mean platelet volume; chr5:122984768 chr5:123022487~123022783:- LUSC cis rs11098499 0.908 rs28559989 ENSG00000248280.1 RP11-33B1.2 5.5 6.18e-08 2.09e-05 0.3 0.25 Corneal astigmatism; chr4:119465472 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs28632018 ENSG00000248280.1 RP11-33B1.2 5.5 6.18e-08 2.09e-05 0.3 0.25 Corneal astigmatism; chr4:119465575 chr4:119440561~119450157:- LUSC cis rs13113518 1 rs13122619 ENSG00000272969.1 RP11-528I4.2 5.5 6.18e-08 2.09e-05 0.28 0.25 Height; chr4:55479339 chr4:55547112~55547889:+ LUSC cis rs7712401 0.562 rs246267 ENSG00000263432.2 RN7SL689P 5.5 6.18e-08 2.09e-05 0.31 0.25 Mean platelet volume; chr5:122920409 chr5:123022487~123022783:- LUSC cis rs2243480 1 rs431318 ENSG00000226824.5 RP4-756H11.3 -5.5 6.18e-08 2.09e-05 -0.49 -0.25 Diabetic kidney disease; chr7:66046610 chr7:66654538~66669855:+ LUSC cis rs1008375 0.797 rs6843530 ENSG00000249502.1 AC006160.5 -5.5 6.18e-08 2.09e-05 -0.24 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17591982 chr4:17587467~17614571:- LUSC cis rs367615 0.66 rs10061221 ENSG00000249476.1 CTD-2587M2.1 5.5 6.18e-08 2.09e-05 0.29 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109503337 chr5:109237120~109326369:- LUSC cis rs16863064 0.866 rs9855318 ENSG00000279891.1 FLJ42393 5.5 6.18e-08 2.09e-05 0.37 0.25 Schizophrenia; chr3:188169593 chr3:188178543~188180812:+ LUSC cis rs9545047 0.604 rs1748762 ENSG00000227676.3 LINC01068 5.5 6.2e-08 2.1e-05 0.3 0.25 Schizophrenia; chr13:79407914 chr13:79566727~79571436:+ LUSC cis rs2243480 1 rs6460260 ENSG00000226824.5 RP4-756H11.3 5.5 6.2e-08 2.1e-05 0.48 0.25 Diabetic kidney disease; chr7:65750468 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs6460261 ENSG00000226824.5 RP4-756H11.3 5.5 6.2e-08 2.1e-05 0.48 0.25 Diabetic kidney disease; chr7:65750593 chr7:66654538~66669855:+ LUSC cis rs9601248 0.627 rs2876741 ENSG00000227676.3 LINC01068 -5.5 6.2e-08 2.1e-05 -0.31 -0.25 Major depressive disorder; chr13:79612577 chr13:79566727~79571436:+ LUSC cis rs17711722 0.701 rs55773927 ENSG00000237310.1 GS1-124K5.4 5.5 6.2e-08 2.1e-05 0.25 0.25 Calcium levels; chr7:65872915 chr7:66493706~66495474:+ LUSC cis rs17711722 0.727 rs35850374 ENSG00000237310.1 GS1-124K5.4 5.5 6.2e-08 2.1e-05 0.25 0.25 Calcium levels; chr7:65892789 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs1796222 ENSG00000237310.1 GS1-124K5.4 -5.5 6.21e-08 2.1e-05 -0.28 -0.25 Aortic root size; chr7:66592167 chr7:66493706~66495474:+ LUSC cis rs1528149 0.504 rs12537888 ENSG00000224683.1 RPL36AP29 -5.5 6.21e-08 2.1e-05 -0.28 -0.25 Sitting height ratio; chr7:16127873 chr7:16208945~16209265:+ LUSC cis rs8072100 0.738 rs9900123 ENSG00000228782.6 CTD-2026D20.3 5.5 6.21e-08 2.1e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47471689 chr17:47450568~47492492:- LUSC cis rs17711722 0.522 rs6957759 ENSG00000228409.4 CCT6P1 -5.5 6.21e-08 2.1e-05 -0.19 -0.25 Calcium levels; chr7:65806798 chr7:65751142~65763354:+ LUSC cis rs7247513 0.964 rs12104149 ENSG00000230310.1 CTD-2192J16.11 -5.5 6.21e-08 2.1e-05 -0.3 -0.25 Bipolar disorder; chr19:12610274 chr19:12552597~12553644:+ LUSC cis rs17572109 0.666 rs11696005 ENSG00000261338.2 RP11-378A13.1 -5.5 6.22e-08 2.1e-05 -0.29 -0.25 Platelet count;Platelet distribution width;Mean platelet volume; chr2:218364918 chr2:218255319~218257366:+ LUSC cis rs67311347 1 rs4571217 ENSG00000223797.4 ENTPD3-AS1 5.5 6.22e-08 2.1e-05 0.27 0.25 Renal cell carcinoma; chr3:40480482 chr3:40313802~40453329:- LUSC cis rs2919917 0.578 rs11783804 ENSG00000254352.1 RP11-578O24.2 5.5 6.23e-08 2.11e-05 0.33 0.25 Lymphocyte counts; chr8:78652776 chr8:78723796~78724136:- LUSC cis rs875971 0.54 rs736270 ENSG00000179406.6 LINC00174 -5.5 6.23e-08 2.11e-05 -0.26 -0.25 Aortic root size; chr7:65963835 chr7:66376044~66401338:- LUSC cis rs17361889 0.685 rs62442360 ENSG00000224683.1 RPL36AP29 5.5 6.23e-08 2.11e-05 0.3 0.25 Pediatric bone mineral content (hip); chr7:16103664 chr7:16208945~16209265:+ LUSC cis rs910316 0.81 rs77939209 ENSG00000279594.1 RP11-950C14.10 -5.5 6.23e-08 2.11e-05 -0.28 -0.25 Height; chr14:75203367 chr14:75011269~75012851:- LUSC cis rs853679 1 rs10456362 ENSG00000204709.4 LINC01556 -5.5 6.24e-08 2.11e-05 -0.38 -0.25 Depression; chr6:28254038 chr6:28943877~28944537:+ LUSC cis rs11098499 0.566 rs17051356 ENSG00000248280.1 RP11-33B1.2 5.5 6.24e-08 2.11e-05 0.3 0.25 Corneal astigmatism; chr4:119664153 chr4:119440561~119450157:- LUSC cis rs7083 1 rs664011 ENSG00000254851.1 RP11-109L13.1 5.5 6.24e-08 2.11e-05 0.32 0.25 Blood protein levels; chr11:117237602 chr11:117135528~117138582:+ LUSC cis rs7181230 0.885 rs749748 ENSG00000275636.1 RP11-521C20.5 5.5 6.25e-08 2.11e-05 0.3 0.25 Dehydroepiandrosterone sulphate levels; chr15:40057708 chr15:40078892~40079347:+ LUSC cis rs11098499 0.865 rs2389809 ENSG00000248280.1 RP11-33B1.2 5.5 6.25e-08 2.11e-05 0.3 0.25 Corneal astigmatism; chr4:119456244 chr4:119440561~119450157:- LUSC cis rs4332428 0.881 rs4531365 ENSG00000239148.1 U8 -5.5 6.26e-08 2.12e-05 -0.27 -0.25 Height; chr10:4942141 chr10:5004710~5004842:+ LUSC cis rs2404602 0.967 rs12148805 ENSG00000259422.1 RP11-593F23.1 5.5 6.26e-08 2.12e-05 0.28 0.25 Blood metabolite levels; chr15:76508318 chr15:76174891~76181486:- LUSC cis rs9611519 0.761 rs35445172 ENSG00000235513.1 RP4-756G23.5 5.5 6.26e-08 2.12e-05 0.28 0.25 Neuroticism; chr22:41264297 chr22:41209122~41217627:- LUSC cis rs11098499 0.954 rs7681544 ENSG00000248280.1 RP11-33B1.2 5.5 6.27e-08 2.12e-05 0.29 0.25 Corneal astigmatism; chr4:119490100 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs11940028 ENSG00000248280.1 RP11-33B1.2 5.5 6.27e-08 2.12e-05 0.29 0.25 Corneal astigmatism; chr4:119490752 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs11935596 ENSG00000248280.1 RP11-33B1.2 5.5 6.27e-08 2.12e-05 0.29 0.25 Corneal astigmatism; chr4:119491302 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs12507964 ENSG00000248280.1 RP11-33B1.2 5.5 6.27e-08 2.12e-05 0.29 0.25 Corneal astigmatism; chr4:119491906 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs11098530 ENSG00000248280.1 RP11-33B1.2 5.5 6.27e-08 2.12e-05 0.29 0.25 Corneal astigmatism; chr4:119491999 chr4:119440561~119450157:- LUSC cis rs2554380 0.628 rs919069 ENSG00000230373.7 GOLGA6L5P -5.5 6.27e-08 2.12e-05 -0.25 -0.25 Height; chr15:83775776 chr15:84507885~84516814:- LUSC cis rs7208859 0.524 rs73988172 ENSG00000266490.1 CTD-2349P21.9 5.5 6.27e-08 2.12e-05 0.3 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30792372~30792833:+ LUSC cis rs75920871 0.528 rs7935834 ENSG00000254851.1 RP11-109L13.1 5.5 6.28e-08 2.12e-05 0.33 0.25 Subjective well-being; chr11:117073721 chr11:117135528~117138582:+ LUSC cis rs9532669 0.511 rs3783164 ENSG00000176268.5 CYCSP34 -5.5 6.28e-08 2.12e-05 -0.26 -0.25 Cervical cancer; chr13:40806227 chr13:40863599~40863902:- LUSC cis rs17711722 0.74 rs7809991 ENSG00000237310.1 GS1-124K5.4 5.5 6.28e-08 2.12e-05 0.25 0.25 Calcium levels; chr7:65941231 chr7:66493706~66495474:+ LUSC cis rs9649213 0.574 rs7802560 ENSG00000272950.1 RP11-307C18.1 -5.5 6.28e-08 2.12e-05 -0.32 -0.25 Prostate cancer (SNP x SNP interaction); chr7:98274494 chr7:98322853~98323430:+ LUSC cis rs801193 0.66 rs1962050 ENSG00000237310.1 GS1-124K5.4 -5.5 6.28e-08 2.12e-05 -0.25 -0.25 Aortic root size; chr7:66775021 chr7:66493706~66495474:+ LUSC cis rs3738443 0.868 rs35229190 ENSG00000259865.1 RP11-488L18.10 5.5 6.28e-08 2.12e-05 0.25 0.25 Alcohol dependence; chr1:247202339 chr1:247187281~247188526:- LUSC cis rs11723261 0.582 rs6814287 ENSG00000275426.1 CH17-262A2.1 5.5 6.29e-08 2.12e-05 0.39 0.25 Immune response to smallpox vaccine (IL-6); chr4:122443 chr4:149738~150317:+ LUSC cis rs7772486 0.84 rs2814867 ENSG00000235652.6 RP11-545I5.3 5.5 6.29e-08 2.13e-05 0.24 0.25 Lobe attachment (rater-scored or self-reported); chr6:146012894 chr6:145799409~145886585:+ LUSC cis rs1707322 0.685 rs28617418 ENSG00000234329.1 RP11-767N6.2 5.5 6.3e-08 2.13e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723854 chr1:45651039~45651826:- LUSC cis rs1707322 0.682 rs28490344 ENSG00000234329.1 RP11-767N6.2 5.5 6.3e-08 2.13e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45732276 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs28501477 ENSG00000234329.1 RP11-767N6.2 5.5 6.3e-08 2.13e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45733412 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs28641748 ENSG00000234329.1 RP11-767N6.2 5.5 6.3e-08 2.13e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747164 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs6697821 ENSG00000234329.1 RP11-767N6.2 5.5 6.3e-08 2.13e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751050 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs4330955 ENSG00000234329.1 RP11-767N6.2 5.5 6.3e-08 2.13e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751813 chr1:45651039~45651826:- LUSC cis rs1707322 0.691 rs12031182 ENSG00000234329.1 RP11-767N6.2 5.5 6.3e-08 2.13e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755327 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs10430123 ENSG00000234329.1 RP11-767N6.2 5.5 6.3e-08 2.13e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755768 chr1:45651039~45651826:- LUSC cis rs1707322 0.691 rs11211174 ENSG00000234329.1 RP11-767N6.2 5.5 6.3e-08 2.13e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755144 chr1:45651039~45651826:- LUSC cis rs11098499 0.954 rs13107475 ENSG00000248280.1 RP11-33B1.2 5.5 6.31e-08 2.13e-05 0.3 0.25 Corneal astigmatism; chr4:119471856 chr4:119440561~119450157:- LUSC cis rs13113518 1 rs13122619 ENSG00000223305.1 RN7SKP30 5.5 6.31e-08 2.13e-05 0.3 0.25 Height; chr4:55479339 chr4:55540502~55540835:- LUSC cis rs925255 0.713 rs9309662 ENSG00000270210.1 RP11-373D23.3 -5.5 6.31e-08 2.13e-05 -0.26 -0.25 Inflammatory bowel disease;Crohn's disease; chr2:28407025 chr2:28425945~28426719:+ LUSC cis rs11096990 0.551 rs11724855 ENSG00000249207.1 RP11-360F5.1 -5.5 6.33e-08 2.14e-05 -0.27 -0.25 Cognitive function; chr4:39163379 chr4:39112677~39126818:- LUSC cis rs7712401 0.601 rs154496 ENSG00000263432.2 RN7SL689P 5.5 6.33e-08 2.14e-05 0.3 0.25 Mean platelet volume; chr5:122886036 chr5:123022487~123022783:- LUSC cis rs875971 0.571 rs160641 ENSG00000179406.6 LINC00174 5.5 6.33e-08 2.14e-05 0.29 0.25 Aortic root size; chr7:66112359 chr7:66376044~66401338:- LUSC cis rs41294858 1 rs76732255 ENSG00000232876.1 CTA-212D2.2 -5.5 6.33e-08 2.14e-05 -0.47 -0.25 Red blood cell count; chr6:135087334 chr6:135055033~135060550:+ LUSC cis rs910316 0.763 rs175047 ENSG00000279594.1 RP11-950C14.10 -5.5 6.34e-08 2.14e-05 -0.29 -0.25 Height; chr14:75012336 chr14:75011269~75012851:- LUSC cis rs1075265 0.73 rs7559380 ENSG00000233266.1 HMGB1P31 5.5 6.34e-08 2.14e-05 0.3 0.25 Chronotype;Morning vs. evening chronotype; chr2:54129660 chr2:54051334~54051760:+ LUSC cis rs7160336 0.628 rs12893501 ENSG00000259065.1 RP5-1021I20.1 5.5 6.34e-08 2.14e-05 0.32 0.25 Blood protein levels; chr14:73990459 chr14:73787360~73803270:+ LUSC cis rs853679 1 rs1778511 ENSG00000204709.4 LINC01556 -5.5 6.34e-08 2.14e-05 -0.4 -0.25 Depression; chr6:28261633 chr6:28943877~28944537:+ LUSC cis rs2337406 0.866 rs11488879 ENSG00000211974.3 IGHV2-70 -5.5 6.34e-08 2.14e-05 -0.33 -0.25 Alzheimer's disease (late onset); chr14:106786097 chr14:106723574~106724093:- LUSC cis rs8072100 0.738 rs9915222 ENSG00000228782.6 CTD-2026D20.3 5.5 6.34e-08 2.14e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47371249 chr17:47450568~47492492:- LUSC cis rs2562456 0.917 rs2650825 ENSG00000268081.1 RP11-678G14.2 5.5 6.35e-08 2.14e-05 0.35 0.25 Pain; chr19:21516423 chr19:21554640~21569237:- LUSC cis rs11159086 1 rs72730186 ENSG00000270000.1 RP3-449M8.9 5.5 6.35e-08 2.14e-05 0.41 0.25 Advanced glycation end-product levels; chr14:74475610 chr14:74471930~74472360:- LUSC cis rs11098499 0.954 rs59866101 ENSG00000248280.1 RP11-33B1.2 5.5 6.35e-08 2.14e-05 0.29 0.25 Corneal astigmatism; chr4:119375436 chr4:119440561~119450157:- LUSC cis rs11098499 0.618 rs6858383 ENSG00000248280.1 RP11-33B1.2 5.5 6.35e-08 2.14e-05 0.29 0.25 Corneal astigmatism; chr4:119375617 chr4:119440561~119450157:- LUSC cis rs11098499 0.697 rs6832410 ENSG00000248280.1 RP11-33B1.2 5.5 6.35e-08 2.14e-05 0.29 0.25 Corneal astigmatism; chr4:119375645 chr4:119440561~119450157:- LUSC cis rs1008375 0.966 rs3796813 ENSG00000249502.1 AC006160.5 -5.5 6.36e-08 2.15e-05 -0.24 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17590025 chr4:17587467~17614571:- LUSC cis rs10759883 0.563 rs690063 ENSG00000175611.10 LINC00476 5.5 6.36e-08 2.15e-05 0.29 0.25 Nicotine dependence; chr9:95931019 chr9:95759231~95875977:- LUSC cis rs7712401 0.601 rs257813 ENSG00000263432.2 RN7SL689P 5.5 6.36e-08 2.15e-05 0.3 0.25 Mean platelet volume; chr5:122881473 chr5:123022487~123022783:- LUSC cis rs9326248 0.52 rs10892060 ENSG00000280143.1 AP000892.6 5.5 6.37e-08 2.15e-05 0.25 0.25 Blood protein levels; chr11:117010946 chr11:117204967~117210292:+ LUSC cis rs2337406 0.866 rs7152038 ENSG00000280411.1 IGHV1-69-2 -5.5 6.37e-08 2.15e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106778230 chr14:106762092~106762588:- LUSC cis rs13113518 0.513 rs13132085 ENSG00000273257.1 RP11-177J6.1 -5.5 6.37e-08 2.15e-05 -0.32 -0.25 Height; chr4:55593918 chr4:55387949~55388271:+ LUSC cis rs2439831 0.85 rs16963953 ENSG00000249839.1 AC011330.5 -5.5 6.38e-08 2.15e-05 -0.49 -0.25 Lung cancer in ever smokers; chr15:43789521 chr15:43663654~43684339:- LUSC cis rs12291225 0.637 rs8570 ENSG00000251991.1 RNU7-49P 5.5 6.38e-08 2.15e-05 0.3 0.25 Sense of smell; chr11:14279213 chr11:14478892~14478953:+ LUSC cis rs2243480 1 rs313798 ENSG00000226824.5 RP4-756H11.3 -5.5 6.38e-08 2.15e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66028044 chr7:66654538~66669855:+ LUSC cis rs950169 0.922 rs12906983 ENSG00000259295.5 CSPG4P12 5.5 6.38e-08 2.15e-05 0.33 0.25 Schizophrenia; chr15:84262270 chr15:85191438~85213905:+ LUSC cis rs7211079 0.879 rs66693363 ENSG00000279259.1 RP11-334C17.3 5.5 6.39e-08 2.16e-05 0.29 0.25 Myocardial infarction; chr17:80155136 chr17:80147250~80148596:+ LUSC cis rs2136613 0.779 rs4141614 ENSG00000238280.1 RP11-436D10.3 -5.5 6.4e-08 2.16e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62854095 chr10:62793562~62805887:- LUSC cis rs78487399 0.71 rs79625619 ENSG00000234936.1 AC010883.5 5.5 6.4e-08 2.16e-05 0.38 0.25 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43367344 chr2:43229573~43233394:+ LUSC cis rs1008375 1 rs2315556 ENSG00000249502.1 AC006160.5 -5.5 6.4e-08 2.16e-05 -0.24 -0.25 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17669238 chr4:17587467~17614571:- LUSC cis rs13434995 0.513 rs4865006 ENSG00000249700.7 SRD5A3-AS1 5.5 6.4e-08 2.16e-05 0.31 0.25 Adiponectin levels; chr4:55526112 chr4:55363971~55395847:- LUSC cis rs2243480 0.522 rs431168 ENSG00000164669.11 INTS4P1 5.5 6.41e-08 2.16e-05 0.6 0.25 Diabetic kidney disease; chr7:66046617 chr7:65141225~65234216:+ LUSC cis rs13113518 1 rs6847529 ENSG00000273257.1 RP11-177J6.1 5.49 6.42e-08 2.16e-05 0.31 0.25 Height; chr4:55518776 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs6822740 ENSG00000273257.1 RP11-177J6.1 5.49 6.42e-08 2.16e-05 0.31 0.25 Height; chr4:55518922 chr4:55387949~55388271:+ LUSC cis rs783540 0.967 rs4779044 ENSG00000255769.6 GOLGA2P10 -5.49 6.42e-08 2.16e-05 -0.3 -0.25 Schizophrenia; chr15:82670601 chr15:82472993~82513950:- LUSC cis rs11098499 0.866 rs12501602 ENSG00000248280.1 RP11-33B1.2 5.49 6.42e-08 2.16e-05 0.29 0.25 Corneal astigmatism; chr4:119366780 chr4:119440561~119450157:- LUSC cis rs8040855 0.621 rs6496796 ENSG00000259774.1 RP11-182J1.13 -5.49 6.42e-08 2.17e-05 -0.29 -0.25 Bulimia nervosa; chr15:85183617 chr15:84422618~84425882:+ LUSC cis rs2742234 0.541 rs10899779 ENSG00000273008.1 RP11-351D16.3 5.49 6.42e-08 2.17e-05 0.28 0.25 Hirschsprung disease; chr10:43228528 chr10:43136824~43138334:- LUSC cis rs9309711 0.544 rs9752130 ENSG00000225234.1 TRAPPC12-AS1 -5.49 6.42e-08 2.17e-05 -0.29 -0.25 Neurofibrillary tangles; chr2:3484731 chr2:3481242~3482409:- LUSC cis rs6502050 0.799 rs7406257 ENSG00000266654.1 RP11-1376P16.1 -5.49 6.42e-08 2.17e-05 -0.24 -0.25 Life satisfaction; chr17:82131464 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs8065210 ENSG00000266654.1 RP11-1376P16.1 -5.49 6.42e-08 2.17e-05 -0.24 -0.25 Life satisfaction; chr17:82133084 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs8065556 ENSG00000266654.1 RP11-1376P16.1 -5.49 6.42e-08 2.17e-05 -0.24 -0.25 Life satisfaction; chr17:82133300 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs7503225 ENSG00000266654.1 RP11-1376P16.1 -5.49 6.43e-08 2.17e-05 -0.24 -0.25 Life satisfaction; chr17:82141763 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs4789744 ENSG00000266654.1 RP11-1376P16.1 -5.49 6.43e-08 2.17e-05 -0.24 -0.25 Life satisfaction; chr17:82143630 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs28481866 ENSG00000266654.1 RP11-1376P16.1 -5.49 6.43e-08 2.17e-05 -0.24 -0.25 Life satisfaction; chr17:82147284 chr17:82160056~82160452:+ LUSC cis rs451417 1 rs236122 ENSG00000275632.1 RP5-967N21.11 5.49 6.43e-08 2.17e-05 0.3 0.25 Menopause (age at onset); chr20:5992882 chr20:6000418~6000941:+ LUSC cis rs7772486 0.875 rs2777479 ENSG00000235652.6 RP11-545I5.3 5.49 6.44e-08 2.17e-05 0.25 0.25 Lobe attachment (rater-scored or self-reported); chr6:145988042 chr6:145799409~145886585:+ LUSC cis rs6502050 0.835 rs8075086 ENSG00000266654.1 RP11-1376P16.1 -5.49 6.44e-08 2.17e-05 -0.24 -0.25 Life satisfaction; chr17:82134773 chr17:82160056~82160452:+ LUSC cis rs2742234 0.59 rs1254962 ENSG00000273008.1 RP11-351D16.3 5.49 6.44e-08 2.17e-05 0.28 0.25 Hirschsprung disease; chr10:43201544 chr10:43136824~43138334:- LUSC cis rs2946504 0.705 rs1879487 ENSG00000251468.2 RP11-369K16.1 -5.49 6.45e-08 2.17e-05 -0.3 -0.25 Type 2 diabetes; chr8:12947413 chr8:12958387~12962200:+ LUSC cis rs9545047 0.604 rs1748763 ENSG00000227676.3 LINC01068 5.49 6.45e-08 2.17e-05 0.3 0.25 Schizophrenia; chr13:79407965 chr13:79566727~79571436:+ LUSC cis rs7246657 0.722 rs11083432 ENSG00000276846.1 CTD-3220F14.3 -5.49 6.45e-08 2.18e-05 -0.37 -0.25 Coronary artery calcification; chr19:37691732 chr19:37314868~37315620:- LUSC cis rs1862618 0.853 rs252904 ENSG00000271828.1 CTD-2310F14.1 5.49 6.45e-08 2.18e-05 0.37 0.25 Initial pursuit acceleration; chr5:56822906 chr5:56927874~56929573:+ LUSC cis rs9611519 0.78 rs2235850 ENSG00000235513.1 RP4-756G23.5 5.49 6.46e-08 2.18e-05 0.28 0.25 Neuroticism; chr22:41261622 chr22:41209122~41217627:- LUSC cis rs2919917 0.628 rs1351742 ENSG00000254352.1 RP11-578O24.2 5.49 6.47e-08 2.18e-05 0.32 0.25 Lymphocyte counts; chr8:78655823 chr8:78723796~78724136:- LUSC cis rs2919917 0.666 rs982032 ENSG00000254352.1 RP11-578O24.2 5.49 6.47e-08 2.18e-05 0.32 0.25 Lymphocyte counts; chr8:78655825 chr8:78723796~78724136:- LUSC cis rs67311347 1 rs73076035 ENSG00000223797.4 ENTPD3-AS1 5.49 6.48e-08 2.18e-05 0.28 0.25 Renal cell carcinoma; chr3:40398390 chr3:40313802~40453329:- LUSC cis rs2732480 0.5 rs1552550 ENSG00000273765.1 RP11-370I10.11 5.49 6.48e-08 2.18e-05 0.28 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48249568 chr12:48360920~48361377:+ LUSC cis rs2732480 0.5 rs2450991 ENSG00000273765.1 RP11-370I10.11 5.49 6.48e-08 2.18e-05 0.28 0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48257838 chr12:48360920~48361377:+ LUSC cis rs2243480 1 rs464895 ENSG00000164669.11 INTS4P1 5.49 6.48e-08 2.18e-05 0.45 0.25 Diabetic kidney disease; chr7:66062119 chr7:65141225~65234216:+ LUSC cis rs875971 0.545 rs221986 ENSG00000179406.6 LINC00174 5.49 6.49e-08 2.19e-05 0.29 0.25 Aortic root size; chr7:66105323 chr7:66376044~66401338:- LUSC cis rs9309711 0.698 rs9750503 ENSG00000225234.1 TRAPPC12-AS1 5.49 6.49e-08 2.19e-05 0.32 0.25 Neurofibrillary tangles; chr2:3488001 chr2:3481242~3482409:- LUSC cis rs8028182 0.549 rs7402293 ENSG00000260269.4 CTD-2323K18.1 5.49 6.49e-08 2.19e-05 0.36 0.25 Sudden cardiac arrest; chr15:75343796 chr15:75527150~75601205:- LUSC cis rs875971 0.545 rs10261710 ENSG00000224316.1 RP11-479O9.2 5.49 6.5e-08 2.19e-05 0.27 0.25 Aortic root size; chr7:66249202 chr7:65773620~65802067:+ LUSC cis rs2993535 1 rs7545292 ENSG00000233626.2 RP11-565J7.1 -5.49 6.5e-08 2.19e-05 -0.53 -0.25 Hip circumference adjusted for BMI; chr1:212105716 chr1:211936249~211936634:+ LUSC cis rs2274273 0.87 rs2016931 ENSG00000258413.1 RP11-665C16.6 -5.49 6.5e-08 2.19e-05 -0.3 -0.25 Protein biomarker; chr14:55375614 chr14:55262767~55272075:- LUSC cis rs2439831 0.85 rs8023458 ENSG00000249839.1 AC011330.5 -5.49 6.51e-08 2.19e-05 -0.49 -0.25 Lung cancer in ever smokers; chr15:43788741 chr15:43663654~43684339:- LUSC cis rs4803480 1 rs11882144 ENSG00000270164.1 LINC01480 -5.49 6.51e-08 2.19e-05 -0.22 -0.25 Schizophrenia; chr19:41566244 chr19:41535183~41536904:+ LUSC cis rs988913 0.706 rs6910384 ENSG00000224984.1 RP11-524H19.2 5.49 6.51e-08 2.2e-05 0.26 0.25 Menarche (age at onset); chr6:54879200 chr6:54840118~54840855:- LUSC cis rs9640161 0.742 rs2108854 ENSG00000261305.1 RP4-584D14.7 -5.49 6.52e-08 2.2e-05 -0.34 -0.25 Blood protein levels;Circulating chemerin levels; chr7:150320319 chr7:150341771~150342607:+ LUSC cis rs2243480 0.901 rs2900904 ENSG00000226824.5 RP4-756H11.3 -5.49 6.52e-08 2.2e-05 -0.48 -0.25 Diabetic kidney disease; chr7:65739282 chr7:66654538~66669855:+ LUSC cis rs910316 0.763 rs175014 ENSG00000279594.1 RP11-950C14.10 -5.49 6.52e-08 2.2e-05 -0.29 -0.25 Height; chr14:74990224 chr14:75011269~75012851:- LUSC cis rs2337406 0.866 rs74092520 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106779632 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs4583128 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106780669 chr14:106723574~106724093:- LUSC cis rs2337406 0.929 rs12050200 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106780983 chr14:106723574~106724093:- LUSC cis rs2337406 0.852 rs12050239 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106781132 chr14:106723574~106724093:- LUSC cis rs2337406 0.929 rs59263250 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106781183 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs58083017 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106781256 chr14:106723574~106724093:- LUSC cis rs2337406 0.789 rs60390024 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106781327 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs74092532 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106781363 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs74092534 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106781364 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs74092535 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106781722 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs74092537 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106781883 chr14:106723574~106724093:- LUSC cis rs2337406 0.81 rs74092538 ENSG00000211974.3 IGHV2-70 -5.49 6.52e-08 2.2e-05 -0.32 -0.25 Alzheimer's disease (late onset); chr14:106781942 chr14:106723574~106724093:- LUSC cis rs6597981 0.592 rs10902218 ENSG00000255142.1 AP006621.6 -5.49 6.53e-08 2.2e-05 -0.19 -0.25 Breast cancer; chr11:743813 chr11:781645~782105:+ LUSC cis rs2562456 0.876 rs62110202 ENSG00000268081.1 RP11-678G14.2 5.49 6.53e-08 2.2e-05 0.35 0.25 Pain; chr19:21571799 chr19:21554640~21569237:- LUSC cis rs2337406 0.866 rs79901786 ENSG00000280411.1 IGHV1-69-2 -5.49 6.54e-08 2.2e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106777623 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs7152809 ENSG00000280411.1 IGHV1-69-2 -5.49 6.54e-08 2.2e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106778385 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs7152832 ENSG00000280411.1 IGHV1-69-2 -5.49 6.54e-08 2.2e-05 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106778427 chr14:106762092~106762588:- LUSC cis rs7246657 0.722 rs2909105 ENSG00000276846.1 CTD-3220F14.3 -5.49 6.54e-08 2.2e-05 -0.37 -0.25 Coronary artery calcification; chr19:37677005 chr19:37314868~37315620:- LUSC cis rs944990 0.576 rs7040832 ENSG00000227603.1 RP11-165J3.6 5.49 6.54e-08 2.2e-05 0.24 0.25 Body mass index; chr9:93436508 chr9:93435332~93437121:- LUSC cis rs1707322 0.721 rs28817701 ENSG00000234329.1 RP11-767N6.2 5.49 6.55e-08 2.2e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720378 chr1:45651039~45651826:- LUSC cis rs1707322 0.691 rs28495425 ENSG00000234329.1 RP11-767N6.2 5.49 6.55e-08 2.2e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45721648 chr1:45651039~45651826:- LUSC cis rs11098499 0.644 rs10050092 ENSG00000250412.1 KLHL2P1 5.49 6.55e-08 2.2e-05 0.29 0.25 Corneal astigmatism; chr4:119610930 chr4:119334329~119378233:+ LUSC cis rs12908161 0.853 rs11633788 ENSG00000259728.4 LINC00933 5.49 6.55e-08 2.21e-05 0.3 0.25 Schizophrenia; chr15:84761911 chr15:84570649~84580175:+ LUSC cis rs2404602 0.583 rs3759853 ENSG00000259422.1 RP11-593F23.1 5.49 6.56e-08 2.21e-05 0.28 0.25 Blood metabolite levels; chr15:76295436 chr15:76174891~76181486:- LUSC cis rs1707322 0.717 rs1135812 ENSG00000234329.1 RP11-767N6.2 5.49 6.56e-08 2.21e-05 0.27 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629600 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs6703748 ENSG00000234329.1 RP11-767N6.2 5.49 6.56e-08 2.21e-05 0.27 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45630304 chr1:45651039~45651826:- LUSC cis rs2562456 0.837 rs62110205 ENSG00000268081.1 RP11-678G14.2 5.49 6.56e-08 2.21e-05 0.36 0.25 Pain; chr19:21577269 chr19:21554640~21569237:- LUSC cis rs11098499 0.754 rs938056 ENSG00000250412.1 KLHL2P1 5.49 6.57e-08 2.21e-05 0.3 0.25 Corneal astigmatism; chr4:119316298 chr4:119334329~119378233:+ LUSC cis rs783540 1 rs698500 ENSG00000276710.3 CSPG4P8 5.49 6.57e-08 2.21e-05 0.26 0.25 Schizophrenia; chr15:82569019 chr15:82459472~82477258:+ LUSC cis rs8040855 0.52 rs11629963 ENSG00000259295.5 CSPG4P12 -5.49 6.57e-08 2.21e-05 -0.32 -0.25 Bulimia nervosa; chr15:84986808 chr15:85191438~85213905:+ LUSC cis rs7119038 0.509 rs10892260 ENSG00000255422.1 AP002954.4 5.49 6.58e-08 2.21e-05 0.33 0.25 Sjögren's syndrome; chr11:118712816 chr11:118704607~118750263:+ LUSC cis rs2303759 0.515 rs2334867 ENSG00000268686.1 AC010524.2 5.49 6.58e-08 2.21e-05 0.34 0.25 Multiple sclerosis; chr19:49284948 chr19:49368705~49388081:- LUSC cis rs28830936 1 rs2412622 ENSG00000250379.1 RP11-23P13.4 5.49 6.6e-08 2.22e-05 0.27 0.25 Diastolic blood pressure; chr15:41668113 chr15:41825099~41827936:- LUSC cis rs17270561 0.609 rs6941933 ENSG00000272462.2 U91328.19 -5.49 6.6e-08 2.22e-05 -0.29 -0.25 Iron status biomarkers; chr6:25745474 chr6:25992662~26001775:+ LUSC cis rs13434995 0.513 rs62310862 ENSG00000249700.7 SRD5A3-AS1 -5.49 6.6e-08 2.22e-05 -0.31 -0.25 Adiponectin levels; chr4:55572594 chr4:55363971~55395847:- LUSC cis rs61270009 0.955 rs6874182 ENSG00000247828.6 TMEM161B-AS1 5.49 6.62e-08 2.23e-05 0.28 0.25 Depressive symptoms; chr5:88407268 chr5:88268895~88436685:+ LUSC cis rs9341808 0.628 rs2490245 ENSG00000272129.1 RP11-250B2.6 5.49 6.62e-08 2.23e-05 0.31 0.25 Sitting height ratio; chr6:80182710 chr6:80355424~80356859:+ LUSC cis rs36229146 1 rs36229146 ENSG00000179428.2 AC073072.5 -5.49 6.63e-08 2.23e-05 -0.31 -0.25 Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells; chr7:22744893 chr7:22725395~22727620:- LUSC cis rs783540 0.846 rs2099259 ENSG00000278603.1 RP13-608F4.5 5.49 6.64e-08 2.23e-05 0.29 0.25 Schizophrenia; chr15:82654937 chr15:82472203~82472426:+ LUSC cis rs7429990 1 rs1665982 ENSG00000229759.1 MRPS18AP1 -5.49 6.64e-08 2.23e-05 -0.26 -0.25 Educational attainment (years of education); chr3:47863589 chr3:48256350~48256938:- LUSC cis rs2919917 0.628 rs10111658 ENSG00000254352.1 RP11-578O24.2 5.49 6.64e-08 2.23e-05 0.32 0.25 Lymphocyte counts; chr8:78652834 chr8:78723796~78724136:- LUSC cis rs2919917 0.59 rs10098472 ENSG00000254352.1 RP11-578O24.2 5.49 6.64e-08 2.23e-05 0.32 0.25 Lymphocyte counts; chr8:78652955 chr8:78723796~78724136:- LUSC cis rs2919917 0.628 rs13251931 ENSG00000254352.1 RP11-578O24.2 5.49 6.64e-08 2.23e-05 0.32 0.25 Lymphocyte counts; chr8:78653990 chr8:78723796~78724136:- LUSC cis rs9309711 0.961 rs11890651 ENSG00000225234.1 TRAPPC12-AS1 -5.49 6.64e-08 2.23e-05 -0.32 -0.25 Neurofibrillary tangles; chr2:3479025 chr2:3481242~3482409:- LUSC cis rs28830936 0.966 rs1107858 ENSG00000250379.1 RP11-23P13.4 5.49 6.64e-08 2.23e-05 0.27 0.25 Diastolic blood pressure; chr15:41676028 chr15:41825099~41827936:- LUSC cis rs8072100 0.713 rs9895776 ENSG00000228782.6 CTD-2026D20.3 5.49 6.65e-08 2.24e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47408637 chr17:47450568~47492492:- LUSC cis rs8072100 0.738 rs3736438 ENSG00000228782.6 CTD-2026D20.3 5.49 6.65e-08 2.24e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47409285 chr17:47450568~47492492:- LUSC cis rs2742234 0.541 rs12416428 ENSG00000273008.1 RP11-351D16.3 5.49 6.65e-08 2.24e-05 0.28 0.25 Hirschsprung disease; chr10:43213550 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs11238476 ENSG00000273008.1 RP11-351D16.3 5.49 6.65e-08 2.24e-05 0.28 0.25 Hirschsprung disease; chr10:43215988 chr10:43136824~43138334:- LUSC cis rs6740322 0.748 rs6544634 ENSG00000234936.1 AC010883.5 5.49 6.65e-08 2.24e-05 0.29 0.25 Coronary artery disease; chr2:43244389 chr2:43229573~43233394:+ LUSC cis rs2136613 0.651 rs16917768 ENSG00000238280.1 RP11-436D10.3 -5.49 6.66e-08 2.24e-05 -0.31 -0.25 Selective IgA deficiency; chr10:62864705 chr10:62793562~62805887:- LUSC cis rs9322193 0.961 rs4870144 ENSG00000268592.3 RAET1E-AS1 5.49 6.66e-08 2.24e-05 0.32 0.25 Lung cancer; chr6:149575540 chr6:149863494~149919507:+ LUSC cis rs4964805 0.594 rs3812805 ENSG00000257681.1 RP11-341G23.4 5.49 6.66e-08 2.24e-05 0.27 0.25 Attention deficit hyperactivity disorder; chr12:103777094 chr12:103746315~103768858:- LUSC cis rs11690935 0.851 rs10930502 ENSG00000228389.1 AC068039.4 5.49 6.67e-08 2.24e-05 0.28 0.25 Schizophrenia; chr2:172025679 chr2:171773482~171775844:+ LUSC cis rs6740322 0.901 rs2163228 ENSG00000234936.1 AC010883.5 5.49 6.67e-08 2.24e-05 0.29 0.25 Coronary artery disease; chr2:43322107 chr2:43229573~43233394:+ LUSC cis rs5751168 0.834 rs393829 ENSG00000211654.2 IGLV5-37 5.49 6.68e-08 2.25e-05 0.38 0.25 Prostate cancer (SNP x SNP interaction); chr22:22484081 chr22:22427540~22428035:+ LUSC cis rs6421571 0.565 rs10892263 ENSG00000255422.1 AP002954.4 5.49 6.69e-08 2.25e-05 0.33 0.25 Primary biliary cholangitis; chr11:118716610 chr11:118704607~118750263:+ LUSC cis rs2834288 0.734 rs743336 ENSG00000273102.1 AP000569.9 -5.49 6.69e-08 2.25e-05 -0.28 -0.25 Gut microbiota (bacterial taxa); chr21:33893080 chr21:33967101~33968573:- LUSC cis rs2834288 0.734 rs743337 ENSG00000273102.1 AP000569.9 -5.49 6.69e-08 2.25e-05 -0.28 -0.25 Gut microbiota (bacterial taxa); chr21:33893220 chr21:33967101~33968573:- LUSC cis rs13434995 0.513 rs6554283 ENSG00000249700.7 SRD5A3-AS1 5.49 6.7e-08 2.25e-05 0.31 0.25 Adiponectin levels; chr4:55521053 chr4:55363971~55395847:- LUSC cis rs13434995 0.513 rs1546004 ENSG00000249700.7 SRD5A3-AS1 5.49 6.7e-08 2.25e-05 0.31 0.25 Adiponectin levels; chr4:55521612 chr4:55363971~55395847:- LUSC cis rs853679 0.55 rs34477097 ENSG00000219392.1 RP1-265C24.5 -5.49 6.7e-08 2.25e-05 -0.33 -0.25 Depression; chr6:28229408 chr6:28115628~28116551:+ LUSC cis rs459571 0.92 rs2520094 ENSG00000235106.7 LINC00094 5.49 6.71e-08 2.25e-05 0.27 0.25 Platelet distribution width; chr9:134054863 chr9:134025439~134034666:+ LUSC cis rs2274273 0.87 rs7153612 ENSG00000258413.1 RP11-665C16.6 -5.49 6.71e-08 2.25e-05 -0.3 -0.25 Protein biomarker; chr14:55322044 chr14:55262767~55272075:- LUSC cis rs2274273 0.87 rs11625423 ENSG00000258413.1 RP11-665C16.6 -5.49 6.71e-08 2.25e-05 -0.3 -0.25 Protein biomarker; chr14:55329195 chr14:55262767~55272075:- LUSC cis rs7580658 0.724 rs6712446 ENSG00000236682.1 AC068282.3 -5.49 6.71e-08 2.25e-05 -0.32 -0.25 Protein C levels; chr2:127240823 chr2:127389130~127400580:+ LUSC cis rs7580658 0.724 rs6712551 ENSG00000236682.1 AC068282.3 -5.49 6.71e-08 2.25e-05 -0.32 -0.25 Protein C levels; chr2:127240909 chr2:127389130~127400580:+ LUSC cis rs17193922 0.798 rs7203644 ENSG00000279344.1 RP11-44F14.7 5.49 6.71e-08 2.26e-05 0.24 0.25 Hip circumference adjusted for BMI; chr16:53513297 chr16:53478957~53481550:- LUSC cis rs9311474 0.967 rs11717383 ENSG00000243224.1 RP5-1157M23.2 -5.49 6.71e-08 2.26e-05 -0.24 -0.25 Electroencephalogram traits; chr3:52253452 chr3:52239258~52241097:+ LUSC cis rs17772222 0.74 rs11159857 ENSG00000258789.1 RP11-507K2.3 -5.49 6.72e-08 2.26e-05 -0.28 -0.25 Coronary artery calcification; chr14:88510796 chr14:88551597~88552493:+ LUSC cis rs750134 0.901 rs1549087 ENSG00000257221.1 RP11-689B22.2 -5.49 6.72e-08 2.26e-05 -0.36 -0.25 Low high density lipoprotein cholesterol levels; chr12:108807550 chr12:108628687~108641318:+ LUSC cis rs673078 0.607 rs73207564 ENSG00000275409.1 RP11-131L12.4 -5.49 6.72e-08 2.26e-05 -0.35 -0.25 Glucose homeostasis traits; chr12:118429566 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs61943447 ENSG00000275409.1 RP11-131L12.4 -5.49 6.72e-08 2.26e-05 -0.35 -0.25 Glucose homeostasis traits; chr12:118430598 chr12:118430147~118430699:+ LUSC cis rs875971 0.862 rs1860469 ENSG00000179406.6 LINC00174 5.49 6.73e-08 2.26e-05 0.27 0.25 Aortic root size; chr7:66641888 chr7:66376044~66401338:- LUSC cis rs875971 0.862 rs4718383 ENSG00000179406.6 LINC00174 5.49 6.73e-08 2.26e-05 0.27 0.25 Aortic root size; chr7:66643422 chr7:66376044~66401338:- LUSC cis rs66887589 0.934 rs7681980 ENSG00000245958.5 RP11-33B1.1 5.49 6.73e-08 2.26e-05 0.23 0.25 Diastolic blood pressure; chr4:119612068 chr4:119454791~119552025:+ LUSC cis rs35740288 0.77 rs745191 ENSG00000202081.1 RNU6-1280P 5.49 6.74e-08 2.26e-05 0.3 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85579939 chr15:85651522~85651628:- LUSC cis rs5758265 1 rs5758265 ENSG00000235513.1 RP4-756G23.5 5.49 6.74e-08 2.26e-05 0.29 0.25 Depressive symptoms (multi-trait analysis); chr22:41221893 chr22:41209122~41217627:- LUSC cis rs367615 0.66 rs4632850 ENSG00000249476.1 CTD-2587M2.1 5.49 6.75e-08 2.27e-05 0.29 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109497182 chr5:109237120~109326369:- LUSC cis rs35160687 0.688 rs12466728 ENSG00000273080.1 RP11-301O19.1 -5.49 6.75e-08 2.27e-05 -0.23 -0.25 Night sleep phenotypes; chr2:86256976 chr2:86195590~86196049:+ LUSC cis rs35160687 0.666 rs36104799 ENSG00000273080.1 RP11-301O19.1 -5.49 6.75e-08 2.27e-05 -0.23 -0.25 Night sleep phenotypes; chr2:86257000 chr2:86195590~86196049:+ LUSC cis rs35160687 0.666 rs7583074 ENSG00000273080.1 RP11-301O19.1 -5.49 6.75e-08 2.27e-05 -0.23 -0.25 Night sleep phenotypes; chr2:86257069 chr2:86195590~86196049:+ LUSC cis rs367615 0.704 rs17161885 ENSG00000249476.1 CTD-2587M2.1 5.49 6.75e-08 2.27e-05 0.29 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109516941 chr5:109237120~109326369:- LUSC cis rs11098499 0.738 rs28408407 ENSG00000248280.1 RP11-33B1.2 5.49 6.75e-08 2.27e-05 0.29 0.25 Corneal astigmatism; chr4:119454875 chr4:119440561~119450157:- LUSC cis rs1707322 0.613 rs1473840 ENSG00000280836.1 AL355480.1 5.49 6.76e-08 2.27e-05 0.3 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46135525 chr1:45581219~45581321:- LUSC cis rs4722166 0.568 rs1880241 ENSG00000179428.2 AC073072.5 -5.49 6.76e-08 2.27e-05 -0.29 -0.25 Lung cancer; chr7:22719850 chr7:22725395~22727620:- LUSC cis rs13113518 0.783 rs1586555 ENSG00000273257.1 RP11-177J6.1 5.49 6.76e-08 2.27e-05 0.32 0.25 Height; chr4:55587104 chr4:55387949~55388271:+ LUSC cis rs1056107 0.931 rs7869523 ENSG00000225513.1 RP11-165N19.2 -5.49 6.76e-08 2.27e-05 -0.27 -0.25 Colorectal cancer; chr9:112220269 chr9:112173522~112173971:- LUSC cis rs4964805 0.594 rs751448 ENSG00000257681.1 RP11-341G23.4 5.49 6.77e-08 2.27e-05 0.28 0.25 Attention deficit hyperactivity disorder; chr12:103773407 chr12:103746315~103768858:- LUSC cis rs17772222 0.638 rs11159859 ENSG00000258789.1 RP11-507K2.3 -5.49 6.77e-08 2.27e-05 -0.28 -0.25 Coronary artery calcification; chr14:88561547 chr14:88551597~88552493:+ LUSC cis rs2274273 0.87 rs8021583 ENSG00000258413.1 RP11-665C16.6 -5.48 6.79e-08 2.28e-05 -0.3 -0.25 Protein biomarker; chr14:55282889 chr14:55262767~55272075:- LUSC cis rs2274273 0.837 rs56949365 ENSG00000258413.1 RP11-665C16.6 -5.48 6.79e-08 2.28e-05 -0.3 -0.25 Protein biomarker; chr14:55323360 chr14:55262767~55272075:- LUSC cis rs2274273 0.87 rs4496026 ENSG00000258413.1 RP11-665C16.6 -5.48 6.79e-08 2.28e-05 -0.3 -0.25 Protein biomarker; chr14:55323794 chr14:55262767~55272075:- LUSC cis rs2274273 0.87 rs4366639 ENSG00000258413.1 RP11-665C16.6 -5.48 6.79e-08 2.28e-05 -0.3 -0.25 Protein biomarker; chr14:55323798 chr14:55262767~55272075:- LUSC cis rs6502050 0.799 rs58538819 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.79e-08 2.28e-05 -0.24 -0.25 Life satisfaction; chr17:82149277 chr17:82160056~82160452:+ LUSC cis rs2554380 0.628 rs6602993 ENSG00000230373.7 GOLGA6L5P -5.48 6.79e-08 2.28e-05 -0.25 -0.25 Height; chr15:83813610 chr15:84507885~84516814:- LUSC cis rs957448 0.607 rs12680842 ENSG00000253704.1 RP11-267M23.4 5.48 6.8e-08 2.28e-05 0.28 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94570378 chr8:94553722~94569745:+ LUSC cis rs957448 0.554 rs12680855 ENSG00000253704.1 RP11-267M23.4 5.48 6.8e-08 2.28e-05 0.28 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94570427 chr8:94553722~94569745:+ LUSC cis rs12680842 0.883 rs13265241 ENSG00000253704.1 RP11-267M23.4 5.48 6.8e-08 2.28e-05 0.28 0.25 Body mass index; chr8:94575129 chr8:94553722~94569745:+ LUSC cis rs950169 0.881 rs72750843 ENSG00000259295.5 CSPG4P12 5.48 6.8e-08 2.28e-05 0.34 0.25 Schizophrenia; chr15:84592552 chr15:85191438~85213905:+ LUSC cis rs17361889 0.738 rs35150436 ENSG00000224683.1 RPL36AP29 5.48 6.81e-08 2.28e-05 0.3 0.25 Pediatric bone mineral content (hip); chr7:16147313 chr7:16208945~16209265:+ LUSC cis rs6740322 0.748 rs6727631 ENSG00000234936.1 AC010883.5 5.48 6.81e-08 2.29e-05 0.29 0.25 Coronary artery disease; chr2:43243269 chr2:43229573~43233394:+ LUSC cis rs11951515 0.508 rs11958046 ENSG00000249286.1 CTD-2210P15.2 5.48 6.81e-08 2.29e-05 0.29 0.25 Metabolite levels (X-11787); chr5:43583287 chr5:43586918~43588223:- LUSC cis rs875971 0.545 rs1796226 ENSG00000179406.6 LINC00174 -5.48 6.81e-08 2.29e-05 -0.28 -0.25 Aortic root size; chr7:66622723 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs73142245 ENSG00000179406.6 LINC00174 -5.48 6.81e-08 2.29e-05 -0.29 -0.25 Aortic root size; chr7:66226662 chr7:66376044~66401338:- LUSC cis rs875971 0.558 rs4433015 ENSG00000237310.1 GS1-124K5.4 -5.48 6.82e-08 2.29e-05 -0.25 -0.25 Aortic root size; chr7:66174736 chr7:66493706~66495474:+ LUSC cis rs8072100 0.676 rs9908049 ENSG00000228782.6 CTD-2026D20.3 5.48 6.82e-08 2.29e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47424730 chr17:47450568~47492492:- LUSC cis rs11763147 1 rs11763147 ENSG00000222364.1 RNU6-96P 5.48 6.83e-08 2.29e-05 0.28 0.25 Corneal structure; chr7:65861834 chr7:66395191~66395286:+ LUSC cis rs13113518 1 rs13146987 ENSG00000223305.1 RN7SKP30 5.48 6.83e-08 2.29e-05 0.3 0.25 Height; chr4:55491628 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs7677085 ENSG00000223305.1 RN7SKP30 5.48 6.83e-08 2.29e-05 0.3 0.25 Height; chr4:55495801 chr4:55540502~55540835:- LUSC cis rs13113518 0.966 rs12510681 ENSG00000223305.1 RN7SKP30 5.48 6.83e-08 2.29e-05 0.3 0.25 Height; chr4:55496737 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs12500162 ENSG00000223305.1 RN7SKP30 5.48 6.83e-08 2.29e-05 0.3 0.25 Height; chr4:55496933 chr4:55540502~55540835:- LUSC cis rs2243480 1 rs437889 ENSG00000226824.5 RP4-756H11.3 -5.48 6.84e-08 2.29e-05 -0.48 -0.25 Diabetic kidney disease; chr7:66044247 chr7:66654538~66669855:+ LUSC cis rs1707322 0.752 rs3811436 ENSG00000234329.1 RP11-767N6.2 5.48 6.84e-08 2.29e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660208 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs12024590 ENSG00000234329.1 RP11-767N6.2 5.48 6.84e-08 2.29e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45661824 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs12027622 ENSG00000234329.1 RP11-767N6.2 5.48 6.84e-08 2.29e-05 0.26 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664580 chr1:45651039~45651826:- LUSC cis rs17772222 0.675 rs1099698 ENSG00000258789.1 RP11-507K2.3 5.48 6.84e-08 2.29e-05 0.27 0.25 Coronary artery calcification; chr14:88414904 chr14:88551597~88552493:+ LUSC cis rs910316 0.737 rs2098251 ENSG00000279594.1 RP11-950C14.10 5.48 6.84e-08 2.29e-05 0.28 0.25 Height; chr14:75025993 chr14:75011269~75012851:- LUSC cis rs910316 0.664 rs2098252 ENSG00000279594.1 RP11-950C14.10 5.48 6.84e-08 2.29e-05 0.28 0.25 Height; chr14:75026029 chr14:75011269~75012851:- LUSC cis rs910316 0.737 rs28687415 ENSG00000279594.1 RP11-950C14.10 5.48 6.84e-08 2.29e-05 0.28 0.25 Height; chr14:75028779 chr14:75011269~75012851:- LUSC cis rs367615 0.55 rs10060801 ENSG00000249476.1 CTD-2587M2.1 5.48 6.85e-08 2.3e-05 0.26 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109546081 chr5:109237120~109326369:- LUSC cis rs4722166 0.564 rs1800797 ENSG00000179428.2 AC073072.5 -5.48 6.85e-08 2.3e-05 -0.31 -0.25 Lung cancer; chr7:22726602 chr7:22725395~22727620:- LUSC cis rs11098499 0.754 rs12711071 ENSG00000250412.1 KLHL2P1 5.48 6.86e-08 2.3e-05 0.29 0.25 Corneal astigmatism; chr4:119319779 chr4:119334329~119378233:+ LUSC cis rs6502050 0.835 rs7503189 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82141610 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs9904520 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82142241 chr17:82160056~82160452:+ LUSC cis rs6502050 0.769 rs9898292 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82142469 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs4789681 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82142670 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs4789680 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82142671 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs7503111 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82143711 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs8066370 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82144229 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs8080423 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82144403 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs6502066 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82145861 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs28376857 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82146475 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs12600852 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82146717 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs12603050 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82146755 chr17:82160056~82160452:+ LUSC cis rs6502050 0.764 rs28676462 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82147224 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs28640920 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82147275 chr17:82160056~82160452:+ LUSC cis rs6502050 0.805 rs56020943 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82147372 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs7502524 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82149385 chr17:82160056~82160452:+ LUSC cis rs6502050 0.731 rs76421195 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82151450 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs7502533 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82151902 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs7501461 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.86e-08 2.3e-05 -0.24 -0.25 Life satisfaction; chr17:82151930 chr17:82160056~82160452:+ LUSC cis rs9487051 0.872 rs9487043 ENSG00000219700.1 PTCHD3P3 5.48 6.86e-08 2.3e-05 0.27 0.25 Reticulocyte fraction of red cells; chr6:109289271 chr6:109288571~109290503:- LUSC cis rs3764021 0.527 rs11052423 ENSG00000256975.1 RP11-525E9.1 -5.48 6.87e-08 2.3e-05 -0.32 -0.25 Type 1 diabetes; chr12:9687442 chr12:9506347~9508440:- LUSC cis rs11096990 0.593 rs4580660 ENSG00000249207.1 RP11-360F5.1 -5.48 6.88e-08 2.31e-05 -0.27 -0.25 Cognitive function; chr4:39152216 chr4:39112677~39126818:- LUSC cis rs442309 1 rs224139 ENSG00000238280.1 RP11-436D10.3 -5.48 6.88e-08 2.31e-05 -0.3 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62713956 chr10:62793562~62805887:- LUSC cis rs9322193 0.884 rs10872648 ENSG00000268592.3 RAET1E-AS1 5.48 6.89e-08 2.31e-05 0.33 0.25 Lung cancer; chr6:149758699 chr6:149863494~149919507:+ LUSC cis rs7267979 0.816 rs8115257 ENSG00000274973.1 RP13-401N8.7 -5.48 6.89e-08 2.31e-05 -0.24 -0.25 Liver enzyme levels (alkaline phosphatase); chr20:25227295 chr20:25845497~25845862:+ LUSC cis rs4141404 0.64 rs9606854 ENSG00000236132.1 CTA-440B3.1 -5.48 6.89e-08 2.31e-05 -0.37 -0.25 Paclitaxel-induced neuropathy; chr22:31534581 chr22:31816379~31817491:- LUSC cis rs13326165 0.543 rs60382084 ENSG00000243224.1 RP5-1157M23.2 -5.48 6.89e-08 2.31e-05 -0.42 -0.25 HDL cholesterol levels;HDL cholesterol; chr3:52264145 chr3:52239258~52241097:+ LUSC cis rs412050 1 rs412050 ENSG00000228050.1 TOP3BP1 -5.48 6.9e-08 2.31e-05 -0.36 -0.25 Attention deficit hyperactivity disorder; chr22:21953147 chr22:22223187~22224566:- LUSC cis rs17772222 1 rs17772288 ENSG00000258789.1 RP11-507K2.3 -5.48 6.9e-08 2.31e-05 -0.28 -0.25 Coronary artery calcification; chr14:88361022 chr14:88551597~88552493:+ LUSC cis rs875971 0.545 rs11767262 ENSG00000179406.6 LINC00174 -5.48 6.9e-08 2.31e-05 -0.29 -0.25 Aortic root size; chr7:66302237 chr7:66376044~66401338:- LUSC cis rs17772222 0.917 rs7157149 ENSG00000258789.1 RP11-507K2.3 -5.48 6.9e-08 2.31e-05 -0.29 -0.25 Coronary artery calcification; chr14:88765501 chr14:88551597~88552493:+ LUSC cis rs1707322 0.627 rs3014213 ENSG00000234329.1 RP11-767N6.2 -5.48 6.9e-08 2.31e-05 -0.27 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45579850 chr1:45651039~45651826:- LUSC cis rs1707322 0.686 rs2152078 ENSG00000234329.1 RP11-767N6.2 -5.48 6.9e-08 2.31e-05 -0.27 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45589928 chr1:45651039~45651826:- LUSC cis rs1707322 0.686 rs2991979 ENSG00000234329.1 RP11-767N6.2 -5.48 6.9e-08 2.31e-05 -0.27 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45590186 chr1:45651039~45651826:- LUSC cis rs2337406 0.714 rs115401799 ENSG00000280411.1 IGHV1-69-2 -5.48 6.9e-08 2.31e-05 -0.24 -0.25 Alzheimer's disease (late onset); chr14:106813739 chr14:106762092~106762588:- LUSC cis rs11098499 0.691 rs28396837 ENSG00000249244.1 RP11-548H18.2 5.48 6.9e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119350386 chr4:119391831~119395335:- LUSC cis rs11098499 0.629 rs28369518 ENSG00000249244.1 RP11-548H18.2 5.48 6.9e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119350475 chr4:119391831~119395335:- LUSC cis rs9341808 0.667 rs3805913 ENSG00000272129.1 RP11-250B2.6 5.48 6.91e-08 2.31e-05 0.31 0.25 Sitting height ratio; chr6:80217605 chr6:80355424~80356859:+ LUSC cis rs11098499 0.754 rs878376 ENSG00000250412.1 KLHL2P1 5.48 6.91e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119316547 chr4:119334329~119378233:+ LUSC cis rs11098499 0.789 rs9991166 ENSG00000250412.1 KLHL2P1 5.48 6.91e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119316696 chr4:119334329~119378233:+ LUSC cis rs11098499 0.708 rs10005237 ENSG00000250412.1 KLHL2P1 5.48 6.91e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119316742 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs10213267 ENSG00000250412.1 KLHL2P1 5.48 6.91e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119317919 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs10212775 ENSG00000250412.1 KLHL2P1 5.48 6.91e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119318089 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs11732087 ENSG00000250412.1 KLHL2P1 5.48 6.91e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119318676 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs2964 ENSG00000250412.1 KLHL2P1 5.48 6.91e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119318976 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs1511025 ENSG00000250412.1 KLHL2P1 5.48 6.91e-08 2.31e-05 0.3 0.25 Corneal astigmatism; chr4:119319083 chr4:119334329~119378233:+ LUSC cis rs13113518 1 rs13108499 ENSG00000223305.1 RN7SKP30 5.48 6.91e-08 2.31e-05 0.3 0.25 Height; chr4:55526514 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs3749474 ENSG00000272969.1 RP11-528I4.2 5.48 6.91e-08 2.31e-05 0.28 0.25 Height; chr4:55434518 chr4:55547112~55547889:+ LUSC cis rs6502050 0.835 rs7219138 ENSG00000266654.1 RP11-1376P16.1 5.48 6.91e-08 2.32e-05 0.24 0.25 Life satisfaction; chr17:82122020 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs7219180 ENSG00000266654.1 RP11-1376P16.1 5.48 6.91e-08 2.32e-05 0.24 0.25 Life satisfaction; chr17:82122092 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs7212441 ENSG00000266654.1 RP11-1376P16.1 5.48 6.91e-08 2.32e-05 0.24 0.25 Life satisfaction; chr17:82122171 chr17:82160056~82160452:+ LUSC cis rs4664293 0.585 rs35081473 ENSG00000226266.5 AC009961.3 5.48 6.91e-08 2.32e-05 0.28 0.25 Monocyte percentage of white cells; chr2:159679970 chr2:159670708~159712435:- LUSC cis rs4664293 0.605 rs7556888 ENSG00000226266.5 AC009961.3 5.48 6.91e-08 2.32e-05 0.28 0.25 Monocyte percentage of white cells; chr2:159683750 chr2:159670708~159712435:- LUSC cis rs875971 0.522 rs9530 ENSG00000237310.1 GS1-124K5.4 5.48 6.91e-08 2.32e-05 0.25 0.25 Aortic root size; chr7:65960907 chr7:66493706~66495474:+ LUSC cis rs889398 0.77 rs8052225 ENSG00000226232.7 RP11-419C5.2 -5.48 6.91e-08 2.32e-05 -0.24 -0.25 Body mass index; chr16:69849750 chr16:69976388~69996188:- LUSC cis rs1075265 0.756 rs6751105 ENSG00000233266.1 HMGB1P31 5.48 6.92e-08 2.32e-05 0.31 0.25 Chronotype;Morning vs. evening chronotype; chr2:54129214 chr2:54051334~54051760:+ LUSC cis rs801193 1 rs4717319 ENSG00000237310.1 GS1-124K5.4 5.48 6.92e-08 2.32e-05 0.25 0.25 Aortic root size; chr7:66777606 chr7:66493706~66495474:+ LUSC cis rs801193 0.904 rs4718403 ENSG00000237310.1 GS1-124K5.4 5.48 6.92e-08 2.32e-05 0.25 0.25 Aortic root size; chr7:66777742 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs3778909 ENSG00000237310.1 GS1-124K5.4 5.48 6.92e-08 2.32e-05 0.25 0.25 Aortic root size; chr7:66790659 chr7:66493706~66495474:+ LUSC cis rs7674212 0.531 rs2866416 ENSG00000246560.2 RP11-10L12.4 5.48 6.92e-08 2.32e-05 0.31 0.25 Type 2 diabetes; chr4:102959554 chr4:102828055~102844075:+ LUSC cis rs7712401 0.584 rs30037 ENSG00000263432.2 RN7SL689P 5.48 6.92e-08 2.32e-05 0.31 0.25 Mean platelet volume; chr5:122942295 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs30035 ENSG00000263432.2 RN7SL689P 5.48 6.92e-08 2.32e-05 0.31 0.25 Mean platelet volume; chr5:122942850 chr5:123022487~123022783:- LUSC cis rs739310 0.597 rs739312 ENSG00000206028.1 CTA-373H7.7 -5.48 6.93e-08 2.32e-05 -0.41 -0.25 Obesity-related traits; chr22:26677895 chr22:26667693~26672654:- LUSC cis rs34792 0.525 rs12923446 ENSG00000207425.1 Y_RNA 5.48 6.93e-08 2.32e-05 0.32 0.25 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15509723 chr16:14915457~14915556:- LUSC cis rs2439831 0.85 rs3825783 ENSG00000249839.1 AC011330.5 -5.48 6.93e-08 2.32e-05 -0.49 -0.25 Lung cancer in ever smokers; chr15:43810111 chr15:43663654~43684339:- LUSC cis rs7181230 0.885 rs28826672 ENSG00000275636.1 RP11-521C20.5 5.48 6.94e-08 2.32e-05 0.3 0.25 Dehydroepiandrosterone sulphate levels; chr15:40068165 chr15:40078892~40079347:+ LUSC cis rs9928842 0.664 rs7205074 ENSG00000280152.1 RP11-331F4.5 -5.48 6.95e-08 2.33e-05 -0.28 -0.25 Alcoholic chronic pancreatitis; chr16:75186111 chr16:75245994~75250077:- LUSC cis rs13113518 1 rs11724094 ENSG00000273257.1 RP11-177J6.1 5.48 6.95e-08 2.33e-05 0.31 0.25 Height; chr4:55501479 chr4:55387949~55388271:+ LUSC cis rs950169 0.922 rs11638445 ENSG00000259295.5 CSPG4P12 5.48 6.95e-08 2.33e-05 0.34 0.25 Schizophrenia; chr15:84594463 chr15:85191438~85213905:+ LUSC cis rs35740288 0.929 rs3858927 ENSG00000202081.1 RNU6-1280P 5.48 6.95e-08 2.33e-05 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85758385 chr15:85651522~85651628:- LUSC cis rs10073892 0.667 rs9327842 ENSG00000250682.4 LINC00491 -5.48 6.95e-08 2.33e-05 -0.29 -0.25 Cognitive decline (age-related); chr5:102362134 chr5:102609156~102671559:- LUSC cis rs783540 0.835 rs8030185 ENSG00000255769.6 GOLGA2P10 -5.48 6.96e-08 2.33e-05 -0.3 -0.25 Schizophrenia; chr15:82722785 chr15:82472993~82513950:- LUSC cis rs8072100 0.713 rs8075058 ENSG00000228782.6 CTD-2026D20.3 5.48 6.96e-08 2.33e-05 0.25 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47405491 chr17:47450568~47492492:- LUSC cis rs66887589 0.616 rs11731675 ENSG00000250412.1 KLHL2P1 5.48 6.96e-08 2.33e-05 0.29 0.25 Diastolic blood pressure; chr4:119291359 chr4:119334329~119378233:+ LUSC cis rs442309 0.967 rs224032 ENSG00000238280.1 RP11-436D10.3 -5.48 6.97e-08 2.33e-05 -0.3 -0.25 Vogt-Koyanagi-Harada syndrome; chr10:62762069 chr10:62793562~62805887:- LUSC cis rs7826238 0.564 rs2921053 ENSG00000173295.6 FAM86B3P 5.48 6.97e-08 2.33e-05 0.27 0.25 Systolic blood pressure; chr8:8462453 chr8:8228595~8244865:+ LUSC cis rs6502050 0.835 rs8077926 ENSG00000266654.1 RP11-1376P16.1 -5.48 6.97e-08 2.33e-05 -0.24 -0.25 Life satisfaction; chr17:82159439 chr17:82160056~82160452:+ LUSC cis rs599083 0.744 rs603129 ENSG00000212093.1 AP000807.1 -5.48 6.97e-08 2.33e-05 -0.29 -0.25 Bone mineral density (spine); chr11:68419201 chr11:68506083~68506166:- LUSC cis rs2732480 0.577 rs2634681 ENSG00000273765.1 RP11-370I10.11 -5.48 6.98e-08 2.34e-05 -0.28 -0.25 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48339301 chr12:48360920~48361377:+ LUSC cis rs7804306 0.826 rs112270482 ENSG00000233264.2 AC006042.8 5.48 6.98e-08 2.34e-05 0.48 0.25 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7981281 chr7:7980312~7982228:+ LUSC cis rs2303759 0.626 rs12982246 ENSG00000268686.1 AC010524.2 -5.48 6.98e-08 2.34e-05 -0.35 -0.25 Multiple sclerosis; chr19:49297912 chr19:49368705~49388081:- LUSC cis rs17711722 0.565 rs4275112 ENSG00000228409.4 CCT6P1 5.48 6.99e-08 2.34e-05 0.19 0.25 Calcium levels; chr7:65733651 chr7:65751142~65763354:+ LUSC cis rs11098499 0.754 rs7672778 ENSG00000250412.1 KLHL2P1 5.48 6.99e-08 2.34e-05 0.3 0.25 Corneal astigmatism; chr4:119327430 chr4:119334329~119378233:+ LUSC cis rs34779708 0.733 rs3936503 ENSG00000230534.5 RP11-297A16.2 -5.48 6.99e-08 2.34e-05 -0.27 -0.25 Inflammatory bowel disease;Crohn's disease; chr10:35260329 chr10:35098006~35127020:- LUSC cis rs17711722 0.522 rs4642526 ENSG00000228409.4 CCT6P1 -5.48 7e-08 2.34e-05 -0.19 -0.25 Calcium levels; chr7:65751755 chr7:65751142~65763354:+ LUSC cis rs1008375 0.898 rs10008445 ENSG00000249502.1 AC006160.5 -5.48 7.02e-08 2.35e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17592355 chr4:17587467~17614571:- LUSC cis rs2404602 1 rs12898430 ENSG00000259422.1 RP11-593F23.1 5.48 7.02e-08 2.35e-05 0.27 0.24 Blood metabolite levels; chr15:76582582 chr15:76174891~76181486:- LUSC cis rs75920871 0.528 rs12274465 ENSG00000254851.1 RP11-109L13.1 5.48 7.02e-08 2.35e-05 0.34 0.24 Subjective well-being; chr11:117086473 chr11:117135528~117138582:+ LUSC cis rs4664293 0.718 rs4477859 ENSG00000226266.5 AC009961.3 5.48 7.04e-08 2.36e-05 0.28 0.24 Monocyte percentage of white cells; chr2:159738616 chr2:159670708~159712435:- LUSC cis rs35160687 0.712 rs4832262 ENSG00000273080.1 RP11-301O19.1 -5.48 7.05e-08 2.36e-05 -0.23 -0.24 Night sleep phenotypes; chr2:86258011 chr2:86195590~86196049:+ LUSC cis rs7712401 0.601 rs386602 ENSG00000263432.2 RN7SL689P -5.48 7.05e-08 2.36e-05 -0.32 -0.24 Mean platelet volume; chr5:122986262 chr5:123022487~123022783:- LUSC cis rs11971779 0.878 rs4732378 ENSG00000273391.1 RP11-634H22.1 5.48 7.06e-08 2.36e-05 0.3 0.24 Diisocyanate-induced asthma; chr7:139435649 chr7:139359032~139359566:- LUSC cis rs2732480 0.5 rs11168464 ENSG00000273765.1 RP11-370I10.11 5.48 7.06e-08 2.36e-05 0.28 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48208332 chr12:48360920~48361377:+ LUSC cis rs1387259 0.899 rs7307566 ENSG00000273765.1 RP11-370I10.11 5.48 7.06e-08 2.36e-05 0.28 0.24 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48210899 chr12:48360920~48361377:+ LUSC cis rs17270561 0.609 rs4712970 ENSG00000272462.2 U91328.19 -5.48 7.07e-08 2.36e-05 -0.29 -0.24 Iron status biomarkers; chr6:25770479 chr6:25992662~26001775:+ LUSC cis rs13113518 0.902 rs12503578 ENSG00000273257.1 RP11-177J6.1 5.48 7.07e-08 2.36e-05 0.31 0.24 Height; chr4:55509367 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs3828480 ENSG00000273257.1 RP11-177J6.1 5.48 7.07e-08 2.36e-05 0.31 0.24 Height; chr4:55510352 chr4:55387949~55388271:+ LUSC cis rs17507216 1 rs17158413 ENSG00000276710.3 CSPG4P8 -5.48 7.07e-08 2.36e-05 -0.29 -0.24 Excessive daytime sleepiness; chr15:82566658 chr15:82459472~82477258:+ LUSC cis rs13434995 0.513 rs7660668 ENSG00000249700.7 SRD5A3-AS1 5.48 7.07e-08 2.36e-05 0.31 0.24 Adiponectin levels; chr4:55535530 chr4:55363971~55395847:- LUSC cis rs9326248 0.559 rs573549 ENSG00000280143.1 AP000892.6 5.48 7.07e-08 2.37e-05 0.25 0.24 Blood protein levels; chr11:116865963 chr11:117204967~117210292:+ LUSC cis rs8133932 0.701 rs3788217 ENSG00000280604.1 PCBP3-OT1 5.48 7.08e-08 2.37e-05 0.32 0.24 Schizophrenia; chr21:45867407 chr21:45914296~45919483:+ LUSC cis rs11098499 0.731 rs6846966 ENSG00000250412.1 KLHL2P1 5.48 7.09e-08 2.37e-05 0.3 0.24 Corneal astigmatism; chr4:119372053 chr4:119334329~119378233:+ LUSC cis rs7712401 0.601 rs246282 ENSG00000263432.2 RN7SL689P 5.48 7.1e-08 2.37e-05 0.31 0.24 Mean platelet volume; chr5:122889910 chr5:123022487~123022783:- LUSC cis rs4674676 1 rs4674676 ENSG00000261428.2 RP11-16P6.1 5.48 7.11e-08 2.38e-05 0.36 0.24 Chin dimples; chr2:222664393 chr2:222566899~222569719:- LUSC cis rs10992756 0.551 rs883784 ENSG00000227603.1 RP11-165J3.6 5.48 7.11e-08 2.38e-05 0.23 0.24 Intelligence (multi-trait analysis); chr9:93519954 chr9:93435332~93437121:- LUSC cis rs4141404 0.851 rs9606833 ENSG00000236132.1 CTA-440B3.1 -5.48 7.11e-08 2.38e-05 -0.35 -0.24 Paclitaxel-induced neuropathy; chr22:31354027 chr22:31816379~31817491:- LUSC cis rs17772222 0.74 rs3783885 ENSG00000258789.1 RP11-507K2.3 -5.48 7.12e-08 2.38e-05 -0.28 -0.24 Coronary artery calcification; chr14:88510714 chr14:88551597~88552493:+ LUSC cis rs875971 0.522 rs4502988 ENSG00000237310.1 GS1-124K5.4 5.48 7.13e-08 2.38e-05 0.25 0.24 Aortic root size; chr7:65832759 chr7:66493706~66495474:+ LUSC cis rs55757919 1 rs55757919 ENSG00000231742.4 LINC01273 5.48 7.13e-08 2.38e-05 0.34 0.24 Monocyte percentage of white cells; chr20:50132011 chr20:50172550~50176671:+ LUSC cis rs7615952 0.8 rs12489350 ENSG00000171084.14 FAM86JP 5.48 7.13e-08 2.38e-05 0.32 0.24 Blood pressure (smoking interaction); chr3:125925273 chr3:125916620~125930024:+ LUSC cis rs1707322 0.647 rs6686944 ENSG00000234329.1 RP11-767N6.2 5.48 7.13e-08 2.38e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690636 chr1:45651039~45651826:- LUSC cis rs875971 0.522 rs4502988 ENSG00000179406.6 LINC00174 -5.47 7.14e-08 2.39e-05 -0.26 -0.24 Aortic root size; chr7:65832759 chr7:66376044~66401338:- LUSC cis rs7665090 1 rs909349 ENSG00000230069.3 LRRC37A15P 5.47 7.14e-08 2.39e-05 0.25 0.24 Primary biliary cholangitis; chr4:102635159 chr4:102727274~102730721:- LUSC cis rs6502050 0.835 rs9902485 ENSG00000266654.1 RP11-1376P16.1 -5.47 7.14e-08 2.39e-05 -0.24 -0.24 Life satisfaction; chr17:82135825 chr17:82160056~82160452:+ LUSC cis rs2136613 0.533 rs7088601 ENSG00000238280.1 RP11-436D10.3 -5.47 7.14e-08 2.39e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62846627 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10740087 ENSG00000238280.1 RP11-436D10.3 -5.47 7.14e-08 2.39e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62847511 chr10:62793562~62805887:- LUSC cis rs34375054 0.624 rs7295689 ENSG00000279233.1 RP11-158L12.4 5.47 7.15e-08 2.39e-05 0.24 0.24 Post bronchodilator FEV1/FVC ratio; chr12:125196376 chr12:125138245~125141711:+ LUSC cis rs673078 0.66 rs17440336 ENSG00000275759.1 RP11-131L12.3 5.47 7.15e-08 2.39e-05 0.36 0.24 Glucose homeostasis traits; chr12:118163305 chr12:118428281~118428870:+ LUSC cis rs6570726 0.791 rs414297 ENSG00000235652.6 RP11-545I5.3 5.47 7.15e-08 2.39e-05 0.24 0.24 Lobe attachment (rater-scored or self-reported); chr6:145566420 chr6:145799409~145886585:+ LUSC cis rs2562456 0.92 rs2650784 ENSG00000268081.1 RP11-678G14.2 -5.47 7.15e-08 2.39e-05 -0.34 -0.24 Pain; chr19:21483795 chr19:21554640~21569237:- LUSC cis rs6502050 0.871 rs8082577 ENSG00000266654.1 RP11-1376P16.1 5.47 7.16e-08 2.39e-05 0.25 0.24 Life satisfaction; chr17:82112705 chr17:82160056~82160452:+ LUSC cis rs11098499 0.754 rs10518300 ENSG00000250412.1 KLHL2P1 -5.47 7.16e-08 2.39e-05 -0.31 -0.24 Corneal astigmatism; chr4:119328344 chr4:119334329~119378233:+ LUSC cis rs7712401 0.601 rs30072 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122956525 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs30069 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122957331 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs30067 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122957973 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs187405 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122959300 chr5:123022487~123022783:- LUSC cis rs7712401 0.562 rs30062 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122960681 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs30060 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122961005 chr5:123022487~123022783:- LUSC cis rs7712401 0.525 rs2910150 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122961050 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs30059 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122961814 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs30058 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122962008 chr5:123022487~123022783:- LUSC cis rs7712401 0.623 rs30057 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122962423 chr5:123022487~123022783:- LUSC cis rs7712401 0.584 rs39820 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122964226 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs30055 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122965384 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs39819 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122965981 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs30054 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122966304 chr5:123022487~123022783:- LUSC cis rs7712401 0.562 rs30053 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122967948 chr5:123022487~123022783:- LUSC cis rs7712401 0.562 rs30052 ENSG00000263432.2 RN7SL689P 5.47 7.16e-08 2.39e-05 0.31 0.24 Mean platelet volume; chr5:122969314 chr5:123022487~123022783:- LUSC cis rs2136613 0.533 rs10761673 ENSG00000238280.1 RP11-436D10.3 -5.47 7.17e-08 2.39e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62855691 chr10:62793562~62805887:- LUSC cis rs9326248 0.539 rs10892058 ENSG00000280143.1 AP000892.6 5.47 7.17e-08 2.39e-05 0.25 0.24 Blood protein levels; chr11:117005905 chr11:117204967~117210292:+ LUSC cis rs9326248 0.52 rs7127881 ENSG00000280143.1 AP000892.6 5.47 7.17e-08 2.39e-05 0.25 0.24 Blood protein levels; chr11:117010082 chr11:117204967~117210292:+ LUSC cis rs7911264 0.967 rs2497318 ENSG00000236493.2 EIF2S2P3 -5.47 7.18e-08 2.4e-05 -0.29 -0.24 Inflammatory bowel disease; chr10:92672243 chr10:92668745~92669743:- LUSC cis rs62025270 0.547 rs338520 ENSG00000202081.1 RNU6-1280P 5.47 7.18e-08 2.4e-05 0.29 0.24 Idiopathic pulmonary fibrosis; chr15:85671567 chr15:85651522~85651628:- LUSC cis rs2303759 0.666 rs66967196 ENSG00000268686.1 AC010524.2 -5.47 7.18e-08 2.4e-05 -0.36 -0.24 Multiple sclerosis; chr19:49305637 chr19:49368705~49388081:- LUSC cis rs11098499 0.954 rs2389802 ENSG00000248280.1 RP11-33B1.2 5.47 7.18e-08 2.4e-05 0.3 0.24 Corneal astigmatism; chr4:119404577 chr4:119440561~119450157:- LUSC cis rs7712401 0.562 rs30073 ENSG00000263432.2 RN7SL689P 5.47 7.19e-08 2.4e-05 0.31 0.24 Mean platelet volume; chr5:122954814 chr5:123022487~123022783:- LUSC cis rs875971 0.545 rs73150604 ENSG00000224316.1 RP11-479O9.2 5.47 7.2e-08 2.4e-05 0.27 0.24 Aortic root size; chr7:66480545 chr7:65773620~65802067:+ LUSC cis rs7429990 0.864 rs13085978 ENSG00000229759.1 MRPS18AP1 5.47 7.2e-08 2.4e-05 0.25 0.24 Educational attainment (years of education); chr3:47608585 chr3:48256350~48256938:- LUSC cis rs7429990 0.727 rs61675361 ENSG00000229759.1 MRPS18AP1 5.47 7.2e-08 2.4e-05 0.25 0.24 Educational attainment (years of education); chr3:47610630 chr3:48256350~48256938:- LUSC cis rs867371 0.502 rs8025964 ENSG00000278603.1 RP13-608F4.5 5.47 7.2e-08 2.4e-05 0.29 0.24 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82229429 chr15:82472203~82472426:+ LUSC cis rs41294858 1 rs41294856 ENSG00000232876.1 CTA-212D2.2 -5.47 7.21e-08 2.4e-05 -0.47 -0.24 Red blood cell count; chr6:135091244 chr6:135055033~135060550:+ LUSC cis rs73173548 0.528 rs12189274 ENSG00000247828.6 TMEM161B-AS1 -5.47 7.22e-08 2.41e-05 -0.29 -0.24 Macular telangiectasia type 2; chr5:88468669 chr5:88268895~88436685:+ LUSC cis rs5770917 0.522 rs5770916 ENSG00000273272.1 CTA-384D8.34 -5.47 7.22e-08 2.41e-05 -0.35 -0.24 Narcolepsy; chr22:50577669 chr22:50542650~50543011:+ LUSC cis rs889398 0.802 rs2291959 ENSG00000226232.7 RP11-419C5.2 -5.47 7.23e-08 2.41e-05 -0.24 -0.24 Body mass index; chr16:69840089 chr16:69976388~69996188:- LUSC cis rs6951245 0.507 rs10227709 ENSG00000224079.1 AC091729.7 -5.47 7.23e-08 2.41e-05 -0.35 -0.24 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1140879 chr7:1074450~1078036:+ LUSC cis rs6502050 0.835 rs10163483 ENSG00000266654.1 RP11-1376P16.1 -5.47 7.24e-08 2.41e-05 -0.24 -0.24 Life satisfaction; chr17:82152520 chr17:82160056~82160452:+ LUSC cis rs6430553 0.929 rs6430547 ENSG00000224043.6 CCNT2-AS1 5.47 7.24e-08 2.42e-05 0.3 0.24 Blood metabolite levels; chr2:134854852 chr2:134735464~134918710:- LUSC cis rs4938330 0.68 rs4938329 ENSG00000254851.1 RP11-109L13.1 5.47 7.24e-08 2.42e-05 0.33 0.24 Blood protein levels; chr11:117057396 chr11:117135528~117138582:+ LUSC cis rs13326165 0.585 rs1767 ENSG00000243224.1 RP5-1157M23.2 -5.47 7.24e-08 2.42e-05 -0.4 -0.24 HDL cholesterol levels;HDL cholesterol; chr3:52256458 chr3:52239258~52241097:+ LUSC cis rs8133932 0.667 rs3788218 ENSG00000280604.1 PCBP3-OT1 5.47 7.24e-08 2.42e-05 0.33 0.24 Schizophrenia; chr21:45867418 chr21:45914296~45919483:+ LUSC cis rs1008375 0.931 rs7435102 ENSG00000249502.1 AC006160.5 -5.47 7.24e-08 2.42e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17569857 chr4:17587467~17614571:- LUSC cis rs17772222 0.74 rs11847417 ENSG00000258789.1 RP11-507K2.3 5.47 7.25e-08 2.42e-05 0.28 0.24 Coronary artery calcification; chr14:88510606 chr14:88551597~88552493:+ LUSC cis rs9322193 0.887 rs4870139 ENSG00000268592.3 RAET1E-AS1 5.47 7.25e-08 2.42e-05 0.32 0.24 Lung cancer; chr6:149575182 chr6:149863494~149919507:+ LUSC cis rs13113518 1 rs4864994 ENSG00000272969.1 RP11-528I4.2 5.47 7.25e-08 2.42e-05 0.28 0.24 Height; chr4:55451955 chr4:55547112~55547889:+ LUSC cis rs9611519 0.78 rs2284079 ENSG00000235513.1 RP4-756G23.5 5.47 7.25e-08 2.42e-05 0.28 0.24 Neuroticism; chr22:41262628 chr22:41209122~41217627:- LUSC cis rs1707322 0.752 rs61784793 ENSG00000234329.1 RP11-767N6.2 5.47 7.25e-08 2.42e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45683613 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs4586014 ENSG00000234329.1 RP11-767N6.2 5.47 7.25e-08 2.42e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684771 chr1:45651039~45651826:- LUSC cis rs1707322 0.648 rs4439382 ENSG00000234329.1 RP11-767N6.2 5.47 7.25e-08 2.42e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45685133 chr1:45651039~45651826:- LUSC cis rs9516 0.564 rs10898993 ENSG00000254974.1 RP11-702H23.2 5.47 7.26e-08 2.42e-05 0.25 0.24 Facial morphology (factor 15, philtrum width); chr11:74463919 chr11:74485580~74486051:- LUSC cis rs2243480 1 rs313814 ENSG00000226824.5 RP4-756H11.3 -5.47 7.26e-08 2.42e-05 -0.48 -0.24 Diabetic kidney disease; chr7:66038306 chr7:66654538~66669855:+ LUSC cis rs3002131 0.522 rs2378583 ENSG00000225265.1 TAF1A-AS1 -5.47 7.26e-08 2.42e-05 -0.37 -0.24 Interleukin-10 levels; chr1:222565958 chr1:222589825~222593032:+ LUSC cis rs8031584 0.56 rs1056118 ENSG00000260382.1 RP11-540B6.2 -5.47 7.26e-08 2.42e-05 -0.32 -0.24 Huntington's disease progression; chr15:30911583 chr15:30882267~30883231:- LUSC cis rs875971 0.522 rs2949690 ENSG00000237310.1 GS1-124K5.4 -5.47 7.26e-08 2.42e-05 -0.25 -0.24 Aortic root size; chr7:66018255 chr7:66493706~66495474:+ LUSC cis rs875971 0.545 rs13311962 ENSG00000224316.1 RP11-479O9.2 -5.47 7.27e-08 2.42e-05 -0.26 -0.24 Aortic root size; chr7:66603142 chr7:65773620~65802067:+ LUSC cis rs17711722 0.701 rs55773927 ENSG00000222364.1 RNU6-96P -5.47 7.27e-08 2.42e-05 -0.28 -0.24 Calcium levels; chr7:65872915 chr7:66395191~66395286:+ LUSC cis rs17711722 0.727 rs35850374 ENSG00000222364.1 RNU6-96P -5.47 7.27e-08 2.42e-05 -0.28 -0.24 Calcium levels; chr7:65892789 chr7:66395191~66395286:+ LUSC cis rs2136613 0.533 rs1571922 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62851189 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10822066 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62851432 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10740091 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62851628 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10822067 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62851949 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10761669 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62852050 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10509173 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62852129 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10822068 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62852505 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10822069 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62853482 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10995331 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62853948 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10822070 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62854149 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs4141617 ENSG00000238280.1 RP11-436D10.3 -5.47 7.27e-08 2.42e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62854308 chr10:62793562~62805887:- LUSC cis rs1345301 1 rs12475055 ENSG00000234389.1 AC007278.3 5.47 7.28e-08 2.43e-05 0.23 0.24 Waist circumference; chr2:102262431 chr2:102438713~102440475:+ LUSC cis rs1707322 0.752 rs11211173 ENSG00000234329.1 RP11-767N6.2 5.47 7.29e-08 2.43e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45753704 chr1:45651039~45651826:- LUSC cis rs17772222 0.727 rs3179969 ENSG00000258983.2 RP11-507K2.2 5.47 7.29e-08 2.43e-05 0.26 0.24 Coronary artery calcification; chr14:88396185 chr14:88499334~88515502:+ LUSC cis rs875971 0.545 rs73376394 ENSG00000179406.6 LINC00174 -5.47 7.29e-08 2.43e-05 -0.29 -0.24 Aortic root size; chr7:66172694 chr7:66376044~66401338:- LUSC cis rs1707322 0.65 rs4553239 ENSG00000234329.1 RP11-767N6.2 5.47 7.29e-08 2.43e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684814 chr1:45651039~45651826:- LUSC cis rs7246657 0.551 rs10419174 ENSG00000276846.1 CTD-3220F14.3 5.47 7.29e-08 2.43e-05 0.4 0.24 Coronary artery calcification; chr19:37114439 chr19:37314868~37315620:- LUSC cis rs17772222 0.638 rs11629164 ENSG00000258789.1 RP11-507K2.3 5.47 7.29e-08 2.43e-05 0.28 0.24 Coronary artery calcification; chr14:88564740 chr14:88551597~88552493:+ LUSC cis rs10759883 0.627 rs689804 ENSG00000175611.10 LINC00476 5.47 7.3e-08 2.43e-05 0.29 0.24 Nicotine dependence; chr9:95868574 chr9:95759231~95875977:- LUSC cis rs1707322 0.721 rs10890337 ENSG00000234329.1 RP11-767N6.2 5.47 7.3e-08 2.43e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658855 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs3811435 ENSG00000234329.1 RP11-767N6.2 5.47 7.3e-08 2.43e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660118 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs9793568 ENSG00000234329.1 RP11-767N6.2 5.47 7.3e-08 2.43e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664701 chr1:45651039~45651826:- LUSC cis rs11098499 0.618 rs35265692 ENSG00000248280.1 RP11-33B1.2 5.47 7.3e-08 2.43e-05 0.3 0.24 Corneal astigmatism; chr4:119403980 chr4:119440561~119450157:- LUSC cis rs13434995 0.513 rs55885973 ENSG00000249700.7 SRD5A3-AS1 -5.47 7.3e-08 2.43e-05 -0.31 -0.24 Adiponectin levels; chr4:55480054 chr4:55363971~55395847:- LUSC cis rs14027 0.883 rs16893025 ENSG00000279347.1 RP11-85I17.2 -5.47 7.3e-08 2.43e-05 -0.23 -0.24 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119701440 chr8:119838736~119840385:- LUSC cis rs944990 0.597 rs61707921 ENSG00000227603.1 RP11-165J3.6 5.47 7.3e-08 2.43e-05 0.24 0.24 Body mass index; chr9:93475813 chr9:93435332~93437121:- LUSC cis rs4722166 0.63 rs6969258 ENSG00000179428.2 AC073072.5 -5.47 7.31e-08 2.43e-05 -0.3 -0.24 Lung cancer; chr7:22742909 chr7:22725395~22727620:- LUSC cis rs9545047 0.553 rs7332004 ENSG00000227676.3 LINC01068 -5.47 7.31e-08 2.44e-05 -0.3 -0.24 Schizophrenia; chr13:79364128 chr13:79566727~79571436:+ LUSC cis rs8072100 0.582 rs3826536 ENSG00000228782.6 CTD-2026D20.3 5.47 7.31e-08 2.44e-05 0.25 0.24 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47424601 chr17:47450568~47492492:- LUSC cis rs4713118 0.824 rs742046 ENSG00000280107.1 AL022393.9 -5.47 7.32e-08 2.44e-05 -0.28 -0.24 Parkinson's disease; chr6:27771475 chr6:28170845~28172521:+ LUSC cis rs75920871 0.528 rs11216245 ENSG00000254851.1 RP11-109L13.1 5.47 7.32e-08 2.44e-05 0.33 0.24 Subjective well-being; chr11:117042486 chr11:117135528~117138582:+ LUSC cis rs7674212 0.507 rs223331 ENSG00000246560.2 RP11-10L12.4 5.47 7.32e-08 2.44e-05 0.31 0.24 Type 2 diabetes; chr4:102872408 chr4:102828055~102844075:+ LUSC cis rs4713118 0.868 rs2893928 ENSG00000280107.1 AL022393.9 -5.47 7.33e-08 2.44e-05 -0.31 -0.24 Parkinson's disease; chr6:27770651 chr6:28170845~28172521:+ LUSC cis rs13113518 1 rs3762837 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55511198 chr4:55387949~55388271:+ LUSC cis rs2617170 0.922 rs2617149 ENSG00000245648.1 RP11-277P12.20 -5.47 7.33e-08 2.44e-05 -0.29 -0.24 Behcet's disease; chr12:10375734 chr12:10363769~10398506:+ LUSC cis rs2337406 0.81 rs7161739 ENSG00000280411.1 IGHV1-69-2 -5.47 7.33e-08 2.44e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106776118 chr14:106762092~106762588:- LUSC cis rs13113518 0.934 rs3805155 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55497842 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs7686261 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55500224 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11729220 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55501629 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11133390 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55501726 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11133391 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55501788 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs13133484 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55504176 chr4:55387949~55388271:+ LUSC cis rs13113518 0.934 rs13127906 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55504201 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs6849433 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55506498 chr4:55387949~55388271:+ LUSC cis rs13113518 0.966 rs12501327 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55507248 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs11133392 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55507729 chr4:55387949~55388271:+ LUSC cis rs13113518 1 rs6838305 ENSG00000273257.1 RP11-177J6.1 5.47 7.33e-08 2.44e-05 0.31 0.24 Height; chr4:55508587 chr4:55387949~55388271:+ LUSC cis rs875971 0.502 rs6460311 ENSG00000237310.1 GS1-124K5.4 -5.47 7.33e-08 2.44e-05 -0.28 -0.24 Aortic root size; chr7:66646886 chr7:66493706~66495474:+ LUSC cis rs13113518 1 rs1047354 ENSG00000272969.1 RP11-528I4.2 5.47 7.34e-08 2.44e-05 0.28 0.24 Height; chr4:55429416 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs1056547 ENSG00000272969.1 RP11-528I4.2 5.47 7.34e-08 2.44e-05 0.28 0.24 Height; chr4:55430596 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs1056545 ENSG00000272969.1 RP11-528I4.2 5.47 7.34e-08 2.44e-05 0.28 0.24 Height; chr4:55430730 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs5863 ENSG00000272969.1 RP11-528I4.2 5.47 7.34e-08 2.44e-05 0.28 0.24 Height; chr4:55430740 chr4:55547112~55547889:+ LUSC cis rs13113518 0.966 rs6828570 ENSG00000272969.1 RP11-528I4.2 5.47 7.34e-08 2.44e-05 0.28 0.24 Height; chr4:55431595 chr4:55547112~55547889:+ LUSC cis rs2337406 0.929 rs12050233 ENSG00000211974.3 IGHV2-70 -5.47 7.34e-08 2.44e-05 -0.31 -0.24 Alzheimer's disease (late onset); chr14:106781123 chr14:106723574~106724093:- LUSC cis rs2337406 0.852 rs12050466 ENSG00000211974.3 IGHV2-70 -5.47 7.34e-08 2.44e-05 -0.31 -0.24 Alzheimer's disease (late onset); chr14:106781131 chr14:106723574~106724093:- LUSC cis rs2337406 0.866 rs8003852 ENSG00000211974.3 IGHV2-70 -5.47 7.34e-08 2.45e-05 -0.32 -0.24 Alzheimer's disease (late onset); chr14:106776648 chr14:106723574~106724093:- LUSC cis rs875971 0.545 rs4441996 ENSG00000179406.6 LINC00174 5.47 7.35e-08 2.45e-05 0.29 0.24 Aortic root size; chr7:66123233 chr7:66376044~66401338:- LUSC cis rs1008375 0.966 rs3775924 ENSG00000249502.1 AC006160.5 -5.47 7.35e-08 2.45e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17584361 chr4:17587467~17614571:- LUSC cis rs1008375 0.898 rs7670500 ENSG00000249502.1 AC006160.5 -5.47 7.35e-08 2.45e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17585334 chr4:17587467~17614571:- LUSC cis rs1008375 0.966 rs7675735 ENSG00000249502.1 AC006160.5 -5.47 7.35e-08 2.45e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17585514 chr4:17587467~17614571:- LUSC cis rs1008375 0.898 rs4698620 ENSG00000249502.1 AC006160.5 -5.47 7.35e-08 2.45e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17585738 chr4:17587467~17614571:- LUSC cis rs1008375 0.966 rs4698621 ENSG00000249502.1 AC006160.5 -5.47 7.35e-08 2.45e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17585942 chr4:17587467~17614571:- LUSC cis rs9640161 0.636 rs3735171 ENSG00000261305.1 RP4-584D14.7 5.47 7.35e-08 2.45e-05 0.35 0.24 Blood protein levels;Circulating chemerin levels; chr7:150336793 chr7:150341771~150342607:+ LUSC cis rs442309 0.846 rs224049 ENSG00000238280.1 RP11-436D10.3 -5.47 7.35e-08 2.45e-05 -0.31 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62732673 chr10:62793562~62805887:- LUSC cis rs28830936 1 rs2004162 ENSG00000250379.1 RP11-23P13.4 5.47 7.36e-08 2.45e-05 0.27 0.24 Diastolic blood pressure; chr15:41673344 chr15:41825099~41827936:- LUSC cis rs4845875 0.514 rs198406 ENSG00000242349.4 NPPA-AS1 -5.47 7.36e-08 2.45e-05 -0.24 -0.24 Midregional pro atrial natriuretic peptide levels; chr1:11837535 chr1:11841017~11848079:+ LUSC cis rs2732480 0.5 rs7315820 ENSG00000273765.1 RP11-370I10.11 5.47 7.36e-08 2.45e-05 0.28 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48205155 chr12:48360920~48361377:+ LUSC cis rs2732480 0.577 rs2634693 ENSG00000240399.1 RP1-228P16.1 5.47 7.37e-08 2.45e-05 0.26 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48312715 chr12:48054813~48055591:- LUSC cis rs2732480 0.577 rs2634691 ENSG00000240399.1 RP1-228P16.1 5.47 7.37e-08 2.45e-05 0.26 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48314476 chr12:48054813~48055591:- LUSC cis rs2742234 0.911 rs3004214 ENSG00000273008.1 RP11-351D16.3 -5.47 7.37e-08 2.45e-05 -0.26 -0.24 Hirschsprung disease; chr10:43136250 chr10:43136824~43138334:- LUSC cis rs1008375 0.898 rs61047804 ENSG00000249502.1 AC006160.5 -5.47 7.37e-08 2.45e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17592342 chr4:17587467~17614571:- LUSC cis rs13326165 0.585 rs11706541 ENSG00000243224.1 RP5-1157M23.2 -5.47 7.37e-08 2.45e-05 -0.4 -0.24 HDL cholesterol levels;HDL cholesterol; chr3:52252333 chr3:52239258~52241097:+ LUSC cis rs910316 1 rs12897094 ENSG00000279594.1 RP11-950C14.10 5.47 7.37e-08 2.45e-05 0.28 0.24 Height; chr14:75112713 chr14:75011269~75012851:- LUSC cis rs17772222 0.74 rs10138002 ENSG00000258789.1 RP11-507K2.3 5.47 7.37e-08 2.45e-05 0.28 0.24 Coronary artery calcification; chr14:88510071 chr14:88551597~88552493:+ LUSC cis rs13434995 0.513 rs4336288 ENSG00000249700.7 SRD5A3-AS1 5.47 7.37e-08 2.45e-05 0.31 0.24 Adiponectin levels; chr4:55584088 chr4:55363971~55395847:- LUSC cis rs270601 0.721 rs270621 ENSG00000233006.5 AC034220.3 5.47 7.38e-08 2.46e-05 0.25 0.24 Acylcarnitine levels; chr5:132270128 chr5:132311285~132369916:- LUSC cis rs8031584 0.672 rs17815726 ENSG00000260382.1 RP11-540B6.2 -5.47 7.38e-08 2.46e-05 -0.36 -0.24 Huntington's disease progression; chr15:31021049 chr15:30882267~30883231:- LUSC cis rs67311347 1 rs4973989 ENSG00000223797.4 ENTPD3-AS1 5.47 7.39e-08 2.46e-05 0.29 0.24 Renal cell carcinoma; chr3:40410052 chr3:40313802~40453329:- LUSC cis rs11098499 0.69 rs34818745 ENSG00000248280.1 RP11-33B1.2 5.47 7.39e-08 2.46e-05 0.29 0.24 Corneal astigmatism; chr4:119335900 chr4:119440561~119450157:- LUSC cis rs3169166 0.521 rs62007839 ENSG00000259562.2 RP11-762H8.2 5.47 7.39e-08 2.46e-05 0.19 0.24 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78278533 chr15:78290527~78291221:- LUSC cis rs1707322 0.752 rs28550303 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723242 chr1:45651039~45651826:- LUSC cis rs1707322 0.716 rs28375469 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45729703 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs28545085 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736278 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs28719889 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736611 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs28812624 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45738064 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs28507722 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45740868 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs28568986 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45742071 chr1:45651039~45651826:- LUSC cis rs1707322 0.717 rs28396194 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747555 chr1:45651039~45651826:- LUSC cis rs1707322 0.717 rs28752166 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747637 chr1:45651039~45651826:- LUSC cis rs1707322 0.717 rs10890345 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45748255 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs10789471 ENSG00000234329.1 RP11-767N6.2 5.47 7.4e-08 2.46e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45749947 chr1:45651039~45651826:- LUSC cis rs1008375 0.931 rs4479701 ENSG00000249502.1 AC006160.5 -5.47 7.4e-08 2.46e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17569873 chr4:17587467~17614571:- LUSC cis rs7829975 0.582 rs6983150 ENSG00000254340.1 RP11-10A14.3 -5.47 7.4e-08 2.46e-05 -0.3 -0.24 Mood instability; chr8:8934916 chr8:9141424~9145435:+ LUSC cis rs7727544 0.735 rs272842 ENSG00000233006.5 AC034220.3 5.47 7.41e-08 2.47e-05 0.23 0.24 Blood metabolite levels; chr5:132320824 chr5:132311285~132369916:- LUSC cis rs7083 0.875 rs536648 ENSG00000254851.1 RP11-109L13.1 5.47 7.42e-08 2.47e-05 0.31 0.24 Blood protein levels; chr11:117272469 chr11:117135528~117138582:+ LUSC cis rs9341808 0.539 rs2490253 ENSG00000272129.1 RP11-250B2.6 5.47 7.42e-08 2.47e-05 0.31 0.24 Sitting height ratio; chr6:80186153 chr6:80355424~80356859:+ LUSC cis rs237743 1 rs238150 ENSG00000222365.1 SNORD12B -5.47 7.43e-08 2.47e-05 -0.27 -0.24 Height; chr20:49235382 chr20:49280319~49280409:+ LUSC cis rs1707322 0.717 rs1972410 ENSG00000234329.1 RP11-767N6.2 5.47 7.43e-08 2.47e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615275 chr1:45651039~45651826:- LUSC cis rs2554380 0.628 rs2081541 ENSG00000230373.7 GOLGA6L5P -5.47 7.43e-08 2.47e-05 -0.24 -0.24 Height; chr15:83774934 chr15:84507885~84516814:- LUSC cis rs9601248 0.627 rs9545151 ENSG00000227676.3 LINC01068 -5.47 7.43e-08 2.47e-05 -0.31 -0.24 Major depressive disorder; chr13:79608400 chr13:79566727~79571436:+ LUSC cis rs17270561 0.609 rs4132072 ENSG00000272462.2 U91328.19 -5.47 7.44e-08 2.48e-05 -0.29 -0.24 Iron status biomarkers; chr6:25717615 chr6:25992662~26001775:+ LUSC cis rs9659323 0.7 rs10923746 ENSG00000231365.4 RP11-418J17.1 -5.47 7.44e-08 2.48e-05 -0.28 -0.24 Body mass index; chr1:119073655 chr1:119140396~119275973:+ LUSC cis rs11105298 0.891 rs10777163 ENSG00000258302.2 RP11-981P6.1 5.47 7.45e-08 2.48e-05 0.25 0.24 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89436943 chr12:89561129~89594878:+ LUSC cis rs35740288 0.822 rs4843092 ENSG00000202081.1 RNU6-1280P 5.47 7.45e-08 2.48e-05 0.31 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85689949 chr15:85651522~85651628:- LUSC cis rs13113518 1 rs10462032 ENSG00000223305.1 RN7SKP30 5.47 7.46e-08 2.48e-05 0.3 0.24 Height; chr4:55479069 chr4:55540502~55540835:- LUSC cis rs390966 0.585 rs13420242 ENSG00000205847.5 OR7E91P -5.47 7.46e-08 2.48e-05 -0.35 -0.24 Erythema nodosum in inflammatory bowel disease; chr2:71036638 chr2:71029028~71029893:+ LUSC cis rs6502050 0.835 rs62078305 ENSG00000266654.1 RP11-1376P16.1 5.47 7.46e-08 2.48e-05 0.25 0.24 Life satisfaction; chr17:82127450 chr17:82160056~82160452:+ LUSC cis rs2337406 0.866 rs8012619 ENSG00000280411.1 IGHV1-69-2 -5.47 7.46e-08 2.48e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106793907 chr14:106762092~106762588:- LUSC cis rs1707322 0.691 rs61784803 ENSG00000234329.1 RP11-767N6.2 -5.47 7.46e-08 2.48e-05 -0.26 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45713599 chr1:45651039~45651826:- LUSC cis rs1707322 0.663 rs3935296 ENSG00000234329.1 RP11-767N6.2 -5.47 7.46e-08 2.48e-05 -0.26 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45714798 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs11211163 ENSG00000234329.1 RP11-767N6.2 5.47 7.46e-08 2.48e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45687876 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs12037803 ENSG00000234329.1 RP11-767N6.2 5.47 7.46e-08 2.48e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690820 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs10789470 ENSG00000234329.1 RP11-767N6.2 5.47 7.46e-08 2.48e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692659 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs61784796 ENSG00000234329.1 RP11-767N6.2 5.47 7.46e-08 2.48e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697584 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs10749856 ENSG00000234329.1 RP11-767N6.2 5.47 7.46e-08 2.48e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45699174 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs10890344 ENSG00000234329.1 RP11-767N6.2 5.47 7.46e-08 2.48e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45700418 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs4564187 ENSG00000234329.1 RP11-767N6.2 5.47 7.46e-08 2.48e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701189 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs28438704 ENSG00000234329.1 RP11-767N6.2 5.47 7.46e-08 2.48e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45704872 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs28442079 ENSG00000234329.1 RP11-767N6.2 5.47 7.46e-08 2.48e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706329 chr1:45651039~45651826:- LUSC cis rs9640161 0.75 rs3735167 ENSG00000261305.1 RP4-584D14.7 5.47 7.46e-08 2.48e-05 0.36 0.24 Blood protein levels;Circulating chemerin levels; chr7:150342466 chr7:150341771~150342607:+ LUSC cis rs875971 0.502 rs2465121 ENSG00000179406.6 LINC00174 5.47 7.47e-08 2.48e-05 0.29 0.24 Aortic root size; chr7:66156017 chr7:66376044~66401338:- LUSC cis rs1008375 0.966 rs2010053 ENSG00000249502.1 AC006160.5 -5.47 7.47e-08 2.48e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17582183 chr4:17587467~17614571:- LUSC cis rs1008375 0.966 rs1476836 ENSG00000249502.1 AC006160.5 -5.47 7.47e-08 2.48e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17583391 chr4:17587467~17614571:- LUSC cis rs801193 1 rs2055682 ENSG00000237310.1 GS1-124K5.4 5.47 7.48e-08 2.49e-05 0.25 0.24 Aortic root size; chr7:66795302 chr7:66493706~66495474:+ LUSC cis rs61270009 0.738 rs73171756 ENSG00000247828.6 TMEM161B-AS1 5.47 7.48e-08 2.49e-05 0.29 0.24 Depressive symptoms; chr5:88446454 chr5:88268895~88436685:+ LUSC cis rs875971 0.522 rs7784623 ENSG00000237310.1 GS1-124K5.4 5.47 7.49e-08 2.49e-05 0.25 0.24 Aortic root size; chr7:65930047 chr7:66493706~66495474:+ LUSC cis rs1008375 0.966 rs3733576 ENSG00000249502.1 AC006160.5 -5.47 7.49e-08 2.49e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17585080 chr4:17587467~17614571:- LUSC cis rs2243480 0.901 rs2456483 ENSG00000226824.5 RP4-756H11.3 -5.47 7.49e-08 2.49e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65996588 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs1701750 ENSG00000226824.5 RP4-756H11.3 -5.47 7.49e-08 2.49e-05 -0.48 -0.24 Diabetic kidney disease; chr7:66002158 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs1701758 ENSG00000226824.5 RP4-756H11.3 -5.47 7.49e-08 2.49e-05 -0.48 -0.24 Diabetic kidney disease; chr7:66005214 chr7:66654538~66669855:+ LUSC cis rs7955901 0.761 rs907721 ENSG00000257265.1 CTD-2021H9.1 -5.47 7.5e-08 2.49e-05 -0.28 -0.24 Type 2 diabetes; chr12:71042257 chr12:71007773~71032083:- LUSC cis rs10829156 0.679 rs4748476 ENSG00000240291.1 RP11-499P20.2 5.47 7.5e-08 2.49e-05 0.27 0.24 Sudden cardiac arrest; chr10:18503946 chr10:18513115~18545651:- LUSC cis rs17711722 0.701 rs4467826 ENSG00000237310.1 GS1-124K5.4 5.47 7.51e-08 2.5e-05 0.25 0.24 Calcium levels; chr7:65903721 chr7:66493706~66495474:+ LUSC cis rs61270009 0.955 rs10214154 ENSG00000247828.6 TMEM161B-AS1 -5.47 7.52e-08 2.5e-05 -0.29 -0.24 Depressive symptoms; chr5:88249502 chr5:88268895~88436685:+ LUSC cis rs950169 0.922 rs11633534 ENSG00000259295.5 CSPG4P12 5.47 7.52e-08 2.5e-05 0.33 0.24 Schizophrenia; chr15:84581411 chr15:85191438~85213905:+ LUSC cis rs950169 0.65 rs12902052 ENSG00000259295.5 CSPG4P12 5.47 7.52e-08 2.5e-05 0.33 0.24 Schizophrenia; chr15:84582607 chr15:85191438~85213905:+ LUSC cis rs2439831 0.867 rs2470134 ENSG00000249839.1 AC011330.5 5.47 7.52e-08 2.5e-05 0.48 0.24 Lung cancer in ever smokers; chr15:43557688 chr15:43663654~43684339:- LUSC cis rs11096990 0.572 rs35040563 ENSG00000249207.1 RP11-360F5.1 -5.46 7.53e-08 2.5e-05 -0.26 -0.24 Cognitive function; chr4:39154262 chr4:39112677~39126818:- LUSC cis rs891378 0.876 rs1367067 ENSG00000274245.1 RP11-357P18.2 5.46 7.54e-08 2.5e-05 0.33 0.24 Spherical equivalent (joint analysis main effects and education interaction); chr1:207269019 chr1:207372559~207373252:+ LUSC cis rs11676348 0.791 rs4133195 ENSG00000261338.2 RP11-378A13.1 5.46 7.54e-08 2.51e-05 0.23 0.24 Ulcerative colitis; chr2:218086522 chr2:218255319~218257366:+ LUSC cis rs2439831 0.867 rs2260160 ENSG00000249839.1 AC011330.5 -5.46 7.54e-08 2.51e-05 -0.46 -0.24 Lung cancer in ever smokers; chr15:43603445 chr15:43663654~43684339:- LUSC cis rs13113518 1 rs4865004 ENSG00000273257.1 RP11-177J6.1 5.46 7.54e-08 2.51e-05 0.31 0.24 Height; chr4:55515118 chr4:55387949~55388271:+ LUSC cis rs988913 0.706 rs10948870 ENSG00000224984.1 RP11-524H19.2 5.46 7.55e-08 2.51e-05 0.26 0.24 Menarche (age at onset); chr6:54880300 chr6:54840118~54840855:- LUSC cis rs7772486 0.79 rs1133832 ENSG00000235652.6 RP11-545I5.3 -5.46 7.55e-08 2.51e-05 -0.23 -0.24 Lobe attachment (rater-scored or self-reported); chr6:145884468 chr6:145799409~145886585:+ LUSC cis rs35740288 0.731 rs11634651 ENSG00000202081.1 RNU6-1280P 5.46 7.55e-08 2.51e-05 0.3 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85550695 chr15:85651522~85651628:- LUSC cis rs7246657 0.524 rs10411251 ENSG00000276846.1 CTD-3220F14.3 5.46 7.56e-08 2.51e-05 0.38 0.24 Coronary artery calcification; chr19:36937853 chr19:37314868~37315620:- LUSC cis rs11096990 0.634 rs6829064 ENSG00000249207.1 RP11-360F5.1 5.46 7.57e-08 2.51e-05 0.26 0.24 Cognitive function; chr4:39290192 chr4:39112677~39126818:- LUSC cis rs13434995 0.513 rs13133077 ENSG00000249700.7 SRD5A3-AS1 5.46 7.57e-08 2.51e-05 0.31 0.24 Adiponectin levels; chr4:55577642 chr4:55363971~55395847:- LUSC cis rs1008375 0.931 rs6449309 ENSG00000249502.1 AC006160.5 -5.46 7.57e-08 2.51e-05 -0.25 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17571585 chr4:17587467~17614571:- LUSC cis rs988913 0.768 rs9396003 ENSG00000224984.1 RP11-524H19.2 5.46 7.57e-08 2.52e-05 0.26 0.24 Menarche (age at onset); chr6:54877055 chr6:54840118~54840855:- LUSC cis rs13113518 0.812 rs6849474 ENSG00000273257.1 RP11-177J6.1 5.46 7.58e-08 2.52e-05 0.32 0.24 Height; chr4:55452295 chr4:55387949~55388271:+ LUSC cis rs13113518 0.812 rs4864996 ENSG00000273257.1 RP11-177J6.1 5.46 7.58e-08 2.52e-05 0.32 0.24 Height; chr4:55452921 chr4:55387949~55388271:+ LUSC cis rs13113518 0.812 rs2412648 ENSG00000273257.1 RP11-177J6.1 5.46 7.58e-08 2.52e-05 0.32 0.24 Height; chr4:55454900 chr4:55387949~55388271:+ LUSC cis rs13113518 0.812 rs12512737 ENSG00000273257.1 RP11-177J6.1 5.46 7.58e-08 2.52e-05 0.32 0.24 Height; chr4:55454938 chr4:55387949~55388271:+ LUSC cis rs13113518 0.812 rs13125984 ENSG00000273257.1 RP11-177J6.1 5.46 7.58e-08 2.52e-05 0.32 0.24 Height; chr4:55455102 chr4:55387949~55388271:+ LUSC cis rs7804306 1 rs34059590 ENSG00000233264.2 AC006042.8 5.46 7.58e-08 2.52e-05 0.42 0.24 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8026584 chr7:7980312~7982228:+ LUSC cis rs875971 0.545 rs7783889 ENSG00000179406.6 LINC00174 -5.46 7.58e-08 2.52e-05 -0.29 -0.24 Aortic root size; chr7:66283366 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs73376401 ENSG00000179406.6 LINC00174 -5.46 7.59e-08 2.52e-05 -0.29 -0.24 Aortic root size; chr7:66174841 chr7:66376044~66401338:- LUSC cis rs9659323 0.67 rs6701378 ENSG00000231365.4 RP11-418J17.1 -5.46 7.6e-08 2.52e-05 -0.28 -0.24 Body mass index; chr1:119095930 chr1:119140396~119275973:+ LUSC cis rs5742933 1 rs4666783 ENSG00000253559.1 OSGEPL1-AS1 -5.46 7.6e-08 2.53e-05 -0.32 -0.24 Ferritin levels; chr2:189748254 chr2:189762704~189765556:+ LUSC cis rs12468226 1 rs58288071 ENSG00000272966.1 RP11-686O6.1 5.46 7.61e-08 2.53e-05 0.39 0.24 Urate levels; chr2:202350016 chr2:202336739~202337200:+ LUSC cis rs1862618 0.627 rs744023 ENSG00000271828.1 CTD-2310F14.1 5.46 7.61e-08 2.53e-05 0.4 0.24 Initial pursuit acceleration; chr5:56901251 chr5:56927874~56929573:+ LUSC cis rs10759883 0.627 rs13294931 ENSG00000175611.10 LINC00476 -5.46 7.62e-08 2.53e-05 -0.28 -0.24 Nicotine dependence; chr9:95833220 chr9:95759231~95875977:- LUSC cis rs950169 0.922 rs2033284 ENSG00000259295.5 CSPG4P12 5.46 7.63e-08 2.53e-05 0.33 0.24 Schizophrenia; chr15:84391575 chr15:85191438~85213905:+ LUSC cis rs2274273 0.87 rs59629906 ENSG00000258413.1 RP11-665C16.6 -5.46 7.64e-08 2.54e-05 -0.3 -0.24 Protein biomarker; chr14:55314471 chr14:55262767~55272075:- LUSC cis rs4964805 0.594 rs954920 ENSG00000257681.1 RP11-341G23.4 5.46 7.65e-08 2.54e-05 0.28 0.24 Attention deficit hyperactivity disorder; chr12:103779532 chr12:103746315~103768858:- LUSC cis rs1056107 0.897 rs7851034 ENSG00000225513.1 RP11-165N19.2 -5.46 7.65e-08 2.54e-05 -0.27 -0.24 Colorectal cancer; chr9:112193100 chr9:112173522~112173971:- LUSC cis rs875971 0.545 rs313830 ENSG00000224316.1 RP11-479O9.2 -5.46 7.66e-08 2.54e-05 -0.26 -0.24 Aortic root size; chr7:66086944 chr7:65773620~65802067:+ LUSC cis rs7181230 0.961 rs7183977 ENSG00000275636.1 RP11-521C20.5 -5.46 7.66e-08 2.54e-05 -0.29 -0.24 Dehydroepiandrosterone sulphate levels; chr15:40084891 chr15:40078892~40079347:+ LUSC cis rs1707322 0.752 rs28890893 ENSG00000234329.1 RP11-767N6.2 5.46 7.69e-08 2.55e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720904 chr1:45651039~45651826:- LUSC cis rs7208859 0.623 rs7220999 ENSG00000266490.1 CTD-2349P21.9 5.46 7.69e-08 2.55e-05 0.3 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822280 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs55638872 ENSG00000266490.1 CTD-2349P21.9 5.46 7.69e-08 2.55e-05 0.3 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822534 chr17:30792372~30792833:+ LUSC cis rs7208859 0.623 rs9899268 ENSG00000266490.1 CTD-2349P21.9 5.46 7.69e-08 2.55e-05 0.3 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30823237 chr17:30792372~30792833:+ LUSC cis rs2243480 1 rs427044 ENSG00000164669.11 INTS4P1 5.46 7.69e-08 2.55e-05 0.45 0.24 Diabetic kidney disease; chr7:66043558 chr7:65141225~65234216:+ LUSC cis rs227275 0.525 rs7698608 ENSG00000246560.2 RP11-10L12.4 5.46 7.69e-08 2.55e-05 0.29 0.24 Allergic disease (asthma, hay fever or eczema); chr4:103016817 chr4:102828055~102844075:+ LUSC cis rs875971 0.545 rs316324 ENSG00000179406.6 LINC00174 5.46 7.7e-08 2.55e-05 0.29 0.24 Aortic root size; chr7:66145627 chr7:66376044~66401338:- LUSC cis rs875971 0.545 rs316323 ENSG00000179406.6 LINC00174 5.46 7.7e-08 2.55e-05 0.29 0.24 Aortic root size; chr7:66146002 chr7:66376044~66401338:- LUSC cis rs227275 0.554 rs223367 ENSG00000246560.2 RP11-10L12.4 5.46 7.7e-08 2.56e-05 0.3 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102843836 chr4:102828055~102844075:+ LUSC cis rs1876905 0.597 rs1215964 ENSG00000255389.1 C6orf3 5.46 7.71e-08 2.56e-05 0.33 0.24 Mean corpuscular hemoglobin; chr6:111225666 chr6:111599875~111602295:+ LUSC cis rs11096990 0.634 rs11947159 ENSG00000249207.1 RP11-360F5.1 5.46 7.71e-08 2.56e-05 0.26 0.24 Cognitive function; chr4:39286900 chr4:39112677~39126818:- LUSC cis rs11096990 0.634 rs10019594 ENSG00000249207.1 RP11-360F5.1 5.46 7.71e-08 2.56e-05 0.26 0.24 Cognitive function; chr4:39287127 chr4:39112677~39126818:- LUSC cis rs6740322 0.748 rs6756625 ENSG00000234936.1 AC010883.5 -5.46 7.71e-08 2.56e-05 -0.28 -0.24 Coronary artery disease; chr2:43262174 chr2:43229573~43233394:+ LUSC cis rs8133932 0.701 rs9637207 ENSG00000280604.1 PCBP3-OT1 5.46 7.72e-08 2.56e-05 0.32 0.24 Schizophrenia; chr21:45863445 chr21:45914296~45919483:+ LUSC cis rs6502050 0.835 rs10163482 ENSG00000266654.1 RP11-1376P16.1 -5.46 7.72e-08 2.56e-05 -0.24 -0.24 Life satisfaction; chr17:82152518 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs6502068 ENSG00000266654.1 RP11-1376P16.1 -5.46 7.72e-08 2.56e-05 -0.24 -0.24 Life satisfaction; chr17:82154347 chr17:82160056~82160452:+ LUSC cis rs2337406 0.789 rs9324095 ENSG00000280411.1 IGHV1-69-2 -5.46 7.72e-08 2.56e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106795885 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs58154560 ENSG00000280411.1 IGHV1-69-2 -5.46 7.72e-08 2.56e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106799601 chr14:106762092~106762588:- LUSC cis rs77204473 0.744 rs80143284 ENSG00000254851.1 RP11-109L13.1 5.46 7.73e-08 2.56e-05 0.57 0.24 Sum eosinophil basophil counts;Eosinophil counts; chr11:117042854 chr11:117135528~117138582:+ LUSC cis rs2243480 1 rs313813 ENSG00000226824.5 RP4-756H11.3 -5.46 7.74e-08 2.57e-05 -0.47 -0.24 Diabetic kidney disease; chr7:66038513 chr7:66654538~66669855:+ LUSC cis rs2742234 0.541 rs7098236 ENSG00000273008.1 RP11-351D16.3 5.46 7.75e-08 2.57e-05 0.28 0.24 Hirschsprung disease; chr10:43245060 chr10:43136824~43138334:- LUSC cis rs1864400 0.69 rs7098237 ENSG00000273008.1 RP11-351D16.3 5.46 7.75e-08 2.57e-05 0.28 0.24 Hirschsprung disease; chr10:43245065 chr10:43136824~43138334:- LUSC cis rs2303759 0.67 rs45549132 ENSG00000268686.1 AC010524.2 -5.46 7.75e-08 2.57e-05 -0.35 -0.24 Multiple sclerosis; chr19:49290771 chr19:49368705~49388081:- LUSC cis rs2880765 0.566 rs12911430 ENSG00000259295.5 CSPG4P12 5.46 7.76e-08 2.57e-05 0.28 0.24 Coronary artery disease; chr15:85468033 chr15:85191438~85213905:+ LUSC cis rs4713118 0.869 rs9461405 ENSG00000280107.1 AL022393.9 -5.46 7.77e-08 2.58e-05 -0.27 -0.24 Parkinson's disease; chr6:27751596 chr6:28170845~28172521:+ LUSC cis rs875971 0.545 rs17138156 ENSG00000179406.6 LINC00174 -5.46 7.77e-08 2.58e-05 -0.29 -0.24 Aortic root size; chr7:66249708 chr7:66376044~66401338:- LUSC cis rs35740288 0.822 rs17637142 ENSG00000202081.1 RNU6-1280P 5.46 7.77e-08 2.58e-05 0.31 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85697272 chr15:85651522~85651628:- LUSC cis rs875971 0.522 rs6960048 ENSG00000237310.1 GS1-124K5.4 5.46 7.77e-08 2.58e-05 0.25 0.24 Aortic root size; chr7:65943052 chr7:66493706~66495474:+ LUSC cis rs4654783 1 rs4654783 ENSG00000228397.1 RP1-224A6.3 5.46 7.78e-08 2.58e-05 0.3 0.24 Endometriosis; chr1:22113027 chr1:22023994~22024968:- LUSC cis rs875971 0.545 rs1547529 ENSG00000179406.6 LINC00174 -5.46 7.78e-08 2.58e-05 -0.29 -0.24 Aortic root size; chr7:66258859 chr7:66376044~66401338:- LUSC cis rs10462794 0.661 rs16873563 ENSG00000260763.1 RP11-445O3.3 -5.46 7.79e-08 2.58e-05 -0.32 -0.24 DNA methylation (variation); chr5:4521716 chr5:4436850~4440259:- LUSC cis rs9341835 0.518 rs6942342 ENSG00000218048.2 RP3-407E4.4 5.46 7.79e-08 2.58e-05 0.29 0.24 Schizophrenia; chr6:63466542 chr6:63440766~63443580:+ LUSC cis rs35160687 0.712 rs4832031 ENSG00000273080.1 RP11-301O19.1 5.46 7.79e-08 2.58e-05 0.23 0.24 Night sleep phenotypes; chr2:86251857 chr2:86195590~86196049:+ LUSC cis rs957448 0.554 rs10956919 ENSG00000253704.1 RP11-267M23.4 5.46 7.79e-08 2.58e-05 0.28 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94572945 chr8:94553722~94569745:+ LUSC cis rs957448 0.554 rs12540967 ENSG00000253704.1 RP11-267M23.4 5.46 7.79e-08 2.58e-05 0.28 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94576862 chr8:94553722~94569745:+ LUSC cis rs957448 0.554 rs4735297 ENSG00000253704.1 RP11-267M23.4 5.46 7.79e-08 2.58e-05 0.28 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94577112 chr8:94553722~94569745:+ LUSC cis rs957448 0.554 rs72674877 ENSG00000253704.1 RP11-267M23.4 5.46 7.79e-08 2.58e-05 0.28 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94580479 chr8:94553722~94569745:+ LUSC cis rs7712401 0.601 rs173480 ENSG00000263432.2 RN7SL689P 5.46 7.8e-08 2.58e-05 0.31 0.24 Mean platelet volume; chr5:122918436 chr5:123022487~123022783:- LUSC cis rs1707322 0.721 rs4415615 ENSG00000234329.1 RP11-767N6.2 5.46 7.8e-08 2.58e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45666437 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs7529699 ENSG00000234329.1 RP11-767N6.2 5.46 7.8e-08 2.58e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668962 chr1:45651039~45651826:- LUSC cis rs1707322 0.716 rs6699444 ENSG00000234329.1 RP11-767N6.2 5.46 7.8e-08 2.58e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669448 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs10430105 ENSG00000234329.1 RP11-767N6.2 5.46 7.8e-08 2.58e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45673204 chr1:45651039~45651826:- LUSC cis rs17711722 0.585 rs6942660 ENSG00000237310.1 GS1-124K5.4 5.46 7.8e-08 2.59e-05 0.25 0.24 Calcium levels; chr7:65837419 chr7:66493706~66495474:+ LUSC cis rs8177876 0.658 rs16954505 ENSG00000261838.4 RP11-303E16.6 5.46 7.81e-08 2.59e-05 0.57 0.24 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81040555 chr16:81069854~81076598:+ LUSC cis rs2243480 1 rs73142162 ENSG00000226824.5 RP4-756H11.3 -5.46 7.81e-08 2.59e-05 -0.49 -0.24 Diabetic kidney disease; chr7:65909309 chr7:66654538~66669855:+ LUSC cis rs4604732 0.642 rs10925048 ENSG00000227135.1 GCSAML-AS1 -5.46 7.81e-08 2.59e-05 -0.34 -0.24 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247477434 chr1:247524679~247526752:- LUSC cis rs910316 0.673 rs2012627 ENSG00000279594.1 RP11-950C14.10 5.46 7.82e-08 2.59e-05 0.29 0.24 Height; chr14:74976400 chr14:75011269~75012851:- LUSC cis rs2243480 0.706 rs34466769 ENSG00000226824.5 RP4-756H11.3 -5.46 7.82e-08 2.59e-05 -0.43 -0.24 Diabetic kidney disease; chr7:65988305 chr7:66654538~66669855:+ LUSC cis rs4639966 0.569 rs603486 ENSG00000255239.1 AP002954.6 5.46 7.83e-08 2.59e-05 0.27 0.24 Systemic lupus erythematosus; chr11:118716638 chr11:118688039~118690600:- LUSC cis rs1021993 0.545 rs4844820 ENSG00000231648.1 RP11-372M18.2 -5.46 7.83e-08 2.59e-05 -0.36 -0.24 Gut microbiome composition (winter); chr1:209381120 chr1:209367662~209379690:+ LUSC cis rs875971 0.66 rs10263935 ENSG00000222364.1 RNU6-96P -5.46 7.84e-08 2.6e-05 -0.28 -0.24 Aortic root size; chr7:66631041 chr7:66395191~66395286:+ LUSC cis rs10504130 0.569 rs4626585 ENSG00000272024.1 RP11-546K22.3 5.46 7.84e-08 2.6e-05 0.35 0.24 Venous thromboembolism (SNP x SNP interaction); chr8:51767380 chr8:51950284~51950690:+ LUSC cis rs3738443 0.868 rs2892054 ENSG00000259865.1 RP11-488L18.10 5.46 7.84e-08 2.6e-05 0.25 0.24 Alcohol dependence; chr1:247203803 chr1:247187281~247188526:- LUSC cis rs13434995 0.513 rs1522109 ENSG00000249700.7 SRD5A3-AS1 -5.46 7.85e-08 2.6e-05 -0.31 -0.24 Adiponectin levels; chr4:55514403 chr4:55363971~55395847:- LUSC cis rs2274273 0.686 rs28631821 ENSG00000258413.1 RP11-665C16.6 -5.46 7.85e-08 2.6e-05 -0.29 -0.24 Protein biomarker; chr14:55379269 chr14:55262767~55272075:- LUSC cis rs9649213 0.531 rs35216698 ENSG00000272950.1 RP11-307C18.1 5.46 7.86e-08 2.6e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98266863 chr7:98322853~98323430:+ LUSC cis rs8072100 0.713 rs57427906 ENSG00000228782.6 CTD-2026D20.3 5.46 7.86e-08 2.6e-05 0.24 0.24 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47416648 chr17:47450568~47492492:- LUSC cis rs35740288 0.929 rs11556865 ENSG00000202081.1 RNU6-1280P 5.46 7.86e-08 2.6e-05 0.31 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85759949 chr15:85651522~85651628:- LUSC cis rs10462794 1 rs6860429 ENSG00000260763.1 RP11-445O3.3 -5.46 7.87e-08 2.61e-05 -0.3 -0.24 DNA methylation (variation); chr5:4482122 chr5:4436850~4440259:- LUSC cis rs7615952 0.932 rs1976458 ENSG00000171084.14 FAM86JP 5.46 7.89e-08 2.61e-05 0.33 0.24 Blood pressure (smoking interaction); chr3:125928669 chr3:125916620~125930024:+ LUSC cis rs7246657 0.722 rs12974225 ENSG00000276846.1 CTD-3220F14.3 -5.46 7.89e-08 2.61e-05 -0.37 -0.24 Coronary artery calcification; chr19:37749458 chr19:37314868~37315620:- LUSC cis rs11098499 0.754 rs2036860 ENSG00000250412.1 KLHL2P1 5.46 7.89e-08 2.61e-05 0.3 0.24 Corneal astigmatism; chr4:119327779 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs6834796 ENSG00000248280.1 RP11-33B1.2 5.46 7.89e-08 2.61e-05 0.29 0.24 Corneal astigmatism; chr4:119493538 chr4:119440561~119450157:- LUSC cis rs228614 0.51 rs223377 ENSG00000246560.2 RP11-10L12.4 5.46 7.9e-08 2.61e-05 0.3 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102834919 chr4:102828055~102844075:+ LUSC cis rs9611519 1 rs5751069 ENSG00000235513.1 RP4-756G23.5 5.46 7.9e-08 2.61e-05 0.29 0.24 Neuroticism; chr22:41231771 chr22:41209122~41217627:- LUSC cis rs2834288 1 rs2834288 ENSG00000237945.6 LINC00649 5.46 7.9e-08 2.61e-05 0.26 0.24 Gut microbiota (bacterial taxa); chr21:33892093 chr21:33915534~33977691:+ LUSC cis rs227275 0.554 rs223382 ENSG00000246560.2 RP11-10L12.4 5.46 7.9e-08 2.61e-05 0.3 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102831145 chr4:102828055~102844075:+ LUSC cis rs9611519 0.894 rs9611486 ENSG00000235513.1 RP4-756G23.5 5.46 7.91e-08 2.62e-05 0.29 0.24 Neuroticism; chr22:41062780 chr22:41209122~41217627:- LUSC cis rs9468199 0.505 rs72847381 ENSG00000219392.1 RP1-265C24.5 -5.46 7.92e-08 2.62e-05 -0.65 -0.24 Parkinson's disease; chr6:27906153 chr6:28115628~28116551:+ LUSC cis rs17767294 0.708 rs72848752 ENSG00000219392.1 RP1-265C24.5 -5.46 7.92e-08 2.62e-05 -0.65 -0.24 Parkinson's disease; chr6:27910490 chr6:28115628~28116551:+ LUSC cis rs9341835 0.518 rs9361816 ENSG00000218048.2 RP3-407E4.4 5.46 7.92e-08 2.62e-05 0.29 0.24 Schizophrenia; chr6:63464534 chr6:63440766~63443580:+ LUSC cis rs11089937 0.651 rs2877023 ENSG00000211639.2 IGLV4-60 5.46 7.92e-08 2.62e-05 0.28 0.24 Periodontitis (PAL4Q3); chr22:22182414 chr22:22162199~22162681:+ LUSC cis rs2274273 0.87 rs946059 ENSG00000258413.1 RP11-665C16.6 -5.46 7.93e-08 2.62e-05 -0.29 -0.24 Protein biomarker; chr14:55380748 chr14:55262767~55272075:- LUSC cis rs11971779 0.941 rs74299967 ENSG00000273391.1 RP11-634H22.1 5.45 7.94e-08 2.62e-05 0.3 0.24 Diisocyanate-induced asthma; chr7:139359023 chr7:139359032~139359566:- LUSC cis rs16843372 0.599 rs10196949 ENSG00000251491.2 OR7E28P -5.45 7.94e-08 2.63e-05 -0.26 -0.24 Obesity-related traits; chr2:158823718 chr2:158862311~158863285:+ LUSC cis rs7829975 0.617 rs4841072 ENSG00000254340.1 RP11-10A14.3 -5.45 7.94e-08 2.63e-05 -0.29 -0.24 Mood instability; chr8:8933743 chr8:9141424~9145435:+ LUSC cis rs7804306 0.655 rs34746652 ENSG00000233264.2 AC006042.8 5.45 7.95e-08 2.63e-05 0.42 0.24 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:8012957 chr7:7980312~7982228:+ LUSC cis rs950880 0.71 rs4851011 ENSG00000234389.1 AC007278.3 5.45 7.95e-08 2.63e-05 0.26 0.24 Serum protein levels (sST2); chr2:102473219 chr2:102438713~102440475:+ LUSC cis rs7826238 0.566 rs2945886 ENSG00000173295.6 FAM86B3P 5.45 7.95e-08 2.63e-05 0.27 0.24 Systolic blood pressure; chr8:8290748 chr8:8228595~8244865:+ LUSC cis rs2274273 0.84 rs11547116 ENSG00000258413.1 RP11-665C16.6 -5.45 7.95e-08 2.63e-05 -0.3 -0.24 Protein biomarker; chr14:55271447 chr14:55262767~55272075:- LUSC cis rs77972916 0.536 rs11679731 ENSG00000234936.1 AC010883.5 5.45 7.95e-08 2.63e-05 0.31 0.24 Granulocyte percentage of myeloid white cells; chr2:43361925 chr2:43229573~43233394:+ LUSC cis rs9311474 1 rs7629072 ENSG00000243224.1 RP5-1157M23.2 -5.45 7.96e-08 2.63e-05 -0.24 -0.24 Electroencephalogram traits; chr3:52271617 chr3:52239258~52241097:+ LUSC cis rs6502050 0.835 rs4789751 ENSG00000266654.1 RP11-1376P16.1 -5.45 7.96e-08 2.63e-05 -0.24 -0.24 Life satisfaction; chr17:82134497 chr17:82160056~82160452:+ LUSC cis rs17361889 0.596 rs17286418 ENSG00000224683.1 RPL36AP29 5.45 7.96e-08 2.63e-05 0.3 0.24 Pediatric bone mineral content (hip); chr7:16097894 chr7:16208945~16209265:+ LUSC cis rs17361889 0.711 rs3857709 ENSG00000224683.1 RPL36AP29 5.45 7.96e-08 2.63e-05 0.3 0.24 Pediatric bone mineral content (hip); chr7:16100477 chr7:16208945~16209265:+ LUSC cis rs442309 0.846 rs224070 ENSG00000238280.1 RP11-436D10.3 -5.45 7.96e-08 2.63e-05 -0.3 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62748658 chr10:62793562~62805887:- LUSC cis rs875971 0.597 rs11763224 ENSG00000224316.1 RP11-479O9.2 5.45 7.96e-08 2.63e-05 0.27 0.24 Aortic root size; chr7:66518628 chr7:65773620~65802067:+ LUSC cis rs1211375 0.607 rs1203978 ENSG00000268836.1 LA16c-OS12.2 -5.45 7.96e-08 2.63e-05 -0.24 -0.24 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:207212 chr16:185748~186294:- LUSC cis rs3738443 0.817 rs61840052 ENSG00000259865.1 RP11-488L18.10 5.45 7.99e-08 2.64e-05 0.25 0.24 Alcohol dependence; chr1:247204036 chr1:247187281~247188526:- LUSC cis rs11763147 1 rs11763147 ENSG00000179406.6 LINC00174 5.45 8e-08 2.65e-05 0.25 0.24 Corneal structure; chr7:65861834 chr7:66376044~66401338:- LUSC cis rs2136613 0.533 rs10822071 ENSG00000238280.1 RP11-436D10.3 -5.45 8.01e-08 2.65e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62855716 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs10822072 ENSG00000238280.1 RP11-436D10.3 -5.45 8.01e-08 2.65e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62856010 chr10:62793562~62805887:- LUSC cis rs6918586 0.658 rs198825 ENSG00000272462.2 U91328.19 -5.45 8.01e-08 2.65e-05 -0.26 -0.24 Schizophrenia; chr6:26122274 chr6:25992662~26001775:+ LUSC cis rs8177876 0.731 rs74878296 ENSG00000261838.4 RP11-303E16.6 5.45 8.02e-08 2.65e-05 0.65 0.24 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81071940 chr16:81069854~81076598:+ LUSC cis rs7712401 0.645 rs246316 ENSG00000263432.2 RN7SL689P 5.45 8.03e-08 2.65e-05 0.3 0.24 Mean platelet volume; chr5:122930502 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs246315 ENSG00000263432.2 RN7SL689P 5.45 8.03e-08 2.65e-05 0.3 0.24 Mean platelet volume; chr5:122930743 chr5:123022487~123022783:- LUSC cis rs6844153 0.887 rs6835631 ENSG00000240005.4 RP11-293A21.1 5.45 8.04e-08 2.66e-05 0.37 0.24 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26946864 chr4:26859806~26860599:- LUSC cis rs875971 0.965 rs7794930 ENSG00000179406.6 LINC00174 5.45 8.04e-08 2.66e-05 0.26 0.24 Aortic root size; chr7:66313559 chr7:66376044~66401338:- LUSC cis rs9402743 0.702 rs9399150 ENSG00000234084.1 RP3-388E23.2 -5.45 8.04e-08 2.66e-05 -0.19 -0.24 Systemic lupus erythematosus; chr6:135599752 chr6:135301568~135307158:+ LUSC cis rs8177876 0.731 rs57606521 ENSG00000261838.4 RP11-303E16.6 5.45 8.04e-08 2.66e-05 0.63 0.24 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81103437 chr16:81069854~81076598:+ LUSC cis rs7772486 0.875 rs56181683 ENSG00000235652.6 RP11-545I5.3 -5.45 8.04e-08 2.66e-05 -0.25 -0.24 Lobe attachment (rater-scored or self-reported); chr6:145965484 chr6:145799409~145886585:+ LUSC cis rs6502050 0.761 rs7225637 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.05e-08 2.66e-05 -0.24 -0.24 Life satisfaction; chr17:82101882 chr17:82160056~82160452:+ LUSC cis rs1008375 0.864 rs4698196 ENSG00000249502.1 AC006160.5 -5.45 8.05e-08 2.66e-05 -0.25 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17573112 chr4:17587467~17614571:- LUSC cis rs891378 0.837 rs11120688 ENSG00000274245.1 RP11-357P18.2 5.45 8.06e-08 2.66e-05 0.33 0.24 Spherical equivalent (joint analysis main effects and education interaction); chr1:207312770 chr1:207372559~207373252:+ LUSC cis rs17270561 0.636 rs7453371 ENSG00000272462.2 U91328.19 -5.45 8.06e-08 2.66e-05 -0.29 -0.24 Iron status biomarkers; chr6:25719028 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs4712957 ENSG00000272462.2 U91328.19 -5.45 8.06e-08 2.66e-05 -0.29 -0.24 Iron status biomarkers; chr6:25719586 chr6:25992662~26001775:+ LUSC cis rs17270561 0.666 rs17320090 ENSG00000272462.2 U91328.19 -5.45 8.06e-08 2.66e-05 -0.29 -0.24 Iron status biomarkers; chr6:25719987 chr6:25992662~26001775:+ LUSC cis rs7615952 0.741 rs13314845 ENSG00000171084.14 FAM86JP 5.45 8.06e-08 2.66e-05 0.33 0.24 Blood pressure (smoking interaction); chr3:125925939 chr3:125916620~125930024:+ LUSC cis rs7615952 0.733 rs13314847 ENSG00000171084.14 FAM86JP 5.45 8.06e-08 2.66e-05 0.33 0.24 Blood pressure (smoking interaction); chr3:125925945 chr3:125916620~125930024:+ LUSC cis rs1707322 0.686 rs1084086 ENSG00000234329.1 RP11-767N6.2 -5.45 8.06e-08 2.66e-05 -0.26 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45575428 chr1:45651039~45651826:- LUSC cis rs17270561 0.553 rs9379784 ENSG00000272462.2 U91328.19 -5.45 8.07e-08 2.66e-05 -0.29 -0.24 Iron status biomarkers; chr6:25725278 chr6:25992662~26001775:+ LUSC cis rs11098499 0.866 rs6847778 ENSG00000250412.1 KLHL2P1 5.45 8.07e-08 2.67e-05 0.3 0.24 Corneal astigmatism; chr4:119372427 chr4:119334329~119378233:+ LUSC cis rs2439831 0.85 rs60883262 ENSG00000249839.1 AC011330.5 -5.45 8.09e-08 2.67e-05 -0.48 -0.24 Lung cancer in ever smokers; chr15:43784305 chr15:43663654~43684339:- LUSC cis rs4713118 0.869 rs6914924 ENSG00000280107.1 AL022393.9 -5.45 8.09e-08 2.67e-05 -0.28 -0.24 Parkinson's disease; chr6:27743751 chr6:28170845~28172521:+ LUSC cis rs4332428 1 rs78836001 ENSG00000239148.1 U8 -5.45 8.11e-08 2.68e-05 -0.28 -0.24 Height; chr10:4939800 chr10:5004710~5004842:+ LUSC cis rs10759883 0.58 rs690495 ENSG00000175611.10 LINC00476 5.45 8.11e-08 2.68e-05 0.29 0.24 Nicotine dependence; chr9:95893511 chr9:95759231~95875977:- LUSC cis rs13113518 1 rs4865013 ENSG00000272969.1 RP11-528I4.2 5.45 8.11e-08 2.68e-05 0.28 0.24 Height; chr4:55559957 chr4:55547112~55547889:+ LUSC cis rs889398 0.934 rs12923231 ENSG00000226232.7 RP11-419C5.2 5.45 8.12e-08 2.68e-05 0.24 0.24 Body mass index; chr16:69538989 chr16:69976388~69996188:- LUSC cis rs9545047 0.604 rs1748761 ENSG00000227676.3 LINC01068 5.45 8.12e-08 2.68e-05 0.3 0.24 Schizophrenia; chr13:79407491 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs2763809 ENSG00000227676.3 LINC01068 5.45 8.12e-08 2.68e-05 0.3 0.24 Schizophrenia; chr13:79407544 chr13:79566727~79571436:+ LUSC cis rs673078 0.607 rs73207504 ENSG00000275409.1 RP11-131L12.4 -5.45 8.12e-08 2.68e-05 -0.35 -0.24 Glucose homeostasis traits; chr12:118427914 chr12:118430147~118430699:+ LUSC cis rs46522 0.585 rs79049364 ENSG00000270781.1 RP11-501C14.9 -5.45 8.13e-08 2.68e-05 -0.26 -0.24 Coronary heart disease; chr17:48937629 chr17:48899131~48899748:+ LUSC cis rs79349575 0.811 rs80032154 ENSG00000270781.1 RP11-501C14.9 -5.45 8.13e-08 2.68e-05 -0.26 -0.24 Type 2 diabetes; chr17:48937630 chr17:48899131~48899748:+ LUSC cis rs2243480 0.901 rs3813708 ENSG00000226824.5 RP4-756H11.3 -5.45 8.13e-08 2.68e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65840645 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs73142122 ENSG00000226824.5 RP4-756H11.3 -5.45 8.13e-08 2.68e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65846311 chr7:66654538~66669855:+ LUSC cis rs2243480 0.901 rs73142137 ENSG00000226824.5 RP4-756H11.3 -5.45 8.13e-08 2.68e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65878455 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs13247184 ENSG00000226824.5 RP4-756H11.3 -5.45 8.13e-08 2.68e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65893941 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs35283677 ENSG00000226824.5 RP4-756H11.3 -5.45 8.13e-08 2.68e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65894246 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs35421653 ENSG00000226824.5 RP4-756H11.3 -5.45 8.13e-08 2.68e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65898442 chr7:66654538~66669855:+ LUSC cis rs16843372 0.599 rs2356510 ENSG00000251491.2 OR7E28P -5.45 8.14e-08 2.69e-05 -0.27 -0.24 Obesity-related traits; chr2:158833318 chr2:158862311~158863285:+ LUSC cis rs6832769 0.961 rs2412647 ENSG00000272969.1 RP11-528I4.2 5.45 8.14e-08 2.69e-05 0.27 0.24 Personality dimensions; chr4:55452938 chr4:55547112~55547889:+ LUSC cis rs7829975 0.582 rs6982832 ENSG00000254340.1 RP11-10A14.3 -5.45 8.14e-08 2.69e-05 -0.3 -0.24 Mood instability; chr8:8934707 chr8:9141424~9145435:+ LUSC cis rs875971 0.522 rs9530 ENSG00000222364.1 RNU6-96P -5.45 8.14e-08 2.69e-05 -0.29 -0.24 Aortic root size; chr7:65960907 chr7:66395191~66395286:+ LUSC cis rs17270561 0.579 rs10456326 ENSG00000272810.1 U91328.22 -5.45 8.15e-08 2.69e-05 -0.33 -0.24 Iron status biomarkers; chr6:25919434 chr6:26013241~26013757:+ LUSC cis rs12216125 0.537 rs12207059 ENSG00000272810.1 U91328.22 -5.45 8.15e-08 2.69e-05 -0.33 -0.24 Iron status biomarkers; chr6:25922157 chr6:26013241~26013757:+ LUSC cis rs13113518 0.812 rs12500601 ENSG00000273257.1 RP11-177J6.1 5.45 8.15e-08 2.69e-05 0.32 0.24 Height; chr4:55451489 chr4:55387949~55388271:+ LUSC cis rs17711722 0.727 rs1880555 ENSG00000237310.1 GS1-124K5.4 5.45 8.15e-08 2.69e-05 0.25 0.24 Calcium levels; chr7:65967580 chr7:66493706~66495474:+ LUSC cis rs2404602 0.583 rs4381566 ENSG00000259422.1 RP11-593F23.1 5.45 8.16e-08 2.69e-05 0.28 0.24 Blood metabolite levels; chr15:76296921 chr15:76174891~76181486:- LUSC cis rs8040855 0.579 rs28521166 ENSG00000259774.1 RP11-182J1.13 -5.45 8.16e-08 2.69e-05 -0.28 -0.24 Bulimia nervosa; chr15:85184801 chr15:84422618~84425882:+ LUSC cis rs875971 0.545 rs316316 ENSG00000179406.6 LINC00174 5.45 8.16e-08 2.69e-05 0.29 0.24 Aortic root size; chr7:66149270 chr7:66376044~66401338:- LUSC cis rs2243480 1 rs3885839 ENSG00000164669.11 INTS4P1 5.45 8.16e-08 2.69e-05 0.45 0.24 Diabetic kidney disease; chr7:65825416 chr7:65141225~65234216:+ LUSC cis rs2739330 0.685 rs4822453 ENSG00000228039.3 KB-1125A3.10 5.45 8.16e-08 2.69e-05 0.31 0.24 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23963780~23964374:+ LUSC cis rs13113518 1 rs13132420 ENSG00000249700.7 SRD5A3-AS1 -5.45 8.17e-08 2.69e-05 -0.27 -0.24 Height; chr4:55526646 chr4:55363971~55395847:- LUSC cis rs2742234 0.541 rs7073849 ENSG00000273008.1 RP11-351D16.3 5.45 8.17e-08 2.69e-05 0.28 0.24 Hirschsprung disease; chr10:43245026 chr10:43136824~43138334:- LUSC cis rs7332672 0.62 rs4319612 ENSG00000280710.1 RP11-214F16.8 -5.45 8.17e-08 2.7e-05 -0.3 -0.24 Eosinophil counts; chr13:99411911 chr13:99498524~99501315:+ LUSC cis rs14027 0.921 rs16893077 ENSG00000279347.1 RP11-85I17.2 -5.45 8.18e-08 2.7e-05 -0.21 -0.24 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119740332 chr8:119838736~119840385:- LUSC cis rs9402682 0.629 rs2223385 ENSG00000232876.1 CTA-212D2.2 -5.45 8.18e-08 2.7e-05 -0.32 -0.24 Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr6:135114033 chr6:135055033~135060550:+ LUSC cis rs9649213 0.574 rs7789440 ENSG00000272950.1 RP11-307C18.1 5.45 8.18e-08 2.7e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98259486 chr7:98322853~98323430:+ LUSC cis rs1707322 0.721 rs10890341 ENSG00000234329.1 RP11-767N6.2 5.45 8.19e-08 2.7e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45681568 chr1:45651039~45651826:- LUSC cis rs67311347 1 rs17078813 ENSG00000223797.4 ENTPD3-AS1 5.45 8.19e-08 2.7e-05 0.28 0.24 Renal cell carcinoma; chr3:40392671 chr3:40313802~40453329:- LUSC cis rs7712401 0.601 rs30027 ENSG00000263432.2 RN7SL689P 5.45 8.19e-08 2.7e-05 0.31 0.24 Mean platelet volume; chr5:122947695 chr5:123022487~123022783:- LUSC cis rs17772222 1 rs56987357 ENSG00000258789.1 RP11-507K2.3 -5.45 8.2e-08 2.7e-05 -0.29 -0.24 Coronary artery calcification; chr14:88358019 chr14:88551597~88552493:+ LUSC cis rs17772222 1 rs1955599 ENSG00000258789.1 RP11-507K2.3 -5.45 8.2e-08 2.7e-05 -0.29 -0.24 Coronary artery calcification; chr14:88358788 chr14:88551597~88552493:+ LUSC cis rs4964805 0.58 rs1866292 ENSG00000257681.1 RP11-341G23.4 5.45 8.2e-08 2.7e-05 0.28 0.24 Attention deficit hyperactivity disorder; chr12:103780414 chr12:103746315~103768858:- LUSC cis rs10462794 0.756 rs896133 ENSG00000260763.1 RP11-445O3.3 5.45 8.2e-08 2.7e-05 0.31 0.24 DNA methylation (variation); chr5:4511476 chr5:4436850~4440259:- LUSC cis rs9611519 0.808 rs5751074 ENSG00000235513.1 RP4-756G23.5 5.45 8.21e-08 2.71e-05 0.28 0.24 Neuroticism; chr22:41269718 chr22:41209122~41217627:- LUSC cis rs35160687 0.712 rs11681689 ENSG00000273080.1 RP11-301O19.1 -5.45 8.21e-08 2.71e-05 -0.23 -0.24 Night sleep phenotypes; chr2:86256039 chr2:86195590~86196049:+ LUSC cis rs7712401 0.623 rs538424 ENSG00000263432.2 RN7SL689P 5.45 8.21e-08 2.71e-05 0.3 0.24 Mean platelet volume; chr5:122893068 chr5:123022487~123022783:- LUSC cis rs6969780 0.915 rs886339 ENSG00000233429.8 HOTAIRM1 -5.45 8.22e-08 2.71e-05 -0.43 -0.24 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27151051 chr7:27095647~27100265:+ LUSC cis rs875971 0.522 rs4718286 ENSG00000237310.1 GS1-124K5.4 5.45 8.22e-08 2.71e-05 0.25 0.24 Aortic root size; chr7:65827777 chr7:66493706~66495474:+ LUSC cis rs35740288 0.787 rs35250181 ENSG00000202081.1 RNU6-1280P 5.45 8.23e-08 2.71e-05 0.31 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85699431 chr15:85651522~85651628:- LUSC cis rs442309 0.807 rs224073 ENSG00000238280.1 RP11-436D10.3 -5.45 8.23e-08 2.71e-05 -0.3 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62750344 chr10:62793562~62805887:- LUSC cis rs4964805 0.626 rs869993 ENSG00000257681.1 RP11-341G23.4 5.45 8.23e-08 2.71e-05 0.28 0.24 Attention deficit hyperactivity disorder; chr12:103781360 chr12:103746315~103768858:- LUSC cis rs79349575 0.783 rs2112617 ENSG00000270781.1 RP11-501C14.9 -5.45 8.23e-08 2.71e-05 -0.25 -0.24 Type 2 diabetes; chr17:48899763 chr17:48899131~48899748:+ LUSC cis rs6502050 0.835 rs8073645 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82153081 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs8067138 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82153150 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs6502067 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82153329 chr17:82160056~82160452:+ LUSC cis rs6502050 0.799 rs6416859 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82153566 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs6502069 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82154723 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs6502070 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82154758 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs3924780 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82155102 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs8078087 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82155446 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs3935129 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82155505 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs3935128 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82155538 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs34960918 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82156049 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs3935403 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82156269 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs9900072 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82156484 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs8070014 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82157371 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs8065565 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82157523 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs8080625 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82157571 chr17:82160056~82160452:+ LUSC cis rs6502050 0.731 rs9891378 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82158159 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs66932937 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82158927 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs67106357 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.23e-08 2.71e-05 -0.24 -0.24 Life satisfaction; chr17:82158950 chr17:82160056~82160452:+ LUSC cis rs9322193 0.566 rs9397070 ENSG00000268592.3 RAET1E-AS1 -5.45 8.25e-08 2.72e-05 -0.35 -0.24 Lung cancer; chr6:149922073 chr6:149863494~149919507:+ LUSC cis rs61270009 0.955 rs12523282 ENSG00000247828.6 TMEM161B-AS1 5.45 8.25e-08 2.72e-05 0.28 0.24 Depressive symptoms; chr5:88407679 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs12651891 ENSG00000247828.6 TMEM161B-AS1 5.45 8.25e-08 2.72e-05 0.28 0.24 Depressive symptoms; chr5:88408187 chr5:88268895~88436685:+ LUSC cis rs1707322 0.721 rs10890336 ENSG00000234329.1 RP11-767N6.2 5.45 8.25e-08 2.72e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645384 chr1:45651039~45651826:- LUSC cis rs228614 0.51 rs3774987 ENSG00000246560.2 RP11-10L12.4 5.45 8.26e-08 2.72e-05 0.3 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799709 chr4:102828055~102844075:+ LUSC cis rs228614 0.51 rs223452 ENSG00000246560.2 RP11-10L12.4 5.45 8.26e-08 2.72e-05 0.3 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102790277 chr4:102828055~102844075:+ LUSC cis rs453301 0.653 rs7016139 ENSG00000254340.1 RP11-10A14.3 -5.45 8.27e-08 2.72e-05 -0.3 -0.24 Joint mobility (Beighton score); chr8:9037960 chr8:9141424~9145435:+ LUSC cis rs7181230 0.885 rs4497657 ENSG00000275636.1 RP11-521C20.5 5.45 8.28e-08 2.73e-05 0.3 0.24 Dehydroepiandrosterone sulphate levels; chr15:40067232 chr15:40078892~40079347:+ LUSC cis rs4604234 0.573 rs11961361 ENSG00000272129.1 RP11-250B2.6 -5.45 8.28e-08 2.73e-05 -0.52 -0.24 Cancer; chr6:80294840 chr6:80355424~80356859:+ LUSC cis rs4604234 0.541 rs11963917 ENSG00000272129.1 RP11-250B2.6 -5.45 8.28e-08 2.73e-05 -0.52 -0.24 Cancer; chr6:80294843 chr6:80355424~80356859:+ LUSC cis rs17772222 0.755 rs12435019 ENSG00000258789.1 RP11-507K2.3 -5.45 8.29e-08 2.73e-05 -0.28 -0.24 Coronary artery calcification; chr14:88365074 chr14:88551597~88552493:+ LUSC cis rs11098499 0.754 rs878372 ENSG00000250412.1 KLHL2P1 5.45 8.29e-08 2.73e-05 0.3 0.24 Corneal astigmatism; chr4:119317625 chr4:119334329~119378233:+ LUSC cis rs2919917 0.628 rs9643739 ENSG00000254352.1 RP11-578O24.2 5.45 8.29e-08 2.73e-05 0.33 0.24 Lymphocyte counts; chr8:78679535 chr8:78723796~78724136:- LUSC cis rs2919917 0.628 rs2170732 ENSG00000254352.1 RP11-578O24.2 5.45 8.29e-08 2.73e-05 0.33 0.24 Lymphocyte counts; chr8:78684261 chr8:78723796~78724136:- LUSC cis rs2919917 0.628 rs6990105 ENSG00000254352.1 RP11-578O24.2 5.45 8.29e-08 2.73e-05 0.33 0.24 Lymphocyte counts; chr8:78689652 chr8:78723796~78724136:- LUSC cis rs2617170 0.922 rs2617160 ENSG00000245648.1 RP11-277P12.20 5.45 8.29e-08 2.73e-05 0.29 0.24 Behcet's disease; chr12:10392998 chr12:10363769~10398506:+ LUSC cis rs1707322 0.721 rs11211157 ENSG00000234329.1 RP11-767N6.2 5.45 8.29e-08 2.73e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667172 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs11211158 ENSG00000234329.1 RP11-767N6.2 5.45 8.29e-08 2.73e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667178 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs6429575 ENSG00000234329.1 RP11-767N6.2 5.45 8.29e-08 2.73e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668544 chr1:45651039~45651826:- LUSC cis rs1707322 0.685 rs6690926 ENSG00000234329.1 RP11-767N6.2 5.45 8.29e-08 2.73e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669306 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs8179402 ENSG00000234329.1 RP11-767N6.2 5.45 8.29e-08 2.73e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45676794 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs8179296 ENSG00000234329.1 RP11-767N6.2 5.45 8.29e-08 2.73e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45678119 chr1:45651039~45651826:- LUSC cis rs1056107 0.541 rs10739349 ENSG00000225513.1 RP11-165N19.2 -5.45 8.3e-08 2.74e-05 -0.27 -0.24 Colorectal cancer; chr9:112415749 chr9:112173522~112173971:- LUSC cis rs1412337 0.52 rs11802276 ENSG00000227777.1 RP4-738P11.3 -5.45 8.31e-08 2.74e-05 -0.33 -0.24 Morbidity-free survival; chr1:168640651 chr1:168542737~168543354:+ LUSC cis rs6502050 0.799 rs9911129 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.31e-08 2.74e-05 -0.24 -0.24 Life satisfaction; chr17:82129943 chr17:82160056~82160452:+ LUSC cis rs6502050 0.635 rs9889327 ENSG00000266654.1 RP11-1376P16.1 -5.45 8.31e-08 2.74e-05 -0.24 -0.24 Life satisfaction; chr17:82129963 chr17:82160056~82160452:+ LUSC cis rs7712401 0.601 rs30026 ENSG00000263432.2 RN7SL689P 5.45 8.31e-08 2.74e-05 0.31 0.24 Mean platelet volume; chr5:122948873 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs30022 ENSG00000263432.2 RN7SL689P 5.45 8.31e-08 2.74e-05 0.31 0.24 Mean platelet volume; chr5:122950021 chr5:123022487~123022783:- LUSC cis rs7712401 0.546 rs30021 ENSG00000263432.2 RN7SL689P 5.45 8.31e-08 2.74e-05 0.31 0.24 Mean platelet volume; chr5:122950199 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs246328 ENSG00000263432.2 RN7SL689P 5.45 8.31e-08 2.74e-05 0.31 0.24 Mean platelet volume; chr5:122951933 chr5:123022487~123022783:- LUSC cis rs42490 1 rs2735870 ENSG00000251136.7 RP11-37B2.1 5.45 8.31e-08 2.74e-05 0.21 0.24 Leprosy; chr8:89730456 chr8:89609409~89757727:- LUSC cis rs763121 0.889 rs4820335 ENSG00000273076.1 RP3-508I15.22 -5.45 8.32e-08 2.74e-05 -0.24 -0.24 Menopause (age at onset); chr22:38539922 chr22:38743495~38743910:+ LUSC cis rs61270009 0.955 rs12654702 ENSG00000247828.6 TMEM161B-AS1 5.45 8.33e-08 2.74e-05 0.28 0.24 Depressive symptoms; chr5:88402882 chr5:88268895~88436685:+ LUSC cis rs240993 0.761 rs9400480 ENSG00000230177.1 RP5-1112D6.4 5.45 8.33e-08 2.74e-05 0.29 0.24 Inflammatory skin disease;Psoriasis; chr6:111529394 chr6:111277932~111278742:+ LUSC cis rs6504950 0.925 rs8082622 ENSG00000275710.1 RP11-257O5.4 -5.45 8.33e-08 2.74e-05 -0.29 -0.24 Breast cancer; chr17:55100206 chr17:54964474~54964679:+ LUSC cis rs2732480 0.577 rs2634684 ENSG00000240399.1 RP1-228P16.1 -5.45 8.33e-08 2.74e-05 -0.26 -0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48337092 chr12:48054813~48055591:- LUSC cis rs6452524 0.618 rs255561 ENSG00000248112.1 RP11-78C3.1 5.45 8.34e-08 2.74e-05 0.26 0.24 Hypertension (SNP x SNP interaction); chr5:83054991 chr5:82919376~82921119:- LUSC cis rs9649213 0.555 rs67132564 ENSG00000272950.1 RP11-307C18.1 5.45 8.34e-08 2.74e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98385588 chr7:98322853~98323430:+ LUSC cis rs7674212 0.507 rs223413 ENSG00000246560.2 RP11-10L12.4 -5.45 8.34e-08 2.75e-05 -0.31 -0.24 Type 2 diabetes; chr4:102811709 chr4:102828055~102844075:+ LUSC cis rs2404602 0.647 rs7181506 ENSG00000259422.1 RP11-593F23.1 5.45 8.34e-08 2.75e-05 0.3 0.24 Blood metabolite levels; chr15:76643336 chr15:76174891~76181486:- LUSC cis rs2554380 0.628 rs7175491 ENSG00000230373.7 GOLGA6L5P -5.45 8.35e-08 2.75e-05 -0.25 -0.24 Height; chr15:83806187 chr15:84507885~84516814:- LUSC cis rs2554380 0.628 rs7177929 ENSG00000230373.7 GOLGA6L5P -5.45 8.35e-08 2.75e-05 -0.25 -0.24 Height; chr15:83809927 chr15:84507885~84516814:- LUSC cis rs11089937 0.963 rs2226943 ENSG00000211638.2 IGLV8-61 -5.45 8.35e-08 2.75e-05 -0.23 -0.24 Periodontitis (PAL4Q3); chr22:22143100 chr22:22098700~22099212:+ LUSC cis rs11098499 0.908 rs71614449 ENSG00000248280.1 RP11-33B1.2 5.45 8.36e-08 2.75e-05 0.3 0.24 Corneal astigmatism; chr4:119465900 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs35063680 ENSG00000248280.1 RP11-33B1.2 5.45 8.36e-08 2.75e-05 0.3 0.24 Corneal astigmatism; chr4:119465947 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs34858317 ENSG00000248280.1 RP11-33B1.2 5.45 8.36e-08 2.75e-05 0.3 0.24 Corneal astigmatism; chr4:119465955 chr4:119440561~119450157:- LUSC cis rs8031584 0.958 rs34909055 ENSG00000260382.1 RP11-540B6.2 5.44 8.37e-08 2.76e-05 0.33 0.24 Huntington's disease progression; chr15:30991967 chr15:30882267~30883231:- LUSC cis rs7083 0.905 rs11216338 ENSG00000254851.1 RP11-109L13.1 5.44 8.37e-08 2.76e-05 0.3 0.24 Blood protein levels; chr11:117261003 chr11:117135528~117138582:+ LUSC cis rs2439831 0.85 rs12441984 ENSG00000249839.1 AC011330.5 -5.44 8.37e-08 2.76e-05 -0.5 -0.24 Lung cancer in ever smokers; chr15:43834087 chr15:43663654~43684339:- LUSC cis rs11098499 0.954 rs17009122 ENSG00000248280.1 RP11-33B1.2 5.44 8.37e-08 2.76e-05 0.3 0.24 Corneal astigmatism; chr4:119441248 chr4:119440561~119450157:- LUSC cis rs6683071 0.688 rs2378604 ENSG00000272750.1 RP11-378J18.8 -5.44 8.38e-08 2.76e-05 -0.33 -0.24 Cognitive performance; chr1:222730968 chr1:222658867~222661512:- LUSC cis rs2274273 0.84 rs6573020 ENSG00000258413.1 RP11-665C16.6 -5.44 8.38e-08 2.76e-05 -0.3 -0.24 Protein biomarker; chr14:55404734 chr14:55262767~55272075:- LUSC cis rs2303759 0.874 rs8108669 ENSG00000268686.1 AC010524.2 -5.44 8.39e-08 2.76e-05 -0.34 -0.24 Multiple sclerosis; chr19:49342638 chr19:49368705~49388081:- LUSC cis rs13326165 0.709 rs352143 ENSG00000243224.1 RP5-1157M23.2 -5.44 8.39e-08 2.76e-05 -0.3 -0.24 HDL cholesterol levels;HDL cholesterol; chr3:52230891 chr3:52239258~52241097:+ LUSC cis rs6504622 0.875 rs11652318 ENSG00000262879.4 RP11-156P1.3 5.44 8.39e-08 2.76e-05 0.25 0.24 Orofacial clefts; chr17:46963728 chr17:46984045~47100323:- LUSC cis rs7712401 0.601 rs30049 ENSG00000263432.2 RN7SL689P 5.44 8.39e-08 2.76e-05 0.31 0.24 Mean platelet volume; chr5:122970402 chr5:123022487~123022783:- LUSC cis rs77204473 1 rs75410648 ENSG00000254851.1 RP11-109L13.1 5.44 8.39e-08 2.76e-05 0.62 0.24 Sum eosinophil basophil counts;Eosinophil counts; chr11:116942722 chr11:117135528~117138582:+ LUSC cis rs9649213 0.574 rs7802541 ENSG00000272950.1 RP11-307C18.1 5.44 8.39e-08 2.76e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98304543 chr7:98322853~98323430:+ LUSC cis rs9649213 0.555 rs7785612 ENSG00000272950.1 RP11-307C18.1 5.44 8.39e-08 2.76e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98304555 chr7:98322853~98323430:+ LUSC cis rs875971 0.522 rs1701760 ENSG00000179406.6 LINC00174 -5.44 8.4e-08 2.76e-05 -0.26 -0.24 Aortic root size; chr7:66008701 chr7:66376044~66401338:- LUSC cis rs910316 1 rs175492 ENSG00000279594.1 RP11-950C14.10 5.44 8.4e-08 2.76e-05 0.27 0.24 Height; chr14:75078517 chr14:75011269~75012851:- LUSC cis rs2439831 0.85 rs8032649 ENSG00000249839.1 AC011330.5 5.44 8.4e-08 2.76e-05 0.47 0.24 Lung cancer in ever smokers; chr15:43842724 chr15:43663654~43684339:- LUSC cis rs1008375 0.966 rs1860591 ENSG00000249502.1 AC006160.5 -5.44 8.4e-08 2.76e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17575706 chr4:17587467~17614571:- LUSC cis rs11098499 0.863 rs1010740 ENSG00000248280.1 RP11-33B1.2 -5.44 8.41e-08 2.77e-05 -0.29 -0.24 Corneal astigmatism; chr4:119542254 chr4:119440561~119450157:- LUSC cis rs11098499 0.754 rs12506610 ENSG00000250412.1 KLHL2P1 5.44 8.41e-08 2.77e-05 0.3 0.24 Corneal astigmatism; chr4:119320504 chr4:119334329~119378233:+ LUSC cis rs11098499 0.743 rs10003567 ENSG00000250412.1 KLHL2P1 5.44 8.41e-08 2.77e-05 0.3 0.24 Corneal astigmatism; chr4:119320519 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs10006259 ENSG00000250412.1 KLHL2P1 5.44 8.41e-08 2.77e-05 0.3 0.24 Corneal astigmatism; chr4:119320990 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs28652763 ENSG00000250412.1 KLHL2P1 5.44 8.41e-08 2.77e-05 0.3 0.24 Corneal astigmatism; chr4:119321157 chr4:119334329~119378233:+ LUSC cis rs17772222 1 rs1955600 ENSG00000258789.1 RP11-507K2.3 -5.44 8.42e-08 2.77e-05 -0.28 -0.24 Coronary artery calcification; chr14:88359040 chr14:88551597~88552493:+ LUSC cis rs875971 0.54 rs4717275 ENSG00000179406.6 LINC00174 5.44 8.43e-08 2.77e-05 0.26 0.24 Aortic root size; chr7:65800193 chr7:66376044~66401338:- LUSC cis rs1412337 0.52 rs12740521 ENSG00000227777.1 RP4-738P11.3 -5.44 8.43e-08 2.77e-05 -0.33 -0.24 Morbidity-free survival; chr1:168640366 chr1:168542737~168543354:+ LUSC cis rs9649213 0.555 rs6955259 ENSG00000272950.1 RP11-307C18.1 5.44 8.43e-08 2.77e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98263044 chr7:98322853~98323430:+ LUSC cis rs6504622 0.875 rs2316330 ENSG00000262879.4 RP11-156P1.3 5.44 8.44e-08 2.77e-05 0.25 0.24 Orofacial clefts; chr17:46962666 chr17:46984045~47100323:- LUSC cis rs6504622 0.905 rs3851785 ENSG00000262879.4 RP11-156P1.3 5.44 8.44e-08 2.77e-05 0.25 0.24 Orofacial clefts; chr17:46962781 chr17:46984045~47100323:- LUSC cis rs2303759 0.709 rs3760667 ENSG00000268686.1 AC010524.2 -5.44 8.44e-08 2.78e-05 -0.36 -0.24 Multiple sclerosis; chr19:49311575 chr19:49368705~49388081:- LUSC cis rs2243480 0.901 rs2949697 ENSG00000226824.5 RP4-756H11.3 -5.44 8.45e-08 2.78e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65999249 chr7:66654538~66669855:+ LUSC cis rs2274273 0.84 rs7153110 ENSG00000258413.1 RP11-665C16.6 -5.44 8.46e-08 2.78e-05 -0.29 -0.24 Protein biomarker; chr14:55353910 chr14:55262767~55272075:- LUSC cis rs2439831 0.85 rs28509275 ENSG00000249839.1 AC011330.5 -5.44 8.46e-08 2.78e-05 -0.53 -0.24 Lung cancer in ever smokers; chr15:43805907 chr15:43663654~43684339:- LUSC cis rs9649213 0.593 rs55825602 ENSG00000272950.1 RP11-307C18.1 5.44 8.46e-08 2.78e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98383727 chr7:98322853~98323430:+ LUSC cis rs708547 0.581 rs10020462 ENSG00000269949.1 RP11-738E22.3 -5.44 8.46e-08 2.78e-05 -0.32 -0.24 Response to bleomycin (chromatid breaks); chr4:56959427 chr4:56960927~56961373:- LUSC cis rs11098499 0.657 rs71614442 ENSG00000248280.1 RP11-33B1.2 5.44 8.47e-08 2.78e-05 0.29 0.24 Corneal astigmatism; chr4:119458191 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs2892848 ENSG00000248280.1 RP11-33B1.2 5.44 8.47e-08 2.78e-05 0.29 0.24 Corneal astigmatism; chr4:119460186 chr4:119440561~119450157:- LUSC cis rs11098499 0.865 rs9994730 ENSG00000248280.1 RP11-33B1.2 5.44 8.47e-08 2.78e-05 0.29 0.24 Corneal astigmatism; chr4:119460409 chr4:119440561~119450157:- LUSC cis rs13392177 0.684 rs11682371 ENSG00000261338.2 RP11-378A13.1 -5.44 8.47e-08 2.78e-05 -0.25 -0.24 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218214790 chr2:218255319~218257366:+ LUSC cis rs13392177 0.684 rs6720105 ENSG00000261338.2 RP11-378A13.1 -5.44 8.47e-08 2.78e-05 -0.25 -0.24 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218215995 chr2:218255319~218257366:+ LUSC cis rs2880765 0.566 rs11630381 ENSG00000259295.5 CSPG4P12 5.44 8.48e-08 2.79e-05 0.28 0.24 Coronary artery disease; chr15:85469272 chr15:85191438~85213905:+ LUSC cis rs2880765 0.545 rs11631739 ENSG00000259295.5 CSPG4P12 5.44 8.48e-08 2.79e-05 0.28 0.24 Coronary artery disease; chr15:85469347 chr15:85191438~85213905:+ LUSC cis rs889398 0.802 rs8050414 ENSG00000226232.7 RP11-419C5.2 -5.44 8.48e-08 2.79e-05 -0.23 -0.24 Body mass index; chr16:69852910 chr16:69976388~69996188:- LUSC cis rs2337406 0.789 rs60000589 ENSG00000254174.1 IGHV1-12 5.44 8.48e-08 2.79e-05 0.23 0.24 Alzheimer's disease (late onset); chr14:106782459 chr14:106122420~106122709:- LUSC cis rs1707322 0.752 rs11211146 ENSG00000234329.1 RP11-767N6.2 5.44 8.48e-08 2.79e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644122 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs11211147 ENSG00000234329.1 RP11-767N6.2 5.44 8.48e-08 2.79e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644422 chr1:45651039~45651826:- LUSC cis rs755249 1 rs4660293 ENSG00000228060.1 RP11-69E11.8 5.44 8.49e-08 2.79e-05 0.26 0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39562508 chr1:39565160~39573203:+ LUSC cis rs1707322 0.752 rs11211152 ENSG00000234329.1 RP11-767N6.2 5.44 8.5e-08 2.79e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648485 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs4607935 ENSG00000234329.1 RP11-767N6.2 5.44 8.5e-08 2.79e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651489 chr1:45651039~45651826:- LUSC cis rs1707322 0.681 rs12048866 ENSG00000234329.1 RP11-767N6.2 5.44 8.5e-08 2.79e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651820 chr1:45651039~45651826:- LUSC cis rs42490 0.966 rs6993133 ENSG00000251136.7 RP11-37B2.1 -5.44 8.5e-08 2.79e-05 -0.21 -0.24 Leprosy; chr8:89746396 chr8:89609409~89757727:- LUSC cis rs7208859 0.623 rs426434 ENSG00000263603.1 CTD-2349P21.5 -5.44 8.5e-08 2.79e-05 -0.34 -0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30598335 chr17:30729469~30731202:+ LUSC cis rs6504622 0.902 rs1052586 ENSG00000262879.4 RP11-156P1.3 -5.44 8.51e-08 2.8e-05 -0.25 -0.24 Orofacial clefts; chr17:46941097 chr17:46984045~47100323:- LUSC cis rs6772849 0.775 rs12486377 ENSG00000277250.1 Metazoa_SRP -5.44 8.52e-08 2.8e-05 -0.29 -0.24 Monocyte percentage of white cells;Monocyte count; chr3:128696010 chr3:128673681~128674021:- LUSC cis rs7927592 0.546 rs554734 ENSG00000212093.1 AP000807.1 5.44 8.52e-08 2.8e-05 0.28 0.24 Total body bone mineral density; chr11:68425050 chr11:68506083~68506166:- LUSC cis rs8177876 0.915 rs73597252 ENSG00000261838.4 RP11-303E16.6 5.44 8.52e-08 2.8e-05 0.61 0.24 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81097740 chr16:81069854~81076598:+ LUSC cis rs1707322 0.827 rs10890347 ENSG00000234329.1 RP11-767N6.2 -5.44 8.52e-08 2.8e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45776660 chr1:45651039~45651826:- LUSC cis rs35740288 0.822 rs11638720 ENSG00000202081.1 RNU6-1280P 5.44 8.52e-08 2.8e-05 0.31 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85686042 chr15:85651522~85651628:- LUSC cis rs35740288 0.822 rs2016517 ENSG00000202081.1 RNU6-1280P 5.44 8.52e-08 2.8e-05 0.31 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85686387 chr15:85651522~85651628:- LUSC cis rs228614 0.509 rs223482 ENSG00000246560.2 RP11-10L12.4 5.44 8.53e-08 2.8e-05 0.3 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766051 chr4:102828055~102844075:+ LUSC cis rs2993535 1 rs4951436 ENSG00000233626.2 RP11-565J7.1 -5.44 8.53e-08 2.8e-05 -0.53 -0.24 Hip circumference adjusted for BMI; chr1:212062815 chr1:211936249~211936634:+ LUSC cis rs8028182 0.549 rs3809547 ENSG00000260269.4 CTD-2323K18.1 5.44 8.54e-08 2.8e-05 0.36 0.24 Sudden cardiac arrest; chr15:75336500 chr15:75527150~75601205:- LUSC cis rs10800713 0.56 rs10919965 ENSG00000260088.1 RP11-92G12.3 -5.44 8.54e-08 2.8e-05 -0.37 -0.24 Tandem gait; chr1:200532134 chr1:200669507~200694250:+ LUSC cis rs2243480 0.708 rs35825036 ENSG00000226824.5 RP4-756H11.3 -5.44 8.54e-08 2.8e-05 -0.47 -0.24 Diabetic kidney disease; chr7:66521515 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs13237037 ENSG00000226824.5 RP4-756H11.3 -5.44 8.54e-08 2.8e-05 -0.47 -0.24 Diabetic kidney disease; chr7:66532895 chr7:66654538~66669855:+ LUSC cis rs2243480 0.901 rs13237344 ENSG00000226824.5 RP4-756H11.3 -5.44 8.54e-08 2.8e-05 -0.47 -0.24 Diabetic kidney disease; chr7:66557269 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs1796228 ENSG00000226824.5 RP4-756H11.3 -5.44 8.54e-08 2.8e-05 -0.47 -0.24 Diabetic kidney disease; chr7:66568097 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs1267820 ENSG00000226824.5 RP4-756H11.3 -5.44 8.54e-08 2.8e-05 -0.47 -0.24 Diabetic kidney disease; chr7:66585308 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs2533288 ENSG00000226824.5 RP4-756H11.3 -5.44 8.54e-08 2.8e-05 -0.47 -0.24 Diabetic kidney disease; chr7:66591724 chr7:66654538~66669855:+ LUSC cis rs7615952 0.576 rs17523380 ENSG00000250012.1 RP11-124N2.1 -5.44 8.54e-08 2.8e-05 -0.27 -0.24 Blood pressure (smoking interaction); chr3:126084031 chr3:126084220~126095349:+ LUSC cis rs9611519 0.78 rs2235849 ENSG00000235513.1 RP4-756G23.5 5.44 8.55e-08 2.81e-05 0.27 0.24 Neuroticism; chr22:41257536 chr22:41209122~41217627:- LUSC cis rs270601 0.721 rs162894 ENSG00000233006.5 AC034220.3 5.44 8.55e-08 2.81e-05 0.25 0.24 Acylcarnitine levels; chr5:132276179 chr5:132311285~132369916:- LUSC cis rs4938573 0.526 rs11216973 ENSG00000255422.1 AP002954.4 5.44 8.55e-08 2.81e-05 0.33 0.24 Follicular lymphoma; chr11:118716292 chr11:118704607~118750263:+ LUSC cis rs35740288 0.77 rs11631660 ENSG00000202081.1 RNU6-1280P -5.44 8.56e-08 2.81e-05 -0.3 -0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85672181 chr15:85651522~85651628:- LUSC cis rs1707322 0.752 rs12062535 ENSG00000234329.1 RP11-767N6.2 5.44 8.56e-08 2.81e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45757208 chr1:45651039~45651826:- LUSC cis rs13113518 1 rs55699500 ENSG00000223305.1 RN7SKP30 5.44 8.57e-08 2.81e-05 0.3 0.24 Height; chr4:55540912 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs56362210 ENSG00000223305.1 RN7SKP30 5.44 8.57e-08 2.81e-05 0.3 0.24 Height; chr4:55540972 chr4:55540502~55540835:- LUSC cis rs875971 0.545 rs6970498 ENSG00000224316.1 RP11-479O9.2 5.44 8.57e-08 2.81e-05 0.26 0.24 Aortic root size; chr7:66275908 chr7:65773620~65802067:+ LUSC cis rs13113518 1 rs12651640 ENSG00000272969.1 RP11-528I4.2 5.44 8.58e-08 2.82e-05 0.28 0.24 Height; chr4:55454154 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs1554483 ENSG00000272969.1 RP11-528I4.2 5.44 8.58e-08 2.82e-05 0.28 0.24 Height; chr4:55455650 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs1464490 ENSG00000272969.1 RP11-528I4.2 5.44 8.58e-08 2.82e-05 0.28 0.24 Height; chr4:55456620 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs10517346 ENSG00000272969.1 RP11-528I4.2 5.44 8.58e-08 2.82e-05 0.28 0.24 Height; chr4:55457027 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs11133384 ENSG00000272969.1 RP11-528I4.2 5.44 8.58e-08 2.82e-05 0.28 0.24 Height; chr4:55457086 chr4:55547112~55547889:+ LUSC cis rs3743772 0.5 rs8045574 ENSG00000279722.1 RP11-44F14.6 -5.44 8.58e-08 2.82e-05 -0.36 -0.24 Depressive symptoms (SSRI exposure interaction); chr16:53395293 chr16:53487607~53489943:- LUSC cis rs910316 0.726 rs61979167 ENSG00000279594.1 RP11-950C14.10 -5.44 8.58e-08 2.82e-05 -0.29 -0.24 Height; chr14:75196907 chr14:75011269~75012851:- LUSC cis rs71403859 0.614 rs12149533 ENSG00000260886.1 TAT-AS1 5.44 8.59e-08 2.82e-05 0.41 0.24 Post bronchodilator FEV1; chr16:71768043 chr16:71565789~71578187:+ LUSC cis rs6502050 0.731 rs9892653 ENSG00000266654.1 RP11-1376P16.1 -5.44 8.59e-08 2.82e-05 -0.24 -0.24 Life satisfaction; chr17:82142315 chr17:82160056~82160452:+ LUSC cis rs9810089 0.676 rs526574 ENSG00000261758.1 RP11-102M11.2 5.44 8.6e-08 2.82e-05 0.23 0.24 Gestational age at birth (child effect); chr3:136384507 chr3:136752630~136755780:+ LUSC cis rs7772486 0.719 rs4391282 ENSG00000235652.6 RP11-545I5.3 -5.44 8.6e-08 2.82e-05 -0.24 -0.24 Lobe attachment (rater-scored or self-reported); chr6:145955644 chr6:145799409~145886585:+ LUSC cis rs9611519 0.964 rs2092563 ENSG00000235513.1 RP4-756G23.5 5.44 8.6e-08 2.82e-05 0.29 0.24 Neuroticism; chr22:41196673 chr22:41209122~41217627:- LUSC cis rs875971 0.545 rs2707851 ENSG00000179406.6 LINC00174 5.44 8.61e-08 2.83e-05 0.29 0.24 Aortic root size; chr7:66624178 chr7:66376044~66401338:- LUSC cis rs1707322 0.721 rs11211149 ENSG00000234329.1 RP11-767N6.2 5.44 8.62e-08 2.83e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45646546 chr1:45651039~45651826:- LUSC cis rs7267979 0.604 rs242130 ENSG00000274973.1 RP13-401N8.7 5.44 8.63e-08 2.83e-05 0.25 0.24 Liver enzyme levels (alkaline phosphatase); chr20:25613384 chr20:25845497~25845862:+ LUSC cis rs6504950 0.85 rs2628321 ENSG00000275710.1 RP11-257O5.4 5.44 8.63e-08 2.83e-05 0.28 0.24 Breast cancer; chr17:55128556 chr17:54964474~54964679:+ LUSC cis rs11650066 0.678 rs57640529 ENSG00000265356.1 RP11-17M24.1 5.44 8.64e-08 2.83e-05 0.29 0.24 Coronary heart disease; chr17:33968614 chr17:33931132~33936206:- LUSC cis rs61270009 0.955 rs415302 ENSG00000247828.6 TMEM161B-AS1 -5.44 8.64e-08 2.83e-05 -0.27 -0.24 Depressive symptoms; chr5:88231628 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs780398 ENSG00000247828.6 TMEM161B-AS1 -5.44 8.64e-08 2.83e-05 -0.27 -0.24 Depressive symptoms; chr5:88234112 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs780399 ENSG00000247828.6 TMEM161B-AS1 -5.44 8.64e-08 2.83e-05 -0.27 -0.24 Depressive symptoms; chr5:88237160 chr5:88268895~88436685:+ LUSC cis rs61270009 0.913 rs380670 ENSG00000247828.6 TMEM161B-AS1 -5.44 8.64e-08 2.83e-05 -0.27 -0.24 Depressive symptoms; chr5:88243132 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs379430 ENSG00000247828.6 TMEM161B-AS1 -5.44 8.64e-08 2.83e-05 -0.27 -0.24 Depressive symptoms; chr5:88243275 chr5:88268895~88436685:+ LUSC cis rs910316 0.737 rs108621 ENSG00000279594.1 RP11-950C14.10 -5.44 8.65e-08 2.84e-05 -0.28 -0.24 Height; chr14:75013934 chr14:75011269~75012851:- LUSC cis rs73173548 0.502 rs12516483 ENSG00000247828.6 TMEM161B-AS1 5.44 8.65e-08 2.84e-05 0.29 0.24 Macular telangiectasia type 2; chr5:88454718 chr5:88268895~88436685:+ LUSC cis rs6723108 0.517 rs6430548 ENSG00000224043.6 CCNT2-AS1 -5.44 8.65e-08 2.84e-05 -0.3 -0.24 Type 2 diabetes; chr2:134854869 chr2:134735464~134918710:- LUSC cis rs17361889 0.671 rs1527201 ENSG00000224683.1 RPL36AP29 -5.44 8.66e-08 2.84e-05 -0.29 -0.24 Pediatric bone mineral content (hip); chr7:16111403 chr7:16208945~16209265:+ LUSC cis rs1008375 1 rs1121090 ENSG00000249502.1 AC006160.5 -5.44 8.66e-08 2.84e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17674814 chr4:17587467~17614571:- LUSC cis rs910316 0.737 rs175055 ENSG00000279594.1 RP11-950C14.10 -5.44 8.66e-08 2.84e-05 -0.28 -0.24 Height; chr14:75022243 chr14:75011269~75012851:- LUSC cis rs1008375 0.931 rs10008337 ENSG00000249502.1 AC006160.5 -5.44 8.67e-08 2.84e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17592226 chr4:17587467~17614571:- LUSC cis rs6502050 0.835 rs10163496 ENSG00000266654.1 RP11-1376P16.1 -5.44 8.67e-08 2.84e-05 -0.24 -0.24 Life satisfaction; chr17:82152991 chr17:82160056~82160452:+ LUSC cis rs11098499 0.954 rs10034623 ENSG00000248280.1 RP11-33B1.2 5.44 8.67e-08 2.84e-05 0.29 0.24 Corneal astigmatism; chr4:119476674 chr4:119440561~119450157:- LUSC cis rs42490 1 rs13252917 ENSG00000251136.7 RP11-37B2.1 -5.44 8.68e-08 2.85e-05 -0.21 -0.24 Leprosy; chr8:89747202 chr8:89609409~89757727:- LUSC cis rs42490 1 rs6470366 ENSG00000251136.7 RP11-37B2.1 -5.44 8.68e-08 2.85e-05 -0.21 -0.24 Leprosy; chr8:89747760 chr8:89609409~89757727:- LUSC cis rs42490 1 rs10112852 ENSG00000251136.7 RP11-37B2.1 -5.44 8.68e-08 2.85e-05 -0.21 -0.24 Leprosy; chr8:89749257 chr8:89609409~89757727:- LUSC cis rs3738443 0.817 rs61840053 ENSG00000259865.1 RP11-488L18.10 5.44 8.68e-08 2.85e-05 0.25 0.24 Alcohol dependence; chr1:247204038 chr1:247187281~247188526:- LUSC cis rs6504950 0.925 rs244377 ENSG00000275710.1 RP11-257O5.4 -5.44 8.69e-08 2.85e-05 -0.29 -0.24 Breast cancer; chr17:55105718 chr17:54964474~54964679:+ LUSC cis rs13113518 1 rs11726198 ENSG00000223305.1 RN7SKP30 5.44 8.7e-08 2.85e-05 0.29 0.24 Height; chr4:55523835 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs7675109 ENSG00000223305.1 RN7SKP30 5.44 8.7e-08 2.85e-05 0.29 0.24 Height; chr4:55525589 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs4865005 ENSG00000223305.1 RN7SKP30 5.44 8.7e-08 2.85e-05 0.29 0.24 Height; chr4:55525781 chr4:55540502~55540835:- LUSC cis rs8059260 0.604 rs12928945 ENSG00000274038.1 RP11-66H6.4 -5.44 8.71e-08 2.85e-05 -0.42 -0.24 Alcohol consumption over the past year; chr16:11106309 chr16:11056556~11057034:+ LUSC cis rs13434995 0.513 rs1021307 ENSG00000249700.7 SRD5A3-AS1 5.44 8.71e-08 2.85e-05 0.31 0.24 Adiponectin levels; chr4:55529547 chr4:55363971~55395847:- LUSC cis rs11098499 0.954 rs11098524 ENSG00000250412.1 KLHL2P1 5.44 8.71e-08 2.86e-05 0.31 0.24 Corneal astigmatism; chr4:119468877 chr4:119334329~119378233:+ LUSC cis rs11098499 0.954 rs11729521 ENSG00000248280.1 RP11-33B1.2 5.44 8.72e-08 2.86e-05 0.29 0.24 Corneal astigmatism; chr4:119495633 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs11734241 ENSG00000248280.1 RP11-33B1.2 5.44 8.72e-08 2.86e-05 0.29 0.24 Corneal astigmatism; chr4:119495717 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs28685688 ENSG00000248280.1 RP11-33B1.2 5.44 8.72e-08 2.86e-05 0.29 0.24 Corneal astigmatism; chr4:119499179 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs7687843 ENSG00000248280.1 RP11-33B1.2 5.44 8.72e-08 2.86e-05 0.29 0.24 Corneal astigmatism; chr4:119500056 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs2306455 ENSG00000248280.1 RP11-33B1.2 5.44 8.72e-08 2.86e-05 0.29 0.24 Corneal astigmatism; chr4:119500814 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs10031483 ENSG00000248280.1 RP11-33B1.2 5.44 8.72e-08 2.86e-05 0.29 0.24 Corneal astigmatism; chr4:119501481 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs10031665 ENSG00000248280.1 RP11-33B1.2 5.44 8.72e-08 2.86e-05 0.29 0.24 Corneal astigmatism; chr4:119501697 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs3733523 ENSG00000248280.1 RP11-33B1.2 5.44 8.72e-08 2.86e-05 0.29 0.24 Corneal astigmatism; chr4:119502564 chr4:119440561~119450157:- LUSC cis rs7804306 0.826 rs6975218 ENSG00000233264.2 AC006042.8 5.44 8.72e-08 2.86e-05 0.47 0.24 Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts; chr7:7981982 chr7:7980312~7982228:+ LUSC cis rs3738443 0.868 rs7546908 ENSG00000259865.1 RP11-488L18.10 -5.44 8.72e-08 2.86e-05 -0.25 -0.24 Alcohol dependence; chr1:247200531 chr1:247187281~247188526:- LUSC cis rs10759883 0.563 rs10739705 ENSG00000175611.10 LINC00476 5.44 8.73e-08 2.86e-05 0.28 0.24 Nicotine dependence; chr9:95900857 chr9:95759231~95875977:- LUSC cis rs9649213 0.593 rs7807555 ENSG00000272950.1 RP11-307C18.1 5.44 8.73e-08 2.86e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98328205 chr7:98322853~98323430:+ LUSC cis rs9649213 0.593 rs7807455 ENSG00000272950.1 RP11-307C18.1 5.44 8.73e-08 2.86e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98328310 chr7:98322853~98323430:+ LUSC cis rs9649213 0.593 rs6465667 ENSG00000272950.1 RP11-307C18.1 5.44 8.73e-08 2.86e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98328573 chr7:98322853~98323430:+ LUSC cis rs9649213 0.593 rs6949214 ENSG00000272950.1 RP11-307C18.1 5.44 8.73e-08 2.86e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98330921 chr7:98322853~98323430:+ LUSC cis rs116139393 0.54 rs12539942 ENSG00000187953.9 PMS2CL -5.44 8.74e-08 2.86e-05 -0.32 -0.24 Alzheimer's disease (APOE e4 interaction); chr7:6736954 chr7:6710128~6753862:+ LUSC cis rs9611519 0.894 rs9611488 ENSG00000235513.1 RP4-756G23.5 5.44 8.74e-08 2.86e-05 0.29 0.24 Neuroticism; chr22:41066588 chr22:41209122~41217627:- LUSC cis rs6502050 0.835 rs3924781 ENSG00000266654.1 RP11-1376P16.1 -5.44 8.74e-08 2.86e-05 -0.24 -0.24 Life satisfaction; chr17:82155254 chr17:82160056~82160452:+ LUSC cis rs9341808 0.667 rs2505944 ENSG00000272129.1 RP11-250B2.6 5.44 8.74e-08 2.86e-05 0.3 0.24 Sitting height ratio; chr6:80178693 chr6:80355424~80356859:+ LUSC cis rs4332428 1 rs66624122 ENSG00000239148.1 U8 -5.44 8.74e-08 2.86e-05 -0.27 -0.24 Height; chr10:4938847 chr10:5004710~5004842:+ LUSC cis rs4332428 1 rs34373625 ENSG00000239148.1 U8 -5.44 8.74e-08 2.86e-05 -0.27 -0.24 Height; chr10:4939009 chr10:5004710~5004842:+ LUSC cis rs12468226 1 rs13426118 ENSG00000272966.1 RP11-686O6.1 5.44 8.75e-08 2.86e-05 0.36 0.24 Urate levels; chr2:202390762 chr2:202336739~202337200:+ LUSC cis rs9611519 0.78 rs5751071 ENSG00000235513.1 RP4-756G23.5 5.44 8.75e-08 2.86e-05 0.28 0.24 Neuroticism; chr22:41260328 chr22:41209122~41217627:- LUSC cis rs638893 0.528 rs521910 ENSG00000278376.1 RP11-158I9.8 5.44 8.75e-08 2.87e-05 0.3 0.24 Vitiligo; chr11:118739920 chr11:118791254~118793137:+ LUSC cis rs66887589 0.775 rs6843229 ENSG00000248280.1 RP11-33B1.2 5.44 8.75e-08 2.87e-05 0.27 0.24 Diastolic blood pressure; chr4:119502932 chr4:119440561~119450157:- LUSC cis rs7712401 0.601 rs246321 ENSG00000263432.2 RN7SL689P 5.44 8.76e-08 2.87e-05 0.31 0.24 Mean platelet volume; chr5:122972604 chr5:123022487~123022783:- LUSC cis rs1707322 0.716 rs10890342 ENSG00000234329.1 RP11-767N6.2 5.44 8.77e-08 2.87e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45691415 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs6658700 ENSG00000234329.1 RP11-767N6.2 5.44 8.77e-08 2.87e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45694588 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs12047629 ENSG00000234329.1 RP11-767N6.2 5.44 8.77e-08 2.87e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697130 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs11211169 ENSG00000234329.1 RP11-767N6.2 5.44 8.77e-08 2.87e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701037 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs11211171 ENSG00000234329.1 RP11-767N6.2 5.44 8.77e-08 2.87e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45702970 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs28623463 ENSG00000234329.1 RP11-767N6.2 5.44 8.77e-08 2.87e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45705086 chr1:45651039~45651826:- LUSC cis rs1707322 0.716 rs28370457 ENSG00000234329.1 RP11-767N6.2 5.44 8.77e-08 2.87e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706390 chr1:45651039~45651826:- LUSC cis rs2243480 0.901 rs35087093 ENSG00000226824.5 RP4-756H11.3 -5.44 8.77e-08 2.87e-05 -0.47 -0.24 Diabetic kidney disease; chr7:65940221 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs35046236 ENSG00000226824.5 RP4-756H11.3 -5.44 8.77e-08 2.87e-05 -0.47 -0.24 Diabetic kidney disease; chr7:65943626 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs36068983 ENSG00000226824.5 RP4-756H11.3 -5.44 8.77e-08 2.87e-05 -0.47 -0.24 Diabetic kidney disease; chr7:65944004 chr7:66654538~66669855:+ LUSC cis rs2243480 1 rs68189316 ENSG00000226824.5 RP4-756H11.3 -5.44 8.77e-08 2.87e-05 -0.47 -0.24 Diabetic kidney disease; chr7:65944182 chr7:66654538~66669855:+ LUSC cis rs2243480 0.803 rs34804747 ENSG00000226824.5 RP4-756H11.3 -5.44 8.77e-08 2.87e-05 -0.47 -0.24 Diabetic kidney disease; chr7:65947955 chr7:66654538~66669855:+ LUSC cis rs12554020 0.582 rs12552323 ENSG00000227603.1 RP11-165J3.6 -5.44 8.78e-08 2.87e-05 -0.39 -0.24 Schizophrenia; chr9:93680532 chr9:93435332~93437121:- LUSC cis rs367615 0.704 rs6889301 ENSG00000249476.1 CTD-2587M2.1 5.44 8.78e-08 2.87e-05 0.28 0.24 Colorectal cancer (SNP x SNP interaction); chr5:109499480 chr5:109237120~109326369:- LUSC cis rs367615 0.661 rs9326775 ENSG00000249476.1 CTD-2587M2.1 5.44 8.78e-08 2.87e-05 0.28 0.24 Colorectal cancer (SNP x SNP interaction); chr5:109501224 chr5:109237120~109326369:- LUSC cis rs875971 0.545 rs66594357 ENSG00000179406.6 LINC00174 -5.44 8.79e-08 2.88e-05 -0.28 -0.24 Aortic root size; chr7:66327797 chr7:66376044~66401338:- LUSC cis rs2554380 0.628 rs963690 ENSG00000230373.7 GOLGA6L5P -5.44 8.8e-08 2.88e-05 -0.24 -0.24 Height; chr15:83771068 chr15:84507885~84516814:- LUSC cis rs8177376 0.727 rs645852 ENSG00000254905.1 RP11-712L6.7 5.44 8.8e-08 2.88e-05 0.32 0.24 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126327509 chr11:126292922~126294254:- LUSC cis rs8177376 0.727 rs646775 ENSG00000254905.1 RP11-712L6.7 5.44 8.8e-08 2.88e-05 0.32 0.24 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126327704 chr11:126292922~126294254:- LUSC cis rs6502050 0.871 rs62079994 ENSG00000266654.1 RP11-1376P16.1 5.44 8.81e-08 2.88e-05 0.25 0.24 Life satisfaction; chr17:82118640 chr17:82160056~82160452:+ LUSC cis rs11846409 0.655 rs79296226 ENSG00000274576.2 IGHV2-70 5.44 8.81e-08 2.88e-05 0.25 0.24 Rheumatic heart disease; chr14:106650436 chr14:106770577~106771020:- LUSC cis rs875971 0.522 rs781144 ENSG00000237310.1 GS1-124K5.4 5.44 8.81e-08 2.88e-05 0.25 0.24 Aortic root size; chr7:65975357 chr7:66493706~66495474:+ LUSC cis rs853679 1 rs2799079 ENSG00000204709.4 LINC01556 5.44 8.82e-08 2.89e-05 0.37 0.24 Depression; chr6:28267398 chr6:28943877~28944537:+ LUSC cis rs910316 0.783 rs11850751 ENSG00000279594.1 RP11-950C14.10 5.43 8.82e-08 2.89e-05 0.28 0.24 Height; chr14:75123410 chr14:75011269~75012851:- LUSC cis rs6969780 0.915 rs17471520 ENSG00000233429.8 HOTAIRM1 5.43 8.82e-08 2.89e-05 0.46 0.24 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27139171 chr7:27095647~27100265:+ LUSC cis rs7432375 0.901 rs1681817 ENSG00000261758.1 RP11-102M11.2 -5.43 8.82e-08 2.89e-05 -0.23 -0.24 Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia; chr3:136754886 chr3:136752630~136755780:+ LUSC cis rs7208859 0.623 rs7214570 ENSG00000263603.1 CTD-2349P21.5 -5.43 8.82e-08 2.89e-05 -0.34 -0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30820146 chr17:30729469~30731202:+ LUSC cis rs2245368 0.523 rs67814714 ENSG00000242435.1 UPK3BP1 5.43 8.82e-08 2.89e-05 0.37 0.24 Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index; chr7:76888105 chr7:77004662~77005774:+ LUSC cis rs7772486 0.875 rs2814871 ENSG00000235652.6 RP11-545I5.3 5.43 8.82e-08 2.89e-05 0.24 0.24 Lobe attachment (rater-scored or self-reported); chr6:145991138 chr6:145799409~145886585:+ LUSC cis rs11098499 0.754 rs4107728 ENSG00000250412.1 KLHL2P1 5.43 8.83e-08 2.89e-05 0.3 0.24 Corneal astigmatism; chr4:119332755 chr4:119334329~119378233:+ LUSC cis rs6502050 0.736 rs12150322 ENSG00000266654.1 RP11-1376P16.1 5.43 8.83e-08 2.89e-05 0.24 0.24 Life satisfaction; chr17:82103706 chr17:82160056~82160452:+ LUSC cis rs889398 0.869 rs862320 ENSG00000226232.7 RP11-419C5.2 5.43 8.84e-08 2.89e-05 0.24 0.24 Body mass index; chr16:69617963 chr16:69976388~69996188:- LUSC cis rs16843372 0.563 rs13397887 ENSG00000251491.2 OR7E28P -5.43 8.84e-08 2.89e-05 -0.26 -0.24 Obesity-related traits; chr2:158830147 chr2:158862311~158863285:+ LUSC cis rs16843372 0.563 rs13398569 ENSG00000251491.2 OR7E28P -5.43 8.84e-08 2.89e-05 -0.26 -0.24 Obesity-related traits; chr2:158830764 chr2:158862311~158863285:+ LUSC cis rs16843372 0.563 rs13398901 ENSG00000251491.2 OR7E28P -5.43 8.84e-08 2.89e-05 -0.26 -0.24 Obesity-related traits; chr2:158831058 chr2:158862311~158863285:+ LUSC cis rs4964805 0.537 rs11111750 ENSG00000257681.1 RP11-341G23.4 5.43 8.84e-08 2.89e-05 0.27 0.24 Attention deficit hyperactivity disorder; chr12:103761762 chr12:103746315~103768858:- LUSC cis rs910316 0.967 rs8007539 ENSG00000279594.1 RP11-950C14.10 -5.43 8.84e-08 2.89e-05 -0.27 -0.24 Height; chr14:75198250 chr14:75011269~75012851:- LUSC cis rs783540 0.967 rs1145173 ENSG00000276710.3 CSPG4P8 5.43 8.84e-08 2.89e-05 0.26 0.24 Schizophrenia; chr15:82554675 chr15:82459472~82477258:+ LUSC cis rs783540 0.967 rs1145172 ENSG00000276710.3 CSPG4P8 5.43 8.84e-08 2.89e-05 0.26 0.24 Schizophrenia; chr15:82554866 chr15:82459472~82477258:+ LUSC cis rs442309 0.841 rs224030 ENSG00000238280.1 RP11-436D10.3 -5.43 8.85e-08 2.9e-05 -0.3 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62760375 chr10:62793562~62805887:- LUSC cis rs7829975 0.606 rs6422352 ENSG00000253893.2 FAM85B 5.43 8.85e-08 2.9e-05 0.28 0.24 Mood instability; chr8:8936683 chr8:8167819~8226614:- LUSC cis rs67311347 1 rs12634013 ENSG00000223797.4 ENTPD3-AS1 5.43 8.86e-08 2.9e-05 0.29 0.24 Renal cell carcinoma; chr3:40410897 chr3:40313802~40453329:- LUSC cis rs9611519 0.894 rs4821998 ENSG00000235513.1 RP4-756G23.5 5.43 8.86e-08 2.9e-05 0.29 0.24 Neuroticism; chr22:41072269 chr22:41209122~41217627:- LUSC cis rs227275 0.524 rs223337 ENSG00000248971.2 KRT8P46 -5.43 8.86e-08 2.9e-05 -0.28 -0.24 Allergic disease (asthma, hay fever or eczema); chr4:102865214 chr4:102728746~102730171:- LUSC cis rs2243480 0.901 rs1701759 ENSG00000226824.5 RP4-756H11.3 -5.43 8.87e-08 2.9e-05 -0.48 -0.24 Diabetic kidney disease; chr7:66005945 chr7:66654538~66669855:+ LUSC cis rs11098499 0.865 rs11722183 ENSG00000248280.1 RP11-33B1.2 5.43 8.87e-08 2.9e-05 0.29 0.24 Corneal astigmatism; chr4:119359442 chr4:119440561~119450157:- LUSC cis rs11098499 0.754 rs1849457 ENSG00000250412.1 KLHL2P1 5.43 8.87e-08 2.9e-05 0.3 0.24 Corneal astigmatism; chr4:119333200 chr4:119334329~119378233:+ LUSC cis rs7955901 0.691 rs10784889 ENSG00000257265.1 CTD-2021H9.1 -5.43 8.87e-08 2.9e-05 -0.28 -0.24 Type 2 diabetes; chr12:71015481 chr12:71007773~71032083:- LUSC cis rs6502050 0.835 rs9900128 ENSG00000266654.1 RP11-1376P16.1 -5.43 8.87e-08 2.9e-05 -0.24 -0.24 Life satisfaction; chr17:82130044 chr17:82160056~82160452:+ LUSC cis rs6502050 0.731 rs11867299 ENSG00000266654.1 RP11-1376P16.1 -5.43 8.87e-08 2.9e-05 -0.24 -0.24 Life satisfaction; chr17:82130799 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs66531647 ENSG00000266654.1 RP11-1376P16.1 -5.43 8.87e-08 2.9e-05 -0.24 -0.24 Life satisfaction; chr17:82131146 chr17:82160056~82160452:+ LUSC cis rs1008375 0.932 rs2302391 ENSG00000249502.1 AC006160.5 -5.43 8.88e-08 2.9e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17658614 chr4:17587467~17614571:- LUSC cis rs7955901 0.837 rs1877527 ENSG00000257265.1 CTD-2021H9.1 -5.43 8.88e-08 2.9e-05 -0.27 -0.24 Type 2 diabetes; chr12:71011426 chr12:71007773~71032083:- LUSC cis rs17270561 0.609 rs7450798 ENSG00000272462.2 U91328.19 -5.43 8.89e-08 2.91e-05 -0.29 -0.24 Iron status biomarkers; chr6:25719052 chr6:25992662~26001775:+ LUSC cis rs7826238 0.524 rs2921055 ENSG00000173295.6 FAM86B3P 5.43 8.9e-08 2.91e-05 0.27 0.24 Systolic blood pressure; chr8:8461832 chr8:8228595~8244865:+ LUSC cis rs2919917 0.59 rs2919919 ENSG00000254352.1 RP11-578O24.2 -5.43 8.9e-08 2.91e-05 -0.33 -0.24 Lymphocyte counts; chr8:78745274 chr8:78723796~78724136:- LUSC cis rs1008375 1 rs917665 ENSG00000249502.1 AC006160.5 5.43 8.9e-08 2.91e-05 0.23 0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17666881 chr4:17587467~17614571:- LUSC cis rs6502050 0.835 rs7502548 ENSG00000266654.1 RP11-1376P16.1 5.43 8.9e-08 2.91e-05 0.24 0.24 Life satisfaction; chr17:82129693 chr17:82160056~82160452:+ LUSC cis rs6502050 0.835 rs7222057 ENSG00000266654.1 RP11-1376P16.1 -5.43 8.9e-08 2.91e-05 -0.24 -0.24 Life satisfaction; chr17:82129771 chr17:82160056~82160452:+ LUSC cis rs4845875 0.535 rs198408 ENSG00000242349.4 NPPA-AS1 -5.43 8.9e-08 2.91e-05 -0.24 -0.24 Midregional pro atrial natriuretic peptide levels; chr1:11838073 chr1:11841017~11848079:+ LUSC cis rs11098499 0.754 rs28643450 ENSG00000250412.1 KLHL2P1 5.43 8.92e-08 2.91e-05 0.3 0.24 Corneal astigmatism; chr4:119324087 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs7672594 ENSG00000250412.1 KLHL2P1 5.43 8.92e-08 2.91e-05 0.3 0.24 Corneal astigmatism; chr4:119327388 chr4:119334329~119378233:+ LUSC cis rs13113518 1 rs4864995 ENSG00000272969.1 RP11-528I4.2 5.43 8.92e-08 2.92e-05 0.28 0.24 Height; chr4:55452853 chr4:55547112~55547889:+ LUSC cis rs2742234 0.504 rs10899780 ENSG00000273008.1 RP11-351D16.3 5.43 8.93e-08 2.92e-05 0.28 0.24 Hirschsprung disease; chr10:43230348 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs11238483 ENSG00000273008.1 RP11-351D16.3 5.43 8.93e-08 2.92e-05 0.28 0.24 Hirschsprung disease; chr10:43233332 chr10:43136824~43138334:- LUSC cis rs7727544 0.904 rs58835386 ENSG00000233006.5 AC034220.3 5.43 8.93e-08 2.92e-05 0.23 0.24 Blood metabolite levels; chr5:132264866 chr5:132311285~132369916:- LUSC cis rs1707322 0.752 rs11211168 ENSG00000234329.1 RP11-767N6.2 5.43 8.94e-08 2.92e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697975 chr1:45651039~45651826:- LUSC cis rs4639966 0.589 rs480958 ENSG00000255422.1 AP002954.4 -5.43 8.95e-08 2.92e-05 -0.27 -0.24 Systemic lupus erythematosus; chr11:118707281 chr11:118704607~118750263:+ LUSC cis rs2739330 0.703 rs5760112 ENSG00000228039.3 KB-1125A3.10 5.43 8.95e-08 2.93e-05 0.31 0.24 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23963780~23964374:+ LUSC cis rs8133932 0.736 rs4818804 ENSG00000280604.1 PCBP3-OT1 5.43 8.96e-08 2.93e-05 0.32 0.24 Schizophrenia; chr21:45862717 chr21:45914296~45919483:+ LUSC cis rs12458462 0.892 rs2007483 ENSG00000274828.1 RP11-567M16.6 5.43 8.97e-08 2.93e-05 0.25 0.24 Monocyte count; chr18:79716131 chr18:79677287~79679358:- LUSC cis rs380904 0.519 rs10102146 ENSG00000254859.1 RP11-661A12.5 5.43 8.98e-08 2.93e-05 0.35 0.24 Venous thromboembolism (SNP x SNP interaction); chr8:143566986 chr8:143541973~143549729:- LUSC cis rs673078 0.607 rs111607725 ENSG00000275409.1 RP11-131L12.4 -5.43 8.99e-08 2.94e-05 -0.35 -0.24 Glucose homeostasis traits; chr12:118442957 chr12:118430147~118430699:+ LUSC cis rs10028773 0.7 rs7671797 ENSG00000250412.1 KLHL2P1 5.43 8.99e-08 2.94e-05 0.3 0.24 Educational attainment; chr4:119327002 chr4:119334329~119378233:+ LUSC cis rs1008375 0.931 rs1860592 ENSG00000249502.1 AC006160.5 -5.43 8.99e-08 2.94e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17575405 chr4:17587467~17614571:- LUSC cis rs1008375 0.898 rs2079892 ENSG00000249502.1 AC006160.5 -5.43 8.99e-08 2.94e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17575540 chr4:17587467~17614571:- LUSC cis rs1008375 0.966 rs6825133 ENSG00000249502.1 AC006160.5 -5.43 8.99e-08 2.94e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17576153 chr4:17587467~17614571:- LUSC cis rs1008375 0.966 rs2315645 ENSG00000249502.1 AC006160.5 -5.43 8.99e-08 2.94e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17578055 chr4:17587467~17614571:- LUSC cis rs1008375 0.966 rs4698619 ENSG00000249502.1 AC006160.5 -5.43 8.99e-08 2.94e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17579332 chr4:17587467~17614571:- LUSC cis rs1008375 0.966 rs10939736 ENSG00000249502.1 AC006160.5 -5.43 8.99e-08 2.94e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17579994 chr4:17587467~17614571:- LUSC cis rs910316 0.967 rs7146523 ENSG00000279594.1 RP11-950C14.10 -5.43 9e-08 2.94e-05 -0.28 -0.24 Height; chr14:75193177 chr14:75011269~75012851:- LUSC cis rs13434995 0.513 rs17779627 ENSG00000249700.7 SRD5A3-AS1 -5.43 9e-08 2.94e-05 -0.31 -0.24 Adiponectin levels; chr4:55483775 chr4:55363971~55395847:- LUSC cis rs9311474 1 rs7614727 ENSG00000243224.1 RP5-1157M23.2 -5.43 9e-08 2.94e-05 -0.24 -0.24 Electroencephalogram traits; chr3:52261879 chr3:52239258~52241097:+ LUSC cis rs11098499 0.865 rs28634456 ENSG00000248280.1 RP11-33B1.2 5.43 9e-08 2.94e-05 0.3 0.24 Corneal astigmatism; chr4:119454623 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs78332141 ENSG00000248280.1 RP11-33B1.2 5.43 9e-08 2.94e-05 0.3 0.24 Corneal astigmatism; chr4:119454627 chr4:119440561~119450157:- LUSC cis rs2243480 1 rs73142166 ENSG00000226824.5 RP4-756H11.3 -5.43 9e-08 2.94e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65910845 chr7:66654538~66669855:+ LUSC cis rs2243480 0.908 rs55876148 ENSG00000226824.5 RP4-756H11.3 -5.43 9e-08 2.94e-05 -0.48 -0.24 Diabetic kidney disease; chr7:65914813 chr7:66654538~66669855:+ LUSC cis rs6832769 0.961 rs6824955 ENSG00000272969.1 RP11-528I4.2 5.43 9e-08 2.94e-05 0.28 0.24 Personality dimensions; chr4:55450969 chr4:55547112~55547889:+ LUSC cis rs11098499 0.909 rs28884220 ENSG00000248280.1 RP11-33B1.2 5.43 9.02e-08 2.95e-05 0.29 0.24 Corneal astigmatism; chr4:119386056 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs28793658 ENSG00000248280.1 RP11-33B1.2 5.43 9.02e-08 2.95e-05 0.29 0.24 Corneal astigmatism; chr4:119386059 chr4:119440561~119450157:- LUSC cis rs35160687 0.712 rs6705366 ENSG00000273080.1 RP11-301O19.1 -5.43 9.02e-08 2.95e-05 -0.23 -0.24 Night sleep phenotypes; chr2:86257659 chr2:86195590~86196049:+ LUSC cis rs7772486 0.79 rs9386141 ENSG00000235652.6 RP11-545I5.3 -5.43 9.02e-08 2.95e-05 -0.24 -0.24 Lobe attachment (rater-scored or self-reported); chr6:145947487 chr6:145799409~145886585:+ LUSC cis rs950880 0.593 rs887972 ENSG00000234389.1 AC007278.3 -5.43 9.04e-08 2.95e-05 -0.26 -0.24 Serum protein levels (sST2); chr2:102424485 chr2:102438713~102440475:+ LUSC cis rs6740322 0.696 rs11685054 ENSG00000234936.1 AC010883.5 5.43 9.04e-08 2.95e-05 0.28 0.24 Coronary artery disease; chr2:43247156 chr2:43229573~43233394:+ LUSC cis rs1707322 0.721 rs11211151 ENSG00000234329.1 RP11-767N6.2 5.43 9.04e-08 2.95e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45647080 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs12045096 ENSG00000234329.1 RP11-767N6.2 5.43 9.04e-08 2.95e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648756 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs4609469 ENSG00000234329.1 RP11-767N6.2 5.43 9.04e-08 2.95e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651513 chr1:45651039~45651826:- LUSC cis rs1707322 0.721 rs12049027 ENSG00000234329.1 RP11-767N6.2 5.43 9.04e-08 2.95e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45652512 chr1:45651039~45651826:- LUSC cis rs1707322 0.752 rs10789467 ENSG00000234329.1 RP11-767N6.2 5.43 9.04e-08 2.95e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45653073 chr1:45651039~45651826:- LUSC cis rs66887589 0.616 rs11732621 ENSG00000250412.1 KLHL2P1 5.43 9.04e-08 2.95e-05 0.28 0.24 Diastolic blood pressure; chr4:119291728 chr4:119334329~119378233:+ LUSC cis rs6504950 0.745 rs12949718 ENSG00000275710.1 RP11-257O5.4 -5.43 9.04e-08 2.95e-05 -0.28 -0.24 Breast cancer; chr17:54904492 chr17:54964474~54964679:+ LUSC cis rs8133932 0.701 rs2183599 ENSG00000280604.1 PCBP3-OT1 5.43 9.04e-08 2.95e-05 0.32 0.24 Schizophrenia; chr21:45868959 chr21:45914296~45919483:+ LUSC cis rs35740288 0.731 rs11638407 ENSG00000202081.1 RNU6-1280P 5.43 9.05e-08 2.95e-05 0.3 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85551424 chr15:85651522~85651628:- LUSC cis rs17711722 0.727 rs1880555 ENSG00000222364.1 RNU6-96P -5.43 9.05e-08 2.96e-05 -0.28 -0.24 Calcium levels; chr7:65967580 chr7:66395191~66395286:+ LUSC cis rs61270009 0.955 rs383385 ENSG00000247828.6 TMEM161B-AS1 -5.43 9.06e-08 2.96e-05 -0.27 -0.24 Depressive symptoms; chr5:88246065 chr5:88268895~88436685:+ LUSC cis rs61270009 0.955 rs396702 ENSG00000247828.6 TMEM161B-AS1 -5.43 9.06e-08 2.96e-05 -0.27 -0.24 Depressive symptoms; chr5:88247486 chr5:88268895~88436685:+ LUSC cis rs6832769 0.961 rs3805147 ENSG00000272969.1 RP11-528I4.2 5.43 9.06e-08 2.96e-05 0.27 0.24 Personality dimensions; chr4:55440563 chr4:55547112~55547889:+ LUSC cis rs6832769 1 rs3736544 ENSG00000272969.1 RP11-528I4.2 5.43 9.06e-08 2.96e-05 0.27 0.24 Personality dimensions; chr4:55443825 chr4:55547112~55547889:+ LUSC cis rs755249 0.958 rs2068663 ENSG00000228060.1 RP11-69E11.8 -5.43 9.06e-08 2.96e-05 -0.26 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572899 chr1:39565160~39573203:+ LUSC cis rs9545047 0.567 rs2296287 ENSG00000227676.3 LINC01068 5.43 9.07e-08 2.96e-05 0.3 0.24 Schizophrenia; chr13:79407045 chr13:79566727~79571436:+ LUSC cis rs2742234 0.541 rs7096500 ENSG00000273008.1 RP11-351D16.3 5.43 9.09e-08 2.97e-05 0.28 0.24 Hirschsprung disease; chr10:43216647 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs4648313 ENSG00000273008.1 RP11-351D16.3 5.43 9.09e-08 2.97e-05 0.28 0.24 Hirschsprung disease; chr10:43221291 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs10793424 ENSG00000273008.1 RP11-351D16.3 5.43 9.09e-08 2.97e-05 0.28 0.24 Hirschsprung disease; chr10:43221668 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs10899778 ENSG00000273008.1 RP11-351D16.3 5.43 9.09e-08 2.97e-05 0.28 0.24 Hirschsprung disease; chr10:43223061 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs11238481 ENSG00000273008.1 RP11-351D16.3 5.43 9.09e-08 2.97e-05 0.28 0.24 Hirschsprung disease; chr10:43223838 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs61268333 ENSG00000273008.1 RP11-351D16.3 5.43 9.09e-08 2.97e-05 0.28 0.24 Hirschsprung disease; chr10:43225922 chr10:43136824~43138334:- LUSC cis rs2742234 0.541 rs60845448 ENSG00000273008.1 RP11-351D16.3 5.43 9.09e-08 2.97e-05 0.28 0.24 Hirschsprung disease; chr10:43226014 chr10:43136824~43138334:- LUSC cis rs910316 1 rs3742773 ENSG00000279594.1 RP11-950C14.10 5.43 9.09e-08 2.97e-05 0.28 0.24 Height; chr14:75112940 chr14:75011269~75012851:- LUSC cis rs8133932 0.736 rs2839020 ENSG00000280604.1 PCBP3-OT1 5.43 9.11e-08 2.97e-05 0.31 0.24 Schizophrenia; chr21:45860087 chr21:45914296~45919483:+ LUSC cis rs2880765 0.566 rs55899824 ENSG00000259295.5 CSPG4P12 5.43 9.11e-08 2.97e-05 0.28 0.24 Coronary artery disease; chr15:85460860 chr15:85191438~85213905:+ LUSC cis rs2243480 1 rs59794892 ENSG00000226824.5 RP4-756H11.3 -5.43 9.11e-08 2.97e-05 -0.47 -0.24 Diabetic kidney disease; chr7:65950886 chr7:66654538~66669855:+ LUSC cis rs2243480 0.803 rs36004293 ENSG00000226824.5 RP4-756H11.3 -5.43 9.11e-08 2.97e-05 -0.47 -0.24 Diabetic kidney disease; chr7:65951525 chr7:66654538~66669855:+ LUSC cis rs2243480 0.803 rs35268390 ENSG00000226824.5 RP4-756H11.3 -5.43 9.11e-08 2.97e-05 -0.47 -0.24 Diabetic kidney disease; chr7:65951549 chr7:66654538~66669855:+ LUSC cis rs950169 0.58 rs17532346 ENSG00000225151.9 GOLGA2P7 -5.43 9.12e-08 2.97e-05 -0.33 -0.24 Schizophrenia; chr15:84628264 chr15:84199311~84230136:- LUSC cis rs916888 0.61 rs142167 ENSG00000261575.2 RP11-259G18.1 -5.43 9.14e-08 2.98e-05 -0.28 -0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46267037~46268694:+ LUSC cis rs9595066 0.712 rs4391951 ENSG00000227258.4 SMIM2-AS1 -5.43 9.14e-08 2.98e-05 -0.39 -0.24 Schizophrenia; chr13:44180935 chr13:44110451~44240517:+ LUSC cis rs17270561 0.609 rs7754733 ENSG00000272462.2 U91328.19 -5.43 9.14e-08 2.98e-05 -0.28 -0.24 Iron status biomarkers; chr6:25744821 chr6:25992662~26001775:+ LUSC cis rs17270561 0.636 rs7754814 ENSG00000272462.2 U91328.19 -5.43 9.14e-08 2.98e-05 -0.28 -0.24 Iron status biomarkers; chr6:25745015 chr6:25992662~26001775:+ LUSC cis rs17270561 0.636 rs7775354 ENSG00000272462.2 U91328.19 -5.43 9.14e-08 2.98e-05 -0.28 -0.24 Iron status biomarkers; chr6:25745038 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs9379789 ENSG00000272462.2 U91328.19 -5.43 9.14e-08 2.98e-05 -0.28 -0.24 Iron status biomarkers; chr6:25745351 chr6:25992662~26001775:+ LUSC cis rs2304003 0.95 rs6742727 ENSG00000235192.1 AC009495.2 5.43 9.14e-08 2.98e-05 0.34 0.24 Social communication problems; chr2:165836176 chr2:165794851~165810010:+ LUSC cis rs17270561 0.609 rs2154218 ENSG00000272462.2 U91328.19 -5.43 9.14e-08 2.98e-05 -0.28 -0.24 Iron status biomarkers; chr6:25776062 chr6:25992662~26001775:+ LUSC cis rs71403859 0.73 rs12447672 ENSG00000260886.1 TAT-AS1 5.43 9.15e-08 2.98e-05 0.39 0.24 Post bronchodilator FEV1; chr16:71681228 chr16:71565789~71578187:+ LUSC cis rs11098499 0.73 rs78971550 ENSG00000248280.1 RP11-33B1.2 5.43 9.17e-08 2.99e-05 0.29 0.24 Corneal astigmatism; chr4:119359886 chr4:119440561~119450157:- LUSC cis rs11098499 0.645 rs78422072 ENSG00000248280.1 RP11-33B1.2 5.43 9.17e-08 2.99e-05 0.29 0.24 Corneal astigmatism; chr4:119359887 chr4:119440561~119450157:- LUSC cis rs3764021 0.509 rs10772070 ENSG00000256975.1 RP11-525E9.1 5.43 9.17e-08 2.99e-05 0.32 0.24 Type 1 diabetes; chr12:9717320 chr12:9506347~9508440:- LUSC cis rs7267979 0.649 rs2500406 ENSG00000274973.1 RP13-401N8.7 5.43 9.18e-08 2.99e-05 0.27 0.24 Liver enzyme levels (alkaline phosphatase); chr20:25421226 chr20:25845497~25845862:+ LUSC cis rs451417 0.818 rs236113 ENSG00000275632.1 RP5-967N21.11 5.43 9.18e-08 2.99e-05 0.3 0.24 Menopause (age at onset); chr20:5953920 chr20:6000418~6000941:+ LUSC cis rs7772486 0.846 rs2144478 ENSG00000235652.6 RP11-545I5.3 5.43 9.2e-08 3e-05 0.24 0.24 Lobe attachment (rater-scored or self-reported); chr6:146060309 chr6:145799409~145886585:+ LUSC cis rs11098499 0.754 rs12510269 ENSG00000250412.1 KLHL2P1 5.43 9.2e-08 3e-05 0.3 0.24 Corneal astigmatism; chr4:119320491 chr4:119334329~119378233:+ LUSC cis rs7712401 0.601 rs398142 ENSG00000263432.2 RN7SL689P -5.43 9.2e-08 3e-05 -0.32 -0.24 Mean platelet volume; chr5:123009881 chr5:123022487~123022783:- LUSC cis rs7712401 0.58 rs383262 ENSG00000263432.2 RN7SL689P -5.43 9.2e-08 3e-05 -0.32 -0.24 Mean platelet volume; chr5:123009989 chr5:123022487~123022783:- LUSC cis rs7267979 0.903 rs6107015 ENSG00000274973.1 RP13-401N8.7 -5.43 9.2e-08 3e-05 -0.25 -0.24 Liver enzyme levels (alkaline phosphatase); chr20:25236128 chr20:25845497~25845862:+ LUSC cis rs11098499 0.865 rs1112817 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119376645 chr4:119440561~119450157:- LUSC cis rs11098499 0.779 rs10016060 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119377257 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs10005644 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119377322 chr4:119440561~119450157:- LUSC cis rs11098499 0.697 rs10016448 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119377690 chr4:119440561~119450157:- LUSC cis rs11098499 0.657 rs9996569 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119377849 chr4:119440561~119450157:- LUSC cis rs11098499 0.908 rs11729050 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119378911 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs28429722 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119378938 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs10014845 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119379922 chr4:119440561~119450157:- LUSC cis rs11098499 0.779 rs7674500 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119382438 chr4:119440561~119450157:- LUSC cis rs11098499 0.697 rs4373140 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119386543 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs13113483 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119387884 chr4:119440561~119450157:- LUSC cis rs11098499 0.542 rs10440343 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119388632 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs28668716 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119388720 chr4:119440561~119450157:- LUSC cis rs11098499 0.542 rs7677836 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119389483 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs10002083 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119389997 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs10024844 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119390373 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs4345162 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119391804 chr4:119440561~119450157:- LUSC cis rs11098499 0.657 rs4463052 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119392103 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs13151285 ENSG00000248280.1 RP11-33B1.2 5.43 9.2e-08 3e-05 0.29 0.24 Corneal astigmatism; chr4:119393586 chr4:119440561~119450157:- LUSC cis rs2439831 0.702 rs3784275 ENSG00000249839.1 AC011330.5 -5.43 9.21e-08 3e-05 -0.53 -0.24 Lung cancer in ever smokers; chr15:43799188 chr15:43663654~43684339:- LUSC cis rs875971 0.505 rs6955582 ENSG00000222364.1 RNU6-96P -5.43 9.22e-08 3e-05 -0.28 -0.24 Aortic root size; chr7:65966699 chr7:66395191~66395286:+ LUSC cis rs11098499 0.663 rs9996501 ENSG00000250412.1 KLHL2P1 5.43 9.22e-08 3e-05 0.3 0.24 Corneal astigmatism; chr4:119317763 chr4:119334329~119378233:+ LUSC cis rs11098499 0.697 rs28458294 ENSG00000250412.1 KLHL2P1 5.43 9.22e-08 3e-05 0.3 0.24 Corneal astigmatism; chr4:119317769 chr4:119334329~119378233:+ LUSC cis rs11098499 0.663 rs28369503 ENSG00000250412.1 KLHL2P1 5.43 9.22e-08 3e-05 0.3 0.24 Corneal astigmatism; chr4:119317770 chr4:119334329~119378233:+ LUSC cis rs9640161 0.742 rs2159236 ENSG00000261305.1 RP4-584D14.7 5.43 9.22e-08 3e-05 0.33 0.24 Blood protein levels;Circulating chemerin levels; chr7:150320125 chr7:150341771~150342607:+ LUSC cis rs10462794 1 rs7709922 ENSG00000260763.1 RP11-445O3.3 -5.43 9.22e-08 3e-05 -0.31 -0.24 DNA methylation (variation); chr5:4483320 chr5:4436850~4440259:- LUSC cis rs875971 0.964 rs160635 ENSG00000224316.1 RP11-479O9.2 5.43 9.23e-08 3e-05 0.24 0.24 Aortic root size; chr7:66063931 chr7:65773620~65802067:+ LUSC cis rs11098499 0.697 rs28655325 ENSG00000248280.1 RP11-33B1.2 5.43 9.23e-08 3.01e-05 0.29 0.24 Corneal astigmatism; chr4:119451844 chr4:119440561~119450157:- LUSC cis rs673078 0.66 rs61946068 ENSG00000275759.1 RP11-131L12.3 -5.43 9.23e-08 3.01e-05 -0.38 -0.24 Glucose homeostasis traits; chr12:118305861 chr12:118428281~118428870:+ LUSC cis rs9516 0.565 rs3867278 ENSG00000254974.1 RP11-702H23.2 -5.43 9.24e-08 3.01e-05 -0.24 -0.24 Facial morphology (factor 15, philtrum width); chr11:74454376 chr11:74485580~74486051:- LUSC cis rs9828933 0.752 rs13434089 ENSG00000280620.1 SCAANT1 -5.43 9.24e-08 3.01e-05 -0.4 -0.24 Type 2 diabetes; chr3:63962890 chr3:63911518~63911772:- LUSC cis rs17270561 0.609 rs4711096 ENSG00000272462.2 U91328.19 -5.43 9.24e-08 3.01e-05 -0.29 -0.24 Iron status biomarkers; chr6:25726826 chr6:25992662~26001775:+ LUSC cis rs496547 0.719 rs472641 ENSG00000278376.1 RP11-158I9.8 -5.43 9.24e-08 3.01e-05 -0.22 -0.24 Hip minimal joint space width; chr11:118746835 chr11:118791254~118793137:+ LUSC cis rs1056107 0.931 rs7855376 ENSG00000225513.1 RP11-165N19.2 5.43 9.25e-08 3.01e-05 0.27 0.24 Colorectal cancer; chr9:112251851 chr9:112173522~112173971:- LUSC cis rs13113518 0.783 rs2171618 ENSG00000273257.1 RP11-177J6.1 5.43 9.26e-08 3.01e-05 0.31 0.24 Height; chr4:55564241 chr4:55387949~55388271:+ LUSC cis rs17711722 0.565 rs4717276 ENSG00000228409.4 CCT6P1 -5.43 9.26e-08 3.01e-05 -0.19 -0.24 Calcium levels; chr7:65829754 chr7:65751142~65763354:+ LUSC cis rs2439831 0.867 rs2245715 ENSG00000249839.1 AC011330.5 -5.43 9.27e-08 3.02e-05 -0.45 -0.24 Lung cancer in ever smokers; chr15:43525854 chr15:43663654~43684339:- LUSC cis rs228614 0.536 rs223478 ENSG00000246560.2 RP11-10L12.4 5.43 9.27e-08 3.02e-05 0.3 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102768648 chr4:102828055~102844075:+ LUSC cis rs228614 0.509 rs223476 ENSG00000246560.2 RP11-10L12.4 5.43 9.27e-08 3.02e-05 0.3 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771000 chr4:102828055~102844075:+ LUSC cis rs228614 0.509 rs150896 ENSG00000246560.2 RP11-10L12.4 5.43 9.27e-08 3.02e-05 0.3 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771186 chr4:102828055~102844075:+ LUSC cis rs944990 0.557 rs7019001 ENSG00000227603.1 RP11-165J3.6 5.43 9.27e-08 3.02e-05 0.23 0.24 Body mass index; chr9:93528942 chr9:93435332~93437121:- LUSC cis rs944990 0.557 rs13292712 ENSG00000227603.1 RP11-165J3.6 5.43 9.27e-08 3.02e-05 0.23 0.24 Body mass index; chr9:93534438 chr9:93435332~93437121:- LUSC cis rs11098499 0.954 rs10518328 ENSG00000248280.1 RP11-33B1.2 5.43 9.28e-08 3.02e-05 0.29 0.24 Corneal astigmatism; chr4:119480624 chr4:119440561~119450157:- LUSC cis rs17772222 0.63 rs816069 ENSG00000258983.2 RP11-507K2.2 -5.43 9.29e-08 3.02e-05 -0.26 -0.24 Coronary artery calcification; chr14:88500992 chr14:88499334~88515502:+ LUSC cis rs35740288 0.895 rs3743332 ENSG00000202081.1 RNU6-1280P 5.42 9.3e-08 3.03e-05 0.31 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85760520 chr15:85651522~85651628:- LUSC cis rs1707322 0.686 rs2050376 ENSG00000234329.1 RP11-767N6.2 5.42 9.3e-08 3.03e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45612958 chr1:45651039~45651826:- LUSC cis rs9326248 0.559 rs476399 ENSG00000280143.1 AP000892.6 5.42 9.31e-08 3.03e-05 0.25 0.24 Blood protein levels; chr11:116863012 chr11:117204967~117210292:+ LUSC cis rs2243480 1 rs437889 ENSG00000164669.11 INTS4P1 5.42 9.34e-08 3.04e-05 0.44 0.24 Diabetic kidney disease; chr7:66044247 chr7:65141225~65234216:+ LUSC cis rs2304003 0.528 rs1023708 ENSG00000235192.1 AC009495.2 5.42 9.34e-08 3.04e-05 0.31 0.24 Social communication problems; chr2:165863084 chr2:165794851~165810010:+ LUSC cis rs10462794 0.853 rs4702793 ENSG00000260763.1 RP11-445O3.3 -5.42 9.34e-08 3.04e-05 -0.31 -0.24 DNA methylation (variation); chr5:4507262 chr5:4436850~4440259:- LUSC cis rs875971 0.545 rs73142233 ENSG00000179406.6 LINC00174 -5.42 9.34e-08 3.04e-05 -0.29 -0.24 Aortic root size; chr7:66221293 chr7:66376044~66401338:- LUSC cis rs7520050 0.807 rs5021934 ENSG00000280836.1 AL355480.1 5.42 9.34e-08 3.04e-05 0.27 0.24 Reticulocyte count;Red blood cell count; chr1:45643632 chr1:45581219~45581321:- LUSC cis rs875971 0.545 rs13311962 ENSG00000179406.6 LINC00174 5.42 9.35e-08 3.04e-05 0.28 0.24 Aortic root size; chr7:66603142 chr7:66376044~66401338:- LUSC cis rs6502050 0.871 rs11870632 ENSG00000266654.1 RP11-1376P16.1 5.42 9.35e-08 3.04e-05 0.24 0.24 Life satisfaction; chr17:82117530 chr17:82160056~82160452:+ LUSC cis rs6502050 0.842 rs9894129 ENSG00000266654.1 RP11-1376P16.1 5.42 9.35e-08 3.04e-05 0.24 0.24 Life satisfaction; chr17:82117824 chr17:82160056~82160452:+ LUSC cis rs6502050 0.871 rs9916649 ENSG00000266654.1 RP11-1376P16.1 5.42 9.35e-08 3.04e-05 0.24 0.24 Life satisfaction; chr17:82117863 chr17:82160056~82160452:+ LUSC cis rs11098499 0.779 rs10011097 ENSG00000248280.1 RP11-33B1.2 5.42 9.36e-08 3.04e-05 0.29 0.24 Corneal astigmatism; chr4:119389204 chr4:119440561~119450157:- LUSC cis rs8040855 0.52 rs67613323 ENSG00000259295.5 CSPG4P12 5.42 9.36e-08 3.04e-05 0.33 0.24 Bulimia nervosa; chr15:84986541 chr15:85191438~85213905:+ LUSC cis rs8040855 0.52 rs11629962 ENSG00000259295.5 CSPG4P12 5.42 9.36e-08 3.04e-05 0.33 0.24 Bulimia nervosa; chr15:84986797 chr15:85191438~85213905:+ LUSC cis rs13113518 1 rs3805148 ENSG00000272969.1 RP11-528I4.2 5.42 9.36e-08 3.05e-05 0.28 0.24 Height; chr4:55440643 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs11133380 ENSG00000272969.1 RP11-528I4.2 5.42 9.36e-08 3.05e-05 0.28 0.24 Height; chr4:55441110 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs12510110 ENSG00000272969.1 RP11-528I4.2 5.42 9.36e-08 3.05e-05 0.28 0.24 Height; chr4:55441567 chr4:55547112~55547889:+ LUSC cis rs13113518 0.966 rs12510990 ENSG00000272969.1 RP11-528I4.2 5.42 9.36e-08 3.05e-05 0.28 0.24 Height; chr4:55441907 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs3805149 ENSG00000272969.1 RP11-528I4.2 5.42 9.36e-08 3.05e-05 0.28 0.24 Height; chr4:55442184 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs11945370 ENSG00000272969.1 RP11-528I4.2 5.42 9.36e-08 3.05e-05 0.28 0.24 Height; chr4:55442875 chr4:55547112~55547889:+ LUSC cis rs13113518 0.966 rs12647677 ENSG00000272969.1 RP11-528I4.2 5.42 9.36e-08 3.05e-05 0.28 0.24 Height; chr4:55444253 chr4:55547112~55547889:+ LUSC cis rs13113518 0.902 rs3805150 ENSG00000272969.1 RP11-528I4.2 5.42 9.36e-08 3.05e-05 0.28 0.24 Height; chr4:55446869 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs4864990 ENSG00000272969.1 RP11-528I4.2 5.42 9.36e-08 3.05e-05 0.28 0.24 Height; chr4:55447523 chr4:55547112~55547889:+ LUSC cis rs9487051 0.872 rs1111864 ENSG00000219700.1 PTCHD3P3 5.42 9.36e-08 3.05e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109289935 chr6:109288571~109290503:- LUSC cis rs35740288 0.822 rs2306225 ENSG00000202081.1 RNU6-1280P 5.42 9.38e-08 3.05e-05 0.31 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85684721 chr15:85651522~85651628:- LUSC cis rs228614 0.536 rs150898 ENSG00000246560.2 RP11-10L12.4 5.42 9.38e-08 3.05e-05 0.3 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769234 chr4:102828055~102844075:+ LUSC cis rs673078 0.607 rs7958652 ENSG00000275409.1 RP11-131L12.4 -5.42 9.38e-08 3.05e-05 -0.35 -0.24 Glucose homeostasis traits; chr12:118442630 chr12:118430147~118430699:+ LUSC cis rs12220777 1 rs72644213 ENSG00000230091.5 TMEM254-AS1 5.42 9.4e-08 3.06e-05 0.53 0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80023904 chr10:80046860~80078912:- LUSC cis rs17361889 0.778 rs56033714 ENSG00000224683.1 RPL36AP29 5.42 9.4e-08 3.06e-05 0.3 0.24 Pediatric bone mineral content (hip); chr7:16171442 chr7:16208945~16209265:+ LUSC cis rs4964805 0.594 rs11111759 ENSG00000257681.1 RP11-341G23.4 5.42 9.4e-08 3.06e-05 0.27 0.24 Attention deficit hyperactivity disorder; chr12:103769405 chr12:103746315~103768858:- LUSC cis rs2439831 0.867 rs2614811 ENSG00000249839.1 AC011330.5 -5.42 9.4e-08 3.06e-05 -0.46 -0.24 Lung cancer in ever smokers; chr15:43621289 chr15:43663654~43684339:- LUSC cis rs17507216 0.588 rs28864981 ENSG00000276710.3 CSPG4P8 -5.42 9.4e-08 3.06e-05 -0.32 -0.24 Excessive daytime sleepiness; chr15:82695420 chr15:82459472~82477258:+ LUSC cis rs9545047 0.625 rs9545109 ENSG00000227676.3 LINC01068 5.42 9.42e-08 3.06e-05 0.3 0.24 Schizophrenia; chr13:79413480 chr13:79566727~79571436:+ LUSC cis rs9545047 0.518 rs7328494 ENSG00000227676.3 LINC01068 5.42 9.42e-08 3.06e-05 0.3 0.24 Schizophrenia; chr13:79414673 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs2147568 ENSG00000227676.3 LINC01068 5.42 9.42e-08 3.06e-05 0.3 0.24 Schizophrenia; chr13:79417091 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs9530917 ENSG00000227676.3 LINC01068 5.42 9.42e-08 3.06e-05 0.3 0.24 Schizophrenia; chr13:79417719 chr13:79566727~79571436:+ LUSC cis rs9545047 0.604 rs7990321 ENSG00000227676.3 LINC01068 5.42 9.42e-08 3.06e-05 0.3 0.24 Schizophrenia; chr13:79418066 chr13:79566727~79571436:+ LUSC cis rs8040855 0.576 rs62022527 ENSG00000259295.5 CSPG4P12 5.42 9.42e-08 3.06e-05 0.32 0.24 Bulimia nervosa; chr15:84988022 chr15:85191438~85213905:+ LUSC cis rs4237845 0.537 rs9645819 ENSG00000257159.1 RP11-58A17.3 5.42 9.42e-08 3.06e-05 0.3 0.24 Intelligence (multi-trait analysis); chr12:57876280 chr12:57967058~57968399:+ LUSC cis rs1862618 0.525 rs2662016 ENSG00000271828.1 CTD-2310F14.1 -5.42 9.43e-08 3.06e-05 -0.37 -0.24 Initial pursuit acceleration; chr5:56973220 chr5:56927874~56929573:+ LUSC cis rs78773383 0.505 rs13123782 ENSG00000249207.1 RP11-360F5.1 5.42 9.44e-08 3.07e-05 0.27 0.24 Mean corpuscular volume;Mean corpuscular hemoglobin; chr4:39375785 chr4:39112677~39126818:- LUSC cis rs17270561 0.609 rs9358873 ENSG00000272462.2 U91328.19 -5.42 9.44e-08 3.07e-05 -0.29 -0.24 Iron status biomarkers; chr6:25731555 chr6:25992662~26001775:+ LUSC cis rs17270561 0.666 rs3923725 ENSG00000272462.2 U91328.19 -5.42 9.44e-08 3.07e-05 -0.29 -0.24 Iron status biomarkers; chr6:25734692 chr6:25992662~26001775:+ LUSC cis rs4489787 1 rs11168576 ENSG00000240399.1 RP1-228P16.1 -5.42 9.45e-08 3.07e-05 -0.39 -0.24 Prostate cancer (SNP x SNP interaction); chr12:48446635 chr12:48054813~48055591:- LUSC cis rs11098499 0.526 rs10026625 ENSG00000250412.1 KLHL2P1 5.42 9.45e-08 3.07e-05 0.28 0.24 Corneal astigmatism; chr4:119358981 chr4:119334329~119378233:+ LUSC cis rs11098499 0.697 rs4560394 ENSG00000248280.1 RP11-33B1.2 5.42 9.46e-08 3.07e-05 0.29 0.24 Corneal astigmatism; chr4:119392280 chr4:119440561~119450157:- LUSC cis rs8072100 0.713 rs11651643 ENSG00000228782.6 CTD-2026D20.3 5.42 9.46e-08 3.08e-05 0.24 0.24 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47405863 chr17:47450568~47492492:- LUSC cis rs13287066 0.692 rs2184255 ENSG00000227603.1 RP11-165J3.6 -5.42 9.46e-08 3.08e-05 -0.23 -0.24 Intelligence (multi-trait analysis); chr9:93413921 chr9:93435332~93437121:- LUSC cis rs7246657 0.638 rs7246461 ENSG00000276846.1 CTD-3220F14.3 -5.42 9.46e-08 3.08e-05 -0.37 -0.24 Coronary artery calcification; chr19:37705680 chr19:37314868~37315620:- LUSC cis rs10759883 0.563 rs1327997 ENSG00000175611.10 LINC00476 5.42 9.47e-08 3.08e-05 0.28 0.24 Nicotine dependence; chr9:95913600 chr9:95759231~95875977:- LUSC cis rs10759883 0.563 rs1327996 ENSG00000175611.10 LINC00476 5.42 9.47e-08 3.08e-05 0.28 0.24 Nicotine dependence; chr9:95913710 chr9:95759231~95875977:- LUSC cis rs10759883 0.563 rs617187 ENSG00000175611.10 LINC00476 5.42 9.47e-08 3.08e-05 0.28 0.24 Nicotine dependence; chr9:95917359 chr9:95759231~95875977:- LUSC cis rs10759883 0.563 rs689619 ENSG00000175611.10 LINC00476 5.42 9.47e-08 3.08e-05 0.28 0.24 Nicotine dependence; chr9:95921689 chr9:95759231~95875977:- LUSC cis rs10759883 0.563 rs10512245 ENSG00000175611.10 LINC00476 5.42 9.47e-08 3.08e-05 0.28 0.24 Nicotine dependence; chr9:95929529 chr9:95759231~95875977:- LUSC cis rs4835473 0.897 rs6835827 ENSG00000249741.2 RP11-673E1.3 -5.42 9.47e-08 3.08e-05 -0.25 -0.24 Immature fraction of reticulocytes; chr4:143712803 chr4:143911514~143912053:- LUSC cis rs11098499 0.954 rs9998585 ENSG00000248280.1 RP11-33B1.2 5.42 9.47e-08 3.08e-05 0.29 0.24 Corneal astigmatism; chr4:119475647 chr4:119440561~119450157:- LUSC cis rs12468226 1 rs112306637 ENSG00000272966.1 RP11-686O6.1 5.42 9.48e-08 3.08e-05 0.39 0.24 Urate levels; chr2:202334195 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs111252524 ENSG00000272966.1 RP11-686O6.1 5.42 9.48e-08 3.08e-05 0.39 0.24 Urate levels; chr2:202334465 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs112753638 ENSG00000272966.1 RP11-686O6.1 5.42 9.48e-08 3.08e-05 0.39 0.24 Urate levels; chr2:202334496 chr2:202336739~202337200:+ LUSC cis rs12468226 0.935 rs113188021 ENSG00000272966.1 RP11-686O6.1 5.42 9.48e-08 3.08e-05 0.39 0.24 Urate levels; chr2:202336237 chr2:202336739~202337200:+ LUSC cis rs12468226 1 rs6731027 ENSG00000272966.1 RP11-686O6.1 5.42 9.48e-08 3.08e-05 0.39 0.24 Urate levels; chr2:202337443 chr2:202336739~202337200:+ LUSC cis rs7712401 0.601 rs246269 ENSG00000263432.2 RN7SL689P 5.42 9.49e-08 3.08e-05 0.3 0.24 Mean platelet volume; chr5:122921046 chr5:123022487~123022783:- LUSC cis rs2274273 0.837 rs7146748 ENSG00000258413.1 RP11-665C16.6 -5.42 9.5e-08 3.08e-05 -0.29 -0.24 Protein biomarker; chr14:55280368 chr14:55262767~55272075:- LUSC cis rs875971 0.545 rs2707851 ENSG00000224316.1 RP11-479O9.2 -5.42 9.5e-08 3.09e-05 -0.26 -0.24 Aortic root size; chr7:66624178 chr7:65773620~65802067:+ LUSC cis rs2842992 0.83 rs2842974 ENSG00000237927.1 RP3-393E18.2 -5.42 9.5e-08 3.09e-05 -0.36 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159738002 chr6:159586955~159589169:- LUSC cis rs3002131 0.562 rs2173401 ENSG00000225265.1 TAF1A-AS1 -5.42 9.52e-08 3.09e-05 -0.35 -0.24 Interleukin-10 levels; chr1:222575992 chr1:222589825~222593032:+ LUSC cis rs11098499 0.754 rs2036857 ENSG00000250412.1 KLHL2P1 5.42 9.52e-08 3.09e-05 0.3 0.24 Corneal astigmatism; chr4:119328085 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs2036856 ENSG00000250412.1 KLHL2P1 5.42 9.52e-08 3.09e-05 0.3 0.24 Corneal astigmatism; chr4:119328133 chr4:119334329~119378233:+ LUSC cis rs11098499 0.754 rs4443261 ENSG00000250412.1 KLHL2P1 5.42 9.52e-08 3.09e-05 0.3 0.24 Corneal astigmatism; chr4:119328146 chr4:119334329~119378233:+ LUSC cis rs459571 0.959 rs410876 ENSG00000235106.7 LINC00094 5.42 9.52e-08 3.09e-05 0.27 0.24 Platelet distribution width; chr9:134028745 chr9:134025439~134034666:+ LUSC cis rs2243480 0.901 rs313808 ENSG00000226824.5 RP4-756H11.3 -5.42 9.53e-08 3.1e-05 -0.48 -0.24 Diabetic kidney disease; chr7:66034886 chr7:66654538~66669855:+ LUSC cis rs17772222 1 rs60310240 ENSG00000258789.1 RP11-507K2.3 -5.42 9.54e-08 3.1e-05 -0.28 -0.24 Coronary artery calcification; chr14:88356365 chr14:88551597~88552493:+ LUSC cis rs1707322 0.717 rs1547925 ENSG00000234329.1 RP11-767N6.2 -5.42 9.54e-08 3.1e-05 -0.26 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619684 chr1:45651039~45651826:- LUSC cis rs6504622 0.818 rs9303532 ENSG00000262879.4 RP11-156P1.3 -5.42 9.54e-08 3.1e-05 -0.26 -0.24 Orofacial clefts; chr17:46956636 chr17:46984045~47100323:- LUSC cis rs6502050 0.835 rs10163485 ENSG00000266654.1 RP11-1376P16.1 -5.42 9.55e-08 3.1e-05 -0.24 -0.24 Life satisfaction; chr17:82152874 chr17:82160056~82160452:+ LUSC cis rs9545047 0.604 rs2765078 ENSG00000227676.3 LINC01068 5.42 9.55e-08 3.1e-05 0.3 0.24 Schizophrenia; chr13:79420604 chr13:79566727~79571436:+ LUSC cis rs2337406 0.789 rs112027230 ENSG00000280411.1 IGHV1-69-2 -5.42 9.55e-08 3.1e-05 -0.23 -0.24 Alzheimer's disease (late onset); chr14:106810329 chr14:106762092~106762588:- LUSC cis rs7267979 0.816 rs6115094 ENSG00000274973.1 RP13-401N8.7 -5.42 9.56e-08 3.1e-05 -0.24 -0.24 Liver enzyme levels (alkaline phosphatase); chr20:25230191 chr20:25845497~25845862:+ LUSC cis rs56080343 0.808 rs1045552 ENSG00000275409.1 RP11-131L12.4 -5.42 9.56e-08 3.1e-05 -0.34 -0.24 Neuroticism; chr12:118417678 chr12:118430147~118430699:+ LUSC cis rs889398 0.802 rs9940315 ENSG00000226232.7 RP11-419C5.2 -5.42 9.57e-08 3.11e-05 -0.23 -0.24 Body mass index; chr16:69842261 chr16:69976388~69996188:- LUSC cis rs2243480 1 rs2961102 ENSG00000164669.11 INTS4P1 5.42 9.57e-08 3.11e-05 0.44 0.24 Diabetic kidney disease; chr7:65959671 chr7:65141225~65234216:+ LUSC cis rs8177876 0.658 rs79603321 ENSG00000261838.4 RP11-303E16.6 5.42 9.57e-08 3.11e-05 0.57 0.24 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81039139 chr16:81069854~81076598:+ LUSC cis rs9341808 0.667 rs6938280 ENSG00000272129.1 RP11-250B2.6 5.42 9.57e-08 3.11e-05 0.3 0.24 Sitting height ratio; chr6:80188065 chr6:80355424~80356859:+ LUSC cis rs875971 0.522 rs2008188 ENSG00000222364.1 RNU6-96P -5.42 9.58e-08 3.11e-05 -0.28 -0.24 Aortic root size; chr7:65964026 chr7:66395191~66395286:+ LUSC cis rs2980439 0.556 rs2921059 ENSG00000253893.2 FAM85B -5.42 9.58e-08 3.11e-05 -0.29 -0.24 Neuroticism; chr8:8460377 chr8:8167819~8226614:- LUSC cis rs6740322 0.895 rs11684601 ENSG00000234936.1 AC010883.5 5.42 9.58e-08 3.11e-05 0.27 0.24 Coronary artery disease; chr2:43347103 chr2:43229573~43233394:+ LUSC cis rs2919917 0.628 rs7823970 ENSG00000254352.1 RP11-578O24.2 5.42 9.59e-08 3.11e-05 0.32 0.24 Lymphocyte counts; chr8:78681364 chr8:78723796~78724136:- LUSC cis rs2919917 0.616 rs7823723 ENSG00000254352.1 RP11-578O24.2 5.42 9.59e-08 3.11e-05 0.32 0.24 Lymphocyte counts; chr8:78681390 chr8:78723796~78724136:- LUSC cis rs17711722 0.74 rs7809991 ENSG00000222364.1 RNU6-96P -5.42 9.59e-08 3.11e-05 -0.28 -0.24 Calcium levels; chr7:65941231 chr7:66395191~66395286:+ LUSC cis rs2880765 0.631 rs55767890 ENSG00000259295.5 CSPG4P12 5.42 9.6e-08 3.12e-05 0.28 0.24 Coronary artery disease; chr15:85460911 chr15:85191438~85213905:+ LUSC cis rs7829975 0.711 rs4841051 ENSG00000253893.2 FAM85B 5.42 9.6e-08 3.12e-05 0.29 0.24 Mood instability; chr8:8828136 chr8:8167819~8226614:- LUSC cis rs2903698 0.651 rs10018377 ENSG00000250735.4 RP11-567N4.3 5.42 9.61e-08 3.12e-05 0.28 0.24 Prion diseases; chr4:75500864 chr4:75401195~75423023:+ LUSC cis rs2903698 0.651 rs7685936 ENSG00000250735.4 RP11-567N4.3 5.42 9.61e-08 3.12e-05 0.28 0.24 Prion diseases; chr4:75504218 chr4:75401195~75423023:+ LUSC cis rs673078 0.607 rs17512644 ENSG00000275409.1 RP11-131L12.4 -5.42 9.61e-08 3.12e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118359963 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs17512652 ENSG00000275409.1 RP11-131L12.4 -5.42 9.61e-08 3.12e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118361278 chr12:118430147~118430699:+ LUSC cis rs2732480 0.577 rs1489109 ENSG00000257735.1 RP11-370I10.6 5.42 9.62e-08 3.12e-05 0.31 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344997 chr12:48350945~48442411:+ LUSC cis rs2732480 0.577 rs1489108 ENSG00000257735.1 RP11-370I10.6 5.42 9.62e-08 3.12e-05 0.31 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344998 chr12:48350945~48442411:+ LUSC cis rs2243480 1 rs34815098 ENSG00000164669.11 INTS4P1 5.42 9.62e-08 3.12e-05 0.44 0.24 Diabetic kidney disease; chr7:65827267 chr7:65141225~65234216:+ LUSC cis rs2243480 1 rs7456042 ENSG00000164669.11 INTS4P1 5.42 9.62e-08 3.12e-05 0.44 0.24 Diabetic kidney disease; chr7:65834791 chr7:65141225~65234216:+ LUSC cis rs2243480 1 rs35735127 ENSG00000164669.11 INTS4P1 5.42 9.62e-08 3.12e-05 0.44 0.24 Diabetic kidney disease; chr7:65835436 chr7:65141225~65234216:+ LUSC cis rs2243480 1 rs34703416 ENSG00000164669.11 INTS4P1 5.42 9.62e-08 3.12e-05 0.44 0.24 Diabetic kidney disease; chr7:65835655 chr7:65141225~65234216:+ LUSC cis rs6061231 1 rs6061231 ENSG00000273619.1 RP5-908M14.9 -5.42 9.63e-08 3.13e-05 -0.23 -0.24 Colorectal cancer; chr20:62381861 chr20:62386303~62386970:- LUSC cis rs6502050 0.667 rs9892469 ENSG00000266654.1 RP11-1376P16.1 -5.42 9.63e-08 3.13e-05 -0.24 -0.24 Life satisfaction; chr17:82135781 chr17:82160056~82160452:+ LUSC cis rs7615952 0.8 rs13086460 ENSG00000171084.14 FAM86JP 5.42 9.64e-08 3.13e-05 0.32 0.24 Blood pressure (smoking interaction); chr3:125927574 chr3:125916620~125930024:+ LUSC cis rs9487051 0.872 rs9372211 ENSG00000219700.1 PTCHD3P3 5.42 9.65e-08 3.13e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109288445 chr6:109288571~109290503:- LUSC cis rs9487051 0.872 rs9487038 ENSG00000219700.1 PTCHD3P3 5.42 9.65e-08 3.13e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109288949 chr6:109288571~109290503:- LUSC cis rs9341808 0.667 rs1408292 ENSG00000272129.1 RP11-250B2.6 5.42 9.66e-08 3.13e-05 0.3 0.24 Sitting height ratio; chr6:80174189 chr6:80355424~80356859:+ LUSC cis rs7712401 0.562 rs2927639 ENSG00000263432.2 RN7SL689P 5.42 9.66e-08 3.13e-05 0.31 0.24 Mean platelet volume; chr5:122943971 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs246274 ENSG00000263432.2 RN7SL689P 5.42 9.66e-08 3.13e-05 0.31 0.24 Mean platelet volume; chr5:122945108 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs246273 ENSG00000263432.2 RN7SL689P 5.42 9.66e-08 3.13e-05 0.31 0.24 Mean platelet volume; chr5:122945280 chr5:123022487~123022783:- LUSC cis rs17361889 0.752 rs62440374 ENSG00000224683.1 RPL36AP29 5.42 9.66e-08 3.13e-05 0.3 0.24 Pediatric bone mineral content (hip); chr7:16172290 chr7:16208945~16209265:+ LUSC cis rs4713118 0.869 rs6930992 ENSG00000280107.1 AL022393.9 -5.42 9.67e-08 3.13e-05 -0.28 -0.24 Parkinson's disease; chr6:27744341 chr6:28170845~28172521:+ LUSC cis rs9890032 0.509 rs11656986 ENSG00000266490.1 CTD-2349P21.9 5.42 9.67e-08 3.14e-05 0.21 0.24 Hip circumference adjusted for BMI; chr17:30694324 chr17:30792372~30792833:+ LUSC cis rs2243480 1 rs160655 ENSG00000164669.11 INTS4P1 5.42 9.67e-08 3.14e-05 0.43 0.24 Diabetic kidney disease; chr7:66068227 chr7:65141225~65234216:+ LUSC cis rs11098499 0.865 rs4001305 ENSG00000248280.1 RP11-33B1.2 5.42 9.67e-08 3.14e-05 0.29 0.24 Corneal astigmatism; chr4:119438081 chr4:119440561~119450157:- LUSC cis rs6502050 0.769 rs9916231 ENSG00000266654.1 RP11-1376P16.1 -5.42 9.68e-08 3.14e-05 -0.24 -0.24 Life satisfaction; chr17:82161769 chr17:82160056~82160452:+ LUSC cis rs2554380 0.628 rs4843158 ENSG00000230373.7 GOLGA6L5P -5.42 9.68e-08 3.14e-05 -0.24 -0.24 Height; chr15:83802884 chr15:84507885~84516814:- LUSC cis rs13326165 0.585 rs6793317 ENSG00000243224.1 RP5-1157M23.2 5.42 9.68e-08 3.14e-05 0.41 0.24 HDL cholesterol levels;HDL cholesterol; chr3:52264970 chr3:52239258~52241097:+ LUSC cis rs17507216 0.628 rs28607761 ENSG00000276710.3 CSPG4P8 -5.42 9.69e-08 3.14e-05 -0.32 -0.24 Excessive daytime sleepiness; chr15:82715317 chr15:82459472~82477258:+ LUSC cis rs875971 0.516 rs6945322 ENSG00000237310.1 GS1-124K5.4 5.42 9.69e-08 3.14e-05 0.25 0.24 Aortic root size; chr7:65871069 chr7:66493706~66495474:+ LUSC cis rs13113518 0.557 rs13142096 ENSG00000272969.1 RP11-528I4.2 5.42 9.7e-08 3.15e-05 0.29 0.24 Height; chr4:55566291 chr4:55547112~55547889:+ LUSC cis rs3779195 0.524 rs80195155 ENSG00000272950.1 RP11-307C18.1 -5.42 9.71e-08 3.15e-05 -0.44 -0.24 Sex hormone-binding globulin levels; chr7:98248841 chr7:98322853~98323430:+ LUSC cis rs7083 1 rs588763 ENSG00000254851.1 RP11-109L13.1 5.42 9.71e-08 3.15e-05 0.3 0.24 Blood protein levels; chr11:117246065 chr11:117135528~117138582:+ LUSC cis rs2554380 0.628 rs4843156 ENSG00000230373.7 GOLGA6L5P -5.42 9.71e-08 3.15e-05 -0.24 -0.24 Height; chr15:83788593 chr15:84507885~84516814:- LUSC cis rs6969780 0.915 rs3807597 ENSG00000233429.8 HOTAIRM1 -5.42 9.71e-08 3.15e-05 -0.42 -0.24 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27149576 chr7:27095647~27100265:+ LUSC cis rs6969780 0.915 rs12666926 ENSG00000233429.8 HOTAIRM1 -5.42 9.71e-08 3.15e-05 -0.42 -0.24 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27149942 chr7:27095647~27100265:+ LUSC cis rs8031584 0.541 rs2955797 ENSG00000260382.1 RP11-540B6.2 -5.42 9.72e-08 3.15e-05 -0.32 -0.24 Huntington's disease progression; chr15:30918778 chr15:30882267~30883231:- LUSC cis rs13434995 0.513 rs7698022 ENSG00000249700.7 SRD5A3-AS1 5.42 9.73e-08 3.15e-05 0.31 0.24 Adiponectin levels; chr4:55541180 chr4:55363971~55395847:- LUSC cis rs2980439 0.557 rs2921056 ENSG00000173295.6 FAM86B3P 5.42 9.73e-08 3.15e-05 0.27 0.24 Neuroticism; chr8:8461672 chr8:8228595~8244865:+ LUSC cis rs13113518 0.812 rs12500456 ENSG00000273257.1 RP11-177J6.1 5.42 9.73e-08 3.15e-05 0.31 0.24 Height; chr4:55561053 chr4:55387949~55388271:+ LUSC cis rs13113518 0.812 rs13116035 ENSG00000273257.1 RP11-177J6.1 5.42 9.73e-08 3.15e-05 0.31 0.24 Height; chr4:55561218 chr4:55387949~55388271:+ LUSC cis rs6502050 0.842 rs62079996 ENSG00000266654.1 RP11-1376P16.1 5.42 9.73e-08 3.16e-05 0.24 0.24 Life satisfaction; chr17:82118986 chr17:82160056~82160452:+ LUSC cis rs6502050 0.814 rs62079997 ENSG00000266654.1 RP11-1376P16.1 5.42 9.73e-08 3.16e-05 0.24 0.24 Life satisfaction; chr17:82119012 chr17:82160056~82160452:+ LUSC cis rs910316 1 rs10142865 ENSG00000279594.1 RP11-950C14.10 5.42 9.74e-08 3.16e-05 0.27 0.24 Height; chr14:75088921 chr14:75011269~75012851:- LUSC cis rs910316 1 rs10142626 ENSG00000279594.1 RP11-950C14.10 5.42 9.74e-08 3.16e-05 0.27 0.24 Height; chr14:75088933 chr14:75011269~75012851:- LUSC cis rs4722166 0.63 rs10950916 ENSG00000179428.2 AC073072.5 -5.42 9.76e-08 3.16e-05 -0.3 -0.24 Lung cancer; chr7:22760048 chr7:22725395~22727620:- LUSC cis rs875971 0.522 rs10807697 ENSG00000222364.1 RNU6-96P -5.42 9.76e-08 3.16e-05 -0.28 -0.24 Aortic root size; chr7:65951183 chr7:66395191~66395286:+ LUSC cis rs4664293 0.801 rs7590595 ENSG00000226266.5 AC009961.3 -5.42 9.76e-08 3.16e-05 -0.28 -0.24 Monocyte percentage of white cells; chr2:159715198 chr2:159670708~159712435:- LUSC cis rs4664293 0.801 rs6432552 ENSG00000226266.5 AC009961.3 -5.42 9.76e-08 3.16e-05 -0.28 -0.24 Monocyte percentage of white cells; chr2:159717613 chr2:159670708~159712435:- LUSC cis rs2732480 0.577 rs2732457 ENSG00000257735.1 RP11-370I10.6 -5.42 9.77e-08 3.16e-05 -0.31 -0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48364596 chr12:48350945~48442411:+ LUSC cis rs889398 1 rs889399 ENSG00000226232.7 RP11-419C5.2 5.42 9.77e-08 3.17e-05 0.23 0.24 Body mass index; chr16:69522680 chr16:69976388~69996188:- LUSC cis rs4604732 0.603 rs10802512 ENSG00000227135.1 GCSAML-AS1 -5.42 9.78e-08 3.17e-05 -0.33 -0.24 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247470428 chr1:247524679~247526752:- LUSC cis rs4604732 0.603 rs10802513 ENSG00000227135.1 GCSAML-AS1 -5.42 9.78e-08 3.17e-05 -0.33 -0.24 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247470617 chr1:247524679~247526752:- LUSC cis rs7580658 0.724 rs4662711 ENSG00000236682.1 AC068282.3 -5.42 9.78e-08 3.17e-05 -0.32 -0.24 Protein C levels; chr2:127233264 chr2:127389130~127400580:+ LUSC cis rs13326165 0.585 rs55847657 ENSG00000243224.1 RP5-1157M23.2 -5.42 9.78e-08 3.17e-05 -0.42 -0.24 HDL cholesterol levels;HDL cholesterol; chr3:52259296 chr3:52239258~52241097:+ LUSC cis rs2980439 0.846 rs2980437 ENSG00000253981.4 ALG1L13P -5.42 9.78e-08 3.17e-05 -0.29 -0.24 Neuroticism; chr8:8237241 chr8:8236003~8244667:- LUSC cis rs11098499 0.535 rs7671759 ENSG00000250412.1 KLHL2P1 5.42 9.78e-08 3.17e-05 0.3 0.24 Corneal astigmatism; chr4:119326939 chr4:119334329~119378233:+ LUSC cis rs13113518 0.812 rs12648271 ENSG00000273257.1 RP11-177J6.1 5.42 9.78e-08 3.17e-05 0.34 0.24 Height; chr4:55501955 chr4:55387949~55388271:+ LUSC cis rs11098499 0.954 rs6822679 ENSG00000248280.1 RP11-33B1.2 5.42 9.78e-08 3.17e-05 0.29 0.24 Corneal astigmatism; chr4:119481547 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs4577559 ENSG00000248280.1 RP11-33B1.2 5.42 9.78e-08 3.17e-05 0.29 0.24 Corneal astigmatism; chr4:119482888 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs7656252 ENSG00000248280.1 RP11-33B1.2 5.42 9.78e-08 3.17e-05 0.29 0.24 Corneal astigmatism; chr4:119483113 chr4:119440561~119450157:- LUSC cis rs11098499 0.865 rs28845498 ENSG00000248280.1 RP11-33B1.2 5.42 9.78e-08 3.17e-05 0.29 0.24 Corneal astigmatism; chr4:119484031 chr4:119440561~119450157:- LUSC cis rs11098499 0.865 rs28753180 ENSG00000248280.1 RP11-33B1.2 5.42 9.78e-08 3.17e-05 0.29 0.24 Corneal astigmatism; chr4:119484212 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs56270433 ENSG00000248280.1 RP11-33B1.2 5.42 9.78e-08 3.17e-05 0.29 0.24 Corneal astigmatism; chr4:119484875 chr4:119440561~119450157:- LUSC cis rs13113518 0.812 rs11133385 ENSG00000273257.1 RP11-177J6.1 5.42 9.79e-08 3.17e-05 0.32 0.24 Height; chr4:55460485 chr4:55387949~55388271:+ LUSC cis rs783540 1 rs1267657 ENSG00000255769.6 GOLGA2P10 5.42 9.79e-08 3.17e-05 0.3 0.24 Schizophrenia; chr15:82546501 chr15:82472993~82513950:- LUSC cis rs783540 1 rs803688 ENSG00000255769.6 GOLGA2P10 5.42 9.79e-08 3.17e-05 0.3 0.24 Schizophrenia; chr15:82548043 chr15:82472993~82513950:- LUSC cis rs673078 0.607 rs17513013 ENSG00000275409.1 RP11-131L12.4 -5.42 9.79e-08 3.17e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118442070 chr12:118430147~118430699:+ LUSC cis rs6502050 0.761 rs9908277 ENSG00000266654.1 RP11-1376P16.1 5.42 9.79e-08 3.17e-05 0.24 0.24 Life satisfaction; chr17:82102953 chr17:82160056~82160452:+ LUSC cis rs8133932 0.701 rs3788228 ENSG00000280604.1 PCBP3-OT1 5.41 9.8e-08 3.17e-05 0.31 0.24 Schizophrenia; chr21:45887755 chr21:45914296~45919483:+ LUSC cis rs11098499 0.954 rs17006190 ENSG00000248280.1 RP11-33B1.2 5.41 9.8e-08 3.17e-05 0.29 0.24 Corneal astigmatism; chr4:119497683 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs3733519 ENSG00000248280.1 RP11-33B1.2 5.41 9.8e-08 3.17e-05 0.29 0.24 Corneal astigmatism; chr4:119502293 chr4:119440561~119450157:- LUSC cis rs453301 0.653 rs2956244 ENSG00000254340.1 RP11-10A14.3 5.41 9.8e-08 3.17e-05 0.3 0.24 Joint mobility (Beighton score); chr8:9027656 chr8:9141424~9145435:+ LUSC cis rs9640161 0.742 rs11983355 ENSG00000261305.1 RP4-584D14.7 5.41 9.8e-08 3.17e-05 0.34 0.24 Blood protein levels;Circulating chemerin levels; chr7:150319608 chr7:150341771~150342607:+ LUSC cis rs7615952 0.932 rs13086087 ENSG00000171084.14 FAM86JP 5.41 9.81e-08 3.18e-05 0.32 0.24 Blood pressure (smoking interaction); chr3:125927438 chr3:125916620~125930024:+ LUSC cis rs2980439 0.557 rs2976876 ENSG00000173295.6 FAM86B3P 5.41 9.81e-08 3.18e-05 0.27 0.24 Neuroticism; chr8:8461340 chr8:8228595~8244865:+ LUSC cis rs910316 0.663 rs175034 ENSG00000279594.1 RP11-950C14.10 -5.41 9.82e-08 3.18e-05 -0.28 -0.24 Height; chr14:74996984 chr14:75011269~75012851:- LUSC cis rs7083 1 rs644215 ENSG00000254851.1 RP11-109L13.1 5.41 9.82e-08 3.18e-05 0.3 0.24 Blood protein levels; chr11:117275202 chr11:117135528~117138582:+ LUSC cis rs13113518 1 rs11133381 ENSG00000272969.1 RP11-528I4.2 5.41 9.83e-08 3.18e-05 0.28 0.24 Height; chr4:55450812 chr4:55547112~55547889:+ LUSC cis rs7429990 0.864 rs1403579 ENSG00000229759.1 MRPS18AP1 5.41 9.84e-08 3.19e-05 0.26 0.24 Educational attainment (years of education); chr3:47617889 chr3:48256350~48256938:- LUSC cis rs1707322 0.717 rs11211161 ENSG00000234329.1 RP11-767N6.2 5.41 9.86e-08 3.19e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45682466 chr1:45651039~45651826:- LUSC cis rs2742234 0.541 rs871763 ENSG00000273008.1 RP11-351D16.3 5.41 9.86e-08 3.19e-05 0.28 0.24 Hirschsprung disease; chr10:43238740 chr10:43136824~43138334:- LUSC cis rs853679 0.824 rs34712084 ENSG00000219392.1 RP1-265C24.5 -5.41 9.86e-08 3.19e-05 -0.41 -0.24 Depression; chr6:28076050 chr6:28115628~28116551:+ LUSC cis rs853679 0.824 rs1321505 ENSG00000219392.1 RP1-265C24.5 -5.41 9.86e-08 3.19e-05 -0.41 -0.24 Depression; chr6:28085045 chr6:28115628~28116551:+ LUSC cis rs6504950 0.924 rs244338 ENSG00000275710.1 RP11-257O5.4 5.41 9.87e-08 3.19e-05 0.28 0.24 Breast cancer; chr17:55123057 chr17:54964474~54964679:+ LUSC cis rs13392177 0.684 rs6720449 ENSG00000261338.2 RP11-378A13.1 -5.41 9.88e-08 3.2e-05 -0.25 -0.24 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218216255 chr2:218255319~218257366:+ LUSC cis rs9487051 0.837 rs4403290 ENSG00000219700.1 PTCHD3P3 5.41 9.88e-08 3.2e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109290380 chr6:109288571~109290503:- LUSC cis rs9487051 0.735 rs882074 ENSG00000219700.1 PTCHD3P3 5.41 9.88e-08 3.2e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109290517 chr6:109288571~109290503:- LUSC cis rs9487051 0.872 rs1320612 ENSG00000219700.1 PTCHD3P3 5.41 9.88e-08 3.2e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109290787 chr6:109288571~109290503:- LUSC cis rs9487051 0.872 rs6924815 ENSG00000219700.1 PTCHD3P3 5.41 9.88e-08 3.2e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109291141 chr6:109288571~109290503:- LUSC cis rs17270561 0.609 rs4712964 ENSG00000272462.2 U91328.19 -5.41 9.88e-08 3.2e-05 -0.28 -0.24 Iron status biomarkers; chr6:25740594 chr6:25992662~26001775:+ LUSC cis rs11098499 0.909 rs9759478 ENSG00000248280.1 RP11-33B1.2 5.41 9.88e-08 3.2e-05 0.29 0.24 Corneal astigmatism; chr4:119446843 chr4:119440561~119450157:- LUSC cis rs7945705 0.776 rs11042069 ENSG00000254860.4 TMEM9B-AS1 -5.41 9.88e-08 3.2e-05 -0.28 -0.24 Hemoglobin concentration; chr11:8795768 chr11:8964675~8977527:+ LUSC cis rs11846409 0.629 rs76295389 ENSG00000274576.2 IGHV2-70 5.41 9.89e-08 3.2e-05 0.26 0.24 Rheumatic heart disease; chr14:106650437 chr14:106770577~106771020:- LUSC cis rs11846409 0.698 rs71419854 ENSG00000274576.2 IGHV2-70 5.41 9.89e-08 3.2e-05 0.26 0.24 Rheumatic heart disease; chr14:106650440 chr14:106770577~106771020:- LUSC cis rs2337406 0.5 rs71419855 ENSG00000274576.2 IGHV2-70 5.41 9.89e-08 3.2e-05 0.26 0.24 Alzheimer's disease (late onset); chr14:106650444 chr14:106770577~106771020:- LUSC cis rs11098499 0.954 rs7436506 ENSG00000248280.1 RP11-33B1.2 5.41 9.9e-08 3.2e-05 0.3 0.24 Corneal astigmatism; chr4:119472614 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs12499324 ENSG00000248280.1 RP11-33B1.2 5.41 9.9e-08 3.2e-05 0.3 0.24 Corneal astigmatism; chr4:119472631 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs10008459 ENSG00000248280.1 RP11-33B1.2 5.41 9.9e-08 3.2e-05 0.3 0.24 Corneal astigmatism; chr4:119473076 chr4:119440561~119450157:- LUSC cis rs6502050 0.871 rs6416857 ENSG00000266654.1 RP11-1376P16.1 5.41 9.92e-08 3.21e-05 0.25 0.24 Life satisfaction; chr17:82105128 chr17:82160056~82160452:+ LUSC cis rs7772486 0.875 rs1331645 ENSG00000235652.6 RP11-545I5.3 5.41 9.92e-08 3.21e-05 0.24 0.24 Lobe attachment (rater-scored or self-reported); chr6:146077271 chr6:145799409~145886585:+ LUSC cis rs2946504 0.628 rs2946510 ENSG00000251468.2 RP11-369K16.1 -5.41 9.93e-08 3.21e-05 -0.29 -0.24 Type 2 diabetes; chr8:12950371 chr8:12958387~12962200:+ LUSC cis rs13113518 1 rs13113518 ENSG00000272969.1 RP11-528I4.2 5.41 9.94e-08 3.21e-05 0.27 0.24 Height; chr4:55533481 chr4:55547112~55547889:+ LUSC cis rs6570726 0.599 rs9403725 ENSG00000235652.6 RP11-545I5.3 -5.41 9.94e-08 3.21e-05 -0.26 -0.24 Lobe attachment (rater-scored or self-reported); chr6:145576486 chr6:145799409~145886585:+ LUSC cis rs2337406 1 rs11849532 ENSG00000211974.3 IGHV2-70 -5.41 9.94e-08 3.22e-05 -0.35 -0.24 Alzheimer's disease (late onset); chr14:106669877 chr14:106723574~106724093:- LUSC cis rs1008375 0.966 rs10939735 ENSG00000249502.1 AC006160.5 -5.41 9.95e-08 3.22e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17577268 chr4:17587467~17614571:- LUSC cis rs11098499 0.954 rs11722872 ENSG00000248280.1 RP11-33B1.2 5.41 9.95e-08 3.22e-05 0.3 0.24 Corneal astigmatism; chr4:119311875 chr4:119440561~119450157:- LUSC cis rs1707322 0.717 rs12023439 ENSG00000234329.1 RP11-767N6.2 5.41 9.95e-08 3.22e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638964 chr1:45651039~45651826:- LUSC cis rs7829975 0.711 rs4481596 ENSG00000253893.2 FAM85B -5.41 9.96e-08 3.22e-05 -0.29 -0.24 Mood instability; chr8:8846820 chr8:8167819~8226614:- LUSC cis rs11098499 0.826 rs4472123 ENSG00000250412.1 KLHL2P1 5.41 9.96e-08 3.22e-05 0.3 0.24 Corneal astigmatism; chr4:119315475 chr4:119334329~119378233:+ LUSC cis rs9840812 0.61 rs34967300 ENSG00000239213.4 NCK1-AS1 -5.41 9.96e-08 3.22e-05 -0.31 -0.24 Fibrinogen levels; chr3:136549976 chr3:136841726~136862054:- LUSC cis rs17270561 0.609 rs9379783 ENSG00000272462.2 U91328.19 -5.41 9.97e-08 3.22e-05 -0.28 -0.24 Iron status biomarkers; chr6:25724979 chr6:25992662~26001775:+ LUSC cis rs853679 1 rs11965538 ENSG00000204709.4 LINC01556 5.41 9.97e-08 3.22e-05 0.39 0.24 Depression; chr6:28272137 chr6:28943877~28944537:+ LUSC cis rs853679 0.882 rs2743555 ENSG00000204709.4 LINC01556 5.41 9.97e-08 3.22e-05 0.39 0.24 Depression; chr6:28273304 chr6:28943877~28944537:+ LUSC cis rs17507216 0.628 rs8032321 ENSG00000276710.3 CSPG4P8 -5.41 9.97e-08 3.23e-05 -0.32 -0.24 Excessive daytime sleepiness; chr15:82698956 chr15:82459472~82477258:+ LUSC cis rs17507216 0.628 rs8040488 ENSG00000276710.3 CSPG4P8 -5.41 9.97e-08 3.23e-05 -0.32 -0.24 Excessive daytime sleepiness; chr15:82699081 chr15:82459472~82477258:+ LUSC cis rs2430307 0.518 rs67763033 ENSG00000242435.1 UPK3BP1 5.41 9.98e-08 3.23e-05 0.37 0.24 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr7:76888360 chr7:77004662~77005774:+ LUSC cis rs910316 0.935 rs3742771 ENSG00000279594.1 RP11-950C14.10 5.41 9.98e-08 3.23e-05 0.28 0.24 Height; chr14:75132944 chr14:75011269~75012851:- LUSC cis rs950169 0.579 rs11633088 ENSG00000225151.9 GOLGA2P7 5.41 9.98e-08 3.23e-05 0.35 0.24 Schizophrenia; chr15:84003429 chr15:84199311~84230136:- LUSC cis rs453301 0.624 rs2979256 ENSG00000254340.1 RP11-10A14.3 5.41 9.98e-08 3.23e-05 0.3 0.24 Joint mobility (Beighton score); chr8:9014200 chr8:9141424~9145435:+ LUSC cis rs867371 0.717 rs3858954 ENSG00000255769.6 GOLGA2P10 -5.41 9.99e-08 3.23e-05 -0.31 -0.24 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82265693 chr15:82472993~82513950:- LUSC cis rs673078 0.607 rs7958551 ENSG00000275409.1 RP11-131L12.4 -5.41 1e-07 3.23e-05 -0.35 -0.24 Glucose homeostasis traits; chr12:118442585 chr12:118430147~118430699:+ LUSC cis rs7772486 0.875 rs2777477 ENSG00000235652.6 RP11-545I5.3 5.41 1e-07 3.23e-05 0.24 0.24 Lobe attachment (rater-scored or self-reported); chr6:145984355 chr6:145799409~145886585:+ LUSC cis rs7772486 0.875 rs1330939 ENSG00000235652.6 RP11-545I5.3 5.41 1e-07 3.23e-05 0.24 0.24 Lobe attachment (rater-scored or self-reported); chr6:145987382 chr6:145799409~145886585:+ LUSC cis rs1707322 0.638 rs1416706 ENSG00000280836.1 AL355480.1 5.41 1e-07 3.23e-05 0.3 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46137172 chr1:45581219~45581321:- LUSC cis rs7712401 0.601 rs13155907 ENSG00000263432.2 RN7SL689P -5.41 1e-07 3.23e-05 -0.31 -0.24 Mean platelet volume; chr5:122998938 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs62377430 ENSG00000263432.2 RN7SL689P -5.41 1e-07 3.23e-05 -0.31 -0.24 Mean platelet volume; chr5:122998993 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs34348084 ENSG00000263432.2 RN7SL689P -5.41 1e-07 3.23e-05 -0.31 -0.24 Mean platelet volume; chr5:122999419 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs13164134 ENSG00000263432.2 RN7SL689P -5.41 1e-07 3.23e-05 -0.31 -0.24 Mean platelet volume; chr5:123002246 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs13185741 ENSG00000263432.2 RN7SL689P -5.41 1e-07 3.23e-05 -0.31 -0.24 Mean platelet volume; chr5:123002315 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs35334805 ENSG00000263432.2 RN7SL689P -5.41 1e-07 3.24e-05 -0.31 -0.24 Mean platelet volume; chr5:122999566 chr5:123022487~123022783:- LUSC cis rs11096990 0.613 rs12505690 ENSG00000249207.1 RP11-360F5.1 -5.41 1e-07 3.24e-05 -0.26 -0.24 Cognitive function; chr4:39167425 chr4:39112677~39126818:- LUSC cis rs2337406 0.866 rs2301536 ENSG00000280411.1 IGHV1-69-2 -5.41 1e-07 3.24e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106790636 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs7144369 ENSG00000280411.1 IGHV1-69-2 -5.41 1e-07 3.24e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106793065 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs78525520 ENSG00000280411.1 IGHV1-69-2 -5.41 1e-07 3.24e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106795643 chr14:106762092~106762588:- LUSC cis rs7829975 0.606 rs891570 ENSG00000253893.2 FAM85B 5.41 1e-07 3.25e-05 0.28 0.24 Mood instability; chr8:8936944 chr8:8167819~8226614:- LUSC cis rs442309 0.875 rs224065 ENSG00000238280.1 RP11-436D10.3 -5.41 1e-07 3.25e-05 -0.29 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62745688 chr10:62793562~62805887:- LUSC cis rs9918079 0.884 rs11728037 ENSG00000273133.1 RP11-799M12.2 -5.41 1.01e-07 3.25e-05 -0.38 -0.24 Obesity-related traits; chr4:15593275 chr4:15563698~15564253:- LUSC cis rs1707322 0.686 rs3014239 ENSG00000234329.1 RP11-767N6.2 -5.41 1.01e-07 3.25e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624129 chr1:45651039~45651826:- LUSC cis rs1707322 0.686 rs3014236 ENSG00000234329.1 RP11-767N6.2 -5.41 1.01e-07 3.25e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625633 chr1:45651039~45651826:- LUSC cis rs10462794 0.853 rs4702795 ENSG00000260763.1 RP11-445O3.3 -5.41 1.01e-07 3.25e-05 -0.31 -0.24 DNA methylation (variation); chr5:4507889 chr5:4436850~4440259:- LUSC cis rs6061231 1 rs11696991 ENSG00000273619.1 RP5-908M14.9 -5.41 1.01e-07 3.25e-05 -0.23 -0.24 Colorectal cancer; chr20:62384638 chr20:62386303~62386970:- LUSC cis rs13113518 1 rs6838882 ENSG00000223305.1 RN7SKP30 5.41 1.01e-07 3.26e-05 0.3 0.24 Height; chr4:55489310 chr4:55540502~55540835:- LUSC cis rs801193 0.967 rs34356500 ENSG00000237310.1 GS1-124K5.4 5.41 1.01e-07 3.26e-05 0.25 0.24 Aortic root size; chr7:66771620 chr7:66493706~66495474:+ LUSC cis rs13113518 1 rs4864546 ENSG00000223305.1 RN7SKP30 5.41 1.01e-07 3.26e-05 0.29 0.24 Height; chr4:55537960 chr4:55540502~55540835:- LUSC cis rs739310 0.556 rs9625070 ENSG00000206028.1 CTA-373H7.7 -5.41 1.01e-07 3.26e-05 -0.41 -0.24 Obesity-related traits; chr22:26687029 chr22:26667693~26672654:- LUSC cis rs9649213 0.593 rs6949718 ENSG00000272950.1 RP11-307C18.1 5.41 1.01e-07 3.26e-05 0.31 0.24 Prostate cancer (SNP x SNP interaction); chr7:98295171 chr7:98322853~98323430:+ LUSC cis rs2742234 0.541 rs1317214 ENSG00000273008.1 RP11-351D16.3 5.41 1.01e-07 3.26e-05 0.28 0.24 Hirschsprung disease; chr10:43238083 chr10:43136824~43138334:- LUSC cis rs1729951 0.575 rs361239 ENSG00000261758.1 RP11-102M11.2 5.41 1.01e-07 3.26e-05 0.23 0.24 Neuroticism; chr3:136982453 chr3:136752630~136755780:+ LUSC cis rs4664293 0.801 rs7589771 ENSG00000226266.5 AC009961.3 -5.41 1.01e-07 3.27e-05 -0.28 -0.24 Monocyte percentage of white cells; chr2:159727621 chr2:159670708~159712435:- LUSC cis rs13113518 1 rs13116194 ENSG00000272969.1 RP11-528I4.2 5.41 1.01e-07 3.27e-05 0.28 0.24 Height; chr4:55531150 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs13117836 ENSG00000272969.1 RP11-528I4.2 5.41 1.01e-07 3.27e-05 0.28 0.24 Height; chr4:55531218 chr4:55547112~55547889:+ LUSC cis rs13113518 0.966 rs7668429 ENSG00000272969.1 RP11-528I4.2 5.41 1.01e-07 3.27e-05 0.28 0.24 Height; chr4:55531811 chr4:55547112~55547889:+ LUSC cis rs73173548 0.502 rs4129236 ENSG00000247828.6 TMEM161B-AS1 5.41 1.01e-07 3.27e-05 0.29 0.24 Macular telangiectasia type 2; chr5:88441542 chr5:88268895~88436685:+ LUSC cis rs11951515 0.509 rs12521249 ENSG00000249286.1 CTD-2210P15.2 -5.41 1.01e-07 3.27e-05 -0.29 -0.24 Metabolite levels (X-11787); chr5:43558527 chr5:43586918~43588223:- LUSC cis rs459571 0.959 rs460888 ENSG00000235106.7 LINC00094 5.41 1.01e-07 3.27e-05 0.28 0.24 Platelet distribution width; chr9:134048001 chr9:134025439~134034666:+ LUSC cis rs9545047 0.604 rs2057573 ENSG00000227676.3 LINC01068 -5.41 1.01e-07 3.27e-05 -0.29 -0.24 Schizophrenia; chr13:79357736 chr13:79566727~79571436:+ LUSC cis rs7615952 0.866 rs1976459 ENSG00000171084.14 FAM86JP 5.41 1.02e-07 3.28e-05 0.32 0.24 Blood pressure (smoking interaction); chr3:125928643 chr3:125916620~125930024:+ LUSC cis rs9649213 0.593 rs6970990 ENSG00000272950.1 RP11-307C18.1 5.41 1.02e-07 3.28e-05 0.31 0.24 Prostate cancer (SNP x SNP interaction); chr7:98296070 chr7:98322853~98323430:+ LUSC cis rs9649213 0.555 rs34695842 ENSG00000272950.1 RP11-307C18.1 5.41 1.02e-07 3.28e-05 0.31 0.24 Prostate cancer (SNP x SNP interaction); chr7:98301750 chr7:98322853~98323430:+ LUSC cis rs442309 0.841 rs224074 ENSG00000238280.1 RP11-436D10.3 -5.41 1.02e-07 3.28e-05 -0.3 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62750627 chr10:62793562~62805887:- LUSC cis rs442309 0.841 rs224076 ENSG00000238280.1 RP11-436D10.3 -5.41 1.02e-07 3.28e-05 -0.3 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62751881 chr10:62793562~62805887:- LUSC cis rs442309 0.841 rs224078 ENSG00000238280.1 RP11-436D10.3 -5.41 1.02e-07 3.28e-05 -0.3 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62752000 chr10:62793562~62805887:- LUSC cis rs442309 0.841 rs224079 ENSG00000238280.1 RP11-436D10.3 -5.41 1.02e-07 3.28e-05 -0.3 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62753470 chr10:62793562~62805887:- LUSC cis rs66887589 0.592 rs62320740 ENSG00000250412.1 KLHL2P1 5.41 1.02e-07 3.28e-05 0.28 0.24 Diastolic blood pressure; chr4:119358331 chr4:119334329~119378233:+ LUSC cis rs2742234 0.578 rs2435354 ENSG00000273008.1 RP11-351D16.3 -5.41 1.02e-07 3.28e-05 -0.27 -0.24 Hirschsprung disease; chr10:43156997 chr10:43136824~43138334:- LUSC cis rs13113518 1 rs55699500 ENSG00000272969.1 RP11-528I4.2 5.41 1.02e-07 3.28e-05 0.28 0.24 Height; chr4:55540912 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs56362210 ENSG00000272969.1 RP11-528I4.2 5.41 1.02e-07 3.28e-05 0.28 0.24 Height; chr4:55540972 chr4:55547112~55547889:+ LUSC cis rs4141404 0.923 rs2413035 ENSG00000236132.1 CTA-440B3.1 5.41 1.02e-07 3.28e-05 0.32 0.24 Paclitaxel-induced neuropathy; chr22:31204474 chr22:31816379~31817491:- LUSC cis rs8133932 0.736 rs2839030 ENSG00000280604.1 PCBP3-OT1 5.41 1.02e-07 3.28e-05 0.32 0.24 Schizophrenia; chr21:45872093 chr21:45914296~45919483:+ LUSC cis rs10462794 0.853 rs10061389 ENSG00000260763.1 RP11-445O3.3 -5.41 1.02e-07 3.29e-05 -0.31 -0.24 DNA methylation (variation); chr5:4509839 chr5:4436850~4440259:- LUSC cis rs34792 0.688 rs153782 ENSG00000207425.1 Y_RNA 5.41 1.02e-07 3.29e-05 0.33 0.24 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15507763 chr16:14915457~14915556:- LUSC cis rs4713118 0.869 rs9283883 ENSG00000280107.1 AL022393.9 -5.41 1.02e-07 3.29e-05 -0.28 -0.24 Parkinson's disease; chr6:27747691 chr6:28170845~28172521:+ LUSC cis rs35740288 0.77 rs11631018 ENSG00000202081.1 RNU6-1280P 5.41 1.02e-07 3.3e-05 0.3 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85597303 chr15:85651522~85651628:- LUSC cis rs7712401 0.601 rs417268 ENSG00000263432.2 RN7SL689P -5.41 1.02e-07 3.3e-05 -0.31 -0.24 Mean platelet volume; chr5:123009317 chr5:123022487~123022783:- LUSC cis rs11098499 0.909 rs2127821 ENSG00000248280.1 RP11-33B1.2 5.41 1.02e-07 3.3e-05 0.29 0.24 Corneal astigmatism; chr4:119473380 chr4:119440561~119450157:- LUSC cis rs17711722 0.701 rs781145 ENSG00000237310.1 GS1-124K5.4 5.41 1.03e-07 3.31e-05 0.25 0.24 Calcium levels; chr7:65975383 chr7:66493706~66495474:+ LUSC cis rs2903698 0.651 rs35362134 ENSG00000250735.4 RP11-567N4.3 5.41 1.03e-07 3.31e-05 0.28 0.24 Prion diseases; chr4:75526249 chr4:75401195~75423023:+ LUSC cis rs12899811 0.53 rs11073967 ENSG00000214432.8 AC068831.10 -5.41 1.03e-07 3.31e-05 -0.29 -0.24 Type 2 diabetes; chr15:91022574 chr15:91022619~91036611:+ LUSC cis rs67311347 1 rs4973994 ENSG00000223797.4 ENTPD3-AS1 5.41 1.03e-07 3.31e-05 0.28 0.24 Renal cell carcinoma; chr3:40411533 chr3:40313802~40453329:- LUSC cis rs17270561 0.666 rs9356988 ENSG00000272462.2 U91328.19 -5.41 1.03e-07 3.31e-05 -0.29 -0.24 Iron status biomarkers; chr6:25777253 chr6:25992662~26001775:+ LUSC cis rs4423214 0.592 rs1790349 ENSG00000254682.1 RP11-660L16.2 -5.41 1.03e-07 3.32e-05 -0.4 -0.24 Vitamin D levels; chr11:71431304 chr11:71448674~71452157:+ LUSC cis rs7772486 0.875 rs2492855 ENSG00000235652.6 RP11-545I5.3 5.41 1.03e-07 3.32e-05 0.24 0.24 Lobe attachment (rater-scored or self-reported); chr6:145975790 chr6:145799409~145886585:+ LUSC cis rs2919917 0.617 rs4641056 ENSG00000254352.1 RP11-578O24.2 5.41 1.03e-07 3.32e-05 0.32 0.24 Lymphocyte counts; chr8:78670261 chr8:78723796~78724136:- LUSC cis rs367615 0.918 rs72797472 ENSG00000249476.1 CTD-2587M2.1 5.41 1.03e-07 3.32e-05 0.32 0.24 Colorectal cancer (SNP x SNP interaction); chr5:109545642 chr5:109237120~109326369:- LUSC cis rs2880765 0.566 rs17553249 ENSG00000202081.1 RNU6-1280P 5.41 1.03e-07 3.32e-05 0.27 0.24 Coronary artery disease; chr15:85463463 chr15:85651522~85651628:- LUSC cis rs1707322 0.682 rs10890334 ENSG00000234329.1 RP11-767N6.2 5.41 1.03e-07 3.32e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634706 chr1:45651039~45651826:- LUSC cis rs1707322 0.682 rs10890335 ENSG00000234329.1 RP11-767N6.2 5.41 1.03e-07 3.32e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634722 chr1:45651039~45651826:- LUSC cis rs2404602 0.967 rs2083762 ENSG00000259422.1 RP11-593F23.1 5.4 1.03e-07 3.33e-05 0.27 0.24 Blood metabolite levels; chr15:76615035 chr15:76174891~76181486:- LUSC cis rs17711722 0.701 rs781143 ENSG00000222364.1 RNU6-96P -5.4 1.03e-07 3.33e-05 -0.28 -0.24 Calcium levels; chr7:65974892 chr7:66395191~66395286:+ LUSC cis rs889398 1 rs889398 ENSG00000226232.7 RP11-419C5.2 5.4 1.03e-07 3.33e-05 0.23 0.24 Body mass index; chr16:69522812 chr16:69976388~69996188:- LUSC cis rs77204473 1 rs77204473 ENSG00000254851.1 RP11-109L13.1 5.4 1.03e-07 3.33e-05 0.67 0.24 Sum eosinophil basophil counts;Eosinophil counts; chr11:116934348 chr11:117135528~117138582:+ LUSC cis rs13113518 1 rs10462032 ENSG00000272969.1 RP11-528I4.2 5.4 1.04e-07 3.34e-05 0.27 0.24 Height; chr4:55479069 chr4:55547112~55547889:+ LUSC cis rs11971779 0.711 rs6961204 ENSG00000273391.1 RP11-634H22.1 5.4 1.04e-07 3.34e-05 0.29 0.24 Diisocyanate-induced asthma; chr7:139362653 chr7:139359032~139359566:- LUSC cis rs1412337 0.52 rs12744842 ENSG00000227777.1 RP4-738P11.3 -5.4 1.04e-07 3.34e-05 -0.33 -0.24 Morbidity-free survival; chr1:168640496 chr1:168542737~168543354:+ LUSC cis rs13113518 1 rs3762837 ENSG00000223305.1 RN7SKP30 5.4 1.04e-07 3.34e-05 0.29 0.24 Height; chr4:55511198 chr4:55540502~55540835:- LUSC cis rs6502050 0.835 rs62080004 ENSG00000266654.1 RP11-1376P16.1 5.4 1.04e-07 3.34e-05 0.24 0.24 Life satisfaction; chr17:82121203 chr17:82160056~82160452:+ LUSC cis rs10788972 0.873 rs11206283 ENSG00000225183.1 RP4-758J24.4 5.4 1.04e-07 3.34e-05 0.29 0.24 Parkinson disease and lewy body pathology; chr1:54110966 chr1:54089856~54090093:+ LUSC cis rs1021993 0.545 rs76234951 ENSG00000231648.1 RP11-372M18.2 -5.4 1.04e-07 3.35e-05 -0.36 -0.24 Gut microbiome composition (winter); chr1:209377881 chr1:209367662~209379690:+ LUSC cis rs13113518 1 rs7691799 ENSG00000273257.1 RP11-177J6.1 5.4 1.04e-07 3.35e-05 0.31 0.24 Height; chr4:55545574 chr4:55387949~55388271:+ LUSC cis rs442309 0.841 rs224042 ENSG00000238280.1 RP11-436D10.3 -5.4 1.04e-07 3.36e-05 -0.3 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62764530 chr10:62793562~62805887:- LUSC cis rs6502050 0.835 rs7406220 ENSG00000266654.1 RP11-1376P16.1 5.4 1.04e-07 3.36e-05 0.24 0.24 Life satisfaction; chr17:82119974 chr17:82160056~82160452:+ LUSC cis rs875971 0.545 rs6969224 ENSG00000224316.1 RP11-479O9.2 5.4 1.05e-07 3.37e-05 0.26 0.24 Aortic root size; chr7:66370011 chr7:65773620~65802067:+ LUSC cis rs442309 0.775 rs7893375 ENSG00000238280.1 RP11-436D10.3 -5.4 1.05e-07 3.37e-05 -0.3 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62757846 chr10:62793562~62805887:- LUSC cis rs13113518 1 rs13114841 ENSG00000223305.1 RN7SKP30 5.4 1.05e-07 3.37e-05 0.3 0.24 Height; chr4:55485974 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs939823 ENSG00000223305.1 RN7SKP30 5.4 1.05e-07 3.37e-05 0.3 0.24 Height; chr4:55487368 chr4:55540502~55540835:- LUSC cis rs73173548 0.502 rs13165428 ENSG00000247828.6 TMEM161B-AS1 -5.4 1.05e-07 3.37e-05 -0.28 -0.24 Macular telangiectasia type 2; chr5:88443945 chr5:88268895~88436685:+ LUSC cis rs9341808 0.667 rs7746917 ENSG00000272129.1 RP11-250B2.6 5.4 1.05e-07 3.37e-05 0.3 0.24 Sitting height ratio; chr6:80221786 chr6:80355424~80356859:+ LUSC cis rs35740288 0.822 rs17574774 ENSG00000202081.1 RNU6-1280P -5.4 1.05e-07 3.37e-05 -0.3 -0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85690139 chr15:85651522~85651628:- LUSC cis rs9487051 0.872 rs4601178 ENSG00000219700.1 PTCHD3P3 5.4 1.05e-07 3.38e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109290043 chr6:109288571~109290503:- LUSC cis rs1021993 0.868 rs906350 ENSG00000231648.1 RP11-372M18.2 -5.4 1.05e-07 3.38e-05 -0.29 -0.24 Gut microbiome composition (winter); chr1:209354763 chr1:209367662~209379690:+ LUSC cis rs1021993 0.818 rs906349 ENSG00000231648.1 RP11-372M18.2 -5.4 1.05e-07 3.38e-05 -0.29 -0.24 Gut microbiome composition (winter); chr1:209354783 chr1:209367662~209379690:+ LUSC cis rs2337406 0.866 rs112089985 ENSG00000254174.1 IGHV1-12 5.4 1.05e-07 3.38e-05 0.23 0.24 Alzheimer's disease (late onset); chr14:106780074 chr14:106122420~106122709:- LUSC cis rs61270009 0.818 rs6452786 ENSG00000247828.6 TMEM161B-AS1 5.4 1.05e-07 3.38e-05 0.28 0.24 Depressive symptoms; chr5:88409022 chr5:88268895~88436685:+ LUSC cis rs2337406 0.925 rs873533 ENSG00000211974.3 IGHV2-70 -5.4 1.05e-07 3.38e-05 -0.35 -0.24 Alzheimer's disease (late onset); chr14:106667442 chr14:106723574~106724093:- LUSC cis rs13113518 0.966 rs1474271 ENSG00000272969.1 RP11-528I4.2 5.4 1.05e-07 3.38e-05 0.28 0.24 Height; chr4:55435912 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs11937487 ENSG00000272969.1 RP11-528I4.2 5.4 1.05e-07 3.38e-05 0.28 0.24 Height; chr4:55436576 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs3805146 ENSG00000272969.1 RP11-528I4.2 5.4 1.05e-07 3.38e-05 0.28 0.24 Height; chr4:55436985 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs11133378 ENSG00000272969.1 RP11-528I4.2 5.4 1.05e-07 3.38e-05 0.28 0.24 Height; chr4:55439472 chr4:55547112~55547889:+ LUSC cis rs13113518 1 rs11942279 ENSG00000272969.1 RP11-528I4.2 5.4 1.05e-07 3.38e-05 0.28 0.24 Height; chr4:55439652 chr4:55547112~55547889:+ LUSC cis rs11098499 0.82 rs13128602 ENSG00000248280.1 RP11-33B1.2 -5.4 1.05e-07 3.38e-05 -0.29 -0.24 Corneal astigmatism; chr4:119538211 chr4:119440561~119450157:- LUSC cis rs1008375 0.966 rs3775925 ENSG00000249502.1 AC006160.5 -5.4 1.05e-07 3.38e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17586814 chr4:17587467~17614571:- LUSC cis rs6772849 1 rs2712379 ENSG00000242551.2 POU5F1P6 -5.4 1.05e-07 3.38e-05 -0.28 -0.24 Monocyte percentage of white cells;Monocyte count; chr3:128590217 chr3:128674735~128677005:- LUSC cis rs897984 0.542 rs6565217 ENSG00000260911.2 RP11-196G11.2 5.4 1.05e-07 3.38e-05 0.22 0.24 Dementia with Lewy bodies; chr16:31072003 chr16:31043150~31049868:+ LUSC cis rs910316 1 rs12589815 ENSG00000279594.1 RP11-950C14.10 5.4 1.05e-07 3.38e-05 0.28 0.24 Height; chr14:75077398 chr14:75011269~75012851:- LUSC cis rs1008375 0.966 rs7658240 ENSG00000249502.1 AC006160.5 5.4 1.05e-07 3.38e-05 0.24 0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17587327 chr4:17587467~17614571:- LUSC cis rs11098499 0.575 rs907204 ENSG00000250412.1 KLHL2P1 5.4 1.05e-07 3.38e-05 0.3 0.24 Corneal astigmatism; chr4:119317499 chr4:119334329~119378233:+ LUSC cis rs11098499 0.575 rs907205 ENSG00000250412.1 KLHL2P1 5.4 1.05e-07 3.38e-05 0.3 0.24 Corneal astigmatism; chr4:119317509 chr4:119334329~119378233:+ LUSC cis rs34435647 1 rs34435647 ENSG00000226266.5 AC009961.3 -5.4 1.05e-07 3.39e-05 -0.28 -0.24 Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells; chr2:159661779 chr2:159670708~159712435:- LUSC cis rs11105298 0.891 rs10858890 ENSG00000258302.2 RP11-981P6.1 5.4 1.06e-07 3.4e-05 0.24 0.24 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89513389 chr12:89561129~89594878:+ LUSC cis rs9611519 0.857 rs4820434 ENSG00000235513.1 RP4-756G23.5 5.4 1.06e-07 3.4e-05 0.29 0.24 Neuroticism; chr22:41241115 chr22:41209122~41217627:- LUSC cis rs34779708 0.733 rs4102764 ENSG00000230534.5 RP11-297A16.2 5.4 1.06e-07 3.4e-05 0.28 0.24 Inflammatory bowel disease;Crohn's disease; chr10:35256464 chr10:35098006~35127020:- LUSC cis rs2554380 0.6 rs6602986 ENSG00000230373.7 GOLGA6L5P -5.4 1.06e-07 3.4e-05 -0.24 -0.24 Height; chr15:83778347 chr15:84507885~84516814:- LUSC cis rs9487051 0.844 rs9386792 ENSG00000219700.1 PTCHD3P3 5.4 1.06e-07 3.4e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109288772 chr6:109288571~109290503:- LUSC cis rs9487051 0.872 rs9398197 ENSG00000219700.1 PTCHD3P3 5.4 1.06e-07 3.4e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109288785 chr6:109288571~109290503:- LUSC cis rs8133932 0.637 rs7283688 ENSG00000280604.1 PCBP3-OT1 5.4 1.06e-07 3.41e-05 0.31 0.24 Schizophrenia; chr21:45881440 chr21:45914296~45919483:+ LUSC cis rs11096990 0.593 rs35552004 ENSG00000249207.1 RP11-360F5.1 -5.4 1.06e-07 3.41e-05 -0.26 -0.24 Cognitive function; chr4:39170914 chr4:39112677~39126818:- LUSC cis rs11096990 0.552 rs7655170 ENSG00000249207.1 RP11-360F5.1 -5.4 1.06e-07 3.41e-05 -0.26 -0.24 Cognitive function; chr4:39171984 chr4:39112677~39126818:- LUSC cis rs1555322 0.53 rs2275275 ENSG00000126005.14 MMP24-AS1 -5.4 1.06e-07 3.41e-05 -0.35 -0.24 Attention deficit hyperactivity disorder; chr20:35284508 chr20:35216462~35278131:- LUSC cis rs67311347 0.955 rs11711994 ENSG00000223797.4 ENTPD3-AS1 5.4 1.06e-07 3.41e-05 0.29 0.24 Renal cell carcinoma; chr3:40349595 chr3:40313802~40453329:- LUSC cis rs13326165 0.585 rs114645176 ENSG00000243224.1 RP5-1157M23.2 -5.4 1.06e-07 3.41e-05 -0.4 -0.24 HDL cholesterol levels;HDL cholesterol; chr3:52245935 chr3:52239258~52241097:+ LUSC cis rs1021993 0.545 rs79960084 ENSG00000231648.1 RP11-372M18.2 -5.4 1.06e-07 3.41e-05 -0.36 -0.24 Gut microbiome composition (winter); chr1:209382825 chr1:209367662~209379690:+ LUSC cis rs910316 1 rs175436 ENSG00000279594.1 RP11-950C14.10 -5.4 1.06e-07 3.41e-05 -0.27 -0.24 Height; chr14:75141980 chr14:75011269~75012851:- LUSC cis rs11098499 0.954 rs13133522 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119403269 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs35091806 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119404374 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs35165976 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119404475 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs3890049 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119405128 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs6846442 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119405168 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs71614438 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119450097 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs66506550 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119450290 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs7659501 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119450397 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs71629403 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119451412 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs28571712 ENSG00000248280.1 RP11-33B1.2 5.4 1.06e-07 3.41e-05 0.29 0.24 Corneal astigmatism; chr4:119454825 chr4:119440561~119450157:- LUSC cis rs367615 0.918 rs4576198 ENSG00000249476.1 CTD-2587M2.1 5.4 1.06e-07 3.41e-05 0.32 0.24 Colorectal cancer (SNP x SNP interaction); chr5:109531649 chr5:109237120~109326369:- LUSC cis rs673078 0.607 rs61944669 ENSG00000275409.1 RP11-131L12.4 -5.4 1.06e-07 3.42e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118448530 chr12:118430147~118430699:+ LUSC cis rs13113518 1 rs7660980 ENSG00000223305.1 RN7SKP30 -5.4 1.06e-07 3.42e-05 -0.29 -0.24 Height; chr4:55542948 chr4:55540502~55540835:- LUSC cis rs6844153 0.938 rs16878655 ENSG00000240005.4 RP11-293A21.1 5.4 1.06e-07 3.42e-05 0.37 0.24 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26964655 chr4:26859806~26860599:- LUSC cis rs910316 0.712 rs175015 ENSG00000279594.1 RP11-950C14.10 -5.4 1.07e-07 3.43e-05 -0.28 -0.24 Height; chr14:74990372 chr14:75011269~75012851:- LUSC cis rs9287719 0.601 rs62128635 ENSG00000243819.4 RN7SL832P 5.4 1.07e-07 3.43e-05 0.21 0.24 Prostate cancer; chr2:10585208 chr2:10690344~10692099:+ LUSC cis rs11098499 0.738 rs34566984 ENSG00000248280.1 RP11-33B1.2 5.4 1.07e-07 3.43e-05 0.29 0.24 Corneal astigmatism; chr4:119440115 chr4:119440561~119450157:- LUSC cis rs11098499 0.954 rs9685777 ENSG00000248280.1 RP11-33B1.2 5.4 1.07e-07 3.43e-05 0.29 0.24 Corneal astigmatism; chr4:119444810 chr4:119440561~119450157:- LUSC cis rs367615 0.66 rs10477972 ENSG00000249476.1 CTD-2587M2.1 5.4 1.07e-07 3.43e-05 0.28 0.24 Colorectal cancer (SNP x SNP interaction); chr5:109496250 chr5:109237120~109326369:- LUSC cis rs1008375 0.966 rs3796812 ENSG00000249502.1 AC006160.5 -5.4 1.07e-07 3.44e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17580428 chr4:17587467~17614571:- LUSC cis rs8091660 0.624 rs907546 ENSG00000278983.1 RP11-426J5.3 5.4 1.07e-07 3.44e-05 0.36 0.24 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48549919 chr18:48564795~48568342:+ LUSC cis rs9890032 0.52 rs2321926 ENSG00000266490.1 CTD-2349P21.9 5.4 1.07e-07 3.44e-05 0.2 0.24 Hip circumference adjusted for BMI; chr17:30714534 chr17:30792372~30792833:+ LUSC cis rs875971 0.522 rs34973832 ENSG00000237310.1 GS1-124K5.4 5.4 1.07e-07 3.44e-05 0.25 0.24 Aortic root size; chr7:65931217 chr7:66493706~66495474:+ LUSC cis rs801193 1 rs4717319 ENSG00000179406.6 LINC00174 -5.4 1.07e-07 3.45e-05 -0.25 -0.24 Aortic root size; chr7:66777606 chr7:66376044~66401338:- LUSC cis rs801193 0.904 rs4718403 ENSG00000179406.6 LINC00174 -5.4 1.07e-07 3.45e-05 -0.25 -0.24 Aortic root size; chr7:66777742 chr7:66376044~66401338:- LUSC cis rs801193 1 rs3778909 ENSG00000179406.6 LINC00174 -5.4 1.07e-07 3.45e-05 -0.25 -0.24 Aortic root size; chr7:66790659 chr7:66376044~66401338:- LUSC cis rs12554020 0.582 rs76849659 ENSG00000227603.1 RP11-165J3.6 5.4 1.07e-07 3.45e-05 0.44 0.24 Schizophrenia; chr9:93685420 chr9:93435332~93437121:- LUSC cis rs8028182 0.525 rs9920028 ENSG00000260269.4 CTD-2323K18.1 -5.4 1.07e-07 3.45e-05 -0.35 -0.24 Sudden cardiac arrest; chr15:75635376 chr15:75527150~75601205:- LUSC cis rs7428 0.52 rs7605890 ENSG00000273196.1 RP11-717A5.2 5.4 1.07e-07 3.45e-05 0.26 0.24 Ear protrusion; chr2:85332402 chr2:85387074~85387146:- LUSC cis rs853679 0.769 rs17720293 ENSG00000280107.1 AL022393.9 -5.4 1.07e-07 3.45e-05 -0.4 -0.24 Depression; chr6:28246920 chr6:28170845~28172521:+ LUSC cis rs4964805 0.626 rs11111771 ENSG00000257681.1 RP11-341G23.4 -5.4 1.08e-07 3.45e-05 -0.28 -0.24 Attention deficit hyperactivity disorder; chr12:103785493 chr12:103746315~103768858:- LUSC cis rs2742234 0.59 rs2293020 ENSG00000273008.1 RP11-351D16.3 5.4 1.08e-07 3.46e-05 0.28 0.24 Hirschsprung disease; chr10:43197439 chr10:43136824~43138334:- LUSC cis rs67311347 1 rs9835219 ENSG00000223797.4 ENTPD3-AS1 5.4 1.08e-07 3.46e-05 0.28 0.24 Renal cell carcinoma; chr3:40382602 chr3:40313802~40453329:- LUSC cis rs67311347 1 rs7642552 ENSG00000223797.4 ENTPD3-AS1 5.4 1.08e-07 3.46e-05 0.28 0.24 Renal cell carcinoma; chr3:40383325 chr3:40313802~40453329:- LUSC cis rs8072100 0.688 rs7221224 ENSG00000228782.6 CTD-2026D20.3 -5.4 1.08e-07 3.46e-05 -0.25 -0.24 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47341695 chr17:47450568~47492492:- LUSC cis rs9611519 0.894 rs9623320 ENSG00000235513.1 RP4-756G23.5 5.4 1.08e-07 3.46e-05 0.29 0.24 Neuroticism; chr22:41082478 chr22:41209122~41217627:- LUSC cis rs1008375 0.931 rs6449310 ENSG00000249502.1 AC006160.5 -5.4 1.08e-07 3.47e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17573907 chr4:17587467~17614571:- LUSC cis rs2243480 1 rs4548056 ENSG00000164669.11 INTS4P1 5.4 1.08e-07 3.47e-05 0.44 0.24 Diabetic kidney disease; chr7:65833886 chr7:65141225~65234216:+ LUSC cis rs11098499 0.866 rs10518329 ENSG00000250412.1 KLHL2P1 5.4 1.08e-07 3.47e-05 0.29 0.24 Corneal astigmatism; chr4:119480680 chr4:119334329~119378233:+ LUSC cis rs7520050 0.778 rs3014218 ENSG00000280836.1 AL355480.1 5.4 1.08e-07 3.47e-05 0.28 0.24 Reticulocyte count;Red blood cell count; chr1:45560656 chr1:45581219~45581321:- LUSC cis rs9487051 0.872 rs9487032 ENSG00000219700.1 PTCHD3P3 5.4 1.08e-07 3.47e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109284120 chr6:109288571~109290503:- LUSC cis rs875971 0.545 rs73142265 ENSG00000179406.6 LINC00174 -5.4 1.08e-07 3.47e-05 -0.29 -0.24 Aortic root size; chr7:66234510 chr7:66376044~66401338:- LUSC cis rs1729951 0.546 rs835632 ENSG00000261758.1 RP11-102M11.2 5.4 1.08e-07 3.48e-05 0.23 0.24 Neuroticism; chr3:136957683 chr3:136752630~136755780:+ LUSC cis rs11098499 0.691 rs12510133 ENSG00000249244.1 RP11-548H18.2 5.4 1.08e-07 3.48e-05 0.3 0.24 Corneal astigmatism; chr4:119350189 chr4:119391831~119395335:- LUSC cis rs11098499 0.754 rs12506487 ENSG00000249244.1 RP11-548H18.2 5.4 1.08e-07 3.48e-05 0.3 0.24 Corneal astigmatism; chr4:119350206 chr4:119391831~119395335:- LUSC cis rs11098499 0.691 rs12502524 ENSG00000249244.1 RP11-548H18.2 5.4 1.08e-07 3.48e-05 0.3 0.24 Corneal astigmatism; chr4:119350259 chr4:119391831~119395335:- LUSC cis rs1056107 0.933 rs7037658 ENSG00000225513.1 RP11-165N19.2 -5.4 1.08e-07 3.48e-05 -0.26 -0.24 Colorectal cancer; chr9:112309244 chr9:112173522~112173971:- LUSC cis rs4803480 1 rs3745937 ENSG00000270164.1 LINC01480 -5.4 1.08e-07 3.48e-05 -0.21 -0.24 Schizophrenia; chr19:41564935 chr19:41535183~41536904:+ LUSC cis rs35740288 0.787 rs2291047 ENSG00000202081.1 RNU6-1280P 5.4 1.08e-07 3.48e-05 0.31 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85682574 chr15:85651522~85651628:- LUSC cis rs889398 0.835 rs62050037 ENSG00000226232.7 RP11-419C5.2 5.4 1.09e-07 3.48e-05 0.24 0.24 Body mass index; chr16:69750767 chr16:69976388~69996188:- LUSC cis rs673078 0.607 rs76809232 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118444979 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs61944660 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118445326 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs61944662 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118445520 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs4254101 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118445877 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs4622305 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118445912 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs2393418 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118445995 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs73207575 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118446711 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs61944663 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118446886 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs73207577 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118447012 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs73207579 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118447123 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs61944664 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118447145 chr12:118430147~118430699:+ LUSC cis rs673078 0.607 rs7969871 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118447331 chr12:118430147~118430699:+ LUSC cis rs673078 0.56 rs7970361 ENSG00000275409.1 RP11-131L12.4 -5.4 1.09e-07 3.48e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118447723 chr12:118430147~118430699:+ LUSC cis rs61160187 0.582 rs13359074 ENSG00000215032.2 GNL3LP1 5.4 1.09e-07 3.49e-05 0.31 0.24 Educational attainment (years of education);Educational attainment (college completion); chr5:60906758 chr5:60891935~60893577:- LUSC cis rs9611519 0.894 rs8136923 ENSG00000235513.1 RP4-756G23.5 5.39 1.09e-07 3.49e-05 0.29 0.24 Neuroticism; chr22:41074518 chr22:41209122~41217627:- LUSC cis rs944990 0.576 rs6479484 ENSG00000227603.1 RP11-165J3.6 5.39 1.09e-07 3.49e-05 0.23 0.24 Body mass index; chr9:93454288 chr9:93435332~93437121:- LUSC cis rs1707322 0.686 rs3014251 ENSG00000234329.1 RP11-767N6.2 -5.39 1.09e-07 3.49e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45611756 chr1:45651039~45651826:- LUSC cis rs1707322 0.686 rs3014235 ENSG00000234329.1 RP11-767N6.2 -5.39 1.09e-07 3.49e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625840 chr1:45651039~45651826:- LUSC cis rs1707322 0.717 rs1135850 ENSG00000234329.1 RP11-767N6.2 5.39 1.09e-07 3.49e-05 0.27 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628020 chr1:45651039~45651826:- LUSC cis rs11098499 0.738 rs34965784 ENSG00000248280.1 RP11-33B1.2 5.39 1.09e-07 3.5e-05 0.29 0.24 Corneal astigmatism; chr4:119440431 chr4:119440561~119450157:- LUSC cis rs7119038 0.509 rs10790261 ENSG00000255422.1 AP002954.4 -5.39 1.09e-07 3.5e-05 -0.33 -0.24 Sjögren's syndrome; chr11:118709038 chr11:118704607~118750263:+ LUSC cis rs875971 0.502 rs2946580 ENSG00000237310.1 GS1-124K5.4 -5.39 1.09e-07 3.5e-05 -0.28 -0.24 Aortic root size; chr7:66066855 chr7:66493706~66495474:+ LUSC cis rs1322639 0.575 rs9294966 ENSG00000223485.1 RP11-417E7.1 -5.39 1.09e-07 3.5e-05 -0.33 -0.24 Pulse pressure; chr6:169165223 chr6:169158092~169162924:- LUSC cis rs13113518 1 rs9312661 ENSG00000272969.1 RP11-528I4.2 5.39 1.09e-07 3.5e-05 0.27 0.24 Height; chr4:55476159 chr4:55547112~55547889:+ LUSC cis rs1707322 0.717 rs3014246 ENSG00000234329.1 RP11-767N6.2 -5.39 1.09e-07 3.51e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620405 chr1:45651039~45651826:- LUSC cis rs783540 0.967 rs1145173 ENSG00000255769.6 GOLGA2P10 5.39 1.09e-07 3.51e-05 0.3 0.24 Schizophrenia; chr15:82554675 chr15:82472993~82513950:- LUSC cis rs783540 0.967 rs1145172 ENSG00000255769.6 GOLGA2P10 5.39 1.09e-07 3.51e-05 0.3 0.24 Schizophrenia; chr15:82554866 chr15:82472993~82513950:- LUSC cis rs2337406 0.866 rs7153964 ENSG00000280411.1 IGHV1-69-2 -5.39 1.09e-07 3.51e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106790480 chr14:106762092~106762588:- LUSC cis rs9907295 1 rs11653051 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35909166 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs11653016 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35909756 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9889977 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35910691 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9894799 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35911085 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9903590 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35911286 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9897665 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35911595 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9912049 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35912530 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9911016 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35913349 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9912894 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35913452 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9303693 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35913595 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9914468 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35913727 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9893004 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35913855 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9899215 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35914215 chr17:35893707~35911023:- LUSC cis rs9907295 1 rs9907145 ENSG00000270977.1 AC015849.16 -5.39 1.09e-07 3.51e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35915237 chr17:35893707~35911023:- LUSC cis rs9402682 0.591 rs2026310 ENSG00000232876.1 CTA-212D2.2 -5.39 1.1e-07 3.51e-05 -0.32 -0.24 Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr6:135144413 chr6:135055033~135060550:+ LUSC cis rs9402682 0.591 rs9376096 ENSG00000232876.1 CTA-212D2.2 -5.39 1.1e-07 3.51e-05 -0.32 -0.24 Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr6:135148614 chr6:135055033~135060550:+ LUSC cis rs17270561 0.609 rs9358879 ENSG00000272462.2 U91328.19 -5.39 1.1e-07 3.51e-05 -0.28 -0.24 Iron status biomarkers; chr6:25742690 chr6:25992662~26001775:+ LUSC cis rs17270561 0.636 rs9358880 ENSG00000272462.2 U91328.19 -5.39 1.1e-07 3.51e-05 -0.28 -0.24 Iron status biomarkers; chr6:25742933 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs4145216 ENSG00000272462.2 U91328.19 -5.39 1.1e-07 3.51e-05 -0.28 -0.24 Iron status biomarkers; chr6:25743331 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs4145217 ENSG00000272462.2 U91328.19 -5.39 1.1e-07 3.51e-05 -0.28 -0.24 Iron status biomarkers; chr6:25743769 chr6:25992662~26001775:+ LUSC cis rs17270561 0.609 rs9393665 ENSG00000272462.2 U91328.19 -5.39 1.1e-07 3.51e-05 -0.28 -0.24 Iron status biomarkers; chr6:25744056 chr6:25992662~26001775:+ LUSC cis rs9545047 0.604 rs314695 ENSG00000227676.3 LINC01068 -5.39 1.1e-07 3.51e-05 -0.29 -0.24 Schizophrenia; chr13:79432206 chr13:79566727~79571436:+ LUSC cis rs11098499 0.909 rs6842762 ENSG00000248280.1 RP11-33B1.2 5.39 1.1e-07 3.51e-05 0.29 0.24 Corneal astigmatism; chr4:119477081 chr4:119440561~119450157:- LUSC cis rs801193 1 rs10234018 ENSG00000179406.6 LINC00174 5.39 1.1e-07 3.52e-05 0.25 0.24 Aortic root size; chr7:66681297 chr7:66376044~66401338:- LUSC cis rs6558530 0.73 rs10100341 ENSG00000253982.1 CTD-2336O2.1 5.39 1.1e-07 3.52e-05 0.3 0.24 Systolic blood pressure; chr8:1775583 chr8:1761990~1764502:- LUSC cis rs11098499 0.754 rs10212714 ENSG00000250412.1 KLHL2P1 5.39 1.1e-07 3.52e-05 0.29 0.24 Corneal astigmatism; chr4:119333147 chr4:119334329~119378233:+ LUSC cis rs73173548 0.502 rs10505855 ENSG00000247828.6 TMEM161B-AS1 5.39 1.1e-07 3.52e-05 0.29 0.24 Macular telangiectasia type 2; chr5:88440962 chr5:88268895~88436685:+ LUSC cis rs73173548 0.502 rs4129235 ENSG00000247828.6 TMEM161B-AS1 5.39 1.1e-07 3.52e-05 0.29 0.24 Macular telangiectasia type 2; chr5:88441465 chr5:88268895~88436685:+ LUSC cis rs712039 0.687 rs11656455 ENSG00000276054.1 RP11-378E13.3 5.39 1.1e-07 3.52e-05 0.31 0.24 Tuberculosis; chr17:37411798 chr17:37386886~37387926:+ LUSC cis rs712039 0.652 rs11656503 ENSG00000276054.1 RP11-378E13.3 5.39 1.1e-07 3.52e-05 0.31 0.24 Tuberculosis; chr17:37411934 chr17:37386886~37387926:+ LUSC cis rs7119038 0.629 rs73001429 ENSG00000255422.1 AP002954.4 5.39 1.1e-07 3.53e-05 0.31 0.24 Sjögren's syndrome; chr11:118732456 chr11:118704607~118750263:+ LUSC cis rs42490 0.966 rs6992985 ENSG00000251136.7 RP11-37B2.1 -5.39 1.1e-07 3.53e-05 -0.21 -0.24 Leprosy; chr8:89746330 chr8:89609409~89757727:- LUSC cis rs4664293 0.546 rs12469866 ENSG00000226266.5 AC009961.3 5.39 1.1e-07 3.53e-05 0.27 0.24 Monocyte percentage of white cells; chr2:159766119 chr2:159670708~159712435:- LUSC cis rs10129255 0.646 rs55995061 ENSG00000280411.1 IGHV1-69-2 -5.39 1.1e-07 3.53e-05 -0.22 -0.24 Kawasaki disease; chr14:106799309 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs76871148 ENSG00000280411.1 IGHV1-69-2 -5.39 1.1e-07 3.53e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106799722 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs61521632 ENSG00000280411.1 IGHV1-69-2 -5.39 1.1e-07 3.53e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106801091 chr14:106762092~106762588:- LUSC cis rs11089937 1 rs11089937 ENSG00000211638.2 IGLV8-61 -5.39 1.1e-07 3.53e-05 -0.23 -0.24 Periodontitis (PAL4Q3); chr22:22152176 chr22:22098700~22099212:+ LUSC cis rs2337406 1 rs11850709 ENSG00000211974.3 IGHV2-70 -5.39 1.1e-07 3.53e-05 -0.35 -0.24 Alzheimer's disease (late onset); chr14:106670844 chr14:106723574~106724093:- LUSC cis rs1707322 0.656 rs9429172 ENSG00000234329.1 RP11-767N6.2 -5.39 1.1e-07 3.53e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45626804 chr1:45651039~45651826:- LUSC cis rs1008375 1 rs3933453 ENSG00000249502.1 AC006160.5 -5.39 1.11e-07 3.54e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17634696 chr4:17587467~17614571:- LUSC cis rs1008375 1 rs10939746 ENSG00000249502.1 AC006160.5 5.39 1.11e-07 3.54e-05 0.24 0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17683328 chr4:17587467~17614571:- LUSC cis rs11098499 0.954 rs67265404 ENSG00000248280.1 RP11-33B1.2 5.39 1.11e-07 3.54e-05 0.29 0.24 Corneal astigmatism; chr4:119438115 chr4:119440561~119450157:- LUSC cis rs11098499 0.909 rs71614422 ENSG00000248280.1 RP11-33B1.2 5.39 1.11e-07 3.54e-05 0.29 0.24 Corneal astigmatism; chr4:119438185 chr4:119440561~119450157:- LUSC cis rs763121 0.819 rs5757161 ENSG00000273076.1 RP3-508I15.22 5.39 1.11e-07 3.54e-05 0.23 0.24 Menopause (age at onset); chr22:38594657 chr22:38743495~38743910:+ LUSC cis rs990171 0.538 rs11123934 ENSG00000234389.1 AC007278.3 5.39 1.11e-07 3.54e-05 0.25 0.24 Lymphocyte counts; chr2:102499109 chr2:102438713~102440475:+ LUSC cis rs7615952 0.932 rs13314869 ENSG00000171084.14 FAM86JP 5.39 1.11e-07 3.55e-05 0.32 0.24 Blood pressure (smoking interaction); chr3:125925826 chr3:125916620~125930024:+ LUSC cis rs2282300 1 rs12796693 ENSG00000254532.1 RP11-624D11.2 5.39 1.11e-07 3.56e-05 0.34 0.24 Morning vs. evening chronotype; chr11:30408036 chr11:30044058~30084343:- LUSC cis rs2136613 0.751 rs10822060 ENSG00000238280.1 RP11-436D10.3 -5.39 1.11e-07 3.56e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62834625 chr10:62793562~62805887:- LUSC cis rs673078 0.66 rs11068917 ENSG00000275759.1 RP11-131L12.3 -5.39 1.11e-07 3.56e-05 -0.33 -0.24 Glucose homeostasis traits; chr12:118353315 chr12:118428281~118428870:+ LUSC cis rs8177876 0.749 rs12927239 ENSG00000245059.2 RP11-303E16.7 5.39 1.11e-07 3.56e-05 0.5 0.24 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81053883 chr16:81077319~81078861:+ LUSC cis rs7712401 0.601 rs246306 ENSG00000263432.2 RN7SL689P 5.39 1.11e-07 3.56e-05 0.31 0.24 Mean platelet volume; chr5:122943523 chr5:123022487~123022783:- LUSC cis rs16863064 1 rs16863064 ENSG00000279891.1 FLJ42393 5.39 1.11e-07 3.56e-05 0.37 0.24 Schizophrenia; chr3:188169789 chr3:188178543~188180812:+ LUSC cis rs61270009 0.955 rs2410766 ENSG00000247828.6 TMEM161B-AS1 5.39 1.11e-07 3.56e-05 0.28 0.24 Depressive symptoms; chr5:88405666 chr5:88268895~88436685:+ LUSC cis rs7712401 0.601 rs448505 ENSG00000263432.2 RN7SL689P -5.39 1.11e-07 3.56e-05 -0.31 -0.24 Mean platelet volume; chr5:123000995 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs2164773 ENSG00000263432.2 RN7SL689P -5.39 1.11e-07 3.56e-05 -0.31 -0.24 Mean platelet volume; chr5:123003222 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs418562 ENSG00000263432.2 RN7SL689P -5.39 1.11e-07 3.56e-05 -0.31 -0.24 Mean platelet volume; chr5:123004567 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs35858098 ENSG00000263432.2 RN7SL689P -5.39 1.11e-07 3.57e-05 -0.31 -0.24 Mean platelet volume; chr5:122998670 chr5:123022487~123022783:- LUSC cis rs11096990 0.634 rs17754 ENSG00000249207.1 RP11-360F5.1 -5.39 1.11e-07 3.57e-05 -0.26 -0.24 Cognitive function; chr4:39287688 chr4:39112677~39126818:- LUSC cis rs8133932 0.701 rs2330327 ENSG00000280604.1 PCBP3-OT1 5.39 1.12e-07 3.57e-05 0.31 0.24 Schizophrenia; chr21:45885263 chr21:45914296~45919483:+ LUSC cis rs748404 0.533 rs2139651 ENSG00000249839.1 AC011330.5 5.39 1.12e-07 3.57e-05 0.3 0.24 Lung cancer; chr15:43126560 chr15:43663654~43684339:- LUSC cis rs875971 0.545 rs73136346 ENSG00000179406.6 LINC00174 5.39 1.12e-07 3.57e-05 0.29 0.24 Aortic root size; chr7:66101095 chr7:66376044~66401338:- LUSC cis rs4834770 1 rs10034579 ENSG00000249244.1 RP11-548H18.2 5.39 1.12e-07 3.57e-05 0.29 0.24 Blood protein levels; chr4:119322874 chr4:119391831~119395335:- LUSC cis rs62103177 0.535 rs34299914 ENSG00000261126.6 RP11-795F19.1 5.39 1.12e-07 3.57e-05 0.32 0.24 Opioid sensitivity; chr18:80191353 chr18:80046900~80095482:+ LUSC cis rs3738443 0.951 rs61840056 ENSG00000259865.1 RP11-488L18.10 5.39 1.12e-07 3.58e-05 0.26 0.24 Alcohol dependence; chr1:247205930 chr1:247187281~247188526:- LUSC cis rs2303759 0.709 rs10422677 ENSG00000268686.1 AC010524.2 -5.39 1.12e-07 3.58e-05 -0.35 -0.24 Multiple sclerosis; chr19:49321033 chr19:49368705~49388081:- LUSC cis rs2303759 0.709 rs10411679 ENSG00000268686.1 AC010524.2 -5.39 1.12e-07 3.58e-05 -0.35 -0.24 Multiple sclerosis; chr19:49323223 chr19:49368705~49388081:- LUSC cis rs2303759 0.709 rs7256363 ENSG00000268686.1 AC010524.2 -5.39 1.12e-07 3.58e-05 -0.35 -0.24 Multiple sclerosis; chr19:49324547 chr19:49368705~49388081:- LUSC cis rs875971 0.502 rs1796227 ENSG00000179406.6 LINC00174 5.39 1.12e-07 3.58e-05 0.29 0.24 Aortic root size; chr7:66622032 chr7:66376044~66401338:- LUSC cis rs853679 1 rs10456362 ENSG00000219392.1 RP1-265C24.5 5.39 1.12e-07 3.58e-05 0.37 0.24 Depression; chr6:28254038 chr6:28115628~28116551:+ LUSC cis rs7777677 1 rs7777677 ENSG00000211750.2 TRBV24-1 -5.39 1.12e-07 3.59e-05 -0.24 -0.24 Alcoholic chronic pancreatitis; chr7:142663616 chr7:142656701~142657213:+ LUSC cis rs7182621 0.512 rs71403471 ENSG00000259363.4 CTD-2054N24.2 -5.39 1.12e-07 3.59e-05 -0.32 -0.24 Colonoscopy-negative controls vs population controls; chr15:99870656 chr15:99807023~99877148:+ LUSC cis rs1056107 0.541 rs2150258 ENSG00000225513.1 RP11-165N19.2 -5.39 1.12e-07 3.59e-05 -0.27 -0.24 Colorectal cancer; chr9:112412328 chr9:112173522~112173971:- LUSC cis rs11089937 0.963 rs5757078 ENSG00000211638.2 IGLV8-61 -5.39 1.12e-07 3.59e-05 -0.23 -0.24 Periodontitis (PAL4Q3); chr22:22145526 chr22:22098700~22099212:+ LUSC cis rs4308124 1 rs4308124 ENSG00000227992.1 AC108463.2 -5.39 1.12e-07 3.59e-05 -0.29 -0.24 Vitiligo; chr2:111252909 chr2:111203964~111206215:- LUSC cis rs2903698 0.651 rs28871288 ENSG00000250735.4 RP11-567N4.3 5.39 1.12e-07 3.59e-05 0.28 0.24 Prion diseases; chr4:75531900 chr4:75401195~75423023:+ LUSC cis rs6502050 0.842 rs7211808 ENSG00000266654.1 RP11-1376P16.1 5.39 1.12e-07 3.59e-05 0.24 0.24 Life satisfaction; chr17:82113368 chr17:82160056~82160452:+ LUSC cis rs13434995 0.513 rs1048004 ENSG00000249700.7 SRD5A3-AS1 -5.39 1.12e-07 3.6e-05 -0.31 -0.24 Adiponectin levels; chr4:55434042 chr4:55363971~55395847:- LUSC cis rs875971 0.545 rs6979636 ENSG00000224316.1 RP11-479O9.2 5.39 1.12e-07 3.6e-05 0.26 0.24 Aortic root size; chr7:66276638 chr7:65773620~65802067:+ LUSC cis rs2136613 0.533 rs10761663 ENSG00000238280.1 RP11-436D10.3 -5.39 1.13e-07 3.6e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62845239 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs1475082 ENSG00000238280.1 RP11-436D10.3 -5.39 1.13e-07 3.6e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62845621 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs1475083 ENSG00000238280.1 RP11-436D10.3 -5.39 1.13e-07 3.6e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62845638 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs1475084 ENSG00000238280.1 RP11-436D10.3 -5.39 1.13e-07 3.6e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62845974 chr10:62793562~62805887:- LUSC cis rs2136613 0.533 rs7088066 ENSG00000238280.1 RP11-436D10.3 -5.39 1.13e-07 3.6e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62846097 chr10:62793562~62805887:- LUSC cis rs1555322 0.505 rs591590 ENSG00000126005.14 MMP24-AS1 5.39 1.13e-07 3.6e-05 0.35 0.24 Attention deficit hyperactivity disorder; chr20:35278225 chr20:35216462~35278131:- LUSC cis rs66887589 0.777 rs2017058 ENSG00000249244.1 RP11-548H18.2 5.39 1.13e-07 3.61e-05 0.28 0.24 Diastolic blood pressure; chr4:119336584 chr4:119391831~119395335:- LUSC cis rs66887589 0.777 rs1814815 ENSG00000249244.1 RP11-548H18.2 5.39 1.13e-07 3.61e-05 0.28 0.24 Diastolic blood pressure; chr4:119336936 chr4:119391831~119395335:- LUSC cis rs1008375 0.933 rs6847966 ENSG00000249502.1 AC006160.5 -5.39 1.13e-07 3.61e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17632632 chr4:17587467~17614571:- LUSC cis rs1008375 1 rs7659718 ENSG00000249502.1 AC006160.5 -5.39 1.13e-07 3.61e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17636397 chr4:17587467~17614571:- LUSC cis rs875971 0.522 rs4502988 ENSG00000222364.1 RNU6-96P -5.39 1.13e-07 3.61e-05 -0.28 -0.24 Aortic root size; chr7:65832759 chr7:66395191~66395286:+ LUSC cis rs2732480 0.557 rs2634682 ENSG00000240399.1 RP1-228P16.1 5.39 1.13e-07 3.61e-05 0.26 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48339160 chr12:48054813~48055591:- LUSC cis rs13113518 1 rs4864994 ENSG00000223305.1 RN7SKP30 5.39 1.13e-07 3.61e-05 0.29 0.24 Height; chr4:55451955 chr4:55540502~55540835:- LUSC cis rs41294858 1 rs56076748 ENSG00000232876.1 CTA-212D2.2 -5.39 1.13e-07 3.61e-05 -0.46 -0.24 Red blood cell count; chr6:135093071 chr6:135055033~135060550:+ LUSC cis rs9341808 0.714 rs4256394 ENSG00000272129.1 RP11-250B2.6 5.39 1.13e-07 3.62e-05 0.29 0.24 Sitting height ratio; chr6:80172425 chr6:80355424~80356859:+ LUSC cis rs13434995 0.513 rs10462033 ENSG00000249700.7 SRD5A3-AS1 -5.39 1.13e-07 3.62e-05 -0.3 -0.24 Adiponectin levels; chr4:55511552 chr4:55363971~55395847:- LUSC cis rs13434995 0.513 rs1915905 ENSG00000249700.7 SRD5A3-AS1 -5.39 1.13e-07 3.62e-05 -0.3 -0.24 Adiponectin levels; chr4:55512381 chr4:55363971~55395847:- LUSC cis rs442309 1 rs442309 ENSG00000238280.1 RP11-436D10.3 -5.39 1.13e-07 3.62e-05 -0.29 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62730735 chr10:62793562~62805887:- LUSC cis rs442309 1 rs224048 ENSG00000238280.1 RP11-436D10.3 -5.39 1.13e-07 3.62e-05 -0.29 -0.24 Vogt-Koyanagi-Harada syndrome; chr10:62731789 chr10:62793562~62805887:- LUSC cis rs1862618 0.853 rs9283717 ENSG00000271828.1 CTD-2310F14.1 5.39 1.14e-07 3.62e-05 0.37 0.24 Initial pursuit acceleration; chr5:56782832 chr5:56927874~56929573:+ LUSC cis rs11098499 0.954 rs10006706 ENSG00000248280.1 RP11-33B1.2 5.39 1.14e-07 3.62e-05 0.29 0.24 Corneal astigmatism; chr4:119487997 chr4:119440561~119450157:- LUSC cis rs7181230 0.813 rs4924417 ENSG00000275636.1 RP11-521C20.5 5.39 1.14e-07 3.62e-05 0.3 0.24 Dehydroepiandrosterone sulphate levels; chr15:40074738 chr15:40078892~40079347:+ LUSC cis rs75422866 0.764 rs67201012 ENSG00000274902.1 RP1-197B17.4 5.39 1.14e-07 3.63e-05 0.68 0.24 Pneumonia; chr12:47715881 chr12:47731908~47732351:+ LUSC cis rs1707322 0.721 rs4660883 ENSG00000234329.1 RP11-767N6.2 5.39 1.14e-07 3.63e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45770426 chr1:45651039~45651826:- LUSC cis rs7712401 0.601 rs418229 ENSG00000263432.2 RN7SL689P -5.39 1.14e-07 3.63e-05 -0.31 -0.24 Mean platelet volume; chr5:123005969 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs374403 ENSG00000263432.2 RN7SL689P -5.39 1.14e-07 3.63e-05 -0.31 -0.24 Mean platelet volume; chr5:123006018 chr5:123022487~123022783:- LUSC cis rs7712401 0.601 rs446782 ENSG00000263432.2 RN7SL689P -5.39 1.14e-07 3.63e-05 -0.31 -0.24 Mean platelet volume; chr5:123006173 chr5:123022487~123022783:- LUSC cis rs7182621 0.639 rs34701806 ENSG00000259363.4 CTD-2054N24.2 -5.39 1.14e-07 3.64e-05 -0.31 -0.24 Colonoscopy-negative controls vs population controls; chr15:99872953 chr15:99807023~99877148:+ LUSC cis rs1707322 0.686 rs2230659 ENSG00000234329.1 RP11-767N6.2 -5.39 1.14e-07 3.64e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613212 chr1:45651039~45651826:- LUSC cis rs17507216 0.628 rs4627310 ENSG00000276710.3 CSPG4P8 -5.39 1.14e-07 3.64e-05 -0.32 -0.24 Excessive daytime sleepiness; chr15:82708330 chr15:82459472~82477258:+ LUSC cis rs10083777 0.551 rs79378252 ENSG00000261838.4 RP11-303E16.6 5.39 1.14e-07 3.64e-05 0.58 0.24 Metabolite levels (small molecules and protein measures); chr16:81014554 chr16:81069854~81076598:+ LUSC cis rs1729951 0.575 rs1654926 ENSG00000261758.1 RP11-102M11.2 5.39 1.14e-07 3.64e-05 0.22 0.24 Neuroticism; chr3:136991082 chr3:136752630~136755780:+ LUSC cis rs13113518 1 rs4864993 ENSG00000272969.1 RP11-528I4.2 5.39 1.14e-07 3.64e-05 0.28 0.24 Height; chr4:55450662 chr4:55547112~55547889:+ LUSC cis rs889312 0.532 rs16886165 ENSG00000271828.1 CTD-2310F14.1 5.39 1.14e-07 3.64e-05 0.4 0.24 Breast cancer (early onset);Breast cancer; chr5:56727256 chr5:56927874~56929573:+ LUSC cis rs17193922 0.876 rs17194040 ENSG00000279344.1 RP11-44F14.7 5.39 1.14e-07 3.65e-05 0.23 0.24 Hip circumference adjusted for BMI; chr16:53516986 chr16:53478957~53481550:- LUSC cis rs6951245 0.58 rs10257426 ENSG00000224079.1 AC091729.7 -5.39 1.15e-07 3.65e-05 -0.36 -0.24 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1174058 chr7:1074450~1078036:+ LUSC cis rs17270561 0.609 rs9358885 ENSG00000272462.2 U91328.19 -5.39 1.15e-07 3.65e-05 -0.29 -0.24 Iron status biomarkers; chr6:25757796 chr6:25992662~26001775:+ LUSC cis rs7083 1 rs655023 ENSG00000254851.1 RP11-109L13.1 5.39 1.15e-07 3.65e-05 0.3 0.24 Blood protein levels; chr11:117256904 chr11:117135528~117138582:+ LUSC cis rs9611519 0.964 rs5995992 ENSG00000235513.1 RP4-756G23.5 5.39 1.15e-07 3.65e-05 0.29 0.24 Neuroticism; chr22:41091214 chr22:41209122~41217627:- LUSC cis rs2404602 0.583 rs35707798 ENSG00000259422.1 RP11-593F23.1 5.39 1.15e-07 3.66e-05 0.27 0.24 Blood metabolite levels; chr15:76272685 chr15:76174891~76181486:- LUSC cis rs2236295 0.503 rs10822064 ENSG00000238280.1 RP11-436D10.3 5.39 1.15e-07 3.66e-05 0.3 0.24 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks); chr10:62849964 chr10:62793562~62805887:- LUSC cis rs2732480 0.557 rs923397 ENSG00000240399.1 RP1-228P16.1 5.38 1.15e-07 3.66e-05 0.26 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48326609 chr12:48054813~48055591:- LUSC cis rs2732480 0.557 rs2409004 ENSG00000240399.1 RP1-228P16.1 5.38 1.15e-07 3.66e-05 0.26 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48327668 chr12:48054813~48055591:- LUSC cis rs2732480 0.577 rs2450994 ENSG00000240399.1 RP1-228P16.1 5.38 1.15e-07 3.66e-05 0.26 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48328049 chr12:48054813~48055591:- LUSC cis rs6772849 1 rs66910450 ENSG00000242551.2 POU5F1P6 -5.38 1.15e-07 3.66e-05 -0.28 -0.24 Monocyte percentage of white cells;Monocyte count; chr3:128585050 chr3:128674735~128677005:- LUSC cis rs62103177 0.525 rs62101233 ENSG00000261126.6 RP11-795F19.1 5.38 1.15e-07 3.66e-05 0.31 0.24 Opioid sensitivity; chr18:79964288 chr18:80046900~80095482:+ LUSC cis rs13113518 0.812 rs11932712 ENSG00000273257.1 RP11-177J6.1 5.38 1.15e-07 3.67e-05 0.31 0.24 Height; chr4:55436423 chr4:55387949~55388271:+ LUSC cis rs13113518 0.812 rs12501746 ENSG00000273257.1 RP11-177J6.1 5.38 1.15e-07 3.67e-05 0.31 0.24 Height; chr4:55437438 chr4:55387949~55388271:+ LUSC cis rs5751168 0.834 rs361676 ENSG00000211654.2 IGLV5-37 5.38 1.15e-07 3.67e-05 0.36 0.24 Prostate cancer (SNP x SNP interaction); chr22:22507724 chr22:22427540~22428035:+ LUSC cis rs5751168 0.834 rs362184 ENSG00000211654.2 IGLV5-37 5.38 1.15e-07 3.67e-05 0.36 0.24 Prostate cancer (SNP x SNP interaction); chr22:22507744 chr22:22427540~22428035:+ LUSC cis rs748404 0.533 rs7165861 ENSG00000249839.1 AC011330.5 5.38 1.15e-07 3.67e-05 0.3 0.24 Lung cancer; chr15:43131129 chr15:43663654~43684339:- LUSC cis rs2933343 0.951 rs796862 ENSG00000231305.3 RP11-723O4.2 5.38 1.15e-07 3.67e-05 0.25 0.24 IgG glycosylation; chr3:128874197 chr3:128861313~128871540:- LUSC cis rs875971 0.571 rs78668714 ENSG00000224316.1 RP11-479O9.2 5.38 1.15e-07 3.67e-05 0.26 0.24 Aortic root size; chr7:66474464 chr7:65773620~65802067:+ LUSC cis rs875971 0.545 rs7810213 ENSG00000224316.1 RP11-479O9.2 5.38 1.15e-07 3.67e-05 0.26 0.24 Aortic root size; chr7:66481592 chr7:65773620~65802067:+ LUSC cis rs9611519 0.754 rs4820435 ENSG00000235513.1 RP4-756G23.5 5.38 1.15e-07 3.67e-05 0.28 0.24 Neuroticism; chr22:41256842 chr22:41209122~41217627:- LUSC cis rs35740288 0.77 rs36044792 ENSG00000202081.1 RNU6-1280P 5.38 1.15e-07 3.68e-05 0.29 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85603320 chr15:85651522~85651628:- LUSC cis rs35740288 0.77 rs11635190 ENSG00000202081.1 RNU6-1280P 5.38 1.15e-07 3.68e-05 0.29 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85605300 chr15:85651522~85651628:- LUSC cis rs35740288 0.77 rs11631449 ENSG00000202081.1 RNU6-1280P 5.38 1.15e-07 3.68e-05 0.29 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85605422 chr15:85651522~85651628:- LUSC cis rs4964805 0.672 rs4964823 ENSG00000257681.1 RP11-341G23.4 5.38 1.15e-07 3.68e-05 0.28 0.24 Attention deficit hyperactivity disorder; chr12:103787642 chr12:103746315~103768858:- LUSC cis rs2404602 0.569 rs283793 ENSG00000259422.1 RP11-593F23.1 5.38 1.15e-07 3.68e-05 0.29 0.24 Blood metabolite levels; chr15:76482411 chr15:76174891~76181486:- LUSC cis rs750134 0.901 rs118023614 ENSG00000257221.1 RP11-689B22.2 -5.38 1.15e-07 3.68e-05 -0.38 -0.24 Low high density lipoprotein cholesterol levels; chr12:108795286 chr12:108628687~108641318:+ LUSC cis rs7181230 0.885 rs35781999 ENSG00000275636.1 RP11-521C20.5 5.38 1.16e-07 3.68e-05 0.3 0.24 Dehydroepiandrosterone sulphate levels; chr15:40063205 chr15:40078892~40079347:+ LUSC cis rs7181230 0.885 rs28444847 ENSG00000275636.1 RP11-521C20.5 5.38 1.16e-07 3.68e-05 0.3 0.24 Dehydroepiandrosterone sulphate levels; chr15:40064403 chr15:40078892~40079347:+ LUSC cis rs1729951 0.575 rs747842 ENSG00000261758.1 RP11-102M11.2 5.38 1.16e-07 3.68e-05 0.22 0.24 Neuroticism; chr3:136984279 chr3:136752630~136755780:+ LUSC cis rs1729951 0.575 rs835642 ENSG00000261758.1 RP11-102M11.2 5.38 1.16e-07 3.68e-05 0.22 0.24 Neuroticism; chr3:136984523 chr3:136752630~136755780:+ LUSC cis rs1707322 0.686 rs2275085 ENSG00000234329.1 RP11-767N6.2 -5.38 1.16e-07 3.69e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620180 chr1:45651039~45651826:- LUSC cis rs1008375 1 rs7673500 ENSG00000249502.1 AC006160.5 -5.38 1.16e-07 3.69e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17619760 chr4:17587467~17614571:- LUSC cis rs1008375 0.9 rs6851783 ENSG00000249502.1 AC006160.5 -5.38 1.16e-07 3.69e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17576846 chr4:17587467~17614571:- LUSC cis rs1008375 0.9 rs7658447 ENSG00000249502.1 AC006160.5 -5.38 1.16e-07 3.69e-05 -0.24 -0.24 Parasitemia in Tripanosoma cruzi seropositivity; chr4:17577792 chr4:17587467~17614571:- LUSC cis rs35740288 1 rs35740288 ENSG00000202081.1 RNU6-1280P 5.38 1.16e-07 3.69e-05 0.3 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85753854 chr15:85651522~85651628:- LUSC cis rs35740288 1 rs17577449 ENSG00000202081.1 RNU6-1280P 5.38 1.16e-07 3.69e-05 0.3 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85753954 chr15:85651522~85651628:- LUSC cis rs11098499 0.863 rs6835635 ENSG00000248280.1 RP11-33B1.2 5.38 1.16e-07 3.7e-05 0.28 0.24 Corneal astigmatism; chr4:119537712 chr4:119440561~119450157:- LUSC cis rs8072100 0.837 rs8070463 ENSG00000228782.6 CTD-2026D20.3 5.38 1.16e-07 3.7e-05 0.22 0.24 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47691470 chr17:47450568~47492492:- LUSC cis rs4713118 0.826 rs2893929 ENSG00000280107.1 AL022393.9 -5.38 1.16e-07 3.7e-05 -0.3 -0.24 Parkinson's disease; chr6:27770953 chr6:28170845~28172521:+ LUSC cis rs4713118 0.666 rs4140646 ENSG00000280107.1 AL022393.9 -5.38 1.16e-07 3.7e-05 -0.3 -0.24 Parkinson's disease; chr6:27771022 chr6:28170845~28172521:+ LUSC cis rs4713118 0.666 rs2893930 ENSG00000280107.1 AL022393.9 -5.38 1.16e-07 3.7e-05 -0.3 -0.24 Parkinson's disease; chr6:27771027 chr6:28170845~28172521:+ LUSC cis rs2732480 0.557 rs2732454 ENSG00000240399.1 RP1-228P16.1 5.38 1.16e-07 3.71e-05 0.26 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48325894 chr12:48054813~48055591:- LUSC cis rs6421571 0.564 rs11216972 ENSG00000255422.1 AP002954.4 5.38 1.17e-07 3.71e-05 0.32 0.24 Primary biliary cholangitis; chr11:118715117 chr11:118704607~118750263:+ LUSC cis rs875971 0.522 rs1917563 ENSG00000222364.1 RNU6-96P 5.38 1.17e-07 3.71e-05 0.28 0.24 Aortic root size; chr7:65950660 chr7:66395191~66395286:+ LUSC cis rs8133932 0.701 rs2839035 ENSG00000280604.1 PCBP3-OT1 5.38 1.17e-07 3.72e-05 0.31 0.24 Schizophrenia; chr21:45888367 chr21:45914296~45919483:+ LUSC cis rs7119038 0.629 rs11217000 ENSG00000255422.1 AP002954.4 5.38 1.17e-07 3.72e-05 0.32 0.24 Sjögren's syndrome; chr11:118734275 chr11:118704607~118750263:+ LUSC cis rs763121 1 rs86796 ENSG00000273076.1 RP3-508I15.22 -5.38 1.17e-07 3.73e-05 -0.24 -0.24 Menopause (age at onset); chr22:38485449 chr22:38743495~38743910:+ LUSC cis rs10788972 0.844 rs6588502 ENSG00000225183.1 RP4-758J24.4 -5.38 1.17e-07 3.73e-05 -0.28 -0.24 Parkinson disease and lewy body pathology; chr1:54097483 chr1:54089856~54090093:+ LUSC cis rs9545047 0.625 rs7338170 ENSG00000227676.3 LINC01068 -5.38 1.17e-07 3.73e-05 -0.29 -0.24 Schizophrenia; chr13:79286030 chr13:79566727~79571436:+ LUSC cis rs13113518 0.934 rs3805155 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55497842 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs7686261 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55500224 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs11729220 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55501629 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs11133390 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55501726 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs11133391 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55501788 chr4:55540502~55540835:- LUSC cis rs13113518 0.966 rs13133484 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55504176 chr4:55540502~55540835:- LUSC cis rs13113518 0.934 rs13127906 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55504201 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs6849433 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55506498 chr4:55540502~55540835:- LUSC cis rs13113518 0.966 rs12501327 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55507248 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs11133392 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55507729 chr4:55540502~55540835:- LUSC cis rs13113518 1 rs6838305 ENSG00000223305.1 RN7SKP30 5.38 1.17e-07 3.73e-05 0.29 0.24 Height; chr4:55508587 chr4:55540502~55540835:- LUSC cis rs2243480 1 rs12698509 ENSG00000226824.5 RP4-756H11.3 -5.38 1.17e-07 3.73e-05 -0.45 -0.24 Diabetic kidney disease; chr7:65953889 chr7:66654538~66669855:+ LUSC cis rs1021993 0.545 rs60534728 ENSG00000231648.1 RP11-372M18.2 -5.38 1.17e-07 3.73e-05 -0.37 -0.24 Gut microbiome composition (winter); chr1:209374826 chr1:209367662~209379690:+ LUSC cis rs1021993 0.545 rs17014396 ENSG00000231648.1 RP11-372M18.2 -5.38 1.17e-07 3.73e-05 -0.37 -0.24 Gut microbiome composition (winter); chr1:209375540 chr1:209367662~209379690:+ LUSC cis rs924712 0.816 rs6918402 ENSG00000224984.1 RP11-524H19.2 -5.38 1.17e-07 3.73e-05 -0.24 -0.24 Breast cancer; chr6:54868121 chr6:54840118~54840855:- LUSC cis rs875971 0.545 rs73136346 ENSG00000237310.1 GS1-124K5.4 -5.38 1.17e-07 3.73e-05 -0.28 -0.24 Aortic root size; chr7:66101095 chr7:66493706~66495474:+ LUSC cis rs2337406 0.636 rs74090069 ENSG00000280411.1 IGHV1-69-2 -5.38 1.18e-07 3.74e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106777532 chr14:106762092~106762588:- LUSC cis rs2337406 0.866 rs74090071 ENSG00000280411.1 IGHV1-69-2 -5.38 1.18e-07 3.74e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106777533 chr14:106762092~106762588:- LUSC cis rs17270561 0.541 rs12192932 ENSG00000272810.1 U91328.22 -5.38 1.18e-07 3.74e-05 -0.32 -0.24 Iron status biomarkers; chr6:25911274 chr6:26013241~26013757:+ LUSC cis rs673078 0.66 rs17619932 ENSG00000275759.1 RP11-131L12.3 -5.38 1.18e-07 3.74e-05 -0.33 -0.24 Glucose homeostasis traits; chr12:118352228 chr12:118428281~118428870:+ LUSC cis rs13113518 0.966 rs11133396 ENSG00000223305.1 RN7SKP30 5.38 1.18e-07 3.74e-05 0.29 0.24 Height; chr4:55524246 chr4:55540502~55540835:- LUSC cis rs2790457 0.518 rs2993984 ENSG00000254635.4 WAC-AS1 -5.38 1.18e-07 3.74e-05 -0.27 -0.24 Multiple myeloma; chr10:28509727 chr10:28522652~28532743:- LUSC cis rs17772222 1 rs12433464 ENSG00000258789.1 RP11-507K2.3 -5.38 1.18e-07 3.75e-05 -0.28 -0.24 Coronary artery calcification; chr14:88357671 chr14:88551597~88552493:+ LUSC cis rs2136613 0.751 rs10995334 ENSG00000238280.1 RP11-436D10.3 -5.38 1.18e-07 3.75e-05 -0.3 -0.24 Selective IgA deficiency; chr10:62858052 chr10:62793562~62805887:- LUSC cis rs240993 0.715 rs6920798 ENSG00000230177.1 RP5-1112D6.4 5.38 1.18e-07 3.75e-05 0.26 0.24 Inflammatory skin disease;Psoriasis; chr6:111526074 chr6:111277932~111278742:+ LUSC cis rs3738443 1 rs3738443 ENSG00000259865.1 RP11-488L18.10 -5.38 1.18e-07 3.76e-05 -0.27 -0.24 Alcohol dependence; chr1:247184887 chr1:247187281~247188526:- LUSC cis rs11673344 0.642 rs11083420 ENSG00000226686.6 LINC01535 5.38 1.18e-07 3.76e-05 0.31 0.24 Obesity-related traits; chr19:37317901 chr19:37251912~37265535:+ LUSC cis rs17373728 1 rs17373728 ENSG00000249395.2 CASC9 -5.38 1.18e-07 3.76e-05 -0.3 -0.24 Diabetic kidney disease; chr8:75313281 chr8:75223404~75324741:- LUSC cis rs957448 1 rs1055800 ENSG00000253704.1 RP11-267M23.4 -5.38 1.18e-07 3.76e-05 -0.28 -0.24 Nonsyndromic cleft lip with cleft palate; chr8:94510810 chr8:94553722~94569745:+ LUSC cis rs41294858 1 rs41294860 ENSG00000232876.1 CTA-212D2.2 -5.38 1.18e-07 3.76e-05 -0.46 -0.24 Red blood cell count; chr6:135092931 chr6:135055033~135060550:+ LUSC cis rs8040855 0.542 rs2342122 ENSG00000259774.1 RP11-182J1.13 -5.38 1.18e-07 3.77e-05 -0.28 -0.24 Bulimia nervosa; chr15:85185304 chr15:84422618~84425882:+ LUSC cis rs8040855 0.644 rs2342120 ENSG00000259774.1 RP11-182J1.13 -5.38 1.18e-07 3.77e-05 -0.28 -0.24 Bulimia nervosa; chr15:85185589 chr15:84422618~84425882:+ LUSC cis rs13113518 1 rs4864546 ENSG00000272969.1 RP11-528I4.2 5.38 1.19e-07 3.77e-05 0.27 0.24 Height; chr4:55537960 chr4:55547112~55547889:+ LUSC cis rs67311347 1 rs6793596 ENSG00000223797.4 ENTPD3-AS1 5.38 1.19e-07 3.77e-05 0.28 0.24 Renal cell carcinoma; chr3:40416304 chr3:40313802~40453329:- LUSC cis rs643506 0.845 rs2850245 ENSG00000230911.1 PPIHP1 -5.38 1.19e-07 3.77e-05 -0.3 -0.24 Breast cancer; chr11:111890014 chr11:112029858~112030367:- LUSC cis rs1707322 0.655 rs3014240 ENSG00000234329.1 RP11-767N6.2 -5.38 1.19e-07 3.77e-05 -0.27 -0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45623553 chr1:45651039~45651826:- LUSC cis rs875971 0.502 rs2465121 ENSG00000224316.1 RP11-479O9.2 -5.38 1.19e-07 3.77e-05 -0.26 -0.24 Aortic root size; chr7:66156017 chr7:65773620~65802067:+ LUSC cis rs61270009 0.913 rs396676 ENSG00000247828.6 TMEM161B-AS1 -5.38 1.19e-07 3.77e-05 -0.27 -0.24 Depressive symptoms; chr5:88220002 chr5:88268895~88436685:+ LUSC cis rs748404 0.511 rs12442190 ENSG00000249839.1 AC011330.5 5.38 1.19e-07 3.77e-05 0.3 0.24 Lung cancer; chr15:43153107 chr15:43663654~43684339:- LUSC cis rs11098499 0.505 rs75122014 ENSG00000248280.1 RP11-33B1.2 5.38 1.19e-07 3.77e-05 0.29 0.24 Corneal astigmatism; chr4:119441271 chr4:119440561~119450157:- LUSC cis rs77204473 0.744 rs6589606 ENSG00000254851.1 RP11-109L13.1 5.38 1.19e-07 3.77e-05 0.55 0.24 Sum eosinophil basophil counts;Eosinophil counts; chr11:117222170 chr11:117135528~117138582:+ LUSC cis rs17270561 0.578 rs76182885 ENSG00000272810.1 U91328.22 -5.38 1.19e-07 3.78e-05 -0.32 -0.24 Iron status biomarkers; chr6:25903857 chr6:26013241~26013757:+ LUSC cis rs875971 0.54 rs4717275 ENSG00000222364.1 RNU6-96P 5.38 1.19e-07 3.78e-05 0.28 0.24 Aortic root size; chr7:65800193 chr7:66395191~66395286:+ LUSC cis rs7208859 0.673 rs9889755 ENSG00000280069.1 CTD-2349P21.3 5.38 1.19e-07 3.78e-05 0.27 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30907487 chr17:30738182~30740275:+ LUSC cis rs9545047 0.604 rs9601226 ENSG00000227676.3 LINC01068 -5.38 1.19e-07 3.78e-05 -0.3 -0.24 Schizophrenia; chr13:79403400 chr13:79566727~79571436:+ LUSC cis rs2732480 0.577 rs2732486 ENSG00000257735.1 RP11-370I10.6 5.38 1.19e-07 3.78e-05 0.31 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344051 chr12:48350945~48442411:+ LUSC cis rs2732480 0.517 rs2634676 ENSG00000257735.1 RP11-370I10.6 5.38 1.19e-07 3.78e-05 0.31 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344453 chr12:48350945~48442411:+ LUSC cis rs875971 0.522 rs34973832 ENSG00000222364.1 RNU6-96P -5.38 1.19e-07 3.78e-05 -0.28 -0.24 Aortic root size; chr7:65931217 chr7:66395191~66395286:+ LUSC cis rs853679 1 rs735765 ENSG00000204709.4 LINC01556 5.38 1.19e-07 3.79e-05 0.43 0.24 Depression; chr6:28202519 chr6:28943877~28944537:+ LUSC cis rs875971 0.522 rs1880556 ENSG00000222364.1 RNU6-96P -5.38 1.19e-07 3.79e-05 -0.28 -0.24 Aortic root size; chr7:65967557 chr7:66395191~66395286:+ LUSC cis rs7826238 0.535 rs2979179 ENSG00000173295.6 FAM86B3P 5.38 1.19e-07 3.79e-05 0.26 0.24 Systolic blood pressure; chr8:8462519 chr8:8228595~8244865:+ LUSC cis rs2980439 0.556 rs2921059 ENSG00000173295.6 FAM86B3P 5.38 1.19e-07 3.79e-05 0.27 0.24 Neuroticism; chr8:8460377 chr8:8228595~8244865:+ LUSC cis rs2739330 0.76 rs1007888 ENSG00000228039.3 KB-1125A3.10 5.38 1.19e-07 3.79e-05 0.3 0.24 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23963780~23964374:+ LUSC cis rs9525916 1 rs9525916 ENSG00000227258.4 SMIM2-AS1 5.38 1.2e-07 3.79e-05 0.28 0.24 Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction); chr13:44128733 chr13:44110451~44240517:+ LUSC cis rs17270561 0.609 rs9348694 ENSG00000272462.2 U91328.19 -5.38 1.2e-07 3.8e-05 -0.28 -0.24 Iron status biomarkers; chr6:25753412 chr6:25992662~26001775:+ LUSC cis rs875971 0.545 rs1909508 ENSG00000179406.6 LINC00174 -5.38 1.2e-07 3.8e-05 -0.28 -0.24 Aortic root size; chr7:66301366 chr7:66376044~66401338:- LUSC cis rs6504950 0.925 rs244315 ENSG00000275710.1 RP11-257O5.4 5.38 1.2e-07 3.8e-05 0.29 0.24 Breast cancer; chr17:55137293 chr17:54964474~54964679:+ LUSC cis rs13113518 0.902 rs12503578 ENSG00000223305.1 RN7SKP30 5.38 1.2e-07 3.8e-05 0.29 0.24 Height; chr4:55509367 chr4:55540502~55540835:- LUSC cis rs13113518 0.966 rs3828480 ENSG00000223305.1 RN7SKP30 5.38 1.2e-07 3.8e-05 0.29 0.24 Height; chr4:55510352 chr4:55540502~55540835:- LUSC cis rs9435732 0.778 rs6662202 ENSG00000235241.1 RP11-108M9.5 5.38 1.2e-07 3.8e-05 0.35 0.24 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:17009758 chr1:16889095~16889602:+ LUSC cis rs9649213 0.574 rs34830366 ENSG00000272950.1 RP11-307C18.1 5.38 1.2e-07 3.81e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98270223 chr7:98322853~98323430:+ LUSC cis rs9649213 0.593 rs34776142 ENSG00000272950.1 RP11-307C18.1 5.38 1.2e-07 3.81e-05 0.32 0.24 Prostate cancer (SNP x SNP interaction); chr7:98270561 chr7:98322853~98323430:+ LUSC cis rs9545047 0.604 rs7331867 ENSG00000227676.3 LINC01068 -5.38 1.2e-07 3.81e-05 -0.3 -0.24 Schizophrenia; chr13:79418791 chr13:79566727~79571436:+ LUSC cis rs62355901 0.505 rs62358079 ENSG00000271828.1 CTD-2310F14.1 5.38 1.2e-07 3.81e-05 0.59 0.24 Breast cancer; chr5:56858020 chr5:56927874~56929573:+ LUSC cis rs11098499 0.754 rs1980025 ENSG00000250412.1 KLHL2P1 -5.38 1.2e-07 3.82e-05 -0.29 -0.24 Corneal astigmatism; chr4:119331651 chr4:119334329~119378233:+ LUSC cis rs875971 0.83 rs427973 ENSG00000224316.1 RP11-479O9.2 5.38 1.2e-07 3.82e-05 0.24 0.24 Aortic root size; chr7:66061661 chr7:65773620~65802067:+ LUSC cis rs9487051 0.872 rs7773331 ENSG00000219700.1 PTCHD3P3 5.38 1.2e-07 3.82e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109288005 chr6:109288571~109290503:- LUSC cis rs9487051 0.872 rs9374079 ENSG00000219700.1 PTCHD3P3 5.38 1.2e-07 3.82e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109288416 chr6:109288571~109290503:- LUSC cis rs9487051 0.802 rs9487039 ENSG00000219700.1 PTCHD3P3 5.38 1.2e-07 3.82e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109288960 chr6:109288571~109290503:- LUSC cis rs9487051 0.872 rs9487042 ENSG00000219700.1 PTCHD3P3 5.38 1.2e-07 3.82e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109289240 chr6:109288571~109290503:- LUSC cis rs17270561 0.636 rs9393656 ENSG00000272462.2 U91328.19 -5.38 1.2e-07 3.82e-05 -0.28 -0.24 Iron status biomarkers; chr6:25721831 chr6:25992662~26001775:+ LUSC cis rs924712 0.844 rs973205 ENSG00000224984.1 RP11-524H19.2 -5.38 1.2e-07 3.82e-05 -0.24 -0.24 Breast cancer; chr6:54865151 chr6:54840118~54840855:- LUSC cis rs2708377 0.79 rs73051387 ENSG00000247157.5 LINC01252 5.38 1.21e-07 3.83e-05 0.4 0.24 Bitter taste perception; chr12:11161864 chr12:11548030~11590369:+ LUSC cis rs270601 0.77 rs10463891 ENSG00000233006.5 AC034220.3 -5.38 1.21e-07 3.83e-05 -0.24 -0.24 Acylcarnitine levels; chr5:132261699 chr5:132311285~132369916:- LUSC cis rs5758659 0.679 rs134870 ENSG00000182057.4 OGFRP1 5.37 1.21e-07 3.83e-05 0.25 0.24 Cognitive function; chr22:42256311 chr22:42269753~42275196:+ LUSC cis rs2337406 0.866 rs2027901 ENSG00000280411.1 IGHV1-69-2 -5.37 1.21e-07 3.83e-05 -0.22 -0.24 Alzheimer's disease (late onset); chr14:106807164 chr14:106762092~106762588:- LUSC cis rs1707322 0.662 rs11211160 ENSG00000234329.1 RP11-767N6.2 5.37 1.21e-07 3.84e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680557 chr1:45651039~45651826:- LUSC cis rs228614 0.509 rs223486 ENSG00000246560.2 RP11-10L12.4 5.37 1.21e-07 3.84e-05 0.29 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102763796 chr4:102828055~102844075:+ LUSC cis rs35740288 0.77 rs34048547 ENSG00000202081.1 RNU6-1280P 5.37 1.21e-07 3.84e-05 0.3 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85637836 chr15:85651522~85651628:- LUSC cis rs12712135 0.706 rs6543114 ENSG00000234389.1 AC007278.3 5.37 1.21e-07 3.84e-05 0.26 0.24 Blood protein levels; chr2:102309534 chr2:102438713~102440475:+ LUSC cis rs910316 0.967 rs4903293 ENSG00000279594.1 RP11-950C14.10 -5.37 1.21e-07 3.84e-05 -0.27 -0.24 Height; chr14:75189865 chr14:75011269~75012851:- LUSC cis rs853679 0.55 rs1150692 ENSG00000280107.1 AL022393.9 -5.37 1.21e-07 3.85e-05 -0.29 -0.24 Depression; chr6:28206179 chr6:28170845~28172521:+ LUSC cis rs9303029 0.8 rs9896620 ENSG00000265458.1 RP13-20L14.6 5.37 1.21e-07 3.85e-05 0.4 0.24 Protein quantitative trait loci; chr17:82453331 chr17:82454273~82458521:- LUSC cis rs2617170 0.922 rs1600128 ENSG00000245648.1 RP11-277P12.20 5.37 1.21e-07 3.85e-05 0.29 0.24 Behcet's disease; chr12:10383559 chr12:10363769~10398506:+ LUSC cis rs2617170 0.922 rs1904123 ENSG00000245648.1 RP11-277P12.20 5.37 1.21e-07 3.85e-05 0.29 0.24 Behcet's disease; chr12:10385181 chr12:10363769~10398506:+ LUSC cis rs17711722 0.64 rs13237956 ENSG00000237310.1 GS1-124K5.4 5.37 1.21e-07 3.85e-05 0.24 0.24 Calcium levels; chr7:65853042 chr7:66493706~66495474:+ LUSC cis rs9545047 0.604 rs912639 ENSG00000227676.3 LINC01068 -5.37 1.21e-07 3.85e-05 -0.29 -0.24 Schizophrenia; chr13:79409788 chr13:79566727~79571436:+ LUSC cis rs67311347 1 rs2276870 ENSG00000223797.4 ENTPD3-AS1 -5.37 1.22e-07 3.85e-05 -0.27 -0.24 Renal cell carcinoma; chr3:40457691 chr3:40313802~40453329:- LUSC cis rs2554380 0.542 rs7164141 ENSG00000230373.7 GOLGA6L5P 5.37 1.22e-07 3.85e-05 0.25 0.24 Height; chr15:83824253 chr15:84507885~84516814:- LUSC cis rs1823913 0.513 rs4334520 ENSG00000227542.1 AC092614.2 5.37 1.22e-07 3.85e-05 0.32 0.24 Obesity-related traits; chr2:191329200 chr2:191229165~191246172:- LUSC cis rs240993 0.715 rs9400483 ENSG00000230177.1 RP5-1112D6.4 5.37 1.22e-07 3.86e-05 0.27 0.24 Inflammatory skin disease;Psoriasis; chr6:111535073 chr6:111277932~111278742:+ LUSC cis rs42490 0.966 rs218936 ENSG00000251136.7 RP11-37B2.1 5.37 1.22e-07 3.86e-05 0.21 0.24 Leprosy; chr8:89743186 chr8:89609409~89757727:- LUSC cis rs8133932 0.701 rs6518258 ENSG00000280604.1 PCBP3-OT1 5.37 1.22e-07 3.86e-05 0.32 0.24 Schizophrenia; chr21:45861915 chr21:45914296~45919483:+ LUSC cis rs10504390 0.585 rs79812520 ENSG00000272010.1 CTD-3025N20.3 -5.37 1.22e-07 3.86e-05 -0.58 -0.24 IgG glycosylation; chr8:65595380 chr8:65591850~65592472:- LUSC cis rs10504390 0.656 rs78912269 ENSG00000272010.1 CTD-3025N20.3 -5.37 1.22e-07 3.86e-05 -0.58 -0.24 IgG glycosylation; chr8:65599211 chr8:65591850~65592472:- LUSC cis rs1707322 0.827 rs6694302 ENSG00000234329.1 RP11-767N6.2 5.37 1.22e-07 3.86e-05 0.26 0.24 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45779973 chr1:45651039~45651826:- LUSC cis rs1862618 0.853 rs190414 ENSG00000271828.1 CTD-2310F14.1 5.37 1.22e-07 3.86e-05 0.37 0.24 Initial pursuit acceleration; chr5:56820945 chr5:56927874~56929573:+ LUSC cis rs7772486 0.875 rs2748502 ENSG00000235652.6 RP11-545I5.3 5.37 1.22e-07 3.86e-05 0.24 0.24 Lobe attachment (rater-scored or self-reported); chr6:145977103 chr6:145799409~145886585:+ LUSC cis rs10740039 0.81 rs10821800 ENSG00000254271.1 RP11-131N11.4 5.37 1.22e-07 3.87e-05 0.33 0.24 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60607812 chr10:60734342~60741828:+ LUSC cis rs4938303 0.718 rs10892023 ENSG00000254851.1 RP11-109L13.1 -5.37 1.22e-07 3.87e-05 -0.37 -0.24 Triglycerides; chr11:116727532 chr11:117135528~117138582:+ LUSC cis rs116139393 0.54 rs13224907 ENSG00000187953.9 PMS2CL -5.37 1.22e-07 3.87e-05 -0.33 -0.24 Alzheimer's disease (APOE e4 interaction); chr7:6734261 chr7:6710128~6753862:+ LUSC cis rs9545047 0.567 rs9574420 ENSG00000227676.3 LINC01068 -5.37 1.22e-07 3.87e-05 -0.3 -0.24 Schizophrenia; chr13:79404342 chr13:79566727~79571436:+ LUSC cis rs73173548 0.502 rs36077166 ENSG00000247828.6 TMEM161B-AS1 5.37 1.22e-07 3.88e-05 0.29 0.24 Macular telangiectasia type 2; chr5:88441770 chr5:88268895~88436685:+ LUSC cis rs6502050 0.761 rs12150321 ENSG00000266654.1 RP11-1376P16.1 5.37 1.22e-07 3.88e-05 0.24 0.24 Life satisfaction; chr17:82103682 chr17:82160056~82160452:+ LUSC cis rs12468226 1 rs13426118 ENSG00000226261.1 AC064836.3 5.37 1.22e-07 3.88e-05 0.38 0.24 Urate levels; chr2:202390762 chr2:202336024~202336727:- LUSC cis rs875971 0.545 rs313830 ENSG00000179406.6 LINC00174 5.37 1.22e-07 3.88e-05 0.29 0.24 Aortic root size; chr7:66086944 chr7:66376044~66401338:- LUSC cis rs13434995 0.513 rs17722870 ENSG00000249700.7 SRD5A3-AS1 -5.37 1.23e-07 3.88e-05 -0.3 -0.24 Adiponectin levels; chr4:55478519 chr4:55363971~55395847:- LUSC cis rs67311347 1 rs7641495 ENSG00000223797.4 ENTPD3-AS1 -5.37 1.23e-07 3.89e-05 -0.27 -0.24 Renal cell carcinoma; chr3:40453199 chr3:40313802~40453329:- LUSC cis rs6570726 0.935 rs366621 ENSG00000235652.6 RP11-545I5.3 5.37 1.23e-07 3.89e-05 0.24 0.24 Lobe attachment (rater-scored or self-reported); chr6:145540139 chr6:145799409~145886585:+ LUSC cis rs801193 1 rs2055682 ENSG00000179406.6 LINC00174 -5.37 1.23e-07 3.89e-05 -0.26 -0.24 Aortic root size; chr7:66795302 chr7:66376044~66401338:- LUSC cis rs10506621 0.685 rs2088159 ENSG00000257265.1 CTD-2021H9.1 5.37 1.23e-07 3.89e-05 0.38 0.24 Gut microbiome composition (winter); chr12:71098049 chr12:71007773~71032083:- LUSC cis rs2720460 0.502 rs223374 ENSG00000246560.2 RP11-10L12.4 5.37 1.23e-07 3.89e-05 0.31 0.24 Testicular germ cell tumor; chr4:102837144 chr4:102828055~102844075:+ LUSC cis rs6502050 0.871 rs8080366 ENSG00000266654.1 RP11-1376P16.1 5.37 1.23e-07 3.89e-05 0.24 0.24 Life satisfaction; chr17:82109422 chr17:82160056~82160452:+ LUSC cis rs11098499 0.691 rs9996644 ENSG00000250412.1 KLHL2P1 5.37 1.23e-07 3.89e-05 0.29 0.24 Corneal astigmatism; chr4:119317722 chr4:119334329~119378233:+ LUSC cis rs11098499 0.691 rs9996494 ENSG00000250412.1 KLHL2P1 5.37 1.23e-07 3.89e-05 0.29 0.24 Corneal astigmatism; chr4:119317725 chr4:119334329~119378233:+ LUSC cis rs367615 0.918 rs10054960 ENSG00000249476.1 CTD-2587M2.1 5.37 1.23e-07 3.89e-05 0.32 0.24 Colorectal cancer (SNP x SNP interaction); chr5:109530747 chr5:109237120~109326369:- LUSC cis rs9487051 0.872 rs1521908 ENSG00000219700.1 PTCHD3P3 5.37 1.23e-07 3.9e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109292783 chr6:109288571~109290503:- LUSC cis rs2153535 0.562 rs10458225 ENSG00000230939.1 RP11-314C16.1 5.37 1.23e-07 3.9e-05 0.28 0.24 Motion sickness; chr6:8385771 chr6:8784178~8785445:+ LUSC cis rs9907295 1 rs9908525 ENSG00000270977.1 AC015849.16 -5.37 1.23e-07 3.9e-05 -0.34 -0.24 Fibroblast growth factor basic levels; chr17:35908605 chr17:35893707~35911023:- LUSC cis rs7211079 0.843 rs73438138 ENSG00000279259.1 RP11-334C17.3 5.37 1.23e-07 3.91e-05 0.28 0.24 Myocardial infarction; chr17:80148608 chr17:80147250~80148596:+ LUSC cis rs2243480 1 rs316331 ENSG00000226824.5 RP4-756H11.3 5.37 1.23e-07 3.91e-05 0.48 0.24 Diabetic kidney disease; chr7:66139635 chr7:66654538~66669855:+ LUSC cis rs9341808 0.667 rs2490241 ENSG00000272129.1 RP11-250B2.6 5.37 1.23e-07 3.91e-05 0.3 0.24 Sitting height ratio; chr6:80136625 chr6:80355424~80356859:+ LUSC cis rs2274273 0.87 rs61210954 ENSG00000258413.1 RP11-665C16.6 -5.37 1.23e-07 3.91e-05 -0.29 -0.24 Protein biomarker; chr14:55298684 chr14:55262767~55272075:- LUSC cis rs2274273 0.901 rs17674563 ENSG00000258413.1 RP11-665C16.6 -5.37 1.23e-07 3.91e-05 -0.3 -0.24 Protein biomarker; chr14:55364407 chr14:55262767~55272075:- LUSC cis rs13113518 0.966 rs7677952 ENSG00000272969.1 RP11-528I4.2 5.37 1.23e-07 3.91e-05 0.27 0.24 Height; chr4:55425312 chr4:55547112~55547889:+ LUSC cis rs673078 0.607 rs61944670 ENSG00000275409.1 RP11-131L12.4 -5.37 1.24e-07 3.91e-05 -0.34 -0.24 Glucose homeostasis traits; chr12:118448697 chr12:118430147~118430699:+ LUSC cis rs9487051 0.872 rs9386794 ENSG00000219700.1 PTCHD3P3 5.37 1.24e-07 3.91e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109290318 chr6:109288571~109290503:- LUSC cis rs9487051 0.898 rs882072 ENSG00000219700.1 PTCHD3P3 5.37 1.24e-07 3.91e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109290603 chr6:109288571~109290503:- LUSC cis rs9487051 0.872 rs6924776 ENSG00000219700.1 PTCHD3P3 5.37 1.24e-07 3.91e-05 0.26 0.24 Reticulocyte fraction of red cells; chr6:109291073 chr6:109288571~109290503:- LUSC cis rs13113518 1 rs13133579 ENSG00000272969.1 RP11-528I4.2 5.37 1.24e-07 3.92e-05 0.27 0.24 Height; chr4:55459921 chr4:55547112~55547889:+ LUSC cis rs13113518 0.902 rs11133386 ENSG00000272969.1 RP11-528I4.2 5.37 1.24e-07 3.92e-05 0.27 0.24 Height; chr4:55461320 chr4:55547112~55547889:+ LUSC cis rs1387259 0.859 rs2054905 ENSG00000226413.2 OR8T1P 5.37 1.24e-07 3.92e-05 0.32 0.24 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48294168 chr12:48442030~48442947:- LUSC cis rs2732480 0.5 rs2732461 ENSG00000226413.2 OR8T1P 5.37 1.24e-07 3.92e-05 0.32 0.24 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48299019 chr12:48442030~48442947:- LUSC cis rs62103177 0.564 rs3930043 ENSG00000261126.6 RP11-